"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT04236440","Study on the Safety of Drug BAY2586116 and How it Works in Patients With Obstructive Sleep Apnea (a Sleep Disorder Caused by the Narrowing and Collapse of the Airway During Sleep) Including the Blood Level of the Drug and Effect of Its Doses and Routes of Administration","KOALA","Not yet recruiting","No Results Available","Sleep Apnea, Obstructive","Drug: BAY2586116 (A1)|Drug: Placebo (A2)|Drug: BAY2586116 (B1)|Drug: BAY2586116 (B2)|Drug: BAY2586116 (B3)","Critical closing pressure (Pcritgs) of the upper airway (cmH2O) during sleep with a polysomnography|Incidence of treatment-emergent adverse events (TEAEs)|Severity of treatment-emergent adverse events (TEAEs)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20732","February 3, 2020","July 24, 2020","August 31, 2020","January 22, 2020",,"January 22, 2020","Adelaide Institute for Sleep Health, Bedford Park, South Australia, Australia",,"https://ClinicalTrials.gov/show/NCT04236440"
2,"NCT04232761","Study to Gather Information on the Safety and How Radium-223 Dichloride, an Alpha Particle-emitting Radioactive Agent, Works Under Routine Clinical Practice in Taiwan in Patients With Castration-resistant Prostate Cancer (CRPC) Which Has Spread to the Bone","RAPIT","Not yet recruiting","No Results Available","Castration-resistant Prostate Cancer","Drug: Radium-223 dichloride (Xofigo, BAY88-8223)","Incidence of treatment-emergent adverse events (TEAEs)|Incidence of drug-related TEAEs|Descriptive analysis of long-term safety information during the extended follow-up period|Overall survival|Time to the first symptomatic skeletal event (SSE)|Proportion of patients with total ALP (tALP) response|Proportion of patients with PSA response|Change in pain status|Change in ECOG-PS","Bayer","Male","Child, Adult, Older Adult",,"300","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","21124","August 1, 2020","January 1, 2024","January 1, 2024","January 18, 2020",,"January 18, 2020","Many locations, Multiple Locations, Taiwan",,"https://ClinicalTrials.gov/show/NCT04232761"
3,"NCT04218266","Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications.","PACIFIC-AF","Not yet recruiting","No Results Available","Atrial Fibrillation (AF)","Drug: BAY2433334|Drug: Apixaban|Other: BAY2433334 matching placebo|Other: Apixaban matching placebo","Number of participants with composite of ISTH major and clinically relevant non-major bleeding|Number of participants with all bleeding|Number of participants with ISTH major bleeding|Number of participants with ISTH clinically relevant non-major bleeding|Number of participants with ISTH minor bleeding","Bayer","All","45 Years and older   (Adult, Older Adult)","Phase 2","750","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","19765|2019-002365-35","January 15, 2020","June 22, 2021","June 22, 2021","January 6, 2020",,"January 6, 2020","Krankenhaus St. Josef Braunau, Braunau, Oberösterreich, Austria|Krankenhaus der Elisabethinen Linz GmbH, Linz, Oberösterreich, Austria|Medizinische Universität Graz, Graz, Steiermark, Austria|Landeskrankenhaus - Universitätskliniken Innsbruck, Innsbruck, Tirol, Austria|Landeskrankenhaus Feldkirch, Feldkirch, Vorarlberg, Austria|Uniklinikum Salzburg - Landeskrankenhaus, Salzburg, Austria|Allgemeines Krankenhaus der Stadt Wien, Wien, Austria|Krankenhauses Nord - Klinik Floridsdorf, Wien, Austria|UZ Leuven Gasthuisberg, Leuven, Vlaams Brabant, Belgium|Imeldaziekenhuis - St-Elisabethkliniek, Bonheiden, Belgium|AZ St-Jan Brugge Oostende AV, Brugge, Belgium|UZ Antwerpen, Edegem, Belgium|Jessa Ziekenhuis, Hasselt, Belgium|VZW Emmaus, Mechelen, Belgium|H. Hartziekenhuis Mol, MOL, Belgium|AZ Delta, Roeselare, Belgium|Royal Alexandra Hospital, Edmonton, Alberta, Canada|Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|Cambridge Cardiac Care Center, Cambridge, Ontario, Canada|Population Health Research Institute, Hamilton, Ontario, Canada|St. Michael's Hospital Health Centre, Toronto, Ontario, Canada|Montreal Heart Institute, Montreal, Quebec, Canada|Clinique Sante Cardio MC, Montreal, Quebec, Canada|Institut universitaire de cardiologie et de pneumologie, Ste-Foy, Quebec, Canada|Oblastni Nemocnice Kladno, Kladno, Czechia|Fakultni nemocnice Plzen, Plzen, Czechia|Fakultni nemocnice Kralovske Vinohrady, Praha 10, Czechia|Institut Klinicke a Experimentalni Mediciny, Praha 4, Czechia|Fakultni nemocnice v Motole, Praha 5, Czechia|Nemocnice Slany, Slany, Czechia|Nemocnice Pardubickeho kraje a.s., Orlickoustecka nemocnice, Usti nad Orlici, Czechia|Krajska nemocnice T. Bati, a.s., Zlin, Czechia|Hôpital Henri Mondor, Creteil, France|Centre Hospitalier Départemental Vendée, La Roche Sur Yon Cedex, France|Centre Hospitalier Louis Pasteur, Le Coudray, France|Hopital de Cardiologie - Lille, LILLE cedex, France|Hopital Bichat - Paris, Paris, France|Centre Hospitalier Régional - Saint Brieuc, Saint Brieuc, France|Hôpital de Rangueil - Toulouse, Toulouse, France|Centre Hospitalier - Valenciennes Cedex, Valenciennes Cedex, France|University of Semmelweis/ Semmelweis Egyetem, Budapest, Hungary|Magyar Honvedseg Egeszsegugyi Kozpont Honvedkorhaz, Budapest, Hungary|Magyar Honvedseg Egeszsegugyi Kozpont Honvedkorhaz, Budapest, Hungary|Kanizsai Dorottya Hospital, Nagykanizsa, Hungary|Medifarma-98 Egeszsegugyi, Kereskedelmi es Szolgaltato Kft., Nyiregyhaza, Hungary|Pecsi Tudomanyegyetem Klinikai Kozpont, Pecs, Hungary|Tolna Megyei Balassa Janos Korhaz, Szekszard, Hungary|Dr. Bugyi Istvan Hopsital (Korhaz), Szentes, Hungary|A.O.U. Policlinico Umberto I, Roma, Lazio, Italy|IRCCS A.O.U. San Martino IST Ist. Nazionale Ricerca Cancro, Genova, Liguria, Italy|ASST Spedali Civili di Brescia, Brescia, Lombardia, Italy|ASUR Marche - Area Vasta 5, Ascoli Piceno, Marche, Italy|A.O. Ospedali Riuniti Villa Sofia-Cervello, Palermo, Sicilia, Italy|AUSL Toscana Sud-Est, Arezzo, Toscana, Italy|AUSL Toscana Sud-Est, Arezzo, Toscana, Italy|A.O. di Perugia, Perugia, Umbria, Italy|Nakamura Cardiovascular Clinic, Itoshima, Fukuoka, Japan|Hyogo Brain and Heart Center, Himeji, Hyogo, Japan|Okinawa Tokushukai Hayama Heart Center, Miura-gun, Kanagawa, Japan|Kishiwada Tokushukai Hospital, Kishiwada, Osaka, Japan|Yao Tokushukai General Hospital, Yao, Osaka, Japan|Nishiarai Heart Center Hospital, Adachi-ku, Tokyo, Japan|Minamino Cardiovascular Hospital, Hachioji, Tokyo, Japan|Tokyo Angel Hospital, Hachioji, Tokyo, Japan|Koto Hospital, Koto-ku, Tokyo, Japan|Doctor's Practice in Cardiology, Daugavpils, Latvia|Daugavpils Regional Hospital, Daugavpils, Latvia|Liepaja Regional Hospital, Liepaja, Latvia|1st Riga Clinical Hospital, Riga, Latvia|Clinic of Obstetrics and Gynaecology, Riga, Latvia|Riga East Clinical University Hospital ""Gailezers"", Riga, Latvia|Ventspils Hospital, Ventspils, Latvia|Amphia Ziekenhuis, locatie Molengracht, Breda, Noord-Brabant, Netherlands|Academisch Medisch Centrum (AMC), Amsterdam, Netherlands|Ziekenhuis Rijnstate, Arnhem, Netherlands|Albert Schweitzer Ziekenhuis, Locatie Dordwijk, Dordrecht, Netherlands|Medisch Spectrum Twente, Enschede, Netherlands|Martini Ziekenhuis, Locatie van Swieten, Groningen, Netherlands|Spaarne Gasthuis - locatie Zuid, Haarlem, Netherlands|Maastricht UMC, Maastricht, Netherlands|Ciutat Sanitària i Universitària de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Ciutat Sanitària i Universitaria de la Vall d'Hebron, Barcelona, Spain|Hospital de la Santa Creu i de Sant Pau, Barcelona, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Hospital Arnau de Vilanova de Valencia, Valencia, Spain|Falu Lasarett, Falun, Sweden|SU/Östra, Göteborg, Sweden|Capio Citykliniken Närsjukvården AB, Lund, Sweden|Skellefteå Lasarett, Skellefteå, Sweden|Södersjukhuset AB, Stockholm, Sweden|Danderyds sjukhus, Stockholm, Sweden|Avdelningen för kliniska prövningar AKP, Örebro, Sweden|Östersunds Sjukhus, Östersund, Sweden|Kantonsspital Aarau, Aarau, Aargau, Switzerland|Universitätsspital Basel, Basel, Basel-Stadt, Switzerland|Kantonsspital St. Gallen, St. Gallen, Sankt Gallen, Switzerland|Kantonsspital Winterthur, Winterthur, Zürich, Switzerland|Inselspital Universitätsspital Bern, Bern, Switzerland|Hôpital Cantonal Universitaire de Genève, Genève, Switzerland|Ospedale regionale di Lugano, Lugano, Switzerland|Luzerner Kantonsspital, Luzern, Switzerland|Staploe Medical Centre, Ely, Cambridgeshire, United Kingdom|Royal Cornwall Hospital, Truro, Cornwall, United Kingdom|Chesterfield Royal Hospital, Chesterfield, Derbyshire, United Kingdom|Queen Elizabeth II Hospital, Welwyn Garden City, Hertfordshire, United Kingdom|Northwick Park Hospital, Harrow, London, United Kingdom|University Hospital of Wales, Cardiff, United Kingdom|Heart and Chest Hospital, Liverpool, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04218266"
4,"NCT04183270","Survey on Belgian Patients Suffering From Irregular Heartbeat and Starting Treatment With a Drug to Prevent Blood Clots in Blood Vessels and the Heart. This Study is Also Called BELANCOS.","BELANCOS","Not yet recruiting","No Results Available","Consumer Expectations","Other: Questionnaires","Age categories of patients|Gender (Female or male) of patients|Patients' level of agreement with various statements of using NOACs in general|Level of patients fear of having a bleeding on a scale from 0 - 10|Level of patients fear of having a stroke or thrombosis on a scale from 0 - 10|Age categories of physicians|Gender (Female or male) of physicians|Physicans' level of agreement with various statement of using NOACs in general|Level of patients fear of having a bleeding assessed by physicans on a scale from 0 - 10|Level of patients fear of having a stroke or thrombosis assessed by physicians on a scale from 0 - 10","Bayer","All","18 Years and older   (Adult, Older Adult)",,"315","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","21153","January 31, 2020","April 30, 2020","June 30, 2020","December 3, 2019",,"January 10, 2020","Many locations, Multiple Locations, Belgium",,"https://ClinicalTrials.gov/show/NCT04183270"
5,"NCT04174859","Study Aims to Collect Information in Routine Clinical Practice in Italy About the Number of Patients Suffering From Irregularly Heart Beats Which Are Not Caused by a Heart Valve Problem (Non-valvular Atrial Fibrillation, NVAF) Who Stopped or Changed Rivaroxaban Treatment","RITMUS-AF","Recruiting","No Results Available","Non-valvular Atrial Fibrillation","Drug: Rivaroxaban (Xarelto, BAY59-7939)","Date of start of rivaroxaban treatment|Date of stop of rivaroxaban treatment|Number of patients who discontinue (i.e: number of discontinuation) from study initiation to end of observation/follow up.|Reasons for discontinuation of rivaroxaban therapy|Reason for dose change of rivaroxaban therapy|Reason for switch to other therapy|Treatment adherence: Self-reported medication adherence measured by the MMAS-8 (Morinsky Scale score)","Bayer|Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)",,"800","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","20999","December 10, 2019","June 1, 2023","December 31, 2023","November 22, 2019",,"January 13, 2020","Many locations, Multiple Locations, Italy",,"https://ClinicalTrials.gov/show/NCT04174859"
6,"NCT04162795","A Study to Evaluate Cooling Sensation of an Allergy Product in Adults With a History of Allergies",,"Completed","No Results Available","Allergic Rhinitis","Drug: BAY76-2211 (Loratadine)","Agreement of perception of cooling sensation|Time to perception of cooling sensation|Duration of cooling sensation|Agreement of perception of refreshing sensation|Agreement of the great tastes of the product|Agreement of the enjoyable product experience|Agreement of liking the flavor sensation of the product|Agreement of the unique sensory experience for an allergy medicine|Agreement of the refreshing of the cooling sensation|Agreement of soothing feeling on the throat","Bayer","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","456","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","21048","November 12, 2019","November 13, 2019","November 13, 2019","November 14, 2019",,"December 16, 2019","Focus Pointe Global, Teaneck, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04162795"
7,"NCT04157088","Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC)","DaroAcT","Not yet recruiting","No Results Available","Prostatic Cancer, Castration-Resistant","Drug: Darolutamide(Nubeqa, BAY1841788)|Drug: Enzalutamide","Proportion of participants with a worsening in TUG (Time Up and Go) time|Proportion of participants with an increase of at least 1 second in TUG time|Proportion of participants with a worsening in Short Physical Performance Battery (SPPB) total score|Mean change from baseline in daily physical activity as assessed by accelerometry|Mean change from baseline in accelerometer-assessed proportion of time spent in light to vigorous physical activity based on a threshold of >100 activity counts per minute|Proportion of participants with a decline in cognitive function|Proportion of participants with a decline using a selected domain of FACT-Cog|Proportion of participants with a worsening of fatigue|Proportion of participants with an increase of at least 1 point in fatigue interference|Proportion of participants with a worsening in scores in the PHQ-9|Number of participants with emergent AEs, SAEs, and AEs leading to study intervention discontinuation|Number of participants with AEs of interest, including falls, fractures, and hypothyroidism","Bayer","Male","18 Years and older   (Adult, Older Adult)","Phase 2","150","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20609","November 30, 2019","December 31, 2022","December 31, 2022","November 8, 2019",,"November 8, 2019",,,"https://ClinicalTrials.gov/show/NCT04157088"
8,"NCT04147819","A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein",,"Not yet recruiting","No Results Available","Cancers With HER2 Expression","Drug: BAY2701439|Drug: BAY2701438","Dose escalation: Incidence of TEAEs including TESAEs|Dose escalation: Severity of TEAEs including TESAEs|Dose escalation: Frequency of DLTs at each dose level|Dose expansion: ORR by RECIST 1.1|Dose expansion: Frequency of TEAEs|Dose expansion: Severity of TEAEs|Dose escalation: Recommended dose level(s) of BAY2701439 for the dose expansion cohorts|Dose escalation: Recommended treatment schedule of BAY2701439 for the dose expansion cohorts|Dose expansion: Recommended dose for further clinical development of BAY2701439|Cmax of thorium-227|Cmax of radium-223|Cmax of total antibody|AUC(0-42 days) of thorium-227|AUC(0-42 days) of radium-223|AUC(0-42 days) of total antibody","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","176","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19829|2019-001741-40","March 1, 2020","October 6, 2024","September 7, 2026","November 1, 2019",,"January 22, 2020","Johns Hopkins Hospital/Health System, Baltimore, Maryland, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Royal Marsden NHS Trust (Surrey), Sutton, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04147819"
9,"NCT04142437","Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body","ON-TRK","Not yet recruiting","No Results Available","Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion","Drug: larotrectinib(Vitrakvi, BAY2757556)","Number of participants with treatment-emergent adverse events (TEAEs)|Severity of TEAEs|Seriousness of TEAEs|Outcome of TEAEs|Causality of TEAEs|Action taken related to larotrectinib treatment|Objective response rate (ORR)|Disease control rate (DCR)|Duration of response (DOR)|Time to response (TTR)|Progression-free survival (PFS)|Overall survival (OS)|Total dose|Starting and ending dose|Dose modification during treatment|Duration of treatment (DOT)|ORR by patient subgroup(s)|DCR by patient subgroup(s)|DOR by patient subgroup(s)|TTR by patient subgroup(s)|PFS by patient subgroup(s)|OS by patient subgroup(s)|Change in height and weight from baseline by visit|Number of patients with abnormal neurological assessments|Number of patients with abnormal developmental milestones|Number of patients with abnormal Tanner stage","Bayer","All","Child, Adult, Older Adult",,"300","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","20324","January 31, 2020","November 30, 2027","March 31, 2028","October 29, 2019",,"January 22, 2020",,,"https://ClinicalTrials.gov/show/NCT04142437"
10,"NCT04137120","Study to Gather Information on the Safety and Use of Aflibercept Injections Into the Eye for the Treatment of Eye Disorders in Mexican Routine Clinical Practice","MAIA","Not yet recruiting","No Results Available","Retinal Disease","Drug: Aflibercept (BAY86-5321, Eylea)","Number of ocular adverse events|Number of serious ocular adverse events|Seriousness reason for ocular adverse events|Severity of ocular adverse events|Number of treatment-related ocular adverse events|Number of injection-related ocular adverse events|Action taken with drug after ocular adverse event|Clinical outcome of ocular adverse event|Duration of ocular adverse events|Duration of patient follow-up after ocular adverse event (in months)|Number of non-ocular adverse events|Number of serious non-ocular adverse events|Seriousness reason for non-ocular adverse events|Severity of non-ocular adverse events|Number of treatment-related non-ocular adverse events|Number of injection-related non-ocular adverse events|Action taken with drug after non-ocular adverse event|Clinical outcome of non-ocular adverse event|Duration of non-ocular adverse events|Duration of patient follow-up after non-ocular adverse event (in months)|Total number of injections with intravitreal aflibercept per study eye|Time between injections in the study eye (in days)|Time between injections in the study eye and fellow eye (in days)|Number of patients receiving bilateral treatment","Bayer|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)",,"69","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","19212","April 15, 2020","January 15, 2022","January 15, 2022","October 23, 2019",,"January 18, 2020","Many locations, Multiple Locations, Mexico",,"https://ClinicalTrials.gov/show/NCT04137120"
11,"NCT04132336","Study to Find Out the Optimal Dose of Caffeine in the Combination Tablet of Naproxen Sodium and Caffeine in Patients Experiencing Moderate to Severe Pain After Having Wisdom Teeth Removed",,"Recruiting","No Results Available","Pain, Postoperative","Drug: Naproxen sodium/Caffeine (BAY2880376)|Drug: Naproxen sodium (Aleve)|Drug: Caffeine|Drug: Placebo","Sum of pain intensity difference (SPID) over 8 hours|Sum of pain intensity difference (SPID) over 2 hours|Sum of pain intensity difference (SPID) over 4 hours|Sum of pain intensity difference (SPID) over 12 hours|Total pain relief (TOTPAR) over 2 hours|Total pain relief (TOTPAR) over 4 hours|Total pain relief (TOTPAR) over 8 hours|Total pain relief (TOTPAR) over 12 hours|Time (hours) to first use of rescue medication|Percentage of participants taking rescue medication|Time (hours) to first perceptible relief measured by a stopwatch|Time (hours) to meaningful relief measured by a stopwatch|Time (hours) to first perceptible relief confirmed by meaningful relief|Pain Intensity Difference (PID) at each evaluation|Pain relief score at each evaluation|Peak pain intensity difference (PID)|Peak pain relief score|Percentage of participants with at least a 2-point PID|Global assessment of the investigational product|Number of participants with adverse events (AE)|Number of subjects with clinically significant changes in physical examinations, vital signs or laboratory assessments","Bayer","All","16 Years and older   (Child, Adult, Older Adult)","Phase 2","190","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","21069|2019-003513-33","November 12, 2019","March 13, 2020","March 13, 2020","October 18, 2019",,"January 13, 2020","JBR Clinical Research, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT04132336"
12,"NCT04126733","Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)",,"Recruiting","No Results Available","Colorectal Cancer","Drug: Regorafenib (BAY73-4506, Stivarga)|Biological: Nivolumab (Opdivo)","ORR (Overall response rate) per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1|Duration of Response (DOR)|Disease control rate (DCR)|Progression-free survival (PFS)|Overall survival (OS)|Incidence and severity of adverse events (AEs) per Common terminology criteria for adverse events (CTCAE) v5","Bayer|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 2","53","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20975","October 14, 2019","September 18, 2020","April 18, 2022","October 15, 2019",,"January 18, 2020","City of Hope National Medical Center, Duarte, California, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Miami Cancer Institute at Baptist Health South Florida, Miami, Florida, United States|Illinois Cancer Specialists, Arlington Heights, Illinois, United States|Minnesota Oncology Hematology, PA, Minneapolis, Minnesota, United States|Nebraska Cancer Specialists, Papillion, Nebraska, United States|New York Oncology Hematology. P.C., Albany, New York, United States|Willamette Valley Cancer Institute and Research Center, Eugene, Oregon, United States|Sarah Cannon Cancer Center, Nashville, Tennessee, United States|Vanderbilt University Medical School, Nashville, Tennessee, United States|Texas Oncology-Arlington North, Arlington, Texas, United States|Baylor Charles A. Sammons Cancer Center at Dallas, Dallas, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Texas Oncology-Sherman, Sherman, Texas, United States|Virginia Oncology Associates, Newport News, Virginia, United States|Northwest Cancer Specialists, PC, Vancouver, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04126733"
13,"NCT04125693","Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety",,"Enrolling by invitation","No Results Available","Cancer","Drug: Rogaratinib (BAY1163877)|Drug: Combination drug","Incidence of treatment-emergent adverse events (TEAEs)|Incidence of treatment-emergent serious adverse events (TESAEs)|Incidence of drug-related TEAEs|Incidence of drug-related TESAEs|Frequency of dose modifications","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20252|2019-000808-15","October 30, 2019","April 29, 2024","April 29, 2024","October 14, 2019",,"January 9, 2020","Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Kantonsspital St. Gallen, St. Gallen, Sankt Gallen, Switzerland",,"https://ClinicalTrials.gov/show/NCT04125693"
14,"NCT04122976","A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described","DAROL","Not yet recruiting","No Results Available","Prostate Cancer","Drug: Darolutamide(Nubeqa, BAY1841788)","Occurrence of treatment-emergent adverse events (TEAEs)|Reasonable causal relationship between darolutamide and an adverse event (AE)|Action taken related to darolutamide treatment|Subject's demographics|Subject's characteristics|Dosage and dose modification of darolutamide|Initiation and termination dates of darolutamide|Reasons for ending treatment and/or observation/follow-up|Reasons for discontinuations or changes of treatments|Metastasis-Free Survival (MFS)|Time to Symptomatic Skeletal Event (TSSE)|Time to Prostate-Specific Antigen (PSA) progression|Survival rate|Imaging exams used to define tumor status|Prior and post - darolutamide treatments for prostate cancer","Bayer","Male","18 Years and older   (Adult, Older Adult)",,"1000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","20590","January 15, 2020","December 30, 2024","March 1, 2025","October 10, 2019",,"January 18, 2020",,,"https://ClinicalTrials.gov/show/NCT04122976"
15,"NCT04099238","Burden of Ischemic Stroke and Intake of Oral Anticoagulants in Patients With Atrial Fibrillation in the UK Primary Care","BEST-AF","Not yet recruiting","No Results Available","Atrial Fibrillation","Drug: Oral anticoagulant","Number of subjects with ischemic stroke|Incidence of ischemic stroke|Number of NVAF patients with OAC prescription prior to ischemic stroke|Duration of OAC treatment before OAC discontinuation for NVAF patients|Time period from OAC discontinuation to ischemic stroke for NVAF patients|Relative risk of NVAF patients for ischemic stroke after OAC discontinuation|Relative risk of NVAF patients for ischemic stroke by time since OAC discontinuation|Relative risk of NVAF patients for ischemic stroke by OAC treatment duration before OAC discontinuation|Relative risk of NVAF patients for ischemic stroke after VKA discontinuation|Relative risk of NVAF patients for ischemic stroke by time since VKA discontinuation|Relative risk of NVAF patients for ischemic stroke by VKA treatment duration before VKA discontinuation|Relative risk of NVAF patients for ischemic stroke after NOAC discontinuation|Relative risk of NVAF patients for ischemic stroke by time since NOAC discontinuation|Relative risk of NVAF patients for ischemic stroke by NOAC treatment duration before NOAC discontinuation|Number of subjects with first diagnosis of NVAF at time of ischemic stroke|Number of subjects with first diagnosis of NVAF within 1 month after ischemic stroke|Number of subjects with first diagnosis of NVAF within 12 months after ischemic stroke","Bayer","All","20 Years to 89 Years   (Adult, Older Adult)",,"7000","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","21094","February 1, 2020","April 30, 2020","April 30, 2020","September 23, 2019",,"January 18, 2020","Many facilities, Multiple Locations, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04099238"
16,"NCT04097912","Study to Gather Information to What Extent Patients Follow the Treatment Regimen of Low-dose Aspirin for Primary and Secondary Prevention of Diseases of the Heart and Blood Vessels","PALACE","Active, not recruiting","No Results Available","Myocardial Infarction|Stroke (Including Ischaemic Stroke and Transient Ischaemic Attack)|Unstable Angina|Angina|Ischaemic Heart Disease","Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)","Adherence to low-dose aspirin|Persistence to low-dose aspirin|Time to switch from dual-antiplatelet to a monotherapy","Bayer","All","18 Years and older   (Adult, Older Adult)",,"99999","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","20749","September 30, 2019","January 31, 2020","January 31, 2020","September 20, 2019",,"January 21, 2020","Many locations, Multiple Locations, Italy",,"https://ClinicalTrials.gov/show/NCT04097912"
17,"NCT04095273","Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug",,"Recruiting","No Results Available","Advanced Solid Tumors","Drug: BAY1895344|Drug: Pembrolizumab","Incidence of Treatment Emergent Adverse Events (TEAEs) including Treatment Emergent Serious Adverse Events (TESAEs)|Severity of Treatment Emergent Adverse Events (TEAEs) including Treatment Emergent Serious Adverse Events (TESAEs)|Frequency of Dose limiting toxicities (DLTs) at each dose level during dose escalation of BAY1895344|Cmax of BAY1895344|AUC(0-12) of BAY1895344|Cmax,md of BAY1895344|AUC(0-12)md of BAY1895344|Incidence of Complete response (CR)|Incidence of partial response (PR)|Incidence of stable disease (SD)|Incidence of progressive disease (PD)|Objective Response Rate (ORR)|Disease control rate (DCR)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","76","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19741|2018-003420-36","September 30, 2019","September 22, 2021","October 20, 2021","September 19, 2019",,"January 22, 2020","Stanford University, Palo Alto, California, United States|Johns Hopkins Hospital/Health System, Baltimore, Maryland, United States|Ohio State University, Columbus, Ohio, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Royal Marsden NHS Trust (Surrey), Sutton, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04095273"
18,"NCT04091386","Study to Learn More About the Physical Activity Level of Patients Suffering From Hemophilia A Treated With Damoctocog Alfa Pegol (LIFE ACTIVE Study)","LIFE-ACTIVE","Not yet recruiting","No Results Available","Hemophilia A","Drug: Damoctocog alfa pegol (Jivi, BAY94-9027)","Time of physical activity per week (wear-time adjusted)|Category of physical activity|Sleeping time per week (wear-time adjusted)|Awake time per week (wear-time adjusted)|Time of moderate to vigorous physical activity per week (wear-time adjusted)|Association between physical activity time per week and annualized bleeding rate (ABR)|Association between physical activity time per week and joint annualized bleeding rate (JABR)|Association between physical activity time per week and hemophilia joint health score (HJHS)|Repeated measure correlation between physical activity time per week and annualized bleeding rate (ABR)|Repeated measure correlation between physical activity time per week and joint annualized bleeding rate (JABR)|Association between physical activity time per week and PRO-scores for treatment satisfaction|Association between physical activity time per week and PRO-scores for health-related life quality|Association between physical activity time per week and PRO-scores for work productivity/ activity impairment|Percentage of children with ≥60 min per day of moderate to vigorous physical activity|Percentage of adults with ≥150 min per week of moderate to vigorous physical activity or with ≥75 min per week of vigorous physical activity|Time of physical activity per week (wear-time adjusted) by subgroup|Category of physical activity by subgroup|Sleeping time per week|Awake time per week|Percentage of sleeping time|Percentage of awake time|Actual wear time per week|Percentage of actual wear time per day","Bayer","All","Child, Adult, Older Adult",,"80","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","20748","January 31, 2020","June 30, 2027","June 30, 2027","September 16, 2019",,"January 18, 2020",,,"https://ClinicalTrials.gov/show/NCT04091386"
19,"NCT04085458","Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophila A (Post-marketing Investigation)",,"Recruiting","No Results Available","Hemophilia A","Drug: Damoctocog alfa pegol (Jivi, BAY94-9027)","FVIII inhibitor development by the Nijmegen Bethesda assay|Number of participants with treatment-emergent adverse events (TEAEs)|Development of treatment-emergent anti-PEG antibodies|Annualized bleeding rate (ABR)","Bayer","Male","18 Years and older   (Adult, Older Adult)","Phase 4","27","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19764|2018-003655-37","September 23, 2019","May 11, 2022","June 8, 2022","September 11, 2019",,"January 10, 2020","UMHAT Tsaritsa Joanna-ISUL EAD Sofia, Sofia, Bulgaria|MHAT Sveta Marina EAD, Varna, Bulgaria|Aarhus Universitetshospital, Skejby, Arhus N, Denmark|Laiko General Hospital of Athens (Sevastoupoleos), Athens, Greece|A.O. Pugliese-Ciaccio, Catanzaro, Calabria, Italy|A.O.U. Policlinico Umberto I, Roma, Lazio, Italy|Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Lazio, Italy|Oslo Universitetssykehus HF, Rikshospitalet, Oslo, Norway|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|SP Szpital Kliniczny Nr 1, Wroclaw, Poland|Ciutat Sanitària i Universitaria de la Vall d'Hebron, Barcelona, Spain|Hospital Universitario ""La Paz"", Madrid, Spain|Hospital Universitari i Politècnic La Fe, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT04085458"
20,"NCT04081831","Effectiveness of Low Dose Aspirin in Decreasing the Chance Getting Stomach and Intestine Cancer","ENgAGE-HK","Active, not recruiting","No Results Available","Gastrointestinal Cancer","Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)","Incidence rate ratio of colorectal cancer among users of low-dose-aspirin (exposed) and users of paracetamol monotherapy (non-exposed)|Incidence rate ratio of gastric cancer among users of low-dose-aspirin (exposed) and users of paracetamol monotherapy (non-exposed)|Incidence rate ratio of esophageal cancer among users of low-dose-aspirin (exposed) and users of paracetamol monotherapy (non-exposed)|Duration of aspirin use|Risk of colorectal, gastric and esophageal cancer after discontinuation of aspirin use|Case-fatality and survival rate","Bayer","All","40 Years and older   (Adult, Older Adult)",,"99999","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","20319","July 31, 2019","April 30, 2020","April 30, 2020","September 9, 2019",,"January 22, 2020","Multiple Locations, Multiple Locations, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04081831"
21,"NCT04069026","A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer",,"Recruiting","No Results Available","Advanced Solid Tumors","Drug: BAY2416964","The incidence of treatment emergent adverse events (TEAEs) including treatment-emergent serious adverse events (TESAEs) and and dose-limiting toxicities (DLTs)|Severity of treatment emergent adverse events (TEAEs) including treatment-emergent serious adverse events (TESAEs) and dose-limiting toxicities (DLTs)|Maximum tolerated dose (MTD) or maximum administered dose (MAD) of BAY2416964|Recommended Phase II dose (RP2D) of BAY2416964|Maximal plasma exposure (Cmax) for once daily (QD) dosing of BAY 2416964 after single-dose and multiple-dose in Cycle 1.|Area under the curve [AUC (0 - 24)] for QD dosing of BAY 2416964 after single-dose in Cycle 1.|Alternatively AUC(0-12) for 2 times daily (BID) dosing after single dose in cycle 1 (based on outcome of PK decision point)|AUC(0-12) after multiple dose|Objective response rate (ORR) by RECIST 1.1|Change from baseline in AhR target gene expression in whole blood after ex-vivo stimulation|Cytokine measurements, e.g. IL-6 (immunoassay), in whole blood after ex-vivo stimulation.","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","114","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20201|2019-000722-22","August 15, 2019","November 21, 2022","February 13, 2023","August 28, 2019",,"January 6, 2020","Yale University School of Medicine, New Haven, Connecticut, United States|Greenville Health System, Greenville, South Carolina, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States|Universitätsklinikum Heidelberg, Heidelberg, Baden-Württemberg, Germany|Royal Marsden NHS Trust (Surrey), Sutton, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04069026"
22,"NCT04067583","A Follow-up Physician Survey to Evaluate Physician Knowledge of Safety and Safe Use Information for Aflibercept Administered by Intravitreal Injection in Europe",,"Recruiting","No Results Available","Ophthalmology, Macular Degeneration","Other: Physician questionnaire","Percentage of physicians responding correctly to each individual knowledge question","Bayer","All","Child, Adult, Older Adult",,"400","Industry","Observational","Observational Model: Other|Time Perspective: Prospective","20285","October 8, 2019","June 30, 2020","September 1, 2020","August 26, 2019",,"January 22, 2020","Many locations, Multiple Locations, Germany",,"https://ClinicalTrials.gov/show/NCT04067583"
23,"NCT04065581","Bioequivalence Study for Acarbose/Metformin FDC",,"Active, not recruiting","No Results Available","Diabetes Mellitus, Type 2","Drug: Acarbose/Metformin FDC(BAY81-9783)|Drug: Glucobay|Drug: Glucophage","RatioCmax (serum glucose)|RatioAUC(0-4) (serum glucose)|Cmax (plasma metformin)|AUC (0-tlast) (plasma metformin)|AUC (plasma metformin)|Frequency of TEAE (treatment-emergent adverse event）","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","19843","October 14, 2019","November 25, 2019","March 31, 2020","August 22, 2019",,"January 6, 2020","Zhongshan Hospital, Fudan University, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04065581"
24,"NCT04059900","Study in Patients Suffering From Heartburn and Backward Flow of Stomach Liquid Into the Esophagus",,"Completed","No Results Available","Functional Gastrointestinal Disorders","Drug: STW5 (Iberogast®, BAY98-7411)|Drug: Placebo","AUC of Patients' assessment of gastrointestinal symptoms evaluated by a daily measured VAS scale.|Global Subject Outcome Assessment at visit 5|Change of the Gastrointestinal Symptoms Profile (GIS) from baseline (visit 3) at the end of study (day 28)|AUC of reflux symptoms assessment measured by daily VAS scale|Quality of Life evaluation as assessed by Functional Dyspepsia Quality of Life (FDDQL)|Relative time with an esophageal pH < 4 during 24 hours of measurement by Bravo™ pH system|Relative time with an esophageal pH < 4 during 24 hours of measurement using intraluminal impedance|Calculation of the DeMeester Score measured based on Bravo™ pH system|System index measurement in parallel to the pH measurement by Bravo™ pH system|Calculation of the DeMeester Score based on intraluminal impedance|Bolus exposition time in minutes and as percentual part of measurement time for acid reflux, non-acid reflux and total (acid and non-acid) reflux using intraluminal impedance|Symptom index measurement in parallel to the pH measurement by intraluminal impedance|Global assessment of efficacy judged by patient using a five point Likert scale|Global assessment of efficacy judged by physician using a five point Likert scale|Change of Individual symptom score from baseline at the end of study (day 28)","Bayer","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","64","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","20985|2008-002305-40","June 18, 2009","May 3, 2013","May 3, 2013","August 16, 2019",,"September 19, 2019","Many locations, Multiple Locations, Germany",,"https://ClinicalTrials.gov/show/NCT04059900"
25,"NCT04059783","Study to Learn More About the Onset of Effect of Iberogast in Patients Suffering From Abnormal Stomach and Intestine Function",,"Completed","No Results Available","Functional Gastrointestinal Disorders","Drug: STW5 (Iberogast®, BAY98-7411)","Change of GIS score from baseline up to 3 weeks after treatment|Global assessment by the physicians using a 4-point likert scale|Global assessment by the patient using a 4-point likert scale|Change of ratings of symptom severity on a 100-mm visual analogue scale (VAS) over time after intake of Iberogast|Onset of improvement assessed by patient on day 1|Onset of improvement assessed by patient on day 2|Onset of improvement assessed by patient on day 3|Onset of improvement assessed by patient on day 4|Onset of improvement assessed by patient on day 5|Onset of improvement assessed by patient on day 6|Onset of improvement assessed by patient on day 7|Onset of improvement assessed by patient on day 8|The number of participants with adverse events|The number of participants who discontinued from treatment|The number of participants with the need of further treatment","Bayer","All","18 Years and older   (Adult, Older Adult)",,"272","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","20984","June 17, 2008","April 27, 2010","February 20, 2011","August 16, 2019",,"September 19, 2019","Many locations, Multiple Locations, Germany",,"https://ClinicalTrials.gov/show/NCT04059783"
26,"NCT04029376","Study to Learn More About the Stomach and Intestine Complaints of Children Aged From 3 to 14 Years",,"Completed","No Results Available","Functional Gastrointestinal Disorders","Drug: Iberogast®","Gastrointestinal Symptoms Profile (GIS) Score|Global Assessment of the Efficacy by the Physicians|Global Assessment of the Efficacy by the Children or Their Parents|Lost Attendance days|Global Assessment of the Tolerability by the Physician|The number of subjects with adverse events","Bayer","All","3 Years to 14 Years   (Child)",,"1032","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","20983","April 1, 2007","October 1, 2008","October 1, 2008","July 23, 2019",,"September 19, 2019","Many locations, Multiple Locations, Germany",,"https://ClinicalTrials.gov/show/NCT04029376"
27,"NCT04027192","Study to Test the Safety of Increasing Multiple Doses of BAY2328065 Given by Mouth, How the Drug is Tolerated and Acts in the Human Body of Healthy Male Participants. Alteration of the Study Drug Effects by Another Drug and the Availability of the Drug Given in Different Formulations is Also Tested.",,"Recruiting","No Results Available","Endometriosis","Drug: BAY2328065 LSF|Drug: BAY2328065 tablet|Drug: Placebo LSF|Drug: Placebo tablet|Drug: Midazolam","Number of subjects with treatment-emergent adverse events (TEAEs)|Severity of TEAEs|AUC(0-12)md (twice daily [BID])|Cmax,md of BAY2328065","Bayer","Male","18 Years to 50 Years   (Adult)","Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","19251|2019-000940-90","July 31, 2019","May 5, 2020","July 3, 2020","July 19, 2019",,"January 18, 2020","CRS Clinical Research Services Berlin GmbH, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT04027192"
28,"NCT04015492","Study to Compare How the Body Distributes and Excretes the Drugs Jivi (BAY 94-9027) and Adynovi in Patients With Severe Hemophilia A (Bleeding Disorder Resulting From a Lack of Blood Clotting Factor VIII)",,"Active, not recruiting","No Results Available","Hemophilia A","Biological: Damoctocog-alfa-pegol (BAY94-9027, Jivi)|Biological: Rurioctocog alfa pegol (Adynovi)","Area under the concentration versus time curve from time 0 to the last data point (AUC(0-tlast)) for BAY 94-9027|Area under the concentration versus time curve from time 0 to the last data point (AUC(0-tlast)) for Adynovi","Bayer","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19742|2018-000507-16","August 8, 2019","October 25, 2019","January 29, 2020","July 11, 2019",,"January 18, 2020","SHATHD Spec. Hospi. for Active Treatm. of Haematol. Dis. EAD, Sofia, Bulgaria",,"https://ClinicalTrials.gov/show/NCT04015492"
29,"NCT04015180","Extension Study to Evaluate the Long-term Outcomes of Subjects in Study 20090","FIREFLEYE next","Not yet recruiting","No Results Available","Retinopathy of Prematurity (ROP)","Drug: Eylea (Aflibercept, BAY86-5321)|Procedure: Laser photocoagulation","Binocular best-corrected visual acuity in Snellen equivalent|Proportion of subjects with ocular AEs and SAEs|Proportion of subjects with systemic AEs and SAEs|Proportion of subjects developing unfavorable ocular structural outcome|Proportion of subjects with absence of active ROP and unfavorable structural outcomes|Best-corrected visual acuity in each eye|Refractive spherical equivalent in each eye|Neurodevelopmental outcomes using BSID-III|Neurodevelopmental outcomes using WPPSI-IV|Neurodevelopmental outcomes using VABS-II|Proportion of subjects with recurrence of ROP|Proportion of subjects requiring treatment for ROP|Proportion of subjects requiring ophthalmological treatment","Bayer","All","up to 13 Months   (Child)","Phase 3","100","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","20275","March 4, 2020","May 15, 2025","May 15, 2025","July 10, 2019",,"January 22, 2020","Hospital de Niños Sor María Ludovica, La Plata, Buenos Aires, Argentina|Hospital Maternal Nuestra Señora del Pilar, Pilar, Buenos Aires, Argentina|Inst. de Mater. y Gineco. Nuestra Señora de las Mercedes, San MIguel de Tucumán, Tucuman, Argentina|Hospital Público Descentralizado ""Dr. Guillermo Rawson"", San Juan, Argentina|Sanatorio Argentino, San Juan, Argentina|Klinikum Klagenfurt am Wörthersee, Klagenfurt, Kärnten, Austria|Medizinische Universität Graz, Graz, Steiermark, Austria|Kepler Universitätsklinikum Campus III, Linz, Austria|Allgemeines Krankenhaus der Stadt Wien, Wien, Austria|AZ St-Jan Brugge Oostende AV, Brugge, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital das Clínicas de Botucatu - UNESP Botucatu, Botucatu, Sao Paulo, Brazil|Hospital Municipal Vila Santa Catarina, São Paulo, Sao Paulo, Brazil|Unifesp/Epm, Sao Paulo, Brazil|UMHAT Sveti Georgi, Plovdiv, Bulgaria|Acibadem City Clinic Multiprofile Hospital for Active Treatm, Sofia, Bulgaria|Spec. Hospital of Ophthalm. for Active Treatment Visus, Sofia, Bulgaria|Spec. Hosp. of Ophthalm. Disease for Active Treatment Varna, Varna, Bulgaria|IWK Health Centre, Halifax, Nova Scotia, Canada|Hospital for Sick Children, Toronto, Ontario, Canada|Fakultni nemocnice Ostrava, Ostrava, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia|East Tallinn Central Hospital, Tallinn, Estonia|Klinikum der Ernst-Moritz-Arndt-Universität, Greifswald, Mecklenburg-Vorpommern, Germany|Medizinische Einrichtungen der Universität Bonn, Bonn, Nordrhein-Westfalen, Germany|Universitätsklinikum Köln, Köln, Nordrhein-Westfalen, Germany|St. Franziskus-Hospital GmbH, Münster, Nordrhein-Westfalen, Germany|Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Sachsen, Germany|Eberhard-Karls-Universität Tübingen, Tübingen, Germany|P & A Kyriakou Children's Hospital, Athens, Greece|University General Hospital of Ioannina, Ioannina, Greece|Papageorgiou General Hospital of Thessaloniki, Thessaloniki, Greece|EKBC, Uj Szent Janos Korhaz es Szakrendelo, Budapest, Hungary|Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary|Rambam Health Corporation, Haifa, Israel|Hadassah Hebrew University Hospital Ein Kerem, Jerusalem, Israel|Clalit Health Services Schneider Children's Medical Center, Petach Tikva, Israel|Kaplan Medical Center, Rehovot, Israel|Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel|Shamir Medical Center (Assaf Harofeh), Zerifin, Israel|IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Lazio, Italy|Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Lazio, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Lombardia, Italy|A.O. di Perugia, Perugia, Umbria, Italy|A.O.U.I. Verona, Verona, Veneto, Italy|Nagoya University Hospital, Nagoya, Aichi, Japan|Fujita Health University Hospital, Toyoake, Aichi, Japan|Juntendo University Urayasu Hospital, Urayasu, Chiba, Japan|Tokyo Women's Medical University Yachiyo Medical Center, Yachiyo, Chiba, Japan|University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan|Kurume University Hospital, Kurume, Fukuoka, Japan|Sapporo City General Hospital, Sapporo, Hokkaido, Japan|Yokohama City University Medical Center, Yokohama, Kanagawa, Japan|Nara Medical University Hospital, Kashihara, Nara, Japan|Okinawa Prefectural Nanbu Medical Center and Children's MC, Shimajiri-gun, Okinawa, Japan|Shiga University of Medical Science Hospital, Otsu, Shiga, Japan|Hamamatsu University Hospital, Hamamatsu, Shizuoka, Japan|Tokyo Metropolitan Children's Medical Center, Fuchu, Tokyo, Japan|Toho University Omori Medical Center, Ota-ku, Tokyo, Japan|National Center for Child Health and Development, Setagaya, Tokyo, Japan|Showa University East Hospital, Shinagawa-ku, Tokyo, Japan|Showa University Hospital, Shinagawa, Tokyo, Japan|Tokyo Metropolitan Bokutoh Hospital, Sumida-ku, Tokyo, Japan|Tokyo Metropolitan Ohtsuka Hospital, Toshima-ku, Tokyo, Japan|Kyushu University Hospital, Fukuoka, Japan|Fukuoka University Hospital, Fukuoka, Japan|Fukushima Medical University Hospital, Fukushima, Japan|Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan|Saitama Children's Medical Center, Saitama, Japan|Soon Chun Hyang University Cheonan Hospital, Cheonan-si, Chungcheongnamdo, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Children's Clinical University Hospital, Riga, Latvia|Lithuanian university of Health science, Kaunas, Lithuania|Hospital Kuala Lumpur, Kuala Lumpur, Malaysia|University Hospital Kebangsaan Malaysia, Kuala Lumpur, Malaysia|Maxima Medisch Centrum, locatie Veldhoven, Veldhoven, Netherlands|Ginekologiczno-Polozniczy SK UM im. K. Marcinkowskiego, Poznan, Poland|Hospital Prof. Dr. Fernando Fonseca, Amadora, Lisboa, Portugal|Hospital Beatriz Angelo, Loures, Lisboa, Portugal|ULSM - Hospital Pedro Hispano, Matosinhos, Porto, Portugal|CHLO - Hospital Sao Francisco Xavier, Lisboa, Portugal|CHUP - Hospital Santo Antonio, Porto, Portugal|Clinical Emergency County Hospital, Cluj-Napoca, Cluj, Romania|Emergency Clinical City Hospital Timisoara, Timisoara, Timis, Romania|Spitalul Clinic de Obstretica si Ginecologie ""Cuza Voda"", Iasi, Romania|FSAI NMRC IRTC ""Eye Microsurgery"", Kaluga's Branch, Kaluga, Russian Federation|Russian National Scientific Medical University, Moscow, Russian Federation|FGBUZ ""NPC of special children care n.a. Voino-Yaseneckogo"", Moscow, Russian Federation|FBSI IRTC Eye Microsurgery n.a. acad. S.N. Fyodorov, Moscow, Russian Federation|Pediatric Medical University, Saint-Petersburg, Russian Federation|City Children Hospital ¿1, Saint-Petersburg, Russian Federation|KK Women's and Children's Hospital, Singapore, Singapore|Narodny ustav detskych chorob, Bratislava, Slovakia|Hospital de Sant Joan de Déu, Esplugues de LLobregat, Barcelona, Spain|Hospital Universitari Son Espases, Palma de Mallorca, Illes Baleares, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario ""La Paz"", Madrid, Spain|Hospital Regional de Málaga, Málaga, Spain|Sahlgrenska Universitetssjukhuset, Göteborg, Sweden|Lunds Universitetssjukhus, Lund, Sweden|S:t Eriks Ögonsjukhus, Stockholm, Sweden|Karolinska Universitetssjukhuset Huddinge Stockholm, Stockholm, Sweden|Inselspital Universitätsspital Bern, Bern, Switzerland|Luzerner Kantonsspital, Luzern, Switzerland|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|Mackay Memorial Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan|S.B.U. Adana Sehir Egitim ve Arastirma Hastanesi, Adana, Turkey|Hacettepe Universitesi Tip Fakultesi, Ankara, Turkey|Baskent Universitesi Tip Fakultesi Hastanesi, Ankara, Turkey|Gazi Universitesi Tip Fakultesi, Ankara, Turkey|Saglik Bilimleri Universitesi Antalya EA Hastanesi, Antalya, Turkey|Eskisehir Osmangazi Universitesi Tip Fakultesi, Eskisehir, Turkey|Acibadem Saglik Hizmetleri ve Tic. A.S, Istanbul, Turkey|National Pediatric Specialized Hospital ""Okhmatdyt"", Kyiv, Ukraine|The Filatov Institute of Eye Diseases and Tissue Therapy, Odesa, Ukraine|Birmingham Womens Hospital, Birmingham, United Kingdom|University of Manchester, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04015180"
30,"NCT04004208","Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy","FIREFLEYE","Recruiting","No Results Available","Retinopathy of Prematurity (ROP)","Drug: Eylea (Aflibercept, BAY86-5321)|Procedure: Laser photocoagulation","Proportion of patients with absence of active ROP and unfavorable structural outcomes|Number of requirement for intervention with a second treatment modality|Recurrence of ROP|To explore new Retinopathy of Prematurity Activity Scale proposed by the International Neonatal Consortium|Number of aflibercept administrations|Number of laser treatments|Proportion of participants with ocular TEAEs and SAEs|Proportion of participants with systemic TEAEs and SAEs|Systemic exposure to free aflibercept (at expected maximum plasma concentration and during elimination period from plasma) determined by sparse sampling|Presence of anti-drug antibodies","Bayer","All","up to 32 Weeks   (Child)","Phase 3","113","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20090|2018-002611-99","September 25, 2019","January 15, 2021","January 15, 2021","July 1, 2019",,"January 22, 2020","Hospital de Niños Sor María Ludovica, La Plata, Buenos Aires, Argentina|Hospital Maternal Nuestra Señora del Pilar, Pilar, Buenos Aires, Argentina|Inst. de Mater. y Gineco. Nuestra Señora de las Mercedes, San MIguel de Tucumán, Tucuman, Argentina|Hospital Público Descentralizado ""Dr. Guillermo Rawson"", San Juan, Argentina|Sanatorio Argentino, San Juan, Argentina|Klinikum Klagenfurt am Wörthersee, Klagenfurt, Kärnten, Austria|Medizinische Universität Graz, Graz, Steiermark, Austria|Kepler Universitätsklinikum Campus III, Linz, Austria|Allgemeines Krankenhaus der Stadt Wien, Wien, Austria|AZ St-Jan Brugge Oostende AV, Brugge, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital das Clínicas de Botucatu - UNESP Botucatu, Botucatu, Sao Paulo, Brazil|Hospital Municipal Vila Santa Catarina, São Paulo, Sao Paulo, Brazil|Unifesp/Epm, Sao Paulo, Brazil|UMHAT Sveti Georgi, Plovdiv, Bulgaria|Acibadem City Clinic Multiprofile Hospital for Active Treatm, Sofia, Bulgaria|II SOGHAT Sheinovo, Sofia, Bulgaria|SHOGAT Prof Dimitar Stamatov, Varna, Bulgaria|IWK Health Centre, Halifax, Nova Scotia, Canada|Hospital for Sick Children, Toronto, Ontario, Canada|Fakultni nemocnice Ostrava, Ostrava, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia|Tallinn Children´s Hospital, Tallinn, Estonia|Hôpital Pellegrin - Bordeaux, Bordeaux, France|Hôpital Arnaud de Villeneuve - Montpellier, Montpellier, France|Fondation A. de Rotschild - Paris, Paris Cedex 19, France|Hopital Necker les enfants malades - Paris, Paris, France|Klinikum der Ernst-Moritz-Arndt-Universität, Greifswald, Mecklenburg-Vorpommern, Germany|Medizinische Einrichtungen der Universität Bonn, Bonn, Nordrhein-Westfalen, Germany|Universitätsklinikum Köln, Köln, Nordrhein-Westfalen, Germany|Augenzentrum am St. Franziskus-Hospital, Münster, Nordrhein-Westfalen, Germany|Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Sachsen, Germany|Eberhard-Karls-Universität Tübingen, Tübingen, Germany|P & A Kyriakou Children's Hospital, Athens, Greece|University General Hospital of Ioannina, Ioannina, Greece|Papageorgiou General Hospital of Thessaloniki, Thessaloniki, Greece|EKBC, Uj Szent Janos Korhaz es Szakrendelo, Budapest, Hungary|Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary|Rambam Health Corporation, Haifa, Israel|Hadassah University Hospital Mount Scopus, Jerusalem, Israel|Clalit Health Services Schneider Children's Medical Center, Petach Tikva, Israel|Kaplan Medical Center, Rehovot, Israel|Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel|Shamir Medical Center (Assaf Harofeh), Zerifin, Israel|IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Lazio, Italy|Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Lazio, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Lombardia, Italy|A.O. di Perugia, Perugia, Umbria, Italy|A.O.U.I. Verona, Verona, Veneto, Italy|Nagoya University Hospital, Nagoya, Aichi, Japan|Fujita Health University Hospital, Toyoake, Aichi, Japan|Juntendo University Urayasu Hospital, Urayasu, Chiba, Japan|Tokyo Women's Medical University Yachiyo Medical Center, Yachiyo, Chiba, Japan|University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan|Kurume University Hospital, Kurume, Fukuoka, Japan|Sapporo City General Hospital, Sapporo, Hokkaido, Japan|Yokohama City University Medical Center, Yokohama, Kanagawa, Japan|Nara Medical University Hospital, Kashihara, Nara, Japan|Okinawa Prefectural Nanbu Medical Center and Children's MC, Shimajiri-gun, Okinawa, Japan|Shiga University of Medical Science Hospital, Otsu, Shiga, Japan|Hamamatsu University Hospital, Hamamatsu, Shizuoka, Japan|Tokyo Metropolitan Children's Medical Center, Fuchu, Tokyo, Japan|Toho University Omori Medical Center, Ota-ku, Tokyo, Japan|National Center for Child Health and Development, Setagaya, Tokyo, Japan|Showa University East Hospital, Shinagawa-ku, Tokyo, Japan|Showa University Hospital, Shinagawa, Tokyo, Japan|Tokyo Metropolitan Bokutoh Hospital, Sumida-ku, Tokyo, Japan|Tokyo Metropolitan Ohtsuka Hospital, Toshima-ku, Tokyo, Japan|Kyushu University Hospital, Fukuoka, Japan|Fukuoka University Hospital, Fukuoka, Japan|Fukushima Medical University Hospital, Fukushima, Japan|Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan|Saitama Children's Medical Center, Saitama, Japan|Soon Chun Hyang University Cheonan Hospital, Cheonan-si, Chungcheongnamdo, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Children's Clinical University Hospital, Riga, Latvia|Lithuanian university of Health science, Kaunas, Lithuania|Hospital Kuala Lumpur, Kuala Lumpur, Malaysia|University Hospital Kebangsaan Malaysia, Kuala Lumpur, Malaysia|Maxima Medisch Centrum, locatie Veldhoven, Veldhoven, Netherlands|Ginekologiczno-Polozniczy SK UM im. K. Marcinkowskiego, Poznan, Poland|Hospital Prof. Dr. Fernando Fonseca, Amadora, Lisboa, Portugal|Hospital Beatriz Angelo, Loures, Lisboa, Portugal|ULSM - Hospital Pedro Hispano, Matosinhos, Porto, Portugal|Hospital Garcia de Orta, Almada, Setúbal, Portugal|CHLO - Hospital Sao Francisco Xavier, Lisboa, Portugal|CHUP - Hospital Santo Antonio, Porto, Portugal|Clinical Emergency County Hospital, Cluj-Napoca, Cluj, Romania|Emergency Clinical City Hospital Timisoara, Timisoara, Timis, Romania|Spitalul Clinic de Obstretica si Ginecologie ""Cuza Voda"", Iasi, Romania|FSAI NMRC IRTC ""Eye Microsurgery"", Kaluga's Branch, Kaluga, Russian Federation|Russian National Scientific Medical University, Moscow, Russian Federation|FGBUZ ""NPC of special children care n.a. Voino-Yaseneckogo"", Moscow, Russian Federation|FBSI IRTC Eye Microsurgery n.a. acad. S.N. Fyodorov, Moscow, Russian Federation|Pediatric Medical University, Saint-Petersburg, Russian Federation|City Children Hospital ¿1, Saint-Petersburg, Russian Federation|KK Women's and Children's Hospital, Singapore, Singapore|Narodny ustav detskych chorob, Bratislava, Slovakia|Hospital de Sant Joan de Déu, Esplugues de LLobregat, Barcelona, Spain|Hospital Universitari Son Espases, Palma de Mallorca, Illes Baleares, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario ""La Paz"", Madrid, Spain|Hospital Regional de Málaga, Málaga, Spain|Sahlgrenska Universitetssjukhuset, Göteborg, Sweden|Lunds Universitetssjukhus, Lund, Sweden|S:t Eriks Ögonsjukhus, Stockholm, Sweden|Karolinska Universitetssjukhuset Huddinge Stockholm, Stockholm, Sweden|Inselspital Universitätsspital Bern, Bern, Switzerland|Luzerner Kantonsspital, Luzern, Switzerland|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|Mackay Memorial Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan|S.B.U. Adana Sehir Egitim ve Arastirma Hastanesi, Adana, Turkey|Hacettepe Universitesi Tip Fakultesi, Ankara, Turkey|Baskent Universitesi Tip Fakultesi Hastanesi, Ankara, Turkey|Gazi Universitesi Tip Fakultesi, Ankara, Turkey|Saglik Bilimleri Universitesi Antalya EA Hastanesi, Antalya, Turkey|Eskisehir Osmangazi Universitesi Tip Fakultesi, Eskisehir, Turkey|Acibadem Saglik Hizmetleri ve Tic. A.S, Istanbul, Turkey|National Pediatric Specialized Hospital ""Okhmatdyt"", Kyiv, Ukraine|MI""Odesa Regional Children's Clinical Hospital"", Odesa, Ukraine|Birmingham Womens Hospital, Birmingham, United Kingdom|Manchester Eye Hospital, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04004208"
31,"NCT04004195","Study to Investigate Safety, Absorption, Elimination, and Drug Effect of BAY2327949 in Participants With Different Renal Function Status",,"Recruiting","No Results Available","Pharmacokinetics","Drug: BAY2327949","Cmax of BAY2327949|AUC of BAY2327949|Cmax,u of BAY2327949|AUCu of BAY2327949|Frequency and nature of treatment-emergent adverse events|Urinary volume|Fluid balance","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","32","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","19224|2019‐000630‐19","July 10, 2019","February 7, 2020","April 29, 2020","July 1, 2019",,"January 2, 2020","APEX GmbH, München, Bayern, Germany|CRS Clinical-Research-Services Kiel GmbH, Kiel, Schleswig-Holstein, Germany",,"https://ClinicalTrials.gov/show/NCT04004195"
32,"NCT03996486","Study to Test the Safety of an Investigational Drug Given Repeatedly to Adult Men With Severe Hemophilia",,"Withdrawn","No Results Available","Hemophilia","Drug: BAY1093884","Frequency of drug-related adverse events|Frequency of drug-related serious adverse events|Frequency of adverse events of special interest","Bayer","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","0","Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Other","20414|2018-004566-34","October 28, 2019","May 29, 2020","July 31, 2020","June 24, 2019",,"October 22, 2019",,,"https://ClinicalTrials.gov/show/NCT03996486"
33,"NCT03996473","Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases",,"Not yet recruiting","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Radium-223 dichloride (Xofigo, BAY 88-8223)|Drug: Pembrolizumab","Number of participants with adverse events (AEs) in Phase 1|Number of participants with dose limiting toxicities (DLTs) in Phase 1|Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 in Phase 2|ORR per RECIST v1.1 in Phase 1|ORR per iRECIST in Phase 1|Duration of response (DOR) per RECIST v1.1 in Phase 1|DOR per iRECIST in Phase 1|Disease control rate (DCR) per RECIST v1.1 in Phase 1|DCR per iRECIST in Phase 1|ORR per iRECIST in Phase 2|DOR per RECIST v1.1 in Phase 2|DOR per iRECIST in Phase 2|DCR per RECIST v1.1 in Phase 2|DCR per iRECIST in Phase 2|Progression free survival (PFS) per RECIST v1.1 in Phase 2|PFS per iRECIST in Phase 2|Overall survival (OS) in Phase 2|Number of participants with AE in Phase 2","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","164","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19781|2018-003704-39","January 20, 2020","April 8, 2023","February 3, 2025","June 24, 2019",,"January 21, 2020","UZ Brussel, Bruxelles - Brussel, Belgium|UZ Gent, Gent, Belgium|CHU de Liège, Liege, Belgium|CHU UCL Namur, Namur, Belgium|Universitätsklinikum der Johann Wolfgang Goethe Universität, Frankfurt, Hessen, Germany|Medizinische Einrichtungen der Universität Bonn, Bonn, Nordrhein-Westfalen, Germany|Kliniken der Stadt Köln - Städt. Krankenhaus Köln-Merheim, Köln, Nordrhein-Westfalen, Germany|Krankenhaus Grosshansdorf, Grosshansdorf, Germany|Edith Wolfson Medical Center, Holon, Israel|Meir Medical Center, Kfar Saba, Israel|Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel|Institut Català d'Oncologia Badalona, Badalona, Barcelona, Spain|Hospital Universitario Clinica Puerta de Hierro, Majadahonda, Madrid, Spain|Ciutat Sanitària i Universitaria de la Vall d'Hebron, Barcelona, Spain|Hospital Clínic i Provincial de Barcelona, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Leeds teaching Hospitals, Leeds, West Yorkshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03996473"
34,"NCT03965741","Study to Gather Information How Often Venous Thromboembolism Occurs in Prostate Cancer Patients in Sweden and How This Condition is Treated With Blood Thinners","PRACTISE","Active, not recruiting","No Results Available","Venous Thromboembolism (VTE)","Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Apixaban(Eliquis)|Drug: Pradaxa (Dabigatran etexilate)","Subject's socio-demographic at the date of an incident PCa diagnosis|Subject's clinical characteristics at the date of an incident PCa diagnosis|Incidence rate of cancer-related VTE|Cancer therapies in PCa at the initial time after diagnosis|Choice of drug|Duration of treatment|Occurrence of recurrent VTE events|Time between a first cancer-related and a recurrent VTE event|Incidence rates of post-VTE bleeding events leading to hospitalization, and mortality by anticoagulation treatment|Subject's socio-demographic at the time of inclusion into the database|Subject's clinical characteristics at the time of inclusion into the database|Incidence rate of VTE events","Bayer|Janssen Research & Development, LLC","Male","Child, Adult, Older Adult",,"99999","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","20653","May 30, 2019","January 31, 2020","January 31, 2020","May 29, 2019",,"January 2, 2020","Many locations, Multiple Locations, Sweden",,"https://ClinicalTrials.gov/show/NCT03965741"
35,"NCT03965728","Study to Investigate Safety, Tolerability, Pharmacokinetics, and Drug-drug Interaction of Multiple Oral Doses of BAY1830839 in Healthy Male Participants",,"Recruiting","No Results Available","Healthy Volunteers","Drug: BAY1830839|Drug: Placebo|Drug: Midazolam|Drug: Methotrexate","Frequency of TEAEs|Severity of TEAEs|AUC(0-24)md of BAY1830839 (QD dosing)|AUC(0-12)md of BAY1830839 (BID dosing only)|Cmax,md of BAY1830839 after multiple dosing|Cav of BAY1830839 after multiple dosing|AUC of midazolam in plasma in presence/absence of BAY1830839|Cmax of midazolam in plasma in presence/absence of BAY1830839|AUC of methotrexate in plasma in presence/absence of BAY1830839|Cmax of methotrexate in plasma in presence/absence of BAY1830839","Bayer","Male","18 Years to 50 Years   (Adult)","Phase 1","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","19401|2019-000632-26","June 5, 2019","July 15, 2020","August 15, 2020","May 29, 2019",,"January 21, 2020","Charité Research Organisation GmbH, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT03965728"
36,"NCT03939767","Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease","XTEND","Recruiting","No Results Available","Wet Age-related Macular Degeneration","Drug: Aflibercept (Eylea, BAY86-5321)","The change in BCVA (best corrected visual acuity)|The change in BCVA|The change in BCVA by intended treatment regimen|The proportion of patients (eyes) gaining or losing a visual acuity compared to baseline|The proportion of patients (eyes) achieving a Snellen equivalent of 20/40 or better|The changes in central retinal thickness (CRT)|The number of injections|The distribution of the intervals between injections","Bayer","All","50 Years and older   (Adult, Older Adult)",,"2000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","20359","May 12, 2019","May 15, 2023","August 15, 2023","May 7, 2019",,"January 21, 2020","Many Locations, Multiple Locations, Argentina|Many Locations, Multiple Locations, Australia|Many Locations, Multiple Locations, Belgium|Many Locations, Multiple Locations, Canada|Many Locations, Multiple Locations, China|Many Locations, Multiple Locations, Colombia|Many Locations, Multiple Locations, Denmark|Many Locations, Multiple Locations, France|Many Locations, Multiple Locations, Greece|Many Locations, Multiple Locations, Ireland|Many Locations, Multiple Locations, Italy|Many Locations, Multiple Locations, Korea, Republic of|Many Locations, Multiple Locations, Norway|Many Locations, Multiple Locations, Spain|Many Locations, Multiple Locations, Sweden|Many Locations, Multiple Locations, Switzerland|Many Locations, Multiple Locations, Thailand|Many Locations, Multiple Locations, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03939767"
37,"NCT03932201","Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A","HEM-POWR","Recruiting","No Results Available","Hemophilia A","Drug: Damoctocog alfa pegol (Jivi, Bay94-9027)","Mean annualized number of reported total bleeds in patients with hemophilia A|Median annualized number of reported total bleeds in patients with hemophilia A|Occurrence of AEs.|Duration of AEs.|Treatment of AEs.|Severity of AEs.|Outcome of AEs.|Number of infusions and FVIII consumption to achieve hemostasis during surgery|Change in joint scores (HJHS)|Joint status evaluation by ultrasound (HEAD-US score), if available or part of standard clinical practice.|Change of number of affected joints by patient|Annualized number of spontaneous, joint, and trauma bleeds.|Number of reported bleeds during the study compared with number of reported bleeds for previous FVIII products in the 12 months prior to enrollment into the study.|Proportion of patients with 0 bleeds, and the difference in proportion comparing to previous prophylaxis treatment.|Cmax for previous FVIII products versus damoctocog alfa pegol.|AUC for previous FVIII products versus damoctocog alfa pegol.|Half-life [t½] for previous FVIII products versus damoctocog alfa pegol.|FVIII trough for previous FVIII products versus damoctocog alfa pegol.|FVIII peak levels for previous FVIII products versus damoctocog alfa pegol.|In-vivo recovery for previous FVIII products versus damoctocog alfa pegol.|Date of bleeding event of treatment of break-through bleeds.|Reason for infusion and location of bleed of treatment of break-through bleeds.|Date of treatment of break-through bleeds.|Number of infusions and dose per infusion for each bleeding event of treatment of break-through bleeds.|Changes of Hemo-SAT A score|Changes of Hemo-QoL (A and SF) score|Changes of WPAI score","Bayer","All","Child, Adult, Older Adult",,"200","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","20002","October 21, 2019","June 30, 2025","September 30, 2025","April 30, 2019",,"January 22, 2020","University of South Alabama, Mobile, Alabama, United States|UC Davis, Davis, California, United States|Orthopaedic Hemophilia Treatment Center, Los Angeles, California, United States|Center for Inherited Blood Disorders, Orange, California, United States|University of Colorado, Aurora, Colorado, United States|Tulane University, New Orleans, Louisiana, United States|University of Minnesota, Minneapolis, Minnesota, United States|East Carolina University, Greenville, North Carolina, United States|Many locations, Multiple Locations, Austria|Many locations, Multiple Locations, Belgium|Many locations, Multiple Locations, Belgium|Many locations, Multiple Locations, Brazil|Many locations, Multiple Locations, Canada|Many locations, Multiple Locations, China|Many locations, Multiple Locations, Colombia|Many locations, Multiple Locations, Denmark|Many locations, Multiple Locations, France|Many locations, Multiple Locations, Germany|Many locations, Multiple Locations, Greece|Many locations, Multiple Locations, Italy|Many locations, Multiple Locations, Japan|Many locations, Multiple Locations, Kuwait|Many locations, Multiple Locations, Luxembourg|Many locations, Multiple Locations, Mexico|Many locations, Multiple Locations, Netherlands|Many locations, Multiple Locations, Norway|Many locations, Multiple Locations, Portugal|Many locations, Multiple Locations, Saudi Arabia|Many locations, Multiple Locations, Slovenia|Many locations, Multiple Locations, Spain|Many locations, Multiple Locations, Sweden|Many locations, Multiple Locations, Switzerland|Many locations, Multiple Locations, Taiwan|Many locations, Multiple Locations, United Arab Emirates",,"https://ClinicalTrials.gov/show/NCT03932201"
38,"NCT03929861","Bioequivalence Trial to Prove Equal Blood Concentrations of Two Different Fluconazole Formulations","Orca","Completed","No Results Available","Pharmacology, Clinical","Drug: Fluconazole (BAYT006267) 150 mg capsules|Drug: Fluconazole 150 mg capsules (DiflucanTM)","Cmax|AUC0-tlast|Number of participants with Adverse Events as a Measure of safety and tolerability|tmax|t½λz|MRT","Bayer","Male","18 Years to 50 Years   (Adult)","Phase 1","26","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","16165|2011-006159-13","July 31, 2012","September 10, 2012","September 10, 2012","April 29, 2019",,"April 29, 2019","Mannheim, Baden-Württemberg, Germany",,"https://ClinicalTrials.gov/show/NCT03929861"
39,"NCT03926143","A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies",,"Enrolling by invitation","No Results Available","Cancer","Drug: BAY94-9343 (Anetumab ravtansine)","Incidence of treatment-emergent adverse events (TEAEs)|Incidence of treatment-emergent serious adverse events (TESAEs)|Incidence of drug-related TEAEs|Incidence of drug-related TESAEs|Overall survival","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","20","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20322|2019-000061-20","June 3, 2019","October 31, 2024","October 31, 2024","April 24, 2019",,"January 18, 2020","University of Chicago, Chicago, Illinois, United States|National Cancer Institute, Bethesda, Maryland, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Mary Crowley Medical Research Center, Dallas, Texas, United States|Hôpital de la Timone - Marseille, Marseille, France|Szpital Wojewodzki W Szczecinie Zdunowie, Szczecin, Poland",,"https://ClinicalTrials.gov/show/NCT03926143"
40,"NCT03904732","Study to Develop a Prediction Model to Understand the Effect of Low-dose Aspirin on Cancer That Develops in the Colon and/or the Rectum, Diseases That Affects the Heart or Blood Vessels and Safety Outcomes in European Countries. The Study is Also Called PEACOS Model EU","PEACOCS","Active, not recruiting","No Results Available","Colorectal Cancer|Cardiovascular Disease|Bleeding","Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)","Number of myocardial infarction and ischaemic stroke|Number of death due to myocardial infarction or due to ischaemic stroke|Number of colorectal cancer (CRC)|Number of death due to CRC|Number of severe gastrointestinal (GI) bleeding requiring hospitalization|Number of intracranial hemorrhage (ICH)|Number of symptomatic peptic ulcers requiring hospitalization|Number of deaths due to any other cause","Bayer","All","50 Years to 69 Years   (Adult, Older Adult)",,"2000000","Industry","Observational","Observational Model: Other|Time Perspective: Other","20751","April 15, 2019","February 29, 2020","February 29, 2020","April 5, 2019",,"January 22, 2020","Mimicked Population, Mimicked Population, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03904732"
41,"NCT03901729","A Trial to Study BAY1753011 in Patients With Congestive Heart Failure","AVANTI","Recruiting","No Results Available","Heart Failure (HF)","Drug: BAY 1753011|Other: Placebo BAY 1753011|Drug: Furosemide|Other: Placebo Furosemide","PART A: Change in body weight|PART A: Change in serum creatinine|PART B: Change in body weight|PART B: Change in BUN/creatinine ratio|Incidence of Treatment-emergent adverse event (including Serious adverse event)|Change in augmentation index","Bayer","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","414","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","17909","May 29, 2019","June 16, 2020","July 21, 2020","April 3, 2019",,"January 18, 2020","Universitätsklinikum St. Pölten, St. Pölten, Niederösterreich, Austria|Krankenhaus St. Josef Braunau, Braunau, Oberösterreich, Austria|Krankenhaus der Elisabethinen Linz GmbH, Linz, Oberösterreich, Austria|Medizinische Universität Graz, Graz, Steiermark, Austria|Allgemeines Krankenhaus der Stadt Wien, Wien, Austria|Krankenhauses Nord - Klinik Floridsdorf, Wien, Austria|MHAT Haskovo, Haskovo, Bulgaria|Spec Hosp for Active Treatm in Cardiology Sv Georgi Pernik, Pernik, Bulgaria|Specialized Hospital for Actrive Treatm of Card - Pleven, Pleven, Bulgaria|UMHAT Dr. Georgi Stranski, Pleven, Bulgaria|Multiprofile Hospital for Active Treatment Medline Clinic, Plovdiv, Bulgaria|UMHAT Sveti Georgi, Plovdiv, Bulgaria|NMTH Tzar Boris III, Sofia, Bulgaria|V MHAT, Sofia, Bulgaria|UMHAT Tsaritsa Joanna-ISUL EAD Sofia, Sofia, Bulgaria|Herz- und Diabeteszentrum Nordrhein-Westfalen (HDZ NRW), Bad Oeynhausen, Nordrhein-Westfalen, Germany|Universitätsklinikum Essen, Essen, Nordrhein-Westfalen, Germany|Kliniken Maria Hilf GmbH, Mönchengladbach, Nordrhein-Westfalen, Germany|Forschungszentrum Ruhr - KliFoCenter GmbH, Witten, Nordrhein-Westfalen, Germany|St. Vincenz und Elisabeth Hospital, Kathol. Klinikum Mainz, Mainz, Rheinland-Pfalz, Germany|Charité Campus Virchow-Klinikum (CVK), Berlin, Germany|Albertinen-Krankenhaus gemeinnützige GmbH, Hamburg, Germany|KAT General Hospital of Athens, Kifisia / Athens, Attica, Greece|G. Gennimatas General State Hospital of Athens, Athens, Greece|University General Hospital of Athens ""ATTIKON"", Chaidari - Athens, Greece|University General Hospital of Ioannina, Ioannina, Greece|University General Hospital of Larissa, Larissa, Greece|Konstantopoulio General Hospital of Nea Ionia - Agia Olga, Nea Ionia / Athens, Greece|University General Hospital of Thessaloniki ""AHEPA"", Thessaloniki, Greece|Hippokration General Hospital of Thessaloniki, Thessaloniki, Greece|Allami Szivkorhaz, Balatonfured, Hungary|Budai Irgalmasrendi Korhaz, Budapest, Hungary|University of Semmelweis/ Semmelweis Egyetem, Budapest, Hungary|Magyar Honvedseg Egeszsegugyi Kozpont Honvedkorhaz, Budapest, Hungary|Kanizsai Dorottya Hospital, Nagykanizsa, Hungary|Josa Andras Hospital, Nyiregyhaza, Hungary|Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz, Szekesfehervar, Hungary|Tolna Megyei Balassa Janos Korhaz, Szekszard, Hungary|Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz, Szolnok, Hungary|Zala Megyei Szent Rafael Korhaz, Zalaegerszeg, Hungary|Barzilai Medical Center, Ashkelon, Israel|Soroka University Medical Center, Be'er Sheva, Israel|Rambam Health Corporation, Haifa, Israel|Hadassah Hebrew University Hospital Ein Kerem, Jerusalem, Israel|Health Corporation of Galilee Medical Center, Nahariya, Israel|Health Corporation of Galilee Medical Center, Nahariya, Israel|Chaim Sheba Medical Center, Ramat Gan, Israel|Kaplan Medical Center, Rehovot, Israel|Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel|Shamir Medical Center (Assaf Harofeh), Zrifin, Israel|A.O.U. di Ferrara Arcispedale S.Anna, Ferrara, Emilia-Romagna, Italy|AUSL della Romagna, Rimini, Emilia-Romagna, Italy|ASST Papa Giovanni XXIII, Bergamo, Lombardia, Italy|ASST Spedali Civili di Brescia, Brescia, Lombardia, Italy|IRCCS Centro Cardiologico Monzino, Milano, Lombardia, Italy|Fondazione Policlinico di Monza, Monza-Brianza, Lombardia, Italy|AUSL Toscana Sud-Est, Arezzo, Toscana, Italy|Fondazione Toscana Gabriele Monasterio (FTGM), Pisa, Toscana, Italy|A.O.U. Senese, Siena, Toscana, Italy|ULSS3 Serenissima, Venezia, Veneto, Italy|Uniwersytecki Szpital Kliniczny w Bialymstoku, Bialystok, Poland|10 Wojskowy Szpital Kliniczny z Poliklinika SPZOZ, Bydgoszcz, Poland|Szpital sw. Wincentego a Paulo, Gdynia, Poland|Samodzielny Publiczny Szpital Kliniczny Szpital Zachodni, Grodzisk Mazowiecki, Poland|Szpital Kliniczny Przemienienia Panskiego, Poznan, Poland|Szpital Wojewodzki Nr 2, Rzeszow, Poland|Uniwersyteckie Centrum Kliniczne Warszawskiego UM, Warszawa, Poland|Uniwersytecki Szpital Kliniczny UM we Wroclawiu, Wroclaw, Poland|Hospital de Cascais, Alcabideche, Lisboa, Portugal|CHLO - Hospital Santa Cruz, Carnaxide, Lisboa, Portugal|CHS - Hospital Sao Bernardo, Setubal, Setúbal, Portugal|CHL - Hospital Santo Andre, Leiria, Portugal|CHLO - Hospital Sao Francisco Xavier, Lisboa, Portugal|Hospital da Luz, Lisboa, Portugal|CHUP - Hospital Santo Antonio, Porto, Portugal|Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain|Hospital Álvaro Cunqueiro, Babio - Beade, Pontevedra, Spain|Hospital del Mar, Barcelona, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Hospital Universitari i Politècnic La Fe, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT03901729"
42,"NCT03901131","PROMES: A Clinical Study in Which Researchers Want to Learn More About the Safety Profile of MESIGYNA (Norethisterone Enantate 50 mg and Estradiol Valerate 5 mg) Used as a Medication to Prevent Pregnancy for Adult Women in Reproductive Age in the Peruvian Population at the Outpatient Clinic.","PROMES","Recruiting","No Results Available","Contraceptive","Drug: Norethisterone enantate/estradiol valerate (Mesigyna, BAY98-7040)","Frequency of Adverse Events|The number of injections|Frequency of using Mesigyna|Presence of Adverse events|Start and stop date of using Mesigyna|Does of using Mesigyna","Bayer","Female","18 Years to 45 Years   (Adult)",,"500","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","19243","August 26, 2019","December 1, 2019","October 1, 2020","April 3, 2019",,"November 20, 2019","Many locations, Multiple Locations, Peru",,"https://ClinicalTrials.gov/show/NCT03901131"
43,"NCT03896984","Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).","PHENIX","Active, not recruiting","No Results Available","Metastatic Castration-resistant Prostate Cancer (mCRPC)","Drug: Radium-223 (Xofigo, BAY88-8223)|Drug: Abiraterone|Drug: Enzalutamide","Overall survival (OS) from initiation of 2L therapy of Radium-223 in patients with mCRPC after 1L NAH therapy|Overall survival (OS) from initiation of 2L therapy of sequential NAH in patients with mCRPC after 1L NAH therapy|Descriptive analysis of patient demography at baseline|Descriptive analysis of clinical characteristics of patients at baseline|Descriptive analysis of lab values at baseline|Frequency of SSEs of Radium-223 versus Abiraterone or Enzalutamide after 2L|Incidence rate of SSEs of Radium-223 versus Abiraterone or Enzalutamide after 2L|Frequency of pathologic fracture of Radium-223 versus Abiraterone or Enzalutamide after 2L|Incidence rate of pathologic fracture of Radium-223 versus Abiraterone or Enzalutamide after 2L|Period of time from initiation of 2L to first SSE","Bayer","Male","Child, Adult, Older Adult",,"300","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","20526","March 18, 2019","March 31, 2020","March 31, 2020","April 1, 2019",,"January 13, 2020","US Flatiron prostate cancer database, Whippany, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03896984"
44,"NCT03890731","A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed",,"Enrolling by invitation","No Results Available","Solid Cancer","Drug: BAY73-4506 (Regorafenib, Stivarga)","Frequency of serious adverse events (SAEs)|Severity of serious adverse events (SAEs)|Frequency of protocol-defined adverse events (AEs)|Severity of protocol-defined adverse events (AEs)|Frequency of dose modifications","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20328|2018-003650-24","April 2, 2019","November 9, 2023","November 9, 2023","March 26, 2019",,"January 18, 2020","Tampa General Medical Group, Tampa, Florida, United States|Eberhard-Karls-Universität Tübingen, Tübingen, Baden-Württemberg, Germany|Universitätsklinikum Köln, Köln, Nordrhein-Westfalen, Germany|A.O.U. Careggi, Firenze, Toscana, Italy|Saiseikai Utsunomiya Hospital, Utsunomiya-shi, Tochigi, Japan|Mount Vernon Hospital, Northwood, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03890731"
45,"NCT03887780","A Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto) for Prevention of Stroke and Systemic Embolism in Indian Patients With Non-valvular Atrial Fibrillation (NVAF)","XARIN","Recruiting","No Results Available","Non-valvular Atrial Fibrillation (NVAF)","Drug: Rivaroxaban (Xarelto,Bay 59-7939)","Incidence of major bleeding events|Incidence of treatment-emergent AEs|Incidence of treatment-emergent SAEs|Incidence of all-cause death|Incidence of symptomatic thromboembolic events|Non-major bleeding events|AE rates in the different NVAF risk factor categories|SAE rates in the different NVAF risk factor categories|Treatment persistence with rivaroxaban","Bayer|Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)",,"1000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","20387","October 3, 2019","February 28, 2021","April 30, 2021","March 25, 2019",,"January 21, 2020","Batra Heart Centre, Delhi, India",,"https://ClinicalTrials.gov/show/NCT03887780"
46,"NCT03875469","Study to Test the Usability of a New Injector to Administer Contrast Media Into Humans for Diagnostic Purposes","PERCENT","Recruiting","No Results Available","Computed Tomography","Device: Centargo injector (BPI 1000045)|Device: Stellant MP injector","Setup time of CT systems|Change time for bottle/ bag containing contrast medium|Patient setup time for the multi-patient set per day|Teardown time of CT-system|Number of multi-patient sets per day|Total cost for multi-patients set and disposables per patient and day|Reason for change of multi-patient syringe set for the injection of contrast media prior to expiration at 24 hours|Volume of unused contrast agent at teardown time|Volume of unused saline at teardown time|Flow rate of contrast agent through the injector|Volume of contrast agent delivered through injector|Injector-generated pressure|Number of automated system alerts|Radiographer satisfaction with contrast-media injector by study-related questionnaire|Number of errors requiring a CT-system reboot","Bayer","All","18 Years and older   (Adult, Older Adult)","Not Applicable","2000","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","20521","June 21, 2019","January 31, 2020","January 31, 2020","March 14, 2019",,"January 18, 2020","Medscan Merrylands, Merrylands, New South Wales, Australia|Maastricht University Medical Center, Maastricht, Limburg, Netherlands",,"https://ClinicalTrials.gov/show/NCT03875469"
47,"NCT03863990","Study Performed at Various Medical Centers to Learn More About Survival and Expected Course of Pulmonary Arterial Hypertension, a Type of High Blood Pressure in the Lungs Related to the Narrowing of the Small Blood Vessels in the Lungs","START","Active, not recruiting","No Results Available","Pulmonary Arterial Hypertension","Drug: PAH medication","Age at baseline|Sex|Ethnicity|Descriptive analysis of comorbidities at baseline|PAH-subgroup at baseline as assessed by physician|Right atrial pressure at baseline by right heart catheterization hemodynamics|Pulmonary artery pressure at baseline by right heart catheterization hemodynamics|Pulmonary vascular resistance at baseline by right heart catheterization hemodynamics|Pulmonary artery wedge pressure (PAWP) at baseline by right heart catheterization hemodynamics|Cardiac Index (CI) at baseline by right heart catheterization hemodynamics|Mixed venous oxygen saturation (SvO2) at baseline by right heart catheterization hemodynamics|Pulmonary vasoreactivity at baseline by pulmonary artery pressure|Peak oxygen consumption by cardiopulmonary exercise test at baseline|Right atrial area at baseline by echocardiography|Pericardial effusion at baseline by echocardiography|Right ventricular function at baseline by echocardiography|Tricuspid annular plane systolic excursion (TAPSE) at baseline by echocardiography|Pulmonary artery systolic pressure at baseline by echocardiography|Left ventricular ejection fraction at baseline by echocardiography|6-minute walking distance at baseline|Pulmonary hypertension functional class according to WHO classification at baseline|Time from onset of diagnostic symptoms to PAH-diagnosis|Symptoms progression at baseline assessed by physician|Syncope frequency at baseline|Systolic blood pressure at baseline|Heart rate at baseline|Body weight at baseline|Body height at baseline|Body mass index at baseline|Concentration of diagnostic markers for heart failure in blood at baseline|Drug class of supportive PAH treatment|Drug class of PAH-treatment after diagnosis|PAH risk status at baseline according to ESC/ERS 2015 guidelines|Overall survival rate|Time from diagnosis to death from any cause|Right atrial pressure at follow-up by right heart catheterization hemodynamics|Pulmonary artery pressure at follow-up by right heart catheterization hemodynamics|Pulmonary vascular resistance at follow-up by right heart catheterization hemodynamics|Pulmonary artery wedge pressure (PAWP) at follow-up by right heart catheterization hemodynamics|Cardiac Index (CI) at follow-up by right heart catheterization hemodynamics|Mixed venous oxygen saturation (SvO2) at follow-up by right heart catheterization hemodynamics|Peak oxygen consumption by cardiopulmonary exercise test at follow-up|Right atrial area at follow-up by echocardiography|Pericardial effusion at follow-up by echocardiography|Right ventricular function at follow-up by echocardiography|Tricuspid annular plane systolic excursion (TAPSE) at follow-up by echocardiography|Pulmonary artery systolic pressure at follow-up by echocardiography|Left ventricular ejection fraction at follow-up by echocardiography|6-minute walking distance at follow-up|Symptoms progression at follow-up|Syncope frequency at follow-up|Concentration of diagnostic markers for heart failure in blood at follow-up|PAH risk status at follow-up according to ESC/ERS 2015 guidelines|Cause of death|Pulmonary transplant|Time from diagnosis to pulmonary transplant|Time from diagnosis to first hospitalization due to PAH-progression|Number of hospitalizations per year due to PAH-progression|Proportion of patients with low PAH risk|Proportion of patients with intermediate+high PAH risk|Survival rate of patients with low risk for PAH|Survival rate of patients with intermediate or high risk for PAH|PAH risk status of patients without transplant being alive at the date of latest medical records according to ESC/ERS 2015 guidelines","Bayer","All","18 Years and older   (Adult, Older Adult)",,"110","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","20267","July 26, 2019","March 1, 2020","March 1, 2020","March 5, 2019",,"January 18, 2020","Many facilities, Multiple Locations, Argentina",,"https://ClinicalTrials.gov/show/NCT03863990"
48,"NCT03853538","A Study to Gain Information How Well Dexpanthenol Dermal Spray Helps the Face Skin to Recover After Cosmetic Lasering",,"Completed","No Results Available","Erythema|Skin Recovery","Drug: BAY207543 (Bepanthol, Bepantol® Derma Spray)|Other: Semisolid vaseline","Transepidermal water loss by TEWL probe|Dermic temperature by thermographic camera (FLIR T530sc)|Skin properties of the participants|Treatment satisfaction|Product evaluation|Number of adverse events by dermatological evaluation|Number of adverse events by ophthalmologic valuation|Severity of adverse events by dermatological evaluation|Severity of adverse events by ophthalmologic valuation","Bayer","Female","30 Years to 60 Years   (Adult)","Phase 4","33","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","20505","January 28, 2019","March 6, 2019","March 6, 2019","February 25, 2019",,"September 19, 2019","Medcin Instituto da Pele, Sao Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT03853538"
49,"NCT03853525","A Study to Gain Information How Well Dexpanthenol Dermal Spray Helps the Skin to Recover After Laser Hair Removal in the Groin and Intimate Area",,"Completed","No Results Available","Skin Recovery","Drug: BAY207543 (Bepanthol, Bepantol® Derma Spray)|Other: Semisolid vaseline","Transepidermal water loss by TEWL probe|Skin properties of the participants|Treatment satisfaction|Product evaluation|Number of adverse events by dermatological evaluation|Severity of adverse events by dermatological evaluation","Bayer","Female","18 Years to 60 Years   (Adult)","Phase 4","35","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","20506","February 11, 2019","March 11, 2019","March 11, 2019","February 25, 2019",,"September 19, 2019","Medcin Instituto da Pele, Sao Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT03853525"
50,"NCT03853512","A Study to Gain Information How Well Dexpanthenol Dermal Spray Helps the Skin to Recover After a Peeling in the External Genital Area of Women",,"Completed","No Results Available","Skin Recovery","Drug: BAY207543 (Bepanthol, Bepantol® Derma Spray)|Other: Semisolid vaseline","Transepidermal water loss by TEWL probe|Skin properties of the participants|Treatment satisfaction|Product evaluation|Number of adverse events by dermatological evaluation|Number of adverse events by gynecological evaluation|Severity of adverse events by dermatological evaluation|Severity of adverse events by gynecological evaluation","Bayer","Female","18 Years to 60 Years   (Adult)","Phase 4","33","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","20507","February 12, 2019","March 13, 2019","March 13, 2019","February 25, 2019",,"November 19, 2019","Medcin Instituto da Pele, Sao Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT03853512"
51,"NCT03852563","A Study to Gain Information How Well Dexpanthenol Derma Cream Helps the Face Skin to Recover After Cosmetic Lasering",,"Completed","No Results Available","Erythema|Skin Recovery","Drug: BAY207543 (Bepanthol)|Other: Semisolid vaseline","Transepidermal water loss by TEWL probe|Dermic temperature by thermographic camera (FLIR)|Skin properties of the participants|Treatment satisfaction|Product evaluation|Number of adverse events by dermatological evaluation|Number of adverse events by ophthalmologic valuation|Severity of adverse events by dermatological evaluation|Severity of adverse events by ophthalmologic valuation","Bayer","Female","30 Years to 60 Years   (Adult)","Not Applicable","33","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","20577","March 18, 2019","April 22, 2019","April 22, 2019","February 25, 2019",,"September 19, 2019","Medcin Instituto da Pele, Sao Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT03852563"
52,"NCT03847181","Study to Learn More About the Benefits and Side-effects of Drugs Rivaroxaban and Apixaban Compared to the Drug Warfarin for Stroke Prevention in Patients With Rapid and Irregular Heartbeat Which is Not Due to a Heart-valve Fault (Non-valvular Atrial Fibrillation) in the UK Routine Clinical Practice","SiERRA UK","Active, not recruiting","No Results Available","Atrial Fibrillation","Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Apixaban (Eliquis)|Drug: Warfarin","Risk of intracranial hemorrhage|Risk of ischemic events|Risk of intracranial hemorrhage in NVAF-patients with renal impairment|Risk of ischemic events in NVAF-patients with renal impairment|Risk of intracranial hemorrhage in NVAF-patients with diabetes|Risk of ischemic events in NVAF-patients with diabetes|All-cause mortality|Drug utilisation|Drug utilisation after first intracranial hemorrhage or ischemic stroke|Patient characteristics|Patient characteristics after first intracranial hemorrhage or ischemic stroke","Bayer|Janssen, LP","All","18 Years and older   (Adult, Older Adult)",,"40000","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","20343|EUPAS28234","February 28, 2019","October 31, 2020","October 31, 2020","February 20, 2019",,"January 18, 2020","Many facilities, Many Sites, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03847181"
53,"NCT03841032","4 Week In-Use Study Evaluating How Well-Tolerated a Skin Care Product Is on Adults With Facial Redness",,"Completed","No Results Available","Rosacea","Drug: Coppertone, BAY1183345","Number of subjects exhibiting increases in papules|Number of subjects exhibiting increases in erythema|Number of subjects exhibiting increases in dryness, telangiectasia and tactile surface roughness|Number of subjects exhibiting increases in any subjective irritation|Change in facial redness measured by spectrophotometer|Change in facial redness measured by digital imaging|Percentages for each response to hedonic questionnaire assessing product experience","Bayer","All","18 Years and older   (Adult, Older Adult)","Not Applicable","35","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","20516","January 28, 2019","February 25, 2019","February 25, 2019","February 15, 2019",,"June 12, 2019","The Education & Research Foundation, Inc., Lynchburg, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03841032"
54,"NCT03808142","PROmyBETAappGame: a Study to Learn More About the Medication Usage & Patient Reported Outcomes Via the myBETAapp and to Find Out More About the Usage of Game Principles and Game Design Elements (Gamification) in Medical Care of Patients With Multiple Sclerosis Treated With Betaferon",,"Recruiting","No Results Available","Multiple Sclerosis","Other: myBETAapp|Other: PEAK|Drug: Betaferon, BAY 86-5046|Device: BETACONNECT","Date of injection as recorded in the myBETAapp, prospectively|Date of injection as recorded in the myBETAapp, retrospectively|EQ-5D-5L Level for each of the 5 dimensions|EQ-5D-5L Health state|EQ-5D-5L EQ VAS score|EQ-5D-5L index value derived from EQ-5D health states|Scores of Treatment Satisfaction Questionnaire for Medication version 2 (TSQM v.II)|Response level of Satisfaction with the BETAPLUS patient support program (service questionnaire)|Response level of Satisfaction with the BETACONNECT autoinjector (service questionnaire)|Response level of Satisfaction with the myBETAapp (service questionnaire)|Feedback based on free text on supporting services or devices|Number of MS patients using the mobile-based cognitive training tool - PEAK|Proportion of MS patients using the mobile-based cognitive training tool - PEAK|Frequency of mobile-based cognitive training tool - PEAK usage (trainings/week)|Duration of mobile-based cognitive training tool - PEAK usage (days)|Scores of the games of cognitive training tool-PEAK","Bayer","All","18 Years and older   (Adult, Older Adult)",,"200","Industry","Observational","Observational Model: Cohort|Time Perspective: Other","20263","February 20, 2019","April 15, 2020","May 15, 2020","January 17, 2019",,"January 21, 2020","Many locations, Multiple Locations, Germany",,"https://ClinicalTrials.gov/show/NCT03808142"
55,"NCT03799016","An Observational Study on Incidence, Natural History and Treatment Patterns of Venous Thromboembolism in Taiwan",,"Completed","No Results Available","Venous Thromboembolism",,"Incident VTE|Potential risk factors that occurred before the incident VTE events|Usage patterns of anticoagulants among incident VTE patients were evaluated during incident VTE hospital admission and after discharge|All-cause mortality|Major bleeding|Recurrent VTE|Adherence of oral anticoagulant treatment was also evaluated with the calculation of MPR within 6 months and 12 months after discharge.","Bayer","All","20 Years and older   (Adult, Older Adult)",,"104215","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","18787","December 15, 2016","July 1, 2017","July 1, 2017","January 10, 2019",,"January 10, 2019","Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT03799016"
56,"NCT03789890","Study to Learn More About the Effect of Itraconazole (ITZ) Given Repeatedly by Mouth on the Way How the Study Drug BAY1902607 Given One Time by Mouth Acts in the Human Body of Healthy Male Participants",,"Completed","No Results Available","Drug Interactions","Drug: BAY1902607|Drug: Itraconazole","Cmax of BAY1902607|Cmax of BAY1902607 with itraconazole|AUC of BAY1902607|AUC of BAY1902607 with itraconazole","Bayer","Male","18 Years to 55 Years   (Adult)","Phase 1","14","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","19431|2018-003212-50","January 8, 2019","March 4, 2019","May 23, 2019","December 31, 2018",,"May 29, 2019","CRS Clinical Research Services Berlin GmbH, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT03789890"
57,"NCT03788863","A Study to Learn More About the Relationship Between the Development of a Gap in the Upper Lip (Cleft Lip) or in the Roof of the Mouth (Cleft Palate) in Newborns and the Use of Glucocorticoids by the Mother During Pregnancy: a Meta-analysis",,"Completed","No Results Available","Relationship Between the Exposure of Glucocorticoids During Pregnancy and Orofacial Cleft Development","Drug: Diflucortolone valerate (BAY866146)","Incidence of any type of orofacial cleft|Potency (mild, moderate, potent, very potent) of glucocorticosteroids|Route of administration of glucocorticosteroids|Types of orofacial cleft","Bayer","Female","Child, Adult, Older Adult",,"99999","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","20638","November 16, 2018","November 29, 2018","November 29, 2018","December 28, 2018",,"December 3, 2019","Many locations, Multiple Locations, Germany",,"https://ClinicalTrials.gov/show/NCT03788863"
58,"NCT03788603","Rogaratinib (BAY1163877) in Chinese Patients",,"Recruiting","No Results Available","Neoplasms","Drug: Rogaratinib (BAY1163877)","Frequency of Treatment-Emergent Adverse Events(TEAEs)|Severity of Treatment-Emergent Adverse Events(TEAEs)|Cmax: Maximum drug concentration in plasma after dose administration|AUC(0-12): AUC from time zero to 12 hours p.a. after first-dose administration|Cmax,md: Cmax after multiple dosing|AUC(0-12)md: AUC(0-12) after multiple dosing|Phosphate levels|Response rate","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19177","January 7, 2019","June 21, 2021","January 12, 2022","December 27, 2018",,"January 13, 2020","Jiangsu Province Hospital, Nanjing, Jiangsu, China|Beijing Hospital, Beijing, China|Shanghai Pulmonary Hospital, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT03788603"
59,"NCT03787368","End-stage Renal Disease (ESRD) Pilot Study",,"Recruiting","No Results Available","Renal Dialysis","Drug: BAY1213790|Drug: 0.9% sodium chloride solution","Number of major and CRNM bleeding events|AUC (AUC(0-tlast) will be used as main parameter if mean AUC(tlast-∞) >20% of AUC)|aPTT will be measured via the kaolin-trigger method (clotting assay)|Factor XI activity will be assessed with an aPTT-based coagulation test using FXI","Bayer","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20046|2018-003109-24","January 31, 2019","December 30, 2020","December 30, 2020","December 26, 2018",,"January 13, 2020","California Institute of Renal Research, Chula Vista, California, United States|Nephrology and Hypertension Associates, Middlebury, Connecticut, United States|Nova Clinical Research, Bradenton, Florida, United States|Florida Kidney Center FMC # 1095, Lauderhill, Florida, United States|Research by Design, LLC, Chicago, Illinois, United States|Renal and Transplant Associates of New England, PC, Springfield, Massachusetts, United States|DaVita Clinical Research, Minneapolis, Minnesota, United States|Dallas Nephrology Associates, Dallas, Texas, United States|El Paso Kidney Specialists, PA, El Paso, Texas, United States|DaVita Med Center Dialysis, Houston, Texas, United States|San Antonio Kidney Disease Center, San Antonio, Texas, United States|CHU de Charleroi Hôpital civil, Lodelinsart, Hainaut, Belgium|UZ Brussel, Bruxelles - Brussel, Belgium|CU Saint-Luc/UZ St-Luc, Bruxelles - Brussel, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Eurodial - Extensao de Obidos, Gaeiras - Obidos, Leiria, Portugal|CHLO - Hospital Santa Cruz, Carnaxide, Lisboa, Portugal|Pluribus Dialise, Cascais, Lisboa, Portugal|CHMT - Hospital Rainha Santa Isabel, Torres Novas, Santarém, Portugal|NephroCare APDP, Lisboa, Portugal|Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain|Ciutat Sanitària i Universitària de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Reina Sofía, Córdoba, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Universitario Dr. Peset, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT03787368"
60,"NCT03784391","Study on Benefits of Therapy With Nifurtimox in Chagas Disease, a Parasitic Illness Mostly Transmitted to Humans by a Bug, Using Information From Patient Medical Records in Argentina",,"Active, not recruiting","No Results Available","Chagas' Disease","Drug: Lampit (Nifurtimox, BAYA2502)","Parasitological cure of adult patients with chronic Chagas' disease|Parasitological cure of pediatric patients with acute and chronic Chagas' disease|Occurrence of cardiac manifestations in patients with chronic Chagas' disease","Bayer","All","Child, Adult, Older Adult",,"4500","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","20302","December 14, 2018","January 15, 2020","January 15, 2020","December 21, 2018",,"December 16, 2019","Many locations, Multiple Locations, Argentina",,"https://ClinicalTrials.gov/show/NCT03784391"
61,"NCT03773068","A Study in Healthy Volunteers Investigating How Quickly and to What Extent BAY1817080 is Taken up, Distributed, Broken Down and Eliminated From the Body, as Well as the Difference Between 2 Different Types of Tablets of BAY1817080 and the Difference Between Oral Dose and Dose in the Vein",,"Completed","No Results Available","Biological Availability","Drug: BAY1817080 - Formulation A|Drug: BAY1817080 - Formulation B|Drug: [13C715N]-BAY 181708 stable isotope label (SIL)","Absolute oral bioavailability (F) of BAY1817080|Relative bioavailability (frel) of Formulation A versus Formulation B given under different diets|Effect of a high-fat, high-calorie meal (HF,HC) on the PK of BAY1817080 after a single oral dose of Formulation B at two doses in comparison to the fasted state evaluated by Cmax|Effect of a high-fat, high-calorie meal (HF,HC) on the PK of BAY1817080 after a single oral dose of Formulation B at two doses in comparison to the fasted state evaluated by AUC|Dose proportionality in BAY1817080 PK after a single oral dose of Formulation B across three doses in fasted state evaluated by Cmax/D|Dose proportionality in BAY1817080 PK after a single oral dose of Formulation B across three doses in fasted state evaluated by AUC/D|Frequency and severity of treatment emergent adverse events (TEAEs)","Bayer","Male","18 Years to 55 Years   (Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","19519|2018-001814-13","December 13, 2018","June 21, 2019","August 12, 2019","December 12, 2018",,"August 19, 2019","PRAHealthSciences, Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT03773068"
62,"NCT03757078","Study to Find Out How Symptoms Severity Changes During the Standard Course of Treatment With the Cream Relief Pro and Suppositories Relief Pro (Active Ingredients Are Fluocortolone + Lidocaine) in Patients Suffering From Twisted and Bulging Veins in the Rectal Area (Acute Hemorrhoids)",,"Completed","No Results Available","Acute Hemorrhoids","Drug: Relief Pro cream|Drug: Relief Pro rectal suppositories","Change in Sodergren hemorrhoid symptom severity score by Sodergern scoring system|Change of the biggest hemorrhoid pile in size|Investigator overall satisfaction with Relief Pro treatment by 5-point Likert scale|Patient's adherence to recommendations of the Investigator by PRO|Patient overall satisfaction with Relief Pro treatment by 5-point Likert scale|Patient preferences on dosage form by PRO|Date of start and end using Relief Pro|Daily frequency of Relief Pro use, captured based on patient verbal response|Change of the severity of pain symptom (VAS)|Change of the severity of bleeding symptom (4-point Likert scale)|Change of the severity of itching symptom (4-point Likert scale)|Change of the severity of swelling symptom (4-point Likert scale)|Change of the severity of discharge (4-point Likert scale)|Change of the severity of discomfort (4-point Likert scale)","Bayer","All","18 Years to 65 Years   (Adult, Older Adult)",,"1000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","20364","November 30, 2018","October 20, 2019","October 20, 2019","November 28, 2018",,"December 2, 2019","State Scientific Center of Coloproctology, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT03757078"
63,"NCT03754660","This Study Tests the Safety of Inhaled BAY1237592, How the Drug is Tolerated and How it Effects Patients With High Blood Pressure in the Arteries of the Lungs in the Two Different Disease Groups Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH)","ATMOS","Recruiting","No Results Available","Hypertension, Pulmonary","Drug: BAY1237592|Drug: PH-monotherapy|Drug: PH-combination therapy|Procedure: NO gas","Peak percent reduction in PVR (Pulmonary vascular resistance) from ""baseline 2"" for untreated patients|Peak percent reduction in PVR from ""baseline"" for pre-treated patients|Incidence of treatment-emergent adverse events (TEAEs)","Bayer","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","60","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","17293|2018-001791-37","January 21, 2019","December 22, 2020","February 8, 2021","November 27, 2018",,"January 7, 2020","Krankenhaus Neuwittelsbach, München, Bayern, Germany|Universitätsklinikum Giessen und Marburg, Gießen, Hessen, Germany|Klinikum der Ernst-Moritz-Arndt-Universität, Greifswald, Mecklenburg-Vorpommern, Germany|Medizinische Hochschule Hannover (MHH), Hannover, Niedersachsen, Germany|Universitätsklinikum Köln, Köln, Nordrhein-Westfalen, Germany|Universitätsklinikum des Saarlandes, Homburg, Saarland, Germany|Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Sachsen, Germany|Universitätsklinikum Leipzig AöR, Leipzig, Sachsen, Germany",,"https://ClinicalTrials.gov/show/NCT03754660"
64,"NCT03754556","Study on Medical Records of Women Using a Coil (Intrauterine Device = IUD) for Birth Control to Analyze the Risk That a Coil Will Slip Out or Perforate the Womb in Relation to Breastfeeding, to the Point in Time When the Coil Was Inserted After Childbirth and in Relation to Different Types of Coils","APEX IUD","Active, not recruiting","No Results Available","Intrauterine Devices","Device: Intrauterine device","Person-time at risk|Confirmed date of uterine perforation|Confirmed date of IUD-expulsion|Incidence rate of uterine perforation|Cumulative incidence of uterine perforation|Incidence rate of IUD-expulsion|Cumulative incidence of IUD-expulsion|Incidence of difficult IUD-insertion|Adjusted hazard ratio of uterine perforation|Adjusted hazard ratio of IUD-expulsion|Adjusted incidence rate ratio (IRR) of uterine perforation|Adjusted incidence rate difference (IRD) of uterine perforation|Adjusted incidence rate ratio (IRR) of IUD-expulsion|Adjusted incidence rate difference (IRD) of IUD-expulsion|Effect modification for uterine perforation|Effect modification for IUD-expulsion","Bayer","Female","up to 50 Years   (Child, Adult)",,"225000","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","19682","December 3, 2018","March 30, 2020","March 30, 2020","November 27, 2018",,"January 18, 2020","Kaiser Permanente Northern California, Oakland, California, United States|Kaiser Permanente Southern California, Pasadena, California, United States|Regenstrief Institute, Indianapolis, Indiana, United States|Kaiser Permanente Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03754556"
65,"NCT03751800","A Study Run at Multiple Study Sites to Test Whether the SAMANTA Questionnaire That is Used to Diagnose Heavy Menstrual Bleeding (HMB), Can Also be Used to Assess Changes of Severity of HMB in Women With HMB Who Are Treated During 12 Months With a Chronic Hormonal Treatment","SAMIRA","Recruiting","No Results Available","Menorrhagia","Drug: Chronic hormonal treatment","SAMANTA questionnaire score|Overall satisfaction with the chronic hormonal treatment measured with a user satisfaction questionnaire|Changes in menstrual bleeding pattern measured with a user satisfaction questionnaire|Correlation between changes in SAMANTA score and changes in women's quality of life measured with SF36v2 questionnaire","Bayer","Female","18 Years and older   (Adult, Older Adult)",,"452","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","20061","December 12, 2018","February 16, 2021","April 28, 2021","November 23, 2018",,"January 22, 2020","Many locations, Multiple Locations, Spain",,"https://ClinicalTrials.gov/show/NCT03751800"
66,"NCT03746301","Xarelto on Prevention of Stroke and Non-Central Nervous Systemic Embolism in Renally Impaired Korean Patients With Non-valvular Atrial Fibrillation","XARENAL","Recruiting","No Results Available","Non-valvular Atrial Fibrillation (NVAF)","Drug: Rivaroxaban(Xarelto,BAY 59-7939)","Incidence proportion of major bleeding|Occurrence of AEs and SAEs|Occurrence of all-cause mortality|Occurrence of Non-major bleeding|Incidence proportion of Symptomatic thromboembolic events|Days of rivaroxaban treatment|The change in creatinine clearance from baseline","Bayer|Janssen Research & Development, LLC","All","19 Years and older   (Adult, Older Adult)",,"1000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","20286","December 3, 2018","March 30, 2021","July 31, 2021","November 19, 2018",,"January 13, 2020","Many locations, Multiple Locations, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03746301"
67,"NCT03746275","Study to Gain Insights in Treatment Patterns and Outcomes in Patients With Atherosclerosis Prescribed to Xarelto in Combination With Acetylsalicylic Acid","XATOA","Recruiting","No Results Available","Atherosclerosis","Drug: Rivaroxaban (BAY59-7939, Xarelto)|Drug: Acetylsalicylic acid","Descriptive analysis of patient history of CAD|Descriptive analysis of patient history of PAD|Descriptive analysis of prior antithrombotic treatment|Descriptive analysis of concomitant antithrombotic treatment|Descriptive analysis of prior secondary prevention therapies|Descriptive analysis of concomitant secondary prevention therapies|Reason for start of rivaroxaban|Decision point for start of rivaroxaban|Reason for discontinuation of rivaroxaban|Planned duration of treatment with rivaroxaban|Actual duration of treatment with rivaroxaban|Planned duration of treatment with acetylsalicylic acid|Actual duration of treatment with acetylsalicylic acid|Occurrence of major adverse cardiac events|Occurrence of stroke|Occurrence of myocardial infarction|Occurrence of cardiovascular death|Occurrence of major adverse limb events|Occurrence of acute/severe limb ischemia|Occurrence of chronic limb ischemia|Occurrence of major amputation|Anti-thrombotic treatment pattern after major adverse limb event|Occurrence of thromboembolic events|Occurrence of haemorrhagic events|Occurrence of death from cardiovascular events|Occurrence of death from any cause|Occurrence of cardiac revascularization procedures|Occurrence of peripheral revascularization procedures|Occurrence of carotid revascularization procedures|Occurrence of hospitalizations|Duration of hospitalization|Total walking distance of PAD patients|Pain-free walking distance of PAD patients","Bayer|Janssen, LP","All","18 Years and older   (Adult, Older Adult)",,"10000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","20280","November 13, 2018","May 31, 2021","June 30, 2021","November 19, 2018",,"January 9, 2020","Multiple facilities, Multiple Locations, Argentina|Multiple facilities, Multiple Locations, Belgium|Multiple facilities, Multiple Locations, Brazil|Multiple facilities, Multiple Locations, Canada|Multiple facilities, Multiple Locations, Colombia|Multiple facilities, Multiple Locations, Denmark|Multiple facilities, Multiple Locations, France|Multiple facilities, Multiple Locations, Germany|Multiple facilities, Multiple Locations, Israel|Multiple facilities, Multiple Locations, Italy|Multiple facilities, Multiple Locations, Korea, Republic of|Multiple facilities, Multiple Locations, Lebanon|Multiple facilities, Multiple Locations, Luxembourg|Multiple facilities, Multiple Locations, Mexico|Multiple facilities, Multiple Locations, Netherlands|Multiple facilities, Multiple Locations, Norway|Multiple facilities, Multiple Locations, Russian Federation|Multiple facilities, Multiple Locations, Saudi Arabia|Multiple facilities, Multiple Locations, Slovakia|Multiple facilities, Multiple Locations, Slovenia|Multiple facilities, Multiple Locations, Spain|Multiple facilities, Multiple Locations, Sweden|Multiple facilities, Multiple Locations, Switzerland|Multiple facilities, Multiple Locations, Taiwan|Multiple facilities, Multiple Locations, Thailand|Multiple facilities, Multiple Locations, United Arab Emirates|Multiple facilities, Multiple Locations, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03746275"
68,"NCT03743883","EffectiveNess of Low-dose Aspirin in Prevention of Cancer in the Stomach and Oesophagus (GastrointEstinal Cancer Prevention) - United Kingdom (""ENgAGE - UK""): Study to Evaluate the Risk of Cancer in the Stomach and Oesophagus Among New Users of Low-dose Aspirin Using the THIN Database in the UK","ENgAGE-UK","Completed","No Results Available","Prevention of Oesophagus Cancer and Stomach Cancer","Drug: Acetylsalicylic Acid(BAYE4465, Aspirin )","Incidence rates of oesophageal cancer and stomach cancer with use of low-dose ASA overall compared to non-use|Incidence rates of oesophageal cancer and stomach cancer with use of low-dose ASA by age compared to non-use|Incidence rates of oesophageal cancer and stomach cancer with use of low-dose ASA by sex-specific compared to non-use|Incidence of oesophageal cancer and stomach cancer among new users of low-dose ASA|Duration of low-dose ASA|Dose-response of low-dose ASA|Number of case-fatality of oesophageal cancer and stomach cancer among new users of low-dose ASA|Incidence of oesophageal cancer and stomach cancer among new users of low-dose ASA for primary or secondary cardiovascular prevention","Bayer","All","40 Years to 89 Years   (Adult, Older Adult)",,"99999","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","20326","October 30, 2018","April 15, 2019","April 15, 2019","November 16, 2018",,"May 29, 2019","Many locations, Multiple Locations, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03743883"
69,"NCT03735628","An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors",,"Recruiting","No Results Available","Non-small Cell Lung Cancer (NSCLC)|Head and Neck Squamous Cell Carcinoma (HNSCC)|Colorectal Cancer (CRC)|Hepatocellular Carcinoma (HCC)","Drug: Copanlisib|Drug: Nivolumab","Phase 1b: Frequency of dose limiting toxicities (DLT) at each dose level associated with administration of copanlisib and nivolumab|Phase 2: Overall response rate (ORR) as per RECIST v 1.1 (Response evaluation criteria in solid tumors, v 1.1) (by local investigator|Phase 1b: Overall response rate (ORR) as per RECIST v 1.1 (by local investigator assessment)|Phase 1b and 2:Maximum drug concentration in plasma (Cmax) of copanlisib|Phase 1b and 2:Area under the curve (AUC) of copanlisib|Phase 1b and 2: Cmax for nivolumab|Phase 1b and 2: Minimum plasma drug concentration (Cmin) for nivolumab|Phase 1b and 2: Overall survival (OS)|Phase 1b and 2: Progression-free survival (PFS)|Phase 1b and 2: Disease control rate (DCR)|Phase 1b and 2: Duration of stable disease (DSD)|Phase 1b and 2: Time to response (TTR)|Phase 1b and 2: Time to progression (TTP)|Phase 1b and 2: Duration of response (DOR)|Phase 1b and 2:Number of participants with Adverse events (AE) and Serious AEs (SAE)|Phase 1b and 2:Number of participants with clinically significantly abnormal changes in electrocardiograms (ECG) including heart rate and measures PR, QRS, QT, and QTc intervals|Phase 1b and 2:Number of participants with changes in dose including interruptions, reductions and dose intensity","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","160","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19769","October 17, 2018","December 30, 2022","December 30, 2022","November 8, 2018",,"January 22, 2020","Sarcoma Oncology Center, Santa Monica, California, United States|White Plains Hospital Medical Center, White Plains, New York, United States|Gabrail Cancer Center, Canton, Ohio, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Princess Margaret Cancer Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03735628"
70,"NCT03724747","Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Anti-tumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Metastatic Castration Resistant Prostate Cancer",,"Recruiting","No Results Available","Metastatic Castration Resistant Prostate Cancer (mCRPC)","Drug: BAY 2315497 Injection","Maximum tolerated dose (MTD) of BAY 2315497 injection|Recommended dose for further clinical development of BAY 2315497 injection|Maximum observed concentration (Cmax) of thorium|Area under the curve from time of dosing to 42 days after dosing [AUC(0-42)] days of thorium|Cmax of radium|AUC(0-42) days of radium|Cmax of total antibody|AUC(0-42) days of total antibody","Bayer","Male","18 Years and older   (Adult, Older Adult)","Phase 1","111","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19445|2018-001490-25","December 18, 2018","September 23, 2022","November 18, 2022","October 30, 2018",,"January 6, 2020","Tulane Medical Center, New Orleans, Louisiana, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|HUS, Meilahden sairaala, Helsinki, Finland|Skånes Universitetssjukhus, Lund, Sweden|Royal Marsden NHS Trust (Surrey), Sutton, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03724747"
71,"NCT03715725","A Nationwide Observational Study Looking at Effectiveness and Bleeding Complications of NOACs vs. VKA in Non-valvular Atrial Fibrillation Patients.","PROTECT-AF","Active, not recruiting","No Results Available","Non-valvular Atrial Fibrillation","Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Apixaban (Eliquis)|Drug: Dabigatran etexilate (Pradaxa)|Drug: Warfarin (Marevan)","Ischemic stroke|Intracranial hemorrhage|Overall stroke|Systemic embolism|Myocardial infarction|All-cause mortality|Major bleeding|Demographic characteristics|Clinical characteristics|Drug utilization patterns","Bayer|Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)",,"70000","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","19468","October 31, 2018","January 31, 2020","January 31, 2020","October 23, 2018",,"December 23, 2019","Many locations, Multiple Locations, Norway",,"https://ClinicalTrials.gov/show/NCT03715725"
72,"NCT03714308","Aflibercept Injection Into the Vitreous Body of the Eye: Study to Learn More About Patient Relevant Outcomes, Real World Treatment Patterns and How Well the Treatment Works for Patients Suffering From Abnormal Growth of New Blood Vessels Under the Retina.","ANDROMEDA","Recruiting","No Results Available","Macular Degeneration","Drug: Ivt. Aflibercept (Eylea, BAY86-5321)","Time to first appearance of non-consistence|Reasons why a patient failed to appear to a scheduled injection visit|Change in best corrected visual acuity (BCVA) letters|Change in central retinal thickness (CRT)|Treatment satisfaction by MAC-TSQ|Change in treatment satisfaction|Vision-specific quality of life by NEI VFQ-25|Change in vision-specific quality of life|Burden of therapy|Information about disease and treatment|Willingness to continue therapy|Reasons for treatment discontinuation|Change in general quality of life by EQ-5D|Percentage of non-persistent patients|Time from baseline to first instance of non-persistence|Percentage of patients receiving 3 initial monthly injections|Percentage of consistently treated patients|Proportion of patients undergoing therapeutic switch|Reasons for therapeutic switching|Proportion of patients discontinuing disease monitoring at participating center|Average time between visits|Average time between injections in the study eye|Number of injections in the study eye per year|Number of visits per study eye per year|Number of visits in clinics/ ophthalmology practices other than the study center per year|Number of examinations of the study eye per year|Number of injections until start of observation|Duration of treatment until start of observation|Type of treatment until start of observation","Bayer|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)",,"1000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","19756","January 28, 2019","December 31, 2022","March 31, 2023","October 22, 2018",,"January 18, 2020","Many locations, Multiple Locations, Germany",,"https://ClinicalTrials.gov/show/NCT03714308"
73,"NCT03708133","Study to Assess Bioequivalence of a New Nifurtimox Oral Tablet Formulation",,"Completed","No Results Available","Bioequivalence","Drug: Nifurtimox (Lampit, BAYA2502)_Test|Drug: Nifurtimox (Lampit, BAYA2502)_Reference","AUC|AUC(0-tlast)|Cmax|Time to reach Cmax (tmax)|Half-life associated with terminal slope(t1/2)|AUC divided by dose per body weight (AUCnorm)|Cmax divided by dose per body weight (Cmax,norm)|Number of participants with adverse events","Bayer","All","18 Years to 45 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","19500","December 5, 2018","April 17, 2019","June 18, 2019","October 17, 2018",,"November 4, 2019","FP Clinical Pharma, Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina",,"https://ClinicalTrials.gov/show/NCT03708133"
74,"NCT03704519","Imaging Study to Compare Effects of Darolutamide and Enzalutamide With Respect to Placebo on the Blood Flow in the Brain in Healthy Male Volunteers.",,"Completed","No Results Available","Cerebrovascular Circulation","Drug: Darolutamide (BAY1841788)|Drug: Enzalutamide|Other: Placebo","Change in grey-matter cerebral blood flow of enzalutamide as compared to placebo|Change in grey-matter cerebral blood flow of darolutamide as compared to placebo|Change in grey-matter cerebral blood flow of enzalutamide as compared to darolutamide|Change in mean regional grey-matter cerebral blood flow in brain areas related to cognitive function during treatment of enzalutamide as compared to placebo|Change in mean regional grey-matter cerebral blood flow in brain areas related to cognitive function during treatment of darolutamide as compared to placebo|Change in mean regional grey-matter cerebral blood flow in brain areas related to cognitive function during treatment of enzalutamide as compared to darolutamide","Bayer","Male","18 Years to 45 Years   (Adult)","Phase 1","26","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","18426|2018-001599-39","October 23, 2018","October 1, 2019","November 5, 2019","October 12, 2018",,"December 6, 2019","Centre for Neuroimaging Sciences, King's College, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03704519"
75,"NCT03699176","Assessment of Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids","ASTEROID 7","Withdrawn","No Results Available","Uterine Fibroids","Drug: Vilaprisan (BAY1002670)|Drug: Placebo","Amenorrhea (yes/no)|Heavy menstrual bleeding (HMB) response (yes/no)|Time to onset of amenorrhea|Time to onset of controlled bleeding|Absence of bleeding (spotting allowed) based on the Uterine Fibroid Daily Bleeding Diary (UF-DBD)|Endometrial histology (eg, benign endometrium, presence or absence of hyperplasia or malignancy)|Endometrial thickness","Bayer","Female","18 Years and older   (Adult, Older Adult)","Phase 3","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","19434","October 27, 2018","December 25, 2019","December 25, 2019","October 9, 2018",,"January 18, 2020","Funabashi Municipal Medical Center, Funabashi, Chiba, Japan|Matsudo City General Hospital, Matsudo, Chiba, Japan|Ena Odori Clinic, Sapporo, Hokkaido, Japan|Tokeidai Memorial Clinic, Sapporo, Hokkaido, Japan|Asahi clinic, Takamatsu, Kagawa, Japan|Kagawa Prefectural Central Hospital, Takamatsu, Kagawa, Japan|Unoki Clinic, Kagoshima, Japan|Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan",,"https://ClinicalTrials.gov/show/NCT03699176"
76,"NCT03684395","Accessibility to New Drugs Versus SOC in Sweden",,"Completed","No Results Available","Anticoagulation","Drug: DOACs: Rivaroxaban, Dabigatran, Apixaban|Drug: Standard of care (Warfarin)","Correlation between socioeconomic factors and use of DOACs vs. Warfarin (as identified from the LISA database before the index date)|Secular trends in the correlation between socioeconomic factors and use of DOACs (vs. warfarin) - Trends based on the date of prescription by year","Bayer","All","18 Years and older   (Adult, Older Adult)",,"68056","Industry","Observational","Observational Model: Case-Crossover|Time Perspective: Retrospective","18984","June 15, 2016","June 30, 2017","June 30, 2017","September 25, 2018",,"March 29, 2019","Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT03684395"
77,"NCT03672383","Functional Study to Investigate the Efficacy of a New Medical Device (Modified Diprobase Formulation)",,"Completed","No Results Available","Dermatitis, Atopic","Device: BAY987534","AUC of the skin hydration assessed of treatment with the test product compared to untreated|AUC of the short term skin hydration|Skin hydration by measuring skin capacitance assessed by Corneometry (unit: a.u.)|Skin hydration after treatment by measuring skin capacitance assessed by Corneometry (unit: a.u.)|Skin pH|Transepidermal water loss|Stratum corneum thickness assessed by Raman Spectrometry (unit: µm)|Water gradient within stratum corneum assessed by Raman Spectrometry|Number of participants with adverse events (AEs)|Compliance check|Water content within stratum corneum assessed by Raman Spectrometry (unit: %)","Bayer","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","42","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","19689","September 17, 2018","October 17, 2018","October 17, 2018","September 14, 2018",,"September 4, 2019","proDerm, Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT03672383"
78,"NCT03670784","Occurrence and Trend of Pregnancies Growing Outside the Womb (Ectopic Pregnancy) 2009-2018. A Study on a Defined Group of Persons",,"Active, not recruiting","No Results Available","Pregnancy, Ectopic","Other: No intervention","Number of ectopic pregnancies|Person-time at risk|Risk factors for ectopic pregnancies|Accuracy of electronic health data to identify diagnosis of ectopic pregnancy|Accuracy of electronic health data to identify contraceptive method at time of diagnosis of ectopic pregnancy|Accuracy of electronic health data to identify contraceptive method over time|Accuracy of electronic health data to identify induced abortions|Numbers of ectopic pregnancies managed surgically|Numbers of ectopic pregnancies managed medically","Bayer","Female","15 Years to 44 Years   (Child, Adult)",,"2000000","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","20257","December 1, 2018","March 31, 2020","March 31, 2020","September 14, 2018",,"January 10, 2020","Kaiser Permanente, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT03670784"
79,"NCT03666273","A First-in-human Study of ILDR2 (Immunoglobulin-like Domain Containing Receptor 2) Function-blocking Antibody BAY1905254",,"Recruiting","No Results Available","Advanced Solid Tumor","Drug: BAY1905254|Drug: BAY1905254 + Pembrolizumab","Incidence of treatment-emergent AEs (TEAEs) including treatment-emergent serious adverse events (TESAEs), adverse events of special interest (AESIs), and dose-limiting toxicities (DLTs)|Severity of treatment-emergent AEs (TEAEs) including treatment-emergent serious adverse events (TESAEs), adverse events of special interest (AESIs), and dose-limiting toxicities (DLTs)|Cmax of BAY1905254 after first dose administration (Cycle 1) for cohorts receiving doses ≥ 20 mg|AUC of BAY1905254 after first dose administration (Cycle 1) for cohorts receiving doses ≥ 20 mg|Maximum tolerated dose (MTD) of BAY1905254|Recommended dose of BAY1905254 for Phase 2|Cmax,md after multiple dosing (Cycle 3) for cohorts receiving doses ≥ 20 mg|AUC after multiple dosing (Cycle 3) for cohorts receiving doses ≥ 20 mg|Incidence of positive anti-drug antibody and neutralizing antibody titer for BAY1905254|Best overall response rate","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","236","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18789|2018-000990-63","September 12, 2018","September 30, 2024","September 30, 2024","September 11, 2018",,"January 18, 2020","University of Southern California, Los Angeles, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|University of Chicago Hospitals, Chicago, Illinois, United States|Henry Ford Health System, Detroit, Michigan, United States|Texas Oncology, PA, Dallas, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03666273"
80,"NCT03655301","Effect of Copanlisib on Metformin Pharmacokinetics and Pharmacodynamics",,"Completed","Has Results","Healthy Volunteers","Drug: Copanlisib (Aliqopa, BAY80-6946)|Drug: Metformin","Maximum Drug Concentration of Metformin in Plasma After Single Dose Administration (Cmax)|Area Under the Plasma Concentration Versus Time Curve From Zero to 24 Hours of Metformin After Single Dose Administration (AUC[0-24])|Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity of Metformin After Single Dose Administration (AUC)|Number of Participants With Treatment-Emergent Adverse Events|Number of Participants With Treatment-Emergent Adverse Events by Severity|Plasma Lactate Levels|Maximum Change From Baseline in Plasma Lactate Levels","Bayer","All","18 Years to 45 Years   (Adult)","Phase 1","13","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19951","September 11, 2018","November 12, 2018","February 12, 2019","August 31, 2018","December 23, 2019","December 23, 2019","Pharmaceutical Product Development (PPD), LLC, Austin, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT03655301/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT03655301/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03655301"
81,"NCT03644511","Use of Sorafenib and/or Regorafenib in Liver Cancer (Hepatocellular Carcinoma) Subsequent to Another Systemic First-line Treatment","SORAGO-HCC","Terminated","No Results Available","Hepatocellular Carcinoma","Drug: Regorafenib (Stivarga, BAY73-4506)|Drug: Sorafenib (Nexavar, BAY43-9006)","Identification of current treatment patterns by means of individual treatment lines in the systemic HCC therapy with regards to Nexavar and Stivarga, i.e. when both drugs are used in ≥ 2nd-line under current practice conditions|Overall Survival (OS) from start of Nexavar or Stivarga therapy and from start of first systemic therapy|Progression free survival (PFS)|Time to progression (TTP)|Duration of Nexavar or Stivarga treatment|Tumor response to treatment|Incidence of treatment-emergent adverse events (TEAE)","Bayer","All","18 Years and older   (Adult, Older Adult)",,"3","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","20215","February 28, 2019","July 18, 2019","July 18, 2019","August 23, 2018",,"September 19, 2019","Many Locations, Multiple Locations, Germany",,"https://ClinicalTrials.gov/show/NCT03644511"
82,"NCT03639675","Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also Studied","VENERA","Completed","No Results Available","Glaucoma, Neovascular","Drug: Aflibercept (EYLEA, BAY86-5321)|Drug: Topical IOP-lowering drugs","Change in IOP (intraocular pressure) from baseline to Week 1|Proportion of subjects who have improved NVI grade from baseline to Week 1","Bayer|Regeneron Pharmaceuticals","All","20 Years and older   (Adult, Older Adult)","Phase 3","16","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19652","October 3, 2018","February 14, 2019","March 14, 2019","August 21, 2018",,"April 4, 2019","University of Fukui Hospital, Yoshida, Fukui, Japan|Tsukazaki Hospital, Himeji, Hyogo, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, Japan|St. Marianna University School of Medicine Hospital, Kawasaki, Kanagawa, Japan|Osaka University Hospital, Suita, Osaka, Japan|Takatsuki Red Cross Hospital, Takatsuki, Osaka, Japan|Shimane University Hospital, Izumo, Shimane, Japan",,"https://ClinicalTrials.gov/show/NCT03639675"
83,"NCT03622801","Study on the Risk of Allergy-like Reactions After Intra-arterial or Intra-venous Injection of the Marketed X-ray Contrast Medium Iopromid","UVIA","Completed","No Results Available","Contrast Medium","Drug: Iopromide (Ultravist, BAY86-4877)","Number of patients with anaphylactoid reactions of Iopromide after administration|Number of patients with anaphylactoid reactions after intra-arterial administration of Iopromide|Number of patients with anaphylactoid reactions after intra-venous administration of Iopromide","Bayer","All","18 Years and older   (Adult, Older Adult)",,"133331","Industry","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","19677","October 12, 2018","February 14, 2019","February 14, 2019","August 9, 2018",,"March 12, 2019","Many Locations, Multiple Locations, Germany",,"https://ClinicalTrials.gov/show/NCT03622801"
84,"NCT03605810","Study to Develop a Tool to Estimate the Kidney Function in Databases Without Laboratory Data",,"Completed","No Results Available","Renal Function","Other: No Intervention","Performance of classification to predict eGFR","Bayer","All","18 Years and older   (Adult, Older Adult)",,"5132200","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","20325","July 15, 2018","December 31, 2018","December 31, 2018","July 30, 2018",,"December 10, 2019","US OPTUM CDM database, Whippany, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03605810"
85,"NCT03603678","Obstructive Sleep Apnea (OSA) Treated With a Potassium Channel Inhibitor","SANDMAN","Completed","No Results Available","Sleep Apnea, Obstructive","Drug: BAY2253651|Drug: Placebo","Rate of responders, defined by reduction of apnoea-hypopnoea-index (AHI) from baseline by ≥ 50%|Incidence of treatment emergent adverse events (TEAEs)|Severity of treatment emergent adverse events (TEAEs)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","34","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","19038|2017-001851-29","August 13, 2018","May 23, 2019","September 2, 2019","July 27, 2018",,"September 25, 2019","University Hospital Zürich, Zürich, Switzerland|Oxford University Hospitals, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03603678"
86,"NCT03603366","Study to Evaluate How Patients Regard the Benefits and Risks of Low-dose Aspirin for the Prevention of Heart and Blood Vessels Disease and for the Prevention of Cancer of the Colon and Rectum",,"Completed","No Results Available","Cardiovascular Disease|Colorectal Cancer","Drug: Acetylsalicylic acid (Aspirin, BAYE4465)","Patients preferences regarding low-dose aspirin using a discrete choice experiment|Patients understanding regarding benefits and risks of low-dose aspirin using a qualitative phone or in-person interviews|Physicians understanding regarding benefits and risks while prescribing low-dose aspirin by using a qualitative phone or in-person interviews","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)",,"1005","Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","20211","August 14, 2019","October 14, 2019","October 14, 2019","July 27, 2018",,"November 27, 2019","Many locations, Multiple Locations, Italy",,"https://ClinicalTrials.gov/show/NCT03603366"
87,"NCT03603275","Assessing Physician and Hemophilia A Patient Reasons and Expectations for Switching Treatment to Kovaltry & Jivi: A Nested Study Within an Existing Registry",,"Recruiting","No Results Available","Hemophilia A","Drug: New FVIII products","Patient reported reasons for switching FVIII replacement treatment to Kovaltry or Jivi using a Bayer designed survey|Patient expectations of switching FVIII replacement therapy to Kovaltry or Jivi would affect lifestyle/quality of life using a Bayer designed survey|Patient expectations when adjusting to the new product after switch using a Bayer designed survey|Patient reported root of expectations using a Bayer designed survey|Patient reported reasons that would deter them from switching FVIII replacement products using a Bayer designed survey|Physicians reported discipline using a Bayer designed survey|Physicians reported reasons for switching FVIII replacement treatment to Kovaltry or Jivi using a Bayer designed survey|Dosing Regimen (pre/post-switch)|Physicians reported reason of newly selected dose/dosing interval using a Bayer designed survey|Physicians reported rationale base for new dosing regimen selection using a Bayer designed survey|Physicians reported communication about adjustment period when switching using a Bayer designed survey|Physicians reported reasons that a provider would not encourage a patient to switch FVIII products using a Bayer designed survey","Bayer|American Thrombosis and Hemostasis Network","All","2 Years and older   (Child, Adult, Older Adult)",,"128","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","19866","August 6, 2018","December 31, 2021","December 31, 2021","July 27, 2018",,"January 21, 2020","University of California, San Diego, La Jolla, California, United States|University of Colorado Denver Hemophilia and Thrombosis Center, Aurora, Colorado, United States|Yale Hemophilia Treatment Center, New Haven, Connecticut, United States|Children's National Medical Center, Washington, District of Columbia, United States|Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States|St. Josephs Hemophilia Treatment Center, Tampa, Florida, United States|Emory / Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Bleeding and Clotting Disorders Institute, Peoria, Illinois, United States|Indiana Hemophilia and Thrombosis Center IHTC, Indianapolis, Indiana, United States|Louisiana Center for Bleeding and Clotting Disorders / Tulane, New Orleans, Louisiana, United States|Maine Hemophilia and Thrombosis Center, Scarborough, Maine, United States|The Johns Hopkins University Hemophilia Treatment Center, Baltimore, Maryland, United States|Boston Hemophilia Center at Children's Hospital of Boston/Brigham Women's, Boston, Massachusetts, United States|Univ of Michigan Hemophilia and Coagulation Disorders, Ann Arbor, Michigan, United States|Michigan State University Center for Bleeding Disorders & Clotting Disorders, East Lansing, Michigan, United States|Children's Mercy Hospital (Kansas City), Kansas City, Missouri, United States|Dartmouth-Hitchcock Comprehensive Hemophilia and Thrombosis Center, Lebanon, New Hampshire, United States|Weill Cornell Medicine, New York, New York, United States|Mary M. Gooley Hemophilia Center, Inc., Rochester, New York, United States|Oregon Health & Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, United States|Penn Comprehensive Hemophilia and Thrombophilia Program / Hospital UPENN, Philadelphia, Pennsylvania, United States|Hemophilia Center of Western Pennsylvania, Pittsburgh, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|UT Southwestern/Children's Health Dallas, Dallas, Texas, United States|BloodWorks (Puget Sound), Seattle, Washington, United States|Blood Center of Wisconsin, Inc. /Childrens Hosp of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03603275"
88,"NCT03602339","Comparison of Gadovist 75% Standard Dose to Dotarem at Full Standard Dose","LEADER75","Recruiting","No Results Available","Magnetic Resonance Imaging","Drug: Gadoterate (Dotarem®/Clariscan™)|Drug: BAY86-4875 (Gadobutrol; Gadovist®/ Gadavist®)","Degree of lesion contrast enhancement|Lesion border delineation|Lesion internal morphology|Number of lesions|Identification of benign or malignant disease|Confidence in diagnosis|Image quality|Contrast enhancement|Number of patients with adverse events","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 4","180","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","19773|2018-000690-78","November 14, 2018","March 6, 2020","March 6, 2020","July 26, 2018",,"January 9, 2020","Palm Beach Neurology, PA, West Palm Beach, Florida, United States|Northwestern University, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Mount Sinai Hospital, New York, New York, United States|Duke Univ. Medical Center, Durham, North Carolina, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Providence Health, Spokane, Washington, United States|Centre Hospitalier Lyon Sud, Pierre Benite, France|CHU STRASBOURG - Hôpital de Hautepierre, Strasbourg, France|Universitätsklinikum Erlangen, Erlangen, Bayern, Germany|Universität Rostock - Medizinische Fakultät, Rostock, Mecklenburg-Vorpommern, Germany|Medizinische Hochschule Hannover (MHH), Hannover, Niedersachsen, Germany|Universitätsklinikum Leipzig AöR, Leipzig, Sachsen, Germany|Universitätsklinikum Schleswig-Holstein (UKSH), Kiel, Schleswig-Holstein, Germany|Universitätsklinikum Schleswig-Holstein / AÖR, Lübeck, Schleswig-Holstein, Germany|Friedrich-Schiller-Uni. Jena, Jena, Thüringen, Germany|A.O.U. Maggiore della Carità, Novara, Piemonte, Italy|ASL Provincia di Barletta-Andria-Trani, Andria, Puglia, Italy|A.O.U. Pisana, Pisa, Toscana, Italy|ULSS2 Marca Trevigiana, Treviso, Veneto, Italy|Ulsan University Hospital, Ulsan, Ulsan Gwang''yeogsi, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Kantonsspital Aarau, Aarau, Aargau, Switzerland|Inselspital Universitätsspital Bern, Bern, Switzerland|Royal Preston Hospital, Preston, Lancashire, United Kingdom|Royal Stoke University Hospital, Stoke on Trent, Staffordshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03602339"
89,"NCT03599323","Study on the Safety of the Approved Product Empedic L Cream During Its Routine Use (Active Ingredient is Clotrimazole 1%)",,"Recruiting","No Results Available","Vaginal Candida","Drug: Clotrimazole 1% (Empecid L Cream, BAYB5097)","Incidence of adverse event (AE) and serious adverse event (SAE) in consumers using Empecid L Cream.|Types of AE recorded in Questionnaire|Patterns and way of use of Empecid L Cream recorded in Questionnaire","Bayer|SATO PHARMACEUTICAL , Ltd.","Female","15 Years to 60 Years   (Child, Adult)",,"1000","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","19439","July 10, 2018","September 15, 2021","October 15, 2021","July 26, 2018",,"December 30, 2019","Many Locations, Multiple Locations, Japan",,"https://ClinicalTrials.gov/show/NCT03599323"
90,"NCT03597022","Multiple Escalating Dose Study of BAY1093884 in Adults With Hemophilia A or B With or Without Inhibitors",,"Terminated","No Results Available","Hemophilia A and B","Drug: BAY1093884","Frequency of drug-related adverse events (AEs)|Frequency of drug-related serious adverse events (SAEs)|Frequency of adverse events of special interest (AESIs)|Frequency of clinically relevant abnormalities in laboratory values","Bayer","Male","18 Years and older   (Adult, Older Adult)","Phase 2","24","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19580|2017-003324-67","July 24, 2018","October 15, 2019","October 15, 2019","July 24, 2018",,"November 7, 2019","Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Allgemeines Krankenhaus der Stadt Wien, Wien, Austria|Medical centre Hipokrat - N EOOD, Plovdiv, Bulgaria|SHATHD Spec. Hospi. for Active Treatm. of Haematol. Dis. EAD, Sofia, Bulgaria|MHAT Sveta Marina EAD, Varna, Bulgaria|Hôpital Louis Pradel - Bron, Bron, France|Hôpital Robert Debré - Reims Cedex, Reims Cedex, France|Pecsi Tudomanyegyetem Klinikai Kozpont, Pecs, Hungary|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Lombardia, Italy|Ogikubo Hospital, Suginami, Tokyo, Japan|Hiroshima University Hospital, Hiroshima, Japan|Eulji University Hospital, Daejeon, Korea, Republic of|Haematology Service, Canterbury Health Laboratories, Christchurch, New Zealand|Changhua Christian Hospital, Changhua, Taiwan|University Hospital of Wales, Cardiff, United Kingdom|Royal Free Hospital, London, United Kingdom|Manchester Royal Infirmary, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03597022"
91,"NCT03596372","Study of BAY1834942 in Patients With Solid Tumors",,"Recruiting","No Results Available","Advanced CEACAM6-expressing Solid Tumors","Drug: BAY1834942","Incidence of treatment-emergent adverse events|Severity of treatment-emergent adverse events|Cmax of BAY1834942 after single dose|AUC(0-504) of BAY1834942 after single dose|AUC(0-504),md of BAY1834942 after multiple doses|Cmax,md of BAY1834942 after multiple doses|Overall response rate (ORR)|Leukocyte immune phenotyping|CEACAM6 receptor occupancy|Cytokine levels|Ex vivo-stimulated cytokine secretion|Concentration of carcinoembryonic antigens (CEA; tumor marker) in serum|Concentration of anti-drug antibodies","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","156","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18650|2018-002561-19","June 19, 2018","June 15, 2021","December 13, 2021","July 23, 2018",,"January 9, 2020","Sarah Cannon Research Institute, Nashville, Tennessee, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Princess Margaret Hospital-University Health Network, Toronto, Ontario, Canada|National University Hospital, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT03596372"
92,"NCT03588299","Factor VIII Gene Therapy Study in Patients With Hemophilia A",,"Recruiting","No Results Available","Hemophilia A","Drug: BAY2599023 (DTX201)","Number of patients with adverse events (AEs), treatment-emergent adverse events (TEAEs), serious adverse events (SAEs) and AEs/SAEs of special interest|Expression pattern of FVIII activity.|Proportion of patients in the respective dose step, that reached an expression of FVIII above 5% at 6 months and 12 months following the IV administration of BAY2599023","Bayer|Ultragenyx Pharmaceutical Inc","Male","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19429|2017-000806-39","November 7, 2018","March 16, 2021","July 22, 2025","July 17, 2018",,"January 7, 2020","Arkansas Children's Hospital, Little Rock, Arkansas, United States|Loma Linda Children's Hospital, San Bernardino, California, United States|C.S. Mott Children's Hospital, Ann Arbor, Michigan, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|University of Wisconsin - Madison, Madison, Wisconsin, United States|SHATHD Spec. Hospi. for Active Treatm. of Haematol. Dis. EAD, Sofia, Bulgaria|Hôpital Calmette - Lille Cedex, Lille Cedex, France|Hôpital de la Timone - Marseille, Marseille, France|Hopital Necker les enfants malades - Paris, Paris, France|Hôpital Pontchaillou, Rennes Cedex, France|Universitätsklinikum der Johann Wolfgang Goethe Universität, Frankfurt, Hessen, Germany|Universitätsklinikum des Saarlandes, Homburg, Saarland, Germany|Vivantes Klinikum im Friedrichshain, Berlin, Germany|Academisch Medisch Centrum (AMC), Amsterdam, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Erasmus Medisch Centrum, Rotterdam, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|Hospital Central de Asturias, Oviedo, Asturias, Spain|Ciutat Sanitària i Universitaria de la Vall d'Hebron, Barcelona, Spain|Hospital de la Santa Creu i de Sant Pau, Barcelona, Spain|Hospital Universitario ""La Paz"", Madrid, Spain|Hospital Regional de Málaga, Málaga, Spain|Hospital Universitari i Politècnic La Fe, Valencia, Spain|St Thomas' Hospital, London, United Kingdom|Manchester Royal Infirmary, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03588299"
93,"NCT03579732","EffectiveNess of Low Dose Aspirin in GastrointEstinal Cancer Prevention - Taiwan","ENgAGE-Taiwan","Completed","No Results Available","Colorectal Neoplasms","Drug: Aspirin (Acetylsalicylic Acid, BAYE4465)|Other: No drug","Number of subjects with colorectal cancer|Number of subjects with esophageal cancer|Number of subjects with gastric cancer|Duration of aspirin use to colorectal cancer|Time from aspirin discontinuation to colorectal cancer|Stage of colorectal cancer|Number of fatal cases due to colorectal cancer","Bayer","All","40 Years and older   (Adult, Older Adult)",,"4710504","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","19882","June 29, 2018","September 30, 2019","September 30, 2019","July 9, 2018",,"October 8, 2019","National University of Taiwan Hospital, Taipeh, Taiwan",,"https://ClinicalTrials.gov/show/NCT03579732"
94,"NCT03577977","Betaferon Use in Children and Adolescents With Multiple Sclerosis",,"Completed","No Results Available","Multiple Sclerosis","Drug: Interferon beta-1b (Betaseron, Betaferon, BAY86-5046)","Mean expanded disability status scale (EDSS) score at the end of trial participation|Proportion of patients having the mean EDSS score of less than or equal to 3.0 and more than or equal to 3.5 at the end of the trial|Mean frequency of complications recorded after start of betaferon therapy|Mean EDSS score on the exacerbations recorded after start of betaferon therapy|Number of adverse events described during the trial and described as possibly, likely, or undoubtedly associated with the test drug|Number of mild, moderate, or severe adverse events|Number of serious adverse events described during the trial|Number of adverse events described during the trial and classified as an flu-like syndrome|Number of adverse events described during the trial and classified as a local reaction|Number of cases of betaferon discontinuation due to adverse events","Bayer","All","up to 18 Years   (Child, Adult)",,"70","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2008/01743","June 1, 2008","April 15, 2009","April 15, 2009","July 5, 2018",,"July 11, 2018","Multiple Locations, Russian Federation",,"https://ClinicalTrials.gov/show/NCT03577977"
95,"NCT03573336","Assess Safety and Efficacy of Vilaprisan in Subjects With Endometriosis","VILLENDO","Active, not recruiting","No Results Available","Endometriosis","Drug: Vilaprisan (BAY1002670)|Drug: Matching Placebo","The change in the subject's 7-day mean 'worst pain' from baseline to month 3|The proportion of subjects with an improvement of the subject's mean 'worst pain' on bleeding days from baseline with no increase in rescue pain medication use|The proportion of subjects with an improvement of the subject's mean 'worst pain' on non-bleeding days from baseline with no increase in rescue pain medication use|The number of participants with adverse events|The number of clinical significant abnormal of endometrial histology|The number of clinical significant abnormal of ultrasound examinations|The number of clinical significant abnormal of bone mineral density|The number of clinical significant abnormal of laboratory parameters","Bayer","Female","18 Years and older   (Adult, Older Adult)","Phase 2","8","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15792|2013-004768-72","July 4, 2018","June 30, 2020","June 30, 2020","June 29, 2018",,"January 22, 2020","Office of Dr. James A. Simon, MD, Washington, District of Columbia, United States|Helix Biomedics, LLC, Boynton Beach, Florida, United States|Solutions Through Advanced Research, Inc., Jacksonville, Florida, United States|Southern Clinical Research Associates LLC, Metairie, Louisiana, United States|Unified Women's Clinical Research - Morehead City, Morehead City, North Carolina, United States|Unified Women's Clinical Research, Winston-Salem, North Carolina, United States|Kepler Universitätsklinikum Campus IV, Linz, Oberösterreich, Austria|Medizinische Universität Graz, Graz, Steiermark, Austria|KABEG Landeskrankenhaus Villach, Villach, Austria|Allgemeines Krankenhaus der Stadt Wien, Wien, Austria|Queen's University, Kingston, Ontario, Canada|Ottawa Hospital-Riverside Campus, Ottawa, Ontario, Canada|Clinique OVO, Montreal, Quebec, Canada|Gynekologie MEDA s.r.o., Brno, Czechia|GynCare MUDr. Michael Svec s.r.o., Plzen, Czechia|VL-Medi Oy, Helsinki, Finland|Satakunnan keskussairaala, Pori, Finland|A.O.U.I. Verona, Verona, Veneto, Italy|Tokeidai Memorial Clinic, Sapporo, Hokkaido, Japan|Ishikawa Prefectural Central Hospital, Kanazawa, Ishikawa, Japan|Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan|Toyama Prefectural Central Hospital, Toyama, Japan|Centrum Medyczne Chodzki, Lublin, Poland",,"https://ClinicalTrials.gov/show/NCT03573336"
96,"NCT03570554","A Pilot Study Assessing the Treatment Responsiveness of a Novel Osteoarthritis Stiffness Scale",,"Completed","No Results Available","Osteoarthritis, Knee","Drug: Treatment A (Naproxen Sodium [Aleve , BAY117031] + Placebo)|Drug: Treatment B (Acetaminophen + Placebo)|Drug: Treatment C (Celecoxib + Placebo)|Drug: Treatment D (Placebo)","Sum of change in Brief Arthritis Stiffness Scale (BASS) score for each treatment|Absolute BASS score at each time point for each treatment|Change in BASS score between Day 1 (baseline) and Day 4 for each treatment","Bayer","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 2","41","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","19783","June 29, 2018","June 14, 2019","June 14, 2019","June 27, 2018",,"July 5, 2019","Radiant Research, Inc., Chandler, Arizona, United States|Radiant Research, Inc., Pinellas Park, Florida, United States|Radiant Research, Inc., Chicago, Illinois, United States|Radiant Research, Inc., Cincinnati, Ohio, United States|Radiant Research, Inc., San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03570554"
97,"NCT03564938","Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).",,"Recruiting","No Results Available","Colorectal Neoplasms","Drug: Regorafenib (Stivarga, BAY73-4506)","Number of Adverse Events|Changes in Eastern Cooperative Oncology Group Performance Status (ECOG PS)|Abnormal laboratory changes with clinical significance|Changes in vital signs|Disease control rate (DCR) defined as proportion of patients achieving complete response (CR), partial response (PR), or SD (stable disease) per Response Evaluation Criteria in Solid Tumors (RECIST) v. 1.1|Overall response rate (ORR) defined as proportion of patients achieving CR, and PR per RECIST v.1.1|Progression free survival (PFS)|Overall survival (OS)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 4","100","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19214","July 30, 2018","October 20, 2021","October 20, 2021","June 21, 2018",,"January 7, 2020","HCG-City Cancer Centre, Vijayawada, Andhra Pradesh, India|Sir Ganga Ram Hospital, New-Delhi, Delhi, India|The Gujarat Cancer & Research Institute, Ahmedabad, Gujarat, India|Healthcare Center Global Hospital, Ahmedabad, Gujarat, India|Manipal Hospital, Bangalore, Karnataka, India|Healthcare Global Enterprises Ltd, Bangalore, Karnataka, India|Amrita Institute of Medical Sciences, Kochi, Kerala, India|Tata Memorial Hospital, Mumbai, Maharashtra, India|Jaslok Hospital and Research Centre, Mumbai, Maharashtra, India|Jehangir Hospital, Pune, Maharashtra, India|Fortis Hospital, West-Mumbai, Maharashtra, India|Sparsh Hospital & Critical Care, Bhubaneswar, Orissa, India|Apollo Speciality Hospitals, Madurai, Tamil N?du, India|IPGME & R / SSKM Hospital, Kolkata, West Bengal, India|Health Point Hospital, Kolkata, West Bengal, India|Indraprastha Apollo Hospital, New Delhi, India",,"https://ClinicalTrials.gov/show/NCT03564938"
98,"NCT03563937","Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. Phenprocoumon","ReLoaDeD","Completed","No Results Available","Atrial Fibrillation","Drug: Phenprocoumon|Drug: Apixaban|Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Edoxaban","Risk of Ischemic stroke (IS) / Systemic embolism(SE) (as combined endpoint and alone), recurrent IS/SE (as combined endpoint) and severe IS in patients with NVAF and renal impairment determined by inpatient claims based diagnoses|Risk of intracranial hemorrhage (ICH) in patients with non-valvular atrial fibrillation (NVAF) with renal impairment determined by inpatient claims based diagnoses|Healthcare resource consumption in patients with non-valvular atrial fibrillation (NVAF) and renal impairment determined by inpatient claims based diagnoses|Overall costs in patients with renal impairment determined by inpatient claims based diagnoses|Sector specific costs in patients with renal impairment determined by inpatient claims based diagnoses|Risk of fatal bleeding in patients with NVAF (overall population as well as patients with renal impairment) determined by inpatient claims based diagnoses|Risk of recurrent hospitalizations (in general and for IS/SE)|Risk of Kidney failure determined by inpatient claims based diagnoses|Risk of Acute kidney injury (AKI) determined by inpatient claims based diagnoses|Risk of treatment discontinuation in patients with NVAF (overall population as well as patients with renal impairment) determined by pharmacy claims|Risk of IS, SE, Severe IS and recurrent IS/SE in patient with NVAF determined determined by inpatient claims based diagnoses","Bayer|Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)",,"58479","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","20031","October 2, 2019","December 10, 2019","December 10, 2019","June 20, 2018",,"December 23, 2019","Many Locations, Multiple Locations, Germany",,"https://ClinicalTrials.gov/show/NCT03563937"
99,"NCT03563014","A Local Retrospective Observational Study to Evaluate the Treatment Patterns of mCRPC Patients in Belgium Treated With Radium-223","BELFIGO","Completed","No Results Available","Prostatic Neoplasms, Castration-Resistant","Drug: Radium-223 (Xofigo, Bay88-8223)","The proportion of patients with 5-6 Radium-223 injections versus 1-4 Radium-223 injections|The proportion of patients with 5-6 Radium-223 injections versus 1-4 Radium-223 injections by Radium-223 line of treatment (1st, 2nd and further line)|The number of prior and post life prolonging systemic anti-cancer therapies will be described|The characteristics of patients according to the experience of the study centers with Radium-223|The occurrence of progression post first dose of Radium-223|The occurrence of SSE related hospitalizations|The frequency of SSE related hospitalizations|The number of discontinuation of Radium-223|The frequency of blood transfusions|The overall survival in routine clinical practice|The number of patients receiving first- and second-line systemic anti-cancer treatment in mCRPC|The timing of progression post first dose of Radium-223|The time between last Radium-223 injection and next line of systemic anti-cancer therapy|The number of patients receiving next line of systemic anti-cancer therapy","Bayer","Male","Child, Adult, Older Adult",,"164","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","20239","July 31, 2018","January 31, 2019","January 31, 2019","June 20, 2018",,"February 15, 2019","Many Locations, Multiple Locations, Belgium",,"https://ClinicalTrials.gov/show/NCT03563014"
100,"NCT03562624","A Study to Compare 3 Doses of a Hormonal Intra-uterine Device Containing Levonorgestrel and Indomethacin With a Hormonal Intra-uterine Device Containing Only Levonorgestrel to Assess the Effect and Safety of the Combined Components","INDessa","Completed","No Results Available","Contraception","Drug: BAY98-7443|Drug: Levonogestrel (Skyla, BAY86-5028)","Number of uterine bleeding/spotting (B/S) days during treatment|Number of subjects showing endometrial histology typical for intrauterine LNG application in biopsies taken at the end of treatment|Frequency of treatment emergent adverse events","Bayer","Female","18 Years to 45 Years   (Adult)","Phase 2","177","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","17700|2018-000128-33","June 22, 2018","May 16, 2019","August 1, 2019","June 19, 2018",,"August 12, 2019","Nuvisan GmbH, Neu-Ulm, Bayern, Germany|Frauenarztpraxis Dr. Wetzel, Blankenburg, Sachsen-Anhalt, Germany|Dinox GmbH Berlin, Berlin, Germany|CRS Clinical Research Services Berlin GmbH, Berlin, Germany|CTC North GmbH & Co. KG, Hamburg, Germany|Praxis Hr. Dr. K. Peters, Hamburg, Germany|PAREXEL International Early Phase Clinical Unit (London), Harrow, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03562624"
101,"NCT03556787","An Evaluation of a Gender Specific Insole to Provide Relief From Knee Pain Due to Osteoarthritis or General Anterior Knee Pain in Male Subjects When Used in Foot Wear Over a Period of Four Weeks",,"Completed","No Results Available","Osteoarthritis, Knee","Device: BPI 1000013 (Dr Scholls Insole)","Osteoarthritis knee pain according to Visual Analog Scale|General anterior knee pain according to Visual Analog Scale|Foot Comfort according to Likert scale|Shoe Fit according to Likert scale|Number of subjects with adverse events|Number of subjects with serious adverse events","Bayer","Male","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","89","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20244","June 4, 2018","November 8, 2018","November 8, 2018","June 14, 2018",,"November 23, 2018","Focus & Testing, Inc., Calabasas, California, United States|The Wolf Group, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03556787"
102,"NCT03547583","Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF","VITALITY-HFpEF","Completed","No Results Available","Chronic Heart Failure With Preserved Ejection Fraction","Drug: Vericiguat (BAY1021189) 2.5 mg, 5 mg or 10 mg IR tablets|Drug: Placebo","Change in KCCQ physical limitation score from baseline to week 24|Change in the Six-minute walk test (6MWT) from baseline to week 24","Bayer|Merck Sharp & Dohme Corp.|Canadian VIGOUR Centre|Duke Clinical Research Institute","All","45 Years and older   (Adult, Older Adult)","Phase 2","788","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","19334|2018-000298-65","June 15, 2018","October 15, 2019","November 4, 2019","June 6, 2018",,"December 18, 2019","WestSide Medical, Beverly Hills, California, United States|Capitol Interventional Cardiology, Carmichael, California, United States|Interventional Cardiology Medical Group, West Hills, California, United States|Penrose-St. Francis Health Services, Colorado Springs, Colorado, United States|Cardiology Associates of Fairfield County, PC, Trumbull, Connecticut, United States|Cardiology Associates Of South Florida PA, Boynton Beach, Florida, United States|Cardiovascular and Vein Center of Florida, Bradenton, Florida, United States|Cardiology Associates Research Company, Daytona Beach, Florida, United States|Life Spring Research, Miami, Florida, United States|Southwest Florida Research, Naples, Florida, United States|East Coast Institute for Research, LLC, Saint Augustine, Florida, United States|Cardiology Partners, Wellington, Florida, United States|Fox Valley Clinical Research Center, LLC, Aurora, Illinois, United States|Advocate Condell Medical Center, Libertyville, Illinois, United States|Reid Health, Richmond, Indiana, United States|Research Integrity, LLC, Owensboro, Kentucky, United States|Heart Clinic of Hammond, Hammond, Louisiana, United States|Anne Arundel Health System, Annapolis, Maryland, United States|Henry Ford Health System, Detroit, Michigan, United States|Riser Medical Associates, Picayune, Mississippi, United States|St. Louis Heart & Vascular, PC, Saint Louis, Missouri, United States|Glacier View Research Institute-Cardiology, Kalispell, Montana, United States|Bryan Heart, Lincoln, Nebraska, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Capital Area Research, LLC, Camp Hill, Pennsylvania, United States|Carolina Heart Specialists, Lancaster, South Carolina, United States|Stern Cardiovascular Center, Germantown, Tennessee, United States|Clinical Advancement Center, PLLC, San Antonio, Texas, United States|Corporation Lane Research Center, Virginia Beach, Virginia, United States|Clínica DIM, Ramos Mejía, Buenos Aires, Argentina|Instituto de Investigaciones Clínicas San Nicolás, San Nicolás, Buenos Aires, Argentina|Centro de Investigaciones Clínicas, Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Centro de Medicina Integral e Investigacion Clínica, Caba, Ciudad Auton. De Buenos Aires, Argentina|Centro de Especialidades Médicas, Villa Luro, Ciudad Auton. De Buenos Aires, Argentina|Sanatorio Parque S.A., Rosario, Santa Fe, Argentina|Inst. de Cardiología de Corrientes Juana Francisca Cabral, Corrientes, Argentina|Centro de Investigaciones Clinicas del Litoral, Santa Fe, Argentina|Universitätsklinikum St. Pölten, St. Pölten, Niederösterreich, Austria|Krankenhaus St. Josef Braunau, Braunau, Oberösterreich, Austria|Krankenhaus der Elisabethinen Linz GmbH, Linz, Oberösterreich, Austria|Medizinische Universität Graz, Graz, Steiermark, Austria|Ordination Dr. Hanusch, Wien, Austria|Allgemeines Krankenhaus der Stadt Wien, Wien, Austria|Krankenhauses Nord - Klinik Floridsdorf, Wien, Austria|Algemeen Stedelijk Ziekenhuis Campus Aalst, Aalst, Belgium|AZ St-Jan Brugge Oostende AV, Brugge, Belgium|UZ Antwerpen, Edegem, Belgium|H. Hartziekenhuis Mol, MOL, Belgium|AZ Delta, Roeselare, Belgium|Multiprofile Hospital for Active Treatment Pazardzhik, Pazardzhik, Bulgaria|Spec Hosp for Active Treatm in Cardiology Sv Georgi Pernik, Pernik, Bulgaria|Specialized Hospital for Actrive Treatm of Card - Pleven, Pleven, Bulgaria|Multiprofile Hospital for Active Treatment Medline Clinic, Plovdiv, Bulgaria|MHAT Dr. Bratan Shukerov AD, Smolyan, Bulgaria|Second Medical Center Sofia EOOD, Sofia, Bulgaria|NMTH Tzar Boris III, Sofia, Bulgaria|V MHAT, Sofia, Bulgaria|MHAT Sveta Marina EAD, Varna, Bulgaria|University of Alberta, Edmonton, Alberta, Canada|SMH Cardiology Clinical Trials Inc, Surrey, British Columbia, Canada|London Health Sciences Centre, London, Ontario, Canada|PACE Cardiology Clinic, Newmarket, Ontario, Canada|Oakville Cardiologists, Inc., Oakville, Ontario, Canada|Cardiovascular CRO Ltd., Sudbury, Ontario, Canada|St. Michael's Hospital Health Centre, Toronto, Ontario, Canada|Clinique Sante Cardio MC, Montreal, Quebec, Canada|Centre De Recherche Du (CRCHUM) - Hotel-Diu, Montreal, Quebec, Canada|CardioVasc HR, Inc., Saint-Jean-sur-Richelieu, Quebec, Canada|Hospital General de Medellin, Medellin, Antioquia, Colombia|IPS Centro Cientifico Asistencial S.A.S, Barranquilla, Atlántico, Colombia|Caja de Compensación Familiar CAFAM, Bogotá, Distrito Capital De Bogotá, Colombia|Mediservis del Tolima IPS S.A.S, Ibague, Tolima, Colombia|Fundación Cardiovascular de Colombia, Floridablanca, Colombia|Klinikum der Universität Würzburg, Würzburg, Bayern, Germany|Zentrum für Klinische Studien Südbrandenburg GmbH, Elsterwerda, Brandenburg, Germany|Herz- und Diabeteszentrum Nordrhein-Westfalen (HDZ NRW), Bad Oeynhausen, Nordrhein-Westfalen, Germany|Kliniken Maria Hilf GmbH, Mönchengladbach, Nordrhein-Westfalen, Germany|St. Vincenz und Elisabeth Hospital, Kathol. Klinikum Mainz, Mainz, Rheinland-Pfalz, Germany|Klinische Forschung Dresden GmbH, Dresden, Sachsen, Germany|Cardiologicum Hamburg - Praxen Wandsbek, Hamburg, Germany|KAT General Hospital of Athens, Kifisia / Athens, Attica, Greece|G. Gennimatas General State Hospital of Athens, Athens, Greece|University General Hospital of Larissa, Larissa, Greece|Konstantopoulio General Hospital of Nea Ionia - Agia Olga, Nea Ionia / Athens, Greece|University General Hospital of Thessaloniki ""AHEPA"", Thessaloniki, Greece|Hippokration General Hospital of Thessaloniki, Thessaloniki, Greece|Budai Irgalmasrendi Korhaz, Budapest, Hungary|Magyar Honvedseg Egeszsegugyi Kozpont Honvedkorhaz, Budapest, Hungary|Magyar Honvedseg Egeszsegugyi Kozpont Honvedkorhaz, Budapest, Hungary|Pharma4Trial Kft., Gyongyos, Hungary|Kanizsai Dorottya Hospital, Nagykanizsa, Hungary|Medifarma-98 Egeszsegugyi, Kereskedelmi es Szolgaltato Kft., Nyiregyhaza, Hungary|HaEmek Medical Center, Afula, Israel|Hillel Yaffe Medical Center, Hadera, Israel|Rambam Health Corporation, Haifa, Israel|Hadassah Hebrew University Hospital Ein Kerem, Jerusalem, Israel|Chaim Sheba Medical Center, Ramat Gan, Israel|Kaplan Medical Center, Rehovot, Israel|The Baruch Padeh Medical Center, Poria, Tiberias, Israel|Health Corporation of the Ziv Medical Center (R.A.), Zefat, Israel|Shamir Medical Center (Assaf Harofeh), Zrifin, Israel|A.O.U. di Bologna Policlinico S.Orsola Malpighi, Bologna, Emilia-Romagna, Italy|A.O.U. di Ferrara Arcispedale S.Anna, Ferrara, Emilia-Romagna, Italy|Asl Roma 6, Roma, Lazio, Italy|ASST Papa Giovanni XXIII, Bergamo, Lombardia, Italy|ASST Spedali Civili di Brescia, Brescia, Lombardia, Italy|IRCCS Istituto Clinico Humanitas (ICH), Milano, Lombardia, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milano, Lombardia, Italy|IRCCS Fondazione Policlinico San Matteo, Pavia, Lombardia, Italy|A.O.U. di Sassari, Sassari, Sardegna, Italy|Seikeikai New Tokyo Heart Clinic, Matsudo, Chiba, Japan|Steel Memorial Yawata Hospital, Kitakyushu, Fukuoka, Japan|Matsuda Cardiovascular clinic, Sapporo, Hokkaido, Japan|National Hospital Organization Kobe Medical Center, Kobe, Hyogo, Japan|Higashi Takarazuka Satoh Hospital, Takarazuka, Hyogo, Japan|National Hospital Organization Kanazawa Medical Center, Kanazawa, Ishikawa, Japan|Iwate Prefectural Central Hospital, Morioka, Iwate, Japan|Uji-Tokushukai Medical Center, Uji, Kyoto, Japan|Hirakata kohsai Hospital, Hirakata, Osaka, Japan|Kishiwada Tokushukai Hospital, Kishiwada, Osaka, Japan|Takatsuki Red Cross Hospital, Takatsuki, Osaka, Japan|Osaka Medical College Hospital, Takatsuki, Osaka, Japan|National Hospital Organization Hamada Medical Center, Hamada, Shimane, Japan|Minamino Cardiovascular Hospital, Hachioji, Tokyo, Japan|Toho University Omori Medical Center, Ota-ku, Tokyo, Japan|Tokyo Women's Medical University Hospital, Shinjuku-ku, Tokyo, Japan|National Hospital Organization Iwakuni Clinical Center, Iwakuni, Yamaguchi, Japan|Fukui Prefectural Hospital, Fukui, Japan|Okayama Rosai Hospital, Okayama, Japan|Osaka General Medical Center, Osaka, Japan|Toyama Prefectural Central Hospital, Toyama, Japan|Hospital Raja Perempuan Zainab II, Kelantan, Malaysia|Institute Jantung Negara, Kuala Lumpur, Malaysia|Sarawak Heart Centre, Sarawak, Malaysia|Uniwersytecki Szpital Kliniczny w Bialymstoku, Bialystok, Poland|10 Wojskowy Szpital Kliniczny z Poliklinika SPZOZ, Bydgoszcz, Poland|CLINICAL MEDICAL RESEARCH Sp. z o. o., Katowice, Poland|SPZOZ Centralny Szpital Kliniczny UM w Lodzi, Lodz, Poland|Szpital Kliniczny Przemienienia Panskiego, Poznan, Poland|Twoja Przychodnia - Szczecinskie Centrum Medyczne, Szczecin, Poland|Uniwersyteckie Centrum Kliniczne Warszawskiego UM, Warszawa, Poland|IV Wojskowy Szpital Kliniczny z Poliklinika, SPZOZ, Wroclaw, Poland|Dolnoslaski Szp. Spec. im T.M. Centrum Medycyny Ratunkowej, Wroclaw, Poland|Hospital de Cascais, Alcabideche, Lisboa, Portugal|CHTS - Hospital Padre Americo, Guilhufe, Porto, Portugal|CHS - Hospital Sao Bernardo, Setubal, Setúbal, Portugal|Hospital Garcia de Orta, Almada, Portugal|CHLO - Hospital Sao Francisco Xavier, Lisboa, Portugal|Hospital da Luz, Lisboa, Portugal|CHUP - Hospital Santo Antonio, Porto, Portugal|Sci-Res. Institute of Complex Cardiovascular Disorders, Kemerovo, Russian Federation|State Sientific Research Center for Preventive Medicine, Moscow, Russian Federation|Moscow State University n.a. M.V. Lomonosov, Moscow, Russian Federation|Samara Regional Clinical Cardiology Dispensary, Samara, Russian Federation|City hospital #15, St. Petersburg, Russian Federation|City Pokrovskaya Hospital, St. Petersburg, Russian Federation|Singapore General Hospital, Singapore, Singapore|National Heart Centre Singapore, Singapore, Singapore|Clinical Trial Systems, Pretoria, Gauteng, South Africa|Durban Medical Centre, Durban, Kwazulu-Natal, South Africa|Nash Ranjith Research Centre, Merebank, Kwazulu-Natal, South Africa|TREAD Research cc, Cape Town, Western Cape, South Africa|Tiervlei Trial Centre, Cape Town, Western Cape, South Africa|Vergelegen Medi-Clinic, Somerset West, Western Cape, South Africa|Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain|Ciutat Sanitària i Universitària de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Sant Joan Despi Moises Broggi, Sant Joan Despi, Barcelona, Spain|Hospital Sanitas La Zarzuela, Aravaca, Madrid, Spain|Hospital Universitario Clinica Puerta de Hierro, Majadahonda, Madrid, Spain|Hospital Álvaro Cunqueiro, Babio - Beade, Pontevedra, Spain|Hospital del Mar, Barcelona, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Complejo Hospitalario Ntra. Sra. de Valme, Sevilla, Spain|Far Eastern Memorial Hospital, New Taipei City, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Cheng Hsin General Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT03547583"
103,"NCT03543657","Maintenance Treatment of Renal Anemia in Dialysis Subjects","MIYABI HD-M","Completed","No Results Available","Anemia|Renal Insufficiency, Chronic","Drug: Molidustat (BAY85-3934)|Drug: Darbepoetin alfa|Drug: Placebo of Molidustat (BAY85-3934)|Drug: Placebo of Darbepoetin alfa","The mean Hb level during the evaluation period|The change in mean Hb level during the evaluation period from baseline|Responder rate: proportion of responders among the subjects|Proportion of subjects who meet each component of the response|Hb level|Change in Hb level|Proportion of subjects whose mean hemoglobin level is in the target range|Proportion of subjects whose mean hemoglobin level is above the target range|Proportion of subjects whose mean hemoglobin level is below the target range|Proportion of subjects with hemoglobin levels in the target range|Proportion of subjects with hemoglobin levels above the target range|Proportion of subjects with hemoglobin levels below the target range|Proportion of subjects whose maximum rise in Hb between each consecutive visits is above 0.5 g/dL/week|Number of participants with serious adverse events|Maximum concentration (Cmax)|Area under the concentration-time curve (AUC)|EPO (Erythropoietin) serum concentration","Bayer","All","20 Years and older   (Adult, Older Adult)","Phase 3","220","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","19352","June 23, 2018","August 7, 2019","December 24, 2019","June 1, 2018",,"January 18, 2020","Hakuyoukai Medical corporation Hakuyoukai Hospital, Nagoya, Aichi, Japan|Shinkashiwa Clinic, Kashiwa, Chiba, Japan|Kisarazu Clinic, Kisarazu, Chiba, Japan|Kuwajima Clinic, Niihama, Ehime, Japan|Sabae kidney Clinic, Sabae, Fukui, Japan|Houshikai Kano hospital, Kasuya-gun, Fukuoka, Japan|Saiseikai Yahata General Hospital, Kitakyushu, Fukuoka, Japan|Sanshikai Toho Hospital, Midori, Gunma, Japan|Asahikawa-Kosei General Hospital, Asahikawa, Hokkaido, Japan|Koizumi Cardiology Medical Clinic, Chitose, Hokkaido, Japan|Ishikari Hospital, Ishikari, Hokkaido, Japan|Itami Kidney Clinic, Noboribetsu, Hokkaido, Japan|Souen Central Hospital, Sapporo, Hokkaido, Japan|Ibaraki Prefectural Central Hospital, Kasama, Ibaraki, Japan|Japanese Red Cross Koga Hospital, Koga, Ibaraki, Japan|Mito Kyodo General Hospital, Mito, Ibaraki, Japan|Tokiwa Clinic, Totte, Ibaraki, Japan|Tsuchiura Beryl Clinic, Tsuchiura, Ibaraki, Japan|Kikuchi Medical Clinic, Tsukuba, Ibaraki, Japan|Public Central Hospital of Matto Ishikawa, Hakusan, Ishikawa, Japan|Kaisei Hospital, Sakaide, Kagawa, Japan|Honatsugi Medical Clinic, Atsugi, Kanagawa, Japan|Chigasaki Central Clinic, Chigasaki, Kanagawa, Japan|Toshiba Rinkan Hospital, Sagamihara, Kanagawa, Japan|Yokohama Jin Clinic, Yokohama, Kanagawa, Japan|Eda Clinic, Yokohama, Kanagawa, Japan|Kaminagaya Saitou Clinic, Yokohama, Kanagawa, Japan|Seisuikai Yoshioka Mahoroba Clinic, Kurokawa-gun, Miyagi, Japan|Eijinkai Hospital, Osaki, Miyagi, Japan|Iida Hospital, Iida, Nagano, Japan|Kanno Dialysis & Vascular Access Clinic, Matsumoto, Nagano, Japan|Matsumoto City Hospital, Matsumoto, Nagano, Japan|Maruko Central Hospital, Ueda, Nagano, Japan|Arisawa General Hospital, Hirakata, Osaka, Japan|Toyonaka Keijinkai Clinic, Toyonaka, Osaka, Japan|Hanyu General Hospital, Hanyu, Saitama, Japan|Higashimatsuyamakohjin Clinic, Higashimatsuyama, Saitama, Japan|Saiyu Clinic, Koshigaya, Saitama, Japan|Todachuo General Hospital, Toda, Saitama, Japan|Hachioji Azumacho Clinic, Hachioji, Tokyo, Japan|Kodaira Kitaguchi Clinic, Kodaira, Tokyo, Japan|Saint Hill Hospital, Ube, Yamaguchi, Japan|Inage Hospital, Chiba, Japan|Ikeda Vascular Access Nephrology Dialysis, Fukuoka, Japan|Oohashi internal medicine circulatory Clinic, Fukuoka, Japan|Ueki Imafuji Clinic, Kumamoto, Japan|Medical Corporation Suzukihinyoukika, Nagano, Japan|Nagasaki Kidney Hospital, Nagasaki, Japan|Akagaki Clinic, Osaka, Japan|Nishi Shinryosho, Osaka, Japan|Chibune Clinic, Osaka, Japan|Iwatsuki-minami Hospital, Saitama, Japan|Yamagata Tokushukai Hospital, Yamagata, Japan",,"https://ClinicalTrials.gov/show/NCT03543657"
104,"NCT03540615","BAY1830839: First in Man, Single Dose Escalation, Safety & Tolerability and Pharmacokinetics",,"Completed","No Results Available","Arthritis, Rheumatoid","Drug: BAY1830839|Drug: Placebo","AUC of BAY1830839 in plasma|Cmax of BAY1830839 in plasma|Frequency of treatment-emergent adverse events|Severity of treatment-emergent adverse events","Bayer","Male","18 Years to 50 Years   (Adult)","Phase 1","64","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","19150|2017-001496-23","June 28, 2018","February 5, 2019","August 1, 2019","May 30, 2018",,"August 28, 2019","CRS Clinical Research Services Berlin GmbH, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT03540615"
105,"NCT03535168","Repeat Doses of BAY1902607 in Healthy Males and Proof of Concept in Chronic Cough Patients",,"Completed","No Results Available","Cough","Drug: BAY1902607|Drug: Matching placebo|Drug: Midazolam","Frequency of treatment-emergent adverse events|Severity of treatment-emergent adverse events|AUC of midazolam without BAY1902607|AUC of midazolam in combination with BAY1902607|Cmax of midazolam in combination with BAY1902607|Cmax of midazolam without BAY1902607|AUC(0-tlast) of midazolam in combination with BAY1902607|AUC(0-tlast) of midazolam without BAY1902607|Number of coughs experienced by the patient","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","59","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","19430|2018-000129-29","May 29, 2018","September 25, 2019","October 11, 2019","May 24, 2018",,"November 4, 2019","Catharina Ziekenhuis, Eindhoven, Noord-Brabant, Netherlands|Isala, Zwolle, Netherlands|Queen's University, Belfast, Antrim, United Kingdom|Birmingham Heartlands Hospital, Birmingham, West Midlands, United Kingdom|Castle Hill Hospital, Cottingham, United Kingdom|King's College Hospital - NHS Foundation Trust, London, United Kingdom|Medicines Evaluation Unit, Manchester, United Kingdom|University Hospital of South Manchester, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03535168"
106,"NCT03521895","An Integrated Analysis of the Effectiveness of Intravitreal (IVT) Aflibercept (Eylea) in Routine Clinical Practice Based on Two Large Observational Studies","GALAXY","Completed","No Results Available","Macular Degeneration","Drug: Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)","Absolute difference in visual acuity (VA) change from baseline will be calculated for each patient as: VA letter score at month 12 - VA letter score at baseline|Mean time from diagnosis by the treating physician to start of treatment|Proportion of patients gaining 5, 10 or 15 or more letters|Proportion of patients with ≥70 letters VA|Proportion of patients with ≥73 letters VA|Proportion of patients losing 5, 10 or 15 or more letters","Bayer","All","Child, Adult, Older Adult",,"1000","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","19694","May 1, 2018","November 30, 2018","November 30, 2018","May 11, 2018",,"January 10, 2020","Many locations, Multiple Locations, Germany",,"https://ClinicalTrials.gov/show/NCT03521895"
107,"NCT03517956","Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors","ROCOCO","Recruiting","No Results Available","Advanced or Metastatic Solid Tumor","Drug: Rogaratinib (BAY1163877)|Drug: Copanlisib (BAY80-6946)","Incidence of treatment-emergent adverse events (TEAEs)|Incidence of drug-related TEAEs|Incidence of treatment-emergent serious adverse events (TESAEs)|Incidence of Dose-limiting toxicities (DLTs)|Objective response rate (ORR) at recommended dose|Maximum plasma concentration of Copanlisib (Cmax)|Area under the plasma concentration versus time curve of Copanlisib (AUC (0-48))|Area under the plasma concentration versus time curve of Rogaratinib (AUC (0-8))|Maximum plasma concentration of Rogaratinib (Cmax)|Objective response rate (ORR)|Disease control rate (DCR)|Duration of response (DOR) for Partial Response and Complete Response|Progression-free survival (PFS)|Overall survival (OS)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","65","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19774|2018-000419-26","July 25, 2018","September 29, 2021","September 29, 2021","May 8, 2018",,"January 18, 2020","USC Norris Hospital and Clinics, Los Angeles, California, United States|Northwestern University, Chicago, Illinois, United States|University of Maryland, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Prisma Health, Greenville, South Carolina, United States|Texas Oncology- Austin Midtown, Austin, Texas, United States|Tyler Cancer Center, Tyler, Texas, United States|CU Saint-Luc/UZ St-Luc, Bruxelles - Brussel, Belgium|UZ Antwerpen, Edegem, Belgium|CHU de Liège, Liege, Belgium|Centre Oscar Lambret - Lille, LILLE cedex, France|Centre Léon Bérard, Lyon Cedex, France|Krankenhaus Nordwest, Frankfurt, Hessen, Germany|Universitätsklinikum Köln, Köln, Nordrhein-Westfalen, Germany|Universitätsklinikum Hamburg Eppendorf (UKE), Hamburg, Germany|Klinikum der Universität Würzburg, Würzburg, Germany|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Yonsei University College of Medicine, Seoul, Korea, Republic of|National University Hospital, Singapore, Singapore|National Cancer Center, Singapore, Singapore|Ciutat Sanitària i Universitaria de la Vall d'Hebron, Barcelona, Spain|Hospital Clínic i Provincial de Barcelona, Barcelona, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|MD Anderson International Espanya, S.A., Madrid, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT03517956"
108,"NCT03517943","A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufactuers Under Fed Conditions in Healthy Adult Subjects",,"Completed","No Results Available","Clinical Pharmacology","Drug: Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-SAG)|Drug: Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-Heist)","AUC(0-tlast) of loratadine and pseudoephedrine|Cmax of loratadine and pseudoephedrine|AUC for loratadine, pseudoephedrine and desloratadine|%AUC(tlast-∞) for loratadine, pseudoephedrine and desloratadine|Tmax for loratadine, pseudoephedrine and desloratadine|Tlast for loratadine, pseudoephedrine and desloratadine|λz for loratadine, pseudoephedrine and desloratadine|t1/2 for loratadine, pseudoephedrine and desloratadine|CL/F for loratadine, pseudoephedrine and desloratadine|AUC(0-tlast) for desloratadine|Cmax for desloratadine|Number of participants with adverse events","Bayer","All","18 Years to 55 Years   (Adult)","Phase 1","29","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","19626","April 24, 2018","August 30, 2018","August 30, 2018","May 8, 2018",,"September 13, 2018","Frontage Clinical Services, Secaucus, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03517943"
109,"NCT03517930","A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufacturers Under Fasted Conditions in Healthy Adult Subjects",,"Completed","No Results Available","Clinical Pharmacology","Drug: Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-SAG)|Drug: Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-Heist)","AUC(0-tlast) of loratadine and pseudoephedrine|Cmax of loratadine and pseudoephedrine|CL/F for loratadine, pseudoephedrine and desloratadine|Number of participants with adverse event|%AUC(tlast-∞) for loratadine, pseudoephedrine and desloratadine|Tmax for loratadine, pseudoephedrine and desloratadine|Tlast for loratadine, pseudoephedrine and desloratadine|λz for loratadine, pseudoephedrine and desloratadine|t1/2 for loratadine, pseudoephedrine and desloratadine|AUC(0-tlast) for desloratadine|Cmax for desloratadine|AUC for loratadine, pseudoephedrine and desloratadine","Bayer","All","18 Years to 55 Years   (Adult)","Phase 1","52","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","19625","April 17, 2018","July 20, 2018","July 20, 2018","May 8, 2018",,"September 19, 2018","Frontage Clinical Services, Secaucus, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03517930"
110,"NCT03507478","An Evaluation of a Customized Insole to Provide Relief From Heel Pain Due to Plantar Fasciitis or General Heel Pain When Used in Footwear Over a Period of Four Weeks",,"Completed","No Results Available","Foot Orthoses","Device: BPI1000013","Foot pain assessment of plantar fasciitis heel pain using the 100 mm VAS|Foot pain assessment of general heel pain using the 100 mm VAS|Foot Comfort/Discomfort is assessed utilizing a 7-point Comfort/Discomfort Likert scale|Shoe/foot Fit with use in shoes is assessed utilizing a 7-point Likert scale|Number of subjects with AEs|Number of subjects with SAEs","Bayer","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","102","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20102","April 10, 2018","July 26, 2018","July 26, 2018","April 25, 2018",,"July 26, 2019","Thomas J. Stephens & Associates, Inc., Phoenix, Arizona, United States|Stephens & Associates, Inc., Richardson, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03507478"
111,"NCT03507452","First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin",,"Recruiting","No Results Available","Advanced Recurrent Epithelioid Mesothelioma|Serous Ovarian Cancer|Metastatic or Locally Advanced Pancreatic Ductal Adenocarcinoma (Optional, Dose Expansion)","Drug: BAY2287411","Incidence of DLTs (dose-limiting toxicity)|The incidence of treatment-emergent adverse events (TEAEs), drug-related adverse events (AEs), and serious adverse events (SAEs)|Cmax of Thorium-227 after single dose of Cycle 1|Cmax of Radium-223 after single dose of Cycle 1|Cmax of Total antibody after single dose of Cycle 1|AUC(0-42 days) of Radium-223 after single dose of Cycle 1|AUC(0-42 days) of Total antibody after single dose of Cycle 1|AUC(0-42 days) of Thorium-227 after single dose of Cycle 1","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","228","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18795|2017-004052-29","June 13, 2018","June 6, 2022","February 20, 2023","April 25, 2018",,"January 21, 2020","National Cancer Institute, Bethesda, Maryland, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|HUS, Meilahden sairaala, Helsinki, Finland|Nederlands Kanker Instituut, Amsterdam, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Erasmus Medisch Centrum, Rotterdam, Netherlands|Skånes Universitetssjukhus, Lund, Sweden|Royal Marsden NHS Trust (Surrey), Sutton, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03507452"
112,"NCT03507439","REALIsM-HF Pilot Study","REALIsM-HF","Recruiting","No Results Available","Heart Failure","Device: VitalPatch Biosensor|Device: DynaPort Move Monitor","Amount of daily physical activity|Duration of daily physical activity|Intensity of daily physical activity|6-minute walking distance (6MWD)|Sleep movements|Sleep patterns|Sit-to-stand behaviour|Quality of Life as measured with the Kansas City Cardiomyopathy Questionnaire score|Biomarkers|Blood pressure|Heart rate|Cardiac function parameters measured by echocardiography|Tissue impedance|Heart rate variability derived from VitalPatch Biosensor|NYHA class according to the New York Heart Association Functional Classification|Number of participants with adverse events","Bayer","All","45 Years and older   (Adult, Older Adult)","Not Applicable","100","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","19167","April 6, 2018","December 31, 2020","December 31, 2020","April 25, 2018",,"January 18, 2020","Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Nordrhein-Westfalen, Germany|Universitätsklinikum Köln, Köln, Nordrhein-Westfalen, Germany|Charité Campus Virchow-Klinikum (CVK), Berlin, Germany|ASST Papa Giovanni XXIII, Bergamo, Lombardia, Italy|ASST Spedali Civili di Brescia, Brescia, Lombardia, Italy",,"https://ClinicalTrials.gov/show/NCT03507439"
113,"NCT03504982","Study to Evaluate the QT / QTc Interval Prolongation Potential of Vericiguat",,"Completed","No Results Available","Coronary Artery Disease","Drug: Vericiguat (BAY1021189)|Drug: Moxifloxacin|Drug: Placebo","Time-matched placebo-corrected change from baseline of the QT interval corrected according to Fridericia (QTcF) after 10 mg vericiguat at steady state.|Time-matched placebo-corrected change from baseline of QTcF after 1st dose of 2.5 mg vericiguat|Time-matched placebo-corrected change from baseline of QTcF after 1st dose of 5 mg vericiguat|Time-matched placebo-corrected change from baseline of QTcF after 1st dose of 10 mg vericiguat|Time-matched placebo-corrected change from baseline of QTcF after 2.5 mg vericiguat at steady state|Time-matched placebo-corrected change from baseline of QTcF after 5 mg vericiguat at steady state|Time-matched placebo-corrected change from baseline of QTcF after single dose of moxifloxacin|Cmax of vericiguat|tmax of vericiguat|Cmax, ss of vericiguat|tmax,ss of vericiguat|Cmax of Moxifloxacin|tmax of Moxifloxacin|The number of subjects with TEAEs (treatment-emergent adverse events)","Bayer|Merck Sharp & Dohme Corp.","All","30 Years to 80 Years   (Adult, Older Adult)","Phase 1","74","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","18979|2017-003094-33","May 17, 2018","November 29, 2018","February 26, 2019","April 20, 2018",,"March 12, 2019","Universitätsherzzentrum Freiburg - Bad Krozingen, Bad Krozingen, Baden-Württemberg, Germany|Universitätsklinikum Heidelberg, Heidelberg, Baden-Württemberg, Germany|Medizinische Einrichtungen der Universität Bonn, Bonn, Nordrhein-Westfalen, Germany|SocraTec R&D Clinical Ward, Erfurt, Thüringen, Germany|Charité Campus Virchow-Klinikum (CVK), Berlin, Germany|PAREXEL GmbH, Berlin, Germany|IMSP Republican Clinical Hospital, Chisinau, Moldova, Republic of|Center for Human Drug Research, Leiden, Netherlands",,"https://ClinicalTrials.gov/show/NCT03504982"
114,"NCT03498430","Copanlisib Chinese PK Study",,"Active, not recruiting","No Results Available","Lymphoma, Non-Hodgkin","Drug: Copanlisib (Aliqopa, BAY80-6946)","Cmax (Cycle 1 Day 1) of Copanlisib|AUC(0-24) (Cycle 1 Day 1) of Copanlisib|AUC(0-tlast) (Cycle 1 Day 1) of Copanlisib|Cmax (Cycle 1 Day 15) of Copanlisib|AUC(0-24) (Cycle 1 Day 15) of Copanlisib|Overall response rate: proportion of patients with confirmed complete response (CR) and partial response (PR)|Overall disease control rate: proportion of patients who have a best response rating of CR, PR or stable disease (SD)|The number of serious drug-related TEAEs (treatment-emergent adverse events)|The number of non-serious drug-related TEAEs|Cmax (Cycle 1 Day 1) of M-1 metabolite|AUC(0-24) (Cycle 1 Day 1) of M-1 metabolite|AUC(0-tlast) (Cycle 1 Day 1) of M-1 metabolite|Cmax (Cycle 1 Day 15) of M-1 metabolite|AUC(0-24) (Cycle 1 Day 15) of M-1 metabolite","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","13","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","16866","April 27, 2018","August 6, 2019","April 3, 2020","April 13, 2018",,"January 22, 2020","Beijing Cancer Hospital, Beijing, China",,"https://ClinicalTrials.gov/show/NCT03498430"
115,"NCT03493295","Non-interventional, Real Life Study on Satisfaction With LNG-IUS in Spanish Young Women (18-30 Years Old) With Different Parity Status and Menstrual Bleeding Pattern","BERTA","Recruiting","No Results Available","Contraception","Drug: Levonogestrel IntraUterine System (LNG-IUS)","Percentage of subjects rating 1 (very dissatisfied) to 5 (very satisfied) in the 5-point Likert scale overall satisfaction with LNG-IUS|Percentage of women rating 1 (very dissatisfied) to 5 (very satisfied) in the 5-point Likert scale of overall satisfaction with the menstrual bleeding profile with LNG-IUS|8 item user satisfaction questionnaire to assess the satisfaction with menstrual bleeding pattern with LNG-IUS|Presence/absence of menstrual bleeding|Quantity of menstrual bleeding(abundant, normal, scarce)|Regularity of menstrual bleeding(regular, one bleeding episode per cycle ; irregular, more than one bleeding episode per cycle)|Painful menstrual bleeding (No pain at all/slight pain/moderate pain/severe pain/very severe pain"")|Presence/absence of inter- menstrual vaginal bleeding|Ease of LNG-IUS insertion will be measured by investigator on an ordinal scale of ""easy"", ""slightly difficult"", ""very difficult""|Pain at LNG-IUS insertion will be assessed by the clinician asking to the user on a ordinal scale of ""none"", ""mild"", ""moderate"" or ""severe""|Reasons for change to/ choice a LNG-IUS assessed by a multiple choice item|Percentage of women that would recommend a LNG-IUS to peers|Frequency of menstrual bleeding(frequent <24 days, normal 24-38 days, infrequent >38 days)|Duration of menstrual bleeding (long >8 days, normal 4-8 days, short <4 days)|Interference in daily activities: (Not at all, mildly, moderately, severely)|Percentage of withdrawal|Reasons for withdrawal|Descriptive analysis of demographic data|Spearman's correlation between overall satisfaction with LNG-IUS and overall satisfaction with menstrual bleeding pattern","Bayer","Female","18 Years to 30 Years   (Adult)",,"660","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","19704","May 10, 2018","November 15, 2020","December 30, 2020","April 10, 2018",,"January 13, 2020","Many locations, Multiple Locations, Spain",,"https://ClinicalTrials.gov/show/NCT03493295"
116,"NCT03493269","A Multiple Dose Study of BAY1834845 in Healthy Male Subjects and in Patients With Psoriasis",,"Recruiting","No Results Available","Healthy Volunteers","Drug: BAY1834845|Other: Matching Placebo|Drug: Midazolam","Frequency of treatment-emergent adverse events (TEAEs)|Severity of treatment-emergent adverse events (TEAEs)|AUC(0-24)md of BAY1834845|AUC(0-12)md of BAY1834845|Cmax,md of BAY1834845|Cav,md of BAY1834845|Cav, md of BAY1834845","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","78","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","18385|2017-001817-10","April 16, 2018","July 29, 2020","August 3, 2020","April 10, 2018",,"January 22, 2020","Charité Research Organisation GmbH, Berlin, Germany|PAREXEL GmbH, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT03493269"
117,"NCT03484585","Rogaratinib (BAY1163877) Human Mass Balance Study",,"Completed","No Results Available","Clinical Trial, Phase I|Pharmacokinetics","Drug: Rogaratinib (BAY1163877)","Cmax of rogaratinib in plasma|AUC(0-tlast) of rogaratinib in plasma|AUC of rogaratinib in plasma|Cmax of total radioactivity in plasma and whole blood|AUC(0-tlast) of total radioactivity in plasma and whole blood|AUC of total radioactivity in plasma and whole blood|AE,ur (%) of rogaratinib and its metabolites|AE,fec (%) of rogaratinib and its metabolites|AE,vom (%) of rogaratinib and its metabolites, if applicable","Bayer","Male","21 Years to 65 Years   (Adult, Older Adult)","Phase 1","6","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18084|2017-002777-19","April 6, 2018","May 25, 2018","August 9, 2018","April 2, 2018",,"August 14, 2018","PRAHealthSciences, Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT03484585"
118,"NCT03484260","Association Between the Prevalence of Cardiovascular Risk Factors and New Use of Testosterone",,"Completed","No Results Available","Hypogonadism","Drug: Testosterone Product","Estimation of the association between cardiovascular risk factors and initiation of testosterone therapy","Bayer","Male","18 Years and older   (Adult, Older Adult)",,"27778","Industry","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","19547","April 1, 2018","May 15, 2018","May 15, 2018","March 30, 2018",,"May 14, 2019","Many Locations, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT03484260"
119,"NCT03481946","A Study to Assess Pharmacokinetics and Pharmacodynamics Following Administration of BAY1093884 in Patients With Severe Hemophilia",,"Completed","No Results Available","Hemophilia A; Hemophilia B","Drug: BAY1093884","AUC (0-tlast) of BAY1093884 in plasma|AUC(0-tlast)/D of BAY1093884 in plasma|Cmax of BAY1093884 in plasma|Cmax/D of BAY1093884 in plasma|Tissue factor plasma inhibitor activity: effect of BAY1093884 to inhibit the anticoagulatory activity of plasma TFPI as assessed by a chromogenic assay","Bayer","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","6","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","19592","May 10, 2018","October 17, 2018","February 20, 2019","March 29, 2018",,"February 28, 2019","Chaim Sheba Medical Center, Ramat Gan, Israel",,"https://ClinicalTrials.gov/show/NCT03481946"
120,"NCT03476928","A Study to Assess the Safety and Efficacy of Vilaprisan in Japanese Subjects With Uterine Fibroids and Heavy Menstrual Bleeding","ASTEROID 8","Active, not recruiting","No Results Available","Uterine Fibroids and Heavy Menstrual Bleeding","Drug: Vilaprisan (BAY1002670)","Incidence of treatment-emergent adverse event|Number of bleeding days","Bayer","Female","18 Years and older   (Adult, Older Adult)","Phase 3","146","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19435","March 30, 2018","March 27, 2020","July 17, 2021","March 26, 2018",,"December 23, 2019","Meitetsu Hospital, Nagoya, Aichi, Japan|Kano's Clinic for Women, Nagoya, Aichi, Japan|Kyoritsu Narashinodai Hospital, Funabashi, Chiba, Japan|Iizuka Hospital, Iizuka, Fukuoka, Japan|Jusendo Hospital, Koriyama, Fukushima, Japan|Sato Hospital, Takasaki, Gunma, Japan|Hashimoto Clinic, Sapporo, Hokkaido, Japan|Yoshio Clinic, Sapporo, Hokkaido, Japan|Asahi clinic, Takamatsu, Kagawa, Japan|Kurashiki Medical Clinic, Kurashiki, Okayama, Japan|Medical Topia Soka Hospital, Soka, Saitama, Japan|Sei Womens Clinic, Bunkyo, Tokyo, Japan|St.Luke's International Hospital, Chuoku, Tokyo, Japan|Akazawa Clinic, Fuchu, Tokyo, Japan|Yokokura Clinic, Minato-ku, Tokyo, Japan|Toranomon Womens Clinic, Minato, Tokyo, Japan|Akasakamitsuke Miyazaki Obstetrics and Gynecology Clinic, Minato, Tokyo, Japan|Tokyo Women's Medical University Hospital, Shinjuku-ku, Tokyo, Japan|Kato Internal medicine and Gynecology Clinic, Fukui, Japan|Hamanomachi Hospital, Fukuoka, Japan|Medical corporation keizukai Chayamachi Ladies Clinic, Osaka, Japan|Medical Corporation Koshinkai Nomura Clinic Namba, Osaka, Japan|Izuma Clinic, Osaka, Japan|Shizuoka Saiseikai General Hospital, Shizuoka, Japan|Toyama Prefectural Central Hospital, Toyama, Japan",,"https://ClinicalTrials.gov/show/NCT03476928"
121,"NCT03474757","Treatment Pattern of NOACs (Non-vitamin K Oral Anticoagulants) in Outpatient Users in Colombian Databases","TREND","Completed","No Results Available","Atrial Fibrillation","Other: Data Collection","Age|Sex|Co-morbidity|Healthcare utilization|Proportion of Naive to non-naive patient|Dose at first prescription|Duration of treatment|Discontinuation|Switch to another study drug|Time trends of usage of study medications","Bayer|Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)",,"10528","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","20104","February 28, 2018","July 30, 2018","July 30, 2018","March 23, 2018",,"July 24, 2019","Many Locations, Multiple Locations, Colombia",,"https://ClinicalTrials.gov/show/NCT03474757"
122,"NCT03473756","Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma","FORT-2","Recruiting","No Results Available","Urothelial Carcinoma","Drug: Rogaratinib (BAY1163877)|Drug: Atezolizumab|Drug: Placebo","Number of subjects with Dose-limiting toxicities(DLTs) in Part A|Number of subjects with treatment-emergent adverse events (TEAEs) in Part A|Number of subjects with drug-related TEAEs in Part A|Number of subjects with treatment-emergent serious adverse events(TESAEs) in Part A|Progression Free Survival(PFS)|Objective Response Rate(ORR) in Part A|Maximal plasma concentration (Cmax) of rogaratinib in Part A|Area under the curve(0-8) (AUC(0-8)) of rogaratinib in Part A|Disease Control Rate(DCR) in Part B|Duration of Response(DOR) in Part B|Overall Survival(OS) in Part B|Objective Response Rate (ORR) in Part B|Concentrations for rogaratinib in Part B|Concentrations for atezolizumab in Part B|Number of subjects with treatment-emergent adverse events (TEAEs) in Part B|Number of subjects with drug-related TEAEs in Part B|Number of subjects with treatment-emergent serious adverse events(TESAEs) in Part B|Number of subjects with significant change in vital signs, physical finding and clinical laboratory results","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","210","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","19131|2017-001483-38","May 15, 2018","April 19, 2023","October 6, 2023","March 22, 2018",,"January 2, 2020","University of Arizona Cancer Center, Tucson, Arizona, United States|University of California - Davis, Sacramento, California, United States|Comprehensive Cancer Center, Chicago, Illinois, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Krankenhaus der Elisabethinen Linz GmbH, Linz, Oberösterreich, Austria|Uniklinikum Salzburg - Landeskrankenhaus, Salzburg, Austria|Krankenhaus der Barmherzigen Brüder, Wien, Austria|Allgemeines Krankenhaus der Stadt Wien, Wien, Austria|Institut Bergonié - Unicancer Nouvelle Aquitaine, Bordeaux Cedex, France|Centre Oscar Lambret - Lille, Lille Cedex, France|Centre René Gauducheau - Nantes, Nantes, France|Eberhard-Karls-Universität Tübingen, Tübingen, Baden-Württemberg, Germany|Universitätsklinikum Essen, Essen, Nordrhein-Westfalen, Germany|Universitätsklinikum Köln, Köln, Nordrhein-Westfalen, Germany|Universitätsmedizin der Johannes Gutenberg Universität Mainz, Mainz, Rheinland-Pfalz, Germany|A.O.U. di Modena - Policlinico, Modena, Emilia-Romagna, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy|IRCCS Istituto Europeo di Oncologia (IEO), Milano, Lombardia, Italy|IRCCS Istituto Oncologico Veneto (IOV), Padova, Veneto, Italy|A.O.U.I. Verona, Verona, Veneto, Italy|National Cancer Center Hospital East, Kashiwa, Chiba, Japan|National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan|University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan|The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Yonsei University College of Medicine, Seoul, Korea, Republic of|Ciutat Sanitària i Universitaria de la Vall d'Hebron, Barcelona, Spain|Hospital Clínic i Provincial de Barcelona, Barcelona, Spain|Hospital de la Santa Creu i de Sant Pau, Barcelona, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital General Universitario de Valencia, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT03473756"
123,"NCT03470103","A Study in Patients With Wet Age-related Macular Degeneration or Diabetic Macular Edema to Assess the freQuency of Use of Intravitreal Aflibercept in Routine Clinical Practices in Latin America","AQUILA","Recruiting","No Results Available","Macular Degeneration","Drug: Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)","Mean change of visual acuity as measured by ETDRS or Snellen chart|Mean change in visual acuity as measured by ETDRS or Snellen chart|Change in retinal thickness as measured by OCT|Mean time between injections by indication|Mean number of injections by indication|Duration of previous treatments by indication|Type (anti-VEGF, laser, steroids, etc) of previous treatments by indication|Percentage of patients with no fluid determined by OCT|Percentage of patients achieving a Snellen equivalent of 20/40 or better|Percentage of patients gaining ≥15 ETDRS letter|Presence/absence of pigment epithelium detachments (PED)|Number of adjunctive therapies|Type of adjunctive therapies based on medical records or on interviewing the patient|Diabetic retinopathy severity (mild, moderate, severe)|Reason to switch to intravitreal aflibercept based on medical records or on interviewing the patient|Number of monitoring visits|Number of combined visits|Number of visits outside the study center|Number of optical coherence tomography (OCT) assessments per patient|Number of visual acuity tests|Number of fundoscopy examinations","Bayer|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)",,"730","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","19518","April 3, 2018","September 30, 2020","November 6, 2020","March 19, 2018",,"January 2, 2020","Many locations, Multiple Locations, Argentina|Many locations, Multiple Locations, Brazil|Many locations, Multiple Locations, Colombia|Many locations, Multiple Locations, Costa Rica|Many locations, Multiple Locations, Mexico",,"https://ClinicalTrials.gov/show/NCT03470103"
124,"NCT03462446","Analysis of the Potential Savings of Rivaroxaban Events Versus Vitamin K Antagonists Events",,"Completed","No Results Available","Atrial Fibrillation","Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Vitamin K antagonists (VKAs)","Time in therapeutic range (TTR) values in the last 6 months|Presence of stroke|Active substance received|Date of stroke|Type of stroke|Duration of treatment (in days)|Dose of the prescribed treatment|Frequency of the prescribed treatment (in hours)","Bayer|Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)",,"249","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","18231","June 1, 2015","May 1, 2016","May 1, 2016","March 12, 2018",,"March 12, 2018","Granada, Spain",,"https://ClinicalTrials.gov/show/NCT03462446"
125,"NCT03458728","Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients",,"Recruiting","No Results Available","Mixed Tumor, Malignant","Drug: BAY806946","The maximum tolerated dose (MTD)|Dose-limiting Toxicities(DLTs)|Number of participants with Treatment-emergent Adverse Events(TEAEs)|Number of participants with Serious Adverse Events (SAEs)|Number of participants with Treatment-related Adverse Events (AEs).|Objective response rate (ORR)|Disease control rate (DCR)|Progression-free survival (PFS)|Copanlisib maximum drug concentration (Cmax)|Area under the curve (AUC(0-168))|Duration of response (DOR)|PFS in each indication except for osteosarcoma|Overall survival (OS)|Number of participants with Treatment-emergent AEs|Number of participants with treatment emergent SAEs|Number of participants with treatment-emergent clinically significant change in laboratory parameters, ECGs or vital signs","Bayer","All","6 Months to 21 Years   (Child, Adult)","Phase 1|Phase 2","130","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19176|2017-000383-15","April 30, 2018","January 24, 2024","March 18, 2026","March 8, 2018",,"January 22, 2020","Children's Hospital of Alabama, Birmingham, Alabama, United States|Children's Hospital of Los Angeles, Los Angeles, California, United States|Children's Hospital of Orange County, Orange, California, United States|The Children's Hospital, Aurora, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Riley Hospital For Children, Indianapolis, Indiana, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|C.S. Mott Children's Hospital, Ann Arbor, Michigan, United States|University of Minnesota Medical Center, Minneapolis, Minnesota, United States|Columbia University Medical Center, New York, New York, United States|Cincinnati Children's Hospital and Medical Center, Cincinnati, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Texas Children's Hospital, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03458728"
126,"NCT03455439","Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban)","FARAONIC","Active, not recruiting","No Results Available","Heart Failure","Drug: Rivaroxaban (Xarelto, BAY59-7939)","Time from the baseline visit to the first hospitalization or admission to emergency services due to a Heart Failure exacerbation|Date of death|Date of all hospitalizations or admissions to emergency service","Bayer|Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)",,"668","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","19584","March 16, 2018","July 31, 2021","October 30, 2021","March 6, 2018",,"January 18, 2020","Many Locations, Multiple Locations, Spain",,"https://ClinicalTrials.gov/show/NCT03455439"
127,"NCT03448536","A Study to Assess Menstrual Cramp Pain Associated With Primary Dysmenorrhea",,"Completed","Has Results","Dysmenorrhea","Drug: Naproxen Sodium, (Aleve, BAY117031)|Drug: Acetaminophen (Tylenol Extra Strength)","Sum of Total Pain Relief (TOTPAR) Over 0-12 Hours|Summed Pain Intensity Difference (SPID) Over 0-12 Hours|SPID Over 0-6 Hours|SPID Over 6-12 Hours|TOTPAR Over 0-6 Hours|TOTPAR 6-12 Hours|Time to First Intake of Rescue Medication|Pain Intensity Difference (PID) Scores at Each Evaluation|Number of Participants by Global Evaluation Scores|Pain Relief Scores at Each Evaluation","Bayer","Female","15 Years to 35 Years   (Child, Adult)","Phase 4","201","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","19737|2017-005031-17","April 5, 2018","September 5, 2018","September 5, 2018","February 28, 2018","October 28, 2019","October 28, 2019","Radiant Research, Inc., Chandler, Arizona, United States|Radiant Research, Inc., Scottsdale, Arizona, United States|Radiant Research, Inc., Pinellas Park, Florida, United States|Radiant Research, Inc., Chicago, Illinois, United States|Radiant Research, Inc., Akron, Ohio, United States|Radiant Research, Inc., Cincinnati, Ohio, United States|Radiant Research, Inc., Dallas, Texas, United States|Synexus US, LP- Plano, Plano, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT03448536/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT03448536/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03448536"
128,"NCT03443843","A Study to Evaluate Changes in Nasal Airflow of Loratadine/Pseudoephedrine Tablet and Fluticasone Propionate Nasal Spray in Subjects Following Allergen Exposure",,"Completed","No Results Available","Rhinitis, Allergic","Drug: loratadine + pseudoephedrine sulfate (BAY818725/Claritin-D)|Drug: Placebo tablet|Drug: Fluticasone Propionate|Drug: Placebo spray","Average percent change in PNIF (Peak Nasal Inspiratory Flow) from 0 to 4 hours after dosing","Bayer","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","82","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","19880","February 21, 2018","May 11, 2018","May 11, 2018","February 23, 2018",,"December 20, 2019","Kingston General Hospital, Kingston, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03443843"
129,"NCT03441568","In-home Use Test of the New Modified Diprobase Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's Control",,"Completed","No Results Available","Atopic Dermatitis","Device: BAY987534","Number of participants with adverse event (AE)|Severity of adverse event","Bayer","All","6 Months to 48 Months   (Child)","Not Applicable","34","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19690|2017-004334-29","September 26, 2018","August 2, 2019","August 2, 2019","February 22, 2018",,"August 13, 2019","West Timperley Medical Centre, Altrincham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03441568"
130,"NCT03427788","BAY2328065 Single Dose Escalation, Safety and Tolerability, Pharmacokinetics, Relative Bioavailability, Food Effect",,"Completed","No Results Available","Endometriosis","Drug: BAY2328065|Drug: Placebo","Incidence of treatment-emergent adverse events|Severity of treatment-emergent adverse events","Bayer","Male","18 Years to 50 Years   (Adult)","Phase 1","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","19250|2017-004056-38","March 21, 2018","October 29, 2018","February 11, 2019","February 9, 2018",,"February 20, 2019","CRS Clinical Research Services Berlin GmbH, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT03427788"
131,"NCT03424135","A Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects Under Fed Conditions",,"Completed","No Results Available","Clinical Pharmacology","Drug: Naproxen sodium and diphenhydramine hydrochloride soft capsules|Drug: Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve PM, BAY98-7111)","AUC|AUC(0-tlast)|Cmax|Number of adverse events as a measure of safety and tolerability","Bayer","All","18 Years to 55 Years   (Adult)","Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17944","March 2, 2018","April 4, 2018","April 4, 2018","February 6, 2018",,"March 20, 2019","ICON Development Solutions, LLC, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03424135"
132,"NCT03419442","Multi-academic Center Study of Xofigo Patients",,"Completed","No Results Available","Prostate Cancer, Castration Resistant","Drug: Xofigo|Drug: Taxotere|Drug: Jevtana","Overall survival|Time to symtomatic skeletal event(SSE)|Reasons for treatment discontinuation|Laboratory-based outcomes collected by questionnaire|Treatments received|Number of hospitalizations|PSA PFS|Non-laboratory based clinically relevant safety outcomes|hospital length of stay","Bayer","Male","18 Years and older   (Adult, Older Adult)",,"150","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","19863","December 3, 2018","October 22, 2019","October 22, 2019","February 5, 2018",,"November 20, 2019","Bayer US, Whippany, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03419442"
133,"NCT03418168","A Study of Molidustat for Treatment of Renal Anemia in Peritoneal Dialysis Subjects","MIYABI PD","Completed","No Results Available","Anemia and Renal Insufficiency, Chronic","Drug: Molidustat (BAY85-3934)","Responder rate: proportion of responders among the subjects|Mean Hb (Hemoglobin) level|Change in mean Hb level|Rate of rise in Hb (Hemoglobin) level (g/dL/week)|Proportion of subjects who meet each component of the response|Hb level|Change in Hb level|Proportion of subjects with mean hemoglobin levels are in the target range|Proportion of subjects with mean hemoglobin levels are above the target range|Proportion of subjects with mean hemoglobin levels are below the target range|Proportion of subjects with hemoglobin levels in the target range|Proportion of subjects with hemoglobin levels above the target range|Proportion of subjects with hemoglobin levels below the target range|Proportion of subjects whose maximum rise in Hb between each consecutive visits is above 0.5 g/dL/week|Percentage of days in the target Hb range during the evaluation period|Percentage of days in the target Hb range during the treatment period|Rate of rise in Hb level (g/dL/week) between each consecutive visits|Percentage of Hb levels in target range during the evaluation period|Percentage of Hb levels in target range during the treatment period|Proportion of subjects who received at least one rescue treatment|Number of participants with serious adverse events|Maximum concentration (Cmax) of Molidustat|Area under the concentration-time curve (AUC) of Molidustat|EPO (Erythropoietin) serum concentration of Molidustat","Bayer","All","20 Years and older   (Adult, Older Adult)","Phase 3","51","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19353","February 22, 2018","July 25, 2019","July 29, 2019","February 1, 2018",,"August 15, 2019","Kainan Hospital, Yatomi, Aichi, Japan|Ehime Prefectural Central Hospital, Matsuyama, Ehime, Japan|Kokura Memorial Hospital, Kitakyushu, Fukuoka, Japan|JCHO Kyushu Hospital, Kitakyushu, Fukuoka, Japan|Kurume University Hospital, Kurume, Fukuoka, Japan|Elm Grove Clinic, Sapporo, Hokkaido, Japan|Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan|Fujisawa City Hospital, Fujisawa, Kanagawa, Japan|Shonan Kamakura General Hospital, Kamakura, Kanagawa, Japan|Toranomon Hospital Kajigaya, Kawasaki, Kanagawa, Japan|Showa University Fujigaoka Hospital, Yokohama, Kanagawa, Japan|Tohoku Medical and Pharmaceutical University Hospital, Sendai, Miyagi, Japan|Niigata Prefectural Shibata Hospital, Shibata, Niigata, Japan|National Hospital Organization Beppu Medical Center, Beppu, Oita, Japan|Okinawa prefectural Chubu Hospital, Uruma, Okinawa, Japan|Fuchu Hospital, Izumi, Osaka, Japan|Fukui-ken Saiseikai Hospital, Fukui, Japan|Kyushu University Hospital, Fukuoka, Japan|Fukuoka University Hospital, Fukuoka, Japan|Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan|Fukushima Medical University Hospital, Fukushima, Japan|Asahi University Hospital, Gifu, Japan|National Hospital Organization Kyoto Medical Center, Kyoto, Japan|Nara Prefecture General Medical Center, Nara, Japan|Niigata City General Hospital, Niigata, Japan|Japanese Red Cross Oita Hospital, Oita, Japan|Osaka General Medical Center, Osaka, Japan",,"https://ClinicalTrials.gov/show/NCT03418168"
134,"NCT03412006","A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY1142524 in Patients With Type II Diabetes and a Clinical Diagnosis of Diabetic Kidney Disease","CADA DIA","Completed","No Results Available","Diabetic Kidney Disease","Drug: Fulacimstat (BAY1142524)|Drug: Placebo","Change in urinary albumin to creatinine ratio (UACR)|Number of patients with treatment-emergent adverse event|Number of patients with serious adverse events","Bayer","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 2","152","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","18933|2017-000656-26","February 2, 2018","October 2, 2019","October 10, 2019","January 26, 2018",,"November 1, 2019","Med Centre Diamedical 2013, Dimitrovgrad, Bulgaria|MCOMH Preventsia-2000, Stara Zagora, Bulgaria|Med. Center Equita, Varna, Bulgaria|Rigshospitalet Copenhagen, Copenhagen, Denmark|Steno Diabetes Center, Gentofte, Denmark|Nordsjællands Hospital, Hillerød, Denmark|Pihlajalinna ITE Kuopio, Kuopio, Finland|Terveystalo Oulu, Oulu, Finland|TAYS TKI Keskus Tutkimusvastaanotto, Tampere, Finland|Turun yliopistollinen keskussairaala, kantasairaala, Turku, Finland|Barzilai Medical Center, Ashkelon, Israel|Edith Wolfson Medical Center, Holon, Israel|Hadassah Hebrew University Hospital Ein Kerem, Jerusalem, Israel|The Nazareth Trust Hospital EMMS, Nazareth, Israel|DMC - Diabetes Medical Center, Tel Aviv, Israel|Shamir Medical Center (Assaf Harofeh), Zerifin, Israel|A.O.U. Policlinico Federico II Napoli, Napoli, Campania, Italy|Univ. Alma Mater - Dip. Medicina Spec, Diagnostica e Sperim, Bologna, Emilia-Romagna, Italy|IRCCS Casa Sollievo della Sofferenza, Foggia, Puglia, Italy|A.O. di Padova, Padova, Veneto, Italy|Complexo Hospitalario Universitario de Ferrol, Ferrol, A Coruña, Spain|Hospital de Galdakao, Galdakao, Vizcaya, Spain|Hospital Fundació Puigvert, Barcelona, Spain|Centralsjukhuset Kristianstad, Kristianstad, Sweden|Akardo MedSite AB, Stockholm, Sweden|S3 Clinical Research Centers, Vällingby, Sweden|Universitetssjukhuset Örebro, Örebro, Sweden",,"https://ClinicalTrials.gov/show/NCT03412006"
135,"NCT03411980","Pharmacokinetics and Safety of Vilaprisan in Renal Impairment",,"Completed","No Results Available","Uterine Fibroids|Endometriosis","Drug: Vilaprisan (BAY1002670)","Area under the concentration versus time curve from zero to infinity after single (first) dose (AUC) of BAY1002670|Maximum observed drug concentration in measured matrix after single dose administration (Cmax) of BAY1002670|Number of participants with adverse events|AUC|unbound AUC (AUCu)|Cmax|Unbound Cmax (Cmax,u)|Apparent oral clearance (CL/F)|Unbound CL/F (CLu/F)|Half-life associated with the terminal slope (t1/2)|Renal clearance (CLR)|Fraction of free (unbound) drug in plasma (fu)","Bayer","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 1","26","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","16524","February 2, 2018","October 10, 2018","February 6, 2019","January 26, 2018",,"December 3, 2019","Clinical Pharmacology of Miami, Inc., Miami, Florida, United States|Orlando Clinical Research Center, Orlando, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03411980"
136,"NCT03411941","Evaluate the Effectiveness of Intravitreal (IVT) Aflibercept Injection in Clinical Practice in naïve Patients With Neovascular Age-related Macular Degeneration (nAMD)","REALE","Completed","No Results Available","Macular Degeneration","Drug: Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)","Mean change in VA|Proportion of patients gaining 15 or more letters|Mean change in CRT in µm (measured by OCT)|Presence/absence of SRF (subretinal fluid) by OCT (yes/no)|Presence/absence of IRF (intraretinal fluid) by OCT (yes/no)|Presence/absence of PED (pigment epithelium detachment) (measured by OCT)|Presence/absence of PED Height|Presence/absence of PED type|Correlation of the mean gain in VA with the total number of injections administered|Mean number of IVT aflibercept injections per study eye|Mean number of monitoring visits per study eye|Mean number of combined visits per study eye|Mean number of OCT assessments per study eye","Bayer|Regeneron Pharmaceuticals","All","50 Years and older   (Adult, Older Adult)",,"116","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","18798","February 28, 2018","March 1, 2019","March 1, 2019","January 26, 2018",,"December 5, 2019","Many locations, Multiple Locations, Spain",,"https://ClinicalTrials.gov/show/NCT03411941"
137,"NCT03410706","Xarelto for Real Life Anticoagulation in Pulmonary Embolism (PE) in China","XAPEC","Recruiting","No Results Available","Pulmonary Embolism","Drug: Rivaroxaban(Xarelto, BAY 59-7939)","Major bleedings|Symptomatic recurrent venous thromboembolic events|Major adverse cardiac events|Other symptomatic thromboembolic events|Drug utilization|Number of participants with adverse events and serious adverse events|Patient treatment satisfaction by using questionnaire of ACTS (Anti-Clot Treatment Scale)","Bayer|Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)",,"300","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","18799","February 1, 2018","January 30, 2023","March 30, 2023","January 25, 2018",,"December 24, 2019","Many Locations, Multiple Locations, China",,"https://ClinicalTrials.gov/show/NCT03410706"
138,"NCT03410693","Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma","FORT-1","Active, not recruiting","No Results Available","Carcinoma, Transitional Cell","Drug: Rogaratinib (BAY1163877)|Drug: Chemotherapy","Overall Survival|Progression-free survival (PFS)|Objective response rate (ORR)|Disease-control rate (DCR)|Duration of response (DOR)|Incidence of Adverse Events as a measure of safety and tolerability","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","171","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17403|2016-004340-11","May 31, 2018","November 30, 2020","November 30, 2020","January 25, 2018",,"January 18, 2020","Alaska Clinical Research Center, LLC, Anchorage, Alaska, United States|University of Arizona Cancer Center, Tucson, Arizona, United States|University of Southern California, Los Angeles, California, United States|UC Davis Comprehensive Cancer Center, Sacramento, California, United States|Sansum Clinic, Santa Barbara, California, United States|Rocky Mountain Cancer Centers, Littleton, Colorado, United States|UF Cancer Center at Orlando Health, Orlando, Florida, United States|University of Kansas Medical Center, Westwood, Kansas, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Compass Oncology, Tigard, Oregon, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Bon Secours St. Francis Hospital, Greenville, South Carolina, United States|Texas Oncology-Denton South, Denton, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Summit Cancer Center, Spokane, Washington, United States|Mid North Coast Cancer Institute, Coffs Harbour, New South Wales, Australia|Northern Cancer Institute, St Leonards, New South Wales, Australia|Macquarie University Hospital, Sydney, New South Wales, Australia|Riverina Cancer Care Centre, Wagga Wagga, New South Wales, Australia|Sydney Adventist Hospital, Wahroonga, New South Wales, Australia|Pindara Private Hospital, Benowa, Queensland, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Landesklinikum Krems, Krems, Austria|Krankenhaus der Barmherzigen Brüder, Wien, Austria|Allgemeines Krankenhaus der Stadt Wien, Wien, Austria|Wilhelminenspital der Stadt Wien, Wien, Austria|UZ Gent, Gent, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Clinique Saint-Pierre, Ottignies, Belgium|Princess Margaret Hospital-University Health Network, Toronto, Ontario, Canada|Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada|Ottawa Hospital-General Campus, Ottawa, Canada|FuJian Medical University Union Hospital, Fuzhou, Fujian, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Hubei Cancer Hospital, Wuhan, Hubei, China|NJ Drum Tower Hospital, the Affil Hos of NJ Univ Med School, Nanjing, Jiangsu, China|Jiangsu Cancer Hospital, Nanjing, Jiangsu, China|Liaoning Cancer Hospital and Institute, Shengyang, Liaoning, China|Fifth Medical Center, General Hospital of the Chinese People, Beijing, China|First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|Fudan University Shanghai Cancer Center, Shanghai, China|Huadong Hospital, Affiliated to Fudan University, Shanghai, China|Fakultni nemocnice Ostrava, Ostrava, Czechia|Fakultni nemocnice Kralovske Vinohrady, Praha 10, Czechia|Fakultni Thomayerova Nemocnice, Praha 4 - Krc, Czechia|Bata Hospital, Zlin, Czechia|Aarhus Universitetshospital, Skejby, Aarhus N, Denmark|Herlev Hospital, Herlev, Denmark|H:S Rigshospitalet, København, Denmark|Docrates Klinikka, Helsinki, Finland|Hopital Jean Minjoz, Besancon, France|Hôpital Saint André - Bordeaux, Bordeaux, France|Centre de Lutte Contre le Cancer François Baclesse, Caen Cedex 5, France|Centre Jean Perrin, Clermont Ferrand Cedex 1, France|Centre Oscar Lambret - Lille, Lille Cedex, France|Centre Léon Bérard, Lyon Cedex, France|Institut Paoli-Calmettes - Marseille, Marseille, France|Cochin - Paris, Paris, France|Hôpital d'Instruction des Armées Begin, Saint Mande, France|Clinique Saint Anne, Strasbourg, France|Centre Médico-Chirurgical Foch, Suresnes, France|Eberhard-Karls-Universität Tübingen, Tübingen, Baden-Württemberg, Germany|Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Nordrhein-Westfalen, Germany|Universitätsmedizin der Johannes Gutenberg Universität Mainz, Mainz, Rheinland-Pfalz, Germany|Prince of Wales Hospital, Shatin, Hong Kong|MH Egeszsegugyi Kozpont, Budapest, Hungary|Orszagos Onkologiai Intezet, Budapest, Hungary|Pecsi Tudomanyegyetem Klinikai Kozpont, Pecs, Hungary|Cork University Hospital, Cork, Ireland|AMNCH, Dublin, Ireland|Rambam Health Corporation, Haifa, Israel|Hadassah Hebrew University Hospital Ein Kerem, Jerusalem, Israel|Meir Medical Center, Kfar Saba, Israel|Clalit Health Services through Rabin Medical Center - Beilinson Campus, Petah Tikva, Israel|Chaim Sheba Medical Center, Ramat Gan, Israel|IRST Istituto Scientifico Romagnolo per studio e cura tumori, Forlì-Cesena, Emilia-Romagna, Italy|AUSL Modena, Modena, Emilia-Romagna, Italy|A.O.U. di Modena - Policlinico, Modena, Emilia-Romagna, Italy|A.O. San Camillo-Forlanini, Roma, Lazio, Italy|Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Lazio, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy|IRCCS Istituto Europeo di Oncologia (IEO), Milano, Lombardia, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milano, Lombardia, Italy|A.O.U. San Luigi Gonzaga, Torino, Piemonte, Italy|A.O.U. Pisana, Pisa, Toscana, Italy|A.O.U.I. Verona, Verona, Veneto, Italy|Nagoya University Hospital, Nagoya, Aichi, Japan|Hirosaki University Hospital, Hirosaki, Aomori, Japan|Gunma University Hospital, Maebashi, Gunma, Japan|Gunma Prefectural Cancer Center, Ota, Gunma, Japan|Sapporo Medical University Hospital, Sapporo, Hokkaido, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, Japan|Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan|University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan|Iwate Medical University Hospital, Morioka, Iwate, Japan|Yokohama City University Hospital, Yokohama, Kanagawa, Japan|Kindai University Hospital, Osakasayama, Osaka, Japan|Saitama Medical University International Medical Center, Hidaka, Saitama, Japan|Nippon Medical School Hospital, Bunkyo-ku, Tokyo, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan|Keio University Hospital, Shinjuku-ku, Tokyo, Japan|Akita University Hospital, Akita, Japan|Kyushu University Hospital, Fukuoka, Japan|Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan|Kumamoto University Hospital, Kumamoto, Japan|Niigata University Medical and Dental Hospital, Niigata, Japan|Osaka International Cancer Institute, Osaka, Japan|Toyama University Hospital, Toyama, Japan|National Cancer Center, Goyang-si, Gyeonggido, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Yonsei University College of Medicine, Seoul, Korea, Republic of|Nederlands Kanker Instituut, Amsterdam, Netherlands|Erasmus Medisch Centrum, Rotterdam, Netherlands|Centrum Onkologii im. Prof. Franciszka Lukaszczyka, Bydgoszcz, Poland|Swietokrzyskie Centrum Onkologii, Kielce, Poland|Przychodnia Lekarska KOMED, Konin, Poland|Samodzielny Publiczny Zespol Gruzlicy i Chorob Pluc, Olsztyn, Poland|Szpital Kliniczny Przemienienia Panskiego, Poznan, Poland|Uniwersytecki Szpital Kliniczny UM we Wroclawiu, Wroclaw, Poland|Hospital Beatriz Angelo, Loures, Lisboa, Portugal|IPO Coimbra, Coimbra, Portugal|Hospital CUF Infante Santo, Lisboa, Portugal|CHULN - Hospital Santa Maria, Lisboa, Portugal|CHUP - Hospital Santo Antonio, Porto, Portugal|Krasnoyarsk Regional Clinical Oncology Dispensary, Krasnoyarsk, Russian Federation|Moscow Scient. Res. Institute of Oncology n.a P.A. Hertzen, Moscow, Russian Federation|Urological Center POMC, Nizhny Novgorod, Russian Federation|Clinical Oncological Dispensary of Omsk Region, Omsk, Russian Federation|Bashkir State Medical University, Ufa, Russian Federation|National University Hospital, Singapore, Singapore|National Cancer Center, Singapore, Singapore|Narodny onkologicky ustav, Bratislava, Slovakia|UROEXAM, spol. s r.o., Nitra, Slovakia|POKO Poprad s.r.o., Poprad, Slovakia|Hospital Reina Sofía, Córdoba, Andalucía, Spain|Institut Català d'Oncologia Badalona, Badalona, Barcelona, Spain|Institut Català d'Oncologia Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital del Mar, Barcelona, Catalunya, Spain|Hospital Universitari Son Espases, Palma de Mallorca, Illes Baleares, Spain|Ciutat Sanitària i Universitaria de la Vall d'Hebron, Barcelona, Spain|Hospital San Pedro de Alcántara, Cáceres, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Instituto Valenciano de Oncología, Valencia, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Södersjukhuset, Stockholm, Sweden|Karolinska Institutet, Stockholm, Sweden|Universitätsspital Basel, Basel, Basel-Stadt, Switzerland|Kantonsspital Graubünden, Chur, Graubünden, Switzerland|Kantonsspital St. Gallen, St. Gallen, Sankt Gallen, Switzerland|Taichung Veterans General Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan|Clatterbridge Centre for Oncology, Bebington, Merseyside, United Kingdom|The Royal Marsden Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03410693"
139,"NCT03408093","Study of Betaferon Adherence in Patients With Multiple Sclerosis Treated With Interferon Beta-1b","ADHERENCE","Completed","No Results Available","Multiple Sclerosis","Drug: Interferon beta-1b (Betaseron, BAY86-5046)","Self-reported adherence to INFb-1b in the previous four weeks assessed by Morisky-Green (MG) test|Demographic data|Number of patients with MS diagnosis|Age at first episode and at diagnosis|Time since last relapse|Assessment of general health status using data from a questionnaire or from their clinical history collected by the investigator team|Expanded Disability Status Scale (EDSS) to assess the degree of disability caused by MS|Number of patients with adverse events during the last month|Clinical setting characteristics like existence of MS unit|Time on INFb-1b therapy","Bayer","All","18 Years to 100 Years   (Adult, Older Adult)",,"120","Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","2008/01880","February 3, 2009","March 30, 2010","March 30, 2010","January 23, 2018",,"June 21, 2018",,,"https://ClinicalTrials.gov/show/NCT03408093"
140,"NCT03405337","Evaluation of Patient and Physician Reported Reasons for Switching Factor VIII Replacement Therapies","PARkER","Completed","No Results Available","Hemophilia A","Drug: FVIII products|Drug: Conventional FVIII replacement therapies","The reasons of patients/caregivers ""switch"" from conventional FVIII replacement therapy to FVIII products with improved half-life|The obstacles of switching among hemophilia A patients who did not switch from conventional therapy to FVIII products with improved half-life but who are open to switching|The clinical characteristics of patients who switch from conventional FVIII replacement therapy to FVIII products with improved half-life|The changes of treatment characteristics from 6 months prior to switching compared to 6 months after switching from conventional FVIII replacement therapy to FVIII products with improved half-life|The changes of bleeding related outcomes from 6 months prior to switching compared to 6 months after switching from conventional FVIII replacement therapy to FVIII products with improved half-life|The reasons for switching from conventional FVIII replacement therapy to FVIII products with improved half-life, from the physician perspective","Bayer","All","12 Years and older   (Child, Adult, Older Adult)",,"160","Industry","Observational","Observational Model: Cohort|Time Perspective: Other","19529","February 14, 2018","June 13, 2018","June 13, 2018","January 23, 2018",,"September 27, 2018","Many Locations, Whippany, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03405337"
141,"NCT03404726","A Study to Investigate BAY2402234, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in Myeloid Malignancies",,"Recruiting","No Results Available","Leukemia","Drug: BAY2402234","Maximum tolerated dose|Number of Adverse Events as a measure of safety and tolerability|AUC (0-24) (Area under the curve)|Cmax (Maximum concentration)|Composite endpoint: Number of AML patients with complete remission (CR) and complete response with partial recovery of peripheral blood counts (CRh)|Change in erythroid response as Histological Improvement criteria for patients with MDS and CMML|Change in platelet response as Histological Improvement criteria for patients with MDS and CMML|Change in neutrophil response as Histological Improvement criteria for patients with MDS and CMML","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","120","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19420|2017-002896-24","March 29, 2018","November 10, 2021","November 10, 2022","January 19, 2018",,"January 18, 2020","Montefiore Medical Center, Bronx, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Institut Gustave Roussy, Villejuif Cedex, France",,"https://ClinicalTrials.gov/show/NCT03404726"
142,"NCT03404206","A Trial to Compare the Duration of Analgesic Efficacy and Safety of Naproxen Sodium Tablets and Ibuprofen Tablets in Postsurgical Dental Pain",,"Completed","Has Results","Pain, Postoperative","Drug: Naproxen Sodium (Aleve, BAY117031)|Drug: Ibuprofen (Advil)|Drug: Placebo","Time to First Use of Rescue Medication|Sum of Pain Intensity Difference (SPID)|Total Pain Relief (TOTPAR)","Bayer","All","16 Years to 40 Years   (Child, Adult)","Phase 4","387","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","19762|2017-005049-67","February 12, 2018","July 6, 2018","July 10, 2018","January 19, 2018","July 18, 2019","July 18, 2019","Jean Brown Research, Salt Lake City, Utah, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT03404206/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT03404206/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03404206"
143,"NCT03402438","Renal Impairment Study",,"Completed","No Results Available","Clinical Trial, Phase I","Drug: Fulacimstat (BAY1142524)","Area under the concentration vs. time curve from zero to infinity after single (first) dose (AUC) of BAY1142524|Maximum observed drug concentration in measured matrix after single dose administration (Cmax) of BAY1142524|AUC of unbound drug (AUCu) of BAY1142524|Cmax of unbound drug (Cmax,u) of BAY1142524|Number of subject with treatment emergent adverse events (TEAEs) as a measure of safety and tolerability","Bayer","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 1","36","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","18106|2017-003301-17","February 12, 2018","December 4, 2018","March 19, 2019","January 18, 2018",,"March 25, 2019","CRS Clinical-Research-Services Kiel GmbH, Kiel, Schleswig-Holstein, Germany",,"https://ClinicalTrials.gov/show/NCT03402438"
144,"NCT03400956","Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4)",,"Active, not recruiting","No Results Available","Leiomyoma","Drug: Vilaprisan (BAY1002670)|Drug: Placebo","Amenorrhea (yes/no)|HMB response|Time to onset of amenorrhea|Time to onset of controlled bleeding|Absence of bleeding (spotting allowed)|Endometrial histology|Endometrial thickness","Bayer","Female","18 Years and older   (Adult, Older Adult)","Phase 3","156","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15790|2016-003561-26","January 24, 2018","December 31, 2020","December 31, 2020","January 17, 2018",,"January 14, 2020","Clearview Medical Research, LLC, Canyon Country, California, United States|Diagnamics, Inc., Encinitas, California, United States|National Research Institute, Huntington Park, California, United States|Grossmont Center for Clinical Research, La Mesa, California, United States|West Coast OB/GYN Associates, La Mesa, California, United States|National Research Institute, Panorama City, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Medical Center for Clinical Research, San Diego, California, United States|Women's Medical Research Group, LLC, Clearwater, Florida, United States|Vital Pharma Research, Hialeah, Florida, United States|Solutions Through Advanced Research, Inc., Jacksonville, Florida, United States|Health Awareness, Inc., Jupiter, Florida, United States|South Florida Clinical Research Institute, Margate, Florida, United States|Savin Medical Group LLC, Miami Lakes, Florida, United States|Suncoast Research Group, LLC, Miami, Florida, United States|Advanced Pharma CR, LLC, Miami, Florida, United States|Genoma Research Group, Inc., Miami, Florida, United States|Florida Research Center, Inc., Miami, Florida, United States|Miami Dade Medical Research Institute, LLC, Miami, Florida, United States|Vista Health Research, Miami, Florida, United States|Palmetto Professional Research, Miami, Florida, United States|A Premier Medical Research of Florida, LLC, Orange City, Florida, United States|Clinical Neurosciences Solutions, Inc. DBA CNS Healthcare, Orlando, Florida, United States|Oviedo Medical Research, LLC, Oviedo, Florida, United States|DMI Research, Pinellas Park, Florida, United States|Physician Care Clinical Research, Sarasota, Florida, United States|Journey Medical Research, Snellville, Georgia, United States|Women's Healthcare Associates, PA, Idaho Falls, Idaho, United States|New England Center for Clinical Research, Inc., Fall River, Massachusetts, United States|Altea Research Institute, Las Vegas, Nevada, United States|Unified Women's Clinical Research, Greensboro, North Carolina, United States|PMG Research of Wilmington, Wilmington, North Carolina, United States|Unified Women's Clinical Research, Winston-Salem, North Carolina, United States|Oregon Health and Science University, Portland, Oregon, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Vista Clinical Research, Columbia, South Carolina, United States|Chattanooga Women for Women, Hixson, Tennessee, United States|Women Partners in Health Obstetrics & Gynecology (OB/GYN), Austin, Texas, United States|Gadolin Research, Beaumont, Texas, United States|Discovery Clinical Trials, Dallas, Texas, United States|Advances in Health, Inc., Houston, Texas, United States|Discovery Clinical Trials, San Antonio, Texas, United States|Center of Reproductive Medicine, Webster, Texas, United States|Tidewater Physicians for Women, Norfolk, Virginia, United States|Seattle Women's: Health, Research, Gynecology, Seattle, Washington, United States|GynPorCentrum s.r.o., Krnov, Czechia|Gynekologie MUDr. Jaromir Karban s.r.o, Neratovice, Czechia|Privatni gynekologicko-porodnicka ordinace, Praha, Czechia|GYNEVI s.r.o., Rokycany, Czechia|Gynekologicka ambulance, Zabreh Na Morave, Czechia|Funabashi Municipal Medical Center, Funabashi, Chiba, Japan|Tsujinaka Hospital Kashiwanoha, Kashiwa, Chiba, Japan|Matsudo City General Hospital, Matsudo, Chiba, Japan|Hashimoto Clinic, Sapporo, Hokkaido, Japan|Ena Odori Clinic, Sapporo, Hokkaido, Japan|Tokeidai Memorial Clinic, Sapporo, Hokkaido, Japan|Yoshio Clinic, Sapporo, Hokkaido, Japan|Kosumo Clinic, Kako-gun, Hyogo, Japan|Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan|Takamatsu Red Cross Hospital, Takamatsu, Kagawa, Japan|Asahi clinic, Takamatsu, Kagawa, Japan|Kagawa Prefectural Central Hospital, Takamatsu, Kagawa, Japan|Shonan Fujisawa Tokushukai Hospital, Fujisawa, Kanagawa, Japan|Kyoto city Hospital, Nakagyo-ku, Kyoto, Japan|Medical Topia Soka Hospital, Soka, Saitama, Japan|Kusatsu General Hospital, Kusatsu, Shiga, Japan|Saiseikai Fukuoka General Hospital, Fukuoka, Japan|Unoki Clinic, Kagoshima, Japan|Tetsu-Nakamura Obstetrics and Gynecology Internal Medicine, Kagoshima, Japan|Four Seasons Ladies' Clinic, Kumamoto, Japan|Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan|Ijinkai Takeda General Hospital, Kyoto, Japan|Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan|Gokeikai Osaka Kaisei Hospital, Osaka, Japan|Osaka City Hospital Organization Osaka City General Hospital, Osaka, Japan|Medical Co. LEADING GIRLS Women's Clinic LUNA Shinsaibashi, Osaka, Japan|Altai State Medical University, Barnaul, Russian Federation|Maternity Hospital, 17, Saint-Petersburg, Russian Federation|Close Joint Stock Company ""Medical Company IDK"", Samara, Russian Federation|Smolensk State Medical University, Smolensk, Russian Federation|Med Estetic Center, St. Petersburg, Russian Federation|""Granti-Med"", St. Petersburg, Russian Federation|Scien. Res. Institute of Obsterics, Gyn. & Reproduction, St. Petersburg, Russian Federation|City Clinical Maternity Hospital No 1, Chernivtsi, Ukraine|Vinnytsia City Clinical Maternity Hospital No 2, Vinnytsia, Ukraine|Zaporizhzhia Regional Clinical Hospital, Zaporizhzhya, Ukraine",,"https://ClinicalTrials.gov/show/NCT03400956"
145,"NCT03400943","Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3)",,"Active, not recruiting","No Results Available","Leiomyoma","Drug: Vilaprisan (BAY1002670)|Drug: Placebo","Amenorrhea (yes/no)|Heavy Menstrual Bleeding (HMB) response|Time to onset of amenorrhea|Time to onset of controlled bleeding|Absence of bleeding (spotting allowed)|Endometrial histology|Endometrial thickness","Bayer","Female","18 Years and older   (Adult, Older Adult)","Phase 3","260","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15787|2017-002997-38","January 17, 2018","December 31, 2020","December 31, 2020","January 17, 2018",,"January 10, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|California Center for Clinical Research, Arcadia, California, United States|Core Healthcare Group, Cerritos, California, United States|AVIVA Research, Escondido, California, United States|National Research Institute, Los Angeles, California, United States|Harbor - UCLA Medical Center, Torrance, California, United States|Ideal Clinical Research, Aventura, Florida, United States|South Florida Medical Research, Aventura, Florida, United States|Helix Biomedics, LLC, Boynton Beach, Florida, United States|Dr. Victoria Garcia & Associates, LLC Doral Medical Research, Doral, Florida, United States|Sweet Hope Research Specialty, Inc., Hialeah, Florida, United States|Clinical Neurosciences Solutions, Inc. DBA CNS Healthcare, Jacksonville, Florida, United States|Altus Research, Lake Worth, Florida, United States|Axcess Medical Research, LLC, Loxahatchee Groves, Florida, United States|Ocean Blue Medical Research Center, Inc., Miami Springs, Florida, United States|Serenity Holistic OBGYN, North Miami Beach, Florida, United States|Accelerated Enrollment Solutions a business of PPD, Orlando, Florida, United States|Discovery Clinical Research, Plantation, Florida, United States|ONCOVA Clinical Research, Inc., Saint Cloud, Florida, United States|Georgia Center For Women, Atlanta, Georgia, United States|Agile Clinical Research Trials, LLC, Atlanta, Georgia, United States|Atlanta Women's Research Institute, Inc., Atlanta, Georgia, United States|Medisense, Inc., Atlanta, Georgia, United States|Paramount Research Solutions, College Park, Georgia, United States|One Health Research Clinic, Norcross, Georgia, United States|Fellows Research Alliance, Savannah, Georgia, United States|GTC Research, Shawnee Mission, Kansas, United States|Omni Fertility and Laser Institute, Shreveport, Louisiana, United States|PharmaSite Research, Inc., Baltimore, Maryland, United States|Simmonds, Martin and Helmbrecht, Gaithersburg, Maryland, United States|Advantia Health, LLC Obstetrics & Gynecology Assoc., Silver Spring, Maryland, United States|SUNY Downstate Medical Center, Brooklyn, New York, United States|Carolinas Healthcare System, Charlotte, North Carolina, United States|Unified Women's Clinical Research - Morehead City, Morehead City, North Carolina, United States|Eastern Carolina Women's Center, New Bern, North Carolina, United States|Wake Research Associates, Raleigh, North Carolina, United States|Main Line Fertility Center, Bryn Mawr, Pennsylvania, United States|Clinical Research of Philadelphia, LLC, Philadelphia, Pennsylvania, United States|Fellows Research Alliance, Inc., Bluffton, South Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Fusion Clinical Research of Spartanburg, LLC, Spartanburg, South Carolina, United States|Chattanooga Medical Research, LLC, Chattanooga, Tennessee, United States|Clinical Neurosciences Solutions, Inc DBA CNS Healthcare, Memphis, Tennessee, United States|Paramount Research Solutions, Nashville, Tennessee, United States|Texas Health Care, PLLC, Fort Worth, Texas, United States|Willowbend Health & Wellness Associates, Frisco, Texas, United States|Family Medicine Clinic, Georgetown, Texas, United States|Biopharma Informatic, Inc., Houston, Texas, United States|Centex Studies, Inc., Houston, Texas, United States|The Center for Clinical Trials, Inc., Houston, Texas, United States|Houston Center for Clinical Research, LLC, Sugar Land, Texas, United States|Millennium Clinical Trials, LLC, Arlington, Virginia, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|Synexus Research, LLC, Richmond, Virginia, United States|Multiprofile Hospital for Active Treatment-Dr. T. Venkova AD, Gabrovo, Bulgaria|Hospital for Active Treatment - Prof.Paraskev Stoyanov AD, Lovech, Bulgaria|MHAT Dr. Bratan Shukerov AD, Smolyan, Bulgaria|MHAT for Women's Health - Nadezhda OOD, Sofia, Bulgaria|900th Hospital of Joint Logistics Support Force, Fuzhou, Fujian, China|Lanzhou University Second Hospital, Lanzhou, Gansu, China|Guangzhou Women and Children's Medical Center, Guangzhou, Guangdong, China|The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China|Boai Hospital of Zhongshan, Zhongshan, Guangdong, China|The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China|Hainan General Hospital, Haikou, Hainan, China|Center for Reproductive Medicine,Tongji Medical college,HUST, Wuhan, Hubei, China|Nanjing Maternity and Child Health Care Hospital, Nanjing, Jiangsu, China|Nanjing First Hospital, Nanjing, Jiangsu, China|NJ Drum Tower Hospital, the Affil Hos of NJ Univ Med School, Nanjing, Jiangsu, China|Zhongda Hospital Southeast University, Nanjing, Jiangsu, China|The Second Affiliated Hospital of Nanjing Medical university, Nanjing, Jiangsu, China|1st Affiliated hospital of Soochow University, Suzhou, Jiangsu, China|Jiangxi Maternal and Child Health Hospital, Nanchang, Jiangxi, China|The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China|The First Hospital of Jilin University, Changchun, Jilin, China|The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China|Shengjing Hospital of China Medical University, Shenyang, Liaoning, China|General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China|The 1st Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China|The Second Affiliated Hospital of Shanxi Medical University, Taiyuan, Shanxi, China|Second Affiliated Hospital Xian Jiaotong University School, Xi'an, Shanxi, China|The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China|Women's Hospital School of Medicine Zhejiang University, Hangzhou, Zhejiang, China|Sir Run Run Shaw Hospital, Zhejiang Univ. School of Medicine, Hangzhou, Zhejiang, China|The First Affiliated Hospital of Wenzhou Medical Univ (New), Wenzhou, Zhejiang, China|The Second Affliated Hospital of Wenzhou Medicial University, Wenzhou, Zhejiang, China|Beijing Hospital of Traditional Chinese Medicine, Beijing, China|Peking University First Hospital, Beijing, China|Beijing Friendship Hospital, Capital Medical University, Beijing, China|Beijing Tiantan Hospital, Captial Medical University, Beijing, China|Beijing Luhe Hospital of Capital Medicial University, Beijing, China|Shanghai East Hospital Affiated to Tongji University, Shanghai, China|Tianjin Medical University General Hospital, Tianjin, China|Gynekologie MEDA s.r.o., Brno, Czechia|Soukroma gynekologicka ambulance, Fulnek, Czechia|Gynekologie Studentsky dum s.r.o., Praha 6, Czechia|MUDr. Ivana Salamonova s.r.o., Vysoke Myto, Czechia|HaEmek Medical Center, Afula, Israel|Hillel Yaffe Medical Center, Hadera, Israel|Lady Davis Carmel Medical Center, Haifa, Israel|Meir Medical Center, Kfar Saba, Israel|University Hospital Kebangsaan Malaysia, Kuala Lumpur, Malaysia|Hospital Wanita dan Kanak-Kanak Sabah, Sabah, Malaysia|Sarawak General Hospital, Sarawak, Malaysia|P3 Research Ltd Hawkes Bay, Hawkes Bay, New Zealand|P3 Research, Tauranga, New Zealand|National University Hospital, Singapore, Singapore|KK Women's and Children's Hospital, Singapore, Singapore|WITS Clinical Research Site, Johannesburg, Gauteng, South Africa|Dr L Reynders Practice, Lyttelton Manor, Gauteng, South Africa|Wilgeheuwel Hospital, Roodepoort, Gauteng, South Africa|Umhlanga Medical Centre, Durban, Kwazulu-Natal, South Africa|Ethekwini Hospital & Heart Centre, Durban, Kwazulu-Natal, South Africa",,"https://ClinicalTrials.gov/show/NCT03400943"
146,"NCT03399526","1404003_OpenPsori.PlaqueTest to Eval.Eff.of Diff.Comp. to Mapracorat",,"Completed","No Results Available","Psoriasis","Drug: Mapracorat (ZK 245186, BAY 86-5319)|Drug: Prednicarbate 0.25% ointment|Drug: Clobetasol 0.05% ointment|Drug: Calcipotriene 0.005% ointment|Drug: Calcipotriene 0.005%/Betamethasone dipropionate 0.05% ointment","Baseline-corrected area under the curve of the psoriatic infiltrate thickness (PIT) measured by 20 MHz B mode ultrasound|Skin thickness measurement of occluded test field on non-lesional skin (mean of triplicate measurement)|Clinical assessment of atrophy using a 5-point score|Clinical assessment of telangiectasia using a 5-point score|Clinical assessment of local tolerability using a 5-point score|PIT measured by 20 MHz B mode ultrasound|Measurement of erythema using chromametry (mean of triplicate measurement)|Clinical efficacy assessment of the skin in the test fields using a 5-point score|Number of participants with adverse events","Bayer","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","16599|2012-004171-39","February 11, 2013","May 31, 2013","May 31, 2013","January 16, 2018",,"January 16, 2018","Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT03399526"
147,"NCT03396250","A Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects",,"Completed","No Results Available","Pain","Drug: Naproxen sodium and diphenhydramine hydrochloride soft capsules|Drug: Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve, PMBAY98-7111)","AUC|AUC(0-tlast)|Cmax|Number of adverse events as a measure of safety and tolerability","Bayer","All","18 Years to 55 Years   (Adult)","Phase 1","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17934","February 12, 2018","March 26, 2018","March 29, 2018","January 10, 2018",,"March 20, 2019","ICON Development Solutions, LLC, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03396250"
148,"NCT03386825","Metastatic Colorectal Cancer Patients With Long-term Response to Regorafenib","COLONG","Completed","No Results Available","Colorectal Neoplasms","Drug: Regorafenib (Stivarga, BAY73-4506)","Proportion of patients with a DoT to Stivarga of more than 4 months versus total study sample|ECOG performance status (0, 1)|Primary site of disease|Tumor resection (yes, no, unknown)|Specific site of metastasis|KRAS mutation (yes, no, unknown)|RAS mutation (yes, no, unknown)|BRAF mutation (yes, no, unknown)|Start date of Stivarga treatment|Number of prior treatment lines for metastatic cancer larger than 3 (yes, no, unknown)|Reason for discontinuation of Stivarga treatment|Subsequent mCRC treatment|Last daily Stivarga dose|Duration of treatment (months)","Bayer","All","18 Years and older   (Adult, Older Adult)",,"76","Industry","Observational","Observational Model: Other|Time Perspective: Retrospective","19577","January 31, 2018","May 1, 2018","May 1, 2018","December 29, 2017",,"May 15, 2018","Belgium, Multiple Locations, Belgium",,"https://ClinicalTrials.gov/show/NCT03386825"
149,"NCT03382587","Observational Study to Assess Intravitreal Aflibercept Injections Used in a ""Treat and Extend"" Regimen in Treatment-naïve Wet Age-related Macular Degeneration Patients","ASTERIA","Completed","No Results Available","Wet Age-related Macular Degeneration","Drug: Aflibercept (Eylea, BAY86-5321)","Mean change from baseline in best-corrected visual acuity in Early Treatment Diabetic Retinopathy Study letters (ETDRS letters)|Mean change from baseline in best-corrected visual acuity (in Early Treatment Diabetic Retinopathy Study (ETDRS) letters)|Mean change in best-corrected visual acuity in relation to the number of injections administered|Mean interval between injections|Reasons for the interval length|Frequency of disease reactivation|Proportion of eyes gaining or losing ≥ 15 Early Treatment Diabetic Retinopathy Study letters compared to baseline|Mean changes from baseline in central retinal thickness (CRT)|Changes from baseline in retinal fluid|Reasons for termination of therapy (including subsequent therapy at time of discontinuation)|Severity of disease reactivation","Bayer|Regeneron Pharmaceuticals","All","55 Years and older   (Adult, Older Adult)",,"163","Industry","Observational","Observational Model: Cohort|Time Perspective: Other","18574","December 5, 2017","November 9, 2018","November 27, 2018","December 26, 2017",,"August 26, 2019","Many Locations, Multiple Locations, Switzerland",,"https://ClinicalTrials.gov/show/NCT03382587"
150,"NCT03374540","Rivaroxaban vs Warfarin for SPAF in Multi-morbid Patients",,"Completed","No Results Available","Nonvalvular Atrial Fibrillation","Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Vitamin K antagonist(VKA)","Stroke|Systemic embolism|Major bleeding|Hemorrhagic stroke|Ischemic stroke|Subtypes of major bleeding|Adverse cardiovascular and limb events|Acute kidney injury|Renal impairment","Bayer","All","18 Years and older   (Adult, Older Adult)",,"99999","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","19859","December 1, 2017","August 30, 2019","August 30, 2019","December 15, 2017",,"October 11, 2019","Truven Health MarketScan Commercial Claims and Medicare Supplemental Databases, Multiple Locations, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03374540"
151,"NCT03373422","A Study to Test Whether Study Drug BAY1128688 Brings Pain Relief to Women With Endometriosis and if so to Get a First Idea Which Dose(s) Work Best","AKRENDO1","Terminated","No Results Available","Endometriosis","Drug: BAY1128688|Drug: Placebo","Absolute change in mean pain of the 7 days with worst EAPP comparing the 28-day baseline cycle (baseline period of daily pain recordings) to the 28-day end of treatment cycle (daily pain recordings during the last 28 days of the treatment period)|Incidence of treatment-emergent adverse events","Bayer","Female","18 Years and older   (Adult, Older Adult)","Phase 2","121","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","17472|2017-000244-18","November 30, 2017","July 23, 2018","October 22, 2018","December 14, 2017",,"October 3, 2019","Kepler Universitätsklinikum, Linz, Oberösterreich, Austria|Medizinische Universität Graz, Graz, Steiermark, Austria|Landeskrankenhaus - Universitätskliniken Innsbruck, Innsbruck, Austria|Allgemeines Krankenhaus der Stadt Wien, Wien, Austria|AZ Jan Palfijn Gent, Gent, Oost-Vlaanderen, Belgium|CU Saint-Luc/UZ St-Luc, Bruxelles - Brussel, Belgium|Ziekenhuis Oost-Limburg, Genk, Belgium|CHU de Tivoli, La Louviere, Belgium|Gynekologie MEDA s.r.o., Brno, Czechia|GYN-F s.r.o., Hradec Kralove, Czechia|G-Centrum Olomouc s.r.o. Dr. Skrivanek, Olomouc, Czechia|Centrum gynekologicke rehabilitace, Pisek, Czechia|GynCare MUDr. Michael Svec s.r.o., Plzen, Czechia|Dr. Smrhova-Kovacs, Tabor, Czechia|Aarhus Universitetshospital, Skejby, Aarhus N, Denmark|H:S Rigshospitalet, København Ø, Denmark|HUS / Naistenklinikka, Helsinki, Finland|Keski-Suomen keskussairaala, Jyväskylä, Finland|Lääkäriasema Cantti Oy, Kuopio, Finland|Lääkärikeskus Gyneko, Oulu, Finland|Centre Hospitalier Universitaire - Angers, Angers, France|Cochin - Paris, Paris, France|Vincentius-Diakonissen-Kliniken gAG, Karlsruhe, Baden-Württemberg, Germany|Praxisklinik am Rosengarten, Mannheim, Baden-Württemberg, Germany|Klinikum rechts der Isar, München, Bayern, Germany|Praxis Hr. Dr. A. Gerick, Aachen, Nordrhein-Westfalen, Germany|Praxis Hr. Dr. S. Fiedler, Aachen, Nordrhein-Westfalen, Germany|Frauenarztpraxis Dr. Wolfgang Clemens, Stolberg, Nordrhein-Westfalen, Germany|Praxis f. Gynäkologie und Geburtshilfe, Bernburg, Sachsen-Anhalt, Germany|Frauenarztpraxis Dr. Wetzel, Blankenburg, Sachsen-Anhalt, Germany|Praxis Hr. Prof. Dr. A. Ebert, Berlin, Germany|Charité Campus Benjamin Franklin (CBF), Berlin, Germany|Semmelweis University, Budapest, Hungary|Semmelweis University, Budapest, Hungary|Bajcsy Zsilinszky Korhaz-Rendelointezet, Budapest, Hungary|Robert Karoly Magankorhaz, Budapest, Hungary|NAP - Rendelo, Private Clinic, Debrecen, Hungary|Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary|SZTE ÁOK Szent Györgyi Albert Klinikai Kozpont, Szeged, Hungary|Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz, Szekesfehervar, Hungary|Casa di Cura Privata Malzoni - Villa dei Platani, Avellino, Campania, Italy|A.O.U. di Bologna Policlinico S.Orsola Malpighi, Bologna, Emilia-Romagna, Italy|A.S.U. Integrata di Udine, Udine, Friuli-Venezia Giulia, Italy|Fondazione Policlinico Universitario Agostino Gemelli, Roma, Lazio, Italy|IRCCS A.O.U. San Martino IST Ist. Nazionale Ricerca Cancro, Genova, Liguria, Italy|A.O.U. Careggi, Firenze, Toscana, Italy|A.O.U. Senese, Siena, Toscana, Italy|A.O.U. Integrata Verona, Verona, Veneto, Italy|Flevoziekenhuis, Almere, Netherlands|Isala, Zwolle, Netherlands|CLINICAL MEDICAL RESEARCH Sp. z o. o., Katowice, Poland|Vita Longa Sp. z o.o., Katowice, Poland|Prywatny Gabinet Lekarski Ginekologia, Poloznictwo i Ultr., Lodz, Poland|Specjalistyczny Gabinet Ginekologiczno-Polozniczy, Lublin, Poland|NZOZ NOVITA, Specjalistyczne Gabinety Lekarskie, Lublin, Poland|VitroLive Sp. z o.o., Szczecin, Poland|Twoja Przychodnia - Szczecinskie Centrum Medyczne, Szczecin, Poland|NZOZ Zieniewicz Medical, Warszawa, Poland|Hospital Clínic i Provincial de Barcelona, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario ""La Paz"", Madrid, Spain|Hospital Regional de Málaga, Málaga, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital General Universitario de Valencia, Valencia, Spain|York Teaching Hospital NHS Foundation Trust, York, North Yorkshire, United Kingdom|Liverpool Womens Hospital, Liverpool, United Kingdom|Norfolk and Norwich Hospital, Norwich, United Kingdom|Whiston Hospital, Prescot, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03373422"
152,"NCT03364998","BAY94-9027 PK Study Comparing to Another Long Acting Product",,"Completed","No Results Available","Hemophilia A","Drug: Damoctocog (Jivi, BAY94-9027)|Drug: Elocta","AUC from time 0 to the last data point","Bayer","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","19096|2017-003201-18","November 30, 2017","January 25, 2018","September 28, 2018","December 7, 2017",,"September 9, 2019","SHATHD Spec. Hospi. for Active Treatm. of Haematol. Dis. EAD, Sofia, Bulgaria",,"https://ClinicalTrials.gov/show/NCT03364998"
153,"NCT03359876","Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal Dysfunction","CALLIPER","Completed","No Results Available","Atrial Fibrillation","Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Warfarin sodium","Ischemic stroke|Intracranial hemorrhage|Bleeding-related hospitalization|Composite endpoint, which is defined as the occurrence of ischemic stroke or intracranial hemorrhage|Progression to stage 5 chronic kidney disease (CKD), kidney failure or need for dialysis","Bayer|Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)",,"16000","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","19721","December 1, 2017","March 29, 2019","March 29, 2019","December 2, 2017",,"December 11, 2019","US Truven MarketScan, Whippany, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03359876"
154,"NCT03353857","Drug-drug Interaction Between Rifampicin and Progestins/Ethinylestradiol and Midazolam",,"Completed","No Results Available","Biological Availability","Drug: levonorgestrel/ Microlut|Drug: Norethindrone/ Noriday|Drug: Desogestrel/ Cerazette|Drug: Dienogest/ Visanne|Drug: Drospirenone, Ethinylestradiol/ Yasmin|Drug: Midazolam/ Midazolam-ratiopharm|Drug: Rifampicin","Area under the plasma concentration time curve from zero to infinity (AUC) of levonorgestrel alone and in the presents of rifampicin|Maximum plasma concentration (Cmax) of levonorgestrel alone and in the presents of rifampicin|Area under the plasma concentration time curve from zero to infinity (AUC) of norethindrone alone and in the presents of rifampicin|Maximum plasma concentration (Cmax) of norethindrone alone and in the presents of rifampicin|Area under the plasma concentration time curve from zero to infinity (AUC) of etonogestrel alone and in the presents of rifampicin|Maximum plasma concentration (Cmax) of etonogestrel alone and in the presents of rifampicin|Area under the plasma concentration time curve from zero to infinity (AUC) of dienogest alone and in the presents of rifampicin|Maximum plasma concentration (Cmax) of dienogest alone and in the presents of rifampicin|Area under the plasma concentration time curve from zero to infinity (AUC) of drospirenone and ethinylestradiol alone and in the presents of rifampicin|Maximum plasma concentration (Cmax) of drospirenone and ethinylestradiol alone and in the presents of rifampicin|Area under the plasma concentration time curve from zero to infinity (AUC) of midazolam alone and in the presents of rifampicin|Maximum plasma concentration (Cmax) of midazolam alone and in the presents of rifampicin","Bayer","Female","45 Years to 70 Years   (Adult, Older Adult)","Phase 1","68","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","19604|2017-002792-26","November 29, 2017","July 4, 2018","February 19, 2019","November 27, 2017",,"February 28, 2019","CRS Clinical-Research-Services Mannheim GmbH, Mannheim, Baden-Württemberg, Germany|CRS Clinical-Research-Services Mönchengladbach GmbH, Mönchengladbach, Nordrhein-Westfalen, Germany",,"https://ClinicalTrials.gov/show/NCT03353857"
155,"NCT03351166","A Study of Molidustat for Correction of Renal Anemia in Dialysis Subjects","MIYABI HD-C","Completed","No Results Available","Anemia|Renal Insufficiency, Chronic","Drug: Molidustat (BAY85-3934)","Rate of rise in Hb (Hemoglobin) level (g/dL/week)|Responder rate: proportion of responders among the subjects|Proportion of subjects who meet each component of the response|Cumulative proportion of subjects who achieve the lower limit of the target Hb range at least once at each visit|Hb level|Change in Hb level|Proportion of subjects whose mean hemoglobin levels are above the target range during the evaluation period|Proportion of subjects whose mean hemoglobin levels are below the target range during the evaluation period|Proportion of subjects whose mean hemoglobin levels are in the target range during the evaluation period|Proportion of subjects with hemoglobin levels above the target range|Proportion of subjects with hemoglobin levels below the target range|Proportion of subjects with hemoglobin levels in the target range|Proportion of subjects whose maximum rise in Hb between each consecutive visits is above 0.5 g/dL/week|Number of participants with serious adverse events|Maximum concentration (Cmax) of Molidustat|Area under the concentration-time curve (AUC) of Molidustat|EPO (Erythropoietin) serum concentration of Molidustat","Bayer","All","20 Years and older   (Adult, Older Adult)","Phase 3","25","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19351","January 22, 2018","October 23, 2018","November 20, 2018","November 22, 2017",,"August 19, 2019","Houshikai Kano hospital, Kasuya-gun, Fukuoka, Japan|Matsunami General Hospital, Hashima-gun, Gifu, Japan|Asahikawa-Kosei General Hospital, Asahikawa, Hokkaido, Japan|Ishikari Hospital, Ishikari, Hokkaido, Japan|Itami Kidney Clinic, Noboribetsu, Hokkaido, Japan|Souen Central Hospital, Sapporo, Hokkaido, Japan|Takasago Seibu Hospital, Takasago, Hyogo, Japan|Japanese Red Cross Koga Hospital, Koga, Ibaraki, Japan|Mito Kyodo General Hospital, Mito, Ibaraki, Japan|Tokiwa Clinic, Totte, Ibaraki, Japan|Tsuchiura Beryl Clinic, Tsuchiura, Ibaraki, Japan|Kikuchi Medical Clinic, Tsukuba, Ibaraki, Japan|Japanese Red Cross Ishinomaki Hospital, Ishinomaki, Miyagi, Japan|Iida Hospital, Iida, Nagano, Japan|Toyonaka Keijinkai Clinic, Toyonaka, Osaka, Japan|Kodaira Kitaguchi Clinic, Kodaira, Tokyo, Japan|Inage Hospital, Chiba, Japan|Fukuoka Renal Clinic, Fukuoka, Japan|Ohmiya Chuo General Hospital, Saitama, Japan|Yamagata Tokushukai Hospital, Yamagata, Japan",,"https://ClinicalTrials.gov/show/NCT03351166"
156,"NCT03350347","A Study of Molidustat for Maintenance Treatment of Renal Anemia in Non-dialysis Subjects","MIYABI ND-M","Completed","No Results Available","Anemia|Renal Insufficiency, Chronic","Drug: Molidustat (BAY85-3934)|Drug: Darbepoetin alfa","Mean Hb (Hemoglobin) level|Change in hemoglobin level from baseline to the average during the evaluation period|Responder rate: proportion of responders among the subjects|Proportion of subjects who meet each component of the response|Hb level|Change in Hb level|Proportion of subjects whose mean hemoglobin levels are in the target range during the evaluation period|Proportion of subjects whose mean hemoglobin levels are above the target range during the evaluation period|Proportion of subjects whose mean hemoglobin levels are below the target range during the evaluation period|Proportion of subjects whose hemoglobin levels are in the target range|Proportion of subjects whose hemoglobin levels are above the target range|Proportion of subjects whose hemoglobin levels are below the target range|Proportion of subjects whose maximum rise in Hb between each consecutive visits is above 0.5 g/dL/week|Number of participants with serious adverse events|Maximum concentration (Cmax) of Molidustat|Area under the concentration-time curve (AUC) of Molidustat|EPO (Erythropoietin) serum concentration of Molidustat","Bayer","All","20 Years and older   (Adult, Older Adult)","Phase 3","162","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19350","December 13, 2017","July 5, 2019","November 28, 2019","November 22, 2017",,"December 17, 2019","Kainan Hospital, Yatomi, Aichi, Japan|Seikeikai New Tokyo Heart Clinic, Matsudo, Chiba, Japan|Ehime Prefectural Central Hospital, Matsuyama, Ehime, Japan|Saiseikai Matsuyama Hospital, Matsuyama, Ehime, Japan|Iizuka Hospital, Iizuka, Fukuoka, Japan|Kokura Memorial Hospital, Kitakyushu, Fukuoka, Japan|Steel Memorial Yawata Hospital, Kitakyushu, Fukuoka, Japan|National Fukuoka-Higashi Medical Center, Koga, Fukuoka, Japan|Kurume University Hospital, Kurume, Fukuoka, Japan|St.Mary's Hospital, Kurume, Fukuoka, Japan|Matsunami Health Promotion Clinic, Hashima-gun, Gifu, Japan|Mazda Hospital of Mazda Motor Corporation, Aki-gun, Hiroshima, Japan|Nippon Kokan Fukuyama Hospital, Fukuyama, Hiroshima, Japan|Higashihiroshima Medical Center, Higashihiroshima, Hiroshima, Japan|Teine Keijinkai Clinic, Sapporo, Hokkaido, Japan|Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan|National Hospital Organization Kobe Medical Center, Kobe, Hyogo, Japan|Mito Kyodo General Hospital, Mito, Ibaraki, Japan|Public Central Hospital of Matto Ishikawa, Hakusan, Ishikawa, Japan|KenAiKai medical corporation Akiyama clinic, Takamatsu, Kagawa, Japan|Ikeda Hospital, Kanoya, Kagoshima, Japan|Fujisawa City Hospital, Fujisawa, Kanagawa, Japan|Koukan Clinic, Kawasaki, Kanagawa, Japan|Showa University Fujigaoka Hospital, Yokohama, Kanagawa, Japan|Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan|Arao Municipal Hospital, Arao, Kumamoto, Japan|JCHO Yokkaichi Hazu Medical Center, Yokkaichi, Mie, Japan|Japanese Red Cross Ishinomaki Hospital, Ishinomaki, Miyagi, Japan|Asama Nanroku Komoro Medical Center, Komoro, Nagano, Japan|Niigata Prefectural Shibata Hospital, Shibata, Niigata, Japan|R.I.A.C Naha City Hospital, Naha, Okinawa, Japan|Osaka Pref. Saiseikai Tondabayashi Hospital, Tondabayashi, Osaka, Japan|Kitasato University Medical Center, Kitamoto, Saitama, Japan|Iwata City Hospital, Iwata, Shizuoka, Japan|Toshima Hospital, Itabashi-ku, Tokyo, Japan|Nihon University Itabashi Hospital, Itabashi-ku, Tokyo, Japan|Showa University Koto Toyosu Hospital, Koto-ku, Tokyo, Japan|National Hospital Organization Tokyo Medical Center, Meguro-ku, Tokyo, Japan|University of Yamanashi Hospital, Chuo, Yamanashi, Japan|Fukui Prefectural Hospital, Fukui, Japan|National Hospital Organization Kyushu Medical Center, Fukuoka, Japan|Kyushu University Hospital, Fukuoka, Japan|Fukuoka University Hospital, Fukuoka, Japan|Asahi University Hospital, Gifu, Japan|National Hospital Organization Kochi National Hospital, Kochi, Japan|Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan|Nara Prefecture General Medical Center, Nara, Japan|Japanese Red Cross Oita Hospital, Oita, Japan|Kitano Hospital, Osaka, Japan|Yodogawa Christian Hospital, Osaka, Japan|National Hospital Organization Osaka National Hospital, Osaka, Japan|Osaka Red Cross Hospital, Osaka, Japan|Nippon Life Hospital, Osaka, Japan|Chibune Clinic, Osaka, Japan|Osaka General Medical Center, Osaka, Japan|Social Corporation Keigakukai Minamiosaka Hospital, Osaka, Japan|Shizuoka Saiseikai General Hospital, Shizuoka, Japan|Suruga Clinic, Shizuoka, Japan|Wakayama Medical University Hospital, Wakayama, Japan",,"https://ClinicalTrials.gov/show/NCT03350347"
157,"NCT03350321","A Study of Molidustat for Correction of Renal Anemia in Non-dialysis Subjects","MIYABI ND-C","Completed","No Results Available","Anemia|Renal Insufficiency, Chronic","Drug: Molidustat (BAY85-3934)|Drug: Darbepoetin alfa","Mean Hb (Hemoglobin) level|Change in hemoglobin level from baseline to the average during the evaluation period|Responder rate: proportion of responders among the subjects|Rate of rise in Hb (Hemoglobin) level (g/dL/week)|Proportion of subjects who meet each component of the response|Cumulative proportion of subjects who achieve the lower limit of the target Hb range at least once|Change in Hb level|Hb level|Proportion of subjects whose mean hemoglobin level is in the target range|Proportion of subjects whose mean hemoglobin level is above the target range|Proportion of subjects whose mean hemoglobin level is below the target range|Proportion of subjects with hemoglobin levels in the target range|Proportion of subjects with hemoglobin levels above the target range|Proportion of subjects with hemoglobin levels below the target range|Proportion of subjects whose maximum rise in Hb between each consecutive visits is above 0.5 g/dL/week|Number of participants with serious adverse events|Maximum concentration (Cmax)|Area under the concentration-time curve (AUC)|EPO (Erythropoietin) serum concentration","Bayer","All","20 Years and older   (Adult, Older Adult)","Phase 3","166","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19349","December 12, 2017","May 17, 2019","October 11, 2019","November 22, 2017",,"October 18, 2019","Kainan Hospital, Yatomi, Aichi, Japan|Seikeikai New Tokyo Heart Clinic, Matsudo, Chiba, Japan|Ehime Prefectural Central Hospital, Matsuyama, Ehime, Japan|Saiseikai Matsuyama Hospital, Matsuyama, Ehime, Japan|Iizuka Hospital, Iizuka, Fukuoka, Japan|Kokura Memorial Hospital, Kitakyushu, Fukuoka, Japan|Steel Memorial Yawata Hospital, Kitakyushu, Fukuoka, Japan|National Fukuoka-Higashi Medical Center, Koga, Fukuoka, Japan|Kurume University Hospital, Kurume, Fukuoka, Japan|St.Mary's Hospital, Kurume, Fukuoka, Japan|Matsunami Health Promotion Clinic, Hashima-gun, Gifu, Japan|Gifu Prefectural Tajimi Hospital, Tajimi, Gifu, Japan|Mazda Hospital of Mazda Motor Corporation, Aki-gun, Hiroshima, Japan|Nippon Kokan Fukuyama Hospital, Fukuyama, Hiroshima, Japan|Teine Keijinkai Clinic, Sapporo, Hokkaido, Japan|Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan|National Hospital Organization Kobe Medical Center, Kobe, Hyogo, Japan|National hospital Organization Mito Medical Center, Higashiibaraki, Ibaraki, Japan|Mito Kyodo General Hospital, Mito, Ibaraki, Japan|KenAiKai medical corporation Akiyama clinic, Takamatsu, Kagawa, Japan|Ikeda Hospital, Kanoya, Kagoshima, Japan|Fujisawa City Hospital, Fujisawa, Kanagawa, Japan|Koukan Clinic, Kawasaki, Kanagawa, Japan|Showa University Fujigaoka Hospital, Yokohama, Kanagawa, Japan|Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan|Arao Municipal Hospital, Arao, Kumamoto, Japan|Kumamoto Rosai Hospital, Yatsushiro, Kumamoto, Japan|Uji-Tokushukai Medical Center, Uji, Kyoto, Japan|JCHO Yokkaichi Hazu Medical Center, Yokkaichi, Mie, Japan|Japanese Red Cross Ishinomaki Hospital, Ishinomaki, Miyagi, Japan|Asama Nanroku Komoro Medical Center, Komoro, Nagano, Japan|Niigata Prefectural Shibata Hospital, Shibata, Niigata, Japan|Okinawa prefectural Chubu Hospital, Uruma, Okinawa, Japan|Osaka Saiseikai Senri Hospital, Suita, Osaka, Japan|Osaka Pref. Saiseikai Tondabayashi Hospital, Tondabayashi, Osaka, Japan|Kitasato University Medical Center, Kitamoto, Saitama, Japan|Iwata City Hospital, Iwata, Shizuoka, Japan|Toshima Hospital, Itabashi-ku, Tokyo, Japan|Nihon University Itabashi Hospital, Itabashi-ku, Tokyo, Japan|Showa University Koto Toyosu Hospital, Koto-ku, Tokyo, Japan|National Hospital Organization Tokyo Medical Center, Meguro-ku, Tokyo, Japan|University of Yamanashi Hospital, Chuo, Yamanashi, Japan|Fukui Prefectural Hospital, Fukui, Japan|National Hospital Organization Kyushu Medical Center, Fukuoka, Japan|Kyushu University Hospital, Fukuoka, Japan|Fukuoka University Hospital, Fukuoka, Japan|Fukushima Medical University Hospital, Fukushima, Japan|Asahi University Hospital, Gifu, Japan|National Hospital Organization Kochi National Hospital, Kochi, Japan|Nara Prefecture General Medical Center, Nara, Japan|Japanese Red Cross Oita Hospital, Oita, Japan|Kitano Hospital, Osaka, Japan|National Hospital Organization Osaka National Hospital, Osaka, Japan|Osaka Red Cross Hospital, Osaka, Japan|Nippon Life Hospital, Osaka, Japan|Chibune Clinic, Osaka, Japan|Osaka General Medical Center, Osaka, Japan|Social Corporation Keigakukai Minamiosaka Hospital, Osaka, Japan|Shizuoka Saiseikai General Hospital, Shizuoka, Japan|Suruga Clinic, Shizuoka, Japan|Wakayama Medical University Hospital, Wakayama, Japan",,"https://ClinicalTrials.gov/show/NCT03350321"
158,"NCT03350295","Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg",,"Completed","No Results Available","Chagas Disease","Drug: Nifurtimox (Lampit, BAYA2502)","AUC(0-tlast) of nifurtimox|Cmax of nifurtimox|AUC of nifurtimox|Number of participants with adverse events|AUC divided by dose: AUC/D|AUC(0-tlast) divided by dose: AUC(0-tlast)/D|Cmax divided by dose: Cmax/D","Bayer","All","18 Years to 45 Years   (Adult)","Phase 1","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16007","June 14, 2018","September 18, 2018","December 14, 2018","November 22, 2017",,"December 12, 2019","FP Clinical Pharma, Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina",,"https://ClinicalTrials.gov/show/NCT03350295"
159,"NCT03349684","Loose-dose Combination of Acarbose and Metformin for T2DM in Metformin-failure Patients",,"Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: Acarbose|Drug: Metformin|Drug: Placebo","Change in the levels of glycosylated hemoglobin (HbA1c)|Change in fasting plasma glucose levels|Change in plasma glucose levels measured 2 hours after a standard meal|Change in fasting serum insulin levels|Responder rates|Number of participants with AEs","Bayer","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 3","287","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","17886","March 5, 2018","August 12, 2019","August 21, 2019","November 21, 2017",,"October 30, 2019","Anhui Provincial Hospital, Hefei, Anhui, China|The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China|The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China|Sun Yat-Sen Memorial Hosp. Sun Yat-Sen Univ., Guangzhou, Guangdong, China|The 3rd Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China|The Second Affliated Hospital of Hainan Medical University, Haikou, Hainan, China|Hainan Third People's Hospital (Province Nongken Sanya Hopt), Sanya, Hainan, China|1st Affiliated Hospital of Henan Science and Technology Univ, Luoyang, Henan, China|The first affiliated hospital of Zhengzhou University, Zhengzhou, Henan, China|Taihe Hospital, Shiyan, Hubei, China|Tongji Hosp. of Tongji Med Coll, Huazhong Uni of Sci & Tech., Wuhan, Hubei, China|Chenzhou No. 1 People's Hospital, Chenzhou, Hunan, China|1st Peopl's Hosp of Changzhou 3rd Affil Hosp of Soochow Univ, Changzhou, Jiangsu, China|Huai'an First People's Hospital, Nanjing Medical University, Huai'An, Jiangsu, China|Jiangsu Province Hospital, Nanjing, Jiangsu, China|Northern Jiangsu People's Hospital, Yangzhou, Jiangsu, China|Jilin Province People's Hospital, Changchun, Jilin, China|1st Affiliated Hospital of Xi'an Jiaotong Medical University, Xi'an, Shaanxi, China|Shandong Provincial Hospital, Jinan, Shandong, China|Affiliated Hospital of Jining Medical University, Jining, Shandong, China|West China Hospital, Sichuan University, Chengdu, Sichuan, China|People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China|Emergency General Hospital, Beijing, China|Peking Union Medical College Hospital CAMS, Beijing, China|Beijing Pinggu Hospital, Beijing, China|Changsha Central Hospital, Changsha, China|Jiangxi PingXiang people's Hospital, Pingxiang, China|Shanghai Tenth People's Hospital, Shanghai, China|Tianjin Union Medicine Centre (People's Hospital of Tianjin), Tianjin, China",,"https://ClinicalTrials.gov/show/NCT03349684"
160,"NCT03347292","Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC",,"Recruiting","No Results Available","Carcinoma, Hepatocellular","Drug: Regorafenib(Stivarga, BAY73-4506)|Drug: Pembrolizumab","Incidence of treatment-emergent adverse event(TEAEs)|Severity of TEAEs|Dose Limiting Toxicities(DLTs)|Maximum Tolerated Dose (MTD)|Progression-free survival (PFS)|Time to progression (TTP)|Overall survival (OS)|Overall response rate (ORR)|Disease control rate (DCR)|Duration of response (DOR)|Duration of stable disease","Bayer|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 1","57","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19497|KN-743|2017-003202-40","June 18, 2018","October 26, 2020","March 2, 2022","November 20, 2017",,"January 13, 2020","USC Norris Hospital and Clinics, Los Angeles, California, United States|University of Florida Health Sciences Center, Gainesville, Florida, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Mount Sinai Medical Center, New York, New York, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Universitätsklinikum Köln, Köln, Nordrhein-Westfalen, Germany|Universitätsmedizin der Johannes Gutenberg Universität Mainz, Mainz, Rheinland-Pfalz, Germany",,"https://ClinicalTrials.gov/show/NCT03347292"
161,"NCT03342859","Mode of Action Study of Vilaprisan and Ulipristal Acetate in Patients With Uterine Fibroids for Whom Surgery is Planned",,"Active, not recruiting","No Results Available","Leiomyoma","Drug: Vilaprisan, BAY1002670|Drug: Ulipristal","Biomarker for glandular and stromal cell proliferation (Ki-67) in the endometrium of the same patient before treatment and when treated with VPR (vilaprisan) prior to surgery|Biomarker for myoma cell proliferation (Ki-67) in fibroid tissue of patients not treated with PRM (progesterone receptor modulator )and those who have been treated with VPR prior to surgery|Biomarkers for apoptotic regulation in the endometrium (BCL-2 (B-cell lymphoma 2), caspase 3) of the same patient before treatment and when treated with VPR prior to surgery|Biomarkers for apoptotic regulation in fibroid tissue (BCL-2, caspase 3) of patients not treated with PRM and those who have been treated with VPR prior to surgery|Nuclear hormone receptors in the endometrium (progesterone receptor (PR), PR-B, estrogen receptor (ER), androgen receptor (AR)) of the same patient before treatment and when treated with VPR prior to surgery|Expression of endometrial and fibroid biomarkers before and when treated with ulipristal acetate (UPA) (prior to surgery)","Bayer","Female","18 Years and older   (Adult, Older Adult)","Phase 1","55","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","15791|2017-000468-13","November 16, 2017","October 19, 2020","November 10, 2020","November 17, 2017",,"January 9, 2020","Edinburgh Royal Infirmary/ NHS Lothian, Edinburgh, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03342859"
162,"NCT03334838","Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients - Dietary Habits Study",,"Active, not recruiting","No Results Available","Chagas' Disease","Drug: Nifurtimox (Lampit, BAYA2502)","AUC(0-tlast) of nifurtimox|Cmax of nifurtimox|Number of participants with adverse events as a measure of safety and tolerability|AUC(0-tlast) divided by dose: AUC(0-tlast)/D|Cmax divided by dose: Cmax/D","Bayer","All","18 Years to 45 Years   (Adult)","Phase 1","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16006","June 10, 2019","November 7, 2019","January 30, 2020","November 7, 2017",,"January 21, 2020","FP Clinical Pharma, Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina",,"https://ClinicalTrials.gov/show/NCT03334838"
163,"NCT03330288","Prospective Multicenter Non-interventional Study in Patients With Knee or Hip Osteoarthritis Having a Theraflex Treatment",,"Active, not recruiting","No Results Available","Osteoarthritis","Drug: Theraflex, BAY 874017","Changes in quality of life assessed by Knee injury and Osteoarthritis Outcome Score (KOOS) in patients with knee OA|Changes in quality of life assessed by Hip injury and Osteoarthritis Outcome Score (HOOS) in patients with hip OA|Drug utilization of Theraflex therapy|Patient satisfaction measured with a Likert response scale|Painkiller usage - type|Painkiller usage - length|Painkiller usage - frequency|Other medical/physical therapy usage-type|Other medical/physical therapy usage-frequency|Other medical/physical therapy usage-length","Bayer","All","45 Years to 75 Years   (Adult, Older Adult)",,"1110","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","19649","November 20, 2017","February 29, 2020","March 30, 2020","November 6, 2017",,"January 21, 2020","Sci-Res Institute of Rheumatology n.a. V.A. Nasonova of RAMS, Moscow, Russian Federation|Many locations, Multiple Locations, Russian Federation",,"https://ClinicalTrials.gov/show/NCT03330288"
164,"NCT03325127","Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study",,"Withdrawn","No Results Available","Prostatic Neoplasms, Castration-Resistant","Drug: radium Ra 223 dichloride (Xofigo, BAY88-8223)|Drug: Zytiga|Drug: Xtandi","Survival rates|Disease progression|Skeletal related events (SRE)|Symptomatic Skeletal Events (SSE)|Time to death|Sequence of treatment regimens|Dose schedule|Duration of therapy|Time to first visceral metastasis|Proportion of patients developing visceral metastasis","Bayer","Male","40 Years and older   (Adult, Older Adult)",,"0","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","19706","October 30, 2017","September 28, 2018","September 28, 2018","October 30, 2017",,"October 31, 2018",,,"https://ClinicalTrials.gov/show/NCT03325127"
165,"NCT03315260","Treatment Satisfaction With Ra-223 in Japan",,"Recruiting","No Results Available","Prostatic Neoplasms","Drug: Radium-223 dichloride (Xofigo, BAY88-8223)","Change in patient satisfaction with treatment using the Cancer Therapy Satisfaction Questionnaire (CTSQ)|Change in the total scores of the CTSQ domains|Change in patient anxiety with prostate cancer using the Memorial Anxiety Scale for Prostate Cancer (MAX-PC)|Change in bone-related symptoms using the Functional Assessment of Cancer Therapy Quality of Life Measurement in Patients with Bone Pain (FACT-BP)|Differences in change in treatment satisfaction (measured by CTSQ) between potential subgroups|Differences in change in prostate cancer anxiety (measured by MAX-PC) between potential subgroups|Differences in change in bone pain (measured by FACT-BP) between potential subgroups","Bayer","Male","20 Years and older   (Adult, Older Adult)",,"150","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","19502","April 11, 2019","June 30, 2020","August 31, 2020","October 20, 2017",,"January 13, 2020","Many Locations, Multiple Locations, Japan",,"https://ClinicalTrials.gov/show/NCT03315260"
166,"NCT03311139","Treatment and Outcomes of Atrial Fibrillation and Acute Coronary Syndrome in Sweden",,"Completed","No Results Available","Atrial Fibrillation","Drug: Antithrombotic agents","Composition of treatment regimens|Frequency of treatment regimens|Prescribed strength of the most common regimens|Prescribed treatment duration of the most common regimens|Hospitalization or death with a diagnosis of bleeding as safety outcome|Hospitalization for recurrent Acute Coronary Syndrom (ACS) as effectiveness outcome|Revascularization procedure ( percutaneous stenting procedure or coronary bypass grafting) as effectiveness outcome|Ischaemic stroke or systemic embolism as effectiveness outcome|Death from any cause as effectiveness outcome","Bayer|Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)",,"14226","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","19562","November 16, 2017","March 23, 2018","March 23, 2018","October 17, 2017",,"January 14, 2019","Many locations, Multiple Locations, Sweden",,"https://ClinicalTrials.gov/show/NCT03311139"
167,"NCT03310645","Repeat Doses of BAY 1817080 in Healthy Males & Proof of Concept in Chronic Cough Patients",,"Completed","No Results Available","Cough","Drug: BAY1817080|Drug: Matching Placebo","Frequency of treatment emergent adverse events in study part 1|Severity of treatment emergent adverse events in study 1|Frequency of treatment emergent adverse events in study part 2|Severity of treatment emergent adverse events in study part 2|24-hour cough counts|24 hour cough counts","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","87","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","18184|2017-001620-22","December 7, 2017","May 28, 2019","June 19, 2019","October 16, 2017",,"July 18, 2019","Queen's University, Belfast, Antrim, United Kingdom|North Tyneside General Hospital, North Shields, Tyne And Wear, United Kingdom|Birmingham Heartlands Hospital, Birmingham, West Midlands, United Kingdom|Castle Hill Hospital, Cottingham, United Kingdom|King's College Hospital - NHS Foundation Trust, London, United Kingdom|University Hospital of South Manchester, Manchester, United Kingdom|Medicines Evaluation Unit, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03310645"
168,"NCT03293407","Evaluation of Inhaled Iloprost Effects Using the Breelib Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension","VENTASTEP","Active, not recruiting","No Results Available","Hypertension, Pulmonary","Drug: Iloprost (Ventavis, BAYQ6256)|Device: Breelib nebulizer","Change of Six-minute walking distance (6MWD)|Change of laboratory results of the biomarkers NT-pro BNP/BNP|Change of Health related Quality of Life-EuroQol five dimensions questionnaire (EQ-5D)|Change of World Health Organization functional class|Change of Distance Walked per day|Changed of Number of Steps per day|Change of number of floors climbed (10 feet) per day|Change of time spent at home per day|Change of number of relevant location changes per day|Change of number of times leaving home per day|Change of number of times standing up per day|Change of 6MWD|The average daily inhalation duration per session|The average number of daily inhalations|Change of sleep quality|Incidence of AEs|Change of heart rate during 6MWD|The average daily proportion of complete/incomplete inhalations|The average association between physical activity level (wearable device based) and time to last inhalation|Heart rates during baseline and observation period","Bayer","All","18 Years and older   (Adult, Older Adult)",,"31","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","19398","February 1, 2018","October 9, 2019","March 31, 2020","September 26, 2017",,"January 22, 2020","Many Locations, Multiple Locations, Germany",,"https://ClinicalTrials.gov/show/NCT03293407"
169,"NCT03290794","Structured Post-marketing Surveillance to Collect the Safety Data of Intravitreal Aflibercept Injection (IVT-AFL) in Patients of Wet Age-related Macular Degeneration During Real World Clinical Practice",,"Recruiting","No Results Available","Wet Age-related Macular Degeneration","Drug: Aflibercept (Eylea, BAY86-5321)","Frequency of reported ocular and non-ocular adverse events during observation period|Percentage of reported ocular and non-ocular adverse events during observation period|Type of ocular tests undertaken|Interval between ocular test|Date of aflibercept injections|Injection dose|Interval (days) between aflibercept injections|Frequency of monitoring / clinic visits","Bayer|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)",,"100","Industry","Observational","Observational Model: Other|Time Perspective: Prospective","19140","February 14, 2019","September 30, 2020","October 31, 2020","September 25, 2017",,"December 30, 2019","Many Locations, Multiple Locations, India",,"https://ClinicalTrials.gov/show/NCT03290794"
170,"NCT03289273","Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)",,"Recruiting","No Results Available","Liver Neoplasms","Drug: Regorafenib (Stivarga, BAY73-4506)","Number of patients with treatment emergent adverse events (TEAEs) leading to dose modifications (including reductions, interruptions and permanent discontinuation)|Overall survival (OS)|Progression-free survival (PFS)|Time to progression (TTP)|Best overall tumor response (ORR)|Duration of regorafenib treatment","Bayer","All","Child, Adult, Older Adult",,"1000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","19244|EUPAS20981","September 13, 2017","February 1, 2022","June 1, 2022","September 20, 2017",,"January 18, 2020","Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|St. Joseph´s Hospital and Medical Center, Phoenix, Arizona, United States|Compassionate Care Research Group, Inc., Fountain Valley, California, United States|Scripps Health, La Jolla, California, United States|Georgetown University Hospital, Lombardi Cancer Center, Washington, District of Columbia, United States|University of Florida Health, Gainesville, Florida, United States|Summit Cancer Center, Savannah, Georgia, United States|Northwestern Medicine, Chicago, Illinois, United States|University of Louisville - Clinical Trials Unit, Louisville, Kentucky, United States|University Medical Center, New Orleans, Louisiana, United States|Mercy Medical Center, Baltimore, Maryland, United States|Lahey Hospital & Medical Center, Burlington, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Rutgers University, Newark, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|C.R.Wood Cancer Center, Glen Falls Hospital, Glens Falls, New York, United States|Westchester Medical Center, Hawthorne, New York, United States|University of Cincinatti, Cincinnati, Ohio, United States|Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania, United States|Einstein Medical Center, Philadelphia, Pennsylvania, United States|Methodist Healthcare, University Hospital, Memphis, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|McGuire VA Medical Center, Richmond, Virginia, United States|Many locations, Multiple Locations, Albania|Many locations, Multiple Locations, Algeria|Many locations, Multiple Locations, Argentina|Many locations, Multiple Locations, Austria|Many locations, Multiple Locations, Belgium|Many locations, Multiple Locations, Brazil|Many locations, Multiple Locations, Canada|Many locations, Multiple Locations, China|Many locations, Multiple Locations, Denmark|Many locations, Multiple Locations, Egypt|Many locations, Multiple Locations, France|Many locations, Multiple Locations, Greece|Many locations, Multiple Locations, India|Many locations, Multiple Locations, Italy|Many locations, Multiple Locations, Japan|Many locations, Multiple Locations, Kazakhstan|Many locations, Multiple Locations, Korea, Republic of|Many locations, Multiple Locations, Lebanon|Many locations, Multiple Locations, Luxembourg|Many locations, Multiple Locations, Mexico|Many locations, Multiple Locations, Netherlands|Many locations, Multiple Locations, Oman|Many locations, Multiple Locations, Russian Federation|Many locations, Multiple Locations, Saudi Arabia|Many locations, Multiple Locations, Spain|Many locations, Multiple Locations, Sweden|Many locations, Multiple Locations, Taiwan|Many locations, Multiple Locations, Thailand|Many locations, Multiple Locations, Turkey|Many locations, Multiple Locations, United Arab Emirates",,"https://ClinicalTrials.gov/show/NCT03289273"
171,"NCT03284762","Xarelto on Prevention of Stroke and Noncentral Nervous System Systemic Embolism in Treatment-naïve Asian Patients With Non-valvular Atrial Fibrillation","XaMINA","Completed","No Results Available","Atrial Fibrillation","Drug: Rivaroxaban (Xarelto, Bay59-7939)","Major bleeding events, collected as Serious Adverse Events (SAEs) or non-serious Adverse Events (AEs)|AEs|SAEs|All-cause mortality|Non-major bleeding events|Symptomatic thromboembolic events|Start of rivaroxaban therapy and, if applicable, stop of rivaroxaban therapy","Bayer|Janssen Research & Development, LLC","All","19 Years and older   (Adult, Older Adult)",,"1216","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","18981","September 11, 2017","August 9, 2019","November 20, 2019","September 15, 2017",,"December 5, 2019","Different facilities, Multiple Locations, Korea, Republic of|Different facilities, Multiple Locations, Taiwan",,"https://ClinicalTrials.gov/show/NCT03284762"
172,"NCT03278262","The Impact of Baseline Visual Acuity on the Treatment Outcomes in Patients Treated With AflIbercept in Real-life Clinical Setting","INSIGHT","Completed","No Results Available","Wet Macular Degeneration","Drug: Aflibercept (Eylea, BAY86-5321)","Change in Visual Acuity (VA) (Snellen)|Change in Early Treatment Diabetic Retinopathy Study (ETDRS)|Change in Lasbarhetsindex (LIX, Readability Index)|Proportion of patients with Gain of vision 5 to 15 letters; > 15 letters; Loss of vision >5 to <15 letters; >15 letters or Stable -5 to +5 letters at the annual time points|Proportion of patients that recuperate 20/20 vision (driving vision) in all patients and stratified by baseline VA (groups 1-3)|Proportion of patients that recuperate 20/40 vision (driving vision) in all patients and stratified by baseline VA (groups 1-3)|Proportion of patients with no need of Vision Aid support","Bayer|Regeneron Pharmaceuticals","All","Child, Adult, Older Adult",,"2312","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","19473","September 1, 2017","December 31, 2017","December 31, 2017","September 11, 2017",,"October 29, 2018","Many locations, Lund, Sweden",,"https://ClinicalTrials.gov/show/NCT03278262"
173,"NCT03276143","FactOr XIa inhibiTion for the pRevention of venOus Thromboembolism in Patients Undergoing Total Knee Arthroplasty","FOXTROT","Completed","No Results Available","Knee Arthroplasty, Total","Drug: BAY1213790|Drug: Enoxaparin|Drug: Apixaban","Incidence of composite endpoint consisting of asymptomatic DVT as detected by mandatory bilateral venography, objectively confirmed symptomatic DVT, non-fatal PE, fatal PE, unexplained death for which PE cannot be excluded|Incidence of composite endpoint of major and clinically relevant non-major bleeding|Incidence of composite endpoint of symptomatic DVT, non-fatal PE, fatal PE, unexplained death for which PE cannot be excluded up to Day 150 or objectively confirmed asymptomatic DVT up to day 12","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","791","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","17664|2016-002681-31","September 21, 2017","August 20, 2018","January 2, 2019","September 8, 2017",,"January 14, 2019","UMHAT Sveti Georgi, Plovdiv, Bulgaria|MHAT Tokuda Hospital Sofia AD, Sofia, Bulgaria|UMHAT Tsaritsa Joanna-ISUL EAD Sofia, Sofia, Bulgaria|Medical Investigative & Clinical Evaluation Inc., Windsor, Ontario, Canada|Fakultni nemocnice u sv. Anny, Brno, Czechia|Nemocnice Ceske Budejovice, a.s., Ceske Budejovice, Czechia|Okresni nemocnice Jindrichuv Hradec, Jindrichuv Hradec, Czechia|Regional Hospital Pardubice, Pardubice, Czechia|KAT General Hospital of Athens, Kifisia, Greece|Konstantopoulio General Hospital of Nea Ionia - Agia Olga, Nea Ionia, Greece|University General Hospital of Patras, Rio / Patras, Greece|Papageorgiou General Hospital of Thessaloniki, Thessaloniki, Greece|Rambam Health Corporation, Haifa, Israel|Lady Davis Carmel Medical Center, Haifa, Israel|Meir Medical Center, Kfar-Saba, Israel|Rabin Medical Center - Beilinson Campus, Petah Tikva, Israel|Kaplan Medical Center, Rehovot, Israel|Liepaja Regional Hospital, Liepaja, Latvia|Hospital of Traumatology and Orthopaedics, Riga, Latvia|Riga 2nd City Hospital, Riga, Latvia|Valmiera Hospital, Valmiera, Latvia|Kaunas clinical hospital (Laisves al.), Kaunas, Lithuania|Lithuanian university of Health science, Kaunas, Lithuania|Vsl Klaipedos universitetine ligonine, Klaipeda, Lithuania|Republican Vilnius University Hospital, Vilnius, Lithuania|Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania|Uniwersytecki Szpital Kliniczny w Bialymstoku, Bialystok, Poland|Wojewódzki Szpital Zespolony, Kielce, Poland|Wojewodzki Szpital Specjalistyczny im. Rydygiera, Krakow, Poland|Centralny Szpital Kliniczny Uniwersytetu Medycznego w Lodzi, Lodz, Poland|Wojewodzki Szpital Specjalistyczny im. S. Wyszynskiego SPZOZ, Lublin, Poland|Uniwersytecki Szpital Kliniczny im. J. Mikulicza-Radeckiego, Wroclaw, Poland|HPP - Hospital de Cascais, Alcabideche, Lisboa, Portugal|Centro Hospitalar do Baixo Vouga - H. Infante D. Pedro, Aveiro, Portugal|Centro Hospitalar de Leiria - Hospital Santo Andre, Leiria, Portugal|Centro Hosp Setubal - Hospital Ortopedico Sant'Iago do Outao, Setúbal, Portugal|Unidade Local De Saude do Alto Minho - Hospital Santa Luzia, Viana do Castelo, Portugal|Russian Scientific Center n.a. acad. G.A. Ilizarov, Kurgan, Russian Federation|Privolzhskiy Federal Medical Research Center, Nizhny Novgorod, Russian Federation|City Hospital #2, St. Petersburg, Russian Federation|Sci-Res. Institute of Traumatology and Orthopaedia, St. Petersburg, Russian Federation|Clinical Hospital for Emergency Care n.a. N.V.Solovyov, Yaroslavl, Russian Federation|Pretoria Academic Hospital New, Pretoria, Gauteng, South Africa|UCT Clinical Research Centre, Cape Town, Western Cape, South Africa|Clinical Projects Research SA, Worcester, Western Cape, South Africa|Ciutat Sanitària i Universitària de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain|Fundación Hospital Alcorcón, Alcorcón, Madrid, Spain|Ciutat Sanitària i Universitaria de la Vall d'Hebron, Barcelona, Spain|Hospital Clínic i Provincial de Barcelona, Barcelona, Spain|Complejo Hospitalario de Jaén, Jaén, Spain|Hospital Clínico Universitario San Carlos, Madrid, Spain|Cherkasy Reg Clinical Hospital of Cherkasy Reg Council, Cherkasy, Ukraine|Ivano-Frankivsk Regional Clinical Hospital, Ivano-Frankivsk, Ukraine|Kyiv Regional Clinical Hospital, Kyiv, Ukraine",,"https://ClinicalTrials.gov/show/NCT03276143"
174,"NCT03269175","BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies",,"Completed","No Results Available","Multiple Sclerosis","Other: Brain MRI|Other: Blood sampling","Number of subjects with diagnosis of multiple sclerosis within fifteen years after Clinically-Isolated Syndrome (CIS) according to McDonald 2001 and 2010 criteria|Disease course since start of BENEFIT as assessed at the time of BENEFIT 15|Time to first relapse|Time to recurrent relapse|Annualized relapse rate|Time to conversion to Clinically-Definite Multiple Sclerosis (CDMS)|Time to conversion to Secondary Progressive Multiple Sclerosis (SPMS)|Expanded Disability Status Scale these scores (EDSS score) for disability assessed by the investigator during the neurological examination|Number of subjects with confirmed and sustained 1-point EDSS progression (Disability progression)|Number of subjects with confirmed 2.5-point EDSS progression (Disability progression)|Multiple Sclerosis Functional Composite (MSFC) score (Neurological status)|Paced Auditory Serial Addition Test (PASAT-3) score (Cognitive function)|Time to use of ambulatory device|Time to dependence on ambulatory device|Time to use of wheelchair|Employment status (Standardized questions)|Multiple sclerosis impact on employment|Resource use assessment questions: Help from family/regular ambulatory services|Resource use assessment questions: Additional ambulatory services during relapse|Resource use assessment questions: Adaptions (past 6 months)|Symbol Digit Modalities Test score (SDMT score)|Relation of SDMT and FSMC (Fatigue Scale for Motor and Cognitive Functions)|Relation of mental processing speed and MRI parameters|European Quality of life - 5 Dimensions Health-related Quality of life (EQ-5D HRQoL) score|European Quality of Life-5 Dimensions Visual Analog Scale (EQ-5D VAS) score|Functional Assessment of Multiple Sclerosis (FAMS score)|Fatigue Scale for Motor and Cognitive Functions (FSMC score)|Center of Epidemiological Studies for Depression (CES-D) score|Time to second line therapy|Time to first disease-modifying therapies (DMT) other than IFNB-1b","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 4","261","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19215|2017-001176-31","September 29, 2017","May 24, 2018","May 24, 2018","August 31, 2017",,"May 16, 2019","Medizinische Universität Graz, Graz, Steiermark, Austria|Landeskrankenhaus - Universitätskliniken Innsbruck, Innsbruck, Austria|CU Saint-Luc/UZ St-Luc, Bruxelles - Brussel, Belgium|UZ Gent, Gent, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|CHU de Liège, Liege, Belgium|Ottawa Hospital-General Campus, Ottawa, Ontario, Canada|CHUM - Hopital Hotel-Dieu, Montreal, Quebec, Canada|Montreal Neurological Hospital, Montreal, Quebec, Canada|Fakultni nemocnice Brno, Brno, Czechia|Fakultni Nemocnice Hradec Kralove, Hradec Kralove, Czechia|Fakultni nemocnice Ostrava, Ostrava-Poruba, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia|Amtssygehuset Glostrup, Glostrup, Denmark|Tampereen yliopistollinen sairaala, keskussairaala, Tampere, Finland|Terveystalo Turku, Turku, Finland|Hôpital Pellegrin - Bordeaux, Bordeaux, France|Hopital general, Dijon, France|Hopital Roger Salengro, Lille, France|Hôpital Pasteur - Nice, Nice, France|Hôpital Pontchaillou, Rennes Cedex, France|Klinikum der Universität München Grosshadern, München, Bayern, Germany|Bezirksklinikum, Regensburg, Bayern, Germany|Krankenhaus Hennigsdorf, Hennigsdorf, Brandenburg, Germany|Universitätsklinik Gießen und Marburg GmbH, Marburg, Hessen, Germany|Sana Klinikum Offenbach GmbH, Offenbach, Hessen, Germany|Universitätsmedizin der Georg-August-Universität Göttingen, Goettingen, Niedersachsen, Germany|Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Nordrhein-Westfalen, Germany|Städt. Krankenhaus Martha-Maria Halle-Dölau gGmbH, Halle, Sachsen-Anhalt, Germany|HELIOS Klinikum Erfurt GmbH, Erfurt, Thüringen, Germany|Universitätsklinikum Charite zu Berlin, Berlin, Germany|Peterfy Sandor utcai Korhaz - Rendelointezet, Budapest, Hungary|Uzsoki Utcai Korhaz, Budapest, Hungary|Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary|Szent-Gyorgyi Albert Orvostudomanyi Egyetem, Szeged, Hungary|Hadassah Hebrew University Hospital Ein Kerem, Jerusalem, Israel|Ospedale San Raffaele, Milano, Lombardia, Italy|IRCCS Ist Neurologico Nazionale C.Mondino, Pavia, Lombardia, Italy|ASST Valle Olona, Varese, Lombardia, Italy|A.O.U. San Luigi Gonzaga, Torino, Piemonte, Italy|A.O.U. Città della Salute e della Scienza di Torino, Torino, Toscana, Italy|Helse Bergen HF Haukeland universitetssjukehus, Bergen, Norway|10 Wojskowy Szpital Kliniczny z Poliklinika SPZOZ, Bydgoszcz, Poland|Szpital Uniwersytecki w Krakowie, Krakow, Poland|Szpital im. N. Barlickiego, Lodz, Poland|Samodzielny Publiczny Szpital Kliniczny nr 4, Lublin, Poland|Uniwersytecki Szpital Kliniczny im. J. Mikulicza-Radeckiego, Wroclaw, Poland|Instituto Português de Oncologia Francisco Gentil - Coimbra, Coimbra, Portugal|Hospital Universitario Virgen de la Macarena, Sevilla, Andalucía, Spain|Ciutat Sanitària i Universitària de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain|Ciutat Sanitària i Universitaria de la Vall d'Hebron, Barcelona, Spain|Hospital Clínic i Provincial de Barcelona, Barcelona, Spain|Hospital Regional de Málaga, Malaga, Spain|Hospital Universitari i Politècnic La Fe, Valencia, Spain|Sahlgrenska Universitetssjukhuset, Göteborg, Sweden|Universitätsspital Basel, Basel, Basel-Stadt, Switzerland|Inselspital Universitätsspital Bern, Bern, Switzerland|Royal Hallamshire Hospital, Sheffield, South Yorkshire, United Kingdom|Aberdeen Royal Infirmary, Aberdeen, United Kingdom|Ninewells Hospital, Dundee, United Kingdom|Charing Cross Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03269175"
175,"NCT03255512","Vericiguat Drug-drug Interaction Study With Isosorbite Mononitrate in Stable Coronary Artery Disease Patients","VISOR","Completed","No Results Available","Coronary Artery Disease","Drug: Vericiguat (BAY1021189) + isosorbite mononitrate|Drug: Placebo + isosorbite mononitrate (ISMN)","Blood pressure|Heart rate|Number of participants with adverse events","Bayer|Merck Sharp & Dohme Corp.","All","30 Years to 80 Years   (Adult, Older Adult)","Phase 1","41","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","18582|2016-005178-36","August 17, 2017","February 6, 2018","March 23, 2018","August 21, 2017",,"April 10, 2018","Universitätsherzzentrum Freiburg - Bad Krozingen, Bad Krozingen, Baden-Württemberg, Germany|Universitätsklinikum Heidelberg, Heidelberg, Baden-Württemberg, Germany|Medizinische Einrichtungen der Universität Bonn, Bonn, Nordrhein-Westfalen, Germany|SocraTec R&D Clinical Ward, Erfurt, Thüringen, Germany|Charité Campus Virchow-Klinikum (CVK), Berlin, Germany|Universitätsklinikum Hamburg Eppendorf (UKE), Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT03255512"
176,"NCT03252002","Clinical Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamic Effects of a Single and Multiple Oral BAY1101042 Tablet Doses in Healthy Male Subjects",,"Completed","No Results Available","Healthy Volunteer","Drug: BAY1101042|Drug: Placebo","Number of treatment emergent adverse events (TEAEs)|AUC(0-24) of BAY1101042|AUC(0-24)/D of BAY1101042|Cmax of BAY1101042|Cmax/D of BAY1101042|AUCτ,md of BAY1101042|AUCτ,md/D of BAY1101042|Cmax,md of BAY1101042|Cmax,md/D of BAY1101042","Bayer","Male","18 Years to 45 Years   (Adult)","Phase 1","96","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other","18747|2017-001212-11","August 16, 2017","April 30, 2019","July 24, 2019","August 16, 2017",,"August 19, 2019","CRS Clinical-Research-Services Mönchengladbach GmbH, Mönchengladbach, Nordrhein-Westfalen, Germany|CRS Clinical Research Services Wuppertal GmbH, Wuppertal, Nordrhein-Westfalen, Germany",,"https://ClinicalTrials.gov/show/NCT03252002"
177,"NCT03244462","Food Effect, Oral & Intravenous Pharmacokinetics and Absolute Bioavailability of BAY1834845 Including Drug-drug Interaction With Methotrexate",,"Completed","No Results Available","Inflammation","Drug: BAY1834845|Drug: Methotrexate","AUC (Area under the concentration-versus-time curve from zero to infinity after single (first) dose) of BAY1834845 after oral administration of BAY1834845 to subjects in fed/fasted state|Maximum concentration attained (Cmax) of BAY1834845 after oral administration of BAY1834845 to subjects in fed/fasted state|Total body clearance (CL) of [13C6] BAY1834845 after intravenous administration|Volume of distribution at steady state (Vss) of [13C6] BAY1834845 after intravenous administration|Absolute oral bioavailability (F) of BAY1834845 in the fasted state|AUC of methotrexate in plasma in presence/absence of BAY1834845|Cmax of methotrexate in plasma in presence/absence of BAY1834845|Frequency of Treatment Emergent Adverse Events (TEAEs) in part A|Severity of TEAEs in part A|Frequency of TEAEs in part B|Severity of TEAEs in part B","Bayer","Male","18 Years to 50 Years   (Adult)","Phase 1","10","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","18387|2016-004393-18","August 18, 2017","January 22, 2018","July 20, 2018","August 9, 2017",,"July 15, 2019","PRAHealthSciences, Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT03244462"
178,"NCT03242278","Real-world Dosing Patterns of Rivaroxaban in the United States",,"Completed","No Results Available","Atrial Fibrillation","Drug: Rivaroxaban (Xarelto, BAY59-7939)","Number of NVAF patients receiving 20 mg Rivaroxaban|Number of NVAF patients receiving 15 mg Rivaroxaban|Baseline renal function","Bayer|Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)",,"12507","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","18733|XA1511US","February 12, 2016","March 1, 2016","March 1, 2016","August 8, 2017",,"August 8, 2017","New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03242278"
179,"NCT03240523","Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids","ASTEROID 5","Active, not recruiting","No Results Available","Uterine Fibroids","Drug: Vilaprisan (BAY1002670)","Amenorrhea (yes/no)|Total volume of menstrual blood loss|Number of bleeding days|Absence of bleeding (spotting allowed)|Time to onset of controlled bleeding|HMB (Heavy Menstrual Bleeding) responder rate|Percent change in volume of largest fibroid compared to baseline|Endometrial histology|Endometrial thickness","Bayer","Female","18 Years and older   (Adult, Older Adult)","Phase 3","766","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15789|2016-002855-48","July 31, 2017","January 15, 2021","January 15, 2021","August 7, 2017",,"January 21, 2020","Paratus Clinical Pty Ltd, Blacktown, New South Wales, Australia|Paratus Clinical Wyong Complex, Kanwal, New South Wales, Australia|Women's Health and Research Institute of Australia-WHRIA, Sydney, New South Wales, Australia|Greenslopes Private Hospital, Greenslopes, Queensland, Australia|Medizinische Universität Graz, Graz, Steiermark, Austria|Landeskrankenhaus Bregenz, Bregenz, Vorarlberg, Austria|Allgemeines Krankenhaus der Stadt Wien, Wien, Austria|AZ Jan Palfijn Gent, Gent, Oost-Vlaanderen, Belgium|CHU Saint-Pierre/UMC Sint-Pieter, Bruxelles - Brussel, Belgium|CU Saint-Luc/UZ St-Luc, Bruxelles - Brussel, Belgium|CHU de Tivoli, La Louviere, Belgium|CHR de la Citadelle, Liege, Belgium|Femicare vzw, Tienen, Belgium|MHAT Blagoevgrad AD, Blagoevgrad, Bulgaria|MHAT Dobrich, Dobrich, Bulgaria|MC Asklepii OOD, Dupnitza, Bulgaria|Multiprofile Hospital for Active Treatment Uni Hospital OOD, Panagyurishte, Bulgaria|MHAT Avis Medika, Pleven, Bulgaria|Specialized Hosp for Act Trm of oncology disord Sofia Region, Sofia, Bulgaria|DCC Alexandrovska EOOD, Sofia, Bulgaria|Medical Center Panaceya, Sofia, Bulgaria|MHAT Niamed, Stara Zagora, Bulgaria|Multiprofile Hospital for Active Treatment Sv. Anna, Varna, Bulgaria|SHOGAT Prof Dimitar Stamatov, Varna, Bulgaria|Ocean West Research Clinic Inc, Surrey, British Columbia, Canada|Strand Clinic, St. John's, Newfoundland and Labrador, Canada|Ottawa Hospital-Riverside Campus, Ottawa, Ontario, Canada|Clinique OVO, Montreal, Quebec, Canada|Clinique Recherche en Sante des Femmes Inc., Quebec, Canada|Centre de recherche Saint-Louis, Quebec, Canada|ALPHA Recherche Clinique, Quebec, Canada|Fakultni Nemocnice Brno, Brno, Czechia|Gynekologicka ordinace, Ceske Budejovice, Czechia|G-Centrum Olomouc s.r.o. Dr. Skrivanek, Olomouc, Czechia|Centrum gynekologicke rehabilitace, Pisek, Czechia|MUDr. Martina Maresova Rosenbergova, gynekologie, Plzen, Czechia|Dr. Smrhova-Kovacs, Tabor, Czechia|MediGyn s.r.o., Trebon, Czechia|GYNEKO spol. s r.o., Vsetin, Czechia|Aarhus Universitetshospital, Skejby, Aarhus N, Denmark|Hillerød Hospital, Hillerød, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Odense Universitetshospital, Odense C, Denmark|HUS / Naistenklinikka, Helsinki, Finland|VL-Medi Oy, Helsinki, Finland|Kymenlaakson keskussairaala, Kotka, Finland|Lääkäriasema Cantti Oy, Kuopio, Finland|Lääkärikeskus Gyneko, Oulu, Finland|Turun yliopistollinen keskussairaala, kantasairaala, Turku, Finland|Praxisklinik am Rosengarten, Mannheim, Baden-Württemberg, Germany|Frauenarztpraxis Dr. Wolfgang Clemens, Stolberg, Nordrhein-Westfalen, Germany|Praxis f. Gynäkologie und Geburtshilfe, Bernburg, Sachsen-Anhalt, Germany|emovis GmbH, Berlin, Germany|Principal SMO Kft., Baja, Hungary|Dr. Rethy Pal Korhaz - Rendelointezet Bekescsaba, Bekescsaba, Hungary|Robert Karoly Magankorhaz, Budapest, Hungary|Szent Anna szuleszeti-nogyogyaszati maganrendelo, Debrecen, Hungary|NAP - Rendelo, Private Clinic, Debrecen, Hungary|Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary|Komaromi Selye Janos Korhaz, Komarom, Hungary|SzSzBMK es EOK Josa Andras Oktatokorhaz, Nyiregyhaza, Hungary|SZTE ÁOK Szent Györgyi Albert Klinikai Kozpont, Szeged, Hungary|Midland Regional Hospital, Mullingar, Westmeath, Ireland|A.O.U. Policlinico - Vittorio Emanuele, Catania, Sicilia, Italy|A.O. Ospedali Riuniti Villa Sofia-Cervello, Palermo, Sicilia, Italy|A.O.U. Careggi, Firenze, Toscana, Italy|A.O.U.I. Verona, Verona, Veneto, Italy|Dongguk University Hospital, Goyang-si, Gyeonggido, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggido, Korea, Republic of|Ajou University Hospital, Suwon, Gyeonggido, Korea, Republic of|Inje University Haeundae Paik Hospital, Busan, Korea, Republic of|Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Kangnam Sacred Heart Hospital, Seoul, Korea, Republic of|CHA Gangnam Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Ewha Womans University Hospital, Seoul, Korea, Republic of|Jsc ""Vakk"", Kaunas, Lithuania|Klaipeda Health Care Center, Klaipeda, Lithuania|JSC Seimos gydytojas family medical center, Vilnius, Lithuania|JSC Gyvenk Silciau Medical Center Maxmeda, Vilnius, Lithuania|Private hospital and outpatient clinic ""Kardiolita"", Vilnius, Lithuania|Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania|Flevoziekenhuis, Almere, Netherlands|VUmc, Amsterdam, Netherlands|Maasstad Ziekenhuis, Rotterdam, Netherlands|Kirkeparken Spesialistpraksis, Fredrikstad, Norway|Nesttun Spesialistpraksis AS, Nesttun, Norway|Medicus Oslo AS, Oslo, Norway|Stavanger Universitetssjukehus, Stavanger, Norway|Medicus AS, Trondheim, Norway|Tomaszewski Medical Center, Bialystok, Poland|Prywatna Klinika Ginekologiczno-Poloznicza, Bialystok, Poland|CLINICAL MEDICAL RESEARCH Sp. z o. o., Katowice, Poland|Vita Longa Sp. z o.o., Katowice, Poland|Medico Praktyka Lekarska, Krakow, Poland|Prywatny Gabinet Lekarski Ginekologia, Poloznictwo i Ultr., Lodz, Poland|Specjalistyczny Gabinet Ginekologiczno-Polozniczy, Lublin, Poland|Centrum Medyczne Chodzki, Lublin, Poland|NZOZ NOVITA, Specjalistyczne Gabinety Lekarskie S.C, Lublin, Poland|VitroLive Sp. z o.o., Szczecin, Poland|NZOZ Zieniewicz Medical, Warszawa, Poland|Centrum Badawcze Wspolczesnej Terapii, Warszawa, Poland|Hospital de Braga, Braga, Portugal|CHUC - Hospitais da Universidade de Coimbra, Coimbra, Portugal|CHLO - Hospital Sao Francisco Xavier, Lisboa, Portugal|Univerzitna nemocnica Bratislava, Nemocnica Ruzinov, Bratislava 2, Slovakia|ULMUS, s r.o., Hlohovec, Slovakia|GA Lucenec s.r.o, Lucenec, Slovakia|GYNEMMA s.r.o., Malacky, Slovakia|Galipea s.r.o., Nitra, Slovakia|Gyncentrum Nitra s.r.o., Nitra, Slovakia|Gynekologicka ambulancia - MUDr. Peter Salko, Velky Krtis, Slovakia|Hospital Sanitas La Zarzuela, Aravaca, Madrid, Spain|Hospital de Basurto, Bilbao, Vizcaya, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Ginemed, Sevilla, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Hospital Universitario de Álava, Vitoria, Álava, Spain|Södersjukhuset AB, Stockholm, Sweden|Karolinska Universitetssjukhuset i Solna, Stockholm, Sweden|Danderyds sjukhus, Stockholm, Sweden|Akademiska Sjukhuset, Uppsala, Sweden|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Mackay Memorial Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan|North Hampshire Hospital, Basingstoke, Hampshire, United Kingdom|North Middlesex University Hospital, London, United Kingdom|Whittington Hospital, London, United Kingdom|Chelsea & Westminster Hospital, London, United Kingdom|St Mary's Hospital (London), London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03240523"
180,"NCT03237416","Drug-drug-interaction Study to Assess the Effect of Darolutamide on the Pharmacokinetics of Probe Substrates of CYP3A4 and P-gp in Healthy Male Volunteers",,"Completed","No Results Available","Prostatic Neoplasms","Drug: Dabigatran etexilate|Drug: Midazolam|Drug: BAY1841788 (darolutamide)","AUC in plasma of non-conjugated dabigatran (AUC(0-tlast), if AUC cannot be calculated)|C(max) in plasma of non-conjugated dabigatran|AUC in plasma of midazolam (AUC(0-tlast), if AUC cannot be calculated)|C(max) in plasma of midazolam|Number of subjects with study drug-related treatment-emergent Adverse Event (TEAE)|AUC in plasma of total dabigatran (AUC(0-tlast), if AUC cannot be calculated)|C(max) in plasma of total dabigatran|AUC in plasma of 1-OH midazolam (AUC(0-tlast), if AUC cannot be calculated)|C(max) in plasma of 1-OH midazolam","Bayer|Orion Corporation, Orion Pharma","Male","45 Years to 65 Years   (Adult, Older Adult)","Phase 1","15","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","18860|2017-001116-11","August 2, 2017","October 5, 2017","December 18, 2017","August 2, 2017",,"November 6, 2018","CRS Clinical-Research-Services Mannheim GmbH, Mannheim, Baden-Württemberg, Germany",,"https://ClinicalTrials.gov/show/NCT03237416"
181,"NCT03235076","Clinical Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamic Effects of a Single Oral 10 mg BAY1101042 Tablet Dose in Men and Woman With Renal Impairment and in Healthy Subjects",,"Completed","No Results Available","Renal Impairment","Drug: BAY1101042","Area under the concentration vs. time curve from zero to infinity after single dose (AUC) of BAY1101042|Maximum observed drug concentration in measured matrix after single dose administration (Cmax) of BAY1101042|AUCu of BAY1101042|Cmax,u of BAY1101042","Bayer","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 1","36","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","18745|2017-001141-28","August 15, 2017","November 7, 2018","March 13, 2019","August 1, 2017",,"April 11, 2019","CRS Clinical-Research-Services Kiel GmbH, Kiel, Schleswig-Holstein, Germany",,"https://ClinicalTrials.gov/show/NCT03235076"
182,"NCT03225352","A Study to Assess Disintegration of the New Aspirin Disintegrating Tablets",,"Completed","No Results Available","Moderate Pain","Drug: 500 mg acetylsalicylic acid (Aspirin, BAYE4465)|Drug: 1000 mg acetylsalicylic acid (Aspirin, BAYE4465)|Drug: 400 mg ibuprofen(Nurofen)|Drug: 400 mg ibuprofen (Dolormin Extra)","Time to complete tablet disintegration|Gastric empty time, if applicable|Time of colon arrival, if applicable|Small intestine transit time, if applicable|Time of onset of release of radiolabel|Site of onset of release of radiolabel|Site of completion of release of radiolabel|Disintegration rate of the tablet estimated from the radioactivity remaining|Time of 50% disintegration of the tablet estimated from the radioactivity remaining|Gastric emptying kinetics of dispersed radioactive material (t50% and t90%)|AUC0-t|Cmax|AUC0-infinity|t1/2|tmax|Cmax/AUC0-infinity","Bayer","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","19220|2016-004546-29","August 7, 2017","October 7, 2017","October 16, 2017","July 21, 2017",,"June 6, 2018","Bio-Images Research Ltd, Glasgow, Glasgow City, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03225352"
183,"NCT03215511","A Study to Test the Safety of the Investigational Drug Loxo-195 in Children and Adults That May Treat Cancer",,"Recruiting","No Results Available","Solid Tumors Harboring NTRK Fusion","Drug: BAY2731954","Phase 1: Maximum tolerated dose (MTD)|Phase 1: Recommended dose|Phase 2: Overall response rate (ORR) for patients <12 years from Cohort 1 by IRC|Phase 2: Overall response rate (ORR) for patient ≥12 years from Cohort 1 by IRC|Phase 1: Incidence of adverse events|Phase 1: Severity of adverse events|Phase 1: Duration of adverse events|Phase 1: Number of subjects with safety-relevant changes in clinical parameters or vital signs after drug administration|Phase 1: Severity of safety-relevant changes in clinical parameters or vital signs after drug administration|Phase 1: Overall response rate (ORR) in patients with NTRK fusion cancer previously treated with TRK inhibitor determined by an IRC|Phase 1: Overall response rate (ORR) in patients with primary central nervous system (CNS) malignancies determined by investigator|Phase 1: Overall survival (OS)|Phase 1: Maximum concentration of BAY2731954 in plasma (Cmax)|Phase 1: Time to maximum concentration of BAY2731954 in plasma (Tmax)|Phase 1: Area under the concentration versus time curve of BAY2731954 in plasma (AUC(0-t))|Phase 1: Area under the concentration versus time curve of BAY2731954 in plasma from time 0 to infinity (AUC(0-∞))|Phase 1: Apparent volume of distribution (Vz/F)|Phase 1: Clearance (CL/F)|Phase 1: Terminal elimination half-life (T1/2)|Phase 2: Incidence of adverse events in patients ≥12 years|Phase 2: Severity of adverse events in patients ≥12 years|Phase 2: Duration of adverse events in patients ≥12 years|Phase 2: Incidence of adverse events in patients <12 years|Phase 2: Severity of adverse events in patients <12 years|Phase 2: Duration of adverse events in patients <12 years|Phase 2: Number of subjects with safety-relevant changes in clinical parameters or vital signs after drug administration|Phase 2: Severity of safety-relevant changes in clinical parameters or vital signs after drug administration|Phase 2: Overall response rate (ORR) in Cohort 2 determined by IRC|Phase 2: Overall response rate (ORR) in Cohort 1 determined by investigator|Phase 2: Overall response rate (ORR) in Cohort 2 determined by investigator|Phase 2: Duration of response (DOR) determined by IRC|Phase 2: Duration of response (DOR) determined by investigator|Phase 2: Progression free survival (PFS) determined by IRC|Phase 2: Progression free survival (PFS) determined by investigator|Phase 2: Overall survival (OS)|Phase 2: Clinical benefit rate (CBR) determined by IRC|Phase 2: Clinical benefit rate (CBR) determined by investigator","Bayer","All","1 Month and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","93","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20810|LOXO-EXT-17005|2017-004246-20","July 3, 2017","October 28, 2021","February 24, 2022","July 12, 2017",,"January 10, 2020","Univ.of California-San Diego Moores Cancer Center, La Jolla, California, United States|UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States|Stanford Cancer Center, Palo Alto, California, United States|Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States|Midwestern Regional Medical Center, Zion, Illinois, United States|Ochsner Medical Center - New Orleans, New Orleans, Louisiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Eastern Regional Medical Center, Philadelphia, Pennsylvania, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Seattle Children's Hospital, Seattle, Washington, United States|Sydney Children's Hospital, Sydney, New South Wales, Australia|Austin Health, Heidelberg, Victoria, Australia|Finsen Centre, Copenhagen, Denmark|Institut Curie - Ulm - Paris, Paris, France|Institut Gustave Roussy, Villejuif, France|Universitätsklinikum Heidelberg, Heidelberg, Baden-Württemberg, Germany|Prince of Wales Hospital, Shatin, Hong Kong|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy|Seoul National University Hospital, Seoul, Korea, Republic of|National Cancer Center, Singapore, Singapore|Ciutat Sanitària i Universitaria de la Vall d'Hebron, Barcelona, Spain|Ciutat Sanitària i Universitaria de la Vall d'Hebron, Barcelona, Spain|Fundacion Jimenez Diaz (Clinica de la Concepcion), Madrid, Spain|Sarah Cannon Research Institute UK Ltd, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03215511"
184,"NCT03214172","Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban",,"Completed","No Results Available","Venous Thromboembolism","Drug: Rivaroxaban (Xarelto, BAY59-7939)","Recurrent Venous thromboembolism|Bleeding (based on the Cunningham algorithm)|Mortality (In-hospital mortality or need for hospice care without subsequent healthcare claims)","Bayer|Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)",,"1000","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","19622","July 15, 2017","September 15, 2017","September 15, 2017","July 11, 2017",,"September 6, 2018","US database, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03214172"
185,"NCT03212586","BAY 1902607: Single Dose Escalation, Safety and Tolerability, Pharmacokinetics, Bioavailability, Food Effect",,"Completed","No Results Available","Clinical Trials, Phase I as Topic","Drug: BAY1902607|Drug: Placebo","Number of subjects with treatment-emergent adverse events|Number of subjects with severity of treatment-emergent adverse events","Bayer","Male","18 Years to 45 Years   (Adult)","Phase 1","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","18922|2017-000978-11","July 18, 2017","May 3, 2018","July 27, 2018","July 11, 2017",,"May 14, 2019","CRS Clinical Research Services Berlin GmbH, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT03212586"
186,"NCT03210246","Drug-drug Interaction Study: Influence of Vilaprisan on Pharmacodynamics (PD) and Pharmacokinetics (PK) of a Combined Oral Contraceptive (COC)",,"Completed","No Results Available","Clinical Trial ,Phase I","Drug: Vilaprisan (BAY 1002670)|Drug: Vilaprisan Placebo|Drug: Microgynon|Drug: Microgynon Placebo","Number of subjects with ovulation (i.e. Hoogland score = 6) or risk of ovulation (Hoogland score = 5)|Number of subjects with a Hoogland score = 4","Bayer","Female","18 Years to 35 Years   (Adult)","Phase 1","71","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","17670|2016-004532-38","July 17, 2017","June 21, 2018","January 23, 2019","July 6, 2017",,"February 28, 2019","Dinox GmbH Berlin, Berlin, Germany|CRS Clinical Research Services Berlin GmbH, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT03210246"
187,"NCT03206931","Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion",,"Available","No Results Available","Solid Tumors Harboring NTRK Fusion","Drug: Selitrectinib (BAY2731954)",,"Bayer","All","1 Month and older   (Child, Adult, Older Adult)",,,"Industry","Expanded Access:Individual Patients",,"21002",,,,"July 2, 2017",,"January 18, 2020",,,"https://ClinicalTrials.gov/show/NCT03206931"
188,"NCT03194646","Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids","ASTEROID 6","Active, not recruiting","No Results Available","Leiomyoma","Drug: Vilaprisan (BAY1002670)|Other: Standard of care","Percentage change in bone mineral density (BMD) of lumbar spine|Number of bleeding days","Bayer","Female","18 Years and older   (Adult, Older Adult)","Phase 3","1302","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16953|2016-004822-41","June 30, 2017","May 16, 2022","May 16, 2022","June 21, 2017",,"January 2, 2020","Central Research Associates, Inc., Birmingham, Alabama, United States|Women's Health Alliance of Mobile, Mobile, Alabama, United States|Coastal Clinical Research, Inc, Mobile, Alabama, United States|Visions Clinical Research - Tucson, Tucson, Arizona, United States|Lynn Institute of the Ozarks, Little Rock, Arkansas, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Diagnamics, Inc., Encinitas, California, United States|Grossmont Center for Clinical Research, La Mesa, California, United States|Medical Center for Clinical Research, San Diego, California, United States|Womens Health Care Research Corporation, San Diego, California, United States|West Coast OB/GYN Associates, San Diego, California, United States|Advanced Women's Health Institute, Greenwood Village, Colorado, United States|Physicians Research Options, LLC, Lakewood, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Stamford Hospital, Stamford, Connecticut, United States|Office of Dr. James A. Simon, MD, Washington, District of Columbia, United States|Helix Biomedics, LLC, Boynton Beach, Florida, United States|Women's Medical Research Group, LLC, Clearwater, Florida, United States|Dr. Victoria Garcia & Associates, LLC Doral Medical Research, Doral, Florida, United States|M & O Clinical Research, LLC, Fort Lauderdale, Florida, United States|Solutions Through Advanced Research, Inc., Jacksonville, Florida, United States|Axcess Medical Research, LLC, Loxahatchee Groves, Florida, United States|Suncoast Clinical Research Center, Inc., New Port Richey, Florida, United States|Suncoast Clinical Research, Palm Harbor, Florida, United States|ONCOVA Clinical Research, Inc., Saint Cloud, Florida, United States|Physician Care Clinical Research, Sarasota, Florida, United States|Agile Clinical Research Trials, LLC, Atlanta, Georgia, United States|Atlanta Women's Research Institute, Inc., Atlanta, Georgia, United States|Medisense Inc at Atlantic Station, Atlanta, Georgia, United States|Augusta University Medical Center, Augusta, Georgia, United States|Paramount Research Solutions, College Park, Georgia, United States|Fellows Research Alliance, Savannah, Georgia, United States|Journey Medical Research, Snellville, Georgia, United States|Center For Women's Research, Palos Heights, Illinois, United States|Professional Research Network of Kansas, LLC, Wichita, Kansas, United States|Research Integrity, LLC, Owensboro, Kentucky, United States|Praetorian Pharmaceutical Research, LLC, Marrero, Louisiana, United States|Southern Clinical Research Associates LLC, Metairie, Louisiana, United States|Omni Fertility and Laser Institute, Shreveport, Louisiana, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Baltimore Suburban Health, LLC, Pikesville, Maryland, United States|Continental Clinical Solutions, LLC, Towson, Maryland, United States|Henry Ford Health System, Detroit, Michigan, United States|Wayne State University Physicians Group, Southfield, Michigan, United States|Women's Clinic of Lincoln, PC, Lincoln, Nebraska, United States|Wake Research - Clinical Research Center of Nevada, LLC, Las Vegas, Nevada, United States|Lawrence OB/GYN Associates, Lawrenceville, New Jersey, United States|Jersey Shore University Medical Center, Neptune, New Jersey, United States|Bosque Womens Care, Albuquerque, New Mexico, United States|SUNY Downstate Medical Center, Brooklyn, New York, United States|Manhattan Medical Research, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Richmond ObGyn Associates PC, Staten Island, New York, United States|Carolinas Healthcare System, Charlotte, North Carolina, United States|Carolina Women's Research & Wellness Center, Durham, North Carolina, United States|Unified Women's Clinical Research, Greensboro, North Carolina, United States|Unified Women's Clinical Research - Morehead City, Morehead City, North Carolina, United States|Eastern Carolina Women's Center, New Bern, North Carolina, United States|Women's Health Alliance, Raleigh, North Carolina, United States|Wake Research Associates, Raleigh, North Carolina, United States|PMG Research of Wilmington, Wilmington, North Carolina, United States|Lyndhurst Clinical Research, Winston-Salem, North Carolina, United States|Valaoras & Lewis OB/GYN, Winston-Salem, North Carolina, United States|Clinical Inquest Center, Ltd., Beavercreek, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|HWC Women's Research Center, Englewood, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Clinical Research of Philadelphia, LLC, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vista Clinical Research, Columbia, South Carolina, United States|VitaLink Research - Greenville, Greenville, South Carolina, United States|Venus Gynecology, LLC former Magnolia OB/GYN Research Center, Myrtle Beach, South Carolina, United States|Invocare Clinical Research Center, LLC, West Columbia, South Carolina, United States|ClinSearch, LLC, Chattanooga, Tennessee, United States|Women's Physician Group, Memphis, Tennessee, United States|Discovery Clinical Trials, Dallas, Texas, United States|Signature GYN Services, Pllc, Fort Worth, Texas, United States|Office of Dr. Delbert Alan Johns, MD, Fort Worth, Texas, United States|Willowbend Health & Wellness Associates, Frisco, Texas, United States|Advances in Health, Inc., Houston, Texas, United States|The Woman's Hospital of Texas, Houston, Texas, United States|Centex Studies, Inc., Houston, Texas, United States|MacArthur OB/GYN Mangement, LLC, Irving, Texas, United States|Family Medicine Clinic, Lampasas, Texas, United States|Seven Oaks Women's Center, San Antonio, Texas, United States|OB-GYN Physicians, Inc., Franklin, Virginia, United States|Tidewater Physicians for Women, Norfolk, Virginia, United States|Clinical Trials of Viriginia, Richmond, Virginia, United States|Synexus Research, LLC, Richmond, Virginia, United States|Virginia Physicians For Women, Richmond, Virginia, United States|MultiCare Health Systems Women's Health Care, Covington, Washington, United States|900th Hospital of Joint Logistics Support Force, Fuzhou, Fujian, China|Sun Yat-Sen Memorial Hosp. Sun Yat-Sen Univ., Guangzhou, Guangdong, China|The First Affiliated Hospital of Guangzhou University of TCM, Guangzhou, Guangdong, China|The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China|Peking University Shenzhen Hospital, Shenzhen, Guangdong, China|The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China|Hainan General Hospital, Haikou, Hainan, China|The 2nd Hospital of Hebei Medical University, Shijiazhuang, Hebei, China|Center for Reproductive Medicine,Tongji Medical college,HUST, Wuhan, Hubei, China|Nanjing Maternity and Child Health Care Hospital, Nanjing, Jiangsu, China|NJ Drum Tower Hospital, the Affil Hos of NJ Univ Med School, Nanjing, Jiangsu, China|Zhongda Hospital Southeast University, Nanjing, Jiangsu, China|Jiangxi Maternal and Child Health Hospital, Nanchang, Jiangxi, China|The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China|The First Hospital of Jilin University, Changchun, Jilin, China|The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China|Shandong Provincial Hospital, Jinan, Shandong, China|The Second Affiliated Hospital of Shanxi Medical University, Taiyuan, Shanxi, China|West China Second University Hospital, Chengdu, Sichuan, China|The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China|Women's Hospital School of Medicine Zhejiang University, Hangzhou, Zhejiang, China|The Second Affliated Hospital of Wenzhou Medicial University, Wenzhou, Zhejiang, China|Beijing Hospital of Traditional Chinese Medicine, Beijing, China|Beijing Obstetrics and Gynecology Hospital,Capital Med.Uni., Beijing, China|Beijing Tiantan Hospital, Captial Medical University, Beijing, China|Peking Union Medical College Hospital CAMS, Beijing, China|Peking University First Hospital, Beijing, China|International Peace Maternity&Child Health Hospital of CWI, Shanghai, China|Changhai Hospital of Second Military Medical University, Shanghai, China|Tianjin Medical University General Hospital, Tianjin, China|First Teaching Hosptial of Tianjin University of TCM, Tianjin, China|Tianjin Central Hospital of Gynecology obstetrics, Tianjin, China|Fakultni Nemocnice Brno, Brno, Czechia|Fakultni Nemocnice Hradec Kralove, Hradec Kralove, Czechia|MUDr. Radek Fiker s.r.o., Jihlava, Czechia|G-Centrum Olomouc s.r.o. Dr. Skrivanek, Olomouc, Czechia|Fakultni Nemocnice Olomouc, Olomouc, Czechia|Centrum gynekologicke rehabilitace, Pisek, Czechia|Dr. Smrhova-Kovacs, Tabor, Czechia|Gynekologie MUDr. Pavlina Nejedla s.r.o., Vodnany, Czechia|Mehiläinen Kuopio, Kuopio, Finland|Lääkärikeskus Gyneko, Oulu, Finland|Queen Mary Hospital, Hongkong, Hong Kong|Kano's Clinic for Women, Nagoya, Aichi, Japan|Kyoritsu Narashinodai Hospital, Funabashi, Chiba, Japan|Juno Vesta Clinic Hatta, Matsudo, Chiba, Japan|Iizuka Hospital, Iizuka, Fukuoka, Japan|Jusendo Hospital, Koriyama, Fukushima, Japan|Sato Hospital, Takasaki, Gunma, Japan|Primo Women's Clinic, Ebetsu, Hokkaido, Japan|Sapporo Maternity Women's Hospital, Sapporo, Hokkaido, Japan|Sapporo Shiroishi Obstetrics and Gynecology Hospital, Sapporo, Hokkaido, Japan|Hashimoto Clinic, Sapporo, Hokkaido, Japan|Ena Odori Clinic, Sapporo, Hokkaido, Japan|Sapporo Maternity Women's Minami1jo Clinic, Sapporo, Hokkaido, Japan|SAPPORO MEDICAL CENTER, NTT East Corporation, Sapporo, Hokkaido, Japan|Sapporo West Ladies Clinic, Sapporo, Hokkaido, Japan|Yoshio Clinic, Sapporo, Hokkaido, Japan|Ishikawa Prefectural Central Hospital, Kanazawa, Ishikawa, Japan|Asahi clinic, Takamatsu, Kagawa, Japan|Kagawa Prefectural Central Hospital, Takamatsu, Kagawa, Japan|Second Kawasaki Saiwai Clinic, Kawasaki, Kanagawa, Japan|Kurashiki Medical Clinic, Kurashiki, Okayama, Japan|Suita Municipal Hospital, Suita, Osaka, Japan|Medical Topia Soka Hospital, Soka, Saitama, Japan|Fuyo Association Seirei Numazu Hospital, Numazu, Shizuoka, Japan|Sei Womens Clinic, Bunkyo, Tokyo, Japan|Ginza Yoshida Clinic, Chuo-ku, Tokyo, Japan|Women's wellness Tsushima Ruriko josei life clinic Ginza, Chuo-ku, Tokyo, Japan|St.Luke's International Hospital, Chuoku, Tokyo, Japan|Akazawa Clinic, Fuchu, Tokyo, Japan|Medical Corp. Seikoukai New Medical Research System Clinic, Hachioji, Tokyo, Japan|Yokokura Clinic, Minato-ku, Tokyo, Japan|Toranomon Womens Clinic, Minato, Tokyo, Japan|Akasakamitsuke Miyazaki Obstetrics and Gynecology Clinic, Minato, Tokyo, Japan|Shirokane Ladies' Clinic, Minato, Tokyo, Japan|Kugayama Hospital, Setagaya-ku, Tokyo, Japan|Tokyo Women's Medical University Hospital, Shinjuku-ku, Tokyo, Japan|Ikebukuro Metropolitan Clinic, Toshima-ku, Tokyo, Japan|Kato Internal medicine and Gynecology Clinic, Fukui, Japan|Sano Wemen's Clinic, Fukuoka, Japan|Unoki Clinic, Kagoshima, Japan|Medical corporation keizukai Chayamachi Ladies Clinic, Osaka, Japan|Chayamachi ladies Clinic Hommachi, Osaka, Japan|Medical Corporation Koshinkai Nomura Clinic Namba, Osaka, Japan|Izuma Clinic, Osaka, Japan|Shizuoka Saiseikai General Hospital, Shizuoka, Japan|Shizuoka City Shimizu Hospital, Shizuoka, Japan|Hospital Universitario ""José Eleuterio González"", Monterrey, Nuevo Leon, Mexico|Centro Integral Médico de San Juan del Río S. C., San Juan del Río, Querétaro, Mexico|Sanatorio Alcocer Pozo S. A. de C. V., Querétaro, Mexico|Kirkeparken Spesialistpraksis, Fredrikstad, Norway|Nesttun Spesialistpraksis AS, Nesttun, Norway|Medicus AS, Trondheim, Norway|Prywatna Klinika Ginekologiczno-Poloznicza, Bialystok, Poland|CLINICAL MEDICAL RESEARCH Sp. z o. o., Katowice, Poland|Vita Longa Sp. z o.o., Katowice, Poland|Gyncentrum Sp. z o.o., Katowice, Poland|Prywatny Gabinet Lekarski Ginekologia, Poloznictwo i Ultr., Lodz, Poland|Specjalistyczny Gabinet Ginekologiczno-Polozniczy, Lublin, Poland|Centrum Medyczne Chodzki, Lublin, Poland|Scientific Center of family health & human reprod. problems, Irkutsk, Russian Federation|Regional Clinical Hospital #2, Krasnodar, Russian Federation|Krasnoyarsk regional perinatal center, Krasnoyarsk, Russian Federation|City Clinical Hospital #13, Moscow, Russian Federation|Endocrinology Scientific Centre, Moscow, Russian Federation|Close Joint Stock Company ""Medical Company IDK"", Samara, Russian Federation|St. Petersburg Medical University n.a. I.P. Pavlov, St. Petersburg, Russian Federation|""Granti-Med"", St. Petersburg, Russian Federation|Scien. Res. Institute of Obsterics, Gyn. & Reproduction, St. Petersburg, Russian Federation|Dr L Reynders Practice, Lyttelton Manor, Gauteng, South Africa|University of Pretoria, Clinical Research Unit, Pretoria, Gauteng, South Africa|Ingenuity House, Umhlanga, Kwazulu-Natal, South Africa|Durban International Clinical Research Site, Wentworth, Kwazulu-Natal, South Africa|Drs AEVITAS Clinic (Pty) Ltd, Cape Town, Western Cape, South Africa|TREAD Research cc, Cape Town, Western Cape, South Africa|University of Cape Town Clinical Research Centre, Cape Town, Western Cape, South Africa|Clintrials Centre for Clinical Research, Panorama, Western Cape, South Africa|Chulalongkorn Hospital, Bangkok, Thailand|Siriraj Hospital, Mahidol, Bangkok, Thailand|Cukurova Universitesi Tip Fakultesi Hastanesi, Adana, Turkey|Ankara Universitesi Tip Fakultesi Hastanesi, Ankara, Turkey|Etlik Zubeyde Hanim Kadin Hastaliklari Egitim Arastirma Hast, Ankara, Turkey|Uludag Universitesi Tip Fakultesi, Bursa, Turkey|Istanbul Universitesi Istanbul Tip Fakultesi, Istanbul, Turkey|Istanbul Universitesi - Cerrahpasa Cerrahpasa Tip Fakultesi, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT03194646"
189,"NCT03194633","Effectiveness and Tolerability of Long-Acting Nifedipine Gastrointestinal Therapeutic System in Chronic Kidney Disease With Uncontrolled Hypertension Patients, a Prospective, Multicenter, Observational Study","ADRENAL","Recruiting","No Results Available","Hypertension","Drug: Nifedipine controlled-release tablets (Adalat, BAYA1040)","Change in office systolic blood pressure from baseline to week 12|Change in office diastolic blood pressure from baseline to week 12|Change in systolic blood pressure and diastolic blood pressure from baseline to week12 according to baseline BP stratification|Change in systolic blood pressure and diastolic blood pressure from baseline to week12 at different stages of Chronic Kidney Disease|Systolic blood pressure and diastolic blood pressure control rate at week 12|Number of participants with adverse events and serious adverse events","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)",,"1023","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","18679","July 10, 2017","March 31, 2020","May 31, 2020","June 21, 2017",,"January 22, 2020","Many Locations, Multiple Locations, China",,"https://ClinicalTrials.gov/show/NCT03194633"
190,"NCT03193372","A Study of Patient Concerns and Treatment Satisfaction in Patients Being Treated With Finacea Foam for Rosacea",,"Completed","No Results Available","Rosacea","Drug: Azelaic Acid (Finacea Foam, BAY39-6251)","Demographics and clinical characteristics|Rosacea-relevant comorbidities and complications|Rosacea subtype|Past use of topical rosacea treatments|Patient concerns collected by Rosacea Treatment Preference Questionnaire|Treatment satisfaction assessed by Satisfaction with Medicines Questionnaire (SATMED-Q)|Quality of life measured by Dermatology Life Quality Index (DLQI)","Bayer","All","18 Years and older   (Adult, Older Adult)",,"2200","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","19638","July 20, 2017","August 8, 2017","November 15, 2017","June 20, 2017",,"October 23, 2018","Xcenda, LLC, Palm Harbor, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03193372"
191,"NCT03188965","First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas",,"Recruiting","No Results Available","Neoplasms","Drug: BAY1895344","The maximum tolerated dose (MTD) and / or recommended Phase II dose (RP2D) of BAY1895344|Incidence of DLTs during Cycle 1 in dose-escalation cohorts during Part A of the study|Incidence of DLTs during Cycle 1 in dose-escalation cohorts during Part A.1 of the study|Incidence of DLTs during Cycle 1 in dose-escalation cohorts during J-arm of the study|The incidence of serious and nonserious treatment-emergent adverse events (TEAEs)|AUC (area under the plasma concentration of BAY1895344 vs. time curve) from zero to 12 hours after single-dose (C1D1) and multiple-dose administrations (C1D10)|Cmax of BAY1895344 in cycle 1 after single-dose (C1D1) and multiple-dose administrations (C1D10)|Incidence of patients with CR, PR, SD or PD (except for patients with castration resistant prostate cancer) consistent with the RECIST 1.1 criteria|Incidence of lymphoma patients with CR, PR, SD or PD consistent with the Lugano Classification|Incidence of castration resistant prostate cancer patients with CR, PR, SD or PD consistent with the recommendations of the Prostate Cancer Working Group 3 (PCWG3)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","276","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18594|2016-004484-39","July 6, 2017","September 3, 2020","October 1, 2020","June 16, 2017",,"January 18, 2020","H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Weill Cornell Medical College, New York, New York, United States|Gabrail Cancer Center, Canton, Ohio, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|US Oncology, Eugene, Oregon, United States|Jefferson Medical College, Philadelphia, Pennsylvania, United States|US Oncology, Fort Worth, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Texas Oncology- San Antonio Northeast, San Antonio, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Fairfax-Northern Virginia Hematology/Oncology, PC, Fairfax, Virginia, United States|Cross Cancer Institute, Edmonton, Alberta, Canada|OHRI - The Ottawa Hospital, Ottawa, Ontario, Canada|CHUQ-Hopital Hotel-Dieu de Quebec, Quebec, Canada|Beijing Cancer Hospital, Beijing, China|Institut Bergonié - Unicancer Nouvelle Aquitaine, Bordeaux Cedex, France|Hôpital Henri Mondor, Creteil Cedex, France|Hôpital Claude Huriez - Lille, Lille Cedex, France|Hôpital Hôtel Dieu, Nantes Cedex, France|Centre Antoine Lacassagne, Nice Cedex 2, France|Centre Hospitalier Lyon Sud, Pierre Benite, France|Institut de Cancérologie de l'Ouest - Saint Herblain, Saint Herblain, France|Institut Claudius Regaud - iUCT Oncopole, Toulouse Cedex 9, France|Institut Gustave Roussy, Villejuif, France|Eberhard-Karls-Universität Tübingen, Tübingen, Baden-Württemberg, Germany|Klinikum der Universität München Grosshadern, München, Bayern, Germany|Universitätsmedizin der Johannes Gutenberg Universität Mainz, Mainz, Rheinland-Pfalz, Germany|Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Sachsen, Germany|National Cancer Center Hospital East, Kashiwa, Chiba, Japan|Shizuoka Cancer Center, Sunto, Shizuoka, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|National University Hospital, Singapore, Singapore|National Cancer Center, Singapore, Singapore|Universitätsspital Basel, Basel, Basel-Stadt, Switzerland|Kantonsspital St. Gallen, St. Gallen, Sankt Gallen, Switzerland|Oncology Institute of Southern Switzerland, Bellinzona, Switzerland|Hôpital Cantonal Universitaire de Genève, Genève, Switzerland|UniversitätsSpital Zürich, Zürich, Switzerland|Belfast City Hospital, Belfast, North Ireland, United Kingdom|Velindre Hospital, Cardiff, South Glamorgan, United Kingdom|Royal Marsden NHS Trust (Surrey), Sutton, Surrey, United Kingdom|Freeman Hospital, Newcastle Upon Tyne, Tyne And Wear, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03188965"
192,"NCT03182140","KYleena Satisfaction Study / Observational Study on User Satisfaction With the Levonorgestrel Intrauterine Delivery System Kyleena (LNG-IUS 12) in New Contraceptive Users and After Switching From Another Contraceptive Method","KYSS","Active, not recruiting","No Results Available","Contraception","Drug: Kyleena","Overall satisfaction with Kyleena assessed by questionnaire|Ease of insertion assessed by investigator|Pain at insertion assessed by participant|Satisfaction with the menstrual bleeding profile with Kyleena assessed by questionnaire","Bayer","Female","Child, Adult, Older Adult",,"1134","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","19186","July 7, 2017","December 19, 2019","March 30, 2020","June 9, 2017",,"January 21, 2020","Jennifer Grube, MD, FACOG, Lakewood, Colorado, United States|Physician Care Clinical Research LLC, Sarasota, Florida, United States|Visions Clinical Research, Wellington, Florida, United States|New England Center for Clinical Research Primacare Research, LLC, Fall River, Massachusetts, United States|Saginaw Valley Medical Research Group, LLC, Saginaw, Michigan, United States|Lawrence OB/GYN Clinical Research, LLC, Lawrenceville, New Jersey, United States|ProHEALTH Care Associates, Port Jefferson, New York, United States|Eastern Carolina Women's Center, New Bern, North Carolina, United States|Radiant Research, Akron, Ohio, United States|TMC Life Research, Houston, Texas, United States|Physician's Research, Draper, Utah, United States|Physician's Research Options LLC - Revere Women's Health OB/GYN Clinic, Pleasant Grove, Utah, United States|Many locations, Multiple Locations, Belgium|Many locations, Multiple Locations, Canada|Many locations, Multiple Locations, Germany|Many locations, Multiple Locations, Mexico|Many locations, Multiple Locations, Norway|Many locations, Multiple Locations, Spain|Many locations, Multiple Locations, Sweden",,"https://ClinicalTrials.gov/show/NCT03182140"
193,"NCT03172884","Study of Copanlisib in Hepatic or Renal Impairment",,"Recruiting","No Results Available","Hepatic Insufficiency","Drug: Copanlisib BAY80-6946","AUC(0-168) and AUC|Cmax|Frequency of treatment-emergent adverse events (TEAE)|Cmax of M-1 metabolite|AUC(0-168) of M-1 metabolite|Severity of treatment-emergent adverse events (TEAE)","Bayer","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","44","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","18041|2016-004561-51","June 14, 2017","February 20, 2020","March 26, 2020","June 1, 2017",,"January 10, 2020","CRS Clinical-Research-Services Mönchengladbach GmbH, Mönchengladbach, Nordrhein-Westfalen, Germany|CRS Clinical-Research-Services Kiel GmbH, Kiel, Schleswig-Holstein, Germany|Institutul National de Boli Infectioase Prof.Dr.Matei Bals, Bucuresti, Romania",,"https://ClinicalTrials.gov/show/NCT03172884"
194,"NCT03161912","A Study to Evaluate the Effectiveness of Intravitreal Aflibercept in Patients With Diabetic Macular Edema and/or Macular Edema Secondary to Retinal Vein Occlusion, Which Either Have or Have Not Been Pretreated for Their Disease","AURIGA","Recruiting","No Results Available","Macular Edema","Drug: Aflibercept (Eylea, BAY86-5321)","Mean change of visual acuity (VA) from baseline to 12 months as evaluated in routine clinical practice per cohort and per country.|Mean change of visual acuity from baseline to 6, 12 and 24 months after first treatment|Number of study eyes with pre-determined VA gains and losses (equivalent to 5, 10 and 15 Early Treatment Diabetic Retinopathy Study (ETDRS) letters) closest to the visit 6, 12 and 24 months after first treatment|Mean change from baseline in central retinal thickness (CRT) as measured with optical coherence tomography (OCT) to closest to the visit 6, 12 and 24 months after first treatment|Proportion of study eyes with no fluid persistence as measured by spectral domain OCT (SD-OCT) closest to the visit 6, 12, and 24 months after first treatment|Treatment pattern based on the number of intravitreal aflibercept injections in the study eye during the first 6 months, the first year, and the 2-year treatment period|Number of visits regarding the study eye by type of visit during the first 6 months, the first year, and the 2-year treatment period|Number of procedures per patient during the first 6 months, the first year, and the 2-year treatment period|Number of patients requiring additional drug treatment and what category of drug (patients switching to steroid treatment only or to other anti-VEGFs are excluded)|Number of performed laser treatments|Treatment pattern based on mean time between visits and mean time between aflibercept injections|Mean change in VA by number of injections during the first 6 months, the first year, and the 2-year treatment period.","Bayer|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)",,"3560","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","19157","November 24, 2017","March 31, 2021","June 30, 2021","May 22, 2017",,"January 2, 2020","Many Locations, Multiple Locations, China|Many Locations, Multiple Locations, Egypt|Many Locations, Multiple Locations, France|Many Locations, Multiple Locations, France|Many Locations, Multiple Locations, Germany|Many Locations, Multiple Locations, Italy|Many Locations, Multiple Locations, Kuwait|Many Locations, Multiple Locations, Lebanon|Many Locations, Multiple Locations, Russian Federation|Many Locations, Multiple Locations, Saudi Arabia|Many Locations, Multiple Locations, Taiwan|Many Locations, Multiple Locations, United Arab Emirates",,"https://ClinicalTrials.gov/show/NCT03161912"
195,"NCT03145038","Relative Bioavailability and Food Effect Study With Vericiguat to Characterize the Pediatric Formulation in Adult Healthy Subjects",,"Completed","No Results Available","Pharmacokinetics","Drug: Vericiguat(BAY1021189, high-dose pediatric-formulation)_fed|Drug: Vericiguat(BAY1021189, high-dose pediatric-formulation)_fasted|Drug: Vericiguat(BAY1021189, low-dose pediatric-formulation)_fed|Drug: Vericiguat(BAY1021189,10 mg IR film-coated tablets,intact)_fed;American breakfast|Drug: Vericiguat(BAY1021189,10 mg IR film-coated tablets,crushed)_fed;American breakfast|Drug: Vericiguat(BAY1021189,10 mg IR film-coated tablets,intact)_fed;Continental breakfast","Vericiguat area under the plasma concentration vs. time curve divided by dose (AUC/D)|Vericiguat maximum plasma concentration divided by dose (Cmax/D))|Number of Adverse Events|Palatability of the oro-dispersible tablets and the crushed IR tablets assessed by questionnaire","Bayer","Male","18 Years to 45 Years   (Adult)","Phase 1","30","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","18581|2016-005074-35","May 16, 2017","August 29, 2017","October 9, 2017","May 9, 2017",,"September 25, 2018","CRS Clinical-Research-Services Mönchengladbach GmbH, Mönchengladbach, Nordrhein-Westfalen, Germany",,"https://ClinicalTrials.gov/show/NCT03145038"
196,"NCT03136666","Single Dose Escalation Study to Investigate the Pharmacokinetics as Well as Safety and Tolerability of a Concomitant Administration of Nifedipne GITS and Candesartan Tablets Under Fasting Conditions in Healthy Male Subjects in an Open Label, Non-randomized, Sequential Design.",,"Completed","No Results Available","Clinical Pharmacology","Drug: Nifedipine gastrointestinal therapeutic system (GITS) (Adalat LA, BAY a1040) + Candesartan cilexetil","Overall summary of adverse events as a measure of safety and tolarability|Safety related laboratory findings|Pharmacokinetic parameters: Maximum drug concentration in plasma after single dose administration divided by dose (mg) (Cmax/D)|Pharmacokinetic parameters: Area under the plasma concentration vs time curve from zero to infinity divided by dose (mg) (AUC/D)|Pharmacokinetic parameters: Maximum drug concentration in plasma after single dose administration (Cmax)|Pharmacokinetic parameters: Area under the plasma concentration vs time curve from zero to infinity after single (first) dose (AUC)|Pharmacokinetic parameters: Maximum drug concentration in plasma after single dose administration divided by dose (mg) per kg body weight (Cmax,norm)|Pharmacokinetic parameters: Area under the curve divided by dose per kg body weight (AUCnorm)|Pharmacokinetic parameters: AUC from time 0 to the last data point (AUC(0-tn))|Pharmacokinetic parameters: Time to reach maximum drug concentration in plasma after single (first) (tmax)|Pharmacokinetic parameters: Half-life associated with the terminal slope (t1/2)|Pharmacokinetic parameters: Mean residence time (MRT)|Pharmacokinetic parameters: Total body clearance of drug from plasma calculated after oral administration (apparent oral clearance) (CL/f)","Bayer","Male","30 Years to 55 Years   (Adult)","Phase 1","12","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14026|2010-018958-12","April 19, 2010","June 7, 2010","June 7, 2010","May 2, 2017",,"May 2, 2017","Wuppertal, Nordrhein-Westfalen, Germany",,"https://ClinicalTrials.gov/show/NCT03136666"
197,"NCT03134573","Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study","PROmyBETAapp","Completed","No Results Available","Multiple Sclerosis","Drug: Interferon beta-1b (Betaferon, BAY86-5046)|Device: Betaconnect auto-injector|Device: myBETAapp","Compliance to therapy (%)|Persistence of therapy (yes, no)|Adherence to therapy (yes, no)|Proportion of patients consenting to participate in this study among those using the myBETAapp|Proportion of patients volunteering to record wellness related data in each of the following categories on the ""Wellness chart"" on the myBETAapp","Bayer","All","18 Years and older   (Adult, Older Adult)",,"96","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","18462|BF1504","September 15, 2017","May 9, 2018","May 9, 2018","May 1, 2017",,"March 26, 2019","Many locations, Multiple Locations, Germany",,"https://ClinicalTrials.gov/show/NCT03134573"
198,"NCT03128320","The Effects of BAY1193397 on Skin Capillary Blood Flow and Transcutaneous Oxygen Pressure",,"Completed","No Results Available","Diabetic Foot","Drug: BAY1193397|Drug: Placebo","Change in resting capillary blood flow velocity (CBV)|Change in peak CBV during reactive hyperemia|Change in time to peak CBV during reactive hyperemia|Change in transcutaneous oxygen pressure (TcPO2)|Incidence of treatment-emergent adverse events (TEAEs)|Severity of TEAEs","Bayer","All","55 Years to 75 Years   (Adult, Older Adult)","Phase 2","23","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other","17500|2015-003799-63","May 25, 2017","September 6, 2019","October 28, 2019","April 25, 2017",,"November 4, 2019","Royal Devon & Exeter Hospital, Exeter, Devon, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03128320"
199,"NCT03127735","BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML)",,"Completed","No Results Available","Leukemia, Myeloid, Acute","Drug: BAY1436032","Maximum tolerated dose (MTD) or RP2D of BAY1436032|Number of participants with Adverse Events as a Measure of|Objective efficacy response|Duration of response|Event-free survival (EFS)|Change of 2 hydroxyglutarate (2-HG) level obtained at baseline and post-baseline|Cmax (maximum observed drug concentration in plasma after a single dose)|AUC(0-8) (AUC from time 0 to 8 h after a single dose)|AUC(0-12) (AUC from time 0 to 12 h after a single dose)|Cmax,md (Cmax after multiple doses)|AUC(0-8)md (AUC from time 0 to 8 h after multiple doses)|AUC(0-12)md (AUC from time 0 to 12 h after multiple doses)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","27","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19036|2016-004095-22","June 14, 2017","December 6, 2018","March 15, 2019","April 25, 2017",,"May 14, 2019","Montefiore Medical Center, Bronx, New York, United States|Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Ohio State University, Columbus, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Universitätsklinikum Heidelberg, Heidelberg, Baden-Württemberg, Germany|Medizinische Hochschule Hannover (MHH), Hannover, Niedersachsen, Germany|Universitätsklinikum Leipzig AöR, Leipzig, Sachsen, Germany|Universitätsklinikum Charite zu Berlin, Berlin, Germany|Universitätsklinikum Hamburg Eppendorf (UKE), Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT03127735"
200,"NCT03127722","Study to Assess Outcomes in Women Undergoing Either Hysteroscopic Sterilization (Essure®) or Laparoscopic Tubal Sterilization",,"Recruiting","No Results Available","Contraception","Procedure: Blood draw|Device: ESSURE (BAY1454032)|Procedure: Laparoscopic tubal sterilization","Pain: The proportion of AEs of chronic lower abdominal and/or pelvic pain after insertion of Essure System compared to the proportion of AEs of chronic lower abdominal and/or pelvic pain after laparoscopic tubal sterilization|Bleeding: The proportion of AEs of abnormal uterine bleeding (AUB) after insertion of Essure System compared to the proportion of AEs of AUB after laparoscopic tubal sterilization|Hypersensitivity / allergy / autoimmune disorders: The proportion of subjects with new onset or worsening allergic/hypersensitivity reactions and newly diagnosed or worsening autoimmune disorders in Essure vs laparoscopic tubal sterilization arms|Proportion of subjects undergoing invasive gynecologic surgery after Essure placement (excluding second placement attempts), including Essure removal compared to subjects undergoing invasive gynecologic surgery after laparoscopic tubal sterilization|Patient reported outcomes for health status|Patient reported outcomes for pain intensity|Patient reported outcomes for pain interference|Patient reported outcomes for bleeding by AMSS|Patient reported outcomes for bleeding by intermenstrual bleeding questions|Patient reported outcomes for centralized pain|Patient reported outcomes on adverse events from device reports|Patient reported outcomes on media sources for their medical decisioning|Rates of AEs in subjects undergoing Essure placement and laparoscopic tubal sterilization","Bayer","Female","21 Years and older   (Adult, Older Adult)","Not Applicable","900","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","18894","May 3, 2017","December 31, 2024","December 31, 2024","April 25, 2017",,"December 19, 2019","New Horizons Women's Care, Chandler, Arizona, United States|Precision Trials, AZ, LLC, Phoenix, Arizona, United States|Visions Clinical Research - Tucson, Tucson, Arizona, United States|Eclipse Clinical Research, Tucson, Arizona, United States|Baptist Health Center for Clinical Research, Little Rock, Arkansas, United States|United Clinical Research, Huntington Beach, California, United States|Orange Coast Women's Medical Group - Laguna Hills Office, Laguna Hills, California, United States|Physicians Research Options, LLC, Lakewood, Colorado, United States|The Women's Health Group, P.C., Thornton, Colorado, United States|M & O Clinical Research, LLC, Fort Lauderdale, Florida, United States|Altus Research, Lake Worth, Florida, United States|Axcess Medical Research, LLC, Loxahatchee Groves, Florida, United States|Universal Axon Clinical Research, Miami, Florida, United States|Emerald Coast Obstetrics & Gynecology, Panama City, Florida, United States|Physician Care Clinical Research, Sarasota, Florida, United States|Clinical Research Prime, LLLP, Idaho Falls, Idaho, United States|John H Stroger Jr. Hospital of Cook County, Chicago, Illinois, United States|Women's Health Advantage, Fort Wayne, Indiana, United States|IU Health University Hospital, Indianapolis, Indiana, United States|Office of Dr. Cindy Basinski, LLC, Newburgh, Indiana, United States|Women's Health Care, PC, Newburgh, Indiana, United States|The Iowa Clinic, PC, West Des Moines, Iowa, United States|University of Kentucky Albert B. Chandler Hospital, Lexington, Kentucky, United States|Horizon Research Group of Opelousas, LLC, Eunice, Louisiana, United States|Mid-Atlantic Permanente Research Institute, Rockville, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Hutzel Women's Hospital, Detroit, Michigan, United States|Women's Integrated Health Care, PC, Grand Blanc, Michigan, United States|Sparrow Clinical Research Institute, Lansing, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Jersey Shore University Medical Center, Neptune, New Jersey, United States|Columbia University Medical Center, New York, New York, United States|Unified Women's Clinical Research, LLC, Greensboro, North Carolina, United States|Women's Health Alliance, Raleigh, North Carolina, United States|Unified Women's Clinical Research, Winston-Salem, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Seven Hills Women's Health Centers, Cincinnati, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Columbus OB-GYN/Radiant Research, Columbus, Ohio, United States|Complete Healthcare for Women, Inc., Columbus, Ohio, United States|Wright State Physicians Health Center, Dayton, Ohio, United States|HWC Women's Research Center, Englewood, Ohio, United States|HillTop Obstetrics & Gynecology, Franklin, Ohio, United States|Amy Brenner, MD & Associates, LLC, Mason, Ohio, United States|AC Clinical Research, Tiffin, Ohio, United States|Oklahoma University, Oklahoma City, Oklahoma, United States|Oregon Health and Science University, Portland, Oregon, United States|St. Luke's Hospital - Allentown Campus, Allentown, Pennsylvania, United States|Women's Health Care Group of PA, Pottstown, Pennsylvania, United States|Reading Hospital, West Reading, Pennsylvania, United States|Women & Infants Hospital (OGCC), Providence, Rhode Island, United States|Palmetto Clinical Research (PCR), Charleston, South Carolina, United States|OB-GYN Centre of Excellence, Chattanooga, Tennessee, United States|University of Tennessee Medical Center, Knoxville, Tennessee, United States|Ben Taub General Hospital, Houston, Texas, United States|The Woman's Hospital of Texas, Houston, Texas, United States|Southeast Texas Family Planning and Cancer Screening, Houston, Texas, United States|Brown Stone Clinical Trials, LLC, Irving, Texas, United States|Tanner Clinic, Layton, Utah, United States|Women's Healthcare Associates, LLC - Tualatin, Pleasant Grove, Utah, United States|Virginia Women's Center, Richmond, Virginia, United States|Tidewater Clinical Research, Inc., Virginia Beach, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03127722"
201,"NCT03126773","A Prospective Multicenter Study on Patients'Satisfaction With Angeliq® Micro in Real Clinical Practice Conducted in Russia",,"Active, not recruiting","No Results Available","Menopause","Drug: BAY86-4891","Patient's satisfaction with the menopausal symptoms treatment after 13 cycles of treatment|Patient's satisfaction with the menopausal symptoms treatment after 3-4 cycles of treatment|Changes in menopause symptoms|Changes in the quality of life|Approaches to menopausal hormonal therapy prescription|Reasons of choice of a low-dosed or ultralow-dosed menopausal hormonal therapy|Patients' compliance|Number of early discontinuation during the first year of therapy|Timing of discontinuation of Angeliq® Micro|Reasons of discontinuation of Angeliq Micro|Tolerability of Angeliq Micro in real clinical practice by using MS-TSQ questionnaire","Bayer","Female","50 Years to 65 Years   (Adult, Older Adult)",,"1570","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","19022","May 5, 2017","November 30, 2019","April 30, 2020","April 24, 2017",,"January 2, 2020","Many locations, Multiple Locations, Russian Federation",,"https://ClinicalTrials.gov/show/NCT03126773"
202,"NCT03126747","Drug Use Investigation (DUI) of YazFlex for Endometriosis-associated Pelvic Pain and/or Dysmenorrhea",,"Recruiting","No Results Available","Endometriosis and Dysmenorrhea","Drug: BAY86-5300_YAZ-Flex","Number of treatment emergent adverse events (TEAEs) and adverse drug reactions (ADRs)|Change in periodic blood loss|Change from baseline of compliance status in the new flexible regimen|Days of menorrhagia|Number of date of using analgesic|Change in severity of pelvic pain by using Numeric Rating Scale (NRS)|Change in severity of dysmenorrhea|Change in quality of Life by using EQ-5D-5L , EIS and/or MDQ","Bayer","Female","Child, Adult, Older Adult",,"600","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","18703","June 29, 2017","June 30, 2020","December 30, 2020","April 24, 2017",,"January 22, 2020","Many locations, Multiple Locations, Japan",,"https://ClinicalTrials.gov/show/NCT03126747"
203,"NCT03119116","Use of Direct Oral Anticoagulants in UK",,"Completed","No Results Available","Stroke","Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Dabigatran|Drug: Apixaban","Demographic Characteristics|Risk factor categories|Previous medical history|Previous medication history|Previous use of VKA|Concurrent co-medication|Daily dose|Dose posology|Naive status and Non-naive status|Treatment Duration|Time-trends","Bayer|Janssen Scientific Affairs, LLC","All","18 Years and older   (Adult, Older Adult)",,"31336","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","19330","May 15, 2017","October 16, 2017","October 16, 2017","April 18, 2017",,"November 22, 2017","Many Locations, Multiple Locations, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03119116"
204,"NCT03119077","Single Ascending Dose, First-in-Human Study on Safety, Tolerability and Pharmacokinetics of BAY1161116",,"Terminated","No Results Available","Polycystic Ovary Syndrome","Drug: BAY1161116|Drug: Placebo|Drug: Itraconazole","Incidence of TEAEs|Severity of TEAEs|AUC of BAY1161116|Cmax of BAY1161116","Bayer","Female","45 Years to 65 Years   (Adult, Older Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","18752|2016-003520-23","April 27, 2017","September 8, 2017","January 31, 2018","April 18, 2017",,"May 17, 2018","CRS Clinical Research Services Berlin GmbH, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT03119077"
205,"NCT03102320","Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors","ARCS-Multi","Recruiting","No Results Available","Neoplasms","Drug: Cisplatin|Drug: Gemcitabine|Drug: Anetumab ravtansine (BAY94-9343)","Maximum tolerated dose (MTD) of anetumab ravtansine in combination with cisplatin and in combination with gemcitabine in patients with mesothelin-expressing cholangiocarcinoma and pancreatic adenocarcinoma|Objective response (qualitative improvement from baseline) of anetumab ravtansine for monotherapy and combination therapy in mesothelin expressing advanced solid tumors|Durable disease control (lack of progression from baseline) of anetumab ravtansine in indications pancreatic and gastric cancer (co-primary endpoint)|Number of serious and non-serious adverse events (AEs)|Disease control rate (DCR)|Duration of response (DOR)|Durable response rate (DRR)|Progression free survival (PFS)|Durable disease control rate (DDCR) of anetumab ravtansine in indications other than pancreatic and gastric cancer","Bayer|ImmunoGen, Inc.|MorphoSys AG","All","18 Years and older   (Adult, Older Adult)","Phase 1","348","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15834|2016-004002-33","May 26, 2017","December 28, 2020","October 28, 2021","April 5, 2017",,"January 21, 2020","Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Mayo Clinic Hospital, Phoenix, Arizona, United States|University of Southern California, Los Angeles, California, United States|Stanford Health Care, Stanford, California, United States|Yale Cancer Center, New Haven, Connecticut, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|Ochsner Medical Center - New Orleans, New Orleans, Louisiana, United States|National Cancer Institute, Bethesda, Maryland, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Barbara Ann Karmanos Cancer Institute, Farmington Hills, Michigan, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Oncology, PA, Dallas, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Blacktown Cancer & Haematology Centre, Blacktown, New South Wales, Australia|Mid North Coast Cancer Institute, Coffs Harbour, New South Wales, Australia|Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia|Northern Cancer Institute, St Leonards, New South Wales, Australia|Flinders Medical Centre, Adelaide, South Australia, Australia|Epworth HealthCare, Richmond, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|St John of God Healthcare, Subiaco, Western Australia, Australia|St John of God Healthcare, Subiaco, Western Australia, Australia|GZA Ziekenhuizen, Wilrijk, Antwerpen, Belgium|Hôpital Erasme/Erasmus Ziekenhuis, Bruxelles - Brussel, Belgium|UZ Antwerpen, Edegem, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|CHU de Liège, Liege, Belgium|Cross Cancer Institute, Edmonton, Alberta, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada|McGill University Health Center, Montreal, Quebec, Canada|Hopital Jean Minjoz, Besancon, France|Hôpital Henri Mondor, Creteil, France|Centre Oscar Lambret - Lille, Lille Cedex, France|Centre Léon Bérard, Lyon Cedex, France|Institut Paoli Calmettes, Marseille Cedex 9, France|C.H.U. Timone, Marseille, France|Centre René Gauducheau, Nantes, France|Centre Antoine Lacassagne, Nice Cedex 2, France|Institut Curie - Ulm - Paris, Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite, France|Hôpital de la Milétrie, POITIERS cedex, France|Hôpital Pontchaillou, Rennes Cedex, France|Centre Eugène Marquis - Rennes Cedex, Rennes Cedex, France|Institue Curie - Saint-Cloud, Saint Cloud, France|Institut Gustave Roussy, Villejuif Cedex, France|Thoraxklinik-Heidelberg gGmbH, Heidelberg, Baden-Württemberg, Germany|Stadt- und Landkreis Kliniken Heilbronn GmbH, Heilbronn, Baden-Württemberg, Germany|Marienhospital, Stuttgart, Baden-Württemberg, Germany|Klinikum der Universität München Innenstadt, München, Bayern, Germany|Städt. Klinikum München, München, Bayern, Germany|Kliniken Nord und Süd, Nürnberg, Bayern, Germany|Universitätsklinikum Essen, Essen, Nordrhein-Westfalen, Germany|Marienhospital Herne Universitätsklinik, Herne, Nordrhein-Westfalen, Germany|Universitätsklinikum Köln, Köln, Nordrhein-Westfalen, Germany|Kliniken der Stadt Köln - Städt. Krankenhaus Köln-Merheim, Köln, Nordrhein-Westfalen, Germany|Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Sachsen, Germany|Universitätsklinikum Leipzig AöR, Leipzig, Sachsen, Germany|SRH Wald-Klinikum Gera gGmbH, Gera, Thüringen, Germany|Evangelische Lungenklinik Berlin, Berlin, Germany|A.O.U. di Bologna Policlinico S.Orsola Malpighi, Bologna, Emilia-Romagna, Italy|A.O.U. di Modena - Policlinico, Modena, Emilia-Romagna, Italy|IRCCS Istituto Clinico Humanitas (ICH), Milano, Lombardia, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milano, Lombardia, Italy|A.O.U.I. Verona, Verona, Veneto, Italy|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Yonsei University College of Medicine, Seoul, Korea, Republic of|Nederlands Kanker Instituut, Amsterdam, Netherlands|Maastricht UMC, Maastricht, Netherlands|Erasmus Medisch Centrum, Rotterdam, Netherlands|National University Hospital, Singapore, Singapore|National Cancer Center, Singapore, Singapore|Institut Català d'Oncologia Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital del Mar, Barcelona, Catalunya, Spain|Hospital Universitario Quirón de Madrid, Pozuelo de Alarcón, Madrid, Spain|Ciutat Sanitària i Universitaria de la Vall d'Hebron, Barcelona, Spain|Hospital Clínic i Provincial de Barcelona, Barcelona, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Centro Integral Oncológico Clara Campal, Madrid, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Kantonsspital Graubünden, Chur, Graubünden, Switzerland|Ospedale Regionale Bellinzona, Bellinzona, Ticino, Switzerland|Leicester Royal Infirmary, Leicester, Leicestershire, United Kingdom|Belfast City Hospital, Belfast, North Ireland, United Kingdom|Royal Marsden NHS Trust (Surrey), Sutton, Surrey, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Guy's Hospital, London, United Kingdom|Royal Marsden Hospital (London), London, United Kingdom|Christie Hospital, Manchester, United Kingdom|Southampton General Hospital, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03102320"
206,"NCT03098979","A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction","PANACHE","Completed","Has Results","Heart Failure","Drug: Neladenoson bialanate (BAY1067197)|Drug: Placebo","Absolute Change From Baseline in 6-minute Walking Distance (6MWD) After 20 Weeks of Treatment|Change From Baseline in Average Weekly Percentage of Maximum Possible Recorded Activity Intensity|Measured Values (Log Transformed) and Absolute Change in NT-proBNP From Baseline to 20 Weeks|Measured Values (Log-transformed) and Absolute Change in High Sensitivity Troponin T (Hs-TNT) From Baseline to 20 Weeks|Measured Values and Absolute Change in 3 Scores From Kansas City Cardiomyopathy Questionnaire (KCCQ) From Baseline to 20 Weeks: Overall Summary Score, Physical Limitation Score and Total Symptom Score","Bayer","All","45 Years and older   (Adult, Older Adult)","Phase 2","305","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","17582|2016-004062-26","May 10, 2017","May 23, 2018","June 20, 2018","April 4, 2017","July 23, 2019","July 23, 2019","Northwestern University, Chicago, Illinois, United States|St. Louis Heart & Vascular, PC, Saint Louis, Missouri, United States|BryanLGH Medical Center East, Lincoln, Nebraska, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Universitätsklinikum St. Pölten, St. Pölten, Niederösterreich, Austria|Krankenhaus St. Josef Braunau, Braunau, Oberösterreich, Austria|Krankenhaus der Elisabethinen Linz GmbH, Linz, Oberösterreich, Austria|Medizinische Universität Graz, Graz, Steiermark, Austria|Allgemeines Krankenhaus der Stadt Wien, Wien, Austria|Krankenhaus Hietzing, Wien, Austria|Jessa Ziekenhuis, Hasselt, Belgium|CHR de la Citadelle, Liege, Belgium|AZ Delta, Roeselare, Belgium|Spec Hosp for Active Treatm in Cardiology Sv Georgi Pernik, Pernik, Bulgaria|Specialized Hospital for Actrive Treatm of Card - Pleven, Pleven, Bulgaria|Medical Center Cardiohelp, Sofia, Bulgaria|NMTH Tzar Boris III, Sofia, Bulgaria|UMHAT Tsaritsa Joanna-ISUL EAD Sofia, Sofia, Bulgaria|MCOMH Preventsia-2000, Stara Zagora, Bulgaria|St. Vincenz und Elisabeth Hospital, Kathol. Klinikum Mainz, Mainz, Rheinland-Pfalz, Germany|Klinische Forschung Dresden GmbH, Dresden, Sachsen, Germany|HELIOS Klinikum Erfurt GmbH, Erfurt, Thüringen, Germany|Charité Campus Virchow-Klinikum (CVK), Berlin, Germany|KAT General Hospital of Athens, Kifisia / Athens, Attica, Greece|G. Gennimatas General State Hospital of Athens, Athens, Greece|General Hospital of Chalkida, Chalkida, Greece|Konstantopoulio General Hospital of Nea Ionia - Agia Olga, Nea Ionia / Athens, Greece|Hippokration General Hospital of Thessaloniki, Thessaloniki, Greece|Asklipieion General Hospital of Voulas, Voula, Greece|Barzilai Medical Center, Ashkelon, Israel|Hillel Yaffe Medical Center, Hadera, Israel|Rambam Health Corporation, Haifa, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Hadassah University Hospital Mount Scopus, Jerusalem, Israel|Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel|Assaf Harofeh Medical Center, Zrifin, Israel|AAS 3 Friuli Alto Medio Collin, Udine, Friuli-Venezia Giulia, Italy|A.O.U. Sant'Andrea, Roma, Lazio, Italy|ASST Papa Giovanni XXIII, Bergamo, Lombardia, Italy|ASST Spedali Civili di Brescia, Brescia, Lombardia, Italy|A.O. Ordine Mauriziano, Torino, Piemonte, Italy|A.O.U. di Sassari, Sassari, Sardegna, Italy|AUSL Toscana Sud-Est, Arezzo, Toscana, Italy|Chuno kosei Hospital, Seki, Gifu, Japan|Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan|National Hospital Organization Kanazawa Medical Center, Kanazawa, Ishikawa, Japan|Shonan Fujisawa Tokushukai Hospital, Fujisawa, Kanagawa, Japan|R.I.A.C Naha City Hospital, Naha, Okinawa, Japan|Kishiwada Tokushukai Hospital, Kishiwada, Osaka, Japan|Takatsuki Red Cross Hospital, Takatsuki, Osaka, Japan|Osaka Medical College Hospital, Takatsuki, Osaka, Japan|Minamino Cardiovascular Hospital, Hachioji, Tokyo, Japan|Tokyo Women's Medical University Hospital, Shinjuku-ku, Tokyo, Japan|Fukui Prefectural Hospital, Fukui, Japan|Okayama Rosai Hospital, Okayama, Japan|Osaka General Medical Center, Osaka, Japan|Tokushima Prefectural Central Hospital, Tokushima, Japan|Uniwersytecki Szpital Kliniczny w Bialymstoku, Bialystok, Poland|Szpital Zachodni w Grodzisku Mazowieckim, Grodzisk Mazowiecki, Poland|Szpital Specjalistyczny im. J. Dietla, Krakow, Poland|Wojewodzki Specjalistyczny Szpital im. dr Wl. Bieganskiego, Lodz, Poland|109 Szpital Wojskowy z przychodnia SPZOZ, Szczecin, Poland|Szpital Wolski im. dr Anny Gostynskiej SPZOZ, Warszawa, Poland|IV Wojskowy Szpital Kliniczny z Poliklinika, SPZOZ, Wroclaw, Poland|CHUC - Hospitais da Universidade de Coimbra, Coimbra, Portugal|CHLO - Hospital São Francisco Xavier, Lisboa, Portugal|Hospital da Luz, Lisboa, Portugal|CHUP, EPE - Hospital de Santo Antonio, Porto, Portugal|Hospital Sanitas La Zarzuela, Aravaca, Madrid, Spain|Hospital Universitario ""Virgen de la Arrixaca"", El Palmar, Murcia, Spain|Hospital del Mar, Barcelona, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Clínico Universitario San Carlos, Madrid, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Universitari i Politècnic La Fe, Valencia, Spain","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT03098979/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT03098979/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03098979"
207,"NCT03092999","Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1002670 (Vilaprisan)",,"Completed","No Results Available","Leiomyoma","Drug: Vilaprisan (BAY1002670)","Area under the concentration vs. time curve in plasma from zero to infinity (AUCu) (unbound)|Maximum observed (unbound) drug concentration (Cmax,u)|Frequency of Treatment Emergent Adverse Events|Severity of Treatment Emergent Adverse Events|Changes in blood laboratory parameters|Changes in urine laboratory parameters|Changes in Vital Signs|Changes in Electrocardiogram (ECG)","Bayer","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 1","36","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","15251|2015-005232-18","March 28, 2017","July 17, 2017","July 17, 2017","March 28, 2017",,"August 18, 2017","CRS Clinical-Research-Services Kiel GmbH, Kiel, Schleswig-Holstein, Germany|Universitätsklinikum Schleswig-Holstein / AÖR, Lübeck, Germany",,"https://ClinicalTrials.gov/show/NCT03092999"
208,"NCT03074058","Bioequivalence Study of BAY 77-1931 Orally Disintegrating Tablet",,"Completed","No Results Available","Clinical Pharmacology","Drug: Fosrenol ODT (Lanthanum Carbonate, BAY77-1931)|Drug: Fosrenol chewable Tablet (Lanthanum Carbonate, BAY77-1931)","Pharmacodynamics: Daily urinary phosphate excretion (mmol) on each day|Bioequivalence: Average of daily urinary phosphate excretion (mmol) over 3-day dosing period|Pharmacodynamics: Daily urinary phosphate excretion (mmol) on Day 3|Plasma lanthanum concentrations (ng/mL)|Pharmacokinetics: Cmax,md of lanthanum in plasma from pre-administration (Day 4) to 48 hours after the last administration (Day 6)|Pharmacokinetics: tmax,md of lanthanum in plasma from pre-administration (Day 4) to 48 hours after the last administration (Day 6)|Pharmacokinetics: Cmax,md,norm of lanthanum in plasma from pre-administration (Day 4) to 48 hours after the last administration (Day 6)|Pharmacokinetics: AUC(0-tlast)md,norm of lanthanum in plasma from pre-administration (Day 4) to 48 hours after the last administration (Day 6)|Pharmacokinetics: t1/2,md of lanthanum in plasmafrom pre-administration (Day 4) to 48 hours after the last administration (Day 6)|Number of adverse events as a measure of safety and tolarability|Pharmacokinetics: AUC(0-tlast)md of lanthanum in plasma from pre-administration (Day 4) to 48 hours after the last administration (Day 6)","Bayer","Male","20 Years to 45 Years   (Adult)","Phase 1","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18060","June 10, 2015","August 4, 2015","August 21, 2015","March 8, 2017",,"March 21, 2017","Fukuoka, Japan",,"https://ClinicalTrials.gov/show/NCT03074058"
209,"NCT03074045","LCS16 vs. COC User Satisfaction and Tolerability Study",,"Active, not recruiting","No Results Available","Contraception","Drug: Levonorgestrel (Kyleena, BAY86-5028)|Drug: Ethinyl estradiol and drospirenone (Yarina, BAY86-5131)","Overall satisfaction rate|Number of adverse events|Discontinuation rates|Bleeding pattern|User satisfaction and bleeding questionnaire","Bayer","Female","18 Years to 29 Years   (Adult)","Phase 3","123","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17878","March 13, 2017","September 3, 2018","September 1, 2022","March 8, 2017",,"January 13, 2020","Altai State Medical University, Barnaul, Russian Federation|Scientific Center of family health & human reprod. problems, Irkutsk, Russian Federation|Krasnoyarsk State Medical University, Krasnoyarsk, Russian Federation|City Clinical Hospital #13, Moscow, Russian Federation|LLC Reafan, Novosibirsk, Russian Federation|Medical Center ""Avicenna"", Novosibirsk, Russian Federation|Smolensk State Medical University, Smolensk, Russian Federation|LLC Medical center PRIME ROSE, St. Petersburg, Russian Federation|Regional perinatal center, Yaroslavl, Russian Federation",,"https://ClinicalTrials.gov/show/NCT03074045"
210,"NCT03056703","Bioequivalence of Single Dose Fast Release Aspirin (1000 mg) Tablet Versus Single Dose of Two 500 mg Fast Release Aspirin Tablets","Mille","Completed","No Results Available","Pain","Drug: Acetylsalicylic acid (Aspirin, BAY1019036)","AUC0-inf (area under plasma concentration versus time curve) for ASA (acetylsalicylic acid)|AUC0-t for ASA|Cmax (maximum plasma concentration) for ASA|AUC0-inf for SA (salicylic acid)|AUC0-t for SA|Cmax for SA|t1/2 for ASA and SA|tmax for ASA and SA|Lambda(z) (terminal rate constant) for ASA and SA","Bayer","All","18 Years to 55 Years   (Adult)","Phase 1","38","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16645","February 2014","March 2014","March 2014","February 17, 2017",,"February 17, 2017","Hackensack, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03056703"
211,"NCT03054402","First in Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and to Explore Pharmacodynamics of BAY1834845",,"Completed","No Results Available","Pelvic Inflammatory Disease","Drug: BAY1834845|Drug: Placebo","Frequency of treatment-emergent adverse events (TEAEs)|Severity of treatment-emergent adverse events|Area under the plasma concentration vs. time curve (AUC)|Maximum drug concentration in plasma after single dose administration (Cmax)","Bayer","Male","18 Years to 50 Years   (Adult)","Phase 1","70","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","18384|2016-002668-15","February 13, 2017","November 30, 2017","March 29, 2018","February 15, 2017",,"March 27, 2019","CRS Clinical Research Services Berlin GmbH, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT03054402"
212,"NCT03048110","Drug-drug Interaction (DDI) Study to Assess ODM-201 as a Victim of CYP3A4 Inhibition or Induction",,"Completed","No Results Available","Biological Availability","Drug: BAY1841788 (ODM-201)|Drug: Itraconazole|Drug: Rifampicin","Area Under the Concentration Versus Time Curve From Time Zero to 72 Hours (AUC[0-72h]) of Darolutamide in Plasma After Single Dose Administration of Darolutamide|Maximum Observed Concentration (Cmax) of Darolutamide in Plasma After Single Dose Administration of Darolutamide|Area Under the Concentration Versus Time Curve From Time Zero to 72 Hours (AUC[0-72h]) of (S,R)-Darolutamide in Plasma After Single Dose Administration of Darolutamide|Maximum Observed Concentration (Cmax) of (S,R)-Darolutamide in Plasma After Single Dose Administration of Darolutamide|Area Under the Concentration Versus Time Curve From Time Zero to 72 Hours (AUC[0-72h]) of (S,S)-Darolutamide in Plasma After Single Dose Administration of Darolutamide|Maximum Observed Concentration (Cmax) of (S,S)-Darolutamide in Plasma After Single Dose Administration of Darolutamide|Area Under the Concentration Versus Time Curve From Time Zero to 72 Hours (AUC[0-72h]) of Keto-Darolutamide in Plasma After Single Dose Administration of Darolutamide|Maximum Observed Concentration (Cmax) of Keto-Darolutamide in Plasma After Single Dose Administration of Darolutamide|Number of Subjects With Study Drug-Related Treatment Emergent Adverse Events (TEAEs)","Bayer|Orion Corporation, Orion Pharma","Male","45 Years to 65 Years   (Adult, Older Adult)","Phase 1","15","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","17726|2016-004469-20","February 15, 2017","May 4, 2017","July 19, 2017","February 9, 2017",,"July 30, 2018","CRS Clinical Research Services Berlin GmbH, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT03048110"
213,"NCT03025360","Expanded Access to Provide Larotrectinib for the Treatment of Cancers With a NTRK Gene Fusion",,"Approved for marketing","No Results Available","Tumors Harboring NTRK Fusion","Drug: Larotrectinib (Vitrakvi, BAY2757556)",,"Bayer","All","Child, Adult, Older Adult",,,"Industry","Expanded Access:Individual Patients",,"20366",,,,"January 19, 2017",,"December 19, 2019",,,"https://ClinicalTrials.gov/show/NCT03025360"
214,"NCT03012347","Evaluation of a Gel Sunscreen in Controlled Use Conditions (208/2016)",,"Completed","No Results Available","Sunscreening Agents","Drug: BAY987517|Drug: BullFrog Gel Sunscreen Land Sport SPF-50","Feeling any discomfort after applying the product assessed by questionnaire","Bayer","All","18 Years to 45 Years   (Adult)","Not Applicable","72","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","19208","January 5, 2017","January 19, 2017","January 19, 2017","January 6, 2017",,"December 7, 2017","Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03012347"
215,"NCT03002922","Evaluation of Sunscreen During Exercise Under Conditions of Profuse Sweating (821/2016)",,"Completed","No Results Available","Sunscreening Agents","Drug: BAY987517","Change of face coverage post exercise compared to the full coverage observed prior to exercise (in percent)|Report of eye stinging assessed by questionnaire","Bayer","All","18 Years to 55 Years   (Adult)","Not Applicable","17","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","18821","January 18, 2017","January 28, 2017","January 28, 2017","December 26, 2016",,"January 26, 2018","Hill Top Research, Saint Petersburg, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03002922"
216,"NCT02995161","Sun Protection Factor Assay (344/2016)",,"Completed","No Results Available","Sunscreening Agents","Drug: BAY987521|Drug: SPF control","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","19344","December 30, 2016","January 4, 2017","January 4, 2017","December 16, 2016",,"February 27, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02995161"
217,"NCT02995148","Sun Protection Factor Assay (343/2016)",,"Completed","No Results Available","Sunscreening Agents","Drug: BAY987521|Drug: SPF Control","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","19343","December 30, 2016","January 6, 2017","January 6, 2017","December 16, 2016",,"February 27, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02995148"
218,"NCT02995135","Sun Protection Factor Assay (341/2016)",,"Completed","No Results Available","Sunscreening Agents","Drug: BAY987517|Drug: SFP Control","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","19341","January 3, 2017","January 6, 2017","January 6, 2017","December 16, 2016",,"February 27, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02995135"
219,"NCT02995122","Sun Protection Factor Assay (339/2016)",,"Completed","No Results Available","Sunscreening Agents","Drug: BAY987516|Drug: SPF Control","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","19339","December 29, 2016","January 6, 2017","January 6, 2017","December 16, 2016",,"December 6, 2017","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02995122"
220,"NCT02995109","Sun Protection Factor Assay (338/2016)",,"Completed","No Results Available","Sunscreening Agents","Drug: BAY987521|Drug: SPF Control","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","19338","January 4, 2017","January 17, 2017","January 17, 2017","December 16, 2016",,"February 27, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02995109"
221,"NCT02995044","Sun Protection Factor Assay (319/2016)","SPF Assay","Terminated","No Results Available","Sunscreening Agents","Drug: BAY987521|Drug: SPF Control","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","5","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","19319","January 4, 2017","January 6, 2017","January 6, 2017","December 16, 2016",,"February 27, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02995044"
222,"NCT02995031","Sun Protection Factor Assay (318/2016)","SPF Assay","Terminated","No Results Available","Sunscreening Agents","Drug: BAY987521|Drug: SPF Control","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","5","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","19318","January 3, 2017","January 6, 2017","January 6, 2017","December 16, 2016",,"February 27, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02995031"
223,"NCT02995018","Sun Protection Factor Assay (317/2016)","SPF Assay","Completed","No Results Available","Sunscreening Agents","Drug: BAY987521|Drug: SPF Control","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","11","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","19317","January 3, 2017","January 25, 2017","January 25, 2017","December 16, 2016",,"February 27, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02995018"
224,"NCT02994992","Sun Protection Factor Assay (316/2016)","SPF Assay","Completed","No Results Available","Sunscreening Agents","Drug: BAY 987516|Drug: SPF Control","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","12","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","19316","December 22, 2016","January 13, 2017","January 13, 2017","December 16, 2016",,"February 27, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02994992"
225,"NCT02992288","A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction","PANTHEON","Completed","Has Results","Heart Failure","Drug: Neladenoson bialanate (BAY1067197)|Drug: Placebo","Absolute Change From Baseline in Left Ventricular Ejection Fraction (LVEF) (%) at Week 20 Measured by Echocardiography|Absolute Change From Baseline in Log-transformed NT-pro B-type Natriuretic Peptide (BNP) at Week 20|Change From Baseline in Left Ventricular End-Systolic Volume (LVESV) at Week 20|Change From Baseline in Left Ventricular End-Diastolic Volume (LVEDV) at Week 20|Change From Baseline in High Sensitivity Troponin T (Hs-TNT) at Week 20|Number of Participants With Composite Efficacy Outcome|Number of Participants With Cardiovascular (CV) Mortality|Number of Participants With Heart Failure (HF) Hospitalization and Urgent Visits for Heart Failure (HF)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","427","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15128|2016-003839-38","February 22, 2017","March 28, 2018","May 16, 2018","December 14, 2016","April 23, 2019","April 23, 2019","Southwest Florida Research, Naples, Florida, United States|Henry Ford Health System, Detroit, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|St. Louis Heart & Vascular, PC, Saint Louis, Missouri, United States|Glacier View Research Institute-Cardiology, Kalispell, Montana, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|St. Elizabeth Youngstown Hospital, Youngstown, Ohio, United States|Tennessee Center for Clinical Trials, Tullahoma, Tennessee, United States|East Texas Cardiology, Houston, Texas, United States|AZ St-Jan Brugge Oostende AV, Brugge, Belgium|Grand Hôpital de Charleroi, Gilly, Belgium|AZ Delta, Roeselare, Belgium|AZ Turnhout, Turnhout, Belgium|Spec Hosp for Active Treatm in Cardiology Sv Georgi Pernik, Pernik, Bulgaria|Specialized Hospital for Actrive Treatm of Card - Pleven, Pleven, Bulgaria|NMTH Tzar Boris III, Sofia, Bulgaria|UMHAT Tsaritsa Joanna-ISUL EAD Sofia, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment Sveta Sofia, Sofia, Bulgaria|MHAT Dr Stefan Cherkezov, Veliko Tarnovo, Bulgaria|Medizinische Hochschule Hannover (MHH), Hannover, Niedersachsen, Germany|Herz- und Diabeteszentrum Nordrhein-Westfalen (HDZ NRW), Bad Oeynhausen, Nordrhein-Westfalen, Germany|St.-Johannes-Hospital Dortmund, Dortmund, Nordrhein-Westfalen, Germany|Kliniken Maria Hilf GmbH, Mönchengladbach, Nordrhein-Westfalen, Germany|Klinikum der Stadt Ludwigshafen am Rhein gGmbH, Ludwigshafen, Rheinland-Pfalz, Germany|Charité Campus Virchow-Klinikum (CVK), Berlin, Germany|KAT General Hospital of Athens, Kifisia / Athens, Attica, Greece|G. Gennimatas General State Hospital of Athens, Athens, Greece|Thriassio General Hospital of Elefsina, Elefsina, Greece|Konstantopoulio General Hospital of Nea Ionia - Agia Olga, Nea Ionia / Athens, Greece|Hippokration General Hospital of Thessaloniki, Thessaloniki, Greece|Barzilai Medical Center, Ashkelon, Israel|Hillel Yaffe Medical Center, Hadera, Israel|Rambam Health Corporation, Haifa, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Hadassah University Hospital Mount Scopus, Jerusalem, Israel|Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel|Assaf Harofeh Medical Center, Zrifin, Israel|A.O.U. Policlinico Federico II Napoli, Napoli, Campania, Italy|Fondazione Policlinico Universitario Agostino Gemelli, Roma, Lazio, Italy|ASST Papa Giovanni XXIII, Bergamo, Lombardia, Italy|ASST Spedali Civili di Brescia, Brescia, Lombardia, Italy|IRCCS Centro Cardiologico Fondazione Monzino, Milano, Lombardia, Italy|AUSL 8 Arezzo, Arezzo, Toscana, Italy|Gunma University Hospital, Maebashi, Gunma, Japan|National Hospital Organization Takasaki General Medical C, Takasaki, Gunma, Japan|Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan|National hospital Organization Mito Medical Center, Higashiibaraki, Ibaraki, Japan|R.I.A.C Naha City Hospital, Naha, Okinawa, Japan|Kishiwada Tokushukai Hospital, Kishiwada, Osaka, Japan|Takatsuki Red Cross Hospital, Takatsuki, Osaka, Japan|Minamino Cardiovascular Hospital, Hachioji, Tokyo, Japan|Nihon University Itabashi Hospital, Itabashi-ku, Tokyo, Japan|Tokyo Women's Medical University Hospital, Shinjuku-ku, Tokyo, Japan|Hiroshima University Hospital, Hiroshima, Japan|Okayama Rosai Hospital, Okayama, Japan|Osaka General Medical Center, Osaka, Japan|Toyama Prefectural Central Hospital, Toyama, Japan|Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands|Ziekenhuis Rijnstate, Arnhem, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Erasmus Medisch Centrum, Rotterdam, Netherlands|KLIMED Marek Klimkiewicz, Bialystok, Poland|CLINICAL MEDICAL RESEARCH Sp. z o. o., Katowice, Poland|Szpital Specjalistyczny im. J. Dietla, Krakow, Poland|Nzoz Salus, Lodz, Poland|Szpital Kliniczny Przemienienia Panskiego, Poznan, Poland|Twoja Przychodnia - Szczecinskie Centrum Medyczne, Szczecin, Poland|IV Wojskowy Szpital Kliniczny z Poliklinika, SPZOZ, Wroclaw, Poland|Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain|Hospital Universitario ""Virgen de la Arrixaca"", El Palmar, Murcia, Spain|Complejo Hospitalario Universitario A Coruña, A Coruña, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Clínico Universitario San Carlos, Madrid, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Universitari i Politècnic La Fe, Valencia, Spain","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT02992288/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT02992288/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02992288"
226,"NCT02991131","Sivextro in Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in Hospitalized Patients. A Global Observational Study","DART","Terminated","No Results Available","Skin Disease, Infectious","Drug: Tedizolid (Sivextro, BAY1192631)|Drug: Linezolid","Number of treatment days|Number of participants with adverse events or safety-relevant changes in laboratory parameters","Bayer","All","18 Years and older   (Adult, Older Adult)",,"108","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","18299|SX1601","December 17, 2016","November 21, 2018","November 21, 2018","December 13, 2016",,"October 2, 2019","Multiple Locations, Mexico|Multiple Locations, Russian Federation|Multiple Locations, Singapore",,"https://ClinicalTrials.gov/show/NCT02991131"
227,"NCT02985541","Mirena Extension Trial","MET","Active, not recruiting","No Results Available","Contraception","Drug: Levonorgestrel IUS (Mirena, BAY86-5028)","Number of pregnancies per 100 women years.|Menstrual blood loss (MBL) is measured by the alkaline hematin method.|Categorized menstrual blood loss (MBL) (>= 80 ml per 30 days).|Number of post-baseline adverse events.","Bayer","Female","18 Years to 35 Years   (Adult)","Phase 3","364","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18649","December 22, 2016","June 4, 2021","June 4, 2021","December 7, 2016",,"January 22, 2020","Mobile, Alabama, United States|Phoenix, Arizona, United States|Scottsdale, Arizona, United States|Tucson, Arizona, United States|Encinitas, California, United States|San Francisco, California, United States|Ventura, California, United States|Aurora, Colorado, United States|Atlanta, Georgia, United States|Idaho Falls, Idaho, United States|Fort Wayne, Indiana, United States|Newburgh, Indiana, United States|Frederick, Maryland, United States|Pikesville, Maryland, United States|Boston, Massachusetts, United States|Saginaw, Michigan, United States|Lincoln, Nebraska, United States|Las Vegas, Nevada, United States|Lebanon, New Hampshire, United States|Lawrenceville, New Jersey, United States|Neptune, New Jersey, United States|Albuquerque, New Mexico, United States|New York, New York, United States|Port Jefferson, New York, United States|Asheville, North Carolina, United States|Durham, North Carolina, United States|Greensboro, North Carolina, United States|Hickory, North Carolina, United States|Morehead City, North Carolina, United States|New Bern, North Carolina, United States|Winston-Salem, North Carolina, United States|Franklin, Ohio, United States|Mayfield Heights, Ohio, United States|Portland, Oregon, United States|Erie, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Chattanooga, Tennessee, United States|Austin, Texas, United States|Fort Worth, Texas, United States|Houston, Texas, United States|Draper, Utah, United States|Midlothian, Virginia, United States|Richmond, Virginia, United States|Roanoke, Virginia, United States|Virginia Beach, Virginia, United States|Seattle, Washington, United States|Seattle, Washington, United States|Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02985541"
228,"NCT02976467","A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY 1142524 in Patients After Acute Myocardial Infarction With Left-ventricular Dysfunction","CHIARA MIA 2","Completed","No Results Available","Myocardial Infarction","Drug: Fulacimstat (BAY1142524)|Drug: Placebo","Change in left-ventricular ejection fraction (LVEF)|Change in end diastolic volume index (EDVI)|Change in end systolic volume index (ESVI)|Number of patients with adverse events|Number of patients with serious adverse events","Bayer","All","40 Years to 79 Years   (Adult, Older Adult)","Phase 2","107","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","16673|2016-002167-33","December 30, 2016","July 31, 2018","September 4, 2018","November 29, 2016",,"September 3, 2019","Kladno, Czechia|Praha 10, Czechia|Praha 4, Czechia|Praha 5, Czechia|Praha 5, Czechia|Hannover, Niedersachsen, Germany|Dortmund, Nordrhein-Westfalen, Germany|Erfurt, Thüringen, Germany|Berlin, Germany|Beer Sheva, Israel|Haifa, Israel|Jerusalem, Israel|Jerusalem, Israel|Petah Tikva, Israel|Tel Aviv, Israel|Bergamo, Lombardia, Italy|Brescia, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Monza-Brianza, Lombardia, Italy|Babio - Beade, Pontevedra, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT02976467"
229,"NCT02975453","Study of Major Cardiovascular Events in Patients With Nonvalvular Atrial Fibrillation Treated With Rivaroxaban","EMIR","Active, not recruiting","No Results Available","Atrial Fibrillation","Drug: Rivaroxaban (Xarelto, BAY59-7939)","2MACE score|Occurrence of MACE to evaluate the performance of the 2MACE index|Incorporation of additional risk factors to the 2MACE index or replacing some of the existing ones|Occurrence of major cardiovascular events (fatal/nonfatal myocardial infarction, cardiac revascularization and cardiovascular death)|Occurrence of stroke|Occurrence of transient ischemic attack (TIA)|Occurrence of systemic embolism|Thromboembolic risk based on the CHADS2 score|Thromboembolic risk based on the CHA2DS2-VASC|Number of MACEs occurring during the study|Patients' profile|Number of cases (frequency) of metabolism syndrome at enrollment with/without the occurrence of myocardial infarction or coronary revascularization","Bayer|Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)",,"1463","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","18884","December 5, 2016","January 30, 2020","March 30, 2020","November 29, 2016",,"January 22, 2020","Multiple Locations, Spain",,"https://ClinicalTrials.gov/show/NCT02975453"
230,"NCT02975440","Drug-drug Interaction Study Between Orally Administered Rifampicin and Vilaprisan",,"Completed","No Results Available","Endometriosis","Drug: Rifampicin|Drug: Midazolam|Drug: BAY1002670_Vilaprisan","AUC of Vilaprisan in plasma with co-medication Rifampicin|Cmax of Vilaprisan in plasma with co-medication Rifampicin|AUC of Vilaprisan in plasma without co-medication Rifampicin|Cmax of Vilaprisan in plasma without co-medication Rifampicin","Bayer","Female","45 Years to 65 Years   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","17773","November 10, 2016","January 27, 2017","April 11, 2017","November 29, 2016",,"July 2, 2017","Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT02975440"
231,"NCT02971930","Exit Interviews to Assess Impact of Infusion Frequency in Hemophilia A",,"Completed","No Results Available","Hemophilia A","Biological: BAY94-9027","Qualitative interviews (with patients) to determine patients' satisfaction|Qualitative interviews (with patients) to determine patients' quality of life|Qualitative interviews (with treating physicians) to determine patients' satisfaction|Qualitative interviews (with treating physicians) to determine patients' quality of life","Bayer","All","18 Years and older   (Adult, Older Adult)",,"30","Industry","Observational","Observational Model: Other|Time Perspective: Prospective","19144","June 20, 2017","November 26, 2017","December 15, 2017","November 23, 2016",,"February 1, 2018","Cleveland, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02971930"
232,"NCT02963675","Incidence of Second Primary Malignancies in Prostate Cancer Patients With Bone Metastases - an Observational Retrospective Cohort Study in Sweden","SMARCOS","Completed","No Results Available","Prostatic Neoplasms",,"Incidences of Second primary malignancies that are characterized by the following ICD-10 codes: C00-C76, C81-C96, D00-D09, D37-D48.|Incidences of any site-specific second primary malignancies|Overall survival|Pathologic fracture|Spinal cord compression|Surgery to bone|Radiation to bone","Bayer","Male","18 Years and older   (Adult, Older Adult)",,"15953","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","18105","November 15, 2016","March 31, 2017","March 31, 2017","November 15, 2016",,"February 12, 2018","Multiple Locations, Sweden",,"https://ClinicalTrials.gov/show/NCT02963675"
233,"NCT02962869","Human Photoallergy Test (824/2016)",,"Completed","No Results Available","Sunscreening Agents","Drug: BAY987517|Other: Untreated skin","Intensity of skin reactions is evaluated by 5 point scale","Bayer","All","18 Years to 60 Years   (Adult)","Not Applicable","53","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single|Primary Purpose: Other","18824","November 3, 2016","December 31, 2016","December 31, 2016","November 11, 2016",,"December 13, 2018","Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02962869"
234,"NCT02962856","Human Phototoxicity Test (823/2016)",,"Completed","No Results Available","Sunscreening Agents","Drug: BAY987517|Other: Untreated Skin","Intensity of skin reactions will be evaluated using the 5 point grading scale","Bayer","All","18 Years to 60 Years   (Adult)","Not Applicable","38","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","18823","November 2, 2016","November 5, 2016","November 5, 2016","November 11, 2016",,"December 13, 2018","Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02962856"
235,"NCT02960880","Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Rivaroxaban vs. Vitamin k Antagonists",,"Completed","No Results Available","Atrial Fibrillation","Drug: Rivaroxaban (Xarelto, BAY597939)|Drug: Phenprocoumon (branded and generics)","Risk of ischemic stroke estimated as the number of hospitalizations with the ICD-10-GM diagnosis|Risk of intracranial hemorrhage (ICH) estimated as the number of hospitalizations with the ICD-10-GM diagnosis|Risk of ischemic stroke or ICH estimated as the number of hospitalizations with the respective ICD-10-GM diagnosis|Risk of systemic embolism (SE) estimated as the number of hospitalizations with the ICD-10-GM diagnosis|Risk of transient ischemic attack (TIA) estimated as the number of hospitalizations with the ICD-10-GM diagnosis|Risk of ischemic stroke or SE or TIA estimated as the number of hospitalizations with the respective ICD-10-GM diagnosis","Bayer|Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)",,"99999","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","18735","October 15, 2016","December 31, 2016","December 31, 2016","November 10, 2016",,"December 26, 2017","Multiple Locations, Germany",,"https://ClinicalTrials.gov/show/NCT02960880"
236,"NCT02959827","Iodinated Contrast Agents and Risk of Hypothyroidism in Young Children in the United States",,"Completed","Has Results","Hypothyroidism","Drug: Iodinated contrast agents","Incidence Rate of Hypothyroidism Detected in Routine Clinical Practice|Baseline Characteristics (Age) of the Cases With Hypothyroidism and of the Rest of the Cohort|Baseline Characteristics (Sex) of the Cases With Hypothyroidism and of the Rest of the Cohort|Baseline Characteristics (Year of Hypothyroidism Diagnosis) of the Cases With Hypothyroidism and of the Rest of the Cohort|Baseline Characteristics (Type of Iodine Contrast Exposure) of the Cases With Hypothyroidism and of the Rest of the Cohort|Baseline Characteristics (Race/Ethnicity) of the Cases With Hypothyroidism and of the Rest of the Cohort|Time From First Iodinated Contrast to First Hypothyroidism Event|Classification of Subclinical/Manifest Hypothyroidism by Type of Exposure|Classification of Hypothyroidism by Etiology","Bayer","All","up to 3 Years   (Child)",,"2320","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","19185","October 15, 2016","June 15, 2017","June 15, 2017","November 9, 2016","January 30, 2019","January 30, 2019","Oakland, Oakland, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT02959827/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02959827"
237,"NCT02957396","Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Subjects",,"Completed","No Results Available","Pharmacokinetics","Drug: Finerenone (BAY94-8862): 20 mg intact tablet|Drug: Finerenone (BAY94-8862): 20 mg crushed and resuspended tablet|Drug: Finerenone (BAY94-8862): 20 mg suspension","Finerenone area under the plasma concentration vs. time curve (AUC)|Finerenone maximum plasma concentration (Cmax)|Appearance of oro-dispersible tablets assessed by questionnaire|Taste of oro-dispersible tablets assessed by questionnaire|Texture of oro-dispersible tablets assessed by questionnaire|Smell of oro-dispersible tablets assessed by questionnaire|Overall impression of oro-dispersible tablets assessed by questionnaire|Whether oro-dispersible tablets are palatable and swallowable assessed by questionnaire|Number of patients with adverse events as a measure of safety and tolerability","Bayer","Male","18 Years to 45 Years   (Adult)","Phase 1","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","16538|2016-002813-24","November 17, 2016","January 13, 2017","March 1, 2017","November 6, 2016",,"April 24, 2017","Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT02957396"
238,"NCT02956109","Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Volunteers",,"Completed","No Results Available","Pharmacokinetics","Drug: Finerenone (BAY94-8862): 1 0mg tablet|Drug: Finerenone (BAY94-8862): 5 X 0.25 mg oro-dispersible tablets|Drug: Finerenone (BAY94-8862): 1.25 mg oro-dispersible tablet","Finerenone area under the plasma concentration vs. time curve (AUC)|Finerenone maximum plasma concentration (Cmax)|Appearance of oro-dispersible tablets assessed by questionnaire|Taste of oro-dispersible tablets assessed by questionnaire|Texture of oro-dispersible tablets assessed by questionnaire|Smell of oro-dispersible tablets assessed by questionnaire|Overall impression of oro-dispersible tablets assessed by questionnaire|Whether oro-dispersible tablets are palatable and swallowable assessed by questionnaire|Number of patients with adverse events as a measure of safety and tolerability","Bayer","Male","18 Years to 45 Years   (Adult)","Phase 1","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","18290|2016-002895-29","November 16, 2016","December 22, 2016","March 17, 2017","November 4, 2016",,"July 11, 2017","Mönchengladbach, Nordrhein-Westfalen, Germany",,"https://ClinicalTrials.gov/show/NCT02956109"
239,"NCT02941783","Drug Use Investigation of Kovaltry in Hemophilia A Patients",,"Recruiting","No Results Available","Hemophilia A","Drug: Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973)","Number of participants with adverse events as measure of safety and tolerability|Number of participants with serious adverse events as measure of safety and tolerability|Number of annual bleeds|Efficacy of controlling of bleeds","Bayer","All","Child, Adult, Older Adult",,"30","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","18706|2015/01011","November 30, 2016","May 31, 2021","November 30, 2021","October 21, 2016",,"January 22, 2020","Many Locations, Multiple Locations, Japan",,"https://ClinicalTrials.gov/show/NCT02941783"
240,"NCT02940002","BAY1003803 Formulation Comparison in Open Psoriasis Plaque Test",,"Completed","No Results Available","Psoriasis","Drug: BAY1003803|Drug: Clobetasol propionate|Drug: Betamethasone/calcipotriene","Change in infiltrate thickness from day 1 to day 29 measured by sonography using 22 MHz B mode ultrasound","Bayer","All","18 Years to 64 Years   (Adult)","Phase 1","23","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","17012|2016-000962-47","October 12, 2016","January 27, 2017","March 17, 2017","October 20, 2016",,"March 21, 2017","Schwerin, Mecklenburg-Vorpommern, Germany|Bochum, Nordrhein-Westfalen, Germany|Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT02940002"
241,"NCT02936583","Sun Protection Factor Assay (SPF Assay 207/2016)",,"Completed","No Results Available","Sunscreening Agents","Drug: BAY987521","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","6","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","19207","October 26, 2016","November 1, 2016","November 1, 2016","October 18, 2016",,"December 13, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02936583"
242,"NCT02936570","Sun Protection Factor Assay (SPF Assay 206/2016)",,"Completed","No Results Available","Sunscreening Agents","Drug: BAY987521","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","5","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","19206","October 26, 2016","November 1, 2016","November 1, 2016","October 18, 2016",,"December 13, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02936570"
243,"NCT02936557","Sun Protection Factor Assay (SPF Assay 205/2016)",,"Completed","No Results Available","Sunscreening Agents","Drug: BAY987521","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","11","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","19205","October 26, 2016","November 17, 2016","November 17, 2016","October 18, 2016",,"December 13, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02936557"
244,"NCT02936544","Sun Protection Factor Assay (SPF Assay 204/2016)",,"Completed","No Results Available","Sunscreening Agents","Drug: BAY987521","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","11","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","19204","October 26, 2016","November 17, 2016","November 17, 2016","October 18, 2016",,"December 13, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02936544"
245,"NCT02936492","BAY1003803 Single and Multiple Dose Escalation, Safety, Tolerability and Pharmacokinetics Study",,"Terminated","No Results Available","Psoriasis","Drug: BAY1003803 0.01% lipophilic cream|Drug: BAY1003803 0.1% lipophilic cream|Drug: BAY1003803 0.01% ointment|Drug: BAY1003803 0.1% ointment|Drug: Lipophilic cream vehicle|Drug: Ointment vehicle|Drug: Clobetasol propionate","Cortisol serum levels for safety|Frequency of treatment-emergent adverse events (TEAEs)|Nature of treatment-emergent adverse events (TEAEs)|Monocytic human leukocyte antigen-DR (HLA-DR) expression (Part 1, single dose)|Monocytic human leukocyte antigen-DR (HLA-DR) expression (Part 2, multiple dose)|Maximum plasma concentration (Cmax) after single dose of BAY1003803|Area under the plasma concentration vs. time curve from zero to infinity (AUC) after single dose of BAY1003803|Area under the curve from time zero to 22 hours [AUC(0-22)] after single dose of BAY1003803|Maximum plasma concentration (Cmax,md) after multiple dose of BAY1003803|Area under the curve from time zero to 24 hours [AUC(0-24)md] after multiple dose of BAY1003803","Bayer","Male","18 Years to 64 Years   (Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","17014","October 24, 2016","April 18, 2017","October 16, 2017","October 18, 2016",,"November 8, 2017","Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT02936492"
246,"NCT02930798","Sun Protection Factor Assay (SPF Assay 203/2016)",,"Completed","No Results Available","Sunscreening Agents","Drug: BAY987516","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","3","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","19203","October 18, 2016","October 19, 2016","October 19, 2016","October 12, 2016",,"December 13, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02930798"
247,"NCT02930785","Sun Protection Factor Assay (SPF Assay 202/2016)",,"Completed","No Results Available","Sunscreening Agents","Drug: BAY987517","Minimal Erythema Dose (MED)|2 Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","5","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","19202","October 12, 2016","October 27, 2016","October 27, 2016","October 12, 2016",,"December 13, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02930785"
248,"NCT02930772","Sun Protection Factor Assay (SPF Assay 201/2016)",,"Completed","No Results Available","Sunscreening Agents","Drug: BAY987516","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","11","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","19201","October 12, 2016","November 3, 2016","November 3, 2016","October 12, 2016",,"December 13, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02930772"
249,"NCT02930759","Sun Protection Factor Assay (SPF Assay 200/2016)",,"Completed","No Results Available","Sunscreening Agents","Drug: BAY987516","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","3","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","19200","October 12, 2016","October 13, 2016","October 13, 2016","October 12, 2016",,"December 13, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02930759"
250,"NCT02930746","Sun Protection Factor Assay (SPF Assay 199/2016)",,"Completed","No Results Available","Sunscreening Agents","Drug: BAY987516","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","3","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","19199","October 12, 2016","October 13, 2016","October 13, 2016","October 12, 2016",,"December 13, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02930746"
251,"NCT02928029","Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma",,"Completed","No Results Available","Multiple Myeloma","Drug: Radium-223 dichloride (Xofigo, BAY88-8223)|Drug: Placebo|Drug: Bortezomib|Drug: Dexamethasone","Phase 1: Number of subjects with dose-limiting toxicities treated with radium-223 dichloride in combination with BOR/DEX|Phase 1: Maximum tolerated dose/ recommended phase-2 dose of radium-223 dichloride in combination with BOR/DEX|Phase 1: Incidence of treatment-emergent adverse events (TEAEs)|Phase 1: Incidence of drug-related TEAEs|Phase 1: Incidence of serious adverse events|Phase 2: Combined CR+VGPR rate|Phase 1: Combined CR+VGPR rate|Phase 2: Number of subjects with adverse events|Phase 2: Objective response rate (ORR)|Phase 2: Overall survival (OS)|Phase 2: Progression-free survival (PFS)|Phase 2. Duration of response (DOR)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","7","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","18987|2016-002438-58","February 10, 2017","March 20, 2019","March 20, 2019","October 7, 2016",,"May 13, 2019","Pacific Oncology/Hematology Associates, Encinitas, California, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|National Cancer Center, Goyang-si, Gyeonggido, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Hospital Universitari Son Espases, Palma de Mallorca, Illes Baleares, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain",,"https://ClinicalTrials.gov/show/NCT02928029"
252,"NCT02924311","Routine Clinical Practice for Use of Intravitreal Aflibercept Treatment in Patients With Diabetic Macular Edema","APOLLON","Completed","No Results Available","Diabetic Retinopathy","Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)","Mean change in Best Corrected Visual Acuity from baseline to month 12 in treatment naïve patients and previously treated patients|Mean change in Best Corrected Visual Acuity between baseline and 12-month follow-up for the entire study population|Mean change in Best Corrected Visual Acuity between baseline and 24-month follow-up for all groups|Mean change in Central Retinal Thickness between baseline and 12-month follow-up for all groups|Mean change in Central Retinal Thickness between baseline visit and 24-month follow-up for all groups|Type of the previous treatment(s) in previously treated patients|Duration (months) of the previous treatment in previously treated patients|Date of the last administered treatment in previously treated patients|Reason for starting intravitreal aflibercept|Number of eyes injected|Number of visits with injection|Interval (days) between injections|Type of adjunctive therapy post IVT aflibercept initiation|Proportion of patients with change in fluorescein angiograph outcomes between baseline and 24-month follow-up for all groups|Proportion of patients with change in fundus photography outcomes between baseline and 24-month follow-up for all groups|Proportion of patients with no fluid determined by optical coherence tomography (OCT) between baseline and 24-month follow-up|Mean change in HbA1c level during macular disease monitoring|Mean change in blood pressure during macular disease monitoring|Number of prior treatments (DME Monitoring)|Number of patients with prior photocoagulation laser therapy (DME Monitoring)|Number of patients with prior anti-VEGF treatment (DME Monitoring)|Number of patients with prior intraocular steroids (DME Monitoring)|Duration of the disease (DME Monitoring)|Number of visits for monitoring only (DME Monitoring)|Number of visits for injection only (DME Monitoring)|Number of visits combining monitoring and injection (DME Monitoring)|Number of visits for diabetes by patients during the 24-months follow-up period by diabetologists or general practitioners (DME Monitoring)|Number of visits with OCT assessments (DME monitoring)|Number of visits with fundus photography assessments (DME monitoring)|Number of visits with fluorescein angiography assessments (DME monitoring)|Number of visits with visual acuity measurements (DME monitoring)|Number of participants with ocular and non-ocular safety events","Bayer|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)",,"402","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","18636","September 21, 2016","August 12, 2019","December 6, 2019","October 5, 2016",,"January 2, 2020","Multiple Locations, France",,"https://ClinicalTrials.gov/show/NCT02924311"
253,"NCT02903888","A Cross-sectional, Observational Multicenter Study to Assess the Reasons for Choosing the 3-year Hormonal IUD and Level of IUDs Knowledge Among Women Aged 18 to 29 Years","ANALIA","Completed","No Results Available","Intrauterine Devices, Medicated","Drug: Levonorgestrel (Jaydess, Skyla, BAY86-5028)","Reason for choosing Jaydess as intrauterine device (IUD)|Reason for switching to Jaydess if used another type of intrauterine device before|Knowledge of Jaydess or other IUDs prior to the visit|Is the first intrauterine device prescribed?|Person who encouraged the use of jaydess?|Reason for not using Jaydess or other intrauterine delivery system (IUD) before|Uterine length as measured by ultrasonography|Presence of dysmenorrhea (Y/N)|Current contraception method|Date of birth|Marital status|Place of birth|Place of residence|Educational level|Employment|Income level|Do you have children? (Y/N)|Number of children|Has she had some birth vaginally? (Y/N)|Date of last birth|Do you plan to have (more) children? (Yes/No/Unknown)|When she plans to have (more) children|Frequency of menstrual bleeding|Regularity of menstrual bleeding|Quantity of menstrual bleeding|Duration of menstrual bleeding|Absence of menstrual bleeding|Questionnaire concerning the physicians' characteristics","Bayer","Female","18 Years to 29 Years   (Adult)",,"886","Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","18883","September 8, 2016","October 30, 2017","December 23, 2017","September 16, 2016",,"January 12, 2018","Multiple Locations, Spain",,"https://ClinicalTrials.gov/show/NCT02903888"
254,"NCT02900404","Verification of XAPPORT: a Decision Support App for Physicians Used for Patients Anticoagulated With Rivaroxaban in Terms of Anticoagulation Management in Elective Surgery: Verification Process of Medical Decision Algorithm","VeriXAPPORT","Withdrawn","No Results Available","Atrial Fibrillation|Venous Thromboembolism|Pulmonary Embolism","Other: XAPPORT|Other: Expert Panel (""gold standard"")","Agreement rate between the recommendations of XAPPORT and the consolidated recommendations of a qualified Expert Panel (""gold standard"").|Reasons for discrepancies between the recommendations of XAPPORT and the consolidated recommendations of the qualified Expert Panel (""gold standard"").","Bayer|Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)",,"0","Industry","Observational","Observational Model: Cohort|Time Perspective: Other","18903","February 15, 2017","March 31, 2017","March 31, 2017","September 14, 2016",,"May 1, 2017",,,"https://ClinicalTrials.gov/show/NCT02900404"
255,"NCT02899104","Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )","Navigant","Completed","No Results Available","Prostatic Neoplasms, Castration-Resistant","Drug: Xofigo (Radium-223 dichloride, BAY88-8223","Determining factors that drive physician decision for treatment selection.|Most common treatment sequences|Integration of Xofigo into the common treatment sequences, monotherapy or in combination.|Mean Xofigo dose|Duration of Xofigo treatment|Overall survival (OS)|Time to radiographic progression|Time to PSA (Prostate specific antigen) progression|Most common SRE (Skeletal Related Event)|Most common clinical intervention|Time to first SSE(Symptomatic Skeletal Events)|Reasons for discontinuation|Change in laboratory values from baseline|Radiological progression free survival (rPFS)|Time to alkaline phosphatase (ALP) progression|Time to visceral metastasis|Time to onset of first subsequent treatment|Pain|Most common symptoms|Type of physician|Change in PSA from baseline to 12 weeks, and baseline to discontinuation|Resource utilization|Change in ALP from baseline to 12 weeks, and baseline to discontinuation|Change in LDH from baseline to 12 weeks, and baseline to discontinuation","Bayer","Male","18 Years and older   (Adult, Older Adult)",,"200","Industry","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","18919","June 15, 2017","March 31, 2019","March 31, 2019","September 14, 2016",,"April 29, 2019","Whippany, Whippany, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02899104"
256,"NCT02894385","Effect of Hepatic and Renal Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1841788 (ODM-201)",,"Completed","No Results Available","Pharmacokinetics|Hepatic Insufficiency|Renal Insufficiency","Drug: BAY1841788","Area under the concentration-time curve of darolutamide from time zero to 48 hours (AUC(0-48)) in plasma|Maximum drug concentration (Cmax) of darolutamide in plasma|Area under the concentration-time curve of darolutamide's diastereomer ((S,R)-darolutamide) from time zero to 48 hours (AUC(0-48)) in plasma|Maximum drug concentration (Cmax) of darolutamide's diastereomer ((S,R)-darolutamide) in plasma|Area under the concentration-time curve of darolutamide's diastereomer ((S,S)-darolutamide) from time zero to 48 hours (AUC(0-48)) in plasma|Maximum drug concentration (Cmax) of darolutamide's diastereomer ((S,S)-darolutamide) in plasma|Area under the concentration-time curve of darolutamide's major metabolite (keto-darolutamide) from time zero to 48 hours (AUC(0-48)) in plasma|Maximum drug concentration (Cmax) of darolutamide's major metabolite (keto-darolutamide) in plasma|Number of subjects with study drug-related treatment-emergent adverse events (TEAEs)","Bayer|Orion Corporation, Orion Pharma","Male","45 Years to 79 Years   (Adult, Older Adult)","Phase 1","29","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","17721|2016-001069-10","September 13, 2016","April 10, 2017","December 15, 2017","September 9, 2016",,"January 7, 2019","Kiel, Schleswig-Holstein, Germany|Lübeck, Germany",,"https://ClinicalTrials.gov/show/NCT02894385"
257,"NCT02891850","Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy","REPLACE","Active, not recruiting","No Results Available","Pulmonary Arterial Hypertension","Drug: Adempas (Riociguat, BAY63-2521)|Drug: Sildenafil|Drug: Tadalafil","Efficacy (Y/N)|Change in 6 Minute Walking Distance (6MWD) from baseline to 24 weeks|Change in N-terminal pro-brain natriuretic peptide (NT-proBNP) from baseline to 24 weeks|Change in World Health Organization Functional Class (WHO FC) from baseline to 24 weeks|Change in clinical worsening from baseline to 24 weeks","Bayer","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","223","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18588|2016-001067-36","January 11, 2017","March 30, 2020","April 30, 2020","September 8, 2016",,"January 22, 2020","Phoenix, Arizona, United States|Tucson, Arizona, United States|Sacramento, California, United States|Orlando, Florida, United States|Weston, Florida, United States|Kansas City, Kansas, United States|Louisville, Kentucky, United States|Detroit, Michigan, United States|Troy, Michigan, United States|Newark, New Jersey, United States|Mineola, New York, United States|New York, New York, United States|Rochester, New York, United States|Cleveland, Ohio, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Richmond, Virginia, United States|Graz, Austria|Leuven, Belgium|Belo Horizonte, Minas Gerais, Brazil|Belo Horizonte, Minas Gerais, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|Blumenal, Santa Catarina, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Montreal, Quebec, Canada|Praha 2, Czechia|Praha 4, Czechia|Aarhus N, Denmark|Le Kremlin-Bicêtre, France|Rouen, France|Heidelberg, Baden-Württemberg, Germany|München, Bayern, Germany|München, Bayern, Germany|Würzburg, Bayern, Germany|Hannover, Niedersachsen, Germany|Köln, Nordrhein-Westfalen, Germany|Homburg, Saarland, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Lübeck, Schleswig-Holstein, Germany|Berlin, Germany|Gießen, Germany|Hamburg, Germany|Chaidari, Greece|Thessaloniki, Greece|Thessaloniki, Greece|Napoli, Campania, Italy|Roma, Lazio, Italy|Pavia, Lombardia, Italy|Palermo, Sicilia, Italy|Nagoya, Aichi, Japan|Sendai, Miyagi, Japan|Bunkyo-ku, Tokyo, Japan|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Culiacan, Sinaloa, Mexico|Mexico D.F., Mexico|Amsterdam, Netherlands|Nijmegen, Netherlands|Wroclaw, Poland|Almada, Lisboa, Portugal|Coimbra, Portugal|Lisboa, Portugal|Las Palmas de Gran Canaria, Las Palmas, Spain|Barcelona, Spain|Barcelona, Spain|Toledo, Spain|Kaoshiung, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Ankara, Turkey|Istanbul, Turkey|Istanbul, Turkey|Izmir, Turkey|Clydebank, West Dunbartonshire, United Kingdom|London, United Kingdom|London, United Kingdom|Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02891850"
258,"NCT02891057","Sun Protection Factor Assay (SPF Assay 104/2016)",,"Completed","No Results Available","Sunscreening Agents","Drug: BAY987517","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19104","August 15, 2016","August 24, 2016","August 24, 2016","September 7, 2016",,"December 13, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02891057"
259,"NCT02891044","Sun Protection Factor Assay (SPF Assay 105/2016)",,"Completed","No Results Available","Sunscreening Agents","Drug: BAY987517","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","12","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","19105","August 15, 2016","September 8, 2016","September 8, 2016","September 7, 2016",,"December 13, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02891044"
260,"NCT02885805","Sun Protection Factor (SPF) Efficacy Assay",,"Completed","No Results Available","Sunscreen Agents","Drug: BAY987516|Drug: SPF 15 Control","Sun Protection Factor (SPF) efficacy on the skin of human subjects before a total of 2 hours of water Immersion|Sun Protection Factor (SPF) efficacy on the skin of human subjects after a total of 2 hours of water Immersion","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","11","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","18322","June 26, 2015","July 1, 2015","July 1, 2015","September 1, 2016",,"December 12, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02885805"
261,"NCT02877511","Supervised Outdoor-Use Test For Sunscreen Products in Adults",,"Completed","No Results Available","Sunscreening Agents","Drug: BAY987517|Drug: Sunscreen Lotion (Y65-110)","Skin response to sun exposure according to the Skin Evaluation Response Scale from 0 to 3","Bayer","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","102","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other","18803","August 20, 2016","August 21, 2016","August 21, 2016","August 24, 2016",,"December 13, 2018","Saint Petersburg, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02877511"
262,"NCT02876718","Xarelto Evidence in Real Life of Patients' Preference and Satisfaction Study","X-PRESS","Completed","No Results Available","Atrial Fibrillation","Drug: Rivaroxaban (Xarelto, BAY 59-7939)","Patient preferences for anticoagulant treatment attributes (utility values obtained in Logit/Probit estimates)|Change of the Anti-clot treatment scale (ACTS) benefit and burden score from baseline (on VKA) to 3 months (on Xarelto)|AF symptoms as measured by European Heart Rhythm Association (EHRA) symtoms (both severity and frequency)|Reasons for switch from VKA to Xarelto","Bayer|Janssen Research & Development, LLC","All","20 Years and older   (Adult, Older Adult)",,"253","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","18728","August 11, 2016","January 9, 2018","January 9, 2018","August 24, 2016",,"December 24, 2018","Many Locations, Multiple Locations, Taiwan",,"https://ClinicalTrials.gov/show/NCT02876718"
263,"NCT02875106","A Digital Non-interventional Atrial Fibrillation (AF) Screening Study With Commercial Pulse Detection Systems","BAYathlon","Completed","No Results Available","Atrial Fibrillation","Device: 12-point-ECG|Device: Polar V800|Device: 360° eMotion FAROS SET + Belt|Device: Adidas Micoach smart run|Device: TomTom Runner Cardio HRM","The rate of correctly detected atrial fibrillation signals by CPDS in reference to ECG (sensitivity of CPDS).|The rate of correctly detected sinus rhythm signals by CPDS in reference to ECG (sensitivity of CPDS).|The rate of correctly detected AF of the applied algorithm of the ECG-data in reference to the primary diagnosis of the investigator using the ECG-graph (sensitivity of algorithm).","Bayer","All","18 Years and older   (Adult, Older Adult)",,"165","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","18796","November 8, 2017","April 5, 2019","May 8, 2019","August 23, 2016",,"May 10, 2019","Many Locations, Multiple Locations, Germany",,"https://ClinicalTrials.gov/show/NCT02875106"
264,"NCT02872246","Sun Protection Factor (SPF) / UVA Protection Factor (UVAPF) - Assay",,"Completed","No Results Available","Sunscreen Agents","Drug: BAY 987516|Drug: SPF 15 Control","Evaluation of water resistant SPF","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","11","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","18321","May 26, 2015","July 1, 2015","July 1, 2015","August 19, 2016",,"December 12, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02872246"
265,"NCT02872233","Sun Protection Factor (SPF) / UVA Protection Factor (UVAPF) Assay",,"Completed","No Results Available","Sunscreen Agents","Drug: BAY 987519|Drug: SPF 15 Control","Evaluation of 2 hours water resistant SPF","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","6","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","18319","May 26, 2015","June 10, 2015","June 10, 2015","August 19, 2016",,"December 12, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02872233"
266,"NCT02872220","To Test for Photo Allergy Reaction of Sunscreens",,"Completed","No Results Available","Photoallergy","Drug: SPF 50 Y65 110 (BAY987519)|Drug: SPF 50 Y51 002 (BAY987519)|Drug: SPF 15 V27 104 (BAY987519)|Drug: Sodium chloride [NaCl]","Evaluation of inflammatory responses|Evaluation of superficial effects|Adverse event collection as a measure of safety and tolerability","Bayer","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","56","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Other","18291","March 23, 2015","May 8, 2015","May 8, 2015","August 19, 2016",,"December 12, 2018","Pinellas Park, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02872220"
267,"NCT02872207","Evaluation of the Stinging Potential in Human Eyes",,"Completed","No Results Available","Sunscreen Agents","Drug: BAY 987516 (Y65-122)|Drug: BAY 987516 (Y65-118)|Drug: Control","Subjective discomfort in the eye was assessed based on questions by an Ophthalmologist to the subject, and a 5-category intensity scale.|Tearing/Lacrimation was assessed by the Ophthalmologist using a 5-category assessment score for each of the categories|Objective inflammation was assessed by the Ophthalmologist using a 5-category assessment score for each of the categories|Post installation pain/stinging was assessed using a 5-category intensity score|Post installation itching was assessed using a 5-category intensity score|Post installation dryness was assessed using a 5-category intensity score|Post installation scratchiness was assessed using a 5-category intensity score|Post installation discomfort preventing sleep was assessed using a 5-category intensity score|Post installation discomfort upon awakening was assessed using a 5-category intensity score|Post installation excessive discharge upon awakening was assessed using a 5-category intensity score|Post installation pain in bright sunlight was assessed using a 5-category intensity score|Number of adverse events as a measure of safety and tolerabilitay","Bayer","All","18 Years to 60 Years   (Adult)","Not Applicable","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other","18196","February 21, 2015","February 22, 2015","February 22, 2015","August 19, 2016",,"December 12, 2018","Saint Petersburg, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02872207"
268,"NCT02872194","Evaluation of the Stinging Potential of Products in Human Eyes",,"Completed","No Results Available","Sunscreen Agents","Drug: BAY987516, Y55-170|Drug: BAY987516, X72-151|Drug: BAY987516, Y49-034|Drug: Standard shampoo mixture (control)","Subjective discomfort in the eye was assessed based on questions by an Ophthalmologist to the subject using a 5-category intensity scale|Tearing/Lacrimation was assessed by the Ophthalmologist using a 5-category assessment score|Objective inflammation was assessed by the Ophthalmologist using a 5-category assessment score|Post installation eye effects were assessed using a 5-category intensity score|Number of adverse events as a measure of safety and tolerability","Bayer","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","21","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Other","17913","September 5, 2014","September 6, 2014","September 6, 2014","August 19, 2016",,"December 12, 2018","Saint Petersburg, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02872194"
269,"NCT02869113","Evaluation of the Stinging Potential of Sunscreen Products in Human Eyes",,"Completed","No Results Available","Sunscreen Agents","Drug: BAY98751 (Y65-110)|Drug: BAY 98751 (Y65-102)|Drug: BAY 98751 (Y65-106)|Drug: Standard shampoo mixture (Control)","Subjective discomfort in the eye was assessed based on questions by an Ophthalmologist to the subject using a 5-category intensity scale|Tearing/Lacrimation was assessed by the Ophthalmologist using a 5-category assessment score|Objective inflammation was assessed by the Ophthalmologist using a 5-category assessment score|Post installation eye effects were assessed using a 5-category intensity score|Number of adverse events as a measure of safety and tolerability","Bayer","All","18 Years to 60 Years   (Adult)","Not Applicable","65","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Other","18067","January 23, 2015","January 24, 2015","January 24, 2015","August 16, 2016",,"December 12, 2018","Saint Petersburg, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02869113"
270,"NCT02864758","Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France","BROTHER","Completed","No Results Available","Atrial Fibrillation","Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Vitamin K antagonists|Drug: dabigatran (Pradaxa)","Stroke and systemic embolism (Effectiveness outcome)|Major Bleeding|Death|Pattern of use (Exposure, Adherence, Discontinuation, Switch)|A composite of stroke and SE, major bleeding and death, clinically relevant bleeding and acute coronary syndrome|Cumulative incidence and incidence rate of stroke and SE, major bleeding, clinically relevant bleeding, death, composite criteria, and acute coronary syndrome as well as according individual diagnose of each of these outcomes|Cumulative incidence of Stroke and SE, major bleeding, clinically relevant bleeding, death, composite criteria, and acute coronary syndrome as well as according individual diagnose of each of these outcomes|Healthcare resources utilisation","Bayer|Janssen Scientific Affairs, LLC","All","2 Years to 99 Years   (Child, Adult, Older Adult)",,"99999","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","18656","September 8, 2016","September 30, 2018","September 30, 2018","August 12, 2016",,"September 27, 2019","Multiple Locations, France",,"https://ClinicalTrials.gov/show/NCT02864758"
271,"NCT02857738","Sun Protection Factor (SPF) - Static and Water Resistant Assay",,"Completed","No Results Available","Sunscreen Agents","Drug: BAY 987519|Drug: SPF 15 Control","Evaluation of water resistant SPF in accordance to ISO 24444","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","12","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","18320","May 26, 2015","June 10, 2015","June 10, 2015","August 5, 2016",,"December 12, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02857738"
272,"NCT02857725","Sun Protection Factor (SPF) Assay",,"Completed","No Results Available","Sunscreen Agents","Drug: BAY 987517|Drug: SPF 15 Control","Evaluation of water resistant SPF in accordance to 21 CFR (Code of Federal Regulations) 207.327","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","12","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","18300","May 18, 2015","June 9, 2015","June 9, 2015","August 5, 2016",,"December 12, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02857725"
273,"NCT02857478","Supervised Outdoor-Use Test to Assess the Safety of a Sunscreen C-Spray on Sport Users",,"Completed","No Results Available","Sunscreen Agents","Drug: BAY 987519, SPF 50, Y51-002|Drug: BAY 987519, SPF 50, P04-147","Evaluation of Erythema as graded on a 5 point scale.|Evaluation of AEs, including eye stinging","Bayer","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","98","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","18317","June 27, 2015","June 28, 2015","June 28, 2015","August 5, 2016",,"December 12, 2018","Saint Petersburg, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02857478"
274,"NCT02854137","Evaluation of the Irritation Potential of Sunscreen Products in Human Eyes",,"Completed","No Results Available","Sunscreening Agents","Drug: BAY987521|Drug: Control","Macroscopic evaluations for Lacrimation (score 0-4)|Macroscopic evaluations for Bulbar Conjuctiva Irritation (score 0-3)|Macroscopic evaluations of Palpebral Conjunctiva Irritation (score 0-3)|Subjective assessment of discomfort (score 0-4)","Bayer","All","18 Years to 60 Years   (Adult)","Not Applicable","23","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","18434","October 14, 2015","October 14, 2015","October 14, 2015","August 3, 2016",,"December 12, 2018","Saint Petersburg, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02854137"
275,"NCT02850263","A Study to Assess the Effectiveness of Aflibercept in Routine Clinical Practice in Patients With Diabetic Macular Oedema","DRAKO","Active, not recruiting","No Results Available","Macular Edema","Drug: Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|Drug: Anti-VEGF therapies including: Eylea Aflibercept, VEGF Trap-Eye, BAY86-5321) and Ophthalmologicals / Antineovascularisation agents (S01LA05)","Change in Best Corrected Visual Acuity (BCVA) in Early Treatment Diabetic Retinopathy Study (ETDRS) letters in patients with DMO treated with intravitreal aflibercept|Change in central subfield thickness (CST) as determined by Spectral Domain Optical Coherence Tomography (SD-OCT) in patients with DMO treated with intravitreal aflibercept|Change in non-refracted visual acuity in patients with DMO treated with intravitreal aflibercept|Change in Best Corrected Visual Acuity (BCVA) in Early Treatment Diabetic Retinopathy Study (ETDRS) letters in patients with DMO treated with intravitreal aflibercept differentiated by BCVA baseline characteristics|Change in central subfield thickness (CST) in patients with DMO treated with intravitreal aflibercept differentiated by CST baseline characteristics|Proportion (%) of patients discontinuing intravitreal aflibercept treatment|Time between the decision to treat for patients with DMO who have not received any previous anti-VEGF treatment|The time between the date of DMO diagnosis for patients with DMO who have received any previous anti-VEGF treatment|Proportion (%) of treated eyes with 5, 10 and 15 letter gain / loss|Proportion (%) of sites that adhere to their stated treatment protocol|Change in QoL score measured by NEI VFQ-25|Change in macular volume|Change in Best Corrected Visual Acuity (BCVA) in Early Treatment Diabetic Retinopathy Study (ETDRS) letters|Change in non-refracted visual acuity (VA).for the fellow eye|Number of DMO treatments required for the fellow eye|Number of visits performed (resources) to assess the fellow eye|Number of clinical procedures performed (resources) to assess the fellow eye|Number of adverse events as a measure of safety and tolerability|Reason for discontinuation of intravitreal aflibercept treatment|Change in Central Subfield Thickness (CST) of the fellow eye|Type of DMO treatments required for the fellow eye","Bayer","All","18 Years and older   (Adult, Older Adult)",,"750","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","18058","July 5, 2016","May 30, 2019","June 30, 2020","July 29, 2016",,"January 18, 2020","Multiple Locations, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02850263"
276,"NCT02842268","Evaluation of Sunscreen During Exercise Under Conditions of Profuse Sweating",,"Completed","No Results Available","Sunscreening Agent","Drug: BAY987517","Change of face coverage post exercise compared to the full coverage observed prior to exercise (in percent).|Eye Stinging on grading scale","Bayer","All","18 Years to 55 Years   (Adult)","Not Applicable","15","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","18818","June 17, 2016","June 22, 2016","June 22, 2016","July 22, 2016",,"December 13, 2018","Saint Petersburg, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02842268"
277,"NCT02840903","A Non-interventional Study to Observe the Computed Tomographic Angiography Image Quality With Different Contrast Media Injection Protocols Under Different Computed Tomography Machines Parameters Setting","RIGHT","Completed","No Results Available","Angiography|Multidetector Computed Tomography","Drug: Iopromide (Ultravist, BAY86-4877)","Contrast opacification of the target vascular segments, measured in Hounsfield Units (HU)|Value of CNR (contrast-noise ratio) of the vascular segments|Value of SNR (signal-noise ratio) of the vascular segments|Score of visual assessment of the CTA image quality|Score of diagnostic confidence of the CTA images|Injected dosage (ml) of the contrast media (CM)|Injection rate (ml/s) of the contrast media|Value of the Idoine delivery rate (IDR) (unit: mg I/s)|Value of the volume CT dose index (CTDIvol) (unit: mGy)|Value of the dose length product (DLP) (unit: mGy*cm)|Value of the effective dose (organ dose) (unit: mSv)|Heart rate of the patients who underwent CCTA before and after the CM injection|Presence of injection pain or discomfort of the patients (Yes/No)|Number of patients with adverse events / adverse drug reactions|Severity of injection pain or discomfort of the patients","Bayer","All","18 Years and older   (Adult, Older Adult)",,"1214","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","17811","July 26, 2016","July 28, 2017","October 11, 2017","July 21, 2016",,"October 2, 2018","Multiple Locations, China",,"https://ClinicalTrials.gov/show/NCT02840903"
278,"NCT02831478","Outdoor-Use Test for Sunscreen Products in Children Ages 3 to 9 Years Old",,"Completed","No Results Available","Sunscreening Agent","Drug: BAY987517|Drug: Sunscreen Lotion (RB# T78-190B)","Skin response to sun exposure according to the Skin Evaluation Response Scale from 0 to 3","Bayer","All","3 Years to 9 Years   (Child)","Not Applicable","98","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","18533","July 9, 2016","July 10, 2016","July 10, 2016","July 13, 2016",,"December 12, 2018","Saint Petersburg, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02831478"
279,"NCT02830477","Study Evaluating ""Real World"" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis","TAURUS","Recruiting","No Results Available","Hemophilia A, Congenital","Biological: Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973","Proportion of patients on 2x weekly prophylaxis|Proportion of patients on 3x weekly prophylaxis|Composite number of reported bleeds (total, spontaneous, joint and trauma)|Proportion of patients in predefined prophylaxis regimen per age group and per country|Overall prophylaxis dose IU/kg in patients per age group and per country|Number of physicians who selected the individual criteria as top 3 reason for the prophylaxis decision|Mean and median composite score for treatment satisfaction (Hemo-SAT)|Score for treatment adherence (VERITAS-PRO)|Incidence of adverse events (AEs) and serious adverse events (SAEs)|Incidence of events of special interest, such as inhibitors|The number of physicians used one or more predefined KOVALTRY PK parameter(s) to define the dose in clinical practice","Bayer","Male","Child, Adult, Older Adult",,"350","Industry","Observational","Observational Model: Other|Time Perspective: Prospective","18559|KV1601","October 14, 2016","December 1, 2020","June 30, 2022","July 13, 2016",,"January 13, 2020","Children's Rehabilitation Services/ University of South Alabama, Mobile, Alabama, United States|University of Colorado Hemophilia and Thrombosis Center, Aurora, Colorado, United States|University of Florida Health Cancer Center, Gainesville, Florida, United States|Nemours Children's Clinic - Division of Pediatric Hematology/Oncology - Jacksonsville, Jacksonville, Florida, United States|Nemours Children's Clinic - Pensacola, Pensacola, Florida, United States|Henry Ford Hospital Adult Hemophilia and Thrombosis Treatment Center, Detroit, Michigan, United States|Washington University Center for Bleeding and Blood Clotting Disorders, Saint Louis, Missouri, United States|Hemophilia Center of Western New York, Buffalo, New York, United States|East Carolina University - Brody School of Medicine, Greenville, North Carolina, United States|Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States|Children's Hospital at OU Medical Center, Oklahoma City, Oklahoma, United States|Intermountain Hemophilia & Thrombosis Center, Salt Lake City, Utah, United States|Comprehensive Center for Bleeding Disorders / Blood Center of Wisconsin, Milwaukee, Wisconsin, United States|Multiple Locations, Belgium|Multiple Locations, Canada|Multiple Locations, Colombia|Multiple Locations, France|Multiple Locations, Germany|Multiple Locations, Greece|Multiple Locations, Italy|Multiple Locations, Luxembourg|Multiple Locations, Netherlands|Multiple Locations, Slovakia|Multiple Locations, Slovenia|Multiple Locations, Spain|Multiple Locations, Switzerland|Multiple Locations, Taiwan",,"https://ClinicalTrials.gov/show/NCT02830477"
280,"NCT02826252","Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20)","VENTASWITCH","Completed","No Results Available","Hypertension, Pulmonary","Drug: Iloprost,(Ventavis, BAYQ6256)|Device: I-Neb AAD system","Number of inhalations on Iloprost 10 ug/mL and 20 ug/mL|Number of delivered doses (none/partial/full) on Iloprost 10 ug/mL and 20 ug/mL|Inhalation durations (min) per session on Iloprost 10 ug/mL and 20 ug/mL","Bayer","All","18 Years and older   (Adult, Older Adult)",,"64","Industry","Observational","Observational Model: Case-Crossover|Time Perspective: Other","18838","September 15, 2016","November 15, 2016","January 24, 2017","July 7, 2016",,"March 15, 2017","Many locations, Germany",,"https://ClinicalTrials.gov/show/NCT02826252"
281,"NCT02825160","Non-interventional, Postauthorization Safety Study of Ventavis for Pulmonary Arterial Hypertension (PAH)",,"Recruiting","No Results Available","Hypertension, Pulmonary","Drug: Ventavis (Iloprost, BAYQ6256)","Number of participants with treatment emergent adverse events (TEAE) of special interest.|Number of participants with adverse drug reaction|Change from baseline in Pulmonary Vascular Resistance (PVR) after 3 and 12 months|Change from baseline in 6-Minute Walking Distance after 3 and 12 months|Change from baseline in tricuspid regurgitation pressure gradient (TRPG) after 3 and 12 months|Change in blood concentration from baseline in brain natriuretic peptide / N-terminal pro-brain natriuretic peptide (BPN/NT-pro BNP) after 3 and 12 months.|Change from baseline in WHO functional class after 3 and 12 months|Time to Clinical Worsening","Bayer","All","Child, Adult, Older Adult",,"270","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","17941","August 1, 2016","March 31, 2022","September 27, 2023","July 7, 2016",,"January 21, 2020","Many Locations, Multiple Locations, Japan",,"https://ClinicalTrials.gov/show/NCT02825160"
282,"NCT02825030","Sun Protection Factor Assay (SPF Assay 18676)","SPF Assay","Completed","No Results Available","Sunscreening Agent","Drug: Coppertone (BAY 987516)","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18676","December 10, 2015","December 17, 2015","December 17, 2015","July 7, 2016",,"December 13, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02825030"
283,"NCT02825017","Sun Protection Factor Assay (SPF Assay 18677)","SPF Assay","Completed","No Results Available","Sunscreening Agent","Drug: Coppertone (BAY 987517)","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18677","December 10, 2015","December 17, 2015","December 17, 2015","July 7, 2016",,"December 13, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02825017"
284,"NCT02824042","Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole",,"Completed","No Results Available","Medical Oncology","Drug: Anetumab ravtansine (BAY94-9343)|Drug: Itraconazole","PR interval duration|QRS interval duration|QT interval duration|Abnormal T/U waves|Heart rate|Cycle 1+2 AUC (area under the plasma concentration vs. time curve from zero to infinity after single (first) dose) of BAY94-9343 analytes|Cycle 1+2 AUC(0-tlast) (AUC from time zero to the last data point > LLOQ [lower limit of quantification]) of BAY94-9343 analytes|Cycle 1+2 Cmax (maximum drug concentration in plasma after the first dose administration) of BAY94-9343 analytes|QTcF (QT interval, corrected for heart rate according to Fridericia's formula) interval duration|QTcP (QT interval, corrected for heart rate using a population-specific correction) interval duration|Incidence of serious adverse events|Incidence of non-serious adverse events|Incidence of positive anti-drug antibody titer|Incidence of neutralizing antibody titers|Cycle 3 Cmax,md (Cmax after multiple-dose administration) of BAY94-9343 analytes|Cycle 3 AUC(0-tlast)md (AUC(0-tlast) after multiple-dose administration) of BAY94-9343 analytes","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","63","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18329|2017-001978-42","September 12, 2016","June 27, 2018","August 5, 2019","July 6, 2016",,"September 19, 2019","UCLA-Santa Monica Medical Center, Santa Monica, California, United States|Henry Ford Health System, Detroit, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Mary Crowley Medical Research Center, Dallas, Texas, United States|Blacktown Cancer & Haematology Centre, Blacktown, New South Wales, Australia|Epworth HealthCare, Richmond, Victoria, Australia|CU Saint-Luc/UZ St-Luc, Bruxelles - Brussel, Belgium|UZ Gent, Gent, Belgium|Hôpital Henri Mondor, Creteil, France|Centre Georges Francois Leclerc Dijon, Dijon, France|Hôpital de la Timone - Marseille, Marseille, France|Nederlands Kanker Instituut, Amsterdam, Netherlands|VUmc, Amsterdam, Netherlands|Universitair Medisch Centrum St. Radboud, Nijmegen, Netherlands|Ciutat Sanitària i Universitaria de la Vall d'Hebron, Barcelona, Spain|Fundacion Jimenez Diaz (Clinica de la Concepcion), Madrid, Spain|Hospital Virgen de la Victoria, Málaga, Spain",,"https://ClinicalTrials.gov/show/NCT02824042"
285,"NCT02823509","Sun Protection Factor Assay","SPF Assay","Completed","No Results Available","Sunscreening Agent","Drug: Coppertone (BAY 987517)","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18668","December 10, 2015","December 14, 2015","December 14, 2015","July 6, 2016",,"December 12, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02823509"
286,"NCT02823496","18349-Human Photoallergy Test",,"Completed","No Results Available","Sunscreening Agents","Other: Sunscreen Lotion , BAY 987521|Other: Untreated skin","Intensity of skin reactions is evaluated by 5 point scale","Bayer","All","18 Years to 60 Years   (Adult)","Not Applicable","60","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","18349","November 2015","November 2015","November 2015","July 6, 2016",,"July 6, 2016","Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02823496"
287,"NCT02823483","18348-Human Phototoxicity Test",,"Completed","No Results Available","Sunscreening Agents","Other: Sunscreen Lotion (BAY987521)|Other: Untreated Skin","Intensity of skin reactions will be evaluated using the 5 point","Bayer","All","18 Years to 60 Years   (Adult)","Not Applicable","35","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","18348","November 2015","November 2015","November 2015","July 6, 2016",,"July 6, 2016","Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02823483"
288,"NCT02822339","Sun Protection Factor Assay","SPF Assay","Completed","No Results Available","Sunscreening Agents","Drug: BAY987517","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","5","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19007","June 23, 2016","June 29, 2016","June 29, 2016","July 4, 2016",,"December 13, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02822339"
289,"NCT02822313","Sun Protection Factor Assay","SPF Assay","Completed","No Results Available","Sunscreening Agent","Drug: Coppertone (BAY987518)","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18672","November 23, 2015","December 3, 2015","December 3, 2015","July 4, 2016",,"December 13, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02822313"
290,"NCT02822300","Sun Protection Factor Assay","SPF Assay","Completed","No Results Available","Sunscreening Agent","Drug: Coppertone (BAY987517)","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18671","November 20, 2015","November 30, 2015","November 30, 2015","July 4, 2016",,"December 13, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02822300"
291,"NCT02822274","Sun Protection Factor Assay","SPF Assay","Completed","No Results Available","Sunscreening Agent","Drug: Coppertone (BAY987517)","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18669","November 19, 2015","December 2, 2015","December 2, 2015","July 4, 2016",,"December 13, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02822274"
292,"NCT02822261","Sun Protection Factor Assay","SPF Assay","Completed","No Results Available","Sunscreening Agent","Drug: Coppertone (BAY987516)","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","11","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18667","November 18, 2015","December 1, 2015","December 1, 2015","July 4, 2016",,"December 12, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02822261"
293,"NCT02822248","Sun Protection Factor Assay","SPF Assay","Completed","No Results Available","Sunscreening Agent","Drug: Coppertone (BAY987516)","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18666","November 19, 2015","December 2, 2015","December 2, 2015","July 4, 2016",,"December 12, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02822248"
294,"NCT02821247","Prospective Observational Study to Assess Effectiveness of Intravitreal Aflibercept in Patients With Wet Macular Degeneration in Greece","PERSEUS-GR","Completed","No Results Available","Choroidal Neovascularization|Macular Degeneration","Drug: VEGF-Trap-Eye (BAY86-5321)","Mean change of visual acuity from baseline to 12 months|Change in best corrected visual acuity (BCVA) (with manifest refraction) from baseline at the 24-month timepoint|Change in visual acuity with glasses from baseline to the 24-month timepoint|Change in central retinal thickness (OCT measurement) at 12 and 24 months|Proportion of patients with no fluid at, 12 and 24 months|Total number of routine clinical evaluation (monitoring) visits at 12 and 24 months|Number of optical coherence tomography (OCT) assessments per patient|Number of visual acuity tests|Number of fundoscopy examinations|Total number of injection visits at 12 and 24 months|Number of combined visits (monitoring and injection) at 12 and 24 months|Number of fluorescein angiography (FA) tests / patient at 12 and 24 months|Number of indocyanine green angiography (ICGA) tests / patient at 12 and 24 months","Bayer|Regeneron Pharmaceuticals","All","50 Years to 100 Years   (Adult, Older Adult)",,"119","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","18033|SIRIUS/OS-CY-1668","July 1, 2016","July 10, 2019","December 13, 2019","July 1, 2016",,"January 10, 2020","Many Locations, Multiple Locations, Greece",,"https://ClinicalTrials.gov/show/NCT02821247"
295,"NCT02818998","Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME)","VIOLET","Completed","Has Results","Macular Edema","Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)","Mean Change From Baseline in Best Corrected Visual Acuity (BCVA)|Mean Change From Baseline in Central Retinal Thickness (CRT)|Number of Participants With Categorized Changes From Baseline in Best Corrected Visual Acuity (BCVA)|Number of Participants With Treatment-emergent Adverse Event (TEAE)|Mean Change From Baseline in Vital Signs","Bayer|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","463","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17613|2014-004938-25","November 16, 2016","November 13, 2018","September 24, 2019","June 30, 2016","December 4, 2019","December 4, 2019","Graz, Steiermark, Austria|Wien, Austria|Halifax, Nova Scotia, Canada|Mississauga, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Sherbrooke, Quebec, Canada|Hradec Kralove, Czechia|Praha 10, Czechia|Creteil Cedex, France|Darmstadt, Hessen, Germany|Frankfurt, Hessen, Germany|Marburg, Hessen, Germany|Göttingen, Niedersachsen, Germany|Bonn, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Dresden, Sachsen, Germany|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Pecs, Hungary|Roma, Lazio, Italy|Genova, Liguria, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Torino, Piemonte, Italy|Cagliari, Sardegna, Italy|Sassari, Sardegna, Italy|Firenze, Toscana, Italy|Padova, Veneto, Italy|Kaunas, Lithuania|Vilnius, Lithuania|Bydgoszcz, Poland|Gdansk, Poland|Katowice, Poland|Krakow, Poland|Lodz, Poland|Lublin, Poland|Poznan, Poland|Warszawa, Poland|Warszawa, Poland|Vila Franca de Xira, Lisboa, Portugal|Coimbra, Portugal|Leiria, Portugal|Lisboa, Portugal|Porto, Portugal|Bratislava, Slovakia|Bratislava, Slovakia|Nitra, Slovakia|Zilina, Slovakia|Zvolen, Slovakia|L'Hospitalet de Llobregat, Barcelona, Spain|Sant Cugat del Vallés, Barcelona, Spain|Albacete, Spain|Barcelona, Spain|Barcelona, Spain|Valencia, Spain|Bern, Switzerland|Genève, Switzerland|Southampton, Hampshire, United Kingdom|Sunderland, Tyne And Wear, United Kingdom|Leeds, West Yorkshire, United Kingdom|London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT02818998/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT02818998/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02818998"
296,"NCT02817100","First in Human Study to Investigate the Safety and Tolerability, Pharmacokinetics, Itraconazole Drug-drug-interaction and Food Effect of BAY1817080",,"Completed","No Results Available","Clinical Trials, Phase I as Topic","Drug: BAY1817080|Drug: Placebo|Drug: Itraconazole","Frequency of treatment-emergent adverse events|Severity of treatment-emergent adverse events","Bayer","Male","18 Years to 45 Years   (Adult)","Phase 1","88","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","18183|2016-000253-12","July 22, 2016","May 11, 2017","August 23, 2017","June 29, 2016",,"September 6, 2017","CRS Clinical Research Services Berlin GmbH, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT02817100"
297,"NCT02815241","Sun Protection Factor Assay","SPF Assay","Completed","No Results Available","Sunscreening Agents","Drug: BAY987517","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","5","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19010","June 29, 2016","July 1, 2016","July 1, 2016","June 28, 2016",,"December 13, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02815241"
298,"NCT02815228","Sun Protection Factor Assay (SPF Assay 19009)",,"Completed","No Results Available","Sunscreening Agents","Drug: BAY987517","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","5","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19009","June 28, 2016","June 30, 2016","June 30, 2016","June 28, 2016",,"December 13, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02815228"
299,"NCT02815202","Sun Protection Factor Assay (SPF Assay 19008)",,"Completed","No Results Available","Sunscreening Agents","Drug: BAY987517","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","5","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19008","June 28, 2016","June 30, 2016","June 30, 2016","June 28, 2016",,"December 13, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02815202"
300,"NCT02811692","Study for Collection of Aflibercept Data in Routine Practice","CODEX","Completed","No Results Available","Eye Diseases","Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)","Change in Best Corrected Visual Acuity (BCVA) using Early Treatment Diabetic Retinopathy Study (ETDRS) or converted to ETDRS.|Change in Central retinal thickness (CRT) as measured by Optical Coherence Tomography (OCT).|Number of injections|Interval (days) between injections per disease|Presence of pigment epithelial detachment (PED) (Y/N)|Proportion of patients with no fluid determined by OCT (absence of fluid includes all types of fluid and location of fluid as determined by the treating ophthalmologist)|Type of adjunctive therapies (ie focal laser, steroids etc.)|Change in score of diabetic retinopathy as determined by treating ophthalmologist","Bayer|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)",,"425","Industry","Observational","Observational Model: Other|Time Perspective: Retrospective","17867|DBOX 2014/00498","September 30, 2016","November 27, 2017","November 27, 2017","June 23, 2016",,"July 2, 2019","Multiple Locations, France",,"https://ClinicalTrials.gov/show/NCT02811692"
301,"NCT02803437","Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases",,"Active, not recruiting","No Results Available","Prostatic Neoplasms, Castration-Resistant","Drug: Radium-223 dichloride (Xofigo, BAY 88-8223)","Number of adverse events as a measure of safety|Number of adverse drug reactions as a measure of safety|Change in laboratory findings (e.g. ALP, bone markers)|Change in analgesic use as a surrogate of pain status|Number of patients with bone fractures|Survival rate|Post-treatment information","Bayer","Male","Child, Adult, Older Adult",,"334","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","18212","July 21, 2016","November 30, 2020","May 31, 2021","June 17, 2016",,"January 9, 2020","Multiple Locations, Japan",,"https://ClinicalTrials.gov/show/NCT02803437"
302,"NCT02803320","To Assess the Safety of a Sunscreen Product",,"Completed","No Results Available","Sunscreening Agents","Drug: SPF 50 Y65 110 (BAY 987516)","Dermatologist´s subjective and objective assessments of potential Adverse events|Final Skin Evaluation","Bayer","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","107","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Other","18309","May 27, 2015","May 29, 2015","May 31, 2015","June 16, 2016",,"December 12, 2018","Saint Petersburg, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02803320"
303,"NCT02803099","Sun Protection Factor Assay","SPF Assay","Completed","No Results Available","Sunscreening Agent","Drug: Coppertone (BAY 987517)","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18657","November 18, 2015","November 20, 2015","November 20, 2015","June 16, 2016",,"December 12, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02803099"
304,"NCT02803060","Sun Protection Factor Assay","SPF Assay","Completed","No Results Available","Sunscreening Agent","Drug: Coppertone (BAY987516)","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","15","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18633","November 9, 2015","November 17, 2015","November 17, 2015","June 16, 2016",,"December 12, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02803060"
305,"NCT02803047","Sun Protection Factor Assay","SPF Assay","Completed","No Results Available","Sunscreening Agent","Drug: Coppertone (BAY987516)","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","11","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18632","November 9, 2015","November 18, 2015","November 18, 2015","June 16, 2016",,"December 12, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02803047"
306,"NCT02803034","Sun Protection Factor Assay","SPF Assay","Completed","No Results Available","Sunscreening Agent","Drug: Coppertone (BAY987516)","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","15","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18631","November 9, 2015","November 18, 2015","November 18, 2015","June 16, 2016",,"December 12, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02803034"
307,"NCT02803021","Sun Protection Factor Assay","SPF Assay","Completed","No Results Available","Sunscreening Agent","Drug: Coppertone (BAY987517)","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18630","October 29, 2015","November 5, 2015","November 5, 2015","June 16, 2016",,"December 12, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02803021"
308,"NCT02803008","Sun Protection Factor Assay","SPF Assay","Completed","No Results Available","Sunscreening Agent","Drug: Coppertone (BAY987517)","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18629","October 29, 2015","November 5, 2015","November 5, 2015","June 16, 2016",,"December 12, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02803008"
309,"NCT02802930","Test the Phototoxicity of Sunscreen Products",,"Completed","No Results Available","Sunscreen Agents","Drug: SPF 50 Y65 110 (BAY987519)|Drug: SPF 50 Y51 002 (BAY987519)|Drug: SPF 15 V27 104 (BAY987519)|Drug: Sodium chloride [NaCl]","Skin irritation|Number of adverse event as a measure of safety and tolerability","Bayer","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","32","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Other","18287","April 20, 2015","April 26, 2015","April 26, 2015","June 16, 2016",,"December 12, 2018","Pinellas Park, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02802930"
310,"NCT02802917","To Evaluate Eye Installation-Tear Free",,"Completed","No Results Available","Sunscreening Agents","Drug: SPF 50 Y49 091 (BAY 987516)|Drug: SPF 50 X15 158 (BAY 987516)|Drug: SPF 50 X15 160 (BAY 987516)|Drug: SPF 50 X57 162 (BAY 987516)|Other: J & J baby shampoo, X46 046 (control)","Subjective discomfort|Objective lacrimation|Objective conjunctival inflammation|Objective cornea and iris inflammation","Bayer","All","18 Years to 60 Years   (Adult)","Not Applicable","83","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other","18271","May 15, 2015","May 24, 2015","May 24, 2015","June 16, 2016",,"December 12, 2018","Saint Petersburg, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02802917"
311,"NCT02801929","18670 - Sun Protection Factor Assay","SPF Assay","Completed","No Results Available","Sunscreening Agent","Drug: Coppertone (BAY987518)","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18670","November 20, 2015","November 30, 2015","November 30, 2015","June 16, 2016",,"December 13, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02801929"
312,"NCT02800642","Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO","CENTERA","Completed","No Results Available","Central Retinal Vein Occlusion","Drug: Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)","The proportion of subjects who gain ≥ 15 letters in best corrected visual acuity on the early treatment diabetic retinopathy score chart|The proportion of subjects with a mean treatment interval between injections of ≥ 8 weeks|The change in best corrected visual acuity as measured by the early treatment diabetic retinopathy letter score|The change in central retinal thickness|The number of injections|The mean treatment interval between injections|The proportion of subjects who gain ≥ 15 letters in best corrected visual acuity on the early treatment diabetic retinopathy chart|The change in retinal perfusion (FA/FP) status|Number and severity of ocular safety events detected by tonometry, indirect ophthalmoscopy, slit lamp biomicroscopy, and gonioscopy","Bayer|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 4","162","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17514|2014-003193-17","June 10, 2016","July 31, 2019","July 31, 2019","June 15, 2016",,"August 5, 2019","Albury, New South Wales, Australia|Sydney, New South Wales, Australia|Parramatta, Australia|Calgary, Alberta, Canada|Hamilton, Ontario, Canada|London, Ontario, Canada|Boisbriand, Quebec, Canada|Sherbrooke, Quebec, Canada|Quebec, Canada|Aalborg, Denmark|Glostrup, Denmark|Bordeaux, France|Dijon Cedex, France|Lyon, France|Freiburg, Baden-Württemberg, Germany|Heidelberg, Baden-Württemberg, Germany|Karlsruhe, Baden-Württemberg, Germany|Augsburg, Bayern, Germany|Göttingen, Niedersachsen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Hannover, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Leipzig, Sachsen, Germany|Roma, Lazio, Italy|Roma, Lazio, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Ancona, Marche, Italy|Pisa, Toscana, Italy|Padova, Veneto, Italy|Oviedo, Asturias, Spain|Sant Cugat del Vallés, Barcelona, Spain|Viladecans, Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Sunderland, Tyne And Wear, United Kingdom|Bradford, West Yorkshire, United Kingdom|Bristol, United Kingdom|Colchester, United Kingdom|Liverpool, United Kingdom|Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02800642"
313,"NCT02799602","ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer","ARASENS","Active, not recruiting","No Results Available","Prostatic Neoplasms","Drug: BAY1841788 / darolutamide (ODM-201)|Drug: Standard ADT (androgen deprivation therapy)|Drug: Docetaxel|Drug: Placebo","Overall survival|Time to castration resistant prostate cancer|Time to initiation of subsequent antineoplastic therapy|Symptomatic skeletal event free survival (SSE-FS)|Time to first symptomatic skeletal event (SSE)|Time to initiation of opioid use|Time to pain progression|Time to worsening of physical symptoms of disease|Number of participants with adverse events as a measure of safety and tolerability","Bayer|Orion Corporation, Orion Pharma","Male","18 Years and older   (Adult, Older Adult)","Phase 3","1303","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","17777|2015-002590-38","November 30, 2016","August 1, 2022","August 1, 2022","June 15, 2016",,"January 18, 2020","Chandler, Arizona, United States|Tucson, Arizona, United States|Beverly Hills, California, United States|Duarte, California, United States|Los Angeles, California, United States|Stanford, California, United States|Washington, District of Columbia, United States|Boca Raton, Florida, United States|Gainesville, Florida, United States|Tampa, Florida, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Peoria, Illinois, United States|Louisville, Kentucky, United States|New Orleans, Louisiana, United States|Baltimore, Maryland, United States|Towson, Maryland, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Detroit, Michigan, United States|Billings, Montana, United States|Omaha, Nebraska, United States|Lebanon, New Hampshire, United States|Englewood, New Jersey, United States|Hackensack, New Jersey, United States|Voorhees, New Jersey, United States|Albuquerque, New Mexico, United States|Bronx, New York, United States|Buffalo, New York, United States|New York, New York, United States|Poughkeepsie, New York, United States|Rochester, New York, United States|Winston-Salem, North Carolina, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Columbus, Ohio, United States|Kettering, Ohio, United States|Oklahoma City, Oklahoma, United States|Bala-Cynwyd, Pennsylvania, United States|Camp Hill, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Charleston, South Carolina, United States|Charleston, South Carolina, United States|Greenville, South Carolina, United States|Myrtle Beach, South Carolina, United States|North Charleston, South Carolina, United States|Dallas, Texas, United States|Temple, Texas, United States|Salt Lake City, Utah, United States|Charlottesville, Virginia, United States|Fairfax, Virginia, United States|Richmond, Virginia, United States|Everett, Washington, United States|Milwaukee, Wisconsin, United States|Randwick, New South Wales, Australia|Sydney, New South Wales, Australia|Adelaide, South Australia, Australia|Melbourne, Victoria, Australia|Kurralta Park, Australia|Wilrijk, Antwerpen, Belgium|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Charleroi, Belgium|Gent, Belgium|Namur, Belgium|Salvador, Bahia, Brazil|Cachoeiro de Itapemirim, Espírito Santo, Brazil|Curitiba, Parana, Brazil|Natal, Rio Grande Do Norte, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|Santo André, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|Rio de Janeiro, Brazil|Rio de Janeiro, Brazil|Gabrovo, Bulgaria|Pleven, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Vratsa, Bulgaria|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Hefei, Anhui, China|Xiamen, Fujian, China|Guangzhou, Guangdong, China|Shijiazhuang, Hebei, China|Zhengzhou, Henan, China|Wuhan, Hubei, China|Wuhan, Hubei, China|Changsha, Hunan, China|Nanjing, Jiangsu, China|Nanjing, Jiangsu, China|Nanchang, Jiangxi, China|Changchun, Jilin, China|Shengyang, Liaoning, China|Shenyang, Liaoning, China|Xi'an, Shaanxi, China|Jinan, Shandong, China|Jinan, Shandong, China|Yantai, Shandong, China|Hangzhou, Zhejiang, China|Hangzhou, Zhejiang, China|Wenzhou, Zhejiang, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Chongqing, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|Tianjin, China|Tianjin, China|Brno, Czechia|Brno, Czechia|Praha 10, Czechia|Praha 2, Czechia|Praha 2, Czechia|Praha 5, Czechia|Praha 8, Czechia|Helsinki, Finland|Jyväskylä, Finland|Kuopio, Finland|Mikkeli, Finland|Oulu, Finland|Tampere, Finland|Turku, Finland|Angers Cedex, France|Besancon, France|Bordeaux Cedex, France|Brest, France|Clermont-ferrand, France|Creteil, France|Marseille, France|Montpellier Cedex, France|Nancy, France|Pierre Benite, France|Poitiers, France|Pontoise, France|REIMS cedex, France|Saint Herblain Cedex, France|Saint-gregoire, France|Strasbourg, France|Villejuif Cedex, France|Freiburg, Baden-Württemberg, Germany|Reutlingen, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|Ulm, Baden-Württemberg, Germany|Erlangen, Bayern, Germany|Rostock, Mecklenburg-Vorpommern, Germany|Braunschweig, Niedersachsen, Germany|Münster, Nordrhein-Westfalen, Germany|Jena, Thüringen, Germany|Berlin, Germany|Magdeburg, Germany|Beer Sheva, Israel|Haifa, Israel|Holon, Israel|Jerusalem, Israel|Petah Tikva, Israel|Tel Aviv, Israel|Zefat, Israel|Zerifin, Israel|Bologna, Emilia-Romagna, Italy|Parma, Emilia-Romagna, Italy|Roma, Lazio, Italy|Milano, Lombardia, Italy|Novara, Piemonte, Italy|Torino, Piemonte, Italy|Trento, Trentino-Alto Adige, Italy|Padova, Veneto, Italy|Verona, Veneto, Italy|Nagoya, Aichi, Japan|Hirosaki, Aomori, Japan|Asahi, Chiba, Japan|Kashiwa, Chiba, Japan|Sakura, Chiba, Japan|Matsuyama, Ehime, Japan|Sapporo, Hokkaido, Japan|Kobe, Hyogo, Japan|Kanazawa, Ishikawa, Japan|Kanazawa, Ishikawa, Japan|Kita, Kagawa, Japan|Yokohama, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Tsu, Mie, Japan|Sendai, Miyagi, Japan|Kashihara, Nara, Japan|Osakasayama, Osaka, Japan|Suita, Osaka, Japan|Hamamatsu, Shizuoka, Japan|Shimotsuke, Tochigi, Japan|Utsunomiya, Tochigi, Japan|Bunkyo-ku, Tokyo, Japan|Bunkyo-ku, Tokyo, Japan|Bunkyo-ku, Tokyo, Japan|Koto-ku, Tokyo, Japan|Meguro-ku, Tokyo, Japan|Minato-ku, Tokyo, Japan|Mitaka, Tokyo, Japan|Nakano-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Yonago, Tottori, Japan|Ube, Yamaguchi, Japan|Chiba, Japan|Chiba, Japan|Fukuoka, Japan|Gifu, Japan|Kumamoto, Japan|Miyazaki, Japan|Nagasaki, Japan|Okayama, Japan|Osaka, Japan|Osaka, Japan|Tokushima, Japan|Wakayama, Japan|Donggu,, Gwangju Gwang''yeogsi, Korea, Republic of|Seongnam-si, Gyeonggido, Korea, Republic of|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Busan, Korea, Republic of|Daegu, Korea, Republic of|Gyeonggi-do, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Ciudad de Mexico, Distrito Federal, Mexico|Mexico, Distrito Federal, Mexico|Cuernavaca, Morelos, Mexico|Monterrey, Nuevo Leon, Mexico|Mazatlán, Sinaloa, Mexico|Querétaro, Mexico|Amsterdam, Netherlands|Amsterdam, Netherlands|Den Haag, Netherlands|Dordrecht, Netherlands|Heerlen, Netherlands|Hilversum, Netherlands|Hoofddorp, Netherlands|Tilburg, Netherlands|Lodz, Poland|Lublin, Poland|Rybnik, Poland|Siedlce, Poland|Waliszew, Poland|Warszawa, Poland|Barnaul, Russian Federation|Chelyabinsk, Russian Federation|Chelyabinsk, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Novosibirsk, Russian Federation|Omsk, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|Sabadell, Barcelona, Spain|Palma de Mallorca, Illes Baleares, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Cáceres, Spain|Córdoba, Spain|Lugo, Spain|Madrid, Spain|Madrid, Spain|Málaga, Spain|Valencia, Spain|Göteborg, Sweden|Lund, Sweden|Stockholm, Sweden|Umeå, Sweden|Uppsala, Sweden|Kaohsiung, Taiwan|Taichung, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Colchester, Essex, United Kingdom|Romford, Essex, United Kingdom|Middlesborough, North Yorkshire, United Kingdom|Belfast, United Kingdom|Glasgow, United Kingdom|London, United Kingdom|London, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02799602"
314,"NCT02788409","Incidence of Second Primary Malignancies in Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the US",,"Completed","No Results Available","Prostatic Neoplasms","Other: Not applicable for study","Incidence rate of second primary malignancy|Incidence rates of skeletal-related events|Proportion with a history of bone metastasis at cohort entry|Proportion who met the definition of castration based solely on Part D data|Overall survival","Bayer|RTI Health Solutions","Male","65 Years and older   (Older Adult)",,"2234","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","18673","May 15, 2016","May 9, 2018","May 9, 2018","June 2, 2016",,"May 8, 2019","Waltham, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02788409"
315,"NCT02788162","18616 - Sun Protection Factor Assay","SPF Assay","Completed","No Results Available","Sunscreening Agent","Drug: Coppertone (BAY 987517)","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18616","October 19, 2015","October 21, 2015","October 21, 2015","June 2, 2016",,"December 12, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02788162"
316,"NCT02784717","Xarelto on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in China: A Non-interventional Study","XASSURE","Completed","No Results Available","Stroke","Drug: Rivaroxaban (Xarelto, BAY 59-7939)","Number of Major bleeding events|Number of Symptomatic thromboembolic events|Number of Non-major bleeding|Treatment satisfaction questionnaire|Adverse event and serious adverse event percentage in the different atrial fibrillation risk factor categories|Number of each reason for any switch from or interruption of rivaroxaban treatment","Bayer|Janssen Scientific Affairs, LLC","All","18 Years and older   (Adult, Older Adult)",,"3064","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","16819|XA1207CN","May 11, 2016","February 21, 2019","September 24, 2019","May 27, 2016",,"September 27, 2019","HangZhou, China",,"https://ClinicalTrials.gov/show/NCT02784717"
317,"NCT02779842","Sun Protection Factor - Assay","SPF Assay","Completed","No Results Available","Sunscreening Agent","Drug: Coppertone (BAY 987517)","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","6","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18431","July 29, 2015","August 11, 2015","August 11, 2015","May 20, 2016",,"December 12, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02779842"
318,"NCT02779829","18432-Sun Protection Factor Assay","SPF Assay","Completed","No Results Available","Sunscreening Agent","Drug: Coppertone (BAY 987517)","Minimal Erythema Dose (MED)|Minimal Persistent Pigment DArkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","13","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18432","July 29, 2015","September 1, 2015","September 1, 2015","May 20, 2016",,"December 12, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02779829"
319,"NCT02779270","Test the Outdoor Usage for Sunscreen Products in Female Adults",,"Completed","No Results Available","Sunscreening Agents","Drug: BAY987518|Drug: Sunscreen Lotion (U77-030 Control)","Skin response to sun exposure according to the Skin Evaluation Response Scale from 0 to 3","Bayer","Female","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","105","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other","18318","September 26, 2015","September 27, 2015","September 27, 2015","May 20, 2016",,"December 12, 2018","Saint Petersburg, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02779270"
320,"NCT02776852","18519 - Sun Protection Factor Assay","SPF Assay","Completed","No Results Available","Sunscreening Agent","Drug: Coppertone (BAY987517)","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18519","August 19, 2015","August 28, 2015","August 28, 2015","May 18, 2016",,"December 12, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02776852"
321,"NCT02776501","18572 - Sun Protection Factor Assay","SPF Assay","Completed","No Results Available","Sunscreening Agent","Drug: Coppertone (BAY987521)","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18572","September 24, 2015","September 29, 2015","September 29, 2015","May 18, 2016",,"December 12, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02776501"
322,"NCT02774252","18475 - Sun Protection Factor Assay","SPF Assay","Completed","No Results Available","Sunscreening Agents","Drug: BAY987521","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","13","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18475","August 13, 2015","September 3, 2015","September 3, 2015","May 17, 2016",,"December 12, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02774252"
323,"NCT02766283","Observational Study on Hypothyroidism in Young Children Following Iodine Contrast Exposure",,"Completed","Has Results","Hypothyroidism","Drug: iodinated contrast agents","Number of Pediatric Patients With Detected Hypothyroidism After Iodinated Contrast Exposure in a Routine Clinical Practice Setting|Baseline Characteristics (Sex) of the Cases With Hypothyroidism and of the Rest of the Cohort|Baseline Characteristics (Age) of the Cases With Hypothyroidism and of the Rest of the Cohort|Baseline Characteristics (Weight) of the Cases With Hypothyroidism and of the Rest of the Cohort|Baseline Characteristics (Comorbidity) of the Cases With Hypothyroidism and of the Rest of the Cohort|Baseline Characteristics (Sum of Examinations) in Cases With an Indication of Hypothyroidism and Cases Without|Baseline Characteristics (Type of 1st Examination) in Cases With an Indication of Hypothyroidism and Cases Without|Baseline Characteristics (Type of 2nd Examination) in Cases With an Indication of Hypothyroidism and Cases Without|Baseline Characteristics (Time Between Examinations) in Cases With an Indication of Hypothyroidism and Cases Without|Time-relation Between Iodine Contrast Exposure and Diagnosis of Hypothyroidism|The Duration of Hypothyroidism Episode in the ""Probable Iodine Induced"" Category","Bayer","All","up to 3 Years   (Child)",,"843","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","18614","June 30, 2016","August 30, 2016","August 30, 2016","May 9, 2016","March 26, 2018","March 26, 2018","Multiple Locations, Israel",,"https://ClinicalTrials.gov/show/NCT02766283"
324,"NCT02760576","18612 - Sun Protection Factor Assay",,"Completed","No Results Available","Sunscreening Agents","Drug: BAY 987521","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18612","October 14, 2015","October 16, 2015","October 16, 2015","May 3, 2016",,"December 12, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02760576"
325,"NCT02760563","18611 - Sun Protection Factor Assay",,"Completed","No Results Available","Sunscreening Agents","Drug: BAY 987517","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18611","October 19, 2015","October 22, 2015","October 22, 2015","May 3, 2016",,"December 12, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02760563"
326,"NCT02759419","A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.","RIALTO","Recruiting","No Results Available","Hypertension, Pulmonary","Drug: Adempas (Riociguat, BAY63-2521)","Number of patients with treatment-emergent adverse events (TEAEs) as measure of safety and tolerability","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 4","25","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18694|2016-000501-36","June 16, 2016","December 28, 2021","December 28, 2021","May 3, 2016",,"January 18, 2020","Besancon, France|Brest, France|Le Kremlin Bicetre Cedex, France|Lille Cedex, France|Rouen, France|Roma, Lazio, Italy|Pavia, Lombardia, Italy|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Krakow, Poland|Lodz, Poland|Otwock, Poland|Wroclaw, Poland|Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT02759419"
327,"NCT02757014","18613 - Sun Protection Factor Assay","SPF Assay","Completed","No Results Available","Sunscreening Agent","Drug: Coppertone (BAY987517)","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18613","October 19, 2015","October 22, 2015","October 22, 2015","April 29, 2016",,"December 12, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02757014"
328,"NCT02756988","18615 - Sun Protection Factor Assay","SPF Assay","Completed","No Results Available","Sunscreening Agent","Drug: Coppertone (BAY987704)","Minimal Erythema Dose (MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18615","October 19, 2015","October 21, 2015","October 21, 2015","April 29, 2016",,"December 12, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02756988"
329,"NCT02754102","Human Phototoxicity Test",,"Completed","No Results Available","Sunscreening Agents","Other: Sunscreen Spray- Liquid (BAY987516)","Intensity of skin reactions will be evaluated using the 5 point grading scale","Bayer","All","18 Years to 60 Years   (Adult)","Not Applicable","35","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Other","18775","May 3, 2016","May 6, 2016","May 6, 2016","April 28, 2016",,"May 1, 2017","Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02754102"
330,"NCT02751918","Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer",,"Completed","No Results Available","Ovarian Neoplasms","Drug: Anetumab ravtansine (BAY94-9343)|Drug: Pegylated Liposomal Doxorubicin","Maximum tolerated dose (MTD) of Anetumab ravtansine in combination with pegylated liposomal doxorubicin when given every three weeks|Incidence of serious and non-serious adverse events (AEs)|AUC (area under the plasma concentration vs. time curve from zero to infinity after single (first) dose) of Anetumab ravtansine analytes (Antibody drug conjugates, Total Antibody, metabolites DM4, and DM4-Me)|AUC(0-tlast) (AUC from time zero to the last data point > lower limit of quantification) of Anetumab ravtansine analytes (Antibody drug conjugates, Total Antibody, metabolites DM4, and DM4-Me)|Cmax (maximum drug concentration in plasma after first dose administration) of Anetumab ravtansine analytes (Antibody drug conjugates, Total Antibody, metabolites DM4, and DM4-Me)|AUC of total pegylated liposomal doxorubicin|AUC(0-tlast) of total pegylated liposomal doxorubicin|Cmax of total pegylated liposomal doxorubicin|Incidence of patients with CR, PR, SD or PD according to RECIST 1.1|Incidence of positive anti-drug antibody titer|Incidence of positive neutralizing antibody titer","Bayer","Female","18 Years and older   (Adult, Older Adult)","Phase 1","65","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18326","June 8, 2016","August 23, 2019","October 31, 2019","April 26, 2016",,"November 22, 2019","Rocky Mountain Cancer Centers, Aurora, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Oklahoma University Health Science Center, Oklahoma City, Oklahoma, United States|UZ Leuven Gasthuisberg, Leuven, Belgium|The Institute of Oncology, Chisinau, Moldova, Republic of|Ciutat Sanitària i Universitaria de la Vall d'Hebron, Barcelona, Spain|Clinica Universidad de Navarra CUN en Madrid, Madrid, Spain|Clínica Universidad de Navarra CUN, Pamplona, Spain|Instituto Valenciano de Oncología, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT02751918"
331,"NCT02751567","18776 - Human Photoallergy Test",,"Withdrawn","No Results Available","Sunscreening Agents","Other: BAY987516|Other: Untreated skin","Intensity of skin reactions is evaluated by 5 point scale","Bayer","All","18 Years to 60 Years   (Adult)","Not Applicable","0","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Participant)","18776","May 2016","June 2016","June 2016","April 26, 2016",,"May 23, 2016",,,"https://ClinicalTrials.gov/show/NCT02751567"
332,"NCT02751541","Human Phototoxicity Test",,"Completed","No Results Available","Sunscreening Agents","Drug: Sunscreen Sport Spray (BAY987519)|Other: Untreated Skin","Intensity of skin reactions will be evaluated using 5 point grading scale.","Bayer","All","18 Years to 60 Years   (Adult)","Not Applicable","35","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18849","May 2, 2016","May 6, 2016","May 6, 2016","April 26, 2016",,"December 13, 2018","Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02751541"
333,"NCT02751515","Human Photoallergy Test",,"Completed","No Results Available","Sunscreening Agents","Other: Bain De Soliel - Solid|Other: Untreated skin","Intensity of skin reactions is evaluated by 5 point scale","Bayer","All","18 Years to 60 Years   (Adult)","Not Applicable","54","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","18601","May 2016","July 2016","July 2016","April 26, 2016",,"July 26, 2016","Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02751515"
334,"NCT02751489","Human Phototoxicity Test",,"Completed","No Results Available","Sunscreening Agents","Other: Bain De Soliel - Solid","Intensity of skin reactions is evaluated by 5 point scale","Bayer","All","18 Years to 60 Years   (Adult)","Not Applicable","35","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","18600","May 2016","May 2016","May 2016","April 26, 2016",,"June 17, 2016","Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02751489"
335,"NCT02751463","18850 - Human Photoallergy Test",,"Completed","No Results Available","Sunscreening Agents","Drug: Sunscreening Sport Spray Rest (BAY987519)|Other: Untreated skin","Intensity of skin reactions is evaluated by 5 point grading scale","Bayer","All","18 Years to 60 Years   (Adult)","Not Applicable","54","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","18850","May 9, 2016","July 1, 2016","July 1, 2016","April 26, 2016",,"December 13, 2018","Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02751463"
336,"NCT02751372","18794 - Human Photo Toxicity Test",,"Completed","No Results Available","Sunscreening Agents","Drug: BAY 987517|Other: Untreated Skin","Intensity of skin reactions will be evaluated using 5 point grading scale","Bayer","All","18 Years to 60 Years   (Adult)","Not Applicable","35","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","18794","May 2, 2016","May 6, 2016","May 6, 2016","April 26, 2016",,"December 13, 2018","Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02751372"
337,"NCT02750488","18793 - Human Photoallergy Test",,"Completed","No Results Available","Sunscreening Agents","Drug: BAY987517|Other: Untreated skin","Intensity of skin reactions is evaluated by 5 point scale","Bayer","All","18 Years to 60 Years   (Adult)","Not Applicable","54","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Other","18793","May 9, 2016","July 1, 2016","July 1, 2016","April 25, 2016",,"December 13, 2018","Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02750488"
338,"NCT02750475","Human Phototoxicity Test",,"Completed","No Results Available","Sunscreening Agents","Drug: Sunscreen Sport Lotion (BAY987516)|Other: Untreated Skin","Intensity of skin reactions will be evaluated using the 5 point grading scale","Bayer","All","18 Years to 60 Years   (Adult)","Not Applicable","35","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","18851","May 2, 2016","May 6, 2016","May 6, 2016","April 25, 2016",,"December 13, 2018","Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02750475"
339,"NCT02750449","Human Photoallergy Test",,"Completed","No Results Available","Sunscreening Agents","Drug: Sun screening Sport Lotion, (BAY987516)|Other: Untreated skin","Intensity of skin reactions is evaluated by 5 point grading scale","Bayer","All","18 Years to 60 Years   (Adult)","Not Applicable","54","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Other","18852","May 9, 2016","July 1, 2016","July 1, 2016","April 25, 2016",,"December 13, 2018","Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02750449"
340,"NCT02749396","EPID Multiple Sclerosis Pregnancy Study",,"Completed","No Results Available","Multiple Sclerosis","Drug: Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG|Drug: Extavia (interferon beta-1b), Novartis Pharma AG|Drug: Rebif (interferon beta-1a), Merck Serono Europe Ltd|Drug: Plegridy (peginterferon beta-1a), Biogen Idec Ltd|Drug: Avonex (interferon beta-1a), Biogen Idec Ltd|Drug: MSDMDs other than Betaseron (Interferon beta-1b, BAY86-5046)|Other: No MSDMDs therapy (control)","Serious adverse pregnancy outcome due to different regimes of IFN-β exposure defined as a composite endpoint including presence of elective Termination of Pregnancy due to Foetal Anomaly (TOPFA), Major Congenital Anomaly (MCA) or stillbirth|Elective TOPFA for other reasons than IFN-β exposure|Elective termination for other reasonsthan IFN-β exposure|Stillbirth due to different regimes of IFN-β exposure|Live birth while different regimes of IFN-β exposure|MCA due to different regimes of IFN-β exposure|Comparison of the prevalence of serious adverse pregnancy outcome due to different regimes of IFN-β exposure defined as a composite endpoint including elective TOPFA, MCA or stillbirth|Comparison of the prevalence of elective termination for other reasons than due to different regimes of IFN-β exposure|Comparison of the prevalence of stillbirth due to different regimes of IFN-β exposure|Comparison of the prevalence of live birth due to different regimes of IFN-β exposure|Comparison of the prevalence of MCA due to different regimes of IFN-β exposure|Comparison of the prevalence of Elective TOPFA due to different regimes of IFN-β exposure|Comparison of the prevalence of ectopic pregnancies due to different regimes of IFN-β exposure|Comparison of the prevalence of spontaneous abortions due to different regimes of IFN-β exposure|Prevalence of elective TOPFA stratified by specific patient characteristics|Prevalence of stillbirth stratified by specific patient characteristics|Prevalence of live birth stratified by specific patient characteristics|Prevalence of MCA stratified by specific patient characteristics","Bayer|EPID Research|Biogen|Merck Serono Europe Ltd|Novartis Pharmaceuticals","Female","Child, Adult, Older Adult",,"2089","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","18219","May 2, 2016","August 14, 2018","August 14, 2018","April 25, 2016",,"August 14, 2019","Many locations, Multiple Locations, Finland",,"https://ClinicalTrials.gov/show/NCT02749396"
341,"NCT02746081","Phase I Study of BAY1436032 in IDH1-mutant Advanced Solid Tumors",,"Active, not recruiting","No Results Available","Solid Tumors","Drug: BAY1436032","Maximum tolerated dose (MTD) of BAY1436032|Number of participants with adverse events as a measure of safety and tolerability of BAY1436032|Recommended Phase II Dose (RP2D) of BAY1436032|Objective response rate (partial and complete response)|Duration of response|Progression free survival (PFS)|Cmax of BAY1436032|AUC(0-12) of BAY1436032|AUC(0-24) of BAY1436032|C(max,md) of BAY1436032|AUC(0-12)md of BAY1436032|Change of 2-hydroxyglutarate (2-HG) concentration in plasma from baseline|Change of 2-hydroxyglutarate (2-HG) concentration in urine from baseline","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","81","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18239|2015-003483-37","May 26, 2016","November 8, 2018","June 30, 2020","April 21, 2016",,"January 18, 2020","Los Angeles, California, United States|Santa Monica, California, United States|Houston, Texas, United States|Charlottesville, Virginia, United States|Copenhagen, Denmark|Heidelberg, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|München, Bayern, Germany|Frankfurt, Hessen, Germany|Essen, Nordrhein-Westfalen, Germany|Nagoya, Aichi, Japan|Kashiwa-shi, Chiba, Japan|Chuo-ku, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT02746081"
342,"NCT02745743","Phase I Trial of BAY1251152 for Advanced Blood Cancers",,"Completed","No Results Available","Hematologic Neoplasms","Drug: BAY1251152","Maximum tolerated dose(MTD)|Recommended Phase 2 dose (RP2D)|Number of adverse events (AE)|Pharmacokinetics (PK) is determined by maximum concentration (Cmax)|Pharmacokinetics (PK) is determined by Area Under concentration versus time Curve (AUC)|Response assessment of BAY 1251152 in hematological malignancies based on the internationally accepted criteria for the specific hematological malignancy which patient is suffering from","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","21","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18117|2015-005122-18","June 17, 2016","August 3, 2018","August 3, 2018","April 20, 2016",,"September 19, 2019","Bronx, New York, United States|New York, New York, United States|Nashville, Tennessee, United States|Dresden, Sachsen, Germany|Madrid, Spain|Cardiff, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02745743"
343,"NCT02742623","A Non-interventional Study on Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer","COSIMO","Completed","No Results Available","Venous Thrombosis and Pulmonary Embolism","Drug: Rivaroxaban (Xarelto, BAY 59-7939)","Treatment satisfaction burden score (ACTS)|Preferences regarding the attributes of the anticoagulation medication options LMWH, VKA, rivaroxaban using DCE survey|Change of ACTS score over time|Patient's quality of life using the FACIT-Fatigue questionnaire|Type of index VTE (venous thromboembolism) event|Date of index VTE event|Type (trade name) of initial anticoagulation treatment|Duration of initial anticoagulation treatment|Reason for drug switch to rivaroxaban|Planned duration of anticoagulation with rivaroxaban|Actual duration of anticoagulation with rivaroxaban|Dosage of rivaroxaban|Reason for any potential dose adjustments during course of treatment with rivaroxaban|Reasons for any switch from rivaroxaban treatment|Reasons for permanent cessation of rivaroxaban treatment|TNM Staging (Clinical characteristics of cancer disease)|Primary site of cancer (Clinical characteristics of cancer disease)|Type of bleeding events|Number of bleeding events|Type of thromboembolic events|Number of thromboembolic events","Bayer|Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)",,"528","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","18137|XA1502","October 11, 2016","November 30, 2018","March 28, 2019","April 19, 2016",,"April 10, 2019","Multiple Locations, Australia|Multiple Locations, Belgium|Multiple Locations, Canada|Multiple Locations, Denmark|Multiple Locations, France|Multiple Locations, Germany|Multiple Locations, Italy|Multiple Locations, Netherlands|Multiple Locations, Spain|Multiple Locations, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02742623"
344,"NCT02741466","18750-Sun Protection Factor Assay","SPF Assay","Completed","No Results Available","Sunscreening Agents","Drug: Coppertone (BAY987517)","Minimal Erythema Dose(MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18750","March 15, 2016","March 30, 2016","March 30, 2016","April 18, 2016",,"December 13, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02741466"
345,"NCT02739802","18751-Sun Protection Factor Assay.","SPF Assay","Completed","No Results Available","Sunscreening Agents","Drug: Coppertone(BAY987517)","Minimal Erythema Dose(MED)|Minimal Persistent Pigment Darkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18751","March 15, 2016","March 30, 2016","March 30, 2016","April 15, 2016",,"December 13, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02739802"
346,"NCT02734628","Pilot Study to Assess Number of Patients for Main Trial",,"Completed","No Results Available","Wound Healing","Drug: Dexpanthenol (Bepanthen® Wund- und Heilsalbe, BAY81-2996)|Drug: Placebo","Wound healing effect (=re-epithelization) at Day 5 of the test product and the placebo|Subjective assessment of cosmetic outcome|Number of participants with adverse events|Wound healing at Days 2, 3, 4, 6, 7, 8, 9, 10 and 15 after wound induction","Bayer","All","18 Years to 45 Years   (Adult)","Phase 4","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","12631|2006-005508-14","March 2007","April 2007","April 2007","April 12, 2016",,"April 12, 2016","Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT02734628"
347,"NCT02729103","Treatment Patterns in Metastatic Prostate Cancer",,"Completed","No Results Available","Prostatic Neoplasm","Drug: Xofigo (Radium 223 dichloride,BAY88-8223)","Distribution of treatment types among lines of therapy|Time to treatment (days)|Duration of treatment (days)|Number of patients on each drug or drug combination|Number of inpatient visits per patient|Length of hospital stay (days) among those with an inpatient visit|Number of outpatient visits per patient|Number of emergency room (ER) visits per patient|Number of physician office visits per patient|Number of medication prescriptions per patient|Number of patients by provider type|Number of claims per patient|Total costs of healthcare|Medical costs of healthcare|Pharmacy costs of healthcare|Per-patient-per-month (PPPM)) costs of healthcare|Mortality rate|Opioid/analgesic use among lines of therapy(Y/N)","Bayer","Male","45 Years and older   (Adult, Older Adult)",,"565","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","18695","October 31, 2016","January 19, 2017","January 19, 2017","April 6, 2016",,"January 25, 2018","Whippany, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02729103"
348,"NCT02728856","Evaluation of the Irritation Potential of Products in Human Eyes.",,"Completed","No Results Available","Sunscreening Agents","Other: Sunscreen Spray SPF50 Z15-034(BAY987516)|Other: Shampoo Control|Other: Sunscreen Spray SPF50 Z15-038(BAY987516)","Subjective assessment of discomfort in the eyes assessed by 5 point scale|Intensity of Lacrimation assessed by 5 grading scale|Intensity of Bulbar Conjunctiva Irritation assessed by 4 grading scale|Intensity of Palpebral Conjunctiva Irritation assessed by 4 grading scale","Bayer","All","18 Years to 60 Years   (Adult)","Not Applicable","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other","18598","February 27, 2016","February 27, 2016","February 27, 2016","April 5, 2016",,"March 31, 2017","St. Petersburg, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02728856"
349,"NCT02722083","Exploratory Study for Allergy Relief Onset",,"Terminated","No Results Available","Rhinitis, Allergic","Drug: Chlorpheniramine maleate (BAY X002134)|Drug: Placebo","The time to the meaningful relief, as defined by at least 15% of reduction from baseline in Total Symptom Score (TSS)|Number of patients with adverse events as a measure of safety","Bayer","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","1","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","18573","May 7, 2016","May 27, 2016","July 13, 2016","March 29, 2016",,"December 12, 2018","Germantown, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02722083"
350,"NCT02717351","18841- Sun Protection Factor Assay","SPF Assay","Completed","No Results Available","Sunscreening Agent","Drug: Coppertone (BAY 987517)","Minimal Erythema Dose (MED)|Minimal Persistent Pigment DArkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18841","March 16, 2016","March 31, 2016","March 31, 2016","March 23, 2016",,"December 13, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02717351"
351,"NCT02717325","18842 - Sun Protection Factor Assay","SPF Assay","Completed","No Results Available","Sunscreening Agent","Drug: Coppertone (BAY987517)","Minimal Erythema Dose (MED)|Minimal Persistent Pigment DArkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18842","March 16, 2016","March 31, 2016","March 31, 2016","March 23, 2016",,"December 13, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02717325"
352,"NCT02714166","Evaluation of the Irritation Potential of Products in Human Eyes",,"Completed","No Results Available","Sunscreening Agents","Other: Sunscreen lotion SPF (Sun Protection Factor) 50 (BAY987521)|Other: Ophthalmic Ointment","Subjective assessment of discomfort in the eyes assessed by 5 point scale.|Intensity of Lacrimation assessed by 5 grading scale.|Intensity of Bulbar Conjunctiva Irritation assessed by 4 grading scale.|Intensity of Palpebral Conjunctiva Irritation assessed by 4 grading scale.","Bayer","All","18 Years to 60 Years   (Adult)","Not Applicable","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other","18766","February 26, 2016","February 26, 2016","February 26, 2016","March 21, 2016",,"March 30, 2017","St. Petersburg, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02714166"
353,"NCT02710708","YAZ Post Authorization Safety Study (PASS)/Post Authorization Efficacy Study (PAES) in China",,"Completed","No Results Available","Contraception","Drug: EE20/DRSP (YAZ, BAY86-5300)","Number of subjects with adverse drug reactions (ADRs)|Number of unintended pregnancies as measured by the Pearl Index (PI)|Cycle control for subjects with and without proceeding abortion|Number of bleeding days|Number of bleeding episodes|Number of Acne lesions","Bayer","Female","18 Years to 45 Years   (Adult)","Phase 4","1921","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18261","May 27, 2016","July 3, 2018","July 3, 2018","March 17, 2016",,"June 28, 2019","Xiamen, Fujian, China|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Shenzhen, Guangdong, China|Liuzhou, Guangxi, China|Nanning, Guangxi, China|Shijiazhuang, Hebei, China|Changsha, Henan, China|Wuhan, Hubei, China|Yueyang, Hunan, China|Changzhou, Jiangsu, China|Nanjing, Jiangsu, China|Nanjing, Jiangsu, China|Wuxi, Jiangsu, China|Nanchang, Jiangxi, China|Xi'an, Shaanxi, China|Weifang, Shandong, China|Weifang, Shandong, China|Zibo, Shandong, China|Taiyuan, Shanxi, China|Chengdu, Sichuan, China|Urumchi, Xinjiang, China|Kunming, Yunnan, China|Kunming, Yunnan, China|Hangzhou, Zhejiang, China|Hangzhou, Zhejiang, China|Hangzhou, Zhejiang, China|Wenzhou, Zhejiang, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Shanghai, China|Shanghai, China|Tianjin, China",,"https://ClinicalTrials.gov/show/NCT02710708"
354,"NCT02702908","Second Primary Cancers in Patients With Castration Resistant Prostate Cancer","BOCARP","Completed","No Results Available","Prostatic Neoplasms",,"Incidences of Second primary malignancies are characterized by the following ICD-10 codes: C00-C76, C81-C96, D00-D09, D37-D48.|Overall survival","Bayer","Male","18 Years and older   (Adult, Older Adult)",,"6442","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","18044|EUPAS12665","March 15, 2016","October 20, 2017","October 20, 2017","March 9, 2016",,"January 19, 2018","Multiple Locations, Germany",,"https://ClinicalTrials.gov/show/NCT02702908"
355,"NCT02696642","Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment",,"Completed","No Results Available","Neoplasms","Drug: Anetumab ravtansine (BAY94-9343)","Incidence of treatment-emergent adverse events (TEAEs, both serious and non-serious) or other abnormalities in safety assessments of BAY94-9343|Cycle 1 AUC (area under the plasma concentration vs. time curve from zero to infinity after single (first) dose) of BAY94-9343 analytes|Cycle 1 AUC(0-tlast) (AUC from time zero to the last data point > LLOQ [lower limit of quantification]) of BAY94-9343 analytes|Cycle 1 Cmax (maximum drug concentration in plasma after the first dose administration) of BAY94-9343 analytes|Cycle 3 Cmax,md (Cmax after multiple-dose administration) of BAY94-9343 analytes|Cycle 3 AUC(0-tlast)md (AUC(0-tlast) after multiple-dose administration) of BAY94-9343 analytes|Immunogenicity as defined by the titer of anti-anetumab ravtansine antibodies (ADA)|Immunogenicity as defined by incidence of neutralizing antibodies (NA)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","54","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18327|2015-003897-33","April 14, 2016","July 31, 2018","August 19, 2019","March 2, 2016",,"September 4, 2019","Caen, France|Dijon, France|Lille Cedex, France|Lyon Cedex, France|Marseille, France|Saint Herblain, France|Toulouse Cedex 9, France|Chisinau, Moldova, Republic of",,"https://ClinicalTrials.gov/show/NCT02696642"
356,"NCT02695303","18790 - Sun Protection Factor Assay","SPF","Completed","No Results Available","Sunscreening Agent","Drug: Coppertone (BAY 987516)","Minimal Erythema Dose (MED)|Minimal Persistent Pigment DArkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18790","February 23, 2016","February 25, 2016","February 25, 2016","March 1, 2016",,"December 13, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02695303"
357,"NCT02690155","Real-world Comparative Effectiveness of Rivaroxaban Versus VKA","RIVA-F","Completed","No Results Available","Atrial Fibrillation","Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: VKA (Vitamin K antagonist)","Incidence of Hospitalization Events (composite endpoint)","Bayer|Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)",,"38831","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","18734","February 12, 2016","March 1, 2016","March 1, 2016","February 24, 2016",,"April 5, 2017","New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02690155"
358,"NCT02687867","Real-world Comparative Effectiveness of Dabigatran Versus Vitamin K Antagonist","DABI-F","Completed","No Results Available","Atrial Fibrillation","Drug: Dabigatran (Pradaxa)|Drug: Vitamin K antagonist","Incidence of Hospitalization Events (composite endpoint)","Bayer","All","18 Years and older   (Adult, Older Adult)",,"56039","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","18732|NN1513US","February 12, 2016","March 1, 2016","March 1, 2016","February 22, 2016",,"April 5, 2017","New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02687867"
359,"NCT02687854","Real-world Comparative Effectiveness of Apixaban Versus Vitamin K Antagonist","PIXI-F","Completed","No Results Available","Atrial Fibrillation","Drug: Apixaban|Drug: Vitamin K antagonist","Incidence of Hospitalization Events (composite endpoint)","Bayer","All","18 Years and older   (Adult, Older Adult)",,"18591","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","18731","February 12, 2016","March 1, 2016","March 1, 2016","February 22, 2016",,"April 5, 2017","New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02687854"
360,"NCT02682654","A Multi-Site Evaluation of the Pain Relief, Support, Fit and Comfort From Use of a Custom Knee or Ankle Brace in Persons Suffering From Chronic Ankle or Knee Pain and Instability",,"Completed","No Results Available","Joint Instability","Device: Dr. Scholl's Prototype Ankle Brace|Device: Dr. Scholl's Prototype Knee Brace","Comfort|Pain Relief of Knee or Ankle joint|Product Fit|Product Support|Freedom of Movement|Subjective Questions","Bayer","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","183","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","18325","February 5, 2016","April 26, 2016","April 26, 2016","February 15, 2016",,"December 12, 2018","Colorado Springs, Colorado, United States|Richardson, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02682654"
361,"NCT02682628","18791 - Sun Protection Factor Assay","SFP","Completed","No Results Available","Sunscreening Agent","Drug: Coppertone (BAY987517)","Minimal Erythema Dose (MED)|Minimal Persistent Pigment DArkening Dose (MPPD)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18791","February 18, 2016","February 22, 2016","February 22, 2016","February 15, 2016",,"December 13, 2018","Union, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02682628"
362,"NCT02671097","Drug-drug Interaction Study Using Rosuvastatin as a Breast Cancer Resistant Protein (Efflux Transporter), Organic Anion-transporting Polypeptide (OATP)1B1, and OATP1B3 (Uptake Transporters) Probe Substrate",,"Completed","No Results Available","Healthy Volunteers|Pharmacokinetics|Drug Interaction","Drug: Rosuvastatin|Drug: BAY1841788 (ODM-201)","Area under the concentration-time curve of Rosuvastatin from time zero to 24 hours (AUC(0-24))|Maximum drug concentration (Cmax) in plasma of Rosuvastatin|Number of subjects with study drug-related treatment-emergent Adverse Events|Area under the concentration-time curve of BAY1841788 from time zero to 24 hours (AUC(0-24)) after single administration|Area under the concentration-time curve of BAY1841788 from time zero to 12 hours (AUC(0-12)) after repeated administration|Maximum drug concentration (Cmax) in plasma of BAY1841788","Bayer","All","45 Years to 65 Years   (Adult, Older Adult)","Phase 1","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","17723|2015-003244-38","February 2016","May 2016","August 2016","February 2, 2016",,"September 8, 2016","CRS Clinical Research Services Berlin GmbH, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT02671097"
363,"NCT02661438","Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation Using Placebo",,"Completed","No Results Available","Bronchiectasis|Pulmonary Disease, Chronic Obstructive","Drug: Placebo to Ciprofloxacin DPI (BAYQ3939)","The user performed the inhalation task based on the given instructions properly (Yes/No).|The user performed the inhalation task safely (Yes/No).|DPI (Dry powder for inhalation) device malfunction (Yes/No).|Subject's subjective feedback (paraphrased) on use-safety and usability|Inhalation time|User friendliness","Bayer|Novartis","All","40 Years and older   (Adult, Older Adult)","Not Applicable","46","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","18253","January 12, 2016","March 17, 2016","March 17, 2016","January 22, 2016",,"December 19, 2018","Vero Beach, Florida, United States|Jamaica, New York, United States",,"https://ClinicalTrials.gov/show/NCT02661438"
364,"NCT02656524","Stivarga Real Life Evidence in Hungary",,"Completed","No Results Available","Colorectal Neoplasms","Drug: Regorafenib (Stivarga, BAY73-4506)","Length of treatment for each treatment episode|Progression Free Survival (PFS)|Overall Survival (OS)|Number of participants with treatment emergent adverse events as a measure of safety and tolerability|Resource utilization per patient","Bayer","All","Child, Adult, Older Adult",,"400","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","18686","July 1, 2016","February 15, 2017","February 15, 2017","January 15, 2016",,"February 12, 2018","Budapest, Hungary",,"https://ClinicalTrials.gov/show/NCT02656524"
365,"NCT02652091","Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction",,"Completed","No Results Available","Multiple Sclerosis, Relapsing-Remitting","Drug: Interferon beta-1b (Betaseron, BAY86-5046)|Device: BETACONNECT device","Number of BETASERON injections as captured by the BETACONNECT device|Time (days) between BETASERON injections as captured by BETACONNECT device|Patient reported satisfaction by a questionnaire","Bayer","All","18 Years and older   (Adult, Older Adult)",,"146","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","17942","February 5, 2016","August 11, 2017","September 13, 2017","January 11, 2016",,"September 6, 2018","Cullman, Alabama, United States|Boca Raton, Florida, United States|New Port Richey, Florida, United States|Tampa, Florida, United States|Atlanta, Georgia, United States|Fulton, Maryland, United States|Foxboro, Massachusetts, United States|Deckerville, Michigan, United States|Saint Louis, Missouri, United States|Stratford, New Jersey, United States|Teaneck, New Jersey, United States|Staten Island, New York, United States|Medford, Oregon, United States|Medford, Oregon, United States|Bala-Cynwyd, Pennsylvania, United States|Lititz, Pennsylvania, United States|Franklin, Tennessee, United States|Memphis, Tennessee, United States|Nashville, Tennessee, United States|Lubbock, Texas, United States|Round Rock, Texas, United States|Fairfax, Virginia, United States|Virginia Beach, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02652091"
366,"NCT02645747","Retrospective Data Analysis of Patients Treated for Macular Edema Due to Central Retinal Vein Occlusion","RETRO CRVO","Completed","No Results Available","Retinal Vein Occlusion","Drug: Aflibercept (Eylea, BAY86-5321)","Treatment duration|Number of eyes treated (mono-and biocular)|Change in visual acuity (BCVA score)|Number of Eylea injections per treated eye|Estimation of percentage (%) of eyes which need additional treatment after 2 years at the discretion of the treating physician.|Sufficiency of reimbursed number of Eylea injections (max. 9 injections/eye in year 1) for treatment of all patients during the first year of treatment.|Number of patients who discontinued their treatment with Eylea prematurely","Bayer|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)",,"126","Industry","Observational","Observational Model: Other|Time Perspective: Retrospective","18586","January 21, 2016","December 23, 2017","December 23, 2017","January 5, 2016",,"September 6, 2018","Multiple Locations, Belgium",,"https://ClinicalTrials.gov/show/NCT02645747"
367,"NCT02639091","Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors",,"Completed","No Results Available","Medical Oncology","Drug: BAY 94-9343|Drug: Pemetrexed|Drug: Cisplatin","Maximum tolerated dose (MTD)|Number of subjects with adverse events and serious adverse events as a measure of safety and tolerability|Plasma concentrations of anetumab ravtansine (BAY 94-9343), pemetrexed and cisplatin|Tumor response evaluation following mRECIST criteria to determine the number of patients with CR, PR, SD or PD|Number of patients with a positive titer of anti-drug antibodies","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","36","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17631|2016-003988-18","February 3, 2016","May 23, 2018","October 17, 2019","December 24, 2015",,"November 7, 2019","Chicago, Illinois, United States|Bethesda, Maryland, United States|Detroit, Michigan, United States|Charleston, South Carolina, United States|Milano, Lombardia, Italy|Milano, Lombardia, Italy",,"https://ClinicalTrials.gov/show/NCT02639091"
368,"NCT02637687","A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children","SCOUT","Recruiting","No Results Available","Solid Tumors Harboring NTRK Fusion","Drug: Larotrectinib (Vitravki, BAY2757556)","Phase 1: Number of participants with adverse events|Phase 1: Severity of adverse events|Phase 2: Overall response rate (ORR) by IRRC|Phase 1: Maximum concentration of larotrectinib in plasma (Cmax)|Phase 1: Area under the concentration versus time curve of larotrectinib in plasma (AUC)|Phase 1: Oral clearance (CL/F)|Phase 1: Cerebral spinal fluid/plasma ratio of larotrectinib|Phase 1: Maximum tolerated dose (MTD)|Phase 1: Recommended dose for Phase 2|Phase 1: Overall response rate (ORR)|Phase 1: Pain level|Phase 1: Health-related quality of life by PedsQL-Core|Phase 2: Overall Response Rate (ORR) by investigator|Phase 2: Duration of response (DOR) by IRRC|Phase 2: Duration of response (DOR) by investigator|Phase 2: Proportion of subjects with any tumor regression as a best response|Phase 2: Progression-free survival (PFS) after larotrectinib|Phase 2: Overall survival time|Phase 2: Number of participants with adverse events|Phase 2: Severity of adverse events|Phase 2: Clinical benefit rate (CBR) by IRRC|Phase 2: Clinical benefit rate (CBR) by investigator|Phase 2: Concordance coefficient|Phase 2: Post-operative stage in patients treated with larotrectinib|Phase 2: Surgical margin status in patients treated with larotrectinib|Phase 2: Descriptive analysis of pretreatment surgical plan|Phase 2: Descriptive analysis of post-treatment plans","Bayer","All","up to 21 Years   (Child, Adult)","Phase 1|Phase 2","174","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20290|LOXO-TRK-15003|2016-003498-16","December 16, 2015","September 2, 2024","September 2, 2024","December 22, 2015",,"January 18, 2020","Children's Hospital of Los Angeles, Los Angeles, California, United States|UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States|Lucille Salter Packard Children's Hospital at Stanford, Palo Alto, California, United States|Nemours Children's Hospital (Orlando), Orlando, Florida, United States|Children's Hospital Boston, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cincinnati Children's Hospital and Medical Center, Cincinnati, Ohio, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|Sydney Children's Hospital, Sydney, New South Wales, Australia|Royal Children's Hospital Melbourne, Parkville, Victoria, Australia|British Columbia Childrens Hospital, Vancouver, British Columbia, Canada|The Hospital for Sick Children (SickKids), Toronto, Ontario, Canada|CHU Sainte-Justine, Montreal, Quebec, Canada|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Beijing Children's Hospital, Capital Medical University, Beijing, China|Tianjin Medical University Cancer Institiute & Hospital, Tianjin, China|Rigshospitalet Copenhagen, Copenhagen, Denmark|Institut Curie - Ulm - Paris, PARIS cedex 5, France|Institut Gustave Roussy, Villejuif Cedex, France|Universitätsklinikum Heidelberg, Heidelberg, Baden-Württemberg, Germany|Olgahospital, Stuttgart, Baden-Württemberg, Germany|Charité Campus Virchow-Klinikum (CVK), Berlin, Germany|Our Lady's Hospital For Sick Children, Crumlin, Dublin, Ireland|Clalit Health Services Schneider Children's Medical Center, Petach Tikva, Israel|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy|A.O. di Padova, Padova, Veneto, Italy|Kanagawa Children's Medical Center, Yokohama, Kanagawa, Japan|Tohoku University Hospital, Sendai, Miyagi, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|Kyushu University Hospital, Fukuoka, Japan|Osaka City Hospital Organization Osaka City General Hospital, Osaka, Japan|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of|Prinses Maxima Centrum, Utrecht, Netherlands|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Ciutat Sanitària i Universitaria de la Vall d'Hebron, Barcelona, Spain|Karolinska Universitetssjukhuset i Solna, Stockholm, Sweden|Universitätskinderspital Zürich, Zürich, Switzerland|Royal Marsden NHS Trust (Surrey), Sutton, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02637687"
369,"NCT02637050","A Study Investigating Routine Practice of Chronic Thromboembolic Pulmonary Hypertension Management in EMEA Countries","EMEA CTEPH","Active, not recruiting","No Results Available","Hypertension, Pulmonary","Other: Standard of care","The clinical functional parameters of CTEPH patients will be assessed by evaluating the change in measures of 6MWD between initial and final visit|The clinical functional parameters of CTEPH patients will be assessed by evaluating the change in measures of WHO Functional Class between initial and final visit|The haemodynamics parameters of CTEPH patients will be assessed by evaluating the change in measures of PVR between initial and final visit|The haemodynamics parameters of CTEPH patients will be assessed by evaluating the change in measures of Cardiac Index (CI) between initial and final visit|The haemodynamics parameters of CTEPH patients will be assessed by evaluating the change in measures of mPAP between initial and final visit|Eligibility for PEA|Rate of recurrent to persistent subtypes after Pulmonary Endarterectomy|Time span between onset of symptoms and CTEPH diagnosis|Usage of diagnostic tools of CTEPH patients (Y/N)|Rate of Pulmonary Hypertension treatments prior to CTEPH diagnosis, at the time of CTEPH diagnosis and at the time of first visit|Treatment duration with Pulmonary Hypertension treatments prior to CTEPH diagnosis, at the time of CTEPH diagnosis and at the time of first visit|Changes in CTEPH treatment during the study period|Number of patients eligible for Pulmonary endarterectomy|NT-proBNP (N-terminal Propeptide Brain Natriuretic Peptide) levels|Mortality due to CTEPH and CTEPH related complications|Number of healthcare professional visits due to CTEPH and CTEPH related complications|The total number of days of hospitalization due to CTEPH and CTEPH related complications|Number of patients eligible for Balloon Pulmonary Angioplasty","Bayer","All","18 Years and older   (Adult, Older Adult)",,"231","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","18303|AD 1502","March 3, 2016","June 30, 2020","July 31, 2020","December 22, 2015",,"January 3, 2020","Multiple Locations, Kazakhstan|Multiple Locations, Kyrgyzstan|Multiple Locations, Lebanon|Multiple Locations, Russian Federation|Multiple Locations, Saudi Arabia|Multiple Locations, Turkey",,"https://ClinicalTrials.gov/show/NCT02637050"
370,"NCT02635672","Phase I Dose Escalation Study for BAY 1251152 in Patients With Advanced Cancer",,"Active, not recruiting","No Results Available","Neoplasms","Drug: BAY 1251152","Incidence of DLT (Dose limit toxicity) of BAY1251152|Maximum observed drug concentration in measured matrix after single dose administration (Cmax) of BAY1251152|Area under the concentration versus time curve from zero to infinity after single (first) dose (AUC) of BAY1251152|AUC from time 0 to the last data point > Lower limit of quantitation (LLOQ) [AUC(0-tlast)] of BAY1251152|Maximum observed drug concentration in measured matrix after multiple dose administration during a dosage interval (Cmax,md) of BAY1251152|AUC from time 0 to the last data point > LLOQ after multiple dosing [AUC(0-tlast)md] of BAY1251152|Recommended phase 2 dose (RP2D) of BAY 1251152|Number of participants with adverse events as a measure safety and tolarability|Tumor response evaluation based on the response criteria as applicable (RECIST v1.1 criteria for solid tumors and revised Cheson's criteria for aggressive NHL)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","33","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17496|2014-004808-30","February 10, 2016","April 30, 2020","April 30, 2020","December 21, 2015",,"January 13, 2020","Aurora, Colorado, United States|Rochester, Minnesota, United States|New York, New York, United States|Madrid, Spain|Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT02635672"
371,"NCT02627989","An Observational Study Investigating the Treatment Satisfaction of Atopic Dermatitis Patients Who Have Switched to Ointment (W/O Emulsion) Formulation of Very Strong Class Topical Corticosteroids","Ointment TS-AD","Completed","No Results Available","Dermatitis, Atopic","Drug: Diflucortolone valerate (Nerisona)|Drug: Diflucortolone valerate (Texmeten)","Treatment satisfaction measured by Treatment Satisfaction Questionnaire for Medication (TSQM-9)|Treatment adherence measured by Morisky Medication Adherence Scale (MMAS-8-Item)|Itchiness according to Visual Analogue Scale (VAS)|Severity Scoring of Atopic Dermatitis (SCORAD)|Eczema Area and Severity Index (EASI)","Bayer","All","20 Years and older   (Adult, Older Adult)",,"55","Industry","Observational","Observational Model: Other|Time Perspective: Prospective","18690","December 10, 2015","November 17, 2016","January 17, 2017","December 11, 2015",,"January 16, 2018","Tsu, Mie, Japan",,"https://ClinicalTrials.gov/show/NCT02627989"
372,"NCT02626455","Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)","CHRONOS-4","Recruiting","No Results Available","Lymphoma, Non-Hodgkin","Drug: Copanlisib (BAY80-6946)|Drug: Placebo|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Bendamustine|Drug: Prednisone","Safety run-in_Determination of the recommended Phase-III dose (RP3D) of copanlisib in combination with standard immunochemotherapy assessed by the occurrence of dose-limiting toxicities / adverse events|Phase III_Evaluation whether copanlisib in combination with standard immunochemotherapy is superior to placebo and standard immunochemotherapy assessed by the prolongation of progression free survival (PFS)|Safety run-in_Best Overall Response (BOR)|Safety run-in_Number of participants with treatment-emergent adverse events|Phase III_Objective tumor response rate (ORR)|Phase III_Duration of tumor response (DOR)|Phase III_Complete tumor response rate (CRR)|Phase III_Time to tumor progression (TTP)|Phase III_Time to next anti-lymphoma treatment (TTNT)|Phase III_Overall survival (OS)|Phase III_Time to improvement in disease-related physical symptoms measured by Lymphoma Symptom Index-18 questionnaire|Phase III_Time to deterioration in disease-related physical symptoms measured by Lymphoma Symptom Index-18 questionnaire|Phase III_Number of participants with treatment-emergent adverse events","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","544","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","17833|2015-001088-38","January 6, 2016","September 30, 2021","December 31, 2024","December 10, 2015",,"January 18, 2020","Alaska Cancer Treatment Center, Anchorage, Alaska, United States|Ironwood Physicians P.C. DBA Ironwood Cancer & Res. Ctr., Chandler, Arizona, United States|Compassionate Cancer Care Medical Group, Inc., Fountain Valley, California, United States|Univ.of California-San Diego Moores Cancer Center, La Jolla, California, United States|Pacific Shores Medical Group, Long Beach, California, United States|Brian J. LeBerthon, MD, West Covina, California, United States|SCL Health Research at St Joseph's Hospital Denver CO, Denver, Colorado, United States|Comprehensive Cancer Care & Research Institute of Colorado, Englewood, Colorado, United States|Hartford Hospital, Hartford, Connecticut, United States|Mid Florida Cancer Centers, Orange City, Florida, United States|John B. Amos Cancer Center, Columbus, Georgia, United States|Lewis Hall Singletary Oncology Center, Thomasville, Georgia, United States|The Queen's Medical Center, Honolulu, Hawaii, United States|St. Luke's Mountain States Tumor Institute - Boise, Boise, Idaho, United States|Alexian Brothers Medical Center, Elk Grove Village, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States|Henry Ford Health System, Detroit, Michigan, United States|Detroit Clinical Research Center, Farmington Hills, Michigan, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Memorial Sloan Kettering Cancer Center- Basking Ridge, Basking Ridge, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center- Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Cancer Center- Bergen, Montvale, New Jersey, United States|Morristown Memorial Hospital, Morristown, New Jersey, United States|Valley Hospital Bolger Medical Arts Building, Westwood, New Jersey, United States|Memorial Sloan Kettering Cancer Center- Commack, Commack, New York, United States|Memorial Sloan Kettering Cancer Center- Westchester, Harrison, New York, United States|Winthrop-University Hospital, Mineola, New York, United States|NYU Langone Medical Center, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Hematology Oncology Center at Nyack Hospital, Nyack, New York, United States|New York Cancer and Blood Specialists, Port Jefferson Station, New York, United States|Memorial Sloan Kettering- Nassau, Uniondale, New York, United States|Mission Hospital, Asheville, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Gabrail Cancer Center, Canton, Ohio, United States|Mid Ohio Oncology/Hematology Inc., Columbus, Ohio, United States|Southwest Oklahoma Cancer Research, Lawton, Oklahoma, United States|Prairie Lakes Cancer Center, Watertown, South Dakota, United States|Oncology Consultants, Houston, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|DBA-Envision Cancer Care, LLC, Laredo, Texas, United States|Joe Arrington Cancer Research & Treatment Center, Lubbock, Texas, United States|University Health System, Lubbock, Texas, United States|Texas Oncology- McAllen, McAllen, Texas, United States|Vista Oncology Inc PS, Olympia, Washington, United States|Medical Oncology Associates, PS, Spokane, Washington, United States|Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia|Calvary Mater Hospital Newcastle, Waratah, New South Wales, Australia|Pindara Private Hospital, Benowa, Queensland, Australia|Royal Brisbane & Women's Hospital, Brisbane, Queensland, Australia|Flinders Medical Centre, Adelaide, South Australia, Australia|Ashford Cancer Centre Pty Ltd, Kurralta Park, South Australia, Australia|Frankston Hospital, Frankston, Victoria, Australia|The Alfred Hospital, Prahran, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Eastern Health Integrated Renal Service, Box Hill, Australia|Klinikum Wels-Grieskirchen GmbH, Wels, Austria|GZA Ziekenhuizen, Wilrijk, Antwerpen, Belgium|AZ Groeninge Campus Kennedylaan, Kortrijk, West-Vlaanderen, Belgium|Institut Jules Bordet/Jules Bordet Instituut, Bruxelles - Brussel, Belgium|Grand Hôpital de Charleroi, Charleroi, Belgium|UZ Gent, Gent, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|CHU de Liège, Liege, Belgium|Centro Integrado de Oncologia de Curitiba, Curitiba, Parana, Brazil|Hosp Bruno Born Sociedade Beneficência e Caridade de Lajeado, Lajeado, Rio Grande Do Sul, Brazil|Irmandade Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Centro de Pesquisas Oncológicas, Florianópolis, Santa Catarina, Brazil|Faculdade de Ciencias Medicas-Universidade Estadual Campinas, Campinas, Sao Paulo, Brazil|Faculdade de Medicina do ABC, Santo Andre, Sao Paulo, Brazil|IEP São Lucas, São Paulo, Sao Paulo, Brazil|Hospital das Clínicas da Faculdade de Medicina da USP, São Paulo, Sao Paulo, Brazil|Casa de Saúde Santa Marcelina, São Paulo, Sao Paulo, Brazil|Instituto Nacional do Cancer Jose Alencar Gomes da Silva, Rio de Janeiro, Brazil|Hospital Samaritano de São Paulo LTDA, Sao Paulo, Brazil|Hospital Israelita Albert Einstein, Sao Paulo, Brazil|UMHAT Sveti Georgi, Plovdiv, Bulgaria|University Multiprofile Hosp. for Active Treat. Sveti Ivan, Sofia, Bulgaria|SHATHD Spec. Hospi. for Active Treatm. of Haematol. Dis. EAD, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment Hristo Botev AD, Vratsa, Bulgaria|Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada|Hopital du Sacre-Coeur de Montreal, Montreal, Quebec, Canada|Hopital de L'Enfant Jesus, Quebec City, Quebec, Canada|Centre Universitaire de Sante de l'Estrie, Sherbrooke, Quebec, Canada|Sociedad de Investigaciones Medicas Ltda, Temuco, Araucanía, Chile|Centro de Investigaciones Clínicas Viña del Mar Ltda., Viña del Mar, Valparaíso, Chile|Fundación Arturo López Perez, Santiago, Chile|Clínica Santa María, Santiago, Chile|Instituto Nacional del Cáncer, Santiago, Chile|FuJian Medical University Union Hospital, Fuzhou, Fujian, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Guangdong General Hospital, Guangzhou, Guangdong, China|Henan Cancer Hospital, Zhengzhou, Henan, China|Jiangsu Cancer Hospital, Nanjing, Jiangsu, China|1st Affiliated hospital of Soochow University, Suzhou, Jiangsu, China|Tangdu Hospital, the 4th Military Medical University of PLA, Xi'an, Shaanxi, China|The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China|West China Hospital, Sichuan University, Chengdu, Sichuan, China|The 1st Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China|Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China|Beijing Friendship Hospital, Capital Medical University, Beijing, China|Fifth Medical Center, General Hospital of the Chinese People, Beijing, China|Jilin Cancer Hospital, Changchun, China|Fudan University Shanghai Cancer Center, Shanghai, China|Xinhua Hos Affiliated to SH Jiaotong Uni School of Medicine, Shanghai, China|Shanghai East Hospital Affiated to Tongji University, Shanghai, China|Tumor Hospital of Hebei Province, Shijiazhuang, China|Tianjin Medical University Cancer Institiute & Hospital, Tianjin, China|Tianjin Union Medicine Centre (People's Hospital of Tianjin), Tianjin, China|Fakultni Nemocnice Hradec Kralove, Hradec Kralove, Czechia|Fakultni nemocnice Kralovske Vinohrady, Praha 10, Czechia|H:S Rigshospitalet, Copenhagen, Denmark|Odense Universitetshospital, Odense C, Denmark|HUS, Meilahden sairaala, Helsinki, Finland|Keski-Suomen keskussairaala, Jyväskylä, Finland|Oulun yliopistollinen sairaala, Oulu, Finland|Tampereen yliopistollinen sairaala, keskussairaala, Tampere, Finland|Turun yliopistollinen keskussairaala, kantasairaala, Turku, Finland|Centre Hospitalier Universitaire - Angers, Angers, France|Centre Hospitalier de la Durance - Avignon, Avignon, France|Centre Hospitalier Intercommunal de la Côte Basque-Bayonne, Bayonne, France|CHU de Caen, Hôpital Côte de la Côte de Nacre, Caen Cedex, France|Hôpital Henri Mondor, Creteil, France|Centre Hospitalier Universite de Grenoble, Grenoble, France|Clinique Victor Hugo - Le Mans, Le Mans Cedex 2, France|Hôpital Dupuytren, Limoges Cedex, France|Centre Léon Bérard, Lyon Cedex, France|Hôpital Saint-Eloi, Montpellier Cedex, France|Hôpital Hôtel Dieu, Nantes Cedex, France|Hôpital Saint Louis, Paris, France|Hopital Saint Antoine - Paris, Paris, France|Centre François Magendie - Pessac, Pessac, France|Centre Hospitalier Lyon Sud, Pierre Benite, France|Hôpital de la Milétrie, Poitiers, France|Centre Henri Becquerel, Rouen, France|Institut de Cancérologie de l'Ouest - Saint Herblain, Saint Herblain, France|Clinique Saint Anne, Strasbourg, France|Stauferklinikum Schwäbisch-Gmünd, Mutlangen, Baden-Württemberg, Germany|Gemeinschaftspraxis Dr.Heinrich/ Prof.Bangerter, Augsburg, Bayern, Germany|Klinikum der Universität München Grosshadern, München, Bayern, Germany|MVZ Praxis Pihusch GbR, Rosenheim, Bayern, Germany|Universität Rostock - Medizinische Fakultät, Rostock, Mecklenburg-Vorpommern, Germany|Medizinische Hochschule Hannover (MHH), Hannover, Niedersachsen, Germany|Onkolog. Gemeinschaftspraxis Dres. D.Reichert & J.Janssen, Westerstede, Niedersachsen, Germany|Marienhospital Herne Universitätsklinik, Herne, Nordrhein-Westfalen, Germany|Universitätsklinikum Münster (UKM), Münster, Nordrhein-Westfalen, Germany|Oncologianova GmbH, Recklinghausen, Nordrhein-Westfalen, Germany|Med. Fakultät der Martin-Luther-Universität Halle-Wittenberg, Halle, Sachsen-Anhalt, Germany|Ruppiner Kliniken GmbH, Neuruppin, Germany|Evangelismos General Hospital of Athens, Athens, Greece|Laiko General Hospital of Athens (Sevastoupoleos), Athens, Greece|University General Hospital of Athens ""ATTIKON"", Chaidari, Greece|University General Hospital of Larissa, Larissa, Greece|University General Hospital of Patras, Patras, Greece|G. Papanikolaou General Hospital of Thessaloniki, Thessaloniki, Greece|Queen Mary Hospital, Hong Kong, Hong Kong|Tuen Mun Hospital, Hongkong, Hong Kong|Queen Elizabeth Hospital, Kowloon, Hong Kong|Prince of Wales Hospital, Shatin, Hong Kong|Semmelweis University, Budapest, Hungary|Orszagos Onkologiai Intezet, Budapest, Hungary|Semmelweis University, Budapest, Hungary|Somogy Megyei Kaposi Mor Oktato Korhaz, Kaposvar, Hungary|Bacs-Kiskun Megyei Korhaz, Kecskemét, Hungary|SzSzBMK es EOK Josa Andras Oktatokorhaz, Nyiregyhaza, Hungary|Pecsi Tudomanyegyetem Klinikai Kozpont, Pecs, Hungary|Szent Borbala Hospital, Tatabanya, Hungary|Cork University Hospital, Cork, Ireland|Misericordiae Hospital, Dublin, Ireland|St James's Hospital, Dublin, Ireland|Rambam Health Corporation, Haifa, Israel|Edith Wolfson Medical Center, Holon, Israel|Hadassah Hebrew University Hospital Ein Kerem, Jerusalem, Israel|Meir Medical Center, Kfar Saba, Israel|Chaim Sheba Medical Center, Ramat Gan, Israel|Shamir Medical Center (Assaf Harofeh), Zerifin, Israel|A.O.U. di Bologna Policlinico S.Orsola Malpighi, Bologna, Emilia-Romagna, Italy|AUSL della Romagna, Ravenna, Emilia-Romagna, Italy|IRCCS A.O.U. San Martino IST Ist. Nazionale Ricerca Cancro, Genova, Liguria, Italy|IRCCS Istituto Clinico Humanitas (ICH), Milano, Lombardia, Italy|IRCCS Istituto Europeo di Oncologia (IEO), Milano, Lombardia, Italy|IRCCS Fondazione Policlinico San Matteo, Pavia, Lombardia, Italy|A.O.U. Ospedali Riuniti ""Umberto I - G.M.Lancisi - G.Salesi"", Ancona, Marche, Italy|National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan|Aichi Cancer Center Hospital, Nagoya, Aichi, Japan|Japanese Red Cross Nagoya Daini Hospital, Nagoya, Aichi, Japan|Nagoya City University Hospital, Nagoya, Aichi, Japan|JCHO Kyushu Hospital, Kitakyushu, Fukuoka, Japan|Kurume University Hospital, Kurume, Fukuoka, Japan|Gunma University Hospital, Maebashi, Gunma, Japan|Hyogo Cancer Center, Akashi, Hyogo, Japan|Kobe University Hospital, Kobe, Hyogo, Japan|Kanagawa Cancer Center, Yokohama, Kanagawa, Japan|Tohoku University Hospital, Sendai, Miyagi, Japan|Shinshu University Hospital, Matsumoto, Nagano, Japan|Tenri Hospital, Tenri, Nara, Japan|Kindai University Hospital, Osakasayama, Osaka, Japan|Saitama Medical University International Medical Center, Hidaka, Saitama, Japan|Saitama Medical Center, Kawagoe, Saitama, Japan|Shimane University Hospital, Izumo, Shimane, Japan|Shizuoka Cancer Center, Sunto, Shizuoka, Japan|Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|Toranomon Hospital, Minato-ku, Tokyo, Japan|Aomori Prefectural Central Hospital, Aomori, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan|Hiroshima Red Cross & Atomic-bomb Survivors Hospital, Hiroshima, Japan|National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan|Kumamoto University Hospital, Kumamoto, Japan|Kyoto Prefectural University of Medicine, Kyoto, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Osaka Red Cross Hospital, Osaka, Japan|Osaka City University Hospital, Osaka, Japan|Yamagata University Hospital, Yamagata, Japan|Pusan National University Hospital, Busan, Busan Gwang''yeogsi, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of|Hospital General de México SS, Ciudad de México, Distrito Federal, Mexico|Instituto Nacional de Cancerología, México, Distrito Federal, Mexico|Centro de Investigación Clínica Chapultepec S.A. de C.V., Morelia, Michoacán, Mexico|Hospital Universitario ""José Eleuterio González"", Monterrey, Nuevo Leon, Mexico|Centro de Atencion e Investigacion Clinica en Oncologia SCP, Merida, Yucatán, Mexico|Centro Especializado en Investigación Clínica S.C., Veracruz, Mexico|Szpital Morski im. PCK, Gdynia, Poland|Malopolskie Centrum Medyczne, Krakow, Poland|Wojew. Szpital Specjalistyczny im. M. Kopernika, Lodz, Poland|Centrum Onkologii Ziemi Lubelskiej im. sw. Jana z Dukli, Lublin, Poland|Hospital de Braga, Braga, Portugal|CHUP - Hospital Santo Antonio, Porto, Portugal|IPO Porto, Porto, Portugal|CHUSJ - Hospital Sao Joao, Porto, Portugal|CHVNGE - Hospital Eduardo Santos Silva, Vila Nova de Gaia, Portugal|Sp. Judetean de Urgenta Dr. Constantin Opris Baia Mare, Baia Mare, Romania|S.C. Policlinica de Diagnostic Rapid S.A., Brasov, Romania|Fundeni Clinical Institute, Bucharest, Romania|Spitalul Clinic Coltea, Bucharest, Romania|Sp. Univ. de Urgenta Militar Central Dr. Carol Davila, Bucuresti, Romania|Spitalul Clinic Colentina, Bucuresti, Romania|Institutul Oncologic Prof. Dr. Ion Chiricuta, Cluj-Napoca, Romania|Spitalul Clinic Municipal Filantropia Craiova, Craiova, Romania|Institutul Regional de Oncologie Iasi, Iasi, Romania|Spitalul Clinic Judetean de Urgenta Sibiu, Sibiu, Romania|Spitalul Clinic Judetean de Urgenta Targu-Mures, Targu-Mures, Romania|State budgetary institution of health of the Kaluga region "", Kaluga, Russian Federation|Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation|Clinical Oncological Dispensary of Omsk Region, Omsk, Russian Federation|Research Institute of Oncology, Rostov-on-Don, Russian Federation|RSRI of Hematology and Transfusiology, Saint-Petersburg, Russian Federation|Oncology Dispensary #2, Sochi, Russian Federation|St. Petersburg Clinical Hospital of RAS, St. Petersburg, Russian Federation|Siberian State Medical University, Tomsk, Russian Federation|Republican Clinical Oncology Dispensary, Ufa, Russian Federation|Regional Clinical Hospital, Yaroslavl, Russian Federation|National University Hospital, Singapore, Singapore|National Cancer Center, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|Raffles Hospital, Singapore, Singapore|Narodny onkologicky ustav, Bratislava, Slovakia|Vychodoslovensky onkologicky ustav a.s., Kosice, Slovakia|Outeniqua Cancercare Oncology Unit, George, Eastern Cape, South Africa|Cancercare Langenhoven Drive Oncology Centre, Port Elizabeth, Eastern Cape, South Africa|Albert Alberts Stem Cell Transplant Research Centre, Pretoria, Gauteng, South Africa|Department of Oncology, Pietermaritzburg, Kwazulu-Natal, South Africa|Constantiaberg Medi Clinic, Cape Town, Western Cape, South Africa|Institut Català d'Oncologia Badalona, Badalona, Barcelona, Spain|Institut Català d'Oncologia Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Clinica Puerta de Hierro, Majadahonda, Madrid, Spain|Complejo Hospitalario Universitario A Coruña, A Coruña, Spain|Ciutat Sanitària i Universitaria de la Vall d'Hebron, Barcelona, Spain|Hospital Clínic i Provincial de Barcelona, Barcelona, Spain|Hospital Regional de Málaga, Málaga, Spain|Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain|Kantonsspital Aarau, Aarau, Aargau, Switzerland|Kantonsspital Baselland - Standort Liestal, Liestal, Basel-Landschaft, Switzerland|Ospedale Regionale Bellinzona, Bellinzona, Ticino, Switzerland|Changhua Christian Hospital, Changhua, Taiwan|Chang Gung Memorial Hospital Kaohsiung, Kaohsiung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Pramongkutklao Hospital, Bangkok, Thailand|Siriraj Hospital, Mahidol, Bangkok, Thailand|Ankara Universitesi Tip Fakultesi Hastanesi, Ankara, Turkey|Trakya Univ. Tip Fak., Edirne, Turkey|Istanbul Universitesi Istanbul Tip Fakultesi, Istanbul, Turkey|Marmara Uni. Tip Fakultesi Pendik Egitim ve Aras. Hastanesi, Istanbul, Turkey|Ege Universitesi Tip Fakultesi, Izmir, Turkey|Dokuz Eylul Universitesi Tip Fakultesi, Izmir, Turkey|Erciyes Universitesi Tip Fakultesi, Kayseri, Turkey|Ondokuz Mayis Uni Tip Fakultesi, Samsun, Turkey|Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey|Cherkasy Oncological Dispensary, Cherkasy, Ukraine|Multidisciplinary Clinical Hosp. 4 Dnipro, Dnipro, Ukraine|National Cancer Institute, Kiev, Ukraine|Institute of Blood Pathology and Transfusion medicine, Lviv, Ukraine|Zaporizhzhia Regional Clinical Hospital, Zaporizhzhya, Ukraine|Royal Cornwall Hospital, Truro, Cornwall, United Kingdom|Royal Devon & Exeter Hospital, Exeter, Devon, United Kingdom|Northwick Park Hospital, Harrow, London, United Kingdom|Royal Marsden NHS Trust (Surrey), Sutton, Surrey, United Kingdom|Freeman Hospital, Newcastle Upon Tyne, Tyne And Wear, United Kingdom|Dorset County Hospital, Dorchester, United Kingdom|St. George's Hospital, London, United Kingdom|Royal Marsden Hospital (London), London, United Kingdom|Manchester Royal Infirmary, Manchester, United Kingdom|Singleton Hospital, Swansea, United Kingdom|Hanoi, Vietnam|Ho Chi Minh City, Vietnam",,"https://ClinicalTrials.gov/show/NCT02626455"
373,"NCT02625974","Prospective Study of a Pediatric Nifurtimox Formulation for Chagas' Disease","CHICO","Active, not recruiting","Has Results","Chagas Disease","Drug: Nifurtimox (Lampit, BAYA2502)|Drug: Placebo","Percentage of Participants Cured|Incidence Rate of Seronegative Conversion for Subjects Received at Least One Dose of the 60-day Nifurtimox Treatment Regimen.(Part 2)|Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 1|Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 3|Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 6|Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 8|Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 9|Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 10|Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 11|Number of Subjects With Positive Results in Concentration Test for T. Cruzi (for Subjects <8 Months of Age)|Number of Subjects With a Positive Serological Response Using Non-conventional Enzyme-linked Immunosorbent Assay-F29 (ELISAF29) Test|Number of Subjects With Positive Quantitative Polymerase Chain Reaction (qPCR) Results|Number of Subjects With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)|Number of Subjects With Treatment-emergent High Blood Chemistry Abnormalities by Treatment (Part 1)|Number of Subjects With Treatment-emergent Low Blood Chemistry Abnormalities by Treatment (Part 1)|Number of Subjects With Treatment-emergent High Hematology Abnormalities by Treatment (Part 1)|Number of Subjects With Treatment-emergent Low Hematology Abnormalities by Treatment (Part 1)|Number of Subjects With Treatment-emergent High Coagulation Abnormalities by Treatment (Part 1)|Number of Subjects With Treatment-emergent Low Coagulation Abnormalities by Treatment (Part 1)|Number of Subjects With Abnormal Urinalysis Findings Considered as Clinically Significant or Reported as Adverse Events (AEs)|Number of Subjects With Abnormal ECG Findings Considered as Clinically Significant by Investigators (Part 1)|Mean Changes in Vital Signs (Systolic Blood Pressure) Between the Treatment Groups From Baseline (Part 1)|Mean Changes in Vital Signs (Diastolic Blood Pressure) Between the Treatment Groups From Baseline (Part 1)|Mean Changes in Vital Signs (Respiratory Rate) Between the Treatment Groups From Baseline (Part 1)|Mean Changes in Vital Signs (Heart Rate) Between the Treatment Groups From Baseline (Part 1)|Mean Changes in Vital Signs(Temperature) Between the Treatment Groups From Baseline (Part 1)|Nifurtimox Concentration Over Time in Plasma at Visit 2 (Part 1)|Nifurtimox Concentration Over Time in Plasma at Visit 3 (Part 1)|Nifurtimox Concentration Over Time in Plasma at Visit 6 (Part 1)|Nifurtimox Concentration Over Time in Plasma at Visit 8 (Part 1)|Incidence of Seronegative Conversion Received at Least One Dose of the 30-day Nifurtimox Treatment Regimen. (Part 2)|Proportion of Responders With Seronegative Conversion and no Evidence of Cardiomyopathy (Part 2)|Antibody Titer in Plasma Over Time in All Subjects (Part 2)","Bayer","All","up to 17 Years   (Child)","Phase 3","330","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","16027","January 27, 2016","July 25, 2018","August 9, 2021","December 9, 2015","October 29, 2019","October 29, 2019","La Plata, Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|San Salvador de Jujuy, Jujuy, Argentina|Posadas, Misiones, Argentina|Rosario, Santa Fe, Argentina|Corrientes, Argentina|Formosa, Argentina|La Rioja, Argentina|Mendoza, Argentina|Mendoza, Argentina|Salta, Argentina|Salta, Argentina|San Juan, Argentina|Santiago del Estero, Argentina|Tucuman, Argentina|Cochabamba, Bolivia|Punata, Bolivia|Tarija, Bolivia|Barranquilla, Atlántico, Colombia|Yopal, Casanare, Colombia|Santa Marta, Magdalena, Colombia|Floridablanca, Santander, Colombia","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT02625974/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT02625974/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02625974"
374,"NCT02617550","Vericiguat Drug-drug Interaction With Nitroglycerin in Stable Coronary Artery Disease Patients","VENICE","Completed","No Results Available","Coronary Artery Disease","Drug: Vericiguat (BAY1021189)|Drug: Placebo|Drug: Nitroglycerin","Number of participants with adverse events as measure of safety and tolerability|Blood pressure|Heart rate","Bayer|Merck Sharp & Dohme Corp.","All","30 Years to 80 Years   (Adult, Older Adult)","Phase 1","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","17849|2015-001444-11","November 2015","May 2016","August 2016","December 1, 2015",,"August 24, 2016","Heidelberg, Baden-Württemberg, Germany|Bonn, Nordrhein-Westfalen, Germany|Wuppertal, Nordrhein-Westfalen, Germany|Wuppertal, Nordrhein-Westfalen, Germany|Erfurt, Thüringen, Germany|Berlin, Germany|Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT02617550"
375,"NCT02617537","To Investigate Efficacy of YAZ in the Treatment of Dysmenorrhea",,"Withdrawn","No Results Available","Dysmenorrhea","Drug: EE20/DRSP(YAZ,BAY86-5300)|Drug: Placebo","Mean change in visual analogue scale (VAS) score for pain due to dysmenorrhea from baseline to Visit 6|Number of participants with adverse events as measure of safety and tolerability|Number of days with dysmenorrhea|Change in dysmenorrhea score|Changes from baseline to each menstrual period of total number of taken supportive analgesic medication|Changes from baseline to each menstrual period of days without supportive analgesic medication.|Clinical Global Impression(CGI)|Self administered SF-36 questionnaire|Changes from baseline to each menstrual period of severity of lumbago|Changes from baseline to each menstrual period of severity of headache|Changes from baseline to each menstrual period of severity of nausea/vomiting","Bayer","Female","18 Years and older   (Adult, Older Adult)","Phase 3","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","16419|2015-003924-29","January 2016","September 2017","October 2017","December 1, 2015",,"February 17, 2016",,,"https://ClinicalTrials.gov/show/NCT02617537"
376,"NCT02616692","HCC Patient Preferences in Japan",,"Completed","No Results Available","Hepatocellular Cancer","Drug: Hepatocellular Cancer (HCC) treatments including oral anti-cancer therapy [Nexavar (Sorafenib, BAY43-9006)]","Preference weight scores for 13 selected HCC treatment attributes associated with Sorafenib, repeated TACE, and HAIC|Response to the direct preference elicitation item asking which is most preferred: oral anti-cancer therapy (Sorafenib), repeated TACE, and HAIC|Like/dislike ratings of each treatment attribute (Extent of patients like or dislike of different treatment attributes)|Willingness to try oral anti-cancer therapy (Sorafenib), TACE, and HAIC|Maximum acceptable risk of hand-foot skin reaction willing to take for oral anti-cancer therapy (Sorafenib) therapy that will stop cancer from getting worse for a specified period of time|Maximum acceptable risk of life-threatening side effect willing to take for oral anti-cancer therapy (Sorafenib) therapy that will stop cancer from getting worse for a specified period of time","Bayer","All","20 Years and older   (Adult, Older Adult)",,"120","Industry","Observational","Observational Model: Other|Time Perspective: Prospective","18234","May 9, 2016","October 7, 2016","October 7, 2016","November 30, 2015",,"September 27, 2017","Many Locations, Japan",,"https://ClinicalTrials.gov/show/NCT02616692"
377,"NCT02615587","Burden of Illness in Atrial Fibrillation",,"Completed","No Results Available","Atrial Fibrillation","Drug: Standard of care in AF in Denmark","Number of patients with (non-valvular) AF in total Danish population and by gender and age groups 18-65, 66-75, 75+, 80+|Number of newly diagnosed patients with (non-valvular) AF per year in total Danish population and by gender and age groups 18-65, 66-75, 75+, 80+|Number of patients with (non-valvular) AF per Danish Region and by gender and age groups 18-65, 66-75, 75+, 80+|Number of newly diagnosed patients with (non-valvular) AF per year and per Danish Region and by gender and age groups 18-65, 66-75, 75+, 80+|Mortality among AF patients compared with that of the general population/the 'controls', if possible by gender and age group|Number of patients with stroke in (non-valvular) AF-patients in Denmark by gender and age groups 18-65, 66-75, 75+, 80+|Number of newly diagnosed patients with stroke in (non-valvular) AF-patients per year in Denmark by gender and age groups 18-65, 66-75, 75+, 80+|Mortality among stroke patients (in AF) compared with that of the population/the 'controls' and the total AF-population, if possible by gender and age group|Direct cost in AF (in total and per patient)|Direct cost in AF-related stroke (in total and per patient)|Indirect cost in AF (in total and per patient)|Indirect cost in AF-related stroke (in total and per patient)|Number of patients with AF-related stroke rated per CHADS2-score (0 to 6) in Danish population|Percentage (%) of patients with AF-related stroke rated per CHADS2-score (0 to 6) in Danish population|Number of patients with AF-related stroke rated per average CHADS-score in Danish population|Percentage (%) of patients with AF-related stroke rated per average CHADS-score in Danish populationPercentage (%) of patients with AF-related stroke rated per average CHADS-score in Danish population|Number of patients with AF-related stroke rated per CH2ADS2-VASc-score (0 to 9) in Danish population|Percentage (%) of patients with AF-related stroke rated per CH2ADS2-VASc-score (0 to 9) in Danish population|Number of patients per HAS-BLED-score (0 to 9) in Danish AF-population|Percentage (%) of patients per HAS-BLED-score (0 to 9) in Danish AF-population|Number of patients per average HAS-BLED-score in Danish AF-population|Percentage (%) of patients per average HAS-BLED-score in Danish AF-population|Number of patients in total and per CH2ADS2-VASc-score receiving Acetylsalicylic Acid [ASA]|Number of patients in total and per CH2ADS2-VASc-score receiving warfarin|Number of patients in total and per CH2ADS2-VASc-score receiving any Novel Oral Anticoagulants [NOACs]|Number of patients in total and per CH2ADS2-VASc-score receiving no treatment|Percentage (%) of patients in total and per CH2ADS2-VASc-score receiving Acetylsalicylic Acid [ASA]|Percentage (%) of patients in total and per CH2ADS2-VASc-score receiving Warfarin|Percentage (%) of patients in total and per CH2ADS2-VASc-score receiving any Novel Oral Anticoagulants [NOACs]|Percentage (%) of patients in total and per CH2ADS2-VASc-score receiving no treatment|Number of patients experiencing events (e.g. stroke, Systemic Embolism [SE], Myocardial Infarction [MI], bleeds, death) since AF-diagnosis per anticoagulant agent (AC)-medication incl. no treatment in total|Percentage (%) of patients experiencing events (e.g. stroke, Systemic Embolism [SE], Myocardial Infarction [MI], bleeds, death) since AF-diagnosis per anticoagulant agent (AC)-medication incl. no treatment in total|Number of patients experiencing events (e.g. stroke, Systemic Embolism [SE], Myocardial Infarction [MI], bleeds, death) since AF-diagnosis per Anticoagulant agent (AC)-medication incl. no treatment per CHADS-VASc-score|Percentage (%) of patients experiencing events (e.g. stroke, Systemic Embolism [SE], Myocardial Infarction [MI], bleeds, death) since AF-diagnosis per Anticoagulant agent (AC)-medication incl. no treatment per CHADS-VASc-score|Vitamin K antagonist (VKA) treated AF-patients in AC-clinics versus GP-setting|Direct and indirect cost of AC medication treatment patterns","Bayer","All","18 Years to 90 Years   (Adult, Older Adult)",,"107532","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","18313","October 2015","December 2015","December 2015","November 26, 2015",,"February 5, 2016","Many Locations, Denmark",,"https://ClinicalTrials.gov/show/NCT02615587"
378,"NCT02615561","Curing Atopic Dermatits in Children With a Commerical Medical Device and Maintaining Healthy Skin by Using a New Cosmetic Product",,"Completed","No Results Available","Dermatitis, Atopic","Device: Bepanthen Itch Relief Cream: Phoenix 2 (Bepanthen Sensiderm, BAY207543)|Other: New cosmetic Bepanthen product: Pumpkin (BAY207543)|Other: Stelatopia (cosmetic comparator)","Efficacy: SCORAD with included parameters ""extent of disease/area affected"" [%] as well as average intensity of pruritus and sleeplessness|Efficacy: Local SCORAD including single symptoms erythema, edema/ papulation, excoriation, lichenification, oozing/crusts, dryness|Efficacy: Quality of Life according to questionnaire|Efficacy: Intensity of pruritus according to diary|Efficacy: Intensity of sleeplessness according to diary|Efficacy: Responder rate: No. of subjects with local SCORAD <5 (Phase 1, only)|Efficacy: Time to flare-up (Phase 2, only)|Efficacy: Percent of subjects with flare-up (Phase 2, only)|Safety: Number of adverse events (AE)|Safety: physical examination|Safety: vital signs|Safety: Local tolerability (by AE assessment)","Bayer","All","1 Month to 4 Years   (Child)","Not Applicable","136","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","17534|2015-003485-92","December 15, 2015","September 7, 2016","September 7, 2016","November 26, 2015",,"September 15, 2017","Karlsruhe, Baden-Württemberg, Germany|Kehl, Baden-Württemberg, Germany|Schwäbisch Hall, Baden-Württemberg, Germany|Welzheim, Baden-Württemberg, Germany|Altdorf b. Nürnberg, Bayern, Germany|Neustadt / Aisch, Bayern, Germany|Rosenheim, Bayern, Germany|Bramsche, Niedersachsen, Germany|Bochum, Nordrhein-Westfalen, Germany|Datteln, Nordrhein-Westfalen, Germany|Dortmund, Nordrhein-Westfalen, Germany|Frankenthal, Rheinland-Pfalz, Germany|Neumünster, Schleswig-Holstein, Germany|Erfurt, Thüringen, Germany",,"https://ClinicalTrials.gov/show/NCT02615561"
379,"NCT02615496","Evaluation of Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept",,"Completed","No Results Available","Macular Degeneration","Behavioral: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)","The proportion of physicians with accurate knowledge and understanding of key safety information (identified risks and prescribing behaviors) contained in the Eylea educational materials as assessed by a study specific questionnaire.|The proportion of patients with accurate knowledge and understanding of key safety information (identified risks and guidelines) contained in the Eylea educational materials as assessed by a study specific interviewer administered questionnaire.","Bayer|RTI Health Solutions","All","18 Years and older   (Adult, Older Adult)",,"716","Industry|Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","16526|EY1301","December 7, 2015","September 30, 2016","January 31, 2017","November 26, 2015",,"September 15, 2017","Many Locations, France|Many Locations, Germany|Many Locations, Italy|Many Locations, Spain|Many Locations, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02615496"
380,"NCT02611635","Atrial Fibrillation Patient Preference Study","PRiSMA-AF","Completed","No Results Available","Atrial Fibrillation","Drug: VKA: Warfarin (Waran)|Drug: NOAC: Rivaroxaban (Xarelto, BAY59-7939)|Drug: NOAC: Dabigatran etexilate|Drug: NOAC: Apixaban|Drug: NOAC: Edoxaban|Drug: NOAC: Lixiana","AF patients`preferences towards anticoagulation treatment with either VKAs or NOACs measured with a DCE (discrete choice experiment) design in a phone interview: Frequency of intake (once/twice daily)|AF patients`preferences towards anticoagulation treatment with either VKAs or NOACs measured with a DCE (discrete choice experiment) design in a phone interview: Need of International normalized ratio (INR) monitoring/dose adjustment (yes/no)|AF patients`preferences towards anticoagulation treatment with either VKAs or NOACs measured with a DCE (discrete choice experiment) design in a phone interview: Need of bridging (yes/no)|AF patients`preferences towards anticoagulation treatment with either VKAs or NOACs measured with a DCE (discrete choice experiment) design in a phone interview: Interactions with food/drugs (yes/no)|AF patients`preferences towards anticoagulation treatment with either VKAs or NOACs measured with a DCE (discrete choice experiment) design in a phone interview: Distance to treating physician (1km or 50km).|Patient-related burden of treatment with anticoagulants measured by the Benefit and Burden Scale of the Anti-clot Treatment Scale (ACTS)|Patient's quality of life measured using the SF-12 (interview version)|Assessment of factors that may be associated with AF patients' preferences towards a specific anticoagulation treatment: Age|Assessment of factors that may be associated with AF patients' preferences towards a specific anticoagulation treatment: Gender|Assessment of factors that may be associated with AF patients' preferences towards a specific anticoagulation treatment: preferred Anticoagulation treatment (agent)|Assessment of factors that may be associated with AF patients' preferences towards a specific anticoagulation treatment: HrQoL as defined by the SF-12 score|Assessment of factors that may be associated with AF patients' preferences towards a specific anticoagulation treatment: AF symptoms as measured by the EHRA|Assessment of factors that may be associated with AF patients' preferences towards a specific anticoagulation treatment: TTR (for VKA patients only)|Assessment of factors that may be associated with AF patients' preferences towards a specific anticoagulation treatment: Lifestyle variables|Assessment of factors that may be associated with AF patients' preferences towards a specific anticoagulation treatment: Previous switch of anticoagulation treatment","Bayer","All","18 Years and older   (Adult, Older Adult)",,"382","Industry","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","18377","February 2, 2016","January 26, 2017","February 16, 2017","November 23, 2015",,"February 7, 2018","Multiple Locations, Sweden",,"https://ClinicalTrials.gov/show/NCT02611635"
381,"NCT02610153","Subtherapeutic INR Levels in Patients With AVK: Incidence, Associated Factors, Prognosis and Control Strategies","SULTAN","Completed","No Results Available","Atrial Fibrillation","Drug: Vitamin K Antagonist","International Normalized Ratio (INR) Time in Therapeutic Range (TTR)|Baseline thromboembolic risk based on the CHADS2 scale|Baseline thromboembolic risk based on the CHA2DS2-VASc scale|Baseline haemorrhagic risk based on the HAS-BLED scale|Changes in INR time in therapeutic range|Patient preferences with regard to anticoagulant treatment based on patients' questionnaires|Satisfaction with the anticoagulant treatment based on the Anti-Clot Treatment Scale (ACTS)|Adherence to the anticoagulant treatment: Morisky-Green test|Number and type of visits by patients to health professionals related to their anticoagulant treatment|Number of patients using anticoagulant treatment strategies|Number of patients treated according to clinical practice guidelines based on the Spanish Agency of Medicines and Medical Devices (AEMPS) therapeutic positioning report|Number of thromboembolic events in patients with inadequate anticoagulation management|Number of haemorrhagic events in patients with inadequate anticoagulation management","Bayer|Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)",,"1013","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","17943","October 1, 2015","June 30, 2018","March 15, 2019","November 20, 2015",,"April 25, 2019","Multiple Locations, Spain",,"https://ClinicalTrials.gov/show/NCT02610153"
382,"NCT02610140","Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)",,"Completed","No Results Available","Mesothelioma","Drug: Anetumab ravtansine (BAY 94-9343)|Drug: Vinorelbine","Progression Free Survival|Overall survival (OS)|Time to worsening of symptoms characteristic of mesothelioma|Time to worsening of pain|Improvement of symptoms characteristic of mesothelioma|Improvement of pain|Objective response|Duration of response (DOR)|Treatment emergent adverse events as a measure of safety and tolerability|Serious adverse events as a measure of safety and tolerability|Disease control|Durable Response","Bayer|ImmunoGen and MorphoSys","All","18 Years and older   (Adult, Older Adult)","Phase 2","248","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15743|2012-003650-88","December 3, 2015","May 31, 2017","July 2, 2019","November 20, 2015",,"September 11, 2019","La Jolla, California, United States|Aurora, Colorado, United States|Norwich, Connecticut, United States|Tampa, Florida, United States|Chicago, Illinois, United States|Chicago, Illinois, United States|New Orleans, Louisiana, United States|Bethesda, Maryland, United States|Rochester, Minnesota, United States|Buffalo, New York, United States|New York, New York, United States|Durham, North Carolina, United States|Cleveland, Ohio, United States|Dallas, Texas, United States|Houston, Texas, United States|St Leonards, New South Wales, Australia|Woolloogabba, Queensland, Australia|Adelaide, South Australia, Australia|Richmond, Victoria, Australia|Nedlands, Western Australia, Australia|Bruxelles - Brussel, Belgium|Edegem, Belgium|Gent, Belgium|Leuven, Belgium|Liege, Belgium|Sint-niklaas, Belgium|Calgary, Alberta, Canada|Hamilton, Ontario, Canada|London, Ontario, Canada|Toronto, Ontario, Canada|Helsinki, Finland|Turku, Finland|Vaasa, Finland|Bordeaux Cedex, France|Caen Cedex 5, France|Lille Cedex, France|Marseille, France|Paris, France|Paris, France|Pierre Benite, France|Pordenone, Friuli-Venezia Giulia, Italy|Bergamo, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Monza-Brianza, Lombardia, Italy|Torino, Piemonte, Italy|Siena, Toscana, Italy|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Amsterdam, Netherlands|Rotterdam, Netherlands|Gdansk, Poland|Krakow, Poland|Krakow, Poland|Szczecin, Poland|Omsk, Russian Federation|Yekaterinburg, Russian Federation|A Coruña, Spain|Alicante, Spain|Barcelona, Spain|Madrid, Spain|Málaga, Spain|Adana, Turkey|Ankara, Turkey|Eskisehir, Turkey|Istanbul, Turkey|Malatya, Turkey|Yenimahalle, Turkey|Plymouth, Devon, United Kingdom|Maidstone, Kent, United Kingdom|Leicester, Leicestershire, United Kingdom|Glasgow, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Newcastle Upon Tyne, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02610140"
383,"NCT02607371","Anticoagulation Preference by AF Patients Study","PRiSMA-AF","Completed","No Results Available","Atrial Fibrillation","Other: VKAs|Other: NOACs including Rivaroxaban (Xarelto, BAY59-7939)|Other: Edoxaban|Other: Apixaban|Other: Dabigatran-etexilate","AF patients`preferences towards anticoagulation treatment with either VKAs or NOACs measured with a DCE (discrete choice experiment) design in a phone interview|Burden associated with anticoagulation treatment measured by the questionnaire ACTS|Health-related quality of life measured by the SF-12 questionnaire|Assessment of factors that may be associated with AF patients preferences towards a specific anticoagulation treatment: preferred anticoagulation treatment (agent)|Assessment of factors that may be associated with AF patients preferences towards a specific anticoagulation treatment: HrQoL as defined by the SF-12 score|Assessment of factors that may be associated with AF patients preferences towards a specific anticoagulation treatment: AF symptoms as measured by the EHRA|Assessment of factors that may be associated with AF patients preferences towards a specific anticoagulation treatment: TTR (for VKA patients only)|Assessment of factors that may be associated with AF patients preferences towards a specific anticoagulation treatment: Age|Assessment of factors that may be associated with AF patients preferences towards a specific anticoagulation treatment: Gender","Bayer","All","18 Years and older   (Adult, Older Adult)",,"198","Industry","Observational","Observational Model: Other|Time Perspective: Prospective","18242","August 27, 2015","October 15, 2016","October 15, 2016","November 18, 2015",,"September 14, 2017","Many Locations, Switzerland",,"https://ClinicalTrials.gov/show/NCT02607371"
384,"NCT02606864","Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients",,"Completed","No Results Available","Chagas Disease","Drug: Nifurtimox (BAYa2502)","Area under the drug-concentration vs. time curve of nifurtimox from time 0 to the last data point[AUC(0-tlast)]|Plasma concentration nifurtimox characterized by Cmax|Plasma concentration of nifurtimox characterized by tmax|Plasma concentration of nifurtimox characterized by AUC|Number of participants with adverse events as a measure of safety and tolerability","Bayer","All","18 Years to 45 Years   (Adult)","Phase 1","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16005","December 2015","April 2016","August 2016","November 17, 2015",,"November 15, 2016","Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina",,"https://ClinicalTrials.gov/show/NCT02606864"
385,"NCT02605356","Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma",,"Withdrawn","No Results Available","Multiple Myeloma","Drug: Radium-223 dichloride (Xofigo, BAY88-8223)|Drug: Placebo|Drug: Bortezomib|Drug: Dexamethasone","Joint positive adjudication of safety summary in Phase 1b by steering committee, investigator and sponsor (Yes/No)|Progression-free survival (PFS) in Phase 2, defined as the time (in days) from date of randomization to disease progression|Objective response rate (ORR) in Phase 1b, in the proportion of subjects in the analysis population who have complete response (CR), stringent complete response (sCR), very good partial response (VGPR), partial response (PR), or stable disease (SD)|Duration of response in Phase 1b, defined as the time (in days) from the date of first response to treatment (CR, sCR, VGPR, PR) to the date of disease progression or death|Number of participants with adverse events in phase 2|Overall survival (OS) in Phase 2, defined as the time (in days) from date of randomization until death from any cause|Time to Symptomatic Skeletal Event (SSE) in Phase 2, defined as the time (days) from the date of randomization to the date of the first on-study SSE|Symptomatic skeletal event free survival in Phase 2, defined as the time from randomization to the occurrence of 1 of the following: First on-study SSE or Death from any cause if death occurs before a documented SSE|Time to pain progression in Phase 2|Duration of response in Phase 2|Objective Response Rate (ORR) in Phase 2","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","17451|2015-000427-82","October 2016","November 2019","July 2021","November 16, 2015",,"October 7, 2016","Scottsdale, Arizona, United States|Little Rock, Arkansas, United States|Encinitas, California, United States|Metairie, Louisiana, United States|Rockville, Maryland, United States|New York, New York, United States|Durham, North Carolina, United States|Winston-Salem, North Carolina, United States|Watertown, South Dakota, United States|Seattle, Washington, United States|Adelaide, South Australia, Australia|Box Hill, Australia|Brugge, Belgium|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Liege, Belgium|Yvoir, Belgium|Quebec, Canada|Tübingen, Baden-Württemberg, Germany|München, Bayern, Germany|Mainz, Rheinland-Pfalz, Germany|Berlin, Germany|Athens, Greece|Rio / Patra, Greece|Afula, Israel|Haifa, Israel|Jerusalem, Israel|Ramat Gan, Israel|Zerifin, Israel|Bologna, Emilia-Romagna, Italy|Reggio Emilia, Emilia-Romagna, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Novara, Piemonte, Italy|Torino, Piemonte, Italy|Cagliari, Sardegna, Italy|Firenze, Toscana, Italy|Pisa, Toscana, Italy|Goyang-si, Gyeonggido, Korea, Republic of|Daegu, Korea, Republic of|Jeollanam-do, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Badalona, Barcelona, Spain|San Sebastián, Guipúzcoa, Spain|Palma de Mallorca, Illes Baleares, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Sevilla, Spain|Valencia, Spain|Taichung, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT02605356"
386,"NCT02602470","Preferences & Treatment Satisfaction Drivers in Rosacea Patients",,"Completed","No Results Available","Rosacea","Drug: Azelaic Acid Gel including: Finacea (Azelaic Acid Gel 15%, BAY39-6251)|Drug: Azelaic Acid Cream|Drug: Metronidazole gel|Drug: Metronidazole cream|Drug: Metronidazole Emulsion|Drug: Metronidazole Lotion|Drug: Brimonidine Tartrate Gel","Self-reported concerns and importance of such concerns regarding their current topical rosacea treatments|Self-reported likelihood of switching to a topical rosacea treatments|Quality of life|Treatment satisfaction|Self-reported concerns and importance (a rating scale) of such concerns that patients would consider when switching to a new topical rosacea treatment","Bayer","All","18 Years and older   (Adult, Older Adult)",,"206","Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","18575","January 8, 2015","March 10, 2016","March 10, 2016","November 11, 2015",,"May 11, 2017","Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02602470"
387,"NCT02593747","To Assess Bioequivalence of Loratadine Oral Solution/Syrup Versus Claritin Peach Syrup","Bordeaux","Completed","No Results Available","Histamine H1 Antagonists, Non-Sedating","Drug: Loratadine oral solution|Drug: Loratadine (Claritin peach syrup)","Primary: Area Under the Concentration Versus Time Curve From Zero to the Last Data Point Greater Than Lower Limit of Quantitation (LLOQ) of Loratadine in Plasma (AUC[0-tlast]) After Single Oral Dose of Loratadine|Maximum Observed Concentration (Cmax) of Loratadine in Plasma After Single Oral Dose of Loratadine|Time to Reach Maximum Concentration (tmax) in Plasma After Single Dose of Loratadine|Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC) of Loratadine in Plasma After Single Dose|Half-Life (t1/2) Associated With the Terminal Slope of Loratadine After Single Dose|Total Body Clearance (CL/F) of Loratadine Calculated After its Single Oral Administration|Percentage of Area Under the Concentration Versus Time Curve (AUC) From the Last Calculated Data Point Greater Than Lower Limit of Quantification [LLOQ]) to Infinity (%AUC[tlast-∞]) After Single Oral Administration of Loratadine|Apparent Terminal Rate Constant (λz) of Loratadine After Single Dose|Area Under the Concentration Versus Time Curve From Zero to 72 Hours (AUC[0-72]) of Lloratadine in Plasma After Single Oral Dose|Maximum Observed Concentration (Cmax) of Desloratadine in Plasma After Single Oral Dose of Loratadine|Time to Reach Maximum Concentration (tmax) of Desloratadine in Plasma After Single Dose of Loratadine|Area Under the Concentration Versus Time Curve From Zero to the Last Data Point Greater Than Lower Limit of Quantitation (LLOQ) of Desoratadine in Plasma (AUC[0-tlast]) After Single Oral Dose of Loratadine|Area Under the Concentration Versus Time Curve From Zero to 72 Hours (AUC[0-72]) of Desloratadine in Plasma After Single Oral Dose of Loratadine|Time of Last Concentration Above the Lower Limit Of Quantitation (LLOQ) of Desloratadine, Directly Taken From Analytical Data (tlast)|Half-Life (t1/2) Associated With the Terminal Slope of Desoratadine After Single Dose of Loratadine|Percentage of Area Under the Concentration Versus Time Curve (AUC) from the Last Data Point Greater Than Lower Limit of Quantitation (LLOQ) to Infinity (%AUC[tlast-∞]) of Desoratadine After Single Oral Administration of Loratadine|Apparent Terminal Rate Constant (λz) of Desoratadine After Single Dose of Loratadine","Bayer","All","18 Years to 55 Years   (Adult)","Phase 1","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18199|2015-002720-12","December 2015","January 2016","March 2016","November 1, 2015",,"February 13, 2017","Neu-Ulm, Bayern, Germany",,"https://ClinicalTrials.gov/show/NCT02593747"
388,"NCT02592785","Phase I Dose Escalation Study of BAY 1163877 (Rogaratinib) in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors",,"Completed","No Results Available","Neoplasms","Drug: BAY1163877","Number of an Treatment Emergent Adverse Event|Intensity of an Treatment Emergent Adverse Event graded using the NCI-CTCAE version 4.03|Maximum observed plasma concentration after single dose administration (Cmax) of BAY1163877|Cmax divided by dose (mg) per kg body weight (Cmax,norm) of BAY1163877|Cmax divided by dose (mg) (Cmax/D) of BAY1163877|Area under the plasma concentration vs time curve from zero to 12 hours p.a. after first-dose administration (AUC(0-12)) of BAY1163877|AUC(0-12) divided by dose (mg) per kg body weight (AUC(0-12) norm) of BAY1163877|AUC(0-12) divided by dose (mg) (AUC(0-12)/D) of BAY1163877|AUC from time zero to the last data point > LLOQ (lower limit of quantification) of BAY1163877 (AUC(0-tlast))|AUC(0-tlast) divided by dose (mg) per kg body weight (AUC(0-tlast) norm) of BAY1163877|AUC(0-tlast) divided by dose (mg) (AUC(0-tlast)/D) of BAY1163877|AUC of BAY1163877|AUCnorm of BAY1163877|AUC/D of BAY1163877|Maximum Observed Drug Concentration in Plasma after multiple administrations (Cmax, md) of BAY1163877|Cmax after multiple administrations divided by dose (mg) per kg body weight (Cmax,norm, md) of BAY1163877|Cmax after multiple administrations divided by dose (mg) (Cmax/Dmd) of BAY1163877|AUC(0-12) after multiple administrations (AUC(0-12)md) of BAY1163877|AUC(0-12) after multiple administrations divided by dose (mg) per kg body weight (AUC(0-12)norm,md) of BAY1163877|AUC(0-12) divided by dose (mg) after multiple administrations (AUC(0-12)/Dmd) of BAY1163877|AUC(0-tlast)after multiple administrations (AUC(0-tlast)md) of BAY1163877|AUC(0-tlast) after multiple administrations divided by dose (mg) per kg body weight (AUC(0-tlast) norm,md) of BAY1163877|AUC(0-tlast) after multiple administrations divided by dose (mg) (AUC(0-tlast)/Dmd) of BAY1163877|Tumor response evaluation based on RECIST 1.1|FGF23 levels|Phosphate levels|FGFR1/2/3 mRNA expression in tumor tissue to evaluate of biomarker status","Bayer","All","20 Years and older   (Adult, Older Adult)","Phase 1","9","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16958","December 15, 2015","February 5, 2017","December 6, 2017","October 30, 2015",,"April 18, 2018","Kashiwa, Chiba, Japan|Koto-ku, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT02592785"
389,"NCT02585401","Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada",,"Completed","No Results Available","Age-related Macular Degeneration (AMD)|Central Retinal Vein Occlusion (CRVO)|Diabetic Macular Edema (DME)","Drug: Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)","Knowledge and understanding of key information contained in the aflibercept educational materials: the Eylea vial preparation instruction card, the intravitreal injection procedure video, and the product monograph|Investigation whether physicians have received the educational materials","Bayer|Regeneron Pharmaceuticals","All","Child, Adult, Older Adult",,"99","Industry","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","18498","February 18, 2016","March 31, 2016","May 19, 2016","October 23, 2015",,"March 21, 2017","Many Locations, Canada",,"https://ClinicalTrials.gov/show/NCT02585401"
390,"NCT02585076","A Cross-sectional Study for the Determination of the Prevalence of Non-valvular Atrial Fibrillation Among Patients Diagnosed With Hypertension","REFINE HT","Completed","No Results Available","Hypertension|Atrial Fibrillation","Other: Standard of care","Frequency of non-valvular atrial fibrillation (NAVF) among hypertensive outpatients|Proportion of NVAF patients for whom the HAS-BLED score has been estimated by the physicians as part of the decision for antithrombotic treatment|Frequency of oral anticoagulation therapy among the study population diagnosed with NVAF|Proportion of untreated patients among the study population diagnosed with NVAF|Proportion of antiplatelet therapy treated patients among the study population diagnosed with NVAF|CHADS2 scores|CHA2DS2-VASc scores|Degree of agreement between the proportions of patients classified at intermediate and high stroke risk according to the two risk stratification systems|CHA2DS2-VASc score in hypertensives without NVAF|Correlation of the CHA2DS2-VASc-assessed risk with the average annual stroke risk as calculated by the Framingham stroke risk scoring system in hypertensives without NVAF|CHA2DS2-VASc score in hypertensives without AF|Correlation of the CHA2DS2-VASc-assessed risk with the average annual AF risk as calculated by the Framingham AF risk scoring system in hypertensives without AF|Frequency of NVAF among the subpopulations of hypertensives adequately versus those inadequately controlled according to the physicians' medical judgement","Bayer","All","60 Years and older   (Adult, Older Adult)",,"1119","Industry","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","18311","November 4, 2015","February 29, 2016","May 30, 2016","October 23, 2015",,"May 22, 2017","Many Locations, Greece",,"https://ClinicalTrials.gov/show/NCT02585076"
391,"NCT02581995","Investigation of the Change of Vision-related Quality of Life in Subjects Treated With Aflibercept According to EU Label for DME.","AQUA","Completed","Has Results","Macular Edema","Drug: Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)","Change From Baseline to Week 52 in NEI VFQ-25 Total Score|Change From Baseline to Week 52 in the NEI VFQ 25 Near Activities Subscale|Change From Baseline to Week 52 in the NEI VFQ 25 Distant Activities Subscale|Change From Baseline to Week 52 in Best Corrected Visual Acuity (BCVA) (Early Treatment Diabetic Retinopathy Study [ETDRS] Letter Score])|Change From Baseline to Week 52 in Central Retinal Thickness (CRT) Measured by Optical Coherence Tomography (OCT)|Proportion of Participants Progressing to Greater or Equal to (>=) 61 on the ETDRS Diabetic Retinopathy Severity Scale (DRSS) as Assessed by Fundus Photography (FP)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 4","560","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17850|2014-005119-17","November 19, 2015","August 9, 2017","August 9, 2017","October 21, 2015","October 10, 2018","October 10, 2018","Graz, Steiermark, Austria|Wien, Austria|Wien, Austria|Halifax, Nova Scotia, Canada|London, Ontario, Canada|Mississauga, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Sherbrooke, Quebec, Canada|Hradec Kralove, Czechia|Praha 10, Czechia|Usti nad Labem, Czechia|Creteil Cedex, France|Marseille, France|Darmstadt, Hessen, Germany|Frankfurt, Hessen, Germany|Marburg, Hessen, Germany|Göttingen, Niedersachsen, Germany|Bonn, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Ludwigshafen, Rheinland-Pfalz, Germany|Mainz, Rheinland-Pfalz, Germany|Dresden, Sachsen, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Pecs, Hungary|Roma, Lazio, Italy|Genova, Liguria, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Torino, Piemonte, Italy|Cagliari, Sardegna, Italy|Sassari, Sardegna, Italy|Firenze, Toscana, Italy|Padova, Veneto, Italy|Kaunas, Lithuania|Vilnius, Lithuania|Bydgoszcz, Poland|Gdansk, Poland|Katowice, Poland|Krakow, Poland|Lodz, Poland|Lublin, Poland|Poznan, Poland|Warszawa, Poland|Warszawa, Poland|Coimbra, Portugal|Leiria, Portugal|Lisboa, Portugal|Porto, Portugal|Vila Franca de Xira, Portugal|Bratislava, Slovakia|Bratislava, Slovakia|Nitra, Slovakia|Zilina, Slovakia|Zvolen, Slovakia|L'Hospitalet de Llobregat, Barcelona, Spain|San Cugat Del Vallès, Barcelona, Spain|Albacete, Spain|Barcelona, Spain|Barcelona, Spain|Valencia, Spain|Bern, Switzerland|Genève, Switzerland|Southampton, Hampshire, United Kingdom|Camberley, Surrey, United Kingdom|Guildford, Surrey, United Kingdom|Newcastle Upon Tyne, Tyne And Wear, United Kingdom|Sunderland, Tyne And Wear, United Kingdom|Leeds, West Yorkshire, United Kingdom|London, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT02581995/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT02581995/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02581995"
392,"NCT02581969","Extension at 10 Years of the: ""Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs On-demand Therapy With Kogenate Bayer in Patients With Severe Haemophilia A.""","POTTER 10","Completed","No Results Available","Hemophilia A","Drug: Recombinant Factor VIII (Kogenate FS, BAY14-2222)","Number of joint bleeding episodes per year|Total number of bleeding episodes per year|Total amount of Recombinant Factor VIII consumption|Changes of prophylaxis dose|Changes of frequency of infusions|Musculoskeletal evaluation by calculating the World Federation of Haemophilia Orthopedic Joint Score (Gilbert score)|Proportions of patients who will change the therapeutic regimen during the study|Musculoskeletal evaluation by calculating the Radiological score (Pettersson Score)|Evaluating the Questionnaires of Health-Related Quality of Life _Haemo Quality of Life (HaemoQol)|Evaluating the Questionnaires of Health-Related Quality of Life _Short Form 36 questions (SF36)|Evaluating the Questionnaires of Health-Related Quality of Life _ Euro Quality 5 Dimension (EQ5D)|Number of days missed from work or school of patients and caregivers because of all the events haemophilia-related|Number of patients with poor compliance|Number of patients with adverse events","Bayer","Male","17 Years to 60 Years   (Child, Adult)",,"43","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","18251","April 14, 2016","March 16, 2017","June 21, 2018","October 21, 2015",,"June 19, 2019","Multiple Locations, Italy",,"https://ClinicalTrials.gov/show/NCT02581969"
393,"NCT02581891","Managing Neovascular (Known as ""Wet"") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye","ARIES","Completed","No Results Available","Macular Degeneration","Drug: Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)","Change in best corrected visual acuity (BCVA) as measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score|Proportion of subjects maintaining vision (<3 lines loss)|Change in BCVA as measured by the ETDRS letter score|Change in central retinal thickness (CRT)|Number of study drug injections|Duration of last re-treatment interval|Proportion of subjects requiring retreatment at 8, 10, 12, 14, and 16 weeks as the last treatment interval|Proportion of 3-line vision gainers","Bayer|Regeneron Pharmaceuticals","All","50 Years and older   (Adult, Older Adult)","Phase 4","287","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17508|2014-003132-39","November 19, 2015","April 26, 2019","April 26, 2019","October 21, 2015",,"May 1, 2019","Strathfield, New South Wales, Australia|Sydney, New South Wales, Australia|Westmead, New South Wales, Australia|East Melbourne, Victoria, Australia|Launceston, Australia|Hamilton, Ontario, Canada|Ottawa, Ontario, Canada|Boisbriand, Quebec, Canada|Creteil Cedex, France|Nice cedex 1, France|Freiburg, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|Hannover, Niedersachsen, Germany|Bonn, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Sulzbach, Saarland, Germany|Chemnitz, Sachsen, Germany|Berlin, Germany|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Pecs, Hungary|Szombathely, Hungary|Roma, Lazio, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Padova, Veneto, Italy|Oviedo, Asturias, Spain|Madrid, Spain|Zaragoza, Spain|Canterbury, Kent, United Kingdom|Bristol, United Kingdom|Liverpool, United Kingdom|London, United Kingdom|Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02581891"
394,"NCT02581878","Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Lymphoma, Non-Hodgkin","Drug: BAY1862864","Maximum tolerated dose assessed by the number of subjects with dose-limiting toxicities (DLTs)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","21","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17845|2014-004140-36","November 20, 2015","April 1, 2019","November 26, 2019","October 21, 2015",,"December 4, 2019","Skanes Universitetssjukhus, Lund, Sweden|Southampton General Hospital, Southampton, Hampshire, United Kingdom|Royal Marsden NHS Trust (Surrey), Sutton, Surrey, United Kingdom|Royal Free Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02581878"
395,"NCT02576431","A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors","NAVIGATE","Recruiting","No Results Available","Solid Tumors Harboring NTRK Fusion","Drug: BAY2757556 (Larotrectinib, Vitrakvi)","Best overall response rate by IRC|Best overall response rate by investigator|Duration of response (DOR) by IRC|Duration of response (DOR) by investigator|Clinical benefit rate (CBR)|Progression-free survival (PFS) after Larotrectinib|Overall survival time|Progression-free survival (PFS) after past cancer therapy|Number of subjects with adverse events|Number of subjects with serious adverse events|Number of subjects with treatment-related adverse events|Severity of adverse events|Severity of serious adverse events|Severity of treatment-related adverse events|Duration of adverse events|Duration of serious adverse events|Duration of treatment-related adverse events|Number of subjects with safety-relevant changes in clinical parameters or vital signs after drug administration|Severity of safety-relevant changes in clinical parameters or vital signs after drug administration|Proportion of subjects that has any tumor regression as a best response|Concordance coefficient","Bayer","All","12 Years and older   (Child, Adult, Older Adult)","Phase 2","120","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20289|LOXO-TRK-15002|2015-003582-28","September 30, 2015","September 30, 2025","September 30, 2025","October 15, 2015",,"January 13, 2020","Stanford Cancer Center, Palo Alto, California, United States|UCLA-Santa Monica Medical Center, Santa Monica, California, United States|MedStar Health Research Institute, Washington, District of Columbia, United States|Memorial Hospital West, Pembroke, Florida, United States|University of Chicago, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of North Carolina Hospitals, Chapel Hill, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Inova Health Care Services, Falls Church, Virginia, United States|University of Washington, Seattle, Washington, United States|West Virginia University, Morgantown, West Virginia, United States|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Beijing Cancer Hospital, Beijing, China|Sichuan University West China Hospital, Chengdu, China|Zhongshan Hospital, Fudan University, Shanghai, China|Finsen Centre, Copenhagen, Denmark|Institut Bergonié - Unicancer Nouvelle Aquitaine, Bordeaux Cedex, France|Charité Comprehensive Cancer Center (CCCC), Berlin, Germany|St. Vincent's University Hospital, Dublin, Ireland|Nagoya University Hospital, Nagoya, Aichi, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, Japan|The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|IPO Porto, Porto, Portugal|National Cancer Center, Singapore, Singapore|Ciutat Sanitària i Universitaria de la Vall d'Hebron, Barcelona, Spain|Fundacion Jimenez Diaz (Clinica de la Concepcion), Madrid, Spain|Centro Integral Oncológico Clara Campal, Madrid, Spain|Hospital Universitario ""Marqués de Valdecilla"", Santander, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Southampton General Hospital, Southampton, Hampshire, United Kingdom|Institute Of Cancer-Barts and The London School of Medicine, London, United Kingdom|University College Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02576431"
396,"NCT02576002","Epidemiology and Treatment Patterns of Paediatric PAH (Pulmonary Arterial Hypertension)",,"Completed","No Results Available","Hypertension, Pulmonary","Drug: Assigned pulmonary hypertension medication","Incidence rate of PAH (pulmonary arterial hypertension)|Prevalence rate of PAH|Assigned drug treatment for PAH measured using the MarketScan database|Diagnostic procedures performed among PAH patients measured using the MarketScan database|Prevalence of comorbidities among PAH patients","Bayer","All","up to 18 Years   (Child, Adult)",,"2691","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","18515","October 2015","January 2016","January 2016","October 15, 2015",,"February 26, 2016","Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02576002"
397,"NCT02574715","An Observational Study to Assess Quality of Life and Satisfaction of Young Women (Aged 18-29) Following 6 (±1) Months Using Jaydess as Their Contraceptive Method","JULIA","Completed","No Results Available","Quality of Life","Drug: Levonorgestrel (Jaydess, BAY86-5028)","Quality of life as determined using the SEC-QoL scale|Age (years)|Marital Status|Place of Birth|Place of residence (province, town, city or rural area)|Educational level (primary, secondary or higher education)|Employment (working outside the home, working from home, unemployed, student)|Maternity status (has children or plans to have children)|Frequency attending this physician's clinic for family planning purposes|History of type of contraceptive use|History of duration of contraceptive use|Prescription of Jaydess (date)|Benefits perceived on ease and comfort of use by means of a structured interview (Yes, No)|Global assessment of the insertion by means of a structured interview for pain questions (any, slight, moderate, severe)|Global assessment of the insertion by means of a structured interview for times questions|Global assessment of the insertion (acceptable without discomfort, with a few of minimal discomfort or with an enormous discomfort and unacceptable)|Global satisfaction with Jaydess, using a structured questionaire|Bleeding pattern features, using a questionnaire to compare current bleeding versus bleeding before the insertion of Jaydess as recalled","Bayer","Female","18 Years to 29 Years   (Adult)",,"1039","Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","18096","September 18, 2015","July 1, 2016","September 28, 2016","October 14, 2015",,"June 29, 2017","Many locations, Spain",,"https://ClinicalTrials.gov/show/NCT02574715"
398,"NCT02571569","A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors",,"Completed","No Results Available","Hemophilia A|Hemophilia B","Drug: BAY1093884","Number of participants (single dose cohors) with adverse events as measure of safety and tolerability|Plasma levels of anti-BAY1093884 antibodies|Plasma concentration of BAY1093884 characterized by AUC(0-tlast)|Plasma concentration of BAY1093884 characterized by AUC(0-tlast)/D|Plasma concentration of BAY1093884 characterized by Cmax|Plasma concentration of BAY1093884 characterized by Cmax/D|Tissue factor pathway inhibitor (TFPI) activity|Number of participants (multiple dose cohort) with adverse events as a measure of safety and tolerability|Plasma levels of anti-BAY1093884 antibodies (multiple dose cohort)|Plasma concentration of BAY1093884 characterized by AUC(0-7d and AUC(0-tau) (multiple dose cohort)|Plasma concentration of BAY1093884 characterized by AUC(0-7d/D and AUC(0-tau)/D after multiple dose|Plasma concentration of BAY1093884 characterized by Cmax after first dose and last dose (Cmax,md)|Plasma concentration of BAY1093884 characterized by Cmax/D after first dose and last dose (Cmax,md/D)|Accumulation of BAY 1093884 in plasma as defined by ratio for Cmax and AUC (after first and last dose)","Bayer","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","32","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","16144|2014-003283-20","October 28, 2015","July 9, 2018","October 11, 2018","October 8, 2015",,"October 18, 2018","Plovdiv, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Gießen, Hessen, Germany|Berlin, Germany|Suginami, Tokyo, Japan|Kiev, Ukraine|Lviv, Ukraine|London, United Kingdom|Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02571569"
399,"NCT02564718","Rivaroxaban for Treatment in Venous or Arterial Thrombosis in Neonates","Einstein Jr","Completed","Has Results","Thromboembolism","Drug: Rivaroxaban (Xarelto, BAY59-7939)","Concentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Day 1|Concentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Day 3|Concentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Day 8|Change From Baseline in Prothrombin Time at Day 1|Change From Baseline in Prothrombin Time at Day 3|Change From Baseline in Activated Partial Thromboplastin Time (aPTT) at Day 1|Change From Baseline in Activated Partial Thromboplastin Time (aPTT) at Day 3|Anti-factor Xa Activity (Anti-Xa) Values at Day 1|Anti-factor Xa Activity (Anti-Xa) Values at Day 3|Anti-factor Xa Activity (Anti-Xa) Values at Day 8|Number of Participants With Major and Clinically Relevant Non-Major Bleeding Events|Number of Participants With Symptomatic Recurrent Venous Thromboembolism and Asymptomatic Deterioration in Thrombotic Burden on Repeat Imaging","Bayer|Janssen Research & Development, LLC","All","up to 6 Months   (Child)","Phase 1|Phase 2","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","17618|2014-002385-74","November 19, 2015","December 18, 2017","December 18, 2017","October 1, 2015","July 10, 2018","July 10, 2018","Wien, Austria|Montpellier, France|Erlangen, Germany|Ramat Gan, Israel|Milano, Lombardia, Italy|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Izmir, Turkey","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT02564718/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT02564718/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02564718"
400,"NCT02563197","Inhalation Flow Rate-study",,"Completed","No Results Available","Bronchiectasis","Device: T-326 Inhaler","Peak inspiratory flow (L/min)|Inspiratory volumes (V in L)|Inspiratory time (t in s)","Bayer|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 1","33","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17607|CIV-15-07-013749","November 23, 2015","February 17, 2016","April 29, 2016","September 30, 2015",,"April 26, 2017","Gauting, Bayern, Germany|Landsberg, Bayern, Germany|München, Bayern, Germany|München, Bayern, Germany|München, Bayern, Germany|Frankfurt, Hessen, Germany|Frankfurt, Hessen, Germany|Neu-Isenburg, Hessen, Germany|Hannover, Niedersachsen, Germany|Grosshansdorf, Germany",,"https://ClinicalTrials.gov/show/NCT02563197"
401,"NCT02562235","Riociguat in Children With Pulmonary Arterial Hypertension (PAH)","PATENT-CHILD","Active, not recruiting","No Results Available","Hypertension, Pulmonary","Drug: Riociguat (Adempas, BAY63-2521)","Change in incidence of treatment-emergent adverse events|Change in incidence of treatment-emergent serious adverse events|Change in heart rate|Change in blood pressure|Change in bone age x-ray of left hand|Plasma concentration of riociguat|Change in 6-Minute Walking Distance (6MWD)|Change in WHO functional class|Change in NT-proBNP or BNP (N-terminal pro-brain natriuretic peptide)|Changes in echocardiograph from baseline|Time to clinical worsening|Change in Quality of Life scores as assessed by patient questionnaire and PedsQL generic score|Questionnaire to assess both taste and texture of pediatric formulation(s)","Bayer|Merck Sharp & Dohme Corp.","All","6 Years to 17 Years   (Child)","Phase 3","24","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15681|2014-003952-29","October 29, 2015","May 19, 2020","November 25, 2031","September 29, 2015",,"December 23, 2019","IPS Centro Médico Imbanaco de Cali S.A., Cali, Valle Del Cauca, Colombia|Universitätsklinikum Heidelberg, Heidelberg, Baden-Württemberg, Germany|Universitätsklinikum Ulm, Ulm, Baden-Württemberg, Germany|Deutsches Herzzentrum, Berlin, Germany|Gottsegen Gyorgy National Cardiology Institute, Budapest, Hungary|SZTE ÁOK Szent Györgyi Albert Klinikai Kozpont, Szeged, Hungary|A.O. di Padova, Padova, Veneto, Italy|Aichi Children's Health and Medical Center, Obu, Aichi, Japan|National Cerebral and Cardiovascular Center, Suita, Osaka, Japan|Osaka University Hospital, Suita, Osaka, Japan|Keio University Hospital, Shinjuku-ku, Tokyo, Japan|Operadora de Hospitales Angeles S. A. de C. V., Huixquilucan, Mexico|Instituto Nacional de Cardiología ""Ignacio Chávez"", Mexico D.F., Mexico|Wojewodzki Szpital Specjalistyczny, Wroclaw, Poland|Veterans General Hospital, Kaoshiung, Taiwan|Hacettepe Universitesi Tip Fakultesi, Ankara, Turkey",,"https://ClinicalTrials.gov/show/NCT02562235"
402,"NCT02559232","An Observational Cross-sectional Study Evaluating the Use of Re-sources and the Sociodemographic and Clinical Characteristics of Patients Diagnosed With Non-valvular Atrial Fibrillation With a Risk of Stroke or Systemic Embolism on Anticoagulant Therapy and Treated in Primary Care Centers","BRONCE-AP","Completed","No Results Available","Stroke|Prevention and Control|Atrial Fibrillation","Drug: Direct Oral Anticoagulant (DOAC)","Age|Gender|Race|Composite of relevant cardiovascular events: stroke, TIA, systemic embolism, bleeding|Composite number of participants with comorbidities: hypertension, heart failure, diabetes mellitus, kidney failure, dyslipidemia|Dose on the Non-Valvular Atrial Fibrillation treatment: relevant active substances|Frequency on the Non-Valvular Atrial Fibrillation treatment: relevant active substances|Duration on the Non-Valvular Atrial Fibrillation treatment: relevant active substances|Concomitant treatments: therapy group of relevant active substances|Risk of thromboembolic event based on the CHADS2 score|Risk of thromboembolic event based on the CHA2DS2-VASc score|Risk of bleeding based on the HAS-BLED score|Adherence to treatment|Satisfaction of treatment by the mean score on the ACTS (Anti Clot Treatment Scale) questionnaire|Compliance with the criteria in therapeutic positioning report UT/V4/23122013|Use of healthcare resources: Number of visits with primary care physician. Number of visits with specialist, Number of visits with nursing staff, Number of visits to A&E, Number of diagnostic tests in the period when the change was made, related to NVAF.","Bayer","All","18 Years and older   (Adult, Older Adult)",,"247","Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","17961","September 2015","December 2015","March 2016","September 24, 2015",,"February 16, 2017","Many Locations, Spain",,"https://ClinicalTrials.gov/show/NCT02559232"
403,"NCT02558465","Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)","JPMS-XAR-VTE","Recruiting","No Results Available","Venous Thromboembolism","Drug: Rivaroxaban (Xarelto, BAY59-7939)","Number of participants with ISTH (International Society on Thrombosis and Haemostasis) major bleeding as a measure of Safety and tolerability|Number of participants with symptomatic recurrent VTE (composite of DVT or nonfatal or fatal pulmonary embolism)|Composite number of all-cause mortality, vascular events (acute coronary syndrome, ischemic stroke, transient ischemic attack, or systemic embolism), clinically relevant non-major bleeding and all other adverse events/ADRs|Number of participants with asymptomatic deterioration of thrombotic burden (change of D-dimer, imaging test such as CT or CCUS) by the end of standard observation period|Frequency of VTE recurrence and adverse events/ADRs comparison between distal and/or proximal DVT localization treatment outcomes","Bayer|Janssen Research & Development, LLC","All","Child, Adult, Older Adult",,"1250","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","17522|XAR-PE-DVT","November 13, 2015","March 31, 2020","March 31, 2021","September 24, 2015",,"January 22, 2020","Many locations, Multiple Locations, Japan",,"https://ClinicalTrials.gov/show/NCT02558465"
404,"NCT02556268","Interaction With HIV Antiretroviral Agents",,"Completed","No Results Available","HIV-DDI","Drug: Riociguat (Adempas, BAY 63-2521)|Drug: ATRIPLA|Drug: COMPLERA|Drug: STRIBILD|Drug: TRIUMEQ|Drug: Antiretroviral protease inhibitor","AUC of riociguat|Cmax of riociguat|AUC of riociguat main metabolite M1 (BAY 60-4552)|Cmax of riociguat main metabolite M1 (BAY 60-4552)","Bayer","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","40","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","17957","February 23, 2016","December 7, 2016","December 7, 2016","September 22, 2015",,"December 6, 2017","Orlando, Florida, United States|Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02556268"
405,"NCT02556203","Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes","GALILEO","Terminated","Has Results","Transcatheter Aortic Valve Replacement","Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Acetylsalicylic Acid (ASA)|Drug: Clopidogrel|Drug: Vitamin K antagonist (VKA)","Number of Participants With Death or First Thromboembolic Event (DTE)|Number of Participants With Primary Bleeding Event (PBE)|Number of Participants With Net-clinical Benefit|Number of Participants With Cardiovascular Death or Thromboembolic Event|Number of Participants With TIMI (Thrombolysis In Myocardial Infarction) Major / Minor Bleeds|Number of Participants With ISTH (International Society on Thrombosis and Haemostasis) Major Bleeds|Number of Participants With Composite Bleeding Endpoint of BARC (Bleeding Academic Research Consortium) 2, 3, or 5 Bleeds","Bayer|Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 3","1653","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","17938|2015-001975-30","December 16, 2015","November 27, 2018","November 27, 2018","September 22, 2015","January 13, 2020","January 13, 2020","Los Angeles, California, United States|Washington, District of Columbia, United States|Clearwater, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Evanston, Illinois, United States|West Des Moines, Iowa, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Detroit, Michigan, United States|Minneapolis, Minnesota, United States|Kansas City, Missouri, United States|Morristown, New Jersey, United States|Manhasset, New York, United States|New York, New York, United States|Roslyn, New York, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Philadelphia, Pennsylvania, United States|Wilkes-Barre, Pennsylvania, United States|Houston, Texas, United States|Houston, Texas, United States|Plano, Texas, United States|Temple, Texas, United States|Burlington, Vermont, United States|Charlottesville, Virginia, United States|Falls Church, Virginia, United States|Tacoma, Washington, United States|Linz, Oberösterreich, Austria|Wels, Oberösterreich, Austria|Graz, Steiermark, Austria|Salzburg, Austria|Wien, Austria|Wien, Austria|Wien, Austria|Genk, Belgium|Hasselt, Belgium|Liege, Belgium|Edmonton, Alberta, Canada|Vancouver, British Columbia, Canada|Victoria, British Columbia, Canada|Winnipeg, Manitoba, Canada|Halifax, Nova Scotia, Canada|Newmarket, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Brno, Czechia|Praha 10, Czechia|Praha 4, Czechia|Aarhus N, Denmark|Copenhagen, Denmark|Odense C, Denmark|Angers, France|Brest, France|Chambray-lès-Tours, France|Lille, France|Paris, France|Paris, France|Toulouse, France|Freiburg, Baden-Württemberg, Germany|Konstanz, Baden-Württemberg, Germany|Lahr, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|Ulm, Baden-Württemberg, Germany|Bad Neustadt, Bayern, Germany|Erlangen, Bayern, Germany|München, Bayern, Germany|München, Bayern, Germany|München, Bayern, Germany|Regensburg, Bayern, Germany|Bad Nauheim, Hessen, Germany|Frankfurt, Hessen, Germany|Fulda, Hessen, Germany|Rotenburg A.d. Fulda, Hessen, Germany|Hannover, Niedersachsen, Germany|Aachen, Nordrhein-Westfalen, Germany|Bonn, Nordrhein-Westfalen, Germany|Dortmund, Nordrhein-Westfalen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Krefeld, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Neuss, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Homburg, Saarland, Germany|Magdeburg, Sachsen-Anhalt, Germany|Leipzig, Sachsen, Germany|Bad Segeberg, Schleswig-Holstein, Germany|Kiel, Schleswig-Holstein, Germany|Bad Berka, Thüringen, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Bremen, Germany|Hamburg, Germany|Bergamo, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Catania, Sicilia, Italy|Pisa, Toscana, Italy|Padova, Veneto, Italy|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Amsterdam, Netherlands|Breda, Netherlands|Rotterdam, Netherlands|Bergen, Norway|Oslo, Norway|Tromsø, Norway|Bielsko-Biala, Poland|Warszawa, Poland|Warszawa, Poland|Oviedo, Asturias, Spain|L'Hospitalet de Llobregat, Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Málaga, Spain|Uppsala, Sweden|Basel, Basel-Stadt, Switzerland|Lugano, Ticino, Switzerland|Bern, Switzerland|Luzern, Switzerland|Zürich, Switzerland|Brighton, East Sussex, United Kingdom|Southampton, Hampshire, United Kingdom|Blackpool, Lancashire, United Kingdom|Leicester, Leicestershire, United Kingdom|Belfast, North Ireland, United Kingdom|Newcastle Upon Tyne, Tyne And Wear, United Kingdom|Leeds, West Yorkshire, United Kingdom|Edinburgh, United Kingdom|London, United Kingdom|London, United Kingdom|Oxford, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT02556203/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT02556203/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02556203"
406,"NCT02555059","Special Drug Use Investigation of Ciproxan Injection in Pediatrics",,"Completed","No Results Available","Cystitis / Pyelonephritis / Cystic Fibrosis / Anthrax","Drug: Cipro (Ciprofloxacin, BAYQ3939)","Number of musculoskeletal adverse events.|Existence of Bacillus anthracis or Escherichia coli or Pseudomonas aeruginosa in urine(Y/N)|Number of participants with adverse events as measure of safety and tolerability|Efficacy|Number of participants with adverse events based on abnormal laboratory measurements","Bayer","All","up to 14 Years   (Child)",,"48","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","18235","July 15, 2016","December 17, 2018","December 17, 2018","September 21, 2015",,"January 14, 2019","Multiple Locations, Japan",,"https://ClinicalTrials.gov/show/NCT02555059"
407,"NCT02550977","Russia/Ukraine Suppression of Ovarian Activity Study",,"Completed","No Results Available","Contraception","Drug: Gestodene/EE Patch (BAY86-5016)","Suppression of ovulatory activity proved by progesterone and estradiol concentrations|Serum concentration, AUC (area under curve) of Gestodene|Serum concentration, AUC (area under curve) of ethinyl estradiol|Serum concentration, AUC (area under curve) of Sexual hormone binding globulin|Number of patients with adverse events|Number of patients with abnormal safety laboratory|Time course of follicle-stimulating hormone|Time course of luteinizing hormone","Bayer","Female","18 Years to 35 Years   (Adult)","Phase 2","91","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","16119","September 18, 2015","July 15, 2016","August 15, 2016","September 16, 2015",,"August 7, 2017","Irkutsk, Russian Federation|Krasnodar, Russian Federation|Moscow, Russian Federation|Smolensk, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|Kiev, Ukraine|Zaporizhzhya, Ukraine",,"https://ClinicalTrials.gov/show/NCT02550977"
408,"NCT02550717","Epidemiological Study on the Safety of Aspirin in The Health Improvement Network (THIN)","EPISAT","Completed","No Results Available","Secondary Prevention|Stroke|Ischemic Heart Disease|Coronary Heart Disease","Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)|Drug: Clopidogrel, Oral Anticoagulants, NSAIDs and SSRIs","Incidence of Intracranial bleeding among new users of low-dose Acetylsalicylic acid (ASA).|Incidence of Upper gastrointestinal bleeding among new users of low-dose ASA.|Incidence of Lower gastrointestinal bleeding among new users of low-dose ASA|Time to Intracranial bleeding among new users of low-dose ASA|Time to Upper gastrointestinal bleeding among new users of low-dose ASA|Time to Lower gastrointestinal bleeding among new users of low-dose ASA|Relative risk of Intracranial bleeding among new users of low dose ASA|Relative risk of Upper gastrointestinal bleeding among new users of low-dose ASA|Relative risk of Lower gastrointestinal bleeding among new users of low-dose ASA|Relative risk of Intracranial bleeding associated with use of other medications.|Relative risk of Upper gastrointestinal bleeding associated with use of other medications|Relative risk of Lower gastrointestinal bleeding associated with use of other medications.","Bayer","All","40 Years to 84 Years   (Adult, Older Adult)",,"398158","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","18116","September 1, 2015","March 31, 2017","March 31, 2017","September 15, 2015",,"October 24, 2018","Multiple Locations, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02550717"
409,"NCT02549469","Bioequivalence of Single Dose Extended Release Naproxen Sodium (660 mg) Tablet Versus Naproxen Sodium (220 mg) Tablet Three Times Daily",,"Completed","No Results Available","Pain","Drug: Naproxen Sodium ER (BAY117031), 20% HPMC|Drug: Naproxen Sodium ER (BAY117031), 30% HPMC|Drug: Naproxen Sodium ER (BAY117031), 40% HPMC|Drug: Aleve (Naproxen Sodium, BAY117031)","Cmax (maximum plasma concentration) for naproxen sodium|AUC0-24 (partial area under the curve ) for naproxen sodium|AUC0-t (areas under the curve ) for naproxen sodium|AUC0-∞ (area under the curve) for naproxen sodium|Tmax (The first time point where Cmax is reached) for naproxen sodium|AUC0-8 (partial area under the curve) for naproxen sodium|AUC8-16 (partial area under the curve ) for naproxen sodium|AUC16-24 (partial area under the curve) for naproxen sodium|λz (terminal elimination rate constant)|t1/2 (terminal half life)|Adverse events (AEs) collection|Serious adverse events (SAEs) collection|Vital signs: sitting blood pressure|Vital signs: repiratory rate|Vital signs : pulse rate|Clinical Laboratory data|Physical examination findings","Bayer","All","18 Years to 55 Years   (Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12656","March 2007","May 2007","May 2007","September 15, 2015",,"September 15, 2015",,,"https://ClinicalTrials.gov/show/NCT02549469"
410,"NCT02545465","A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice","CAPTURE","Completed","No Results Available","Hypertension, Pulmonary","Drug: Riociguat (Adempas, BAY63-2521)","Starting Dose|Dose Increments|Final Dose","Bayer","All","Child, Adult, Older Adult",,"125","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","17983|AD1501","September 15, 2015","May 31, 2016","August 31, 2016","September 10, 2015",,"May 24, 2017","Many Locations, Belgium|Many Locations, Canada|Many Locations, Colombia|Many Locations, Germany|Many Locations, Japan|Many Locations, Sweden|Many Locations, Turkey",,"https://ClinicalTrials.gov/show/NCT02545465"
411,"NCT02545452","Effect of Concomitant Use of an Antimycotic, an Antibiotic, a Spermicide or Tampons on Pharmacokinetics of Anastrozole and Levonorgestrel Released From Intra-vaginal Ring",,"Completed","No Results Available","Endometriosis","Drug: Anastrozole / Levonorgestrel (BAY98-7196)|Drug: Gyno-Daktarin|Drug: Sobelin vaginal creme|Drug: Patentex oval|Other: Tampon","Average concentration (Cav) anastrozole after insertion of the intra-vaginal ring for all groups|Average concentration (Cav) anastrozole after insertion of the intra-vaginal ring for Tampon group|Average concentration (Cav) levonorgestrel after insertion of the intra-vaginal ring for all groups|Average concentration (Cav) levonorgestrel after insertion of the intra-vaginal ring for Tampon group|Maximum observed plasma concentration before co-medication or tampons (Cmax)|Time to reach maximum observed concentration before co-medication or tampons (tmax)|Plasma concentration 28 days after intra-vaginal ring (IVR) insertion (Treatment group D, Day 29) (C(28d))|Plasma concentration 35 days after IVR insertion (Treatment group D, Day 36)(C(35d))|Average concentration in the extended wearing period (Treatment D, Days 29-36 using the same IVR)|Terminal half-life associated with the terminal slope after removal of IVR (t1/2)|Number of participants with adverse events as a measure of safety and tolerability","Bayer","Female","18 Years to 50 Years   (Adult)","Phase 1","52","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","16997|2014-005167-32","September 15, 2015","March 14, 2016","July 29, 2016","September 10, 2015",,"July 24, 2017","Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT02545452"
412,"NCT02545049","Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease","FIGARO-DKD","Active, not recruiting","No Results Available","Diabetic Kidney Disease","Drug: Finerenone (BAY94-8862)|Drug: Placebo","Time to the first occurrence of the composite endpoint of cardiovascular death and non-fatal cardiovascular events (myocardial infarction, stroke, or hospitalization for heart failure)|Time to first occurrence of the following composite endpoints: onset of kidney failure, a sustained decrease in estimated glomerular filtration rate (eGFR)of ≥40% from baseline over at least 4 weeks and renal death|Time to all-cause mortality|Time to all-cause hospitalization|Change in urinary albumin-to-creatine ratio (UCAR) from baseline to month 4|Time to first occurrence of the following composite endpoint: onset of kidney failure, a sustained decrease in estimated glomerular filtration rate (eGFR) of ≥ 57% from baseline over at least 4 weeks or renal death.","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","7437","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","17530|2015-000950-39","September 17, 2015","June 21, 2021","July 21, 2021","September 9, 2015",,"January 21, 2020","Birmingham, Alabama, United States|Fort Payne, Alabama, United States|Huntsville, Alabama, United States|Mesa, Arizona, United States|Phoenix, Arizona, United States|Phoenix, Arizona, United States|Prescott, Arizona, United States|Tucson, Arizona, United States|Tucson, Arizona, United States|Bakersfield, California, United States|Carlsbad, California, United States|Chula Vista, California, United States|Dublin, California, United States|El Centro, California, United States|Fresno, California, United States|Fresno, California, United States|La Mesa, California, United States|Loma Linda, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|Northridge, California, United States|Port Hueneme, California, United States|Poway, California, United States|Rancho Cucamonga, California, United States|Rialto, California, United States|Roseville, California, United States|San Diego, California, United States|Santa Rosa, California, United States|Torrance, California, United States|New Haven, Connecticut, United States|Waterbury, Connecticut, United States|Fort Lauderdale, Florida, United States|Fort Lauderdale, Florida, United States|Fort Lauderdale, Florida, United States|Hialeah, Florida, United States|Hialeah, Florida, United States|Hollywood, Florida, United States|Jacksonville, Florida, United States|Miami Beach, Florida, United States|Miami Lakes, Florida, United States|Miami Lakes, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|New Port Richey, Florida, United States|Ocala, Florida, United States|Orlando, Florida, United States|Palm Harbor, Florida, United States|Sarasota, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Winter Haven, Florida, United States|Atlanta, Georgia, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Lawrenceville, Georgia, United States|Lilburn, Georgia, United States|Macon, Georgia, United States|Honolulu, Hawaii, United States|Chicago, Illinois, United States|Elgin, Illinois, United States|Morton, Illinois, United States|Springfield, Illinois, United States|Indianapolis, Indiana, United States|Iowa City, Iowa, United States|West Des Moines, Iowa, United States|Hutchinson, Kansas, United States|Topeka, Kansas, United States|Wichita, Kansas, United States|Metairie, Louisiana, United States|Monroe, Louisiana, United States|New Orleans, Louisiana, United States|Shreveport, Louisiana, United States|Boston, Massachusetts, United States|Ann Arbor, Michigan, United States|Flint, Michigan, United States|Flint, Michigan, United States|Kalamazoo, Michigan, United States|Minneapolis, Minnesota, United States|Columbia, Missouri, United States|Columbia, Missouri, United States|Jefferson City, Missouri, United States|Kansas City, Missouri, United States|Kansas City, Missouri, United States|Saint Louis, Missouri, United States|Saint Louis, Missouri, United States|Omaha, Nebraska, United States|Omaha, Nebraska, United States|Las Vegas, Nevada, United States|Las Vegas, Nevada, United States|Las Vegas, Nevada, United States|Las Vegas, Nevada, United States|Las Vegas, Nevada, United States|Reno, Nevada, United States|Newark, New Jersey, United States|Albuquerque, New Mexico, United States|Albany, New York, United States|Brooklyn, New York, United States|Brooklyn, New York, United States|New York, New York, United States|Rosedale, New York, United States|Smithtown, New York, United States|Staten Island, New York, United States|Asheboro, North Carolina, United States|Chapel Hill, North Carolina, United States|Charlotte, North Carolina, United States|Greenville, North Carolina, United States|New Bern, North Carolina, United States|Winston-Salem, North Carolina, United States|Canton, Ohio, United States|Willoughby Hills, Ohio, United States|Beaver, Pennsylvania, United States|Bethlehem, Pennsylvania, United States|Hershey, Pennsylvania, United States|Jersey Shore, Pennsylvania, United States|Anderson, South Carolina, United States|Charleston, South Carolina, United States|Greer, South Carolina, United States|Murrells Inlet, South Carolina, United States|Myrtle Beach, South Carolina, United States|Orangeburg, South Carolina, United States|Chattanooga, Tennessee, United States|Memphis, Tennessee, United States|Memphis, Tennessee, United States|Memphis, Tennessee, United States|Nashville, Tennessee, United States|Nashville, Tennessee, United States|Nashville, Tennessee, United States|Arlington, Texas, United States|Corpus Christi, Texas, United States|Dallas, Texas, United States|Dallas, Texas, United States|Dallas, Texas, United States|El Paso, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Kingwood, Texas, United States|McAllen, Texas, United States|McKinney, Texas, United States|Missouri City, Texas, United States|Pearland, Texas, United States|Pflugerville, Texas, United States|San Antonio, Texas, United States|San Antonio, Texas, United States|San Antonio, Texas, United States|Sugar Land, Texas, United States|Sugar Land, Texas, United States|Tomball, Texas, United States|Waco, Texas, United States|Salt Lake City, Utah, United States|Burlington, Vermont, United States|Alexandria, Virginia, United States|Charlottesville, Virginia, United States|Manassas, Virginia, United States|Salem, Virginia, United States|Virginia Beach, Virginia, United States|Spokane, Washington, United States|Tacoma, Washington, United States|Junín, Buenos Aires, Argentina|Lanús, Buenos Aires, Argentina|Mar del Plata, Buenos Aires, Argentina|Sarandí, Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Ciudad Autón. de Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Buenos Aires, Ciudad Auton., Argentina|Córdoba, Argentina|Córdoba, Argentina|San Luis, Argentina|Garran, Australian Capital Territory, Australia|Gosford, New South Wales, Australia|Kanwal, New South Wales, Australia|Liverpool, New South Wales, Australia|New Lambton Heights, New South Wales, Australia|Wollongong, New South Wales, Australia|Brisbane, Queensland, Australia|Adelaide, South Australia, Australia|Fitzroy, Victoria, Australia|Heidelberg, Victoria, Australia|Melbourne, Victoria, Australia|Prahran, Victoria, Australia|Reservoir, Victoria, Australia|Richmond, Victoria, Australia|St. Albans, Victoria, Australia|Elizabeth Vale, Australia|Linz, Oberösterreich, Austria|Linz, Oberösterreich, Austria|Graz, Steiermark, Austria|Saint Stefan, Steiermark, Austria|Zams, Tirol, Austria|Feldkirch, Vorarlberg, Austria|Innsbruck, Austria|Salzburg, Austria|Wels, Austria|Wien, Austria|Wien, Austria|Wien, Austria|Wien, Austria|Bruxelles - Brussel, Belgium|Edegem, Belgium|Gent, Belgium|Ieper, Belgium|Kortrijk, Belgium|Leuven, Belgium|Liege, Belgium|Roeselare, Belgium|Fortaleza, Ceará, Brazil|Fortaleza, Ceará, Brazil|Fortaleza, Ceará, Brazil|Brasilia, Distrito Federal, Brazil|Aparecida de Goiania, Goiás, Brazil|Goiania, Goiás, Brazil|Juiz de Fora, Minas Gerais, Brazil|Uberlândia, Minas Gerais, Brazil|Campina Grande do Sul, Parana, Brazil|Curitiba, Parana, Brazil|Curitiba, Parana, Brazil|Curitiba, Parana, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|São Bernardo do Campo, Sao Paulo, Brazil|São José do Rio Preto, Sao Paulo, Brazil|São José dos Campos, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|Rio de Janeiro, Brazil|Rio de Janeiro, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Blagoevgrad, Bulgaria|Botevgrad, Bulgaria|Dimitrovgrad, Bulgaria|Gorna Oryahovitsa, Bulgaria|Kazanlak, Bulgaria|Kozloduy, Bulgaria|Lukovit, Bulgaria|Plovdiv, Bulgaria|Plovdiv, Bulgaria|Razgrad, Bulgaria|Sliven, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Stara Zagora, Bulgaria|Varna, Bulgaria|Yambol, Bulgaria|Edmonton, Alberta, Canada|Burnaby, British Columbia, Canada|Coquitlam, British Columbia, Canada|New Westminster, British Columbia, Canada|Mount Pearl, Newfoundland and Labrador, Canada|St. John's, Newfoundland and Labrador, Canada|Halifax, Nova Scotia, Canada|Cambridge, Ontario, Canada|Hamilton, Ontario, Canada|Hamilton, Ontario, Canada|Kitchener, Ontario, Canada|Newmarket, Ontario, Canada|Oshawa, Ontario, Canada|Ottawa, Ontario, Canada|Sarnia, Ontario, Canada|Smith Falls, Ontario, Canada|Sudbury, Ontario, Canada|Thornhill, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Waterloo, Ontario, Canada|Greenfield Park, Quebec, Canada|Mirabel, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Quebec, Canada|Osorno, Los Lagos, Chile|Santiago, Chile|Santiago, Chile|Santiago, Chile|Santiago, Chile|Santiago, Chile|Santiago, Chile|Xiamen, Fujian, China|Xiamen, Fujian, China|Lanzhou, Gansu, China|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Zhuhai, Guangdong, China|Nanning, Guangxi, China|Nanning, Guangxi, China|Haikou, Hainan, China|Haikou, Hainan, China|Wuhan, Hubei, China|Wuhan, Hubei, China|Changsha, Hunan, China|Changsha, Hunan, China|Changsha, Hunan, China|Hohhot, Inner Mongolia, China|Changzhou, Jiangsu, China|Huai'An, Jiangsu, China|Lianyungang, Jiangsu, China|Nanjing, Jiangsu, China|Nanjing, Jiangsu, China|Nanjing, Jiangsu, China|Nanjing, Jiangsu, China|Nanjing, Jiangsu, China|Suzhou, Jiangsu, China|Wuxi, Jiangsu, China|Yancheng, Jiangsu, China|Nanchang, Jiangxi, China|Nanchang, Jiangxi, China|Changchun, Jilin, China|Changchun, Jilin, China|Shenyang, Liaoning, China|Shenyang, Liaoning, China|Yinchuan, Ningxia, China|Xi'an, Shaanxi, China|Qingdao, Shandong, China|Taiyuan, Shanxi, China|Chengdu, Sichuan, China|Chengdu, Sichuan, China|Urumqi, Xinjiang, China|Hangzhou, Zhejiang, China|Taizhou, Zhejiang, China|Wenzhou, Zhejiang, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Chongqing, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|Tianjin, China|Tianjin, China|Medellin, Antioquia, Colombia|Medellín, Antioquia, Colombia|Medellín, Antioquia, Colombia|Barranquilla, Atlántico, Colombia|Barranquilla, Atlántico, Colombia|Manizales, Caldas, Colombia|Zipaquirá, Cundinamarca, Colombia|Bogotá, Distrito Capital De Bogotá, Colombia|Bogotá, Distrito Capital De Bogotá, Colombia|Cundinamarca, Distrito Capital De Bogotá, Colombia|Pasto, Nariño, Colombia|Armenia, Quindío, Colombia|Pereira, Risaralda, Colombia|Cali, Valle Del Cauca, Colombia|Barranquilla, Colombia|Bogota, Colombia|Floridablanca, Colombia|Medellín, Colombia|Beroun, Czechia|Brandys nad Labem, Czechia|Breclav, Czechia|Ceska Lipa, Czechia|Cesky Krumlov, Czechia|Cesky Krumlov, Czechia|Frydek-Mistek, Czechia|Hodonin, Czechia|Holesov, Czechia|Hranice, Czechia|Koprivnice, Czechia|Krnov, Czechia|Mlada Boleslav, Czechia|Olomouc, Czechia|Olomouc, Czechia|Ostrava, Czechia|Plzen, Czechia|Prague 6, Czechia|Praha 2, Czechia|Praha 4, Czechia|Praha 4, Czechia|Praha 5, Czechia|Vlasim, Czechia|Aalborg, Denmark|Aarhus N, Denmark|Esbjerg, Denmark|Gentofte, Denmark|Hellerup, Denmark|Herlev, Denmark|Hillerød, Denmark|Holbæk, Denmark|Holstebro, Denmark|Hvidovre, Denmark|Kolding, Denmark|København NV, Denmark|Svendborg, Denmark|Viborg, Denmark|Jyväskylä, Finland|Kajaani, Finland|Kerava, Finland|Klaukkala, Finland|Kuopio, Finland|Nurmijärvi, Finland|Oulu, Finland|Rauma, Finland|Seinäjoki, Finland|Tampere, Finland|Turku, Finland|Vantaa, Finland|Bois-guillaume, France|Boulogne Sur Mer, France|Brest, France|COLMAR Cedex, France|Dijon, France|Grenoble Cedex 9, France|Le Coudray, France|Le Creusot, France|Lyon Cedex, France|Mulhouse, France|NIMES cedex 9, France|Paris, France|Saint Herblain, France|Tourcoing, France|Vandoeuvre-les-nancy, France|Venissieux, France|Heidelberg, Baden-Württemberg, Germany|Ludwigsburg, Baden-Württemberg, Germany|Sinzheim, Baden-Württemberg, Germany|Nürnberg, Bayern, Germany|Schweinfurt, Bayern, Germany|Würzburg, Bayern, Germany|Elsterwerda, Brandenburg, Germany|Bad Homburg, Hessen, Germany|Bad König, Hessen, Germany|Frankfurt, Hessen, Germany|Frankfurt, Hessen, Germany|Göttingen, Niedersachsen, Germany|Hannover, Niedersachsen, Germany|Bad Oeynhausen, Nordrhein-Westfalen, Germany|Bochum, Nordrhein-Westfalen, Germany|Dortmund, Nordrhein-Westfalen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Nettetal, Nordrhein-Westfalen, Germany|Witten, Nordrhein-Westfalen, Germany|Ludwigshafen, Rheinland-Pfalz, Germany|Mainz, Rheinland-Pfalz, Germany|Magdeburg, Sachsen-Anhalt, Germany|Dresden, Sachsen, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Leipzig, Sachsen, Germany|Leipzig, Sachsen, Germany|Jena, Thüringen, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Hamburg, Germany|Alexandroupolis, Greece|Athens, Greece|Athens, Greece|Chaidari, Greece|Larissa, Greece|Nea Ionia, Greece|Thessaloniki, Greece|Thessaloniki, Greece|Hong Kong, Hong Kong|Kowloon, Hong Kong|Shatin, Hong Kong|Baja, Hungary|Balatonfured, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Eger, Hungary|Kistarcsa, Hungary|Nyiregyhaza, Hungary|Nyiregyhaza, Hungary|Papa, Hungary|Siofok, Hungary|Szeged, Hungary|Szekesfehervar, Hungary|Szentes, Hungary|Szombathely, Hungary|Cork, Ireland|Dublin, Ireland|Galway, Ireland|Afula, Israel|Ashkelon, Israel|Beer Sheva, Israel|Haifa, Israel|Holon, Israel|Jerusalem, Israel|Kfar Saba, Israel|Nahariya, Israel|Nahariya, Israel|Nazareth, Israel|Ramat Gan, Israel|Rehovot, Israel|Sakhnin, Israel|Tel Aviv, Israel|Tel Aviv, Israel|Tel Aviv, Israel|Tel Aviv, Israel|Tiberias, Israel|Zefat, Israel|Zerifin, Israel|Napoli, Campania, Italy|Bologna, Emilia-Romagna, Italy|Parma, Emilia-Romagna, Italy|Reggio Emilia, Emilia-Romagna, Italy|Genova, Liguria, Italy|Genova, Liguria, Italy|Bergamo, Lombardia, Italy|Bergamo, Lombardia, Italy|Bergamo, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Monza-Brianza, Lombardia, Italy|Torino, Piemonte, Italy|Torino, Piemonte, Italy|Cagliari, Sardegna, Italy|Sassari, Sardegna, Italy|Catania, Sicilia, Italy|Messina, Sicilia, Italy|Pisa, Toscana, Italy|Verona, Veneto, Italy|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Toyota, Aichi, Japan|Funabashi, Chiba, Japan|Ichikawa, Chiba, Japan|Matsuyama, Ehime, Japan|Matsuyama, Ehime, Japan|Chikushino, Fukuoka, Japan|Kasuga, Fukuoka, Japan|Kitakyushu, Fukuoka, Japan|Kitakyushu, Fukuoka, Japan|Kitakyushu, Fukuoka, Japan|Kitakyushu, Fukuoka, Japan|Shirakawa, Fukushima, Japan|Ogaki, Gifu, Japan|Maebashi, Gunma, Japan|Higashihiroshima, Hiroshima, Japan|Asahikawa, Hokkaido, Japan|Hakodate, Hokkaido, Japan|Obihiro, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Kobe, Hyogo, Japan|Naka, Ibaraki, Japan|Ushiku, Ibaraki, Japan|Komatsu, Ishikawa, Japan|Sanuki, Kagawa, Japan|Takamatsu, Kagawa, Japan|Takamatsu, Kagawa, Japan|Atsugi, Kanagawa, Japan|Fujisawa, Kanagawa, Japan|Kamakura, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Tamana, Kumamoto, Japan|Yatsushiro, Kumamoto, Japan|Sasebo, Nagasaki, Japan|Beppu, Oita, Japan|Yufu, Oita, Japan|Nakagami-gun, Okinawa, Japan|Shimajiri, Okinawa, Japan|Matsubara, Osaka, Japan|Suita, Osaka, Japan|Kawaguchi, Saitama, Japan|Sayama, Saitama, Japan|Otsu, Shiga, Japan|Iwata, Shizuoka, Japan|Oyama, Tochigi, Japan|Minato, Tokyo, Japan|Musashino, Tokyo, Japan|Shibuya-ku, Tokyo, Japan|Tacchikawa, Tokyo, Japan|Fukui, Japan|Fukui, Japan|Fukuoka, Japan|Fukuoka, Japan|Fukuoka, Japan|Kagoshima, Japan|Kumamoto, Japan|Kumamoto, Japan|Kumamoto, Japan|Nagasaki, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Saitama, Japan|Wonju-si, Gang''weondo, Korea, Republic of|Anyang-si, Gyeonggido, Korea, Republic of|Seongnam-si, Gyeonggido, Korea, Republic of|Busan, Korea, Republic of|Daegu, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Kaunas, Lithuania|Kaunas, Lithuania|Kaunas, Lithuania|Kaunas, Lithuania|Klaipeda, Lithuania|Utena, Lithuania|Vilnius, Lithuania|Ipoh, Malaysia|Johor Bahru, Malaysia|Kelantan, Malaysia|Kelantan, Malaysia|Kuala Lumpur, Malaysia|Pahang, Malaysia|Perak, Malaysia|Pulau Pinang, Malaysia|Putrajaya, Malaysia|Selangor, Malaysia|Ciudad de México, Distrito Federal, Mexico|Ciudad de México, Distrito Federal, Mexico|Ciudad de México, Distrito Federal, Mexico|México D.F., Distrito Federal, Mexico|México, D. F., Distrito Federal, Mexico|México, D. F., Distrito Federal, Mexico|Guadalajara, Jalisco, Mexico|Guadalajara, Jalisco, Mexico|Cuernavaca, Morelos, Mexico|Monterrey, Nuevo Leon, Mexico|Queretaro, Querétaro, Mexico|San Juan del Río, Querétaro, Mexico|Culiacán, Sinaloa, Mexico|Culiacán, Sinaloa, Mexico|Mazatlán, Sinaloa, Mexico|Puerto de Veracruz, Veracruz, Mexico|Xalapa, Veracruz, Mexico|Aguascalientes, Mexico|Chihuahua, Mexico|Durango, Mexico|Alkmaar, Netherlands|Almere, Netherlands|Amersfoort, Netherlands|Amsterdam, Netherlands|Amsterdam, Netherlands|Apeldoorn, Netherlands|Breda, Netherlands|Den Haag, Netherlands|Eindhoven, Netherlands|Groningen, Netherlands|Hoogeveen, Netherlands|Sittard-geleen, Netherlands|Zwijndrecht, Netherlands|Auckland, New Zealand|Auckland, New Zealand|Christchurch, New Zealand|Hamilton, New Zealand|Hawkes Bay, New Zealand|Palmerston North, New Zealand|Tauranga, New Zealand|Wellington, New Zealand|Hamar, Norway|Hamar, Norway|Kløfta, Norway|Kongsvinger, Norway|Kristiansand, Norway|Levanger, Norway|Lierskogen, Norway|Oslo, Norway|Oslo, Norway|Skedsmokorset, Norway|Ålesund, Norway|Iloilo City, Philippines|Marikina City, Philippines|Pasig City, Philippines|Quezon City, Philippines|Quezon City, Philippines|Quezon City, Philippines|Bialystok, Poland|Bydgoszcz, Poland|Chojnice, Poland|Gdansk, Poland|Gdynia, Poland|Katowice, Poland|Krakow, Poland|Krakow, Poland|Krakow, Poland|Krakow, Poland|Lodz, Poland|Lodz, Poland|Lodz, Poland|Lublin, Poland|Poznan, Poland|Rzeszow, Poland|Skorzewo, Poland|Szczecin, Poland|Torun, Poland|Warszawa, Poland|Warszawa, Poland|Wroclaw, Poland|Wroclaw, Poland|Zabrze, Poland|Covilha, Castelo Branco, Portugal|Loures, Lisboa, Portugal|Matosinhos, Porto, Portugal|Funchal, Região Autónoma Da Madeira, Portugal|Torres Novas, Santarém, Portugal|Setubal, Setúbal, Portugal|Almada, Portugal|Amadora, Portugal|Braga, Portugal|Leiria, Portugal|Lisboa, Portugal|Lisboa, Portugal|Lisboa, Portugal|Lisboa, Portugal|Porto, Portugal|Porto, Portugal|Viana do Castelo, Portugal|Cidra, Puerto Rico|San Juan, Puerto Rico|San Juan, Puerto Rico|Alba-Iulia, Alba, Romania|Oradea, Bihor, Romania|Baia Mare, Maramures, Romania|Ploiesti, Prahova, Romania|Timisoara, Timis, Romania|Brasov, Romania|Bucuresti, Romania|Bucuresti, Romania|Bucuresti, Romania|Bucuresti, Romania|Bucuresti, Romania|Bucuresti, Romania|Bucuresti, Romania|Cluj-Napoca, Romania|Galati, Romania|Iasi, Romania|Oradea, Romania|Satu Mare, Romania|Timisoara, Romania|Arkhangelsk, Russian Federation|Barnaul, Russian Federation|Chelyabinsk, Russian Federation|Irkutsk, Russian Federation|Izhevsk, Russian Federation|Kazan, Russian Federation|Kazan, Russian Federation|Kemerovo, Russian Federation|Kemerovo, Russian Federation|Kemerovo, Russian Federation|Kirov, Russian Federation|Krasnodar, Russian Federation|Krasnoyarsk, Russian Federation|Kursk, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Nizhny Novgorod, Russian Federation|Nizhny Novgorod, Russian Federation|Novosibirsk, Russian Federation|Novosibirsk, Russian Federation|Novosibirsk, Russian Federation|Novosibirsk, Russian Federation|Novosibirsk, Russian Federation|Omsk, Russian Federation|Omsk, Russian Federation|Omsk, Russian Federation|Orenburg, Russian Federation|Perm, Russian Federation|Saratov, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|Stavropol, Russian Federation|Syktyvkar, Russian Federation|Voronezh, Russian Federation|Voronezh, Russian Federation|Yaroslavl, Russian Federation|Yaroslavl, Russian Federation|Yekaterinburg, Russian Federation|Riyadh, Saudi Arabia|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|Banska Bystrica, Slovakia|Bardejov, Slovakia|Nitra, Slovakia|Rimavska Sobota, Slovakia|Roznava, Slovakia|Zilina, Slovakia|Port Elizabeth, Eastern Cape, South Africa|Johannesburg, Gauteng, South Africa|Johannesburg, Gauteng, South Africa|Lenasia South, Gauteng, South Africa|Newtown, Gauteng, South Africa|Petoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Soweto, Gauteng, South Africa|Durban, Kwazulu-Natal, South Africa|Isipingo Rail, Kwazulu-Natal, South Africa|Tongaat, Kwazulu-Natal, South Africa|Middelburg, Mpumalanga, South Africa|Witbank, Mpumalanga, South Africa|Cape Town, Western Cape, South Africa|Cape Town, Western Cape, South Africa|Somerset West, Western Cape, South Africa|Worcester, Western Cape, South Africa|Ferrol, A Coruña, Spain|Badalona, Barcelona, Spain|L'Hospitalet de Llobregat, Barcelona, Spain|Manresa, Barcelona, Spain|Sant Joan Despi, Barcelona, Spain|Jerez de la Frontera, Cádiz, Spain|Burela, Lugo, Spain|Alcalá de Henares, Madrid, Spain|Getafe, Madrid, Spain|Sagunto, Valencia, Spain|A Coruña, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Córdoba, Spain|Granada, Spain|Jaén, Spain|Madrid, Spain|Madrid, Spain|Málaga, Spain|Valencia, Spain|Valencia, Spain|Valencia, Spain|Valencia, Spain|Göteborg, Sweden|Göteborg, Sweden|Lund, Sweden|Lund, Sweden|Rättvik, Sweden|Skövde, Sweden|Stockholm, Sweden|Stockholm, Sweden|Stockholm, Sweden|Uppsala, Sweden|Uppsala, Sweden|Örebro, Sweden|Örebro, Sweden|St. Gallen, Sankt Gallen, Switzerland|St. Gallen, Sankt Gallen, Switzerland|Olten, Solothurn, Switzerland|Lausanne, Vaud, Switzerland|Bern, Switzerland|Genève, Switzerland|Changhua, Taiwan|Kaohsiung, Taiwan|New Taipei City, Taiwan|Taichung, Taiwan|Taichung, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Bangkok, Thailand|Bangkok, Thailand|Chiangmai, Thailand|Khon Kaen, Thailand|Adana, Turkey|Ankara, Turkey|Antalya, Turkey|Antalya, Turkey|Aydin, Turkey|Istanbul, Turkey|Istanbul, Turkey|Istanbul, Turkey|Izmir, Turkey|Izmir, Turkey|Izmir, Turkey|Kayseri, Turkey|Kocaeli, Turkey|Malatya, Turkey|Sivas, Turkey|Cherkasy, Ukraine|Chernivtsi, Ukraine|Dnipro, Ukraine|Dnipro, Ukraine|Ivano-Frankivsk, Ukraine|Kharkiv, Ukraine|Kharkiv, Ukraine|Kharkiv, Ukraine|Kharkiv, Ukraine|Kiev, Ukraine|Kiev, Ukraine|Kiev, Ukraine|Kiev, Ukraine|Kiev, Ukraine|Kyiv, Ukraine|Lviv, Ukraine|Mykolayiv, Ukraine|Ternopil, Ukraine|Vinnytsia, Ukraine|Zaporizhzhya, Ukraine|Zaporozhye, Ukraine|Llanelli, Carmarthenshire, United Kingdom|Liverpool, Merseyside, United Kingdom|Northampton, Northamptonshire, United Kingdom|Carshalton, Surrey, United Kingdom|Birmingham, West Midlands, United Kingdom|Chichester, West Sussex, United Kingdom|Bristol, United Kingdom|Glasgow, United Kingdom|London, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Middlesborough, United Kingdom|Ha Noi, Vietnam|Ha Noi, Vietnam|Ho Chi Minh City, Vietnam|Ho Chi Minh City, Vietnam",,"https://ClinicalTrials.gov/show/NCT02545049"
413,"NCT02541084","Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan",,"Completed","No Results Available","Wet Macular Degeneration","Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)","Degree of caregiving burden on caregivers (BIC-11)|Relationship between BIC-11 and the number of hospital visits for wAMD treatments|Frequency of hospital visits|Time spent by accompanying caregivers for a clinic visit for wAMD management (minutes)|Estimated costs spent by accompanying caregivers on hospital visits for wAMD management|Level of depression among caregivers (CES-D)|Types of treatments for wAMD|Frequency of treatments|Length of treatment|Dosing schedule|Percentage of patients accompanied by primary caregivers","Bayer|Regeneron Pharmaceuticals","All","Child, Adult, Older Adult",,"72","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","17945","August 18, 2015","March 30, 2016","July 30, 2016","September 4, 2015",,"August 22, 2017","Many Locations, Japan",,"https://ClinicalTrials.gov/show/NCT02541084"
414,"NCT02540993","Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease","FIDELIO-DKD","Active, not recruiting","No Results Available","Diabetic Kidney Disease","Drug: Finerenone (BAY94-8862)|Drug: Placebo","Time to the first occurrence of the composite endpoint of onset of kidney failure, a sustained decrease of estimated glomerular filtration rate ( eGFR) ≥ 40% from baseline over at least 4 weeks or renal death.|Time to first occurrence of the composite endpoint: cardiovascular death or non-fatal cardiovascular events (myocardial infarction, stroke, hospitalization for heart failure)|Time to all-cause mortality|Time to all-cause hospitalizations|Time to first occurrence of the following composite endpoint: onset of kidney failure, a sustained decrease in estimated glomerular filtration rate (eGFR) of ≥ 57% from baseline over at least 4 weeks or renal death.|Change in urinary albumin-to-creatinine ratio (UACR) from baseline to month 4","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","5734","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","16244|2015-000990-11","September 17, 2015","April 26, 2020","May 25, 2020","September 4, 2015",,"January 14, 2020","Birmingham, Alabama, United States|Fort Payne, Alabama, United States|Huntsville, Alabama, United States|Mesa, Arizona, United States|Phoenix, Arizona, United States|Phoenix, Arizona, United States|Prescott, Arizona, United States|Tucson, Arizona, United States|Tucson, Arizona, United States|Arvin, California, United States|Chula Vista, California, United States|Dublin, California, United States|El Centro, California, United States|Fresno, California, United States|Fresno, California, United States|La Mesa, California, United States|Loma Linda, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|Northridge, California, United States|Port Hueneme, California, United States|Poway, California, United States|Rancho Cucamonga, California, United States|Rialto, California, United States|Roseville, California, United States|San Diego, California, United States|San Francisco, California, United States|Torrance, California, United States|New Haven, Connecticut, United States|Waterbury, Connecticut, United States|Fleming Island, Florida, United States|Fort Lauderdale, Florida, United States|Gainesville, Florida, United States|Hialeah, Florida, United States|Hialeah, Florida, United States|Hollywood, Florida, United States|Jacksonville, Florida, United States|Miami Beach, Florida, United States|Miami Gardens, Florida, United States|Miami Lakes, Florida, United States|Miami Lakes, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|New Port Richey, Florida, United States|Ocala, Florida, United States|Orlando, Florida, United States|Palm Harbor, Florida, United States|Sarasota, Florida, United States|Tampa, Florida, United States|Tampa, Florida, United States|Winter Haven, Florida, United States|Atlanta, Georgia, United States|Atlanta, Georgia, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Duluth, Georgia, United States|Lilburn, Georgia, United States|Macon, Georgia, United States|Honolulu, Hawaii, United States|Chicago, Illinois, United States|Chicago, Illinois, United States|Elgin, Illinois, United States|Indianapolis, Indiana, United States|Iowa City, Iowa, United States|Hutchinson, Kansas, United States|Topeka, Kansas, United States|Wichita, Kansas, United States|Metairie, Louisiana, United States|Monroe, Louisiana, United States|New Orleans, Louisiana, United States|Shreveport, Louisiana, United States|Takoma Park, Maryland, United States|Boston, Massachusetts, United States|Ann Arbor, Michigan, United States|Flint, Michigan, United States|Flint, Michigan, United States|Minneapolis, Minnesota, United States|Columbia, Missouri, United States|Columbia, Missouri, United States|Jefferson City, Missouri, United States|Kansas City, Missouri, United States|Kansas City, Missouri, United States|Saint Louis, Missouri, United States|Saint Louis, Missouri, United States|Lincoln, Nebraska, United States|Omaha, Nebraska, United States|Omaha, Nebraska, United States|Las Vegas, Nevada, United States|Las Vegas, Nevada, United States|Las Vegas, Nevada, United States|Las Vegas, Nevada, United States|Las Vegas, Nevada, United States|Reno, Nevada, United States|Newark, New Jersey, United States|Albuquerque, New Mexico, United States|Albany, New York, United States|Brooklyn, New York, United States|Flushing, New York, United States|Mineola, New York, United States|New York, New York, United States|New York, New York, United States|New York, New York, United States|Rosedale, New York, United States|Smithtown, New York, United States|Staten Island, New York, United States|Asheboro, North Carolina, United States|Chapel Hill, North Carolina, United States|Charlotte, North Carolina, United States|Greenville, North Carolina, United States|New Bern, North Carolina, United States|Winston-Salem, North Carolina, United States|Winston-Salem, North Carolina, United States|Canton, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Beaver, Pennsylvania, United States|Bethlehem, Pennsylvania, United States|Hershey, Pennsylvania, United States|Lansdale, Pennsylvania, United States|Anderson, South Carolina, United States|Charleston, South Carolina, United States|Greenville, South Carolina, United States|Greer, South Carolina, United States|Murrells Inlet, South Carolina, United States|Orangeburg, South Carolina, United States|Chattanooga, Tennessee, United States|Memphis, Tennessee, United States|Memphis, Tennessee, United States|Nashville, Tennessee, United States|Nashville, Tennessee, United States|Nashville, Tennessee, United States|Arlington, Texas, United States|Corpus Christi, Texas, United States|Dallas, Texas, United States|Dallas, Texas, United States|Dallas, Texas, United States|El Paso, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Kingwood, Texas, United States|McAllen, Texas, United States|McKinney, Texas, United States|Pearland, Texas, United States|Pflugerville, Texas, United States|San Antonio, Texas, United States|San Antonio, Texas, United States|San Antonio, Texas, United States|Sugar Land, Texas, United States|Sugar Land, Texas, United States|Waco, Texas, United States|Saint George, Utah, United States|Salt Lake City, Utah, United States|Burlington, Vermont, United States|Alexandria, Virginia, United States|Manassas, Virginia, United States|Salem, Virginia, United States|Virginia Beach, Virginia, United States|Spokane, Washington, United States|Tacoma, Washington, United States|Milwaukee, Wisconsin, United States|Junín, Buenos Aires, Argentina|Lanús, Buenos Aires, Argentina|Mar del Plata, Buenos Aires, Argentina|Sarandí, Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Ciudad Autón. de Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|De Buenos Aires, Ciudad Auton, Argentina|Córdoba, Argentina|Córdoba, Argentina|San Luis, Argentina|Garran, Australian Capital Territory, Australia|Gosford, New South Wales, Australia|Liverpool, New South Wales, Australia|New Lambton Heights, New South Wales, Australia|Wollongong, New South Wales, Australia|Adelaide, South Australia, Australia|Fitzroy, Victoria, Australia|Heidelberg, Victoria, Australia|Reservoir, Victoria, Australia|Richmond, Victoria, Australia|St. Albans, Victoria, Australia|Box Hill, Australia|Elizabeth Vale, Australia|Linz, Oberösterreich, Austria|Linz, Oberösterreich, Austria|Graz, Steiermark, Austria|Saint Stefan, Steiermark, Austria|Feldkirch, Vorarlberg, Austria|Innsbruck, Austria|Salzburg, Austria|St. Pölten, Austria|Wels, Austria|Wien, Austria|Wien, Austria|Wien, Austria|Wien, Austria|Antwerpen, Belgium|Bruxelles - Brussel, Belgium|Edegem, Belgium|Gent, Belgium|Ieper, Belgium|Kortrijk, Belgium|Leuven, Belgium|Liege, Belgium|Roeselare, Belgium|Feira de Santana, Bahia, Brazil|Salvador, Bahia, Brazil|Fortaleza, Ceará, Brazil|Fortaleza, Ceará, Brazil|Fortaleza, Ceará, Brazil|Brasilia, Distrito Federal, Brazil|Aparecida de Goiania, Goiás, Brazil|Goiania, Goiás, Brazil|Juiz de Fora, Minas Gerais, Brazil|Uberlândia, Minas Gerais, Brazil|Campina Grande do Sul, Parana, Brazil|Curitiba, Parana, Brazil|Curitiba, Parana, Brazil|Curitiba, Parana, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|Santo Andre, Sao Paulo, Brazil|São José do Rio Preto, Sao Paulo, Brazil|São José dos Campos, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|Rio de Janeiro, Brazil|Rio de Janeiro, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Blagoevgrad, Bulgaria|Botevgrad, Bulgaria|Dimitrovgrad, Bulgaria|Gorna Oryahovitsa, Bulgaria|Kazanlak, Bulgaria|Kozloduy, Bulgaria|Lukovit, Bulgaria|Plovdiv, Bulgaria|Plovdiv, Bulgaria|Razgrad, Bulgaria|Sliven, Bulgaria|Smolyan, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Stara Zagora, Bulgaria|Varna, Bulgaria|Yambol, Bulgaria|Burnaby, British Columbia, Canada|Coquitlam, British Columbia, Canada|New Westminster, British Columbia, Canada|Mount Pearl, Newfoundland and Labrador, Canada|St. John's, Newfoundland and Labrador, Canada|Halifax, Nova Scotia, Canada|Cambridge, Ontario, Canada|Hamilton, Ontario, Canada|Hamilton, Ontario, Canada|Kitchener, Ontario, Canada|Newmarket, Ontario, Canada|Oshawa, Ontario, Canada|Ottawa, Ontario, Canada|Sarnia, Ontario, Canada|Smith Falls, Ontario, Canada|Sudbury, Ontario, Canada|Thornhill, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Waterloo, Ontario, Canada|Greenfield Park, Quebec, Canada|Laval, Quebec, Canada|Mirabel, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Quebec, Canada|Osorno, Los Lagos, Chile|Santiago, Chile|Santiago, Chile|Santiago, Chile|Santiago, Chile|Santiago, Chile|Santiago, Chile|Santiago, Chile|Fuzhou, Fujian, China|Xiamen, Fujian, China|Xiamen, Fujian, China|Lanzhou, Gansu, China|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Zhuhai, Guangdong, China|Nanning, Guangxi, China|Nanning, Guangxi, China|Haikou, Hainan, China|Haikou, Hainan, China|Wuhan, Hubei, China|Wuhan, Hubei, China|Changsha, Hunan, China|Changsha, Hunan, China|Changsha, Hunan, China|Changzhou, Jiangsu, China|Huai'An, Jiangsu, China|Lianyungang, Jiangsu, China|Nanjing, Jiangsu, China|Nanjing, Jiangsu, China|Nanjing, Jiangsu, China|Nanjing, Jiangsu, China|Suzhou, Jiangsu, China|Wuxi, Jiangsu, China|Yancheng, Jiangsu, China|Nanchang, Jiangxi, China|Nanchang, Jiangxi, China|Changchun, Jilin, China|Changchun, Jilin, China|Shenyang, Liaoning, China|Shenyang, Liaoning, China|Yinchuan, Ningxia, China|Xi'an, Shaanxi, China|Qingdao, Shandong, China|Qingdao, Shandong, China|Taiyuan, Shanxi, China|Chengdu, Sichuan, China|Chengdu, Sichuan, China|Hangzhou, Zhejiang, China|Taizhou, Zhejiang, China|Wenzhou, Zhejiang, China|Beijing, China|Beijing, China|Chongqing, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|Tianjin, China|Tianjin, China|Tianjin, China|Medellín, Antioquia, Colombia|Medellín, Antioquia, Colombia|Medellín, Antioquia, Colombia|Barranquilla, Atlántico, Colombia|Barranquilla, Atlántico, Colombia|Manizales, Caldas, Colombia|Zipaquirá, Cundinamarca, Colombia|Bogotá, Distrito Capital De Bogotá, Colombia|Cundinamarca, Distrito Capital De Bogotá, Colombia|Armenia, Quindío, Colombia|Cali, Valle Del Cauca, Colombia|Floridablanca, Colombia|Medellín, Colombia|Beroun, Czechia|Brandys nad Labem, Czechia|Breclav, Czechia|Ceska Lipa, Czechia|Cesky Krumlov, Czechia|Cesky Krumlov, Czechia|Frydek-Mistek, Czechia|Hodonin, Czechia|Holesov, Czechia|Hranice, Czechia|Koprivnice, Czechia|Krnov, Czechia|Mlada Boleslav, Czechia|Olomouc, Czechia|Olomouc, Czechia|Ostrava, Czechia|Plzen, Czechia|Prague 6, Czechia|Praha 2, Czechia|Praha 4, Czechia|Praha 4, Czechia|Praha 5, Czechia|Vlasim, Czechia|Aalborg, Denmark|Aarhus N, Denmark|Esbjerg, Denmark|Gentofte, Denmark|Hellerup, Denmark|Herlev, Denmark|Hillerød, Denmark|Holbæk, Denmark|Holstebro, Denmark|Hvidovre, Denmark|Kolding, Denmark|København NV, Denmark|Odense C, Denmark|Svendborg, Denmark|Viborg, Denmark|Jyväskylä, Finland|Kajaani, Finland|Kerava, Finland|Klaukkala, Finland|Kuopio, Finland|Nurmijärvi, Finland|Oulu, Finland|Rauma, Finland|Seinäjoki, Finland|Tampere, Finland|Turku, Finland|Vantaa, Finland|Bois-guillaume, France|Bordeaux, France|Boulogne Sur Mer, France|Brest, France|COLMAR Cedex, France|Dijon, France|La Rochelle, France|La Tronche, France|Le Coudray, France|Le Creusot, France|Lyon Cedex, France|Mulhouse, France|NIMES cedex 9, France|Paris, France|PESSAC cedex, France|Saint Herblain, France|Saint Priest En Jarez, France|Tourcoing, France|Vandoeuvre-les-nancy, France|Venissieux, France|Heidelberg, Baden-Württemberg, Germany|Ludwigsburg, Baden-Württemberg, Germany|Schweinfurt, Bayern, Germany|Würzburg, Bayern, Germany|Elsterwerda, Brandenburg, Germany|Bad König, Hessen, Germany|Frankfurt, Hessen, Germany|Frankfurt, Hessen, Germany|Göttingen, Niedersachsen, Germany|Hannover, Niedersachsen, Germany|Aachen, Nordrhein-Westfalen, Germany|Bad Oeynhausen, Nordrhein-Westfalen, Germany|Bochum, Nordrhein-Westfalen, Germany|Dortmund, Nordrhein-Westfalen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Nettetal, Nordrhein-Westfalen, Germany|Witten, Nordrhein-Westfalen, Germany|Ludwigshafen, Rheinland-Pfalz, Germany|Mainz, Rheinland-Pfalz, Germany|Dresden, Sachsen, Germany|Dresden, Sachsen, Germany|Hoyerswerda, Sachsen, Germany|Leipzig, Sachsen, Germany|Leipzig, Sachsen, Germany|Jena, Thüringen, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Hamburg, Germany|Alexandroupolis, Greece|Athens, Greece|Athens, Greece|Chaidari, Greece|Larissa, Greece|Nea Ionia, Greece|Thessaloniki, Greece|Thessaloniki, Greece|Hong Kong, Hong Kong|Kowloon, Hong Kong|Shatin, Hong Kong|Baja, Hungary|Balatonfured, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Eger, Hungary|Kaposvar, Hungary|Kistarcsa, Hungary|Nyiregyhaza, Hungary|Nyiregyhaza, Hungary|Papa, Hungary|Siofok, Hungary|Szeged, Hungary|Szekesfehervar, Hungary|Szentes, Hungary|Szombathely, Hungary|Veszprem, Hungary|Cork, Ireland|Dublin, Ireland|Dublin, Ireland|Galway, Ireland|Afula, Israel|Ashkelon, Israel|Beer Sheva, Israel|Hadera, Israel|Haifa, Israel|Holon, Israel|Jerusalem, Israel|Kfar Saba, Israel|Nahariya, Israel|Nahariya, Israel|Nazareth, Israel|Ramat Gan, Israel|Rehovot, Israel|Sakhnin, Israel|Tel Aviv, Israel|Tel Aviv, Israel|Tel Aviv, Israel|Tel Aviv, Israel|Tiberias, Israel|Zefat, Israel|Zerifin, Israel|Napoli, Campania, Italy|Bologna, Emilia-Romagna, Italy|Parma, Emilia-Romagna, Italy|Reggio Emilia, Emilia-Romagna, Italy|Genova, Liguria, Italy|Genova, Liguria, Italy|Bergamo, Lombardia, Italy|Bergamo, Lombardia, Italy|Bergamo, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Monza-Brianza, Lombardia, Italy|Torino, Piemonte, Italy|Torino, Piemonte, Italy|Cagliari, Sardegna, Italy|Sassari, Sardegna, Italy|Catania, Sicilia, Italy|Messina, Sicilia, Italy|Padova, Veneto, Italy|Verona, Veneto, Italy|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Toyota, Aichi, Japan|Funabashi, Chiba, Japan|Ichikawa, Chiba, Japan|Matsuyama, Ehime, Japan|Matsuyama, Ehime, Japan|Chikushino, Fukuoka, Japan|Kasuga, Fukuoka, Japan|Kitakyushu, Fukuoka, Japan|Kitakyushu, Fukuoka, Japan|Kitakyushu, Fukuoka, Japan|Kitakyushu, Fukuoka, Japan|Shirakawa, Fukushima, Japan|Ogaki, Gifu, Japan|Maebashi, Gunma, Japan|Higashihiroshima, Hiroshima, Japan|Asahikawa, Hokkaido, Japan|Hakodate, Hokkaido, Japan|Obihiro, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Kobe, Hyogo, Japan|Naka, Ibaraki, Japan|Ushiku, Ibaraki, Japan|Komatsu, Ishikawa, Japan|Sanuki, Kagawa, Japan|Takamatsu, Kagawa, Japan|Takamatsu, Kagawa, Japan|Atsugi, Kanagawa, Japan|Fujisawa, Kanagawa, Japan|Kamakura, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Tamana, Kumamoto, Japan|Yatsushiro, Kumamoto, Japan|Sasebo, Nagasaki, Japan|Beppu, Oita, Japan|Yufu, Oita, Japan|Nakagami-gun, Okinawa, Japan|Shimajiri, Okinawa, Japan|Suita, Osaka, Japan|Kawaguchi, Saitama, Japan|Sayama, Saitama, Japan|Otsu, Shiga, Japan|Iwata, Shizuoka, Japan|Oyama, Tochigi, Japan|Minato, Tokyo, Japan|Musashino, Tokyo, Japan|Shibuya-ku, Tokyo, Japan|Fukui, Japan|Fukui, Japan|Fukuoka, Japan|Fukuoka, Japan|Fukuoka, Japan|Kagoshima, Japan|Kumamoto, Japan|Kumamoto, Japan|Kumamoto, Japan|Nagasaki, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Saitama, Japan|Wonju-si, Gang''weondo, Korea, Republic of|Anyang-si, Gyeonggido, Korea, Republic of|Goyang-si, Gyeonggido, Korea, Republic of|Incheon Gwangyeogsi,, Incheon Gwang''yeogsi, Korea, Republic of|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Busan, Korea, Republic of|Busan, Korea, Republic of|Daejeon, Korea, Republic of|Gang''weondo, Korea, Republic of|Seoul,, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Kaunas, Lithuania|Kaunas, Lithuania|Kaunas, Lithuania|Klaipeda, Lithuania|Utena, Lithuania|Vilnius, Lithuania|Ipoh, Malaysia|Johor Bahru, Malaysia|Kelantan, Malaysia|Kelantan, Malaysia|Kuala Lumpur, Malaysia|Pahang, Malaysia|Perak, Malaysia|Pulau Pinang, Malaysia|Putrajaya, Malaysia|Selangor, Malaysia|Ciudad de México, Distrito Federal, Mexico|México D.F., Distrito Federal, Mexico|México, D. F., Distrito Federal, Mexico|México, D. F., Distrito Federal, Mexico|Guadalajara, Jalisco, Mexico|Guadalajara, Jalisco, Mexico|Cuernavaca, Morelos, Mexico|Queretaro, Querétaro, Mexico|San Juan del Río, Querétaro, Mexico|Culiacán, Sinaloa, Mexico|Culiacán, Sinaloa, Mexico|Mazatlán, Sinaloa, Mexico|Puerto de Veracruz, Veracruz, Mexico|Xalapa, Veracruz, Mexico|Aguascalientes, Mexico|Chihuahua, Mexico|Ciudad de México, Mexico|Alkmaar, Netherlands|Almere, Netherlands|Amersfoort, Netherlands|Amsterdam, Netherlands|Amsterdam, Netherlands|Apeldoorn, Netherlands|Breda, Netherlands|Den Haag, Netherlands|Dordrecht, Netherlands|Eindhoven, Netherlands|Groningen, Netherlands|Hoogeveen, Netherlands|Nieuwegein, Netherlands|Sittard-geleen, Netherlands|Zwijndrecht, Netherlands|Auckland, New Zealand|Auckland, New Zealand|Christchurch, New Zealand|Hamilton, New Zealand|Hawkes Bay, New Zealand|Palmerston North, New Zealand|Tauranga, New Zealand|Wellington, New Zealand|Hamar, Norway|Hamar, Norway|Kløfta, Norway|Kristiansand, Norway|Levanger, Norway|Oslo, Norway|Oslo, Norway|Skedsmokorset, Norway|Trondheim, Norway|Ålesund, Norway|Iloilo City, Philippines|Marikina City, Philippines|Pasig City, Philippines|Quezon City, Philippines|Quezon City, Philippines|Quezon City, Philippines|Bialystok, Poland|Bydgoszcz, Poland|Chojnice, Poland|Gdansk, Poland|Gdynia, Poland|Katowice, Poland|Krakow, Poland|Krakow, Poland|Krakow, Poland|Krakow, Poland|Lodz, Poland|Lodz, Poland|Lodz, Poland|Lublin, Poland|Olsztyn, Poland|Poznan, Poland|Rzeszow, Poland|Skorzewo, Poland|Szczecin, Poland|Torun, Poland|Warszawa, Poland|Warszawa, Poland|Wroclaw, Poland|Wroclaw, Poland|Zabrze, Poland|Covilha, Castelo Branco, Portugal|Loures, Lisboa, Portugal|Matosinhos, Porto, Portugal|Funchal, Região Autónoma Da Madeira, Portugal|Torres Novas, Santarém, Portugal|Setubal, Setúbal, Portugal|Almada, Portugal|Amadora, Portugal|Braga, Portugal|Faro, Portugal|Leiria, Portugal|Lisboa, Portugal|Lisboa, Portugal|Lisboa, Portugal|Lisboa, Portugal|Porto, Portugal|Porto, Portugal|Viana do Castelo, Portugal|Cidra, Puerto Rico|San Juan, Puerto Rico|Alba-Iulia, Alba, Romania|Baia Mare, Maramures, Romania|Ploiesti, Prahova, Romania|Timisoara, Timis, Romania|Bucuresti, Romania|Bucuresti, Romania|Bucuresti, Romania|Bucuresti, Romania|Bucuresti, Romania|Bucuresti, Romania|Bucuresti, Romania|Cluj-Napoca, Romania|Galati, Romania|Iasi, Romania|Oradea, Romania|Satu Mare, Romania|Timisoara, Romania|Arkhangelsk, Russian Federation|Barnaul, Russian Federation|Chelyabinsk, Russian Federation|Irkutsk, Russian Federation|Izhevsk, Russian Federation|Kazan, Russian Federation|Kazan, Russian Federation|Kemerovo, Russian Federation|Kemerovo, Russian Federation|Kemerovo, Russian Federation|Kirov, Russian Federation|Krasnodar, Russian Federation|Krasnoyarsk, Russian Federation|Kursk, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Nizhny Novgorod, Russian Federation|Nizhny Novgorod, Russian Federation|Novosibirsk, Russian Federation|Novosibirsk, Russian Federation|Novosibirsk, Russian Federation|Novosibirsk, Russian Federation|Omsk, Russian Federation|Omsk, Russian Federation|Omsk, Russian Federation|Orenburg, Russian Federation|Perm, Russian Federation|Ryazan, Russian Federation|Saratov, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|Stavropol, Russian Federation|Syktyvkar, Russian Federation|Voronezh, Russian Federation|Voronezh, Russian Federation|Yaroslavl, Russian Federation|Yaroslavl, Russian Federation|Yekaterinburg, Russian Federation|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|Bardejov, Slovakia|Nitra, Slovakia|Rimavska Sobota, Slovakia|Roznava, Slovakia|Zilina, Slovakia|Port Elizabeth, Eastern Cape, South Africa|Johannesburg, Gauteng, South Africa|Johannesburg, Gauteng, South Africa|Lenasia South, Gauteng, South Africa|Newtown, Gauteng, South Africa|Petoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Soweto, Gauteng, South Africa|Durban, Kwazulu-Natal, South Africa|Isipingo Rail, Kwazulu-Natal, South Africa|Tongaat, Kwazulu-Natal, South Africa|Middelburg, Mpumalanga, South Africa|Witbank, Mpumalanga, South Africa|Cape Town, Western Cape, South Africa|Cape Town, Western Cape, South Africa|Somerset West, Western Cape, South Africa|Worcester, Western Cape, South Africa|Pretoria, South Africa|Ferrol, A Coruña, Spain|Badalona, Barcelona, Spain|L'Hospitalet de Llobregat, Barcelona, Spain|Manresa, Barcelona, Spain|Sant Joan Despi, Barcelona, Spain|Jerez de la Frontera, Cádiz, Spain|Burela, Lugo, Spain|Alcalá de Henares, Madrid, Spain|Boadilla del Monte, Madrid, Spain|Getafe, Madrid, Spain|Sagunto, Valencia, Spain|A Coruña, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Córdoba, Spain|Granada, Spain|Jaén, Spain|Madrid, Spain|Madrid, Spain|Málaga, Spain|Valencia, Spain|Valencia, Spain|Valencia, Spain|Valencia, Spain|Göteborg, Sweden|Göteborg, Sweden|Lund, Sweden|Lund, Sweden|Rättvik, Sweden|Skövde, Sweden|Stockholm, Sweden|Stockholm, Sweden|Stockholm, Sweden|Stockholm, Sweden|Uppsala, Sweden|Uppsala, Sweden|Örebro, Sweden|Örebro, Sweden|Liestal, Basel-Landschaft, Switzerland|St. Gallen, Sankt Gallen, Switzerland|St. Gallen, Sankt Gallen, Switzerland|Olten, Solothurn, Switzerland|Frauenfeld, Thurgau, Switzerland|Lausanne, Vaud, Switzerland|Bern, Switzerland|Genève, Switzerland|Changhua, Taiwan|Kaohsiung, Taiwan|New Taipei City, Taiwan|Taichung, Taiwan|Taichung, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Bangkok, Thailand|Bangkok, Thailand|Chiangmai, Thailand|Khon Kaen, Thailand|Ankara, Turkey|Antalya, Turkey|Battalgazi / Malatya, Turkey|Edirne, Turkey|Izmir, Turkey|Kocaeli, Turkey|Melikgazi/Kayseri, Turkey|Samsun, Turkey|Sivas, Turkey|Cherkasy, Ukraine|Chernivtsi, Ukraine|Dnipro, Ukraine|Dnipro, Ukraine|Ivano-Frankivsk, Ukraine|Kharkiv, Ukraine|Kharkiv, Ukraine|Kharkiv, Ukraine|Kharkiv, Ukraine|Kiev, Ukraine|Kiev, Ukraine|Kiev, Ukraine|Kiev, Ukraine|Kiev, Ukraine|Kyiv, Ukraine|Lviv, Ukraine|Mykolayiv, Ukraine|Ternopil, Ukraine|Uzhgorod, Ukraine|Vinnytsia, Ukraine|Zaporizhzhya, Ukraine|Zaporozhye, Ukraine|Llanelli, Carmarthenshire, United Kingdom|Leicester, Leicestershire, United Kingdom|Salford, Manchester, United Kingdom|Liverpool, Merseyside, United Kingdom|Northampton, Northamptonshire, United Kingdom|Carshalton, Surrey, United Kingdom|Newcastle Upon Tyne, Vale Of Glamorgan, The, United Kingdom|Chichester, West Sussex, United Kingdom|Bristol, United Kingdom|London, United Kingdom|London, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Middlesborough, United Kingdom|Portsmouth, United Kingdom|Ha Noi, Vietnam|Ha Noi, Vietnam|Ho Chi Minh City, Vietnam|Ho Chi Minh City, Vietnam",,"https://ClinicalTrials.gov/show/NCT02540993"
415,"NCT02540967","Drug Use Investigation of Gadovist.",,"Completed","No Results Available","Magnetic Resonance Imaging|Image Enhancement","Drug: Gadobutrol (Gadavist/Gadovist, BAY86-4875)","Number of episodes of adverse events as a measure of safety and tolerability|Number of episodes of adverse drug reactions and adverse events|Contrast enhancement","Bayer","All","Child, Adult, Older Adult",,"3357","Industry","Observational","Observational Model: Other|Time Perspective: Prospective","17512","October 27, 2015","November 2, 2017","November 2, 2017","September 4, 2015",,"October 29, 2018","Many Locations, Multiple Locations, Japan",,"https://ClinicalTrials.gov/show/NCT02540967"
416,"NCT02540954","Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)",,"Active, not recruiting","No Results Available","Macular Degeneration","Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)","Change in Early Treatment Diabetic Retinopathy Study best corrected visual acuity (EDTRS BCVA) letter score for the study eye|Number of participants with adverse events as measure of safety and tolerability|Proportion of subjects maintaining vision (i.e. loss of < 15 letters) in the study eye|Proportion of subjects who gained from baseline ≥ 5 letters in the study eye|Mean change from baseline in central retinal thickness (CRT) in the study eye|Mean change from baseline in choroidal neovascularization (CNV) area in the study eye|Proportion of subjects who lost ≥ 30 letters|Mean change from baseline in total score for National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25)","Bayer|Regeneron Pharmaceuticals","All","51 Years and older   (Adult, Older Adult)","Phase 3","329","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16598|2013-000120-33","September 29, 2015","December 24, 2019","June 4, 2020","September 4, 2015",,"January 18, 2020","Wien, Austria|Wien, Austria|Toronto, Ontario, Canada|Clinique medicale de l'oeil de l'Estrie, Sherbrooke, Quebec, Canada|Hradec Kralove, Czechia|Plzen, Czechia|Praha 10, Czechia|Praha 2, Czechia|Praha 5, Czechia|Paris, Cedex 12, France|Bordeaux, France|Dijon Cedex, France|Lyon Cedex 04, France|Nice Cedex, France|Paris, France|Würzburg, Bayern, Germany|Darmstadt, Hessen, Germany|Frankfurt, Hessen, Germany|Marburg, Hessen, Germany|Göttingen, Niedersachsen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Leipzig, Sachsen, Germany|Berlin, Germany|Berlin, Germany|Hamburg, Germany|Budapest, Hungary|Debrecen, Hungary|Pecs, Hungary|Roma, Lazio, Italy|Roma, Lazio, Italy|Genova, Liguria, Italy|Brescia, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Torino, Piemonte, Italy|Catania, Sicilia, Italy|Pisa, Toscana, Italy|Verona, Veneto, Italy|Parma, Italy|Kaunas, Lithuania|Vilnius, Lithuania|Gdansk, Poland|Olsztyn, Poland|Coimbra, Portugal|Leiria, Portugal|Lisboa, Portugal|Porto, Portugal|Bratislava, Slovakia|Bratislava, Slovakia|Nitra, Slovakia|L'Hospitalet de Llobregat, Barcelona, Spain|Barcelona, Spain|Valencia, Spain|Bern, Switzerland|Genève, Switzerland|Southampton, Hampshire, United Kingdom|Liverpool, Merseyside, United Kingdom|Great Yarmouth, Norfolk, United Kingdom|Middlesborough, North Yorkshire, United Kingdom|Pontyclun, Rhondda, Cynon, Taff, United Kingdom|Guildford, Surrey, United Kingdom|Newcastle Upon Tyne, Tyne And Wear, United Kingdom|Sunderland, Tyne And Wear, United Kingdom|Rugby, Warwickshire, United Kingdom|Wakefield, West Yorkshire, United Kingdom|Hull, York, United Kingdom|Colchester, United Kingdom|London, United Kingdom|London, United Kingdom|Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02540954"
417,"NCT02540369","To Describe the Use of Intravitreal Aflibercept and to Describe Follow-up as Well as Treatment Patterns in Patients With Wet Age-related Macular Degeneration (wAMD) or Diabetic Macular Edema (DME) in Routine Clinical Practice in Canada.","PEGASUS","Completed","No Results Available","Wet Macular Degeneration","Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)","Mean change of visual acuity.|Change of visual acuity.|Change of visual acuity by number of Injections.|Change in Retinal thickness.|Treatment patterns used in routine clinical practice setting.|Maximum interval between treatments.|Mean time between injections.|Number of injections at 12 months.|Time to achieve stability of disease.|Number of injections in a year to achieve stability of disease.|In previously treated subpopulation duration of previous treatments|In previously treated subpopulation type of previous treatments.|In previously treated subpopulation reason to switch to Eylea.|Proportion of patients with no fluid determined by Optical coherence tomography (OCT).|Numbers of patients require adjunctive therapies.|Type of adjunctive therapies required by patients|Number of participants with adverse events as a measure of safety and tolerability.|Presence of pigment epithelial detachment (PED) (Y/N)|Diabetic retinopathy severity (mild, moderate, severe).","Bayer|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)",,"2150","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","17995","December 14, 2015","September 25, 2017","January 26, 2018","September 3, 2015",,"February 15, 2019","Multiple Locations, Canada",,"https://ClinicalTrials.gov/show/NCT02540369"
418,"NCT02538393","Relative Bioavailability of Sorafenib Tablet for Oral Suspension",,"Completed","No Results Available","Biological Availability","Drug: Sorafenib (BAY43-9006) Film-coated tablet|Drug: Sorafenib (BAY43-9006) Oral suspension","Area Under the Concentration Versus Time Curve From Zero to Last Data Point Greater Than Lower Limit of Quantitation (LLOQ) of Sorafenib in Plasma (AUC[0-tlast]) After Single Oral Dose|Maximum Observed Drug Concentration After Single Dose Administration (Cmax) of Sorafenib in Plasma|Maximum Observed Drug Concentration After Single Dose Administration Divided by Dose (Cmax/D) of Sorafenib in Plasma|Area Under the Concentration Versus Time Curve From Zero to Infinity After Single Dose (AUC) of Sorafenib in Plasma|Area Under the Concentration Versus Time Curve From Zero to Infinity After Single Dose Divided by Dose (AUC/D) of Sorafenib in Plasma|Area Under the Concentration Versus Time Curve From Zero to Last Data Point Divided by Dose (AUC[0-tlast]/D) of Sorafenib in Plasma|Total Body Clearance of Sorafenib Calculated After Extravascular Administration (CL/F)|Time to Reach Maximum Concentration (tmax) of Sorafenib in Plasma|Half-life Associated With the Terminal Slope (t1/2) of Sorafenib in Plasma|Number of Subjects With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)|Number of Subjects With Various Acceptance Regarding the Taste and Palatability of the Tablet Formulations","Bayer","Male","18 Years to 45 Years   (Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","18175|2015-002083-16","November 20, 2015","March 15, 2016","June 15, 2016","September 2, 2015",,"June 1, 2017","Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT02538393"
419,"NCT02537457","Bioequivalence Study of Rivaroxaban",,"Completed","No Results Available","Embolism, Atrial Fibrillation and Venous Thrombosis","Drug: Rivaroxaban (BAY 59-7939)|Drug: Rivaroxaban (Xarelto, BAY 59-7939)","Cmax (maximum observed drug concentration in measured matrix after single dose administration)|AUC(0-tlast) (AUC from time 0 to the last data point > LLOQ (lower limit of quantitation))|Number of participants with adverse events as a measure of safety and tolerability","Bayer","Male","20 Years to 40 Years   (Adult)","Phase 1","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17017","January 2014","March 2014","April 2014","September 1, 2015",,"September 1, 2015","Kumamoto, Japan",,"https://ClinicalTrials.gov/show/NCT02537457"
420,"NCT02537405","Bioequivalence Study of Rivaroxaban in Japanese Healthy Adult Male Subjects",,"Completed","No Results Available","Embolism, Atrial Fibrillation and Venous Thrombosis","Drug: Rivaroxaban (BAY 59-7939)|Drug: Rivaroxaban (Xarelto, BAY 59-7939)","Cmax (maximum observed drug concentration in measured matrix after single dose administration)|AUC(0-tlast) (AUC from time 0 to the last data point > LLOQ (lower limit of quantitation))|Number of participants with adverse events as a measure of safety and tolerability","Bayer","Male","20 Years to 40 Years   (Adult)","Phase 1","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17018","February 2014","March 2014","April 2014","September 1, 2015",,"September 1, 2015","Kumamoto, Japan",,"https://ClinicalTrials.gov/show/NCT02537405"
421,"NCT02536534","Electronic Activity Level Monitoring Pilot in Pulmonary Hypertension","e-MOTION PH","Completed","No Results Available","Hypertension, Pulmonary","Other: Correlation assessment","6-minute walk distance (6MWD)|Number of steps per day|Change in quality of life recorded by patient questionnaire Living with Pulmonary hypertension Questionnaire (LPH)|Change in compliance with medication using the Moriky´s Questionnaire|Change in World Health Organization (WHO) functional Class recorded by investigator in conjunction with the 6MWD|Change in Borg Dyspnea value recorded by investigator in conjunction with the 6MWD|Healthcare provider Satisfaction and Usability questionnaire|Caregiver Satisfaction and Usability questionnaire|Patient Satisfaction and Usability questionnaire","Bayer","All","18 Years and older   (Adult, Older Adult)",,"35","Industry","Observational","Observational Model: Other|Time Perspective: Prospective","17926|DBOX 2014/00466","June 30, 2015","November 25, 2016","December 21, 2016","September 1, 2015",,"December 20, 2017","Multiple Locations, Canada",,"https://ClinicalTrials.gov/show/NCT02536534"
422,"NCT02534532","Atrial Fibrillation Screening With a Smartphone Device and iECG Application","AFScreenCol","Withdrawn","No Results Available","Atrial Fibrillation","Other: AF screening","Number of patients screened in whom the screening device detect an abnormal cardiac rhythm|Number of patients screened in whom Atrial Fibrillation (AF) was confirmed with ECG|Number of patients in whom abnormal cardiac rhythm was detected with screening device and AF was confirmed with ECG","Bayer","All","65 Years and older   (Older Adult)",,"0","Industry","Observational","Time Perspective: Cross-Sectional","18250","October 2015","April 2016","April 2016","August 27, 2015",,"November 25, 2015",,,"https://ClinicalTrials.gov/show/NCT02534532"
423,"NCT02532361","Proportion of Hysterectomy After Female Sterilization",,"Completed","No Results Available","Hysterectomy","Device: Hysteroscopic device placement including Essure (ESS305, BAY1454032)|Procedure: Tubal ligation","Percentage of patients having hysterectomy procedure post-sterilization through hysteroscopic device placement|Percentage of patients having hysterectomy procedure post-sterilization through through tubal ligation","Bayer","Female","18 Years to 49 Years   (Adult)",,"10578","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","18473","August 2015","December 2015","December 2015","August 25, 2015",,"December 23, 2016","New Jersey, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02532361"
424,"NCT02527278","Retrospective Claims Analysis of Hysterectomy After Sterilization",,"Completed","No Results Available","Contraception","Procedure: Laparoscopic tubal ligation|Procedure: Hysteroscopic sterilization","Proportion of women undergoing hysterectomy after hysteroscopic sterilization or laparoscopic tubal ligation|Proportion of women undergoing salpingectomy after hysteroscopic sterilization or laparoscopic tubal ligation|Proportion of women undergoing salpingostomy after hysteroscopic sterilization or laparoscopic tubal ligation|Proportion of women undergoing hysteroscopy after hysteroscopic sterilization or laparoscopic tubal ligation|Proportion of women who have a diagnosis of pelvic pain after hysteroscopic sterilization or laparoscopic tubal ligation","Bayer","Female","18 Years to 49 Years   (Adult)",,"19317","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","18477","July 30, 2015","February 9, 2016","February 9, 2016","August 18, 2015",,"March 21, 2017","Whippany, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02527278"
425,"NCT02518698","Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare Population",,"Completed","No Results Available","Prostate Cancer","Drug: Radium-223 dichloride (Xofigo, BAY88-8223)","Overall survival of mCRPC patients|Number of skeletal related events (SREs) of the mCRPC patients|Type of skeletal related events (SREs) of the mCRPC patients|Number of patients with mCRPC with bone metastases|Type of treatments associated with mCRPC|Duration for each treatment identified|Distribution of providers by treatment|Clinical and demographic characteristics of the mCRPC patients|Treatment patterns of mCRPC patients with bone metastases|Progression of the disease of mCRPC patients|All-cause healthcare resource utilization for mCRPC patients|mCRPC-specific healthcare resource utilization for mCRPC patients|All-cause healthcare costs for mCRPC patients|mCRPC-specific healthcare costs for mCRPC patients","Bayer","Male","55 Years to 88 Years   (Adult, Older Adult)",,"1163","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","18273","August 31, 2015","September 30, 2017","September 30, 2017","August 10, 2015",,"September 18, 2018","Louisville, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT02518698"
426,"NCT02510443","Observational Study on Contraception With Essure in France","SUCCES II","Completed","No Results Available","Contraception","Device: ESS305 (Essure, BAY1454032)","Number of patients being satisfied with successful Essure procedure having no complications at 5 years|Number of patients with moderate or important pain when placement is performed|Number of unsatisfied patients|Number of satisfied patients at 3, 12 and 24 months|Number of examinations by patients|Number of good insert position by implant and patients with success in final result of the procedure|Causes of unsatisfied patients|Type of examinations by patients|Number of patients with regrets","Bayer|Hôpital André Mignot Centre Hospitalier de Versailles","Female","18 Years and older   (Adult, Older Adult)",,"2644","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","18097|ES0810FR","June 23, 2008","September 29, 2016","November 25, 2016","July 29, 2015",,"September 13, 2017","Le Chesnay, France",,"https://ClinicalTrials.gov/show/NCT02510443"
427,"NCT02504216","Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities","VOYAGER PAD","Active, not recruiting","No Results Available","Peripheral Artery Disease","Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Rivaroxaban-Placebo","Time from randomization to the first occurrence of any of the following major thrombotic vascular events: MI (Myocardial infarction), ischemic stroke, CV (Cardiovascular) death, ALI (Acute limb ischemia), and major amputation|Time from randomization to first occurrence of major bleeding events according to the Thrombolysis in Myocardial Infarction (TIMI) classification|Time from randomization to first occurrence of myocardial infarction, ischemic stroke, coronary heart disease mortality, acute limb ischemia, and major amputation of a vascular etiology|Time from randomization to first occurrence of an unplanned index limb revascularization for recurrent limb ischemia|Time from randomization to first occurrence of hospitalization for a coronary or peripheral cause (either lower limb) of a thrombotic nature|Time from randomization to the first occurrence of MI, ischemic stroke, all-cause mortality, acute limb ischemia, and major amputation of a vascular etiology|Time from randomization to first occurrence of myocardial infarction, all-cause stroke, cardiovascular death, acute limb ischemia, and major amputation of a vascular etiology|Time from randomization to first occurrence of all-cause mortality|Time from randomization to first occurrence of venous thromboembolic (VTE) events","Bayer|Janssen Research & Development, LLC|Colorado Prevention Center","All","50 Years and older   (Adult, Older Adult)","Phase 3","6564","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","17454|2014-005569-58","August 18, 2015","November 27, 2019","January 7, 2020","July 21, 2015",,"January 9, 2020","Alexander City, Alabama, United States|Birmingham, Alabama, United States|Fort Payne, Alabama, United States|Huntsville, Alabama, United States|Avondale, Arizona, United States|Glendale, Arizona, United States|Phoenix, Arizona, United States|Mission Viejo, California, United States|Northridge, California, United States|Palo Alto, California, United States|Roseville, California, United States|Stanford, California, United States|Torrance, California, United States|Aurora, Colorado, United States|Denver, Colorado, United States|Washington, District of Columbia, United States|Washington, District of Columbia, United States|Atlantis, Florida, United States|Clearwater, Florida, United States|Daytona Beach, Florida, United States|Gainesville, Florida, United States|Hudson, Florida, United States|Jacksonville, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Ocala, Florida, United States|Pensacola, Florida, United States|Tallahassee, Florida, United States|Wellington, Florida, United States|Arlington Heights, Illinois, United States|Elk Grove Village, Illinois, United States|Springfield, Illinois, United States|Springfield, Illinois, United States|Urbana, Illinois, United States|Fort Wayne, Indiana, United States|Fort Wayne, Indiana, United States|Merrillville, Indiana, United States|Iowa City, Iowa, United States|Lexington, Kentucky, United States|Alexandria, Louisiana, United States|Covington, Louisiana, United States|Shreveport, Louisiana, United States|Shreveport, Louisiana, United States|Auburn, Maine, United States|Baltimore, Maryland, United States|Baltimore, Maryland, United States|Clinton, Maryland, United States|Bay City, Michigan, United States|Dearborn, Michigan, United States|Detroit, Michigan, United States|Lansing, Michigan, United States|Midland, Michigan, United States|Muskegon, Michigan, United States|Wyoming, Michigan, United States|Minneapolis, Minnesota, United States|Saint Cloud, Minnesota, United States|Jackson, Mississippi, United States|Tupelo, Mississippi, United States|Saint Louis, Missouri, United States|Springfield, Missouri, United States|Lincoln, Nebraska, United States|Lincoln, Nebraska, United States|Lebanon, New Hampshire, United States|Flemington, New Jersey, United States|Linden, New Jersey, United States|Teaneck, New Jersey, United States|New York, New York, United States|New York, New York, United States|Saratoga Springs, New York, United States|Chapel Hill, North Carolina, United States|Charlotte, North Carolina, United States|Durham, North Carolina, United States|Winston-Salem, North Carolina, United States|Minot, North Dakota, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Dayton, Ohio, United States|Springfield, Ohio, United States|Toledo, Ohio, United States|Oklahoma City, Oklahoma, United States|Hillsboro, Oregon, United States|Camp Hill, Pennsylvania, United States|Erie, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|York, Pennsylvania, United States|Greenville, South Carolina, United States|Rapid City, South Dakota, United States|Knoxville, Tennessee, United States|Amarillo, Texas, United States|Austin, Texas, United States|Dallas, Texas, United States|Dallas, Texas, United States|Edinburg, Texas, United States|Houston, Texas, United States|Humble, Texas, United States|Kingwood, Texas, United States|Palestine, Texas, United States|San Antonio, Texas, United States|Tyler, Texas, United States|Victoria, Texas, United States|Madison, Wisconsin, United States|Manitowoc, Wisconsin, United States|Wausau, Wisconsin, United States|Bahia Blanca, Buenos Aires, Argentina|Ciudadela, Buenos Aires, Argentina|Coronel Suarez, Buenos Aires, Argentina|Junín, Buenos Aires, Argentina|La Plata, Buenos Aires, Argentina|La Plata, Buenos Aires, Argentina|Mar del Plata, Buenos Aires, Argentina|San Isidro, Buenos Aires, Argentina|San Martín, Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Santa Rosa, La Pampa, Argentina|Rosario, Santa Fe, Argentina|Rosario, Santa Fe, Argentina|Rosario, Santa Fe, Argentina|Ciudad Auton. de Buenos Aires, Argentina|Corrientes, Argentina|Córdoba, Argentina|Córdoba, Argentina|Córdoba, Argentina|Santa Fe, Argentina|Klagenfurt, Kärnten, Austria|Graz, Steiermark, Austria|Innsbruck, Tirol, Austria|Feldkirch, Vorarlberg, Austria|Linz, Austria|Wien, Austria|Wien, Austria|Wien, Austria|Wien, Austria|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Genk, Belgium|Gent, Belgium|Kortrijk, Belgium|Leuven, Belgium|Fortaleza, Ceará, Brazil|Belo Horizonte, Minas Gerais, Brazil|Belo Horizonte, Minas Gerais, Brazil|Belo Horizonte, Minas Gerais, Brazil|Belo Horizonte, Minas Gerais, Brazil|Uberlândia, Minas Gerais, Brazil|Curitiba, Parana, Brazil|Canoas, Rio Grande Do Sul, Brazil|Passo Fundo, Rio Grande Do Sul, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|Belo Horizonte, Sao Paulo, Brazil|Campinas, Sao Paulo, Brazil|Santo André, Sao Paulo, Brazil|São Bernardo do Campo, Sao Paulo, Brazil|São José do Rio Preto, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|Tatui, Sao Paulo, Brazil|Rio de Janeiro, Brazil|Burgas, Bulgaria|Panagyurishte, Bulgaria|Plovdiv, Bulgaria|Ruse, Bulgaria|Ruse, Bulgaria|Samokov, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Stara Zagora, Bulgaria|Varna, Bulgaria|Yambol, Bulgaria|Winnipeg, Manitoba, Canada|St. John's, Newfoundland and Labrador, Canada|Hamilton, Ontario, Canada|London, Ontario, Canada|Ottawa, Ontario, Canada|Chicoutimi, Quebec, Canada|Gatineau, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|St. Jerome, Quebec, Canada|Montreal, Quebec, Canada|Quebec, Canada|Vancouver, Canada|Hefei, Anhui, China|Chongqing, Chongqing, China|Fuzhou, Fujian, China|Zhangzhou, Fujian, China|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Zhanjiang, Guangdong, China|Zhongshan, Guangdong, China|Haikou, Hainan, China|Wuhan, Hubei, China|Wuhan, Hubei, China|Changsha, Hunan, China|Changsha, Hunan, China|Changzhou, Jiangsu, China|Nanjing, Jiangsu, China|Changchun, Jilin, China|Xi'an, Shaanxi, China|Qingdao, Shandong, China|Taiyuan, Shanxi, China|Taizhou, Zhejiang, China|Wenzhou, Zhejiang, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Shanghai, China|Shanghai, China|Tianjin, China|Brno, Czechia|Hodonin, Czechia|Hradec kralove, Czechia|Kladno, Czechia|Liberec, Czechia|Olomouc, Czechia|Plzen, Czechia|Praha 10, Czechia|Praha 2, Czechia|Praha 5, Czechia|Praha 5, Czechia|Prostejov, Czechia|Vratimov, Czechia|Aarhus N, Denmark|Kolding, Denmark|København Ø, Denmark|Odense C, Denmark|Viborg, Denmark|Tallinn, Estonia|Tallin, Estonia|Tartu, Estonia|Helsinki, Finland|Oulu, Finland|Tampere, Finland|Bordeaux, France|Bordeaux, France|Caen Cedex, France|Castelnau Le Lez, France|Grenoble, France|Le Coudray, France|Limoges, France|Montpellier Cedex, France|Nice, France|Paris Cedex 15, France|Paris, France|POITIERS cedex, France|Rennes Cedex, France|Strasbourg, France|Toulouse, France|Toulouse, France|Bad Friedrichshall, Baden-Württemberg, Germany|Bad Krozingen, Baden-Württemberg, Germany|Freudenstadt, Baden-Württemberg, Germany|Heidelberg, Baden-Württemberg, Germany|Karlsbad, Baden-Württemberg, Germany|Karlsruhe, Baden-Württemberg, Germany|Ulm, Baden-Württemberg, Germany|Erlangen, Bayern, Germany|Immenstadt, Bayern, Germany|München, Bayern, Germany|München, Bayern, Germany|München, Bayern, Germany|Regensburg, Bayern, Germany|Rosenheim, Bayern, Germany|Bad Nauheim, Hessen, Germany|Darmstadt, Hessen, Germany|Frankfurt, Hessen, Germany|Frankfurt, Hessen, Germany|Frankfurt, Hessen, Germany|Arnsberg, Nordrhein-Westfalen, Germany|Bielefeld, Nordrhein-Westfalen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Krefeld, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Wesel, Nordrhein-Westfalen, Germany|Kaiserslautern, Rheinland-Pfalz, Germany|Mainz, Rheinland-Pfalz, Germany|Magdeburg, Sachsen-Anhalt, Germany|Dresden, Sachsen, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Lübeck, Schleswig-Holstein, Germany|Jena, Thüringen, Germany|Sonneberg, Thüringen, Germany|Berlin, Germany|Berlin, Germany|Bremen, Germany|Dresden, Germany|Hamburg, Germany|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Gyor, Hungary|Kaposvar, Hungary|Kistarcsa, Hungary|Miskolc, Hungary|Nyiregyhaza, Hungary|Pecs, Hungary|Szeged, Hungary|Szekesfehervar, Hungary|Szombathely, Hungary|Potenza, Basilicata, Italy|Avellino, Campania, Italy|Napoli, Campania, Italy|Bologna, Emilia-Romagna, Italy|Ravenna, Emilia-Romagna, Italy|Reggio Emilia, Emilia-Romagna, Italy|Roma, Lazio, Italy|Milano, Lombardia, Italy|Varese, Lombardia, Italy|Macerata, Marche, Italy|Torino, Piemonte, Italy|Lecce, Puglia, Italy|Palermo, Sicilia, Italy|Ragusa, Sicilia, Italy|Firenze, Toscana, Italy|Perugia, Umbria, Italy|Nagakute, Aichi, Japan|Matsuyama, Ehime, Japan|Kitakyushu, Fukuoka, Japan|Kitakyushu, Fukuoka, Japan|Kurume, Fukuoka, Japan|Shibukawa, Gunma, Japan|Hatsukaichi, Hiroshima, Japan|Asahikwa, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Tomakomai, Hokkaido, Japan|Amagasaki, Hyogo, Japan|Himeji, Hyogo, Japan|Himeji, Hyogo, Japan|Kobe, Hyogo, Japan|Kobe, Hyogo, Japan|Takarazuka, Hyogo, Japan|Morioka, Iwate, Japan|Takamatsu, Kagawa, Japan|Kawasaki, Kanagawa, Japan|Sagamihara, Kanagawa, Japan|Matsusaka, Mie, Japan|Matsumoto, Nagano, Japan|Kashihara, Nara, Japan|Beppu, Oita, Japan|Habikino, Osaka, Japan|Kawagoe, Saitama, Japan|Omihachiman, Shiga, Japan|Hamada, Shimane, Japan|Bunkyo-ku, Tokyo, Japan|Fuchu, Tokyo, Japan|Itabashi-ku, Tokyo, Japan|Itabashi-ku, Tokyo, Japan|Meguro-ku, Tokyo, Japan|Minato-ku, Tokyo, Japan|Minato, Tokyo, Japan|Suginami-ku, Tokyo, Japan|Gifu, Japan|Kagoshima, Japan|Kumamoto, Japan|Kyoto, Japan|Kyoto, Japan|Miyazaki, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Saitama, Japan|Shizuoka, Japan|Goyang-si, Gyeonggido, Korea, Republic of|Seongnam-si, Gyeonggido, Korea, Republic of|Incheon, Incheon Gwang''yeogsi, Korea, Republic of|Busan, Korea, Republic of|Daegu, Korea, Republic of|Daegu, Korea, Republic of|Daejeon, Korea, Republic of|Jung-gu Daejeon, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Daugavpils, Latvia|Liepaja, Latvia|Riga, Latvia|Riga, Latvia|Kaunas, Lithuania|Kaunas, Lithuania|Panevezys, Lithuania|Vilnius, Lithuania|Vilnius, Lithuania|Den Bosch, Netherlands|Eindhoven, Netherlands|Enschede, Netherlands|Heerlen, Netherlands|Utrecht, Netherlands|Veldhoven, Netherlands|Zwolle, Netherlands|Bialystok, Poland|Bydgoszcz, Poland|Gdynia, Poland|Katowice, Poland|Krakow, Poland|Lodz, Poland|Lublin, Poland|Lublin, Poland|Poznan, Poland|Szczecin, Poland|Warszawa, Poland|Warszawa, Poland|Warszawa, Poland|Wroclaw, Poland|Almada, Setúbal, Portugal|Lisboa, Portugal|Ponta Delgada, Portugal|Porto, Portugal|Porto, Portugal|Vila Nova de Gaia, Portugal|Pitesti, Arges, Romania|Bucharest, Romania|Bucharest, Romania|Bucharest, Romania|Cluj Napoca, Romania|Iasi, Romania|Oradea, Romania|Targu Mures, Romania|Timisoara, Romania|Kemerovo, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Nizhny Novgorod, Russian Federation|Novosibirsk, Russian Federation|Novosibirsk, Russian Federation|Rostov-on-Don, Russian Federation|Ryazan, Russian Federation|Saint-Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|Tomsk, Russian Federation|Tver, Russian Federation|Voronezh, Russian Federation|Belgrade, Serbia|Belgrade, Serbia|Belgrade, Serbia|Beograd, Serbia|Nis, Serbia|Bardejov, Slovakia|Bratislava 37, Slovakia|Bratislava, Slovakia|Bratislava, Slovakia|Dunajska Streda, Slovakia|Kosice, Slovakia|Nitra, Slovakia|Nove Zamky, Slovakia|Trnava, Slovakia|Zilina, Slovakia|Cádiz, Andalucía, Spain|L'Hospitalet de Llobregat, Barcelona, Spain|Sabadell, Barcelona, Spain|A Coruña, Spain|Barcelona, Spain|Barcelona, Spain|Ciudad Real, Spain|Granada, Spain|Madrid, Spain|Pamplona, Spain|Tarragona, Spain|Göteborg, Sweden|Linköping, Sweden|Malmö, Sweden|Solna, Sweden|Växjö, Sweden|Basel, Basel-Stadt, Switzerland|Chur, Graubünden, Switzerland|St. Gallen, Sankt Gallen, Switzerland|Baden, Switzerland|Bern, Switzerland|Fribourg, Switzerland|Genève, Switzerland|Luzern, Switzerland|Hsinchu City, Taiwan|Kaohsiung, Taiwan|Kaohsiung, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Bangkok, Thailand|Bangkok, Thailand|Bangkok, Thailand|Bangkok, Thailand|Khon Kaen, Thailand|Songkla, Thailand|Dnipro, Ukraine|Ivano-Frankivsk, Ukraine|Ivano-Frankivsk, Ukraine|Kharkiv, Ukraine|Kiev, Ukraine|Kyiv, Ukraine|Lviv, Ukraine|Vinnytsia, Ukraine|Zaporizhzhya, Ukraine|Carlisle, Cumbria, United Kingdom|Hull, Humberside, United Kingdom|Harrow, London, United Kingdom|Doncaster, South Yorkshire, United Kingdom|Newcastle Upon Tyne, Tyne And Wear, United Kingdom|Birmingham, West Midlands, United Kingdom|Leeds, West Yorkshire, United Kingdom|Worcester, Worcestershire, United Kingdom|Cambridge, United Kingdom|Cheltenham, United Kingdom|London, United Kingdom|London, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Manchester, United Kingdom|Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02504216"
428,"NCT02497716","Phase I Study on Rivaroxaban Granules for Oral Suspension Formulation in Children",,"Completed","No Results Available","Thrombosis","Drug: Rivaroxaban (Xarelto, BAY59-7939","AUC (area under the curve)|Cmax (maximum observed drug concentration)|Prothrombin time (PT)|Activated partial thromboplastin time (aPTT)|Composite of major bleeding and clinically relevant non-major bleeding","Bayer|Janssen Research & Development, LLC","All","2 Months to 12 Years   (Child)","Phase 1","47","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","17992|2015-000962-76","November 4, 2015","May 22, 2018","May 22, 2018","July 14, 2015",,"April 16, 2019","Arkansas Children's Hospital, Little Rock, Arkansas, United States|Children's Hospital Oakland, Oakland, California, United States|Riley Hospital For Children, Indianapolis, Indiana, United States|Carolinas Healthcare System, Charlotte, North Carolina, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|UZ Leuven Gasthuisberg, Leuven, Belgium|University of Alberta Hospital, Edmonton, Alberta, Canada|McMaster Children's Hospital, Hamilton, Ontario, Canada|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|Hospital for Sick Children, Toronto, Ontario, Canada|HUS Lastenklinikka, HUS, Finland|Turun yliopistollinen keskussairaala, kantasairaala, Turku, Finland|Hôpital Arnaud de Villeneuve - Montpellier, Montpellier, France|Hopital Necker les enfants malades - Paris, Paris, France|University of Semmelweis/ Semmelweis Egyetem, Budapest, Hungary|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Lombardia, Italy|A.O.U. Città della Salute e della Scienza di Torino, Torino, Piemonte, Italy|A.O. di Padova, Padova, Veneto, Italy|Hospital de Sant Joan de Déu, Esplugues de LLobregat, Barcelona, Spain|Ciutat Sanitària i Universitaria de la Vall d'Hebron, Barcelona, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT02497716"
429,"NCT02490774","To Investigate the Pharmacological Effects, Drug Blood Levels and Safety of an Intrauterine System Releasing the Study Drug BAY1007626 in Comparison to Mirena and Jaydess in Healthy Young Women Treated for 90 Days to Determine the Drug Dose for Further Development",,"Terminated","No Results Available","Contraception","Drug: BAY1007626|Drug: Jaydess|Drug: Mirena","Number of bleeding and spotting days|Progestin effects on endometrial histology|Ovulation(Yes/no)|Endometrial thickness|Bleeding characterization (Intensity, pattern)|Serum levels of estradiol|Serum levels of progesterone|Serum levels of luteinizing hormone|Serum levels of follicle-stimulating hormone|Cervix function (Insler score)|Number of participants with adverse events as a measure of safety and tolerability.|Cmax of BAY1007626|AUC of BAY1007626|T1/2 of BAY1007626","Bayer","Female","18 Years to 40 Years   (Adult)","Phase 2","174","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","15731|2013-003980-74","June 22, 2015","May 26, 2016","July 22, 2016","July 7, 2015",,"June 4, 2019","Hannover, Niedersachsen, Germany|Berlin, Germany|Berlin, Germany|Hamburg, Germany|Hamburg, Germany|Groningen, Netherlands|Belfast, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02490774"
430,"NCT02486640","Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon","BETAPREDICT","Active, not recruiting","No Results Available","Multiple Sclerosis","Drug: Interferon beta-1b (Betaferon, BAY86-5046)|Device: Betaconnect Autoinjector","Compliance to therapy (%)|Persistence of therapy (Yes or No)|Overall adherence to therapy (Yes or No)|Satisfaction with the BETACONNECT autoinjector, recorded by the patient questionnaire|Adherence to Betaferon treatment is associated with: depression, health related quality of life, coping mechanisms, self-management mechanisms, social support, fatigue, and cognition. (Yes or No)|Adherence to Betaferon treatment is associated with number of relapses (Yes or No)|Adherence to Betaferon treatment is associated with EDSS change (Yes or No)|Adherence to Betaferon treatment is associated with utilities of treatment, recorded by the EQ5-D quality of life questionnaire (Yes or No)","Bayer","All","18 Years and older   (Adult, Older Adult)",,"162","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","18016|BF1502","September 8, 2015","October 31, 2019","December 31, 2019","July 1, 2015",,"December 26, 2019","Multiple Locations, Germany",,"https://ClinicalTrials.gov/show/NCT02486640"
431,"NCT02485873","Real-Life Evidence on Stroke Prevention in SPAF","RELIEF","Completed","No Results Available","Atrial Fibrillation (Prevention of Stroke)","Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Vitamin K antagonists","Time to first occurrence of any of the following: Ischemic stroke (IS), Transient ischemic attack (TIA), Intracerebral hemorrhage (IH), Other non-traumatic intracranial hemorrhage including subdural hemorrhage, Myocardial infarction (MI)|Time to first occurrence of IS|Time to first occurrence of TIA|Time to first occurrence of IH|Time to first occurrence of Other non-traumatic intracranial hemorrhage including subdural hemorrhage|Time to first occurrence of MI|Incidence density in study population of IS|Incidence density in study population of TIA|Incidence density in study population of IH|Incidence density in study population of Other non-traumatic intracranial hemorrhage including subdural hemorrhage|Incidence density in study population of MI|Incidence density in study population of any of the following: IS, TIA, IH, Other non-traumatic intracranial hemorrhage including subdural hemorrhage, MI","Bayer|Janssen, LP","All","18 Years and older   (Adult, Older Adult)",,"8607","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","18073|DBOX 2014/00799","May 2015","September 2015","September 2015","June 30, 2015",,"November 11, 2015","Many Locations, Germany",,"https://ClinicalTrials.gov/show/NCT02485873"
432,"NCT02485119","Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies",,"Completed","No Results Available","Neoplasms","Drug: BAY94-9343","Number of Treatment-emergent Adverse Events (TEAEs) as a measure of safety and tolerability|Intensity of TEAEs acc. to NCI CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) v.4.03|Cmax (maximum drug concentration in plasma after single dose administration ) for BAY94-9343, total antibody compound, DM4, metabolite DM4-Me|Cmax,norm (Cmax divided by dose (mg) per kg body weight) for BAY94-9343, total antibody compound, DM4, metabolite DM4-Me|Cmax/D (Cmax divided by dose (mg)) for BAY94-9343, total antibody compound, DM4, metabolite DM4-Me|AUC(0-tlast) (area under the plasma concentration vs time curve from time 0 to the last data point) for BAY94-9343, total antibody compound, DM4, metabolite DM4-Me|AUC(0-tlast)norm (AUC(0-tlast) divided by dose (mg) per kg body weight) for BAY94-9343, total antibody compound, DM4, metabolite DM4-Me|AUC(0-tlast)/D (AUC(0-tlast) divided by dose (mg)) for BAY94-9343, total antibody compound, DM4, metabolite DM4-Me|tmax (time to reach maximum drug concentration in plasma) for BAY94-9343, total antibody compound, DM4, metabolite DM4-Me|Tumor response based on RECIST (Response Evaluation Criteria in Solid Tumors)|Level of mesothelin expression using IHC (Immunohistochemistry) staining for the tumor tissue obtained from fresh or archival tumor tissue|Plasma levels of soluble mesothelin|Immunogenicity evaluation based on anti-BAY94-9343 antibody count","Bayer","All","20 Years and older   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15404","August 14, 2015","April 28, 2017","July 4, 2017","June 30, 2015",,"June 4, 2018","National Cancer Center Hospital East, Kashiwa, Chiba, Japan|National Cancer Center Hospital, Tyuo, Japan",,"https://ClinicalTrials.gov/show/NCT02485119"
433,"NCT02483208","Single Dose Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and Advate",,"Completed","No Results Available","Hemophilia A","Drug: BAY81-8973|Drug: Advate","AUC(0-tlast)","Bayer","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","17608|2014-005173-36","June 2015","July 2015","December 2015","June 26, 2015",,"February 17, 2016","Sofia, Bulgaria",,"https://ClinicalTrials.gov/show/NCT02483208"
434,"NCT02475356","Prospective, Non-interventional, Multi-center Safety Study of Mirena for Heavy Menstrual Bleeding and Dysmenorrhea","J-MIRAI","Active, not recruiting","No Results Available","Menorrhagia, Dysmenorrhea","Drug: Mirena (Levonorgestrel IUS, BAY86-5028)","Number of participants with adverse drug reaction|Number of participants with adverse events|Change from baseline in bleeding characterized by Pictorial Blood loss Assessment Chart (PBAC) score to 12 months|Change from baseline in monthly bleeding intensities (the number of spotting and/or bleeding days) to 12 months|Change from baseline in Quality of Life parameters assessed using MMAS or MDQ score after 3 and 12 months|Change from baseline in dysmenorrhea pain using Visual Analogue scale|Use of analgesic","Bayer","Female","Child, Adult, Older Adult",,"601","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","18252","August 4, 2015","January 18, 2019","December 31, 2019","June 18, 2015",,"December 24, 2019","Multiple Locations, Japan",,"https://ClinicalTrials.gov/show/NCT02475356"
435,"NCT02470767","An Observational Cross-sectional Study Evaluating the Sociodemographic and Clinical Characteristics of Patients Diagnosed With NVAF With a Risk of Stroke or Systemic Embolism, Who Are on Treatment to Adequately Control Their Coagulation and Treated in Primary Care Centres","SILVER-AP","Completed","No Results Available","Stroke|Prevention and Control|Atrial Fibrillation","Drug: Direct Oral Anticoagulant (DOAC)","Composite of demographic characteristics: age, gender and race|Composite of relevant cardiovascular events: stroke, TIA, systemic embolism, bleeding|Composite of comorbidities: hypertension, heart failure, diabetes mellitus, kidney failure, dyslipidemia,|Data on the Non-Valvular Atrial Fibrillation treatment: relevant active substances|Concomitant treatments: relevant active substances|Risk of thromboembolic event based on the CHADS2 score|Risk of thromboembolic event based on the CHA2DS2-VASc score|Risk of bleeding based on the HAS-BLED score|Adherence to treatment|Satisfaction of treatment|Reason of the change in treatment: according to Spanish guideline for the SPAF management: IPT (Informe de Posicionamiento Terapeutico)","Bayer","All","18 Years and older   (Adult, Older Adult)",,"792","Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","17964","May 2015","December 2015","March 2016","June 12, 2015",,"February 16, 2017","Many Locations, Spain",,"https://ClinicalTrials.gov/show/NCT02470767"
436,"NCT02468102","Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)",,"Active, not recruiting","No Results Available","Acute Coronary Syndrome|Venous Thrombosis|Pulmonary Embolism|Atrial Fibrillation","Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Standard of care drugs","Descriptive analysis of demographic and clinical characteristics of patients who are prescribed oral rivaroxaban for the first time in comparison with those who are prescribed standard of care for the first time|Safety and effectiveness: occurrence of hospitalization for a) intracranial haemorrhage, (b) gastrointestinal bleeding, (c) urogenital bleeding among users of rivaroxaban in comparison with individuals receiving current standard of care|Occurrence of hospitalization for bleeding events not specified as primary safety outcomes (""other bleeding"", secondary safety outcome) in individuals receiving rivaroxaban, in comparison with those receiving current standard of care.|Occurrence of non-infective liver disease (secondary safety outcome) in individuals receiving rivaroxaban in comparison with those receiving current standard of care.|Outcomes related to effectiveness (ischaemic stroke or myocardial infarction) in individuals receiving rivaroxaban in comparison with those receiving current standard of care.|All-cause mortality as well as cause-specific mortality.","Bayer|Janssen Scientific Affairs, LLC","All","Child, Adult, Older Adult",,"99999","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","17543|XA1405SE","June 15, 2015","October 31, 2018","April 1, 2020","June 10, 2015",,"January 18, 2020","Many Locations, Multiple Locations, Sweden",,"https://ClinicalTrials.gov/show/NCT02468102"
437,"NCT02465814","Assess Safety and Efficacy of Vilaprisan in Patients With Uterine Fibroids","ASTEROID 2","Completed","No Results Available","Leiomyoma","Drug: Vilaprisan (BAY1002670)|Drug: Vilaprisan (BAY1002670|Drug: Ulipristal","Amenorrhea (yes/no)|Number of bleeding days|Time to onset of controlled bleeding|Percent change in volume of largest fibroid from baseline to end of treatment.|Endometrial histology|Endometrial thickness measured by transvaginal ultrasound.","Bayer","Female","18 Years to 50 Years   (Adult)","Phase 2","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","17541|2014-004221-41","June 2015","October 2016","October 2016","June 9, 2015",,"November 22, 2016","Villach, Kärnten, Austria|Graz, Steiermark, Austria|Innsbruck, Tirol, Austria|Wien, Austria|Tienen, Vlaams Brabant, Belgium|Bruxelles - Brussel, Belgium|Edegem, Belgium|Pleven, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Stara Zagora, Bulgaria|Brno, Czech Republic|Ceske Budejovice, Czech Republic|Olomouc, Czech Republic|Olomouc, Czech Republic|Pisek, Czech Republic|Plzen, Czech Republic|Praha 2, Czech Republic|Praha 8, Czech Republic|Praha, Czech Republic|Helsinki, Finland|Pori, Finland|Turku, Finland|Bernburg, Sachsen-Anhalt, Germany|Blankenburg, Sachsen-Anhalt, Germany|Dresden, Sachsen, Germany|Berlin, Germany|Budapest, Hungary|Debrecen, Hungary|Debrecen, Hungary|Szentes, Hungary|Modena, Emilia-Romagna, Italy|Cagliari, Sardegna, Italy|Catania, Sicilia, Italy|Vilnius, Lithuania|Vilnius, Lithuania|Vilnius, Lithuania|Almere, Netherlands|Heerlen, Netherlands|Nieuwegein, Netherlands|Zwolle, Netherlands|Fredrikstad, Norway|Lørenskog, Norway|Nesttun, Norway|Stavanger, Norway|Bialystok, Poland|Lodz, Poland|Lublin, Poland|Lublin, Poland|Warszawa, Poland|Coimbra, Portugal|Lisboa, Portugal|Porto, Portugal|Aravaca, Madrid, Spain|Barcelona, Spain|Valencia, Spain|Valencia, Spain|Stockholm, Sweden|Stockholm, Sweden|Umeå, Sweden|Harrow, London, United Kingdom|London, United Kingdom|Nottingham, United Kingdom|Portsmouth, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02465814"
438,"NCT02465502","Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer",,"Completed","No Results Available","Colorectal Neoplasms","Drug: Regorafenib (Stivarga, BAY73-4506)","Percentage of participants without disease progression or death at the end of 8 weeks|Progression-Free Survival (PFS)|Overall Survival (OS)|Overall Response Rate (ORR)|Disease Control Rate (DCR)|Metabolic response measured by [18F] fluorodeoxyglucose positron emission tomography (FDG PET)|Percentage of participants with grade 1 or higher adverse events, using NCI Common Terminology Criteria for Adverse Events (CTC-AE) Version 4.03","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","59","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17217","July 21, 2015","May 2, 2017","December 11, 2017","June 8, 2015",,"November 7, 2018","São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT02465502"
439,"NCT02457351","Roniciclib (BAY 1000394) Drug-Drug Interaction (DDI) Study",,"Completed","No Results Available","Medical Oncology","Drug: Roniciclib (BAY 1000394)|Drug: Itraconazole (Sporanox)","Maximum observed drug concentration (Cmax) of roniciclib on Cycle 1 Day 1 (without itraconazole)|Area under the concentration vs. time curve from zero to infinity (AUC) of roniciclib on Cycle 1 Day 1 (without itraconazole)|Maximum observed drug concentration (Cmax) of roniciclib on Cycle 1 Day 6 (with itraconazole)|Area under the concentration vs. time curve from zero to infinity (AUC) of roniciclib on Cycle 1 Day 6 (with itraconazole)|Collection of Adverse events as a measure of safety and tolerability of roniciclib dosing when administered with and without itraconazole|Laboratory analyses to assess safety and tolerability of roniciclib dosing when administered with and without itraconazole|Monitoring of vital signs to assess safety and tolerability of roniciclib dosing when administered with and without itraconazole|East Coast Oncology Group (ECOG) performance status to assess safety and tolerability of roniciclib dosing when administered with and without itraconazole|Electrocardiogram (12 lead ECG) readings to assess safety and tolerability of roniciclib dosing when administered with and without itraconazole|Physical examination to assess safety and tolerability of roniciclib dosing when administered with and without itraconazole|Maximum observed drug concentration (Cmax) of roniciclib after a light meal on Cycle 1 Day -2 (without itraconazole)|Area under the concentration vs. time curve from zero to 24 hr (AUC) of roniciclib after a light meal on Cycle 1 Day -2 (without itraconazole)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","14","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","17616","July 2015","February 2016","April 2016","May 29, 2015",,"May 23, 2016","Edmonton, Alberta, Canada|Hamilton, Ontario, Canada|London, Ontario, Canada|Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02457351"
440,"NCT02456129","Study in Postmenopausal Women to Investigate the Drug-drug Interaction (DDI) Between Itraconazole(ITZ) and Orally Administered Vilaprisan; Absolute Bioavailability Using Intravenous Microtracer Dose of [14C]Vilaprisan",,"Completed","No Results Available","Clinical Trial, Phase I","Drug: Vilaprisan (BAY1002670)|Drug: [14C] Vilaprisan|Other: Itraconazole(ITZ)","Area under the concentration time curve [AUC(0-11d)] after single oral dose of vilaprisan with and without ITZ.|Maximum plasma concentration (Cmax) after single oral dose of vilaprisan with and without ITZ.","Bayer","Female","45 Years to 70 Years   (Adult, Older Adult)","Phase 1","14","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","15250|2014-004929-41","July 2015","September 2015","February 2016","May 28, 2015",,"March 2, 2016","Leeds, West Yorkshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02456129"
441,"NCT02455297","Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)",,"Terminated","No Results Available","Lymphoma, Mantle-Cell","Drug: Copanlisib (BAY80-6946)","Objective response rate (ORR)|Complete response rate (CRR)|Disease control rate (DCR)|Progression-free survival (PFS)|Duration of response (DOR)|Overall survival (OS)|Number of participants with treatment emergent adverse events (TEAEs) as a measure of safety and tolerability","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","4","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17120","August 24, 2015","April 8, 2016","August 31, 2016","May 27, 2015",,"October 2, 2017","Baltimore, Maryland, United States|Hackensack, New Jersey, United States|New York, New York, United States|New York, New York, United States|Burlington, Vermont, United States",,"https://ClinicalTrials.gov/show/NCT02455297"
442,"NCT02452515","A Single-blind Pilot Study to Investigate Safety and Tolerability of the Chymase Inhibitor BAY1142524 in Clinically Stable Patients With Left-ventricular Dysfunction","CHIARA MIA 1","Completed","No Results Available","Heart Failure","Drug: BAY1142524|Drug: Placebo","Number of participants with adverse events|Number of participants with serious adverse events","Bayer","All","40 Years to 79 Years   (Adult, Older Adult)","Phase 2","49","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other","17055|2014-005297-12","July 2015","January 2016","March 2016","May 22, 2015",,"November 7, 2017","Copenhagen Ø, Denmark|Copenhagen, Denmark|Hellerup, Denmark|Herlev, Denmark|Frankfurt, Hessen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Erfurt, Thüringen, Germany|Berlin, Germany|Bergamo, Lombardia, Italy|Brescia, Lombardia, Italy",,"https://ClinicalTrials.gov/show/NCT02452515"
443,"NCT02450812","Non-interventional Study With Ra-223 Dichloride Assessing Overall Survival and Effectiveness Predictors for mCRPC Patients in a Real Life Setting in Germany","URANIS","Active, not recruiting","No Results Available","Prostatic Neoplasms, Castration-Resistant","Drug: Radium-223-dichloride (Xofigo, BAY88-8223)","Overall survival (OS)|Evaluation of symptomatic skeletal event free survival (SSE-FS) of mCRPC patients|Estimation of the incidence of pathological fractures.|Time to next tumor treatment(s) (TTNT)|Incidence of treatment-emergent adverse events (TEAE)|Quality of life as patient reported outcome estimated using Functional Assessment of Cancer Therapy - Prostate (FACT-P) questionnaire|Activities of daily living assessed according to the Katz-Index|Body function assessed in dimensions of ""mobility"", ""self-care"" and ""domestic life"" using the Medical Oncology Status in Europe Survey (MOSES) questionnaire|Estimation of the non-pathological fractures|Estimation of the bone associated events","Bayer","Male","18 Years and older   (Adult, Older Adult)",,"86","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","18043|XF 1503|EUPAS24796","May 28, 2015","November 30, 2023","March 31, 2024","May 21, 2015",,"January 18, 2020","Many Locations, Multiple Locations, Germany",,"https://ClinicalTrials.gov/show/NCT02450812"
444,"NCT02442063","Phase Ib Study of Radium Ra 223 Dichloride in Combination With Paclitaxel in Cancer Subjects With Bone Lesions",,"Completed","No Results Available","Neoplasms|Bone Diseases","Drug: Radium Ra 223 dichloride (Xofigo, BAY88-8223)|Drug: paclitaxel","The percentage of participants with thrombocytopenia during cycle 1 (paclitaxel alone), 2 and 3 (combination treatment)|The percentage of participants with neutropenia during cycle 1 (paclitaxel alone), 2 and 3 (combination treatment)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","15","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","17110|2015-000083-34","August 2015","October 2016","October 2016","May 13, 2015",,"November 30, 2016","HUS, Finland|Haifa, Israel|Tel Aviv, Israel|Sutton, Surrey, United Kingdom|Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02442063"
445,"NCT02439346","Phase I Dose Escalation and Expansion of Oral BAY 1143269 in Combination With Intravenous Docetaxel",,"Terminated","No Results Available","Medical Oncology","Drug: BAY1143269 tablet","Maximum Tolerated Dose (MTD) of Oral BAY1143269 Alone and in Combination With Intravenous Docetaxel|Maximum Observed Drug Concentration (Cmax) in Plasma After Single and Multiple Dose Administration of BAY1143269|Area Under the Concentration-time Curve From Time Zero to 24 Hours [AUC(0-24)] After Single and Multiple Dose Administration of BAY1143269|Tumor response","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","15","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17450|2014-004810-27","June 15, 2015","March 27, 2017","April 24, 2017","May 8, 2015",,"March 7, 2018","Dallas, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Sutton, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02439346"
446,"NCT02434640","Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of BAY1128688 After Multiple Oral Administrations in Healthy Women",,"Completed","No Results Available","Endometriosis","Drug: BAY1128688|Drug: Placebo","Frequency of Treatment Emergent Adverse Events (TEAEs) with severity grading|Cmax,md (maximum concentration) of BAY1128688 after multiple dose|Cav,md (average steady state concentration) of BAY1128688 after multiple dose","Bayer","Female","18 Years to 68 Years   (Adult, Older Adult)","Phase 1","51","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)","16742|2014-005298-36","April 2015","December 2015","April 2016","May 5, 2015",,"May 19, 2016","Neu-Ulm, Bayern, Germany|Berlin, Germany|Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT02434640"
447,"NCT02428985","Prospective, Non-interventional, Multi-center, Post-authorization Safety Study of Riociguat for Pulmonary Arterial Hypertension (PAH)","JPMS-PAH","Recruiting","No Results Available","Hypertension, Pulmonary","Drug: Riociguat (ADEMPAS, BAY63-2521)","Number of participants with treatment emergent adverse events. Adverse events of special interest:Hypotension,Gastrointestinal disorder,Hemoptysis, pulmonary hemorrhage and Pulmonary congestion, pulmonary edema|Number of participants with adverse drug reaction|Change from baseline in 6-Minute Walking Distance at 3 months and 12 months|Change from baseline in Pulmonary Vascular Resistance (PVR) after 3 and 12 months|Change from baseline in tricuspid regurgitation pressure gradient (TRPG) after 3 and 12 months|Change in blood concentration from baseline in brain natriuretic peptide / N-terminal pro-brain natriuretic peptide (BPN/NT-pro BNP) after 3 and 12 months.|Change from baseline in WHO functional class after 3 and 12 months|Time to Clinical Worsening","Bayer","All","Child, Adult, Older Adult",,"600","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","17519|AD1510JP","June 29, 2015","September 30, 2022","January 16, 2024","April 29, 2015",,"January 13, 2020","Many Locations, Multiple Locations, Japan",,"https://ClinicalTrials.gov/show/NCT02428985"
448,"NCT02425501","Special Drug Use Investigation of EYLEA for Diabetic Macular Edema",,"Completed","No Results Available","Choroidal Neovascularization","Drug: Aflibercept (Eylea, BAY86-5321)","Number of participants of Adverse Events|Number of participants of Serious Adverse Events|Mean change in visual acuity from baseline to 12 months|Mean change in retina thickness from baseline to 12 months","Bayer|Regeneron Pharmaceuticals","All","Child, Adult, Older Adult",,"662","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","17544|EY1510JP","January 20, 2015","April 26, 2019","August 13, 2019","April 24, 2015",,"September 13, 2019","Multiple Locations, Japan",,"https://ClinicalTrials.gov/show/NCT02425501"
449,"NCT02425462","To Evaluate Effectiveness of Visanne in Improving Quality of Life in Asian Women With Endometriosis","ENVISIOeN","Completed","No Results Available","Endometriosis","Drug: Dienogest (Visanne, BAY86-5258)","The mean change from baseline to 6 months of treatment in pain-related Quality of Life measured by EHP-30.|The mean change from baseline to 24 months of treatment in pain-related Quality of Life measured by EHP-30 for patients who continue to take Visanne up to 24 months.|Mean change from baseline to 6 months and baseline to 24 months of treatment in other domain of Quality of life measured by EHP-30|Mean change of Endometriosis-associated pelvic pain (EAPP) from baseline in patients with endometriosis either surgically or clinically diagnosed.|Patient and physician's satisfaction score on Visanne® treatment|Proportion of subjects who continue treatment with Visanne®|Reasons for stopping of treatment with Visanne®|Proportion of patients with amenorrhea, intermenstrual bleeding/spotting or irregular bleeding while treatment with Visanne®|Proportion of patients who experienced pain recurrence in patients taking Visanne up to 24 months|Time point for first pain recurrence after stopping taking Visanne and before to start any treatment.|Proportion of patients who underwent repeated surgery in patients taking Visanne up to 24 months|Proportion of patients who underwent repeated surgery between stopping Visanne treatment and starting any other treatment than surgery|Patient's assessment of overall symptom development using the Clinical Global Impression (CGI) scale","Bayer","Female","18 Years and older   (Adult, Older Adult)",,"895","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","17444","April 28, 2015","September 28, 2018","December 14, 2018","April 24, 2015",,"September 25, 2019","Multiple Locations, Indonesia|Multiple Locations, Korea, Republic of|Multiple Locations, Malaysia|Multiple Locations, Philippines|Multiple Locations, Singapore|Multiple Locations, Thailand",,"https://ClinicalTrials.gov/show/NCT02425462"
450,"NCT02414919","Duration of Use of Highly Effective Reversible Contraception",,"Completed","No Results Available","Pregnancy","Drug: Mirena (Levonorgestrel IUS, BAY86-5028)|Drug: ParaGard|Drug: Implanon/Nexplanon","Proportion of women who use HERC|Duration of real world use of three different HERC devices","Bayer|University of Utah","Female","15 Years to 44 Years   (Child, Adult)",,"13880","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","17714","April 1, 2015","March 28, 2016","March 28, 2016","April 13, 2015",,"March 16, 2017","Salt Lake, Utah, United States",,"https://ClinicalTrials.gov/show/NCT02414919"
451,"NCT02413515","Blood Pressure Control of Nifedipine GITS 60mg Treatment in Chinese Hypertensive Subjects Uncontrolled on Starting-dose Mono-therapyo-therapy.","ADEPT","Completed","No Results Available","Hypertension","Drug: Nifedipine (Adalat GITS, BAY1040)","Percentage of subjects with a Mean Sitting Systolic Blood Pressure (<130mmHg for subjects with diabetes and <140mmHg for others) of Nifedipine GITs 60mg|Changes in the Mean Sitting SBP(MSSBP) and Mean Sitting DBP(MSDBP) from baseline at Week 8|Percentage of subjects with a Mean Sitting Systolic Blood Pressure Lower than 140mmHg and MSDBP less than 90 mmHg (130 and 80 for diabetis patients) of Nifedipine GITs 60mg|The percentage of subjects with a MSDBP lower than 90 (80 for diabetis)|The percentage of subjects achieving both a ≥10mmHg|Time to reach the MSSBP target (based on the BP measurements during office visits)|Changes in the 24-h, daytime (from 06:00 to 22:00), and nighttime (from 22:00 to 06:00) average SBP and DBP assessed by ABPM from baseline at Week 8|incidence of all treatment-emergent adverse events|incidence of drug-related treatment-emergent adverse events","Bayer","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","278","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17677","March 26, 2015","August 8, 2016","August 8, 2016","April 10, 2015",,"August 4, 2017","Fuzhou, Fujian, China|Tangshan, Hebei, China|Wudan, Hubei, China|Changsha, Hunan, China|Nanjing, Jiangsu, China|Xi'an, Shanxi, China|Hangzhou, Zhejiang, China|Beijing, China|Beijing, China|Beijing, China|Shandong, China|Shanghai, China|Tangshang, China|Tianjin, China",,"https://ClinicalTrials.gov/show/NCT02413515"
452,"NCT02410031","Risk Minimisation Study for Diane-35 and Its Generics",,"Completed","No Results Available","Acne Vulgaris","Drug: Cyproterone acetate 2mg/ethinylestradiol 35 μg (Diane-35)","The knowledge of the physician concerning Diane-35","Bayer|RTI Health Solutions","All","18 Years and older   (Adult, Older Adult)",,"759","Industry|Other","Observational","Observational Model: Other|Time Perspective: Other","17195","June 26, 2015","March 4, 2016","March 4, 2016","April 7, 2015",,"April 5, 2017","Many Locations, Austria|Many Locations, Czech Republic|Many Locations, France|Many Locations, Netherlands|Many Locations, Spain",,"https://ClinicalTrials.gov/show/NCT02410031"
453,"NCT02403401","Safety and Contraceptive Efficacy of an Intravaginal Ring With LNG (Levonorgestrel) Over One Year in Healthy Women",,"Completed","No Results Available","Contraception","Drug: Levonorgestrel (BAY98-7196)","Pregnancy rate (Pearl Index)|Cumulative failure rate","Bayer","Female","18 Years to 35 Years   (Adult)","Phase 3","1471","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","16803","May 15, 2015","July 7, 2016","July 7, 2016","March 31, 2015",,"July 6, 2017","Mobile, Alabama, United States|Chandler, Arizona, United States|Mesa, Arizona, United States|Phoenix, Arizona, United States|Tucson, Arizona, United States|Little Rock, Arkansas, United States|La Mesa, California, United States|Sacramento, California, United States|Sacramento, California, United States|San Diego, California, United States|San Diego, California, United States|San Diego, California, United States|Denver, Colorado, United States|Denver, Colorado, United States|New London, Connecticut, United States|Clearwater, Florida, United States|Jacksonville, Florida, United States|Jupiter, Florida, United States|Lake Worth, Florida, United States|Leesburg, Florida, United States|Miami Beach, Florida, United States|Miami, Florida, United States|North Miami, Florida, United States|Oviedo, Florida, United States|Saint Petersburg, Florida, United States|Wellington, Florida, United States|Atlanta, Georgia, United States|Roswell, Georgia, United States|Idaho Falls, Idaho, United States|Champaign, Illinois, United States|Chicago, Illinois, United States|Newburgh, Indiana, United States|Shawnee, Kansas, United States|Wichita, Kansas, United States|Annapolis, Maryland, United States|Baltimore, Maryland, United States|Lutherville, Maryland, United States|Saginaw, Michigan, United States|Kansas City, Missouri, United States|Lincoln, Nebraska, United States|Las Vegas, Nevada, United States|Las Vegas, Nevada, United States|Las Vegas, Nevada, United States|Lawrenceville, New Jersey, United States|New Brunswick, New Jersey, United States|Albuquerque, New Mexico, United States|Johnson City, New York, United States|Port Jefferson, New York, United States|Rochester, New York, United States|Williamsville, New York, United States|Cary, North Carolina, United States|Charlotte, North Carolina, United States|Durham, North Carolina, United States|Greensboro, North Carolina, United States|New Bern, North Carolina, United States|Raleigh, North Carolina, United States|Raleigh, North Carolina, United States|Salisbury, North Carolina, United States|Wilmington, North Carolina, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Columbia, South Carolina, United States|Mount Pleasant, South Carolina, United States|Myrtle Beach, South Carolina, United States|Summerville, South Carolina, United States|Jackson, Tennessee, United States|Corpus Christi, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Draper, Utah, United States|Pleasant Grove, Utah, United States|Salt Lake City, Utah, United States|Richmond, Virginia, United States|Virginia Beach, Virginia, United States|Seattle, Washington, United States|Spokane, Washington, United States|Tacoma, Washington, United States|Funabashi, Chiba, Japan|Yotsukaido, Chiba, Japan|Yanagawa, Fukuoka, Japan|Aki-gun, Hiroshima, Japan|Asahikawa, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Yokohama, Kanagawa, Japan|Kurashiki, Okayama, Japan|Chiyoda-ku, Tokyo, Japan|Chuo-ku, Tokyo, Japan|Hachioji, Tokyo, Japan|Minato-ku, Tokyo, Japan|Nakano-ku, Tokyo, Japan|Nishitokyo, Tokyo, Japan|Ota-ku, Tokyo, Japan|Setagaya-ku, Tokyo, Japan|Shinjuku, Tokyo, Japan|Toshima-ku, Tokyo, Japan|Fukui, Japan|Fukui, Japan|Fukui, Japan|Fukuoka, Japan|Kagoshima, Japan|Kagoshima, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan",,"https://ClinicalTrials.gov/show/NCT02403401"
454,"NCT02398526","Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases","PARABO","Active, not recruiting","No Results Available","Castration-Resistant Prostatic Cancer","Drug: Radium-223 dichloride, (Xofigo, BAY88-8223)","Pain response|Change of pain over time|Change in bone pain related quality of life|Pain control rate|Pain progression rate|Time to first pain progression|Time to first opioid use|Summary description of covariates on pain response|Relation between bone uptake in known lesions and pain palliation|Dosage of Radium-223|Number of injections of Radium-223|Course of blood count presented as percentage of patients below limit for further injections according to the local product information|Number of participants with Treatment-emergent Adverse Events (TEAE)|Time to next tumor treatment(s) (TTNT)|Time to first symptomatic skeletal event (SSE)|Overall survival|Bone Scan Index (BSI) as Imaging Biomarker in metastatic castration-resistant prostate cancer (mCRPC)|Effect of concomitant drug treatment on pain, quality of life, and overall survival|Time from castration resistance to treatment with Radium-223|Description of covariates on duration of therapy|Factors positively influencing mCRPC patients to get ≥ 5 injections versus ≤ 4 injections|Incidence of pathological fractures, non-pathological fractures and bone associated events during treatment and follow up","Bayer","Male","18 Years and older   (Adult, Older Adult)",,"348","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","17550|XF1412DE","March 19, 2015","June 30, 2023","September 30, 2023","March 25, 2015",,"January 13, 2020","Multiple Locations, Germany",,"https://ClinicalTrials.gov/show/NCT02398526"
455,"NCT02398513","Regorafenib Phase I Study in Mainland Chinese Patients",,"Completed","No Results Available","Oncology","Drug: Regorafenib (Stivarga, BAY73-4506)","Cmax (maximum drug concentration in plasma)|AUC(0-24) (AUC from time 0 h to time 24 h post-administration)|AUC(0-tlast) (AUC from time zero to the last data point>LLOQ)|Cmax.ss (Cmax at steady-state during a dosage interval)|AUCt.ss (AUC for the dosing interval at steady-state)|Number of participants with adverse events as a measure of safety and tolerability|Tumor Response base don RECIST 1.1 criteria","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","18","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15823","April 2015","November 2015","June 2016","March 25, 2015",,"August 1, 2016","Shanghai, China",,"https://ClinicalTrials.gov/show/NCT02398513"
456,"NCT02396862","Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment","ECHO","Completed","No Results Available","Hemophilia A","Drug: Available Recombinant, and Human Factor VIII products incl. Kogenate FS (Recombinant Factor VIII, BAY14-2222)","Patient Reported Outcome: Change of function as measured by Hemophilia Activities List (HAL), Daily Activities including Work Productivity and Activity Impairment Scale (WPAI).|Patient Reported Outcome: Change of Quality of Life as measured by EuroQol-5 Dimension questionnaire 5 Level (EQ5D), Short Form Health Survey (SF-12), Hemophilia Quality of Life Measure for Adults (HAEMO-QoL-A)|Patient Reported Outcome: Change of treatment patterns as measured by Hemophilia Treatment Satisfaction Questionnaire (Hemo-SAT) and Validated Hemophilia Regimen Treatment Adherence Scale (Veritas Pro/PRN)|Patient Reported outcome: Change of adherence as measured by and Validated Hemophilia Regimen Treatment Adherence Scale (Veritas Pro/PRN)|Patient Reported outcome: Change of satisfaction as measured by Hemophilia Treatment Satisfaction Questionnaire (Hemo-SAT)|Patient Reported outcome: Change of pain as measured by Brief Pain Inventory (Short Form) (BPI-SF)|Patient Reported outcome: Change of pain as measured by Brief Pain Inventory (BPI-SF)|Patient Reported outcome: Change of number of resource utilization as evaluated from the patient perspective|Patient Reported outcome: Change of well-being as measured by Psychological General Well Being Schedule (PGWBI) as well as Smoking and drinking behavior and recreational drug use|Clinical Outcome: Change of Hemophilia A status|Clinical Outcome: Change of Joint Status|Clinical Outcome: Baseline disease characteristics|Clinical Outcome: Change of treatment patterns including Hemophilia treatments via patient chart","Bayer","Male","16 Years and older   (Child, Adult, Older Adult)",,"272","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","17285|KG1301","December 9, 2015","January 17, 2018","March 26, 2018","March 24, 2015",,"March 27, 2019","Phoenix, Arizona, United States|Aurora, Colorado, United States|Washington, District of Columbia, United States|New Orleans, Louisiana, United States|Detroit, Michigan, United States|Minneapolis, Minnesota, United States|Columbus, Ohio, United States|Multiple Locations, Japan|Multiple Locations, Spain|Multiple Locations, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02396862"
457,"NCT02396316","Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients","VEGA","Completed","Has Results","Glaucoma, Neovascular","Drug: Aflibercept (Eylea, BAY 86-5321)|Drug: Sham Injection","Change in Intraocular Pressure (IOP) From Baseline to Pre-dose at Week 1|Percentage of Subjects Who Had Improved Neovascularization of the Iris (NVI) Grade From Baseline to Pre-dose at Week 1","Bayer|Regeneron Pharmaceuticals","All","20 Years and older   (Adult, Older Adult)","Phase 3","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","17584","April 2, 2015","June 16, 2016","September 6, 2016","March 24, 2015","July 21, 2017","September 15, 2017","Yoshida, Fukui, Japan|Amagasaki, Hyogo, Japan|Himeji, Hyogo, Japan|Kobe, Hyogo, Japan|Kanazawa, Ishikawa, Japan|Kawasaki, Kanagawa, Japan|Sendai, Miyagi, Japan|Yufu, Oita, Japan|Hirakata, Osaka, Japan|Suita, Osaka, Japan|Takatsuki, Osaka, Japan|Izumo, Shimane, Japan|Bunkyo-ku, Tokyo, Japan|Mitaka, Tokyo, Japan|Ube, Yamaguchi, Japan|Chuo, Yamanashi, Japan|Gifu, Japan|Kyoto, Japan|Osaka, Japan",,"https://ClinicalTrials.gov/show/NCT02396316"
458,"NCT02394093","To Evaluate the Bioavailability of a Single Oral Dose of the Acetylsalicylic Acid Containing Dry Powder 500 mg in Comparison to the Bioavailability of a Single Oral Dose of Aspirin Tablets and Aspirin Effervescent Tablets in Healthy Adults.","Icicle","Completed","No Results Available","Pharmacology, Clinical","Drug: Aspirin (Acetylsalicylic acid, BAYe4465)","Plasma concentration of Acetylsalicylic Acid (ASA) characterized by AUC0-t|Plasma concentration of Acetylsalicylic Acid (ASA) characterized by AUC0-∞|Plasma concentration of Acetylsalicylic Acid (ASA) characterized by Cmax|Plasma concentration of Acetylsalicylic Acid (ASA) characterized by tmax|Plasma concentration of Acetylsalicylic Acid (ASA) characterized by λz (Kel)|Plasma concentration of Acetylsalicylic Acid (ASA) characterized by t1/2|Plasma concentration of Acetylsalicylic Acid (ASA) characterized by t lag|Plasma concentration of Acetylsalicylic Acid (ASA) characterized by Cmax/AUC0-∞|Plasma concentration of Acetyl salicylic Acid (ASA) characterized by MRT|Plasma concentration of Salicylic Acid (SA) characterized by AUC0-t|Plasma concentration of Salicylic Acid (SA) characterized by AUC0-∞|Plasma concentration of Salicylic Acid (SA) characterized by Cmax|Plasma concentration of Salicylic Acid (SA) characterized by tmax|Plasma concentration of Salicylic Acid (SA) characterized by λz (Kel)|Plasma concentration of Salicylic Acid (SA) characterized by t1/2|Plasma concentration of Salicylic Acid (SA) characterized by t lag|Plasma concentration of Salicylic Acid (SA) characterized by Cmax/AUC0-∞|Plasma concentration of Salicylic Acid (SA) characterized by MRT|Plasma concentration of Acetylsalicylic Acid (ASA) characterized by AUC0-t /AUC0-∞|Plasma concentration of Salicylic Acid (SA) characterized by AUC0-t /AUC0-∞|Number of participants with Adverse Events as measure of safety and tolerability","Bayer","All","18 Years to 55 Years   (Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17494","February 2015","March 2015","March 2015","March 20, 2015",,"September 19, 2016","Hackensack, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02394093"
459,"NCT02391116","Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)",,"Completed","Has Results","Diffuse, Large B-Cell, Lymphoma","Drug: Copanlisib (Aliqopa, BAY80-6946)","Objective Response Rate (ORR) in Total Population Based on Investigator Assessment|ORR by CD79b Status Based on Investigator Assessment|ORR by DLBCL/COO Subtype Based on Investigator Assessment|Duration of Response (DOR) in Total Population|DOR by CD79b Status|DOR by DLBCL/COO Subtype|Progression-free Survival (PFS) in Total Population|PFS by CD79b Status|PFS by DLBCL/COO Subtype|Overall Survival (OS) in Total Population|OS by CD79b Status|OS by DLBCL/COO Subtype|Duration of Stable Disease (DOSD) in Total Population|Disease Control Rate (DCR) in Total Population|DCR by CD79b Status|DCR by DLBCL/COO Subtype|Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","67","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17119|2014-004848-36","May 8, 2015","July 5, 2016","January 19, 2018","March 18, 2015","January 8, 2018","January 4, 2019","Kingswood, New South Wales, Australia|Ballarat, Victoria, Australia|Prahran, Victoria, Australia|Box Hill, Australia|Wilrijk, Antwerpen, Belgium|Bruxelles - Brussel, Belgium|Edegem, Belgium|Gent, Belgium|Leuven, Belgium|St. John's, Newfoundland and Labrador, Canada|Brampton, Ontario, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Sherbrooke, Quebec, Canada|Aarhus C, Denmark|Odense C, Denmark|Caen Cedex, France|Creteil, France|Lille, France|PARIS cedex, France|Pierre Benite, France|POITIERS cedex, France|Münster, Nordrhein-Westfalen, Germany|Leipzig, Sachsen, Germany|Berlin, Germany|Milano, Lombardia, Italy|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Singapore, Singapore|Truro, Cornwall, United Kingdom|Southampton, Hampshire, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02391116"
460,"NCT02390154","Roniciclib Mass Balance Study",,"Completed","No Results Available","Neoplasms","Drug: roniciclib (BAY 1000394)","Amount of Roniciclib in urine as percentage of the dose of total radioactivity.|Amount of Roniciclib in feces as percentage of the dose of total radioactivity.|Amount of Roniciclib in vomit as percentage of the dose of total radioactivity|Cmaxof roniciclib in plasma|AUC(0-tlast) of roniciclib in plasma|AUC of roniciclib in plasma|Cmax of total radioactivity in whole blood and plasma|AUC(0-tlast) of total radioactivity in whole blood and plasma|AUC of total radioactivity in whole blood and plasma","Bayer","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","7","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15022|2014-002797-37","April 2015","March 2016","June 2016","March 17, 2015",,"July 15, 2016","PRA Magyarorszag Kft. Fazis I-es Klin.Farmakol. Vizsgalohely, Budapest, Hungary",,"https://ClinicalTrials.gov/show/NCT02390154"
461,"NCT02369029","BAY1238097, First in Man",,"Terminated","No Results Available","Neoplasms","Drug: BAY 1238097","incidence of DLT(dose-limiting toxicities)|Tumor response evaluation based on the response criteria as applicable","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","8","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17437|2014-003131-19","March 2015","January 2016","January 2016","February 23, 2015",,"March 9, 2016","Houston, Texas, United States|HUS, Finland|Villejuif Cedex, France|Heidelberg, Baden-Württemberg, Germany|Bellinzona, Switzerland|Oxford, Oxfordshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02369029"
462,"NCT02369016","Phase III Copanlisib in Rituximab-refractory iNHL","CHRONOS-2","Active, not recruiting","No Results Available","Lymphoma, Non-Hodgkin","Drug: Copanlisib (BAY 80-6946)","Number of patients with treatment-emergent adverse events|Number of patients with serious adverse events|Number of patients with abnormal lab parameters|Number of patients with abnormal vital signs","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","25","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17322|2014-000925-19","September 22, 2015","November 30, 2020","November 30, 2020","February 23, 2015",,"December 24, 2019","Jaú, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|Sao Paulo, Brazil|Plovdiv, Bulgaria|Harbin, Heilongjiang, China|Athens, Greece|Bologna, Emilia-Romagna, Italy|Genova, Liguria, Italy|Jeollabuk-do, Korea, Republic of|Jeollanam-do, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Gdynia, Poland|Almada, Portugal|Kazan, Russian Federation|Kemerovo, Russian Federation|Moscow, Russian Federation|Omsk, Russian Federation|Penza, Russian Federation|Johannesburg, Gauteng, South Africa|Taipei, Taiwan|Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT02369016"
463,"NCT02368951","Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)",,"Terminated","No Results Available","Medical Oncology","Drug: BAY1187982","Maximum tolerated dose(MTD)|Number of subjects with adverse events as a measure of safety and tolerability|Number of subjects with serious adverse events as a measure of safety and tolerability|Cmax (maximum observed drug concentration in measured matrix after single dose administration)|AUC(0-tlast) AUC from time 0 to the last data point >LLOQ|AUC)0-504 (AUC from zero to 504 hours post infusion)|AUC (area under the concentration vs. time curve from zero to infinity after single (first)|Cmax,md (maximum observed drug concentration in measured matrix after multiple dose administration during a dosage interval)|AUC(0-tlast)md (AUC from time 0 to the last data point >LLOQ after multiple dosing)|AUC(0-504)md|FGFR2 levels in tumor tissue sample|CK18 levels in tumor tissue sample|Nucleosome level in plasma|Development of anti-drug antibodies (ADAs) in plasma as an indicator of immunogenicity|Tumor response","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16897","March 24, 2015","July 27, 2016","July 27, 2016","February 23, 2015",,"July 12, 2017","San Francisco, California, United States|Santa Monica, California, United States|New Haven, Connecticut, United States|Chicago, Illinois, United States|Baltimore, Maryland, United States|Saint Louis, Missouri, United States|New York, New York, United States|Nashville, Tennessee, United States|Houston, Texas, United States|Seattle, Washington, United States|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT02368951"
464,"NCT02367040","Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)","CHRONOS-3","Recruiting","No Results Available","Lymphoma,Non-Hodgkin","Drug: Copanlisib (BAY 80-6946)|Drug: Placebo|Drug: Rituximab","Progression free survival (PFS)|Objective tumor response|Duration of response (DOR)|Complete response|Time to progression (TTP)|Overall survival (OS)|Time to deterioration in DRS-P of at least 3 points as measured by the FLymSI-18 (Lymphoma Symptom Index -18)questionnaire|Number of participants with adverse Events as a measure of safety and tolerability|Time to improvement in DRS-P of at least 3 points, as measured by the FLymSI-18 questionnaire, will be evaluated for patients with a baseline DRS-P score of 30 points or less","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","450","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","17067|2013-003893-29","August 3, 2015","May 31, 2020","August 28, 2020","February 20, 2015",,"January 13, 2020","Little Rock, Arkansas, United States|Rogers, Arkansas, United States|Bakersfield, California, United States|Long Beach, California, United States|West Covina, California, United States|Whittier, California, United States|Denver, Colorado, United States|Hartford, Connecticut, United States|Miami, Florida, United States|Orange City, Florida, United States|Columbus, Georgia, United States|Maywood, Illinois, United States|Ashland, Kentucky, United States|Louisville, Kentucky, United States|Bethesda, Maryland, United States|Farmington Hills, Michigan, United States|Las Vegas, Nevada, United States|Basking Ridge, New Jersey, United States|Englewood, New Jersey, United States|Middletown, New Jersey, United States|Montvale, New Jersey, United States|Morristown, New Jersey, United States|MSK Basking Ridge, New Jersey, New Jersey, United States|MSK Bergen, New Jersey, New Jersey, United States|MSK Monmoth, New Jersey, New Jersey, United States|Commack, New York, United States|Harrison, New York, United States|MSK Westchester, Harrison, New York, United States|MSK Commack, Long Island City, New York, United States|MSK Rockville Centre, Long Island City, New York, United States|New York, New York, United States|New York, New York, United States|Uniondale, New York, United States|Goldsboro, North Carolina, United States|Canton, Ohio, United States|Cleveland, Ohio, United States|Bend, Oregon, United States|Allentown, Pennsylvania, United States|Danville, Pennsylvania, United States|Watertown, South Dakota, United States|Salt Lake City, Utah, United States|Olympia, Washington, United States|Spokane, Washington, United States|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Cordoba, Córdoba, Argentina|Rosario, Santa Fe, Argentina|San Miguel de Tucumán, Tucuman, Argentina|Ciudad Auton. de Buenos Aires, Argentina|Córdoba, Argentina|Kingswood, New South Wales, Australia|Kogarah, New South Wales, Australia|Orange, New South Wales, Australia|Waratah, New South Wales, Australia|Ballarat, Victoria, Australia|Nedlands, Australia|Linz, Oberösterreich, Austria|Graz, Steiermark, Austria|Leoben, Steiermark, Austria|Landeskrankenhaus Rankweil, Rankweil, Vorarlberg, Austria|Krems, Austria|Linz, Austria|Salzburg, Austria|Wien, Austria|Wien, Austria|Lesnoy, Belarus|Minsk, Belarus|Bruxelles - Brussel, Belgium|Ottignies, Belgium|Turnhout, Belgium|Verviers, Belgium|Ijuí, Rio Grande Do Sul, Brazil|Passo Fundo, Rio Grande Do Sul, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|Barretos, Sao Paulo, Brazil|Jaú, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|Brazil, Brazil|Rio de Janeiro, Brazil|Sao Paulo, Brazil|Plovdiv, Bulgaria|Plovdiv, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Temuco, Araucanía, Chile|Santiago, Chile|Santiago, Chile|Hefei, Anhui, China|Fuzhou, Fujian, China|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Zhengzhou, Henan, China|Wuhan, Hubei, China|Wuhan, Hubei, China|Nanjing, Jiangsu, China|Nanjing, Jiangsu, China|Suzhou, Jiangsu, China|Nanchang, Jiangxi, China|Changchun, Jilin, China|Shengyang, Liaoning, China|Chengdu, Sichuan, China|Urumchi, Xinjiang, China|Urumqi, Xinjiang, China|Hangzhou, Zhejiang, China|Hangzhou, Zhejiang, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|China, China|Chongqing, China|Shanghai, China|Shanghai, China|Shanghai, China|Tianjin, China|Tianjin, China|Tianjin, China|Medellín, Antioquia, Colombia|Barranquilla, Atlántico, Colombia|Bogotá, Cundinamarca, Colombia|Montería, Córdoba, Colombia|Floridablanca, Santander, Colombia|Cali, Valle Del Cauca, Colombia|Cali, Valle Del Cauca, Colombia|Bogota, Colombia|Aalborg, Denmark|Aarhus C, Denmark|Copenhagen, Denmark|Odense C, Denmark|Roskilde, Denmark|Bayonne, France|Brest, France|Limoges, France|Metz Cedex 03, France|Nantes, France|NICE Cedex 2, France|Perigueux, France|Pessac, France|Poitiers, France|Vandoeuvre-les-nancy, France|Aschaffenburg, Bayern, Germany|Landshut, Bayern, Germany|München, Bayern, Germany|Potsdam, Berlin, Germany|Recklinghausen, Nordrhein-Westfalen, Germany|Halle, Sachsen-Anhalt, Germany|Chemnitz, Sachsen, Germany|Dresden, Sachsen, Germany|Berlin, Germany|Hamburg, Germany|Athens, Greece|Athens, Greece|Chaidari, Greece|Larissa, Greece|Patras, Greece|Piraeus, Greece|Thessaloniki, Greece|Chai wan, Hong Kong|Hong Kong, Hong Kong|Kowloon, Hong Kong|New Territories, Hong Kong|Shatin, Hong Kong|Budapest, Hungary|Budapest, Hungary|Gyor, Hungary|Kaposvar, Hungary|Pecs, Hungary|Tatabanya, Hungary|Dublin 4, Ireland|Dublin, Ireland|Dublin, Ireland|Dublin, Ireland|Galway, Ireland|Bologna, Emilia-Romagna, Italy|Pordenone, Friuli-Venezia Giulia, Italy|Udine, Friuli-Venezia Giulia, Italy|Genova, Liguria, Italy|Bergamo, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Cagliari, Sardegna, Italy|Firenze, Toscana, Italy|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Maebashi, Gunma, Japan|Kobe, Hyogo, Japan|Nankoku, Kochi, Japan|Sendai, Miyagi, Japan|Matsumoto, Nagano, Japan|Omura, Nagasaki, Japan|Kurashiki, Okayama, Japan|Hirakata, Osaka, Japan|Izumo, Shimane, Japan|Chuo-ku, Tokyo, Japan|Shinagawa-ku, Tokyo, Japan|Aomori, Japan|Fukuoka, Japan|Kumamoto, Japan|Niigata, Japan|Okayama, Japan|Osaka, Japan|Yamagata, Japan|Busan, Korea, Republic of|Busan, Korea, Republic of|Jeollanam-do, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Kaunas, Lithuania|Esch-sur-alzette, Luxembourg|Luxembourg, Luxembourg|Ipoh, Malaysia|Kelantan, Malaysia|Kota Kinabalu, Malaysia|Kuala Lumpur, Malaysia|Kuala Lumpur, Malaysia|Pulau Pinang, Malaysia|Selangor, Malaysia|México, D.F., Distrito Federal, Mexico|Morelia, Michoacán, Mexico|Monterrey, Nuevo Leon, Mexico|Monterrey, Nuevo Leon, Mexico|Oaxaca, Mexico|Tauranga, New Zealand|Cebu City, Philippines|Manila, Philippines|Pasig City, Philippines|Quezon City, Philippines|Gdansk, Poland|Gdynia, Poland|Gliwice, Poland|Krakow, Poland|Lublin, Poland|Almada, Lisboa, Portugal|Vila Nova de Gaia, Porto, Portugal|Porto, Portugal|Porto, Portugal|Porto, Portugal|Baia Mare, Romania|Brasov, Romania|Bucharest, Romania|Bucuresti, Romania|Bucuresti, Romania|Bucuresti, Romania|Cluj-Napoca, Romania|Craiova, Romania|Iasi, Romania|Targu-Mures, Romania|Chelyabinsk, Russian Federation|Engels, Russian Federation|Irkutsk, Russian Federation|Kazan, Russian Federation|Kemerovo, Russian Federation|Kirov, Russian Federation|Krasnoyarsk, Russian Federation|Moscow, Russian Federation|Novosibirsk, Russian Federation|Omsk, Russian Federation|Penza, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|Tula, Russian Federation|Volgograd, Russian Federation|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|Poprad, Slovakia|George, Eastern Cape, South Africa|Johannesburg, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Saxonwold, Gauteng, South Africa|L'Hospitalet de Llobregat, Barcelona, Spain|Majadahonda, Madrid, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Málaga, Spain|Salamanca, Spain|Falun, Sweden|Uddevalla, Sweden|Changhua, Taiwan|Kaohsiung, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Bangkok, Thailand|Bangkok, Thailand|Chiang Mai, Thailand|Khon Kaen, Thailand|Pathumthani, Thailand|Ankara, Turkey|Ankara, Turkey|Istanbul, Turkey|Izmir, Turkey|Kayseri, Turkey|Trabzon, Turkey|Cherkasy, Ukraine|Dnipro, Ukraine|Khmel'nytsky, Ukraine|Kiev, Ukraine|Lviv, Ukraine|Uzhgorod, Ukraine|Vinnitsa, Ukraine|Zaporizhzhya, Ukraine|Ha Noi, Vietnam|Ho Chi Minh City, Vietnam",,"https://ClinicalTrials.gov/show/NCT02367040"
465,"NCT02367027","Relative Bioavailability Study in Healthy Subjects Comparing 2 Dry Powder Oral Suspensions of Rivaroxaban Under Fasting and 20 mg of an Oral Suspension of Rivaroxaban Under Fed Conditions to 10 mg of an Immediate Release Tablet Under Fasting Conditions",,"Completed","No Results Available","Pharmacokinetics","Drug: Rivaroxaban (Xarelto, BAY59-7939)","Plasma concentration of rivaroxaban characterized by AUC|Plasma concentration of rivaroxaban characterized by AUC/D|Plasma concentration of rivaroxaban characterized by Cmax|Plasma concentration of rivaroxaban characterized by Cmax/D","Bayer|Janssen Research & Development, LLC","Male","18 Years to 55 Years   (Adult)","Phase 1","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","17769|2014-004337-69","February 2015","April 2015","June 2015","February 20, 2015",,"June 10, 2015","Mannheim, Baden-Württemberg, Germany",,"https://ClinicalTrials.gov/show/NCT02367027"
466,"NCT02366949","Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel",,"Completed","No Results Available","Medical Oncology","Drug: BAY 1217389|Drug: Paclitaxel","Maximum tolerated dose (MTD)|Number of subjects with adverse events and serious adverse events as a measure of safety and tolerability.|Plasma concentration of Paclitaxel characterized by Cmax.|Plasma concentration of BAY 1217389 characterized by Cmax.","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","75","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17350|2014-004821-41","February 27, 2015","March 30, 2018","April 18, 2019","February 19, 2015",,"May 6, 2019","Santa Monica, California, United States|Denver, Colorado, United States|New Haven, Connecticut, United States|Hackensack, New Jersey, United States|Houston, Texas, United States|San Antonio, Texas, United States|Rotterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT02366949"
467,"NCT02363855","Phase 1 Dose Escalation Study of BAY 1841788 in Japanese Metastatic Castration-resistant Prostate Cancer (mCRPC) Subjects",,"Completed","No Results Available","Prostatic Neoplasms","Drug: BAY 1841788(ODM-201)","Number of participants with Treatment Emergent Adverse Event as measure of safety and tolerability|The intensity of an adverse event graded using the NCI CTCAE version 4.03|Plasma concentration of BAY 1841788 characterized by Cmax|Plasma concentration of BAY 1841788 characterized by tmax|Plasma concentration of BAY 1841788 characterized by AUC(0-12)|Plasma concentration of metabolite BAY 1896953 characterized by Cmax|Plasma concentration of metabolite BAY 1896953 characterized by tmax|Plasma concentration of metabolite BAY 1896953 characterized by AUC(0-12)|Plasma concentration of diastereomers BAY 1896951 characterized by Cmax|Plasma concentration of diastereomers BAY 1896951 characterized by tmax|Plasma concentration of diastereomers BAY 1896951 characterized by AUC(0-12)|Plasma concentration of diastereomers BAY 1896952 characterized by Cmax|Plasma concentration of diastereomers BAY 1896952 characterized by tmax|Plasma concentration of diastereomers BAY 1896952 characterized by AUC(0-12)","Bayer","Male","20 Years and older   (Adult, Older Adult)","Phase 1","9","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17719","February 23, 2015","November 19, 2015","January 18, 2018","February 16, 2015",,"January 25, 2018","Kashiwa, Chiba, Japan",,"https://ClinicalTrials.gov/show/NCT02363855"
468,"NCT02349815","JAYDESS Drug Utilization Study in Sweden",,"Active, not recruiting","No Results Available","Contraception","Drug: Levonorgestrel (Jaydess, Skyla, BAY86-5028)","Duration of use of JAYDESS|Indication for use|Age at insertion and removal","Bayer|Karolinska Institutet, Stockholm, Sweden","Female","18 Years to 64 Years   (Adult)",,"10000","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","16903|JD1311SE","January 1, 2017","December 31, 2022","December 31, 2022","January 29, 2015",,"December 30, 2019","Many Locations, Multiple Locations, Sweden",,"https://ClinicalTrials.gov/show/NCT02349815"
469,"NCT02349399","Drug Utilization Study on Diane-35 (and Generics) in Three European Healthcare Databases",,"Completed","No Results Available","Acne Vulgaris","Drug: Cyproterone / Ethinylestradiol (Diane-35, BAY86-5264) and its Generics","Proportion (%) of new users of Diane-35 (or generics) with a previous diagnosis of Acne|Proportion (%) of new users of Diane-35 (or generics) with a previous diagnosis of Hirsutism|Proportion (%) of new users of Diane-35 (or generics) with a previous diagnosis of other Hyperandrogenic Conditions (e.g. androgenic alopecia, seborrhea, polycystic ovary syndrome)|Determination of previous acne treatments (prescription drugs only) of Diane-35 (or generics) users with a previous diagnosis of acne.|Proportion (%) of new Diane-35 (or generics) users, who have concomitant prescriptions of other combined oral contraceptives","Bayer","Female","18 Years to 64 Years   (Adult)",,"26065","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","17660|DI1402","May 1, 2015","March 1, 2016","March 1, 2016","January 28, 2015",,"April 5, 2017","Many locations, Italy|Many locations, Netherlands|Many Locations, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02349399"
470,"NCT02347852","Assessment of Physical Activity During Therapy With Regorafenib for Metastatic Colorectal Cancer","REGO-ACT","Completed","No Results Available","Colorectal Neoplasms","Drug: Regorafenib (Stivarga, BAY73-4506)","Amount of physical activity assessed by a pedometer (smartLAB) and an international physical activity questionnaire|Relation of the amount of physical activity to QoL (Quality of Life) data assessed in CORRELATE (NCT02042144, 'Safety and Effectiveness of Regorafenib in Routine Clinical Practice Settings')|Relation of the amount of physical activity to fatigue data assessed in CORRELATE (NCT02042144, 'Safety and Effectiveness of Regorafenib in Routine Clinical Practice Settings')|Relation of the amount of physical activity to DCR (Disease Control Rate) data assessed in CORRELATE (NCT02042144, 'Safety and Effectiveness of Regorafenib in Routine Clinical Practice Settings')|Relation of the amount of physical activity to OS (Overall Survival) data assessed in CORRELATE (NCT02042144, 'Safety and Effectiveness of Regorafenib in Routine Clinical Practice Settings')|Relation of the amount of physical activity to PFS (Progression Free Survival) data assessed in CORRELATE (NCT02042144, 'Safety and Effectiveness of Regorafenib in Routine Clinical Practice Settings')","Bayer","All","18 Years and older   (Adult, Older Adult)",,"25","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","17816|SV1415AT","January 20, 2015","September 8, 2016","September 8, 2016","January 27, 2015",,"September 10, 2018","Klinikum Kreuzschwestern Wels GmbH, Multiple Locations, Austria",,"https://ClinicalTrials.gov/show/NCT02347852"
471,"NCT02345382","Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia",,"Completed","No Results Available","Leukemia","Drug: Atuveciclib, BAY1143572","Maximum Tolerated Dose (MTD) of BAY1143572 in Advanced Acute Leukemia Subjects|Maximum Total Observed Drug Concentration (Cmax) of BAY1143572 after Single Dose Administration in Plasma|Maximum Total Observed Drug Concentration of BAY1143572 after Multiple Dose Administration in Plasma (Cmax,md)|Area Under the Concentration Versus Time Curve from Zero to 24 hours (AUC[0-24h]) of BAY1143572 in Plasma After Single Dose Administration|Area Under the Concentration Versus Time Curve from Zero to 24 hours of BAY1143572 in Plasma after Multiple Dose Administration (AUC[O-24h]md)|Area Under the Concentration Versus Time Curve from Zero to Last Data Point Greater than Lower Limit of Quantitation (LLOQ) of BAY1143572 in Plasma (AUC[0-tlast]) after Single Dose Administration|Time to Reach Maximum Drug Concentration (tmax) of BAY1143572 in Plasma after Single Dose Administration|Time to Reach Maximum Drug Concentration of BAY1143572 in Plasma after Multiple Dose Administration (tmax,md)|Number of Subjects With Leukemia Response|Number of Subjects with Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)|Area Under the Concentration Versus Time Curve from Zero to Infinity (AUC) of BAY1143572 after Single Dose Administration in Plasma","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","42","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16520|2014-000410-57","February 19, 2015","September 14, 2016","July 30, 2017","January 26, 2015",,"June 25, 2018","Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Columbia University Medical Center, New York, New York, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Universitätsklinikum der Johann Wolfgang Goethe Universität, Frankfurt, Hessen, Germany|Medizinische Fakultät Carl Gustav Carus, Dresden, Sachsen, Germany",,"https://ClinicalTrials.gov/show/NCT02345382"
472,"NCT02342665","Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL",,"Active, not recruiting","No Results Available","Lymphoma Non-Hodgkin","Drug: Copanlisib (BAY80-6946)","Number of participants with Adverse Events|Intensity of AE|Objective Tumor Response (OR)|Recommended dose determined in the dose escalation/safety evaluation","Bayer","All","20 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","25","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17792","April 21, 2015","September 14, 2018","October 31, 2021","January 21, 2015",,"December 30, 2019","Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Maebashi, Gunma, Japan|Kobe, Hyogo, Japan|Sendai, Miyagi, Japan|Chuo-ku, Tokyo, Japan|Koto-ku, Tokyo, Japan|Fukuoka, Japan|Fukuoka, Japan|Kyoto, Japan",,"https://ClinicalTrials.gov/show/NCT02342665"
473,"NCT02332031","Sorafenib Drug Drug Interaction Study in Healthy Male Subjects",,"Completed","No Results Available","Drug Interactions","Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Levothyroxine","Area under the concentration vs. time curve from zero to infinity after single (first) dose (AUC) of sorafenib|AUC from time 0 to the last data point > LLOQ (AUC(0-tlast))of Sorafenib and metabolite M-2|Maximum observed drug concentration in measured matrix after single dose administration (Cmax) of Sorafenib and metabolite M-2|Time to reach Cmax (in case of two identical Cmax values, the first tmax will be used) (Tmax Sorafenib) and metabolite M-2|Half-life associated with the terminal slope (t1/2) of Sorafenib and metabolite M-2|Apparent volume of distribution at steady state after extravascular administration (Vss/F) of Sorafenib|Total body clearance of Sorafenib calculated after extravascular administration (CL/F)|AUC of metabolite M-2|Metabolite to parent AUC(0-tlast) ratios|Number of participants with adverse events as a measure of safety and tolerability","Bayer","Male","18 Years to 45 Years   (Adult)","Phase 1","25","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","17436|2014-001907-36","February 2015","June 2015","September 2015","January 6, 2015",,"October 12, 2015","Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT02332031"
474,"NCT02331303","A Drug Utilization Study of Radium-223 in Sweden",,"Completed","No Results Available","Neoplasms","Other: Radium-223 dichloride (Xofigo, BAY88-8223)","Proportion of men with metastatic castration resistant prostate cancer (mCRPC) of Xofigo use|Proportion of being women of Xofigo use|Proportion of being children of Xofigo use|Proportion of bone metastasis but having a diagnosis of other cancer than mCRPV|Dosage of Xofigo (kBq/kg)|Proportion of participants of dose outside label recommendation","Bayer","All","Child, Adult, Older Adult",,"37","Industry","Observational","Observational Model: Cohort|Time Perspective: Other","17399","April 15, 2015","December 19, 2017","December 19, 2017","January 6, 2015",,"January 23, 2018","Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT02331303"
475,"NCT02321241","Real Life of Aflibercept in France in Patients Refractory to Ranibizumab: Observational Study in Wet AMD","TITAN","Completed","No Results Available","Wet Macular Degeneration","Drug: Aflibercept (EYLEA, BAY-86-5321)","Treatment success rate (defined as a gain of at least 1 letter in BCVA and/or a diminution of CRT (expressed in µm))|Proportion of patients whose BCVA increases by ≥ 0 letter, ≥ 5 letters, ≥ 10 letters, ≥15 letters|Proportion of patients with less than 15 letters loss|Proportion of patients with dry-OCT|Mean duration of treatment with ranibizumab before initiation of aflibercept|Mean change in Central retinal thickness in µm (OCT)","Bayer|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)",,"236","Industry","Observational","Observational Model: Cohort|Time Perspective: Other","17405|EY1413FR","February 1, 2016","January 18, 2017","August 18, 2017","December 22, 2014",,"July 2, 2018","Multiple Locations, France",,"https://ClinicalTrials.gov/show/NCT02321241"
476,"NCT02319070","2-cohort Study of Adult Patients With Severe Hemophilia A in Greece","HAMLET","Completed","No Results Available","Hemophilia A","Other: Survey","Annual direct medical cost of specialized hemophilia centre for patients with the on-demand strategy|Annual direct medical cost of specialized hemophilia centre for patients with secondary prophylaxis|Mean cost per joint bleed episodes for overall patients|Mean cost per joint bleed episodes by cohort for patients|Number of joint bleed episodes for overall patients|Number of joint bleed episodes by cohort for patients.|Severity of joint bleed episodes for overall patients.|Severity of joint bleed episodes by cohort for patients.|Mean EQ-VAS score as reported from patients at the time of a major bleed.|Mean EQ-5D score as reported from patients at the time of a major bleed.|Mean change from baseline in Quality of Life scores derived from the Haem-A-Qol and EQ-5D questionnaires","Bayer","Male","18 Years and older   (Adult, Older Adult)",,"72","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","17493|KG1411GR","January 13, 2015","May 28, 2017","February 28, 2018","December 18, 2014",,"June 20, 2018","Multiple Locations, Greece",,"https://ClinicalTrials.gov/show/NCT02319070"
477,"NCT02313909","Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)","NAVIGATE ESUS","Terminated","Has Results","Stroke","Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Acetylsalicylic acid (Aspirin, BAY1019036)|Other: Rivaroxaban-Placebo|Other: Aspirin-Placebo","Incidence Rate of the Composite Efficacy Outcome (Adjudicated)|Incidence Rate of a Major Bleeding Event According to the International Society on Thrombosis and Haemostasis (ISTH) Criteria (Adjudicated)|Incidence Rate of Any of the Following: Cardiovascular Death, Recurrent Stroke, Systemic Embolism and Myocardial Infarction|Incidence Rate of All-Cause Mortality|Incidence Rate of the Following: Stroke, Ischemic Stroke, Disabling Stroke, Cardiovascular (CV) Death, Myocardial Infarction|Incidence Rate of Life-Threatening Bleeding Events|Incidence Rate of Clinically Relevant Non-Major Bleeding Events|Incidence Rate of Intracranial Hemorrhage","Bayer|Janssen Research & Development, LLC|Population Health Research Institute","All","50 Years and older   (Adult, Older Adult)","Phase 3","7213","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","16573|2013-000768-27","December 23, 2014","February 15, 2018","February 15, 2018","December 10, 2014","January 9, 2019","January 9, 2019","Tucson, Arizona, United States|Long Beach, California, United States|Stanford, California, United States|Torrance, California, United States|New Haven, Connecticut, United States|Gainesville, Florida, United States|Joliet, Illinois, United States|Iowa City, Iowa, United States|Lexington, Kentucky, United States|New Orleans, Louisiana, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Worcester, Massachusetts, United States|Ann Arbor, Michigan, United States|Mount Clemens, Michigan, United States|New Brunswick, New Jersey, United States|Buffalo, New York, United States|New York, New York, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Cleveland, Ohio, United States|Portland, Oregon, United States|Portland, Oregon, United States|Erie, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Charleston, South Carolina, United States|Columbia, South Carolina, United States|Nashville, Tennessee, United States|Austin, Texas, United States|Dallas, Texas, United States|El Paso, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Temple, Texas, United States|Salt Lake City, Utah, United States|Seattle, Washington, United States|Banfield, Buenos Aires, Argentina|Ciudad Auton. de Buenos Aires, Buenos Aires, Argentina|Mar del Plata, Buenos Aires, Argentina|San Martín, Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Rosario, Santa Fe, Argentina|Rosario, Santa Fe, Argentina|Ciudad Auton. de Buenos Aires, Argentina|Córdoba, Argentina|Santa Fe, Argentina|Camperdown, New South Wales, Australia|Waratah, New South Wales, Australia|Brisbane, Queensland, Australia|Southport, Queensland, Australia|Launceston, Tasmania, Australia|Clayton, Victoria, Australia|Footscray, Victoria, Australia|Murdoch, Western Australia, Australia|Elizabeth Vale, Australia|Nedlands, Australia|Klagenfurt, Kärnten, Austria|Villach, Kärnten, Austria|Bad Pirawarth, Niederösterreich, Austria|St. Pölten, Niederösterreich, Austria|Vöcklabruck, Oberösterreich, Austria|Feldbach, Steiermark, Austria|Feldkirch, Vorarlberg, Austria|Salzburg, Austria|Wien, Austria|Wien, Austria|Brugge, West-Vlaanderen, Belgium|Antwerpen, Belgium|Brussel, Belgium|Bruxelles - Brussel, Belgium|Dendermonde, Belgium|Edegem, Belgium|Hasselt, Belgium|Salvador, Bahia, Brazil|Belo Horizonte, Minas Gerais, Brazil|Belo Horizonte, Minas Gerais, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|Joinville, Santa Catarina, Brazil|Botucatu, Sao Paulo, Brazil|Campinas, Sao Paulo, Brazil|Matão, Sao Paulo, Brazil|Ribeirão Preto, Sao Paulo, Brazil|Ribeirão Preto, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|Rio de Janeiro, Brazil|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Edmonton, Alberta, Canada|Lethbridge, Alberta, Canada|Vancouver, British Columbia, Canada|Victoria, British Columbia, Canada|Brandon, Manitoba, Canada|Saint John, New Brunswick, Canada|Halifax, Nova Scotia, Canada|Burlington, Ontario, Canada|Hamilton, Ontario, Canada|Kingston, Ontario, Canada|London, Ontario, Canada|London, Ontario, Canada|Mississauga, Ontario, Canada|Ottawa, Ontario, Canada|Thunder Bay, Ontario, Canada|Toronto, Ontario, Canada|Chicoutimi, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|St. Jerome, Quebec, Canada|Quebec, Canada|Los Angeles, Bío-Bío, Chile|Osorno, Los Lagos, Chile|Puerto Montt, Los Lagos, Chile|Valdivia, Los Lagos, Chile|Viña del Mar, Valparaíso, Chile|Santiago, Chile|Santiago, Chile|Viña del Mar, Chile|Fuzhou, Fujian, China|Fuzhou, Fujian, China|Lanzhou, Gansu, China|Foshan, Guangdong, China|Guangzhou, Guangdong, China|Haikou, Hainan, China|Shijiazhuang, Hebei, China|Harbin, Heilongjiang, China|Zhengzhou, Henan, China|Wuhan, Hubei, China|Wuhan, Hubei, China|Wuhan, Hubei, China|Changsha, Hunan, China|Baotou, Inner Mongolia, China|Nantong, Jiangsu, China|Nanchang, Jiangxi, China|Changchun, Jilin, China|Shenyang, Liaoning, China|Qingdao, Shandong, China|Yantai, Shandong, China|Baoji, Shanxi, China|Xi'an, Shanxi, China|Kunming, Yunnan, China|Hangzhou, Zhejiang, China|Taizhou, Zhejiang, China|Wenzhou, Zhejiang, China|Beijing, China|Beijing, China|Chongqing, China|Guangzhou, China|Shanghai, China|Tianjin, China|Tianjin, China|Blansko, Czechia|Brno, Czechia|Brno, Czechia|Hradec Kralove, Czechia|Jihlava, Czechia|Olomouc, Czechia|Ostrava Vitkovice, Czechia|Ostrava-Poruba, Czechia|Praha 2, Czechia|Praha 3, Czechia|Vyskov, Czechia|Aalborg, Denmark|Aarhus C, Denmark|Copenhagen, Denmark|Glostrup, Denmark|Herlev, Denmark|Hillerød, Denmark|Helsinki, Finland|Lappeenranta, Finland|OYS, Finland|Sairaalamäki, Finland|Tampere, Finland|Turku, Finland|Vaasa, Finland|Antony Cedex, France|Bordeaux, France|Brest Cedex, France|Caen Cedex, France|Dijon, France|Le Chesnay, France|Limoges, France|Nantes, France|NIMES cedex 9, France|PARIS cedex 14, France|Paris, France|Paris, France|Paris, France|Paris, France|Saint Priest En Jarez, France|Strasbourg, France|Freiburg, Baden-Württemberg, Germany|Mannheim, Baden-Württemberg, Germany|München, Bayern, Germany|Regensburg, Bayern, Germany|Würzburg, Bayern, Germany|Hannover, Niedersachsen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Meerbusch, Nordrhein-Westfalen, Germany|Wuppertal, Nordrhein-Westfalen, Germany|Halle, Sachsen-Anhalt, Germany|Dresden, Sachsen, Germany|Dresden, Sachsen, Germany|Markkleeberg, Sachsen, Germany|Wermsdorf, Sachsen, Germany|Altenburg, Thüringen, Germany|Berlin, Germany|Hamburg, Germany|Athens, Greece|Athens, Greece|Ioannina, Greece|Larissa, Greece|Thessaloniki, Greece|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Eger, Hungary|Gyor, Hungary|Kistarcsa, Hungary|Miskolc, Hungary|Nagykanizsa, Hungary|Nyiregyhaza, Hungary|Sopron, Hungary|Szeged, Hungary|Zalaegerszeg, Hungary|Dublin, Ireland|Galway, Ireland|Ashkelon, Israel|Beer Sheva, Israel|Haifa, Israel|Haifa, Israel|Jerusalem, Israel|Petah Tikva, Israel|Ramat Gan, Israel|Tel Aviv, Israel|L'Aquila, Abruzzo, Italy|Vibo Valentia, Calabria, Italy|Parma, Emilia-Romagna, Italy|Trieste, Friuli-Venezia Giulia, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Pavia, Lombardia, Italy|Ancona, Marche, Italy|Isernia, Molise, Italy|Cagliari, Sardegna, Italy|Perugia, Umbria, Italy|Perugia, Umbria, Italy|Perugia, Umbria, Italy|Verona, Veneto, Italy|Verona, Veneto, Italy|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Okazaki, Aichi, Japan|Seto, Aichi, Japan|Toyota, Aichi, Japan|Kitakyushu, Fukuoka, Japan|Kitakyushu, Fukuoka, Japan|Koriyama, Fukushima, Japan|Fukuyama, Hiroshima, Japan|Asahikawa, Hokkaido, Japan|Hakodate, Hokkaido, Japan|Kushiro, Hokkaido, Japan|Kobe, Hyogo, Japan|Kobe, Hyogo, Japan|Kobe, Hyogo, Japan|Nishinomiya, Hyogo, Japan|Isehara, Kanagawa, Japan|Kawasaki, Kanagawa, Japan|Sendai, Miyagi, Japan|Sasebo, Nagasaki, Japan|Tenri, Nara, Japan|Kurashiki, Okayama, Japan|Matsubara, Osaka, Japan|Sakai, Osaka, Japan|Suita, Osaka, Japan|Hidaka, Saitama, Japan|Bunkyo-ku, Tokyo, Japan|Hachioji, Tokyo, Japan|Kodaira, Tokyo, Japan|Musashino, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Sumida-ku, Tokyo, Japan|Fukuoka, Japan|Fukuoka, Japan|Fukuoka, Japan|Hiroshima, Japan|Kakogawa, Japan|Kochi, Japan|Kyoto, Japan|Kyoto, Japan|Kyoto, Japan|Niigata, Japan|Okayama, Japan|Donggu,, Gwangju Gwang''yeogsi, Korea, Republic of|Anyang-si, Gyeonggido, Korea, Republic of|Goyang, Gyeonggido, Korea, Republic of|Seongnam-si, Gyeonggido, Korea, Republic of|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Busan, Korea, Republic of|Daegu, Korea, Republic of|Daegu, Korea, Republic of|Incheon, Korea, Republic of|Seoul,, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Delegación Gustavo A. Madero, Distrito Federal, Mexico|México, D.F., Distrito Federal, Mexico|Morelia, Michoacán, Mexico|México D.F., México, Mexico|Monterrey, Nuevo Leon, Mexico|Merida, Yucatán, Mexico|Aguascalientes, Mexico|México D.F., Mexico|Bialystok, Poland|Chelm, Poland|Gdansk, Poland|Gdansk, Poland|Katowice, Poland|Konskie, Poland|Lodz, Poland|Lodz, Poland|Olsztyn, Poland|Sandomierz, Poland|Siedlce, Poland|Skarzysko-Kamienna, Poland|Warszawa, Poland|Warszawa, Poland|Warszawa, Poland|Vilanova De Gaia, Porto, Portugal|Almada, Portugal|Amadora, Portugal|Coimbra, Portugal|Lisboa, Portugal|Porto, Portugal|Porto, Portugal|Vila Franca de Xira, Portugal|Chelyabinsk, Russian Federation|Ekaterinburg, Russian Federation|Kaluga, Russian Federation|Kazan, Russian Federation|Krasnoyarsk, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Nizhny Novgorod, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|Tomsk, Russian Federation|Ulyanovsk, Russian Federation|Volgograd, Russian Federation|Yaroslavl, Russian Federation|Yekaterinburg, Russian Federation|Cape Town, Western Cape, South Africa|Somerset West, Western Cape, South Africa|Durban, South Africa|Santiago de Compostela, A Coruña, Spain|Badalona, Barcelona, Spain|L'Hospitalet de Llobregat, Barcelona, Spain|Sant Joan Despi, Barcelona, Spain|Castellón de la Plana, Castellón, Spain|El Palmar (Murcia), Murcia, Spain|A Coruña, Spain|Badajoz, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Bilbao, Spain|Cáceres, Spain|Girona, Spain|Granada, Spain|León, Spain|Lleida, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Sevilla, Spain|Sevilla, Spain|Valencia, Spain|Valladolid, Spain|Zaragoza, Spain|Goteborg, Sweden|Hässleholm, Sweden|Lund, Sweden|Malmö, Sweden|Umeå, Sweden|Aarau, Aargau, Switzerland|Basel, Basel-Stadt, Switzerland|Lugano, Ticino, Switzerland|Baden, Switzerland|Bern, Switzerland|Fribourg, Switzerland|Genève, Switzerland|Zürich, Switzerland|Ankara, Turkey|Ankara, Turkey|Antakya, Turkey|Istanbul, Turkey|Istanbul, Turkey|Kahramanmaras, Turkey|Konya, Turkey|Konya, Turkey|High Wycombe, Buckinghamshire, United Kingdom|Milton Keynes, Buckinghamshire, United Kingdom|Cambridge, Cambridgeshire, United Kingdom|Exeter, Devon, United Kingdom|Colchester, Essex, United Kingdom|Westcliff-on-Sea, Essex, United Kingdom|Gloucester, Gloucestershire, United Kingdom|Watford, Hertfordshire, United Kingdom|Ashford, Kent, United Kingdom|Margate, Kent, United Kingdom|Leicester, Leicestershire, United Kingdom|Boston, Lincolnshire, United Kingdom|Harrow, London, United Kingdom|Great Yarmouth, Norfolk, United Kingdom|Taunton, Somerset, United Kingdom|Yeovil, Somerset, United Kingdom|Sheffield, South Yorkshire, United Kingdom|Stoke-On-Trent, Staffordshire, United Kingdom|Glasgow, Stratchclyde, United Kingdom|Gateshead, Tyne And Wear, United Kingdom|Sunderland, Tyne And Wear, United Kingdom|Wolverhampton, West Midlands, United Kingdom|Leeds, West Yorkshire, United Kingdom|Salisbury, Wiltshire, United Kingdom|Aberdeen, United Kingdom|Durham, United Kingdom|Edinburgh, United Kingdom|London, United Kingdom|London, United Kingdom|London, United Kingdom|London, United Kingdom|Luton, United Kingdom|Norwich, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT02313909/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT02313909/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02313909"
478,"NCT02312973","To Investigate Pharmacokinetics (Absorption, Distribution, Elimination), Safety and Tolerability of a Single Oral Dose of 75 mg Molidustat Tablet in Male and Female Subjects Requiring Hemo- or Peritoneal Dialysis Compared to Healthy Subjects",,"Completed","No Results Available","Renal Insufficiency, Chronic","Drug: Molidustat(BAY85-3934)","Pharmacokinetics characterized by Cmax of Molidustat|Pharmacokinetics characterized by AUC of Molidustat|Pharmacokinetics characterized by Cmax,norm of Molidustat|Pharmacokinetics characterized by (AUCnorm) of Molidustat|Pharmacokinetics characterized by Cmax of erythropoietin|Pharmacokinetics characterized by AUC (0-tlast) of erythropoietin|Pharmacokinetics characterized by tmax of erythropoietin|Number of subjects with Treatment Emergent Adverse Event (TEAE)","Bayer","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 1","40","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","17767|2014-003292-31","January 2015","December 2015","June 2016","December 9, 2014",,"June 15, 2016","Velbert, Nordrhein-Westfalen, Germany|Kiel, Schleswig-Holstein, Germany",,"https://ClinicalTrials.gov/show/NCT02312973"
479,"NCT02312960","Radium-223 Dichloride Long-term Follow-up Program",,"Recruiting","No Results Available","Neoplasm Metastasis / Bone and Bones","Other: Data Collection","Incidence of radium-223 dichloride related Adverse Events|Severity of radium-223 dichloride related Adverse Events|Incidence of radium-223 dichloride related Serious Adverse Events|Incidence of placebo-related Adverse Events|Severity of placebo-related Adverse Events|Incidence of placebo-related Serious Adverse Events|Incidence of leukemia|Incidence of myelodysplastic syndrome|Incidence of aplastic anemia|Incidence of primary bone cancer|Incidence of any other new primary malignancy|Incidence of bone fractures|Incidence of bone-associated events|Incidence of febrile neutropenia in subjects who receive cytotoxic chemotherapy|Incidence of hemorrhage in subjects who receive cytotoxic chemotherapy","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 4","800","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","16996|2014-002407-25","December 18, 2014","September 15, 2025","September 15, 2025","December 9, 2014",,"January 9, 2020","Anchorage, Alaska, United States|Tucson, Arizona, United States|Plantation, Florida, United States|Indianapolis, Indiana, United States|Ashland, Kentucky, United States|New Orleans, Louisiana, United States|Shreveport, Louisiana, United States|Detroit, Michigan, United States|Omaha, Nebraska, United States|Syracuse, New York, United States|Pittsburgh, Pennsylvania, United States|Watertown, South Dakota, United States|Darlinghurst, New South Wales, Australia|Westmead, New South Wales, Australia|Heidelberg, Victoria, Australia|Bruxelles - Brussel, Belgium|Edegem, Belgium|Kortrijk, Belgium|Leuven, Belgium|Montreal, Quebec, Canada|Santiago, Chile|Praha 2, Czechia|Helsinki, Finland|Tampere, Finland|Bordeaux Cedex, France|Nantes, France|NIMES cedex 9, France|Poitiers, France|Saint Cloud, France|Toulouse Cedex 9, France|Tours, France|Villejuif, France|Freiburg im Breisgau, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|Ulm, Baden-Württemberg, Germany|Erlangen, Bayern, Germany|München, Bayern, Germany|München, Bayern, Germany|Rostock, Mecklenburg-Vorpommern, Germany|Aachen, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Dresden, Sachsen, Germany|Jena, Thüringen, Germany|Berlin, Germany|Berlin, Germany|Bremen, Germany|Hamburg, Germany|Magdeburg, Germany|Afula, Israel|Beer Sheva, Israel|Haifa, Israel|Jerusalem, Israel|Jerusalem, Israel|Kfar Saba, Israel|Petah Tikva, Israel|Ramat Gan, Israel|Tel Aviv, Israel|Zrifin, Israel|Bologna, Emilia-Romagna, Italy|Forlì-Cesena, Emilia-Romagna, Italy|Modena, Emilia-Romagna, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Torino, Piemonte, Italy|Cagliari, Sardegna, Italy|Trento, Trentino-Alto Adige, Italy|Matsuyama, Ehime, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Kanazawa, Ishikawa, Japan|Yokohama, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Sendai, Miyagi, Japan|Kurashiki, Okayama, Japan|Osakasayama, Osaka, Japan|Hidaka, Saitama, Japan|Kita-Adachigun, Saitama, Japan|Bunkyo-ku, Tokyo, Japan|Bunkyo-ku, Tokyo, Japan|Koto-ku, Tokyo, Japan|Chiba, Japan|Chiba, Japan|Fukuoka, Japan|Fukuoka, Japan|Kumamoto, Japan|Miyazaki, Japan|Osaka, Japan|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Busan, Korea, Republic of|Incheon, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Bodø, Norway|Oslo, Norway|Bialystok, Poland|Warszawa, Poland|Moscow, Russian Federation|Obninsk, Russian Federation|Singapore, Singapore|Singapore, Singapore|Badalona (Barcelona), Barcelona, Spain|Palma de Mallorca, Illes Baleares, Spain|A Coruña, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Málaga, Spain|Pamplona, Spain|Sevilla, Spain|Sevilla, Spain|Kaohsiung, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Truro, Cornwall, United Kingdom|Plymouth, Devon, United Kingdom|Nottingham, Nottinghamshire, United Kingdom|Taunton, Somerset, United Kingdom|Sheffield, South Yorkshire, United Kingdom|Bristol, United Kingdom|Cottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02312960"
480,"NCT02309411","EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis","EINSTEINJr","Completed","Has Results","Venous Thromboembolism","Drug: Rivaroxaban (Xarelto, BAY59-7939)","Number of Subjects With Major Bleeding and Clinically Relevant Non-Major Bleeding Events|Number of Subjects With Symptomatic Recurrent Venous Thromboembolism|Number of Subjects With Asymptomatic Deterioration in Thrombotic Burden on Repeat Imaging|Change From Baseline in Prothrombin Time at Specified Time Points|Change From Baseline in Activated Partial Thromboplastin Time at Specified Time Points|Concentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Specified Time Points","Bayer|Janssen Research & Development, LLC","All","6 Months to 5 Years   (Child)","Phase 2","46","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14374|2014-000566-22","January 15, 2015","April 5, 2017","April 5, 2017","December 5, 2014","June 13, 2018","August 21, 2018","Gainesville, Florida, United States|Pensacola, Florida, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Chicago, Illinois, United States|Indianapolis, Indiana, United States|Parkville, Victoria, Australia|Wien, Austria|São Paulo, Sao Paulo, Brazil|São Paulo, Brazil|Toronto, Ontario, Canada|Budapest, Hungary|Jerusalem, Israel|Ramat Gan, Israel|Milano, Lombardia, Italy|Torino, Piemonte, Italy|Padova, Veneto, Italy|Setagaya, Tokyo, Japan|Nijmegen, Netherlands|Gdansk, Poland|Olsztyn, Poland|Moscow, Russian Federation|Nizhny Novgorod, Russian Federation|St. Petersburg, Russian Federation|Barcelona, Spain|Valencia, Spain|Bern, Switzerland|Newcastle Upon Tyne, Tyne And Wear, United Kingdom|Birmingham, West Midlands, United Kingdom|Cardiff, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02309411/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02309411/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02309411"
481,"NCT02305238","Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration","ALTAIR","Completed","Has Results","Wet Macular Degeneration","Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)","Mean Change From Baseline in BCVA at Week 52|Percentage of Participants Who Maintained Vision at Week 52|Percentage of Participants Who Gained at Least 15 Letters of Vision Compared to Baseline at Week 52|Mean Change in Central Retinal Thickness (CRT) From Baseline at Week 52|Percentage of Participants Without Fluid on Optical Coherence Tomography (OCT) at Week 52","Bayer|Regeneron Pharmaceuticals","All","50 Years and older   (Adult, Older Adult)","Phase 4","288","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17668","December 19, 2014","December 22, 2016","December 20, 2017","December 2, 2014","March 12, 2018","January 8, 2019","Ichinomiya, Aichi, Japan|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Toyoake, Aichi, Japan|Asahi, Chiba, Japan|Sakura, Chiba, Japan|Koriyama, Fukushima, Japan|Kure, Hiroshima, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Kobe, Hyogo, Japan|Inashiki-gun, Ibaraki, Japan|Mito, Ibaraki, Japan|Morioka, Iwate, Japan|Yokohama, Kanagawa, Japan|Nankoku, Kochi, Japan|Miyakonojo, Miyazaki, Japan|Iida, Nagano, Japan|Matsumoto, Nagano, Japan|Hirakata, Osaka, Japan|Moriguchi, Osaka, Japan|Osakasayama, Osaka, Japan|Takatsuki, Osaka, Japan|Otsu, Shiga, Japan|Chiyoda-ku, Tokyo, Japan|Chuoku, Tokyo, Japan|Hachioji, Tokyo, Japan|Mitaka, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Taito-ku, Tokyo, Japan|Shimonoseki, Yamaguchi, Japan|Ube, Yamaguchi, Japan|Chuo, Yamanashi, Japan|Fukuoka, Japan|Fukuoka, Japan|Miyazaki, Japan|Okayama, Japan|Osaka, Japan|Osaka, Japan",,"https://ClinicalTrials.gov/show/NCT02305238"
482,"NCT02303444","An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors","RIFTOS MKI","Active, not recruiting","No Results Available","Thyroid Neoplasms","Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Other Multikinase inhibitors","Time to symptomatic progression (TTSP) from study entry|Overall survival (OS) from time of study entry|Progression free survival (PFS) from time of study entry|OS from time of being diagnosed as radioactive iodine (RAI) refractory|Post-progression survival (PPS) from time of symptomatic progression|OS from initiation of the first Multikinase Inhibitor (MKI)|PFS from initiation of first MKI|OS from initiation of any systemic treatment regimen|PFS from initiation of any systemic treatment regimen|Duration of each systemic treatment regimen|Response assessment to each systemic treatment regimen according to the categories ""Complete Response"", ""Partial Response"", ""Stable Disease"", ""Clinical Progression"", ""Radiological Progression"", and ""Not evaluable at this visit""|OS from initiation of sorafenib|PFS from initiation of sorafenib|Daily dose of sorafenib per patient throughout the treatment period|Number of adverse events during treatment with sorafenib","Bayer","All","18 Years and older   (Adult, Older Adult)",,"661","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","17852|NX1401","April 8, 2015","March 31, 2020","July 31, 2020","December 1, 2014",,"January 9, 2020","Birmingham, Alabama, United States|Los Angeles, California, United States|Torrance, California, United States|Aurora, Colorado, United States|Washington, District of Columbia, United States|Plantation, Florida, United States|Atlanta, Georgia, United States|Honolulu, Hawaii, United States|Chicago, Illinois, United States|New Orleans, Louisiana, United States|Boston, Massachusetts, United States|Ann Arbor, Michigan, United States|Bronx, New York, United States|Durham, North Carolina, United States|Philadelphia, Pennsylvania, United States|Dallas, Texas, United States|Multiple Locations, Algeria|Multiple Locations, Argentina|Multiple Locations, Brazil|Multiple Locations, Egypt|Multiple Locations, France|Multiple Locations, Germany|Multiple Locations, Greece|Multiple Locations, India|Multiple Locations, Israel|Multiple Locations, Japan|Multiple Locations, Lebanon|Multiple Locations, Mexico|Multiple Locations, Netherlands|Multiple Locations, Philippines|Multiple Locations, Russian Federation|Multiple Locations, Saudi Arabia|Multiple Locations, Spain|Multiple Locations, Taiwan|Multiple Locations, Turkey",,"https://ClinicalTrials.gov/show/NCT02303444"
483,"NCT02292459","Efficacy and Safety of Polyethylene Glycol 3350 (PEG 3350) for Relief of Constipation (MK-8114-005)",,"Withdrawn","No Results Available","Constipation","Drug: Polyethylene Glycol 3350 Powder for Solution (PEG 3350)|Drug: Polyethylene Glycol 4000 Powder for Solution (PEG 4000)","Number of bowel movements per week|Time to first bowel movement|Number of participants who experience changes in straining and hard or lumpy stools|Number of participants who experience changes in stool consistency|Number of participants who experience changes in the sensation of stool evacuation","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18128|CL2012-15|8114-005","December 2015","December 2015","December 2015","November 17, 2014",,"July 16, 2015",,,"https://ClinicalTrials.gov/show/NCT02292459"
484,"NCT02289924","Aflibercept (Eylea) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy","PERSEUS-IT","Completed","No Results Available","Wet Macular Degeneration","Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)","Mean change of visual acuity from baseline to 12 months.|Mean change of visual acuity from baseline to 24 months.|Number of clinical visits (visits for injections)|Number of monitoring visits (visits only for diagnostic purposes, but without injections)|Number of combined visits (visits for monitoring and injection)|Number of post-injection monitoring visits (visits only for safety checks after injection)|Number of visits outside the study center after 12 and 24 months|Number of optical coherence tomography (OCT) assessments per patient|Number of visual acuity tests|Number of fundoscopy examinations|Mean time between the injections and visits|Mean time between the first symptoms and diagnosis|Mean time from indication of the Eylea treatment by the treating physician to treatment|Proportion of patients with no fluid|Mean change in retinal thickness from baseline","Bayer|Regeneron Pharmaceuticals","All","Child, Adult, Older Adult",,"912","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","17634|EY1415IT","January 9, 2015","March 28, 2019","July 8, 2019","November 13, 2014",,"July 30, 2019","Multiple Locations, Italy",,"https://ClinicalTrials.gov/show/NCT02289924"
485,"NCT02287025","A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Outcomes?","SMART","Terminated","Has Results","Physician Education","Drug: Regorafenib (Stivarga, BAY73-4506)|Other: iPAD application|Other: Bayer specialist","Proportion of Patients Who Discontinue Prior to Documented Progression of Disease (PD) or Death|Duration of Treatment|Dose Intensity as Percentage of Planned Dose|Incidence of Grade 3 Hand-foot-skin Reaction (HFSR), Fatigue, Diarrhea, Hypertension|Investigator Comfort With the Use of Regorafenib and Management of AEs as Measured by Questionnaire|Satisfaction of Investigator/Nurse With Enhanced Drug-specific Information Via SMART Questionnaire","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 4","23","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","17347","November 11, 2014","February 26, 2016","April 8, 2016","November 10, 2014","October 19, 2017","October 19, 2017","Anniston, Alabama, United States|Anaheim, California, United States|Orange, California, United States|Lake City, Florida, United States|Skokie, Illinois, United States|Skokie, Illinois, United States|Lafayette, Indiana, United States|Columbia, Maryland, United States|Fayetteville, North Carolina, United States|Canton, Ohio, United States|Tulsa, Oklahoma, United States|Gettysburg, Pennsylvania, United States|Kingsport, Tennessee, United States|Houston, Texas, United States|Tyler, Texas, United States|Bristol, Virginia, United States|Portsmouth, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02287025"
486,"NCT02284789","Colorado Adult Joint Assessment Scale (CAJAS) Validation","CAJAS","Completed","No Results Available","Hemophilia A","Other: Colorado Adult Joint Assessment Evaluation","Colorado Adult Joint Assessment Score (CAJAS)","Bayer","Male","18 Years to 50 Years   (Adult)","Not Applicable","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","17819","February 2015","October 2015","October 2015","November 6, 2014",,"December 3, 2015","Orange, California, United States|Aurora, Colorado, United States|Indianapolis, Indiana, United States|Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT02284789"
487,"NCT02283762","Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis",,"Completed","Has Results","Scleroderma, Systemic","Drug: Riociguat (Adempas, BAY63-2521)|Drug: Placebo","Change From Baseline in Modified Rodnan Skin Score (mRSS) to Week 52|CRISS (American College of Rheumatology Composite Response Index for Clinical Trials) at Week 52 Reported as Number of Participants With a CRISS Probability >=0.60 or <0.60 From Baseline to Week 52|Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score to Week 52|Change From Baseline in Patient's Global Assessment Score to Week 52|Change From Baseline in Physician's Global Assessment Score to Week 52|Change From Baseline in Forced Vital Capacity (FVC) Percent Predicted to Week 52","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","121","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","16277|2014-001353-16","January 15, 2015","December 15, 2017","March 28, 2019","November 5, 2014","January 25, 2019","January 6, 2020","Mayo Clinic - Scottsdale, Scottsdale, Arizona, United States|UCLA David Geffen School of Medicine, Los Angeles, California, United States|Stanford University School of Medicine, Palo Alto, California, United States|University of Connecticut Health Center, Farmington, Connecticut, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|Medical University of South Carolina Medical Center, Charleston, South Carolina, United States|Memorial Hermann-Texas Medical Center, Houston, Texas, United States|University of Utah Health Care, Salt Lake City, Utah, United States|Liverpool Hospital, Liverpool, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Monash Medical Centre, Clayton, Victoria, Australia|St Vincent's Hospital, Fitzroy, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|CU Saint-Luc/UZ St-Luc, Bruxelles - Brussel, Belgium|UZ Gent, Gent, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|St. Joseph's Healthcare - Hamilton, Hamilton, Ontario, Canada|Arthritis Program Research Group, Inc., Newmarket, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada|Revmatologicky ustav, Praha 2, Czechia|Hôpital Pellegrin - Bordeaux, Bordeaux, France|Centre Hospitalier Universitaire - Grenoble, Grenoble, France|Hopital Claude-Huriez CHRU, Lille, France|Cochin - Paris, Paris, France|CHU STRASBOURG - Hôpital de Hautepierre, Strasbourg, France|Universitätsklinikum Ulm, Ulm, Baden-Württemberg, Germany|Universitätsklinikum Erlangen, Erlangen, Bayern, Germany|Kerckhoff-Klinik GmbH, Bad Nauheim, Hessen, Germany|Universitätsklinikum Köln, Köln, Nordrhein-Westfalen, Germany|Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary|Pecsi Tudomanyegyetem Klinikai Kozpont, Pecs, Hungary|A.O.U. Policlinico Umberto I, Roma, Lazio, Italy|A.O.U. di Cagliari, Cagliari, Sardegna, Italy|A.O.U. Careggi, Firenze, Toscana, Italy|A.O.U. Pisana, Pisa, Toscana, Italy|A.O. di Padova, Padova, Veneto, Italy|Gunma University Hospital, Maebashi, Gunma, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, Japan|Tohoku University Hospital, Sendai, Miyagi, Japan|Nippon Medical School Hospital, Bunkyo-ku, Tokyo, Japan|Institute of Rheumatology Tokyo Women's Medical University, Shinjuku-ku, Tokyo, Japan|Universitair Medisch Centrum St. Radboud, Nijmegen, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|Wellington Hospital, Wellington, New Zealand|Kantonsspital St. Gallen, St. Gallen, Sankt Gallen, Switzerland|Universitätsspital Basel, Basel, Switzerland|UniversitätsSpital Zürich, Zürich, Switzerland|Cukurova Univ. Tip. Fak. Balcali Hastanesi, Adana, Turkey|Hacettepe Universitesi Tip Fakultesi, Ankara, Turkey|Istanbul Universitesi Istanbul Tip Fakultesi, Istanbul, Turkey|Dokuz Eylul Universitesi Tip Fakultesi, Izmir, Turkey|Hope Hospital, Salford, Manchester, United Kingdom|Freeman Hospital, Newcastle Upon Tyne, Tyne And Wear, United Kingdom|Ninewells Hospital, Dundee, United Kingdom|Aintree University Hospital, Liverpool, United Kingdom|Royal Free Hospital, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT02283762/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT02283762/SAP_002.pdf","https://ClinicalTrials.gov/show/NCT02283762"
488,"NCT02279537","Real Life of Aflibercept In FraNce: oBservatiOnnal Study in Wet AMD","RAINBOW","Completed","No Results Available","Wet Macular Degeneration","Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)","Change in the measurement of best-corrected visual acuity (BCVA) from baseline to 12 months.|Change in Best Corrected Visual Acuity (BCVA) during the second year and until the fourth year of treatment versus the initial visit|Percentage of patients who experienced a gain in BCVA, from initial visit to each follow-up visit (letter score of ≥ 0 letters, ≥ 5 letters, ≥ 10 letters, ≥ 15 letters)|Percentage of patients losing fewer than 15 letters from the initial visit visual acuity at each follow-up visit","Bayer|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)",,"593","Industry","Observational","Observational Model: Cohort|Time Perspective: Other","17374|EY1411FR","January 2, 2014","April 17, 2019","April 17, 2019","October 31, 2014",,"July 5, 2019","Multiple Locations, France",,"https://ClinicalTrials.gov/show/NCT02279537"
489,"NCT02263066","Retrospective Study in Chinese Pediatric Hemophilia A Patients With rFⅧ Contained Regular Prophylaxis","ReCARE","Completed","No Results Available","Hemophilia A","Biological: BAY14-2222_Kogenate-FS FVIII","Duration of regular prophylaxis|Prophylaxis infusion dose|Percentage of rFVIII usage in prophylaxis|Bleeding frequency|Joint radiographic score|Joint physical examination score|Quality of life by questionnaire","Bayer","Male","2 Years to 18 Years   (Child, Adult)",,"181","Industry","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","17653","October 2014","July 2015","July 2015","October 13, 2014",,"July 17, 2015","Many Locations, China",,"https://ClinicalTrials.gov/show/NCT02263066"
490,"NCT02262676","Observational Study to Assess Sociodemographic and Clinical Features of Patients Treated With Rivaroxaban in Routine Clinical Practice of Hematologists, Cardiologists and Internists of Spain","HEROIC","Completed","No Results Available","Atrial Fibrillation","Drug: Rivaroxaban (Xarelto, BAY59-7939)","Demographic Data|Medical History|Assess regional differences among the different Spanish autonomous communities on the management of patients with rivaroxaban treatment during the routine clinical practice|Adherence to rivaroxaban treatment|Assess the satisfaction of rivaroxaban treatment|Assess the quality of life in patients","Bayer|Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)",,"2251","Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","17671","October 2014","February 2015","May 2015","October 13, 2014",,"January 23, 2017","Many Locations, Spain",,"https://ClinicalTrials.gov/show/NCT02262676"
491,"NCT02262663","Study in Healthy Young Women to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of Vilaprisan",,"Completed","No Results Available","Clinical Trial, Phase I","Drug: Vilaprisan (BAY1002670)","Hoogland score during treatment, day 9 to day 28|Hoogland score during treatment, day 63 to day 84|Hoogland score during follow up cycle 1|Hoogland score during follow up cycle 2|Number of subjects without bleeding/spotting|Exposure-response analysis of vilaprisan by population pharmacokinetic/pharmacodynamic modeling|Number of subjects with TEAEs (treatment-emergent adverse events)|Number of subjects with PAEC (progesterone-receptor-modulator associated endometrial changes)","Bayer","Female","18 Years to 40 Years   (Adult)","Phase 1","70","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","15818|2014-000329-19","October 2014","September 2015","December 2015","October 13, 2014",,"March 16, 2016","Berlin, Germany|Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT02262663"
492,"NCT02260687","Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization",,"Completed","No Results Available","Choroidal Neovascularization","Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)","Number of episodes of Adverse drug reaction (ADR's)|Number of episodes of Infections|Number of episodes of Serious Adverse Events(SAE's)|Number of episodes of Ocular Adverse events|Mean changes in visual acuity|Mean changes in retina thickness","Bayer|Regeneron Pharmaceuticals","All","Child, Adult, Older Adult",,"353","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","17416|EY1414JP","December 5, 2014","April 2, 2018","August 22, 2018","October 9, 2014",,"September 19, 2019","Multiple Locations, Japan",,"https://ClinicalTrials.gov/show/NCT02260687"
493,"NCT02258464","Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer",,"Completed","No Results Available","Breast Neoplasms","Drug: Radium-223 dichloride (Xofigo, BAY88-8223)|Drug: Placebo (saline)|Other: Background hormonal therapy","Symptomatic skeletal event free survival (SSE-FS).|Overall survival|Time to opiate use for cancer pain|Time to pain progression (only in subjects with baseline worst pain score ≤8)|Time to cytotoxic chemotherapy|Radiological progression-free survival (rPFS)|Frequency of abnormalities in laboratory examinations.|Pain Improvement Rate|To measure new primary malignancies and hematopoietic reserve for tolerability of subsequent chemotherapy","Bayer","Female","18 Years and older   (Adult, Older Adult)","Phase 2","99","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","16298|2014-002113-39","March 2, 2015","August 13, 2019","August 13, 2019","October 7, 2014",,"September 6, 2019","Bakersfield, California, United States|La Jolla, California, United States|Aurora, Colorado, United States|New Haven, Connecticut, United States|Cedar Rapids, Iowa, United States|Annapolis, Maryland, United States|Ann Arbor, Michigan, United States|Pontiac, Michigan, United States|Saint Louis, Missouri, United States|Pittsburgh, Pennsylvania, United States|Houston, Texas, United States|Linz, Oberösterreich, Austria|Innsbruck, Austria|Winnipeg, Manitoba, Canada|London, Ontario, Canada|Newmarket, Ontario, Canada|Toronto, Ontario, Canada|Ostrava, Czechia|Praha 2, Czechia|Copenhagen, Denmark|Herlev, Denmark|Helsinki, Finland|Tampere, Finland|Angers Cedex, France|Saint Cloud, France|Tübingen, Baden-Württemberg, Germany|Bonn, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Kowloon, Hong Kong|Cork, Ireland|Dublin, Ireland|Afula, Israel|Haifa, Israel|Jerusalem, Israel|Jerusalem, Israel|Kfar Saba, Israel|Ramat Gan, Israel|Tel Aviv, Israel|Zerifin, Israel|Busan, Korea, Republic of|Daegu, Korea, Republic of|Incheon, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Nieuwegein, Netherlands|Zwolle, Netherlands|Oslo, Norway|Bialystok, Poland|Gdynia, Poland|Warszawa, Poland|Singapore, Singapore|L'Hospitalet de Llobregat, Barcelona, Spain|A Coruña, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Málaga, Spain|Sevilla, Spain|Zaragoza, Spain|Aarau, Aargau, Switzerland|Taipei, Taiwan|Plymouth, Devon, United Kingdom|Northwood, Middlesex, United Kingdom|Nottingham, Nottinghamshire, United Kingdom|Taunton, Somerset, United Kingdom|Cottingham, United Kingdom|Merseyside, United Kingdom|Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02258464"
494,"NCT02258451","Study of Radium-223 Dichloride Versus Placebo and Treatment With Exemestane / Everolimus in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer",,"Active, not recruiting","No Results Available","Breast Neoplasms","Drug: Radium-223 dichloride (Xofigo, BAY88-8223)|Drug: Placebo (saline)|Drug: Exemestane|Drug: Everolimus","Symptomatic skeletal event free survival (SSE-FS).|Overall survival|Time to opiate use for cancer pain|Time to pain progression (only in subjects with baseline worst pain score (WPS) ≤8)|Time to cytotoxic chemotherapy|Radiological progression-free survival (rPFS)|Frequency of abnormalities in laboratory examinations|Pain improvement rate|To measure new primary malignancies and hematopoietic reserve for tolerability of subsequent chemotherapy","Bayer","Female","18 Years and older   (Adult, Older Adult)","Phase 2","283","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","17096|2014-002114-23","June 4, 2015","June 30, 2020","June 30, 2020","October 7, 2014",,"January 3, 2020","Yuma, Arizona, United States|La Jolla, California, United States|Long Beach, California, United States|Los Angeles, California, United States|San Francisco, California, United States|New Haven, Connecticut, United States|Hollywood, Florida, United States|Ashland, Kentucky, United States|Rockville, Maryland, United States|Ann Arbor, Michigan, United States|Detroit, Michigan, United States|Pontiac, Michigan, United States|Rochester, Minnesota, United States|Saint Louis, Missouri, United States|Newark, New Jersey, United States|Jamaica, New York, United States|Lake Success, New York, United States|Watertown, South Dakota, United States|Spokane, Washington, United States|Innsbruck, Austria|Bruxelles - Brussel, Belgium|Edegem, Belgium|Kortrijk, Belgium|Leuven, Belgium|Angers Cedex, France|Nantes, France|Nimes, France|Saint Cloud, France|Tours, France|Tübingen, Baden-Württemberg, Germany|Bonn, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Herne, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Chai wan, Hong Kong|Kowloon, Hong Kong|New Territories, Hong Kong|Afula, Israel|Beer Sheva, Israel|Haifa, Israel|Holon, Israel|Jerusalem, Israel|Jerusalem, Israel|Ramat Gan, Israel|Tel Aviv, Israel|Zrifin, Israel|Bologna, Emilia-Romagna, Italy|Forlì-Cesena, Emilia-Romagna, Italy|Modena, Emilia-Romagna, Italy|Reggio Emilia, Emilia-Romagna, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Genova, Liguria, Italy|Cremona, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Bari, Puglia, Italy|Palermo, Sicilia, Italy|Pisa, Toscana, Italy|Padova, Veneto, Italy|Verona, Veneto, Italy|Nagoya, Aichi, Japan|Sapporo, Hokkaido, Japan|Osakasayama, Osaka, Japan|Hidaka, Saitama, Japan|Kita-Adachigun, Saitama, Japan|Koto-ku, Tokyo, Japan|Kagoshima, Japan|Kagoshima, Japan|Osaka, Japan|Suwon-si, Gyeonggido, Korea, Republic of|Busan, Korea, Republic of|Daegu, Korea, Republic of|Incheon, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Oslo, Norway|Bialystok, Poland|Gdansk, Poland|Gdynia, Poland|Poznan, Poland|Warszawa, Poland|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|Palma de Mallorca, Illes Baleares, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Pamplona, Spain|Sevilla, Spain|Sevilla, Spain|Aarau, Aargau, Switzerland|Viganello, Ticino, Switzerland|Kaoshiung, Taiwan|Taichung, Taiwan|Taipei, Taiwan|Truro, Cornwall, United Kingdom|Plymouth, Devon, United Kingdom|Nottingham, Nottinghamshire, United Kingdom|Taunton, Somerset, United Kingdom|Guildford, Surrey, United Kingdom|Coventry, West Midlands, United Kingdom|Belfast, United Kingdom|Bristol, United Kingdom|Cottingham, United Kingdom|Merseyside, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02258451"
495,"NCT02253420","COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients",,"Completed","No Results Available","Medical Oncology","Drug: Copanlisib (BAY80-6946)|Drug: Itraconazole|Drug: Rifampin","AUC (0-168)|AUC|Cmax|QTcF|AUC(0-tlast)|tmax|tlast|t1/2|Urine [AE,ur(0-24)]|Number of participants with adverse events as a measure of safety and tolerability|PR intervals|QRS intervals|ECG waveform morphology|Left ventricular ejection fraction (LVEF)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","51","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","16270","October 8, 2014","March 12, 2018","August 13, 2019","October 1, 2014",,"September 3, 2019","Dallas, Texas, United States|Edmonton, Alberta, Canada|Vancouver, British Columbia, Canada|Hamilton, Ontario, Canada|Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02253420"
496,"NCT02247310","BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon",,"Completed","No Results Available","Multiple Sclerosis, Relapsing Remitting","Drug: Interferon beta-1b (Betaferon®, BAY 86-5046)|Device: BETACONNECT","Adherence to therapy at the final visit.|Satisfaction with and evaluation of the BETACONNECT auto-injector|Injection site pain and prophylactic analgesic use|Health related quality of life|Anxiety|Depression|Fatigue|Cognition|Local skin reactions|Injection-related specifics","Bayer","All","Child, Adult, Older Adult",,"498","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","17591|BF1401","October 20, 2014","July 19, 2016","November 8, 2016","September 25, 2014",,"November 7, 2017","Many locations, Austria|Many locations, Belgium|Many Locations, Bosnia and Herzegovina|Many locations, Croatia|Many Locations, Czechia|Many locations, France|Many locations, Greece|Many locations, Hungary|Many locations, Italy|Many locations, Spain|Many locations, Switzerland",,"https://ClinicalTrials.gov/show/NCT02247310"
497,"NCT02246686","Efficacy/Safety Pilot Study to Investigate Iberogast N's Efficacy in Mild to Moderate Colitis Ulcerosa Patients",,"Terminated","No Results Available","Colitis, Ulcerative","Drug: STW5-II (Iberogast N, BAY98-7410)|Drug: Placebo","Proportion of patients being in remission at final visit|Change of endoscopic index (EI)|Change of histological index (HI) based on Riley|Proportion of patients reaching a clinical CAI ≤ 2 points|Time to remission, defined as days from Day 0 until first remission is reached|Time to sustained remission (CAI ≤ 2 points) defined as days from Day 0 until first sustained remission is reached|Number of patients who reached a remission at least once during the course of the study|Number of patients who reached a sustained remission at least once during the course of the study|Change from baseline of absolute CAI values to final visit|Change from baseline in Inflammatory Bowel Disease Questionnaire (IBDQ-D) (German version) at final visit|Change from baseline in Irritable Bowel Severity Score (IBSS) at final visit|Change from baseline in EuroQol 5 dimensions questionnaire (EQ-5D) at final visit|Mayo Score throughout the study|Change of of oral mesalazine dose throughout the study period|Change in ulcerative colitis (UC) markers","Bayer","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","3","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","17155|2013-000891-13","November 2014","February 2015","April 2016","September 23, 2014",,"October 18, 2016","Dachau, Bayern, Germany|Lüneburg, Niedersachsen, Germany|Köln, Nordrhein-Westfalen, Germany|Ludwigshafen, Rheinland-Pfalz, Germany|Lübeck, Schleswig-Holstein, Germany|Berlin, Germany|Essen, Germany|Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT02246686"
498,"NCT02234843","EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis","EINSTEIN Jr","Completed","No Results Available","Venous Thromboembolism","Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Standard of Care","Composite number of all symptomatic recurrent venous thromboembolism.|Composite number of overt major and clinically relevant non-major bleeding.|Composite number of all symptomatic recurrent venous thromboembolism and asymptomatic deterioration on repeat imaging.","Bayer|Janssen Research & Development, LLC","All","up to 17 Years   (Child)","Phase 3","499","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14372|2014-000565-47","November 13, 2014","January 30, 2019","January 30, 2019","September 9, 2014",,"February 25, 2019","Phoenix, Arizona, United States|Little Rock, Arkansas, United States|Los Angeles, California, United States|Los Angeles, California, United States|San Diego, California, United States|Gainesville, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Pensacola, Florida, United States|Saint Petersburg, Florida, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Indianapolis, Indiana, United States|Lansing, Michigan, United States|Kansas City, Missouri, United States|Durham, North Carolina, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Philadelphia, Pennsylvania, United States|Dallas, Texas, United States|Fort Worth, Texas, United States|Houston, Texas, United States|San Miguel de Tucumán, Tucuman, Argentina|Parkville, Victoria, Australia|South Brisbane, Australia|Linz, Oberösterreich, Austria|Graz, Steiermark, Austria|Innsbruck, Tirol, Austria|Wien, Austria|Bruxelles - Brussel, Belgium|Edegem, Belgium|Leuven, Belgium|Campinas, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Sofia, Bulgaria|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Hamilton, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Hangzhou, Zhejiang, China|Beijing, China|Beijing, China|Shanghai, China|Turku, Finland|Montpellier, France|Paris, France|TOULOUSE Cedex 9, France|Erlangen, Bayern, Germany|Halle, Sachsen-Anhalt, Germany|Dresden, Sachsen, Germany|Berlin, Germany|Hong Kong, Hong Kong|Budapest, Hungary|Crumlin, Dublin, Ireland|Afula, Israel|Jerusalem, Israel|Petach Tikva, Israel|Ramat Gan, Israel|Milano, Lombardia, Italy|Torino, Piemonte, Italy|Padova, Veneto, Italy|Obu, Aichi, Japan|Azumino, Nagano, Japan|Bunkyo-ku, Tokyo, Japan|Ciudad de México, Distrito Federal, Mexico|Guadalajara, Jalisco, Mexico|Amsterdam, Netherlands|Groningen, Netherlands|Nijmegen, Netherlands|Rotterdam, Netherlands|Utrecht, Netherlands|Carnaxide, Lisboa, Portugal|Kazan, Russian Federation|Kemerovo, Russian Federation|Krasnodar, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Nizhny Novgorod, Russian Federation|Sankt-Peterburg, Russian Federation|St. Petersburg, Russian Federation|Volgograd, Russian Federation|Yekaterinburg, Russian Federation|Singapore, Singapore|Singapore, Singapore|Bratislava, Slovakia|Esplugues de LLobregat, Barcelona, Spain|A Coruña, Spain|Barcelona, Spain|Solna, Sweden|Bern, Switzerland|Luzern, Switzerland|Zürich, Switzerland|Adana, Turkey|Istanbul, Turkey|Konya, Turkey|Newcastle Upon Tyne, Tyne And Wear, United Kingdom|Birmingham, West Midlands, United Kingdom|Leeds, West Yorkshire, United Kingdom|Cardiff, United Kingdom|Edinburgh, United Kingdom|Glasgow, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Oxford, United Kingdom|Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02234843"
499,"NCT02229461","Naproxen Sodium/ASA Platelet Study","Kontakt","Completed","Has Results","Hematology","Drug: Naproxen Sodium (Aleve, BAY117031)|Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)","Inhibition of Serum Thromboxane B2 (TXB2) on Day 16 at 24 Hour Post IR ASA 81 mg Administration|Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration|Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration|Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","117","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15525","February 2015","May 2015","May 2015","September 1, 2014","June 10, 2016","July 15, 2016","Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02229461"
500,"NCT02222207","Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration","DREAM","Terminated","Has Results","Macular Degeneration","Drug: Regorafenib, ophthalmic oily suspension (BAY73-4506)|Procedure: Sham IVT|Drug: Ranibizumab|Drug: Placebo","Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Study Week 4 for Study Part A|Change From Baseline in BCVA as Measured by ETDRS Letter Score at Study Week 12 for Study Part A|Percentage of Participants With Individual Changes in BCVA of Greater Than Equal to (>=) 0 Letters of Vision From Study Week 4 to Week 12 for Study Part A|Percentage of Participants With a Loss in BCVA of >= 10 Letters From Baseline to Study Week 12 for Study Part A","Bayer","All","50 Years and older   (Adult, Older Adult)","Phase 2","52","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15984|2012-003763-22","October 2014","May 2015","June 2015","August 21, 2014","September 8, 2016","September 8, 2016","Tucson, Arizona, United States|Arcadia, California, United States|Beverly Hills, California, United States|Campbell, California, United States|Costa Mesa, California, United States|Laguna Hills, California, United States|Mountain View, California, United States|Santa Ana, California, United States|Golden, Colorado, United States|Boynton Beach, Florida, United States|Fort Myers, Florida, United States|Miami, Florida, United States|Plantation, Florida, United States|Sarasota, Florida, United States|Stuart, Florida, United States|Winter Haven, Florida, United States|Decatur, Georgia, United States|New Albany, Indiana, United States|Leawood, Kansas, United States|Wichita, Kansas, United States|Louisville, Kentucky, United States|Eunice, Louisiana, United States|Boston, Massachusetts, United States|Grand Rapids, Michigan, United States|Florissant, Missouri, United States|Teaneck, New Jersey, United States|Asheville, North Carolina, United States|West Mifflin, Pennsylvania, United States|Greenville, South Carolina, United States|Rapid City, South Dakota, United States|Austin, Texas, United States|Houston, Texas, United States|McAllen, Texas, United States|San Antonio, Texas, United States|Temple, Texas, United States|The Woodlands, Texas, United States|Charlottesville, Virginia, United States|Strathfield, New South Wales, Australia|Sydney, New South Wales, Australia|Westmead, New South Wales, Australia|Nedlands, Western Australia, Australia|Parramatta, Australia|Wien, Austria|Wien, Austria|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Vancouver, British Columbia, Canada|Halifax, Nova Scotia, Canada|London, Ontario, Canada|Mississauga, Ontario, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Sherbrooke, Quebec, Canada|Osorno, Los Lagos, Chile|Metropolitana, Santiago, Chile|Vitacura, Santiago, Chile|Santiago, Chile|Bogota, Distrito Capital de Bogotá, Colombia|Hradec Kralove, Czech Republic|Praha 2, Czech Republic|Praha 4, Czech Republic|Praha 7, Czech Republic|Paris, Cedex 12, France|Boredaux, France|Lyon, France|Tübingen, Baden-Württemberg, Germany|München, Bayern, Germany|München, Bayern, Germany|Bonn, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Dresden, Sachsen, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Berlin, Germany|Hamburg, Germany|Hong Kong, Hong Kong|Kowloon, Hong Kong|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Pecs, Hungary|Afula, Israel|Beer Sheva, Israel|Haifa, Israel|Haifa, Israel|Jerusalem, Israel|Kfar Saba, Israel|Petah Tikva, Israel|Ramat Gan, Israel|Rehovot, Israel|Tel Aviv, Israel|Zerifin, Israel|Udine, Friuli-Venezia Giulia, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Firenze, Toscana, Italy|Padova, Veneto, Italy|Ancona, Italy|Bologna, Italy|Milano, Italy|Sassari, Italy|Inba-gun, Chiba, Japan|Miyako-gun, Fukuoka, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Himeji, Hyogo, Japan|Yamato, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Iga, Mie, Japan|Chofu, Tokyo, Japan|Itabashi-ku, Tokyo, Japan|Ota-ku, Tokyo, Japan|Taito-ku, Tokyo, Japan|Fukuoka, Japan|Kumamoto, Japan|Nagasaki, Japan|Nara, Japan|Osaka, Japan|Osaka, Japan|Seongnam-si, Gyeonggido, Korea, Republic of|Busan, Korea, Republic of|Incheon, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Bratislava, Slovakia|Ruzomberok, Slovakia|Trencin, Slovakia|Zilina, Slovakia|Zilina, Slovakia|L'Hospitalet de Llobregat, Barcelona, Spain|San Cugat del Vallès, Barcelona, Spain|Barakaldo, Vizcaya, Spain|Albacete, Spain|Barcelona, Spain|Sevilla, Spain|Sevilla, Spain|Valencia, Spain|Valencia, Spain|Valladolid, Spain|Bern, Switzerland|Lausanne, Switzerland|Zürich, Switzerland",,"https://ClinicalTrials.gov/show/NCT02222207"
501,"NCT02212080","First in Human Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of BAY1214784",,"Completed","No Results Available","Clinical Trials, Phase I as Topic","Drug: BAY1214784|Drug: Placebo","Number of adverse events|Severity of adverse events (mild, moderate, severe)","Bayer","Female","45 Years to 65 Years   (Adult, Older Adult)","Phase 1","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","16924|2014-000412-34","September 2014","March 2015","March 2015","August 8, 2014",,"March 11, 2015","Mönchengladbach, Nordrhein-Westfalen, Germany|Erfurt, Thüringen, Germany",,"https://ClinicalTrials.gov/show/NCT02212080"
502,"NCT02210819","Treatment of Venous Thromboembolism (VTE) With Either Rivaroxaban or Current Standard of Care Therapy","XALIA LEA","Completed","No Results Available","Deep Vein Thrombosis (DVT)|Pulmonary Embolism (PE)","Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Recommended VTE pharmacological treatments according to international guidelines","Number of major bleedings defined as overt bleeding|Number of patients with symptomatic recurrent venous thromboembolic events|All cause mortality|Number of adverse cardiovascular events|Number of patients with other symptomatic thromboembolic events|Treatment satisfaction (patient reported outcomes)","Bayer|Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)",,"1987","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","17237|XA1402","June 27, 2014","November 3, 2016","January 20, 2017","August 7, 2014",,"August 29, 2019","Multiple Locations, Algeria|Multiple Locations, Egypt|Multiple Locations, Indonesia|Multiple Locations, Jordan|Multiple Locations, Kazakhstan|Multiple Locations, Kenya|Multiple Locations, Korea, Republic of|Multiple Locations, Kuwait|Multiple Locations, Lebanon|Multiple Locations, Malaysia|Multiple Locations, Mexico|Multiple Locations, Morocco|Multiple Locations, Philippines|Multiple Locations, Qatar|Multiple Locations, Russian Federation|Multiple Locations, Saudi Arabia|Multiple Locations, Singapore|Multiple Locations, Taiwan|Multiple Locations, Turkey|Multiple Locations, Ukraine|Multiple Locations, United Arab Emirates",,"https://ClinicalTrials.gov/show/NCT02210819"
503,"NCT02203331","Bay98-7196, Dose Finding / POC Study",,"Completed","Has Results","Endometriosis","Drug: Placebo|Drug: Levonorgestrel|Drug: Anastrozole|Drug: Lupron / Leuprolide acetate","Absolute Change in Mean Pain of the 7 Days With Worst EAPP From Baseline (Last 28 Days Before Randomization) to End of Treatment (Last 28 Days of Treatment Period, Days 57-84) as Measured on NRS by Question 1 of ESD|Absolute Change in Mean Pain of the 7 Days With Worst EAPP From Baseline (Last 28 Days Before Randomization) to First Cycle Under Study Treatment (Day 1-28) and to Second Cycle Under Study Treatment (Day 29-56) as Measured on NRS by Question 1 of ESD|Absolute Change in Mean Pain From Baseline (Last 28 Days Before Randomization) to First Cycle Under Study Treatment(Day1-28), Second Cycle Under Study Treatment(Day29-56),Third Cycle Under Study Treatment (Day57-84) as Measured on NRS by Question1 of ESD|Percentage of Days During Baseline (Last 28 Days Before Randomization) and Cycles 1, 2, and 3 With Pain Greater Than or Equal to (>=) 7 as Measured on NRS by Question 1 of ESD as Measured on NRS by Question 1 of ESD|Change From Baseline (Last 28 Days Before Randomization) to Cycle 1, 2, and 3 in Percentage of Days With Pain >=7 as Measured on NRS by Question 1 of ESD|Percentage of Days During Baseline (Last 28 Days Before Randomization) and Cycles 1, 2, and 3 With Pain >=4 as Measured on NRS by Question 1 of ESD|Change From Baseline (Last 28 Days Before Randomization) to Cycle 1, 2, and 3 in Percentage of Days With Pain >=4 as Measured on NRS by Question 1 of ESD","Bayer","Female","Child, Adult, Older Adult","Phase 2","319","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","15832|2013-005090-53","October 16, 2014","October 24, 2016","October 24, 2016","July 29, 2014","January 4, 2018","January 4, 2018","San Diego, California, United States|San Francisco, California, United States|Torrance, California, United States|New Haven, Connecticut, United States|Clearwater, Florida, United States|Fort Myers, Florida, United States|Gainesville, Florida, United States|Miami, Florida, United States|New Port Richey, Florida, United States|Atlanta, Georgia, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Sandy Springs, Georgia, United States|Chicago, Illinois, United States|Palos Heights, Illinois, United States|Wichita, Kansas, United States|Marrero, Louisiana, United States|Canton, Michigan, United States|Detroit, Michigan, United States|Saginaw, Michigan, United States|Lincoln, Nebraska, United States|Neptune, New Jersey, United States|Plainsboro, New Jersey, United States|New York, New York, United States|Durham, North Carolina, United States|Greensboro, North Carolina, United States|Winston-Salem, North Carolina, United States|Columbus, Ohio, United States|Dayton, Ohio, United States|Philadelphia, Pennsylvania, United States|Chattanooga, Tennessee, United States|Seattle, Washington, United States|Madison, Wisconsin, United States|Villach, Kärnten, Austria|Linz, Oberösterreich, Austria|Innsbruck, Tirol, Austria|Feldkirch, Vorarlberg, Austria|Salzburg, Austria|Wien, Austria|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Edegem, Belgium|Gent, Belgium|Liege, Belgium|Hamilton, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Quebec, Canada|Brno, Czechia|Brno, Czechia|Ceske Budejovice, Czechia|Hradec Kralove, Czechia|Olomouc, Czechia|Ostrava, Czechia|Pisek, Czechia|Plzen, Czechia|Praha 2, Czechia|Praha 7, Czechia|Tabor, Czechia|Aarhus N, Denmark|Copenhagen, Denmark|Odense C, Denmark|Espoo, Finland|Helsinki, Finland|Hyvinkää, Finland|Jyväskylä, Finland|Kuopio, Finland|Oulu, Finland|Turku, Finland|Turku, Finland|Esslingen, Baden-Württemberg, Germany|Heidelberg, Baden-Württemberg, Germany|Karlsruhe, Baden-Württemberg, Germany|Mannheim, Baden-Württemberg, Germany|Erlangen, Bayern, Germany|München, Bayern, Germany|Hannover, Niedersachsen, Germany|Aachen, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Bernburg, Sachsen-Anhalt, Germany|Blankenburg, Sachsen-Anhalt, Germany|Dippoldiswalde, Sachsen, Germany|Dresden, Sachsen, Germany|Jena, Thüringen, Germany|Berlin, Germany|Berlin, Germany|Hamburg, Germany|Hamburg, Germany|Genova, Liguria, Italy|Brescia, Lombardia, Italy|Pavia, Lombardia, Italy|Siena, Toscana, Italy|Kitakyushu, Fukuoka, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Akashi, Hyogo, Japan|Kawanishi, Hyogo, Japan|Omitama, Ibaraki, Japan|Kanazawa, Ishikawa, Japan|Kawasaki, Kanagawa, Japan|Kurashiki, Okayama, Japan|Osakasayama, Osaka, Japan|Hamamatsu, Shizuoka, Japan|Bunkyo-ku, Tokyo, Japan|Minatoku, Tokyo, Japan|Shinagawa-ku, Tokyo, Japan|Kumamoto, Japan|Nagano, Japan|Osaka, Japan|Almere, Netherlands|Groningen, Netherlands|Nieuwegein, Netherlands|Zwolle, Netherlands|Asker, Norway|Stokmarknes, Norway|Tromsø, Norway|Trondheim, Norway|Tønsberg, Norway|Bialystok, Poland|Katowice, Poland|Krakow, Poland|Leczna, Poland|Lodz, Poland|Lublin, Poland|Szczecin, Poland|Aravaca, Madrid, Spain|Collado Villalba, Madrid, Spain|Pozuelo de Alarcón, Madrid, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Sevilla, Spain|Valencia, Spain|Valencia, Spain|Vitoria, Álava, Spain|Lugano, Ticino, Switzerland|Lausanne, Vaud, Switzerland|Bern, Switzerland|Frauenklinik, Switzerland|Luzern, Switzerland|Zürich, Switzerland",,"https://ClinicalTrials.gov/show/NCT02203331"
504,"NCT02200614","Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Nonmetastatic Castration-resistant Prostate Cancer","ARAMIS","Active, not recruiting","Has Results","Prostate Cancer Non-Metastatic|Castration-Resistant","Drug: Darolutamide (BAY1841788)|Drug: Placebo","Metastasis-Free Survival|Overall Survival|Time to Pain Progression|Time to Initiation of First Cytotoxic Chemotherapy for Prostate Cancer|Time to First Symptomatic Skeletal Event (SSE)","Bayer|Orion Corporation, Orion Pharma","Male","18 Years and older   (Adult, Older Adult)","Phase 3","1509","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","17712|2013-003820-36","September 12, 2014","September 3, 2018","December 31, 2020","July 25, 2014","October 29, 2019","January 10, 2020","Homewood, Alabama, United States|Anchorage, Alaska, United States|Tucson, Arizona, United States|Fountain Valley, California, United States|La Jolla, California, United States|Laguna Hills, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|San Diego, California, United States|Whittier, California, United States|Denver, Colorado, United States|Denver, Colorado, United States|Parker, Colorado, United States|Boca Raton, Florida, United States|Orlando, Florida, United States|Port Saint Lucie, Florida, United States|Coeur d'Alene, Idaho, United States|Chicago, Illinois, United States|Evanston, Illinois, United States|Springfield, Illinois, United States|Greenwood, Indiana, United States|Indianapolis, Indiana, United States|Jeffersonville, Indiana, United States|West Des Moines, Iowa, United States|Wichita, Kansas, United States|New Orleans, Louisiana, United States|Annapolis, Maryland, United States|Baltimore, Maryland, United States|Salisbury, Maryland, United States|Boston, Massachusetts, United States|Grand Rapids, Michigan, United States|Royal Oak, Michigan, United States|Omaha, Nebraska, United States|Omaha, Nebraska, United States|Lebanon, New Hampshire, United States|Voorhees, New Jersey, United States|Bronx, New York, United States|Bronx, New York, United States|Syracuse, New York, United States|Asheboro, North Carolina, United States|Charlotte, North Carolina, United States|Canton, Ohio, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Gahanna, Ohio, United States|Middleburg Heights, Ohio, United States|Oklahoma City, Oklahoma, United States|Bala-Cynwyd, Pennsylvania, United States|Bryn Mawr, Pennsylvania, United States|Myrtle Beach, South Carolina, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Fairfax, Virginia, United States|Richmond, Virginia, United States|Virginia Beach, Virginia, United States|Wheeling, West Virginia, United States|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Santa Fé, Santa Fe, Argentina|San Miguel de Tucumán, Tucuman, Argentina|Córdoba, Argentina|Córdoba, Argentina|Córdoba, Argentina|La Rioja, Argentina|Randwick, New South Wales, Australia|St Leonards, New South Wales, Australia|Douglas, Queensland, Australia|South Brisbane, Queensland, Australia|Fitzroy, Victoria, Australia|Kurralta Park, Australia|Wien, Austria|Wien, Austria|Lesnoy, Belarus|Minsk, Belarus|Bonheiden, Belgium|Kortrijk, Belgium|Libramont, Belgium|Liege, Belgium|Sint-truiden, Belgium|Salvador-Bahia, Bahia, Brazil|Fortaleza, Ceará, Brazil|Goiânia, Goiás, Brazil|Belo Horizonte, Minas Gerais, Brazil|Juiz de Fora, Minas Gerais, Brazil|Uberlandia, Minas Gerais, Brazil|Curitiba, Parana, Brazil|Recife, Pernambuco, Brazil|Passo Fundo, Rio Grande Do Sul, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|Itajaí, Santa Catarina, Brazil|Barretos, Sao Paulo, Brazil|Jau, Sao Paulo, Brazil|Ribeirao Preto - SP, Sao Paulo, Brazil|Sorocaba, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|Sofia, Bulgaria|Varna, Bulgaria|Calgary, Alberta, Canada|Halifax, Nova Scotia, Canada|Burlington, Ontario, Canada|Hamilton, Ontario, Canada|Kingston, Ontario, Canada|London, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Granby, Quebec, Canada|Pointe-Claire, Quebec, Canada|Medellín, Antioquia, Colombia|Montería, Córdoba, Colombia|Floridablanca, Santander, Colombia|Jablonec nad Nisou, Czechia|Kolin, Czechia|Olomouc, Czechia|Opava, Czechia|Praha 2, Czechia|Praha 2, Czechia|Praha 6, Czechia|Praha 8, Czechia|Tallinn, Estonia|Helsinki, Finland|Kuopio, Finland|Seinäjoki, Finland|Tampere, Finland|Turku, Finland|Angers, France|Bayonne, France|Besancon, France|Bordeaux Cedex, France|CAEN cedex 05, France|Cergy Pontoise, France|Clermont Ferrand Cedex 1, France|Creteil, France|Dijon, France|LA ROCHE SUR YON cedex, France|Limoges Cedex, France|Montpellier Cedex, France|Montpellier Cedex, France|Nancy, France|Nantes Cedex, France|Paris, France|Paris, France|Pierre Benite, France|POITIERS cedex, France|REIMS cedex, France|Rennes Cedex, France|Rouen Cedex, France|Saint Mande, France|Strasbourg, France|Suresnes, France|Tours, France|Villejuif Cedex, France|Emmendingen, Baden-Württemberg, Germany|Kirchheim unter Teck, Baden-Württemberg, Germany|Mühlacker, Baden-Württemberg, Germany|Nürtingen, Baden-Württemberg, Germany|Reutlingen, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|Zirndorf, Bayern, Germany|Frankfurt, Hessen, Germany|Marburg, Hessen, Germany|Hagenow, Mecklenburg-Vorpommern, Germany|Herzberg Am Harz, Niedersachsen, Germany|Holzminden, Niedersachsen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Mülheim, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Wuppertal, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Magdeburg, Sachsen-Anhalt, Germany|Dresden, Sachsen, Germany|Berlin, Germany|Hamburg, Germany|Hamburg, Germany|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Gyor, Hungary|Nyiregyhaza, Hungary|Szeged, Hungary|Szekszard, Hungary|Szolnok, Hungary|Zalaegerszeg, Hungary|Haifa, Israel|Chieti, Abruzzo, Italy|Catanzaro, Calabria, Italy|Napoli, Campania, Italy|Forlì-Cesena, Emilia-Romagna, Italy|Modena, Emilia-Romagna, Italy|Parma, Emilia-Romagna, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Torino, Piemonte, Italy|Torino, Piemonte, Italy|Lecce, Puglia, Italy|Messina, Sicilia, Italy|Palermo, Sicilia, Italy|Arezzo, Toscana, Italy|Nagoya, Aichi, Japan|Kashiwa, Chiba, Japan|Kurume, Fukuoka, Japan|Koriyama, Fukushima, Japan|Maebashi, Gunma, Japan|Otake, Hiroshima, Japan|Sapporo, Hokkaido, Japan|Kobe, Hyogo, Japan|Higashiibaraki, Ibaraki, Japan|Kanazawa, Ishikawa, Japan|Sagamihara, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Yokosuka, Kanagawa, Japan|Sendai, Miyagi, Japan|Ueda, Nagano, Japan|Kashihara, Nara, Japan|Yufu, Oita, Japan|Osakasayama, Osaka, Japan|Wako, Saitama, Japan|Hamamatsu, Shizuoka, Japan|Utsunomiya, Tochigi, Japan|Bunkyo-ku, Tokyo, Japan|Bunkyo-ku, Tokyo, Japan|Itabashi-ku, Tokyo, Japan|Minato-ku, Tokyo, Japan|Mitaka, Tokyo, Japan|Nakano-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Sumida-ku, Tokyo, Japan|Ube, Yamaguchi, Japan|Chiba, Japan|Fukui, Japan|Hiroshima, Japan|Kyoto, Japan|Nagasaki, Japan|Nagasaki, Japan|Okayama, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Toyama, Japan|Donggu,, Gwangju Gwang''yeogsi, Korea, Republic of|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Chungchungbuk-do, Korea, Republic of|Daegu, Korea, Republic of|Daegu, Korea, Republic of|Incheon, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Daugavpils, Latvia|Jelgava, Latvia|Leipaja, Latvia|Riga, Latvia|Riga, Latvia|Riga, Latvia|Kaunas, Lithuania|Kaunas, Lithuania|Klaipeda, Lithuania|Vilnius, Lithuania|Vilnius, Lithuania|La Victoria, Arequipa, Peru|Lima, Peru|Lima, Peru|San Isidro, Peru|Elblag, Poland|Gdansk, Poland|Lodz, Poland|Lublin, Poland|Otwock, Poland|Rzeszow, Poland|Siedlce, Poland|Warszawa, Poland|Warszawa, Poland|Warszawa, Poland|Wroclaw, Poland|Guimaraes, Braga, Portugal|Almada, Lisboa, Portugal|Matosinhos, Porto, Portugal|Braga, Portugal|Lisboa, Portugal|Lisboa, Portugal|Lisboa, Portugal|Lisboa, Portugal|Porto, Portugal|Porto, Portugal|Bucuresti, Romania|Bucuresti, Romania|Bucuresti, Romania|Bucuresti, Romania|Cluj-Napoca, Romania|Craiova, Romania|Craiova, Romania|Oradea, Romania|Ploiesti, Romania|Targu-Mures, Romania|Chelyabinsk, Russian Federation|Ivanovo, Russian Federation|Kazan, Russian Federation|Krasnoyarsk, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Nizhny Novgorod, Russian Federation|Novosibirsk, Russian Federation|Obninsk, Russian Federation|Omsk, Russian Federation|Orenburg, Russian Federation|Pyatigorsk, Russian Federation|Rostov-on-Don, Russian Federation|Saratov, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|Tyumen, Russian Federation|Ufa, Russian Federation|Vladimir, Russian Federation|Belgrade, Serbia|Belgrade, Serbia|Nis, Serbia|Bratislava, Slovakia|Bratislava, Slovakia|Martin, Slovakia|Trencin, Slovakia|George, Eastern Cape, South Africa|Port Elizabeth, Eastern Cape, South Africa|Pretoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Paarl, Western Cape, South Africa|Rondebosch, Western Cape, South Africa|Cape Town, South Africa|Cape Town, South Africa|Elche, Alicante, Spain|Cádiz, Andalucía, Spain|L'Hospitalet de Llobregat, Barcelona, Spain|Sabadell, Barcelona, Spain|Terrassa, Barcelona, Spain|Jerez de la Frontera, Cádiz, Spain|Manacor, Illes Baleares, Spain|Palma de Mallorca, Illes Baleares, Spain|Alcorcón, Madrid, Spain|Barcelona, Spain|Barcelona, Spain|Bilbao, Spain|Córdoba, Spain|Granada, Spain|Lugo, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Málaga, Spain|Salamanca, Spain|Sevilla, Spain|Sevilla, Spain|Valencia, Spain|Valencia, Spain|Valencia, Spain|Göteborg, Sweden|Stockholm, Sweden|Uppsala, Sweden|Örebro, Sweden|Kaohsiung City ,, Taiwan|Kaoshiung, Taiwan|Taichung, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Ankara, Turkey|Istanbul, Turkey|Izmir, Turkey|Izmir, Turkey|Manisa, Turkey|Sivas, Turkey|Chernivtsi, Ukraine|Dnipro, Ukraine|Kharkiv, Ukraine|Kryvyi Rih, Ukraine|Kyiv, Ukraine|Kyiv, Ukraine|Uzhgorod, Ukraine|Zaporozhye, Ukraine|Reading, Berkshire, United Kingdom|Llanelli, Carmarthenshire, United Kingdom|Romford, Essex, United Kingdom|Stevenage, Hertfordshire, United Kingdom|Dartford, Kent, United Kingdom|Maidstone, Kent, United Kingdom|Preston, Lancashire, United Kingdom|Bebington, Merseyside, United Kingdom|Scunthorpe, North East Lincolnshire, United Kingdom|Bath, Somerset, United Kingdom|Stoke-on-Trent, Staffordshire, United Kingdom|Dudley, West Midlands, United Kingdom|Huddersfield, West Yorkshire, United Kingdom|Wakefield, West Yorkshire, United Kingdom|Cardiff, United Kingdom|Glasgow, United Kingdom|London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT02200614/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT02200614/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02200614"
505,"NCT02191137","Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)",,"Completed","Has Results","Hypertension, Pulmonary","Drug: Riociguat (Adempas, BAY63-2521)","Change From Baseline to Week 24 in the Living With Pulmonary Hypertension (LPH) Questionnaire Total Score|Change From Baseline to Weeks 4 and 16 in the LPH Total Score|Change From Week 16 to Week 24 in the LPH Total Score (Completers Analysis Set Only)|Change From Baseline to Weeks 4, 16, and 24 in the LPH Physical Dimension Score|Change From Week 16 to Week 24 in the LPH Physical Dimension Score (Completers Analysis Set Only)|Change From Baseline to Weeks 4, 16, and 24 in the LPH Emotional Dimension Score|Change From Week 16 to Week 24 in the LPH Emotional Dimension Score (Completers Analysis Set Only)|Percentage of Patients With a Minimal Clinically Significant Important Difference (MCID) From Baseline in LPH Total Score at Weeks 4, 16, and 24|Percentage of Patients With an MCID From Baseline in LPH Physical Dimension Score at Weeks 4, 16, and 24|Percentage of Patients With an MCID From Baseline in LPH Emotional Dimension Score at Weeks 4, 16, and 24|Percentage of Patients With an MCID From Week 16 in LPH Total Score at Week 24 (Completers Analysis Set Only)|Percentage of Patients With an MCID From Week 16 in Physical Dimension Score at Week 24 (Completers Analysis Set Only)|Percentage of Patients With an MCID From Week 16 in Emotional Dimension Score at Week 24 (Completers Analysis Set Only)|Change From Baseline to Weeks 4, 16, and 24 in the WLQ Time Management, Physical Demands, Mental-Interpersonal Demands and Output Demands Scores|Change From Baseline to Weeks 4, 16, and 24 in the WLQ Percentage of Productivity Loss|Change From Week 16 to Week 24 in the WLQ Time Management, Physical Demands, Mental-Interpersonal Demands, and Output Demands Scores (Completers Analysis Set Only)|Change From Week 16 to Week 24 in the WLQ Percentage of Productivity Loss (Completers Analysis Set Only)|Change From Baseline to Weeks 4, 16, and 24 in the Short Form-12 Health Survey (SF-12) Physical Component Summary (PCS) Score and Mental Component Summary (MCS) Score|Change From Week 16 to Week 24 in the SF-12 PCS Score and MCS Score (Completers Analysis Set Only)|Change From Baseline to Weeks 4, 16, and 24 in the WHO Functional Class|Change From Week 16 to Week 24 in the WHO Functional Class (Completers Analysis Set Only)|Change From Baseline to Weeks 16 and 24 in the Modified Borg Dyspnea Scale|Change From Week 16 to Week 24 in the Modified Borg Dyspnea Scale (Completers Analysis Set Only)|Change From Baseline to Weeks 16 and 24 in the 6MWD|Change From Week 16 to Week 24 in the 6MWD (Completers Analysis Set Only)","Bayer","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","75","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17407","September 23, 2014","July 16, 2016","July 16, 2016","July 16, 2014","October 13, 2017","October 13, 2017","Tucson, Arizona, United States|La Jolla, California, United States|Moreno Valley, California, United States|Pomona, California, United States|Sacramento, California, United States|San Juan Capistrano, California, United States|Santa Barbara, California, United States|Aurora, Colorado, United States|Hartford, Connecticut, United States|Celebration, Florida, United States|Jacksonville, Florida, United States|Miami Beach, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Weston, Florida, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Austell, Georgia, United States|Marietta, Georgia, United States|Chicago, Illinois, United States|Fort Wayne, Indiana, United States|Indianapolis, Indiana, United States|Iowa City, Iowa, United States|Louisville, Kentucky, United States|New Orleans, Louisiana, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|North Dartmouth, Massachusetts, United States|Detroit, Michigan, United States|Troy, Michigan, United States|Pascagoula, Mississippi, United States|Lincoln, Nebraska, United States|Omaha, Nebraska, United States|Newark, New Jersey, United States|Albuquerque, New Mexico, United States|Albany, New York, United States|Brooklyn, New York, United States|Liverpool, New York, United States|Mineola, New York, United States|New Hyde Park, New York, United States|Stony Brook, New York, United States|Syracuse, New York, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Toledo, Ohio, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Providence, Rhode Island, United States|Sioux Falls, South Dakota, United States|El Paso, Texas, United States|Houston, Texas, United States|Temple, Texas, United States|Milwaukee, Wisconsin, United States|Milwaukee, Wisconsin, United States|Guaynabo, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT02191137"
506,"NCT02185560","Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib","JPMS-DTC","Recruiting","No Results Available","Thyroid Carcinoma","Drug: Sorafenib (Nexavar, BAY43-9006)","Number of participants with Adverse drug reaction as a measure of safety and tolerability.|Number of participants with Serious adverse events as a measure of safety and tolerability.|Number of participants with Serious adverse drug reaction as a measure of safety and tolerability|2-year survival|Time of treatment failure (TTF)","Bayer","All","Child, Adult, Older Adult",,"443","Industry","Observational","Observational Model: Cohort|Time Perspective: Other","17391|NEXAVAR-TC-01","June 27, 2014","March 31, 2020","June 30, 2021","July 9, 2014",,"January 22, 2020","Multiple Locations, Japan",,"https://ClinicalTrials.gov/show/NCT02185560"
507,"NCT02170038","Clinical Study Investigating the Conversion of the Contraceptive Compound Norethisterone Within the Body Towards the Contraceptive Compound Ethinylestradiol",,"Completed","No Results Available","Pharmacokinetics","Drug: Microgynon|Drug: Noristerat(BAY86-6308)","Maximum observed drug concentration of ethinylestradiol at steady state after multiple administrations of Microgynon (Cmax)ss|Area under the concentration-time curve of ethinylestradiol at steady state after multiple administrations of Microgynon {AUC(0-24)}ss|Maximum observed drug concentration of ethinylestradiol after single administration of Noristerat (Cmax)|Area under the concentration-time curve of ethinylestradiol after single administration of Noristerat (AUC)|Maximum observed drug concentration of Norethisterone after single administration of Noristerat (Cmax)|Area under the concentration-time curve of Norethisterone after single administration of Noristerat (AUC)","Bayer","Female","18 Years to 45 Years   (Adult)","Phase 1","16","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","17004|2013-005280-89","June 2014","December 2014","March 2015","June 23, 2014",,"February 18, 2016","Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT02170038"
508,"NCT02170025","Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients",,"Terminated","Has Results","Cystic Fibrosis","Drug: Riociguat (Adempas, BAY63-2521)|Drug: Placebo","Change of Sweat Chloride Content From Baseline|Change of FEV1 From Baseline","Bayer|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 2","21","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","17020|2013-004595-35","September 30, 2014","January 17, 2017","September 22, 2017","June 23, 2014","March 29, 2018","September 13, 2018","Birmingham, Alabama, United States|Denver, Colorado, United States|Saint Louis, Missouri, United States|Bruxelles - Brussel, Belgium|Toronto, Ontario, Canada|Paris, France|Berlin, Germany|Rotterdam, Netherlands|Belfast, North Ireland, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02170025"
509,"NCT02168777","Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer",,"Terminated","Has Results","Neoplasms","Drug: Refametinib (BAY86-9766)|Drug: Regorafenib (Stivarga, BAY73-4506)","Maximum Drug Concentration in Plasma After Multiple Dose (Cmax,md) for Refametinib|Maximum Drug Concentration in Plasma After Multiple Dose (Cmax,md) for Refametinib Metabolite M-11|Area Under the Plasma Concentration-time Curve From 0 to 12 h After Multiple Dose (AUC(0-12)md) for Refametinib|Area Under the Plasma Concentration-time Curve From 0 to 12 h After Multiple Dose (AUC(0-12)md) for Refametinib Metabolite M-11|Maximum Drug Concentration in Plasma After Multiple Dose (Cmax,md) for Regorafenib|Maximum Drug Concentration in Plasma After Multiple Dose (Cmax,md) for Regorafenib Metabolite M-2|Maximum Drug Concentration in Plasma After Multiple Dose (Cmax,md) for Regorafenib Metabolite M-5|Area Under the Plasma Concentration-time Curve From 0 to 24 h After Multiple Dose (AUC(0-24)md) for Regorafenib|Area Under the Plasma Concentration-time Curve From 0 to 24 h After Multiple Dose (AUC(0-24)md) for Regorafenib Metabolite M-2|Area Under the Plasma Concentration-time Curve From 0 to 24 h After Multiple Dose (AUC(0-24)md) for Regorafenib Metabolite M-5|Tumor Response During Phase 2 as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1|Number of Participants With Dose Limiting Toxicities (DLTs)|Maximum Drug Concentration in Plasma After Single (First) Dose (Cmax) for Refametinib and Its Metabolite M-11|Time to Reach Maximum Drug Concentration in Plasma After Single (First) Dose (Tmax) for Refametinib and Its Metabolite M-11|Area Under the Plasma Concentration-time Curve From 0 to 8 h (AUC(0-8)) After Single (First) Dose for Refametinib and Its Metabolite M-11|Time to Reach Maximum Drug Concentration in Plasma After Multiple Dose (Tmax,md) for Refametinib and Its Metabolite M-11|Maximum Drug Concentration in Plasma After Single (First) Dose (Cmax) for Regorafenib and Its Metabolites M-2 and M-5|Time to Reach Maximum Drug Concentration in Plasma After Single (First) Dose (Tmax) for Regorafenib and Its Metabolites M-2 and M-5|Area Under the Plasma Concentration-time Curve From 0 to 24 h (AUC(0-24)) After Single (First) Dose for Regorafenib and Its Metabolites M-2 and M-5|Time to Reach Maximum Drug Concentration in Plasma After Multiple Dose (Tmax,md) for Regorafenib and Its Metabolites M-2 and M-5|Tumor Response During Phase 1b as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1|Overall Survival During Phase 2|Time to Progression During Phase 2|Progression-free Survival During Phase 2","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17064|2013-004861-15","June 23, 2014","October 23, 2015","April 5, 2016","June 20, 2014","January 26, 2018","January 26, 2018","New Haven, Connecticut, United States|Detroit, Michigan, United States|Saint Louis, Missouri, United States|Chapel Hill, North Carolina, United States|Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02168777"
510,"NCT02161419","RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer","CONCEPT-SCLC","Terminated","No Results Available","Small Cell Lung Carcinoma","Drug: Roniciclib (BAY1000394)|Drug: Placebo","Progression free survival (PFS)|Overall survival (OS)|Time to progression (TTP)|Overall response rate (ORR)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","142","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","14615|2013-004198-28","July 30, 2014","December 31, 2015","May 25, 2016","June 11, 2014",,"June 25, 2018","Boca Raton, Florida, United States|Port Saint Lucie, Florida, United States|Saint Louis, Missouri, United States|Hershey, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Charleston, South Carolina, United States|Nashville, Tennessee, United States|Bruxelles - Brussel, Belgium|Liege, Belgium|Brest, France|Lille Cedex, France|Marseille Cedex 20, France|Paris, France|Heidelberg, Baden-Württemberg, Germany|Oldenburg, Niedersachsen, Germany|Essen, Nordrhein-Westfalen, Germany|Grosshansdorf, Germany|Budapest, Hungary|Matrahaza, Hungary|Torokbalint, Hungary|Genova, Liguria, Italy|Monza-Brianza, Lombardia, Italy|Sondrio, Lombardia, Italy|Torino, Piemonte, Italy|Kurume, Fukuoka, Japan|Bunkyo, Tokyo, Japan|Seongnam-si, Gyeonggido, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Gdansk, Poland|Szczecin-Zdunowo, Poland|Warszawa, Poland",,"https://ClinicalTrials.gov/show/NCT02161419"
511,"NCT02159326","Microgynon Riociguat Drug Interaction Study in Healthy Postmenopausal Women",,"Completed","No Results Available","Drug Interactions","Drug: Microgynon|Drug: Riociguat (Adempas,BAY63-2521)","Area under the plasma concentration time curve (AUC) of Ethinylestradiol (EE)|Area under the plasma concentration time curve (AUC) of Levonorgestrel (LNG)|Maximal concentration (Cmax) of Ethinylestradiol (EE)|Maximal concentration (Cmax) of Levonorgestrel (LNG)|Number of participants with adverse events as a measure of safety and tolerability","Bayer","Female","52 Years to 65 Years   (Adult, Older Adult)","Phase 1","31","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","17309|2014-000829-20","June 2014","March 2015","July 2015","June 9, 2014",,"August 14, 2015","Mönchengladbach, Nordrhein-Westfalen, Germany",,"https://ClinicalTrials.gov/show/NCT02159326"
512,"NCT02159313","Relative Bioavailability Study",,"Completed","No Results Available","Healthy Volunteers","Drug: Riociguat(Adempas,BAY63-2521)","Pharmacokinetics of riociguat in plasma by Area under the plasma concentration time curve (AUC)|Pharmacokinetics of riociguat in plasma by maximal concentration (Cmax)|Number of participants with adverse events as a measure of safety and tolerability","Bayer","Male","18 Years to 45 Years   (Adult)","Phase 1","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","17306|2013-005166-18","June 2014","September 2014","January 2015","June 9, 2014",,"February 18, 2016","Mönchengladbach, Nordrhein-Westfalen, Germany",,"https://ClinicalTrials.gov/show/NCT02159313"
513,"NCT02159261","Assess Satisfaction of Patients and Physicians With Results of Yaz Plus Treatment for 13 Cycles",,"Completed","No Results Available","Contraception","Drug: BAY98-7071_EE20/DRSP/L-5-MTHF","Satisfaction measured with a Likert response scale (from 1 - poor to 5 - excellent)|Changes in EVAPIL scale for assessment of tolerability of oral contraceptives.|Number of participants with adverse events as a measure of safety and tolerability","Bayer","Female","18 Years and older   (Adult, Older Adult)",,"1500","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","17177|YZ1410RU","July 15, 2014","August 14, 2016","August 14, 2016","June 9, 2014",,"August 9, 2017","Many Locations, Russian Federation",,"https://ClinicalTrials.gov/show/NCT02159261"
514,"NCT02155582","Copanlisib Pharmacodynamic Study",,"Completed","No Results Available","Non Hodgkin Lymphoma","Drug: Copanlisib (BAY80-6946)","Maximum change from baseline in expression of pathway inhibition (pAKT) in surrogate tissue (platelet rich plasma) during copanlisib monotherapy|Maximum change from baseline in plasma glucose during 2 cycles of copanlisib monotherapy|AUC(0-168) of copanlisib after each copanlisib IV infusion during 2 cycles of copanlisib monotherapy|AEs as characterized by type, frequency, severity (as graded by CTCAE) and relationship to study drug|Maximum change from baseline in insulin during 2 cycles of copanlisib|Maximum change from baseline in C-peptide during 2 cycles of copanlisib|FDG PET early response (decreased SUVmax compared to baseline) after dosing with copanlisib for non-diabetic patients with detectable FDG tumor uptake at baseline|Change from baseline in expression and / or phosphorylation of PI3K pathway proteins in paired tumor biopsies","Bayer","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 1","63","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","16790|2013-004746-42","August 12, 2014","October 4, 2016","March 16, 2017","June 4, 2014",,"June 16, 2017","Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Gent, Belgium|Caen Cedex 5, France|Lille, France|Nice Cedex 2, France|Pierre Benite, France|Sutton, Surrey, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02155582"
515,"NCT02141438","Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer","REASSURE","Active, not recruiting","No Results Available","Metastatic Castration-resistant Prostate Cancer","Drug: Radium-223 dichloride (Xofigo, BAY88-8223)","Incidence of developing second primary malignancies|Incidence of treatment-emergent SAEs|Incidence of drug-related treatment-emergent adverse events|Incidence of drug-related SAEs|Bone marrow suppression|Overall survival|The worst pain score and pain interference score over time as determined by patient responses on the ""Brief pain inventory short form"" (BPI-SF) questionnaire|Incidence of bone fractures|The number of bone associated events","Bayer","Male","18 Years and older   (Adult, Older Adult)",,"1474","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16913","August 20, 2014","December 31, 2024","February 28, 2025","May 19, 2014",,"December 30, 2019","Homewood, Alabama, United States|Anchorage, Alaska, United States|Scottsdale, Arizona, United States|Daly City, California, United States|Long Beach, California, United States|Sacramento, California, United States|San Diego, California, United States|Colorado Springs, Colorado, United States|Boca Raton, Florida, United States|Fort Myers, Florida, United States|Jacksonville, Florida, United States|Lakewood Ranch, Florida, United States|Plantation, Florida, United States|Atlanta, Georgia, United States|Decatur, Georgia, United States|Honolulu, Hawaii, United States|Evanston, Illinois, United States|Maywood, Illinois, United States|Urbana, Illinois, United States|Warrenville, Illinois, United States|Wichita, Kansas, United States|Ashland, Kentucky, United States|New Orleans, Louisiana, United States|Baltimore, Maryland, United States|Rockville, Maryland, United States|Towson, Maryland, United States|Boston, Massachusetts, United States|Troy, Michigan, United States|Saint Louis, Missouri, United States|Billings, Montana, United States|Omaha, Nebraska, United States|Lebanon, New Hampshire, United States|Neptune, New Jersey, United States|Township, New Jersey, United States|Buffalo, New York, United States|East Setauket, New York, United States|Lake Success, New York, United States|Syracuse, New York, United States|Winston-Salem, North Carolina, United States|Middleburg Heights, Ohio, United States|Oklahoma City, Oklahoma, United States|Springfield, Oregon, United States|Abington, Pennsylvania, United States|Charleston, South Carolina, United States|Myrtle Beach, South Carolina, United States|Nashville, Tennessee, United States|Houston, Texas, United States|Lubbock, Texas, United States|San Antonio, Texas, United States|Temple, Texas, United States|Charlottesville, Virginia, United States|Virginia Beach, Virginia, United States|Seattle, Washington, United States|Multiple Locations, Argentina|Multiple Locations, Austria|Multiple Locations, Belgium|Multiple Locations, Canada|Multiple Locations, Colombia|Multiple Locations, Czechia|Multiple Locations, Denmark|Multiple Locations, France|Multiple Locations, Germany|Multiple Locations, Greece|Multiple Locations, Israel|Multiple Locations, Italy|Multiple Locations, Luxembourg|Multiple Locations, Mexico|Multiple Locations, Netherlands|Multiple Locations, Portugal|Multiple Locations, Spain|Multiple Locations, Sweden|Multiple Locations, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02141438"
516,"NCT02138825","Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)","RISE-IIP","Terminated","Has Results","Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary","Drug: Riociguat (Adempas, BAY63-2521)|Drug: Placebo","Mean Change in 6 Minute Walking Distance (6MWD) From Baseline to Week 26|Number of Participants With Clinical Worsening","Bayer","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","147","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","13605|2010-024332-42","June 4, 2014","May 5, 2016","September 14, 2016","May 15, 2014","June 5, 2017","December 4, 2017","University of California, Los Angeles, Los Angeles, California, United States|San Francisco, California, United States|Aurora, Colorado, United States|Miami, Florida, United States|Orlando, Florida, United States|Via Christi Clinic, Wichita, Kansas, United States|Louisville, Kentucky, United States|Columbia University Medical Center, New York, New York, United States|Durham, North Carolina, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Portland, Oregon, United States|Pittsburgh, Pennsylvania, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Falls Church, Virginia, United States|Mar del Plata, Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Godoy Cruz, Mendoza, Argentina|San Miguel de Tucumán, Tucuman, Argentina|Camperdown, New South Wales, Australia|Darlinghurst, New South Wales, Australia|Sydney, New South Wales, Australia|Chermside, Queensland, Australia|Adelaide, South Australia, Australia|Prahran, Victoria, Australia|Murdoch, Western Australia, Australia|Leuven, Belgium|Vancouver, British Columbia, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Quebec, Canada|Bogotá, Distrito Capital de Bogotá, Colombia|Floridablanca-Bucaramanga, Santander, Colombia|Cali, Valle del Cauca, Colombia|Bogotá, Colombia|Santafe de Bogotá, Colombia|Aarhus N, Denmark|Bron, France|Lille Cedex, France|Marseille, France|Paris Cedex 15, France|München, Bayern, Germany|München, Bayern, Germany|Würzburg, Bayern, Germany|Gießen, Hessen, Germany|Hannover, Niedersachsen, Germany|Essen, Nordrhein-Westfalen, Germany|Dresden, Sachsen, Germany|Grosshansdorf, Germany|Athens, Greece|Haidari, Greece|Ioannina, Greece|Thessaloniki, Greece|Haifa, Israel|Jerusalem, Israel|Petah Tikva, Israel|Ramat Gan, Israel|Forlì-Cesena, Emilia-Romagna, Italy|Roma, Lazio, Italy|Monza-Brianza, Lombardia, Italy|Palermo, Sicilia, Italy|Siena, Toscana, Italy|Seto, Aichi, Japan|Yokohama, Kanagawa, Japan|Sakai, Osaka, Japan|Shibuya-ku, Tokyo, Japan|Chiba, Japan|Auckland, New Zealand|Christchurch, New Zealand|Coimbra, Portugal|Porto, Portugal|Vila Nova de Gaia, Portugal|Moscow, Russian Federation|Moscow, Russian Federation|St. Petersburg, Russian Federation|Vladimir, Russian Federation|Riyadh, Saudi Arabia|Riyadh, Saudi Arabia|Riyadh, Saudi Arabia|Barcelona, Spain|Barcelona, Spain|Valencia, Spain|Bern, Switzerland|Genève, Switzerland|Zürich, Switzerland|Denizli, Turkey|Izmir, Turkey|Cambridge, Cambridgeshire, United Kingdom|Clydebank, West Dunbartonshire, United Kingdom|London, United Kingdom|Newcastle, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02138825"
517,"NCT02138812","Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel",,"Terminated","No Results Available","Medical Oncology","Drug: BAY1161909|Drug: Paclitaxel","Maximum tolerated dose (MTD)|Number of subjects with adverse events and serious adverse events as a measure of safety and tolerability.|Plasma concentration of Paclitaxel characterized by Cmax|Plasma concentration of BAY1161909 characterized by Cmax","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","69","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16804","May 9, 2014","April 28, 2017","October 2, 2017","May 15, 2014",,"October 12, 2018","Santa Monica, California, United States|New Haven, Connecticut, United States|Boston, Massachusetts, United States|Detroit, Michigan, United States|Nashville, Tennessee, United States|San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02138812"
518,"NCT02134197","Dose-escalation Study of Lupartumab Amadotin (BAY1129980)",,"Terminated","No Results Available","Neoplasms","Drug: Lupartumab Amadotin (BAY1129980)","Maximum tolerated dose (MTD)|Number of participants with adverse events as a measure of safety and tolerability|C4.4a expression levels in tumour tissue as measured by immunohistochemistry (IHC)|Tumor response evaluation following RECIST 1.1 criteria|Plasma concentration of BAY1129980 characterized by AUC (0-tlast)|Antidrug and antibody titer","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","69","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16044","May 22, 2014","August 30, 2018","August 30, 2018","May 9, 2014",,"December 11, 2019","La Jolla, California, United States|Stanford, California, United States|Aurora, Colorado, United States|Washington, District of Columbia, United States|Gainesville, Georgia, United States|Westwood, Kansas, United States|Hackensack, New Jersey, United States|Buffalo, New York, United States|New York, New York, United States|Durham, North Carolina, United States|Philadelphia, Pennsylvania, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Houston, Texas, United States|Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02134197"
519,"NCT02131662","Bay1002670, Fibroids, Safety and Efficacy EU,US,Can, Jap","ASTEROID 1","Completed","Has Results","Leiomyoma","Drug: BAY1002670|Drug: Placebo","Percentage of Subjects With Amenorrhea, Defined as no Scheduled or Unscheduled Bleeding/Spotting After the End of the Initial Bleeding Episode Until End of Treatment|Change in Volume of Menstrual Blood Loss Per 28 Days From Baseline During Treatment by Reference Period (Assessed by Alkaline Hematin Method)|Time to Onset of Controlled Bleeding|Change in Volume of Largest Fibroid Compared to Baseline Measured by MRI","Bayer","Female","18 Years to 50 Years   (Adult)","Phase 2","309","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15788|2013-003945-40","May 15, 2014","May 4, 2016","May 4, 2016","May 6, 2014","December 8, 2017","December 8, 2017","Mesa, Arizona, United States|Tucson, Arizona, United States|San Diego, California, United States|San Diego, California, United States|Denver, Colorado, United States|Southington, Connecticut, United States|Washington, District of Columbia, United States|Gainesville, Florida, United States|Jacksonville, Florida, United States|Plantation, Florida, United States|South Miami, Florida, United States|Sandy Springs, Georgia, United States|Naperville, Illinois, United States|Newburgh, Indiana, United States|Marrero, Louisiana, United States|Lincoln, Nebraska, United States|Moorestown, New Jersey, United States|Neptune City, New Jersey, United States|New Brunswick, New Jersey, United States|New York, New York, United States|Durham, North Carolina, United States|Raleigh, North Carolina, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Chattanooga, Tennessee, United States|Dallas, Texas, United States|Frisco, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Norfolk, Virginia, United States|Seattle, Washington, United States|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Charleroi, Belgium|Leuven, Belgium|Liege, Belgium|Pleven, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Stara Zagora, Bulgaria|Winnipeg, Manitoba, Canada|Hamilton, Ontario, Canada|Ottawa, Ontario, Canada|Pointe-Claire, Quebec, Canada|Quebec, Canada|Ceske Budejovice, Czechia|Hradec Kralove, Czechia|Olomouc, Czechia|Pisek, Czechia|Praha 2, Czechia|Praha, Czechia|Espoo, Finland|Helsinki, Finland|Joensuu, Finland|Kuopio, Finland|Oulu, Finland|Karlsruhe, Baden-Württemberg, Germany|Erlangen, Bayern, Germany|Geseke, Nordrhein-Westfalen, Germany|Bernburg, Sachsen-Anhalt, Germany|Blankenburg, Sachsen-Anhalt, Germany|Dresden, Sachsen, Germany|Lübeck, Schleswig-Holstein, Germany|Berlin, Germany|Ilsede, Germany|Debrecen, Hungary|Debrecen, Hungary|Kecskemet, Hungary|Szeged, Hungary|Szentes, Hungary|Matsudo, Chiba, Japan|Iizuka, Fukuoka, Japan|Koriyama, Fukushima, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Kanazawa, Ishikawa, Japan|Omura, Nagasaki, Japan|Numazu, Shizuoka, Japan|Kita, Tokyo, Japan|Nakano-ku, Tokyo, Japan|Tacchikawa, Tokyo, Japan|Kumamoto, Japan|Nagano, Japan|Nesttun, Norway|Oslo, Norway|Sellebakk, Norway|Trondheim, Norway|Trondheim, Norway|Aravaca, Madrid, Spain|Barcelona, Spain|Barcelona, Spain|Sevilla, Spain|Sevilla, Spain|Valencia, Spain|Göteborg, Sweden|Stockholm, Sweden|Uppsala, Sweden|Örebro, Sweden|Bern, Switzerland",,"https://ClinicalTrials.gov/show/NCT02131662"
520,"NCT02122913","A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer",,"Active, not recruiting","No Results Available","Solid Tumors Harboring NTRK Fusion","Drug: Larotrectinib (Vitrakvi, BAY2757556)","Number of participants with adverse events|Severity of adverse events|Maximum tolerated dose (MTD)|Recommended dose for dose expansion|Maximum concentration of larotrectinib in plasma (Cmax)|Time to maximum concentration of larotrectinib in plasma (Tmax)|Half-life of larotrectinib in plasma (t1/2)|Area under the concentration versus time curve of larotrectinib in plasma (AUC)|Overall Response Rate (ORR)|Duration of Response (DOR)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","75","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20288|LOXO-TRK-14001","May 4, 2014","February 1, 2017","March 30, 2021","April 25, 2014",,"January 10, 2020","University of Colorado, Aurora, Colorado, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02122913"
521,"NCT02121444","BAY86-5046 (Betaseron), Non Interventional Studies","BETAEVAL","Completed","No Results Available","Multiple Sclerosis","Drug: Interferon beta-1b (Betaferon, BAY 86-5046)|Device: BETACONNECT auto-injector.","Adherence measure to Betaferon therapy based on the real BETACONNECT injections|Satisfaction with and evaluation of the BETACONNECT auto-injector recorded by patient questionnaire|Evaluation of health related quality of life,measured with the self-administered Functional Assessment of Multiple Sclerosis (FAMS) questionnaire|Evaluation of Anxiety measured with the self-administered Hospital Anxiety and Depression Scale (HADS)|Evaluation of Depression measured with the self-administered Center for Epidemiologic Studies Depression Scale (CES-D)|Evaluation of Fatigue measured with the self-administered Fatigue Scale for Motor and Cognitive functions (FSMC)|Evaluation of Cognition will be measured by the HCP with the Symbol Digit Modalities Test (SDMT)|Local skin reactions recorded by Health Care Provider (HCP) evaluation|Evaluation of injection-related specifics such as injection date, time, and speed will be recorded by the BETACONNECT device|Number of Treatment-emergent Adverse Events (TEAE)","Bayer","All","18 Years and older   (Adult, Older Adult)",,"151","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","17101|BF1414DE","June 23, 2014","March 9, 2016","June 1, 2016","April 23, 2014",,"October 18, 2017","Many Locations, Germany",,"https://ClinicalTrials.gov/show/NCT02121444"
522,"NCT02120950","Aflibercept in Polypoidal Choroidal Vasculopathy","PLANET","Completed","Has Results","Neovascular Macular Degeneration","Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Other: Visudyne","Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment of Diabetic Retinopathy Study (ETDRS) Letter Scores From Baseline to Week 52 - Last Observation Carried Forward (LOCF)|Percentage of Subjects Who Avoided at Least 15 Letters Loss in ETDRS at Week 52","Bayer|Regeneron Pharmaceuticals","All","50 Years and older   (Adult, Older Adult)","Phase 4","333","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","16995|2013-004464-54","May 29, 2014","August 12, 2016","July 7, 2017","April 23, 2014","January 15, 2019","January 15, 2019","Liverpool, New South Wales, Australia|Strathfield, New South Wales, Australia|Westmead, New South Wales, Australia|East Melbourne, Victoria, Australia|Parramatta, Australia|München, Germany|Hong Kong, Hong Kong|Kowloon, Hong Kong|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Nagoya, Aichi, Japan|Urayasu, Chiba, Japan|Ogaki, Gifu, Japan|Maebashi, Gunma, Japan|Asahikawa, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Amagasaki, Hyogo, Japan|Kobe, Hyogo, Japan|Kita, Kagawa, Japan|Tsu, Mie, Japan|Kashihara, Nara, Japan|Hirakata, Osaka, Japan|Suita, Osaka, Japan|Otsu, Shiga, Japan|Hamamatsu, Shizuoka, Japan|Shimotsuke, Tochigi, Japan|Bunkyo-ku, Tokyo, Japan|Chiyoda-ku, Tokyo, Japan|Meguro-ku, Tokyo, Japan|Mitaka, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Akita, Japan|Aomori, Japan|Chiba, Japan|Fukuoka, Japan|Fukuoka, Japan|Fukushima, Japan|Kumamoto, Japan|Kyoto, Japan|Kyoto, Japan|Nagasaki, Japan|Okayama, Japan|Osaka, Japan|Tokushima, Japan|Wakayama, Japan|Seongnam-si, Gyeonggido, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Singapore, Singapore|Singapore, Singapore|Changhua City, Changhua, Taiwan|Kaohsiung, Taiwan|Taipei City, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT02120950"
523,"NCT02119221","Copanlisib Mass Balance Study",,"Completed","No Results Available","Healthy Volunteers","Drug: Copanlisib (BAY80-6946)","Pharmacokinetics of copanlisib in plasma by maximum concentration (Cmax)|Pharmacokinetics of copanlisib in plasma by area under the measured matrix concentration versus time curve from the first time point (t=0) extrapolated to infinity (AUC)|Pharmacokinetics of copanlisib in plasma by area under the measured matrix concentration versus time curve to the last data point above the lower limit of quantitation (AUC(0-tlast))|Pharmacokinetics of total radioactivity in plasma by Cmax|Pharmacokinetics of total radioactivity in plasma by AUC|Pharmacokinetics of total radioactivity in plasma by AUC(0-tlast)|Pharmacokinetics of total radioactivity in whole blood by Cmax|Pharmacokinetics of total radioactivity in whole blood by AUC|Pharmacokinetics of total radioactivity in whole blood by AUC(0-tlast)|Radioactivity excreted in urine as a percentage of the dose (AE,ur)|Radioactivity excreted in feces as a percentage of the dose (AE,fec)|Metabolite profile in plasma|Metabolite profile in urine|Metabolite profile in feces|Number of participants with adverse events as a measure of safety and tolerability","Bayer","Male","45 Years to 65 Years   (Adult, Older Adult)","Phase 1","6","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","16353|2013-002544-90","February 2014","April 2014","October 2014","April 21, 2014",,"October 28, 2014","Zuidlaren, Netherlands",,"https://ClinicalTrials.gov/show/NCT02119221"
524,"NCT02117791","Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Riociguat for Chronic Thromboembolic Pulmonary Hypertension (CTEPH )","JPMS-CTEPH","Active, not recruiting","No Results Available","Hypertension, Pulmonary","Drug: Riociguat (ADEMPAS, BAY63-2521)","Number of participants with treatment emergent adverse events and adverse drug reactions|Change from baseline in 6MWD (6-Minute Walking Distance) after 4 and 12 months|Change from baseline in Pulmonary Vascular Resistance (PVR) after 4 and 12 months|Change from baseline in TRPG (Tricuspid Regurgitation Pressure Gradient) after 4 and 12 months|Change from baseline in BNP/NT-pro BNP after 4 and 12 months|Change from baseline in WHO (World Health Organization) functional class after 4 and 12 months|Time to Clinical Worsening","Bayer","All","Child, Adult, Older Adult",,"1298","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16843|ADEMPAS-CTEPH","July 16, 2014","September 30, 2022","January 16, 2024","April 21, 2014",,"January 2, 2020","Multiple Locations, Japan",,"https://ClinicalTrials.gov/show/NCT02117791"
525,"NCT02114658","Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients",,"Completed","No Results Available","Thyroid Carcinoma","Drug: Sorafenib (Nexavar,BAY43-9006)","Number of subjects with adverse events and serious adverse events as a measure of safety and tolerability|Change in red blood cell count|Change in white blood cell count|Change in alanine aminotransaminase level (ALT)|Change in aspartate aminotransferase level (AST)|Change in blood pressure|Best overall response based on RECIST 1.1 criteria|Plasma concentration of sorafenib|Progression-free survival (PFS)|Overall survival (OS)|Response rate (RR)|Disease control rate (DCR)|Maximum reduction from baseline in the target lesion size|Maximum percentage change of calcitonin and Carcinoembryonic antigen (CEA) values from baseline","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","18","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17073","April 15, 2014","February 23, 2015","August 2, 2016","April 15, 2014",,"August 3, 2017","Kobe, Hyogo, Japan|Matsumoto, Nagano, Japan|Bunkyo-ku, Tokyo, Japan|Koto-ku, Tokyo, Japan|Osaka, Japan",,"https://ClinicalTrials.gov/show/NCT02114658"
526,"NCT02106858","Stivarga Regulatory Post-Marketing Surveillance Study in Korea","StivargaPMS","Completed","No Results Available","Colorectal Neoplasms","Drug: Regorafenib (Stivarga,BAY73-4506)","Percentage of patients with serious adverse events|Percentage of patients with adverse drug reactions (ADRs)|Overall response|Progression free survival (PFS)|Overall survival (OS)","Bayer","All","Child, Adult, Older Adult",,"316","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16778|SV1314KR","June 25, 2014","May 7, 2019","May 7, 2019","April 8, 2014",,"June 13, 2019","Multiple Locations, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02106858"
527,"NCT02106845","Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors.",,"Completed","No Results Available","Neoplasms","Drug: Digoxin|Drug: Rosuvastatin|Drug: Regorafenib (Stivarga, BAY73-4506)","Area under the plasma concentration-time curve from time zero to 24 hours (AUC(0-24)) for Digoxin|Maximum drug concentration (Cmax) in plasma for Digoxin|Area under the plasma concentration-time curve from time zero to 24 hours (AUC(0-24)) for rosuvastatin|Maximum drug concentration (Cmax) in plasma for rosuvastatin|Tumor Response following RECIST criteria|Number of participants with adverse events as a measure of safety and tolerability|Number of participants with drug related adverse events as a measure of safety and tolerability","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","42","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16674|2013-003613-18","April 22, 2014","April 27, 2015","June 12, 2018","April 8, 2014",,"June 7, 2019","Freiburg, Baden-Württemberg, Germany|Frankfurt, Hessen, Germany|Herne, Nordrhein-Westfalen, Germany|Budapest, Hungary|Budapest, Hungary",,"https://ClinicalTrials.gov/show/NCT02106845"
528,"NCT02106832","Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)","RESPIRE 2","Completed","Has Results","Bronchiectasis","Drug: Ciprofloxacin (BAYQ3939) dry powder for inhalation|Drug: Placebo","Time to First Exacerbation Event Within 48 Weeks - Cipro 28 vs. Pooled Placebo|Time to First Exacerbation Event Within 48 Weeks - Cipro 14 vs. Pooled Placebo|Number of Participants With Exacerbation Events With Worsening of at Least Three Signs/Symptoms Over 48 Weeks|Number of Participants With Exacerbation Events With Worsening of at Least One Sign/Symptom Over 48 Weeks|Percentage of Participants With Pathogen Eradication at End of Treatment (Week 44/46)|Mean Change From Baseline in Patient Reported Outcome Saint George's Respiratory Questionnaire (SGRQ) Symptoms Component Score at End of Treatment (Week 44/46)|Percentage of Participants With Occurrence of New Pathogens Present at End of Treatment (Week 44/46)|Mean Change From Baseline in Patient Reported Outcome Quality of Life Questionnaire for Bronchiectasis (QoL-B) Respiratory Symptoms Domain Score at End of Treatment (Week 44/46)|Mean Change From Baseline in Forced Expiratory Volume in One Second (FEV1) at End of Treatment (Week 44/46)","Bayer|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","521","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15626|2013-004659-19","April 30, 2014","September 13, 2016","October 19, 2016","April 8, 2014","September 1, 2017","October 2, 2017","Peoria, Arizona, United States|Fountain Valley, California, United States|La Jolla, California, United States|Long Beach, California, United States|Newport Beach, California, United States|San Diego, California, United States|Kissimmee, Florida, United States|Miami, Florida, United States|Sarasota, Florida, United States|Tampa, Florida, United States|Decatur, Georgia, United States|Skokie, Illinois, United States|Olathe, Kansas, United States|Rochester, Minnesota, United States|Brooklyn, New York, United States|Mineola, New York, United States|Asheville, North Carolina, United States|Portland, Oregon, United States|Doylestown, Pennsylvania, United States|Greenville, South Carolina, United States|Edinburg, Texas, United States|Tyler, Texas, United States|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Capital Federal, Ciudad Auton. de Buenos Aires, Argentina|Godoy Cruz, Mendoza, Argentina|Córdoba, Argentina|Vicente López, Argentina|Kogarah, New South Wales, Australia|New Lambton Heights, New South Wales, Australia|Adelaide, South Australia, Australia|Adelaide, South Australia, Australia|Parkville, Victoria, Australia|Murdoch, Western Australia, Australia|Perth, Western Australia, Australia|Graz, Austria|Salzburg, Austria|Belo Horizonte, Minas Gerais, Brazil|Recife, Pernambuco, Brazil|Porto Alegre, Rio Grande do Sul, Brazil|Porto Alegre, Rio Grande do Sul, Brazil|São Paulo, Sao Paulo, Brazil|Porto Alegre, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Gabrovo, Bulgaria|Kozloduy, Bulgaria|Lovech, Bulgaria|Razgrad, Bulgaria|Ruse, Bulgaria|Sevlievo, Bulgaria|Sliven, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Stara Zagora, Bulgaria|Fuzhou, Fujian, China|Guangzhou, Guangdong, China|Hohehot, Inner Mongolia, China|Suzhou, Jiangsu, China|Wuxi, Jiangsu, China|Nanchang, Jiangxi, China|Shenyang, Liaoning, China|Yinchuan, Ningxia, China|Chengdu, Sichuan, China|Beijing, China|Beijing, China|Chongqing, China|Shanghai, China|Shanghai, China|Shanghai, China|Brno, Czechia|Prague 4, Czechia|Praha 2, Czechia|Praha 8, Czechia|Treuenbrietzen, Brandenburg, Germany|Frankfurt, Hessen, Germany|Neu-Isenburg, Hessen, Germany|Hannover, Niedersachsen, Germany|Hannover, Niedersachsen, Germany|Gelsenkirchen, Nordrhein-Westfalen, Germany|Leipzig, Sachsen, Germany|Bad Berka, Thüringen, Germany|Jena, Thüringen, Germany|Berlin, Germany|Berlin, Germany|Hamburg, Germany|Hong Kong, Hong Kong|Kowloon, Hong Kong|New Territories, Hong Kong|Shatin, Hong Kong|Daejeon, Daejeon Gwang''yeogsi, Korea, Republic of|Bucheon, Gyeonggido, Korea, Republic of|Incheon Gwangyeogsi,, Incheon Gwang''yeogsi, Korea, Republic of|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Daegu, Korea, Republic of|Incheon, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Daugavpils, Latvia|Daugavpils, Latvia|Jurmala, Latvia|Kraslava, Latvia|Riga, Latvia|Riga, Latvia|Riga, Latvia|Riga, Latvia|Talsi, Latvia|Klaipeda, Lithuania|Vilnius, Lithuania|Alkmaar, Netherlands|Assen, Netherlands|Groningen, Netherlands|Helmond, Netherlands|Maastricht, Netherlands|Sittard-Geleen, Netherlands|Veldhoven, Netherlands|City of San Fernando, Philippines|Manila, Philippines|Manila, Philippines|Quezon City, Philippines|Quezon City, Philippines|Bielsko-Biala, Poland|Czestochowa, Poland|Gorzow Wielkopolski, Poland|Grudziadz, Poland|Katowice, Poland|Kielce, Poland|Kielce, Poland|Kielce, Poland|Krakow, Poland|Ksawerow, Poland|Mrozy, Poland|Ostrowiec Swietokrzyski, Poland|Rzeszow, Poland|Warszawa, Poland|Vila Nova de Gaia, Porto, Portugal|Angra do Heroísmo, Região Autónoma dos Açores, Portugal|Faro, Portugal|Lisboa, Portugal|Lisboa, Portugal|Bragadiru, Romania|Brasov, Romania|Bucharest, Romania|Bucharest, Romania|Bucharest, Romania|Bucharest, Romania|Codlea, Romania|Constanta, Romania|Iasi, Romania|Ploiesti, Romania|Timisoara, Romania|Arkhangelsk, Russian Federation|Chelyabinsk, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Nizhny Novgorod, Russian Federation|Novosibirsk, Russian Federation|Novosibirsk, Russian Federation|Novosibirsk, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|Tomsk, Russian Federation|Ufa, Russian Federation|Voronezh, Russian Federation|Yaroslavl, Russian Federation|Belgrade, Serbia|Belgrade, Serbia|Cacak, Serbia|Knez Selo, Serbia|Kragujevac, Serbia|Sombor, Serbia|Sremska Kamenica, Serbia|Valjevo, Serbia|Bratislava, Slovakia|Presov, Slovakia|Johannesburg, Gauteng, South Africa|Amanzimtoti, Kwazulu-Natal, South Africa|Cape Town, Western Cape, South Africa|Cape Town, Western Cape, South Africa|Chiayi, Taiwan|Kaohsiung, Taiwan|New Taipei City,, Taiwan|Taichung, Taiwan|Taipei, Taiwan|Bangkok, Thailand|Bangkok, Thailand|Chiangmai, Thailand|Khon Kaen, Thailand|NakhonRatchasima, Thailand|Phitsanulok, Thailand|Udonthani, Thailand|Ankara, Turkey|Ankara, Turkey|Balcali, Turkey|Izmir, Turkey|Kampus, Turkey|Konya, Turkey|Maltepe, Turkey|Mersin, Turkey|Pendik, Turkey|Samsun, Turkey|Sehitkamil, Turkey",,"https://ClinicalTrials.gov/show/NCT02106832"
529,"NCT02092818","EXPERT, EXPosurE Registry RiociguaT in Patients With Pulmonary Hypertension","EXPERT","Completed","No Results Available","Hypertension, Pulmonary","Drug: Riociguat (Adempas, BAY63-2521)","Number of adverse events|Number of serious adverse events|All-cause mortality|Number of adverse event (AE) in the different pulmonary hypertension(PH) indications (pulmonary arterial hypertension (PAH) chronic thromboembolic pulmonary hypertension(CTEPH)|Number of serious adverse event (SAE) in different PH indications (PAH and CTEPH)|Incidence of AE of special interest overall|Incidence of AE of special interest in different PH indications (PAH, CTEPH)|6 minute walking distance|Functional class of pulmonary hypertension according to NYHA/ WHO|Borg Dyspnoea Index|EQ5D visual analogue scale (VAS) score|Number of patients with hemodynamic measurements|Concentration of biomarkers for heart insufficiency (Brain Natriuretic Peptide (BNP) and N-Terminal pro BNP (NTpro BNP))|Number of hospitalization|Number of outpatient visits|Number of days in home care|Number of days in rehabilitation|Number of days in nursery home|Drug treatment for PH","Bayer","All","Child, Adult, Older Adult",,"1316","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16657|AD1301","May 31, 2014","March 31, 2018","June 29, 2018","March 20, 2014",,"June 19, 2019","Multiple Locations, Argentina|Multiple Locations, Australia|Multiple Locations, Austria|Multiple Locations, Belgium|Multiple Locations, Canada|Multiple Locations, Colombia|Multiple Locations, Czechia|Multiple Locations, Denmark|Multiple Locations, Estonia|Multiple Locations, Finland|Multiple Locations, France|Multiple Locations, Germany|Multiple Locations, Greece|Multiple Locations, Ireland|Multiple Locations, Italy|Multiple Locations, Luxembourg|Multiple Locations, Netherlands|Multiple Locations, Norway|Multiple Locations, Portugal|Multiple Locations, Russian Federation|Multiple Locations, Saudi Arabia|Multiple Locations, Slovakia|Multiple Locations, Spain|Multiple Locations, Sweden|Multiple Locations, Switzerland|Multiple Locations, Taiwan|Multiple Locations, Turkey|Multiple Locations, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02092818"
530,"NCT02090543","BAY 59-7939 (Xarelto, SPAF), Non Interventional Studies",,"Completed","No Results Available","Atrial Fibrillation","Drug: Phenprocoumon (Marcumar)|Drug: Rivaroxaban (Xarelto, BAY-59 7939)","A prescription of patient preferences pattern including 5 attributes for Discrete-Choice-Experiment(DCE)-design in patients with atrial fibrillation|Patient relevant burden/benefit due to anticoagulation using the ACTS-questionnaire","Bayer|Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)",,"647","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","17019|OR-ITW-01-13","January 2014","September 2014","October 2014","March 18, 2014",,"January 23, 2017","Many Locations, Germany",,"https://ClinicalTrials.gov/show/NCT02090543"
531,"NCT02085148","A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy",,"Active, not recruiting","No Results Available","Pediatric Oncology","Drug: Regorafenib (BAY73-4506)|Drug: Vincristine (Cellcristin®)|Drug: Irinotecan (Irinotecan Cell pharm®)","Safety: Maximum Tolerated Dose|Safety: Recommended Phase II Dose|Number of participants with Adverse Events|AUC(0-24)md based on nominal dosing|Overall survival|Time to progression|Tumor response: tumor assessment by RECIST v. 1.1|Taste and texture questionnaire of the regorafenib formulations|Cmax(0-24)md based on individual dosing|Cav(0-24)md based on individual dosing|t1/2eff,md based on individual dosing|AUC(0-24)md based on individual dosing|Clearance of irinotecan and SN-38","Bayer","All","6 Months to 18 Years   (Child, Adult)","Phase 1","62","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","15906|2013-003579-36","April 11, 2014","May 5, 2019","April 11, 2022","March 12, 2014",,"January 13, 2020","Lyon Cedex, France|Marseille, France|Paris, France|Villejuif Cedex, France|Genova, Liguria, Italy|Milano, Lombardia, Italy|Madrid, Spain|Valencia, Spain|Sutton, Surrey, United Kingdom|Newcastle Upon Tyne, Tyne And Wear, United Kingdom|Birmingham, West Midlands, United Kingdom|Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02085148"
532,"NCT02084628","Magnetic Resonance Imaging of the Liver in Children 0-2 Months of Age With an Intravenous Injection of Eovist/Primovist Which is a Contrast Agent",,"Terminated","Has Results","Magnetic Resonance Imaging","Drug: Gadoxetate disodium (Eovist/Primovist, BAY86-4873)","Number of Subjects With Additional Diagnostic Information From Combined (Pre-contrast And Post-contrast) Images Compared With Pre-contrast Images|Number of Subjects With Adverse Events|Number of Subjects With Serious Adverse Events|Number of Lesions Detected for the Pre-contrast Images|Number of Lesions Detected for the Combined Images|Contrast Enhancement of the Liver for the Combined Images Assessed by Yes or no Question|Contrast Enhancement of the Biliary System for the Combined Images Assessed by Yes or no Question|Visualization of the Biliary System for the Pre-contrast and Combined Images Assessed by Yes or no Question|Change in Diagnosis for the Combined Images Compared With Precontrast Images|Diagnostic Confidence for the Pre-contrast and Combined Images Assessed by Yes or no Question","Bayer","All","up to 2 Months   (Child)","Phase 3","1","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","16078|2012-000952-32","February 2015","August 2015","August 2015","March 12, 2014","September 23, 2016","September 23, 2016","Los Angeles, California, United States|Palo Alto, California, United States|Washington, District of Columbia, United States|Brooklyn, New York, United States|New York, New York, United States|Cincinnati, Ohio, United States|Philadelphia, Pennsylvania, United States|Seattle, Washington, United States|Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02084628"
533,"NCT02066402","Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)",,"Completed","Has Results","Bacterial Infections","Drug: Tedizolid (BAY119-2631)|Drug: Placebo Tedizolid (BAY119-2631)|Drug: Linezolid|Drug: Placebo Linezolid","Percentage of Participants With Early Clinical Response at 48-72 Hours After the First Infusion of Study Drug in the ITT Analysis Set.|Programmatically Defined Clinical Response at End of Therapy (EOT) Visit in the ITT Analysis Set|Programmatically Defined Clinical Response at End of Therapy (EOT) Visit in the Clinically Evaluable at EOT (CE-EOT) Analysis Set|Overall Investigator's Assessment of Clinical Success at Post Therapy Evaluation (PTE) Visit (7-14 Days After EOT Visit) in the ITT Analysis Set|Overall Investigator's Assessment of Clinical Success at Post Therapy Evaluation (PTE) Visit (7-14 Days After EOT Visit) in the Clinically Evaluable at Post Therapy Evaluation (CE-PTE) Analysis Set|Investigator's Assessment of Clinical Response at 48-72 Hours|Investigator's Assessment of Clinical Response at Day 7 Visit|Value of the Visual Analog Scale (VAS) Pain Scores at Each Time Point|Change From Baseline in the Visual Analog Scale (VAS) Pain Scores at Each Time Point|Value of the Faces Rating Scale (FRS) Pain Scores at Each Time Point|Change From Baseline in the Faces Rating Scale (FRS) Pain Scores at Each Time Point","Bayer|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 3","598","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","16121","March 4, 2014","March 6, 2016","April 18, 2016","February 19, 2014","June 7, 2017","June 7, 2017","Chula Vista, California, United States|La Mesa, California, United States|Oceanside, California, United States|Las Vegas, Nevada, United States|Teaneck, New Jersey, United States|Wuhu, Anhui, China|Fuzhou, Fujian, China|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Wuhan, Hubei, China|Changsha, Hunan, China|Changsha, Hunan, China|Changsha, Hunan, China|Nanjing, Jiangsu, China|Nanjing, Jiangsu, China|Suzhou, Jiangsu, China|Wuxi, Jiangsu, China|Changchun, Jilin, China|Dalian, Liaoning, China|Shenyang, Liaoning, China|Shenyang, Liaoning, China|Xi'an, Shaanxi, China|Xi'an, Shaanxi, China|Jinan, Shandong, China|Taiyuan, Shanxi, China|Chengdu, Sichuan, China|Urumchi, Xinjiang, China|Urumqi, Xinjiang, China|Kunming, Yunnan, China|Hangzhou, Zhejiang, China|Hangzhou, Zhejiang, China|Hangzhou, Zhejiang, China|Hangzhou, Zhejiang, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Chongqing, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|Tianjin, China|Tianjin, China|Quezon City, Philippines|Taguig City, Philippines|Kaohsiung, Taiwan|Kaohsiung, Taiwan|Taichung, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT02066402"
534,"NCT02064439","Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)","EinsteinChoice","Completed","Has Results","Pulmonary Embolism|Thromboembolism|Thrombosis|Venous Thrombosis|Venous Thromboembolism","Drug: BAY 59-7939|Drug: ASA","Number of Participants With the Composite of Fatal or Non-fatal Symptomatic Recurrent Venous Thromboembolism|Number of Participants With First Treatment-emergent Major Bleeding|Number of Participants With the Composite of the Primary Efficacy Outcome, Myocardial Infarction, Ischemic Stroke or Systemic Non-CNS Embolism|Number of Participants With Non-major Bleeding Associated With Study Drug Interruption for > 14 Days","Bayer|Janssen Scientific Affairs, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 3","3365","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","16416|2013-000619-26","March 5, 2014","September 22, 2016","November 4, 2016","February 17, 2014","December 19, 2017","December 19, 2017","Beverly Hills, California, United States|La Jolla, California, United States|Ventura, California, United States|Denver, Colorado, United States|Jacksonville, Florida, United States|Columbus, Georgia, United States|Joliet, Illinois, United States|Rockport, Maine, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Detroit, Michigan, United States|Butte, Montana, United States|Las Vegas, Nevada, United States|Raleigh, North Carolina, United States|Columbus, Ohio, United States|Toledo, Ohio, United States|Philadelphia, Pennsylvania, United States|San Antonio, Texas, United States|Fredericksburg, Virginia, United States|Bellevue, Washington, United States|Seattle, Washington, United States|Spokane, Washington, United States|Tacoma, Washington, United States|Garran, Australian Capital Territory, Australia|Concord, New South Wales, Australia|Kogarah, New South Wales, Australia|Lismore, New South Wales, Australia|Randwick, New South Wales, Australia|St Leonards, New South Wales, Australia|Westmead, New South Wales, Australia|Brisbane, Queensland, Australia|Clayton, Victoria, Australia|Box Hill, Australia|Melbourne, Australia|Redcliffe, Australia|Graz, Steiermark, Austria|Innsbruck, Tirol, Austria|Wien, Austria|Aalst, Belgium|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Hasselt, Belgium|Leuven, Belgium|Belo Horizonte, Minas Gerais, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|Campinas, Sao Paulo, Brazil|Santo André, Sao Paulo, Brazil|Santo André, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|Rio de Janeiro, Brazil|Sao Paulo, Brazil|Edmonton, Alberta, Canada|Victoria, British Columbia, Canada|Saint John, New Brunswick, Canada|Halifax, Nova Scotia, Canada|Hamilton, Ontario, Canada|Hamilton, Ontario, Canada|Hamilton, Ontario, Canada|London, Ontario, Canada|Ottawa, Ontario, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|St. Jerome, Quebec, Canada|Fuzhou, Fujian, China|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Nanning, Guangxi, China|Shijiazhuang, Hebei, China|Harbin, Heilongjiang, China|Wuhan, Hubei, China|Changsha, Hunan, China|Changsha, Hunan, China|Nantong, Jiangsu, China|Suzhou, Jiangsu, China|Changchun, Jilin, China|Shengyang, Liaoning, China|Shenyang, Liaoning, China|Yinchuan, Ningxia, China|Xi'an, Shaanxi, China|Xi'an, Shaanxi, China|Jinan, Shandong, China|Qingdao, Shandong, China|Taiyuan, Shanxi, China|Chengdu, Sichuan, China|Kunming, Yunnan, China|Hangzhou, Zhejiang, China|Hangzhou, Zhejiang, China|Wenzhou, Zhejiang, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|Tianjin, China|Tianjin, China|Tianjin, China|Kladno, Czechia|Liberec, Czechia|Litomysl, Czechia|Ostrava, Czechia|Ostrava, Czechia|Prague, Czechia|Praha 1, Czechia|Praha 5, Czechia|Usti nad Labem, Czechia|Aarhus N, Denmark|Copenhagen, Denmark|Glostrup, Denmark|Hellerup, Denmark|Herning, Denmark|København NV, Denmark|Svendborg, Denmark|Angers, France|Arras, France|Besancon, France|Bois-guillaume, France|BREST Cedex 9, France|Brest Cedex, France|Castelnau Le Lez, France|Clermont Ferrand, France|Colombes Cedex, France|Dijon, France|Grenoble, France|Le Kremlin Bicetre Cedex, France|Le Mans, France|Limoges Cedex, France|Nice, France|Paris Cedex 15, France|Paris, France|Paris, France|Quimper, France|Saint Etienne, France|Strasbourg Cedex, France|Toulon, France|Toulouse, France|Vernon, France|Heidelberg, Baden-Württemberg, Germany|München, Bayern, Germany|Darmstadt, Hessen, Germany|Witten, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Magdeburg, Sachsen-Anhalt, Germany|Dresden, Sachsen, Germany|Dresden, Sachsen, Germany|Erfurt, Thüringen, Germany|Berlin, Germany|Karlsbad, Germany|Baja, Hungary|Budapest, Hungary|Debrecen, Hungary|Gyula, Hungary|Kecskemet, Hungary|Miskolc, Hungary|Pecs, Hungary|Szentes, Hungary|Szombathely, Hungary|Zalaegerszeg, Hungary|Afula, Israel|Haifa, Israel|Haifa, Israel|Holon, Israel|Kfar Saba, Israel|Nahariya, Israel|Petah Tikva, Israel|Tel-Aviv, Israel|Zefat, Israel|Chieti, Abruzzo, Italy|Cosenza, Calabria, Italy|Piacenza, Emilia-Romagna, Italy|Reggio Emilia, Emilia-Romagna, Italy|Varese, Lombardia, Italy|Perugia, Umbria, Italy|Padova, Veneto, Italy|Treviso, Veneto, Italy|Treviso, Veneto, Italy|Donggu,, Gwangju Gwang''yeogsi, Korea, Republic of|Busan, Korea, Republic of|Daegu, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Leon, Guanajuato, Mexico|León, Guanajuato, Mexico|Guadalajara, Jalisco, Mexico|Guadalajara, Jalisco, Mexico|Monterrey, Nuevo Leon, Mexico|Xalapa, Veracruz, Mexico|Merida, Yucatán, Mexico|Aguascalientes, Mexico|Chihuahua, Mexico|Alkmaar, Netherlands|Almere, Netherlands|Amsterdam, Netherlands|Assen, Netherlands|Dordrecht, Netherlands|Groningen, Netherlands|Hoofddorp, Netherlands|Maastricht, Netherlands|Sittard, Netherlands|Zwolle, Netherlands|Auckland, New Zealand|Auckland, New Zealand|Auckland, New Zealand|Christchurch, New Zealand|Palmerston North, New Zealand|Wellington, New Zealand|Fredrikstad, Norway|Oslo, Norway|Quezon City, Philippines|Bialystok, Poland|Bydgoszcz, Poland|Poznan, Poland|Warszawa, Poland|Wroclaw, Poland|Barnaul, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Novosibirsk, Russian Federation|Novosibirsk, Russian Federation|Rostov-on-Don, Russian Federation|Ryazan, Russian Federation|Sochi, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|Tver, Russian Federation|Johannesburg, Gauteng, South Africa|Johannesburg, Gauteng, South Africa|Pretoria West, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Roodepoort, Gauteng, South Africa|Worcester, Western Cape, South Africa|Bloemfontein, South Africa|Torrevieja, Alicante, Spain|L'Hospitalet de Llobregat, Barcelona, Spain|San Sebastián de los Reyes, Madrid, Spain|Girona, Spain|Madrid, Spain|Göteborg, Sweden|Kristianstad, Sweden|Basel, Basel-Stadt, Switzerland|Lausanne, Vaud, Switzerland|Bern, Switzerland|Fribourg, Switzerland|Genève, Switzerland|Luzern, Switzerland|New Taipei City, Taiwan|Taichung, Taiwan|Taipei, Taiwan|Bangkok, Thailand|Khon Kaen, Thailand|Istanbul, Turkey|Istanbul, Turkey|Plymouth, Devon, United Kingdom|Hull, Humberside, United Kingdom|Newcastle Upon Tyne, Tyne And Wear, United Kingdom|Cardiff, United Kingdom|London, United Kingdom|Ha Noi, Vietnam|Ho Chi Minh, Vietnam",,"https://ClinicalTrials.gov/show/NCT02064439"
535,"NCT02064426","Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934","DIALOGUE5","Completed","No Results Available","Anemia|Renal Insufficiency, Chronic","Drug: Molidustat (BAY85-3934)|Biological: Epoetin alfa/beta","Change in local laboratory hemoglobin level from baseline|Number of participants with serious adverse events as a measure of safety and tolerability|Maintenance in hemoglobin target range (10.0 to 11.0 g/dL)|Maintenance in hemoglobin target range (9.5 to 11.5 g/dL)|Duration of treatment exposure|Number of subjects requiring titration of dose|Change of reticulocyte count from baseline of this study|Change of reticulocyte count from baseline of study 16208|Change of red blood cell count from baseline of this study|Change of red blood cell count from baseline of study 16208|Change of hematocrit from baseline of this study|Change of hematocrit from baseline of study 16208|Change of central laboratory hemoglobin level from baseline of this study|Change of central laboratory hemoglobin level from baseline of study 16208","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","88","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16209","March 13, 2014","October 19, 2016","November 16, 2016","February 17, 2014",,"September 20, 2019","Azusa, California, United States|Long Beach, California, United States|Lynwood, California, United States|Northridge, California, United States|San Dimas, California, United States|Whittier, California, United States|Whittier, California, United States|New Port Richey, Florida, United States|Pembroke Pines, Florida, United States|Detroit, Michigan, United States|Creve Coeur, Missouri, United States|Buffalo, New York, United States|Cincinnati, Ohio, United States|Toledo, Ohio, United States|Oklahoma City, Oklahoma, United States|Nashville, Tennessee, United States|Fort Worth, Texas, United States|Fort Worth, Texas, United States|Fort Worth, Texas, United States|Grand Prairie, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Mansfield, Texas, United States|Muroran, Hokkaido, Japan|Kuwana, Mie, Japan|Kyoto, Japan",,"https://ClinicalTrials.gov/show/NCT02064426"
536,"NCT02064413","Essure (Model ESS310) Placement Rate Study",,"Completed","No Results Available","Contraception","Device: ESS310 (BAY1454032)","Rate of successful bilateral placement of the ESS310 insert at first attempt in subjects who undergo attempted ESS310 placement|Successful bilateral placement rate of the ESS310 insert at first attempt in all subjects who undergo hysteroscopy with the intent of having bilateral ESS310 placement|Evaluation of investigator questionnaire regarding ESS310 design and usability|Evaluation of investigator questionnaire regarding potential factors predictive of failure to achieve bilateral placement of the ESS310 insert at first attempt|Hysteroscopy time to perform the procedure|Number of participants with Adverse device effects (ADE) as a measure of safety and tolerability|Number of participants with Adverse procedure-related events as a measure of safety and tolerability","Bayer","Female","21 Years to 44 Years   (Adult)","Phase 3","134","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","17069","March 2014","October 2014","November 2014","February 17, 2014",,"December 15, 2015","Glendale, Arizona, United States|Phoenix, Arizona, United States|Colorado Springs, Colorado, United States|Augusta, Georgia, United States|Fort Wayne, Indiana, United States|Newburgh, Indiana, United States|Grand Blanc, Michigan, United States|Saginaw, Michigan, United States|Southfield, Michigan, United States|Rochester, Minnesota, United States|Winston-Salem, North Carolina, United States|Dayton, Ohio, United States|Nashville, Tennessee, United States|Nashville, Tennessee, United States|Fort Worth, Texas, United States|Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02064413"
537,"NCT02055651","Cardiovascular Disease Risk Factors Prevalence Among Bayer's Employees in São Paulo, Brazil",,"Completed","No Results Available","Occupational Health","Behavioral: Examination and survey","Cardiovascular health metrics on a three-point scale (poor, intermediate, ideal)|Number of participants who are suggested to participate in a lifestyle change program and show up for at least one session","Bayer","All","20 Years and older   (Adult, Older Adult)",,"361","Industry","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","17312|NN1325BR","August 2013","November 2014","October 2016","February 5, 2014",,"November 11, 2016","Sao Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT02055651"
538,"NCT02055482","Long-term Pre-dialysis Extension in Europe and Asia Pacific","DIALOGUE 3","Completed","No Results Available","Anemia|Renal Insufficiency, Chronic","Drug: Molidustat (BAY85-3934)|Biological: Darbepoetin","Change in local laboratory hemoglobin level from baseline|Number of participants with serious adverse events (SAEs) and adjucated adverse events as a measure of safety and tolerability|Number of participants with liver function-related AEs including abnormal liver function tests and any hospitalization|Time within hemoglobin target range (10.0 to 12.0 g/dL)|Duration of treatment exposure|Number of subjects requiring titration of dose|Change of reticulocyte count from baseline of this study|Change of red blood cell count from baseline of this study|Change of hematocrit from baseline of this study|Change of central laboratory hemoglobin level from baseline of this study|Responders in Hb levels|Number of subjects meeting specific Hb criteria|Number of subjects with Hb values >13 g/dL or having excessive Hb increase|Number of participants with non-serious adverse events|Change in heart rate (HR)|Change in blood pressure (BP)|Laboratory abnormalities","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","166","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15653|2013-001190-24","June 24, 2014","November 15, 2016","December 12, 2016","February 5, 2014",,"November 22, 2017","Gosford, New South Wales, Australia|Melbourne, Victoria, Australia|Reservoir, Australia|Burgas, Bulgaria|Dobrich, Bulgaria|Gabrovo, Bulgaria|Karlovo, Bulgaria|Lovech, Bulgaria|Montana, Bulgaria|Pazardjik, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Stara Zagora, Bulgaria|Veliko Tarnovo, Bulgaria|Brest Cedex, France|Grenoble Cedex 9, France|Limoges Cedex1, France|Pierre Benite Cedex, France|Valenciennes, France|Pirmasens, Baden-Württemberg, Germany|Villingen-Schwenningen, Baden-Württemberg, Germany|Bonn, Nordrhein-Westfalen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Halle (Saale), Sachsen-Anhalt, Germany|Berlin, Germany|Wuppertal, Germany|Baja, Hungary|Budapest, Hungary|Debrecen, Hungary|Esztergom, Hungary|Kaposvar, Hungary|Pecs, Hungary|Szigetvar, Hungary|Ashkelon, Israel|Hadera, Israel|Jerusalem, Israel|Kfar Saba, Israel|Nahariya, Israel|Chieti, Abruzzo, Italy|Napoli, Campania, Italy|Modena, Emilia-Romagna, Italy|Brescia, Lombardia, Italy|Cremona, Lombardia, Italy|Lecco, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Pavia, Lombardia, Italy|Livorno, Toscana, Italy|Kitakyushu, Fukuoka, Japan|Okawa, Fukuoka, Japan|Muroran, Hokkaido, Japan|Hakusan, Ishikawa, Japan|Morioka, Iwate, Japan|Fujisawa, Kanagawa, Japan|Kamakura, Kanagawa, Japan|Kuwana, Mie, Japan|Chiba, Japan|Fukuoka, Japan|Nagano, Japan|Nara, Japan|Bucheon-si, Gyeonggido, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Bialystok, Poland|Poznan, Poland|Radom, Poland|Szczecin, Poland|Zyrardow, Poland|Brasov, Romania|Bucharest, Romania|Bucharest, Romania|Bucharest, Romania|Constanta, Romania|Oradea, Romania|Targu-Mures, Romania|Santiago de Compostela, A Coruña, Spain|L'Hospitalet de Llobregat, Barcelona, Spain|San Sebastián de los Reyes, Madrid, Spain|Alicante, Spain|Barcelona, Spain|Barcelona, Spain|Córdoba, Spain|Madrid, Spain|Madrid, Spain|Ankara Univ. Medical Faculty, Ankara, Turkey|Baskent University Medical Faculty, Ankara, Turkey|Sifa University Medical Faculty, Izmir, Turkey|Reading, Berkshire, United Kingdom|Cambridge, Cambridgeshire, United Kingdom|Dundee, Dundee City, United Kingdom|Brighton, East Sussex, United Kingdom|Salford, Manchester, United Kingdom|Hexham, Northumberland, United Kingdom|Doncaster, South Yorkshire, United Kingdom|Leeds, West Yorkshire, United Kingdom|Chorley, United Kingdom|Glasgow, United Kingdom|Liverpool, United Kingdom|Liverpool, United Kingdom|London, United Kingdom|London, United Kingdom|Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02055482"
539,"NCT02047890","Japanese BAY1000394 Monotherapy Phase I Study",,"Completed","No Results Available","Neoplasms","Drug: BAY1000394 (2.5mg)|Drug: BAY1000394 (5mg)","Number of participants with adverse events as a measure of safety and tolerability|Number of participants with abnormal lab parameters based on descriptive statistics|Maximum observed drug concentration (Cmax) for BAY1000394 and its metabolite M-1|Cmax divided by dose per body weight (Cmax,norm) for BAY1000394 and its metabolite M-1|Cmax divided by dose (Cmax/D) for BAY1000394 and its metabolite M-1|Area under the concentration versus time curve from zero to infinity after single dose (AUC) for BAY1000394 and its metabolite M-1|AUC from time 0 to 12 hours after single dose (AUC(0-12) for BAY1000394 and its metabolite M-1|AUC divided by dose per body weight (AUCnorm) for BAY1000394 and its metabolite M-1|AUCnorm from time 0 to 12 hours after single dose (AUC(0-12),norm) for BAY1000394 and its metabolite M-1|AUC divided by dose (AUC/D) for BAY1000394 and its metabolite M-1|Time to reach Cmax (tmax) for BAY1000394 and its metabolite M-1|Terminal half-life (t½) for BAY1000394 and its metabolite M-1|Maximum observed drug concentration after multiple dosing (Cmax,md) for BAY1000394 and its metabolite M-1|Cmax divided by dose per body weight after multiple dosing (Cmax,norm,md) for BAY1000394 and its metabolite M-1|Cmax divided by dose (Cmax,md/D) for BAY1000394 and its metabolite M-1|AUC from time 0 to 12 hours after multiple dosing (AUC(0-12),md) for BAY1000394 and its metabolite M-1|AUCnorm from time 0 to 12 hours after multiple dosing (AUC(0-12),norm,md) for BAY1000394 and its metabolite M-1|AUC from time 0 to 12 hours divided by dose after multiple dosing for BAY1000394 and its metabolite M-1|Tumor response","Bayer","All","20 Years and older   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15200","May 19, 2014","January 6, 2015","July 19, 2018","January 28, 2014",,"June 24, 2019","Kashiwa, Chiba, Japan|Fukuoka, Japan",,"https://ClinicalTrials.gov/show/NCT02047890"
540,"NCT02047019","Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination in Subjects With Essential Hypertension Inadequately Controlled on Candesartan Cilexetil",,"Withdrawn","No Results Available","Hypertension","Drug: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Drug: Candesartan Cilexetil|Drug: Candesartan matching placebo|Drug: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106) 30/16mg matching placebo","Change in mean seated systolic blood pressure (MSSBP).|Change in mean seated diastolic blood pressure (MSDBP).|Blood pressure Response Rate|Blood pressure Control Rate|Mean change in systolic blood pressure and diastolic blood pressure in ambulatory blood pressure monitoring over 24 hours.|Number of participants with adverse events as a measure of safety and tolerability.","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","14727|2012-004493-26","December 1, 2017","December 8, 2019","December 8, 2019","January 28, 2014",,"May 22, 2017","Fondazione Università G.D'Annunzio, Chieti, Abruzzo, Italy|A.O.U. di Bologna Policlinico S.Orsola Malpighi, Bologna, Emilia-Romagna, Italy|AAS 3 Friuli Alto Medio Collin, Udine, Friuli-Venezia Giulia, Italy|Fondazione Salvatore Maugeri, Pavia, Lombardia, Italy|IRCCS Ist Neurologico Mediterraneo, Isernia, Molise, Italy|A.O.U. di Sassari, Sassari, Sardegna, Italy|A.O.U. Pisana, Pisa, Toscana, Italy|AULSS 07 Pieve Soligo, Treviso, Veneto, Italy",,"https://ClinicalTrials.gov/show/NCT02047019"
541,"NCT02043678","Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms","ERA 223","Active, not recruiting","Has Results","Prostatic Neoplasms","Drug: Radium-223 dichloride (Xofigo, BAY88-8223)|Drug: Matching placebo (normal saline)|Drug: Abiraterone|Drug: Prednisone/Prednisolone","Symptomatic Skeletal Event Free Survival (SSE-FS)|Overall Survival (OS)|Radiological Progression Free Survival (rPFS)|Time to Pain Progression|Time to Cytotoxic Chemotherapy|Time to Opiate Use for Cancer Pain","Bayer|Janssen Research & Development, LLC","Male","18 Years and older   (Adult, Older Adult)","Phase 3","806","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15396|2013-003438-33","March 30, 2014","February 15, 2018","June 30, 2020","January 23, 2014","March 5, 2019","January 3, 2020","Anchorage, Alaska, United States|Tucson, Arizona, United States|Tucson, Arizona, United States|Oceanside, California, United States|Denver, Colorado, United States|Washington, District of Columbia, United States|Fort Myers, Florida, United States|Atlanta, Georgia, United States|Jeffersonville, Indiana, United States|New Orleans, Louisiana, United States|Baltimore, Maryland, United States|Rockville, Maryland, United States|Towson, Maryland, United States|Boston, Massachusetts, United States|Burlington, Massachusetts, United States|Detroit, Michigan, United States|Traverse City, Michigan, United States|Saint Louis, Missouri, United States|Omaha, Nebraska, United States|Las Vegas, Nevada, United States|Hackensack, New Jersey, United States|Poughkeepsie, New York, United States|Syracuse, New York, United States|Bala-Cynwyd, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Norfolk, Virginia, United States|Seattle, Washington, United States|Spokane, Washington, United States|Wheeling, West Virginia, United States|St Leonards, New South Wales, Australia|Adelaide, South Australia, Australia|East Bentleigh, Victoria, Australia|Heidelberg, Victoria, Australia|Melbourne, Victoria, Australia|Darlinghurst, Australia|East Melbourne, Australia|Randwick, Australia|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Edegem, Belgium|Gent, Belgium|Belo Horizonte, Minas Gerais, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|Barretos, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|Sao Paulo, Brazil|Calgary, Alberta, Canada|Vancouver, British Columbia, Canada|Winnipeg, Manitoba, Canada|Hamilton, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Quebec, Canada|Helsinki, Finland|Kuopio, Finland|Seinäjoki, Finland|Tampere, Finland|Besancon, France|Bordeaux Cedex, France|Paris, France|Paris, France|POITIERS cedex, France|Saint Herblain, France|Toulouse Cedex 9, France|Ulm, Baden-Württemberg, Germany|München, Bayern, Germany|Marburg, Hessen, Germany|Münster, Nordrhein-Westfalen, Germany|Dresden, Sachsen, Germany|Jena, Thüringen, Germany|Berlin, Germany|Afula, Israel|Beer Sheva, Israel|Haifa, Israel|Jerusalem, Israel|Kfar Saba, Israel|Petah Tikva, Israel|Ramat Gan, Israel|Tel Aviv, Israel|Zerifin, Israel|Modena, Emilia-Romagna, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Genova, Liguria, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Cagliari, Sardegna, Italy|Arezzo, Toscana, Italy|Trento, Trentino-Alto Adige, Italy|Nagoya, Aichi, Japan|Hirosaki, Aomori, Japan|Kashiwa, Chiba, Japan|Matsuyama, Ehime, Japan|Sapporo, Hokkaido, Japan|Kobe, Hyogo, Japan|Tsukuba, Ibaraki, Japan|Kanazawa, Ishikawa, Japan|Kita, Kagawa, Japan|Yokohama, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Sendai, Miyagi, Japan|Matsumoto, Nagano, Japan|Kurashiki, Okayama, Japan|Osakasayama, Osaka, Japan|Hamamatsu, Shizuoka, Japan|Bunkyo-ku, Tokyo, Japan|Bunkyo-ku, Tokyo, Japan|Koto-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Ube, Yamaguchi, Japan|Chiba, Japan|Chiba, Japan|Fukuoka, Japan|Fukuoka, Japan|Kumamoto, Japan|Miyazaki, Japan|Nagasaki, Japan|Okayama, Japan|Amsterdam, Netherlands|Nijmegen, Netherlands|Zwolle, Netherlands|Bodø, Norway|Lørenskog, Norway|Oslo, Norway|Gdansk, Poland|Gdynia, Poland|Gliwice, Poland|Poznan, Poland|Moscow, Russian Federation|Obninsk, Russian Federation|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|Badalona, Barcelona, Spain|Hospitalet de Llobregat, Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Málaga, Spain|Oviedo, Spain|Pamplona, Spain|Sevilla, Spain|Linköping, Sweden|Stockholm, Sweden|Sundsvall, Sweden|Umeå, Sweden|Växjö, Sweden|Edinburgh, Lothian, United Kingdom|Bebington, Merseyside, United Kingdom|Northwood, Middlesex, United Kingdom|Guildford, Surrey, United Kingdom|Sutton, Surrey, United Kingdom|Newcastle Upon Tyne, Tyne And Wear, United Kingdom|Coventry, Warwickshire, United Kingdom|Belfast, United Kingdom|Leeds, United Kingdom|London, United Kingdom|Romford, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02043678/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02043678/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02043678"
542,"NCT02042144","Safety and Effectiveness of Regorafenib","Correlate","Completed","No Results Available","Neoplasms","Drug: Stivarga (Regorafenib, BAY73-4506)","Incidence of all treatment-emergent adverse events (TEAE) - Patients will be monitored for TEAE using the NCI-CTCAE Version 4.3|Overall Survival (OS), OS is defined as the time interval from the start of regorafenib therapy to death, due to any cause.|Progression free survival (PFS) is defined as the time interval measured from the day of start with regorafenib treatment to (radiological or clinical) progression or death, whichever comes first.|Disease control rate (DCR) - DCR is defined as percentage of patients, whose best response was not progressive disease (i.e. CR, PR or SD). Stable disease must be at least 6 weeks in duration.|Quality of Life - HRQoL using PRO questionnaire EQ-5D (8) in applicable countries|Healthcare resource utilization","Bayer","All","18 Years and older   (Adult, Older Adult)",,"1034","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16821|SV1302","April 8, 2014","August 19, 2017","November 10, 2017","January 22, 2014",,"January 16, 2018","Multiple Locations, Argentina|Multiple Locations, Austria|Multiple Locations, Czechia|Multiple Locations, Denmark|Multiple Locations, France|Multiple Locations, Italy|Multiple Locations, Luxembourg|Multiple Locations, Mexico|Multiple Locations, Netherlands|Multiple Locations, Singapore|Multiple Locations, Spain|Multiple Locations, Switzerland|Multiple Locations, Taiwan",,"https://ClinicalTrials.gov/show/NCT02042144"
543,"NCT02040233","Multiple Dose Study in Heart Failure of BAY 1067197","PARSiFAL","Completed","No Results Available","Heart Failure","Drug: BAY1067197 (10 mg)|Drug: BAY1067197|Drug: Placebo (10 mg)|Drug: Placebo","Number of Subjects With Relevant Changes in Heart Rate|Number of Subjects With Relevant Changes in Blood Pressure|Number of Subjects With More than First Degree Atrio-Ventricular (AV) Block|Change From Baseline in Left Ventricular Ejection Fraction (LVEF)|Maximum Observed Concentration of BAY84-3174 in Plasma (Cmax) After First Dose of BAY1067197|Maximum Observed Concentration of BAY84-3174 in Plasma Divided by Dose (Cmax/D) After First Dose of BAY1067197|Area Under the Concentration Versus Time Curve of BAY84-3174 for the Dosing Interval (AUCtau) After First Dose of BAY1067197|Area Under the Concentration Versus Time Curve of BAY84-3174 for the Dosing Interval Divided by Dose (AUCtau/D) After First Dose of BAY1067197|Maximum Observed Concentration of BAY84-3174 in Plasma (Cmax,md) After Multiple Dose Administration During a Dosing Interval|Maximum Observed Concentration of BAY84-3174 in Plasma Divided by Dose (Cmax,md/D) After Multiple Dose Administration During a Dosing Interval|Area Under the Concentration Versus Time Curve of BAY84-3174 During any Dosing Interval (AUCtau,md) After Multiple Dose Administration|Area Under the Concentration Versus Time Curve of BAY84-3174 During any Dosing Interval Divided by Dose (AUCtau,md/D) After Multiple Dose Administration|Changes From Baseline for Wall Motion Score Index at Day (WMSI) as Measured by Cardiac Magnetic Resonance at Day 7|Number of Subjects With Clinically Relevant Changes Observed in Echocardiography Parameters|Number of Subjects With Clinically Relevant Changes Observed in Biomarkers|Time to Reach Maximum Observed Concentration of BAY84-3174 in Plasma (tmax) After First Dose of BAY1067197|Area Under the Concentration Versus Time Curve of BAY84-3174 for the Dosing Interval Divided by Dose per Body Weight (AUCtau,md,norm) After Multiple Dose Administration|Maximum Observed Concentration of BAY84-3174 in Plasma Divided by Dose per Body Weight (Cmax,md,norm) After Multiple Dose Administration|Time to Reach Maximum Observed Concentration of BAY84-3174 in Plasma (tmax,md) After Multiple Dose Administration|Half-Life Associated With the Terminal Slope (t1/2,md) After Multiple-Dose Administration|Maximum Observed Concentration of BAY84-3174 in Plasma After First Dose Divided by Dose per Body Weight (Cmax,norm)|Area Under the Concentration Versus Time Curve of BAY84-3174 for the Dosing Interval Divided by Dose per Body Weight (AUCtau,norm) After First Dose of BAY1067197","Bayer","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","31","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","16782|2013-002522-23","January 28, 2014","January 29, 2015","April 2, 2015","January 20, 2014",,"June 21, 2019","Berlin, Germany|Bergamo, Lombardia, Italy|Brescia, Lombardia, Italy|Milano, Lombardia, Italy|Groningen, Netherlands|Wroclaw, Poland",,"https://ClinicalTrials.gov/show/NCT02040233"
544,"NCT02040220","Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Eylea for Central Retinal Vein Occlusion (CRVO)","JPMS-CRVO","Completed","No Results Available","Retinal Vein Occlusion","Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)","Number of episodes of adverse drug reactions and adverse events(serious or non-serious, related or not related, ocular or non ocular)|Effectiveness (visual acuity)|Effectiveness (retina thickness)","Bayer|Regeneron Pharmaceuticals","All","Child, Adult, Older Adult",,"385","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16641|EYL-CRVO","January 24, 2014","June 1, 2018","November 9, 2018","January 20, 2014",,"April 10, 2019","Multiple Locations, Japan",,"https://ClinicalTrials.gov/show/NCT02040220"
545,"NCT02034552","A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)",,"Completed","Has Results","Prostatic Neoplasms","Drug: Radium-223 dichloride (Xofigo, BAY88-8223)|Drug: Abiraterone acetate|Drug: Prednisone|Drug: Enzalutamide","Patient Bone Scan Response Rate|Bone Scan Lesion Area|Radiological Progression Free Survival|Time to Radiological Progression|Time to Radiological Bone Progression|Time to First Symptomatic Skeletal Event|Symptomatic Skeletal Event-free Survival|Overall Survival","Bayer","Male","18 Years and older   (Adult, Older Adult)","Phase 2","68","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16544","March 7, 2014","July 15, 2016","June 26, 2018","January 13, 2014","July 2, 2017","July 23, 2019","Scottsdale, Arizona, United States|Tucson, Arizona, United States|Los Angeles, California, United States|New Haven, Connecticut, United States|Newark, Delaware, United States|Washington, District of Columbia, United States|Plantation, Florida, United States|Indianapolis, Indiana, United States|New Orleans, Louisiana, United States|Shreveport, Louisiana, United States|Rockville, Maryland, United States|Detroit, Michigan, United States|Saint Louis, Missouri, United States|Omaha, Nebraska, United States|Bronx, New York, United States|Syracuse, New York, United States|Springfield, Oregon, United States|Houston, Texas, United States|Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02034552"
546,"NCT02032836","Comparative PK PD Study in PAH Patients (Fox vs. I-Neb)",,"Completed","No Results Available","Pulmonary Arterial Hypertension","Drug: lloprost(Ventavis,BAYQ6252, 20 µg/mL)|Drug: lloprost(Ventavis,BAYQ6252, 10 µg/mL)","The proportion of patients with a meaningful maximum increase (i.e. >=25%) in heart rate AND/OR a meaningful maximum decrease (i.e. >=20%) in systolic blood pressure within the 30 minutes after the start of inhalation|Maximum change in systolic, diastolic and mean arterial blood pressure|Maximum change in heart rate within the 30 minutes following inhalation|Maximum change in oxygen saturation within the 30 minutes following inhalation using finger pulse oxymetry|AUC (area under the plasma concentration curve of BAYQ6256 from zero to infinity)|Maximum observed drug concentration in plasma after single dose administration|Time to reach maximum drug observed concentration in plasma after single dose|half-life (associated with terminal slope)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","27","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16483|2013-002783-12","March 10, 2014","January 7, 2015","September 29, 2017","January 10, 2014",,"September 26, 2018","Graz, Steiermark, Austria|München, Bayern, Germany|Würzburg, Bayern, Germany|Gießen, Hessen, Germany|Köln, Nordrhein-Westfalen, Germany|Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT02032836"
547,"NCT02023697","Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone",,"Completed","Has Results","Prostatic Neoplasms","Drug: Radium-223 dichloride (Xofigo, BAY88-8223)","Number of Participants With an Event Defining SSE Free Survival - High Dose vs. Standard Dose|Symptomatic Skeletal Event-Free Survival - High Dose vs. Standard Dose|Number of Participants With an Event Defining SSE Free Survival - Extended Dose vs. Standard Dose|Symptomatic Skeletal Event-Free Survival - Extended Dose vs. Standard Dose|Number of Participants With an Event Defining SSE Free Survival - Three Dose Groups As Randomized|Symptomatic Skeletal Event Free Survival - Three Dose Groups As Randomized|Number of Participants With an Overall Survival Event - High Dose vs. Standard Dose|Overall Survival - High Dose vs. Standard Dose|Number of Participants With an Overall Survival Event - Extended Dose vs. Standard Dose|Overall Survival - Extended Dose vs. Standard Dose|Number of Participants With an Overall Survival - Three Dose Groups As Randomized|Overall Survival Event - Three Dose Groups as Randomized|Number of Participants With First Symptomatic Skeletal Event - High Dose vs. Standard Dose|Time to First Symptomatic Skeletal Event - High Dose vs. Standard Dose|Number of Participants With First Symptomatic Skeletal Event - Extended Dose vs. Standard Dose|Time to First Symptomatic Skeletal Event - Extended Dose vs. Standard Dose|Number of Participants With First Symptomatic Skeletal Event - Three Dose Groups as Randomized|Time to First Symptomatic Skeletal Event - Three Dose Groups as Randomized|Number of Participants With a Radiological Progression Event-Free - High Dose vs. Standard Dose|Radiological Progression Free Survival - High Dose vs. Standard Dose|Number of Participants With a Radiological Progression Event-Free - Extended Dose vs. Standard Dose|Radiological Progression Free Survival - Extended Dose vs. Standard Dose|Number of Participants With a Radiological Progression Event-Free - Three Dose Groups as Randomized|Radiological Progression Free Survival - Three Dose Groups as Randomized|Number of Participants With a Radiological Progression Event - High Dose vs. Standard Dose|Time to Radiological Progression - High Dose vs. Standard Dose|Number of Participants With a Radiological Progression Event - Extended Dose vs. Standard Dose|Time to Radiological Progression - Extended Dose vs. Standard Dose|Number of Participants With a Radiological Progression Event - Three Dose Groups as Randomized|Time to Radiological Progression - Three Dose Groups as Randomized|Timepoint Pain Improvement Rate - Three Dose Groups as Randomized|Timepoint Pain Improvement Rate - Extended Dose vs. Standard Dose|Number of Participants With a Pain Progression Event - High Dose vs. Standard Dose|Time to Pain Progression - High Dose vs. Standard Dose|Number of Participants With a Pain Progression Event - Extended Dose vs. Standard Dose|Time to Pain Progression - Extended Dose vs. Standard Dose|Number of Participants With a Pain Progression Event - Three Dose Groups as Randomized|Time to Pain Progression - Three Dose Groups as Randomized|Number of Participants With Treatment-Emergent Adverse Events","Bayer","Male","18 Years and older   (Adult, Older Adult)","Phase 2","391","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16507|2013-003118-42","March 10, 2014","March 1, 2017","August 9, 2018","December 30, 2013","July 12, 2018","July 12, 2019","Scottsdale, Arizona, United States|New Haven, Connecticut, United States|Fort Myers, Florida, United States|Bethesda, Maryland, United States|Rockville, Maryland, United States|Ann Arbor, Michigan, United States|Detroit, Michigan, United States|Saint Louis, Missouri, United States|Omaha, Nebraska, United States|East Setauket, New York, United States|Portland, Oregon, United States|Pittsburgh, Pennsylvania, United States|Adelaide, South Australia, Australia|Melbourne, Victoria, Australia|Box Hill, Australia|Darlinghurst, Australia|Westmead, Australia|Irmandade Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Instituto do Câncer do Estado de São Paulo, São Paulo, Sao Paulo, Brazil|IBCC - Instituto Brasileiro de Controle do Cancer, São Paulo, Sao Paulo, Brazil|Hospital Israelita Albert Einstein, São Paulo, Sao Paulo, Brazil|London, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Santiago, Chile|Chomutov, Czechia|Praha 5, Czechia|Nantes, France|Vandoeuvre les Nancy, France|Villejuif Cedex, France|Tübingen, Baden-Württemberg, Germany|München, Bayern, Germany|Dresden, Sachsen, Germany|Beer Sheva, Israel|Haifa, Israel|Jerusalem, Israel|Kfar Saba, Israel|Petah Tikva, Israel|Ramat Gan, Israel|Meldola, Emilia-Romagna, Italy|Roma, Lazio, Italy|Torino, Piemonte, Italy|Arezzo, Toscana, Italy|Busan, Busan Gwang''yeogsi, Korea, Republic of|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Hospitalet de Llobregat, Barcelona, Spain|Palma de Mallorca, Illes Baleares, Spain|Barcelona, Spain|Madrid, Spain|Pamplona, Spain|Göteborg, Sweden|Karlstad, Sweden|Sundsvalls, Sweden|Umeå, Sweden|Taipei City, Taipei, Taiwan|Guishan Township, Taoyuan, Taiwan|Kaohsiung, Taiwan|Taichung, Taiwan|Taipei, Taiwan|Bebington, Merseyside, United Kingdom|Taunton, Somerset, United Kingdom|Northwood, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/97/NCT02023697/Prot_002.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/97/NCT02023697/SAP_003.pdf","https://ClinicalTrials.gov/show/NCT02023697"
548,"NCT02021409","Maintenance Treatment of Anemia in Pre-dialysis Subjects With Chronic Kidney Disease on Darbepoetin Treatment Versus BAY85-3934","DIALOGUE 2","Completed","No Results Available","Anemia|Renal Insufficiency, Chronic","Drug: BAY85-3934|Biological: Darbepoetin alfa","Change in local laboratory hemoglobin level from baseline to the average during the last 4 weeks treatment period|Maintenance in hemoglobin target range (10.0 to 12.0 g/dL)|Change in hemoglobin level|Number of patients with hemoglobin levels outside the target range|Dose level in the evaluation period|Duration of exposure on each dose level|Number of subjects requiring titration of dose|Number of participants with serious adverse events as a measure of safety and tolerability","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","126","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15261|2013-001192-21","January 28, 2014","October 15, 2015","November 23, 2015","December 27, 2013",,"September 19, 2019","Gosford, New South Wales, Australia|Reservoir, Victoria, Australia|Dobrich, Bulgaria|Lovech, Bulgaria|Montana, Bulgaria|Pazardjik, Bulgaria|Sofia, Bulgaria|Stara Zagora, Bulgaria|Grenoble Cedex 9, France|Pierre Benite Cedex, France|Bonn, Nordrhein-Westfalen, Germany|Baja, Hungary|Budapest, Hungary|Esztergom, Hungary|Kaposvar, Hungary|Pecs, Hungary|Szigetvar, Hungary|Ashkelon, Israel|Hadera, Israel|Kfar Saba, Israel|Nahariya, Israel|Napoli, Campania, Italy|Brescia, Lombardia, Italy|Cremona, Lombardia, Italy|Lecco, Lombardia, Italy|Pavia, Lombardia, Italy|Livorno, Toscana, Italy|Kitakyushu, Fukuoka, Japan|Okawa, Fukuoka, Japan|Muroran, Hokkaido, Japan|Morioka, Iwate, Japan|Fujisawa, Kanagawa, Japan|Kuwana, Mie, Japan|Chiba, Japan|Fukuoka, Japan|Nagano, Japan|Bucheon-si, Gyeonggido, Korea, Republic of|Bialystok, Poland|Radom, Poland|Bucharest, Romania|Bucharest, Romania|Oradea, Romania|Targu-Mures, Romania|L'Hospitalet de Llobregat, Barcelona, Spain|San Sebastián de los Reyes, Madrid, Spain|Madrid, Spain|Ankara Univ. Medical Faculty, Ankara, Turkey|Baskent University Medical Faculty, Ankara, Turkey|Sifa University Medical Faculty, Izmir, Turkey|Cambridge, Cambridgeshire, United Kingdom|Liverpool, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02021409"
549,"NCT02021370","15141 Fixed Dose Correction / naïve and Pre Dialysis (Europe and Asia Pacific)","DIALOGUE 1","Completed","No Results Available","Anemia|Renal Insufficiency, Chronic","Drug: BAY85-3934|Drug: Placebo","Change in local laboratory hemoglobin level from baseline to the average during the last 4 weeks treatment period|Change in local laboratory hemoglobin level from baseline|Speed of change in hemoglobin level per unit time|Duration of treatment exposure|Number of participants with serious adverse events as a measure of safety and tolerability|Pharmacodynamics characterized by erythropoietin concentration|Pharmacodynamics characterized by reticulocyte count","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","121","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15141|2013-001193-14","February 10, 2014","September 15, 2015","September 23, 2015","December 27, 2013",,"September 20, 2019","Gosford, New South Wales, Australia|Melbourne, Victoria, Australia|Gabrovo, Bulgaria|Lovech, Bulgaria|Montana, Bulgaria|Pazardjik, Bulgaria|Stara Zagora, Bulgaria|Veliko Tarnovo, Bulgaria|Limoges Cedex1, France|Villingen-Schwenningen, Baden-Württemberg, Germany|Bonn, Nordrhein-Westfalen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Halle (Saale), Sachsen-Anhalt, Germany|Baja, Hungary|Budapest, Hungary|Pecs, Hungary|Ashkelon, Israel|Hadera, Israel|Nahariya, Israel|Napoli, Campania, Italy|Modena, Emilia-Romagna, Italy|Cremona, Lombardia, Italy|Pavia, Lombardia, Italy|Livorno, Toscana, Italy|Kitakyushu, Fukuoka, Japan|Okawa, Fukuoka, Japan|Muroran, Hokkaido, Japan|Hakusan, Ishikawa, Japan|Morioka, Iwate, Japan|Kamakura, Kanagawa, Japan|Kuwana, Mie, Japan|Chiba, Japan|Fukuoka, Japan|Nara, Japan|Bucheon-si, Gyeonggido, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Bialystok, Poland|Malbork, Poland|Poznan, Poland|Radom, Poland|Szczecin, Poland|Zyrardow, Poland|Bucharest, Romania|Constanta, Romania|Oradea, Romania|Targu-Mures, Romania|Santiago de Compostela, A Coruña, Spain|L'Hospitalet de Llobregat, Barcelona, Spain|Ankara Univ. Medical Faculty, Ankara, Turkey|Baskent University Medical Faculty, Ankara, Turkey|Sifa University Medical Faculty, Izmir, Turkey|Cambridge, Cambridgeshire, United Kingdom|Doncaster, South Yorkshire, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02021370"
550,"NCT02007629","Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor","RESPITE","Completed","No Results Available","Hypertension, Pulmonary","Drug: Riociguat (Adempas, BAY63-2521)","Change from baseline in 6 Minute Walking Distance (6MWD)","Bayer","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","61","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16719|2013-001759-10","February 18, 2014","December 29, 2016","December 29, 2016","December 11, 2013",,"February 21, 2019","La Jolla, California, United States|Sacramento, California, United States|Iowa City, Iowa, United States|Boston, Massachusetts, United States|Saint Louis, Missouri, United States|Pittsburgh, Pennsylvania, United States|Providence, Rhode Island, United States|Bruxelles - Brussel, Belgium|Leuven, Belgium|Montreal, Quebec, Canada|Praha 2, Czechia|GRENOBLE Cedex 09, France|Le Kremlin Bicetre Cedex, France|Marseille, France|Heidelberg, Baden-Württemberg, Germany|Regensburg, Bayern, Germany|Hannover, Niedersachsen, Germany|Köln, Nordrhein-Westfalen, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Roma, Lazio, Italy|Pavia, Lombardia, Italy|Zürich, Switzerland|Newcastle Upon Tyne, Tyne And Wear, United Kingdom|Clydebank, West Dunbartonshire, United Kingdom|London, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02007629"
551,"NCT02001909","Effect of Neomycin on the Pharmacokinetics of Regorafenib",,"Completed","No Results Available","Neoplasms","Drug: Regorafenib (Stivarga, BAY73-4506)|Drug: Neomycin","AUC (area under the plasma concentration vs. time curve) for regorafenib|Cmax (maximum drug concentration) for regorafenib|AUC(0-24) (area under the plasma concentration vs. time curve) for regorafenib|AUC(0-tlast) (area under the plasma concentration vs. time curve) for regorafenib|AUC (area under the plasma concentration vs. time curve) for BAY75-7495 (M-2) and BAY81-8752 (M-5)|Cmax (maximum drug concentration) for M-2 and M-5|tmax (time to reach maximum drug concentration in plasma after single dose) for regorafenib, M-2 and M-5|tlast (time of last concentration above lower limit of quantification) for regorafenib, M-2 and M-5|t1/2 (half-life associated with the terminal slope) for regorafenib, M-2 and M-5|AE,ur(0-72) (amount of drug excreted via urine during the collection interval 0-72 hours post administration) for metabolites BAY86-6651 (M-7) and BAY86-6652 (M-8)|Number of participants with adverse events as a measure of safety and tolerability","Bayer","Male","18 Years to 45 Years   (Adult)","Phase 1","27","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","16675|2013-001721-18","December 2013","April 2014","April 2014","December 5, 2013",,"August 13, 2015","Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT02001909"
552,"NCT01982097","Sorafenib as Neoadjuvant Therapy Before Cytoreductive Nephrectomy in Patients With Metastatic Renal Cell Carcinoma","SANE","Completed","No Results Available","Carcinoma, Renal Cell","Drug: Sorafenib (Nexavar, BAY 43-9006)","Maximum percent reduction (based on the minimum post baseline value) in the longest diameter of the primary tumor in response to neoadjuvant Nexavar treatment.|Response rate of residual disease to Nexavar according to RECIST 1.1 with baseline after cytoreductive nephrectomy.|Response before cytoreductive nephrectomy according to RECIST 1.1.|Maximum percent reduction in the sum of longest diameters of target lesions according to RECIST 1.1 while on Nexavar treatment before cytoreductive nephrectomy|Maximum percent reduction in the sum of longest diameters of target lesions of residual disease after cytoreductive nephrectomy according to RECIST 1.1 while on Nexavar treatment with baseline after cytoreductive nephrectomy.|Number of participants with AEs, including intra- and postoperative complications, relation to Nexavar treatment, AEs treatment, AEs outcome.","Bayer","All","18 Years and older   (Adult, Older Adult)",,"61","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16933|NX1307RU","January 10, 2014","January 31, 2017","December 7, 2017","November 13, 2013",,"February 7, 2018","Multiple Locations, Russian Federation",,"https://ClinicalTrials.gov/show/NCT01982097"
553,"NCT01976741","Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)",,"Completed","No Results Available","Neoplasms","Drug: Rogaratinib (BAY1163877)","Maximum tolerated dose (MTD), defined as maximum dose at which the incidence of Drug Limiting Toxicities (DLTs) during cycle 1 is below 20%|Cmax(maximum drug concentration in plasma after first dose administration)|AUC(0-12) (AUC from time zero to 12 hours p.a. after first-dose administration|AUC(0-tlast) (AUC from time zero to the last data point > LLOQ)|AUC (area under the plasma concentration vs time curve from zero to infinity after single (first) dose)|Cmax/D (maximum drug concentration in plasma after single dose administration divided by dose)|AUC(0-12)/D(AUC from time zero to 12 hours after single dose administration divided by dose)|AUC(0-tlast)/D (AUC from time zero to the last data point >>LLOQ(lower limit of quantification) after single dose administration divided by dose|AUC/D (AUC divided by dose)|Cmax,md (Cmax after multiple-dose administration)|Cmax/Dmd (Maximum drug concentration in plasma after multiple dose administration divided by dose)|AUC(0-12)md (AUC(0-12) after multiple-dose administration)|AUC(0-12)/Dmd (AUC from time zero to 12 hours after multiple dose administration divided by dose|AUC(0-tlast)md (AUC from time zero to the last data point>LLOQ after multiple dose administration)|AUC(0-tlast)/Dmd (AUC from time zero to the last data point>LLOQ after multiple dose administration divided by dose)|AE,ur(0-12) amount of drug excreted via urine during the collection interval 0 - 12 hours post administration|AE,ur(0-24) amount of drug excreted via urine during the collection interval 0 - 24 hours post administration|AE,ur(12-24) amount of drug excreted via urine during the collection interval 12 - 24 hours post administration|Tumor response evaluation based on RECIST 1.1|Evaluation of biomarker status|Evaluation of Pharmacodynamic Parameters (PD)|Evaluation of relative bioabailability of the tablet formulation in comparison to the solution formulation of BAY1163877","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","168","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16443|2013-002155-15","December 30, 2013","March 11, 2019","January 9, 2020","November 6, 2013",,"January 22, 2020","Chicago, Illinois, United States|Chicago, Illinois, United States|Pittsburgh, Pennsylvania, United States|Besancon, France|Creteil, France|Dijon, France|Lille Cedex, France|Lyon Cedex, France|Heidelberg, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|Weiden, Bayern, Germany|Würzburg, Bayern, Germany|Essen, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Dresden, Sachsen, Germany|Hamburg, Germany|Magdeburg, Germany|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Singapore, Singapore|Singapore, Singapore|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Valencia, Spain|Chur, Graubünden, Switzerland|St. Gallen, Sankt Gallen, Switzerland|Genève, Switzerland",,"https://ClinicalTrials.gov/show/NCT01976741"
554,"NCT01975818","Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934","DIALOGUE4","Completed","No Results Available","Anemia|Renal Insufficiency, Chronic","Drug: Molidustat (BAY 85-3934)|Biological: Epoetin alfa/beta","Change in local laboratory hemoglobin level from baseline to the average during the last 4 weeks treatment period|Mean of the hemoglobin (Hb) levels in the target range (10.0 to 11.0 g/dL)|Mean of the hemoglobin levels in the target range (9.5 to 11.5 g/dL)|Change from baseline in Hb during active treatment|Number of patients with hemoglobin levels outside the target range|Dose level in the evaluation period|Duration of exposure on each dose level|Number of subjects requiring titration of dose|Number of participants with serious adverse events as a measure of safety and tolerability","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","201","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16208","October 28, 2013","October 23, 2015","December 15, 2015","November 5, 2013",,"September 20, 2019","Azusa, California, United States|Long Beach, California, United States|Los Angeles, California, United States|Lynwood, California, United States|Northridge, California, United States|San Dimas, California, United States|Whittier, California, United States|Whittier, California, United States|New Port Richey, Florida, United States|Pembroke Pines, Florida, United States|Detroit, Michigan, United States|Detroit, Michigan, United States|Creve Coeur, Missouri, United States|Eatontown, New Jersey, United States|Brooklyn, New York, United States|Buffalo, New York, United States|Fresh Meadows, New York, United States|Cincinnati, Ohio, United States|Toledo, Ohio, United States|Oklahoma City, Oklahoma, United States|Nashville, Tennessee, United States|Fort Worth, Texas, United States|Fort Worth, Texas, United States|Fort Worth, Texas, United States|Grand Prairie, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Mansfield, Texas, United States|San Antonio, Texas, United States|San Antonio, Texas, United States|Muroran, Hokkaido, Japan|Himeji, Hyogo, Japan|Kuwana, Mie, Japan|Kyoto, Japan|Nagano, Japan",,"https://ClinicalTrials.gov/show/NCT01975818"
555,"NCT01973868","Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination",,"Completed","No Results Available","Neoplasms","Drug: Regorafenib (Stivarga, BAY73-4506)|Drug: Cetuximab (ERBITUX)","Maximum tolerated dose (MTD) of regorafenib in combination with cetuximab|Number of participants with Adverse Events as a measure of safety and tolerability|Cmax,md (Cmax after multiple dose) for regorafenib and cetuximab|AUC(0-24)md (AUC from time zero to 24 hours after multiple-dose administration) for regorafenib|AUC(0-26)md (AUC from time zero to 26 hours after multiple-dose administration) for cetuximab|Tumor response according to RECIST 1.1|tmax,md (tmax after multiple-dose administration) for regorafenib, its metabolites M-2 (BAY75-7495) and M-5 (BAY81-8752) and cetuximab|tlast,md (tlast after multiple dosing) for regorafenib, its metabolites M-2 (BAY75-7495) and M-5 (BAY81-8752) and cetuximab|Cmax,md for metabolites M-2 (BAY75-7495) and M-5 (BAY81-8752)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","42","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16547","November 21, 2013","January 31, 2017","April 3, 2018","November 1, 2013",,"April 9, 2019","University of Southern California, Los Angeles, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of Pittsburgh Medical Center Health System, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01973868"
556,"NCT01971450","Non-interventional Study on Compliance of Inhaled Treatment With Ventavis in Patient With Pulmonary Hypertension","IVENT","Completed","No Results Available","Hypertension, Pulmonary","Drug: Iloprost (Ventavis, BAYQ6256)","Number of days without any drug administration at all|Number of fully inhaled doses in relation to the total number of inhalations per day|Number of missed doses per day as recommended|Number of actually inhaled doses per day vs. the recommended number of inhalations - either as recommended by the treating physician or as recommended by the label|6 minute walking distance test (MWDT) value|Score on dyspnea Borg CR (category ratio) 10 scale|Patients' quality of life, assessed by validated questionnaire|Assessment of the structural changes in the lungs using X-ray examination of the lungs|Assessment of the structural changes in the lungs using spirography|Assessment of lung haemodynamics using the data of echocardiography|Assessment of lung haemodynamics using the data of catheterization|Reason for omission of inhalation as assessed by the physician|Concomitant medication for other indications than pulmonary hypertension|Number of participants with adverse events (AEs)|Severity of AEs|AE relation to treatment|AE treatment|AE outcomes","Bayer","All","18 Years and older   (Adult, Older Adult)",,"89","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16777|VE1311RU","November 21, 2013","June 28, 2017","April 18, 2018","October 29, 2013",,"March 26, 2019","Multiple Locations, Russian Federation",,"https://ClinicalTrials.gov/show/NCT01971450"
557,"NCT01968668","Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan)",,"Completed","No Results Available","Diabetic Nephropathies","Drug: BAY94-8862|Drug: Placebo|Drug: BAY 94-8862","Change of urinary albumin-to creatinine ratio|Change in serum potassium concentration","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","96","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","16816","October 2013","October 2014","November 2014","October 24, 2013",,"January 9, 2015","Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Saijo, Ehime, Japan|Kurume, Fukuoka, Japan|Kurume, Fukuoka, Japan|Obihiro, Hokkaido, Japan|Amagasaki, Hyogo, Japan|Koga, Ibaraki, Japan|Tsuchiura, Ibaraki, Japan|Tsukuba, Ibaraki, Japan|Kahoku-gun, Ishikawa, Japan|Sakaide, Kagawa, Japan|Izumisano, Osaka, Japan|Yao, Osaka, Japan|Katsushika, Tokyo, Japan|Osaka, Japan",,"https://ClinicalTrials.gov/show/NCT01968668"
558,"NCT01967225","Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections",,"Completed","Has Results","Skin Diseases, Infectious","Drug: Tedizolid Phosphate (Sivextro, BAY1192631)|Drug: Linezolid","Clinical Response at Test of Cure (TOC)|Microbiological Response at Test of Cure (TOC)|Clinical Response at End of Treatment Visit (EOT)|Microbiological Response at End of Treatment (EOT)|Change of the Lesion Size From the Screening Visit by Visit (Only Skin and Soft Tissue Infection [SSTI])|Reduction Ratio of the Lesion Size From the Screening Visit to Day 3 to Day 4 Visit (Only Skin and Soft Tissue Infection [SSTI])","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","125","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16099","November 23, 2013","October 28, 2016","October 28, 2016","October 22, 2013","October 4, 2018","October 4, 2018","Nagakute, Aichi, Japan|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Toyoake, Aichi, Japan|Yoshida, Fukui, Japan|Kasuga, Fukuoka, Japan|Kitakyushu, Fukuoka, Japan|Miyako-gun, Fukuoka, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Amagasaki, Hyogo, Japan|Kobe, Hyogo, Japan|Inashiki-gun, Ibaraki, Japan|Tsukuba, Ibaraki, Japan|Kamakura, Kanagawa, Japan|Sagamihara, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Koshi, Kumamoto, Japan|Tsu, Mie, Japan|Sendai, Miyagi, Japan|Nakagami-gun, Okinawa, Japan|Shimajiri, Okinawa, Japan|Hamamatsu, Shizuoka, Japan|Iwata, Shizuoka, Japan|Numazu, Shizuoka, Japan|Meguro-ku, Tokyo, Japan|Musashimurayama, Tokyo, Japan|Ota-ku, Tokyo, Japan|Ota-ku, Tokyo, Japan|Ota-ku, Tokyo, Japan|Setagaya-ku, Tokyo, Japan|Shinagawa, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Tachikawa, Tokyo, Japan|Yonago, Tottori, Japan|Shimonoseki, Yamaguchi, Japan|Kofu, Yamanashi, Japan|Fukuoka, Japan|Gifu, Japan|Kochi, Japan|Kumamoto, Japan|Nagasaki, Japan|Osaka, Japan|Shizuoka, Japan|Shizuoka, Japan|Toyama, Japan",,"https://ClinicalTrials.gov/show/NCT01967225"
559,"NCT01961388","Study to Assess the Dietary Carbohydrate Content of Indian Diabetics With Special Therapeutic View on Effectiveness of Acarbose and Metformin Monotherapy","STARCH AM","Withdrawn","No Results Available","Diabetes Mellitus","Drug: Bay G5421 Glucobay|Drug: Metformin","The mean change in post-meal glucose levels from baseline at the end of observation period of up to 16 weeks|Mean change of HbA1c|Mean change of fasting blood glucose(FBG)|Mean change of low density lipoprotein cholesterol(LDL)|Mean change of high density lipoprotein cholesterol(HDL)|Mean change of total cholesterol(TC)|Mean change of Body weight|Mean change of triglyceride(TG)|Compare the mean change between acarbose and metformin arm of postprandial blood glucose (PPBG)|Compare the mean change between acarbose and metformin arm of HbA1c|Compare the mean change between acarbose and metformin arm of FBG|Compare the mean change between acarbose and metformin arm of LDL|Compare the mean change between acarbose and metformin arm of HDL|Compare the mean change between acarbose and metformin arm of TC|Compare the mean change between acarbose and metformin arm of TG|Compare the mean change between acarbose and metformin arm of Body weight|Change in gastrointestinal tolerability to therapy from post baseline visit to the end of observation period of up to 16 weeks|Incidence rate of adverse drug reactions in acarbose and metformin treated groups during 16 weeks observation period","Bayer","All","18 Years to 80 Years   (Adult, Older Adult)",,"0","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16667|GB1311IN","August 2015","December 2016","June 2017","October 11, 2013",,"June 15, 2016",,,"https://ClinicalTrials.gov/show/NCT01961388"
560,"NCT01961375","MIRENA for Contraception In InDian Subjects User continuAtion and Satisfaction Study: MIDAS Study","MIDAS","Active, not recruiting","No Results Available","Contraception","Drug: Levonorgestrel- Intra Uterine System (BAY 86-5028_Mirena)","Percentage continuation rate of LNG IUS at end of observation period.|Percentage of Women with user satisfaction scoring somewhat satisfied to very satisfied|Cumulative discontinuation rate for pregnancy|Cumulative discontinuation rate for other medical reasons|Cumulative discontinuation rate for non-medical reasons|Mean percentage of women with amenorrhea|Mean percent of women with spotting, inter-menstrual bleeding|Distribution of contraceptive usage patterns|Incidence rate of drug-related adverse events","Bayer","Female","18 Years to 49 Years   (Adult)",,"600","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16199|MA1210IN","October 30, 2015","November 28, 2018","March 31, 2020","October 11, 2013",,"January 13, 2020","Multiple Locations, India",,"https://ClinicalTrials.gov/show/NCT01961375"
561,"NCT01959269","Investigating the Use of Regorafenib (Stivarga®) in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard Therapy","RECORA","Completed","No Results Available","Colorectal Neoplasm","Drug: Regorafenib (Stivarga, BAY 73-4506)","Overall survival|Progression-free survival|Time to progression|Disease control rate (DCR)|Duration of Stivarga treatment|Tumor status at different visits|Incidence of treatment emergent adverse events (TEAE)","Bayer","All","18 Years and older   (Adult, Older Adult)",,"483","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16665|SV1313","October 31, 2013","March 31, 2017","July 7, 2017","October 9, 2013",,"March 8, 2018","Multiple Locations, Germany",,"https://ClinicalTrials.gov/show/NCT01959269"
562,"NCT01958684","Bleeding Pattern Difference Between Levonorgestrel Intrauterine System (LNG-IUS) and Copper Intrauterine Devices (IUDs) Immediately Inserted After Abortion","POST","Completed","No Results Available","Contraception","Drug: Levonorgestrel IUS (Mirena, BAY86-5028)|Device: Copper-IUD","The number of bleeding/spotting days assessed over the second 90-day reference period after induced abortion|Menstrual bleeding intensity|Abortion related bleeding days|Time to the first menstrual bleeding following abortion|Participants continuation rates of Mirena and Cu-IUD|Reasons for discontinuation of Mirena and Cu-IUD|Participants satisfaction rates of Mirena and Cu-IUD|Percentage of participants with adverse events","Bayer","Female","18 Years and older   (Adult, Older Adult)",,"512","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16954|MA1310CN","October 2013","October 2014","October 2014","October 9, 2013",,"October 16, 2015","Many Locations, China",,"https://ClinicalTrials.gov/show/NCT01958684"
563,"NCT01955876","Fosrenol Post-marketing Surveillance in Japan",,"Completed","No Results Available","Hyperphosphatemia|Kidney Disease","Drug: Lanthanum Carbonate (Fosrenol, BAY77-1931)","Incidence/number of episodes of adverse drug reactions and adverse events|Adverse drug event rate related to the digestive system|Incidence/number of episodes of adverse events for 6, 12 months ,and from month 13 to the conduction of dialysis after starting the treatment with Lanthanum carbonate.|Incidence/number of episodes of adverse drug reactions for 6, 12 months ,and from month 13 to the conduction of dialysis after starting the treatment with Lanthanum carbonate according to patient characteristics and treatment with Lanthanum carbonate.|Serum P level for six months after start of treatment with the drug in comparison with baseline (at the time of start of treatment with fosrenol)|Serum intact PTH level for six months after start of treatment with the drug in comparison with baseline|Serum P level at 12 months after starting the treatment with Lanthanum carbonate in comparison with baseline (at the time of starting the treatment with Fosrenol).|Serum P level at the conduction of dialysis from 13 months after starting the treatment with Lanthanum carbonate in comparison with baseline (at the time of starting the treatment with Fosrenol).|Serum intact PTH level at 12 months after starting the treatment with Lanthanum carbonate in comparison with baseline (at the time of starting the treatment with Lanthanum carbonate).|Serum intact PTH level at the conduction of dialysis from 13 months after starting the treatment with Lanthanum carbonate in comparison with baseline (at the time of starting the treatment with Lanthanum carbonate).","Bayer","All","Child, Adult, Older Adult",,"343","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","16626|FOSRENOL-PRED","October 10, 2013","February 18, 2016","August 5, 2016","October 8, 2013",,"February 23, 2018","Multiple Locations, Japan",,"https://ClinicalTrials.gov/show/NCT01955876"
564,"NCT01955694","Phase IIb Safety and Efficacy Study of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Moderate Chronic Kidney Disease Alone","ARTS-HF Japan","Completed","No Results Available","Heart Failure","Drug: BAY94-8862|Drug: Eplerenone|Drug: Placebo","The percentage of subjects with a relative decrease in N-terminal prohormone B-type natriuretic peptide of more than 30% from baseline to Visit 10|Change in serum potassium","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","16815","November 2013","January 2015","February 2015","October 7, 2013",,"October 17, 2016","Seto, Aichi, Japan|Toyota, Aichi, Japan|Funabashi, Chiba, Japan|Kamogawa, Chiba, Japan|Kamogawa, Chiba, Japan|Matsuyama, Ehime, Japan|Chikushino, Fukuoka, Japan|Amagasaki, Hyogo, Japan|Kobe, Hyogo, Japan|Kobe, Hyogo, Japan|Higashiibaraki, Ibaraki, Japan|Hiratsuka, Kanagawa, Japan|Kawasaki, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Uji, Kyoto, Japan|Sendai, Miyagi, Japan|Naha, Okinawa, Japan|Naha, Okinawa, Japan|Urasoe, Okinawa, Japan|Sayama, Saitama, Japan|Sayama, Saitama, Japan|Kusatsu, Shiga, Japan|Shinjuku-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Kofu, Yamanashi, Japan|Fukuoka, Japan|Kagoshima, Japan|Kyoto, Japan|Okayama, Japan|Osaka, Japan|Shizuoka, Japan",,"https://ClinicalTrials.gov/show/NCT01955694"
565,"NCT01951638","Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)",,"Completed","No Results Available","Heart Failure","Drug: Vericiguat (BAY1021189) (1.25 mg)|Drug: Vericiguat (BAY1021189) (5 mg)|Drug: Placebo","Change of log-transformed N-terminal pro-brain natriuretic peptide (NT-proBNP)|Change of left atrial volume (LAV)|Number of participants with adverse events as a measure of safety and tolerability","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","477","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15829|2013-002288-25","November 2013","August 2015","September 2015","September 26, 2013",,"November 3, 2015","Fountain Valley, California, United States|La Jolla, California, United States|Los Angeles, California, United States|Wilmington, Delaware, United States|Ft. Lauderdale, Florida, United States|Jacksonville, Florida, United States|Naples, Florida, United States|Atlanta, Georgia, United States|Macon, Georgia, United States|Chicago, Illinois, United States|Indianapolis, Indiana, United States|Iowa City, Iowa, United States|New Orleans, Louisiana, United States|Detroit, Michigan, United States|Detroit, Michigan, United States|Minneapolis, Minnesota, United States|Jackson, Mississippi, United States|Omaha, Nebraska, United States|Newark, New Jersey, United States|Buffalo, New York, United States|Columbus, Ohio, United States|Fairfield, Ohio, United States|Pittsburgh, Pennsylvania, United States|Charleston, South Carolina, United States|Germantown, Tennessee, United States|Nashville, Tennessee, United States|Burlington, Vermont, United States|Milwaukee, Wisconsin, United States|Darlinghurst, New South Wales, Australia|Brisbane, Queensland, Australia|Brisbane, Queensland, Australia|Redcliffe, Queensland, Australia|Hobart, Tasmania, Australia|Prahran, Victoria, Australia|St. Pölten, Niederösterreich, Austria|Linz, Oberösterreich, Austria|Linz, Oberösterreich, Austria|Graz, Steiermark, Austria|Salzburg, Austria|Wien, Austria|Wien, Austria|Wien, Austria|Brugge, Belgium|Bruxelles - Brussel, Belgium|Edegem, Belgium|Gent, Belgium|Gilly, Belgium|Hasselt, Belgium|HUY, Belgium|Ieper, Belgium|Mechelen, Belgium|MOL, Belgium|Roeselare, Belgium|Burgas, Bulgaria|Dimitrovgrad, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Stara Zagora, Bulgaria|Brampton, Ontario, Canada|Cambridge, Ontario, Canada|Scarborough, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Saint-Jean-sur-Richelieu, Quebec, Canada|Sherbrooke, Quebec, Canada|Quebec, Canada|Beijing, China|Shanghai, China|Shanghai, China|Hradec kralove, Czech Republic|Kromeriz, Czech Republic|Ostrava, Czech Republic|Praha 10, Czech Republic|Praha 2, Czech Republic|Praha 4, Czech Republic|Praha 6 - Stresovice, Czech Republic|Slany, Czech Republic|Aalborg, Denmark|Aarhus N, Denmark|Hellerup, Denmark|Holbaek, Denmark|Randers, Denmark|Vejle, Denmark|Viborg, Denmark|Brest, France|BRON Cedex, France|La Tronche, France|Lille Cedex, France|PARIS cedex 10, France|Paris Cedex 15, France|Pessac, France|Rouen, France|Toulouse, France|Bad Krozingen, Baden-Württemberg, Germany|München, Bayern, Germany|Bad Homburg, Hessen, Germany|Frankfurt, Hessen, Germany|Greifswald, Mecklenburg-Vorpommern, Germany|Hannover, Niedersachsen, Germany|Köln, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Homburg, Saarland, Germany|Erfurt, Thüringen, Germany|Hamburg, Germany|Athens, Attica, Greece|Haidari, Attica, Greece|Nea Ionia / Athens, Greece|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Eger, Hungary|Hodmezovasarhely, Hungary|Jaszbereny, Hungary|Kaposvar, Hungary|Kistarcsa, Hungary|Szekesfehervar, Hungary|Afula, Israel|Ashkelon, Israel|Hadera, Israel|Haifa, Israel|Jerusalem, Israel|Petah Tikva, Israel|Ramat Gan, Israel|Rehovot, Israel|Tel Aviv, Israel|Tiberias, Israel|Zrifin, Israel|Cortona, Arezzo, Italy|San Fermo della Battaglia, Como, Italy|Rho, Milano, Italy|Legnago, Verona, Italy|Ancona, Italy|Bergamo, Italy|Brescia, Italy|Milano, Italy|Milano, Italy|Milano, Italy|Pavia, Italy|Seto, Aichi, Japan|Toyota, Aichi, Japan|Iizuka, Fukuoka, Japan|Himeji, Hyogo, Japan|Higashiibaraki, Ibaraki, Japan|Kanazawa, Ishikawa, Japan|Takamatsu, Kagawa, Japan|Sagamihara, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Yokosuka, Kanagawa, Japan|Uji, Kyoto, Japan|Sendai, Miyagi, Japan|Naha, Okinawa, Japan|Sakai, Osaka, Japan|Takatsuki, Osaka, Japan|Yao, Osaka, Japan|Ureshino, Saga, Japan|Komatsushima, Tokushima, Japan|Meguro-ku, Tokyo, Japan|Minato-ku, Tokyo, Japan|Fukui, Japan|Gifu, Japan|Hiroshima, Japan|Kumamoto, Japan|Nagasaki, Japan|Osaka, Japan|Tokushima, Japan|Toyama, Japan|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Amsterdam, Netherlands|Apeldoorn, Netherlands|Deventer, Netherlands|Groningen, Netherlands|Heerenveen, Netherlands|Hoorn, Netherlands|Leeuwarden, Netherlands|Sneek, Netherlands|Veldhoven, Netherlands|Weert, Netherlands|Bialystok, Poland|Katowice, Poland|Krakow, Poland|Krakow, Poland|Legnica, Poland|Lodz, Poland|Lodz, Poland|Olsztyn, Poland|Poznan, Poland|Szczecin, Poland|Warszawa, Poland|Warszawa, Poland|Wroclaw, Poland|Almada, Portugal|Lisboa, Portugal|Lisboa, Portugal|Lisboa, Portugal|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|L'Hospitalet de Llobregat, Barcelona, Spain|Santander, Cantabria, Spain|Majadahonda, Madrid, Spain|El Palmar, Murcia, Spain|Alicante, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Valencia, Spain|Valencia, Spain|Helsingborg, Sweden|Karlstad, Sweden|Linköping, Sweden|Malmö, Sweden|Stockholm, Sweden|Örebro, Sweden|Liestal, Basel-Landschaft, Switzerland|Basel, Basel-Stadt, Switzerland|Lugano, Ticino, Switzerland|Bruderholz, Switzerland|Genève, Switzerland|Zürich, Switzerland|Kaohsiung, Taiwan|New Taipei City, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Chesterfield, Derbyshire, United Kingdom|Stevenage, Hertfordshire, United Kingdom|Northampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01951638"
566,"NCT01951625","Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)",,"Completed","No Results Available","Heart Failure","Drug: Vericiguat (BAY1021189) (1.25 mg)|Drug: Vericiguat (BAY1021189) (5 mg)|Drug: Placebo","Change in log-transformed N-terminal pro-brain natriuretic peptide (NT-proBNP)|Number of participants with adverse events as a measure of safety and tolerability","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","456","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15371|2013-002287-11","November 2013","May 2015","June 2015","September 26, 2013",,"October 17, 2016","Fountain Valley, California, United States|La Jolla, California, United States|Los Angeles, California, United States|Wilmington, Delaware, United States|Ft. Lauderdale, Florida, United States|Jacksonville, Florida, United States|Naples, Florida, United States|Atlanta, Georgia, United States|Macon, Georgia, United States|Indianapolis, Indiana, United States|Iowa City, Iowa, United States|New Orleans, Louisiana, United States|Detroit, Michigan, United States|Detroit, Michigan, United States|Minneapolis, Minnesota, United States|Jackson, Mississippi, United States|Omaha, Nebraska, United States|Newark, New Jersey, United States|Buffalo, New York, United States|Columbus, Ohio, United States|Fairfield, Ohio, United States|Pittsburgh, Pennsylvania, United States|Charleston, South Carolina, United States|Germantown, Tennessee, United States|Nashville, Tennessee, United States|Burlington, Vermont, United States|Milwaukee, Wisconsin, United States|Darlinghurst, New South Wales, Australia|Brisbane, Queensland, Australia|Brisbane, Queensland, Australia|Redcliffe, Queensland, Australia|Hobart, Tasmania, Australia|Prahran, Victoria, Australia|St. Pölten, Niederösterreich, Austria|Linz, Oberösterreich, Austria|Graz, Steiermark, Austria|Salzburg, Austria|Wien, Austria|Brugge, Belgium|Bruxelles - Brussel, Belgium|Edegem, Belgium|Gent, Belgium|Gilly, Belgium|Hasselt, Belgium|HUY, Belgium|Ieper, Belgium|Mechelen, Belgium|MOL, Belgium|Roeselare, Belgium|Burgas, Bulgaria|Dimitrovgrad, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Stara Zagora, Bulgaria|Brampton, Ontario, Canada|Cambridge, Ontario, Canada|Scarborough, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Saint-Jean-sur-Richelieu, Quebec, Canada|Sherbrooke, Quebec, Canada|Quebec, Canada|Beijing, China|Shanghai, China|Shanghai, China|Hradec kralove, Czech Republic|Kromeriz, Czech Republic|Fakultni nemocnice Ostrava, Ostrava, Czech Republic|Praha 10, Czech Republic|Praha 2, Czech Republic|Praha 4, Czech Republic|Praha 6, Czech Republic|Slany, Czech Republic|Aalborg, Denmark|Aarhus N, Denmark|Hellerup, Denmark|Vejle, Denmark|Viborg, Denmark|Brest, France|BRON Cedex, France|La Tronche, France|Lille Cedex, France|Paris Cedex 15, France|Pessac, France|Rouen, France|Bad Krozingen, Baden-Württemberg, Germany|München, Bayern, Germany|Bad Homburg, Hessen, Germany|Frankfurt, Hessen, Germany|Limburg, Hessen, Germany|Greifswald, Mecklenburg-Vorpommern, Germany|Hannover, Niedersachsen, Germany|Köln, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Homburg, Saarland, Germany|Erfurt, Thüringen, Germany|Hamburg, Germany|Athens, Greece|Haidari, Greece|Nea Ionia, Greece|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Eger, Hungary|Hodmezovasarhely, Hungary|Jaszbereny, Hungary|Kaposvar, Hungary|Kistarcsa, Hungary|Szekesfehervar, Hungary|Afula, Israel|Ashkelon, Israel|Hadera, Israel|Haifa, Israel|Jerusalem, Israel|Petah Tikva, Israel|Ramat Gan, Israel|Rehovot, Israel|Tel Aviv, Israel|Tiberias, Israel|Zrifin, Israel|San Fermo della Battaglia, Como, Italy|Bergamo, Lombardia, Italy|Brescia, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Monza, Lombardia, Italy|Pavia, Lombardia, Italy|Ancona, Marche, Italy|Arezzo, Toscana, Italy|Verona, Veneto, Italy|Seto, Aichi, Japan|Iizuka, Fukuoka, Japan|Shirakawa, Fukushima, Japan|Himeji, Hyogo, Japan|Kanazawa, Ishikawa, Japan|Takamatsu, Kagawa, Japan|Sagamihara, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Yokosuka, Kanagawa, Japan|Sendai, Miyagi, Japan|Naha, Okinawa, Japan|Sakai, Osaka, Japan|Takatsuki, Osaka, Japan|Yao, Osaka, Japan|Ureshino, Saga, Japan|Shimada, Shizuoka, Japan|Komatsushima, Tokushima, Japan|Meguro-ku, Tokyo, Japan|Minato-ku, Tokyo, Japan|Fukui, Japan|Hiroshima, Japan|Kumamoto, Japan|Nagasaki, Japan|Tokushima, Japan|Toyama, Japan|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Amsterdam, Netherlands|Apeldoorn, Netherlands|Deventer, Netherlands|Groningen, Netherlands|Heerenveen, Netherlands|Hoorn, Netherlands|Leeuwarden, Netherlands|Sneek, Netherlands|Veldhoven, Netherlands|Weert, Netherlands|Bialystok, Poland|Katowice, Poland|Krakow, Poland|Legnica, Poland|Lodz, Poland|Olsztyn, Poland|Poznan, Poland|Warszawa, Poland|Warszawa, Poland|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|L'Hospitalet de Llobregat, Barcelona, Spain|Santander, Cantabria, Spain|Majadahonda, Madrid, Spain|El Palmar, Murcia, Spain|Alicante, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Valencia, Spain|Valencia, Spain|Helsingborg, Sweden|Karlstad, Sweden|Linköping, Sweden|Malmö, Sweden|Stockholm, Sweden|Örebro, Sweden|Liestal, Basel-Landschaft, Switzerland|Basel, Basel-Stadt, Switzerland|Bruderholz, Switzerland|Genève, Switzerland|Lugano, Switzerland|Zürich, Switzerland|Kaohsiung, Taiwan|New Taipei City, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Chesterfield, Derbyshire, United Kingdom|Stevenage, Hertfordshire, United Kingdom|Northampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01951625"
567,"NCT01948882","Evaluation of Safety and Effectiveness of the Essure (Model ESS505) Device to Prevent Pregnancy in Women",,"Active, not recruiting","No Results Available","Contraception","Device: ESS505 (BAY1454033)","Number of confirmed pregnancies at 1 year among subjects told to rely on ESS505 for contraception|Reliance rate, defined as number of subjects told to rely on ESS505 after the Essure confirmation test divided by the number of subjects who had insert placement attempted|Number of confirmed pregnancies at 10 years among subjects told to rely on ESS505 for contraception|Safety of the ESS505 placement procedure defined as number of subjects who experience an AE assessed as related to the ESS505 placement procedure divided by the number of subjects in who at least one ESS505 was introduced into the fallopian tube|Safety of subsequent wearing of the insert defined as number of subjects who experience an AE assessed as related to wearing of ESS505 divided by the number of subjects in whom the presence of an AE could be assessed","Bayer","Female","21 Years to 44 Years   (Adult)","Not Applicable","612","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","16973","September 30, 2013","September 16, 2015","December 16, 2024","September 24, 2013",,"January 13, 2020","Aurora, Colorado, United States|Aurora, Colorado, United States|Boynton Beach, Florida, United States|Arlington Heights, Illinois, United States|Fort Wayne, Indiana, United States|Newburgh, Indiana, United States|Saginaw, Michigan, United States|Rochester, Minnesota, United States|Bronx, New York, United States|New York, New York, United States|Asheville, North Carolina, United States|Cincinnati, Ohio, United States|Dallas, Texas, United States|Houston, Texas, United States|Irving, Texas, United States|Norfolk, Virginia, United States|Spokane, Washington, United States|Hamilton, Ontario, Canada|Regina, Saskatchewan, Canada|Zwolle, Netherlands|L'Hospitalet de llobregat, Barcelona, Spain|Córdoba, Spain",,"https://ClinicalTrials.gov/show/NCT01948882"
568,"NCT01948869","Efficacy/Safety Study to Explore a New Revised Topical Formulation in Atopic Dermatitis","Phoenix II","Completed","No Results Available","Dermatitis, Atopic","Device: Phoenix II (BAY81-2996)|Device: Phoenix I (BAY81-2996)","Local scored atopic dermatitis (SCORAD) as clinical assessment by means of the intensity items of the SCORAD index|Number of subjects with abnormal vital signs|Number of patients with adverse events as a measure of safety and tolerability|Erythema by means of chromametry|Transepidermal water loss (TEWL) as a measure for skin barrier function|Skin hydration by means of corneometry|Intensity of pruritus by means of visual analogue scale (VAS)","Bayer","All","18 Years to 60 Years   (Adult)","Not Applicable","35","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","16960|2013-002569-20","October 2013","June 2014","June 2014","September 24, 2013",,"August 7, 2014","Münster, Nordrhein-Westfalen, Germany",,"https://ClinicalTrials.gov/show/NCT01948869"
569,"NCT01947998","Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)",,"Completed","No Results Available","Venous Thrombosis|Pulmonary Embolism|Atrial Fibrillation|Acute Coronary Syndrome","Drug: Rivaroxaban (Xarelto, Bay59-7939)|Drug: Warfarin|Drug: Antiplatelet drugs","Descriptive analysis of demographic and clinical characteristics of patients who are prescribed oral rivaroxaban for the first time in comparison with those who are prescribed standard of care for the first time|Characteristics of rivaroxaban use in comparison with standard of care|Safety: occurrence of intracranial haemorrhage leading to hospitalization among users of rivaroxaban in comparison with individuals receiving current standard of care|Safety: occurrence of gastrointestinal bleeding leading to hospitalization among users of rivaroxaban in comparison with individuals receiving current standard of care|Safety: occurrence urogenital bleeding leading to hospitalization|Safety: occurrence of bleeding events leading to hospitalization not specified as primary safety outcomes (""other bleeding"") in individuals receiving rivaroxaban, in comparison with those receiving current standard of care|Safety: occurrence of non-infective liver disease leading to hospitalization in individuals receiving rivaroxaban in comparison with those receiving current standard of care.|Effectiveness: occurrence of deep vein thrombosis (DVT) or pulmonary embolism (PE) in individuals receiving rivaroxaban in comparison with those receiving current standard of care.|Effectiveness: occurrence of Ischaemic stroke in individuals receiving rivaroxaban in comparison with those receiving current standard of care|Effectiveness: occurrence acute myocardial infarction (MI) in individuals receiving rivaroxaban in comparison with those receiving current standard of care|All-cause mortality as well as cause-specific mortality","Bayer|Janssen Research & Development, LLC","All","2 Years and older   (Child, Adult, Older Adult)",,"50299","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16647|EUPAS11299","December 22, 2011","December 31, 2018","December 31, 2019","September 23, 2013",,"January 13, 2020","Multiple Locations, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01947998"
570,"NCT01947985","Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)",,"Completed","No Results Available","Venous Thrombosis|Pulmonary Embolism|Atrial Fibrillation|Acute Coronary Syndrome","Drug: Rivaroxoban (Xarelto, Bay59-7939)|Drug: Standard of care","Descriptive analysis of demographic and clinical characteristics of patients who are prescribed oral rivaroxaban for the first time in comparison with those who are prescribed standard of care for the first time|Characteristics of rivaroxaban use in comparison with standard of care|Safety: occurrence of intracranial haemorrhage leading to hospitalization among users of rivaroxaban in comparison with individuals receiving current standard of care|Safety: occurrence of gastrointestinal bleeding leading to hospitalization among users of rivaroxaban in comparison with individuals receiving current standard of care|Safety: occurrence urogenital bleeding leading to hospitalization among users of rivaroxaban in comparison with individuals receiving current standard of care|Safety: occurrence of bleeding events leading to hospitalization not specified as primary safety outcomes (""other bleeding"") in individuals receiving rivaroxaban, in comparison with those receiving current standard of care|Safety: occurrence of non-infective liver disease leading to hospitalization in individuals receiving rivaroxaban in comparison with those receiving current standard of care|Effectiveness: occurrence of deep vein thrombosis (DVT) or pulmonary embolism (PE) in individuals receiving rivaroxaban in comparison with those receiving current standard of care|Effectiveness: occurrence of Ischaemic stroke in individuals receiving rivaroxaban in comparison with those receiving current standard of care|Effectiveness: occurrence acute myocardial infarction (MI) in individuals receiving rivaroxaban in comparison with those receiving current standard of care|All-cause mortality as well as cause-specific mortality","Bayer|Janssen Scientific Affairs, LLC","All","2 Years and older   (Child, Adult, Older Adult)",,"208958","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16646|EUPAS11141","February 1, 2012","December 31, 2018","December 31, 2019","September 23, 2013",,"January 13, 2020","Multiple Locations, Netherlands",,"https://ClinicalTrials.gov/show/NCT01947985"
571,"NCT01947959","Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)",,"Completed","No Results Available","Venous Thrombosis|Pulmonary Embolism|Atrial Fibrillation|Acute Coronary Syndrome","Drug: Rivaroxaban (Xarelto, Bay59-7939)|Drug: Standard of care","Descriptive analysis of demographic and clinical characteristics of patients who are prescribed oral rivaroxaban for the first time in comparison with those who are prescribed standard of care for the first time|Characteristics of rivaroxaban use in comparison with standard of care|Safety: occurrence of intracranial haemorrhage leading to hospitalization among users of rivaroxaban in comparison with individuals receiving current standard of care|Safety: occurrence of gastrointestinal bleeding leading to hospitalization among users of rivaroxaban in comparison with individuals receiving current standard of care|Safety: occurrence urogenital bleeding leading to hospitalization among users of rivaroxaban in comparison with individuals receiving current standard of care|Safety: occurrence of bleeding events leading to hospitalization not specified as primary safety outcomes (""other bleeding"") in individuals receiving rivaroxaban, in comparison with those receiving current standard of care|Safety: occurrence of non-infective liver disease leading to hospitalization in individuals receiving rivaroxaban in comparison with those receiving current standard of care|Effectiveness: occurrence of deep vein thrombosis (DVT) or pulmonary embolism (PE) in individuals receiving rivaroxaban in comparison with those receiving current standard of care|Effectiveness: occurrence of Ischaemic stroke in individuals receiving rivaroxaban in comparison with those receiving current standard of care|Effectiveness: occurrence acute myocardial infarction (MI) in individuals receiving rivaroxaban in comparison with those receiving current standard of care|All-cause mortality as well as cause-specific mortality","Bayer|Janssen Research & Development, LLC","All","2 Years and older   (Child, Adult, Older Adult)",,"665533","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16159|XA1201|EUPAS11145","December 22, 2011","December 31, 2018","December 31, 2019","September 23, 2013",,"January 13, 2020","Multiple Locations, Germany",,"https://ClinicalTrials.gov/show/NCT01947959"
572,"NCT01945606","Study to Assess the Safety of BAY1067197 in Stable Heart Failure Patients on Standard Therapy Including ß-blocker",,"Completed","No Results Available","Heart Failure","Drug: Placebo (treatment 1)|Drug: BAY1067197 (treatment 2)","Number of patients with occurrence of AV-Block > I°|Pharmacokinetic profile determined by tmax|Pharmacokinetic profile determined by t1/2|Heart rate|Blood pressure|Number of participants with adverse events as a measure of safety and tolerability","Bayer","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","11","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","16718|2013-001287-34","November 29, 2013","September 9, 2014","March 17, 2015","September 18, 2013",,"September 19, 2019","Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT01945606"
573,"NCT01940848","Efficacy/Safety Study to Confirm Iberogast's Efficacy in Patients With Irritable Bowel Syndrome Diagnosed on ROME III Criteria Compared to Placebo",,"Completed","No Results Available","Irritable Bowel Syndrome","Drug: STW5 (Iberogast, BAY98-7411)|Drug: Placebo","Number of responders with decrease in pain intensity compared with baseline for at least 14 single days within 4 weeks of treatment|Number of responders with decrease in pain intensity compared with baseline for at least 7 single days within first 2 weeks of treatment|Score on IBS-QOL (Irritable Bowel Syndrome - Quality of Life Measure) scale|Stool consistency (IBS-D): Decrease in weekly average of >1 in terms of BSS (Bristol Stool Form Scale)|Stool frequency (IBS-C): Increase of 1 or more complete spontaneous bowel movements (CSBM) per week compared with Baseline|Numbers of participants with adverse events (AEs)|Vital signs|Laboratory parameters|Global assessment of tolerability on a 5-point Likert scale by Investigator and patient","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","243","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","17063|STW5/212-D-011-III-V|2011-002613-10","October 11, 2013","October 25, 2017","October 25, 2017","September 12, 2013",,"October 29, 2018","Ludwigsburg, Baden-Württemberg, Germany|Mannheim, Baden-Württemberg, Germany|Sinzheim, Baden-Württemberg, Germany|Potsdam, Brandenburg, Germany|Lollar, Hessen, Germany|Wiesbaden, Hessen, Germany|Wardenburg, Niedersachsen, Germany|Winsen, Niedersachsen, Germany|Essen, Nordrhein-Westfalen, Germany|Hagen, Nordrhein-Westfalen, Germany|Löhne, Nordrhein-Westfalen, Germany|Marl, Nordrhein-Westfalen, Germany|Ludwigshafen, Rheinland-Pfalz, Germany|Halle, Sachsen-Anhalt, Germany|Reinfeld, Schleswig-Holstein, Germany|Apolda, Thüringen, Germany|Blankenhain, Thüringen, Germany|Berlin, Germany|Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT01940848"
574,"NCT01939223","Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo‑Controlled Phase-III STudy","COAST","Terminated","Has Results","Colorectal Neoplasms","Drug: Regorafenib (Stivarga, BAY73-4506)|Drug: Placebo","Disease Free Survival (DFS) as Assessed by the Investigator|Overall Survival (OS)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","25","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15983|2012-004369-42","December 2, 2013","August 29, 2016","August 29, 2016","September 11, 2013","October 20, 2017","October 20, 2017","Laguna Hills, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|New Haven, Connecticut, United States|New Orleans, Louisiana, United States|Baltimore, Maryland, United States|Detroit, Michigan, United States|Rochester, Minnesota, United States|Omaha, Nebraska, United States|New Brunswick, New Jersey, United States|Buffalo, New York, United States|New York, New York, United States|Syracuse, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Philadelphia, Pennsylvania, United States|Chattanooga, Tennessee, United States|Germantown, Tennessee, United States|Dallas, Texas, United States|Richmond, Virginia, United States|Kirkland, Washington, United States|Seattle, Washington, United States|Seattle, Washington, United States|Liverpool, New South Wales, Australia|East Melbourne, Victoria, Australia|Bentleigh East, Australia|Malvern, Australia|Edegem, Belgium|Leuven, Belgium|Liege, Belgium|Belo Horizonte, Minas Gerais, Brazil|Porto Alegre, Rio Grande do Sul, Brazil|São José do Rio Preto, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|Edmonton, Alberta, Canada|Toronto, Ontario, Canada|Sherbrooke, Quebec, Canada|Montreal, Canada|Fujian Medical University Union Hospital, Fuzhou, Fujian, China|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Harbin, Heilongjiang, China|Wuhan, Hubei, China|Changsha, Hunan, China|Xi'an, Shaanxi, China|Xi'an, Shaanxi, China|Kunming, Yunnan, China|Hangzhou, Zhejiang, China|Hangzhou, Zhejiang, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Shanghai, China|Shanghai, China|Shanghai, China|Bordeaux, France|Brest, France|Clermont-Ferrand, France|LYON Cedex 08, France|Marseille, France|Paris, France|Poitiers Cedex, France|Tours, France|Villejuif, France|München, Bayern, Germany|Frankfurt, Hessen, Germany|Oldenburg, Niedersachsen, Germany|Mainz, Rheinland-Pfalz, Germany|Berlin, Germany|Haifa, Israel|Ramat Gan, Israel|Tel Aviv, Israel|Napoli, Campania, Italy|Reggio Emilia, Emilia-Romagna, Italy|Udine, Friuli-Venezia Giulia, Italy|Roma, Lazio, Italy|Brescia, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Foggia, Puglia, Italy|Firenze, Toscana, Italy|Pisa, Toscana, Italy|Kashiwa, Chiba, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Akashi, Hyogo, Japan|Amagasaki, Hyogo, Japan|Kobe, Hyogo, Japan|Kasama, Ibaraki, Japan|Yokohama, Kanagawa, Japan|Suita, Osaka, Japan|Takatsuki, Osaka, Japan|Sunto, Shizuoka, Japan|Shimotsuke, Tochigi, Japan|Koto-ku, Tokyo, Japan|Minato-ku, Tokyo, Japan|Mitaka, Tokyo, Japan|Shinagawa, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Fukuoka, Japan|Fukuoka, Japan|Fukuoka, Japan|Almada, Portugal|Porto, Portugal|Santa Maria da Feira, Portugal|Alicante, Spain|Badajoz, Spain|Barcelona, Spain|Córdoba, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Valencia, Spain|Valencia, Spain|Royal Marsden NHS Trust (Surrey), Sutton, Surrey, United Kingdom|Bristol, United Kingdom|London, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01939223"
575,"NCT01938638","Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer",,"Completed","No Results Available","Neoplasms","Drug: BAY1143572","Number of participants with adverse events as a measure of safety and tolerability|Maximum tolerated dose (MTD) of BAY1143572|Maximum total drug concentration (Cmax)|Area under the plasma concentration-time curve from time zero to 24 hours (AUC(0-24)|Area under the plasma concentration-time curve from time zero to infinity (AUC)|Time of maximum observed concentration (tmax)|Tumor response based on RECIST 1.1 or Cheson 2007 criteria|Biomarker evaluation by determination of MYC protein expression and PCNA mRNA","Bayer","All","21 Years and older   (Adult, Older Adult)","Phase 1","80","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16519","September 26, 2013","August 17, 2016","September 19, 2016","September 10, 2013",,"October 20, 2017","Fayetteville, Arkansas, United States|Boston, Massachusetts, United States|Ann Arbor, Michigan, United States|Hackensack, New Jersey, United States|New York, New York, United States|Charleston, South Carolina, United States|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Singapore, Singapore|Singapore, Singapore|Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01938638"
576,"NCT01934790","Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases",,"Completed","Has Results","Prostatic Neoplasms","Drug: Radium-223 dichloride (Xofigo, BAY88-8223)","Number of Participants With Treatment-emergent Adverse Events (AEs)|Number of Participants With Treatment-emergent Serious Adverse Events (SAEs)|Number of Participants With Radium-223 Dichloride-related AEs in the Active Follow-up Period|Number of Participants With Radium-223 Dichloride-related SAEs in the Active Follow-up Period|Number of Participants With High/Low Abnormalities in Hematology Variables at Any Visit After Treatment Start|Number of Participants With High/Low Abnormalities in Biochemistry Variables at Any Visit After Treatment Start|Number of Participants Who Discontinued Radium-223 Dichloride Treatment Due to Treatment Emergent AEs or Death","Bayer","Male","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","45","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16506|2013-003046-17","December 22, 2013","June 4, 2015","April 12, 2017","September 4, 2013","September 29, 2016","March 26, 2018","New Orleans, Louisiana, United States|Omaha, Nebraska, United States|Syracuse, New York, United States|Kuopio, Finland|Haifa, Israel|Jerusalem, Israel|Kfar Saba, Israel|Petah Tikva, Israel|Forlì-Cesena, Emilia-Romagna, Italy|Milano, Lombardia, Italy|Bergen, Norway|Lørenskog, Norway|Córdoba, Andalucía, Spain|Barcelona, Spain|Málaga, Spain|Umeå, Sweden",,"https://ClinicalTrials.gov/show/NCT01934790"
577,"NCT01933958","Regorafenib Post-marketing Surveillance in Japan",,"Active, not recruiting","No Results Available","Gastrointestinal Stromal Tumors","Drug: Regorafenib (Stivarga, BAY73-4506)","Number of patients with adverse drug reactions (ADRs) from the first administration of regorafenib.|Number of patients with serious adverse events(SAEs) from the first administration of regorafenib.|Number of Patients with serious adverse drug reactions (SADRs) from the first administration of Regorafenib|overall survival (OS)|time to treatment failure (TTF)|tumour response|Integration analysis for safety in drug use investigations (DUIs) for both colorectal cancer and gastrointestinal stromal tumor.","Bayer","All","Child, Adult, Older Adult",,"72","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16732|STIVARGA-GIST-01","September 4, 2013","November 30, 2020","January 30, 2021","September 2, 2013",,"January 2, 2020","Multiple Locations, Japan",,"https://ClinicalTrials.gov/show/NCT01933958"
578,"NCT01933945","Outcomes of HCC (Hepatocellular Carcinoma) Patients Treated With TACE (Transarterial Chemoembolization) and Early, Not Early or Not at All Followed by Sorafenib","OPTIMIS","Completed","No Results Available","Carcinoma, Hepatocellular","Procedure: TACE (transarterial chemoembolization)|Drug: Sorafenib (Nexavar, BAY43-9006)","Overall survival (OS)|Overall survival from initial TACE|Progression-free survival (PFS) from initial TACE|Time to progression (TTP) from initial TACE|Tumor response according to mRECIST criteria|Duration of TACE treatment|Number of patients with TEAEs (treatment emergent adverse events)|TACE unsuitability|Time to TACE non-eligibility|Deterioration of liver dysfunction|OS from initiation of sorafenib|PFS from initiation of sorafenib|Tumor status at different visits response according to mRECIST|Duration of sorafenib treatment|TTP from initiation of sorafenib","Bayer","All","Child, Adult, Older Adult",,"1676","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16560|NX1301","October 28, 2013","July 22, 2017","November 10, 2017","September 2, 2013",,"November 6, 2018","Multiple Locations, Austria|Multiple Locations, Brazil|Multiple Locations, Canada|Multiple Locations, China|Multiple Locations, Czechia|Multiple Locations, Denmark|Multiple Locations, Egypt|Multiple Locations, France|Multiple Locations, Greece|Multiple Locations, Hong Kong|Multiple Locations, Hungary|Multiple Locations, India|Multiple Locations, Indonesia|Multiple Locations, Israel|Multiple Locations, Japan|Multiple Locations, Kazakhstan|Multiple Locations, Korea, Republic of|Multiple Locations, Mexico|Multiple Locations, Netherlands|Multiple Locations, Pakistan|Multiple Locations, Poland|Multiple Locations, Russian Federation|Multiple Locations, Singapore|Multiple Locations, Slovakia|Multiple Locations, Spain|Multiple Locations, Sweden|Multiple Locations, Switzerland|Multiple Locations, Taiwan|Multiple Locations, Thailand|Multiple Locations, Turkey|Multiple Locations, Vietnam",,"https://ClinicalTrials.gov/show/NCT01933945"
579,"NCT01933152","Study to Assess the EffectiVeness of exIsting Anti-vascular Endothelial groWth Factor (Anti-VEGF) Treatment Regimens in Patients With Wet Age-related Macular Degeneration","REVIEW","Completed","No Results Available","Macular Degeneration","Drug: Ranibizumab","Changes in visual acuity after start of Anti vascular endothelial growth factor (anti VEGF) therapy with ranibizumab, assessed by Early Treatment Diabetic Retinopathy (ETDRS) or Snellen chard|Demographic characteristics of patients included in the study (Age, Sex, Race)|Mean time from first clinical presentation to diagnosis|Mean time from diagnosis to treatment|Mean time from diagnosis to end of follow-up|Mean change of visual acuity, from diagnosis to end of follow-up, assessed by Early Treatment Diabetic Retinopathy (ETDRS) or Snellen chart|Mean change of retinal thickness from diagnosis to end of follow-up, assessed by Optical Coherence Tomography (OCT)|Mean change of lesion size from diagnosis to end of follow-up, assessed by Fluorescein Angiography (FA)|Average number of treatments given from diagnosis to end of follow-up","Bayer","All","18 Years and older   (Adult, Older Adult)",,"137","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","16378","August 2012","April 2013","April 2013","September 2, 2013",,"October 1, 2014","Many Locations, Portugal",,"https://ClinicalTrials.gov/show/NCT01933152"
580,"NCT01929655","Japanese BAY88-8223 Monotherapy Phase II Study",,"Completed","No Results Available","Prostatic Neoplasms","Drug: Radium-223 dichloride (Xofigo, BAY88-8223)","Percentage of change in total alkaline phosphatase from baseline at 12 weeks|Percentage of change in total alkaline phosphatase at the end of treatment|Percentages of change in bone ALP at 12 weeks|Percentages of change in bone ALP at the end of treatment|The proportion of subjects who have total alkaline phosphatase normalization at 12 weeks|The proportion of subjects who have total alkaline phosphatase normalization at the end of treatment|The proportion of subjects who have bone alkaline phosphatase normalization at 12 weeks|The proportion of subjects who have bone alkaline phosphatase normalization at the end of treatment|Time to prostate specific antigen progression|Overall survival|Percentages of change in biomarkers of bone turnover at each time point|Number of participants with drug related adverse events and serious adverse events as a measure of safety and tolerability|Incidence of treatment-emergent adverse events (TEAEs)|Number of participants with abnormal laboratory values","Bayer","Male","20 Years and older   (Adult, Older Adult)","Phase 2","49","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16430","September 30, 2013","May 16, 2017","May 16, 2017","August 28, 2013",,"April 24, 2018","Kashiwa, Chiba, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Kanazawa, Ishikawa, Japan|Yokohama, Kanagawa, Japan|Sendai, Miyagi, Japan|Osakasayama, Osaka, Japan|Hamamatsu, Shizuoka, Japan|Bunkyo-ku, Tokyo, Japan|Bunkyo-ku, Tokyo, Japan|Koto-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Chiba, Japan|Fukuoka, Japan|Kumamoto, Japan|Okayama, Japan",,"https://ClinicalTrials.gov/show/NCT01929655"
581,"NCT01928979","Retrospective Registry Providing Baseline Data on the Outcome of Left Atrial (LA) or LA Appendage (LAA) Thrombus in Patients With Nonvalvular Atrial Fibrillation (AF) or Atrial Flutter After Standard of Care (SoC) Anticoagulant Therapy","CLOT-AF","Completed","No Results Available","Atrial Fibrillation","Other: no drug","Thrombus resolution (completely disappeared) rate confirmed on TEE.|Stroke or non central nervous system (CNS) systemic thromboembolism rate|All bleeding (major, non-major, unknown severity) rates","Bayer","All","18 Years and older   (Adult, Older Adult)",,"160","Industry","Observational","Time Perspective: Retrospective","16677|NN1301","May 2013","December 2014","December 2014","August 27, 2013",,"December 23, 2014","Many Locations, Bulgaria|Many Locations, France|Many Locations, Nordrhein-Westfalen, Germany|Many Locations, Poland|Many Locations, Russian Federation|Many Locations, Turkey|Many Locations, Ukraine",,"https://ClinicalTrials.gov/show/NCT01928979"
582,"NCT01928888","Placebo Controlled Phase IV Study to Compare the Efficacy and Safety of a Single Dose of Oral Talcid, a Single Dose of Oral Famotidine and a Single Dose of Placebo in Patients With Acute Heartburn Episodes",,"Completed","No Results Available","Heartburn","Drug: Talcid (Hydrotalcite, BAY4516H)|Drug: Famotidine|Drug: Placebo","Total heartburn relief over 0-60 min|Total heartburn relief 0-30 min after comparison hydrotalcite vs. placebo and vs famotidine|Total heartburn relief 0-3 h after comparison hydrotalcite vs. placebo and vs famotidine","Bayer","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","559","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11201","May 2003","February 2004","February 2004","August 27, 2013",,"December 25, 2014","Frankfurt, Hessen, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|ask Central Contact, Germany|Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT01928888"
583,"NCT01927224","Study to Assess Bioequivalence of 30 and 120 mg Nifurtimox Tablets in Chronic Chagas' Patients",,"Completed","No Results Available","Chagas Disease","Drug: Nifurtimox (BAYa2502) (4 x 30 mg tablet)|Drug: Nifurtimox (BAYa2502) (slurry of 4 x 30 mg tablets in tap water)|Drug: Nifurtimox (BAYa2502) (120 mg tablet)","Area under the drug-concentration vs. time curve of nifurtimox from time 0 to the last data point [AUC(0-tn)]|Maximum drug concentration of nifurtimox in plasma (Cmax)|Number of participants with adverse events as a measure of safety and tolerability","Bayer","All","18 Years to 45 Years   (Adult)","Phase 1","37","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16004","November 2013","May 2014","September 2014","August 22, 2013",,"October 16, 2015","Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina",,"https://ClinicalTrials.gov/show/NCT01927224"
584,"NCT01926847","Digital Flow Enhancement in Raynaud's Phenomenon With an sGC (Soluble Guanylate Cyclase) Stimulator","DIGIT","Completed","No Results Available","Raynaud Disease","Drug: Riociguat (Adempas, BAY63-2521)|Drug: Placebo","Number of participants with adverse events as a measure of safety and tolerability|Blood pressure|Pulse rate|Incidence of participants showing changes during clinical laboratory and hematology assessment|Plasma concentration at 2 h after riociguat administration|Placebo corrected change in digital blood flow at room temperature, measured by Laser Doppler Perfusion Imaging|Placebo corrected change in digital blood flow during cold exposure, measured by Laser Doppler Perfusion Imaging","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","23","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","16787|2013-001899-38","October 2013","June 2014","June 2014","August 21, 2013",,"June 16, 2014","Köln, Nordrhein-Westfalen, Germany",,"https://ClinicalTrials.gov/show/NCT01926847"
585,"NCT01925755","Non-interventional Local Study on Prescription Behavior of Anticoagulation Therapy in Secondary Stroke Prevention in Atrial Fibrillation Patients","NEURO-XAR","Completed","No Results Available","Stroke|Embolism","Other: Rivaroxaban ( Xarelto, BAY59-7939)","Prescription pattern of neurologists in secondary stroke or non-CNS systemic embolism prevention in patients with AF and prior stroke or TIA who treat with rivaroxaban|Descriptive characteristics of patients after prior stroke/TIA in the need of secondary stroke prevention with Xarelto (gender, age, race, alcohol/smoking, BMI and BP abnormalities, CHA2DS2 VASC, HAS BLED, Rankin Score)|Identify time of start of anticoagulation therapy immediately after event (stroke or TIA) for secondary prevention in real life practice|Describe AE characteristics (frequency, severity, relation to treatment, AE treatment, AE outcome)","Bayer|Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)",,"209","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16627|XA2012-01RU","July 2013","January 2015","July 2015","August 20, 2013",,"January 23, 2017","Many locations, Russian Federation",,"https://ClinicalTrials.gov/show/NCT01925755"
586,"NCT01925638","Effect of Ketoconazole on the Pharmacokinetics of Refametinib",,"Completed","No Results Available","Drug Interactions","Drug: BAY86-9766|Drug: Ketoconazole","Cmax(maximum observed drug concentration in measured matrix after single dose administration) of BAY86-9766|AUC(area under the concentration vs. time curve from zero to infinity after single (first) dose) of BAY86-9766|t1/2(half-life associated with the terminal slope) of BAY86-9766|Number of participants with adverse events as a measure of safety and tolerability|AUC(0-tlast)(AUC from time 0 to the last data point > LLOQ) of BAY86-9766 and Metabolites M-11 and M-17|tmax(time to reach Cmax) of BAY86-9766 and Metabolites M-11 and M-17|tlast(time of last observed concentration value above lower limit of quantitation) of BAY86-9766 and Metabolites M-11 and M-17|Cmax(maximum observed drug concentration in measured matrix after single dose administration) of Metabolites M-11 and M-17|AUC(area under the concentration vs. time curve from zero to infinity after single (first) dose) of Metabolites M-11 and M-17|t1/2(half-life associated with the terminal slope) of Metabolites M-11 and M-17|CL/F(total body clearance of drug calculated after extravascular administration) of BAY 86-9766)","Bayer","Male","18 Years to 45 Years   (Adult)","Phase 1","18","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","14751","September 2013","December 2013","December 2013","August 20, 2013",,"January 8, 2014","Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01925638"
587,"NCT01921855","Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors","MATCHBOX","Completed","No Results Available","Hemophilia A|Hemophilia B","Drug: BAY Factor VII (BAY86-6150)|Drug: Placebo","Number of participants with adverse events as a measure of safety and tolerability|Pharmacokinetic assessment, based on plasma concentration of BAY86-6150|Pharmacodynamic assessment, based on plasma hemostasis marker level|Immunogenicity assessment, based on anti-BAY86-6150 binding antibody levels","Bayer","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","13787|2008-000117-29","January 2009","December 2009","December 2009","August 13, 2013",,"August 21, 2014","Warszawa, Poland|Bloemfontein, Freestate, South Africa|Johannesburg, Gauteng, South Africa|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01921855"
588,"NCT01915602","Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)",,"Completed","No Results Available","Carcinoma, Hepatocellular","Drug: Refametinib (BAY86-9766)|Drug: Sorafenib (BAY43-9006)","Objective tumor response according to Modified Response Evaluation Criteria in Solid Tumors (mRECIST) assessed by central radiological review|Objective tumor response according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 assessed by central radiological review|Objective tumor response according to RECIST 1.1 and mRECIST assessed by investigators|Disease control (central and investigator's assessment)|Overall survival|Time to radiographic tumor progression (central and investigator's assessment)|Duration of response (central and investigator's assessment)|Time to objective response (central and investigator's assessment).|Change in tumor size (central and investigator's assessment)|Best overall response (central and investigator's assessment)|Progression-free survival (central and investigator's assessment)|Number of participants with adverse events as a measure of safety and tolerability","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","14","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16728|2013-000241-39","September 27, 2013","July 29, 2015","February 8, 2017","August 5, 2013",,"May 15, 2017","La Jolla, California, United States|Washington, D.C., District of Columbia, United States|Fairway, Kansas, United States|Louisville, Kentucky, United States|Ann Arbor, Michigan, United States|New York, New York, United States|Cleveland, Ohio, United States|Wien, Austria|Bruxelles - Brussel, Belgium|Edegem, Belgium|Leuven, Belgium|Liege, Belgium|Guangzhou, Guangdong, China|Nanjing, Jiangsu, China|Beijing, China|Beijing, China|Shanghai, China|Hradec Kralove, Czechia|Olomouc, Czechia|Praha 5, Czechia|Bordeaux, France|Caen Cedex, France|Clichy, France|Lille, France|Lyon, France|Marseille, France|Nice Cedex 3, France|Paris, France|Saint-priest-en-jarez, France|Vandoeuvre-les-nancy, France|Heidelberg, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|Frankfurt, Hessen, Germany|Hannover, Niedersachsen, Germany|Essen, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Magdeburg, Sachsen-Anhalt, Germany|Berlin, Germany|Hamburg, Germany|Hong Kong, Hong Kong|Budapest, Hungary|Debrecen, Hungary|Pecs, Hungary|Zalaegerszeg, Hungary|Beer Sheva, Israel|Haifa, Israel|Jerusalem, Israel|Petah Tikva, Israel|Rehovot, Israel|Tel Aviv, Israel|Bologna, Emilia-Romagna, Italy|Roma, Lazio, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Nagoya, Aichi, Japan|Chiba-shi, Chiba, Japan|Fukuoka-shi, Fukuoka, Japan|Yokohama, Kanagawa, Japan|Osakasayama-shi, Osaka, Japan|Irima-gun, Saitama, Japan|Bunkyo-ku, Tokyo, Japan|Itabashi-ku, Tokyo, Japan|Kyoto, Japan|Osaka, Japan|Osaka, Japan|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Daegu, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Auckland, New Zealand|Singapore, Singapore|Santiago de Compostela, A Coruña, Spain|Oviedo, Asturias, Spain|Hospitalet de Llobregat, Barcelona, Spain|Vigo, Pontevedra, Spain|Madrid, Spain|Madrid, Spain|Bern, Switzerland|Tainan, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Chiang Mai, Thailand|Khon Kaen, Thailand|Songkhla, Thailand|Istanbul, Turkey|Istanbul, Turkey|Istanbul, Turkey|Mersin, Turkey|Birmingham, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01915602"
589,"NCT01915589","Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)",,"Completed","No Results Available","Carcinoma, Hepatocellular","Drug: Refametinib (BAY86-9766)","Objective tumor response according to Modified Response Evaluation Criteria in Solid Tumors (mRECIST) assessed by central radiological review|Objective tumor response according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 assessed by central radiological review|Objective tumor response according to RECIST 1.1 and mRECIST assessed by investigators|Disease control (central and investigator's assessment)|Overall survival|Time to radiographic tumor progression (central and investigator's assessment)|Duration of response (central and investigator's assessment)|Time to objective response (central and investigator's assessment)|Change in tumor size (central and investigator's assessment)|Best overall response (central and investigator's assessment)|Progression-free survival (central and investigator's assessment)|Number of participants with adverse events as a measure of safety and tolerability","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","16","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16553|2013-000311-25","September 16, 2013","October 8, 2014","October 8, 2014","August 5, 2013",,"June 14, 2017","Los Angeles, California, United States|Orange, California, United States|Washington, D.C., District of Columbia, United States|Miami, Florida, United States|Tampa, Florida, United States|Atlanta, Georgia, United States|Westwood, Kansas, United States|Louisville, Kentucky, United States|New York, New York, United States|Rochester, New York, United States|Dallas, Texas, United States|Galveston, Texas, United States|Seattle, Washington, United States|Graz, Austria|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Charleroi, Belgium|Gent, Belgium|Leuven, Belgium|Praha 2, Czechia|CLERMONT-FERRAND Cedex 1, France|Creteil, France|Lille, France|Marseille, France|Montpellier Cedex, France|Vandoeuvre-les-nancy, France|Heidelberg, Baden-Württemberg, Germany|München, Bayern, Germany|Hannover, Niedersachsen, Germany|Essen, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Berlin, Germany|Shatin, Hong Kong|Budapest, Hungary|Debrecen, Hungary|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Kashiwa-shi, Chiba, Japan|Kobe, Hyogo, Japan|Moriguchi, Osaka, Japan|Osaka-shi, Osaka, Japan|Osakasayama-shi, Osaka, Japan|Sunto, Shizuoka, Japan|Shimotsuke, Tochigi, Japan|Chuo-ku, Tokyo, Japan|Osaka, Japan|Shizuoka, Japan|Busan, Korea, Republic of|Daegu, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Auckland, New Zealand|Santiago de Compostela, A Coruña, Spain|Barcelona, Catalunya, Spain|Alicante, Spain|Pontevedra, Spain|Valencia, Spain|Genève 14, Genève, Switzerland|Bern, Switzerland|Kaohsiung City, Taiwan|Tainan, Taiwan|Bangkok, Thailand|Bangkok, Thailand|Bangkok, Thailand|Birmingham, West Midlands, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01915589"
590,"NCT01915576","Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients",,"Completed","No Results Available","Neoplasms","Drug: BAY1125976","Number of participants with adverse events as a measure of safety and tolerability|Maximum tolerated dose (MTD) of BAY1125976|Area under the plasma concentration vs time curve from zero to infinity after single (first) dose|Food effect assessment|Tumor response will be evaluated based on Response Evaluation Criteria in Solid Tumors (RECIST) definitions","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","79","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16447|2012-004671-39","September 2013","July 2016","December 2016","August 5, 2013",,"December 28, 2016","Santa Monica, California, United States|Boston, Massachusetts, United States|St. Louis, Missouri, United States|Houston, Texas, United States|Villejuif Cedex, France|Heidelberg, Baden-Württemberg, Germany|St. Gallen, Sankt Gallen, Switzerland",,"https://ClinicalTrials.gov/show/NCT01915576"
591,"NCT01915264","GLucobay M - Evaluation Of Safety and Effectiveness in Type 2 Diabetes Not Well Controlled on Monotherapy in Real Life Practice","GLORY","Withdrawn","No Results Available","Diabetes Mellitus, Type 2","Drug: Acarbose/Metformin (Glucobay M, BAY81-9783)","Incidence of severe hypoglycemia or documented symptomatic or asymptomatic hypoglycemic events reported as adverse events|Incidence of adverse events other than hypoglycemia reported|Mean change in HbA1c level|Mean change in fasting blood sugar|Mean change in postprandial blood sugar|Mean change in body weight|Mean change in serum LDL(low‐density lipoprotein) cholesterol|Mean change in serum triglyceride|Mean change in serum HDL (High density lipoproteins) cholesterol|Change in percent satisfaction to the therapy from baseline as measured by 5 point satisfaction scale|Number of patient with adverse event (Tolerability)","Bayer","All","Child, Adult, Older Adult",,"0","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16445|GB1310IN","August 2015","December 2016","March 2017","August 2, 2013",,"April 25, 2016",,,"https://ClinicalTrials.gov/show/NCT01915264"
592,"NCT01914380","Investigating the Effectiveness of Eylea in Patients With Wet Age-related Macular Degeneration","PERSEUS","Completed","No Results Available","Wet Age-related Macular Degeneration","Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)","Mean change of visual acuity for the total patient population|Mean change of visual acuity for the subgroup of pretreated patients|Mean change of visual acuity for the subgroup of non-pretreated patients|Monitoring of disease activity|Monitoring of treatment patterns|Mean time from indication of Eylea-treatment by the treating physician to start of treatment","Bayer|Regeneron Pharmaceuticals","All","Child, Adult, Older Adult",,"988","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16623|EY1313DE","July 29, 2013","March 31, 2017","March 31, 2017","August 2, 2013",,"March 29, 2018","Multiple Locations, Germany",,"https://ClinicalTrials.gov/show/NCT01914380"
593,"NCT01908322","Investigating Patient Characteristics of Intermediate Stage Hepatocellular Carcinoma Patients Treated With Nexavar and Their Distribution to Different Treatment Groups as Well as Determining Effectiveness and Safety","SORINT","Completed","No Results Available","Carcinoma, Hepatocellular","Drug: Sorafenib (Nexavar, BAY43-9006)","Distribution of intermediate stage hepatocellular carcinoma (HCC) patients treated with Nexavar to different treatment groups will be evaluated by the relative frequency of patients in each treatment group.|Characteristics of patients with intermediate stage HCC (BCLC-B) treated with Nexavar will be determined by evaluating demographic data, medical history, previous treatment of HCC, specific concomitant conditions (amongst others).|Overall Survival is measured as the time interval from start of Nexavar therapy to the date of death, due to any reason.|Time to progression is defined as the time interval from start of Nexavar therapy to the date of diagnosed progression.|Progression free survival is measured as the time interval from the start of Nexavar treatment to diagnosed (radiological or clinical) progression or death, whichever comes first.|Time to treatment failure is defined as the time interval from start of Nexavar therapy to the date of diagnosed progression or permanent discontinuation due to toxicity.|Duration of Nexavar treatment is measured as the time interval from start of Nexavar therapy to the date of permanent discontinuation of Nexavar therapy (regardless of the reason for discontinuation).|Tumor status at different visits will be evaluated according to radiological or clinical evaluation. The best overall response will be analyzed providing absolute and relative frequencies of the tumor status categories.|Further possible prognostic factors will be evaluated.|Safety variables will be summarized using descriptive statistics based on adverse events collection.","Bayer","All","Child, Adult, Older Adult",,"19","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16628","August 2013","June 2015","September 2015","July 25, 2013",,"November 11, 2015","Many Locations, Germany",,"https://ClinicalTrials.gov/show/NCT01908322"
594,"NCT01907048","Patient and Physician Knowledge of Key Safety Messages",,"Recruiting","No Results Available","Anticoagulation","Behavioral: Rivaroxaban (Xarelto, BAY59-7939)","Knowledge and understanding among physicians regarding key safety information contained in the prescriber guide assessed by web-based questionnaire|Knowledge and understanding of patients regarding the key safety information contained in the patient alert card assessed by paper-based questionnaire","Bayer|Janssen Research & Development, LLC|RTI Health Solutions","All","18 Years and older   (Adult, Older Adult)",,"5000","Industry|Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","16167|XA1202","September 15, 2014","February 29, 2020","March 15, 2020","July 24, 2013",,"January 18, 2020","Multiple Locations, France|Multiple Locations, Germany|Multiple Locations, Spain|Multiple Locations, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01907048"
595,"NCT01902264","Study of Treatment With the Combination of Drospirenone Plus Ethinyl Estradiol Plus Levomefolate Calcium in Mexican Women Seeking Contraception",,"Completed","No Results Available","Contraception","Drug: EE20/DRSP/L-5-MTHF (Beyaz, BAY98-7071)","Change in RBC folate concentration from baseline to Week 24|Change in plasma folate concentration from baseline to Week 24|RBC folate concentration|Plasma folate concentration","Bayer","Female","18 Years to 45 Years   (Adult)","Phase 3","34","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","16484","August 2013","February 2015","February 2015","July 18, 2013",,"April 29, 2016","Mexico, D.F., Distrito Federal, Mexico",,"https://ClinicalTrials.gov/show/NCT01902264"
596,"NCT01894035","Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation","COMPHI","Completed","No Results Available","Pulmonary Hypertension","Drug: Iloprost (Ventavis, BAYQ 6256)","Percentage of compliant patients|Observed treatment duration days|Expected treatment duration days|Changes in WHO/ NYHA Functional Class|Change in 6 MWDT (6 minute walking distance test) scale value|Change in Dyspnea Borg CR (category ratio) 10 scale value|Quality of life using validated scales (EuroQol questionnaire [EQ-5D], Living with Pulmonary Hypertension questionnaire [LPH])|Adjusted percentage treatment duration","Bayer","All","18 Years and older   (Adult, Older Adult)",,"13","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16755|VE1310PT","September 23, 2013","July 20, 2016","April 13, 2017","July 9, 2013",,"April 9, 2018","Multiple Locations, Portugal",,"https://ClinicalTrials.gov/show/NCT01894035"
597,"NCT01892904","Comparative Study of BAY86-5300 With a Flexible Extended Regimen for Dysmenorrhea",,"Completed","No Results Available","Dysmenorrhea","Drug: EE20/DRSP(BAY86-5300)","Number of days with dysmenorrheic pain over 140 days of evaluation period|Change in Dysmenorrhea score from baseline to period of withdrawal bleeding|Change of severity of pain Description|Number of days with at least moderate dysmenorrheic pain over 140 days of evaluation period|Number of days with rescue medicine used for relief of dysmenorrhea or pelvic pain over 140 days of evaluation period|Number of days with interference of dysmenorrheic pain with daily activity over 140 days of evaluation period|Endometrial thickness|Number of days with bleeding and spotting over treatment phase","Bayer","Female","20 Years and older   (Adult, Older Adult)","Phase 3","216","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16114","July 2013","January 2015","August 2015","July 8, 2013",,"September 9, 2015","Matsudo, Chiba, Japan|Hachioji, Tokyo, Japan|Minato, Tokyo, Japan|Setagaya-ku, Tokyo, Japan|Suginami-ku, Tokyo, Japan|Toshima-ku, Tokyo, Japan|Osaka, Japan|Osaka, Japan",,"https://ClinicalTrials.gov/show/NCT01892904"
598,"NCT01890434","Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)","GadaCAD 2","Completed","Has Results","Coronary Artery Disease","Drug: Gadobutrol (Gadavist, Gadovist, BAY86-4875)","Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Primary Analysis of Sensitivity Based on Blinded Readers' Assessment|Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Additional Secondary Analysis of Sensitivity Based on Blinded Readers' Assessment|Absence of Myocardial Perfusion Defect Excluding Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Primary Analysis of Specificity Based on Blinded Readers' Assessment|Absence of a Myocardial Perfusion Defect Excluding Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Additional Secondary Analysis of Specificity Based on Blinded Readers' Assessment|Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI Versus Unenhanced Wall Motion CMRI Images - Primary Analysis of Sensitivity Comparison Based on the Blinded Readers' Assessment|Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI Versus Unenhanced Wall Motion CMRI Images - Additional Secondary Analysis of Sensitivity Comparison Based on the Blinded Readers' Assessment|Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Secondary Analysis of Sensitivity Based on Investigator's Assessment|Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Additional Secondary Analysis of Sensitivity Based on Investigator's Assessment|Absence of a Myocardial Perfusion Defect Excluding Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Secondary Analysis of Specificity Based on Investigator's Assessment|Absence of a Myocardial Perfusion Defect Excluding Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Additional Secondary Analysis of Specificity Based on Investigator's Assessment|Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI Versus Unenhanced Wall Motion CMRI Images - Secondary Analysis of Sensitivity Comparison Based on the Investigator's Assessment|Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI and Unenhanced Wall Motion CMRI Images - Additional Secondary Analysis of Sensitivity Comparison Based on the Investigator's Assessment|Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI Versus GSPECT - Secondary Analysis of Sensitivity Comparison Based on Majority Blinded Reader's and Investigator's Assessment|Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI and GSPECT - Additional Secondary Analysis of Sensitivity Based on Majority Blinded Reader's and Investigator's Assessment|Absence of a Myocardial Perfusion Defect Excluding Significant CAD Per Participant on Gadobutrol-enhanced CMRI Versus GSPECT -- Secondary Analysis of Specificity Comparison Based on Majority Blinded Reader's and Investigator's Assessment|Absence of a Myocardial Perfusion Defect Excluding Significant CAD Per Participant on Gadobutrol-enhanced CMRI and GSPECT - Additional Secondary Analysis of Specificity Based on Majority Blinded Reader's and Investigator's Assessment|Localization of a Myocardial Perfusion Defect to Each Coronary Territory on Gadobutrol-enhanced CMRI - Secondary Analysis of Sensitivity Based on Blinded Readers' and Investigator's Assessment|Localization of a Myocardial Perfusion Defect to LAD and Non-LAD Territory on GSPECT - Secondary Analysis of Sensitivity Based on Blinded Readers' and Investigator's Assessment|Localization of a Myocardial Perfusion Defect to Each Coronary Territory on Gadobutrol-enhanced CMRI - Additional Secondary Analysis of Sensitivity Based on Blinded Readers' and Investigator's Assessment|Localization of a Myocardial Perfusion Defect to Each Coronary Territory on Gadobutrol-enhanced CMRI - Secondary Analysis of Specificity Based on Blinded Readers' and Investigator's Assessment|Localization of a Myocardial Perfusion Defect to LAD and Non-LAD Territory on GSPECT - Secondary Analysis of Specificity Based on Blinded Readers' and Investigator's Assessment|Localization of a Myocardial Perfusion Defect to Each Coronary Territory on Gadobutrol-enhanced CMRI - Additional Secondary Analysis of Specificity Based on Blinded Readers' and Investigator's Assessment|Detection of Myocardial Perfusion Defect(s) on Gadobutrol-enhanced CMRI in Participants With Significant LMS Stenosis - Based on Blinded Readers' and Investigator's Assessment|Presence of a Myocardial Perfusion Defect Indicating Significant CAD in Participants With Single or Multi-vessel Disease Evaluated on Gadobutrol-enhanced CMRI - Secondary Analysis of Sensitivity Based on Blinded Readers' and Investigator's Assessment|Presence of a Myocardial Perfusion Defect Indicating Significant CAD in Participants With Single-vessel Disease Evaluated on Gadobutrol-enhanced CMRI and GSPECT - Additional Secondary Analysis of Sensitivity by Majority Blinded Reader and Investigator|Presence of a Myocardial Perfusion Defect Indicating Significant CAD in Participants With Multi-vessel Disease Evaluated on Gadobutrol-enhanced CMRI and GSPECT - Additional Secondary Analysis of Sensitivity by Majority Blinded Reader and Investigator|Number of Participants by Their Lowest Confidence in Diagnosis Obtained on Gadobutrol-enhanced CMRI and Unenhanced Wall Motion CMRI - Based on Blinded Readers' and Investigator's Assessment","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","478","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","15962|2013-000066-11","August 26, 2013","August 6, 2016","November 10, 2016","July 1, 2013","May 16, 2018","July 31, 2019","Tucson, Arizona, United States|Los Angeles, California, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Bethesda, Maryland, United States|Bethesda, Maryland, United States|Boston, Massachusetts, United States|Saint Louis, Missouri, United States|Durham, North Carolina, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Philadelphia, Pennsylvania, United States|Charleston, South Carolina, United States|Houston, Texas, United States|Charlottesville, Virginia, United States|Adelaide, South Australia, Australia|Perth, Western Australia, Australia|Chermside, Australia|North Adelaide, Australia|London, Ontario, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Singapore, Singapore|Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT01890434"
599,"NCT01890421","Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)","GadaCAD 1","Completed","Has Results","Coronary Artery Disease","Drug: Gadobutrol (Gadovist, Gadavist, BAY86-4875)","Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI (Based on RPS) - Primary Analysis of Sensitivity Based on Blinded Readers' Assessment|Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI (Based on RPS) - Additional Secondary Analysis of Sensitivity Based on the Blinded Readers' Assessment|Absence of a Myocardial Perfusion Defect Excluding Significant CAD Per Participant on Gadobutrol-enhanced CMRI (Based on RPS) - Primary Analysis of Specificity Based on the Blinded Readers' Assessment|Absence of a Myocardial Perfusion Defect Excluding Significant CAD Per Participant on Gadobutrol-enhanced CMRI (Based on RPS) - Additional Secondary Analysis of Specificity Based on the Blinded Readers' Assessment|Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI Versus Unenhanced Wall Motion CMRI Images - Primary Analysis of Sensitivity Comparison Based on the Blinded Readers' Assessment|Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI Versus Unenhanced Wall Motion CMRI Images - Additional Secondary Analysis of Sensitivity Comparison Based on the Blinded Readers' Assessment|Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Secondary Analysis of Sensitivity Based on Investigator's Assessment|Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Additional Secondary Analysis of Sensitivity Comparison Based on Investigator's Assessment|Absence of a Myocardial Perfusion Defect Excluding Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Secondary Analysis of Specificity Based on Investigator's Assessment|Absence of a Myocardial Perfusion Defect Excluding Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Additional Secondary Analysis of Specificity Based on Investigator's Assessment|Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI Versus Unenhanced Wall Motion CMRI Images - Secondary Analysis of Sensitivity Comparison Based on Investigator's Assessment|Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI Versus Unenhanced Wall Motion CMRI Images - Additional Secondary Analysis of Sensitivity Comparison Based on Investigator's Assessment|Localization of a Myocardial Perfusion Defect to a Coronary Territory on Gadobutrol-Enhanced CMRI - Secondary Analysis of Sensitivity Based on Blinded Readers' and Investigator's Assessments|Localization of a Myocardial Perfusion Defect to a Coronary Territory on Gadobutrol-enhanced CMRI - Additional Secondary Analysis of Sensitivity Based on Blinded Readers' and Investigator's Assessments|Localization of a Myocardial Perfusion Defect to a Coronary Territory on Gadobutrol-enhanced CMRI - Secondary Analysis of Specificity Based on Blinded Readers' and Investigator's Assessments|Localization of a Myocardial Perfusion Defect to a Coronary Territory on Gadobutrol-enhanced CMRI - Additional Secondary Analysis of Specificity Based on Blinded Readers' and Investigator's Assessments|Detection of Myocardial Perfusion Defect(s) on Gadobutrol-enhanced CMRI in Participants With Significant LMS Stenosis - Based on Blinded Readers' and Investigator's Assessments|Presence/Absence of a MPD Indicating/Excluding Significant CAD in Participants With Multi Versus Single Vessel Disease Evaluated on Gadobutrol-enhanced CMRI-Secondary Analysis of Sensitivity Based on Blinded Readers' and Investigator's Assessments|Presence/Absence of a MPD Indicating/Excluding Significant CAD in Participants With Multi Vs Single Vessel Disease Evaluated on Gadobutrol-enhanced CMRI-Additional Secondary Analysis of Sensitivity Based on Blinded Readers' and Investigator's Assessments|Percentage of Participants by Their Lowest Confidence in Diagnosis Obtained on Gadobutrol-enhanced CMRI and Unenhanced Wall Motion CMRI - Based on Blinded Readers' and Investigator's Assessments","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","426","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","15961|2012-002563-10","July 19, 2013","April 10, 2015","August 31, 2017","July 1, 2013","May 16, 2018","May 16, 2018","Minneapolis, Minnesota, United States|Marseille, France|Saint-Etienne, France|Bad Krozingen, Baden-Württemberg, Germany|Stuttgart, Baden-Württemberg, Germany|Tuebingen, Baden-Württemberg, Germany|Darmstadt, Hessen, Germany|Göttingen, Niedersachsen, Germany|Bonn, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Leipzig, Sachsen, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Incheon, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Yangsan-si, Korea, Republic of|Auckland, New Zealand|Lugano, Ticino, Switzerland|Leicester, United Kingdom|Liverpool, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01890421"
600,"NCT01885104","Safety and Tolerability of Oral Polyethylene Glycol (PEG 3350) Solution in Participants With Constipation (MK-8114-003)",,"Completed","Has Results","Constipation","Drug: Polyethylene Glycol (PEG 3350)|Drug: Placebo|Drug: Bisacodyl laxative tablets (rescue medication)","Number of Participants With Inflammation of the Oral Mucosa|Number of Participants With Inflammation of the Esophageal Mucosa","Bayer","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","65","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","18127|CL2012-13|8114-003","April 2013","September 2013","October 2013","June 24, 2013","September 25, 2014","March 11, 2015",,,"https://ClinicalTrials.gov/show/NCT01885104"
601,"NCT01881217","First-in-man Dose Escalation Study of BAY1179470 in Patients With Advanced, Refractory Solid Tumors",,"Completed","No Results Available","Neoplasms","Drug: BAY1179470","Number of participants with Adverse Events as a Measure of Safety and Tolerability|Maximum drug concentration versus time curve (AUC) from zero to infinity after single (first) and multiple doses of BAY1179470|Maximum drug concentration (Cmax) and minimal drug concentration (Cmin) of BAY1179470 in plasma after single and multiple dose administration|Tumor response|Biomarker (plasma)|Biomarker (biopsy)|Immunogenicity","Bayer","All","20 Years and older   (Adult, Older Adult)","Phase 1","35","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16182","June 28, 2013","March 18, 2016","August 16, 2016","June 19, 2013",,"September 14, 2017","Kashiwa, Chiba, Japan|Kita-Adachigun, Saitama, Japan|Chuo-ku, Tokyo, Japan|Koto-ku, Tokyo, Japan|Fukuoka, Japan|Seoul, Korea, Republic of|Singapore, Singapore|Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT01881217"
602,"NCT01874431","Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy","ARTS-DN","Completed","No Results Available","Diabetic Nephropathies","Drug: Finerenone (BAY 94-8862)|Drug: Placebo","Change of Urinary Albumin-to-Creatinine Ratio (UACR) at Visit 90|Change From Baseline to Day 90 in Serum Potassium|Change From Baseline to Day 90 in Renal Function|Change in Health-Related Quality of Life (HRQoL) (Kidney Disease QOL [KDQOL]-36 Questionnaire)|Change in Health-Related Quality of Life (EuroQol Group 5-Dimension, 3-Level [EQ-5D-3L] Questionnaire)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","823","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","16243|2012-004179-38","June 2013","July 2014","August 2014","June 11, 2013",,"August 13, 2015","Birmingham, Alabama, United States|Chula Vista, California, United States|Los Angeles, California, United States|Los Gatos, California, United States|New Haven, Connecticut, United States|Miami, Florida, United States|Pembroke Pines, Florida, United States|Chicago, Illinois, United States|Chicago, Illinois, United States|Flint, Michigan, United States|Flushing, New York, United States|Orangeburg, South Carolina, United States|Chattanooga, Tennessee, United States|Dallas, Texas, United States|Houston, Texas, United States|Burlington, Vermont, United States|St Leonards, New South Wales, Australia|Clayton, Victoria, Australia|Melbourne, Victoria, Australia|Prahran, Victoria, Australia|Box Hill, Australia|Reservoir, Australia|Woolloongabba, Australia|Graz, Austria|Innsbruck, Austria|Salzburg, Austria|Salzburg, Austria|St. Pölten, Austria|Wien, Austria|Wien, Austria|Wien, Austria|Haskovo, Bulgaria|Lukovit, Bulgaria|Plovdiv, Bulgaria|Ruse, Bulgaria|Sofia, Bulgaria|Stara Zagora, Bulgaria|Varna, Bulgaria|Varna, Bulgaria|Vancouver, British Columbia, Canada|Vancouver, British Columbia, Canada|Courtice, Ontario, Canada|Kitchener, Ontario, Canada|Scarborough, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Quebec, Canada|Bilovec, Czech Republic|Chrudim, Czech Republic|Koprivnice, Czech Republic|Krnov, Czech Republic|Praha 2, Czech Republic|Praha 4, Czech Republic|Praha 4, Czech Republic|Aarhus C, Denmark|Gentofte, Denmark|Herlev, Denmark|Hillerød, Denmark|Holbaek, Denmark|Holstebro, Denmark|Kolding, Denmark|Køge, Denmark|Helsinki, Finland|Jyväskylä, Finland|Oulu, Finland|Tampere, Finland|Turku, Finland|Amiens, France|La Tronche, France|Lyon Cedex, France|Paris Cedex 15, France|Reims, France|Strasbourg, France|Heidelberg, Baden-Württemberg, Germany|Hannover, Niedersachsen, Germany|Bad Oeynhausen, Nordrhein-Westfalen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Ludwigshafen, Rheinland-Pfalz, Germany|Neuwied, Rheinland-Pfalz, Germany|Magdeburg, Sachsen-Anhalt, Germany|Hong Kong, Hong Kong|Shatin, Hong Kong|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Eger, Hungary|Nagykanizsa, Hungary|Papa, Hungary|Ashkelon, Israel|Hadera, Israel|Holon, Israel|Jerusalem, Israel|Kfar Saba, Israel|Petach Tikva, Israel|Tel Aviv, Israel|Tel Aviv, Israel|Tel Hashomer, Israel|Ranica, Bergamo, Italy|Bollate, Milano, Italy|Bergamo, Italy|Cagliari, Italy|Desio, Italy|Milano, Italy|Napoli, Italy|Padova, Italy|Pisa, Italy|San Giovanni Rotondo, Italy|Treviglio, Italy|Busan, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|AlMERE, Netherlands|Eindhoven, Netherlands|Groningen, Netherlands|Hoogeveen, Netherlands|Maastricht, Netherlands|Hamar, Norway|Ålesund, Norway|Bialystok, Poland|Bydgoszcz, Poland|Lodz, Poland|Lodz, Poland|Lublin, Poland|Olawa, Poland|Olsztyn, Poland|Warszawa, Poland|Wroclaw, Poland|Almeda, Portugal|Coimbra, Portugal|Faro, Portugal|Lisboa, Portugal|Lisboa, Portugal|Lisboa, Portugal|Klipsruit West, Gauteng, South Africa|Krugersdorp, Gauteng, South Africa|Lenasia South, Gauteng, South Africa|Newtown, Gauteng, South Africa|Parktown, Gauteng, South Africa|Durban, KwaZulu Natal, South Africa|Durban, KwaZulu Natal, South Africa|Durban, Kwazulu-Natal, South Africa|Merebank, Kwazulu-Natal, South Africa|Tongaat, Kwazulu-Natal, South Africa|Cape Town, Western Cape, South Africa|Goodwood, Western Cape, South Africa|Somerset West, Western Cape, South Africa|Worcester, Western Cape, South Africa|Ferrol, A Coruña, Spain|Jerez de la Frontera, Cádiz, Spain|Sagunto, Valencia, Spain|Barcelona, Spain|Girona, Spain|Madrid, Spain|Madrid, Spain|Karlstad, Sweden|Kristianstad, Sweden|Skövde, Sweden|Stockholm, Sweden|Stockholm, Sweden|Stockholm, Sweden|Uppsala, Sweden|Vällingby, Sweden|Örebro, Sweden|Kaohsiung, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01874431"
603,"NCT01861886","The Safety and Effectiveness of the Essure (Model ESS505) Device to Prevent Pregnancy in Women",,"Completed","No Results Available","Contraception","Device: ESS505 (BAY1454033)","Occurrence of confirmed pregnancy at 3 months among successful bilateral implant subjects relying solely on the ESS505 for contraception.|Occurrence of confirmed pregnancy at 12 months among successful bilaterally implant subjects relying solely on the ESS505 for contraception|Frequency (number) of reported ESS505 placement procedure-related AEs|Severity of reported ESS505 placement procedure-related AEs|Frequency (number) of reported ESS505 (device) wearing-related AEs|Severity of reported ESS505 wearing-related AEs","Bayer","Female","21 Years to 44 Years   (Adult)","Not Applicable","73","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","16972|ESS505-003","January 31, 2013","December 19, 2013","September 30, 2014","May 24, 2013",,"March 21, 2017","Hoofddorp, Netherlands|Nieuwegein, Netherlands|Tiel, Netherlands|Zwolle, Netherlands|Córdoba, Spain",,"https://ClinicalTrials.gov/show/NCT01861886"
604,"NCT01855139","Belgian Real Life Non-interventional Study (NIS) on Xarelto in Non-valvular Atrial Fibrillation (AF) Patients Treated for the Prevention of Stroke and Systemic Embolism","BOX-AF","Completed","No Results Available","Atrial Fibrillation","Drug: Rivaroxaban (Xarelto, BAY59-7939)","Number of patients with major bleedings|Number of patients with symptomatic thromboembolic events|All-cause mortality|Adverse events|Treatment satisfaction measured by means of Anti-clot treatment scale (ACTS)|Quantities of resource use consumption","Bayer|Janssen Scientific Affairs, LLC","All","18 Years and older   (Adult, Older Adult)",,"106","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16851|XA1313BE","July 2013","October 2014","December 2014","May 16, 2013",,"January 18, 2017","Many locations, Belgium",,"https://ClinicalTrials.gov/show/NCT01855139"
605,"NCT01855100","Belgian Real Life Non-interventional Study (NIS) in Patients Treated With Xarelto Following an Acute Deep Vein Thrombosis (DVT)","BOX-DVT","Completed","No Results Available","Venous Thrombosis","Drug: Rivaroxaban (Xarelto, BAY59-7939)","Number of patients with major bleedings|Number of patients with symptomatic recurrent Venous Thrombus Embolism (VTE)|All-cause mortality|Adverse events|Treatment satisfaction measured by means of Anti-clot treatment scale (ACTS)|Quantities of resource use consumption","Bayer|Janssen Scientific Affairs, LLC","All","18 Years and older   (Adult, Older Adult)",,"131","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16852|XA1314BE","July 2013","November 2014","December 2014","May 16, 2013",,"January 18, 2017","Many locations, Belgium",,"https://ClinicalTrials.gov/show/NCT01855100"
606,"NCT01853800","Relative Bioavailability of Oral Suspension of Rivaroxaban Compared to Standard Tablet",,"Completed","No Results Available","Biological Availability","Drug: Rivaroxaban (Xarelto, BAY59-7939)","Area Under the Concentration Versus Time Curve From Zero to Infinity After a Single Dose (AUC)|Area Under the Concentration Versus Time Curve From Zero to Infinity Divided by Dose (AUC/D)|Maximum Observed Drug Concentration in Measured Matrix After a Single Dose (Cmax)|Maximum Observed Drug Concentration in Measured Matrix Divided by Dose (Cmax/D)|Area Under the Concentration Versus Time Curve From Zero to Infinity Divided by Dose per Kilogram Body Weight (AUC,norm)|Area Under the Concentration Versus Time Curve From Zero to Last Quantifiable Concentration [AUC(0tlast)]|Maximum Observed Drug Concentration Divided by Dose per Kilogram Body Weight (Cmax,norm)|Mean Residence Time (MRT)|Maximum Observed Drug Concentration Divided by Drug Concentration at 24 hours (Cmax/C24h)|Time to Reach Maximum Observed Drug Concentration (tmax)|Terminal Half Life (t1/2)","Bayer|Janssen Research & Development, LLC","Male","18 Years to 55 Years   (Adult)","Phase 1","14","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","16886|2013-001720-19","May 2013","July 2013","August 2013","May 15, 2013",,"January 23, 2017","Wuppertal, Nordrhein-Westfalen, Germany",,"https://ClinicalTrials.gov/show/NCT01853800"
607,"NCT01853319","Regorafenib in Subjects With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy","REGARD","Completed","No Results Available","Colorectal Neoplasms","Drug: Regorafenib (Stivarga, BAY73- 4506)","Number of participants with adverse events as a measure of safety and tolerability|Number of participants with adverse events which caused withdrawal, dose reduction, interruption or discontinuation|Number of death|Number of participants with serious adverse events as a measure of safety and tolerability|Progression-Free Survival (PFS)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","100","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16754","July 24, 2013","April 24, 2015","June 11, 2018","May 15, 2013",,"April 22, 2019","Ankara, Turkey|Ankara, Turkey|Antalya, Turkey|Balcali/Adana, Turkey|Bursa, Turkey|Gaziantep, Turkey|Istanbul, Turkey|Istanbul, Turkey|Izmir, Turkey|Kayseri, Turkey|Samsun, Turkey",,"https://ClinicalTrials.gov/show/NCT01853319"
608,"NCT01853046","Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment",,"Completed","Has Results","Neoplasms","Drug: Regorafenib (Stivarga, BAY73-4506)","AUC(0-tlast) [Area Under the Concentration-time Curve After Single (First) Dose From Time Zero to the Last Data Point >LLOQ (Lower Limit of Quantification)] for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5|AE,ur(0-24) (Amount of Drug Excreted Via Urine During the Collection Interval 0-24 Hours Post Administration) for Metabolites M-7 and M-8|AUC (Area Under the Plasma Concentration vs. Time Curve From Zero to Infinity After Single (First) Dose) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5|AUC(0-24) (AUC From Time Zero to 24 Hours p.a. After Single (First) Dose Administration) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5|Cmax (Maximum Drug Concentration in Plasma After Single (First) Dose Administration) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5|Tmax (Time to Reach Maximum Drug Concentration in Plasma After Single (First) Dose) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5|Tlast (Time of Last Data Point >LLOQ) After Single (First) Dose for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5|t1/2 (Half-life Associated With the Terminal Slope) After Single (First) Dose for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5|CL/F (Total Body Clearance of Drug After Extravascular Administration) After Single (First) Dose for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5|Vz/F (Apparent Volume of Distribution During Terminal Phase After Single (First) Oral Administration) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5|AUC(0-24)md ((AUC(0-24) After Multiple-dose Administration) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5|Cmax,md (Cmax After Multiple-dose Administration) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5|AUC(0-tlast)md (AUC(0-tlast) After Multiple-dose Administration) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5|Tmax,md (Time to Reach Maximum Drug Concentration in Plasma After Multiple-dose Administration) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5|Tlast,md (Tlast After Multiple-dose Administration) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5|RACmax (Accumulation Ratio Calculated From Cmax,md and Cmax) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5|RAAUC (Accumulation Ratio Calculated From AUC(0-24)md and AUC(0-24)) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5|RLin (Linearity Factor Calculated as Ratio From AUC(0-24)md and AUC) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5|AE,ur(0-24)md (AE,ur(0-24) After Multiple-dose Administration) for Metabolites M-7 and M-8|AE,ur(0-10) Stage 1 (Amount of Drug Excreted Via Urine During the Collection Interval 0-10 Hours Post Administration) for Metabolites M-7 and M-8|AE,ur(10-24) Stage 1 ((Amount of Drug Excreted Via Urine During the Collection Interval 10-24 Hours Post Administration) for Metabolites M-7 and M-8|AE,ur(0-10) Stage 2 for Metabolites M-7 and M-8|AE,ur(10-24) Stage 2 for Metabolites M-7 and M-8","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16653","June 2013","July 2015","November 2015","May 14, 2013","February 20, 2017","February 20, 2017","Los Angeles, California, United States|Aurora, Colorado, United States|St. Louis, Missouri, United States|Lebanon, New Hampshire, United States|Buffalo, New York, United States|Edmonton, Alberta, Canada|Vancouver, British Columbia, Canada|Hamilton, Ontario, Canada|Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01853046"
609,"NCT01843400","Regorafenib Post-marketing Surveillance",,"Completed","No Results Available","Colorectal Neoplasms","Drug: Regorafenib (Stivarga, BAY73-4506)","Number of patients with adverse drug reactions (ADRs) from the first administration of regorafenib|Number of patients with serious adverse events(SAEs) from the first administration of regorafenib.|Number of pateints with ADRs in subpopulations|Number of patients with SAEs in supopulations|Overall survival (OS)|Overall survival in subpopulations|Time to treatment failure (TTF)|Time to Treatment failure in subpopulations|Tumor response assessed by RECIST or physicians own evaluation","Bayer","All","Child, Adult, Older Adult",,"1301","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16472|STIVARGA-CRC-01","April 22, 2013","September 12, 2016","November 14, 2016","April 30, 2013",,"August 2, 2018","Multiple Locations, Japan",,"https://ClinicalTrials.gov/show/NCT01843400"
610,"NCT01839630","Sorafenib Concomitantly Used With TACE (Transarterial Chemoembolization) in uHCC (Unresectable Hepatocellular Carcinoma) Patients in China","SUCCESS","Completed","No Results Available","Carcinoma, Hepatocellular","Drug: Sorafenib (Nexavar, BAY43-9006)","Summarized patient characteristics|Number of participants with adverse events( AE) and Serious adverse events(SAE) as a measure of safety and tolorability|overall survival (OS) by the mRECIST (Modified Response Evaluation Criteria in Solid Tumor) Criteria for treatment of uHCC patients|progression-free survival (PFS) by the mRECIST for treatment of uHCC patients|time to progression (TTP) by the mRECIST for treatment of uHCC patients|response rate (RR) by the mRECIST for treatment of uHCC patients|Clinical control Rate (DCR) by the mRECIST for treatment of uHCC patients|Clinical benefit rate (CBR) by the mRECIST for treatment of uHCC patients|Treatment pattern of Sorafenib","Bayer","All","Child, Adult, Older Adult",,"302","Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","16608|NX1216CN","May 30, 2013","August 6, 2016","December 29, 2016","April 25, 2013",,"December 20, 2017","Multiple Locations, China",,"https://ClinicalTrials.gov/show/NCT01839630"
611,"NCT01839357","Exploring the Efficacy of Once Daily Oral Rivaroxaban for Treatment of Thrombus in Left Atrial/Left Atrial Appendage in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter","X-TRA","Completed","No Results Available","Atrial Fibrillation","Drug: Rivaroxaban (Xarelto, BAY59-7939)","The percentage of subjects with complete resolution of left atrial or left atrial appendage thrombus at the end of treatment|Categories of thrombus outcome in subjects: resolved, reduced, unchanged, enlarged or new|The composite number of stroke and non-central nervous system systemic embolism events|The number of all bleeding events","Bayer|Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 3","60","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16320|2012-001062-15","August 2013","November 2014","December 2014","April 24, 2013",,"July 25, 2016","Plovdiv, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Creteil, France|Marseille, France|Paris, France|TOULOUSE cedex, France|Bonn, Nordrhein-Westfalen, Germany|Leipzig, Sachsen, Germany|Berlin, Germany|Hamburg, Germany|Krakow, Poland|Lodz, Poland|Lublin, Poland|Warszawa, Poland|Warszawa, Poland|Wroclaw, Poland|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Saratov, Russian Federation|St. Petersburg, Russian Federation|Istanbul, Turkey|Istanbul, Turkey|Istanbul, Turkey|Samsun, Turkey|Donetsk, Ukraine|Kiev, Ukraine|Odesa, Ukraine|Uzhhorod, Ukraine",,"https://ClinicalTrials.gov/show/NCT01839357"
612,"NCT01833793","Descriptive, Prospective, Non-interventional Study (NIS) to Describe Mirena and Amenorrhea Related Acceptability in Contraception Indication in Medical Practice","MARILIA","Completed","No Results Available","Female Contraception","Drug: Levonorgestrel IUD (Mirena, BAY86-5028)","Proportion of Mirena users who have at least one period of Amenorrhea of at least three months|Cumulative incidence rate of Amenorrhea over the duration of follow up period in Mirena users|Proportion of Mirena users who have menstrual disorders|Proportion of Mirena users with menorrhagia|Cumulative rate of satisfaction in Mirena users","Bayer","Female","18 Years to 40 Years   (Adult)",,"35","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16314|MA1211DZ","February 2013","November 2014","May 2015","April 17, 2013",,"September 14, 2015","Many Locations, Algeria",,"https://ClinicalTrials.gov/show/NCT01833793"
613,"NCT01822080","Phase 3 Study of Dienogest for the Treatment of Endometriosis in Chinese Patients",,"Completed","No Results Available","Endometriosis","Drug: Dienogest (Visanne, BAY86-5258)|Drug: Placebo","Change of endometriosis associated pelvic pain (EAPP) measured by visual analog scale (VAS) from baseline to 24 weeks|Percentage of treatment responders|Score on B&B (Biberoglu and Behrman severity profile for symptoms and findings)|Quality of life assessed by patient questionnaire|Number of participants with adverse events as a measure of safety and tolerability|Vaginal bleeding intensity recorded by patient diary and measured on a 5-point scale (none, spotting, light, normal, heavy)","Bayer","Female","18 Years to 45 Years   (Adult)","Phase 3","250","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","13390","March 2013","April 2015","November 2015","April 2, 2013",,"November 25, 2015","Guangzhou, Guangdong, China|Shijiazhuang, Hebei, China|Wuhan, Hubei, China|Hengyang, Hunan, China|Changchun, Jilin, China|Dalian, Liaoning, China|Shenyang, Liaoning, China|Xi'an, Shaanxi, China|Chengdu, Sichuan, China|Chengdu, Sichuan, China|Hangzhou, Zhejiang, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Chongqing, China|Chongqing, China|Chongqing, China|Kunming, China|Shanghai, China|Shanghai, China|Shanghai, China",,"https://ClinicalTrials.gov/show/NCT01822080"
614,"NCT01818544","Safety and Efficacy of Oral BAY85-8501 in Patients With Non-CF (Cystic Fibrosis) Bronchiectasis",,"Completed","No Results Available","Bronchiectasis","Drug: BAY85-8501|Drug: Placebo","Number Of Subjects Who Need To Discontinue Study Medication Due To Findings In Physical Examination|Change From Baseline in Systolic Blood Pressure At Days 7, 14, 21, 28, 56|Change From Baseline in Diastolic Blood Pressure At Days 7, 14, 21, 28, 56|Change From Baseline in Heart Rate At Days 7, 14, 21, 28, 56|Number of Subjects With new Abnormal (Pathologic) Electrocardiogram (ECG) Findings From Baseline to Day 28|Number of Subjects who Show Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Total Bilirubin (TB) Abnormalities in Their Safety Lab Assessment|Number of Subjects With Drug Related Adverse Events as a Measure of Safety And Tolerability|Change From Baseline in Pulmonary Function Test Forced Expired Volume in 1 Second (FEV1) At Days 7, 14, 21, 28, 56|Change From Baseline in Pulmonary Function Test Forced Vital Capacity (FVC) at Days 7, 14, 21, 28, 56|Change From Baseline in Pulmonary Function Test Forced Expiratory Flow Over the Middle Half of Subject's Forced Vital Capacity (FVC) (FEF2575) at Days 7, 14, 21, 28, 56|Change From Baseline in Total Score on St. George's Respiratory Questionnaire (SGRQ) at Day 28 and 56|Change From Baseline in 24 Hours Sputum Weight at Day 28|Change From Baseline of Biomarkers in Sputum at Days 14, 28, 56: Alpha1 Antitrypsin Human Neutrophil Elastase (A1AHNE) Complex, Interleukin-8(IL-8)|Change From Baseline of Biomarkers in Sputum at Days 14, 28, 56: Neutrophil cell Count|Change From Baseline of Human Neutrophil Elastase (NE) Activity in Sputum at Days 14, 28, 56|Change From Baseline of Human Neutrophil Elastase (NE) Concentration in Sputum at Days 14, 28, 56|Change From Baseline of Biomarkers in Blood at Days 14, 28, 56: C-reactive Protein|Change From Baseline of Biomarkers in Blood at Days 14, 28, 56: Interleukin-8 (IL8)|Change From Baseline of Biomarkers in Blood at Days 14, 28, 56: Neutrophil cell Count|Change From Baseline of Biomarkers in Urine At Days 14, 28, 56: Creatinine|Change From Baseline of Biomarkers in Urine at Days 14, 28, 56: Desmosine|Change From Baseline of Biomarkers in Urine at Days 14, 28, 56: Normalized Desmosine Value to Creatinine","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","94","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","16359|2012-004491-18","April 2013","June 2014","June 2014","March 26, 2013",,"July 9, 2015","Nice, France|Perpignan, France|Donaustauf, Bayern, Germany|Rüdersdorf, Brandenburg, Germany|Hannover, Niedersachsen, Germany|Leipzig, Sachsen, Germany|Großhansdorf, Schleswig-Holstein, Germany|Kiel, Schleswig-Holstein, Germany|Lübeck, Schleswig-Holstein, Germany|Jena, Thüringen, Germany|Hamburg, Germany|Orbassano, Torino, Italy|Genova, Italy|Milano, Italy|Napoli, Italy|Padova, Italy|Siena, Italy|Badalona, Barcelona, Spain|Salt, Girona, Spain|Majadahonda, Madrid, Spain|Madrid, Spain|Southampton, Hampshire, United Kingdom|Cottingham, Humberside, United Kingdom|Leicester, Leicestershire, United Kingdom|Liverpool, Merseyside, United Kingdom|Sheffield, South Yorkshire, United Kingdom|Dundee, Tayside, United Kingdom|Newcastle Upon Tyne, Tyne and Wear, United Kingdom|South Shields, Tyne and Wear, United Kingdom|Wolverhampton, West Midlands, United Kingdom|Bradford, West Yorkshire, United Kingdom|Glasgow, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01818544"
615,"NCT01817868","Comparison of Efficacy, Safety and Costs of Recombinant FVIII Products Between On-demand and Secondary Prophylaxis Groups in Haemophilia A Patients",,"Completed","No Results Available","Hemophilia","Other: Recombinant Factor VIII (Kogenate, BAY14-2222)","Median ±SD, range of number of joint bleeds per year of prophylaxis versus on-demand group|Mean ±SD, range of number of joint bleeds per year of prophylaxis versus on-demand group|Number of overall bleeding episodes|Musculoskeletal evaluation recommended by World Federation of Hemophilia: Orthopedic Joint Score (Gilbert Score)|Musculoskeletal evaluation recommended by World Federation of Hemophilia: Radiological evaluation (Pettersson Score)|Cost-effectiveness (cost of additional joint bleed)|Cost-utility|Comparison of patient compliance between prophylaxis and on-demand therapy groups|Number of spontaneous bleeds|Quality of life as measured with the SF-36|Quality of life as measured with Hemo-QoL","Bayer","All","18 Years and older   (Adult, Older Adult)",,"73","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16368|KG1210TR","January 4, 2013","July 16, 2018","May 23, 2019","March 26, 2013",,"June 20, 2019","Multiple Locations, Turkey",,"https://ClinicalTrials.gov/show/NCT01817868"
616,"NCT01816815","Study in Healthy Tubal Ligated Women to Evaluate Pharmacodynamics, Safety and Pharmacokinetics of BAY1002670",,"Completed","No Results Available","Leiomyoma","Drug: BAY1002670|Drug: Placebo","Non-bleeding rate (i.e. women without bleeding from treatment day 9 until the end of treatment)|Return of menstrual bleeding after treatment","Bayer","Female","18 Years to 45 Years   (Adult)","Phase 1","73","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","14723|2011-001760-22","November 2011","October 2012","January 2013","March 22, 2013",,"April 21, 2014","Antwerpen, Belgium|Neu-Ulm, Bayern, Germany|Neuss, Nordrhein-Westfalen, Germany|Berlin, Germany|Berlin, Germany|Belfast, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01816815"
617,"NCT01810770","Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis",,"Completed","No Results Available","Prostatic Neoplasms","Drug: Radium-223 dichloride (Xofigo, BAY88-8223)","Number of participants with adverse events as a measure of safety and tolerability|Number of participants with laboratory changes|Number of participants with changes in vital signs|Number of participants with changes in electrocardiogram (ECG)|Overall Survival (OS)|Changes in total Alkaline Phosphate (ALP) in serum|Number of participants with total-ALP normalization|Time to total ALP progression|Changes in prostate specific antigen (PSA) in serum|Time to PSA progression|Time to first skeletal related event (SRE)|SRE free survival|Time to occurrence of first use of radio-isotopes to relieve skeletal symptoms|Time to occurrence of first start of any other anti-cancer treatment|Time to occurrence of first deterioration of Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)|Quality of life (QoL)|Time to pain progression","Bayer","Male","18 Years and older   (Adult, Older Adult)","Phase 3","243","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15397","March 26, 2013","September 25, 2017","September 25, 2017","March 14, 2013",,"September 19, 2018","Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Nanjing, Jiangsu, China|Nanjing, Jiangsu, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Guangzhou, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|Donggu,, Gwangju Gwang''yeogsi, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|Taipei City, Taipei, Taiwan|Kaohsiung, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT01810770"
618,"NCT01810666","Prophylaxis Versus on Demand Treatment for Children With Hemophilia A",,"Completed","Has Results","Hemophilia A","Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)","Difference of Annualized Number of All Bleeds Between On-demand and Prophylaxis Period|Difference of Annualized Number of Joint Bleeds Between On-demand and Prophylaxis Period|Difference of Intra-individual Change of Joint Function During Each Period Assessed by the Hemophilia Joint Health Score Between On-demand and Prophylaxis Period","Bayer","Male","2 Years to 16 Years   (Child)","Phase 4","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16287|2014-001362-10","March 2013","January 2014","January 2014","March 13, 2013","January 5, 2015","May 19, 2015","Guangzhou, Guangdong, China|Wuhan, Hubei, China|Beijing, China|Beijing, China|Tianjin, China",,"https://ClinicalTrials.gov/show/NCT01810666"
619,"NCT01810653","A Study to Compare the Effect of Transipeg 2.95 g or Forlax Junior 4 g in Children With Constipation",,"Completed","No Results Available","Constipation","Drug: Macrogol (Transipeg, BAY81-8430)|Drug: Macrogol (Forlax)","Symptom Based Weekly Total Sum Score (TSS) Over 52 Weeks|Change From Baseline in Total Sum Score (TSS) at Week 52|Short Term Change of Total Sum Score (TSS): Average of Weeks 1 to 8 Minus Baseline|Long Term Change of Total Sum Score (TSS): Average of Weeks 26 and 52 Minus Baseline|Overall Change of Total Sum Score (TSS): Average of all Diaries Obtained Minus Baseline|Dose Range Determination: Mean Dose Based on Sachets Used|Dose Range Determination: Mean Dose per Kilogram Body Weight Based on Sachets Used|Percentage of Treatment Success|Individual Symptoms: Defecation Frequency|Individual Symptoms: Consistency of the Feces|Individual Symptoms: Strains During Defecation|Individual Symptoms: Quantity of Stools|Individual Symptoms: Percentage of Subjects With Pain During Defecation|Individual Symptoms: Frequency of Pain (Times per Week)|Percentage of Subjects With Abdominal Pain|Individual Symptoms: Frequency of Abdominal Pain (Times per Week)|Individual Symptoms: Relation of Abdominal Pain With Defecation|Individual Symptoms: Fecal Incontinence (Times per Week) and Fecal Incontinence (Times per Week) at Night|Individual Symptoms: Percentage of Subjects with Fecal Incontinence at Specified Time points|Individual Symptoms: Percentage of Subjects With Urgency for Defecation|Individual Symptoms: Frequency of Urgency for Defecation (Times per Week)|Individual Symptoms: Percentage of Subjects With Urine Incontinence (UI) During Day and Night|Individual Symptoms: Frequency of Urine Incontinence During Day and Night (Times per Week)|Individual Symptoms: Percentage of Subjects With Good, Moderate or Bad Appetite|Individual Symptoms: Average Score for Diary Reported Diarrhoea|Individual Symptoms: Average Score for Diary Reported Flatulence|Individual Symptoms: Average Score for Diary Reported Nausea","Bayer","All","6 Months to 15 Years   (Child)","Phase 4","97","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","12052|2015-000081-63","April 2006","December 2008","December 2008","March 13, 2013",,"August 13, 2015","Amsterdam, Netherlands|Eindhoven, Netherlands|Veldhoven, Netherlands|Woerden, Netherlands",,"https://ClinicalTrials.gov/show/NCT01810653"
620,"NCT01807221","Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone","ARTS-HF","Completed","No Results Available","Heart Failure","Drug: Finerenone (BAY94-8862)|Drug: Placebo|Drug: Inspra (eplerenone)","Relative decrease in N-terminal prohormone B-type natriuretic peptide (NT-proBNP)|Change in serum potassium|Change in blood pressure|Change in heart rate|Number of participants with adverse events as a measure of safety and tolerability","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","1058","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","14564|2012-002627-15","June 2013","November 2014","December 2014","March 8, 2013",,"October 17, 2016","Birmingham, Alabama, United States|La Jolla, California, United States|Los Angeles, California, United States|San Francisco, California, United States|Ft. Lauderdale, Florida, United States|Jacksonville, Florida, United States|Atlanta, Georgia, United States|Macon, Georgia, United States|New Orleans, Louisiana, United States|New Orleans, Louisiana, United States|Baltimore, Maryland, United States|Detroit, Michigan, United States|Detroit, Michigan, United States|Petoskey, Michigan, United States|Newark, New Jersey, United States|Hickory, North Carolina, United States|Fairfield, Ohio, United States|Philadelphia, Pennsylvania, United States|Darlinghurst, New South Wales, Australia|Adelaide, South Australia, Australia|Concord, Australia|Geelong, Australia|Herston, Australia|Prahran, Australia|Krems an der Donau, Niederösterreich, Austria|Linz, Oberösterreich, Austria|Graz, Steiermark, Austria|Graz, Steiermark, Austria|Innsbruck, Tirol, Austria|Salzburg, Austria|Wien, Austria|Wien, Austria|Burgas, Bulgaria|Pazardjik, Bulgaria|Ruse, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Calgary, Alberta, Canada|Vancouver, British Columbia, Canada|Victoria, British Columbia, Canada|Cambridge, Ontario, Canada|Hamilton, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Saint-Jean-sur-Richelieu, Quebec, Canada|Sherbrooke, Quebec, Canada|St-Charles-Borromee, Quebec, Canada|Quebec, Canada|Brno, Czech Republic|Jindrichuv Hradec, Czech Republic|Liberec, Czech Republic|Ostrava, Czech Republic|Plzen - Bory, Czech Republic|Praha 5, Czech Republic|Slany, Czech Republic|Valasske Mezirici, Czech Republic|Copenhagen Ø, Denmark|Esbjerg, Denmark|Glostrup, Denmark|Hellerup, Denmark|Herlev, Denmark|Hvidovre, Denmark|København NV, Denmark|Køge, Denmark|Odense, Denmark|Svendborg, Denmark|Viborg, Denmark|Espoo, Finland|Helsinki, Finland|Jyväskylä, Finland|Rovaniemi, Finland|Turku, Finland|Bron, France|Creteil, France|Nice, France|PARIS cedex 10, France|Paris cedex 13, France|Rouen, France|Toulouse, France|Vandoeuvre les Nancy, France|Würzburg, Bayern, Germany|Frankfurt, Hessen, Germany|Limburg, Hessen, Germany|Göttingen, Niedersachsen, Germany|Hannover, Niedersachsen, Germany|Stade, Niedersachsen, Germany|Bad Oeynhausen, Nordrhein-Westfalen, Germany|Bochum, Nordrhein-Westfalen, Germany|Mönchengladbach, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Homburg, Saarland, Germany|Erfurt, Thüringen, Germany|Berlin, Germany|Athens, Greece|Athens, Greece|Haidari, Greece|Larissa, Greece|Nea Ionia / Athens, Greece|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Nagykanizsa, Hungary|Szekesfehervar, Hungary|Afula, Israel|Ashkelon, Israel|Hadera, Israel|Haifa, Israel|Jerusalem, Israel|Kfar Saba, Israel|Nahariya, Israel|Petah Tikva, Israel|Rehovot, Israel|Tel Aviv, Israel|Zefat, Israel|Zerifin, Israel|Roma, Lazio, Italy|Bergamo, Lombardia, Italy|Milano, Lombardia, Italy|Monza, Lombardia, Italy|Foggia, Puglia, Italy|Arezzo, Toscana, Italy|Pisa, Toscana, Italy|Perugia, Umbria, Italy|Wonju-si, Gang''weondo, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Kaunas, Lithuania|Kaunas, Lithuania|Kaunas, Lithuania|Klaipeda, Lithuania|Klaipeda, Lithuania|Vilnius, Lithuania|Amsterdam, Netherlands|Delft, Netherlands|Groningen, Netherlands|Groningen, Netherlands|Hoogeveen, Netherlands|Nijmegen, Netherlands|Rotterdam, Netherlands|Veldhoven, Netherlands|Zutphen, Netherlands|Bodø, Norway|Haugesund, Norway|Stavanger, Norway|Tromsø, Norway|Tønsberg, Norway|Bialystok, Poland|Bydgoszcz, Poland|Gdansk, Poland|Katowice, Poland|Kielce, Poland|Krakow, Poland|Szczecin, Poland|Warszawa, Poland|Warszawa, Poland|Wroclaw, Poland|Almada, Portugal|Faro, Portugal|Lisboa, Portugal|Lisboa, Portugal|Lisboa, Portugal|Porto, Portugal|Petoria, Gauteng, South Africa|Isipingo Rail, Kwazulu-Natal, South Africa|Merebank, Kwazulu-Natal, South Africa|Tongaat, Kwazulu-Natal, South Africa|Cape Town, Western Cape, South Africa|Kuils River, Western Cape, South Africa|Pinelands, Western Cape, South Africa|Somerset West, Western Cape, South Africa|Worcester, Western Cape, South Africa|Olot, Girona, Spain|Majadahonda, Madrid, Spain|El Palmar, Murcia, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Valencia, Spain|Valencia, Spain|Falun, Sweden|Göteborg, Sweden|Stockholm, Sweden|Stockholm, Sweden|Stockholm, Sweden|Umeå, Sweden|Örebro, Sweden|New Taipei City, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taizung, Taiwan|Ankara, Turkey|Ankara, Turkey|Ankara, Turkey|Antalya, Turkey|Izmir, Turkey",,"https://ClinicalTrials.gov/show/NCT01807221"
621,"NCT01805544","Satisfaction/Quality of Life With Rivaroxaban in DVT (Deep Venous Thrombosis) Indication","SATORI","Completed","No Results Available","Venous Thrombosis","Drug: Rivaroxaban (Xarelto, BAY59-7939)","Change of the Anti Clot Treatment Scale (ACTS) score at 3 months compared with baseline score|Change of ACTS score after 1 and 6 months of treatment|Continuation rate at 1, 3 and 6 months|Change of SF36 score at 1, 3 and 6 months (health related quality of life determined by SF36 questionnaire)|Physician's satisfaction at 1, 3 and 6 months assessed by a 5-point Likert scale response (""very satisfied"", ""satisfied"", ""neutral"", ""unsatisfied"" or ""very unsatisfied"")|Patient's compliance with VKA treatment at baseline and with Xarelto treatment at 1, 3 and 6 months assessed by the investigator as good (≥80%), average (50-80%) or poor (<50%)","Bayer|Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)",,"113","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16409|XA1214FR","May 2013","April 2015","June 2015","March 6, 2013",,"January 23, 2017","Many locations, France",,"https://ClinicalTrials.gov/show/NCT01805544"
622,"NCT01805531","Satisfaction/Quality of Life With Rivaroxaban in SPAF (Stroke Prevention in Atrial Fibrillation) Indication","SAFARI","Completed","No Results Available","Atrial Fibrillation","Drug: Rivaroxaban (Xarelto, BAY59-7939)","Change of the Anti Clot Treatment Scale (ACTS) score at 3 months compared with baseline score|Change of ACTS score after 1 and 6 months of treatment|Continuation rate at 1, 3 and 6 months|Change of SF36 score at 1, 3 and 6 months (health related quality of life determined by SF36 questionnaire)|Physician's satisfaction at 1, 3 and 6 months assessed by a 5-point Likert scale response (""very satisfied"", ""satisfied"", ""neutral"", ""unsatisfied"" or ""very unsatisfied"")|Patient's compliance with VKA treatment at baseline and with Xarelto treatment at 1, 3 and 6 months assessed by the investigator as good (≥80%), average (50-80%) or poor (<50%)","Bayer|Janssen Scientific Affairs, LLC","All","18 Years and older   (Adult, Older Adult)",,"411","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16398|XA1213FR","April 2013","January 2015","March 2015","March 6, 2013",,"January 18, 2017","Many locations, France",,"https://ClinicalTrials.gov/show/NCT01805531"
623,"NCT01800006","Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Latinamerica and EMEA Region","XANTUS-EL","Completed","No Results Available","Atrial Fibrillation","Drug: Rivaroxaban (Xarelto, BAY59-7939)","Adjudicated major bleeding events|Safety variables will be summarized using descriptivestatistics based on adverse events collection|All cause mortality|Adjudicated symptomatic thromboembolic events|Non-major bleeding, collected as SAEs or non-serious AEs and defined as all bleeding events that do not fall in the category of major bleedings|Treatment satisfaction|Adverse events rates in the different AF risk factor categories|Persistence with rivaroxaban treatment|Reasons for switch of rivaroxaban treatment|Reasons for interruption of rivaroxaban treatment|Healthcare resource","Bayer|Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)",,"2101","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16691|XA1206","January 14, 2013","January 16, 2016","June 20, 2016","February 27, 2013",,"June 21, 2017","Many Locations, Argentina|Many Locations, Azerbaijan|Many Locations, Bahrain|Many Locations, Chile|Many Locations, Colombia|Many Locations, Egypt|Many Locations, Georgia|ManyLocations, Jordan|Many Locations, Kazakhstan|Many Locations, Kenya|ManyLocations, Lebanon|Many Locations, Mexico|Many Locations, Russian Federation|ManyLocations, Saudi Arabia|Many Locations, United Arab Emirates|Many Locations, Uruguay|Many Locations, Venezuela",,"https://ClinicalTrials.gov/show/NCT01800006"
624,"NCT01799993","Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia","INHALE 1","Completed","Has Results","Pneumonia, Bacterial","Drug: Amikacin Inhalation Solution (BAY41-6551)|Drug: Aerosolized Placebo","Number of Participants Surviving Through LFU Visit|Number of Participants With Adjudicated Pneumonia-Related Death Through LFU Visit|Number of Participants With Early Clinical Response|Number of Days on Mechanical Ventilation Through LFU Visit|Number of Days in the ICU Through LFU Visit","Bayer|Nektar Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 3","725","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","13084|2013-001048-73","April 13, 2013","April 7, 2017","April 7, 2017","February 27, 2013","June 26, 2018","July 23, 2018","Birmingham, Alabama, United States|Mobile, Alabama, United States|Phoenix, Arizona, United States|Danbury, Connecticut, United States|Hartford, Connecticut, United States|Newark, Delaware, United States|Hollywood, Florida, United States|Miami, Florida, United States|Tampa, Florida, United States|Atlanta, Georgia, United States|Springfield, Illinois, United States|Muncie, Indiana, United States|Iowa City, Iowa, United States|Hazard, Kentucky, United States|Kalamazoo, Michigan, United States|Saint Louis, Missouri, United States|Springfield, Missouri, United States|Butte, Montana, United States|Las Vegas, Nevada, United States|Brooklyn, New York, United States|Mineola, New York, United States|New York, New York, United States|New York, New York, United States|Asheville, North Carolina, United States|Greensboro, North Carolina, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Youngstown, Ohio, United States|Oklahoma City, Oklahoma, United States|Charleston, South Carolina, United States|Blacktown, New South Wales, Australia|Clayton, Victoria, Australia|Wollongong, Australia|Belo Horizonte, Minas Gerais, Brazil|Campinas, Sao Paulo, Brazil|São José do Rio Preto, Sao Paulo, Brazil|Kingston, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Quebec, Canada|Barranquilla, Atlántico, Colombia|Cali, Valle Del Cauca, Colombia|Praha 10, Czechia|Zlin, Czechia|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|México, D.F., Distrito Federal, Mexico|Guadalajara, Jalisco, Mexico|Monterrey, Nuevo Leon, Mexico|Aguascalientes, Mexico|San Luis Potosí, Mexico|Quezon City, Philippines|Quezon City, Philippines|Kaohsiung, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Chiang Mai, Thailand|Khon Kaen, Thailand|Ankara, Turkey|Trabzon, Turkey","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT01799993/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT01799993/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01799993"
625,"NCT01798108","Dose Escalation Study of Radium-223 Dichloride in Patients With Advanced Skeletal Metastases",,"Completed","No Results Available","Neoplasm Metastasis","Radiation: Radium-223 dichloride (BAY88-8223)","Number of participants with predetermined adverse events (dose limiting toxicity [DLT]) as a measure of safety and tolerability while dose escalating|Blood clearance of radioactivity|Quality of Life Questionnaire","Bayer","All","30 Years and older   (Adult, Older Adult)","Phase 1","31","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","15522|ATI-BC-1","August 14, 2001","June 25, 2003","June 25, 2003","February 25, 2013",,"May 19, 2017","The Norwegian Radium Hospital, Oslo, Norway|University Hospital of North Norway, Tromsoe, Norway|Karolinska University Hospital, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT01798108"
626,"NCT01797809","Qlaira rPMS (Regulatory Post Marketing Surveillance) Study in Korea",,"Completed","No Results Available","Contraception","Drug: EV/DNG (Qlaira, BAY86-5027)","Incidence of adverse events (AEs) including serious adverse events (SAEs) and Adverse Drug Reactions (ADRs)|Contraceptive Efficacy by Number of unintended pregnancies|Contraceptive Efficacy by Compliance with Qlaira taking : Administered tablet number/prescribed tablet number|The relief of heavy menstrual bleeding symptom also will be calculated as an efficacy variable from admission to the study until final visit by subject's assessment|Number of subjects with improved heavy menstrual bleeding","Bayer","Female","Child, Adult, Older Adult",,"757","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16344|QL1212KR","May 11, 2013","January 16, 2018","May 8, 2018","February 25, 2013",,"April 9, 2019","Multiple Locations, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01797809"
627,"NCT01795872","Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis",,"Completed","No Results Available","Multiple Sclerosis","Procedure: Several diagnostic procedures","Time to First Relapse by Kaplan-Meier Estimates|Time to Clinically Definite Multiple Sclerosis (CDMS) Represented by Kaplan-Meier Estimates|Number of Subjects With Diagnosis of Multiple Sclerosis Within Eleven years after Clinically-Isolated Syndrome (CIS) According to McDonald 2001 and 2010 Criteria|Disease Course as Assessed at the Time of BENEFIT 11|Percentage of Subjects Converting to Secondary Progressive Multiple Sclerosis (SPMS)|Time to Secondary Progressive Multiple Sclerosis (SPMS) Represented by Kaplan-Meier Estimates|Expanded Disability Status Scale (EDSS) at Year 11|Number of Subjects With Confirmed and Sustained 1-point Expanded Disability Status Scale (EDSS) Progression at Year 11|Number of Subjects With Confirmed 2.5-point Expanded Disability Status Scale (EDSS) Progression at Year 11|Percentage of Subjects who Ever Reached a Disability Status Scale (DSS) 3 and 6|Disability Based Efficacy Domain: Time to Disability Status Scale (DSS) 3 by Kaplan-Meier Estimates|Disability Based Efficacy Domain: Time to Disability Status Scale (DSS) 6 by Kaplan-Meier Estimates|Multiple Sclerosis Functional Composite (MSFC) at Year 11|Multiple Sclerosis Severity Score (MSSS) at Year 11|Cognitive Function: Paced Auditory Serial Addition Test-3 (PASAT-3) at Year 11|Cognitive function: Symbol Digit Modalities Test (SDMT)|Relapse-Based Efficacy domain: Hazard Ratio for Recurrent Relapses|Relapse Based Efficacy Domain: Annualized Relapse Rate|Time to use of Ambulatory Device Represented by Kaplan-Meier Estimates|Time to Dependence of Ambulatory Device for Walking Represented by Kaplan-Meier Estimates|Number of Subjects With Wheelchair Use After 11 years|Education Status at Year 11|Living Conditions at Year 11|Employment Status at Year 11|Multiple Sclerosis Impact on Employment at Year 11|Resource Use: Hospitalization During Last 12 months|Resource Use: Visits to Other Specialists During Last 12 months|Resource Use Assessment Questionnaire: Help from Family/Regular Ambulatory Services|Resource Use Assessment Questionnaire: Additional Ambulatory Services During Relapse|Resource Use Assessment Questionnaire: Adaptions past 6 months|Patient-Reported Outcomes (PRO)-based Efficacy Domain: Center of Epidemiological Studies Depression Scale (CES-D) Total Score at Year 11|PRO-based Efficacy Domain: Fatigue Scale for Sensory and Motor Functions (FSMC)|Functional Assessment of Multiple Sclerosis (FAMS) Trial Outcome Index (TOI) at Year 11|Functional Assessment of Multiple Sclerosis (FAMS) Total Score at Year 11|PRO-based Efficacy Domain: European Quality of Life - 5 Dimensions (EQ-5D) Score at Year 11|European Quality of Life - 5 Dimensions (EQ-5D) Health-related quality of life (HRQoL) Score at Year 11|Number of Subjects who Started Second Line Therapy at Year 11|Number of Subjects who Started First Disease-Modifying Treatment (DMT) other than IFNB at Year 11|Magnet-Resonance Imaging (MRI): Number of Newly Active Lesions|Magnet-Resonance Imaging (MRI): Number of Lesions on T1- and T2-Weighted Scans|Magnet-Resonance Imaging (MRI): Volume of Lesions on T1- and T2-Weighted Scans|Magnet-Resonance Imaging (MRI): Normalized Brain Volume|Optical Coherence Tomography (OCT) Parameter - Retinal Nerve Fiber Layer (RNFL)|Optical Coherence Tomography (OCT) Parameter - Total Macular Volume (TMV)|Optical Coherence Tomography (OCT) Parameter - Pupillo Macular Bundle (PMB)|Optical Coherence Tomography (OCT) Parameter - Ganglion Cell Inner Plexiform Layer|Ophthalmological examination - Optic Nerve Head|Ophthalmological examination - Slit lamp Biomicroscopy|Ophthalmological examination - Visual Acuity|Number of Subjects with Vitamin D Intake","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 4","278","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16401|2012-005262-35","September 2013","April 2014","June 2014","February 21, 2013",,"July 27, 2015","Graz, Steiermark, Austria|Innsbruck, Austria|Bruxelles - Brussel, Belgium|Gent, Belgium|Leuven, Belgium|Liege, Belgium|Calgary, Alberta, Canada|London, Ontario, Canada|Ottawa, Ontario, Canada|Montreal, Quebec, Canada|Brno, Czech Republic|Hradec Kralove, Czech Republic|Ostrava-Poruba, Czech Republic|Praha 2, Czech Republic|Glostrup, Denmark|Oulu, Finland|Seinäjoki, Finland|Tampere, Finland|Turku, Finland|Bordeaux, France|Clermont ferrand, France|Dijon, France|Lille, France|Nice, France|Rennes, France|Toulouse, France|Ulm, Baden-Württemberg, Germany|München, Bayern, Germany|Regensburg, Bayern, Germany|Würzburg, Bayern, Germany|Hennigsdorf, Brandenburg, Germany|Gießen, Hessen, Germany|Marburg, Hessen, Germany|Offenbach, Hessen, Germany|Greifswald, Mecklenburg-Vorpommern, Germany|Göttingen, Niedersachsen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Halle, Sachsen-Anhalt, Germany|Erfurt, Thüringen, Germany|Münster, Germany|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Szeged, Hungary|Jerusalem, Israel|Tel Hashomer, Israel|Orbassano, Torino, Italy|Gallarate, Italy|Milano, Italy|Padova, Italy|Pavia, Italy|Torino, Italy|Sittard, Netherlands|Bergen, Norway|Bydgoszcz, Poland|Krakow, Poland|Lodz, Poland|Lublin, Poland|Wroclaw, Poland|Coimbra, Portugal|Ljubljana, Slovenia|Sevilla, Andalucía, Spain|L'Hospitalet de Llobregat, Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Málaga, Spain|Valencia, Spain|Göteborg, Sweden|Basel, Basel-Stadt, Switzerland|St. Gallen, Sankt Gallen, Switzerland|Bern, Switzerland|Sheffield, South Yorkshire, United Kingdom|Aberdeen, United Kingdom|Dundee, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01795872"
628,"NCT01788722","Regulatory Post Marketing Surveillance Study in Korea",,"Completed","No Results Available","Endometriosis","Drug: Dienogest (Visanne, BAY86-5258)","Number of participants with adverse events( AE) and Serious adverse events(SAE) as a measure of safety and tolerability|Changes of relief of endometriosis-associated pelvic pain (EAPP) will be measured on VAS for total study population|Evaluation of VAS score changes for sub analysis( In case of VAS score≥ 30mm in initial visit).","Bayer","Female","Child, Adult, Older Adult",,"3223","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16625|VS1310KR","July 19, 2013","August 11, 2017","August 11, 2017","February 11, 2013",,"August 2, 2018","Multiple Locations, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01788722"
629,"NCT01788358","Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension",,"Completed","Has Results","Hypertension","Drug: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)","Number of Subjects With All Treatment-emergent Adverse Events (TEAEs) and Drug-related TEAEs up to Week 28|Number of Subjects With Treatment-emergent Adverse Events (TEAEs) of Special Interest up to Week 28|Number of Subjects With All Treatment-emergent Adverse Events (TEAEs) and Drug-related TEAEs up to Week 52/End of Study (EOS)|Number of Subjects With Treatment-emergent Adverse Events (TEAEs) of Special Interest up to Week 52/End of Study (EOS)|Number of Subjects With Clinically Relevant Changes in Laboratory Parameters|Change From Baseline In Mean Seated Systolic Blood Pressure (MSSBP) At Weeks 28 And 52|Change From Baseline in Mean Seated Diastolic Blood Pressure (MSDBP) at Weeks 28 and 52|Blood Pressure Control Rate at Weeks 28 and 52|Blood Pressure Response Rate at Weeks 28 and 52","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","508","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14801|2012-004515-32","February 14, 2013","May 1, 2014","May 1, 2014","February 11, 2013","August 17, 2015","October 24, 2017","Foley, Alabama, United States|Carmichael, California, United States|Los Angeles, California, United States|Spring Valley, California, United States|Milford, Connecticut, United States|Coral Gables, Florida, United States|Hallandale Beach, Florida, United States|Hollywood, Florida, United States|Jacksonville, Florida, United States|Jupiter, Florida, United States|Tampa, Florida, United States|Atlanta, Georgia, United States|Valparaiso, Indiana, United States|Newton, Kansas, United States|Wichita, Kansas, United States|Lexington, Kentucky, United States|New Orleans, Louisiana, United States|Auburn, Maine, United States|Elkridge, Maryland, United States|Brockton, Massachusetts, United States|Saint Louis, Missouri, United States|Shelby, North Carolina, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Greenville, South Carolina, United States|Mount Pleasant, South Carolina, United States|Rapid City, South Dakota, United States|Nashville, Tennessee, United States|New Tazewell, Tennessee, United States|Beaumont, Texas, United States|Bryan, Texas, United States|Carrollton, Texas, United States|Dallas, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Salt Lake City, Utah, United States|Kenosha, Wisconsin, United States|Moorsel, Oost-Vlaanderen, Belgium|Wetteren, Oost-Vlaanderen, Belgium|Steenokkerzeel, Vlaams Brabant, Belgium|Deurne, Belgium|HAM, Belgium|Burnaby, British Columbia, Canada|Langley, British Columbia, Canada|Vancouver, British Columbia, Canada|Brampton, Ontario, Canada|Burlington, Ontario, Canada|Etobicoke, Ontario, Canada|London, Ontario, Canada|Newmarket, Ontario, Canada|Sarnia, Ontario, Canada|Stayner, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Woodstock, Ontario, Canada|Pointe-Claire, Quebec, Canada|Ste-Foy, Quebec, Canada|Frankfurt, Hessen, Germany|Bochum, Nordrhein-Westfalen, Germany|Magdeburg, Sachsen-Anhalt, Germany|Görlitz, Sachsen, Germany|Leipzig, Sachsen, Germany|Berlin, Germany|Dresden, Germany|Gdynia, Poland|Katowice, Poland|Warszawa, Poland|Wroclaw, Poland|Reading, Berkshire, United Kingdom|Chesterfield, Derbyshire, United Kingdom|Blackpool, Lancashire, United Kingdom|Bath, Somerset, United Kingdom|Bury St Edmonds, Suffolk, United Kingdom|Coventry, Warwickshire, United Kingdom|Birmingham, West Midlands, United Kingdom|Cardiff, United Kingdom|Chorley, United Kingdom|Glasgow, United Kingdom|Liverpool, United Kingdom|Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01788358"
630,"NCT01784562","Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)","EAS","No longer available","No Results Available","Hypertension, Pulmonary","Drug: Adempas (Riociguat, BAY63-2521)",,"Bayer","All","18 Years to 80 Years   (Adult, Older Adult)",,,"Industry","Expanded Access",,"16097|2012-002104-40",,,,"February 6, 2013",,"January 6, 2016","Tucson, Arizona, United States|La Jolla, California, United States|Los Angeles, California, United States|Sacramento, California, United States|Aurora, Colorado, United States|Weston, Florida, United States|Chicago, Illinois, United States|Iowa City, Iowa, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Ann Arbor, Michigan, United States|Omaha, Nebraska, United States|Newark, New Jersey, United States|New York, New York, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Fairfield, Ohio, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Providence, Rhode Island, United States|Dallas, Texas, United States|El Paso, Texas, United States|Houston, Texas, United States|Graz, Steiermark, Austria|Innsbruck, Tirol, Austria|Wien, Austria|Bruxelles - Brussel, Belgium|Leuven, Belgium|Calgary, Alberta, Canada|London, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Bogotá, Cundinamarca, Colombia|Bogotá, Distrito Capital de Bogotá, Colombia|Cali, Valle del Cauca, Colombia|Bogotá, Colombia|Santa Fe de Bogotá, Colombia|Praha 2, Czech Republic|Aarhus N, Denmark|Besancon, France|Brest, France|Bron, France|Caen, France|Le Kremlin-bicetre, France|Montpellier, France|Pessac, France|Rouen, France|Vandoeuvre Les Nancy, France|Heidelberg, Baden-Württemberg, Germany|München, Bayern, Germany|Regensburg, Bayern, Germany|Würzburg, Bayern, Germany|Gießen, Hessen, Germany|Greifswald, Mecklenburg-Vorpommern, Germany|Hannover, Niedersachsen, Germany|Köln, Nordrhein-Westfalen, Germany|Homburg, Saarland, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Hamburg, Germany|Pavia, Italy|Roma, Italy|Trieste, Italy|Nagoya, Aichi, Japan|Sendai, Miyagi, Japan|Bunkyo-ku, Tokyo, Japan|Chiba, Japan|Mexico. D.F., Distrito Federal, Mexico|México D.F., Distrito Federal, Mexico|Monterrey, Nuevo Leon, Mexico|Amsterdam, Netherlands|Nieuwegein, Netherlands|Rotterdam, Netherlands|Almada, Portugal|Coimbra, Portugal|Lisboa, Portugal|Lisboa, Portugal|Novosibirsk, Russian Federation|St. Petersburg, Russian Federation|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Sevilla, Spain|Linköping, Sweden|Lund, Sweden|Umeå, Sweden|St. Gallen, Sankt Gallen, Switzerland|Lausanne, Vaud, Switzerland|Bern, Switzerland|Zürich, Switzerland|Ankara, Turkey|Istanbul, Turkey|Istanbul, Turkey|Istanbul, Turkey|Izmir, Turkey|Izmir, Turkey|Cambridge, Cambridgeshire, United Kingdom|Sheffield, South Yorkshire, United Kingdom|Newcastle Upon Tyne, Tyne and Wear, United Kingdom|Glasgow, West Dunbartonshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01784562"
631,"NCT01783925","Eylea Post Marketing Surveillance(PMS)",,"Completed","No Results Available","Macular Degeneration","Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)","Adverse events (AEs) [including serious adverse events (SAEs) and ocular AEs, especially AEs due to intravitreal injection procedure] and adverse drug reactions (ADRs)|Measurement of BCVA (prior to injection and performing other ocular assessments) by eye chart. [BCVA: Best Corrected Visual Acuity]|Central retinal thickness by OCT with or without.[OCT: Optical Coherence Tomography]|Findings of FAG and/or ICAG. [FAG: Fluorescein Angiography].ICAG: Indocyanine Green Angiography]|IOP(if performed, before/after injection).[IOP: Intra Ocular Pressure]|Measurement of fundus lesion by fundoscopy","Bayer|Regeneron Pharmaceuticals","All","Child, Adult, Older Adult",,"3206","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16469|EY1310KR","April 29, 2014","December 31, 2018","December 31, 2018","February 5, 2013",,"January 8, 2019","Many Locations, Multiple Locations, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01783925"
632,"NCT01783886","Efficacy and Safety of VEGF Trap Eye in Diabetic Macular Edema (DME) With Central Involvement","VIVID EAST","Completed","Has Results","Macular Edema","Biological: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Procedure: Macular Laser Photocoagulation","Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation Carried Forward (LOCF)|Percentage of Participants Who Gained at Least 10 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF|Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF|Percentage of Participants With a Greater Than Equal (>=) Two-step Improvement From Baseline in the ETDRS Diabetic Retinopathy Severity Score (DRSS) as Assessed by Fundus Photography (FP) at Week 52 - LOCF|Change From Baseline in Central Retinal Thickness (CRT) at Week 52 as Assessed on Optical Coherence Tomography (OCT) - LOCF|Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Near Activities Subscale at Week 52 - LOCF|Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Distance Activities Subscale at Week 52 - LOCF","Bayer|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","381","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15161","February 2013","March 2015","March 2015","February 5, 2013","April 5, 2016","May 12, 2016","Guangzhou, Guangdong, China|Wuhan, Hubei, China|Changsha, Hunan, China|Shenyang, Liaoning, China|Xi'an, Shaanxi, China|Qingdao, Shandong, China|Chengdu, Sichuan, China|Hangzhou, Zhejiang, China|Wenzhou, Zhejiang, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Chongqing, China|Shanghai, China|Tianjin, China|Hong Kong, Hong Kong|Kowloon, Hong Kong|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Moscow, Russian Federation|Moscow, Russian Federation|Novosibirsk, Russian Federation|St. Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT01783886"
633,"NCT01781052","Observational Description of Compliance for the Daily Ventavis Use Via the Insight Program in Class III Pulmonary Arterial Hypertension Patients","DAILY","Completed","No Results Available","Pulmonary Arterial Hypertension","Drug: Ventavis (Iloprost, BAYQ6256)","Compliance for each subject assessed by the mean daily number of inhalations of Ventavis.|Compliance for each subject assessed by the mean daily number of inhalations of Ventavis|Total distance (meters) walked within 6 minutes assessed by the 6 Minutes Walking Distance Test|Dyspnea Borg Category Ration 10 Scale values|Quality of Life (EQ5D and LPH [Living with Pulmonary Hypertension] questionnaires)|Investigator and patient satisfaction in the use of I-neb Insight tool assessed by a five level likert scale|Population characteristics","Bayer","All","18 Years and older   (Adult, Older Adult)",,"17","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16133|VE1210FR|2011/00416","September 11, 2013","May 26, 2016","January 16, 2017","January 31, 2013",,"December 4, 2017","Multiple Locations, France",,"https://ClinicalTrials.gov/show/NCT01781052"
634,"NCT01776424","Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease","COMPASS","Active, not recruiting","Has Results","Prevention & Control","Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Aspirin|Drug: Aspirin placebo|Drug: Rivaroxaban placebo|Drug: Pantoprazole","The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death|The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria|The First Occurrence of Myocardial Infarction (MI), Ischemic Stroke, Acute Limb Ischemia (ALI), or Coronary Heart Disease (CHD) Death|The First Occurrence of MI, Ischemic Stroke, ALI, or Cardiovascular (CV) Death|All-cause Mortality","Bayer|Population Health Research Institute|Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 3","27395","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","15786|2012-004180-43","February 28, 2013","July 21, 2017","March 31, 2022","January 28, 2013","October 5, 2018","January 18, 2020","Birmingham, Alabama, United States|Mobile, Alabama, United States|Anaheim, California, United States|Laguna Hills, California, United States|Northridge, California, United States|Palo Alto, California, United States|Santa Rosa, California, United States|Sylmar, California, United States|Torrance, California, United States|Norwalk, Connecticut, United States|Stamford, Connecticut, United States|Trumbull, Connecticut, United States|Atlantis, Florida, United States|Clearwater, Florida, United States|Coral Springs, Florida, United States|Jacksonville Beach, Florida, United States|Largo, Florida, United States|New Port Richey, Florida, United States|Safety Harbor, Florida, United States|Sarasota, Florida, United States|Meridian, Idaho, United States|Arlington Heights, Illinois, United States|Hazel Crest, Illinois, United States|Davenport, Iowa, United States|West Des Moines, Iowa, United States|Crestview Hills, Kentucky, United States|Baltimore, Maryland, United States|Haverhill, Massachusetts, United States|Alpena, Michigan, United States|Jackson, Michigan, United States|Saint Louis, Missouri, United States|Kalispell, Montana, United States|New Brunswick, New Jersey, United States|Cortlandt Manor, New York, United States|Kingston, New York, United States|Saratoga Springs, New York, United States|Durham, North Carolina, United States|Pinehurst, North Carolina, United States|Elyria, Ohio, United States|Sandusky, Ohio, United States|Toledo, Ohio, United States|Doylestown, Pennsylvania, United States|Langhorne, Pennsylvania, United States|Yardley, Pennsylvania, United States|Sioux Falls, South Dakota, United States|Dallas, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Bellevue, Washington, United States|Puyallup, Washington, United States|Seattle, Washington, United States|Spokane, Washington, United States|Adrogue, Buenos Aires, Argentina|Bahía Blanca, Buenos Aires, Argentina|Coronel Suarez, Buenos Aires, Argentina|Junín, Buenos Aires, Argentina|La Plata, Buenos Aires, Argentina|La Plata, Buenos Aires, Argentina|La Plata, Buenos Aires, Argentina|La Plata, Buenos Aires, Argentina|Mar del Plata, Buenos Aires, Argentina|Merlo, Buenos Aires, Argentina|Munro, Buenos Aires, Argentina|Quilmes, Buenos Aires, Argentina|Ramos Mejía, Buenos Aires, Argentina|San Martín, Buenos Aires, Argentina|San Nicolás, Buenos Aires, Argentina|Vicente López, Buenos Aires, Argentina|Zárate, Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Ciudad Autón. de Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Villa Allende, Córdoba, Argentina|Villa María, Córdoba, Argentina|Santa Rosa, La Pampa, Argentina|Rafaela, Santa Fe, Argentina|Rosario, Santa Fe, Argentina|Rosario, Santa Fe, Argentina|Rosario, Santa Fe, Argentina|Venado Tuerto, Santa Fe, Argentina|San Miguel de Tucumán, Tucuman, Argentina|San Miguel de Tucumán, Tucuman, Argentina|Ciudad Auton. de Buenos Aires, Argentina|Ciudad Auton. de Buenos Aires, Argentina|Ciudad Auton. de Buenos Aires, Argentina|Corrientes, Argentina|Córdoba, Argentina|Córdoba, Argentina|Córdoba, Argentina|Córdoba, Argentina|Córdoba, Argentina|Córdoba, Argentina|Salta, Argentina|San Juan, Argentina|San luis, Argentina|Santa Fe, Argentina|Bruce, Australian Capital Territory, Australia|Gosford, New South Wales, Australia|New Lambton Heights, New South Wales, Australia|Birtinya, Queensland, Australia|Brisbane, Queensland, Australia|Brisbane, Queensland, Australia|Redcliffe, Queensland, Australia|Woolloongabba, Queensland, Australia|Adelaide, South Australia, Australia|Hobart, Tasmania, Australia|Launceston, Tasmania, Australia|Geelong, Victoria, Australia|Melbourne, Victoria, Australia|Melbourne, Victoria, Australia|Prahran, Victoria, Australia|Murdoch, Western Australia, Australia|Nedlands, Western Australia, Australia|Taree, Australia|Antwerpen, Belgium|Bonheiden, Belgium|Brugge, Belgium|Bruxelles - Brussel, Belgium|Charleroi, Belgium|Genk, Belgium|Hasselt, Belgium|Kortrijk, Belgium|Leuven, Belgium|Liege, Belgium|Roeselare, Belgium|Goiania, Goiás, Brazil|Belo Horizonte, Minas Gerais, Brazil|Uberaba, Minas Gerais, Brazil|Uberlândia, Minas Gerais, Brazil|Campina Grande do Sul, Parana, Brazil|Curitiba, Parana, Brazil|Canoas, Rio Grande Do Sul, Brazil|Pelotas, Rio Grande Do Sul, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|Blumenau, Santa Catarina, Brazil|Campinas, Sao Paulo, Brazil|Campinas, Sao Paulo, Brazil|Campinas, Sao Paulo, Brazil|Matão, Sao Paulo, Brazil|São José do Rio Preto, Sao Paulo, Brazil|São José do Rio Preto, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|Votuporanga, Sao Paulo, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|New Westminster, British Columbia, Canada|Victoria, British Columbia, Canada|Winnipeg, Manitoba, Canada|Winnipeg, Manitoba, Canada|Winnipeg, Manitoba, Canada|Winnipeg, Manitoba, Canada|Moncton, New Brunswick, Canada|Saint John, New Brunswick, Canada|Halifax, Nova Scotia, Canada|Brampton, Ontario, Canada|Burlington, Ontario, Canada|Burlington, Ontario, Canada|Cambridge, Ontario, Canada|Cambridge, Ontario, Canada|Grimsby, Ontario, Canada|Hamilton, Ontario, Canada|Hamilton, Ontario, Canada|London, Ontario, Canada|London, Ontario, Canada|Mississauga, Ontario, Canada|Newmarket, Ontario, Canada|Newmarket, Ontario, Canada|Oakville, Ontario, Canada|Oshawa, Ontario, Canada|Oshawa, Ontario, Canada|Ottawa, Ontario, Canada|Peterborough, Ontario, Canada|Scarborough, Ontario, Canada|Sudbury, Ontario, Canada|Sudbury, Ontario, Canada|Toronto, Ontario, Canada|Waterloo, Ontario, Canada|Windsor, Ontario, Canada|Chicoutimi, Quebec, Canada|Laval, Quebec, Canada|Levis, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Sherbrooke, Quebec, Canada|Terrebonne, Quebec, Canada|Thetford Mines, Quebec, Canada|Trois-Rivieres, Quebec, Canada|Ontario, Canada|Quebec, Canada|Temuco, Araucanía, Chile|Temuco, Araucanía, Chile|Temuco, Araucanía, Chile|Concepción, Bío-Bío, Chile|Osorno, Los Lagos, Chile|Valdivia, Los Lagos, Chile|Viña del Mar, Valparaíso, Chile|Santiago, Chile|Santiago, Chile|Santiago, Chile|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Wudan, Hubei, China|Wuhan, Hubei, China|Changsha, Hunan, China|Nanjing, Jiangsu, China|Nanjing, Jiangsu, China|Changchun, Jilin, China|Changchun, Jilin, China|Shenyang, Liaoning, China|Xi'an, Shanxi, China|Chengdu, Sichuan, China|Hangzhou, Zhejiang, China|Hangzhou, Zhejiang, China|Wenzhou, Zhejiang, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|Barranquilla, Atlántico, Colombia|Cartagena, Bolívar, Colombia|Manizales, Caldas, Colombia|Montería, Córdoba, Colombia|Pasto, Nariño, Colombia|Armenia, Quindío, Colombia|Pereira, Risaralda, Colombia|Bucaramanga, Santander, Colombia|Floridablanca, Santander, Colombia|Espinal, Tolima, Colombia|Cali, Valle Del Cauca, Colombia|Barranquilla, Colombia|Santafe de Bogotá, Colombia|Brno, Czechia|Brno, Czechia|Ceske Budejovice, Czechia|Cesky Krumlov, Czechia|Hodonin, Czechia|Hradec Kralove, Czechia|Jablonec nad Nisou, Czechia|Kolin, Czechia|Liberec, Czechia|Olomouc, Czechia|Ostrava, Czechia|Ostrava, Czechia|Pardubice, Czechia|Praha 10, Czechia|Praha 13, Czechia|Praha 2, Czechia|Praha 4, Czechia|Praha 5, Czechia|Praha 5, Czechia|Praha 6, Czechia|Slany, Czechia|Susice, Czechia|Trebic, Czechia|Trinec, Czechia|Uherske Hradiste, Czechia|Zlin, Czechia|Aalborg, Denmark|Aarhus N, Denmark|Hellerup, Denmark|Holbaek, Denmark|Hvidovre, Denmark|Kolding, Denmark|København Ø, Denmark|København, Denmark|Viborg, Denmark|Guayaquil, Guayas, Ecuador|Quito, Pichincha, Ecuador|Quito, Ecuador|Kuopio, Finland|Kuusankoski, Finland|Tampere, Finland|Turku, Finland|Vantaa, Finland|Amiens, France|Clermont Ferrand, France|Limoges Cedex, France|Montpellier, France|Nice, France|NIMES cedex 9, France|Paris Cedex 15, France|Paris, France|Paris, France|Saint-priest-en-jarez, France|Nürnberg, Bayern, Germany|Würzburg, Bayern, Germany|Bad Homburg, Hessen, Germany|Frankfurt, Hessen, Germany|Kassel, Hessen, Germany|Bielefeld, Nordrhein-Westfalen, Germany|Dortmund, Nordrhein-Westfalen, Germany|Wuppertal, Nordrhein-Westfalen, Germany|Magdeburg, Sachsen-Anhalt, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Bottrop, Germany|Frankfurt, Germany|Hamburg, Germany|Warendorf, Germany|Balatonfured, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Mosonmagyarovar, Hungary|Pecs, Hungary|Sopron, Hungary|Szekesfehervar, Hungary|Szekszard, Hungary|Ballinasloe, Co. Galway, Ireland|Cork, Ireland|Dublin, Ireland|Dublin, Ireland|Dublin, Ireland|Galway, Ireland|Afula, Israel|Ashkelon, Israel|Bnei Brak, Israel|Haifa, Israel|Haifa, Israel|Holon, Israel|Nahariya, Israel|Tel Aviv, Israel|Tel Aviv, Israel|Zefat, Israel|Caserta, Campania, Italy|Bologna, Emilia-Romagna, Italy|Forlì-Cesena, Emilia-Romagna, Italy|Ravenna, Emilia-Romagna, Italy|Trieste, Friuli-Venezia Giulia, Italy|Udine, Friuli-Venezia Giulia, Italy|Udine, Friuli-Venezia Giulia, Italy|Udine, Friuli-Venezia Giulia, Italy|Brescia, Lombardia, Italy|Cremona, Lombardia, Italy|Pavia, Lombardia, Italy|Ancona, Marche, Italy|Isernia, Molise, Italy|Foggia, Puglia, Italy|Lecce, Puglia, Italy|Catania, Sicilia, Italy|Palermo, Sicilia, Italy|Arezzo, Toscana, Italy|Firenze, Toscana, Italy|Perugia, Umbria, Italy|Terni, Umbria, Italy|Nagoya, Aichi, Japan|Toyoake, Aichi, Japan|Kisarazu, Chiba, Japan|Matsudo, Chiba, Japan|Imabari, Ehime, Japan|Matsuyama, Ehime, Japan|Kasuga, Fukuoka, Japan|Kitakyushu, Fukuoka, Japan|Miyako-gun, Fukuoka, Japan|Onga-gun, Fukuoka, Japan|Maebashi, Gunma, Japan|Onomichi, Hiroshima, Japan|Asahikawa, Hokkaido, Japan|Asahikawa, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Spporo, Hokkaido, Japan|Tomakomai, Hokkaido, Japan|Kobe, Hyogo, Japan|Takarazuka, Hyogo, Japan|Kaga, Ishikawa, Japan|Miura-gun, Kanagawa, Japan|Sagamihara, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Naha, Okinawa, Japan|Kishiwada, Osaka, Japan|Takatsuki, Osaka, Japan|Tokorozawa, Saitama, Japan|Komatsushima, Tokushima, Japan|Akishima, Tokyo, Japan|Bunkyo-ku, Tokyo, Japan|Itabashi-ku, Tokyo, Japan|Shimonoseki, Yamaguchi, Japan|Chiba, Japan|Fukuoka, Japan|Fukuoka, Japan|Gifu, Japan|Gifu, Japan|Kumamoto, Japan|Kyoto, Japan|Kyoto, Japan|Kyoto, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Wonju-si, Gang''weondo, Korea, Republic of|Goyang-si, Gyeonggido, Korea, Republic of|Seongnam-si, Gyeonggido, Korea, Republic of|Jeju, Jejudo, Korea, Republic of|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Busan, Korea, Republic of|Daejeon, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Batu Caves, Selangor, Malaysia|Kedah, Malaysia|Kuala Lumpur, Malaysia|Kuala Lumpur, Malaysia|Selangor, Malaysia|Sungai Buloh Selangor, Malaysia|Amsterdam, Netherlands|Apeldoorn, Netherlands|Arnhem, Netherlands|Breda, Netherlands|Delft, Netherlands|Den Bosch, Netherlands|Deventer, Netherlands|Doetinchem, Netherlands|Drachten, Netherlands|EDE, Netherlands|Gorinchem, Netherlands|Gouda, Netherlands|Groningen, Netherlands|Heerlen, Netherlands|Helmond, Netherlands|Hoogeveen, Netherlands|Hoorn, Netherlands|Leeuwarden, Netherlands|Meppel, Netherlands|Nijmegen, Netherlands|Roermond, Netherlands|Roosendaal, Netherlands|Rotterdam, Netherlands|Rotterdam, Netherlands|Sneek, Netherlands|Tiel, Netherlands|Zwolle, Netherlands|Batangas, Philippines|Cebu City, Philippines|Dagupan City, Philippines|Dasmarinas, Philippines|Iloilo City, Philippines|Laoag City, Philippines|Manila, Philippines|Manila, Philippines|Metro Manila, Philippines|Muntinlupa City, Philippines|Palawan, Philippines|Pasig city, Philippines|Quezon City, Philippines|Quezon City, Philippines|Quezon City, Philippines|Tacloban City, Philippines|Gdansk, Poland|Kielce, Poland|Krakow, Poland|Krakow, Poland|Krakow, Poland|Krakow, Poland|Lodz, Poland|Tarnow, Poland|Wroclaw, Poland|Timisoara, Timis, Romania|Brasov, Romania|Bucharest, Romania|Bucharest, Romania|Bucharest, Romania|Bucharest, Romania|Bucharest, Romania|Bucharest, Romania|Bucharest, Romania|Bucuresti, Romania|Cluj Napoca, Romania|Iasi, Romania|Iasi, Romania|Targu Mures, Romania|Targu Mures, Romania|Timisoara, Romania|Barnaul, Russian Federation|Kemerovo, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Novosibirsk, Russian Federation|Tomsk, Russian Federation|Zhukovskiy, Russian Federation|Bratislava, Slovakia|Bratislava, Slovakia|Kosice, Slovakia|Nitra, Slovakia|Presov, Slovakia|Vrable, Slovakia|Pinelands, Eastern Cape, South Africa|Port Elizabeth, Eastern Cape, South Africa|Bloemfontein, Freestate, South Africa|Johannesburg, Gauteng, South Africa|Cape Town, Western Cape, South Africa|Observatory, Western Cape, South Africa|Pinelands, Western Cape, South Africa|Worcester, Western Cape, South Africa|Somerset West, South Africa|Göteborg, Sweden|Helsingborg, Sweden|Kristianstad, Sweden|Skellefteå, Sweden|Stockholm, Sweden|Stockholm, Sweden|Stockholm, Sweden|Stockholm, Sweden|Vällingby, Sweden|Örebro, Sweden|Östersund, Sweden|Lugano, Ticino, Switzerland|Dnipropetrovsk, Ukraine|Kharkiv, Ukraine|Kharkiv, Ukraine|Kharkiv, Ukraine|Kiev, Ukraine|Kiev, Ukraine|Kiev, Ukraine|Lviv, Ukraine|Lviv, Ukraine|Lviv, Ukraine|Simferopol, Ukraine|Vinnitsa, Ukraine|Zaporozhye, Ukraine|Zaporozhye, Ukraine|Belfast, Antrim, United Kingdom|Londonderry Co. Londonderry, Derry, United Kingdom|Basildon, Essex, United Kingdom|Stevenage, Hertfordshire, United Kingdom|Blackpool, Lancashire, United Kingdom|Harrow, London, United Kingdom|Portadown, North Ireland, United Kingdom|Middlesborough, North Yorkshire, United Kingdom|Northampton, Northamptonshire, United Kingdom|Hardwick, Stockton-on-Tees, United Kingdom|Nuneaton, Warwickshire, United Kingdom|West Bromich, West Midlands, United Kingdom|Wolverhampton, West Midlands, United Kingdom|Worcester, Worcestershire, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT01776424/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT01776424/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01776424"
635,"NCT01775618","Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A",,"Active, not recruiting","No Results Available","Hemophilia A","Biological: BAY94-9027","Annualized number of all bleeds|Pharmacokinetics profile of BAY94-9027 based on blood concentration over the defined time period|Response of acute bleeding events to treatment based on a 4-point scale (poor, moderate, good, or excellent)|Characterization of a potential immune response|Inhibitor development after 10 to 15 exposure days (EDs)|Inhibitor development after 50 EDs|Number of participants with adverse events as a measure of safety and tolerability","Bayer","Male","up to 12 Years   (Child)","Phase 3","73","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15912|2012-004434-42","May 29, 2013","March 19, 2015","February 14, 2020","January 25, 2013",,"January 3, 2020","Sacramento, California, United States|Pensacola, Florida, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Hershey, Pennsylvania, United States|Salt Lake City, Utah, United States|La Plata, Buenos Aires, Argentina|Wien, Austria|Gent, Belgium|Leuven, Belgium|Plovdiv, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Calgary, Alberta, Canada|Toronto, Ontario, Canada|Thessaloniki, Greece|Ramat Gan, Israel|Milano, Lombardia, Italy|Palermo, Sicilia, Italy|Padova, Veneto, Italy|Vilnius, Lithuania|Amsterdam, Netherlands|Utrecht, Netherlands|Christchurch, New Zealand|Hamilton, New Zealand|Oslo, Norway|Lodz, Poland|Olsztyn, Poland|Bucharest, Romania|Bucharest, Romania|Timisoara, Romania|Esplugues de LLobregat, Barcelona, Spain|Newcastle Upon Tyne, Tyne And Wear, United Kingdom|Bristol, United Kingdom|Manchester, United Kingdom|Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01775618"
636,"NCT01774344","Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma","RESORCE","Completed","Has Results","Carcinoma, Hepatocellular","Drug: Regorafenib (Stivarga, BAY73-4506)|Drug: Placebo","Overall Survival (OS)|Time to Progression (TTP)|Progression Free Survival (PFS)|Objective Tumor Response Rate (ORR)|Disease Control Rate (DCR)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","573","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15982|2012-003649-14","May 14, 2013","February 29, 2016","July 5, 2019","January 24, 2013","June 5, 2017","August 20, 2019","Los Angeles, California, United States|Los Angeles, California, United States|Orange, California, United States|Aurora, Colorado, United States|Washington, District of Columbia, United States|Gainesville, Florida, United States|Tampa, Florida, United States|Chicago, Illinois, United States|Louisville, Kentucky, United States|Worcester, Massachusetts, United States|Minneapolis, Minnesota, United States|Saint Louis, Missouri, United States|New York, New York, United States|Rochester, New York, United States|Pittsburgh, Pennsylvania, United States|Richmond, Virginia, United States|Seattle, Washington, United States|Pilar, Buenos Aires, Argentina|Camperdown, New South Wales, Australia|Liverpool, New South Wales, Australia|Herston, Queensland, Australia|Clayton, Victoria, Australia|Box Hill, Australia|Linz, Oberösterreich, Austria|Graz, Steiermark, Austria|Wien, Austria|Bruxelles - Brussel, Belgium|La Louviere, Belgium|Salvador, Bahia, Brazil|Sao Paulo, Brazil|Hefei, Anhui, China|Fuzhou, Fujian, China|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Nanning, Guangxi, China|Harbin, Heilongjiang, China|Wuhan, Hubei, China|Changsha, Hunan, China|Nanjing, Jiangsu, China|Suzhou, Jiangsu, China|Dalian, Liaoning, China|Xi'an, Shaanxi, China|Xi'an, Shaanxi, China|Xi'an, Shaanxi, China|Chengdu, Sichuan, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Chongqing, China|Shanghai, China|Shanghai, China|Shanghai, China|Tianjin, China|Hradec Kralove, Czechia|Olomouc, Czechia|Praha 2, Czechia|Angers, France|Caen, France|Clichy, France|Creteil, France|Dijon, France|La Tronche, France|Lille, France|Lyon, France|Marseille, France|Montpellier Cedex, France|Nice Cedex 3, France|Paris, France|Paris, France|Perpignan, France|Reims Cedex, France|Rennes Cedex, France|Toulouse, France|Vandoeuvre les Nancy, France|Villejuif Cedex, France|Heidelberg, Baden-Württemberg, Germany|München, Bayern, Germany|Frankfurt, Hessen, Germany|Hannover, Niedersachsen, Germany|Aachen, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Magdeburg, Sachsen-Anhalt, Germany|Berlin, Germany|Hamburg, Germany|Budapest, Hungary|Debrecen, Hungary|Kaposvar, Hungary|Napoli, Campania, Italy|Bologna, Emilia-Romagna, Italy|Modena, Emilia-Romagna, Italy|Roma, Lazio, Italy|Genova, Liguria, Italy|Bergamo, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Novara, Piemonte, Italy|Torino, Piemonte, Italy|Foggia, Puglia, Italy|Cagliari, Sardegna, Italy|Pisa, Toscana, Italy|Padova, Veneto, Italy|Chiba-shi, Chiba, Japan|Kashiwa-shi, Chiba, Japan|Fukuoka-shi, Fukuoka, Japan|Iizuka-shi, Fukuoka, Japan|Yokohama-shi, Kanagawa, Japan|Kumamoto-shi, Kumamoto, Japan|Osaka-shi, Osaka, Japan|Osakasayama-shi, Osaka, Japan|Utsunomiya-shi, Tochigi, Japan|Chiyoda-ku, Tokyo, Japan|Chuo-ku, Tokyo, Japan|Musashino-shi, Tokyo, Japan|Busan, Busan Gwang''yeogsi, Korea, Republic of|Daegu, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Amsterdam, Netherlands|Leiden, Netherlands|Barnaul, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Singapore, Singapore|Oviedo, Asturias, Spain|Alicante, Spain|Barcelona, Spain|Barcelona, Spain|Córdoba, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Zaragoza, Spain|Bellinzona, Ticino, Switzerland|Bern, Switzerland|Kaohsiung City, Kaohsiung, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Birmingham, West Midlands, United Kingdom|Leeds, West Yorkshire, United Kingdom|Bristol, United Kingdom|London, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01774344"
637,"NCT01771081","Evaluation of Changes in Visual Acuity in Patients With Diabetic Macular Edema (DME) Starting Treatment With an Approved Anti-VEGF Therapy","POLARIS","Completed","No Results Available","Ophthalmology|Macular Edema|Macular Degeneration","Drug: Ranibizumab (or other DME treatment)","Changes in visual acuity, assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) or SNELLEN|Demographic and clinical characteristics (Age, sex, race, employment status, severity of DME)|Mean time from diagnosis to first commencement with an approved anti-VEGF therapy|Changes in retinal thickness, measured by Optical Coherence Tomography (OCT)|Presence of clinically significant macular edema, measured as defined by the ETDRS Research Group|Resource utilization in terms of treatment choices, frequency and duration|Mean change in quality of life score (using the NEI VFQ 25), only in countries where used as part of routine practice","Bayer|Regeneron Pharmaceuticals","All","Child, Adult, Older Adult",,"911","Industry","Observational","Observational Model: Cohort","16459|NN1201","April 2013","January 2015","April 2015","January 18, 2013",,"October 28, 2015","Many Locations, France|Many Locations, Germany|Many Locations, Greece|Many Locations, Portugal|Many Locations, Russian Federation|Many Locations, Slovakia|Many Locations, Spain|Many Locations, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01771081"
638,"NCT01766063","Investigating the Relationship Between Sleep, Quality of Life,Other Disorders and Therapies in MS Patients on Betaferon","BetaSleep","Completed","No Results Available","Multiple Sclerosis","Drug: Interferon beta-1b (Betaferon, BAY 86-5046)","Sleep quality will be assessed by the Pittsburgh Sleep Quality Index (PSQI)|Fatique assessed by the Modified Fatigue Impact Scale (MFIS)|Functional health status assessed by Short Form-36 (SF-36)|Daytime sleepiness is measured with the Epworth Sleepiness Scale (ESS)|Depression and anxiety is measured with the Hospital anxiety and depression scale (HADS)|Pain is measured with the Hamburg Pain Adjective List (Hamburger Schmerz Adjektiv Liste (HSAL)|Severity of restless legs syndrome measured with the International Restless Legs Syndrome Study (IRLSS) group rating scale.","Bayer","All","18 Years and older   (Adult, Older Adult)",,"138","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16352|BF1212DE","December 6, 2012","January 9, 2017","March 14, 2017","January 11, 2013",,"February 19, 2018","Multiple Locations, Germany",,"https://ClinicalTrials.gov/show/NCT01766063"
639,"NCT01764841","Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)","RESPIRE 1","Completed","Has Results","Bronchiectasis","Drug: Ciprofloxacin DPI (BAYQ3939)|Drug: Placebo","Time to First Exacerbation Event Within 48 Weeks|Number of Participants With Exacerbation Events With Worsening of at Least Three Signs/Symptoms Over 48 Weeks|Number of Participants With Exacerbation Events With Worsening of at Least One Sign/Symptom Over 48 Weeks|Percentage of Participants With Pathogen Eradication at End of Treatment (Week 44/46)|Mean Change From Baseline in Patient Reported Outcome Saint George's Respiratory Questionnaire (SGRQ) Symptoms Component Score at End of Treatment (Week 44/46)|Percentage of Participants With Occurrence of New Pathogens Present at End of Treatment (Week 44/46)|Mean Change From Baseline in Patient Reported Outcome Quality of Life Questionnaire for Bronchiectasis (QoL-B) Respiratory Symptoms Domain Score at End of Treatment (Week 44/46)|Mean Change From Baseline in Forced Expiratory Volume in One Second (FEV1) at End of Treatment (Week 44/46)","Bayer|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","416","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15625|2011-004208-39","May 2, 2013","March 9, 2016","March 9, 2016","January 10, 2013","May 24, 2017","January 24, 2018","Jasper, Alabama, United States|Flagstaff, Arizona, United States|Phoenix, Arizona, United States|Scottsdale, Arizona, United States|Fort Smith, Arkansas, United States|Los Angeles, California, United States|Torrance, California, United States|Ventura, California, United States|Farmington, Connecticut, United States|Waterbury, Connecticut, United States|Washington, District of Columbia, United States|Celebration, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Weston, Florida, United States|Winter Park, Florida, United States|Lawrenceville, Georgia, United States|Marietta, Georgia, United States|Chicago, Illinois, United States|Michigan City, Indiana, United States|Hazard, Kentucky, United States|Chesterfield, Missouri, United States|Summit, New Jersey, United States|New Hyde Park, New York, United States|New York, New York, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Charleston, South Carolina, United States|Fort Worth, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Kingwood, Texas, United States|McKinney, Texas, United States|Tyler, Texas, United States|Abingdon, Virginia, United States|Richmond, Virginia, United States|Spokane, Washington, United States|Tacoma, Washington, United States|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Godoy Cruz, Mendoza, Argentina|Vicente López, Argentina|Woolloongabba, Queensland, Australia|Adelaide, South Australia, Australia|Adelaide, South Australia, Australia|Woodville, South Australia, Australia|Parkville, Victoria, Australia|Prahran, Victoria, Australia|Murdoch, Western Australia, Australia|Box Hill, Australia|Cairns, Australia|Frankston, Australia|Kogarah, Australia|Toorak Gardens, Australia|Aarhus C, Denmark|Hellerup, Denmark|Naestved, Denmark|Roskilde, Denmark|Clermont Ferrand, France|Montpellier, France|Nimes, France|Toulon, France|Heidelberg, Baden-Württemberg, Germany|Cottbus, Brandenburg, Germany|Frankfurt, Hessen, Germany|Neu-Isenburg, Hessen, Germany|Hannover, Niedersachsen, Germany|Hannover, Niedersachsen, Germany|Koblenz, Rheinland-Pfalz, Germany|Geesthacht, Schleswig-Holstein, Germany|Jena, Thüringen, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Hamburg, Germany|Afula, Israel|Ashkelon, Israel|Beer Sheva, Israel|Haifa, Israel|Haifa, Israel|Jerusalem, Israel|Petah Tikva, Israel|Ramat Gan, Israel|Rehovot, Israel|Tel Aviv, Israel|Benevento, Campania, Italy|Trieste, Friuli-Venezia Giulia, Italy|Roma, Lazio, Italy|Pavia, Lombardia, Italy|Varese, Lombardia, Italy|Bari, Puglia, Italy|Cagliari, Sardegna, Italy|Catania, Sicilia, Italy|Pisa, Toscana, Italy|Verona, Veneto, Italy|Toon, Ehime, Japan|Nakagun, Ibaraki, Japan|Koshi, Kumamoto, Japan|Matsusaka, Mie, Japan|Tsu, Mie, Japan|Sakai, Osaka, Japan|Hamamatsu, Shizuoka, Japan|Kiyose, Tokyo, Japan|Mitaka, Tokyo, Japan|Fukuoka, Japan|Daugavpils, Latvia|Daugavpils, Latvia|Jurmala, Latvia|Kraslava, Latvia|Riga, Latvia|Riga, Latvia|Riga, Latvia|Riga, Latvia|Talsu, Latvia|Auckland, New Zealand|Auckland, New Zealand|Christchurch, New Zealand|Dunedin, New Zealand|Hamilton, New Zealand|Tauranga, New Zealand|Wellington, New Zealand|Bratislava, Slovakia|Presov, Slovakia|Santiago de Compostela, A Coruña, Spain|Elda, Alicante, Spain|Oviedo, Asturias, Spain|Badalona, Barcelona, Spain|L'Hospitalet, Barcelona, Spain|Sant Boi de Llobregat, Barcelona, Spain|Terrassa, Barcelona, Spain|Pozuelo de Alarcón, Madrid, Spain|Barcelona, Spain|Barcelona, Spain|Cáceres, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Pontevedra, Spain|Valencia, Spain|Valencia, Spain|Cambridge, Cambridgeshire, United Kingdom|Exeter, Devon, United Kingdom|Plymouth, Devon, United Kingdom|Torbay, Devon, United Kingdom|Dundee, Dundee City, United Kingdom|Belfast, North Ireland, United Kingdom|Shrewsbury, Shropshire, United Kingdom|Newcastle Upon Tyne, Tyne And Wear, United Kingdom|Londonderry, United Kingdom|London, United Kingdom|Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01764841"
640,"NCT01764828","BAY86-9766 Plus Gemcitabine Phase I Study in Asian",,"Completed","No Results Available","Neoplasms","Drug: Refametinib (BAY86-9766)|Drug: Gemcitabine","Plasma concentration of BAY86-9766|Plasma concentration of M17 and M11|Plasma concentration of Gemcitabine|Plasma concentration of dFdU|Number of adverse events, or abnormal parameters as a measure of safety and tolerability|Efficacy of BAY86-9766 shown by a discrete scale","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","23","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","14747","February 5, 2013","December 18, 2014","February 10, 2015","January 10, 2013",,"November 1, 2018","Shanghai, China|Kashiwa, Chiba, Japan|Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01764828"
641,"NCT01756261","EYLEA [AMD-QOL(Age-Related Macular Degeneration-Quality of Life)] Post-marketing Surveillance in Japan",,"Completed","No Results Available","Macular Degeneration","Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)","Changes in mean NEI-VFQ-25 overall scores of patients after the first intravitreal(ITV) injection of EYLEA|Changes in mean NEI-VFQ-25 subscale scores of patients after the first ITV injection of EYLEA|Changes in mean NEI-VFQ-25 overall scores after the first ITV injection of EYLEA in subpopulations of patient background characteristics and status of EYLEA treatments, ie. Frequency, visual acuity, etc|Changes in mean NEI-VFQ-25 subscale scores after the first ITV injection of EYLEA in subpopulations of patient background characteristics and status of EYLEA treatments, ie. Frequency, visual acuity, etc","Bayer|Regeneron Pharmaceuticals","All","Child, Adult, Older Adult",,"757","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16656|EYL-AMD-QOL","December 26, 2012","July 20, 2016","February 27, 2017","December 25, 2012",,"June 19, 2018","Multiple Locations, Japan",,"https://ClinicalTrials.gov/show/NCT01756261"
642,"NCT01756248","EYLEA Age-Related Macular Degeneration (AMD) Post-marketing Surveillance in Japan",,"Completed","No Results Available","Macular Degeneration","Drug: Aflibercept(Eylea, VEGF Trap-Eye, BAY86-5321)","Number of participants with adverse drug reactions(ADRs) and infections from the first intravitreal(ITV) injection of EYLEA|Number of participants with serious adverse events (SAEs) and ocular adverse events(AEs) (especially AEs due to ITV injection procedure) from the first ITV injection of EYLEA|Number of participants with ADRs, SAEs and ocular AEs ( especially AEs due to ITV injection procedure) in subpopulations of patients background characteristics and status of EYLEA treatments from the first ITV injection of EYLEA|Mean changes in visual acuity|Proportion of patients who maintained visual acuity(corresponding to <15 letters of Early Treatment Diabetic Retinopathy Study(ETDRS) from baseline) and improved visual acuity(corresponding to >0 letter of ETDRS from baseline)|Mean changes in visual acuity in subpopulations of patients background characteristics and status of EYLEA treatments|Number and intervals of ITV injection of EYLEA","Bayer|Regeneron Pharmaceuticals","All","Child, Adult, Older Adult",,"4017","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","15895|EYL-AMD","December 26, 2012","December 31, 2018","May 20, 2019","December 25, 2012",,"June 25, 2019","Multiple Locations, Japan",,"https://ClinicalTrials.gov/show/NCT01756248"
643,"NCT01751763","Sorafenib for Residue Disease After Resection With Curative Intent","SECURE","Completed","No Results Available","Carcinoma, Hepatocellular","Drug: Sorafenib (Nexavar, BAY43-9006)","Patient characteristics: demographic, baseline characteristic, HCC diagnosis, prior HCC treatment, tumor status at operation, hepatic resection, time interval between surgery and Sorafenib, postoperative anti HCC treatment if any, past medical history|Treatment pattern of Sorafenib: duration and doses of Sorafenib, dose modification/discontinuation of Sorafenib, concomitant anti-cancer therapy, treatment after observed radiological recurrence.|Number of participants with adverse events( AE) and Serious adverse events(SAE) as a measure of safety and tolerability|Disease-free survival (DFS)|Recurrence rate by year|survival rate by year|Overall survival (OS)|Time to recurrence (TTR)","Bayer","All","18 Years and older   (Adult, Older Adult)",,"106","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16621|NX1218CN","July 9, 2013","December 31, 2016","September 8, 2017","December 18, 2012",,"September 25, 2017","Many Locations, China",,"https://ClinicalTrials.gov/show/NCT01751763"
644,"NCT01750788","Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Asia","XANAP","Completed","No Results Available","Atrial Fibrillation","Drug: Rivaroxaban (Xarelto, BAY59-7939)","Adjudicated major bleeding events|Safety variables will be summarized using descriptive statistics based on adverse events collection|All cause mortality|Adjudicated symptomatic thromboembolic events|Non-major bleeding, collected as SAEs or non-serious AEs and defined as all bleeding events that do not fall in the category of major bleedings|Treatment satisfaction as per patient assessment of rivaroxaban treatment by the physician at the final visit|Healthcare resource|Adverse events rates in the different AF risk factor categories|Persistence with rivaroxaban treatment measured as percentage of patients on rivaroxaban treatment at 1 year after start of study treatment|Reasons for switch of rivaroxaban treatment as per physician assessment during or at end of study|Reasons for interruption of rivaroxaban treatment as per physician assessment during or at end of study","Bayer|Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)",,"2297","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16371|XA1205","January 13, 2013","October 12, 2015","October 12, 2015","December 17, 2012",,"September 21, 2017","Many Locations, Hong Kong|Many Locations, India|Many Locations, Indonesia|Many Locations, Korea, Republic of|Many Locations, Malaysia|Many Locations, Pakistan|Many Locations, Philippines|Many Locations, Singapore|Many Locations, Taiwan|Many Locations, Thailand|Many Locations, Vietnam",,"https://ClinicalTrials.gov/show/NCT01750788"
645,"NCT01740687","A Study to Evaluate the Effectiveness of Essure Post-NovaSure Radiofrequency Endometrial Ablation Procedure Following a Successful Essure Confirmation Test","ESS-NSPAS","Active, not recruiting","No Results Available","Contraception|Menorrhagia","Device: ESS305 (Essure, BAY1454032)|Procedure: NovaSure","1-Year Pregnancy Rate|3-Year Pregnancy Rate|Incidence of Adverse Events when Novasure endometrial ablation is performed in the presence of Essure inserts","Bayer","Female","21 Years to 50 Years   (Adult)",,"209","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16975","November 13, 2012","July 3, 2021","July 29, 2021","December 4, 2012",,"January 18, 2020","Aurora, Colorado, United States|Ocala, Florida, United States|Decatur, Illinois, United States|Fort Wayne, Indiana, United States|Newburgh, Indiana, United States|Easton, Maryland, United States|Grand Blanc, Michigan, United States|Maplewood, Minnesota, United States|Las Vegas, Nevada, United States|Neptune, New Jersey, United States|Winston-Salem, North Carolina, United States|Englewood, Ohio, United States|Mason, Ohio, United States|Pottstown, Pennsylvania, United States|Nashville, Tennessee, United States|Norfolk, Virginia, United States|Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01740687"
646,"NCT01731132","DIU-QoL. Quality of Life Evaluation in Intrauterine Device Users.","DIUQoL","Completed","No Results Available","Contraception","Drug: Levonorgestrel IUD or Copper IUD","Impact on quality of life of women initiating IUD in a Spanish population assessed by questionnaire.|Demographic Data (Age, Place of Birth, Level of Education, Employment status, Personal marital situation, etc.) assessed by questionnaire.","Bayer","Female","18 Years to 49 Years   (Adult)",,"207","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16341|MA1213ES|BAY-DIU-2011-01","July 2012","February 2014","July 2014","November 21, 2012",,"July 16, 2015","Many Locations, Spain",,"https://ClinicalTrials.gov/show/NCT01731132"
647,"NCT01728948","Sorafenib in Elderly mRCC",,"Completed","No Results Available","Carcinoma, Renal Cell","Drug: Sorafenib (Nexavar, BAY43-9006)","Overall survival|Progression free survival by the Response Evaluation Criteria in Solid Tumor (RECIST) Criteria|Disease control rate by the Response Evaluation Criteria in Solid Tumor (RECIST) Criteria|Survival rate by one year|Number of participants with adverse events (AE) and Serious adverse events (SAE) as a measure of safety and tolerability|Patient characteristics (birthdate (at least year), sex, weight, height, etc)|Response rate (RR)|Time to first relief of clinical symptoms and physical signs|Treatment pattern","Bayer","All","65 Years and older   (Older Adult)",,"60","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16399|NX1212CN","January 6, 2013","January 4, 2016","January 16, 2017","November 20, 2012",,"November 9, 2017","Many Locations, China",,"https://ClinicalTrials.gov/show/NCT01728948"
648,"NCT01728740","Bioequivalence Study for Acarbose / Metformin FDC",,"Completed","No Results Available","Diabetes Mellitus, Type II","Drug: Acarbose/Metformin FDC (BAY81-9783)|Drug: Acarbose (Glucobay, BAYG5421)|Drug: Metformin","Ratio of postprandial maximum concentration (Cmax) of plasma glucose following sucrose load with (Day 1) and without acarbose (Day 0)|Ratio of postprandial Area Under the Curve (AUC(0 4)) of plasma glucose following sucrose load with (Day 1) and without acarbose (Day 0)|Cmax of metformin|AUC(0-tn) of metformin","Bayer","Male","18 Years to 45 Years   (Adult)","Phase 1","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","15420","September 2012","December 2012","December 2012","November 20, 2012",,"December 19, 2012","Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01728740"
649,"NCT01728311","Open Label Study of BAY1082439 in Patients With Advanced Cancer",,"Completed","No Results Available","Neoplasms","Drug: BAY1082439","Number of participants with adverse events as a measure of safety and tolerability|Maximum tolerated dose of BAY1082439|Maximum observed plasma concentration (Cmax) of BAY1082439 after a single dose|Time to Cmax (tmax) of BAY1082439 after a single dose|Area under the plasma concentration-time curve (AUC[0-t]) of BAY1082439 after a single dose|Area under the concentration-time curve over the dosing interval (AUC[0-tau])|Maximum observed concentration (Cmax)|Time of occurrence of Cmax (tmax)|Terminal phase half-life (t1/2)|Tumor response based on Response Evaluation Criteria in Solid Tumors, Version 1.1","Bayer","All","21 Years and older   (Adult, Older Adult)","Phase 1","60","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15734","November 21, 2012","June 3, 2016","February 6, 2017","November 19, 2012",,"January 30, 2018","Seoul, Korea, Republic of|Seoul, Korea, Republic of|Singapore, Singapore|Singapore, Singapore|Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01728311"
650,"NCT01723475","First-in-man Dose Escalation Study of BAY2010112 in Patients With Prostate Cancer",,"Completed","No Results Available","Prostatic Neoplasms","Biological: BAY2010112","Number of participants with Adverse Events as a Measure of Safety and Tolerability|Maximum Tolerated Dose (MTD)|Maximum drug concentration (Cmax) of BAY2010112 in serum after single and multiple doses administration|Area under the concentration versus time curve (AUC) from zero to infinity after single (first) and multiple doses of BAY2010112|Tumor response|Prostate-specific antigen (PSA) response","Bayer","Male","18 Years and older   (Adult, Older Adult)","Phase 1","47","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15590|2012-000691-42","November 2, 2012","July 18, 2018","September 26, 2018","November 8, 2012",,"September 27, 2019","Linz, Oberösterreich, Austria|Wien, Austria|Heidelberg, Baden-Württemberg, Germany|Würzburg, Bayern, Germany|Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT01723475"
651,"NCT01706055","Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon (INFLUENCE)","INFLUENCE","Completed","No Results Available","Multiple Sclerosis","Biological: Interferon beta-1b (Betaseron, BAY86-5046)","Mean severity score of Flu-Like Symptoms (FLS) recorded within the first 6 months following treatment initiation|MS patient with Flu-Like Symptoms (FLS) demographic profile|Frequency of usage of particular pharmacological and non-pharmacological practices applied by investigators to prevent or manage FLS|The impact of FLS on patients daily activities as measured by current professional/educational status|Betaferon tolerability measured as occurrence of Adverse Events (AE) and FLS over 6 months period","Bayer","All","18 Years and older   (Adult, Older Adult)",,"629","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16400|BF1213PL","September 2012","September 2015","March 2016","October 15, 2012",,"March 14, 2017","Many Locations, Poland",,"https://ClinicalTrials.gov/show/NCT01706055"
652,"NCT01697111","Comparative Study of BAY86-5300 With an Extended Flexible Regimen for Endometriosis",,"Completed","No Results Available","Endometriosis","Drug: EE20/DRSP(BAY86-5300)|Drug: Placebo|Drug: Dienogest","Change of pelvic pain from baseline period (8 weeks before start of treatment) to period of treatment (weeks 17-24)|Pelvic pain during menstrual or withdrawal bleeding period (except for dyspareunia and defecation pain)|Pelvic pain during non-menstrual period and non-withdrawal bleeding period (except for dyspareunia and defecation pain)|Dyspareunia|Average of pain|Size of chocolate cyst|Endometrial thickness|Number of days with spotting/bleeding","Bayer","Female","20 Years and older   (Adult, Older Adult)","Phase 3","312","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","15457","October 2012","March 2014","December 2014","October 2, 2012",,"February 18, 2016","Anjo, Aichi, Japan|Ichinomiya, Aichi, Japan|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Matsudo, Chiba, Japan|Takasaki, Gunma, Japan|Itami, Hyogo, Japan|Kawanishi, Hyogo, Japan|Kobe, Hyogo, Japan|Kanazawa, Ishikawa, Japan|Kamakura, Kanagawa, Japan|Kawasaki, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Toyonaka, Osaka, Japan|Kitamoto, Saitama, Japan|Bunkyo, Tokyo, Japan|Chuo-ku, Tokyo, Japan|Fuchu, Tokyo, Japan|Hachioji, Tokyo, Japan|Itabashi, Tokyo, Japan|Machida, Tokyo, Japan|Minato, Tokyo, Japan|Minato, Tokyo, Japan|Nishitokyo, Tokyo, Japan|Fukui, Japan|Fukui, Japan|Gifu, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan",,"https://ClinicalTrials.gov/show/NCT01697111"
653,"NCT01691209","Efficacy/Safety Study to Explore a New Topical Formulation in Atopic Dermatitis","Phoenix","Withdrawn","No Results Available","Dermatitis, Atopic","Device: Phoenix (BAY81-2996)|Drug: 1% Hydrocortison cream","Number of participants with abnormal vital signs|Number of participants with adverse events as a measure of safety and tolerability","Bayer","All","18 Years to 60 Years   (Adult)","Not Applicable","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","16200|2012-001504-38","October 2013","April 2014","June 2014","September 24, 2012",,"August 13, 2013","Münster, Nordrhein-Westfalen, Germany",,"https://ClinicalTrials.gov/show/NCT01691209"
654,"NCT01690559","Ciprofloxacin Special Drug Use Investigation - To Investigate the Safety and Efficacy in Patients With Ciprofloxacin iv Administration Without Dilution",,"Completed","No Results Available","Infection","Drug: Cipro (Ciprofloxacin, BAYQ3939)","Incidence of adverse drug reactions (ADRs) and serious adverse events (AEs)|Clinical efficacy by four grade (Response, Minor Response, No Response, and Indeterminable) at an investigator discretion|ADR incidence rates classified by patient's background factors|Efficacy rate calculated with Response and Minor Response considered as responder|Efficacy rates classified by patient's background factors","Bayer","All","7 Years and older   (Child, Adult, Older Adult)",,"704","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","16516|CIPRO-IV-2010","April 2010","January 2012","January 2012","September 21, 2012",,"September 21, 2012","Many Locations, Japan",,"https://ClinicalTrials.gov/show/NCT01690559"
655,"NCT01690533","Special Drug Use Investigation - Assessment of Efficacy and Safety in Treating Secondary Infection of Chronic Respiratory Disease",,"Completed","No Results Available","Anti-Infective Agents","Drug: Avelox (Moxifloxacin, BAY12-8039)","Number of adverse drug reactions (ADRs) and serious adverse events (SAEs)|Clinical efficacy rate (Response, Minor Response, No Response and Indeterminable) assessed by investigator's discretion. Efficacy rate is calculated as number of patients with Response or Minor Response proportional to number of all cases.|ADR incidence rates classified by patient's background factors|Efficacy rates classified by patient's background factors","Bayer","All","20 Years and older   (Adult, Older Adult)",,"497","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","16515","May 13, 2008","December 14, 2010","July 19, 2013","September 21, 2012",,"May 21, 2018","Multiple Locations, Japan",,"https://ClinicalTrials.gov/show/NCT01690533"
656,"NCT01689376","Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program)",,"No longer available","No Results Available","Gastrointestinal Stromal Tumors","Drug: Regorafenib (BAY73-4506)",,"Bayer","All","18 Years to 99 Years   (Adult, Older Adult)",,,"Industry","Expanded Access",,"16040",,,,"September 21, 2012",,"August 16, 2016",,,"https://ClinicalTrials.gov/show/NCT01689376"
657,"NCT01687920","Dose Proportionality Study With BAY94-8862 IR (Immediate Release) Tablets",,"Completed","No Results Available","Heart Failure","Drug: BAY94-8862 (1.25mg)|Drug: BAY94-8862 (2.5mg)|Drug: BAY94-8862 (5mg)|Drug: BAY94-8862 (7.5mg)|Drug: BAY94-8862 (10mg)","Dose proportionality of BAY94-8862 exposure in plasma when given as 1.25, 2.5, 5.0, 7.5 and 10 mg IR tablets|Number of participants with adverse events as a measure of safety and tolerability of BAY94-8862","Bayer","Male","18 Years to 46 Years   (Adult)","Phase 1","25","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","15481|2012-003055-10","September 2012","November 2012","November 2012","September 19, 2012",,"January 10, 2014","Mönchengladbach, Nordrhein-Westfalen, Germany",,"https://ClinicalTrials.gov/show/NCT01687920"
658,"NCT01685502","Special Drug Use Investigation of Glucobay OD",,"Completed","No Results Available","Diabetes Mellitus","Drug: Glucobay ODT (Acarbose, BAYG5421)","Incidence of adverse drug reactions (ADRs) and serious adverse events (SAEs)|Decrease rate of HbA1c|Body weight","Bayer","All","Child, Adult, Older Adult",,"2289","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","16517|Glucobay OD","November 2010","September 2013","August 2014","September 14, 2012",,"October 20, 2014","Many Locations, Japan",,"https://ClinicalTrials.gov/show/NCT01685502"
659,"NCT01684423","Oral Rivaroxaban in Children With Venous Thrombosis","EINSTEINJunior","Completed","Has Results","Venous Thrombosis","Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Active comparator|Drug: Rivaroxaban (BAY59-7939) suspension","Number of Subjects With Major and Clinically Relevant Non-Major Bleeding Events|Number of Subjects With Symptomatic Recurrent Venous Thromboembolism|Number of Subjects With Asymptomatic Deterioration in Thrombotic Burden|Change From Baseline in Prothrombin Time at Specified Time Points|Change From Baseline in Activated Partial Thromboplastin Time at Specified Time Points|Anti-factor Xa Values at Specified Time Points|Concentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Specified Time Points","Bayer|Janssen Research & Development, LLC","All","6 Years to 17 Years   (Child)","Phase 2","64","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14373|2011-004539-30","February 19, 2013","September 1, 2016","September 1, 2016","September 13, 2012","September 21, 2017","September 21, 2017","Little Rock, Arkansas, United States|Los Angeles, California, United States|Orange, California, United States|Chicago, Illinois, United States|Indianapolis, Indiana, United States|Detroit, Michigan, United States|Minneapolis, Minnesota, United States|New Hyde Park, New York, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Philadelphia, Pennsylvania, United States|Houston, Texas, United States|Richmond, Virginia, United States|Westmead, New South Wales, Australia|Parkville, Victoria, Australia|South Brisbane, Australia|Linz, Oberösterreich, Austria|Graz, Steiermark, Austria|Innsbruck, Tirol, Austria|Wien, Austria|Edmonton, Alberta, Canada|Hamilton, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Quebec, Canada|BORDEAUX cedex, France|Montpellier Cedex, France|NANTES Cedex 1, France|Paris, France|Paris, France|Rennes Cedex, France|TOULOUSE Cedex 9, France|Freiburg, Baden-Württemberg, Germany|Erlangen, Bayern, Germany|Frankfurt, Hessen, Germany|Dresden, Sachsen, Germany|Lübeck, Schleswig-Holstein, Germany|Berlin, Germany|Beer Sheva, Israel|Haifa, Israel|Jerusalem, Israel|Petach Tikva, Israel|Ramat Gan, Israel|Genova, Liguria, Italy|Milano, Lombardia, Italy|Pavia, Lombardia, Italy|Torino, Piemonte, Italy|Bari, Puglia, Italy|Padova, Veneto, Italy|Amsterdam, Netherlands|Amsterdam, Netherlands|Nijmegen, Netherlands|Rotterdam, Netherlands|Utrecht, Netherlands|Basel, Basel-Stadt, Switzerland|St. Gallen, Sankt Gallen, Switzerland|Bern, Switzerland|Luzern, Switzerland|Zürich, Switzerland",,"https://ClinicalTrials.gov/show/NCT01684423"
660,"NCT01679587","Dose Escalation Study to Investigate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY85-3934 in Subjects With Chronic Kidney Disease (CKD)",,"Completed","No Results Available","Kidney Diseases","Drug: Molidustat (BAY85-3934)|Drug: Placebo","Number of participants with adverse events|Blood pressure|Heart rate|Cmax|Cmax/D|AUC|AUC/D|Heart rate over 1 min|Standing blood pressure procedure|Impedance cardiography|Change of hematology profile|Cmax,norm|AUCnorm|AUC(0-24)|AUC(0-tlast)|t½|tmax|MRT|CL/F|Vz/F|Geometric mean erythropoietin Cmax|Geometric mean reticulocyte count|Geometric mean erythrocyte count|Geometric mean reticulocytes/erythrocytes values|Geometric mean hemoglobin values|Geometric mean hematocrit|Geometric mean erythropoietin tmax|Geometric mean erythropoietin AUC(0-24)","Bayer","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 1","49","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)","16370|2012-002375-33","September 2012","February 2013","July 2013","September 6, 2012",,"May 2, 2016","München, Bayern, Germany|Mönchengladbach, Nordrhein-Westfalen, Germany|Kiel, Schleswig-Holstein, Germany",,"https://ClinicalTrials.gov/show/NCT01679587"
661,"NCT01674647","Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion","X-VERT","Completed","Has Results","Atrial Fibrillation","Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Vitamin K antagonist (VKA)","Number of Participants With Composite of the Following Events, Adjudicated Centrally: Stroke, Transient Ischemic Attack, Non-central Nervous System Systemic Embolism, Myocardial Infarction and Cardiovascular Death|Number of Participants With Major Bleedings as Per Central Adjudication|Number of Participants With Composite of Strokes and Non-central Nervous System Systemic Embolisms|Number of Participants With Composite of Strokes, Transient Ischemic Attacks, Non-central Nervous System Systemic Embolisms, Myocardial Infarctions and All-cause Mortality|Number of Participants With Strokes|Number of Participants With Transient Ischemic Attacks|Number of Participants With Non-central Nervous System Systemic Embolisms|Number of Participants With Myocardial Infarctions|Number of Participants With Cardiovascular Deaths|Number of Participants With All-cause Mortality|Number of Participants With Composite of Major and Non-major Bleeding Events","Bayer|Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 3","1504","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","15693|2011-002234-39","October 2012","January 2014","January 2014","August 29, 2012","February 3, 2015","April 30, 2015","Mobile, Alabama, United States|Scottsdale, Arizona, United States|East Palo Alto, California, United States|El Cajon, California, United States|National City, California, United States|Sacramento, California, United States|Santa Rosa, California, United States|Torrance, California, United States|New Haven, Connecticut, United States|Stamford, Connecticut, United States|Wilmington, Delaware, United States|Clearwater, Florida, United States|Daytona Beach, Florida, United States|Deltona, Florida, United States|Ft. Lauderdale, Florida, United States|Ft. Lauderdale, Florida, United States|Hollywood, Florida, United States|Jacksonville, Florida, United States|Lakeland, Florida, United States|Melbourne, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|St. Augustine, Florida, United States|Tallahassee, Florida, United States|Savannah, Georgia, United States|Aurora, Illinois, United States|Chicago, Illinois, United States|Chicago, Illinois, United States|Elk Grove Village, Illinois, United States|Joliet, Illinois, United States|Rockford, Illinois, United States|Annapolis, Maryland, United States|Columbia, Maryland, United States|Rockville, Maryland, United States|Lincoln, Nebraska, United States|North Las Vegas, Nevada, United States|Bridgewater, New Jersey, United States|Manalapan, New Jersey, United States|Albuquerque, New Mexico, United States|Buffalo, New York, United States|New York, New York, United States|New York, New York, United States|Troy, New York, United States|Asheville, North Carolina, United States|Cantan, Ohio, United States|Cleveland, Ohio, United States|Mansfield, Ohio, United States|Toledo, Ohio, United States|Beaver, Pennsylvania, United States|Butler, Pennsylvania, United States|Doylestown, Pennsylvania, United States|Hershey, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Rapid City, South Dakota, United States|Johnson City, Tennessee, United States|Nashville, Tennessee, United States|Nashville, Tennessee, United States|Austin, Texas, United States|Dallas, Texas, United States|Fort Sam Houston, Texas, United States|Tyler, Texas, United States|Layton, Utah, United States|Bellingham, Washington, United States|Burien, Washington, United States|Wausau, Wisconsin, United States|Leuven, Vlaams Brabant, Belgium|Bruxelles - Brussel, Belgium|Gilly, Belgium|Hasselt, Belgium|Liege, Belgium|MOL, Belgium|Curitiba, Parana, Brazil|Porto Alegre, Rio Grande do Sul, Brazil|Campinas, Sao Paulo, Brazil|Campinas, Sao Paulo, Brazil|Sao Paulo, Brazil|Edmonton, Alberta, Canada|Victoria, British Columbia, Canada|Saint John, New Brunswick, Canada|St. John's, Newfoundland and Labrador, Canada|Hamilton, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Quebec, Canada|Guangzhou, Guangdong, China|Wuhan, Hubei, China|Changsha, Hunan, China|Nanchang, Jiangxi, China|Changchun, Jilin, China|Xi'an, Shaanxi, China|Urumqi, Xinjiang, China|Beijing, China|Shanghai, China|Shenyang, China|Hellerup, Denmark|Herning, Denmark|København NV, Denmark|Viborg, Denmark|Helsinki, Finland|Jyväskylä, Finland|Lappeenranta, Finland|Oulu, Finland|Pori, Finland|Rovaniemi, Finland|Tampere, Finland|Turku, Finland|Vaasa, Finland|Arras, France|Lille Cedex, France|Paris cedex 13, France|Paris, France|Paris, France|Pessac, France|TOULOUSE cedex, France|Tours, France|Vandoeuvre-les-nancy, France|Freiburg, Baden-Württemberg, Germany|Nürnberg, Bayern, Germany|Frankfurt, Hessen, Germany|Bad Oeynhausen, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Mönchengladbach, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Berlin, Germany|Hamburg, Germany|Alexandroupolis, Greece|Attica / Athens, Greece|Heraklion, Greece|Thessaloniki, Greece|Acquaviva delle Fonti, Bari, Italy|San Fermo della Battaglia, Como, Italy|San Donato Milanese, Milano, Italy|Mestre, Venezia, Italy|Ancona, Italy|Catania, Italy|Roma, Italy|Torino, Italy|Arnhem, Netherlands|Haarlem, Netherlands|Heerlen, Netherlands|Leeuwarden, Netherlands|Maastricht, Netherlands|Martinho do Bispo, Coimbra, Portugal|Carnaxide, Lisboa, Portugal|Almada, Portugal|Faro, Portugal|Lisboa, Portugal|Vila Nova de Gaia, Portugal|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|Alberton, Gauteng, South Africa|Soweto, Gauteng, South Africa|Cape Town, Western Cape, South Africa|Cape Town, Western Cape, South Africa|Kuils River, Western Cape, South Africa|Somerset West, Western Cape, South Africa|Worcester, Western Cape, South Africa|Bloemfontein, South Africa|Sabadell, Barcelona, Spain|Majadahonda, Madrid, Spain|Barcelona, Spain|Granada, Spain|Madrid, Spain|Pamplona, Spain|Chesterfield, Derbyshire, United Kingdom|Bournemouth, Dorset, United Kingdom|Welwyn Garden City, Hertfordshire, United Kingdom|Leicester, Leicestershire, United Kingdom|Nottingham, Nottinghamshire, United Kingdom|Cliftonville, United Kingdom|London, United Kingdom|Portsmouth, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01674647"
662,"NCT01670435","Assessment of the Safety and Efficacy of Ciproxan-I.V. in Daily Clinical Practice - Analysis Results From a Post-marketing Surveillance",,"Completed","No Results Available","Infection","Drug: Ciprofloxacin (BAYQ3939)","Incidence of adverse drug reactions (ADRs) and serious adverse events (AEs)|Clinical efficacy by four grade (Response, Minor Response, No Response, and Indeterminable) at an investigator discretion|ADR incidence rates classified by patient's background factors|Efficacy rate calculated with Response and Minor Response considered as responder|Efficacy rates classified by patient's background factors","Bayer","All","7 Years and older   (Child, Adult, Older Adult)",,"3274","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","15029|CIPRO-IV-2007","May 2007","June 2010","October 2010","August 22, 2012",,"August 28, 2012","Many Locations, Japan",,"https://ClinicalTrials.gov/show/NCT01670435"
663,"NCT01669824","Pharmacy Based Pharmacoepidemiological Observational Study With Aspirin Protect 100 mg",,"Completed","No Results Available","Aspirin|Drug Safety|Effects, Longterm","Drug: Acetylsalicylic acid (Aspirin, BAYE4465)","Overall and gastrointestinal tolerability assessed by questionnaire","Bayer","All","Child, Adult, Older Adult",,"4235","Industry","Observational","Time Perspective: Prospective","12557|MUE 053","August 2007",,"May 2009","August 21, 2012",,"August 21, 2012","Many Locations, Germany",,"https://ClinicalTrials.gov/show/NCT01669824"
664,"NCT01666678","Compare Pharmacokinetic (PK) Profiles of Naproxen Sodium, Diphenhydramine Hydrochloride, and Naproxen Sodium and Diphenhydramine Hydrochloride Combination","Morpheus PK","Completed","No Results Available","Therapeutic Equivalence","Drug: BAY98-7111|Drug: Naproxen Sodium (Aleve, BAYH6689)|Drug: Diphenhydramine HCl","AUC(0-tn) (area under the measurement versus time curve from time 0 to the last data point) of naproxen sodium|AUC(0-tn) (area under the measurement versus time curve from time 0 to the last data point) of DPH HCL(Diphenhydramine Hydrochloride)|Cmax(Maximum drug concentration) in plasma of naproxen sodium|Cmax(Maximum drug concentration) in plasma of DPH HCL(Diphenhydramine Hydrochloride)|Number of participants with adverse events as a measure of safety and tolerability","Bayer","All","18 Years to 55 Years   (Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","16135","January 2012","February 2012","March 2012","August 16, 2012",,"August 21, 2014","Hackensack, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01666678"
665,"NCT01664052","ESS505 Pre-hysterectomy Protocol",,"Completed","Has Results","Contraception","Device: ESS505 (Essure, BAY1454033)|Device: ESS305 (Essure, BAY1454032)|Device: ESS505-A (Essure, BAY1454033)","Number of Occluded Fallopian Tubes 60 Minutes After Placement of the Insert as Measured by an HSG Evaluation|Number of Occluded Fallopian Tubes 30 Days Following Placement as Measured by an HSG Evaluation|Number of Occluded Fallopian Tubes 60 Days Following Placement as Measured by an HSG Evaluation|Number of Occluded Fallopian Tubes 90 Days Following Placement as Measured by an HSG Evaluation","Bayer","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","66","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","17035|ESS505-002","July 2012","March 2013","March 2013","August 14, 2012","May 19, 2016","August 4, 2016","Regina, Saskatchewan, Canada|Chihuahua, Mexico",,"https://ClinicalTrials.gov/show/NCT01664052"
666,"NCT01660841","Safety and Efficacy of Gadobutrol 1.0 Molar in Japanese Subjects for CNS Imaging",,"Completed","No Results Available","Magnetic Resonance Imaging","Drug: Gadobutrol (Gadovist, BAY86-4875)","Scores for visualization parameter: degree of contrast enhancement|Scores for visualization parameter: border delineation|Scores for visualization parameter: internal morphology|Number of detected lesions|Percentage of exact match of the MRI diagnosis with the final clinical diagnosis|Sensitivity and specificity to detect abnormal/normal brain tissue|Sensitivity and specificity to detect malignant Central Nervous System(CNS) lesions|Number of participants with treatment emergent adverse events as a measure of safety and tolerability","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","223","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","16260","September 2012","August 2013","August 2013","August 9, 2012",,"October 1, 2014","Nagoya, Aichi, Japan|Funabashi, Chiba, Japan|Kitakyushu, Fukuoka, Japan|Fukuyama, Hiroshima, Japan|Kobe, Hyogo, Japan|Kobe, Hyogo, Japan|Fujisawa, Kanagawa, Japan|Kawasaki, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Daito, Osaka, Japan|Kishiwada, Osaka, Japan|Shimonoseki, Yamaguchi, Japan|Ube, Yamaguchi, Japan|Fukuoka, Japan|Fukuoka, Japan",,"https://ClinicalTrials.gov/show/NCT01660841"
667,"NCT01660451","Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas",,"Active, not recruiting","Has Results","Lymphoma, Non-Hodgkin","Drug: Copanlisib (Aliqopa, BAY80-6946)","Objective Response Rate (ORR) Based on Independent Review-Part A|Objective Response Rate (ORR) Based on Independent Review-Part B|ORR Based on Investigator Assessment-Part A|ORR Based on Investigator Assessment-Part B|Duration of Response (DOR) Based on Independent Review|DOR Based on Investigator Assessment|Progression Free Survival (PFS) Based on Independent Review|PFS Based on Investigator Assessment|Overall Survival (OS)|Functional Assessment of Cancer Therapy - Lymphoma Lymphoma Subscale (FACT-Lym LymS) at Week 16 - Part B|Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) Total Score at Week 16 - Part B","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","227","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16349|2012-002602-52","November 19, 2012","June 22, 2016","March 8, 2021","August 8, 2012","January 8, 2018","January 18, 2020","Birmingham, Alabama, United States|Gilbert, Arizona, United States|Anaheim, California, United States|Aurora, Colorado, United States|Englewood, Colorado, United States|Fort Collins, Colorado, United States|Port Saint Lucie, Florida, United States|Louisville, Kentucky, United States|Detroit, Michigan, United States|Saint Louis Park, Minnesota, United States|Lake Success, New York, United States|Goldsboro, North Carolina, United States|Canton, Ohio, United States|San Antonio, Texas, United States|Spokane, Washington, United States|Garran, Australian Capital Territory, Australia|Linz, Austria|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Gent, Belgium|Leuven, Belgium|Turnhout, Belgium|Wilrijk, Belgium|Sofia, Bulgaria|Saint John, New Brunswick, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Helsinki, Finland|Oulu, Finland|Tampere, Finland|Turku, Finland|Brest, France|Creteil, France|La Roche Sur Yon, France|Lille, France|PARIS cedex, France|Pessac, France|Pierre Benite, France|Poitiers, France|Rouen, France|Vandoeuvre-les-nancy, France|München, Bayern, Germany|Potsdam, Berlin, Germany|Münster, Nordrhein-Westfalen, Germany|Recklinghausen, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Dresden, Sachsen, Germany|Berlin, Germany|Berlin, Germany|Athens, Greece|Hong Kong, Hong Kong|Shatin, Hong Kong|Budapest, Hungary|Budapest, Hungary|Kaposvar, Hungary|Galway, Ireland|Petah Tikva, Israel|Ramat Gan, Israel|Zerifin, Israel|Napoli, Campania, Italy|Bologna, Emilia-Romagna, Italy|Roma, Lazio, Italy|Brescia, Lombardia, Italy|Milano, Lombardia, Italy|Torino, Piemonte, Italy|Busan, Busan Gwang''yeogsi, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Christchurch, New Zealand|Gdynia, Poland|Krakow, Poland|Lisboa, Portugal|Kemerovo, Russian Federation|Moscow, Russian Federation|Nizhny Novgorod, Russian Federation|Omsk, Russian Federation|Saratov, Russian Federation|St. Petersburg, Russian Federation|Singapore, Singapore|Singapore, Singapore|Majadahonda, Madrid, Spain|Marbella, Málaga, Spain|Barcelona, Spain|Madrid, Spain|Sevilla, Spain|Valencia, Spain|Uddevalla, Sweden|Ankara, Turkey|Istanbul, Turkey|Izmir, Turkey|Izmir, Turkey|Cambridge, Cambridgeshire, United Kingdom|Plymouth, Devon, United Kingdom|Southampton, Hampshire, United Kingdom|Harrow, London, United Kingdom|Liverpool, Merseyside, United Kingdom|Sutton, Surrey, United Kingdom|Birmingham, West Midlands, United Kingdom|Leeds, United Kingdom|Manchester, United Kingdom|Romford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01660451"
668,"NCT01653639","Comparative Pharmacokinetic Study of Two Different Strengths of BAY14-2222",,"Completed","No Results Available","Hemophilia A","Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)","Maximum plasma concentration (Cmax) of BAY14-2222|Area under the plasma concentration vs time curve from time 0 to time of last measurable concentration AUC(0-tlast) of BAY14-2222","Bayer","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15495|2012-001045-40","July 2012","December 2012","December 2012","July 31, 2012",,"January 10, 2014","Sofia, Bulgaria",,"https://ClinicalTrials.gov/show/NCT01653639"
669,"NCT01646593","Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy",,"No longer available","No Results Available","Gastrointestinal Stromal Tumors","Drug: Regorafenib (BAY73-4506)",,"Bayer","All","18 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access",,"16339",,,,"July 20, 2012",,"December 15, 2014",,,"https://ClinicalTrials.gov/show/NCT01646593"
670,"NCT01643304","A Swedish Questionnaire Study to Investigate the Perception of Menstrual Bleedings",,"Completed","No Results Available","Menorrhagia","Behavioral: No drug","Prevalence of subjectively experienced heavy menstrual bleeding assessed by questionnaire|Social consequences of heavy menstrual bleedings assessed by questionnaire|Costs; e.g. pads, absence from work, loss of income assessed by questionnaire|The treatments given for heavy menstrual bleedings, as surgery or medication assessed by questionnaire","Bayer","Female","40 Years to 45 Years   (Adult)",,"1547","Industry","Observational","Time Perspective: Cross-Sectional","16384|NN1223SE","May 2012",,"June 2012","July 18, 2012",,"November 21, 2013","Many Locations, Sweden",,"https://ClinicalTrials.gov/show/NCT01643304"
671,"NCT01643122","Validation Study for Endometriosis PRO","VALEPRO","Completed","No Results Available","Endometriosis","Other: No drug","Endometriosis symptoms rated by the Endometriosis Symptom Diary","Bayer","Female","18 Years to 45 Years   (Adult)",,"275","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","15849","August 2012","July 2013","September 2013","July 17, 2012",,"October 13, 2014","Jonesboro, Arkansas, United States|Sacramento, California, United States|San Diego, California, United States|San Diego, California, United States|San Francisco, California, United States|New Haven, Connecticut, United States|Decatur, Georgia, United States|Champaign, Illinois, United States|Worcester, Massachusetts, United States|Rochester, Minnesota, United States|Brooklyn, New York, United States|Greensboro, North Carolina, United States|Cincinnati, Ohio, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|San Angelo, Texas, United States|Salt Lake City, Utah, United States|Sandy, Utah, United States|Norfolk, Virginia, United States|Seattle, Washington, United States|Many Locations, Germany",,"https://ClinicalTrials.gov/show/NCT01643122"
672,"NCT01638923","Study of a 4-phasic Oral Contraceptive for the Treatment of Heavy Menstrual Bleeding",,"Completed","No Results Available","Metrorrhagia","Drug: EV/DNG (Qlaira, Natazia, BAY86-5027)|Drug: placebo","Absolute change in Menstrual Blood Loss (MBL) at baseline and 90 days|Proportion of subjects with successful treatment|Percent change of MBL at baseline and 90 day period during treatment phase|Absolute change of average MBL at baseline and up to cycle 7 (one cycle = 28 days)|Proportion of subjects with improvement in the investigator's global assessment scale on Day 84|Proportion of subjects with improvement in the investigator's global assessment scale on Day 196|Proportion of subjects with improvement in the subject's global assessment scale on Day 84|Proportion of subjects with improvement in the subject's global assessment scale on Day 196|Number of participants with adverse events as a measure of safety and tolerability","Bayer","Female","18 Years and older   (Adult, Older Adult)","Phase 3","339","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","91774|X311965","June 2012","June 2015","June 2015","July 12, 2012",,"July 10, 2015","Guangzhou, Guangdong, China|Nanning, Guangxi, China|Shijiazhuang, Hebei, China|Wuhan, Hubei, China|Wuhan, Hubei, China|Changsha, Hunan, China|Hengyang, Hunan, China|Dalian, Liaoning, China|Shenyang, Liaoning, China|Xi'an, Shaanxi, China|Jinan, Shandong, China|Chengdu, Sichuan, China|Chengdu, Sichuan, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Changchun, China|Chongqing, China|Qingdao, China|Shanghai, China|Shanghai, China|Tianjin, China|Tianjin, China|Manila, Philippines|Quezon City, Philippines|Irkutsk, Russian Federation|Ivanovo, Russian Federation|Krasnodar, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|Singapore, Singapore|Singapore, Singapore|Taichung, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Bangkok, Thailand|Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT01638923"
673,"NCT01638910","Efficacy and Safety of a Combined Oral Contraceptive of Estradiol Valerate and Dienogest in Healthy Female Subjects",,"Completed","No Results Available","Contraception","Drug: EV/DNG (Qlaira, BAY86-5027)","Number of unintended pregnancies|Number of expected bleeding days|Number of unexpected bleeding days|Number of expected bleeding episodes|Number of unexpected bleeding episodes|Number of participants with Adverse Events as a Measure of Safety and Tolerability","Bayer","Female","18 Years to 50 Years   (Adult)","Phase 3","955","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","91773","June 2012","November 2014","November 2014","July 12, 2012",,"December 17, 2014","Guangzhou,, Guangdong, China|Guangzhou, Guangdong, China|Shijiazhuang, Hebei, China|Wuhan, Hubei, China|Wuhan, Hubei, China|Changsha, Hunan, China|Hengyang, Hunan, China|Nanjing, Jiangsu, China|Dalian, Liaoning, China|Shenyang, Liaoning, China|Jinan, Shandong, China|Chengdu, Sichuan, China|Wenzhou, Zhejiang, China|Beijing, China|Beijing, China|Chongqing, China|Chongqing, China|Chongqing, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|Tianjin, China|Hongkong, Hong Kong|Pune, Maharashtra, India|Chandigarh, India|Karnal, India|New Delhi, India|Pune, India|Secunderabad, India|Kaohsiung, Taiwan|Taichung, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Bangkok, Thailand|Bangkok, Thailand|Chiangmai, Thailand",,"https://ClinicalTrials.gov/show/NCT01638910"
674,"NCT01625390","A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150",,"Completed","No Results Available","Hemophilia A, Hemophilia B","Drug: BAY86-6150|Drug: eptacog alfa [activated]","Successful treatments of bleeding episodes.|Proportion of successful treatments of bleeding episodes on subject level.|Time to stop the bleed|Number of injections needed to stop the bleeding episode.|Effectiveness of treatment as rated by the subject's assessment (very effective, effective, partially effective, not effective).|Participant's reported outcome as assessed by Euro QoL (EQ-5D).|Participant's reported outcome as assessed by Brief Pain Inventory.|Participant's reported outcome as assessed by Work Productivity and Activity Impairment Questionaire.","Bayer","Male","12 Years to 62 Years   (Child, Adult)","Phase 2|Phase 3","10","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15534|2011-000323-33|U1111-1133-2156","June 2012","March 2014","March 2014","June 21, 2012",,"July 1, 2015","Sacramento, California, United States|Chattanooga, Tennessee, United States|Melbourne, Victoria, Australia|São Paulo, Sao Paulo, Brazil|Rio de Janeiro, Brazil|Sao Paulo, Brazil|Sofia, Bulgaria|Santiago, Chile|Guangzhou, Guangdong, China|Beijing, China|Tianjin, China|Barranquilla, Atlántico, Colombia|Bogotá, Colombia|Aarhus N, Denmark|Lyon Cedex, France|Tours, France|Villingen-Schwenningen, Baden-Württemberg, Germany|Mainz, Rheinland-Pfalz, Germany|Budapest, Hungary|Debrecen, Hungary|Hyderabad, Andhra Pradesh, India|Ludhiana, Punjab, India|Bangalore, India|Pune, India|Tel Hashomer, Israel|Firenze, Italy|Milano, Italy|Kashihara, Nara, Japan|Shinjuku-ku, Tokyo, Japan|Suginami, Tokyo, Japan|Seoul, Korea, Republic of|Guadalajara, Jalisco, Mexico|México D. F., Mexico|Oaxaca, Mexico|San Luis Potosí, Mexico|Utrecht, Netherlands|Christchurch, New Zealand|Warszawa, Poland|Timisoara, Timis, Romania|Bucharest, Romania|Bucharest, Romania|Ekaterinburg, Russian Federation|Khabarovsk, Russian Federation|Samara, Russian Federation|St. Petersburg, Russian Federation|Singapore, Singapore|Singapore, Singapore|Bloemfontein, Freestate, South Africa|Johannesburg, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Göteborg, Sweden|Changhua, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Istanbul, Turkey|Izmir, Turkey|Donetsk, Ukraine|Lviv, Ukraine|Odessa, Ukraine|London, United Kingdom|Truro, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01625390"
675,"NCT01619007","Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy","XALIA","Completed","No Results Available","Deep Vein Thrombosis|Venous Thrombosis","Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Standard of care","Major bleedings defined as overt bleeding associated with: A fall in hemoglobin of ≥2 g/dL; or a transfusion of ≥2 units of packed red blood cells or whole blood; or occurrence at a critical site|Number of patients with symptomatic recurrent venous thromboembolic events|All cause mortality|Safety variables will be summarized using descriptive statistics based on adverse cardiac events collection|Number of patients with other symptomatic thromboembolic events|Treatment satisfaction (patient reported outcomes)","Bayer|Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)",,"5145","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","15915|XA1102","June 2012","March 2015","July 2015","June 14, 2012",,"January 23, 2017","Many Locations, Austria|Many Locations, Belgium|Many Locations, Canada|Many Locations, Czech Republic|Many Locations, Denmark|Many Locations, France|Many Locations, Germany|Many Locations, Greece|Many Locations, Hungary|Many Locations, Israel|Many Locations, Italy|Many Locations, Moldova, Republic of|Many Locations, Netherlands|Many Locations, Norway|Many Locations, Portugal|Many Locations, Slovenia|Many Locations, Spain|Many Locations, Sweden|Many Locations, Switzerland|Many Locations, Ukraine|Many Locations, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01619007"
676,"NCT01618370","Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases",,"Completed","No Results Available","Prostatic Neoplasms","Drug: Radium-223 dichloride (BAY88-8223)","Acute safety, variables will be summarized using descriptive statistics based on adverse events collection|Long-term safety, variables will be summarized using descriptive statistics based on adverse events collection|Brief Pain Inventory, as assessed by BPI-SF questionnaire (Brief Pain Inventory-Short Form)","Bayer","Male","18 Years and older   (Adult, Older Adult)","Phase 3","705","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16216|2012-000075-16","July 22, 2012","August 13, 2014","February 28, 2016","June 13, 2012",,"March 31, 2017","Brugge, Belgium|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Edegem, Belgium|Gent, Belgium|Kortrijk, Belgium|Leuven, Belgium|Ottignies, Belgium|Edmonton, Alberta, Canada|Vancouver, British Columbia, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Brno, Czech Republic|Ostrava, Czech Republic|Plzen - Bory, Czech Republic|Praha 4, Czech Republic|Praha 5, Czech Republic|Herlev, Denmark|København, Denmark|Odense, Denmark|Helsinki, Finland|HUS, Finland|Kuopio, Finland|Seinäjoki, Finland|Tampere, Finland|Angers Cedex 01, France|Avignon, France|Caen Cedex 5, France|Clermont Ferrand Cedex 1, France|Grenoble, France|La Roche Sur Yon Cedex, France|Lille Cedex, France|Lille, France|Montpellier Cedex, France|Montpellier, France|Paris Cedex 15, France|Paris, France|Paris, France|Poitiers Cedex, France|Saint Herblain, France|Suresnes, France|TOULOUSE cedex, France|Vandoeuvre les Nancy, France|Villejuif Cedex, France|Freiburg im Breisgrau, Baden-Württemberg, Germany|Heidelberg, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|Ulm, Baden-Württemberg, Germany|Erlangen, Bayern, Germany|München, Bayern, Germany|München, Bayern, Germany|Frankfurt, Hessen, Germany|Marburg, Hessen, Germany|Greifswald, Mecklenburg-Vorpommern, Germany|Rostock, Mecklenburg-Vorpommern, Germany|Rostock, Mecklenburg-Vorpommern, Germany|Braunschweig, Niedersachsen, Germany|Göttingen, Niedersachsen, Germany|Hannover, Niedersachsen, Germany|Hannover, Niedersachsen, Germany|Aachen, Nordrhein-Westfalen, Germany|Bonn, Nordrhein-Westfalen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Recklinghausen, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Homburg, Saarland, Germany|Chemnitz, Sachsen, Germany|Dresden, Sachsen, Germany|Jena, Thüringen, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Bremen, Germany|Hamburg, Germany|Magdeburg, Germany|Cork, Ireland|Dublin 6, Ireland|Galway, Ireland|Beer Sheva, Israel|Haifa, Israel|Jerusalem, Israel|Kfar Saba, Israel|Petah Tikva, Israel|Ramat Gan, Israel|Rehovot, Israel|Tel Aviv, Israel|Zerifin, Israel|Napoli, Campania, Italy|Forlì, Emilia-Romagna, Italy|Modena, Emilia-Romagna, Italy|Reggio Emilia, Emilia-Romagna, Italy|Pordenone, Friuli-Venezia Giulia, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Genova, Liguria, Italy|Genova, Liguria, Italy|Bergamo, Lombardia, Italy|Brescia, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Torino, Piemonte, Italy|Torino, Piemonte, Italy|Bari, Puglia, Italy|Brindisi, Puglia, Italy|Foggia, Puglia, Italy|Cagliari, Sardegna, Italy|Messina, Sicilia, Italy|Arezzo, Toscana, Italy|Firenze, Toscana, Italy|Pisa, Toscana, Italy|Trento, Trentino-Alto Adige, Italy|Padova, Veneto, Italy|Treviso, Veneto, Italy|Verona, Veneto, Italy|Mexico, D.F., Distrito Federal, Mexico|México, Distrito Federal, Mexico|Alkmaar, Netherlands|Amsterdam, Netherlands|Leiden, Netherlands|Nijmegen, Netherlands|Zwolle, Netherlands|Bergen, Norway|Bodø, Norway|Lørenskog, Norway|Oslo, Norway|Oslo, Norway|Ålesund, Norway|Bialystok, Poland|Warszawa, Poland|Moscow, Russian Federation|Obninsk, Russian Federation|Santiago de Compostela, A Coruña, Spain|Córdoba, Andalucía, Spain|Hospitalet de Llobregat, Barcelona, Spain|Cruces/Barakaldo, Bilbao, Spain|Santa Cruz de Tenerife, Canarias, Spain|Palma de Mallorca, Illes Baleares, Spain|Las Palmas de Gran Canaria, Las Palmas, Spain|A Coruña, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|León, Spain|Lugo, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Malaga, Spain|Málaga, Spain|Oviedo, Spain|Pamplona, Spain|Salamanca, Spain|Santander, Spain|Sevilla, Spain|Sevilla, Spain|Valencia, Spain|Valencia, Spain|Valencia, Spain|Zaragoza, Spain|Eskilstuna, Sweden|Kalmar, Sweden|Karlstad, Sweden|Linköping, Sweden|Lund, Sweden|Stockholm, Sweden|Sundsvall, Sweden|Umeå, Sweden|Uppsala, Sweden|Örebro, Sweden|Aarau, Aargau, Switzerland|Basel, Basel-Stadt, Switzerland|Chur, Graubünden, Switzerland|St. Gallen, Sankt Gallen, Switzerland|Bellinzona, Ticino, Switzerland|Lausanne, Vaud, Switzerland|Bern, Switzerland|Zürich, Switzerland|Cambridge, Cambridgeshire, United Kingdom|Romford, Essex, United Kingdom|Leicester, Leicestershire, United Kingdom|Edinburgh, Lothian, United Kingdom|Bebington, Merseyside, United Kingdom|Northwood, Middlesex, United Kingdom|Nottingham, Nottinghamshire, United Kingdom|Taunton, Somerset, United Kingdom|Sheffield, South Yorkshire, United Kingdom|Guildford, Surrey, United Kingdom|Sutton, Surrey, United Kingdom|Coventry, Warwickshire, United Kingdom|Birmingham, West Midlands, United Kingdom|Wolverhampton, West Midlands, United Kingdom|Aberdeen, United Kingdom|Belfast, United Kingdom|Bristol, United Kingdom|Cardiff, United Kingdom|Derby, United Kingdom|Glasgow, United Kingdom|Hull, United Kingdom|Leeds, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Newcastle Upon Tyne, United Kingdom|Plymouth, United Kingdom|Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01618370"
677,"NCT01613105","Diabetes Treatment With Glucobay in Combination With Sulfonylurea",,"Completed","No Results Available","Type 2 Diabetes Mellitus","Drug: Acarbose (Precose/Glucobay, BAYG5421)","Data collection on body weight|Data collection on blood glucose|Data collection on Hba1c|Data collection on pre treatment concomitant diseases|Safety variables will be summarized using descriptive statistics based on adverse events collection","Bayer","All","18 Years and older   (Adult, Older Adult)",,"4564","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","13927|GB0712IN","April 2008","December 2008","December 2008","June 6, 2012",,"June 26, 2013","Many Locations, India",,"https://ClinicalTrials.gov/show/NCT01613105"
678,"NCT01612741","Diabetes Treatment With Glucobay in Combination With Metformin",,"Completed","No Results Available","Type 2 Diabetes Mellitus","Drug: Acarbose (Precose/Glucobay, BAYG5421)","Data collection on body weight|Data collection on blood glucose|Data collection on Hba1c|Data collection on pre treatment concomitant diseases|Safety variables will be summarized using descriptive statistics based on adverse events collection","Bayer","All","18 Years and older   (Adult, Older Adult)",,"19509","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","13925|GB0711IN","April 2008","January 2009","January 2009","June 6, 2012",,"July 8, 2014","Many Locations, India",,"https://ClinicalTrials.gov/show/NCT01612741"
679,"NCT01606995","Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation","XANTUS","Completed","No Results Available","Atrial Fibrillation","Drug: Rivaroxaban (Xarelto, BAY59-7939)","Adjudicated major bleeding events|Safety variables will be summarized using descriptive statistics based on adverse events collection|All cause mortality|Adjudicated symptomatic thromboembolic events|Persistence with rivaroxaban treatment: Reasons for any switch from or interruption of rivaroxaban treatment","Bayer|Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)",,"6784","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","15914|XA1101","June 2012","March 2015","March 2015","May 28, 2012",,"January 23, 2017","Many Locations, Austria|Many Locations, Belgium|Many Locations, Canada|Many Locations, Czech Republic|Many Locations, Denmark|Many Locations, France|Many Locations, Germany|Many Locations, Hungary|Many Locations, Ireland|Many Locations, Israel|Many Locations, Moldova, Republic of|Many Locations, Netherlands|Many Locations, Norway|Many Locations, Poland|Many Locations, Portugal|Many Locations, Russian Federation|Many Locations, Slovakia|Many Locations, Slovenia|Many Locations, Sweden|Many Locations, Ukraine|Many Locations, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01606995"
680,"NCT01602770","Qlaira Post-authorization Safety Study Related to Most Common Adverse Events in Mexican Women Who Wish to Avoid Pregnancy",,"Completed","No Results Available","Contraception","Drug: EV/DNG (Qlaira, BAY86-5027)","Safety variables will be summarized using descriptive statistics based on adverse events collection|Continuation rate, as proportion of patients still using Qlaira|Reasons for discontinuation related or unrelated to adverse events|Patient satisfaction with Qlaira","Bayer","Female","18 Years to 40 Years   (Adult)",,"1","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16233|QL1210MX","February 6, 2015","May 17, 2017","October 31, 2017","May 21, 2012",,"April 29, 2019","Multiple Locations, Mexico",,"https://ClinicalTrials.gov/show/NCT01602770"
681,"NCT01598051","Xarelto [SPAF-QOL] Post-marketing Surveillance in Japan",,"Completed","No Results Available","Non-valvular Atrial Fibrillation (NVAF)","Drug: Rivaroxaban (Xarelto_ BAY59-7939)","Improvement of treatment satisfaction (Evaluated through ACTS and TSQM questionnaires)|Incidence of ADRs and serious AEs (especially for hemorrhagic events, and liver disfunction with increase of liver-function-relating enzymes including bilirubin)|Incidence of events of stroke|Incidence of events of non-central nervous system embolism","Bayer|Janssen Scientific Affairs, LLC","All","20 Years and older   (Adult, Older Adult)",,"741","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","16296","May 31, 2012","June 9, 2016","March 31, 2017","May 15, 2012",,"May 30, 2019","Multiple Locations, Japan",,"https://ClinicalTrials.gov/show/NCT01598051"
682,"NCT01595724","Daily Practice Treatment and Influence of Visanne on the Patient Assessment of Quality of Life","DIVA","Completed","No Results Available","Endometriosis","Drug: Visanne (Dienogest, BAY86-5258)","Percentage of patients, who show an improvement of the EHP-5 items|Mean changes of EHP-5 items by using scores for pre-defined categories|Baseline demographic characteristics and disease status of patients with endometriosis treated with Visanne|Patient reported severity of endometriosis related pain|Reasons for treatment discontinuation|Safety variables will be summarized using descriptive statistics based on adverse events collection","Bayer","Female","18 Years and older   (Adult, Older Adult)",,"3006","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16108|VS1101","May 2012","July 2014","May 2015","May 10, 2012",,"July 10, 2015","Many Locations, Belarus|Many Locations, Egypt|Many Locations, Jordan|Many Locations, Kazakhstan|Many Locations, Kuwait|Many Locations, Lebanon|Many Locations, Qatar|Many Locations, Russian Federation|Many Locations, Saudi Arabia|Many Locations, Ukraine|Many Locations, United Arab Emirates",,"https://ClinicalTrials.gov/show/NCT01595724"
683,"NCT01595022","FR01 and FR20 IUS (Intrauterine System) Wearing Study",,"Completed","No Results Available","Contraception","Drug: Placebo: Flexi ring FR01|Drug: Placebo: Flexi ring FR20|Drug: Placebo: Ultra low dose levonorgestrel contraceptive system (LCS)","Pelvic pain during the IUS wearing period (wearing comfort) measured by 5-point Likert scale (no pain/mild/moderate/severe/very severe pain)","Bayer","Female","18 Years to 40 Years   (Adult)","Phase 1","90","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","13830","January 2010","September 2010","September 2010","May 9, 2012",,"April 3, 2015","Helsinki, Finland|Kuopio, Finland|Tampere, Finland|Turku, Finland|Den Helder, Netherlands|Heerlen, Netherlands|Zwijndrecht, Netherlands|Stockholm, Sweden|Uppsala, Sweden|Örebro, Sweden",,"https://ClinicalTrials.gov/show/NCT01595022"
684,"NCT01592149","Survey of Prevalence of Loss of Appetite in Subject With Health Disorders","SPLASH","Completed","No Results Available","Appetite","Other: No Drug","Percentage of patients with loss of appetite|Percentage of patients with fatigue|Distribution of fatigue among the patients with respect to disease|Percentage of patients with moderate to very severe Fatigue.","Bayer","All","18 Years and older   (Adult, Older Adult)",,"16629","Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","16235","May 2012","March 2014","January 2015","May 7, 2012",,"February 11, 2015","Many Locations, India",,"https://ClinicalTrials.gov/show/NCT01592149"
685,"NCT01590537","Non-interventional Study of Long-term Intrauterine Contraceptives Acceptability and User Satisfaction","Mirabel","Completed","No Results Available","Contraception","Drug: Levonorgestrel (Mirena, BAY86-5028)|Device: Copper IUD","User satisfaction of the contraception method with Mirena or Copper IUD|Safety evaluation of Mirena or Copper IUD in routine practice Safety parameters include number of AEs, severity,relationship to Mirena or Cooper IUD|Contraceptive reliability of Mirena or Cooper IUD in routine practice ( fixing number of pregnancies)|Continuation/discontinuation rate ( number of cases with contraceptive method continuation and discontinuations)|Relationship between different parameters and women preferences in choosing Mirena or Cooper IUD as their contraceptive method ( demographic parameters, age group, residence, reproductive history and plans, etc.) using patients questionnaire","Bayer","Female","20 Years to 40 Years   (Adult)",,"2348","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","15508|MA1010RU","September 2011","March 2014","October 2014","May 3, 2012",,"October 16, 2015","Many Locations, Russian Federation",,"https://ClinicalTrials.gov/show/NCT01590537"
686,"NCT01588639","To Evaluate Clinical Outcome and Injection Compliance of Scilin","SEAS","Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: Insulin (Scilin N, BAY81-9924)|Drug: Insulin (Scilin R _BAY81-9924|Drug: Insulin(Scilin M30_BAY81-9924)","Occurrence rate of serious adverse drug reactions including severe hypoglycaemic events|Occurrence rate of hypoglycemic events|Change in HbA1c|Change in FPG (Fasting Plasma Glucose)|Change in PPG (Postprandial Glucose)|The ratio of compliance injection (following physician's advice)|Number and ratio of missed injections","Bayer","All","Child, Adult, Older Adult",,"2683","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16372|SL1210CN","August 2012","October 2013","January 2014","May 1, 2012",,"January 13, 2015","Many Locations, China",,"https://ClinicalTrials.gov/show/NCT01588639"
687,"NCT01587885","Comparison of Two Omeprazole-Containing Products for Relief of Frequent Heartburn (MK-0764A-036)",,"Completed","Has Results","Heartburn","Drug: Omeprazole 20 mg + Sodium Bicarbonate 1100 mg|Drug: Omeprazole 20 mg","Time-to-onset of Heartburn Relief|Percentage of Participants Experiencing Onset and Demonstrating Duration of Heartburn Relief Over Time|Number of Participants Preferring Each Treatment for Heartburn Control: Final Subjective Questionnaire|Number of Participants Preferring Each Treatment for Heartburn Relief: Final Subjective Questionnaire|Number of Participants Preferring Each Treatment Overall: Final Subjective Questionnaire|Percentage of Participants Affected By Heartburn Symptoms: End of Treatment Quality of Life Questionnaire","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 4","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18131|PT 11-29|0764A-036","January 2012","April 2012","May 2012","April 30, 2012","May 22, 2013","March 11, 2015",,,"https://ClinicalTrials.gov/show/NCT01587885"
688,"NCT01585974","Duration of Treatment With Tyrosine Kinase Inhibitors in the Treatment of Metastatic Renal Cell Carcinoma","TURCOS","Completed","No Results Available","Renal Cell Carcinoma","Other: No intervention","Duration of treatment: from start of tyrosine kinase inhibitor treatment to permanent discontinuation of the product|Incidence of treatment-emergent adverse events (TEAE)|Change of Tumor status","Bayer","All","18 Years and older   (Adult, Older Adult)",,"151","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16263|NX1211TR","October 2012","June 2015","November 2015","April 26, 2012",,"October 19, 2016","Many Locations, Turkey",,"https://ClinicalTrials.gov/show/NCT01585974"
689,"NCT01585870","Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of Sorafenib and Eribulin in Combination",,"Completed","No Results Available","Neoplasms","Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Eribulin","Number of participants with Adverse Events as a Measure of Safety and Tolerability|AUC (area under the plasma concentration vs time curve) of BAY43-9006|Cmax (maximum drug concentration in plasma after single dose administration) of BAY43-9006|QT time, assessed by QTcF / QTcB (QT interval corrected for heart rate according to Fridericia / Bazett)|Clinical benefit and response measured by RESIST (1.1) criteria","Bayer|Onyx Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","40","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15977|2011-005849-12","July 2012","September 2015","September 2015","April 26, 2012",,"October 27, 2015","Toulouse, France|Freiburg, Baden-Württemberg, Germany|Heidelberg, Baden-Württemberg, Germany|Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT01585870"
690,"NCT01584830","Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy","CONCUR","Completed","No Results Available","Colorectal Neoplasms","Drug: Regorafenib (BAY73-4506)|Drug: Placebo","Overall Survival (OS)|Progression-free Survival (PFS)|The percentage of subjects with total number of Complete Response (CR) + total number of Partial Response (PR).|Disease Control Rate (DCR)|Safety variables will be summarized using descriptive statistics based on adverse events collection","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","204","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","15808","April 2012","November 2013","January 2016","April 25, 2012",,"February 8, 2016","Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Harbin, Heilongjiang, China|Nanjing, Jiangsu, China|Xi'an, Shaanxi, China|Qingdao, Shandong, China|Chengdu, Sichuan, China|Hangzhou, Zhejiang, China|Beijing, China|Beijing, China|Beijing, China|Changchun, China|Shanghai, China|Shanghai, China|Shanghai, China|Tianjin, China|Shatin, New Territories, Hong Kong|Hong Kong, Hong Kong|Seoul, Korea, Korea, Republic of|Taipei, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Hanoi, Vietnam|Hcmc, Vietnam|Ho Chi Minh City, Vietnam",,"https://ClinicalTrials.gov/show/NCT01584830"
691,"NCT01582737","Xarelto [SPAF] Post-marketing Surveillance in Japan",,"Active, not recruiting","No Results Available","Brain Ischemia","Drug: Rivaroxaban(Xarelto, BAY59-7939)","Incidence of ADRs and serious AEs (especially for hemorrhagic events, and liver disfunction with increase of liver-function-relating enzymes including bilirubin)|Incidence of events of stroke|Incidence of events of non-central nervous system embolism|Determination of patient's demography to affect the safety and efficacy of Xarelto using standard observational survey and follow-up survey|Determination of patient's medical history to affect the safety and efficacy of Xarelto using standard observational survey and follow-up survey|Determination of patient's background to affect the safety and efficacy of Xarelto using standard observational survey and follow-up survey","Bayer|Janssen Research & Development, LLC","All","Child, Adult, Older Adult",,"11311","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","15798|XAR-SPAF","May 30, 2012","March 31, 2019","January 17, 2020","April 23, 2012",,"January 3, 2020","Multiple Locations, Japan",,"https://ClinicalTrials.gov/show/NCT01582737"
692,"NCT01580293","A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A","PROTECT-VIII","Completed","Has Results","Hemophilia A","Biological: BAY94-9027","Annualized Number of Total Bleeds in On-demand Treatment Arm (Weeks 0 -36) and in Each Prophylaxis Arm (Weeks 10 - 36, Excluding Rescue Bleeds) - Part A, Main Trial|Annualized Number of Joint Bleeds, Trauma, Spontaneous Bleeds in On-demand Treatment Arm (Weeks 0 -36) and in Each Prophylaxis Arm (Weeks 10 - 36, Excluding Rescue Bleeds) - Part A|Annualized Number of Total Bleeds in On-demand Treatment Arm and in Each Prophylaxis Arm, Part A, Extension|Number of Participants Developed Human Coagulation Factor VIII (FVIII) Inhibitor - Part A|Number of Bleeds Requiring 1, 2 or >= 3 Infusions to Control the Bleed - Part A|Number of Bleeds According to Locations - Part A|Number of Bleeds Over Time Since Previous Prophylaxis Infusion - Part A|Number of Bleeds According to Participant's Assessment of Response to Treatment - Part A|Recombinant Human Factor VIII (rFVIII) Usage Expressed as Total Dose Per Kilogram Per Year - Part A|Recombinant Human Factor VIII (rFVIII) Usage Expressed as Dose Per Kilogram Per Infusion - Part A|Number of Participants Requiring an Increase in Dose Frequency, or Dose Increase, During Weeks 10 to 36 - Part A|Number of Surgeries According to Physician's Assessment of Adequacy of Hemostasis in Major Surgery - Part B|Recombinant Human Factor VIII (rFVIII) Usage Expressed as Dose Per Kilogram Per Infusion for Major Surgery - Part B|Recombinant Human Factor VIII (rFVIII) Usage Expressed as Number of Infusions for Major Surgery - Part B|Maximum Drug Plasma Concentration (Cmax) Following Single and Multiple Doses of BAY94-9027, Chromogenic Assay - Part A|Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC) Following Single and Multiple Doses of BAY94-9027, Chromogenic Assay - Part A|Terminal Elimination Half Life (t1/2) Following Single and Multiple Doses of BAY94-9027, Chromogenic Assay - Part A|Overall Human Coagulation Factor VIII (FVIII) Recovery Value by Chromogenic Assay - Part A|Change From Baseline in Quality of Life by Hemophilia Specific Quality of Life Instrument or Questionnaire for Adults (Haemo-QoL-A) Overall Score at Week 36 - Part A","Bayer","Male","12 Years to 65 Years   (Child, Adult, Older Adult)","Phase 2|Phase 3","145","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13024|2011-005210-11","April 23, 2012","June 13, 2014","November 21, 2019","April 19, 2012","December 6, 2018","December 16, 2019","Tucson, Arizona, United States|Sacramento, California, United States|San Diego, California, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Chicago, Illinois, United States|Detroit, Michigan, United States|Minneapolis, Minnesota, United States|Syracuse, New York, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Hershey, Pennsylvania, United States|Richmond, Virginia, United States|Wien, Austria|Brugge, Belgium|London, Ontario, Canada|Medellín, Antioquia, Colombia|Barranquilla, Atlántico, Colombia|Aarhus N, Denmark|BRON cedex, France|Marseille, France|Reims Cedex, France|Rennes Cedex, France|Heidelberg, Baden-Württemberg, Germany|Bonn, Nordrhein-Westfalen, Germany|Ramat Gan, Israel|Napoli, Campania, Italy|Roma, Lazio, Italy|Milano, Lombardia, Italy|Torino, Piemonte, Italy|Nagoya, Aichi, Japan|Nishinomiya, Hyogo, Japan|Kashihara, Nara, Japan|Shinjuku-ku, Tokyo, Japan|Suginami, Tokyo, Japan|Hiroshima, Japan|Busan, Busan Gwang''yeogsi, Korea, Republic of|Daejeon, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Amsterdam, Netherlands|Den Haag, Netherlands|Groningen, Netherlands|Maastricht, Netherlands|Oslo, Norway|Wroclaw, Poland|Timisoara, Romania|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|Changhua, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Ankara, Turkey|Izmir, Turkey|Newcastle Upon Tyne, Vale Of Glamorgan, The, United Kingdom|London, United Kingdom|Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01580293"
693,"NCT01573338","Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Small Cell Lung Cancer)",,"Terminated","No Results Available","Small Cell Lung Carcinoma","Drug: Roniciclib (BAY 1000394)|Drug: Etoposide|Drug: Cisplatin|Drug: Carboplatin","Safety variables will be summarized using descriptive statistics based on adverse events collection|tumor response - number of subjects with best tumor response that is achieved during or within 30 days after end of therapy|Maximum Tolerated Dose (MTD) - measured by adverse event profile at the end of Cycle 1. MTD will be the highest dose level achieved during dose escalation where non or 1 of 6 subjects experience a dose limiting toxicity as defined in the protocol|Maximum drug concentration in plasma after single dose administration(Cmax) of BAY1000394|Area under the concentration versus time curve from zero to infinity after single (first) dose(AUC) of BAY1000394|Disease control rate (DCR)|Overall survival (OS)|Time to progression (TTP)|Progression-free survival (PFS)|Duration of response (DOR)|Stable disease (SD)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","43","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14858|2011-004155-39","February 25, 2013","March 25, 2016","June 23, 2016","April 9, 2012",,"April 26, 2017","Saint Louis, Missouri, United States|Buffalo, New York, United States|Cleveland, Ohio, United States|Caen Cedex, France|Lyon Cedex, France|Marseille, France|Villejuif Cedex, France|Seoul, Korea, Republic of|Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01573338"
694,"NCT01565746","Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese Patients",,"Completed","No Results Available","Prostatic Neoplasms","Drug: Radium-223 dichloride (Xofigo, BAY88-8223)","Number of participants with Critical toxicities|Maximum drug concentration in blood after single dose administration (Cmax) of BAY88-8223 for blood samples|Area under the concentration - time curve (AUC) of BAY88-8223 for blood samples|Changes in prostate specific antigen (PSA)|Overall Survival","Bayer","Male","20 Years and older   (Adult, Older Adult)","Phase 1","19","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15354","March 2012","October 2012","April 2016","March 29, 2012",,"October 17, 2016","Kashiwa, Chiba, Japan|Yokohama, Kanagawa, Japan|Osakasayama, Osaka, Japan",,"https://ClinicalTrials.gov/show/NCT01565746"
695,"NCT01561794","A Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics/Pharmacodynamics of BAYQ3939 in Patients With Bacterial Pneumonia",,"Completed","No Results Available","Pneumonia","Drug: Ciprofloxacin (Cipro, BAYQ3939)","Safety variables will be summarized using descriptive statistics based on adverse events collection|AUC (Area under the blood concentration/time curve)|Cmax (Maximum observed concentration)|AUC/MIC (Minimum inhibitory concentration)|Cmax/MIC|AUC/MPC (Mutant prevention concentration)|Cmax/MPC|Clinical response rate based on resolution of signs and symptoms|Microbiological response rate, assessed as eradication rate based on microbiologically evaluable patients|Test of cure rate based on resolution of signs, symptoms, and the clinical response","Bayer","All","20 Years and older   (Adult, Older Adult)","Phase 3","44","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15992","May 2012","March 2015","March 2015","March 23, 2012",,"April 27, 2015","Nagakute, Aichi, Japan|Kobe, Hyogo, Japan|Kahoku-gun, Ishikawa, Japan|Yokohama, Kanagawa, Japan|Isahaya, Nagasaki, Japan|Isahaya, Nagasaki, Japan|Sasebo, Nagasaki, Japan|Unzen, Nagasaki, Japan|Yufu, Oita, Japan|Kishiwada, Osaka, Japan|Ureshino, Saga, Japan|Hamamatsu, Shizuoka, Japan|Nagasaki, Japan|Nagasaki, Japan|Nagasaki, Japan|Niigata, Japan|Niigata, Japan|Niigata, Japan|Okayama, Japan|Osaka, Japan",,"https://ClinicalTrials.gov/show/NCT01561794"
696,"NCT01557127","Nexavar Dosing in Renal Cancer Patients in ""Real-life"" Setting","NEXST","Completed","No Results Available","Carcinoma, Renal Cell","Drug: Sorafenib (Nexavar, BAY43-9006)","Percentage of patients in whom the actual dose of sorafenib equaled the planned dose|Overall tolerability of treatment as measured by rate of adverse events","Bayer","All","18 Years and older   (Adult, Older Adult)",,"205","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16268","November 1, 2011","May 16, 2014","March 31, 2016","March 19, 2012",,"March 28, 2017","Many Locations, Poland",,"https://ClinicalTrials.gov/show/NCT01557127"
697,"NCT01555463","Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea",,"Completed","Has Results","Papulopustular Rosacea","Drug: Azelaic acid foam, 15% (BAY39-6251)|Drug: Vehicle foam","Percentage of Participants With Investigator's Global Assessment (IGA) Based Therapeutic Success at End of Treatment (LOCF: Last Observation Carried Forward)|Nominal Change From Baseline in Inflammatory Lesion (IL) Count at End of Treatment (LOCF)|Percent Change From Baseline in Inflammatory Lesion Count at End of Treatment (LOCF)|Percentage of Participants With Investigator's Global Assessment (IGA) Based Therapeutic Response at End of Treatment (LOCF)|Grouped Changes From Baseline in Erythema Intensity Score at End of Treatment (LOCF)|Percentage of Participants With Investigator's Global Assessment (IGA) Scores at End of Treatment (LOCF)|Nominal Value of Inflammatory Lesion Count at End of Treatment (LOCF)|Percentage of Participants With Erythema Intensity Score at End of Treatment (LOCF)|Grouped Changes From Baseline in Telangiectasia Intensity Score at End of Treatment (LOCF)|Percentage of Participants With Facial Skin Color Rating at End of Treatment (LOCF)|Participants' Global Assessment of Treatment Response at End of Treatment|Participants' Global Assessment of Tolerability at End of Treatment|Participants' Opinion on Cosmetic Acceptability at End of Treatment|Participants' Opinion on Practicability of Product Use in Facial Areas Next to the Hairline at End of Treatment|Change From Baseline in Rosacea Quality of Life (RosaQoL) Questionnaire at End of Treatment - Overall Quality of Life Score|Number of Participants With Change From Baseline in Dermatology Life Quality Index (DLQI) Questionnaire at End of Treatment - Overall Score|Change From Baseline in EuroQol Group Questionnaire-Visual Analogue Scale (EQ-VAS) at End of Treatment|Change From Baseline in Index Value at End of Treatment","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","961","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","16080|1401846","September 2012","January 2014","January 2014","March 15, 2012","January 27, 2015","February 1, 2016","Birmingham, Alabama, United States|Birmingham, Alabama, United States|Birmingham, Alabama, United States|Fremont, California, United States|Los Angeles, California, United States|Sacramento, California, United States|San Diego, California, United States|San Francisco, California, United States|Santa Ana, California, United States|Santa Monica, California, United States|Colorado Springs, Colorado, United States|Boynton Beach, Florida, United States|Boynton Beach, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miramar, Florida, United States|Ormond Beach, Florida, United States|St. Augustine, Florida, United States|Buffalo Grove, Illinois, United States|Chicago, Illinois, United States|Plainfield, Indiana, United States|Louisville, Kentucky, United States|Richmond, Kentucky, United States|New Orleans, Louisiana, United States|Warren, Michigan, United States|West Bloomfield, Michigan, United States|Fridley, Minnesota, United States|St. Louis, Missouri, United States|Omaha, Nebraska, United States|Las Vegas, Nevada, United States|Las Vegas, Nevada, United States|East Windsor, New Jersey, United States|New York, New York, United States|Stony Brook, New York, United States|Chapel Hill, North Carolina, United States|Hickory, North Carolina, United States|High Point, North Carolina, United States|Raleigh, North Carolina, United States|Winston-Salem, North Carolina, United States|Johnston, Rhode Island, United States|Anderson, South Carolina, United States|Knoxville, Tennessee, United States|Austin, Texas, United States|Plano, Texas, United States|Webster, Texas, United States|Salt Lake City, Utah, United States|Seattle, Washington, United States|Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01555463"
698,"NCT01554631","A 3-fold Crossover Bioequivalence Study Between Glucobay ODT (Orally Disintegrating Tablet) 100 mg and Glucobay Standard Tablet 100 mg",,"Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: Acarbose (Glucobay ODT, BAYG5421)|Drug: Acarbose (Glucobay, BAYG5421)","Ratio of postprandial maximum concentration (Cmax) of blood glucose following sucrose load with Glucobay (Day 1) and without Glucobay (Day 0)|Ratio of postprandial Area under curve from 0 to 4 hours (AUC(0-4)) of blood glucose following sucrose load with Glucobay (Day 1) and without Glucobay (Day 0)|Difference in postprandial maximum concentration (Cmax) of blood glucose and serum insulin following sucrose load with acarbose (day 1) and without acarbose (day 0)|Difference in postprandial area under curve from 0 to 4 hours (AUC(0-4)) of blood glucose and serum insulin following sucrose load with acarbose (day 1) and without acarbose (day 0)|Safety parameters","Bayer","Male","18 Years to 45 Years   (Adult)","Phase 1","34","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","16025|2012-000245-12","March 2012","May 2012","May 2012","March 15, 2012",,"June 14, 2013","Mönchengladbach, Nordrhein-Westfalen, Germany",,"https://ClinicalTrials.gov/show/NCT01554631"
699,"NCT01552798","Efficacy of a Single Dose of Aspirin vs. Acetaminophen in Tension Type Headache","Tarot Headache","Terminated","No Results Available","Headache","Drug: Acetylsalicylic acid (Aspirin, BAY1019036)|Drug: Acetaminophen|Drug: Placebo","Time to meaningful pain relief (defined as the time when the subject indicates pain relief that is meaningful to the subject)|Time to first perceptible relief|Time to first perceptible relief confirmed|Change from baseline in pain intensity score at different time points (on an 11-point Categorical Pain Intensity Scale, 0 = no pain, 10 = severe pain)|Pain Relief on 5-point Categorical Scale (0 = no relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief, and 4 = complete relief)|Summed time weighted of Pain Intensity Differences (PID) scores over first hour (SPID0-1)|Summed time weighted of Pain Intensity Differences (PID) scores over 2 hours (SPID0-2)|Summed time weighted total pain relief scores over first hour (TOTPAR0-1)|Summed time weighted of Total Pain Relief Scores (TOTPAR) scores over 2 hours (TOTPAR0-2)|Summed, time weighted of Pain Relief and Pain Intensity Differences (PID) over first hour (SPRID0-1)|Summed, time weighted of Pain Relief and Pain Intensity Differences (PID) over 2 hours (SPRID0-2)|Time to first intake of rescue medication|Cumulative proportion of subjects taking rescue medication by time point|Global assessment of the investigational product as a pain reliever: 0 = poor, 1 = fair, 2 = good, 3 = very good or 4 = excellent|Safety variable will be summarized using descriptive statistic based on adverse events collection","Bayer","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","9","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","15771","March 12, 2012","June 4, 2012","June 4, 2012","March 13, 2012",,"December 19, 2018","Westside Family Medical Center, Kalamazoo, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT01552798"
700,"NCT01544166","Gadobutrol Pharmacokinetic and Safety Study in Pediatric Subjects Aged <2 Years (Term Newborn Infants to Toddlers 23 Months of Age Inclusive)",,"Completed","Has Results","Magnetic Resonance Imaging","Drug: Gadobutrol (Gadavist, BAY86-4875)","Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to Infinity of Gadobutrol: Individual|Body Weight-Normalized Total Body Clearance (CL) of Gadobutrol From Plasma: Individual|Body Weight-Normalized Apparent Volume of Distribution at Steady State (Vss) of Gadobutrol in Plasma: Individual|Mean Residence Time (MRT) of Gadobutrol in Plasma: Individual|Terminal Elimination Half-Life (t1/2) of Gadobutrol From Plasma: Individual|Simulation of Plasma Concentration of Gadobutrol at 20 Minutes Post-Injection (C20)|Simulation of Plasma Concentration of Gadobutrol at 30 Minutes Post-Injection (C30)|Number of Subjects With Anatomical Area Evaluated|Number of Subjects With Technical Adequacy for Diagnosis|Number of Subjects With Technical Adequacy for Diagnosis by Body Region|Number of Subjects by Overall Contrast Quality|Number of Subjects by Overall Contrast Quality by Body Region|Number of Subjects With Presence of Pathology|Number of Subjects With Presence of Pathology by Body Region|Number of Subjects With Number of Lesions Detected|Number of Subjects With Number of Lesions Detected by Body Region|Contrast Enhancement in Lesion or Vessel|Contrast Enhancement in Lesion or Vessel by Body Region|Number of Subjects With Border Delineation of Lesion of Vessel|Number of Subjects With Border Delineation of Lesion of Vessel by Body Region|Number of Subjects by Visualization of Lesion-Internal Morphology or Homogeneity of Vessel Enhancement|Number of Subjects by Visualization of Lesion-Internal Morphology or Homogeneity of Vessel Enhancement by Body Region|Number of Subjects With Diagnoses|Number of Subjects With Diagnoses by Body Region|Number of Subjects With Additional Diagnostic Gain|Number of Subjects With Additional Diagnostic Gain by Body Region|Number of Subjects With Confidence in Diagnosis|Number of Subjects With Confidence in Diagnosis by Body Region|Number of Subjects With Final Diagnosis|Number of Subjects With Final Diagnosis by Body Region|Number of Subjects With Change in Diagnosis From Unenhanced to Combined MRI|Number of Subjects With Change in Diagnosis From Unenhanced to Combined MRI by Body Region|Number of Subjects With Change in Diagnosis From Unenhanced MRI to Final Diagnosis|Number of Subjects With Change in Diagnosis From Unenhanced MRI to Final Diagnosis by Body Region|Number of Subjects With Change in Diagnosis From Combined MRI to Final Diagnosis|Number of Subjects With Change in Diagnosis From Combined MRI to Final Diagnosis by Body Region|Number of Subjects With Change in Management From Unenhanced to Combined MRI|Number of Subjects With Change in Management From Unenhanced to Combined MRI by Body Region|Number of Subjects With Clinically Significant Abnormal Laboratory Values|Estimated Glomerular Filtration Rate (eGFR) Prior to Gadobutrol Injection","Bayer","All","up to 2 Years   (Child)","Phase 1","44","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","91741|2010-023003-96","May 2012","November 2013","November 2013","March 5, 2012","November 26, 2014","July 3, 2015","Atlanta, Georgia, United States|Savannah, Georgia, United States|Chicago, Illinois, United States|Boston, Massachusetts, United States|New York, New York, United States|Cincinnati, Ohio, United States|Houston, Texas, United States|Edmonton, Alberta, Canada|Halle, Sachsen-Anhalt, Germany|Dresden, Sachsen, Germany|Jena, Thüringen, Germany",,"https://ClinicalTrials.gov/show/NCT01544166"
701,"NCT01539681","Sorafenib in Hepatocellular Carcinoma Clinical Practice in Italy","STELLA","Completed","No Results Available","Hepatocellular Carcinoma","Drug: Sorafenib (Nexavar, BAY43-9006)","Efficacy (analyzed by overall survival rate) of sorafenib under real-life practice conditions in patients with Hepatocellular Carcinoma.|Adverse event collection of sorafenib under real-life practice conditions in patients with Hepatocellular Carcinoma.|Overall survival|Time to Progression","Bayer","All","18 Years and older   (Adult, Older Adult)",,"234","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16028|NX1110IT","February 2012","January 2014","February 2015","February 27, 2012",,"February 18, 2016","Many Locations, Italy",,"https://ClinicalTrials.gov/show/NCT01539681"
702,"NCT01538680","Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy","CONSIGN","No longer available","No Results Available","Colorectal Neoplasms","Drug: Regorafenib (BAY73-4506)",,"Bayer","All","18 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access",,"15967|2011-005836-25",,,,"February 24, 2012",,"May 29, 2019","Duarte, California, United States|La Jolla, California, United States|La Jolla, California, United States|Long Beach, California, United States|Los Angeles, California, United States|Orange, California, United States|Santa Maria, California, United States|Denver, Colorado, United States|New Haven, Connecticut, United States|Washington, District of Columbia, United States|Aventura, Florida, United States|Jacksonville, Florida, United States|Miami Beach, Florida, United States|Ocala, Florida, United States|Orlando, Florida, United States|Atlanta, Georgia, United States|Columbus, Georgia, United States|Savannah, Georgia, United States|Park Ridge, Illinois, United States|Cedar Rapids, Iowa, United States|Sioux City, Iowa, United States|Louisville, Kentucky, United States|New Orleans, Louisiana, United States|Shreveport, Louisiana, United States|Brewer, Maine, United States|Boston, Massachusetts, United States|Burlington, Massachusetts, United States|Ann Arbor, Michigan, United States|Detroit, Michigan, United States|Detroit, Michigan, United States|Rochester, Minnesota, United States|Jackson, Mississippi, United States|Jefferson City, Missouri, United States|Omaha, Nebraska, United States|Las Vegas, Nevada, United States|Lebanon, New Hampshire, United States|Bronx, New York, United States|Lake Success, New York, United States|New York, New York, United States|New York, New York, United States|New York, New York, United States|Stony Brook, New York, United States|Charlotte, North Carolina, United States|Winston-Salem, North Carolina, United States|Fargo, North Dakota, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Toledo, Ohio, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Providence, Rhode Island, United States|Charleston, South Carolina, United States|Sumter, South Carolina, United States|Memphis, Tennessee, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Temple, Texas, United States|Portsmouth, Virginia, United States|Richmond, Virginia, United States|Seattle, Washington, United States|Concord, New South Wales, Australia|St Leonards, New South Wales, Australia|Woodville South, South Australia, Australia|Footscray, Victoria, Australia|Parkville, Victoria, Australia|Wels, Oberösterreich, Austria|Graz, Steiermark, Austria|Innsbruck, Tirol, Austria|Wien, Austria|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Edegem, Belgium|Leuven, Belgium|Roeselare, Belgium|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Mississauga, Ontario, Canada|Oshawa, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Quebec, Canada|Brno, Czechia|Praha, Czechia|Aarhus C, Denmark|Copenhagen, Denmark|Helsinki, Finland|HUS, Finland|Avignon, France|Bordeaux, France|CLERMONT-FERRAND Cedex 1, France|Le Mans Cedex 2, France|Lille Cedex, France|Lille Cedex, France|Marseille, France|Montpellier Cedex, France|Nice, France|Paris Cedex 15, France|Paris, France|Paris, France|Reims Cedex, France|Saint Herblain, France|Strasbourg Cedex, France|Toulouse, France|Esslingen, Baden-Württemberg, Germany|Freiburg, Baden-Württemberg, Germany|Heidelberg, Baden-Württemberg, Germany|Mannheim, Baden-Württemberg, Germany|Stuttgart, Baden-Württemberg, Germany|Ulm, Baden-Württemberg, Germany|München, Bayern, Germany|München, Bayern, Germany|München, Bayern, Germany|Hannover, Niedersachsen, Germany|Oldenburg, Niedersachsen, Germany|Bochum, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Herne, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Leverkusen, Nordrhein-Westfalen, Germany|Mönchengladbach, Nordrhein-Westfalen, Germany|Porta Westfalica, Nordrhein-Westfalen, Germany|Recklinghausen, Nordrhein-Westfalen, Germany|Trier, Rheinland-Pfalz, Germany|Halle, Sachsen-Anhalt, Germany|Magdeburg, Sachsen-Anhalt, Germany|Dresden, Sachsen, Germany|Berlin, Germany|Hamburg, Germany|Heraklion, Greece|Kifissia / Athens, Greece|Budapest, Hungary|Cork, Ireland|Dublin, Ireland|Beer Sheva, Israel|Haifa, Israel|Jerusalem, Israel|Petah Tikva, Israel|Tel Aviv, Israel|Napoli, Campania, Italy|Modena, Emilia-Romagna, Italy|Reggio Emilia, Emilia-Romagna, Italy|Roma, Lazio, Italy|Genova, Liguria, Italy|Brescia, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Ancona, Marche, Italy|Foggia, Puglia, Italy|Palermo, Sicilia, Italy|Firenze, Toscana, Italy|Pisa, Toscana, Italy|Padova, Veneto, Italy|Mexico, D.F., Distrito Federal, Mexico|Mexico, D.F., Distrito Federal, Mexico|México, D.F., Distrito Federal, Mexico|México, Distrito Federal, Mexico|Irapuato, Guanajuato, Mexico|Guadalajara, Jalisco, Mexico|Aguascalientes, Mexico|Oaxaca, Mexico|Toluca, Mexico|Veracruz, Mexico|Amsterdam, Netherlands|Amsterdam, Netherlands|Leiden, Netherlands|Oslo, Norway|Bialystok, Poland|Poznan, Poland|Coimbra, Portugal|Porto, Portugal|Kazan, Russian Federation|Krasnodar, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Obninsk, Russian Federation|Orenburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|Córdoba, Andalucía, Spain|Badalona (Barcelona), Barcelona, Spain|Hospitalet de Llobregat, Barcelona, Spain|Sabadell, Barcelona, Spain|Santander, Cantabria, Spain|A Coruña, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Málaga, Spain|Sevilla, Spain|Valencia, Spain|Linköping, Sweden|Uppsala, Sweden|Basel, Basel-Stadt, Switzerland|Chur, Graubünden, Switzerland|Bern, Switzerland|Genève, Switzerland|Zürich, Switzerland|Leicester, Leicestershire, United Kingdom|Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01538680"
703,"NCT01538667","Study to Characterize Lung Deposition, Pharmacokinetics, Safety and Tolerability of Single Inhalations of Radiolabeled Ciprofloxacin Dry Powder in Healthy Subjects and Patients With Chronic Lung Diseases",,"Completed","No Results Available","Respiratory System","Drug: Ciprofloxacin (Cipro Inhale, BAYQ3939)","Ciprofloxacin pharmacokinetics including lung deposition|Adverse Events collection","Bayer","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11523|2011-000342-38","April 2012","July 2012","July 2012","February 24, 2012",,"August 21, 2014","Gauting, Bayern, Germany",,"https://ClinicalTrials.gov/show/NCT01538667"
704,"NCT01523418","Study to Observe Safety of Xarelto in VTE Prophlylaxis After Elective TKR (Total Knee Replacement) or THR (Total Hip Replacement)","XYRIS","Withdrawn","No Results Available","Prophylaxis, Thromboembolism, Venous|Total Knee Replacement|Total Hip Replacement","Drug: Rivaroxaban (Xarelto, BAY59-7939)","Safety related variables are bleeding events reported as major or non-major adverse events|Symptomatic thromboembolic events (Deep vein thrombosis, Pulmonary embolism) reported as adverse events|All cause mortality","Bayer","All","18 Years and older   (Adult, Older Adult)",,"0","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","15871|XA1111IN","October 2014","November 2016","November 2016","February 1, 2012",,"February 4, 2016",,,"https://ClinicalTrials.gov/show/NCT01523418"
705,"NCT01518855","Controlled Release Nifedipine and Valsartan Combination Therapy in Patients With Essential Hypertension",,"Completed","No Results Available","Hypertension","Drug: Nifedipine (Adalat, BAYA1040)|Drug: Amlodipine (Norvasc)|Drug: Diovan","Mean treatment cost* for 16-week of double-blind treatment period|Proportion of participants** achieving target blood pressure at the end of double-blind treatment period|Treatment cost per subject to achieve the target blood pressure (Total costs for the double-blind treatment period / Number of patients who achieve the target blood pressure at the end of double-blind treatment period)|The change in blood pressure (SBP and DBP) from the baseline (end of pretreatment period) .|Proportion of participants for each age group to target blood pressure level|Incidence of treatment-emergent drug-related adverse events|Safety variables will be summarized using descriptive statistics based on adverse events collections","Bayer","All","20 Years to 79 Years   (Adult, Older Adult)","Phase 4","514","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11518","March 2004","April 2005","April 2005","January 26, 2012",,"January 26, 2012","Sapporo, Hokkaido, Japan|Setagaya-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Hiroshima, Japan",,"https://ClinicalTrials.gov/show/NCT01518855"
706,"NCT01518387","Open Study of BAY77-1931 (Lanthanum Carbonate) in Continuous Ambulatory Peritoneal Dialysis Patients",,"Completed","No Results Available","Hyperphosphatemia","Drug: Lanthanum Carbonate (BAY77-1931)","Change from baseline in serum phosphate levels at the end of the treatment period|Number of participants achieving the target PSPL (Pre-dialysis serum phosphate level) and time to achievement|Serum calcium level corrected by serum albumin level at the end of the treatment period|Serum calcium x phosphate product at the end of the treatment period|Serum intact-PTH (Parathyroid) levels at the end of the treatment period|Safety variables will be summarized using descriptive statistics based on adverse events collection","Bayer","All","20 Years to 75 Years   (Adult, Older Adult)","Phase 3","43","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11878","January 2006","July 2006","July 2006","January 26, 2012",,"March 14, 2016","Asahikawa, Hokkaido, Japan|Kamakura, Kanagawa, Japan|Yokosuka, Kanagawa, Japan|Osaki, Miyagi, Japan|Sendai, Miyagi, Japan|Meguro-ku, Tokyo, Japan|Fukuoka, Japan|Gifu, Japan|Hiroshima, Japan|Okayama, Japan|Tokushima, Japan",,"https://ClinicalTrials.gov/show/NCT01518387"
707,"NCT01516840","Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients",,"Completed","No Results Available","Deep Vein Thrombosis","Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Unfractionated heparin|Drug: Warfarin","Number of participants with newly onset of symptomatic venous thromboembolism (VTE)|Number of clinically relevant bleedings|Number of participants with improvement in thrombotic burden|Number of participants with deterioration in thrombotic burden|Number of participants with the composite of newly onset of symptomatic VTE or asymptomatic deterioration of thrombus","Bayer|Janssen Scientific Affairs, LLC","All","20 Years and older   (Adult, Older Adult)","Phase 3","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","14568","March 2012","December 2013","January 2014","January 25, 2012",,"January 18, 2017","Toyoake, Aichi, Japan|Sakura, Chiba, Japan|Maebashi, Gunma, Japan|Otake, Hiroshima, Japan|Sapporo, Hokkaido, Japan|Takarazuka, Hyogo, Japan|Kahoku-gun, Ishikawa, Japan|Kanazawa, Ishikawa, Japan|Yokohama, Kanagawa, Japan|Tsu, Mie, Japan|Sasebo, Nagasaki, Japan|Osakasayama, Osaka, Japan|Suita, Osaka, Japan|Bunkyo-ku, Tokyo, Japan|Chuoku, Tokyo, Japan|Itabashi-ku, Tokyo, Japan|Meguro-ku, Tokyo, Japan|Shinagawa, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Aomori, Japan|Fukuoka, Japan|Kumamoto, Japan|Niigata, Japan|Okayama, Japan|Osaka, Japan|Osaka, Japan|Shizuoka, Japan|Tokushima, Japan|Wakayama, Japan",,"https://ClinicalTrials.gov/show/NCT01516840"
708,"NCT01516814","Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) Patients",,"Completed","No Results Available","Pulmonary Embolism","Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Unfractionated heparin|Drug: Warfarin","Number of participants with newly onset of symptomatic venous thromboembolism (VTE)|Number of clinically relevant bleedings|Number of participants with improvement in thrombotic burden|Number of participants with deterioration in thrombotic burden|Number of participants with the composite of newly onset of symptomatic VTE or asymptomatic deterioration of thrombus","Bayer|Janssen Research & Development, LLC","All","20 Years and older   (Adult, Older Adult)","Phase 3","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15960","February 2012","October 2013","November 2013","January 25, 2012",,"January 23, 2017","Nagoya, Aichi, Japan|Toyoake, Aichi, Japan|Sakura, Chiba, Japan|Kurume, Fukuoka, Japan|Maebashi, Gunma, Japan|Sapporo, Hokkaido, Japan|Kahoku-gun, Ishikawa, Japan|Kanazawa, Ishikawa, Japan|Yokohama, Kanagawa, Japan|Tsu, Mie, Japan|Matsumoto, Nagano, Japan|Suwa, Nagano, Japan|Osakasayama, Osaka, Japan|Suita, Osaka, Japan|Shimotsuke, Tochigi, Japan|Bunkyo-ku, Tokyo, Japan|Bunkyo-ku, Tokyo, Japan|Chuoku, Tokyo, Japan|Itabashi-ku, Tokyo, Japan|Meguro-ku, Tokyo, Japan|Shinagawa, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Aomori, Japan|Chiba, Japan|Kumamoto, Japan|Niigata, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Saga, Japan|Shizuoka, Japan",,"https://ClinicalTrials.gov/show/NCT01516814"
709,"NCT01516762","Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases",,"No longer available","No Results Available","Prostatic Neoplasms","Drug: Radium-223 dichloride (BAY88-8223)",,"Bayer","Male","18 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access",,"15995|2011-004469-33",,,,"January 25, 2012",,"July 14, 2014","Birmingham, Alabama, United States|Phoenix, Arizona, United States|Scottsdale, Arizona, United States|Greenbrae, California, United States|La Jolla, California, United States|San Francisco, California, United States|Stanford, California, United States|Aurora, Colorado, United States|Newark, Delaware, United States|Washington, District of Columbia, United States|Washington, District of Columbia, United States|Fort Myers, Florida, United States|Miami Beach, Florida, United States|Tampa, Florida, United States|Atlanta, Georgia, United States|Honolulu, Hawaii, United States|Goshen, Indiana, United States|Iowa City, Iowa, United States|New Orleans, Louisiana, United States|Shreveport, Louisiana, United States|Baltimore, Maryland, United States|Baltimore, Maryland, United States|Baltimore, Maryland, United States|Bethesda, Maryland, United States|Rockville, Maryland, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Ann Arbor, Michigan, United States|Detroit, Michigan, United States|Detroit, Michigan, United States|Minneapolis, Minnesota, United States|St. Louis, Missouri, United States|Las Vegas, Nevada, United States|New Brunswick, New Jersey, United States|Newark, New Jersey, United States|New Hyde Park, New York, United States|New York, New York, United States|New York, New York, United States|Syracuse, New York, United States|Durham, North Carolina, United States|Raleigh, North Carolina, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Springfield, Oregon, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Myrtle Beach, South Carolina, United States|Myrtle Beach, South Carolina, United States|Nashville, Tennessee, United States|Houston, Texas, United States|Plano, Texas, United States|San Antonio, Texas, United States|Temple, Texas, United States|Hampton, Virginia, United States|Norfolk, Virginia, United States|Seattle, Washington, United States|Wheeling, West Virginia, United States|Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01516762"
710,"NCT01514851","Phase III Double-blind Comparative Study of BAY77-1931 (Lanthanum Carbonate) With Calcium Carbonate",,"Completed","No Results Available","Hyperphosphatemia","Drug: Lanthanum carbonate (BAY77-1931)|Drug: Calcium carbonate","Change from baseline in pre-dialysis serum phosphate levels (PSPL) at the end of the double-blind period|Presence/absence of incidence of hypercalcemia up to 8 weeks|Number of participants achieving target PSPL and time to achievement|Serum calcium x phosphate product at the end of the double-blind treatment period|Serum intact-PTH (Parathyroid) levels|Serum calcium level corrected by serum albumin level at the end of the double-blind treatment period|Number of participants achieving the target serum calcium levels|Safety variables will be summarized using descriptive statistics based on adverse events collection","Bayer","All","20 Years and older   (Adult, Older Adult)","Phase 3","259","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11877","January 2006","May 2006","May 2006","January 23, 2012",,"June 8, 2012","Toyohashi, Aichi, Japan|Yatomi, Aichi, Japan|Asahi, Chiba, Japan|Kashiwa, Chiba, Japan|Matsudo, Chiba, Japan|Narita, Chiba, Japan|Kurume, Fukuoka, Japan|Kurume, Fukuoka, Japan|Isesaki, Gunma, Japan|Kobe, Hyogo, Japan|Mito, Ibaraki, Japan|Tsuchiura, Ibaraki, Japan|Takamatsu, Kagawa, Japan|Osaki, Miyagi, Japan|Sendai, Miyagi, Japan|Suita, Osaka, Japan|Fuji, Shizuoka, Japan|Hamamatsu, Shizuoka, Japan|Arakawa-ku, Tokyo, Japan|Kodaira, Tokyo, Japan|Nerima-ku, Tokyo, Japan|Shibuya-ku, Tokyo, Japan|Shinjyuku-ku, Tokyo, Japan|Chiba, Japan|Hiroshima, Japan|Kochi, Japan|Okayama, Japan|Saitama, Japan|Saitama, Japan|Saitama, Japan|Tokushima, Japan",,"https://ClinicalTrials.gov/show/NCT01514851"
711,"NCT01512966","Japanese Safety Study of VEGF Trap-Eye in DME (Diabetic Macular Edema)","VIVID-Japan","Completed","No Results Available","Macular Edema","Biological: VEGF Trap-Eye (BAY86-5321)","Adverse Event collection|Change from baseline in BCVA (best corrected visual acuity) letter score","Bayer|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","73","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15657","January 2012","September 2013","September 2013","January 20, 2012",,"October 9, 2014","Matsuyama, Ehime, Japan|Maebashi, Gunma, Japan|Kobe, Hyogo, Japan|Mito, Ibaraki, Japan|Kita, Kagawa, Japan|Kawasaki, Kanagawa, Japan|Sendai, Miyagi, Japan|Kashihara, Nara, Japan|Suita, Osaka, Japan|Otsu, Shiga, Japan|Shimotsuke, Tochigi, Japan|Kagoshima, Japan|Kyoto, Japan|Okayama, Japan|Osaka, Japan|Osaka, Japan|Saga, Japan|Wakayama, Japan",,"https://ClinicalTrials.gov/show/NCT01512966"
712,"NCT01508364","Nexavar as First Targeted Therapy in Patients With Advanced Renal Cell Carcinoma","NEXTAR","Completed","No Results Available","Carcinoma, Renal Cell","Drug: Sorafenib (Nexavar, BAY 43-9006)","Duration of Nexavar treatment|Overall Survival (OS)|Health related quality of life (HRQoL)|Progression-free survival (PFS)|Tumor status, of patients will be evaluated according to the categories ""Complete Response"", ""Partial Response"", ""Stable Disease"", ""Clinical Progression"", ""Radiological Progression"".|Incidence of Treatment-emergent Adverse Events (TEAE)","Bayer","All","Child, Adult, Older Adult",,"20","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16091|NX1111","July 2012","December 2013","December 2013","January 12, 2012",,"January 21, 2015","Many Locations, Germany",,"https://ClinicalTrials.gov/show/NCT01508364"
713,"NCT01507051","Switching Study From Warfarin to Rivaroxaban",,"Completed","Has Results","Venous Thrombosis","Drug: Warfarin (Coumadin)|Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Placebo|Drug: Vitamin K (Konakion)","Emax (Maximum Effect) on Prothrombin Time (PT) (Coagulation Test)|Emax,BA (Baseline Adjusted Maximum Effect) on Prothrombin Time (Coagulation Test)|AUC(0-tn) (Area Under the Measurement Versus Time Curve From Time 0 to the Last Data Point) of Prothrombin Time (Coagulation Test)|AUCBA(0-tn) (Baseline Adjusted Area Under the Measurement Versus Time Curve From Time 0 to the Last Data Point) of Prothrombin Time (Coagulation Test)|Emax on PT (Measured as INR=International Normalized Ratio)|AUC(0-tn) (Area Under the Measurement Versus Time Curve From Time 0 to the Last Data Point) for PT (Measured as INR=International Normalized Ratio)|Emax on Factor Xa Activity|AUC(0-tn) (Area Under the Inverse Measurement Versus Time Curve From Time 0 to the Last Data Point) of Factor Xa Activity|Emax (Maximum Effect) on Anti-Factor Xa Activity|AUC(0-tn) (Area Under the Measurement Versus Time Curve From Time 0 to the Last Data Point) of Anti-Factor Xa Activity|Emax (Maximum Effect) on aPTT (Activated Partial Thromboplastin Time)|AUC(0-tn) (Area Under the Measurement Versus Time Curve From Time 0 to the Last Data Point) of aPTT (Activated Partial Thromboplastin Time)|Emax (Maximum Effect) on HepTest (Coagulation Test)|AUC(0-tn) (Area Under the Measurement Versus Time Curve From Time 0 to the Last Data Point) of HepTest (Coagulation Test)|Emax (Maximum Effect) on PiCT (Prothrombinase-induced Clotting Time)|AUC(0-tn) (Area Under the Measurement Versus Time Curve From Time 0 to the Last Data Point) of PiCT (Prothrombinase-induced Clotting Time)|Emax (Maximum Effect) on ETP (Endogenous Thrombin Potential) AUC|AUC(0-tn) (Area Under the Measurement Versus Time Curve From Time 0 to the Last Data Point) of ETP (Endogenous Thrombin Potential) AUC|Emax (Maximum Effect) on ETP (Endogenous Thrombin Potential) Lag Time|AUC(0-tn) (Area Under the Measurement Versus Time Curve From Time 0 to the Last Data Point) of ETP (Endogenous Thrombin Potential) Lag Time|Emax (Maximum Effect) on ETP (Endogenous Thrombin Potential) Peak|AUC(0-tn) (Area Under the Measurement Versus Time Curve From Time 0 to the Last Data Point) of ETP (Endogenous Thrombin Potential) Peak|Emax (Maximum Effect) on ETP (Endogenous Thrombin Potential) Peak Time|AUC(0-tn) (Area Under the Measurement Versus Time Curve From Time 0 to the Last Data Point) of ETP (Endogenous Thrombin Potential) Peak Time|Emax (Maximum Effect) on Factor VIIa Activity|AUC(0-tn) (Area Under the Measurement Versus Time Curve From Time 0 to the Last Data Point) of Factor VIIa Activity|Emax (Maximum Effect) on Factor IIa Activity|AUC(0-tn) (Area Under the Measurement Versus Time Curve From Time 0 to the Last Data Point) of Factor IIa Activity|Area Under the Plasma Concentration Versus Time Curve From Time 0 to 24 Hours [AUC(0-24)] of Rivaroxaban After First Dose|Maximum Drug Concentration in Plasma (Cmax) of Rivaroxaban After First Dose|Half Life Associated With Terminal Slope (t1/2) of R-warfarin After the Last Dose of Warfarin|Half Life Associated With Terminal Slope (t1/2) of S-warfarin After the Last Dose of Warfarin|Area Under the Plasma Concentration Versus Time Curve From Time 0 to 24 Hours Divided by Dose Per kg Body Weight [AUC(0-24)Norm] of Rivaroxaban After First Dose|Maximum Drug Concentration in Plasma Divided by Dose Per kg Body Weight (Cmax,Norm) of Rivaroxaban After First Dose|Time to Reach Maximum Drug Concentration in Plasma (Tmax) of Rivaroxaban After First Dose|Drug Concentration in Plasma at Expected Time of Maximum (Peak) Concentration (Cpeak) of Rivaroxaban After Second to Fourth Dose|Drug Concentration in Plasma at Expected Time of Minimum (Trough) Concentration (Ctrough) of Rivaroxaban After Second to Fourth Dose|Half Life Associated With Terminal Slope (t1/2) of Rivaroxaban After Last Dose|Drug Concentration in Plasma at Steady State at Expected Time of Minimum (Trough) Concentration (Ctrough,ss) of R-warfarin After the Last Dose of Warfarin|Drug Concentration in Plasma at Steady State at Expected Time of Minimum (Trough) Concentration, Normalized by Dose (Ctrough,ss/D) of R-warfarin After the Last Dose of Warfarin|Drug Concentration in Plasma at Steady State at Expected Time of Minimum (Trough) Concentration (Ctrough,ss) of S-warfarin After the Last Dose of Warfarin|Drug Concentration in Plasma at Steady State at Expected Time of Minimum (Trough) Concentration, Normalized by Dose (Ctrough,ss/D) of S-warfarin After the Last Dose of Warfarin","Bayer|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Male","18 Years to 45 Years   (Adult)","Phase 1","96","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)","10849|2008-005540-16","November 2008","November 2009","November 2009","January 10, 2012","April 26, 2012","February 9, 2015","Köln, Nordrhein-Westfalen, Germany|Mönchengladbach, Nordrhein-Westfalen, Germany",,"https://ClinicalTrials.gov/show/NCT01507051"
714,"NCT01495858","Evaluate Analgesic / Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain","Morpheus/DPH","Completed","Has Results","Pain, Postoperative","Drug: Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)|Drug: Naproxen Sodium 440 mg (BAYH6689)|Drug: DPH 50 mg","Wake Time After Sleep Onset (WASO) Measured by Actigraphy|Sleep Latency Measured by Actigraphy|Total Sleep Time Measured by Actigraphy|Sleep Efficiency Measured by Actigraphy|Global Assessment of Investigational Product as a Sleep Aid|Karolinska Sleep Diary - Sleep Quality|Karolinska Sleep Diary - Calmness of Sleep|Karolinska Sleep Diary - Easiness to Fall Asleep|Karolinska Sleep Diary - Premature Awakening|Karolinska Sleep Diary - Ease of Awakening|Karolinska Sleep Diary - Well Rested|Karolinska Sleep Diary - Sufficient Sleep|Subjective Sleep Questionnaire - Quality of Your Sleep Last Night|Subjective Sleep Questionnaire - Refreshing Nature of Your Sleep Last Night|Subjective Sleep Questionnaire - Time to Fall Asleep Last Night|Subjective Sleep Questionnaire - Number of Minutes You Think That You Were Awake From the Time You Fell Asleep Until the Time You Got Out of Bed|Change From Baseline in Pain Intensity|Overall Rating of Pain Relief|Time to Rescue Medication|Cumulative Proportion of Participants Taking Rescue Medication by Hour|Global Assessment of Investigational Product as a Pain Reliever","Bayer","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","267","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","15881","December 2011","February 2012","February 2012","December 20, 2011","June 17, 2014","June 8, 2015","Austin, Texas, United States|Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01495858"
715,"NCT01491100","Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis","CogniPlus","Completed","No Results Available","Multiple Sclerosis","Drug: Interferon beta-1b (Betaseron, BAY86-5046)","Cognitive performance as measured by SDMT (Symbol Digit Modalities Test)|Physical activity as measured by the Baecke questionnaire|Disability as measured by EDSS (Expanded Disability Status Scale)|Fatigue as measured by FSMC (Fatigue Scale for Motor and Cognitive Functions)|Depression as measured by the CES-D (Center for Epidemiologic Studies Depression)|Quality of life as measured by the SF-12 (Mental and physical health-scale measure of quality of life)","Bayer","All","12 Years to 70 Years   (Child, Adult, Older Adult)",,"1085","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16036|BF1101","April 30, 2012","December 22, 2016","April 5, 2017","December 13, 2011",,"April 5, 2018","Multiple Locations, Albania|Multiple Locations, Algeria|Multiple Locations, Argentina|Multiple Locations, Belgium|Multiple Locations, Czechia|Multiple Locations, Egypt|Multiple Locations, France|Multiple Locations, Germany|Multiple Locations, Greece|Multiple Locations, Hungary|Multiple Locations, Israel|Multiple Locations, Kazakhstan|Multiple Locations, Netherlands|Multiple Locations, Portugal|Multiple Locations, Saudi Arabia|Multiple Locations, Tunisia|Multiple Locations, Turkey",,"https://ClinicalTrials.gov/show/NCT01491100"
716,"NCT01490294","Myocardial Perfusion MRI",,"Completed","Has Results","Myocardial Perfusion Imaging|Magnetic Resonance Imaging","Drug: Gadobutrol (Gadavist,Gadovist, BAY86-4875)","Percentage Agreement Between Gadobutrol Perfusion Magnetic Resonance Imaging (MRI) (Blinded Reading) and SPECT (Central Reading) Regarding the Diagnosis for Detection of Cardiac Perfusion Deficits Based on Myocardial Regions|Percentage Agreement Between Gadobutrol Perfusion MRI (Blinded Reading) and SPECT (Central Reading) Regarding the Diagnosis for Detection of Cardiac Perfusion Deficits Based on Myocardial Segments|Percentage Agreement Between Gadobutrol Perfusion MRI (Clinical Evaluation) and SPECT (Central Reading) Regarding the Diagnosis for Detection of Cardiac Perfusion Deficits Based on Myocardial Regions|Percentage Agreement Between Gadobutrol Perfusion MRI (Clinical Evaluation) and SPECT (Central Reading) Regarding the Diagnosis for Detection of Cardiac Perfusion Deficits Based on Myocardial Segments|Diagnosis 'Scar': Percentage Agreement Between Gadobutrol Perfusion MRI (Blinded Reading) and SPECT (Central Reading) Regarding the Diagnosis Scar Based on Myocardial Regions|Diagnosis ""Scar"": Percentage Agreement Between Gadobutrol Perfusion MRI (Blinded Reading) and SPECT (Central Reading) Regarding the Diagnosis ""Scar"" Based on Myocardial Segments|Diagnosis ""Scar"": Percentage Agreement Between Gadobutrol Perfusion MRI (Clinical Evaluation) and SPECT (Central Reading) Regarding the Diagnosis ""Scar"" Based on Myocardial Regions|Diagnosis ""Scar"": Percentage Agreement Between Gadobutrol Perfusion MRI (Clinical Evaluation) and SPECT (Central Reading) Regarding the Diagnosis ""Scar"" Based on Myocardial Segments|Diagnosis ""Ischemia"": Percentage Agreement Between Gadobutrol Perfusion MRI (Blinded Reading) and SPECT (Central Reading) Regarding the Diagnosis of Ischemia Based on Myocardial Regions|Diagnosis ""Ischemia"": Percentage Agreement Between Gadobutrol Perfusion MRI (Blinded Reading) and SPECT (Central Reading) Regarding the Diagnosis of Ischemia Based on Myocardial Segments|Diagnosis ""Ischemia"": Percentage Agreement Between Gadobutrol Perfusion MRI (Clinical Evaluation) and SPECT (Central Reading) Regarding the Diagnosis of Ischemia Based on Myocardial Regions|Diagnosis ""Ischemia"": Percentage Agreement Between Gadobutrol Perfusion MRI (Clinical Evaluation) and SPECT (Central Reading) Regarding the Diagnosis of Ischemia Based on Myocardial Segments|Percentage Agreement Between Gadobutrol Perfusion MRI (Blinded Reading) and SPECT (Central Reading) Regarding a Detailed Diagnosis of Cardiac Perfusion Deficits i.e. Scar, Ischemia or a Mixture of Both, Based on Myocardial Regions|Percentage Agreement Between Gadobutrol Perfusion MRI (Blinded Reading) and SPECT (Central Reading) Regarding a Detailed Diagnosis of Cardiac Perfusion Deficits i.e. Scar, Ischemia or a Mixture of Both Based on Myocardial Segments|Percentage Agreement Between Gadobutrol Perfusion MRI (Clinical Evaluation) and SPECT (Central Reading) Regarding a Detailed Diagnosis of Cardiac Perfusion Deficits i.e. Scar, Ischemia or a Mixture of Both Based on Myocardial Regions|Percentage Agreement Between Gadobutrol Perfusion MRI (Clinical Evaluation) and SPECT (Central Reading) Regarding a Detailed Diagnosis of Cardiac Perfusion Deficits i.e. Scar, Ischemia or a Mixture of Both Based on Myocardial Segments|Percent Agreement Between Combined Gadobutrol Perfusion MRI (Perfusion Imaging and Delayed (DE) Imaging; Blinded Reading) and SPECT (Central Reading) Regarding a Detailed Diagnosis of Perfusion Deficits Based on Myocardial Regions|Percent Agreement Between Combined Gadobutrol Perfusion MRI (Perfusion Imaging and Delayed (DE) Imaging; Blinded Reading) and SPECT (Central Reading) Regarding a Detailed Diagnosis of Perfusion Deficits Based on Myocardial Segments|Percentage of Artifacts in Gadobutrol Perfusion MRI (Blinded Reading) Based on Myocardial Segments|Percentage of Artifacts in Gadobutrol Perfusion MRI (Clinical Evaluation) Based on Myocardial Segments|Percentage Agreement Between Gadobutrol Perfusion MRI (Blinded Reading, Based on Myocardial Regions) and Coronary Angiography (Central Reading) Regarding Detection of Significant Stenoses|Percentage Agreement Between the Semiquantitative Gadobutrol Perfusion MRI Parameter ""Myocardial Perfusion Reserve Index (MPRI) "" (Expert Evaluation) and Detection of Significant Stenoses by Coronary Angiography (MR Based on Myocardial Regions)|Percentage Agreement Between Gadobutrol Perfusion MRI (Blinded Reading) and the Truth Panel Diagnosis (SoT) Regarding Perfusion Defects Based on Regions|Percentage Agreement Between the Semiquantitative Gadobutrol Perfusion MRI Parameter ""Myocardial Perfusion Reserve Index (MPRI)"" (Expert Evaluation) and SPECT (Central Reading) Based on Myocardial Regions|Percentage Agreement Between the Semiquantitative Gadobutrol Perfusion MRI Parameter ""Myocardial Perfusion Reserve Index (MPRI)"" (Expert Evaluation) and SPECT (Central Reading) Based on Myocardial Segments|Percentage Agreement Between the Visual (Blinded Reading) and the Semiquantitative (MPRI; Expert Evaluation) Gadobutrol Perfusion MRI Diagnosis Based on Myocardial Regions|Percentage Agreement Between the Visual (Blinded Reading) and Semiquantitative (MPRI; Expert Evaluation) Gadobutrol Perfusion MRI Diagnosis Based on Myocardial Segments|Signal Intensity (SIrel) Based on Segments|Upslope Based on Segments|Time to Peak Based on Segments|Percentage Agreement Between Presence/Absence of Delayed Enhancement in MRI (Blinded Reading) and Scar in SPECT (Central Reading) Based on Myocardial Regions|Percentage Agreement Between Presence/Absence of Delayed Enhancement in MRI (Blinded Reading) and Scar in SPECT (Central Reading) Based on Myocardial Segments|Percentage Agreement Between Presence/Absence of Delayed Enhancement in MRI (Clinical Evaluation) and Scar in SPECT (Central Reading) Based on Myocardial Regions|Percentage Agreement Between Presence/Absence of Delayed Enhancement in MRI (Clinical Evaluation) and Scar in SPECT (Central Reading) Based on Myocardial Segments|Assessment of the Overall Confidence in the Presence of Delayed Enhancement (DE) at 5 Minutes Post Injection (Blinded Reading)|Assessment of the Overall Confidence in the Presence of Delayed Enhancement (DE) at 5 Minutes Post Injection (Clinical Evaluation) (Only Participants With DE in at Least One Segment, PPS)|Assessment of the Overall Confidence in the Presence of Delayed Enhancement (DE) at 10 Minutes Post Injection (Blinded Reading) (Only Participants With DE in at Least One Segment, PPS)|Assessment of the Overall Confidence in the Presence of Delayed Enhancement (DE) at 10 Minutes Post Injection (Clinical Evaluation) (Only Participants With DE in at Least One Segment, PPS)|Assessment of the Overall Confidence in the Presence of Delayed Enhancement (DE) at 15 Minutes Post Injection (Blinded Reading) (Only Participants With DE in at Least One Segment, PPS)|Assessment of the Overall Confidence in the Presence of Delayed Enhancement (DE) at 15 Minutes Post Injection (Clinical Evaluation) (Only Participants With DE in at Least One Segment, PPS)|Assessment of the Overall Confidence in the Presence of Delayed Enhancement (DE) at 20 Minutes Post Injection (Blinded Reading) (Only Participants With DE in at Least One Segment, PPS)|Assessment of the Overall Confidence in the Presence of Delayed Enhancement (DE) at 20 Minutes Post Injection (Clinical Evaluation) (Only Participants With DE in at Least One Segment, PPS)|Assessment of Contrast Quality of Delayed Enhancement (DE) at 5 Minutes Post Injection (Blinded Reading) (Only Participants With DE in at Least One Segment, PPS)|Assessment of Contrast Quality of Delayed Enhancement (DE) at 5 Minutes Post Injection (Clinical Evaluation) (Only Participants With DE in at Least One Segment, PPS)|Assessment of Contrast Quality of Delayed Enhancement (DE) at 10 Minutes Post Injection (Blinded Reading) (Only Participants With DE in at Least One Segment, PPS)|Assessment of Contrast Quality of Delayed Enhancement (DE) at 10 Minutes Post Injection According to Clinical Evaluation (Only Participants With DE in at Least One Segment, PPS)|Assessment of Contrast Quality of Delayed Enhancement (DE) at 15 Minutes Post Injection According to Blinded Reading (Only Participants With DE in at Least One Segment, PPS)|Assessment of Contrast Quality of Delayed Enhancement (DE) at 15 Minutes Post Injection According to Clinical Evaluation (Only Participants With DE in at Least One Segment, PPS)|Assessment of Contrast Quality of Delayed Enhancement (DE) at 20 Minutes Post Injection According to Blinded Reading (Only Participants With DE in at Least One Segment, PPS)|Assessment of Contrast Quality of Delayed Enhancement (DE) at 20 Minutes Post Injection According to Clinical Evaluation (Only Participants With DE in at Least One Segment, PPS)|Percent Agreement Between Gadobutrol Perfusion MRI Diagnosis (Blinded Reading) and the Presence/Absence of Delayed Enhancement (DE) at the Time Point of Highest Agreement Between SPECT (Central Reading) and DE Based on Myocardial Regions|Percentage Agreement Between Gadobutrol Perfusion MRI Diagnosis (Blinded Reading) and the Presence/Absence of Delayed Enhancement (DE) at the Time Point of Highest Agreement Between SPECT (Central Reading) and DE Based on Myocardial Segments|Percentage Agreement Between Gadobutrol Perfusion MRI Diagnosis (Clinical Evaluation) and the Presence/Absence of Delayed Enhancement (DE) at the Time Point of Highest Agreement Between SPECT (Central Reading) and DE Based on Myocardial Segments|Percentage Agreement Between Gadobutrol Perfusion MRI Diagnosis (Clinical Evaluation) and Presence/Absence of Delayed Enhancement (DE) at the Time Point of Highest Agreement Between SPECT (Central Reading) and DE Based on Myocardial Regions|Percentage of Segments With Artifacts on Delayed Enhancement Images (Blinded Reading)|Percentage of Segments With Artifacts on Delayed Enhancement Images (Clinical Evaluation)|Percentage of Participants With Deviation of MRI Procedure (Clinical Evaluation)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","232","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","91054|305501|2005-005158-32","March 2004","May 2006","May 2006","December 12, 2011","June 28, 2012","May 22, 2014","Poelten, Austria|Freiburg, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|Ulm, Baden-Württemberg, Germany|München, Bayern, Germany|München, Bayern, Germany|Frankfurt, Hessen, Germany|Bad Oeynhausen, Nordrhein-Westfalen, Germany|Bonn, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Berlin, Germany|Krakow, Poland|Basel, Basel-Stadt, Switzerland|Lugano, Ticino, Switzerland",,"https://ClinicalTrials.gov/show/NCT01490294"
717,"NCT01489488","Relative Bioavailability and Food Effect Study",,"Completed","No Results Available","Pharmacology, Clinical","Drug: Riociguat (BAY63-2521)","Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC) of Riociguat and its Analyte M1 (BAY60-4552)|Maximum Observed Drug Concentration (Cmax) of Riociguat and its Analyte M1 (BAY60-4552) After a Single Dose|Area Under the Concentration Versus Time Curve From Zero to Infinity Divided by Dose (AUC/D) of Riociguat and its Analyte M1 (BAY60-4552) After a Single Dose|Maximum Observed Drug Concentration Adjusted by Dose (Cmax/D) of Riociguat and its Analyte M1 (BAY60-4552) After a Single Dose|Area Under the Concentration Versus Time Curve From Zero to Infinity Divided by Dose per Kilogram Body Weight (AUC,norm) of Riociguat and its Analyte M1 (BAY60-4552) After a Single Dose|Maximum Observed Plasma Concentration Divided by Dose per Kilogram Body Weight (Cmax,norm) of Riociguat and its Analyte M1 (BAY60-4552) After a Single Dose|Time to Reach Maximum Drug Concentration in Plasma (tmax) of Riociguat and its Analyte M1 (BAY60-4552) After a Single Dose|Terminal Half Life (t1/2) of Riociguat and its Analyte M1 (BAY60-4552)|Mean Residence Time (MRT) of Riociguat and its Analyte M1 (BAY604552)|Area Under the Concentration Versus Time Curve From Zero to Last Quantifiable Concentration (AUC[0-tlast]) of Riociguat and its Analyte M1 (BAY60-4552) After a Single Dose|Area Under the Concentration Versus Time Curve From Zero to Last Quantifiable Concentration Divided by Dose per Kilogram Body Weight (AUC[0-tlast]norm) of Riociguat and its Analyte M1 (BAY60-4552) After a Single Dose|Area Under the Concentration Versus Time Curve From Zero to Last Quantifiable Concentration Divided by Dose (AUC[0-tlast]/D) of Riociguat and its Analyte M1 (BAY60-4552) After a Single Dose","Bayer","All","18 Years to 45 Years   (Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","14986|2011-001893-24","January 2012","April 2012","May 2012","December 9, 2011",,"July 1, 2015","Köln, Nordrhein-Westfalen, Germany",,"https://ClinicalTrials.gov/show/NCT01489488"
718,"NCT01482910","VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)",,"Completed","Has Results","Macular Degeneration","Biological: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Drug: Visudyne","Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by ETDRS Letter Score at Week 28 - Last Observation Carried Forward (LOCF)|Percentage of Participants Who Lost Fewer Than 15 Letters at Week 28 - LOCF","Bayer|Regeneron Pharmaceuticals","All","50 Years and older   (Adult, Older Adult)","Phase 3","304","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","13406","December 2011","March 2014","August 2014","December 1, 2011","March 13, 2015","November 4, 2016","Guangzhou, Guangdong, China|Changsha, Hunan, China|Xi'an, Shaanxi, China|Qingdao, Shandong, China|Chengdu, Sichuan, China|Hangzhou, Zhejiang, China|Hangzhou, Zhejiang, China|Wenzhou, Zhejiang, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Shanghai, China|Tianjin, China",,"https://ClinicalTrials.gov/show/NCT01482910"
719,"NCT01479387","Zevalin Post-marketing Surveillance for Adequateness of Image Interpretation Criteria in Japan","ZEVALIN-SDUI","Completed","No Results Available","Non-Hodgkin's Lymphoma (NHL)","Drug: [111]In-ibritumomab tiuxetan (Zevalin, BAY86-5128)","Assessment of abnormal distribution of In-111 Zevalin by the investigator [Two scales; Yes or No]|Assessment of abnormal distribution of In-111 Zevalin by the central committee [Two scales; Yes or No]","Bayer","All","Child, Adult, Older Adult",,"72","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","15043","August 2008",,"February 2011","November 24, 2011",,"November 24, 2011","Many Locations, Japan",,"https://ClinicalTrials.gov/show/NCT01479387"
720,"NCT01473121","Hepatocellular Carcinoma Registry for Turkey (3K Trial)",,"Completed","No Results Available","Hepatocellular Carcinoma","Other: No Intervention","Descriptive analysis of HCC risk factors|Descriptive analysis of clinical profile of newly diagnosed HCC patients|Number of participants with underlying liver disease and family history|Treatment options as applied by doctors to HCC patients|Overall survival time since diagnosis|Number of participants with adverse events|Descriptive analysis of demographic characteristics of HCC patients|Descriptive analysis of clinical characteristics of HCC patients|Descriptive analysis of tumor properties","Bayer","All","18 Years and older   (Adult, Older Adult)",,"600","Industry","Observational","Observational Model: Other|Time Perspective: Prospective","15807|NX1110TR","August 13, 2012","June 30, 2017","July 12, 2018","November 17, 2011",,"July 5, 2019","Multiple Locations, Turkey",,"https://ClinicalTrials.gov/show/NCT01473121"
721,"NCT01473108","Study to Investigate the Natriuretic Effects, Safety, Tolerability and Pharmacokinetics of BAY94-8862",,"Completed","No Results Available","Pharmacology, Clinical","Drug: Finerenone (BAY 94-8862) PEG solution|Drug: Finerenone (BAY 94-8862) immediate release tablet|Drug: Eplerenone (Inspra®)|Drug: Placebo","Log10 (10*urinary Na+/K+ ratio)|AUC|Cmax|Number of participants with adverse events","Bayer","Male","18 Years to 46 Years   (Adult)","Phase 1","68","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)","13786|2010-018500-90","March 2010","November 2010","May 2011","November 17, 2011",,"December 2, 2015","Neuss, Nordrhein-Westfalen, Germany",,"https://ClinicalTrials.gov/show/NCT01473108"
722,"NCT01469234","A Study of Onset of Action of Loratadine and Fexofenadine in Participants With Seasonal Allergic Rhinitis (P08712)",,"Completed","Has Results","Rhinitis","Drug: loratadine|Drug: fexofenadine|Drug: placebo to loratadine|Drug: placebo to fexofenadine","Mean Major Symptom Complex (MSC) Score by Post-Treatment Evaluation Time Point (From 180 Minutes to 300 Minutes)|Mean Individual Symptom Score for Runny Nose by Post-Treatment Evaluation Time Point|Mean Individual Symptom Score for Itchy Nose by Post-Treatment Evaluation Time Point|Mean Individual Symptom Scores for Sneezing by Post-Treatment Evaluation Time Point|Mean Individual Symptom Scores for Watery Eyes by Post-Treatment Evaluation Time Point|Mean Individual Symptom Scores for Itchy Eyes by Post-Treatment Evaluation Time Point|Mean Individual Symptom Scores for Nasal Congestion by Post-Treatment Evaluation Time Point|Mean Individual Symptom Scores for Itchy Mouth/Throat/Ears by Post-Treatment Evaluation Time Point","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 4","255","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","18126|PT11-37|P08712","October 2011","November 2011","November 2011","November 10, 2011","March 22, 2013","March 11, 2015",,,"https://ClinicalTrials.gov/show/NCT01469234"
723,"NCT01469169","Inhaled Iloprost (Ventavis): Efficacy, Safety, and Pharmacokinetics (PK) Confirmation Study","IBUKI","Completed","No Results Available","Hypertension, Pulmonary","Drug: Iloprost (Ventavis inhaled, BAYQ6256)","Change in Pulmonary vascular resistance (PVR) from screening (baseline) to week 12 (after inhalation)|Number of participants with adverse events as a measure of safety and tolerability|Area under the plasma concentration vs time curve from start of inhalation to infinity after single inhalation (AUC)|Maximum drug concentration in plasma after start of inhalation (Cmax)|Change of Pulmonary vascular resistance index (PVRI) from baseline to week 12|Change of mean of pulmonary artery pressure from baseline to week 12|Change of systolic pulmonary artery pressure from baseline to week 12|Change of diastolic pulmonary artery pressure from baseline to week 12|Change in Mean right atrial pressure (RAPm)|Change in Pulmonary capillary wedge pressure (PCWP)|Change in Cardiac output (CO)|Change in Mean arterial pressure (MAP)|Change Mixed venous oxygen saturation (SVO2)|Change in Systemic vascular resistance (SVR)|Change in Systemic vascular resistance index (SVRI)|Change in Cardiac index|Change in 6-minute walking test (6MWT)|Change in Borg CR 10 Score|Change in New York Heart Association/ World Health Organization (NYHA/WHO) class|Change in N-terminal pro-B-type natriuretic peptide (NT-ProBNP)|Quality of life assessed by EQ-5D and Living with Pulmonary Hypertension (LPH) questionnaires|Time to clinical worsening during the study|Mortality during the study|Need for transplantation during the study|AUC from time start of inhalation to the last data point AUC(0-tlast)|AUC divided by dose per kg body weight (AUCnorm)|AUC divided by dose (μg) (AUC/D)|Maximum drug concentration in plasma after start of inhalation divided by dose (μg) per kg body weight (Cmax,norm)|Maximum drug concentration in plasma after start of inhalation divided by dose (μg) (Cmax/D)|Time to reach maximum drug concentration in plasma after start of inhalation (tmax )|Half-life associated with the terminal slope (t1/2)","Bayer","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","27","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15503","June 19, 2012","December 26, 2014","December 14, 2016","November 10, 2011",,"December 7, 2017","Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Kurume, Fukuoka, Japan|Asahikwa, Hokkaido, Japan|Kobe, Hyogo, Japan|Kawasaki, Kanagawa, Japan|Sendai, Miyagi, Japan|Tomigusuku, Okinawa, Japan|Bunkyo-ku, Tokyo, Japan|Chuoku, Tokyo, Japan|Mitaka, Tokyo, Japan|Ota-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Tanabe, Wakayama, Japan|Ube, Yamaguchi, Japan|Chiba, Japan|Tokushima, Japan",,"https://ClinicalTrials.gov/show/NCT01469169"
724,"NCT01468545","Educational Training Influence in Patients With PAH(Pulmonary Artery Hypertension) on Inhaled Ventavis Treatment Adherence Evaluated Trough INSIGHT System","Inventa","Completed","No Results Available","Pulmonary Arterial Hypertension","Other: Iloprost (Ventavis inhaled, BAYQ6256)","The influence of educational training on Ventavis treatment compliance through the Insight system|Number of events requiring non-planned visit or hospital admission related to PAH(Pulmonary Artery Hypertension), depending on the education sessions received.|Number of events due to Inhaler-related errors|The difference of adherence patient information (subjective data) through the Morisky-Green questionnaire and the one shown by the Insight registry (objective data)","Bayer|Dra. Pilar Escribano Subías - Coordinator - HU 12 de Octubre - Madrid (Spain)","All","18 Years and older   (Adult, Older Adult)",,"38","Industry|Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","15554|BAY-ILO-2010-01","October 2011","January 2013","June 2014","November 9, 2011",,"August 29, 2014","Many Locations, Spain",,"https://ClinicalTrials.gov/show/NCT01468545"
725,"NCT01465009","Placebo and Active Controlled Study to Compare the Efficacy of Aspirin and Paracetamol in Treatment of Sore Throat Associated With a Common Cold",,"Completed","No Results Available","Common Cold|Pharyngitis|Tonsillitis","Drug: Acetylsalicylic acid (Aspirin, BAYE4465)|Drug: Paracetamol|Drug: Placebo","Pain intensity difference to baseline of Acetylsalicylic Acid in comparison to Paracetamol|Pain intensity difference to baseline of Acetylsalicylic Acid in comparison to Placebo|Total pain relief of Acetylsalicylic Acid in comparison to Paracetamol|Total pain relief of Acetylsalicylic Acid in comparison to Placebo|Evaluation of Upper Respiratory Tract Infection symtoms|Adverse Event collection","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 4","508","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11381","November 2003",,"March 2005","November 4, 2011",,"December 11, 2014","Reading, Berkshire, United Kingdom|Manchester, Greater Manchester, United Kingdom|Chorley, Lancashire, United Kingdom|Wigan, Lancashire, United Kingdom|Liverpool, Merseyside, United Kingdom|Liverpool, Merseyside, United Kingdom|Cardiff, South Glamorgan, United Kingdom|Birmingham, West Midlands, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01465009"
726,"NCT01464983","Placebo and Active Controlled, Double Dummy Study to Compare Efficacy of Aspirin and Ibuprofen in Treatment of Episodic Tension-type Headache",,"Completed","No Results Available","Headache|Tension-Type Headache|Tension-Type Headache (Episodic)","Drug: Acetylsalicylic acid (Aspirin, BAYE4465)|Drug: Ibuprofen|Drug: Placebo","Percentage of subjects with total or meaningful headache relief at 2 hours after intake of study medication|Headache pain relief measured serially on a categorical scale|Measuring the functional ability on conducting everydays activity on a 4 point categorical scale|Global assessment of pain therapy|Safety - assessment of adverse events","Bayer","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","1115","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11220","January 2004",,"August 2004","November 4, 2011",,"December 25, 2014","Reading, Berkshire, United Kingdom|Manchester, Greater Manchester, United Kingdom|Chorley, Lancashire, United Kingdom|Wigan, Lancashire, United Kingdom|Liverpool, Merseyside, United Kingdom|Liverpool, Merseyside, United Kingdom|Cardiff, South Glamorgan, United Kingdom|Glasgow, Strathclyde, United Kingdom|Birmingham, West Midlands, United Kingdom|Coventry, West Midlands, United Kingdom|Wolverhampton, West Midlands, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01464983"
727,"NCT01464944","Placebo and Active Controlled Study to Compare the Antipyretic Efficacy of Aspirin® in Patients With Acute Febrile Upper Respiratory Tract Infections Suspected to be of Viral Origin",,"Completed","No Results Available","Respiratory Tract Infections|Fever","Drug: Acetylsalicylic acid (Aspirin, BAYE4465)|Drug: Paracetamol|Drug: Placebo","Area under the curve (AUC) of the orally measured change of body temparature from baseline over a period of 0 - 4 hours post dose.|Maximum temperature difference between baseline and the lowest measured temperature|Time to reach the maximum temperature difference|Intensity of Upper Respiratory Tract Infection symptoms|Safety - assessment of adverse events","Bayer","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","392","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11202","November 2003",,"April 2004","November 4, 2011",,"November 8, 2011","Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Kiev, Ukraine|Kiev, Ukraine|Lugansk, Ukraine",,"https://ClinicalTrials.gov/show/NCT01464944"
728,"NCT01460537","Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer",,"Completed","No Results Available","Neoplasms","Drug: Gemcitabine|Drug: BAY80-6946|Drug: Cisplatin|Drug: NaCl|Drug: BAY80-6964 fixed dose","Adverse event collection|Maximum tolerated dose, measured by adverse event profile|Maximum drug concentration in plasma (Cmax) of Copanlisib with gemcitabine or cisplatin plus gemcitabine|The time of the maximum concentration (Tmax) of Copanlisib with gemcitabine or cisplatin plus gemcitabine|Area under the curve (AUC) of Copanlisib with gemcitabine or cisplatin plus gemcitabine|Area under the concentration time curve (AUC (0-tn)) of Copanlisib with gemcitabine or cisplatin plus gemcitabine|Half life (t1/2) of Copanlisib with gemcitabine or cisplatin plus gemcitabine|Biomarker evaluation including analysis of pathway activation in tumor tissue and blood/plasma|Tumor Response as measured by RECIST 1.1 criteria","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","50","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12875","November 18, 2011","July 20, 2015","December 18, 2015","October 27, 2011",,"October 4, 2017","Tampa, Florida, United States|Rochester, Minnesota, United States|Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01460537"
729,"NCT01458041","Iloprost Therapy in Patients With Critical Limb Ischemia",,"Completed","No Results Available","Peripheral Arterial Disease","Drug: Iloprost (Ilomedin, BAYQ6256)","Change of limb pain at rest assessed by visual analogue scale|Incidence of ulcer healing|Collection of interventional / surgical procedures including 1) Rate of revascularization procedures; 2) Minor amputations; 3) Frequency and height of major amputations|Mortality and/or severe cardiovascular events (AMI, stroke)|Hemodynamic measurements: peripheral arterial blood flow and pressure on ankle / hallux level by Doppler scanner|Changes of transcutaneously measured tissue oxygen tension values","Bayer","All","18 Years and older   (Adult, Older Adult)",,"126","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","15439|VE1011HU","August 2011","May 2014","December 2014","October 24, 2011",,"March 2, 2015","Many locations, Hungary",,"https://ClinicalTrials.gov/show/NCT01458041"
730,"NCT01458028","Age and Gender Effects on the Pharmacokinetics of BAY85-3934",,"Completed","No Results Available","Anemia","Drug: BAY85-3934|Drug: Placebo","Area under the plasma concentration vs time curve from zero to infinity after single (first) dose of BAY85-3934|Maximum drug concentration in plasma after single dose administration of BAY85-3934|Safety and tolerability of BAY 85-3934 after single dose administration as determined by physical examination (changes from baseline)|Safety and tolerability of BAY 85-3934 after single dose administration as determined by adverse events monitoring (number of subjects with a specific event)|Safety and tolerability of BAY 85-3934 after single dose administration as determined by electrocardigram and and vital sign measurememnt (changes from baseline)|Safety and tolerability of BAY 85-3934 after single dose administration as determined by laboratory testing (changes from baseline)|Pharmacodynamic effects on erythropoietin as the change from baseline at 48 hours|Pharmacodynamic effects on reticulocytes as the change from baseline at 96 hours|Pharmacodynamic effects on hemoglobin as the change from baseline at 48 hours|Pharmacodynamic effects on hematocrit as the change from baseline at 96 hours|Pharmacodynamic effects on vascular endothelial growth factor (VEGF) as the change from baseline at 96 hours","Bayer","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","14631","September 2011","December 2011","December 2011","October 24, 2011",,"May 6, 2014","Fargo, North Dakota, United States",,"https://ClinicalTrials.gov/show/NCT01458028"
731,"NCT01453400","Evaluate the Time of Pain Relief of Fast Acting Aspirin Versus Acetaminophen in Subjects Diagnosed With Sore Throat Pain","Tarot","Completed","No Results Available","Pharyngitis","Drug: Acetylsalicylic Acid (Aspirin, BAY1019036) + placebo|Drug: Acetaminophen + placebo|Drug: Placebo","Time to meaningful pain relief from the Sore Throat Pain Intensity Scale (STPIS) 100 mm visual analog scale|Global assessment of the investigational product as a pain reliever by grading from 0 to 4 (from poor to excellent)|Time to first perceptible relief (defined as the time when the subject presses the first stopwatch)|Time weighted sum of pain intensity differences (PID) scores over first hour|Time weighted sum of pain intensity differences (PID) scores over 2 hours|Percentage difference from baseline Sore Throat Pain Intensity Scale (STPIS) to STPIS at time of meaningful relief","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","177","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","15772","September 27, 2011","April 5, 2012","April 6, 2012","October 17, 2011",,"December 7, 2018","Storrs, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT01453400"
732,"NCT01450592","Study To Assess the Dietary Carbohydrate Content of Indian Diabetic Population","STARCH","Completed","No Results Available","Metabolic Disease|Diabetes Mellitus","Other: No drug","Percentage of total energy intake as carbohydrate by Indian diabetic population|Percentage of complex carbohydrate intake from total carbohydrate by Indian diabetic population|Difference in the percentage of total energy intake as carbohydrate by diabetic versus non-diabetic population|Difference in the percentage of complex carbohydrate content of diabetic versus non-diabetic population|Difference in the percentage of total energy intake as proteins & fats by diabetics versus non-diabetic population|Percentage of diabetics population who follows diet plan|Percentage of diabetic population with glycaemic control","Bayer","All","18 Years and older   (Adult, Older Adult)",,"796","Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","15922|NN1120IN","May 2012","September 2012","September 2012","October 12, 2011",,"December 30, 2013","Many Locations, India",,"https://ClinicalTrials.gov/show/NCT01450592"
733,"NCT01448538","Non-Persistence/Non-Adherence (NP/NA) in Wet Age-related Macular Degeneration (wAMD) Patients in Germany",,"Completed","No Results Available","Wet Macular Degeneration","Drug: Anti-VEGF injections","Non-Persistence (NP) in the wAMD therapy in alternative study-specific definitions: (1) no eye exam for a period of at least 3 months OR (2) no 2 subsequent Anti-VEGF injections despite a clear medical need for injections|Extent of Non-Adherence (NA) in the Anti-VEGF-therapy in a study-specific definition: (1) no eye exam every 4th week OR (2) no Anti-VEGF injection despite a medical need for an injection|Identifying NA/NP causes (multivariate analysis based on patient interviews; main factors are sociodemographics and patient preferences)|Identifying NA/NP outcomes (assessed by visual acuity)|Identifying patients' preferences (based on patients' questionnaires) towards treatment and treatment schemes","Bayer","All","18 Years and older   (Adult, Older Adult)",,"480","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","15785|HE-WAMD-01","August 2011","December 2013","February 2014","October 7, 2011",,"September 14, 2015","Many Locations, Germany",,"https://ClinicalTrials.gov/show/NCT01448538"
734,"NCT01447043","Study to Assess the Effectiveness of Existing Anti vascUlar Endothelial Growth Factor (Anti VEGF) in Patients With Wet Age-related Macular Degeneration (wAMD) (AURA)","AURA","Completed","No Results Available","Ophthalmology, Macular Degeneration","Drug: Ranibizumab","Changes in visual acuity after start of Anti vascUlar endothelial growth factor (anti VEGF) therapy with ranibizumab, assessed by Early Treatment Diabetic Retinopathy (ETDRS) or Snellen chard|Demographic characteristics of patients included in the study (Age, Sex, Race)|Mean time from first clinical presentation to diagnosis|Mean time from diagnosis to treatment|Mean time from diagnosis to end of follow-up|Mean change of visual acuity, from diagnosis to end of follow-up, assessed by Early Treatment Diabetic Retinopathy (ETDRS) or SNELLEN|Mean change of retinal thickness from diagnosis to end of follow-up, assessed by Optical Coherence Tomography (OCT)|Mean change of lesion size from diagnosis to end of follow-up, assessed by Fluorescein Angiography (FA)|Average number of treatments given from diagnosis to end of follow-up|Vital Signs (blood pressure, heart rate, temperature) of patients included in the study|Medical and surgical history (diseases and surgeries) of patients included in the study","Bayer","All","18 Years and older   (Adult, Older Adult)",,"2609","Industry","Observational","Time Perspective: Retrospective","15913|NN1101","January 2009","August 2011","November 2012","October 5, 2011",,"January 27, 2014","Many Locations, Australia|Many Locations, Canada|Many Locations, France|Many Locations, Germany|Many Locations, Ireland|Many Locations, Italy|Many Locations, Japan|Many Locations, Netherlands|Many Locations, United Kingdom|Many Locations, Venezuela",,"https://ClinicalTrials.gov/show/NCT01447043"
735,"NCT01444586","Russian Non-Interventional Study on Compliance of Venous Thromboembolism (VTE)","SOPRANO","Completed","No Results Available","Arthroplasty, Replacement, Hip|Arthroplasty, Replacement, Knee","Drug: Rivaroxaban (Xarelto, BAY59-7939)","Real life out-patient thromboprophylaxis after arthroplasty: Share of patients who follow physician's prescriptions; true duration of out-patient thromboprophylaxis; duration of treatment interruptions; in case of switching - reasons, drug regimen.|Descriptive characteristics of prescription behaviour of orthopedists (VTE prevention recommended at discharge): continuation of rivaroxaban, switching to other products (name, dose, duration, efficacy control), mechanical prophylaxis, etc.|Adverse event characteristics (frequency, severity, relation to VTE prevention treatment, AE treatment, AE outcome)","Bayer|Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)",,"2293","Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","16002|XA2011-01RU","October 2011","August 2013","July 2014","October 3, 2011",,"January 23, 2017","Many locations, Russian Federation",,"https://ClinicalTrials.gov/show/NCT01444586"
736,"NCT01442792","Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary Intervention","X-PLORER","Completed","No Results Available","Cardiovascular Disease, Coronary Artery Disease","Drug: UFH|Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Rivaroxaban (Xarelto, BAY59-7939) and UFH","The percentage of subjects who require bail-out anticoagulant therapy in the context of an ischemic coronary event|The percentage of subjects who experience an angiographic flow limiting thrombotic event|The percentage of subjects who experience thrombus formation on the Percutaneous Coronary Intervention equipment|The percentage of subjects who experience an Myocardial Infarction due to the Percutaneous Coronary Intervention equipment procedure|Bleeding (Thrombolysis in Myocardial Infarction major, minor and Bleeding academic research consortium type 2, 3 and 5)|Composite of clinical ischemic events (all death, non-fatal Myocardial Infarction, non-fatal stroke and target lesion revascularization|Coagulation profile of Rivaroxaban (Activated Partial Thromboplastin Time)|Coagulation profile of Rivaroxaban (Prothrombin time)|Coagulation profile of Rivaroxaban (Thrombin Time)|Coagulation profile of Rivaroxaban (Prothrombin Fragment 1+2)|Coagulation profile of Rivaroxaban (Thrombin Anti-thrombin III Complexes)|Coagulation profile of Rivaroxaban (Anti-Xa Activity)|Coagulation profile of Rivaroxaban (endogenous thrombin potential)|Plasma concentration of Rivaroxaban","Bayer|Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 2","108","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","15572|2011-001094-58","October 2011","January 2013","March 2013","September 29, 2011",,"March 11, 2019","Hasselt, Belgium|Liege, Belgium|Roeselare, Belgium|Amsterdam, Netherlands|Amsterdam, Netherlands|Eindhoven, Netherlands|Zwolle, Netherlands",,"https://ClinicalTrials.gov/show/NCT01442792"
737,"NCT01439152","Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.",,"Completed","No Results Available","Oncology","Drug: BAY94-9343|Drug: BAY94-9343 (Expansion)|Drug: BAY94-9343 (1.8 mg/kg)|Drug: BAY94-9343 (2.2 mg/kg)","Incidence of DLT (dose limiting toxicity) of BAY 94-9343|Determination of the Pharmacokinetic profile of BAY94-9343 and its metabolites (ADC, Total Antibody, DM4 and DM4-Me)|Biomarker evaluation: mesothelin plasma and Cytokeratin 18 (CK18) levels|Tumor response: assessment of best response, TTP (time to progression), and PFS (progression free survival) according to RECIST (Response Evaluation Criteria in Solid Tumours) 1.1|Immunogenicity assessment: assessment of anti BAY 94-9343 antibodies|Biomarker evaluation - Levels of mesothelin expression in tumor tissue","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","147","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15051","September 7, 2011","December 31, 2016","July 30, 2019","September 23, 2011",,"August 16, 2019","New Haven, Connecticut, United States|Chicago, Illinois, United States|Bethesda, Maryland, United States|Detroit, Michigan, United States|Oklahoma City, Oklahoma, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01439152"
738,"NCT01436838","China Betaferon Adherence, Coping and Nurse Support Study",,"Completed","No Results Available","Multiple Sclerosis, Chronic Progressive","Drug: Interferon beta-1b (Betaseron, BAY86-5046)","Adherence to Betaferon treatment: proportion of patients adhering to Betaferon treatment|Ways of Coping Questionnaire (WCQ)|Hospital Anxiety and Depression Scale (HAD)","Bayer","All","18 Years to 75 Years   (Adult, Older Adult)",,"110","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","15916|BF1110CN","March 2012","September 2015","December 2015","September 20, 2011",,"September 5, 2016","Many locations, China",,"https://ClinicalTrials.gov/show/NCT01436838"
739,"NCT01436825","Validation Study of a cOmputer Pharmacokinetic Tool to assIst in the Follow up Care of haeMophilia A Patients","OPTIMS","Completed","No Results Available","Haemophilia A","Drug: Recombinant Factor VIII (Kogenate FS, BAY14-2222)","The difference of the recovery rate calculated by the physician and the recovery rate calculated by an independent calculator With OPTIMS Tool|The difference of the elimination half-life calculated by the physician and the ones calculated by an independent calculator With OPTIMS Tool|The difference of the clearance calculated by the physician and the ones calculated by an independent calculator With OPTIMS Tool|The dosage of factor VIII calculated by OPTIMS calculator|The practicality of the OPTIMS calculator by a physician's satisfaction questionnaire","Bayer","All","Child, Adult, Older Adult",,"69","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","15453|KG110FR","October 2011","June 2014","July 2015","September 20, 2011",,"August 10, 2015","Many Locations, France|Many Locations, Italy",,"https://ClinicalTrials.gov/show/NCT01436825"
740,"NCT01436526","Bioequivalence Study in Healthy Subjects, 2*5 mg Tablets Rivaroxaban Versus 1*10 mg Tablet Rivaroxaban",,"Completed","Has Results","Therapeutic Equivalency","Drug: Rivaroxaban (Xarelto, BAY59-7939)","Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity After Single Dose (AUC) Incl. Bioequivalence (BE) Evaluation|Area Under the Plasma Concentration Versus Time Curve From Time Zero to Last Quantifiable Concentration [AUC (0-tn)] Incl. Bioequivalence (BE) Evaluation|Maximum Observed Drug Concentration in Plasma After Single Dose Administration (Cmax) Incl. Bioequivalence (BE) Evaluation|Area Under the Plasma Concentration Versus Time Curve Divided by Dose Per kg Body Weight (AUCnorm)|Maximum Observed Drug Concentration in Plasma After Single Dose Administration Divided by Dose Per kg Body Weight (Cmax, Norm)|Mean Residence Time (MRT)|Time to Reach Maximum Drug Concentration in Plasma After Single Dose (Tmax)|Half-life Associated With the Terminal Slope (t½)","Bayer|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Male","18 Years to 45 Years   (Adult)","Phase 1","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","14588|2009-013032-20","August 2009","September 2009","September 2009","September 19, 2011","December 22, 2011","April 22, 2015","Mönchengladbach, Nordrhein-Westfalen, Germany",,"https://ClinicalTrials.gov/show/NCT01436526"
741,"NCT01434173","Risk of Acute Liver Injury in Users of Antimicrobials",,"Completed","No Results Available","Drug-Induced Liver Injury","Drug: Moxifloxacin (Avelox, BAY12-8039)|Drug: Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin","Incidence ratio of noninfectious acute liver injury fulfilling the International Consensus Meeting criteria for drug-induced liver disorders in the study population during periods of treatment with each of the study antimicrobials and nonuse|Incidence rate ratio of noninfectious acute liver injury fulfilling the International Consensus Meeting criteria for drug-induced liver disorders during treatment with each of the study antimicrobials compared to that during of nonuse|Incidence rate and incidence rate ratio of noninfectious severe hepatocellular injury as defined by the Hy's Law criteria modified by the FDA Working Group (FDA Working group, 2000; Temple, 2006; Navarro and Senior, 2006)|Incidence rate and incidence rate ratio of noninfectious acute liver failure, defined as acute liver injury with evidence of coagulation abnormality and any degree of mental alteration (encephalopathy) (Polson and Lee, 2005)|Cumulative incidence of noninfections acute liver injury, noninfectious severe hepatocellular injury, and noninfectious acute liver failure at weekly intervals after the start of first episode of treatment with each of the study antimicrobials","Bayer|RTI Health Solutions","All","18 Years and older   (Adult, Older Adult)",,"1299056","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","14705","July 2001","March 2009","March 2009","September 14, 2011",,"July 8, 2014","Many Locations, Delaware, United States",,"https://ClinicalTrials.gov/show/NCT01434173"
742,"NCT01434160","LCS12 Adolescent Study",,"Completed","No Results Available","Contraception","Drug: Skyla (Levonorgestrel, BAY86-5028)","Number of adverse events reported by study subjects|Portion of subjects reporting adverse events|Overall satisfaction rating from 1 to 5 (from very satisfied to very dissatisfied)|Pearl index|Bleeding patterns collected from patients' diary|Concentration of Levonorgestrel in serum|Concentration of sex hormone binding globulin in serum|Discontinuation rate","Bayer","Female","12 Years to 17 Years   (Child)","Phase 3","304","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","14371|2011-002065-37","September 2011","June 2013","May 2015","September 14, 2011",,"July 27, 2015","St. Pölten, Niederösterreich, Austria|Bregenz, Austria|Voitsberg, Austria|Wien, Austria|Zeltweg, Austria|Antwerpen, Belgium|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Charleroi, Belgium|Leuven, Belgium|København NV, Denmark|København S, Denmark|Århus C, Denmark|Helsinki, Finland|Helsinki, Finland|Kuopio, Finland|Oulu, Finland|Oulu, Finland|Erlangen, Bayern, Germany|Geseke, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Blankenburg, Sachsen-Anhalt, Germany|Dippoldiswalde, Sachsen, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Leipzig, Sachsen, Germany|Hamburg, Germany|Hamburg, Germany|Alkmaar, Netherlands|Almere, Netherlands|Den Helder, Netherlands|Enschede, Netherlands|Heerlen, Netherlands|Nieuwegein, Netherlands|Tilburg, Netherlands|Fornebu, Norway|Sellebakk, Norway|Göteborg, Sweden|Stockholm, Sweden|Stockholm, Sweden|Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT01434160"
743,"NCT01430533","Human Repeated Insult Patch Test (HRIPT) of Azelaic Acid Pre Foam Formulation",,"Completed","No Results Available","Healthy","Drug: azelaic acid pre foam formulation|Drug: Vehicle pre foam formulation|Drug: Water","skin sensitization reaction","Bayer","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","240","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","15854|1401842","September 2011","December 2011","December 2011","September 8, 2011",,"February 28, 2014","Robert I. Cooper, MD, Fargo, North Dakota, United States",,"https://ClinicalTrials.gov/show/NCT01430533"
744,"NCT01430312","21 Day Irritancy Test of Azelaic Acid Pre-foam Formulation",,"Completed","No Results Available","Healthy","Drug: azelaic acid pre-foam formulation|Drug: Vehicle pre-foam formulation|Drug: Water|Drug: Sodium lauryl sulfate","irritancy rating scale","Bayer","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","15853|1401841","September 2011","December 2011","December 2011","September 8, 2011",,"February 28, 2014","Robert I. Cooper, MD, Fargo, North Dakota, United States",,"https://ClinicalTrials.gov/show/NCT01430312"
745,"NCT01427803","Actual Use Trial of Naproxen Sodium","Kiefer AUT","Completed","Has Results","Pain","Drug: Naproxen Sodium ER (BAYH6689)","Estimated Percentage of Misuse for Non-Therapeutic Reasons|Non-therapeutic Reasons for Misuse|Estimated Percentage of Misuse for Non-Therapeutic Reasons Using the First 10-Day Treatment Course|Percentage of Participants Took >/= 2 Tablets/Use Day in Any 10 Use Days|Percentage of Participants Who Took Product With Mean Daily Use >/= 2 Tablets /Use Day|Percentage of Participants With at Least One Dosing Occasion Where More Than One Tablet Was Taken|Percentage of Dosing Occasions Where More Than One Tablet Was Taken|Percentage of Participants Where a Dose Was Taken Less Than 22 Hours After the Most Recent Previous Dose|Percentage of Dosing Occasions Where a Dose Was Taken Less Than 22 Hours After the Most Recent Previous Dose","Bayer","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","778","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15647","September 2011","December 2011","December 2011","September 2, 2011","May 20, 2013","October 15, 2015","Hoover, Alabama, United States|McCalla, Alabama, United States|Pinson, Alabama, United States|Mesa, Arizona, United States|Anaheim, California, United States|Oceanside, California, United States|Yorba Linda, California, United States|Overland Park, Kansas, United States|Baltimore, Maryland, United States|Andover, Minnesota, United States|Elk River, Minnesota, United States|Fridley, Minnesota, United States|Northfield, Minnesota, United States|Rosemount, Minnesota, United States|Roseville, Minnesota, United States|Kansas City, Missouri, United States|Savannah, Missouri, United States|St. Joseph, Missouri, United States|Albuquerque, New Mexico, United States|Albuquerque, New Mexico, United States|Taos, New Mexico, United States|Bountiful, Utah, United States|Hurricane, Utah, United States|Layton, Utah, United States|Ogden, Utah, United States|Salt Lake City, Utah, United States|Salt Lake City, Utah, United States|Syracuse, Utah, United States|West Jordan, Utah, United States|Montpelier, Virginia, United States|Richmond, Virginia, United States|Bellevue, Washington, United States|Kenmore, Washington, United States|Snohomish, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01427803"
746,"NCT01420094","Evaluate Onset of Action of a Fast Release Aspirin","TAROT compare","Completed","No Results Available","Healthy Subjects","Drug: Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)|Drug: Acetaminophen (Tylenol extra strength)|Drug: Placebo","Time to Meaningful Pain Relief (PR)|Time to First Perceptible Pain Relief|Time to First Perceptible Pain Relief Confirmed|Pain Intensity at 5, 10, 15, 20, 25, 30, 35, 40, 50, and 60 minutes and at 1.5, 2, 3, 4, 5, and 6 hours After Dosing|Pain Relief at 5, 10, 15, 20, 25, 30, 35, 40, 50, and 60 minutes and at 1.5, 2, 3, 4, 5, and 6 hours After Dosing|Pain Intensity Difference (PID) at 5, 10, 15, 20, 25, 30, 35, 40, 50, and 60 minutes and at 1.5, 2, 3, 4, 5, and 6 hours After Dosing|Summed Pain Intensity Differences (SPID) from Hour 0 through Hour 2, Hour 4 and Hour 6|Summed Total Pain Relief (TOTPAR) from Hour 0 through Hour 2, Hour 4 and Hour 6|Time to First use of Rescue Medication|Cumulative Percentage of Subjects Taking Rescue Medication|Global Assessment of the Investigational Product as a Pain Reliever at 6 hours After Dosing or Immediately Before the First Intake of Rescue Medication","Bayer","All","16 Years to 45 Years   (Child, Adult)","Phase 3","510","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","15529|2014-005270-11","June 16, 2011","September 8, 2011","September 8, 2011","August 19, 2011",,"December 19, 2018","Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01420094"
747,"NCT01419327","Fosrenol Post-marketing Surveillance for Hemodialysis in Japan","FOSRENOL-HD","Completed","No Results Available","Hyperphosphatemia","Drug: Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet","Incidence of adverse drug reactions in subjects who received Fosrenol|Incidence of serious adverse events in subjects who received Fosrenol|Incidence of adverse drug reactions in subpopulation with baseline data [such as demographic data, concomitant disease, duration of treatment, maximum daily dose] and dose of Fosrenol|Effectiveness evaluation assessment [achievement rate of a goal phosphate level; 3.5-6 mg/dL]|Effectiveness evaluation assessment [achievement rate of a goal calcium level; 8.4-10.0 mg/dL]|Clinical test value collection: calciotropic hormones|Clinical test value collection: bone turnover markers","Bayer","All","Child, Adult, Older Adult",,"3267","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","15077","March 23, 2009","January 30, 2019","May 28, 2019","August 18, 2011",,"August 14, 2019","Multiple Locations, Japan",,"https://ClinicalTrials.gov/show/NCT01419327"
748,"NCT01416506","Community-Acquired Pneumonia (CAP) Surveillance",,"Completed","No Results Available","Pneumonia","Other: No Drug","In vitro Minimal Inhibitory Concentration Detection|In vitro Gene Mutation Detection","Bayer","All","18 Years and older   (Adult, Older Adult)",,"560","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","15465|NN1010CN","September 2010","August 2012","January 2013","August 15, 2011",,"November 5, 2013","Many Locations, China",,"https://ClinicalTrials.gov/show/NCT01416506"
749,"NCT01415414","Observational Study of Ultravist in Patients Requiring CECT","INDEX","Completed","No Results Available","Diagnostic Imaging","Drug: Iopromide (Ultravist, BAY86-4877)","Image quality evaluated by calculated CNR (Contrast to Noise Ratio)|Image quality evaluated by calculated SNR (Signal Noise Ratio)|Descriptive analysis of contrast medial injection protocol|Radiation dose (CTDIvol)","Bayer","All","Child, Adult, Older Adult",,"11660","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","15515|UV1011CN","September 2011","July 2012","November 2013","August 12, 2011",,"January 21, 2015","Many locations, China",,"https://ClinicalTrials.gov/show/NCT01415414"
750,"NCT01414816","Betaferon® Regulatory Post-Marketing Surveillance",,"Completed","No Results Available","Multiple Sclerosis|Clinically Isolated System","Drug: Interferon beta-1b (Betaseron, BAY86-5046)","Safety variables will be summarized using descriptive statistics based on adverse events.|The efficacy data regarding prevention of relapse due to MS will be estimated based on the number of relapse.|Progression or aggravation to Multiple sclerosis (MS) will be identified based on the change of Expanded Disability Status Scale (EDSS) and the Magnetic Resonance Imaging (MRI) outcome.","Bayer","All","12 Years and older   (Child, Adult, Older Adult)",,"355","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14839|BF0814KR","April 2008","July 2012","July 2012","August 11, 2011",,"August 21, 2014","Many Locations, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01414816"
751,"NCT01414140","Mirena Post-marketing Surveillance in Japan",,"Completed","No Results Available","Contraception","Drug: Levonorgestrel IUS (Mirena, BAY86-5028)","Incidence of adverse drug reactions and serious adverse events in women who are inserted Mirena|Incidence of adverse drug reactions, especially Pelvic inflammatory disease in women who are inserted Mirena|Incidence of adverse drug reactions in subpopulation in a variety of baseline data (such as demographic data, concomitant disease) and duration of Mirena|Pregnancy rate|Released amount of Levonorgestrel [estimated from removed Mirena]","Bayer","Female","Child, Adult, Older Adult",,"567","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","15036|MIRENA","May 2007","October 2012","October 2012","August 11, 2011",,"January 9, 2014","Many locations, Japan",,"https://ClinicalTrials.gov/show/NCT01414140"
752,"NCT01413958","Effects of Phenylephrine Extended-Release Tablets on Allergy-Related Nasal Congestion (P08498 AM1)",,"Completed","Has Results","Seasonal Allergic Rhinitis","Drug: Phenylephrine|Drug: Placebo|Drug: Loratadine","Mean Change From Baseline in Daily Reflective Nasal Congestion Score|Mean Change From Baseline in the Morning Reflective Symptom Assessment Score|Mean Change From Baseline in the Evening Reflective Symptom Assessment Score|Mean Change From Baseline in Daily Instantaneous Symptom Assessment Score|Mean Change From Baseline in Daily Reflective Nasal Congestion Score Per Day|Mean Change From Baseline in Daily Instantaneous Symptom Assessment Score Per Day|Time to Maximal Phenylephrine Effect|Day 7 Mean Change From Baseline in Daily Instantaneous Symptom Assessment Score|Mean Change From Baseline in Morning Predose Instantaneous Nasal Congestion Symptom Score|Mean Change From Baseline for the Morning Reflective Symptom Assessment Scores for Each Day During the Treatment Period.|Mean Change From Baseline for the Evening Reflective Symptom Assessment Scores for Each Day During the Treatment Period|Mean Change From Baseline for the Morning Instantaneous Symptom Assessment Scores for Each Day During the Treatment Period|Mean Change From Baseline for the Evening Instantaneous Symptom Assessment Scores for Each Day During the Treatment Period.|Rhinoconjunctivitis Quality of Life Questionnaire With Standardized Activities (RQLQ)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","575","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","18125|CL2011-06|P08498","August 2011","October 2011","October 2011","August 10, 2011","January 29, 2013","March 11, 2015",,,"https://ClinicalTrials.gov/show/NCT01413958"
753,"NCT01412671","Nexavar Post-marketing Surveillance for RCC in Japan: Early Access Program",,"Completed","No Results Available","Carcinoma, Renal Cell","Drug: Sorafenib (Nexavar, BAY43-9006)","Incidence of adverse drug reactions and serious adverse events in subjects who received Nexavar|Incidence of adverse drug reactions in subpopulation in a variety of baseline data [such as demographic data, concomitant disease, clinical staging of RCC, Eastern Cooperative Oncology Group-Performance Status (ECOG-PS)]|Effectiveness evaluation assessment [overall survival, response rate, stable disease rate, progression disease rate] by investigator-determined overall best response [according to the General rule for clinical and pathological studies on RCC]|The status of therapy with Nexavar [duration of treatment, daily dose]","Bayer","All","Child, Adult, Older Adult",,"117","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","15037|NEXAVAR-RCC-01","February 27, 2008","September 21, 2011","February 28, 2016","August 9, 2011",,"June 6, 2018","Multiple Locations, Japan",,"https://ClinicalTrials.gov/show/NCT01412671"
754,"NCT01412398","Fosrenol Post-marketing Surveillance for Continuous Cyclic Peritoneal Dialysis in Japan","FOSRENOL-CAPD","Completed","No Results Available","Hyperphosphatemia","Drug: Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet","Incidence of adverse drug reactions in subjects who received Fosrenol|Incidence of serious adverse events in subjects who received Fosrenol|Incidence of adverse drug reactions in subpopulation with baseline data [such as demographic data, concomitant disease, duration of treatment, maximum daily dose] and dose of Fosrenol|Effectiveness evaluation assessment [achievement rate of a goal phosphate level; 3.5-6 mg/dL]|Effectiveness evaluation assessment [achievement rate of a goal calcium level; 8.4-10.0 mg/dL]|Clinical test value collections [calciotropic hormones, bone turnover markers]","Bayer","All","13 Years and older   (Child, Adult, Older Adult)",,"446","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","15076","April 7, 2009","April 8, 2014","September 1, 2016","August 9, 2011",,"January 19, 2018","Multiple Locations, Japan",,"https://ClinicalTrials.gov/show/NCT01412398"
755,"NCT01411449","Primovist Post-marketing Surveillance in Japan","PRIMOVIST","Completed","No Results Available","Diagnostic Imaging","Drug: Gadoxetic Acid Disodium (Primovist, BAY86-4873)","Incidence of adverse drug reactions and serious adverse events in subjects who received Primovist|Incidence of adverse drug reactions in patients with renal impairment|Incidence of adverse drug reactions in subpopulation in a variety of baseline data [such as demographic data, concomitant disease and dose of Primovist]|MRI image evaluation assessment by the five rank scales of 1 to 5: 1) much improved; 2) improved; 3) slightly improved; 4) not improved; and 5) impaired","Bayer","All","Child, Adult, Older Adult",,"2030","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","15040","March 11, 2008","December 14, 2010","February 18, 2015","August 8, 2011",,"March 17, 2017","Many Locations, Japan",,"https://ClinicalTrials.gov/show/NCT01411449"
756,"NCT01411436","Nexavar Post-marketing Surveillance for Hepatocellular Carcinoma in Japan",,"Completed","No Results Available","Carcinoma, Hepatocellular","Drug: Sorafenib (Nexavar, BAY43-9006)","Incidence of adverse drug reactions and serious adverse events in subjects who received Nexavar|Demography|Effectiveness evaluation assessment [overall survival, complete response rate, partial response rate, stable disease rate] by the Response Evaluation Criteria in Solid Tumor (RECIST)|Effectiveness evaluation assessment [time to progression, response rate, stable disease rate, progression rate] by investigator-determined overall best response|The status of therapy with Nexavar [duration of treatment, daily dose] in a various settings according to baseline data [such as demographic data, Child-Pugh status, ECOG-PS]","Bayer","All","Child, Adult, Older Adult",,"1637","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","15039|NEXAVAR-HCC-01","May 2009","March 2014","February 2015","August 8, 2011",,"March 4, 2015","Many locations, Japan",,"https://ClinicalTrials.gov/show/NCT01411436"
757,"NCT01411423","Nexavar Post-marketing Surveillance for Renal Cell Carcinoma in Japan",,"Completed","No Results Available","Carcinoma, Renal Cell","Drug: Sorafenib (Nexavar, BAY43-9006)","Incidence of adverse drug reactions and serious adverse events in subjects who received Nexavar|Incidence of adverse drug reactions in subpopulation in a variety of baseline data [such as demographic data, concomitant disease, medical history data, clinical staging, etiology of HCC, Eastern Cooperative Oncology Group-Performance Status (ECOG-PS)]|Effectiveness evaluation assessment [overall survival, response rate, stable disease rate, progression disease rate] by investigator-determined overall best response [according to the General rule for clinical and pathological studies on RCC]|The status of therapy with Nexavar [duration of treatment, daily dose]","Bayer","All","Child, Adult, Older Adult",,"3305","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","15038|NEXAVAR-RCC-02","April 18, 2008","March 16, 2012","February 28, 2016","August 8, 2011",,"June 6, 2018","Multiple Locations, Japan",,"https://ClinicalTrials.gov/show/NCT01411423"
758,"NCT01411410","Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer",,"Completed","No Results Available","Neoplasms","Drug: Paclitaxel|Drug: Copanlisib (BAY80-6946)","Adverse event collection|Maximum tolerated dose, measured by adverse event profile|Pharmacokinetics characterized by Cmax of BAY80-6946 (and its metabolite(s), if needed)|Pharmacokinetics characterized by Cmax/D of BAY80-6946 (and its metabolite(s), if needed)|Pharmacokinetics characterized by tmax of BAY80-6946 (and its metabolite(s), if needed)|Pharmacokinetics characterized by AUC(0-tlast) of BAY80-6946 (and its metabolite(s), if needed)|Pharmacokinetics characterized by AUC (if possible) of BAY80-6946 (and its metabolite(s), if needed)|Pharmacokinetics characterized by AUC/D of BAY80-6946 (and its metabolite(s), if needed)|Pharmacokinetics characterized by half-life of BAY80-6946 (and its metabolite(s), if needed)|Pharmacokinetics characterized by partial AUC values [eg, AUC(0-25)] of BAY80-6946 (and its metabolite(s), if needed)|Pharmacokinetics characterized by clearance of BAY80-6946 (and its metabolite(s), if needed)|Pharmacokinetics characterized by volume of distribution of BAY80-6946 (and its metabolite(s), if needed)|Estimation of percent of dose excreted [unchanged or as metabolites, if relevant) renally during 0 - 25 h after start of BAY80-6946 infusion (AE,ur(0-25)] (for Cohort 4 only)|Pharmacokinetics characterized by Cmax of Paclitaxel and 6-OH paclitaxel|Pharmacokinetics characterized by tmax of Paclitaxel and 6-OH paclitaxel|Pharmacokinetics characterized by AUC(0-t) of Paclitaxel and 6-OH paclitaxel|Pharmacokinetics characterized by AUC of Paclitaxel and 6-OH paclitaxel|Pharmacokinetics characterized by half-life of Paclitaxel and 6-OH paclitaxel|Pharmacokinetics characterized by clearance of Paclitaxel and 6-OH paclitaxel|Pharmacokinetics characterized by volume of distribution (If possible and needed) of Paclitaxel and 6-OH paclitaxel|Effect of BAY80-6946 on paclitaxel PK will be assessed by comparing Cmax of Cycle 1 Day 1 and Cycle 1 Day 15|Effect of BAY80-6946 on paclitaxel PK will be assessed by comparing AUC(0-tlast) of Cycle 1 Day 1 and Cycle 1 Day 15|Number of patients with mutational status|Tumor Response as measured by RECIST 1.1 criteria","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","55","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12874","August 24, 2011","October 22, 2014","June 29, 2015","August 8, 2011",,"October 11, 2017","Saint Louis, Missouri, United States|New York, New York, United States|Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01411410"
759,"NCT01408511","HPA Axis Study in Adults",,"Completed","No Results Available","Atopic Dermatitis|Eczema","Drug: Mapracorat","HPA axis response to Cosyntropin: Number of subjects with adrenal suppression","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","23","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15446|1403161","July 2011","December 2011","December 2011","August 3, 2011",,"March 20, 2015","Bloemfontein, South Africa|George, South Africa|Port Elizabeth, South Africa",,"https://ClinicalTrials.gov/show/NCT01408511"
760,"NCT01407510","HPA Axis Study in Japanese Adults",,"Completed","No Results Available","Atopic Dermatitis|Eczema","Drug: Mapracorat","number of subjects with adrenal suppression","Bayer","All","20 Years and older   (Adult, Older Adult)","Phase 2","12","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15519|1403460","May 2011","September 2011","April 2012","August 2, 2011",,"February 18, 2015","Saitama, Japan|Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT01407510"
761,"NCT01404390","Japanese BAY80-6946 Monotherapy Phase I Study",,"Completed","No Results Available","Neoplasms","Drug: BAY80-6946","Number of subjects with adverse events|Maximum drug concentration in plasma after single dose administration (Cmax)|Cmax divided by dose (mg) per kg body weight (Cmax,norm)|Cmax divided by dose (mg) (Cmax/D)|Area under the concentration-time curve time 0 to 8 hours (AUC(0-8))|Area under the concentration-time curve from time 0 to 25 hours (AUC(0-25))|AUC(0-25) divided by dose (mg) per kg body weight (AUC(0-25)norm)|AUC(0-25) divided by dose (mg) (AUC(0-25)/D)|AUC from time 0 to last data point (AUC(0-tlast))|Time to maximum drug concentration in plasma (tmax)|Area under the plasma concentration-time curve of (AUC) of BAY80-6946|Half-life associated with terminal slope of drug in plasma (t1/2)|Mean residence time of drug in plasma (MRT)|Total body clearance of drug from plasma (CL)|Volume of drug distribution during terminal phase after single dose administration (Vz)|Volume of drug distribution during steady state after single dose administration (Vss)|Accumulation ratio calculated from AUC(0-8) after multiple dosing and AUC(0-8) after single dosing (RAAUC(0-8))|Accumulation ratio calculated from AUC(0-25) after multiple dosing and AUC(0-25) after single dosing (RAAUC(0-25))|Accumulation ration calculated from Cmax after multiple dosing and Cmax after single dosing (RACmax)|Overall tumor response rate|Overall disease control rate|Time to progression of cancer growth|Progression-free survival time","Bayer","All","20 Years to 80 Years   (Adult, Older Adult)","Phase 1","10","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15205","August 18, 2011","March 22, 2012","July 12, 2012","July 28, 2011",,"December 14, 2017","Kashiwa, Chiba, Japan",,"https://ClinicalTrials.gov/show/NCT01404390"
762,"NCT01401114","Wellnara Post-marketing Surveillance in Japan","WELLNARA","Completed","No Results Available","Osteoporosis, Postmenopausal","Drug: E2/LNG oral (Wellnara, BAY86-5029)","Incidence of adverse drug reactions and serious adverse events in subject who received Wellnara|Incidence of adverse drug reactions in subpopulation with baseline data (such as demographic data, concomitant disease) and dose of Wellnara|Effectiveness evaluation assessment by the three rank scales: improvement, not changed, and worse","Bayer","Female","Child, Adult, Older Adult",,"411","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","15041","March 2009","August 2014","September 2014","July 25, 2011",,"September 28, 2015","Many Locations, Japan",,"https://ClinicalTrials.gov/show/NCT01401114"
763,"NCT01397955","Julina Post-marketing Surveillance for Postmenopausal Osteoporosis in Japan",,"Completed","No Results Available","Osteoporosis, Postmenopausal","Drug: E2 transdermal (Julina, BAY86-5435)","Incidence of adverse drug reactions and serious adverse events in subject who received Julina|Incidence of adverse drug reactions in subpopulation with baseline data (such as demographic data, concomitant disease, hysterectomy) and dose of Julina|Effectiveness evaluation assessment by the three rank scales: improvement, not changed, and worse","Bayer","Female","Child, Adult, Older Adult",,"148","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","15075","January 2009","January 2014","April 2014","July 20, 2011",,"April 17, 2015","Many Locations, Japan",,"https://ClinicalTrials.gov/show/NCT01397955"
764,"NCT01397097","LCS12 vs. ENG Subdermal Implant (Nexplanon) Discontinuation Rate Study",,"Completed","No Results Available","Contraception","Drug: LNG-IUS (BAY 86-5028)|Drug: 68 mg etonorgestrel implant for subdermal use (Nexplanon)","Discontinuation rate by treatment group|Discontinuation rates by treatment group|Overall satisfaction rating and questionnaires on User satisfaction and bleeding and Contraceptive tolerability|Pregnancy rate, as determined by Pearl index","Bayer","Female","18 Years to 35 Years   (Adult)","Phase 3","766","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","13363|2010-023911-32","September 2011","June 2013","April 2015","July 19, 2011",,"July 25, 2016","Ashfield, New South Wales, Australia|Sydney, New South Wales, Australia|North Adelaide, South Australia, Australia|Parkville, Victoria, Australia|Nedlands, Western Australia, Australia|Espoo, Finland|Helsinki, Finland|Helsinki, Finland|Helsinki, Finland|Kuopio, Finland|Tampereen yliopisto, Finland|Tampere, Finland|Turku, Finland|Turku, Finland|Biarritz, France|Bordeaux, France|Marseille, France|Quetigny, France|Reims, France|Schiltigheim, France|Seclin, France|Strasbourg, France|Elverum, Norway|Haugesund, Norway|Ski, Norway|Straume, Norway|Trondheim, Norway|Göteborg, Sweden|Göteborg, Sweden|Linköping, Sweden|Luleå, Sweden|Malmö, Sweden|Malmö, Sweden|Stockholm, Sweden|Stockholm, Sweden|Uppsala, Sweden|Örebro, Sweden|Cambridge, Cambridgeshire, United Kingdom|Sheffield, South Yorkshire, United Kingdom|Leeds, West Yorkshire, United Kingdom|Liverpool, United Kingdom|London, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01397097"
765,"NCT01392534","Effects of Telmisartan/Hydrochlorothiazide Treatment in Hypertensive Patients Under Real-life Setting","POTASSIUM","Completed","No Results Available","Primary Hypertension","Drug: Telmisartan/hydrochlorothiazide (Pritor Plus, BAY98-7103)","Change in systolic (SBP) and diastolic (DBP) blood pressure between first and final visit|Change in plasma potassium between initial and final visit|Change in fasting plasma glucose between initial and final visit|Change in glycated haemoglobin A1C between initial and final visit|Change in plasma high density lipoprotein between initial and (continued)|Change in plasma low density lipoprotein between initial and final visit|Change in plasma cholesterol between initial and final visit|Change in plasma triglycerides between initial and final visit|Adverse events collection","Bayer","All","18 Years and older   (Adult, Older Adult)",,"1586","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","15297|KL1010PL","July 2010","December 2010","December 2010","July 12, 2011",,"July 4, 2012","Many Locations, Poland",,"https://ClinicalTrials.gov/show/NCT01392534"
766,"NCT01392521","Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY86-9766) in Patients With Advanced Cancer",,"Completed","No Results Available","Neoplasms","Drug: Copanlisib + Refametinib (BAY86-9766)","Maximum Tolerated Dose|Comparison of the Copanlisib AUC when given alone with the AUC when given with Refametinib (BAY86-9766)|Comparison of the Refametinib (BAY86-9766) AUC when given alone with the AUC when given with Copanlisib|Tumor Response as measured by RECIST 1.1 criteria|Biomarker evaluation including analysis of pathway activation in blood and plasma|Tumor Response as measured by FDG-PET at MTD and expansion cohort(s)|Pharmacodynamic biomarker evaluation analysis using paired tumor biopsies","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","64","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12876|2010-024082-45","July 2011","February 2014","April 2014","July 12, 2011",,"April 17, 2015","Scottsdale, Arizona, United States|Las Vegas, Nevada, United States|Greenville, South Carolina, United States|Houston, Texas, United States|Tyler, Texas, United States|Vancouver, Washington, United States|Freiburg, Baden-Württemberg, Germany|Rotterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT01392521"
767,"NCT01389284","Evaluate Efficacy and Safety of Extended Release (ER) Naproxen Sodium","VERNE","Completed","Has Results","Pain, Postoperative","Drug: Naproxen Sodium ER (BAYH6689)|Drug: Naproxen Sodium IR (Aleve, BAYH6689)|Drug: Naproxen Sodium ER Placebo|Drug: Naproxen Sodium IR Placebo","Summed, Time-weighted Pain Intensity Difference From 0 to 24 Hours Postdose (SPID0-24)|Summed, Time-weighted Pain Intensity Differences (SPID)|Summed, Time-weighted Total Pain Relief Scores (TOTPARs)|Pain Intensity Differences (PIDs) by Time From Initial Dose|Pain Relief From Initial Dose|Median Time to First Intake of Rescue Medication|Cumulative Percentage of Participants Who Took Rescue Medication|Number of Times the Participants Took Rescue Medication Over the 24-hour Period|Global Assessment of the Investigational Product as a Pain Reliever","Bayer","All","15 Years and older   (Child, Adult, Older Adult)","Phase 3","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","15142|2014-005272-28","June 2011","September 2011","September 2011","July 8, 2011","May 7, 2013","August 25, 2015","Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01389284"
768,"NCT01389271","Inhaled Iloprost in the Treatment of Patients With Pulmonary Hypertension up to 4 Years","OPTION","Completed","No Results Available","Pulmonary Hypertension","Drug: Ventavis inhaled (Iloprost, BAYQ6256)","6 Minutes walking distance (change in meters)|Adverse events, weight, vital findings|6 Minutes walking distance (% change)|New York Heart Association Functional Class|Change in drug dosage or frequency, need for PAH specific drug combination, need for drug change|Pulmonary hypertension related hospitalization|Heart and/or lung transplantation, mortality","Bayer","All","18 Years and older   (Adult, Older Adult)",,"118","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14990|VE0910TR","February 3, 2011","March 8, 2017","June 18, 2018","July 8, 2011",,"April 25, 2019","Multiple Locations, Turkey",,"https://ClinicalTrials.gov/show/NCT01389271"
769,"NCT01388153","A 3-fold Crossover Bioequivalence Study Between Glucobay Orally Disintegrating Tablet (ODT) and Glucobay Standard Tablet",,"Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: Acarbose (Glucobay ODT, BAYG5421)|Drug: Acarbose (Glucobay, BAYG5421)","Difference of postprandial maximum concentration (Cmax) of blood glucose following sucrose load without (Day 1) and with Glucobay (Day 2)|Difference of postprandial Area under curve from 0 to 4 hours (AUC(0-4)) of blood glucose following sucrose load without (Day 1) and with Glucobay (Day 2)|Time to reach maximum drug concentration in plasma after single dose (tmax) of blood glucose following sucrose load without (Day 1) and with Glucobay (Day 2)|Difference of postprandial Cmax of serum insulin following sucrose load without (Day 1) and with Glucobay (Day 2)|Difference of postprandial AUC(0-4) of serum insulin following sucrose load without (Day 1) and with Glucobay (Day 2)|Tmax of serum insulin following sucrose load without (Day 1) and with Glucobay (Day 2)","Bayer","Male","18 Years to 45 Years   (Adult)","Phase 1","33","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","15624|2011-000904-17","June 2011","July 2011","August 2011","July 6, 2011",,"August 28, 2013","Mönchengladbach, Nordrhein-Westfalen, Germany",,"https://ClinicalTrials.gov/show/NCT01388153"
770,"NCT01386281","Julina Post-marketing Surveillance for Climacteric Symptoms in Japan","JULINA-CLIMA","Completed","No Results Available","Osteoporosis, Postmenopausal","Drug: E2 transdermal (Julina, BAY86-5435)","Incidence of adverse drug reactions and serious adverse events in subject who received Julina|Incidence of adverse drug reactions in subpopulation with baseline data (such as demographic data, concomitant disease) and dose of Julina|Change from baseline in grad of hot flush and sweating at the end of Julina treatment|Change from baseline in with/without vaginal atrophy at the end of Julina treatment","Bayer","Female","Child, Adult, Older Adult",,"506","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","15073","October 20, 2008","April 15, 2014","April 15, 2014","July 1, 2011",,"April 18, 2018","Multiple Locations, Japan",,"https://ClinicalTrials.gov/show/NCT01386281"
771,"NCT01386268","Kogenate FS Regulatory Post-Marketing Surveillance","KG0910KR","Completed","No Results Available","Hemophilia A","Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)","Safety variables will be summarized using descriptive statistics based on adverse events collection|Type of the treatment (prophylaxis, on demand, surgery)|Total consumption of FVIII|Daily dosage/frequency of FVIII (if used for prophylaxis, on demand, surgery/peri-operatively)|General assessment of therapy by physician by grading from 1 to 4: 1) excellent; 2) good; 3) sufficient; 4) insufficient","Bayer","All","Child, Adult, Older Adult",,"64","Industry","Observational","Time Perspective: Prospective","14927|KG0910KR","June 2011","January 2013","August 2013","July 1, 2011",,"August 21, 2014","Many locations, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01386268"
772,"NCT01383486","Self Selection Trial of Naproxen Sodium","KEIFER SST","Completed","Has Results","Pain","Drug: Naproxen sodium ER (BAYH6689)|Drug: Advil","The Percentage of Participants Who Selected Naproxen Sodium ER and Expected Their Pain to Last More Than 12 Hours|The Percentage of Participants Who Selected Naproxen Sodium ER , Expected Their Pain to Last More Than 12 Hours and Reported Their Selection Decision Within First 24 Hours|The Percentage of Low Literacy Participants Who Selected Naproxen Sodium ER and Expected Their Pain to Last More Than 12 Hours","Bayer","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","253","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","15833|2014-005305-20","July 2011","August 2011","August 2011","June 28, 2011","November 29, 2012","October 15, 2015","Anaheim, California, United States|Yorba Linda, California, United States|Pembroke Pines, Florida, United States|Griffin, Georgia, United States|Andover, Minnesota, United States|Roseville, Minnesota, United States|Bountiful, Utah, United States|West Jordan, Utah, United States|Bellevue, Washington, United States|Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01383486"
773,"NCT01376739","Magnevist Post-marketing Surveillance in Japan",,"Completed","No Results Available","Diagnostic Imaging","Drug: Gadopentetate dimeglumine (Magnevist, BAY86-4882)","Incidence of adverse drug reactions and serious adverse events in subjects who received Magnevist|Incidence of adverse drug reactions, especially Nephrogenic Systemic Fibrosis and Nephrogenic Fibrosing Dermopathy (NSF/NFD) in patients with reduced renal functions|MRI image evaluation assessment by the four rank scales of 1 to 4: 1) sufficient extraction; 2) almost sufficient extraction; 3) not sufficient extraction; and 4) insufficient extraction|Incidence of adverse drug reactions in subpopulation with baseline data","Bayer","All","Child, Adult, Older Adult",,"2051","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","15035|MAGNEVIST","August 2007","June 2010","June 2010","June 20, 2011",,"June 20, 2011","Many Locations, Japan",,"https://ClinicalTrials.gov/show/NCT01376739"
774,"NCT01375998","YAZ Post-marketing Surveillance in Japan",,"Completed","No Results Available","Dysmenorrhea","Drug: EE20/DRSP(YAZ, BAY86-5300)","Incidence of adverse drug reactions and sever adverse events|Change from baseline in severity of dysmenorrhea at 6th cycles (28 days per cycle)|Incidence of adverse events|Unpleasant physical symptoms collection|Unpleasant psychological symptoms collection|Analgesic drug for dysmenorrhea|QOL survey using Short-Form 36-Item Health Survey (SF-36)","Bayer","Female","Child, Adult, Older Adult",,"3273","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","15328|YAZ-DUI","June 9, 2011","December 5, 2017","March 8, 2018","June 20, 2011",,"March 7, 2019","Multiple Locations, Japan",,"https://ClinicalTrials.gov/show/NCT01375998"
775,"NCT01365052","Safety Trial of Naproxen Sodium/ Diphenhydramine","MUST","Completed","Has Results","Pain","Drug: Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111)|Drug: Placebo","Percentage of Subjects With Any Adverse Event for Those Subjects Who Were Randomized and Took at Least One Dose of Investigational Product|Percentage of Subjects With Any Serious Adverse Event for Those Subjects Who Were Randomized and Took at Least One Dose of Investigational Product","Bayer","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","326","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)","15560","May 2011","July 2011","July 2011","June 3, 2011","June 16, 2014","June 8, 2015","Chandler, Arizona, United States|Mesa, Arizona, United States|Peoria, Arizona, United States|Anaheim, California, United States|Rancho Cucamonga, California, United States|Sacramento, California, United States|Colorado Springs, Colorado, United States|Kissimmee, Florida, United States|Pembroke Pines, Florida, United States|South Miami, Florida, United States|Stockbridge, Georgia, United States|Metairie, Louisiana, United States|Elkridge, Maryland, United States|Warwick, Rhode Island, United States|Mt. Pleasant, South Carolina, United States|Fort Worth, Texas, United States|San Angelo, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01365052"
776,"NCT01363336","Post-marketing Surveillance for Hypertensive Patients With Diabetes and/or Chronic Kidney Disease",,"Completed","No Results Available","Hypertension","Drug: Nifedipine (Adalat CR, BAYA1040)","Evaluation of participants with Adverse Events for Safety purpose in real practice|General evaluation of patient concerning efficacy of AdalatCR treatment in real practice|Blood pressure, Pulse rate|Clinical test values, in specially, microalbumin urea and serum creatinine|Overall evaluation","Bayer","All","Child, Adult, Older Adult",,"1882","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","15190","November 2009","June 2013","July 2013","June 1, 2011",,"April 6, 2015","Many Locations, Japan",,"https://ClinicalTrials.gov/show/NCT01363336"
777,"NCT01361399","Active and Placebo Controlled Study to Test the Efficacy and Safety of an Aspirin-Lidocaine Lozenge in the Symptomatic Treatment of Sore Throat Associated With a Common Cold",,"Completed","No Results Available","Common Cold|Pharyngitis|Tonsillitis","Drug: Acetylsalicylic acid (Aspirin, BAYE4465) & Lidocain|Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)|Drug: Lidocain|Drug: Placebo","Sum of pain intensity differences SPID|Pain intensity difference to baseline (PID12 min)|Pain intensity difference to baseline (PID120 min)|Pain intensity difference to baseline (PID)|Total pain relief to baseline (TOTPAR)|Symptoms of common cold (headache, sinus pressure/pain, feverish discomfort, muscle aches and pain)|Overall assessment of treatment|Assessment of safety and tolerability","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","1088","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11640","November 2004",,"May 2005","May 26, 2011",,"May 26, 2011","ask Contact, Russian Federation|ask Contact, Ukraine",,"https://ClinicalTrials.gov/show/NCT01361399"
778,"NCT01359787","Efficacy and Safety of Different Concentrations of Mapracorat Ointment Over 4 Weeks in Atopic Dermatitis (AD)",,"Completed","No Results Available","Atopic Dermatitis|Eczema","Drug: Mapracorat|Drug: Vehicle without active","Eczema Area and Severity Index (EASI)|Subjects´ assessment of pruritus","Bayer","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","197","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15616|1403440|2010-024279-14","May 2011","September 2011","September 2011","May 25, 2011",,"January 21, 2015","Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT01359787"
779,"NCT01355380","Efficacy of Ventavis Used in Real-life Setting.","SPHERA","Completed","No Results Available","Pulmonary Arterial Hypertension","Drug: Inhaled iloprost (Ventavis, BAYQ6256)","Changes of the exercise capacity as measured by 6-minutes walking distance|Changes of depression score over time|Changes of functional capacity as measured by WHO classification system|Changes of pulmonary haemodynamics|Changes of serum level of natriuretic peptide B|Changes of Quality of Life score|Changes in cardiac echo parameters|Number of patients with treatment-emergent adverse events","Bayer","All","18 Years and older   (Adult, Older Adult)",,"55","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","15308|VE1010PL","August 5, 2010","April 28, 2016","September 22, 2016","May 18, 2011",,"October 17, 2017","Many Locations, Poland",,"https://ClinicalTrials.gov/show/NCT01355380"
780,"NCT01355367","High Dose BAYA1040 CR: a Long Term Extension Study",,"Completed","No Results Available","Hypertension","Drug: Nifedipine (Adalat, BAYA1040)","Safety variables will be summarized using descriptive statistics based on adverse events collection|Changes from baseline in diastolic blood pressure (DBP) while sitting|Changes from baseline in systolic blood pressure (SBP) while sitting|Proportion of subjects achieving a target BP based on the Japanese Society of Hypertension (JSH) 2009 guidelines|Proportion of subjects achieving a target DBP and SBP based on JSH 2009 guidelines or a >10 mmHg reduction of DBP","Bayer","All","20 Years and older   (Adult, Older Adult)","Phase 3","120","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14023","January 2011","September 2011","April 2012","May 18, 2011",,"January 29, 2014","Hirosaki, Aomori, Japan|Kamagaya, Chiba, Japan|Asahikawa, Hokkaido, Japan|Asahikawa, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Kawasaki, Kanagawa, Japan|Daito, Osaka, Japan|Kishiwada, Osaka, Japan|Yao, Osaka, Japan|Tokorozawa, Saitama, Japan|Hachioji, Tokyo, Japan|Meguro, Tokyo, Japan|Minato, Tokyo, Japan|Minato, Tokyo, Japan|Shizuoka, Japan",,"https://ClinicalTrials.gov/show/NCT01355367"
781,"NCT01354665","Depression and Fatigue in MS Patients Treated With Betaferon.","FADO","Completed","No Results Available","Multiple Sclerosis","Biological: Interferon beta-1b (Betaferon, BAY86-5046)","Changes of fatigue score over time|Changes of depression score over time|Treatment adherence|Clinical course of the disease|Overall treatment tolerability as measured by rate of adverse events","Bayer","All","18 Years and older   (Adult, Older Adult)",,"567","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","15307|BF1012PL","May 2010","June 2013","June 2013","May 17, 2011",,"January 21, 2015","Many Locations, Poland",,"https://ClinicalTrials.gov/show/NCT01354665"
782,"NCT01354418","Bioequivalence of Single Dose Phenylephrine Extended Release Tablets and Phenylephrine HCl Immediate Release Tablets Dosed Every Four Hours (P08340)(COMPLETED)",,"Completed","No Results Available","Nasal Congestion","Drug: Phenylephrine HCl Extended Release|Drug: Phenylephrine HCl Immediate Release","Maximum plasma concentration (Cmax) of phenylephrine|Time to Cmax (Tmax) of phenylephrine|Area under the concentration versus time curve from time 0 to the last measurable concentration (AUC[0-t])|Area under the concentration versus time curve from time 0 to infinity (AUC[0-∞])|Terminal rate constant (λz)|Terminal elimination half-life (t1/2)","Bayer","All","18 Years to 45 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18124|CL2010-18|P08340","May 2011","June 2011","July 2011","May 16, 2011",,"February 23, 2015",,,"https://ClinicalTrials.gov/show/NCT01354418"
783,"NCT01353794","Study to Observe Safety and Efficacy of Nexavar in Treatment of Kidney Cancer","POWER-NEXT","Withdrawn","No Results Available","Carcinoma, Renal Cell","Drug: Sorafenib (Nexavar, BAY43-9006)","Efficacy related variables are status of tumor / metastases.|Efficacy related variables are patient's performance status.|Efficacy related variables are efficacy assessment by the physician.|Efficacy related variable - Quality of Life (QOL) assessment by the patient|General tolerability assessment by physician and reports of adverse events.","Bayer","All","Child, Adult, Older Adult",,"0","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","15246|NX0913IN","December 2014","September 2017","April 2018","May 16, 2011",,"January 30, 2015",,,"https://ClinicalTrials.gov/show/NCT01353794"
784,"NCT01350609","Pivotal Bioequivalence FDC Nifedipine / Candesartan vs. Loose Combination of Single Components, Fed",,"Completed","No Results Available","Hypertension, Essential","Drug: Nifedipine/Candesartan (BAY 98-7106)|Drug: Nifedipine (Adalat, BAY A1040) and Candesartan (Atacand, BAY 12-9333)","Cmax|AUC(0-tlast)|AUC|Cmax,norm|AUCnorm|AUC(0-48)|Tmax|t1/2|MRT|CL/F|Number of participants with adverse events","Bayer","Male","18 Years to 45 Years   (Adult)","Phase 1","49","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","14028|2011-000322-29","April 2011","August 2011","September 2011","May 10, 2011",,"December 10, 2015","Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT01350609"
785,"NCT01348880","Vardenafil ODT (Orally Disintegrating Tablet) - Nifedipine Interaction Study",,"Completed","No Results Available","Erectile Dysfunction","Drug: Vardenafil ODT, (Staxyn, BAY38-9456)|Drug: Placebo","The primary pharmacodynamic variable (endpoint) is the placebo-corrected mean maximal decrease in supine systolic blood pressure from baseline (1 hour before dose) to within 8 hours of dosing with 10 mg ODT formulation of vardenafil HCl and nifedipine.|Mean maximal decrease in standing SBP|Mean maximal decrease in standing diastolic blood pressure (DBP)|Mean maximal decrease in supine DBP|Mean maximal orthostatic change in SBP (the supine SBP minus the standing SBP)|Mean maximal increase in supine and standing heart rate|Mean area under effect curve (AUEC) in standing and supine systolic and diastolic blood pressure, and heart rate|Safety parameters|Pharmacokinetics parameter","Bayer|GlaxoSmithKline|Merck Sharp & Dohme Corp.","Male","65 Years to 80 Years   (Older Adult)","Phase 1","42","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","15345","May 2011","December 2011","December 2011","May 6, 2011",,"May 19, 2014","Miami, Florida, United States|Knoxville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01348880"
786,"NCT01345656","BAY94-8862 Dose Finding Trial in Subjects With Chronic Heart Failure and Mild (Part A) or Moderate (Part B) Chronic Kidney Disease","ARTS","Completed","No Results Available","Heart Failure","Drug: BAY94-8862|Drug: Placebo|Drug: Spironolactone","Change of serum potassium|Change in serum magnesium|Change in blood pressure|Change in heart rate","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","458","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","14563|2011-000301-45","May 2011","May 2012","July 2012","May 2, 2011",,"April 8, 2016","Linz, Oberösterreich, Austria|Graz, Steiermark, Austria|Feldkirch, Vorarlberg, Austria|Salzburg, Austria|Wien, Austria|Brasschaat, Belgium|Bruxelles - Brussel, Belgium|Leuven, Belgium|Roeselare, Belgium|Brno, Czech Republic|Liberec, Czech Republic|Praha 2, Czech Republic|Praha 5, Czech Republic|Copenhagen Ø, Denmark|Esbjerg, Denmark|Frederiksberg, Denmark|Hellerup, Denmark|Herlev, Denmark|Hvidovre, Denmark|København NV, Denmark|Køge, Denmark|Odense, Denmark|Svendborg, Denmark|Viborg, Denmark|Helsinki, Finland|Jyväskylä, Finland|Turku, Finland|Frankfurt, Hessen, Germany|Dortmund, Nordrhein-Westfalen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Dresden, Sachsen, Germany|Wermsdorf, Sachsen, Germany|Wedel, Schleswig-Holstein, Germany|Erfurt, Thüringen, Germany|Berlin, Germany|Afula, Israel|Ashkelon, Israel|Hadera, Israel|Petach Tikva, Israel|Rehovot, Israel|Safed, Israel|Tel Aviv, Israel|Oslo, Norway|Stavanger, Norway|Krakow, Poland|Piotrkow Trybunalski, Poland|Szczecin, Poland|Warszawa, Poland|Wroclaw, Poland|Kristianstad, Sweden|Lund, Sweden|Stockholm, Sweden|Stockholm, Sweden|Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT01345656"
787,"NCT01344460","Gadobutrol Enhanced MRA of the Renal Arteries","GRAMS","Completed","Has Results","Renal Artery Obstruction","Drug: Gadobutrol (Gadovist, BAY86-4875)","Percentage of Assessable Vascular Segments Using Gadobutrol-Enhanced MRA and Unenhanced MRA|Sensitivity for Detection of Clinically Significant Disease Using Gadobutrol-Enhanced MRA and Unenhanced MRA|Specificity for Exclusion of Clinically Significant Disease Using Gadobutrol-Enhanced MRA and Unenhanced MRA|Minimum Gadobutrol Performance for Sensitivity: Sensitivity More Than (>) 50%|Minimum Gadobutrol Performance for Specificity: Specificity > 50%|Length of the Right and Left Renal Arteries Assessed by Gadobutrol-enhanced MRA and Unenhanced MRA - Blinded Reader|Length of the Right and Left Renal Arteries Assessed by Computed Tomographic Angiography (CTA) - Blinded Reader|Vessel Diameter (Millimeter [mm]) at the Normal Point and the Narrowest Point in Gadobutrol-Enhanced MRA, Unenhanced MRA and CTA Images|The Percentage of Location of Stenosis >= 50% (Within and Beyond 5 Millimeter From the Aorta) in the Proximal Segments Assessed by Gadobutrol-Enhanced MRA and Unenhanced MRA|The Percentage of Segments With Artifacts Presence|Types of Artifacts Assessed by Gadobutrol-enhanced MRA and Unenhanced MRA by Blinded Reader 1|Types of Artifacts Assessed by Gadobutrol-enhanced MRA and Unenhanced MRA by Blinded Reader 2|Types of Artifacts Assessed by Gadobutrol-enhanced MRA and Unenhanced MRA by Blinded Reader 3|The Percentage of Accessory (Non-dominant) Renal Artery Presence Assessed by Gadobutrol-Enhanced MRA and Unenhanced MRA|The Presence of Any Aneurysmal Dilatation in Each Segment (Proximal, Mid- and Distal) in the Right and the Left Renal Arteries Assessed by Gadobutrol-Enhanced MRA and Unenhanced MRA|The Percentage of Participants With Diagnosis of Fibromuscular Dysplasia and Arteriosclerosis Assessed by Gadobutrol-Enhanced MRA and Unenhanced MRA|Diagnostic Confidence by the Blinded Readers Using Gadobutrol-Enhanced MRA and Unenhanced MRA|The Percentage of Participants With Additional Imaging Studies Recommended by the Blinded Readers and the Clinical Investigator After Evaluation of the Gadobutrol-Enhanced and Unenhanced MRA Images|Types of Additional Imaging Studies Recommended by the Blinded Readers After Evaluation of the Gadobutrol-Enhanced and Unenhanced MRA Images - Blinded Reader 1|Types of Additional Imaging Studies Recommended by the Blinded Readers After Evaluation of the Gadobutrol-Enhanced and Unenhanced MRA Images - Blinded Reader 2|Types of Additional Imaging Studies Recommended by the Blinded Readers After Evaluation of the Gadobutrol-Enhanced and Unenhanced MRA Images - Blinded Reader 3|Types of Additional Imaging Studies Recommended by the Clinical Investigator After Evaluation of the Unenhanced and Gadobutrol-Enhanced MRA Images","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","317","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","91759|2010-023002-13","May 2011","July 2012","July 2012","April 29, 2011","August 26, 2015","August 26, 2015","Tucson, Arizona, United States|Los Angeles, California, United States|Los Angeles, California, United States|Orange, California, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Savannah, Georgia, United States|Chicago, Illinois, United States|Baltimore, Maryland, United States|Durham, North Carolina, United States|Providence, Rhode Island, United States|Memphis, Tennessee, United States|San Antonio, Texas, United States|Madison, Wisconsin, United States|Milwaukee, Wisconsin, United States|Adrogué, Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Rosario, Santa Fe, Argentina|Innsbruck, Tirol, Austria|Wiener Neustadt, Austria|Wien, Austria|Porto Alegre, Rio Grande do Sul, Brazil|São Paulo, Sao Paulo, Brazil|Rio de Janeiro, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Medellín, Antioquia, Colombia|Barranquilla, Atlántico, Colombia|Cali, Valle del Cauca, Colombia|Bogotá, Colombia|Brno, Czech Republic|Olomouc, Czech Republic|Plzen, Czech Republic|Praha 2, Czech Republic|Praha 5, Czech Republic|La Tronche, France|Paris Cedex 13, France|Paris, France|Paris, France|Rouen Cedex, France|Vandoeuvre-les-nancy, France|Karlsruhe, Baden-Württemberg, Germany|Frankfurt, Hessen, Germany|Münster, Nordrhein-Westfalen, Germany|Kiel, Schleswig-Holstein, Germany|Lübeck, Schleswig-Holstein, Germany|Jena, Thüringen, Germany|Berlin, Germany|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Suwon, Korea, Republic of|Krakow, Poland|Lodz, Poland|Lublin, Poland|Warszawa, Poland|Basel, Basel-Stadt, Switzerland|Olten, Solothurn, Switzerland|Bern, Switzerland|Zürich, Switzerland|Kaoshiung, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Ankara, Turkey|Istanbul, Turkey|Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT01344460"
788,"NCT01344447","Gadobutrol Enhanced MRA of the Supra-aortic Vessels","GEMSAV","Completed","Has Results","Carotid Stenosis","Drug: Gadobutrol (Gadovist, BAY86-4875)","Percentage of Assessable Vascular Segments Using Gadobutrol-Enhanced MRA and Unenhanced MRA|Sensitivity for Detection of Clinically Significant Disease Using Gadobutrol-Enhanced MRA and Unenhanced MRA|Specificity for Exclusion of Clinically Significant Disease Using Gadobutrol-Enhanced MRA and Unenhanced MRA|Minimum Gadobutrol Performance for Sensitivity: Sensitivity > 50%|Minimum Gadobutrol Performance for Specificity: Specificity > 50%|Vessel Diameter (Millimeter [mm]) at the Normal Point and the Narrowest Point in Gadobutrol-Enhanced MRA, Unenhanced MRA and CTA Images|The Percentage of Segments With Artifacts Presence|Types of Artifacts on a Segment Basis by Blinded Reader 1|Types of Artifacts on a Segment Basis by Blinded Reader 2|Types of Artifacts on a Segment Basis by Blinded Reader 3|The Percentage of Location of Stenosis (>=70%) in the Proximal Segments Assessed by Gadobutrol-Enhanced MRA and Unenhanced MRA|Length of Stenosis (>=70%) in the Proximal Segments Assessed by Gadobutrol-Enhanced MRA and Unenhanced MRA|The Percentage of Presence of Secondary Radiologic Indicators for Diagnosis of Clinically Relevant Disease|Type of Secondary Radiologic Indicators for Diagnosis of Clinically Relevant Disease|Diagnostic Confidence by the Blinded Readers Using Gadobutrol-Enhanced MRA and Unenhanced MRA|The Percentage of Participants With Additional Imaging Studies Recommended by the Blinded Readers and the Clinical Investigator After Evaluation of the Unenhanced and Gadobutrol-Enhanced MRA Images|Types of Additional Imaging Studies Recommended by the Blinded Readers After Evaluation of the Unenhanced and Gadobutrol-Enhanced MRA Images - Blinded Reader 1|Types of Additional Imaging Studies Recommended by the Blinded Readers After Evaluation of the Unenhanced and Gadobutrol-Enhanced MRA Images - Blinded Reader 2|Types of Additional Imaging Studies Recommended by the Blinded Readers After Evaluation of the Unenhanced and Gadobutrol-Enhanced MRA Images - Blinded Reader 3|Types of Additional Imaging Studies Recommended by the Clinical Investigator After Evaluation of the Unenhanced and Gadobutrol-Enhanced MRA Images","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","479","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","14607|2010-023001-36","May 12, 2011","May 28, 2014","May 28, 2014","April 29, 2011","August 26, 2015","January 4, 2019","Tucson, Arizona, United States|Jacksonville, Florida, United States|Savannah, Georgia, United States|Louisville, Kentucky, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Ann Arbor, Michigan, United States|Jackson, Mississippi, United States|Bronx, New York, United States|Rochester, New York, United States|Philadelphia, Pennsylvania, United States|Providence, Rhode Island, United States|Memphis, Tennessee, United States|Seattle, Washington, United States|Madison, Wisconsin, United States|Adrogué, Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|New Lambton Heights, New South Wales, Australia|Clayton, Victoria, Australia|Parkville, Victoria, Australia|Innsbruck, Tirol, Austria|Wien, Austria|Shanghai, China|Shanghai, China|Brno, Czechia|Brest Cedex, France|BRON Cedex, France|Marseille, France|Paris Cedex 15, France|Paris, France|Karlsruhe, Baden-Württemberg, Germany|Augsburg, Bayern, Germany|Erlangen, Bayern, Germany|Münster, Nordrhein-Westfalen, Germany|Jena, Thüringen, Germany|Ferrara, Emilia-Romagna, Italy|Roma, Lazio, Italy|Catania, Sicilia, Italy|Massa-Carrara, Toscana, Italy|Aosta, Valle d'Aosta, Italy|Venezia, Veneto, Italy|Donggu,, Gwangju Gwang''yeogsi, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Bydgoszcz, Poland|Lodz, Poland|Warszawa, Poland|Wroclaw, Poland|Linköping, Sweden|Uppsala, Sweden|St. Gallen, Sankt Gallen, Switzerland|Antalya, Turkey|Erzurum, Turkey|Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT01344447"
789,"NCT01339104","Open Label Regorafenib Study to Evaluate Cardiovascular Safety Parameters, Tolerability, and Anti-tumor Activity",,"Completed","No Results Available","Neoplasms","Drug: Regorafenib (Stivarga, BAY73-4506)","Effect of regorafenib on cardiovascular safety parameters measured by change in QT\QTc on the ECG in patients with advanced solid tumors|Effect on Left Ventricular Ejection Fraction (LVEF)|Decrease in tumor size based on investigator assessed RECIST criteria","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","53","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14814","April 2011","August 2013","August 2013","April 20, 2011",,"October 1, 2014","Aurora, Colorado, United States|Ann Arbor, Michigan, United States|St. Louis, Missouri, United States|Oklahoma City, Oklahoma, United States|Nashville, Tennessee, United States|Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01339104"
790,"NCT01337804","A Study to Compare Omeprazole Administered as Zegerid® Powder and as Prilosec® Capsule in Healthy Participants (P08050)(CL2010-12)",,"Completed","No Results Available","Heartburn","Drug: omeprazole/sodium bicarbonate|Drug: omeprazole magnesium","Area under the plasma concentration-time curve from 0 to infinity (AUC[0-∞])|Maximum plasma concentration (Cmax)","Bayer","All","18 Years to 45 Years   (Adult)","Phase 1","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18136|P08050","January 2011","January 2011","January 2011","April 19, 2011",,"February 23, 2015",,,"https://ClinicalTrials.gov/show/NCT01337804"
791,"NCT01335373","Observational Program Neo-Penotran® Forte",,"Completed","No Results Available","Vaginal Candidiasis|Bacterial Vaginosis|Trichomonal Vaginitis","Drug: Metronidazole/Miconazole (Neo-Penotran Forte, BAY86-5276)","Percent rate of different vaginal infections|Clinical characteristics of vaginitis after treatment.|Change of microbiological characteristics after treatment|Patient rating of tolerability and treatment results|Physician's rating of tolerability and treatment results","Bayer","Female","18 Years to 90 Years   (Adult, Older Adult)",,"13024","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","15511|NP1010KZ","October 2010","December 2011","April 2015","April 14, 2011",,"July 25, 2016","Many Locations, Kazakhstan",,"https://ClinicalTrials.gov/show/NCT01335373"
792,"NCT01335256","Clinical Study to Evaluate Safety and Maximum Tolerated Dose of BAY1000394 Given in a 4 Week on / 2 Week Off Schedule in Subjects With Advanced Malignancies",,"Completed","No Results Available","Neoplasms","Drug: BAY1000394","Number of subjects with Adverse Events as a measure safety|Maximum tolerated dose: Measured by adverse event profile|Biomarkers evaluation measured by Enzyme-linked immunosorbent assay (ELISA)|Tumor Response evaluation measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1)|Peak Plasma Concentration (Cmax) of BAY1000394|Pharmacokinetics parameters will be measured using Peak Plasma Time (tmax) of BAY1000394|Area under the plasma concentration versus time curve from 0 to tn (AUC(0 tn)) of BAY1000394|Area under the plasma concentration versus time curve (AUC) of BAY1000394|Half-life of BAY1000394","Bayer","Female","18 Years and older   (Adult, Older Adult)","Phase 1","10","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14856|2010-019191-79","December 2010","September 2011","September 2011","April 14, 2011",,"May 3, 2013","Scottsdale, Arizona, United States|St. Louis, Missouri, United States|Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01335256"
793,"NCT01333774","Influence of Different Approaches to Dietary Advising on the Effects of Acarbose Treatment in Obese Diabetic Patients Under Real-life Setting","CATERING","Completed","No Results Available","Diabetes Mellitus","Drug: Glucobay (Acarbose, BAYG5421)","Change in HbA1c value between initial and final visit|Number of participants with adverse events in both study groups. The influence of different approaches to dietary advising on the appearance of adverse events.","Bayer","All","18 Years and older   (Adult, Older Adult)",,"423","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","13928|GB0810PL","May 2008","March 2009","March 2009","April 12, 2011",,"May 4, 2012","Many Locations, Poland",,"https://ClinicalTrials.gov/show/NCT01333774"
794,"NCT01332942","Combined Single / Multiple Dose Escalation Study in Patients With Renal Anemia Due to CKD (Chronic Kidney Disease)",,"Completed","No Results Available","Anemia","Drug: BAY85-3934","Number of Subjects with Treatment-Emergent Adverse Events (TEAE)|Mean Change in Heart Rate Within 4 hours Post-dose|Mean Change in Heart Rate Over 1 Minute for Doses 25, 50, 75 Milligrams|Mean Change in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Within 4 hours Post-dose|Number of Subjects with Clinically Relevant Abnormal Findings in the Electrocardiogram (ECG)|Number of Subjects with Clinically Relevant Laboratory Values|Maximum Observed Drug Concentration (Cmax) in Plasma of Molidustat and its Metabolite After Single Dose of Molidustat|Maximum Observed Drug Concentration Divided by Dose (Cmax/D) in Plasma of Molidustat and its Metabolite After Single Dose of Molidustat|Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC) in Plasma of Molidustat and its Metabolite After Single Dose of Molidustat|Area Under the Concentration Versus Time Curve From Zero to Infinity Divided by Dose (AUC/D) in Plasma of Molidustat and its Metabolite After Single Dose of Molidustat|Maximum Observed Drug Concentration (Cmax,md) in Plasma of Molidustat and its Metabolite After Multiple Dose Administration of Molidustat|Maximum Observed Drug Concentration in Plasma Divided by Dose (Cmax,md/D) of Molidustat and its Metabolite After Multiple Dose Administration of Molidustat|Area Under the Concentration Versus Time Curve From 0 to 24 hour (AUC[0-24]md) in Plasma During any Dose Interval of Molidustat and its Metabolite After Multiple Dose of Molidustat|Area Under the Concentration Versus Time Curve From 0 to 24 hour Divided by Dose (AUC[0-24] md/D) in Plasma During any Dose Interval of Molidustat and its Metabolite After Multiple Dose of Molidustat|Maximum Observed Drug Concentration in Plasma Divided by Dose per Kilogram Body Weight (Cmax,norm) of Molidustat and its Metabolite After Single Dose of Molidustat|Area Under the Concentration Versus Time Curve From Zero to Infinity in Plasma Divided by Dose per Kilogram Body Weight (AUCnorm) of Molidustat and its Metabolite After Single Dose of Molidustat|Area Under the Concentration Versus Time Curve From Zero to 24 hour (AUC[0-24]) in Plasma of Molidustat and its Metabolite After Single Dose of Molidustat|Area Under the Concentration Versus Time Curve From Zero to the Last Data Point Above the Lower Limit of Quantification (AUC[0-tlast]) in Plasma of Molidustat and its Metabolite After Single Dose of Molidustat|Half Life Associated With the Terminal Slope (t1/2) in Plasma of Molidustat and its Metabolite After Single Dose of Molidustat|Time to Reach Maximum Drug Concentration (tmax) in Plasma of Molidustat and its Metabolite After Single Dose of Molidustat|Mean Residence Time (MRT) of Molidustat and its Metabolite After Single Dose of Molidustat|Apparent Oral Clearance (CL/F) of Molidustat and its Metabolite After Single Dose of Molidustat|Apparent Volume of Distribution During Terminal Phase (Vz/F) After Single Dose of Molidustat|Amount Excreted into Urine (Aeur) of Molidustat and its Metabolite After Single Dose of Molidustat|Renal Body Clearance of Drug (CLR) of Molidustat and its Metabolite After Single Dose of Molidustat|Maximum Observed Concentration Divided by Dose per Kilogram Body Weight (Cmax,md,norm) in Plasma After Multiple Dose Administration During a Dosage Interval|Area Under the Concentration Versus Time Curve From 0 to 24 hour Divided by Dose per Kilogram Body Weight (AUC[0-24]md,norm) in Plasma After Multiple Dose Administration During a Dosage Interval|Half Life Associated With the Terminal Slope (t1/2,md) in Plasma of Molidustat and its Metabolite After Multiple Dose of Molidustat|Time to Reach Maximum Drug Concentration (tmax,md) in Plasma of Molidustat and its Metabolite After Multiple Dose of Molidustat|Amount Excreted into Urine (Aeur,md)of Molidustat and its Metabolite After Multiple Dose of Molidustat|Renal Body Clearance (CLR,md) of Molidustat and its Metabolite After Multiple Dose of Molidustat|Accumulation Ratio of AUC in the Dosing Interval (RAAUC) of Molidustat|Accumulation Ratio of Cmax (RACmax) of Molidustat|Linearity Factor of Pharmacokinetics After Repeated Administration of Identical Doses (RLin) of Molidustat|Erythropoietin Concentration: Area Under the Concentration Versus Time Curve From 0 to 24 hour (AUC[0-24]) Post-dose on Day 1 (0d)|Erythropoietin Concentration: Area Under the Concentration Versus Time Curve From 0 to 24 hour (AUC[0-24]md) in Plasma After Multiple Dose on Day 14 (13d)|Erythropoietin Concentration: Maximum Observed Drug Concentration in Plasma (Cmax[0-24]) After Single Dose of Molidustat on Day 1 (0d)|Erythropoietin Concentration: Maximum Observed Drug Concentration in Plasma (Cmax [0-24]md) Within 0-24 hours Post Dose on Day 14 (13d)|Pharmacodynamic Parameter: Maximum Observed Drug Concentration in Plasma (Cmax) of Reticulocytes (Absolute) Within Day 1 (0d) - Day 14 (13d)|Pharmacodynamic Parameter: Maximum Observed Drug Concentration in Plasma (Cmax) of Reticulocytes ( Ratio-to-Baseline-Adjusted) Within Day 1(0d) - Day 14 (13d)|Pharmacodynamic Parameter: Maximum Observed Drug Concentration in Plasma (Cmax) of Hemoglobin (Absolute) Within Day 1 (0d) - Day 14 (13d)|Pharmacodynamic Parameter: Maximum Observed Drug Concentration in Plasma (Cmax) of Hemoglobin ( Ratio-to-Baseline-Adjusted) Within Day 1 (0d) - Day|Pharmacodynamic Parameter: Maximum Observed Drug Concentration in Plasma (Cmax) of Hematocrit (Absolute) Within Day 1 (0d) - Day 14(13d)|Pharmacodynamic Parameter: Maximum Observed Drug Concentration in Plasma (Cmax) of Hematocrit (Ratio-to-Baseline-Adjusted) Within Day 1( 0d) - Day 14 (13d)","Bayer","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","44","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)","14627|2010-023585-50","April 2011","May 2013","December 2013","April 11, 2011",,"July 14, 2015","München, Bayern, Germany|Hannover, Niedersachsen, Germany|Hannover, Niedersachsen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Kiel, Schleswig-Holstein, Germany|Berlin, Germany|Berlin, Germany|Hamburg, Germany|Wuppertal, Germany|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01332942"
795,"NCT01331681","Intravitreal Aflibercept Injection in Vision Impairment Due to DME","VIVID-DME","Completed","Has Results","Diabetes Mellitus|Macular Edema","Biological: VEGF Trap-Eye (BAY86-5321)|Procedure: Macular Laser Photocoagulation (Control)","Change From Baseline in BCVA (Best Corrected Visual Acuity) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation Carried Forward (LOCF)|Percentage of Participants Who Gained at Least 10 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF|Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF|Percentage of Participants With a ≥2-step Improvement From Baseline in the ETDRS DRSS (Diabetic Retinopathy Severity Score) as Assessed by FP (Fundus Photography) at Week 52 - LOCF|Change From Baseline in Central Retinal Thickness (CRT) at Week 52 as Assessed on Optical Coherence Tomography (OCT) - LOCF|Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Near Activities Subscale at Week 52 - LOCF|Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Distance Activities Subscale at Week 52 - LOCF","Bayer|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","406","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","91745|2010-022364-12","May 2011","June 2013","March 2015","April 8, 2011","September 9, 2014","April 19, 2016","Chatswood, New South Wales, Australia|Sydney, New South Wales, Australia|Westmead, New South Wales, Australia|East Melbourne, Victoria, Australia|Prahran, Victoria, Australia|Nedlands, Western Australia, Australia|Parramatta, Australia|Linz, Oberösterreich, Austria|Linz, Austria|Wien, Austria|Hradec Kralove, Czech Republic|Olomouc, Czech Republic|Ostrava, Czech Republic|Praha 10, Czech Republic|Zlin, Czech Republic|Glostrup, Denmark|Odense C, Denmark|Århus C, Denmark|Bordeaux, France|Creteil Cedex, France|Lyon, France|Marseille, France|Nantes Cedex, France|Paris, France|Paris, France|Paris, France|Freiburg, Baden-Württemberg, Germany|Heidelberg, Baden-Württemberg, Germany|Mannheim, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|München, Bayern, Germany|Darmstadt, Hessen, Germany|Göttingen, Niedersachsen, Germany|Aachen, Nordrhein-Westfalen, Germany|Bochum, Nordrhein-Westfalen, Germany|Bonn, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Ludwigshafen, Rheinland-Pfalz, Germany|Mainz, Rheinland-Pfalz, Germany|Chemnitz, Sachsen, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Kiel, Schleswig-Holstein, Germany|Berlin, Germany|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Veszprem, Hungary|Zalaegerszeg, Hungary|Ancona, Italy|Milano, Italy|Milano, Italy|Padova, Italy|Roma, Italy|Roma, Italy|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Asahikwa, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Kawasaki, Kanagawa, Japan|Sendai, Miyagi, Japan|Matsumoto, Nagano, Japan|Yufu, Oita, Japan|Hirakata, Osaka, Japan|Chiyoda-ku, Tokyo, Japan|Itabashi-ku, Tokyo, Japan|Mitaka, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Akita, Japan|Chiba, Japan|Fukuoka, Japan|Nagasaki, Japan|Osaka, Japan|Wakayama, Japan|Bialystok, Poland|Bytom, Poland|Wroclaw, Poland|Wroclaw, Poland|Santiago de Compostela, A Coruña, Spain|Oviedo, Asturias, Spain|San Cugat del Vallès, Barcelona, Spain|Alicante, Spain|Barcelona, Spain|Pamplona, Spain|Valencia, Spain|Changhua City, Changhua, Taiwan|Kaohsiung, Taiwan|Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01331681"
796,"NCT01331655","Clinical Study of a Conventional and Flexible Extended Oral Contraceptive of EE/DRSP With or Without Metafolin in Latin America",,"Withdrawn","No Results Available","Contraception","Drug: EE20/DRSP (BAY86-5300)|Drug: EE20/DRSP/L-5-MTHF (BAY98-7071)|Drug: EE20/DRSP/L-5-MTHF (BAY98-7071) + L-5-MTHF (BAY86-7660)","Number of bleeding days|Difference in the number of missed tablets between Arms A and B|Bleeding pattern and cycle control parameters|Number of cycles per subject","Bayer","Female","18 Years to 35 Years   (Adult)","Phase 3","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14700","April 2013","November 2014","November 2014","April 8, 2011",,"July 15, 2014",,,"https://ClinicalTrials.gov/show/NCT01331655"
797,"NCT01330017","Effects of Phenylephrine on Nasal Congestion in Participants With Seasonal Allergic Rhinitis (P08156 AM2)(Completed)",,"Completed","Has Results","Rhinitis|Seasonal Rhinitis","Drug: Phenylephrine HCl|Drug: Placebo|Drug: Loratadine","Mean Change From Baseline Over the Entire Treatment Period in the Daily Reflective Nasal Congestion Score|Mean Change From Baseline in the Morning (a.m.) Symptom Score for the Nasal Reflective Symptom Assessment by Study Day of the Treatment Period|Mean Change From Baseline in the Evening (p.m.) Symptom Score for the Nasal Reflective Symptom Assessment by Study Day of the Treatment Period|Mean Change From Baseline in the a.m. Symptom Score for the Instantaneous Nasal Symptom Assessment by Study Day of the Treatment Period|Mean Change From Baseline for the Daily Reflective Nasal Symptom Assessment Score by Study Day of the Treatment Period|Mean Change From Baseline for the Instantaneous Nasal Symptom Assessment Score By Study Day of the Treatment Period|Time to Maximal Effect|Change From Baseline for the Instantaneous Nasal Symptom Assessment Score at Day 7","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","539","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18123|CL2010-06|P08156","March 2011","May 2011","June 2011","April 6, 2011","November 7, 2012","March 11, 2015",,,"https://ClinicalTrials.gov/show/NCT01330017"
798,"NCT01327105","Essure Transvaginal Ultrasound (TVU) Study",,"Active, not recruiting","No Results Available","Contraceptive Usage","Device: TVU","Effectiveness","Bayer","Female","21 Years to 44 Years   (Adult)","Phase 4","547","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16974|ESS-TVU","May 17, 2011","July 16, 2014","July 28, 2023","April 1, 2011",,"January 18, 2020","Chandler, Arizona, United States|Glendale, Arizona, United States|Phoenix, Arizona, United States|Tucson, Arizona, United States|Arvada, Colorado, United States|Fort Wayne, Indiana, United States|Saginaw, Michigan, United States|Rochester, Minnesota, United States|Bronx, New York, United States|Asheville, North Carolina, United States|Winston-Salem, North Carolina, United States|Columbus, Ohio, United States|Houston, Texas, United States|Regina, Saskatchewan, Canada|Amsterdam, Netherlands|Hoofddorp, Netherlands|Nieuwegein, Netherlands|Tiel, Netherlands|Veldhoven, Netherlands|Zwolle, Netherlands|Córdoba, Spain",,"https://ClinicalTrials.gov/show/NCT01327105"
799,"NCT01322438","Effect of Rifampin on the Pharmacokinetics of BAY73-4506",,"Completed","No Results Available","Neoplasms","Drug: Regorafenib (BAY73-4506) + rifampin","Pharmacokinetic profile|Proportion of subjects with adverse event collection","Bayer","Male","18 Years to 45 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","15524","March 2011","June 2011","June 2011","March 24, 2011",,"December 19, 2014","Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01322438"
800,"NCT01320709","Effect of Piroxicam on Ovulation",,"Completed","No Results Available","Contraception, Postcoital","Drug: Piroxicam ( BAYl1902)|Drug: Placebo","Effect of piroxicam on ovulation (delay or inhibition) when given after the onset of LH surge|course of follicle sizes|course of gonadotropins (follicle-stimulating hormone [FSH], LH) and ovarian steroids (estradiol [E2], progesterone)|Concentration-times courses of piroxicam","Bayer","Female","18 Years to 35 Years   (Adult)","Phase 2","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","14835|2010-021195-28","March 2011","March 2012","May 2012","March 22, 2011",,"July 10, 2015","Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT01320709"
801,"NCT01318551","Single Dose Group Stratified Study in Renal Impaired and Healthy Aged and Gender Matched Subjects",,"Completed","No Results Available","Anemia","Drug: BAY85-3934","Number of participants with adverse events|Area under the plasma concentration versus time curve (AUC) of BAY85-3934|Peak Plasma Concentration (Cmax) of BAY85-3934|Dose-normalized area under the plasma concentration-time curve (AUCnorm) of BAY85-3934|Dose- and body weight-normalised Cmax (Cmax-norm) of BAY85-3934","Bayer","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 1","56","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","15557|2011-000055-16","March 2011","September 2013","September 2013","March 18, 2011",,"October 13, 2014","Kiel, Schleswig-Holstein, Germany",,"https://ClinicalTrials.gov/show/NCT01318551"
802,"NCT01318265","Effect of Ketoconazole on Regorafenib (BAY73-4506) Pharmacokinetics",,"Completed","No Results Available","Pharmacokinetics","Drug: Regorafenib (BAY73-4506); Regorafenib (BAY73-4506) plus ketoconazole","Area under the plasma concentration versus time curve from zero to infinity ( Plasma AUCinf) of BAY73-4506 given alone or with ketoconazole.|Peak plasma concentration (Cmax) of BAY73-4506 given alone or with ketoconazole|Plasma AUCinf of metabolites of a single oral dose BAY73-4506 given alone or with ketoconazole.|Plasma Cmax of metabolites of a single oral dose BAY73-4506 given alone or with ketoconazole.|Number of subjects with adverse events following a single oral dose of BAY73-4506, adminstered alone and concomitantly with ketoconazole.","Bayer","Male","18 Years to 45 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","12435","March 2011","July 2011","July 2011","March 18, 2011",,"November 3, 2014","Brighton, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01318265"
803,"NCT01311648","BAY81-8973 Pediatric Safety and Efficacy Trial",,"Active, not recruiting","No Results Available","Haemophilia A","Biological: Recombinant Factor VIII (Kovaltry, BAY81-8973)","Annualized number of bleeds within 48 hours (h) after a prophylaxis injection|Incidence of inhibitory antibody|Total annualized consumption of FVIII per subject|Number of infusions for the treatment of a bleed|Recovery of FVIII after infusion|t1/2","Bayer","Male","up to 12 Years   (Child)","Phase 3","94","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13400|2010-021781-29","June 9, 2011","March 31, 2021","March 31, 2021","March 9, 2011",,"January 21, 2020","New Orleans, Louisiana, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Bahía Blanca, Buenos Aires, Argentina|Plovdiv, Bulgaria|Varna, Bulgaria|Edmonton, Alberta, Canada|Hamilton, Ontario, Canada|Toronto, Ontario, Canada|Århus N, Denmark|Budapest, Hungary|Debrecen, Hungary|Mohacs, Hungary|Crumlin, Dublin, Ireland|Ramat Gan, Israel|Roma, Lazio, Italy|Milano, Lombardia, Italy|Bari, Puglia, Italy|Catania, Sicilia, Italy|Padova, Veneto, Italy|Riga, Latvia|Vilnius, Lithuania|Guadalajara, Jalisco, Mexico|San Juan del Río, Querétaro, Mexico|Oaxaca, Mexico|Oslo, Norway|Lodz, Poland|Warszawa, Poland|Wroclaw, Poland|Bucharest, Romania|Bucharest, Romania|Cluj-Napoca, Romania|Timisoara, Romania|Kazan, Russian Federation|Kirov, Russian Federation|Volgograd, Russian Federation|Esplugues de LLobregat, Barcelona, Spain|A Coruña, Spain|Alicante, Spain|Cáceres, Spain|Madrid, Spain|Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT01311648"
804,"NCT01303783","Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension","DISTINCT","Completed","No Results Available","Hypertension, Essential","Drug: Candesartan cilexetil (Atacand), 4 mg|Drug: Candesartan cilexetil (Atacand), 8 mg|Drug: Nifedipine GITS (Adalat, BAYA1040), 20 mg|Drug: Nifedipine GITS (Adalat, BAYA1040), 30 mg|Drug: Nifedipine GITS (Adalat, BAYA1040), 60 mg|Drug: Placebo|Drug: Candesartan cilexetil (Atacand), 16 mg|Drug: Candesartan cilexetil (Atacand), 32 mg","The primary efficacy variable is the change from baseline in mean seated diastolic blood pressure (MSDBP) at Week 8|Change in mean seated systolic blood pressure (MSSBP) at Week 8|Control rate at Week 8|Response rate at Week 8|Peripheral Edema|Time to achieve first BP control","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","1381","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","14725|2009-017077-37","April 2011","May 2012","May 2012","February 25, 2011",,"April 18, 2017","Mobile, Alabama, United States|Los Angeles, California, United States|Coral Gables, Florida, United States|Deerfield Beach, Florida, United States|Deerfield Beach, Florida, United States|Ft. Lauderdale, Florida, United States|Jacksonville, Florida, United States|West Palm Beach, Florida, United States|Atlanta, Georgia, United States|Valparaiso, Indiana, United States|Charlotte, North Carolina, United States|Harrisburg, North Carolina, United States|Raleigh, North Carolina, United States|Salisbury, North Carolina, United States|Cincinnati, Ohio, United States|Philadelphia, Pennsylvania, United States|Greenville, South Carolina, United States|Mt. Pleasant, South Carolina, United States|Dallas, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Salt Lake City, Utah, United States|Kenosha, Wisconsin, United States|Bahía Blanca, Buenos Aires, Argentina|Quilmes, Buenos Aires, Argentina|Zárate, Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Rosario, Santa Fe, Argentina|Corrientes, Argentina|Córdoba, Argentina|Córdoba, Argentina|Santa Fe, Argentina|Wetteren, Oost-Vlaanderen, Belgium|De Pinte, Belgium|Deurne, Belgium|HAM, Belgium|Fortaleza, Ceará, Brazil|Brasília, Distrito Federal, Brazil|Goiania, Goiás, Brazil|Campinas, Sao Paulo, Brazil|Campinas, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|Rio de Janeiro, Brazil|Sao Paulo, Brazil|Langley, British Columbia, Canada|St. John's, Newfoundland and Labrador, Canada|St. John's, Newfoundland and Labrador, Canada|Brampton, Ontario, Canada|Corunna, Ontario, Canada|Downsview, Ontario, Canada|Etobicoke, Ontario, Canada|London, Ontario, Canada|London, Ontario, Canada|Newmarket, Ontario, Canada|Sarnia, Ontario, Canada|Strathroy, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Chieti, Abruzzo, Italy|Bologna, Emilia-Romagna, Italy|Trieste, Friuli-Venezia Giulia, Italy|Milano, Lombardia, Italy|Pavia, Lombardia, Italy|Sassari, Sardegna, Italy|Pisa, Toscana, Italy|Perugia, Umbria, Italy|Mercato San Severino, Italy|Daejeon, Daejeon Gwang''yeogsi, Korea, Republic of|Wonju-si, Gang''weondo, Korea, Republic of|Anyang-si, Gyeonggido, Korea, Republic of|Goyang-Si, Gyeonggido, Korea, Republic of|Goyang-si, Gyeonggido, Korea, Republic of|Goyang-si, Gyeonggido, Korea, Republic of|Goyang-si, Gyeonggido, Korea, Republic of|Uijeongbu, Gyeonggido, Korea, Republic of|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Busan, Korea, Republic of|Chungchungbuk-do, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Alytus, Lithuania|Kaunas, Lithuania|Kaunas, Lithuania|Vilnius, Lithuania|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Smolensk, Russian Federation|St Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|Port Elizabeth, Eastern Cape, South Africa|Johannesburg, Gauteng, South Africa|Petoria, Gauteng, South Africa|Roodepoort, Gauteng, South Africa|Durban, KwaZulu Natal, South Africa|Witbank, Mpumalanga, South Africa|Somerset West, Western Cape, South Africa|Stellenbosch, Western Cape, South Africa|Santiago de Compostela, A Coruña, Spain|Benidorm, Alicante, Spain|Petrer, Alicante, Spain|Oviedo, Asturias, Spain|Hostalets de Balenyà, Barcelona, Spain|Peralada, Girona, Spain|Barcelona, Spain|Granada, Spain|Huelva, Spain|Valencia, Spain|Dnipropetrovsk, Ukraine|Kharkiv, Ukraine|Kiev, Ukraine|Kiev, Ukraine|Kiev, Ukraine|Kiev, Ukraine|Kiev, Ukraine|Vinnitsa, Ukraine|Zaporizhzhya, Ukraine|Zhytomyr, Ukraine|Bath, Avon, United Kingdom|Fowey, Cornwall, United Kingdom|Penzance, Cornwall, United Kingdom|Penzance, Cornwall, United Kingdom|St Austell, Cornwall, United Kingdom|Chesterfield, Derbyshire, United Kingdom|Glasgow, Glasgow City, United Kingdom|Glasgow, Glasgow City, United Kingdom|Blackpool, Lancashire, United Kingdom|Bath, Somerset, United Kingdom|Addlestone, Surrey, United Kingdom|Coventry, Warwickshire, United Kingdom|Leamington Spa, Warwickshire, United Kingdom|Chippenham, Wiltshire, United Kingdom|Trowbridge, Wiltshire, United Kingdom|Westbury, Wiltshire, United Kingdom|Bath, United Kingdom|Bath, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01303783"
805,"NCT01297530","Clinical Study to Evaluate the Maximum Tolerated Dose of BAY87-2243 in Patients With Advanced Malignancies",,"Terminated","No Results Available","Neoplasms","Drug: BAY87-2243","Frequency of adverse events|Maximum tolerated dose, measured by adverse event profile|Plasma concentrations of BAY87-2243, measured by Cmax, tmax, AUC(0-tn), AUC and half-life|Biomarkers evaluation (analysis of carbonic anhydrase 9 and VEGF in plasma)|Tumor response evaluation based on RECIST 1.1 every 2 cycles","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","5","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15044|2010-023403-10","April 2011","July 2012","July 2012","February 16, 2011",,"July 30, 2013","Freiburg, Baden-Württemberg, Germany|Oslo, Norway|Sutton, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01297530"
806,"NCT01295294","Management of Initial Bleeding/Spotting Associated With the Levonorgestrel-releasing Intrauterine System (MIRENA)",,"Completed","No Results Available","Uterine Hemorrhage","Drug: Tranexamic acid|Drug: Mefenamic acid|Drug: Placebo|Drug: Mirena (Levonorgestrel IUS, BAY86-5028)","The primary efficacy variable will be the cumulative number of bleeding / spotting days|To describe and compare the bleeding patterns observed in women during treatment period|To describe and compare the bleeding patterns observed in women during follow-up period|Satisfaction with oral blinded study drug treatment for bleeding / spotting|Occurrence of dysmenorrhea|Continuation rate with study drug|Continuation rate with Mirena|Adverse Events Collection|Number of spotting-only days|Number of bleeding / spotting episodes|Length of bleeding / spotting episodes|Number of bleeding days with heavy intensity|Change in the number of B/S days between Day 60 and Day 90 of MIRENA use and the 30-day follow-up period|Satisfaction with levonorgestrel-releasing intrauterine system|Number of days of pain medication for dysmenorrhea during the 90 day treatment period|Number of bleeding-only days","Bayer","Female","18 Years to 45 Years   (Adult)","Phase 4","187","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15105|2010-020922-16","March 2011","December 2011","December 2011","February 14, 2011",,"November 4, 2014","København NV, Denmark|Odense C, Denmark|Skive, Denmark|Søborg, Denmark|Ålborg, Denmark|Århus C, Denmark|Mallow, Cork, Ireland|Blackrock, Dublin, Ireland|Cork, Ireland|Elverum, Norway|Haugesund, Norway|Trondheim, Norway",,"https://ClinicalTrials.gov/show/NCT01295294"
807,"NCT01294215","High Dose BAYA1040_Nifedipine: a Long Term Combination Study",,"Completed","No Results Available","Hypertension","Drug: Nifedipine (Adalat, BAYA1040)","Efficacy changes measured by sitting diastolic blood pressure (DBP)|Efficacy changes measured by sitting systolic blood pressure (SBP)|Proportion of subjects achieving a target BP based on the Japanese Society of Hypertension (JSH) 2009 guidelines|Proportion of subjects achieving a target DBP and SBP based on JSH 2009 guidelines or a >10 mmHg reduction of DBP|Safety variables","Bayer","All","20 Years and older   (Adult, Older Adult)","Phase 3","72","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14024","February 2011","November 2011","June 2012","February 11, 2011",,"June 23, 2014","Ebina, Kanagawa, Japan|Sagamihara, Kanagawa, Japan|Kawaguchi, Saitama, Japan|Shinjuku, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT01294215"
808,"NCT01289821","First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib",,"Completed","Has Results","Colorectal Neoplasms","Drug: Regorafenib (Stivarga, BAY73-4506)|Drug: Oxaliplatin|Drug: Folinic acid|Drug: 5-FU (mFOLFOX6)","Objective Response (OR)|Overall Survival (OS)|Progression-free Survival (PFS)|Disease Control (DC)|Duration of Response (DOR)|Duration of Stable Disease (DOSD)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","54","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11728|2010-020121-41","February 2011","March 2012","June 2014","February 4, 2011","September 4, 2013","March 15, 2017","Chicago, Illinois, United States|Concord, New South Wales, Australia|Woodville South, South Australia, Australia|Bruxelles - Brussel, Belgium|Edegem, Belgium|Leuven, Belgium|Stuttgart, Baden-Württemberg, Germany|Oldenburg, Niedersachsen, Germany|Herne, Nordrhein-Westfalen, Germany|Dresden, Sachsen, Germany|Napoli, Campania, Italy|Genova, Liguria, Italy|Ancona, Marche, Italy|Santander, Cantabria, Spain|Barcelona, Spain|Madrid, Spain|Glasgow, United Kingdom|Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01289821"
809,"NCT01287598","BAY73-4506 Probe Substrate Study",,"Completed","No Results Available","Neoplasms","Drug: Regorafenib (Stivarga, BAY73-4506)|Drug: Warfarin|Drug: Omeprazole|Drug: Midazolam|Drug: Rosiglitazone","Pharmacokinetics of probe substrates (AUC, Cmax, etc.)|Tumor Response evaluation measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1)|Adverse event collection","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","41","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12434","August 2, 2011","July 3, 2018","July 30, 2018","February 1, 2011",,"July 10, 2019","Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Agency-Vancouver Centre, Vancouver, British Columbia, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01287598"
810,"NCT01287260","High Dose BAYA1040_Nifedipine: a Dose-comparative Study",,"Completed","No Results Available","Hypertension","Drug: Nifedipine (Adalat, BAYA1040)","Efficacy changes measured by sitting diastolic blood pressure (DBP)|Efficacy changes measured by sitting systolic blood pressure (SBP)|Achievement rate: Proportion of subjects achieving a target BP based on the Japanese Society of Hypertension (JSH) 2009 guidelines|Responder rate: Proportion of subjects achieving a target DBP and SBP based on JSH 2009 guidelines or a &gt;10 mmHg reduction of DBP","Bayer","All","20 Years and older   (Adult, Older Adult)","Phase 3","352","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","13176","January 2011","August 2011","August 2011","February 1, 2011",,"January 29, 2014","Hirosaki, Aomori, Japan|Kamagaya, Chiba, Japan|Asahikawa, Hokkaido, Japan|Asahikawa, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Kawasaki, Kanagawa, Japan|Daito, Osaka, Japan|Kishiwada, Osaka, Japan|Yao, Osaka, Japan|Tokorozawa, Saitama, Japan|Hachioji, Tokyo, Japan|Meguro, Tokyo, Japan|Minato, Tokyo, Japan|Minato, Tokyo, Japan|Shizuoka, Japan",,"https://ClinicalTrials.gov/show/NCT01287260"
811,"NCT01283724","Visanne Study to Assess Safety in Adolescents","VISADO","Completed","No Results Available","Endometriosis","Drug: Dienogest (Visanne, BAY86-5258)","Relative change in bone mineral density (BMD) of the lumbar spine as assessed by dual energy X-ray absorptiometry (DEXA)|Relative Percent Change From Baseline in Whole Body Bone Mineral Density (BMD) at Week 52 Assessed by Dual-Energy X-ray Absorptiometry (DEXA)|Change From Baseline in Spinal Lumbar Vertebrae 2 to 4 (L2-L4) Z scores at week 52|Change From Baseline in Whole Body Z-scores at Week 52|Percentage of Responders at Week 24|Change From Baseline in Pelvic Pain Over 52 Weeks Using Modified Biberoglu and Behrman Severity Profile|Change From Baseline in Dysmenorrhea Over 52 Weeks Using Modified Biberoglu and Behrman Severity Profile|Percentage of Subjects With Pelvic Pain Over 52 Weeks Using Modified Biberoglu and Behrman Severity Profile|Percentage of Subjects With Dysmenorrhea Over 52 Weeks Using Modified Biberoglu and Behrman Severity Profile|Percentage of Subjects With Dyspareunia Over 52 Weeks Using Modified Biberoglu and Behrman Severity Profile|Percentage of Subjects With Pelvic Tenderness Over 52 Weeks Using Modified Biberoglu and Behrman Severity Profile|Percentage of Subjects With Induration Over 52 Weeks Using Modified Biberoglu and Behrman Severity Profile|Percentage of Subjects With Clinical Global Impression (CGI) Scores - Assessed by the Investigator|Percentage of Subjects With Clinical Global Impression (CGI) Scores -Assessed by the Subject","Bayer","Female","12 Years to 17 Years   (Child)","Phase 2","111","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13788|2009-017169-53","March 2011","March 2013","June 2014","January 26, 2011",,"August 13, 2015","St. Pölten, Niederösterreich, Austria|Linz, Oberösterreich, Austria|Graz, Steiermark, Austria|Graz, Austria|Innsbruck, Austria|Wien, Austria|Wien, Austria|Brno, Czech Republic|Ceske Budejovice, Czech Republic|Pisek, Czech Republic|Praha 2, Czech Republic|Praha, Czech Republic|Espoo, Finland|Helsinki, Finland|Turku, Finland|Angers Cedex 01, France|Le Kremlin Bicetre, France|Paris, France|Rouen, France|Erlangen, Bayern, Germany|Oldenburg, Niedersachsen, Germany|Westerstede, Niedersachsen, Germany|Münster, Nordrhein-Westfalen, Germany|Lübeck, Schleswig-Holstein, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Hamburg, Germany|Benidorm, Alicante, Spain|Vigo, Pontevedra, Spain|Sevilla, Spain|Sevilla, Spain|Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT01283724"
812,"NCT01280591","Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain","Morpheus II","Completed","Has Results","Pain, Postoperative","Drug: Naproxen sodium 440 mg / DPH 50 mg (BAY98-7111)|Drug: Naproxen sodium 220 mg / DPH 50 mg (BAY98-7111)|Drug: Naproxen sodium 440 mg (BAYH6689)|Drug: DPH 50 mg","Wake Time After Sleep Onset (WASO) Measured by Actigraphy|Sleep Latency Measured by Actigraphy|Total Sleep Time Measured by Actigraphy|Sleep Efficiency Measured by Actigraphy|Global Assessment of Investigational Product as a Sleep Aid|Karolinska Sleep Diary - Sleep Quality|Karolinska Sleep Diary - Calmness of Sleep|Karolinska Sleep Diary - Easiness to Fall Asleep|Karolinska Sleep Diary - Premature Awakening|Karolinska Sleep Diary - Ease of Awakening|Karolinska Sleep Diary - Well Rested|Karolinska Sleep Diary - Sufficient Sleep|Subjective Sleep Questionnaire - Quality of Your Sleep Last Night|Subjective Sleep Questionnaire - Refreshing Nature of Your Sleep Last Night|Subjective Sleep Questionnaire - Time to Fall Asleep Last Night|Subjective Sleep Questionnaire - Number of Minutes You Think That You Were Awake From the Time You Fell Asleep Until the Time You Got Out of Bed|Change From Baseline in Pain Intensity|Overall Rating of Pain Relief|Time to Rescue Medication|Cumulative Proportion of Subjects Taking Rescue Medication by Hour|Global Assessment of Investigational Product as a Pain Reliever","Bayer","All","12 Years to 45 Years   (Child, Adult)","Phase 3","712","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","14837","October 2010","January 2011","February 2011","January 21, 2011","June 17, 2014","June 8, 2015","Austin, Texas, United States|Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01280591"
813,"NCT01271712","Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)","GRID","Completed","Has Results","Gastrointestinal Stromal Tumors","Drug: Regorafenib (Stivarga, BAY73-4506)|Drug: Placebo|Drug: Best supportive care","Progression-free Survival|Overall Survival|Time to Progression (TTP)|Tumor Response|Objective Response Rate|Disease Control Rate (DCR)|Duration of Response (DOR)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","199","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","14874|2009-017957-37","January 4, 2011","January 26, 2012","April 15, 2019","January 7, 2011","October 25, 2013","May 21, 2019","Scottsdale, Arizona, United States|Evanston, Illinois, United States|Skokie, Illinois, United States|Boston, Massachusetts, United States|Minneapolis, Minnesota, United States|New York, New York, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Seattle, Washington, United States|Graz, Steiermark, Austria|Innsbruck, Austria|Wien, Austria|Leuven, Belgium|Edmonton, Alberta, Canada|London, Ontario, Canada|Toronto, Ontario, Canada|Guangzhou, Guangdong, China|Nanjing, Jiangsu, China|Beijing, China|Shanghai, China|HUS, Finland|Bordeaux Cedex, France|Lille Cedex, France|Lyon Cedex 08, France|Villejuif, France|Mannheim, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|Bad Saarow, Brandenburg, Germany|Hannover, Niedersachsen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Tel Aviv, Israel|Bologna, Emilia-Romagna, Italy|Milano, Lombardia, Italy|Torino, Piemonte, Italy|Palermo, Sicilia, Italy|Nagoya, Aichi, Japan|Kashiwa, Chiba, Japan|Sapporo, Hokkaido, Japan|Chuo-ku, Tokyo, Japan|Niigata, Japan|Osaka, Japan|Goyang-si, Gyeonggido, Korea, Republic of|Busan, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Leiden, Netherlands|Nijmegen, Netherlands|Warszawa, Poland|Singapore, Singapore|L'Hospitalet de Llobregat, Barcelona, Spain|Barcelona, Spain|Leicester, Leicestershire, United Kingdom|London, United Kingdom|Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01271712"
814,"NCT01260870","European Study of POBA Versus Cotavance(R) Paclitaxel Coated Balloon for the Treatment of Infrapopliteal Lesions in Critical Limb Ischemia (EURO CANAL)",,"Terminated","No Results Available","PAD","Device: Cotavance Paclitaxel Coated Balloon|Device: Standard balloon angioplasty","Evaluate procedural safety|Identify and characterize therapeutic and functional endpoint assessments","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","44","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EURO CANAL","August 2011","July 2013","July 2013","December 15, 2010",,"July 3, 2015","Graz, Austria|Dendermonde, Belgium|Gent, Belgium|Bern, Switzerland|Zurich, Switzerland|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01260870"
815,"NCT01258660","Assessment of the Pharmacodynamic Effect on Plasma Folate and Red Blood Cell Folate and Comparison of the Folate Metabolites During the 24 Weeks of Treatment (Yasmin + Metafolin Versus Yasmin + Folic Acid) Followed by a 20 Week Elimination Phase of Folate",,"Completed","Has Results","Contraception","Drug: EE 0.03 mg/DRSP 3 mg/Metafolin + folic acid placebo|Drug: EE 0.03 mg/DRSP 3 mg (Yasmin) + folic acid","Area Under the Curve (AUC) From Time 0 to 24 Weeks [AUC(0-24weeks)] for Plasma Folate and RBC (Red Blood Cell) Folate (Baseline Uncorrected)|Area Under the Curve From Time 0 to 24 Weeks [AUC(0-24weeks)] for Plasma Folate and RBC (Red Blood Cell) Folate (Baseline Corrected)|Proportion of Participants With RBC Folate Below 906 Nmol/L in the Yasmin + Metafolin Group in the Folate Elimination Phase (Week 24 to 44)|Folate Metabolite Pattern in Plasma at Baseline|Folate Metabolite Pattern in Plasma at Cycle 3|Folate Metabolite Pattern in Plasma at Cycle 6|Homocysteine Concentrations in Plasma at Baseline and at the End of Treatment (Week 24) With Metafolin|Homocysteine Concentrations in Plasma at Baseline and at the End of Treatment (Week 24) With Folic Acid","Bayer","Female","18 Years to 40 Years   (Adult)","Phase 1","172","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","91509|2006-003522-29|309763","December 2006","January 2008","January 2008","December 13, 2010","May 13, 2011","September 20, 2013","Nuvisan GmbH, Neu-Ulm, Bayern, Germany",,"https://ClinicalTrials.gov/show/NCT01258660"
816,"NCT01257984","Study to Investigate Compliance With the Oral Contraceptive SH T00186D in a Flexible Extended Regimen Supported by a Dispenser With a Reminder Function",,"Completed","No Results Available","Contraception","Drug: BAY86-5300","Mean daily delay of tablet release, i.e. the time of tablet-release which will be compared to the reference tablet release time|Number of delayed and missed pills|Bleeding pattern and cycle control parameters|Length of the tablet break and the length of the bleeding episode preceding the tablet break","Bayer","Female","18 Years to 35 Years   (Adult)","Phase 3","508","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14701|2010-019902-17","December 2010","August 2012","September 2012","December 10, 2010",,"October 28, 2014","Biarritz, France|Marly Le Roi, France|Nancy, France|Olivet, France|Paris, France|Paris, France|Paris, France|Paris, France|Strasbourg, France|Toulouse, France|Heidelberg, Baden-Württemberg, Germany|Frankfurt, Hessen, Germany|Wuppertal, Nordrhein-Westfalen, Germany|Blankenburg, Sachsen-Anhalt, Germany|Burg, Sachsen-Anhalt, Germany|Magdeburg, Sachsen-Anhalt, Germany|Gera, Thüringen, Germany|Kahla, Thüringen, Germany|Hamburg, Germany|Bologna, Italy|Brescia, Italy|Cagliari, Italy|Catania, Italy|Milano, Italy|Modena, Italy|Napoli, Italy|Palermo, Italy|Pavia, Italy|Pisa, Italy|Roma, Italy|Siena, Italy|Elda, Alicante, Spain|Boadilla del Monte, Madrid, Spain|Barcelona, Spain|Córdoba, Spain|Málaga, Spain|Chesterfield, Derbyshire, United Kingdom|Nottingham, Nottinghamshire, United Kingdom|Bath, Somerset, United Kingdom|East Horsley, Surrey, United Kingdom|Bradford-on-Avon, Wiltshire, United Kingdom|Corsham, Wiltshire, United Kingdom|Cardiff, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01257984"
817,"NCT01257919","Safety and Pharmacokinetics of Azelaic Acid Foam, 15% in Papulopustular Rosacea",,"Completed","No Results Available","Papulopustular Rosacea","Drug: Azelaic Acid Foam|Drug: Azelaic Acid Gel","Baseline corrected area under the curve (AUC)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","21","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","15386|1401843","January 2011","March 2011","March 2011","December 10, 2010",,"February 21, 2014","Novum Pharmaceutical Research Services of Nevada Inc., Las Vegas, Nevada, United States",,"https://ClinicalTrials.gov/show/NCT01257919"
818,"NCT01254292","LCS12 vs Combined Oral Contraceptive (COC) User Satisfaction Study",,"Completed","Has Results","Contraception","Drug: Levonorgestrel IUD (LCS, BAY86-5028)|Drug: Yasmin (EE30/DRSP, BAY86-5131)","Overall Satisfaction Rate at 18 Months (Last Observation Carried Forward, LOCF)|Overall Satisfaction Rating by the 5-point Likert Item at 6 Months|Overall Satisfaction Rating by the 5-point Likert Item at 12 Months|Overall Satisfaction Rating by the 5-point Likert Item at 18 Months|Overall Satisfaction Rating by the 5-point Likert Item at End of Study (EOS)|Overall Satisfaction Rate at 6 Months (LOCF)|Overall Satisfaction Rate at 12 Months (LOCF)|User Satisfaction - Acceptability of the Administration of Study Treatment|User Satisfaction - Choices Upon Completion of the Study|User Satisfaction - Amount of Menstrual Bleeding|User Satisfaction - Satisfaction With Menstrual Bleeding Pattern|User Satisfaction - Frequency of Experiencing Unexpected Bleeding|User Satisfaction - Satisfaction With Menstrual Bleeding Absence|User Satisfaction - Comparison of Menstrual Pain Intensity Between Now and Before Treatment|User Satisfaction - Rating of Usual Menstrual Pain Intensity|EVAPIL-R Scores at Screening - Composite Score|EVAPIL-R Scores at Screening - Bother Score|EVAPIL-R Scores at 6 Months|EVAPIL-R Scores at 12 Months - Bother Score|EVAPIL-R Scores at 12 Months - Composite Score|EVAPIL-R Scores at 18 Months/EOS|Cumulative Drop-out Rate|Pearl Index (PI)|Compliance Rate for Yasmin Pill Intake","Bayer","Female","18 Years to 29 Years   (Adult)","Phase 3","567","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","13362|2010-020181-21","January 6, 2011","January 8, 2013","May 28, 2014","December 6, 2010","April 7, 2014","September 25, 2017","Visions Clinical Research - Tucson, Tucson, Arizona, United States|Tucson, Arizona, United States|Grossmont Center for Clinical Research, La Mesa, California, United States|La Mesa, California, United States|Genesis Center for Clinical Research, San Diego, California, United States|San Diego, California, United States|Medical Center for Clinical Research, San Diego, California, United States|San Diego, California, United States|Visions Clinical Research, Boynton Beach, Florida, United States|Boynton Beach, Florida, United States|Boston Medical Center, Boston, Massachusetts, United States|Boston, Massachusetts, United States|Women's Clinic of Lincoln, PC, Lincoln, Nebraska, United States|Lincoln, Nebraska, United States|Columbus Center for Women's Health Research, Columbus, Ohio, United States|Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Portland, Oregon, United States|Clinical Research of Philadelphia, LLC, Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Advanced Research Associates, Corpus Christi, Texas, United States|Corpus Christi, Texas, United States|Seattle Women's: Health, Research, Gynecology, Seattle, Washington, United States|Seattle, Washington, United States|Ordination Dr. Schmidl-Amann, St. Pölten, Niederösterreich, Austria|St. Pölten, Niederösterreich, Austria|Dr. Max Stiglbauer, Wiener Neustadt, Niederösterreich, Austria|Wiener Neustadt, Niederösterreich, Austria|Ordination Dr. Trost, Voitsberg, Steiermark, Austria|Voitsberg, Steiermark, Austria|Landeskrankenhaus Bregenz, Bregenz, Vorarlberg, Austria|Bregenz, Vorarlberg, Austria|Praxis Dr. Hannes Kahr, Graz, Austria|Graz, Austria|Dr. Bernhard Svejda, Klagenfurt, Austria|Klagenfurt, Austria|Ordination Dr. Sator, Tulln, Austria|Tulln, Austria|Dr. Brigitte Wiesenthal, Wien, Austria|Wien, Austria|Dr. Wolfgang Bartl, Wien, Austria|Wien, Austria|Dr. Walter Paulik, Zeltweg, Austria|Zeltweg, Austria|Dr. Philip Loquet, Antwerpen, Belgium|Antwerpen, Belgium|Hôpital Erasme/Erasmus Ziekenhuis, Bruxelles-brussel, Belgium|Bruxelles-brussel, Belgium|Gynaecologen Noord Antwerpen, Ekeren, Belgium|Ekeren, Belgium|UZ Gent, Gent, Belgium|Gent, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Leuven, Belgium|Praxis Hr. Dr. A. Soder, Ettlingen, Baden-Württemberg, Germany|Ettlingen, Baden-Württemberg, Germany|Praxis Hr. Dr. K. Greven, Hannover, Niedersachsen, Germany|Hannover, Niedersachsen, Germany|Praxis Hr. Dr. E. Goeckeler-Leopold, Geseke, Nordrhein-Westfalen, Germany|Geseke, Nordrhein-Westfalen, Germany|Evangelisches Krankenhaus Köln Weyertal gGmbH, Köln, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Praxis f. Gynäkologie und Geburtshilfe, Bernburg, Sachsen-Anhalt, Germany|Bernburg, Sachsen-Anhalt, Germany|Frauenarztpraxis Dr. Wetzel, Blankenburg, Sachsen-Anhalt, Germany|Blankenburg, Sachsen-Anhalt, Germany|Praxis Hr. H. Thelen, Jessen, Sachsen-Anhalt, Germany|Jessen, Sachsen-Anhalt, Germany|Praxis Fr. Dr. A. Braune, Magdeburg, Sachsen-Anhalt, Germany|Magdeburg, Sachsen-Anhalt, Germany|Frauenarztpraxis Dr. Robert Hantschel, Dippoldiswalde, Sachsen, Germany|Dippoldiswalde, Sachsen, Germany|Praxis Hr. Dr. U. Kopprasch, Dresden, Sachsen, Germany|Dresden, Sachsen, Germany|Frauenarztpraxis Dr. Bernd Pittner, Leipzig, Sachsen, Germany|Leipzig, Sachsen, Germany|Praxis Fr. C. Burgkhardt, Leipzig, Sachsen, Germany|Leipzig, Sachsen, Germany|Praxis Hr. Dr. D. Rautenberg, Hamburg, Germany|Hamburg, Germany|Praxis Hr. Dr. K. Peters, Hamburg, Germany|Hamburg, Germany|Praxis Hr. Dr. K. Buehling, Hamburg, Germany|Hamburg, Germany|Altai State Medical University, Barnaul, Russian Federation|Barnaul, Russian Federation|Scientific Center of family health & human reprod. problems, Irkutsk, Russian Federation|Irkutsk, Russian Federation|Instit. of Motherhood & Childhood care n.a. Gorodkov, Ivanovo, Russian Federation|Ivanovo, Russian Federation|City Perinatal Center, Novosibirsk, Russian Federation|Novosibirsk, Russian Federation|Institute of Obsteric & Gyn., St. Petersburg, Russian Federation|St. Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT01254292"
819,"NCT01253187","Investigation of Bioequivalence of Ethinylestradiol (EE) and Drospirenone (DRSP) in Two Different Tablet Formulations: YAZ and YAZ + Levomefolate Calcium (Metafolin) & L-5-MTHF in Two Different Tablet Formulations: Levomefolate Calcium (Metafolin) and YAZ + Levomefolate Calcium (Metafolin)",,"Completed","Has Results","Contraception","Drug: EE 0.02 mg/DRSP 3 mg (YAZ, BAY86-5300)|Drug: EE 0.02 mg/DRSP 3 mg/L-5-MTHF Ca 0.451 mg (EE20/DRSP/L-5-MTHF Ca)|Drug: L-5-MTHF 0.451mg (Metafolin)","Mean Maximum Concentration (Cmax) of EE Incl. Bioequivalence (BE) Evaluation|Mean Area Under the Concentration-time Curve From Administration to the Last Measurement [AUC(0-tlast)] of EE Incl. Bioequivalence (BE) Evaluation|Mean Maximum Concentration (Cmax) of DRSP Incl. Bioequivalence (BE) Evaluation|Mean Area Under the Concentration-time Curve From Administration to the Last Measurement [AUC(0-tlast)] of DRSP Incl. Bioequivalence (BE) Evaluation|Mean Maximum Concentration (Cmax) of L-5-methyl-THF (Baseline Corrected) Incl. Bioequivalence (BE) Evaluation|Mean Area Under the Concentration-time Curve From Administration to the Last Measurement [AUC(0-tlast)] of L-5-methyl-THF (Baseline Corrected) Incl. Bioequivalence (BE) Evaluation|Mean Maximum Concentration (Cmax) of L-5-methyl-THF (Baseline Uncorrected) Incl. Bioequivalence (BE) Evaluation|Mean Area Under the Concentration-time Curve From Administration to the Last Measurement [AUC(0-tlast)] of L-5-methyl-THF (Baseline Uncorrected) Incl. Bioequivalence (BE) Evaluation|Time to Reach Maximum Concentration (Tmax) of EE|Mean Area Under the Concentration-time Curve From Administration up to 72h AUC(0-72h) of DRSP|Time to Reach Maximum Concentration (Tmax) of DRSP|Time to Reach Maximum Concentration (Tmax) of L-5-methyl-THF","Bayer","Female","18 Years to 38 Years   (Adult)","Phase 1","44","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","91460|2005-003049-15|309664","October 2006","September 2007","September 2007","December 3, 2010","May 9, 2011","August 7, 2013","Dinox B.V., Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT01253187"
820,"NCT01253174","Investigation of Bioequivalence of Ethinylestradiol (EE) and Drospirenone (DRSP) in Two Different Tablet Formulations: Yasmin and Yasmin + Levomefolate Calcium (Metafolin) & L-5-MTHF in Two Different Tablet Formulations: Levomefolate Calcium (Metafolin) and Yasmin + Levomefolate Calcium (Metafolin)",,"Completed","Has Results","Contraception","Drug: EE 0.03 mg/DRSP 3 mg (Yasmin, BAY86-5131)|Drug: EE 0.03mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE30/DRSP/L-5-MTHF Ca)|Drug: L-5-MTHF Ca 0.451 mg (Metafolin)","Mean Maximum Concentration (Cmax) of EE Incl. Bioequivalence (BE) Evaluation|Mean Area Under the Concentration-time Curve From Administration to the Last Measurement [AUC(0-tlast)] of EE Incl. Bioequivalence (BE) Evaluation|Mean Maximum Concentration (Cmax) of DRSP Incl. Bioequivalence (BE) Evaluation|Mean Area Under the Concentration-time Curve (AUC) of DRSP Incl. Bioequivalence (BE) Evaluation|Mean Maximum Concentration (Cmax) of L-5-methyl-THF (Baseline Corrected) Incl. Bioequivalence (BE) Evaluation|Mean Area Under the Concentration-time Curve From Administration to the Last Measurement [AUC(0-tlast)] of L-5-methyl-THF (Baseline Corrected) Incl. Bioequivalence (BE) Evaluation|Mean Maximum Concentration (Cmax) of L-5-methyl-THF (Baseline Uncorrected) Incl. Bioequivalence (BE) Evaluation|Mean Area Under the Concentration-time Curve From Administration to the Last Measurement [AUC(0-tlast)] of L-5-methyl-THF (Baseline Uncorrected) Incl. Bioequivalence (BE) Evaluation|Time to Reach Maximum Concentration (Tmax) of EE|Mean Area Under the Concentration-time Curve From Administration up to 72h AUC(0-72h) of DRSP|Time to Reach Maximum Concentration (Tmax) of DRSP|Time to Reach Maximum Concentration (Tmax) of L-5-methyl-THF","Bayer","Female","18 Years to 38 Years   (Adult)","Phase 1","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","91457|2005-001913-16","August 2006","July 2007","July 2007","December 3, 2010","May 9, 2011","August 7, 2013","Scope International, Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT01253174"
821,"NCT01251640","Combination With Gemcitabine in Advanced Pancreatic Cancer","BAGPAC","Completed","No Results Available","Pancreatic Neoplasms","Drug: BAY86-9766+Gemcitabine","Number of Subjects With Dose Limiting Toxicities (DLT): Phase I|Tumor Response (Adjudicated Blinded Read Assessment): Phase II|Tumor Response: Investigator Assessment: Phase I|Disease Control (DC): Phase I|Disease Control (DC): Phase II|Duration of Response (DOR): Phase I|Duration of Response: Phase II|Time to Progression (TTP): Phase I|Time to Progression (TTP): Phase II|Progression-Free Survival (PFS): Phase I|Progression-Free Survival (PFS): Phase II|Overall Survival (OS): Phase I|Overall Survival (OS): Phase II","Bayer","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1|Phase 2","90","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14905|2010-019588-12","January 1, 2011","February 11, 2013","August 1, 2013","December 2, 2010",,"November 14, 2018","Aurora, Colorado, United States|Pittsfield, Massachusetts, United States|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Edegem, Belgium|Brno, Czechia|Olomouc, Czechia|CLERMONT-FERRAND Cedex 1, France|Heilbronn, Baden-Württemberg, Germany|München, Bayern, Germany|Marburg, Hessen, Germany|Bochum, Nordrhein-Westfalen, Germany|Berlin, Germany|Brescia, Lombardia, Italy|Ancona, Marche, Italy|Oslo, Norway|Oslo, Norway|Bialystok, Poland|Gdansk, Poland|Warszawa, Poland|London, United Kingdom|London, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01251640"
822,"NCT01249664","VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV)","Myrror","Completed","Has Results","Myopia, Pathological","Biological: VEGF Trap-Eye (BAY86-5321)|Procedure: No Drug","Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) From Baseline to Week 24 - Last Observation Carried Forward (LOCF)|Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS at Week 24 Using the LOCF Approach|Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by ETDRS From Baseline to Week 24 - Observed Cases|Percentage of Participants Who Gained at Least 10 Letters in BCVA at Week 24 - LOCF|Percentage of Participants Who Gained at Least 5 Letters in BCVA at Week 24 - LOCF|Percentage of Participants Who Gained at Least 15 Letters in BCVA at Week 48 - LOCF|Percentage of Participants Who Gained at Least 10 Letters in BCVA at Week 48 - LOCF|Percentage of Participants Who Gained at Least 5 Letters in BCVA at Week 48 - LOCF|Percentage of Participants Who Lost at Least 15 Letters in BCVA at Week 24 - LOCF|Percentage of Participants Who Lost at Least 10 Letters in BCVA at Week 24 - LOCF|Percentage of Participants Who Lost at Least 5 Letters in BCVA at Week 24 - LOCF|Percentage of Participants Who Lost at Least 15 Letters in BCVA at Week 48 - LOCF|Percentage of Participants Who Lost at Least 10 Letters in BCVA at Week 48 - LOCF|Percentage of Participants Who Lost at Least 5 Letters in BCVA at Week 48 - LOCF|Mean Change in Central Retinal Thickness (CRT) as Assessed by Optical Coherence Tomography (OCT) From Baseline to Week 24 - LOCF|Mean Change in Central Retinal Thickness (CRT) as Assessed by Optical Coherence Tomography (OCT) From Baseline to Week 48 - LOCF|Mean Change in Choroidal Neovascularization (CNV) Lesion Size as Assessed by Fluorescein Angiography (FA) From Baseline to Week 24 - LOCF|Mean Change in Choroidal Neovascularization (CNV) Lesion Size as Assessed by Fluorescein Angiography (FA) From Baseline to Week 48 - LOCF|Mean Change in European Five-dimensional Health Scale (EQ-5D) Score From Baseline to Week 24 - LOCF|Mean Change in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Total Score From Baseline to Week 24 - LOCF|Percentage of Participants Who Were Withdrawn From Study Drug During the First 24 Weeks|Mean Change in Area of Leakage From Baseline at Week 24 - LOCF","Bayer|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","122","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15170","December 2010","February 2013","August 2013","November 30, 2010","April 1, 2014","May 5, 2014","Kowloon, Hong Kong|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Urayasu, Chiba, Japan|Matsuyama, Ehime, Japan|Sendai, Miyagi, Japan|Suita, Osaka, Japan|Otsu, Shiga, Japan|Bunkyo-ku, Tokyo, Japan|Chiyoda-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Fukuoka, Japan|Fukushima, Japan|Kyoto, Japan|Osaka, Japan|Osaka, Japan|Seoul, Korea, Republic of|Singapore, Singapore|Taipei, Taiwan|Taoyuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT01249664"
823,"NCT01248481","GlucoFriend-evaluation the Effectiveness of Glucobay When Combined With a Basal Insulin",,"Completed","No Results Available","Diabetes Mellitus","Drug: Acarbose (Glucobay, BAYG5421)","Change in HbA1c|Duration and dose of acarbose treatment|Postprandial Blood Glucose","Bayer","All","18 Years and older   (Adult, Older Adult)",,"539","Industry","Observational","Time Perspective: Prospective","15316|GB1010KR","September 2010",,"July 2012","November 25, 2010",,"June 20, 2013","Many Locations, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01248481"
824,"NCT01235455","Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectors","POR-BetaPlus","Completed","No Results Available","Relapsing Remitting Multiple Sclerosis (RRMS)|Secondary Progressive Multiple Sclerosis (SPMS)","Drug: Interferon beta-1b (Betaseron, BAY86-5046)","Identification of reasons why patients are switched from other disease modifying drugs to Betaferon due to perceived lack of efficacy, adverse events, poor compliance, and others.|Assessment of factors predictive of non-adherence to disease modifying drugs such as demographic data, course of disease, drug history, patients characteristics, history of poor compliance to prior therapy or others.|Assessment of impact of supportive elements of the BetaPlus Program like nurse support, auto-injector, website, etc on treatment adherence.|Evaluation of impact of Betaferon treatment on health related quality of life using the Functional Assessment of Multiple Sclerosis Questionnaire - FAMS.|Assessment of coping processes by applying the Ways of Coping Questionnaire.|Measurement of safety of Betaferon by assessing the number of participants with adverse events and severe adverse events. Classification by MedDRA category.","Bayer","All","18 Years and older   (Adult, Older Adult)",,"10","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14235|BF0710PT","August 2007",,"May 2011","November 5, 2010",,"November 1, 2012","Many Locations, Portugal",,"https://ClinicalTrials.gov/show/NCT01235455"
825,"NCT01234337","Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer",,"Completed","Has Results","Breast Cancer","Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Placebo|Drug: Capecitabine","Progression-free Survival (PFS) Assessed by the Independent Review Panel According to Response Evaluation Criteria for Solid Tumors (RECIST) 1.1|Overall Survival (OS)|Time to Progression (TTP) by Central Review|Objective Response Rate (ORR) by Central Review|Disease Control Rate (DCR) by Central Review|Duration of Response (DOR) by Central Reader","Bayer|Onyx Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","537","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12444|2010-018501-10","February 21, 2011","May 12, 2014","October 20, 2017","November 4, 2010","September 3, 2015","November 6, 2018","Greenbrae, California, United States|Sylmar, California, United States|West Palm Beach, Florida, United States|Joliet, Illinois, United States|Evansville, Indiana, United States|Louisville, Kentucky, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Jackson, Mississippi, United States|Springfield, Missouri, United States|Albuquerque, New Mexico, United States|Lake Success, New York, United States|Durham, North Carolina, United States|Philadelphia, Pennsylvania, United States|Bristol, Tennessee, United States|Memphis, Tennessee, United States|El Paso, Texas, United States|Burlington, Vermont, United States|Madison, Wisconsin, United States|Mar del Plata, Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Garran, Australian Capital Territory, Australia|Liverpool, New South Wales, Australia|Waratah, New South Wales, Australia|Adelaide, South Australia, Australia|Bendigo, Victoria, Australia|Frankston, Victoria, Australia|Perth, Western Australia, Australia|Linz, Oberösterreich, Austria|Wien, Austria|Liege, Liège, Belgium|Brugge, Belgium|Bruxelles - Brussel, Belgium|Edegem, Belgium|Hasselt, Belgium|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Shenyang, Liaoning, China|Beijing, China|Beijing, China|Nanning, China|Shanghai, China|Tianjin, China|Xi'an, China|Ceske Budejovice, Czechia|Nova Ves Pod Plesi, Czechia|Nymburk, Czechia|Olomouc, Czechia|Praha 10, Czechia|Praha 2, Czechia|Praha 5, Czechia|Praha 5, Czechia|Clermont Ferrand Cedex 1, France|Lille, France|Nantes, France|Saint Cloud, France|Toulouse, France|Erlangen, Bayern, Germany|Frankfurt, Hessen, Germany|Offenbach, Hessen, Germany|Köln, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Stendal, Sachsen-Anhalt, Germany|Leipzig, Sachsen, Germany|Berlin, Germany|Athens, Greece|Heraklion, Greece|Ioannina, Greece|Larissa, Greece|Patras, Greece|Budapest, Hungary|Nyiregyhaza, Hungary|Pecs, Hungary|Szentes, Hungary|Szolnok, Hungary|Cork, Ireland|Dublin, Ireland|Dublin, Ireland|Dublin, Ireland|Dublin, Ireland|Galway, Ireland|Beer Sheva, Israel|Haifa, Israel|Haifa, Israel|Jerusalem, Israel|Jerusalem, Israel|Petah Tikva, Israel|Ramat Gan, Israel|Bologna, Emilia-Romagna, Italy|Forlì-Cesena, Emilia-Romagna, Italy|Modena, Emilia-Romagna, Italy|Ravenna, Emilia-Romagna, Italy|Roma, Lazio, Italy|Cremona, Lombardia, Italy|Milano, Lombardia, Italy|Monza-Brianza, Lombardia, Italy|Ancona, Marche, Italy|Palermo, Sicilia, Italy|Pisa, Toscana, Italy|Nagoya, Aichi, Japan|Matsuyama, Ehime, Japan|Suita, Osaka, Japan|Hidaka, Saitama, Japan|Kita-Adachigun, Saitama, Japan|Bunkyo, Tokyo, Japan|Koto-ku, Tokyo, Japan|Chiba, Japan|Fukuoka, Japan|Kagoshima, Japan|Osaka, Japan|Gdansk, Poland|Gdynia, Poland|Poznan, Poland|San Juan, Puerto Rico|Chelyabinsk, Russian Federation|Kazan, Russian Federation|Port Elizabeth, Eastern Cape, South Africa|Johannesburg, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Santiago de Compostela, A Coruña, Spain|Sabadell, Barcelona, Spain|Terrassa, Barcelona, Spain|Castellón de la Plana, Castellón, Spain|Palma de Mallorca, Illes Baleares, Spain|Reus, Tarragona, Spain|A Coruña, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Lleida, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Palma de Mallorca, Spain|Sevilla, Spain|Sevilla, Spain|Valencia, Spain|Valencia, Spain|Valencia, Spain|Stockholm, Sweden|Stockholm, Sweden|Truro, Cornwall, United Kingdom|Nottingham, Nottinghamshire, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Northwood, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01234337"
826,"NCT01233258","A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A","Leopold II","Completed","Has Results","Hemophilia A","Biological: rFVIII (BAY81-8973) on demand|Biological: rFVIII (BAY81-8973) prophylaxis low-dose|Biological: rFVIII (BAY81-8973) prophylaxis high-dose","Annualized Number of All Bleeds|Annualized Number of All Bleeds During CS/EP Period|Annualized Number of All Bleeds During CS/ADJ Period|Percentage of Bleeds Per Participant Controlled With ≤ 2 Injections in Participants Treated on Demand With rFVIII (BAY81-8973)","Bayer","Male","12 Years to 65 Years   (Child, Adult, Older Adult)","Phase 3","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14319|2009-012150-20","January 2011","December 2012","December 2012","November 3, 2010","February 11, 2014","November 28, 2016","Dayton, Ohio, United States|Houston, Texas, United States|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Rosario, Santa Fe, Argentina|Corrientes, Argentina|Guangzhou, Guangdong, China|Suzhou, Jiangsu, China|Beijing, China|Shanghai, China|Tianjin, China|Bogotá, Distrito Capital de Bogotá, Colombia|Bucaramanga, Santander, Colombia|Olomouc, Czech Republic|Hyderabad, India|Jakarta, Indonesia|Nishinomiya, Hyogo, Japan|Kashihara, Nara, Japan|Shinjuku-ku, Tokyo, Japan|Suginami, Tokyo, Japan|Hiroshima, Japan|Guadalajara, Jalisco, Mexico|San Luis Potosí, Mexico|Timisoara, Timis, Romania|Baia Mare, Romania|Bucharest, Romania|Bucharest, Romania|Barnaul, Russian Federation|Khabarovsk, Russian Federation|St. Petersburg, Russian Federation|Yekaterinburg, Russian Federation|Beograd, Serbia|Kragujevac, Serbia|Nis, Serbia|Novi Sad, Serbia|Bratislava, Slovakia|Johannesburg, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Taichung, Taiwan|Taipei, Taiwan|Bangkok, Thailand|Bangkok, Thailand|Adana, Turkey|Antalya, Turkey|Izmir, Turkey|Kiev, Ukraine|Lviv, Ukraine|Simferopol, Ukraine",,"https://ClinicalTrials.gov/show/NCT01233258"
827,"NCT01233245","BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus Program",,"Completed","No Results Available","Relapsing Remitting MS (RRMS)|Secondary Progressive MS (SPMS)","Drug: Interferon beta-1b (Betaseron, BAY86-5046)","Identification of reasons why patients are switched from other disease modifying drugs to Betaferon due to perceived lack of efficacy, adverse events, poor compliance, and others.|Assessment of factors predictive of non-adherence to disease modifying drugs such as demographic data, course of disease, drug history, patients characteristics, history of poor compliance to prior therapy or others.|Assessment of impact of supportive elements of the BetaPlus Program like nurse support, auto-injector, website, etc on treatment adherence.|Evaluation of impact of Betaferon treatment on health related quality of life using the Functional Assessment of Multiple Sclerosis Questionnaire - FAMS.|Assessment of coping processes by applying the Ways of Coping Questionnaire.|Measurement of safety of Betaferon by assessing the number of participants with adverse events and severe adverse events. Classification by MedDRA category.","Bayer","All","18 Years and older   (Adult, Older Adult)",,"1077","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14192|BF0704","April 2004","June 2009","June 2009","November 3, 2010",,"November 15, 2012","Many Locations, Czech Republic|Many Locations, France|Many Locations, Germany|Many Locations, Iran, Islamic Republic of|Many Locations, Israel|Many Locations, Italy|Many Locations, Jordan|Many Locations, Korea, Republic of|Many Locations, Lebanon|Many Locations, Netherlands|Many Locations, Portugal|Many Locations, Saudi Arabia|Many Locations, Spain|Many Locations, Taiwan|Many Locations, Turkey",,"https://ClinicalTrials.gov/show/NCT01233245"
828,"NCT01228513","Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)",,"Completed","No Results Available","Atopic Dermatitis","Drug: ZK245186|Drug: Placebo (vehicle without active ingredient)","Eczema Area and Severity Index (EASI)|EASI|Subjects' assessment of pruritus|Subject's assessment of pruritus","Bayer","All","18 Years to 55 Years   (Adult)","Phase 2","263","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15267|1403380","November 2010","July 2011","April 2012","October 26, 2010",,"January 21, 2016","Anaheim, California, United States|Honolulu, Hawaii, United States|Boise, Idaho, United States|Chicago, Illinois, United States|Boston, Massachusetts, United States|Warren, Michigan, United States|Fridley, Minnesota, United States|New York, New York, United States|Portland, Oregon, United States|Austin, Texas, United States|College Station, Texas, United States|San Antonio, Texas, United States|Webster, Texas, United States|Kawaguchi Saitama, Japan|Tokyo, Japan|Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT01228513"
829,"NCT01227603","Single Dose Bioequivalence Study Comparing Nifedipine/Candesartan FDC (Fixed Dose Combination) With Loose Combination of Nifedipine GITS (Gastro-intestinal Therapeutic System) Plus Candesartan and Single Components Under Fasting Conditions",,"Completed","No Results Available","Hypertension, Essential","Drug: Nifedipine-candesartan FDC (BAY 98-7106)|Drug: Nifedipine GITS (Adalat LA, BAYA1040)|Drug: Candesartan (Atacand)","Cmax|AUC(0-tn)|AUC|Cmax,norm|AUCnorm|AUC(0-48)|tmax|t½|MRT|CL/f|Number of participants with adverse events","Bayer","Male","18 Years to 45 Years   (Adult)","Phase 1","49","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14027|2010-021966-31","November 2010","March 2011","July 2011","October 25, 2010",,"December 10, 2015","Köln, Nordrhein-Westfalen, Germany",,"https://ClinicalTrials.gov/show/NCT01227603"
830,"NCT01219582","GLucobay M OBservation Study for Efficacy and Safety in Treatment of Type-2 Diabetes Patients","GLOBE","Completed","No Results Available","Type 2 Diabetes","Drug: Glucobay M (Acarbose/Metformin, BAY81-9783)","Change in fasting blood glucose levels|Change in post-prandial glucose values|Change in Hemoglobin A1c (HbA1c) levels|Number of patient with adverse events|Percentage of patients with satisfaction of treatment","Bayer","All","18 Years and older   (Adult, Older Adult)",,"9364","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14954|GB0910IN","October 2010","January 2012","December 2012","October 13, 2010",,"November 13, 2013","Many Locations, India",,"https://ClinicalTrials.gov/show/NCT01219582"
831,"NCT01219556","Xirtam H Combination In the Treatment of Hypertension Evaluation Study.","XCITE","Completed","No Results Available","Hypertension","Drug: Olmesartan plus hydrochlorothiazide (Xirtam H, BAY98-7105)","Changes in seated diastolic pressure|Changes in seated systolic pressure|Achievement of target blood pressure as per Sixth Report of the Joint National Committee of High Blood Pressure (JNC-VII)|Number of patients with adverse events as measure of safety|Percentage of patients with satisfaction to treatment","Bayer","All","18 Years and older   (Adult, Older Adult)",,"8704","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14916|XI0911IN","November 2010","January 2012","February 2013","October 13, 2010",,"January 28, 2014","Many Locations, India",,"https://ClinicalTrials.gov/show/NCT01219556"
832,"NCT01217879","COugh Among Hypertensive Patients Treated With Telmisartan, Who Had to Stop previoUs ACE-i Treatment Due to couGH in Slovakia","COUGH","Completed","No Results Available","Hypertension","Drug: Telmisartan (Kinzal/Pritor, BAY68-9291)","Cough frequency among telmisartan treated patients, who had to stop their previous ACE-I treatment due to cough|Number of Participants with Adverse Events among patients, who had to stop their previous ACE-I treatment due to cough","Bayer","All","18 Years and older   (Adult, Older Adult)",,"980","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","15379|KL0910SK|14881 - KL0910PL|GM.2009-04-06.0017","January 2010","September 2010","September 2010","October 8, 2010",,"November 16, 2012","Many Locations, Slovakia",,"https://ClinicalTrials.gov/show/NCT01217879"
833,"NCT01215409","Real Life Safety and Efficacy of Vardenafil",,"Terminated","No Results Available","Erectile Dysfunction","Drug: Vardenafil (Levitra, BAY38-9456)","General assessment of patients concerning efficacy and tolerability of vardenafil treatment|Time to first intercourse after intake of vardenafil|Percentage of successful second intercourse within 24 hours|Percentage of participants who are willing to continue treatment|Number of participants with adverse events","Bayer","Male","18 Years and older   (Adult, Older Adult)",,"372","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","14328|LV0611TW","February 2008","November 2008","November 2008","October 6, 2010",,"May 19, 2014","Many Locations, Taiwan",,"https://ClinicalTrials.gov/show/NCT01215409"
834,"NCT01212445","Dose-Finding Trial of Polyethylene Glycol 3350 Laxative Plus Electrolytes for the Treatment of Constipation (Protocol P07515)",,"Completed","Has Results","Constipation","Drug: PEG 3350 laxative plus electrolytes (PEG + E)/Macrogol (Movicol®, BAY81-8430)","Percentage of Participants With Successful Bowel Movement (BM) Within 24 Hours of PEG + E Administration|Number of Participants With Time To First Successful BM In 0 Days Through 0.5 Days, >0.5 Days Through 1.0 Days, or >1.0 Days Through 1.5 Days After PEG+E Administration|Percentage of Participants With Successful BM Within 12 Hours of PEG+E Administration|Mean Visual Analog Scale (VAS) Rating for BM Control|Mean VAS Rating for Gas|Mean VAS Rating for Bloating|Mean VAS Rating for Abdominal Discomfort/Cramping|Mean Participant Global Assessment of Treatment","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","154","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18129|2010-021367-32","October 2010","November 2011","November 2011","September 30, 2010","March 11, 2013","March 15, 2016","ORK, Ireland",,"https://ClinicalTrials.gov/show/NCT01212445"
835,"NCT01211171","COugh Among Hypertensive Patients Treated With Telmisartan, Who Had to Stop previoUs ACE-I Treatment Due to couGH in Poland","COUGH","Completed","No Results Available","Hypertension","Drug: Telmisartan (Kinzal/Pritor, BAY68-9291)","Cough frequency among telmisartan treated patients, who had to stop their previous ACE-I treatment due to cough|General tolerability and safety of telmisartan treatment among patients, who had to stop their previous ACE-I treatment due to cough","Bayer","All","18 Years and older   (Adult, Older Adult)",,"2498","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14881|KL0910PL|15379 - KL0910SK|GM.2009-04-06.0017","May 2009","December 2009","December 2009","September 29, 2010",,"February 13, 2014","Many Locations, Poland",,"https://ClinicalTrials.gov/show/NCT01211171"
836,"NCT01207947","LEVITRA® Specific Drug Use Investigation. To Investigate the Safety Profile in Combination Use With Alpha-blockers",,"Completed","No Results Available","Erectile Dysfunction","Drug: Vardenafil (Levitra, BAY38-9456)","Efficacy of Levitra treatment, namely satisfactory or not is evaluated by inquiring to the enrolled patient according to the following rating scale: 1.very satisfied, 2.satisfied, 3.unsatisfied|Safety of Levitra treatment, namely incidence of Adverse Events or Adverse Drug Reactions are evaluated|Tolerability of patients with Levitra treatment, namely satisfactory or not is evaluated by inquiring to the enrolled patient according to the following rating scale: 1.very satisfied, 2.satisfied, 3.unsatisfied","Bayer","Male","18 Years and older   (Adult, Older Adult)",,"491","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","13931|LV0702JP","October 2007","June 2009","March 2010","September 23, 2010",,"January 21, 2015","Many Locations, Japan",,"https://ClinicalTrials.gov/show/NCT01207947"
837,"NCT01206972","Dose-confirmatory Bridging Study in Total Knee Replacement",,"Completed","No Results Available","Venous Thromboembolism","Drug: Rivaroxaban (BAY59-7939)|Drug: Enoxaparin","A composite endpoint of any deep vein thrombosis (proximal and/or distal), non-fatal pulmonary embolism and death from all causes|Treatment-emergent bleeding (major, non-major clinically relevant, other non-major)|deep vein thrombosis (total, proximal, distal)|symptomatic venous thromboembolism|major venous thromboembolism (proximal deep vein thromboembolism, pulmonary embolism or venous thromboembolism-related death)","Bayer|Janssen Scientific Affairs, LLC","All","20 Years and older   (Adult, Older Adult)","Phase 3","302","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","14398","October 2010","May 2011","June 2011","September 22, 2010",,"January 18, 2017","Nagoya, Aichi, Japan|Matsudo, Chiba, Japan|Matsuyama, Ehime, Japan|Kawanuma, Fukushima, Japan|Koriyama, Fukushima, Japan|Asahikawa, Hokkaido, Japan|Hakodate, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Kakogawa, Hyogo, Japan|Kobe, Hyogo, Japan|Nishinomiya, Hyogo, Japan|Tsukuba, Ibaraki, Japan|Iida, Nagano, Japan|Sasebo, Nagasaki, Japan|Tomigusuku, Okinawa, Japan|Hirakata, Osaka, Japan|Izumisano, Osaka, Japan|Izumi, Osaka, Japan|Kishiwada, Osaka, Japan|Kishiwada, Osaka, Japan|Osakasayama, Osaka, Japan|Sakai, Osaka, Japan|Takatsuki, Osaka, Japan|Adachi, Tokyo, Japan|Nerima-ku, Tokyo, Japan|Fukuoka, Japan|Fukuoka, Japan|Kyoto, Japan|Osaka, Japan|Osaka, Japan|Saga, Japan|Saitama, Japan|Toyama, Japan",,"https://ClinicalTrials.gov/show/NCT01206972"
838,"NCT01206257","The Safety and toleRability of UltraviSt in Patients Undergoing Cardiac CaTheterization (TRUST)","TRUST","Completed","No Results Available","Angiocardiography","Drug: Iopromide (Ultravist, BAY86-4877)","Evaluation of the safety and tolerability of Ultravist® in patients Undergoing cardiac catheterization.|Estimation of the image quality of Ultravist®","Bayer","All","Child, Adult, Older Adult",,"17513","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","15454|UV1010CN","August 2010","September 2011","September 2011","September 21, 2010",,"June 11, 2013","Many Locations, China",,"https://ClinicalTrials.gov/show/NCT01206257"
839,"NCT01205932","Dose-confirmatory Bridging Study in Total Hip Replacement",,"Completed","No Results Available","Venous Thromboembolism","Drug: Rivaroxaban (BAY59-7939)|Drug: Enoxaparin","A composite endpoint of any deep vein thrombosis (proximal and/or distal), non-fatal pulmonary embolism and death from all causes|Treatment-emergent bleeding (major, non-major clinically relevant, other non-major)|Deep vein thrombosis (total, proximal, distal)|Symptomatic venous thromboembolism|Major venous thromboembolism (proximal deep vein thrombosis, pulmonary embolism or venous thromboembolism-related death)","Bayer|Janssen Research & Development, LLC","All","20 Years and older   (Adult, Older Adult)","Phase 3","402","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","14397","September 2010","June 2011","August 2011","September 21, 2010",,"January 23, 2017","Nagoya, Aichi, Japan|Matsudo, Chiba, Japan|Narashino, Chiba, Japan|Matsuyama, Ehime, Japan|Koriyama, Fukushima, Japan|Asahikawa, Hokkaido, Japan|Hakodate, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Kakogawa, Hyogo, Japan|Kobe, Hyogo, Japan|Nishinomiya, Hyogo, Japan|Tsukuba, Ibaraki, Japan|Kamakura, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Iida, Nagano, Japan|Sasebo, Nagasaki, Japan|Sasebo, Nagasaki, Japan|Kurashiki, Okayama, Japan|Tomigusuku, Okinawa, Japan|Hirakata, Osaka, Japan|Hirakata, Osaka, Japan|Izumisano, Osaka, Japan|Izumi, Osaka, Japan|Kishiwada, Osaka, Japan|Kishiwada, Osaka, Japan|Osakasayama, Osaka, Japan|Sakai, Osaka, Japan|Suita, Osaka, Japan|Takatsuki, Osaka, Japan|Nerima-ku, Tokyo, Japan|Setagaya, Tokyo, Japan|Fukuoka, Japan|Fukuoka, Japan|Kagoshima, Japan|Kumamoto, Japan|Kyoto, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Saga, Japan|Toyama, Japan",,"https://ClinicalTrials.gov/show/NCT01205932"
840,"NCT01204190","Investigation of Three Contraceptive Hormone Patches in Regard to Inhibition of Ovulation Following Application Over 3 Treatment Cycles in Healthy, Young Women.",,"Completed","No Results Available","Contraception","Drug: Gestodene/EE Patch (BAY86-5016)","Hoogland score to evaluate the inhibition of ovulation|Blood level time course of gonadotropins i.e. follicle stimulating hormone (FSH) and luteinizing formone (LH) as well as steroid hormones estradiol and progesterone|Follicle size measured by transvaginal ultrasound examination|Pharmacokinetics of ethinyl estradiol (EE), gestodene (GSD) and sex hormone binding globuline (SHBG)","Bayer","Female","18 Years to 35 Years   (Adult)","Phase 2","173","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","15264|2010-021255-81","September 2010","July 2011","August 2011","September 17, 2010",,"November 4, 2014","Berlin, Germany|Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT01204190"
841,"NCT01204177","Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer.","BASIL","Completed","No Results Available","Carcinoma, Hepatocellular","Drug: BAY86-9766 MEK Inhibitor + Sorafenib","Disease Control Rate (DCR)|Overall Survival (OS)|Time To Progression (TTP)|Response Rate (RR)|Duration Of Response (DOR)|Safety: physical examination, vital signs, adverse events, safety lab|Patients reported hepatobiliary cancer symptoms and Health Related Quality of Life (HRQoL)|Pharmacokinetic (PK) profiles of BAY86-9766 and sorafenib to evaluate drug exposure (not in all patients)|Biomarkers","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","70","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14899","December 2010","August 2011","August 2013","September 17, 2010",,"September 6, 2013","Shatin, New Territories, Hong Kong|Hong Kong, Hong Kong|Jung-gu, Daegu Gwang''yeogsi, Korea, Republic of|Goyang-si, Gyeonggido, Korea, Republic of|Busan, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Singapore, Singapore|Singapore, Singapore|Kaohsiung, Taiwan|Tainan, Taiwan|Tainan, Taiwan|Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01204177"
842,"NCT01200186","Non-interventional Study on Oral Contraception Not Containing Ethinylestradiol (EE) to Assess Continuation Rates and Satisfaction",,"Completed","No Results Available","Contraceptives, Oral","Drug: EV/DNG (Qlaira, BAY86-5027)|Drug: Progestin Only Pills","The primary outcome measure will be time-to-event for discontinuation due to bleeding irregularities.|Time to event for discontinuation due to reasons other than bleeding irregularities|Number of intracyclic bleeding|Number of heavy and/or prolonged bleeding|Number of unintended pregnancies|Discontinuation rate for the following reasons: Occasional absent or persistent absent withdrawal bleeding , intracyclic bleeding, heavy and/or prolonged bleeding, other medical reasons, non-medical reasons|Global assessment of well-being and satisfaction|Adverse events (AEs) at any time point, whether or not related to the therapy or reference therapy","Bayer","Female","18 Years to 50 Years   (Adult)",,"3258","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","15217|QL0901","October 2010","February 2014","October 2014","September 13, 2010",,"October 16, 2015","Many Locations, Czech Republic|Many Locations, France|Many Locations, Germany|Many Locations, Greece|Many Locations, Hungary|Many locations, Israel|Many Locations, Italy|Many Locations, Russian Federation|Many Locations, Slovakia|Many Locations, Sweden|Many Locations, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01200186"
843,"NCT01198457","Study to Investigate Adherence of Patients to Clodronate (Bonefos) Treatment","BONA","Completed","No Results Available","Breast Neoplasms|Prostatic Neoplasms|Multiple Myeloma|Osteolysis","Drug: Clodronate (Bonefos, BAY94-8393)","Adherence to treatment with oral clodronate (PDC, proportion of days covered).|Efficacy evaluation of the therapy based on incidence of skeletal events|Efficacy of the therapy in pain releif will be investigated exploratory based on questionnaire","Bayer","All","18 Years and older   (Adult, Older Adult)",,"147","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14561|BO0910CZ","January 2009","June 2010","June 2010","September 10, 2010",,"September 7, 2012","Many Locations, Czech Republic",,"https://ClinicalTrials.gov/show/NCT01198457"
844,"NCT01198444","To Evaluate Compliance to Treatment Regimen (Rate of Deviations From the Prescribed Regimen) in Polish Females Treated With Different Low Dose Oral Contraceptives","DOC","Completed","No Results Available","Contraception","Drug: EE/DRSP (Yasmin Product Family)","The percentage of users showing noncompliant behaviors|The characteristics of noncompliant behavior|The relation between noncompliant behavior and selected factors","Bayer","Female","18 Years to 50 Years   (Adult)",,"11884","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14340|YA0712PL","December 2007","May 2008","May 2008","September 10, 2010",,"November 2, 2011","Many Locations, Poland",,"https://ClinicalTrials.gov/show/NCT01198444"
845,"NCT01195649","Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or Interleukin-2 Based Therapy",,"Terminated","No Results Available","Carcinoma, Renal Cell","Drug: Sorafenib (Nexavar, BAY43-9006)","Evaluation of Safety and Efficacy of treatments and average doses that are used for patients with Renal Cell Carcinoma (collection of number of adverse events)|Evaluation of Safety and Efficacy of treatments and average doses that are used for patients with Renal Cell Carcinoma (collection of changes in tumor status)","Bayer","All","18 Years and older   (Adult, Older Adult)",,"11","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","15242|NX1010TW","December 13, 2010","June 8, 2012","August 31, 2012","September 6, 2010",,"June 4, 2019",,,"https://ClinicalTrials.gov/show/NCT01195649"
846,"NCT01191385","GIDEON Non-Nexavar Arm - HCC Patients Who Are Treated With Any Therapy Other Than Nexavar at Individual Study Start",,"Withdrawn","No Results Available","Carcinoma, Hepatocellular","Drug: Any treatment for unresectable HCC as chosen by the physician","Determination of 'real-life' practice patterns of physicians involved in the care of patients with HCC (collection of data on treatments prescribed as well as demographic data and data on the entire medical history)|Evaluation of patient demographics, disease characteristics, methods of patient evaluation, diagnosis and follow-up of patients with HCC, regionally and globally (collection of data on demographics, medical history, diagnostic measurements, follow-up)|Evaluation of natural course and outcomes of patients with HCC (collection of data of disease status during the course of the study and the outcome of treatment)|Evaluation of treatment modalities that are used for patients with HCC during the course of their disease (collection of data of all treatments prescribed during the course of the study)|Evaluation of safety and tolerability of treatments that are used for patients with HCC (collection of all adverse events)|Evaluation efficacy parameters including: overall survival (OS), progression-free survival (PFS), time to progression (TTP), response rate (RR) and stable disease (SD) rate of the various interventions employed in the care of patients with HCC|To evaluate the comorbidities in patients with HCC and their influence on treatment options and outcome (collection of data on concomitant diseases)","Bayer|Amgen","All","18 Years and older   (Adult, Older Adult)",,"0","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14611|NX0901","November 2010","December 2013","December 2013","August 30, 2010",,"August 16, 2017","Multiple Locations, Arkansas, United States|Multiple Locations, California, United States|Multiple Locations, Colorado, United States|Multiple Locations, District of Columbia, United States|Multiple Locations, Florida, United States|Multiple Locations, Georgia, United States|Multiple Locations, Illinois, United States|Multiple Locations, Indiana, United States|Multiple Locations, Iowa, United States|Multiple Locations, Kentucky, United States|Multiple Locations, Louisiana, United States|Multiple Locations, Maryland, United States|Multiple Locations, Massachusetts, United States|Multiple Locations, Michigan, United States|Multiple Locations, Minnesota, United States|Multiple Locations, Missouri, United States|Multiple Locations, New Hampshire, United States|Multiple Locations, New Jersey, United States|Multiple Locations, New York, United States|Multiple Locations, Oregon, United States|Multiple Locations, Pennsylvania, United States|Multiple Locations, South Carolina, United States|Multiple Locations, Texas, United States|Multiple Locations, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01191385"
847,"NCT01188252","Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies",,"Completed","No Results Available","Neoplasms","Drug: Roniciclib (BAY1000394)","Safety: Frequency of adverse events|Maximum tolerated dose: Measured by adverse event profile|Pharmacokinetics: Plasma concentrations of BAY1000394 will be measured. The following parameters will be calculated: Cmax, tmax, AUC(0-tn), AUC, and half-life.|Biomarkers evaluation: analysis of apoptosis marker CK18/M30 and total soluble cytokeratin CK18/M65|Assessment of expression (IHC) and amplification status (FISH) of markers related to cell proliferation and the cell cycle in Paraffin-embedded archival tumor samples. These will include, but may not be limited to Cyclin E, Cyclin D, p21, and Ki67|Functional testing of peripheral leucocytes, for example induction of cytokine synthesis|Assessment of intracellular biomarkers of apoptosis (for example activated caspase 3, annexin V, expression of MCL 1 for patients with chronic lymphocytic leucemia only|Tumor response evaluation based on RECIST 1.1 (solid tumors) or response based on the pertinent guidelines (malignant lymphoma, chronic lymphocytic leukemia) every 2 cycles","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","112","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14484|2010-019191-79","August 2010","June 2016","December 2016","August 25, 2010",,"January 9, 2017","St. Louis, Missouri, United States|Buffalo, New York, United States|Cleveland, Ohio, United States|Caen Cedex, France|Lyon Cedex, France|Marseille Cedex 20, France|Villejuif Cedex, France|Heidelberg, Baden-Württemberg, Germany|Herne, Nordrhein-Westfalen, Germany",,"https://ClinicalTrials.gov/show/NCT01188252"
848,"NCT01187628","Long-term Study in Chronic Kidney Disease (Extension From Study 14817)",,"Completed","No Results Available","Hyperphosphatemia","Drug: Fosrenol (Lanthanum Carbonate, BAY77-1931)","Incidence of treatment emergent adverse events","Bayer|Shire","All","20 Years and older   (Adult, Older Adult)","Phase 3","123","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15074","September 2010","April 2013","April 2013","August 24, 2010",,"April 3, 2015","Anjo, Aichi, Japan|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Seto, Aichi, Japan|Toyohashi, Aichi, Japan|Yatomi, Aichi, Japan|Kamogawa, Chiba, Japan|Kisarazu, Chiba, Japan|Kitakyushu, Fukuoka, Japan|Kitakyushu, Fukuoka, Japan|Koga, Fukuoka, Japan|Sapporo, Hokkaido, Japan|Amagasaki, Hyogo, Japan|Fujisawa, Kanagawa, Japan|Kamakura, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Beppu, Oita, Japan|Kurashiki, Okayama, Japan|Sakai, Osaka, Japan|Koto, Tokyo, Japan|Meguro-ku, Tokyo, Japan|Minato-ku, Tokyo, Japan|Musashino, Tokyo, Japan|Shinagawa, Tokyo, Japan|Fukuoka, Japan|Fukuoka, Japan|Kyoto, Japan|Oita, Japan|Okayama, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Saga, Japan|Shizuoka, Japan|Tokushima, Japan|Wakayama, Japan",,"https://ClinicalTrials.gov/show/NCT01187628"
849,"NCT01187615","Determination of Safety, Efficacy, and Pharmacokinetics of ""Regorafenib"" Combined With Pemetrexed and Cisplatin in Patients With Nonsquamous Non-Small Cell Lung Cancer",,"Terminated","No Results Available","Small Cell Lung Carcinoma","Drug: Regorafenib (BAY73-4506) - sequential / Cisplatin / Pemetrexed|Drug: Regorafenib (BAY73-4506) - continuous / Cisplatin / Pemetrexed","Number of participants with treatment related toxicities and adverse events and change from baseline in vitals signs and laboratory parameters|Pharmacokinetics assessments of Alimta, Cisplatin, and regorafenib in Cycle 1 and 2|Biomarkers (includes but not limited to plasma protein analysis of angiogenesis-related proteins, DNA mutational anaylsis of tumor tissue and plasma)|Tumor Assessments according to Response Evaluation Criteria in Solid Tumors (RECIST) every second cycle","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","9","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14458","August 2010","June 2012","June 2012","August 24, 2010",,"July 8, 2014","New Haven, Connecticut, United States|Las Vegas, Nevada, United States|New York, New York, United States|Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01187615"
850,"NCT01185678","Data on Oral Contraceptives Compliance in Non Stop Regimen","DOC Non Stop","Completed","No Results Available","Contraception","Drug: Qlaira or Yaz (BSP products defined as Combined Oral Contraceptive) and Cerazette or Azalia (competitor's products defined as Progestogen Only Pill)","The percentage of users showing noncompliant behaviors|The characteristics of noncompliant behavior.|The relation between noncompliant behavior and selected factors.","Bayer","Female","18 Years to 50 Years   (Adult)",,"8416","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","15253|WH1011PL","May 2010","November 2010","November 2010","August 20, 2010",,"June 27, 2013","Many Locations, Poland",,"https://ClinicalTrials.gov/show/NCT01185678"
851,"NCT01184833","Evaluation of Risk Factors for Early Termination of Injection Treatment With Betaferon in Patients Suffering From Multiple Sclerosis","BREAK","Completed","No Results Available","Multiple Sclerosis","Drug: Interferon beta-1b (Betaseron, BAY86-5046)","Rate of discontinuation of Betaferon|Number of missed doses of Betaferon|Depression score as measured by CES-D questionnaire|Neurological disability score as measured by EDSS scale|Overall tolerability of treatment as measured by rate of adverse events","Bayer","All","18 Years and older   (Adult, Older Adult)",,"852","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14323|BF0813PL","September 2008",,"August 2011","August 19, 2010",,"June 25, 2013","Many Locations, Poland",,"https://ClinicalTrials.gov/show/NCT01184833"
852,"NCT01184820","Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration",,"Completed","No Results Available","Hemophilia A","Biological: BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Biological: BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222))","Safety as assessed by measuring immunogenicity|Adverse events collection|Area under the plasma concentration vs time curve from time 0 to the last data point (AUC0-tlast)|Area under the plasma concentration vs time curve from zero to infinity after single (first) dose (AUC0-inf)|Maximum drug concentration in plasma (Cmax)|Half-life associated with the terminal slope (t1/2)|Time to reach maximum drug concentration in plasma after single (first) dose (Tmax)|Mean residence time (MRT)|Total body clearance (CL)|Apparent volume of distribution at steady state (Vss)|Incremental recovery of FVIII","Bayer","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","14","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","13401","October 13, 2010","October 10, 2011","October 10, 2011","August 19, 2010",,"September 7, 2018","Davis, California, United States|Boston, Massachusetts, United States|Minneapolis, Minnesota, United States|Syracuse, New York, United States",,"https://ClinicalTrials.gov/show/NCT01184820"
853,"NCT01179334","Evaluation of the Pharmacodynamic Effect of the Combination of Sildenafil and Riociguat on Blood Pressure and Other Safety Parameters.","PATENT PLUS","Completed","Has Results","Pulmonary Hypertension","Drug: Riociguat (Adempas, BAY63-2521)|Drug: Placebo|Drug: Sildenafil","Maximum Change From Baseline in Supine Systolic Blood Pressure (SBP) Within 4 Hours Post-dose at Visit 6 (Week 12)|Maximum Change From Baseline in Standing Systolic Blood Pressure (SBP) Within 4 Hours Post-dose at Visit 6 (Week 12)|Maximum Change From Baseline in Supine Diastolic Blood Pressure (DBP) Within 4 Hours Post-dose at Visit 6 (Week 12)|Maximum Change From Baseline in Standing Diastolic Blood Pressure (DBP) Within 4 Hours Post-dose at Visit 6 (Week 12)|Maximum Change From Baseline in Supine Heart Rate (HR) Within 4 Hours Post-dose at Visit 6 (Week 12)|Maximum Change From Baseline in Standing Heart Rate (HR) Within 4 Hours Post-dose at Visit 6 (Week 12)|Area Under Effect Curve (AUEC) of Supine SBP Within 4 Hours Post-dose at Visit 6 (Week 12)|Area Under Effect Curve (AUEC) of Standing SBP Within 4 Hours Post-dose at Visit 6 (Week 12)|Area Under Effect Curve (AUEC) of Supine DBP Within 4 Hours Post-dose at Visit 6 (Week 12)|Area Under Effect Curve (AUEC) of Standing DBP Within 4 Hours Post-dose at Visit 6 (Week 12)|Area Under Effect Curve (AUEC) of Supine HR Within 4 Hours Post-dose at Visit 6 (Week 12)|Area Under Effect Curve (AUEC) of Standing HR Within 4 Hours Post-dose at Visit 6 (Week 12)","Bayer","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15096|2010-018863-40","August 2010","June 2012","May 2013","August 11, 2010","December 25, 2013","August 29, 2016","Aurora, Colorado, United States|Columbus, Ohio, United States|Providence, Rhode Island, United States|Innsbruck, Austria|Villach, Austria|Vseobecna fakultni nemocnice, Praha 2, Czech Republic|Heidelberg, Baden-Württemberg, Germany|Regensburg, Bayern, Germany|Würzburg, Bayern, Germany|Gießen, Hessen, Germany|Hannover, Niedersachsen, Germany|Köln, Nordrhein-Westfalen, Germany|Mönchengladbach, Nordrhein-Westfalen, Germany|Dresden, Sachsen, Germany|Berlin, Germany|Hamburg, Germany|Bologna, Emilia-Romagna, Italy|Pavia, Lombardia, Italy|Auckland, New Zealand|Christchurch, New Zealand|Otwock, Poland|Warszawa, Poland|Barcelona, Spain|Papworth Hospital, Cambridge, Cambridgeshire, United Kingdom|Clydebank, West Dunbartonshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01179334"
854,"NCT01179295","Japanese BAY86-9766 Monotherapy Phase I Study",,"Completed","No Results Available","Neoplasms","Drug: BAY86-9766","Safety evaluation due to results of physical examinations, vital signs, AEs, abnormal laboratory tests and 12-lead ECG, cardiac function test and ophthalmological examination.|Calculation of pharmacokinetic parameters of BAY86-9766 and its metabolite (M17).|Response rate|Disease control rate","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15091","November 19, 2010","April 27, 2012","April 27, 2012","August 11, 2010",,"June 20, 2017","Kashiwa, Chiba, Japan",,"https://ClinicalTrials.gov/show/NCT01179295"
855,"NCT01172756","A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Diastolic Dysfunction","DILATE","Terminated","No Results Available","Hypertension, Pulmonary|Ventricular Dysfunction, Left","Drug: Riociguat (BAY63-2521)|Drug: Placebo","Pulmonary artery mean pressure at rest|Adverse event collection|Plasma concentrations to obtain pharmacokinetic profile of Riociguat","Bayer","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","39","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","14554|2010-018436-41","July 2010","October 2012","October 2012","July 30, 2010",,"November 4, 2014","Linz, Oberösterreich, Austria|Graz, Steiermark, Austria|Graz, Steiermark, Austria|Salzburg, Austria|Wien, Austria|Praha 2, Czech Republic|Köln, Nordrhein-Westfalen, Germany",,"https://ClinicalTrials.gov/show/NCT01172756"
856,"NCT01168895","Study in COPD (Chronic Obstructive Pulmonary Disease) Subjects to Investigate Safety, Tolerability, and Pharmacokinetics of Ciprofloxacin After Single Dose Inhalations of 50 mg and 75 mg Ciprofloxacin Inhalation Powder",,"Completed","No Results Available","Infection|Pulmonary Disease, Chronic Obstructive","Drug: Cipro Inhale (Ciprofloxacin, BAYQ3939)","Determination of ciprofloxacin pharmacokinetics derived from drug concentrations in blood, urine and sputum|Adverse events collection","Bayer","All","40 Years to 75 Years   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","14972|2010-018521-19","July 2010","September 2010","September 2010","July 23, 2010",,"April 14, 2014","Großhansdorf, Schleswig-Holstein, Germany",,"https://ClinicalTrials.gov/show/NCT01168895"
857,"NCT01168817","Clinical Proof-of-concept Study for the Combination BAY60-4552 / Vardenafil for the Treatment of Erectile Dysfunction Not Sufficiently Responsive to Standard Therapy With PDE5 Inhibitors",,"Completed","No Results Available","Erectile Dysfunction","Drug: BAY60-4552 plus Vardenafil|Drug: Vardenafil|Drug: Placebo","Severity of erectile dysfunction assessed by the IIEF-EF (International Index of Erectile Function - Erectile Function subscale)|Success rate assessed by subject diary question: 'Maintenance' (Did your erection last long enough to have sexual intercourse?)|Success rate assessed by subject diary question: Penetration' (Were you able to insert your penis into your partner's vagina?)","Bayer","Male","18 Years to 64 Years   (Adult)","Phase 2","140","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","14694|2010-020122-18","August 2010","May 2011","May 2011","July 23, 2010",,"November 4, 2014","Oulu, Finland|Tampere, Finland|Turku, Finland|Chambery Cedex, France|Garches, France|Lille, France|Lyon Cedex, France|Nice, France|Nimes, France|Weiden, Bayern, Germany|Marburg, Hessen, Germany|Osnabrück, Niedersachsen, Germany|Mülheim, Nordrhein-Westfalen, Germany|Koblenz, Rheinland-Pfalz, Germany|Leipzig, Sachsen, Germany|Leipzig, Sachsen, Germany|Hamburg, Germany|Hamburg, Germany|Firenze, Italy|Milano, Italy|Napoli, Italy|Roma, Italy|Den Haag, Netherlands|Groningen, Netherlands|Leiden, Netherlands|Aravaca, Madrid, Spain|Majadahonda, Madrid, Spain|Barcelona, Spain|Barcelona, Spain|Málaga, Spain|Eskilstuna, Sweden|Göteborg, Sweden|Halmstad, Sweden|Jönköping, Sweden|Linköping, Sweden|Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT01168817"
858,"NCT01167231","Prevention of Postprandial Hyperglycemia by Acarbose May be a Promising Therapeutic Strategy for Reducing the Increased Risk for Cardiovascular Disease","ABDOMEN","Completed","No Results Available","Diabetes Mellitus","Drug: Acarbose (Glucobay, BAYG5421)","Safety, tolerability of acarbose and its effect on body weight, waist circumference and blood pressure|Effect of acarbose on HbA1c, fasting and postprandial glycemia and on lipid profile","Bayer","All","18 Years and older   (Adult, Older Adult)",,"3310","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","13066|GB0710PL","May 2007","March 2008","June 2008","July 22, 2010",,"August 25, 2010","Many Locations, Poland",,"https://ClinicalTrials.gov/show/NCT01167231"
859,"NCT01165931","Coronary Vasomotor Response After Riociguat Exposure","CORONARIES","Withdrawn","No Results Available","Coronary Artery Disease","Drug: Riociguat (BAY63-2521)","The ratio of the coronary blood flow after Riociguat to the corresponding flow observed after adenosine, compared to that after nitroglycerin administration|Adverse event collection","Bayer","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","0","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14550","May 2012","January 2013","January 2013","July 20, 2010",,"October 23, 2013","Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01165931"
860,"NCT01164696","A Prospective Observational Study to Evaluate the Quality of Life and the Costs in a Real Life Setting in Patients Who Are Treated With 90Y-Zevalin",,"Completed","No Results Available","Lymphoma, Follicular|Non-Hodgkin Lymphoma","Drug: [90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)","The medical resources consumed due to hematological adverse events that occurred following treatment with 90Y-Zevalin treatment|the health related quality of life prior to and following treatment (using EQ-5D and FACT-LYM)|the clinical outcomes (survival status, response status), TTNT (time to next treatment)","Bayer","All","18 Years and older   (Adult, Older Adult)",,"30","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","13455|ZV0710BE","August 2007","May 2009","May 2009","July 19, 2010",,"August 24, 2010","Many Locations, Belgium",,"https://ClinicalTrials.gov/show/NCT01164696"
861,"NCT01160692","A Study to Evaluate The Effects Of a Multivitamin/Mineral With Ginko In Subjects With Age Associated Memory Impairment",,"Completed","No Results Available","Age-Related Memory Disorders","Dietary Supplement: Multivitamin/Multimineral/Ginkgo (BAY 81-2775)|Other: Placebo","The effect of the multi-vitamin/-mineral preparation containing gingko on major aspects of human cognitive function employing a computerized cognitive assessment system.|The effects of the multi-vitamin/-mineral preparation containing gingko on subjective memory using questionnaires.|Tolerance of the daily oral intake of the multi-vitamin/-mineral preparation containing gingko.|The effects of the multi-vitamin/-mineral preparation containing gingko on mood using questionnaires.","Bayer","All","60 Years and older   (Adult, Older Adult)","Phase 3","132","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11954","February 2006","July 2008","July 2008","July 12, 2010",,"August 2, 2010","Newcastle upon Tyne, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01160692"
862,"NCT01159587","Prophylaxis Versus On-demand Therapy Through Economic Report","POTTER","Completed","No Results Available","Hemophilia A","Drug: Recombinant Factor VIII (Kogenate FS, BAY14-2222)","Evaluate the efficacy, safety and pharmacoeconomic of long-term secondary prophylaxis with Kogenate Bayer in comparison to on-demand treatment with Kogenate Bayer in terms of joint bleeding episodes per year|Efficacy, safety, pharmacoeconomic impact of secondary prophylaxis versus on demand group in terms of overall bleeding episodes|Muscolo skeletal evaluation by Orthopedic Joint Score|Radiological Evaluation by Pettersson Score|Health related quality of life|cost-effectiveness and utility, patient compliance, adverse events","Bayer","All","12 Years to 55 Years   (Child, Adult)",,"58","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","11856","July 2004","December 2010","December 2010","July 9, 2010",,"April 13, 2011","Many Locations, Italy",,"https://ClinicalTrials.gov/show/NCT01159587"
863,"NCT01158183","Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis","ROBUST","Completed","No Results Available","Multiple Sclerosis, Relapsing-Remitting","Drug: BAY86-5046_Interferon-beta-1b","Key Objective: To collect patient reported outcomes and clinical assessments via the same web-based data capture tool in a real world setting in relapse-remitting multiple sclerosis patients","Bayer","All","18 Years to 65 Years   (Adult, Older Adult)",,"226","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14838|BF0714US|311644","July 2007","September 2009","September 2009","July 8, 2010",,"July 8, 2010","Many Locations, Alabama, United States|Many Locations, California, United States|Many Locations, Colorado, United States|Many Locations, Florida, United States|Many Locations, Illinois, United States|Many Locations, Iowa, United States|Many Locations, Kansas, United States|Many Locations, Louisiana, United States|Many Locations, Maine, United States|Many Locations, Massachusetts, United States|Many Locations, Michigan, United States|Many Locations, Missouri, United States|Many Locations, Nevada, United States|Many Locations, New Hampshire, United States|Many Locations, New Jersey, United States|Many Locations, New York, United States|Many Locations, North Carolina, United States|Many Locations, North Dakota, United States|Many Locations, Ohio, United States|Many Locations, Oregon, United States|Many Locations, Pennsylvania, United States|Many Locations, Rhode Island, United States|Many Locations, Tennessee, United States|Many Locations, Texas, United States|Many Locations, Virginia, United States|Many Locations, Washington, United States|Many Locations, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01158183"
864,"NCT01145859","Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects",,"Completed","No Results Available","Venous Thrombosis|Pediatrics","Drug: Rivaroxaban (Xarelto, BAY59-7939)","Pharmacokinetics parameters (AUC and Cmax)|Pharmacodynamics parameters (PT, aPTT and anti-factor Xa)|Safety and tolerability of rivaroxaban in pediatric subjects","Bayer|Janssen Research & Development, LLC","All","6 Months to 18 Years   (Child, Adult)","Phase 1","59","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","12892|2009-017313-30","November 2010","July 2015","July 2015","June 17, 2010",,"August 6, 2015","Little Rock, Arkansas, United States|Los Angeles, California, United States|Los Angeles, California, United States|Orange, California, United States|Gainesville, Florida, United States|St. Petersburg, Florida, United States|Chicago, Illinois, United States|Indianapolis, Indiana, United States|Indianapolis, Indiana, United States|Detroit, Michigan, United States|New Hyde Park, New York, United States|Chapel Hill, North Carolina, United States|Durham, North Carolina, United States|Cleveland, Ohio, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Brisbane, Queensland, Australia|Parkville, Victoria, Australia|Linz, Austria|Wien, Austria|Edmonton, Alberta, Canada|Hamilton, Ontario, Canada|Toronto, Ontario, Canada|CLERMONT-FERRAND Cedex 1, France|Montpellier, France|Paris, France|TOULOUSE Cedex 9, France|Lübeck, Schleswig-Holstein, Germany|Crumlin, Dublin, Ireland|Jerusalem, Israel|Tel Hashomer, Israel|Genova, Italy|Milano, Italy|Pavia, Italy|Torino, Italy|Basel, Basel-Stadt, Switzerland",,"https://ClinicalTrials.gov/show/NCT01145859"
865,"NCT01122602","Evaluate Analgesic Efficacy of Fast Release Aspirin","TAROT","Completed","No Results Available","Drugs, Investigational","Drug: Acetylsalicyclic acid (Fast acting Aspirin, BAY1019036)|Drug: Acetylsalicyclic acid (Aspirin, BAYE4465)|Drug: Placebo","Time to First Perceptible Pain Relief (PR)|Time to First Perceptible Pain Relief Confirmed|Time to meaningful pain relief|Pain Intensity at 10, 20, 30, 40, 50, and 60 minutes and at 2, 3, 4, 5, and 6 hours After Dosing|Pain Intensity Difference (PID) at 10, 20, 30, 40, 50, and 60 minutes and at 2, 3, 4, 5, and 6 hours After Dosing|Pain Relief at 10, 20, 30, 40, 50, and 60 minutes and at 2, 3, 4, 5, and 6 hours After Dosing|Summed Pain Intensity Differences (SPID ) from Hour 0 through Hour 2, Hour 4 and Hour 6|Summed Total Pain Relief (TOTPAR ) from Hour 0 through Hour 2, Hour 4 and Hour 6|Time to First use of Rescue Medication|Cumulative Percentage of Subjects Taking Rescue Medication|Global Assessment of the Investigational Product as a Pain Reliever at 6 hours After Dosing or Immediately Before the First Intake of Rescue Medication","Bayer","All","16 Years to 45 Years   (Child, Adult)","Phase 3","500","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","15082|2014-005278-12","April 29, 2010","July 29, 2010","August 6, 2010","May 13, 2010",,"December 19, 2018","Austin, Texas, United States|Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01122602"
866,"NCT01118286","Treatment of Hypertension With Adalat® in Combination With Other Drugs",,"Completed","No Results Available","Hypertension","Drug: Nifedipine (Adalat, BAYA1040)","Evaluation of treatment success (lowering of blood pressure in mmHg) in adult hypertensive patients","Bayer","All","18 Years and older   (Adult, Older Adult)",,"4497","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14296|AL0701|AdADOSE","January 2010",,"September 2011","May 6, 2010",,"June 27, 2012","Many Locations, Bahrain|Many Locations, Egypt|Many Locations, Jordan|Many Locations, Lebanon|Many Locations, Morocco|Many Locations, Oman|Many Locations, Pakistan|Many Locations, Qatar|Many Locations, Russian Federation|Many Locations, Saudi Arabia|Many Locations, United Arab Emirates",,"https://ClinicalTrials.gov/show/NCT01118286"
867,"NCT01118273","Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine",,"Completed","Has Results","Sleep","Drug: Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg|Drug: Naproxen Sodium 440 mg (BAYH6689)|Drug: Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg|Drug: Naproxen Sodium 220 mg (BAYH6689)|Drug: DPH 50mg|Drug: Ibuprofen 400 mg / Diphenhydramine citrate 76 mg","Total Sleep Time Measured by Actigraphy|Wake After Sleep Onset (WASO) Measured by Actigraphy|Sleep Latency Measured by Actigraphy|Global Assessment of Study Medication as a Sleep-aid|Karolinska Sleep Diary - Sleep Quality|Karolinska Sleep Diary - Calmness of Sleep|Karolinska Sleep Diary - Easiness to Fall Asleep|Karolinska Sleep Diary - Premature Awakening|Karolinska Sleep Diary - Ease of Awakening|Karolinska Sleep Diary - Well Rested|Karolinska Sleep Diary - Sufficient Sleep|Total Sleep Time by Subject Assessment|Sleep Quality Index|Overall Rating of Severity in Categorical Pain Rating Scale Score|Change From Baseline in Categorical Pain Rating Scale Score|Overall Rating of Severity in Visual Analog Scale (VAS) Score|Change From Baseline in Visual Analog Scale (VAS) Score|Overall Rating of Pain Relief|Time to Rescue Medication|Cumulative Proportion of Participants Taking Rescue Medication by Hour|Global Assessment of Study Medication as a Pain Reliever|Number of Times Participants Took Rescue Medication|Total Wake Time Measured by Actigraphy|Sleep Efficiency Measured by Actigraphy|Activity Mean Measured by Actigraphy|Wake Episode Measured by Actigraphy","Bayer","All","16 Years to 45 Years   (Child, Adult)","Phase 4","162","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","13053","January 2008","February 2008","February 2008","May 6, 2010","June 17, 2014","June 8, 2015","Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01118273"
868,"NCT01117636","Evaluate Analgesic Efficacy of Fast Release Aspirin","TAROT","Completed","No Results Available","Drugs, Investigational","Drug: Acetylsalicylic acid (Fast release Aspirin, BAY1019036)|Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)|Drug: Placebo","Time to First Perceptible Pain Relief (PR)|Time to First Perceptible Pain Relief (PR) Confirmed|Time to Meaningful Pain Relief (PR)|Pain Intensity at 10, 20, 30, 40, 50, and 60 Minutes and at 2, 3, 4, 5, and 6 Hours After Dosing|Pain Intensity Difference (PID) at 10, 20, 30, 40, 50, and 60 Minutes and at 2, 3, 4, 5, and 6 Hours After Dosing|Pain Relief at 10, 20, 30, 40, 50, and 60 Minutes and at 2, 3, 4, 5, and 6 Hours After Dosing|Summed Pain Intensity Differences (SPID) From Hour 0 Through Hour 2, Hour 4 and Hour 6|Summed Total Pain Relief (TOTPAR) From Hour 0 Through Hour 2, Hour 4 and Hour 6|Time to First use of Rescue Medication|Cumulative Percentage of Subjects Taking Rescue Medication|Global Assessment of the Investigational Product as a Pain Reliever at 6 Hours After Dosing or Immediately Before the First Intake of Rescue Medication","Bayer","All","16 Years to 45 Years   (Child, Adult)","Phase 3","514","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","15120|2014-005271-81","April 28, 2010","July 7, 2010","July 7, 2010","May 5, 2010",,"December 19, 2018","Austin, Texas, United States|Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01117636"
869,"NCT01117623","Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies",,"Completed","Has Results","Neoplasm","Drug: Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg|Drug: Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg|Drug: Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg|Drug: Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg|Drug: Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg|Drug: HCC Child-Pugh A expansion cohort: Regorafenib 100 mg|Drug: HCC Child-Pugh B expansion cohort: Regorafenib 100 mg|Drug: NSCLC expansion cohort: Regorafenib 100 mg","Maximum Tolerated Dose (MTD)|Maximum Observed Plasma Concentration After Single Dose Administration (Cmax)|Area Under the Concentration vs. Time Curve From Zero to Infinity After Single (First) Dose (AUC)|Cmax at Steady State During a Dosing Interval (Cmax,ss)|AUC From Time 0 to 24 Hours at Steady State(AUC(0-24),ss)|AUC From Time 0 to the Last Data Point > Lower Limit of Quantification (LLOQ) (AUC(0-tlast))|Area Under the Concentration vs. Time Curve From Zero to Infinity After Single (First) Dose Divided by Dose (AUC/D)|Maximum Observed Plasma Concentration After Single Dose Administration Divided by Dose (Cmax/D)|Time to Reach Maximum Observed Plasma Concentration (Tmax)|Half-life Associated With the Terminal Slope (T1/2)|Cmax at Steady State During a Dosing Interval Divided by Dose (Cmax,ss/D)|AUC From Time 0 to 24 Hours at Steady State Divided by Dose (AUC(0-24)ss/D)|Time to Reach Maximum Observed Plasma Concentration at Steady State (Tmax,ss)|Ratio of Cmax,ss/Cmax (RACmax)|Ratio of Cmin,ss/Cmin (RACmin)|Ratio of AUCt,ss/AUCt (RAAUC)|Ratio of AUCt,ss/AUC (RLIN)|Biomarker Vascular Endothelial Growth Factor (VEGF) Plasma Levels|Biomarker Soluble Vascular Endothelial Growth Factor Receptor 2 (sCEGFR-2) Plasma Levels","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","86","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","11651","February 2007","November 2013","November 2013","May 5, 2010","January 19, 2015","November 18, 2015","Los Angeles, California, United States|Aurora, Colorado, United States|Houston, Texas, United States|San Antonio, Texas, United States|San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01117623"
870,"NCT01110629","Study in Chronic Kidney Disease (CKD) Not on Dialysis",,"Completed","No Results Available","Hyperphosphatemia","Drug: Fosrenol (Lanthanum Carbonate, BAY77-1931)|Drug: Placebo","The change from baseline in serum phosphate concentrations|Achievement of target serum phosphate level (2.7 to 4.6 mg/dL)|Change in serum Calcium x Phosphor product|Serum intact PTH level|Phosphate excretion in urine","Bayer|Shire","All","20 Years and older   (Adult, Older Adult)","Phase 3","143","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","14817","June 2010","November 2011","November 2011","April 26, 2010",,"October 15, 2014","Anjo, Aichi, Japan|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Seto, Aichi, Japan|Toyohashi, Aichi, Japan|Yatomi, Aichi, Japan|Kamogawa, Chiba, Japan|Kisarazu, Chiba, Japan|Kitakyushu, Fukuoka, Japan|Kitakyushu, Fukuoka, Japan|Koga, Fukuoka, Japan|Sapporo, Hokkaido, Japan|Amagasaki, Hyogo, Japan|Fujisawa, Kanagawa, Japan|Kamakura, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Beppu, Oita, Japan|Kurashiki, Okayama, Japan|Sakai, Osaka, Japan|Koto, Tokyo, Japan|Meguro-ku, Tokyo, Japan|Minato-ku, Tokyo, Japan|Musashino, Tokyo, Japan|Shinagawa, Tokyo, Japan|Fukuoka, Japan|Fukuoka, Japan|Kyoto, Japan|Oita, Japan|Okayama, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Saga, Japan|Shizuoka, Japan|Tokushima, Japan|Wakayama, Japan",,"https://ClinicalTrials.gov/show/NCT01110629"
871,"NCT01110590","Multiple Dose Escalation Study (14 Days) to Investigate Safety, Tolerability, PK and PD of Vardenafil and BAY60-4552",,"Completed","No Results Available","Erectile Dysfunction","Drug: BAY60-4552 + Vardenafil|Drug: Placebo","Adverse Event reporting|Plasma concentration of study drugs; Pharmacokinetic parameters: AUC, Cmax, AUC/D, Cmax;norm, Cmax/D, t1/2, tmax|Plasma concentration of cyclic guanosine monophosphate (cGMP)","Bayer","Male","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","37","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","14612|2009-015894-11","January 2010","April 2010","May 2010","April 26, 2010",,"February 22, 2013","Mönchengladbach, Nordrhein-Westfalen, Germany",,"https://ClinicalTrials.gov/show/NCT01110590"
872,"NCT01106352","A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)",,"Completed","Has Results","Bone Metastases|Castration-Resistant Prostate Cancer","Drug: Radium-223 dichloride (Xofigo, BAY88-8223)|Drug: Docetaxel","Number of Subjects With Dose-Limiting Toxicities - Dose Escalation Part|Number of Subjects With Treatment-Emergent Adverse Events (TEAE), Treatment-Emergent Serious Adverse Events (TESAE) With a CTCAE Grade of 3 or 4|Change From Baseline in Serum Biochemistry (Albumin, Protein, Hemoglobin) During the Treatment Period|Change From Baseline in Serum Biochemistry (Alkaline Phosphatase [AP], Alanine Aminotransferase [AAT], Lactate Dehydrogenase [LD]) During the Treatment Period|Change From Baseline in Serum Biochemistry (Bilirubin, Creatinine) During the Treatment Period|Change From Baseline in Serum Biochemistry (Calcium, Chloride, Magnesium, Potassium, Phosphate, Sodium, Urea) During the Treatment Period|Change From Baseline in Serum Biochemistry (Platelets, Leukocytes, Lymphocytes, Neutrophils, Monocytes, Eosinophils, Basophils) During the Treatment Period|Change From Baseline in Serum Biochemistry (Erythrocytes) During the Treatment Period|Changes From Baseline in Systolic and Diastolic Blood Pressure During the Treatment Period|Changes From Baseline in Respiratory Rate During the Treatment Period|Changes From Baseline in Heart Rate During the Treatment Period|Changes From Baseline in Weight During the Treatment Period|Number of Subjects With Physical Examination During the Treatment Period|Number of Subjects With Signs of Long-Term Radiation Toxicity","Bayer","Male","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","70","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15469|BC1-10|2011-000822-31","July 2010","June 2015","June 2015","April 19, 2010","November 9, 2016","January 4, 2017","San Francisco, California, United States|Evanston, Illinois, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|New York, New York, United States|Seattle, Washington, United States|Villejuif Cedex, France",,"https://ClinicalTrials.gov/show/NCT01106352"
873,"NCT01106118","Therapeutic Effectiveness of Vardenafil in Patients With Erectile Dysfunction and Metabolic Syndrome in Daily Clinical Practice","REVITALISE","Completed","No Results Available","Erectile Dysfunction","Drug: Vardenafil (Levitra, BAY38-9456)","The percentage of patients with a clinically relevant, intra-individual improvement in erectile function defined as an increase of 4 points in the erectile function domain of the International Index of Erectile Function (IIEF)|Patients with an increase of 5 points in the Erectile Dysfunction domain of the IIEF after approx. 12 weeks|Subjects with normal erectile function (IIEF-EF ³26) After approx. 12 weeks|Subjects with mild Erectile Dysfunction (IIEF-EF 22-25) After approx. 12 weeks|Optional by country, the effect of vardenafil on health-related quality of life (HRQoL) using the Aging Males Symptoms (AMS) Scale","Bayer","Male","18 Years and older   (Adult, Older Adult)",,"2289","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14872|LV0901","January 2010","December 2012","August 2013","April 19, 2010",,"October 17, 2016","Many Locations, Egypt|Many Locations, Israel|Many Locations, Kazakhstan|Many Locations, Korea, Republic of|Many Locations, Kyrgyzstan|Many Locations, Lebanon|Many Locations, Russian Federation|Many Locations, Saudi Arabia|Many Locations, Singapore|Many Locations, Ukraine",,"https://ClinicalTrials.gov/show/NCT01106118"
874,"NCT01105208","Cross Over Study to Prove Bioequivalence Between Two Brands of Cefalexin Suspension",,"Completed","No Results Available","Anti-Infective Agents","Drug: Cephalexin suspension (Optocef, BAYO5448 )|Drug: Cephalexin suspension (Keflex)","Least square estimator of average maximum plasmatic concentration (log transformed)|Least square estimator of area under the pharmacokinetic curve (log transformed)|Time at which maximum concentration is reached|Area under the pharmacokinetic curve from time=0 to last blood sample|Clearance constant of plasmatic concentrations of study drug|Half life of plasmatic concentration of study drug|Adverse events collection","Bayer|Corporación Bonima S.A. de C.V.","All","18 Years to 55 Years   (Adult)","Phase 1","26","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15188|Biocef-S","March 2010","March 2010","March 2010","April 16, 2010",,"May 20, 2014","Morelia, Michoacán, Mexico",,"https://ClinicalTrials.gov/show/NCT01105208"
875,"NCT01104584","Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)","GEMMA 2","Completed","Has Results","Breast Cancer","Drug: Gadobutrol (Gadavist, Gadovist, BAY86-4875)","Difference of Sensitivity for Detection of Full Extent of Malignant Breast Disease Using CMRM vs UMRM Per Reader|Sensitivity for Detection of Full Extent of Malignant Breast Disease Using CMRM vs UMRM Per Reader|Breast Level Specificity of CMRM for Non-malignant Breasts by Reader|Breast Level Specificity of CMRM Based on Malignant Breasts|Percentage Difference of Participants Whose Index Cancers Were Detected Using CMRM vs UMRM, CMRM vs XRM, and CMRM vs CMRM+XRM|Percentage Difference of Participants Whose Additional Index Cancers Were Detected Using CMRM vs UMRM, CMRM vs XRM, and CMRM vs CMRM+XRM|Difference of Confidence in Diagnosis for Breast Region Diagnosis Using CMRM vs UMRM, CMRM+XRM vs UMRM+XRM and CMRM+XRM vs XRM by Reader, Participant Level","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","460","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","91782|2009-009598-90","May 2010","September 2011","January 2012","April 15, 2010","November 11, 2014","November 11, 2014","Tucson, Arizona, United States|Oakland, California, United States|Englewood, Colorado, United States|Chicago, Illinois, United States|New York, New York, United States|Columbus, Ohio, United States|Providence, Rhode Island, United States|San Antonio, Texas, United States|Tacoma, Washington, United States|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Hamilton, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Erlangen, Bayern, Germany|München, Bayern, Germany|Frankfurt, Hessen, Germany|Greifswald, Mecklenburg-Vorpommern, Germany|Göttingen, Niedersachsen, Germany|Göttingen, Niedersachsen, Germany|Bochum, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Gera, Thüringen, Germany|Berlin, Germany|Mumbai, Maharashtra, India|Delhi, India|Mumbai, India|Eindhoven, EJ, Netherlands|Maastricht, Netherlands|Nijmegen, Netherlands|Bydgoszcz, Poland|Gliwice, Poland|Krakow, Poland|Szczecin, Poland|Warszawa, Poland|Sabadell, Barcelona, Spain|Alzira, Valencia, Spain|Barcelona, Spain|Cordoba, Spain|Girona, Spain|Taichung, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taizung, Taiwan",,"https://ClinicalTrials.gov/show/NCT01104584"
876,"NCT01103323","Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy",,"Completed","Has Results","Metastatic Colorectal Cancer","Drug: Regorafenib (Stivarga, BAY73-4506)|Drug: Placebo|Other: Best Supportive Care (BSC)","Overall Survival|Progression-free Survival (Based on Investigator's Assessment)|Objective Tumor Response|Disease Control|Tumor Response","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","760","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","14387|2009-012787-14","April 2010","July 2011","January 2014","April 14, 2010","November 19, 2012","June 24, 2015","Beverly Hills, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|Mission Hills, California, United States|Orange, California, United States|Redlands, California, United States|Santa Maria, California, United States|Aventura, Florida, United States|Jacksonville, Florida, United States|Peoria, Illinois, United States|Cedar Rapids, Iowa, United States|New Orleans, Louisiana, United States|Ann Arbor, Michigan, United States|Rochester, Minnesota, United States|St. Cloud, Minnesota, United States|Jefferson City, Missouri, United States|Neptune, New Jersey, United States|New York, New York, United States|Fargo, North Dakota, United States|Toledo, Ohio, United States|Scranton, Pennsylvania, United States|Charleston, South Carolina, United States|Sumter, South Carolina, United States|Dallas, Texas, United States|Salt Lake City, Utah, United States|Green Bay, Wisconsin, United States|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Rosario, Santa Fe, Argentina|San Miguel de Tucumán, Tucuman, Argentina|Capital Federal-Buenos Aires, Argentina|Concord, New South Wales, Australia|St Leonards, New South Wales, Australia|Woolloogabba, Queensland, Australia|Woodville South, South Australia, Australia|Footscray, Victoria, Australia|Parkville, Victoria, Australia|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Edegem, Belgium|Leuven, Belgium|Roeselare, Belgium|Salvador, Bahia, Brazil|Fortaleza, Ceará, Brazil|Belo Horizonte, Minas Gerais, Brazil|Ijuí, Rio Grande do Sul, Brazil|Vancouver, British Columbia, Canada|Winnipeg, Manitoba, Canada|Moncton, New Brunswick, Canada|London, Ontario, Canada|Mississauga, Ontario, Canada|Oshawa, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Quebec, Canada|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Nanjing, Jiangsu, China|Nanjing, Jiangsu, China|Qingdao, Shandong, China|Beijing, China|Beijing, China|Changchun, China|Chongqing, China|Chongqing, China|Fuzhou, China|Fuzhou, China|Ha'erbin, China|Hanghzou, China|Shanghai, China|Shanghai, China|Tianjin, China|Brno, Czech Republic|Hradec Kralove, Czech Republic|Olomouc, Czech Republic|Praha, Czech Republic|Avignon, France|Le Mans Cedex 2, France|Lille Cedex, France|Lille Cedex, France|Marseille, France|Montpellier, France|Paris, France|Reims, France|Rennes, France|Strasbourg Cedex, France|Freiburg, Baden-Württemberg, Germany|Karlsruhe, Baden-Württemberg, Germany|Mannheim, Baden-Württemberg, Germany|Stuttgart, Baden-Württemberg, Germany|München, Bayern, Germany|München, Bayern, Germany|München, Bayern, Germany|Hannover, Niedersachsen, Germany|Oldenburg, Niedersachsen, Germany|Essen, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Leverkusen, Nordrhein-Westfalen, Germany|Porta Westfalica, Nordrhein-Westfalen, Germany|Trier, Rheinland-Pfalz, Germany|Halle, Sachsen-Anhalt, Germany|Magdeburg, Sachsen-Anhalt, Germany|Dresden, Sachsen, Germany|Berlin, Germany|Budapest, Hungary|Debrecen, Hungary|Nyiregyhaza, Hungary|Szeged, Hungary|Ashkelon, Israel|Beer Sheva, Israel|Haifa, Israel|Holon, Israel|Jerusalem, Israel|Petach Tikva, Israel|Rehovot, Israel|Tel Aviv, Israel|Tel Hashomer, Israel|Zrifin, Israel|Brescia, Italy|Genova, Italy|Milano, Italy|Milano, Italy|Modena, Italy|Napoli, Italy|Pisa, Italy|Reggio Emilia, Italy|Roma, Italy|Nagoya, Aichi, Japan|Kashiwa, Chiba, Japan|Matsuyama, Ehime, Japan|Sapporo, Hokkaido, Japan|Osakasayama, Osaka, Japan|Takatsuki, Osaka, Japan|Hidaka, Saitama, Japan|Kita-Adachigun, Saitama, Japan|Sunto, Shizuoka, Japan|Shimotsuke, Tochigi, Japan|Utsunomiya, Tochigi, Japan|Bunkyo-ku, Tokyo, Japan|Chuo-ku, Tokyo, Japan|Koto-ku, Tokyo, Japan|Mitaka, Tokyo, Japan|Chiba, Japan|Fukuoka, Japan|Kochi, Japan|Kumamoto, Japan|Osaka, Japan|Amsterdam, Netherlands|Hoofddorp, Netherlands|Leeuwarden, Netherlands|Leiden, Netherlands|Aveiro, Portugal|Coimbra, Portugal|Lisboa, Portugal|Porto, Portugal|Porto, Portugal|Hospitalet de Llobregat, Barcelona, Spain|Sabadell, Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Málaga, Spain|Sevilla, Spain|Chur, Graubünden, Switzerland|Genève, Switzerland|Ankara, Turkey|Instanbul, Turkey|Istanbul, Turkey|Izmir, Turkey",,"https://ClinicalTrials.gov/show/NCT01103323"
877,"NCT01098760","Hepatocellular Carcinoma - Advanced Stage - Sorafenib Trial in Taiwanese Patients","HATT","Completed","No Results Available","Hepatocellular Carcinoma","Drug: Sorafenib (Nexavar, BAY43-9006) Sorafenib (Nexavar, BAY43-9006) + Nerison Fatty Ointment Sorafenib (Nexavar, BAY43-9006)+Neribas Fatty Ointment","Time to progression|Progression-free survival|Overall survival|Adverse event and serious adverse event (SAE) profiles|Child-Pugh status progression|Plasma Sorafenib exposure (AUC0-12)|For subjects randomized into HFSR study subgroup: overall HFSR incidence in the first 3 weeks of Sorafenib treatment|For HFSR study subgroup: a mean HFSR grade determined at the end of the first 3 weeks of sorafenib treatment.","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 4","151","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14898|HATT","August 2010","March 2013","October 2013","April 5, 2010",,"October 31, 2013","Chia Yi, Taiwan|Hualien county, Taiwan|Kaohsiung City, Taiwan|Kaohsiung City, Taiwan|Taichung City, Taiwan|Taipei City,, Taiwan|Taoyuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT01098760"
878,"NCT01096511","Moxifloxacin i.v. in the Treatment of Complicated Intra-Abdominal Infection (cIAI)",,"Completed","No Results Available","Secondary Peritonitis|Abscess, Intra-Abdominal","Drug: Moxifloxacin (Avelox, BAY12-8039)","Types of cIAI infections|Cure rate|Clinical signs and symptoms|Duration until improvement and cure|Adverse event collection","Bayer","All","18 Years and older   (Adult, Older Adult)",,"1001","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14537|AX0910CN","December 2009","January 2011","January 2011","March 31, 2010",,"June 21, 2013","Many locations, China",,"https://ClinicalTrials.gov/show/NCT01096511"
879,"NCT01096498","Cross -Over Study to Prove Bioequivalence Between Two Oral Formulations of Levonorgestrel","LEVEQ-2","Completed","No Results Available","Contraception|Contraception, Postcoital","Drug: Levonorgestrel Emergency Pill (BAY86-5028/Opxion)|Drug: Levonorgestrel (Postday)","Least square estimator of average maximum plasmatic concentration (log transformed)|Least square estimator of area under the pharmacokinetic curve (log transformed)|Time at which maximum concentration is reached|Area under the pharmacokinetic curve from time=0 to last blood sample|Half life of plasmatic concentration of study drug|Clearance constant of plasmatic concentration of study drug|Adverse event collection","Bayer","Male","18 Years to 55 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","14355","February 2009","March 2009","March 2009","March 31, 2010",,"June 11, 2013","Morelia, Michoacán, Mexico",,"https://ClinicalTrials.gov/show/NCT01096498"
880,"NCT01096485","Cross-over Study to Prove Bioequivalence Between Two Oral Formulations of Levonorgestrel","LEVEQ-1","Completed","No Results Available","Contraception|Contraception, Postcoital","Drug: Levonorgestrel Emergency Pill (BAY86-5028/Opxion)|Drug: Levonorgestrel (Postday)","Least square estimator of average maximum plasmatic concentration (log transformed)|Least square estimator of area under the pharmacokinetic curve (log transformed)|Time at which maximum concentration is reached|Area under the pharmacokinetic curve from time=0 to time of last blood sample|Clearance constant of plasmatic concentration of study drug|Half life of plasmatic concentration of study drug|Adverse events collection","Bayer","Male","18 Years to 55 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","13956","February 2009","March 2009","March 2009","March 31, 2010",,"June 11, 2013","Morelia, Michoacán, Mexico",,"https://ClinicalTrials.gov/show/NCT01096485"
881,"NCT01096030","Phase I Study of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors",,"Completed","No Results Available","Neoplasms","Drug: Regorafenib (Stivarga, BAY73-4506)","Pharmacokinetics as measured by cmax and AUC|Adverse Event collection|Objective tumor response rate","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","33","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14996","July 2010","November 2012","November 2012","March 30, 2010",,"November 19, 2013","Shatin, N.T, Hong Kong|Hong Kong, Hong Kong|Singapore, Singapore|Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT01096030"
882,"NCT01095081","GARDIAN, Gadovist in Routine Diagnostic Magnetic Resonance Imaging Administration in Non-selected Patients","GARDIAN","Completed","No Results Available","Magnetic Resonance Imaging|Magnetic Resonance Angiography","Drug: Gadobutrol (Gadovist, BAY86-4875)","Number of Adverse Event Collection / Calculation of Adverse Event rates in Study population and subgroups|Analysis of Adverse Event Collection rates according to age, gender, concomitant diseases and risk factors, dose administered.","Bayer","All","Child, Adult, Older Adult",,"23775","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14823|GV0901","July 2010","April 2013","April 2013","March 29, 2010",,"January 21, 2015","Many Locations, Bosnia and Herzegovina|Many Locations, Canada|Many Locations, China|Many Locations, Czech Republic|Many Locations, France|Many Locations, Germany|Many Locations, Greece|Many Locations, Hong Kong|Many Locations, Hungary|Many Locations, Italy|Many Locations, Kazakhstan|Many Locations, Korea, Republic of|Many Locations, Kyrgyzstan|Many Locations, Poland|Many Locations, Russian Federation|Many Locations, South Africa|Many Locations, Spain|Many Locations, Taiwan|Many Locations, Thailand|Many Locations, Vietnam",,"https://ClinicalTrials.gov/show/NCT01095081"
883,"NCT01092858","NEBIDO in Symptomatic Late Onset Hypogonadism (SLOH)",,"Terminated","No Results Available","Hypogonadism","Drug: Testosterone Undeconate (Nebido, BAY86-5037)|Drug: Placebo","Dynamic maximum strength -one repetition maximum (1-RM ) - of upper and lower extremity after 54 weeks|Isometric maximum strength|Grip strength|Chair raising test|Arm curl test|Bicycle stress test with spirometry|SF-36 Questionnaire|AMS-Questionnaire|FINGER Questionnaire","Bayer","Male","60 Years and older   (Adult, Older Adult)","Phase 4","4","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","14853|2009-017139-16","September 2010","July 2011","July 2011","March 25, 2010",,"November 5, 2014","Köln, Nordrhein-Westfalen, Germany",,"https://ClinicalTrials.gov/show/NCT01092858"
884,"NCT01085487","MiCo - Mirena or Conventional Medical Treatment for Menorrhagia",,"Completed","No Results Available","Idiopathic Menorrhagia","Drug: Levonorgestrel (Mirena, BAY86-5028)|Drug: Hormonal treatment|Drug: Antifibrinolytic treatment","Cumulative continuation rate at 12 months stratified by history of previous treatment(s) for menorrhagia|Bleeding pattern|Patient satisfaction at end of documentation|Impact of the therapy in terms of patient-reported health outcomes assessed using a validated questionnaire (Shaw RW et. al., British Journal of Obstetrics and Gynaecology, Vol 105(11), 1998.)|Safety profile (adverse events)","Bayer","Female","18 Years to 45 Years   (Adult)",,"1211","Industry","Observational","Observational Model: Case Control|Time Perspective: Prospective","14536|MA0901|MA0701-14697","April 2009",,"June 2011","March 12, 2010",,"April 10, 2012","Many Locations, Albania|Many Locations, Bosnia and Herzegovina|Many Locations, Colombia|Many Locations, Croatia|Many Locations, Czech Republic|Many Locations, Jordan|Many Locations, Lebanon|Many Locations, Macedonia, The Former Yugoslav Republic of|Many Locations, Moldova, Republic of|Many Locations, Romania|Many Locations, South Africa|Many Locations, Syrian Arab Republic|Many Locations, Ukraine|Many Locations, Venezuela",,"https://ClinicalTrials.gov/show/NCT01085487"
885,"NCT01083264","Relative Bioavailability, Transdermally Administered EE and GSD, 3 Applications Sites",,"Completed","No Results Available","Contraception","Drug: Gestodene/EE Patch (BAY86-5016)","AUC(0-168) for EE and Gestodene during week 4 of each treatment period|Pharmacokinetic parameters of EE and GSD: Cmax, Cmin, Cav, tmax, t1/2 obtained during week 4, Ctrough obtained at the end of each week|Adverse Events","Bayer","Female","18 Years to 45 Years   (Adult)","Phase 1","43","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","91608|2009-011151-52","October 2009","May 2010","May 2010","March 9, 2010",,"June 23, 2014","Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT01083264"
886,"NCT01081353","Pharmacokinetic Study Comparing Aspirin and Effervescent Aspirin",,"Completed","No Results Available","Pharmacokinetics","Drug: Acetylsalicylic Acid (Aspirin BAY1019036)|Drug: Alka Seltzer Extra Strength|Drug: Aspirin Migraine|Drug: Aspirin Aspro","Bioavailability of new formulation aspirin versus marketed effervescent tablets (500mg aspirin)|Adverse event collection","Bayer","All","18 Years to 55 Years   (Adult)","Phase 1","26","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14961","February 2010","March 2010","March 2010","March 5, 2010",,"June 26, 2014","Hackensack, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01081353"
887,"NCT01077076","Pharmacodynamic Study Comparing the Effects of Two Different Forms of Omeprazole (P07812) (COMPLETED)",,"Completed","Has Results","Intragastric Acidity","Drug: Zegerid|Drug: Prilosec OTC™ Tablets|Other: Placebo","Percent Time With Intragastric pH>4 During the First 4 Hours Following Administration on Day 4 of Treatment","Bayer","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","18132|P07812","December 2008","March 2009","March 2009","February 26, 2010","April 2, 2010","March 11, 2015",,,"https://ClinicalTrials.gov/show/NCT01077076"
888,"NCT01076595","Prospective, Multicenter Non Interventional Study to Evaluate Adherence to Betaferon Over a 2 Years Period","SEPLUS","Completed","No Results Available","Multiple Sclerosis","Drug: Interferon beta-1b (Betaseron, BAY86-5046)","The adherence to treatment (rate of patients continuing with Betaferon® regimen after 24 months)|Compliance to Betaferon according physician (rate of patients with compliance rater > 94,5%)|Adherence to treatment (rate of patients continuing with the Betaferon® regimen at 6 and 12 months)|Rate of patients with prematurely study discontinuation|Patient's autonomy with regard to the Betaferon® injections (Number of injections realized by the patient alone/total number of injections)|Tolerability of Betaferon injections (rate and number of injections)|Patient's Quality of Life (Mean total score of FAMS [Functional Assessment of Multiple Sclerosis])|Fatigue (mean total score of FSS [Fatigue Severity scale])|Progression of clinical Condition( annual rate of Relapses)|Percentage of patients with change of in EDSS (Expanded Disability Status Scale) < 1 between M0 and end of the study|Percentage of patients with change in EDSS< 1 and no relapse between M0 and M24","Bayer","All","18 Years and older   (Adult, Older Adult)",,"73","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","15098|BF0910FR","May 2010","November 2013","July 2014","February 26, 2010",,"July 3, 2015","Many Locations, France",,"https://ClinicalTrials.gov/show/NCT01076595"
889,"NCT01076582","Comparative Trial in Hormone Withdrawal Associated Symptoms",,"Completed","No Results Available","Oral Contraceptive","Drug: EE20/DRSP (YAZ, BAY86-5300)|Drug: Ethinylestradiol (EE) and desogestrel (DSG) (Mercilon)","Change from baseline to cycle 4 in the sum of composite score during cycle days 22 - 28. The composite score comprises headache, pelvic pain and bloating (each measured by 7-point Likert scales).|change from baseline to cycle 4 in the sum of individual scores during cycle days 22 - 28 (AUC of days 22 - 28 for each score),|change from baseline to cycle 4 in number of days, where individual hormone withdrawal symptoms are present on cycle days 22 - 28 (i.e. Likert Scale >= 1),|change from baseline to cycle 4 in maximum intensity of individual hormone withdrawal symptoms on cycle days 22 - 28,|rescue medication consumption|bleeding pattern|evaluation of questionnaires: Q-LES-Q (short version)|Adverse Event collection|heart rate|blood pressure","Bayer","Female","18 Years to 35 Years   (Adult)","Phase 3","592","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","14567|2009-014911-11","April 2010","October 2011","October 2011","February 26, 2010",,"October 28, 2014","Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Rosario, Santa Fe, Argentina|Santiago de Chile, Santiago, Chile|Santiago de Chile, Chile|Santiago, Chile|Santiago, Chile|Santiago, Chile|Temuco, Chile|Bucaramanga, Santander, Colombia|Bogotá, Colombia|Medellín, Colombia|Brno, Czech Republic|Praha 2, Czech Republic|Tabor, Czech Republic|Heidelberg, Baden-Württemberg, Germany|Fürth, Bayern, Germany|Hannover, Niedersachsen, Germany|Magdeburg, Sachsen-Anhalt, Germany|Leipzig, Sachsen, Germany|Jena, Thüringen, Germany|Firenze, Italy|Milano, Italy|Siena, Italy|Seoul, Korea, Korea, Republic of|Seoul, Korea, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Manila, Philippines|Pasig City, Philippines|Coimbra, Portugal|Lisboa, Portugal|Porto, Portugal|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Basel, Basel-Stadt, Switzerland|St. Gallen, Sankt Gallen, Switzerland|Bern, Switzerland|Bangkok, Thailand|Bangkok, Thailand|Songkla, Thailand|Leeds, West Yorkshire, United Kingdom|Liverpool, United Kingdom|London, United Kingdom|Caracas, Venezuela",,"https://ClinicalTrials.gov/show/NCT01076582"
890,"NCT01073904","Cross-over Study to Prove Bioequivalence Between Two Oral Formulations of Levonorgestrel 1.5 mg","LEVEQ-3","Completed","No Results Available","Contraceptives, Postcoital","Drug: Levonorgestrel Emergency Pill (BAY86-5028)|Drug: Postinor 2","Least square estimator of average maximum plasmatic concentration (log transformed)|Least square estimator of area under the pharmacokinetic curve (log transformed)|Time at which maximum concentration is reached|Area under the pharmacokinetic curve from time=0 to last blood sample|Half life of plasmatic concentration of study drug|Clearance constant of plasmatic concentration of study drug|Adverse events collection","Bayer","Male","18 Years to 55 Years   (Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","14782","September 2009","September 2009","September 2009","February 23, 2010",,"April 3, 2014","Morelia, Michoacán, Mexico",,"https://ClinicalTrials.gov/show/NCT01073904"
891,"NCT01073891","Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults",,"Completed","No Results Available","Healthy","Drug: Moxifloxacin (Avelox, BAY12-8039)|Drug: Moxifloxacin (BAY12-8039)","Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC) of Moxifloxacin after a Single Dose|Maximum Observed Drug Concentration (Cmax) of Moxifloxacin after a Single Dose|Area Under the Concentration Versus Time Curve From Zero to Infinity Divided by Dose(AUC/D) of Moxifloxacin after a Single Dose|Maximum Observed Drug Concentration Adjusted by Dose (Cmax/D) of Moxifloxacin after a Single Dose|Area Under the Concentration Versus Time Curve From Zero to Infinity Divided by Dose per Kilogram Body Weight (AUC,norm) of Moxifloxacin after a Single Dose|Area Under the Concentration Versus Time Curve From Zero to Last Quantifiable Concentration [AUC(0-tlast)] of Moxifloxacin after a Single Dose|Maximum Observed Plasma Concentration Divided by Dose per Kilogram Body Weight (Cmax,norm) of Moxifloxacin after a Single Dose|Mean Residence Time (MRT) of Moxifloxacin after a Single Dose|Time to Reach Maximum Drug Concentration in Plasma (tmax) of Moxifloxacin after a Single Dose|Terminal Half Life Associated With the Terminal Slope (t1/2) of Moxifloxacin after a Single Dose|Apparent Oral Clearance (CL/F) of Moxifloxacin after a Single Dose","Bayer","All","18 Years to 55 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","14413|2009-017070-21","May 2010","November 2010","January 2011","February 23, 2010",,"July 1, 2015","Wuppertal, Nordrhein-Westfalen, Germany",,"https://ClinicalTrials.gov/show/NCT01073891"
892,"NCT01073553","Cross-over Study to Prove Bioequivalence Between Two Brands of Cefalexin Capsules",,"Completed","No Results Available","Anti-Infective Agents","Drug: Cephalexin capsules (Optocef, BAYO5448 )|Drug: Cephalexin capsules (Keflex)","Least square estimator of average maximum plasmatic concentration (log transformed)|Least square estimator of area under the pharmacokinetic curve (log transformed)|Time at which maximum concentration is reached|Area under the pharmacokinetic curve from time=0 to last blood sample|Clearance constant of plasmatic concentration of study drug|Half life of plasmatic concentration of study drug|Adverse events collection","Bayer|Corporación Bonima S.A. de C.V.","All","18 Years to 55 Years   (Adult)","Phase 1","26","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14784","October 2009","October 2009","October 2009","February 23, 2010",,"April 3, 2015","Morelia, Michoacán, Mexico",,"https://ClinicalTrials.gov/show/NCT01073553"
893,"NCT01073540","Cross-over Study to Prove Bioequivalence Between Two Brands of Cefalexin Suspension",,"Completed","No Results Available","Anti-Infective Agents","Drug: Cephalexin suspension (Optocef, BAYO5448)|Drug: Cephalexin suspension (Keflex)","Least square estimator of average maximum plasmatic concentration (log transformed)|Least square estimator of area under the pharmacokinetic curve (log transformed)|Time at which maximum concentration is reached|Area under the pharmacokinetic curve from time=0 to last blood sample|Clearance constant of plasmatic concentration of study drug|Half life of plasmatic concentration of study drug|Adverse events collection","Bayer|Corporación Bonima S.A. de C.V.","All","18 Years to 55 Years   (Adult)","Phase 1","26","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14783","September 2009","September 2009","September 2009","February 23, 2010",,"April 3, 2014","Morelia, Michoacán, Mexico",,"https://ClinicalTrials.gov/show/NCT01073540"
894,"NCT01072942","To Evaluate the Safety, Tolerability, Pulmonary Deposition, Pharmacokinetics and Pharmacodynamics of Ciprofloxacin Inhale in Japanese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD, GOLD II-III)",,"Completed","No Results Available","Pulmonary Disease, Chronic Obstructive","Drug: Ciprofloxacin (Cipro InhaIe, BAYQ3939)|Drug: Placebo","Adverse event collection|Microbiological examination|Ciprofloxacin concentration in sputum|Ciprofloxacin concentration in plasma","Bayer","All","20 Years to 80 Years   (Adult, Older Adult)","Phase 1","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","14019","January 2010","June 2010","July 2010","February 22, 2010",,"April 2, 2014","Yufu, Oita, Japan",,"https://ClinicalTrials.gov/show/NCT01072942"
895,"NCT01072604","Pharmacokinetic Study Comparing Aspirin and Aspirin Granules",,"Completed","No Results Available","Pharmacokinetics","Drug: Acetylsalicylic acid (Aspirin, BAY1019036)|Drug: Acetylsalicylic acid (Aspirin, BAYE4465)","Bioequivalence of new formula aspirin relative to the established commercial aspirin plain tablet and aspirin dry granules when taken orally by healthy adult subjects|To assess safety and tolerability of the new aspirin formula|To assess additional pharmacokinetic parameters","Bayer","All","18 Years to 55 Years   (Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14558","July 2009","August 2009","August 2009","February 22, 2010",,"April 21, 2014","Hackensack, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01072604"
896,"NCT01071694","QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea",,"Withdrawn","No Results Available","Multiple Sclerosis, Relapsing-Remitting","Drug: Interferon beta 1-b (Betaferon/Betaseron, BAY86-5046)","Quality of life evaluated by several validated questionnaire|Information about safety of Betaferon in routine clinical use","Bayer","All","18 Years and older   (Adult, Older Adult)",,"0","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","15110|Qolbet|BF1010KR","January 2011","December 2012","December 2012","February 19, 2010",,"April 16, 2012","Many locations, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01071694"
897,"NCT01071681","Survey to Assess Why People Are Not Responding to Treatment in Hypertension",,"Completed","No Results Available","Arterial Hypertension","Drug: Telmisartan (Kinzal/Pritor, BAY68-9291)","Percentage of patients, according to the level of cardiovascular risk, who, at the end of the visit:- do not present any modification of hypertension treatment (therapeutic inertia) - present a change in the hypertension therapeutic|Analyses of the factors that had an impact on the therapeutic decision","Bayer|International Clinical Trials Association","All","18 Years and older   (Adult, Older Adult)",,"1589","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","14675|KL0911FR|BI INTENS","November 2009","September 2010","September 2010","February 19, 2010",,"November 2, 2011","Many Locations, France",,"https://ClinicalTrials.gov/show/NCT01071681"
898,"NCT01071122","FOCUS (Nifedipine GITS's Effect on Central Pressure Assessed by Applanation Tonometry)",,"Completed","No Results Available","Hypertension","Drug: Nifedipine (Adalat, BAYA1040) and Valsartan|Drug: Nifedipine (Adalat, BAYA1040)|Drug: Valsartan","Central systolic blood pressure|Change in central diastolic blood pressure and pulse pressure|Change in central systolic blood pressure|Change in brachial systolic blood pressure and diastolic blood pressure|Change in brachial pulse pressure|Change in augmentation index and augmentation pressure|Response rate(≥10 mmHg decrease of brachial SBP and ≥5mmHg decrease of brachial DBP)|Control rate (≤140/90 mmHg, 130/80 mmHg for diabetes, of brachial BP","Bayer","All","20 Years to 70 Years   (Adult, Older Adult)","Phase 4","365","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14696","January 2010","February 2012","February 2012","February 19, 2010",,"January 27, 2014","Goyang-si, Gyeonggido, Korea, Republic of|Goyang, Gyeonggido, Korea, Republic of|Chungchungbuk-do, Korea, Korea, Republic of|Seoul, Korea, Korea, Republic of|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Busan, Korea, Republic of|Gwangju, Korea, Republic of|Joong-gu, Korea, Republic of|Kungki-do, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Suwan, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01071122"
899,"NCT01070485","BAY88-8223, Alpharadin, Breast Cancer Patients With Bone Dominant Disease",,"Completed","No Results Available","Breast Cancer|Bone Metastases","Drug: Radium-223 chloride (BAY88-8223)","Changes in bone markers (urine levels of NTX (uNTX) and bone-alkaline phosphatase (ALP)|All safety data, including adverse events, changes in laboratory variables, vitals signs, physical examination, late toxicity|Biochemical markers (additional bone markers and CA15.3)|Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)|Pain","Bayer","Female","21 Years and older   (Adult, Older Adult)","Phase 2","23","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15468|2009-012189-30|BC1-09","January 2010","March 2011","January 2012","February 18, 2010",,"June 25, 2014","Brussels, Belgium|Liège, Belgium|Oslo, Norway|Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01070485"
900,"NCT01069900","Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection","MOXIPEDIA","Completed","Has Results","Intraabdominal Infections","Drug: Moxifloxacin (Avelox, BAY12-8039)|Drug: Ertapenem|Drug: Amoxicillin/Clavulanate|Drug: Moxifloxacin placebo|Drug: Ertapenem placebo|Drug: Amoxicillin/Clavulanate placebo","Number of Subjects With Adverse Events|Number of Subjects With Clinical Cardiac Adverse Events|Number of Subjects With Musculoskeletal Adverse Events|Incidence Rates of Musculoskeletal Adverse Events by Primary System Organ Class (SOC) and Preferred Term|Heart Rate Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3|PR Interval Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3|RR Interval Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3|QRS Interval Changes in Electrocardiogram (ECG) Profiles From Predose to Post-dose on Treatment Day 1 and Treatment Day 3|QT Interval Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3|Corrected QT (QTc) Interval Calculated (Calc) Bazett Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3|Corrected QT (QTc) Interval Calculated (Calc) Fridericia Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3|Potentially Clinically Significant Electrocardiogram (ECG) QTc Interval Prolongation - by QTc Interval Calc Fridericia Correction on Treatment Day 1 and During Therapy Day 3|Potentially Clinically Significant Electrocardiogram (ECG) QTc Interval Prolongation - by QTc Calc Bazett Correction on Treatment Day 1 and During Therapy Day 3|Clinical Response at Test-of-Cure (TOC) Visit|Bacteriological Response at Test-of-Cure (TOC) Visit|Clinical Response at Test-of-Cure (TOC) Visit in Subjects With Bacteriologically Confirmed Complicated Intra-abdominal Infection (cIAI)|Clinical Response at a 'During Therapy' Visit|Bacteriological Response at a 'During Therapy' Visit|Clinical Response at the End-of-Treatment (EOT) Visit|Bacteriological Response at the End of Treatment (EOT) Visit","Bayer","All","3 Months to 17 Years   (Child)","Phase 3","458","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11643|1962 (Avelox pediatrics)|2009-015578-37","July 21, 2010","January 21, 2015","January 21, 2015","February 17, 2010","December 8, 2015","March 20, 2018","San Diego, California, United States|Springfield, Massachusetts, United States|Hospital de Agudos ""Dr. Carlos Bocalandro"", Tres De Febrero, Buenos Aires, Argentina|Pleven, Bulgaria|Plovdiv, Bulgaria|Ruse, Bulgaria|Sofia, Bulgaria|Stara Zagora, Bulgaria|Calgary, Alberta, Canada|Hamilton, Ontario, Canada|Montreal, Quebec, Canada|Santiago, Chile|Olomouc, Czechia|Prague, Czechia|Stuttgart, Baden-Württemberg, Germany|Regensburg, Bayern, Germany|Wuppertal, Nordrhein-Westfalen, Germany|Athens, Greece|Budapest, Hungary|Gyor, Hungary|Daugavpils, Latvia|Rezekne, Latvia|Riga, Latvia|Kaunas, Lithuania|Vilnius, Lithuania|México, D.F., Distrito Federal, Mexico|Ecatepec de Morelos, Estado De Mexico, Mexico|Guadalajara, Jalisco, Mexico|Cusco, Peru|Lima, Peru|Lima, Peru|Iasi, Romania|Timisoara, Romania|Smolensk, Russian Federation|Vladikavkaz, Russian Federation|Dnipropetrovsk, Ukraine|Ivano-Frankovsk, Ukraine|Lviv, Ukraine|Simferopol, Ukraine",,"https://ClinicalTrials.gov/show/NCT01069900"
901,"NCT01069328","Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)",,"Completed","No Results Available","Carcinoma, Non-Small-Cell Lung|Lung Cancer","Drug: Nexavar (Sorafenib, BAY43-9006)|Drug: Bevacizumab|Drug: Paclitaxel|Drug: Carboplatin","The primary objective of this study is to define the safety profile and maximum tolerated dose (MTD) of BAY43-9006 (sorafenib) administered in combination with, carboplatin, paclitaxel and bevacizumab|The secondary objectives include evaluation of pharmacokinetics, biomarkers, pharmacodynamics and tumor response of patients treated with BAY43-9006 (sorafenib) in combination with bevacizumab, paclitaxel and carboplatin","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","33","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","11956","July 2006","September 2011","October 2011","February 17, 2010",,"November 13, 2013","Rochester, Minnesota, United States|Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01069328"
902,"NCT01067976","Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI",,"Completed","Has Results","Breast Cancer|Diagnostic Imaging","Drug: Gadobutrol (Gadavist, Gadovist, BAY86-4875)","Difference for Sensitivity for Detection of Full Extent of Malignant Breast Disease Using CMRM vs UMRM Per Reader|Sensitivity for Detection of Full Extent of Malignant Breast Disease Using CMRM vs UMRM Per Reader|Breast Level Specificity of CMRM for Non-malignant Breasts by Reader|Breast Level Specificity of CMRM Based on Malignant Breasts|Percentage Difference of Participants Whose Index Cancers Were Detected Using CMRM vs UMRM, CMRM vs XRM, and CMRM vs CMRM+XRM|Percentage Difference of Participants Whose Additional Cancers Were Detected Using CMRM vs UMRM, CMRM vs XRM, and CMRM vs CMRM+XRM","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","446","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","91743|GEMMA 1|2009-009597-27","February 2010","July 2011","January 2012","February 12, 2010","November 11, 2014","November 11, 2014","La Jolla, California, United States|Los Angeles, California, United States|Newport Beach, California, United States|Washington, District of Columbia, United States|Springfield II, Illinois, United States|Boston, Massachusetts, United States|San Antonio, Texas, United States|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|São Paulo, Sao Paulo, Brazil|Rio de Janeiro, Brazil|Sao Paulo, Brazil|Medellin, Antioquia, Colombia|Bogotá, Cundinamarca, Colombia|Barranquilla, Colombia|Helsinki, Finland|Tampere, Finland|Tübingen, Baden-Württemberg, Germany|Marburg, Hessen, Germany|Hannover, Niedersachsen, Germany|Bielefeld, Nordrhein-Westfalen, Germany|Dortmund, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Magdeburg, Sachsen-Anhalt, Germany|Lübeck, Schleswig-Holstein, Germany|Potsdam, Germany|San Donato Milanese, Milano, Italy|Milano, Italy|Milano, Italy|Napoli, Italy|Udine, Italy|Ansan Si, Kyungki Do, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Chur, Graubünden, Switzerland|Baden, Switzerland|Bern, Switzerland",,"https://ClinicalTrials.gov/show/NCT01067976"
903,"NCT01067859","A Phase IIb Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 µg/h, 10 µg/h) Given Intravenously to Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)","COMPOSE 2","Terminated","No Results Available","Acute Heart Failure","Drug: Cinaciguat (BAY58-2667)|Drug: Placebo","Pulmonary Capillary Wedge Pressure|Cardiac index (CI)|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Right atrial pressure (RAP)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","5","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","14663|2009-014378-16","March 2010","September 2010","November 2010","February 12, 2010",,"October 8, 2015","Birmingham, Alabama, United States|Jacksonville, Florida, United States|Boston, Massachusetts, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Philadelphia, Pennsylvania, United States|Quilmes, Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Graz, Steiermark, Austria|Innsbruck, Tirol, Austria|Aalst, Belgium|Bruxelles - Brussel, Belgium|Leuven, Belgium|Creteil, France|PARIS cedex 10, France|Toulouse, France|Bad Krozingen, Baden-Württemberg, Germany|Bad Nauheim, Hessen, Germany|Bad Oeynhausen, Nordrhein-Westfalen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Berlin, Germany|Dublin, Ireland|Guadalajara, Jalisco, Mexico|Guadalajara, Jalisco, Mexico|Mexico D.F., México, Mexico|México D.F., Mexico|Quezon City, Philippines",,"https://ClinicalTrials.gov/show/NCT01067859"
904,"NCT01065623","Clinical Study to Evaluate the Maximum Tolerated Dose of BAY79-4620 Given Every 2 Weeks to Patients With Advanced Solid Tumors",,"Terminated","No Results Available","Neoplasms","Drug: BAY79-4620","Adverse Event reporting|Pharmacokinetics profile of BAY79-4620|Biomarkers evaluation|Tumor response evaluation|Immunogenicity evaluation","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","2","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12672|2009-015085-58","April 2010","August 2010","August 2010","February 9, 2010",,"October 1, 2014","Rotterdam, Netherlands|Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT01065623"
905,"NCT01065454","A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction","LEPHT","Active, not recruiting","Has Results","Hypertension, Pulmonary|Ventricular Dysfunction, Left","Drug: Riociguat (Adempas, BAY63-2521)|Drug: Placebo","Pulmonary Artery Mean Pressure (PAPmean) at Rest - Change From Baseline to Week 16|Venous Oxygen Saturation (SvO2) - Change From Baseline to Week 16|Pulmonary Vascular Resistance (PVR) - Change From Baseline to Week 16|Pulmonary Vascular Resistance Index (PVRi) - Change From Baseline to Week 16|Systemic Vascular Resistance (SVR) - Change From Baseline to Week 16|Systemic Vascular Resistance Index (SVRi) - Change From Baseline to Week 16|Transpulmonary Pressure Gradient (TPG) - Change From Baseline to Week 16|Pulmonary Capillary Wedge Pressure (PCWP) - Change From Baseline to Week 16|Tricuspid Annular Plane Systolic Excursion (TAPSE) - Change From Baseline to Week 16|Systolic Pulmonary Arterial Pressure (PAPsyst) - Change From Baseline to Week 16|Left Ventricular Ejection Fraction (LVEF) - Change From Baseline to Week 16|Left Ventricular End-systolic Volume (LVESV) - Change From Baseline to Week 16|Left Ventricular End-diastolic Volume (LVEDV) - Change From Baseline to Week 16|E-wave Deceleration Time - Change From Baseline to Week 16|Ratio of Mitral Peak Velocity of Early Filling to Mitral Peak Velocity of Late Filling (E/A) - Change From Baseline to Week 16|6-minute Walking Distance (6MWD) - Change From Baseline to Week 16|WHO (World Health Organization) Functional Class - Change From Baseline to Week 16|Percentage of Participants With Clinical Worsening|Borg CR 10 Scale - Change From Baseline to Week 16|EQ-5D Utility Score - Change From Baseline to Week 16|Minnesota Living With Heart Failure Questionnaire (MLHF) Score - Change From Baseline to Week 16|Cystatin C - Change From Baseline to Week 16|N-terminal Pro-brain Natriuretic Peptide (NT-pro BNP) - Change From Baseline to Week 16|Troponin T - Change From Baseline to Week 16|Asymmetric Dimethylarginine (ADMA) - Change From Baseline to Week 16|Osteopontin - Change From Baseline to Week 16","Bayer","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","201","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","14308|2009-015878-35","April 14, 2010","June 6, 2012","April 30, 2021","February 9, 2010","December 25, 2013","January 10, 2020","Fountain Valley, California, United States|Los Angeles, California, United States|San Diego, California, United States|Torrance, California, United States|Miami, Florida, United States|Iowa City, Iowa, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Rochester, Minnesota, United States|Saint Louis, Missouri, United States|Cincinnati, Ohio, United States|Fairfield, Ohio, United States|Falls Church, Virginia, United States|Milwaukee, Wisconsin, United States|Darlinghurst, New South Wales, Australia|Chermside, Queensland, Australia|Prahran, Victoria, Australia|Innsbruck, Tirol, Austria|Wien, Austria|Aalst, Belgium|Bruxelles - Brussel, Belgium|Gent, Belgium|Leuven, Belgium|Edmonton, Alberta, Canada|Vancouver, British Columbia, Canada|Montreal, Quebec, Canada|Quebec, Canada|Beijing, China|Shanghai, China|Shanghai, China|Brno, Czechia|Olomouc, Czechia|Praha 2, Czechia|Praha 4, Czechia|Aarhus N, Denmark|Bron, France|Lille Cedex, France|Nantes, France|Pessac, France|Rouen, France|Toulouse, France|Heidelberg, Baden-Württemberg, Germany|Augsburg, Bayern, Germany|Greifswald, Mecklenburg-Vorpommern, Germany|Köln, Nordrhein-Westfalen, Germany|Erfurt, Thüringen, Germany|Napoli, Campania, Italy|Pavia, Lombardia, Italy|Nagoya, Aichi, Japan|Seto, Aichi, Japan|Ogaki, Gifu, Japan|Higashiibaraki, Ibaraki, Japan|Tsu, Mie, Japan|Sendai, Miyagi, Japan|Suita, Osaka, Japan|Kusatsu, Shiga, Japan|Sunto, Shizuoka, Japan|Arakawa-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Tanabe, Wakayama, Japan|Osaka, Japan|Osaka, Japan|Amsterdam, Netherlands|Amsterdam, Netherlands|Nijmegen, Netherlands|Bydgoszcz, Poland|Gdansk, Poland|Warszawa, Poland|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|Majadahonda, Madrid, Spain|El Palmar, Murcia, Spain|Son Ferriol, Palma De Mallorca, Spain|A Coruña, Spain|Barcelona, Spain|Madrid, Spain|Valencia, Spain|Lugano, Ticino, Switzerland|Genève, Switzerland|Zürich, Switzerland|Cambridge, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01065454"
906,"NCT01065077","BAY58-2667 Dose Finding Trial Investigating Fixed Doses in Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)","COMPOSE 1","Terminated","No Results Available","Acute Heart Failure","Drug: Cinaciguat (BAY58-2667)|Drug: Placebo","Pulmonary Capillary Wedge Pressure|Cardiac index (CI)|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Right atrial pressure (RAP)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","14560|2009-014377-40","March 2010","January 2011","February 2011","February 9, 2010",,"October 8, 2015","Ridgewood, New Jersey, United States|Winston-Salem, North Carolina, United States|Cleveland, Ohio, United States|Fairfield, Ohio, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Linz, Oberösterreich, Austria|Wien, Austria|Zagreb, Croatia|Helsinki, Finland|Oulu, Finland|Greifswald, Mecklenburg-Vorpommern, Germany|Köln, Nordrhein-Westfalen, Germany|Homburg, Saarland, Germany|Erfurt, Thüringen, Germany|Jena, Thüringen, Germany|Haifa, Israel|Jerusalem, Israel|Tiberias, Israel|San Fermo della Battaglia, Como, Italy|Brescia, Italy|Ferrara, Italy|Mantova, Italy|Torino, Italy|Nagoya, Aichi, Japan|Kure, Hiroshima, Japan|Higashiibaraki, Ibaraki, Japan|Kawasaki, Kanagawa, Japan|Omura, Nagasaki, Japan|Bunkyo-ku, Tokyo, Japan|Shinagawa, Tokyo, Japan|Osaka, Japan|Gdansk, Poland|Lodz, Poland|Warszawa, Poland|Warszawa, Poland|Wroclaw, Poland|Zabrze, Poland|Zgorzelec, Poland|Bucharest, Romania|Cluj-Napoca, Romania|Krasnoyarsk, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Beograd, Serbia|Nis, Serbia|Sremska Kamenica, Serbia|Lucenec, Slovakia|Martin, Slovakia|Celje, Slovenia|Golnik, Slovenia|Ljubljana, Slovenia|Göteborg, Sweden|Uppsala, Sweden|Lugano, Ticino, Switzerland|Zürich, Switzerland|Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT01065077"
907,"NCT01065051","Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation Kinetics","HEARTWORK","Terminated","Has Results","Hypertension, Pulmonary|Ventricular Dysfunction, Left","Drug: Riociguat (Adempas, BAY63-2521)|Drug: Placebo","Change in Peak Power Index at Rest|Change in Left Ventricular Stroke Work Index (LVSWI) at Rest|Change in Left Ventricular Ejection Fraction (LVEF) at Rest|Change in End-systolic Elastance at Rest|Change in Peak Power Index During the Cardiopulmonary Exercise Tests|Change in Lateral Mitral Annular Peak Systolic Velocity (Sm) During the Cardiopulmonary Exercise Tests|Change in Peak Systolic Tricuspid Annular Velocity (RV-Sm) During the Cardiopulmonary Exercise Tests|Change in Tricuspid Annular Plane Systolic Excursion (TAPSE) During the Cardiopulmonary Exercise Tests|Change in Lateral Mitral Annular Peak Early Diastolic Velocity (E') During the Cardiopulmonary Exercise Tests|Change in the Slope of the Relationship Between Work Rate and Mean Pulmonary Arterial Pressure (PAPmean) During the Cardiopulmonary Exercise Tests|Change in the Ventilatory Efficiency (V'E/V'CO2) Measured From Baseline to the Anaerobic Threshold (AT) During the Cardiopulmonary Exercise Tests (CPET)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","1","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","14549","November 2010","January 2011","January 2011","February 9, 2010","January 6, 2014","January 6, 2014","Boston, Massachusetts, United States|Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01065051"
908,"NCT01064453","Angeliq Regulatory Post Marketing Surveillance","Angeliq rPMS","Completed","No Results Available","Postmenopausal Period|Osteoporosis, Postmenopausal","Drug: E2/DRSP (Angeliq, BAY86-4891)","Adverse event collection|Improvement of menopausal symptoms","Bayer","Female","Child, Adult, Older Adult",,"4078","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14841|AQ0710KR","June 2007","December 2012","December 2012","February 8, 2010",,"November 19, 2013","Many Locations, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01064453"
909,"NCT01064037","A Phase IIb Study to Investigate the Efficacy and Tolerability of Cinaciguat (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF)","COMPOSE EARLY","Terminated","No Results Available","Heart Failure|Heart Decompensation","Drug: Cinaciguat (BAY58-2667)|Drug: Placebo","Dyspnea VAS (using a visual analogue scale)|Dyspnea assessment (Likert Scale)|Overall health status assessment (EQ-5D)|Changes in the dyspnea VAS at other time points|Dyspnea assessment through Likert scale|Overall health status assessment through EQ-5D Health Questionnaire|Global clinical assessment by the physician|Change in concomitant medications|Safety variables","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","62","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","14836|2009-017082-39","April 2010","February 2011","March 2011","February 8, 2010",,"October 8, 2015","Chicago, Illinois, United States|Detroit, Michigan, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Nashville, Tennessee, United States|Houston, Texas, United States|Calgary, Alberta, Canada|Vancouver, British Columbia, Canada|Quebec, Canada|Brno, Czech Republic|Pardubice, Czech Republic|Praha 10, Czech Republic|Praha 5, Czech Republic|Praha 5, Czech Republic|Jyväskylä, Finland|Turku, Finland|Dommartin-les-toul, France|Paris Cedex 04, France|Paris cedex 13, France|Paris, France|POITIERS Cedex, France|Nürnberg, Bayern, Germany|Melsungen, Hessen, Germany|Mönchengladbach, Nordrhein-Westfalen, Germany|Kiel, Schleswig-Holstein, Germany|Erfurt, Thüringen, Germany|Berlin, Germany|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Kecskemet, Hungary|Szekesfehervar, Hungary|Ballinasloe, Co. Galway, Ireland|Dublin, Ireland|Dublin, Ireland|Haifa, Israel|Nahariya, Israel|Rehovot, Israel|Safed, Israel|Pontedecimo, Genova, Italy|Casarano, Lecce, Italy|Cotignola, Ravenna, Italy|Bari, Italy|Ferrara, Italy|Padova, Italy|Roma, Italy|Roma, Italy|Kanazawa, Ishikawa, Japan|Chigasaki, Kanagawa, Japan|Matsumoto, Nagano, Japan|Sunto, Shizuoka, Japan|Tanabe, Wakayama, Japan|Kagoshima, Japan|Shizuoka, Japan|Seoul, Jongno-gu,, Korea, Republic of|Seoul, Songpa-gu, Korea, Republic of|Bydgoszcz, Poland|Krakow, Poland|Olsztyn, Poland|Szczecin, Poland|Johannesburg, Gauteng, South Africa|Johannesburg, Gauteng, South Africa|Kuils River, Western Cape, South Africa|Worcester, Western Cape, South Africa|Torrevieja, Alicante, Spain|Majadahonda, Madrid, Spain|El Palmar, Murcia, Spain|Barcelona, Spain|Harrow, London, United Kingdom|Northampton, Northamptonshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01064037"
910,"NCT01062360","Placebo and Active Controlled Study to Assess Efficacy and Tolerability of Aspirin Plus Pseudoephedrine",,"Completed","No Results Available","Common Cold|Pharyngitis","Drug: Acetylsalicylic Acid (Aspirin Complex, BAYE4465) + Pseudoephedrine|Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)|Drug: Pseudoephedrine|Drug: Placebo","The primary efficacy parameter for the nasal congestion was the AUC calculated for baseline adjusted NCS for the initial 2 hours post dosing|The primary efficacy parameter for sore throat was SPID2 hours|The Pain Intensity Difference at time point: 15, 30, 60, 90, 120, 240, and 360 minutes after the first dose|The Nasal Congestion Score|The Nasal Congestion Relief Score|Sore throat pain relief|The symptoms of common cold (headache, sinus pressure/pain, feverish discomfort, muscle aches, and pain) at 120 minutes post dose|The results of an overall assessment of treatment by the subjects at 120 minutes post dose|The results of an overall assessment of treatment by the subjects at the end of Day 3 after the first dose, or at the end of treatment (6 hours after last dose of study drug)|Nasal Congestion, Pain Intensity Difference and pain relief at the end of Day 2 and at the end of Day 3, or at the end of treatment (6 hours after the last study drug intake)|The symptoms of common cold (headache, sinus pressure/pain, feverish discomfort, muscle aches, and pain) at the end of Day 2 and at the end of Day 3, or at the end of treatment (6 hours after the last study drug intake)|Total amount of drug intake","Bayer","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","1016","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11764|2005-001720-36","December 23, 2005","May 14, 2007","May 14, 2007","February 4, 2010",,"September 1, 2017","New York, New York, United States|New York, New York, United States|Alassio, Italy|Albenga, Italy|Arenzano, Italy|Civitella Paganico, Italy|Follonica, Italy|Genova, Italy|Genova, Italy|Genova, Italy|Genova, Italy|Genova, Italy|Genova, Italy|Genova, Italy|Genova, Italy|Genova, Italy|Genova, Italy|Grosseto, Italy|Grossetto, Italy|Isola del Cantone, Italy|Loano, Italy|Masone, Italy|Orbetello, Italy|Pegli, Italy|Quiliano, Italy|Rivarolo, Italy|Ronco Scrivia, Italy|Sampierdarena, Italy|Scansano, Italy|Serra Ricco, Italy|Varazze, Italy|Ciechocin, Poland|Debowa Gora, Poland|Kattowitz, Poland|Kattowitz, Poland|Kattowitz, Poland|Krakau, Poland|Lodzi, Poland|Piaseczno, Poland|Skierniewice, Poland|Szczecin, Poland|Szczecin, Poland|Thorn, Poland|Warszawa, Poland|Warszawa, Poland|Warszawa, Poland|Warszawa, Poland|Warszawa, Poland|Warszawa, Poland|Zabrze, Poland|Bratislava, Slovakia|Bratislava, Slovakia|Bratislava, Slovakia|Bratislava, Slovakia|Bratislava, Slovakia|Bratislava, Slovakia|Bratislava, Slovakia|Pezinok, Slovakia|Stupava, Slovakia",,"https://ClinicalTrials.gov/show/NCT01062360"
911,"NCT01062282","Hypertension Study of Ventavis® Inhalation Therapy in the Treatment of Patients With Pulmonary Arterial Hypertension (VENIS)",,"Completed","No Results Available","Pulmonary Hypertension","Drug: Iloprost (Ventavis BAYQ6256)","The primary efficacy variable is 6-minute walking distance|New York Heart Association functional class|PH-related symptoms and change of concomitant medication|Hemodynamic parameters|Adverse Event collection","Bayer","All","18 Years and older   (Adult, Older Adult)",,"41","Industry","Observational","Time Perspective: Prospective","14184|VENIS|VE0610KR","July 2006","June 2009","June 2009","February 4, 2010",,"April 4, 2011","Many Locations, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01062282"
912,"NCT01053676","Bioequivalence Study of BAY77-1931 Granule",,"Completed","No Results Available","Hyperphosphatemia","Drug: Lanthanum Carbonate (Fosrenol, BAY77-1931) Granule|Drug: Lanthanum Carbonate (Fosrenol, BAY77-1931) Chewable tablet","Bioequivalence based on daily urinary phosphate excretion|Adverse event collection","Bayer","Male","20 Years to 45 Years   (Adult)","Phase 1","59","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13287","January 2010","April 2010","April 2010","January 21, 2010",,"June 23, 2014","Osaka, Japan",,"https://ClinicalTrials.gov/show/NCT01053676"
913,"NCT01052298","Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)",,"Completed","No Results Available","Disease, Pulmonary","Drug: Ciprofloxacin (Cipro inhale, BAYQ3939)|Drug: Placebo","Vital signs: evaluated by heart rate, blood pressure, clinical laboratory|Electrocardiogram: evaluated by shape and time intervals|Pulmonary function test evaluated by FEV1|Pulse oximetry by peripheral oxygen concentration|Determination of ciprofloxacin concentration in blood|Determination of ciprofloxacin concentration in urine|Determination of ciprofloxacin concentration in sputum|Determination of ciprofloxacin concentration in oral rinsing fluid","Bayer|Novartis","All","35 Years and older   (Adult, Older Adult)","Phase 1","25","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","13013|2008-006770-14","April 2009","September 2009","September 2009","January 20, 2010",,"May 30, 2013","Mannheim, Baden-Württemberg, Germany",,"https://ClinicalTrials.gov/show/NCT01052298"
914,"NCT01050829","Gadobutrol Magnevist-controlled Body Study",,"Completed","No Results Available","Magnetic Resonance Imaging","Drug: Gadobutrol (Gadovist, BAY86-4875)|Drug: Gadopentetate Dimeglumine (Magnevist, BAY86-4882)","The total score of the following 3 visualization parameters is used for primary variable: Degree of contrast enhancement; Border delineation; Internal morphology.|Sensitivity and specificity for the detection of malignant lesions|Exact match of the MR diagnosis with the final clinical diagnosis based on medical records up until 3 months after the scan|Confidence in diagnosis","Bayer","All","20 Years and older   (Adult, Older Adult)","Phase 3","370","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic","13297","January 2010","April 2011","April 2011","January 15, 2010",,"December 30, 2014","Nanjing, Jiangsu, China|Suzhou, Jiangsu, China|Xi'an, Shanxi, China|Beijing, China|Shanghai, China|Shanghai, China|Kamogawa, Chiba, Japan|Matsuyama, Ehime, Japan|Chikushino, Fukuoka, Japan|Kobe, Hyogo, Japan|Sunto, Shizuoka, Japan|Bunkyo-ku, Tokyo, Japan|Fukuoka, Japan|Seoul, Korea, Republic of|Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01050829"
915,"NCT01049022","Safety, Tolerability and Pharmacokinetics of Single Dose Intravenous Moxifloxacin in Pediatric Patients",,"Completed","No Results Available","Infections","Drug: Moxifloxacin (Avelox, BAY12-8039)","Area under the Concentration-Time Curve (AUC) of Moxifloxacin and its Metabolites|Maximum Observed Drug Concentration in Plasma (Cmax) of Moxifloxacin and its Metabolites|Number of Subjects With Treatment Emergent Findings on Joint Assessment: Baseline|Number of Subjects With Treatment Emergent Findings on Joint Assessment : At any Time During Treatment|Time to Reach Maximum Drug Concentration in Plasma (tmax) of Moxifloxacin and its Metabolites|Half Life Associated With Terminal Slope (t1/2) of Moxifloxacin and its Metabolites|Total Amount Excreted in the Urine (Aeur) of Moxifloxacin and its Metabolites|Volume of Distribution at Steady State (Vss) of Moxifloxacin and its Metabolites|Plasma Clearance (CL) of Moxifloxacin and its Metabolites|Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity Divided by Dose Per kilogram Body Weight (AUCnorm) of Moxifloxacin and its Metabolites|Maximum Observed Plasma Concentration Divided by Dose Per kilogram Body Weight (Cmax,Norm) of Moxifloxacin and its Metabolites","Bayer","All","3 Months to 14 Years   (Child)","Phase 1","31","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","11826|2012-000737-40","May 2010","December 2012","August 2013","January 14, 2010",,"July 22, 2015","Little Rock, Arkansas, United States|Orange, California, United States|San Diego, California, United States|Louisville, Kentucky, United States|New Orleans, Louisiana, United States|Boston, Massachusetts, United States|Kansas City, Missouri, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Toledo, Ohio, United States|Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01049022"
916,"NCT01045902","BAY12-8039, iv/Oral Pulmonary Abscess/Aspiration Pneumonia",,"Completed","No Results Available","Pneumonia, Aspiration|Lung Abscess","Drug: Avelox (Moxifloxacin, BAY12-8039)|Drug: Sulbactam/Ampicillin","Adverse events occuring after first application of study medication up to the test of cure visit for non-serious adverse events|Clinical Response","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","139","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10381","February 2001",,"January 2005","January 11, 2010",,"January 11, 2010","Mannheim, Baden-Württemberg, Germany|Nürnberg, Bayern, Germany|Regensburg, Bayern, Germany|Treuenbrietzen, Brandenburg, Germany|Frankfurt, Hessen, Germany|Hildesheim, Niedersachsen, Germany|Rotenburg, Niedersachsen, Germany|Lüdenscheid, Nordrhein-Westfalen, Germany|Oberhausen, Nordrhein-Westfalen, Germany|Paderborn, Nordrhein-Westfalen, Germany|Magdeburg, Sachsen-Anhalt, Germany|Leipzig, Sachsen, Germany|Lübeck, Schleswig-Holstein, Germany|Berlin, Germany|Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT01045902"
917,"NCT01043523","Liver MRI With Primovist/Eovist in Pediatric Subjects Who Are Suspected or Have Focal Liver Lesions.",,"Completed","Has Results","Liver Neoplasms|Adenoma|Carcinoma|Liver Abscess","Drug: Gadoxetic Acid Disodium (Eovist, BAY86-4873)","Percentage of Participants With Overall Change in Additional Diagnostic Information Obtained When Comparing the Combined Precontrast/Postcontrast Images With the Precontrast Images.|Number of Participants With Laboratory Values Considered to be Clinically Relevant Values or Abnormalities at Pre-injection Time Point|Number of Participants With Laboratory Values Considered to be Clinically Relevant Values or Abnormalities 24 Hours Post-injection|Vital Signs: Mean Change From Baseline in Heart Rate|Vital Signs: Mean Change From Baseline in Systolic Blood Pressure|Vital Signs: Mean Change From Baseline in Diastolic Blood Pressure|Change in Diagnosis Obtained From the Combined Precontrast and Postcontrast Images as Compared With the Precontrast Images|Change in Confidence of Diagnosis Obtained From the Combined Precontrast and Postcontrast Images as Compared With the Precontrast Images|Change in Number of Nonmalignant Lesions Obtained From the Combined Precontrast and Postcontrast Images as Compared With the Precontrast Images|Change in Number of Malignant Lesions Obtained From the Combined Precontrast and Postcontrast Images as Compared With the Precontrast Images|Change in Recommended Next Course of Subject Management/Therapy Obtained From the Combined Precontrast and Postcontrast Images as Compared With the Precontrast Images|Change in Recommended Next Course of Subject Management / Therapy - Comparison of Precontrast Versus Combined Precontrast/Postcontrast Images (Only Subjects for Whom a Change Was Documented)|The Overall Image Quality for the Postcontrast Image Only|Final Diagnosis (SoT) by Clinical Investigator|Sensitivity, Specificity and Accuracy of Blinded Read of Precontrast and Combined Precontrast/Postcontrast Images Based on Final Diagnosis.","Bayer","All","2 Months to 18 Years   (Child, Adult)",,"52","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","13729","December 2009","April 2013","April 2013","January 6, 2010","June 3, 2014","November 28, 2016","Palo Alto, California, United States|New York, New York, United States|Durham, North Carolina, United States|Cinncinati, Ohio, United States|Hershey, Pennsylvania, United States|Many Locations, Italy|Many Locations, Japan|Many Locations, Singapore|Many Locations, Taiwan",,"https://ClinicalTrials.gov/show/NCT01043523"
918,"NCT01035164","Evaluation of ZK 6032924 in Probable Alzheimer's Disease Patients Versus Healthy Volunteers and the Radiation Dosimetry of ZK 6032924 in Healthy Volunteers",,"Completed","No Results Available","Positron-Emission Tomography|Alzheimer's Disease","Drug: F-18 FEDAA1106 (BAY85-8101)","Visual analysis/description of the uptake and description of brain PET scans|Standardized uptake value (SUV) in various cerebral regions/volumes of interest (ROI/VOI) assumed and found to be involved in the pathophysiology of Alzheimer's disease.|Standard quantification variables derived from 3D PET imaging and brain modeling|Standard Safety Measurement:adverse event collection|Standard Safety Measurement:electrocardiogram|Standard Safety Measurement:safety laboratory|Standard Safety Measurement: vital signs","Bayer","All","50 Years and older   (Adult, Older Adult)","Phase 1","25","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","91683|2006-006045-14|311401","June 2007","January 2010","January 2010","December 18, 2009",,"January 8, 2015","Amsterdam, Netherlands|Stockholm, Sweden|Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT01035164"
919,"NCT01033526","Symptomatic Treatment of Common Cold Symptoms",,"Completed","No Results Available","Common Cold","Drug: Aspirin (Acetylsalicylic acid, BAYE4465)|Drug: Placebo","Change in Cold Symptoms (patient Wisconsin Upper Respiratory Symptom Survey (WURSS domain 2 score) from baseline|Changes in Common Cold Profile (sum of WURSS domains 1 182 3)|Changes in Global Cold Severity (WURSS domain 1)|Changes in Cold Symptoms (WURSS domain 2)|Changes in Cold-specific Functional Impairments (WURSS domain 3)|Changes in Global Cold Severity (WURSS domain 4)|Adverse Event Collection","Bayer","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","388","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11756|EudraCT: 2004-004683-71","October 2005",,"June 2007","December 16, 2009",,"December 16, 2009","Borgo Di Terzo, Bergamo, Italy|Brembate, Bergamo, Italy|Calusco d'Adda, Bergamo, Italy|Capriate San Gervasio, Bergamo, Italy|Caravaggio, Bergamo, Italy|Casazza, Bergamo, Italy|Cologno Al Serio, Bergamo, Italy|Covo, Bergamo, Italy|Dalmine, Bergamo, Italy|Mozzanica, Bergamo, Italy|Ponte San Pietro, Bergamo, Italy|Seriate, Bergamo, Italy|Verdello, Bergamo, Italy|Vertova, Bergamo, Italy|Villa d'Adda, Bergamo, Italy|Angera, Varese, Italy|Carnago, Varese, Italy|Cavaria, Varese, Italy|Comerio, Varese, Italy|Cunardo, Varese, Italy|Fagnano Olona, Varese, Italy|Induno Olona, Varese, Italy|Sesto Calende, Varese, Italy|Solbiate Olona, Varese, Italy|Vedano Olona, Varese, Italy|Vergiate, Varese, Italy|Albano Sant'Alessandro, Italy|Varese, Italy",,"https://ClinicalTrials.gov/show/NCT01033526"
920,"NCT01031459","Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.",,"Completed","No Results Available","Multiple Sclerosis","Drug: Betaseron (Interferon beta-1b, BAY86-5046)","Descriptive exploration of mortality, EDSS, cognition, resource use, SPMS status and employment history by length of exposure to Betaseron and stratified by the original clinical trial group assignment (1.6 MIU, 8 MIU, placebo)","Bayer","All","18 Years and older   (Adult, Older Adult)",,"176","Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","14261|20Y-LTF","January 2010","December 2010","December 2010","December 14, 2009",,"January 5, 2012","Birmingham, Alabama, United States|Tucson, Arizona, United States|San Francisco, California, United States|Chicago, Illinois, United States|Baltimore, Maryland, United States|Philadelphia, Pennsylvania, United States|Vancouver, British Columbia, Canada|London, Ontario, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01031459"
921,"NCT01031355","Bioequivalence Study: 3 mg Estradiol Valerate (EV) With and Without Levomefolate Calcium",,"Completed","No Results Available","Contraception|Ovulation Inhibition","Drug: Estradiol Valerate (EV) / Levomefolate Calcium (BAY98-7078)|Drug: Estradiol Valerate (EV) (BAY86-4980)|Drug: Levomefolate Calcium (BAY86-7660)","Uncorrected Cmax and AUC(0-tlast) and baseline corrected Cmax and AUC (if possible) for E1, E2, E1S, and L-5- methyl-THF","Bayer","Female","45 Years to 75 Years   (Adult, Older Adult)","Phase 1","42","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13468|2009-011962-27","December 2009","February 2010","March 2010","December 14, 2009",,"February 20, 2014","Neu-Ulm, Bayern, Germany",,"https://ClinicalTrials.gov/show/NCT01031355"
922,"NCT01031199","Evaluation of the Positron Emission Tomography (PET) Tracer ZK 6032924 in Patients With Multiple Sclerosis Compared to Healthy Volunteers",,"Completed","No Results Available","Positron-Emission Tomography|Multiple Sclerosis","Drug: F-18 FEDAA1106 (BAY85-8101)","Standard quantification variables derived from 3D PET imaging and brain modeling.|Visual analysis/description of the uptake and description of brain PET scans.|Standard Safety Parameter: Adverse Event Collection|Standard Safety Parameter: Electrocardiogram|Standard Safety Parameter: Safety laboratory|Standard Safety Parameter: Vital signs","Bayer","All","20 Years to 55 Years   (Adult)","Phase 1","16","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","13101|2008-000981-22","January 2009","December 2009","December 2009","December 14, 2009",,"April 2, 2014","Heidelberg, Victoria, Australia|Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT01031199"
923,"NCT01029743","Xarelto Regulatory Post-Marketing Surveillance",,"Completed","No Results Available","Venous Thromboembolism","Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Pharmacologic agents (e.g. LMWH/VKA/Fondaparinux/Aspirin and etc.)","Adverse event collection|Duration of treatment","Bayer|Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)",,"3388","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14793|XA0910KR","December 2009","March 2015","January 2016","December 10, 2009",,"January 23, 2017","Many Locations, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01029743"
924,"NCT01029340","Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A","Leopold I","Completed","Has Results","Blood Coagulation Disorders|Hemophilia A","Biological: Recombinant Factor VIII (BAY81-8973)|Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)","Part A - Area Under the Drug Concentration-time Curve (AUC)|Part A - Half-life (t 1/2)|Part B - Annualized Number of Total Bleeds|Part B - The in Vivo Recovery Values of Human Factor VIII (FVIII)|Part B - Annualized Number of Bleeds in Each 6-month Potency Assignment Period|Part B - Control of Bleeding as Measured by the Number of Injections Required to Treat a Bleed|Part B - Changes From Baseline at 12 Months in Quality of Life (QoL) as Measured by Transformed Total Score of Haemo-QoL Questionnaire|Part B - Changes From Baseline at 12 Months in Utility Index as Measured by EQ-5D Questionaire|Part A - Number of Participants With Inhibitory Antibody Formation|Part B - Number of Participants With Incidence of Inhibitory Antibody Formation|Part C - Number of Participants With Incidence of Inhibitory Antibody Formation|Part A - Number of Participants With Incidence of Antibody Formation to Heat-shock Protein (HSP-70)|Part B - Number of Participants With Incidence of Antibody Formation to Heat-shock Protein (HSP-70)|Part C - Number of Participants With Incidence of Antibody Formation to Heat-shock Protein (HSP-70)|Part A - Number of Participants With Incidence of Antibody Formation to Host Cell Proteins (HCP)|Part B - Number of Participants With Incidence of Antibody Formation to Host Cell Proteins (HCP)|Part C - Number of Participants With Incidence of Antibody Formation to Host Cell Proteins (HCP)|Part B - Number of Participants With Assessment of the Hemostasis During Major Surgery|Part C - Number of Participants With Assessment of the Hemostasis During Major Surgery","Bayer","Male","12 Years to 65 Years   (Child, Adult, Older Adult)","Phase 3","74","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12954|2009-012149-43","December 2009","June 2012","March 2013","December 9, 2009","November 18, 2013","November 28, 2016","Orange, California, United States|Sacramento, California, United States|Tampa, Florida, United States|Boston, Massachusetts, United States|East Lansing, Michigan, United States|Kansas City, Missouri, United States|Cleveland, Ohio, United States|Bahia Blanca, Buenos Aires, Argentina|Rosario, Santa Fe, Argentina|Graz, Austria|Wien, Austria|Zagreb, Croatia|DK-Aarhus N, Denmark|Frankfurt, Hessen, Germany|Bonn, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Homburg, Saarland, Germany|Magdeburg, Sachsen-Anhalt, Germany|Hongkong, Hong Kong|Bangalore, India|Mumbai, India|Pune, India|Jakarta, Indonesia|Ramat Gan, Israel|Catanzaro, Calabria, Italy|Napoli, Campania, Italy|Napoli, Campania, Italy|Roma, Lazio, Italy|Milano, Lombardia, Italy|Vicenza, Veneto, Italy|Oslo, Norway|Karachi, Pakistan|Krakow, Poland|Warszawa, Poland|Belgrade, Serbia|Beograd, Serbia|Nis, Serbia|Novi Sad, Serbia|Pretoria, Gauteng, South Africa|Parktown, South Africa|Oviedo, Asturias, Spain|Santander, Cantabria, Spain|A Coruña, Spain|Barcelona, Spain|Jaén, Spain|Valencia, Spain|Göteborg, Sweden|Malmö, Sweden|Karolinska Universitetssjukhuset i Solna, Stockholm, Sweden|Changhua, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Bangkok, Thailand|Bangkok, Thailand|Adana, Turkey|Antalya, Turkey|Izmir, Turkey|Dundee, Dundee City, United Kingdom|Oxford, Oxfordshire, United Kingdom|Sheffield, South Yorkshire, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01029340"
925,"NCT01028755","To Determine Maximum Tolerated Dose of BAY79-4620 in Patients With Advanced Solid Tumors",,"Completed","No Results Available","Neoplasms","Drug: BAY79-4620","Safety, tolerability, maximum tolerated dose|Pharmacokinetics profile of BAY79-4620 and its key metabolites|Biomarker evaluation|Tumor response|Immunogenicity","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12671","November 2009","April 2013","April 2013","December 9, 2009",,"January 21, 2015","Nashville, Tennessee, United States|San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01028755"
926,"NCT01028079","Placebo and Active Controlled, Double Dummy Study to Prove Efficacy of Aspirin in Treatment of Acute Low Back Pain",,"Completed","No Results Available","Low Back Pain","Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)|Drug: Ibuprofen|Drug: Placebo","Area under the curve of the baseline adjusted pain intensity curve over the initial 48 hours (AUC-PI0-48hours) after first dosing|Total pain relief 6, 72, 96 and 120 hours after first dosing|Pain intensity relief over initial 6 hours|Pain intensity difference after 48, 72, 96 and 120 hours after first dosing|Overall efficacy after 48, 72, 96 and 120 hours after first dosing|Total dose used over 5 days|Time till use of rescue medication|Safety - assessment of adverse events","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","338","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11818","November 2005",,"December 2006","December 9, 2009",,"December 9, 2009","Bad Lippspringe, Germany|Beckum, Germany|Einbeck, Germany|Hamburg, Germany|Hamburg, Germany|Hamburg, Germany|Hamburg, Germany|Hannover, Germany|Künzing, Germany|Straßkirchen, Germany|Fowey, United Kingdom|Saltash, United Kingdom|Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01028079"
927,"NCT01025635","Safety and Efficacy of Azelaic Acid Foam, 15% in Papulopustular Rosacea",,"Completed","Has Results","Papulopustular Rosacea","Drug: Azelaic acid foam 15%|Drug: Vehicle foam","Percentage of Participants With Investigator's Global Assessment (IGA) Based Therapeutic Success at End of Treatment (LOCF: Last Observation Carried Forward)|Nominal Change From Baseline in Inflammatory Lesion (IL) Count (Sum of Papules and Pustules) Per Participant at End of Treatment (LOCF)|Percent Change From Baseline in IL Count (Sum of Papules and Pustules) Per Participant at End of Treatment (LOCF)|Percentage of Participants With Investigator's Global Assessment (IGA) Based Patient Response at End of Treatment (LOCF)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","401","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","14955|1403120","December 2009","August 2010","August 2010","December 3, 2009","July 1, 2013","May 5, 2014","Birmingham, Alabama, United States|Birmingham, Alabama, United States|Fremont, California, United States|Santa Monica, California, United States|Miami, Florida, United States|Miramar, Florida, United States|Omaha, Nebraska, United States|Albuquerque, New Mexico, United States|High Point, North Carolina, United States|Wilmington, North Carolina, United States|Winston Salem, North Carolina, United States|Portland, Oregon, United States|Johnston, Rhode Island, United States|Simpsonville, South Carolina, United States|Knoxville, Tennessee, United States|Nashville, Tennessee, United States|Austin, Texas, United States|Plano, Texas, United States|Salt Lake City, Utah, United States|Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01025635"
928,"NCT01021436","Safety, Tolerability and Pharmacokinetics of Aerosolized Amikacin in Intubated and Mechanically-ventilated Patients With Nosocomial Pneumonia",,"Completed","No Results Available","Pneumonia","Drug: Amikacin inhalation solution (BAY41-6551)","Cmax|Tmax|AUC0-12h|Xu0-12h|Xu12-24h|Xu0-24h|Tracheal aspirate|Epithelial lining fluid (ELF) concentration|Number of participants with adverse events","Bayer|Nektar Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","06-IN-AK004|2006-005079-17","March 2007","August 2007","August 2007","November 30, 2009",,"February 18, 2016","Birminghan, Alabama, United States|Cincinnati, Ohio, United States|Memphis, Tennessee, United States|Houston, Texas, United States|Paris, Cedex 13, France|Limoges, Cedex, France",,"https://ClinicalTrials.gov/show/NCT01021436"
929,"NCT01014247","Influence of Moxifloxacin on QTc Interval in Healthy Subjects for Positive Control Validation",,"Completed","No Results Available","QTc Evaluation|Electrocardiography","Drug: Avelox (Moxifloxacin, BAY12-8039)|Drug: Placebo","QTc interval at 3 hours|Safety variables|Pharmacokinetic parameters","Bayer","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","13796|2009-012363-34","November 2009","June 2010","June 2010","November 16, 2009",,"June 3, 2013","Melbourne, Victoria, Australia|Gießen, Hessen, Germany|Dresden, Sachsen, Germany|Singapore, Singapore|Singapore, Singapore|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01014247"
930,"NCT01013909","Comparative Safety and Efficacy Study of New Bifonazol Spray vs Terbinafine Solution vs Placebo","Porsche","Completed","No Results Available","Tinea Pedis","Drug: Bifonazole spray once daily|Drug: Bifonazole spray twice daily|Drug: Placebo|Drug: Lamisil Once","Assessment of erythema, scaling, vesiculation maceration, and pruritus based on a categorial scale (0=absent to 3 =severe), assessment of mycological cure based on cultures and microscopy|Local side effects on the skin|Clinical cure|Mycological cure|Rate of negative culture|Rate of microscopy negative|Rate of absence of itching and burning|Incidence and severity of Adverse Event|Vital Signs|Local side effects","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","220","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","13957|2008-005654-21","December 2009","May 2010","May 2010","November 16, 2009",,"January 27, 2015","Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT01013909"
931,"NCT01012973","Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)","GALILEO","Completed","Has Results","Retinal Vein Occlusion","Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Other: Sham treatment","Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 24 With Discontinued Participants Before Week 24 Evaluated as Failures|Change From Baseline in BCVA as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 24 - Last Observation Carried Forward (LOCF)|Change From Baseline in Central Retinal Thickness (CRT) at Week 24 - LOCF|Percentage of Participants Who Developed Neovascularization During the First 24 Weeks|Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Total Score at Week 24 - LOCF|Change From Baseline in European Five-dimensional Health Scale (EQ-5D) Score at Week 24 - LOCF","Bayer|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","177","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","14130|2009-010973-19","October 2009","February 2011","February 2012","November 13, 2009","November 22, 2012","November 3, 2014","Chatswood, New South Wales, Australia|Parramatta, New South Wales, Australia|Sydney, New South Wales, Australia|Westmead, New South Wales, Australia|East Melbourne, Victoria, Australia|Nedlands, Western Australia, Australia|Innsbruck, Austria|Linz, Austria|Wien, Austria|Paris, Cedex 12, France|Nantes, Cedex 1, France|Bordeaux, France|Dijon, France|Marseille, France|Paris, France|Freiburg, Baden-Württemberg, Germany|Heidelberg, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|München, Bayern, Germany|Regensburg, Bayern, Germany|Darmstadt, Hessen, Germany|Frankfurt, Hessen, Germany|Marburg, Hessen, Germany|Göttingen, Niedersachsen, Germany|Aachen, Nordrhein-Westfalen, Germany|Bonn, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Ludwigshafen, Rheinland-Pfalz, Germany|Mainz, Rheinland-Pfalz, Germany|Homburg, Saarland, Germany|Chemnitz, Sachsen, Germany|Dresden, Sachsen, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Kiel, Schleswig-Holstein, Germany|Lübeck, Schleswig-Holstein, Germany|Berlin, Germany|Hamburg, Germany|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Veszprem, Hungary|Zalaegerszeg, Hungary|Ancona, Italy|Bari, Italy|Catania, Italy|Firenze, Italy|Milano, Italy|Milano, Italy|Milano, Italy|Padova, Italy|Roma, Italy|Roma, Italy|Torino, Italy|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Urayasu, Chiba, Japan|Suita, Osaka, Japan|Chiyoda-ku, Tokyo, Japan|Kyoto, Japan|Seongnam-si, Gyeonggido, Korea, Republic of|Incheon, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Riga, Latvia|Riga, Latvia|Singapore, Singapore|Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT01012973"
932,"NCT01012011","Regulatory Post Marketing Surveillance Study on Nexavar®",,"Completed","No Results Available","Carcinoma, Hepatocellular|Carcinoma, Renal Cell","Drug: Sorafenib (Nexavar, BAY43-9006)","Adverse events collection|Duration of treatment, dosage and indication|Tumor status|Performance status","Bayer","All","20 Years to 91 Years   (Adult, Older Adult)",,"2845","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14792|NX0910KR","September 2009","January 2015","August 2015","November 11, 2009",,"September 21, 2015","Many Locations, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01012011"
933,"NCT01010100","Prevent/Delay Development of Type 2 Diabetes in Subjects With Impaired Glucose Homeostasis Treated With Acarbose in Primary Care",,"Completed","No Results Available","Diabetes Mellitus","Drug: Acarbose (Glucobay, BAYG5421)|Drug: Placebo","The principal objective was to determine if the administration of small doses of Acarbose could prevent or delay the appearance of Type 2 DM in a population of subjects with impaired glucose homeostasis.|Regression to the normality (NO impaired glucose homeostasis)|Evolution of the cardiovascular risk markers (microalbuminuria, triglycerides, fasting glycaemia, after overload glycaemia, HbA1c, C-peptide, insulinemia)|Evolution of blood pressure|Evolution of lipid profile|Evolution of anthropometric measurements|The appearance or progression of cardiovascular events: angina, myocardial infarction, cerebrovascular accident, congestive heart failure, peripheral vascular disease, revascularisation procedure|Delay in the conversion to diabetes mellitus","Bayer","All","40 Years to 75 Years   (Adult, Older Adult)","Phase 3","204","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","10139|PREDIAP","August 2000","May 2007","May 2007","November 9, 2009",,"December 28, 2010","Agost, Alicante, Spain|Crevillente, Alicante, Spain|Novelda, Alicante, Spain|San Vicente del Raspeig, Alicante, Spain|Terrassa, Barcelona, Spain|Trobajo del Camino, León, Spain|Begonte, Lugo, Spain|Villalba, Lugo, Spain|Camas, Sevilla, Spain|Constanti, Tarragona, Spain|Cornudella, Tarragona, Spain|El Morell, Tarragona, Spain|Falset, Tarragona, Spain|Les Borges del Camp, Tarragona, Spain|Reus, Tarragona, Spain|Reus, Tarragona, Spain|Reus, Tarragona, Spain|Tortosa, Tarragona, Spain|Vinebre, Tarragona, Spain|Alicante, Spain|Madrid, Spain|Tarragona, Spain|Tarragona, Spain",,"https://ClinicalTrials.gov/show/NCT01010100"
934,"NCT01009359","Evaluation of the Neuroinflammation Pattern of BAY85-8102 F-18, DPA-714 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of F 18, DPA-714 in Healthy Volunteers",,"Completed","No Results Available","Diagnostic Imaging","Drug: F-18 DPA-714 (BAY85-8102)","Discrimination of probable Alzhemimer disease patients from healthy volunteers by BAY85-81 F-18, DPA-714 brain PET imaging as evaluated by different quantification approaches|Discrimination of probable Alzhemimer disease patients from healthy volunteers by BAY85-81 F-18, DPA-714 brain PET imaging as evaluated by visual analysis and standard parameters(e.g. Standardized Uptake Values = SUV)|Electrocardiogram (ECG)|Blood pressure|Serum protein|Serum creatinine|Serum GOT (Glutamat-Oxalacetate-Transaminase)|Adverse events collection","Bayer","All","50 Years and older   (Adult, Older Adult)","Phase 1","22","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","13150|2009-009358-26","October 2009","July 2010","October 2010","November 6, 2009",,"July 31, 2013","Turku, Finland|Amsterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT01009359"
935,"NCT01007578","Drug-Eluting Balloon Catheters and the Treatment of Peripheral Arterial Occlusive Disease",,"Completed","No Results Available","Peripheral Arterial Disease|Stenotic Femoro-popliteal Arteries|Occluded Femoro-popliteal Arteries|Atherosclerosis","Device: Paclitaxel-coated balloon catheter angioplasty","Plasma levels of paclitaxel in patients with stenotic or occluded femoro-popliteal arteries following application of paclitaxel-coated balloon catheter angioplasty at baseline|Plasma levels of paclitaxel in patients with stenotic or occluded femoro-popliteal arteries following application of paclitaxel-coated balloon catheter angioplasty 0.5 hours post-procedure|Plasma levels of paclitaxel in patients with stenotic or occluded femoro-popliteal arteries following application of paclitaxel-coated balloon catheter angioplasty 1 hour post-procedure|Plasma levels of paclitaxel in patients with stenotic or occluded femoro-popliteal arteries following application of paclitaxel-coated balloon catheter angioplasty 2 hours post-procedure|Plasma levels of paclitaxel in patients with stenotic or occluded femoro-popliteal arteries following application of paclitaxel-coated balloon catheter angioplasty 4 hours post-procedure|Plasma levels of paclitaxel in patients with stenotic or occluded femoro-popliteal arteries following application of paclitaxel-coated balloon catheter angioplasty 8 hours post-procedure|Plasma levels of paclitaxel in patients with stenotic or occluded femoro-popliteal arteries following application of paclitaxel-coated balloon catheter angioplasty 1 week post-procedure|Plasma levels of paclitaxel in patients with stenotic or occluded femoro-popliteal arteries following application of paclitaxel-coated balloon catheter angioplasty 2 weeks post-procedure|Plasma levels of paclitaxel in patients with stenotic or occluded femoro-popliteal arteries following application of paclitaxel-coated balloon catheter angioplasty 3 weeks post-procedure|Plasma levels of paclitaxel in patients with stenotic or occluded femoro-popliteal arteries following application of paclitaxel-coated balloon catheter angioplasty 4 weeks post-procedure|Changes in blood cell counts as measure of safety at baseline|Changes in blood cell counts as measure of safety 0.5, 1, 2, 4, 8 and 24 hours post-procedure|Changes in blood cell counts as measure of safety 1, 2, 3, and 4 weeks post-procedure|Changes in serum biochemistry parameters as measure of safety at baseline|Changes in serum biochemistry parameters as measure of safety 0.5, 1, 2, 4, 8 and 24 hours post-procedure|Changes in serum biochemistry parameters as measure of safety 1, 2, 3, and 4 weeks post-procedure|Number of participants with adverse events (AEs) as a measure of safety|Number of participants with serious adverse events (SAEs) as a measure of safety|Number of participants with adverse device effects (ADEs) as a measure of safety|Number of participants with adverse events (AEs) judged as possible/probable/definitely related to the paclitaxel coating and/or device by the investigator as a measure of tolerability","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","14","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NT-4601-900","September 2007","December 2007","December 2007","November 4, 2009",,"March 25, 2015","Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany",,"https://ClinicalTrials.gov/show/NCT01007578"
936,"NCT01005719","Study to Compare Gastric Inhibition of Two Proton Pump Inhibitors (CL2008-18)(P07815)(COMPLETED)",,"Completed","Has Results","Human Experimentation","Drug: Zegerid|Drug: Prevacid®","Achievement of Sustained Difference in Inhibition of Intragastric Acidity Based on Median pH Values Between the Two Active Study Treatments at Steady-state on Day 7|Achievement of Sustained Difference in Inhibition of Intragastric Acidity Based on Median pH Values Between the Two Active Study Treatments at Steady-state on Day 1|The Difference in the Onset of Action Based on Median pH Values Between the Two Active Treatments Compared to No Treatment on Day 1 and Day 7|Median Time to Achieve Intragastric pH > = 3.5 for a 10-Minute Period|Percentage Time Intragastric pH >4 During the First 4 Hours After Dosing on Day 7|Median 24-hr Intragastric pH on Day 7|Percentage of Time Intragastric is pH >4 Over 24-hour Period on Day 7|Percentage of Time Intragastric pH >3.5 Over 24-hour Period on Day 7|Number of Participants With Intragastric pH >4 for More Than 50% of the Time on Day 7|Number of Participants With Intragastric pH >3.5 for More Than 50% of the Time on Day 7|Percentage of Time Intragastric pH >4 Over the Nocturnal Period on Day 7|Time to Achieve Sustained Intragastric pH > 3.5 at Steady-state on Day 7|Time to Onset of Inhibition of Acid Secretion on Day 1|Number of Participants Maintaining Intragastric pH > 4 for at Least 12 Hours on Day 1|Number of Participants Maintaining Intragastric pH > 3.5 for at Least 12 Hours on Day 1|Percentage of Time Intragastric pH >4 Over the Nocturnal Period on Day 1|Percentage of Time Intragastric pH >4 During the First 4 Hours on Day 1|Time to Achieve Sustained Advantage Over No Treatment During the First 4 Hours After Dosing","Bayer","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","63","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18135|CL2008-18|P07815","September 2009","January 2010","January 2010","November 1, 2009","January 28, 2011","March 11, 2015",,,"https://ClinicalTrials.gov/show/NCT01005719"
937,"NCT01004445","A Study to Determine the Correct Dose of Amikacin Which is Delivered Directly to the Lungs of Ventilated Patients as an Aerosol Via an Investigational Device Called the Pulmonary Delivery Device System (PDDS)",,"Completed","No Results Available","Pneumonia","Drug: Amikacin (BAY41-6551)|Drug: Placebo","Proportion of patients who achieve a C(max) for amikacin in tracheal aspirates at least 25 times greater than the reference MIC for hospital-acquired organisms and an AUC (0-24 hr) / MIC ratio that is 100 or greater on Day 1|Mean C(max) and mean AUC of amikacin in tracheal aspirates|Mean ratio of C (max) / MIC and mean ratio of AUC (0-24 hr) / MIC|Clinical cure rate|Microbiological eradication rate of identified pathogens|Microbiological persistence rate|New infection rate|Assessment of adverse events related to drug or device|Assessment of abnormal laboratory values","Bayer|Nektar Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 2","69","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","AMIK-04-02","May 2005","June 2006","June 2006","October 30, 2009",,"April 8, 2011","Birmingham, Alabama, United States|Melbourne, Florida, United States|Albany, New York, United States|Winston-Salem, North Carolina, United States|Columbus, Ohio, United States|Houston, Texas, United States|San Antonio, Texas, United States|Angers Cedex 9, France|Limoges Cedex, France|Paris Cedex 13, France|Paris Cedex 14, France|Paris Cedex 15, France|Paris, France|Rouen cedex, France|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Murcia, Spain",,"https://ClinicalTrials.gov/show/NCT01004445"
938,"NCT01003015","Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma",,"Completed","No Results Available","Carcinoma, Hepatocellular","Drug: BAY73-4506","Adverse Event Collection|Time to progression|Objective response rate|Disease control rate|Overall survival|Trough concentration of Regorafenib and metabolites (for Europe only)|Full Pharmacokinetics profile of BAY73-4506 and metabolites (for Korea only)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","36","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14596|2009-012570-13","September 2009","November 2010","March 2013","October 28, 2009",,"April 3, 2015","Regensburg, Bayern, Germany|Frankfurt, Hessen, Germany|Essen, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Magdeburg, Sachsen-Anhalt, Germany|Rozzano, Milano, Italy|Bologna, Italy|Milano, Italy|Milano, Italy|Roma, Italy|Daegu, Korea, Republic of|Seoul, Korea, Republic of|Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT01003015"
939,"NCT01002378","The Effect of Food (High Fat and Low Fat Breakfast) on the Pharmacokinetics of Regorafenib",,"Completed","No Results Available","Dietary Fats|Pharmacokinetics","Drug: Regorafenib (Stivarga, BAY73-4506)","Primary PK parameters: AUC, Cmax of BAY 73-4506|Sec. PK Parameters: tmax and t1/2 of BAY73-4506|AUC, Cmax, tmax and t1/2 of Metabolites","Bayer","Male","18 Years to 45 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Screening","14656","October 2009","February 2010","February 2010","October 27, 2009",,"May 23, 2013","Brighton, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01002378"
940,"NCT01001975","Determination of Sun Protection in Sunscreen Formulas (Study SR09-15)(P08236)(COMPLETED)","PFA and SPF","Completed","Has Results","Sun Protection","Drug: Sunscreen Test Code: V53-028|Drug: Sunscreen Test Code: V53-030|Drug: Standard SPF 4 Sunscreen","Determination of Sunscreen Protection Factor (SPF)|Determination of Ultraviolet A Protection Factor (PFA)","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","10","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","18119|SR09-15|P08236","July 2009","August 2009","August 2009","October 27, 2009","December 7, 2010","March 11, 2015",,,"https://ClinicalTrials.gov/show/NCT01001975"
941,"NCT00998673","Silica Gel Fiber Wound Dressing for Chronic Venous Leg Ulcers",,"Terminated","No Results Available","Venous Ulcer","Device: Silica Gel Fiber|Device: Standard-of-Care","Time to healing of target ulcer, defined as the treatment period day during the weekly visit at which the surface area of the wound was noted as zero and completely healed|Incidence of complete wound healing of target ulcer at 4, 8 and 12 weeks, defined as full epithelialisation of the wound with the absence of drainage|Rate of recurrence of wound at end of follow-up period of 3 months|Size (cm2, measured by Visitrak Wound Measurement System) of target ulcer (Absolute size measured once per week and change between assessments at weeks 0, 4, 8, and 12)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","121","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SGF271-01","April 2009","June 2011","June 2011","October 20, 2009",,"July 14, 2015","Berlin, Germany|Bochum, Germany|Bonn, Germany|Dresden, Germany|Essen, Germany|Frankfurt, Germany|Freiburg, Germany|Greifswald, Germany|Göttingen, Germany|Hamburg, Germany|Köln, Germany|Mannheim, Germany|Regensburg, Germany|Ulm, Germany",,"https://ClinicalTrials.gov/show/NCT00998673"
942,"NCT00998257","Regulatory Post Marketing Surveillance Study on YAZ",,"Completed","No Results Available","Contraception|Premenstrual Syndrome|Acne","Drug: EE20/DRSP (YAZ, BAY86-5300)","Adverse event collection|Contraception efficacy|Drug compliance|Release of Premenstrual Dysphoric Disorder (PMDD) or acne|Number of patients who used YAZ just for contraception|Number of patients who used YAZ for PMDD + contraception|Number of patients who used YAZ for Acne + contraception","Bayer","Female","18 Years to 50 Years   (Adult)",,"770","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14785|YA0910KR|YAZ rPMS","July 2009","November 2011","November 2011","October 20, 2009",,"January 21, 2015","Many Locations, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00998257"
943,"NCT00997997","Avelox in Complicated Skin and Skin Structure Infections","ARTOS","Completed","No Results Available","Skin Diseases, Bacterial","Drug: Moxifloxacin (Avelox, BAY12-8039)","Efficacy: course of severity of infection, course of clinical signs and symptoms, duration until improvement, duration until recovery, duration until wound closure, overall assessment of efficacy by the physician, reuse of Avelox|Adverse events collection|Overall assessment of tolerability by the physician","Bayer","All","10 Years and older   (Child, Adult, Older Adult)",,"6127","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","12237|12236 (AX0502DE)|12237 (AX0502AT)|12519 (AX0502SI)|12645 (AX0502BG)|12646 (AX0502PK)|12754 (AX0502GR)|12865 (AX0502KR)|12866 (AX0502TW)|13045 (AX0502ID)|13165 (AX0502PH)|13206 (AX0502EG)|13924 (AX0502SA)","October 2005","December 2008","December 2008","October 20, 2009",,"November 16, 2012","Many Locations, Austria|Many Locations, Bulgaria|Many Locations, Egypt|Many Locations, Germany|Many Locations, Greece|Many Locations, Indonesia|Many Locations, Korea, Republic of|Many Locations, Pakistan|Many Locations, Philippines|Many Locations, Saudi Arabia|Many Locations, Slovenia|Many Locations, Taiwan",,"https://ClinicalTrials.gov/show/NCT00997997"
944,"NCT00993109","Low-dose Nifedipine-Valsartan Combination Compared to Up-titrated Valsartan Monotherapy in Essential Hypertension",,"Completed","No Results Available","Hypertension","Drug: Adalat (Nifedipine, BAYA1040)|Drug: Diovan (Valsartan)","Mean Systolic BP and Diastolic BP on office Blood Pressure monitoring|Response rate (>/=10mmHg decrease of office SBP and >/=5mmHg decrease of office DBP)|Control rate (</=140/90 of office BP)|Change in pulse pressure (difference between SBP and DBP)|Reduction in Urinary microalbumin excretion(UAE) in patients with microalbuminuria|Adverse Event reporting|Vitals signs|Laboratory tests","Bayer","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","360","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14511|ADVISE","February 2010","May 2011","May 2011","October 12, 2009",,"June 5, 2014","Guangzhou, Guangdong, China|Shijiazhuang, Hebei, China|Changsha, Hunan, China|Changsha, Hunan, China|Nanjing, Jiangsu, China|Nanjing, Jiangsu, China|Shenyang, Liaoning, China|Beijing, China|Beijing, China|Shanghai, China|Donggu,, Gwangju Gwang''yeogsi, Korea, Republic of|Bucheon-si,, Gyeonggido, Korea, Republic of|Yangsan-si, Gyeongnam, Korea, Republic of|Jongno-gu, Korea, Republic of|Jung-gu, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00993109"
945,"NCT00988910","Effects of Drospirenone-containing or -Not Containing Combined Oral Contraceptives on General and Sexual Well-being","COSME","Completed","No Results Available","Contraception","Drug: EE30-DRSP (Yasmin, BAY86-5131)|Drug: Other combined oral contraceptives","Psychophysical well-being evaluated by the Psychological General Well-Being Index (PGWBI)|Sexual well-being evaluated by the Female Sexual Function Index (FSFI)","Bayer","Female","18 Years to 45 Years   (Adult)",,"632","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14182|YA0711IT","January 2008","December 2009","December 2010","October 2, 2009",,"June 26, 2014","Many Locations, Italy",,"https://ClinicalTrials.gov/show/NCT00988910"
946,"NCT00987792","CAPRIVI: Community Acquired Pneumonia: Treatment With Avelox® in Hospitalized Patients",,"Completed","No Results Available","Pneumonia","Drug: Moxifloxacin (Avelox, BAY12-8039)","The primary objective is to evaluate the distribution of the CRB-65 severity index at baseline in hospitalized patients suffering from CAP and to whom moxifloxacin (starting with intravenous administration) was prescribed, in countries from South Eastern|Assessment of use of different diagnostic measures in daily routine practice, especially chest radiography and microbiology|Determination of the proportion of patients treated with moxifloxacin as antibiotic second-line therapy|Assessment of clinical signs and symptoms before and after therapy with moxifloxacin|Measurement of moxifloxacin treatment success in terms of effectiveness and outcome|Evaluation of safety and tolerability of moxifloxacin in hospitalized CAP patients","Bayer","All","18 Years and older   (Adult, Older Adult)",,"2595","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14522|AX0801","September 2009","June 2011","October 2012","October 1, 2009",,"August 7, 2015","Many Locations, Croatia|Many Locations, France|Many Locations, Hungary|Many Locations, Jordan|Many Locations, Kazakhstan|Many Locations, Lebanon|Many Locations, Macedonia, The Former Yugoslav Republic of|Many Locations, Moldova, Republic of|Many Locations, Romania|Many Locations, Russian Federation|Many Locations, Ukraine",,"https://ClinicalTrials.gov/show/NCT00987792"
947,"NCT00984789","Birth Control Patch Study",,"Completed","No Results Available","Contraception","Drug: Ethinylestradiol/Gestodene (FC Patch Low BAY86-5016)|Drug: Norelgestromin/Ethinylestradiol (EVRA)","Bleeding Patterns and cycle control|Contraceptive efficacy|Adverse Event Collection|Population pharmacokinetics|Compliance to treatment|Subjective assessment of treatment","Bayer|Parexel","Female","18 Years to 35 Years   (Adult)","Phase 3","393","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","13082|2008-007308-27","May 2009","September 2010","September 2010","September 25, 2009",,"April 2, 2014","Mödling, Niederösterreich, Austria|Wiener Neustadt, Niederösterreich, Austria|Graz, Steiermark, Austria|Wörgl, Tirol, Austria|Bregenz, Vorarlberg, Austria|Graz, Austria|Innsbruck, Austria|Wien, Austria|Wien, Austria|Zeltweg, Austria|Brno, Czech Republic|Ceske Budejovice, Czech Republic|Hradec Kralove, Czech Republic|Olomouc, Czech Republic|Pisek, Czech Republic|Praha 10, Czech Republic|Praha 2, Czech Republic|Praha 7, Czech Republic|Praha, Czech Republic|De Bilt, Netherlands|Den Helder, Netherlands|Heerlen, Netherlands|Nijmegen, Netherlands",,"https://ClinicalTrials.gov/show/NCT00984789"
948,"NCT00984282","Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer",,"Completed","Has Results","Thyroid Neoplasms","Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Placebo","Progression-free Survival (PFS) Based on Central Assessment Incl. Clinical Progression Due to Bone Irradiation|Overall Survival (OS)|Time to Progression (TTP) Based on Central Assessment Incl. Clinical Progression Due to Bone Irradiation|Disease Control Rate (DCR) Based on Central Assessment|Response Rate Based on Central Assessment|Duration of Response (DOR) Based on Central Assessment|Maximum Percent Reduction in Target Lesion Size Based on Central Assessment|AUC(0-12h),ss (Area Under the Concentration Time Curve From Time 0 to 12 Hours at Steady State)","Bayer|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","417","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","14295|2009-012007-25","October 15, 2009","August 31, 2012","August 30, 2017","September 25, 2009","December 10, 2013","September 13, 2018","Los Angeles, California, United States|Stanford, California, United States|New Haven, Connecticut, United States|Atlanta, Georgia, United States|Boston, Massachusetts, United States|Ann Arbor, Michigan, United States|Saint Louis, Missouri, United States|Albuquerque, New Mexico, United States|New York, New York, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Houston, Texas, United States|Seattle, Washington, United States|Wien, Austria|Bruxelles - Brussel, Belgium|Sofia, Bulgaria|Guangzhou, Guangdong, China|Beijing, China|Beijing, China|Chengdu, China|Hangzhou, China|Shanghai, China|Shanghai, China|Tianjin, China|Odense C, Denmark|Angers, France|Bordeaux, France|Caen, France|LILLE cedex, France|Lyon, France|MARSEILLE cedex, France|Paris, France|Villejuif, France|Erlangen, Bayern, Germany|München, Bayern, Germany|Würzburg, Bayern, Germany|Essen, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Leipzig, Sachsen, Germany|Napoli, Campania, Italy|Genova, Liguria, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Catania, Sicilia, Italy|Pisa, Toscana, Italy|Siena, Toscana, Italy|Perugia, Umbria, Italy|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Kashiwa, Chiba, Japan|Koto-ku, Tokyo, Japan|Asan Medical Center, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Daejeon, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Groningen, Netherlands|Leiden, Netherlands|Gliwice, Poland|Poznan, Poland|Warszawa, Poland|Warszawa, Poland|Obninsk, Russian Federation|Riyadh, Saudi Arabia|Majadahonda, Madrid, Spain|Barcelona, Spain|Göteborg, Sweden|Linköping, Sweden|Lund, Sweden|Stockholm, Sweden|Aberdeen, Aberdeenshire, United Kingdom|Cardiff, United Kingdom|Glasgow, United Kingdom|Leeds, United Kingdom|London, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Newcastle Upon Tyne, United Kingdom|Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00984282"
949,"NCT00980135","Sinecort Pilot Efficacy Study","Sinecort Pilot","Completed","No Results Available","Atopic Dermatitis","Device: Sinecort cream|Drug: Hydrocortison cream|Other: Untreated skin","Efficacy rate versus comparator and untreated skin|Local side effects on the skin|Local SCORAD as clinical assessment by means of the intensity items of the SCORAD index) at Visit 2 through Visit 6|Transepidermal water loss (TEWL) as a measure for skin barrier function at Visit 2 through Visit 6|Skin hydration by means of corneometry at visit 2 through visit 6|Erythema by means of chromametry at Visit 2 through Visit 6|Intensity of pruritus at each day of the dosing period (day 1- day 29) as reported in the patients diary and at Visit 2 through Vist 6 by means of visual analogue scale (VAS)|Incidence and severity of Adverse Event|Vital signs|Local side effects","Bayer","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","13932|2008-008136-82","November 2009","May 2010","May 2010","September 18, 2009",,"April 2, 2014","Münster, Nordrhein-Westfalen, Germany",,"https://ClinicalTrials.gov/show/NCT00980135"
950,"NCT00976209","Consumer Preference Study of Two Formulations of Phenylephrine Hydrochloride (Study CL2008-15)(P07530)(COMPLETED)",,"Completed","Has Results","Vasomotor Rhinitis|Seasonal Allergic Rhinitis","Drug: Phenylephrine Hydrochloride (HCl) Extended Release (ER) Tablets 30 mg|Drug: Phenylephrine Hydrochloride (HCl) Immediate Release (IR) tablets, 10 mg","Percentage of Participants That Preferred Phenylephrine HCl 30 mg Extended Release Tablets, as Compared to Phenylephrine HCl 10 mg Immediate Release Tablets for the Relief of Nasal Congestion|Percentage of Participants That Preferred the Convenience of Phenylephrine HCl 30 mg Extended Release Tablets, as Compared to Phenylephrine HCl 10 mg Immediate Release Tablets","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","331","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","18122|CL2008-15|P07530","August 2009","November 2009","November 2009","September 14, 2009","March 25, 2011","March 11, 2015",,,"https://ClinicalTrials.gov/show/NCT00976209"
951,"NCT00975299","Positron Emission Tomography/Computed Tomography (PET/CT) Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-4367 in Patients With Prostate Cancer and Healthy Volunteers",,"Terminated","No Results Available","Diagnostic Imaging","Drug: BAY86-4367","Visual assessment of lesions|Quantitative analysis of BAY86-4367 uptake into lesions (Standardized Uptake Values = SUVs)|Electrocardiogram (ECG)|Blood pressure|Serum protein|Serum creatinine|Serum GOT (Glutamat-Oxalacetat-Transaminase)|Adverse events collection","Bayer","Male","45 Years and older   (Adult, Older Adult)","Phase 1","16","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","13991|2008-007460-42","September 2009","October 2010","October 2010","September 11, 2009",,"June 26, 2014","München, Bayern, Germany|Zürich, Switzerland",,"https://ClinicalTrials.gov/show/NCT00975299"
952,"NCT00973323","BAY59-7939 Japanese in Atrial Fibrillation (2nd)",,"Completed","No Results Available","Atrial Fibrillation","Drug: Xarelto (Rivaroxaban, BAY59-7939)|Drug: Warfarin","(Safety) Incidence of bleeding|(PK/PD) BAY 59-7939 concentrations / Factor Xa activity, PT, PT-INR, PTT and HEPTEST","Bayer","All","20 Years and older   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","12024","September 2005",,"March 2006","September 9, 2009",,"December 30, 2014","Kurume, Fukuoka, Japan|Maebaru, Fukuoka, Japan|Kitahiroshima, Hokkaido, Japan|Kushiro, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Nomi, Ishikawa, Japan|Yokohama, Kanagawa, Japan|Tokorozawa, Saitama, Japan|Fukui, Japan|Oita, Japan",,"https://ClinicalTrials.gov/show/NCT00973323"
953,"NCT00973245","BAY59-7939 in Atrial Fibrillation Once Daily (OD)",,"Completed","No Results Available","Atrial Fibrillation","Drug: Xarelto (Rivaroxaban, BAY59-7939)|Drug: Warfarin","(Safety) Incidence of bleeding|(PK/PD) BAY 59-7939 concentrations / Factor Xa activity, PT, PT-INR, PTT and HEPTEST","Bayer","All","20 Years and older   (Adult, Older Adult)","Phase 2","102","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","11866","July 2006",,"January 2007","September 9, 2009",,"December 30, 2014","Chikushino, Fukuoka, Japan|Nogata, Fukuoka, Japan|Asahikawa, Hokkaido, Japan|Kobe, Hyogo, Japan|Takarazuka, Hyogo, Japan|Kuwana, Mie, Japan|Sendai, Miyagi, Japan|Sendai, Miyagi, Japan|Tokorozawa, Saitama, Japan|Shinagawa-ku, Tokyo, Japan|Fukuoka, Japan",,"https://ClinicalTrials.gov/show/NCT00973245"
954,"NCT00970528","Glucose Reduction by Early Acarbose Treatment in Basal Insulin","GREAN","Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: Acarbose (Glucobay, BAYG5421)|Drug: Voglibose (Basen)","Glycosylated hemoglobin (HbA1c)|Self monitoring blood glucose concentration|Fasting blood glucose concentration|Blood concentration of triglyceride|Blood concentration of low density lipoprotein|Blood concentration of total cholesterol|Blood concentration of high density lipoprotein|Blood concentration of apolipoprotein A-1|Blood concentration of apolipoprotein B|Blood concentration of Glucagon-like peptide-1 (GLP-1)|Body weight, Body Mass Index(BMI)|High Sensitivity C-reactive protein (hs-CRP)","Bayer","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 4","124","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14081","November 2009","March 2012","March 2012","September 2, 2009",,"February 20, 2014","Wonju-si, Gang''weondo, Korea, Republic of|Busan, Korea, Korea, Republic of|Gyeonggi-do, Korea, Korea, Republic of|Gyeonggi-do, Korea, Korea, Republic of|Pusan, Korea, Korea, Republic of|Seoul, Korea, Korea, Republic of|Daegu, Korea, Republic of|Jeonju-si, Korea, Republic of|Seongbuk-gu Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00970528"
955,"NCT00969449","Pharmacokinetics Study Comparing Naproxen Sodium Extended Release and Naprelan",,"Completed","No Results Available","Pharmacokinetics","Drug: Naproxen Sodium, (BAY H6689)|Drug: Naprelan, (BAY H6689)","Pharmacokinetic profile of Naproxen Sodium ER 660 mg compared to Naprelan|To assess safety and tolerability of the extended release naproxen sodium|To assess additional pharmacokinetic parameters","Bayer","All","18 Years to 55 Years   (Adult)","Phase 1","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14566","April 2009","May 2009","May 2009","September 1, 2009",,"May 20, 2014","Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00969449"
956,"NCT00969319","Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America",,"Completed","No Results Available","Blood Coagulation Disorders|Hemophilia A","Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)","Total consumption of FVIII|Number of bleedings|Kind of bleedings|Continuation of therapy|Overall assessment by the physician|Adverse event collection","Bayer","Male","Child, Adult, Older Adult",,"105","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14285|KG0802","September 2009","February 2013","February 2014","September 1, 2009",,"January 19, 2015","Many locations, Mexico|Many locations, Venezuela",,"https://ClinicalTrials.gov/show/NCT00969319"
957,"NCT00963833","Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis",,"Completed","No Results Available","Multiple Sclerosis","Drug: Interferon beta-1b (Betaseron, BAY86-5046)","Safety and tolerability of Betaferon in this patient population|Proportion of patients being relapse free|Time to first relapse|Annualized relapse rate|Disability progression measured by the expanded disability status scale (EDSS)|Outcome on neurological function|Fatigue assessed by Fatigue Severity Scale (FSS)|MRI measurements (if available)|MRI measurements and potential correlation with neuropsychological impairment|Laboratory outcomes","Bayer","All","12 Years to 16 Years   (Child)",,"68","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14438|BF0802","December 17, 2009","April 12, 2016","September 1, 2016","August 24, 2009",,"July 12, 2017","Many Locations, Austria|Many Locations, Belgium|Many Locations, Finland|Many Locations, Germany|Many Locations, Israel|Many Locations, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00963833"
958,"NCT00963443","Acetylsalicylic Acid Combined With Pseudoephedrine in Common Cold",,"Completed","No Results Available","Common Cold","Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)|Drug: Pseudoephedrine|Drug: Placebo","Reduction of nasal congestion and relief of pain|Area under the curve for nasal airflow conductance from baseline|Sum of subjective nasal congestion intensity differences|Total subjective nasal congestion relief|Global assessment of nasal congestion|Global assessment of pain relief|Sum of pain intensity differences|Total pain relief|Adverse Event collection and physical examination","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","833","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","13700|2009-011355-46","September 2009","March 2012","March 2012","August 21, 2009",,"December 5, 2014","Cardiff, South Glamorgan, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00963443"
959,"NCT00962611","BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer",,"Completed","No Results Available","Neoplasms","Drug: Copanlisib (Aliqopa, BAY80-6946)","Characterize safety, tolerability + pharmacokinetics, to determine the maximum tolerated dose of BAY80-6946 administered 1x weekly for 3 weeks, every 4weeks, as a 1h-intravenous infusion. Evaluate biomarkers that may be predictive of tumor response.|Determine the effects of BAY80-6946 on blood glucose and insulin, and its safety in patients with type I or II diabetes.|Evaluate for early signs of efficacy in expansion cohorts","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","57","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12871","November 19, 2009","February 23, 2016","February 23, 2016","August 20, 2009",,"October 6, 2017","Scottsdale, Arizona, United States|Pittsburgh, Pennsylvania, United States|San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00962611"
960,"NCT00961831","Radiation Dosimetry, Metabolism, Safety, Tolerability and Positron Emission Tomography/Computed Tomography (PET/CT) Imaging With BAY 85-8050 in Healthy Volunteers and Patients",,"Completed","No Results Available","Neoplasm","Drug: F-18 (BAY85-8050)","Visual assessment of lesions|Quantitative analysis of BAY 85-8050 uptake into lesions (Standardized Uptake Values, SUVs)|Serum chemistry:Glutamate pyruvate transaminase (GPT/ALAT), gamma-glutamyl transferase (gamma-GT), glutamate-oxaloacetate transaminase (GOT), alkaline phosphatase, total bilirubin, creatinine, total protein|Electrocardiogram (ECG)|Vital signs: Heart rate, blood pressure|Adverse events collection","Bayer","All","35 Years to 75 Years   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","13107|2008-000962-21","April 2009","December 2009","December 2009","August 19, 2009",,"February 20, 2014","Ulm, Baden-Württemberg, Germany|München, Bayern, Germany",,"https://ClinicalTrials.gov/show/NCT00961831"
961,"NCT00961038","Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",,"Completed","No Results Available","Pulmonary Disease, Chronic Obstructive","Drug: Ciprofloxacin (PulmoSphere, BAYQ3939)|Drug: Placebo","Vital signs|Electrocardiogram (ECG)|Pulmonary function test|Pulse-oximetry|Ciprofloxacin concentrations in blood|Ciprofloxacin concentrations in urine|Ciprofloxacin concentrations in sputum|Ciprofloxacin concentrations in mouth fluid","Bayer|Novartis Pharmaceuticals","All","40 Years to 75 Years   (Adult, Older Adult)","Phase 1","19","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","13014|2008-006771-79","August 2009","March 2010","March 2010","August 18, 2009",,"April 1, 2014","Hannover, Niedersachsen, Germany",,"https://ClinicalTrials.gov/show/NCT00961038"
962,"NCT00960258","Phase I Study to Investigate Pharmacokinetics and Safety of BAY73-4506 in Asian (Japanese) Patients With Solid Tumors.",,"Completed","No Results Available","Tumors","Drug: Regorafenib (BAY73-4506)","Grade 4 neutropenia for >/= 7 days, febrile neutropenia with Grade 4 neutropenia, Grade 4 thrombocytopenia, Grade 3 or 4 non-hematologic toxicity, hypertension and skin toxicity of Grade 3 or 4 which are not manageable and pharmacokinetics|Biomarker|Response rate","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","15","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13172","July 1, 2009","April 26, 2010","November 11, 2013","August 17, 2009",,"September 27, 2017","Kashiwa-shi, Chiba, Japan|Hidaka, Saitama, Japan|Chuo-ku, Tokyo, Japan|Mitaka, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT00960258"
963,"NCT00944632","Dose Escalation of Different Concentrations of ZK 245186 in Atopic Dermatitis",,"Completed","No Results Available","Atopic Dermatitis","Drug: ZK 245186|Drug: Placebo (vehicle ointment)","Assessment of the severity of atopic dermatitis at target lesion, based on clinical signs of inflammation|Investigator's Global Assessment of target area","Bayer","All","18 Years to 55 Years   (Adult)","Phase 2","64","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","14501|1402942","July 2009","September 2010","September 2010","July 23, 2009",,"February 21, 2014","Bloemfontein, South Africa|George, South Africa|Newton Park, South Africa",,"https://ClinicalTrials.gov/show/NCT00944632"
964,"NCT00941863","Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006)",,"Completed","Has Results","Carcinoma","Drug: Sorafenib 100 mg (50-mg tablet)|Drug: Sorafenib 200 mg (50-mg tablet)|Drug: Sorafenib 400 mg (50-mg tablet)|Drug: Sorafenib 400 mg (200-mg tablet)|Drug: Sorafenib 400 mg (Expansion)","Maximum Tolerated Dose (MTD) of Sorafenib in Combination With Paclitaxel and Carboplatin|Participants With Hematological and Biochemical Toxicities|Tumor Response|Area Under the Curve From Time 0 to 12 Hours Post-dose (AUC 0-12) Start From Day 2 of Cycle 1|Maximum Concentration (CMAX) Start From Day 2 of Cycle 1|Time of Maximum Concentration (TMAX) Start From Day 2 of Cycle 1","Bayer|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","158","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","100375","July 2002","May 2005","April 2008","July 20, 2009","October 8, 2010","March 22, 2016","Philadelphia, Pennsylvania, United States|Nashville, Tennessee, United States|Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00941863"
965,"NCT00941057","Bioequivalence Study: 2 mg Estradiol Valerate (EV) and 3 mg Dienogest (DNG) Without and With Levomefolate Calcium",,"Completed","No Results Available","Pharmacology, Clinical","Drug: BAY 98-7079, Estradiolvalerate (EV) / Dienogest (DNG) / Levomefolate calcium|Drug: BAY 86-5027,Estradiolvalerate(EV) / Dienogest (DNG)|Drug: BAY 86-7660,levomefolate calcium","AUC|Cmax|AUC(0-tlast)|tmax|t½|λz","Bayer","Female","45 Years to 75 Years   (Adult, Older Adult)","Phase 1","43","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","13469|2009-011963-35","September 2009","December 2009","January 2010","July 17, 2009",,"August 1, 2016","Neu-Ulm, Bayern, Germany",,"https://ClinicalTrials.gov/show/NCT00941057"
966,"NCT00937391","Contrast-enhanced MRI in Children 2 Months to <2 Years",,"Completed","Has Results","Magnetic Resonance Imaging","Drug: Gadopentetate dimeglumine (Magnevist, BAY86-6661)","Number of Participants With Diagnostic Adequacy - Open-label Clinical Investigators (Per Protocol Set)|Dose Determined by Blinded Readers to be Superior for Diagnosis|Paired-dose Comparison of Number of Participants With Dose Superiority Determined for 4 Lesion Visualization Variables - Blinded Readers|PK Analysis - Total Clearance (CL)|PK Analysis - Total Clearance (CL)/Body Weight (BW)|PK Analysis - Volume of Distribution at Steady State (Vss)|PK Analysis - Volume of Distribution at Steady State (Vss) /Body Weight (BW)|PK Analysis - Area Under the Drug Concentration-time Curve (AUC)|PK Analysis - t 1/2|Number of Participants With Number of Lesions Detected - Stage 1|Number of Participants With Number of Lesions Detected - Stage 2|Number of Participants With Quality of Lesion Visualization - Stage 1|Number of Participants With Quality of Lesion Visualization - Stage 2|Number of Participants With Quality of Border Delineation - Stage 1|Number of Participants With Quality of Border Delineation - Stage 2|Most Frequent Diagnostic Findings With Unenhanced Images - Stage 1|Most Frequent Diagnostic Findings With Unenhanced Images - Stage 2|Overall Number of Participants With Change in Diagnosis From Unenhanced to Combined Images - Stage 1|Overall Number of Participants With Change in Diagnosis From Unenhanced to Combined Images - Stage 2|Number of Participants With Specific Change in the Diagnosis From Unenhanced to Combined Images - Stage 1|Number of Participants With Specific Change in the Diagnosis From Unenhanced to Combined Images - Stage 2|Number of Participants With Diagnostic Confidence - Stage 1|Number of Participants With Diagnostic Confidence - Stage 2|Management Based on Unenhanced Images - Stage 1|Management Based on Unenhanced Images - Stage 2|Overall Number of Participants With Change in Management From Unenhanced to Combined Images - Stage 1|Overall Number of Participants With Change in Management From Unenhanced to Combined Images - Stage 2|Number of Participants With Specific Change in Management From Unenhanced to Combined Images - Stage 1|Number of Participants With Specific Change in Management From Unenhanced to Combined Images - Stage 2","Bayer","All","2 Months to 23 Months   (Child)","Phase 3","54","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","91784|2009-013081-17|312046","January 2010","September 2010","September 2010","July 13, 2009","October 13, 2011","November 18, 2015","San Diego, California, United States|Aurora, Colorado, United States|Chicago, Illinois, United States|Iowa City, Iowa, United States|Kansas City, Missouri, United States|St. Louis, Missouri, United States|Akron, Ohio, United States|Hershey, Pennsylvania, United States|Houston, Texas, United States|Halle, Sachsen-Anhalt, Germany|Dresden, Sachsen, Germany|Kiel, Schleswig-Holstein, Germany|Jena, Thüringen, Germany",,"https://ClinicalTrials.gov/show/NCT00937391"
967,"NCT00934882","Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI",,"Completed","No Results Available","Colorectal Neoplasms","Drug: Regorafenib (BAY73-4506)","Adverse Event Collection|Effect of BAY73-4506 on the pharmacokinetics of mFOLFOX6 and FOLFIRI (Cmax, AUC, through concentration of BAY73-4506 and Cmax, AUC of Platinum, Irinotecan and its metabolite SN-38, 5-Flourouracil)|Biomarker status|Pharmacodynamic parameters|Tumor response","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","45","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11656|2008-007151-27","August 2009","April 2012","April 2012","July 8, 2009",,"June 2, 2014","Freiburg, Baden-Württemberg, Germany|Heidelberg, Baden-Württemberg, Germany|Mannheim, Baden-Württemberg, Germany|Oldenburg, Niedersachsen, Germany|Herne, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Dresden, Sachsen, Germany",,"https://ClinicalTrials.gov/show/NCT00934882"
968,"NCT00933179","FC Patch Low: Metabolism Study",,"Completed","No Results Available","Contraception","Drug: Gestodene/EE Patch (BAY86-5016)|Drug: EE/Levonorgestrel (Microgynon, BAY86-4977)","Prothrombin fragment 1+2, D-dimer|Procoagulatory parameters|Anticoagulatory parameters|Thrombin and Fibrin turnover parameters","Bayer","Female","18 Years to 35 Years   (Adult)","Phase 2","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","91557|2008-007024-26","June 2009","September 2010","September 2010","July 7, 2009",,"November 14, 2014","Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT00933179"
969,"NCT00932867","Surveillance of Efficacy and Safety of Drug PRITOR in patieNts With Arterial Hypertension, Who do Not Tolerate ACE inhibitoR Treatment","SONAR","Completed","No Results Available","Hypertension","Drug: Kinzal/Pritor (Telmisartan, BAY68-9291)","To evaluate efficacy and safety of telmisartan in patients with arterial hypertension, who do not tolerate ACEI treatment","Bayer","All","18 Years and older   (Adult, Older Adult)",,"3114","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14010|14010 - KL0711SK|14327 - KL0711RO","December 2007","June 2008","August 2009","July 3, 2009",,"April 20, 2010","Many Locations, Romania|Many Location, Slovakia",,"https://ClinicalTrials.gov/show/NCT00932867"
970,"NCT00932802","Greatest International Antiinfective Trial With Avelox","GIANT","Completed","No Results Available","Bronchitis, Chronic|Bronchial Diseases","Drug: Moxifloxacin (Avelox, BAY12-8039)","Evaluation of impact of AECB on the patient and the community as well as effect and safety of a treatment with moxifloxacin tablets in daily life clinical practice|Course of symptom relief|Speed of return to normal daily life activities|Adverse events collection|Evaluation of frequency of new exacerbations|Progression of chronic respiratory disease","Bayer","All","12 Years and older   (Child, Adult, Older Adult)",,"50000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","12219|AX0401|11828|12206|12214|12234|12213|12212|12216|12220|12217|12225|12223|12229|12221|12218|12222|12230|12211|12227|12228|12226|12235|12233|12224|12215|12231|12232","February 2004","November 2007","November 2007","July 3, 2009",,"November 19, 2012","Many Locations, Austria|Many Locations, Brazil|Many Locations, China|Many Locations, Colombia|Many Locations, Croatia|Many Locations, Egypt|Many Locations, El Salvador|Many Locations, Germany|Many Locations, Hong Kong|Many Locations, Hungary|Many Locations, Indonesia|Many Locations, Korea, Republic of|Many Locations, Malaysia|Many Locations, Mexico|Many Locations, Morocco|Many Locations, Netherlands|Many Locations, Pakistan|Many Locations, Philippines|Many Locations, Poland|Many Locations, Singapore|Many Locations, Slovenia|Many Locations, Switzerland|Many Locations, Taiwan|Many Locations, Turkey",,"https://ClinicalTrials.gov/show/NCT00932802"
971,"NCT00932555","EffeKt Taiwan- Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Taiwan",,"Completed","No Results Available","Hemophilia A","Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)","Efficacy and Safety of Kogenate FS","Bayer","Male","Child, Adult, Older Adult",,"82","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14344|KG0803","April 2009",,"December 2011","July 3, 2009",,"March 14, 2012","Many Locations, Taiwan",,"https://ClinicalTrials.gov/show/NCT00932555"
972,"NCT00931827","Acceptability of Long-term Progestin-only Contraception in Europe",,"Completed","No Results Available","Contraception","Drug: Levonorgestrel IUS (Mirena, BAY86-5028)|Drug: Implanon (Etonogestrel)","Continuation rate|Bleeding intensity, dysmenorrhea, and user satisfaction (questionnaires completed by patient)|Cumulative discontinuation rate for unintended pregnancy, bleeding problems, other medical reasons, for non-medical reasons|Incidence of Adverse Events, Serious Adverse Events|The return to fertility of women discontinuing the method for wish for pregnancy","Bayer","Female","20 Years to 35 Years   (Adult)",,"436","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14688|MA0801|14239|14177|14176|14016","January 2008","November 2011","November 2011","July 2, 2009",,"December 24, 2013","Many Locations, France|Many Locations, Ireland|Many Locations, Slovakia|Many Locations, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00931827"
973,"NCT00930982","Evaluation of Cipro Inhale in Patients With Non-cystic Fibrosis Bronchiectasis",,"Completed","Has Results","Bronchiectasis","Drug: Ciprofloxacin (Cipro, BAYQ3939)|Drug: Placebo","Change From Baseline in Total Bacterial Load in the Sputum at End of Treatment (Day 29).|Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)|Change From Baseline in Forced Vital Capacity (FVC)|Time to Exacerbation With Antibiotic Intervention|Effect of Ciprofloxacin Inhale Treatment on Health-related Quality of Life (HRQoL) as Measured by the Saint George's Respiratory Questionnaire (SGRQ), Total Score|Effect of Ciprofloxacin Inhale Treatment on Health-related Quality of Life (HRQoL) as Measured by Chronic Respiratory Questionnaire - Self Administered Standardized (CRQ-SAS)|Change From Baseline in High Sensitive C-reactive Protein (hsCRP)|Change From Baseline in Absolute Neutrophil Count (ANC)|24-hour Sputum Volume|24-hour Sputum Color (Percentage of Participants With Non-clear Sputum)|Microbiological Response of Cipro Inhale Per Participant|Microbiological Response of Cipro Inhale Per Pathogen|Emergence of New Potential Respiratory Pathogens|Emergence of Resistance Among Baseline Pathogens","Bayer|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 2","124","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12965|2009-009869-34","June 2009","September 2010","September 2010","July 2, 2009","January 30, 2012","December 12, 2014","Little Rock, Arkansas, United States|La Jolla, California, United States|Denver, Colorado, United States|Farmington, Connecticut, United States|Washington, District of Columbia, United States|Naples, Florida, United States|Michigan City, Indiana, United States|Mineola, New York, United States|Houston, Texas, United States|Tyler, Texas, United States|Payson, Utah, United States|Concord, New South Wales, Australia|South Brisbane, Queensland, Australia|Woollongabba, Queensland, Australia|Adelaide, South Australia, Australia|Adelaide, South Australia, Australia|Heidelberg, Victoria, Australia|Prahran, Victoria, Australia|Nedlands, Western Australia, Australia|Löwenstein, Baden-Württemberg, Germany|Rüdersdorf, Brandenburg, Germany|Frankfurt, Hessen, Germany|Gelnhausen, Hessen, Germany|Hannover, Niedersachsen, Germany|Hannover, Niedersachsen, Germany|Witten, Nordrhein-Westfalen, Germany|Koblenz, Rheinland-Pfalz, Germany|Mainz, Rheinland-Pfalz, Germany|Geesthacht, Schleswig-Holstein, Germany|Großhansdorf, Schleswig-Holstein, Germany|Bad Berka, Thüringen, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Santiago de Compostela, A Coruña, Spain|Palma de Mallorca, Illes Baleares, Spain|Badajoz, Spain|Barcelona, Spain|Uppsala, Sweden|Bristol, Avon, United Kingdom|Cambridge, Cambridgeshire, United Kingdom|Liverpool, Merseyside, United Kingdom|Belfast, North Ireland, United Kingdom|Newcastle Upon Tyne, Tyne and Wear, United Kingdom|Edinburgh, United Kingdom|Norwich, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00930982"
974,"NCT00930488","Treatment of Patients With Acute Sinusitis",,"Completed","No Results Available","Acute Bacterial Sinusitis","Drug: Avelox (Moxifloxacin, BAY12-8039)","Evaluation of potential benefits of an antibacterial therapy with Avelox® (moxifloxacin) in patients with acute bacterial sinusitis to whom this treatment was prescribed. Especially the time to improvement and resolution of clinical signs and symptoms of|Evaluation of tolerability and safety of Avalox® in daily practice were investigated.|Patient characteristics in acute bacterial sinusitis|History and frequency of sinusitis episodes|Diagnostic procedures and therapeutic options chosen by physicians in daily practice","Bayer","All","Child, Adult, Older Adult",,"6777","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","12803|TOPAS|AX 0601|12867 - AX0601AT|12868 - AX0601PK|12869 - AX0601EG|12870 - AX0601NL|12973 - AX0601SK|12974 - AX0601SG|13026 - AX0601ID|13046 - AX0601PH|13111 - AX0601RO|13065 - AX0601CN|13207 - AX0601FR|13166 - AX0601MY","March 2007","December 2008","December 2008","June 30, 2009",,"November 20, 2012","Many Locations, Austria|Many Locations, Bahrain|Many Locations, China|Many Locations, Egypt|Many Locations, France|Many Locations, Germany|Many Locations, Indonesia|Many Locations, Jordan|Many Locations, Kuwait|Many Locations, Lebanon|Many Locations, Malaysia|Many Locations, Netherlands|Many Locations, Pakistan|Many Locations, Philippines|Many Locations, Romania|Many Locations, Saudi Arabia|Many Locations, Singapore|Many Locations, United Arab Emirates|Many Locations, Yemen",,"https://ClinicalTrials.gov/show/NCT00930488"
975,"NCT00928967","Open, Multicentric, Prospective, Quality of Life Study in Multiple Sclerosis Patients",,"Completed","No Results Available","Multiple Sclerosis","Drug: Interferon beta-1b, (Betaseron BAY86-5046)","Evolution of the Daily Life score: Analysis of variance for repeated measurements.|Evolution of the SF 36 score, Fatigue score, Beck's depression score: analysis of variance for repeated measurements|Correlation coefficient with quality of life scales|Kinetics of treatment discontinuation: Kaplan Meier|Rate of treatment continuation","Bayer","All","18 Years and older   (Adult, Older Adult)",,"67","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14168|Daily Life Study|BF0610FR","May 2007","March 2010","November 2010","June 26, 2009",,"October 9, 2015","Many Locations, France",,"https://ClinicalTrials.gov/show/NCT00928967"
976,"NCT00927667","Joint Status in Subjects With Severe Hemophilia A in Relation to Different Treatment Regimens",,"Completed","No Results Available","Hemophilia A","Procedure: No Drug","Maximum ankle MRI score|Total MRI score of the maximum index joint|Number of bleeds in each index joint over previous 5 years|Number of total joint bleeds and their locations over previous 5 years|Physical joint score (Gilbert Score)","Bayer","Male","12 Years to 35 Years   (Child, Adult)","Phase 4","156","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","12948|2009-010147-14","June 2009","December 2010","December 2010","June 25, 2009",,"February 20, 2013","Heidelberg, Baden-Württemberg, Germany|Bonn, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Magdeburg, Sachsen-Anhalt, Germany|Athens, Greece|Milano, Italy|Padova, Italy|Parma, Italy|Roma, Italy|A Coruña, Spain|Valencia, Spain|Malmö, Sweden|Stockholm, Sweden|Canterbury, Kent, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00927667"
977,"NCT00927537","Therapy of Essential Hypertension With Kinzal®/ Kinzalplus®",,"Completed","No Results Available","Hypertension","Drug: Telmisartan (Kinzal/Pritor, BAY68-9291)|Drug: Telmisartan (Kinzal/Pritor, BAY68-9291) + Hydrochlorothiazide","Blood pressure|Change in Mean heart rate (bpm)|Change in Mean Weight (kg)|Change in Mean laboratory parameters (total cholesterol, LDL, HDL, triglyceride, fasting blood glucose)|Patient Medical History: Duration of hypertension, Pre-treatment of hypertension, Comorbidities and Concomitant treatment|Final evaluation of efficacy (very good, good, sufficient, insufficient) and tolerability (very good, good, sufficient, insufficient) of treatment by the physician.","Bayer","All","18 Years and older   (Adult, Older Adult)",,"2052","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","13599|KL0810CH","April 2008","October 2011","October 2011","June 25, 2009",,"September 4, 2013","Many Locations, Switzerland",,"https://ClinicalTrials.gov/show/NCT00927537"
978,"NCT00924248","Primovist Regulatory Post Marketing Surveillance (PMS)",,"Completed","No Results Available","Liver","Drug: Gadoxetic acid disodium (Primovist, BAY86-4873)","Safety evaluation in real practice (SAE/AE/ADR collection)|Assessment of contrast effect by imaging after administration|Overall contrast effects by combining individual assessment|Assessment of contrast enhancement effect","Bayer","All","Child, Adult, Older Adult",,"4358","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14332|PR0810KR","October 2007",,"May 2011","June 18, 2009",,"September 19, 2012","Many Locations, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00924248"
979,"NCT00923572","Yasmin Post Marketing Surveillance",,"Completed","No Results Available","Contraception","Drug: EE30/DRSP (Yasmin, BAY86-5131)","Safety and efficacy in real practice|Demography|Medical History|Administration period of Yasmin|Patient's compliance|Adverse Event / Serious AE collection","Bayer","Female","18 Years and older   (Adult, Older Adult)",,"777","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14339|YA0510KR","December 2007","May 2013","August 2013","June 18, 2009",,"November 11, 2015","Many Locations, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00923572"
980,"NCT00922597","Non-interventional Observation of Practical Implementation, Efficacy and Safety of Continuous Infusion With KOGENATE Bayer in Surgery","NO PEACKS","Completed","No Results Available","Hemophilia A","Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)","Total consumption of FVIII (in IU/kg) during continuous infusion, FVIII:C achieved compared to expected levels, reasons and number of unplanned bolus infusion, amount of blood loss, transfusion requirements|General tolerability and development of inhibitors","Bayer","Male","Child, Adult, Older Adult",,"26","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","13213|KG0701","August 2008",,"September 2011","June 17, 2009",,"April 20, 2015","Many Locations, Austria|Many Locations, Germany|Many Locations, Greece|Many Locations, Italy|Many Locations, Netherlands|Many Locations, Slovenia|Many Locations, Spain",,"https://ClinicalTrials.gov/show/NCT00922597"
981,"NCT00921245","FREEDOM - First Real-Life Evaluation of Enablex Done in ZA Overactive Bladder Patients During a 3 Months Period","FREEDOM","Completed","No Results Available","Overactive Bladder","Drug: Darifenacin (Emselex, BAY79-4998)","To evaluate safety and tolerability of Darifenacin in the daily practice for the treatment of the OAB (Over Active Bladder) syndrome.|To evaluate the patient's perception of bladder condition, the patient's use of the patient support program, the patient's and physician's assessment of treatment regarding efficacy and tolerability and patient's compliance with the treatment","Bayer","All","18 Years and older   (Adult, Older Adult)",,"9","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","13027|EX0710ZA","June 2007","October 2008","February 2009","June 16, 2009",,"April 20, 2015","Many Locations, South Africa",,"https://ClinicalTrials.gov/show/NCT00921245"
982,"NCT00920985","US Cycle Control and Blood Pressure Study",,"Completed","No Results Available","Contraception","Drug: Gestodene/EE (FC Patch Low, BAY86-5016)|Drug: Oral contraceptive (equivalent to the active treatment tablets of Levlite), 21-day blister SH D00593A","Cycle control parameters and bleeding pattern indices|Number of pregnancies while on treatment up to 14 days after removal of the last patch|Evaluation of blood pressure changes during the dosing-free interval","Bayer","Female","18 Years to 45 Years   (Adult)","Phase 3","346","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","91556","June 2009","August 2010","September 2010","June 16, 2009",,"October 9, 2015","Chandler, Arizona, United States|Glendale, Arizona, United States|Phoenix, Arizona, United States|Tucson, Arizona, United States|Anaheim, California, United States|San Diego, California, United States|Clearwater, Florida, United States|Daytona Beach, Florida, United States|Lake Worth, Florida, United States|Leesburg, Florida, United States|Miami, Florida, United States|Atlanta, Georgia, United States|Decatur, Georgia, United States|Metairie, Louisiana, United States|Kalamazoo, Michigan, United States|St. Louis, Missouri, United States|Las Vegas, Nevada, United States|New Brunswick, New Jersey, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Wexford, Pennsylvania, United States|Columbia, South Carolina, United States|Richmond, Virginia, United States|Renton, Washington, United States|Seattle, Washington, United States|La Crosse, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00920985"
983,"NCT00919022","Androcur Non-interventional Study Among Patients With Carcinoma of the Prostate","ANES","Terminated","No Results Available","Prostate Cancer","Drug: Cyproterone Acetate (Androcur, BAY94-8367)","Correlation of treatment with Androcur (concomitant treatment), disease stage, testosterone level, age with erectile dysfunction (measured by IIEF-5 validated questionnaire)|Correlation of PSA level and erectile dysfunction|Sexual activity of Czech patients with inoperable prostate cancer","Bayer","Male","18 Years and older   (Adult, Older Adult)",,"194","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14556|AC0910CZ","August 2009",,"August 2011","June 11, 2009",,"November 1, 2012","Many Locations, Czech Republic",,"https://ClinicalTrials.gov/show/NCT00919022"
984,"NCT00915915","Inhibition of Ovulation and Pharmacokinetics of Transdermal Ethinylestradiol (EE) and Gestodene (GSD)",,"Completed","No Results Available","Contraception|Ovulation Inhibition","Drug: Ethinylestradiol/Gestodene (BAY86-5016)","The primary efficacy variable will be the proportion of volunteers with ovulation in at least one of the treatment cycles 2 and 3|Course of gonadotropins (FSH, LH, P, E2)|Endometrial thickness and Follicle size|Pharmacokinetics of Ethinylestradiol (EE), Gestodene (GSD) and SHBG in treatment cycles 2 and 3|Cervical effects (Insler Score) for determination of hormonal effects on the cervix and the cervical mucus during pre-treatment cycle and treatment cycle 3","Bayer","Female","18 Years to 35 Years   (Adult)","Phase 2","108","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14348|2009-009177-10","June 2009","April 2010","April 2010","June 8, 2009",,"October 28, 2014","Berlin, Germany|Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT00915915"
985,"NCT00914693","EU/LA Pearl Index Study - Transdermal Contraceptive Patch",,"Completed","No Results Available","Contraception","Drug: Ethinylestradiol/Gestodene (BAY86-5016)","Occurrence of pregnancy|Cervical smear|Adverse events|Bleeding pattern and cycle control","Bayer","Female","18 Years to 35 Years   (Adult)","Phase 3","1694","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","91554|2008-004214-27|310801","April 2009","September 2011","September 2011","June 5, 2009",,"December 5, 2014","Lanus Oeste, Buenos Aires, Argentina|San Isidro, Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Rosario, Santa Fe, Argentina|Ashfield, New South Wales, Australia|Adelaide, South Australia, Australia|North Adelaide, South Australia, Australia|Clayton, Victoria, Australia|Nedlands, Western Australia, Australia|Temuco, Araucanía, Chile|Santiago, Chile|Santiago, Chile|Santiago, Chile|Temuco, Chile|Biarritz, France|Montargis, France|Nimes, France|Quetigny, France|REIMS Cedex, France|Saint Germain En Laye, France|Toulouse, France|Frankfurt, Hessen, Germany|Aachen, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Siegen, Nordrhein-Westfalen, Germany|Wuppertal, Nordrhein-Westfalen, Germany|Blankenburg, Sachsen-Anhalt, Germany|Jessen, Sachsen-Anhalt, Germany|Magdeburg, Sachsen-Anhalt, Germany|Dippoldiswalde, Sachsen, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Leipzig, Sachsen, Germany|Gera, Thüringen, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Francavilla Fontana, Brindisi, Italy|Bologna, Italy|Cagliari, Italy|Catanzaro, Italy|Firenze, Italy|Modena, Italy|Palermo, Italy|Pavia, Italy|Perugia, Italy|Pisa, Italy|Siena, Italy|Torreón, Coahuila, Mexico|Chihuahua, Mexico|Mexico D.F., Mexico|México D.F., Mexico|México, D.F., Mexico|San Luis Potosí, Mexico|San Fernando, Cádiz, Spain|Vigo, Pontevedra, Spain|Dos Hermanas, Sevilla, Spain|Alava, Vitoria, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Lugo, Spain|Pamplona, Spain|Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT00914693"
986,"NCT00913926","Effects of Wellnara on Climacteric Symptoms",,"Completed","No Results Available","Postmenopause","Drug: E2/LNG oral (Wellnara, BAY86-5029)","Primary endpoint in the observation of efficacy concerning climacteric complaints is the change in Menopause Rating Scale (MRS II) in relation to the status immediately before starting treatment (Baseline).|Effects on climacteric-related skin, hair, and sexual problems|Subjective assessment of efficacy|Body weight|Blood Pressure|Waist-hip-ratio (as far as routinely used in the practice)|Occurrence of vaginal bleeding|Subjective assessment of tolerability|Adverse drug reactions","Bayer","Female","Child, Adult, Older Adult",,"749","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14575|WN0810DE","September 2007","May 2009","May 2009","June 4, 2009",,"April 22, 2015","Many Locations, Germany",,"https://ClinicalTrials.gov/show/NCT00913926"
987,"NCT00911001","SALTO - Epidemiological Study on Compliance and Treatment Satisfaction","SALTO","Completed","No Results Available","Thromboembolism","Behavioral: No Drug","To measure the Treatment Satisfaction with medication through the self administered scale TSQM.|To measure compliance with medication and the relationship with satisfaction through the Moriski-Green Questionaire","Bayer","All","18 Years and older   (Adult, Older Adult)",,"480","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14343|NN0811ES","November 2008","March 2009","March 2009","June 1, 2009",,"September 19, 2013","Many Locations, Spain",,"https://ClinicalTrials.gov/show/NCT00911001"
988,"NCT00910637","Study Investigating the Efficacy and Safety of a Contraceptive Patch for 13 Cycles",,"Completed","No Results Available","Contraception","Drug: Gestodene/EE Patch (BAY86-5016)","Occurrence of pregnancy (yes/no) while on treatment|Vital signs|Physical and gynecological examinations|Laboratory assessments|Adverse events (AE monitoring)","Bayer","Female","18 Years to 45 Years   (Adult)","Phase 3","1502","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","91555|310802","May 2009","December 2010","December 2010","June 1, 2009",,"February 8, 2013","Birmingham, Alabama, United States|Glendale, Arizona, United States|Phoenix, Arizona, United States|Tucson, Arizona, United States|Carmichael, California, United States|Pacific Palisades, California, United States|Paramount, California, United States|San Diego, California, United States|San Diego, California, United States|San Diego, California, United States|San Francisco, California, United States|Santa Ana, California, United States|Torrance, California, United States|Denver, Colorado, United States|Littleton, Colorado, United States|Littleton, Colorado, United States|New London, Connecticut, United States|Boynton Beach, Florida, United States|Bradenton, Florida, United States|Gainesville, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Pembroke Pines, Florida, United States|St. Petersburg, Florida, United States|West Palm Beach, Florida, United States|Atlanta, Georgia, United States|Decatur, Georgia, United States|Roswell, Georgia, United States|Boise, Idaho, United States|Idaho Falls, Idaho, United States|Chicago, Illinois, United States|Newburgh, Indiana, United States|South Bend, Indiana, United States|Marrero, Louisiana, United States|Boston, Massachusetts, United States|Chaska, Minnesota, United States|Chesterfield, Missouri, United States|Lincoln, Nebraska, United States|Las Vegas, Nevada, United States|Las Vegas, Nevada, United States|Las Vegas, Nevada, United States|Lawrenceville, New Jersey, United States|Moorestown, New Jersey, United States|Morristown, New Jersey, United States|Albuquerque, New Mexico, United States|New York, New York, United States|New Bern, North Carolina, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Wadsworth, Ohio, United States|Oklahoma City, Oklahoma, United States|Eugene, Oregon, United States|Medford, Oregon, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Warwick, Rhode Island, United States|Columbia, South Carolina, United States|Mt. Pleasant, South Carolina, United States|Chattanooga, Tennessee, United States|Knoxville, Tennessee, United States|Memphis, Tennessee, United States|Nashville, Tennessee, United States|Nashville, Tennessee, United States|Corpus Christi, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Norfolk, Virginia, United States|Seattle, Washington, United States|Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00910637"
989,"NCT00910429","BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension","CHEST-2","Completed","No Results Available","Pulmonary Hypertension","Drug: Riociguat (Adempas, BAY63-2521)","Safety and tolerability (e.g. adverse event collection)|Change in 6-Minute Walking Distance (6MWD) from baseline","Bayer","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","237","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11349|2008-003539-19","July 1, 2009","August 19, 2019","August 19, 2019","May 29, 2009",,"August 29, 2019","La Jolla, California, United States|Sacramento, California, United States|Iowa City, Iowa, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Dallas, Texas, United States|Corrientes, Argentina|Prahran, Victoria, Australia|Wien, Austria|Bruxelles - Brussel, Belgium|Leuven, Belgium|Porto Alegre, Rio Grande Do Sul, Brazil|São Paulo, Sao Paulo, Brazil|Rio de Janeiro, Brazil|Calgary, Alberta, Canada|London, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Beijing, China|Beijing, China|Shanghai, China|Praha 2, Czechia|Aarhus N, Denmark|Brest, France|Le Kremlin Bicetre Cedex, France|Rouen, France|Vandoeuvre Les Nancy, France|Heidelberg, Baden-Württemberg, Germany|München, Bayern, Germany|Würzburg, Bayern, Germany|Gießen, Hessen, Germany|Hannover, Niedersachsen, Germany|Köln, Nordrhein-Westfalen, Germany|Homburg, Saarland, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Hamburg, Germany|Rabin Medical Center - Beilinson Campus, Petach Tikva, Israel|Pavia, Lombardia, Italy|Nagoya, Aichi, Japan|Kitakyushu, Fukuoka, Japan|Komatsu, Ishikawa, Japan|Fujisawa, Kanagawa, Japan|Kawasaki, Kanagawa, Japan|Sendai, Miyagi, Japan|Suwa, Nagano, Japan|Bunkyo-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Chiba, Japan|Fukuoka, Japan|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Monterrey, Nuevo Leon, Mexico|Mexico D.F., Mexico|Querétaro, Mexico|Krakow, Poland|Otwock, Poland|Coimbra, Portugal|Centro Hospitalar de Lisboa Norte - Hospital Santa Maria, Lisboa, Portugal|Novosibirsk, Russian Federation|St. Petersburg, Russian Federation|Bratislava 37, Slovakia|Barcelona, Spain|Zürich, Switzerland|Taipei, Taiwan|Ankara, Turkey|Istanbul, Turkey|Izmir, Turkey|Cambridge, Cambridgeshire, United Kingdom|Glasgow, West Dunbartonshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00910429"
990,"NCT00910351","Cipro Inhaler for Cystic Fibrosis Children Ages 6-12",,"Completed","No Results Available","Pseudomonas Infection","Drug: Ciprofloxacin (Cipro, BAYQ3939)","To investigate the safety and tolerability of inhaled ciprofloxacin given as single inhalation dose to pediatric CF patients, aged 6 - 12 years|To investigate the pharmacokinetics of ciprofloxacin in plasma and sputum after inhalation administration","Bayer","All","6 Years to 12 Years   (Child)","Phase 1","19","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12759","July 2009","October 2010","October 2010","May 29, 2009",,"November 21, 2013","Atlanta, Georgia, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Syracuse, New York, United States",,"https://ClinicalTrials.gov/show/NCT00910351"
991,"NCT00910065","BAY81-8781, I.V. Aspirin in the Indication of Acute Coronary Syndrome (ACS)","ACUTE","Completed","No Results Available","Acute Coronary Syndrome","Drug: D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 500 mg IV|Drug: D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 250 mg IV|Drug: Acetylsalicylic acid (Aspirin, BAYe4465) 300 mg Tablet","Concentration of Thromboxane B2 (TXB2) at 5 Minutes Post-dose|Concentration of Thromboxane B2 (TXB2) at 20 Minutes Post-dose|Platelet Aggregation Inhibition (PAI) at 5 Minutes and 20 Minutes After Single Dose of Study Drug Administration Measured as Response to Treatment|Serum Concentration of Prostacyclin Metabolite at 5 and 20 Minutes Post-dose|Incidence of the Composite Clinical Endpoint of Cardiovascular Death, Stroke and Myocardial Infarction up to Day 30 After Single Dose of Study Drug Administration|Incidence of Post-randomization Deaths From all Causes, Cardiovascular Deaths, Myocardial Re/Infarctions and Ischemic Strokes Within 24 Hours, 7 Days And 30 Days After Single Dose of Study Drug Administration","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","270","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12946|2007-005163-94","March 2011","April 2014","July 2014","May 29, 2009",,"June 25, 2015","Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Changsha, Hunan, China|Nanchang, Jiangxi, China|Shenyang, Liaoning, China|Shenyang, Liaoning, China|Hangzhou, Zhejiang, China|Beijing, China|Beijing, China|Shanghai, China|Bad Krozingen, Baden-Württemberg, Germany|Heidelberg, Baden-Württemberg, Germany|Coburg, Bayern, Germany|Dachau, Bayern, Germany|Melsungen, Hessen, Germany|Bonn, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Mönchengladbach, Nordrhein-Westfalen, Germany|Soest, Nordrhein-Westfalen, Germany|Ludwigshafen, Rheinland-Pfalz, Germany|Mainz, Rheinland-Pfalz, Germany|Worms, Rheinland-Pfalz, Germany|Magdeburg, Sachsen-Anhalt, Germany|Berlin, Germany|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|San Juan, Alicante, Spain|Sabadell, Barcelona, Spain|Alicante, Spain|Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT00910065"
992,"NCT00909857","Effect on Primary Dysmenorrhea",,"Completed","Has Results","Primary Dysmenorrhea","Drug: Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)|Drug: Ethinyl estradiol, Levonorgestrel (Miranova)|Drug: Placebo Match to SH T00658ID|Drug: Placebo Match to SH D593B","Change Between Baseline Evaluation Period and Treatment Evaluation Period in the Number of Days With Dysmenorrheic Pain|Change Between Baseline Evaluation Period and Treatment Evaluation Period in the Sum of Score Points of Dysmenorrheic Pain|Change Between Baseline Evaluation Period and Treatment Evaluation Period in Number of Days With Pelvic Pain Independent of Occurrence of Vaginal Bleeding|Change Between Baseline Evaluation Period and Treatment Evaluation Period in Number of Days With Pelvic Pain During Unscheduled Bleeding|Change Between Baseline Evaluation Period and Treatment Evaluation Period in Rescue Medication Use (Only Bleeding Episodes Used Including the Two Days Before the Episode)|Change Between Baseline Evaluation Period and Treatment Evaluation Period in Rescue Medication Use (Entire Evaluation Period Used)|Percentage of Participants With Interference of Dysmenorrheic Pain With Work/School and Social or Other Activity (Only Bleeding Episodes Used Including the Two Days Before)|Percentage of Participants With Interference of Dysmenorrheic Pain With Work/School and Social or Other Activity (Entire Evaluation Period Used)|Percentage of Participants Satisfied With Study Treatment|Number of Days With Bleeding or Spotting|Number of Episodes With Bleeding or Spotting|Mean Length of Bleeding or Spotting Episodes|Maximum Length of Bleeding or Spotting Episodes|Difference in Duration Between Longest and Shortest Bleeding or Spotting Episode|Number of Days With Spotting-only|Number of Episodes With Spotting-only|Mean Length of Spotting Only Episodes|Maximum Length of Spotting Only Episodes|Difference in Duration Between Longest and Shortest Spotting Only Episode|Percentage of Participants With Withdrawal Bleeding at Cycle 1|Percentage of Participants With Withdrawal Bleeding at Cycle 3|Length of Withdrawal Bleeding Episodes at Cycle 1|Length of Withdrawal Bleeding Episodes at Cycle 3|Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 1|Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 3|Onset of Withdrawal Bleeding Episodes at Cycle 1|Onset of Withdrawal Bleeding Episodes at Cycle 3|Percentage of Participants With Intracyclic Bleeding at Cycle 1|Percentage of Participants With Intracyclic Bleeding at Cycle 3|Number of Intracyclic Bleeding Episodes at Cycle 1|Number of Intracyclic Bleeding Episodes at Cycle 3|Maximum Length of Intracyclic Bleeding Episodes at Cycle 1|Maximum Length of Intracyclic Bleeding Episodes at Cycle 3|Number of Intracyclic Bleeding Days at Cycle 1|Number of Intracyclic Bleeding Days at Cycle 3|Percentage of Participants With Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 1|Percentage of Participants With Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 3|Percentage of Participants Missing Time From Work Due to Dysmenorrheic Pain at Screening|Percentage of Participants Missing Time From Work Due to Dysmenorrheic Pain at Baseline Cycle|Percentage of Participants Missing Time From Work Due to Dysmenorrheic Pain at Cycle 2|Percentage of Participants Missing Time From Work Due to Dysmenorrheic Pain at Final Examination|Own Costs of Physiotherapy Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire|Own Costs of Pain Medication Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire|Own Costs of Vitamins Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire|Own Costs of Massages Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire|Own Costs of Acupuncture Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire|Own Costs of Medical Counseling Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire|Own Costs of Alternative Medicine Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire|Own Costs of Herbs/Teas Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire|Other Own Costs Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire|Participants With Improvement in the Investigators' Assessment in the Clinical Global Impression|Participants With Improvement in Participants' Assessment in the Clinical Global Impression|Physical Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle|Physical Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination|Social Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle|Social Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination|Mental Health as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle|Mental Health as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination|Vitality as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle|Vitality as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination|General Health as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle|General Health as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination|Role Physical as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle|Role Physical as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination|Role Emotional as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle|Role Emotional as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination|Bodily Pain as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle|Bodily Pain as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination","Bayer","Female","14 Years to 50 Years   (Child, Adult)","Phase 3","507","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","91781|2008-005625-11|312042","April 2009","November 2010","November 2010","May 29, 2009","February 27, 2012","August 24, 2015","Tucson, Arizona, United States|San Diego, California, United States|Hialeah, Florida, United States|Leesburg, Florida, United States|Sandy Springs, Georgia, United States|Idaho Falls, Idaho, United States|Winston-Salem, North Carolina, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|La Crosse, Wisconsin, United States|Langley, British Columbia, Canada|Toronto, Ontario, Canada|Pointe-Claire, Quebec, Canada|Ste-Foy, Quebec, Canada|Regina, Saskatchewan, Canada|Santiago de Chile, Chile|Santiago, Chile|Talcahuano, Chile|Temuco, Chile|Freiburg, Baden-Württemberg, Germany|Essen, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Bernburg, Sachsen-Anhalt, Germany|Magdeburg, Sachsen-Anhalt, Germany|Leipzig, Sachsen, Germany|Hamburg, Germany|Francavilla Fontana, Brindisi, Italy|Bologna, Italy|Brescia, Italy|Milano, Italy|Modena, Italy|Perugia, Italy|Roma, Italy|Siena, Italy|Torino, Italy|Udine, Italy|Cebu City, Philippines|Cebu, Philippines|Davao, Philippines|Metro Manila, Philippines|Metro Manila, Philippines|Quezon City, Philippines",,"https://ClinicalTrials.gov/show/NCT00909857"
993,"NCT00909233","LEVITRA® 20mg Special Drug Use Investigation (Long-term)",,"Completed","No Results Available","Erectile Dysfunction","Drug: Vardenafil, (Levitra, BAY38-9456)","Efficacy of patients with LEVITRA treatment|LEVITRA treatment improved the patient's erection|LEVITRA improved the patient's erection after Minimum and Maximum Intervals between LEVITRA intake and the start of intercourse|Reporting a second successful intercourse within 24 hours of dosing|Patients prefer LEVITRA over last Erectile Dysfunction treatment|Tolerability of patients with LEVITRA treatment","Bayer","Male","18 Years to 64 Years   (Adult)",,"1221","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","13930|LV0701JP","August 2007","March 2010","December 2011","May 27, 2009",,"December 15, 2014","Many locations, Japan",,"https://ClinicalTrials.gov/show/NCT00909233"
994,"NCT00909142","Bonefos and the Consumption of Analgesics","BICAM","Completed","No Results Available","Bone Neoplasms","Drug: Bonefos (Clodronate, BAY94-8393)","Analgesics consumption after 12 months of treatment with Bonefos in patients with bone metastases and breast or prostate cancer or multiple myeloma|Decrease in pain measured by VAS (Visual Analogue Scale)","Bayer","All","18 Years and older   (Adult, Older Adult)",,"149","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14236|Bonefos","April 2007","February 2009","February 2009","May 27, 2009",,"April 6, 2012","Many locations, Czech Republic",,"https://ClinicalTrials.gov/show/NCT00909142"
995,"NCT00909051","GlucoVIP - Diabetes Treatment by Glucobay® With a Special Therapeutic View to Chosen Patient Groups",,"Completed","No Results Available","Diabetes Mellitus","Drug: Acarbose (Glucobay, BAYG5421)","Data collection on patients weight and waist circumference, fasting blood glucose, postprandial blood glucose (2h), HbA1C; exploratory analysis according to patient groups (concomitant cardiovascular disease groups, BMI)","Bayer","All","18 Years and older   (Adult, Older Adult)",,"15729","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14284|GB0701","March 2009","December 2010","December 2010","May 27, 2009",,"January 19, 2012","Many Locations, Algeria|Many Locations, Bosnia and Herzegovina|Many Locations, Cambodia|Many Locations, China|Many Locations, Hong Kong|Many Locations, India|Many Locations, Indonesia|Many Locations, Korea, Republic of|Many Locations, Malaysia|Many Locations, Moldova, Republic of|Many Locations, Pakistan|Many Locations, Philippines|Many Locations, Russian Federation|Many Locations, Singapore|Many Locations, Thailand|Many Locations, Vietnam",,"https://ClinicalTrials.gov/show/NCT00909051"
996,"NCT00908674","Androcur Effects on Quality of Life",,"Completed","No Results Available","Prostate Cancer","Drug: Cyproterone acetate (Androcur)","Quality of life change measured by SF-35 questionnaire","Bayer","Male","18 Years and older   (Adult, Older Adult)",,"245","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14166|AC0710HU","June 2008","January 2010","January 2010","May 27, 2009",,"April 13, 2010","Many Locations, Hungary",,"https://ClinicalTrials.gov/show/NCT00908674"
997,"NCT00908596","Primovist / Eovist in Renally Impaired Patients","PERI","Completed","Has Results","Contrast Media","Drug: Gadoxetic acid disodium (Primovist, BAY86-4873)","Number of Participants With Moderate to Severe Renal Impairment, Who Develop NSF (Nephrogenic Systemic Fibrosis), Based on Diagnostically Specific Clinical and Histopathological Information|Number of Participants With Moderate to Severe Renal Impairment in Whom no Biopsy Was Obtained Who Develop NSF-like Symptoms Based on Diagnostically Specific Clinical Information Summarized by Clinical Score|Confidence of the Investigator to Make a Diagnosis Based on the Primovist/Eovist Enhanced MRI (Magnetic Resonance Imaging)|Number of Participants With ""Excellent / Good / Adequate / Insufficient"" Scores for Lesion Detection|Number of Participants With ""Excellent / Good / Adequate / Insufficient"" Scores for Lesion Delineation|Number of Participants With ""Excellent / Good / Adequate / Insufficient"" Scores for Lesion Characterization","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 4","357","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","13701|2008-005867-33","May 2009","July 2013","July 2013","May 27, 2009","August 7, 2014","July 23, 2015","Los Angeles, California, United States|Jacksonville, Florida, United States|Honolulu, Hawaii, United States|Topeka, Kansas, United States|Baltimore, Maryland, United States|Ann Arbor, Michigan, United States|Brooklyn, New York, United States|New York, New York, United States|Durham, North Carolina, United States|Memphis, Tennessee, United States|Houston, Texas, United States|San Antonio, Texas, United States|Herston, Queensland, Australia|Woollongabba, Queensland, Australia|Adelaide, South Australia, Australia|Geelong, Victoria, Australia|Westmead NSW, Australia|Graz, Austria|Wien, Austria|Heidelberg, Baden-Württemberg, Germany|Stuttgart, Baden-Württemberg, Germany|Erlangen, Bayern, Germany|Frankfurt, Hessen, Germany|Marburg, Hessen, Germany|Hannover, Niedersachsen, Germany|Dortmund, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Magdeburg, Sachsen-Anhalt, Germany|Dresden, Sachsen, Germany|Gera, Thüringen, Germany|Berlin, Germany|Rozzano, Milano, Italy|Pozzuoli, Napoli, Italy|Candiolo, Torino, Italy|Brescia, Italy|Milano, Italy|Napoli, Italy|Palermo, Italy|Pisa, Italy|Busan, South Korea, Korea, Republic of|Seoul, South Korea, Korea, Republic of|Seoul, Korea, Republic of|Granada, Spain|Bangkok, Thailand|Bangkok, Thailand|Songkhla, Thailand|Bristol, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00908596"
998,"NCT00905879","Observational Study on the Safety and Tolerability of Gadobutrol (Gadovist) Among Filipino Patients in Magnetic Resonance Imaging",,"Completed","No Results Available","Magnetic Resonance Imaging","Drug: Gadobutrol (Gadovist, BAY86-4875)","The primary outcome measures would be safety and tolerability of Gadovist which would be measured by change in Vital signs before and after the procedure and the occurrence of serious or non-serious adverse events","Bayer","All","18 Years and older   (Adult, Older Adult)",,"30","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","13926|GV0811PH","June 2009",,"January 2011","May 21, 2009",,"April 26, 2013","Many Locations, Philippines",,"https://ClinicalTrials.gov/show/NCT00905879"
999,"NCT00905684","Effects of Counseling on the Continuation Rates and Compliance for Newly Prescribed Oral Contraceptives (Yasmin® or Any Other Oral Contraceptives (OC)",,"Completed","No Results Available","Contraception","Drug: EE30/DRSP (Yasmin, BAY86-5131)|Drug: Any other OC","Analyses of continuation rates and compliance stratified by the subject's knowledge on the respective topics and time spent for counseling.|Analyses stratified by baseline factors such as age group, presence or absence of cycle disorders, and history of oral contraceptive method will be performed as well.|Special attention will be paid to serious adverse events and unexpected or unlisted ADRs.","Bayer","Female","18 Years and older   (Adult, Older Adult)",,"5446","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14565|YA0801","June 2009",,"December 2011","May 20, 2009",,"March 7, 2012","Many locations, Albania|Many Locations, Bahrain|Many locations, Egypt|Many locations, Hungary|Many Locations, Jordan|Many locations, Kenya|Many Locations, Kuwait|Many Locations, Lebanon|Many locations, Macedonia, The Former Yugoslav Republic of|Many Locations, Oman|Many Locations, Qatar|Many Locations, Saudi Arabia|Many locations, United Arab Emirates",,"https://ClinicalTrials.gov/show/NCT00905684"
1000,"NCT00902135","Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)",,"Completed","No Results Available","Relapsing-Remitting Multiple Sclerosis","Drug: Interferon beta-1b (Betaseron, BAY86-5046)","Drop out rate over 2 years|Disability status|Grade of depressiveness|Grade of fatigue|Quality of life|Cognitive status|Injection regularity","Bayer","All","18 Years and older   (Adult, Older Adult)",,"702","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14543|BF0801DE","May 2009","December 2013","August 2014","May 14, 2009",,"July 17, 2015","Many Locations, Germany",,"https://ClinicalTrials.gov/show/NCT00902135"
1001,"NCT00901901","Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma","SEARCH","Completed","Has Results","Carcinoma, Hepatocellular","Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Erlotinib (Tarceva)|Drug: Placebo","Overall Survival|Time to Radiological Tumor Progression (TTP)|Disease Control|Health-related Quality of Life and Utility Values as Measured by EQ-5D - Index|Health-related Quality of Life and Utility Values as Measured by EQ-5D - VAS","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","732","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","12917|2008-006021-14","May 21, 2009","April 17, 2012","May 23, 2018","May 14, 2009","September 30, 2013","May 30, 2019","San Francisco, California, United States|Washington, District of Columbia, United States|Gainesville, Florida, United States|Miami, Florida, United States|Atlanta, Georgia, United States|Honolulu, Hawaii, United States|Maywood, Illinois, United States|Westwood, Kansas, United States|Louisville, Kentucky, United States|New Orleans, Louisiana, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Worcester, Massachusetts, United States|Detroit, Michigan, United States|Minneapolis, Minnesota, United States|New York, New York, United States|Rochester, New York, United States|Valhalla, New York, United States|Charlotte, North Carolina, United States|Philadelphia, Pennsylvania, United States|Houston, Texas, United States|Seattle, Washington, United States|Randwick, New South Wales, Australia|Brisbane, Queensland, Australia|Herston, Queensland, Australia|Clayton, Victoria, Australia|Melbourne, Victoria, Australia|Nedlands, Western Australia, Australia|Wien, Austria|Bruxelles - Brussel, Belgium|Edegem, Belgium|Gent, Belgium|Kortrijk, Belgium|La Louviere, Belgium|Leuven, Belgium|Liege, Belgium|Belo Horizonte, Minas Gerais, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|São Paulo, Sao Paulo, Brazil|Rio de Janeiro, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Plovdiv, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Varna, Bulgaria|Edmonton, Alberta, Canada|Montreal, Quebec, Canada|Santiago, Chile|Santiago, Chile|Guangzhou, Guangdong, China|Nanjing, Jiangsu, China|Hangzhou, Zhejiang, China|Beijing, China|Beijing, China|Floridablanca, Colombia|Medellín, Colombia|Bordeaux, France|Clichy, France|Creteil, France|La Roche Sur Yon, France|Lille, France|Lyon, France|Marseille, France|Paris, France|Pessac, France|Vandoeuvre-les-nancy, France|Villejuif, France|Freiburg, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|München, Bayern, Germany|Regensburg, Bayern, Germany|Frankfurt, Hessen, Germany|Hannover, Niedersachsen, Germany|Essen, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Homburg, Saarland, Germany|Berlin, Germany|Athens, Greece|Larissa, Greece|Thessaloniki, Greece|Thessaloniki, Greece|Hong Kong, Hong Kong|Shatin, Hong Kong|Beer Sheva, Israel|Haifa, Israel|Petah Tikva, Israel|Rehovot, Israel|Zrifin, Israel|Milano, Lombardia, Italy|Goyang-si, Gyeonggido, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Auckland, New Zealand|Christchurch, New Zealand|Wellington South, New Zealand|Lima, Peru|Lima, Peru|Bydgoszcz, Poland|Gdansk, Poland|Gliwice, Poland|Warszawa, Poland|Barnaul, Russian Federation|Moscow, Russian Federation|Nizhny Novgorod, Russian Federation|Singapore, Singapore|Singapore, Singapore|Johannesburg, Gauteng, South Africa|Cape Town, Western Cape, South Africa|Hospitalet de Llobregat, Barcelona, Spain|Barcelona, Spain|Lugo, Spain|Madrid, Spain|Santander, Spain|Valencia, Spain|Valencia, Spain|Tainan, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Sheffield, South Yorkshire, United Kingdom|Glasgow, United Kingdom|London, United Kingdom|Newcastle Upon Tyne, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00901901"
1002,"NCT00896571","Transdermal Contraceptive Patch - Endometrial Effects Study",,"Completed","No Results Available","Contraception","Drug: Ethinylestradiol/Gestogene (BAY86-5016)","Effect on the endometrium at cycle 13|Cervical smear|Adverse events|Cycle control|Safety laboratory|Occurence of pregnancy","Bayer","Female","18 Years to 35 Years   (Adult)","Phase 2","92","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","14287|2009-010599-45","July 2009","May 2011","August 2011","May 11, 2009",,"November 26, 2014","Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT00896571"
1003,"NCT00895674","Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar",,"Completed","No Results Available","Carcinoma, Renal Cell|Carcinoma, Renal Cell (Advanced)","Drug: Nexavar (Sorafenib, BAY43-9006)","Tumor status|Treatment duration|Safety of sorafenib treatment|Progression-free survival|Status of Metastases|Performance status (ECOG)","Bayer","All","18 Years and older   (Adult, Older Adult)",,"2840","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14686|NX0601|PREDICT|12649|12650|12943|12808|12807|12806|12755|12731|12730|12944|13094|13167|13209|13210|13211|13274|13277|13601|14178|14242|13068|13121|13095|13049","July 2006","August 2010","August 2010","May 8, 2009",,"September 30, 2010","Many Locations, Argentina|Many Locations, Austria|Many Locations, China|Many Locations, Colombia|Many Locations, Czech Republic|Many Locations, France|Many Locations, Germany|Many Locations, Greece|Many Locations, Indonesia|Many Locations, Korea, Republic of|Many Locations, Mexico|Many Locations, Netherlands|Many Locations, Philippines|Many Locations, Poland|Many Locations, Russian Federation|Many Locations, Slovakia|Many Locations, Slovenia|Many Locations, Sweden",,"https://ClinicalTrials.gov/show/NCT00895674"
1004,"NCT00893217","BEYOND Pilot Study",,"Completed","No Results Available","Multiple Sclerosis|Relapsing-Remitting","Drug: Betaseron (Interferon beta-1b, BAY86-5046)","To evaluate the safety and tolerability of IFNB-1b 500 mcg given subcutaneously (SC) QOD compared with the standard dose of 250 mcg QOD in patients with RRMS.","Bayer","All","18 Years to 55 Years   (Adult)","Phase 2","71","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","91232|BEYOND pilot|307000","November 2002",,"June 2003","May 5, 2009",,"November 9, 2009","Los Angeles, California, United States|Washington, District of Columbia, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Kansas City, Kansas, United States|Louisville, Kentucky, United States|Ann Arbor, Michigan, United States|Reno, Nevada, United States|Stony Brook, New York, United States|Durham, North Carolina, United States|High Point, North Carolina, United States|Winston-Salem, North Carolina, United States|Columbus, Ohio, United States|Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00893217"
1005,"NCT00885937","Comparative Safety Study of New Sinecort Formulation Versus Positive Control",,"Completed","No Results Available","Healthy","Drug: Dexpanthenol (Sinecort, BAY81-2996)|Drug: Positive control, Na-laurylsulfat-solution|Device: Untreated skin under application chamber","Irritation rate|Irritation potential","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","33","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","13941|2008-008138-36|Sinecort","April 2009","May 2009","May 2009","April 22, 2009",,"June 23, 2014","Münster, Nordrhein-Westfalen, Germany",,"https://ClinicalTrials.gov/show/NCT00885937"
1006,"NCT00884260","GA Levonorgestrel Intrauterine Contraceptive System (LCS) Phase III Study China",,"Completed","No Results Available","Contraception","Drug: Levonorgestrel IUS (LCS, BAY86-5028)","Primary efficacy variable is the occurrence of pregnancy, the Pearl Index (PI) is defined as the number of pregnancies per 100 woman years.|LCS expulsion rate|Discontinuation rates|Adverse events|Laboratory tests","Bayer","Female","18 Years to 40 Years   (Adult)","Phase 3","918","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","91775|MAGIC|311966","April 2009","June 2013","June 2013","April 20, 2009",,"August 21, 2014","Ashfield, New South Wales, Australia|Herston, Queensland, Australia|Parkville, Victoria, Australia|Subiaco, Western Australia, Australia|Guangzhou, Guangdong, China|Wuhan, Hubei, China|Nanjing, Jiangsu, China|Nanjing, Jiangsu, China|Nanjing, Jiangsu, China|Dalian, Liaoning, China|Jinan, Shandong, China|Chengdu, Sichuan, China|Beijing, China|Beijing, China|Beijing, China|Chongqing, China|Chongqing, China|Shanghai, China|Shanghai, China|Shanghai, China|Sungnam-si, Gyeonggido, Korea, Republic of|Seoul, Korea, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00884260"
1007,"NCT00883662","Mirena Observational Program",,"Completed","No Results Available","Contraception|Menorrhagia|Endometrial Hyperplasia|Estrogen Replacement Therapy","Drug: Levonorgestrel (Mirena, BAY86-5028)","Patient distribution per indication|Patient compliance","Bayer","Female","18 Years and older   (Adult, Older Adult)",,"2725","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14474|MA0910KZ","May 2009","April 2014","November 2015","April 20, 2009",,"September 30, 2016","Many Locations, Kazakhstan",,"https://ClinicalTrials.gov/show/NCT00883662"
1008,"NCT00882947","Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH)",,"Completed","No Results Available","Primary Hypertension","Drug: Ventavis (Iloprost, BAYQ6256)","Frequency of Adverse Events|6 minute walking test (6-MWT)|NYHA functional class","Bayer","All","18 Years to 65 Years   (Adult, Older Adult)",,"38","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14183|VE0611CN","February 2006","September 2008","September 2008","April 17, 2009",,"April 17, 2009","Many Locations, China",,"https://ClinicalTrials.gov/show/NCT00882947"
1009,"NCT00882453","Physical Activity and Fatigue in Early Multiple Sclerosis (MS)","BEGIN","Completed","No Results Available","Multiple Sclerosis","Drug: Interferon beta-1b (Betaseron, BAY86-5046)","Physical Activity and Fatigue|Health-related Quality of Life|Depression","Bayer","All","18 Years and older   (Adult, Older Adult)",,"1739","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","13853|BF0601|310721","August 2006","March 2011","March 2011","April 16, 2009",,"May 30, 2012","Many Locations, Australia|Many Locations, Austria|Many Locations, Bahrain|Many Locations, Belgium|Many Locations, Canada|Many Locations, Colombia|Many Locations, Czech Republic|Many Locations, Denmark|Many Locations, Egypt|Many Locations, France|Many Locations, Germany|Many Locations, Greece|Many Locations, Indonesia|Many Locations, Israel|Many Locations, Italy|Many Locations, Jordan|Many Locations, Kazakhstan|Many Locations, Korea, Republic of|Many Locations, Kuwait|Many Locations, Lebanon|Many Locations, Mexico|Many Locations, Netherlands|Many Locations, Norway|Many Locations, Oman|Many Locations, Portugal|Many Locations, Slovenia|Many Locations, Spain|Many Locations, Sweden|Many Locations, Switzerland|Many Locations, Taiwan|Many Locations, Thailand|Many Locations, United Arab Emirates|Many Locations, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00882453"
1010,"NCT00879008","SYMPROVE III: Health Services Research Study for Treatment of the Moderate and Severe Acute Exacerbations of Chronic Bronchitis (AECB)","SYMPROVE III","Completed","No Results Available","Chronic Bronchitis","Drug: Moxifloxacin (Avelox, BAY12-8039)","Effectiveness and tolerance of/to the different therapies|Possible hospitalisation rate","Bayer","All","18 Years and older   (Adult, Older Adult)",,"345","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","12629|AX0710DE","December 2009","August 2010","August 2010","April 9, 2009",,"June 23, 2014","Many Locations, Germany",,"https://ClinicalTrials.gov/show/NCT00879008"
1011,"NCT00876577","VICTOR - Avelox® Intravenous (i.v.) in Acute Exacerbations of Chronic Bronchitis","VICTOR","Completed","No Results Available","Chronic Bronchitis|Disease Exacerbation","Drug: Moxifloxacin (Avelox, BAY12-8039)","clinical cure rate:clinical cure was defined as disappearance of acute signs and symptoms|Time to cure: time when symptoms are disappeared after Moxifloxacin treatment|Improvement time: time when patients feel improvemen|Time of patients recover from fever|Clinical efficacy rate of Moxifloxacin","Bayer","All","18 Years and older   (Adult, Older Adult)",,"1206","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14495|AX0810CN","May 2009","March 2011","March 2011","April 6, 2009",,"September 10, 2012","Many Locations, China",,"https://ClinicalTrials.gov/show/NCT00876577"
1012,"NCT00876083","PMS Study Ultravist-IMAGE, IoproMide (UltrAvist) to Gain Further Information on Tolerability and Safety in X-ray Examination","IMAGE","Completed","No Results Available","Diagnostic Imaging","Drug: Ultravist (Iopromide, BAY86-4877)","Occurrence of adverse events|General contrast quality in the region of interest as assessed by physicians","Bayer","All","Child, Adult, Older Adult",,"44920","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14692|UV0701|13422|13421|14480|13276|14336|14181|13602|14243|13275|14180|14338|13859|14376|14337|14245|13212|14526|14527|14528|14586|14661","March 2008","September 2009","September 2009","April 6, 2009",,"February 28, 2011","Many Locations, Bosnia and Herzegovina|Many Locations, China|Many Locations, Germany|Many Locations, Hungary|Many Locations, Indonesia|Many Locations, Iran, Islamic Republic of|Many Locations, Italy|Many Locations, Korea, Republic of|Many Locations, Malaysia|Many Locations, Moldova, Republic of|Many Locations, Pakistan|Many Locations, Philippines|Many Locations, Poland|Many Locations, Romania|Many Locations, Russian Federation|Many Locations, Saudi Arabia|Many Locations, Singapore|Many Locations, Taiwan|Many Locations, Thailand|Many Locations, Ukraine|Many Locations, Vietnam",,"https://ClinicalTrials.gov/show/NCT00876083"
1013,"NCT00874926","EFFEKT - Efficacy and Safety of Long-term Treatment With KOGENATE Bayer/FS",,"Completed","No Results Available","Hemophilia A","Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)","Efficacy and Safety of Kogenate Bayer/FS","Bayer","Male","Child, Adult, Older Adult",,"405","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","13405|KG0702","June 2008","November 2012","April 2013","April 3, 2009",,"January 29, 2014","Many Locations, Bahrain|Many Locations, Bosnia and Herzegovina|Many Locations, Croatia|Many Locations, Germany|Many Locations, Israel|Many Locations, Kazakhstan|Many Locations, Kuwait|Many Locations, Libyan Arab Jamahiriya|Many Locations, Morocco|Many Locations, Oman|Many Locations, Qatar|Many Locations, Romania|Many Locations, Russian Federation|Many Locations, Saudi Arabia|Many Locations, Slovenia|Many Locations, Tunisia|Many Locations, United Arab Emirates",,"https://ClinicalTrials.gov/show/NCT00874926"
1014,"NCT00874679","REPEAT - Real-Life Perception of Efficacy, Attitude, Satisfaction and Safety of Levitra Therapy",,"Completed","No Results Available","Erectile Dysfunction","Drug: Levitra (Vardenafil, BAY38-9456)","Physician's assessment of safety (incidence of adverse events)|Severity of ED symptoms|General quality of partnership as assessed by patient|General quality of partnership as assessed by partner","Bayer","Male","18 Years and older   (Adult, Older Adult)",,"7293","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","12805|REPEAT|LV0602|12942 - LV0602KR|12975 - LV0602HR|12976 - LV0602CN|12977 - LV0602SG|13047 - LV0602SE|13048 - LV0602ZA|13067 - LV0602HU|13093 - LV0602MY|13112 - LV0602ID|13208 - LV0602TH|13416 - LV0602ES|13417 - LV0602SA|13600 - LV0602PL|14525 - LV0602FR","March 2007","April 2010","April 2010","April 2, 2009",,"November 11, 2011","Many Locations, China|Many Locations, Croatia|Many Locations, France|Many Locations, Germany|Many Locations, Hungary|Many Locations, Indonesia|Many Locations, Korea, Republic of|Many Locations, Malaysia|Many Locations, Poland|Many Locations, Saudi Arabia|Many Locations, Singapore|Many Locations, South Africa|Many Locations, Spain|Many Locations, Sweden|Many Locations, Thailand",,"https://ClinicalTrials.gov/show/NCT00874679"
1015,"NCT00874653","Survey on Patient Satisfaction Rate for Mirena Use in Heavy Menstrual Bleeding",,"Completed","No Results Available","Menorrhagia","Drug: Levonorgestrel (Mirena, BAY86-5028)","The quality of life on the basis of the validated Health-Related Quality of Life questionnaire (HRQL SF-36)","Bayer","Female","30 Years to 49 Years   (Adult)",,"78","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14175|MA0711IT","April 2008",,"December 2008","April 2, 2009",,"June 23, 2014","Many Locations, Italy",,"https://ClinicalTrials.gov/show/NCT00874653"
1016,"NCT00874640","Patient Characteristics in Daily Radiological Practice of Gadovist® Application (PATRON)",,"Completed","No Results Available","Epidemiologic Factors","Biological: Gadobutrol (Gadovist, BAY86-4875)","Patient Profile|Dosing of Gadovist in different indications|Adverse Events","Bayer","All","7 Years and older   (Child, Adult, Older Adult)",,"3711","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14317|GV0810DE","March 2009","September 2011","November 2011","April 2, 2009",,"February 20, 2014","Many Locations, Germany",,"https://ClinicalTrials.gov/show/NCT00874640"
1017,"NCT00874120","Safety Study Comparing Phenylephrine HCL Extended Release Tablets 30 mg and Placebo (Study CL2007-07)(P07529)(COMPLETED)",,"Completed","Has Results","Blood Pressure|Human Experimentation","Drug: Phenylephrine Hydrochloride (HCl) Extended-Release tablets 30 mg|Drug: Placebo","Average Systolic Blood Pressure (SBP) Readings for a 5-hour Range Around the Time of Maximum Concentration (Tmax).","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","116","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)","18121|CL2007-07|P07529","December 2008","February 2009","February 2009","April 2, 2009","July 5, 2010","March 11, 2015",,,"https://ClinicalTrials.gov/show/NCT00874120"
1018,"NCT00873483","US Ovulation Inhibition Study in Obese Women",,"Completed","No Results Available","Contraception","Drug: Ethinylestradiol/Gestodene (BAY86-5016)","Determination of Hoogland Scores|Laboratory values for E2, progesterone, FSH and LH|Endometrial thickness|Follicle size","Bayer","Female","18 Years to 35 Years   (Adult)","Phase 2","173","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","13871","April 2009","March 2010","March 2010","April 1, 2009",,"October 1, 2014","Tucson, Arizona, United States|San Diego, California, United States|Sandy Springs, Georgia, United States|Philadelphia, Pennsylvania, United States|Houston, Texas, United States|Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00873483"
1019,"NCT00873340","Physical Disability in Patients Treated With Betaferon",,"Completed","No Results Available","Multiple Sclerosis","Drug: Interferon-1beta (Betaseron, BAY86-5046)","To collect observational local data about effectivity related to physical disability progression on the daily routine basis in patients treated with Betaferon|To evaluate Betaferon safety on the daily routine basis|To evaluate patient adherence to Betaferon treatment","Bayer","All","18 Years and older   (Adult, Older Adult)",,"83","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14173|BF0712CO|2007- 001 Col","October 2007","January 2011","January 2011","April 1, 2009",,"June 26, 2014","Many Locations, Colombia",,"https://ClinicalTrials.gov/show/NCT00873340"
1020,"NCT00868153","Mirena in Idiopathic Menorrhagia",,"Completed","No Results Available","Idiopathic Menorrhagia","Drug: Levonorgestrel IUS (Mirena , BAY86-5028)","To evaluate the improvement in the quality of life and the degree of satisfaction of women with idiopathic menorrhagia treated with Mirena|Information about the pattern of menstrual bleeding recorded in an ongoing way throughout the duration of the study|The health-related quality of life questionnaire SF-36 at Visits 1 and 4|The user satisfaction as recorded at Visit 4|Adverse reactions recorded in an ongoing way throughout the duration of the study|Laboratory parameters as measured at Visits 1 and 4","Bayer","Female","30 Years to 45 Years   (Adult)",,"1125","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14494|MA0501","August 2004","November 2008","November 2008","March 24, 2009",,"February 18, 2015","Many Locations, Bulgaria|Many Locations, Croatia|Many Locations, India|Many Locations, Jordan|Many Locations, Kuwait|Many Locations, Pakistan|Many Locations, Romania|Many Locations, Russian Federation|Many Locations, Saudi Arabia|Many Locations, Serbia|Many Locations, Sri Lanka|Many Locations, Turkey|Many Locations, United Arab Emirates",,"https://ClinicalTrials.gov/show/NCT00868153"
1021,"NCT00867815","PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)",,"Terminated","Has Results","Anterior Ischemic Optic Neuropathy","Drug: Diagnostic procedures","Number of Participants With Confirmed Diagnosis of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)|Number of Participants With Most Frequent Medical History Findings by Primary System Organ Class at Visit 1|Number of Participants With Any Adverse Events Reported at Visit 2","Bayer","Male","40 Years and older   (Adult, Older Adult)","Phase 4","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","12912|2010-023586-22","July 13, 2009","December 29, 2017","March 28, 2018","March 24, 2009","January 23, 2019","January 23, 2019","Greider Eye Associates, Vista, California, United States|Palm Beach Eye Center, Atlantis, Florida, United States|West Coast Eye Care, Fort Myers, Florida, United States|National Ophthalmic Research Institute, Fort Myers, Florida, United States|Sarasota Retina Institute, Sarasota, Florida, United States|Midwest Eye Institute, Indianapolis, Indiana, United States|Spoor and Associates, Warren, Michigan, United States|Asheville Eye Associates, Asheville, North Carolina, United States|Office of Dr. Avrom Epstein, MD, Columbus, Ohio, United States|Tulsa Clinical Research, LLC, Tulsa, Oklahoma, United States|Retinal and Ophthalmic Consultants, Houston, Texas, United States|Save Sight Institute, Sydney, New South Wales, Australia|Midwest Eye Institute, Toronto, Ontario, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT00867815/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT00867815/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT00867815"
1022,"NCT00865709","Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects",,"Completed","Has Results","Metastatic Colorectal Cancer","Drug: Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)|Drug: Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)","Progression-Free Survival (PFS)|Overall Survival (OS)|Time to Progression (TTP)|Overall Response|Duration of Response","Bayer|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","198","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","13162|2008-005025-11","March 2009","January 2011","February 2012","March 19, 2009","March 20, 2012","December 11, 2014","Wichita, Kansas, United States|Metairie, Louisiana, United States|Brockton, Massachusetts, United States|Burlington, Massachusetts, United States|Dallas, Texas, United States|Antwerpen, Belgium|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Gent, Belgium|Leuven, Belgium|Liege, Belgium|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Gyor, Hungary|Kecskemet, Hungary|Szeged, Hungary|Szekesfehervar, Hungary|Castelfranco Veneto, Treviso, Italy|Genova, Italy|Macerata, Italy|Palermo, Italy|Pordenone, Italy|Torino, Italy|Udine, Italy|Verona, Italy|Bialystok, Poland|Elblag, Poland|Gdansk, Poland|Gdynia, Poland|Krakow, Poland|Krakow, Poland|Olsztyn, Poland|Warszawa, Poland|Warszawa, Poland|Wroclaw, Poland|Alba Iulia, Romania|Baia Mare, Romania|Bucharest, Romania|Bucharest, Romania|Cluj-Napoca, Romania|Craiova-Dolj, Romania|Iasi, Romania|Oradea, Romania|Suceava, Romania|Timisoara, Romania|Arkhangelsk, Russian Federation|Astrakhan, Russian Federation|Chelyabinsk, Russian Federation|Ekaterinburg, Russian Federation|Irkutsk, Russian Federation|Ivanovo, Russian Federation|Izhevsk, Russian Federation|Kazan, Russian Federation|Khabarovsk, Russian Federation|Krasnodar, Russian Federation|Kursk, Russian Federation|Magnitogorsk, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Nizhny Novgorod, Russian Federation|Novosibirsk, Russian Federation|Obninsk, Russian Federation|Pjatygorsk, Russian Federation|Rostov-on-Don, Russian Federation|Samara, Russian Federation|Sochi, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|Syktyvkar, Russian Federation|Tula, Russian Federation|Ulyanovsk, Russian Federation|Vladimir, Russian Federation|Volgograd, Russian Federation|Yaroslavl, Russian Federation|L'Hospitalet de Llobregat, Barcelona, Spain|Manresa, Barcelona, Spain|Santander, Cantabria, Spain|Palma de Mallorca, Illes Baleares, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Málaga, Spain|Sevilla, Spain|Valencia, Spain|Valencia, Spain|Cherkassy, Ukraine|Dnepropetrovsk, Ukraine|Dnipropetrovsk, Ukraine|Donetsk, Ukraine|Ivano-Frankovsk, Ukraine|Kharkov, Ukraine|Kiev, Ukraine|Krivoy Rog, Ukraine|Lugansk, Ukraine|Lviv, Ukraine|Mariupol, Ukraine|Sumy, Ukraine|Uzhgorod, Ukraine|Bristol, Avon, United Kingdom|Liverpool, Merseyside, United Kingdom|Northwood, Middlesex, United Kingdom|Nottingham, Nottinghamshire, United Kingdom|Aberdeen, United Kingdom|Belfast, United Kingdom|Glasgow, United Kingdom|Hull, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Newcastle Upon Tyne, United Kingdom|Portsmouth, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00865709"
1023,"NCT00864552","International PMS Study - KOGENATE Bayer",,"Completed","No Results Available","Hemophilia A","Drug: Kogenate (BAY14-2222)",,"Bayer","Male","Child, Adult, Older Adult",,"200","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","11145|12252 - KG0201CH,|12253 - KG0201BE,|12256 - KG0201AT,|12258 - KG0201IT,|12259 - KG0201GR,|12260 - KG0201ES,|12261 - KG0201FR,|12264 - KG0201SE,|12266 - KG0201NL","December 2002",,"December 2005","March 18, 2009",,"June 30, 2009","Many Locations, Austria|Many Locations, Belgium|Many Locations, Denmark|Many Locations, France|Many Locations, Greece|Many Locations, Italy|Many Locations, Netherlands|Many Locations, Spain|Many Locations, Sweden|Many Locations, Switzerland",,"https://ClinicalTrials.gov/show/NCT00864552"
1024,"NCT00864136","Mirena or Conventional Medical Treatment for Menorrhagia",,"Completed","No Results Available","Menorrhagia","Drug: Levonorgestrel (Mirena, BAY86-5028)|Drug: Conventional medical treatment","Cumulative continuation rate stratified by history of previous treatment(s) for menorrhagia|Bleeding pattern|Patient satisfaction at end of documentation|Impact of the therapy in terms of patient-derived health outcomes (validated patient questionnaire)|Adverse events collection","Bayer","Female","18 Years to 45 Years   (Adult)",,"647","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14697|MA0701|MA0901 - non-East Asia","November 2008","November 2010","November 2010","March 18, 2009",,"July 1, 2015","Many Locations, China|Many Locations, Hong Kong|Many Locations, Indonesia|Many Locations, Korea, Republic of|Many Locations, Malaysia|Many Locations, Pakistan|Many Locations, Taiwan|Many Locations, Thailand",,"https://ClinicalTrials.gov/show/NCT00864136"
1025,"NCT00863746","A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).","MISSION","Completed","Has Results","Carcinoma|Non-Small-Cell Lung","Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Placebo","Overall Survival|Progression-free Survival|Disease Control|Objective Tumor Response|Time to Progression|Mean Change From Baseline in European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire for Palliative Care (EORTC QLQ-C15-PAL) - Global Health Status|Mean Change From Baseline in European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire Lung Cancer Module (EORTC QLQ-LC13) - Coughing Subscale|Mean Change From Baseline in European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire Lung Cancer Module (EORTC QLQ-LC13) - Dyspnea|Mean Change From Baseline in EuroQol-5D (EQ-5D) - Index Score|Mean Change From Baseline in EuroQol-5D (EQ-5D) - VAS Score","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","703","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","13266|2008-006914-62","April 2009","March 2012","April 2013","March 18, 2009","July 30, 2013","January 19, 2015","Fayetteville, Arkansas, United States|Stanford, California, United States|Philadelphia, Pennsylvania, United States|Ramos Mejía, Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Rosario, Santa Fe, Argentina|Rosario, Santa Fe, Argentina|Córdoba, Argentina|Córdoba, Argentina|Santa Fé, Argentina|Graz, Austria|Linz, Austria|Wien, Austria|Antwerpen, Belgium|Bruxelles - Brussel, Belgium|Charleroi, Belgium|Genk, Belgium|Brasilia, Distrito Federal, Brazil|Belo Horizonte, Minas Gerais, Brazil|Porto Alegre, Rio Grande do Sul, Brazil|Porto Alegre, Rio Grande do Sul, Brazil|Santo André, Sao Paulo, Brazil|São José dos Campos, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|Sao Paulo, Brazil|Plovdiv, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Varna, Bulgaria|Montreal, Quebec, Canada|Santiago, Chile|Santiago, Chile|Guangzhou, Guangdong, China|Nanjing, Jiangsu, China|Chengdu, Sichuan, China|Hangzhou, Zhejiang, China|Hangzhou, Zhejiang, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Guangzhou, China|Shanghai, China|Shanghai, China|Caen, France|Dijon, France|La Roche Sur Yon Cedex, France|La Tronche, France|Lille, France|Lyon Cedex, France|Saint Herblain, France|Tours, France|Heidelberg, Baden-Württemberg, Germany|Karlsruhe, Baden-Württemberg, Germany|Mannheim, Baden-Württemberg, Germany|Ulm, Baden-Württemberg, Germany|Gauting, Bayern, Germany|München, Bayern, Germany|Kassel, Hessen, Germany|Köln, Nordrhein-Westfalen, Germany|Großhansdorf, Schleswig-Holstein, Germany|Bad Berka, Thüringen, Germany|Hamburg, Germany|Athens, Greece|Heraklion, Greece|Thessaloniki, Greece|Shatin, N.T, Hong Kong|Hongkong, Hong Kong|Kowloon, Hong Kong|Budapest, Hungary|Budapest, Hungary|Edeleny, Hungary|Farkasgyepu, Hungary|Torokbalint, Hungary|Zalaegerszeg, Hungary|Mumbai, Maharashtra, India|Pune, Maharashtra, India|Kerala, India|Bandung, Indonesia|Jakarta, Indonesia|Holon, Israel|Jerusalem, Israel|Jerusalem, Israel|Kfar Saba, Israel|Petach Tikva, Israel|Zrifin, Israel|Rozzano, Milano, Italy|Monza, Monza-Brianza, Italy|Orbassano, Torino, Italy|Avellino, Italy|Genova, Italy|Livorno, Italy|Parma, Italy|Perugia, Italy|Roma, Italy|Nagoya, Aichi, Japan|Kashiwa, Chiba, Japan|Akashi, Hyogo, Japan|Osakasayama, Osaka, Japan|Sakai, Osaka, Japan|Itabashi-ku, Tokyo, Japan|Koto-ku, Tokyo, Japan|Fukuoka, Japan|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Amsterdam, Netherlands|Harderwijk, Netherlands|Heerlen, Netherlands|Helmond, Netherlands|Nieuwegein, Netherlands|Zwolle, Netherlands|Lahore, Punjab, Pakistan|Karachi, Sindh, Pakistan|Callao, Peru|Lima, Peru|Lima, Peru|Lima, Peru|Lima, Peru|San Borja, Peru|Cebu City, Philippines|Manila, Philippines|Metro Manila, Philippines|Quezon City, Philippines|Kielce, Poland|Krakow, Poland|Olsztyn, Poland|Rzeszow, Poland|Szczecin, Poland|Warszawa, Poland|Kazan, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|St. Petersburg, Russian Federation|Yaroslavl, Russian Federation|Singapore, Singapore|Singapore, Singapore|Port Elizabeth, Eastern Cape, South Africa|Johannesburg, Gauteng, South Africa|Prietoria, Gauteng, South Africa|Durban, Kwazulu-Natal, South Africa|Cape Town, Western Cape, South Africa|Cruces/Barakaldo, Bilbao, Spain|Orense, Ourense, Spain|Barcelona, Spain|Barcelona, Spain|Lleida, Spain|Lugo, Spain|Madrid, Spain|Málaga, Spain|Sevilla, Spain|Zamora, Spain|Falun, Sweden|Göteborg, Sweden|Linköping, Sweden|Lund, Sweden|Stockholm, Sweden|Kaohsiung, Taiwan|Taichung, Taiwan|Taichung, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Bangkok, Thailand|Chiang Mai, Thailand|Songkhla, Thailand|Ankara, Turkey|Instanbul, Turkey|Istanbul, Turkey|Izmir, Turkey|Kocaeli, Turkey|Bristol, Avon, United Kingdom|Cambridge, Cambridgeshire, United Kingdom|Greater Manchester, Manchester, United Kingdom|Sutton, Surrey, United Kingdom|Leeds, West Yorkshire, United Kingdom|Aberdeen, United Kingdom|London, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00863746"
1026,"NCT00863681","BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension","PATENT-2","Completed","No Results Available","Hypertension, Pulmonary","Drug: Riociguat (BAY63-2521)","Safety (adverse events collection) and tolerability|Change in 6MWD (6 minute walking distance) from baseline","Bayer","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","396","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12935|2008-003610-94","March 12, 2009","August 19, 2019","August 19, 2019","March 18, 2009",,"September 11, 2019","Los Angeles, California, United States|Sacramento, California, United States|Aurora, Colorado, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Omaha, Nebraska, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Fairfield, Ohio, United States|Dallas, Texas, United States|El Paso, Texas, United States|Capital Federal, Argentina|Darlinghurst, New South Wales, Australia|Auchenflower, Queensland, Australia|Chermside, Queensland, Australia|Hobart, Tasmania, Australia|Prahran, Victoria, Australia|Linz, Oberösterreich, Austria|Innsbruck, Austria|Wien, Austria|Bruxelles - Brussel, Belgium|Leuven, Belgium|Porto Alegre, Rio Grande Do Sul, Brazil|São Paulo, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|Rio de Janeiro, Brazil|Calgary, Alberta, Canada|Montreal, Quebec, Canada|Guangzhou, Guangdong, China|Beijing, China|Beijing, China|Shanghai, China|Shanghai, China|Praha 2, Czechia|Aarhus N, Denmark|Besancon, France|Brest, France|GRENOBLE Cedex 09, France|Lille Cedex, France|Montpellier, France|Pessac, France|Rouen, France|Heidelberg, Baden-Württemberg, Germany|München, Bayern, Germany|Gießen, Hessen, Germany|Greifswald, Mecklenburg-Vorpommern, Germany|Hannover, Niedersachsen, Germany|Köln, Nordrhein-Westfalen, Germany|Homburg, Saarland, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Chaidari, Greece|Trieste, Friuli-Venezia Giulia, Italy|Roma, Lazio, Italy|Milano, Lombardia, Italy|Pavia, Lombardia, Italy|Nagoya, Aichi, Japan|Kobe, Hyogo, Japan|Toride, Ibaraki, Japan|Tsukuba, Ibaraki, Japan|Kanazawa, Ishikawa, Japan|Sendai, Miyagi, Japan|Tomigusuku, Okinawa, Japan|Bunkyo-ku, Tokyo, Japan|Mitaka, Tokyo, Japan|Ota-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Hiroshima, Japan|Okayama, Japan|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Antiguo Hospital Civil de Guadalajara ""Fray Antonio Alcalde"", Guadalajara, Jalisco, Mexico|Pulmocritic, Guadalajara, Jalisco, Mexico|Monterrey, Nuevo Leon, Mexico|Culiacan, Sinaloa, Mexico|Mexico D.F., Mexico|Querétaro, Mexico|Otwock, Poland|Coimbra, Portugal|Lisboa, Portugal|Centro Hospitalar de Lisboa Norte - Hospital Santa Maria, Lisboa, Portugal|Moscow, Russian Federation|St. Petersburg, Russian Federation|Singapore, Singapore|Singapore, Singapore|Umeå, Sweden|Zürich, Switzerland|Kaoshiung, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Bangkok, Thailand|Chiang Mai, Thailand|Ankara, Turkey|Istanbul, Turkey|Izmir, Turkey|Cambridge, Cambridgeshire, United Kingdom|Clydebank, West Dunbartonshire, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00863681"
1027,"NCT00862459","Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)",,"Completed","Has Results","Brain Diseases|Spinal Cord Diseases","Drug: Gadobutrol~0.03 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)|Drug: Gadobutrol~0.1 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)|Drug: Gadobutrol~0.3 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)|Drug: OptiMARK~0.1 mmol/kg BW","Categorical Visualization Score (CVS)|Difference in Number of Lesions Detected in Pre-contrast and Combined Pre-/Post-contrast MRI.|Assessment of Lesion Contrast Enhancement|Assessment of Border Delineation|Assessment of Internal Morphology|Contrast to Noise Ratio (CNR) Between White and Gray Matter With Gadobutrol Perfusion MRI|Accuracy Comparison of Gadobutrol Doses - Detection of Matched Lesions: Blinded Reader 1|Accuracy Comparison of Gadobutrol Doses - Detection of Matched Lesions: Blinded Reader 2|Accuracy Comparison of Gadobutrol Doses - Detection of Matched Lesions: Blinded Reader 3|Accuracy Comparison of Gadobutrol Doses - Detection of Matched Enhanced Lesions: Blinded Reader 1|Accuracy Comparison of Gadobutrol Doses - Detection of Matched Enhanced Lesions: Blinded Reader 2|Accuracy Comparison of Gadobutrol Doses - Detection of Matched Enhanced Lesions: Blinded Reader 3|Evaluation of the Correct Diagnosis Following Gadobutrol-enhanced and Unenhanced MRI|Evaluation of the Diagnostic Confidence Based on Unenhanced MRI and Combined Unenhanced and Enhanced MRI|Evaluation of Perfusion Map Quality (Uncorrected Cerebral Blood Volume [CBV]) - Blinded Reader 1|Evaluation of Perfusion Map Quality (Uncorrected Cerebral Blood Volume (CBV)) - Blinded Reader 2|Evaluation of Perfusion Map Quality (Uncorrected Cerebral Blood Volume (CBV)) - Blinded Reader 3|Evaluation of Perfusion Map Quality (Corrected Cerebral Blood Volume (CBV)) - Blinded Reader 1|Evaluation of Perfusion Map Quality (Corrected Cerebral Blood Volume (CBV)) - Blinded Reader 2|Evaluation of Perfusion Map Quality (Corrected Cerebral Blood Volume (CBV)) - Blinded Reader 3|Evaluation of Perfusion Map Quality (Cerebral Blood Flow (CBF)) - Blinded Reader 1|Evaluation of Perfusion Map Quality (Cerebral Blood Flow (CBF)) - Blinded Reader 2|Evaluation of Perfusion Map Quality (Cerebral Blood Flow (CBF)) - Blinded Reader 3|Evaluation of Perfusion Map Quality (Time to Peak (TTP)) - Blinded Reader 1|Evaluation of Perfusion Map Quality (Time to Peak (TTP)) - Blinded Reader 2|Evaluation of Perfusion Map Quality (Time to Peak (TTP)) - Blinded Reader 3|Evaluation of Perfusion Map Quality (Mean Transit Time (MTT)) - Blinded Reader 1|Evaluation of Perfusion Map Quality (Mean Transit Time (MTT)) - Blinded Reader 2|Evaluation of Perfusion Map Quality (Mean Transit Time (MTT)) - Blinded Reader 3|Evaluation of Perfusion Map Quality (Permeability Factor (PF) - Blinded Reader 1|Evaluation of Perfusion Map Quality (Permeability Factor (PF) - Blinded Reader 2|Evaluation of Perfusion Map Quality (Permeability Factor (PF)) - Blinded Reader 3|Evaluation of Perfusion Map Parameter Value (Uncorrected Cerebral Blood Volume (CBV)) - Independent Radiologist|Evaluation of Perfusion Map Parameter Value (Corrected Cerebral Blood Volume (CBV)) - Independent Radiologist|Evaluation of Perfusion Map Parameter Value (Cerebral Blood Flow (CBF)) - Independent Radiologist|Evaluation of Perfusion Map Parameter Value (Time to Peak (TTP)) - Independent Radiologist|Evaluation of Perfusion Map Parameter Value (Mean Transit Time (MTT)) - Independent Radiologist|Evaluation of Perfusion Map Parameter Value (Permeability Factor (PF)) - Independent Radiologist|Evaluation of Perfusion Map Artifacts (Uncorrected Cerebral Blood Volume (CBV)) - Blinded Reader|Evaluation of Perfusion Map Artifacts (Corrected Cerebral Blood Volume (CBV)) - Blinded Reader|Evaluation of Perfusion Map Artifacts (Cerebral Blood Flow (CBF)) - Blinded Reader|Evaluation of Perfusion Map Artifacts (Time to Peak (TTP)) - Blinded Reader|Evaluation of Perfusion Map Artifacts (Mean Transit Time (MTT)) - Blinded Reader|Evaluation of Perfusion Map Artifacts (Permeability Factor (PF)) - Blinded Reader|Evaluation of MRI Tumor Grade Agreement With Biopsy Results by Dose Group|Contrast to Noise Ratio (CNR) of Lesion/Gray Matter and Lesion/White Matter","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","237","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","91400|308200","August 2005","March 2007","March 2007","March 17, 2009","January 30, 2012","January 13, 2014","University of California Davis Medical Center, Sacramento, California, United States|University of California-San Diego Medical Center, San Diego, California, United States|Shands Jacksonville Medical Center, Jacksonville, Florida, United States|Emory University School of Medicine, Atlanta, Georgia, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|Indiana Neuroscience Institute, Indianapolis, Indiana, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Methodist Hospital, Omaha, Nebraska, United States|NYU Langone Medical Center, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center Health System, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Methodist Le Bonheur Healthcare, Memphis, Tennessee, United States|University of Washington Medical Center, Seattle, Washington, United States|University of Wisconsin - Madison, Madison, Wisconsin, United States|Fundacion Cientifica del Sur, Lornas de Zamora, Buenos Aires, Argentina|TCba Salguero, Buenos Aires, Argentina|Hospital da Beneficiência Portuguesa, Sao Paulo, Brazil|Centro de Diagnostico Medico, Medellín, Antioquia, Colombia|Fundación Instituto de Alta tecnología médica de Antioquia, Medellín, Antioquia, Colombia|DIME Clinica Neurocardiovascular S.A., Cali, Valle del Cauca, Colombia|Fundación Clínica Valle del Lili, Cali, Colombia",,"https://ClinicalTrials.gov/show/NCT00862459"
1028,"NCT00859196","Study to Assess on a Molecular Level the Influence of a 5 % Dexpanthenol Ointment in Subjects With Superficial Injuries",,"Completed","No Results Available","Wound Healing|Cell Proliferation|Gene Expression","Drug: Dexpanthenol (BAY81-2996)|Drug: Placebo","Investigation of gene expression in dermal fibroblasts and keratinocytes on a molecular level.","Bayer","All","18 Years to 45 Years   (Adult)","Phase 4","15","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","13069|2008-002069-30","February 2009","February 2009","March 2009","March 10, 2009",,"December 9, 2014","Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT00859196"
1029,"NCT00855660","Effect of Riociguat on Bone Metabolism",,"Completed","No Results Available","Pharmacology, Clinical","Drug: Riociguat (Adempas, BAY63-2521) immediate release tablet of 2.5 mg|Drug: Placebo","Urinary excretion (over 24 hours) of C-terminal cross-linking telopeptides of type I collagen (CTX)|AUC(0-7)|AUC(0-7)ss|Cmax|Cmax,ss|Number of participants with adverse events|Ctrough|AUC(0-7)norm|AUC(0-7)ss,norm|Cmax,norm|Cmax,ss,norm|tmax|tmax,ss|Aeur(0-7)|%Aeur(0-7)|Urinary excretion (over 24 hours) of N-terminal cross-linking telopeptides of type I collagen (NTX)|Serum CTX|Serum N-terminal propeptide of type I collagen (PINP)|Serum bone-specific alkaline phosphatase (bAP)|Serum albumin, protein|Cyclic guanosine monophosphate (cGMP)|Calcium, sodium, potassium|Urine volume|Renin|Creatinine clearance|Serum osteocalcin|Creatinine|Phosphate|Parathyroid hormone (PTH)","Bayer","Male","18 Years to 45 Years   (Adult)","Phase 1","17","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","13790|2008-005569-70","March 2009","December 2009","July 2010","March 4, 2009",,"January 11, 2016","Köln, Nordrhein-Westfalen, Germany",,"https://ClinicalTrials.gov/show/NCT00855660"
1030,"NCT00855595","Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea",,"Completed","Has Results","Papulopustular Rosacea","Drug: Azelaic acid (Finacea, BAY39-6251)|Drug: Metronidazole (Metrogel)|Drug: Doxycycline (Oracea)","Nominal Change From Baseline in Inflammatory Lesion (IL) Count (Sum of Papules and Pustules) at Week 2 (LOCF: Last Observation Carried Forward)|Number of Inflammatory Lesions at Weeks 2, 4, 6, 8 and 12 (LOCF)|Nominal Change From Baseline in IL Count at Weeks 4, 6, 8 and 12 (LOCF)|Percent Change From Baseline in IL Count at Weeks 2, 4, 6, 8 and 12 (LOCF)|Percentage of Participants With at Least a 25%, 50%, or 75% Improvement in Facial IL Counts From Baseline to Weeks 2, 4, 6, 8 and 12 (LOCF)|Percentage of Participants With Investigator's Global Assessment (IGA) Based Therapeutic Success at Weeks 2, 4, 6, 8 and 12 (LOCF)|Percentage of Participants With IGA Based Patient Response at Weeks 2, 4, 6, 8 and 12 (LOCF)|Percentage of Participants With Respective Disease Severity Measured by IGA Scores at Week 2|Percentage of Participants With Respective Disease Severity Measured by IGA Scores at Week 4|Percentage of Participants With Respective Disease Severity Measured by IGA Scores at Week 6|Percentage of Participants With Respective Disease Severity Measured by IGA Scores at Week 8|Percentage of Participants With Respective Disease Severity Measured by IGA Scores at Week 12|Investigator Rating of Overall Improvement at End of Study (Week 12)|Patient Rating of Overall Improvement at End of Study (Week 12)|Patient Opinion of Cosmetic Acceptability at End of Study (Week 12)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 4","207","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","14366|1402604|256-0024","February 2009","April 2009","July 2009","March 4, 2009","August 29, 2012","February 28, 2014","Birmingham, Alabama, United States|Denver, Colorado, United States|West Palm Beach, Florida, United States|Boston, Massachusetts, United States|Warren, Michigan, United States|Fridley, Minnesota, United States|Henderson, Nevada, United States|Albuquerque, New Mexico, United States|Stony Brook, New York, United States|Mason, Ohio, United States|Portland, Oregon, United States|Austin, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Norfolk, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00855595"
1031,"NCT00855465","A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.","CHEST-1","Completed","Has Results","Pulmonary Hypertension","Drug: Riociguat (Adempas, BAY63-2521)|Drug: Placebo","6 Minutes Walking Distance (6MWD) - Change From Baseline to Week 16|Pulmonary Vascular Resistance (PVR) - Change From Baseline to Week 16|N-terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP) - Change From Baseline to Week 16|World Health Organization (WHO) Functional Class - Change From Baseline to Week 16|Percentage of Participants With Clinical Worsening|Borg CR 10 Scale - Change From Baseline to Week 16|EQ-5D Utility Score - Change From Baseline to Week 16|Living With Pulmonary Hypertension (LPH) Questionnaire - Change From Baseline to Week 16","Bayer","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","262","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11348|2007-000072-16","February 2009","June 2012","June 2012","March 4, 2009","March 11, 2014","November 28, 2016","Birmingham, Alabama, United States|La Jolla, California, United States|Sacramento, California, United States|Aurora, Colorado, United States|Gainesville, Florida, United States|Miami, Florida, United States|Weston, Florida, United States|Atlanta, Georgia, United States|Decatur, Georgia, United States|Iowa City, Iowa, United States|Baltimore, Maryland, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Rochester, Minnesota, United States|Rochester, New York, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Fairfield, Ohio, United States|Pittsburgh, Pennsylvania, United States|Providence, Rhode Island, United States|Dallas, Texas, United States|Houston, Texas, United States|Murray, Utah, United States|Milwaukee, Wisconsin, United States|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Capital Federal, Argentina|Corrientes, Argentina|Camperdown, New South Wales, Australia|Auchenflower, Queensland, Australia|Chermside, Queensland, Australia|Prahran, Victoria, Australia|Innsbruck, Austria|Wien, Austria|Bruxelles - Brussel, Belgium|Leuven, Belgium|Porto Alegre, Rio Grande do Sul, Brazil|São Paulo, Sao Paulo, Brazil|Rio de Janeiro, Brazil|São Paulo, Brazil|Calgary, Alberta, Canada|Hamilton, Ontario, Canada|London, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Qingdao, Shandong, China|Beijing, China|Beijing, China|Beijing, China|Shanghai, China|Vseobecna fakultni nemocnice, Praha 2, Czech Republic|Aarhus N, Denmark|Besancon, France|Brest, France|Caen, France|Hopital Antoine Beclere, Clamart Cedex, France|GRENOBLE Cedex 09, France|Lille Cedex, France|Montpellier, France|Nice, France|Pessac, France|Rouen, France|Tours, France|Vandoeuvre Les Nancy, France|Heidelberg, Baden-Württemberg, Germany|Heidelberg, Baden-Württemberg, Germany|München, Bayern, Germany|Regensburg, Bayern, Germany|Würzburg, Bayern, Germany|Gießen, Hessen, Germany|Greifswald, Mecklenburg-Vorpommern, Germany|Hannover, Niedersachsen, Germany|Köln, Nordrhein-Westfalen, Germany|Homburg, Saarland, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Hamburg, Germany|Dublin, Ireland|Petah Tikva, Israel|Roma, Lazio, Italy|Pavia, Lombardia, Italy|Nagoya, Aichi, Japan|Seto, Aichi, Japan|Kitakyushu, Fukuoka, Japan|Komatsu, Ishikawa, Japan|Fujisawa, Kanagawa, Japan|Isehara, Kanagawa, Japan|Kawasaki, Kanagawa, Japan|Sendai, Miyagi, Japan|Suwa, Nagano, Japan|Suita, Osaka, Japan|Bunkyo-ku, Tokyo, Japan|Mitaka, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Chiba, Japan|Fukuoka, Japan|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Guadalajara, Jalisco, Mexico|Monterrey, Nuevo Leon, Mexico|Monterrey, Nuevo Leon, Mexico|Mexico D.F., Mexico|Querétaro, Mexico|Amsterdam, Netherlands|Amsterdam, Netherlands|Nieuwegein, Netherlands|Krakow, Poland|Otwock, Poland|Wroclaw, Poland|Coimbra, Portugal|Lisboa, Portugal|Porto, Portugal|Novosibirsk, Russian Federation|St. Petersburg, Russian Federation|Bratislava 37, Slovakia|Barcelona, Spain|Madrid, Spain|Zürich, Switzerland|Kaohsiung, Taiwan|Taipei, Taiwan|Ankara, Turkey|Istanbul, Turkey|Izmir, Turkey|Cambridge, Cambridgeshire, United Kingdom|Glasgow, West Dunbartonshire, United Kingdom|London, United Kingdom|London, United Kingdom|Newcastle, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00855465"
1032,"NCT00855218","A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).",,"Completed","Has Results","Carcinoma, Hepatocellular","Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Placebo","Time to Progression (TTP) - Independent Radiological Review (Primary Analysis)|Overall Survival (OS)|Time to Untreatable Progression (TTUP)|Time to Vascular Invasion/Extrahepatic Spread (TTVI/ES)|Tumor Response - Independent Radiological Review|Tumor Response - Investigator Assessment","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","307","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12918|2008-005056-24","March 2009","July 2011","February 2013","March 4, 2009","September 24, 2012","August 18, 2017","La Jolla, California, United States|Los Angeles, California, United States|San Francisco, California, United States|Gainesville, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Atlanta, Georgia, United States|Ann Arbor, Michigan, United States|Detroit, Michigan, United States|Abbott Northwestern Hospital, Minneapolis, Minnesota, United States|Saint Louis, Missouri, United States|New York, New York, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Portland, Oregon, United States|Richmond, Virginia, United States|Seattle, Washington, United States|Seattle, Washington, United States|Camperdown, New South Wales, Australia|St Leonards, New South Wales, Australia|Greenslopes, Queensland, Australia|Clayton, Victoria, Australia|Heidelberg, Victoria, Australia|Melbourne, Victoria, Australia|Nedlands, Western Australia, Australia|Innsbruck, Austria|Wien, Austria|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Leuven, Belgium|Liege, Belgium|Calgary, Alberta, Canada|Halifax, Nova Scotia, Canada|Toronto, Ontario, Canada|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Xi'an, Shannxi, China|Beijing, China|Beijing, China|Shanghai, China|Shanghai, China|Creteil, France|Lille, France|Lyon Cedex, France|Lyon, France|Marseille, France|Paris, France|Paris, France|Vandoeuvre-les-nancy, France|Villejuif, France|Villejuif, France|Freiburg, Baden-Württemberg, Germany|Heidelberg, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|Erlangen, Bayern, Germany|München, Bayern, Germany|Regensburg, Bayern, Germany|Frankfurt, Hessen, Germany|Hannover, Niedersachsen, Germany|Essen, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Homburg, Saarland, Germany|Jena, Thüringen, Germany|Berlin, Germany|Hamburg, Germany|Napoli, Campania, Italy|Bologna, Emilia-Romagna, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Torino, Piemonte, Italy|Bari, Puglia, Italy|Palermo, Sicilia, Italy|Pisa, Toscana, Italy|Padova, Veneto, Italy|Verona, Veneto, Italy|Daegu, Korea, Republic of|Gyeonggi-do, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Gangnam Severance Hospital, Yonsei University, Seoul, Korea, Republic of|Singapore, Singapore|Singapore, Singapore|Santiago de Compostela, A Coruña, Spain|Hospital Central de Asturias, Oviedo, Asturias, Spain|Badalona, Barcelona, Spain|Sabadell, Barcelona, Spain|Cruces/Barakaldo, Bilbao, Spain|Barcelona, Catalunya, Spain|Fundación Hospital Alcorcón, Alcorcón, Madrid, Spain|La Laguna, Santa Cruz de Tenerife, Spain|A Coruña, Spain|Alicante, Spain|Barcelona, Spain|Córdoba, Spain|Madrid, Spain|Madrid, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Valencia, Spain|Changhua Christian Hospital, Changhua, Taiwan|Taipei, Taiwan|Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT00855218"
1033,"NCT00847314","Efficacy and Tolerability of Testogel/Nebido in Combination With Exercise and Diet in Hypogonadal Male Patients",,"Completed","No Results Available","Hypogonadism","Drug: Testosterone Undeconate (Nebido-R, BAY86-5037)","Waist Circumference","Bayer","Male","35 Years to 64 Years   (Adult)",,"30","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","13899|NE0602","June 2007","October 2008","October 2008","February 19, 2009",,"June 21, 2013","Many locations, Germany",,"https://ClinicalTrials.gov/show/NCT00847314"
1034,"NCT00846911","AVANTI - Avelox® in Acute Exacerbations of chroNic bronchiTIs",,"Completed","No Results Available","Bronchitis, Chronic","Drug: Moxifloxacin (Avelox, BAY12-8039)","Time until improvement of acute exacerbation|Time until cure of acute exacerbation|Severity of AECB according to Antonisen criteria|Impact of AECB on daily life activities|Safety of Avelox under daily life treatment conditions","Bayer","All","35 Years and older   (Adult, Older Adult)",,"2672","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14689|AX0701|13598|13855|13856|13857|14008|14007|14009","April 2008","April 2010","April 2010","February 19, 2009",,"July 9, 2012","Many Locations, Albania|Many Locations, Bosnia and Herzegovina|Many Locations, Kazakhstan|Many Locations, Macedonia, The Former Yugoslav Republic of|Many Locations, Moldova, Republic of|Many Locations, Russian Federation|Many Locations, Slovakia|Many Locations, Ukraine",,"https://ClinicalTrials.gov/show/NCT00846911"
1035,"NCT00845338","Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor Overactivity",,"Terminated","No Results Available","Multiple Sclerosis|Overactive Detrusor","Drug: Darifenacin (BAY79-4998)","Change from baseline in volume at first detrusor contraction as determined by urodynamics|Detrusor pressure at first contraction|Volume at first detectable leakage|Volume at 10/20/30/40 cm H2O|Compliance|Maximum cystometric bladder capacity|7-day micturition diary: Micturitions|7-day micturition diary: Urgency episodes|7-day micturition diary: Urge urinary incontinence episodes","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","7","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12331|2006-002361-39","February 2007","October 2007","October 2007","February 18, 2009",,"December 2, 2014","Emmendingen, Baden-Württemberg, Germany|Heidelberg, Baden-Württemberg, Germany|Lahr, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|Villingen-Schwenningen, Baden-Württemberg, Germany|Planegg, Bayern, Germany|Oberursel, Hessen, Germany|Herne, Nordrhein-Westfalen, Germany|Mönchengladbach, Nordrhein-Westfalen, Germany|Mülheim, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Halle, Sachsen-Anhalt, Germany|Bad Berka, Thüringen, Germany|Berlin, Germany|Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT00845338"
1036,"NCT00839826","ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial","ODiXaHip","Completed","No Results Available","Thromboembolism|Prevention","Drug: Rivaroxaban (BAY59-7939)|Drug: Enoxaparin","The primary efficacy endpoint is a composite endpoint of: - Any DVT (proximal and/or distal) and - Non fatal PE and - Death from all causes. The primary endpoint will be evaluated 5 - 9 days after surgery.|Incidence of DVTs (total, proximal, distal)|Incidence of symptomatic VTEs|The composite endpoint that results from the primary endpoint by using alternative definition of deaths (i.e. VTE related death)|Incidence of symptomatic VTEs (total, PE, DVT) within 30 days after stop of treatment with the study drug.","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","641","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","10942","December 2002","November 2003","November 2003","February 10, 2009",,"December 17, 2014","Wiener Neustadt, Niederösterreich, Austria|Linz, Oberösterreich, Austria|Wien, Austria|Baudour, Belgium|Bruxelles, Belgium|Gent, Belgium|HUY, Belgium|Hellerup, Denmark|Herlev, Denmark|Hørsholm, Denmark|Silkeborg, Denmark|Amiens, France|Lille Cedex, France|Nancy, France|Rheinfelden, Baden-Württemberg, Germany|Fürth, Bayern, Germany|Garmisch-Partenkirchen, Bayern, Germany|Frankfurt, Hessen, Germany|Frankfurt, Hessen, Germany|Dresden, Sachsen, Germany|Berlin, Germany|Haifa, Israel|Tel Aviv, Israel|Tel Hashomer, Israel|Zerifin, Israel|Amersfoort, Netherlands|Zwolle, Netherlands|Notodden, Norway|Oslo, Norway|Rjukan, Norway|Bialystok, Poland|Gdansk, Poland|Krakow, Poland|Lodz, Poland|Lublin, Poland|Lublin, Poland|Warszawa, Poland|Göteborg, Sweden|Jönköping, Sweden|Kungälv, Sweden|London, Greater London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00839826"
1037,"NCT00839462","Efficacy of Dexpanthenol in Thermic Erythema",,"Completed","No Results Available","Erythema","Drug: Dexpanthenol foam spray, new formulation|Drug: Dexpanthenol foam spray, old formulation","Global sum of scores for evaluating the cooling/soothing effect evaluated after first and second application|Skin temperature|Evaluation of the cooling/soothing effect (scores) after first and second application|Evaluation of the foam covering properties after first application|Incidence of adverse events","Bayer","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","55","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","12039","September 2007","September 2007","September 2007","February 9, 2009",,"October 21, 2013","Villeurbanne, France",,"https://ClinicalTrials.gov/show/NCT00839462"
1038,"NCT00839280","Moisturizing Effect of Two Dexpanthenol Formulations",,"Completed","No Results Available","Skin Abnormalities","Drug: Dexpanthenol foam spray, new formulation|Drug: Dexpanthenol foam spray, old formulation","Area Under Curve (AUC) of the cutaneous hydration rate measured with corneometer between T0 and T5h|Cutaneous hydration rate|Incidence of Adverse Events","Bayer","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","19","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","12040","August 2007","September 2007","September 2007","February 9, 2009",,"October 15, 2014","Villeurbanne, France",,"https://ClinicalTrials.gov/show/NCT00839280"
1039,"NCT00839163","Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT)",,"Completed","No Results Available","Venous Thrombosis|Deep Vein Thrombosis","Drug: Xarelto (Rivaroxaban, BAY59-7939)|Drug: Enoxaparin/Vitamin K-Antagonist","Response to treatment as determined by a Complete Compression Ultra sound (CCUS)|Response to treatment as determined by a Complete Compression Ultrasound (CCUS) and perfusion lung scan|Response to treatment and residual vein diameter as assessed by Complete Compression Ultrasound (CCUS)|Incidence of symptomatic and confirmed recurrence or extension of Deep Vein Thrombosis (DVT)|Composite endpoint of symptomatic and confirmed recurrence and extension of Deep Vein Thrombosis (DVT) and symptomatic Pulmonary Embolism (PE) (nonfatal DVT and/or nonfatal PE) and deaths during the 3 months treatment period|Incidence of symptomatic and confirmed recurrence and extension of Deep Vein Thrombosis (DVT) and symptomatic Pulmonary Embolism (PE) within 30 days after stop of treatment with study drug","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","613","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11223|2004-001083-43|ODIXa-DVT","March 2004","October 2005","October 2005","February 9, 2009",,"October 28, 2014","Sydney, New South Wales, Australia|Adelaide, South Australia, Australia|Adelaide, South Australia, Australia|Melbourne, Victoria, Australia|Melbourne, Victoria, Australia|Melbourne, Victoria, Australia|Perth, Western Australia, Australia|Graz, Steiermark, Austria|Wien, Austria|Wien, Austria|Duffel, Belgium|Leuven, Belgium|Sao Paulo, SP, Brazil|São Paulo, SP, Brazil|Vancouver, British Columbia, Canada|Hamilton, Ontario, Canada|Hamilton, Ontario, Canada|North Bay, Ontario, Canada|Oshawa, Ontario, Canada|Ottawa, Ontario, Canada|Sudbury, Ontario, Canada|Toronto, Ontario, Canada|Windsor, Ontario, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Barranquilla, Colombia|Bogotá, Colombia|Medellín, Colombia|Brno, Czech Republic|Kladno, Czech Republic|Ostrava, Czech Republic|Plzen, Czech Republic|Praha 10, Czech Republic|Praha 2, Czech Republic|Praha 6, Czech Republic|Heidelberg, Baden-Württemberg, Germany|Karlsbad, Baden-Württemberg, Germany|Mannheim, Baden-Württemberg, Germany|München, Bayern, Germany|Darmstadt, Hessen, Germany|Bergisch Gladbach, Nordrhein-Westfalen, Germany|Paderborn, Nordrhein-Westfalen, Germany|Dresden, Sachsen, Germany|Berlin, Germany|Berlin, Germany|Budapest, Hungary|Debrecen, Hungary|Pecs, Hungary|Szentes, Hungary|Afula, Israel|Ashkelon, Israel|Haifa, Israel|Holon, Israel|Jerusalem, Israel|Kfar Saba, Israel|Tel Aviv, Israel|Rozzano, Milano, Italy|Bologna, Italy|Milano, Italy|Milano, Italy|Padova, Italy|Palermo, Italy|Perugia, Italy|Piacenza, Italy|Reggio Emilia, Italy|Varese, Italy|Arnhem, Netherlands|Den Bosch, Netherlands|Den Haag, Netherlands|Dirksland, Netherlands|Enschede, Netherlands|Leidschendam, Netherlands|Rotterdam, Netherlands|Auckland, New Zealand|Auckland, New Zealand|Christchurch, New Zealand|Lima Cercado, Peru|Lima, Peru|Lima, Peru|Bialystok, Poland|Bytom, Poland|Gdansk, Poland|Katowice, Poland|Lublin, Poland|Olsztyn, Poland|Poznan, Poland|Warszawa, Poland|Bloemfontein, Freestate, South Africa|Pretoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Cape Town, Western Cape, South Africa|Somerset West, Western Cape, South Africa|Badalona, Barcelona, Spain|Olot, Girona, Spain|La Laguna, Tenerife, Spain|Barcelona, Spain|Girona, Spain|Madrid, Spain|Madrid, Spain|Valencia, Spain|Göteborg, Sweden|Göteborg, Sweden|Halmstad, Sweden|Jönköping, Sweden|Lund, Sweden|Basel, Switzerland|Bern, Switzerland|Luzern, Switzerland|Zürich, Switzerland",,"https://ClinicalTrials.gov/show/NCT00839163"
1040,"NCT00838838","Efficacy of Nebido on Bone Mineral Density (BMD) in Hypogonadal Paraplegic Patients With Confirmed Osteoporosis",,"Completed","No Results Available","Hypogonadism|Paraplegia|Bone Density|Osteoporosis","Drug: Testosterone Undeconate (Nebido-R, BAY86-5037)","Bone mineral density (CT lumbar spine)","Bayer","Male","18 Years and older   (Adult, Older Adult)",,"26","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","13900|NE0501","September 2005","May 2009","May 2009","February 6, 2009",,"April 14, 2010","Many Locations, Germany",,"https://ClinicalTrials.gov/show/NCT00838838"
1041,"NCT00831714","Xarelto for VTE Prophylaxis After Hip or Knee Arthroplasty","XAMOS","Completed","No Results Available","Venous Thromboembolism","Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Standard care treatment for VTE prophylaxis","Data collection on: Bleeding events reported as serious or non-serious adverse events; Symptomatic thromboembolic events (DVT, PE) reported as adverse events; Uncommon adverse events (incidence rate between 0.1 % and 1 %); All cause mortality","Bayer|Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)",,"19076","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","13802|XA0801","February 2009","June 2011","April 2013","January 29, 2009",,"January 23, 2017","Many Locations, Australia|Many Locations, Austria|Many Locations, Belgium|Many Locations, Bosnia and Herzegovina|Many Locations, Brazil|Many Locations, Canada|Many Locations, Chile|Many Locations, China|Many Locations, Colombia|Many Locations, Cyprus|Many Locations, Czech Republic|Many Locations, Denmark|Many Locations, Estonia|Many Locations, Finland|Many Locations, France|Many Locations, Germany|Many Locations, Greece|Many Locations, Hong Kong|Many Locations, Hungary|Many Locations, India|Many Locations, Italy|Many Locations, Korea, Republic of|Many Locations, Latvia|Many Locations, Lebanon|Many Locations, Lithuania|Many Locations, Macedonia, The Former Yugoslav Republic of|Many Locations, Mexico|Many Locations, Netherlands|Many Locations, Norway|Many Locations, Philippines|Many Locations, Portugal|Many Locations, Serbia|Many Locations, Singapore|Many Locations, Slovakia|Many Locations, South Africa|Many Locations, Spain|Many Locations, Sweden|Many Locations, Switzerland|Many Locations, United Arab Emirates|Many Locations, United Kingdom|Many Locations, Venezuela|Many Locations, Vietnam",,"https://ClinicalTrials.gov/show/NCT00831714"
1042,"NCT00829231","Hepatic Impairment Study",,"Completed","No Results Available","Liver Disease","Drug: Sorafenib (Nexavar, BAY43-9006)","PK measurements|Physical Exam|Labotatory Safety, Chemistry panel, PTT, hematology Urine Analysis|ECG|Vital Signs|Follow up phone call","Bayer","All","50 Years to 75 Years   (Adult, Older Adult)","Phase 1","45","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12349","January 2009","July 2009","July 2009","January 26, 2009",,"November 3, 2014","Miami, Florida, United States|Orlando, Florida, United States|Knoxville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00829231"
1043,"NCT00828971","A Study to Assess Efficacy and Safety of IV/PO Moxifloxacin in the Treatment of cSSSIs","MERAK","Completed","No Results Available","Infectious Diseases","Drug: Avelox (Moxifloxacin, BAY12-8039)|Drug: Amoxicilline/clavulanic","Clinical response up to 14-21 days after the completion of study drug therapy (Test-of-Cure visit [TOC]).|Clinical response assessed by the investigator on treatment Day 3-5|Clinical response assessed by the investigator at the end-of-therapy (EOT).|Time to switch from oral to IV therapy|Bacteriological response (for microbiologically valid population) at the EOT and TOC","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12670|2007-001491-36","November 2008","September 2009","October 2009","January 26, 2009",,"December 8, 2014","Bagno di Ripoli, Firenze, Italy|Bari, Italy|Bergamo, Italy|Bologna, Italy|Brescia, Italy|Ferrara, Italy|Firenze, Italy|Foggia, Italy|Genova, Italy|Mantova, Italy|Messina, Italy|Napoli, Italy|Padova, Italy|Perugia, Italy|Reggio Emilia, Italy|Rimini, Italy|Roma, Italy|Roma, Italy|Torino, Italy|Udine, Italy|Varese, Italy|Verona, Italy",,"https://ClinicalTrials.gov/show/NCT00828971"
1044,"NCT00828737","Safety of Gadovist in Renally Impaired Patients","GRIP","Completed","No Results Available","Fibrosis|Renal Impairment","Drug: Gadobutrol (Gadovist, BAY86-4875)","Number of patients with moderate to severe renal impairment, who develop Nephrogenic Systemic Fibrosis (NSF), based on diagnostically specific clinical and histopathological information|Number of Participants With Moderate to Severe Renal Impairment in Whom no Biopsy was Obtained who Develop Nephrogenic Systemic Fibrosis (NSF) Based on Diagnostically Specific Clinical Information|Number of Participants With Different Criteria of Diagnostic Confidence of the Investigator Based on|Number of Participants With Image Quality Sufficient for Diagnosis|Evaluation of Creactive Protein (CRP) in Participants With Moderate and Severe Renal Impairment|Evaluation of Macrophage Inflammatory Proteins (MIP) and Monocyte Chemotactic Proteins (MCP) in Participants With Moderate and Severe Renal Impairment|Evaluation of Osteopontin and Tissue Inhibitor of Metallo Proteinase 1 (TIMP1) in Participants With Moderate and Severe Renal Impairment|Number of Participants With Treatmentemergent Adverse Events (TEAEs), Treatmentemergent Serious Adverse Event (TESAE), Drugrelated Treatmentemergent Adverse Events (TEAEs) and Drugrelated Treatmentemergent Serious Adverse Events (TESAEs)","Bayer","All","2 Years and older   (Child, Adult, Older Adult)","Phase 4","927","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13273|2008-004496-22","December 2008","January 2015","January 2015","January 26, 2009",,"February 18, 2016","Adelaide, South Australia, Australia|Clayton, Victoria, Australia|Geelong, Victoria, Australia|Westmead NSW, Australia|Innsbruck, Tirol, Austria|Ehenbichl, Austria|Graz, Austria|Leoben, Austria|Wien, Austria|Wien, Austria|Calgary, Alberta, Canada|Hamilton, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Fleurimont, Quebec, Canada|Le Kremlin-bicetre, France|Lille Cedex, France|Marseille, France|Paris, France|Reims, France|Mannheim, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|Coburg, Bayern, Germany|Erlangen, Bayern, Germany|München, Bayern, Germany|Regensburg, Bayern, Germany|Neuruppin, Brandenburg, Germany|Frankfurt, Hessen, Germany|Hannoversch Münden, Niedersachsen, Germany|Osnabrück, Niedersachsen, Germany|Dortmund, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Lüdenscheid, Nordrhein-Westfalen, Germany|Magdeburg, Sachsen-Anhalt, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Gera, Thüringen, Germany|Berlin, Germany|Berlin, Germany|Hamburg, Germany|Rozzano, Milano, Italy|Ancona, Italy|Brescia, Italy|Firenze, Italy|Genova, Italy|Milano, Italy|Milano, Italy|Napoli, Italy|Pisa, Italy|Roma, Italy|Roma, Italy|Torino, Italy|Treviso, Italy|Verona, Italy|SeongNam-si, Gyeonggido, Korea, Republic of|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Busan, Korea, Republic of|Jeonju-Si, Jeonrabuk-Do, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Sabadell, Barcelona, Spain|Barcelona, Spain|Granada, Spain|Basel, Basel-Stadt, Switzerland|Lugano, Ticino, Switzerland|Bangkok, Thailand|Bangkok, Thailand|Songkhla, Thailand",,"https://ClinicalTrials.gov/show/NCT00828737"
1045,"NCT00824187","YAZ Premenstrual Dysphoric Disorder (PMDD) in China",,"Completed","No Results Available","Premenstrual Dysphoric Disorder ( PMDD)","Drug: EE20/DRSP(YAZ, BAY86-5300)|Drug: Placebo","The difference in DRSP scale scores for the first 21 items, comparing average scores from the last 5 days before menses of the 3rd cycle in the treatment phase to average scores from the last 5 days before menses of the 2 run in cycles|The difference in DRSP scale scores for the 3 functional impairment items, comparing the average over the last 5 days of daily scores from the 3rd cycle in the treatment phase to the average of daily scores from the 2 run in cycles|Descriptive statistics for total DRSP scale scores (sum of the first 21 items) of the last 5 days for each of the 2 run in cycles, each of the 3 cycles in the treatment phase, and the average of the 3 cycles in the treatment phase|Descriptive statistics for change in total DRSP scale scores (sum of the first 21 items) of the last 5 days from baseline to each cycle in the treatment phase and to the average of the 3 cycles in the treatment phase|Assessment of CGI scores|Adverse events|Laboratory tests","Bayer","Female","18 Years to 45 Years   (Adult)","Phase 3","187","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","91771|311962","January 2009","January 2011","January 2011","January 16, 2009",,"April 2, 2014","Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Wuhan, Hubei, China|Changsha, Hunan, China|Nanjing, Jiangsu, China|Dalian, Liaoning, China|Jinan, Shandong, China|Xi'an, Shanxi, China|Xi'an, Shanxi, China|Chengdu, Sichuan, China|Kunming, Yunnan, China|Hangzhou, Zhejiang, China|Beijing, China|Beijing, China|Beijing, China|Tianjin, China",,"https://ClinicalTrials.gov/show/NCT00824187"
1046,"NCT00819312","YAZ, Oral Contraceptive Registration in China",,"Completed","No Results Available","Contraception","Drug: YAZ (SH T00186, BAY86-5300)","The primary efficacy variable is the number of unintended pregnancies as measured by the Pearl Index (PI) during 13 cycles of treatment.|Bleeding pattern indices|Cycle control parameters|Adverse events|Laboratory tests","Bayer","Female","18 Years to 45 Years   (Adult)","Phase 3","675","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","91619|311041","December 2008","January 2011","January 2011","January 8, 2009",,"January 29, 2013","Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Wuhan, Hubei, China|Nanjing, Jiangsu, China|Nanjing, Jiangsu, China|Yangzhou, Jiangsu, China|Shenyang, Liaoning, China|Jinan, Shandong, China|Xi An, Shanxi, China|Chengdu, Sichuan, China|Beijing, China|Beijing, China|Chongqing, China|Chongqing, China|Shanghai, China|Shanghai, China|Hongkong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT00819312"
1047,"NCT00818519","GA YAZ ACNE in China Phase III",,"Completed","Has Results","Acne Vulgaris","Drug: EE20/Drospirenone (YAZ, BAY86-5300)|Drug: Placebo","Percent Change From Cycle 6 to Baseline in the Total Lesion Count (Open and Closed Comedones, Papules, Pustules, and Nodules) in the FAS (Full Analysis Set)|Percent Change From Cycle 6 to Baseline in the Total Lesion Count (Open and Closed Comedones, Papules, Pustules, and Nodules) in the PPS (Per Protocol Set)|Percentage of Participants Classified as ""0"" or ""1"" on the 6-point ISGA (Investigator Static Global Assessment) Scale at Screening Visit|Percentage of Participants Classified as ""0"" or ""1"" on the 6-point ISGA (Investigator Static Global Assessment) Scale at Cycle 1|Percentage of Participants Classified as ""0"" or ""1"" on the 6-point ISGA (Investigator Static Global Assessment) Scale at Cycle 3|Percentage of Participants Classified as ""0"" or ""1"" on the 6-point ISGA (Investigator Static Global Assessment) Scale at Cycle 6|Percent Change From Cycle 6 to Baseline in Inflammatory Lesion Count (Papules, Pustules, and Nodules), Non-inflammatory Lesion Count|Percent Change From Cycle 6 to Baseline in Lesion Count of Papules|Percent Change From Cycle 6 to Baseline in Lesion Count of Pustules|Percent Change From Cycle 6 to Baseline in Lesion Count of Nodules|Percent Change From Cycle 6 to Baseline in Lesion Count of Open Comedones|Percent Change From Cycle 6 to Baseline in Lesion Count of Closed Comedones|Percentage of Participants Classified as ""Improved"" According to the Investigator's Overall Improvement Rating and on the Participant's Overall Self-Assessment Rating","Bayer","Female","14 Years to 45 Years   (Child, Adult)","Phase 3","179","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","91772|311963|2014-004612-10","December 2008","May 2010","May 2010","January 7, 2009","June 9, 2011","August 25, 2015","Guangzhou, Guangdong, China|Changsha, Hunan, China|Nanjing, Jiangsu, China|Chengdu, Sichuan, China|Beijing, China|Beijing, China|Shanghai, China",,"https://ClinicalTrials.gov/show/NCT00818519"
1048,"NCT00818415","Naproxen Sodium ER Pharmacokinetic Study",,"Completed","No Results Available","Pain","Drug: Naproxen sodium ER (BAYH6689)|Drug: Commercial Naproxen (Aleve, BAYH6689)","Pharmacokinetic (PK) Profile of an extended release tablet of Naproxen Sodium under fed conditions|Assess the safety and tolerability of an extended release tablet of Naproxen Sodium","Bayer","All","18 Years to 55 Years   (Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13965","November 2008","November 2008","November 2008","January 7, 2009",,"May 19, 2014","Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00818415"
1049,"NCT00812175","Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib","GIDEON","Completed","No Results Available","Carcinoma, Hepatocellular","Drug: Sorafenib (Nexavar, BAY43-9006)","The safety of Nexavar in all patients with unresectable HCC who are candidates for systemic therapy and in whom a decision to treat with Nexavar has been made under real-life practice conditions|Efficacy [overall survival (OS), progression-free survival (PFS), time to progression (TTP), response rate (RR), stable disease(SD) rate] by the Response Evaluation Criteria in Solid Tumor (RECIST) Criteria of Nexavar|The duration of therapy with Nexavar in a variety of settings according to patient characteristics and other variables|To evaluate the methods of patient evaluation, diagnosis and follow up|To evaluate the co-morbidities in patients with unresectable HCC and their influence on treatment and outcome|To evaluate the practice patterns of the physicians involved in the care of patients with HCC under real-life conditions|Reports of adverse events","Bayer","All","18 Years and older   (Adult, Older Adult)",,"3371","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","13414|NX0802","January 2009","April 2012","April 2012","December 22, 2008",,"October 17, 2016","Many Locations, Alabama, United States|Many Locations, Arizona, United States|Many Locations, Arkansas, United States|Many Locations, California, United States|Many Locations, Colorado, United States|Many Locations, Connecticut, United States|Many Locations, Florida, United States|Many Locations, Georgia, United States|Many Locations, Hawaii, United States|Many Locations, Illinois, United States|Many Locations, Indiana, United States|Many Locations, Iowa, United States|Many Locations, Kansas, United States|Many Locations, Kentucky, United States|Many Locations, Louisiana, United States|Many Locations, Maryland, United States|Many Locations, Massachusetts, United States|Many Locations, Michigan, United States|Many Locations, Minnesota, United States|Many Locations, Missouri, United States|Many Locations, Nebraska, United States|Many Locations, Nevada, United States|Many Locations, New Hampshire, United States|Many Locations, New Jersey, United States|Many Locations, New York, United States|Many Locations, North Carolina, United States|Many Locations, Ohio, United States|Many Locations, Oklahoma, United States|Many Locations, Oregon, United States|Many Locations, Pennsylvania, United States|Many Locations, South Carolina, United States|Many Locations, Tennessee, United States|Many Locations, Texas, United States|Many Locations, Utah, United States|Many Locations, Virginia, United States|Many Locations, Washington, United States|Many Locations, Wisconsin, United States|Many Locations, Canada|Many Locations, China|Many Locations, Colombia|Many Locations, Croatia|Many Locations, Czech Republic|Many Locations, Finland|Many Locations, France|Many Locations, Greece|Many Locations, Hong Kong|Many Locations, Hungary|Many Locations, India|Many Locations, Indonesia|Many Locations, Israel|Many Locations, Italy|Many Locations, Japan|Many Locations, Kazakhstan|Many Locations, Korea, Republic of|Many Locations, Libyan Arab Jamahiriya|Many Locations, Malaysia|Many Locations, Mexico|Many Locations, Norway|Many Locations, Pakistan|Many Locations, Philippines|Many Locations, Portugal|Many Locations, Qatar|Many Locations, Romania|Many Locations, Russian Federation|Many Locations, Singapore|Many Locations, Slovakia|Many Locations, Spain|Many Locations, Sweden|Many Locations, Syrian Arab Republic|Many Locations, Thailand|Many Locations, Ukraine|Many Locations, United Arab Emirates|Many Locations, Uruguay|Many Locations, Venezuela|Many Locations, Vietnam",,"https://ClinicalTrials.gov/show/NCT00812175"
1050,"NCT00810693","A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)","PATENT-1","Completed","Has Results","Pulmonary Hypertension","Drug: Riociguat (Adempas, BAY63-2521)|Drug: Placebo","6 Minutes Walking Distance (6MWD) - Change From Baseline to Week 12|Pulmonary Vascular Resistance (PVR) - Change From Baseline to Week 12|N-terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP) - Change From Baseline to Week 12|World Health Organization (WHO) Functional Class - Change From Baseline to Week 12|Percentage of Participants With Clinical Worsening|Borg CR 10 Scale - Change From Baseline to Week 12|EQ-5D Utility Score - Change From Baseline to Week 12|Living With Pulmonary Hypertension (LPH) Questionnaire - Change From Baseline to Week 12","Bayer","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","445","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12934|2008-003482-68","December 2008","May 2012","May 2012","December 18, 2008","February 26, 2014","November 28, 2016","Birmingham, Alabama, United States|Tuscon, Arizona, United States|Fresno, California, United States|La Jolla, California, United States|Los Angeles, California, United States|Sacramento, California, United States|Torrance, California, United States|Aurora, Colorado, United States|Gainesville, Florida, United States|Miami, Florida, United States|Sarasota, Florida, United States|Weston, Florida, United States|Atlanta, Georgia, United States|Decatur, Georgia, United States|Iowa City, Iowa, United States|Louisville, Kentucky, United States|Portland, Maine, United States|Baltimore, Maryland, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Ann Arbor, Michigan, United States|Rochester, Minnesota, United States|St. Louis, Missouri, United States|Omaha, Nebraska, United States|Newark, New Jersey, United States|New York, New York, United States|Rochester, New York, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Fairfield, Ohio, United States|Pittsburgh, Pennsylvania, United States|Providence, Rhode Island, United States|Dallas, Texas, United States|El Paso, Texas, United States|Houston, Texas, United States|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Capital Federal, Argentina|Vicente López, Argentina|Darlinghurst, New South Wales, Australia|New Lambton Heights, New South Wales, Australia|Auchenflower, Queensland, Australia|Chermside, Queensland, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Heidelberg, Victoria, Australia|Prahran, Victoria, Australia|Linz, Oberösterreich, Austria|Innsbruck, Austria|Wien, Austria|Bruxelles - Brussel, Belgium|Leuven, Belgium|Porto Alegre, Rio Grande do Sul, Brazil|São Paulo, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|Rio de Janeiro, Brazil|São Paulo, Brazil|Calgary, Alberta, Canada|Hamilton, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Quebec, Canada|Guangzhou, Guangdong, China|Beijing, China|Beijing, China|Shanghai, China|Shanghai, China|Praha 2, Czech Republic|Aarhus N, Denmark|Besancon, France|Brest, France|Bron, France|Caen, France|Clamart Cedex, France|GRENOBLE Cedex 09, France|Lille Cedex, France|Marseille, France|Montpellier, France|Nice, France|Pessac, France|Rouen, France|Tours, France|Heidelberg, Baden-Württemberg, Germany|München, Bayern, Germany|Gießen, Hessen, Germany|Greifswald, Mecklenburg-Vorpommern, Germany|Hannover, Niedersachsen, Germany|Köln, Nordrhein-Westfalen, Germany|Homburg, Saarland, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Haidari, Greece|Kallithea / Athens, Greece|Dublin, Ireland|Jerusalem, Israel|Petah Tikva, Israel|Tel Aviv, Israel|Bologna, Emilia-Romagna, Italy|Trieste, Friuli-Venezia Giulia, Italy|Roma, Lazio, Italy|Milano, Lombardia, Italy|Pavia, Lombardia, Italy|Torino, Piemonte, Italy|Nagoya, Aichi, Japan|Toyoake, Aichi, Japan|Yoshida, Fukui, Japan|Asahikwa, Hokkaido, Japan|Kobe, Hyogo, Japan|Toride, Ibaraki, Japan|Tsukuba, Ibaraki, Japan|Kanazawa, Ishikawa, Japan|Sagamihara, Kanagawa, Japan|Sendai, Miyagi, Japan|Tomigusuku, Okinawa, Japan|Hamamatsu, Shizuoka, Japan|Bunkyo-ku, Tokyo, Japan|Mitaka, Tokyo, Japan|Ota-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Fukuoka, Japan|Hiroshima, Japan|Okayama, Japan|Tokushima, Japan|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Guadalajara, Jalisco, Mexico|Guadalajara, Jalisco, Mexico|Monterrey, Nuevo Leon, Mexico|Culiacan, Sinaloa, Mexico|Mexico D.F., Mexico|Querétaro, Mexico|Amsterdam, Netherlands|Rotterdam, Netherlands|Christchurch, New Zealand|Krakow, Poland|Otwock, Poland|Almada, Portugal|Coimbra, Portugal|Lisboa, Portugal|Lisboa, Portugal|Porto, Portugal|Moscow, Russian Federation|St. Petersburg, Russian Federation|Singapore, Singapore|Singapore, Singapore|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Sevilla, Spain|Linköping, Sweden|Lund, Sweden|Umeå, Sweden|Zürich, Switzerland|Kaoshiung, Taiwan|Taichung, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Bangkok, Thailand|Bangkok, Thailand|Chiang Mai, Thailand|Ankara, Turkey|Istanbul, Turkey|Istanbul, Turkey|Izmir, Turkey|Cambridge, Cambridgeshire, United Kingdom|Clydebank, West Dunbartonshire, United Kingdom|London, United Kingdom|London, United Kingdom|Newcastle, United Kingdom|Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00810693"
1051,"NCT00805415","Ovulation Inhibition of Two 4-phasic Oral Contraceptive Regimens",,"Completed","No Results Available","Ovulation Inhibition","Drug: EV/DNG (Qlaira, BAY86-5027, SH T00658K)|Drug: EV/DNG (SH T00658L)","Proportion of subjects with a Hoogland score of 5-6 (luteinized unruptured follicle [LUF] or ovulation)|Proportion of subjects with a Hoogland score of 5-6 (LUF or ovulation)|Measurements of endometrial thickness|Visibility of cervical mucus|Ovarian activity (Hoogland score)|Measurements of follicle size|Measurements of hormone levels (follicle-stimulating hormone [FSH], luteinizing hormone [LH], progesterone and estradiol)|Compliance|Medical, surgical and medication history, concomitant medication, general physical and gynecological examination, cervical smear, pregnancy test, adverse events, safety laboratory determinations, cycle control, vital signs","Bayer","Female","18 Years to 35 Years   (Adult)","Phase 2","209","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","91271|307300","March 2003","February 2004","February 2004","December 9, 2008",,"July 15, 2011","Dinox GmbH Berlin, Berlin, Germany|Dinox B.V., Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT00805415"
1052,"NCT00798980","Scandinavian Mirena Insertion Nulliparous Trial.",,"Completed","No Results Available","Nulliparous","Drug: Mirena (BAY86-5028)","Evaluation of the insertion procedure of Mirena in nulliparous women|Pain|Continuation rate|Bleeding Pattern|Satisfaction","Bayer","Female","14 Years and older   (Child, Adult, Older Adult)",,"224","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14015|MA0710SE|SCAN 68/06|2006/0601120","February 2007","June 2008","November 2009","November 27, 2008",,"April 22, 2015","Many Locations, Sweden",,"https://ClinicalTrials.gov/show/NCT00798980"
1053,"NCT00792350","INSIGHT - Post Marketing Surveillance","INSIGHT","Completed","No Results Available","Carcinoma, Hepatocellular","Drug: Sorafenib (Nexavar, BAY43-9006)","Efficacy: status of tumor, patients performance status|Duration of treatment|Time of survival|Reports of adverse events","Bayer","All","18 Years and older   (Adult, Older Adult)",,"791","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14690|13419|13420|NX0801DE|NX0801AT|NX0801","April 2008","October 2013","April 2014","November 17, 2008",,"May 14, 2014","Many Locations, Austria|Many Locations, Germany",,"https://ClinicalTrials.gov/show/NCT00792350"
1054,"NCT00791778","Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer",,"Completed","Has Results","Ovarian Neoplasms","Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Placebo","Progression-free Survival (PFS), Based on Radiological or Pathologic Assessment|Time to First Pathologic CA-125 (Cancer-associated Tumor Marker) Serum Level|Overall Survival (OS)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","246","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","12007|2008-004429-41","November 2008","July 2011","December 2012","November 17, 2008","November 30, 2012","September 28, 2015","La Jolla, California, United States|Jacksonville, Florida, United States|Augusta, Georgia, United States|Scarborough, Maine, United States|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Edegem, Belgium|La Louviere, Belgium|Leuven, Belgium|Wilrijk, Belgium|Hamilton, Ontario, Canada|London, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Jyväskylä, Finland|Kuopio, Finland|ANGERS cedex 9, France|Caen Cedex 5, France|Lyon Cedex, France|Tours, France|Villejuif, France|Berlin, Germany|Hong Kong, Hong Kong|HongKong, Hong Kong|Meldola, Forlì, Italy|Campobasso, Italy|Milano, Italy|Roma, Italy|Roma, Italy|Nagoya, Aichi, Japan|Kashiwa, Chiba, Japan|Isehara, Kanagawa, Japan|Shimotsuke, Tochigi, Japan|Koto-ku, Tokyo, Japan|Minato-ku, Tokyo, Japan|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Daegu, Korea, Republic of|Gyeonggi-do, Korea, Republic of|Incheon, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Sowon, Korea, Republic of|Den Haag, Netherlands|Maastricht, Netherlands|Bialystok, Poland|Gdynia, Poland|Krakow, Poland|Lublin, Poland|Poznan, Poland|Poznan, Poland|Warszawa, Poland|Singapore, Singapore|Singapore, Singapore|Sabadell, Barcelona, Spain|Lugo, Spain|Madrid, Spain|Madrid, Spain|Sevilla, Spain",,"https://ClinicalTrials.gov/show/NCT00791778"
1055,"NCT00787657","Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment","BEACON","Completed","No Results Available","Relapsing Remitting Multiple Sclerosis (RRMS)","Drug: Interferon beta-1b (Betaseron, BAY86-5046)","Proportion of patients adhering to treatment|Rate of early treatment termination|Rate of study dropout|Predictive value of BL parameters, WCQ, HADS, RODQ|WCQ (Ways of Coping Questionnaire)|HADS (Hospital Anxiety and Depression Scale)|RODQ (Risk of Dropout Questionnaire)|EDSS (Expanded Disability Status Scale)|Relapse rate","Bayer","All","12 Years and older   (Child, Adult, Older Adult)",,"1723","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","13852|311941|BF0703","June 2008","September 2013","October 2014","November 7, 2008",,"October 16, 2015","Many Locations, Argentina|Many Locations, Bahrain|Many Locations, Belgium|Many Locations, Bosnia and Herzegovina|Many Locations, Canada|Many Locations, China|Many Locations, Colombia|Many Locations, Czech Republic|Many Locations, Egypt|Many Locations, Estonia|Many Locations, France|Many Locations, Germany|Many Locations, Iran, Islamic Republic of|Many Locations, Israel|Many Locations, Italy|Many Locations, Jordan|Many Locations, Korea, Republic of|Many Locations, Kuwait|Many Locations, Lebanon|Many Locations, Libyan Arab Jamahiriya|Many Locations, Mexico|Many Locations, Netherlands|Many Locations, New Zealand|Many Locations, Norway|Many Locations, Pakistan|Many Locations, Portugal|Many Locations, Saudi Arabia|Many Locations, Singapore|Many Locations, Slovakia|Many Locations, Slovenia|Many Locations, Sweden|Many Locations, Syrian Arab Republic|Many Locations, Taiwan|Many Locations, United Arab Emirates|Many Locations, United Kingdom|Many Locations, Venezuela",,"https://ClinicalTrials.gov/show/NCT00787657"
1056,"NCT00786448","Post Marketing Surveillance Study on Emselex After Launch in Germany",,"Completed","No Results Available","Overactive Bladder","Drug: Darifenacin, Emselex (BAY79-4998)","Adverse events, Adverse drug reactions, physician's global assessment of tolerability|Incontinence|Urgency episodes|Micturitions / nycturitions|Physician's assessment of improvement/efficacy|Physician's assessment of patient's satisfaction with therapeutic effect|Physician's assessment of patient's ability to hold urine|Dose and treatment duration of Emselex","Bayer","All","18 Years and older   (Adult, Older Adult)",,"5821","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","12245|EX0501DE","January 2005","February 2006","February 2006","November 6, 2008",,"April 30, 2010","Many Locations, Germany",,"https://ClinicalTrials.gov/show/NCT00786448"
1057,"NCT00786422","Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer",,"Completed","Has Results","Venous Thrombosis|Deep Vein Thrombosis","Drug: Rivaroxaban (Xarelto, BAY59-7939)","Pharmacodynamics - Prothrombin Time (PT), Baseline Value|Pharmacodynamics - Prothrombin Time (PT), Slope|Pharmacokinetics - AUC(0-24)ss (Area Under the Measurement Versus Time Curve From Time 0 to 24 Hours After First Dosing on a Day at Steady State) of Rivaroxaban|Pharmacokinetics - Cmax,ss (Maximum Observed Drug Concentration in Measured Matrix at Steady State During a Dosage Interval) of Rivaroxaban|Pharmacokinetics - Cmin,ss (Minimum Observed Drug Concentration in Measured Matrix at Steady State During a Dosage Interval) of Rivaroxaban|Percentage of Participants With Clinically Relevant Bleeding (i.e. Major Bleeding and Clinically Relevant Non-major Bleeding)|Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Non-fatal or Fatal Pulmonary Embolism [PE]) Until the Intended End of Study Treatment|Percentage of Participants With All Deaths|Percentage of Participants With Treatment Emergent Deaths - 7 Days Window|Percentage of Participants With Other Vascular Events","Bayer|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","All","18 Years and older   (Adult, Older Adult)","Phase 2","25","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13238|2008-003303-31","May 2009","May 2011","June 2011","November 6, 2008","June 13, 2014","November 18, 2015","Redcliffe, Queensland, Australia|Wien, Austria|São Paulo, Sao Paulo, Brazil|München, Bayern, Germany|Debrecen, Hungary|Ashkelon, Israel|Holon, Israel|Pavia, Italy|Amsterdam, Netherlands|Johannesburg, Gauteng, South Africa|Johannesburg, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Roodepoort, Gauteng, South Africa|Somerset West, Western Cape, South Africa|Worcester, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT00786422"
1058,"NCT00786253","Sustainable Efficacy of Vardenafil OD Versus Vardenafil PRN in Erectile Dysfunction",,"Completed","No Results Available","Erectile Dysfunction","Drug: Levitra (Vardenafil, BAY38-9456)","Erectile Dysfunction change score from baseline of the ED change score from baseline of the International Index of Erectile Function (IIEF-EF)|SEP 2|SEP 3","Bayer","Male","18 Years to 64 Years   (Adult)","Phase 2","236","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","11875|EudraCT No: 2005-001678-28|RESTORE","October 2005",,"January 2007","November 6, 2008",,"October 28, 2014","Tübingen, Baden-Württemberg / 277, Germany|München, Bayern / 280, Germany|Regensburg, Bayern / 280, Germany|Weiden, Bayern / 280, Germany|Berlin, Berlin / 285, Germany|Hamburg, Hamburg / 287, Germany|Hamburg, Hamburg / 287, Germany|Hamburg, Hamburg / 287, Germany|Marburg, Hessen / 307, Germany|Hagenow, Mecklenburg-Vorpommern / 309, Germany|Hannover, Niedersachsen / 291, Germany|Osnabrück, Niedersachsen / 293, Germany|Düsseldorf, Nordrhein-Westfalen / 296, Germany|Münster, Nordrhein-Westfalen / 298, Germany|Leverkusen, Nordrhein-Westfalen / 331, Germany|Grevenbroich, Nordrhein-Westfalen / 623, Germany|Leipzig, Sachsen / 313, Germany|Meißen, Sachsen / 313, Germany|Halle, Sachsen-Anhalt / 311, Germany",,"https://ClinicalTrials.gov/show/NCT00786253"
1059,"NCT00785226","RDEA119 and Sorafenib Combination Dose Escalation Study",,"Completed","No Results Available","Advanced Cancer","Drug: RDEA119|Drug: Sorafenib","To evaluate the safety and tolerability of escalating continuous oral dosing of RDEA119 in combination with sorafenib in advanced cancer patients.|Determine PK and PD of drugs in combination, describe responses, correlate toxicity and response profiles to select biomarkers, and evaluate the safety and tolerability of the MTD of this combination in select tumors in Phase 2 portion.","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","62","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15507|RDEA119-103","November 2008","April 2012","April 2012","November 5, 2008",,"October 17, 2016","USC/Norris Comprehensive Cancer Center and LAC/USC Medical Center, Los Angeles, California, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|New York Oncology Hematology, PC, Albany, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|James P. Wilmot Cancer Center, Rochester, New York, United States|UPenn, Philadelphia, Pennsylvania, United States|Greenville Hospital System University Medical Center, (ITOR), Greenville, South Carolina, United States|Texas Oncology - Baylor Charles A. Simmons Cancer Center, Dallas, Texas, United States|Texas Oncology-Tyler, Tyler, Texas, United States|Toronto General Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00785226"
1060,"NCT00782470","Evaluation of the Reasons and Consequences of Bleeding in Late Teens and Early Adulthood Patients With Severe Hemophilia A",,"Completed","No Results Available","Hematologic Disease|Blood Coagulation Disorders","Behavioral: Recombinant Factor VIII (Kogenate, BAY 14-2222)","To evaluate the frequency of all bleeds (spontaneous and trauma) during the study|To evaluate the change from baseline in HRQoL (health-related quality of life)|To evaluate number of patients that want to return to prophylaxis treatment after having switched to on-demand therapy|To evaluate the change from baseline in the Gilbert score|To evaluate the number of target joint development","Bayer","Male","14 Years to 29 Years   (Child, Adult)",,"38","Industry","Observational","Observational Model: Cohort","12749","December 2007","November 2010","November 2010","October 31, 2008",,"November 3, 2014","Duarte, California, United States|Denver, Colorado, United States|Peoria, Illinois, United States|Jefferson City, Missouri, United States|Las Vegas, Nevada, United States|Fort Worth, Texas, United States|Houston, Texas, United States|Many Locations, Canada|Many Locations, Germany|Many Locations, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00782470"
1061,"NCT00781820","Comparative Efficacy of Bifonazole Cream vs Placebo After Nail Ablation With Urea Paste",,"Completed","No Results Available","Onychomycosis","Drug: Bifonazole cream 1%|Drug: Placebo cream","Overall cure rate comprising clinical cure and mycological cure microscopy + culture negative|Clinical cure rate|Culture negative|Microscopy negative|Relapse rate (overall cure at visit 3 but positive clinical or mycological findings at visit 4|Mycological cure rate (microscopy + culture negative)|Incidence of adverse events","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","693","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","12999|2008-003215-13","October 2008","January 2010","January 2010","October 29, 2008",,"June 11, 2013","Chomutov, Czech Republic|Hlinsko, Czech Republic|Kutna Hora, Czech Republic|Louny, Czech Republic|Olomouc, Czech Republic|Praha, Czech Republic|Rychnov nad Kneznou, Czech Republic|Slany, Czech Republic|Svitavy, Czech Republic|Usti nad Labem, Czech Republic|Freiburg, Baden-Württemberg, Germany|Augsburg, Bayern, Germany|Augsburg, Bayern, Germany|Murnau, Bayern, Germany|Oberschleißheim, Bayern, Germany|Straubing, Bayern, Germany|Potsdam, Brandenburg, Germany|Frankenberg, Hessen, Germany|Marburg, Hessen, Germany|Hannover, Niedersachsen, Germany|Northeim, Niedersachsen, Germany|Aachen, Nordrhein-Westfalen, Germany|Dülmen, Nordrhein-Westfalen, Germany|Wuppertal, Nordrhein-Westfalen, Germany|Halle, Sachsen-Anhalt, Germany|Chemnitz, Sachsen, Germany|Dresden, Sachsen, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Löbau, Sachsen, Germany|Reichenbach, Sachsen, Germany|Lübeck, Schleswig-Holstein, Germany|Gera, Thüringen, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Hamburg, Germany|Bialystok, Poland|Gdansk, Poland|Gdansk, Poland|Olsztyn, Poland|Pruszkow, Poland|Wroclaw, Poland",,"https://ClinicalTrials.gov/show/NCT00781820"
1062,"NCT00781586","Efficacy of ONE A DAY Weightsmart Advanced Versus Caffeine and Placebo on Energy Expenditure, Thermogenesis and Perceived Energy Levels in Women.",,"Completed","No Results Available","Energy Expenditure","Dietary Supplement: One-A-Day Weight S.A. (Multi-Vitamins, BAY94-9350)|Drug: Caffeine|Drug: Placebo","Area Under the Curve (AUC) of RMR for the first 2 hours|AUC of RMR for the last 2 hours|AUC of Respiratory Quotient (RQ) for the first 2 hours|AUC of RQ for the last 2 hours|Perceived Energy scales - Visual Analog Scale (VAS)|AUC for heart rate for the first 2 hours|AUC for heart rate for the last 2 hours|Change from baseline for Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP), respiration and temperature","Bayer","Female","25 Years to 45 Years   (Adult)","Phase 4","22","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","12956","October 2, 2007","April 21, 2008","April 21, 2008","October 29, 2008",,"December 19, 2018","New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00781586"
1063,"NCT00780455","Rehabilitation Study in MS Patients",,"Terminated","Has Results","Multiple Sclerosis, Relapsing-Remitting","Drug: Interferon beta-1b, FRP within 15 days after randomization|Drug: Interferon beta-1b, FRP about 6 weeks after randomization","Total Walking Area (in Covered Meters) Either After 6 Minute or at the Time of the Premature Stop of the Test.|Time of Discomfort Appearance|Distance of Discomfort Appearance|Rhythm Change During 6 Minutes Walking Test|Covered Distance Gain Between MR2 Visit and MR3 Visit|Knee Isokinetic Gain Between Baseline and 12 Weeks After MR1 Visit|Posturography Gain in Static Equilibrium Performances Between Baseline and 12 Weeks After MR1 Visit|Posturography Gain in Static Equilibrium Performances Between MR2 and MR3 Visits|Number of Participants With Fatigue Based on Participants Self Assessment Using the Fatigue Severity Scale (FSS)|Quality of Life Assessed by Use of Self-questionnaire (SEP-59)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 4","4","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13089|2006-006673-24|308083","October 2008","September 2009","September 2009","October 27, 2008","February 26, 2013","May 29, 2015","Rennes, Bretagne, France|Avignon, France|Lille, France|Lomme, France|Montpellier, France|Mulhouse, France|Nimes, France|Quimper, France|Reims Cedex, France|Toulouse, France",,"https://ClinicalTrials.gov/show/NCT00780455"
1064,"NCT00779064","BAY59-7939, Japanese Phase II in Atrial FibrillationTrial Status",,"Completed","No Results Available","Atrial Fibrillation","Drug: Rivaroxaban (BAY59-7939)","Pharmacokinetics (PK) CL/f, AUC, Cmax, Pharmacodynamics (PD), Factor Xa activity, PT, PT-INR, aPTT and HEPTEST(R)|Each category of bleeding events and adverse event","Bayer","All","20 Years and older   (Adult, Older Adult)","Phase 2","36","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","11390","July 2004","June 2005","June 2005","October 24, 2008",,"December 25, 2014","Kitakyushu, Fukuoka, Japan|Kurume, Fukuoka, Japan|Onga, Fukuoka, Japan|Kitahiroshima, Hokkaido, Japan|Amagasaki, Hyogo, Japan|Kawachinagano, Osaka, Japan|Suita, Osaka, Japan|Fukuoka, Japan|Fukuoka, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan",,"https://ClinicalTrials.gov/show/NCT00779064"
1065,"NCT00778609","Effect of a New Oral Contraceptive Pill on Hormone Related Symptoms Such as Pelvic Pain and Headache",,"Completed","No Results Available","Oral Contraceptive|Headache|Pelvic Pain","Drug: EV/DNG (Qlaira, BAY86-5027)|Drug: Encapsulated Microgynon + Placebo","To compare SH T00658ID (Qlaira) to Microgynon with regard to changes in frequency and intensity of the hormone withdrawal associated symptoms headache and pelvic pain on cycle days 22-28 combined into a single endpoint|Rescue medication consumption|Frequency and intensity of other hormone-related symptoms (bloating or swelling, breast tenderness, and nausea or vomiting) during cycle days 22 to 28|Prevalence of individual hormone-related symptoms during cycle days 1 to 21|Prevalence of individual hormone-related symptoms during hormone-free interval, i.e. cycle days 27+28 for EV/DNG capsules and cycle days 22 to 28 for the comparator|Change in the average of the 3 highest VAS values of the hormone withdrawal associated symptoms pelvic pain or headache during cycle days 22 to 28 from baseline to cycle 3|Bleeding pattern and cycle control|QoL Questionnaires: Psychological General Well-Being Index (PGWBI), Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) and Clinical Global Index (CGI)|AEs and SAEs. Concomitant medication. Vital signs (heart rate and blood pressure). Body weight|General physical and gynecological examination","Bayer","Female","18 Years to 50 Years   (Adult)","Phase 3","449","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","91550|310787|2008-003226-42","December 2008","December 2010","December 2010","October 23, 2008",,"January 14, 2016","Ashfield, New South Wales, Australia|Blacktown, New South Wales, Australia|Caringbah, New South Wales, Australia|Sydney, New South Wales, Australia|Fortitude Valley, Queensland, Australia|Kipparing, Queensland, Australia|Adelaide, South Australia, Australia|Norwood, South Australia, Australia|Clayton, Victoria, Australia|Nedlands, Western Australia, Australia|Subiaco, Western Australia, Australia|Helsinki, Finland|Helsinki, Finland|Helsinki, Finland|Kuopio, Finland|Kuopio, Finland|Brignoles, France|Maison Lafitte, France|Nancy, France|Nantes, France|Nantes, France|Olivet, France|Paris, France|Paris, France|Paris, France|Saint Germain En Laye, France|Seclin, France|Tarare, France|Toulouse, France|Rheinstetten, Baden-Württemberg, Germany|Frankfurt, Hessen, Germany|Hannover, Niedersachsen, Germany|Bochum, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Wuppertal, Nordrhein-Westfalen, Germany|Magdeburg, Sachsen-Anhalt, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Lübeck, Schleswig-Holstein, Germany|Hamburg, Germany|Mexico, México, Mexico|Hermosillo, Sonora, Mexico|Mexico, D.F., Mexico|México, D.F., Mexico|Benidorm, Alicante, Spain|Petrer, Alicante, Spain|Gijón, Asturias, Spain|Barcelona, Catalunya, Spain|Barcelona, Spain|Madrid, Spain|Basel, Basel-Stadt, Switzerland|Bern, Switzerland|Bern, Switzerland|Zürich, Switzerland|Bangkok, Thailand|Bangkok, Thailand|Bangkok, Thailand|Cheadle, Cheshire, United Kingdom|Northwood, Middlesex, United Kingdom|Weston-super-Mare, North Somerset, United Kingdom|Nottingham, Nottinghamshire, United Kingdom|Glasgow, Stratchclyde, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00778609"
1066,"NCT00771147","A Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar ®","PONDIAC","Completed","No Results Available","Carcinoma, Renal Cell|Carcinoma, Renal Cell (Advanced)","Drug: Sorafenib (Nexavar, BAY43-9006)","Proportion of patients who are progression-free at one year according to the RECIST criteria. The proportion of patients who are progression-free at 1, 3, 6 and 9 months will also be calculated","Bayer","All","18 Years and older   (Adult, Older Adult)",,"71","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","13102|NX0710BE","June 2008",,"November 2010","October 13, 2008",,"June 15, 2012","Many Locations, Belgium",,"https://ClinicalTrials.gov/show/NCT00771147"
1067,"NCT00770432","Study Comparing PEG 3350 Laxative to Placebo in the Treatment of Occasional Constipation (Study CL2007-12)(P08216)",,"Completed","Has Results","Constipation","Drug: Polyethylene glycol 3350|Other: Placebo, maltodextrin 500 powder for solution","Number of Participants With a Complete Resolution at the Final Visit","Bayer","All","17 Years and older   (Child, Adult, Older Adult)","Phase 4","203","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","18130|CL2007-12|P08216","November 2007","January 2008","January 2008","October 10, 2008","August 12, 2009","October 2, 2018",,,"https://ClinicalTrials.gov/show/NCT00770432"
1068,"NCT00769496","BAY 77-1931 Long-term Extension From Phase II Study",,"Completed","No Results Available","Hyperphosphatemia","Drug: BAY 77-1931","Changes in pre-dialysis serum phosphate levels|Achievement rate of the target predialysis serum phosphate levels (3.5 mg/dL and 5.5 mg/dL)|Changes in corrected serum calcium level|Changes in the product of serum calcium and phosphate|Changes in serum intact-PHT levels|Changes in bone metabolism markers","Bayer","All","20 Years to 75 Years   (Adult, Older Adult)","Phase 2","145","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11551","January 2005","May 2008","May 2008","October 9, 2008",,"January 23, 2013","Toyohashi, Aichi, Japan|Yatomi, Aichi, Japan|Kashiwa, Chiba, Japan|Narita, Chiba, Japan|Sakura, Chiba, Japan|Asahikawa, Hokkaido, Japan|Suita, Osaka, Japan|Chiba, Japan|Hiroshima, Japan|Kochi, Japan|Kochi, Japan|Kochi, Japan|Okayama, Japan|Tokushima, Japan",,"https://ClinicalTrials.gov/show/NCT00769496"
1069,"NCT00769171","Dragon Study (the Safety and Efficacy for Treatment of Patients With Complicated Intra Abdominal Infections)","DRAGON","Completed","No Results Available","Infection, Intra-abdominal","Drug: Avelox (Moxifloxacin, BAY12-8039)|Drug: Ceftriaxone + Metronidazole","Clinical Response|Clinical and bacteriological response|Bacteriological and radiological response|Clinical response at the TOC visit in patients with bacteriological proven intra abdominal infection|Mortality attributable to intra abdominal infection","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","364","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","11647","October 2005","December 2006","January 2007","October 8, 2008",,"December 18, 2014","Nanjing, Jiangsu, China|Chengdu, Sichuan, China|Hangzhou, Zhejiang, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|Tianjin, China|Shatin, New Territories, Hong Kong|Hong Kong, Hong Kong|Bandung, West Java, Indonesia|Uijeongbu, Kyonggi-do, Korea, Republic of|Incheon, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Kuching, Sarawak, Malaysia|Terengganu, Malaysia|Kaoshiung, Taiwan|Tainan, Taiwan|Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT00769171"
1070,"NCT00768560","Nifedipine (Adalat CR, BAY A1040) High Dose PK/PD Study",,"Completed","Has Results","Hypertension","Drug: Nifedipine (Adalat CR, BAYA1040) 80mg OD|Drug: Nifedipine (Adalat CR, BAYA1040) 40mg BID|Drug: Nifedipine (Adalat CR, BAYA1040) 40mg OD","Change of Sitting Blood Pressure|Differences of Systolic Blood Pressure Profile|Differences of Diastolic Blood Pressure Profile|Target Blood Pressure Achievement in Elderly (≥65)|Target Blood Pressure Achievement in Non-elderly (<65)|Target Blood Pressure Achievement in Subjects With Diabetes Mellitus or Chronic Renal Disorder|Target Blood Pressure Achievement in All Subjects","Bayer","All","20 Years to 75 Years   (Adult, Older Adult)","Phase 2","35","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","13012","January 2008","May 2008","May 2008","October 8, 2008","February 2, 2010","June 8, 2015","Sendai, Miyagi, Japan|Suita, Osaka, Japan|Koshigaya, Saitama, Japan",,"https://ClinicalTrials.gov/show/NCT00768560"
1071,"NCT00767637","Long-term Treatment on BAY77-1931 (Lanthanum Carbonate) to Measure Lanthanum Concentrations in Bone",,"Completed","No Results Available","Hyperphosphatemia|Dialysis","Drug: Lanthanum Carbonate (BAY77-1931)","Changes in pre-dialysis serum phosphate levels|Achievement rate of the target predialysis serum phosphate levels (3.5 mg/dL and 5.5 mg/dL)|Changes in corrected serum calcium level|Changes in the product of serum calcium and phosphate|Changes in serum intact-PHT levels|Changes in bone metabolism markers","Bayer","All","20 Years and older   (Adult, Older Adult)","Phase 2","14","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11810|Fosrenol","June 2005","October 2008","October 2008","October 7, 2008",,"June 20, 2014","Isesaki, Gunma, Japan|Yonago, Tottori, Japan",,"https://ClinicalTrials.gov/show/NCT00767637"
1072,"NCT00765206","A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (Study CL2008-02)(P07814)(COMPLETED)",,"Completed","Has Results","Gastric Acid|Human Experimentation","Drug: Omeprazole/sodium bicarbonate|Drug: omeprazole magnesium (20 mg equivalent)","Change From Baseline in Median 24-hour Intragastric pH on the 7th Day of Drug Administration","Bayer|Bausch Health Americas, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","18134|CL2008-02|P07814","May 2008","August 2008","August 2008","October 2, 2008","April 30, 2010","March 11, 2015",,,"https://ClinicalTrials.gov/show/NCT00765206"
1073,"NCT00764881","Effects of SH T00658ID on Libido",,"Completed","Has Results","Contraception|Libido","Drug: EV/DNG (Qlaira, BAY86-5027, SH T00658ID)|Drug: Microgynon|Drug: Placebo","Change From Baseline to Cycle 6 in the Total of Questions 1 to 6 of the Female Sexual Function Index (FSFI) - Full Analysis Set (FAS)|Change From Baseline to Cycle 6 in the Total of Questions 1 to 6 of the Female Sexual Function Index (FSFI) - Per Protocol Set (PPS)|The Mean Absolute Values of FSFI Domain Score (Desire) at Baseline|The Mean Absolute Values of FSFI Domain Score (Desire) at Cycle 6|Mean Change From Baseline to Cycle 6 in FSFI Domain Score (Desire)|The Mean Absolute Values of FSFI Domain Score (Arousal) at Baseline|The Mean Absolute Values of FSFI Domain Score (Arousal) at Cycle 6|Mean Change From Baseline to Cycle 6 in FSFI Domain Score (Arousal)|The Mean Absolute Values of FSFI Domain Score (Lubrication) at Baseline|The Mean Absolute Values of FSFI Domain Score (Lubrication) at Cycle 6|Mean Change From Baseline to Cycle 6 in FSFI Domain Score (Lubrication)|The Mean Absolute Values of FSFI Domain Score (Orgasm) at Baseline|The Mean Absolute Values of FSFI Domain Score (Orgasm) at Cycle 6|Mean Change From Baseline to Cycle 6 in FSFI Domain Score (Orgasm)|The Mean Absolute Values of FSFI Domain Score (Satisfaction) at Baseline|The Mean Absolute Values of FSFI Domain Score (Satisfaction) at Cycle 6|Mean Change From Baseline to Cycle 6 in FSFI Domain Score (Satisfaction)|The Mean Absolute Values of FSFI Domain Score (Pain) at Baseline.|The Mean Absolute Values of FSFI Domain Score (Pain) at Cycle 6|Mean Change From Baseline to Cycle 6 in FSFI Domain Score (Pain)|The Mean Absolute Values of FSFI Total Score at Baseline|The Mean Absolute Values of FSFI Total Score at Cycle 6|Mean Change From Baseline to Cycle 6 in FSFI Total Score|The Mean Absolute Values of Female Sexual Distress Scale (FSDS-R) Total Score at Baseline|The Mean Absolute Values of Female Sexual Distress Scale (FSDS-R) Total Score at Cycle 6|Mean Change From Baseline to Cycle 6 in Female Sexual Distress Scale (FSDS-R) Total Score|The Mean Absolute Values of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) (Short Version) Total Score at Baseline|The Mean Absolute Values of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) (Short Version) Total Score at Cycle 6|Mean Change From Baseline to Cycle 6 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) (Short Version) Total Score|The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) Global Score at Baseline|The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) Global Score at Cycle 6|Mean Change From Baseline to Cycle 6 in Psychological General Well-Being Index (PGWBI) Global Score|The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Anxiety at Baseline|The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Anxiety at Cycle 6|Mean Change From Baseline to Cycle 6 in Psychological General Well-Being Index (PGWBI) - Anxiety|The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Depressed Mood at Baseline|The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Depressed Mood at Cycle 6|Mean Change From Baseline to Cycle 6 in Psychological General Well-Being Index (PGWBI) - Depressed Mood|The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Positive Well-being at Baseline|The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Positive Well-being at Cycle 6|Mean Change From Baseline to Cycle 6 in Psychological General Well-Being Index (PGWBI) - Positive Well-being|The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Self-control at Baseline|The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Self-control at Cycle 6|Mean Change From Baseline to Cycle 6 in Psychological General Well-Being Index (PGWBI) - Self-control|The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - General Health at Baseline|The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - General Health at Cycle 6|Mean Change From Baseline to Cycle 6 in Psychological General Well-Being Index (PGWBI) - General Health|The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Vitality at Baseline|The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Vitality at Cycle 6|Mean Change From Baseline to Cycle 6 in Psychological General Well-Being Index (PGWBI) - Vitality|Percentage of Participants With Improvement in the Investigator's Assessment in Clinical Global Impression (CGI) at Cycle 6|Percentage of Participants With Improvement in Participant's Assessment in Clinical Global Impression (CGI) at Cycle 6|Vaginal Effects Evaluated by Vaginal pH at Cycle 6|Vaginal Effects Evaluated by the Mean Absolute Values of Atrophy Symptom Questionnaire (ASQ) at Baseline|Vaginal Effects Evaluated by the Mean Absolute Values of Atrophy Symptom Questionnaire (ASQ) at Cycle 6|Vaginal Effects Evaluated by the Mean Change From Baseline to Cycle 6 in Atrophy Symptom Questionnaire (ASQ)|Vaginal Effects Evaluated by the Mean Absolute Values of Vaginal Health Assessment (VHA) at Baseline|Vaginal Effects Evaluated by the Mean Absolute Values of Vaginal Health Assessment (VHA) at Cycle 6|Vaginal Effects Evaluated by the Mean Change From Baseline to Cycle 6 in Vaginal Health Assessment (VHA)|Number of Bleeding / Spotting Days in Reference Period 1|Number of Bleeding / Spotting Days in Reference Period 2|Number of Bleeding / Spotting Episodes in Reference Period 1|Number of Bleeding / Spotting Episodes in Reference Period 2|Mean Length of Bleeding / Spotting Episodes in Reference Period 1|Mean Length of Bleeding / Spotting Episodes in Reference Period 2|Maximum Length of Bleeding / Spotting Episodes in Reference Period 1|Maximum Length of Bleeding / Spotting Episodes in Reference Period 2|Difference in Duration Between Longest and Shortest Bleeding / Spotting Episodes in Reference Period 1|Difference in Duration Between Longest and Shortest Bleeding / Spotting Episodes in Reference Period 2|Number of Spotting Only Days in Reference Period 1|Number of Spotting Only Days in Reference Period 2|Number of Spotting Only Episodes in Reference Period 1|Number of Spotting Only Episodes in Reference Period 2|Mean Length of Spotting-only Episodes in Reference Period 1|Mean Length of Spotting-only Episodes in Reference Period 2|Maximum Length of Spotting-only Episodes in Reference Period 1|Maximum Length of Spotting-only Episodes in Reference Period 2|Difference in Duration Between Longest and Shortest Spotting-only Episodes in Reference Period 1|Difference in Duration Between Longest and Shortest Spotting-only Episodes in Reference Period 2|Percentage of Participants With / Without Withdrawal Bleeding at Cycle 1|Percentage of Participants With / Without Withdrawal Bleeding at Cycle 3|Percentage of Participants With / Without Withdrawal Bleeding at Cycle 6|Length of Withdrawal Bleeding Episodes at Cycle 1|Length of Withdrawal Bleeding Episodes at Cycle 3|Length of Withdrawal Bleeding Episodes at Cycle 6|Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 1|Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 3|Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 6|Percentage of Participants by Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 1|Percentage of Participants by Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 3|Percentage of Participants by Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 6|Onset of Withdrawal Bleeding Episodes at Cycle 1|Onset of Withdrawal Bleeding Episodes at Cycle 3|Onset of Withdrawal Bleeding Episodes at Cycle 6|Percentage of Participants With Presence or Absence of Intracyclic Bleeding at Cycle 1|Percentage of Participants With Presence or Absence of Intracyclic Bleeding at Cycle 3|Percentage of Participants With Presence or Absence of Intracyclic Bleeding at Cycle 6|Number of Intracyclic Bleeding Episodes at Cycle 1|Number of Intracyclic Bleeding Episodes at Cycle 3|Number of Intracyclic Bleeding Episodes at Cycle 6|Maximum Length of Intracyclic Bleeding Episodes at Cycle 1|Maximum Length of Intracyclic Bleeding Episodes at Cycle 3|Maximum Length of Intracyclic Bleeding Episodes at Cycle 6|Number of Intracyclic Bleeding Days at Cycle 1|Number of Intracyclic Bleeding Days at Cycle 3|Number of Intracyclic Bleeding Days at Cycle 6|Percentage of Participants by Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 1|Percentage of Participants by Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 3|Percentage of Participants by Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 6|Percentage of Participants With at Least 1 Intracyclic Bleeding Episode","Bayer","Female","18 Years to 50 Years   (Adult)","Phase 3","217","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","91548|2008-002263-13|310785","January 2009","July 2010","July 2010","October 2, 2008","April 3, 2012","December 30, 2014","Sydney Centre for Reproductive Health Reseach, Ashfield, New South Wales, Australia|Royal Hospital for Women, Sydney, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|The Alfred Hospital, Prahran, Victoria, Australia|Queen Elizabeth II Medical Centre, Nedlands, Western Australia, Australia|King Edward Memorial Hospital, Subiaco, Western Australia, Australia|Ordination Dr. Schmidl-Amann, St. Pölten, Niederösterreich, Austria|Ordination Dr.Hohlweg, Graz, Steiermark, Austria|Ordination Dr. Schaffer, Graz, Steiermark, Austria|Dr. Brigitte Wiesenthal, Wien, Austria|Clin Pharm International GmbH Studienzentrum Wien, Wien, Austria|Dr. Wolfgang Bartl, Wien, Austria|Dr. Walter Paulik, Zeltweg, Austria|Hôpital Erasme/Erasmus Ziekenhuis, Bruxelles - Brussel, Belgium|UZ Gent, Gent, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Universitätsklinikum Freiburg, Freiburg, Baden-Württemberg, Germany|Universitätsklinikum Aachen, Aachen, Nordrhein-Westfalen, Germany|Frauenarztpraxis Dr. Bernd Pittner, Leipzig, Sachsen, Germany|Praxis Dr. A. Schwenkhagen-Stodieck, Hamburg, Germany|A.O.U. di Cagliari, Monserrato, Cagliari, Italy|A.O.U. Policlinico - Vittorio Emanuele, Catania, Italy|IRCCS Fondazione Maugeri - Montescano (Pavia), Pavia, Italy|A.O.U. Pisana, Pisa, Italy|Diatros Gava- Centre Assistencial Ntra. Sra. de Burgues, Gava, Barcelona, Spain|Centro de Planificacion Familiar Alicante 3, Alicante, Spain|USP Institut Universitari Dexeus, Barcelona, Spain|Hospital Universitario Virgen de las Nieves, Granada, Spain|Instituto Palacios de Salud y Medicina de la Mujer, Madrid, Spain|Chulalongkorn Hospital, Bangkok, Thailand|Ramathibodhi Hospital, Bangkok, Thailand|Siriraj Hospital, Mahidol, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT00764881"
1074,"NCT00764621","Health Economic Evaluation of Primovist-enhanced Liver MRI",,"Completed","No Results Available","Colorectal Neoplasms|Neoplasm Metastasis","Procedure: Primovist MRI|Procedure: Extracellular contrast media (ECCM) MRI|Procedure: Contrast-enhanced CT","Primary variable is the proportion of patients in each of the three treatment groups for whom further imaging is required after initial imaging to come to a therapy decision.|Proportion of patients with intra-operatively modified surgical plans based on initial imaging with either Primovist-, ECCM-MRI or CE-CT","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 4","360","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","91789|312041|2008-000583-16","October 2008","September 2010","November 2010","October 2, 2008",,"November 4, 2014","Graz, Austria|Wien, Austria|Wien, Austria|Karlsruhe, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|München, Bayern, Germany|München, Bayern, Germany|Frankfurt, Hessen, Germany|Greifswald, Mecklenburg-Vorpommern, Germany|Dortmund, Nordrhein-Westfalen, Germany|Dortmund, Nordrhein-Westfalen, Germany|Magdeburg, Sachsen-Anhalt, Germany|Dresden, Sachsen, Germany|Berlin, Germany|Candiolo, Torino, Italy|Ancona, Italy|Bologna, Italy|Brescia, Italy|Chieti, Italy|Napoli, Italy|Seoul,, Korea, Korea, Republic of|Gyeunggi-do, South Korea, Korea, Republic of|Hwasun, Korea, Republic of|Jeonbuk, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Amsterdam, Netherlands|Leiden, Netherlands|Utrecht, Netherlands|Santa Cruz de Tenerife, Canarias, Spain|Barcelona, Spain|Sevilla, Spain|Stockholm, Sweden|Stockholm, Sweden|Uppsala, Sweden|Basel, Basel-Stadt, Switzerland|St. Gallen, Sankt Gallen, Switzerland|Bern, Switzerland|Genève, Switzerland|Luzern, Switzerland|Bangkok, Thailand|Songkhla, Thailand",,"https://ClinicalTrials.gov/show/NCT00764621"
1075,"NCT00764387","Contrast Enhanced MRI of the CNS - Patients With Known Cerebral Neoplastic Lesions.",,"Completed","No Results Available","Neoplastic CNS Lesions","Drug: Gadovist® (Gadobutrol, BAY86-4875)|Drug: Dotarem","The primary analysis will be the comparison of the enhancements characteristics of Gadobutrol and Gd-TOTA on a lesion per lesion basis.","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 4","166","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic","91780|2007-005693-31|312021","March 2008","May 2009","May 2009","October 2, 2008",,"December 5, 2014","Andria, Bari, Italy|Catania, Italy|Chieti, Italy|Messina, Italy|Milano, Italy|Napoli, Italy|Novara, Italy|Roma, Italy|Roma, Italy|Siena, Italy|Trieste, Italy|Verona, Italy",,"https://ClinicalTrials.gov/show/NCT00764387"
1076,"NCT00761462","BAY 0 9867 Cipro Pediatric Use Study (QUIP)",,"Completed","Has Results","Infectious Diseases","Drug: Ciprofloxacin|Drug: Non-quinolone antibiotic","Incidence of Arthropathy (Cumulative)|Incidence of Nervous System Events (Cumulative)","Bayer","All","2 Months to 16 Years   (Child)","Phase 3","1029","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","100201|2014-004622-18","October 1999","January 2008","January 2008","September 29, 2008","April 14, 2009","July 31, 2015","Mobile, Alabama, United States|Fort Smith, Arkansas, United States|Corona, California, United States|Fountain Valley, California, United States|Long Beach, California, United States|Orange, California, United States|Pico Rivera, California, United States|San Bernardino, California, United States|San Luis Obispo, California, United States|Centennial, Colorado, United States|Denver, Colorado, United States|Ft. Walton Beach, Florida, United States|Gainesville, Florida, United States|Hialeah, Florida, United States|Jacksonville, Florida, United States|Jupiter, Florida, United States|Miami, Florida, United States|Pensacola, Florida, United States|Tampa, Florida, United States|Tampa, Florida, United States|Snellville, Georgia, United States|Honolulu, Hawaii, United States|Idaho Falls, Idaho, United States|Park Ridge, Illinois, United States|Springfield, Illinois, United States|Indianapolis, Indiana, United States|Overland Park, Kansas, United States|Bardstown, Kentucky, United States|New Orleans, Louisiana, United States|Boston, Massachusetts, United States|Red Wing, Minnesota, United States|Omaha, Nebraska, United States|Omaha, Nebraska, United States|Las Vegas, Nevada, United States|Hackensack, New Jersey, United States|Voorhees, New Jersey, United States|Bronx, New York, United States|New Hyde Park, New York, United States|New York, New York, United States|New York, New York, United States|Stony Brook, New York, United States|Durham, North Carolina, United States|Wilmington, North Carolina, United States|Akron, Ohio, United States|Cleveland, Ohio, United States|Dayton, Ohio, United States|Youngstown, Ohio, United States|Oklahoma City, Oklahoma, United States|Oklahoma City, Oklahoma, United States|Tulsa, Oklahoma, United States|Elverson, Pennsylvania, United States|Havertown, Pennsylvania, United States|Charleston, South Carolina, United States|Memphis, Tennessee, United States|Austin, Texas, United States|Benbrook, Texas, United States|El Paso, Texas, United States|Fort Worth, Texas, United States|Galveston, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Temple, Texas, United States|Layton, Utah, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Morgantown, West Virginia, United States|Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00761462"
1077,"NCT00761436","Pilot Study of Safety and Efficacy of Spheramine",,"Terminated","No Results Available","Parkinson's Disease","Biological: Spheramine (BAY86-5280)","The primary outcome measure for evaluating efficacy will be the motor subscore of the Unified Parkinson's Disease Rating Scale (UPDRS) (version 3.0) in the practically defined ""off"" state. During the Screening and at Baseline Evaluations.|Involuntary Movements, time Motor Tests|Motor Fluctuation and Percent OFF Time Evaluation|Quality of Life and Physician's and Patients Global Evaluations|Neuropsychological Evaluations","Bayer|Titan Pharmaceuticals","All","40 Years to 70 Years   (Adult, Older Adult)","Phase 2","6","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","91677|311361","February 2000","May 2012","May 2012","September 29, 2008",,"December 2, 2014","Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT00761436"
1078,"NCT00755053","Comparative Efficacy of Ovule vs Tablet",,"Completed","No Results Available","Clotrimazole|Ovulen|Vulvovaginal Candidiasis","Drug: Clotrimazole, vaginal ovule|Drug: Clotrimazole, vaginal tablet","Percentage of Subjects With Overall Response at Visit 2 (Day 10 to 14)|Percentage of Subjects With Overall Response at Visit 3 (Week 6 to 8)|Percentage of Subjects With Clinical Cure at Visit 2 (Day 10 to 14)|Percentage of Subjects With Clinical Cure at Visit 3 (Week 6 to 8)|Percentage of Subjects With Mycological Cure at Visit 2 (Day 10 to 14)|Percentage of Subjects With Mycological Cure at Visit 3 (Week 6 to 8)","Bayer","Female","14 Years to 50 Years   (Child, Adult)","Phase 3","466","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","13071|2008-000718-63","September 2008","May 2009","May 2009","September 18, 2008",,"August 6, 2015","Freiburg, Baden-Württemberg, Germany|München, Bayern, Germany|München, Bayern, Germany|Frankfurt, Hessen, Germany|Fulda, Hessen, Germany|Wiesbaden, Hessen, Germany|Hannover, Niedersachsen, Germany|Osnabrück, Niedersachsen, Germany|Dortmund, Nordrhein-Westfalen, Germany|Krefeld, Nordrhein-Westfalen, Germany|Hamburg, Germany|Hamburg, Germany|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT00755053"
1079,"NCT00754871","Pharmacodynamic Characterization of Dienogest",,"Completed","No Results Available","Pharmacodynamics","Drug: Dienogest (81150037)|Drug: Dienogest (81150231)|Drug: Dienogest (SH T00660A)|Drug: Dienogest (81150746)","No primary variables defined, all variables are considered exploratory since no confirmatory statistical analysis planned|Course of gonadotropins (FSH, LH, P, E2)|Endometrial thickness|Grading of ovarian activity|Effects on the cervix and the cervical mucus|mRNA expression profile of endometrial biopsies and in blood|Concentrations of DNG in serum|Safety and tolerability","Bayer","Female","18 Years to 35 Years   (Adult)","Phase 1","102","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)","13180|2008-003611-13","September 2008","July 2009","September 2009","September 18, 2008",,"January 27, 2015","Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT00754871"
1080,"NCT00754065","To Compare SH T00658ID Over Ortho Tri-Cyclen Lo (US/Canada)",,"Completed","Has Results","Contraception","Drug: Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)|Drug: Ortho Tri Cyclen Lo","The Change in Average of the 3 Highest Visual Analog Scale (VAS) Values of the Hormone Withdrawal-associated Symptoms Pelvic Pain or Headache During Cycle Days 22 to 28 From Baseline to Cycle 6|The Change From Baseline to Cycle 6 in the Number of Ibuprofen Tablets Used as Rescue Medication|The Change From Baseline to Cycle 13 in the Number of Ibuprofen Tablets Used as Rescue Medication|Change From Baseline to Cycle 6 in the Number of Days With at Least Moderate Pain/Intensity of Other Hormone-related Symptoms During Cycle Days 22-28|Change From Baseline to Cycle 13 in the Number of Days With at Least Moderate Pain/Intensity of Other Hormone-related Symptoms During Cycle Days 22-28|Change From Baseline to Cycle 6 in the Number of Days With at Least Moderate Pain/Intensity of Individual Hormone-related Symptoms During Cycle Days 1-21|Change From Baseline to Cycle 13 in the Number of Days With at Least Moderate Pain/Intensity of Individual Hormone-related Symptoms During Cycle Days 1-21|Change From Baseline to Cycle 6 in the Number of Days With at Least Moderate Pain/Intensity of Individual Hormone-related Symptoms During the Hormone-free Interval Cycle Days 27 to 28 for EV/DNG and Cycle Days 22 to 28 for EE/NGM|Change From Baseline to Cycle 13 in the Number of Days With at Least Moderate Pain/Intensity of Individual Hormone-related Symptoms During the Hormone-free Interval Cycle Days 27 to 28 for EV/DNG and Cycle Days 22 to 28 for EE/NGM|Change From Baseline to Cycle 3 in the Average of the Three Highest VAS Values of the Hormone Withdrawal-associated Symptoms Pelvic Pain or Headache During Cycle Days 22 to 28|Change From Baseline to Cycle 13 in the Average of the Three Highest VAS Values of the Hormone Withdrawal-associated Symptoms Pelvic Pain or Headache During Cycle Days 22 to 28|Number of Days With Bleeding or Spotting in Reference Period 1|Number of Days With Bleeding or Spotting in Reference Period 2|Number of Days With Bleeding or Spotting in Reference Period 3|Number of Days With Bleeding or Spotting in Reference Period 4|Number of Bleeding / Spotting Episodes in Reference Period 1|Number of Bleeding / Spotting Episodes in Reference Period 2|Number of Bleeding / Spotting Episodes in Reference Period 3|Number of Bleeding / Spotting Episodes in Reference Period 4|Mean Length of Bleeding / Spotting Episodes in Reference Period 1|Mean Length of Bleeding / Spotting Episodes in Reference Period 2|Mean Length of Bleeding / Spotting Episodes in Reference Period 3|Mean Length of Bleeding / Spotting Episodes in Reference Period 4|Maximum Length of Bleeding / Spotting Episodes in Reference Period 1|Maximum Length of Bleeding / Spotting Episodes in Reference Period 2|Maximum Length of Bleeding / Spotting Episodes in Reference Period 3|Maximum Length of Bleeding / Spotting Episodes in Reference Period 4|Difference in Duration Between Longest and Shortest Bleeding / Spotting Episodes in Reference Period 1|Difference in Duration Between Longest and Shortest Bleeding / Spotting Episodes in Reference Period 2|Difference in Duration Between Longest and Shortest Bleeding / Spotting Episodes in Reference Period 3|Difference in Duration Between Longest and Shortest Bleeding / Spotting Episodes in Reference Period 4|Number of Days With Spotting-only in Reference Period 1|Number of Days With Spotting-only in Reference Period 2|Number of Days With Spotting-only in Reference Period 3|Number of Days With Spotting-only in Reference Period 4|Number of Spotting-only Episodes in Reference Period 1|Number of Spotting-only Episodes in Reference Period 2|Number of Spotting-only Episodes in Reference Period 3|Number of Spotting-only Episodes in Reference Period 4|Mean Length of Spotting-only Episodes in Reference Period 1|Mean Length of Spotting-only Episodes in Reference Period 2|Mean Length of Spotting-only Episodes in Reference Period 3|Mean Length of Spotting-only Episodes in Reference Period 4|Maximum Length of Spotting-only Episodes in Reference Period 1|Maximum Length of Spotting-only Episodes in Reference Period 2|Maximum Length of Spotting-only Episodes in Reference Period 3|Maximum Length of Spotting-only Episodes in Reference Period 4|Difference in Duration Between Longest and Shortest Spotting-only Episodes in Reference Period 1|Difference in Duration Between Longest and Shortest Spotting-only Episodes in Reference Period 2|Difference in Duration Between Longest and Shortest Spotting-only Episodes in Reference Period 3|Difference in Duration Between Longest and Shortest Spotting-only Episodes in Reference Period 4|Percentage of Participants With / Without Withdrawal Bleeding at Cycle 1|Percentage of Participants With / Without Withdrawal Bleeding at Cycle 3|Percentage of Participants With / Without Withdrawal Bleeding at Cycle 6|Percentage of Participants With / Without Withdrawal Bleeding at Cycle 13|Length of Withdrawal Bleeding Episodes at Cycle 1|Length of Withdrawal Bleeding Episodes at Cycle 3|Length of Withdrawal Bleeding Episodes at Cycle 6|Length of Withdrawal Bleeding Episodes at Cycle 13|Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 1|Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 3|Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 6|Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 13|Onset of Withdrawal Bleeding Episodes at Cycle 1|Onset of Withdrawal Bleeding Episodes at Cycle 3|Onset of Withdrawal Bleeding Episodes at Cycle 6|Onset of Withdrawal Bleeding Episodes at Cycle 13|Percentage of Participants With Presence or Absence of Intracyclic Bleeding at Cycle 1|Percentage of Participants With Presence or Absence of Intracyclic Bleeding at Cycle 3|Percentage of Participants With Presence or Absence of Intracyclic Bleeding at Cycle 6|Percentage of Participants With Presence or Absence of Intracyclic Bleeding at Cycle 13|Number of Intracyclic Bleeding Episodes at Cycle 1|Number of Intracyclic Bleeding Episodes at Cycle 3|Number of Intracyclic Bleeding Episodes at Cycle 6|Number of Intracyclic Bleeding Episodes at Cycle 13|Maximum Length of Intracyclic Bleeding Episodes at Cycle 1|Maximum Length of Intracyclic Bleeding Episodes at Cycle 3|Maximum Length of Intracyclic Bleeding Episodes at Cycle 6|Maximum Length of Intracyclic Bleeding Episodes at Cycle 13|Number of Intracyclic Bleeding Days at Cycle 1|Number of Intracyclic Bleeding Days at Cycle 3|Number of Intracyclic Bleeding Days at Cycle 6|Number of Intracyclic Bleeding Days at Cycle 13|Percentage of Participants by Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 1|Percentage of Participants by Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 3|Percentage of Participants by Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 6|Percentage of Participants by Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 13|Percentage of Participants With at Least 1 Intracyclic Bleeding Episode at Cycles 2 to 6|Percentage of Participants With at Least 1 Intracyclic Bleeding Episode at Cycles 2 to 13|Mean Change From Baseline to Cycle 6 in Psychological General Well-Being Index (PGWBI)|Mean Change From Baseline to Cycle 13 in Psychological General Well-Being Index (PGWBI)|Mean Change From Baseline to Cycle 6 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Physical Health|Mean Change From Baseline to Cycle 13 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Physical Health|Mean Change From Baseline to Cycle 6 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Participant Feeling|Mean Change From Baseline to Cycle 13 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Participant Feeling|Mean Change From Baseline to Cycle 6 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Work|Mean Change From Baseline to Cycle 13 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Work|Mean Change From Baseline to Cycle 6 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Household Duties|Mean Change From Baseline to Cycle 13 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Household Duties|Mean Change From Baseline to Cycle 6 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - School/Course Work|Mean Change From Baseline to Cycle 13 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - School/Course Work|Mean Change From Baseline to Cycle 6 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Leisure Time Activities|Mean Change From Baseline to Cycle 13 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Leisure Time Activities|Mean Change From Baseline to Cycle 6 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Social Relationship|Mean Change From Baseline to Cycle 13 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Social Relationship|Mean Change From Baseline to Cycle 6 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - General Activities|Mean Change From Baseline to Cycle 13 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - General Activities|Mean Change From Baseline to Cycle 6 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Item Satisfaction|Mean Change From Baseline to Cycle 13 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Item Satisfaction|Mean Change From Baseline to Cycle 6 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Overall Life Satisfaction and Contentment|Mean Change From Baseline to Cycle 13 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Overall Life Satisfaction and Contentment|Percentage of Participants With Improvement in the Investigator's Assessment in Clinical Global Impression (CGI) at Cycle 6|Percentage of Participants With Improvement in the Investigator's Assessment in Clinical Global Impression (CGI) at Cycle 13|Percentage of Participants With Improvement in the Participant's Assessment in Clinical Global Impression (CGI) at Cycle 6|Percentage of Participants With Improvement in the Participant's Assessment in Clinical Global Impression (CGI) at Cycle 13","Bayer","Female","18 Years to 50 Years   (Adult)","Phase 3","409","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","13108","September 2008","May 2011","May 2011","September 17, 2008","August 28, 2012","July 19, 2013","Precision Trials, LLC, Glendale, Arizona, United States|Precision Trials, Phoenix, Arizona, United States|Pacific Coast Research Center Inc., Encinitas, California, United States|Medical Center for Clinical Research, San Diego, California, United States|Blue Hill Medical Group, Santa Monica, California, United States|Cherry Creek Family Practice, Denver, Colorado, United States|Downtown Women's Healthcare, Denver, Colorado, United States|Altitude Family Medicine, PC, Littleton, Colorado, United States|Women's Medical Research Group, LLC, Clearwater, Florida, United States|University of Florida College of Medicine, Jacksonville, Florida, United States|Comprehensive Clinical Trials, West Palm Beach, Florida, United States|Soapstone Center for Clinical Research, Decatur, Georgia, United States|Women's Health Associates, Boise, Idaho, United States|The Women's Clinic, Boise, Idaho, United States|Rosemark Clinical Research, Idaho Falls, Idaho, United States|Internal Medicine and Pediatrics, Fishers, Indiana, United States|First Care Family Medicine, Indianapolis, Indiana, United States|Northern Indiana Womens Heatlh Research, Inc., South Bend, Indiana, United States|Clinical Trials Management, LLC, Metairie, Louisiana, United States|PPS Clinical Research, LLC, Chesterfield, Missouri, United States|New Ballas OB-GYN, Inc., St. Louis, Missouri, United States|Women's Clinic of Lincoln, PC, Lincoln, Nebraska, United States|Office of Dr. R. Garn Mabey, MD, Las Vegas, Nevada, United States|Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|Lyndhurst Gynecologic Associates, Winston-Salem, North Carolina, United States|Associates in OB-GYN, Inc., Cincinnati, Ohio, United States|Columbus Center for Women's Health Research, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Clinical Research of Philadelphia, LLC, Philadelphia, Pennsylvania, United States|Holston Medical Group, Bristol, Tennessee, United States|Adam Patterson OB-GYN, Memphis, Tennessee, United States|The Woman's Hospital of Texas, Houston, Texas, United States|North Spokane Women's Health Research, Spokane, Washington, United States|University of Wisconsin - La Crosse, La Crosse, Wisconsin, United States|Glover Medical Clinic, Langley, British Columbia, Canada|Maritimes Research Center, Bathurst, New Brunswick, Canada|White Hills Medical Clinic, St. John's, Newfoundland and Labrador, Canada|MSHJ Research Associates, Halifax, Nova Scotia, Canada|Corunna Medical Research Centre, Corunna, Ontario, Canada|Office of Dr. Ivor Teitelbaum, MD, Downsview, Ontario, Canada|Office of Dr. Allen S. Greenspoon, MD, Hamilton, Ontario, Canada|Hamilton Medical Research Group, Hamilton, Ontario, Canada|Office of Dr. Sami Henein, MD, Newmarket, Ontario, Canada|Ottawa Hospital-Riverside Campus, Ottawa, Ontario, Canada|London Road Diagnostic Centre, Sarnia, Ontario, Canada|Prime Health Research, Toronto, Ontario, Canada|Manna Research, Toronto, Ontario, Canada|Devonshire Clinical Research, Inc., Woodstock, Ontario, Canada|Island Clinical Trials, Charlottetown, Prince Edward Island, Canada|Rhodin Recherche Clinique, Drummondville, Quebec, Canada|Omnispec Recherche Clinique Inc., Mirabel, Quebec, Canada|Dynamik Clinical Research Group, Pointe-Claire, Quebec, Canada|Kells Medical Research Group, Inc., Pointe-Claire, Quebec, Canada|Clinique de Gynecologie, Shawinigan, Quebec, Canada|Clinique Médicale des Campus, Ste-Foy, Quebec, Canada|Regina Medical Centre, Regina, Saskatchewan, Canada|Acadia Medical Centre, Saskatoon, Saskatchewan, Canada|Lenore Center Medical Clinic, Saskatoon, Saskatchewan, Canada|ALPHA Recherche Clinique, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00754065"
1081,"NCT00751556","Single/Multiple Dose Bioavailability Trial",,"Completed","No Results Available","Healthy","Drug: Naproxen Sodium 660mg|Drug: Commercial Aleve 220 mg","Pharmacokinetics parameters|Assess the safety and tolerability of the investigational product","Bayer","All","18 Years to 55 Years   (Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13106","February 2008","March 2008","March 2008","September 12, 2008",,"April 21, 2014","Little Rock, Arkansas, United States",,"https://ClinicalTrials.gov/show/NCT00751556"
1082,"NCT00751400","Naproxen Sodium Extended-Release Actual Use Study",,"Completed","Has Results","Pain","Drug: Naproxen Sodium ER (BAYH6689)","Use Days With One or More Misuse Occasions|Dosing Occasions With One and More Than One Tablet Taken|Use Days With and Without Next Dose Less Than 22 Hours Later|Number of Subjects With and Without More Than One Tablet Taken Per Dose|Number of Subjects With and Without Next Dose Less Than 22 Hours Later|Number of Subjects With and Without More Than 660 mg at Least Once|Average Daily Dose|Number of Subjects That Have Taken Study Drug on More Than 10 Consecutive Days and Not on More Than 10 Consecutive Days|Number of Total Dosing Occasions Per Subject|Number of Dosing Occasions Per Subject That Exceeded 660 mg","Bayer|Pegus Research, Inc.","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","497","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","13129|2014-005268-13","July 2008","November 2008","November 2008","September 12, 2008","May 17, 2011","August 25, 2015","Anaheim, California, United States|Oceanside, California, United States|San Dimas, California, United States|Overland Park, Kansas, United States|Anoka, Minnesota, United States|Blaine, Minnesota, United States|Elk River, Minnesota, United States|St. Francis, Minnesota, United States|St. Louis Park, Minnesota, United States|Belton, Missouri, United States|Savannah, Missouri, United States|St. Joseph, Missouri, United States|Cary, North Carolina, United States|Chapel Hill, North Carolina, United States|Raleigh, North Carolina, United States|Raleigh, North Carolina, United States|Bountiful, Utah, United States|Ogden, Utah, United States|Salt Lake City, Utah, United States|Syracuse, Utah, United States|West Jordan, Utah, United States|Kenmore, Washington, United States|Seattle, Washington, United States|Snohomish, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00751400"
1083,"NCT00751205","Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)",,"Completed","No Results Available","Prostate Cancer|Ovarian Cancer","Drug: Sagopilone 16 mg/m^2 i.v., Acetyl-L-Carnitine (ALC) 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid|Drug: Sagopilone 16 mg/m^2 i.v. and placebo 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid","Overall incidence of peripheral neuropathy (any grade) during at most 6 cycles of Sagopilone treatment, based on the Adverse Events.|Efficacy of ALC: incidence of neuropathy of grade 3 or 4, time to onset of neuropathy, duration of neuropathy.|Efficacy of ALC: Percentage of discontinuations due to neuropathy.|Safety of Sagopilone in combination with ALC.|Efficacy of Sagopilone: 'best overall response' according to modRECIST criteria|Efficacy of Sagopilone: 'best overall response' according to CA-125 or PSA response|Efficacy of Sagopilone: Time to disease progression, Progression-free survival|Efficacy of Sagopilone: Duration of response|Efficacy of Sagopilone: WHO performance status.|Pharmacokinetic: Sagopilone concentrations (optional)|Pharmacokinetic: ALC concentrations|Pharmacogenomics (optional): in tumor tissue, blood and ascites","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","150","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","91695|2008-000879-26","August 2008","February 2010","August 2010","September 11, 2008",,"October 28, 2014","Bruxelles - Brussel, Belgium|Caen, France|Montpellier Cedex, France|Nantes, France|Paris, France|Villejuif, France|Tübingen, Baden-Württemberg, Germany|Rostock, Mecklenburg-Vorpommern, Germany|Bonn, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Magdeburg, Sachsen-Anhalt, Germany|Meldola, Forlì, Italy|Bologna, Italy|Rimini, Italy|Roma, Italy|Amsterdam, Netherlands|Amsterdam, Netherlands|Leiden, Netherlands|Maastricht, Netherlands|Leicester, Leicestershire, United Kingdom|Northwood, Middlesex, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00751205"
1084,"NCT00750113","Study Evaluating the Efficacy of Nifedipine GITS - Telmisartan Combination in Blood Pressure Control.",,"Completed","No Results Available","Hypertension","Drug: Nifidipine|Drug: Telmisartan|Drug: Nifedipine/Telmisartan","The primary efficacy parameter will be the 24 hour mean systolic Blood Pressure on Ambulatory Blood Pressure Monitoring (ABPM)|Office blood pressure, response rate (> 10mmHg decrease control rate (< 130/80) mean SBP, mean DBP.|ABPM: % patients achieving BP < 125/80 mmHg morning BP increase/surge,24h mean diastolic BP,day average BP, night average BP,BP variability, pulse pressure through to peak ratio,smoothness index dipping or non dipping|Microalbuminuria in subgroup (any reduction)|Metabolic parameters: fasting blood glucose, total cholesterol, LDL cholesterol, HDL cholesterol, Triglycerides|Inflammatory markers: sRAGE (soluble receptors for advanced glycation end products) eotaxin-3, CRP (C-Reactive Protein)","Bayer","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","405","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","12313|2006-006436-22","October 2007","July 2009","August 2009","September 10, 2008",,"December 5, 2014","Pozzilli, Isernia, Italy|Monza, Monza-Brianza, Italy|Somma Lombardo, Varese, Italy|Ancona, Italy|Bologna, Italy|Brescia, Italy|Broni, Italy|Catania, Italy|Cinisello Balsamo, Italy|Ferrara, Italy|L'Aquila, Italy|Milano, Italy|Napoli, Italy|Napoli, Italy|Novara, Italy|Padova, Italy|Palermo, Italy|Pavia, Italy|Perugia, Italy|Pisa, Italy|Reggio Emilia, Italy|Roma, Italy|Roma, Italy|Roma, Italy|Sassari, Italy|Siena, Italy|Siracusa, Italy|Treviso, Italy|Trieste, Italy|Varese, Italy|Venezia, Italy|Ferrol, A Coruña, Spain|Gijón, Asturias, Spain|Badalona, Barcelona, Spain|Jerez de la Frontera, Cádiz, Spain|Las Palmas de Gran Canaria, Las Palmas, Spain|Beniganim, Valencia, Spain|Badajoz, Spain|Ciudad Real, Spain|Madrid, Spain|Madrid, Spain|Málaga, Spain|Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT00750113"
1085,"NCT00748046","Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton",,"Completed","No Results Available","Prostate Cancer|Metastases|Pharmacokinetics","Drug: Radium-223 chloride (BAY88-8223)","All safety data, including adverse events, occurrence of treatment-emergent adverse events, changes in laboratory variables, vital signs, ECG, physical examination, long term radiation toxicity, including results of bone marrow biopsy|Biodistribution, dosimetry and pharmacokinetics (whole body activity assessment, the counts in region-of-interest (ROIs) from anterior and posterior whole-body images, and the assay of activity in blood|Post-treatment PSA effect: PSA decline, time to PSA progression after PSA response|Post-treatment bone markers effect: Changes in bone marker values from pre- to post administration|Circulating tumor cells (CTCs) enumeration and role of molecular profiling of CTC in predicting sensitivity to treatment and treatment response","Bayer","Male","18 Years and older   (Adult, Older Adult)","Phase 1","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","15303|BC1-08","August 2008","October 2009","October 2009","September 8, 2008",,"June 25, 2014","New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00748046"
1086,"NCT00744939","Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist",,"Completed","Has Results","Fibrosis|Kidney Failure|Renal Insufficiency","Drug: Gadopentetate dimeglumine (Magnevist, BAY86-4882)","Number of Participants Who Developed Nephrogenic Systemic Fibrosis (NSF), Based on Diagnostically Specific Clinical and Histopathological Information-cohort Analysis and Full Analysis Set|Number of Participants Who Developed NSF, Based on Diagnostically Specific Clinical and Histopathological Information-full Analysis Set|Number of Participants Who Developed NSF, Based on Diagnostically Specific Clinical and Histopathological Information-cohort Analysis and Per Protocol Set|Number of Participants Who Developed NSF, Based on Diagnostically Specific Clinical and Histopathological Information-per Protocol Set|Total Number of Participants With Clinicopathological Correlation of 'NSF' or 'Consistent With NSF' and Subjects Without Biopsy Developing Clinical Signs Consistent With NSF-cohort Analysis and Full Analysis Set|Total Number of Participants With Clinicopathological Correlation of 'NSF' or 'Consistent With NSF' and Subjects Without Biopsy Developing Clinical Signs Consistent With NSF-full Analysis Set|Total Number of Participants With Clinicopathological Correlation of 'NSF' or 'Consistent With NSF' and Subjects Without Biopsy Developing Clinical Signs Consistent With NSF-cohort Analysis and Per Protocol Set|Total Number of Participants With Clinicopathological Correlation of 'NSF' or 'Consistent With NSF' and Subjects Without Biopsy Developing Clinical Signs Consistent With NSF-per Protocol Set|Number of Participants With Adverse Events (AEs) Reported in Association With the Administration of Magnevist-cohort Analysis and Full Analysis Set|Number of Participants With Adverse Events (AEs) Reported in Association With the Administration of Magnevist-full Analysis Set|Number of Participants With Adverse Events (AEs) Reported in Association With the Administration of Magnevist-cohort Analysis and Per Protocol Set|Number of Participants With Adverse Events (AEs) Reported in Association With the Administration of Magnevist-per Protocol Set","Bayer","All","2 Years and older   (Child, Adult, Older Adult)",,"168","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","13256|X312141","November 2008","July 2013","November 2013","September 1, 2008","September 22, 2014","September 22, 2014","Phoenix, Arizona, United States|Chula Vista, California, United States|Los Angeles, California, United States|Santa Rosa, California, United States|Pueblo, Colorado, United States|New Haven, Connecticut, United States|Jacksonville, Florida, United States|Honolulu, Hawaii, United States|Honolulu, Hawaii, United States|Topeka, Kansas, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Brooklyn, New York, United States|New York, New York, United States|Stony Brook, New York, United States|Cleveland, Ohio, United States|Danville, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Memphis, Tennessee, United States|Houston, Texas, United States|San Antonio, Texas, United States|Charlottesville, Virginia, United States|Tacoma, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00744939"
1087,"NCT00738400","Study of Vardenafil in Patients Suffering From Erectile Dysfunction and Metabolic Syndrome",,"Completed","Has Results","Erectile Dysfunction|Metabolic Syndrome","Drug: Vardenafil (Levitra, BAY38-9456)|Drug: Placebo","Change From Baseline in International Index of Erectile Function - Erectile Function Domain (IIEF-EF) Subscore at Week 8 or Last Observation Carried Forward (LOCF)|Change in Percentage From Baseline in Success of Penetration (SEP2: Sexual Encounter Profile Question 2) at Week 8|Change in Percentage From Baseline in Success of Erection Maintenance (SEP3: Sexual Encounter Profile Question 3) at Week 8|Percentage of Participants Achieving ""Back to Normal"" Erectile Function at Week 8 or Last Observation Carried Forward (LOCF)|Change in Percentage From Baseline in Ability to Obtain an Erection (SEP1) at Week 8|Change in Percentage From Baseline in Ability to Ejaculate (SEP6) at Week 8|Number of Participants Who Can Stay on the Initially Provided Dosage of Vardenafil (10 mg PRN (Pro re Nata))","Bayer","Male","18 Years to 64 Years   (Adult)","Phase 4","150","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","13171|2008-002140-41|ED-METABOLIC","November 2008","October 2009","October 2009","August 20, 2008","June 1, 2011","November 16, 2015","Cham, Bayern, Germany|Regensburg, Bayern, Germany|Frankfurt, Hessen, Germany|Marburg, Hessen, Germany|Stuhr, Niedersachsen, Germany|Bonn, Nordrhein-Westfalen, Germany|Grevenbroich, Nordrhein-Westfalen, Germany|Leverkusen, Nordrhein-Westfalen, Germany|Mülheim, Nordrhein-Westfalen, Germany|Wuppertal, Nordrhein-Westfalen, Germany|Dierdorf, Rheinland-Pfalz, Germany|Koblenz, Rheinland-Pfalz, Germany|Trier, Rheinland-Pfalz, Germany|Homburg, Saarland, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Berlin, Germany|Berlin, Germany|Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT00738400"
1088,"NCT00729404","Inhibition of Ovulation, Patch, Ethinylestradiol and Gestodene",,"Terminated","No Results Available","Contraception|Ovulation Inhibition","Drug: Ethinylestradiol/Gestodene (BAY86-5016)","The primary efficacy variable will be the proportion of volunteers with ovulation in at least one of the treatment cycles 2 and 3.|Assessment of ovarian activity during treatment cycle2 and 3 (Hoogland score)|Course of gonadotropins (FSH, LH, P, E2)|Endometrial thickness|Follicle size|Pharmacokinetics of EE, GSD and SHBG in treatment cycles 2 and 3","Bayer","Female","18 Years to 35 Years   (Adult)","Phase 2","17","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","91558|2008-001198-13","August 2008","February 2009","February 2009","August 7, 2008",,"December 2, 2014","Berlin, Germany|Berlin, Germany|Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT00729404"
1089,"NCT00722189","Observational Study of Efficacy and Safety of Travogen Cream and Travocort Cream in the Treatment of Mycoses",,"Completed","No Results Available","Skin Mycoses",,"Efficacy of Travogen / Travocort in the treatment of skin mycoses / Travogen Cream and Travocort Cream will be prescribed by a physician|Patient satisfaction","Bayer","All","Child, Adult, Older Adult",,"900","Industry","Observational","Time Perspective: Prospective","2008/01850","July 2008","January 2009","February 2009","July 25, 2008",,"March 19, 2015","Kashkin Clinical Research Mycological Institute, St Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT00722189"
1090,"NCT00720057","Assessing the Analgesic Efficacy of Naproxen Sodium in Postsurgical Dental Pain.",,"Completed","Has Results","Toothache","Drug: Naproxen Sodium ER (BAYH6689)|Drug: Placebo","Summed Pain Intensity Difference (SPID)|Total Pain Relief (TOTPAR)|Summed Pain Intensity Difference at Specific Time Intervals|Time to First Use of Rescue Medication|Global Assessment of the Investigational Product as a Pain Reliever|Time to Onset of Effect","Bayer","All","16 Years to 45 Years   (Child, Adult)","Phase 3","312","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","13130|2014-005269-66","June 2008","August 2008","August 2008","July 22, 2008","January 25, 2011","August 25, 2015","Austin, Texas, United States|Austin, Texas, United States|Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT00720057"
1091,"NCT00717561","A Study to Assess the Efficacy and Safety of IV/PO Moxifloxacin in Subjects With Community-acquired Pneumonia",,"Completed","No Results Available","Pneumonia","Drug: Avelox (Moxifloxacin, BAY12-8039)|Drug: Ceftriaxone; Azithromycin; Amoxicilline/clavulanate; Clarithromycin","Clinical response 20 days after completion of study treatment (Test-of-Cure visit)|Clinical and bacteriological response on the day of switch from IV to oral therapy|Clinical and bacteriological response on treatment Day 3-5 (if the day of switch is different from Day 3, 4 or 5)|Bacteriological response at TOC|Clinical and bacteriological response at the end of treatment|Mortality attributable to pneumonia at the Test-of-Cure visit","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12669|2007-001320-12","February 2008","May 2009","June 2009","July 17, 2008",,"November 4, 2014","Lungro, Cosenza, Italy|San Cesario, Lecce, Italy|Fossombrone, Pesaro e Urbino, Italy|Pregiato di Cava dei Tirreni, Salerno, Italy|Vittorio Veneto, Treviso, Italy|Ascoli Piceno, Italy|Benevento, Italy|Brescia, Italy|Catania, Italy|Chieti, Italy|Foggia, Italy|Lucca, Italy|Macerata, Italy|Messina, Italy|Milano, Italy|Milano, Italy|Palermo, Italy|Roma, Italy|Roma, Italy|Roma, Italy|Sassari, Italy|Torino, Italy|Udine, Italy",,"https://ClinicalTrials.gov/show/NCT00717561"
1092,"NCT00713011","Adalat XL vs Diltiazem on Proteinuria and Blood Pressure in Hypertensive Diabetic Patients","CARDINAL","Withdrawn","No Results Available","Diabetic Nephropathies|Hypertension","Drug: Adalat XL|Drug: Tiazac XC","Change in Proteinuria|Percentage of subjects reaching a BP target of 130/80 mmHg at Week 18|Number and doses of anti-hypertensives used in the 2 treatment arms|Levels of urinary albumin and protein content and estimated glomerular filtration rate (GFR) in the 2 treatment groups|Early BP reduction from randomization achieved with the starting dose in the 2 treatment arms|Adverse Events leading to early withdrawal|All Adverse Events especially, edema|Change in index of glycemia (HbA1c)","Bayer","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12716","November 2008","March 2009","March 2009","July 11, 2008",,"November 16, 2012",,,"https://ClinicalTrials.gov/show/NCT00713011"
1093,"NCT00710827","Nebido Versus Placebo in Elderly Men With Typical Symptoms of Late Onset Hypogonadism Over a Period of 54 Weeks",,"Withdrawn","No Results Available","Hypogonadism","Drug: NEBIDO|Drug: PLACEBO","To assess the change from baseline in lean body mass after 54 weeks of treatment with NEBIDO compared to placebo|Change from baseline in total body mass|Change from baseline in fat mass|Change from baseline in bone mineral density|Aging Male Symptoms (AMS) rating scale|International Index of Erectile Function- erectile function domain (IIEF-EF)|Change in serum levels of testosterone (central laboratory)|Change in waist circumference","Bayer","Male","50 Years and older   (Adult, Older Adult)","Phase 4","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","91579|2008-002053-20|310874","October 2008",,"October 2008","July 4, 2008",,"November 27, 2012","Bonn, Nordrhein-Westfalen, Germany|Halle, Sachsen-Anhalt, Germany|Milano, Italy|Napoli, Italy|Roma, Italy|Riga, Latvia|Lodz, Poland|Warszawa, Poland|Warszawa, Poland|Warszawa, Poland|Wroclaw, Poland|Moscow, Russian Federation|Moscow, Russian Federation|Novosibirsk, Russian Federation|St. Petersburg, Russian Federation|Volgograd, Russian Federation|Reading, Berkshire, United Kingdom|Lichfield, Staffordshire, United Kingdom|Glasgow, Stratchclyde, United Kingdom|Birmingham, West Midlands, United Kingdom|Cardiff, United Kingdom|Chorley, United Kingdom|London, United Kingdom|London, United Kingdom|Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00710827"
1094,"NCT00709852","Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging",,"Completed","Has Results","Diagnostic Imaging|Central Nervous System Diseases","Drug: Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Drug: Gadoteridol (ProHance)","Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Combined Unenhanced/Gadobutrol-enhanced Magnetic Resonance Imaging (MRI) Compared to Unenhanced MRI by Blinded Reader 1 (BR1)|Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Combined Unenhanced/Gadobutrol-enhanced Magnetic Resonance Imaging (MRI) Compared to Unenhanced MRI by Blinded Reader 2 (BR2)|Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Combined Unenhanced/Gadobutrol-enhanced Magnetic Resonance Imaging (MRI) Compared to Unenhanced MRI by Blinded Reader 3 (BR3)|Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Combined Unenhanced/Gadobutrol-enhanced Magnetic Resonance Imaging (MRI) Compared to Unenhanced MRI by Average Reader (AR)|Number of Lesions for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Blinded Readers|Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Normal Structures for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Blinded Reader 1 (BR1)|Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Normal Structures for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Blinded Reader 2 (BR2)|Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Normal Structures for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Blinded Reader 3 (BR3)|Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Normal Structures for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Average Reader (AR)|Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Lesions for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Blinded Reader 1 (BR1)|Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Lesions for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Blinded Reader 2 (BR2)|Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Lesions for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Blinded Reader 3 (BR3)|Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Lesions for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Average Reader (AR)|Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Combined Unenhanced/Gadoteridol-enhanced MRI Compared to Unenhanced MRI by Average Reader|Number of Lesions for Combined Unenhanced/Gadoteridol-enhanced MRI Compared to Unenhanced MRI by Average Reader|Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Combined Unenhanced/Gadoteridol-enhanced MRI by Average Reader|Number of Lesions for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Combined Unenhanced/Gadoteridol-enhanced MRI by Average Reader|Percentage of Participants With More Lesions Detected for Combined Unenhanced/Gadobutrol-enhanced MRI or for Unenhanced MRI by Blinded Readers|Percentage of Participants With More Lesions Detected for Combined Unenhanced/Gadoteridol-enhanced MRI or for Unenhanced MRI by Average Reader|Percentage of Participants With More Lesions Detected for Combined Unenhanced/Gadobutrol-enhanced MRI or for Combined Unenhanced/Gadoteridol-enhanced MRI by Average Reader|Scores for Two Visualization Parameters (Border Delineation and Internal Morphology) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Clinical Investigator|Number of Lesions for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Clinical Investigator|Scores for Two Visualization Parameters (Border Delineation and Internal Morphology) for Normal Structures for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Clinical Investigator|Scores for Two Visualization Parameters (Border Delineation and Internal Morphology) for Lesions for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Clinical Investigator|Scores for Two Visualization Parameters (Border Delineation and Internal Morphology) for Combined Unenhanced/Gadoteridol-enhanced MRI Compared to Unenhanced MRI by Clinical Investigator|Number of Lesions for Combined Unenhanced/Gadoteridol-enhanced MRI Compared to Unenhanced MRI by Clinical Investigator|Scores for Two Visualization Parameters (Border Delineation and Internal Morphology) for Normal Structures for Combined Unenhanced/Gadoteridol-enhanced MRI Compared to Unenhanced MRI by Clinical Investigator|Scores for Two Visualization Parameters (Border Delineation and Internal Morphology) for Lesions for Combined Unenhanced/Gadoteridol-enhanced MRI Compared to Unenhanced MRI by Clinical Investigator|Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Combined Unenhanced/Gadoteridol-enhanced MRI by Clinical Investigator|Number of Lesions for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Combined Unenhanced/Gadoteridol-enhanced MRI by Clinical Investigator|Scores for Contrast Enhancement, Border Delineation and Internal Morphology for Normal Structures for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Combined Unenhanced/Gadoteridol-enhanced MRI by Clinical Investigator|Scores for Contrast Enhancement, Border Delineation and Internal Morphology for Lesions for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Combined Unenhanced/Gadoteridol-enhanced MRI by Clinical Investigator|Percentage (Per.) of the Exact Diagnostic Matches (Accuracy of Diagnosis) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Majority Reader|Percentage (Per.) of the Exact Diagnostic Matches (Accuracy of Diagnosis) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Clinical Investigator|Percentage (Per.) of the Exact Diagnostic Matches (Accuracy of Diagnosis) for Combined Unenhanced/Gadoteridol-enhanced MRI Compared to Unenhanced MRI by Majority Reader|Percentage (Per.) of the Exact Diagnostic Matches (Accuracy of Diagnosis) for Combined Unenhanced/Gadoteridol-enhanced MRI Compared to Unenhanced MRI by Clinical Investigator|Percentage (Per.) of the Exact Diagnostic Matches (Accuracy of Diagnosis) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Combined Unenhanced/Gadoteridol-enhanced MRI by Majority Reader|Percentage (Per.) of the Exact Diagnostic Matches (Accuracy of Diagnosis) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Combined Unenhanced/Gadoteridol-enhanced MRI by Clinical Investigator|Accuracy of Detection of Normal/Abnormal Brain Tissue for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Majority Reader Using T1-weighted (T1w) Images|Sensitivity of Detection of Normal/Abnormal Brain Tissue for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Majority Reader Using T1-weighted (T1w) Images|Specificity of Detection of Normal/Abnormal Brain Tissue for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Majority Reader Using T1-weighted (T1w) Images|Accuracy of Detection of Normal/Abnormal Brain Tissue for Combined Unenhanced/Gadoteridol-enhanced MRI Compared to Unenhanced MRI by Majority Reader Using T1-weighted (T1w) Images|Sensitivity of Detection of Normal/Abnormal Brain Tissue for Combined Unenhanced/Gadoteridol-enhanced MRI Compared to Unenhanced MRI by Majority Reader Using T1-weighted (T1w) Images|Specificity of Detection of Normal/Abnormal Brain Tissue for Combined Unenhanced/Gadoteridol-enhanced MRI Compared to Unenhanced MRI by Majority Reader Using T1-weighted (T1w) Images|Accuracy of Detection of Normal/Abnormal Brain Tissue for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Combined Unenhanced/Gadoteridol-enhanced MRI by Majority Reader Using T1-weighted (T1w) Images|Sensitivity of Detection of Normal/Abnormal Brain Tissue for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Combined Unenhanced/Gadoteridol-enhanced MRI by Majority Reader Using T1-weighted (T1w) Images|Specificity of Detection of Normal/Abnormal Brain Tissue for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Combined Unenhanced/Gadoteridol-enhanced MRI by Majority Reader Using T1-weighted (T1w) Images|Accuracy of Detection of Malignant Lesions (ML) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Majority Reader|Sensitivity of Detection of Malignant Lesions (ML) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Majority Reader|Specificity of Detection of Malignant Lesions (ML) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Majority Reader|Accuracy of Detection of Malignant Lesions (ML) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Clinical Investigator|Sensitivity of Detection of Malignant Lesions (ML) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Clinical Investigator|Specificity of Detection of Malignant Lesions (ML) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Clinical Investigator|Accuracy of Detection of Malignant Lesions (ML) for Combined Unenhanced/Gadoteridol-enhanced MRI Compared to Unenhanced MRI by Majority Reader|Sensitivity of Detection of Malignant Lesions (ML) for Combined Unenhanced/Gadoteridol-enhanced MRI Compared to Unenhanced MRI by Majority Reader|Specificity of Detection of Malignant Lesions (ML) for Combined Unenhanced/Gadoteridol-enhanced MRI Compared to Unenhanced MRI by Majority Reader|Accuracy of Detection of Malignant Lesions (ML) for Combined Unenhanced/Gadoteridol-enhanced MRI Compared to Unenhanced MRI by Clinical Investigator|Sensitivity of Detection of Malignant Lesions (ML) for Combined Unenhanced/Gadoteridol-enhanced MRI Compared to Unenhanced MRI by Clinical Investigator|Specificity of Detection of Malignant Lesions (ML) for Combined Unenhanced/Gadoteridol-enhanced MRI Compared to Unenhanced MRI by Clinical Investigator|Accuracy of Detection of Malignant Lesions (ML) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Combined Unenhanced/Gadoteridol-enhanced MRI by Majority Reader|Sensitivity of Detection of Malignant Lesions (ML) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Combined Unenhanced/Gadoteridol-enhanced MRI by Majority Reader|Specificity of Detection of Malignant Lesions (ML) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Combined Unenhanced/Gadoteridol-enhanced MRI by Majority Reader|Accuracy of Detection of Malignant Lesions (ML) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Combined Unenhanced/Gadoteridol-enhanced MRI by Clinical Investigator|Sensitivity of Detection of Malignant Lesions (ML) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Combined Unenhanced/Gadoteridol-enhanced MRI by Clinical Investigator|Specificity of Detection of Malignant Lesions (ML) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Combined Unenhanced/Gadoteridol-enhanced MRI by Clinical Investigator|Diagnostic Confidence for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Average Reader|Diagnostic Confidence for Combined Unenhanced/Gadoteridol-enhanced MRI Compared to Unenhanced MRI by Average Reader|Diagnostic Confidence for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Combined Unenhanced/Gadoteridol-enhanced MRI by Average Reader|Diagnostic Confidence for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Clinical Investigator|Diagnostic Confidence for Combined Unenhanced/Gadoteridol-enhanced MRI Compared to Unenhanced MRI by Clinical Investigator|Diagnostic Confidence for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Combined Unenhanced/Gadoteridol-enhanced MRI by Clinical Investigator|Comparison of Image Quality Between Gadobutrol and Gadoteridol by Blinded Readers|Percentage of Participants for Which Blinded Readers Said Image Quality Was Higher|Assessment of the Number of Contrast-enhanced Lesions for Gadobutrol and Gadoteridol by Blinded Readers|Percentage of Lesion Enhancement From Unenhanced to Combined Unenhanced/Enhanced for Gadobutrol and Gadoteridol by Blinded Readers","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","402","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","91681|2007-004746-33|310123","June 2008","April 2009","April 2009","July 3, 2008","March 6, 2012","December 30, 2014","West Alabama Research, Inc., Birmingham, Alabama, United States|Achieve Clinical Research, LLC, Tuscaloosa, Alabama, United States|Los Gatos MRI, Los Gatos, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Redwood Regional Medical Group, Inc., Santa Rosa, California, United States|University of Florida - Jacksonville, Jacksonville, Florida, United States|NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States|Atchison Hospital, Atchison, Kansas, United States|University of Maryland Hospital System, Baltimore, Maryland, United States|Johns Hopkins Hospital/Health System, Baltimore, Maryland, United States|Shields MRI - Brockton, Brockton, Massachusetts, United States|VA Boston Healthcare System-West Roxbury Division, West Roxbury, Massachusetts, United States|Washington University School of Medicine, St. Louis, Missouri, United States|University of New Mexico School of Medicine, Alburquerque, New Mexico, United States|Kingston Neurological Associates, PC, Kingston, New York, United States|NYU Hospital for Joint Diseases, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|The Cleveland Clinic, Cleveland, Ohio, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of Washington Medical Center, Seattle, Washington, United States|Aurora Saint Luke's Medical Center, Milwaukee, Wisconsin, United States|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|St George Hospital, Kogarah, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Landeskrankenhaus Donauregion Tulln, Tulln, Niederösterreich, Austria|LNK Wagner Jauregg, Linz, Oberösterreich, Austria|Medizinische Universität Graz, Graz, Steiermark, Austria|Allgemeines Krankenhaus der Stadt Wien Universitätskliniken, Wien, Austria|Fundación Instituto de Alta tecnología médica de Antioquia, Medellín, Antioquia, Colombia|Fundación Santa Fe de Bogotá - Hospital Universitario, Bogotá, Cundinamarca, Colombia|DIME Clinica Neurocardiovascular S.A., Cali, Valle del Cauca, Colombia|Centro de Diagnostico Medico, Medellín, Colombia|Deutsches Krebsforschungszentrum, Heidelberg, Baden-Württemberg, Germany|Städtisches Klinikum Karlsruhe gGmbH, Karlsruhe, Baden-Württemberg, Germany|Klinikum Mannheim gGmbH, Mannheim, Baden-Württemberg, Germany|Zentralklinikum Augsburg, Augsburg, Bayern, Germany|Universitätsklinikum Erlangen, Erlangen, Bayern, Germany|LMU Klinikum der Universität München - Großhadern, München, Bayern, Germany|Klinikum rechts der Isar, München, Bayern, Germany|Klinikum Ernst von Bergmann, Potsdam, Brandenburg, Germany|Krankenhaus Nordwest, Frankfurt, Hessen, Germany|Kliniken der Medizinischen Hochschule Hannover, Hannover, Niedersachsen, Germany|Medizinische Einrichtungen der Universität Bonn, Bonn, Nordrhein-Westfalen, Germany|Medizinisches Versorgungszentrum Prof. Dr. D. Uhlenbrock, Dortmund, Nordrhein-Westfalen, Germany|Universitätsklinikum Köln, Köln, Nordrhein-Westfalen, Germany|Universitätskliniken des Saarlandes, Homburg, Saarland, Germany|Medizinische Fakultät Carl Gustav Carus, Dresden, Sachsen, Germany|Universitätsklinikum Leipzig AöR, Leipzig, Sachsen, Germany|Klinikum der Christian-Albrechts-Universität, Kiel, Schleswig-Holstein, Germany|HELIOS Klinikum Erfurt GmbH, Erfurt, Thüringen, Germany|Universitätsklinikum Charite zu Berlin, Berlin, Germany|Universitätsklinikum Hamburg Eppendorf (UKE), Hamburg, Germany|CT /MRI centre, Indore, Madhya Pradesh, India|Piramal Diagnostic- Jankharia Imaging, Mumbai, Maharashtra, India|Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India|Bombay Hospital, Institute of Medical sciences, Mumbai, India|Nagoya Kyoritsu Clinic, Nagoya, Aichi, Japan|Nagoya Kyoritsu Hospital, Nagoya, Aichi, Japan|Social Insurance Chukyo Hospital, Nagoya, Aichi, Japan|Himeji Medical Center, Himeji, Hyogo, Japan|Himeji Central Hospital, Himeji, Hyogo, Japan|Institute of Biomedical Research and Innovation, Kobe, Hyogo, Japan|Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan|Shinsuma Hospital, Kobe, Hyogo, Japan|Kishiwada Tokushukai Hospital, Kishiwada, Osaka, Japan|Shimonoseki Kosei Hospital, Shimonoseki, Yamaguchi, Japan|Utano National Hospital, Kyoto, Japan|Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan|Osaka National Hospital, Osaka, Japan|Osaka General Medical Center, Osaka, Japan|Universitätsspital Basel, Basel, Basel-Stadt, Switzerland|Kantonsspital St. Gallen, St. Gallen, Sankt Gallen, Switzerland|Inselspital Bern, Bern, Switzerland|Hôpital Cantonal Universitaire de Genève, Genève, Switzerland|Luzerner Kantonsspital, Luzern, Switzerland",,"https://ClinicalTrials.gov/show/NCT00709852"
1095,"NCT00699751","A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases","ALSYMPCA","Completed","Has Results","Hormone Refractory Prostate Cancer|Bone Metastases","Drug: Radium-223 dichloride (Xofigo, BAY88-8223)|Drug: Placebo|Drug: Best standard of care (BSoC)","Overall Survival|Time to Total Alkaline Phosphatase (ALP) Progression|Percentage of Participants With Total ALP Response at Week 12|Percentage of Participants With Total ALP Response at End of Treatment (EOT; Week 24 or at the Time the Patient Dies or Discontinues Treatment Phase)|Percentage of Participants With Total ALP Normalization at Week 12|Percentage Change From Baseline in Total ALP at Week 12|Maximum Percentage Decrease From Baseline in Total ALP up to Week 12|Percentage Change From Baseline in Total ALP at EOT (Week 24 or at the Time the Patient Dies or Discontinues Treatment Phase)|Maximum Percentage Decrease From Baseline in Total ALP During the 24 Week Treatment|Time to Prostate Specific Antigen (PSA) Progression|Percentage of Participants With PSA Response at Week 12|Percentage of Participants With PSA Response at EOT (Week 24 or at the Time the Patient Dies or Discontinues Treatment Phase)|Percentage Change From Baseline in PSA at Week 12|Maximum Percentage Decrease From Baseline in PSA up to Week 12|Percentage Change From Baseline in PSA at EOT (Week 24 or at the Time the Patient Dies or Discontinues Treatment Phase)|Maximum Percentage Decrease From Baseline in PSA Response During the 24 Week Treatment Period|Time to First Skeletal Related Event (SRE)|Time to Occurrence of First Use of External Beam Radiation Therapy (EBRT) to Relieve Skeletal Symptoms|Time to Occurrence of First Use of Radioisotopes to Relieve Skeletal Symptoms|Time to Occurrence of First New Symptomatic Pathological Bone Fractures, Vertebral and Non-vertebral|Time to Occurrence of First Tumor Related Orthopedic Surgical Intervention|Time to Occurrence of First Spinal Cord Compression|Time to Occurrence of First Start of Any Other Anti-cancer Treatment|Time to Occurrence of First Deterioration of Eastern Cooperative Oncology Group Performance Status (ECOG PS) by at Least 2 Points From Baseline","Bayer","Male","18 Years and older   (Adult, Older Adult)","Phase 3","921","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15245|BC1-06|2007-006195-11","June 2008","July 2011","February 2014","June 18, 2008","May 7, 2014","May 27, 2016","Los Angeles, California, United States|Roseville, California, United States|Tampa, Florida, United States|New Orleans, Louisiana, United States|St. Louis, Missouri, United States|Las Vegas, Nevada, United States|Philadelphia, Pennsylvania, United States|Liverpool, New South Wales, Australia|Randwick, New South Wales, Australia|St Leonards, New South Wales, Australia|Sydney, New South Wales, Australia|Wahroonga, New South Wales, Australia|Wollongong, New South Wales, Australia|Brisbane, Queensland, Australia|Toowoomba, Queensland, Australia|Adelaide, South Australia, Australia|Adelaide, South Australia, Australia|Hobart, Tasmania, Australia|Fitzroy, Victoria, Australia|Nedlands, Western Australia, Australia|Kortrijk, Belgium|Ottignies, Belgium|Salvador, Bahia, Brazil|Belo Horizonte, Minas Gerais, Brazil|Porto Alegre, Rio Grande do Sul, Brazil|Barretos, Sao Paulo, Brazil|Piracicaba, Sao Paulo, Brazil|Belo Horizonte, Brazil|Rio de Janeiro, Brazil|Sao Paulo, Brazil|Edmonton, Alberta, Canada|London, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Brno, Czech Republic|Chomutov, Czech Republic|Olomouc, Czech Republic|Ostrava, Czech Republic|Plzen - Bory, Czech Republic|Praha 4, Czech Republic|Usti nad Labem, Czech Republic|La Roche Sur Yon, France|Montbeliard, France|Saint Cloud, France|Ulm, Baden-Württemberg, Germany|Frankfurt, Hessen, Germany|Marburg, Hessen, Germany|Göttingen, Niedersachsen, Germany|Hannover, Niedersachsen, Germany|Dortmund, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Berlin, Germany|Berlin, Germany|Hamburg, Germany|Chai Wan, Hong Kong|Hong Kong, Hong Kong|Hongkong, Hong Kong|Kowloon, Hong Kong|Beer Sheva, Israel|Kfar Saba, Israel|Tel Aviv, Israel|Zrifin, Israel|Meldola, Forlì, Italy|Candiolo, Torino, Italy|Bergamo, Italy|Milano, Italy|Reggio Emilia, Italy|Alkmaar, Netherlands|Nijmegen, Netherlands|Rotterdam, Netherlands|Bergen, Norway|Bodø, Norway|Kristiansand, Norway|Oslo, Norway|Oslo, Norway|Tromsø, Norway|Trondheim, Norway|Ålesund, Norway|Bydgoszcz, Poland|Gliwice, Poland|Kielce, Poland|Krakow, Poland|Luiblin, Poland|Warszawa, Poland|Wroclaw, Poland|Wroclaw, Poland|Singapore, Singapore|Singapore, Singapore|Banska Bystrica, Slovakia|Bratislava, Slovakia|Bratislava, Slovakia|Martin, Slovakia|Presov, Slovakia|Trnava, Slovakia|Santiago de Compostela, A Coruña, Spain|Alcorcón, Madrid, Spain|Barakaldo, Vizcaya, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Córdoba, Spain|Pamplona, Spain|Valencia, Spain|Zaragoza, Spain|Göteborg, Sweden|Jönköping, Sweden|Kalmar, Sweden|Malmö, Sweden|Sandviken, Sweden|Stockholm, Sweden|Sundsvall, Sweden|Umeå, Sweden|Romford, Essex, United Kingdom|Leicester, Leicestershire, United Kingdom|Bebington, Merseyside, United Kingdom|Nottingham, Nottinghamshire, United Kingdom|Taunton, Somerset, United Kingdom|Ipswich, Suffolk, United Kingdom|Guildford, Surrey, United Kingdom|Sutton, Surrey, United Kingdom|Coventry, Warwickshire, United Kingdom|Birmingham, West Midlands, United Kingdom|Belfast, United Kingdom|Brighton, United Kingdom|Bristol, United Kingdom|Cardiff, United Kingdom|Derby, United Kingdom|Hull, United Kingdom|Leeds, United Kingdom|Manchester, United Kingdom|Northwood, United Kingdom|Plymouth, United Kingdom|Sheffield, United Kingdom|Southampton, United Kingdom|Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00699751"
1096,"NCT00696202","Mirena Efficiency and Tolerability During the First Year of Use",,"Completed","No Results Available","Medicated Intrauterine Devices|Contraception","Drug: Mirena (BAY86-5028)","Adverse event related to the product causing a subject to withdraw, or be withdrawn, from the study at any time up to 12 months from the insertion of Mirena|General safety assessment","Bayer","Female","25 Years to 39 Years   (Adult)","Phase 4","199","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","91295|307702","September 2003",,"March 2005","June 12, 2008",,"December 31, 2014","Amiens Cedex 01, France",,"https://ClinicalTrials.gov/show/NCT00696202"
1097,"NCT00694850","Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH)",,"Active, not recruiting","No Results Available","Hypertension, Pulmonary","Drug: Riociguat (Adempas, BAY63-2521)","Safety and tolerability|Pharmacokinetics|6-Minute Walk Test|Modified borg scale|Quality of life assessments|Hemodynamic parameters|Laboratory Parameters|Electrocardiogram (ECG)|Blood pressure and heart rate","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","22","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12916|2007-003928-37","August 2, 2008","October 1, 2021","October 1, 2021","June 11, 2008",,"January 22, 2020","München, Bayern, Germany|Gießen, Hessen, Germany|Hannover, Niedersachsen, Germany|Homburg, Saarland, Germany|Dresden, Sachsen, Germany",,"https://ClinicalTrials.gov/show/NCT00694850"
1098,"NCT00692770","Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)","STORM","Completed","Has Results","Carcinoma, Hepatocellular","Drug: Nexavar (Sorafenib, BAY43-9006)|Drug: Placebo","Recurrence Free Survival (RFS) by Independent Assessment|Time to Recurrence (TTR) by Independent Assessment|Overall Survival (OS)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","1114","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12414|2008-001087-36","August 15, 2008","November 29, 2013","November 28, 2014","June 6, 2008","December 1, 2014","August 8, 2018","Birmingham, Alabama, United States|Phoenix, Arizona, United States|Los Angeles, California, United States|Los Angeles, California, United States|San Francisco, California, United States|Washington, District of Columbia, United States|Miami, Florida, United States|Atlanta, Georgia, United States|Indianapolis, Indiana, United States|Louisville, Kentucky, United States|New Orleans, Louisiana, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Burlington, Massachusetts, United States|Ann Arbor, Michigan, United States|Minneapolis, Minnesota, United States|Minneapolis, Minnesota, United States|New York, New York, United States|Cleveland, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|Portland, Oregon, United States|Pittsburgh, Pennsylvania, United States|Houston, Texas, United States|Richmond, Virginia, United States|Seattle, Washington, United States|Seattle, Washington, United States|Pilar, Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Rosario, Santa Fe, Argentina|Camperdown, New South Wales, Australia|Randwick, New South Wales, Australia|Brisbane, Queensland, Australia|Heidelberg, Victoria, Australia|Melbourne, Victoria, Australia|Innsbruck, Austria|Linz, Austria|Wien, Austria|Bruxelles - Brussel, Belgium|Gent, Belgium|Leuven, Belgium|Liege, Belgium|Porto Alegre, Rio Grande Do Sul, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|São Paulo, Sao Paulo, Brazil|Sao Paulo, Brazil|Plovdiv, Bulgaria|Varna, Bulgaria|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Vancouver, British Columbia, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Santiago de Chile, Santiago, Chile|Reñaca, Valparaíso, Chile|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Nanning, Guangxi, China|Wuhan, Hubei, China|Changsha, Hunan, China|Changsha, Hunan, China|Nanjing, Jiangsu, China|Xi'an, Shanxi, China|Xi'an, Shanxi, China|Xi'an, Shanxi, China|Chengdu, Sichuan, China|Chengdu, Sichuan, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijng, China|Chongqing, China|Dalian, China|Hefei, China|Shanghai, China|Shanghai, China|Tianjin, China|ANGERS cedex 09, France|Bondy, France|Bordeaux, France|Creteil, France|Lille, France|Lyon, France|Marseille, France|Nice, France|Paris, France|Paris, France|Rennes, France|Toulouse, France|Vandoeuvre-les-nancy, France|Villejuif, France|München, Bayern, Germany|München, Bayern, Germany|Regensburg, Bayern, Germany|Göttingen, Niedersachsen, Germany|Hannover, Niedersachsen, Germany|Aachen, Nordrhein-Westfalen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Homburg/Saar, Saarland, Germany|Halle/Saale, Sachsen-Anhalt, Germany|Magdeburg, Sachsen-Anhalt, Germany|Berlin, Germany|Hamburg, Germany|Athens / Greece, Greece|Hong Kong, Hong Kong|Kwun Tong, Hong Kong|Shatin, Hong Kong|Benevento, Campania, Italy|Napoli, Campania, Italy|Napoli, Campania, Italy|Bologna, Emilia-Romagna, Italy|Modena, Emilia-Romagna, Italy|Roma, Lazio, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Torino, Piemonte, Italy|Bari, Puglia, Italy|Cagliari, Sardegna, Italy|Catania, Sicilia, Italy|Palermo, Sicilia, Italy|Padova, Veneto, Italy|Kashiwa-shi, Chiba, Japan|Kanazawa, Ishikawa, Japan|Yokohama-shi, Kanagawa, Japan|Osakasayama-shi, Osaka, Japan|Suita, Osaka, Japan|Bunkyo-ku, Tokyo, Japan|Chuo-ku, Tokyo, Japan|Itabashi-ku, Tokyo, Japan|Minato-ku, Tokyo, Japan|Shibuya-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Fukuoka, Japan|Kumamoto, Japan|Kyoto, Japan|Okayama, Japan|Osaka, Japan|Tokushima, Japan|Goyang-si, Gyeonggido, Korea, Republic of|Goyang-si, Gyeonggido, Korea, Republic of|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Busan, Korea, Republic of|Daegu, Korea, Republic of|Jeollabuk-do, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|México, D.F., Distrito Federal, Mexico|Monterrey, Nuevo Leon, Mexico|México, D.F., Mexico|Auckland, New Zealand|Coimbra, Portugal|Bucharest, Romania|Cluj-Napoca, Romania|Iasi, Romania|Moscow, Russian Federation|Moscow, Russian Federation|Obninsk, Russian Federation|St. Petersburg, Russian Federation|Singapore, Singapore|Singapore, Singapore|Oviedo, Asturias, Spain|Sabadell, Barcelona, Spain|Cruces/Barakaldo, Bilbao, Spain|Barcelona, Catalunya, Spain|Majadahonda, Madrid, Spain|Badajoz, Spain|Barcelona, Spain|Córdoba, Spain|Madrid, Spain|Madrid, Spain|Valladolid, Spain|Göteborg, Sweden|Stockholm, Sweden|Bern, Switzerland|Zürich, Switzerland|Changhua, Taiwan|Kaohsiung City, Taiwan|Kaohsung, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Southampton, Hampshire, United Kingdom|Birmingham, West Midlands, United Kingdom|Leeds, West Yorkshire, United Kingdom|London, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Newcastle Upon Tyne, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00692770"
1099,"NCT00692016","Fast & Fed Pharmacokinetic (PK) Study","Keifer","Completed","No Results Available","Bioavailability","Drug: Naproxen sodium","PK parameters|Assess the tolerability of the investigational product.","Bayer","All","18 Years to 55 Years   (Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13080","January 2008","February 2008","March 2008","June 6, 2008",,"May 3, 2013","Little Rock, Arkansas, United States",,"https://ClinicalTrials.gov/show/NCT00692016"
1100,"NCT00683865","Uncomplicated Pelvic Inflammatory Disease. Treatment With Moxifloxacin.","MAIDEN","Completed","No Results Available","Pelvic Inflammatory Disease","Drug: Ofloxacin|Drug: Avelox (Moxifloxacin, BAY12-8039)","Clinical response 5 to 24 days after the last dose of study medication|Bacterial response at the test of cure visit and at the FU visit 28 to 42 days after last dose of study medication|Clinical response at during-treatment visit (Day 4-7) and at follow-up 28 to 42 days after last dose|Reduction from baseline in pain report at the different assessment visits|Necessity for modifying antibiotic therapy at the during-treatment visit and TOC visit and necessity for institution of an antibiotic therapy at follow-up","Bayer","Female","18 Years and older   (Adult, Older Adult)","Phase 3","749","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","10995","April 2003","October 2004","October 2004","May 26, 2008",,"October 15, 2014","Hvidovre, Denmark|Odense C, Denmark|Roskilde, Denmark|Helsinki, Finland|Hämeenlinna, Finland|Joensuu, Finland|Kotka, Finland|Antony Cedex, France|Beaumont, France|Bordeaux, France|Brive-la-gaillarde, France|Cenon, France|Colombes Cedex, France|Creteil Cedex, France|Domont, France|Lille, France|Montauban, France|Montpellier, France|Muret, France|Nancy Cedex, France|Paris, France|Paris, France|Toulouse, France|München, Bayern, Germany|Rostock, Mecklenburg-Vorpommern, Germany|Essen, Nordrhein-Westfalen, Germany|Grevenbroich, Nordrhein-Westfalen, Germany|Leverkusen, Nordrhein-Westfalen, Germany|Wuppertal, Nordrhein-Westfalen, Germany|Berlin, Germany|Berlin, Germany|Athens, Attica, Greece|Athens, Attica, Greece|Dourouti-Ioannina, Ioannina, Greece|Budapest, Hungary|Budapest, Hungary|Eger, Hungary|Györ, Hungary|Kecskemet, Hungary|Pavia, Italy|Perugia, Italy|Trieste, Italy|Klaipeda, Lithuania|Vilnius, Lithuania|Vilnius, Lithuania|Vilnius, Lithuania|Bialystok, Poland|Krakow, Poland|Lodz, Poland|Lublin, Poland|Owock, Poland|Poznan, Poland|Warszawa, Poland|Warszawa, Poland|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Bloemfontein, Free State, South Africa|Johannesburg, Gauteng, South Africa|Johannesburg, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Durban, KwaZulu Natal, South Africa|Cape Town, Western Cape, South Africa|Cape Town, Western Cape, South Africa|Göteborg, Sweden|Linköping, Sweden|Lund, Sweden|Trollhättan, Sweden|Varberg, Sweden|Bristol, Avon, United Kingdom|London, Greater London, United Kingdom|London, Greater London, United Kingdom|London, Greater London, United Kingdom|Southampton, Hampshire, United Kingdom|Nottingham, Nottinghamshire, United Kingdom|Birmingham, West Midlands, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00683865"
1101,"NCT00682019","Study Evaluation the Efficacy and Safety of Vardenafil in Subjects With Erectile Dysfunction for 10 Weeks",,"Completed","No Results Available","Erectile Dysfunction","Drug: Levitra (Vardenafil, BAY38-9456)|Drug: Placebo","Per-patient success rates based on Sexual Encounter Profile, Question 3|Per-subject success rates based on Sexual Encounter Profile, Question 2|International Index of Erectile Function- Erectile Function domain score|Global Assessment Question (GAQ)|Safety and tolerability","Bayer|GlaxoSmithKline","Male","18 Years and older   (Adult, Older Adult)","Phase 3","383","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","100493","December 2003",,"August 2004","May 21, 2008",,"October 14, 2013",,,"https://ClinicalTrials.gov/show/NCT00682019"
1102,"NCT00681772","Evaluation of the Safety and Efficacy of Vardenafil in Subjects With Erectile Dysfunction",,"Completed","No Results Available","Erectile Dysfunction","Drug: Levitra (Vardenafil, BAY38-9456)","International Index of Erectile Function - Erectile Function Domain|Sexual Encounter Profile Question 2 and 3|Global Assessment Question|Other diary based variables|Safety and tolerability","Bayer|GlaxoSmithKline","Male","18 Years and older   (Adult, Older Adult)","Phase 4","333","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","100541","March 2003",,"November 2003","May 21, 2008",,"December 11, 2014",,,"https://ClinicalTrials.gov/show/NCT00681772"
1103,"NCT00681551","Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Patients With Brain Metastasis",,"Completed","No Results Available","Brain Neoplasms","Drug: Magnevist (SH L 451A)","Diagnostic ability|Visibility|Diagnostic confidence","Bayer","All","20 Years and older   (Adult, Older Adult)","Phase 3","45","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","91103|305624","February 2003",,"March 2004","May 21, 2008",,"December 15, 2014","Yokohama-shi, Kanagawa, Japan|Osaka-shi, Osaka, Japan|Osaka-shi, Osaka, Japan|Hamamatsu-shi, Shizuoka, Japan|Bunkyo-ku, Tokyo, Japan|Ota-ku, Tokyo, Japan|Shinagawa-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Nakakoma-gun, Yamanashi, Japan",,"https://ClinicalTrials.gov/show/NCT00681551"
1104,"NCT00680654","Interaction Study in Patients With Pulmonary Hypertension and Stable Treatment of Sildenafil 20 mg TID",,"Completed","No Results Available","Hypertension, Pulmonary","Drug: Riociguat (Adempas, BAY63-2521)","Impact of a single dose of BAY63-2521 on pharmacodynamic parameters of the pulmonary system, on safety, tolerability and pharmacokinetics.","Bayer","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","7","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11917|2008-000914-65","October 2008","August 2009","November 2009","May 20, 2008",,"December 16, 2015","Heidelberg, Baden-Württemberg, Germany|Löwenstein, Baden-Württemberg, Germany|Gießen, Hessen, Germany|Greifswald, Mecklenburg-Vorpommern, Germany|Dresden, Sachsen, Germany",,"https://ClinicalTrials.gov/show/NCT00680654"
1105,"NCT00678704","BAY38-9456 - Pivotal Trial for Diabetes Patient",,"Completed","No Results Available","Erectile Dysfunction|Diabetes Mellitus","Drug: Levitra (Vardenafil, BAY38-9456)|Drug: Placebo","The Erectile Function (EF) domain score of IIEF calculated as the sum of scores from Questions 1 to 5 and 15|The Global Assessment Question|The IIEF EF domain score|IIEF domain scores other than the EF domain score[intercourse satisfaction (Q6 to Q8), overall satisfaction (Q13, Q14), orgasmic function (Q9, Q10), sexual desire (Q11, Q12)]|Scores of Questions 1 to 15 on the IIEF Questionnaire|Patient's diary response concerning hardness of erection, maintenance of erection, satisfaction with overall hardness of erection, ability of insertion, overall satisfaction with sexual experience and ejaculation|Safety data","Bayer","Male","20 Years to 64 Years   (Adult)","Phase 3","790","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","100607","January 2004",,"November 2004","May 15, 2008",,"December 19, 2014",,,"https://ClinicalTrials.gov/show/NCT00678704"
1106,"NCT00678288","A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer.",,"Terminated","Has Results","Carcinoma, Renal Cell","Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Sorafenib (Nexavar, BAY43-9006) + Interferon","Progression-Free Survival|Response Rate|Time to Progression|Duration of Response|Overall Survival","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12782|2007-005083-28|CONCERT","April 2008","June 2009","June 2009","May 15, 2008","October 1, 2010","December 11, 2014","Salzburg, Austria|Wien, Austria|Avignon, France|Bayonne, France|Bordeaux, France|Marseille, France|Marseille, France|Nantes, France|Paris, France|Paris, France|Reims, France|Strasbourg, France|Toulouse, France|Vandoeuvre Les Nancy, France|Cork, Ireland|Dublin, Ireland|Aviano, Pordenone, Italy|Legnago, Verona, Italy|Napoli, Italy|Pavia, Italy|Perugia, Italy|Reggio Emilia, Italy|Gdansk, Poland|Lublin, Poland|Warszawa, Poland|Wroclaw, Poland|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Oviedo, Spain|Pamplona, Spain|Valencia, Spain|Northwood, Middlesex, United Kingdom|Newcastle Upon Tyne, Tyne and Wear, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00678288"
1107,"NCT00676533","Cipro® XR in Therapeutic Response and Activity (eXtRa) - Assessing Symptom Relief in Urinary Tract Infections",,"Completed","No Results Available","Urinary Tract Infection","Drug: Cipro XR (Ciprofloxacin, BAYQ3939)","Time to improvement of the signs and symptoms (eg, dysuria, frequency, urgency, gross hematuria, suprapubic pain, hesitancy, low back pain) of acute, uncomplicated, symptomatic, lower UTIs|Activity Impairment Assessment (AIA) questionnaire|Clinical and bacteriological success rates|Incidence rates of adverse events","Bayer","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","276","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","100544","June 2003",,"January 2004","May 13, 2008",,"October 14, 2013","Birmingham, Alabama, United States|Huntsville, Alabama, United States|Montgomery, Alabama, United States|Tallassee, Alabama, United States|Chandler, Arizona, United States|Mesa, Arizona, United States|Phoenix, Arizona, United States|Tempe, Arizona, United States|Fresno, California, United States|Mission Hills, California, United States|San Diego, California, United States|San Diego, California, United States|San Diego, California, United States|Yorba Linda, California, United States|Avon, Connecticut, United States|Chiefland, Florida, United States|Gainesville, Florida, United States|Jacksonville, Florida, United States|Ocala, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Atlanta, Georgia, United States|Atlanta, Georgia, United States|Conyers, Georgia, United States|Fayetteville, Georgia, United States|Hayden, Idaho, United States|Evansville, Indiana, United States|Baltimore, Maryland, United States|Millersville, Maryland, United States|Ann Arbor, Michigan, United States|Elizabeth, New Jersey, United States|Camillus, New York, United States|Eugene, Oregon, United States|Feasterville, Pennsylvania, United States|Simpsonville, South Carolina, United States|Lake Jackson, Texas, United States|Salt Lake City, Utah, United States|Salt Lake City, Utah, United States|Seattle, Washington, United States|Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00676533"
1108,"NCT00674115","A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (CL2007-17 )(P07813)(COMPLETED)",,"Completed","Has Results","Gastric Acid|Human Experimentation","Drug: Omeprazole/sodium bicarbonate|Drug: omeprazole magnesium|Drug: sodium bicarbonate","Change From Baseline in Median 24-hour Intragastric pH on the 7th Day of Drug Administration","Bayer|Bausch Health Americas, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","18133|CL2007-17|P07813","April 2008","June 2008","June 2008","May 7, 2008","April 30, 2010","March 11, 2015",,,"https://ClinicalTrials.gov/show/NCT00674115"
1109,"NCT00673686","Study to Investigate the Effect of Missed Pills on Follicular Development in Two Application Regimens of SH T 00186 D",,"Completed","No Results Available","Contraceptives, Oral","Drug: YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|Drug: Yasminelle (SH T 00186 D)","Hoogland scores in cycles 2 and 3|Follicle size|Hormone levels of progesterone, estradiol, luteinizing hormone, follicle stimulating hormone|Endometrial thickness|Cervical mucus","Bayer","Female","18 Years to 35 Years   (Adult)","Phase 2","105","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","91377|308382","May 2004","February 2005","February 2005","May 7, 2008",,"October 13, 2014","Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT00673686"
1110,"NCT00672113","Effects of Adalat LA and Coracten on Drug Levels, Blood Pressure, and Heart Rate in Fed Patients With Hypertension",,"Completed","No Results Available","Hypertension","Drug: Adalat (Nifedipine, BAYA1040)|Drug: Coracten","Maximum change in plasma norepinephrine in fed state dose administration to within 6 hours after the first dose|Single dose: change in epinephrine, SBP, DBP, HR, and plasma nifedipine concentration time profile including Cmax and tmax under fed conditions|Multi-dose: the change in norepinephrine, epinephrine, SBP, DBP, HR, and plasma nifedipine concentration time profile including Cmax and tmax under fed conditions|The switch: the change in norepinephrine, epinephrine, SBP, DBP, HR, and plasma nifedipine concentration time profile including Cmax and tmax under fed conditions after switching from Coracten to nifedipine and vice versa","Bayer","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","43","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","100128","December 2003",,"August 2004","May 6, 2008",,"December 19, 2014","Cambridge, Cambridgeshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00672113"
1111,"NCT00670215","BAYQ3939, 1000 mg Tablet in Transrectal Needle Biopsies of the Prostate (TRNBP) - Infection Prophylaxis",,"Completed","No Results Available","Bacterial Infections","Drug: Ciprofloxacin single dose|Drug: Ciprofloxacin triple dose","Bacteriological Response (bacteriuria vs. no bacteriuria)|Clinical Response (patients without clinical symptoms or signs of bacteriuria vs. patients with clinical symptoms or signs of bacteriuria)|Incidence of post-procedure GU tract infections other than bacteriuria","Bayer","Male","18 Years and older   (Adult, Older Adult)","Phase 3","497","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","100588","April 2004",,"October 2004","May 1, 2008",,"December 19, 2014","Birmingham, Alabama, United States|San Diego, California, United States|San Francisco, California, United States|Sherman Oaks, California, United States|Waterbury, Connecticut, United States|Ocala, Florida, United States|Atlanta, Georgia, United States|Roswell, Georgia, United States|Chicago, Illinois, United States|Hopedale, Massachusetts, United States|New Brunswick, New Jersey, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Philadelphia, Pennsylvania, United States|Simpsonville, South Carolina, United States|San Antonio, Texas, United States|Norfolk, Virginia, United States|Spokane, Washington, United States|Salvador, Bahia, Brazil|Belo Horizonte, Minas Gerais, Brazil|Porto Alegre, RS, Brazil|Rio de Janeiro, Brazil|São Paulo, Brazil|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Victoria, British Columbia, Canada|Hamilton, Ontario, Canada|Kingston, Ontario, Canada|London, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Chicoutimi, Quebec, Canada|Fleurimont, Quebec, Canada|Laval, Quebec, Canada|Quebec, Canada|Bergamo, Italy|Milano, Italy|Napoli, Italy|Padova, Italy|Roma, Italy|Zapopan, Jalisco, Mexico|Villahermosa, Tabasco, Mexico|Monterrey, Mexico|México D.F., Mexico|México, D. F., Mexico|México, D.F., Mexico|Vigo, Pontevedra, Spain|Barcelona, Spain|Madrid, Spain|Sevilla, Spain|Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT00670215"
1112,"NCT00669994","Trial to Evaluate the Efficacy and Safety of Cipro® XR in Treating Female Patients With Lower Urinary Tract Infections",,"Completed","No Results Available","Urinary Tract Infection","Drug: Ciprofloxacin","Bacteriologic outcome in patients with UTI caused by S. saprophyticus|Adverse Events Collection|Clinical Response|Incidence of premature terminations","Bayer","Female","18 Years to 44 Years   (Adult)","Phase 4","180","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","100546","July 2003",,"October 2003","May 1, 2008",,"December 19, 2014","Birmingham, Alabama, United States|Birmingham, Alabama, United States|Pelham, Alabama, United States|Phoenix, Arizona, United States|Laguna Hills, California, United States|Long Beach, California, United States|San Diego, California, United States|San Luis Obispo, California, United States|San Mateo, California, United States|Sylmar, California, United States|Yorba Linda, California, United States|Avon, Connecticut, United States|Clearwater, Florida, United States|Pembroke Pines, Florida, United States|Evansville, Indiana, United States|Milford, Massachusetts, United States|Royal Oak, Michigan, United States|Elizabeth, New Jersey, United States|Holmdel, New Jersey, United States|Camillus, New York, United States|Beaver, Pennsylvania, United States|Feasterville, Pennsylvania, United States|Hatboro, Pennsylvania, United States|Summerville, South Carolina, United States|San Antonio, Texas, United States|Murray, Utah, United States|Salt Lake City, Utah, United States|Salt Lake City, Utah, United States|Salt Lake City, Utah, United States|West Jordan, Utah, United States|Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00669994"
1113,"NCT00668304","Trial to Evaluate Time to Symptom Relief and Elimination of Infecting Bacteria in Treating Sinusitis With Avelox","SPEED","Completed","No Results Available","Maxillary Sinusitis","Drug: Avelox (Moxifloxacin, BAY12-8039)","Time to bacteriological eradication in those who are microbiologically valid for S. pneumoniae, M. catarrhalis, and H. influenzae|Patient-reported symptom improvement using SNOT-16 questionnaire|Clinical Response|Bacteriological Response|Activity Impairment Assessment questionnaire|Incidence of Premature Termination|Adverse Events Collection","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 4","192","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","100569","June 2004",,"January 2005","April 29, 2008",,"December 19, 2014","Birmingham, Alabama, United States|Hoover, Alabama, United States|Jonesboro, Arkansas, United States|Searcy, Arkansas, United States|Fresno, California, United States|Riverside, California, United States|San Francisco, California, United States|Colorado Springs, Colorado, United States|Longmont, Colorado, United States|Bridgeport, Connecticut, United States|DeLand, Florida, United States|Shreveport, Louisiana, United States|Detroit, Michigan, United States|North Massapequa, New York, United States|Rochester, New York, United States|Columbus, Ohio, United States|Oklahoma City, Oklahoma, United States|Yukon, Oklahoma, United States|Lake Oswego, Oregon, United States|Harrisburg, Pennsylvania, United States|Greenville, South Carolina, United States|Orangeburg, South Carolina, United States|Jackson, Tennessee, United States|Carrollton, Texas, United States|Salt Lake City, Utah, United States|Charlottesville, Virginia, United States|Richmond, Virginia, United States|Winchester, Virginia, United States|Spokane, Washington, United States|Florencio Varela, Buenos Aires, Argentina|Buenos Aires, Capital Federal, Argentina|Buenos Aires, Capital Federal, Argentina|Rosario, Santa Fé, Argentina|San Miguel de Tucumán, Tucumán, Argentina|Córdoba, Argentina",,"https://ClinicalTrials.gov/show/NCT00668304"
1114,"NCT00668135","Assessment of Vardenafil in Patients With Erectile Dysfunction in Asia",,"Completed","No Results Available","Erectile Dysfunction","Drug: Vardenafil (Levitra, BAY38-9456)|Drug: Placebo","International Index of Erectile Function (IIEF) Questionnaire and Sexual Encounter Profile question 2 (SEP 2) and Sexual Encounter Profile question 3 (SEP 3)|Global Assessment Question|Other diary responses|Safety and tolerability","Bayer","Male","20 Years to 65 Years   (Adult, Older Adult)","Phase 4","348","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","10657","March 2003","April 2004","April 2004","April 29, 2008",,"December 17, 2014","Hong Kong, Hong Kong|Jakarta, Indonesia|Petlaing Jaya, Salangor, Malaysia|Kuching, Sarawak, Malaysia|Kuala Lumpur, Malaysia|Kuala Lumpur, Malaysia|Manila, Philippines|Manila, Philippines|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|Bangkok, Thailand|Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT00668135"
1115,"NCT00668122","Efficacy and Safety of CIPRO XR Versus CIPRO IR in Patients With Complicated Urinary Tract Infections","EMERON","Completed","No Results Available","Urinary Tract Infection","Drug: Cipro XR (Ciprofloxacin, BAYQ3939)|Drug: Cipro IR (Ciprofloxacin, BAYQ3939)","Bacteriological response 5 to 9 days after the last dose of study medication (TOC visit).|Bacteriological outcome during treatment|Bacteriological outcome at follow-up|Clinical outcome during treatment|Clinical outcome at the test-of-cure visit|Clinical outcome at follow-up|Adverse event collection","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","212","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","11454","March 2004",,"January 2006","April 28, 2008",,"June 30, 2009","Monza, Milano, Italy|Camposampiero, Padova, Italy|Orbassano, Torino, Italy|Busto Arsizio, Varese, Italy|Bassano del Grappa, Vicenza, Italy|Alessandria, Italy|Bari, Italy|Benevento, Italy|Bergamo, Italy|Bologna, Italy|Caserta, Italy|Catania, Italy|Chieti, Italy|Firenze, Italy|Frosinone, Italy|Genova, Italy|Genova, Italy|L'Aquila, Italy|Mantova, Italy|Massa Carrara, Italy|Messina, Italy|Milano, Italy|Napoli, Italy|Palermo, Italy|Perugia, Italy|Potenza, Italy|Reggio Calabria, Italy|Reggio Emilia, Italy|Rimini, Italy|Roma, Italy|Roma, Italy|Roma, Italy|Sassari, Italy|Siracusa, Italy|Torino, Italy|Trieste, Italy|Varese, Italy|Verona, Italy",,"https://ClinicalTrials.gov/show/NCT00668122"
1116,"NCT00668109","Assessment of Efficacy of Vardenafil in Subjects With Erectile Dysfunction and Diabetes, Hypertension or Hyperlipidemia","LUTECIA","Completed","No Results Available","Erectile Dysfunction","Drug: Levitra (Vardenafil, BAY38-9456)|Drug: Tadalafil","Sexual encounter profile question 3 observed within 15 minutes to 4 hours for vardenafil and 22 to 26 hours for the tadalafil group|Sexual encounter profile question 2|Hardness of erection|Other diary based variables|Safety and tolerability","Bayer","Male","18 Years and older   (Adult, Older Adult)","Phase 3","614","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10893","December 2003","June 2004","June 2004","April 28, 2008",,"December 23, 2014","Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Edegem, Belgium|Roeselare, Belgium|Barranquilla, Colombia|Bogotá, Colombia|Medellín, Colombia|Santa Fé de Bogotá, Colombia|Santafe de Bogotá, Colombia|Helsinki, Finland|Helsinki, Finland|Oulu, Finland|Freiburg, Baden-Württemberg, Germany|Stuttgart, Baden-Württemberg, Germany|Königsbrunn, Bayern, Germany|München, Bayern, Germany|München, Bayern, Germany|Weiden, Bayern, Germany|Marburg, Hessen, Germany|Hannover, Niedersachsen, Germany|Osnabrück, Niedersachsen, Germany|Westerstede, Niedersachsen, Germany|Mönchengladbach, Nordrhein-Westfalen, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Hamburg, Germany|Haifa, Israel|Jerusalem, Israel|Tel Aviv, Israel|Tel Hashomer, Israel|Catania, Italy|Milano, Italy|Milano, Italy|Milano, Italy|Padova, Italy|Pavia, Italy|Perugia, Italy|Pisa, Italy|Iguala, Guerrero, Mexico|Monterrey, Nuevo León, Mexico|Durango, Mexico|México, D. F., Mexico|México, D.F., Mexico|México, D.F., Mexico|Nijverdal, Netherlands|Utrecht, Netherlands|Moelv, Norway|Oslo, Norway|Sarpsborg, Norway|Trondheim, Norway|Callao, Peru|Lima, Peru|Lima, Peru|George, Eastern Cape, South Africa|Johannesburg, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Pietermaritzburg, Kwa Zulu Natal, South Africa|Newcastle, Kwa Zulu-Natal, South Africa|Durban, KwaZulu Natal, South Africa|Durban, KwaZulu- Natal, South Africa|Durban, KwaZulu-Natal, South Africa|Cape Town, Western Cape, South Africa|Cape Town, Western Cape, South Africa|San Juan de Alicante, Alicante, Spain|L'Hospitalet de Llobregat, Barcelona, Spain|Vigo, Pontevedra, Spain|A Coruña, Spain|Castellón de la Plana, Spain|Málaga, Spain|Palma de Mallorca, Spain|Zaragoza, Spain|Borås, Sweden|Skövde, Sweden|Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT00668109"
1117,"NCT00668096","A Randomised Study of Levitra to Treat Men With Erections Problems and Previously Untreated With Similar Therapy.","FINDER","Completed","No Results Available","Erectile Dysfunction","Drug: Levitra (Vardenafil, BAY38-9456)|Drug: Placebo","Hierarchical significance testing was applied to the 3 primary efficacy parameters at the 5% significance level. Parameters were to be tested: GAQ first, Sexual Encounter Profile 3 second and SEP 2 third. SEP 3 will only be tested if GAQ is sign.|International Index of Erectile Function|Treatment Satisfaction Scale|Other patient diary based variables|Safety and tolerability","Bayer","Male","18 Years to 64 Years   (Adult)","Phase 4","260","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","11334","May 2004","January 2005","January 2005","April 28, 2008",,"December 25, 2014","Bruxelles - Brussel, Belgium|Drieslinter, Belgium|Genk, Belgium|Leuven, Belgium|Gentofte, Denmark|Naestved, Denmark|Svendborg, Denmark|Viborg, Denmark|Kerava, Finland|Oulu, Finland|Tampere, Finland|Grenoble, France|Lille, France|Lyon, France|Marseille, France|Marseille, France|Marseille, France|Montpellier, France|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Leipzig, Sachsen, Germany|Leisnig, Sachsen, Germany|Meißen, Sachsen, Germany|Harrislee, Schleswig-Holstein, Germany|Norderstedt, Schleswig-Holstein, Germany|Wahlstedt, Schleswig-Holstein, Germany|Altenburg, Thüringen, Germany|Hamburg, Germany|Hamburg, Germany|Hamburg, Germany|Gavà, Barcelona, Spain|L'Hospitalet de Llobregat, Barcelona, Spain|Badalona (Barcelona), Cataluña, Spain|Barcelona, Spain|Crowborough, East Sussex, United Kingdom|Chipping Norton, Oxfordshire, United Kingdom|Lichfield, Staffordshire, United Kingdom|Hamilton, Strathclyde, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00668096"
1118,"NCT00668057","BAY38-9456 (Vardenafil HCL Tablet) in ED Treatment for China Registration.",,"Completed","No Results Available","Erectile Dysfunction","Drug: Levitra (Vardenafil, BAY38-9456)|Drug: Placebo","Erectile Function domain score of the International Index of Erectile Function, questions 1-5 and 15|Global Assessment Questionnaire|Erectile Function domain score of the International Index of Erectile Function|Safety and tolerability","Bayer","Male","22 Years and older   (Adult, Older Adult)","Phase 3","624","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","10690","December 2002","September 2003","September 2003","April 28, 2008",,"March 6, 2015","Hangzhou, Zhejiang, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Shanghai, China|Shanghai, China",,"https://ClinicalTrials.gov/show/NCT00668057"
1119,"NCT00668044","Ciprofloxacin on Burned Patients",,"Completed","No Results Available","Burns|Bacterial Infections","Drug: Ciprofloxacin (BAYO9867)","Achievement of a population mean plasma level/time profile for the 400mg i.v. ciprofloxacin aimed to validate a pk model|Evaluation of AreaUnderCurve/Minimal Inhibiting Concentration Ratio","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","18","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10627|COB","November 2002","November 2003","November 2003","April 28, 2008",,"October 27, 2009","Cesena, Forlì, Italy|Catania, Italy|Genova, Italy|Genova, Italy|Padova, Italy|Palermo, Italy|Roma, Italy",,"https://ClinicalTrials.gov/show/NCT00668044"
1120,"NCT00668031","Effect of Aprotinin on Transfusion Requirements and Blood Loss in Patients Undergoing Elective Primary Total Hip Replacement",,"Completed","No Results Available","Blood Loss, Surgical","Drug: Trasylol (Aprotinin, BAYA0128)|Drug: Placebo","Percent of subjects requiring a blood transfusion (predonated blood or packed red blood cells, autologous or allogenic) anytime in the intra-operative or post-operative period (up to the earlier of Day 7 or discharge)|The percent of subjects receiving an allogenic transfusion of blood or packed red cells during surgery and up to the earlier of Day 7 or discharge.|The percent of subjects who did and did not predonate blood receiving an allogenic transfusion of blood or packed red cells during surgery and up to the earlier of Day 7 or discharge.|The number of units of blood or packed red cells transfused. There will be analyses for the combination of autologous and allogenic transfusion and for allogenic alone.|The number of units of blood or packed red cells transfused per patient requiring transfusion.|The estimated blood loss during surgery, drainage (in milliliters) from the operative site in the first six hours post-operatively, and total drainage until removal of drains.|The change from preoperative hemoglobin concentration to postoperative hemoglobin concentration (obtained in the morning of postoperative Day 2, or, if transfused earlier, prior to transfusion|Surgeon's assessment of the degree to which bleeding obscures his/her view of the surgical field, relative to past, similar procedures.|Changes in blood markers related to inflammation and blood coagulation","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","359","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","11694","February 2005","January 2006","January 2006","April 28, 2008",,"December 30, 2014","Birmingham, Alabama, United States|Mobile, Alabama, United States|Phoenix, Arizona, United States|La Jolla, California, United States|San Diego, California, United States|Aurora, Colorado, United States|Farmington, Connecticut, United States|Bay Pines, Florida, United States|Jacksonville Beach, Florida, United States|Sarasota, Florida, United States|St. Petersburg, Florida, United States|Boise, Idaho, United States|Indianapolis, Indiana, United States|Mooresville, Indiana, United States|Iowa City, Iowa, United States|Baltimore, Maryland, United States|Worcester, Massachusetts, United States|Kalamazoo, Michigan, United States|Ypsilanti, Michigan, United States|Durham, North Carolina, United States|Greensboro, North Carolina, United States|Bend, Oregon, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Dallas, Texas, United States|Lubbock, Texas, United States|San Antonio, Texas, United States|Edmonton, Alberta, Canada|Kelowna, British Columbia, Canada|Vancouver, British Columbia, Canada|Fredericton, New Brunswick, Canada|Halifax, Nova Scotia, Canada|Guelph, Ontario, Canada|Kitchener, Ontario, Canada|London, Ontario, Canada|Oshawa, Ontario, Canada|Oshawa, Ontario, Canada|Richmond Hill, Ontario, Canada|Quebec, Canada|San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00668031"
1121,"NCT00668018","Assess Efficacy of Vardenafil 10mg in Erectile Dysfunction Within Intake of 6 Hours",,"Completed","No Results Available","Erectile Dysfunction","Drug: Levitra (Vardenafil, BAY38-9456)","Successful attempt rate reported between drug ingestion and a maximum of 6 hours after drug intake|International Index of Erectile Function|Global Assessment Question (GAQ)|Other diary responses|General Safety","Bayer","Male","18 Years and older   (Adult, Older Adult)","Phase 3","887","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10678","January 2003","October 2003","October 2003","April 28, 2008",,"December 23, 2014",,,"https://ClinicalTrials.gov/show/NCT00668018"
1122,"NCT00668005","Evaluating the Efficacy and Safety of Vardenafil in Subjects With Erectile Dysfunction and Hypertension",,"Completed","No Results Available","Erectile Dysfunction","Drug: Levitra (Vardenafil, BAY38-9456)|Drug: Placebo","Sexual Encounter Profile (SEP), questions 2 and 3|International Index of Erectile Function (IIEF) - EF (Erectile Function) domain|Global Assessment Questionnaire (GAQ)|Safety and tolerability","Bayer|GlaxoSmithKline","Male","18 Years and older   (Adult, Older Adult)","Phase 3","388","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","100539","February 2003",,"September 2003","April 28, 2008",,"December 16, 2014",,,"https://ClinicalTrials.gov/show/NCT00668005"
1123,"NCT00667979","Evaluating the Efficacy of Vardenafil in Subjects With Erectile Dysfunction (ED) Administered 12, 18 or 24 Hours Prior to Intercourse",,"Completed","No Results Available","Erectile Dysfunction","Drug: Levitra (Vardenafil, BAY38-9456)|Drug: Placebo","Sexual encounter profile Question 3|Safety and Tolerability","Bayer|GlaxoSmithKline","Male","18 Years to 64 Years   (Adult)","Phase 4","264","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","11586","September 2004",,"December 2004","April 28, 2008",,"June 30, 2009",,,"https://ClinicalTrials.gov/show/NCT00667979"
1124,"NCT00667966","Assess Efficacy in Subjects With Traumatic Spinal Cord Injury","LEMDE","Completed","No Results Available","Erectile Dysfunction|Spinal Cord Injury","Drug: Vardenafil (Levitra, BAY 38-9456), 10 mg|Drug: Placebo|Drug: Vardenafil (Levitra, BAY 38-9456), 20 mg","Characteristics of responders and non responder with respect to the electrophysiological (skin sympathetic response, bulbocavernosus reflex and somatosensory and pudendal evoked potential), urodynamical and clinical (ASIA group) tests|Duration of an erection ≥ 60% in the base induced by an erectogenic stimulus (vibrator and/or manual) in each subject after administering a 10 mg dose of vardenafil or placebo|Duration of an erection ≥ 60% in the base induced by an erectogenic stimulus (vibrator and/or manual) in each subject after administering a 20 mg dose of vardenafil or placebo|Number of participants with adverse events","Bayer","Male","18 Years to 64 Years   (Adult)","Phase 4","45","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","11861|2004-005282-37","July 2005",,"February 2007","April 28, 2008",,"May 6, 2015","Badalona, Barcelona, Spain|Toledo, Spain",,"https://ClinicalTrials.gov/show/NCT00667966"
1125,"NCT00667537","PK in Pts With HRPC & Skeletal Metastes",,"Completed","No Results Available","Prostatic Neoplasms","Drug: Radium-223 chloride (Xofigo®, BAY88-8223) injection","Estimation of whole-body retention of radioactivity at each imaging time post-injection|Estimation of the individual organ uptake/retention of radioactivity at each time-point post injection|Estimate retention of administered radioactivity in blood|Estimation of elimination of radioactivity in urine and faeces|Calculation of estimated absorbed radiation dose to target organs|Pharmacokinetics|Comparison of the biodistribution and dosimetry after the first and second injection|Prostate specific antigen (PSA) response|Survival|Adverse events|Laboratory variables; serum biochemistry and haematology|Vital signs|ECG (12 leads)|Physical examination","Bayer","Male","18 Years and older   (Adult, Older Adult)","Phase 1","6","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","15302|2006-006101-88|BC1-05","July 2007","December 2008","December 2008","April 28, 2008",,"December 14, 2015","Sutton, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00667537"
1126,"NCT00667199","BAY88-8223, Does Response Study in HRPC Patients",,"Completed","No Results Available","Hormone Refractory Prostate Cancer|Bone Metastases","Drug: Radium-223 dichloride (BAY88-8223)","Pain Assessment (using a 100mm Visual Analogue Scale)|Analgesic consumption|Reduction of pain: the pain dimension of Quality of Life assessed using the Brief Pain Inventory (BPI) form, with total pain score and subtotals, after injection and compared to scores at baseline|Duration of pain relief: measured as the time between the first and last evaluation time points at which the pain response criteria were met|The safety of radium-223: the total safety profile including adverse events and clinical laboratory measurements, with emphasis on haematological toxicity. Adverse events will be recorded continuously during the study period.|The date of death (if within 24 months after the injection of study drug)","Bayer","Male","40 Years and older   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","15305|BC1-03|2004-000299-15","May 30, 2005","April 1, 2008","October 6, 2009","April 28, 2008",,"December 19, 2018",,,"https://ClinicalTrials.gov/show/NCT00667199"
1127,"NCT00666809","Vardenafil in Tinnitus",,"Completed","No Results Available","Tinnitus","Drug: Levitra (Vardenafil, BAY38-9456)|Drug: Placebo","Total score of the Tinnitus|Audiometric measurements (mode, frequency and loudness of tinnitus, pure tone audiogram, speech audiogram)|Quality of life (SF 36 Questionnaire)|Serum human chorionic Gonadotropin (hcG), pregnancy test|Safety and tolerability","Bayer","All","18 Years to 64 Years   (Adult)","Phase 2","43","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","12049|2006-000463-29","October 2006",,"May 2007","April 25, 2008",,"December 9, 2014","Berlin, Berlin / 285, Germany",,"https://ClinicalTrials.gov/show/NCT00666809"
1128,"NCT00665496","A Study to Investigate the Time to Onset of Action of 10 mg and 20 mg of Vardenafil Compared to Placebo in Males With Erectile Dysfunction",,"Completed","No Results Available","Erectile Dysfunction","Drug: Levitra (Vardenafil, BAY38-9456)|Drug: Placebo","- Earliest elapsed time from dosing to attainment of an erection perceived to be adequate for penetration leading to completion of successful intercourse as measured by Sexual Encounter Profile Question 3 (SEP 3)|- Earliest elapsed time from dosing to attainment of an erection perceived to be adequate for penetration as measured by Sexual Encounter Profile Question 2 (SEP 2).|- The erectile function (EF) domain score of the International Index of Erectile Function (IIEF) calculated as the sum of scores from Questions 1-5 and 15 at Week 4 as well as all other IIEF factor subscores.|- Responder time to onset, where onset is time from dosing to attainment of an erection perceived to be adequate for penetration.|- Other diary questions|- Safety and tolerability","Bayer","Male","18 Years and older   (Adult, Older Adult)","Phase 3","732","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","100492|ONTIME","June 2003",,"November 2003","April 24, 2008",,"December 17, 2014","Phoenix, Arizona, United States|Beverly Hills, California, United States|San Bernardino, California, United States|Aurora, Colorado, United States|Trumbull, Connecticut, United States|Aventura, Florida, United States|Jacksonville, Florida, United States|Pembroke Pines, Florida, United States|Lawrenceville, New Jersey, United States|New York, New York, United States|Charlotte, North Carolina, United States|Wilmington, North Carolina, United States|Calgary, Alberta, Canada|Winnipeg, Manitoba, Canada|St. John, New Brunswick, Canada|Kentville, Nova Scotia, Canada|Barrie, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Sherbrooke, Quebec, Canada|Carpentras, France|Lille, France|Lyon Cedex, France|Lyon, France|Marseille, France|Montpellier, France|Nimes, France|Paris, France|Garmisch-Partenkirchen, Bayern, Germany|München, Bayern, Germany|München, Bayern, Germany|Marburg, Hessen, Germany|Hannover, Niedersachsen, Germany|Osnabrück, Niedersachsen, Germany|Westerstede, Niedersachsen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Mönchengladbach, Nordrhein-Westfalen, Germany|Niederkassel, Nordrhein-Westfalen, Germany|Halle, Sachsen-Anhalt, Germany|Leipzig, Sachsen, Germany|Hamburg, Germany|Milano, Italy|Milano, Italy|Modena, Italy|Napoli, Italy|Padova, Italy|Amsterdam, Netherlands|Den Haag, Netherlands|Nijmegen, Netherlands|Roermond, Netherlands|Utrecht, Netherlands|Moelv, Norway|Oslo, Norway|Sarpsborg, Norway|Trondheim, Norway|Koscierzyna, Poland|Lodz, Poland|Poznan, Poland|Warszawa, Poland|Warszawa, Poland|Wroclaw, Poland|Badalona, Barcelona, Spain|L'Hospitalet de Llobregat, Barcelona, Spain|Galdakao, Bizkaia, Spain|Barcelona, Cataluña, Spain|Barcelona, Spain|Castellón de la Plana, Spain|Madrid, Spain|Zaragoza, Spain|Borås, Sweden|Göteborg, Sweden|Skövde, Sweden|Stockholm, Sweden|Bristol, Avon, United Kingdom|Bristol, Avon, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00665496"
1129,"NCT00665340","Investigate the Responsiveness of the Erectile Quality Scale to Vardenafil Flexible Dose vs Placebo in Males With Erectile Dysfunction (ED)",,"Completed","No Results Available","Erectile Dysfunction","Drug: Placebo|Drug: Levitra (Vardenafil, BAY38-9456)","Erection Quality Scale|International Index of Erectile Function- Erectile Function domain score|Per-subject success rates based on Sexual Encounter Profile, Question 2|Safety and tolerability|Patient Diary Questions|Global Assessment Question (GAQ)|Percentage of subjects achieving back to normal rates of erectile functioning (IIEF-EF > 25)|Penetration (SEP2) and Maintenance (SEP3) reliability","Bayer","Male","18 Years to 64 Years   (Adult)","Phase 4","219","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11561","July 2004","January 2005","January 2005","April 23, 2008",,"October 11, 2013","Phoenix, Arizona, United States|Beverly Hills, California, United States|Laguna Hills, California, United States|Newport Beach, California, United States|Aurora, Colorado, United States|Trumbull, Connecticut, United States|Aventura, Florida, United States|Lawrenceville, New Jersey, United States|Poughkeepsie, New York, United States|Statesville, North Carolina, United States|Wilmington, North Carolina, United States|Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00665340"
1130,"NCT00665327","Avelox for Treatment of Elderly Patients With Community Acquired Pneumonia",,"Completed","No Results Available","Pneumonia","Drug: Avelox (Moxifloxacin, BAY12-8039)|Drug: Levofloxacin","Incidence of a composite safety end point (including cardiac arrest, sustained and non-sustained ventricular tachycardia), based on digital Holter ECG recordings|Incidence of a composite safety end point (including atrial fibrillation sustained and unsustained supraventricular tachycardia, third degree AV block and long RR pauses), based on Holter|Adverse Events Collection|Clinical Response|Mortality attributable to pneumonia|Bacteriological Response|Overall cost of hospitalization","Bayer","All","65 Years and older   (Older Adult)","Phase 4","401","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","10872","November 2002","April 2004","April 2004","April 23, 2008",,"November 18, 2014","Mobile, Alabama, United States|Tucson, Arizona, United States|Tucson, Arizona, United States|Brea, California, United States|Fullerton, California, United States|La Jolla, California, United States|Madera, California, United States|Bridgeport, Connecticut, United States|Farmington, Connecticut, United States|Stamford, Connecticut, United States|Brandon, Florida, United States|Jacksonville, Florida, United States|Orlando, Florida, United States|Sarasota, Florida, United States|Tampa, Florida, United States|Austell, Georgia, United States|Blue Ridge, Georgia, United States|Columbus, Georgia, United States|Fort Gordon, Georgia, United States|Marietta, Georgia, United States|Honolulu, Hawaii, United States|Coeur d'Alene, Idaho, United States|Elk Grove Village, Illinois, United States|Springfield, Illinois, United States|Fort Wayne, Indiana, United States|Indianapolis, Indiana, United States|Indianapolis, Indiana, United States|Lexington, Kentucky, United States|New Orleans, Louisiana, United States|New Orleans, Louisiana, United States|New Orleans, Louisiana, United States|Shreveport, Louisiana, United States|Cumberland, Maryland, United States|Kalamazoo, Michigan, United States|Royal Oak, Michigan, United States|Duluth, Minnesota, United States|Columbia, Missouri, United States|St. Louis, Missouri, United States|Anaconda, Montana, United States|Omaha, Nebraska, United States|Holmdel, New Jersey, United States|Neptune, New Jersey, United States|Newark, New Jersey, United States|Albany, New York, United States|Johnson City, New York, United States|Kingston, New York, United States|Manhasset, New York, United States|Mineola, New York, United States|New York, New York, United States|New York, New York, United States|Syracuse, New York, United States|Chapel Hill, North Carolina, United States|Elizabeth City, North Carolina, United States|Winston-Salem, North Carolina, United States|Winston-Salem, North Carolina, United States|Akron, Ohio, United States|Columbus, Ohio, United States|Dayton, Ohio, United States|Lima, Ohio, United States|Tulsa, Oklahoma, United States|Allentown, Pennsylvania, United States|Beaver, Pennsylvania, United States|Hershey, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Summerville, South Carolina, United States|Jackson, Tennessee, United States|Knoxville, Tennessee, United States|Memphis, Tennessee, United States|El Paso, Texas, United States|San Antonio, Texas, United States|San Antonio, Texas, United States|San Antonio, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Lynchburg, Virginia, United States|Norfolk, Virginia, United States|San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00665327"
1131,"NCT00665054","BAY38-9456, 5/10/20mg, vs.Placebo in Erectile Dysfunction",,"Completed","No Results Available","Erectile Dysfunction","Drug: Levitra (Vardenafil, BAY38-9456)|Drug: Placebo","LOCF improved compared to baseline GAQ results at the end of the study|IIEF scores|OF, SD, IS scores in IIEF Questionnaire|Scores of all individual questions on IIEF questionnaire|Subject's diary response|SSES-E scores|Summary score from the responses to SSES-E|Response scores and summary score from the responses to the SF-36","Bayer|GlaxoSmithKline","Male","18 Years to 64 Years   (Adult)","Phase 4","160","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","11382","August 2004","August 2005","August 2005","April 23, 2008",,"December 25, 2014","Adana, Turkey|Ankara, Turkey|Ankara, Turkey|Antalya, Turkey|Istanbul, Turkey|Istanbul, Turkey|Izmir, Turkey|Samsun, Turkey",,"https://ClinicalTrials.gov/show/NCT00665054"
1132,"NCT00664833","Evaluation of LEVITRA to Advance the Treatment of Erectile Dysfunction",,"Completed","No Results Available","Erectile Dysfunction","Behavioral: Levitra (Vardenafil, BAY38-9456)|Other: No Education","Effect of education of the primary care physician or of the subject, in treating erectile dysfunction with vardenafil, relative to usual care, on the subject's treatment outcome of ED and quality of life.|To assess the safety and efficacy of vardenafil in Canadian men, when it is prescribed by the PCP, rather than specialist, and to compare the efficacy in these subgroups of subjects.|To assess the effectiveness of the physician education program(s) by means of a questionnaire.","Bayer","Male","18 Years and older   (Adult, Older Adult)","Phase 4","1029","Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)","100537|ELATED","May 2004",,"October 2005","April 23, 2008",,"December 9, 2014",,,"https://ClinicalTrials.gov/show/NCT00664833"
1133,"NCT00664326","A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCC",,"Completed","Has Results","Carcinoma, Renal Cell","Drug: Regorafenib (Stivarga, BAY73-4506)","Objective Tumor Response|Tumor Response|Disease Control|Overall Survival|Progression-free Survival (PFS)|Time to Progression (TTP)|Duration of Response|Duration of Stable Disease (SD)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","49","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11726|2008-000107-28","April 30, 2008","May 31, 2009","April 2, 2019","April 22, 2008","November 28, 2012","June 5, 2019","Los Angeles, California, United States|Houston, Texas, United States|HUS, Finland|Turku, Finland|Nantes, France|Paris, France|Frankfurt, Hessen, Germany|Dresden, Sachsen, Germany|Berlin, Germany|Hamburg, Germany|Bialystok, Poland|Lublin, Poland|Poznan, Poland|Leicester, Leicestershire, United Kingdom|Bristol, United Kingdom|Cambridge, United Kingdom|London, United Kingdom|Northwood, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00664326"
1134,"NCT00663845","Assessing Efficacy and Safety of Flexible Dosing With Vardenafil in Subjects With Erectile Dysfunction and Hyperlipidemia",,"Completed","No Results Available","Erectile Dysfunction","Drug: Levitra (Vardenafil, BAY38-9456)|Drug: Placebo","Sexual Encounter Profile Question 2 and 3 and International Index of Erectile Function - Erectile Function domain|Duration of erection leading to positive Sexual Encounter Profile Question 3|Safety and tolerability|Other patient diary based variables","Bayer|GlaxoSmithKline","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","395","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","12165","May 2006",,"April 2007","April 22, 2008",,"October 11, 2013",,,"https://ClinicalTrials.gov/show/NCT00663845"
1135,"NCT00663806","A Phase IV Study of Cipro XR in Uncomplicated UTI","EXPRESS","Completed","No Results Available","Urinary Tract Infections","Behavioral: Cipro XR (Ciprofloxacin, BAYQ3939)","To compare the effect on knowledge of uncomplicated urinary tract infection (uUTI) in patients who were given a disease-directed educational brochure to read versus patients who were not given the brochure.|To examine the difference between physician and patient perceptions of the symptoms of uUTI.|To collect data on the clinical efficacy and safety of Cipro XR, 500 mg, PO once daily, for 3 days, in the treatment of uUTI in a naturalistic setting.","Bayer","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","7614","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","100534","February 2003",,"July 2003","April 22, 2008",,"December 2, 2014",,,"https://ClinicalTrials.gov/show/NCT00663806"
1136,"NCT00663741","Sorafenib Gastric Cancer Asian Phase I Study",,"Completed","No Results Available","Gastric Cancer","Drug: Sorafenib (Nexavar, BAY43-9006)","Safety and pharmacokinetics|1 year survival rate|Overall survival|Progression free survival|Response rate|Duration of response","Bayer","All","18 Years to 74 Years   (Adult, Older Adult)","Phase 1","13","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12931","May 2008","March 2010","April 2010","April 22, 2008",,"June 11, 2013","Kashiwa, Chiba, Japan|Kobe, Hyogo, Japan|Chuo-ku, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT00663741"
1137,"NCT00663728","Assessment of Duration of Erection With Vardenafil 10 mg",,"Completed","No Results Available","Erectile Dysfunction","Drug: Levitra (Vardenafil, BAY38-9456)|Drug: Placebo","Effect of vardenafil on the duration of erection|Perception of erection to be hard enough for penetration","Bayer|GlaxoSmithKline","Male","18 Years to 64 Years   (Adult)","Phase 4","201","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","11575","September 2004","April 2005","April 2005","April 22, 2008",,"December 30, 2014",,,"https://ClinicalTrials.gov/show/NCT00663728"
1138,"NCT00663598","Levitra® - Real Life Safety and Efficacy of Levitra","REALISE","Completed","No Results Available","Erectile Dysfunction","Drug: Levitra (Vardenafil, BAY38-9456)","Improvement of Erectile Disfunction|Onset of Drug Effect|Second successful intercourse|General Safety Parameters","Bayer","Male","18 Years and older   (Adult, Older Adult)","Phase 4","30825","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","100477","October 2003",,"September 2004","April 22, 2008",,"December 19, 2014",,,"https://ClinicalTrials.gov/show/NCT00663598"
1139,"NCT00663130","Evaluating the Efficacy Vardenafil 10 mg vs Tadalafil 10 mg in in Subjects With Erectile Dysfunction (ED)",,"Completed","No Results Available","Erectile Dysfunction","Drug: Levitra (Vardenafil, BAY38-9456)|Drug: Tadalafil","Sexual Encounter Profile Question 3 (SEP-3)|Sexual Encounter Profile Question 2 (SEP-2)|International Index of Erectile Function|Global Confidence Question (GCQ)|Erection Quality Scale (EQS)|General Safety","Bayer|GlaxoSmithKline","Male","18 Years to 64 Years   (Adult)","Phase 4","759","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","11333","April 2004","July 2004","July 2004","April 22, 2008",,"October 11, 2013",,,"https://ClinicalTrials.gov/show/NCT00663130"
1140,"NCT00662441","Evaluating of the Efficacy and Safety of Vardenafil in Subjects With Erectile Dysfunction",,"Completed","No Results Available","Erectile Dysfunction","Drug: Levitra (Vardenafil, BAY38-9456)","International Index of Erectile Function- Erectile Function domain|Global Assessment Questionnaire (GAQ)|Safety and tolerability","Bayer|GlaxoSmithKline","Male","18 Years and older   (Adult, Older Adult)","Phase 4","102","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","100578","September 2003",,"June 2004","April 21, 2008",,"June 22, 2009",,,"https://ClinicalTrials.gov/show/NCT00662441"
1141,"NCT00661700","A Double-blind ""Preferred"" Vardenafil Dose Study of QoL and Functional Outcomes in Males With Erectile Dysfunction",,"Completed","No Results Available","Erectile Dysfunction","Drug: Levitra (Vardenafil, BAY38-9456)|Drug: Placebo","The primary efficacy comparison is EF domain of the IIEF, vardenafil preferred dose versus placebo at week 18 (after 4 weeks of preferred treatment).|The relationship between the change from baseline score for; EF domain, SEP2, SEP3 and GEQ with that for ED-QoL and EDITS will be explored for the vardenafil 10mg and 20mg groups respectively|Global Assessment Question (GAQ) responses|Treatment groups will be compared with respect to the incidence rates of premature termination, adverse events, lab abnormalities, ECG abnormalities, and concomitant medication use|Measurements and changes from baseline in vital signs (blood pressure and pulse rate), continuous laboratory variables, ECG cardiac cycle measurements, and ECG heart rate|Measurements and changes from baseline in vital signs (blood pressure and pulse rate), continuous laboratory variables,","Bayer","Male","18 Years and older   (Adult, Older Adult)","Phase 3","611","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","10940|CTX0010/0267/A","April 2003","May 2004","May 2004","April 18, 2008",,"November 18, 2014","Dublin, Ireland|Reading, Berkshire, United Kingdom|Durham, County Durham, United Kingdom|Rhyl, Denbighshire, United Kingdom|Plymouth, Devon, United Kingdom|London, Greater London, United Kingdom|Manchester, Greater Manchester, United Kingdom|Manchester, Greater Manchester, United Kingdom|Portsmouth, Hampshire, United Kingdom|Northwood, Middlesex, United Kingdom|Norwich, Norfolk, United Kingdom|Belfast, Northern Ireland, United Kingdom|Chipping Norton, Oxfordshire, United Kingdom|Shrewsbury, Shropshire, United Kingdom|Cardiff, South Glamorgan, United Kingdom|Doncaster, South Yorkshire, United Kingdom|Lichfield, Staffordshire, United Kingdom|Glasgow, Strathclyde, United Kingdom|Hamilton, Strathclyde, United Kingdom|Motherwell, Strathclyde, United Kingdom|Coventry, Warwickshire, United Kingdom|Leeds, West Yorkshire, United Kingdom|Dublin, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00661700"
1142,"NCT00661596","Assessment of Efficacy of Vardenafil, Influence on Self-esteem and Self-confidence in Subjects With Erectile Dysfunction",,"Completed","No Results Available","Erectile Dysfunction","Drug: Levitra (Vardenafil, BAY38-9456)|Drug: Placebo","International Index of Erectile Function - Erectile Function Domain|Global Assessment Questionnaire|IIEF-EF domain score|Other diary based variables|Safety and tolerability","Bayer","Male","18 Years and older   (Adult, Older Adult)","Phase 3","129","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","11139","May 2003","January 2004","January 2004","April 18, 2008",,"December 30, 2014","Oviedo, Asturias, Spain|Sabadell, Barcelona, Spain|Barcelona, Cataluña, Spain|Hondarribia, Guipuzcoa, Spain|Leganés, Madrid, Spain|Móstoles, Madrid, Spain|Vigo, Pontevedra, Spain|Alicante, Spain|Granada, Spain|Málaga, Spain|Sevilla, Spain|Valencia, Spain|Valladolid, Spain",,"https://ClinicalTrials.gov/show/NCT00661596"
1143,"NCT00661375","BAY43-9006 Phase II Study for Renal Cell Carcinoma",,"Completed","No Results Available","Carcinoma, Renal Cell","Drug: Nexavar (Sorafenib, BAY43-9006)","Tumor response rate|Time to progression|Proportion of patients with CR and PR according to the criteria of General Rule for Clinical and Pathological Studies on Renal Cell carcinomaCR and PR rate according to General Rule for Clinical and Pathological Studies on Renal Cell carcinoma|Time to death|Overall response duration and time to objective response|Overall disease control rate|FACT-G and FKSI","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","131","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11515","November 2004","March 2006","March 2006","April 18, 2008",,"December 25, 2014","Nagoya, Aichi, Japan|Asahi, Chiba, Japan|Matsuyama, Ehime, Japan|Kurume, Fukuoka, Japan|Isesaski, Gunma, Japan|Maebashi, Gunma, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sunagawa, Hokkaido, Japan|Tsukuba, Ibaraki, Japan|Morioka, Iwate, Japan|Kita, Kagawa, Japan|Tsu, Mie, Japan|Natori, Miyagi, Japan|Sendai, Miyagi, Japan|Kashihara, Nara, Japan|Kurashiki, Okayama, Japan|Osakasayama, Osaka, Japan|Suita, Osaka, Japan|Irima-gun, Saitama, Japan|Tokorozawa, Saitama, Japan|Hamamatsu, Shizuoka, Japan|Sunto, Shizuoka, Japan|Utsunomiya, Tochigi, Japan|Ube, Yamaguchi, Japan|Nakakoma, Yamanashi, Japan|Akita, Japan|Chiba, Japan|Chiba, Japan|Fukuoka, Japan|Fukuoka, Japan|Kagoshima, Japan|Kyoto, Japan|Kyoto, Japan|Nagasaki, Japan|Niigata, Japan|Okayama, Japan|Osaka, Japan|Tokushima, Japan|Tokyo, Japan|Tokyo, Japan|Tokyo, Japan|Tokyo, Japan|Tokyo, Japan|Tokyo, Japan|Tokyo, Japan|Wakayama, Japan|Wakayama, Japan|Yamagata, Japan",,"https://ClinicalTrials.gov/show/NCT00661375"
1144,"NCT00661297","Study Evaluating the Efficacy, Safety, and Reliability of Vardenafil",,"Completed","No Results Available","Erectile Dysfunction","Drug: Levitra (Vardenafil, BAY38-9456)|Drug: Placebo","Sexual Encounter Profile question 2 (SEP 2)|Sexual Encounter Profile question 3 (SEP 3)|International Index of Erectile Function (IIEF) - EF (Erectile Function) domain|Safety and Tolerability","Bayer|GlaxoSmithKline","Male","18 Years and older   (Adult, Older Adult)","Phase 3","523","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","100536","June 2003",,"January 2004","April 18, 2008",,"December 2, 2014",,,"https://ClinicalTrials.gov/show/NCT00661297"
1145,"NCT00661219","Depression Related Improvement With Vardenafil for Erectile Response","DRIVER","Completed","No Results Available","Erectile Dysfunction|Depression","Drug: Levitra (Vardenafil, BAY38-9456)|Drug: Placebo","The primary efficacy variables are the change from baseline in the IIEF-EF domain score and the change from baseline in the HAM-D17 total score.|Patient Diary questions of treatment compared to placebo.|Global assessment question (GAQ) of treatment compared to placebo.|The scores for the IIEF questionnaire.|Responses on the Center for Epidemiologic Studies Depression Scale (CES-D).|Responses on the Rosenberg Self Esteem Scale.|Responses on the Clinical Global Impressions scale, Items 1 and 2.|Reliability in early responders.|Other IIEF domain scores than EF domain score at 12 weeks.|Safety assessment","Bayer","Male","18 Years and older   (Adult, Older Adult)","Phase 3","280","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","10621","December 2002","November 2003","November 2003","April 18, 2008",,"December 23, 2014","Huntsville, Alabama, United States|Anchorage, Alaska, United States|Beverly Hills, California, United States|Irvine, California, United States|La Mesa, California, United States|San Diego, California, United States|Aventura, Florida, United States|Atlanta, Georgia, United States|Atlanta, Georgia, United States|Boston, Massachusetts, United States|New Brunswick, New Jersey, United States|Albuquerque, New Mexico, United States|New York, New York, United States|Durham, North Carolina, United States|Charlottesville, Virginia, United States|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Vancouver, British Columbia, Canada|Hamilton, Ontario, Canada|Markham, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Hull, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Pointe-Claire, Quebec, Canada|Sherbrooke, Quebec, Canada|Lille, France|Lyon Cedex, France|Lyon, France|Lyon, France|Marseille, France|Marseille, France|Marseille, France|Nantes, France|Nice, France|Paris, France|Bari, Italy|Firenze, Italy|Milano, Italy|Milano, Italy|Milano, Italy|Modena, Italy|Napoli, Italy|Padova, Italy|Pisa, Italy|Roma, Italy|Galdakao, Bizkaia, Spain|Barcelona, Spain|Madrid, Spain|Sevilla, Spain|Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT00661219"
1146,"NCT00661180","Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec","ORACLE","Completed","No Results Available","Chronic Myelogenous Leukemia","Drug: Nexavar (Sorafenib, BAY43-9006)","To determine the major hematologic response rate (i.e. complete and partial hematologic responses) associated with BAY 43-9006 in patients with chronic phase CML resistant to Gleevec.|To determine the cytogenetic response rate associated with BAY 43-9006.|To evaluate the duration of hematologic response to BAY 43-9006.|To evaluate the duration of cytogenetic response to BAY 43-9006.|To assess time to progression.|To assess overall survival..|To evaluate the molecular response and to perform the pharmacodynamic assessment by analysis the following biomarkers: phospho-Erk, Crkl, phospho-S6|To assess the safety of BAY 43-9006 in patients with chronic phase CML resistant to Gleevec.","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","10","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10941","January 2004","February 2005","February 2005","April 18, 2008",,"December 23, 2014","Portland, Oregon, United States|Lyon Cedex, France|Paris, France|Poitiers Cedex, France",,"https://ClinicalTrials.gov/show/NCT00661180"
1147,"NCT00661115","To Investigate the Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction.",,"Completed","No Results Available","Erectile Dysfunction","Drug: Levitra (Vardenafil, BAY38-9456)|Drug: Placebo","Erectile function (EF) domain score of the International Index of Erectile Function (IIEF)calculated as the sum of scores from Questions 1 to 5 and 15|Success in penetration and maintenance as recorded in subject diaries|Scores for questions 3 and 4 of the IIEF|Other IIEF domain scores|Global Assessment Question (GAQ) responses|Rates of premature termination, adverse events, laboratory abnormalities, ECG abnormalities, and concomitant medication use.","Bayer","Male","21 Years and older   (Adult, Older Adult)","Phase 3","173","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","10695","May 2003","February 2004","February 2004","April 18, 2008",,"December 16, 2014","Bangalore, Karnataka, India|Bangalore, Karnataka, India|Belagum, Karnataka, India|Mumbai, Maharashtra, India|Mumbai, Maharashtra, India|Madurai, Tamilnadu, India",,"https://ClinicalTrials.gov/show/NCT00661115"
1148,"NCT00660998","Evaluation of Efficacy and Safety of Vardenafil in Patients With Erectile Dysfunction and Type 1 Diabetes",,"Completed","No Results Available","Erectile Dysfunction","Drug: Levitra (Vardenafil, BAY38-9456)|Drug: Placebo","Sexual Encounter Profile Question 2|Sexual Encounter Profile Question 3|International Index of Erectile Function - Erectile Function Domain|Safety and Tolerability","Bayer","Male","18 Years and older   (Adult, Older Adult)","Phase 4","318","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","100540","February 2003",,"January 2004","April 18, 2008",,"December 11, 2014",,,"https://ClinicalTrials.gov/show/NCT00660998"
1149,"NCT00658177","Study Evaluating the Efficacy and Safety of Flexible-dose Vardenafil in Subjects With Erectile Dysfunction",,"Completed","No Results Available","Erectile Dysfunction","Drug: Levitra (Vardenafil, BAY38-9456)|Drug: Placebo","Sexual Encounter Profile Question 2|Sexual Encounter Profile Question 3|Internation Index of Erectile Function-Erectile Function domain|Safety and tolerability","Bayer|GlaxoSmithKline","Male","18 Years and older   (Adult, Older Adult)","Phase 3","463","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","100497","June 2003",,"February 2004","April 14, 2008",,"December 2, 2014",,,"https://ClinicalTrials.gov/show/NCT00658177"
1150,"NCT00657839","Assessment of Efficacy of Vardenafil in the Treatment of Subjects With Symptomatic Benign Prostatic Hyperplasia",,"Completed","No Results Available","Benign Prostatic Hyperplasia","Drug: Levitra (Vardenafil, BAY38-9456)|Drug: Placebo","International Prostate Symptom Score and maximal urinary flow|International Prostate Symptom Score, storing and voiding subscore|IIEF-EF domains score|Safety and tolerability","Bayer","Male","45 Years to 64 Years   (Adult)","Phase 2","222","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","11863|EudraCT No. 2005-002796-32","October 2005",,"June 2006","April 14, 2008",,"October 28, 2014","Biberach, Baden-Württemberg / 277, Germany|München, Bayern / 280, Germany|Rosenheim, Bayern / 280, Germany|Starnberg, Bayern / 280, Germany|Weiden, Bayern / 280, Germany|Hamburg, Hamburg / 287, Germany|Hamburg, Hamburg / 287, Germany|Marburg, Hessen / 307, Germany|Tostedt, Niedersachsen / 292, Germany|Osnabrück, Niedersachsen / 293, Germany|Düsseldorf, Nordrhein-Westfalen / 296, Germany|Leverkusen, Nordrhein-Westfalen / 331, Germany|Mülheim, Nordrhein-Westfalen / 481, Germany|Leipzig, Sachsen / 313, Germany|Kiel, Schleswig-Holstein / 306, Germany",,"https://ClinicalTrials.gov/show/NCT00657839"
1151,"NCT00657644","Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction",,"Completed","No Results Available","Erectile Dysfunction","Drug: Levitra (Vardenafil, BAY38-9456)","Erectile Function (EF) domain score|Change from baseline of Erectile Function domain score|IIEF domain scores|Patient Diary Questions|Global Assessment Question (GAQ)|Premature termination, adverse events, laboratory abnormalities and concomitant medication usage|Measurements and changes from baseline in vital signs, ECG cardiac cycle measurements and ECG heart rate|Haematology, Clinical Chemistry, Urinalysis","Bayer|Amgen","Male","18 Years and older   (Adult, Older Adult)","Phase 3","130","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11182","August 2003","March 2004","March 2004","April 14, 2008",,"December 25, 2014","Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|St Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT00657644"
1152,"NCT00657254","Extension Program for Bay 43-9006",,"Completed","No Results Available","Neoplasm|Metastasis","Drug: Nexavar (Sorafenib, BAY43-9006)","Survival|Objective Tumour Response Rate|Overall Response Duration|Time to Objective Response|Time to Disease Progression|Safety Parameters","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","9","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10922","December 2002","June 2005","June 2005","April 14, 2008",,"December 23, 2014","Boston, Massachusetts, United States|Bruxelles - Brussel, Belgium|Hamilton, Ontario, Canada|Toronto, Ontario, Canada|Essen, Nordrhein-Westfalen, Germany|Herne, Nordrhein-Westfalen, Germany",,"https://ClinicalTrials.gov/show/NCT00657254"
1153,"NCT00657033","Study to Investigate the Efficacy and Safety of Vardenafil Flexible Dose Versus Placebo in Males With Erectile Dysfunction",,"Completed","No Results Available","Erectile Dysfunction","Drug: Levitra (Vardenafil, BAY38-9456)|Drug: Placebo","The primary measures of efficacy in this study will be improved success of erection maintenance in men with ED and improvement in female partner's sexual quality of life.|SEP3 at weeks 4 and 12 of treatment compared to placebo.|Additional Patient Diary questions at 4 weeks, 8 weeks, 12 weeks, LOCF, and over entire treatment period compared to placebo. Per-subject success rates will be calculated as the number of successes divided by the number of sexual attempts with a resp|Global assessment question (GAQ) at weeks 4 and 12 of treatment compared to placebo|Global confidence question (GCQ) at 12 weeks of treatment compared to placebo.|The score for the IIEF questionnaire EF domain (IIEF-EF) at weeks 4, 12, and LOCF of treatment compared to placebo|Scores from the Treatment Satisfaction Scale (TSS) -- Subject Active Medication module at week 12 and LOCF of treatment compared to placebo. The TSS is a self-report measure of subject and partner's satisfaction with various aspects of erectile function|Scores from the mSLQQ-QOL at week 12 and LOCF of treatment compared to placebo|Percentage of subjects achieving back to normal rates of erectile functioning (IIEF-EF > 25) at week 12 of treatment compared to placebo.","Bayer|GlaxoSmithKline","Male","18 Years and older   (Adult, Older Adult)","Phase 3","229","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","100519","October 2003",,"August 2004","April 14, 2008",,"October 14, 2013","Phoenix, Arizona, United States|Beverly Hills, California, United States|Irvine, California, United States|Newport Beach, California, United States|San Bernardino, California, United States|San Diego, California, United States|San Diego, California, United States|Trumbull, Connecticut, United States|Jacksonville, Florida, United States|Riverdale, Georgia, United States|Greenbelt, Maryland, United States|Lutherville, Maryland, United States|Lawrenceville, New Jersey, United States|New Brunswick, New Jersey, United States|New York, New York, United States|Charlotte, North Carolina, United States|Statesville, North Carolina, United States|Wilmington, North Carolina, United States|Calgary, Alberta, Canada|Barrie, Ontario, Canada|Burlington, Ontario, Canada|Kitchener, Ontario, Canada|London, Ontario, Canada|Oakville, Ontario, Canada|Saskatoon, Saskatchewan, Canada|Victoria, Canada",,"https://ClinicalTrials.gov/show/NCT00657033"
1154,"NCT00656981","Evaluate Safety and Efficacy of an Oral Contraceptive (OC) Preparation Versus Placebo for 6 Treatment Cycles in Women With Moderate Acne",,"Completed","No Results Available","Acne Vulgaris","Drug: YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|Drug: Placebo","Percent change in inflammatory lesion counts (including papules, pustules, and nodules), non-inflammatory lesion counts (including open and closed comedones), total lesion count, and the ISGA.|Change from baseline in count of papules|Change from baseline in count of pustules|Change from baseline in count of nodules|Change from baseline in count of open comedones|Change from baseline in count of closed comedones|Percentage of subjects classified as ""improved"" according to the Investigator's Overall Improvement Rating|Percentage of subjects classifying themselves as ""improved"" on the Subject's Overall Self-Assessment Rating","Bayer","Female","14 Years to 45 Years   (Child, Adult)","Phase 3","541","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","91231|306996","January 2003",,"June 2004","April 14, 2008",,"December 30, 2014","Mobile, Alabama, United States|Kingman, Arizona, United States|Encino, California, United States|San Diego, California, United States|San Diego, California, United States|Westlake Village, California, United States|Castle Rock, Colorado, United States|Denver, Colorado, United States|Palm Springs, Florida, United States|St. Petersburg, Florida, United States|Venice, Florida, United States|Boise, Idaho, United States|Shawnee, Kansas, United States|Louisville, Kentucky, United States|Fridley, Minnesota, United States|East Steauket, New York, United States|New York, New York, United States|Medford, Oregon, United States|Portland, Oregon, United States|Byran, Texas, United States|Arlington, Virginia, United States|Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00656981"
1155,"NCT00656747","Moxifloxacin Versus Amoxicillin Clavulanic Acid in Treatment of Acute Exacerbation of Chronic Bronchitis",,"Completed","No Results Available","Chronic Bronchitis","Drug: Avelox (Moxifloxacin, BAY12-8039)|Drug: Amoxicillin clavulanic acid","Clinical failure at 8 weeks post therapy|Clinical failure rates|Bacteriological eradication rates|Clinical failure rates for subjects with positive sputum culture at enrollment|Weekly mean symptom scores measured by the AECB SS|Rates and speed of symptom relief measured by the AECB SS|Clinical failure rates for subjects with co-administration of systemic corticosteroids (stratum 1)|Clinical failure rates for subjects without co-administration of systemic corticosteroids (stratum 2)|Need for any change in dosage or additional respiratory medication such as bronchodilators and inhaled steroids, excluding short acting bronchodilators|Improvement in symptoms burden measured by the AECB SS|Improvement in health related QoL measured by the SGRQ|spirometry tests will be compared between treatment groups|HCRU relat. to chronic bronchitis management incl. rescue med., concomitant med., therap. adjuncts, diagn. procedures, other medical care/medical staff requirement, hospitalizations (incl. ward and duration), and work productivity and activity impairment|Safety and tolerability of moxifloxacin versus amoxicillin clavulanic acid, with particular attention to rates of diarrhea","Bayer","All","60 Years and older   (Adult, Older Adult)","Phase 4","1372","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11980|2007-006096-37","March 2008","December 2010","December 2010","April 11, 2008",,"December 1, 2014","Escaldes - Engordany, Andorra|Florencio Varela, Buenos Aires, Argentina|Quilmes, Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|San Miguel de Tucumán, Tucuman, Argentina|San Miguel de Tucumán, Tucuman, Argentina|Vicente López, Argentina|Concord, New South Wales, Australia|Brisbane, Queensland, Australia|Adelaide, South Australia, Australia|Woodville, South Australia, Australia|Nedlands, Western Australia, Australia|Aalst, Belgium|Antwerpen, Belgium|Bruxelles - Brussel, Belgium|Halen, Belgium|Lommel, Belgium|Moerkerke, Belgium|Namur, Belgium|Yvoir, Belgium|Juiz de Fora, Minas Gerais, Brazil|Porto Alegre, Rio Grande do Sul, Brazil|São Paulo, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Edmonton, Alberta, Canada|Kelowna, British Columbia, Canada|Vancouver, British Columbia, Canada|Winnipeg, Manitoba, Canada|Winnipeg, Manitoba, Canada|Saint John, New Brunswick, Canada|Saint John, New Brunswick, Canada|Antigonish, Nova Scotia, Canada|Sydney Mines, Nova Scotia, Canada|Burlington, Ontario, Canada|Hamilton, Ontario, Canada|London, Ontario, Canada|London, Ontario, Canada|Toronto, Ontario, Canada|Longueuil, Quebec, Canada|Montreal, Quebec, Canada|Sherbrooke, Quebec, Canada|Santiago, Chile|Valparaíso, Chile|Viña del Mar, Chile|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Changsha, Hunan, China|Shengyang, Liaoning, China|Shenyang, Liaoning, China|Chengdu, Sichuan, China|Beijing, China|Beijing, China|Shanghai, China|Shanghai, China|Shanghai, China|Tianjin, China|Cali, Cauca, Colombia|Bogotá, Colombia|Bucaramanga, Colombia|Cali, Colombia|Medellín, Colombia|Santafe de Bogotá, Colombia|Osijek, Croatia|Petrinja, Croatia|Rijeka, Croatia|Zagreb, Croatia|Kyjov, Czech Republic|Lovosice, Czech Republic|Neratovice, Czech Republic|Pardubice - Trnova, Czech Republic|Praha - Malesice, Czech Republic|Praha - Troja, Czech Republic|Marseille, France|Mont-de-marsan, France|Nice, France|Perpignan, France|Bad Dürrheim, Baden-Württemberg, Germany|Augsburg, Bayern, Germany|Cottbus, Brandenburg, Germany|Rüdersdorf, Brandenburg, Germany|Zossen, Brandenburg, Germany|Frankfurt, Hessen, Germany|Frankfurt, Hessen, Germany|Fulda, Hessen, Germany|Neubrandenburg, Mecklenburg-Vorpommern, Germany|Lüdenscheid, Nordrhein-Westfalen, Germany|Neuwied, Rheinland-Pfalz, Germany|Böhlen, Sachsen, Germany|Delitzsch, Sachsen, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Leipzig, Sachsen, Germany|Leipzig, Sachsen, Germany|Meißen, Sachsen, Germany|Bad Segeberg, Schleswig-Holstein, Germany|Lübeck, Schleswig-Holstein, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Hamburg, Germany|Hamburg, Germany|Athens, Attica, Greece|Mezourlo, Larissa, Greece|Rio, Patras, Greece|Athens, Greece|Ioannina, Greece|HongKong, Hong Kong|Kowloon, Hong Kong|Bandung, Indonesia|Jakarta, Indonesia|Surabaya, Indonesia|Killarney, Kerry, Ireland|Enniscorthy, Wexford, Ireland|Gorey, Wexford, Ireland|Bray, Wicklow, Ireland|Longford, Ireland|Pregiato di Cava dei Tirreni, Salerno, Italy|Busto Arsizio, Varese, Italy|Bussolengo, Verona, Italy|Ascoli Piceno, Italy|Catania, Italy|Chieti, Italy|Milano, Italy|Milano, Italy|Perugia, Italy|Kraslava, Latvia|Riga, Latvia|Riga, Latvia|Riga, Latvia|Talsu, Latvia|Valmiera, Latvia|Ventspils, Latvia|Kaunas, Lithuania|Kaunas, Lithuania|Klaipeda, Lithuania|Siauliai, Lithuania|Vilnius, Lithuania|Vilnius, Lithuania|Guadalajara, Jalisco, Mexico|Huixquilucan, México, Mexico|Monterrey, Nuevo Leon, Mexico|Monterrey, Nuevo Leon, Mexico|Mérida, Yucatán, Mexico|Chihuahua, Mexico|Zacatecas, Mexico|Eindhoven, Noord-Brabant, Netherlands|Heerlen, Netherlands|Hoofddorp, Netherlands|Meppel, Netherlands|Utrecht, Netherlands|Karachi, Sindh, Pakistan|Islamabad, Pakistan|Karachi, Pakistan|Callao, Peru|Lima, Peru|Lima, Peru|Lima, Peru|Lima, Peru|Lima, Peru|Manila, Philippines|Quezon City, Philippines|Torres Vedras, Lisboa, Portugal|Matosinhos, Porto, Portugal|Vila Nova de Gaia, Porto, Portugal|Coimbra, Portugal|Lisboa, Portugal|Lisboa, Portugal|Porto, Portugal|S. Martinho do Bispo, Portugal|Santarém, Portugal|Port Elizabeth, Eastern Cape, South Africa|Bloemfontein, Freestate, South Africa|Benoni, Gauteng, South Africa|Centurion, Gauteng, South Africa|Kempton Park, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Durban, KwaZulu Natal, South Africa|Durban, KwaZulu Natal, South Africa|Thabazimbi, Limpopo, South Africa|Witbank, Mpumalanga, South Africa|Cape Town, Western Cape, South Africa|Paarl, Western Cape, South Africa|Somerset West, Western Cape, South Africa|Badalona, Barcelona, Spain|Sant Boi de Llobregat, Barcelona, Spain|Palma de Mallorca, Illes Baleares, Spain|Requena, Valencia, Spain|Barcelona, Spain|Barcelona, Spain|Guadalajara, Spain|Madrid, Spain|Aarau, Aargau, Switzerland|Laufen, Basel-Landschaft, Switzerland|Oberwil, Basel-Landschaft, Switzerland|Binningen, Basel-Stadt, Switzerland|Basel, Switzerland|Bern, Switzerland|Thun, Switzerland|Wettingen, Switzerland|Zürich, Switzerland|Zürich, Switzerland|Bangkok, Thailand|Chiang Mai, Thailand|Nonthaburi, Thailand|Glasgow, Stratchclyde, United Kingdom|Glasgow, Stratchclyde, United Kingdom|Glasgow, Stratchclyde, United Kingdom|Glasgow, Stratchclyde, United Kingdom|Glasgow, Stratchclyde, United Kingdom|Coventry, Warwickshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00656747"
1156,"NCT00656188","Placebo-controlled Study Evaluating the Efficacy and Safety of Vardenafil in Subjects With Erectile Dysfunction",,"Completed","No Results Available","Erectile Dysfunction","Drug: Levitra (Vardenafil, BAY38-9456)|Drug: Placebo","Erectile Function domain of the International Index of Erectile Function|Sexual Encounter Profile Question 2|Sexual Encounter Profile Question 3|Erectile Function domain scores > 26|Sexual Encounter Profile 2|Global Assessment Question|Reliability of insertion|Reliability of maintenance|Other subject diary based variables|Safety and tolerability","Bayer|GlaxoSmithKline","Male","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","463","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","10898|GSK 001","October 2002","May 2003","May 2003","April 10, 2008",,"October 10, 2013",,,"https://ClinicalTrials.gov/show/NCT00656188"
1157,"NCT00655629","Vardenafil Orodispersible Tablet (ODT) Versus Placebo in Males With Erectile Dysfunction, 50% of Whom Are to be 65 Years or Older.",,"Completed","Has Results","Erectile Dysfunction","Drug: Vardenafil ODT (STAXYN, BAY38-9456)|Drug: Placebo","Change From Baseline in International Index of Erectile Function (IIEF-EF Sub-Score) at 12 Weeks or Last Observation Carried Forward (LOCF)|Change in Percentage From Baseline in Success of Penetration (SEP2) at 12 Weeks|Change From Baseline in Success of Erection Maintenance at 12 Weeks|Percentage of Subjects Achieving ""Back to Normal"" Erectile Function|Change in Percentage From Baseline in Ability to Obtain an Erection at 12 Weeks|Change in Percentage From Baseline in Satisfaction With the Hardness of Erection at 12 Weeks|Change in Percentage From Baseline in Overall Satisfaction at 12 Weeks|Change in Percentage From Baseline in Ability to Ejaculate at 12 Weeks|Number of Sexual Attempts Till First Successful Attempt|Change From Baseline in Ease With Erection at 12 Weeks or LOCF|Change From Baseline in Erectile Function Satisfaction at 12 Weeks or LOCF|Change From Baseline in Pleasure of Sexual Activity at 12 Weeks or LOCF|Change From Baseline in Satisfaction With Orgasm at 12 Weeks or LOCF|Change From Baseline in Confidence for Completion at 12 Weeks or LOCF|Satisfaction With Medication at Week 12 or LOCF|Patient Self Reported Improvement of Erectile Function Under Treatment Using a Categorical Rating Scale","Bayer|GlaxoSmithKline|Schering-Plough","Male","18 Years and older   (Adult, Older Adult)","Phase 3","339","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","12094","April 2008","February 2009","February 2009","April 10, 2008","January 21, 2011","August 1, 2014","East Valley Family Physicians, PLC, Chandler, Arizona, United States|Mesa Family Medical Center, Mesa, Arizona, United States|Desert Clinical Research, Mesa, Arizona, United States|Arizona Research Center, Inc., Phoenix, Arizona, United States|Tatum Highlands Medical Associates, PLLC, Phoenix, Arizona, United States|Fiel Family & Sports Medicine, PC, Tempe, Arizona, United States|Irvine Center for Clinical Research, Irvine, California, United States|Synergy Clinical Research Center, National City, California, United States|San Diego Uro-Research, San Diego, California, United States|San Diego Clinical Trials, San Diego, California, United States|South Florida Medical Research, Aventura, Florida, United States|Jacksonville Impotence Treatment Center, Jacksonville, Florida, United States|University Clinical Research, Inc., Pembroke Pines, Florida, United States|Tulane Medical Center, New Orleans, Louisiana, United States|Office of Dr. Bruce Gilbert, MD, Great Neck, New York, United States|Mount Sinai Medical Center, New York, New York, United States|The Urology Group, Cincinnati, Ohio, United States|Columbus Urology Research, LLC, Columbus, Ohio, United States|Family Medical Associates, Levittown, Pennsylvania, United States|Pearl Clinical Research, Norristown, Pennsylvania, United States|Office of Dr. Roger Fincher, MD, Spokane, Washington, United States|Sydney Men's Health, Bondi Junction, New South Wales, Australia|Berry Road Medical Centre, St Leonards, New South Wales, Australia|South Terrace Urology, Adelaide, South Australia, Australia|Cabrini Medical Centre, Melbourne, Victoria, Australia|Queen Elizabeth II Medical Centre, Nedlands, Western Australia, Australia|Perth Human Sexuality Centre, Perth, Western Australia, Australia|St.Joseph's Health Care-London, London, Ontario, Canada|The Male Health Centres, Oakville, Ontario, Canada|Office of Dr. Rajiv Singal, MD, Toronto, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Clinique d'Urologie du Saguenay, Chicoutimi, Quebec, Canada|Urology South Shore Research, Greenfield Park, Quebec, Canada|Centre de Recherche en Sante Sexuelle du Quebec, Montreal, Quebec, Canada|Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada|Hospital Dalinde, México, D. F., Distrito Federal, Mexico|Consultorio Dr. Rodríguez Rivera, Guadalajara, Jalisco, Mexico|Centro Médico de las Américas, Mérida, Yucatán, Mexico|Asociación Mexicana para la Salud Sexual A. C., México D. F., Mexico|Hospital Santa Fé, México, D. F., Mexico",,"https://ClinicalTrials.gov/show/NCT00655629"
1158,"NCT00655590","Assess the Effect of Daily Treatment of Vardenafil 20mg or Sildenafil 100mg and Placebo on Sperm Function",,"Completed","No Results Available","Erectile Dysfunction","Drug: Levitra (Vardenafil, BAY38-9456)|Drug: Sildenafil|Drug: Placebo","Proportion of vardenafil subjects with a 50% or greater decrease from baseline in mean sperm concentration at 6 months (LOCF), compared to placebo after repeated use|Mean sperm concentration|Mean sperm count|Sperm morphology|Sperm motility|Reproductive hormones|Proportion of sildenafil subjects with a 50% or greater decrease from baseline in mean sperm concentration at 6 months (LOCF), compared to placebo and vardenafil after repeated use","Bayer","Male","25 Years to 64 Years   (Adult)","Phase 4","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","11520","January 2005","June 2006","June 2006","April 10, 2008",,"December 30, 2014","Phoenix, Arizona, United States|Tempe, Arizona, United States|Beverly Hills, California, United States|La Mesa, California, United States|Laguna Hills, California, United States|San Diego, California, United States|Torrance, California, United States|Van Nuys, California, United States|Waterbury, Connecticut, United States|Aventura, Florida, United States|New Orleans, Louisiana, United States|Ann Arbor, Michigan, United States|Minneapolis, Minnesota, United States|Rochester, Minnesota, United States|Great Neck, New York, United States|New York, New York, United States|Cincinnati, Ohio, United States|San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00655590"
1159,"NCT00654914","A Study to Assess the Efficacy and Safety of Vardenafil in the Treatment of Male Patients With Erectile Dysfunction","VIS","Completed","No Results Available","Erectile Dysfunction","Drug: Levitra (Vardenafil, BAY38-9456)","Percentage of success rate at the end of treatment period versus baseline.|The Erectile Function (EF) domain score of the International Index of Erectile Function (IIEF-Appendix 10.3) calculated as the sum of scores from Questions 1-5 and 15 at Visit 5 using the last Visit vs baseline.|Global Assessment Question|Italian validated Version of SF-12 Health Survey","Bayer","Male","18 Years and older   (Adult, Older Adult)","Phase 3","527","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10781","May 2003","February 2004","February 2004","April 9, 2008",,"December 23, 2014",,,"https://ClinicalTrials.gov/show/NCT00654914"
1160,"NCT00654680","Evaluating the Efficacy and Safety of Vardenafil in Patients Erectile Dysfunction Solely Secondary to Spinal Cord Injury",,"Completed","No Results Available","Erectile Dysfunction","Drug: Vardenafil (Levitra, BAY38-9456)|Drug: Placebo","International Index of Erectile Function-Erectile Function domain|Sexual Encounter Profile Question 2|Sexual Encounter Profile Question 3|Other diary based variables|Safety and tolerability","Bayer|GlaxoSmithKline","Male","18 Years and older   (Adult, Older Adult)","Phase 3","418","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","10473","October 2002","January 2004","January 2004","April 9, 2008",,"September 30, 2013",,,"https://ClinicalTrials.gov/show/NCT00654680"
1161,"NCT00653614","Cycle Control and Safety of E2-DRSP",,"Completed","No Results Available","Contraceptive, Oral, Hormonal","Drug: E2/DRSP (BAY 86-4891) dose 1 (SH T04984E)|Drug: E2/DRSP (BAY 86-4891) dose 2 (80458739)|Drug: E2/DRSP (BAY 86-4891) dose 3 (80458755)|Drug: E2/DRSP (BAY 86-4891) dose 4 (80458720)|Drug: E2/DRSP (BAY 86-4891) dose 5 (80458712)|Drug: DRSP (ZK 30595) dose 1 (SH T04984F)|Drug: DRSP (ZK 30595) dose 2 (80458690)|Drug: Placebo","Number of intracyclic bleeding episodes during cycles 2 to 7|Number of intracyclic bleeding days (including spotting) in Cycles 2 to 7|Number of withdrawal bleeding episodes in Cycles 1 to 6|Bleeding pattern|Cycle control|Subjective assessment of treatment|Number of participants with adverse events","Bayer","Female","18 Years to 35 Years   (Adult)","Phase 2","635","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","91765|2007-005258-22|311926","March 2008","June 2009","June 2009","April 7, 2008",,"April 23, 2015","Krumbach, Bayern, Germany|Nürnberg, Bayern, Germany|Dietzenbach, Hessen, Germany|Frankfurt, Hessen, Germany|Frankfurt, Hessen, Germany|Fulda, Hessen, Germany|Mühlheim, Hessen, Germany|Blankenburg, Sachsen-Anhalt, Germany|Burg, Sachsen-Anhalt, Germany|Jessen, Sachsen-Anhalt, Germany|Magdeburg, Sachsen-Anhalt, Germany|Magdeburg, Sachsen-Anhalt, Germany|Dippoldiswalde, Sachsen, Germany|Dresden, Sachsen, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Leipzig, Sachsen, Germany|Wurzen, Sachsen, Germany|Gera, Thüringen, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Hamburg, Germany|Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT00653614"
1162,"NCT00652418","Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Magnetic Resonance Angiography",,"Completed","No Results Available","Magnetic Resonance Angiography|Peripheral Vascular Diseases|Peripheral Arterial Diseases","Drug: Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A)","Diagnostic ability|Visibility|Diagnostic confidence","Bayer","All","20 Years and older   (Adult, Older Adult)","Phase 2","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","91396|308612","July 2004","October 2004","October 2004","April 3, 2008",,"October 14, 2013","Hirosaki-shi, Aomori, Japan|Funai-gun, Kyoto, Japan|Hamamatsu-shi, Shizuoka, Japan",,"https://ClinicalTrials.gov/show/NCT00652418"
1163,"NCT00652262","BAY38-9456 - Supportive Trial for Spinal Injury",,"Completed","No Results Available","Erectile Dysfunction|Sexual Dysfunction|Spinal Cord Injury","Drug: Levitra (Vardenafil, BAY38-9456)","The Erectile Function (EF) domain score of IIEF calculated as the sum of scores from Questions 1 to 5 and 15|The Global Assessment Question|The IIEF EF domain score|IIEF domain scores other than the EF domain score[intercourse satisfaction (Q6 to Q8), overall satisfaction (Q13, Q14), orgasmic function (Q9, Q10), sexual desire (Q11, Q12)]|Scores of Questions 1 to 15 on the IIEF Questionnaire|Patient's diary response concerning hardness of erection, maintenance of erection, satisfaction with overall hardness of erection, ability of insertion, overall satisfaction with sexual experience and ejaculation|Safety data","Bayer","Male","20 Years to 64 Years   (Adult)","Phase 3","32","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","100608","March 2004",,"November 2004","April 3, 2008",,"December 23, 2014","Nagoya, Aichi, Japan|Iizuka, Fukuoka, Japan|Beppu, Oita, Japan",,"https://ClinicalTrials.gov/show/NCT00652262"
1164,"NCT00651846","Investigate Impact of Yasmin vs Microgynon on Hemostasis Parameters in Healthy Women",,"Completed","No Results Available","Healthy","Drug: Yasmin (DRSP 3mg/EE 0.03 mg)|Drug: Microgynon (LNG 0.15 mg/EE 0.03 mg)","Pro-coagulatory parameters: Factor VIII (activity), Fibrinogen|Anti-coagulatory parameters: Protein C (activity), Antithrombin III(activity), APC resistance (factor V mutation)|Rosing test: APC sensitivity ratio|Pro-coagulatory parameters: Factor VIII (activity), Activation markers: D-dimer, Prothrombin fragment 1+2","Bayer","Female","18 Years to 35 Years   (Adult)","Phase 4","43","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","91270|307286","June 2003",,"February 2005","April 3, 2008",,"December 30, 2014","Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT00651846"
1165,"NCT00651599","Treatment of Vasomotor Symptoms in Korean Post Menopausal Women",,"Completed","No Results Available","Vasomotor Symptoms","Drug: Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|Drug: Placebo","Hot flush (frequency and severity)|Menopausal symptoms|Urogenital symptoms|Assessment of bleeding","Bayer","Female","45 Years to 65 Years   (Adult, Older Adult)","Phase 3","90","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","91354|308381","July 2004",,"May 2005","April 3, 2008",,"December 31, 2014","Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00651599"
1166,"NCT00651469","Evaluate Safety and Efficacy of an OC Preparation vs Placebo for 6 Treatment Cycles in Women With Moderate Acne.",,"Completed","No Results Available","Acne Vulgaris","Drug: YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|Drug: Placebo","Percent change in inflammatory lesion counts (including papules, pustules, and nodules), non-inflammatory lesion counts (including open and closed comedones), total lesion count, and the ISGA.|Change from baseline in count of papules|Change from baseline in count of pustules|Change from baseline in count of nodules|Change from baseline in count of open comedones|Change from baseline in count of closed comedones|Percentage of subjects classified as ""improved"" according to the Investigator's Overall Improvement Rating|Percentage of subjects classifying themselves as ""improved"" on the Subject's Overall Self-Assessment Rating","Bayer","Female","14 Years to 45 Years   (Child, Adult)","Phase 3","534","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","91209|306820","January 2003",,"July 2004","April 2, 2008",,"December 30, 2014","Birmingham, Alabama, United States|Huntsville, Alabama, United States|Mesa, Arizona, United States|Los Angeles, California, United States|San Diego, California, United States|Washington, District of Columbia, United States|Miami, Florida, United States|St. Petersburg, Florida, United States|Tampa, Florida, United States|Boise, Idaho, United States|Chicago, Illinois, United States|Indianapolis, Indiana, United States|New Orleans, Louisiana, United States|Wellesley, Massachusetts, United States|Kansas City, Missouri, United States|Albuquerque, New Mexico, United States|Winston-Salem, North Carolina, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Hershey, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Warwick, Rhode Island, United States|Austin, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Tacoma, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00651469"
1167,"NCT00645788","Study to Evaluate the Safety and Efficacy of Ciprofloxacin (Inhaled) in Patients With Cystic Fibrosis",,"Completed","Has Results","Cystic Fibrosis","Drug: Ciprofloxacin (Cipro Inhale, BAYQ3939)|Drug: Placebo","Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Day 28‑30|Change From Baseline in FEV1 at Visits 4, 5, and Follow-up Visits 8 and 9|Change From Baseline in P. Aeruginosa Density in the Sputum at Visits 4, 5, 7, 8 and 9|Time to First Pulmonary Exacerbation Requiring Intervention|Change From Baseline in Forced Vital Capacity (FVC) at Visits 4, 5, 7, 8 and 9|Change From Baseline in Forced Expiratory Flow (FEF 25-75%) at Visits 4, 5, 7, 8 and 9|Number of Participants Developing Ciprofloxacin-resistant Mucoid P.Aeruginosa Isolates|Number of Participants Developing Ciprofloxacin-resistant Non-mucoid P.Aeruginosa Isolates|Effect of Ciprofloxacin DPI Treatment on Quality of Life Measured by Cystic Fibrosis Quality of Life Questionnaire Revised (CFQ-R), Respiratory Scale|Plasma Concentrations of Ciprofloxacin From Selected Participants During Treatment|Sputum Concentrations of Ciprofloxacin From Selected Participants During Treatment|Number of Participants With the Occurrence of Drug Induced Bronchospasms","Bayer|Novartis","All","12 Years and older   (Child, Adult, Older Adult)","Phase 2","288","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12429|2008-008314-40","May 2008","January 2011","January 2011","March 28, 2008","July 3, 2012","June 9, 2014","Phoenix, Arizona, United States|Tucson, Arizona, United States|Little Rock, Arkansas, United States|Los Angeles, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|Orange, California, United States|San Diego, California, United States|San Francisco, California, United States|Ventura, California, United States|Aurora, Colorado, United States|Hartford, Connecticut, United States|New Haven, Connecticut, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Orlando, Florida, United States|Orlando, Florida, United States|Augusta, Georgia, United States|Chicago, Illinois, United States|Chicago, Illinois, United States|Glenview, Illinois, United States|Maywood, Illinois, United States|Indianapolis, Indiana, United States|Iowa city, Iowa, United States|Lexington, Kentucky, United States|Louisville, Kentucky, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Ann Arbor, Michigan, United States|Kalamazoo, Michigan, United States|Jackson, Mississippi, United States|Las Vegas, Nevada, United States|Livingston, New Jersey, United States|Long Branch, New Jersey, United States|Morristown, New Jersey, United States|Somerville, New Jersey, United States|Albany, New York, United States|New Hyde Park, New York, United States|Valhalla, New York, United States|Durham, North Carolina, United States|Akron, Ohio, United States|Cincinnati, Ohio, United States|Toledo, Ohio, United States|Oklahoma City, Oklahoma, United States|Oklahoma City, Oklahoma, United States|Tulsa, Oklahoma, United States|Hershey, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Charleston, South Carolina, United States|Knoxville, Tennessee, United States|Austin, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Charlottesville, Virginia, United States|Seattle, Washington, United States|Madison, Wisconsin, United States|Brisbane, Queensland, Australia|Chermside, Queensland, Australia|South Brisbane, Queensland, Australia|Adelaide, South Australia, Australia|Clayton, Victoria, Australia|Parkville, Victoria, Australia|Nedlands, Western Australia, Australia|St. John's, Newfoundland and Labrador, Canada|Hamilton, Ontario, Canada|London, Ontario, Canada|Montreal, Quebec, Canada|Copenhagen, Denmark|München, Bayern, Germany|Frankfurt, Hessen, Germany|Leipzig, Sachsen, Germany|Berlin, Germany|Haifa, Israel|Jerusalem, Israel|Petach Tikva, Israel|Tel Hashomer, Israel|Oslo, Norway|Göteborg, Sweden|Lund, Sweden|Uppsala, Sweden|Cambridge, Cambridgeshire, United Kingdom|Southampton, Hampshire, United Kingdom|Belfast, North Ireland, United Kingdom|Birmingham, West Midlands, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00645788"
1168,"NCT00640315","Single Dose Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertension.",,"Completed","Has Results","Hypertension, Pulmonary|Pulmonary Disease, Chronic Obstructive","Drug: Riociguat (Adempas, BAY63-2521) 1.0 mg|Drug: Riociguat (Adempas, BAY63-2521) 2.5 mg","Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Mean Pulmonary Artery Pressure (PAPmean)|Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Pulmonary Vascular Resistance (PVR)|Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC) of Riociguat and Metabolite M1 After Single Dose of Riociguat|Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity Divided by Dose (AUC/D) of Riociguat and Metabolite M1 After Single Dose of Riociguat|Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity Divided by Dose Per kg Body Weight (AUCnorm) of Riociguat and Metabolite M1 After Single Dose of Riociguat|Maximum Drug Concentration in Plasma (Cmax) of Riociguat and Metabolite M1 After Single Dose of Riociguat|Maximum Drug Concentration in Plasma Divided by Dose (Cmax/D) of Riociguat and Metabolite M1 After Single Dose of Riociguat|Maximum Drug Concentration in Plasma Divided by Dose Per kg Body Weight (Cmax,Norm) of Riociguat and Metabolite M1 After Single Dose of Riociguat|Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Mean Right Atrial Pressure (RAPmean)|Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Systolic Pulmonary Artery Pressure (PAPsyst)|Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Diastolic Pulmonary Artery Pressure (PAPdiast)|Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Pulmonary Capillary Wedge Pressure (PCWP)|Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Heart Rate (HR)|Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Systolic Blood Pressure (SBP)|Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Diastolic Blood Pressure (DBP)|Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Mean Arterial Pressure (MAP)|Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Cardiac Output (CO)|Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Pulmonary Vascular Resistance Index (PVRI)|Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Systemic Vascular Resistance (SVR)|Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Systemic Vascular Resistance Index (SVRI)|Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Cardiac Index|Blood Gas Analysis - Percentage Change From Baseline at 2 Hours Post Dose of Arterial Partial Oxygen Pressure (PaO2)|Blood Gas Analysis - Percentage Change From Baseline at 2 Hours Post Dose of Arterial Partial Pressure of Carbon Dioxide (PaCO2)|Blood Gas Analysis - Percentage Change From Baseline at 2 Hours Post Dose of Venous Oxygen Pressure (PvO2)|Blood Gas Analysis - Percentage Change From Baseline at 2 Hours Post Dose of Arterial Oxygen Saturation (SaO2)|Blood Gas Analysis - Percentage Change From Baseline at 2 Hours Post Dose of Venous Oxygen Saturation (SvO2)|Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Forced Expiratory Volume in 1 Second (FEV1)|Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Percent of Predicted FEV1|Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Forced Vital Capacity (FVC)|Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Percent of Predicted FVC|Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of FEV1/FVC|Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Total Lung Capacity (TLC)|Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Percent of Predicted TLC|Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Residual Volume (RV)|Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Percent of Predicted RV|Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Maximal Expiratory Flow at 75% of Expiratory Vital Capacity (MEF75)|Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Maximal Expiratory Flow at 50% of Expiratory Vital Capacity (MEF50)|Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Maximal Expiratory Flow at 25% of Expiratory Vital Capacity (MEF25)|Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Total Airway Resistance (Raw)|Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Vital Capacity (VC)|Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Percent of Predicted VC|Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)|Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Total Lung Capacity at the Time When the DLCO is Measured (Alveolar Volume, VA)|Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Specific Diffusing Capacity|Multiple Inert Gas Elimination Technique (MIGET) Analysis - Change From Baseline at 1 Hour Post Dose of Total Ventilation (V)|Multiple Inert Gas Elimination Technique (MIGET) Analysis - Change From Baseline at 1 Hour Post Dose of Total Perfusion (Q)|Multiple Inert Gas Elimination Technique (MIGET) Analysis - Change From Baseline at 1 Hour Post Dose of Dead Space Ventilation|Multiple Inert Gas Elimination Technique (MIGET) Analysis - Change From Baseline at 1 Hour Post Dose of Low V/Q Perfusion|Multiple Inert Gas Elimination Technique (MIGET) Analysis - Change From Baseline at 1 Hour Post Dose of Normal V/Q Perfusion|Multiple Inert Gas Elimination Technique (MIGET) Analysis - Change From Baseline at 1 Hours Post Dose of Ventilation-perfusion Distribution Presented as Standard Deviation (SD) of Perfusion|Multiple Inert Gas Elimination Technique (MIGET) Analysis - Change From Baseline at 1 Hour Post Dose of Ventilation-perfusion Distribution Presented as Standard Deviation (SD) of Ventilation|Multiple Inert Gas Elimination Technique (MIGET) Analysis - Change From Baseline at 1 Hour Post Dose of Intrapulmonary Shunt Flow|Time to Reach Maximum Drug Concentration in Plasma (Tmax) of Riociguat and Metabolite M1 After Single Dose of Riociguat|Half-life Associated With the Terminal Slope (t1/2) of Riociguat and Metabolite M1 After Single Dose of Riociguat|Mean Residence Time (MRT) of Riociguat and Metabolite M1 After Single Dose of Riociguat|Area Under the Plasma Concentration Verse Time Curve From Zero to the Last Data Point (AUC0-tn) of Riociguat and Metabolite M1 After Single Dose of Riociguat","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","23","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12915|2007-003919-31","August 2008","September 2009","September 2009","March 21, 2008","February 28, 2014","December 28, 2016","Heidelberg, Baden-Württemberg, Germany|Löwenstein, Baden-Württemberg, Germany|München, Bayern, Germany|Bad Nauheim, Hessen, Germany|Gießen, Hessen, Germany|Greifswald, Mecklenburg-Vorpommern, Germany|Dresden, Sachsen, Germany",,"https://ClinicalTrials.gov/show/NCT00640315"
1169,"NCT00637377","Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)","VIEW 2","Completed","Has Results","Macular Degeneration","Drug: Ranibizumab|Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)","Percentage of Participants Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF)|Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by ETDRS Letter Score at Week 52 - LOCF|Percentage of Participants Who Gained at Least 15 Letters of Vision in the ETDRS Letter Score in the Study Eye at Week 52 - LOCF|Mean Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Total Score at Week 52 - LOCF|Mean Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 52 - LOCF","Bayer|Regeneron Pharmaceuticals","All","50 Years and older   (Adult, Older Adult)","Phase 3","1240","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","91689|2007-000583-25","April 2008","September 2010","August 2011","March 18, 2008","January 23, 2012","December 12, 2014","Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Rosario, Santa Fe, Argentina|Córdoba, Argentina|Chatswood, New South Wales, Australia|Sydney, New South Wales, Australia|Westmead, New South Wales, Australia|East Melbourne, Victoria, Australia|Parkville, Victoria, Australia|Nedlands, Western Australia, Australia|Parramatta, Australia|Innsbruck, Austria|Linz, Austria|Wien, Austria|Liege, Belgium|Ribeirão Preto, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|Minas Gerais, Brazil|Sao Paulo, Brazil|Medellín, Antioquia, Colombia|Cali, Cauca, Colombia|Bogota, Distrito Capital de Bogotá, Colombia|Brno, Czech Republic|Olomouc, Czech Republic|Praha 10, Czech Republic|Praha 4, Czech Republic|Usti nad Labem, Czech Republic|Paris, Cedex 12, France|Nantes, Cedex 1, France|Besancon, France|Bordeaux, France|Dijon, France|Lyon, France|Lyon, France|Marseille, France|Paris, France|Paris, France|Freiburg, Baden-Württemberg, Germany|Heidelberg, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|München, Bayern, Germany|Regensburg, Bayern, Germany|Darmstadt, Hessen, Germany|Aachen, Nordrhein-Westfalen, Germany|Bonn, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Ludwigshafen, Rheinland-Pfalz, Germany|Mainz, Rheinland-Pfalz, Germany|Homburg, Saarland, Germany|Dresden, Sachsen, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Kiel, Schleswig-Holstein, Germany|Lübeck, Schleswig-Holstein, Germany|Berlin, Germany|Hamburg, Germany|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Veszprem, Hungary|Ahemedabad - 4, Gujrat, India|Wadala, Mumbai, Maharashtra, India|Chennai, Tamil Nadu, India|Coimbatore, Tamil Nadu, India|Madurai, Tamil Nadu, India|Pondicherry, Tamil Nadu, India|Bangalore, India|Chandigarh, India|Hyderabad, India|Kerala, India|Kolkata, India|Mumbai, India|New Delhi, India|New Delhi, India|Orissa, India|Afula, Israel|Beer Sheva, Israel|Haifa, Israel|Jerusalem, Israel|Kfar Saba, Israel|Petach Tikva, Israel|Rehovot, Israel|Tel Aviv, Israel|Tel Hashomer, Israel|Zrifin, Israel|Ancona, Italy|Bari, Italy|Catania, Italy|Genova, Italy|Milano, Italy|Milano, Italy|Milano, Italy|Padova, Italy|Roma, Italy|Roma, Italy|Roma, Italy|Torino, Italy|Udine, Italy|Varese, Italy|Verona, Italy|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Urayasu, Chiba, Japan|Maebashi, Gunma, Japan|Sapporo, Hokkaido, Japan|Kita, Kagawa, Japan|Hirakata, Osaka, Japan|Suita, Osaka, Japan|Otsu, Shiga, Japan|Chiyoda-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Fukuoka, Japan|Fukushima, Japan|Kagoshima, Japan|Kyoto, Japan|Seongnam, Gyeonggido, Korea, Republic of|Incheon, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Riga, Latvia|Riga, Latvia|Riga, Latvia|Mexico City, Distrito Federal, Mexico|Zapopan, Jalisco, Mexico|Metepec, México, Mexico|Monterrey, Nuevo Leon, Mexico|Monterrey, Nuevo Leon, Mexico|Chihuahua, Mexico|Mexico City, Mexico|México D.F., Mexico|Leiden, ZA, Netherlands|Amsterdam, Netherlands|Groningen, Netherlands|Nijmegen, Netherlands|Rotterdam, Netherlands|Bydgoszcz, Poland|Gdansk, Poland|Katowice, Poland|Poznan, Poland|Warszaa, Poland|Warszawa, Poland|Wroclaw, Poland|Coimbra, Portugal|Porto, Portugal|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|Banska Bystrica, Slovakia|Bratislava, Slovakia|Santiago de Compostela, A Coruña, Spain|Oviedo, Asturias, Spain|Pamplona, Navarra, Spain|Alicante, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Malaga, Spain|Sevilla, Spain|Sevilla, Spain|Valencia, Spain|Valencia, Spain|Valladolid, Spain|Linköping, Sweden|Stockholm, Sweden|Örebro, Sweden|Basel, Switzerland|Bern, Switzerland|Genève, Switzerland|Zürich, Switzerland|Southampton, Hampshire, United Kingdom|Camberley, Surrey, United Kingdom|Aberdeen, United Kingdom|Belfast, United Kingdom|Birmingham, United Kingdom|Liverpool, United Kingdom|London, United Kingdom|London, United Kingdom|Plymouth, United Kingdom|Torquay, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00637377"
1170,"NCT00632814","Russian Kogenate Pediatric Study",,"Completed","Has Results","Hemophilia A","Drug: rFVIII-FS (Kogenate FS, BAY14-2222) 70 IU/kg, dosing once per week|Drug: rFVIII-FS (Kogenate FS, BAY14-2222), 70 IU/kg twice per week (30 IU/kg + 40 IU/kg)|Drug: rFVIII-FS (Kogenate FS, BAY14-2222) 75 IU/kg, dosing three times per week (3 x 25 IU/kg)","Percentage of Participants With Less Than 2 Joint Bleeds During the 9-month Treatment Period|Number of Bleeds Per Participant During the 9-month Treatment Period|Number of Participants With Bleeding Events During the 9-month Treatment Period|Number of Participants With Joint Bleeds During the 9-month Treatment Period|Number of Participants in Each Group at the End of the Study|Actual Monthly rFVIII-FS Consumption|Change From Baseline in Stockholm Hemophilia Joint Score at 9 Months of Treatment|Haemo-QoL Standardized Total Score at 9 Months of Treatment (Completed by Participants in the Total Group)|Haemo-QoL Standardized Total Score (Completed by Parents/Caregivers in the Total Group) at 9 Months of Treatment","Bayer","Male","1 Year to 12 Years   (Child)","Phase 4","32","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12684|2014-005253-39","June 2007","September 2009","September 2009","March 11, 2008","February 8, 2011","July 1, 2015","Ekaterinburg, Russian Federation|Kirov, Russian Federation|Moscow, Russian Federation|St. Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT00632814"
1171,"NCT00631969","Vardenafil ODT Versus Placebo in Males With Erectile Dysfunction",,"Completed","Has Results","Erectile Dysfunction","Drug: Vardenafil ODT (STAXYN, BAY38-9456)|Drug: Placebo","Change From Baseline in International Index of Erectile Function (IIEF-EF Sub-Score) at 12 Weeks or LOCF|Change in Percentage From Baseline in Success of Penetration at 12 Weeks|Change From Baseline in Success of Erection Maintenance at 12 Weeks|Percentage of Subjects Achieving ""Back to Normal"" Erectile Function|Change in Percentage From Baseline in Ability to Obtain an Erection at 12 Weeks|Change in Percentage From Baseline in Satisfaction With the Hardness of Erection at 12 Weeks|Change in Percentage From Baseline in Overall Satisfaction at 12 Weeks|Change in Percentage From Baseline in Ability to Ejaculate at 12 Weeks|Number of Sexual Attempts Till First Successful Attempt|Change From Baseline in Ease With Erection at 12 Weeks or LOCF|Change From Baseline in Erectile Function Satisfaction at 12 Weeks or LOCF|Change From Baseline in Pleasure of Sexual Activity at 12 Weeks or LOCF|Change From Baseline in Satisfaction With Orgasm at 12 Weeks or LOCF|Change From Baseline in Confidence for Completion at 12 Weeks or LOCF|Satisfaction With Medication at Week 12 or LOCF|Patient Self Reported Improvement of Erectile Function Under Treatment Using a Categorical Rating Scale|Pharmacokinetics Measured as Area Under Curve (AUC) of Vardenafil in Plasma|Pharmacokinetics Measured as Maximum Concentration (Cmax) of Vardenafil in Plasma|Pharmacokinetics Measured as Area Under Curve (AUC) of Metabolite M-1 (BAY44-5576) in Plasma|Pharmacokinetics Measured as Maximum Concentration (Cmax) of Metabolite M-1 (BAY44-5576) in Plasma","Bayer|GlaxoSmithKline|Schering-Plough","Male","18 Years and older   (Adult, Older Adult)","Phase 3","362","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","12093|2008-000536-40","April 2008","January 2009","January 2009","March 10, 2008","January 21, 2011","December 30, 2014","Antwerpen, Belgium|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Genk, Belgium|Gent, Belgium|Liege, Belgium|Lille, France|Lyon Cedex, France|Lyon, France|Marseille, France|Marseille, France|Mont-de-marsan, France|Paris, France|München, Bayern, Germany|Weiden, Bayern, Germany|Osnabrück, Niedersachsen, Germany|Mönchengladbach, Nordrhein-Westfalen, Germany|Mülheim, Nordrhein-Westfalen, Germany|Bautzen, Sachsen, Germany|Leipzig, Sachsen, Germany|Meißen, Sachsen, Germany|Hamburg, Germany|Hamburg, Germany|Arnhem, Netherlands|Deurne, Netherlands|Leiden, Netherlands|Losser, Netherlands|Maastricht, Netherlands|Nijverdal, Netherlands|Centurion, Gauteng, South Africa|Johannesburg, Gauteng, South Africa|Johannesburg, Gauteng, South Africa|Krugersdorp, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Durban, KwaZulu Natal, South Africa|Durban, KwaZulu Natal, South Africa|Durban, Kwazulu-Natal, South Africa|Cape Town, Western Cape, South Africa|Cape Town, Western Cape, South Africa|Alicante, Spain|Barcelona, Spain|Barcelona, Spain|La Laguna, Spain|Valencia, Spain|Vigo, Spain",,"https://ClinicalTrials.gov/show/NCT00631969"
1172,"NCT00631124","A Study to Evaluate Inhibition of Ovulation of Two Oral Estrogen/Progestogen Regimens in Healthy, Young Females Over a Period of 3 Treatment Cycles",,"Completed","No Results Available","Contraception","Drug: BAY86-4891 (Estradiol / Drospirenone)","The primary efficacy variable will be the proportion of volunteers with ovulation in at least one of the treatment cycles 2 and 3, based on the binary variable ovulation (i.e. Hoogland score 6) with the levels yes and no|Assessment of ovarian activity in treatment cycles 2 and 3|Course of gonadotropins (FSH, LH)|Endometrial growth|Pharmacokinetics of estrogen and progestin in treatment cycle 3","Bayer","Female","18 Years to 35 Years   (Adult)","Phase 2","103","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","91697|2007-004544-73|311623","February 2008","October 2008","December 2008","March 7, 2008",,"December 2, 2014","Berlin, Germany|Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT00631124"
1173,"NCT00629837","Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980",,"Completed","No Results Available","Hemophilia A","Biological: Recomb. Factor VIII (Kogenate FS Liposome, BAY79-4980)|Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)","To determine the pk profile after single administration of two doses of BAY 79-4980 (high and low: 35 IU FVIII/Kg reconstituted in 22 mg and 13 mg of liposomes/kg, respectively) compared to rFVIII-FS (35 IU/Kg reconstituted in 2.5 mL WFI/1000 IU) in PTPs|To determine the infusion tolerability of both BAY 79-4980 doses, by evaluation of vital signs and adverse events|To determine the safety of both BAY 79-4980 doses by measuring the effects on laboratory parameters - especially the lipid profile and adverse events|To determine the pk characteristics of liposomes - esp body clearance by measuring the major liposome component 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (POPC) and the non-biological liposome component, MPEG 2000 DSPE, as surrogate marker|To determine the activity of rFVIII over time (as determined by thrombin generation assay and the rotation thromboelastography [RoTEG] assay) for both doses of BAY 79-4980 compared to rFVIII-FS|Additional analyses of the number and timing of spontaneous bleeds after each study treatment will be assessed","Bayer","Male","12 Years to 60 Years   (Child, Adult)","Phase 1","27","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","11876|LipLong","September 2005",,"March 2006","March 6, 2008",,"November 18, 2014","Davis, California, United States|Orange, California, United States",,"https://ClinicalTrials.gov/show/NCT00629837"
1174,"NCT00625378","Sorafenib Long Term Extension Program","STEP","Active, not recruiting","No Results Available","Neoplasms","Drug: Sorafenib (Nexavar, BAY43-9006)","Long term safety of patients coming from completed sorafenib trials.","Bayer|ICON Clinical Research","All","16 Years and older   (Child, Adult, Older Adult)","Phase 3","206","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12311|2007-002604-17","December 21, 2007","September 30, 2020","September 30, 2020","February 28, 2008",,"January 3, 2020","Los Angeles, California, United States|New Haven, Connecticut, United States|Philadelphia, Pennsylvania, United States|San Antonio, Texas, United States|Randwick, New South Wales, Australia|Bruxelles - Brussel, Belgium|Charleroi, Belgium|Sao Paulo, Brazil|Plovdiv, Bulgaria|Varna, Bulgaria|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Guangzhou, Guangdong, China|Xi'an, Shanxi, China|Hangzhou, Zhejiang, China|Beijing, China|Shanghai, China|Floridablanca, Santander, Colombia|Bordeaux, France|Gauting, Bayern, Germany|Regensburg, Bayern, Germany|Essen, Nordrhein-Westfalen, Germany|Grosshansdorf, Schleswig-Holstein, Germany|Berlin, Germany|Hamburg, Germany|Hong Kong, Hong Kong|Bologna, Emilia-Romagna, Italy|Reggio Emilia, Emilia-Romagna, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Pavia, Lombardia, Italy|Torino, Piemonte, Italy|Pisa, Toscana, Italy|Pisa, Toscana, Italy|Siena, Toscana, Italy|Perugia, Umbria, Italy|Daegu, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Auckland, New Zealand|Gdansk, Poland|Poznan, Poland|Szczecin, Poland|Warszawa, Poland|Warszawa, Poland|Wroclaw, Poland|Oviedo, Asturias, Spain|Alicante, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Valencia, Spain|Kaohsiung, Taiwan|Taichung, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Kiev, Ukraine|Southampton, Hampshire, United Kingdom|Maidstone, Kent, United Kingdom|Cardiff, South Glamorgan, United Kingdom|Sutton, Surrey, United Kingdom|Glasgow, United Kingdom|London, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00625378"
1175,"NCT00624130","Yasmin 20 Cycle Control - Yasmin 20 Versus Mercilon in Healthy Female Volunteers",,"Completed","No Results Available","Contraception","Drug: Yasmin 20|Drug: Mercilon","Cycle control and bleeding pattern|Pearl index|Laboratory tests|Adverse Events|General Physical and gynecological examinations|Vital signs|Body weight","Bayer","Female","18 Years to 35 Years   (Adult)","Phase 3","453","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","91352|308020","March 2004",,"June 2005","February 26, 2008",,"December 31, 2014","Horn, Austria|Leibnitz, Austria|Moedling, Austria|St. Poelten, Austria|Wien, Austria|Woergl, Austria|Paernu, Estonia|Talinn, Estonia|Tartu, Estonia|Helsinki, Finland|Helsinki, Finland|Tampere, Finland|Turku, Finland|Kaunas, Lithuania|Kaunas, Lithuania|Vilnius, Lithuania|Vilnius, Lithuania",,"https://ClinicalTrials.gov/show/NCT00624130"
1176,"NCT00623727","BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A",,"Terminated","Has Results","Hemophilia A","Biological: rFVIII-FS/pegylated liposomes (BAY79-4980)|Biological: rFVIII-FS/WFI (BAY14-2222)","Percentage of Participants With Less Than 9 Total Bleeds Per Year|Percentage of Participants With Less Than 5 Joint Bleeds Per Year|Number of Joint Bleeds Per Participant Per Year in Responders","Bayer","Male","12 Years to 70 Years   (Child, Adult, Older Adult)","Phase 2","143","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12781|2007-003718-32","June 2008","April 2010","October 2010","February 26, 2008","August 17, 2011","July 15, 2013","Orange, California, United States|Sacramento, California, United States|San Francisco, California, United States|Aurora, Colorado, United States|New Orleans, Louisiana, United States|Boston, Massachusetts, United States|Detroit, Michigan, United States|East Lansing, Michigan, United States|Rochester, Minnesota, United States|Kansas City, Missouri, United States|Las Vegas, Nevada, United States|Albuquerque, New Mexico, United States|Buffalo, New York, United States|Rochester, New York, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Houston, Texas, United States|Milwaukee, Wisconsin, United States|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Rosario, Santa Fe, Argentina|Perth, Western Australia, Australia|Graz, Austria|Wien, Austria|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Leuven, Belgium|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Halifax, Nova Scotia, Canada|Hamilton, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Santiago de Chile, Chile|Santiago, Chile|Zagreb, Croatia|Århus N, Denmark|Tallinn, Estonia|Tallin, Estonia|Besancon, France|Le Kremlin-bicetre, France|Lyon Cedex, France|Marseille, France|Montpellier Cedex, France|Paris, France|Paris, France|Rennes Cedex, France|Strasbourg, France|Bonn, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Berlin, Germany|Tel Hashomer, Israel|Catania, Italy|Firenze, Italy|Milano, Italy|Napoli, Italy|Napoli, Italy|Torino, Italy|Klaipeda, Lithuania|Vilnius, Lithuania|Groningen, Netherlands|Nijmegen, Netherlands|Utrecht, Netherlands|Auckland, New Zealand|Christchurch, New Zealand|Oslo, Norway|Gdansk, Poland|Krakow, Poland|Lodz, Poland|Poznan, Poland|Warszawa, Poland|Timisoara, Timis, Romania|Brasov, Romania|Bucharest, Romania|Johannesburg, Gauteng, South Africa|Sevilla, Andalucía, Spain|Oviedo, Asturias, Spain|Sta. Cruz de Tenerife, Santa Cruz de Tenerife, Spain|Barcelona, Spain|Madrid, Spain|Valencia, Spain|Bern, Switzerland|Changhua, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Adana, Turkey|Antalya, Turkey|Izmir, Turkey|Cambridge, Cambridgeshire, United Kingdom|Cardiff, South Glamorgan, United Kingdom|Sheffield, South Yorkshire, United Kingdom|Birmingham, United Kingdom|London, United Kingdom|Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00623727"
1177,"NCT00623480","Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment","SPINART","Completed","Has Results","Hemophilia A","Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)","Bleeding Frequency (Number of Total Bleeds)|Change From Baseline to 3 Years in the MRI (Magnetic Resonance Imaging) Scale.|Change From Baseline to 3 Years in the Colorado Adult Joint Assessment Scale","Bayer","Male","12 Years to 50 Years   (Child, Adult)","Phase 3","84","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12800|2008-000985-21","March 2008","September 2011","November 2013","February 26, 2008","August 7, 2013","November 17, 2014","Tucson, Arizona, United States|Little Rock, Arkansas, United States|Orange, California, United States|Sacramento, California, United States|Aurora, Colorado, United States|Washington, District of Columbia, United States|Orlando, Florida, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Chicago, Illinois, United States|Indianapolis, Indiana, United States|Iowa City, Iowa, United States|Louisville, Kentucky, United States|Boston, Massachusetts, United States|Detroit, Michigan, United States|Minneapolis, Minnesota, United States|Kansas City, Missouri, United States|Las Vegas, Nevada, United States|Newark, New Jersey, United States|New York, New York, United States|New York, New York, United States|Cleveland, Ohio, United States|Hershey, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Knoxville, Tennessee, United States|Houston, Texas, United States|Salt Lake City, Utah, United States|Milwaukee, Wisconsin, United States|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Rosario, Santa Fe, Argentina|Plovdiv, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Timisoara, Timis, Romania|Brasov, Romania|Bucharest, Romania|Bucharest, Romania|Constanta, Romania",,"https://ClinicalTrials.gov/show/NCT00623480"
1178,"NCT00623467","Safety and Efficacy of Gadobutrol 1.0 Molar ( Gadavist ) in Patients for Central Nervous System (CNS) Imaging",,"Completed","Has Results","Central Nervous System Diseases","Drug: Gadobutrol (Gadavist, Gadovist, BAY86-4875)","Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Combined Unenhanced/Gadobutrol-enhanced Magnetic Resonance Imaging (MRI) Compared to Unenhanced MRI by Blinded Reader 1 (BR1)|Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Combined Unenhanced/Gadobutrol-enhanced Magnetic Resonance Imaging (MRI) Compared to Unenhanced MRI by Blinded Reader 2 (BR2)|Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Combined Unenhanced/Gadobutrol-enhanced Magnetic Resonance Imaging (MRI) Compared to Unenhanced MRI by Blinded Reader 3 (BR3)|Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Combined Unenhanced/Gadobutrol-enhanced Magnetic Resonance Imaging (MRI) Compared to Unenhanced MRI by Average Reader (AR)|Number of Lesions for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Blinded Readers|Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Clinical Investigator|Number of Lesions for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Clinical Investigator|Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Lesions for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Blinded Reader 1 (BR1)|Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Lesions for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Blinded Reader 2 (BR2)|Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Lesions for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Blinded Reader 3 (BR3)|Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Lesions for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Average Reader (AR)|Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Normal Structures for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Blinded Reader 1 (BR1)|Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Normal Structures for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Blinded Reader 2 (BR2)|Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Normal Structures for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Blinded Reader 3 (BR3)|Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Normal Structures for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Average Reader (AR)|Scores for Contrast Enhancement for Lesions for Combined Unenhanced/Gadobutrol-enhanced MRI by Clinical Investigator|Scores for Two Visualization Parameters (Border Delineation and Internal Morphology) for Lesions for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Clinical Investigator|Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Normal Structures for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Clinical Investigator|Percentage (Per.) of the Exact Diagnostic Matches (Accuracy of Diagnosis) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Majority Reader|Percentage (Per.) of the Exact Diagnostic Matches (Accuracy of Diagnosis) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Clinical Investigator|Accuracy of Detection of Normal/Abnormal Brain Tissue for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Majority Reader Using T1-weighted (T1w) Images|Sensitivity of Detection of Normal/Abnormal Brain Tissue for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Majority Reader Using T1-weighted (T1w) Images|Specificity of Detection of Normal/Abnormal Brain Tissue for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Majority Reader Using T1-weighted (T1w) Images|Accuracy of Detection of Malignant Lesions (ML) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Majority Reader|Sensitivity of Detection of Malignant Lesions (ML) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Majority Reader|Specificity of Detection of Malignant Lesions (ML) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Majority Reader|Accuracy of Detection of Malignant Lesions (ML) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Clinical Investigator|Sensitivity of Detection of Malignant Lesions (ML) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Clinical Investigator|Specificity of Detection of Malignant Lesions (ML) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Clinical Investigator|Diagnostic Confidence for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Average Reader|Diagnostic Confidence for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Clinical Investigator","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","343","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","91682","December 2007","December 2008","December 2008","February 26, 2008","October 6, 2011","February 10, 2014","HOPE Research Institute, LLC, Phoenix, Arizona, United States|Scottsdale Medical Imaging, Ltd., Scottsdale, Arizona, United States|Radiology Ltd., Tucson, Arizona, United States|Landmark Imaging Medical Group, Los Angeles, California, United States|Cedars- Sinai Medical Center, Los Angeles, California, United States|Sharp & Children's MRI Center, San Diego, California, United States|University of Florida - Jacksonville, Jacksonville, Florida, United States|University of South Florida, Tampa, Florida, United States|River Birch Research Alliance, LLC, Blue Ridge, Georgia, United States|Eisenhower Army Medical Center, Fort Gordon, Georgia, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Bio-Magnetic Resonance, Inc., Madison Heights, Michigan, United States|Maimonides Medical Center, Brooklyn, New York, United States|Mount Sinai Medical Center, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States|Hahnemann University Hospital, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Baylor College of Medicine, Houston, Texas, United States|Investigaciones Médicas, Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Milbet Diagnostico por Imagenes, Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Hospital Italiano Buenos Aires, Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Centro de Diagnóstico Dr. Enrique Rossi, Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Zhongda Hosp. affiliated of Southeast Univ., Nanjing, Jiangsu, China|The 1st Affiliated Hosp of the 4th Military Med Uni, Xi'an, Shaanxi, China|Chinese PLA General Hosp., Beijing, China|Affiliated Ruijin Hosp. Shanghai Jiaotong Univ. Med School, Shanghai, China|Fudan University Huashan Hospital, Shanghai, China|Fundación Instituto de Alta tecnología médica de Antioquia, Medellín, Antioquia, Colombia|Fundación Santa Fe de Bogotá - Hospital Universitario, Bogotá, Cundinamarca, Colombia|The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, Korea, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00623467"
1179,"NCT00622479","Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia.",,"Terminated","No Results Available","Carcinoma, Renal Cell","Drug: Sorafenib (Nexavar, BAY43-9006)","To evaluate a potential mechanism of hypophosphatemia related to sorafenib treatment based on measurement of phosphate regulating factors, peptides, and related laboratory variables|To assess the effect of sorafenib treatment on left ventricular ejection fraction (LVEF) and B-type Natriuretic Peptide (BNP) in plasma","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","12345","May 2008","October 2010","November 2010","February 25, 2008",,"December 18, 2014","Scottsdale, Arizona, United States|Jacksonville, Florida, United States|Maywood, Illinois, United States|Detroit, Michigan, United States|Rochester, Minnesota, United States|Hackensack, New Jersey, United States|Stony Brook, New York, United States",,"https://ClinicalTrials.gov/show/NCT00622479"
1180,"NCT00621673","Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia A",,"Terminated","No Results Available","Hemophilia A","Drug: Kogenate (BAY 14-2222)","To evaluate whether a switch of replacement therapy from an rFVIII produced in a CHO cell line to an rFVIII produced in a BHK cell line is associated with a risk of inhibitor formation.|To quantify the risk of inhibitor formation, to assess the efficacy of the rFVIII-FS while on regular replacement therapy and to assess the quality-of-life (QoL) before and after the study.","Bayer","Male","12 Years to 60 Years   (Child, Adult)","Phase 4","1","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","12112","May 2006",,"October 2006","February 22, 2008",,"December 18, 2014","Detroit, Michigan, United States|Las Vegas, Nevada, United States",,"https://ClinicalTrials.gov/show/NCT00621673"
1181,"NCT00618982","Sorafenib Dose Escalation in Renal Cell Carcinoma",,"Completed","Has Results","Carcinoma, Renal Cell","Drug: Sorafenib (Nexavar, BAY43-9006)","Best Response - mITT (Modified Intent-to-treat) Population|Tumor Response - ITT (Intent to Treat) Population|Pharmacokinetics (PK) Analysis - Area Under the Drug Concentration-time Curve From Time Zero to 10 Hours Postdose (AUC(0-10),ss)|Pharmacokinetics (PK) Analysis - Area Under the Drug Concentration-time Curve From Time Zero to 12 Hours Postdose (AUC(0-12),ss)|Pharmacokinetics (PK) Analysis - Maximum Observed Concentration in Plasma (Cmax)|Pharmacokinetics (PK) Analysis - Time to Maximum Concentration (Tmax)|Progression-free Survival (PFS)|Time to Progression (TTP)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","83","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12913|2007-004875-21","February 2008","April 2009","January 2011","February 20, 2008","May 27, 2010","December 24, 2015","Bordeaux, France|La Roche Sur Yon, France|Marseille, France|Nantes, France|Paris Cedex 10, France|Tours, France|Tübingen, Baden-Württemberg, Germany|Marburg, Hessen, Germany|Hannover, Niedersachsen, Germany|Mainz, Rheinland-Pfalz, Germany|Jena, Thüringen, Germany|Aviano, Pordenone, Italy|Milano, Italy|Pavia, Italy|Olsztyn, Poland|Warszawa, Poland|Warszawa, Poland|Wroclaw, Poland|Greater Manchester, Manchester, United Kingdom|Cardiff, South Glamorgan, United Kingdom|Glasgow, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00618982"
1182,"NCT00617903","Exploration of Safety and Efficacy of AzA 15% Foam Twice a Day in Rosacea",,"Completed","Has Results","Papulopustular Rosacea","Drug: Azelaic acid|Drug: Vehicle foam","Nominal Change From Baseline in Inflammatory Lesion (IL) Count (Sum of Papules and Pustules) Per Participant at End of Study (LOCF: Last Observation Carried Forward)|Percentage of Participants With Investigator's Global Assessment (IGA) Based Therapeutic Success at End of Study (LOCF)|Grouped Change From Baseline in Erythema Intensity Score at End of Study (LOCF)|Mean of Inflammatory Lesion Count Per Participant at Weeks 4, 8, 12 and End of Study (LOCF)|Nominal Change From Baseline in Inflammatory Lesion Count Per Participant at Weeks 4, 8 and 12|Percent Change From Baseline in Inflammatory Lesion Count Per Participant at Weeks 4, 8, 12 and End of Study (LOCF)|Percentage of Participants With Respective Disease Severity Measured by IGA Scores at Weeks 4, 8, 12 and End of Study (LOCF)|Change From Baseline in IGA Scores at Weeks 4, 8, 12 and End of Study (LOCF)|Percentage of Participants With Erythema Intensity Scores at Weeks 4, 8, 12 and End of Study (LOCF)|Change From Baseline in Erythema Intensity Scores at Weeks 4, 8, 12 and End of Study (LOCF)|Grouped Change From Baseline in Erythema Intensity Score at Weeks 4, 8 and 12|Percentage of Participants With Telangiectasia Intensity Scores at Weeks 4, 8, 12 and End of Study (LOCF)|Change From Baseline in Telangiectasia Intensity Scores at Weeks 4, 8, 12 and End of Study (LOCF)|Grouped Change From Baseline in Telangiectasia Intensity Scores at Weeks 4, 8, 12 and End of Study (LOCF)|Investigator's Rating of Overall Improvement at End of Study|Patients' Rating of Overall Improvement at End of Study|Patients' Opinion on Cosmetic Acceptability at End of Study|Percentage of Participants With IGA Based Therapeutic Success at Weeks 4, 8 and 12|Percentage of Participants With IGA Based Patient Response at Weeks 4, 8, 12 and End of Study (LOCF)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","83","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1402140","January 2008","June 2008","June 2008","February 18, 2008","July 4, 2013","January 31, 2014","Denver, Colorado, United States|Olathe, Kansas, United States|Henderson, Nevada, United States|Albuquerque, New Mexico, United States|Mason, Ohio, United States|Austin, Texas, United States|Norfolk, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00617903"
1183,"NCT00611845","Aprotinin US Special Access Protocol",,"No longer available","No Results Available","Postoperative Hemorrhage","Drug: Aprotinin (Trasylol, BAYA0128)",,"Bayer","All","18 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access",,"13087",,,,"February 11, 2008",,"June 23, 2014","Decatur, Alabama, United States|Glendale, California, United States|Pismo Beach, California, United States|Santa Monica, California, United States|Ventura, California, United States|Fort Wayne, Indiana, United States|Edgewood, Kentucky, United States|New Brunswick, New Jersey, United States|Asheville, North Carolina, United States|Medford, Oregon, United States|Portland, Oregon, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Knoxville, Tennessee, United States|Lynchburg, Virginia, United States|Milwaukee, Wisconsin, United States|Wausau, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00611845"
1184,"NCT00610194","Phase 1 Dose-escalation PK/PD Trial in Advanced Cancer Patients",,"Completed","No Results Available","Advanced Cancer","Drug: RDEA119","Safety will be assessed as adverse and drug related events, clinical laboratory test results (hematology, chemistry, coagulation, and urinalysis), vital signs, 12-lead electrocardiograms (ECGs), and physical examination|Pharmacokinetics and Pharmacodynamics","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","69","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15505|RDEA119-101","November 2007","November 2010","August 2012","February 7, 2008",,"January 1, 2015","Scottsdale, Arizona, United States|Aurora, Colorado, United States|Buffalo, New York, United States",,"https://ClinicalTrials.gov/show/NCT00610194"
1185,"NCT00606125","Sorafenib/ Carboplatin/ Paclitaxel in Patients With Solid Tumors",,"Completed","No Results Available","Neoplasms","Drug: Nexavar (Sorafenib, BAY43-9006)","Safety and pharmacokinetics of the three agents: sorafenib administered daily, without a break in dosing, in combination with carboplatin and paclitaxel, administered every 3 weeks|To determine the safety profile and pharmacokinetics of oral sorafenib daily in combination with every 3-weekly carboplatin and paclitaxel.","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","16","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11988","May 2007","July 2008","February 2009","February 1, 2008",,"June 23, 2014","New Haven, Connecticut, United States|San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00606125"
1186,"NCT00606060","BAY14-2222 Continuous Infusion in Surgeries",,"Completed","No Results Available","Hemophilia","Drug: Kogenate (BAY14-2222)","efficacy of continuous infusion of recombinant Factor VIII - sucrose-formulated (rFVIII-FS) in the treatment of patients with hemophilia A|Evaluate the safety of rFVIII-FS.","Bayer","Male","12 Years to 65 Years   (Child, Adult, Older Adult)","Phase 3","15","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11486","July 2004",,"May 2005","February 1, 2008",,"April 13, 2010","Tel Hashomer, Israel",,"https://ClinicalTrials.gov/show/NCT00606060"
1187,"NCT00586521","BAY14-2222 Prophylaxis and Joint Function Improvement (Adults)",,"Completed","Has Results","Hematologic Disease|Hemophilia A","Drug: Kogenate (BAY14-2222)","Number of Joint Bleeds|Number of All Bleeds|Physical Assessment Compared to On-demand Treatment as Determined by the Gilbert Score|Quality of Life Compared to On-demand Treatment as Measured by the Haemo-QoL A Questionnaire","Bayer","Male","30 Years to 45 Years   (Adult)","Phase 4","20","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11859|2005-002757-45","February 2006","March 2008","March 2008","January 4, 2008","November 19, 2009","November 3, 2014","Aurora, Colorado, United States|Chapel Hill, North Carolina, United States|Houston, Texas, United States|Strasbourg, France|Firenze, Italy|Pavia, Italy|Roma, Italy|Sta. Cruz de Tenerife, Santa Cruz de Tenerife, Spain|Madrid, Spain|Cardiff, South Glamorgan, United Kingdom|Sheffield, South Yorkshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00586521"
1188,"NCT00586495","Long-term Extension From RCC Phase II (11515)",,"Completed","Has Results","Carcinoma, Renal Cell","Drug: Sorafenib (Nexavar, BAY43-9006)","Progression Free Survival (PFS)|Best Tumor Response|Overall Survival (OS)|Overall Response Duration|Time to Objective Response|Overall Disease Control","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","95","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12056","December 2005","June 2008","July 2008","January 4, 2008","February 2, 2010","December 13, 2013","Asahi, Chiba, Japan|Matsuyama, Ehime, Japan|Kurume, Fukuoka, Japan|Isesaki, Gunma, Japan|Maebashi, Gunma, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sunagawa, Hokkaido, Japan|Tsukuba, Ibaraki, Japan|Morioka, Iwate, Japan|Tsu, Mie, Japan|Natori, Miyagi, Japan|Kashihara, Nara, Japan|Kurashiki, Okayama, Japan|Osakasayama, Osaka, Japan|Suita, Osaka, Japan|Hidaka, Saitama, Japan|Irima-gun, Saitama, Japan|Tokorozawa, Saitama, Japan|Hamamatsu, Shizuoka, Japan|Sunto, Shizuoka, Japan|Utsunomiya, Tochigi, Japan|Arakawa-ku, Tokyo, Japan|Bunkyo-ku, Tokyo, Japan|Chuo-ku, Tokyo, Japan|Itabashi-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Ube, Yamaguchi, Japan|Akita, Japan|Chiba, Japan|Chiba, Japan|Fukuoka, Japan|Fukuoka, Japan|Kagoshima, Japan|Kyoto, Japan|Kyoto, Japan|Okayama, Japan|Osaka, Japan|Tokushima, Japan|Yamagata, Japan",,"https://ClinicalTrials.gov/show/NCT00586495"
1189,"NCT00586105","Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC)",,"Completed","Has Results","Carcinoma, Renal Cell","Drug: Sorafenib (Nexavar, BAY43-9006)","Pharmacokinetics Measured as Area Under Curve (AUC[0-12h])|Pharmacokinetics Measured as Concentration (Cmax at Tmax and Cmin at Tmin)|Pharmacokinetics Measured as Concentration (Cmax Normalized at Tmax and Cmin Normalized at Tmin)|Progression Free Survival (PFS)|Overall Survival (OS)|Time to Progression (TTP)|Disease Control (DC)|Overall Best Response|Overall Response Duration|Time to Objective Response","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","39","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11559","December 2005","May 2008","May 2008","January 4, 2008","October 1, 2010","April 16, 2014","Nanjing, Jiangsu, China|Beijing, China|Shanghai, China|Shanghai, China|Tainan, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT00586105"
1190,"NCT00571649","Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients","MAGELLAN","Completed","Has Results","Venous Thromboembolism","Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Enoxaparin|Drug: Rivaroxaban placebo|Drug: Enoxaparin placebo","Percentage of Participants With Composite Endpoint of Venous Thromboembolism [VTE] (Any Deep Vein Thrombosis [DVT], Non Fatal Pulmonary Embolism [PE]) and VTE-related Death up to Day 35 + 6 Days|Percentage of Participants With Composite Endpoint of VTE (Any DVT, Non Fatal PE) and VTE-related Death up to Day 10 + 5 Days|Percentage of Participants With Composite Endpoint of VTE (Any DVT, Non Fatal PE) and All-cause Mortality up to Day 35 + 6 Days|Percentage of Participants With Composite Endpoint of VTE (Any DVT, Non Fatal PE) and VTE-related Death up to Day 10 + 5 Days Per mITT Population|Percentage of Participants With VTE Combined With All-cause Mortality up to Day 10 + 5 Days|Percentage of Participants With Symptomatic VTE, Including and Excluding VTE-related Death up to Days 10, 35, and 90|Percentage of Participants With Net Clinical Benefit (Any DVT, Non-fatal PE, VTE-related Death, Plus Major and Clinically Relevant Non-major Bleeding Events) up to Day 35 + 6 Days|Percentage of Participants With Net Clinical Benefit (Any DVT, Non-fatal PE, VTE-related Death, Plus Major and Clinically Relevant Non-major Bleeding Events) up to Day 10 + 5 Days|Percentage of Participants With Major Vascular Events up to Days 10, 35, and 90|Percentage of Participants With Each Component of the Composite Endpoint of VTE (Any DVT, Non Fatal PE) and VTE-related Death up to Day 35 + 6 Days|Percentage of Participants With Each Component of the Composite Endpoint of VTE (Any DVT, Non Fatal PE) and VTE-related Death up to Day 10 + 5 Days|Percentage of Participants With All-cause Mortality up to Day 90 + 7 Days|Percentage of Participants With the Composite of Treatment Emergent Major Bleeding Events and Non-major Clinically Relevant Bleeding Events up to 2 Days After Last Intake of Any Study Medication (Day 35 + 6 Days)|Percentage of Participants With the Composite of Treatment Emergent Major Bleeding Events and Non-major Clinically Relevant Bleeding Events up to 2 Days After Last Application of a Study Medication Syringe (Day 10 + 5 Days)","Bayer|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","All","40 Years and older   (Adult, Older Adult)","Phase 3","8101","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","12839|2007-004614-14","December 2007","August 2010","November 2010","December 12, 2007","June 27, 2012","September 15, 2016","Birmingham, Alabama, United States|Birmingham, Alabama, United States|Dothan, Alabama, United States|Office of Dr. John Simmons, MD, Geneva, Alabama, United States|Mobile, Alabama, United States|Montgomery, Alabama, United States|Tuscaloosa, Alabama, United States|Tuscaloosa, Alabama, United States|Little Rock, Arkansas, United States|Chula Vista, California, United States|Duarte, California, United States|Encinitas, California, United States|Fountain Valley, California, United States|Fullerton, California, United States|Glendale, California, United States|Oceanside, California, United States|Pasadena, California, United States|Redlands, California, United States|Sacramento, California, United States|San Diego, California, United States|Santa Barbara, California, United States|Torrance, California, United States|Denver, Colorado, United States|Pueblo, Colorado, United States|Wheat Ridge, Colorado, United States|Farmington, Connecticut, United States|Newark, Delaware, United States|Washington, District of Columbia, United States|Aventura, Florida, United States|Boyton Beach, Florida, United States|Clearwater, Florida, United States|Delray Beach, Florida, United States|Ft. Lauderdale, Florida, United States|Hollywood, Florida, United States|Jupiter, Florida, United States|Miami Springs, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Pembroke Pines, Florida, United States|Port Charlotte, Florida, United States|Sarasota, Florida, United States|Vero Beach, Florida, United States|Atlanta, Georgia, United States|Decatur, Georgia, United States|Fort Gordon, Georgia, United States|Savannah, Georgia, United States|Idaho Falls, Idaho, United States|Chicago, Illinois, United States|Springfield, Illinois, United States|Anderson, Indiana, United States|Noblesville, Indiana, United States|Des Moines, Iowa, United States|Olathe, Kansas, United States|Lafayette, Louisiana, United States|New Orleans, Louisiana, United States|Shreveport, Louisiana, United States|Biddeford, Maine, United States|Rockport, Maine, United States|Baltimore, Maryland, United States|Baltimore, Maryland, United States|Framingham, Massachusetts, United States|Ann Arbor, Michigan, United States|Detroit, Michigan, United States|Detroit, Michigan, United States|Grand Rapids, Michigan, United States|Lansing, Michigan, United States|Petoskey, Michigan, United States|Pontiac, Michigan, United States|St. Clair Shores, Michigan, United States|Minneapolis, Minnesota, United States|Kansas City, Missouri, United States|St. Louis, Missouri, United States|St. Louis, Missouri, United States|Anaconda, Montana, United States|Great Falls, Montana, United States|Omaha, Nebraska, United States|Hackensack, New Jersey, United States|New Brunswick, New Jersey, United States|Somerville, New Jersey, United States|Summit, New Jersey, United States|Teaneck, New Jersey, United States|Brooklyn, New York, United States|Buffalo, New York, United States|Jamaica, New York, United States|New Hyde Park, New York, United States|New York, New York, United States|New York, New York, United States|Stony Brook, New York, United States|Valhalla, New York, United States|Durham, North Carolina, United States|Elizabeth City, North Carolina, United States|Greensboro, North Carolina, United States|Fargo, North Dakota, United States|Canton, Ohio, United States|Columbus, Ohio, United States|Maumee, Ohio, United States|Toledo, Ohio, United States|Bethlehem, Pennsylvania, United States|Camp Hill, Pennsylvania, United States|Danville, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Scranton, Pennsylvania, United States|Wilkes-Barre, Pennsylvania, United States|Charleston, South Carolina, United States|Memphis, Tennessee, United States|Nashville, Tennessee, United States|Corsicana, Texas, United States|Dallas, Texas, United States|Edinburg, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|McAllen, Texas, United States|San Antonio, Texas, United States|Ogden, Utah, United States|Richmond, Virginia, United States|Richmond, Virginia, United States|Everett, Washington, United States|Tacoma, Washington, United States|Clarksburg, West Virginia, United States|Avellaneda, Buenos Aires, Argentina|San Miguel, Buenos Aires, Argentina|Hospital de Agudos ""Dr. Carlos Bocalandro"", Tres de Febrero, Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Hospital Británico, Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Sanatorio Mitre, Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Vicente López, Argentina|Garran, Australian Capital Territory, Australia|Kogarah, New South Wales, Australia|Lismore, New South Wales, Australia|Sydney, New South Wales, Australia|Auchenflower, Queensland, Australia|Brisbane, Queensland, Australia|Brisbane, Queensland, Australia|Redcliffe, Queensland, Australia|Southport, Queensland, Australia|Woollongabba, Queensland, Australia|Adelaide, South Australia, Australia|Launceston, Tasmania, Australia|Box Hill, Victoria, Australia|Clayton, Victoria, Australia|Melbourne, Victoria, Australia|Melbourne, Victoria, Australia|Perth, Western Australia, Australia|Kittsee, Burgenland, Austria|Oberpullendorf, Burgenland, Austria|Wolfsberg, Kärnten, Austria|Linz, Oberösterreich, Austria|Gratwein, Steiermark, Austria|Graz, Steiermark, Austria|Hartberg, Steiermark, Austria|Leoben, Steiermark, Austria|Zams, Tirol, Austria|Innsbruck, Austria|Linz, Austria|Mürzzuschlag, Austria|St. Pölten, Austria|Wien, Austria|Wien, Austria|Wien, Austria|Aalst, Belgium|Brugge, Belgium|Bruxelles - Brussel, Belgium|Dendermonde, Belgium|Hasselt, Belgium|HUY, Belgium|Ieper, Belgium|Leuven, Belgium|Malmedy, Belgium|MOL, Belgium|Montigny S/sambre, Belgium|Mortsel, Belgium|Roeselare, Belgium|Sint-niklaas, Belgium|Tubize, Belgium|Turnhout, Belgium|Curitiba, Parana, Brazil|Porto Alegre, Rio Grande do Sul, Brazil|Campinas, Sao Paulo, Brazil|Santo Andre, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Pleven, Bulgaria|Ruse, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Stara Zagora, Bulgaria|Varna, Bulgaria|Veliko Tarnovo, Bulgaria|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Edmonton, Alberta, Canada|Edmonton, Alberta, Canada|Vancouver, British Columbia, Canada|Saint John, New Brunswick, Canada|Cobourg, Ontario, Canada|Ottawa, Ontario, Canada|Scarborough, Ontario, Canada|Toronto, Ontario, Canada|Hotel Dieu-Grace Hospital, Windsor, Ontario, Canada|Greenfield Park, Quebec, Canada|CHUM - Hopital Notre-Dame, Montreal, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Ste-Foy, Quebec, Canada|Quebec, Canada|Quebec, Canada|Santiago, Chile|Santiago, Chile|Viña del Mar, Chile|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Changsha, Hunan, China|Nanjing, Jiangsu, China|Nanjing, Jiangsu, China|Changchun, Jilin, China|Dalian, Liaoning, China|Shenyang, Liaoning, China|Shenyang, Liaoning, China|Shenyang, Liaoning, China|The 1st Affiliated Hosp of the 4th Military Med Uni, Xi'an, Shaanxi, China|1st Affiliated Hosp., Med College Xi'an Jiaotong Univ., Xi'an, Shaanxi, China|Chengdu, Sichuan, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijing Friendship Hosp., Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Chongqing, China|Chongqing, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|Medellín, Antioquia, Colombia|Bogotá, Distrito Capital de Bogotá, Colombia|Cali, Valle del Cauca, Colombia|Bogota, Colombia|Bogotá, Colombia|Cali, Colombia|Medellín, Colombia|Osijek, Croatia|Rijeka, Croatia|Zadar, Croatia|Zagreb, Croatia|Zagreb, Croatia|Brno, Czech Republic|Kutna Hora, Czech Republic|Nove Mesto na Morave, Czech Republic|Olomouc, Czech Republic|Plzen, Czech Republic|Praha 2, Czech Republic|Praha 2, Czech Republic|Praha 2, Czech Republic|Ricany, Czech Republic|Znojmo, Czech Republic|Esbjerg, Denmark|Frederiksberg C, Denmark|Kolding, Denmark|København NV, Denmark|København S, Denmark|Roskilde, Denmark|Tallinn, Estonia|Tallinn, Estonia|Tallinn, Estonia|Tartu, Estonia|Helsinki, Finland|Hämeenlinna, Finland|Jyväskylä, Finland|Lahti, Finland|Lappeenranta, Finland|Raisio, Finland|Turku, Finland|Turku, Finland|Arras, France|Besancon, France|Brest Cedex, France|Castelnau Le Lez, France|Clermont Ferrand, France|Colombes Cedex, France|Dijon, France|Lille, France|Lille, France|Limoges, France|Lomme, France|Lyon, France|Montpellier Cedex, France|Nice, France|Nimes, France|Paris, France|Paris, France|Paris, France|Paris, France|Pierre Benite, France|Reims, France|Roubaix, France|Saint Herblain Cedex, France|Saint-etienne, France|Strasbourg Cedex, France|Toulouse, France|TOURCOING cedex, France|Vandoeuvre Les Nancy, France|Bad Mergentheim, Baden-Württemberg, Germany|Esslingen, Baden-Württemberg, Germany|Heidelberg, Baden-Württemberg, Germany|Karlsbad, Baden-Württemberg, Germany|Weiden, Bayern, Germany|Beeskow, Brandenburg, Germany|Frankfurt/Oder, Brandenburg, Germany|Dortmund, Nordrhein-Westfalen, Germany|Jülich, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Leverkusen, Nordrhein-Westfalen, Germany|Mönchengladbach, Nordrhein-Westfalen, Germany|Neuss, Nordrhein-Westfalen, Germany|Oberhausen, Nordrhein-Westfalen, Germany|Paderborn, Nordrhein-Westfalen, Germany|Soest, Nordrhein-Westfalen, Germany|Stolberg, Nordrhein-Westfalen, Germany|Troisdorf, Nordrhein-Westfalen, Germany|Viersen, Nordrhein-Westfalen, Germany|Wuppertal, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Neuwied, Rheinland-Pfalz, Germany|Halle, Sachsen-Anhalt, Germany|Dresden, Sachsen, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Pirna, Sachsen, Germany|Berlin, Germany|Bremen, Germany|Elefsina, Attica, Greece|Kifisia / Athens, Attica, Greece|Abelokipi - Athens, Greece|Athens, Greece|Athens, Greece|Athens, Greece|Nea Ionia, Greece|Piraeus, Greece|Rio / Patras, Greece|Shatin, N.t., Hong Kong|Shatin, Hong Kong|Baja, Hungary|Balassagyarmat, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Gyor, Hungary|Hodmezovasarhely, Hungary|Kecskemet, Hungary|Szekesfehervar, Hungary|Tatabanya, Hungary|Zalaegerszeg-Pozva, Hungary|Ahmedabad, Gujar?t, India|Bangalore, Karn?taka, India|Bangalore, Karn?taka, India|Calicut, Kerala, India|Thiruvananthapuram, Kerala, India|Pune, Maharashtra, India|Pune, Maharashtra, India|Ludhiana, Punjab, India|Chennai, Tamil N?du, India|Coimbatore, Tamil N?du, India|Kolkata, West Bengal, India|Hyderabad, India|Hyderabad, India|Hyderabad, India|Mumbai, India|Noida, India|Jakarta, Indonesia|Jakarta, Indonesia|Surabaya, Indonesia|Afula, Israel|Ashkelon, Israel|Haifa, Israel|Haifa, Israel|Holon, Israel|Kfar Saba, Israel|Rehovot, Israel|Tel Aviv, Israel|Zefat, Israel|Acquaviva delle Fonti, Bari, Italy|Napoli, Campania, Italy|Modena, Emilia-Romagna, Italy|Parma, Emilia-Romagna, Italy|Piacenza, Emilia-Romagna, Italy|Reggio Emilia, Emilia-Romagna, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Genova, Liguria, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Varese, Lombardia, Italy|Campobasso, Molise, Italy|Fidenza, Parma, Italy|Catania, Sicilia, Italy|Palermo, Sicilia, Italy|Terni, Trentino-Alto Adige, Italy|Perugia, Umbria, Italy|Perugia, Umbria, Italy|Domodossola, Verbano-Cusio-Ossola, Italy|Bergamo, Italy|Latina, Italy|Reggio Calabria, Italy|Vicenza, Italy|Ichinomiya, Aichi, Japan|Kasugai, Aichi, Japan|Obu, Aichi, Japan|Matsuyama, Ehime, Japan|Toon, Ehime, Japan|Chikushino, Fukuoka, Japan|Takasaki, Gunma, Japan|Kure, Hiroshima, Japan|Hakodate, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Amagasaki, Hyogo, Japan|Kanazawa, Ishikawa, Japan|Hanamaki, Iwate, Japan|Ebina, Kanagawa, Japan|Kamakura, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Nangoku, Kochi, Japan|Matsusaka, Mie, Japan|Tsu, Mie, Japan|Tsu, Mie, Japan|Kashiwazaki, Niigata, Japan|Tomigusuku, Okinawa, Japan|Urasoe, Okinawa, Japan|Daito, Osaka, Japan|Yao, Osaka, Japan|Kusatsu, Shiga, Japan|Hamamatsu, Shizuoka, Japan|Meguro-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Shimonoseki, Yamaguchi, Japan|Fukui, Japan|National Hospital Organization Ibaraki Higashi Hospital, Ibaraki, Japan|Kumamoto, Japan|Kyoto, Japan|Gyeongi-do, Korea, Korea, Republic of|Seoul National University Hospital, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Seoul Metropolitan Boramae Hospital, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Gyeonggi-do, Korea, Republic of|Jeollanam-do, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Daugavpils, Latvia|Liepaja, Latvia|Riga, Latvia|Riga, Latvia|Riga, Latvia|Riga, Latvia|Valmiera, Latvia|Ventspils, Latvia|Kaunas, Lithuania|Kaunas, Lithuania|Kaunas, Lithuania|Klaipeda, Lithuania|Klaipeda, Lithuania|Siauliai, Lithuania|Utena, Lithuania|Vilnius, Lithuania|Vilnius, Lithuania|Vilnius, Lithuania|Kirchberg, Luxembourg|Luxembourg, Luxembourg|Niederkorn, Luxembourg|Kuala Lumpur, Malaysia|Negeri Sembilan,, Malaysia|Sarawak, Malaysia|Tuxtla Gutiérrez, Chiapas, Mexico|Torreón, Coahuila, Mexico|Mexico D. F., Distrito Federal, Mexico|Mexico D.F., Distrito Federal, Mexico|Mexico D.F., Distrito Federal, Mexico|México, D.F., Distrito Federal, Mexico|México, D.F., Distrito Federal, Mexico|México, D.F, Distrito Federal, Mexico|Guadalajara, Jalisco, Mexico|Morelia, Michoacán, Mexico|Metepec, México, Mexico|Monterrey, Nuevo Leon, Mexico|Hermosillo, Sonora, Mexico|Mérida, Yucatán, Mexico|Aguascalientes, Mexico|Chihuahua, Mexico|Puebla, Mexico|Zacatecas, Mexico|Amersfoort, Netherlands|Amsterdam, Netherlands|Enschede, Netherlands|Heerlen, Netherlands|Maastricht, Netherlands|Nieuwegein, Netherlands|Rotterdam, Netherlands|Sittard, Netherlands|Utrecht, Netherlands|Auckland, New Zealand|Auckland, New Zealand|Auckland, New Zealand|Christchurch, New Zealand|Fredrikstad, Norway|Gjøvik, Norway|Hamar, Norway|Oslo, Norway|Oslo, Norway|Karachi, Pakistan|Karachi, Pakistan|Lahore, Pakistan|Callao, Peru|Lima Cercado, Peru|Lima, Peru|Lima, Peru|Lima, Peru|Lima, Peru|Bialystok, Poland|Bydgoszcz, Poland|Krakow, Poland|Krakow, Poland|Lublin, Poland|Olsztyn, Poland|Piotrkow Trybunalski, Poland|Siedlce, Poland|Starogard Gdanski, Poland|Szczecin, Poland|Tarnów, Poland|Warszawa, Poland|Warszawa, Poland|Warszawa, Poland|Wloclawek, Poland|S. Martinho do Bispo, Coimbra, Portugal|Amadora, Portugal|Cascais, Portugal|Coimbra, Portugal|Lisboa, Portugal|Lisboa, Portugal|Lisboa, Portugal|Lisboa, Portugal|Matosinhos, Portugal|Porto, Portugal|Porto, Portugal|Santarém, Portugal|Viana do Castelo, Portugal|Bucharest, Romania|Bucharest, Romania|Bucharest, Romania|Constanta, Romania|Suceava, Romania|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Nizhny Novgorod, Russian Federation|Nizhny Novgorod, Russian Federation|Yaroslavl, Russian Federation|Yaroslavl, Russian Federation|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|Changi General Hospital, Singapore, Singapore|Bratislava, Slovakia|Bratislava, Slovakia|Lucenec, Slovakia|Martin, Slovakia|Zilina, Slovakia|Golnik, Slovenia|Ljubljana, Slovenia|Novo mesto, Slovenia|Bloemfontein, Freestate, South Africa|Johannesburg, Gauteng, South Africa|Johannesburg, Gauteng, South Africa|Johannesburg, Gauteng, South Africa|Kempton Park, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Roodepoort, Gauteng, South Africa|Goodwood, Western Cape, South Africa|Somerset West, Western Cape, South Africa|Stellenbosch, Western Cape, South Africa|Worcester, Western Cape, South Africa|Sandton, Gauteng, South Africa|Badalona, Barcelona, Spain|Sabadell, Barcelona, Spain|Cabra, Córdoba, Spain|Olot, Girona, Spain|Cartagena, Murcia, Spain|Vélez, Málaga, Spain|Vigo, Pontevedra, Spain|Barcelona, Spain|Barcelona, Spain|Cuenca, Spain|Córdoba, Spain|Girona, Spain|Zaragoza, Spain|Borås, Sweden|Hässleholm, Sweden|Karlshamn, Sweden|Kristianstad, Sweden|Lund, Sweden|Malmö, Sweden|Skövde, Sweden|Stockholm, Sweden|Stockholm, Sweden|Sundsvall, Sweden|Umeå, Sweden|Visby, Sweden|Bruderholz, Basel-Landschaft, Switzerland|Basel, Basel-Stadt, Switzerland|Liestal, Basel-Stadt, Switzerland|Langenthal, Bern, Switzerland|Baden, Switzerland|Bern, Switzerland|Genève, Switzerland|Luzern, Switzerland|Zürich, Switzerland|Kaohsiung, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Bangkok, Thailand|Bangkok, Thailand|Chiangmai, Thailand|Istanbul, Turkey|Istanbul, Turkey|Izmir, Turkey|Izmir, Turkey|Donetsk, Ukraine|Donetsk, Ukraine|Ivano-Frankivsk, Ukraine|Kharkiv, Ukraine|Kharkiv, Ukraine|Kharkiv, Ukraine|Kiev, Ukraine|Kiev, Ukraine|Kiev, Ukraine|Kyiv, Ukraine|Lviv, Ukraine|Odessa, Ukraine|Odessa, Ukraine|Simferopol, Ukraine|Simferopol, Ukraine|Middlesborough, Cleveland, United Kingdom|Dumfries, Dumfries and Galloway, United Kingdom|Liverpool, Merseyside, United Kingdom|Sheffield, South Yorkshire, United Kingdom|Glasgow, Stratchclyde, United Kingdom|Newcastle Upon Tyne, Tyne and Wear, United Kingdom|Leeds, West Yorkshire, United Kingdom|London, United Kingdom|London, United Kingdom|London, United Kingdom|Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00571649"
1191,"NCT00569244","SH T00186 in the Treatment of Primary Dysmenorrhea",,"Completed","No Results Available","Primary Dysmenorrhea","Drug: Drug: YAZ flex (SH T00186D)|Drug: YAZ (SH T00186D)","Number of days with dysmenorrheic pain|Use of rescue medication|Interference with daily activity|Number of days: with at least moderate dysmenorrheic pain|Number of days with pelvic pain|Number of days with dysmenorrheic pain associated with withdrawal bleeding|Number of days with dysmenorrheic pain associated with unscheduled bleeding|Bleeding patterns|Assessment of treatment","Bayer","Female","18 Years to 40 Years   (Adult)","Phase 3","223","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","91587|2006-004899-13|310882","December 2007","December 2009","December 2009","December 7, 2007",,"October 29, 2014","Heidelberg, Baden-Württemberg, Germany|Nürnberg, Bayern, Germany|Frankfurt, Hessen, Germany|Fulda, Hessen, Germany|Mühlheim, Hessen, Germany|Hannover, Niedersachsen, Germany|Hannover, Niedersachsen, Germany|Bernburg, Sachsen-Anhalt, Germany|Blankenburg, Sachsen-Anhalt, Germany|Burg, Sachsen-Anhalt, Germany|Jessen, Sachsen-Anhalt, Germany|Magdeburg, Sachsen-Anhalt, Germany|Magdeburg, Sachsen-Anhalt, Germany|Magdeburg, Sachsen-Anhalt, Germany|Leipzig, Sachsen, Germany|Leipzig, Sachsen, Germany|Leipzig, Sachsen, Germany|Wurzen, Sachsen, Germany|Gera, Thüringen, Germany|Kahla, Thüringen, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Chesterfield, Derbyshire, United Kingdom|Newcastle Upon Tyne, Tyne and Wear, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00569244"
1192,"NCT00568945","Study to Investigate the Effect of the A1 Agonist Capadenoson on Ventricular HR in Patients With Persistent or Permanent Atrial Fibrillation.",,"Completed","No Results Available","Atrial Fibrillation","Drug: Capadenoson (BAY68-4986)","The effect of capadenoson (BAY68-4986) on rate control in patients with atrial fibrillation|To investigate safety and tolerability of this treatment with capadenoson","Bayer","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","28","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12679|2007-003619-30","January 2008","November 2008","December 2008","December 6, 2007",,"October 29, 2014","Erfurt, Thüringen, Germany",,"https://ClinicalTrials.gov/show/NCT00568945"
1193,"NCT00568412","A Clinical Study in Children and Adolescents With Mild to Moderate Atopic Dermatitis",,"Completed","No Results Available","Mild to Moderate Atopic Dermatitis","Device: Zarzenda|Drug: Elidel","Investigator's Global Assessment|EASI|Affected body surface area|Patient's assessment of itch, quality of sleep, and global assessment|Children's Dermatological Life Quality Index","Bayer","All","2 Years to 17 Years   (Child)","Phase 4","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1401920","December 2007","September 2008","September 2008","December 6, 2007",,"February 18, 2015","Klinik und Poliklinik fuer Dermatologie, Universtitaetsklinikum, Bonn, Germany",,"https://ClinicalTrials.gov/show/NCT00568412"
1194,"NCT00567164","Efficacy and Safety of Two Flexible Extended Regimens of BAY86-5300 (SH T00186D) in Comparison With the Conventional Regimen of YAZ",,"Completed","Has Results","Contraception|Ovulation Inhibition|Contraceptives, Oral","Drug: EE20/DRSP (BAY86-5300)|Drug: EE20/DRSP (YAZ, BAY86-5300)","Pearl Index|Number of Bleeding Days (Including Spotting Days)|Number of Bleeding Days (Excluding Spotting Days)|Number of Days With Bleeding (Including and Excluding Spotting) Within 90-day Reference Period 1.|Number of Days With Bleeding (Including and Excluding Spotting) Within 90-day Reference Period 2.|Number of Days With Bleeding (Including and Excluding Spotting) Within 90-day Reference Period 3|Number of Days With Bleeding/ (Including and Excluding Spotting) Within 90-day Reference Period 4|Percentage of Participants With a Withdrawal Bleeding Episode for Cycle 1|Percentage of Participants With a Withdrawal Bleeding Episode for Cycle 2|Percentage of Participants With a Withdrawal Bleeding Episode for Cycle 3|Percentage of Participants With a Withdrawal Bleeding Episode for Cycle 4|Percentage of Participants With a Withdrawal Bleeding Episode for Cycle 5|Percentage of Participants With a Withdrawal Bleeding Episode for Cycle 6|Percentage of Participants With a Withdrawal Bleeding Episode for Cycle 7|Percentage of Participants With a Withdrawal Bleeding Episode for Cycle 8|Percentage of Participants With a Withdrawal Bleeding Episode for Cycle 9|Percentage of Participants With a Withdrawal Bleeding Episode for Cycle 10|Percentage of Participants With a Withdrawal Bleeding Episode for Cycle 11|Percentage of Participants With a Withdrawal Bleeding Episode for Cycle 12|Percentage of Participants With a Withdrawal Bleeding Episode for Cycle 13|Percentage of Participants With a Withdrawal Bleeding Episode for Cycle 14|Number of Intracyclic Bleeding Days|Number of Scheduled and Unscheduled Bleeding Days|Length of Cycles","Bayer","Female","18 Years to 45 Years   (Adult)","Phase 3","1887","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","91698|311642","October 2007","November 2009","November 2009","December 4, 2007","March 12, 2014","March 12, 2014","Montgomery, Alabama, United States|Chandler, Arizona, United States|Mesa, Arizona, United States|Mesa, Arizona, United States|Phoenix, Arizona, United States|Tempe, Arizona, United States|Tucson, Arizona, United States|Tucson, Arizona, United States|Anaheim, California, United States|Beverly Hills, California, United States|Pacific Palisades, California, United States|San Diego, California, United States|San Diego, California, United States|Santa Ana, California, United States|Vallejo, California, United States|Colorado Springs, Colorado, United States|Denver, Colorado, United States|Greenwood Village, Colorado, United States|Littleton, Colorado, United States|Waterbury, Connecticut, United States|Boynton Beach, Florida, United States|Brooksville, Florida, United States|Clearwater, Florida, United States|Coral Gables, Florida, United States|Crystal River, Florida, United States|Jacksonville, Florida, United States|Lake Worth, Florida, United States|Miami, Florida, United States|Naples, Florida, United States|North Miami, Florida, United States|Pembroke Pines, Florida, United States|Plantation, Florida, United States|South Miami, Florida, United States|St. Petersburg, Florida, United States|West Palm Beach, Florida, United States|Atlanta, Georgia, United States|Decatur, Georgia, United States|Boise, Idaho, United States|Boise, Idaho, United States|Idaho Falls, Idaho, United States|Champaign, Illinois, United States|Chicago, Illinois, United States|Newburgh, Indiana, United States|Wichita, Kansas, United States|Lexington, Kentucky, United States|Marrero, Louisiana, United States|Paw Paw, Michigan, United States|Chesterfield, Missouri, United States|Kansas City, Missouri, United States|Lincoln, Nebraska, United States|Las Vegas, Nevada, United States|Las Vegas, Nevada, United States|LasVegas, Nevada, United States|Moorestown, New Jersey, United States|New Brunswick, New Jersey, United States|Rochester, New York, United States|Durham, North Carolina, United States|New Bern, North Carolina, United States|Winston-Salem, North Carolina, United States|Bismarck, North Dakota, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Oklahoma City, Oklahoma, United States|Portland, Oregon, United States|Portland, Oregon, United States|Jenkintown, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Columbia, South Carolina, United States|Mt. Pleasant, South Carolina, United States|Chattanooga, Tennessee, United States|Jackson, Tennessee, United States|Knoxville, Tennessee, United States|Memphis, Tennessee, United States|Nashville, Tennessee, United States|Colleyville, Texas, United States|Corpus Christi, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|West Jordan, Utah, United States|Richmond, Virginia, United States|Richmond, Virginia, United States|Seattle, Washington, United States|Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00567164"
1195,"NCT00566384","Efficacy and Safety of Oral Dehydroepiandrosterone as a Concomitant Therapy to Oral Contraceptives in Women Complaining of Reduced Libido",,"Completed","No Results Available","Libido","Drug: Dehydroepiandrosterone, BAY86-5314|Drug: Placebo","FSDS questionnaire (sexual desire and arousal component scores)|Change from baseline period to cycle 6 in the number of satisfactory sexual events|FSFI questionnaire (absolute values and change from baseline) - All domains|FSDS-R questionnaire results|FSEP questionnaire results|PGWBI questionnaire results|Serum hormone levels (SHBG, T, DHEA, DHEA-S)|Vaginal pH","Bayer","Female","18 Years to 35 Years   (Adult)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","91692|310741|2006-004397-27","November 2007","April 2009","April 2009","December 3, 2007",,"December 2, 2014","Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT00566384"
1196,"NCT00565565","Single Dose Escalation Study in Patients With Chronic Heart Failure",,"Completed","No Results Available","Heart Failure","Drug: BAY60-4552","Change in pulmonary capillary wedge pressure|Change in mean pulmonary artery pressure|AUC|AUC/D|Cmax|Cmax/D|Number of participants with adverse events|Mean right atrial pressure|Systolic pulmonary artery pressure|Diastolic pulmonary artery pressure|Heart rate|Cardiac output|Pulmonary vascular resistance|Pulmonary vascular resistance index|Systemic vascular resistance|Systemic vascular resistance index|Cardiac index|Mean arterial pressure|Systemic blood pressure|Diastolic blood pressure|Dyspnea Score|AUC(0-6)|AUCnorm|AUC(0-tn)|AUC(0-tn)norm|Cmax,norm|tmax|t½|Mean residence time|Total body clearance of drug from plasma calculated after oral administration (apparent oral clearance)|Apparent volume of distribution associated with the terminal phase (after oral administration)|Amount of drug excreted via urine|Percent amount of drug excreted via urine|Renal clearance of drug|Renin activity|Change from baseline of noradrenaline after drug administration|N-terminal pro-atrial natriuretic peptide|NT-pro B-type natriuretic peptide|Big endothelin-1|Cystatin C|Change from baseline of osteopontin after drug administration|Cyclic guanosine mono-phosphate","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","55","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12356|2007-003216-54","October 2007","December 2008","April 2009","November 30, 2007",,"August 10, 2016","Bad Nauheim, Hessen, Germany|Gießen, Hessen, Germany",,"https://ClinicalTrials.gov/show/NCT00565565"
1197,"NCT00562913","Phase I Study of Sorafenib Dosed Continuously With Cyclophosphamide and Doxorubicin",,"Completed","No Results Available","Cancer","Drug: Nexavar (Sorafenib, BAY43-9006)","To determine the pharmacokinetics and safety of cyclophosphamide when co-administered with 400 mg BID sorafenib and doxorubicin administered|To evaluate the tumor response to the combination of cyclophosphamide, doxorubicin and sorafenib","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","21","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12347","December 2007","June 2009","March 2010","November 26, 2007",,"November 26, 2013","Edmonton, Alberta, Canada|Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00562913"
1198,"NCT00562523","Sorafenib/Docetaxel Dose Escalation Trial",,"Completed","No Results Available","Neoplasms","Drug: Sorafenib (Nexavar, BAY43-9006)","To determine the safety, maximum tolerated dose and dose-limiting toxicities of oral sorafenib|To determine if there is a pharmacokinetic interaction between sorafenib and docetaxel when they are administered together","Bayer|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","17","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12438","November 2007","March 2009","March 2009","November 22, 2007",,"May 23, 2013","Tampa, Florida, United States|Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00562523"
1199,"NCT00561717","A Randomized, Placebo Controlled Study to Determine the Efficacy and Speed of a Nasal Spray in Allergen Induced Seasonal Allergic Rhinitis","GEYSER","Completed","No Results Available","Seasonal Allergic Rhinitis","Drug: Azelastine and placebo|Drug: Loratadine and Placebo|Drug: Cetirizine and Placebo|Drug: Placebo and Placebo (spray and Tablet)","Onset of action measured by change in total nasal symptom score Until ""Onset of action"" = until drug demonstrates and maintains a change greater than placebo compared to baseline|Change from baseline for individual symptoms of allergic seasonal rhinitis; overall assessment of efficacy","Bayer|Kingston Health Sciences Centre","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","70","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","12962|9427-B2171-22C (CR Number)","October 2007","December 2007","February 2008","November 21, 2007",,"May 7, 2013","Kingston, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00561717"
1200,"NCT00559650","Placebo Controlled, Randomized, Double-blind, Multi-center Study to Investigate the Efficacy and Tolerability of BAY58-2667",,"Terminated","No Results Available","Congestive Heart Failure","Drug: Placebo|Drug: Cinaciguat (BAY58-2667)","The primary efficacy outcome measure will be the change of pulmonary capillary wedge pressure (PCWP) from baseline to 8 hours versus placebo.|Quality of Life|Rehospitalization|Other hemodynamic measurements|Safety variables|Plasma concentrations","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","150","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12480|2007-003059-36","December 2007","February 2009","March 2009","November 16, 2007",,"April 18, 2017","San Diego, California, United States|Washington, District of Columbia, United States|Boston, Massachusetts, United States|Cincinnati, Ohio, United States|Fairfield, Ohio, United States|Dallas, Texas, United States|Halifax, Nova Scotia, Canada|Toronto, Ontario, Canada|Ste-Foy, Quebec, Canada|Split, Croatia|Zagreb, Croatia|Brno, Czech Republic|Brno, Czech Republic|Hradec kralove, Czech Republic|Plzen, Czech Republic|Praha 2, Czech Republic|Praha 2, Czech Republic|Tallin, Estonia|Tartu, Estonia|Heidelberg, Baden-Württemberg, Germany|Würzburg, Bayern, Germany|Bad Nauheim, Hessen, Germany|Greifswald, Mecklenburg-Vorpommern, Germany|Bad Oeynhausen, Nordrhein-Westfalen, Germany|Bonn, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Homburg, Saarland, Germany|Halle, Sachsen-Anhalt, Germany|Erfurt, Thüringen, Germany|Jena, Thüringen, Germany|Berlin, Germany|Budapest, Hungary|Debrecen, Hungary|Vac, Hungary|Zalaegerszeg, Hungary|Haifa, Israel|Jerusalem, Israel|Ramat Gan, Israel|Zefat, Israel|Bologna, Emilia-Romagna, Italy|Ferrara, Emilia-Romagna, Italy|Milano, Lombardia, Italy|Pavia, Lombardia, Italy|Perugia, Umbria, Italy|Bergamo, Italy|Kaunas, Lithuania|Vilnius, Lithuania|Gdansk, Poland|Krakow, Poland|Szczecin, Poland|Wroclaw, Poland|Zabrze, Poland|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Beograd, Serbia|Sremska Kamenica, Serbia|Celje, Slovenia|Golnik, Slovenia|Ljubljana, Slovenia|Murska Sobota, Slovenia|Santiago de Compostela, A Coruña, Spain|Sabadell, Barcelona, Spain|Majadahonda, Madrid, Spain|Barcelona, Spain|Girona, Spain|Göteborg, Sweden|Uppsala, Sweden|Chesterfield, Derbyshire, United Kingdom|Barnet, Hertfordshire, United Kingdom|Harrow, Middlesex, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00559650"
1201,"NCT00558636","A Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)",,"Terminated","Has Results","Carcinoma, Non-Small-Cell Lung","Drug: Sorafenib + Paclitaxel + Carboplatin|Drug: Placebo + Paclitaxel + Carboplatin","Progression Free Survival|Overall Survival (OS)|Best Tumor Response (Number of Responses Per Category) According to Response Evaluation Criteria in Solid Tumors (RECIST)|Duration of Response|Change From Baseline of Lung Cancer Symptoms (LCS) Score Assessed at Each Treatment Cycle (21 Days Per Cycle) Starting With Cycle 2|Change From Baseline of Health-Related Quality of Life (HRQoL) Score Assessed at Treatment Cycle 3 and Cycle 5|Change From Baseline of Health-Related Quality of Life (HRQoL) Score Assessed at Treatment Cycle 7","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","91","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","12621","September 2007","May 2008","May 2008","November 15, 2007","October 20, 2010","December 27, 2013","Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Shatin, Hong Kong, China|Nanjing, Jiangsu, China|Hangzhou, Zhejiang, China|Hangzhou, Zhejiang, China|Beijing, China|Beijing, China|Beijing, China|Chongqing, China|Shanghai, China|Shanghai, China|Mumbai, Maharashtra, India|New- Delhi, India|Gyeonggi-do, Korea, Republic of|Seoul, Korea, Republic of|Singapore, Singapore|Singapore, Singapore|Changhua, Taiwan|Taipei, Taiwan|Bangkok, Thailand|Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT00558636"
1202,"NCT00555919","ZK 230211 in Postmenopausal Woman With Metastatic Breast Cancer",,"Completed","No Results Available","Metastatic Breast Cancer","Drug: Lonaprisan (ZK 230211, BAY86-5044)","To evaluate efficacy (clinical benefit) of two doses of ZK PRA (25 mg and 100 mg) when administered once daily p.o.|To evaluate safety and tolerability|To evaluate the pharmacokinetics of ZK PRA|To evaluate the effect of ZK PRA on quality of life (QoL)|To perform exploratory analysis of biomarkers|Progression-free survival (PFS)|Objective response rate (ORR) / Duration of response - in the subset of patients with measurable disease|Duration of Clinical Benefit|Overall Survival (OS)","Bayer","Female","18 Years and older   (Adult, Older Adult)","Phase 2","68","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","91484|2005-005581-36|309821","March 2008","April 2010","March 2011","November 9, 2007",,"October 10, 2014","Graz, Austria|Innsbruck, Austria|Salzburg, Austria|Wien, Austria|Turku, Finland|Vaasa, Finland|Lille, France|Lyon Cedex, France|Montpellier, France|Nantes, France|Paris, France|Reims, France|Tübingen, Baden-Württemberg, Germany|Erlangen, Bayern, Germany|Frankfurt, Hessen, Germany|Rostock, Mecklenburg-Vorpommern, Germany|Kiel, Schleswig-Holstein, Germany|Rozzano, Milano, Italy|Bialystok, Poland|Gdansk, Poland|Olsztyn, Poland|Poznan, Poland|Madrid, Spain|Göteborg, Sweden|Sundsvall, Sweden|Växjö, Sweden|St. Gallen, Sankt Gallen, Switzerland|Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00555919"
1203,"NCT00544037","BENEFIT Extension Study",,"Completed","No Results Available","Multiple Sclerosis","Drug: Interferon beta-1b (Betaseron, BAY86-5046)","To obtain further clinical data of patients with a first demyelinating event suggestive of Multiple Sclerosis enrolled in the BENEFIT Study","Bayer","All","23 Years to 50 Years   (Adult)",,"283","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","91713|311129","September 2007","January 2011","January 2011","October 16, 2007",,"March 5, 2012","Many Locations, Austria|Many Locations, Belgium|Many Locations, Canada|Many Locations, Czech Republic|Many Locations, Denmark|Many Locations, Finland|Many Locations, France|Many Locations, Germany|Many Locations, Hungary|Many Locations, Israel|Many Locations, Italy|Many Locations, Netherlands|Many Locations, Norway|Many Locations, Poland|Many Locations, Slovenia|Many Locations, Spain|Many Locations, Sweden|Many Locations, Switzerland",,"https://ClinicalTrials.gov/show/NCT00544037"
1204,"NCT00537836","ZK283197 for Treatment of Vasomotor Symptoms",,"Completed","No Results Available","Vasomotor System","Drug: BAY 86-5310 (ZK 283197)|Drug: Placebo|Drug: 17ß-estradiol","Relative change in frequency of moderate to severe hot flushes per week between baseline and Week 8 of the treatment phase|Number of participants with adverse events|Exposure-response relationship|Change from baseline to all treatment weeks in frequency and severity of moderate to severe hot flushes|Change from baseline to all treatment weeks in severity and frequency of all hot flushes|Trough levels at every visit|AUC(0-24h)|Cmax|tmax|Cmin|Cave|Vaginal cytology|Endometrial thickness|Endometrial histology","Bayer","Female","45 Years to 65 Years   (Adult, Older Adult)","Phase 2","116","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","91544|2007-001791-36|310781","October 2007","December 2008","December 2008","October 1, 2007",,"April 9, 2015","Berlin, Germany|Berlin, Germany|Groningen, Netherlands|Cambridge, Cambridgeshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00537836"
1205,"NCT00528112","Levonorgestrel Contraceptive Intrauterine Systems (LCS) Pearl Index Study",,"Completed","Has Results","Contraception","Drug: LCS12|Drug: LCS16","Pearl Index up to 3 Years|Pearl Index for LCS16 up to 5 Years|Bleeding Patterns in Days by 90-day Reference Periods - Reference Period 1|Bleeding Patterns in Days by 90-day Reference Periods - Reference Period 2|Bleeding Patterns in Days by 90-day Reference Periods - Reference Period 3|Bleeding Patterns in Days by 90-day Reference Periods - Reference Period 4|Bleeding Patterns in Days by 90-day Reference Periods - Reference Period 12|Bleeding Patterns in Days by 30-day Reference Periods - Reference Period 1|Bleeding Patterns in Days by 30-day Reference Periods - Reference Period 2|Bleeding Patterns in Days by 30-day Reference Periods - Reference Period 3|Bleeding Patterns in Days by 30-day Reference Periods - Reference Period 4|Bleeding Patterns in Days by 30-day Reference Periods - Reference Period 12|Number of Participants With/Without Ovulation - Year 1|Number of Participants With/Without Ovulation - Year 2|Number of Participants With/Without Ovulation - Year 3|Average Total Cervical Score - Year 1|Average Total Cervical Score - Year 2|Average Total Cervical Score - Year 3|Classification of Endometrium - Year 1|Classification of Endometrium - Year 2|Classification of Endometrium - Year 3 / End of Study|Degree of User Overall Satisfaction With Study Treatment|Number of Participants With Partial or Total Expulsion|Bleeding Patterns in Days by 90-day Reference Periods - Reference Period 13|Bleeding Patterns in Days by 90-day Reference Periods - Reference Period 20|Degree of User Overall Satisfaction With Study Treatment up to 5 Years|Number of Participants With Partial or Total Expulsion up to 5 Years","Bayer","Female","18 Years to 35 Years   (Adult)","Phase 3","2885","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","91665|310442|G04209F|G04209G|2007-000420-40","August 2007","July 2011","June 2013","September 12, 2007","September 24, 2012","January 25, 2017","Mobile, Alabama, United States|Glendale, Arizona, United States|Phoenix, Arizona, United States|Tucson, Arizona, United States|Carmichael, California, United States|Pacific Palisades, California, United States|San Diego, California, United States|San Diego, California, United States|San Diego, California, United States|San Diego, California, United States|Torrance, California, United States|Denver, Colorado, United States|Littleton, Colorado, United States|Boyton Beach, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|West Palm Beach, Florida, United States|Atlanta, Georgia, United States|Decatur, Georgia, United States|Boise, Idaho, United States|Idaho Falls, Idaho, United States|Chicago, Illinois, United States|Evansville, Indiana, United States|South Bend, Indiana, United States|Marrero, Louisiana, United States|Boston, Massachusetts, United States|Kalamazoo, Michigan, United States|Chaska, Minnesota, United States|Chesterfield, Missouri, United States|Lincoln, Nebraska, United States|Las Vegas, Nevada, United States|Las Vegas, Nevada, United States|Las Vegas, Nevada, United States|Moorestown, New Jersey, United States|New Brunswick, New Jersey, United States|Albuquerque, New Mexico, United States|New York, New York, United States|New Bern, North Carolina, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Medford, Oregon, United States|Portland, Oregon, United States|Jenkintown, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Columbia, South Carolina, United States|Chattanooga, Tennessee, United States|Memphis, Tennessee, United States|Nashville, Tennessee, United States|Austin, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Norfolk, Virginia, United States|Seattle, Washington, United States|Spokane, Washington, United States|Lanus Oeste, Buenos Aires, Argentina|San Isidro, Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Rosario, Santa Fe, Argentina|Calgary, Alberta, Canada|Winnipeg, Manitoba, Canada|Winnipeg, Manitoba, Canada|Kingston, Ontario, Canada|London, Ontario, Canada|Waterloo, Ontario, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Shawinigan, Quebec, Canada|Sherbrooke, Quebec, Canada|Saskatoon, Saskatchewan, Canada|Quebec, Canada|Quebec, Canada|Santiago de Chile, Chile|Santiago, Chile|Espoo, Finland|Helsinki, Finland|Helsinki, Finland|Joensuu, Finland|Kotka, Finland|Kuopio, Finland|Lahti, Finland|Oulu, Finland|Oulu, Finland|Oulu, Finland|Tampere, Finland|Turku, Finland|Turku, Finland|Turku, Finland|COMPIEGNE cedex, France|Grenoble, France|Le Chesnay, France|Lille, France|Nimes, France|Quetigny, France|REIMS Cedex, France|Roanne, France|Szeged, Csongrad, Hungary|Bekescsaba, Hungary|Budapest, Hungary|Eger, Hungary|Esztergom, Hungary|Kecskemet, Hungary|Nyiregyhaza, Hungary|Szentes, Hungary|Torreón, Coahuila, Mexico|México, D.F., Distrito Federal, Mexico|Monterrey, Nuevo Leon, Mexico|Hermosillo, Sonora, Mexico|México, D.F., Mexico|México, D.F., Mexico|Alkmaar, Netherlands|Den Haag, Netherlands|Eindhoven, Netherlands|Heerlen, Netherlands|Helmond, Netherlands|Hoofddorp, Netherlands|Nijmegen, Netherlands|Rotterdam, Netherlands|Utrecht, Netherlands|Elverum, Norway|Kolbotn, Norway|Larvik, Norway|Oslo, Norway|Trondheim, Norway|Göteborg, Sweden|Luleå, Sweden|Malmö, Sweden|Norrköping, Sweden|Stockholm, Sweden|Stockholm, Sweden|Stockholm, Sweden|Stockholm, Sweden|Umeå, Sweden|Uppsala, Sweden|Örebro, Sweden",,"https://ClinicalTrials.gov/show/NCT00528112"
1206,"NCT00526188","Efficacy and Safety of Primovist in Chinese Patients",,"Completed","Has Results","Known or Suspected Focal Liver Lesions","Drug: Gadoxetic Acid Disodium (Primovist, BAY86-4873)","Difference in Sensitivity of Lesion Detection in MRI Images (Post-contrast MRI Minus Pre-contrast MRI) Measured as Percentage Points|Difference in Sensitivity of Lesion Detection in MRI Images (Post-contrast MRI Minus Pre-contrast MRI) Assessed by Investigators Measured in Percentage Points|Difference in Precision of Lesion Characterization (Combined Pre- and Post-contrast Minus Pre-contrast MRI) Measured in Percentage Points","Bayer","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","234","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","91531|310682","August 2007","August 2008","August 2008","September 10, 2007","December 30, 2009","May 1, 2015","Nanjing, Jiangsu, China|Suzhou, Jiangsu, China|Xi'an, Shaanxi, China|Beijing, China|Shanghai, China|Shanghai, China",,"https://ClinicalTrials.gov/show/NCT00526188"
1207,"NCT00522951","SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study",,"Completed","Has Results","Brain Metastases","Drug: Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Drug: ProHance","Number of Lesions Detected by Blinded Readers (BR) and Investigator|Score of Visibility Assessment - Degree of Lesion Contrast Enhancement by Blinded Reader|Score of Visibility Assessment - Degree of Lesion Contrast Enhancement by Investigator|Score of Visibility Assessment - Border Delineation by Blinded Reader|Score of Visibility Assessment - Border Delineation by Investigator|Treatment Planning Confidence - Gadobutrol 0.1 mmol/kg bw vs. Gadoteridol (ProHance) 0.2 mmol/kg bw by Treatment Planning Experts (TPE)|Treatment Planning Confidence - Gadobutrol 0.1 mmol/kg bw vs. Gadoteridol (ProHance) 0.2 mmol/kg bw by Investigator|Treatment Planning Confidence - Gadobutrol 0.2 mmol/kg bw vs. Gadoteridol (ProHance) 0.2 mmol/kg bw by TPE|Treatment Planning Confidence - Gadobutrol 0.2 mmol/kg bw vs. Gadoteridol (ProHance) 0.2 mmol/kg bw by Investigator|Number of Participants With Performance in Stereotactic Radiosurgery (SRS) Planning by TPE|Number of Participants With Performance in Stereotactic Radiosurgery (SRS) Planning by Investigator|Number of Participants With Reasons for Performance in SRS Planning by TPE|Number of Participants With Reasons for Performance in SRS Planning by Investigator|Lesion Size Evaluated by Independent Radiologist|Contrast Noise Ratio (CNR) of Lesions Evaluated by Independent Radiologist|Intraclass Correlation Coefficient (ICC) Among 3 Blinded Readers on the Number of Detected Lesions","Bayer","All","20 Years and older   (Adult, Older Adult)","Phase 3","165","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic","91569|310864","August 2007","August 2008","August 2008","August 30, 2007","August 3, 2011","August 28, 2017","Nagoya, Aichi, Japan|Matsuyama, Ehime, Japan|Kitakyushu, Fukuoka, Japan|Sapporo, Hokkaido, Japan|Kobe, Hyogo, Japan|Sagamihara, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Habikino, Osaka, Japan|Habikino, Osaka, Japan|Osakasayama, Osaka, Japan|Hamamatsu, Shizuoka, Japan|Sunto, Shizuoka, Japan|Bunkyo-ku, Tokyo, Japan|Bunkyo-ku, Tokyo, Japan|Chuo-ku, Tokyo, Japan|Mitaka, Tokyo, Japan|Shinagawa-ku, Tokyo, Japan|Yonago, Tottori, Japan|Fukuoka, Japan|Osaka, Japan",,"https://ClinicalTrials.gov/show/NCT00522951"
1208,"NCT00522873","Endometrial Safety Study",,"Completed","Has Results","Postmenopause","Drug: 0.25mg DRSP / 0.5mg E2 (BAY86-4891)|Drug: 0.5mg NETA / 1.0mg E2 (Activella)","Number of Participants in the DRSP/E2 Group With an Assessment of Endometrial Hyperplasia or Worse at End of Study (EoS) (1 Year of Treatment)|Number of Participants With Amenorrhea During Month 1 to 3 of Treatment|Number of Participants With Amenorrhea During Month 10 to 12 of Treatment","Bayer|Laboratorium für Klinische Forschung|Diagnostic Cytology Laboratory|University of California, San Francisco","Female","40 Years to 65 Years   (Adult, Older Adult)","Phase 3","662","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","91508|2006-006199-39|310523","August 2007","August 2009","August 2009","August 30, 2007","June 28, 2012","December 31, 2014","Chandler, Arizona, United States|San Diego, California, United States|San Diego, California, United States|Denver, Colorado, United States|Greenwood Village, Colorado, United States|Boynton Beach, Florida, United States|Clearwater, Florida, United States|Boise, Idaho, United States|Amite, Louisiana, United States|Marrero, Louisiana, United States|Las Vegas, Nevada, United States|Cleveland, Ohio, United States|Philadelphia, Pennsylvania, United States|Columbia, South Carolina, United States|Corpus Christi, Texas, United States|Richmond, Virginia, United States|Seattle, Washington, United States|Lanus Oeste, Buenos Aires, Argentina|San Isidro, Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Mödling, Niederösterreich, Austria|Wiener Neustadt, Niederösterreich, Austria|Fuerstenfeld, Steiermark, Austria|Wörgl, Tirol, Austria|Bregenz, Vorarlberg, Austria|Innsbruck, Austria|Klagenfurt, Austria|Mürzzuschlag, Austria|St. Poelten, Austria|Wien, Austria|Wien, Austria|Wien, Austria|Wien, Austria|Zeltweg, Austria|Goiania, Goiás, Brazil|Curitiba, Parana, Brazil|Porto Alegre, Rio Grande do Sul, Brazil|Sao Paulo, Brazil|Alborg, Denmark|Ballerup, Denmark|Vejle, Denmark|Bologna, Italy|Cagliari, Italy|Modena, Italy|Novara, Italy|Parma, Italy|Pisa, Italy|Sassari, Italy|Siena, Italy|Mexico, Distrito Federal, Mexico|Mexico, Mexico|Monterrey, Mexico|México, D.F., Mexico|Moscow, Russian Federation|Moscow, Russian Federation|Moskva, Russian Federation|Moskva, Russian Federation|Moskva, Russian Federation",,"https://ClinicalTrials.gov/show/NCT00522873"
1209,"NCT00518921","Capadenoson in Angina Pectoris",,"Withdrawn","No Results Available","Chronic Stable Angina","Drug: Capadenoson (BAY 68-4986)|Drug: Placebo","Total exercise time|Time to angina onset","Bayer","All","35 Years to 75 Years   (Adult, Older Adult)","Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","12484|EudraCT 2007-000425-22","March 2008",,"November 2008","August 21, 2007",,"January 13, 2011","Brno, Czech Republic|Hodonin, Czech Republic|Kromeriz, Czech Republic|Olomouc, Czech Republic|Ostrava, Czech Republic|Plzen, Czech Republic|Praha 13, Czech Republic|Praha 6, Czech Republic|Balatonfured, Hungary|Kecskemet, Hungary|Miskolc, Hungary|Pecs, Hungary|Zalaegerszeg, Hungary|Hadera, Israel|Rehovot, Israel|Safed, Israel|Mestre, Venezia, Italy|Genova, Italy|Pavia, Italy|Trieste, Italy|Bialystok, Poland|Gdansk, Poland|Gdynia, Poland|Katowice, Poland|Krakow, Poland|Legnica, Poland|Lodz, Poland|Starogard Gdanski, Poland|Szczecin, Poland|Warszawa, Poland|Wroclaw, Poland|Wroclaw, Poland|Bratislava, Slovakia|Bratislava, Slovakia|Nitra, Slovakia|Nove Zamky, Slovakia",,"https://ClinicalTrials.gov/show/NCT00518921"
1210,"NCT00511797","SH T00186 Phase II/ III Optimal Drospirenone (DRSP) Dose Finding and Placebo-controlled Comparative Study",,"Completed","Has Results","Dysmenorrhea","Drug: SH T04740B|Drug: SH T00186DF|Drug: SH T04740F|Drug: Placebo","Change From Baseline in Total Dysmenorrheal Score at Final Evaluation|Change From Baseline in Total Dysmenorrheal Score at Cycle 1 up to Cycle 4|Number of Participants With Severity of Lower Abdominal Pain During Menstruation at Cycle 4|Number of Participants With Severity of Low Back Pain During Menstruation at Cycle 4|Number of Participants With Severity of Headache During Menstruation at Cycle 4|Number of Participants With Severity of Nausea or Vomiting During Menstruation at Cycle 4|Number of Participants With Total Pelvic Pain Score at Times Other Than During Menstruation at Cycle 4|Change From Baseline in Visual Analogue Scale (VAS) for Dysmenorrhea at Times Other Than During Menstruation at Cycle 4|Visual Analogue Scale (VAS) for Pelvic Pain at Times Other Than During Menstruation at Cycle 4|Change From Baseline in Endometrial Thickness After 4-cycle Treatment|Number of Bleeding / Spotting Episodes|Number of Bleeding / Spotting Days|Participants With Withdrawal Bleeding|Participants With Intracyclic Bleeding|Participants With Non-heavy Intracyclic Bleeding|Participants With Non-heavy Withdrawal Bleeding|Change From Baseline in Serum Carbohydrate Antigen-125 (CA125) After 4-cycle Treatment|Change From Baseline in Serum C-reactive Protein (CRP) After 4-cycle Treatment|Change From Baseline in Serum Estradiol Level After 4-cycle Treatment|Change From Baseline in Serum Progesterone Level at Cycle 4","Bayer","Female","20 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","249","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","91615|310283","July 2007","January 2009","January 2009","August 6, 2007","October 4, 2010","January 26, 2017","Maebashi, Gunma, Japan|Kobe, Hyogo, Japan|Nishinomiya, Hyogo, Japan|Yokohama, Kanagawa, Japan|Sendai, Miyagi, Japan|Chuo-ku, Tokyo, Japan|Hachioji, Tokyo, Japan|Setagaya-ku, Tokyo, Japan|Setagaya-ku, Tokyo, Japan|Toshima-ku, Tokyo, Japan|Kyoto, Japan|Osaka, Japan",,"https://ClinicalTrials.gov/show/NCT00511797"
1211,"NCT00501059","A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease","ARRIVE","Completed","Has Results","Moderate Risk of CVD","Drug: Aspirin (Acetylsalicylic acid, BAYE4465)|Drug: Placebo","Time to the First Occurrence of the Composite Outcome of MI (Myocardial Infarction), Stroke, Cardiovascular Death, UA (Unstable Angina) or TIA (Transient Ischemic Attack)|Time to the First Occurrence of the Composite Outcome of Cardiovascular Death, MI, or Stroke (Ischemic, Hemorrhagic, or Unknown)|Time to the First Occurrence of the Individual Components of the Primary: Non-fatal MI, Total MI, Non-fatal Stroke, Total Stroke, Cardiovascular Death, UA and TIA|Time to All-cause Mortality, the First Occurrence of All Cancers Excluding Non-melanoma Skin Cancer (NMSC) and the First Occurrence of Colon Cancer|Incidence of All-cause Mortality, All Cancers Excluding Non-melanoma Skin Cancer and Colon Cancer|Incidence of Confirmed MI, Stroke, Cardiovascular Death, UA, and TIA Separately","Bayer","All","55 Years and older   (Adult, Older Adult)","Phase 3","12546","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","12198|2006-003622-29","July 5, 2007","November 15, 2016","November 15, 2016","July 13, 2007","January 8, 2018","October 26, 2018","Birmingham, Alabama, United States|Graysville, Alabama, United States|Pell City, Alabama, United States|Phoenix, Arizona, United States|Scottsdale, Arizona, United States|Tucson, Arizona, United States|Hot Springs, Arkansas, United States|Fremont, California, United States|Huntington Park, California, United States|Los Angeles, California, United States|Rancho Cucamonga, California, United States|Rolling Hills Estates, California, United States|Helping Hands Clinical Trials, Santa Ana, California, United States|Newark, Delaware, United States|Medical Research Trust, Boynton Beach, Florida, United States|Gainesville, Florida, United States|Hialeah, Florida, United States|Medical Research Centers of South Florida, Inc., Hollywood, Florida, United States|Office of Dr.Larry Levinson, DO, Hollywood, Florida, United States|Kissimmee, Florida, United States|Largo, Florida, United States|Marianna, Florida, United States|Panama City, Florida, United States|Tallahassee Memorial Family, Quincy, Florida, United States|Tampa, Florida, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Chicago, Illinois, United States|Lockport, Illinois, United States|Vernon Hills, Illinois, United States|Evansville, Indiana, United States|Fort Wayne, Indiana, United States|Lebanon, Kentucky, United States|Prince Frederick, Maryland, United States|Bridgman, Michigan, United States|Cadillac, Michigan, United States|Interlochen, Michigan, United States|Troy, Michigan, United States|Port Gibson, Mississippi, United States|Florissant, Missouri, United States|Broken Bow, Nebraska, United States|Omaha, Nebraska, United States|Omaha, Nebraska, United States|Belvidere, New Jersey, United States|Cherry Hill, New Jersey, United States|Clifton, New Jersey, United States|Hainesport, New Jersey, United States|Jersey City, New Jersey, United States|Lawrenceville, New Jersey, United States|Linden, New Jersey, United States|PharmaTrials, Inc., Perth Amboy, New Jersey, United States|Stratford, New Jersey, United States|Burlington, North Carolina, United States|Columbus, North Carolina, United States|Greensboro, North Carolina, United States|Raleigh, North Carolina, United States|Carlisle, Ohio, United States|Marion, Ohio, United States|Montgomery, Ohio, United States|Perrysburg, Ohio, United States|Doylestown, Pennsylvania, United States|Duncansville, Pennsylvania, United States|Sellersville, Pennsylvania, United States|Taylors, South Carolina, United States|Daingerfield, Texas, United States|McKinney, Texas, United States|Rockwall, Texas, United States|San Antonio, Texas, United States|San Marcos, Texas, United States|Stephenville, Texas, United States|Sugar Land, Texas, United States|Honaker, Virginia, United States|Merit Medical Group, Inc., Richlands, Virginia, United States|Benningen, Baden-Württemberg, Germany|Deggingen, Baden-Württemberg, Germany|Dossenheim, Baden-Württemberg, Germany|Ettlingen, Baden-Württemberg, Germany|Graben-Neudorf, Baden-Württemberg, Germany|Heilbronn, Baden-Württemberg, Germany|Hockenheim, Baden-Württemberg, Germany|Ludwigsburg, Baden-Württemberg, Germany|Schwetzingen, Baden-Württemberg, Germany|Sinzheim, Baden-Württemberg, Germany|Stockach, Baden-Württemberg, Germany|Stuttgart, Baden-Württemberg, Germany|Trossingen, Baden-Württemberg, Germany|Weinheim, Baden-Württemberg, Germany|Arzberg, Bayern, Germany|Bergrheinfeld, Bayern, Germany|Dinkelsbühl, Bayern, Germany|Gars, Bayern, Germany|Hohenau, Bayern, Germany|Künzing, Bayern, Germany|München, Bayern, Germany|Oberaurach, Bayern, Germany|Sand Am Main, Bayern, Germany|Schrobenhausen, Bayern, Germany|Spalt, Bayern, Germany|Strasskirchen, Bayern, Germany|Sulzbach-Rosenberg, Bayern, Germany|Ursensollen, Bayern, Germany|Cottbus, Brandenburg, Germany|Elsterwerda, Brandenburg, Germany|Gransee, Brandenburg, Germany|Ketzin, Brandenburg, Germany|Potsdam, Brandenburg, Germany|Frankfurt, Hessen, Germany|Frankfurt, Hessen, Germany|Hanau, Hessen, Germany|Kelkheim, Hessen, Germany|Rotenburg, Hessen, Germany|Wetter, Hessen, Germany|Aurich, Niedersachsen, Germany|Bockenem, Niedersachsen, Germany|Braunschweig, Niedersachsen, Germany|Horneburg, Niedersachsen, Germany|Jühnde, Niedersachsen, Germany|Loxstedt, Niedersachsen, Germany|Nienburg, Niedersachsen, Germany|Northeim, Niedersachsen, Germany|Papenburg, Niedersachsen, Germany|Stuhr, Niedersachsen, Germany|Wardenburg, Niedersachsen, Germany|Weyhe, Niedersachsen, Germany|Winsen, Niedersachsen, Germany|Aachen, Nordrhein-Westfalen, Germany|Aachen, Nordrhein-Westfalen, Germany|Arnsberg, Nordrhein-Westfalen, Germany|Bad Lippspringe, Nordrhein-Westfalen, Germany|Bad Salzuflen, Nordrhein-Westfalen, Germany|Bad Salzuflen, Nordrhein-Westfalen, Germany|Bad Sassendorf, Nordrhein-Westfalen, Germany|Bergkamen, Nordrhein-Westfalen, Germany|Bochum, Nordrhein-Westfalen, Germany|Dortmund, Nordrhein-Westfalen, Germany|Dortmund, Nordrhein-Westfalen, Germany|Dortmund, Nordrhein-Westfalen, Germany|Duisburg, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Freudenberg, Nordrhein-Westfalen, Germany|Greven, Nordrhein-Westfalen, Germany|Hamm, Nordrhein-Westfalen, Germany|Hünxe, Nordrhein-Westfalen, Germany|Kamp-Lintfort, Nordrhein-Westfalen, Germany|Krefeld, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Langenfeld, Nordrhein-Westfalen, Germany|Lienen, Nordrhein-Westfalen, Germany|Lippetal, Nordrhein-Westfalen, Germany|Löhne, Nordrhein-Westfalen, Germany|Marl, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Netphen, Nordrhein-Westfalen, Germany|Porta Westfalica, Nordrhein-Westfalen, Germany|Remscheid, Nordrhein-Westfalen, Germany|Siegen, Nordrhein-Westfalen, Germany|Viersen, Nordrhein-Westfalen, Germany|Welver, Nordrhein-Westfalen, Germany|Wetter, Nordrhein-Westfalen, Germany|Witten, Nordrhein-Westfalen, Germany|Kallstadt, Rheinland-Pfalz, Germany|Ludwigshafen, Rheinland-Pfalz, Germany|Mainz, Rheinland-Pfalz, Germany|Mainz, Rheinland-Pfalz, Germany|Nassau, Rheinland-Pfalz, Germany|Rhaunen, Rheinland-Pfalz, Germany|Speyer, Rheinland-Pfalz, Germany|Bitterfeld, Sachsen-Anhalt, Germany|Halle, Sachsen-Anhalt, Germany|Magdeburg, Sachsen-Anhalt, Germany|Beucha, Sachsen, Germany|Borna, Sachsen, Germany|Delitzsch, Sachsen, Germany|Dresden, Sachsen, Germany|Dresden, Sachsen, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Leipzig, Sachsen, Germany|Markkleeberg, Sachsen, Germany|Meißen, Sachsen, Germany|Oberwiesenthal, Sachsen, Germany|Riesa, Sachsen, Germany|Wermsdorf, Sachsen, Germany|Bad Bramstedt, Schleswig-Holstein, Germany|Reinfeld, Schleswig-Holstein, Germany|Apolda, Thüringen, Germany|Blankenhain, Thüringen, Germany|Grimma, Thüringen, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Daaden, Germany|Hamburg, Germany|Hamburg, Germany|Hamburg, Germany|Hamburg, Germany|Hamburg, Germany|Rehburg-Loccum, Germany|Riede, Germany|Thedinghausen, Germany|Bishopstown, Cork, Ireland|Kilmallock, Limerick, Ireland|Rathkeale, Limerick, Ireland|Tallow, Waterford, Ireland|Enniscorthy, Wexford, Ireland|Gorey, Wexford, Ireland|Bray, Wicklow, Ireland|Cork, Ireland|Dublin, Ireland|Chieti, Abruzzo, Italy|Amandola, Ascoli Piceno, Italy|Napoli, Campania, Italy|Reggio Emilia, Emilia-Romagna, Italy|Chiavari, Genova, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Como, Lombardia, Italy|Varese, Lombardia, Italy|Legnano, Milano, Italy|Novara, Piemonte, Italy|Torino, Piemonte, Italy|Foggia, Puglia, Italy|Catania, Sicilia, Italy|Chieri, Torino, Italy|Moncalieri, Torino, Italy|Grosseto, Toscana, Italy|Asti, Italy|Bergamo, Italy|Reggio Emilia, Italy|Bialystok, Poland|Bydgoszcz, Poland|Bydgoszcz, Poland|Chrzanow, Poland|Czechowice-Dziedzice, Poland|Elblag, Poland|Gdansk, Poland|Gdansk, Poland|Gdansk, Poland|Gdynia, Poland|Gliwice, Poland|Grodzisk Mazowiecki, Poland|Katowice, Poland|Katowice, Poland|Krakow, Poland|Krakow, Poland|Krakow, Poland|Krakow, Poland|Krakow, Poland|Krakow, Poland|Kutno, Poland|Lancut, Poland|Linia, Poland|Lodz, Poland|Lublin, Poland|Lublin, Poland|Lublin, Poland|Malaszewicze, Poland|Malbork, Poland|Naklo nad Notecia, Poland|Olkusz, Poland|Ostrow Wielkopolski, Poland|Poznan, Poland|Przeworsk, Poland|Radom, Poland|Skierniewice, Poland|Skierniewice, Poland|Sobotka, Poland|Sopot, Poland|Szczyrk, Poland|Wabrzezno, Poland|Warszawa, Poland|Warszawa, Poland|Warszawa, Poland|Wejherowo, Poland|Wloclawek, Poland|Wola, Poland|Wroclaw, Poland|Wroclaw, Poland|Zabrze, Poland|Guaynabo, Puerto Rico|Manati, Puerto Rico|Orocovis, Puerto Rico|San Juan, Puerto Rico|Trujilo Alto, Puerto Rico|Sobrado Dos Monxes, A Coruña, Spain|La Roda, Albacete, Spain|Benidorm, Alicante, Spain|Elche, Alicante, Spain|Petrer, Alicante, Spain|Xixona, Alicante, Spain|Oviedo, Asturias, Spain|Oviedo, Asturias, Spain|Posada De Llanes, Asturias, Spain|Vic (Barcelona), Catalunya, Spain|Begonte, Lugo, Spain|Viveiro, Lugo, Spain|Espinardo, Murcia, Spain|Orense, Ourense, Spain|Gümar, Santa Cruz De Tenerife, Spain|La Victoria, Santa Cruz De Tenerife, Spain|Alcover, Tarragona, Spain|Albacete, Spain|Alicante, Spain|Badajoz, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Huelva, Spain|León, Spain|León, Spain|Lugo, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Murcia, Spain|Murcia, Spain|Murcia, Spain|Salamanca, Spain|Santander, Spain|Valladolid, Spain|Ballymena, Antrim, United Kingdom|Ballymena, Antrim, United Kingdom|Crumlin, Antrim, United Kingdom|Newtonabbey, Antrim, United Kingdom|Craigavon, Armagh, United Kingdom|Bath, Avon, United Kingdom|Bath, Avon, United Kingdom|Radstock, Avon, United Kingdom|Irvine, Ayrshire, United Kingdom|Luton, Bedfordshire, United Kingdom|Slough, Berkshire, United Kingdom|Ely, Cambridgeshire, United Kingdom|Ely, Cambridgeshire, United Kingdom|Peterborough, Cambridgeshire, United Kingdom|Peterborough, Cambridgeshire, United Kingdom|Sandbach, Cheshire, United Kingdom|Boscastle, Cornwall, United Kingdom|Fowey, Cornwall, United Kingdom|Penzance, Cornwall, United Kingdom|Penzance, Cornwall, United Kingdom|Penzance, Cornwall, United Kingdom|Saltash, Cornwall, United Kingdom|St Austell, Cornwall, United Kingdom|Chesterfield, Derbyshire, United Kingdom|Dronfield, Derbyshire, United Kingdom|Plymouth, Devon, United Kingdom|Carryduff, Down, United Kingdom|Annan, Dumfries And Galloway, United Kingdom|Bishop Auckland, Durham, United Kingdom|Darlington, Durham, United Kingdom|Darlington, Durham, United Kingdom|Darlington, Durham, United Kingdom|Leigh-on-Sea, Essex, United Kingdom|Tiptree, Essex, United Kingdom|High Valleyfield, Fife, United Kingdom|Glasgow, Glasgow City, United Kingdom|Bangor, Gwynedd, United Kingdom|Hitchin, Hertfordshire, United Kingdom|Letchworth, Hertfordshire, United Kingdom|Letchworth, Hertfordshire, United Kingdom|Canterbury, Kent, United Kingdom|Chestfield, Kent, United Kingdom|Whitstable, Kent, United Kingdom|Carstairs, Lanarkshire, United Kingdom|Coatbridge, Lanarkshire, United Kingdom|Forth, Lanarkshire, United Kingdom|Blackpool, Lancashire, United Kingdom|Blackpool, Lancashire, United Kingdom|Bolton, Lancashire, United Kingdom|Bolton, Lancashire, United Kingdom|Hinckley, Leicestershire, United Kingdom|Wells-Next-The-Sea, Norfolk, United Kingdom|Wymondham, Norfolk, United Kingdom|Antrim, North Ireland, United Kingdom|Antrim, North Ireland, United Kingdom|Antrim, North Ireland, United Kingdom|Tyrone, North Ireland, United Kingdom|Wellingborough, Northamptonshire, United Kingdom|Chipping Norton, Oxfordshire, United Kingdom|Eccles, Sheffield, United Kingdom|Bath, Somerset, United Kingdom|Barry, SOuth Glamorgan, United Kingdom|Doncaster, South Yorkshire, United Kingdom|Sheffield, South Yorkshire, United Kingdom|Chapelhall, Stratchclyde, United Kingdom|Glasgow, Stratchclyde, United Kingdom|Hamilton, Stratchclyde, United Kingdom|Johnstone, Stratchclyde, United Kingdom|Motherwell, Stratchclyde, United Kingdom|Bury Saint Edmonds, Suffolk, United Kingdom|Bury St. Edmunds, Suffolk, United Kingdom|Bury St. Edmunds, Suffolk, United Kingdom|Hadleigh, Suffolk, United Kingdom|Stowmarket, Suffolk, United Kingdom|Addlestone, Surrey, United Kingdom|East Horsley, Surrey, United Kingdom|Worcester Park, Surrey, United Kingdom|Newcastle Upon Tyne, Tyne And Wear, United Kingdom|Coventry, Warwickshire, United Kingdom|Coventry, Warwickshire, United Kingdom|Rugby, Warwickshire, United Kingdom|Coventry, West Midlands, United Kingdom|Brighton, West Sussex, United Kingdom|Crawley, West Sussex, United Kingdom|Crawley, West Sussex, United Kingdom|Leeds, West Yorkshire, United Kingdom|Leeds, West Yorkshire, United Kingdom|Leeds, West Yorkshire, United Kingdom|Leeds, West Yorkshire, United Kingdom|Leeds, West Yorkshire, United Kingdom|Leeds, West Yorkshire, United Kingdom|Leeds, West Yorkshire, United Kingdom|Leeds, West Yorkshire, United Kingdom|Bradford-on-Avon, Wiltshire, United Kingdom|Chippenham, Wiltshire, United Kingdom|Chippenham, Wiltshire, United Kingdom|Corsham, Wiltshire, United Kingdom|Trowbridge, Wiltshire, United Kingdom|Westbury, Wiltshire, United Kingdom|Aberdeen, United Kingdom|Airedire, United Kingdom|Antrim, United Kingdom|Bath, United Kingdom|Bath, United Kingdom|Belfast, United Kingdom|Belfast, United Kingdom|Belfast, United Kingdom|Belfast, United Kingdom|Belfast, United Kingdom|Belfast, United Kingdom|Belfast, United Kingdom|Belfast, United Kingdom|Bellshill, United Kingdom|Blantyre, United Kingdom|Cardiff, United Kingdom|Coatrbridge, United Kingdom|Crossgar, United Kingdom|Doncaster, United Kingdom|Dundee, United Kingdom|Glasgow, United Kingdom|Glasgow, United Kingdom|Glasgow, United Kingdom|Glasgow, United Kingdom|Hamilton, United Kingdom|Hamilton, United Kingdom|Inverness, United Kingdom|Ipswich, United Kingdom|Lockerbie, United Kingdom|London, United Kingdom|Manchester, United Kingdom|New Stevenson, United Kingdom|Paisley, United Kingdom|Peterborough, United Kingdom|Thornhill, United Kingdom|Watford, United Kingdom|Wishaw, United Kingdom|Witley Bay, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00501059"
1212,"NCT00498784","HR-QoL and Sexuality in Mirena Inserted Contraception Users",,"Completed","No Results Available","Contraception","Drug: Mirena","Health-related QoL score|Sexuality Index, treatment satisfaction, usual safety outcomes","Bayer","Female","18 Years to 35 Years   (Adult)","Phase 4","141","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","91458|2005-002955-42|309663","November 2005","October 2007","October 2007","July 10, 2007",,"January 23, 2013","Bordeaux, Gironde, France",,"https://ClinicalTrials.gov/show/NCT00498784"
1213,"NCT00494871","Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation",,"Completed","Has Results","Atrial Fibrillation","Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Warfarin|Drug: Rivaroxaban placebo|Drug: Warfarin placebo","Event Rate of the Composite Endpoint of Adjudicated Major Bleeding or Adjudicated Non-major Clinically Relevant Bleeding|Event Rate of the Composite Endpoint of Adjudicated Stroke and Non-central Nervous System (CNS) Systemic Embolism|Event Rate of the Composite Endpoint of Adjudicated Stroke, Non-CNS Systemic Embolism, and Vascular Death|Event Rate of the Composite Endpoint of Adjudicated Stroke, Non-CNS Systemic Embolism, Myocardial Infarction, and Vascular Death|Event Rate of Stroke|Event Rate of Non-CNS Systemic Embolism|Event Rate of Myocardial Infarction|Event Rate of Vascular Death|Event Rate of Stroke With Serious Residual Disability|Event Rate of All-cause Death|Event Rate of Adjudicated Major Bleeding|Event Rate Adjudicated Non-major Clinically Relevant Bleeding","Bayer|Janssen R&D, L.L.C.","All","20 Years and older   (Adult, Older Adult)","Phase 3","1280","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","12620","June 2007","December 2009","January 2010","July 2, 2007","April 19, 2012","April 20, 2015","Kasugai, Aichi, Japan|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Okazaki, Aichi, Japan|Goshogawara, Aomori, Japan|Hirosaki, Aomori, Japan|Hirosaki, Aomori, Japan|Asahi, Chiba, Japan|Funabashi, Chiba, Japan|Imba, Chiba, Japan|Matsudo, Chiba, Japan|Matsudo, Chiba, Japan|Yotsukaido, Chiba, Japan|Imabari, Ehime, Japan|Matsuyama, Ehime, Japan|Matsuyama, Ehime, Japan|Matsuyama, Ehime, Japan|Niihama, Ehime, Japan|Saijo, Ehime, Japan|Toon, Ehime, Japan|Chikushi-gun, Fukuoka, Japan|Chikushino, Fukuoka, Japan|Chikushino, Fukuoka, Japan|Kasuga, Fukuoka, Japan|Kasuga, Fukuoka, Japan|Kitakyushu, Fukuoka, Japan|Kitakyushu, Fukuoka, Japan|Kurume, Fukuoka, Japan|Ogori, Fukuoka, Japan|Yame, Fukuoka, Japan|Yame, Fukuoka, Japan|Koriyama, Fukushima, Japan|Ogaki, Gifu, Japan|Maebashi, Gunma, Japan|Mebashi, Gunma, Japan|Otake, Hiroshima, Japan|Asahikawa, Hokkaido, Japan|Chitose, Hokkaido, Japan|Hakodate, Hokkaido, Japan|Muroran, Hokkaido, Japan|Otaru, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sunagawa, Hokkaido, Japan|Tomakomai, Hokkaido, Japan|Kobe, Hyogo, Japan|Kobe, Hyogo, Japan|Kobe, Hyogo, Japan|Higashiibaraki, Ibaraki, Japan|Hitachi, Ibaraki, Japan|Joso, Ibaraki, Japan|Kasama, Ibaraki, Japan|Moriya, Ibaraki, Japan|Namegata, Ibaraki, Japan|Toride, Ibaraki, Japan|Kanazawa, Ishikawa, Japan|Nomi, Ishikawa, Japan|Hanamaki, Iwate, Japan|Morioka, Iwate, Japan|Marugame, Kagawa, Japan|Takamatsu, Kagawa, Japan|Izumi, Kagoshima, Japan|Atsugi, Kanagawa, Japan|Fujisawa, Kanagawa, Japan|Fujisawa, Kanagawa, Japan|Kamakura, Kanagawa, Japan|Kawasaki, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Nangoku, Kochi, Japan|Uji, Kyoto, Japan|Kuwana, Mie, Japan|Sendai, Miyagi, Japan|Sendai, Miyagi, Japan|Sendai, Miyagi, Japan|Sendai, Miyagi, Japan|Sendai, Miyagi, Japan|Komoro, Nagano, Japan|Matsumoto, Nagano, Japan|Suwa, Nagano, Japan|Joetsu, Niigata, Japan|Nagaoka, Niigata, Japan|Beppu, Oita, Japan|Beppu, Oita, Japan|Yufu, Oita, Japan|Kasaoka, Okayama, Japan|Shimajiri, Okinawa, Japan|Daito, Osaka, Japan|Higashiosaka, Osaka, Japan|Hirakata, Osaka, Japan|Hirakata, Osaka, Japan|Kawachinagano, Osaka, Japan|Kishiwada, Osaka, Japan|Takatsuki, Osaka, Japan|Toyonaka, Osaka, Japan|Yao, Osaka, Japan|Hanyu, Saitama, Japan|Kasukage, Saitama, Japan|Kitamoto, Saitama, Japan|Tokorozawa, Saitama, Japan|Tokorozawa, Saitama, Japan|Wako, Saitama, Japan|Kusatsu, Shiga, Japan|Fujinomiya, Shizuoka, Japan|Fukuroi, Shizuoka, Japan|Hamamatsu, Shizuoka, Japan|Hamamatsu, Shizuoka, Japan|Iwata, Shizuoka, Japan|Shimada, Shizuoka, Japan|Naruto, Tokushima, Japan|Edogawa-ku, Tokyo, Japan|Hachioji, Tokyo, Japan|Higashikurume, Tokyo, Japan|Itabashi-ku, Tokyo, Japan|Itabashi-ku, Tokyo, Japan|Meguro-ku, Tokyo, Japan|Ota-ku, Tokyo, Japan|Shibuya-ku, Tokyo, Japan|Shinagawa-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Higashikawada, Yamagata, Japan|Shimonoseki, Yamaguchi, Japan|Shunan, Yamaguchi, Japan|Fukui, Japan|Fukuoka, Japan|Fukuoka, Japan|Fukuoka, Japan|Fukuoka, Japan|Gifu, Japan|Kagoshima, Japan|Kumamoto, Japan|Kyoto, Japan|Nagasaki, Japan|Oita, Japan|Oita, Japan|Oita, Japan|Oita, Japan|Okayama, Japan|Okayama, Japan|Okinawa, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Shizuoka, Japan|Shizuoka, Japan|Shizuoka, Japan|Tokushima, Japan|Tottori, Japan|Toyama, Japan|Wakayama, Japan",,"https://ClinicalTrials.gov/show/NCT00494871"
1214,"NCT00494299","Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)",,"Completed","Has Results","Carcinoma, Hepatocellular","Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Placebo","Time to Progression (TTP)|Overall Survival (OS)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","458","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11721","April 2006","July 2009","November 2010","June 29, 2007","January 20, 2011","December 20, 2013","Nagoya, Aichi, Japan|Kashiwa, Chiba, Japan|Matsuyama, Ehime, Japan|Toon, Ehime, Japan|Iizuka, Fukuoka, Japan|Kitakyushu, Fukuoka, Japan|Kitakyushu, Fukuoka, Japan|Kurume, Fukuoka, Japan|Isesaki, Gunma, Japan|Maebashi, Gunma, Japan|Kure, Hiroshima, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Akashi, Hyogo, Japan|Kobe, Hyogo, Japan|Kasama, Ibaraki, Japan|Kanazawa, Ishikawa, Japan|Isehara, Kanagawa, Japan|Sagamihara, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Sendai, Miyagi, Japan|Sendai, Miyagi, Japan|Matsumoto, Nagano, Japan|Omura, Nagasaki, Japan|Kawachinagano, Osaka, Japan|Moriguchi, Osaka, Japan|Osakasayama, Osaka, Japan|Suita, Osaka, Japan|Izunokuni, Shizuoka, Japan|Sunto, Shizuoka, Japan|Shimotsuke, Tochigi, Japan|Chuo-ku, Tokyo, Japan|Itabashi-ku, Tokyo, Japan|Meguro-ku, Tokyo, Japan|Minato-ku, Tokyo, Japan|Musashino, Tokyo, Japan|Nerima-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Yonago, Tottori, Japan|Shimonoseki, Yamaguchi, Japan|Ube, Yamaguchi, Japan|Chuo, Yamanashi, Japan|Chiba, Japan|Fukui, Japan|Fukuoka, Japan|Gifu, Japan|Hiroshima, Japan|Hiroshima, Japan|Hiroshima, Japan|Kagoshima, Japan|Kagoshima, Japan|Kagoshima, Japan|Kumamoto, Japan|Kumamoto, Japan|Kumamoto, Japan|Kyoto, Japan|Miyazaki, Japan|Okayama, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Toyama, Japan|Yamagata, Japan|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Daegu, Korea, Republic of|Incheon, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00494299"
1215,"NCT00493038","Study to Evaluate the Efficacy and Safety of Moxifloxacin Versus Amoxicillin/Clavulanate in the Treatment of Acute Bacterial Rhinosinusitis",,"Terminated","Has Results","Sinusitis|Bacterial Infections","Drug: Moxifloxacin (Avelox, BAY12-8039)|Drug: Amoxicillin/Clavulanate","Number of Participants With Response (Per-protocol Population)|Number of Participants With Response (Intent-to-treat Population)|Number of Participants With Response (Microbiologically Valid Patients)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 4","293","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","11881|2005-002779-34","February 2006","January 2008","January 2008","June 27, 2007","April 13, 2009","November 7, 2014","San Benedetto del Tronto, Ascoli Piceno, Italy|Esine, Brescia, Italy|Lamezia Terme, Catanzaro, Italy|Cesena, Forlì, Italy|Sestri Ponente, Genova, Italy|Monza, Monza-Brianza, Italy|Comiso, Ragusa, Italy|Bari, Italy|Benevento, Italy|Bergamo, Italy|Bologna, Italy|Bolzano, Italy|Caserta, Italy|Catania, Italy|Catania, Italy|Firenze, Italy|Foggia, Italy|Lecce, Italy|Lecco, Italy|Matera, Italy|Milano, Italy|Milano, Italy|Novara, Italy|Pavia, Italy|Perugia, Italy|Pisa, Italy|Roma, Italy|Roma, Italy|Roma, Italy|Siena, Italy|Torino, Italy|Torino, Italy|Treviso, Italy|Udine, Italy",,"https://ClinicalTrials.gov/show/NCT00493038"
1216,"NCT00492986","An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma",,"Completed","No Results Available","Carcinoma, Renal Cell","Drug: Nexavar (Sorafenib, BAY43-9006)","Safety Parameters|Collection of radiological evaluations","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","1150","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11941|2005-002524-34","October 2005","November 2008","November 2008","June 27, 2007",,"December 30, 2014","Bruxelles - Brussel, Belgium|Leuven, Belgium|Århus C, Denmark|Bordeaux, France|Lyon Cedex, France|Villejuif, France|München, Bayern, Germany|Darmstadt, Hessen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Koblenz, Rheinland-Pfalz, Germany|Mainz, Rheinland-Pfalz, Germany|Homburg, Saarland, Germany|Dresden, Sachsen, Germany|Lübeck, Schleswig-Holstein, Germany|Berlin, Germany|Hamburg, Germany|Milano, Italy|Modena, Italy|Pavia, Italy|Perugia, Italy|Reggio Emilia, Italy|Amsterdam, Netherlands|Warszawa, Poland|Oviedo, Asturias, Spain|Barcelona, Spain|Madrid, Spain|Göteborg, Sweden|Stockholm, Sweden|Basel, Basel-Stadt, Switzerland|Genève, Switzerland|Glasgow, Stratchclyde, United Kingdom|Sutton, Surrey, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00492986"
1217,"NCT00492752","A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma",,"Completed","Has Results","Carcinoma, Hepatocellular","Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Placebo","Overall Survival|Time to Symptomatic Progression (TTSP)|Time to Progression (TTP)|Disease Control|Change in Functional Assessment of Cancer Therapy (FACT) Hepatobiliary Symptom Index-8 (FHSI-8) Score From Baseline to Cycle 1 and Cycle 3|Change in Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) Score From Baseline to Cycle 3 and End of Treatment|Number of Participants With Different Tumor Response|Duration of Response|Time to Response|Area Under the Curve From Time 0 to 12 Hours Post-dose (AUC 0-12) After 21 Days of Sorafenib Treatment|Normalized Area Under the Curve (AUC Norm) After 21 Days of Sorafenib Treatment|Maximum Concentration (Cmax) After 21 Days of Sorafenib Treatment|Normalized Maximum Concentration (Cmaxnorm) After 21 Days of Sorafenib Treatment|Time of Maximum Concentration (Tmax) After 21 Days of Sorafenib Treatment","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","226","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11849","October 2005","March 2007","July 2009","June 27, 2007","January 13, 2011","April 16, 2014","Hefei, Anhui, China|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Wuhan, Hubei, China|Nanjing, Jiangsu, China|Nanjing, Jiangsu, China|Dalian, Liaoning, China|Dalian, Liaoning, China|Hangzhou, Zhejiang, China|Beijing, China|Beijing, China|Chongqing, China|Shanghai, China|Shanghai, China|Tianjin, China|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Daegu, Korea, Republic of|Seoul, Korea, Republic of|Changhua, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT00492752"
1218,"NCT00492726","Therapy of Complicated Intra-Abdominal Infections With Moxifloxacin or Ertapenem",,"Completed","Has Results","Infection","Drug: Moxifloxacin (Avelox, BAY12-8039)|Drug: Ertapenem intravenous","Number of Subjects Achieving Clinical Cure at Test of Cure (TOC) Visit in the Per Protocol Population|Number of Subjects Achieving Clinical Improvement During Treatment in the Per Protocol Population|Number of Subjects Achieving Bacteriological Success During Treatment in the Per Protocol Population With Causative Organism(s)|Number of Subjects Achieving Clinical Cure at End of Therapy (EOT) Visit in the Per Protocol Population|Number of Subjects Achieving Bacteriological Success at EOT Visit in the Per Protocol Population With Causative Organism(s)|Number of Subjects Achieving Bacteriological Success at TOC Visit in the Per Protocol Population With Causative Organism(s)|Number of Subjects Achieving Clinical Cure at TOC Visit in the Per Protocol Population With Causative Organism(s)|Number of Subjects Who Died Due to Intra-abdominal Infections|Duration of Hospitalization|Duration of Hospitalization Postoperatively","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","804","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","11976|2006-000874-56","July 2006","February 2009","February 2009","June 27, 2007","March 3, 2010","November 7, 2014","Ciudadela, Buenos Aires, Argentina|de Febrero 3, Buenos Aires, Argentina|Florencio Varela, Buenos Aires, Argentina|Merlo, Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Rosario, Santa Fe, Argentina|Capital Federal, Argentina|Córdoba, Argentina|Mendoza, Argentina|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Gent, Belgium|Pleven, Bulgaria|Rousse, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Kohtla-Jarve, Estonia|Tallin, Estonia|Tartu, Estonia|Amilly Cedex, France|Besancon, France|Heidelberg, Baden-Württemberg, Germany|Beeskow, Brandenburg, Germany|Hannover, Niedersachsen, Germany|Paderborn, Nordrhein-Westfalen, Germany|Homburg, Saarland, Germany|Rio Patras, Greece|Haifa, Israel|Kfar Saba, Israel|Daugavpils, Latvia|Liepaja, Latvia|Rezekne, Latvia|Riga, Latvia|Riga, Latvia|Valmiera, Latvia|Kaunas, Lithuania|Klaipeda, Lithuania|Vilnius, Lithuania|Vilnius, Lithuania|Brasov, Romania|Bucharest, Romania|Cluj-Napoca, Romania|Oradea, Romania|Timisoara, Romania|Moscow, Russian Federation|Moscow, Russian Federation|Smolensk, Russian Federation|Cape Town, Cape, South Africa|Pretoria, Gauteng, South Africa|Somerset West, Western Cape, South Africa|L'Hospitalet de Llobregat, Barcelona, Spain|Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT00492726"
1219,"NCT00492635","Study to Compare the Tolerability and Efficacy of Once Daily Vardenafil vs Vardenafil PRN vs Placebo in Men Immediately After Nerve-sparing Prostatectomy for Improving ED",,"Completed","No Results Available","Erectile Dysfunction|Sexual Dysfunction, Physiological","Drug: Levitra (Vardenafil, BAY38-9456)|Drug: Placebo","Determine whether early, NIGHTLY dosing with vardenafil Significantly improves recovery of erectile function after surgery as compared to placebo, and whether early PRN dosing with vardenafil also improves recovery of function as compared to placebo|Assess whether early dosing of either NIGHTLY or PRN vardenafil over 9 months, followed by 2 months of withdrawal, increases efficacy of subsequent PRN use significantly better than placebo","Bayer","Male","18 Years to 64 Years   (Adult)","Phase 3","628","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","11336|2004-002172-42","December 2004","September 2007","September 2007","June 27, 2007",,"October 28, 2014","Laguna Hills, California, United States|Jeffersonville, Indiana, United States|Des Moines, Iowa, United States|Jackson, Mississippi, United States|Poughkeepsie, New York, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Oklahoma City, Oklahoma, United States|Lancaster, Pennsylvania, United States|Providence, Rhode Island, United States|Spokane, Washington, United States|Graz, Steiermark, Austria|Salzburg, Austria|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Edegem, Belgium|Hasselt, Belgium|Leuven, Belgium|Liege, Belgium|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Barrie, Ontario, Canada|London, Ontario, Canada|Oakville, Ontario, Canada|Toronto, Ontario, Canada|Chicoutimi, Quebec, Canada|Fleurimont, Quebec, Canada|St. John, Canada|Victoria, Canada|Oulu, Finland|Oulu, Finland|Tampere, Finland|Carpentras, France|Lille, France|Lyon Cedex, France|Nimes, France|Saint Genis Laval Cedex, France|Mannheim, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|München, Bayern, Germany|München, Bayern, Germany|Weiden, Bayern, Germany|Offenbach, Hessen, Germany|Braunschweig, Niedersachsen, Germany|Osnabrück, Niedersachsen, Germany|Dortmund, Nordrhein-Westfalen, Germany|Herne, Nordrhein-Westfalen, Germany|Leverkusen, Nordrhein-Westfalen, Germany|Hamburg, Germany|Bari, Italy|Firenze, Italy|Genova, Italy|Milano, Italy|Milano, Italy|Napoli, Italy|Trieste, Italy|Leiden, Netherlands|Nijmegen, Netherlands|Rotterdam, Netherlands|Moelv, Norway|Tønsberg, Norway|Johannesburg, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Pietermaritzburg, Kwazulu-Natal, South Africa|Cape Town, Western Cape, South Africa|Cape Town, Western Cape, South Africa|Vigo, Pontevedra, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Málaga, Spain|Valencia, Spain|Valencia, Spain|Göteborg, Sweden|Göteborg, Sweden|Halmstad, Sweden|Lund, Sweden|Skövde, Sweden|Västerås, Sweden|Bern, Switzerland|Bath, Avon, United Kingdom|Bristol, Avon, United Kingdom|Slough, Berkshire, United Kingdom|Taunton, Somerset, United Kingdom|London, United Kingdom|Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00492635"
1220,"NCT00492297","A Phase II, Multi-Center, Open-Label, Uncontrolled Study to Evaluate the Efficacy and Safety of Sorafenib Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic Melanoma",,"Completed","Has Results","Melanoma","Drug: Sorafenib (Nexavar, BAY43-9006) + Dacarbazine (DTIC)","Overall Best Response|Progression-free Survival|Percentage of Subjects With Progression-free Survival at Specific Time-points|Overall Survival|Duration of Response|Duration of Complete Response|Duration of Partial Response|Disease Control (DC)|Duration of Stable Disease|Time to Response|Time to Progression","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","83","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11538|2004-000725-30","April 2005","June 2008","July 2008","June 27, 2007","January 25, 2011","October 31, 2014","Bordeaux, France|Lyon Cedex, France|Toulouse, France|Villejuif, France|Cambridge, Cambridgeshire, United Kingdom|Southampton, Hampshire, United Kingdom|Northwood, Middlesex, United Kingdom|Sutton, Surrey, United Kingdom|London, United Kingdom|London, United Kingdom|London, United Kingdom|Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00492297"
1221,"NCT00492024","BAY12-8039: 5 Days for Sinusitis vs Placebo",,"Completed","Has Results","Sinusitis","Drug: Moxifloxacin (Avelox, BAY12-8039)|Drug: Placebo","Percentage of Subjects With Clinical Cure (Modified Intent-to-Treat (MITT))|Treatment Day When Patients Reached Symptom Improvement as Measured by Patient Reported Data, Using Last Observation Carried Forward (LOCF) Approach|Treatment Day When Patients Returned to Normal Activities as Measured by Patient Reported Data, Using LOCF Approach|Percentage of Subjects With Clinical Improvement During Therapy|Percentage of Subjects With Continued Clinical Cure During Long-Term Follow-Up","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","374","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11566","January 2005","March 2008","March 2008","June 27, 2007","December 2, 2009","November 26, 2013","Birmingham, Alabama, United States|Northport, Alabama, United States|Jonesboro, Arkansas, United States|Little Rock, Arkansas, United States|Fresno, California, United States|Fresno, California, United States|Garden Grove, California, United States|Orange, California, United States|Roseville, California, United States|San Diego, California, United States|San Luis Obispo, California, United States|Colorado Springs, Colorado, United States|Bridgeport, Connecticut, United States|Dunnellon, Florida, United States|Hialeah, Florida, United States|North Miami Beach, Florida, United States|Pembroke Pines, Florida, United States|Plantation, Florida, United States|Atlanta, Georgia, United States|Warner Robbins, Georgia, United States|Warner Robins, Georgia, United States|Louisville, Kentucky, United States|Detroit, Michigan, United States|Livonia, Michigan, United States|Portage, Michigan, United States|Butte, Montana, United States|Elizabeth, New Jersey, United States|Lawrenceville, New Jersey, United States|Somerville, New Jersey, United States|Rochester, New York, United States|Charlotte, North Carolina, United States|Raleigh, North Carolina, United States|Cincinnati, Ohio, United States|Dayton, Ohio, United States|Eugene, Oregon, United States|Levittown, Pennsylvania, United States|Norristown, Pennsylvania, United States|Palmyra, Pennsylvania, United States|Clarksville, Tennessee, United States|Austin, Texas, United States|College Station, Texas, United States|El Paso, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Salt Lake City, Utah, United States|West Jordan, Utah, United States|West Jordan, Utah, United States|Tappahannock, Virginia, United States|Bellingham, Washington, United States|Greenfield, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00492024"
1222,"NCT00488241","Multicenter Clinical Study to Examine the Efficacy and Safety of Zarzenda in Patients With Hand Eczema",,"Completed","No Results Available","Hand Eczema","Device: Zarzenda","Hand eczema severity index (HECSI)at the end of study|Investigator's Global Assessment|Patients assessment of itch|Hand surface area|Clinical signs of hand eczema","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 4","40","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1401663","June 2007","September 2007","September 2007","June 20, 2007",,"February 26, 2014","Intendis GmbH, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT00488241"
1223,"NCT00481689","Study To Evaluate The Efficacy And Safety Of Ciprofloxacin Extended-Release (Cipro® XR) 1000 mg Tablets Given Once Daily For 7 To 14 Days In The Treatment Of Patients 18 Years Or Older With Complicated Urinary Tract Infections Caused By Pseudomonas Aeruginosa And Other Common Uropathogens",,"Completed","No Results Available","Urinary Tract Infections","Drug: Cipro XR (Ciprofloxacin, BAYQ3939)","To evaluate safety and efficacy of ciprofloxacin XR for treatment of subjects with complicated urinary tract infections caused by P. aeruginosa and other urinary pathogens.|Clinical response|Clinical response post- treatment|Adverse Event collection","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 4","500","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11490","May 2004",,"September 2005","June 4, 2007",,"June 26, 2009","Birmingham, Alabama, United States|Birmingham, Alabama, United States|Huntsville, Alabama, United States|Scottsdale, Arizona, United States|Cudahy, California, United States|Fresno, California, United States|La Mesa, California, United States|Laguna Hills, California, United States|Long Beach, California, United States|Los Angeles, California, United States|San Diego, California, United States|Torrance, California, United States|Waterbury, Connecticut, United States|Ocala, Florida, United States|Pembroke Pines, Florida, United States|Indianapolis, Indiana, United States|Des Moines, Iowa, United States|Iowa City, Iowa, United States|Watertown, Massachusetts, United States|St. Louis, Missouri, United States|Las Vegas, Nevada, United States|Reno, Nevada, United States|East Orange, New Jersey, United States|Albuquerque, New Mexico, United States|Albuquerque, New Mexico, United States|Manhasset, New York, United States|North Massapequa, New York, United States|Troy, New York, United States|Eugene, Oregon, United States|Philadelphia, Pennsylvania, United States|Memphis, Tennessee, United States|San Antonio, Texas, United States|Richmond, Virginia, United States|Tacoma, Washington, United States|Cheyenne, Wyoming, United States",,"https://ClinicalTrials.gov/show/NCT00481689"
1224,"NCT00478881","A Study To Assess If 10 mg Vardenafil (BAY38-9456) Taken Twice Daily For 6 Weeks Has An Effect On Bladder Function",,"Completed","Has Results","Overactive Bladder|Detrusor Overactivity","Drug: Vardenafil HCl (Levitra, BAY38-9456)|Drug: Placebo","Change From Baseline in Bladder Volume at First Detrusor Contraction at 6 Weeks|Change From Baseline in Average Number of Daily Micturitions at 6 Weeks|Change From Baseline in H2O Detrusor Pressure at First Contraction at 6 Weeks|Change From Baseline in Volume at First Detectable Leakage at 6 Weeks|Change From Baseline in Maximum Cystometric Bladder Capacity at 6 Weeks|Change From Baseline in Volume at First Desire to Void at 6 Weeks|Change From Baseline in Average Number of Urgencies Per Day at 6 Weeks|Change From Baseline in Average Number of Daily Involuntary Discharges of Urine at 6 Weeks|Change From Baseline in Peak Urinary Flow at 6 Weeks in Men Aged 50 Years and Older|Change From Baseline in the Total Score of the Overactive Bladder Questionnaire (OAB-q) at 6 Weeks","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","397","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","12392|2006-005145-11","August 2007","November 2008","November 2008","May 25, 2007","December 24, 2009","December 11, 2014","Bruxelles - Brussel, Belgium|Victoria, British Columbia, Canada|Brantford, Ontario, Canada|Kitchener, Ontario, Canada|Montreal, Quebec, Canada|Olomouc, Czech Republic|Praha 4, Czech Republic|Praha 6, Czech Republic|Paris Cedex 20, France|Paris, France|Emmendingen, Baden-Württemberg, Germany|Bad Griesbach-Therme, Bayern, Germany|Weiden, Bayern, Germany|Schwedt, Brandenburg, Germany|Greifswald, Mecklenburg-Vorpommern, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Mönchengladbach, Nordrhein-Westfalen, Germany|Wuppertal, Nordrhein-Westfalen, Germany|Neunkirchen, Saarland, Germany|Leipzig, Sachsen, Germany|Berlin, Germany|Berlin, Germany|Budapest, Hungary|Budapest, Hungary|Haifa, Israel|Jerusalem, Israel|Petach Tikva, Israel|Eindhoven, Noord-Brabant, Netherlands|Amsterdam, Netherlands|Amsterdam, Netherlands|Maastricht, Netherlands|Rotterdam, Netherlands|Utrecht, Netherlands|Bydgoszcz, Poland|Chorzow, Poland|Siedlce, Poland|Warszawa, Poland|Warszawa, Poland|Warszawa, Poland|Amadora, Portugal|Lisboa, Portugal|Porto, Portugal|Porto, Portugal|S. Martinho do Bispo, Portugal|Moscow, Russian Federation|Moscow, Russian Federation|St. Petersburg, Russian Federation|Santiago de Compostela, A Coruña, Spain|Barcelona, Spain|Barcelona, Spain|Granada, Spain|Madrid, Spain|Valencia, Spain|Basel, Basel-Stadt, Switzerland",,"https://ClinicalTrials.gov/show/NCT00478881"
1225,"NCT00473460","Intermittent Moxifloxacin Therapy For The Prevention Of Acute Exacerbations In Patients With Chronic Bronchitis",,"Completed","No Results Available","Lung Diseases|Bronchitis, Chronic","Drug: Avelox (Moxifloxacin, BAY12-8039)|Drug: Placebo","Number of exacerbations after 48 weeks of intermittent pulse treatment|Impact of treatment on the health related Quality of Life in St. George's Respiratory Questionaire (SGRQ) scores|Deterioration in lung function test (PFEV1)|Frequency of hospitalisation|Mortality rates|Time of first exacerbation|Frequency of acute exacerbation of chronic bronchitis|Time to next exacerbation from last pulsed dose|Length of exacerbations|Percentage of exacerbation free time","Bayer","All","45 Years to 90 Years   (Adult, Older Adult)","Phase 3","1404","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","11229|EudraCT No: 2004-000404-40","October 2004","January 2007","January 2007","May 15, 2007",,"October 28, 2014","Tucson, Arizona, United States|Long Beach, California, United States|Los Angeles, California, United States|Bay Pines, Florida, United States|Kansas City, Missouri, United States|Buffalo, New York, United States|Dallas, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Richmond, Virginia, United States|Escaldes - Engordany, Andorra|Florencio Varela, Buenos Aires, Argentina|Buenos Aires, Capital Federal, Argentina|Buenos Aires, Capital Federal, Argentina|Buenos Aires, Capital Federal, Argentina|Juiz de Fora, MG, Brazil|Porto Alegre, RS, Brazil|Sao Paulo, SP, Brazil|Sao Paulo, SP, Brazil|Santiago, Chile|Valparaiso, Chile|Arras, France|Mont-de-marsan, France|Nice, France|Orthez, France|Rosiers D'egletons, France|Strasbourg, France|Kaufbeuren, Bayern, Germany|Gelnhausen, Hessen, Germany|Hannover, Niedersachsen, Germany|Rotenburg, Niedersachsen, Germany|Witten, Nordrhein-Westfalen, Germany|Neuwied, Rheinland-Pfalz, Germany|Bad Segeberg, Schleswig-Holstein, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Hamburg, Germany|Rio, Patras, Greece|Athens, Greece|Dublin, Ireland|Dublin, Ireland|Afula, Israel|Ashkelon, Israel|Bat Yam, Israel|Tel Aviv, Israel|Ferrara, Italy|Milano, Italy|Milano, Italy|Pavia, Italy|Guadalajara, Jalisco, Mexico|Mérida, Yucatán, Mexico|Mérida, Yucatán, Mexico|Chihuahua, Mexico|Bloemfontein, Free State, South Africa|Bloemfontein, Free State, South Africa|Johannesburg, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Durban, KwaZulu Natal, South Africa|Cape Town, Western Cape, South Africa|Cape Town, Western Cape, South Africa|Paarl, Western Cape, South Africa|Badalona, Barcelona, Spain|Ronda, Málaga, Spain|Barcelona, Spain|Madrid, Spain|Valencia, Spain|Valladolid, Spain|Bristol, Avon, United Kingdom|London, Greater London, United Kingdom|London, Greater London, United Kingdom|London, Greater London, United Kingdom|London, Greater London, United Kingdom|London, Greater London, United Kingdom|Birmingham, West Midlands, United Kingdom|Leeds, West Yorkshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00473460"
1226,"NCT00471991","Valette (Combined Oral Contraceptive SH T04769G and SH D00659AF) Low Ovulation Inhibition",,"Completed","No Results Available","Oral Contraceptive","Drug: SH T04769G|Drug: Ethinyl estradiol / dienogest (SH D00659 AF)","The primary efficacy variable is ovulation inhibition in Cycle 2 (yes/no). Ovarian activity will be classified according to Hoogland and Skouby (1993).|Follicle size (leading follicle) by transvaginal ultrasonography|Endogenous hormones (estradiol, progesterone, FSH, LH)|Assessment of cervical mucus according to Insler|Pharmacokinetic evaluation in volunteers who receive SH T04769G","Bayer","Female","18 Years to 35 Years   (Adult)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","91539|2006-006633-41|310723","April 2007","December 2007","December 2007","May 10, 2007",,"January 25, 2013","Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT00471991"
1227,"NCT00471003","The Real-Life Efficacy and Safety of Telmisartan in Patients With Arterial Hypertension","METABOLIC","Completed","No Results Available","Hypertension","Drug: Pritor (Telmisartan , BAY68-9291)","Efficacy and safety of the treatment with telmisartan reported by the physician|Changes in metabolic parameters in telmisartan treated patients","Bayer","All","18 Years and older   (Adult, Older Adult)",,"5448","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","12729|KL0601PL|13929 - KL0601SI|12804 - KL0601SK|14326 - KL0601HR","September 2006","November 2009","November 2009","May 8, 2007",,"January 20, 2010","Many Locations, Croatia|Many Locations, Poland|Many Locations, Slovakia|Many Locations, Slovenia",,"https://ClinicalTrials.gov/show/NCT00471003"
1228,"NCT00470886","Assessment of Compliance With Antihypertensive Telmisartan Therapy","COAST","Completed","No Results Available","Hypertension","Drug: Telmisartan (Kinzal/Pritor, BAY68-9291)","Efficacy and safety of the treatment with telmisartan reported by the physician with regard to usage the HelpingHand device|Compliance with the treatment calculated on the basis of by HelpingHand and patients questionnaires","Bayer|Bang & Olufsen Medicom","All","18 Years and older   (Adult, Older Adult)",,"3400","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","12827|KL0710PL|14237 - KL0710SK","April 2007","January 2010","January 2010","May 8, 2007",,"November 16, 2012","Many Locations, Poland|Many Locations, Slovakia",,"https://ClinicalTrials.gov/show/NCT00470886"
1229,"NCT00470873","Vardenafil Treatment Of Erectile Dysfunction In Depressive And Non-Depressive Men",,"Completed","No Results Available","Erectile Dysfunction","Drug: Levitra (Vardenafil, BAY38-9456)","Efficacy, safety, tolerance of the treatment with Vardenafil reported by the physician|Influence of vardenafil on depressive symptoms and self-esteem measured with CES-D and Rosenberg scale","Bayer","Male","18 Years and older   (Adult, Older Adult)",,"2471","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","12842|LV0610PL|VALOR","January 2007",,"February 2008","May 8, 2007",,"December 2, 2014","Many locations, Poland",,"https://ClinicalTrials.gov/show/NCT00470873"
1230,"NCT00468819","A Study of Magnetic Resonance Imaging (MRI) With Gadavist in Children",,"Completed","Has Results","Magnetic Resonance Imaging","Drug: Gadobutrol (Gadavist, Gadovist, BAY86-4875)","Plasma Clearance Estimates of Gadobutrol by Age Group|Body Weight-corrected Plasma Clearance Estimates of Gadobutrol by Age Group|Volume Distribution at Steady State (Vss) Estimates of Gadobutrol by Age Group|Body Weight-corrected Volume Distribution at Steady State (Vss) Estimates of Gadobutrol by Age Group|Area Under the Drug Concentration-time Curve of Gadobutrol by Age Group|Terminal Elimination Half Life Estimates of Gadobutrol by Age Group|Mean Residence Time (MRT) Estimates of Gadobutrol by Age Group|Urinary Excretion of Gadolinium as Percent of Administered Dose|Number of Participants With Basic Technical Adequacy of Magnetic Resonance (MR) Images for Diagnosis by Age Group|Number of Participants With Overall Contrast Quality of Post Contrast Images by Age Group|Pre-Contrast Lesions by Location and by Age Group|Post-Contrast Lesions by Location and by Age Group|Pre-Contrast Delineation of Lesion/Vessel Border by Age Group|Post-Contrast Delineation of Lesion/Vessel Border by Age Group|Pre-Contrast Lesion Characterization by Age Group|Post-Contrast Lesion Characterization by Age Group|Degree of Contrast Enhancement in Lesion/Vessel by Age Group (Given Are Total Numbers of Lesions)|Number of Participants With Change in Diagnostic Confidence by Age Group","Bayer","All","2 Years to 17 Years   (Child)","Phase 1","140","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","91552|2006-004153-22|310788","May 2007","April 2008","April 2008","May 3, 2007","September 5, 2011","July 22, 2015","Wien, Austria|Edmonton, Alberta, Canada|Toronto, Ontario, Canada|Erlangen, Bayern, Germany|Bonn, Nordrhein-Westfalen, Germany|Halle, Sachsen-Anhalt, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Kiel, Schleswig-Holstein, Germany|Kiel, Schleswig-Holstein, Germany|Jena, Thüringen, Germany|Göteborg, Sweden|Stockholm, Sweden|Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT00468819"
1231,"NCT00468481","Efficacy and Safety Study for an Oral Contraceptive Containing Folate",,"Completed","Has Results","Neural Tube Defects|Contraception|Oral Contraceptives (OC)","Drug: Drospirenone/Ethinylestradiol/Methyltetrahydrofolate|Drug: Drospirenone/Ethinylestradiol (Yaz)","Red Blood Cell (RBC) Folate Level at 24 Weeks|Plasma Folate Level at 24 Weeks|Mean Neural Tube Defect (NTD) Risk Reduction at Week 24|Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 4|Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 8|Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 12|Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 16|Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 20|Mean Change From Baseline in Plasma Folate Levels at Week 4|Mean Change From Baseline in Plasma Folate Levels at Week 8|Mean Change From Baseline in Plasma Folate Levels at Week 12|Mean Change From Baseline in Plasma Folate Levels at Week 16|Mean Change From Baseline in Plasma Folate Levels at Week 20|Mean Change From Baseline in Plasma Homocysteine Levels at Week 4|Mean Change From Baseline in Plasma Homocysteine Levels at Week 8|Mean Change From Baseline in Plasma Homocysteine Levels at Week 12|Mean Change From Baseline in Plasma Homocysteine Levels at Week 16|Mean Change From Baseline in Plasma Homocysteine Levels at Week 20|Mean Change From Baseline in Plasma Homocysteine Levels at Week 24","Bayer","Female","18 Years to 40 Years   (Adult)","Phase 3","385","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","91523|310662","April 2007","August 2008","September 2008","May 2, 2007","January 25, 2011","April 23, 2014","Orange County Clinical Trials, Anaheim, California, United States|Medical Center for Clinical Research, San Diego, California, United States|SNBL Clinical Pharmacology Center, Inc., Baltimore, Maryland, United States|Columbia University Medical Center, New York, New York, United States|AAIPharma, Inc., Morrisville, North Carolina, United States|Lyndhurst Gynecologic Associates, Winston-Salem, North Carolina, United States|Coastal Carolina Research Center, Mt. Pleasant, South Carolina, United States|New Orleans Center for Clinical Research, Knoxville, Tennessee, United States|NorthWest Kinetics, Tacoma, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00468481"
1232,"NCT00463450","Efficacy of Gynodian® Depot in Women With Impaired Well-being",,"Completed","No Results Available","Hormone Replacement Therapy","Drug: Gynodian® Depot (BAY86-5032)|Drug: BAY86-4980","To assess the difference in the Global Severity Index (GSI) of both treatment sequences with Gynodian Depot and with estradiol valerate|To assess the difference in the GSI in both treatment sequences|To assess the difference in the scores of the psychometric tests and rating scales SCL-90-R, Menopause rating scale, HADS and Visual analog Scale in both treatment sequences|To assess serum hormone levels of DHEA, DHEAS, androsterone, testosterone, dihydrotestosterone, androstenediol-glucuronid, estradiol, estrone, and SHBG","Bayer|Ecron Acunova GmbH|LKF Laboratory","Female","45 Years to 65 Years   (Adult, Older Adult)","Phase 3","140","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","90651|303401","May 2002",,"April 2004","April 20, 2007",,"December 30, 2014",,,"https://ClinicalTrials.gov/show/NCT00463450"
1233,"NCT00461565","FDA Phase IV - Commitment - Retinal Function Study",,"Completed","No Results Available","Safety","Drug: Sildenafil|Drug: Placebo|Drug: Vardenafil (Levitra, BAY38-9456)","The change from baseline in Fansworth Munsell (FM) 100 test total error score (TES) in both the left and right eyes for vardenafil treated subjects as compared to placebo|The change from baseline in Electroretinogram (ERG) as measured by amplitude and implicit time of b wave in both the left and right eyes for vardenafil treated subjects as compared to placebo|Change in the FM-100 total error score from baseline at approximately 6 hours and 24 hours post dose|Safety and tolerability of 20 mg vardenafil after at least 15 oral doses of 20 mg vardenafil or placebo (dosed over approximately 8 weeks)|ERG and FM-100 total error score from baseline at approximately 2 hours following one dose of sildenafil 200 mg","Bayer|GlaxoSmithKline","Male","18 Years to 55 Years   (Adult)","Phase 4","63","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11337|VAR 102 162","February 2005",,"October 2006","April 18, 2007",,"March 19, 2015",,,"https://ClinicalTrials.gov/show/NCT00461565"
1234,"NCT00461396","Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron","START","Completed","No Results Available","Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting","Drug: Interferon-1beta (Betaseron, BAY86-5046)","Evaluate the impact of titration, analgesics and 12-month BETA nurse follow-up on adherence to Betaseron treatment|Extended Disability Status Scale (EDSS)|Functional Assessment in Multiple Sclerosis (FAMS)|Cytokine and neurotrophic factor production|Visual function assessed by OCT and NEI-VFQ-25 (25-Item National Eye Institute Visual Functioning Questionnaire)","Bayer","All","18 Years to 50 Years   (Adult)",,"104","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14465|311501|BF0713US","May 2007","June 2009","November 2009","April 18, 2007",,"April 8, 2011","Many Locations, Alabama, United States|Many Locations, Arizona, United States|Many Locations, Delaware, United States|Many Locations, District of Columbia, United States|Many Locations, Florida, United States|Many Locations, Georgia, United States|Many Locations, Illinois, United States|Many Locations, Iowa, United States|Many Locations, Louisiana, United States|Many Locations, Maine, United States|Many Locations, Minnesota, United States|Many Locations, Missouri, United States|Many Locations, New Jersey, United States|Many Locations, New York, United States|Many Locations, North Carolina, United States|Many Locations, Ohio, United States|Many Locations, Pennsylvania, United States|Many Locations, Tennessee, United States|Many Locations, West Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00461396"
1235,"NCT00461305","Safety Study of Ethinylestradiol/Drospirenone in Dysmenorrhea",,"Completed","Has Results","Dysmenorrhea","Drug: DRSP 3 mg/EE 20 µg (13 cycles)|Drug: DRSP 3 mg/EE 30 µg (6 cycles)","Number of Participants With Intracyclic Bleeding at Cycle 6|Number of Participants With a Change in Total Dysmenorrhea Score From Baseline to Cycle 6|Number of Participants With a Change in Total Dysmenorrhea Score From Baseline to Cycle 13|Distribution of Total Dysmenorrhea Score at Cycle 6|Distribution of Total Dysmenorrhea Score at Cycle 13|Distribution of Severity of Lower Abdominal Pain During Menstruation at Cycle 6|Distribution of Severity of Lower Abdominal Pain During Menstruation at Cycle 13|Distribution of Severity of Lumbago During Menstruation at Cycle 6|Distribution of Severity of Lumbago During Menstruation at Cycle 13|Distribution of Severity of Headache During Menstruation at Cycle 6|Distribution of Severity of Headache During Menstruation at Cycle 13|Distribution of Severity of Nausea or Vomiting During Menstruation at Cycle 6|Distribution of Severity of Nausea or Vomiting During Menstruation at Cycle 13|Number of Participants With a Total Pelvic Pain Score of 0 up to 6 at Times Other Than During Menstruation at Cycle 6|Number of Participants With a Total Pelvic Pain Score of 0 up to 6 at Times Other Than During Menstruation at Cycle 13|Change in Visual Analogue Scale (VAS) for Dysmenorrhea at Times Other Than During Menstruation From Baseline to Cycle 6|Change in Visual Analogue Scale (VAS) for Dysmenorrhea at Times Other Than During Menstruation From Baseline to Cycle 13|Change in Visual Analogue Scale (VAS) for Pelvic Pain at Times Other Than During Menstruation From Baseline to Cycle 6|Change in Visual Analogue Scale (VAS) for Pelvic Pain at Times Other Than During Menstruation From Baseline to Cycle 13|Number of Any Bleeding Episodes From Cycle 1 to Cycle 6|Number of Any Bleeding Episodes From Cycle 1 to Cycle 13|Number of Any Bleeding Days From Cycle 1 to Cycle 6|Number of Any Bleeding Days From Cycle 1 to Cycle 13|Number of Participants With Intracyclic Bleeding From Cycle 1 to Cycle 6|Number of Participants With Intracyclic Bleeding From Cycle 1 to Cycle 13|Number of Participants With Withdrawal Bleeding From Cycle 1 to Cycle 6|Number of Participants With Withdrawal Bleeding From Cycle 1 to Cycle 13|Percentage of Participants With Non-heavy Intracyclic Bleeding From Cycle 1 to Cycle 6|Percentage of Participants With Non-heavy Intracyclic Bleeding From Cycle 1 to Cycle 13|Percentage of Participants With Non-heavy Withdrawal Bleeding From Cycle 1 to Cycle 6|Percentage of Participants With Non-heavy Withdrawal Bleeding From Cycle 1 to Cycle 13|Change in Serum Carbohydrate Antigen-125 (CA-125) From Baseline to Cycle 6|Change in Serum CA-125 From Baseline to Cycle 13|Change in Serum C-reactive Protein (CRP) From Baseline to Cycle 6|Change in Serum CRP From Baseline to Cycle 13","Bayer","Female","20 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","420","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","91616|310284","February 2007","January 2009","August 2009","April 18, 2007","October 1, 2010","January 24, 2013","Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Maebashi, Gunma, Japan|Takasaki, Gunma, Japan|Kobe, Hyogo, Japan|Nishinomiya, Hyogo, Japan|Yamato, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Sendai, Miyagi, Japan|Sendai, Miyagi, Japan|Sendai, Miyagi, Japan|Toyonaka, Osaka, Japan|Chuo-ku, Tokyo, Japan|Hachioji, Tokyo, Japan|Machida, Tokyo, Japan|Musashino, Tokyo, Japan|Ota-ku, Tokyo, Japan|Setagaya-ku, Tokyo, Japan|Setagaya-ku, Tokyo, Japan|Shibuya-ku, Tokyo, Japan|Shinagawa-ku, Tokyo, Japan|Suginami-ku, Tokyo, Japan|Toshima-ku, Tokyo, Japan|Osaka, Japan|Osaka, Japan",,"https://ClinicalTrials.gov/show/NCT00461305"
1236,"NCT00461123","Vardenafil in Greenlight(TM) Laser Surgery of Benign Prostate Hypertrophy",,"Completed","Has Results","Prostatic Hypertrophy, Benign","Drug: Vardenafil (Levitra, BAY38-9456)|Drug: Placebo","Baseline-adjusted Least Squared (LS) Means of Peak Urinary Flow (Qmax) at 3 Months After Surgery or Last Observation Carried Forward (LOCF)|Baseline-adjusted Least Squared (LS) Means of International Prostate Symptom Score (IPSS) Total Score at 3 Months After Surgery or Last Observation Carried Forward (LOCF)|Baseline-adjusted Least Squared (LS) Means of Post-void Residual (PVR) Volume at 3 Months After Surgery or Last Observation Carried Forward (LOCF)|Baseline-adjusted Least Squared (LS) Means of the Number of Urinary Incontinence Episodes Per Week at 3 Months After Surgery or Last Observation Carried Forward (LOCF)|Duration of Surgery","Bayer","Male","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","12496|2006-004633-15","March 2007","June 2008","June 2008","April 17, 2007","January 21, 2010","December 19, 2014","Heidelberg, Baden-Württemberg, Germany",,"https://ClinicalTrials.gov/show/NCT00461123"
1237,"NCT00459667","BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose","Beyond","Completed","Has Results","Multiple Sclerosis, Relapsing-Remitting","Drug: Interferon beta-1b (Betaseron, BAY86-5046)","Flu-like-syndrome|Injection-site Reactions|Liver Enzyme Elevations|Hematological Abnormalities|Percentage of Patients With Neutralizing Antibody Titer to IFNB-1b of Different Cut-off Values","Bayer","All","18 Years to 55 Years   (Adult)","Phase 3","1420","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","91656|2006-005270-47|309363","May 2007","March 2008","March 2008","April 12, 2007","August 17, 2009","April 23, 2015","Birmingham, Alabama, United States|Cullman, Alabama, United States|Phoenix, Arizona, United States|Tucson, Arizona, United States|Berkeley, California, United States|La Jolla, California, United States|Sacramento, California, United States|San Francisco, California, United States|Fort Collins, Colorado, United States|Newark, Delaware, United States|Washington, District of Columbia, United States|Maitland, Florida, United States|Miami, Florida, United States|Tampa, Florida, United States|Tampa, Florida, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Chicago, Illinois, United States|Fort Wayne, Indiana, United States|Indianapolis, Indiana, United States|Des Moines, Iowa, United States|Kansas City, Kansas, United States|Louisville, Kentucky, United States|Shreveport, Louisiana, United States|Detroit, Michigan, United States|Duluth, Minnesota, United States|St. Louis, Missouri, United States|Henderson, Nevada, United States|Reno, Nevada, United States|Newark, New Jersey, United States|Albuquerque, New Mexico, United States|Mineola, New York, United States|Rochester, New York, United States|Stony Brook, New York, United States|Charlotte, North Carolina, United States|Durham, North Carolina, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Tualatin, Oregon, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Providence, Rhode Island, United States|Charleston, South Carolina, United States|Nashville, Tennessee, United States|Houston, Texas, United States|San Antonio, Texas, United States|Fairfax, Virginia, United States|Seattle, Washington, United States|Tacoma, Washington, United States|Milwaukee, Wisconsin, United States|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Cordoba, Córdoba, Argentina|Rosario, Santa Fe, Argentina|Rosario, Santa Fe, Argentina|Buenos Aires, Argentina|Kogarah, New South Wales, Australia|Fitzroy, Victoria, Australia|Parkville, Victoria, Australia|Nedlands, Western Australia, Australia|Liverpool, Australia|Wyoming, Australia|St Poelten, Niederösterreich, Austria|Graz, Austria|Innsbruck, Austria|Linz, Austria|Brussel, Belgium|Leuven, Belgium|Melsbroek, Belgium|Curitiba, Parana, Brazil|Recife, Pernambuco, Brazil|Porto Alegre, Rio Grande do Sul, Brazil|Campinas, Sao Paulo, Brazil|Rio de Janeiro, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Calgary, Alberta, Canada|Vancouver, British Columbia, Canada|Halifax, Nova Scotia, Canada|London, Ontario, Canada|Mississauga, Ontario, Canada|Nepean, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Greenfield Park, Quebec, Canada|Hull, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Aarhus, Denmark|Oulu, Finland|Tampere, Finland|Rennes, Bretagne, France|Bordeaux, Gironde, France|Clermont ferrand, France|Dijon, France|Lille, France|Nancy, France|Nantes, France|Nice, France|Nimes, France|Toulouse, France|Heidelberg, Baden-Württemberg, Germany|Bayreuth, Bayern, Germany|Regensburg, Bayern, Germany|Hennigsdorf, Brandenburg, Germany|Gießen, Hessen, Germany|Marburg, Hessen, Germany|Offenbach, Hessen, Germany|Greifswald, Mecklenburg-Vorpommern, Germany|Göttingen, Niedersachsen, Germany|Hannover, Niedersachsen, Germany|Hannover, Niedersachsen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Halle, Sachsen-Anhalt, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Berlin, Germany|Berlin, Germany|Hamburg, Germany|Hamburg, Germany|Athens, Attica, Greece|Thessaloniki, Greece|Budapest, Hungary|Budapest, Hungary|Györ, Hungary|Miskolc, Hungary|Pecs, Hungary|Zalaegerszeg-Pozva, Hungary|Cork, Ireland|Dublin, Ireland|Dublin, Ireland|Dublin, Ireland|Ashkelon, Israel|Haifa, Israel|Jerusalem, Israel|Tel Hashomer, Israel|Tel-Aviv, Israel|Zerifin, Israel|Orbassano, Torino, Italy|Bari, Italy|Firenze, Italy|Milano, Italy|Padova, Italy|Roma, Italy|Riga, Latvia|Breda, Netherlands|Nijmegen, Netherlands|Sittard, Netherlands|Bergen, Norway|Gdansk, Poland|Katowice, Poland|Lodz, Poland|Poznan, Poland|Warszawa, Poland|Warszawa, Poland|Wroclaw, Poland|Moskva, Russian Federation|Moskva, Russian Federation|Moskva, Russian Federation|Moskva, Russian Federation|Moskva, Russian Federation|Nizhy Novgorod, Russian Federation|Novosibirsk, Russian Federation|Sankt-Peterburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|Yaroslavl, Russian Federation|Ljubljana, Slovenia|Maribor, Slovenia|L'Hospitalet de Llobregat, Barcelona, Spain|Malaga, Spain|Sevilla, Spain|Stockholm, Sweden|Uppsala, Sweden|Bern, Switzerland|St. Gallen, Switzerland|Donetsk, Ukraine|Kharkiv, Ukraine|Kiev, Ukraine|Lviv, Ukraine",,"https://ClinicalTrials.gov/show/NCT00459667"
1238,"NCT00459654","A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer",,"Completed","No Results Available","Prostate Cancer|Neoplasm Metastasis","Drug: Radium-223 dichloride (BAY88-8223)|Drug: Saline","Time to occurrence of Skeletal-related Events (SRE)|Relative change (%) in bone-ALP levels from baseline to 4 weeks after last injection|Number of SREs per patient|Changes in the levels of biochemical markers of bone formation|Change in Prostate Specific Antigen (PSA)|Change in pain level|Changes in analgesic use during study period|Changes in Edmonton Symptom Assessment Scale (ESAS) from baseline|Overall survival|Adverse events|Clinical laboratory tests including haematology, renal and liver function parameters","Bayer","Male","40 Years and older   (Adult, Older Adult)","Phase 2","64","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15280|BC1-02","February 2004","May 2006","May 2007","April 12, 2007",,"June 25, 2014","Linköping, Sweden|Sundsvall, Sweden|Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00459654"
1239,"NCT00454558","An Open Multiple Dose Titration Study In Patients With Pulmonary Hypertension",,"Completed","No Results Available","Hypertension, Pulmonary","Drug: Riociguat (Adempas, BAY63-2521)","To investigate the safety, tolerability and feasibility of individual titration of BAY63-2521 according to peripheral systolic blood pressure|To investigate the long term safety and tolerability of BAY63-2521|6MWT|Right heart catheter invasive hemodynamics|WHO functional class assessment|NT-pro BNP|Imaging by echo","Bayer","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","75","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12166|2006-003520-10","January 2007","July 2014","September 2014","March 30, 2007",,"October 16, 2015","Heidelberg, Baden-Württemberg, Germany|Löwenstein, Baden-Württemberg, Germany|München, Bayern, Germany|Regensburg, Bayern, Germany|Bad Nauheim, Hessen, Germany|Gießen, Hessen, Germany|Greifswald, Mecklenburg-Vorpommern, Germany|Hannover, Niedersachsen, Germany|Köln, Nordrhein-Westfalen, Germany|Homburg, Saarland, Germany|Halle, Sachsen-Anhalt, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Berlin, Germany|Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT00454558"
1240,"NCT00453349","A Trial Comparing Moxifloxacin Versus Levofloxacin Plus Metronidazole In Uncomplicated Pelvic Inflammatory Disease",,"Completed","Has Results","Pelvic Inflammatory Disease","Drug: Moxifloxacin (Avelox, BAY12-8039)|Drug: Levofloxacin & Metronidazole","Clinical Response 7 to 14 Days After Completion of Study Drug Therapy in Per Protocol (PP) Population|Clinical Response 7 to 14 Days After Completion of Study Drug Therapy on Intent To Treat (ITT) Population|Clinical Response on Treatment for Per Protocol Population|Clinical Response on Treatment for Intent To Treat Population|Bacteriological Response at Test Of Cure (TOC) Visit Microbiologically Valid|Bacteriological Response at Test Of Cure (TOC) Visit in Intent To Treat Population With Causative Organism|Clinical Response at Follow-up Visit on Per Protocol Population|Clinical Response at Follow-up Visit on Intent To Treat Population|Bacteriological Response at Follow-up Visit Microbiologically Valid|Bacteriological Response at Follow-up Visit in Intent To Treat Population With Causative Organism|Number of Subjects Who Received Alternative Medicine","Bayer","Female","18 Years and older   (Adult, Older Adult)","Phase 3","460","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","11981|2006-000874-56","January 2007","May 2008","May 2008","March 28, 2007","November 30, 2009","September 8, 2014","Shenyang, Liaoning, China|Chengdu, Sichuan, China|Beijing, China|Beijing, China|Chongqing, China|Shanghai, China|Jakarta, Indonesia|Seoul, Korea, Republic of|Karachi, Pakistan|Manila, Philippines|Taipei, Taiwan|Taizung, Taiwan|Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT00453349"
1241,"NCT00449033","A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC)","NEXUS","Completed","Has Results","Carcinoma, Non-Small-Cell Lung","Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Placebo|Drug: Gemcitabine|Drug: Cisplatin","Overall Survival (OS) in the ITT (Non-squamous) Population|OS in the ITT (Both Squamous and Non-squamous) Population|OS in the ITT (Squamous) Population|Progression-free Survival (PFS) in the ITT (Non-squamous) Population|Time to Progression (TTP) in the ITT (Non-squamous) Population|Percentage of Participants With Different Tumor Response in the ITT (Non-squamous) Population|Disease Control (DC) in the ITT (Non-squamous) Population|Duration of Response in the ITT (Non-squamous) Population|Duration of Stable Disease (SD) in the ITT (Non-squamous) Population|Time to Response (TTR) in the ITT (Non-squamous) Population|Functional Assessment of Cancer Treatment-Lung (FACT-L) Scores in the ITT (Non-squamous) Population|Lung Cancer Subscale (LCS) Scores in the ITT (Non-squamous) Population|Time to Symptomatic Deterioration (TSD) in the ITT (Non-squamous) Population|Euro Quality of Life - 5D (EQ-5D) Index Scores in the ITT (Non-squamous) Population|EQ-5D Visual Analog Scale (VAS) Scores in the ITT (Non-squamous) Population","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","904","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12006|2006-002688-26","February 2007","April 2010","June 2011","March 19, 2007","September 9, 2011","April 23, 2015","Innsbruck, Austria|Linz, Austria|Wien, Austria|Wien, Austria|Brasschaat, Belgium|Bruxelles - Brussel, Belgium|Edegem, Belgium|Leuven, Belgium|Liege, Belgium|Namur, Belgium|Salvador, Bahia, Brazil|Salvador, Bahia, Brazil|Salvador, Bahia, Brazil|Brasília, Distrito Federal, Brazil|Goiania, Goiás, Brazil|Goiânia, Goiás, Brazil|Belo Horizonte, Minas Gerais, Brazil|Porto Alegre, Rio Grande do Sul, Brazil|Porto Alegre, Rio Grande do Sul, Brazil|Jaú, Sao Paulo, Brazil|Santo Andre, Sao Paulo, Brazil|Santo André, Sao Paulo, Brazil|Sorocaba, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|Rio de Janeiro, Brazil|Montreal, Quebec, Canada|Guangzhou, Guangdong, China|Wuhan, Hubei, China|Nanjing, Jiangsu, China|Hangzhou, Zhejiang, China|Hangzhou, Zhejiang, China|Beijing, China|Shanghai, China|Shanghai, China|Nicosia, Cyprus|HUS, Finland|Preitilä, Finland|Tampere, Finland|Bayonne, France|Grenoble, France|Grenoble, France|Hyeres, France|Le Mans Cedex 2, France|Marseille, France|Nantes, France|Nimes Cedex 2, France|Paris Cedex 15, France|Perpignan, France|Pierre Benite, France|Strasbourg, France|Tours, France|Heidelberg, Baden-Württemberg, Germany|Karlsruhe, Baden-Württemberg, Germany|Löwenstein, Baden-Württemberg, Germany|Gauting, Bayern, Germany|Frankfurt, Hessen, Germany|Hofheim, Hessen, Germany|Essen, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Leipzig, Sachsen, Germany|Großhansdorf, Schleswig-Holstein, Germany|Bad Berka, Thüringen, Germany|Hamburg, Germany|Heraklion, Creta, Greece|Athens, Greece|Budapest, Hungary|Budapest, Hungary|Deszk, Hungary|Matrahaza, Hungary|Szekesfehervar, Hungary|Torokbalint, Hungary|Ashkelon, Israel|Holon, Israel|Kfar Saba, Israel|Rehovot, Israel|Tel Hashomer, Israel|Rozzano, Milano, Italy|Monza, Monza-Brianza, Italy|Aviano, Pordenone, Italy|Bologna, Italy|Catania, Italy|Firenze, Italy|Livorno, Italy|Milano, Italy|Roma, Italy|Sassari, Italy|Venezia, Italy|Verona, Italy|México, Distrito Federal, Mexico|Guadalajara, Jalisco, Mexico|Monterrey, Nuevo Leon, Mexico|Den Bosch, Netherlands|Ede, Netherlands|Harderwijk, Netherlands|Heerlen, Netherlands|Nieuwegein, Netherlands|Terrassa, Barcelona, Spain|Cruces/Barakaldo, Bilbao, Spain|A Coruña, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Málaga, Spain|Sevilla, Spain|Valencia, Spain|Valencia, Spain|Valencia, Spain|Basel, Basel-Stadt, Switzerland|Genéve, Genève, Switzerland|Bern, Switzerland|Cambridge, Cambridgeshire, United Kingdom|Aberdeen, Grampian, United Kingdom|Leicester, Leicestershire, United Kingdom|Sutton, Surrey, United Kingdom|Wolverhampton, West Midlands, United Kingdom|Birmingham, United Kingdom|London, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00449033"
1242,"NCT00446199","Low-dose Hormone Therapy for Relief of Vasomotor Symptoms",,"Completed","Has Results","Vasomotor Symptoms|Hot Flashes","Drug: 0.5mg DRSP / 0.5mg E2 (BAY86-4891)|Drug: 0.25mg DRSP / 0.5mg E2 (BAY86-4891)|Drug: Estradiol (E2 0.3mg)|Drug: Placebo","Change From Baseline to Week 12 in Weekly Frequency of Moderate to Severe Hot Flushes (Median Value)|Change From Baseline to Week 4 in Weekly Frequency of Moderate to Severe Hot Flushes (Median Value)|Change From Baseline to Week 12 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Median Value)|Change From Baseline to Week 4 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Median Value)|Change From Baseline to Week 12 in Vaginal pH|Change From Baseline to Week 12 in Vaginal Maturation Value|Symptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Vaginal Dryness'|Symptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Vaginal and/or Vulvar Irritation/Itching'|Symptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Dysuria'|Symptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Vaginal Pain Associated With Sexual Activity'|Symptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Vaginal Bleeding Associated With Sexual Activity'|Urogenital Symptoms: Number of Participants With Symptom 'Frequent Urination'|Urogenital Symptoms: Number of Participants With Symptom 'Involuntary Urination When Laughing or Coughing'|Urogenital Symptoms: Number of Participants With Symptom 'Urination at Night'","Bayer","Female","40 Years and older   (Adult, Older Adult)","Phase 3","735","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","91493|310184","March 2007","October 2008","November 2008","March 12, 2007","April 18, 2012","May 6, 2015","Mobile, Alabama, United States|Chandler, Arizona, United States|Phoenix, Arizona, United States|Tucson, Arizona, United States|Tucson, Arizona, United States|Little Rock, Arkansas, United States|Paramount, California, United States|San Diego, California, United States|San Diego, California, United States|San Diego, California, United States|San Diego, California, United States|Valley Village, California, United States|Vista, California, United States|Colorado Springs, Colorado, United States|Denver, Colorado, United States|New Britain, Connecticut, United States|Boynton Beach, Florida, United States|Clearwater, Florida, United States|Daytona Beach, Florida, United States|Fort Myers, Florida, United States|Jacksonville, Florida, United States|Lake Worth, Florida, United States|Leesburg, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|New Port Richey, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Atlanta, Georgia, United States|Atlanta, Georgia, United States|Decatur, Georgia, United States|Boise, Idaho, United States|Idaho Falls, Idaho, United States|Arlington Heights, Illinois, United States|Champaign, Illinois, United States|La Grange Park, Illinois, United States|Newburgh, Indiana, United States|Lexington, Kentucky, United States|Amite, Louisiana, United States|Marrero, Louisiana, United States|Paw Paw, Michigan, United States|Chaska, Minnesota, United States|Springfield, Missouri, United States|Billings, Montana, United States|Billings, Montana, United States|Lincoln, Nebraska, United States|Las Vegas, Nevada, United States|Reno, Nevada, United States|Lawrenceville, New Jersey, United States|New Brunswick, New Jersey, United States|Princeton, New Jersey, United States|Albuquerque, New Mexico, United States|Raleigh, North Carolina, United States|Winston-Salem, North Carolina, United States|Fargo, North Dakota, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Oklahoma City, Oklahoma, United States|Tulsa, Oklahoma, United States|Erie, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Wexford, Pennsylvania, United States|Columbia, South Carolina, United States|Sioux Falls, South Dakota, United States|Chattanooga, Tennessee, United States|Chattanooga, Tennessee, United States|Memphis, Tennessee, United States|Dallas, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Burlington, Vermont, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Renton, Washington, United States|Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00446199"
1243,"NCT00440193","Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study",,"Completed","Has Results","Venous Thrombosis","Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Enoxaparin followed by VKA","Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal Pulmonary Embolism [PE]) Until the Intended End of Study Treatment|Percentage of Participants With the Composite Variable Comprising Recurrent DVT, Non-fatal PE and All Cause Mortality Until the Intended End of Study Treatment|Percentage of Participants With an Event for Net Clinical Benefit 1 Until the Intended End of Study Treatment|Percentage of Participants With Recurrent DVT Until the Intended End of Study Treatment|Percentage of Participants With Clinically Relevant Bleeding, Treatment-emergent (Time Window: Until 2 Days After Last Dose)|Percentage of Participants With All Deaths|Percentage of Participants With Other Vascular Events, On-treatment (Time Window: Until 1 Day After Last Dose)","Bayer|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","All","18 Years and older   (Adult, Older Adult)","Phase 3","3449","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11702a|2006-004495-13|11702b","March 2007","April 2010","April 2010","February 26, 2007","January 24, 2013","February 27, 2014","Little Rock, Arkansas, United States|Redlands, California, United States|Bay Pines, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Idaho Falls, Idaho, United States|Covington, Louisiana, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Albuquerque, New Mexico, United States|Chapel Hill, North Carolina, United States|Greensboro, North Carolina, United States|Greensboro, North Carolina, United States|Oklahoma City, Oklahoma, United States|Camp Hill, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Corsicana, Texas, United States|San Antonio, Texas, United States|Murray, Utah, United States|Salt Lake City, Utah, United States|Fredericksburg, Virginia, United States|Spokane, Washington, United States|Tacoma, Washington, United States|Garran, Australian Capital Territory, Australia|Darlinghurst, New South Wales, Australia|Gosford, New South Wales, Australia|Kogarah, New South Wales, Australia|Lismore, New South Wales, Australia|St Leonards, New South Wales, Australia|Sydney, New South Wales, Australia|Sydney, New South Wales, Australia|Sydney, New South Wales, Australia|Brisbane, Queensland, Australia|Redcliffe, Queensland, Australia|Southport, Queensland, Australia|Woolloongabba, Queensland, Australia|Adelaide, South Australia, Australia|Woodville South, South Australia, Australia|Box Hill, Victoria, Australia|Clayton, Victoria, Australia|Geelong, Victoria, Australia|Melbourne, Victoria, Australia|Melbourne, Victoria, Australia|Fremantle, Western Australia, Australia|Perth, Western Australia, Australia|Graz, Steiermark, Austria|Feldkirch, Vorarlberg, Austria|Innsbruck, Austria|Salzburg, Austria|Wien, Austria|Wien, Austria|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Duffel, Belgium|Genk, Belgium|Gent, Belgium|Hasselt, Belgium|Leuven, Belgium|Liege, Belgium|Lier, Belgium|Namur, Belgium|Yvoir, Belgium|Zottegem, Belgium|Uberaba, Minas Gerais, Brazil|Curitiba, Parana, Brazil|Londrina, Parana, Brazil|Botucatu, Sao Paulo, Brazil|Sorocaba, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|Sao Paulo, SP, Brazil|Sao Paulo, SP, Brazil|São Paulo, SP, Brazil|Rio de Janeiro, Brazil|Winnipeg, Manitoba, Canada|London, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Harbin, Heilongjiang, China|Wuhan, Hubei, China|Suzhou, Jiangsu, China|Shenyang, Liaoning, China|Hangzhou, Zhejiang, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Shanghai, China|Shanghai, China|Shanghai, China|Karlovy Vary, Czech Republic|Kladno, Czech Republic|Ostrava-Poruba, Czech Republic|Ostrava, Czech Republic|Prague 5, Czech Republic|Prague, Czech Republic|Praha 1, Czech Republic|Praha 2, Czech Republic|Usti nad Lebem, Czech Republic|Aarhus C, Denmark|Braedstrup, Denmark|Frederiksberg, Denmark|Hellerup, Denmark|Seinäjoki, Finland|Agen Cedex 9, France|Amiens, France|Angers Cedex 01, France|Arras, France|Besancon, France|Bordeaux, France|Brest Cedex, France|Castelnau Le Lez, France|Clamart, France|Clermont Ferrand, France|Colombes Cedex, France|Creteil, France|Dijon, France|Grenoble, France|Grenoble, France|Lille Cedex, France|Limoges, France|Metz-tessy, France|Montpellier Cedex, France|Nantes, France|Nice, France|Nimes Cedex 9, France|Orthez, France|Paris Cedex 15, France|Paris, France|Paris, France|Paris, France|Paris, France|Pierre Benite, France|Roanne, France|Rouen Cedex, France|Saint Etienne, France|Strasbourg Cedex, France|Toulon, France|Toulouse, France|Tours, France|Valenciennes Cedex, France|Vandoeuvre Les Nancy, France|Vernon, France|Bruchsal, Baden-Württemberg, Germany|Heidelberg, Baden-Württemberg, Germany|Karlsbad, Baden-Württemberg, Germany|Mannheim, Baden-Württemberg, Germany|Neckargemünd, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|Augsburg, Bayern, Germany|München, Bayern, Germany|München, Bayern, Germany|Würzburg, Bayern, Germany|Darmstadt, Hessen, Germany|Frankfurt, Hessen, Germany|Frankfurt, Hessen, Germany|Gießen, Hessen, Germany|Wiesbaden, Hessen, Germany|Greifswald, Mecklenburg-Vorpommern, Germany|Hannover, Niedersachsen, Germany|Rotenburg, Niedersachsen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Paderborn, Nordrhein-Westfalen, Germany|Soest, Nordrhein-Westfalen, Germany|Witten, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Homburg, Saarland, Germany|Homburg, Saarland, Germany|Halle, Sachsen-Anhalt, Germany|Magdeburg, Sachsen-Anhalt, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Berlin, Germany|Berlin, Germany|Hamburg, Germany|Hong Kong, Hong Kong|Wanchai, Hong Kong|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Kecskemet, Hungary|Kistarcsa, Hungary|Miskolc, Hungary|Szentes, Hungary|Szombathely, Hungary|Kochi, Kerala, India|Mumbai, Maharashtra, India|Hyderabad, India|Kolkata, India|New Delhi, India|Pune, India|Bandung, Indonesia|Jakarta, Indonesia|Jakarta, Indonesia|Medan, Indonesia|Semarang, Indonesia|Afula, Israel|Ashkelon, Israel|Beer Sheva, Israel|Haifa, Israel|Haifa, Israel|Haifa, Israel|Holon, Israel|Jerusalem, Israel|Kfar Saba, Israel|Petach Tikva, Israel|Rehovot, Israel|Safed, Israel|Tel Aviv, Israel|Bologna, Italy|Chieti, Italy|Cremona, Italy|Milano, Italy|Milano, Italy|Milano, Italy|Napoli, Italy|Padova, Italy|Palermo, Italy|Parma, Italy|Pavia, Italy|Piacenza, Italy|Reggio Emilia, Italy|Varese, Italy|Venezia, Italy|Seoul, Korea, Korea, Republic of|Daegu, Korea, Republic of|Daegu, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Taegu, Korea, Republic of|Selangor, Malaysia|Amsterdam, Netherlands|Arnhem, Netherlands|Dordrecht, Netherlands|Enschede, Netherlands|Groningen, Netherlands|Hoofddorp, Netherlands|Maastricht, Netherlands|Rotterdam, Netherlands|Zwijndrecht, Netherlands|Zwolle, Netherlands|Auckland, New Zealand|Auckland, New Zealand|Auckland, New Zealand|Christchurch, New Zealand|Palmerston North, New Zealand|Wellington South, New Zealand|Fredrikstad, Norway|Oslo, Norway|Rud, Norway|Trondheim, Norway|Quezon City, Philippines|Quezon City, Philippines|Bialystok, Poland|Bydgoszcz, Poland|Gdansk, Poland|Katowice, Poland|Krakow, Poland|Lodz, Poland|Lublin, Poland|Poznan, Poland|Poznan, Poland|Torun, Poland|Warszawa, Poland|Warszawa, Poland|Warszawa, Poland|Wroclaw, Poland|Wroclaw, Poland|San Juan, Puerto Rico|Singapore, Singapore|Singapore, Singapore|Cape Town, Cape, South Africa|Johannesburg, Gauteng, South Africa|Johannesburg, Gauteng, South Africa|Johannesburg, Gauteng, South Africa|Johannesburg, Gauteng, South Africa|Johannesburg, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Cape Town, Western Cape, South Africa|Somerset West, Western Cape, South Africa|Worcester, Western Cape, South Africa|Terrassa, Barcelona, Spain|Alcorcón, Madrid, Spain|Fuenlabrada, Madrid, Spain|Xàtiva, Valencia, Spain|Barcelona, Spain|Barcelona, Spain|Girona, Spain|Madrid, Spain|Pamplona, Spain|Borås, Sweden|Göteborg, Sweden|Göteborg, Sweden|Jönköping, Sweden|Sundsvall, Sweden|Västervik, Sweden|Genéve 14, Genève 14, Switzerland|Chur, Graubünden, Switzerland|Lausanne, Waadt, Switzerland|Lausanne, Waadt, Switzerland|Luzern, Switzerland|Zürich, Switzerland|Kaosiung, Kaoshiong, Taiwan|Taichung, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Bangkok, Thailand|Bangkok, Thailand|Pathumwan, Bangkok, Thailand|Plymouth, Devon, United Kingdom|Chelmsford, Essex, United Kingdom|Isleworth, Greater London, United Kingdom|London, Greater London, United Kingdom|London, Greater London, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00440193"
1244,"NCT00439777","Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study",,"Completed","Has Results","Pulmonary Embolism","Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Enoxaparin overlapping with and followed by VKA","Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal Pulmonary Embolism [PE]) Until the Intended End of Study Treatment|Percentage of Participants With the Composite Variable Comprising Recurrent DVT, Non-fatal PE and All Cause Mortality Until the Intended End of Study Treatment|Percentage of Participants With an Event for Net Clinical Benefit 1 Until the Intended End of Study Treatment|Percentage of Participants With Recurrent PE Until the Intended End of Study Treatment|Percentage of Participants With Recurrent DVT Until the Intended End of Study Treatment|Percentage of Participants With Clinically Relevant Bleeding, Treatment-emergent (Time Window: Until 2 Days After Last Dose)|Percentage of Participants With All Deaths|Percentage of Participants With Other Vascular Events, On-treatment (Time Window: Until 1 Day After Last Dose)","Bayer|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","All","18 Years and older   (Adult, Older Adult)","Phase 3","4833","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11702b|2006-004495-13","March 2007","September 2011","December 2011","February 26, 2007","January 24, 2013","February 27, 2014","Little Rock, Arkansas, United States|Redlands, California, United States|Bay Pines, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Idaho Falls, Idaho, United States|Covington, Louisiana, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Chesterfield, Missouri, United States|Albuquerque, New Mexico, United States|Chapel Hill, North Carolina, United States|Greensboro, North Carolina, United States|Greensboro, North Carolina, United States|Oklahoma City, Oklahoma, United States|Camp Hill, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|San Antonio, Texas, United States|Murray, Utah, United States|Salt Lake City, Utah, United States|Fredericksburg, Virginia, United States|Spokane, Washington, United States|Tacoma, Washington, United States|Escaldes - Engordany, Andorra|Garran, Australian Capital Territory, Australia|Gosford, New South Wales, Australia|Kogarah, New South Wales, Australia|Lismore, New South Wales, Australia|St Leonards, New South Wales, Australia|Sydney, New South Wales, Australia|Sydney, New South Wales, Australia|Sydney, New South Wales, Australia|Brisbane, Queensland, Australia|Redcliffe, Queensland, Australia|Southport, Queensland, Australia|Woolloongabba, Queensland, Australia|Adelaide, South Australia, Australia|Woodville South, South Australia, Australia|Launceston, Tasmania, Australia|Box Hill, Victoria, Australia|Clayton, Victoria, Australia|Geelong, Victoria, Australia|Melbourne, Victoria, Australia|Melbourne, Victoria, Australia|Fremantle, Western Australia, Australia|Perth, Western Australia, Australia|Graz, Steiermark, Austria|Feldkirch, Vorarlberg, Austria|Innsbruck, Austria|Linz, Austria|Wien, Austria|Wien, Austria|Wien, Austria|Aalst, Belgium|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Duffel, Belgium|Genk, Belgium|Gent, Belgium|Hasselt, Belgium|Leuven, Belgium|Liege, Belgium|Lier, Belgium|Namur, Belgium|Yvoir, Belgium|Zottegem, Belgium|Curitiba, Parana, Brazil|Londrina, Parana, Brazil|Botucatu, Sao Paulo, Brazil|Sorocaba, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|Rio de Janeiro, Brazil|Sao Paulo, Brazil|Winnipeg, Manitoba, Canada|London, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Nanning, Guangxi, China|Harbin, Heilongjiang, China|Wuhan, Hubei, China|Suzhou, Jiangsu, China|Shenyang, Liaoning, China|Hangzhou, Zhejiang, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Shanghai, China|Shanghai, China|Shanghai, China|Kladno, Czech Republic|Ostrava-Poruba, Czech Republic|Ostrava, Czech Republic|Prague 5, Czech Republic|Praha 1, Czech Republic|Praha 2, Czech Republic|Rakovnik, Czech Republic|Usti nad Lebem, Czech Republic|Aarhus C, Denmark|Braedstrup, Denmark|Frederiksberg, Denmark|Tallinn, Estonia|Tampere, Finland|Turku, Finland|Agen Cedex 9, France|Amiens, France|Angers Cedex 01, France|Arras, France|Besancon, France|Bordeaux, France|Brest Cedex, France|Castelnau Le Lez, France|Clamart, France|Clermont Ferrand, France|Colombes Cedex, France|Dijon, France|Grenoble, France|Limoges, France|Metz-tessy, France|Montpellier Cedex, France|Nantes, France|Nice, France|Orthez, France|Paris Cedex 15, France|Paris, France|Paris, France|Paris, France|Paris, France|Pierre Benite, France|Roanne, France|Rouen Cedex, France|Saint Etienne, France|Strasbourg Cedex, France|Toulon, France|Toulouse, France|Valenciennes Cedex, France|Vandoeuvre Les Nancy, France|Vernon, France|Bruchsal, Baden-Württemberg, Germany|Heidelberg, Baden-Württemberg, Germany|Heidelberg, Baden-Württemberg, Germany|Karlsbad, Baden-Württemberg, Germany|Neckargemünd, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|Augsburg, Bayern, Germany|München, Bayern, Germany|München, Bayern, Germany|Würzburg, Bayern, Germany|Darmstadt, Hessen, Germany|Frankfurt, Hessen, Germany|Frankfurt, Hessen, Germany|Greifswald, Mecklenburg-Vorpommern, Germany|Rotenburg, Niedersachsen, Germany|Essen, Nordrhein-Westfalen, Germany|Paderborn, Nordrhein-Westfalen, Germany|Witten, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Halle, Sachsen-Anhalt, Germany|Magdeburg, Sachsen-Anhalt, Germany|Dresden, Sachsen, Germany|Nordhausen, Thüringen, Germany|Berlin, Germany|Bottrop, Germany|Hamburg, Germany|Hong Kong, Hong Kong|Wanchai, Hong Kong|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Kecskemet, Hungary|Kistarcsa, Hungary|Miskolc, Hungary|Szekszard, Hungary|Szentes, Hungary|Szombathely, Hungary|Zalaegerszeg, Hungary|Kochi, Kerala, India|Hyderabad, India|New Delhi, India|Pune, India|Bandung, Indonesia|Jakarta, Indonesia|Jakarta, Indonesia|Medan, Indonesia|Semarang, Indonesia|Ballinasloe, Co. Galway, Ireland|Afula, Israel|Ashkelon, Israel|Haifa, Israel|Haifa, Israel|Haifa, Israel|Holon, Israel|Jerusalem, Israel|Kfar Saba, Israel|Petach Tikva, Israel|Rehovot, Israel|Safed, Israel|Tel Aviv, Israel|Rozzano, Milano, Italy|Bologna, Italy|Chieti, Italy|Milano, Italy|Milano, Italy|Milano, Italy|Padova, Italy|Palermo, Italy|Parma, Italy|Pavia, Italy|Piacenza, Italy|Reggio Emilia, Italy|Varese, Italy|Venezia, Italy|Seoul, Korea, Korea, Republic of|Daegu, Korea, Republic of|Seoul, Korea, Republic of|Taegu, Korea, Republic of|Liepaja, Latvia|Kaunas, Lithuania|Vilnius, Lithuania|Selangor, Malaysia|Amsterdam, Netherlands|Arnhem, Netherlands|Enschede, Netherlands|Groningen, Netherlands|Hoofddorp, Netherlands|Maastricht, Netherlands|Zwolle, Netherlands|Auckland, New Zealand|Auckland, New Zealand|Auckland, New Zealand|Christchurch, New Zealand|Palmerston North, New Zealand|Wellington South, New Zealand|Fredrikstad, Norway|Oslo, Norway|Rud, Norway|Trondheim, Norway|Quezon City, Philippines|Quezon City, Philippines|Bialystok, Poland|Krakow, Poland|Lodz, Poland|Lublin, Poland|Poznan, Poland|Poznan, Poland|Torun, Poland|Warszawa, Poland|Wroclaw, Poland|Wroclaw, Poland|San Juan, Puerto Rico|Singapore, Singapore|Singapore, Singapore|Johannesburg, Gauteng, South Africa|Johannesburg, Gauteng, South Africa|Johannesburg, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Roodepoort, Gauteng, South Africa|Cape Town, Western Cape, South Africa|Somerset West, Western Cape, South Africa|Worcester, Western Cape, South Africa|Terrassa, Barcelona, Spain|Valladolid, Castilla - León, Spain|Palma de Mallorca, Illes Baleares, Spain|Requena, Valencia, Spain|Barcelona, Spain|Barcelona, Spain|Girona, Spain|Madrid, Spain|Pamplona, Spain|Borås, Sweden|Göteborg, Sweden|Göteborg, Sweden|Jönköping, Sweden|Stockholm, Sweden|Sundsvall, Sweden|Genéve 14, Genève 14, Switzerland|Chur, Graubünden, Switzerland|Lausanne, Vaud, Switzerland|Lausanne, Waadt, Switzerland|Bern, Switzerland|Luzern, Switzerland|Zürich, Switzerland|Taichung, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Bangkok, Thailand|Chiang Mai, Thailand|Pathumwan, Bangkok, Thailand|Plymouth, Devon, United Kingdom|Isleworth, London, United Kingdom|London, United Kingdom|London, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00439777"
1245,"NCT00439725","Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study",,"Completed","Has Results","Venous Thromboembolism","Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Placebo","Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal Pulmonary Embolism [PE]) Until the Intended End of Study Treatment|Percentage of Participants With the Composite Variable Comprising Recurrent DVT, Non-fatal PE and All Cause Mortality Until the Intended End of Study Treatment|Percentage of Participants With the Composite Variable Comprising Recurrent DVT, Non-fatal PE, All Cause Mortality, Strokes and Myocardial Infarctions Until the Intended End of Study Treatment|Percentage of Participants With Net Clinical Benefit as Composite of Recurrent DVT or Non-fatal or Fatal PE and Major Bleeding Events Until the Intended End of Study Treatment|Percentage of Participants With Recurrent VTE (PE or DVT) Until the Intended End of Study Treatment|Percentage of Participants With Recurrent DVT Until the Intended End of Study Treatment|Percentage of Participants With Major Bleeding|Percentage of Participants With Clinically Relevant Bleeding|Percentage of Participants With All Death|Percentage of Participants With Other Vascular Events","Bayer|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","All","18 Years and older   (Adult, Older Adult)","Phase 3","1197","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","11899|2006-004494-96","February 2007","August 2009","September 2009","February 26, 2007","April 12, 2012","November 4, 2014","Little Rock, Arkansas, United States|Los Angeles, California, United States|Redlands, California, United States|Bay Pines, Florida, United States|Melbourne, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Decatur, Georgia, United States|Idaho Falls, Idaho, United States|Covington, Louisiana, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Albuquerque, New Mexico, United States|Chapel Hill, North Carolina, United States|Greensboro, North Carolina, United States|Greensboro, North Carolina, United States|Oklahoma City, Oklahoma, United States|Pittsburgh, Pennsylvania, United States|Corsicana, Texas, United States|San Antonio, Texas, United States|Murray, Utah, United States|Salt Lake City, Utah, United States|Burlington, Vermont, United States|Fredericksburg, Virginia, United States|Spokane, Washington, United States|Garran, Australian Capital Territory, Australia|Gosford, New South Wales, Australia|Kogarah, New South Wales, Australia|Lismore, New South Wales, Australia|St Leonards, New South Wales, Australia|Sydney, New South Wales, Australia|Sydney, New South Wales, Australia|Sydney, New South Wales, Australia|Sydney, New South Wales, Australia|Brisbane, Queensland, Australia|Redcliffe, Queensland, Australia|Southport, Queensland, Australia|Woolloongabba, Queensland, Australia|Adelaide, South Australia, Australia|Adelaide, South Australia, Australia|Box Hill, Victoria, Australia|Clayton, Victoria, Australia|Geelong, Victoria, Australia|Melbourne, Victoria, Australia|Melbourne, Victoria, Australia|Prahran, Victoria, Australia|Fremantle, Western Australia, Australia|Perth, Western Australia, Australia|Graz, Steiermark, Austria|Innsbruck, Tirol, Austria|Feldkirch, Vorarlberg, Austria|Salzburg, Austria|Wien, Austria|Wien, Austria|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Duffel, Belgium|Genk, Belgium|Gent, Belgium|Hasselt, Belgium|Leuven, Belgium|Liege, Belgium|Lier, Belgium|Namur, Belgium|Sint-Truiden, Belgium|Yvoir, Belgium|Zottegem, Belgium|Uberaba, Minas Gerais, Brazil|Curitiba, Parana, Brazil|Londrina, Parana, Brazil|Porto Alegre, Rio Grande do Sul, Brazil|Botucatu, Sao Paulo, Brazil|Sorocaba, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|Rio de Janeiro, Brazil|Sao Paulo, Brazil|Winnipeg, Manitoba, Canada|Toronto, Ontario, Canada|Guangzhou, Guangdong, China|Harbin, Heilongjiang, China|Wuhan, Hubei, China|Suzhou, Jiangsu, China|Shenyang, Liaoning, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Shanghai, China|Shanghai, China|Shanghai, China|Brno, Czech Republic|Karlovy Vary, Czech Republic|Kladno, Czech Republic|Ostrava-Poruba, Czech Republic|Ostrava, Czech Republic|Prague 5, Czech Republic|Praha 1, Czech Republic|Praha 2, Czech Republic|Praha 4, Czech Republic|Usti nad Lebem, Czech Republic|Aarhus C, Denmark|Braedstrup, Denmark|Frederiksberg, Denmark|Hellerup, Denmark|Seinäjoki, Finland|Agen Cedex 9, France|Amiens, France|Angers Cedex 01, France|Arras, France|Bordeaux, France|Brest Cedex, France|Castelnau Le Lez, France|Clamart, France|Clermont Ferrand, France|Colombes, France|Creteil, France|Dijon, France|Grenoble, France|Grenoble, France|Lille Cedex, France|Limoges, France|Montpellier Cedex, France|Nantes, France|Nimes Cedex 9, France|Orthez, France|Paris Cedex 15, France|Paris, France|Paris, France|Paris, France|Pierre Benite, France|Roanne, France|Rouen Cedex, France|Saint Etienne, France|Strasbourg Cedex, France|Toulon, France|Toulouse, France|Tours, France|Valenciennes Cedex, France|Vandoeuvre Les Nancy, France|Vernon, France|Bruchsal, Baden-Württemberg, Germany|Heidelberg, Baden-Württemberg, Germany|Karlsbad, Baden-Württemberg, Germany|Mannheim, Baden-Württemberg, Germany|Neckargemünd, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|Augsburg, Bayern, Germany|München, Bayern, Germany|München, Bayern, Germany|Würzburg, Bayern, Germany|Darmstadt, Hessen, Germany|Frankfurt, Hessen, Germany|Gießen, Hessen, Germany|Wiesbaden, Hessen, Germany|Greifswald, Mecklenburg-Vorpommern, Germany|Hannover, Niedersachsen, Germany|Rotenburg, Niedersachsen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Paderborn, Nordrhein-Westfalen, Germany|Soest, Nordrhein-Westfalen, Germany|Witten, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Homburg, Saarland, Germany|Homburg, Saarland, Germany|Halle, Sachsen-Anhalt, Germany|Magdeburg, Sachsen-Anhalt, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Berlin, Germany|Berlin, Germany|Hamburg, Germany|Hong Kong, Hong Kong|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Kecskemet, Hungary|Kistarcsa, Hungary|Miskolc, Hungary|Nyiregyhaza, Hungary|Szentes, Hungary|Szombathely, Hungary|Kochi, Kerala, India|Vellore, Kerala, India|Mumbai, Maharashtra, India|Mumbai, Maharashtra, India|Mumbai, Maharashtra, India|Hyderabad, India|Kolkata, India|New Delhi, India|Pune, India|Bandung, Indonesia|Jakarta, Indonesia|Medan, Indonesia|Semarang, Indonesia|Afula, Israel|Ashkelon, Israel|Beer Sheva, Israel|Haifa, Israel|Haifa, Israel|Haifa, Israel|Holon, Israel|Jerusalem, Israel|Kfar Saba, Israel|Petach Tikva, Israel|Rehovot, Israel|Safed, Israel|Tel Aviv, Israel|Bologna, Italy|Chieti, Italy|Milano, Italy|Milano, Italy|Napoli, Italy|Padova, Italy|Palermo, Italy|Parma, Italy|Pavia, Italy|Piacenza, Italy|Venezia, Italy|Daegu, Daegu Gwang'yeogsi, Korea, Republic of|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Daegu, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Taegu, Korea, Republic of|Selangor, Malaysia|Amsterdam, Netherlands|Arnhem, Netherlands|Den Bosch, Netherlands|Dordrecht, Netherlands|Enschede, Netherlands|Groningen, Netherlands|Hoofddorp, Netherlands|Maastricht, Netherlands|Rotterdam, Netherlands|Zwijndrecht, Netherlands|Zwolle, Netherlands|Auckland, New Zealand|Auckland, New Zealand|Christchurch, New Zealand|Palmerston North, New Zealand|Wellington South, New Zealand|Fredrikstad, Norway|Oslo, Norway|Oslo, Norway|Rud, Norway|Quezon City, Philippines|Quezon City, Philippines|Bialystok, Poland|Bydgoszcz, Poland|Gdansk, Poland|Katowice, Poland|Krakow, Poland|Lodz, Poland|Lublin, Poland|Poznan, Poland|Poznan, Poland|Torun, Poland|Warszawa, Poland|Warszawa, Poland|Warszawa, Poland|Wroclaw, Poland|Wroclaw, Poland|Singapore, Singapore|Singapore, Singapore|Cape Town, Cape, South Africa|Johannesburg, Gauteng, South Africa|Johannesburg, Gauteng, South Africa|Johannesburg, Gauteng, South Africa|Johannesburg, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Roodepoort, Gauteng, South Africa|Cape Town, Western Cape, South Africa|Somerset West, Western Cape, South Africa|Worcester, Western Cape, South Africa|Terrassa, Barcelona, Spain|Alcorcón, Madrid, Spain|Fuenlabrada, Madrid, Spain|Xàtiva, Valencia, Spain|Barcelona, Spain|Barcelona, Spain|Girona, Spain|Madrid, Spain|Pamplona, Spain|Borås, Sweden|Göteborg, Sweden|Göteborg, Sweden|Jönköping, Sweden|Sundsvall, Sweden|Västervik, Sweden|Bruderholz, Basel-Landschaft, Switzerland|Genéve 14, Genève 14, Switzerland|Chur, Graubünden, Switzerland|Brig, Valais, Switzerland|Lugano, Switzerland|Luzern, Switzerland|Zürich, Switzerland|Kaohsiung, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Bangkok, Thailand|Bangkok, Thailand|Pathumwan, Bangkok, Thailand|Plymouth, Devon, United Kingdom|Chelmsford, Essex, United Kingdom|Romford, Essex, United Kingdom|Isleworth, London, United Kingdom|Edinburgh, Lothian, United Kingdom|Liverpool, Merseyside, United Kingdom|London, United Kingdom|London, United Kingdom|London, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00439725"
1246,"NCT00432302","Investigation of Mass Balance of the Test Drug and Major Metabolites",,"Completed","No Results Available","Neoplasms","Drug: Sagopilone (BAY 86-5302, ZK 219477)","Blood, urine and fecal samples will be collected over a period of 336 hours (14 days) to measure 14C, ZK 219477 and its major metabolites following the intravenous administration of 14C-ZK 219477.|Cmax|tmax|AUC|AUC(0-tlast)|AUC(0-24)|MRT|t1/2|λz|CL|Vss|Vz|Number of participants with adverse events|Overall response|Best overall response|Responders","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","7","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","91490|2006-000188-26|310301","January 2007","November 2007","November 2007","February 7, 2007",,"December 14, 2015","Liege, Belgium",,"https://ClinicalTrials.gov/show/NCT00432302"
1247,"NCT00431678","Efficacy and Safety of Sequential IV/PO Moxifloxacin in Comparison to IV Levofloxacin Plus IV Ceftriaxone Followed by PO Levofloxacin, in the Treatment of Patients With Community-acquired Pneumonia",,"Completed","No Results Available","Pneumonia","Drug: Avelox (Moxifloxacin, BAY12-8039)|Drug: Levofloxacin + Ceftriaxone","Clinical response|Clinical and bacteriological response|Clinical and bacteriological response on treatment|Bacteriological response|Mortality attributable to pneumonia|Symptoms course of community-acquired pneumonia|Adverse Event Collection","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","738","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","11215","January 2004","July 2005","July 2005","February 6, 2007",,"December 17, 2014","Vicente López, Buenos Aires, Argentina|Buenos Aires, Capital Federal, Argentina|Buenos Aires, Capital Federal, Argentina|Buenos Aires, Capital Federal, Argentina|Buenos Aires, Capital Federal, Argentina|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Leuven, Belgium|Liege, Belgium|Namur, Belgium|Temuco, IX Region, Chile|Viña del Mar, V Region, Chile|Santiago de Chile, Chile|Santiago, Chile|Bogotá, Colombia|Bucaramanga, Colombia|Santafé de Bogotá, Colombia|Agen, France|Aix-en-provence, France|Argenteuil, France|Avignon, France|Belfort, France|Bordeaux, France|Brive-la-gaillarde, France|Paris, France|Saint-gaudens, France|Toulon, France|Vesoul, France|Bochum, Nordrhein-Westfalen, Germany|Bochum, Nordrhein-Westfalen, Germany|Lüdenscheid, Nordrhein-Westfalen, Germany|Paderborn, Nordrhein-Westfalen, Germany|Halle, Sachsen-Anhalt, Germany|Magdeburg, Sachsen-Anhalt, Germany|Berlin, Germany|Berlin, Germany|Rio, Patras, Greece|Athens, Greece|Thessaloniki, Greece|Afula, Israel|Ashkelon, Israel|Holon, Israel|Tel Aviv, Israel|Tel Hashomer, Israel|Kaunas, Lithuania|Kaunas, Lithuania|Vilnius, Lithuania|Vilnius, Lithuania|Toluca, Edo. de México, Mexico|Guadalajara, Jalisco, Mexico|Monterrey, Nuevo León, Mexico|México, D.F., Mexico|México, D.F., Mexico|México, D.F., Mexico|México, D.F., Mexico|Eindhoven, Noord Brabant, Netherlands|Den Bosch, Netherlands|EDE, Netherlands|Harderwijk, Netherlands|Heerlen, Netherlands|Callao, Peru|Lima Cercado, Peru|Lima, Peru|Bydgoszcz, Poland|Gdansk, Poland|Krakow, Poland|Lodz, Poland|Warszawa, Poland|Warszawa, Poland|Wroclaw, Poland|Lisboa, Portugal|Bloemfontein, Free State, South Africa|Bloemfontein, Freestate, South Africa|Brits, Gauteng, South Africa|Johannesburg, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Cape Town, Western Cape, South Africa|Somerset West, Western Cape, South Africa|Huesca, Aragón, Spain|L'Hospitalet de Llobregat, Barcelona, Spain|Alcalá de Henares, Madrid, Spain|Barcelona, Spain|Barcelona, Spain|Guadalajara, Spain|Madrid, Spain|Valencia, Spain|Jönköping, Sweden|Kalmar, Sweden|Karlstad, Sweden|Skövde, Sweden|Middlesborough, Cleveland, United Kingdom|Dumfries, Dumfries and Galloway, United Kingdom|Hull, Humberside, United Kingdom|Edinburgh, Lothian, United Kingdom|Rotherham, South Yorkshire, United Kingdom|Sheffield, South Yorkshire, United Kingdom|Newcastle Upon Tyne, Tyne and Wear, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00431678"
1248,"NCT00420342","Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension",,"Completed","Has Results","Postmenopause|Hypertension|Pre-Hypertension","Drug: Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)|Drug: SH K 00641 C - Medroxyprogesterone acetate / conjugated equine (Prempro TM)","Change From Baseline to Week 8 in Mean 24-hour SBP From the Ambulatory Blood Pressure Monitoring (ABPM) Measurements in Full Analysis Set (FAS) Population|Change From Baseline to Week 8 in Mean 24-hour SBP From the ABPM Measurements in Per Protocol Population|Change From Baseline to Week 8 in Mean 24-hour DBP From the ABPM Measurements|Change From Baseline to Week 8 in Office Cuff SBP and DBP at Trough|Change From Baseline to Week 8 in Mean Day Time, Mean Nighttime and Mean Trough SBP From the ABPM Measurements|Change From Baseline to Week 8 in Mean Day Time, Mean Nighttime and Mean Trough DBP From the ABPM Measurements|Number of Subjects Who Are Sodium Sensitive at Baseline and Week 8|Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean > 112 mmHg (Posthoc Analysis)|Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean > 116 mmHg (Posthoc Analysis)|Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean > 120 mmHg (Posthoc Analysis)|Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean > 124 mmHg (Posthoc Analysis)|Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean > 130 mmHg (Posthoc Analysis)","Bayer","Female","45 Years to 65 Years   (Adult, Older Adult)","Phase 2","92","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","91507|310522","January 2007","September 2008","September 2008","January 11, 2007","January 20, 2010","June 2, 2015","Greenbrae, California, United States|San Diego, California, United States|Daytona Beach, Florida, United States|Miami, Florida, United States|Paw Paw, Michigan, United States|Las Vegas, Nevada, United States|Philadelphia, Pennsylvania, United States|Columbia, South Carolina, United States|Arlington, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00420342"
1249,"NCT00417937","A Multicenter Trial of a Topical Medication for Papulopustular Rosacea Applied Twice Daily Versus Once Daily",,"Completed","No Results Available","Papulopustular Rosacea","Drug: azelaic acid 15% gel","Investigator's global assessment scored on a seven point scale|Inflammatory lesion count, erythema, telangiectasia, patient self assessment, patient opinion about therapy","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 4","98","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","14428|1401460","January 2007","June 2007","June 2007","January 4, 2007",,"February 21, 2014","Intendis GmbH, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT00417937"
1250,"NCT00414687","Aerosolized Randomized Iloprost Study II (AIR - II) Long-Term Safety, Tolerability, and Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary Hypertension",,"Completed","No Results Available","Hypertension, Pulmonary","Drug: Ventavis (Iloprost, BAYQ6256)","Tolerability: Adverse events (AE) and safety variables, Variables to describe clinical effects: NYHA class, Walking distance (6-min walk), Mahler Dyspnea Index, EuroQoL, Karnofsky Index, Hemodynamic and gas exchange|Mortality and lung/heart-lung transplantation, Acute effects of iloprost inhalation on hemodynamics and gas exchange|Overall clinical tolerability of the long-term use of iloprost aerosol|Serious Adverse Events and deaths|Effect of long-term administration of inhaled iloprost on mortality and transplantation|Exercise capacity|Acute effect of inhaled iloprost on hemodynamics and gas exchange|Effects of long-term administration of inhaled iloprost on hemodynamics and gas exchange|Quality of Life","Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","63","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","90427|300341","July 1998",,"May 2001","December 21, 2006",,"May 15, 2009",,,"https://ClinicalTrials.gov/show/NCT00414687"
1251,"NCT00410306","Use of Nebido® to Assess Tolerability and Treatment Outcomes in Daily Clinical Practice","IPASS Nebido","Completed","No Results Available","Male|Hypogonadism","Drug: Testosterone Undecanoate (Nebido, BAY86-5037)","Adverse events, adverse drug reactions, patient reported tolerability|Change in laboratory values (total testosterone, estradiol, SHGB, FSH, LH) from baseline to end of observation|Change in subjective assessment of the patient (overall sexual desire/libido, vigor/vitality, mood, ability to concentrate) from baseline to end of observation|Change in intensity of symptoms or disorders associated with low testosterone (hot flushes or excessive sweating, sleep disturbances, decreased physical strength and erectile dysfunction) from baseline to end of observation|Patient reported outcome at end of observation (satisfaction with current androgen therapy, comparison to previous androgen therapy, if applicable)|Treatment continuation rate|Vital signs and anthropometric measurements (Blood pressure, heart rate, weight and waist circumference)|Laboratory values (PSA, hemoglobin, hematocrit, HbA1C, T-chol, HDL-chol, LDL-chol, triglycerides)|Digital rectal examination","Bayer","Male","18 Years and older   (Adult, Older Adult)",,"1493","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14203|2005/00888|MP-04199|NE0601|39732","October 2006","July 2010","July 2010","December 12, 2006",,"September 24, 2010","Many Locations, Australia|Many Locations, Austria|Many Locations, Bulgaria|Many Locations, Colombia|Many Locations, Czech Republic|Many Locations, Estonia|Many Locations, Germany|Many Locations, Hong Kong|Many Locations, Indonesia|Many Locations, Italy|Many Locations, Jordan|Many Locations, Kazakhstan|Many Locations, Korea, Republic of|Many Locations, Latvia|Many Locations, Lebanon|Many Locations, Lithuania|Many Locations, Macedonia, The Former Yugoslav Republic of|Many Locations, Malaysia|Many Locations, Malta|Many Locations, Mexico|Many Locations, Moldova, Republic of|Many Locations, Philippines|Many Locations, Romania|Many Locations, Russian Federation|Many Locations, Saudi Arabia|Many Locations, Singapore|Many Locations, Slovenia|Many Locations, Spain|Many Locations, Taiwan|Many Locations, Thailand|Many Locations, Turkey|Many Locations, Ukraine|Many Locations, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00410306"
1252,"NCT00408330","A Study of Azelaic Acid (AzA) 15% Gel in the Treatment of Seborrheic Dermatitis of the Face",,"Completed","No Results Available","Seborrheic Dermatitis on the Face","Drug: Azelaic Acid 15% Gel|Drug: Inactive 15% gel base","Sum Score of the symptoms of seborrheic dermatitis and the investigator's global assessment.|Investigators' and patients' subjective assessment of improvement; frequency and intensity of single symptoms","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1401201|2006-002060-26","December 2006","March 2007","March 2007","December 6, 2006",,"March 19, 2015","Blankenfelde-Mahlow, Germany|Buchholz, Germany|Hamburg, Germany|Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT00408330"
1253,"NCT00403949","A Study of Azelaic Acid (AzA) 15% in Topical Treatment of Mild to Moderate Perioral Dermatitis",,"Completed","No Results Available","Perioral Dermatitis","Drug: Azelaic acid 15% gel|Drug: Non-active base from azelaic acid 15% gel","The sum score derived from the most important signs and symptoms of perioral dermatitis|Intensity of single signs and symptoms|Safety outcomes measures will be all adverse events reported by the patients or observed by the investigator","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1400418|2006-002471-40","November 2006","March 2007","March 2007","November 27, 2006",,"February 18, 2015","Berlin, Germany|Dülmen, Germany|Essen, Germany|Recklinghausen, Germany",,"https://ClinicalTrials.gov/show/NCT00403949"
1254,"NCT00402727","Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection",,"Completed","Has Results","Abscess|Wound Infection|Diabetic Foot|Ulcer","Drug: Moxifloxacin (Avelox, BAY12-8039)|Drug: Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid","Percentage of Cured Participants as Determined by the Data Review Committee (DRC) at Test of Cure Visit in the Per Protocol (PP) Population|Percentage of Cured Participants as Determined by the Data Review Committee (DRC) at Test of Cure Visit in the Intent to Treat (ITT) Population|Percentage of Participants Assessed as Improvements by the Data Review Committee (DRC) at the During Treatment Day 3-5 in the Per Protocol (PP) Population|Percentage of Participants Assessed as Improvements by the Data Review Committee (DRC) at the During Treatment Day 3-5 in the Intent to Treat (ITT) Population|Percentage of Participants Assessed as Resolution by the Data Review Committee (DRC) at End of Therapy in the Per Protocol (PP) Population|Percentage of Participants Assessed as Resolution by the Data Review Committee (DRC) at End of Therapy in the Intent to Treat (ITT) Population|Percentage of Participants With Bacteriological Success (BS) at 3 to 5 Days After Start of Treatment in the ITT Population With Causative Organisms|Percentage of Participants With Bacteriological Success (BS) at 3 to 5 Days After Start of Treatment in the Microbiological Valid (MBV) Population|Percentage of Participants With Bacteriological Success (BS) After 7 - 21 Days of Treatment in the ITT Population With Causative Organisms|Percentage of Participants With Bacteriological Success (BS) After 7 - 21 Days of Treatment in the Microbiological Valid (MBV) Population|Percentage of Participants With Bacteriological Success (BS) After 14 - 28 Days After Last Dose of Study Medication in the ITT Population With Causative Organisms|Percentage of Participants With Bacteriological Success (BS) After 14 - 28 Days After Last Dose of Study Medication in the Microbiological Valid (MBV) Population","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","813","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","11974|2006-001599-18","September 2006","June 2008","June 2008","November 22, 2006","January 11, 2010","November 7, 2014","Graz, Steiermark, Austria|Graz, Austria|Wien, Austria|Bornem, Belgium|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Edegem, Belgium|Dobrich, Bulgaria|Pleven, Bulgaria|Ruse, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Annecy, France|Avignon, France|Boulogne Sur Mer, France|Denain, France|Grenoble, France|Le Grau Du Roi, France|Nevers, France|Quimper, France|Tourcoing, France|Mannheim, Baden-Württemberg, Germany|München, Bayern, Germany|Darmstadt, Hessen, Germany|Wiesbaden, Hessen, Germany|Hannover, Niedersachsen, Germany|Bochum, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Magdeburg, Sachsen-Anhalt, Germany|Lübeck, Schleswig-Holstein, Germany|Hamburg, Germany|Athens, Attica, Greece|Athens, Attica, Greece|Athens, Greece|Athens, Greece|Rio Patras, Greece|Thessaloniki, Greece|Budapest, Hungary|Debrecen, Hungary|Györ, Hungary|Kaposvar, Hungary|Szekesfehervar, Hungary|Veszprem, Hungary|Wilton, Cork, Ireland|Dublin, Ireland|Dublin, Ireland|Dublin, Ireland|Galway, Ireland|Sligo, Ireland|Haifa, Israel|Tel Hashomer, Israel|Chieti, Italy|Milano, Italy|Pavia, Italy|Roma, Italy|Siena, Italy|Daugavpils, Latvia|Liepaja, Latvia|Riga, Latvia|Riga, Latvia|Riga, Latvia|Valmiera, Latvia|Kaunas, Lithuania|Siauliai, Lithuania|Ukmerge, Lithuania|Vilnius, Lithuania|Alkmaar, Netherlands|Eindhoven, Netherlands|Kraków, Poland|Lublin, Poland|Lublin, Poland|Lublin, Poland|Poznan, Poland|Pulawy, Poland|Warszawa, Poland|Bucharest, Romania|Bucharest, Romania|Bucharest, Romania|Cluj-Napoca, Romania|Iasi, Romania|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Smolensk, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|Yaroslavl, Russian Federation|Johannesburg, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Cape Town, Western Cape, South Africa|Cape Town, Western Cape, South Africa|Cape Town, Western Cape, South Africa|Worcester, Western Cape, South Africa|Oviedo, Asturias, Spain|Terrassa (Barcelona), Catalunya, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Salamanca, Spain|Ivano-Frankivsk, Ukraine|Kiev, Ukraine|Kiev, Ukraine|Kiev, Ukraine|Kiev, Ukraine|Lviv, Ukraine|Odessa, Ukraine|Uzhgorod, Ukraine|London, Greater london, United Kingdom|Winchester, Hampshire, United Kingdom|Inverness, Highland, United Kingdom|Edinburgh, Lothian, United Kingdom|Glasgow, Stratchclyde, United Kingdom|Newcastle Upon Tyne, Tyne and Wear, United Kingdom|Leeds, West Yorkshire, United Kingdom|Manchester, United Kingdom|York, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00402727"
1255,"NCT00402467","An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study",,"Completed","No Results Available","Venous Thromboembolism","Drug: Rivaroxaban (BAY59-7939)|Drug: Rivaroxaban, (BAY59-7939)|Drug: Enoxaparine","Composite endpoints of Deep vein Thrombosis (proximal and/or distal),non fatal PE and death from all causes|Incidence of DVTs (total, proximal, distal)|Incidence of symptomatic VTEs|The composite endpoint that results from the primary endpoint by substituting VTE related death for all deaths|Incidence of symptomatic VTEs (total, PE, DVT)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","613","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention","10945","February 2004","November 2004","November 2004","November 22, 2006",,"December 23, 2014","Birmingham, Alabama, United States|Phoenix, Arizona, United States|Tucson, Arizona, United States|La Mesa, California, United States|Torrance, California, United States|Aurora, Colorado, United States|Aurora, Colorado, United States|Jacksonville, Florida, United States|Palm Beach Gardens, Florida, United States|Sarasota, Florida, United States|St. Petersburg, Florida, United States|Decatur, Georgia, United States|Cincinnati, Ohio, United States|Dallas, Texas, United States|Lubbock, Texas, United States|Edmonton, Alberta, Canada|Red Deer, Alberta, Canada|Kelowna, British Columbia, Canada|Vancouver, British Columbia, Canada|Winnipeg, Manitoba, Canada|Fredericton, New Brunswick, Canada|Barrie, Ontario, Canada|Kitchener, Ontario, Canada|Niagara Falls, Ontario, Canada|Oshawa, Ontario, Canada|Ottawa, Ontario, Canada|Peterborough, Ontario, Canada|Richmond Hill, Ontario, Canada|St. Catharines, Ontario, Canada|Sudbury, Ontario, Canada|Thunder Bay, Ontario, Canada|Toronto, Ontario, Canada|Welland, Ontario, Canada|Charlottetown, Prince Edward Island, Canada|Montreal, Quebec, Canada|Quebec City, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00402467"
1256,"NCT00398905","Dose-Ranging Study of BAY 59-7939 on the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement","ODIXa-HIP2","Completed","No Results Available","Venous Thromboembolism","Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Enoxaparin","Composite Endpoint: Any Deep Vein Thrombosis (DVT) (proximal and/or distal) and Non fatal Pulmonary Embolism (PE) and Death from all causes|Incidence of DVTs (total, proximal, distal)|Incidence of symptomatic Venous Thrombo Embolisms (VTEs)|Incidence of symptomatic VTEs (total, PE, DVT) within 30 days after stop of treatment with the study drug|Healthcare Resource Utilisation Questionnaire","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","726","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","10944","January 2004",,"September 2004","November 14, 2006",,"May 8, 2009","Wiener Neustadt, Niederösterreich, Austria|Linz, Oberösterreich, Austria|Wien, Austria|Baudour, Belgium|Bruxelles - Brussel, Belgium|Genk, Belgium|HUY, Belgium|Sint-truiden, Belgium|Hellerup, Denmark|Herlev, Denmark|Hørsholm, Denmark|Silkeborg, Denmark|Amiens, France|Lille Cedex, France|Poitiers, France|Rheinfelden, Baden-Württemberg, Germany|Ulm, Baden-Württemberg, Germany|Fürth, Bayern, Germany|Garmisch-Partenkirchen, Bayern, Germany|Sommerfeld, Brandenburg, Germany|Frankfurt, Hessen, Germany|Frankfurt, Hessen, Germany|Marburg, Hessen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Dresden, Sachsen, Germany|Berlin, Germany|Haifa, Israel|Tel Aviv, Israel|Tel Hashomer, Israel|Zerifin, Israel|Rozzano, Milano, Italy|Gubbio, Perugia, Italy|Milano, Italy|Pavia, Italy|Perugia, Italy|Reggio Emilia, Italy|Varese, Italy|Hilversum, Netherlands|Nijmegen, Netherlands|Sittard, Netherlands|Bodø, Norway|Drammen, Norway|Notodden, Norway|Oslo, Norway|Rjukan, Norway|Bialystok, Poland|Gdansk, Poland|Krakow, Poland|Lodz, Poland|Lublin, Poland|Lublin, Poland|Warszawa, Poland|Badalona, Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Valencia, Spain|Göteborg, Sweden|Halmstad, Sweden|Jönköping, Sweden|Kungälv, Sweden|London, Greater London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00398905"
1257,"NCT00396786","Dose-ranging Study of Once-daily Regimen of BAY 59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement","ODIXaHIP-OD","Completed","No Results Available","Venous Thromboembolism","Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Enoxaparin","Composite Endpoint of Deep Vein Thrombosis (DVT), non-fatal Pulmonary Embolism (PE) and Death from all causes|Incidence of DVTs (total, proximal, distal)|Incidence of symptomatic Venous Thrombo Embolisms (VTEs)|Incidence of major VTE (ie, Proximal DVT, PE or VTE-related death)|The composite endpoint that results from the primary endpoint by substituting VTE related death for all death|Incidence of symptomatic VTEs (total, PE, DVT) within 30 days after stop of treatment with the study drug","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","877","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","11527|EudraCT No: 2004-001341-14","November 2004","July 2005","July 2005","November 7, 2006",,"October 28, 2014","Wiener Neustadt, Niederösterreich, Austria|Linz, Oberösterreich, Austria|Linz, Oberösterreich, Austria|Wien, Austria|Antwerpen, Belgium|Bonheiden, Belgium|Genk, Belgium|Hasselt, Belgium|Hellerup, Denmark|Herlev, Denmark|Hørsholm, Denmark|Silkeborg, Denmark|Paris Cedex 14, France|Paris Cedex 19, France|Poitiers, France|Saint Herblain, France|Rheinfelden, Baden-Württemberg, Germany|Fürth, Bayern, Germany|Garmisch-Partenkirchen, Bayern, Germany|Sommerfeld, Brandenburg, Germany|Frankfurt, Hessen, Germany|Frankfurt, Hessen, Germany|Marburg, Hessen, Germany|Melsungen, Hessen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Dresden, Sachsen, Germany|Petach Tikva, Isarel, Israel|Haifa, Israel|Holon, Israel|Kfar Saba, Israel|Petach Tikva, Israel|Tel Aviv, Israel|Zerifin, Israel|Monza, Milano, Italy|Rozzano, Milano, Italy|Gubbio, Perugia, Italy|Bologna, Italy|Milano, Italy|Milano, Italy|Hilversum, Netherlands|Hoofddorp, Netherlands|Nijmegen, Netherlands|Notodden, Norway|Oslo, Norway|Rjukan, Norway|Bialystok, Poland|Gdansk, Poland|Krakow, Poland|Lublin, Poland|Lublin, Poland|Warszawa, Poland|Badalona, Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Valencia, Spain|Göteborg, Sweden|Halmstad, Sweden|Jönköping, Sweden|Kungälv, Sweden|London, Greater London, United Kingdom|London, Greater London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00396786"
1258,"NCT00395772","Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis",,"Completed","No Results Available","Venous Thromboembolism","Drug: Xarelto (Rivaroxaban, BAY59-7939)|Drug: (LMW) Heparin + Vitamin K Antagonist","The primary efficacy endpoint was the composite of symptomatic recurrent DVT or symptomatic fatal and non-fatal PE at 12 weeks and deterioration in thrombotic burden, as assessed by CUS and PLS, at baseline and at 12 weeks.|The principal safety outcome is all clinically relevant bleeding (i.e. major bleeding and clinically relevant non-major bleeding) within 12 weeks.|The separate components of the primary efficacy outcome at 12 weeks.","Bayer|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","All","18 Years and older   (Adult, Older Adult)","Phase 2","543","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","11528|EudraCT: 2004-002171-16","December 2004",,"December 2005","November 3, 2006",,"October 28, 2014","Albuquerque, New Mexico, United States|Albuquerque, New Mexico, United States|Chapel Hill, North Carolina, United States|Fredericksburg, Virginia, United States|Seattle, Washington, United States|Canberra, Australian Capital Territory, Australia|Sydney, New South Wales, Australia|Sydney, New South Wales, Australia|Brisbane, Queensland, Australia|Melbourne, Victoria, Australia|Melbourne, Victoria, Australia|Melbourne, Victoria, Australia|Curitiba, Paraná, Brazil|Porto Alegre, RS, Brazil|Sorocaba, Sao Paulo, Brazil|São Paulo, SP, Brazil|Edmonton, Alberta, Canada|Halifax, Nova Scotia, Canada|London, Ontario, Canada|Hradec Kralove, Czech Republic|Karlovy Vary, Czech Republic|Ostrava, Czech Republic|Plzen, Czech Republic|Praha 10, Czech Republic|Praha 5, Czech Republic|Usti nad Labem, Czech Republic|Aarhus, Denmark|Brædstrup, Denmark|Frederiksberg, Denmark|Brest Cedex, France|Grenoble, France|Montpellier Cedex, France|Paris Cedex 15, France|Paris, France|Saint-etienne, France|Valenciennes Cedex, France|Afula, Israel|Ashkelon, Israel|Haifa, Israel|Haifa, Israel|Haifa, Israel|Holon, Israel|Kfar Saba, Israel|Petach Tikva, Israel|Safed, Israel|Tel Aviv, Israel|Tel Hashomer, Israel|Milano, Italy|Milano, Italy|Milano, Italy|Padova, Italy|Pavia, Italy|Reggio Emilia, Italy|Venezia, Italy|Amersfoort, Netherlands|Amsterdam, Netherlands|Amsterdam, Netherlands|Arnhem, Netherlands|Groningen, Netherlands|Hoofddorp, Netherlands|Maastricht, Netherlands|Sittard-geleen, Netherlands|Zwolle, Netherlands|Bydgoszcz, Poland|Warszawa, Poland|Warszawa, Poland|Wroclaw, Poland|Wroclaw, Poland|Johannesburg, Gauteng, South Africa|Johannesburg, Gauteng, South Africa|Johannesburg, Gauteng, South Africa|Johannesburg, Gauteng, South Africa|Johannesburg, Gauteng, South Africa|Göteborg, Sweden|Jönköping, Sweden|Stockholm, Sweden|Stockholm, Sweden|Västervik, Sweden",,"https://ClinicalTrials.gov/show/NCT00395772"
1259,"NCT00395733","Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Vascular Diseases in Chinese Patients",,"Completed","Has Results","Vascular Diseases","Drug: Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Drug: Gadopentate dimeglumine (Magnevist, BAY86-4882)","Number of Vessel Segments Visualized With Diagnostic Quality|Change in Diagnostic Confidence From Pre- to Post-contrast MRA by Investigator|Change in Diagnostic Confidence From Pre- to Post-contrast MRA by Blinded Reader 1|Change in Diagnostic Confidence From Pre- to Post-contrast MRA by Blinded Reader 2|Change in Diagnostic Confidence From Pre- to Post-contrast MRA by Blinded Reader 3|MRA Diagnosis by Investigators|MRA Diagnosis by Blinded Reader 1|MRA Diagnosis by Blinded Reader 2|MRA Diagnosis by Blinded Reader 3","Bayer","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","83","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic","91537|309762","October 2006","October 2007","October 2007","November 3, 2006","August 3, 2011","December 18, 2013","Chengdu, Sichuan, China|Beijing, China|Shanghai, China",,"https://ClinicalTrials.gov/show/NCT00395733"
1260,"NCT00395460","Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients",,"Completed","Has Results","Central Nervous System Diseases","Drug: Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Drug: Magnevist","Change in Contrast to Noise Ratio (CNR) Between Pre- and Post-contrast Magnetic Resonance Imaging (MRI) Scan of Central Nervous System (CNS) Lesions|Change in Number of Detected Lesions From Pre- to Post-contrast MRI Scan|Change in Diagnostic Confidence From Pre- to Post-contrast Magnetic Resonance Imaging by Treatment|Change in Lesion Contrast Enhancement From Pre- to Post-contrast MRI|Change in Lesion Delineation Between Pre- and Post-contrast MRI Scan of CNS Lesions","Bayer","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","147","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic","91536|Project DE 00562|309761","September 2006","April 2007","April 2007","November 3, 2006","November 1, 2011","June 8, 2015","Jiangsu Province Hospital, Nanjing, Jiangsu, China|The 1st Affiliated Hosp of the 4th Military Med Uni, Xi'an, Shaanxi, China|Chinese PLA General Hosp., Beijing, China|Fudan University Huashan Hospital, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT00395460"
1261,"NCT00393198","Bleeding Pattern and User Satisfaction During Second Consecutive MIRENA® in Contraception and Treatment of Menorrhagia",,"Completed","No Results Available","Contraception|Menorrhagia","Drug: Levonorgestrel (Mirena, BAY86-5028)|Drug: Cytotec|Drug: Placebo","Primary efficacy variable will be bleeding profile|Secondary efficacy variables will be insertion assessment, continuation rate, pregnancy rate and menstrual comfort and user satisfaction","Bayer","Female","23 Years to 45 Years   (Adult)","Phase 4","204","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","91473|2006-000394-30|309988","October 2006","October 2012","October 2012","October 27, 2006",,"November 3, 2014","Helsinki, Finland|Hyvinkää, Finland|Jyväskylä, Finland|Kuopio, Finland|Tampere, Finland|Turku, Finland|Brignoles, France|Compiegne Cedex, France|Nancy Cedex, France|Quetigny, France|Reims, France|Roanne, France|Mallow, Cork, Ireland|Drogheda, Ireland|Stockholm, Sweden|Stockholm, Sweden|Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT00393198"
1262,"NCT00377793","Levitra (Vardenafil, BAY38-9456) Partner Satisfaction Study II",,"Completed","No Results Available","Sexual Dysfunction|Male Erectile Dysfunction","Drug: Levitra (Vardenafil, BAY38-9456)|Drug: Placebo","Maintenance of erection in men with ED, Improvement of their female partners sexual quality of life|SEP3 at weeks 4, 12, 18, and 24 of treatment compared to placebo|Additional Subject Diary questions at weeks 4, 12, 18, and 24, LOCF, and over entire treatment period compared to placebo|Global confidence question (GCQ) at weeks 12, and 24 of treatment compared to placebo. IIEF, TSS, mSLQQ-QOL, Partnership questionnaire (PFB20)","Bayer","Male","18 Years to 64 Years   (Adult)","Phase 4","352","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","12146|EudraCT 2006-001228-37","July 2006",,"August 2007","September 18, 2006",,"December 24, 2014","Bruxelles - Brussel, Belgium|Genk, Belgium|Leuven, Belgium|Liege, Belgium|Roeselare, Belgium|La Rochelle, France|Lille, France|Lyon, France|Marseille, France|Marseille, France|Mont-de-marsan, France|Paris, France|Toulouse, France|Hamburg, Hamburg / 287, Germany|Hamburg, Hamburg / 287, Germany|Hamburg, Hamburg / 287, Germany|Hannover, Niedersachsen / 291, Germany|Brühl, Nordrhein-Westfalen / 325, Germany|Mülheim, Nordrhein-Westfalen / 481, Germany|Wuppertal, Nordrhein-Westfalen / 616, Germany|Bautzen, Sachsen / 313, Germany|Dresden, Sachsen / 313, Germany|Leipzig, Sachsen / 313, Germany|Leisnig, Sachsen / 313, Germany|Meißen, Sachsen / 313, Germany|Wahlstedt, Schleswig-Holstein / 306, Germany|Bergamo, Italy|Firenze, Italy|Milano, Italy|Napoli, Italy|Roma, Italy|Arnhem, Netherlands|Deventer, Netherlands|Enschede, Netherlands|Nijverdal, Netherlands|Bloemfontein, Free State, South Africa|Johannesburg, Gauteng, South Africa|Newcastle, Kwa Zulu-Natal, South Africa|Durban, KwaZulu Natal, South Africa|Durban, KwaZulu Natal, South Africa|La Roca del Vallès, Barcelona, Spain|Barcelona, Cataluña, Spain|Vigo, Pontevedra, Spain|La Laguna, Tenerife, Spain|Alicante, Spain|Barcelona, Spain|Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT00377793"
1263,"NCT00375453","Dose Escalation Study of SH U04722 in Solid Tumors",,"Terminated","No Results Available","Tumors","Drug: SH U04722","The number of patients with dose limiting toxicity (DLT) observed between Days 1 and 21 after start of treatment (after first 3 weekly administrations of SH U04722 plus 7 days)|The number of patients with DLT observed by the end of Week 8|dose intensity (whether or not 75% of the planned dose can be done) for 8 weeks after the first dosing","Bayer","All","20 Years to 74 Years   (Adult, Older Adult)","Phase 1","10","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","91526|310681","January 2007","October 2007","October 2007","September 13, 2006",,"December 31, 2014","Hidaka-shi, Saitama, Japan|Iruma-gun, Saitama, Japan|Koutou-ku, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT00375453"
1264,"NCT00370071","Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis",,"Completed","Has Results","Multiple Sclerosis","Drug: Interferon beta-1b (Betaseron, BAY86-5046)","Difference Between the Number of Newly Active Lesions in Magnetic Resonance Imaging (MRI) Per Three Months During the 6-month Treatment Period and the Number of Newly Active Lesions During 3-month Pre-treatment|Difference Between the Number of New Gadolinium (Gd)-Enhancing Lesions Per 3 Months During the 6-month Treatment Period and the Number of New Gd-enhancing Lesions During 3-month Pre-treatment|Difference Between the Number of New or Enlarging T2 Lesions Per 3 Months During the 6-month Treatment Period and the Number of New or Enlarging T2 Lesions During 3-month Pre-treatment|Volume of Gadolinium-enhancing Lesions at Baseline, Weeks 12 and 24|Number of New Gadolinium (T1)-Enhancing Lesions at Baseline, Weeks 12 and 24|Number of T2 Lesions at Baseline, Weeks 12 and 24|Assessment of Relapses: Relapse Rate|Assessment of Relapses: Number of Relapses|Assessment of Relapses: Percentage of Relapse-free Subjects After 24 Weeks|Assessment of Relapses: Relapse Severity|Expanded Disability Status Scale (EDSS)|Percentage of Subjects Without EDSS Progression","Bayer","All","16 Years to 55 Years   (Child, Adult)","Phase 3","39","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","91386|MP-00102|308720|2014-004613-93","November 2006","September 2008","September 2008","August 30, 2006","February 10, 2010","October 29, 2015","Beijing, China|Beijing, China|Shanghai, China",,"https://ClinicalTrials.gov/show/NCT00370071"
1265,"NCT00367276","Study to Evaluate the Effect of Six Cycles of Treatment With a Combined Oral Contraceptive (EE 0.30 mg/DRSP 3 mg) on Quality of Life.",,"Completed","No Results Available","Healthy","Drug: Yasmin (30 µg EE, 3 mg Drospirenone, BAY86-5131)","Change of Psychological General Well Being Questionnaire score|Changes in body composition (evaluated by Multifrequency Bioelectrical Impedance Analysis)|Subject satisfaction with treatment at final visit|Subject evaluation of changes in greasy skin and greasy hair","Bayer","Female","18 Years to 35 Years   (Adult)","Phase 3","221","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","91070|305545","December 2002",,"May 2004","August 22, 2006",,"October 11, 2013",,,"https://ClinicalTrials.gov/show/NCT00367276"
1266,"NCT00362232","Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.","RECORD 4","Completed","Has Results","Venous Thromboembolism","Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Enoxaparin|Drug: Placebo: tablet of Rivaroxaban|Drug: Placebo: syringes of Enoxaparin","Composite Endpoint of Total Venous Thrombo Embolism (VTE) i.e.: Any Deep Vein Thromboembolism (DVT) (Proximal and/or Distal), Non Fatal Pulmonary Embolism (PE), Death of All Causes Per Protocol Population|Composite Endpoint of Total VTE i.e.: Any DVT (Proximal and/or Distal), Non Fatal PE, Death of All Causes Per Modified Intent to Treat Population.|Incidence of the Composite Endpoint Comprising Proximal DVT, Non-fatal PE and VTE- Related Death (Major VTE) Per Protocol Population of Major VTE|Incidence of the Composite Endpoint Comprising Proximal DVT, Non-fatal PE and VTE- Related Death (Major VTE) Per Modified Intent to Treat Population of Major VTE.|Incidence of Symptomatic VTE (DVT, PE) Per Protocol Population.|Incidence of Symptomatic VTE (DVT, PE) Per Modified Intent to Treat Population.|Incidence of DVT (Proximal, Distal) Per Protocol Population.|Incidence of DVT (Proximal, Distal) Per Modified Intent to Treat Population.|Incidence of Symptomatic VTE During Follow-up Per Protocol Population.|Incidence of Symptomatic VTE During Follow-up Per Modified Intent to Treat Population.|The Composite Endpoint Comprising Major VTE and Treatment-emergent Major Bleeding Per Subjects Valid for Analysis of Net Clinical Benefit|Incidence of the Composite Endpoint That Results From the Primary Endpoint by Substituting VTE Related Death for All Death Per Protocol Population.|Incidence of the Composite Endpoint That Results From the Primary Endpoint by Substituting VTE Related Death for All Death Per Modified Intent to Treat Population.|Incidence of the Composite Endpoint That Results From Major VTE by Substituting All Cause Mortality for VTE-related Death Per Protocol of Major VTE Population.|Incidence of the Composite Endpoint That Results From Major VTE by Substituting All Cause Mortality for VTE-related Death Per Modified Intent to Treat of Major VTE Population.|Treatment-emergent Major Bleedings Per Safety Population.","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","3148","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","11355|2006-002402-60","June 2006","January 2007","January 2008","August 9, 2006","June 13, 2012","November 4, 2014","Birmingham, Alabama, United States|Tuscaloosa, Alabama, United States|Phoenix, Arizona, United States|Little Rock, Arkansas, United States|Bakersfield, California, United States|Encinitas, California, United States|Fountain Valley, California, United States|La Jolla, California, United States|Torrance, California, United States|Yuba City, California, United States|Centennial, Colorado, United States|Denver, Colorado, United States|Englewood, Colorado, United States|Boynton Beach, Florida, United States|Clearwater, Florida, United States|DeLand, Florida, United States|Hollywood, Florida, United States|Jacksonville, Florida, United States|Pensacola, Florida, United States|Pinellas Park, Florida, United States|Decatur, Georgia, United States|Boise, Idaho, United States|Meridian, Idaho, United States|Towson, Maryland, United States|Missoula, Montana, United States|Teaneck, New Jersey, United States|Greensboro, North Carolina, United States|Cincinnati, Ohio, United States|Oklahoma City, Oklahoma, United States|Johnstown, Pennsylvania, United States|State College, Pennsylvania, United States|Charleston, South Carolina, United States|Dallas, Texas, United States|Grapevine, Texas, United States|Houston, Texas, United States|Lubbock, Texas, United States|Plano, Texas, United States|San Antonio, Texas, United States|San Antonio, Texas, United States|Spokane, Washington, United States|Pleven, Bulgaria|Plovdiv, Bulgaria|Sofia, Bulgaria|Red Deer, Alberta, Canada|Kelowna, British Columbia, Canada|Penticton, British Columbia, Canada|Fredericton, New Brunswick, Canada|Ajax, Ontario, Canada|Brantford, Ontario, Canada|Oakville, Ontario, Canada|Oshawa, Ontario, Canada|Ottawa, Ontario, Canada|Peterborough, Ontario, Canada|Scarborough, Ontario, Canada|Scarborough, Ontario, Canada|Sudbury, Ontario, Canada|Thunder Bay, Ontario, Canada|Woodstock, Ontario, Canada|Charlottetown, Prince Edward Island, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Hellerup, Denmark|Herlev, Denmark|Hvidovre, Denmark|Hørsholm, Denmark|Silkeborg, Denmark|Viborg, Denmark|Hyderabad, Andhra Pradesh, India|Secunderabad, Andhra Pradesh, India|Secundrabad, Andhra Pradesh, India|Ahmedabad, Gujarat, India|Ahmedabad, Gujarat, India|Pune, Maharashtra, India|Pune, Maharashtra, India|Ludhiana, Punjab, India|Chennai, Tamil Nadu, India|Bangalore, India|Bangalore, India|Baroda, India|Hyderabad, India|New Delhi, India|Beer Sheva, Israel|Holon, Israel|Kfar Saba, Israel|Petach Tikva, Israel|Tel Aviv, Israel|Zerifin, Israel|Kaunas, Lithuania|Kaunas, Lithuania|Klaipeda, Lithuania|Panevezys, Lithuania|Vilnius, Lithuania|Guadalajara, Jalisco, Mexico|Guadalajara, Jalisco, Mexico|Zapopan, Jalisco, Mexico|Monterrey, Nuevo Leon, Mexico|Monterrey, Nuevo Leon, Mexico|Mérida, Yucatán, Mexico|Edo. de Mexico, Mexico|Baerum postterminal, Norway|Gjövik, Norway|Kongsvinger, Norway|Lillehammer, Norway|Karachi, Sindh, Pakistan|Karachi, Sindh, Pakistan|Bydgoszcz, Poland|Elblag, Poland|Gdansk, Poland|Kielce, Poland|Konskie, Poland|Krakow, Poland|Lublin, Poland|Sosnowiec, Poland|Warszawa, Poland|Warszawa, Poland|Colombo-80, Sri Lanka|Kotte, Sri Lanka|Ragama, Sri Lanka|Göteborg, Sweden|Hässleholm, Sweden|Stockholm, Sweden|Västervik, Sweden|Växjö, Sweden|Örebro, Sweden",,"https://ClinicalTrials.gov/show/NCT00362232"
1267,"NCT00361894","Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). A Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement.","RECORD 3","Completed","No Results Available","Prevention|Venous Thromboembolism","Drug: Rivaroxaban (BAY59-7939)|Drug: Enoxaparin","Composite endpoint of total VTE i.e.: Any DVT (proximal and/or distal), Non fatal PE, Death of all causes|Incidence of the composite endpoint comprising proximal DVT, non-fatal PE and VTE- related death (major VTE)|Incidence of symptomatic VTE (DVT, PE)|Incidence of DVT (total, proximal, distal)|Incidence of symptomatic VTE during follow-up|The composite endpoint comprising major VTE and treatment-emergent major bleeding|Incidence of the composite endpoint that results from the primary endpoint by substituting VTE related death for all death|Incidence of the composite endpoint that results from major VTE by substituting all cause mortality for VTE-related death|Treatment-emergent major bleedings","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","2531","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","11356|EudraCT: 2005-004620-40","February 2006","January 2007","January 2007","August 9, 2006",,"October 27, 2014","Linz, Oberösterreich, Austria|Graz, Steiermark, Austria|Innsbruck, Tirol, Austria|Wien, Austria|Antwerpen, Belgium|Hasselt, Belgium|Liege, Belgium|Merksem, Belgium|Pellenberg, Belgium|Reet, Belgium|Roeselare, Belgium|Penticton, British Columbia, Canada|St. John, New Brunswick, Canada|Burlington, Ontario, Canada|Kitchener, Ontario, Canada|Oakville, Ontario, Canada|Oshawa, Ontario, Canada|Ottawa, Ontario, Canada|Peterborough, Ontario, Canada|Scarborough, Ontario, Canada|Windsor, Ontario, Canada|Beijing, China|Beijing, China|Beijing, China|Shanghai, China|Shanghai, China|Shanghai, China|Bogotá, Colombia|Cali, Colombia|Medellín, Colombia|Praha 8, Tschechien, Czech Republic|Brno, Czech Republic|Chomutov, Czech Republic|Havlickuv Brod, Czech Republic|Jihlava, Czech Republic|Kolin, Czech Republic|Pardubice, Czech Republic|Plzen, Czech Republic|Frederiksberg, Denmark|Hellerup, Denmark|Herlev, Denmark|Hørsholm, Denmark|Silkeborg, Denmark|Bois-guillaume, France|Clermont Ferrand, France|Lievin, France|Marseille, France|Monaco, France|Nantes Cedex 2, France|Nice, France|Nice, France|Paris Cedex 14, France|Paris Cedex 19, France|Paris Cedex 20, France|Paris, France|Soyaux, France|Vandoeuvre Les Nancy, France|Bad Mergentheim, Baden-Württemberg, Germany|Rheinfelden, Baden-Württemberg, Germany|Fürth, Bayern, Germany|Garmisch-Partenkirchen, Bayern, Germany|Würzburg, Bayern, Germany|Sommerfeld, Brandenburg, Germany|Frankfurt, Hessen, Germany|Frankfurt, Hessen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Witten, Nordrhein-Westfalen, Germany|Bremen, Germany|Beer Sheva, Israel|Haifa, Israel|Holon, Israel|Kfar Saba, Israel|Tel Aviv, Israel|Tel Hashomer, Israel|Zerifin, Israel|San Donato Milanese, Milano, Italy|Abano Terme, Padova, Italy|Gubbio, Perugia, Italy|Alghero, Sassari, Italy|Bologna, Italy|Firenze, Italy|Lecco, Italy|Padova, Italy|Parma, Italy|Roma, Italy|Udine, Italy|Varese, Italy|Chihuahua, Chih., Chihuahua, Mexico|Guadalajara, Jalisco, Mexico|Hermosillo, Sonora, Mexico|Amsterdam, Netherlands|Hilversum, Netherlands|Hoofddorp, Netherlands|Leiden, Netherlands|Nijmegen, Netherlands|OSS, Netherlands|Zwolle, Netherlands|Elverum, Norway|Gjövik, Norway|Kongsvinger, Norway|Lillehammer, Norway|Namsos, Norway|Callao, Peru|Lima, Peru|Lima, Peru|Bialystok, Poland|Bydgoszcz, Poland|Gdansk, Poland|Krakow, Poland|Lodz, Poland|Lublin, Poland|Lublin, Poland|Szczecin, Poland|Warszawa, Poland|Warszawa, Poland|Bloemfontein, Freestate, South Africa|Johannesburg, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Randburg, Gauteng, South Africa|Newcastle, Kwa Zulu-Natal, South Africa|Durban, KwaZulu Natal, South Africa|Somerset West, Western Cape, South Africa|Worcester, Western Cape, South Africa|Badalona, Barcelona, Spain|Alcorcón, Madrid, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Castellón de la Plana, Spain|Jaén, Spain|Madrid, Spain|Pamplona, Spain|Valencia, Spain|Falköping, Sweden|Göteborg, Sweden|Halmstad, Sweden|Hässleholm, Sweden|Jönköping, Sweden|Kungälv, Sweden|Lidköping, Sweden|Varberg, Sweden",,"https://ClinicalTrials.gov/show/NCT00361894"
1268,"NCT00360490","Study in Women With Idiopathic Menorrhagia to Determine the Reduction in Menstrual Blood Loss (MBL) After Treatment With the Levonorgestrel-releasing Intrauterine System (IUS)",,"Completed","Has Results","Menorrhagia","Drug: Levonorgestrel IUS (Mirena, BAY86-5028)|Drug: Medroxyprogesterone acetate","The Change in Absolute Value From Baseline Menstrual Blood Loss (MBL) to the End-of-study MBL (Cycle 6)|Percentage of Patients With Successful Treatment|Percent Change From Baseline MBL to End of Study MBL (Cycle 6)|Absolute Change From Baseline MBL to Mid-study MBL (Cycle 3)|Percent Change From Baseline MBL to Mid-study MBL (Cycle 3)|Percentage of Subjects Who Completed the Study in Levonorgestrel Intrauterine System (LNG IUS) Group|Total Number of Bleeding Days|Total Number of Spotting and Bleeding Days|Total Number of Spotting Days|Total Number of Bleeding Episodes|Percent Change in Hemoglobin|Percent Change in Hematocrit|Percent Change in Serum Ferritin|Percentage of Patients With Improvement in the Investigator Global Assessment Scale|Percentage of Patients With Improvement in the Patients Overall Assessment Scale","Bayer","Female","18 Years and older   (Adult, Older Adult)","Phase 3","165","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","91518|309849","July 2006","June 2008","June 2008","August 4, 2006","November 19, 2009","December 9, 2013","Tucson, Arizona, United States|Beverly Hills, California, United States|Carmichael, California, United States|San Diego, California, United States|San Diego, California, United States|Santa Monica, California, United States|Torrance, California, United States|Littleton, Colorado, United States|Boynton Beach, Florida, United States|Jacksonville, Florida, United States|West Palm Beach, Florida, United States|Boise, Idaho, United States|Chicago, Illinois, United States|Newburgh, Indiana, United States|South Bend, Indiana, United States|Amite, Louisiana, United States|Marrero, Louisiana, United States|Boston, Massachusetts, United States|Saginaw, Michigan, United States|Chesterfield, Missouri, United States|Lincoln, Nebraska, United States|Las Vegas, Nevada, United States|LasVegas, Nevada, United States|Moorestown, New Jersey, United States|New Brunswick, New Jersey, United States|Winston-Salem, North Carolina, United States|Medford, Oregon, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Columbia, South Carolina, United States|Clarksville, Tennessee, United States|Houston, Texas, United States|Houston, Texas, United States|Burlington, Vermont, United States|Norfolk, Virginia, United States|Seattle, Washington, United States|Buenos Aires, Argentina|Buenos Aires, Argentina|Curitiba, Parana, Brazil|Campinas, Sao Paulo, Brazil|Bathurst, New Brunswick, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Mirabel, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Pointe-Claire, Quebec, Canada|Shawinigan, Quebec, Canada|Regina, Saskatchewan, Canada|Quebec, Canada|Mexico, México, Mexico|Monterrey, Nuevo Leon, Mexico|Mexico Df, Mexico",,"https://ClinicalTrials.gov/show/NCT00360490"
1269,"NCT00359359","A Study of a New Chemotherapy Agent in Combination With Cisplatin to Treat Small Cell Lung Cancer",,"Completed","No Results Available","Carcinoma, Small Cell","Drug: Sagopilone (BAY86-5302, ZK 219477)|Drug: Cisplatin","Phase 1: Safety measure to establish the MTD or RPDII dose of Sagopilone used in combination with cisplatin|Phase 2: Efficacy measure|Phase 1: PK of Sagopilone + Cisplatin|Phase 2: Duration of CR or PR|Phase 2: TTP|Phase 2: PFS|Phase 2: OS","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","26","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","91495|2006-000067-29|310101","July 2006","March 2009","August 2009","August 2, 2006",,"November 4, 2014","Gerlingen, Baden-Württemberg, Germany|Löwenstein, Baden-Württemberg, Germany|München, Bayern, Germany|München, Bayern, Germany|Frankfurt, Hessen, Germany|Wiesbaden, Hessen, Germany|Essen, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Berlin, Germany|Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT00359359"
1270,"NCT00356447","Safety/Efficacy Study of Drospirenone/Estradiol to Treat Postmenopausal Chinese Women With Vasomotor Symptoms.",,"Completed","No Results Available","Vasomotor Symptoms","Drug: Estradiol/DRSP (Angeliq, BAY86-4891)|Drug: Placebo","Frequency of hot flushes|Change in intensity of hot flushes|Change in other climacteric symptoms|Vaginal Bleeding pattern|Global clinical impression","Bayer","Female","45 Years to 65 Years   (Adult, Older Adult)","Phase 3","249","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","91442|309341","May 2006","October 2007","October 2007","July 26, 2006",,"October 1, 2014","Wuhan, Hubei, China|Nanjing, Jiangsu, China|Jinan, Shandong, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Chongqing, China|Shanghai, China",,"https://ClinicalTrials.gov/show/NCT00356447"
1271,"NCT00352859","Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib",,"Terminated","No Results Available","Carcinoma, Renal Cell","Drug: Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon|Drug: Gemcitabine or Interferon (only)","Progression Free Survival (PFS)|Disease Control Rate (DCR)|Overall Best Response|Duration of response|Time to response|Overall Survival (OS)|Adverse Event Collection and Tolerability","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 4","2","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12178","August 2006",,"November 2006","July 17, 2006",,"December 30, 2014","Kansas City, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT00352859"
1272,"NCT00350051","ZK-Epo Given With Prednisone in Patients With Metastatic Androgen-independent Prostate Cancer",,"Completed","No Results Available","Prostate Cancer","Drug: Sagopilone (ZK 219477) + prednisone","PSA Response to treatment with ZK-Epo plus prednisone after 6 cycles|Safety & Tolerability of ZK-Epo plus prednisone","Bayer","Male","18 Years and older   (Adult, Older Adult)","Phase 2","53","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","91500|307976","August 2006","September 2008","December 2009","July 10, 2006",,"December 4, 2014","Fountain Valley, California, United States|Sarasota, Florida, United States|Baltimore, Maryland, United States|Ann Arbor, Michigan, United States|Billings, Montana, United States|Omaha, Nebraska, United States|Bronx, New York, United States|Canton, Ohio, United States|Portland, Oregon, United States|Altoona, Pennsylvania, United States|Fort Worth, Texas, United States|Seattle, Washington, United States|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Argentina|Buenos Aires, Argentina|Buenos Aires, Argentina|Córdoba, Argentina",,"https://ClinicalTrials.gov/show/NCT00350051"
1273,"NCT00337155","BAY88-8223, Dose Finding Study in Patients With HRPC",,"Completed","No Results Available","Prostate Cancer|Neoplasm Metastasis","Drug: Radium-223 dichloride (BAY88-8223)","Proportion of participants in each dose group with a confirmed PSA response|The maximum percent decrease in PSA level compared to baseline|Time to PSA Progression|Bone-ALP response (classified as for PSA response) and decrease in bone-ALP level compared to baseline|Total number of SRE per patient|Pain Assessment and analgesic consumption|Time to death from first treatment|Time to Skeletal Related Events (SRE)|Adverse events, blood chemistry and haematological toxicity","Bayer","Male","18 Years and older   (Adult, Older Adult)","Phase 2","122","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","15304|2005-003680-22|BC1-04","May 2006","December 2008","December 2009","June 15, 2006",,"December 24, 2014","Sutton, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00337155"
1274,"NCT00335218","Fat Distribution in Healthy Early Postmenopausal Women",,"Completed","No Results Available","Healthy|Postmenopause","Drug: Climodien / Lafamme (BAY86-5027)|Drug: Placebo","Individual relative change of abdominal visceral fat measured by magnetic resonance imaging|Parameters of body composition and lipid metabolism|Adverse events collection","Bayer","Female","48 Years to 60 Years   (Adult)","Phase 4","67","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","91161|306387","July 2002",,"August 2004","June 9, 2006",,"December 30, 2014","Wien, Austria|Wien, Austria|Wien, Austria",,"https://ClinicalTrials.gov/show/NCT00335218"
1275,"NCT00332020","Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, a Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement","RECORD 2","Completed","No Results Available","Prevention|Venous Thromboembolism","Drug: Rivaroxaban (BAY59-7939)|Drug: Enoxaparin","Composite endpoint of total VTE i.e.: Any DVT (proximal and/or distal), Non fatal PE, Death of all causes|Incidence of the composite endpoint comprising proximal DVT, non-fatal PE and VTE- related death (major VTE)|Incidence of symptomatic VTE (DVT, PE)|Incidence of DVT (total, proximal, distal)|Incidence of symptomatic VTE during follow-up|The composite endpoint comprising major VTE and treatment-emergent major bleeding|Incidence of the composite endpoint that results from the primary endpoint by substituting VTE related death for all death|Incidence of the composite endpoint that results from major VTE by substituting all cause mortality for VTE-related death|Treatment-emergent major bleedings","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","2457","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11357|2005-004691-20","February 2006","May 2007","June 2007","May 31, 2006",,"January 27, 2015","Birmingham, Alabama, United States|Denver, Colorado, United States|Bay Pines, Florida, United States|Miami, Florida, United States|Oklahoma City, Oklahoma, United States|Canberra, Australian Capital Territory, Australia|Lismore, New South Wales, Australia|Sydney, New South Wales, Australia|Southport, Queensland, Australia|Geelong, Victoria, Australia|Melbourne, Victoria, Australia|Belo Horizonte, Minas Gerais, Brazil|Belo Horizonte, Minas Gerais, Brazil|Curitiba, Paraná, Brazil|Passo Fundo, Rio Grande do Sul, Brazil|Batatais, Sao Paulo, Brazil|Marília, Sao Paulo, Brazil|Sao Paulo, SP, Brazil|Rio de Janeiro, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Red Deer, Alberta, Canada|Penticton, British Columbia, Canada|Winnipeg, Manitoba, Canada|St. John, New Brunswick, Canada|Oshawa, Ontario, Canada|Ottawa, Ontario, Canada|Ottawa, Ontario, Canada|Scarborough, Ontario, Canada|Scarborough, Ontario, Canada|Thunder Bay, Ontario, Canada|Windsor, Ontario, Canada|Guangzhou,, Guangdong, China|Jinan, Shandong, China|Qingdao, Shandong, China|Xi'an, Shanxi, China|Beijing, China|Beijing, China|Beijing, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|Barranquilla, Colombia|Bogotá, Colombia|Cali, Colombia|Medellín, Colombia|Copenhagen, Denmark|Copenhagen, Denmark|Frederiksberg, Denmark|Glostrup, Denmark|Herlev, Denmark|Holbaek, Denmark|Hvidovre, Denmark|Silkeborg, Denmark|Viborg, Denmark|Tallinn, Estonia|Tartu, Estonia|Hyderabad, Andhra Pradesh, India|Secundrabad, Andra Pradesh, India|Ludhiana, Punjab, India|Bangalore, India|Bangalore, India|Mumbai, India|Bandung, West Java, Indonesia|Surabaya, Indonesia|Genova, Italy|Lecco, Italy|Modena, Italy|Napoli, Italy|Parma, Italy|Siena, Italy|Udine, Italy|Daegu, Korea, Republic of|Kyunggido, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Liepaja, Latvia|Riga, Latvia|Kaunas, Lithuania|Klaipeda, Lithuania|Panevezys, Lithuania|Siauliai, Lithuania|Chihuahua, Chih., Chihuahua, Mexico|Guadalajara, Jalisco, Mexico|Auckland, New Zealand|Auckland, New Zealand|Kongsvinger, Norway|Namsos, Norway|Oslo, Norway|Oslo, Norway|Tynset, Norway|Callao, Peru|Lima Cercado, Peru|Lima, Peru|Lima, Peru|Lima, Peru|Lima, Peru|Lisboa, Portugal|Porto, Portugal|Setúbal, Portugal|Torres Vedras, Portugal|Bloemfontein, Freestate, South Africa|Johannesburg, Gauteng, South Africa|Randburg, Gauteng, South Africa|Newcastle, Kwa Zulu-Natal, South Africa|Cape Town, Western Cape, South Africa|Falköping, Sweden|Hässleholm, Sweden|Kungälv, Sweden|Lidköping, Sweden|Stockholm, Sweden|Sundsvall, Sweden|Varberg, Sweden|Växjö, Sweden|Örebro, Sweden|Kaohsiung, Taiwan|Taoyuan, Taiwan|Chesterfield, Derbyshire, United Kingdom|Dumfries, Dumfries and Galloway, United Kingdom|Kirkcaldy, Fife, United Kingdom|London, Greater London, United Kingdom|Liverpool, Merseyside, United Kingdom|Great Yarmouth, Norfolk, United Kingdom|Northampton, Northamptonshire, United Kingdom|Epsom, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00332020"
1276,"NCT00329628","Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin",,"Completed","No Results Available","Venous Thromboembolism","Drug: Rivaroxaban (BAY59-7939)|Drug: Enoxaparin","Composite endpoint of total VTE i.e.: Any DVT (proximal and/or distal), Non fatal PE, Death of all causes|Incidence of the composite endpoint comprising proximal DVT, non-fatal PE and VTE- related death (major VTE)|Incidence of symptomatic VTE (DVT, PE)|Incidence of DVT (total, proximal, distal)|Incidence of symptomatic VTE during follow-up|The composite endpoint comprising major VTE and treatment-emergent major bleeding|Incidence of the composite endpoint that results from the primary endpoint by substituting VTE related death for all death|Incidence of the composite endpoint that results from major VTE by substituting all cause mortality for VTE-related death|Treatment-emergent major bleedings","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","4541","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11354|EudraCT: 2005-004351-35","February 2006","March 2007","March 2007","May 25, 2006",,"October 28, 2014","Birmingham, Alabama, United States|Northport, Alabama, United States|Phoenix, Arizona, United States|Benton, Arkansas, United States|La Jolla, California, United States|Aurora, Colorado, United States|Decatur, Georgia, United States|Missoula, Montana, United States|Charleston, South Carolina, United States|Dallas, Texas, United States|Grapevine, Texas, United States|Lubbock, Texas, United States|San Antonio, Texas, United States|Avellaneda, Buenos Aires, Argentina|Berazategui, Buenos Aires, Argentina|Buenos Aires, Capital Federal, Argentina|Buenos Aires, Capital Federal, Argentina|Buenos Aires, Capital Federal, Argentina|Buenos Aires, Capital Federal, Argentina|Buenos Aires, Capital Federal, Argentina|Sydney, New South Wales, Australia|Adelaide, South Australia, Australia|Melbourne, Victoria, Australia|Melbourne, Victoria, Australia|Fremantle, Western Australia, Australia|Wiener Neustadt, Niederösterreich, Austria|Linz, Oberösterreich, Austria|Linz, Oberösterreich, Austria|Ried, Oberösterreich, Austria|Wels, Oberösterreich, Austria|Graz, Steiermark, Austria|Innsbruck, Tirol, Austria|Wien, Austria|Antwerpen, Belgium|Brasschaat, Belgium|Brugge, Belgium|Genk, Belgium|Hasselt, Belgium|HUY, Belgium|Merksem, Belgium|Pellenberg, Belgium|Reet, Belgium|Roeselare, Belgium|Porto Alegre, RS, Brazil|Porto Alegre, RS, Brazil|Rio de Janeiro, Brazil|São Paulo, Brazil|Edmonton, Alberta, Canada|Kitchener, Ontario, Canada|Oakville, Ontario, Canada|Oshawa, Ontario, Canada|Peterborough, Ontario, Canada|Stratford, Ontario, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Quebec, Canada|Santiago, Chile|Bogotá, Colombia|Ceske Budejovice, Czech Republic|Hradec Kralove, Czech Republic|Jindrichuv Hradec, Czech Republic|Karlovy Vary, Czech Republic|Mlada Boleslav, Czech Republic|Olomouc, Czech Republic|Plzen, Czech Republic|Praha 6, Czech Republic|Pribram I, Czech Republic|Prostejov, Czech Republic|Frederiksberg, Denmark|Hellerup, Denmark|Herlev, Denmark|Hørsholm, Denmark|Silkeborg, Denmark|Jyväskylä, Finland|Mikkeli, Finland|Seinäjoki, Finland|Bois-guillaume, France|Le Chesnay, France|Lievin, France|Monaco, France|Nantes Cedex 2, France|Paris Cedex 14, France|Paris Cedex 19, France|Paris Cedex 20, France|Paris, France|Saint Herblain, France|Soyaux, France|Vandoeuvre Les Nancy, France|Vannes, France|Bad Mergentheim, Baden-Württemberg, Germany|Heidelberg, Baden-Württemberg, Germany|Rheinfelden, Baden-Württemberg, Germany|Stuttgart, Baden-Württemberg, Germany|Fürth, Bayern, Germany|Garmisch-Partenkirchen, Bayern, Germany|Würzburg, Bayern, Germany|Birkenwerder, Brandenburg, Germany|Sommerfeld, Brandenburg, Germany|Frankfurt, Hessen, Germany|Frankfurt, Hessen, Germany|Marburg, Hessen, Germany|Wiesbaden, Hessen, Germany|Rostock, Mecklenburg-Vorpommern, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Witten, Nordrhein-Westfalen, Germany|Dresden, Sachsen, Germany|Bremen, Germany|Haidari, Attica, Greece|Kifisia, Attica, Greece|Bekescsaba, Hungary|Budapest, Hungary|Budapest, Hungary|Györ, Hungary|Kaposvar, Hungary|Kecskemet, Hungary|Szeged, Hungary|Szekesfehervar, Hungary|Szekszard, Hungary|Beer Sheva, Israel|Haifa, Israel|Holon, Israel|Kfar Saba, Israel|Petach Tikva, Israel|Tel Aviv, Israel|Tel Hashomer, Israel|Zerifin, Israel|Monza, Milano, Italy|Rozzano, Milano, Italy|San Donato Milanese, Milano, Italy|Gubbio, Perugia, Italy|Alghero, Sassari, Italy|Busto Arsizio, Varese, Italy|Ancona, Italy|Bergamo, Italy|Bologna, Italy|Ferrara, Italy|Firenze, Italy|Genova, Italy|Milano, Italy|Milano, Italy|Palermo, Italy|Reggio Emilia, Italy|Roma, Italy|Sassari, Italy|Torino, Italy|Varese, Italy|Kaunas, Lithuania|Vilnius, Lithuania|Monterrey, Nuevo Leon, Mexico|Monterrey, Nuevo León, Mexico|Edo. de Mexico, Mexico|Amsterdam, Netherlands|Hilversum, Netherlands|Hoofddorp, Netherlands|Leiden, Netherlands|Nijmegen, Netherlands|OSS, Netherlands|Zwolle, Netherlands|Baerum postterminal, Norway|Elverum, Norway|Gjövik, Norway|Lillehammer, Norway|Notodden, Norway|Bialystok, Poland|Bydgoszcz, Poland|Bydgoszcz, Poland|Gdansk, Poland|Katowice, Poland|Krakow, Poland|Krakow, Poland|Krakow, Poland|Lodz, Poland|Lublin, Poland|Lublin, Poland|Opole, Poland|Poznan, Poland|Sosnowiec, Poland|Szczecin, Poland|Warszawa, Poland|Warszawa, Poland|Warszawa, Poland|Wroclaw, Poland|Bratislava, Slovakia|Kosice - Saca, Slovakia|Zilina, Slovakia|Pretoria, Gauteng, South Africa|Somerset West, Western Cape, South Africa|Worcester, Western Cape, South Africa|Santiago de Compostela, A Coruña, Spain|Oviedo, Asturias, Spain|Badalona, Barcelona, Spain|L'Hospitalet de llobregat, Barcelona, Spain|Alcorcón, Madrid, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Castellón de la Plana, Spain|Jaén, Spain|Madrid, Spain|Pamplona, Spain|Valencia, Spain|Vitoria, Spain|Göteborg, Sweden|Halmstad, Sweden|Jönköping, Sweden|Lidköping, Sweden|Varberg, Sweden|Västervik, Sweden|Adana, Turkey|Istanbul, Turkey|Istanbul, Turkey|Istanbul, Turkey|Izmir, Turkey",,"https://ClinicalTrials.gov/show/NCT00329628"
1277,"NCT00327379","Effect of Aprotinin on Transfusion Requirements in Patients Undergoing Elective Spinal Fusion Surgery",,"Terminated","No Results Available","Blood Loss, Surgical|Postoperative Hemorrhage","Drug: Trasylol (Aprotinin, BAYA0128)|Drug: Placebo","Percent of patients requiring a blood transfusion (blood or packed red blood cells, autologous or allogenic)|The percent of patients receiving an allogenic transfusion of blood or packed red cells during surgery and up to the earlier of Day 7 or discharge|The percent of patients who did and did not predonate blood receiving an allogenic transfusion of blood or packed red cells during surgery and up to the earlier of Day 7 or discharge|The number of units of blood or packed red cells transfused. There will be analyses for the combination of autologous and allogenic transfusion and for allogenic alone|The number of units of blood or packed red cells transfused per patient requiring transfusion|Drainage (in milliliters) from the operative site in the first 8 hours postoperatively, and total drainage until removal of drains or until hospital discharge (whichever is earlier)|Blood loss during surgery, based on qualitative and quantitative estimates|The change from preoperative hemoglobin concentration to postoperative hemoglobin concentration (obtained in the morning of Day 3, or, if transfused earlier, prior to transfusion).|Surgeons assessment of the degree to which bleeding obscured his/her view of the surgical field, relative to past, similar procedures|The percent of patients receiving colloid or other blood products, and the number of units transfused|Changes in blood markers related to inflammation and blood coagulation|Changes in FEV1","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","11799|2005-003999-38","February 27, 2006","March 1, 2007","March 1, 2007","May 18, 2006",,"June 4, 2019","Oshawa, Ontario, Canada|Windsor, Ontario, Canada|Montreal, Quebec, Canada|Karlsbad, Baden-Württemberg, Germany|Münster, Nordrhein-Westfalen, Germany|Neustadt, Schleswig-Holstein, Germany|Berlin, Germany|Berlin, Germany|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Pamplona, Spain|Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT00327379"
1278,"NCT00325351","ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer",,"Completed","No Results Available","Ovarian Neoplasms","Drug: Sagopilone (ZK 219477) + carboplatin","Response to treatment with ZK-Epo after 6 cycles|Safety and tolerability of ZK-Epo given with carboplatin","Bayer","Female","18 Years and older   (Adult, Older Adult)","Phase 2","45","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","91476|307979","August 2006","July 2008","March 2009","May 12, 2006",,"November 3, 2014","Tucson, Arizona, United States|Little Rock, Arkansas, United States|Bakersfield, California, United States|La Jolla, California, United States|San Diego, California, United States|Savannah, Georgia, United States|South Bend, Indiana, United States|Baltimore, Maryland, United States|Albuquerque, New Mexico, United States|Winston-Salem, North Carolina, United States|Cleveland, Ohio, United States|Oklahoma City, Oklahoma, United States|Knoxville, Tennessee, United States|Roanoke, Virginia, United States|Calgary, Alberta, Canada|Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00325351"
1279,"NCT00318799","Impact of SH T00658ID as Compared to a Monophasic Contraceptive Containing Ethinylestradiol and Levonorgestrel (SH D01155E) on Hemostatic Parameters",,"Completed","No Results Available","Pregnancy, Unplanned","Drug: EV/DNG (Qlaira, BAY86-5027, SH T00658ID)|Drug: SH D01155E","Intraindividual absolute changes from Baseline in the Parameters of thrombin and fibrin turnover|Intraindividual absolute changes from Baseline in Pro- and anti-coagulatory parameters and the parameter of thrombin and fibrin turnover (activation marker): Prothrombin (Factor II).|Adverse events","Bayer","Female","18 Years and older   (Adult, Older Adult)","Phase 2","29","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","91477|2005-004688-45|310122","April 2006","May 2007","May 2007","April 27, 2006",,"November 25, 2013","Dinox B.V., Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT00318799"
1280,"NCT00317941","Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif",,"Completed","Has Results","Relapsing-remitting Multiple Sclerosis","Drug: Betaferon/Betaseron|Drug: Rebif","Percentage of the Sites Developing a Injection Site Reaction (ISR) Reported by Participants 24 Hours After Each Injection|Percentage of Sites Developing a Injection Site Reaction (ISR) Reported by Participants 48 Hours After Each Injection|Mean Scores of Reaction After Injection Reported by Participants|Percentage of Injection Sites With Pain Reported by Physicians|Percentage of Injection Sites Per Participant With Reaction Reported by Physicians|Percentage of Participants Without ISR Reported by Participants|Percentage of Sites Developing a Severe Reaction 24 Hours After Injection|Percentage of Sites Developing a Severe Reaction 48 Hours After Injection|Percentage of Participants Without Pain Reported by Participants|Percentage of Injection Sites Without Pain Reported by Physicians|Percentage of Injection Sites Without Pain Reported by Participants|Mean Pain Assessment Using Visual Analogue Scale (VAS) Reported by Participants Immediately After Injection|Mean Pain Assessment Using Visual Analogue Scale (VAS) Reported by Participants 30 Minutes After Injection|Mean Pain Assessment Using Visual Analogue Scale (VAS) Reported by Participants 1 Hour After Injection|Mean Pain Assessment Using Visual Analogue Scale (VAS) Reported by Participants 24 Hours After Injection|Percentage of Sites Without Reaction 24 Hours After Injection Reported by Participants|Percentage of Sites Without Reaction 48 Hours After Injection Reported by Participants","Bayer","All","18 Years to 55 Years   (Adult)","Phase 4","220","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","91489|2005-005583-91|308084|Avantage","March 2006","April 2008","April 2008","April 25, 2006","October 21, 2013","October 21, 2013","Aix en Provence, France|Alkirch, France|Annecy Cedex, France|Aurillac, France|Belfort, France|Blaye, France|Bordeaux, France|Boulogne sur Mer, France|Brest Cedex, France|Brive La Gaillarde, France|Carcassonne, France|Castelnau le Lez, France|ChamaliÃ¿res, France|Champigny sur Marne, France|Colmar, France|Corbeil Essones Cedex, France|CrÃ©teil, France|Dijon, France|Dreux, France|Dunkerque, France|Elbeuf, France|Evreux Cedex, France|Evry, France|La Seyne sur Mer, France|Le Mans Cedex, France|Le Mans, France|Libourne Cedex, France|Lille, France|Lomme Cedex, France|Lyon, France|Marseille, France|Montpellier Cedex 5, France|Montpellier, France|Nancy Cedex, France|Nancy, France|Nantes, France|Nice, France|Nimes Cedex 9, France|Paris, France|Pau, France|Perpignan, France|Poissy, France|Quimper Cedex, France|Quimper, France|Quimper, France|Reims, France|Rennes, France|Rouen, France|Rueil Malmaison, France|Saint Herblain, France|Saint Quentin, France|St Etienne, France|St LÃ¿, France|St Omer, France|Strasbourg, France|Toulouse, France|Tourcoing, France|Trelaze, France|Vendome, France|Vesoul, France|Vichy, France",,"https://ClinicalTrials.gov/show/NCT00317941"
1281,"NCT00313976","Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)",,"Withdrawn","No Results Available","Multiple Sclerosis","Drug: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)","Magnetic Resonance Imaging (MRI): T2-lesions|Further Magnetic Resonance Imaging (MRI) parameters|Relapses|Changes in Expanded Disability Status Score (EDSS) and Multiple Sclerosis Impact Scale (MSIS)|Hospitalizations|Neutralizing antibodies|Adverse events","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","91449|EudraCT: 2005-001540-23|309560",,,,"April 12, 2006",,"March 10, 2015","ask Contact, Denmark|Copenhagen, Denmark|Hillerød, Denmark|Holstebro, Denmark|Stockholm, Sweden|Stockholm, Sweden|Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT00313976"
1282,"NCT00313248","Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer",,"Completed","No Results Available","Breast Neoplasm","Drug: Sagopilone (ZK 219477)","Response to treatment with ZK-Epo after 6 cycles|Safety and tolerability of ZK-Epo","Bayer","Female","18 Years and older   (Adult, Older Adult)","Phase 2","65","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","91466|307975","April 2006","October 2008","November 2008","April 12, 2006",,"December 10, 2015","Birmingham, Alabama, United States|Anchorage, Alaska, United States|Tucson, Arizona, United States|Hot Springs, Arkansas, United States|Bakersfield, California, United States|Palm Springs, California, United States|Aurora, Colorado, United States|Washington, District of Columbia, United States|Daytona Beach, Florida, United States|Decatur, Illinois, United States|New Albany, Indiana, United States|Baltimore, Maryland, United States|Minneapolis, Minnesota, United States|Livingston, New Jersey, United States|New York, New York, United States|Syracuse, New York, United States|Portland, Oregon, United States|Pittsburgh, Pennsylvania, United States|Houston, Texas, United States|San Antonio, Texas, United States|Tacoma, Washington, United States|Toronto, Ontario, Canada|Greenfield Park, Quebec, Canada|Montreal, Quebec, Canada|Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00313248"
1283,"NCT00310609","Magnevist® Injection Enhanced MRA Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Aortic Arch and Cerebral Branches",,"Completed","No Results Available","Cardiovascular Abnormalities","Drug: Gadopentetate dimeglumine (Magnevist)","Accuracy, sensitivity, and specificity based on quantitative assessment of stenosis assesses by blinded reader|Diagnostic confidence|Visual assessment of stenosis|Difference in degree of stenosis|Other diagnostic findings|Location and matching of stenosis|Image quality|Image evaluability and presence of artifacts|Ability to visualize arterial segments|Proportion of correctly categorized maximum stenosis per segment|Number of evaluable segments|Duration if 2D TOF and CE-MRA|Patient management|Safety variables","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","123","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","90941|304630","December 2003",,"October 2004","April 4, 2006",,"December 30, 2014",,,"https://ClinicalTrials.gov/show/NCT00310609"
1284,"NCT00310596","Cardiovascular Safety Study of Magnevist® Injection at Two Dose Levels and Two Injection Rates in Normal Subjects",,"Completed","No Results Available","Healthy","Drug: Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Drug: Moxifloxacin (BAY12-8039)|Drug: Placebo","The primary study variable was heart-rate corrected QT (QTc) interval|Adverse event monitoring, laboratory evaluations|ECG variables and overall interpretation","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","71","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","91024|305340","January 2004",,"March 2004","April 4, 2006",,"December 30, 2014","Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00310596"
1285,"NCT00310557","Magnevist® Injection-enhanced MRA Compared to Non Contrast MRA for the Detection of Stenosis of the Renal Arteries",,"Completed","No Results Available","Renal Artery Stenosis","Drug: Gadopentetate dimeglumine (Magnevist)","Accuracy, sensitivity and specificity based on quantitative assessment of stenosis|Diagnostic confidence|Accuracy, sensitivity, and specificity based on visual assessment of stenosis assesses|Difference in degree of stenosis|Other diagnostic findings|Localisation matching of maximum stenosis|Image quality|Image evaluability and presence of artifacts|Proportions of correctly categorised arteries with regard to maximum stenosis|Number of evaluable arteries|Patient management|Safety","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","116","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","90940|304629","December 2003",,"December 2004","April 4, 2006",,"December 30, 2014",,,"https://ClinicalTrials.gov/show/NCT00310557"
1286,"NCT00310544","Depiction of Delayed Enhancement in Patients With Documented Myocardial Infarction",,"Completed","No Results Available","Myocardial Infarction","Drug: Magnevist (Gadopentetate dimeglumine, BAY86-4882)","Quantitative measurement of the total area of delayed enhancement|Quantitative measures of area of delayed enhancement and signal intensities|Semiquantitative measures of area of delayed enhancement|Presence of delayed enhancement|Wall motion endpoints|Safety","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","73","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic","91230|DE-03899|306947","March 2006",,"September 2006","April 4, 2006",,"December 15, 2014","San Diego, California, United States|Winston-Salem, North Carolina, United States|Tulsa, Oklahoma, United States|Portland, Oregon, United States|Hershey, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Buenos Aires, Argentina",,"https://ClinicalTrials.gov/show/NCT00310544"
1287,"NCT00310531","3-year Study of Menostar Versus Evista to Prevent Osteoporosis in Post-menopausal Women",,"Completed","No Results Available","Osteopenia","Drug: Menostar (Estradiol, BAY86-5435)|Drug: Raloxifene","Percentage change in Bone Mineral Density at the lumbar spine|Percentage change in Bone Mineral Density of the hip|Percentage change in biochemical markers of bone turnover|Proportion of patients with hot flushes|Change in Women's Health Questionnaire|Proportion of patients with an abnormal endometrial biopsy|Pharmacogenetic analysis|Digital breast density analysis","Bayer","Female","55 Years to 80 Years   (Adult, Older Adult)","Phase 3","500","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","91213|306871","February 2004",,"June 2007","April 4, 2006",,"December 30, 2014",,,"https://ClinicalTrials.gov/show/NCT00310531"
1288,"NCT00309075","Magnevist® Injection Enhanced MRA Compared to Non Contrast MRA for the Detection of Stenosis in the Calf and/or Pedal Arteries",,"Completed","No Results Available","Stenosis","Drug: Gadopentetate dimeglumine (Magnevist)","Accuracy, sensitivity, and specificity based on visual assessment of stenosis assesses by blinded reader|Diagnostic confidence|Accuracy, sensitivity, and specificity based on visual assessment of stenosis assesses by open label reader|Location and matching of stenosis|Image quality|Image evaluability and presence of artefacts|Ability to visualize arteries|Exact categorization of stenosis|Number of evaluable arteries|Duration of 2D-TOF and MRA|Artery appropriate for bypass|Patient management|Safety","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","126","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","91251|307260","December 2003",,"November 2004","March 31, 2006",,"December 30, 2014",,,"https://ClinicalTrials.gov/show/NCT00309075"
1289,"NCT00307866","Identification of Hepatic Lesions",,"Completed","No Results Available","Hepatic Neoplasms","Procedure: Resovist (BAY86-4884, SH U 555 A)","To assess the proportion of correct final, therapy deciding diagnosis based on unenhanced plus SH U 555 A enhanced MR imaging compared to contrast-enhanced dual-phase spiral CT.|To assess the number, size , location and character of liver lesions.|To assess the diagnostic confidence of MRI and CT.|To assess the proportion of changed therapeutical decisions.|To assess sensitivity and specificity of MRI and CT.|To assess safety and tolerability of SH U 555 A administration.","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","218","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","90956|304668","April 2001",,"May 2003","March 28, 2006",,"May 18, 2009","Bari, BA, Italy|Bologna, BO, Italy|Brescia, BS, Italy|Firenze, FI, Italy|Genova, GE, Italy|Milano, MI, Italy|Milano, MI, Italy|Milano, MI, Italy|Palermo, PA, Italy|Pisa, PI, Italy|Sassari, SS, Italy|Torino, TO, Italy|Trieste, TS, Italy|Verona, VE, Italy|Chieti, Italy|L'Aquila, Italy|Roma, Italy|Roma, Italy|Udine, Italy",,"https://ClinicalTrials.gov/show/NCT00307866"
1290,"NCT00307801","Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding",,"Completed","Has Results","Metrorrhagia","Drug: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)|Drug: Placebo","Proportion of Participants With no Dysfunctional Uterine Bleeding (DUB) Symptoms|Proportion of Participants Cured From Prolonged Bleeding|Proportion of Participants Cured From Excessive Bleeding|Proportion of Participants Cured From Frequent Bleeding|Proportion of Participants With Improvement in the Investigator's Global Assessment Scale at Treatment Day 84|Proportion of Participants With Improvement in the Investigator's Global Assessment Scale at Treatment Day 196|Proportion of Participants With Improvement in the Patient's Overall Assessment Scale at Treatment Day 84|Proportion of Participants With Improvement in the Patient's Overall Assessment Scale at Treatment Day 196|Change From Baseline in Blood Loss Volume for All Participants to the Reference Period of 90 Days Under Treatment|Menstrual Blood Loss Volume for All Participants at Cycle 1|Menstrual Blood Loss Volume for All Participants at Cycle 3|Menstrual Blood Loss Volume for All Participants at Cycle 7|Change From Baseline in Blood Loss Volume for Participants With Excessive Bleeding to the Reference Period of 90 Days Under Treatment.|Menstrual Blood Loss Volume for Participants With Excessive Bleeding at Cycle 1.|Menstrual Blood Loss Volume for Participants With Excessive Bleeding at Cycle 3.|Menstrual Blood Loss Volume for Participants With Excessive Bleeding at Cycle 7.|Change From Baseline in Number of Bleeding Episodes to the Reference Period of 90 Days Under Treatment|Change From Baseline in Number of Bleeding Days to the Reference Period of 90 Days Under Treatment|Change From Baseline in Number of Sanitary Protection Used at 90 Days of Treatment|Change From Baseline in Hemoglobin Concentration at Treatment Day 84|Change From Baseline in Hemoglobin Concentration at Treatment Day 196|Change From Baseline in Hematocrit at Treatment Day 196.|Change From Baseline in Ferritin Concentration at Treatment Day 84|Change From Baseline in Ferritin Concentration at Treatment Day 196|Change From Baseline in Psychological General Well-Being Index (PGWBI) Score at Treatment Day 84.|Change From Baseline in Psychological General Well-Being Index (PGWBI) Score at Treatment Day 196.|Change From Baseline in McCoy Female Sexuality Questionnaire (MFSQ) Score at Treatment Day 84|Change From Baseline in McCoy Female Sexuality Questionnaire (MFSQ) Score at Treatment Day 196|Change From Baseline in EuroQol 5 Dimensional (EQ-5D) Score at Treatment Day 84|Change From Baseline in EuroQol 5 Dimensional (EQ-5D) Score at Treatment Day 196|Change From Baseline in Visual Analogue Scale (VAS) of the EQ-5D Score at Treatment Day 84.|Change From Baseline in Visual Analogue Scale (VAS) of the EQ-5D Score at Treatment Day 196.|Resource Use Assessment by Use of a Self Administered Questionnaire （Change in the Employment Status） at Treatment Day 84.|Resource Use Assessment by Use of a Self Administered Questionnaire （Change in the Employment Status） at Treatment Day 196.|Resource Use Assessment by Use of a Self Administered Questionnaire （Days Missed From Work） at Treatment Day 84|Resource Use Assessment by Use of a Self Administered Questionnaire （Days Missed From Work） at Treatment Day 196|Resource Use Assessment by Use of a Self Administered Questionnaire （Productivity While Working） at Treatment Day 84.|Resource Use Assessment by Use of a Self Administered Questionnaire （Productivity While Working） at Treatment Day 196.|Resource Use Assessment by Use of a Self Administered Questionnaire （Regular Daily Activities） at Treatment Day 84|Resource Use Assessment by Use of a Self Administered Questionnaire （Regular Daily Activities） at Treatment Day 196.|Resource Use Assessment by Use of a Self Administered Questionnaire （Unscheduled Outpatient Visit at Hospital） at Treatment Day 84|Resource Use Assessment by Use of a Self Administered Questionnaire （Unscheduled Outpatient Visit at Hospital） at Treatment Day 196|Resource Use Assessment by Use of a Self Administered Questionnaire （Unscheduled Outpatient Visit to Physician） at Treatment Day 84|Resource Use Assessment by Use of a Self Administered Questionnaire （Unscheduled Outpatient Visit to Physician） at Treatment Day 196|Resource Use Assessment by Use of a Self Administered Questionnaire （Additional Unscheduled Procedures） at Treatment Day 84|Resource Use Assessment by Use of a Self Administered Questionnaire （Additional Unscheduled Procedures） at Treatment Day 196|Resource Use Assessment by Use of a Self Administered Questionnaire （Received Ambulatory Services） at Treatment Day 84|Resource Use Assessment by Use of a Self Administered Questionnaire （Received Ambulatory Services） at Treatment Day 196|Resource Use Assessment by Use of a Self Administered Questionnaire （no Out-of-pocket Expenses） at Treatment Day 84|Resource Use Assessment by Use of a Self Administered Questionnaire （no Out-of-pocket Expenses） at Treatment Day 196|Resource Use Assessment by Use of a Self Administered Questionnaire （Not Have Any Medical Treatment） at Treatment Day 84|Resource Use Assessment by Use of a Self Administered Questionnaire （Not Have Any Medical Treatment） at Treatment Day 196","Bayer","Female","18 Years and older   (Adult, Older Adult)","Phase 3","231","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","91470|2005-004340-32|308961","February 2006","May 2008","May 2008","March 28, 2006","July 29, 2011","December 30, 2014","Private Practice Dr. Ian Fraser, Ashfield, New South Wales, Australia|King Edward Memorial Hospital, Subiaco, Western Australia, Australia|Gynekologicka ambulance Vanda Horejsi, MD, Ceske Budejovice, Czech Republic|Center for Clinical& Basic Research, Pardubice, Czech Republic|Gynekologicko-poradnicka ambulance Dr. Hlavackova, Pisek, Czech Republic|Lekarsky dum Praha 7 a.s.Gynekologicka ambulance Dr. Jenicek, Praha 7, Czech Republic|Adenova Lääkärikeskus Oy, Espoo, Finland|Terveystalo Lahti, Lahti, Finland|Koskiklinikka, Tampere, Finland|Ylioppilaiden terveydenhoitosäätiö, Turku, Turku, Finland|Praxis Hr. Dr. U. Kohoutek, Karlsruhe, Baden-Württemberg, Germany|Praxis Hr. Dr. S. Schönian, Rheinstetten, Baden-Württemberg, Germany|Praxis Hr. Dr. K. Greven, Hannover, Niedersachsen, Germany|ClinPharm International GmbH, Dresden, Sachsen, Germany|emovis GmbH, Berlin, Germany|University of Semmelweis, Budapest, Hungary|Selya Janos Hospital, Komarom, Hungary|Borsod-Abauj-Zemplen County Hospital, Miskolc, Hungary|Medisch Spectrum Twente, Locatie Ariensplein, Enschede, Netherlands|PreCare Trial & Recruitment, Geleen, Netherlands|Menox BV, Nijmegen, Netherlands|Poliklinika Ginekologiczna- Poloznicza, Bialystok, Poland|Instytut Centrum Zdrowia Matki Polki, Lodz, Poland|SPSK nr 1, Lublin, Poland|Szpital Kliniczny nr 3, Poznan, Poland|CSK MSWiA, Warszawa, Poland|Skånes Universitetssjukhus, Lund, Sweden|Karolinska Universitetssjukhuset Huddinge, Stockholm, Sweden|Akademiska Sjukhuset, Uppsala, Sweden|Dept. of obstetrics and gynaecology, Kiev, Ukraine|Instr. of Pediatrics, Obstetrics & Gynecology, Kiev, Ukraine|Kyiv Medical Academy of Postdyploma Education, Kiev, Ukraine|Lviv Regional Center Perinatal Center, Lviv, Ukraine|Bridge House Medical Centre, Cheadle, Cheshire, United Kingdom|Luton & Dunstable Hospital, Luton, United Kingdom|MeDiNova Research, Northwood, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00307801"
1291,"NCT00306150","Efficacy and Safety of Aprotinin on Transfusion Requirements in Patients Undergoing Radical or Total Cystectomy",,"Terminated","No Results Available","Blood Loss, Surgical|Postoperative Hemorrhage","Drug: Trasylol (Aprotinin, BAYA0128)|Drug: Placebo","The primary criterion for efficacy is the percent of patients requiring a blood transfusion anytime in the intra-operative or post-operative period (up to the earlier of Day 7 or discharge)|The number of units of blood or packed red cells transfused. There will be an analysis for the combination of autologous and allogenic transfusion and for allogenic alone|The number of units of blood or packed red cells transfused per patient requiring transfusion|The intraoperative blood loss determined as follow: a) by surgeon estimate b) summing weight of the blood in gauze and other materials and the suction drainage volume|The drainage volume (in milliliters) from the operative site|Transfusion of platelets, colloids, plasma and number of patients requiring these products|The change from preoperative hemoglobin concentration to postoperative hemoglobin concentration|Surgeon s assessment of the degree to which bleeding obscures his/her view of the surgical field, relative to past, similar procedures|Changes in blood markers related to inflammation and blood coagulation; baseline until Discharge or day 7|Time to discontinuing of mechanical ventilation|Changes in FEV1|Changes in the patients health related quality of life (HRQoL) (at baseline and 6+-2 weeks post surgery) using the Functional Assessment Cancer Therapy for patients with Bladder cancer (FACT-Bl) questionnaire","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","57","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","12002|2005-004055-35","December 2005",,"March 2007","March 23, 2006",,"December 17, 2014","Los Angeles, California, United States|Denver, Colorado, United States|Miami, Florida, United States|Chicago, Illinois, United States|Chicago, Illinois, United States|Portland, Maine, United States|Baltimore, Maryland, United States|Ann Arbor, Michigan, United States|Rochester, Minnesota, United States|Chapel Hill, North Carolina, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Oklahoma City, Oklahoma, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Nashville, Tennessee, United States|Houston, Texas, United States|Burlington, Vermont, United States|Gent, Belgium|Leuven, Belgium|Nantes Cedex, France|Nice, France|Tübingen, Baden-Württemberg, Germany|München, Bayern, Germany|Regensburg, Bayern, Germany|Fulda, Hessen, Germany|Mainz, Rheinland-Pfalz, Germany|Homburg, Saarland, Germany|Dresden, Sachsen, Germany|Maastricht, Netherlands|Nijmegen, Netherlands|Linköping, Sweden|Lund, Sweden|Stockholm, Sweden|Uppsala, Sweden|Cambridge, Cambridgeshire, United Kingdom|Newcastle Upon Tyne, Tyne and Wear, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00306150"
1292,"NCT00306137","Study to Investigate the Effect of Aprotinin of Transfusion Requirements in Patients Undergoing Surgical Procedures for Lung or Esophageal Cancer",,"Terminated","No Results Available","Blood Loss, Surgical","Drug: Trasylol (Aprotinin, BAYA0128)|Drug: Placebo","Percent of patients requiring a blood transfusion anytime in the intra-operative or post-operative period|Number of units of blood or packed red cells transfused|Number of units transfused per patient|Intra-operative blood loss|Drainage volume|Transfusion of platelets, colloids and plasma|Change from pre-operative to post-operative hemoglobin concentration|Surgeon's assessment of obscurement of operative field by bleeding|Blood markers of inflammation and coagulation|Time to discontinuation of mechanical ventilation|Health related quality of life measurements","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","104","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11800|EudraCT: 2005-004689-18","December 2005",,"March 2007","March 23, 2006",,"December 9, 2014","Atlanta, Georgia, United States|Augusta, Georgia, United States|Indianapolis, Indiana, United States|Indianapolis, Indiana, United States|Boston, Massachusetts, United States|St. Louis, Missouri, United States|Durham, North Carolina, United States|Cleveland, Ohio, United States|Pittsburgh, Pennsylvania, United States|Houston, Texas, United States|Salt Lake City, Utah, United States|Charlottesville, Virginia, United States|ask Contact, Australia|ask Contact, Austria|ask Contact, Belgium|ask Contact, Canada|ask Contact, Denmark|ask Contact, France|ask Contact, Germany|ask Contact, Spain|ask Contact, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00306137"
1293,"NCT00302666","Bleeding Pattern Study",,"Completed","No Results Available","Oral Contraceptive","Drug: Valette (Dienogest/EE30, BAY86-5038)","Bleeding pattern|Safety, contraceptive efficacy","Bayer","Female","18 Years to 40 Years   (Adult)","Phase 3","1315","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","91227|306903","June 2003",,"February 2005","March 14, 2006",,"May 18, 2009","Eberbach, Baden-Württemberg, Germany|Höchstadt a. d. Aisch, Bayern, Germany|Krumbach, Bayern, Germany|Neubiberg, Bayern, Germany|Nürnberg, Bayern, Germany|Dietzenbach, Hessen, Germany|Frankfurt, Hessen, Germany|Frankfurt, Hessen, Germany|Frankfurt, Hessen, Germany|Fulda, Hessen, Germany|Kelkheim, Hessen, Germany|Langen, Hessen, Germany|Mühlheim, Hessen, Germany|Neustrelitz, Mecklenburg-Vorpommern, Germany|Hannover, Niedersachsen, Germany|Hannover, Niedersachsen, Germany|Ronnenberg, Niedersachsen, Germany|Gevelsberg, Nordrhein-Westfalen, Germany|Gütersloh, Nordrhein-Westfalen, Germany|Kirchheimbolanden, Rheinland-Pfalz, Germany|Speyer, Rheinland-Pfalz, Germany|Bernburg, Sachsen-Anhalt, Germany|Blankenburg, Sachsen-Anhalt, Germany|Jessen, Sachsen-Anhalt, Germany|Magdeburg, Sachsen-Anhalt, Germany|Magdeburg, Sachsen-Anhalt, Germany|Magdeburg, Sachsen-Anhalt, Germany|Magdeburg, Sachsen-Anhalt, Germany|Magdeburg, Sachsen-Anhalt, Germany|Dresden, Sachsen, Germany|Dresden, Sachsen, Germany|Döbeln, Sachsen, Germany|Leipzig, Sachsen, Germany|Leipzig, Sachsen, Germany|Leipzig, Sachsen, Germany|Wurzen, Sachsen, Germany|Eisenberg, Thüringen, Germany|Gera, Thüringen, Germany|Jena, Thüringen, Germany|Kahla, Thüringen, Germany|Saalfeld, Thüringen, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Hamburg, Germany|Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT00302666"
1294,"NCT00300885","A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)",,"Terminated","Has Results","Carcinoma, Non-Small Cell Lung","Drug: Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel|Drug: Carboplatin plus Paclitaxel","Overall Survival (OS) in Patients Treated With Carboplatin, Paclitaxel and Sorafenib to OS in Patients Treated With Carboplatin, Paclitaxel and Placebo|Progression Free Survival (PFS)|Overall Best Response|Duration of Response|Patient Reported Outcome as Assessed by FACT-L Score. Change From Baseline in Total FACT-L at Cycles 3,5,7,9 and End of Treatment (EOT)|Patient Reported Outcome as Assessed by LCS Subscale Score. Change From Baseline in LCS Subscale at Cycles 2 Through 9 and at End of Treatment (EOT)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","926","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","11961|2005-005245-19","February 2006","October 2007","February 2009","March 10, 2006","September 20, 2010","November 4, 2014","Birmingham, Alabama, United States|Mobile, Alabama, United States|Tucson, Arizona, United States|Little Rock, Arkansas, United States|Springdale, Arkansas, United States|Anaheim, California, United States|Beverly Hills, California, United States|Burbank, California, United States|Corona, California, United States|Encinitas, California, United States|Highland, California, United States|Los Angeles, California, United States|Orange, California, United States|Sacramento, California, United States|Denver, Colorado, United States|Lakeland, Florida, United States|Merritt Island, Florida, United States|Orlando, Florida, United States|Orlando, Florida, United States|Atlanta, Georgia, United States|Marietta, Georgia, United States|Savannah, Georgia, United States|Chicago, Illinois, United States|Skokie, Illinois, United States|Skokie, Illinois, United States|Fort Wayne, Indiana, United States|Indianapolis, Indiana, United States|Indianapolis, Indiana, United States|Indianapolis, Indiana, United States|Kokomo, Indiana, United States|Sioux City, Iowa, United States|Hutchinson, Kansas, United States|Wichita, Kansas, United States|Louisville, Kentucky, United States|Baton Rouge, Louisiana, United States|Metairie, Louisiana, United States|Boston, Massachusetts, United States|Pittsfield, Massachusetts, United States|Ann Arbor, Michigan, United States|Detroit, Michigan, United States|Hattiesburg, Mississippi, United States|Jefferson City, Missouri, United States|Kansas City, Missouri, United States|Kansas City, Missouri, United States|St. Louis, Missouri, United States|Lincoln, Nebraska, United States|Las Vegas, Nevada, United States|Las Vegas, Nevada, United States|Hackensack, New Jersey, United States|Morristown, New Jersey, United States|New York, New York, United States|Rochester, New York, United States|Staten Island, New York, United States|Bismarck, North Dakota, United States|Fargo, North Dakota, United States|Columbus, Ohio, United States|Columbus, Ohio, United States|Dayton, Ohio, United States|Dover, Ohio, United States|Oklahoma City, Oklahoma, United States|Tulsa, Oklahoma, United States|Portland, Oregon, United States|Allentown, Pennsylvania, United States|Bethlehem, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pottsville, Pennsylvania, United States|Sayre, Pennsylvania, United States|Charleston, South Carolina, United States|Greenville, South Carolina, United States|Knoxville, Tennessee, United States|Nashville, Tennessee, United States|Trophy Club, Texas, United States|Salt Lake City, Utah, United States|Abingdon, Virginia, United States|Fairfax, Virginia, United States|Richlands, Virginia, United States|Richmond, Virginia, United States|Richmond, Virginia, United States|Morgantown, West Virginia, United States|Milwaukee, Wisconsin, United States|El Palomar - Morón, Buenos Aires, Argentina|La Plata, Buenos Aires, Argentina|Mar del Plata, Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Rosario, Santa Fe, Argentina|Capital Federal-Buenos Aires, Argentina|Santa Fé, Argentina|Port Macquarie, New South Wales, Australia|Wollongong, New South Wales, Australia|Brisbane, Queensland, Australia|Adelaide, South Australia, Australia|Frankston, Victoria, Australia|Melbourne, Victoria, Australia|Perth, Western Australia, Australia|Bruxelles - Brussel, Belgium|Charleroi, Belgium|La Louviere, Belgium|Liege, Belgium|Salvador, Bahia, Brazil|Fortaleza, Ceará, Brazil|Fortaleza, Ceará, Brazil|Brasília, Distrito Federal, Brazil|Goiânia, Goiás, Brazil|Nova Lima, Minas Gerais, Brazil|Curitiba, Parana, Brazil|Porto Alegre, Rio Grande do Sul, Brazil|Porto Alegre, Rio Grande do Sul, Brazil|Joinville, Santa Catarina, Brazil|Barretos, Sao Paulo, Brazil|Jaú, Sao Paulo, Brazil|Ribeirao Preto, Sao Paulo, Brazil|Santo Andre, Sao Paulo, Brazil|Sorocaba, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|Belo Horizonte, Brazil|North Vancouver, British Columbia, Canada|Barrie, Ontario, Canada|Brampton, Ontario, Canada|Montreal, Quebec, Canada|Regina, Saskatchewan, Canada|Santiago, Chile|Santiago, Chile|Santiago, Chile|Santiago, Chile|Bobigny Cedex, France|Caen, France|Clamart, France|Metz, France|Nancy, France|Nice Cedex 2, France|Strasbourg, France|Heidelberg, Baden-Württemberg, Germany|Mannheim, Baden-Württemberg, Germany|Gauting, Bayern, Germany|München, Bayern, Germany|Hofheim, Hessen, Germany|Göttingen, Niedersachsen, Germany|Hannover, Niedersachsen, Germany|Oldenburg, Niedersachsen, Germany|Essen, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Hemer, Nordrhein-Westfalen, Germany|Leverkusen, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Großhansdorf, Schleswig-Holstein, Germany|Berlin, Germany|Hamburg, Germany|Hong Kong, Hong Kong|Budapest, Hungary|Deszk, Hungary|Gyula, Hungary|Matrahaza, Hungary|Torokbalint, Hungary|Orbassano, Torino, Italy|Bergamo, Italy|Genova, Italy|Milano, Italy|Parma, Italy|Pavia, Italy|Perugia, Italy|Roma, Italy|Torino, Italy|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Eindhoven, Noord-Brabant, Netherlands|Zwolle, Netherlands|Gdansk, Poland|Krakow, Poland|Olsztyn, Poland|Otwock, Poland|Warszawa, Poland|Warszawa, Poland|Wroclaw, Poland|San Juan, Puerto Rico|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|St. Petersburg, Russian Federation|Elche, Alicante, Spain|Zaragoza, Aragón, Spain|Majadahonda, Madrid, Spain|Alicante, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Pontevedra, Spain|Zamora, Spain|Gävle, Sweden|Stockholm, Sweden|Uppsala, Sweden|Taichung, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Plymouth, Devon, United Kingdom|Bornemouth, Dorset, United Kingdom|Leicester, Leicestershire, United Kingdom|London, United Kingdom|Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00300885"
1295,"NCT00299390","Safety and Efficacy Study of a New Chemotherapy Agent to Treat Small Cell Lung Cancer",,"Terminated","No Results Available","Small Cell Lung Carcinoma","Drug: Sagopilone (BAY86-5302, ZK 219477)","Response to treatment according to the modRECIST (complete response or partial response)|Duration of complete or partial tumor response|Time to tumor progression|Number of participants with adverse events","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","91375|2005-000597-53|307972","April 2006","April 2007","April 2007","March 6, 2006",,"December 31, 2015",,,"https://ClinicalTrials.gov/show/NCT00299390"
1296,"NCT00296855","Comparison Study of Vasovist® Magnetic Resonance Angiography (MRA) and an MRA With a Conventional Extracellular Contrast Agent With X-ray Angiography in Patients With Peripheral Artery Disease",,"Completed","No Results Available","Peripheral Vascular Diseases","Drug: Vasovist (BAY86-5283, MS-325)","Diagnostic potential of Vasovist enhanced MRA|Comparison of the quantitative assessment and the qualitative assessment of arterial stenosis/disease as compared to X-ray angiography|Quantitative assessment of vessel enhancement|Qualitative assessment of disease|Qualitative assessment of plaque morphology|Evaluation of quality of vascular anatomy and delineation of vessel wall, venous enhancement and diagnostic potential of venous enhancement","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","261","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","91463|EudraCT No. 2005-002547-66|308861","February 2006",,"February 2007","February 27, 2006",,"April 23, 2010","Lornas de Zamora, Buenos Aires, Argentina|Buenos Aires, Capital Federal, Argentina|Buenos Aires, Capital Federal, Argentina|Buenos Aires, Argentina|St. Pölten, Niederösterreich, Austria|Graz, Steiermark, Austria|Wien, Austria|Wien, Austria|Curitiba, Parana, Brazil|Rio de Janeiro, RJ, Brazil|Sao Paulo, SP, Brazil|São Paulo, SP, Brazil|Frankfurt, Hessen, Germany|Frankfurt, Hessen, Germany|Bonn, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Berlin, Germany|Hamburg, Germany|Monterrey, Nuevo León, Mexico|Mexico D. F., Mexico|México D.F., Mexico|Baden, Switzerland|Basel, Switzerland",,"https://ClinicalTrials.gov/show/NCT00296855"
1297,"NCT00293059","Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding",,"Completed","Has Results","Metrorrhagia","Drug: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)|Drug: Placebo","Proportion of Participants With no Dysfunctional Uterine Bleeding (DUB) Symptoms|Proportion of Participants Cured From Prolonged Bleeding|Proportion of Participants Cured From Frequent Bleeding|Proportion of Participants Cured From Excessive Bleeding|Proportion of Participants With Improvement in the Investigator's Global Assessment Scale at Treatment Day 84|Proportion of Participants With Improvement in the Investigator's Global Assessment Scale at Treatment Day 196|Proportion of Participants With Improvement in the Participant's Overall Assessment Scale at Treatment Day 84|Proportion of Participants With Improvement in the Participant's Overall Assessment Scale at Treatment Day 196|Change From Baseline in Blood Loss Volume for All Participants to the Reference Period of 90 Days Under Treatment|Menstrual Blood Loss Volume for All Participants at Cycle 1|Menstrual Blood Loss Volume for All Participants at Cycle 3|Menstrual Blood Loss Volume for All Participants at Cycle 7|Change From Baseline in Blood Loss Volume for Participants With Excessive Bleeding to the Reference Period of 90 Days Under Treatment|Menstrual Blood Loss Volume for Participants With Excessive Bleeding at Cycle 1|Menstrual Blood Loss Volume for Participants With Excessive Bleeding at Cycle 3|Menstrual Blood Loss Volume for Participants With Excessive Bleeding at Cycle 7|Change From Baseline in Number of Bleeding Days to the Reference Period of 90 Days Under Treatment|Change From Baseline in Number of Bleeding Episodes to the Reference Period of 90 Days Under Treatment|Change From Baseline in Number of Sanitary Protection Used at 90 Days of Treatment|Change From Baseline in Psychological General Well-Being Index (PGWBI) Scores at Treatment Day 84|Change From Baseline in Psychological General Well-Being Index (PGWBI) Scores at Treatment Day 196|Change From Baseline in McCoy Female Sexuality Questionnaire (MFSQ) Scores at Treatment Day 84|Change From Baseline in McCoy Female Sexuality Questionnaire (MFSQ) Scores at Treatment Day 196|Change From Baseline in EuroQoL (Quality of Life) 5 Dimensional Health Questionnaire (EQ-5D) Scores at Treatment Day 84|Change From Baseline in EuroQoL (Quality of Life) 5 Dimensional Health Questionnaire (EQ-5D) Scores at Treatment Day 196|Change From Baseline in Visual Analogue Scale (VAS) of the EQ-5D Score at Treatment Day 84|Change From Baseline in Visual Analogue Scale (VAS) of the EQ-5D Score at Treatment Day 196|Resource Use Assessment by Use of a Self Administered Questionnaire (Change in the Employment Status) at Treatment Day 84|Resource Use Assessment by Use of a Self Administered Questionnaire (Days Missed From Work) at Treatment Day 84|Resource Use Assessment by Use of a Self Administered Questionnaire (Productivity While Working) at Treatment Day 84|Resource Use Assessment by Use of a Self Administered Questionnaire (Regular Daily Activities) at Treatment Day 84|Resource Use Assessment by Use of a Self Administered Questionnaire (Unscheduled Outpatient Visit at Hospital) at Treatment Day 84|Resource Use Assessment by Use of a Self Administered Questionnaire (Unscheduled Visit to Physician) at Treatment Day 84|Resource Use Assessment by Use of a Self Administered Questionnaire (Additional Unscheduled Procedures) at Treatment Day 84|Resource Use Assessment by Use of a Self Administered Questionnaire (Received Ambulatory Services) at Treatment Day 84|Resource Use Assessment by Use of a Self Administered Questionnaire (Out-of-pocket Expenses) at Treatment Day 84|Resource Use Assessment by Use of a Self Administered Questionnaire (Any Medical Treatment) at Treatment Day 84|Resource Use Assessment by Use of a Self Administered Questionnaire (Change in the Employment Status) at Treatment Day 196|Resource Use Assessment by Use of a Self Administered Questionnaire (Days Missed From Work) at Treatment Day 196|Resource Use Assessment by Use of a Self Administered Questionnaire (Productivity While Working) at Treatment Day 196|Resource Use Assessment by Use of a Self Administered Questionnaire (Regular Daily Activities) at Treatment Day 196|Resource Use Assessment by Use of a Self Administered Questionnaire (Unscheduled Outpatient Visit at Hospital) at Treatment Day 196|Resource Use Assessment by Use of a Self Administered Questionnaire (Unscheduled Visit to Physician) at Treatment Day 196|Resource Use Assessment by Use of a Self Administered Questionnaire (Additional Unscheduled Procedures) at Treatment Day 196|Resource Use Assessment by Use of a Self Administered Questionnaire (Received Ambulatory Services) at Treatment Day 196|Resource Use Assessment by Use of a Self Administered Questionnaire (Out-of-pocket Expenses) at Treatment Day 196|Resource Use Assessment by Use of a Self Administered Questionnaire (Any Medical Treatment) at Treatment Day 196|Change From Baseline in Hematocrit (Hct) Concentrations at Treatment Day 196|Change From Baseline in Serum Ferritin Concentration at Treatment Day 84|Change From Baseline in Serum Ferritin Concentration at Treatment Day 196|Change From Baseline in Hemoglobin Concentration at Treatment Day 84|Change From Baseline in Hemoglobin Concentration at Treatment Day 196","Bayer","Female","18 Years and older   (Adult, Older Adult)","Phase 3","190","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","91469|308960","December 2005","May 2008","May 2008","February 17, 2006","June 6, 2011","November 27, 2013","Women and Child, LPP, Lake Havasu CIty, Arizona, United States|Marin Endocrine Associates, Greenbrae, California, United States|Impact Clinical Trials - Los Angeles, Los Angeles, California, United States|Blue Hill Medical Group, Pacific Palisades, California, United States|Genesis Center for Clinical Research, San Diego, California, United States|Medical Center for Clinical Research, San Diego, California, United States|Women's Health Care, Inc., San Diego, California, United States|Clinical Trial Center of Colorado, Greenwood Village, Colorado, United States|Clinical Trial Center of Colorado, Littleton, Colorado, United States|South Florida Medical Research, Aventura, Florida, United States|Women's Medical Research Group, LLC, Clearwater, Florida, United States|Clinical Physiology Associates, Inc., Fort Myers, Florida, United States|New Age Medical Research Corp., Miami, Florida, United States|Insignia Care for Women, P.A., Tampa, Florida, United States|Mount Vernon Clinical Research, Atlanta, Georgia, United States|Atlanta West Women's Center, Douglasville, Georgia, United States|Women's Health Practice, Champaign, Illinois, United States|Physicians Research Group, Indianapolis, Indiana, United States|Advanced Biomedical Research of America, Las Vegas, Nevada, United States|NYU Langone Medical Center, New York, New York, United States|Eastern Carolina Women's Center, New Bern, North Carolina, United States|Hawthorne Medical Research, Inc., Winston-Salem, North Carolina, United States|Womens Medical Center, Bismark, North Dakota, United States|Reproductive Medical Research, Cincinnati, Ohio, United States|Rapid Medical Research Inc., Cleveland, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Clinical Research of Philadelphia, LLC, Philadelphia, Pennsylvania, United States|Women's Health Care Group of PA, Pottstown, Pennsylvania, United States|South Carolina Clinical Research Center, Columbia, South Carolina, United States|Brown Clinic, P.L.L.P., Watertown, South Dakota, United States|New South Medical, Clarksville, Tennessee, United States|Advanced Research Associates, Corpus Christi, Texas, United States|Obstetrical & Gynecological Associates, PA, Houston, Texas, United States|Research Across America, Plano, Texas, United States|National Clinical Research, Inc., Richmond, Virginia, United States|North Spokane Women's Clinic, Spokane, Washington, United States|Dr. John Lenihan, MD, Tacoma, Washington, United States|Maritimes Research Center, Bathurst, New Brunswick, Canada|Total Concept Health Care Inc., Kitchener, Ontario, Canada|Prime Health Research, Toronto, Ontario, Canada|Centre d'étude clinique de Montréal Inc., Montreal, Quebec, Canada|Les Gynecologues Associes, Montreal, Quebec, Canada|Clinique de Gynecologie, Shawinigan, Quebec, Canada|Q & T Research, Inc., Sherbrooke, Quebec, Canada|Clinique Médicale des Campus, Ste-Foy, Quebec, Canada|Clinique Recherche en Sante des Femmes Inc., Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00293059"
1298,"NCT00288691","Menorrhagia Study in Women With Treatment-resistant Menorrhagia",,"Completed","No Results Available","Menorrhagia","Drug: Asoprisnil (BAY86-5294)|Drug: Placebo","Individual relative change in uterine bleeding scores by PBAC|Endometrial thickness|Adverse events collection|Bleeding pattern|Endometrial histology incl. immunohistochemical evaluations","Bayer|TAP Pharmaceutical Products Inc.","Female","30 Years to 55 Years   (Adult)","Phase 2","26","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","90955|304667","November 2001",,"January 2004","February 8, 2006",,"December 30, 2014",,,"https://ClinicalTrials.gov/show/NCT00288691"
1299,"NCT00288249","Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Breast Cancer",,"Completed","No Results Available","Breast Neoplasms|Breast Cancer, Metastatic","Drug: Sagopilone (BAY86-5302, ZK 219477)","Tumor response rate (complete or partial response according to RECIST)|Duration of complete or partial tumor response|Time to tumor progression","Bayer","Female","18 Years and older   (Adult, Older Adult)","Phase 2","82","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","91464|2005-003216-30|309544","December 2005","March 2008","January 2009","February 7, 2006",,"December 2, 2014","Wien, Austria|Wien, Austria|Brasschaat, Belgium|Plovdiv, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Angers, France|Bordeaux, France|Clermont Ferrand, France|Saint Herblain Cedex, France|Vandoeuvre les Nancy, France|Berlin, Germany|Forlì, FC, Italy|Milano, MI, Italy|Reggio Emilia, RE, Italy|Olsztyn, Poland|Warszawa, Poland|Ljubljana, Slovenia|Madrid, Spain|Málaga, Spain|Manchester, Greater Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00288249"
1300,"NCT00280657","Study on Safety and Efficacy of an Oral Contraceptive in Treating Acne Papulopustulosa",,"Completed","No Results Available","Acne Vulgaris","Drug: Valette|Drug: Diane|Drug: Placebo","Change in lesions|ISGA|Parameters of safety and tolerability","Bayer","Female","16 Years to 45 Years   (Child, Adult)","Phase 3","1326","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","91299|307760","March 2004","May 2005","May 2005","January 23, 2006",,"December 18, 2014","Caslav, Czech Republic|Chomutov, Czech Republic|Kutna Hora, Czech Republic|Louny, Czech Republic|Olomouc, Czech Republic|Praha 10, Czech Republic|Praha, Czech Republic|Slany, Czech Republic|Svitavy, Czech Republic|Usti nad Labem, Czech Republic|Grudziadz, Poland|Lodz, Poland|Lublin, Poland|Poznan, Poland|Warszawa, Poland|Warszawa, Poland|Warszawa, Poland|Warszawa, Poland|Wroclaw, Poland|Korolev, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moskva, Russian Federation|Moskva, Russian Federation|Moskva, Russian Federation|Moskva, Russian Federation|Moskva, Russian Federation|Petrozavodsk, Russian Federation|Sankt-Peterburg, Russian Federation|Sankt-Peterburg, Russian Federation|Sankt-Peterburg, Russian Federation|Sankt-Peterburg, Russian Federation|Sankt-Peterburg, Russian Federation|Sankt-Peterburg, Russian Federation|Sankt-Peterburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|Kosice, Zapad, Slovakia|Banska Bystrica, Slovakia|Bratislava, Slovakia|Kosice - Saca, Slovakia|Nitra, Slovakia|Chernivtsi, Chernivetska, Ukraine|Dnipropetrovsk, Dnipropetrovska, Ukraine|Donetsk, Donetska, Ukraine|Ivano-Frankivsk, Ivano-Frankivska, Ukraine|Kharkiv, Kharkivska, Ukraine|Kiev, Kyivska, Ukraine|Alchevsk, Luhanska, Ukraine|Lviv, Lvivska, Ukraine|Poltava, Poltavska, Ukraine|Simferopol, Respublika Krym, Ukraine|Uzhhorod, Zakarpatska, Ukraine|Zaporizhzhia, Zaporizka, Ukraine|Kiev, Ukraine|Kiev, Ukraine|Lugansk, Ukraine|Makeevka, Ukraine|Odessa, Ukraine|Rovno, Ukraine|Ternopil, Ukraine",,"https://ClinicalTrials.gov/show/NCT00280657"
1301,"NCT00266032","Study on Safety and Efficacy of an Oral Contraceptive in Long Cycles",,"Completed","Has Results","Contraception","Drug: Flexible (extended) treatment of EE20/DRSP (YAZ, BAY86-5300)|Drug: Fixed extended treatment of EE20/DRSP (YAZ, BAY86-5300)|Drug: Standard 24+4 treatment of EE20/DRSP (YAZ, BAY86-5300)","Number of Days With Bleeding Including Spotting|Number of Unintended Pregnancies in Yaz Flexible Arm|Pearl Index|Number of Unintended Pregnancies Due to Method Failure|Adjusted Pearl Index|Number of Days With Bleeding Excluding Spotting|Number of Bleeding Days During One Year of Treatment in Subjects With at Least 248 Days of Exposure Normalized to 372 Days|Number of Bleeding / Spotting Days by 90-day Reference Period|Number of Bleeding / Spotting Episodes in 90 Day Reference Period|Days With Scheduled Versus Unscheduled Bleeding","Bayer","Female","18 Years to 35 Years   (Adult)","Phase 3","1166","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","91450|2005-002125-32|308683","December 2005","October 2008","October 2008","December 15, 2005","March 3, 2010","November 3, 2014","Drummondville, Quebec, Canada|Montreal, Quebec, Canada|Pointe-Claire, Quebec, Canada|Shawinigan, Quebec, Canada|Ste-Foy, Quebec, Canada|Quebec, Canada|Ettlingen, Baden-Württemberg, Germany|Karlsruhe, Baden-Württemberg, Germany|Ansbach, Bayern, Germany|Krumbach, Bayern, Germany|Nürnberg, Bayern, Germany|Dietzenbach, Hessen, Germany|Frankfurt, Hessen, Germany|Frankfurt, Hessen, Germany|Frankfurt, Hessen, Germany|Frankfurt, Hessen, Germany|Mühlheim, Hessen, Germany|Bovenden, Niedersachsen, Germany|Hannover, Niedersachsen, Germany|Osnabrück, Niedersachsen, Germany|Bernburg, Sachsen-Anhalt, Germany|Jessen, Sachsen-Anhalt, Germany|Magdeburg, Sachsen-Anhalt, Germany|Magdeburg, Sachsen-Anhalt, Germany|Magdeburg, Sachsen-Anhalt, Germany|Wurzen, Sachsen, Germany|Gera, Thüringen, Germany|Jena, Thüringen, Germany|Kahla, Thüringen, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Hamburg, Germany|Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT00266032"
1302,"NCT00259129","Effect of BAY 43-9006 (Sorafenib) on Cardiovascular Safety Parameters in Cancer Patients",,"Completed","No Results Available","Neoplasms","Drug: Sorafenib (Nexavar, BAY43-9006)","Effect of sorafenib on cardiovascular safety parameters|Pharmacokinetics|Anti-tumor activity|Adverse Event Collection","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","53","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","100561","August 2005","February 2007","March 2008","November 29, 2005",,"November 13, 2014","Boston, Massachusetts, United States|San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00259129"
1303,"NCT00250640","Observation of Patients With Primary Pulmonary Hypertension Receiving Prescribed Ventavis Inhalation Therapy Regarding Safety and Efficacy for up to 4 Years",,"Completed","No Results Available","Hypertension, Pulmonary","Drug: Iloprost (Ventavis, BAYQ6256)","The primary efficacy variable is 6-minute walking distance. Focus will lay on the individual changes (in meters) at Month 3 (after inhalation) compared to the value measured at baseline.|Relative change in the 6-minutes walking distance (%), as compared to baseline (BL): clinical improvement is defined as an increase of at least 10% vs BL; clinically significant deterioration is defined as a decrease of at least 30% vs BL.|Changes in the NYHA class (to determine the patients' clinical conditions) vs. baseline will be classified into: improved, unchanged and deteriorated. Improvement is a negative difference; deterioration is a NYHA class increase from baseline.|Mortality, defined as all-cause mortality, will be assessed for all patients included in this study.|The safety and tolerability of Ventavis will be assessed by an examination of the adverse event data collected in this study.|Other safety variable|Other safety variables (optional assessment)","Bayer","All","18 Years and older   (Adult, Older Adult)",,"106","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","91430|308120","April 2005","April 2012","July 2012","November 8, 2005",,"February 2, 2015","Brest, France|Clamart Cedex, France|Lille, France|Lyon Cedex 03, France|Pessac, France|Reims, France|Strasbourg, France|Vandoeuvre les Nancy Cedex, France|Donaueschingen, Baden-Württemberg, Germany|Heidelberg, Baden-Württemberg, Germany|Heidelberg, Baden-Württemberg, Germany|Löwenstein, Baden-Württemberg, Germany|Erlangen, Bayern, Germany|München, Bayern, Germany|München, Bayern, Germany|Regensburg, Bayern, Germany|Gießen, Hessen, Germany|Bonn, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Mönchengladbach, Nordrhein-Westfalen, Germany|Wuppertal, Nordrhein-Westfalen, Germany|Homburg/Saar, Saarland, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Erfurt, Thüringen, Germany|Berlin, Germany|Berlin, Germany|Hamburg, Germany|Bologna, Italy|Pavia, Italy|Pisa, Italy|Roma, Italy|Coimbra, Portugal|Lisboa, Portugal|Barcelona, Spain|Barcelona, Spain|Córdoba, Spain|Madrid, Spain|Glasgow, United Kingdom|London, United Kingdom|Newcastle upon Tyne, United Kingdom|Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00250640"
1304,"NCT00246688","Efficacy and Safety Study of ZK219477 in Patients With Recurrent Ovarian Cancer",,"Completed","No Results Available","Ovarian Neoplasms","Drug: Sagopilone (BAY86-5302 , ZK219477)","Proportion of responders|Duration of response|Time to disease progression|Number of participants with adverse events","Bayer","Female","18 Years and older   (Adult, Older Adult)","Phase 2","63","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","91447|2005-000635-15|307970","November 2005","June 2007","June 2007","October 30, 2005",,"December 31, 2015",,,"https://ClinicalTrials.gov/show/NCT00246688"
1305,"NCT00244140","Ultravist: Safety and Efficacy in Computed Tomography of Head and Body",,"Completed","Has Results","Computed Tomography|Diagnostic Imaging","Drug: Iopromide 370 mg I/mL|Drug: Iopromide 300 mg I/mL","The Quality of Visualization of the Contrast-Enhanced Computed Tomography (CECT) Images, Based on the Blinded Readers' Assessment.|The Ability of the Investigator to Make a Diagnosis Based on the CECT Images|The Quality of Visualization of the Contrast-Enhanced Computed Tomography (CECT) Images, Based on the Investigators' Assessment.|The Ability of the Blinded Readers to Make a Diagnosis Based on the CECT Images","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","435","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","91462|309660","October 2005","April 2008","April 2008","October 26, 2005","July 20, 2009","February 28, 2014","Tucson, Arizona, United States|Miami, Florida, United States|Tallahassee, Florida, United States|Atlanta, Georgia, United States|Atlanta, Georgia, United States|Evanston, Illinois, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Ann Arbor, Michigan, United States|Detroit, Michigan, United States|New York, New York, United States|Stony Brook, New York, United States|Cleveland, Ohio, United States|Danville, Pennsylvania, United States|Charleston, South Carolina, United States|Medellín, Antioquia, Colombia|Bogota, Colombia|Bogotá, Colombia|Mumbai-400026, India|Tamil Nadu, India|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00244140"
1306,"NCT00235989","Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis",,"Completed","Has Results","Multiple Sclerosis, Relapsing-Remitting","Drug: Interferon beta 1b (Betaseron, BAY86-5046)","Safety and Tolerability as Defined by the Number of Subjects With Flu-like Syndrome, Fever, Myalgia, Injection Site Reactions, Injection Site Reactions Pain, Asthenia, Headache, Liver Function Abnormalities, and Bone Marrow Function Abnormalities|Frequency (Number of Patients Per Group Defined by Cut Off Values and Per Treatment Arm) of Neutralizing Antibody (NAb) Titer to IFNB-1b","Bayer","All","18 Years to 55 Years   (Adult)","Phase 2","63","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","91272|307320|Beyond","June 2003","January 2008","January 2008","October 12, 2005","July 3, 2009","May 8, 2014","Los Angeles, California, United States|San Francisco, California, United States|Washington, District of Columbia, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Kansas City, Kansas, United States|Louisville, Kentucky, United States|Ann Arbor, Michigan, United States|Ann Arbor, Michigan, United States|Reno, Nevada, United States|Stony Brook, New York, United States|Durham, North Carolina, United States|High Point, North Carolina, United States|Winston-Salem, North Carolina, United States|Columbus, Ohio, United States|Nashville, Tennessee, United States|Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00235989"
1307,"NCT00225199","Efficacy and Safety of SH T00660AA in Treatment of Endometriosis",,"Completed","No Results Available","Endometriosis","Drug: Visanne (BAY86-5258, SH T00660AA)|Drug: Placebo","Efficacy|Adverse event collection|Treatment satisfaction by patient","Bayer","Female","18 Years to 45 Years   (Adult)","Phase 3","198","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","91233|307041","March 2004",,"September 2006","September 23, 2005",,"April 23, 2010",,,"https://ClinicalTrials.gov/show/NCT00225199"
1308,"NCT00225186","Safety and Efficacy of SH T00660AA in Treatment of Endometriosis",,"Completed","No Results Available","Endometriosis","Drug: Visanne (SH T00660AA , BAY86-5258)","Safety assessment of the drug|Efficacy (reduction of pelvic pain)","Bayer","Female","18 Years to 45 Years   (Adult)","Phase 3","168","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","91234|307059","July 2004","March 2008","March 2008","September 23, 2005",,"January 9, 2014","Heidelberg, Baden-Württemberg, Germany|Tuebingen, Baden-Württemberg, Germany|Krumbach, Bayern, Germany|München, Bayern, Germany|Nuernberg, Bayern, Germany|Giessen, Hessen, Germany|Mühlheim, Hessen, Germany|Aachen, Nordrhein-Westfalen, Germany|Gevelsberg, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Kalbe, Sachsen-Anhalt, Germany|Dippoldiswalde, Sachsen, Germany|Leipzig, Sachsen, Germany|Marienberg, Sachsen, Germany|Weißig, Sachsen, Germany|Lübeck, Schleswig-Holstein, Germany|Greifswald, Germany|Brescia, Italy|Cagliari, Italy|Napoli, Italy|Roma, Italy|Torino, Italy|Chernivtsi, Ukraine|Kiev, Ukraine|Kiev, Ukraine|Kiev, Ukraine|Kiev, Ukraine|Vinnitsa, Ukraine",,"https://ClinicalTrials.gov/show/NCT00225186"
1309,"NCT00220324","Pearl Index Study With Low Dose Combined Oral Contraceptive",,"Completed","No Results Available","Contraception","Drug: Minisiston (SH D00342A)","Unadjusted Pearl Index|Adjusted Pearl Index|Cumulative pregnancy rate|Bleeding pattern|Cycle control","Bayer","Female","18 Years to 40 Years   (Adult)","Phase 3","840","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","91313|307987","February 2004",,"November 2005","September 22, 2005",,"April 3, 2015","Hannover, Niedersachsen, Germany|Aschersleben, Sachsen-Anhalt, Germany|Burg, Sachsen-Anhalt, Germany|Egeln, Sachsen-Anhalt, Germany|Halberstadt, Sachsen-Anhalt, Germany|Halberstadt, Sachsen-Anhalt, Germany|Jessen, Sachsen-Anhalt, Germany|Magdeburg, Sachsen-Anhalt, Germany|Magdeburg, Sachsen-Anhalt, Germany|Magdeburg, Sachsen-Anhalt, Germany|Dresden, Sachsen, Germany|Dresden, Sachsen, Germany|Dresden, Sachsen, Germany|Dresden, Sachsen, Germany|Großpösna, Sachsen, Germany|Leipzig, Sachsen, Germany|Leipzig, Sachsen, Germany|Leipzig, Sachsen, Germany|Suhl, Thüringen, Germany|Weida, Thüringen, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT00220324"
1310,"NCT00220298","Assessment of Long Term Treatment With Testosterone Undecanoate in Males With Hypogonadism",,"Completed","No Results Available","Hypogonadism","Drug: Testosterone undecanoate (TU) - NebidoTM","Efficacy and Safety of long term treatment with TU under real-life conditions|Assessment of treatment satisfaction by patient","Bayer","Male","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","96","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","91186|306605","February 2003","October 2007","October 2007","September 22, 2005",,"December 30, 2014","Nürnberg, Bayern, Germany|Marburg, Hessen, Germany|Wolfsburg, Niedersachsen, Germany|Münster, Nordrhein-Westfalen, Germany|Halle, Sachsen-Anhalt, Germany|Naumburg, Sachsen-Anhalt, Germany|Leipzig, Sachsen, Germany|Jena, Thueringen, Germany|Jena, Thueringen, Germany|Eisenberg, Thüringen, Germany|Gera, Thüringen, Germany|Berlin, Germany|Berlin, Germany|Leipzig, Germany",,"https://ClinicalTrials.gov/show/NCT00220298"
1311,"NCT00220285","Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Non-Hodgkin's Lymphoma|Lymphoma, B-Cell|Lymphoma, Low-Grade","Drug: Zevalin (SH L 749 , BAY86-5128)","Best overall response rates (the percentage of patients who achieved PR or better response)|The incidence of critical toxicity|Safety evaluation|Complete response (CR or CRu) rates|Progression-free survival (PFS)","Bayer","All","20 Years to 74 Years   (Adult, Older Adult)","Phase 2","45","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","91102|305618","August 2004",,"October 2005","September 22, 2005",,"December 30, 2014","Nagoya-shi, Aichi, Japan|Kashiwa-shi, Chiba, Japan|Maebashi-shi, Gunma, Japan|Kanazawa-shi, Ishikawa, Japan|Isehara-shi, Kanagawa, Japan|Kyoto-shi, Kyoto, Japan|Sendai-shi, Miyagi, Japan|Chuo-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT00220285"
1312,"NCT00206687","STEPS Trial - Spheramine Safety and Efficacy Study",,"Terminated","No Results Available","Parkinson Disease","Biological: Spheramine (BAY86-5280)|Procedure: Placebo","Change in UPDRS part III (Motor Score) in the defined medication at 12 months post surgery|Change in total UPDRS in ON and OFF at 12 months post surgery|Change in UPDRS Part III in ON at 12 months post surgery|Amount of L-dopa reduction at 12 months post surgery|Activities of Daily Living subscore of the UPDRS at 12 months post surgery|Quality of Life as assessed by PDQ-39, SF-36 and EQ-5D at 12 months post surgery|Percent time spent in ON and OFF at 12 months post surgery","Bayer|Titan Pharmaceuticals","All","30 Years to 70 Years   (Adult, Older Adult)","Phase 2","71","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","91039|305405","January 2003","May 2012","May 2012","September 21, 2005",,"October 9, 2015","Birmingham, Alabama, United States|Los Angeles, California, United States|Tampa, Florida, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Kansas City, Kansas, United States|Boston, Massachusetts, United States|New York, New York, United States|Philadelphia, Pennsylvania, United States|Houston, Texas, United States|Marburg, Hessen, Germany|Homburg, Saarland, Germany|Dresden, Sachsen, Germany|Hamburg, Germany|Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT00206687"
1313,"NCT00206648","An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS","ABOVE","Completed","No Results Available","Multiple Sclerosis, Relapsing-Remitting","Drug: Betaferon/Betaseron","Time to onset of first relapse|Number of patients relapse free at week 104","Bayer","All","18 Years to 60 Years   (Adult)","Phase 4","271","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","91293|307245","March 2003",,"October 2005","September 21, 2005",,"December 31, 2014","Tucson, Arizona, United States|Berkeley, California, United States|Irvine, California, United States|Loma Linda, California, United States|Los Angeles, California, United States|Sacramento, California, United States|San Jose, California, United States|Walnut Creek, California, United States|Walnut Creek, California, United States|Wilmington, Delaware, United States|Melbourne, Florida, United States|Miami, Florida, United States|Tampa, Florida, United States|Tampa, Florida, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Columbus, Georgia, United States|Savannah, Georgia, United States|Flossmoor, Illinois, United States|Springfield, Illinois, United States|Fort Wayne, Indiana, United States|Indianapolis, Indiana, United States|Des Moines, Iowa, United States|Kansas City, Kansas, United States|Shreveport, Louisiana, United States|Baltimore, Maryland, United States|Detroit, Michigan, United States|Golden Valley, Minnesota, United States|Minneapolis, Minnesota, United States|Rochester, Minnesota, United States|Kansas City, Missouri, United States|St. Louis, Missouri, United States|Reno, Nevada, United States|Albuquerque, New Mexico, United States|Albany, New York, United States|Buffalo, New York, United States|Mineola, New York, United States|New York, New York, United States|Asheville, North Carolina, United States|Winston-Salem, North Carolina, United States|Dayton, Ohio, United States|Oklahoma City, Oklahoma, United States|Medford, Oregon, United States|Philadelphia, Pennsylvania, United States|Providence, Rhode Island, United States|Charleston, South Carolina, United States|Houston, Texas, United States|Fairfax, Virginia, United States|Roanoke, Virginia, United States|Seattle, Washington, United States|Tacoma, Washington, United States|Nepean, Ontario, Canada|Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00206648"
1314,"NCT00206635","Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis",,"Completed","No Results Available","Multiple Sclerosis","Drug: Interferon beta-1b (Betaseron, BAY86-5046)","Description of long term course of disease|Comparison to natural history cohort","Bayer","All","33 Years and older   (Adult, Older Adult)",,"432","Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","308272","January 2005",,"December 2005","September 21, 2005",,"November 22, 2012","Many Locations, Alabama, United States|Many Locations, Arizona, United States|Many Locations, California, United States|Many Locations, Illinois, United States|Many Locations, Maryland, United States|Many Locations, Pennsylvania, United States|Many Locations, British Columbia, Canada|Many Locations, Ontario, Canada|Many Locations, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00206635"
1315,"NCT00206622","Efficacy and Safety Study in Postmenopausal Women to Determine the Lowest Effective Dose for Relief of Moderate to Severe Hot-Flushes",,"Completed","No Results Available","Hot Flashes","Drug: Climara PRO (Estradiol / Levonorgestrel transdermal)|Drug: Menostar (Estradiol transdermal)|Drug: Placebo transdermal","Lowest effective dose in decreasing the frequency and severity of hot flushes|Other symptoms related to menopause","Bayer","Female","40 Years and older   (Adult, Older Adult)","Phase 4","425","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","91429|308261","December 2004",,"February 2006","September 21, 2005",,"May 29, 2009","Huntsville, Alabama, United States|Chandler, Arizona, United States|Phoenix, Arizona, United States|Tucson, Arizona, United States|Fair Oaks, California, United States|Oakland, California, United States|San Diego, California, United States|San Diego, California, United States|San Diego, California, United States|New Britain, Connecticut, United States|West Hartford, Connecticut, United States|Fort Myers, Florida, United States|Gainesville, Florida, United States|Jacksonville, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Alpharetta, Georgia, United States|Boise, Idaho, United States|Idaho Falls, Idaho, United States|Champaign, Illinois, United States|Chicago, Illinois, United States|Peoria, Illinois, United States|South Bend, Indiana, United States|Lexington, Kentucky, United States|New Orleans, Louisiana, United States|New Orleans, Louisiana, United States|Detroit, Michigan, United States|St. Louis, Missouri, United States|Lincoln, Nebraska, United States|Reno, Nevada, United States|New Brunswick, New Jersey, United States|Albuquerque, New Mexico, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Memphis, Tennessee, United States|Arlington, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Temple, Texas, United States|Salt Lake City, Utah, United States|Burlington, Vermont, United States",,"https://ClinicalTrials.gov/show/NCT00206622"
1316,"NCT00206583","Efficacy and Safety Study of an Oral Contraceptive in Healthy Females",,"Completed","No Results Available","Contraception","Drug: EV/DNG (Qlaira, BAY86-5027, SH T00658ID)","Number of unintended pregnancies after 1 year|Bleeding pattern and cycle control parameters after 1 year","Bayer","Female","18 Years to 35 Years   (Adult)","Phase 3","499","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","90959|304742","March 2005","June 2007","July 2007","September 21, 2005",,"October 1, 2014","Women and Children's Hospital, Los Angeles, Los Angeles, California, United States|Lifespan Research, Palo Alto, California, United States|Genesis Center for Clinical Research, San Diego, California, United States|Medical Center for Clinical Research, San Diego, California, United States|Harbor - UCLA Medical Center, Torrance, California, United States|Clinical Trial Center of Colorado, Castle Rock, Colorado, United States|New Age Medical Research Corp., Miami, Florida, United States|Visions Clinical Research, Palm Springs, Florida, United States|Insignia Care for Women, P.A., Tampa, Florida, United States|Comprehensive Clinical Trials, West Palm Beach, Florida, United States|Physicians Research Group, Indianapolis, Indiana, United States|Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States|Women's Clinic of Lincoln, PC, Lincoln, Nebraska, United States|Women's Care Source, Morristown, New Jersey, United States|OB/GYN Health Center, Medford, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Clinical Research of Philadelphia, LLC, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center Health System, Pittsburgh, Pennsylvania, United States|Eastern Virginia Medical School, Norfolk, Virginia, United States|Seattle Women's: Health, Research, Gynecology, Seattle, Washington, United States|Total Concept Health Care Inc., Kitchener, Ontario, Canada|Temple Green Clinic, Waterloo, Ontario, Canada|Rhodin Recherche Clinique, Drummondville, Quebec, Canada|Centre d'étude clinique de Montréal Inc., Montreal, Quebec, Canada|Les Gynecologues Associes, Montreal, Quebec, Canada|Clinique de Gynecologie, Shawinigan, Quebec, Canada|Diex Recherche Inc., Sherbrooke, Quebec, Canada|Clinique Médicale des Campus, Ste-Foy, Quebec, Canada|Clinique Recherche en Sante des Femmes Inc., Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00206583"
1317,"NCT00185510","Efficacy and Safety Study of Advantan for Maintenance Treatment of Atopic Dermatitis",,"Completed","No Results Available","Dermatitis, Atopic","Drug: Methylprednisolone Aceponate (Advantan, BAY86-4862)|Drug: Placebo","Time to relapse in the maintenance phase (MP)|Patients' number of relapses in the maintenance phase|Treatment success as assessed by Investigator Global Assessment (IGA) score|Percentage change during Acute Phase (AP) and MP assessed by Modified Eczema Area and Severity Index (mEASI)|Index lesion monitoring|Change of disease during AP and MP as assessed by Patient Global Assessment|Visual assessment of signs of atrophy|Ultrasound for measurement of skin thickness in selected sites|Dermatology Life Quality Index (CDLQI, DLQI)|Adverse Event Collection","Bayer","All","12 Years and older   (Child, Adult, Older Adult)","Phase 4","250","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","91424|2004-002673-22|309189","March 2005","May 2006","June 2006","September 16, 2005",,"February 25, 2014",,,"https://ClinicalTrials.gov/show/NCT00185510"
1318,"NCT00185484","Efficacy and Safety Oral Contraceptive Study",,"Completed","No Results Available","Contraception","Drug: YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)","Rate of unintended pregnancies (Pearl index)|Physical and gynecological examination|Vital signs|Body weight|Cervical smear","Bayer","Female","18 Years to 35 Years   (Adult)","Phase 3","1113","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","91353|308021","March 2004",,"January 2006","September 16, 2005",,"December 31, 2014",,,"https://ClinicalTrials.gov/show/NCT00185484"
1319,"NCT00185458","Assessment of the Transfer of Using Levonorgestrel Intrauterine System (LNG IUS) as a Contraceptive to Using it as Part of Hormone Replacement Therapy (HRT).",,"Completed","Has Results","Menopause","Drug: LNG IUS","Number of Bleeding Days|Number of Spotting Days|Percentage of Participants With Successful Treatment|Assessment of QOL as Measured by Women's Health Questionnaire|Continuation Rates|Progestogenic Symptom 1: Headache (as Measured by a Visual Analogue Scale (VAS))|Progestogenic Symptom 2: Depressive Mood (as Measured by a VAS)|Progestogenic Symptom 3: Acne or Greasy Skin (as Measured by a VAS)|Progestogenic Symptom 4: Nausea (as Measured by a VAS)|Progestogenic Symptom 5: Edema (as Measured by a VAS)|Progestogenic Symptom 6: Decreased Libido (as Measured by a VAS)|Climacteric Symptom 1: Hot Flushes (as Measured by a VAS)|Climacteric Symptom 2: Sweating Episodes (as Measured by a VAS)|Climacteric Symptom 3: Vaginal Dryness (as Measured by a VAS)|Climacteric Symptom 4: Sleep Problems (as Measured by a VAS)|Climacteric Symptom 5: Irritability (as Measured by a VAS)|Climacteric Symptom 6: Breast Tension (as Measured by a VAS)|Progestogenic Symptom 7: Hair Loss (as Measured by a VAS)|Progestogenic Symptom 8: Greasy Hair (as Measured by a VAS)","Bayer","Female","46 Years to 51 Years   (Adult)","Phase 3","394","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","90660|300400","May 2000","May 2008","May 2008","September 16, 2005","November 19, 2009","November 27, 2013","Gent, Belgium|HUY, Belgium|Espoo, Finland|Turku, Finland|Turku, Finland|Heerlen, Netherlands|Venlo, Netherlands|Zaandam, Netherlands|Zwijndrecht, Netherlands|Cambridge, Cambridgeshire, United Kingdom|Poole, Dorset, United Kingdom|Newcastle upon Tyne, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00185458"
1320,"NCT00185419","A Clinical Study on Yasmin® vs. Marvelon® in Chinese Women Requiring Contraception",,"Completed","No Results Available","Contraception","Drug: Yasmin|Drug: Marvelon","The primary efficacy variable is the comparison of cycle control from randomisation to cycle 13. This will be based on the number of subjects reporting at least 1 unexpected intracyclic bleeding episode between cycles 2 to 13.|Weight changes|Contraceptive reliability|Effects on skin condition|Changes in MDQ subscale scores|Adverse Events","Bayer","Female","20 Years to 35 Years   (Adult)","Phase 3","842","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","91330|308062","November 2003","March 2006","March 2006","September 16, 2005",,"January 14, 2009","ask Contact, China",,"https://ClinicalTrials.gov/show/NCT00185419"
1321,"NCT00185393","Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy",,"Completed","No Results Available","Lymphoma, Non-Hodgkin","Biological: Zevalin ([90]Y-ibritumomab tiuxetan, BAY86-5128)|Other: no treatment","Progression free survival|Clinical and molecular response rates|Overall survival|Quality of Life|Adverse events / Toxicity Grading|Clinical laboratory results|Vital signs / physical examination|ECG|Co-medication","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","414","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","90966|304820|NHL FIT","August 2001",,"February 2007","September 16, 2005",,"December 1, 2008","Antwerpen, Belgium|Brugge, Belgium|Bruxelles, Belgium|Gent, Belgium|Leuven, Belgium|Yvoir, Belgium|Edmonton, Alberta, Canada|Vancouver, British Columbia, Canada|Hamilton, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Aarhus, Denmark|Copenhagen, Denmark|Rennes, Bretagne, France|Angers Cedex 1, France|Besancon, France|Bordeaux, France|Creteil, France|Grenoble Cedex 9, France|Le Mans, France|Lille, France|Lyon, France|Paris Cedex 15, France|Pierre Benite, France|Rouen, France|Strasbourg, France|Tours, France|Tübingen, Baden-Wuerttemberg, Germany|Augsburg, Bayern, Germany|München, Bayern, Germany|Göttingen, Niedersachsen, Germany|Münster, Nordrhein-Westfalen / 298, Germany|Hamm, Nordrhein-Westfalen / 358, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Dresden, Sachsen, Germany|Hamburg, Germany|Bologna, BO, Italy|San Giovanni Rotondo, Foggia, Italy|Milano, MI, Italy|Milano, MI, Italy|Rozzano, MI, Italy|Pisa, PI, Italy|Torino, TO, Italy|Milano, Italy|Napoli, Italy|Palermo, Italy|Roma, Italy|Amersfoort, Netherlands|Amsterdam, Netherlands|Amsterdam, Netherlands|Den Haag, Netherlands|Eindhoven, Netherlands|Enschede, Netherlands|Groningen, Netherlands|Leiden, Netherlands|Maastricht, Netherlands|Nijmegen, Netherlands|Rotterdam, Netherlands|Utrecht, Netherlands|Zwolle, Netherlands|Oslo, Norway|Tromso, Norway|Coimbra, Portugal|Lisboa, Portugal|Lisboa, Portugal|Porto, Portugal|Hospitalet de Llobregat, Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Malaga, Spain|Salamanca, Spain|Valencia, Spain|Göteborg, Sweden|Umeå, Sweden|Uppsala, Sweden|Zürich, Bern / 633, Switzerland|St. Gallen, St. Gallen / 633, Switzerland|Aarau, Switzerland|Bellinzona, Switzerland|Bern, Switzerland|Geneva, Switzerland|Lausanne, Switzerland|Glasgow, United Kingdom|London, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Newcastle-Upon-Tyne, United Kingdom|Plymouth, United Kingdom|Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00185393"
1322,"NCT00185380","Dose-finding Study for the Ultralow-dose Levonorgestrel Intrauterine Contraceptive System (LCS)",,"Completed","Has Results","Contraception","Drug: Levonorgestrel IUS (BAY86-5028, G04209B)|Drug: Levonorgestrel IUS (BAY86-5028, G04209C)|Drug: Levonorgestrel IUS (Mirena, BAY86-5028)","Pearl Index|Number of Subjects With Total or Partial Expulsions|Bleeding Pattern by 90-day Reference Periods - Reference Period 1|Bleeding Pattern by 90-day Reference Periods - Reference Period 2|Bleeding Pattern by 90-day Reference Periods - Reference Period 3|Bleeding Pattern by 90-day Reference Periods - Reference Period 4|Bleeding Pattern by 90-day Reference Periods - Reference Period 12","Bayer","Female","21 Years to 40 Years   (Adult)","Phase 2","742","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","91412|2004-002291-42|308901","April 2005","December 2008","December 2008","September 16, 2005","March 10, 2010","June 10, 2015","Espoo, Finland|Helsinki, Finland|Joensuu, Finland|Jyväskylä, Finland|Kotka, Finland|Kuopio, Finland|Lahti, Finland|Oulu, Finland|Oulu, Finland|Oulu, Finland|Tampere, Finland|Turku, Finland|Turku, Finland|Turku, Finland|Bekescsaba, Hungary|Eger, Hungary|Nyiregyhaza, Hungary|Szeged, Hungary|Drammen, Norway|Elverum, Norway|Kolbotn, Norway|Larvik, Norway|Oslo, Norway|Trondheim, Norway|Göteborg, Sweden|Huddinge, Sweden|Kalmar, Sweden|Luleå, Sweden|Norrköping, Sweden|Stockholm, Sweden|Umeå, Sweden|Örebro, Sweden|Chesterfield, Derbyshire, United Kingdom|Sheffield, South Yorkshire, United Kingdom|Chesterfield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00185380"
1323,"NCT00185367","Comparative Cycle Control Europe",,"Completed","No Results Available","Contraception","Drug: EV/DNG (Qlaira, BAY86-5027, SH T00658K)|Drug: SH D 593 B (Miranova)","Bleeding pattern|Number of unintended pregnancies|Adverse event collection","Bayer","Female","18 Years to 50 Years   (Adult)","Phase 3","798","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","90883|EudraCT: 2004-001613-34|304004","March 2005",,"September 2006","September 16, 2005",,"July 15, 2011","Soukroma gynekologicka ambulance, Fulnek, Czech Republic|Soukroma gynekologicka ambulance, Ostrava - Zabreh, Czech Republic|Soukroma gynekologicka ambulance, Plzen, Czech Republic|Provozorna Gynekologicka ordinace Dr. Tesar, Praha 10, Czech Republic|Femina Sana s.r.o, Praha, Czech Republic|Dr. Jocelyne Nataf-Maurin, Brignoles, France|Dr. Marie-Helene Malbranche-Aupecle, Dijon, France|Centre Hospitalier de l Estuaire, Honfleur, France|Dr. Annette Mercier, Morlaix, France|Clinique d Occitanie, Muret, France|Centre Medical du Val de Loire, Nevers, France|Dr. Anne-Isabelle Richet, Paris, France|Cabinet medical, Quetigny, France|Dr. Gwendoline Servan, Tarare, France|Dr. Aliette Siboni-Frisch, Toulouse, France|Frauenarztpraxis Dr. Buchberger, Neubiberg, Bayern, Germany|Praxis Hr. Dr. R. Kuett, Nürnberg, Bayern, Germany|Praxis Dr. Larbig, Fulda, Hessen, Germany|Praxis Fr. Dr. J. Schmidt-Pich, Hannover, Niedersachsen, Germany|Frauenarztpraxis Dr. Wetzel, Blankenburg, Sachsen-Anhalt, Germany|Frauenarztpraxis Dipl. med. Michael Stellmacher, Burg, Sachsen-Anhalt, Germany|Praxis Fr. Dr. A. Braune, Magdeburg, Sachsen-Anhalt, Germany|Praxis Hr. Prof. Dr. H.-J. Ahrendt, Magdeburg, Sachsen-Anhalt, Germany|Praxis Fr. Dr. K. Kopprasch, Dresden, Sachsen, Germany|Praxis Fr. R. Hellmich, Dresden, Sachsen, Germany|Praxis Fr. Dr. A. Münzberger, Döbeln, Sachsen, Germany|Frauenarztpraxis Dr. Bernd Pittner, Leipzig, Sachsen, Germany|Praxis Fr. Dr. C. Burgkhardt, Leipzig, Sachsen, Germany|Praxis Hr. R. Wähnert, Gera, Thüringen, Germany|Praxis Fr. Dr. A.Mönch-Hering, Kahla, Thüringen, Germany|Frauenarztpraxis Hr. Dr. H. Lindecke, Berlin, Germany|Praxis Fr. Dr. B. Heuberger, Berlin, Germany|Praxis Hr. Dr. Karl-Heinz Belling, Berlin, Germany|Frauenarztpraxis Hr. Dr. B. Hamann, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT00185367"
1324,"NCT00185354","FC Patch Comparator Study",,"Completed","No Results Available","Contraception","Drug: BAY86-5016, SH P00331F|Drug: SH P00331N","Bleeding pattern and cycle control|Number of pregnancies|Adverse events collection|Endometrial biopsy|Physical and gynecological exam","Bayer","Female","18 Years to 35 Years   (Adult)","Phase 3","422","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","91402|2004-000821-31|307969","November 2004","April 2006","April 2006","September 16, 2005",,"December 31, 2015","Wörgl, Tirol, Austria|Bregenz, Austria|Graz, Austria|Wien, Austria|Wien, Austria|Zeltweg, Austria|Helsinki, Finland|Helsinki, Finland|Turku, Finland|Turku, Finland|Biarritz, France|Bordeaux, France|COMPIEGNE cedex, France|Compiegne, France|Maisons lafitte, France|Montargis, France|Nancy Cedex, France|Pantin, France|Paris, France|Roanne, France|Saint Germain En Laye, France|Toulouse, France|San Fernando, Cádiz, Spain|Pontevedra, Galicia, Spain|Salt, Girona, Spain|Barcelona, Spain|Guadalajara, Spain|Santiago de Compostela, Spain",,"https://ClinicalTrials.gov/show/NCT00185354"
1325,"NCT00185341","Study to Investigate the Efficacy of a Non-hormonal Drug Against Endometriosis Associated Pelvic Pain",,"Completed","No Results Available","Endometriosis","Drug: CCR1-Antagonist (BAY86-5047, ZK811752)|Drug: Placebo","Individual absolute change in endometriosis associated pelvic pain (EAPP)|Individual change in intake of rescue medication|Number of participants with adverse events","Bayer","Female","18 Years to 45 Years   (Adult)","Phase 2","110","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","91399|2004-000630-37|308601","February 2005","February 2007","February 2007","September 16, 2005",,"May 2, 2016","Hradec Kralove, Czech Republic|Praha, Czech Republic|Praha, Czech Republic|Praha, Czech Republic|Aarhus, Denmark|Glostrup, Denmark|Helsinki, Finland|Helsinki, Finland|Joensuu, Finland|Kuopio, Finland|Oulu, Finland|Turku, Finland|Bordeaux, France|Clermont Ferrand, France|Lyon, France|Amsterdam, Netherlands|Amsterdam, Netherlands|Maastricht, Netherlands|Nijmegen, Netherlands|Oviedo, Asturias, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Sevilla, Spain|Valencia, Spain|Göteborg, Sweden|Lund, Sweden|Skövde, Sweden|Stockholm, Sweden|Stockholm, Sweden|Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT00185341"
1326,"NCT00185328","Efficacy and Tolerability of Angeliq in Thai Women",,"Completed","No Results Available","Postmenopause","Drug: Estradiol/DRSP (Angeliq, BAY86-4891)","The relative change in the frequency of hot flushes|The change in intensity of hot flushes|The relative change in frequency of hot flushes|The proportions of subjects with urogenital symptoms|Bleeding pattern|Adverse events collection","Bayer","Female","45 Years and older   (Adult, Older Adult)","Phase 4","55","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","91436|309367","September 2005",,"December 2006","September 16, 2005",,"December 12, 2008",,,"https://ClinicalTrials.gov/show/NCT00185328"
1327,"NCT00185315","Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary Hypertension",,"Completed","No Results Available","Hypertension, Pulmonary","Drug: Ventavis (Iloprost, BAYQ6256)","Adverse events|Tolerability of treatment","Bayer","All","18 Years to 71 Years   (Adult, Older Adult)","Phase 3","71","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","90570|303045|Follow-up 90419-300180","February 2000",,"August 2005","September 16, 2005",,"April 20, 2010","Bruxelles, Belgium|Leuven, Belgium|Clamart Cedex, France|Grenoble Cedex 9, France|Lille, France|Reims, France|Tours Cedex, France|Bologna, BO, Italy|Montescano, Pavia, Italy|Pisa, PI, Italy|Amsterdam, Netherlands|Warszawa, Poland|Coimbra, Portugal|Vila Nova de Gaia, Portugal|Barcelona, Spain|Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT00185315"
1328,"NCT00185302","Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma",,"Completed","No Results Available","Melanoma","Drug: Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)","Overall tumor response rate (the proportion of subjects with the best tumor response of PR or CR within the first 6 cycles of treatment)|Time to tumor progression|Survival|Tumor response rate at each tumor assessment time point (CR/PR/SD/PD/not assessable)|Time to death|Number of participants with adverse events","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","91410|2004-002395-41|309100","December 2004","July 2006","July 2006","September 16, 2005",,"December 14, 2015",,,"https://ClinicalTrials.gov/show/NCT00185302"
1329,"NCT00185289","Study to Investigate Efficacy and Safety of a New Oral Contraceptive",,"Completed","No Results Available","Contraception","Drug: EV/DNG (Qlaira, BAY86-5027, SH T00658K)","Number of unintended pregnancies|Adverse event collection","Bayer","Female","18 Years to 50 Years   (Adult)","Phase 3","1392","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","91191|EudraCT: 2004-002098-22|306660","April 2004",,"July 2006","September 16, 2005",,"July 15, 2011","Dr. Max Stiglbauer, Wiener Neustadt, Niederösterreich, Austria|Praxis Dr. Langer, Fuerstenfeld, Steiermark, Austria|Dr. Meusburger, Wolfurt, Vorarlberg, Austria|Landeskrankenhaus Bregenz, Bregenz, Austria|Dr. Roswitha Wessely, Graz, Austria|Institut für Hormonstörungen und Kinderwunsch, Graz, Austria|Praxis Dr. Gudrun Lorenz-Eberhard, Graz, Austria|Praxis Dr. Hannes Kahr, Graz, Austria|Universitätsklinikum Innsbruck, Innsbruck, Austria|Dr. Peter Mayr, Kufstein, Austria|Dr. Michaela Boeckl, Salzburg, Austria|Dr. Sigrid Schmidl-Amann, St. Poelten, Austria|Dr. Guenther Heytmanek, Wien, Austria|Dr. Ewald Boschitsch, Wien, Austria|Dr. Brigitte Wiesenthal, Wien, Austria|Allgemeines Krankenhaus der Stadt Wien Universitätskliniken, Wien, Austria|Dr. Wolfgang Bartl, Wien, Austria|Dr. Walter Paulik, Zeltweg, Austria|Praxis Hr. Dr. A. Soder, Ettlingen, Baden-Württemberg, Germany|Praxis Hr. Dr. U. Kohoutek, Karlsruhe, Baden-Württemberg, Germany|Praxis Hr. Dr. L. Weihe, Ansbach, Bayern, Germany|Frauenarztpraxis Dr. med. Wolfram Brach, Dietzenbach, Hessen, Germany|Praxis Hr. Dr. Werner Göttker-Schnetmann, Frankfurt, Hessen, Germany|Praxis Dr. S. El Tobgui-Jensen, Frankfurt, Hessen, Germany|Praxis Dr. S. Clauss-Hoffmann, Frankfurt, Hessen, Germany|Praxis Hr. Dr. P. Schwaner, Frankfurt, Hessen, Germany|Praxis Dr. Kindt, Langen, Hessen, Germany|Praxis Fr. Dr. J. Tyagi, Mühlheim, Hessen, Germany|Praxis Hr. Dr. H. Zabel, Bovenden, Niedersachsen, Germany|Praxis Hr. Dr. K. Brauns, Hameln, Niedersachsen, Germany|Praxis Hr. Dr. K. Greven, Hannover, Niedersachsen, Germany|Praxis Hr. Dr. H. Frommeyer, Osnabrück, Niedersachsen, Germany|Frauenarztpraxis Dr. Schoenberg, Rheine, Nordrhein-Westfalen, Germany|Praxis Hr. H. Thelen, Jessen, Sachsen-Anhalt, Germany|Frauenarztpraxis Dr. med. Gabriele Weinreich, Magdeburg, Sachsen-Anhalt, Germany|Praxis Fr. I. Gröger, Wurzen, Sachsen, Germany|Praxis Hr. Dr. R. Etzrodt, Gera, Thüringen, Germany|Frauenarztpraxis Fr. Dr. H. Schlegel, Saalfeld, Thüringen, Germany|Dinox GmbH Berlin, Berlin, Germany|Charité Campus Benjamin Franklin, Berlin, Germany|Frauenarztpraxis Fr. Dr. S. Gramatte, Berlin, Germany|Praxis Fr. Dr. B. Wernecke, Berlin, Germany|Praxis Fr. Dr. I. Hannig, Berlin, Germany|Praxis Fr. Dr. K. Maar, Berlin, Germany|Praxis Hr. Dr. D. Rautenberg, Hamburg, Germany|Diatros Gava- Centre Assistencial Ntra. Sra. de Burgues, Gava, Barcelona, Spain|Hospital Universitario MAterno Infantil de Canarias, Las Palmas, Gran Canaria, Spain|USP Institut Universitari Dexeus, Barcelona, Spain|Instituto Palacios de Salud y Medicina de la Mujer, Madrid, Spain|Complejo Hospitalario Ntra. Sra. de Valme, Sevilla, Spain",,"https://ClinicalTrials.gov/show/NCT00185289"
1330,"NCT00185276","Magnevist® Injection Enhanced MRA at Two Dose Levels Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Infrarenal Aorta and Peripheral Arteries",,"Completed","No Results Available","Peripheral Vascular Disease","Drug: Gadopentetate dimeglumine (Magnevist, BAY86-4882)","Sensitivity, specificity and accuracy of the higher dose of Magnevist® Injection and 2D-TOF MRA for the detection of clinically significant disease|Diagnostic confidence|Visual assessment of stenosis|Difference in degree of stenosis|Other diagnostic findings|Image quality|Image evaluability and presence of artifacts|Ability to visualize arterial segments|Number of evaluable segments|Location and matching of stenosis|SI measurements|Patient management|Safety","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","365","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","91208|306781","March 2003",,"August 2004","September 16, 2005",,"December 30, 2014",,,"https://ClinicalTrials.gov/show/NCT00185276"
1331,"NCT00185250","Betaferon/ Betaseron (Interferon Beta-1b) in Patients With Chronic Viral Cardiomyopathy",,"Completed","No Results Available","Cardiomyopathies|Heart Diseases","Drug: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|Drug: Placebo","Presence of Adenovirus, Enterovirus and/or Parvovirus in endomyocardium|Changes in NYHA functional class|Six-minute walking test|Single clinical symptoms (dyspnea, fatigue, palpitation, atypical angina and angina pectoris)|Quality of life|Left ventricular ejection fraction at rest and on exertion|Regional and global wall motion, left ventricular enddiastolic diameter, and left ventricular endsystolic diameter|Inflammatory state in endomyocardial biopsies|Peripheral blood analyses for viral treatment effect and disease markers|Composite clinical endpoint|Hemodynamics","Bayer","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","138","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","91115|305852","December 2002",,"November 2005","September 16, 2005",,"December 19, 2008","Nantes, France|Poitiers Cedex, France|Bad Krozingen, Baden-Württemberg, Germany|Ulm, Baden-Württemberg, Germany|München, Bayern, Germany|Greifswald, Mecklenburg-Vorpommern, Germany|Rostock, Mecklenburg-Vorpommern, Germany|Göttingen, Niedersachsen, Germany|Bad Oeynhausen, Nordrhein-Westfalen, Germany|Dortmund, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Wuppertal, Nordrhein-Westfalen, Germany|Ludwigshafen, Rheinland-Pfalz, Germany|Homburg, Saarland, Germany|Halle, Sachsen-Anhalt, Germany|Leipzig, Sachsen, Germany|Kiel, Schleswig-Holstein, Germany|Bad Berka, Thüringen, Germany|Berlin, Germany|Brandenburg, Germany|Hamburg, Germany|Bergamo, BG, Italy|Milano, MI, Italy|Pavia, Italy|Warszawa, Poland|Warszawa, Poland|Madrid, Spain|Göteborg, Sweden|Glasgow, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00185250"
1332,"NCT00185237","Treatment of Hot Flushes in Asian Women With Ultra-low Dose Estradiol Patch",,"Completed","No Results Available","Hot Flashes","Drug: Menostar (estradiol transdermal delivery system)|Drug: Placebo","Relative change in frequency of hot flushes|Change in intensity of hot flushes|Changes in vaginal pH|Changes in vaginal maturation index|Occurrence of urogenital symptoms|Change in MENQOL (menopausal quality of life questionaire)|Bleeding profile|Safety","Bayer","Female","45 Years to 65 Years   (Adult, Older Adult)","Phase 3","165","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","91441|309120","July 2005","November 2006","November 2006","September 16, 2005",,"December 23, 2014",,,"https://ClinicalTrials.gov/show/NCT00185237"
1333,"NCT00185224","Metabolism Study to Investigate the Impact of a Sequential Oral Contraceptive",,"Completed","No Results Available","Contraception","Drug: EV/DNG (Qlaira, BAY86-5027, SH T00658K)|Drug: SH D00264A (Triquilar)","Impact on metabolic parameters (e.g. hemostatic parameters) after 6 month treatment|Measurement of PK parameters","Bayer","Female","18 Years to 50 Years   (Adult)","Phase 2","58","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","90927|EudraCT: 2004-001614-13|301886","March 2005",,"March 2006","September 16, 2005",,"July 15, 2011","Bayer Schering Pharma AG - Clin. Pharm. Berlin, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT00185224"
1334,"NCT00185211","BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study",,"Completed","Has Results","Multiple Sclerosis","Drug: Interferon beta-1b (Betaseron, BAY86-5046)","Time to Clinically Definite Multiple Sclerosis (CDMS) Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With CDMS at Selected Points in Time|Time to Confirmed Expanded Disability Status Scale (EDSS) Progression Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With Confirmed EDSS Progression at Selected Points in Time|Functional Assessment of Multiple Sclerosis (FAMS) Trial Outcome Index (TOI) at Month 60|Relapse-based Efficacy Domain: Time to Multiple Sclerosis (MS) According to McDonald Criteria|Relapse-based Efficacy Domain: Hazard Ratio for Recurrent Relapses|Relapse-based Efficacy Domain (Supportive): Annualized Relapse Rate|Disability-based Efficacy Domain: Multiple Sclerosis Functional Composite (MSFC) at Month 60|MRI (Magnet-Resonance Imaging)-Based Efficacy Domain: Cumulative Number of Newly Active Lesions at Month 60|MRI-based Efficacy Domain: Absolute Change of T2 Lesion Volume From Screening MRI to Month 60|MRI-based Efficacy Domain: Absolute Change of Volume of Black Holes From Screening MRI to Month 60|MRI-based Efficacy Domain: Percentage Change of Brain Volume From Screening MRI to Month 60","Bayer","All","18 Years to 48 Years   (Adult)","Phase 3","468","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","91031|305207","August 2002","May 2008","May 2008","September 16, 2005","November 30, 2010","December 30, 2013","Graz, Austria|Innsbruck, Austria|Wien, Austria|Bruxelles, Belgium|Gent, Belgium|Leuven, Belgium|Liège 1, Belgium|Calgary, Alberta, Canada|Vancouver, British Columbia, Canada|London, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Brno, Czech Republic|Hradec Kralove, Czech Republic|Ostrava, Czech Republic|Plzen, Czech Republic|Prag, Czech Republic|Prag, Czech Republic|Glostrup, Denmark|Helsinki, Finland|Kuopio, Finland|Oulu, Finland|Seinäjoki, Finland|Tampere, Finland|Turku, Finland|Rennes, Bretagne, France|Bordeaux, Gironde, France|Clermont ferrand, France|Dijon, France|Lille, France|Nancy, France|Nice, France|Paris, France|Toulouse, France|Ulm, Baden-Württemberg, Germany|München, Bayern, Germany|Regensburg, Bayern, Germany|Würzburg, Bayern, Germany|Hennigsdorf, Brandenburg, Germany|Gießen, Hessen, Germany|Marburg, Hessen, Germany|Offenbach, Hessen, Germany|Greifswald, Mecklenburg-Vorpommern, Germany|Braunschweig, Niedersachsen, Germany|Göttingen, Niedersachsen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Homburg, Saarland, Germany|Halle, Sachsen-Anhalt, Germany|Magdeburg, Sachsen-Anhalt, Germany|Erfurt, Thüringen, Germany|Berlin, Germany|Berlin, Germany|Szeged, Csongrad, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Haifa, Israel|Tel Hashomer, Israel|Gallarate, Varese, Italy|Milano, Italy|Padova, Italy|Pavia, Italy|Torino, Italy|Sittard, Netherlands|Tilburg, Netherlands|Bergen, Norway|Bydgoszcz, Poland|Krakow, Poland|Lodz, Poland|Lublin, Poland|Wroclaw, Poland|Coimbra, Portugal|Lubljana, Slovenia|Hospitalet de Llobregat, Barcelona, Spain|Barakaldo, Vizcaya, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Malaga, Spain|Sevilla, Spain|Valencia, Spain|Göteborg, Sweden|Basel, Basel-Stadt, Switzerland|St. Gallen, Switzerland|Dundee, Scotland, United Kingdom|Aberdeen, United Kingdom|London, United Kingdom|Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00185211"
1335,"NCT00185198","Efficacy and Safety of Testogel® in Men With Partial Androgen Deficiency of Aging Males (PADAM)",,"Completed","No Results Available","Androgens (Deficiency)|Male","Drug: Testogel (Testosterone, BAYV001915)|Drug: Placebo","Lean body mass at 6 months|Change in total body mass, fat mass and bone density|Evaluation of symptoms by the aging males symptoms rating scale|Change in testosterone|Safety parameters","Bayer","Male","50 Years to 80 Years   (Adult, Older Adult)","Phase 3","363","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","91297|2004-001545-15|307720","September 2004","September 2006","October 2007","September 16, 2005",,"April 2, 2014","Graz, Austria|Innsbruck, Austria|Salzburg, Austria|Wien, Austria|Wien, Austria|Helsinki, Finland|Oulu, Finland|Tampere, Finland|Bonn, Nordrhein-Westfalen, Germany|Halle, Sachsen-Anhalt, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Magdeburg, Germany|Dublin, Ireland|Milano, Italy|Napoli, Italy|Roma, Italy|Roma, Italy|Hospitalet de Llobregat, Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Goteborg, Sweden|Malmo, Sweden|Stockholm, Sweden|Reading, Berkshire, United Kingdom|Wigan, Manchester, United Kingdom|Cardiff, United Kingdom|London, United Kingdom|London, United Kingdom|Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00185198"
1336,"NCT00160069","Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non-small-cell Lung Cancer",,"Completed","No Results Available","Carcinoma, Non Small Cell Lung","Drug: Sagopilone (BAY86-5302, ZK 219477)","The primary efficacy variable is defined as Proportion of patients with either CR or PR as 'best overall response'. Tumor assessment is performed according to RECIST criteria.|Secondary objectives : investigate the safety and tolerability of ZK 219477","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","128","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","91374|2005-000586-19|307971","August 2005","April 2008","April 2009","September 12, 2005",,"December 4, 2014","Löwenstein, Baden-Württemberg, Germany|Augsburg, Bayern, Germany|Gauting, Bayern, Germany|Nürnberg, Bayern, Germany|Frankfurt, Hessen, Germany|Frankfurt, Hessen, Germany|Greifswald, Mecklenburg-Vorpommern, Germany|Stralsund, Mecklenburg-Vorpommern, Germany|Halle, Sachsen-Anhalt, Germany|Magdeburg, Sachsen-Anhalt, Germany|Leipzig, Sachsen, Germany|Großhansdorf, Schleswig-Holstein, Germany|Berlin, Germany|Berlin, Germany|Bremen, Germany|Ebensfeld, Germany|Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT00160069"
1337,"NCT00160043","Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non Small Cell Lung Cancer.",,"Completed","No Results Available","Non Small Cell Lung Cancer","Drug: SH T00268C|Drug: PTK787/ ZK 222584","Tumor response rate (complete or partial response according to RECIST).|Time to disease progression.","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","112","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","91411|2004-002290-22|308801","March 2005","August 2007","November 2008","September 12, 2005",,"December 16, 2014","Paris, France|Paris, France|Villejuif, France|Göttingen, Niedersachsen, Germany|Essen, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany",,"https://ClinicalTrials.gov/show/NCT00160043"
1338,"NCT00119639","Study to Evaluate the Effect of Renal Function on the Single-Dose Pharmacokinetics of BAY 43-9006",,"Completed","No Results Available","Kidney Diseases","Drug: Sorafenib (BAY43-9006, Nexavar)","Pharmacokinetics of sorafenib in plasma and urine; single-dose safety of sorafenib in patients with renal impairment","Bayer","All","40 Years to 75 Years   (Adult, Older Adult)","Phase 1","32","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","11804","June 2005",,"December 2005","July 14, 2005",,"January 16, 2009",,,"https://ClinicalTrials.gov/show/NCT00119639"
1339,"NCT00117637","BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma",,"Completed","Has Results","Carcinoma, Renal Cell","Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Interferon","Progression-free Survival (PFS) Based on Independent Radiological Review for the First Intervention Period|Progression-free Survival (PFS) Based on Investigator Assessment for the First Intervention Period|Disease Control (DC) According to Independent Central Review for the First Intervention Period|Disease Control (DC) According to the Investigator Assessment for the First Intervention Period|Disease Control (DC) According to the Investigator Assessment for the Second Intervention Period|Analysis of the Quality of Life by Use of the Respiratory Domain of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI) After Intervention for the First Intervention Period|Analysis of the Quality of Life by Use of the Respiratory Domain of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI) for the Second Intervention Period|Analysis of the Quality of Life by Use of Total Score of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI) for the First Intervention Period|Analysis of the Quality of Life by Use of Total Score of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI) for the Second Intervention Period|Analysis of the Quality of Life (QoL) by Use of Functional Assessment of Cancer Therapy-Biologic-response Modifiers (FACT-BRM) for the First Intervention Period|Analysis of the Quality of Life (QoL) by Use of Functional Assessment of Cancer Therapy-Biologic-response Modifiers (FACT-BRM) for the Second Intervention Period|Analysis of the Treatment Tolerability (Effectiveness) by Use of Treatment Satisfaction Questionnaire for Medication (TSQM) for the First Intervention Period|Analysis of the Treatment Tolerability (Side Effects) by Use of Treatment Satisfaction Questionnaire for Medication (TSQM) for the First Intervention Period|Analysis of the Treatment Tolerability (Convenience) by Use of Treatment Satisfaction Questionnaire for Medication (TSQM) for the First Intervention Period|Analysis of the Treatment Tolerability (Global Satisfaction) by Use of Treatment Satisfaction Questionnaire for Medication (TSQM) for the First Intervention Period|Analysis of the Treatment Tolerability (Effectiveness) by Use of Treatment Satisfaction Questionnaire for Medication (TSQM) for the Second Intervention Period|Analysis of the Treatment Tolerability (Side Effects) by Use of Treatment Satisfaction Questionnaire for Medication (TSQM) for the Second Intervention Period|Analysis of the Treatment Tolerability (Convenience) by Use of Treatment Satisfaction Questionnaire for Medication (TSQM) for the Second Intervention Period|Analysis of the Treatment Tolerability (Global Satisfaction) by Use of Treatment Satisfaction Questionnaire for Medication (TSQM) for the Second Intervention Period|Tumor Response According to the Independent Radiological Review for the First Intervention Period|Tumor Response According to the Investigator Assessment for the First Intervention Period|Tumor Response According to the Investigator Assessment for the Second Intervention Period|Progression Free Survival According to the Investigator Assessment (Second Intervention Period)|Overall Survival (OS)|Slope - Change in Trough Concentration/Cycle|Average of All Trough Plasma Concentrations|Duration of Response According to the Independent Radiological Review for the First Intervention Period|Duration of Response According to the Investigator Assessment for the First Intervention Period|Duration of Response According to the Investigator Assessment for the Second Intervention Period|Time to Response According to the Independent Radiological Review for the First Intervention Period|Time to Response According to the Investigator Assessment for the First Intervention Period|Time to Response According to the Investigator Assessment for the Second Intervention Period|Analysis of the Eastern Co-operative Oncology Group (ECOG) Status at the End of the First Intervention Period|Analysis of the Eastern Co-operative Oncology Group (ECOG) Status at the End of the Second Intervention Period","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","189","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11848|2005-000544-86","June 2005","September 2006","March 2009","July 8, 2005","December 15, 2010","October 31, 2014","Sacramento, California, United States|Aurora, Colorado, United States|Chicago, Illinois, United States|Frederick, Maryland, United States|Las Vegas, Nevada, United States|Cleveland, Ohio, United States|Portland, Oregon, United States|Dallas, Texas, United States|Seattle, Washington, United States|Bordeaux, France|Lille Cedex, France|Lyon Cedex, France|Marseille, France|Nantes, France|Paris Cedex 15, France|Toulouse, France|Villejuif, France|Ulm, Baden-Württemberg, Germany|München, Bayern, Germany|Frankfurt, Hessen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Berlin, Germany|Hamburg, Germany|Gdansk, Poland|Krakow, Poland|Poznan, Poland|Szczecin, Poland|Warszawa, Poland|Warszawa, Poland|Wroclaw, Poland|Kazan, Russian Federation|Kirov, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|St. Petersburg, Russian Federation|Donetsk, Ukraine|Kharkiv, Ukraine|Kiev, Ukraine|Lviv, Ukraine|Sutton, Surrey, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00117637"
1340,"NCT00111020","Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma",,"Completed","No Results Available","Carcinoma, Renal Cell","Drug: Sorafenib (Nexavar, BAY43-9006)","Safety parameters|Limited radiological evaluations","Bayer","All","15 Years and older   (Child, Adult, Older Adult)","Phase 3","2567","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11868","June 2005","June 2007","October 2008","May 17, 2005",,"August 6, 2014","Bessemer, Alabama, United States|Cullman, Alabama, United States|Mobile, Alabama, United States|Anchorage, Alaska, United States|Glendale, Arizona, United States|Scottsdale, Arizona, United States|Tucson, Arizona, United States|Conway, Arkansas, United States|Hot Springs, Arkansas, United States|Little Rock, Arkansas, United States|Pine Bluff, Arkansas, United States|Springdale, Arkansas, United States|Bakersfield, California, United States|Beverly, California, United States|Concord, California, United States|Duarte, California, United States|Fountain Valley, California, United States|Glendale, California, United States|Highland, California, United States|La Jolla, California, United States|La Jolla, California, United States|Loma Linda, California, United States|Long Beach, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|Newport Beach, California, United States|Orange, California, United States|Rancho Mirage, California, United States|Sacramento, California, United States|Salinas, California, United States|San Diego, California, United States|San Francisco, California, United States|Stanford, California, United States|Sunnyvale, California, United States|Vallejo, California, United States|Aurora, Colorado, United States|Colorado Springs, Colorado, United States|Denver, Colorado, United States|Denver, Colorado, United States|Glenwood Springs, Colorado, United States|Lafayette, Colorado, United States|Loveland, Colorado, United States|Greenwich, Connecticut, United States|Hartford, Connecticut, United States|Middletown, Connecticut, United States|New Britain, Connecticut, United States|New Haven, Connecticut, United States|Norwich, Connecticut, United States|Southington, Connecticut, United States|Stamford, Connecticut, United States|Trumbull, Connecticut, United States|Boca Raton, Florida, United States|Daytona Beach, Florida, United States|Fort Myers, Florida, United States|Ft Lauderdale, Florida, United States|Gainesville, Florida, United States|Hialeah, Florida, United States|Jacksonville, Florida, United States|Lakeland, Florida, United States|Melbourne, Florida, United States|Miami Beach, Florida, United States|Miami, Florida, United States|Ocala, Florida, United States|Ocoee, Florida, United States|Orlando, Florida, United States|Ormond Beach, Florida, United States|Panama City, Florida, United States|Pensacola, Florida, United States|Pensacola, Florida, United States|St Petersburg, Florida, United States|Stuart, Florida, United States|Tampa, Florida, United States|Weston, Florida, United States|Albany, Georgia, United States|Atlanta, Georgia, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Columbus, Georgia, United States|Macon, Georgia, United States|Tamc, Hawaii, United States|Coeur D Alene, Idaho, United States|Chicago, Illinois, United States|Chicago, Illinois, United States|Decatur, Illinois, United States|Harvey, Illinois, United States|Joliet, Illinois, United States|Joliet, Illinois, United States|Niles, Illinois, United States|Peoria, Illinois, United States|Springfield, Illinois, United States|Urbana, Illinois, United States|Beech Grove, Indiana, United States|Evansville, Indiana, United States|Fishers, Indiana, United States|Goshen, Indiana, United States|Indianapolis, Indiana, United States|Indianapolis, Indiana, United States|Kokomo, Indiana, United States|Laporte, Indiana, United States|South Bend, Indiana, United States|Valparaiso, Indiana, United States|Ames, Iowa, United States|Cedar Rapids, Iowa, United States|Cedar Rapids, Iowa, United States|Council Bluffs, Iowa, United States|Des Moines, Iowa, United States|Dubuqe, Iowa, United States|Sioux City, Iowa, United States|Hutchinson, Kansas, United States|Lawrence, Kansas, United States|Olathe, Kansas, United States|Overland Park, Kansas, United States|Wichita, Kansas, United States|Louisville, Kentucky, United States|Louisville, Kentucky, United States|Louisville, Kentucky, United States|Louisville, Kentucky, United States|Baton Rouge, Louisiana, United States|Houma, Louisiana, United States|Lafayette, Louisiana, United States|Metairie, Louisiana, United States|Shreveport, Louisiana, United States|Bangor, Maine, United States|Scarborough, Maine, United States|Annapolis, Maryland, United States|Baltimore, Maryland, United States|Baltimore, Maryland, United States|Baltimore, Maryland, United States|Bethesda, Maryland, United States|Chevy Chase, Maryland, United States|Clinton, Maryland, United States|Rockville, Maryland, United States|Boston, Massachusetts, United States|Jamaica Plain, Massachusetts, United States|Milford, Massachusetts, United States|Quincy, Massachusetts, United States|Springfield, Massachusetts, United States|Springfield, Massachusetts, United States|Ann Arbor, Michigan, United States|Clinton Township, Michigan, United States|Detroit, Michigan, United States|Detroit, Michigan, United States|Grand Rapids, Michigan, United States|Marquette, Michigan, United States|MT Clemens, Michigan, United States|Muskegon, Michigan, United States|Duluth, Minnesota, United States|Minneapolis, Minnesota, United States|St Louis Park, Minnesota, United States|St Louis Park, Minnesota, United States|Willmar, Minnesota, United States|Kansas City, Missouri, United States|Springfield, Missouri, United States|St Joseph, Missouri, United States|St Louis, Missouri, United States|St Louis, Missouri, United States|St Louis, Missouri, United States|Missoula, Montana, United States|Lincoln, Nebraska, United States|Lincoln, Nebraska, United States|North Platte, Nebraska, United States|Omaha, Nebraska, United States|Omaha, Nebraska, United States|Omaha, Nebraska, United States|Las Vegas, Nevada, United States|Las Vegas, Nevada, United States|Lebanon, New Hampshire, United States|Portsmouth, New Hampshire, United States|Belleville, New Jersey, United States|East Orange, New Jersey, United States|Hackensack, New Jersey, United States|Long Branch, New Jersey, United States|Montclair, New Jersey, United States|Morristown, New Jersey, United States|New Brunswick, New Jersey, United States|Newark, New Jersey, United States|Phillipsburg, New Jersey, United States|Summit, New Jersey, United States|Albuquerque, New Mexico, United States|Albuquerque, New Mexico, United States|Santa Fe, New Mexico, United States|Armonk, New York, United States|Bayshore, New York, United States|Bronx, New York, United States|Bronx, New York, United States|Buffalo, New York, United States|Cooperstown, New York, United States|Dunkirk, New York, United States|East Syracuse, New York, United States|Fresh Meadows, New York, United States|Glens Falls, New York, United States|Jamaica, New York, United States|Johnson City, New York, United States|Latham, New York, United States|Mineola, New York, United States|Mount Kisco, New York, United States|New York, New York, United States|New York, New York, United States|New York, New York, United States|Poughkeepsie, New York, United States|Rochester, New York, United States|Setauket, New York, United States|Stony Brook, New York, United States|Utica, New York, United States|Williamsville, New York, United States|Burlington, North Carolina, United States|Chapel Hill, North Carolina, United States|Charlotte, North Carolina, United States|Charlotte, North Carolina, United States|Greenville, North Carolina, United States|Hickory, North Carolina, United States|Kinston, North Carolina, United States|Pollocksville, North Carolina, United States|Bismarck, North Dakota, United States|Fargo, North Dakota, United States|Fargo, North Dakota, United States|Barberton, Ohio, United States|Canton, Ohio, United States|Canton, Ohio, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Columbus, Ohio, United States|Columbus, Ohio, United States|Dayton, Ohio, United States|Mayfield Heights, Ohio, United States|Middletown, Ohio, United States|Lawton, Oklahoma, United States|Midwest City, Oklahoma, United States|Oklahoma City, Oklahoma, United States|Tulsa, Oklahoma, United States|Bend, Oregon, United States|Medford, Oregon, United States|Portland, Oregon, United States|Portland, Oregon, United States|Allentown, Pennsylvania, United States|Bethlehem, Pennsylvania, United States|Dunmore, Pennsylvania, United States|East Stroudsburg, Pennsylvania, United States|Harrisburg, Pennsylvania, United States|Hermitage, Pennsylvania, United States|Kittanning, Pennsylvania, United States|Lancaster, Pennsylvania, United States|Lemoyne, Pennsylvania, United States|Monongahela, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pottsville, Pennsylvania, United States|State College, Pennsylvania, United States|Wynnewood, Pennsylvania, United States|York, Pennsylvania, United States|Cranston, Rhode Island, United States|Charleston, South Carolina, United States|Charleston, South Carolina, United States|Columbia, South Carolina, United States|Florence, South Carolina, United States|North Charleston, South Carolina, United States|Sioux Falls, South Dakota, United States|Clarksville, Tennessee, United States|Memphis, Tennessee, United States|Memphis, Tennessee, United States|Memphis, Tennessee, United States|Nashville, Tennessee, United States|Amarillo, Texas, United States|Arlington, Texas, United States|Austin, Texas, United States|Austin, Texas, United States|Austin, Texas, United States|Dallas, Texas, United States|Dallas, Texas, United States|Dallas, Texas, United States|Fort Worth, Texas, United States|Houston, Texas, United States|Midland, Texas, United States|San Antonio, Texas, United States|San Antonio, Texas, United States|San Antonio, Texas, United States|Temple, Texas, United States|Tyler, Texas, United States|Tyler, Texas, United States|Ogden, Utah, United States|Salt Lake City, Utah, United States|Bennington, Vermont, United States|Charlottesville, Virginia, United States|Fairfax, Virginia, United States|Lynchburg, Virginia, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Richmond, Virginia, United States|Richmond, Virginia, United States|Richmond, Virginia, United States|Richmond, Virginia, United States|Lacey, Washington, United States|Seattle, Washington, United States|Seattle, Washington, United States|Tacoma, Washington, United States|Vancouver, Washington, United States|Yakima, Washington, United States|Charleston, West Virginia, United States|Huntington, West Virginia, United States|Morgantown, West Virginia, United States|Glendale, Wisconsin, United States|Green Bay, Wisconsin, United States|Madison, Wisconsin, United States|Marshfield, Wisconsin, United States|Milwaukee, Wisconsin, United States|Milwaukee, Wisconsin, United States|Wausau, Wisconsin, United States|Edmonton, Alberta, Canada|Winnipeg, Manitoba, Canada|Halifax, Nova Scotia, Canada|Hamilton, Ontario, Canada|London, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00111020"
1341,"NCT00111007","A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma",,"Completed","Has Results","Melanoma","Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Carboplatin/Paclitaxel|Drug: Placebo","Progression Free Survival (PFS)|Overall Survival (OS)|Time to Progression (TTP)|Duration of Response (DOR)|Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status to the Visit When the Best Tumor Response Was Noted","Bayer|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","270","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11718|2005-000941-12","May 2005","September 2006","January 2009","May 17, 2005","February 23, 2011","October 31, 2014","Birmingham, Alabama, United States|Tucson, Arizona, United States|Los Angeles, California, United States|Aurora, Colorado, United States|Tampa, Florida, United States|Chicago, Illinois, United States|Park Ridge, Illinois, United States|Louisville, Kentucky, United States|St. Louis, Missouri, United States|Omaha, Nebraska, United States|Montclair, New Jersey, United States|Buffalo, New York, United States|New York, New York, United States|Columbus, Ohio, United States|Pittsburgh, Pennsylvania, United States|Nashville, Tennessee, United States|Houston, Texas, United States|Charlottesville, Virginia, United States|Seattle, Washington, United States|Camperdown, New South Wales, Australia|Warartah, New South Wales, Australia|Westmead, New South Wales, Australia|Brisbane, Queensland, Australia|East Melbourne, Victoria, Australia|Heidelberg, Victoria, Australia|Malvern, Victoria, Australia|Melbourne, Victoria, Australia|Nedlands, Western Australia, Australia|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|London, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Bordeaux, France|Boulogne-billancourt, France|Brest, France|Lyon Cedex, France|Montpellier Cedex, France|Paris, France|Paris, France|Villejuif, France|Heidelberg, Baden-Württemberg, Germany|Mannheim, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|München, Bayern, Germany|Frankfurt, Hessen, Germany|Frankfurt, Hessen, Germany|Essen, Nordrhein-Westfalen, Germany|Trier, Rheinland-Pfalz, Germany|Homburg, Saarland, Germany|Kiel, Schleswig-Holstein, Germany|Berlin, Germany|Amsterdam, Netherlands|Rotterdam, Netherlands|Utrecht, Netherlands|Southampton, Hampshire, United Kingdom|Leicester, Leicestershire, United Kingdom|Bebington, Merseyside, United Kingdom|Nottingham, Nottinghamshire, United Kingdom|Sutton, Surrey, United Kingdom|Leeds, West Yorkshire, United Kingdom|London, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Swansea, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00111007"
1342,"NCT00110994","Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma",,"Completed","Has Results","Cancer|Melanoma","Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Placebo|Drug: Dacarbazine","Progression Free Survival (PFS)|Overall Survival (OS)|Number of Participants in Tumor Response Categories|Time to Progression (TTP)|Duration of Response (DOR)|Change in Eastern Cooperative Oncology Group (ECOG) Performance Status From Baseline to the Visit When the Best Tumor Response Was Noted|Change of European Quality of Life 5-dimensional (EQ-5D) Questionnaire Index Score From Baseline to the Visit at Which Best Response Was First Noted|Change of European Quality of Life 5-dimensional (EQ-5D) Questionnaire Index Score From Baseline to the End of Treatment|Change of European Quality of Life Visual Analogue Scale (EQ-VAS) Score From Baseline to the Visit at Which Best Response Was First Noted|Change of European Quality of Life Visual Analogue Scale (EQ-VAS) Score From Baseline to the End of Treatment","Bayer|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","101","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","11715","April 2005","October 2006","March 2008","May 17, 2005","June 1, 2011","June 8, 2015","Tucson, Arizona, United States|Aurora, Colorado, United States|Lakeland, Florida, United States|Park Ridge, Illinois, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|St. Louis, Missouri, United States|Omaha, Nebraska, United States|Charlotte, North Carolina, United States|Pittsburgh, Pennsylvania, United States|Hilton Head Island, South Carolina, United States|Nashville, Tennessee, United States|San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00110994"
1343,"NCT00110344","Research Study for Patients With Metastatic Renal Cell Carcinoma",,"Terminated","No Results Available","Carcinoma, Renal Cell","Drug: Nexavar (Sorafenib, BAY43-9006)|Drug: Placebo","Best Overall Response Rate (complete and partial response rate)|Progression-free survival|Overall response rate|Time to response|Safety","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","1","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","11547","November 2005","June 2006","June 2006","May 9, 2005",,"October 11, 2013","Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00110344"
1344,"NCT00108953","A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma",,"Completed","Has Results","Carcinoma, Hepatocellular","Drug: Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin|Drug: Doxorubicin/Placebo","Time to Progression (TTP)|Overall Survival|Progression Free Survival (PFS)|Percentage of Participants in Each Category of Best Tumor Response|Time to Symptomatic Progression (TTSP)|Duration of Response|Time to Response (TTR)|Percentage of Participants for Whom Disease Control Was Achieved","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","96","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","11546|2004-001770-40","April 2005","April 2008","April 2008","April 22, 2005","June 11, 2009","October 31, 2014","Birmingham, Alabama, United States|Beverly Hills, California, United States|Orange, California, United States|Palo Alto, California, United States|San Francisco, California, United States|San Francisco, California, United States|Sylmar, California, United States|Miami, Florida, United States|Lafayette, Louisiana, United States|Minneapolis, Minnesota, United States|Hackensack, New Jersey, United States|New York, New York, United States|Rochester, New York, United States|Nashville, Tennessee, United States|Seattle, Washington, United States|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Neuquen, Neuquén, Argentina|Buenos Aires, Argentina|Toronto, Ontario, Canada|Hong Kong, Hong Kong|Kazan, Russian Federation|Kirov, Russian Federation|Krasnodar, Russian Federation|Maidstone, Kent, United Kingdom|Bebington, Merseyside, United Kingdom|Birmingham, West Midlands, United Kingdom|London, United Kingdom|Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00108953"
1345,"NCT00105443","A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma","SHARP","Completed","Has Results","Carcinoma, Hepatocellular","Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Placebo","Overall Survival (OS)|Time to Symptomatic Progression (TTSP)|Time to Progression (TTP)|Disease Control (DC)|Patients Reported Outcome (PRO) by Use of the FACT-Hep Questionnaire","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","602","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","100554|2004-001773-26","March 2005","November 2008","November 2008","March 15, 2005","September 27, 2010","October 31, 2014","Phoenix, Arizona, United States|Tucson, Arizona, United States|Los Angeles, California, United States|Los Angeles, California, United States|Orange, California, United States|San Francisco, California, United States|Stanford, California, United States|Farmington, Connecticut, United States|New Haven, Connecticut, United States|Gainesville, Florida, United States|Miami, Florida, United States|Tampa, Florida, United States|Atlanta, Georgia, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Chicago, Illinois, United States|Lexington, Kentucky, United States|Ann Arbor, Michigan, United States|Detroit, Michigan, United States|St. Louis, Missouri, United States|Omaha, Nebraska, United States|Manhasset, New York, United States|New York, New York, United States|New York, New York, United States|New York, New York, United States|New York, New York, United States|Canton, Ohio, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Houston, Texas, United States|Richmond, Virginia, United States|Seattle, Washington, United States|Seattle, Washington, United States|Mar del Plata, Buenos Aires, Argentina|Pilar, Buenos Aires, Argentina|Bueno Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|San Miguel de Tucumán, Tucuman, Argentina|San Miguel de Tucumán, Tucuman, Argentina|Camperdown, New South Wales, Australia|Randwick, New South Wales, Australia|Westmead, New South Wales, Australia|East Bentleigh, Victoria, Australia|Heidelberg, Victoria, Australia|Melbourne, Victoria, Australia|Brugge, Belgium|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Gent, Belgium|Leuven, Belgium|Porto Alegre, Rio Grande do Sul, Brazil|Porto Alegre, Rio Grande do Sul, Brazil|Belo Horizonte, Brazil|Belo Horizonte, Brazil|Sao Paulo, Brazil|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Stara Zagora, Bulgaria|Varna, Bulgaria|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Vancouver, British Columbia, Canada|Winnipeg, Manitoba, Canada|London, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Santiago de Chile, Santiago, Chile|Santiago de Chile, Chile|Santiago Región Metropolitana, Chile|Zagreb, Croatia|Bondy, France|Bordeaux, France|Clichy, France|Dijon, France|Lille Cedex, France|Marseille, France|Nantes, France|Paris, France|Rennes Cedex, France|Vandoeuvre-les-nancy, France|Freiburg, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|München, Bayern, Germany|München, Bayern, Germany|Regensburg, Bayern, Germany|Frankfurt, Hessen, Germany|Hannover, Niedersachsen, Germany|Bonn, Nordrhein-Westfalen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Homburg, Saarland, Germany|Halle, Sachsen-Anhalt, Germany|Magdeburg, Sachsen-Anhalt, Germany|Berlin, Germany|Hamburg, Germany|Haidari, Attica, Greece|Athens, Greece|Ioannina, Greece|Thessaloniki, Greece|Thessaloniki, Greece|Thessaloniki, Greece|Haifa, Israel|Petach Tikva, Israel|Tel Aviv, Israel|Zrifin, Israel|Rozzano, Milano, Italy|Avellino, Italy|Bologna, Italy|Forlì, Italy|Milano, Italy|Milano, Italy|Padova, Italy|Palermo, Italy|Pavia, Italy|Pisa, Italy|Roma, Italy|México, Distrito Federal, Mexico|Monterrey, Mexico|México, D.F., Mexico|México, D.F., Mexico|Auckland, New Zealand|Wellington South, New Zealand|Comas Lima, Peru|Lima Cercado, Peru|Lima, Peru|Gdansk, Poland|Poznan, Poland|Warszawa, Poland|Warszawa, Poland|Timisoara, Timis, Romania|Craiova Dolj, Romania|Iasi, Romania|Ekaterinburg, Russian Federation|Ekaterinburg, Russian Federation|Kazan, Russian Federation|Kirov, Russian Federation|Krasnodar, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|Tolgliatti, Russian Federation|Badalona, Barcelona, Spain|Cruces/Barakaldo, Bilbao, Spain|Alicante, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Córdoba, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Pamplona, Spain|Valencia, Spain|St. Gallen, Sankt Gallen, Switzerland|Bern, Switzerland|Genève, Switzerland|Zürich, Switzerland|Bristol, Avon, United Kingdom|Oxford, Oxfordshire, United Kingdom|Glasgow, Stratchclyde, United Kingdom|London, United Kingdom|London, United Kingdom|Newcastle-upon-Tyne, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00105443"
1346,"NCT00102141","Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women",,"Completed","No Results Available","Hypertension|Postmenopause","Drug: Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|Drug: Placebo","Mean change in systolic office blood pressure measured at through|Mean change in 24-hour systolic ambulatory blood pressure measurement (ABPM)|Mean change in diastolic blood pressure measured at through|Mean changes in 24-hour diastolic ABPM|Mean change in daytime systolic ABPM|Mean change in daytime diastolic ABPM|Mean change in nighttime systolic ABPM|Mean change in nighttime diastolic ABPM|Mean change in systolic APBM at through|Mean change in diastolic APBM at through","Bayer","Female","45 Years to 75 Years   (Adult, Older Adult)","Phase 3","750","Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","91202|306743","April 2004",,"July 2005","January 24, 2005",,"December 15, 2014",,,"https://ClinicalTrials.gov/show/NCT00102141"
1347,"NCT00101413","BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC)",,"Completed","Has Results","Cancer|Carcinoma, Non-Small Cell Lung","Drug: Sorafenib (Nexavar, BAY43-9006)","Anti-cancer Activity (eg, Percentage of Patients With Confirmed Complete Responses (CR) and Partial Responses (PR) Per RECIST (Response Evaluation Criteria in Solid Tumors) Criteria in Patients With Stage IV Non-small Cell Lung Carcinoma (NSCLC)|Duration of Stable Disease|Overall Survival|Percentage of Subjects With Stable Disease (SD)|Change From Baseline of Health-Related Quality of Life (HRQOL) Score Assessed at Cycle 2, Cycle 4, and End of Treatment (EOT)","Bayer|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","52","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","100557","April 2004","June 2005","April 2008","January 11, 2005","April 8, 2010","October 30, 2013","Houston, Texas, United States|Großhansdorf, Schleswig-Holstein, Germany",,"https://ClinicalTrials.gov/show/NCT00101413"
1348,"NCT00101400","BAY43-9006 - Phase II in Advanced Breast Cancer",,"Completed","Has Results","Breast Neoplasms|Breast Cancer","Drug: Sorafenib (Nexavar, BAY43-9006)","Number of Subjects With Response (Complete or Partial)|Time to Progression|Time to Objective Response|Overall Response Duration|Survival Time|Number of Subjects With Stable Disease up to Cycle 4","Bayer","Female","18 Years and older   (Adult, Older Adult)","Phase 2","54","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","100555","February 2004","January 2006","January 2008","January 11, 2005","June 23, 2009","December 13, 2013","Stuttgart, Baden-Württemberg, Germany|München, Bayern, Germany|Frankfurt, Hessen, Germany|Bologna, Italy|Milano, Italy|Milano, Italy|Parma, Italy",,"https://ClinicalTrials.gov/show/NCT00101400"
1349,"NCT00099502","BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients",,"Completed","No Results Available","Multiple Sclerosis, Relapsing-Remitting","Drug: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|Drug: Copaxone","Hazard ratio for relapses|Time to confirmed Expanded Disability Status Score (EDSS) progression|Magnetic Resonance Imaging (MRI): Change from screening in volume of hypointense lesion on enhanced T1 weighted images","Bayer","All","18 Years to 55 Years   (Adult)","Phase 3","2244","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","91162|EudraCT: 2005-002235-27|306440|Beyond","November 2003",,"August 2007","December 16, 2004",,"December 19, 2008","Birmingham, Alabama, United States|Cullman, Alabama, United States|Phoenix, Arizona, United States|Tucson, Arizona, United States|Berkeley, California, United States|La Jolla, California, United States|Sacramento, California, United States|San Francisco, California, United States|Englewood, Colorado, United States|Fort Collins, Colorado, United States|Wilmington, Delaware, United States|Washington, District of Columbia, United States|Miami, Florida, United States|Tampa, Florida, United States|Tampa, Florida, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Chicago, Illinois, United States|Fort Wayne, Indiana, United States|Indianapolis, Indiana, United States|Des Moines, Iowa, United States|Kansas City, Kansas, United States|Lexington, Kentucky, United States|Louisville, Kentucky, United States|Shreveport, Louisiana, United States|Detroit, Michigan, United States|Duluth, Minnesota, United States|St. Louis, Missouri, United States|Henderson, Nevada, United States|Reno, Nevada, United States|Lebanon, New Hampshire, United States|New Brunswick, New Jersey, United States|Albuquerque, New Mexico, United States|Albany, New York, United States|Mineola, New York, United States|Rochester, New York, United States|Stony Brook, New York, United States|Charlotte, North Carolina, United States|Durham, North Carolina, United States|High Point, North Carolina, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Tualatin, Oregon, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Providence, Rhode Island, United States|Charleston, South Carolina, United States|Nashville, Tennessee, United States|Houston, Texas, United States|San Antonio, Texas, United States|Fairfax, Virginia, United States|Seattle, Washington, United States|Tacoma, Washington, United States|Marshfield, Wisconsin, United States|Milwaukee, Wisconsin, United States|Buenos Aires, Capital Federal, Argentina|Buenos Aires, Capital Federal, Argentina|Rosario, Santa Fe, Argentina|Rosario, Santa Fe, Argentina|Buenos Aires, Argentina|Cordoba, Argentina|Gosford, New South Wales, Australia|Kogarah, New South Wales, Australia|Liverpool, New South Wales, Australia|Melbourne, Victoria, Australia|Parkville, Victoria, Australia|Nedlands, Western Australia, Australia|St. Pölten, Niederösterreich, Austria|Graz, Steiermark, Austria|Innsbruck, Tirol, Austria|Linz, Austria|Bruxelles - Brussel, Belgium|Leuven, Belgium|Melsbroek, Belgium|Curitiba, Parana, Brazil|Recife, PE, Brazil|Rio de Janeiro, RJ, Brazil|Porto Alegre, RS, Brazil|Campinas, Sao Paulo, Brazil|Sao Paulo, SP, Brazil|Sao Pulo, SP, Brazil|Sao Paulo, Brazil|Calgary, Alberta, Canada|Vancouver, British Columbia, Canada|Winnipeg, Manitoba, Canada|Halifax, Nova Scotia, Canada|London, Ontario, Canada|Mississauga, Ontario, Canada|Nepean, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Greenfield Park, Quebec, Canada|Hull, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Aarhus C, Denmark|Oulu, Finland|Tampere, Finland|Rennes, Bretagne, France|Bordeaux, Gironde, France|Caen, France|Clermont ferrand, France|Dijon, France|Lille, France|Lyon, France|Nancy, France|Nantes, France|Nice, France|Nimes, France|Toulouse, France|Heidelberg, Baden-Württemberg, Germany|Bayreuth, Bayern, Germany|Regensburg, Bayern, Germany|Hennigsdorf, Brandenburg, Germany|Gießen, Hessen, Germany|Marburg, Hessen, Germany|Offenbach, Hessen, Germany|Greifswald, Mecklenburg-Vorpommern, Germany|Göttingen, Niedersachsen, Germany|Hannover, Niedersachsen, Germany|Hannover, Niedersachsen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Asbach, Rheinland-Pfalz, Germany|Halle, Sachsen-Anhalt, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Berlin, Germany|Berlin, Germany|Hamburg, Germany|Hamburg, Germany|Athens, Attica, Greece|Athens, Greece|Thessaloniki, Greece|Budapest, Hungary|Budapest, Hungary|Györ, Hungary|Miskolc, Hungary|Pecs, Hungary|Zalaegerszeg, Hungary|Dublin, Dublin 24, Ireland|Cork, Ireland|Dublin, Ireland|Dublin, Ireland|Dublin, Ireland|Ashkelon, Israel|Haifa, Israel|Haifa, Israel|Jerusalem, Israel|Petach Tikva, Israel|Tel Hashomer, Israel|Tel-Aviv, Israel|Zerifin, Israel|Bari, BA, Italy|Firenze, FI, Italy|Milano, MI, Italy|Padova, PD, Italy|Roma, RO, Italy|Orbassano, TO, Italy|Riga, Latvia|Nijmegen, Gelderland, Netherlands|Breda, Netherlands|Sittard, Netherlands|Bergen, Norway|Gdansk, Poland|Katowice, Poland|Lodz, Poland|Poznan, Poland|Warszawa, Poland|Warszawa, Poland|Wroclaw, Poland|Moscow, Russian Federation|Moscow, Russian Federation|Moskva, Russian Federation|Moskva, Russian Federation|Moskva, Russian Federation|Nizhny Novogorod, Russian Federation|Novosibirsk, Russian Federation|Sankt-Peterburg, Russian Federation|Sankt-Peterburg, Russian Federation|St. Petersburg, Russian Federation|Yaroslavl, Russian Federation|Ljubljana, Slovenia|Maribor, Slovenia|L'Hospitalet de Llobregat, Barcelona, Spain|Málaga, Spain|Sevilla, Spain|Helsingborg, Sweden|Stockholm, Sweden|Uppsala, Sweden|Bern, Switzerland|St. Gallen, Switzerland|Donetsk, Ukraine|Kharkiv, Ukraine|Kiev, Ukraine|Lviv, Ukraine",,"https://ClinicalTrials.gov/show/NCT00099502"
1350,"NCT00079612","Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer",,"Completed","No Results Available","Carcinoma, Renal Cell","Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Placebo","Number of progressions post randomization to placebo or sorafenib|Time to progression|Duration of objective tumor response|Overall survival time","Bayer|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","501","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","100391","September 2002",,"January 2007","March 11, 2004",,"December 19, 2014","Chicago, Illinois, United States|Philadelphia, Pennsylvania, United States|Houston, Texas, United States|San Antonio, Texas, United States|London, Greater London, United Kingdom|Glasgow, Strathclyde, United Kingdom|Sutton, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00079612"
1351,"NCT00073307","Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer",,"Completed","Has Results","Carcinoma, Renal Cell","Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Placebo","Final Overall Survival (OS) - Primary Analysis in the ITT (Intent To Treat) Population|Final Overall Survival - Secondary Analysis (Placebo Data Censored at 30June2005) in the ITT Population|Final Progression-Free Survival (PFS) - Independent Radiological Review|Best Overall Response - Independent Radiological Review|Health-related Quality of Life (HRQOL) by FKSI-10 (Functional Assessment of General Therapy Kidney Symptom Index 10) Assessment|Health-related Quality of Life (HRQOL) by Physical Well-Being (PWB) Score of the FACT-G (Functional Assessment of Cancer Therapy-General Version) Assessment","Bayer|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","903","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11213","November 2003","September 2006","April 2010","November 21, 2003","December 14, 2011","February 6, 2014","Tucson, Arizona, United States|Los Angeles, California, United States|Los Angeles, California, United States|Sacramento, California, United States|Aurora, Colorado, United States|Hamden, Connecticut, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Louisville, Kentucky, United States|Lafayette, Louisiana, United States|Frederick, Maryland, United States|Boston, Massachusetts, United States|Minneapolis, Minnesota, United States|Columbia, Missouri, United States|St. Louis, Missouri, United States|Bronx, New York, United States|Brooklyn, New York, United States|New York, New York, United States|Canton, Ohio, United States|Cleveland, Ohio, United States|Dayton, Ohio, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Spartanburg, South Carolina, United States|Dallas, Texas, United States|Laredo, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Richmond, Virginia, United States|Seattle, Washington, United States|Milwaukee, Wisconsin, United States|Rosario, Santa Fe, Argentina|Santa Fé, Santa Fe, Argentina|Capital Federal-Buenos Aires, Argentina|Mendoza, Argentina|Garran, Australian Capital Territory, Australia|Camperdown, New South Wales, Australia|Liverpool, New South Wales, Australia|Westmead, New South Wales, Australia|Heidelberg, Victoria, Australia|Wodonga, Victoria, Australia|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Curitiba, Parana, Brazil|Porto Alegre, Rio Grande do Sul, Brazil|Porto Alegre, Rio Grande do Sul, Brazil|Edmonton, Alberta, Canada|Hamilton, Ontario, Canada|London, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Santiago de Chile, Chile|Bordeaux, France|Caen Cedex 5, France|Lille Cedex, France|Lyon Cedex, France|Marseille, France|Nantes, France|Paris Cedex 15, France|Strasbourg, France|Toulouse, France|Villejuif, France|Mannheim, Baden-Württemberg, Germany|Ulm, Baden-Württemberg, Germany|München, Bayern, Germany|Regensburg, Bayern, Germany|Darmstadt, Hessen, Germany|Frankfurt, Hessen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Dresden, Sachsen, Germany|Berlin, Germany|Hamburg, Germany|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Zalaegerszeg, Hungary|Haifa, Israel|Tel Aviv, Israel|Milano, Italy|Modena, Italy|Pavia, Italy|Perugia, Italy|Reggio Emilia, Italy|Roma, Italy|Nijmegen, Netherlands|Gdansk, Poland|Krakow, Poland|Lodz, Poland|Lublin, Poland|Poznan, Poland|Szczecin, Poland|Warszawa, Poland|Warszawa, Poland|Wroclaw, Poland|Barnaul, Russian Federation|Kazan, Russian Federation|Kirov, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Obninsk, Russian Federation|St. Petersburg, Russian Federation|Bloemfontein, Freestate, South Africa|Pretoria, Gauteng, South Africa|Durban, Kwazulu-Natal, South Africa|Cape Town, Western Cape, South Africa|Cruces/Barakaldo, Bilbao, Spain|Barcelona, Spain|Madrid, Spain|Valencia, Spain|Donetsk, Ukraine|Kharkiv, Ukraine|Kiev, Ukraine|Lviv, Ukraine|Poltava, Ukraine|Northwood, Middlesex, United Kingdom|Cardiff, South Glamorgan, United Kingdom|Glasgow, Stratchclyde, United Kingdom|Sutton, Surrey, United Kingdom|Newcastle Upon Tyne, Tyne and Wear, United Kingdom|Birmingham, West Midlands, United Kingdom|Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00073307"
1352,"NCT00059462","Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection",,"Completed","No Results Available","HIV Infections","Drug: Interleukin-2 SA|Drug: HAART",,"Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","10630","December 2002","March 2005","March 2005","June 2, 2003",,"December 23, 2014","Birmingham, Alabama, United States|Davis, California, United States|Los Angeles, California, United States|Palo Alto, California, United States|San Francisco, California, United States|Chicago, Illinois, United States|Chicago, Illinois, United States|Bethesda, Maryland, United States|Cleveland, Ohio, United States|Creteil, France|London, Greater London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00059462"
1353,"NCT00044915","Repinotan in Patients With Acute Ischemic Stroke",,"Completed","No Results Available","Stroke|Acute Ischemic Stroke","Drug: Repinotan HCl (BAYX3702)|Drug: Placebo",,"Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","782","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","100282","December 2000",,"September 2004","September 9, 2002",,"June 12, 2009","Los Angeles, California, United States|Oceanside, California, United States|San Diego, California, United States|San Jose, California, United States|Boynton Beach, Florida, United States|Ft. Lauderdale, Florida, United States|Ocala, Florida, United States|Tampa, Florida, United States|Decatur, Georgia, United States|Honolulu, Hawaii, United States|Des Moines, Iowa, United States|Baltimore, Maryland, United States|Robbinsdale, Minnesota, United States|Great Falls, Montana, United States|Edison, New Jersey, United States|Ridgewood, New Jersey, United States|New Hyde Park, New York, United States|Stony Brook, New York, United States|Chapel Hill, North Carolina, United States|Winston-Salem, North Carolina, United States|Cleveland, Ohio, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Upland, Pennsylvania, United States|Beaufort, South Carolina, United States|Chattanooga, Tennessee, United States|Houston, Texas, United States|Bellevue, Washington, United States|Gosford, New South Wales, Australia|New Lambton Heights, New South Wales, Australia|Southport, Queensland, Australia|Hobart, Tasmania, Australia|Melbourne, Victoria, Australia|Melbourne, Victoria, Australia|Melbourne, Victoria, Australia|Melbourne, Victoria, Australia|Klosterneuburg, Niederösterreich, Austria|Linz, Oberösterreich, Austria|Wien, Austria|Bornem, Belgium|Bruxelles - Brussel, Belgium|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Lethbridge, Alberta, Canada|North Vancouver, British Columbia, Canada|Penticton, British Columbia, Canada|Vancouver, British Columbia, Canada|Victoria, British Columbia, Canada|Winnipeg, Manitoba, Canada|St. John, New Brunswick, Canada|Halifax, Nova Scotia, Canada|London, Ontario, Canada|Mississauga, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Chicoutimi, Quebec, Canada|Greenfield Park, Quebec, Canada|Quebec City, Quebec, Canada|Saskatoon, Saskatchewan, Canada|Helsinki, Finland|Kuopio, Finland|Lahti, Finland|Mikkeli, Finland|Bordeaux, France|Nice, France|Freiburg, Baden-Württemberg, Germany|Heidelberg, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|Aschaffenburg, Bayern, Germany|Bad Neustadt, Bayern, Germany|Erlangen, Bayern, Germany|München, Bayern, Germany|München, Bayern, Germany|Nürnberg, Bayern, Germany|Regensburg, Bayern, Germany|Würzburg, Bayern, Germany|Frankfurt, Hessen, Germany|Greifswald, Mecklenburg-Vorpommern, Germany|Essen, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Minden, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Kaiserslautern, Rheinland-Pfalz, Germany|Magdeburg, Sachsen-Anhalt, Germany|Leipzig, Sachsen, Germany|Berlin, Germany|Berlin, Germany|Miskolc, Hungary|Petach Tikva, Isarel, Israel|Ashkelon, Israel|Haifa, Israel|Haifa, Israel|Holon, Israel|Nahariya, Israel|Tel Aviv, Israel|Tel Hashomer, Israel|Como, Italy|L'Aquila, Italy|Milano, Italy|Pavia, Italy|Perugia, Italy|Reggio Emilia, Italy|Roma, Italy|Verona, Italy|Vibo Valentia, Italy|Vicenza, Italy|Groningen, Netherlands|Nijmegen, Netherlands|Santiago de Compostela, A Coruña, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Valencia, Spain|Zaragoza, Spain|Stockholm, Sweden|Umeå, Sweden|Leicester, Leicestershire, United Kingdom|Glasgow, Strathclyde, United Kingdom|Dundee, Tayside, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00044915"
1354,"NCT00044564","Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma",,"Completed","No Results Available","Carcinoma, Renal Cell","Drug: Bay 59-8862","Objective overall tumor response rate calculated as the percentage of patients with complete and partial responses|Duration of response|Overall survival|Time to progression|Pharmacokinetics assessment|Qualitative and quantitative toxicity profile|Physical examinations|Vital signs data|Abnormal laboratory tests","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","54","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","100386","December 2001",,"January 2003","September 4, 2002",,"December 19, 2014","La Jolla, California, United States|Muncie, Indiana, United States|New Orleans, Louisiana, United States|Baltimore, Maryland, United States|Greenbelt, Maryland, United States|Detroit, Michigan, United States|Southfield, Michigan, United States|St. Louis, Missouri, United States|St. Louis, Missouri, United States|Billings, Montana, United States|New Brunswick, New Jersey, United States|Salt Lake City, Utah, United States|Milwaukee, Wisconsin, United States|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Sudbury, Ontario, Canada|Caen Cedex 5, France|Montpellier Cedex, France|Heidelberg, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|München, Bayern, Germany|München, Bayern, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Rotterdam, Netherlands|Plymouth, Devon, United Kingdom|Manchester, Greater Manchester, United Kingdom|Cardiff, South Glamorgan, United Kingdom|Sutton, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00044564"
1355,"NCT00044551","Evaluation of Bay 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Lymphoma, Non-Hodgkin","Drug: Taxane (Cytotoxic, BAY59-8862)",,"Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","29","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","100389","February 2002",,"July 2003","September 4, 2002",,"October 14, 2013","Miami Beach, Florida, United States|Chicago, Illinois, United States|Shreveport, Louisiana, United States|New Brunswick, New Jersey, United States|Bronx, New York, United States|Brooklyn, New York, United States|Manhasset, New York, United States|Syracuse, New York, United States|Valhalla, New York, United States|Cleveland, Ohio, United States|Memphis, Tennessee, United States|Seattle, Washington, United States|Milwaukee, Wisconsin, United States|Edmonton, Alberta, Canada|Paris, France|Pierre Benite, France|Vandoeuvre-les-nancy, France|Freiburg, Baden-Württemberg, Germany|Berlin, Germany|Amsterdam, Netherlands|Groene Hilledijk, Netherlands|Cambridge, Cambridgeshire, United Kingdom|Maidstone, Kent, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00044551"
1356,"NCT00044538","Evaluation of BAY 59-8862 in Taxane Resistant Non-Small Cell Lung Cancer Patients",,"Completed","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: BAY59-8862 (Cytotoxic Taxane)",,"Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","102","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10653","December 2001",,"June 2004","September 4, 2002",,"June 22, 2009","Tucson, Arizona, United States|Waterbury, Connecticut, United States|Louisville, Kentucky, United States|Metairie, Louisiana, United States|Buffalo, New York, United States|Columbus, Ohio, United States|Nashville, Tennessee, United States|Edmonton, Alberta, Canada|Hamilton, Ontario, Canada|Thunder Bay, Ontario, Canada|Montreal, Quebec, Canada|Quebec, Canada|Gauting, Bayern, Germany|Berlin, Germany|Kfar Saba, Israel|Tel Aviv, Israel|Tel Hashomer, Israel|Modena, Italy|Parma, Italy|Pisa, Italy|Torino, Italy|Udine, Italy|Elche, Alicante, Spain|Barakaldo, Bizkaia, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT00044538"
1357,"NCT00044525","Evaluation of BAY59-8862 in Taxane-Resistant Metastatic Breast Cancer Patients",,"Completed","No Results Available","Breast Neoplasms|Breast Cancer, Metastatic","Drug: BAY59-8862 (Cytotoxic Taxane)",,"Bayer","Female","18 Years and older   (Adult, Older Adult)","Phase 2","82","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10654","April 2002","February 2004","February 2004","September 4, 2002",,"December 23, 2014","Stuttgart, Baden-Württemberg, Germany|Jena, Thüringen, Germany|Berlin, Germany|Maroussi, Attica, Greece|Heraklion, Creta, Greece|Ashkelon, Israel|Haifa, Israel|Tel Aviv, Israel|Tel Hashomer, Israel|Treviglio, Bergamo, Italy|Rozzano, Milano, Italy|Biella, Italy|Cuneo, Italy|Forlì, Italy|Parma, Italy|Udine, Italy|Olsztyn, Poland|Warszawa, Poland|Warszawa, Poland|Aarau, Aargau, Switzerland|London, Greater London, United Kingdom|London, Greater London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00044525"
1358,"NCT00044512","A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma",,"Completed","Has Results","Carcinoma, Hepatocellular","Drug: Sorafenib (Nexavar, BAY43-9006)","Percentage of Participants for Each Type of Response|Duration of Response|Time to Response|Time to Progression|Duration of Stable Disease|Time to Minor Response|Duration of Minor Response|Overall Survival","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","137","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10874","August 2002","February 2008","February 2008","September 4, 2002","August 6, 2009","April 16, 2014","Los Angeles, California, United States|New York, New York, United States|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Gent, Belgium|Leuven, Belgium|Lille Cedex, France|Marseille, France|Paris, France|Rennes Cedex, France|Saint Herblain, France|Haifa, Israel|Jerusalem, Israel|Petach Tikva, Israel|Rehovot, Israel|Tel Aviv, Israel|Tel Hashomer, Israel|Rozzano, Milano, Italy|Forlì, Italy|Milano, Italy|Pisa, Italy|Verona, Italy",,"https://ClinicalTrials.gov/show/NCT00044512"
1359,"NCT00031096","Comparison of Efficacy and Safety of Azelaic Acid 15% Gel With Its Vehicle in Subjects With Mild to Moderate Acne",,"Completed","No Results Available","Acne Vulgaris","Drug: Azelaic Acid Gel 15% (Finacea, BAY39-6251)|Drug: Vehicle gel (SH H 655 PBA)","The nominal and percent change in lesions counts from baseline to last available visit (end of treatment) and treatment success rates based on Investigator's assessment of mild to moderate acne|Investigators rating of overall improvement and patients self assessment of overall improvement and cosmetic acceptability|Adverse event reports and patient's opinion on local tolerability of the study gels at the end of study","Bayer","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","879","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","90905|304343 (90905)|306100 (91138)|4343","January 2002","July 2002","July 2002","February 22, 2002",,"February 25, 2014","Mobile, Alabama, United States|Boulder, Colorado, United States|Newnan, Georgia, United States|Shawnee, Kansas, United States|Wichita, Kansas, United States|Lexington, Kentucky, United States|Albuquerque, New Mexico, United States|Bayshore, New York, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Portland, Oregon, United States|Hershey, Pennsylvania, United States|Knoxville, Tennessee, United States|Byran, Texas, United States|San Antonio, Texas, United States|Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00031096"
1360,"NCT04233697","Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma",,"Not yet recruiting","No Results Available","T-Cell Lymphoma Relapsed & Refractory","Drug: Copanlisib|Drug: Romidepsin","Maximum tolerated dose (MTD)","Changchun Deng|Bayer|Columbia University","All","18 Years and older   (Adult, Older Adult)","Phase 1","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","AAAR5207","February 2020","July 30, 2022","July 30, 2023","January 18, 2020",,"January 18, 2020","Center for Lymphoid Malignancies, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04233697"
1361,"NCT04217447","Assessment of Quitting Versus Using Aspirin Therapy In Patients Treated With Oral Anticoagulation for Atrial Fibrillation With Stabilized Coronary Artery Disease","AQUATIC","Not yet recruiting","No Results Available","Coronary Artery Disease","Drug: OAC + Aspirin 100mg od|Drug: OAC + placebo of Aspirin 100mg od","Primary efficacy outcome : rate of composite of cardiovascular mortality and thrombotic cardiovascular events|Primary safety outcome : rate of major bleeding|Secondary efficacy outcomes : rate of composite of CV mortality, MI, stroke; CV mortality; all cause of death; thrombotic cardiovascular events.|Secondary safety outcomes : rate of major and clinically relevant non major bleeding","University Hospital, Brest|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","2000","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","29BRC19.0116","April 2020","April 2024","April 2024","January 3, 2020",,"January 7, 2020","CHRU d'Amiens, Amiens, France|CHU d'Angers, Angers, France|CH d'Annecy-Genevois, Annecy, France|CH d'Antibes, Antibes, France|Hopital privé d'Antony, Antony, France|CH d'Arras, Arras, France|CH d'Avignon, Avignon, France|CH de la Côte Basque - Bayonne, Bayonne, France|Hôpital Haut Lévêque -CHU Bordeaux-Pessac, Bordeaux, France|CHRU de Brest, Brest, France|Hôpital Louis Pradel - Bron, Bron, France|CH Pierre Nouveau -Cannes, Cannes, France|Centre Hospitalier René Dubos - Cergy Pontoise, Cergy-Pontoise, France|CH Louis Pasteur - Chartres - Le Coudray, Chartres, France|CHU de Clermont-Ferrand, Clermont-Ferrand, France|CH Sud Francilien Corbeil-Essonnes, Corbeil-Essonnes, France|Hôpital Henri Mondor - Créteil, Créteil, France|CHU de Dijon, Dijon, France|GHM - Grenoble, Grenoble, France|CHU de Grenoble, Grenoble, France|Clinique St Clothilde -La Réunion, La Réunion, France|CH de Lens, Lens, France|CHRU de Lille, Lille, France|CHU de Limoges, Limoges, France|CH St Joseph-St Luc Lyon, Lyon, France|Marseille-Hôpital Nord, Marseille, France|Marseille- Hôpital La Timone, Marseille, France|Clinique Les Fontaines - Melun, Melun, France|CHR de Metz, Metz, France|GHI Le Raincy-Montfermeil, Montfermeil, France|CHU de Montpellier, Montpellier, France|Clinique du Millénaire - Montpellier, Montpellier, France|CHU de Nîmes, Nîmes, France|CHR d'Orléans, Orléans, France|Paris-Lariboisière, Paris, France|Paris-St Antoine, Paris, France|Paris-Pitié-Salpêtrière, Paris, France|Paris-HEGP Cardiologie, Paris, France|Paris-HEGP Médecine vasculaire, Paris, France|Paris-Bichat, Paris, France|CH de Pau, Pau, France|CHU de Rennes, Rennes, France|Clinique St Hilaire - Rouen, Rouen, France|CHU de Rouen, Rouen, France|CH de Seclin, Seclin, France|Clinique Rhena - Strasbourg, Strasbourg, France|CHU de Strasbourg, Strasbourg, France|CHU de Toulouse, Toulouse, France|Clinique Pasteur-Toulouse, Toulouse, France|CHRU de Tours, Tours, France|Hôpital André Mignot - CH de Versailles, Versailles, France",,"https://ClinicalTrials.gov/show/NCT04217447"
1362,"NCT04200404","A Study of CS1001 in Subjects With Advanced or Refractory Solid Tumors",,"Recruiting","No Results Available","Advanced Solid Tumor","Drug: CS1001|Drug: Regorafenib","Number of participants with adverse events|Dose Limiting Toxicity (DLT)|Objective response rate (ORR)|Area under the plasma concentration-time curve (AUC)|Maximum plasma concentration (Cmax)|Time to reach maximum plasma concentration (Tmax)|Terminal elimination half-life (t1/2)|Anti-CS1001 antibody","CStone Pharmaceuticals|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","138","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CS1001/Regorafenib-101","December 13, 2019","December 30, 2022","July 30, 2023","December 16, 2019",,"January 22, 2020","Ashford Cancer Centre Research, Kurralta Park, South Australia, Australia",,"https://ClinicalTrials.gov/show/NCT04200404"
1363,"NCT04180436","Pharmacokinetics of Rivaroxaban After Bariatric Surgery","ABSORB","Recruiting","No Results Available","Bariatric Surgery|Morbid Obesity","Drug: rivaroxaban 20 mg once daily 8 days","AUC of rivaroxaban|Cmax of rivaroxaban|Tmax of rivaroxaban|Prothrombin time|Activated partial thromboplatin time (aPTT)|Fibrinogen levels|Rivaroxaban anti-Xa activity|Bleedings|Other adverse events","University Hospital, Brest|Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","64","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ABSORB (29BRC19.0078)","January 15, 2020","July 15, 2020","July 30, 2020","November 27, 2019",,"January 21, 2020","CHRU de Brest, Brest, France",,"https://ClinicalTrials.gov/show/NCT04180436"
1364,"NCT04126317","Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration","CANDELA","Recruiting","No Results Available","Neovascular (Wet) Age-Related Macular Degeneration","Drug: aflibercept|Drug: High-Dose aflibercept","Incidence of treatment-emergent adverse events|Incidence of serious adverse events (SAEs)|Proportion of patients without retinal fluid in the center subfield","Regeneron Pharmaceuticals|Bayer","All","50 Years and older   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","VGFTe (HD)-AMD-1905","November 1, 2019","October 5, 2020","May 4, 2021","October 15, 2019",,"January 9, 2020","Regeneron Study Site, Fullerton, California, United States|Regeneron Study Site, Colorado Springs, Colorado, United States|Regeneron Study Site, Largo, Florida, United States|Regeneron Study Site, Asheville, North Carolina, United States|Regeneron Study Site, Ladson, South Carolina, United States|Regeneron Study Site, West Columbia, South Carolina, United States|Regeneron Study Site, Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04126317"
1365,"NCT04113538","Treat and Extend Analysis Trial With Aflibercept in Wet-AMD",,"Recruiting","No Results Available","Wet Age-related Macular Degeneration","Drug: Aflibercept","Best Corrected Visual Acuity|Injections|Treatment-free intervals|Gain of letters|Loss of letters","Michel Giunta|Bayer|GOGiunta","All","50 Years and older   (Adult, Older Adult)","Phase 3","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GOGIUNTA","July 24, 2019","December 2020","January 2021","October 2, 2019",,"October 4, 2019","GOGIUNTA, Sherbrooke, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT04113538"
1366,"NCT04096547","Rivaroxaban in Elderly NVAF Patients With or Without Renal Impairment","XAIENT","Not yet recruiting","No Results Available","Atrial Fibrillation|Rivaroxaban|Elderly|Renal Insufficiency","Drug: Rivaroxaban","Composite incidence of stroke/ non-CNS SE|Bleeding incidence","Samsung Medical Center|Bayer","All","65 Years and older   (Older Adult)",,"1200","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB 2019-06-078","September 25, 2019","August 30, 2020","August 30, 2021","September 20, 2019",,"September 20, 2019",,,"https://ClinicalTrials.gov/show/NCT04096547"
1367,"NCT04073316","AntiCoagulants and COGnition","ACCOG","Not yet recruiting","No Results Available","Nonvalvular Atrial Fibrillation","Drug: Rivaroxaban 20 MG|Drug: Warfarin","Change in global cognitive performance|Change in executive functions|Change in episodic memory|Change in the volume and subvolumes of the brain|Change in independence and autonomy|Change in serum concentration of vitamin K","University Hospital, Angers|Bayer","All","70 Years and older   (Older Adult)","Phase 4","48","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","2019-000794-23","October 2019","October 2021","October 2021","August 29, 2019",,"August 29, 2019","Angers University Hospital, Angers, France",,"https://ClinicalTrials.gov/show/NCT04073316"
1368,"NCT04071756","Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions",,"Recruiting","No Results Available","Solid Tumor|Hand-Foot Skin Reaction (HFSR)","Drug: Topical Tazarotene|Other: Placebo","The Proportion of Patients in Each Arm Who Develop Grade-2 or Higher HFSR Within The First 8 Weeks of Protocol Therapy|The Proportion of Patients in Each Intervention Arm Who Develop HFSR of Any Grade|Investigation of whether tazarotene plus BPS improves the impact of HFSR symptoms as measured by differences in HFS-14 scores|Investigation of whether the intervention decreases global stress associated with HFSR","Dana-Farber Cancer Institute|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","70","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","19-099","October 9, 2019","October 1, 2021","March 1, 2022","August 28, 2019",,"December 12, 2019","Dana Farber Cancer Institute, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04071756"
1369,"NCT00086775","Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia",,"Completed","No Results Available","Leukemia","Biological: alemtuzumab|Biological: rituximab|Drug: fludarabine phosphate",,"Bayer|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2",,"Industry","Interventional","Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment","BRLX-FLUCAM106|CDR0000365631|BRLX-STA1-03-058|OHSU-HEM-03050-P|DMS-F0334","July 2003","June 2005","October 2009","July 12, 2004",,"August 2, 2013","Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States|Jackson Oncology Associates, PLLC, Jackson, Mississippi, United States|Cancer Institute of New Jersey at Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|Western Pennsylvania Cancer Institute, Pittsburgh, Pennsylvania, United States|Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00086775"
1370,"NCT04040725","Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression",,"Withdrawn","No Results Available","Bladder Cancer","Drug: Rogaratinib","Complete Response|Duration of Response|Rate Toxicity Occurs","Dana-Farber Cancer Institute|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19-205","November 27, 2019","November 27, 2019","November 27, 2019","August 1, 2019",,"December 17, 2019",,,"https://ClinicalTrials.gov/show/NCT04040725"
1371,"NCT04032665","Reveal Transition - A Mechanistic Study in Transition / Stabilized Phase of CAD","RevealTrans","Enrolling by invitation","No Results Available","Cardiovascular Diseases","Diagnostic Test: Rivaroxaban","Inflammation, Thrombogenicity and Mechanistic Insights During Transition from acute to chronic phase|Biomarker Expression","University Hospital Tuebingen|Bayer","All","18 Years and older   (Adult, Older Adult)",,"55","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","Reveal Transition","July 23, 2019","October 2021","December 2021","July 25, 2019",,"July 25, 2019","University Hospital Tuebingen, Tuebingen, Germany",,"https://ClinicalTrials.gov/show/NCT04032665"
1372,"NCT04016025","A Clinical Study of Adherence to Methylprednisolone Aceponate in Different Carriers","AD-HERE","Not yet recruiting","No Results Available","Adherence, Patient|Chronic Eczema","Behavioral: Adherence to topical standard therapy assessed","Adherence to treatment|Measurement 1|Measurement 2|Individual amount of topical drug|Truly applicated daily dose|Change of Hand Eczema","Jena University Hospital|Bayer","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","80","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","ZKSJ0119_AD-HERE|2019-001324-35","February 1, 2020","May 1, 2021","December 31, 2021","July 11, 2019",,"January 18, 2020",,,"https://ClinicalTrials.gov/show/NCT04016025"
1373,"NCT04010240","A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study","NTRK","Enrolling by invitation","No Results Available","Metastatic Solid Tumors","Other: Retrospective cohort","Frequency of NTRK fusions in subjects with locally advanced/unresectable or metastatic solid tumors.|Treatment outcome in terms of objective response rate.|Treatment outcome in terms of progression-free survival.","Institut Bergonié|Bayer","All","1 Month and older   (Child, Adult, Older Adult)",,"3750","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","IB2015-NTRK|MR 0112040319","December 23, 2015","December 2020","December 2020","July 8, 2019",,"July 8, 2019","Institut Bergonié, Bordeaux, Aquitaine, France",,"https://ClinicalTrials.gov/show/NCT04010240"
1374,"NCT03970447","A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma","GBM AGILE","Recruiting","No Results Available","Glioblastoma","Drug: Temozolomide|Drug: Lomustine|Drug: Regorafenib|Radiation: Radiation","Overall Survival (OS)|Progression-free survival (PFS)|Tumor Response|Duration of Response (CR + PR)","Global Coalition for Adaptive Research|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","550","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCAR-7213","July 30, 2019","December 2022","December 2022","May 31, 2019",,"January 13, 2020","Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Piedmont Atlanta Hospital, Atlanta, Georgia, United States|LSU Health Sciences Center - New Orleans, New Orleans, Louisiana, United States|Henry Ford Health System, Detroit, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Washington University School of Medicine - Siteman Cancer Center, Saint Louis, Missouri, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|University of Utah - Huntsman Cancer Institute, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT03970447"
1375,"NCT03925116","Contraceptive Pathway and Contraception Continuation Rates",,"Not yet recruiting","No Results Available","Contraceptive Usage","Other: COntraceptive pathway","Continued Use of Contraception at 1 year|Subject satisfaction with contraceptive counseling|Pregnancy rates","Rutgers, The State University of New Jersey|Bayer","Female","18 Years to 49 Years   (Adult)","Not Applicable","400","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","Pro2018002901","August 30, 2019","June 2020","June 2021","April 23, 2019",,"August 28, 2019",,,"https://ClinicalTrials.gov/show/NCT03925116"
1376,"NCT03909906","Chronic Effects of Euphytose® on Psychological and Physiological Measures of Stress",,"Recruiting","No Results Available","Mood","Drug: Euphytose®|Drug: Placebo Oral Tablet","Chronic treatment effects on anxiety following a psychological stressor|Chronic (14 days) treatment effects on general anxiety|Chronic (14 days) treatment effects on general psychological health|Chronic (14 Days) treatment effects on stress|Chronic (14 days) treatment effects on psychological distress|Chronic (14 days) treatment effects on subjective mood as assessed by visual analogue scales following a psychological stressor|Chronic (14 days) treatment effects on subjective ratings of stress as assessed by visual analogue scales following a psychological stressor|Chronic (14 days) treatment effects on physiological stress responses|Chronic (14 days) treatment effects on other physiological stress responses|Chronic (14 days) treatment effects on gut microbiota|Chronic (14 days) treatment effects on cognitive performance during psychological stressor|7 days treatment effects on cognitive performance|13 days treatment effects on cognitive performance|7 days treatment effects on subjective ratings of mood as assessed by visual analogue scales|13 days treatment effects on subjective ratings of mood as assessed by visual analogue scales|7 days treatment effects on subjective ratings of stress as assessed by visual analogue scales|13 days treatment effects on subjective ratings of stress as assessed by visual analogue scales|7 days treatment effects on stress|13 days treatment effects on stress|7 days treatment effects on sedation|13 days treatment effects on sedation","Northumbria University|Bayer","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other","9BW1","April 3, 2019","September 30, 2019","September 30, 2019","April 10, 2019",,"September 4, 2019","Brain performance and nutrition research centre, Northumbria university, Newcastle upon Tyne, Tyne And Wear, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03909906"
1377,"NCT03877055","A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma",,"Recruiting","No Results Available","Mantle Cell Lymphoma (MCL)","Drug: Copanlisib|Drug: Ibrutinib","complete response (Phase II)","Memorial Sloan Kettering Cancer Center|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","45","Other|Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-450","March 13, 2019","March 2021","March 2021","March 15, 2019",,"October 25, 2019","Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, United States",,"https://ClinicalTrials.gov/show/NCT03877055"
1378,"NCT03851627","Effects of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Obese Men With T2DM and Hypogonadism","Test2Func","Not yet recruiting","No Results Available","Fatty Liver|Obesity|Type2 Diabetes Mellitus|Hypogonadism, Male","Drug: Testosterone Undecanoate|Drug: Placebo","Liver fat|body weight|waist, hip and neck circumference|insulin sensitivity|Level of HbA1c|Concentration of lipids|quality of live questionnaire|blood pressure|sexual function questionnaire|diabetes management satisfaction questionnaire","Alexandra Kautzky-Willer|Bayer|Medical University of Vienna","Male","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","32","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","T2F12017|2017-001611-37","April 2019","April 2023","December 2023","February 22, 2019",,"February 22, 2019","Abt. für Endokrinologie & Stoffwechsel, Univ. Klin f. Innere Medizin III, Wien, Austria",,"https://ClinicalTrials.gov/show/NCT03851627"
1379,"NCT03809156","Upfront Combination Pulmonary Arterial Hypertension Therapy",,"Recruiting","No Results Available","Pulmonary Hypertension","Drug: Riociguat Oral Product","Pulmonary Vascular resistance|Hemodynamic Variables|Echocardiographic parameters|RV function|NT-PRo-BNP|Exercise capacity|Dyspnea|Quality of Life Assessment|Functional Class|Survival|Clinical worsening","University of Calgary|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 4","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-3056","April 26, 2016","December 31, 2019","January 31, 2020","January 18, 2019",,"January 18, 2019","Peter Lougheed Center, Calgary, Alberta, Canada|Vancouver General Hospital, The Lung Centre, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT03809156"
1380,"NCT03805191","A Study for Sufficient Acarbose Decreased Glucose Excursion in Type 2 Diabetic Patients","FLAT","Recruiting","No Results Available","Type 2 Diabetes Mellitus|Poor Glycemic Control",,"The extent of change in MAGE|The extent of change in PPGE,LAGE|The control rate of HbA1c","Qilu Hospital of Shandong University|Bayer","All","18 Years and older   (Adult, Older Adult)",,"900","Other|Industry","Observational","Observational Model: Other|Time Perspective: Prospective","RD-OI-1257","January 1, 2019","November 30, 2020","December 30, 2022","January 15, 2019",,"April 12, 2019","Qilu Hospital of Shandong University, Jinan, China",,"https://ClinicalTrials.gov/show/NCT03805191"
1381,"NCT03803631","CNV in AMD Analyzed by OCT Angiography Under IntravitreaL Eylea (COCTAEyl)","COCTAEyl","Recruiting","No Results Available","AMD|Exudative Macular Degeneration",,"presence of flow on OCTA|presence of collaterals on OCTA|presence of peripheral arcade on OCTA|presence of arteriolization on OCTA|presence of vascular loops on OCTA|presence of dark halo on OCTA|presence of feeder vessel on OCTA|presence of flow void on OCTA|measure of neovascular area on OCTA|measure of neovascular density on OCTA|Intraretinal and/or subretinal fluid in SD-OCT|visual acuity in logmar|presence or abscence of hemorrhage, fibrosis and atrophy on fundus color photography|presence or abscence of hemorrhage on fundus color photography|presence or abscence of fibrosis on fundus color photography|presence or abscence of atrophy on fundus color photography|type of choroidal neovascularization on fluorescein angiography (type 1, type 2 or mixed lesions)|type of choroidal neovascularization on indocyanine green angiography (type 1, type 2 or mixed lesions)|choroidal thickness on EDI-OCT|type of choroidal neovascularization on SD-OCT (type 1, type 2 or mixed lesions)","Centre Hospitalier Intercommunal Creteil|Bayer","All","55 Years and older   (Adult, Older Adult)",,"49","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","COCTAEyl","September 4, 2018","May 30, 2019","May 30, 2020","January 14, 2019",,"January 14, 2019","Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France|CHI de Créteil, Créteil, France|Hôpital La Croix Rousse, Lyon, France|Hôpital Lariboisière, APHP, Paris, France|Centre Ophtalmologique d'Imagerie et de Laser,, Paris, France",,"https://ClinicalTrials.gov/show/NCT03803631"
1382,"NCT03796377","Rivaroxaban Hypericum Trial",,"Completed","No Results Available","Drug Interaction Study","Drug: St Johns Wort Extract|Drug: Rivaroxaban","Pharmacokinetic outcome measures: area under the curve (AUC).|Pharmacokinetic outcome measures: maximal concentration of rivaroxaban.|Pharmacodynamic outcome measures: Factor Xa activity|Pharmacokinetic parameters: Time to reach maximal concentration|Pharmacokinetic parameters: Plasma elimination half-life|Phenotyping metrics: AUC fexofenadine|Phenotyping metrics: AUC ratios midazolam|Phenotyping metrics: Single point metabolic ratios midazolam","University Hospital Inselspital, Berne|Bayer","All","18 Years to 45 Years   (Adult)","Phase 1","12","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Other","Studien-Nr. 3459","February 13, 2019","April 9, 2019","April 9, 2019","January 8, 2019",,"May 7, 2019","Inselspital, Bern, Switzerland",,"https://ClinicalTrials.gov/show/NCT03796377"
1383,"NCT03780361","Changes in Inflammatory Biomarkers Including Soluble CD14 and Hyperreflective Foci in DME Patients Treated With Aflibercept (FORESIGHT)","FORESIGHT","Not yet recruiting","No Results Available","Diabetic Macular Edema","Drug: Aflibercept Injection","Change in the level of sCD14 in the aqueous humor|Change in the levels of cytokines (MCP-1, IL-6, ICAM-1) in the aqueous humor|Change in the number of hyperreflective foci (HF) on optical coherence tomography (OCT)|Change in the thickeness of macula on OCT|Change in mean visual acuity (ETDRS)","Hyewon Chung|Bayer|Konkuk University Medical Center","All","19 Years and older   (Adult, Older Adult)","Phase 4","47","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","20658","February 15, 2019","January 1, 2020","October 1, 2020","December 19, 2018",,"February 19, 2019",,,"https://ClinicalTrials.gov/show/NCT03780361"
1384,"NCT03772457","Predictive Value of Infarction Volume on Hemorrhagic Transformation in Ischemic Stroke/TIA With Non-valve Atrial Fibrillation(NVAF) Patients Using Rivaroxaban",,"Not yet recruiting","No Results Available","Cerebrovascular Stroke|Intracranial Hemorrhages|Anticoagulant|Matrix Metalloproteinases","Drug: Rivaroxaban","Susceptibility weighted imaging(SWI) detection of newly developed hemorrhagic transformation after 14 days of rivaroxaban treatment","Second Affiliated Hospital, School of Medicine, Zhejiang University|Bayer","All","18 Years and older   (Adult, Older Adult)",,"400","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","InV HT RAF 1010","January 1, 2019","January 1, 2021","January 15, 2021","December 11, 2018",,"December 11, 2018",,,"https://ClinicalTrials.gov/show/NCT03772457"
1385,"NCT03729544","Computerized Decision Support to Increase Detection of Chronic Thromboembolic Pulmonary Hypertension in Patients With Prior Pulmonary Embolism","CTEPH-DETECT","Recruiting","No Results Available","Chronic Thromboembolic Pulmonary Hypertension","Behavioral: On-screen computerized decision support alert","Frequency of echocardiographic screening for CTEPH in patients with prior PE and symptoms/signs suggestive of pulmonary hypertension or recent pulmonary testing suggesting unexplained respiratory symptoms at 3 months following randomization.|Frequency of CTEPH diagnosis at three months.","Brigham and Women's Hospital|Bayer","All","18 Years and older   (Adult, Older Adult)","Not Applicable","400","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Screening","2018P001681","March 1, 2019","January 30, 2021","March 30, 2021","November 2, 2018",,"July 17, 2019","Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03729544"
1386,"NCT03708809","Immediate Versus Delayed Initiation of Intrauterine System","JANESS","Recruiting","No Results Available","Contraception","Device: Intrauterine system|Other: Alternative contraception to intrauterine system","Continuation rate after one year from insertion|Expulsion rate","Sheba Medical Center|Bayer","Female","18 Years to 42 Years   (Adult)","Not Applicable","270","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","4671-17-SMC","March 1, 2019","January 1, 2020","May 1, 2020","October 17, 2018",,"July 9, 2019","Sheba Medical Center, Ramat Gan, Israel",,"https://ClinicalTrials.gov/show/NCT03708809"
1387,"NCT03629327","Inducing Immune Quiescence the Genital Tract With ASA","IIQ-2","Not yet recruiting","No Results Available","Hiv","Drug: ASA 100mg|Drug: Placebo|Drug: ASA 300mg","Changes in the proportion of HIV Target cells (CD4+CCR5+)","University of Manitoba|Bayer","Female","18 Years to 45 Years   (Adult)","Not Applicable","300","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","HS19749(B2016:042)|B2016:042","January 1, 2020","December 31, 2022","December 31, 2024","August 14, 2018",,"September 24, 2019","Kenyan Aids Control Project/University of Nairobi, Nairobi,, Kenya",,"https://ClinicalTrials.gov/show/NCT03629327"
1388,"NCT03574571","A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer",,"Recruiting","No Results Available","Prostate Cancer","Drug: Docetaxel 75 mg/m2|Drug: Docetaxel 60 mg/m2|Drug: Radium-223","Overall survival","Memorial Sloan Kettering Cancer Center|Bayer","Male","18 Years and older   (Adult, Older Adult)","Phase 3","738","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-150|2018-002944-10","June 19, 2018","June 2022","June 2023","July 2, 2018",,"January 2, 2020","Yale University- Yale Cancer Center, New Haven, Connecticut, United States|Helen Graham Cancer Center (Christiana Care), Newark, Delaware, United States|Rush University Medical Center, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Ochsner Cancer Institute, New Orleans, Louisiana, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|University of Massachusetts, Worcester, Massachusetts, United States|University of Michigan Cancer Center, Ann Arbor, Michigan, United States|GU Research Network / Urology Cancer Center, Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|MD Anderson Cancer Center at Cooper, Camden, New Jersey, United States|Memoral Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Northwell Health, Manhasset, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|New York Presbyterian Hospital-Weill Medical College of Cornell University, New York, New York, United States|Bronx VA Hospital, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Memorial Sloan Kettering Rockville Centre, Rockville Centre, New York, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|University of Oklahoma, Oklahoma City, Oklahoma, United States|MidLantic Urology, Bala-Cynwyd, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Millennium Oncology, Houston, Texas, United States|Millennium Physicians, Houston, Texas, United States|University of Washington, Seattle, Washington, United States|Northwestern Hospital Group (NWZ), Alkmaar, Netherlands|Ziekenhuisgroep Twente (ZGT), Almelo, Netherlands|Amphia Hospital, Breda, Netherlands|Haaglanden Medical Center, Den Haag, Netherlands|Tergooi Hospital, Hilversum, Netherlands|Canisius Wilhelmina Ziekenhuis (CWZ), Nijmegen, Netherlands|Erasmus MC Cancer Institute, Rotterdam, Netherlands|Franciscus Gasthuis & Vlietland, Rotterdam, Netherlands|Maasstad Hospital, Rotterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT03574571"
1389,"NCT03453281","Early Anatomical, Physiological, and Clinical Changes in Diabetic Macular Edema After Intravitreal Aflibercept Injection",,"Completed","No Results Available","Diabetic Macular Edema|Diabetic Retinopathy|Clinically Significant Macular Edema","Drug: Aflibercept Injection [Eylea]","Central macular thickness|Amplitude of P1 wave|Amplitude of N1 wave|Amplitude of N2 wave|Implisit time of P1 wave|Implisit time of N1 wave|Implisit time of N2 wave|Best corrected visual acuity|Best corrected visual acuity (number of letters)|Uncorrected visual acuity|Uncorrected visual acuity (number of letters)","Indonesia University|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 4","36","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-07-0750","October 10, 2017","April 9, 2018","May 18, 2018","March 5, 2018",,"July 12, 2018","Dept. of Ophthalmology, Faculty of Medicine Universitas Indonesia, RSCM Kirana, Jakarta Pusat, DKI Jakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT03453281"
1390,"NCT03432949","Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With M+CRPC","TRANCE","Recruiting","No Results Available","Metastatic Prostate Cancer","Drug: Dexamethasone plus Radium-223","Percentage of total doses delivered on schedule","University Health Network, Toronto|Bayer","Male","Child, Adult, Older Adult","Phase 4","24","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-5196","February 23, 2018","February 15, 2021","February 15, 2022","February 14, 2018",,"January 13, 2020","University Health Network, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03432949"
1391,"NCT03418610","Azelaic Acid Foam 15% in the Treatment of Papulopustular Rosacea",,"Completed","No Results Available","Rosacea, Papulopustular","Drug: Azelaic Acid foam 15%","Inflammatory Lesion Count|Investigator Global Assessment","Clinical Research Center of the Carolinas|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 4","5","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Bayer Rosacea","December 6, 2017","January 9, 2019","January 9, 2019","February 1, 2018",,"July 24, 2019","Clinical Research Center of the Carolinas, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03418610"
1392,"NCT03414437","Post-eRADicAte - A Long Term Follow up of Subjects That Completed the eRADicAte Study (NCT 02097303)","Post-eRADicAte","Active, not recruiting","No Results Available","Prostate Cancer Metastatic",,"To investigate the overall survival of subjects that completed the ""eRADicAte"" study.|To investigate subsequent prostate cancer therapies and medications of subjects that completed the ""eRADicAte"" study.|To investigate radiographic changes of subjects that completed the ""eRADicAte"" study.|To investigate SSE's of subjects that completed the ""eRADicAte"" study|To investigate the incidence of bone marrow failure of subjects that completed the ""eRADicAte"" study.|To investigate the occurence of subsequent diagnosis with secondary malignancies of subjects that completed the ""eRADicAte"" study.","Carolina Research Professionals, LLC|Bayer","Male","Child, Adult, Older Adult",,"31","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Other","CRP-PCA-01.1","October 1, 2017","October 1, 2021","October 1, 2021","January 30, 2018",,"March 19, 2019","Chesapeake urology Research Associates, Towson, Maryland, United States|Urology Cancer Center and GU Research Network, Omaha, Nebraska, United States|Associated Medical Professionals, Syracuse, New York, United States|Oregon Urology Institute, Springfield, Oregon, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03414437"
1393,"NCT03409588","Treatment of Exercise-Induced Pulmonary Vascular Dysfunction in Symptomatic Patients After Pulmonary Thromboendarterectomy",,"Not yet recruiting","No Results Available","Chronic Thromboembolic Disease (CTED)|Exercise Intolerance Post PEA Surgery","Drug: Adempas","Change in mean pulmonary arterial pressure|Change in cardiac output|Change in Pulmonary artery compliance|Change in 6 minute walk test|Change in New York Heart Association (NYHA) functional class|Change in the University of California San Diego (UCSD) shortness of Breath Score","University of Colorado, Denver|Bayer","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-2349","April 2020","April 2020","May 2020","January 24, 2018",,"January 18, 2020","University of Colorado, Anschutz Medical Campus, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT03409588"
1394,"NCT03358030","A Study of ISIS 416858 Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis","EMERALD","Completed","No Results Available","End-stage Renal Disease (ESRD)","Drug: ISIS 416858|Drug: Placebo","Incidence of treatment-emergent adverse events (safety and tolerability)|Incidence of clinically relevant and non-major bleeding (safety and tolerability)|Changes in liver function tests (safety and tolerability)|Changes in hematologic cell counts (cells/L) (safety and tolerability)|Pharmacodynamic Outcomes as measured by absolute and percent change in FXI antigen and activity over time.|Pharmacodynamic Outcomes as measured by frequency of clotting on the dialysis filters and circuit.|Pharmacokinetic Outcome to assess steady state trough concentration (C trough) of ISIS 416858","Ionis Pharmaceuticals, Inc.|Bayer","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","213","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","ISIS 416858 CS5|2017-002165-21|NL62709.000.17","December 1, 2017","July 10, 2019","July 10, 2019","November 30, 2017",,"August 8, 2019","Ionis Investigative Site, Santiago De Compostela, A Coruna, Spain|Ionis Investigative Site, Alcalá De Henares, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT03358030"
1395,"NCT03315650","Rivaroxaban in Patients With Atrial Fibrillation Undergoing PCI","RIVA-PCI","Recruiting","No Results Available","Non-valvular Atrial Fibrillation|Acute Coronary Syndrome|Percutaneous Coronary Intervention|Antithrombotic Therapy",,"Antithrombotic combination therapies (treatment patterns) in patients with non-valvular AF undergoing PCI|Evaluation of antithrombotic medication during long-term follow-up|Adverse Events during baseline and follow-up|Treatment adherence of patients","IHF GmbH - Institut für Herzinfarktforschung|Bayer","All","18 Years and older   (Adult, Older Adult)",,"2100","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","RIVA-PCI","January 1, 2018","October 2019","December 2020","October 20, 2017",,"August 13, 2019","Kerckhoff-Klinik, Bad Nauheim, Germany|Segeberger Kliniken, Bad Segeberg, Germany|Gesundheitszentrum Bitterfeld-Wolfen, Bitterfeld-Wolfen, Germany|Klinikum Links der Weser, Bremen, Germany|Krankenhaus Buchholz, Buchholz, Germany|Klinikum Coburg, Coburg, Germany|SLK-Kliniken Heilbronn, Heilbronn, Germany|Städtisches Klinikum Ludwigshafen, Ludwigshafen, Germany|Universitätsklinikum Mannheim, Mannheim, Germany|Klinikum der Universität München , Campus Großhadern, Munich, Germany|Kreisklinikum Siegen, Siegen, Germany|Robert-Bosch-Krankenhaus, Stuttgart, Germany|Schwarzwald-Baar Klinikum, Villingen-Schwenningen, Germany",,"https://ClinicalTrials.gov/show/NCT03315650"
1396,"NCT03304418","Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone","RROPE","Recruiting","No Results Available","Prostate Cancer Metastatic to Bone","Drug: Radium Ra 223 Dichloride|Radiation: Radiation","Time to Androgen Deprivation Therapy (ADT) Use|Time from start of study therapy to start of ADT.|Evaluate health related quality of life (QOL)|Evaluate changes in general function and well being|Evaluate time to first skeletal related event (SRE)|Evaluate the PSA doubling time|Evaluate Overall Surival","University of Utah|Bayer","Male","18 Years and older   (Adult, Older Adult)","Phase 2","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HCI102312","February 12, 2018","November 2022","November 2022","October 9, 2017",,"December 12, 2019","Huntsman Cancer Institute, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT03304418"
1397,"NCT03223727","Treatment Outcomes in a Non-study Population of Symptomatic mCRPC Patients Treated With Radium-223","ROTOR","Unknown status","No Results Available","Prostate Cancer Metastatic|Bone Metastases","Diagnostic Test: Blood tests","Efficacy of treatment on pain outcomes, as mentioned by the patient|Efficacy of treatment by patient records|Symptomatic Skeletal Event|Clinical Parameters assessed by the WHO PS.|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Subsequent therapy after Radium-223: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Biomarkers","The Netherlands Cancer Institute|Bayer","Male","18 Years and older   (Adult, Older Adult)",,"100","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","m15RTO","October 30, 2015","October 30, 2018","October 30, 2018","July 21, 2017",,"August 22, 2017","The Netherlands Cancer Intitute, Amsterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT03223727"
1398,"NCT03223597","Registry of Treatment Outcomes of Symptomatic Metastasized Castration Resistant Prostate Cancer Treated With Radium-223","ROTOR","Unknown status","No Results Available","Prostate Cancer Metastatic|Bone Metastases","Drug: Radium-223 dichloride","Reported analgesic use and pain outcome|Efficacy on clinical parameters of treatment with Radium-223|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Subsequent therapy after Radium-223: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Efficacy of subsequent treatment on clinical parameters|Symptomatic Skeletal Events|Evaluate the efficacy of Radium-223 by patient records","The Netherlands Cancer Institute|Bayer","Male","18 Years and older   (Adult, Older Adult)",,"300","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","m14ROT","September 17, 2015","April 1, 2018","April 1, 2018","July 21, 2017",,"August 22, 2017","Meander Medical Center, Amersfoort, Utrecht, Netherlands|Jeroen Bosch Hospital, 's Hertogenbosch, Netherlands|Noordwest Ziekenhuisgroep, Alkmaar, Netherlands|Zorggroep Twente, Almelo, Netherlands|The Netherlands Cancer Intitute, Amsterdam, Netherlands|Rijnstate, Arnhem, Netherlands|Amphia Ziekenhuis, Breda, Netherlands|Reinier de Graaf Hospital, Delft, Netherlands|Deventer Ziekenhuis, Deventer, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|Groene Hart Ziekenhuis, Gouda, Netherlands|Martini Ziekenhuis, Groningen, Netherlands|Atrium Medisch Centrum Parkstad, Heerlen, Netherlands|Spaarne Gasthuis, Hoofddorp, Netherlands|Antonius Ziekenhuis, Nieuwegein, Netherlands|Franciscus Gasthuis-Vlietland, Rotterdam, Netherlands|Haga Ziekenhuis, The Hague, Netherlands|MC Haaglanden, The Hague, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Isala Klinieken, Zwolle, Netherlands",,"https://ClinicalTrials.gov/show/NCT03223597"
1399,"NCT03179592","VOLtage-based Contrast Media AdaptatioN in Coronary Computed Tomography Angiography","VOLCANIC-CTA","Completed","No Results Available","Coronary Artery Disease|Cardiovascular Diseases","Drug: Ultravist 370Mg I/Ml Solution for Injection","Qualitative assessment of image quality|Quantitative assessment of image quality|Radiation dose of coronary CTA","Medical University of South Carolina|Bayer","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","120","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Pro00060805","March 22, 2017","February 11, 2019","February 11, 2019","June 7, 2017",,"November 8, 2019","Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03179592"
1400,"NCT03169660","Intravitreal Aflibercept for Submacular Hemorrhage",,"Completed","No Results Available","Exudative Age-related Macular Degeneration","Drug: Vascular endothelial growth factor trap-eye","Changes in Early Treatment of Diabetic Retinopathy Study visual acuity Score|Proportion of patients who exhibited 15 letters or greater change in visual acuity|Changes in central macular thickness|Duration of complete hemorrahge resolution|Incidence of recurrence of submacular hemorrhage or fluid|Leakage on angiography","Kim's Eye Hospital|Bayer","All","50 Years and older   (Adult, Older Adult)","Phase 4","29","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","A-2014-032","December 2015","January 20, 2019","January 20, 2019","May 30, 2017",,"February 21, 2019","Kim's Eye Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03169660"
1401,"NCT03168685","Hemophilia Mobile App Usability Pilot",,"Active, not recruiting","No Results Available","Hemophilia","Device: SureSource Engage application","Usage of the SureSource Engage application as assessed by ActiLife software|Device usability as assessed by the System Usability Scale (SUS)","Healthcare Innovation Technology Lab|Bayer","All","18 Years to 63 Years   (Adult)","Not Applicable","20","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","Pro00021564","May 22, 2017","May 11, 2018","May 11, 2018","May 30, 2017",,"April 19, 2018","Healthcare Innovation and Technology Lab, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03168685"
1402,"NCT03117634","An Open Label-study to Compare the Efficacy of Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy Using a Modified Intensive Treat and Extend Regime to a Fixed Dosing Regimen",,"Unknown status","No Results Available","Age Related Macular Degeneration|Polypoidal Choroidal Vasculopathy","Drug: Treat and Extend with Aflibercept 2mg|Drug: Fixed Dosing with Aflibercept 2mg","Best corrected visual acuity (BCVA)|Closure rate|Number of injections","Singapore National Eye Centre|Bayer","All","45 Years to 90 Years   (Adult, Older Adult)","Phase 4","52","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R1448/31/2017","October 1, 2017","December 31, 2018","July 1, 2019","April 18, 2017",,"October 5, 2017","Singapore National Eye Centre, Singapore, Singpore, Singapore",,"https://ClinicalTrials.gov/show/NCT03117634"
1403,"NCT03045419","Added Value of Gadoxetic Acid-enhanced Liver MRI",,"Completed","No Results Available","Hcc|Diagnosis","Procedure: gadoxetic acid-enhanced liver MRI","sensitivity to diagnose HCC, per-nodule base|specificity to diagnose HCC, per-nodule base|sensitivity to diagnose HCC, per-patient base|specificity to diagnose HCC, per-patient base","Seoul National University Hospital|Bayer","All","18 Years and older   (Adult, Older Adult)",,"130","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","SNUH-2009-5441","December 29, 2009","November 24, 2013","December 31, 2016","February 7, 2017",,"February 7, 2017","Seoul National University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03045419"
1404,"NCT03042689","Study of Regorafenib in Patients With Advanced Myeloid Malignancies",,"Recruiting","No Results Available","Acute Myeloid Leukemia","Drug: Regorafenib","Maximum tolerated dose of regorafenib in patients with advanced myeloid malignancies|Pharmacodynamic effects of regorafenib on cell signaling pathways|Progression Free Survival|Overall Survival|To Measure Changes In Specific Markers Of Allele Burden","Massachusetts General Hospital|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","28","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-464","April 17, 2017","January 2020","January 2023","February 3, 2017",,"July 10, 2019","Massachusetts general Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03042689"
1405,"NCT03023722","Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer",,"Completed","No Results Available","Pancreatic Cancer","Drug: anetumab ravtansine","Response rate as measured per RECIST 1.1 criteria|Time to Progression|Drug Toxicity","Yale University|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","18","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1608018265","May 11, 2017","August 6, 2019","December 11, 2019","January 18, 2017",,"January 14, 2020","Yale Cancer Center, New Haven, Connecticut, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03023722"
1406,"NCT03010722","Prospective Translational Study Investigating Molecular Predictors of Resistance and Response to Regorafenib Monotherapy","PROSPECT-R","Unknown status","No Results Available","Metastatic Colorectal Cancer","Drug: Regorafenib","disease control rate (DCR), measured in months|progression free survival (PFS), measured in months|overall survival (OS), measured in months|Median values of volume transfer constant (Ktrans) and enhancing fraction (EF) and their product KEF (product of summarised median values of Ktrans x EF/100) will be compared at baseline and on day 15","Royal Marsden NHS Foundation Trust|Bayer","All","18 Years and older   (Adult, Older Adult)",,"49","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","4164","January 2015","January 2017","July 2017","January 5, 2017",,"January 5, 2017","The Royal Marsden NHS Foundation Trust London and Surrey, Carshalton, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03010722"
1407,"NCT03004534","A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide",,"Completed","No Results Available","Breast Cancer Female","Drug: darolutamide","Explore/Define Molecular Alterations in Core Tissue Tumor Samples Following Darolutamide Administration|Number of participants with treatment-related adverse events as assessed by CTCAE v4.03","Translational Research in Oncology|Bayer","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","36","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TRIO030|2016-004151-79|HC6-24-c 201058","September 5, 2017","February 14, 2019","March 13, 2019","December 29, 2016",,"April 19, 2019","UCLA, Los Angeles, California, United States|Valley Breast Care and Women's Health Center, Los Angeles, California, United States|Torrance Memorial Physician Network, Cancer Care Associates, Redondo Beach, California, United States|Central Coast Medical Oncology, Santa Maria, California, United States|UF Health Cancer Center - Orlando Health, Orlando, Florida, United States|Cross Cancer Institute, Edmonton, Alberta, Canada|Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada|McGill University Hospital, Montreal, Quebec, Canada|(CIUSSS) de l'Est-de-l'Île-de-Montréal - l'Hôpital Maisonneuve-Rosemont, Montréal, Quebec, Canada|Centre Hospitalier Affilie Universitaire De Quebec - Hospital Du Saint-Sacrement, Quebec City, Quebec, Canada|Universitatsklinikum Erlangen, Erlangen, Germany|Interdisziplinares Onkologisches Zentrum, Muenchen, Germany|Department of Women's Health, Tubingen, Germany",,"https://ClinicalTrials.gov/show/NCT03004534"
1408,"NCT03003442","Effects of Supradyn® Energy 3RDA on Fatigue/Stress, Substrate Metabolism During Exercise and Demanding Cognitive Tasks",,"Completed","No Results Available","Healthy","Dietary Supplement: Supradyn® Energy 3RDA|Dietary Supplement: Placebo","Acute treatment effects on energy expenditure/metabolism during physical stress|Acute treatment effects on energy expenditure/metabolism during mental stress|Chronic treatment effects on energy expenditure/metabolism during physical stress|Chronic treatment effects on energy expenditure/metabolism during mental stress|Acute treatment effects on subjective arousal/stress/fatigue ratings as assessed by visual analogue scales during physical stress|Acute treatment effects on subjective arousal/stress/fatigue ratings as assessed by visual analogue scales during mental stress.|Chronic (28 days) treatment effects on subjective arousal/stress/fatigue ratings as assessed by visual analogue scales, during physical stress|Chronic (28 days) treatment effects on subjective arousal/stress/fatigue ratings as assessed by visual analogue scales, during mental stress|Acute treatment effects on recovery biomarkers|Chronic (28 days) treatment effects on recovery biomarkers|Acute treatment effects on vitamin/mineral/homocysteine levels|Chronic (28 days) treatment effects on vitamin/mineral/homocysteine levels|Acute treatment effects on cognitive performance|Chronic (28 days) treatment effects on cognitive performance","Northumbria University|Bayer","All","18 Years to 35 Years   (Adult)","Not Applicable","91","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other","18769","November 1, 2016","October 16, 2017","October 18, 2017","December 28, 2016",,"March 13, 2018","Northumbria University, Newcastle upon Tyne, Tyne & Wear, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03003442"
1409,"NCT03002220","Trial of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR-V7 Status",,"Active, not recruiting","No Results Available","Prostate Cancer","Drug: radium-223","Assess the efficacy of radium-223 in terms of radiological rPFS|AEs and serious adverse events (SAEs) will be assessed to determine the safety and tolerability|Radiographic progression-free survival (rPFS) depending on AR-V7 status.|Overall survival (OS).|Time to first symptomatic skeletal event (SSE).|Time to PSA progression according to the ALSYMPCA study criteria.|Determination percentage of PSA progression|Alkaline phosphatase level response (AF), normalization of alkaline phosphatase level|Assessment of AR-V7 mutation evolution|Determination changes in CTCs number","MedSIR|Bayer","Male","18 Years and older   (Adult, Older Adult)","Phase 2","52","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MedOPP098","November 2016","September 2019","April 2021","December 23, 2016",,"April 8, 2019","MedSIR Investigative site, Barcelona, Spain|MedSIR Investigative site, Cáceres, Spain|MedSIR Investigative site, Córdoba, Spain|MedSIR Investigative site, Lugo, Spain|MedSIR Investigative site, Madrid, Spain|MedSIR investigative site, Palma De Mallorca, Spain",,"https://ClinicalTrials.gov/show/NCT03002220"
1410,"NCT02981797","Assess Gamma H2AX Positivity in Circulating Prostate Cancer Cells Before and After Radium 223",,"Active, not recruiting","No Results Available","Prostate Cancer|Prostate Adenocarcinoma","Other: Blood Collection During Standard of Care Treatment","Changes in Gamma H2AX Positivity|Changes in Circulating Prostate Cancer Cell Numbers|Pain Response|Changes in Narcotic Analgesic Use|PSA Response","H. Lee Moffitt Cancer Center and Research Institute|Bayer","Male","18 Years and older   (Adult, Older Adult)",,"10","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","MCC-17725|ONC-2013-067","March 5, 2015","August 29, 2017","December 2020","December 5, 2016",,"January 21, 2020","H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02981797"
1411,"NCT02973984","The European Registry of Older Subjects With Atrial Fibrillation (EUROSAF)","EUROSAF","Recruiting","No Results Available","Atrial Fibrillation",,"all-cause mortality and vascular mortality|thromboembolic events,|bleeding side-effects|vascular-related hospitalization rates|bleeding-related hospitalization rates|MPI value and different mortality risk class|presence/absence of anticoagulant treatments","Alberto Pilotto|Bayer|Ente Ospedaliero Ospedali Galliera","All","65 Years and older   (Older Adult)",,"3000","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","28UCS2015|162REG2016","November 18, 2016","December 2019","March 2020","November 28, 2016",,"July 18, 2019","S.C. Geriatria, Genova, Italy",,"https://ClinicalTrials.gov/show/NCT02973984"
1412,"NCT02972060","ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer",,"Recruiting","No Results Available","Prostate Cancer","Drug: ODM-201|Drug: ADT","PSA response|EORTC QLQ-PR25|Objective tumor response|90% PSA response rate|evaluation of safety","European Organisation for Research and Treatment of Cancer - EORTC|Bayer","Male","18 Years and older   (Adult, Older Adult)","Phase 2","250","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EORTC-1532|2016-004334-17","December 1, 2017","December 2020","May 2022","November 23, 2016",,"April 25, 2018","Hopitaux Universitaires Bordet-Erasme - Hopital Universitaire Erasme, Brussels, Belgium|CHU Dinant Godinne - UCL Namur, Yvoir, Belgium|Institut Catala d'Oncologia - ICO Badalona - Hospital Germans Trias i Pujol, Badalona, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario Virgen De La Victoria, Malaga, Spain|Hospital Universitario de Salamanca, Salamanca, Spain",,"https://ClinicalTrials.gov/show/NCT02972060"
1413,"NCT00002238","Phase III Randomized Double-Blind Placebo Controlled Study To Evaluate the Safety and Efficacy of Betaseron in AIDS and Advanced ARC Patients Receiving a Reduced-Dose AZT Regimen",,"Completed","No Results Available","HIV Infections","Drug: Interferon beta-1b|Drug: Zidovudine",,"Bayer|NIH AIDS Clinical Trials Information Service","All","18 Years and older   (Adult, Older Adult)","Phase 3",,"Industry","Interventional","Masking: Double|Primary Purpose: Treatment","002A|TBO1-310188",,,,"August 31, 2001",,"June 24, 2005","Alta Bates / Herrick Hosp, Berkeley, California, United States|USC School of Medicine / Norris Cancer Hosp, Los Angeles, California, United States|Cedars Sinai Med Ctr, Los Angeles, California, United States|UCLA CARE Ctr, Los Angeles, California, United States|Summitt Med Ctr / San Francisco Gen Hosp, Oakland, California, United States|UCI Med Ctr, Orange, California, United States|Davies Med Ctr, San Francisco, California, United States|Santa Clara Valley Med Ctr, San Jose, California, United States|Dr William Davis, Washington, District of Columbia, United States|George Washington Univ Med Ctr, Washington, District of Columbia, United States|Univ of South Florida, Tampa, Florida, United States|AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States|Northwestern Univ Med School, Chicago, Illinois, United States|Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States|Johns Hopkins Hosp, Baltimore, Maryland, United States|Boston Med Ctr, Boston, Massachusetts, United States|Beth Israel Med Ctr / Peter Krueger Clinic, New York, New York, United States|Chelsea Village Med Ctr, New York, New York, United States|Dr Douglas Dieterich, New York, New York, United States|Mem Sloan - Kettering Cancer Ctr, New York, New York, United States|Univ Hosp of Cleveland / Case Western Reserve Univ, Cleveland, Ohio, United States|Thomas Jefferson Med College, Philadelphia, Pennsylvania, United States|Saint Christopher's Hosp for Children, Philadelphia, Pennsylvania, United States|Graduate Hosp, Philadelphia, Pennsylvania, United States|Univ TX Galveston Med Branch, Galveston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00002238"
1414,"NCT02957292","A Study to Compare the Menstrual Bleeding Profile Among Jaydess® and Copper Intrauterine Device (IUD) Users. COLIBRI STUDY (Copper and Levonorgestrel IUD Barcelona Research Initiative).","COLIBRI","Recruiting","No Results Available","Contraception","Drug: Levonorgestrel (13,5 mg) intrauterine device|Device: Cooper (380mm2) intrauterine device","Number of menstrual bleeding days|Amount of Menstrual bleeding","Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Bayer","Female","18 Years to 45 Years   (Adult)","Phase 4","106","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","IIBSP-DIU-2015-85","June 2016","March 2020",,"November 7, 2016",,"November 7, 2016","Hospital de la Santa Creu i Sant Pau, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT02957292"
1415,"NCT02940548","Nifedipine GITS and Amlodipine Besylate on Recovery of Blood Pressure Rhythm and Arterial Stiffness","NARRAS","Unknown status","No Results Available","Hypertension","Drug: Nifedipine GITS|Drug: Amlodipine besylate","Nighttime systolic blood pressure reduction|The proportion of recovery of dipper rhythm of blood pressure|Change of pulse wave velocity","Jing Liu|Bayer|Peking University People's Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","120","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016PHB013-02","December 2016","June 2018","December 2018","October 21, 2016",,"December 14, 2016","Peking University People's Hospital, Beijing, China",,"https://ClinicalTrials.gov/show/NCT02940548"
1416,"NCT02924987","Effect of Aflibercept (Eylea®) in the Management of Bevacizumab (Avastin®) Resistant Diabetic Macular Edema","Eylea","Unknown status","No Results Available","Diabetic Macular Edema","Drug: Aflibercept Injection","Macular central subfield thickness in micrometers|Macular central subfield thickness in micrometers at 12 months measured by optical coherence tomography in micrometers (HRT+OCT Spectralis model, Heidelberg Engineering, Heidelberg, Germany)|Best corrected visual acuity at 12 months measured in letters using ETDRS chart|Best corrected visual acuity at 6 months measured in letters using ETDRS chart","Maisonneuve-Rosemont Hospital|Bayer","All","Child, Adult, Older Adult","Phase 4","40","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Hôpital Maisonneuve-Rosemont","November 2016","November 2017","November 2017","October 5, 2016",,"March 27, 2017","Maisonneuve Rosemont Hospital, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02924987"
1417,"NCT02915835","Riociguat in Scleroderma Associated Digital Ulcers","RESCUE","Completed","Has Results","Scleroderma|Digital Ulcers","Drug: Riociguat|Drug: Placebo","Change From Baseline to End of Double-blind Treatment (Week 16) in Digital Ulcer Net Burden|Proportion of Participants With Healing of Their Cardinal DU by Week 16|Proportion of Participants With Healing of All DUs at Baseline by Week 16|Proportion of Participants With no DUs at Week 16|Proportion of Participants With New Active and Indeterminate DU(s) Over the Course of the Double-blind Period|Proportion of Participants Who Develop Pressure Ulcers at Distal Interphalangeal (DIP) Location Over the Course of the Double-blind Period.|Proportion of Participants Who Develop Pressure Ulcers at Proximal Interphalangeal (PIP) Location Over the Course of the Double-blind Period.|Proportion of Participants Who Develop Pressure Ulcers at Metacarpophalangeal (MCPs) Location Over the Course of the Double-blind Period.|Proportion of Participants Who Develop Pressure Ulcers at the Elbows Over the Course of the Double-blind Period.|Proportion of Participants With Healing of All Pressure Ulcers at the Distal Interphalangeal (DIP) Over the Course of the Double-blind Period.|Proportion of Participants With Healing of All Pressure Ulcers at the Proximal Interphalangeal (PIP) Over the Course of the Double-blind Period.|Proportion of Participants With Healing of All Pressure Ulcers at the Metacarpophalangeal (MCPs) Over the Course of the Double-blind Period.|Proportion of Participants With Healing of All Pressure Ulcers at the Elbows Over the Course of the Double-blind Period.|Time to Healing of Cardinal DU|Time to Healing of All Baseline DU|Time to Development of New ('Active' or 'Indeterminate') DU|Change From Baseline to Week 16 in Raynaud's Condition Score|Change From Baseline to Week 16 in Number of Raynaud's Attacks/Day|Change From Baseline to Week 16 in Duration of Raynaud's Attacks|Change From Baseline to Week 16 in Patient's Assessment of Pain During a Raynaud's Attack|Change From Baseline to Week 16 in Patient's Assessment of Numbness During a Raynaud's Attack|Change From Baseline to Week 16 in Patient's Assessment of Tingling During a Raynaud's Attack|Change From Baseline to Week 16 in Physician's Assessment of Severity of Raynaud's Disease|Change From Baseline to Week 16 in Physician's Assessment of Severity of Digital Ulcers|Change From Baseline to Week 16 in Patient's Assessment of Severity of Raynaud's Disease|Change From Baseline to Week 16 in Patient's Assessment of Severity of Digital Ulcers|Change From Baseline to Week 16 in Patient's Global Assessment for Overall Disease.|Change From Baseline to Week 16 in Physician's Global Assessment for Overall Disease.|Change From Baseline to Week 16 in PROMIS-29 Physical Function|Change From Baseline to Week 16 in PROMIS-29 Anxiety|Change From Baseline to Week 16 in PROMIS-29 Depression|Change From Baseline to Week 16 in PROMIS-29 Fatigue|Change From Baseline to Week 16 in PROMIS-29 Sleep Disturbance|Change From Baseline to Week 16 in PROMIS-29 Pain Interference|Change From Baseline to Week 16 in PROMIS-29 Ability to Participate in Social Roles and Activities|Change From Baseline to Week 16 in PROMIS-29 Pain Intensity|Change From Baseline to Week 16 in Overall HAQ-DI Score|Change From Baseline to Week 16 in HAQ-DI Dressing and Grooming|Change From Baseline to Week 16 in HAQ-DI Hygiene|Change From Baseline to Week 16 in HAQ-DI Arising|Change From Baseline to Week 16 in HAQ-DI Reach|Change From Baseline to Week 16 in HAQ-DI Eating|Change From Baseline to Week 16 in HAQ-DI Grip|Change From Baseline to Week 16 in HAQ-DI Walking|Change From Baseline to Week 16 in HAQ-DI Common Daily Activities (IADL).|Change From Baseline to Week 16 in HAQ-DI Composite Score for Hand Function|Change From Baseline to Week 16 in Total Hand Disability in Systemic Sclerosis-DU (HDISS-DU) Score|Change From Baseline to Week 16 in Scleroderma-HAQ-DI Visual Analogue Scales (VAS) Assessing Burden of Digital Ulcers|Change From Baseline to Week 16 in Scleroderma-HAQ-DI Visual Analogue Scales (VAS) Assessing Raynaud's Disease|Change From Baseline to Week 16 in Scleroderma-HAQ-DI Visual Analogue Scales (VAS) Assessing Gastrointestinal Involvement|Change From Baseline to Week 16 in Scleroderma-HAQ-DI Visual Analogue Scales (VAS) Assessing Breathing|Change From Baseline to Week 16 in Scleroderma-HAQ-DI Visual Analogue Scales (VAS) Assessing Overall Disease,|Proportion of Participants Who Experience Digital Ischemia Requiring Intravenous Prostacyclin or Digital Gangrene or Amputation During the Trial.|Proportion of Participants Who Develop Osteomyelitis During The Trial|Change From Baseline to Week 16 in Vascular Biomarker VEGF in the Plasma|Change From Baseline to Week 16 in Vascular Biomarker tPA in the Plasma|Change From Baseline to Week 16 in Vascular Biomarker sE-Selectin in the Plasma|Change From Baseline to Week 16 in Vascular Biomarker BFGF in the Plasma|Change From Baseline to Week 16 in Vascular Biomarker VCAM-1 in the Plasma|Change From Baseline to Week 16 in Vascular Biomarker ICAM in the Plasma","Dinesh Khanna, MD, MS|Bayer|University of Michigan","All","18 Years and older   (Adult, Older Adult)","Phase 2","17","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BAY63-2521","September 2016","July 24, 2018","July 24, 2018","September 27, 2016","September 24, 2019","September 24, 2019","Georgetown University, Washington, District of Columbia, United States|University of Michigan, Ann Arbor, Michigan, United States|Hospital of Special Surgery (HSS), New York, New York, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Utah, Salt Lake City, Utah, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT02915835/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT02915835/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02915835"
1418,"NCT02904239","Cardiac Pathologies in Standard Thoracic CT Imaging","CaPaCT","Completed","No Results Available","Coronary Artery Disease",,"Evaluate visibility and management of coronary artery disease (CAD)|Objective image quality|Subjective image quality","Maastricht University Medical Center|Bayer","All","18 Years to 100 Years   (Adult, Older Adult)",,"221","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16-4-116","July 2016","March 5, 2018","March 5, 2018","September 16, 2016",,"May 2, 2018","Maastricht University Medical Center, Maastricht, Limburg, Netherlands",,"https://ClinicalTrials.gov/show/NCT02904239"
1419,"NCT02880644","Ultra-wide Fluorescein Angiography in Patients With Central Retinal Vein Occlusion Treated by Afilbercept","HERMES","Recruiting","No Results Available","Retinal Vein Occlusion",,"Change from baseline in non-perfused areas in both macula and peripheral retina at 12 months|Change in visual acuity from baseline to months 3, 6, 12 and 24|Change from baseline in non-perfused areas in both macula and peripheral retina at 3, 6 and 12 months|Mean time between the last two injections|Mean number of injections by patient from baseline to end-of-study visit|Mean number of visits by patient from baseline to end-of-study visit|Change from baseline in central retinal thickness at 3, 6, 12 and 24 months|Change in vascular density in OCT-A from baseline to months 3, 6, 12, 24","Centre Hospitalier Intercommunal Creteil|Bayer","All","18 Years to 100 Years   (Adult, Older Adult)",,"50","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","HERMES","January 26, 2017","January 2020","January 2020","August 26, 2016",,"February 6, 2019","Centre Hospitalier Intercommunal Créteil, Créteil, France|Centre Monticelli Paradis d'Ophtalmologie, Marseille, France|Centre Hospitalier Universitaire De Nantes, Nantes, France|CHU Nice-Saint-Roch, Nice, France|Centre d'exploration ophtalmologique de l'odéon, Paris, France|Centre d'Imagerie et de laser, Paris, France|CHNO des Quinze-Vingts, Paris, France|Hôpital Lariboisière - APHP, Paris, France|Hôpital Robert Debré - CHU Reims, Reims, France",,"https://ClinicalTrials.gov/show/NCT02880644"
1420,"NCT02874859","Intravitreal Aflibercept InjectiOn in Vitrectomized Eyes for Treatment of Diabetic Macular Edema","MODEVA","Recruiting","No Results Available","Diabetic Macular Edema",,"Estimation of visual acuity Early Treatment Diabetic Retinopathy Study (ETDRS)|Measure of the central macular thickness|Quantification of number of Aflibercept injections received","Lille Catholic University|Bayer","All","18 Years to 90 Years   (Adult, Older Adult)",,"50","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","RC-P0051","November 9, 2016","December 2019","December 2019","August 22, 2016",,"November 1, 2018","Pr MILAZZO Solange, Amiens, Hauts De France, France|Tran Thi Ha Chau, Lomme, Hauts De France, France|Bénédicte DUPAS, Paris, Ile De France, France|Stéphanie BAILLIF, Nice, Paca, France",,"https://ClinicalTrials.gov/show/NCT02874859"
1421,"NCT02846532","Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure","UNIVERSE","Active, not recruiting","No Results Available","Thrombosis","Drug: Rivaroxaban|Drug: Acetylsalicylic Acid","Maximum Observed Plasma Concentration (Cmax)|Area Under the Analyte ConcentrationTime Curve From Time 0 to 24 Hours (AUC24)|Maximum Plasma Concentration (Cmax,ss) at Steady State|Minimum Plasma Concentration (Cmin,ss) at Steady State|Absolute Prothrombin Time (PT)|Activated Partial Thromboplastin Time (aPTT)|Anti-Factor Xa (FXa)|Number of Participants With Major Bleeding Events|Number of Participants With Incidence of Thrombotic Events|Number of Participants With Adverse Events as a Measure of Safety and Tolerability|Number of Participants With Clinically Relevant Non-Major Bleeding Events|Number of Participants With Trivial (Minimal) Bleeding","Janssen Research & Development, LLC|Bayer","All","2 Years to 8 Years   (Child)","Phase 3","112","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CR108075|39039039CHD3001|2015-002610-76","November 16, 2016","July 17, 2020","July 17, 2020","July 27, 2016",,"January 13, 2020","Los Angeles, California, United States|Gainesville, Florida, United States|Oak Lawn, Illinois, United States|Indianapolis, Indiana, United States|Iowa City, Iowa, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Minneapolis, Minnesota, United States|Omaha, Nebraska, United States|Durham, North Carolina, United States|Cincinnati, Ohio, United States|Hershey, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Memphis, Tennessee, United States|Houston, Texas, United States|Salt Lake City, Utah, United States|Milwaukee, Wisconsin, United States|Buenos Aires, Argentina|Cordoba, Argentina|Brussel, Belgium|Gent, Belgium|Leuven, Belgium|Curitiba, Brazil|Porto Alegre, Brazil|São Paulo, Brazil|Vancouver, British Columbia, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Fukuoka, Japan|Kitakyushu-shi,, Japan|Setagaya-ku, Japan|Shizuoka-shi, Shizuoka, Japan|Kuala Lumpur, Malaysia|Mexico, Mexico|Leiden, Netherlands|Rotterdam, Netherlands|Utrecht, Netherlands|A Coruña, Spain|Barcelona, Spain|Bilbao, Spain|Madrid, Spain|Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT02846532"
1422,"NCT02835924","Study Comparing Different Dose Approaches of Induction Treatment of Regorafenib in MCRC","RE-ARRANGE","Active, not recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Regorafenib","Percentage of patients with G3/G4 treatment-related AEs in each arm according to CTCAE v4.03 criteria.|Percentage of total administrated dose over the planned dose accomplished in each arm.|Dose intensity during the whole treatment.|Dose intensity during first two cycles.|Disease control rate (DCR)|Progression-free survival (PFS)|Time to treatment failure (TTF)|Overall survival (OS)","Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","299","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TTD-16-01","July 2016","September 2018","September 2019","July 18, 2016",,"April 11, 2019","Spanish Cooperative Group for the Treatment of Digestive Tumors, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT02835924"
1423,"NCT02758964","Evaluation of Cerebral Thrombembolism After TAVR","EARTH - TAVR","Completed","No Results Available","Aortic Valve Stenosis|Transcatheter Aortic Valve Replacement|Intracranial Embolism","Other: MRI, neurocognitive Testing","Total volume of new cerebral lesions on MRI, 3 months after TAVR versus Baseline|New lesion volume of cerebral embolization in patients treated with ASS and rivaroxaban 10mg OD versus an antiplatelet -based strategy with ASS and clopidogrel.|extent and location of new cerebral lesions early AFTER TAVR and after 3 months|Assessment of different neurocognitive tests (NIHSS-score, MOCA-score, MOT-score, PAL-score, RTI-score, SWM-score, AST-score, CAM-Score); change of sum scores before, after and 3 months after TAVR procedure.|Extent and localization of clinically apparent non-cerebral emboli after TAVR|Evaluation of possible changes in quality of life after TAVI with EQ-5D questionnaire sum score.","Charite University, Berlin, Germany|Bayer","All","18 Years and older   (Adult, Older Adult)",,"55","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","EARTH - TAVR 01","September 2016","January 2019","January 2019","May 3, 2016",,"April 2, 2019","Charité - Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany|Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT02758964"
1424,"NCT02746185","Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban","CASTA-DIVA","Completed","No Results Available","Neoplasm|Venous Thromboembolism","Drug: rivaroxaban|Drug: Low-molecular-weight heparin","Symptomatic DVT|Symptomatic PE|Unsuspected PE and DVT|Worsening of pulmonary vascular or venous obstruction|Major and clinically significant bleedings during the 3-month treatment period|Symptomatic recurrences of PE or DVT of the legs|Major and non-major clinically significant bleedings at day 90|Mortality","Assistance Publique - Hôpitaux de Paris|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","159","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","P141204","September 2016","April 25, 2018","April 25, 2018","April 21, 2016",,"August 13, 2018","CHU Amiens - Medecine vasculaire (003), Amiens, France|CHU Angers - Medecin Interne (002), Angers, France|Espace Artois Santé, Arras, France|Hopital Saint Andre - Medecine vasculaire (015), Bordeaux, France|CHU Brest - Departement de medecin interne et pneumologie (008), Brest, France|CHU Le Bocage - Medecine interne 1 (014), Dijon, France|CHU Grenoble - Medecine vasculaire (007), Grenoble, France|CH Départemental La Roche sur Yon, La Roche-sur-Yon, France|Centre hospitalier Lyon Sud - Medecine interne (011), Lyon, France|CHRU de Nîmes - Pneumologie (012), Nîmes, France|HEGP - Pneumologie et soins intensifs (001), Paris, France|Institut Curie - Soins de support en Cancerologie (020), Paris, France|CHU Saint Etienne - Medecin vasculaire et therapeutique (006), Saint Etienne, France|Hopital Saine Musse - Service de Medecine Vasculaire (010), Toulon, France|CHU Rangueil - Medecin Vasculaire (019), Toulouse, France",,"https://ClinicalTrials.gov/show/NCT02746185"
1425,"NCT02712008","Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema","RUBY","Completed","Has Results","Diabetic Macular Edema","Drug: REGN910-3|Drug: Intravitreal Aflibercept Injection (IAI)","Change From Baseline in Best Corrected Visual Acuity (BCVA) Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 12|Change From Baseline in Best Corrected Visual Acuity (BCVA) Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 36|Change From Baseline in Central Sub-field Retinal Thickness (CST) Measured by Spectral Domain Optical Coherence Tomography (SD-OCT) at Week 12|Change From Baseline in Central Sub-field Retinal Thickness (CST) Measured by Spectral Domain Optical Coherence Tomography (SD-OCT) at Week 36|Percentage of Participants With a ≥ 2-step Improvement at Week 12 in Diabetic Retinopathy Severity Scale (DRSS) From Baseline|Percentage of Participants With a ≥ 2-step Improvement at Week 36 in Diabetic Retinopathy Severity Scale (DRSS) From Baseline","Regeneron Pharmaceuticals|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","302","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R910-3-DME-1518","March 2, 2016","July 10, 2017","July 10, 2017","March 17, 2016","October 3, 2018","October 3, 2018","Mesa, Arizona, United States|Tucson, Arizona, United States|Arcadia, California, United States|Beverly Hills, California, United States|Mountain View, California, United States|Oceanside, California, United States|Palm Desert, California, United States|Colorado Springs, Colorado, United States|New London, Connecticut, United States|Lakeland, Florida, United States|Tampa, Florida, United States|Winter Haven, Florida, United States|Augusta, Georgia, United States|Decatur, Georgia, United States|'Aiea, Hawaii, United States|Chicago, Illinois, United States|New Albany, Indiana, United States|Shawnee Mission, Kansas, United States|Lexington, Kentucky, United States|Portland, Maine, United States|Baltimore, Maryland, United States|Rockville, Maryland, United States|Boston, Massachusetts, United States|Grand Rapids, Michigan, United States|Jackson, Michigan, United States|Minneapolis, Minnesota, United States|Florissant, Missouri, United States|Las Vegas, Nevada, United States|Bloomfield, New Jersey, United States|Edison, New Jersey, United States|Teaneck, New Jersey, United States|Albany, New York, United States|Rochester, New York, United States|Asheville, North Carolina, United States|Charlotte, North Carolina, United States|Kingston, Pennsylvania, United States|Florence, South Carolina, United States|West Columbia, South Carolina, United States|Rapid City, South Dakota, United States|Germantown, Tennessee, United States|Nashville, Tennessee, United States|Abilene, Texas, United States|Austin, Texas, United States|Dallas, Texas, United States|Fort Worth, Texas, United States|Harlingen, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|The Woodlands, Texas, United States|Willow Park, Texas, United States|Bellevue, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT02712008/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT02712008/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02712008"
1426,"NCT02672384","Chronic Periodontitis in Critically Ill Patients: Diagnosis and Epidemiology","CP-ICU","Completed","No Results Available","Chronic Periodontitis|Intensive Care Unit","Procedure: Dental examination and a point of care P. gingivalis test (Denka Seiken Co (Japan) )","Result (positive/negative) of the point-of-care P. gingivalis test in saliva and P. gingivalis antibodies in sera|Ratio of enrolled patients/eligible patients|Number of patient with discrepancies in findings of dental exam and point of care P. gingivalis test combined|Mortality at 90 days after intubation|Incidence of CP (Chronic periodontitis) in mechanically ventilated patients|Incidence of VAP(Ventilator-Associated Pneumonia)|Recruitment rate","University Hospital, Brest|Bayer","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CP-ICU STUDY (RB 15.108)","January 20, 2017","October 14, 2018","October 14, 2018","February 3, 2016",,"December 7, 2018","Brest, University Hospital, Brest, France",,"https://ClinicalTrials.gov/show/NCT02672384"
1427,"NCT02664077","A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer","ARGO","Completed","No Results Available","Stage III (IIIB or IIIC) Colon Cancer","Drug: Regorafenib|Drug: Placebo","Disease-free survival (DFS) - time from randomization until first colon cancer recurrence, second primary colon cancer, or death due to any cause.|Overall Survival (OS) - time from randomization until death from any cause.|Toxicity - frequency and severity of adverse events categorized using the NCI Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)|Compliance - Time to discontinuation of study therapy.|Correlative Science - Biomarker evaluations|Correlative Science - Pharmacokinetics - Plasma regorafenib concentrations|Correlative Science - Pharmacodynamics|Compare the symptoms experienced by patients receiving regorafenib to patients receiving placebo during treatment as measured by Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","NSABP Foundation Inc|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","34","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NSABP C-13|17808","June 2016","October 2019","October 2019","January 26, 2016",,"November 12, 2019","St. Joseph Hospital of Orange, Orange, California, United States|St. Joseph Heritage Healthcare, Santa Rosa, California, United States|Kaiser Permanente Medical Center - Vallejo, Vallejo, California, United States|Colorado Cancer Research Program, Denver, Colorado, United States|Yale University, New Haven, Connecticut, United States|University of Florida, Gainesville, Florida, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|Cancer Care Specialists of Illinois - Decatur Memorial Hospital, Decatur, Illinois, United States|Edward Hospital Cancer Center, Naperville, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States|Oncology Associates at Mercy Medical Center, Cedar Rapids, Iowa, United States|Genesis Medical Center - West Campus, Davenport, Iowa, United States|University of Iowa, Iowa City, Iowa, United States|Covenant Cancer Treatment Center, Waterloo, Iowa, United States|Norton Cancer Institute, Norton Healthcare Pavilion, Louisville, Kentucky, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|New England Cancer Specialists, Scarborough, Maine, United States|Berkshire Medical Center Cancer and Infusion Center, Pittsfield, Massachusetts, United States|Breslin Cancer Center, Lansing, Michigan, United States|Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota, United States|Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|Nevada Cancer Research Foundation, Inc., Las Vegas, Nevada, United States|MD Anderson Cancer Center at Cooper, Camden, New Jersey, United States|Monmouth Medical Center, Long Branch, New Jersey, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|Community Medical Center, Toms River, New Jersey, United States|Waverly Hematology Oncology, Cary, North Carolina, United States|CaroMont Regional Medical Center, Gastonia, North Carolina, United States|Margaret R. Pardee Memorial Hospital, Hendersonville, North Carolina, United States|First Health of the Carolinas Cancer Center, Pinehurst, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|James Cancer Hospital and Solove Research Institute at the Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Toledo Clinic Cancer Center, Toledo, Ohio, United States|Abington Hospital -Jefferson South, Abington, Pennsylvania, United States|Penn State Cancer Institute at Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|UPMC Cancer Centers, Pittsburgh, Pennsylvania, United States|Guthrie Medical Group, PC, Sayre, Pennsylvania, United States|Scranton Hematology Oncology, Scranton, Pennsylvania, United States|Reading Hospital - McGlinn Cancer Institute, West Reading, Pennsylvania, United States|AnMed Health Cancer Center, Anderson, South Carolina, United States|McLeod Cancer Center for Treatment and Research, Florence, South Carolina, United States|Wellmont Medical Associates Oncology and Hematology, Kingsport, Tennessee, United States|Thompson Cancer Survival Center, Knoxville, Tennessee, United States|Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|West Virginia University, Morgantown, West Virginia, United States|Green Bay Oncology, Ltd. - St. Vincent Hospital, Green Bay, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02664077"
1428,"NCT02661711","Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) Study","AMOUR","Unknown status","No Results Available","Macular Oedema|Retinitis Pigmentosa","Drug: Aflibercept","The efficacy of Eylea in cystoid macular oedema (CMO) associated with Retinitis Pigmentosa (RP)|The safety of Eylea in cystoid macular oedema (CMO) associated with Retinitis Pigmentosa (RP)|The mean central macular thickness (CMT) on Spectral Domain OCT (SDOCT) at 6 months|The mean change in Central Macular Thickness on Spectral Domain Optical Coherence tomography (SD-OCT) from baseline to 6 months and baseline to 12 months|The mean Best Corrected Visual Acuity (BCVA) using the ETDRS visual acuity chart at 6 and 12 months|The mean change in ETDRS BCVA from baseline to 6 months and baseline to 12 months|The mean macular volume on SDOCT at 6 and 12 months|The mean change in macular volume on SDOCT from baseline to 6 months and baseline to 12 months|Report all Adverse Events and Serious Adverse Events|The mean retinal sensitivity using microperimetry at 6 and 12 months|The mean change in retinal sensitivity using microperimetry from baseline to 6 months and baseline to 12 months|The mean number of intravitreal injections administered","Moorfields Eye Hospital NHS Foundation Trust|Bayer","All","16 Years and older   (Child, Adult, Older Adult)","Phase 2","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MICM1014|2015-003723-65","March 2016","October 2017","October 2017","January 22, 2016",,"September 14, 2016","Moorfields Eye Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02661711"
1429,"NCT02657551","A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer",,"Recruiting","No Results Available","Thyroid Cancer","Drug: Regorafenib","Response and Progression-free survival|Safety variables - AEs, laboratory changes, changes in vital signs and ECG and, changes in chest x-ray images, at the investigator's discretion (e.g., for evaluation for pneumonia).|Radiographic response|Biomarkers associated with response","Dana-Farber Cancer Institute|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","33","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-350","January 2016","December 2020","October 2022","January 18, 2016",,"October 25, 2019","Dana-Farber Cancer Institute, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02657551"
1430,"NCT02656849","BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors",,"Withdrawn","No Results Available","Solid Tumor","Drug: BAY 1000394","Six-month progression-free survival rate|Response Rate Mcl1-amplified tumors|Response Rate MYC-amplified tumors|Response Rate CCNE1-amplified tumors|Overall Survival|Time to Progression","Dana-Farber Cancer Institute|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-380","February 2016","October 2019","May 2023","January 15, 2016",,"July 1, 2016","Dana Farber Cancer Institute, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02656849"
1431,"NCT02656563","Radium 223 Following Intermittent ADT","RAND","Withdrawn","No Results Available","Prostate Cancer","Radiation: Radium 223 Dichloride (Xofigo®)","PSA > 5.0ng/ml","Canadian Urology Research Consortium|Bayer","Male","45 Years to 85 Years   (Adult, Older Adult)","Phase 2","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CURC-004|17848","October 2015","October 2020","October 2020","January 15, 2016",,"October 14, 2016","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02656563"
1432,"NCT02651701","Rectal Cancer Staging Using Whole Body MR-PET",,"Completed","No Results Available","Rectal Cancer","Procedure: MR-PET","the concordance rate between rectal cancer staging performed by WB MR-PET and the current standard of care (chest/abdominopelvic CT and rectal MRI|incidence of recommendation for further workup after examination|concordance rate of clinical staging between standard of care and that obtained by combination of WB MR-PET and chest CT.|concordance rate of clinical stagings and true M staging obtained by biopsy or follow-up","Seoul National University Hospital|Bayer","All","18 Years and older   (Adult, Older Adult)",,"71","Other|Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","MRPET-CRC","January 2016","August 8, 2017","November 30, 2019","January 11, 2016",,"December 12, 2019","Seoul National University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02651701"
1433,"NCT02651415","Phase II Study of Perindopril and Regorafenib in mCRC","PARICCA","Completed","Has Results","Metastatic Colorectal Cancer","Drug: Regorafenib|Drug: Perindopril","Number of Participants That Have Any Grade HFSR Toxicity|The Number of Participants That Experienced Any Grade of Hypertension as Assessed by CTCAE v4.03 Criteria When Treated With a Combination of Regorafenib and Perindopril|The Number of Participants That Experienced All Grade Toxicities as Assessed by CTCAE v4.03 Criteria When Treated With a Combination of Regorafenib and Perindopril|Number of Participants With Maximal Severity of HFSR as Assessed by CTCAE v4.03 Criteria When Treated With a Combination of Regorafenib and Perindopril|Median Time Course to Development of Worst Grade (Grade 3) HFSR as Assessed by CTCAE v4.03 Criteria When Treated With a Combination of Regorafenib and Perindopril|Median Time to Progression Free Survival (PFS)","British Columbia Cancer Agency|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","12","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H15-02424","August 2016","March 2018","November 7, 2018","January 11, 2016","September 12, 2019","September 12, 2019","BC Cancer Agency - Vancouver Cancer Centre, Vancouver, British Columbia, Canada","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT02651415/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02651415"
1434,"NCT02641821","Effect of Nifedipine GITS in Patients With Mild-to-moderate Primary Hypertension",,"Recruiting","No Results Available","Hypertension","Drug: Nifedipine GITS","Control rate of hypertension evaluated by office blood pressure at 8 weeks|Control rate of hypertension evaluated by office blood pressure at 4 weeks|Control rate of hypertension evaluated by office blood pressure at 2 weeks|Control rate of hypertension evaluated by 24-hour ABPM at 8 weeks|Change of office blood pressure from baseline to 8 weeks|Change of 24-hour ABPM from baseline to 8 weeks","Peking University First Hospital|Bayer","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","700","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Nifedipine-HT-1.0","October 2015","December 2019","December 2019","December 29, 2015",,"March 22, 2019","Division of Cardiology, Peking University First Hospital, Beijing, China",,"https://ClinicalTrials.gov/show/NCT02641821"
1435,"NCT02638766","Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST","REGISTRI","Recruiting","No Results Available","Gastrointestinal Stromal Tumors","Drug: regorafenib","Disease Control Rate|Progression free survival|Overall survival|Responses determined by CHOI|Correlation with translational research|Safety (adverse events following CTCAE v4.03)|Early metabolic response by PET scan|Quality of life by EORCT QLQ C30 questionnaire|Quality of life by EQ-ED-5L questionnaire","Grupo Espanol de Investigacion en Sarcomas|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","39","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","REGISTRI (GEIS 40)","November 2015","December 2023","December 2024","December 23, 2015",,"December 19, 2019","Institute Bergonie, Bordeaux, France|Centre Leon Berard, Lyon, France|Gustave Roussy, Villejuif, France|Fondazione IRCCS Istituto Dei Tumori di Milano, Milan, Italy|Istituto Clinico Humanitas Milano, Milan, Italy|Policlinico Universitario Campus Bio-Medico, Roma, Italy|Istituto di Candiolo - IRCSS, Torino, Italy|Hospital Universitario de Canarias, La Laguna, Santa Cruz De Tenerife, Spain|Hospital de Cruces, Barakaldo, Spain|Hospital Universitario Vall d´hebron, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital Universitario Virgen de la Macarena, Sevilla, Spain|Instituto Valenciano de Oncología, Valencia, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT02638766"
1436,"NCT02634203","Riociguat Versus Balloon Pulmonary Angioplasty in Non-operable Chronic thromboEmbolic Pulmonary Hypertension","RACE","Unknown status","No Results Available","Chronic Thromboembolic Pulmonary Hypertension","Procedure: Balloon Pulmonary Angioplasty (BPA)|Drug: Riociguat","Change from baseline in Pulmonary Vascular Resistance (PVR)|Change from Baseline in 6 Minute Walking Distance (6MWD)|Change from Baseline in WHO functional class (FC)|Change from Baseline in brain natriuretic peptide (BNP)|Change from Baseline in Borg dyspnea score (measured at the end of the 6MWD Test|Time To Clinical Worsening defined by the occurence of - Death (all-cause mortality or Lung - or Heart-lung transplantation - or Hospitalization due to persistent worsening of PH or - Start of PAH specific treatment","Assistance Publique - Hôpitaux de Paris|Bayer","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","124","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AOM14123","January 2016","September 2019","September 2019","December 17, 2015",,"November 20, 2017","AP-HP, Bicêtre Hospital, Le Kremlin Bicetre, France",,"https://ClinicalTrials.gov/show/NCT02634203"
1437,"NCT02633852","Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen of Aflibercept (EYLEA) as a Second Line Treatment for Diabetic Macular Edema",,"Completed","No Results Available","Diabetic Macular Edema (DME)","Drug: Aflibercept","macular thickness changes|visual acuity|treatment/injection number required|progression of diabetic retinopathy","Hadassah Medical Organization|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 4","48","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHOTADI- HMO-CTIL","May 24, 2016","August 28, 2018","September 6, 2018","December 17, 2015",,"September 14, 2018",,,"https://ClinicalTrials.gov/show/NCT02633852"
1438,"NCT02631590","Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma",,"Active, not recruiting","No Results Available","Biliary Carcinoma|Gall Bladder Carcinoma|Cholangiocarcinoma|Gastrointestinal Tumor","Drug: Cisplatin|Drug: Gemcitabine|Drug: Copanlisib","Progression Free Survival (PFS)|Response Rate|Overall Survival (OS)","H. Lee Moffitt Cancer Center and Research Institute|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","25","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-18435","June 28, 2016","November 23, 2019","December 2020","December 16, 2015",,"January 3, 2020","H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02631590"
1439,"NCT02628873","Can SIS Using Air Bubbles Replace HSG for Fallopian Tubal Patency After Essure Placement","HyCoSy","Terminated","No Results Available","Contraception","Device: HyCoSy","Fallopian tube patency - HyCoSy vs HSG|Pain scores|Physician evaluation of uterine cavity","Wright State University|Bayer","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","Lindheim2015-01","December 2015","September 2018","October 2018","December 11, 2015",,"October 3, 2018","Wright State Physicians, Dayton, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02628873"
1440,"NCT02611115","Optimizing Protocols for the Individual Patient in CT Pulmonary Angiography.","OptIPeCT","Completed","No Results Available","Pulmonary Embolism",,"Image quality|Reduction of radiation dose","Maastricht University Medical Center|Bayer","All","18 Years and older   (Adult, Older Adult)",,"235","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","15-4-167","September 2015","December 2016","December 2016","November 20, 2015",,"October 5, 2017","Maastricht University Medical Center, Maastricht, Limburg, Netherlands",,"https://ClinicalTrials.gov/show/NCT02611115"
1441,"NCT02599090","Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma",,"Withdrawn","No Results Available","Glioblastoma|Gliosarcoma","Drug: Temozolomide|Radiation: Radiation|Drug: Sorafenib","Time to Progression","M.D. Anderson Cancer Center|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2008-0059 Phase II|NCI-2012-01617","December 2008","December 2012","December 2012","November 6, 2015",,"November 6, 2015",,,"https://ClinicalTrials.gov/show/NCT02599090"
1442,"NCT02584660","A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department","MERCURY PE","Completed","Has Results","Pulmonary Embolism","Drug: Rivaroxaban|Drug: Standard-of-care","Mean Duration of Hospitalization|Percentage of Participants With Reoccurrence of Symptomatic Venous Thromboembolism Event (VTE) (Composite of Recurrent PE, New or Recurrent DVT) or VTE-related Death|Percentage of Participants With Number of Unplanned Hospital Visits or Physician Office for VTE Symptoms and/or Bleeding|Mean Combined Duration of Initial and Subsequent Emergency Department (ED) Hospitalization for Any Reason|Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS)|Percentage of Participants Satisfied Using Site-of-Care Satisfaction Questionnaire","Janssen Scientific Affairs, LLC|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 4","114","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR107694|39039039APE4001","October 15, 2015","March 22, 2017","March 22, 2017","October 22, 2015","April 20, 2018","June 1, 2018","Montgomery, Alabama, United States|Chandler, Arizona, United States|Phoenix, Arizona, United States|Tucson, Arizona, United States|Los Angeles, California, United States|Sacramento, California, United States|Sylmar, California, United States|New Haven, Connecticut, United States|Washington, District of Columbia, United States|Pensacola, Florida, United States|Tampa, Florida, United States|Davenport, Iowa, United States|Iowa City, Iowa, United States|Baltimore, Maryland, United States|Springfield, Massachusetts, United States|Detroit, Michigan, United States|Jackson, Michigan, United States|Lansing, Michigan, United States|Royal Oak, Michigan, United States|Saint Louis, Missouri, United States|Atlantic City, New Jersey, United States|Camden, New Jersey, United States|Brooklyn, New York, United States|Buffalo, New York, United States|New York, New York, United States|Stony Brook, New York, United States|Chapel Hill, North Carolina, United States|Charlotte, North Carolina, United States|Durham, North Carolina, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Toledo, Ohio, United States|Zanesville, Ohio, United States|Portland, Oregon, United States|Allentown, Pennsylvania, United States|Bethlehem, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|West Reading, Pennsylvania, United States|Charleston, South Carolina, United States|Dallas, Texas, United States|Fort Worth, Texas, United States|Houston, Texas, United States|Salt Lake City, Utah, United States|Charlottesville, Virginia, United States|Bellingham, Washington, United States|Everett, Washington, United States|Spokane, Washington, United States|Tacoma, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/60/NCT02584660/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/60/NCT02584660/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02584660"
1443,"NCT02584465","REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression","REGOVAR","Active, not recruiting","No Results Available","Ovarian Carcinoma","Drug: Tamoxifen|Drug: Regorafenib","Progression Free survival (PFS)|Objective Response Rate (ORR)|Time to start of first subsequent chemotherapy (TFST)|Second progression-Free Survival (PFS2)|Overall Survival (OS)|Adverse events","ARCAGY/ GINECO GROUP|Bayer","Female","18 Years and older   (Adult, Older Adult)","Phase 2","68","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GINECO-OV235","August 28, 2015","June 2020","June 2020","October 22, 2015",,"January 9, 2020","ICO Paul Papin, Angers, France|Institut Sainte-Catherine, Avignon, France|Hôpital Jean Minjoz, Besancon, France|Institut Bergonié, Bordeaux, France|Polyclinique Bordeaux Nord, Bordeaux, France|Centre François Baclesse, Caen, France|Centre Hospitalier de Cholet, Cholet, France|Centre Jean Perrin, Clermont-ferrand, France|Centre Oscar Lambret, Lille, France|Centre Hospitalier Universitaire Dupuytren, Limoges, France|Centre Léon Bérard, Lyon, France|Institut Paoli Calmettes, Marseille, France|Hôpital de Mont-de-Marsan, Mont de Marsan, France|Centre Azuréen de Cancérologie, Mougins, France|ORACLE - Centre d'Oncologie de Gentilly, Nancy, France|Centre Catherine de Sienne, Nantes, France|Centre Hospitalier Régional d'Orléans, Orléans, France|Institut Mutualiste Montsouris, Paris, France|Clinique Francheville, Perigueux, France|Centre Hospitalier Lyon Sud, Pierre-Benite, France|Centre CARIO - HPCA, Plerin SUR MER, France|Centre Hospitalier Annecy Genevois, Pringy, France|Institut Jean Godinot, Reims, France|ICO Centre René Gauducheau, Saint-herblain, France|Centre de Radiothérapie - Clinique Sainte-Anne, Strasbourg, France|Centre Paul Strauss, Strasbourg, France|Centre Hospitalier Universitaire Bretonneau, Tours, France",,"https://ClinicalTrials.gov/show/NCT02584465"
1444,"NCT02561923","A Study to Assess the Independent Effects of 4-Factor Prothrombin Complex Concentrate and Tranexamic Acid on Bleeding/Pharmacodynamics in Healthy Participants",,"Completed","No Results Available","Healthy","Drug: Rivaroxaban|Drug: Tranexamic acid|Drug: Kcentra, a 4-factor PCC|Drug: Saline","Change From Baseline in Blood Volume in Part 1|Change From Baseline in Bleeding Duration in Part 1|Mean Change in Thrombin Generation Assay (TGA) - Endogenous Thrombin Potential (ETP) Lag-time in Part 2|Mean Change in Thrombin Generation Assay (TGA) - Endogenous Thrombin Potential (ETP) Peak in Part 2|Mean Change in Thrombin Generation Assay (TGA) - Endogenous Thrombin Potential (ETP) Time to Peak in Part 2|Mean Change in Thrombin Generation Assay (TGA) - Endogenous Thrombin Potential (ETP) Area Under Curve (AUC) in Part 2|Mean Change in Prothrombin Time (PT) in Part 2|Change From Baseline in Blood Volume in Part 2|Change From Baseline in Bleeding Duration in Part 2|Maximum Observed Plasma Concentration (Cmax) in Part 1|Time to Maximum Observed Plasma Concentration in Part 1 (Tmax)|Area under Plasma Concentration Time Curve From Time 0 to 24 in Part 1 (AUC [0 TO 24]|Maximum Observed Plasma Concentration (Cmax) in Part 2|Minimum Observed Plasma Concentration (Cmin) in Part 2|Time to Maximum Observed Plasma Concentration (Tmax) in Part 2|Area under plasma concentration time curve during the dosing interval (AUCtau) in Part 2|Mean Change in Thrombin Generation Assay (TGA) Endogenous Thrombin Potential (ETP) Lag-time in Part 1|Mean Change in Thrombin Generation Assay (TGA) Endogenous Thrombin Potential (ETP) Peak in Part 1|Mean Change in Thrombin Generation Assay (TGA) Endogenous Thrombin Potential (ETP) Time to Peak in Part 1|Mean Change in Thrombin Generation Assay (TGA) Endogenous Thrombin Potential (ETP) Area Under Curve (AUC) in Part 1|Mean Change in Prothrombin Time (PT) in Part 1|Trough Plasma Concentration (Ctrough) in Part 2|Number of Participants With Adverse Events as a Measure of Safety and Tolerability","Janssen Scientific Affairs, LLC|Bayer","All","18 Years to 55 Years   (Adult)","Phase 1","158","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR107832|39039039NAP1004","August 27, 2015","June 17, 2016","June 17, 2016","September 28, 2015",,"June 14, 2017","Overland Park, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT02561923"
1445,"NCT02555878","A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants",,"Completed","Has Results","Neoplasms","Drug: Rivaroxaban|Drug: Placebo","Percentage of Participants With Time to First Occurrence of Primary Efficacy Endpoint (Composite and Components)|Percentage of Participants With Time to the First Occurrence of Major Bleeding Events as Defined by International Society of Thrombosis and Haemostasis (ISTH)|Percentage of Participants With Time to the First Occurrence of Symptomatic VTE Events or VTE-Related Deaths|Percentage of Participants With All-Cause Mortality|Percentage of Participants With Time to the First Occurrence of Fatal or Non-fatal Arterial Thromboembolic Events (ATE)|Percentage of Participants With Time to the First Occurrence of Fatal or Non-fatal Visceral VTE|Percentage of Participants With Time to the First Occurrence of Composite Efficacy Endpoint 1|Percentage of Participants With Time to First Occurrence of Composite Efficacy Endpoint 2|Percentage of Participants With Time to First Occurrence of Composite Efficacy Endpoint 3|Percentage of Participants With Time to First Occurrence of Composite Efficacy Endpoint 4|Percentage of Participants With Time to the First Occurrence of Clinically Relevant Non-major Bleeding|Percentage of Participants With Time to the First Occurrence of Minor Bleeding|Percentage of Participants With Time to the First Occurrence of Any Bleeding","Janssen Research & Development, LLC|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","841","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","CR107047|39039039STM4001|2015-001630-21","September 11, 2015","August 24, 2018","August 24, 2018","September 22, 2015","September 12, 2019","September 12, 2019","Phoenix, Arizona, United States|Tucson, Arizona, United States|Little Rock, Arkansas, United States|Los Angeles, California, United States|Martinez, California, United States|Santa Barbara, California, United States|Torrance, California, United States|Upland, California, United States|Denver, Colorado, United States|Norwich, Connecticut, United States|Gainesville, Florida, United States|Miami Shores, Florida, United States|Miami, Florida, United States|New Port Richey, Florida, United States|Atlanta, Georgia, United States|Evanston, Illinois, United States|Joliet, Illinois, United States|Peoria, Illinois, United States|Rockford, Illinois, United States|Skokie, Illinois, United States|Urbana, Illinois, United States|Anderson, Indiana, United States|Cedar Rapids, Iowa, United States|Brewer, Maine, United States|Baltimore, Maryland, United States|Silver Spring, Maryland, United States|Boston, Massachusetts, United States|Detroit, Michigan, United States|Rochester, Minnesota, United States|Saint Cloud, Minnesota, United States|Kansas City, Missouri, United States|Grand Island, Nebraska, United States|Las Vegas, Nevada, United States|Lebanon, New Hampshire, United States|Albany, New York, United States|Bronx, New York, United States|East Syracuse, New York, United States|New York, New York, United States|Rochester, New York, United States|Charlotte, North Carolina, United States|High Point, North Carolina, United States|Cleveland, Ohio, United States|Eugene, Oregon, United States|Portland, Oregon, United States|Erie, Pennsylvania, United States|Charleston, South Carolina, United States|Greenville, South Carolina, United States|North Charleston, South Carolina, United States|Rapid City, South Dakota, United States|Nashville, Tennessee, United States|Abilene, Texas, United States|Austin, Texas, United States|Beaumont, Texas, United States|Bedford, Texas, United States|Dallas, Texas, United States|Denton, Texas, United States|Flower Mound, Texas, United States|Garland, Texas, United States|Houston, Texas, United States|Paris, Texas, United States|San Antonio, Texas, United States|Sugar Land, Texas, United States|Temple, Texas, United States|The Woodlands, Texas, United States|Tyler, Texas, United States|Waco, Texas, United States|Roanoke, Virginia, United States|Winchester, Virginia, United States|Green Bay, Wisconsin, United States|Weston, Wisconsin, United States|Amberloup, Belgium|Bonheiden, Belgium|Brussel, Belgium|Bruxelles, Belgium|Edegem, Belgium|Laken (brussel), Belgium|Turnhout, Belgium|Wilrijk, Belgium|Barretos, Brazil|Caxias do Sul, Brazil|Curitiba, Brazil|Itajai, Brazil|Lajeado, Brazil|Londrina, Brazil|Mogi das Cruzes, Brazil|Porto Alegre, Rs, Brazil|Porto Alegre, Brazil|Rio de Janeiro, Brazil|Santo André, Brazil|Sao Jose do Rio Preto, Brazil|Sao Paulo, Brazil|Sorocaba, Brazil|São Paulo, Brazil|Plovdiv N/a, Bulgaria|Plovdiv, Bulgaria|Sofia, Bulgaria|Toronto, Ontario, Canada|Saint-Jerome, Quebec, Canada|Quebec, Canada|Benesov Nad Cernou, Czechia|Brno, Czechia|Jindrichuv Hradec, Czechia|Kladno, Czechia|Liberec, Czechia|Novy Jicin, Czechia|Olomouc, Czechia|Pardubice, Czechia|Praha 4, Czechia|Praha 5, Czechia|Tabor, Czechia|Angers Cedex 9, France|Angers, France|Avignon Cedex 9, France|Dijon Cedex, France|Hyers, France|Le Mans Cedex 2, France|Le Mans cedex 9, France|Paris, France|Rennes Cedex, France|Saint Herblain, France|Valenciennes, France|Berlin, Germany|Brandenburg, Germany|Dortmund, Germany|Dresden, Germany|Esslingen, Germany|Gauting, Germany|Hamburg, Germany|Hannover, Germany|Herne, Germany|Kiel, Germany|Koeln, Germany|Leipzig, Germany|Luebeck, Germany|Magdeburg, Germany|Merseburg, Germany|Minden, Germany|München, Germany|Paderborn, Germany|Recklinghausen, Germany|Weiden, Germany|Arkhangelsk, Russian Federation|Chelyabinsk, Russian Federation|Kursk, Russian Federation|Moscow, Russian Federation|Novosibirsk, Russian Federation|Omsk, Russian Federation|Saint Petersburg, Russian Federation|St Petersburg, Russian Federation|Tomsk, Russian Federation|Yaroslavi, Russian Federation|Bournemouth, United Kingdom|Cheltenham, United Kingdom|Dundee, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Plymouth, United Kingdom|Swindon, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02555878/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02555878/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02555878"
1446,"NCT02553889","A Study of Safety, PK, & PD of ISIS 416858 Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis",,"Completed","No Results Available","End-stage Renal Disease (ESRD)","Drug: ISIS 416858|Drug: Placebo","Safety and Tolerability - evaluated by reviewing frequency and severity of Adverse events (including bleeding events) and use of concomitant medications, changes in vital signs and laboratory evaluations for all patients|Pharmacodynamic Outcomes in FXI antigen and activity as measured by absolute change over time.|Pharmacodynamic Outcomes in FXI antigen and activity as measured by percent change over time.|Pharmacodynamic Outcomes in aPTT as measured by absolute change over time.|Pharmacodynamic Outcomes in aPTT as measured by percent change over time.|Pharmacodynamic Outcomes for PT and the PT derived INR as measured by absolute change over time.|Pharmacodynamic Outcomes for PT and the PT derived INR as measured by percent change over time.","Ionis Pharmaceuticals, Inc.|Bayer","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","49","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","ISIS 416858 CS4","October 2015","November 2016","November 2016","September 18, 2015",,"December 13, 2016","Ionis Investigative Site, Edmonton, Alberta, Canada|Ionis Investigative Site, Halifax, Nova Scotia, Canada|Ionis Investigative Site, Hamilton, Ontario, Canada|Ionis Investigative Site, London, Ontario, Canada|Ionis Investigative Site, Toronto, Ontario, Canada|Ionis Investigative Site, Toronto, Ontario, Canada|Ionis Investigative Site, Montreal, Quebec, Canada|Ionis Investigative Site, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02553889"
1447,"NCT02531386","System Accuracy Evaluation of 6 CE-marked Blood Glucose Monitoring System Following ISO 15197:2013",,"Completed","No Results Available","Diabetes","Device: 6 blood glucose monitoring systems for self-testing (blood glucose meters)","System accuracy criteria (see description)","Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm|Bayer","All","18 Years and older   (Adult, Older Adult)","Not Applicable","120","Other|Industry","Interventional",,"IDT-1525-BL","August 2015","September 2015","November 2015","August 24, 2015",,"November 9, 2015","Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm, Ulm, Germany",,"https://ClinicalTrials.gov/show/NCT02531386"
1448,"NCT02520921","Aspirin Twice a Day in Patients With Diabetes and Acute Coronary Syndrome","ANDAMAN","Recruiting","No Results Available","Diabetes Mellitus|Acute Coronary Syndrome|Coronary Artery Disease","Drug: Novel strategy Aspirin|Drug: Conventional strategy Aspirin","first main vascular event occurring within the 18 months after randomization among the following: Death (any), Myocardial infarction, Stroke, Urgent coronary revascularization and/or stent thrombosis, Acute arterial thrombotic event|Major bleeding (type 3 to 5 following BARC classification|Net clinical benefit: Death (any), Myocardial infarction, Stroke, Urgent coronary revascularization and/or stent thrombosis, Acute arterial thrombotic event, Major bleeding|Cardiac endpoint: Cardiovascular death / Myocardial infarction|Death, myocardial infarction, stroke, urgent revascularization, stent thrombosis, acute arterial thrombotic event and major bleeding analyzed specifically and separately","Assistance Publique - Hôpitaux de Paris|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 4","2574","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P141005|2015-000947-18","June 13, 2016","December 2021","December 2021","August 13, 2015",,"July 24, 2019","Department of Cardiology - Lariboisiere Hospital, Paris, France",,"https://ClinicalTrials.gov/show/NCT02520921"
1449,"NCT02499822","REducing Blood Pressure Variability in Essential Hypertension With RAmipril vErsus Nifedipine GITS Trial","REVERENT","Recruiting","No Results Available","Hypertension|High Blood Pressure Variability","Drug: Nifedipine GITS|Drug: Ramipril","Variability (standard deviation) of home systolic blood pressure at final visit|Variability (standard deviation) of home diastolic blood pressure measured at final visit|Short term 24h variability of systolic blood pressure at final visit (24h weighted standard deviation)|Short term 24h variability of diastolic blood pressure at final visit (24h weighted standard deviation)|Visit-to-visit variability (standard deviation) of systolic blood pressure assessed over the three last visits|Visit-to-visit variability (standard deviation) of diastolic blood pressure assessed over the three last visits|Mean 24 hour systolic blood pressure at final visit|Mean 24 hour diastolic blood pressure at final visit|Sokolow index at the end of the extension study|Cornell voltage duration index at the end of the extension study|Left ventricular mass index at the end of the extension study|Microalbuminuria (albumin-creatinine ratio) at the end of the extension study|Estimated glomerular filtration rate (eGFR, by CKD-EPI formula) at the end of the extension study|Carotid-femoral pulse wave velocity (cfPWV) at the end of the extension study","Istituto Auxologico Italiano|Bayer","All","35 Years to 75 Years   (Adult, Older Adult)","Phase 4","168","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","09F401","October 2015","December 2019","December 2019","July 16, 2015",,"February 27, 2019","Centre for Epidemiological Studies and Clinical Trials, Ruijin Hospital Shanghai Institute of Hypertension, Shanghai Jiaotong University School of Medicine, Shanghai, China|Hypertension Center, Third University Department of Medicine, Sotiria Hospital, Athens, Greece|Istituto Auxologico Italiano, Milan, Italy",,"https://ClinicalTrials.gov/show/NCT02499822"
1450,"NCT02494297","Drug Utilization Study on the Prescribing Indications for Cyproterone Acetate and Ethinyl Estradiol in 5 European Countries",,"Unknown status","No Results Available","Hirsutism|Seborrheic Alopecia|Severe Acne|Seborrhea",,"Drug utilization pattern of Cyproterone Acetate and Ethinyl Estradiol","Center for Epidemiology and Health Research, Germany|Bayer","Female","Child, Adult, Older Adult",,"5000","Other|Industry","Observational","Time Perspective: Cross-Sectional","ZEG2014_04","March 2015","January 2017","May 2017","July 10, 2015",,"November 3, 2016","Center of Epidemiology and Health Research, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT02494297"
1451,"NCT02482402","Iloprost for Bridging to Heart Transplantation in PH","BRIDGE","Withdrawn","No Results Available","Chronic Left Ventricular Failure|Pulmonary Hypertension","Drug: Inhaled Iloprost|Drug: Placebo","safety and tolerability measured by adverse events rates|hemodynamics right atrial pressure|hemodynamics pulmonary arterial pressure|hemodynamics pulmonary arterial wedge pressure|hemodynamics Cardiac output|hemodynamics Cardiac index|hemodynamics venuous oxygen saturation|Echocardiography systolic pulmonary arterial pressure|Echocardiography Tei index|Echocardiography right atrial area|Echocardiography right ventricular area|Echocardiography tricuspid annular plane systolic excursion|Echocardiography left ventricular pump function|WHO functional class|Lung function tests and Blood Gas analysis|6-minute walking distance and Borg dyspnea Score (CR 10)|Quality of Life SF 36- questionnaire|Quality of Life CAMPHOR|Blood pressure|heart rate measurements|Electrocardiography|Clinical laboratory Haematology|Clinical laboratory Leucocytes|Clinical laboratory erythrocytes|Clinical laboratory haemoglobin|Clinical laboratory haematocrit|Clinical laboratory platelets|Clinical laboratory Substrates|Clinical laboratory Bilirubin|Clinical laboratory LDL/HDL|Clinical laboratory cholesterol|Clinical laboratory triglycerides|Clinical laboratory creatinine|Clinical laboratory uric acid|Clinical laboratory urea|Clinical laboratory total protein|Clinical laboratory albumin|Clinical laboratory glucose|Clinical laboratory Electrolytes|Clinical laboratory sodium|Clinical laboratory potassium|Clinical laboratory calcium|Clinical laboratory chloride|Clinical laboratory SGOT/ASAT|Clinical laboratory SGPT/ALAT|Clinical laboratory Gamma-GT|Clinical laboratory GLDH|Clinical laboratory AP|Clinical laboratory LDH|Clinical laboratory CK|Clinical laboratory INR|Clinical laboratory PTT|Clinical laboratory β-HCG test for women with childbearing potential at|Clinical laboratory CRP|Clinical laboratory NT-proBNP","Heidelberg University|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IG 43|2013-001613-33","February 2015","March 17, 2015","March 17, 2015","June 26, 2015",,"December 23, 2019","Klinik für Thorax- und Kardiovaskularchirurgie, Bad Oeynhausen, Germany|Thoraxclinic at the University of Heidelberg, Heidelberg, Germany",,"https://ClinicalTrials.gov/show/NCT02482402"
1452,"NCT02466802","Study of Regorafenib and Sildenafil for Advanced Solid Tumors",,"Active, not recruiting","No Results Available","Solid Tumor","Drug: Regorafenib|Drug: Sildenafil Citrate","To determine the recommended phase 2 dose (RP2D) of the combination of regorafenib and of sildenafil when given to patients with advanced solid tumors.|To evaluate the safety and toxicity of the regorafenib and sildenafil combination|To explore the antitumor effects of the regorafenib and sildenafil combination|To determine the pre-treatment expression of phosphodiesterase type 5 (PDE5) in tumor samples|To evaluate the impact of sildenafil on the pharmacokinetics of regorafenib","Virginia Commonwealth University|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","37","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-13-09812|HM20004297|NCI-2015-01101","July 1, 2015","January 28, 2019","June 30, 2020","June 9, 2015",,"April 2, 2019","Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02466802"
1453,"NCT02466009","Regorafenib in Metastatic Colorectal Cancer",,"Active, not recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Regorafenib","Number of subjects who experience grade 3-5 toxicity as a measure of safety and tolerability.|Number of subjects who respond to study treatment.|Association of adverse events with the Comprehensive Geriatric Assessments.|Subject's quality of life as assessed by the Comprehensive Geriatric Assessment form while receiving study treatment.","University of Rochester|Bayer","All","70 Years and older   (Older Adult)","Phase 2","26","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","55555","March 2015","July 2019","July 2020","June 9, 2015",,"October 8, 2019","Mayo Clinic, Rochester, Minnesota, United States|University of Rochester, Rochester, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02466009"
1454,"NCT02462044","Contrast Enhancement on Coronary Computed Tomographic Angiography","EICAR","Completed","No Results Available","Coronary Artery Disease|Coronary Stenosis","Drug: 240 mg Iodine|Drug: 300 mg Iodine|Drug: 370 mg Iodine","intravascular contrast enhancement|time to peak|bolus homogeneity|patient comfort","Maastricht University Medical Center|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 4","200","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Diagnostic","METC 13-1-033","August 2014","August 2015","September 2015","June 3, 2015",,"January 5, 2016","Maastricht University Medical Center, Maastricht, Netherlands",,"https://ClinicalTrials.gov/show/NCT02462044"
1455,"NCT02461394","User Performance Evaluation of Contour Plus, Accu-Chek Active, Accu-Chek Performa and OneTouch Select Simple Blood Glucose Monitoring Systems Following ISO 15197:2013",,"Completed","No Results Available","Diabetes","Device: Blood glucose monitoring systems for self-testing","Acceptance criteria defined by ISO 15197:2013 (see description)","Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm|Bayer","All","18 Years and older   (Adult, Older Adult)","Not Applicable","150","Other|Industry","Interventional",,"IDT-1469-BL","May 2015","December 2015",,"June 3, 2015",,"January 26, 2016","Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm, Ulm, Germany",,"https://ClinicalTrials.gov/show/NCT02461394"
1456,"NCT02444221","Rivaroxaban Evaluation in Real Life Settings","RIVER","Active, not recruiting","No Results Available","Atrial Fibrillation|Stroke",,"Rate of Stroke in Registry participants|Rate of Systemic Embolisation in Registry participants","Thrombosis Research Institute|Bayer","All","18 Years and older   (Adult, Older Adult)",,"5000","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","TRI08890","May 2015","May 2019","December 2019","May 14, 2015",,"May 10, 2019","Prof. Jean-Yues LeHeuzey, National Coordinating Investigator, Hopital Europeen Georges Pompidou, Paris, France|Thrombosis Research Institute, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02444221"
1457,"NCT02418650","Mass Balance, Pharmacokinetics, Biotransformation and Bioavailability Study of ODM-201 in Healthy Male Subjects","ARIADME","Completed","No Results Available","Healthy","Drug: ODM-201 300 mg tablet|Drug: intravenous14C-ODM-201|Drug: 300 mg 14C-ODM-201 oral solution","Amount of 14C-ODM-201 dose excreted and cumulative amount excreted in urine and faeces and total. Amount excreted and cumulative amount excreted in urine, faeces and total expressed as a percentage of the administered dose.","Orion Corporation, Orion Pharma|Bayer","Male","50 Years to 65 Years   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","3104005","March 2015","May 2015","June 2015","April 16, 2015",,"June 23, 2015","Quotient Clinical, Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02418650"
1458,"NCT02406521","Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets",,"Active, not recruiting","No Results Available","Metastatic Renal Cell Carcinoma","Drug: Pazopanib|Drug: Sorafenib|Drug: Radium-223","Biomarkers of osteoblast and osteoclast activity|Symptomatic skeletal events (SSEs)|Time to SSE|Quality of life using the FKSI-19|Pain using the Brief Pain Inventory (Short Form)|Analgesic use|Overall response rate by RECIST version 1.1|Duration of response by RECIST version 1.1|Overall survival|Progression-free survival|Response as determined by PERCIST Criteria|Response as determined by MDA Bone Response Criteria|Response within bone biomarker subgroups|Time to first SSE within bone biomarker subgroups|PFS within bone biomarker subgroups|OS within bone biomarker subgroups","Dana-Farber Cancer Institute|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","30","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14-523","April 2015","December 2017","February 2021","April 2, 2015",,"December 11, 2019","Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02406521"
1459,"NCT02403596","Blood-sparing During Hip Prosthesis Surgery With Exacyl® in Patients Treated With Rivaroxaban","ESPER","Completed","No Results Available","Blood Loss After a Total Hip Replacement","Drug: Exacyl®|Other: Placebo of Exacyl®","Total blood loss|Difference in haemoglobin level (g/dL) between Day-1 and Day+3|Maximum difference in haemoglobin level (g/dL) from D-1 up to D+3|Number of transfusions and volume in mL performed during hospitalisation (operating theatre and unit)|Major haemorrhagic events, clinically significant non-major haemorrhagic events and minor haemorrhagic events|Surgical revision|Occurrence of venous or arterial thromboembolic events|Local infectious complications|Death due to any cause and death due to cardiovascular cause","University Hospital, Brest|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","231","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ESPER|RB15.005","October 20, 2015","August 29, 2017","August 29, 2017","March 31, 2015",,"January 9, 2018","HIA Clermont Tonnerre Brest, Brest, France|Polyclinique de Keraudren, Brest, France|CHRU Brest, Brest, France|CH Morlaix, Morlaix, France",,"https://ClinicalTrials.gov/show/NCT02403596"
1460,"NCT02402036","A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer",,"Terminated","Has Results","Colon Cancer","Drug: Regorafenib","Serum microRNA Quantification","Georgetown University|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2014-0133","February 2015","November 2017","November 2017","March 30, 2015","January 29, 2019","January 29, 2019","Georgetown University, Washington, District of Columbia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT02402036/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02402036"
1461,"NCT02401594","PROphylaxis in NOn Major Orthopaedic Surgery","PRONOMOS","Terminated","No Results Available","Non-major Orthopaedic Surgery","Drug: Rivaroxaban|Drug: Enoxaparin","Major VTE|Major bleeding|Clinically relevant non-major bleeding|Overt thrombocytopenia|Mortality","Centre Hospitalier Universitaire de Saint Etienne|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","3608","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","1408143|2015-000981-70","December 8, 2015","April 11, 2018","April 16, 2018","March 30, 2015",,"December 7, 2018","CHU AMIENS Picardie, Amiens, France|CHU Angers, Angers, France|Clinique Générale d'ANNECY, Annecy, France|CHU BESANCON- Hôpital Jean Minjoz, Besancon, France|Hopital Ambroise Pare, Boulogne Billancourt, France|Médipôle de Savoie, Challes Les Eaux, France|Clinique Léonard de Vinci, Chambray Les Tours, France|CHU de Dijon- Bocage, Dijon, France|Hôpitaux Universitaires de Strasbourg C.C.O.M, Illkirch-Graffenstaden, France|CHU de Grenoble 6 Hôpital Michallon, La Tronche, France|Chu Kremlin Bicetre, Le Kremlin Bicetre, France|CHRU Lille -Hôpital Roger Sallengro, Lille, France|CHU Dupuytren, Limoges, France|Ch Lyon Sud Pierre Benite, Lyon, France|Ch Les Chanaux, Macon, France|Chu Marseille La Timone, Marseille, France|CHU de MONTPELLIER - Lapeyronnie, Montpellier, France|CHRU NANTES - Hôtel Dieu, Nantes, France|CHU Carémeau, Nîmes, France|Clinique ARAGO, Paris, France|GH Paris Saint-Joseph, Paris, France|Hopital Cochin, Paris, France|Hopital Europeen Georges POMPIDOU, Paris, France|Ch Paris Pitie Salpetriere, Paris, France|Ch Saint Louis-Lariboisiere, Paris, France|CHU Bordeaux, Pessac, France|Polyclynique de Poitiers, Poitiers, France|CHU de Reims - Hôpital MAsion Blanche, Reims, France|Hôpital Robert Debré, Reims, France|CHU de Rennes - Hôpital Pontchaillou, Rennes, France|CHU de Rouen, Rouen, France|Chp Saint Gregoire, Saint Gregoire, France|CHU de SAINT-ETIENNE, Saint-etienne, France|Clinique de la Mutualiste, Saint-etienne, France|Polyclinique Du Parc, Saint-saulve, France|CHRU de Strasbourg- Hôpital Hautepierre, Strasbourg, France|Clinique Médipôle, Toulouse, France|CHU Toulouse - Hôpital Pierre-Paul Riquet, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT02401594"
1462,"NCT02395991","Evaluation of Transient Dyspnea During Gadoxetic Acid Enhanced Multiphasic Liver MRI",,"Active, not recruiting","No Results Available","Dyspnea","Drug: gadoxetic acid|Other: Magnetic resonance imaging (MRI)","incidence of transient dyspnea|Pattern of transient dyspnea","Seoul National University Hospital|Bayer","All","18 Years and older   (Adult, Older Adult)",,"60","Other|Industry","Observational","Observational Model: Other|Time Perspective: Prospective","CS_2015_ISS","April 2015","October 2016","October 2018","March 24, 2015",,"March 23, 2018","Seoul National University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02395991"
1463,"NCT02391064","Validation of Brief Computerized Cognitive Assessment in Multiple Sclerosis (BCCAMS)","BICAFMS","Completed","No Results Available","Multiple Sclerosis","Behavioral: Cognitive evaluation|Behavioral: Expanded Disability Status Scale (EDSS) score","Prediction by the z score BCCAMS of cognitive impairment (at least two tests MACFIMS battery <1.5 SD of control subjects|Determine values of neuropsychological tests in healthy according to age subjects, gender and the level education|Ability of the CEVMT to detect episodic memory deficiencies in patients with multiple sclerosis, as compared to established tests of episodic memory|Correlation between alternate forms of the CEVMT and the Brief visual memory test-revised (BVMT-R)|Prediction between cognitive impairment and occupational status/leisure activities|Effect of possible confounders on results of cognitive testing, including depression, mood, anxiety and fatigue|Reproducibility of CSCT, CEVMT and the symbol-digit modalities test in clinical settings in patients with multiple sclerosis","University Hospital, Bordeaux|Bayer","All","18 Years to 64 Years   (Adult)","Not Applicable","421","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CHUBX 2013/23","February 17, 2015","February 18, 2018","February 18, 2018","March 18, 2015",,"March 8, 2018","CHU de Bordeaux, Bordeaux, France|CHU de Caen, Caen, France|CHU de Clermont-Ferrand, Clermont-Ferrand, France|Hôpital du Bocage, Dijon, France|CH de Dunkerque, Dunkerque, France|Centre Hospitalier Saint Vincent de Paul, Lille, France|Hôpital Roger Salengro, Lille, France|CHU de Marseille, Marseille, France|CHU Montpellier, Montpellier, France|CHU de Nancy, Nancy, France|CHU de Nice, Nice, France|Hôpital Tenon, Paris, France|Hôpital de Poissy Saint Germain, Poissy, France|CHU de Reims, Reims, France|CHU de Strasbourg, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT02391064"
1464,"NCT02381964","The Effects of Differing Cognitive Task Demands on Whole-body Energy Metabolism and Cerebral Blood-flow: Modulation by Multivitamins/Minerals and Coenzyme Q10",,"Completed","No Results Available","Metabolic Processes","Dietary Supplement: Supradyn® (1RDA+CoQ10)|Dietary Supplement: Supradyn® (3RDA)|Dietary Supplement: Placebo","Concentration change in oxygenated hemoglobin (Near Infrared Spectroscopy)|Fat oxidation (Indirect calorimetry)|Concentration change in deoxygenated hemoglobin (Near Infrared Spectroscopy)|Concentration change in total hemoglobin (Near Infrared Spectroscopy)|Carbohydrate oxidation (Indirect calorimetry)|Total energy expenditure (Indirect calorimetry)|Serial 3 subtractions accuracy (Computerised cognitive task)|Serial 7 subtractions accuracy (Computerised cognitive task)|Serial 17 subtractions accuracy (Computerised cognitive task)|3-back task accuracy (Computerised cognitive task)|3-back task reaction time (Computerised cognitive task)|Stroop task accuracy (Computerised cognitive task)|Stroop task reaction time (Computerised cognitive task)|Subjective rating of task difficulty for Serial 3 subtractions (Computerised Visual Analogue Scale)|Subjective rating of task difficulty for Serial 7 substractions (Computerised Visual Analogue Scale)|Subjective rating of task difficulty for Serial 17 substractions (Computerised Visual Analogue Scale)|Subjective rating of task difficulty for 3 back task (Computerised Visual Analogue Scale)|Subjective rating of task difficulty for stroop task (Computerised Visual Analogue Scale)|Subjective rating of task difficulty for Serial 7 subtractions (Computerised Visual Analogue Scale)|Subjective rating of task difficulty for Serial 17 subtractions (Computerised Visual Analogue Scale)|Subject ratings of energy levels (Computerised Visual Analogue Scale)|Subject ratings of calmness (Computerised Bond-Lader mood scales)|Subject ratings of contentedness (Computerised Bond-Lader mood scales)|Subject ratings of alertness (Computerised Bond-Lader mood scales)","Northumbria University|Bayer","Female","25 Years to 50 Years   (Adult)","Not Applicable","106","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","9L4","March 2012","February 2013","February 2013","March 6, 2015",,"March 30, 2018","Brain performance and nutrition research centre, Northumbria university, Newcastle upon Tyne, Tyne And Wear, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02381964"
1465,"NCT02376127","Metastatic Spinal Bone Marrow Response to Radiation Therapy Using T1 Weighted Dynamic Contrast-Enhanced Perfusion",,"Recruiting","No Results Available","Solid Cancer|Metastatic Spinal Lesions","Procedure: Dynamic contrast enhancement MRI","response to treatment","Memorial Sloan Kettering Cancer Center|Bayer","All","18 Years and older   (Adult, Older Adult)",,"30","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14-203","February 24, 2015","September 2020","September 2020","March 3, 2015",,"October 2, 2019","Memorial Sloan Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02376127"
1466,"NCT02366130","Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer",,"Active, not recruiting","No Results Available","Breast Cancer","Drug: Ra-223 dichloride|Drug: Denosumab|Drug: Hormone Therapy","Disease Control Rate|Tumor Response Rate","M.D. Anderson Cancer Center|Bayer","Female","18 Years and older   (Adult, Older Adult)","Phase 2","45","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014-0508|NCI-2015-00508","February 11, 2015","February 2020","February 2021","February 19, 2015",,"May 23, 2019","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02366130"
1467,"NCT02362373","Women With Epilepsy: a Pilot Study of PK and PD Anti-epileptic Drug Effects in Levonorgestrel Intrauterine System Users","WESAIL","Completed","Has Results","Epilepsy|Contraception","Drug: levonorgestrel IUS","Percent of Participants That Experienced Clinically Meaningful Change in Lamotrigine Level|Percent of Participants That Experienced Clinically Meaningful Change in Levetiracetam Level|Percent of Participants That Experienced Clinically Meaningful Change in Oxcarbazepine Level|Change in Seizure Frequency|Number of Participants Continuing With IUD","Columbia University|Bayer","Female","18 Years to 45 Years   (Adult)","Phase 4","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","AAAI0750","August 2011","January 2014","January 2014","February 12, 2015","January 18, 2016","January 18, 2016","Columbia University, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02362373"
1468,"NCT02358408","System Accuracy Evaluation of Karajishi Contour and Karajishi TS Blood Glucose Monitoring Systems Following ISO 15197:2013",,"Completed","No Results Available","Diabetes","Device: Blood glucose monitoring systems for self-testing","Evaluation of System Accuracy according to ISO 15197 (see description)","Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm|Bayer","All","18 Years and older   (Adult, Older Adult)","Not Applicable","136","Other|Industry","Interventional",,"IDT-1416-BL","January 2015","February 2015","April 2015","February 9, 2015",,"January 28, 2016","Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm, Ulm, Germany",,"https://ClinicalTrials.gov/show/NCT02358408"
1469,"NCT02346526","A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer",,"Active, not recruiting","No Results Available","Prostate Cancer|Castration-resistant Prostate Cancer|Castration-resistant Prostate Cancer Metastatic to Bone","Procedure: Blood Tests|Procedure: CT scan and bone scan|Procedure: FACBC PET/MRI in a subset of participants|Drug: Radium-223 dichloride","Change from baseline in bone scan index at 2 months|Mean percent change in bone scan lesion area by 18 month survival status|Changes in circulating tumor cell (CTC) number|Circulating biomarkers of the tumor microenvironment|Changes in circulating tumor cell (CTC) number and translational biomarkers","Massachusetts General Hospital|Bayer","Male","18 Years and older   (Adult, Older Adult)","Phase 2","22","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14-375|ONC-2013-119","April 2015","October 2019","February 2021","January 27, 2015",,"November 20, 2019","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02346526"
1470,"NCT02311205","Efficacy and Safety of Concurrent TACE and Sorafenib in Patients With HCC and Extrahepatic Metastasis (COTSOM Study)","COTSOM","Unknown status","No Results Available","Hepatocellular Carcinoma|Metastasis","Procedure: Conventional Transarterial Chemoembolization (TACE)|Drug: sorafenib","Overall survival (OS)|Safety (adverse events and laboratory values)|Liver dysfunction (laboratory values related to liver)|Time to progression (TTP)|Time to TACE failure (TTTF)|Time to sorafenib failure (TTSF)|Tumor response rate (TRR)|Disease control rate (DCR)","Asan Medical Center|Bayer","All","20 Years and older   (Adult, Older Adult)","Phase 2","55","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014-0902","December 2014","December 2017","June 2018","December 8, 2014",,"December 18, 2017","Asan Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02311205"
1471,"NCT02310477","Regorafenib in Metastatic Colorectal Cancer : a Cohort Study in the Real-life Setting","REBECCA","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: regorafenib","Overall survival (OS)|Patients and tumor baseline characteristics|Time under REG treatment|Compliance|Safety of REG|Potential predictive factors|Progression-free survival (PFS)","Centre Oscar Lambret|Bayer","All","18 Years and older   (Adult, Older Adult)",,"704","Other|Industry","Observational","Observational Model: Cohort","REBECCA-1305","February 2014","October 2014","December 2014","December 8, 2014",,"August 9, 2016","Centre Oscar Lambret, Lille, France",,"https://ClinicalTrials.gov/show/NCT02310477"
1472,"NCT02309281","Intravitreal Aflibercept in Neovascular AMD With Limited Response to Ranibizumab",,"Completed","No Results Available","Neovascular Age-related Macular Degeneration","Drug: aflibercept 2mg","mean maximum recurrence-free treatment interval (Imax in weeks) with aflibercept treatment during the 24 months study peroid|mean changes in BCVA score at 24 weeks compared to baseline (Δ BCVAscore=BCVAscore 24 weeks - BCVAscore Baseline)|mean changes in CRT (central retinal thickness; in µm) at 24 weeks compared to baseline (Δ CRT=CRT 24 weeks - CRT Baseline)|percentage of patients with a maximum recurrence-free treatment interval of more than 4 weeks at 24 weeks|mean number of treatments needed during the 24 weeks study follow-up|percentage of lesions showing incidence of fluorescein leakage at baseline and 24 weeks.|mean change in total lesion area at 24 weeks compared to baseline (ΔTotalArea=TotalArea 24weeks - TotalArea Baseline)|mean change in area of leakage from CNV at 24 weeks compared to baseline (ΔLeakageArea=LeakageArea 24weeks - LeakageArea Baseline)|change of quality of life scores (VFQ-25, EQ 5D) from baseline to 24 weeks.|number of participants with adverse events (not fullfilling the criteria of serious adverse events) as a measure of safety and tolerability of up to 4weekly dosing of aflibercept in CNV due to AMD|number of participants with serious adverse events as a measure of safety and tolerability of up to 4weekly dosing of aflibercept in CNV due to AMD","Vista Klinik|Bayer","All","50 Years and older   (Adult, Older Adult)","Phase 4","33","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Eylea1","May 2013","May 2014","July 2014","December 5, 2014",,"October 16, 2018",,,"https://ClinicalTrials.gov/show/NCT02309281"
1473,"NCT02304510","Prevalence of Heavy Menstrual Bleeding in Female Population Living in Beijing",,"Completed","No Results Available","Menorrhagia",,"Prevalence of HMB|Prevalence of HMB in different subgroups|Identify risk factors associated with HMB","Peking University|Bayer","Female","18 Years to 50 Years   (Adult)",,"2455","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","PEKU-BJ-2014","November 2014","September 2015","December 2016","December 2, 2014",,"December 31, 2018","Peking University Health Science Center, Beijing, China",,"https://ClinicalTrials.gov/show/NCT02304510"
1474,"NCT02289703","A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis",,"Completed","No Results Available","End-Stage Renal Disease","Drug: Rivaroxaban 15 mg","Maximum Observed Plasma Concentration (Cmax) of Rivaroxaban|Area Under the Plasma Concentration-time Curve From Time Zero to Last Quantifiable Time (AUClast) of Rivaroxaban|Area Under the Plasma Concentration-time Curve From Time Zero to Extrapolated Infinite Time (AUCinfinity) of Rivaroxaban|Maximum Observed Effect (Emax) for Prothrombin Time (PT), Factor Xa (FXa) Inhibition and Anti-FXa|Area Under the Dose-Response Curve for Prothrombin Time (PT), Factor Xa (FXa) Inhibition and Anti-FXa|Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)","Janssen Research & Development, LLC|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","16","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR105711|RIVAROXCRF1001","January 2015","March 2015","March 2015","November 13, 2014",,"January 24, 2017","Knoxville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02289703"
1475,"NCT02279940","Rivaroxaban Acute Stroke Safety Study","RASS","Completed","No Results Available","Acute Ischemic Stroke|Transient Ischemic Attack",,"Symptomatic Hemorrhagic Transformation Rate|Any parenchymal haemorrhage (PH1 or PH2) on follow-up MRI scan at 7±2 days post-enrolment.|Recurrent Transient Ischemic Attack/Ischemic Stroke within 90 days of enrolment.|Systemic hemorrhagic complication rate within 90 days of enrolment.","University of Alberta|Bayer","All","18 Years and older   (Adult, Older Adult)",,"50","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","Version 1.0","March 2014","January 2016",,"October 31, 2014",,"April 6, 2016","University of Alberta, Edmonton, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT02279940"
1476,"NCT02278783","Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer",,"Terminated","Has Results","Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer","Drug: regorafenib","6 Month Progression Free Survival (PFS)|Incidence of Adverse Events (Grade 2 or Higher), Assessed According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0|Estimate Progression Free Survival|Frequency of Clinical Benefit (Stable Disease, Partial and Complete Response)","University of Utah|Bayer","Female","18 Years and older   (Adult, Older Adult)","Phase 2","1","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HCI77685","March 2015","July 2016","January 2017","October 30, 2014","December 2, 2016","October 6, 2017","Huntsman Cancer Institute, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT02278783"
1477,"NCT02273609","INR Control and Atrial Fibrillation in Primary Care in Spain (PAULA)","PAULA","Completed","No Results Available","Atrial Fibrillation and Flutter","Drug: Vitamin K antagonists (acenocoumarol or warfarin)","Anticoagulation control with vitamin K antagonists","Vivencio Barrios|Bayer|Hospital Universitario Ramon y Cajal","All","18 Years and older   (Adult, Older Adult)",,"1524","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","BAY-AVK-2013-01","February 2014","July 2014","October 2014","October 24, 2014",,"October 29, 2014",,,"https://ClinicalTrials.gov/show/NCT02273609"
1478,"NCT02248610","Follow-up in Rivaroxaban Patients in Setting of Thromboembolism","FIRST","Unknown status","No Results Available","Venous Thromboembolism","Other: Non-interventional study","Incidence of long term complications|Incidence of major post-thrombotic complications|Incidence of treatment-emergent bleeding rates|All-cause mortality|Treatment adherence|Quality of life assessment|Healthcare resource utilisation|Incidence of other thromboembolic events","King's College Hospital NHS Trust|Bayer","All","18 Years and older   (Adult, Older Adult)",,"1500","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","FIRST registry","November 2014","November 2017","November 2019","September 25, 2014",,"September 4, 2015","Basingstoke Hospital, Basingstoke, United Kingdom|Bournemouth Hospital, Bournemouth, United Kingdom|Kings College Hospital NHS Foundation Trust, London, United Kingdom|Salisbury Hospital, Salisbury, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02248610"
1479,"NCT02237534","Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia","LAVALIER","Enrolling by invitation","No Results Available","Renal Insufficiency, Chronic|Hyperphosphatemia|Bone Diseases, Metabolic","Drug: Lanthanum carbonate|Drug: Calcium Carbonate","Coronary artery calcification score|Endothelial function|Serum bone metabolic markers|Serum concentrations of calcium, phosphate, intact parathyroid hormone, 25-hydroxyvitamin D, and 1,25-dihydroxyvitamin D over time|Estimated glomerular filtration rate over time|Bone mineral density|Serum osteoprotegerin concentration|Urinary alpha-Klotho to creatinine ratio|Urinary liver-type fatty acid binding protein (L-FABP) to creatinine ratio|End-stage renal disease requiring renal replacement therapy|Cardiovascular event requiring hospitalization|Death","Osaka University|Bayer","All","20 Years and older   (Adult, Older Adult)","Phase 4","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CKDR-002","September 2014","December 2020","June 2021","September 11, 2014",,"August 31, 2018","Osaka University Hospital, Suita, Osaka, Japan",,"https://ClinicalTrials.gov/show/NCT02237534"
1480,"NCT02204943","Pharmacodynamic Study of Radium-223 in Men With Bone Metastatic Castration-Resistant Prostate Cancer",,"Completed","No Results Available","Bone Metastatic Castration-Resistant Prostate Cancer","Device: Biomarker analysis|Drug: Administration of radium-223","Proportion of patients who overexpress alkaline phosphatase (ALP) in Circulating Tumor Cells (CTCs) at each time point|Change in biomarkers of epithelial plasticity and osteomimicry expressed in the bone metastases of men with bone metastatic CRPC","Duke University|Bayer","Male","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","Pro00053925","May 6, 2015","July 31, 2017","July 31, 2017","July 31, 2014",,"June 8, 2018","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02204943"
1481,"NCT02196857","Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation",,"Completed","Has Results","Leukemia","Drug: Azacytidine|Drug: Sorafenib","Participants With a Response CR + PR + CRi|Toxicity Profile of Azacytidine and Sorafenib","M.D. Anderson Cancer Center|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","16","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014-0076|NCI-2014-01702","February 6, 2015","November 27, 2018","November 27, 2018","July 22, 2014","January 6, 2020","January 14, 2020","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02196857/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02196857"
1482,"NCT02180828","Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis",,"Completed","Has Results","Candidiasis, Vulvovaginal","Drug: Clotrimazole vaginal tablet|Drug: Fluconazole","Therapeutic Efficacy 1|Therapeutic Efficacy 2|Therapeutic Efficacy 3|Therapeutic Efficacy 4|Adverse Events 1|Adverse Events 2|Adverse Events 3|Adverse Events 4|Total Adverse Events","Peking University Shenzhen Hospital|Bayer","Female","18 Years to 48 Years   (Adult)","Phase 4","240","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","pkuszh-2014-02","July 2014","September 2015","September 2015","July 3, 2014","September 30, 2016","May 2, 2017","Peking University Shenzhen Hospital, Shenzhen, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT02180828"
1483,"NCT02175654","Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab","PREVIUM","Terminated","No Results Available","Colorectal Neoplasms|Metastatic Disease","Drug: Regorafenib","Progression free survival rate at 6 months|Objective response rate based on the Response Evaluation Criteria in Solid Tumors criteria|Disease control rate|Response according other criteria (Appendix 9)|Time to response|Progression free survival|Time to treatment failure|Response duration|Duration of stable disease|Overall survival|Time to progression|Incidence and severity of adverse events (AE) (NCI CTC, version 3.0)|Changes in laboratory values|Change in vital signs (weight loss and hypertension)|Incidence of dose adjustments and compliance|Incidence of concomitant medication|Changes in ECOG performance status over time from baseline","Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TTD-14-01|2014-000703-26","June 2014","February 2016","February 2016","June 26, 2014",,"August 1, 2017","Spanish Cooperative Group for Digestive Tumour Therapy (TTD), Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT02175654"
1484,"NCT02161081","A Study on Improved Dynamic Myocardial Perfusion With Less Effective Radiation Dose in CT (SIMPLE CT)",,"Completed","No Results Available","Myocardial Ischemia","Procedure: Myocardial CT perfusion","AUC (area under the curve) of CT perfusion for detection of perfusion defects : 30-second scanning protocol versus 21-second scanning protocol|Effective radiation dose for each component of the CT examination is calculated as the product of the dose-length product multiplied by a conversion coefficient of 0.014 (mSv/[mGycm]).","Samsung Medical Center|Bayer","All","30 Years to 80 Years   (Adult, Older Adult)","Not Applicable","120","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","SMC2011-05-032-023","January 2012","December 2013","July 2014","June 11, 2014",,"December 6, 2017","Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02161081"
1485,"NCT02157077","Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration","ARI2","Completed","No Results Available","Macular Degeneration|Wet Macular Degeneration|Retinal Degeneration|Retinal Diseases|Eye Diseases","Drug: Aflibercept","Change from baseline in maximal height of pigment epithelium detachment (PED) at 12 weeks|Change from baseline in central retinal thickness by SD OCT at 12 weeks|Change from Baseline in visual acuity at 12 weeks|Change from Baseline in volume of pigment epithelium detachment at 12 weeks|Association with genes involved in AMD history|Number of participants with adverse events from baseline to 32 weeks|Change from Baseline in pigment epithelium detachment height at 12 weeks|Change from baseline in central retinal thickness at 32 weeks|Change from Baseline in pigment epithelium detachment height at 32 weeks|Change from Baseline in visual acuity at 32 weeks|Change from Baseline in volume of pigment epithelium detachment at 32 weeks","Centre Hospitalier Intercommunal Creteil|Bayer","All","50 Years and older   (Adult, Older Adult)","Phase 3","90","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHIC-ARI2|2013-002869-19","December 2013","December 2015","December 2015","June 5, 2014",,"June 21, 2016","Hôpital Pellegrin, Bordeaux, France|Centre Hospitalier Intercommunal de Créteil, Créteil, France|Hôpital général de Dijon, Dijon, France|Centre d'Ophtalmologie Rabelais, Lyon, France|Cabinet Alpes Rétine, Montbonnot-Saint-Martin, France|CHR Hôtel Dieu, Nantes, France|Centre d'explorations ophtalmologiques de l'odéon, Paris, France|Hôpital des Quinze-Vingts, Paris, France|Clinique Mathilde, Rouen, France",,"https://ClinicalTrials.gov/show/NCT02157077"
1486,"NCT02155491","Global Anticoagulant Registry in the FIELD- Venous Thromboembolic Events","GARFIELD-VTE","Active, not recruiting","No Results Available","Venous Thromboembolism|Deep Vein Thrombosis|Pulmonary Embolism",,"Rate of recurrent symptomatic VTE (DVT and fatal or non-fatal PE)|Bleeding events|Hospitalization|Post Thrombotic Syndrome|Chronic thromboembolic pulmonary hypertension|IVC filter placement|Other urgent interventions for VTE|Anticoagulation therapy persistence|All cause of mortality|International Normalized Ratio (INR) Values in Patients treated with Vitamin K Antagonists|Stroke|Trans Ischemic Attack (TIA)|Myocardial Infarction|Unstable angina|Quality of life and patient treatment satisfaction over a three year period","Thrombosis Research Institute|Bayer","All","18 Years to 99 Years   (Adult, Older Adult)",,"10000","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","TRI08889","July 7, 2014","January 4, 2020","January 4, 2020","June 4, 2014",,"May 13, 2019","Dr Terence Hart, Muscle Shoals, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT02155491"
1487,"NCT02146950","European Active Surveillance Study of LCS12","EURAS_LCS12","Recruiting","No Results Available","Contraception",,"Unintended pregnancy|Pelvic inflammatory disease (PID)|Ectopic pregnancy|Uterine perforations","Center for Epidemiology and Health Research, Germany|Bayer","Female","up to 39 Years   (Child, Adult)",,"38000","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ZEG2013_10|16470|EUPAS6476","June 17, 2014","June 2022","September 2022","May 26, 2014",,"November 5, 2019","Center for Epidemiology and Health Research Berlin, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT02146950"
1488,"NCT02123524","Rivaroxaban Anticoagulation for Superficial Vein Thrombosis","RASET","Completed","No Results Available","Symptomatic Superficial Vein Thrombosis","Drug: Rivaroxaban|Drug: Placebo","Efficacy|Safety","McMaster University|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","85","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","OCOG-2013-RASET","November 11, 2014","December 3, 2018","December 3, 2018","April 25, 2014",,"December 4, 2018","University of Alberta Hospital, Edmonton, Alberta, Canada|Hamilton General Hospital, Hamilton, Ontario, Canada|St Josephs Healthcare, Hamilton, Ontario, Canada|Juravinski Hospital, Hamilton, Ontario, Canada|McMaster Hospital, Hamilton, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|Hopital Maisonneuve - Rosemount, Montreal, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Hopital Sacre Coeur, Montreal, Quebec, Canada|Montreal General Hospital, Montreal, Quebec, Canada|St Mary's Hospital, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02123524"
1489,"NCT02115542","Single Agent Regorafenib in Refractory Advanced Biliary Cancers",,"Active, not recruiting","Has Results","Cancer of the Bile Duct","Drug: Regorafenib","Overall Survival (OS) at 6 Months|Disease Control Response (DCR)|Progression Free Survival (PFS)","H. Lee Moffitt Cancer Center and Research Institute|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","39","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-17651","April 10, 2014","December 10, 2018","October 2020","April 16, 2014","January 13, 2020","January 21, 2020","H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|VCU Massey Cancer Center, Richmond, Virginia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT02115542/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02115542"
1490,"NCT02111564","A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients","MARINER","Completed","Has Results","Heart Failure|Respiratory Insufficiency|Stroke Acute|Infectious Diseases|Rheumatic Diseases","Drug: Rivaroxaban, 10 mg|Drug: Rivaroxaban, 7.5 mg|Drug: Placebo","Time From Randomization to First Occurrence of Composite of All Symptomatic Venous Thromboembolism (VTE) and VTE Related Death Adjudicated by Clinical Event Committee (CEC)|Event Rate Based on Time From Randomization to the First Occurrence of Major Bleeding Adjudicated by CEC|Event Rate Based on Time From Randomization to First Occurrence of VTE-Related Death Adjudicated by CEC|Event Rate Based on Time From Randomization to the First Occurrence of a Symptomatic Venous Thromboembolism Event (VTE) Adjudicated by CEC|Event Rate Based on Time From Randomization to the First Occurrence of a Composite of Symptomatic VTE and All-Cause Mortality (ACM) Adjudicated by CEC|Event Rate Based on Time From Randomization to the First Occurrence of a Composite of Symptomatic VTE, Myocardial Infarction (MI), Non-Hemorrhagic Stroke, and Cardiovascular (CV) Death Adjudicated by CEC|Event Rate Based on Time From Randomization to First Occurrence of All-Cause Mortality (ACM) Adjudicated by CEC","Janssen Research & Development, LLC|Bayer","All","40 Years and older   (Adult, Older Adult)","Phase 3","12024","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention","CR103834|2014-000305-13|RIVAROXDVT3002","January 7, 2014","March 6, 2018","May 3, 2018","April 11, 2014","November 25, 2019","November 25, 2019","Birmingham, Alabama, United States|Mobile, Alabama, United States|Sheffield, Alabama, United States|Scottsdale, Arizona, United States|Fort Smith, Arkansas, United States|Little Rock, Arkansas, United States|Anaheim, California, United States|Beverly Hills, California, United States|Fullerton, California, United States|Los Angeles, California, United States|Newport Beach, California, United States|Orange, California, United States|Sacramento, California, United States|San Jose, California, United States|San Marino, California, United States|Santa Ana, California, United States|Colorado Springs, Colorado, United States|Bridgeport, Connecticut, United States|Danbury, Connecticut, United States|New Haven, Connecticut, United States|Waterbury, Connecticut, United States|Washington, District of Columbia, United States|Atlantis, Florida, United States|Bay Pines, Florida, United States|Bradenton, Florida, United States|Brandon, Florida, United States|Celebration, Florida, United States|Clearwater, Florida, United States|Daytona Beach, Florida, United States|Jacksonville Beach, Florida, United States|Jacksonville, Florida, United States|Largo, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Pensacola, Florida, United States|Saint Cloud, Florida, United States|Sebring, Florida, United States|Tampa, Florida, United States|Vero Beach, Florida, United States|Wellington, Florida, United States|West Palm Beach, Florida, United States|Atlanta, Georgia, United States|Marietta, Georgia, United States|Idaho Falls, Idaho, United States|Chicago, Illinois, United States|Normal, Illinois, United States|North Chicago, Illinois, United States|Hammond, Indiana, United States|Lafayette, Indiana, United States|Michigan City, Indiana, United States|Des Moines, Iowa, United States|Kansas City, Kansas, United States|Topeka, Kansas, United States|Alexandria, Louisiana, United States|Lafayette, Louisiana, United States|Metairie, Louisiana, United States|Minden, Louisiana, United States|New Orleans, Louisiana, United States|Shreveport, Louisiana, United States|Slidell, Louisiana, United States|Rockport, Maine, United States|Annapolis, Maryland, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Detroit, Michigan, United States|Royal Oak, Michigan, United States|Saginaw, Michigan, United States|Troy, Michigan, United States|Minneapolis, Minnesota, United States|Saint Paul, Minnesota, United States|Bridgeton, Missouri, United States|Columbia, Missouri, United States|Saint Louis, Missouri, United States|Omaha, Nebraska, United States|Las Vegas, Nevada, United States|Atlantic City, New Jersey, United States|Bridgewater, New Jersey, United States|Marlton, New Jersey, United States|Newark, New Jersey, United States|Albuquerque, New Mexico, United States|Albany, New York, United States|Buffalo, New York, United States|Cortlandt Manor, New York, United States|Jamaica, New York, United States|Johnson City, New York, United States|Manhasset, New York, United States|New Hyde Park, New York, United States|New York, New York, United States|Staten Island, New York, United States|Valhalla, New York, United States|Durham, North Carolina, United States|Greensboro, North Carolina, United States|Raleigh, North Carolina, United States|Statesville, North Carolina, United States|Canton, Ohio, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Maumee, Ohio, United States|Springfield, Ohio, United States|Willoughby, Ohio, United States|Oklahoma City, Oklahoma, United States|Portland, Oregon, United States|Abington, Pennsylvania, United States|Camp Hill, Pennsylvania, United States|Chambersburg, Pennsylvania, United States|Doylestown, Pennsylvania, United States|Jefferson Hills, Pennsylvania, United States|Johnstown, Pennsylvania, United States|Lancaster, Pennsylvania, United States|Langhorne, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Shippensburg, Pennsylvania, United States|Pawtucket, Rhode Island, United States|Columbia, South Carolina, United States|Summerville, South Carolina, United States|Athens, Tennessee, United States|Amarillo, Texas, United States|Austin, Texas, United States|Channelview, Texas, United States|Corsicana, Texas, United States|Dallas, Texas, United States|Fort Worth, Texas, United States|Houston, Texas, United States|McAllen, Texas, United States|Tyler, Texas, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Roanoke, Virginia, United States|Richland, Washington, United States|Seattle, Washington, United States|Huntington, West Virginia, United States|La Crosse, Wisconsin, United States|Marshfield, Wisconsin, United States|Bahia Blanca, Argentina|Buenos Aires, Argentina|Ciudad de Buenos Aires, Argentina|Cordoba, Argentina|Coronel Suarez, Argentina|Corrientes, Argentina|Córdoba, Argentina|Esperanza, Argentina|La Plata, Argentina|Merlo, Argentina|Moron, Argentina|Munro, Argentina|Rosario, Argentina|Santa Fe, Argentina|Santa Fé, Argentina|Tucuman, Argentina|Bedford Park, Australia|Box Hill, Australia|Caboolture, Australia|Cairns, Australia|Chermside, Australia|East Saint Kilda, Australia|Kogarah, Australia|Launceston, Australia|Lismore, Australia|Meadowbrook, Australia|Milton, Australia|Nedlands, Australia|Parkwood, Australia|Penrith, Australia|Redcliffe, Australia|South Brisbane, Australia|Sydney, Australia|VIC, Parkville, Australia|Feldkirch, Austria|Graz, Austria|Linz, Austria|Salzburg, Austria|Wien, Austria|Gomel, Belarus|Grodno, Belarus|Minsk, Belarus|Mogilev, Belarus|Vitebsk, Belarus|Vychulki, Brest Region, Brest, Belarus|Banja Luka, Bosnia and Herzegovina|Bihac, Bosnia and Herzegovina|Foca, Bosnia and Herzegovina|Mostar, Bosnia and Herzegovina|Sarajevo, Bosnia and Herzegovina|Tuzla, Bosnia and Herzegovina|Zenica, Bosnia and Herzegovina|Belo Horizonte, Brazil|Blumenau, Brazil|Brasília, Brazil|Campina Grande do Sul, Brazil|Campinas, Brazil|Canoas, Brazil|Curitiba, Brazil|Itajaí, Brazil|Natal, Brazil|Passo Fundo, Brazil|Porto Alegre, Brazil|Recife, Brazil|Ribeirão Preto, Brazil|Salvador, Brazil|San Paulo, Brazil|Santo André, Brazil|Sao Paulo, Brazil|São José Do Rio Preto, Brazil|São Paulo, Brazil|Votuporanga, Brazil|Blagoevgrad, Bulgaria|Burgas, Bulgaria|Dimitrovgrad, Bulgaria|Gabrovo, Bulgaria|Kozlodui, Bulgaria|Lom, Bulgaria|Lovech, Bulgaria|Montana, Bulgaria|Pernik, Bulgaria|Pleven, Bulgaria|Plovdiv, Bulgaria|Razlog, Bulgaria|Ruse, Bulgaria|Sandanski, Bulgaria|Sliven, Bulgaria|Sofia, Bulgaria|Veliko Tarnovo, Bulgaria|Vidin, Bulgaria|Edmonton, Alberta, Canada|Saint John, New Brunswick, Canada|Hamilton, Ontario, Canada|London, Ontario, Canada|Ottawa, Ontario, Canada|Scarborough, Ontario, Canada|Toronto, Ontario, Canada|Waterloo, Ontario, Canada|Greenfield Park, Quebec, Canada|Montreal, Quebec, Canada|Saint-Jerome, Quebec, Canada|Sherbrooke, Quebec, Canada|Quebec, Canada|Armenia, Colombia|Barranquilla, Colombia|Bogota, Colombia|Bogotá, Colombia|Cali, Colombia|Chia, Colombia|Floridablanca, Colombia|Medellin, Colombia|Medellín, Colombia|Villavicencio, Colombia|Cakovec, Croatia|Karlovac, Croatia|Krapinske Toplice, Croatia|Osijek, Croatia|Pula, Croatia|Rijeka, Croatia|Sibenik, Croatia|Virovitica, Croatia|Zabok, Croatia|Zadar, Croatia|Zagreb, Croatia|Boskovice, Czechia|Brno, Czechia|Cesky Krumlov, Czechia|Jablonec Na Nisou, Czechia|Karvina, Czechia|Kladno, Czechia|Krnov, Czechia|Kyjov, Czechia|Liberec, Czechia|Litomysl, Czechia|Mestec Kralove, Czechia|Nove Mesto na Morave, Czechia|Nymburk N/a, Czechia|Olomouc, Czechia|Opava, Czechia|Ostrava, Czechia|Pardubice, Czechia|Praha 10, Czechia|Praha 2, Czechia|Praha 4, Czechia|Praha 5, Czechia|Praha 8, Czechia|Pribram, Czechia|Písek, Czechia|Slany, Czechia|Sternberk, Czechia|Svitavy, Czechia|Teplice, Czechia|Trinec, Czechia|Trutnov, Czechia|Uherske Hradiste, Czechia|Usti Nad Labem, Czechia|Usti nad Orlici, Czechia|Zlin, Czechia|Aalborg, Denmark|Copenhagen, Denmark|Esbjerg, Denmark|Frederiksberg, Denmark|Hellerup, Denmark|Hilleroed, Denmark|Hvidovre, Denmark|København S, Denmark|Roskilde, Denmark|Tallinn, Estonia|Batumi, Georgia|Kutaisi, Georgia|Marneuli, Georgia|Rustavi, Georgia|T'bilisi, Georgia|Tbilisi, Georgia|Telavi, Georgia|Berlin, Germany|Coburg, Germany|Dresden, Germany|Esslingen, Germany|Frankfurt, Germany|Heidelberg, Germany|Jülich, Germany|Karlsbad, Germany|Leipzig, Germany|Limburg, Germany|Mannheim, Germany|Minden, Germany|Mönchengladbach, Germany|Neuwied, Germany|Troisdorf, Germany|Witten, Germany|Achaïa, Greece|Alexandroupolis, Greece|Athens, Greece|Heraklion, Greece|Ioannina, Greece|Kifisia, Athens, Greece|Magoula, Greece|Patra, Greece|Thessalonikis, Greece|Thessaloniki, Greece|Voula, Greece|Ajka, Hungary|Baja, Hungary|Balassagyarmat, Hungary|Berettyóújfalú, Hungary|Budapest, Hungary|Cegléd, Hungary|Debrecen, Hungary|Eger, Hungary|Farkasgyepü, Hungary|Gyula, Hungary|Gyõr, Hungary|Gödöllő, Hungary|Hodmezovasarhely, Hungary|Kalocsa, Hungary|Kaposvar, Hungary|Kecskemet N/a, Hungary|Kecskemet, Hungary|Keszthely, Hungary|Kistarcsa, Hungary|Komarom, Hungary|Miskolc, Hungary|Nagykanizsa, Hungary|Orosháza, Hungary|Pecs, Hungary|Pécs, Hungary|Szeged, Hungary|Szekesfehervar, Hungary|Szekszárd, Hungary|Szentes, Hungary|Szolnok, Hungary|Szombathely, Hungary|Székesfehérvár, Hungary|Sátoraljaújhely, Hungary|Zalaegerszeg, Hungary|Beersheba, Israel|Hadera, Israel|Haifa, Israel|Holon, Israel|Jerusalem, Israel|Kfar-Saba, Israel|Modi'in, Israel|Nahariya, Israel|Petah Tikva, Israel|Petah Tiqwa, Israel|Rehovot, Israel|Safed, Israel|Tel-Hashomer, Israel|Tiberias, Israel|Zefat, Israel|Balvi, Latvia|Daugavpils, Latvia|Jekabpils, Latvia|Jelgava, Latvia|Krāslavas Apriņķis, Latvia|Kuldiga, Latvia|Liepaja, Latvia|Riga, Latvia|Ventspils, Latvia|Kaunas, Lithuania|Klaipeda, Lithuania|Panevezys, Lithuania|Siauliai, Lithuania|Taurage, Lithuania|Utena, Lithuania|Vilniaus Apskritis, Lithuania|Vilnius, Lithuania|Aguascalientes, Mexico|Cuernavaca, Mexico|Guadalajara, Mexico|Merida, Mexico|Monterrey, Mexico|San Pedro Garza Garcia, Mexico|Alkmaar, Netherlands|Almelo, Netherlands|Amsterdam, Netherlands|Arnhem, Netherlands|Den Haag, Netherlands|Harderwijk, Netherlands|Heerlen, Netherlands|Hoorn, Netherlands|Maastricht, Netherlands|Nieuwegein, Netherlands|s-Hertogenbosch, Netherlands|Sittard-Geleen, Netherlands|Sneek, Netherlands|Tilburg, Netherlands|Veldhoven, Netherlands|Zutphen, Netherlands|Zwolle, Netherlands|Bitola, North Macedonia|Ohrid, North Macedonia|Skopje, North Macedonia|Struga, North Macedonia|Štip, North Macedonia|Callao, Peru|Lima, Peru|Bialystok, Poland|Bielsko-Biala, Poland|Bydgoszcz, Poland|Bystra, Poland|Czeladz, Poland|Gdynia, Poland|Kielce, Poland|Klodzko, Poland|Krakow, Poland|Kraków, Poland|Leczna, Poland|Lodz, Poland|Lublin, Poland|Olawa, Poland|Ostroleka, Poland|Ostrow Mazowiecka, Poland|Pabianice, Poland|Plock, Poland|Poznan, Poland|Proszowice, Poland|Pulawy, Poland|Rabka-Zdroj, Poland|Siedlce, Poland|Sopot,Gdynia, Poland|Sosnowiec, Poland|Szczecin, Poland|Tarn W N/a, Poland|Torun, Poland|Warszawa N/a, Poland|Warszawa, Poland|Wegrow, Poland|Wroclaw, Poland|Braga, Portugal|Coimbra, Portugal|Covilhã, Portugal|Figueira da Foz, Portugal|Guimarães, Portugal|Lisboa, Portugal|Porto, Portugal|Vila Nova de Gaia, Portugal|San Juan, Puerto Rico|Bacau, Romania|Baia Mare, Romania|Braila, Romania|Brasov, Romania|Bucuresti, Romania|Bucureşti, Romania|Cluj-Napoca, Romania|Craiova, Romania|Focsani, Romania|Iasi, Romania|Iaşi, Romania|Oradea, Romania|Pitesti, Romania|Tg Mures, Romania|Timisoara, Romania|Arkhangelsk, Russian Federation|Chelyabinsk, Russian Federation|Ekaterinburg, Russian Federation|Irkutsk, Russian Federation|Kazan, Russian Federation|Kemerovo, Russian Federation|Krasnodar, Russian Federation|Krasnoyarsk, Russian Federation|Moscow, Russian Federation|Moskva, Russian Federation|Novosibirsk, Russian Federation|Orenburg, Russian Federation|Penza, Russian Federation|Rostov on Don, Russian Federation|Saint Petersburg, Russian Federation|Saint-Petersburg, Russian Federation|Saratov, Russian Federation|Smolensk, Russian Federation|St. Petersburg, Russian Federation|Tomsk, Russian Federation|Ulyanovsk, Russian Federation|Vsevolzhsk, Russian Federation|Yaroslavl, Russian Federation|Belgrade, Serbia|Beograd, Serbia|Cacak, Serbia|Cuprija, Serbia|Dedinje, Serbia|Kragujevac, Serbia|Leskovac, Serbia|Nis, Serbia|Novi Sad, Serbia|Sabac, Serbia|Smederevo, Serbia|Sremska Kamenica, Serbia|Subotica, Serbia|Valjevo, Serbia|Vranje, Serbia|Zaječar, Serbia|Kosice, Slovakia|Martin, Slovakia|Nitra, Slovakia|Bellville, South Africa|Bloemfontein, South Africa|Cape Town, South Africa|Durban Kwa Zulu Natal, South Africa|Durban, South Africa|Gatesville Cape Town, South Africa|Groenkloof, Pretoria, South Africa|Johannesburg, South Africa|Kempton Park, South Africa|Kuils River, South Africa|Pretoria, South Africa|Somerset West, South Africa|Stellenbosch, South Africa|Worcester, South Africa|Alcalá de Henares, Spain|Alicante, Spain|Almeria, Spain|Alzira, Spain|Aranjuez, Spain|Avila, Spain|Balea, Spain|Barcelona, Spain|Burgos, Spain|Cartagena, Spain|Cáceres, Spain|Don Benito, Spain|Elche, Spain|Getafe, Spain|Granada, Spain|Huelva N/a, Spain|La Laguna, Spain|Las Palmas de Gran Canaria, Spain|Logroño, Spain|Madrid, Spain|Majadahonda-Madrid, Spain|Malaga, Spain|Murcia, Spain|Móstoles, Spain|Olot, Spain|Oviedo, Spain|Palma de Mallorca, Spain|Pamplona, Spain|Sabadell, Spain|San Sebastian de los Reyes, Spain|Sanchinarro, Spain|Sant Boi de Llobregat, Spain|Sant Joan d'Alacant, Spain|Santander N/a, Spain|Sarrià, Spain|Sevilla, Spain|Torrelavega Cantabria, Spain|Valencia, Spain|Zaragoza, Spain|Adana, Turkey|Ankara, Turkey|Antalya, Turkey|Istanbul, Turkey|Izmir, Turkey|Konya, Turkey|Rize, Turkey|Samsun, Turkey|Cherkasy, Ukraine|Chernihiv, Ukraine|Dnipropetrovsk, Ukraine|Ivano-Frankivsky, Ukraine|Kharkiv, Ukraine|Kherson, Ukraine|Kyiv, Ukraine|Lutsk, Ukraine|Lviv, Ukraine|Odessa, Ukraine|Poltava, Ukraine|Sumy, Ukraine|Uzhgorod, Ukraine|Vinnytsia, Ukraine|Zaporizhzhia, Ukraine|Zaporizhzhya, Ukraine|Zhytomyr, Ukraine|Angus, United Kingdom|Cardiff, United Kingdom|Craigavon, United Kingdom|Glasgow, United Kingdom|Leeds, United Kingdom|Manchester, United Kingdom|Norwich, United Kingdom|Plymouth, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT02111564/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT02111564/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02111564"
1491,"NCT02098538","Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma",,"Active, not recruiting","No Results Available","Adenoid Cystic Carcinoma","Drug: Regorafenib","patients alive without disease progression|best overall response rate|Safety","Memorial Sloan Kettering Cancer Center|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","38","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13-244","March 2014","March 2020","March 2020","March 28, 2014",,"April 25, 2019","Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States",,"https://ClinicalTrials.gov/show/NCT02098538"
1492,"NCT02097303","Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis","eRADicAte","Completed","Has Results","Prostate Cancer","Drug: Concurrent use of Radium Ra 223 dichloride and Abiraterone Acetate plus Prednisone","Number and Percentage of Participants With Clinically Meaningful Improvement (Between Baseline and End of Treatment) in Quality-of-Life Determined by the Minimum Increase From Baseline in Scores as Per the QOL CMI Criteria|Number and Percentage of Participants With Clinically Meaningful Improvement (CMI) in Pain (Between Baseline and End of Treatment)|Safety Data Was Analyzed and Summarized in Subjects Who Receive at Least One Infusion of Radium Ra 223 Dichloride. Number of Adverse Events Are Being Reported.|Alkaline Phosphatase (ALP) and Prostate Specific Antigen (PSA) Levels Before and After Treatment|Radiologic Assessment Mean Number of Bone Lesions Before and After the Treatment","Carolina Research Professionals, LLC|Bayer","Male","18 Years and older   (Adult, Older Adult)","Phase 2","36","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CRP-PCA-01 eRADicAte","March 2014","December 2015","December 2015","March 27, 2014","February 1, 2018","February 1, 2018","Chesapeake urology Research Associates, Towson, Maryland, United States|Urology Cancer Center and GU Research Network, Omaha, Nebraska, United States|Associated Medical Professionals, Syracuse, New York, United States|Oregon Urology Institute, Springfield, Oregon, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02097303"
1493,"NCT02094001","Pilot Study to Evaluate Right Ventricular Function With Riociguat in CTEPH",,"Completed","No Results Available","Chronic Thromboembolic Pulmonary Hypertension","Radiation: Cardiac PET imaging using F-18-FDG, N-13 ammonia( NH3)","Evidence of changes in glucose metabolism and myocardial RV blood flow in patients treated with riociguat using PET imaging.|Evidence of improved RV function and volumes using 3D echocardiography and magnetic resonance imagining (MRI)","Ottawa Heart Institute Research Corporation|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","6","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","20130903-01H","May 2014","June 2016","June 2016","March 21, 2014",,"August 29, 2018","University of Ottawa Heart Institute, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02094001"
1494,"NCT02080260","A Study of Regorafenib in Advanced Pancreatic Cancer Patients",,"Completed","Has Results","Pancreatic Cancer","Drug: regorafenib","Number of Patients Progression Free and Surviving at 16 Weeks as a Percent of All Enrolled Subjects|Progression Free Survival|Overall Survival|Overall Response|Disease Control","Stuart Salmon, MD|Bayer|Atrium Health","All","18 Years and older   (Adult, Older Adult)","Phase 2","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LCI-GI-PAN-REG-001","June 6, 2014","June 28, 2017","June 28, 2017","March 6, 2014","July 19, 2019","July 19, 2019","Levine Cancer Institute-Albemarle, Albemarle, North Carolina, United States|Levine Cancer Institute-South Tryon, Charlotte, North Carolina, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Levine Cancer Institute - Pineville, Charlotte, North Carolina, United States|Levine Cancer Institute - Southpark, Charlotte, North Carolina, United States|Levine Cancer Institute - Mallard Creek, Charlotte, North Carolina, United States|Levine Cancer Institute - University, Charlotte, North Carolina, United States|Levine Cancer Institute - Ballantyne, Charlotte, North Carolina, United States|Levine Cancer Institute - Concord, Concord, North Carolina, United States|Levine Cancer Institute-Monroe, Monroe, North Carolina, United States|Levine Cancer Institute - Cleveland, Shelby, North Carolina, United States|Low Country Hematology Oncology, Charleston, South Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/60/NCT02080260/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02080260"
1495,"NCT02066662","Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification",,"Active, not recruiting","No Results Available","Atrial Fibrillation or Pulmonary Embolism|Need of Long Term Oral Anticoagulation Therapy (OAT)|Existent Coronary or Valvular Calcification, or Both and Agatston Score > 50 in at Least One Location","Drug: Rivaroxaban or Marcumar","Progression of coronary and aortic valve calcification (Agatston, volume & mass score as assessed by cardiac CT)|Serum chemistry including Matrix Gla Protein (MPG) level changes and Fetuin-A (baseline/ follow up)|Changes in intima-media thickness of carotid artery (IMT) and flow-mediated vasodilation of brachial artery (FMD)|Progression of aortic calcification (aortic Agatston Score)|Changes in ventricular diastolic function parameters as determined by echocardiography (strain/strain-rate imaging)","RWTH Aachen University|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 4","192","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science","12-001","July 2013","March 2020","March 2020","February 19, 2014",,"December 20, 2019","Hospital Coburg, Med. Clinic II for Internal Medicine and Cardiology, Coburg, Bavaria, Germany|University Hospital Aachen, Department of Cardiology, Aachen, North Rhine Westphalia, Germany|St.-Antonius-Hospital Eschweiler, Internal Medicine, Eschweiler, North Rhine Westphalia, Germany",,"https://ClinicalTrials.gov/show/NCT02066662"
1496,"NCT02053376","A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy",,"Completed","Has Results","Metastatic Biliary Tract Carcinoma","Drug: Regorafenib","Progression-free Survival (PFS)|Progression-free Survival (PFS) - Two or More Doses|Proportion of Participants With Overall Response (OR)|Overall Survival (OS)|Overall Survival (OS) - Two or More Doses|Disease Control Rate (DCR)|Changes in Cancer Antigen 19-9 (CA19-9) Level|Change in Carcinoembryonic Antigen (CEA)","Nathan Bahary, MD|Bayer|University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Phase 2","43","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13-100","January 2014","January 7, 2018","May 14, 2018","February 3, 2014","January 30, 2019","January 30, 2019","UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT02053376/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02053376"
1497,"NCT02042534","Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation","TripleAXEL","Completed","Has Results","Ischemic Stroke|Transient Ischemic Attack","Drug: Rivaroxaban|Drug: Warfarin","Number of Participants With Intracranial Bleeding and/or Recurrent Ischemic Lesion as Confirmed by MRI Imaging|The Number of Patients With Intracranial Bleeding|The Number of Patients With Recurrent Ischemic Lesion|Length of Hospitalization|Number of Participants With Modified Rankin Score of 0 or 1 at Week 4","Asan Medical Center|Bayer","All","19 Years and older   (Adult, Older Adult)","Phase 2","195","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LMI-2013-1013","January 2014","December 2015","December 2015","January 23, 2014","February 8, 2017","February 8, 2017","Asan Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02042534"
1498,"NCT02016222","Tear Analysis in the Diagnosis of Multiple Sclerosis","LARMES","Completed","No Results Available","Primary Progressive Multiple Sclerosis","Procedure: tears sampling","Concordance between the quantification of oligoclonal IgG bands by isoelectric focusing in tears and in the cerebrospinal fluid in patients with primary progressive multiple sclerosis|Isoelectrophoretic profile of tears|Isoelectrophoretic profiles of tears by digital recording and analysis of images","Lille Catholic University|Bayer","All","18 Years and older   (Adult, Older Adult)","Not Applicable","80","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","RC-P0006","April 2011","March 2016","March 2016","December 19, 2013",,"September 20, 2016","Centre hospitalier universitaire (CHU), Nice, Nice, Alpes Maritimes, France|Groupement des Hôpitaux de l'Institut Catholique de Lille (GHICL), Lille, Nord, France|Centre hospitaliere universitaire, Bordeaux, France|Centre hospitalier universitaire, Caen, France|Centre hospitalier régional universitaire, Clermont-Ferrand, France|Centre hospitalier universitaire, Dijon, France|Centre hospitalier régional universitaire, Lille, France|Hospices civils de Lyon, Lyon, France|Assistance Publique - Hôpitaux de Marseille, Marseille, France|Centre hospitalier universitaire, Nancy, France|Centre hospitalier universitaire, Nimes, France|Centre hospitalier intercommunal, Poissy, France|Centre hospitalier régional universtaire, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT02016222"
1499,"NCT01996969","Identification of Predictive Biomarker of Regorafenib in Refractory Colorectal Cancer",,"Completed","No Results Available","Metastatic Colorectal Cancer","Drug: Regorafenib","Predictive biomarker in terms of disease control rate|Disease control rate|Progression-free survival|Overall survival|number of participants with adverse events|Progression-free survival according to biomarker status|Overall survival according to biomarker status|Assessment of adequate response evaluation modality after regorafenib treatment","Seoul National University Hospital|Bayer","All","20 Years and older   (Adult, Older Adult)","Not Applicable","117","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","Regorafenib biomarker","October 2013","June 2015","May 2016","November 27, 2013",,"February 22, 2019","Seoul National University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01996969"
1500,"NCT01994005","Randomized Controlled Trial of Adjunctive Social Media for More Effective Contraceptive Counseling",,"Completed","No Results Available","Contraception","Behavioral: Facebook|Behavioral: Pamphlet","Contraceptive knowledge score|Contraceptive Choice","New York Presbyterian Hospital|Bayer","Female","18 Years to 45 Years   (Adult)","Not Applicable","144","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)","5327714500|ACOG/Bayer Healthcare","October 2012","February 2013","February 2013","November 25, 2013",,"November 25, 2013","Women's Health Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01994005"
1501,"NCT01950741","Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy","VAULT","Completed","Has Results","Exudative Age-related Macular Degeneration|Polypoidal Choroidal Vasculopathy","Drug: aflibercept","Percentage of Patients Lose Visual Acuity Less Than 15 Letters|Change in Visual Acuity From Baseline to 12 Months|Percentage of Patients With Visual Acuity >=20/200|Percentage of Patients With Visual Acuity >=20/40|Percentage of Patients Having Complete Resulution of Polypoidal Lesion in ICG Angiography|VFQ (Visual Function Questionaire)-25 Score","Pusan National University Hospital|Bayer","All","Child, Adult, Older Adult","Phase 4","48","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D-1304-013-014","September 2013","May 2015","August 2015","September 25, 2013","April 29, 2016","April 29, 2016","Busan Paik Hospital, Busanjin-gu, Busan, Korea, Republic of|Haeundae Paik Hospital, Haeundae, Busan, Korea, Republic of|Gospel Hospital, Seo-gu, Busan, Korea, Republic of|Pusan National University Hospital, Seo-gu, Busan, Korea, Republic of|Keimyung University Dongsan Medical Center, Jung-gu, Daegu, Korea, Republic of|Kyungpook National University Hospital, Jung-gu, Daegu, Korea, Republic of|Yeungnam University Medical Center, Nam-gu, Daegu, Korea, Republic of|Gyeongsang National University Hospital, Jinju, Gyeongsangnam-do, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01950741"
1502,"NCT01929694","The Effect of Consuming a guaraná and Vitamin/Mineral Complex Pre-exercise on Affect, Exertion, Metabolism and Cognition",,"Completed","No Results Available","Affect and Exertion During and Post-exercise","Dietary Supplement: Berocca Boost|Dietary Supplement: Placebo","Affect|Exertion","Northumbria University|Bayer","Male","18 Years to 35 Years   (Adult)","Phase 4","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","9B2","September 2013","April 2014","April 2014","August 28, 2013",,"October 3, 2014","Brain, Performance and Nutrition Research Centre, Northumbria Univerity, Newcastle upon Tyne, Tyne and Wear, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01929694"
1503,"NCT01919294","Testosterone Replacement in Non-alcoholic Steatohepatitis (TEREPINS)","TEREPINS","Completed","No Results Available","Nonalcoholic Steatohepatitis|Hypogonadism","Drug: testosterone undecanoate","steatosis histology|Proportion of patients in whom liver inflammation improves|Proportion of patients in whom liver ballooning improves|Proportion of patients in whom liver fibrosis improves|Change in fat content of liver|Change in HOMA index|Change in serum liver enzymes|Adverse events","Sheffield Teaching Hospitals NHS Foundation Trust|Bayer","Male","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","3","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STH16037|2012-002564-27","July 2013","January 30, 2017","January 30, 2017","August 9, 2013",,"April 26, 2017","Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, South Yorkshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01919294"
1504,"NCT01918878","Aflibercept (EYLEA)as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration.",,"Unknown status","No Results Available","Neovascular Age-related Macular Degeneration","Drug: Aflibercept (EYLEA)","Central macular thickness change|change in best corrected Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity and Change in CNV size","Hadassah Medical Organization|Bayer","All","50 Years and older   (Adult, Older Adult)","Phase 4","48","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHO123-HMO-CTIL","October 2013","April 2016","April 2016","August 8, 2013",,"January 13, 2016","Hadassah Medical Organization, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT01918878"
1505,"NCT01913639","FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer",,"Completed","No Results Available","Esophageal Cancer|Gastric Cancer","Drug: Regorafenib|Drug: 5-Fluorouracil|Drug: Leucovorin|Drug: Oxaliplatin","progression free survival (PFS)|overall survival (OS)|response rate|Toxicity","Memorial Sloan Kettering Cancer Center|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","39","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13-080","July 2013","June 2019","June 2019","August 1, 2013",,"June 24, 2019","Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States|Memoral Sloan Kettering Cancer Center@Phelps Memorial Hospital, Sleepy Hollow, New York, United States",,"https://ClinicalTrials.gov/show/NCT01913639"
1506,"NCT01900743","Phase II Study of Regorafenib in Metastatic Soft Tissue Sarcoma","REGO-SARC","Active, not recruiting","No Results Available","Sarcoma","Drug: Regorafenib|Drug: Placebo","Progression-free survival (PFS)|Growth modulation index|Toxicity according to NCI-CTC AE V4.0.|Progression-free rate at 3 and 6 months (PFR-3 and PFR-6)|Time to progression|Overall survival|Response rate|Duration of response","Centre Oscar Lambret|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","219","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","REGO-SARC-1214|2012-005743-24","June 5, 2013","February 2019","March 31, 2019","July 16, 2013",,"April 3, 2018","Medizinische Universität Graz, Graz, Austria|Universitätsklinik für Innere Medizin I, Innsbruck, Austria|LKH, Klagenfurt, Austria|Krankenhaus der Barmherzigen Schwestern Linz, Linz, Austria|AKH-Wien, Wien, Austria|Hôpital St Jacques, Besancon, France|Institut Bergonié, Bordeaux, France|Centre François Baclesse, Caen, France|Centre GF Leclercq, Dijon, France|Centre Oscar Lambret, Lille, France|Centre Léon Bérard, Lyon, France|Institut Paoli Calmettes, Marseille, France|Hôpital de La Timone, Marseille, France|Centre René Gauducheau, Nantes, France|Centre Antoine Lacassagne, Nice, France|Institut Curie, Paris, France|Hôpital Saint Louis, Paris, France|Hôpital Cochin, Paris, France|Centre Eugène Marquis, Rennes, France|Centre Henri Becquerel, Rouen, France|Institut Curie - Hôpital René Huguenin, Saint Cloud, France|Institut de Cancérologie Lucien Neuwirth (ICL), St Priest En Jarez, France|Institut Claudius Regaud, Toulouse, France|Centre Alexis Vautrin, Vandoeuvre Les Nancy, France|Institut Gustave Roussy, Villejuif, France",,"https://ClinicalTrials.gov/show/NCT01900743"
1507,"NCT01880944","Evaluation of Usefulness of Contrast Enhanced MRI in Evaluation of Spine Trauma: Prospective Study",,"Completed","No Results Available","Trauma","Other: NC-MRI, CE-MRI","The rate (%) of change of treatment option between non-surgery vs. surgery, after review of enhanced MRI finding, compared with non-enhanced MRI only|Confidence level|Diagnostic accuracy of non-enhanced and enhanced MRI|Inter- and intra-reader agreement of confidence level","Seoul National University Bundang Hospital|Bayer","All","19 Years and older   (Adult, Older Adult)",,"300","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","B-1304-199-003","June 24, 2013","December 14, 2016","February 14, 2017","June 19, 2013",,"October 5, 2018","Guen Young Lee, Seongnam-si, Gyenggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01880944"
1508,"NCT01877915","A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure","COMMANDER HF","Completed","Has Results","Heart Failure|Coronary Artery Disease","Drug: Rivaroxaban|Drug: Placebo|Other: Standard of care for heart failure and coronary artery disease","Event Rate of All-Cause Mortality, Myocardial Infarction (MI), or Stroke|Event Rate of Either Fatal Bleeding or Bleeding Into a Critical Space With Potential for Permanent Disability|Event Rate of Cardio Vascular Death or Re-Hospitalization for Worsening of Heart Failure (RHHF)|Event Rate of Cardio Vascular Death|Event Rate of Re-Hospitalization for Worsening of Heart Failure|Event Rate of Re-Hospitalization for Cardio Vascular Events (RHCV)|Event Rate of All-Cause Mortality (ACM) or Re-Hospitalization for Worsening Heart Failure|Event Rate of Bleeding Events That Requiring Hospitalization|Event Rate of International Society on Thrombosis and Haemostasis (ISTH) Major Bleeding Event","Janssen Research & Development, LLC|Bayer","All","18 Years to 95 Years   (Adult, Older Adult)","Phase 3","5081","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CR101940|RIVAROXHFA3001|2013-000046-19","September 10, 2013","April 19, 2018","April 19, 2018","June 14, 2013","May 10, 2019","May 10, 2019","Alexander City, Alabama, United States|Birmingham, Alabama, United States|Mobile, Alabama, United States|Anchorage, Alaska, United States|Tucson, Arizona, United States|Jonesboro, Arkansas, United States|Beverly Hills, California, United States|Chula Vista, California, United States|El Cajon, California, United States|Glendale, California, United States|La Mesa, California, United States|Los Angeles, California, United States|Newport Beach, California, United States|Orange, California, United States|Stockton, California, United States|Torrance, California, United States|Aurora, Colorado, United States|Denver, Colorado, United States|New Haven, Connecticut, United States|Atlantis, Florida, United States|Daytona Beach, Florida, United States|Jupiter, Florida, United States|Orlando, Florida, United States|Saint Petersburg, Florida, United States|Tallahassee, Florida, United States|Wellington, Florida, United States|Winter Haven, Florida, United States|Athens, Georgia, United States|Atlanta, Georgia, United States|Cumming, Georgia, United States|Macon, Georgia, United States|Tucker, Georgia, United States|Chicago, Illinois, United States|Evanston, Illinois, United States|Fairview Heights, Illinois, United States|Peoria, Illinois, United States|Rockford, Illinois, United States|Urbana, Illinois, United States|Anderson, Indiana, United States|Indianapolis, Indiana, United States|Merrillville, Indiana, United States|Munster, Indiana, United States|South Bend, Indiana, United States|Iowa City, Iowa, United States|Elizabethtown, Kentucky, United States|Lexington, Kentucky, United States|Louisville, Kentucky, United States|Owensboro, Kentucky, United States|Bossier City, Louisiana, United States|Hammond, Louisiana, United States|Shreveport, Louisiana, United States|Slidell, Louisiana, United States|Biddeford, Maine, United States|Baltimore, Maryland, United States|Columbia, Maryland, United States|Randallstown, Maryland, United States|Bay City, Michigan, United States|Grand Blanc, Michigan, United States|Mount Clemens, Michigan, United States|Pontiac, Michigan, United States|Ypsilanti, Michigan, United States|Saint Paul, Minnesota, United States|Saint Louis, Missouri, United States|Springfield, Missouri, United States|Washington, Missouri, United States|Lincoln, Nebraska, United States|Las Vegas, Nevada, United States|Bridgewater, New Jersey, United States|Elmer, New Jersey, United States|Haddon Heights, New Jersey, United States|Manalapan, New Jersey, United States|Ridgewood, New Jersey, United States|Sewell, New Jersey, United States|Albuquerque, New Mexico, United States|Buffalo, New York, United States|Cortlandt Manor, New York, United States|Jamaica, New York, United States|Mineola, New York, United States|New York, New York, United States|Charlotte, North Carolina, United States|High Point, North Carolina, United States|Pinehurst, North Carolina, United States|Canton, Ohio, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Dayton, Ohio, United States|Fairfield, Ohio, United States|Kettering, Ohio, United States|Bartlesville, Oklahoma, United States|Oklahoma City, Oklahoma, United States|Tulsa, Oklahoma, United States|Portland, Oregon, United States|Doylestown, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Sayre, Pennsylvania, United States|Sellersville, Pennsylvania, United States|Wynnewood, Pennsylvania, United States|Yardley, Pennsylvania, United States|York, Pennsylvania, United States|Charleston, South Carolina, United States|Sioux Falls, South Dakota, United States|Nashville, Tennessee, United States|Cypress, Texas, United States|Dallas, Texas, United States|Fort Worth, Texas, United States|Houston, Texas, United States|Huntsville, Texas, United States|Kingwood, Texas, United States|Lubbock, Texas, United States|McKinney, Texas, United States|Burlington, Vermont, United States|Newport News, Virginia, United States|Bellingham, Washington, United States|Tacoma, Washington, United States|Huntington, West Virginia, United States|Bahia Blanca, Argentina|Buenos Aires, Argentina|Caba, Argentina|Ciudad Autonoma de Buenos Aires, Argentina|Cordoba, Argentina|Córdoba, Argentina|La Plata, Argentina|Mar del Plata, Argentina|Mendoza, Argentina|Merlo, Argentina|Quilmes, Argentina|Resistencia, Argentina|Rosario, Argentina|San Miguel de Tucuman, Argentina|San Nicolas, Argentina|Santa Fe, Argentina|Santiago del Estero, Argentina|Tucuman, Argentina|Vicente Lopez, Argentina|Bedford, Australia|Cairns, Australia|Concord, Australia|Darlinghurst, Australia|Hobart, Australia|Launceston, Australia|Perth, Australia|Sydney, Australia|Wollongong, Australia|Woolloongabba, Australia|Belo Horizonte, Brazil|Belém, Brazil|Blumenal, Brazil|Brasília, Brazil|Campina Grande do Sul, Brazil|Campinas, Brazil|Campo Grande, Brazil|Canoas, Brazil|Curitiba, Brazil|Goiania, Brazil|Goiânia, Brazil|Marília, Brazil|Passo Fundo, Brazil|Porto Alegre, Brazil|Recife, Brazil|Ribeirão Preto, Brazil|Rio de Janeiro, Brazil|Salvador, Brazil|São Jose do Rio Preto, Brazil|São Paulo, Brazil|São Pedro, Brazil|Tatuí, Brazil|Uberlândia, Brazil|Votuporanga, Brazil|Blagoevgrad, Bulgaria|Burgas, Bulgaria|Dimitrovgrad, Bulgaria|Kazanlak, Bulgaria|Pazardzhik, Bulgaria|Pleven, Bulgaria|Plovdiv, Bulgaria|Ruse, Bulgaria|Sofia, Bulgaria|Stara Zagora, Bulgaria|Varna, Bulgaria|Veliko Tarnovo, Bulgaria|Edmonton, Alberta, Canada|Maple Ridge, British Columbia, Canada|St. John's, Newfoundland and Labrador, Canada|Halifax, Nova Scotia, Canada|Cambridge, Ontario, Canada|Kitchener, Ontario, Canada|London, Ontario, Canada|Ottawa, Ontario, Canada|Scarborough, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Montréal, Quebec, Canada|Baotou, China|Beijing, China|Changchun, China|Changsha, China|Chengdu, China|Daqing, China|Guangzhou, China|Haikou, China|Hangzhou, China|Hunan, China|Jinan, China|Jining, China|Lanzhou, China|Nanchang, China|Nanjing, China|Nanning, China|Qingdao, China|Shanghai, China|Shenyang, China|Shijiazhuang, China|Suzhou, China|Taiyuan, China|Tianjin, China|Wuhan, China|Xi'an, China|Xian, China|Yang Zhou, China|Yichang, China|Brno, Czechia|Hodonín, Czechia|Hradec Králové, Czechia|Hranice, Czechia|Karlovy Vary, Czechia|Kladno, Czechia|Kolín, Czechia|Litomyšl, Czechia|Mladá Boleslav, Czechia|Olomouc, Czechia|Plze?-Bory, Czechia|Praha 10, Czechia|Praha 8 - Libe?, Czechia|Praha, Czechia|Slany, Czechia|Teplice, Czechia|Uherské Hradišt?, Czechia|Valašské Mezi?í?í, Czechia|Esbjerg, Denmark|Herlev, Denmark|Hjørring, Denmark|Hvidovre, Denmark|Køge, Denmark|Tallinn, Estonia|Besancon, France|Bron Cedex, France|Chambray-Lès-Tours, France|Corbeil Essonnes, France|Lille, France|Montpellier, France|Nantes, France|Nice, France|Pau, France|Rouen, France|Toulouse, France|Vandoeuvre-les-nancy, France|Berlin, Germany|Bielefeld, Germany|Bonn, Germany|Coburg, Germany|Dresden, Germany|Halle, Germany|Hamburg, Germany|Heidelberg, Germany|Konstanz, Germany|Langen, Germany|Leipzig, Germany|Ludwigshafen, Germany|Magdeburg, Germany|Mainz, Germany|Markkleeberg, Germany|Papenburg, Germany|Stuttgart, Germany|Ulm, Germany|Witten, Germany|Athens, Greece|Heraklion -Crete, Greece|Larisa, Greece|Thessalonikis, Greece|Voula, Greece|Balatonfüred, Hungary|Berettyóújfalu, Hungary|Budapest, Hungary|Gyor, Hungary|Miskolc, Hungary|Nagykanizsa, Hungary|Szekszárd, Hungary|Szolnok, Hungary|Székesfehérvár, Hungary|Zalaegerszeg, Hungary|Aichi, Japan|Chiba, Japan|Chikushino-shi, Japan|Ehime, Japan|Fukuoka, Japan|Gifu, Japan|Gunma, Japan|Hatsukaichi, Japan|Hitachi, Japan|Hokkaido, Japan|Hyogo, Japan|Ibaraki, Japan|Ishikawa, Japan|Izumo, Japan|Kagawa, Japan|Kahoku-District, Japan|Kanagawa, Japan|Kobe-shi, Japan|Komatsushima-shi, Japan|Koshigaya-shi, Japan|Kumamoto, Japan|Kyoto, Japan|Miyazaki, Japan|Nagano-shi, Japan|Nagano, Japan|Nagasaki, Japan|Nagoya, Japan|Niigata, Japan|Oita, Japan|Okayama, Japan|Okinawa, Japan|Osaka-shi, Japan|Osaka, Japan|Saga, Japan|Saitama, Japan|Sapporo, Japan|Sendai, Japan|Shiga, Japan|Shimane, Japan|Shizuoka, Japan|Tachikawa, Japan|Takaraduka, Japan|Tochigi, Japan|Tokushima, Japan|Tokyo, Japan|Toyama, Japan|Toyoake, Japan|Tsu, Japan|Wakayama, Japan|Yamaguchi, Japan|Yatsushiro, Japan|Yokohama, Japan|Yonago, Japan|Busan, Korea, Republic of|Cheongju, Korea, Republic of|Daegu, Korea, Republic of|Daejeon, Korea, Republic of|Gwangju, Korea, Republic of|Seongnam-si, Korea, Republic of|Seoul, Korea, Republic of|Wonju, Korea, Republic of|Daugavpils, Latvia|Kuldiga, Latvia|Liepaja, Latvia|Riga, Latvia|Sigulda, Latvia|Ventspils, Latvia|Alytus, Lithuania|Kaunas, Lithuania|Klaipeda, Lithuania|Panevezys, Lithuania|Siauliai, Lithuania|Vilnius, Lithuania|Cheras, Malaysia|Johor Bahru, Malaysia|Kota Kinabalu, Malaysia|Kuala Lumpur, Malaysia|Kuching, Malaysia|Penang, Malaysia|Selangor, Malaysia|Selayang, Malaysia|Aguascalientes, Mexico|Benito Juárez, Mexico|Chihuahua, Mexico|Culiacan, Mexico|Durango, Mexico|Guadalajara, Mexico|León, Mexico|Mexico City, Mexico|Mexico, Mexico|Oaxaca, Mexico|Pachuca, Mexico|Puebla, Mexico|Queretaro, Mexico|San Luis Potosí, Mexico|Tampico, Mexico|Veracruz, Mexico|Almere, Netherlands|Amsterdam, Netherlands|Blaricum, Netherlands|Breda, Netherlands|Deventer, Netherlands|Doetinchem, Netherlands|Ede, Netherlands|Groningen, Netherlands|Heerlen, Netherlands|Helmond, Netherlands|Maastricht, Netherlands|Meppel, Netherlands|Tilburg, Netherlands|Będzin, Poland|Gdynia, Poland|Gliwice, Poland|Grodzisk Mazowiecki, Poland|Inowrocław, Poland|Katowice, Poland|Kielce, Poland|Krakow, Poland|Kraków, Poland|Kutno, Poland|Lodz, Poland|Lubin, Poland|Lublin, Poland|Myslenice, Poland|Olsztyn, Poland|Ostroleka, Poland|Ostrowiec Swietokrzyski, Poland|Oswiecim, Poland|Plock, Poland|Pulawy, Poland|Rabka-Zdrój, Poland|Skierniewice, Poland|Starogard Gdanski, Poland|Szczecin, Poland|Torun, Poland|Warszawa, Poland|Wloclawek, Poland|Wrocław, Poland|Zabrze, Poland|Zamosc, Poland|Łódż, Poland|Almada, Portugal|Aveiro, Portugal|Braga, Portugal|Carnaxide, Portugal|Coimbra, Portugal|Covilhã, Portugal|Leiria, Portugal|Lisboa, Portugal|Matosinhos, Portugal|Viana do Castelo, Portugal|Vila Real, Portugal|Bacau, Romania|Baia Mare, Romania|Braila, Romania|Brasov, Romania|Bucharest, Romania|Bucuresti, Romania|Buzau, Romania|Cluj Napoca, Romania|Cluj-Napoca, Romania|Craiova, Romania|Focsani, Romania|Galati, Romania|Iasi, Romania|Oradea, Romania|Pitesti, Romania|Sibiu, Romania|Targu Mures, Romania|Targu-Mures, Romania|Timisoara, Romania|Arkhangelsk, Russian Federation|Barnaul, Russian Federation|Chita, Russian Federation|Ekaterinburg, Russian Federation|Ivanovo, Russian Federation|Izhevsk, Russian Federation|Kaluga, Russian Federation|Kemerovo, Russian Federation|Kirov, Russian Federation|Krasnoyarsk, Russian Federation|Kursk, Russian Federation|Moscow, Zelenograd, Russian Federation|Moscow, Russian Federation|Nizhniy Novgorod, Russian Federation|Nizhny Novgorod, Russian Federation|Novosibirsk, Russian Federation|Orenburg, Russian Federation|Perm, Russian Federation|Rostov on Don, Russian Federation|Ryazan, Russian Federation|Saint Petersburg, Russian Federation|Samara, Russian Federation|Saratov, Russian Federation|Syktyvkar, Russian Federation|Tomsk, Russian Federation|Tyumen, Russian Federation|Voronezh, Russian Federation|Yaroslavl, Russian Federation|Banska Bystrica, Slovakia|Bardejov, Slovakia|Kosice, Slovakia|Lucenec, Slovakia|Moldava nad Bodvou, Slovakia|Nitra, Slovakia|Povazska Bystrica, Slovakia|Svidnik, Slovakia|Bloemfontein, South Africa|Cape Town, South Africa|Centurion, South Africa|Durban, South Africa|Pinelands, South Africa|Pretoria, South Africa|Tongaat, South Africa|A Coruña, Spain|Alicante, Spain|Almería, Spain|Avila, Spain|Barcelona, Spain|Burgos, Spain|Cáceres, Spain|Elche, Spain|Granada, Spain|La Coruña, Spain|Lorca, Spain|Madrid, Spain|Majadahonda, Spain|Murcia, Spain|Olot, Spain|Orihuela, Spain|Palma de Mallorca, Spain|San Juan, Spain|Sanlúcar de Barrameda, Spain|Sant Joan Despí, Spain|Santander, Spain|Sevilla, Spain|Terrassa, Spain|Torrevieja, Spain|Valencia, Spain|Vigo, Spain|Viladecans, Spain|Falun, Sweden|Jönköping, Sweden|Ljungby, Sweden|Stockholm, Sweden|Uppsala, Sweden|Ankara, Turkey|Bursa, Turkey|Diyarbakir, Turkey|Eskisehir, Turkey|Istanbul, Turkey|Kahramanmaras, Turkey|Kocaeli, Turkey|Konya, Turkey|Kırıkkale, Turkey|Mersin, Turkey|Sivas, Turkey|Cherkassy, Ukraine|Cherkasy, Ukraine|Dnipro, Ukraine|Donetsk, Ukraine|Kharkiv, Ukraine|Kyiv, Ukraine|Lutsk, Ukraine|Lviv, Ukraine|Odesa, Ukraine|Poltava, Ukraine|Sumy, Ukraine|Vinnitsa, Ukraine|Vinnytsia, Ukraine|Zaporizhzhia, Ukraine|Zaporizhzhya, Ukraine|Zhytomir, Ukraine|Aberdeen, United Kingdom|Airdrie, United Kingdom|Birmingham, United Kingdom|Chesterfield, United Kingdom|Chichester, United Kingdom|Clydebank, United Kingdom|Cottingham, United Kingdom|Dudley, United Kingdom|Dundee, United Kingdom|East Kilbride, United Kingdom|Exeter, United Kingdom|Inverness, United Kingdom|Manchester, United Kingdom|Ta1 5da, United Kingdom|Wirral, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT01877915/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT01877915/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01877915"
1509,"NCT01875380","Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer","REFRAME","Completed","No Results Available","Colorectal Neoplasms|Metastatic Disease","Drug: Regorafenib","Progression-free survival rate at 6 months|Objective response rate|Disease control rate|Time to response|Time to progression|Progression-free survival|Time to treatment failure|Response duration|Duration of stable disease|Overall survival|Incidence and severity of Adverse Events (NCI CTC, version 4.0)|Changes in laboratory values (transaminases, bilirubin, lactate dehydrogenase (LDH), anaemia,neutropenia and thrombocytopenia)|Change in vital signs (weight loss and hypertension)|Incidence of dose adjustments and compliance|Incidence of concomitant medication|Changes in ECOG performance status over time from baseline","Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","46","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TTD-13-01|2013-000236-94","June 2013","April 2016","April 2016","June 11, 2013",,"August 1, 2017","Spanish Cooperative Group for Digestive Tumour Therapy (TTD), Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01875380"
1510,"NCT01871194","An Observational Post-Authorization Safety Specialist Cohort Event Monitoring Study (SCEM) to Monitor the Safety and Utilization of Rivaroxaban (Xarelto®).","ROSE","Completed","No Results Available","Atrial Fibrillation|Deep Vein Thrombosis|Pulmonary Embolism",,"Cumulative incident risk of haemorrhage within gastrointestinal and urogenital organ sites (which meets the criteria for a major bleed) and all intracranial sites.","Professor Saad Shakir|Bayer|Drug Safety Research Unit, Southampton, UK","All","18 Years and older   (Adult, Older Adult)",,"3400","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ROSE","May 2013","January 2016","September 2017","June 6, 2013",,"January 30, 2018","Drug Safety Research Unit, Southampton, Hampshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01871194"
1511,"NCT01833520","Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma",,"Active, not recruiting","No Results Available","Sarcoma","Drug: Ra-223 Dichloride","Maximum Tolerated Dose (MTD) of Ra-223 Dichloride in Osteosarcoma|Objective Response of Osteosarcoma Indicator Lesions to 223-Radium Dichloride","M.D. Anderson Cancer Center|Bayer","All","15 Years and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2012-0952|NCI-2013-02267","October 16, 2013","October 31, 2020","October 31, 2020","April 17, 2013",,"January 2, 2020","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01833520"
1512,"NCT01830543","A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention","PIONEER AF-PCI","Completed","Has Results","Atrial Fibrillation|Percutaneous Coronary Intervention","Drug: rivaroxaban 2.5 mg|Drug: rivaroxaban 15 mg|Drug: rivaroxaban 10 mg|Drug: aspirin (ASA)|Drug: vitamin K antagonist (VKA)|Drug: clopidogrel|Drug: prasugrel|Drug: ticagrelor","Percentage of Participants With Clinically Significant Bleeding|Percentage of Participants With Thrombolysis in Myocardial Infarction (TIMI) Major Bleeding|Percentage of Participants With Thrombolysis in Myocardial Infarction (TIMI) Minor Bleeding|Percentage of Participants With Bleeding Requiring Medical Attention (BRMA)|Percentage of Participants With Composite of Adverse Cardiovascular Events (Cardiovascular Death, Myocardial Infarction (MI) and Stroke)|Percentage of Participants With Cardiovascular Death|Percentage of Participants With Myocardial Infarction|Percentage of Participants With Stroke|Percentage of Participants With Stent Thrombosis","Janssen Scientific Affairs, LLC|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","2124","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR100758|RIVAROXAFL3003|2012-001491-11","May 10, 2013","July 28, 2016","July 28, 2016","April 12, 2013","July 31, 2017","September 19, 2017","Huntsville, Alabama, United States|Los Alamitos, California, United States|Mission Viejo, California, United States|Oceanside, California, United States|Riverside, California, United States|Sacramento, California, United States|San Francisco, California, United States|Stockton, California, United States|Thousand Oaks, California, United States|Torrance, California, United States|Colorado Springs, Colorado, United States|Lakewood, Colorado, United States|Littleton, Colorado, United States|Danbury, Connecticut, United States|Washington, D.C., District of Columbia, United States|Atlantis, Florida, United States|Clearwater, Florida, United States|Daytona Beach, Florida, United States|Jacksonville, Florida, United States|Port Charlotte, Florida, United States|Safety Harbor, Florida, United States|Saint Petersburg, Florida, United States|Tallahassee, Florida, United States|Tampa, Florida, United States|Columbus, Georgia, United States|Macon, Georgia, United States|Marietta, Georgia, United States|Boise, Idaho, United States|Hazel Crest, Illinois, United States|Indianapolis, Indiana, United States|Munster, Indiana, United States|Hammond, Louisiana, United States|Lake Charles, Louisiana, United States|Slidell, Louisiana, United States|Auburn, Maine, United States|Bangor, Maine, United States|Baltimore, Maryland, United States|Detroit, Michigan, United States|Lansing, Michigan, United States|Mount Clemens, Michigan, United States|Petoskey, Michigan, United States|Ypsilanti, Michigan, United States|Kansas City, Missouri, United States|Saint Louis, Missouri, United States|Kalispell, Montana, United States|Las Vegas, Nevada, United States|Hackensack, New Jersey, United States|Haddon Heights, New Jersey, United States|New Brunswick, New Jersey, United States|Newark, New Jersey, United States|Ridgewood, New Jersey, United States|Albuquerque, New Mexico, United States|New York, New York, United States|Peekskill, New York, United States|Sanford, North Carolina, United States|Bartlesville, Oklahoma, United States|Oklahoma City, Oklahoma, United States|Tulsa, Oklahoma, United States|Bend, Oregon, United States|Portland, Oregon, United States|Abington, Pennsylvania, United States|Camp Hill, Pennsylvania, United States|Doylestown, Pennsylvania, United States|Erie, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Sayre, Pennsylvania, United States|York, Pennsylvania, United States|Greenville, South Carolina, United States|Mount Pleasant, South Carolina, United States|Rapid City, South Dakota, United States|Jackson, Tennessee, United States|Knoxville, Tennessee, United States|Austin, Texas, United States|Fort Worth, Texas, United States|Humble, Texas, United States|Odessa, Texas, United States|Plano, Texas, United States|Layton, Utah, United States|Charlottesville, Virginia, United States|Manassas, Virginia, United States|Midlothian, Virginia, United States|Richmond, Virginia, United States|Bellevue, Washington, United States|Seattle, Washington, United States|Milwaukee, Wisconsin, United States|Weston, Wisconsin, United States|Bahia Blanca, Argentina|Buenos Aires, Argentina|C.a.b.a., Argentina|Cordoba, Argentina|Corrientes, Argentina|La Plata, Argentina|Resistencia, Argentina|Rosario, Argentina|Santa Fe, Argentina|Vicente Lopez, Argentina|Chermside N/A, Australia|Epping, Australia|Hobart, Australia|Kogarah, Australia|Liverpool, Australia|New Lambton, Australia|Wollongong, Australia|Aalst, Belgium|Bonheiden, Belgium|Brasschaat, Belgium|Brugge, Belgium|Bruxelles, Belgium|Genk, Belgium|Gent, Belgium|Liège, Belgium|Mechelen, Belgium|Mol, Belgium|Roeselare, Belgium|Turnhout, Belgium|Belo Horizonte, Brazil|Blumenau, Brazil|Brasilia, Brazil|Campina Grande Do Sul, Brazil|Campinas, Brazil|Curitiba, Brazil|Marilia, Brazil|Passo Fundo, Brazil|Porto Alegre, Brazil|Recife, Brazil|Sao Paulo, Brazil|São José Do Rio Preto, Brazil|São Paulo, Brazil|Uberlandia, Brazil|Votuporanga, Brazil|Blagoevgrad, Bulgaria|Burgas, Bulgaria|Pazardjik, Bulgaria|Pleven, Bulgaria|Plovdiv, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Veliko Tarnovo, Bulgaria|Edmonton, Alberta, Canada|Maple Ridge, British Columbia, Canada|New Westminster, British Columbia, Canada|Vancouver, British Columbia, Canada|Victoria, British Columbia, Canada|St. John'S, Newfoundland and Labrador, Canada|London, Ontario, Canada|Ottawa, Ontario, Canada|Sudbury, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Sherbrooke, Quebec, Canada|Chicoutimi, Canada|Quebec, Canada|Saint John, Canada|Alto, Chile|Concepcion, Chile|Punta Arenas, Chile|Santiago, Chile|Temuco, Chile|Brno 2, Czechia|Brno, Czechia|Hradec Kralove, Czechia|Jablonec Na Nisou, Czechia|Karlovy Vary, Czechia|Kladno, Czechia|Litomysl, Czechia|Olomouc, Czechia|Plzen, Czechia|Praha 10 N/A, Czechia|Praha 2, Czechia|Praha, Czechia|Slany, Czechia|Uherske Hradiste, Czechia|Aalborg, Denmark|Copenhagen, Denmark|Esbjerg, Denmark|Herlev, Denmark|Herning, Denmark|Hvidovre, Denmark|Koege, Denmark|Naestved, Denmark|Odense, Denmark|Roskilde, Denmark|Svendborg N/A, Denmark|Vejle, Denmark|Besancon Cedex Franche-Comté, France|Caen Cedex 9, France|Centres, France|Chartres, France|Lille, France|Limoges Cedex, France|Marseille Cedex 05, France|Montfermeil, France|Nantes Cedex 1, France|Nimes, France|Paris 75, France|Paris, France|Pau, France|Pessac, France|Poitiers, France|Toulouse, France|Bad Friedrichshall, Germany|Bad Nauheim, Germany|Berlin, Germany|Dresden, Germany|Esslingen, Germany|Frankfurt Am Main, Germany|Freiburg, Germany|Greifswald, Germany|Göttingen, Germany|Hamburg, Germany|Heidelberg, Germany|Köln, Germany|Limburg, Germany|Mannheim, Germany|Ulm, Germany|Witten, Germany|Busan, Korea, Republic of|Daejeon, Korea, Republic of|Gyeonggi-Do, Korea, Republic of|Incheon, Korea, Republic of|Seongnam, Korea, Republic of|Seoul, Korea, Republic of|Suwon, Korea, Republic of|Uijeongbu, Korea, Republic of|Wonju, Korea, Republic of|Georgetown, Malaysia|Johor Bahru, Malaysia|Kajang, Malaysia|Kuala Lumpur, Malaysia|Aguascalientes, Mexico|Guadalajara, Mexico|Leon, Mexico|Mexico, Mexico|Pachuca, Mexico|Puebla, Mexico|Queretaro, Mexico|Villahermosa, Mexico|Zapopan, Mexico|Alkmaar, Netherlands|Amsterdam Zuidoost, Netherlands|Amsterdam, Netherlands|Breda, Netherlands|Delft, Netherlands|Den Bosch, Netherlands|Gorinchem, Netherlands|Leiden, Netherlands|Maastricht, Netherlands|Nieuwegein, Netherlands|Sneek, Netherlands|Uden, Netherlands|Bedzin, Poland|Bielsko-Biala, Poland|Chrzanow, Poland|Gdynia, Poland|Grodzisk Mazowiecki, Poland|Katowice, Poland|Krakow, Poland|Lodz, Poland|Mielec, Poland|Nowy Targ, Poland|Ostrowiec Swietokrzyski, Poland|Oswiecim, Poland|Plock, Poland|Rzeszow Poland, Poland|Starachowice, Poland|Starogard Gdanski, Poland|Szczecin, Poland|Torun, Poland|Tychy, Poland|Ustron, Poland|Warszawa, Poland|Zamosc, Poland|Bucharest, Romania|Bucuresti, Romania|Cluj Napoca, Romania|Targu-Mures, Romania|Tg Mures, Romania|Arkhangelsk, Russian Federation|Barnaul, Russian Federation|Chita, Russian Federation|Ekaterinburg, Russian Federation|Kemerovo, Russian Federation|Krasnodar, Russian Federation|Krasnoyarsk, Russian Federation|Moscow, Russian Federation|Nizhny Novgorod, Russian Federation|Perm, Russian Federation|Rostov On Don, Russian Federation|Samara, Russian Federation|Saratov, Russian Federation|St. Petersburg, Russian Federation|Syktyvkar, Russian Federation|Tumen, Russian Federation|Tyumen, Russian Federation|Cape Town, South Africa|Centurion, South Africa|Linksfield West, Johannesburg, South Africa|Somerset West, South Africa|Falun, Sweden|Göteborg, Sweden|Jönköping, Sweden|Lund, Sweden|Malmö, Sweden|Stockholm N/A, Sweden|Stockholm, Sweden|Umeå, Sweden|Örebro, Sweden|Kaohsiung, Taiwan|Taichung, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Ankara, Turkey|Antalya, Turkey|Bursa, Turkey|Gaziantep, Turkey|Istanbul Nap, Turkey|Istanbul, Turkey|Izmir, Turkey|Kayseri, Turkey|Sivas, Turkey|Cherkassy, Ukraine|Dnepropetrovsk, Ukraine|Ivano-Frankivsk, Ukraine|Kharkiv, Ukraine|Kharkov, Ukraine|Khemelnitskiy, Ukraine|Kyiv, Ukraine|Lviv, Ukraine|Odessa, Ukraine|Rivne, Ukraine|Uzhgorod, Ukraine|Zaporizhzhya, Ukraine|Bath, United Kingdom|Birmingham, United Kingdom|Blackburn, United Kingdom|Bradford, United Kingdom|Clydebank, United Kingdom|Cottingham, United Kingdom|Coventry, United Kingdom|Dorchester, United Kingdom|Dundee, United Kingdom|Edinburgh, United Kingdom|Exeter, United Kingdom|Hampshire, United Kingdom|Harrow, United Kingdom|High Wycombe, United Kingdom|London, United Kingdom|Middlesbrough N/A, United Kingdom|Norwich, United Kingdom|Nottingham, United Kingdom|Plymouth, United Kingdom|Portsmouth, United Kingdom|Torquay, United Kingdom|Truro, United Kingdom|Worcester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01830543"
1513,"NCT01830530","HIGH Altitude CArdiovascular REsearch in the ANDES","HIGHCARE-A","Completed","No Results Available","Hypertension|High Altitude","Drug: Telmisartan|Drug: Nifedipine|Drug: placebo","Effect of study treatment on 24 h ambulatory systolic blood pressure at high altitude|Effect of study treatment on ambulatory blood pressure at high altitude (other variables)|Lake Louise Score|Effect of high altitude on ambulatory blood pressure|Effect of high altitude on conventional blood pressure|Effect of study treatment on conventional blood pressure at high altitude.|Rate of adverse events|Effect of study treatment on ambulatory heart rate at high altitude","Istituto Auxologico Italiano|Bayer","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","100","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","09F102","May 2012","September 2012","October 2012","April 12, 2013",,"April 12, 2013","Universidad Peruana Cayetano Heredia, Lima, Peru",,"https://ClinicalTrials.gov/show/NCT01830530"
1514,"NCT01789021","Analytical Performance Evaluation of Blood Glucose Monitoring Systems- Investigator Sponsored Contour® XT Comparator Study - Ulm Germany","IDT-1206-BA","Completed","No Results Available","Diabetes","Device: 4 blood glucose monitoring systems","Differences in accuracy between blood glucose monitoring systems across the overall tested glucose range by comparing the mean absolute value of relative (percent) difference (MARD) between the meter value and the reference value","Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm|Bayer","All","18 Years and older   (Adult, Older Adult)","Not Applicable","120","Other|Industry","Interventional",,"IDT-1206-BA","February 2013","April 2013","April 2013","February 11, 2013",,"June 18, 2015","Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm, Ulm, Germany",,"https://ClinicalTrials.gov/show/NCT01789021"
1515,"NCT01762150","Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma",,"Completed","No Results Available","Renal Cell Carcinoma","Drug: Sorafenib|Drug: Gemcitabine|Drug: Cisplatin","progress-free survival,PFS|adverse event, AE","Beijing Cancer Hospital|Bayer","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","26","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BCH-RCC-120601","June 2011","December 2016","June 2018","January 7, 2013",,"November 20, 2018","Beijing Cancer Hospital, Beijing, Beijing, China|Sun Yat-sen university cancer center, Guangzhou, Guangdong, China|Shenyang general hospital of Shenyang military command, Shenyang, Liaoning, China|Xijing Hospital, Xi'an, Shanxi, China|West China Hospital, Chengdu, Sichuan, China",,"https://ClinicalTrials.gov/show/NCT01762150"
1516,"NCT01733160","Stroke Prevention and Rhythm Interventions in Atrial Fibrillation","SPRINT-AF","Completed","No Results Available","Cardiovascular Diseases",,"To determine how Canadian physicians assess stroke risk in adults with atrial fibrillation and make therapeutic decisions around anticoagulation|To assess the adequacy of anticoagulation in treated patients|To understand how new oral anticoagulants are incorporated into clinical practice|To assess quality of life in patients with AF|To evaluate how physicians select between rate and rhythm control options for AF|To evaluate regional differences in care|To compare management strategies between primary care physicians and cardiovascular specialists","Canadian Collaborative Research Network|Bayer","All","18 Years and older   (Adult, Older Adult)",,"2499","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","SPRINT-AF 18-10-2012","November 2013","August 15, 2017","August 15, 2017","November 26, 2012",,"October 27, 2017","CCRN, Brampton, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01733160"
1517,"NCT01729871","A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy","VENTURE-AF","Completed","Has Results","Atrial Fibrillation","Drug: rivaroxaban|Drug: uninterrupted vitamin K antagonist (VKA)","Number of Participants With Incidence of Post-Procedure Major Bleeding Events|Number of Participants With Composite Endpoint of Myocardial Infarction (MI), Ischemic Stroke, Non-Central Nervous System (Non-CNS) Systemic Embolism and Vascular Death|Number of Participants With Myocardial Infarction (MI)|Number of Participants With Ischemic Stroke|Number of Participants With Non-Central Nervous System (Non-CNS) Systemic Embolism|Number of Participants With Vascular Death","Janssen Scientific Affairs, LLC|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","253","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR100732|RIVAROXAFL3002|2012-001484-79","February 2013","October 2014","October 2014","November 20, 2012","November 10, 2015","March 6, 2017","Beverly Hills, California, United States|Los Angeles, California, United States|Sacramento, California, United States|San Francisco, California, United States|Jacksonville, Florida, United States|Maywood, Illinois, United States|Kansas City, Kansas, United States|Boston, Massachusetts, United States|St Louis Park, Minnesota, United States|Ridgewood, New Jersey, United States|Flushing, New York, United States|Durham, North Carolina, United States|Columbus, Ohio, United States|Portland, Oregon, United States|Erie, Pennsylvania, United States|Hershey, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Nashville, Tennessee, United States|Austin, Texas, United States|Dallas, Texas, United States|Tyler, Texas, United States|Charlottesville, Virginia, United States|Seattle, Washington, United States|Tacoma, Washington, United States|Aalst, Belgium|Antwerpen, Belgium|Brugge, Belgium|Genk, Belgium|Hasselt, Belgium|Brest Cedex 2, France|Montpellier, France|Pessac Cedex, France|Toulouse Cedex 9 N/A, France|Vandoeuvre Les Nancy, France|Bad Krozingen, Germany|Bad Nauheim, Germany|Berlin, Germany|Dresden, Germany|Jena, Germany|Mönchengladbach, Germany|Neuwied, Germany|Bournemouth, United Kingdom|Cottingham, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01729871"
1518,"NCT01724606","Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM)",,"Active, not recruiting","No Results Available","Breast Cancer|Brain Metastases","Radiation: Whole Brain Radiotherapy (WBRT)|Drug: Sorafenib","Maximum Tolerated Dose|assessing toxicity by the number of adverse events|CNS progression-free survival","Memorial Sloan Kettering Cancer Center|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","21","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12-046","November 2012","November 2021","November 2021","November 12, 2012",,"October 29, 2019","Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, United States",,"https://ClinicalTrials.gov/show/NCT01724606"
1519,"NCT01701856","Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis",,"Terminated","No Results Available","Relapsing-remitting Multiple Sclerosis","Drug: Interferon beta-1b","Annualized relapse rate on study compared to annualized relapse rate in the year prior to natalizumab initiation on first line disease modifying treatment (month -24 to -12)|Severity of relapses|Proportion of relapse free patients|3-month confirmed EDSS progression|MSFC|Change of EDSS score compared to change in the year prior to natalizumab treatment (month -24 to-12|Change of MSFC score compared to change in the year prior to natalizumab treatment (month -24 to-12|Number of new/enlarging T2-hyperintense lesions|Number of Gd-enhancing lesions|EQ-5D|FAMS","Claudio Gobbi|Bayer|Ospedale Civico, Lugano","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","5","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EOC.NSI.11.01","September 2012","October 2013","October 2013","October 5, 2012",,"January 22, 2014","Ospedale Regionale di Lugano - Civico, Lugano, Ticino, Switzerland",,"https://ClinicalTrials.gov/show/NCT01701856"
1520,"NCT01656330","A Study to Assess the Effects of 2 Different Prothrombin Complex Concentrates on the Pharmacodynamics of Rivaroxaban in Healthy Adult Volunteers",,"Completed","No Results Available","Healthy","Drug: Rivaroxaban 20 mg twice daily|Drug: Rivaroxaban 20 mg once daily|Drug: Profilnine SD|Drug: Beriplex P/N|Other: Saline","Measurement of pharmacodynamic (PD) variables: prothrombin time (PT), International Normalized Ratio (INR), activated partial thromboplastin time (aPTT), thrombin generation assay (TGA) and anti-Factor Xa (anti-FXa)|Rivaroxaban plasma concentrations|The number of healthy volunteers reporting adverse events|Changes from baseline in clinical laboratory tests performed|Change from baseline in electrocardiogram (ECG) findings|Change from baseline physical examination findings|Change from baseline in vital signs measurements","Janssen Research & Development, LLC|Bayer","All","18 Years to 55 Years   (Adult)","Phase 1","35","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","CR100867|RIVAROXNAP1003|2012-002313-20","July 2012","August 2012","August 2012","August 3, 2012",,"January 24, 2017","Merksem, Belgium",,"https://ClinicalTrials.gov/show/NCT01656330"
1521,"NCT01640665","Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors",,"Completed","No Results Available","Metastatic Breast Cancer|Gastrointestinal Tumors","Drug: Sorafenib|Drug: Capecitabine","Maximum Tolerated Dose / Safety|Response","Yale University|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","24","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GC0212","July 2012","August 2014","August 2014","July 16, 2012",,"September 16, 2016","Yale Cancer Center, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT01640665"
1522,"NCT01631656","Combination Gel and Vascular ND in Mild to Moderate Rosacea",,"Completed","Has Results","Rosacea","Drug: Azelaic acid|Device: Nd:Yag laser","IGA of Improvement","Wake Forest University Health Sciences|Bayer","All","18 Years and older   (Adult, Older Adult)","Not Applicable","10","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IRB00012702","July 2010","February 2011","February 2011","June 29, 2012","November 28, 2017","September 12, 2018","Wake Forest University Health Sciences Dept of Dermatology, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01631656"
1523,"NCT01624285","Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer",,"Active, not recruiting","No Results Available","Adult Primary Hepatocellular Carcinoma|Localized Resectable Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer|Recurrent Adult Primary Liver Cancer","Drug: sorafenib tosylate|Other: placebo|Other: laboratory biomarker analysis","Recurrence-free survival, evaluated using the new international criteria proposed by the Modified Response Evaluation Criteria in Solid Tumors (mRECIST) Committee|Overall survival|Recurrence-free survival, evaluated using the new international criteria proposed by the mRECIST Committee|Adverse events assessed in terms of seriousness, severity, and relationship to the study material according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Impact of drug-drug interactions|Impact of biomarkers (AFP and PIVKA II)|Time to wound healing|Time to first HCV viral recurrence","Jonsson Comprehensive Cancer Center|Bayer","All","19 Years and older   (Adult, Older Adult)","Phase 2","356","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","11-003311|NCI-2012-00911","July 16, 2012","July 2020","July 2021","June 20, 2012",,"September 13, 2019","University of Alabama, Birmingham, Alabama, United States|Jonsson Comprehensive Cancer Center, Los Angeles, California, United States|University of Colorado, Denver, Colorado, United States|Mount Sinai Hospital, Hartford, Connecticut, United States|Lombardi Comprehensive Cancer Center at Georgetown University, Washington, District of Columbia, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Johns Hopkins University, Baltimore, Maryland, United States|Lahey Clinic Medical Center, Burlington, Massachusetts, United States|University of Michigan University Hospital, Ann Arbor, Michigan, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|University of Pennsylvania Health System, Cherry Hill, New Jersey, United States|New York University Langone Medical Center, New York, New York, United States|New York Presbyterian-The University Hospital of Columbia and Cornell, New York, New York, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Integris-Baptist Medical, Oklahoma City, Oklahoma, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Vanderbilt University, Nashville, Tennessee, United States|Baylor College of Medicine, Houston, Texas, United States|The Methodist Hospital Research Institute, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01624285"
1524,"NCT01613131","Mirena and Estrogen for Control of Perimenopause Symptoms and Ovulation Suppression",,"Completed","Has Results","Menopausal and Other Perimenopausal Disorders","Drug: Mirena|Drug: Estradiol|Drug: Placebo Gel","Hot Flashes|Sleep|Depression|Fatigue","University of Colorado, Denver|Bayer","Female","40 Years to 52 Years   (Adult)","Not Applicable","39","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11-1711","April 2012","June 2014","June 2014","June 6, 2012","December 2, 2015","December 2, 2015","University of Colorado, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT01613131"
1525,"NCT01608867","A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors",,"Completed","No Results Available","Solid Tumors","Biological: OMP-54F28","• To determine the safety of OMP-54F28 in subjects with previously treated solid tumors|To determine the pharmacokinetics of OMP-54F28 in subjects with previously treated solid tumors|To determine the immunogenicity of OMP-54F28 in subjects with previously treated solid tumors|To assess the preliminary efficacy of OMP-54F28 in subjects with previously treated solid tumors","OncoMed Pharmaceuticals, Inc.|Bayer","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 1","26","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","54F28-001","June 2012","August 2016","June 2017","May 31, 2012",,"July 27, 2017","Pinnacle Oncology Hematology,, Scottsdale, Arizona, United States|University of Colorado Hospital, Aurora, Colorado, United States|University of Michigan Health System, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT01608867"
1526,"NCT01588106","Evaluation of CONTOUR® USB BGMS on Glycaemic Control in Insulin-treated Diabetic Patients","CONGO","Completed","Has Results","Diabetes Mellitus Type 2",,"Reduction in HbA1c","GWT-TUD GmbH|Bayer","All","18 Years and older   (Adult, Older Adult)",,"154","Other|Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","GWT-2011-1","June 2012","October 2015","January 2016","April 30, 2012","March 9, 2017","March 9, 2017","Diabetespraxis Prenzlauer Allee, Berlin, Germany|Praxis Dr. Fießelmann, Berlin, Germany|Praxis Dr. Stephan, Berlin, Germany|Gemeinschaftspraxis Lorra/Bonnermann, Bochum, Germany|Praxis Dr. Holderied, Brand-Erbisdorf, Germany|Spreewaldklinik, Burg, Germany|Diabeteszentrum DO, Dortmund, Germany|Studienzentrum Prof. Hanefeld, Dresden, Germany|Universitätsklinikum Dresden, Medizinische Klinik III, Dresden, Germany|Gemeinschaftspraxis Schaden, Düsseldorf, Germany|Praxis Dr. Stier, Freital, Germany|SMO.MD GmbH, Magdeburg, Germany|Praxis Dr. Ruhland, München, Germany|Metabolicum, München, Germany|Praxis Dr. Engelmayer, München, Germany|Diabeteszentrum Oschatz, Oschatz, Germany",,"https://ClinicalTrials.gov/show/NCT01588106"
1527,"NCT01567553","The Inflammatory Process and the Medical Imaging in Patients With an Inflammatory Disease of the Central Nervous System.","USPIO-CIS","Terminated","No Results Available","Multiple Sclerosis (MS)|Inflammatory Disease","Other: USPIO MRI - Gadolinium MRI","▪ Change in USPIO enhancing MS lesion|Comparison of primary outcome measures with clinical outcomes and role of USPIO|Relationship of USPIO (SH U 555 C) enhancing MRI lesions with other MR parameters|Change in USPIO and/or Gadolinium enhancing MS lesions (primary outcome measure)","Rennes University Hospital|Bayer","All","18 Years to 45 Years   (Adult)",,"37","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","2007-005363-10","April 2009","June 2014","June 2015","March 30, 2012",,"October 28, 2015","La Timone University Hospital (APHM), Marseille, France|La Pitie-Salpaetriere Hospital (APHP), Paris, France|Maison Blanche Hospital, Reims, France|Rennes University Hospital, Rennes, France|Purpan Hospital, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT01567553"
1528,"NCT01521559","Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)","VIBRANT","Completed","Has Results","Branch Retinal Vein Occlusion","Procedure: Macular Laser Photocoagulation|Drug: Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)","Participants Who Gained at Least 15 Letters in Best Corrected Visual Acuity (BCVA) at Week 24 - LOCF|Change From Baseline to Week 24 in BCVA Score - LOCF|Change From Baseline in Central Retinal Thickness (CRT) at Week 24 - LOCF|Change From Baseline in the National Eye Institute Visual Function Questionnaire - 25 (NEI VFQ-25) Questionnaire Total Score at Week 24 - LOCF","Regeneron Pharmaceuticals|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","183","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","VGFTe-RVO-1027","April 2012","August 2013","March 2014","January 30, 2012","November 13, 2014","November 13, 2014","Phoenix, Arizona, United States|Tucson, Arizona, United States|Beverly Hills, California, United States|La Jolla, California, United States|Mountain View, California, United States|Palm Desert, California, United States|Sacramento, California, United States|Colorado Springs, Colorado, United States|Fort Myers, Florida, United States|Miami, Florida, United States|Plantation, Florida, United States|Stuart, Florida, United States|Tampa, Florida, United States|Winter Haven, Florida, United States|Augusta, Georgia, United States|Chicago, Illinois, United States|Baltimore (2 locations), Maryland, United States|Hagerstown, Maryland, United States|Boston (2 locations), Massachusetts, United States|Grand Rapids, Michigan, United States|Jackson, Michigan, United States|Southfield, Michigan, United States|Florissant, Missouri, United States|Lincoln, Nebraska, United States|Las Vegas, Nevada, United States|Teaneck, New Jersey, United States|Orchard Park, New York, United States|Syracuse, New York, United States|Charlotte, North Carolina, United States|Oklahoma City, Oklahoma, United States|Portland, Oregon, United States|Kingston, Pennsylvania, United States|West Mifflin, Pennsylvania, United States|Florence, South Carolina, United States|Ladson, South Carolina, United States|West Columbia, South Carolina, United States|Rapid City, South Dakota, United States|Nashville, Tennessee, United States|Abilene, Texas, United States|Ft. Worth, Texas, United States|Harlingen, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Seattle, Washington, United States|Milwaukee, Wisconsin, United States|Vancouver, British Columbia, Canada|Victoria, British Columbia, Canada|Mississauga, Ontario, Canada|Toronto, Ontario, Canada|Urayasu-shi, Chiba, Japan|Amagasaki, Hyogo, Japan|Kagoshima-shi, Kagoshima, Japan|Hamamatsu-shi, Shizuoka, Japan|Fukushima, Japan|Kyoto, Japan|Osaka, Japan",,"https://ClinicalTrials.gov/show/NCT01521559"
1529,"NCT01519778","A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study",,"Completed","Has Results","Major Cutaneous Abscess|Cellulitis|Erysipelas","Drug: TR701 FA","Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)","Trius Therapeutics LLC|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","1986-011|TR701-126","February 15, 2012","August 27, 2012","August 27, 2012","January 27, 2012","March 12, 2015","August 29, 2018","Trius Investigator Site #118, Anaheim, California, United States|Trius Investigator Site #129, Buena Park, California, United States|Trius Investigator Site 103, Chula Vista, California, United States|Trius Investigator Site 105, La Mesa, California, United States|Trius Investigator Site #106, Long Beach, California, United States|Trius Investigator Site 104, Oceanside, California, United States|Trius Investigator Site 101, Columbus, Georgia, United States|Trius Investigator Site 102, Savannah, Georgia, United States|Trius Investigator Site 128, Las Vegas, Nevada, United States|Trius Investigator Site 115, Somers Point, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01519778"
1530,"NCT01510756","Sorafenib for the Treatment of Chronic Lymphocytic Leukemia (CLL)",,"Terminated","Has Results","Chronic Lymphocytic Leukemia","Drug: Sorafenib","Overall Response Rate|To Determine the iwCLL-WG Defined Overall Response Rate (ORR) - Complete Response (CR) and Partial Responses (PR) to 3 Cycles of Sorafenib Therapy and Following the Completion of All Therapy.|Safety and Tolerability","Thomas Kipps|Bayer|University of California, San Diego","All","18 Years and older   (Adult, Older Adult)","Phase 2","4","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","110574","December 2011","May 2014","December 2014","January 16, 2012","October 5, 2015","January 21, 2016","UCSD Medical Center, La Jolla, California, United States",,"https://ClinicalTrials.gov/show/NCT01510756"
1531,"NCT01501240","Gadoxetic Acid-enhanced MR Evaluation of Hepatocellular Carcinoma and Dysplastic Nodules in the Cirrhotic Liver","PriMPa","Withdrawn","No Results Available","Liver Cirrhosis|Carcinoma, Hepatocellular",,"Diagnostic sensitivity of gadoxetic acid-enhanced MR imaging to detect HCC in the cirrhotic liver, using thin-section whole-explant as the standard of reference|Specificity of gadoxetic acid-enhanced MR imaging to detect HCC in the cirrhotic liver, using thin-section whole-explant as standard of reference|Sensitivity and specificity of gadoxetic acid-enhanced MR imaging to detect dysplastic nodules|To characterize borderline hepatocelluar nodules","Jae Ho Byun|Bayer|Asan Medical Center","All","20 Years to 80 Years   (Adult, Older Adult)",,"0","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","AMC-2011-0797","January 2012","December 2012","August 2013","December 29, 2011",,"January 28, 2014","Asan Medical Center, Seoul, Korea, Republic of|Division of Abdomen, Department of Radiology & Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01501240"
1532,"NCT01499953","Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux",,"Completed","No Results Available","Superficial Vein Thrombosis","Drug: Rivaroxaban|Drug: Fondaparinux","Composit-Endpoint VTE|composite primary efficacy outcome|each component of primary efficacy outcome up to day 45 and day 90|rate of major VTE|rates of surgery for SVT","GWT-TUD GmbH|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","472","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SURPRISE-2011","April 2012","June 2016","June 2016","December 26, 2011",,"September 13, 2016","Hautarztpraxis, Freiburg, Baden-Württemberg, Germany|Gemeinschaftspraxis Mietaschk, Bilderling, Kaiser, Tato, München, Bayern, Germany|Chriurgische Praxisklinik, Baesweiler, Nordrhein-Westfalen, Germany|Krankenhaus Dresden-Friedrichstadt, Dresden, Sachsen, Germany|Universitätsklinikum Dresden, Dresden, Sachsen, Germany|Oberlausitz-Gefäßpraxis, Görlitz, Sachsen, Germany|Franziskus-Krankenhaus Berlin, Berlin, Germany|MVZ Ramdohr, Praxis für Cardiovaskulär- u. Ultraschalldiagnostik, Berlin, Germany|Praxis für Chirurgie & Gefäßmedizin, Berlin, Germany|Klinikum Darmstadt GmbH, Darmstadt, Germany|Gemeinschaftspraxis Eggeling und Winter, Eschwege, Germany|Asklepios Westklinikum Hamburg, Hamburg, Germany|Universitätsklinikum Heidelberg, Heidelberg, Germany|Internistische Praxisgemeinschaft, Hoppegarten, Germany|Akademie für Gefäßkrankheiten e.V., Karlsbach, Germany|Praxis für Allgemeinmedizin und Phlebologie, Köln, Germany|Universitätsklinikum Leipzig AöR Innere Medizin - Angiologische Ambulanz, Leipzig, Germany|Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck, Germany|Praxis Dr. Franke, Magdeburg, Germany|Kardiologie Mühldorf am Inn, Mühldorf am Inn, Germany|Praxis Dr. Kähler, Rostock, Germany|Praxis für Gefäßmedizin am Tegernsee, Rottach-Egern, Germany|Venenzentrum Wiesbaden, Wiesbaden, Germany",,"https://ClinicalTrials.gov/show/NCT01499953"
1533,"NCT01496898","Changes in Vaginal, Cervical and Uterine Microflora With Levonorgestrel Intrauterine Device Placement",,"Completed","No Results Available","Human Microbiome|Metagenome|Contraception|Cytokine",,"Changes in vaginal, cervical and uterine bacterial species with levonorgestrel intrauterine device placement|Inflammatory cytokine changes with levonorgestrel intrauterine device placement","University of Utah|Bayer","Female","18 Years to 45 Years   (Adult)",,"13","Other|Industry","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","uufpf 43416","January 2011","December 2011","July 2013","December 21, 2011",,"January 13, 2016","University of Utah Hospital, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01496898"
1534,"NCT01493479","Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma","FIZZ","Completed","No Results Available","Follicular Lymphoma","Drug: 90Y Ibritumomab tiuxetan|Drug: Rituximab","Overall response rate|Combined Complete Response rate|Partial Response Rate|Time to disease progression|Response duration","The Christie NHS Foundation Trust|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","76","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","06_DOG05_33","June 6, 2007","January 2011","November 6, 2015","December 16, 2011",,"October 15, 2019","Centre Hospitalier Universitaire de Lille, Lille, France|Centre Hospitalier Universitaire de Nantes, Nantes, France|Centre Henri Becquerel, Rouen, France|St George's Hospital, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Poole Hospital NHS Foundation Trust, Poole, United Kingdom|Southampton University Hospital, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01493479"
1535,"NCT01490918","Study to Evaluate the Efficacy of Acarbose,Metformin,Sitagliptin Combination Treatment in DM Patients",,"Completed","No Results Available","Type-II Diabetes Mellitus","Drug: Acarbose","To see if there's any change in HbA1c at Visit 5(16W) compared Visit 2(baseline) within each group and between the two group.|To see if there's any Changes in CGMS, mixed meal tolerance test (active GLP-1, total GLP-1, GIP and insulin) and oxidative stress markers (8-OHdG, nitro tyrosine and CML) in Group-1 and Group-2","The Catholic University of Korea|Bayer","All","20 Years to 80 Years   (Adult, Older Adult)","Phase 3","165","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ACADEMIC","April 2012","September 2014","September 2014","December 13, 2011",,"September 15, 2014","MedicalExcellence, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01490918"
1536,"NCT01471353","Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer","SorCape","Completed","Has Results","Colorectal Cancer Metastatic","Drug: Sorafenib Plus Capecitabine (SorCape)","Sorafenib Activity|Overall Survival|Response Rate|Response Duration|Toxicity (Percentage of Subjects That Experienced an Adverse Event)|Correlative Tissue Analysis","University of Florida|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","43","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ONC2010-23|IRB201701484","November 2011","October 2015","May 2017","November 16, 2011","March 30, 2017","July 29, 2019","UF Health Cancer Center, Gainesville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01471353"
1537,"NCT01470937","Early Diabetes Intervention Program","EDIP","Completed","No Results Available","Type 2 Diabetes Mellitus","Drug: Acarbose|Drug: Placebo","Progression of fasting glucose >140 mg/dL","Indiana University School of Medicine|Bayer|Indiana University","All","25 Years to 80 Years   (Adult, Older Adult)","Phase 4","219","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","9705-34","February 1998","September 2004","September 2004","November 11, 2011",,"November 11, 2011","Indiana University Hospital GCRC, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT01470937"
1538,"NCT01464450","Pharmacokinetics Study of Oral Rivaroxaban in Healthy Participants",,"Completed","No Results Available","Pharmacokinetics|Bioavailability|Healthy Participants","Drug: Rivaroxaban","Rivaroxaban plasma concentrations|The number of patients with adverse events reported|Change from baseline in coagulation tests (prothrombin time [PT] and partial thromboplastin time [PTT])|Change from baseline in Electrocardiograms (ECGs)|Number of participants with abnormal vital signs|Number of participants with changes in physical examinations|Urine Drug Screen|Change from baseline in clinical lab assessments (chemistry, hemotology)","Janssen Scientific Affairs, LLC|Bayer","All","18 Years to 55 Years   (Adult)","Phase 1","55","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR100688|RIVAROXNAP1001","October 2011","December 2011","December 2011","November 3, 2011",,"January 24, 2017","Neptune, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01464450"
1539,"NCT01448928","Zevalin Post-marketing Surveillance in Japan","ZEVALIN-DUI","Unknown status","No Results Available","Non-Hodgkin's Lymphoma (NHL)","Drug: [90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)","Incidence of adverse drug reactions in subjects who received Zevalin|Incidence of serious adverse events, especially secondary malignant tumors, in subjects who received Zevalin|Incidence of adverse drug reactions in subpopulation in a variety of baseline data [such as demographic data, medical history data, clinical staging]|Effectiveness evaluation assessment [complete remission rate, complete remission uncertain rate, partial remission rate, stable disease rate, progression disease rate] by investigator-determined overall best response|Effectiveness evaluation assessment [progression free survival] by investigator-determined overall best response|Change in hemoglobin from baseline|Change in neutrophil from baseline|Change in platelet from baseline|Change in leukocyte from baseline","Spectrum Pharmaceuticals, Inc|Bayer","All","Child, Adult, Older Adult",,"400","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","15042","September 2008","January 2018","January 2018","October 7, 2011",,"November 2, 2015","Many Locations, Japan",,"https://ClinicalTrials.gov/show/NCT01448928"
1540,"NCT01446666","Gadoxetic Acid-MRI Versus Ultrasonography for the Surveillance of Hepatocellular Carcinoma in High-risk Patients","PRIUS","Completed","Has Results","Cirrhosis of Liver",,"Detection Rate of Patients With HCC|Detection Rate of Patients With Early Stage HCC|Detection Rate of Patients With Very Early Stage HCC|False Positive Rate|Positive Predictive Value for HCC","Asan Medical Center|Bayer","All","20 Years and older   (Adult, Older Adult)",,"423","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","AMC2011-0587","November 2011","December 2014","December 2014","October 5, 2011","January 14, 2019","February 1, 2019","Asan Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01446666"
1541,"NCT01432704","Colecalciferol as an Add-on Treatment to Subcutaneously-Administered Interferon-beta-1b for Treatment of Multiple Sclerosis (MS)","100207MS-H","Completed","No Results Available","Multiple Sclerosis","Drug: colecalciferol","To evaluate the safety and tolerability of add-on -treatment with colecalciferol of MS patients treated with interferon beta-1b and|To estimate the effect of interferon-beta-1b with an add-on of colecalciferol versus interferon-beta-1b with an add-on of placebo on MRI T2 BOD at 12 months in comparison with MRI T2 BOD at baseline|Number of Gadolinium-enhancing lesions on T1 and /or new enlarging lesions on T2/PD based on MRI done 12 months following randomisation compared with the MRI done at the time of randomisation","University of Turku|Bayer","All","18 Years to 50 Years   (Adult)","Phase 2|Phase 3","70","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EudraCT 2007-001958-99","March 2008","May 2011","August 2011","September 13, 2011",,"September 13, 2011",,,"https://ClinicalTrials.gov/show/NCT01432704"
1542,"NCT01400646","A Study to Explore the Pharmacodynamic Changes When Transitioning From Rivaroxaban to Warfarin in Healthy Volunteers",,"Completed","No Results Available","Healthy","Drug: Rivaroxaban|Drug: Warfarin|Drug: Vitamin K","Prothrombin time (PT)|International Ratio (INR)|Plasma concentrations of Rivaroxaban|Plasma concentrations of Warfarin","Janssen Research & Development, LLC|Bayer","All","18 Years to 60 Years   (Adult)","Phase 1","46","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR018664|RIVAROXAFL1004|2011-002890-46","October 2011","May 2012","May 2012","July 22, 2011",,"January 24, 2017","Merksem, Belgium",,"https://ClinicalTrials.gov/show/NCT01400646"
1543,"NCT01387048","Study for Long-term Treatment of Acne Vulgaris With Skinoren Versus Differin","SKADI","Completed","No Results Available","Acne Vulgaris","Drug: skinoren|Drug: differin","Superiority of Skinoren 15% Gel|Non-inferiority of Skinoren 15 % gel over the Differin 0.1% gel|- Change of non-inflammatory, inflammatory and total lesions at all visits.|Change of non-inflammatory, inflammatory and total lesions at all visits|change of non-inflammatory, inflammatory and total lesions at all visits","University of Magdeburg|Bayer","Female","18 Years to 45 Years   (Adult)","Phase 4","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","BS-HAU-2011|2011-000152-42","August 2011","August 2012","October 2012","July 4, 2011",,"July 8, 2013","Clinic for Dermatology and Vereology, Central Hospital Magdeburg, Magdeburg, Saxony-Anhalt, Germany",,"https://ClinicalTrials.gov/show/NCT01387048"
1544,"NCT01376453","Pre-operative 5-Fluorouracil (5-FU) and Sorafenib With External Radiation in Locally Advanced Rectal Cancer",,"Completed","No Results Available","Rectal Cancer","Drug: Sorafenib|Drug: 5-Fluorouracil (5-FU)|Radiation: Radiation","Maximum Tolerated Dose (MTD)|Number of Participants With Pathologic Response|Number of Participants With Serious Adverse Events (SAEs)","H. Lee Moffitt Cancer Center and Research Institute|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","18","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-16475|IST 000575","June 2011","November 2014","March 2016","June 20, 2011",,"September 12, 2016","H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01376453"
1545,"NCT01363440","Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema","VISTA DME","Completed","Has Results","Diabetic Macular Edema","Drug: Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)|Procedure: Macular Laser Photocoagulation","Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation Carried Forward (LOCF)|Percentage of Participants Who Gained at Least 10 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF|Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF|Percentage of Participants With a ≥2-step Improvement From Baseline in the ETDRS DRSS (Diabetic Retinopathy Severity Score) as Assessed by FP (Fundus Photography) at Week 52 - LOCF|Change From Baseline in Central Retinal Thickness (CRT) at Week 52 as Assessed on Optical Coherence Tomography (OCT) - LOCF|Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Near Activities Subscale at Week 52 - LOCF|Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Distance Activities Subscale at Week 52 - LOCF","Regeneron Pharmaceuticals|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","466","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VGFT-OD-1009","May 2011","January 2013","November 2014","June 1, 2011","April 20, 2015","May 30, 2016","Phoenix, Arizona, United States|Tucson, Arizona, United States|Arcadia, California, United States|Beverly Hills, California, United States|La Jolla, California, United States|Mountain View, California, United States|Oakland, California, United States|Palm Desert, California, United States|Sacramento, California, United States|San Francisco, California, United States|Santa Barbara, California, United States|Torrance, California, United States|Colorado Springs, Colorado, United States|Golden, Colorado, United States|New London, Connecticut, United States|Fort Lauderdale, Florida, United States|Fort Myers, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Winter Haven, Florida, United States|Augusta, Georgia, United States|Aiea, Hawaii, United States|Wichita, Kansas, United States|Portland, Maine, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Missoula, Montana, United States|Las Vegas, Nevada, United States|New Brunswick, New Jersey, United States|Northfield, New Jersey, United States|Teaneck, New Jersey, United States|Lynbrook, New York, United States|Orchard Park, New York, United States|Rochester, New York, United States|Asheville, North Carolina, United States|Charlotte, North Carolina, United States|Raleigh, North Carolina, United States|Portland, Oregon, United States|Kingston, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Florence, South Carolina, United States|West Columbia, South Carolina, United States|Rapid City, South Dakota, United States|Nashville, Tennessee, United States|Abilene, Texas, United States|Austin, Texas, United States|Harlingen, Texas, United States|Houston, Texas, United States|San Antonio (2 locations), Texas, United States|The Woodlands, Texas, United States|Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01363440"
1546,"NCT01317602","Current Clinical Practice in the Management of Atrial Fibrillation in Greece: the MANAGE-AF Study","MANAGE-AF","Completed","No Results Available","Atrial Fibrillation",,"Evaluation of the management of patients with Atrial Fibrillation.|Evaluation of the risk of strokes.|Assessment of morbidity and mortality of patients with AF.|Assessment of the compliance of patients to treatment.|Assessment of the awareness of patients about the Atrial Fibrillation.|Assessment of patients' quality of life.","Hellenic Cardiovascular Research Society|Bayer","All","18 Years and older   (Adult, Older Adult)",,"603","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","HellenicCardiovascularRS","March 2011","September 2011",,"March 17, 2011",,"April 16, 2015","University Hospital of Alexandroupoli, Alexandroupoli, Greece|7th IKA Hospital of Athens, Athens, Greece|Alexandra Hospital, Athens, Greece|Euroclinic Athens, Athens, Greece|General Hospital of Athens Evangelismos, Athens, Greece|Henry Dunant Hospital, Athens, Greece|KAT General Hospital, Athens, Greece|Korgialenio Benakio EES Hospital, Athens, Greece|Laiko General Hospital, Athens, Greece|Sismanoglio General Hospital, Athens, Greece|Ygeia Hospital, Athens, Greece|General Hospital of Chalkida, Chalkida, Greece|General Hospital of Chania, Chania, Greece|General Hospital of Chios, Chios, Greece|General Hospital of Edessa, Edessa, Greece|Thriassio General Hospital of Elefsina, Elefsina, Greece|University Hospital of Heraklion, Heraklion, Greece|General Hospital Of Heraklio Venizeleio, Heraklio, Greece|General Hospital of Kavala, Kavala, Greece|General Hospital of Komotini Sismanoglio, Komotini, Greece|General Hospital of Ptolemaida Mpodosakeio, Ptolemaida, Greece|General Hospital of Serres, Serres, Greece|2nd IKA Hospital of Thessaloniki, Thessaloniki, Greece|Agios Loukas Clinic, Thessaloniki, Greece|Ippokrateio Hospital of Thessaloniki, Thessaloniki, Greece|University Hospital of Thessaloniki AXEPA, Thessaloniki, Greece|General Hospital of Volos, Volos, Greece",,"https://ClinicalTrials.gov/show/NCT01317602"
1547,"NCT01309438","A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney Function",,"Completed","No Results Available","Healthy|Renal Insufficiency","Drug: Rivaroxaban (normal renal function)|Drug: Rivaroxaban (mild and moderate renal impairment)|Drug: Erythromycin (normal renal function)|Drug: Erythromycin (mild and moderate renal function)","Rivaroxaban plasma concentrations|Erythromycin plasma concentrations|Rivaroxaban urine concentrations|The number of patients with adverse events reported|Coagulation tests (prothrombin time [PT] and activated partial thromboplastin time [aPTT])","Janssen Research & Development, LLC|Bayer","All","35 Years to 75 Years   (Adult, Older Adult)","Phase 1","29","Industry","Interventional","Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR017968|RIVAROXACS1001","February 2011","March 2012","March 2012","March 7, 2011",,"October 8, 2014","Orlando, Florida, United States|Minneapolis, Minnesota, United States|St. Paul, Minnesota, United States|Knoxville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01309438"
1548,"NCT01305577","Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat",,"Completed","Has Results","Moderate or Severe Submental Fullness","Drug: Deoxycholic acid injection|Drug: Placebo","Percentage of Participants With a Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) 1-grade Response|Percentage of Participants With a Subject Self Rating Scale (SSRS) Response|Percentage of Participants With a CR-SMFRS 2-grade Response|Change From Baseline in CR-SMFRS Scores|Change From Baseline in SSRS Scores|Change From Baseline in Submental Fat Thickness|Change From Baseline in Patient-reported Submental Fat Rating Scale (PR-SMFRS)|Change From Baseline in Patient-Reported Submental Fat Impact Scale (PR-SMFIS)|Change From Baseline in Self-rating of Attractiveness|Change From Baseline in Derriford Appearance Scale 24 (DAS24)|Change From Baseline in Body Image Quality of Life Inventory (BIQLI)","Kythera Biopharmaceuticals|Bayer","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","363","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ATX-101-10-16|2010-020690-17","December 2010","January 2012","January 2012","February 28, 2011","June 15, 2015","July 14, 2015","Investigational Site, Oudenaarde, Minderbroederstaraat, Belgium|Investigational Site, Arras, France|Investigational Site, Cannes, France|Investigational Site, Nice, France|Investigational Site, Pantin, France|Investigational Site, Paris, France|Investigational Site, Paris, France|Investigational Site, Augsburg, Germany|Investigational Site, Augsburg, Germany|Investigational Site, Berlin, Germany|Investigational Site, Darmstadt, Germany|Investigational Site, Frankfurt/Main, Germany|Investigational Site, Landau, Germany|Investigational Site, Ludwigshafen, Germany|Investigational Site, München, Germany|Investigational Site, Northeim, Germany|Investigational Site, Potsdam, Germany|Investigational Site, Starnberg, Germany|Investigational Site, Wuppertal, Germany|Investigational Site, Barcelona, Spain|Investigational Site, Barcelona, Spain|Investigational Site, Barcelona, Spain|Investigational Site, Barcelona, Spain|Investigational Site, Salford, Manchester, United Kingdom|Investigational Site, Cheltenham, United Kingdom|Investigational Site, London, United Kingdom|Investigational Site, Northampton, United Kingdom|Investigational Site, Nottingham, United Kingdom|Investigational Site, Nottingham, United Kingdom|Investigational Site, Plymouth, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01305577"
1549,"NCT01302951","Penetration of Moxifloxacin Into Liver Tissue of Patients Undergoing Liver Resection.","MOXI","Completed","No Results Available","Side-effect of Antibiotic","Drug: Moxifloxacin 400 mg","Concentration (mg/L) of moxifloxacin in liver tissue|Maximum concentration (mg/L) of moxifloxacin in serum|Number of participants with adverse events|Area under the plasma concentration versus time curve (AUC) of moxifloxacin (mg*h/L)","University Hospital, Saarland|Bayer","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","34","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","24/06|2008-001902-18","July 2008","July 2010","July 2010","February 24, 2011",,"February 24, 2011","University hospital of the Saarland, Homburg/Saar, Germany",,"https://ClinicalTrials.gov/show/NCT01302951"
1550,"NCT01298570","Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer",,"Active, not recruiting","Has Results","Colorectal Cancer Metastatic","Drug: Regorafenib (BAY 73-4506)|Drug: FOLFIRI|Drug: Placebo","Progression Free Survival (PFS)|Overall Response(OR)Rate|Disease Control (DC) Rate|Overall Survival (OS)|Drug Metabolism|Percentage of Patients With Severe Adverse Events","UNC Lineberger Comprehensive Cancer Center|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","181","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","LCCC 1029|10-2176","April 7, 2011","November 15, 2016","July 2, 2020","February 17, 2011","February 28, 2018","July 5, 2019","Rocky Mountain Cancer Centers, Denver, Colorado, United States|Mount Sinai Medical Center-Miami, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Georgia Cancer Specialists, Atlanta, Georgia, United States|Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|University of Louisville James Brown Cancer Center, Louisville, Kentucky, United States|North Shore Long Island Jewish Health System, Manhasset, New York, United States|New York University Langone Medical Center, New York, New York, United States|Seby B. Jones Cancer Center, Boone, North Carolina, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Carolinas HealthCare System, Charlotte, North Carolina, United States|Southeast Medical Oncology Center, Goldsboro, North Carolina, United States|The Moses Cone Regional Cancer Center, Greensboro, North Carolina, United States|Leo W. Jenkins Cancer Center at ECU Medical School, Greenville, North Carolina, United States|First Health of the Carolinas, Moore Regional Hospital, Pinehurst, North Carolina, United States|Rex Cancer Center at Rex Hospital, Raleigh, North Carolina, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|University of Virginia, Charlottesville, Virginia, United States|Portsmouth Naval Medical Center, Portsmouth, Virginia, United States|Multicare Regional Cancer Center, Tacoma, Washington, United States|Ireland Cooperative Clinical Research Group, Dublin, Ireland",,"https://ClinicalTrials.gov/show/NCT01298570"
1551,"NCT01294644","Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat",,"Completed","Has Results","Moderate or Severe Submental Fullness","Drug: Deoxycholic acid injection|Drug: Placebo","Percentage of Participants With a Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) 1-grade Response|Percentage of Participants With a Subject Self Rating Scale (SSRS) Response|Percentage of Participants With a CR-SMFRS 2-grade Response|Change From Baseline in CR-SMFRS Score|Change From Baseline in SSRS Scores|Change From Baseline in Submental Fat Thickness|Change From Baseline in Patient-reported Submental Fat Rating Scale (PR-SMFRS)|Change From Baseline in Patient-Reported Submental Fat Impact Scale (PR-SMFIS)|Change From Baseline in Self-rating of Attractiveness|Change From Baseline in Derriford Appearance Scale 24 (DAS24)|Change From Baseline in Body Image Quality of Life Inventory (BIQLI)","Kythera Biopharmaceuticals|Bayer","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","360","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ATX-101-10-17|2010-020691-28","January 2011","February 2012","February 2012","February 11, 2011","June 12, 2015","June 12, 2015","Investigational Site, Geel, Belgium|Investigational Site, Genk, Belgium|Investigational Site, Besançon, France|Investigational Site, Nice, France|Investigational Site, Paris, France|Investigational Site, Paris, France|Investigational Site, Rouen, France|Investigational Site, Recklinghausen, Nordrhein-Westfalen, Germany|Investigational Site, Berlin, Germany|Investigational Site, Berlin, Germany|Investigational Site, Bochum, Germany|Investigational Site, Dresden, Germany|Investigational Site, Dresden, Germany|Investigational Site, Erlangen, Germany|Investigational Site, Freiburg, Germany|Investigational Site, Hamburg, Germany|Investigational Site, Hamburg, Germany|Investigational Site, Kassel, Germany|Investigational Site, Lübeck, Germany|Investigational Site, Mahlow, Germany|Investigational Site, Monchengladbach, Germany|Investigational Site, Münster, Germany|Investigational Site, Regensburg, Germany|Investigational Site, Roma, Italy|Investigational Site, Madrid, Spain|Investigational Site, Birmingham, United Kingdom|Investigational Site, Cardiff, United Kingdom|Investigational Site, London, United Kingdom|Investigational Site, Loughborough, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01294644"
1552,"NCT01270854","Normal Saline Versus Plasmalyte in Initial Resuscitation of Trauma Patients",,"Completed","No Results Available","Wounds and Injuries|Multiple Trauma|Disorder of Fluid Balance","Other: Plasmalyte A|Other: Normal Saline","Change in the base deficit|Mortality","University of California, Davis|Bayer","All","18 Years and older   (Adult, Older Adult)","Not Applicable","46","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","200917793","February 2011","February 2012","April 2012","January 5, 2011",,"May 30, 2017","University of California, Davis, Medical Center, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT01270854"
1553,"NCT01266421","Visanne Post-approval Observational Study (VIPOS)",,"Active, not recruiting","No Results Available","Endometriosis",,"Anemia|Depression","Center for Epidemiology and Health Research, Germany|Bayer","Female","Child, Adult, Older Adult",,"28400","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ZEG2010_03","December 2010","November 2018","March 2019","December 24, 2010",,"August 10, 2018","Center for Epidemiology and Health Research, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT01266421"
1554,"NCT01266408","INAS-FOCUS (International Active Surveillance Study - Folate in Oral Contraceptives Utilization Study)",,"Completed","No Results Available","Contraception",,"Absolute risk of Venous Thromboembolic Events|Absolute risk of Acute Myocardial Infarction|Absolute risk of Cerebrovascular Accidents|Colorectal cancer|Other cancer entities","Center for Epidemiology and Health Research, Germany|Bayer","Female","Child, Adult, Older Adult",,"82921","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ZEG2010_02|15346|EUPAS1597","November 22, 2010","September 29, 2019","October 2, 2019","December 24, 2010",,"November 5, 2019","Center for Epidemiology and Health Research, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT01266408"
1555,"NCT01255007","Comparison of Primovist-enhanced MRI, Diffusion Weighted MRI and Multidetector CT of Colorectal Liver Metastases",,"Completed","No Results Available","Colorectal Liver Metastases","Other: MR imaging","To establish superiority of Primovist-enhanced liver MRI and DWI to MDCT in the preoperative detection of colorectal liver metastases in patients who have received prior chemotherapy by comparison against pathology or Intra-operative ultrasound.|To compare diagnostic performance of MDCT, Diffusion Weighted MR and Primovist-enhanced MRI in the differentiation of viable from non-viable metastatic tumour compared to reference standard of pathology.|To investigate in the cohort of patients who have pre and post-chemotherapy MRI the role of DWI in predicting treatment response by baseline pretreatment Apparent Diffusion Coefficient (ADC) values.|To assess performance of Primovist-enhanced MRI, DW-MRI and MDCT in assessment of treatment response following chemotherapy in the cohort of patients who have pre and post-chemotherapy MRI.|To compare accuracies of Primovist-enhanced MRI and DWI to MDCT in the characterization of non-metastatic liver lesions against histopathology or intra-operative ultrasound.","University Health Network, Toronto|Bayer","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","UHN100405CE2010","September 2010","July 2014","December 2014","December 7, 2010",,"January 7, 2015","University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01255007"
1556,"NCT01250665","Study Comparing Corpus Callosum Atrophy as a Marker of Later Development of Cognitive Impairment in Patients With Multiple Sclerosis",,"Unknown status","No Results Available","Multiple Sclerosis|Cognitive Impairment",,"Multiple Sclerosis Inventory Cognition (MUSIC)|Annual Corpus Callosum Index decrease|Corpus callosum Index at baseline|Time to clinically definite MS|The Symbol Digit Modalities Test (SDMT)|Ratio treatment duration to disease duration","Cantonal Hospital of St. Gallen|Bayer","All","18 Years to 55 Years   (Adult)",,"65","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","CogImp01","January 2011","June 2011","June 2011","December 1, 2010",,"December 1, 2010","Cantonal Hospital of Saint Gallen, Saint Gallen, Switzerland",,"https://ClinicalTrials.gov/show/NCT01250665"
1557,"NCT01189370","Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell Cancer",,"Completed","Has Results","Renal Cell Cancer","Drug: sorafenib","Number of Participants Who Could Tolerate Each Dose Level|Overall Number of Participants That Had Disease Progression on Study","University of Kansas Medical Center|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","25","Other|Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11277","June 2008","April 2015","April 2015","August 26, 2010","June 1, 2017","June 1, 2017","University of Kansas Medical Center, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT01189370"
1558,"NCT01187212","Sorafenib Trial in Advanced and/or Recurrent Gastric Adenocarcinoma: Treatment Evaluation: STARGATE",,"Completed","No Results Available","Malignant Neoplasm of Stomach|Effects of Chemotherapy","Drug: Capecitabine/Cisplatin + Sorafenib|Drug: Capecitabine/Cisplatin","Progression-free survival|Overall survival|Best tumor response|Duration of response|Disease control rate|Safety profiles|Best tumoral response of 2nd line sorafenib|Progression-free survival of 2nd line sorafenib|Biomarker for sorafenib","Asan Medical Center|Bayer","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","195","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMC1002","August 2010","November 2013","August 2014","August 24, 2010",,"January 7, 2020","Asan Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01187212"
1559,"NCT01159327","Study of Sorafenib Maintenance in Patients With ED-SCLC After Response to Induction Chemotherapy",,"Terminated","No Results Available","Small Cell Lung Cancer","Drug: Sorafenib","Progression-free survival|Overall survival|Toxicity","National Cancer Center, Korea|Bayer","All","18 Months and older   (Child, Adult, Older Adult)","Phase 2","13","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCCCTS-10-476","December 2010","April 2013","June 2013","July 9, 2010",,"November 11, 2015","National Cancer Center, Korea, Goyang-si, Gyeonggi-do, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01159327"
1560,"NCT01109979","Effect of Estradiol+Drospirenone Versus Estradiol+MPA on Endothelial Function",,"Completed","Has Results","Cardiovascular Diseases","Drug: Estradiol+MPA|Drug: Estradiol+Drospirenone","Brachial Artery Reactivity % Flow Mediated Dilation (BAR %FMD)","Brigham and Women's Hospital|Bayer","Female","45 Years to 75 Years   (Adult, Older Adult)","Phase 4","24","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","2006p002137","December 2009","January 2012","June 2016","April 23, 2010","May 3, 2013","July 12, 2016","Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01109979"
1561,"NCT01094886","Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement",,"Completed","Has Results","Arthritis|Osteoarthritis, Knee|Osteoarthritis, Hip|Thromboembolism","Drug: Rivaroxaban","Summary of Change From Day 3 to Day 1 in Maximum Anti-Factor Xa (aFXa)|Summary of Change From Day 3 to Day 1 in Maximum Prothrombin Time|Summary of Change From Day 1 to Day 3 in Area Under the Curve (AUC) of aFXa|Summary of Change From Day 1 to Day 3 in AUC of Prothrombin Time","Ortho-McNeil Janssen Scientific Affairs, LLC|Bayer","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","56","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CR016531|RIVAROXCPK3001","March 2010","December 2010","December 2010","March 29, 2010","February 27, 2012","March 17, 2017","Denver, Colorado, United States|Hollywood, Florida, United States|Tamarac, Florida, United States|Vero Beach, Florida, United States|Glen Cove, New York, United States",,"https://ClinicalTrials.gov/show/NCT01094886"
1562,"NCT01082939","Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)",,"Completed","Has Results","Chronic Lymphocytic Leukemia","Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Alemtuzumab|Drug: Rituximab","Number of Participants With an Overall Response","M.D. Anderson Cancer Center|Bayer","All","Child, Adult, Older Adult","Phase 2","80","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DM02-593","December 2002","January 2011","January 2011","March 9, 2010","October 21, 2011","February 20, 2012","UT MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01082939"
1563,"NCT01065714","A Study to Investigate the Use of Hydrogel Vehicle in Maintaining the Skin Barrier in Persons With Atopic Dermatitis",,"Completed","Has Results","Atopic Dermatitis","Drug: Hydrogel vehicle|Drug: Eucerin Lotion","Percent Change of Trans Epidermal Water Loss (TEWL) With Use of Eucerin Lotion|Percent Change of Trans Epidural Water Loss (TEWL) With the Use of Hydrogel Vehicle|Percentage of Participants With an Increase in Skin Hydration Using Eucerin Lotion on Targeted Area on One Half of Body|Percentage of Participants With an Increase in Skin Hydration Using Hydrogel Vehicle on Targeted Area of One Half of Body.","Derm Research, PLLC|Bayer","All","12 Years and older   (Child, Adult, Older Adult)","Phase 4","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","HGV0901","February 2010","November 2010","November 2010","February 9, 2010","April 25, 2013","April 25, 2013","DermResearch, PLLC, Louisville, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT01065714"
1564,"NCT01038869","Efficacy and Safety Study of Finacea to Treat Acne Vulgaris and Post-Inflammatory Hyperpigmentation (PIH)",,"Completed","Has Results","Acne Vulgaris|Post Inflammatory Hyperpigmentation","Drug: Azelaic acid","Percentage of Participants With Improvement in Acne IGA (Investigator Global Assessment)|Percentage of Participants With Improvement in the IGA of Post Inflammatory Hyperpigmentation(PIH)|Percentage of Participants With an Improvement in Post Inflammatory Hyperpigmentation (PIH) % Distribution|Percentage Change in Total Lesion Counts|Tolerability Assessments as Measured by the Number of Participants With Side Effects","Derm Research, PLLC|Bayer","All","12 Years and older   (Child, Adult, Older Adult)","Phase 4","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FIN0901","December 2009","April 2010","May 2010","December 24, 2009","September 25, 2012","September 25, 2012","DermResearch, PLLC, Louisville, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT01038869"
1565,"NCT01032850","Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma",,"Terminated","Has Results","Hepatocellular Carcinoma","Drug: Sorafenib & Capecitabine","Number of Participants Experiencing Adverse Events|Disease Control Rate of Response (DCR)|Overall Survival (OS)|Progression Free Survival (PFS)","New Mexico Cancer Care Alliance|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","INST 0820|NCI-2011-02945","September 2009","February 2012","September 2015","December 16, 2009","July 17, 2015","July 26, 2016","University of New Mexico Cancer Center @ Lovelace Medical Center, Albuquerque, New Mexico, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Cancer Center at Presbyterian Hospital, Albuquerque, New Mexico, United States",,"https://ClinicalTrials.gov/show/NCT01032850"
1566,"NCT00999284","Ophthalmologic Examinations After Infusion of ZK200775",,"Completed","No Results Available","Visual Acuity","Drug: ZK200775|Drug: Sodium Chloride","Visual acuity|Color vision (Panel D-15 test), dark vision (adaptometer), full-field electroretinogram","Charite University, Berlin, Germany|Bayer","Male","55 Years to 65 Years   (Adult, Older Adult)","Phase 1","18","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","96048","December 1996","April 1998","April 1998","October 21, 2009",,"October 21, 2009","Charité Unviversitätsmedizin Berlin, Augenklinik Campus Virchow-Klinikum, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT00999284"
1567,"NCT00989469","Sorafenib With Irinotecan in Metastatic Colorectal Cancer (mCRC) and K-RAS Mutation","NEXIRI","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: Nexavar (Sorafenib) and irinotecan (Campto)","disease control|toxicity|progression free survival|overall survival","Institut du Cancer de Montpellier - Val d'Aurelle|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","64","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NEXIRI","February 2009","February 2011","February 2012","October 5, 2009",,"February 10, 2012","Centre Oscar Lambret, Lille, France|Hopital Saint Eloi, Montpellier, France|Centre Rene Gauducheau, Nantes, France|Centre Antoine Lacassagne, Nice, France|CHU Robert Debre, Reims, France",,"https://ClinicalTrials.gov/show/NCT00989469"
1568,"NCT00984776","Detection of Coronary Vulnerable Plaque With Contrast-enhanced Magnetic Resonance Imaging","T9M","Completed","No Results Available","Coronary Artery Disease|Stable Angina|Unstable Angina","Other: Contrast enhanced MRI with Gadofosveset","Validation of MRI: comparison with IVUS. Can plaque be detected?|uptake contrast agent gadofosveset in atherosclerotic plaque in the coronary vessel wall?","Maastricht University Medical Center|Bayer","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","20","Other|Industry","Interventional","Primary Purpose: Diagnostic","MEC 06-1-036","March 2007","February 2009",,"September 25, 2009",,"September 25, 2009","Maastricht University Medical Center, Maastricht, Netherlands",,"https://ClinicalTrials.gov/show/NCT00984776"
1569,"NCT00964795","Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular (""Wet"") Age-related Macular Degeneration (AMD)",,"Completed","Has Results","Neovascular Age-related Macular Degeneration","Drug: Intravitreal Aflibercept Injection 2mg","Safety and Tolerability of Intravitreal Aflibercept Injection in Participants With Neovascular AMD|Change in BCVA Letter Score (mLOCF)","Regeneron Pharmaceuticals|Bayer","All","50 Years and older   (Adult, Older Adult)","Phase 3","323","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VGFT-OD-0910","December 2009","August 2013","August 2013","August 25, 2009","March 23, 2015","March 23, 2015","Birmingham (2 locations), Alabama, United States|Phoenix (2 locations), Arizona, United States|Tucson (2 locations), Arizona, United States|Arcadia, California, United States|Beverly Hills, California, United States|Campbell, California, United States|Fresno, California, United States|Fullerton, California, United States|La Jolla, California, United States|Loma Linda, California, United States|Mountain View, California, United States|Oakland, California, United States|Orange, California, United States|Palm Desert, California, United States|Sacramento, California, United States|San Mateo, California, United States|Santa Ana, California, United States|Torrance, California, United States|Westlake Village, California, United States|Yorba Linda, California, United States|Colorado Springs, Colorado, United States|Denver (2 Locations), Colorado, United States|Bridgeport, Connecticut, United States|New Haven, Connecticut, United States|New London, Connecticut, United States|Altamonte Springs, Florida, United States|Boynton Beach, Florida, United States|Fort Myers (2 locations), Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Orlando (2 locations), Florida, United States|Oscala, Florida, United States|Palm Beach Gardens, Florida, United States|Pensacola, Florida, United States|Stuart, Florida, United States|Tampa, Florida, United States|Winter Haven, Florida, United States|Augusta, Georgia, United States|Aiea, Hawaii, United States|Glenview, Illinois, United States|Fort Wayne, Indiana, United States|Indianapolis, Indiana, United States|New Albany, Indiana, United States|Iowa City, Iowa, United States|Wichita, Kansas, United States|Louisville, Kentucky, United States|New Orleans, Louisiana, United States|Bangor, Maine, United States|Portland, Maine, United States|Baltimore (3 Locations), Maryland, United States|Chevy Chase, Maryland, United States|Hagerstown, Maryland, United States|Boston (2 Locations), Massachusetts, United States|Peabody, Massachusetts, United States|Ann Arbor, Michigan, United States|Battle Creek, Michigan, United States|Grand Rapids, Michigan, United States|Jackson, Michigan, United States|Southfield, Michigan, United States|Minneapolis, Minnesota, United States|Rochester, Minnesota, United States|Florissant, Missouri, United States|Kansas City, Missouri, United States|Springfield, Missouri, United States|St. Louis, Missouri, United States|Missoula, Montana, United States|Lincoln, Nebraska, United States|Las Vegas, Nevada, United States|Portsmouth, New Hampshire, United States|Lawrenceville, New Jersey, United States|Northfield, New Jersey, United States|Toms River, New Jersey, United States|Albuquerque, New Mexico, United States|Albany, New York, United States|Brooklyn, New York, United States|Lynbrook, New York, United States|New York (6 locations), New York, United States|Rochester (2 locations), New York, United States|Slingerlands, New York, United States|Syracuse, New York, United States|Asheville, North Carolina, United States|Charlotte, North Carolina, United States|Raleigh, North Carolina, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Oklahoma City, Oklahoma, United States|Ashland, Oregon, United States|Portland (3 Locations), Oregon, United States|Salem, Oregon, United States|Kingston, Pennsylvania, United States|Philadelphia (3 locations), Pennsylvania, United States|Pittsburgh (2 locations), Pennsylvania, United States|West Mifflin, Pennsylvania, United States|Columbia, South Carolina, United States|Greenville, South Carolina, United States|West Columbia, South Carolina, United States|Rapid City, South Dakota, United States|Nashville, Tennessee, United States|Austin (3 Locations), Texas, United States|Dallas, Texas, United States|Fort Worth (2 locations), Texas, United States|Houston, Texas, United States|McAllen, Texas, United States|Odessa, Texas, United States|San Antonio (2 locations), Texas, United States|Tyler, Texas, United States|Salt Lake City (2 locations), Utah, United States|Burlington, Vermont, United States|Charlottesville, Virginia, United States|Fairfax, Virginia, United States|Richmond, Virginia, United States|Seattle, Washington, United States|Madison (2 Locations), Wisconsin, United States|Milwaukee, Wisconsin, United States|Calgary, Alberta, Canada|Vancouver, British Columbia, Canada|Victoria, British Columbia, Canada|Halifax, Nova Scotia, Canada|London, Ontario, Canada|Mississauga, Ontario, Canada|Ottawa, Ontario, Canada|Montreal (2 locations), Quebec, Canada|Regina, Saskatchewan, Canada",,"https://ClinicalTrials.gov/show/NCT00964795"
1570,"NCT00964743","Depocyt® With Sorafenib in Neoplastic Meningitis",,"Terminated","Has Results","Neoplastic Meningitis","Drug: DepoCyt|Drug: Sorafenib","Number of Participants With Adverse Events (AEs)|Number of Participants With Progression Free Survival (PFS) at 6 Months|Number of Participants With Overall Survival (OS)|Sorafenib Levels in Cerebrospinal Fluid (CSF)|CSF and Serum Vascular Endothelial Growth Factor (VEGF) Levels","H. Lee Moffitt Cancer Center and Research Institute|Bayer","All","18 Years and older   (Adult, Older Adult)","Not Applicable","2","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-15783|Bayer IST000266","August 2009","February 2011","February 2011","August 25, 2009","April 19, 2012","September 9, 2013","H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00964743"
1571,"NCT00954278","Intra-patient Dose Escalation Study of Sorafenib in Advanced Non-small Cell Lung Cancer",,"Completed","No Results Available","Carcinoma, Non Small Cell Lung","Drug: sorafenib","Toleration of dose escalation (dose-limiting toxicities)|Safety of sorafenib in dose-escalation (adverse events and serious adverse events)","University of Wisconsin, Madison|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","24","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CO08511|H-2009-0011|IST 000381|A534260|SMPH/MEDICINE/MEDICINE*H|NCI-2011-00813","July 28, 2009","December 23, 2015","December 23, 2015","August 7, 2009",,"November 15, 2019","University of Wisconsin - Madison, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00954278"
1572,"NCT00943072","Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)",,"Completed","Has Results","Macular Edema Secondary to Central Retinal Vein Occlusion","Biological: VEGF Trap-Eye 2.0mg|Drug: Sham","Percentage of Participants Who Gained at Least 15 Letters in BCVA at Week 24 as Measured by ETDRS Letter Score|Change From Baseline in BCVA as Measured by ETDRS Letter Score at Week 24 - Last Observation Carried Forward (LOCF)|Change From Baseline in Central Retinal Thickness (CRT) at Week 24 - LOCF|Percentage of Participants Progressing to Any of the Following: Anterior Segment Neovascularization, New Vessels of the Disc (NVD) or New Vessels Elsewhere (NVE) During the First 24 Weeks|Change From Baseline in the NEI VFQ-25 in Total Score at Week 24 (LOCF)","Regeneron Pharmaceuticals|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","189","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VGFT-OD-0819","July 2009","October 2010","April 2012","July 21, 2009","May 27, 2013","May 27, 2013","Phoenix, Arizona, United States|Phoenix, Arizona, United States|Tucson, Arizona, United States|Arcadia, California, United States|Beverly Hills, California, United States|La Jolla, California, United States|Mountain View, California, United States|Oakland, California, United States|Sacramento, California, United States|Torrance, California, United States|New London, Connecticut, United States|Altamonte Springs, Florida, United States|Fort Lauderdale, Florida, United States|Fort Myers, Florida, United States|Fort Myers, Florida, United States|Miami, Florida, United States|Palm Beach Gardens, Florida, United States|Winter Haven, Florida, United States|Augusta, Georgia, United States|Chicago, Illinois, United States|Wichita, Kansas, United States|Baltimore, Maryland, United States|Hagerstown, Maryland, United States|Towson, Maryland, United States|Boston, Massachusetts, United States|Grand Rapids, Michigan, United States|Jackson, Michigan, United States|Lincoln, Nebraska, United States|Las Vegas, Nevada, United States|Northfield, New Jersey, United States|Toms River, New Jersey, United States|Rochester, New York, United States|Winston-Salem, North Carolina, United States|Cleveland, Ohio, United States|Oklahoma City, Oklahoma, United States|Portland, Oregon, United States|Salem, Oregon, United States|Kingston, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|West Columbia, South Carolina, United States|Rapid City, South Dakota, United States|Nashville, Tennessee, United States|Abilene, Texas, United States|Ft Worth, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Vancouver, British Columbia, Canada|Victoria, British Columbia, Canada|Halifax, Nova Scotia, Canada|London, Ontario, Canada|Mississauga, Ontario, Canada|Toronto, Ontario, Canada|Medellin, Antioquia, Colombia|Bogota, Colombia|Hyderabad, A.p., India|Bangalore, Karnataka, India|Kolkata, West Bengal, India|Kfar-Saba, Israel|Petah Tikva, Israel|Rehovot, Israel|Tel Aviv, Israel",,"https://ClinicalTrials.gov/show/NCT00943072"
1573,"NCT00940342","Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia",,"Completed","Has Results","Leukemia","Drug: GM-CSF (Sargramostim)|Drug: Rituximab","Overall Response Rate","M.D. Anderson Cancer Center|Bayer","All","15 Years and older   (Child, Adult, Older Adult)","Phase 2","130","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2004-0102|NCI-2012-01670","October 12, 2004","January 5, 2017","January 5, 2017","July 16, 2009","September 19, 2018","September 19, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00940342"
1574,"NCT00930605","The Effectiveness of Alemtuzumab Given in Combination With CHOP and ESHAP in Patients Newly Diagnosed With Peripheral T-Cell Lymphoma (PTCL)","C+CHOP/ESHAP","Completed","No Results Available","Peripheral T-cell Lymphoma","Drug: CHOP regimen alternate with ESHAP regimen|Drug: Alemtuzumab","The response to treatment and the treatment-related toxicity.","King Chulalongkorn Memorial Hospital|Bayer","All","15 Years to 65 Years   (Child, Adult, Older Adult)","Phase 2","16","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TH011001","January 2005","November 2006","July 2008","June 30, 2009",,"October 6, 2011","King Chulalongkorn Memorial Hospital, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT00930605"
1575,"NCT00930553","An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab",,"Completed","Has Results","Multiple Sclerosis, Relapsing-Remitting","Biological: alemtuzumab","Annualized Relapse Rate (ARR)|Annualized Relapse Rate (ARR) Before and After Receiving Alemtuzumab|Annualized Relapse Rate (ARR) Before and After Alemtuzumab Retreatment|Number of Participants With Sustained Accumulation of Disability (SAD)|Number of Participants With Sustained Accumulation of Disability (SAD) Before and After Alemtuzumab Treatment: 2 Year Comparison|Number of Participants With Sustained Reduction in Disability (SRD) Assessed by EDSS at Year 6|Number of Participants With Sustained Reduction in Disability (SRD) Assessed by EDSS (After Alemtuzumab Treatment) at Year 2 of the Extension Study|Change From Initial Study Baseline in EDSS Score at Year 3, 4, 5 and 6|Change From Initial Study Baseline in EDSS Score Before and After Alemtuzumab Treatment: 2 Year Comparison|Change From Retreatment Baseline in EDSS Score After Alemtuzumab Retreatment|Percentage of Participants Without New or Enlarging Magnetic Resonance Imaging (MRI)-T2-Hypertense Lesion Activity|Percentage of Participants Without New or Enlarging MRI-T2-Hypertense Lesion Activity Before and After Alemtuzumab Treatment|Percentage of Participants Without New or Enlarging MRI-T2-Hypertense Lesion Activity Before and After Alemtuzumab Retreatment|Percentage Change From Baseline in MRI-T2-Hypertense Lesion Volumes at Year 3, 4, 5, 6|Percentage of Participants Without New Gadolinium-enhancing MRI Lesion Activity|Percent Change From Baseline in Brain Parenchymal Fractions (BPF) at Year 3, 4, 5 and 6|Percentage of Relapse Free Participants|Change From Baseline in Physical Component Score (PCS) of Short Form-36 (SF-36) Health Survey at Year 3, 4, 5 and 6|Change From Baseline in Physical Component Score (PCS) of Short Form-36 (SF-36) Health Survey Before and After Alemtuzumab Treatment: 2 Year Comparison|Change From Baseline in Mental Component Score (MCS) of Short Form-36 (SF-36) at Year 3, 4, 5, and 6|Change From Baseline in Mental Component Score (MCS) of Short Form-36 (SF-36) Before and After Alemtuzumab Treatment: 2 Year Comparison|Change From Baseline in Self-reported Quality of Life as Assessed by Functional Assessment of Multiple Sclerosis (FAMS) Score at Year 3, 4, 5 and 6|Change From Baseline in Self-reported Quality of Life as Assessed by Functional Assessment of Multiple Sclerosis (FAMS) Score Before and After Alemtuzumab Treatment: 2 Year Comparison|Change From Baseline in European Quality of Life -5 Dimension (EQ-5D) Visual Analog Scale Score at Year 3, 4, 5 and 6|Change From Baseline in European Quality of Life -5 Dimension (EQ-5D) Visual Analog Scale Score Before and After Alemtuzumab Treatment: 2 Year Comparison","Genzyme, a Sanofi Company|Bayer|Sanofi","All","Child, Adult, Older Adult","Phase 3","1314","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","CAMMS03409|2009-010788-18|LTE12824","August 2009","February 2016","February 2016","June 30, 2009","May 15, 2017","May 15, 2017","North Central Neurology Associates, P.C., Cullman, Alabama, United States|HOPE Research Institute, Phoenix, Arizona, United States|St. Joseph's Hospital and Medical Center Barrow Neurology Clinics - Barrow Neurological Institute, Phoenix, Arizona, United States|Mayo Clinic Arizona (Scottsdale), Scottsdale, Arizona, United States|Northwest NeuroSpecialists, PLLC, Tucson, Arizona, United States|East Bay Physicians Medical Group/ Sutter East Bay Medical Foundation, Berkeley, California, United States|Neurology Center North Orange County, La Habra, California, United States|University of Southern California Keck School of Medicine/University of Southern California LAC & USC Medical Center, Los Angeles, California, United States|Neuro-Therapeutics, Inc., Pasadena, California, United States|Stanford University Medical Center, Stanford, California, United States|University of Colorado Health Science Center - Aurora, Aurora, Colorado, United States|Advanced Neurology of Colorado, Fort Collins, Colorado, United States|Yale MS Research Center, New Haven, Connecticut, United States|The George Washington University Medical Faculty Associates, Washington, D.C., District of Columbia, United States|University of Florida Neuroscience Institute, Jacksonville, Florida, United States|Neurology Associates, P.A., Maitland, Florida, United States|Neurological Associates, Pompano Beach, Florida, United States|Negroski, Stein, Sutherland and Hanes Neurology, Sarasota, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|University of South Florida College of Medicine, Tampa, Florida, United States|Emory University Department of Neurology, Atlanta, Georgia, United States|Shepherd Center Multiple Sclerosis Institute, Atlanta, Georgia, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Consultants in Neurology, LTD, Northbrook, Illinois, United States|Fort Wayne Neurological Center, Fort Wayne, Indiana, United States|Indiana University Multiple Sclerosis Center, Indianapolis, Indiana, United States|Iowa Health Physicians, Des Moines, Iowa, United States|Ruan Neurology Clinic and Clinical Research Center, Mercy Medical Center, Des Moines, Iowa, United States|University of Kansas Medical Center, Department of Neurology, Kansas City, Kansas, United States|MidAmerica Neuroscience Institute, Lenexa, Kansas, United States|Associates in Neurology, P.S.C., Lexington, Kentucky, United States|Kentucky Neuroscience Research, Louisville, Kentucky, United States|University of Maryland, Maryland Center for MS, Baltimore, Maryland, United States|The MS Center at St. Elizabeth's, Boston, Massachusetts, United States|UMass Memorial Medical Center, Worcester, Massachusetts, United States|University of Michigan Medical School, Ann Arbor, Michigan, United States|Michigan Neurology Association, Clinton, Michigan, United States|Wayne State University, The School of Medicine, Department of Neurology, Detroit, Michigan, United States|Spectrum Health Medical Group, Neurology/Michigan Medical P.C., West Michigan MS Clinic, Grand Rapids, Michigan, United States|Northern Michigan Neurology, Traverse City, Michigan, United States|Saint Luke's Brain & Stroke Institute, Kansas City, Missouri, United States|Renown Institute for Neurosciences, Reno, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|MS Center at Holy Name Hospital, Teaneck, New Jersey, United States|University of New Mexico, Dept. of Neurology, Albuquerque, New Mexico, United States|Empire Neurology P.C., Latham, New York, United States|Winthrop University Hospital Multiple Sclerosis Treatment Center, Mineola, New York, United States|MS Care Center at NYUMC and HJD, New York, New York, United States|The Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai, New York, New York, United States|South Shore Neurologic Associates, P.C., Patchogue, New York, United States|Rochester Multiple Sclerosis Center, Rochester, New York, United States|SUNY Upstate Medical University, Department of Neurology, Syracuse, New York, United States|The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Wake Forest University Health Science Department of Neurology, Winston-Salem, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Oak Clinic for Multiple Sclerosis, Uniontown, Ohio, United States|OMRF Multiple Sclerosis Center of Excellence, Oklahoma City, Oklahoma, United States|Lehigh Valley Hospital Neurosciences and Pain Research, Allentown, Pennsylvania, United States|Rhode Island Hospital MS Center - The Neurology Foundation, Inc, Providence, Rhode Island, United States|Neurology Clinic PC, Cordova, Tennessee, United States|Advanced Neurosciences Institute, Franklin, Tennessee, United States|Hope Neurology, Knoxville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor College of Medicine, Maxine Mesinger MS Clinic, Houston, Texas, United States|Central Texas Neurology Consultants, Round Rock, Texas, United States|Integra Clinical Research, San Antonio, Texas, United States|Neurology Center of San Antonio, San Antonio, Texas, United States|MS Center of Greater Washington, Vienna, Virginia, United States|Swedish Medical MS Center, Seattle, Washington, United States|DIABAID, Buenos Aires, Argentina|Concord Repatriation General Hospital, Concord, New South Wales, Australia|Southern Neurology, Kogarah, New South Wales, Australia|Liverpool Hospital, Liverpool, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Gold Coast Hospital, Southport, Queensland, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|St. Vincent's Hospital, Fitzroy, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|The Wesley Research Institute, Auchenflower QLD, Australia|The Queen Elizabeth Hospital, Woodville, SA, Australia|AKH Wien-Universitätskliniken für Neurologie, Vienna, Austria|Cliniques Universitaires Saint-luc, Brussel, Belgium|CHU Ourthe Amblève, Esneux, Belgium|University Hospital Leuven, Campus Gasthuisberg, Leuven, Belgium|Hospital Mae de Deus, Porto Alegre, Brazil|Hospital da Restauração, Neurology department, Recife, PE, Brazil|Irmandade da Santa Casa de Misericórdio de São Paulo, Neurology department, São Paulo, SP, Brazil|Hospital das Clínicas da Faculdade de Medicina da USP, Neurology department, São Paulo,SP, Brazil|University of Calgary, Department of Neurology, Calgary, Alberta, Canada|Kingston General Hospital MS Clinic, Kingston, Ontario, Canada|Clinique Neuro-Outaouais, Gatineau, Quebec, Canada|Recherche Sepmus, Inc., Greenfield Park, Quebec, Canada|Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada|London Health Sciences Centre - University Hospital, London, ON, Canada|The Ottawa Hospital - MS Research, Ottawa, Ontario, Canada|University of British Columbia, Vancouver, BC, Canada|Clinical Hospital Osijek, Osijek, Croatia|Clinical Hospital Centre Rijeka, Rijeka, Croatia|General Hospital Varazdin, Department for Neurology, Varazdin, Croatia|Clinical Hospital Centre ""Sestre Milosrdnice"", Zagreb, Croatia|Clinical Hospital Centre Zagreb, Zagreb, Croatia|Clinical Hospital Sveti Duh, Zagreb, Croatia|St. Anne's University Hospital Brno, Brno, Czechia|University Hospital Hradec Králové, Hradec Kralove, Czechia|General Hospital, 128 21 Praha 2, Prague, Czechia|Hospital Teplice, Neurology Department, MS centrum, Teplice, Czechia|Rigshospitalet Department of Neurology, Copenhagen, Denmark|Aarhus Sygehus, Århus C, Denmark|Hôpital Général, Dijon Cedex, France|Groupe Hospitalier Pitié-Salpêtrière, Fédération de Maladies du System Nerveux Central, Paris Cedex 13, France|CHU Pontchaillou, Rennes Cedex 9, France|Hôpital Civil, Strasbourg Cedex, France|CHU de Toulouse, Hôpital Purpan, Toulouse Cedex 9, France|Klinik und Poliklinik für Neurologie, Universitätsklinikum Bonn, Bonn, DE, Germany|Jüdisches Krankenhaus Berlin, Berlin-Mitte, Germany|Universitätsklinik Carl Gustav Carus Dresden, Dresden, Germany|Klinikum der JW Goethe Universität, Frankfurt am Main, Germany|Asklepios Klinik Barmbek, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Oberhavel Klinicum GmbH - Krankenhaus Hennigsdorf, Hennigsdorf, Germany|Klinikum Ingolstadt, Ingolstadt, Germany|Klinikum rechts der Isar, München, Germany|Medizinische Fakultät der Universität Rostock,Zentrum für Nervenheilkunde, Rostock, Germany|Universitätsklinikum Ulm, Klinik für Neurologie im RKU, Ulm, Germany|Fachkrankenhaus Hubertusburg GmbH, Klinik für Neurologie und Neurologische Intensivmedizin, Wermsdorf, Germany|Hadassah Medical Center Ein Karem, Ein Karem, Jerusalem, Israel|Sheba Medical Center, Ramat Gan, Israel|Sourasky Tel Aviv Medical Center, Tel Aviv, Israel|Università di Cagliari, Cagliari, Italy|Ospedale S. Antonio Abate di Gallarate, Gallarate (Varese), Italy|Ospedale S. Luigi Gonzaga, Orbassano (TO), Italy|Universita Degli Studi di Roma ""La Sapienza"", Roma, Italy|Unidad de Investigación en Salud, Chihuahua, CHH, Mexico|Medica Sur, Mexico City, DFE, Mexico|Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands|Orbis Medisch Concern, Sittard-Geleen, Netherlands|Centrum Neurologii Klinicznej Sp. Zo.o., Krakow, Poland|Samodzielny Publiczny ZOZ, Uniwersytecki Szpital Kliniczny Nr1 im. Norberta Barlickiego, Lodz, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie, Lublin, Poland|Szpital Kliniczny im. Heliodora Swiecickiego Uniwersytetu Med. im. Karola Marcinkowskiego w Poznaniu, Poznan, Poland|Institute of Psychiatry and Neurology/Instytut Psychiatrii i Neurologii, Warsaw, Poland|Research Medical Complex ""Your Health"" Ltd, Kazan, Russian Federation|Moscow State Public Medical Institution Clinical Hospital #11, Neurology Department, Moscow, Russian Federation|Neurology Research Center under the Russian Academy of Medical Sciences, Moscow, Russian Federation|Russian State Medical University, Department of Neurology and Neurosurgery, Moscow, Russian Federation|Municipal Treatment and Prevention Institution, City Hospital #33, Nizhny Novgorod, Russian Federation|Federal State Public Medical Institution: Siberian District Medical Center under the Federal Agency, Novosibirsk, Russian Federation|Municipal Public Medical Institution: City Hospital #2 of Pyatigorsk, Neurology Department, Pyatigorsk, Russian Federation|Samara Regional Clinical Hospital n.a. Kalinin, Samara, Russian Federation|Institute of Human Brain RAS, Laboratory of Neuroimmunology, St. Petersburg, Russian Federation|St Petersburg State Pavlov Medical University, Dept of Neurology and Neurosurgery with a Hospital, St. Petersburg, Russian Federation|St. Petersburg General Hospital #2, Neurology Department #2, St. Petersburg, Russian Federation|St. Petersburg State Public Medical Institution: Nikolayevskaya Hospital, St. Petersburg, Russian Federation|State Public Medical Institution: Republican Clinical Hospital n.a. G.G. Kuvatov, Ufa, Russian Federation|Clinical Centre Serbia, Institute of Neurology,Dr.Subotica 6,Belgrade, Belgrade, Serbia|Military Medical Academy, Institute of Neurology, Belgrade, Serbia|Clinical Centre Kragujevac, Clinic of Neurology, Kragujevac, Serbia|Clinical Centre Nis, Clinic of Neurology, Nis, Serbia|Clinical Centre Vojvodina, Novi Sad, Serbia|Hospital Universitario Vall d' Hebron, Barcelona, Spain|Hospital Clínico Universitario San Carlos, Madrid, Spain|Hospital Carlos Haya, Neurology Service, Málaga, Spain|Hospital Virgen Macarena, Seville, Spain|SU/Östra sjukhuset, Göteborg, Sweden|Norrlands Universitets sjukhus, Umeå, Sweden|Institute of Neurology, Psychiatry and Narcology under the AMS of Ukraine, Dep of Neuroinfection& MS, Kharkov, Ukraine|Hospital of Directorate of the Medical Corps within the Ukrainian Security Service, Neurology Dept., Kiev-21, Ukraine|Kiev Municipal Clinical Hospital #4, Department of Demyelinating Diseases of the Nervous System, Kiev, Ukraine|Lviv National Medical University n.a. Danylo Galytsky, Department of Neurology, Lviv, Ukraine|Frenchay Hospital, Bristol, United Kingdom|Addenbrookes Hospital, Cambridge, United Kingdom|University Hospital of Wales, Dept of Neurology, Cardiff, United Kingdom|Royal London Hospital, London, United Kingdom|Salford Royal NHS Foundation Trust, Salford, United Kingdom|Royal Hallamshire Hospital, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00930553"
1576,"NCT00924807","Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer",,"Terminated","Has Results","Prostate Cancer","Drug: Leuprolide acetate, Bicalutamide, Sorafenib","Determine the Safety and Maximally Tolerated Dose of Sorafenib Administered Concurrently With Radiotherapy in the Treatment of Intermediate- and High-risk Localized Prostate Cancer.|Biochemical Disease-free Survival","Beth Israel Medical Center|Bayer","Male","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","4","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB# 004-08|SR06-959","September 2008","December 2013","December 2013","June 19, 2009","March 17, 2015","December 11, 2018","St.Luke's-Roosevelt Hospital Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00924807"
1577,"NCT00919061","Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy",,"Completed","Has Results","Extrahepatic Bile Duct Cancer|Gallbladder Cancer","Drug: Gemcitabine|Drug: Cisplatin|Drug: Sorafenib","Progression-Free Survival|Median PFS","Memorial Sloan Kettering Cancer Center|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","39","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09-029","August 2009","March 2014","March 2014","June 12, 2009","February 3, 2016","February 3, 2016","Memorial Sloan Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00919061"
1578,"NCT00917462","Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer",,"Completed","Has Results","Esophageal Cancer|Gastroesophageal Junction Cancer","Drug: Sorafenib, administered orally|Procedure: CT/MRI","2-month Progression-free Survival (PFS) of Sorafenib in Patients With Metastatic or Recurrent Esophageal and Gastroesophageal (GE) Junction Cancer.|Overall Response Rate (Partial Response and Complete Response) of Sorafenib.|Number of Participants With Adverse Events|Exploratory Analysis of Differential Response Between Squamous Cell Carcinoma and Adenocarcinoma.|Percentage of Tumors With High Phosphorylated Extracellular Signal-regulated Kinase Expression","Memorial Sloan Kettering Cancer Center|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","35","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09-016","June 2009","August 2018","August 2018","June 10, 2009","March 13, 2019","March 27, 2019","Memorial Sloan Kettering Cancer Center, New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT00917462/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT00917462"
1579,"NCT00895089","Moxifloxacin Versus Ceftriaxone in the Treatment of Primary Pyogenic Liver Abscess",,"Completed","No Results Available","Liver Abscess","Drug: Moxifloxacin (Avelox)|Drug: ceftriaxone","Treatment efficacy|Clinical response|Clinical and radiological response|All cause mortality|Mortality attributable to liver abscess during treatment|Rates of complication (metastatic infections to the central nervous system and/or eyes)|Rates of gastrointestinal colonization of Klebsiella pneumoniae in patients and rates of resistance post-antibiotic use.","Kaohsiung Veterans General Hospital.|Bayer","All","20 Years and older   (Adult, Older Adult)","Phase 4","24","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VGHKS98-CT2-20","May 2009","December 2010","December 2011","May 7, 2009",,"December 2, 2015","Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan",,"https://ClinicalTrials.gov/show/NCT00895089"
1580,"NCT00893373","Study Evaluating Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Less Than 60 Years of Age","SORAML","Completed","No Results Available","Acute Myeloid Leukemia (AML)","Drug: sorafenib|Drug: placebo","Event-free survival|Overall survival|Rate of complete remissions|Toxicity","Technische Universität Dresden|Bayer","All","18 Years to 60 Years   (Adult)","Phase 2","276","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TUD-SORAML-034","March 2009","November 2011","September 2014","May 6, 2009",,"February 5, 2016","Sozialstiftung Bamberg Klinikum am Bruderwald, Bamberg, Germany|Klinikum Bayreuth, Bayreuth, Germany|Charite Campus Benjamin Franklin, Berlin, Germany|Ev. Diakonie-Krankenhaus gGmbH Bremen, Bremen, Germany|University Hospital Dresden, Dresden, Germany|Klinikum Frankfurt (Oder) GmbH, Frankfurt (Oder), Germany|Westpfalz-Klinikum GmbH, Kaiserslautern, Germany|Agaplesion Diakoniekrankenhaus Rotenburg, Rotenburg, Germany|Robert-Bosch-Krankenhaus, Stuttgart, Germany",,"https://ClinicalTrials.gov/show/NCT00893373"
1581,"NCT00884416","Sorafenib in Newly Diagnosed High Grade Glioma",,"Completed","No Results Available","Glioblastoma|Gliosarcoma|Anaplastic Astrocytoma|Anaplastic Oligoastrocytoma|Anaplastic Oligodendroglioma","Drug: Sorafenib dose escalation","Safety and tolerability of sorafenib in combination with radiation and temozolomide chemotherapy|Maximum Observed Plasma Concentration (Cmax) and Area under the curve (AUC) of sorafenib and temozolomide|Response rate|Time to treatment failure|6 month progression-free survival|Event free survival|Overall survival","University Hospital, Geneva|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","17","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","08-122|2009DR1029|13031","March 2009","December 2011","March 2012","April 20, 2009",,"November 4, 2014","Geneva University Hospital (Hopitaux Universitaires de Geneve), Department of Oncology, Geneva, GE, Switzerland",,"https://ClinicalTrials.gov/show/NCT00884416"
1582,"NCT00876382","Community Oncology Setting Disease Outcomes of Sorafenib (Nexavar) Use in Advanced Renal Cell Carcinoma",,"Completed","No Results Available","Renal Cell Carcinoma",,"To evaluate the safety and efficacy of Nexavar as second-line therapy in patients with advanced renal cell carcinoma treated with Nexavar after first-line therapy with Sutent or Avastin.|To evaluate safety and efficacy of Nexavar as first-line therapy in patients with advanced renal cell carcinoma and as first-line therapy followed by Sutent as second-line therapy in patients with advanced renal cell carcinoma.","SCRI Development Innovations, LLC|Bayer","All","18 Years and older   (Adult, Older Adult)",,"47","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","SCRI OUTCOMES 06","May 2009","February 2011","August 2011","April 6, 2009",,"November 14, 2013","Northeast Arkansas Clinic, Jonesboro, Arkansas, United States|Gulfcoast Oncology Associates, St. Petersburg, Florida, United States|Medical Oncology Associates of Augusta, Augusta, Georgia, United States|Consultants in Blood Disorders and Cancer, Louisville, Kentucky, United States|Jackson Oncology Associates, Jackson, Mississippi, United States|St. Louis Cancer Care, Chesterfield, Missouri, United States|Oncology Hematology Care, Cincinnati, Ohio, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00876382"
1583,"NCT00875745","Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)",,"Completed","No Results Available","Leukemia, Myeloid, Acute|Leukemia, Promyelocytic, Acute|Myelodysplastic Syndromes","Drug: Sorafenib-Vorinostat","Determine the maximum tolerated dose of a combination of Sorafenib and Vorinostat administered to patients with poor-risk AML, or MDS with >10% blasts.|Evaluate response and the duration of response to this combination targeted therapy|Evaluate the toxicity of the combination of Sorafenib and Vorinostat in patients receiving this therapy","Indiana University School of Medicine|Bayer|Indiana University","All","18 Years and older   (Adult, Older Adult)","Phase 1","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0902-08; IUCRO-0234","April 2009","May 2010","October 2013","April 3, 2009",,"September 18, 2014","Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT00875745"
1584,"NCT00864032","Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients With Soft Tissue Sarcoma of the Extremity and Body Wall",,"Completed","Has Results","Soft Tissue Sarcoma","Drug: Sorafenib","Number of Dose Limiting Toxicities","University of California, Davis|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","8","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STS Sorafenib","March 2009","August 2011","August 2011","March 18, 2009","April 10, 2013","April 10, 2013","University of california, Davis Medical Center, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT00864032"
1585,"NCT00858117","A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL",,"Active, not recruiting","No Results Available","Leukemia","Biological: Alemtuzumab|Biological: Rituximab","To determine the response rate to the study medications, Alemtuzumab and Rituximab|Collect data on the toxicity of the study medications, Alemtuzumab and Rituximab","Northwestern University|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NU 04H6|STU00004494","March 2005","December 2020","December 2021","March 9, 2009",,"May 3, 2019","Northwestern University, Northwestern Medical Faculty Foundation, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT00858117"
1586,"NCT00844688","Study of Sorafenib and Gemcitabine in Advanced Hepatocellular Carcinoma (HCC)","HCC","Unknown status","No Results Available","Hepatocellular Carcinoma","Drug: sorafenib|Drug: Gemcitabine","RECIST criteria for response evaluation by CT sacan abdomen in Target lesion of HCC|Toxicity evaluation in accordance with CTCAE v3.0","Combined Military Hospital, Pakistan|Bayer","All","Child, Adult, Older Adult","Phase 2","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HCC","September 2008","October 2009","December 2009","February 16, 2009",,"February 16, 2009","Combined Military Hospital, Rawalpindi, Punjab, Pakistan",,"https://ClinicalTrials.gov/show/NCT00844688"
1587,"NCT00837148","Sorafenib and Dacarbazine in Soft Tissue Sarcoma",,"Completed","Has Results","Sarcoma|Synovial Sarcoma|Leiomyosarcoma|Malignant Peripheral Nerve Sheath Tumor","Drug: Sorafenib and Dacarbazine","Overall Objective Response","Memorial Sloan Kettering Cancer Center|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","37","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","08-068","February 2009","November 2013","November 2013","February 5, 2009","November 20, 2015","November 20, 2015","Memorial Sloan-Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00837148"
1588,"NCT00829660","Acarbose Cardiovascular Evaluation Trial","ACE","Completed","No Results Available","Coronary Heart Disease|Acute Coronary Syndrome|Impaired Glucose Tolerance|Type 2 Diabetes Mellitus (T2DM)","Drug: Acarbose|Drug: Matching Placebo","A composite cardiovascular outcome defined as the time after randomisation to the first occurrence of any one of the following: -Cardiovascular death -Non-fatal MI -Non-fatal stroke -Hospitalisation for Unstable Angina -Hospitalisation for Heart Failure|Transition to type 2 diabetes confirmed by two successive diagnostic plasma glucose values (FPG >7.0 mmol/l and/or 2HPG > 11.1 mmol/l), with no intervening non-diagnostic values.|All cause mortality|Each of the components of the primary composite cardiovascular outcome will also be analysed individually, both as first and as total events.|Major Cardiovascular Event (MACE) composite cardiovascular outcome, defined as the time after randomisation to the first occurrence of any one of the following: - Cardiovascular death - Non-fatal MI - Non-fatal stroke|Impaired renal function as evidenced by: A reduced estimate of glomerular filtration rate( eGFR <30 ml/minute/ 1.73 m2) estimated using the Chinese MDRD formula, a doubling of the baseline plasma creatinine level, a halving of the baseline eGFR|Resource use, costs and cost effectiveness","University of Oxford|Bayer","All","50 Years and older   (Adult, Older Adult)","Phase 4","6526","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","11232|ISRCTN91899513","February 17, 2009","April 11, 2017","April 18, 2017","January 27, 2009",,"July 25, 2017","The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China|Beijing Chuiyangliu Hospital, Beijing, Beijing, China|China Meitan General Hospital, Beijing, Beijing, China|Beijing Anzhen Hospital of The Capital University of Medical Sciences, Beijing, Beijing, China|China-Japan Friendship Hospital, Beijing, Beijing, China|Peking University First Hospital, Beijing, Beijing, China|Beijing Ji Shui Tan Hospital, Beijing, Beijing, China|Beijing Shijitan Hospital, Beijing, Beijing, China|Fu Xing Hospital, Beijing, Beijing, China|Beijing Shijingshan Hospital, Beijing, Beijing, China|Peking University People's Hospital, Beijing, Beijing, China|Aerospace Central Hospital, Beijing, Beijing, China|Affiliated to The Capital University of Medical Sciences Beijing Friendship Hospital, Beijing, Beijing, China|Wangjing Hospital of CACMS, Beijing, Beijing, China|Xuanwu Hospital Capital Medical University, Beijing, Beijing, China|Beijing Healthy Palace Hospital, Beijing, Beijing, China|Aerospace 731 Hospital, Beijing, Beijing, China|General Hospital of Second Artillery PLA, Beijing, Beijing, China|Peking Union Medical College Hospital, Beijing, Beijing, China|PLA General Hospital, Beijing, Beijing, China|Anzhen Hospital of The Capital University of Medical Sciences 2nd., Beijing, Beijing, China|Beijing Pinggu Hospital, Beijing, Beijing, China|Beijing Yanhua Hospital, Beijing, Beijing, China|Chongqing Medical University Second Afflicated Hospital, Chongqing, Chongqing, China|Chongqing Zhongshan Hospital, Chongqing, Chongqing, China|Chongqing Third People's Hospital, Chongqing, Chongqing, China|The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China|Da Ping Hospital, Chongqing, Chongqing, China|The Second People's Hospital of Chongqing, Chongqing, Chongqing, China|Fujian Provincial Hospital, Fuzhou, Fujian, China|Union Hospital Affiliated to Fujian Medical University, Fuzhou, Fujian, China|The People's Hospital of Fujian Province, Fuzhou, Fujian, China|The First Hospital of Xiamen, Xiamen, Fujian, China|Zhongshan Hospital Xiamen University, Xiamen, Fujian, China|Guangdong General Hospital, Guangzhou, Guangdong, China|The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China|The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China|Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China|The Third Affiliated Hospital of Guangzhou Medical College, Guangzhou, Guangdong, China|Wu Jing Zhong Dui Hospital of Guangdong Province, Guangzhou, Guangdong, China|The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China|Peking University Shenzhen Hospital, Shenzhen, Guangdong, China|Zhong Shan City People's Hospital, Zhongshan, Guangdong, China|The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, Guangdong, China|Liuzhou Worker's Hospital, Liuzhou, Guangxi, China|Liuzhou People's Hospital, Liuzhou, Guangxi, China|Minzu Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China|303 Hospital of People's Liberation Army, Nanning, Guangxi, China|The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China|The Affiliated Hospital of Guiyang Medical College, Guiyang, Guizhou, China|Cangzhou Central Hospital, Cangzhou, Hebei, China|The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China|The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China|Bethune International Peace Hospital, Shijiazhuang, Hebei, China|Tangshan Workers Hospital, Tangshan, Hebei, China|The Affiliated Hospital of North China Coal Medical University, Tangshan, Hebei, China|Yu Tian County Hospital, Tangshan, Hebei, China|The Third Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, China|Da Qing Oilfield General Hospital, Da Qing, Heilongjiang, China|The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China|The First Affiliated Hospital of Henan Science & Technology University, Luoyang, Henan, China|Luo Yang Central Hospital, Affiliated to Zhengzhou University, Luoyang, Henan, China|The First Affiliated Hospital of Henan College of TCM, Zhengzhou, Henan, China|The People's Hospital of Zhengzhou, Zhengzhou, Henan, China|The Second Affiliated Hospital of Zhengzhou University, ZhengZhou, Henan, China|Union Hospital of Tongji Medical College of Huazhong, Wuhan, Hubei, China|Wuhan Asia Heart Hospital, Wuhan, Hubei, China|Tongji Hospital of Tongji Medical College of Huazhong, Wuhan, Hubei, China|Pu'ai Hospital of Wuhan City, Wuhan, Hubei, China|Renmin Hospital of Wuhan University, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China|Hunan Provincial People's Hospital, Changsha, Hunan, China|The Fourth Hospital of Changsha, Changsha, Hunan, China|Xiangya Hospital Central-South University, Changsha, Hunan, China|The Third Hospital of Changsha, Changsha, Hunan, China|The First Affiliated Hospital of Baotou Medical College, Baotou, Inner Mongolia, China|Baotou Central Hospital, Baotou, Inner Mongolia, China|Chifeng Municipal Hospital, Chifeng, Inner Mongolia, China|Inner Mongolia Hospital, Hohhot, Inner Mongolia, China|81st Hospital of Chinese PLA, NanJing, Jiangsu, China|Nanjing First Hospital, Nanjing, Jiangsu, China|Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China|Nanjing Zhongda Hospital, Nanjing, Jiangsu, China|BENQ Hospital, Nanjing, Jiangsu, China|Jiangsu Province Official Hospital, NanJing, Jiangsu, China|Jiangsu Province Hospital, Nanjing, Jiangsu, China|Jiangsu Provincial Hospital of TCM, NanJing, Jiangsu, China|Nanjing Jiangning Hospital, Nanjing, Jiangsu, China|Suzhou Municipal Hospital, Suzhou, Jiangsu, China|Wuxi No.2 People's Hospital, Wuxi, Jiangsu, China|Wuxi People's Hospital, Wuxi, Jiangsu, China|Wuxi No.3 People's Hospital, Wuxi, Jiangsu, China|Hospital Affiliated Xuzhou Medical University, Xuzhou, Jiangsu, China|The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China|Zhenjiang First People's Hospital, Zhenjiang, Jiangsu, China|Jiujiang University Hospital, Jiujiang, Jiangxi, China|Jiangxi Provincial People's Hospital, Nanchang, Jiangxi, China|The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China|The Third Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China|China-Japan Union Hospital of Jilin University, Changchun, Jilin, China|The Second Hospital of Jilin University, Changchun, Jilin, China|The Central Hospital of Anshan, Anshan, Liaoning, China|Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning, China|The First Hospital of Dalian Medical University, Dalian, Liaoning, China|Dalian Central Hospital, Dalian, Liaoning, China|Xianyang Central Hospital, Shengyang, Liaoning, China|Shengjing Hospital of China Medical University, Shenyang, Liaoning, China|The People's Hospital of Liaoning Province, Shenyang, Liaoning, China|Shengjing Hospital of China Medical University, Shenyang, Liaoning, China|The Fourth Hospital of China Medical University, Shenyang, Liaoning, China|The First Hospital of Yinchuan, Yinchuan, Ningxia, China|Affiliated Hospital of Ningxia Medical University, Yinchuan, Ningxia, China|The People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, Ningxia, China|Xi'an Central Hospital, Xi'an, Shaanxi, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China|Affiliated Hospital of Xi'an Medical college, Xi'an, Shaanxi, China|Affiliated Hospital of Yan'an University, Yan'an, Shaanxi, China|Yan'an People's Hospital, Yanan, Shaanxi, China|The First Hospital of Yulin, Yulin, Shaanxi, China|The Central Hospital of Jinan, Jinan, Shandong, China|The First People's Hospital of Jinan, Jinan, Shandong, China|The General Hospital of Jinan Military Region, Jinan, Shandong, China|Linyi People's Hospital, Linyi, Shandong, China|Hospital Affiliated of Medical School, Qingdao University, Qingdao, Shandong, China|The Qingdao Municiple Hospital, Qingdao, Shandong, China|Qingdao Fuwai Hospital, Shibei, Shandong, China|Taian City Central Hospital, Taian, Shandong, China|Shanghai Ninth People's Hospital, Shanghai, Shanghai, China|Ruijin Hospital Affiliated to the Shanghai Jiaotong University Medical School, Shanghai, Shanghai, China|Shanghai Central Hospital of Xuhui District, Shanghai, Shanghai, China|Shanghai Zhongshan Hospital, Shanghai, Shanghai, China|Shanghai Huadong Hospital, Shanghai, Shanghai, China|Shanghai Putuo District People's Hospital, Shanghai, Shanghai, China|Putuo District Center Hospital, Shanghai, Shanghai, China|Tongji Hospital of Tongji University, Shanghai, Shanghai, China|Shanghai Tenth People's Hospital, Shanghai, Shanghai, China|Number 411 Hospital of PLA, Shanghai, Shanghai, China|Shanghai Central Hospital of Yangpu District, Shanghai, Shanghai, China|Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China|Shanghai East Hospital, Shanghai, Shanghai, China|Renji Hospital Affilicated to Jiaotong University School of Medicine, Shanghai, Shanghai, China|Shanghai Pudong New Area Gongli Hospital, Shanghai, Shanghai, China|Changhai Hospital, Shanghai, Shanghai, China|Shanghai Zhabei District Shibei Hospital, Shanghai, Shanghai, China|Shanghai Jinshan Hospital, Shanghai, Shanghai, China|Shanghai Pudong New District People's Hospital, Shanghai, Shanghai, China|General Hospital of Tisco, Taiyuan, Shanxi, China|The Third Engineering Bureau Hospital of Ministry of Railway, Taiyuan, Shanxi, China|Taiyuan City Central Hospital, Taiyuan, Shanxi, China|Shanxi Cardiovascular Hospital, Taiyuan, Shanxi, China|PLA No.323 Hospital, Xi'an, Shanxi, China|Chengdu First People's Hospital, Chengdu, Sichuan, China|Chengdu Second People's Hospital, Chengdu, Sichuan, China|Sichuan Provincial People's Hospital, Chengdu, Sichuan, China|The West China Hospital, Chengdu, Sichuan, China|Sichuan Mianyang 404 Hospital, Sichuan, Sichuan, China|Tianjin Union Hospital, Tianjin, Tianjin, China|Tianjin Chest Hospital, Tianjin, Tianjin, China|Tianjin Union Medicine Centre, Tianjin, Tianjin, China|Army Police's Medical College Affiliated Hospital, Tianjin, Tianjin, China|Tianjin Third Central Hospital, Tianjin, Tianjin, China|Tianjin First Center Hospital, Tianjin, Tianjin, China|The Second Hospital of Tianjin Medical University, Tianjin, Tianjin, China|Dagang Oil-Field General Hospital, Tianjin, Tianjin, China|The Fifth Central Hospital of Tianjin, Tianjin, Tianjin, China|First Affiliated Hospital of the Medical College, Shihezi, Xinjiang, China|Xin Jiang Traditional Chinese Medicine Hospital, Urumqi, Xinjiang, China|General Hospital of Xinjiang Production and Construction Corps, Urumqi, Xinjiang, China|The 474th Hospital of PLA, Urumqi, Xinjiang, China|The First Teaching Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China|The First Affiliated Hospital of Kunming Medical College, Kunming, Yunnan, China|The First People's Hospital of Yunnan Province, Kunming, Yunnan, China|The Second Affiliated Hospital of Kunming Medical College, Kunming, Yunnan, China|People's Hospital of Yuxi City, Yuxi, Yunnan, China|Zhe Jiang Hospital, Hangzhou, Zhejiang, China|Sir Run Run Shaw Hospital Affiliated With School of Medicine, Zhe Jiang University, Hangzhou, Zhejiang, China|Prince of Wales Hospital, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT00829660"
1589,"NCT00815295","Study of Sorafenib/Cetuximab in Head and Neck Cancer",,"Completed","Has Results","Squamous Cell Cancer","Drug: Sorafenib|Drug: Cetuximab","Phase 1 - Maximum Tolerated Dose (MTD) of Sorafenib Administered With Cetuximab (400 mg/m2 Loading Dose Followed by 250 mg/m2 Weekly)|Tumor Control Rate|Median Survival|Median Progression-Free Survival (PFS)|Phase 2 - Mean Change From Baseline in Quality of Life - Functional Assessment of Cancer Therapy - Head and Neck (FACT-H&N)","Duke University|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","31","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00001516","January 2008","July 2013","July 2013","December 30, 2008","December 8, 2014","December 8, 2014","Duke University Health System, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00815295"
1590,"NCT00810394","Sorafenib in Treating Patients With Advanced Malignant Solid Tumors",,"Completed","Has Results","Unspecified Adult Solid Tumor, Protocol Specific","Drug: Sorafenib","Percentage of Patients Tolerating Re-escalated Dose of Sorafenib for 28 Days Without Dose Interruption or De-escalation for Toxicity|Overall Response Rate|Time to Disease Progression","University of California, Davis|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCDCC#213|236614|IST000375|UCDCC-213","December 2008","October 2011","March 2012","December 18, 2008","March 10, 2017","January 10, 2018","University of California Davis Cancer Center, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT00810394"
1591,"NCT00809965","An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome",,"Completed","Has Results","Acute Coronary Syndrome|Myocardial Infarction|Myocardial Ischemia|Unstable Angina","Drug: Rivaroxaban 2.5 mg|Drug: Rivaroxaban 5 mg|Drug: Placebo|Drug: Standard of care","The Percentage of Patients With the Composite Endpoint of Cardiovascular Death, Myocardial Infarction, or Stroke|The Percentage of Patients With the Composite of All Cause Death, Myocardial Infarction, or Stroke|The Percentage of Patients With the Composite of Cardiovascular Death, Myocardial Infarction, Ischemic Stroke, or TIMI Major Bleeding Event Not Associated With Coronary Artery Bypass Graft Surgery|The Percentage of Patients With the Composite of Cardiovascular Death, Myocardial Infarction, Stroke, or Severe Recurrent Ischemia Requiring Revascularization|The Percentage of Patients With the Composite of Cardiovascular Death, Myocardial Infarction, Stroke, or Severe Recurrent Ischemia Leading to Hospitalization","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","15526","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CR014710|RIVAROXACS3001","November 2008","September 2011","September 2011","December 17, 2008","June 2, 2014","September 17, 2014","Birmingham, Alabama, United States|Geneva, Alabama, United States|Mobile, Alabama, United States|Anaheim, California, United States|Burbank, California, United States|Los Angeles, California, United States|Mission Hills, California, United States|San Diego, California, United States|Aurora, Colorado, United States|Littleton, Colorado, United States|Jacksonville, Florida, United States|Jupiter, Florida, United States|Kissimmee, Florida, United States|Miami, Florida, United States|Ocala, Florida, United States|Orlando, Florida, United States|Ormond Beach, Florida, United States|St Petersburg, Florida, United States|St. Petersburg, Florida, United States|Columbus, Georgia, United States|Rome, Georgia, United States|Aurora, Illinois, United States|Indianapolis, Indiana, United States|Merrillville, Indiana, United States|Munster, Indiana, United States|Valparaiso, Indiana, United States|Overland Park, Kansas, United States|Wichita, Kansas, United States|Lacombe, Louisiana, United States|Bethesda, Maryland, United States|Boston, Massachusetts, United States|Flint, Michigan, United States|Grand Blanc, Michigan, United States|Grand Rapids, Michigan, United States|Kalamazoo, Michigan, United States|Mount Clemens, Michigan, United States|Petoskey, Michigan, United States|Tupelo, Mississippi, United States|Saint Louis, Missouri, United States|Kalispell, Montana, United States|Bridgewater, New Jersey, United States|Linden, New Jersey, United States|Buffalo, New York, United States|Cortlandt Manor, New York, United States|Saratoga Springs, New York, United States|Stony Brook, New York, United States|Syracuse, New York, United States|Winston Salem, North Carolina, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Dayton, Ohio, United States|Fairview Park, Ohio, United States|Bartlesville, Oklahoma, United States|Oklahoma City, Oklahoma, United States|Doylestown, Pennsylvania, United States|Langhorne, Pennsylvania, United States|Ridley Park, Pennsylvania, United States|Sayre, Pennsylvania, United States|West Chester, Pennsylvania, United States|York, Pennsylvania, United States|Greenville, South Carolina, United States|Johnson City, Tennessee, United States|Memphis, Tennessee, United States|Amarillo, Texas, United States|Lubbock, Texas, United States|Odessa, Texas, United States|Tomball, Texas, United States|Salt Lake City, Utah, United States|Burlington, Vermont, United States|Danville, Virginia, United States|Roanoke, Virginia, United States|Spokane, Washington, United States|Wausau, Wisconsin, United States|Buenos Aires, Argentina|Cordoba, Argentina|Corrientes, Argentina|Junin, Argentina|La Plata, Argentina|Mar Del Plata, Argentina|Moron, Argentina|Morón, Argentina|Resistencia, Argentina|Rosario, Argentina|Salta, Argentina|San Luis, Argentina|Santa Fe, Argentina|Tucuman, Argentina|Bedford Park, Australia|Chermside N/A, Australia|Coffs Harbour South, Australia|Douglas, Australia|Epping, Australia|Fremantle, Australia|Heidelberg, Australia|Herston, Australia|Launceston, Australia|Milton, Australia|Newcastle, Australia|Parkville, Australia|Perth, Australia|Southport, Australia|Woolloongabba N/A, Australia|Bonheiden, Belgium|Brussels, Belgium|Eupen, Belgium|Genk, Belgium|Huy, Belgium|Leuven, Belgium|Mol, Belgium|Tienen, Belgium|Belo Horizonte, Brazil|Blumenau, Brazil|Campina Grande Do Sul, Brazil|Campinas, Brazil|Curitiba, Brazil|Porto Alegre, Brazil|Recife, Brazil|Ribeirao Preto, Brazil|Rio De Janeiro, Brazil|Salvador, Brazil|Sao Jose Do Rio Preto, Brazil|Sao Paulo, Brazil|São Paulo, Brazil|Bourgas, Bulgaria|Dimitrovgrad, Bulgaria|Haskovo, Bulgaria|Pazardjik, Bulgaria|Pleven, Bulgaria|Plovdiv, Bulgaria|Rousse, Bulgaria|Sevlievo, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Veliko Tarnovo, Bulgaria|Edmonton, Alberta, Canada|Kelowna, British Columbia, Canada|Maple Ridge, British Columbia, Canada|Victoria, British Columbia, Canada|St. John'S, Newfoundland and Labrador, Canada|London, Ontario, Canada|Newmarket, Ontario, Canada|Oshawa, Ontario, Canada|Ottawa, Ontario, Canada|Sudbury, Ontario, Canada|Granby, Quebec, Canada|Montreal, Quebec, Canada|Quebec City, Quebec, Canada|Saint-Charles-Borromee, Quebec, Canada|Saint-Georges, Quebec, Canada|Sherbrooke, Quebec, Canada|Ste-Foy, Quebec, Canada|North Battleford, Saskatchewan, Canada|Laval, Canada|Antofagasta, Chile|Chile, Chile|Osorno X Región, Chile|Punta Arenas, Chile|San Bernardo, Chile|Santiago Rm, Chile|Santiago, Chile|Talcahuano, Chile|Temuco, Chile|Valdivia X Región, Chile|Victoria, Chile|Vina Del Mar, Chile|Beijing Prc, China|Beijing, China|Changsha, China|Daqing, China|Guangzhou, China|Hangzhou, China|Harbin, China|Jinan, China|Nanjing, China|Shanghai, China|Shen Yang, China|Shenyang, China|Tianjin, China|Xi'An, China|Armenia, Colombia|Barranquilla, Colombia|Bogotá Dc, Colombia|Cali Valle Del Cauca, Colombia|Envigado, Colombia|Manizales, Colombia|Medellin, Colombia|Santander, Colombia|Rijeka, Croatia|Slavonski Brod, Croatia|Suska 6, Croatia|Benesov Nad Cernou, Czech Republic|Brno, Czech Republic|Ceske Budejovice, Czech Republic|Cesky Krumlov N/A, Czech Republic|Hradec Kralove, Czech Republic|Kolin N/A, Czech Republic|Kromeriz, Czech Republic|Litomysl, Czech Republic|Nachod N/A, Czech Republic|Pardubice N/A, Czech Republic|Plzeò 1, Czech Republic|Poruba, Czech Republic|Praha 10 N/A, Czech Republic|Praha 2, Czech Republic|Praha 8, Czech Republic|Praha, Czech Republic|Slany, Czech Republic|Teplice, Czech Republic|Usti Nad Labem, Czech Republic|Znojmo N/A, Czech Republic|Aalborg, Denmark|Esbjerg, Denmark|Holbæk, Denmark|Horsens N/A, Denmark|Kolding, Denmark|København, Denmark|Odense, Denmark|Alexandria, Egypt|Cairo, Egypt|Ismailia, Egypt|Menofeya, Egypt|Besancon, France|Cannes, France|Chambray-Les-Tours, France|Chartres, France|Creteil N/A, France|Dijon, France|Haguenau, France|Lagny, France|Marseille, France|Montfermeil, France|Paris, France|Poitiers, France|Bad Friedrichshall, Germany|Berlin, Germany|Bonn, Germany|Dresden, Germany|Essen, Germany|Esslingen, Germany|Frankfurt / Main, Germany|Freiburg, Germany|Greifswald, Germany|Göttingen, Germany|Halle, Germany|Hamburg, Germany|Hannover, Germany|Heidelberg, Germany|Kiel, Germany|Leipzig, Germany|Limburg, Germany|Lübeck, Germany|Magdeburg, Germany|Mannheim, Germany|Weiden, Germany|Wermsdorf, Germany|Witten, Germany|Athens, Greece|Larisa, Greece|Rhodes, Greece|Thessalonikis, Greece|Budapest N/A, Hungary|Budapest, Hungary|Debrecen, Hungary|Győr, Hungary|Kecskemet, Hungary|Komarom, Hungary|Miskolc, Hungary|Szolnok, Hungary|Szombathely, Hungary|Zalaegerszeg, Hungary|Ahmedabad, India|Allahabad, India|Bangalore, India|Chandigarh, India|Chennai, India|Cochin, India|Coimbatore, India|Ernakulam, India|Gandhinagar Guiarat, India|Gurgaon, India|Hyderabad, India|Jaipur, India|Karamsad, India|Kochi, India|Kolkata, India|Lucknow Gpo, India|Ludhiana, India|Madurai, India|Mangalore, India|Mumbai, India|Mysore, India|Nagpur, India|Nasik, India|New Delhi, India|Pune, India|Surat, India|Trissur, India|Trivandrum, India|Vadodara, India|Vijayawada, India|Afula, Israel|Hadera, Israel|Haifa, Israel|Jerusalem, Israel|Nahariya, Israel|Petah Tikva, Israel|Rehovot, Israel|Safed, Israel|Tel Aviv, Israel|Tiberias, Israel|Anan, Japan|Fukui, Japan|Fukuoka-Shi,, Japan|Fukuyama-City,, Japan|Gifu-City, Japan|Higashiosaka-City, Japan|Kagoshima-City, Japan|Kanazawa-City, Japan|Kasuga, Japan|Kawachinagano-City, Japan|Kawasaki-City, Japan|Kisarazu-City, Japan|Kobe-City, Japan|Kobe-Shi, Japan|Kumamoto-City, Japan|Kumamoto, Japan|Kuwana-City, Japan|Maebashi-City Gunma, Japan|Matsudo-City, Japan|Matsumoto, Japan|Matsuyama-City Ehime, Japan|Miyazaki-Gun, Japan|Nagano-City, Japan|Nagasaki, Japan|Nagoya-City, Japan|Nagoya, Japan|Namegata-City, Japan|Nankoku-City, Japan|Nishinomiya, Japan|Okayama-City, Japan|Osaka-City, Japan|Osaka, Japan|Sakaide-City, Japan|Sakura-Shi, Japan|Suwa-City, Japan|Tokushima-City, Japan|Tokushima, Japan|Tokyo,, Japan|Tokyo, Japan|Toyama-City, Japan|Urasoe-City, Japan|Yamaguchi, Japan|Yokohama N/A, Japan|Yokohama-City, Japan|Yokohama-Shi, Japan|Yokohama, Japan|Yonago-Shi, Japan|Daejeon, Korea, Republic of|Gwangju, Korea, Republic of|Seognam-Si, Kyungki-Do, Korea, Republic of|Seoul, Korea, Republic of|Suwon, Korea, Republic of|Daugavpils, Latvia|Liepaja, Latvia|Riga, Latvia|Kaunas, Lithuania|Klaipeda, Lithuania|Siauliai, Lithuania|Vilnius Lt, Lithuania|Vilnius, Lithuania|Johor Bahru, Malaysia|Kelantan, Malaysia|Kota Samarahan, Malaysia|Kuala Lumpur, Malaysia|Selayang N/A, Malaysia|Aguascalientes, Mexico|Cd. Juarez, Mexico|Ciudad De Mexico, Mexico|Culiacan, Mexico|Guadalajara, Mexico|Leon, Mexico|Mexico, Mexico|Monterrey, Mexico|Queretaro, Mexico|San Luis Potosi, Mexico|Sinaloa, Mexico|Veracruz, Mexico|Zapopan, Mexico|Marrakech, Morocco|Meknès, Morocco|Rabat, Morocco|Amsterdam, Netherlands|Arnhem, Netherlands|Delft, Netherlands|Den Haag, Netherlands|Eindhoven, Netherlands|Gorinchem, Netherlands|Gouda, Netherlands|Haarlem, Netherlands|Harderwijk, Netherlands|Hengelo Ov, Netherlands|Nieuwegein, Netherlands|Nijmegen, Netherlands|Sittard, Netherlands|Vlaardingen, Netherlands|Auckland, New Zealand|Dunedin, New Zealand|Hamilton, New Zealand|Lower Hutt, New Zealand|Nelson, New Zealand|New Plymouth, New Zealand|Iloilo City, Philippines|Marikina City, Philippines|Quezon City, Philippines|Bedzin, Poland|Białystok, Poland|Bielsko-Biala, Poland|Bydgoszcz, Poland|Bytom, Poland|Dąbrowa Górnicza, Poland|Gdynia, Poland|Gorlice, Poland|Katowice N/A, Poland|Katowice-Ochojec, Poland|Katowice, Poland|Koszalin, Poland|Krakow N/A, Poland|Krakow, Poland|Kutno, Poland|Lodz, Poland|Nowy Targ, Poland|Opole, Poland|Plock, Poland|Poznan N/A, Poland|Poznan, Poland|Ruda Slaska, Poland|Starogard Gdanski Nap, Poland|Szczecin N/A, Poland|Szczecin, Poland|Torun, Poland|Warszawa N/A, Poland|Warszawa, Poland|Wloclawek, Poland|Wroclaw, Poland|Zamosc, Poland|Aveiro, Portugal|Braga, Portugal|Coimbra, Portugal|Faro, Portugal|Leiria, Portugal|Lisboa, Portugal|Penafiel, Portugal|Porto, Portugal|Vila Nova De Gaia, Portugal|Bucuresti, Romania|Craiova, Romania|Focsani, Romania|Oradea, Romania|Pitesti, Romania|Tg Mures, Romania|Timisoara, Romania|Arkhangelsk, Russian Federation|Barnaul, Russian Federation|Chelyabinsk, Russian Federation|Ekaterinburg, Russian Federation|Ivanovo, Russian Federation|Kaliningrad, Russian Federation|Kemerovo, Russian Federation|Kirov, Russian Federation|Krasnodar, Russian Federation|Krasnoyarsk, Russian Federation|Kursk, Russian Federation|Lyubertsy, Russian Federation|Moscow N/A, Russian Federation|Moscow, Russian Federation|Nizhny Novgorod, Russian Federation|Novosibirsk, Russian Federation|Omsk, Russian Federation|Orenburg, Russian Federation|Penza, Russian Federation|Perm, Russian Federation|Pskov, Russian Federation|Pushkin, Saint-Petersburg, Russian Federation|Ryazan, Russian Federation|Saint-Petersbrug, Russian Federation|Saint-Petersburg, Russian Federation|Sestroretsk, Saint-Petersburg, Russian Federation|St Petersburg N/A, Russian Federation|St Petersburg, Russian Federation|St. Petersburg, Russian Federation|Syktyvkar, Russian Federation|Tomsk, Russian Federation|Tula, Russian Federation|Tumen Region, Russian Federation|Vladimir, Russian Federation|Voronezh, Russian Federation|Yaroslavl Nap, Russian Federation|Belgrade, Serbia|Beograd, Serbia|Kragujevac, Serbia|Niska Banja, Serbia|Nis, Serbia|Bratislava, Slovakia|Nové Zámky, Slovakia|Zilina, Slovakia|Alicante N/A, Spain|Aviles Asturias, Spain|Barcelona, Spain|Burgos, Spain|Elche, Spain|Figueres, Spain|Guadalajara, Spain|Huelva N/A, Spain|Madrid, Spain|Malaga, Spain|Málaga, Spain|Salamanca, Spain|Santander, Spain|Sevilla, Spain|Tarragona, Spain|Valencia, Spain|Vigo, Spain|Danderyd, Sweden|Göteborg, Sweden|Jönköping, Sweden|Linköping, Sweden|Lund, Sweden|Malmö, Sweden|Umeå, Sweden|Örebro, Sweden|Östersund, Sweden|Bangkok, Thailand|Chiang Mai, Thailand|Pathumthani, Thailand|Phathumwan, Thailand|Sfax, Tunisia|Sousse, Tunisia|Tunis, Tunisia|Ankara, Turkey|Aydin, Turkey|Bursa, Turkey|Erzurum, Turkey|Istanbul, Turkey|Izmir, Turkey|Kayseri, Turkey|Samsun, Turkey|Sivas, Turkey|Cherkassy, Ukraine|Dnepropetrovsk, Ukraine|Donetsk, Ukraine|Ivano-Frankivsk, Ukraine|Kharkov, Ukraine|Khemelnitskiy, Ukraine|Kiev, Ukraine|Lugansk, Ukraine|Lutsk, Ukraine|Lviv, Ukraine|Nikolaev, Ukraine|Poltava, Ukraine|Sumy, Ukraine|Ternopol, Ukraine|Uzhgorod, Ukraine|Vinnitsa, Ukraine|Zaporozhye, Ukraine|Zhytomir, Ukraine|Birmingham, United Kingdom|Blackpool, United Kingdom|Bristol, United Kingdom|Chertsey, United Kingdom|Chesterfield, United Kingdom|East Sussex, United Kingdom|Exeter, United Kingdom|Hampshire, United Kingdom|Harrow, United Kingdom|Hull, United Kingdom|Leicester, United Kingdom|Lincoln, United Kingdom|Manchester, United Kingdom|Middlesbrough, United Kingdom|Portadown, United Kingdom|Stockport, United Kingdom|Warwick, United Kingdom|Worcester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00809965"
1592,"NCT00807196","Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma",,"Unknown status","No Results Available","Non-Hodgkins Lymphoma","Drug: Rituximab|Drug: 90Y ibritumomab tiuxetan (Zevalin)|Drug: Cyclophosphamide|Drug: Fludarabine|Other: Non myeloablative allogeneic stem cell transplantation","Engraftment, chimerism, transplant related toxicity, acute and chronic GVHD|Overall response rate, overall and disease free survival","Maisonneuve-Rosemont Hospital|Bayer","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ZEV0701","September 2008","December 2011","December 2012","December 11, 2008",,"December 11, 2008","Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00807196"
1593,"NCT00800943","Study of Subcutaneous Campath-1H in Patients With B-Cell CLL and Residual Disease After Chemotherapy","CRC005","Unknown status","No Results Available","B-Cell Chronic Lymphocytic Leukemia","Biological: Alemtuzumab (Campath-1H)","To evaluate whether CAMPATH-1H given to patients with CLL after maximum response to chemotherapy will: a) eliminate residual disease (documented by flow cytometry) or b) convert partial remission to complete remission|To evaluate the time-to-progression of patients according to pretreatment characteristics and response status at study entry.|To evaluate whether CAMPATH-1H given to patients with CLL after maximum response to chemotherapy will eliminate minimal residual disease as determined by real-time quantitative PCR.","Chronic Lymphocytic Leukemia Research Consortium|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","31","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CRC005","December 2003","August 2010","August 2010","December 3, 2008",,"December 3, 2008","University of California San Diego, La Jolla, California, United States|Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States|M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00800943"
1594,"NCT00794859","Sorafenib in Previously Treated Malignant Mesothelioma","SMS","Unknown status","No Results Available","Mesothelioma","Drug: Sorafenib","Progression-free survival|Response rate as assessed with CT scan|Overall survival|Change in FDG-PET avidity","King's College London|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","54","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2007-005091-13","October 2008","December 2009",,"November 20, 2008",,"August 4, 2009","Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00794859"
1595,"NCT00789477","DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact","DA VINCI","Completed","Has Results","Diabetic Macular Edema","Procedure: Laser Photocoagulation|Drug: Intravitreal Aflibercept Injection","Change in BCVA From Baseline to Week 24 - Last Observation Carried Forward (LOCF)|Change in BCVA From Baseline to Week 52 - LOCF|Participants With Gains in ETDRS Letter Score of at Least 15 Letters - LOCF|Change From Baseline in Central Retinal Thickness (CRT) as Assessed by Optical Coherence Tomography (OCT) - LOCF|Number of Focal Laser Treatments","Regeneron Pharmaceuticals|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","221","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VGFT-OD-0706","December 2008","December 2009","September 2010","November 11, 2008","September 9, 2014","September 9, 2014","Artesia, California, United States|Beverly Hills, California, United States|Mountain View, California, United States|Pasadena, California, United States|Sacramento, California, United States|Santa Ana, California, United States|Hamden, Connecticut, United States|New London, Connecticut, United States|Boynton Beach, Florida, United States|Fort Lauderdale, Florida, United States|Fort Myers, Florida, United States|Ocala, Florida, United States|Palm Beach Gardens, Florida, United States|Winter Haven, Florida, United States|Augusta, Georgia, United States|Honolulu, Hawaii, United States|Indianapolis, Indiana, United States|Bangor, Maine, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Jackson, Michigan, United States|Kansas City, Missouri, United States|Lincoln, Nebraska, United States|New Brunswick, New Jersey, United States|Northfield, New Jersey, United States|Toms River, New Jersey, United States|Rochester, New York, United States|Charlotte, North Carolina, United States|Raleigh, North Carolina, United States|Cincinnati, Ohio, United States|Pittsburgh, Pennsylvania, United States|Greenville, South Carolina, United States|West Columbia, South Carolina, United States|Nashville, Tennessee, United States|Abilene, Texas, United States|Arlington, Texas, United States|Austin, Texas, United States|Houston, Texas, United States|McAllen, Texas, United States|San Antonio, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Wien, Austria|Vancouver, British Columbia, Canada|Victoria, British Columbia, Canada|London, Ontario, Canada|Mississauga, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00789477"
1596,"NCT00780169","Phase I Trial of Sorafenib + FOLFIRI In Metastatic Colorectal Cancer",,"Completed","No Results Available","Metastatic Colorectal Cancer","Drug: sorafenib + FOLFIRI","Toxicity spectrum of Sorafenib (MTD, DLT) and the recommended dose (RD) for phase II studies of Sorafenib when combined with FOLFIRI in first line patients with metastatic colorectal cancer (mCRC)|Pharmacokinetics of Irinotecan in the presence of Sorafenib|Response according to Response Evaluation Criteria in Solid Tumors (RECIST)|Time to Progression and Overall Survival","Ottawa Hospital Research Institute|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","16","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OTT 06-08","October 2008","May 2011","December 2012","October 27, 2008",,"May 13, 2013","The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00780169"
1597,"NCT00779311","A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer",,"Terminated","Has Results","Metastatic Colorectal Cancer","Drug: sorafenib|Drug: bevacizumab|Drug: mFOLFOX6 regimen","Determination of the Maximum Tolerated Dose (MTD) of Sorafenib When Given in Combination With mFOLFOX6 and Bevacizumab|Determination of Progression Free Survival (PFS) Among Patients on This Regimen|Determination of Quality of Life (QoL) as Indicated by Patient Care Monitor (PCM) Data Among Patients on This Regimen","Accelerated Community Oncology Research Network|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","8","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AFMSMCRC0706","October 2008","March 2011","March 2011","October 24, 2008","October 26, 2011","November 2, 2011","Central Georgia Cancer Care, Macon, Georgia, United States|Hematology Oncology Centers of the Northern Rockies, Billings, Montana, United States|The West Clinic, Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00779311"
1598,"NCT00775632","Alemtuzumab and Cyclosporine for the Prevention of Graft vs Host Disease After Stem Cell Transplants",,"Completed","No Results Available","Graft Versus Host Disease|Bone Marrow Transplantation","Drug: Alemtuzumab|Drug: mycophenolate or cyclosporine and methotrexate","Chronic extensive GVHD at 1-year (yes vs. no)","University Health Network, Toronto|Bayer","All","16 Years to 70 Years   (Child, Adult, Older Adult)","Phase 2","78","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UHN REB 07-0436C","October 2008","September 2010","September 2010","October 20, 2008",,"June 23, 2016","Princess Margaret Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00775632"
1599,"NCT00761384","High Dose, Absorbed Dose Adjusted 90Y-ibritumomab With Peripheral Blood Stem Cells (PBSC) Support in B-cell Lymphoma","HITT","Completed","No Results Available","B-cell Lymphoma","Drug: 90Y-ibritumomab","Maximal tolerable dose (MTD) absorbed dose to the liver, safety and time to treatment failure (TTF)|Overall response (OR), complete response (CR), their duration, absorbed dose to normal organ and tumours, relapse pattern, the effect of radioimmunotherapy (RIT) in its own right as assessed by positron emission tomography (PET)","Lund University Hospital|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","7","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","6th radioimmunotherapy prot.|EudraCT number: 2007-002762-35","April 2008","January 2016","January 2016","September 29, 2008",,"February 19, 2016","Lund University Hospital, Lund, Sweden",,"https://ClinicalTrials.gov/show/NCT00761384"
1600,"NCT00759928","PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors",,"Completed","No Results Available","Refractory Solid Tumors","Drug: Erlotinib|Drug: Sorafenib","To determine the pharmacokinetics (PK) of erlotinib when administered in combination with sorafenib on a continuous schedule in Refractory Solid Tumors in patients who are smokers and in patients who are nonsmokers.|To evaluate safety of this combination in patients with Refractory Solid Tumors.","SCRI Development Innovations, LLC|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","48","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCRI LUN 175","October 2008","September 2013","June 2014","September 25, 2008",,"July 2, 2014","Florida Cancer Specialists, Fort Myers, Florida, United States|Tennessee Oncology, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00759928"
1601,"NCT00754923","Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer",,"Terminated","Has Results","Lung Cancer","Drug: sorafenib","Progression-free Survival at 6 Months|Overall Survival Rate|Incidence of Adverse Events Sssessed by Common Terminology Criteria for Adverse Events (CTCAE)|Mutational Status for EGFR or Kras","Ohio State University Comprehensive Cancer Center|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","11","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OSU-08017|NCI-2011-03192","October 2008","April 2012","April 2012","September 18, 2008","June 4, 2014","March 6, 2019","Ohio State University, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00754923"
1602,"NCT00734526","Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma",,"Terminated","No Results Available","Glioblastoma|Gliosarcoma","Drug: Temozolomide|Radiation: Radiation|Drug: Sorafenib","Phase I: Sorafenib Maximum Tolerated Dose (MTD)|Second MTD|Phase II: Time to Progression","M.D. Anderson Cancer Center|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","18","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2008-0059|NCI-2012-01617","December 18, 2008","December 2012","December 2012","August 14, 2008",,"November 9, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00734526"
1603,"NCT00722800","A Study to Examine the Safety and Efficacy of Drospirenone and Ethinyl Estradiol (YAZ) Versus Placebo In HS",,"Terminated","Has Results","Hidradenitis Suppurativa","Drug: drospirenone and ethinyl estradiol (YAZ)|Drug: Placebo","Mean Improvement in the Sartorius Severity Score at Month 6.|Change From Baseline in VAS Pain Scale at Month 6.|Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Month 6.","Massachusetts General Hospital|Bayer","Female","14 Years to 45 Years   (Child, Adult)","Phase 2","4","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20080p-000843","October 2008","December 2011","December 2011","July 28, 2008","January 16, 2014","February 10, 2014","Clinical Unit for Research Trials in Skin, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00722800"
1604,"NCT00722761","Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne",,"Completed","Has Results","Acne Vulgaris","Drug: drospirenone and ethinyl estradiol|Drug: Placebo tablet","Percent Change in Truncal Lesion Counts|Percentage of Subjects Rated Clear or Almost Clear on the IGA and SGA at Week 24/ Early Termination","Massachusetts General Hospital|Bayer","Female","18 Years to 45 Years   (Adult)","Phase 3","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2008-P-000754","April 2009","April 2012","April 2012","July 28, 2008","March 5, 2013","March 5, 2013","Clinical Unit for Research Trials in Skin, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00722761"
1605,"NCT00718705","Reduction of Spontaneous Prematurity by Antibiotic Treatment (Josamycin)","PREMYC","Completed","No Results Available","Prematurity","Drug: Josamycin|Drug: Placebo","Premature birth|Antenatal :occurence of a miscarriage late|Antenatal : premature delivery|Antenatal : hospitalisation for risk of premature delivery|antenatal : Number of day of hospitalisation for risk of premature delivery|Antenatal : premature rupture of membranes|Antenatal : occurence of chorioamnionitis defined by 2 of the following criteria :maternal temperature > 38°C, uterine contractions, Fetid leucorrhoeas, foetal tachycardia > 160bpm, C reactive protein >10mg/l|During childbirth : Hyperthermia > 38°C|During childbirth : fetal tachycardia > 160 bpm|Post-partum : Hyperthermia > 38°C for more than 24hours|Post partum :need an antibiotic treatment for more than 48 hours|Neonatal : neonatal mortality late|Neonatal : early neonatal mortality|Neonatal morbidity : immediate neonatal state|Neonatal morbidity : infection|Neonatal morbidity : respiratory disease|Neonatal morbidity : digestive disease","Assistance Publique - Hôpitaux de Paris|Bayer","Female","18 Years and older   (Adult, Older Adult)","Phase 3","3200","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","P060216","July 2008","September 2011","September 2011","July 21, 2008",,"December 29, 2011","Groupe Hospitalier Chenevier-Mondor, CHI, Creteil, France",,"https://ClinicalTrials.gov/show/NCT00718705"
1606,"NCT00714948","Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma",,"Terminated","Has Results","Bladder Cancer|URINARY BLADDER","Drug: gemcitabine and cisplatin plus sorafenib","To Determine the Progression Free Survival Rate at One Year Untreated Patients With Advanced/Metastatic Urothelial Carcinoma Treated With the Combination of Sorafenib, Gemcitabine, and Cisplatin.","Memorial Sloan Kettering Cancer Center|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","2","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","07-168","July 2008","November 2011","November 2011","July 14, 2008","November 16, 2015","November 16, 2015","Memorial Sloan Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00714948"
1607,"NCT00705211","A 52-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05245)",,"Completed","No Results Available","Hypercholesterolemia|Familial Hypercholesterolemia|Homozygous Sitosterolemia","Drug: Ezetimibe|Drug: Ezetimibe + other lipid-lowering medication(s)","A primary endpoint is the incidence of adverse events.|A primary endpoint is change in LDL-C","Merck Sharp & Dohme Corp.|Bayer","All","Child, Adult, Older Adult",,"1794","Industry","Observational","Time Perspective: Prospective","P05245","June 2007","December 2009","December 2009","June 25, 2008",,"February 25, 2015",,,"https://ClinicalTrials.gov/show/NCT00705211"
1608,"NCT00704444","A 12-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05244)",,"Completed","No Results Available","Hypercholesterolemia|Familial Hypercholesterolemia|Homozygous Sitosterolemia","Drug: Ezetimibe|Drug: Ezetimibe + other lipid-lowering medication(s)","Incidence of adverse events|Change in LDL-C","Merck Sharp & Dohme Corp.|Bayer","All","Child, Adult, Older Adult",,"11332","Industry","Observational","Time Perspective: Prospective","P05244","June 2007","September 2009","September 2009","June 25, 2008",,"February 25, 2015",,,"https://ClinicalTrials.gov/show/NCT00704444"
1609,"NCT00694291","Sorafenib in Hormone Naïve Biochemical Recurrence of Prostate Cancer",,"Withdrawn","No Results Available","Prostate Cancer","Drug: Sorafenib|Drug: Placebo","To compare the median PSA slope of patients with non-castrate, high risk biochemical recurrence of prostate cancer following definitive local therapy treated with Sorafenib for six months compared to those treated with placebo.|To determine the response rate based on PSA criteria and duration of PSA response.|To compare the time to PSA progression between the Sorafenib arm and the placebo arm.|To document the safety and tolerability of Sorafenib in this patient population.","Fox Chase Cancer Center|Bayer","Male","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","FCCC 07-038","June 2008","June 2010",,"June 10, 2008",,"March 6, 2015","Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00694291"
1610,"NCT00689169","Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell Lymphoma","ZBEAM2","Completed","No Results Available","Lymphoma, Large Cell, Diffuse","Drug: ZBEAM (Zevalin, BCNU, Etoposide, Aracytine, Melphalan)|Procedure: ASCT|Drug: Rituximab","Event free survival (EFS): events being death from any cause, relapse for complete responders and unconfirmed complete responders, progression during and after treatment and changes of therapy|Overall response rate (ORR) (Complete Response CR and Partial Response PR)","Lymphoma Study Association|Bayer","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","75","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ZBEAM2|2007-000270-23","August 2007","January 2011","January 2014","June 3, 2008",,"March 7, 2018","service d'onco hématologie adultes, hôpital Saint Louis, Paris, France",,"https://ClinicalTrials.gov/show/NCT00689169"
1611,"NCT00688363","Blood Glucose Self Monitoring and HbA1c Effects on Glucose Control",,"Completed","No Results Available","Type 2 Diabetes","Procedure: weekly blood glucose profile|Procedure: three-monthly haemoglobin A1c|Procedure: no blood-glucose self-control","Haemoglobin A1c after one year|a representative blood glucose profile (self monitoring) during the week before the end of the trial|body weight at the end of the trial|serum, triglycerides and cholesterol (total HDL as well as LDL-cholesterol) at the end of the trial|therapy-satisfaction (questionnaire)|changes of the antidiabetic therapy|number of hospitalization as a result of hypoglycaemic episodes|the number of serious hypoglycaemic episodes (hypoglycaemic episodes when the patient needs help from other people)","Deutsche Diabetes Gesellschaft|Bayer","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 4","300","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","KKS 2003-Nauck-01","February 2003","September 2008","December 2008","June 2, 2008",,"August 1, 2011","Diabeteszentrum Bad Lauterberg, Bad Lauterberg, Niedersachsen, Germany|Koch, Peter, Bad Harzburg, Germany|Maxeiner, Stefan, Bad Kreuznach, Germany|Friedrichs, Michael, Bad Lauterberg, Germany|Jödicke, Carmen, Bad Lauterberg, Germany|Mulch-Wiemer, Christa, Bad Nauheim, Germany|Bellmann, Renate, Berlin, Germany|Schoch, Daniela, Berlin, Germany|Warmers, Ulrike, Bitburg, Germany|Leupold, Manfred, Borna, Germany|Kamke, Wolfram, Burg/Sreewald, Germany|Hildebrandt, Rüdiger, Clausthal-Zellerfeld, Germany|Lemmerhirt, Jürgen, Cuxhaven, Germany|Preuß, Uwe, Datteln, Germany|Weller, Ulrich, Dorsten, Germany|Fischer, Harald, Düren, Germany|Krege, Peter, Emsdetten, Germany|Gölz, Stefan, Esslingen, Germany|Wollersen, Karin, Freiburg, Germany|Hendel, Andreas, Grassau, Germany|Pfeiffer, Martha, Gronau, Germany|Jäger, Michael, Höchst, Germany|Müller, Ulrich. A., Jena, Germany|Niemetz, Ingo, Kassel, Germany|Schmitz, Ulrike, Krefeld, Germany|Kourbanova, Zarema, Langenfeld, Germany|Willms, Gerhard, Leverkusen, Germany|Ley, Heinz-Georg, Marl, Germany|Grossmann, J., Mönchengladbach, Germany|Füchtenbusch, Martin, München, Germany|Fueting, Frank, Nassau, Germany|Behnke, Thomas, Neuwied, Germany|Böhme, Rainer, Nordhausen, Germany|Fels, Stefan, Oldenburg, Germany|Klein, Frank, Schenklengsfeld, Germany|Naumann, Rainer, Schöppenstedt, Germany|Rieth-Kunert, Anna, Stade, Germany|Nowack, Kirsten, Torgau, Germany|Schmidt-Reinwald, Astrid, Waldrach, Germany|Bödecker, A.-W., Wiehl, Germany|Oerter, Erika-Maria, Würzburg, Germany",,"https://ClinicalTrials.gov/show/NCT00688363"
1612,"NCT00676065","Long-term Active Surveillance Study for Oral Contraceptives (LASS)",,"Completed","Has Results","Arterial Thromboembolism|Venous Thromboembolism|Breast Cancer",,"Arterial Thromboembolism|Venous Thromboembolism|Breast Cancer","Center for Epidemiology and Health Research, Germany|Bayer","Female","Child, Adult, Older Adult",,"58303","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ZEG2006_03","February 2001","March 2011","December 2011","May 12, 2008","November 19, 2014","November 19, 2014","Center for Epidemiology and Health Research, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT00676065"
1613,"NCT00673361","Pilot Trial of ""Chemo-Switch"" Regimen to Treat Advanced Melanoma",,"Terminated","Has Results","Melanoma","Drug: Concurrent decrescendo biochemotherapy regimen|Drug: Low-dose Temozolomide plus Sorafenib","Progression Free Survival (PFS)|Response Rate as Determined by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria","Duke University|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","9","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","9361|SR05-888","March 2007","January 2009","January 2009","May 7, 2008","April 26, 2013","January 13, 2016",,,"https://ClinicalTrials.gov/show/NCT00673361"
1614,"NCT00672178","Stereotactic Body Radiotherapy (SBRT) and Sorafenib in Patients With Metastatic, Recurrent, or Unresectable Renal Cell Cancer (RCC)",,"Terminated","Has Results","Renal Cell Carcinoma","Radiation: Stereotactic body radiation","Number of Participants With Overall Complete and Partial Response (CR+PR)","Duke University|Bayer","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","1","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00001398","March 2008","September 2009","September 2009","May 6, 2008","December 15, 2010","January 12, 2017","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00672178"
1615,"NCT00667589","Sorafenib-induced Hand- Foot Skin Reaction Treatment",,"Terminated","Has Results","Hand-foot Skin Reaction|Rash","Drug: urea 40% cream|Drug: fluocinonide 0.05% cream|Drug: tazarotene 0.1% cream|Drug: bland emollient cream (Udderly smooth® Udder Cream)","Change in Skindex-16 Total Score Between Baseline and 8 Weeks|Change in Skindex-16 Total Score Between Baseline and 2 Weeks","Northwestern University|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","6","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","STU2149","June 2008","December 2010","December 2010","April 28, 2008","May 27, 2013","June 5, 2013","Northwestern University Feinberg School of Medicine, Department of Dermatology, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT00667589"
1616,"NCT00639262","Combination of Sorafenib and Radiation for Brain Metastases and Primary Brain Tumors",,"Completed","No Results Available","Brain Metastases|Primary Brain Tumors","Drug: Sorafenib|Drug: Temozolomide|Radiation: Radiotherapy","Maximum Tolerated Dose of Sorafenib|Response Rate|Prediction of 1-year Recurrence|Safety and Toxicity of Sorafenib","Sidney Kimmel Cancer Center at Thomas Jefferson University|Bayer|Thomas Jefferson University","All","18 Years and older   (Adult, Older Adult)","Phase 1","35","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","07P.381|2006-58","March 2008","September 2012","September 2012","March 20, 2008",,"October 21, 2016","Thomas Jefferson University, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00639262"
1617,"NCT00633360","The Oral Contraceptive Pill for Premenstrual Worsening of Depression",,"Completed","Has Results","Premenstrual Syndrome|Depression","Drug: Drospirenone and ethinyl estradiol|Drug: Placebo","Percent Change in Luteal Montgomery-Asberg Depression Rating Scale (MADRS)|Percent Change in Daily Record of Severity of Problems (DRSP)","Massachusetts General Hospital|Bayer","Female","18 Years to 45 Years   (Adult)","Not Applicable","32","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2007-P-002057","February 2008","May 2011","May 2011","March 12, 2008","March 20, 2017","March 20, 2017","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00633360"
1618,"NCT00629135","Moxifloxacin Plus Metronidazole Versus Piperacillin/Tazobactam for the Treatment of Patients With Intra-abdominal Abscesses","MEMO","Completed","No Results Available","Abscess, Intra-Abdominal","Drug: Moxifloxacin/Metronidazole or Piperacillin/Tazobactam","Clinical success / failure rate at the Test-of-Cure visit|Clinical + Bacteriological response at End-of-Treatment-visit|Time to discharge from hospital|Course of disease on the basis of clinical and laboratory parameters|safety and tolerability of the study medication|cost effectiveness of treatment regimes","Hannover Medical School|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","180","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MHH-MW-01","November 15, 2005","August 15, 2011","August 15, 2011","March 5, 2008",,"July 24, 2018","Medical School Hannover, Hannover, Germany",,"https://ClinicalTrials.gov/show/NCT00629135"
1619,"NCT00623415","Flupirtine as Oral Treatment in Multiple Sclerosis","FLORIMS","Terminated","No Results Available","Relapsing Remitting Multiple Sclerosis","Drug: Flupirtine|Drug: Placebo","Cumulative number of new T2-hypertensive lesions on cranial magnetic resonance imaging (MRI)|Cerebral atrophy (brain parenchymal fraction)|Number of new and total gadolinium(Gd)-enhancing lesions|Disease progression (measured by Expanded Disability Status (EDSS), Multiple Sclerosis Functional Composite (MSFC))|Retinal nerve fiber layer thickness, assessed by Optical coherence tomography","Charite University, Berlin, Germany|Bayer","All","18 Years to 60 Years   (Adult)","Phase 2","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2006-005262-39","December 2007","November 2012","November 2012","February 26, 2008",,"March 20, 2018","NeuroCure Clinical Research Center, Charité Berlin, Berlin, Germany|Carl-Thiem-Clinic Cottbus, Cottbus, Germany|University of Göttingen, Department of Neurology, Göttingen, Germany|University of Ulm, Department of Neurology, Ulm, Germany",,"https://ClinicalTrials.gov/show/NCT00623415"
1620,"NCT00619242","The Effects of Sorafenib on Molecular Barrett's Esophagus Cancer","Barrett's","Terminated","Has Results","Esophageal Cancer","Drug: sorafenib","Ki-67","University of Chicago|Bayer","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","3","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14374B","June 2006","September 2009","September 2009","February 20, 2008","October 21, 2013","March 12, 2014","University of Chicago, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT00619242"
1621,"NCT00613145","Study of the Pharmacokinetics/Safety of Sorafenib + Capecitabine in Advanced Solid Tumors",,"Completed","No Results Available","Refractory Malignancy","Drug: Capecitabine and Sorafenib","Safety and tolerability of the combination therapy|Evaluation of antitumor activity of the combination therapy","SCRI Development Innovations, LLC|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","32","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCRI REFMAL 122","February 2008","May 2009","May 2010","February 12, 2008",,"February 4, 2013","Tennessee Oncology, PLLC, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00613145"
1622,"NCT00607854","Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007)","ZEVALLO","Completed","No Results Available","Diffuse Large B-Cell Lymphoma|Mantle Cell Lymphoma","Drug: Ibritumomab Tiuxetan (Zevalin)","the treatment-related mortality rate (except if the death is related to the lymphoma exclusively).|The event-free-survival (EFS)(an event is defined as: death from any cause, relapse or progression, need to another treatment except for donor-lymphocytes injection (DLI), patient lost for follow-up)|The rate of hematologic recovery (defined as ANC above 500/mm3 and platelets count above 20.000/mm3 for three consecutive days without stimulating growth support neither platelet transfusion)|Biological post allogenic effects of Zevalin® on the incidence of GVHD and B-cell and T-cell reconstitution|Chimérism","University Hospital, Bordeaux|Bayer","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","31","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHUBX 2007/11","February 2008","February 2011","November 2011","February 6, 2008",,"October 5, 2016","Service d'hématologie - CHU de Besançon, Besançon, France|Service des maladies du sang - Hôpital Haut-Lévêque - avenue de magellan, Bordeaux - Pessac, France|Service d'hématologie - CHU Hôtel Dieu Clermont-Ferrand, Clermont-Ferrand, France|Service de médecine nucléaire - Centre de Lutte contre le Cancer de la Région Auvergne Jean Perrin, Clermont-Ferrand, France|Hôpital Edouard Herriot, Lyon, France|Service d'Oncologie Hématologie, Institut Paoli Calmettes - 232 Bd Ste Marguerite, Marseille, France|Hématologie et Oncologie médicale - CHU Lapeyronie, Montpellier, France|Service d'Hématologie, Hôpital Hôtel Dieu, CHU Nantes - 1 Place Alexis Ricordeau, Nantes, France|Service d'hématologie clinique - Hôpital l'Archet 1, Nice, France|Service d'Hématologie Adultes - Hôpital Necker-Enfants Malade, Paris, France|Pôle hématologie et immunologie clinique - Hôpital Saint-Louis, Paris, France|Département d'hématologie et d'Oncologie - CHRU Hautepierre, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT00607854"
1623,"NCT00606866","MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma","MRI","Completed","No Results Available","Metastatic Renal Cell Carcinoma","Drug: placebo|Drug: Sorafenib","To determine whether a new experimental MRI technique called ""Dynamic Contrast Enhanced MRI"" (DCE-MRI) can determine the best dose of sorafenib|To predict which patients are most likely to experience tumor shrinkage.","University of Chicago|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","57","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","12977A","July 2004","January 2007","June 2008","February 5, 2008",,"March 27, 2014","The University of Chicago, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT00606866"
1624,"NCT00601003","Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma",,"Active, not recruiting","No Results Available","Neuroblastoma|Medulloblastoma","Drug: Nifurtimox|Drug: Cyclophosphamide|Drug: Topotecan","Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Best Radiological Response in Participants using the RECIST criteria|Evaluate the correlation between the pharmacologic serum levels of nifurtimox (in combination with cyclophosphamide and topotecan) with tumor response.|Quality of life and neurocognitive evaluation/questionnaire.|Biology studies to include: genomic analysis of cells pre- and post- treatment, correlation of in vitro response to in vivo response, flow cytometry of tumor burden in bone marrow and biomarker development.","Giselle Sholler|Bayer|Spectrum Health Hospitals","All","up to 21 Years   (Child, Adult)","Phase 2","112","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","V0706","February 2008","May 1, 2020","December 1, 2020","January 25, 2008",,"September 9, 2019","Rady Children's Hospital, San Diego, California, United States|Connecticut Children's Hospital, Hartford, Connecticut, United States|Arnold Palmer Hospital for Children- MD Anderson, Orlando, Florida, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Tufts Medical Center, Boston, Massachusetts, United States|Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States|Children's Hospital and Clinics on Minnesota, Minneapolis, Minnesota, United States|Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States|Cardinal Glennon Children's Medical Center, Saint Louis, Missouri, United States|Levine Children's Hospital, Charlotte, North Carolina, United States|Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Children's Medical Center, Dallas, Texas, United States|Texas Children's Cancer and Hematology Centers, Houston, Texas, United States|Primary Children's Hospital, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT00601003"
1625,"NCT00600015","Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)",,"Completed","Has Results","Non-Small Cell Lung Cancer","Drug: Erlotinib + Sorafenib|Drug: Erlotinib + Placebo","Overall Objective Response Rate (ORR)|Progression Free Survival (PFS)|Disease Control Rate (DCR)|Duration of Response|6-month PFS|Overall Survival (OS)","SCRI Development Innovations, LLC|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","166","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","SCRI LUN 160","February 2008","February 2009","February 2009","January 24, 2008","September 21, 2012","September 21, 2012","Florida Cancer Specialists, Fort Myers, Florida, United States|Northeast Georgia Medical Center, Gainesville, Georgia, United States|Wellstar Cancer Research, Marietta, Georgia, United States|Kansas City Cancer Centers, Overland Park, Kansas, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, United States|Methodist Cancer Center, Omaha, Nebraska, United States|Cancer Care of Western North Carolina, Asheville, North Carolina, United States|Oncology Hematology Care, Cincinnati, Ohio, United States|Mid Ohio Oncology/Hematology, Inc./ The Mark H. Zangmeister Center, Columbus, Ohio, United States|South Carolina Oncology Associates, PA, Columbia, South Carolina, United States|Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States|Family Cancer Center, Collierville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Coastal Bend Cancer Center, Corpus Christi, Texas, United States|Virginia Cancer Institute, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00600015"
1626,"NCT00598507","Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma",,"Completed","Has Results","Melanoma","Drug: ZK-EPO","Response Rate (RR)|Median Progression Free Survival (PFS)|Median Overall Survival (OS)|Occurrence of Attributable Serious Adverse Events (SAEs)","H. Lee Moffitt Cancer Center and Research Institute|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","35","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-14965|ZK219477|108.0701","May 2007","January 2013","January 2013","January 22, 2008","November 15, 2013","December 11, 2013","H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00598507"
1627,"NCT00587847","Campath Maintenance in Chronic Lymphocytic Leukemia",,"Terminated","Has Results","Chronic Lymphocytic Leukemia","Drug: Campath","Time to Progression (Months)|Rate of Infections","Northwell Health|Bayer","All","18 Years and older   (Adult, Older Adult)","Not Applicable","12","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","05.10.030|Berlex Study# 106.0621","August 2005","November 2009","November 2009","January 8, 2008","October 15, 2015","October 15, 2015","Long Island Jewish Medical Center, New Hyde Park, New York, United States",,"https://ClinicalTrials.gov/show/NCT00587847"
1628,"NCT00576056","Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC",,"Terminated","Has Results","Carcinoma, Hepatocellular","Drug: Sorafenib|Drug: TACE","Determine Progression-free Survival in This Patient Population Treated With the Proposed Combination Treatment Modality|Determine the Overall Survival in Patients Treated With This Combination Regimen","University of Pittsburgh|Bayer","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","19","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","07-047","January 2008","March 2010","April 2010","December 18, 2007","December 28, 2016","February 15, 2017","University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00576056"
1629,"NCT00560430","Regulation of Inflammatory Parameters by Telmisartan in Hypertensive Patients","METATEL","Completed","No Results Available","Hypertension|Metabolic Syndrome|Hypertriglyceridemia","Drug: telmisartan|Drug: placebo","change in IL-6|change in fasting lipids;|change in postprandial lipid metabolism|change in inflammatory parameters|change in glucose metabolism","Ludwig-Maximilians - University of Munich|Bayer","All","19 Years to 60 Years   (Adult)","Phase 3","56","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","KPUK0106|EudraCT 2006-003567-31","November 2007","September 2009","October 2009","November 19, 2007",,"July 15, 2010","Center for Cardiovascular Research, University Berlin, Berlin, Germany|Med. Dept. 2, University Munich, Munich, Germany",,"https://ClinicalTrials.gov/show/NCT00560430"
1630,"NCT00557830","Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma",,"Terminated","Has Results","Renal Cell Carcinoma","Drug: Sorafenib Escalated Dose|Drug: Sorafenib Standard Dose","Overall Response Rate (CR + PR) Determined by the Response Evaluation Criteria in Solid Tumors (RECIST) Criteria.|PFS Rate at 9, 13 and 17 Months|Overall Survival Rate|Changes From Baseline in Symptom Burden","Accelerated Community Oncology Research Network|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","12","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AVJARCC0702","January 2008","April 2011","April 2011","November 14, 2007","July 18, 2013","July 18, 2013","Clopton Clinic, Jonesboro, Arkansas, United States|Wilshire Oncology Medical Group, Inc., La Verne, California, United States|Advanced Medical Specialties, Miami, Florida, United States|Northeast Georgia Cancer Care, Athens, Georgia, United States|Peachtree Hematology Oncology Consultants, Atlanta, Georgia, United States|Central Georgia Cancer Care, Macon, Georgia, United States|Northwest Georgia Oncology Centers, Marietta, Georgia, United States|Mid-Illinois Hematology and Oncology Associates, Ltd., Normal, Illinois, United States|Hematology Oncology Centers of the Northern Rockies, Billings, Montana, United States|Gaston Hematology and Oncology, Gastonia, North Carolina, United States|Pacific Oncology, PC, Beaverton, Oregon, United States|The Lancaster Cancer Center, Ltd, Lancaster, Pennsylvania, United States|The West Clinic, Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00557830"
1631,"NCT00555087","Treatment of Erectile Dysfunction in Hypogonadal Men With Testosterone Undecanoate","Nebidolocal","Unknown status","No Results Available","Erectile Dysfunction|Hypogonadotrophic Males","Drug: Testosterone Undecanoate and/or PDE-5","Score higher than or equal to 21 of the erectile dysfunction domain of the IIEF, or response to treatment|and/or an affirmative response to the GAQ will be considered for the analysis","Hospital Santa Fe|Bayer","Male","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","50","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2006/1084","May 2007",,"January 2008","November 7, 2007",,"November 7, 2007","Hospital Santa Fe, Mexico city, D.f., Mexico|Hospital General de Occidente, Guadalajara, Jalisco, Mexico|Hospital General de Occidente, Guadalajara, Jalisco, Mexico|Hospital Universitario de Nuevo León, Monterrey, Nuevo León, Mexico",,"https://ClinicalTrials.gov/show/NCT00555087"
1632,"NCT00549861","Characterization of Irreversible Myocardial Injury in Cardiomyopathies by Contrast-enhanced CMR",,"Completed","No Results Available","Cardiomyopathy, Dilated|Cardiomyopathies, Secondary","Procedure: Cardiac Magnetic Resonance study","Extent and spatial distribution of irreversible tissue injury within the group of dilated forms of cardiomyopathies|Use of Gadobutrol (Gadovist®) identifies small areas of irreversible tissue injury better than standard contrast agents and may be beneficial for diagnosing small fibrotic changes.","Oliver Strohm|Bayer|University of Calgary","All","Child, Adult, Older Adult","Not Applicable","40","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Gadovist001","September 2007","August 2008","August 2008","October 26, 2007",,"October 4, 2011","Stephenson CMR Centre at Foothills Medical Centre, University of Calgary, Calgary, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT00549861"
1633,"NCT00548899","Neoadjuvant Chemotherapy Including Sorafenib in Women With Previously Untreated Primary Breast Cancer","SOFIA","Completed","No Results Available","Breast Cancer","Drug: Nexavar (Sorafenib)","to establish the most feasible regimen of EC-P (P-EC) with sorafenib|Safety of preoperative regimen|Determine clinical response rate|Histopathological axillary nodal status after neoadjuvant therapy|Correlate baseline and change in tumor and serum genetic, gene expression and proteomic patterns with clinical and pathological response|pCR rate at surgery","German Breast Group|Bayer","Female","18 Years and older   (Adult, Older Adult)","Phase 2","36","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GBG 45|2007-000124-41","November 2007","September 2011","December 2011","October 24, 2007",,"March 9, 2015","St. Gertrauden Krankenhaus, Berlin, Germany|Klinikum der J. W. Goethe Universität, Frankfurt am Main, Germany|Henriettenstiftung, Hannover, Germany|Elisabeth Krankenhaus, Kassel, Germany|Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany|Klinikum der Universität zu Köln, Köln, Germany|Klinikum Offenbach, Offenbach, Germany|Klinikum Südstadt, Rostock, Germany|Dr.-Horst-Schmidt-Kliniken GmbH, Wiesbaden, Germany",,"https://ClinicalTrials.gov/show/NCT00548899"
1634,"NCT00548847","Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation",,"Completed","Has Results","Leukemia","Biological: GM-CSF|Biological: Interferon-α-2b","Efficacy of GM-CSF and Pegylated Interferon-alpha 2b When Administered to Patients With AML, ALL, Blast Phase CML, and MDS Relapse After Allogeneic Transplantation, Defined as Progression-free Survival of > 33% at 3 Months|Overall Survival at 6 Months (Evaluate Overall Responses; Perform Lab Experiments to Test Hypothesis That Exposure to Interferon-alpha and GM-CSF Up-regulates Co-stimulatory Molecule Expression on Relapsed Acute Leukemia Cells)","Emory University|Bayer","All","1 Year and older   (Child, Adult, Older Adult)","Phase 2","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00002219|WCI1228-06","January 2007","March 2015","March 2015","October 24, 2007","August 18, 2016","October 26, 2016","Emory University Winship Cancer Institute, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT00548847"
1635,"NCT00548405","Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two","CARE-MS II","Completed","Has Results","Multiple Sclerosis, Relapsing-Remitting","Biological: Alemtuzumab 12 mg|Biological: Alemtuzumab 24 mg|Biological: Interferon beta-1a","Percentage of Participants With Sustained Accumulation of Disability (SAD)|Annualized Relapse Rate|Percentage of Participants Who Were Relapse Free at Year 2|Change From Baseline in Expanded Disability Status Scale (EDSS) Score at Year 2|Change From Baseline in Multiple Sclerosis Functional Composite (MSFC) Score at Year 2|Percent Change From Baseline in Magnetic Resonance Imaging Time Constant 2 (MRI-T2) Hyperintense Lesion Volume at Year 2","Genzyme, a Sanofi Company|Bayer|Sanofi","All","18 Years to 55 Years   (Adult)","Phase 3","840","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","CAMMS32400507|2007-001162-32|CAMMS324,|ISRCTN70702834|ACTRN12608000426381|NTR1469|CARE-MS II","October 2007","September 2011","September 2011","October 24, 2007","January 8, 2015","April 17, 2017","North Central Neurology Associates, P.C., Cullman, Alabama, United States|Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Hope Research Institute, Phoenix, Arizona, United States|Mayo Clinic Arizona, Department of Neurology, Scottsdale, Arizona, United States|Northwest NeuroSpecialists, PLLC, Tucson, Arizona, United States|East Bay Physicians Medical Group/Sutter East Bay Medical Foundation, Berkeley, California, United States|Neurology Center of North Orange County, La Habra, California, United States|Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, California, United States|Neuro-Therapeutics Inc., Pasadena, California, United States|Neuro-Therapeutics, Inc, Pasadena, California, United States|University of California, Davis Medical Center, Sacramento, California, United States|Stanford University School of Medicine, Stanford, California, United States|University of Colorado Hospital, Anschutz Outpatient Pavilioin, Aurora, Colorado, United States|Neurological Consultants, Denver, Colorado, United States|Advanced Neurosciences Research, Fort Collins, Colorado, United States|Yale University, New Haven, Connecticut, United States|George Washington University Medical Faculty Associates, Washington, District of Columbia, United States|University of Florida Neuroscience Institute, Jacksonville, Florida, United States|Neurology Associates, P.A., Maitland, Florida, United States|Neurological Associates, Pompano Beach, Florida, United States|Negroski, Stein, Sutherland and Hanes Neurology, Sarasota, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|University of South Florida, Department of Neurology, Tampa, Florida, United States|Emory University, Department of Neurology, Atlanta, Georgia, United States|Shepherd Center, Inc., Atlanta, Georgia, United States|Idaho Falls Multiple Sclerosis Center, PLLC, Idaho Falls, Idaho, United States|University of Chicago Medical Center, Department of Neurology, Chicago, Illinois, United States|Consultants in Neurology, Ltd, Northbrook, Illinois, United States|Fort Wayne Neurological Center, Fort Wayne, Indiana, United States|Indiana University School of Medicine, Department of Neurology, Indianapolis, Indiana, United States|Josephson Wallack Munshower Neurology P.C., Indianapolis, Indiana, United States|Iowa Health Physicians, Des Moines, Iowa, United States|Ruan Neurology Clinic and Research Center, Des Moines, Iowa, United States|University of Kansas Medical Center, Department of Neurology, Kansas City, Kansas, United States|MidAmerica Neuroscience Institute, Lenexa, Kansas, United States|Associates in Neurology, PSC, Lexington, Kentucky, United States|University of Louisville Research Foundation, Louisville, Kentucky, United States|Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States|Caritas St. Elizabeth's Medical Center, Boston, Massachusetts, United States|Partners Multiple Sclerosis Center/Brigham and Women's Hospital, Boston, Massachusetts, United States|Springfield Neurology Associates, LLC, Springfield, Massachusetts, United States|UMass Memorial Medical Center, Worcester, Massachusetts, United States|University of Michigan Department of Neurology, Ann Arbor, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Wayne State University, School of Medicine, Department of Neurology, Detroit, Michigan, United States|Spectrum Health Medical Group, Neurology (Previously known as Michigan Medical P.C., Neurology), Grand Rapids, Michigan, United States|Michigan Neurology Associates, P.C., St. Clair Shores, Michigan, United States|Northern Michigan Neurology, Traverse City, Michigan, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Neurology Consultants of Kansas City, Inc., Kansas City, Missouri, United States|Montana Neurobehavioral Specialists, Missoula, Montana, United States|University of Nevada School of Medicine, Las Vegas, Nevada, United States|Renown Institute for Neurosciences / Renown regional Medical Center, Reno, Nevada, United States|Dartmouth-Hitchcock Medical Center, Norris Cotton Cancer Center, Lebanon, New Hampshire, United States|MS Center at Holy Name Hospital, Teaneck, New Jersey, United States|University of New Mexico, Health Sciences Center, MS Specialty Clinic, Alburquerque, New Mexico, United States|Empire Neurology, PC, Latham, New York, United States|Winthrop University Hospital, Clinical Trials Center, Mineola, New York, United States|Mount Sinai School of Medicine, Corinne Goldsmith Dickinson Center for Multiple Sclerosis, New York, New York, United States|Comprehensive Multiple Sclerosis Care Center at South Shore Neurologic Associates, P.C., Patchogue, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|SUNY Upstate Medical University, Department of Neurology, Syracuse, New York, United States|University of North Carolina-Chapel Hill, Department of Neurology, Chapel Hill, North Carolina, United States|Wake Forest University Health Science, Department of Neurology, Winston-Salem, North Carolina, United States|Cleveland Clinic Foundation, Mellen Center, Cleveland, Ohio, United States|Neurology Specialists, Inc., Dayton, Ohio, United States|Oak Clinic for Multiple Sclerosis, Uniontown, Ohio, United States|MS Center of Oklahoma, Oklahoma City, Oklahoma, United States|Lehigh Valley Hospital, Neuroscience and Pain Research, Allentown, Pennsylvania, United States|Northshore Clinical Associates, Erie, Pennsylvania, United States|University of Pittsburgh, Kaufmann Medical Building, Pittsburgh, Pennsylvania, United States|The Neurology Foundation, Inc., Providence, Rhode Island, United States|Neurology Clinic, P.C., Cordova, Tennessee, United States|Advanced Neurosciences Institute, Franklin, Tennessee, United States|Biomedical Research Alliance of NY, LLC, Franklin, Tennessee, United States|Hope Neurology PC, Knoxville, Tennessee, United States|Vanderbilt Multiple Sclerosis Center, Nashville, Tennessee, United States|Clinical Center for Multiple Sclerosis, Dallas, Texas, United States|Central Texas Neurology, Round Rock, Texas, United States|Integra Clinical Research, San Antonio, Texas, United States|Neurology Center of San Antonio, San Antonio, Texas, United States|MS Center of Greater Washington, P.C., Vienna, Virginia, United States|Swedish Neuroscience Institute, Seattle, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Rockwood Clinical Research Center, Spokane, Washington, United States|DIABAID, Buenos Aires, Argentina|Westmead Hospital, Westmead, New South Wales, Australia|The Wesley Research Institute, Auchenflower, Queensland, Australia|Griffith School of Medicine, Gold Coast Campus, Griffith University, Southport, Queensland, Australia|Clinical Cognitive Research Unit/Clinical Trials, The Queen Elizabeth Hospital, Neurology Department, Woodville South, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|St. Vincent's Hospital, MS Education & Research, Department of Clinical Neurosciences, Fitzroy, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Royal Melbourne Hospital, Department of Neurology, Parkville, Victoria, Australia|Concord Repatriation General Hospital, Neurosciences Department, Concord, Australia|Southern Neurology, Kogarah, Australia|Liverpool Hospital, Neurology Department, Liverpool, Australia|AKH Wien, Universitätsklinikum für Neurologie, Wien, Austria|Cliniques Universitaires Saint-Luc, Neurology, Brussel, Belgium|CHU Ourthe Amblève, Neurology, Esneux, Belgium|University Hospital Leuven, Campus Gasthuisberg, Neurology, Leuven, Belgium|Hospital da Restauracao, Recife, PE, Brazil|Hospital Sao Lucas PUC-RS, Porto Alegre, RS, Brazil|Hospital de Clínicas USP, Sao Paulo, Brazil|Irmandade da Santa Casa de Misericordia de Sao Paulo, Sao Paulo, Brazil|UBC Hospital, Vancouver, British Columbia, Canada|Multiple Sclerosis Clinic, Connell 7, Kingston General Hospital, Kingston, Ontario, Canada|London Health Sciences Centre- University Hospital, London, Ontario, Canada|The Ottawa Hospital, General Campus, Ottawa, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Centre de Sante et de Services Sociaux de Gatineau-Hull Hospital, Gatineau, Quebec, Canada|Clinique Neuro rive-sud, Recherche sepmus inc, Greenfield park, Quebec, Canada|Hospital Maisonneuve-Rosemont, Montreal, Quebec, Canada|Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada|Clinical Hospital Centre Rijeka, Clinic for Neurology, Rijeka, Croatia|General Hospital Varazdin, Department of neurology, Varazdin, Croatia|Clinical Hospital Centre Zagreb, Zagreb, Croatia|Clinical Hospital Sestre Milosrdnice, Zagreb, Croatia|General Hospital "" Sveti Duh"", Department of neurology, Zagreb, Croatia|MS Center, Department of Neurology, Hradec Kralove, Czech Republic|St. Anne's University Hospital Brno, Pekarska, Czech Republic|Department of Neurology 1st Faculty of Medicine and General Teaching Hospital, MS Center, Praha 2, Czech Republic|Krajska zdravotni a.s. - Hospital Teplice, Teplice, Czech Republic|Århus Universitetshospital, Scleroseklinikken, Århus Sygehus, Aarhus, Denmark|Scleroseklinikken, Rigshospitalet, København, Denmark|Odense University Hospital, Odense, Denmark|CHU Clermont-Ferrand, Hôpital Gabriel Montpied, Clermont-Ferrand, France|Hôpital General, Service de Neurologie, Dijon Cedex, France|Hospital Roger Salengro, Lille Cedex, France|Hôpital Pitié Salpétrière, Service de Neurologie, Paris, France|Sevice de Neurologie, Rennes Cedex, France|Hôpital Civil, Departement de Neurologie, Strasbourg Cedex, France|Krankenhaus Hohe Warte, Betriebsstätte der Bayreuth, Bayreuth, Germany|Judisches Krankenhaus Berlin, Berlin, Germany|Neurologisches Fachzentrum Berlin, Berlin, Germany|Neurologische Universitätsklinik Bonn, Bonn, Germany|Multiple Sklerose Zentrum am, Zentrum für klinische Neurowissenschaften, Neurologische Uniklinik Dresden, Dresden, Germany|Asklepios Klinic Barmbek, Hamburg, Germany|Medizinische Hochshule Hannover, Hannover, Germany|Oberhavelkliniken Hennigsdorf, Hennigsdorf, Germany|Klinikum Ingolstadt, Neurologische Klinik, Ingolstadt, Germany|Klinikum Rechts der Isar, Klinik für Neurologie, Muenchen, Germany|Klinik und Poliklinik fur Neurologie der Universitat Rockstock, Rostock, Germany|Universitatsklinik Ulm, Ulm, Germany|Fachkrankenhaus Hubertusburg, Wermsdorf, Germany|Hadassah Medical Center Ein Karem, Jerusalem, Israel|Tel Aviv Sourasky Medical Center, Department of Neurology, Tel Aviv, Israel|Sheba Medical Centre, Tel Hashomer, Israel|Ospedale Binaghi - Centro Sclerosi Multipla, Cagliari, Italy|Ospedale S. Antonio Abate di Gallarate, Gallarate, Italy|Università di Genova Dipartimento di Neuroscienze Oftalmologia e Genetica, Genova, Italy|Ospedale Civile di Brescia c/o Ospedale Richiedei, Centro di riferimento per la Sclerosi Multiple, Montichiari, Italy|Ospedale San Luigi di Orbassano, Orbassano, Italy|Azienda Ospedaliera Sant'Andrea Neurologia, Roma, Italy|Hospital Medica Sur CIF-BIOTEC, Delegacion, Tlalpan, Mexico|Unidad de Investigación en Salud de Chihuahua, S.C., Chihuahua, Mexico|Hospital Angeles del Pedregal; Camino a Santa Teresa, Mexico City, Mexico|Jeroen Bosch Ziekenhuis, Hertogenbosch, Netherlands|Orbis Medisch Centrum, Department of Neurology, Sittard, Netherlands|Independent Public Healthcare Facility, Norbert Barlicki University Hospital No. 1 of the Medical University of Lodz, Lodz, Poland|Independent Public Teaching Hospital No. 4 in Lublin, Lublin, Poland|Heliodor Swiecicki Teaching Hospital of the Poznan, University of Medical Sciences, Poznan, Poland|Research Medical Complex ""Your Health"" Ltd, Kazan, Russian Federation|Institution of the Russian Academy of Medical Sciences, ""Neurology Scientific Center under RAMS"", Moscow, Russian Federation|Moscow State Medical Institution City Clinical Hospital #11, Moscow City Center for Multiple Sclerosis, Moscow, Russian Federation|Moscow State Public Medical Institution, City Clinical Hospital #11, Moscow, Russian Federation|Municipal Treatment and Prevention Institution, ""City Hospital #33"", Nizhniy Novgorod, Russian Federation|Federal State Institution: Siberian District Medical Center, Novosibirsk, Russian Federation|State Medical Institution, ""Samara Regional Clinical Hospital n.a. M.I. Kalinin"", Samara, Russian Federation|Institution of the Russian Academy of Sciences, ""Institute of the Human Brain n.a. N.P. Bekhtereva within the Russian Academy of Sciences"", St. Petersburg, Russian Federation|St. Petersburg Pavlov State Medical University, Department of Neurology and Neurosurgery with a Clinic, St. Petersburg, Russian Federation|St.Petersburg State Medical Institution, ""City Multispecialty Hospital #2"", St. Petersburg, Russian Federation|St.Petersburg State Medical Institution, ""Nikolayevskaya Hospital"", St. Petersburg, Russian Federation|Clinic of Neurology, Clinical Centre of Serbia, Belgrade, Serbia|Military Medical Academy, Belgrade, Serbia|Clinical Centre of Kragujevac, Kragujevac, Serbia|Clinical Centre Vojvodina Institute of Neurology, Novi Sad, Serbia|Servicio de Neurología Hospital Vall d'Hebron Paseo de Vall d'Hebron, Barcelona, Spain|Servicio de Neurología Hospital Clínico San Carlos, Madrid, Spain|Servicio de Neurología Hospital Carlos Haya, Malaga, Spain|Servicio de Neurología Hospital Virgen de la Macarena, Sevilla, Spain|Sahlgrenska University Hospital, Neurologkliniken, Gothenburg, Sweden|Norrlands Universitets sjukhus, Umea, Sweden|Institute of Neurology, Psychiatry and Narcology under the Academy of Medical Sciences of Ukraine, Kharkov, Ukraine|Kyiv Municipal Clinical Hospital #4, Department of Demyelinating Diseases of the Nervous System, Kyiv, Ukraine|Danylo Halytsky Lviv National Medical University, Department of Neurology, Lviv, Ukraine|Department Of Neurosciences, Addenbrookes Hospital, Cambridge, England, United Kingdom|Centre for Neuroscience & Trauma, Blizard Institute of Cell and Molecular Science Barts and The London School of Medicine and Dentistry, London, England, United Kingdom|Frenchay Hospital, Bristol, United Kingdom|Salford Royal NHS Foundation Trust, Clinical Trials Unit, Salford, United Kingdom|Department of Neurology Glossop Road, Royal Hallamshire Hospital, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00548405"
1636,"NCT00544817","Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme",,"Completed","Has Results","Glioblastoma Multiforme","Radiation: Radiation Therapy|Drug: Temozolomide|Drug: Sorafenib","Progression-free Survival|Overall Survival|Objective Response","SCRI Development Innovations, LLC|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","47","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCRI CNS 09","April 2007","June 2008","August 2010","October 16, 2007","December 13, 2012","September 1, 2016","Florida Cancer Specialists, Fort Myers, Florida, United States|Northeast Georgia Medical Center, Gainesville, Georgia, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, United States|Methodist Cancer Center, Omaha, Nebraska, United States|Oncology Hematology Care, Cincinnati, Ohio, United States|Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States|Tennessee Oncology, Nashville, Tennessee, United States|South Texas Oncology and Hematology, San Antonio, Texas, United States|Virginia Cancer Institute, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00544817"
1637,"NCT00544167","Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer",,"Completed","Has Results","Breast Cancer","Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Paclitaxel|Drug: Sorafenib","The Safety and Tolerability of Protocol Treatment, Defined as the Percentage of Patients Experiencing Severe or Life-threatening Side Effects Per CTCAE Version 3.0.","SCRI Development Innovations, LLC|Bayer","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","45","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCRI BRE 112","May 2007","January 2008","April 2011","October 16, 2007","January 25, 2013","April 1, 2013","Integrated Community Oncology Network, Jacksonville, Florida, United States|Florida Hospital Cancer Institute, Orlando, Florida, United States|Consultants in Blood Disorders and Cancer, Louisville, Kentucky, United States|Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, United States|Methodist Cancer Center, Omaha, Nebraska, United States|Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Peninsula Cancer Institute, Newport News, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00544167"
1638,"NCT00543335","Sorafenib and Thoracic Radiation for Patients With Non-Small Cell Lung Cancer",,"Terminated","No Results Available","Lung Cancer","Drug: Sorafenib|Procedure: Radiation Therapy","Maximal tolerated dose (MTD) of sorafenib concurrent with thoracic radiation for poor prognosis NSCLC (phase I)|Efficacy of combination assessed by tumor response and local progression failure (phase II)","M.D. Anderson Cancer Center|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2007-0352|NCI-2010-00795","January 25, 2008","January 2011","January 2011","October 12, 2007",,"November 15, 2018","UT MD . Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00543335"
1639,"NCT00542971","Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)",,"Completed","Has Results","AML|Acute Myeloid Leukemia|Myelodysplastic Disorders","Drug: Idarubicin|Drug: Sorafenib|Drug: Ara-C","Maximum Tolerated Dose (MTD)|Number of Participants With Complete Response","M.D. Anderson Cancer Center|Bayer","All","15 Years to 60 Years   (Child, Adult)","Phase 1|Phase 2","78","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2006-0977","October 2007","May 2011","May 2011","October 12, 2007","July 13, 2012","August 23, 2018","The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00542971"
1640,"NCT00536575","Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients",,"Completed","Has Results","Multiple Myeloma","Drug: Bortezomib|Drug: Sorafenib","Objective Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment","SCRI Development Innovations, LLC|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","13","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCRI MM 14","November 2007","February 2010","August 2010","September 28, 2007","February 27, 2013","February 27, 2013","Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00536575"
1641,"NCT00533923","Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders",,"Completed","No Results Available","AML|ALL|CLL|Myelodysplastic Syndrome|Non-Hodgkin's Lymphoma|Hodgkin's Lymphoma|Multiple Myeloma|Aplastic Anemia|Myeloproliferative Disorder","Drug: Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF","Primary objective of study is to determine the safety of non-myeloablative allogenic stem cell transplantation from matched unrelated donors in patients with hematologic malignancies with a focus on the incidence of treatment-related mortality.|Secondary clinical endpoints includes; incidence of graft failure or rejection; incidence and severity of acute and chronic GVHD; tumor response, and long-term overall and disease-free survival.","Beth Israel Deaconess Medical Center|Bayer","All","up to 65 Years   (Child, Adult, Older Adult)","Phase 2","25","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2002P000219","December 2002","January 2007","January 2007","September 24, 2007",,"July 18, 2016","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00533923"
1642,"NCT00533585","BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)",,"Completed","No Results Available","Lung Cancer","Drug: BAY 43-9006|Drug: Paclitaxel|Drug: Carboplatin|Drug: Bevacizumab","Maximum Tolerated Dose (MTD) of BAY 43-9006 (sorafenib) and Bevacizumab in Combination with Carboplatin and Paclitaxel","M.D. Anderson Cancer Center|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","23","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2005-0818|NCI-2012-01647","May 2006","January 2016","January 2016","September 21, 2007",,"February 10, 2016","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00533585"
1643,"NCT00530348","Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One","CARE-MS I","Completed","Has Results","Multiple Sclerosis, Relapsing-Remitting","Biological: Alemtuzumab|Biological: Interferon beta-1a","Percentage of Participants With Sustained Accumulation of Disability (SAD)|Annualized Relapse Rate|Percentage of Participants Who Were Relapse Free at Year 2|Change From Baseline in Expanded Disability Status Scale (EDSS) Score at Year 2|Change From Baseline in Multiple Sclerosis Functional Composite (MSFC) Score at Year 2|Percent Change From Baseline in Magnetic Resonance Imaging Time Constant 2 (MRI-T2) Hyperintense Lesion Volume at Year 2","Genzyme, a Sanofi Company|Bayer|Sanofi","All","18 Years to 50 Years   (Adult)","Phase 3","581","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","CAMMS323|ISRCTN21534255|ACTRN12608000435381|CARE-MS I|2007-001161-14","August 2007","April 2011","April 2011","September 17, 2007","November 24, 2014","November 24, 2014","North Central Neurology Associates, P.C., Cullman, Alabama, United States|Barrow Neurological Institute, St. Joseph's Hospital & Medical Center, Phoenix, Arizona, United States|Mayo Clinic Arizona, Scottsdale, Arizona, United States|Northwest NeuroSpecialists, PLLC, Tucson, Arizona, United States|Advanced Neurosciences Research, Fort Collins, Colorado, United States|Neurological Associates, Pompano Beach, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|Idaho Falls Multiple Sclerosis Center, PLLC, Idaho Falls, Idaho, United States|Consultants in Neurology, Ltd., Northbrook, Illinois, United States|Fort Wayne Neurological Center, Fort Wayne, Indiana, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|MidAmerican Neuroscience Institute, Lenexa, Kansas, United States|Associates in Neurology, PSC, Lexington, Kentucky, United States|University of Louisville Research Foundation, Louisville, Kentucky, United States|Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States|UMass Memorial Medical Center, Worcester, Massachusetts, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Wayne State University, Detroit, Michigan, United States|University of Nevada School of Medicine, Las Vegas, Nevada, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|University of New Mexico, Health Sciences Center, MS Specialty Clinic, Albuquerque, New Mexico, United States|Empire Neurology, Latham, New York, United States|Comprehensive Multiple Sclerosis Care Center at South Shore Neurologic Associates, P.C., Patchogue, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Carolinas Medical Center (CMC), Neurosciences & Spine Institute (NSSI), Charlotte, North Carolina, United States|The Ohio State University Medical Center, Multiple Sclerosis Center, Columbus, Ohio, United States|Oak Clinic for Multiple Sclerosis, Uniontown, Ohio, United States|MS Center of Oklahoma, Oklahoma City, Oklahoma, United States|Lehigh Valley Hospital Neurosciences and Pain Research, Allentown, Pennsylvania, United States|Advanced Neurosciences Institute, Franklin, Tennessee, United States|Biomedical Research Alliance of NY, LLC, Franklin, Tennessee, United States|Hope Neurology PC, Knoxville, Tennessee, United States|Baylor College of Medicine, Maxine Mesinger MS Clinic, Houston, Texas, United States|Central Texas Neurology, Round Rock, Texas, United States|Integra Clinical Research, San Antonio, Texas, United States|Neurology Center of San Antonio, San Antonio, Texas, United States|DIABAID, Buenos Aires, Argentina|The Wesley Research Institute, Auchenflower, Queensland, Australia|Griffith University School of Medicine, Southport, Queensland, Australia|The Queen Elizabeth Hospital, Woodville South, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|St Vincent's Hospital, Fitzroy, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Royal Melbourne Hospital, Department of Neurology, Ward 4 East, Parkville, Victoria, Australia|Concord Repatriation General Hospital, Concord, Australia|Westmead Hospital, Westmead, Australia|Hospital da Restauracao, Av Governador Agamenon Magalhaes, Recife, Pernambuco, Brazil|Hospital Sao Lucas PUC-RS, Porto Alegre, RS, Brazil|Hospital de Clínicas USP, Sao Paulo, SP, Brazil|University of Calgary and Foothills Medical Cenre, Calgary, Alberta, Canada|UBC Hospital, Vancouver, British Columbia, Canada|The Ottawa Hospital, General Campus, Ottawa, Ontario, Canada|Clinique Nuero-outaouais, Gatineau, Quebec, Canada|Clinique Neuro rive-sud, Recherche Sepmus, Inc., Greenfield park, Quebec, Canada|Clinical Hospital Centre Rijeka, Rijeka, Croatia|General Hospital Varazdin, Varazdin, Croatia|Clinical Hospital Centre ""Sestre Milosrdnice"", Zagreb, Croatia|Clinical Hospital Centre Zagreb, Zagreb, Croatia|General Hospital ""Sveti Duh"", Zagreb, Croatia|Department of Neurology, 1st Faculty of Medicine and General Teaching Hospital, Praha 2, Czech Republic|Krajska zdravotni a.s., Hospital Teplice, Teplice, Czech Republic|Hopital Purpan, Toulouse, France|Judisches Krankenhaus Berlin, Berlin, Germany|Universitätsklinik Carl Gustav Carus Dresden, Dresden, Germany|Klinikum der Goethe Universität Frankfurt, Frankfurt, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Oberhavelkliniken Hennigsdorf, Hennigsdorf, Germany|Asklepios Klinikum Brandenburg, Teupitz, Germany|Hospital Angeles del Pedregal, Camino de Santa Teresa, Mexico City, Mexico|Hospital Medica Sur CIF-BIOTEC, Mexico City, Mexico|Clinical Neurology Centre Sp. z o.o. (Ltd), Cracow, Poland|Independent Public Healthcare Facility, Norbert Barlicki University Hospital No. 1 of the Medical University of Lodz, Lodz, Poland|Independent Public Teaching Hospital No. 4 in Lublin, Lublin, Poland|Heliodor Swiecicki Teaching Hospital of the Poznan University of Medical Sciences, Poznan, Poland|Research Medical Complex ""Your Health"" Ltd, Kazan, Russian Federation|Moscow City Hospital #11, Moscow, Russian Federation|Moscow State Medical Institution City Clinical Hospital #11, Moscow, Russian Federation|Scientific Neurology Center RAMS, Moscow, Russian Federation|Municipal City Hospital #33, Nizhniy Novgorod, Russian Federation|Federal State Institution Siberian Rettitorial Medical Center under Federal Medical-Biological Agency of Russia, Novosibirsk, Russian Federation|City Clinical Hospital #2, Pyatigorsk, Russian Federation|Samara Regional Clinical Hospital n.a. Kalinin, Samara, Russian Federation|Institute of Human Brain RAS, St. Petersburg, Russian Federation|Nikolaevskaya Hospital, St. Petersburg, Russian Federation|St. Petersburg Pavlov State Medical University, St. Petersburg, Russian Federation|State Medical Institution: Republican Clinical Hospital n.a. G.G. Kuvatov, Ufa, Russian Federation|Clinical Centre Serbia, Institute for Neurology, Belgrade, Serbia|Military Medical Academy, Belgrade, Serbia|Clinical centre Kragujevac, Kragujevac, Serbia|Clinical Center Nis, Clinic for neurology, Nis, Serbia|Clinical Centre of Vojvodina, Clinic for neurology, Novi Sad, Serbia|Sahlgrenska University Hospital, Goteborg, Sweden|Chernihiv Regional Hospital, Chernihiv, Ukraine|Institute of Neurology, Psychiatry and Narcology under the Academy of Medical Sciences of Ukraine, Department of Neuroinfection and Multiple Sclerosis, Kharkiv, Ukraine|Hospoital of the Directorate of the Medical Corps within the Ukrainian Security Service, Neurology Department, Kyiv, Ukraine|Kyiv Municipal Clinical Hospital #4, Kyiv, Ukraine|Danylo Halytsky Lviv National Medical University, Lviv, Ukraine|Department Of Neurosciences, Addenbrookes Hospital, Cambridge, England, United Kingdom|Centre for Neuroscience & Trauma, Blizard Institute of Cell and Molecular Science, Barts and The London School of Medicine and Dentistry, London, England, United Kingdom|University Hospital of Wales, Cardiff, Wales, United Kingdom|Royal Hallamshire Hospital, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00530348"
1644,"NCT00527423","Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMD",,"Completed","Has Results","Macular Degeneration","Drug: VEGF Trap Eye","Number of Participants With Adverse Events (AE)|Frequency (Number of Injections)|Mean Change From Baseline of Original Study in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score of Study Eye - Observed Values","Regeneron Pharmaceuticals|Bayer","All","50 Years and older   (Adult, Older Adult)","Phase 2","157","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","VGFT-OD-0702","August 2007","October 2011","October 2011","September 10, 2007","June 12, 2013","June 12, 2013","Peoria, Arizona, United States|Phoenix, Arizona, United States|Tucson, Arizona, United States|Beverly Hills, California, United States|Loma Linda, California, United States|Palm Springs, California, United States|Pasadena, California, United States|Poway, California, United States|Westlake Village, California, United States|Ft. Myers, Florida, United States|Stuart, Florida, United States|Winter Haven, Florida, United States|Augusta, Georgia, United States|Glenview, Illinois, United States|Indianapolis, Indiana, United States|Baltimore, Maryland, United States|Hagerstown, Maryland, United States|Boston, Massachusetts, United States|West Springfield, Massachusetts, United States|Toms River, New Jersey, United States|Lynbrook, New York, United States|Charlotte, North Carolina, United States|Oklahoma City, Oklahoma, United States|Portland, Oregon, United States|W. Columbia, South Carolina, United States|Rapid City, South Dakota, United States|Nashville, Tennessee, United States|Austin, Texas, United States|Fort Worth, Texas, United States|Houston, Texas, United States|McAllen, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT00527423"
1645,"NCT00525603","CFAR Study in Patients With Chronic Lymphocytic Leukemia",,"Completed","Has Results","Leukemia|Chronic Lymphocytic Leukemia","Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Alemtuzumab|Drug: Rituximab","Overall Participant Response","M.D. Anderson Cancer Center|Bayer","All","up to 69 Years   (Child, Adult, Older Adult)","Phase 2","60","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2005-0269","June 2005","July 2011","July 2011","September 6, 2007","March 4, 2013","March 4, 2013","The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00525603"
1646,"NCT00525161","Study Adding Multikinase Inhibitor Sorafenib to Existing Endocrine Therapy in Patients With Advanced Breast Cancer",,"Terminated","Has Results","Breast Cancer","Drug: sorafenib","Response Rate|Time to Progression|Clinical Benefit Rate","Suleiman Massarweh|Bayer|University of Kentucky","Female","18 Years and older   (Adult, Older Adult)","Phase 2","11","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","07-BRE-41-BP","October 2007","January 2013","January 2015","September 5, 2007","January 13, 2015","January 26, 2015","University of Kentucky, Lexington, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT00525161"
1647,"NCT00523614","Use of Oral Contraceptives (OCs) Containing Dienogest and Risk of Venous Thromboembolism",,"Completed","Has Results","Venous Thromboembolism",,"Risk of Venous Thromboembolism (VTE) Between Women Who Use Dienogest/Ethinylestradiol (DNG/EE) and Women Who Use Other Low-dose Combined Oral Contraceptives (COC)","Center for Epidemiology and Health Research, Germany|Bayer","Female","15 Years to 49 Years   (Child, Adult)",,"3400","Other|Industry","Observational","Observational Model: Case Control","ZEG2007_02","July 2007",,"June 2008","August 31, 2007","December 2, 2009","March 23, 2010","Center for Epidemilogy and Health Research, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT00523614"
1648,"NCT00510289","Sorafenib in Myelodysplastic Syndrome",,"Terminated","Has Results","Myelodysplastic Syndromes|Leukemia, Myelomonocytic, Chronic","Drug: Sorafenib","Number of Subjects Achieving Hematological Response|Number of Subjects Requiring Dose Reductions|Time to Progression|Overall Survival|Change in Microvessel Density","Duke University|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","19","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00008151","July 2006","July 2011","July 2011","August 1, 2007","February 11, 2014","April 19, 2016","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00510289"
1649,"NCT00510250","A Phase I/II Study of Cisplatin and Radiation in Combination With Sorafenib in Cervical Cancer",,"Completed","No Results Available","Cancer of the Cervix","Drug: Sorafenib|Drug: Cisplatin|Procedure: Radiation","Determine the biologic activity of sorafenib in cervix cancer.|Determine the acute and late toxicity, and effect of sorafenib in combination with radiation and chemotherapy on the disease-free survival of patients with high-risk cervix cancer.","University Health Network, Toronto|Bayer","Female","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","13","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DDPDRO-002|Bayer Protocol# 12138","June 2007","September 2010","July 2015","August 1, 2007",,"July 27, 2015","Princess Margaret Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00510250"
1650,"NCT00509795","Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)","VIEW1","Completed","Has Results","Macular Degeneration","Biological: ranibizumab|Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)","Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF)|Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - LOCF|Percentage of Patients Who Gained at Least 15 Letters of Vision in the ETDRS Letter Score in the Study Eye at Week 52 - LOCF.|Mean Change From Baseline in National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25) Total Score at Week 52 - LOCF|Mean Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 52 (LOCF)","Regeneron Pharmaceuticals|Bayer","All","50 Years and older   (Adult, Older Adult)","Phase 3","1217","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VGFT-OD-0605","August 2007","September 2010","July 2011","August 1, 2007","April 16, 2012","December 28, 2012","Birmingham, Alabama, United States|Birmingham, Alabama, United States|Phoenix, Arizona, United States|Phoenix, Arizona, United States|Tucson, Arizona, United States|Tucson, Arizona, United States|Beverly Hills, California, United States|Campbell, California, United States|Fullerton, California, United States|Glendale, California, United States|Irvine, California, United States|La Jolla, California, United States|Loma Linda, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|Menlo Park, California, United States|Mountain View, California, United States|Oakland, California, United States|Palm Springs, California, United States|Pasadena, California, United States|Poway, California, United States|Sacramento, California, United States|San Diego, California, United States|San Francisco, California, United States|Santa Ana, California, United States|Torrance, California, United States|Ventura, California, United States|Westlake Village, California, United States|Yorba Linda, California, United States|Aurora, Colorado, United States|Denver, Colorado, United States|Denver, Colorado, United States|Bridgeport, Connecticut, United States|Hamden, Connecticut, United States|New Haven, Connecticut, United States|New London, Connecticut, United States|Altamonte Springs, Florida, United States|Boynton Beach, Florida, United States|Fort Myers, Florida, United States|Ft. Lauderdale, Florida, United States|Ft. Myers, Florida, United States|Gainesville, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Mount Dora, Florida, United States|Orlando, Florida, United States|Orlando, Florida, United States|Oscala, Florida, United States|Palm Beach Gardens, Florida, United States|Pensacola, Florida, United States|Sarasota, Florida, United States|Stuart, Florida, United States|Tampa, Florida, United States|Winter Haven, Florida, United States|Augusta, Georgia, United States|Aiea, Hawaii, United States|Honolulu, Hawaii, United States|Oak Brook, Illinois, United States|Fort Wayne, Indiana, United States|Indianapolis, Indiana, United States|Indianapolis, Indiana, United States|Indianapolis, Indiana, United States|New Albany, Indiana, United States|Iowa City, Iowa, United States|Wichita, Kansas, United States|Louisville, Kentucky, United States|Louisville, Kentucky, United States|Paducah, Kentucky, United States|New Orleans, Louisiana, United States|New Orleans, Louisiana, United States|Shreveport, Louisiana, United States|Bangor, Maine, United States|Portland, Maine, United States|Baltimore, Maryland, United States|Baltimore, Maryland, United States|Chevy Chase, Maryland, United States|Hagerstown, Maryland, United States|Towson, Maryland, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Peabody, Massachusetts, United States|Ann Arbor, Michigan, United States|Battle Creek, Michigan, United States|Detroit, Michigan, United States|Grand Rapids, Michigan, United States|Jackson, Michigan, United States|Royal Oak, Michigan, United States|Southfield, Michigan, United States|West Bloomfield, Michigan, United States|Edina, Minnesota, United States|Minneapolis, Minnesota, United States|Rochester, Minnesota, United States|Florissant, Missouri, United States|Kansas City, Missouri, United States|Kansas City, Missouri, United States|Springfield, Missouri, United States|St. Louis, Missouri, United States|Missoula, Montana, United States|Lincoln, Nebraska, United States|Omaha, Nebraska, United States|Las Vegas, Nevada, United States|Lawrenceville, New Jersey, United States|New Brunswick, New Jersey, United States|Northfield, New Jersey, United States|Teaneck, New Jersey, United States|Toms River, New Jersey, United States|Albuquerque, New Mexico, United States|Albany, New York, United States|Brooklyn, New York, United States|Lynbrook, New York, United States|New York, New York, United States|New York, New York, United States|New York, New York, United States|Poughkeepsie, New York, United States|Rochester, New York, United States|Rochester, New York, United States|Slingerlands, New York, United States|Syracuse, New York, United States|Asheville, North Carolina, United States|Charlotte, North Carolina, United States|Raleigh, North Carolina, United States|Southern Pines, North Carolina, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Toledo, Ohio, United States|Oklahoma City, Oklahoma, United States|Ashland, Oregon, United States|Portland, Oregon, United States|Portland, Oregon, United States|Salem, Oregon, United States|Kingston, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pittsberg, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|West Mifflin, Pennsylvania, United States|Wyomissing, Pennsylvania, United States|Providence, Rhode Island, United States|Charleston, South Carolina, United States|Columbia, South Carolina, United States|Greenville, South Carolina, United States|West Columbia, South Carolina, United States|Rapid City, South Dakota, United States|Memphis, Tennessee, United States|Memphis, Tennessee, United States|Nashville, Tennessee, United States|Abilene, Texas, United States|Austin, Texas, United States|Corpus Cristi, Texas, United States|Dallas, Texas, United States|DeSoto, Texas, United States|Ft. Worth, Texas, United States|Ft. Worth, Texas, United States|Galveston, Texas, United States|Houston, Texas, United States|McAllen, Texas, United States|Odessa, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Salt Lake City, Utah, United States|Burlington, Vermont, United States|Charlottesville, Virginia, United States|Fairfax, Virginia, United States|Richmond, Virginia, United States|Seattle, Washington, United States|Silverdale, Washington, United States|Madison, Wisconsin, United States|Madison, Wisconsin, United States|Milwaukee, Wisconsin, United States|Calgary, Alberta, Canada|Vancouver, British Columbia, Canada|Victoria, British Columbia, Canada|Halifax, Nova Scotia, Canada|London, Ontario, Canada|Mississauga, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Regina, Saskatchewan, Canada",,"https://ClinicalTrials.gov/show/NCT00509795"
1651,"NCT00509613","Phase 1 Study With Sorafenib and Sirolimus",,"Completed","No Results Available","Advanced Solid Tumor|Refractory to Standard Therapies","Drug: Sorafenib|Drug: Sirolimus","identify the recommended doses for the combination of sorafenib and sirolimus for subsequent phase II studies|to determine the safety profile of the combination therapy of sorafenib with sirolimus|to determine, if possible, the Maximum Tolerated Dose (MTD) of sorafenib and sirolimus in combination therapy|to analyze pharmacokinetic PK profiles (AUC, Cmax) during combination therapy for sorafenib and sirolimus|to evaluate efficacy of the combination descriptively (response rate and rate of stable diseases)","Radboud University|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1",,"Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","UMCNONCO 2006_01|2006-006454-10","June 2007","May 2009",,"July 31, 2007",,"September 18, 2009","UMC St Radboud, Nijmegen, Netherlands",,"https://ClinicalTrials.gov/show/NCT00509613"
1652,"NCT00506311","Evaluating the Use of Fibrin Tissue Adhesive in Melanoma Patients",,"Completed","No Results Available","Melanoma","Drug: Fibrin Sealant","Time-to-Drain Removal","M.D. Anderson Cancer Center|Bayer","All","Child, Adult, Older Adult","Not Applicable","53","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GS01-564","February 2003","December 2007","March 2008","July 25, 2007",,"August 2, 2012","U.T.M.D. Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00506311"
1653,"NCT00505921","Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma",,"Terminated","Has Results","Lymphoma","Drug: Campath-1H|Drug: G-CSF|Drug: GM-CSF|Drug: BCNU|Drug: Stem Cell Transplant|Drug: Preparative Regimen for Allogenic Stem Cell Transplantation|Drug: Cytarabine|Drug: Etoposide|Drug: Melphalan|Drug: Campath|Drug: Fludarabine|Drug: Cyclophosphamide|Radiation: Low dose total body irradiation","Participant Progression Free Survival at 2 Years","M.D. Anderson Cancer Center|Bayer","All","up to 70 Years   (Child, Adult, Older Adult)","Phase 2","27","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","ID02-645","March 2003","November 2009","November 2009","July 25, 2007","November 6, 2011","November 16, 2011","UT MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00505921"
1654,"NCT00502359","Testing Ascensia Contour Glucometer for the Measurement of Blood Glucose",,"Completed","No Results Available","Gestational Diabetes","Device: capillary blood glucose measurement",,"University of Zurich|Bayer","Female","Child, Adult, Older Adult",,"2005","Other|Industry","Observational","Observational Model: Defined Population|Primary Purpose: Screening|Time Perspective: Cross-Sectional|Time Perspective: Prospective","keinen","April 2005",,"December 2006","July 17, 2007",,"July 20, 2007","Clinic of obstetrics, University Hospital of Zurich, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT00502359"
1655,"NCT00499343","G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients",,"Completed","Has Results","Lymphoma","Drug: Etoposide|Drug: G-CSF|Drug: GM-CSF|Drug: Isophosphamide|Drug: Rituximab|Procedure: Apheresis","CD34+ Cells/kg in Blood Stem Cells","M.D. Anderson Cancer Center|Bayer","All","up to 70 Years   (Child, Adult, Older Adult)","Phase 2","84","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ID03-0242","January 2004","October 2008","October 2008","July 11, 2007","July 7, 2009","August 2, 2013","U.T.M.D. Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00499343"
1656,"NCT00480389","Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal",,"Completed","No Results Available","Renal Cell Carcinoma|Metastatic Disease","Drug: Sorafenib","To measure primary pathological response data and determine if it relates with time to progression|Safety of preoperative Sorafenib will be assessed.|Tumour vascularity.|Immunohistochemistry will be used to assess the effects of Sorafenib on angiogenic and tumorigenic promoters. Signals from VEGFR2, PDGF-alpha, c-KIT, Flt-3, CAIX and Raf-1 will be assessed.|A DNA microarray will be used for gene expression profiling of the tissue harvested at biopsy and surgery.","University Health Network, Toronto|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","19","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","06-0655-C","May 2007","October 2012","March 2013","May 30, 2007",,"December 9, 2015","Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00480389"
1657,"NCT00478114","Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC)",,"Completed","No Results Available","Renal Cell Carcinoma","Drug: sorafenib","To evaluate the efficacy (time to progression and progression free survival) of sorafenib in patients with advanced RCC|To evaluate the safety (all drug-related adverse events, all adverse events NCI CTCAE 3.0 Grade 3 or higher) of sorafenib in patients with advanced RCC","Mahidol University|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","15","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12750","May 2007","August 2009","March 2010","May 24, 2007",,"August 29, 2011","Siriraj Hospital, Department of Medicine, Bangkoknoi, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT00478114"
1658,"NCT00477087","Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer",,"Terminated","Has Results","Prostatic Neoplasms","Drug: Mitoxantrone|Drug: GM-CSF","Progression-free Survival (PFS)|Number of Participants With > 50% Decrease in Prostate-specific Antigen Levels (PSA Response)|Overall Survival (OS)","Stanford University|Bayer","Male","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-04738|96817|PROS0017","July 2006","October 2009","January 2010","May 22, 2007","November 29, 2017","November 29, 2017","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT00477087"
1659,"NCT00472433","The Efficacy and Safety of Alemtuzumab in Auotoimmune Cytopenias",,"Terminated","No Results Available","Autoimmune Cytopenias","Drug: Alemtuzumab","To investigate the efficacy of alemtuzumab in terms of objective response rate (ORR: complete remission [CR], partial remission [PR]), progression free survival (PFS), and relapse rate in patients with autoimmune cytopenias|To determine the safety profiles of alemtuzumab in patients with autoimmune cytopenias.","Phramongkutklao College of Medicine and Hospital|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TH011003","March 2007","May 2009","May 2009","May 11, 2007",,"June 22, 2009","Phramongkutklao Hospital, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT00472433"
1660,"NCT00468182","Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis",,"Completed","No Results Available","Multiple Sclerosis","Drug: Interferon-beta 1b (Betaseron)","Relative gene expression in plasmacytoid dendritic cells (pDCs)","Rutgers, The State University of New Jersey|Bayer","All","18 Years to 60 Years   (Adult)",,"24","Other|Industry","Observational","Time Perspective: Prospective","0220060228","April 2007","December 2011","December 2011","May 2, 2007",,"May 7, 2015","Rutgers-RWJMS, New Brunswick, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT00468182"
1661,"NCT00461851","Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma",,"Completed","Has Results","Bladder Cancer","Drug: Gemcitabine|Drug: Carboplatin|Drug: Sorafenib","Progression Free Survival (PFS)|Dose Ruction (Toxicity)|Best Reported Response","Yale University|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","17","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0609001823","March 2007","August 2013","August 2013","April 18, 2007","November 1, 2016","December 14, 2017","Yale University, Comprehensive Cancer Center, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT00461851"
1662,"NCT00461253","Case-Control-Study on the Breast Cancer Risk of Mirena® Compared With Copper IUDs",,"Completed","Has Results","Breast Cancer","Device: Levonorgestrel-releasing IUD|Device: Copper IUD","Breast Cancer Risk","Center for Epidemiology and Health Research, Germany|Bayer","Female","up to 50 Years   (Child, Adult)",,"25565","Other|Industry","Observational","Observational Model: Case Control","ZEG2006_02","October 2006","March 2014","March 2014","April 17, 2007","January 25, 2016","January 25, 2016","Center for Epidemiology and Health Research, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT00461253"
1663,"NCT00461175","European Active Surveillance Study for Intrauterine Devices","EURAS-IUD","Completed","Has Results","Uterine Perforation",,"Uterine Perforation Rate","Center for Epidemiology and Health Research, Germany|Bayer","Female","18 Years and older   (Adult, Older Adult)",,"63194","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ZEG2006_01","November 2006","May 2012","December 2013","April 17, 2007","October 22, 2014","July 17, 2015","Center for Epidemiology and Health Research, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT00461175"
1664,"NCT00452387","Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC)",,"Terminated","Has Results","Metastatic Prostate Cancer","Drug: Mitoxantrone|Drug: Prednisone|Drug: Sorafenib","Median Time to Progression (TTP) by Imaging|Correlation of Biochemical Criteria (PSA, Prostate-specific Antigen) With Objective Imaging|Quality of Life (QoL)|Median Overall Survival (OS)","Accelerated Community Oncology Research Network|Bayer","Male","18 Years and older   (Adult, Older Adult)","Phase 2","22","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACORN AVAHRPC0607","May 2007","July 2008","January 2009","March 27, 2007","May 26, 2010","September 16, 2011","Wilshire Oncology Medical Group, Inc., La Verne, California, United States|Peachtree Hematology Oncology Consultants, Atlanta, Georgia, United States|Central Georgia Cancer Care, Macon, Georgia, United States|Northwest Georgia Oncology Centers, Marietta, Georgia, United States|Hematology Oncology Centers of the Northern Rockies, PC, Billings, Montana, United States|Mid-Ohio Oncology/Hematology, Inc., Columbus, Ohio, United States|Lancaster Cancer Center, Lancaster, Pennsylvania, United States|Pennsylvania Oncology Hematmology Associates, Philadelphia, Pennsylvania, United States|The West Clinic, Memphis, Tennessee, United States|Cancer Specialists of Tidewater, Chesapeake, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00452387"
1665,"NCT00452218","Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)",,"Completed","No Results Available","Pulmonary Arterial Hypertension","Drug: Sorafenib","Monthly 6MW/B|Efficacy|World Health Organization (WHO) function class|Right heart catheterization|Naughton Balke-Treadmill Test","University of Chicago|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","12","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14636A","March 2007","May 2012","May 2012","March 27, 2007",,"August 24, 2016","The University of Chicago, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT00452218"
1666,"NCT00450008","Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer",,"Terminated","No Results Available","Prostatic Neoplasms","Drug: GM-CSF|Drug: thalidomide|Drug: docetaxel","To assess the relative efficacy of the combination of GM-CSF, Thalidomide and Docetaxel in patients with prostate cancer.|Collect data on hormonal responses produced by GM-CSF, Thalidomide and Docetaxel.|Evaluate safety and toxicity of the combination of GM-CSF, Thalidomide and Docetaxel for patients with hormone naïve prostate cancer.","The Methodist Hospital System|Bayer","Male","18 Years and older   (Adult, Older Adult)","Phase 2","9","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HMRI IRB#1006-0153|PCa-06-102","December 2006","August 2008","September 2008","March 21, 2007",,"March 17, 2016","The Methodist Hospital Research Institute, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00450008"
1667,"NCT00449280","Drug Interaction Study of Sorafenib and Rapamycin in Advanced Malignancies",,"Completed","No Results Available","Advanced Solid Tumor","Drug: Sorafenib|Drug: Rapamycin","Pharmacokinetic interactions|Response Rate","University of Chicago|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","34","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14908B","November 2006","June 2009","September 2009","March 20, 2007",,"June 12, 2013","University of Chicago, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT00449280"
1668,"NCT00447473","Trial of GM-CSF Given in Combination With Ketoconazole and Mitoxantrone in Patients With Progressive Prostate Cancer",,"Terminated","No Results Available","Prostatic Neoplasms","Drug: GM-CSF|Drug: Ketoconazole|Drug: Mitoxantrone","To evaluate the effect of the combination of ketoconazole and mitoxantrone plus GM-CSF on time to clinical progression in patients with prostate cancer that has progressed on prior therapy.|To evaluate the objective response frequency of the combination of ketoconazole and mitoxantrone plus GM-CSF.|To investigate the safety of ketoconazole and mitoxantrone given in combination with GM-CSF.","The Methodist Hospital System|Bayer","Male","18 Years and older   (Adult, Older Adult)","Phase 2","31","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HMRI IRB#0106-0010|PC-Keto-Mito.2006","July 2006","August 2008","September 2008","March 14, 2007",,"March 17, 2016","Baylor College of Medicine - Methodist Hospital, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00447473"
1669,"NCT00447304","Acute Cholecystitis - Early Laparoscopic Surgery Versus Antibiotic Therapy and Delayed Elective Cholecystectomy","ACDC","Completed","No Results Available","Acute Cholecystitis","Drug: moxifloxacin|Procedure: cholecystectomy","morbidity at the test-of-cure visit|Morbidity over 75 days using the score system showed in table 1|Morbidity 3 days after cholecystectomy (early or elective)|Necessity rate of conversion from laparoscopic to open surgery|Change of antibiotic due to non-response or non-toleration of moxifloxacin|Mortality at day 75|Cost-efficiency (comparing both trial branches)|Hospital time|Safety and tolerability of Moxifloxacin|In-hospital time after cholecystectomy (days)","Heidelberg University|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","644","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2006-002056-14|AC-DC-01/Version 02/6.04.06","October 2006","November 2010","December 2010","March 14, 2007",,"July 23, 2012","University Hospital Heidelberg, Heidelberg, Germany",,"https://ClinicalTrials.gov/show/NCT00447304"
1670,"NCT00441025","The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL",,"Terminated","No Results Available","Peripheral T-Cell Lymphoma","Drug: Alemtuzumab","To determine the effectiveness of alemtuzumab given in combination with CHOP in terms of the rates of objective response rate (ORR:complete remission[CR] and|partial remission[PR]),progressive disease-free(PFS) and overall survivals(OS)|in patients newly diagnosed with PTCL.|To determine the safety profiles of alemtuzumab given in combination with CHOP","Mahidol University|Bayer","All","15 Years to 65 Years   (Child, Adult, Older Adult)","Phase 2","4","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TH 011002","September 2006",,"August 2009","February 27, 2007",,"June 25, 2009","Siriraj Hospital, Mahidol University, Bangkoknoi, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT00441025"
1671,"NCT00440583","The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP",,"Completed","No Results Available","Diffuse Large B-cell Lymphoma","Drug: chemotherapy followed by Zevalin","- Determine the 2-years progression-free survival of consolidation therapy with Yt90-Zevalin.|Determine the response duration(time to progression)after therapy.|Determine safety and tolerability of Yt90-Zevalin consolidation therapy.","Mahidol University|Bayer","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TH011101","September 2006","September 2011","May 2012","February 27, 2007",,"January 30, 2015","Siriraj Hospital, Mahidol University, Bangkoknoi, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT00440583"
1672,"NCT00429104","Herceptin and GM-CSF for Metastatic Breast Cancer",,"Completed","Has Results","Breast Cancer","Drug: Herceptin|Drug: GM-CSF","Number of Participants With Tumor Response (Stable Disease)|Duration of Stable Disease","M.D. Anderson Cancer Center|Bayer","Female","Child, Adult, Older Adult","Phase 2","18","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DM01-0100","August 2002","November 2009","November 2009","January 31, 2007","April 15, 2011","December 6, 2012","U.T.M.D. Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00429104"
1673,"NCT00426452","A Drug-drug Interaction Study of Oral 1250 mg of Vatalinib Administered Under Fasting and Fed Conditions With a Proton-pump Inhibitor in Healthy Sterile or Postmenopausal Female Volunteers",,"Completed","No Results Available","Healthy","Drug: Vatalinib","Assess the effect of multiple doses of a proton-pump inhibitor on the pharmacokinetics of a single dose of Vatalinib under fasting and fed conditions.|Safety of a single dose of Vatalinib before and after a proton-pump inhibitor under fasting and fed conditions as assessed by adverse events, laboratory values, electrocardiograms, and vital signs.","Novartis|Bayer","Female","35 Years to 70 Years   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CPTK787A2121","July 2006",,,"January 24, 2007",,"November 19, 2009",,,"https://ClinicalTrials.gov/show/NCT00426452"
1674,"NCT00403793","Hormonal Contraception in Healthy Young Men (P42306)(COMPLETED)(P06057)",,"Completed","No Results Available","Contraception","Drug: etonogestrel with testosterone undecanoate|Drug: Placebo","% of men who had a sperm concentration of 1 million/ml or less at week 16.|Semen Parameters|Reversibility of Suppression|Hormones|Pharmacokinetics|Safety","Merck Sharp & Dohme Corp.|Bayer","Male","18 Years to 45 Years   (Adult)","Phase 2","350","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","P06057","October 2003","December 2006","December 2006","November 27, 2006",,"July 14, 2015",,,"https://ClinicalTrials.gov/show/NCT00403793"
1675,"NCT00403767","An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation",,"Completed","Has Results","Atrial Fibrillation|Stroke|Embolism","Drug: Rivaroxaban|Drug: Warfarin|Drug: Matching placebo for Rivaroxaban arm (Warfarin placebo)|Drug: Matching placebo for Warfarin arm (Rivaroxaban placebo)","The Composite Event of Stroke/Non-CNS Systemic Embolism: Primary Efficacy (Non-Inferiority)|The Composite of Event of Stroke/Non-CNS Systemic Embolism: Primary Efficacy (Superiority)|The Composite Event of Major/Non-major Clinically Relevant Bleeding Events: Primary Safety|The Composite Event of Stroke/Non-CNS Systemic Embolism/Vascular Death|The Composite Event of Stroke/Non-CNS Systemic Embolism/Myocardial Infarction/Vascular Death|The Individual Components of the Composite Primary and Major Secondary Efficacy Outcome Measures: Stroke|The Individual Components of the Composite Primary and Major Secondary Efficacy Outcome Measures: Non-CNS Systemic Embolism|The Individual Components of the Composite Primary and Major Secondary Efficacy Outcome Measures: Myocardial Infarction|The Individual Components of the Composite Primary and Major Secondary Efficacy Outcome Measures: Vascular Death|All-cause Mortality","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","14269","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CR012157|39039039AFL3001|ROCKET AF|2006-004595-13","December 2006","September 2010","September 2010","November 27, 2006","July 17, 2012","April 29, 2014","Birmingham, Alabama, United States|Dothan, Alabama, United States|Geneva, Alabama, United States|Mobile, Alabama, United States|Pell City, Alabama, United States|Glendale, Arizona, United States|Phoenix, Arizona, United States|Scottsdale, Arizona, United States|Tucson, Arizona, United States|Fort Smith, Arkansas, United States|Little Rock, Arkansas, United States|Anaheim, California, United States|Bakersfield, California, United States|Carmichael, California, United States|Corona, California, United States|Fair Oaks, California, United States|Glendale, California, United States|Healdsburg, California, United States|Laguna Hills, California, United States|Long Beach, California, United States|Los Angeles, California, United States|Los Gatos, California, United States|Mission Viejo, California, United States|Modesto, California, United States|Mountain View, California, United States|Northridge, California, United States|Oakland, California, United States|Orange, California, United States|Pismo Beach, California, United States|Sacramento, California, United States|San Diego, California, United States|San Leandro, California, United States|Santa Clara, California, United States|Santa Monica, California, United States|Santa Rosa, California, United States|Sylmar, California, United States|Torrance, California, United States|Ventura, California, United States|Yuba City, California, United States|Boulder, Colorado, United States|Denver, Colorado, United States|Littleton, Colorado, United States|Pueblo, Colorado, United States|Danbury, Connecticut, United States|Guilford, Connecticut, United States|Newark, Delaware, United States|Bradenton, Florida, United States|Clearwater, Florida, United States|Daytona Beach, Florida, United States|Debary, Florida, United States|Deerfield Beach, Florida, United States|Fort Lauderdale, Florida, United States|Fort Myers, Florida, United States|Fort Walton Beach, Florida, United States|Hialeah, Florida, United States|Hollywood, Florida, United States|Hudson, Florida, United States|Inverness, Florida, United States|Jacksonville, Florida, United States|Jupiter, Florida, United States|Kissimmee, Florida, United States|Largo, Florida, United States|Melbourne, Florida, United States|Miami Beach, Florida, United States|Miami, Florida, United States|Ocala, Florida, United States|Orange Park, Florida, United States|Orlando, Florida, United States|Ormond Beach, Florida, United States|Palm Beach Gardens, Florida, United States|Palm Harbor, Florida, United States|Port Charlotte, Florida, United States|Safety Harbor, Florida, United States|St. Petersburg, Florida, United States|Tallahassee, Florida, United States|Tamarac, Florida, United States|Tampa, Florida, United States|Albany, Georgia, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Columbus, Georgia, United States|Savannah, Georgia, United States|Boise, Idaho, United States|Idaho Falls, Idaho, United States|Nampa, Idaho, United States|Aurora, Illinois, United States|Bannockburn, Illinois, United States|Chicago, Illinois, United States|Evergreen Park, Illinois, United States|Fulton, Illinois, United States|Lombard, Illinois, United States|Melrose Park, Illinois, United States|Moline, Illinois, United States|Park Ridge, Illinois, United States|Peoria, Illinois, United States|Quincy, Illinois, United States|Rock Island, Illinois, United States|Rockford, Illinois, United States|Springfield, Illinois, United States|Watseka, Illinois, United States|Anderson, Indiana, United States|Hammond, Indiana, United States|Indianapolis, Indiana, United States|Merrillville, Indiana, United States|Muncie, Indiana, United States|Munster, Indiana, United States|South Bend, Indiana, United States|Waterloo, Iowa, United States|Crestview Hills, Kentucky, United States|Edgewood, Kentucky, United States|Lexington, Kentucky, United States|Louisville, Kentucky, United States|Madisonville, Kentucky, United States|Mt Sterling, Kentucky, United States|Owensboro, Kentucky, United States|Houma, Louisiana, United States|Lake Charles, Louisiana, United States|New Orleans, Louisiana, United States|Thibodaux, Louisiana, United States|Vidalia, Louisiana, United States|Bangor, Maine, United States|Scarborough, Maine, United States|Annapolis, Maryland, United States|Beltsville, Maryland, United States|Columbia, Maryland, United States|Salisbury, Maryland, United States|Boston, Massachusetts, United States|Brighton, Massachusetts, United States|Framingham, Massachusetts, United States|Bay City, Michigan, United States|Bridgman, Michigan, United States|Chelsea, Michigan, United States|Dearborn, Michigan, United States|Detroit, Michigan, United States|Lansing, Michigan, United States|Mount Clemens, Michigan, United States|Petoskey, Michigan, United States|Traverse City, Michigan, United States|Troy, Michigan, United States|Minneapolis, Minnesota, United States|Saint Paul, Minnesota, United States|Picayune, Mississippi, United States|Tupelo, Mississippi, United States|Lexington, Missouri, United States|Saint Louis, Missouri, United States|Springfield, Missouri, United States|Anaconda, Montana, United States|Great Falls, Montana, United States|Beatrice, Nebraska, United States|Lincoln, Nebraska, United States|Omaha, Nebraska, United States|Las Vegas, Nevada, United States|Pahrump, Nevada, United States|Manchester, New Hampshire, United States|Bridgewater, New Jersey, United States|Elmer, New Jersey, United States|Haddon Heights, New Jersey, United States|New Brunswick, New Jersey, United States|Paterson, New Jersey, United States|Ridgewood, New Jersey, United States|Sewell, New Jersey, United States|Springfield, New Jersey, United States|Toms River, New Jersey, United States|Wayne, New Jersey, United States|Albuquerque, New Mexico, United States|Bronx, New York, United States|Brooklyn, New York, United States|Buffalo, New York, United States|Cortlandt Manor, New York, United States|East Syracuse, New York, United States|New York, New York, United States|Northport, New York, United States|Saratoga Springs, New York, United States|Schenectady, New York, United States|Staten Island, New York, United States|Stony Brook, New York, United States|Syracuse, New York, United States|Williamsville, New York, United States|Asheville, North Carolina, United States|Durham, North Carolina, United States|Greensboro, North Carolina, United States|Hickory, North Carolina, United States|Jacksonville, North Carolina, United States|New Bern, North Carolina, United States|Raleigh, North Carolina, United States|Reidsville, North Carolina, United States|Rocky Mount, North Carolina, United States|Statesville, North Carolina, United States|Winston Salem, North Carolina, United States|Fargo, North Dakota, United States|Minot, North Dakota, United States|Canton, Ohio, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Dayton, Ohio, United States|Fairfield, Ohio, United States|Mansfield, Ohio, United States|Massillon, Ohio, United States|Maumee, Ohio, United States|Toledo, Ohio, United States|Zanesville, Ohio, United States|Bartlesville, Oklahoma, United States|Midwest City, Oklahoma, United States|Norman, Oklahoma, United States|Oklahoma City, Oklahoma, United States|Yukon, Oklahoma, United States|Portland, Oregon, United States|Beaver, Pennsylvania, United States|Bethlehem, Pennsylvania, United States|Danville, Pennsylvania, United States|Doylestown, Pennsylvania, United States|Jeannette, Pennsylvania, United States|Jersey Shore, Pennsylvania, United States|Lansdale, Pennsylvania, United States|Leetsdale, Pennsylvania, United States|Lewistown, Pennsylvania, United States|Norristown, Pennsylvania, United States|North Wales, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Philipsburg, Pennsylvania, United States|Phoenixville, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Sayre, Pennsylvania, United States|Scranton, Pennsylvania, United States|Shippensburg, Pennsylvania, United States|State College, Pennsylvania, United States|Topton, Pennsylvania, United States|Wilkes Barre, Pennsylvania, United States|Wormleysburg, Pennsylvania, United States|Wyomissing, Pennsylvania, United States|Pawtucket, Rhode Island, United States|Westerly, Rhode Island, United States|Anderson, South Carolina, United States|Charleston, South Carolina, United States|Columbia, South Carolina, United States|Easley, South Carolina, United States|Sumter, South Carolina, United States|Rapid City, South Dakota, United States|Athens, Tennessee, United States|Bristol, Tennessee, United States|Chattanooga, Tennessee, United States|Harriman, Tennessee, United States|Jackson, Tennessee, United States|Johnson City, Tennessee, United States|Kingsport, Tennessee, United States|Knoxville, Tennessee, United States|Lexington, Tennessee, United States|Memphis, Tennessee, United States|Nashville, Tennessee, United States|Amarillo, Texas, United States|Beaumont, Texas, United States|Brownsville, Texas, United States|Corpus Christi, Texas, United States|Daingerfield, Texas, United States|Dallas, Texas, United States|Desoto, Texas, United States|Fort Sam Houston, Texas, United States|Fort Worth, Texas, United States|Houston, Texas, United States|Humble, Texas, United States|Hurst, Texas, United States|Kerrville, Texas, United States|Kingwood, Texas, United States|Lubbock, Texas, United States|Mcallen, Texas, United States|Odessa, Texas, United States|Plano, Texas, United States|San Antonio, Texas, United States|Sugar Land, Texas, United States|Tomball, Texas, United States|Victoria, Texas, United States|Murray, Utah, United States|Salt Lake City, Utah, United States|Burlington, Vermont, United States|Blacksburg, Virginia, United States|Chester, Virginia, United States|Danville, Virginia, United States|Fairfax, Virginia, United States|Fredericksburg, Virginia, United States|Lynchburg, Virginia, United States|Richmond, Virginia, United States|Roanoke, Virginia, United States|Virginia Beach, Virginia, United States|Williamsburg, Virginia, United States|Bellingham, Washington, United States|Port Orchard, Washington, United States|Seattle, Washington, United States|Spokane, Washington, United States|Tacoma, Washington, United States|Vancouver, Washington, United States|Burlington, Wisconsin, United States|Elkhorn, Wisconsin, United States|La Crosse, Wisconsin, United States|Milwaukee, Wisconsin, United States|Wausau, Wisconsin, United States|Bahia Blanca, Argentina|Buenos Aires, Argentina|Cipolletti, Argentina|Ciudad Autonoma De Buenos Aires, Argentina|Cordoba, Argentina|Corrientes, Argentina|La Plata, Argentina|Mar Del Plata, Argentina|Quilmes, Argentina|Rosario, Argentina|Salta, Argentina|San Martin, Argentina|Santa Fe, Argentina|Tucuman, Argentina|Adelaide, Australia|Auchenflower, Australia|Bedford Park, Australia|Box Hill, Australia|Caboolture, Australia|Cairns, Australia|Camperdown, Australia|Chermside, Australia|Clayton, Australia|Coffs Harbour, Australia|Footscray, Australia|Garran, Australia|Geelong, Australia|Gosford, Australia|Heidelberg Heights, Australia|Herston, Australia|Hobart, Australia|Joondalup, Australia|Lismore, Australia|Liverpool, Australia|Miranda, Australia|Nedlands, Australia|New Lambton Heights, Australia|Parkville, Australia|Penrith, Australia|Prahran, Australia|Reservoir, Australia|Southport, Australia|Windsor, Australia|Wolloongabba, Australia|Feldkirch Vorarlberg Vorarlber, Austria|Graz, Austria|Tulln Niederosterreich Niedero, Austria|Wien N/A, Austria|Wien Wien, Austria|Wien, Austria|Antwerpen, Belgium|Bonheiden, Belgium|Brasschaat, Belgium|Brugge, Belgium|Brussel, Belgium|Bruxelles, Belgium|Gent, Belgium|Haine-Saint-Paul, Belgium|Leuven, Belgium|Mol, Belgium|Nivelles, Belgium|Ottignies, Belgium|Roeselare, Belgium|Seraing, Belgium|Tienen, Belgium|Belo Horizonte, Brazil|Blumenau, Brazil|Brasilia, Brazil|Campina Grande Do Sul, Brazil|Campinas, Brazil|Campo Grande, Brazil|Curitiba, Brazil|Fortaleza, Brazil|Goiania, Brazil|Goiânia, Brazil|Maceio, Brazil|Marilia, Brazil|Maringa, Brazil|Porto Alegre, Brazil|Recife, Brazil|Rio De Janeiro Br, Brazil|Rio De Janeiro, Brazil|Salvador, Brazil|Santo Andre, Brazil|Sao Caetano Do Sul, Brazil|Sao Paulo, Brazil|Sorocaba, Brazil|São José Do Rio Preto, Brazil|São Paulo, Brazil|Uberlandia, Brazil|Dimitrovgrad, Bulgaria|Pleven, Bulgaria|Plovdiv, Bulgaria|Russel, Bulgaria|Sofia, Bulgaria|Veliko Turnovo, Bulgaria|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Abbotsford, British Columbia, Canada|Burnaby, British Columbia, Canada|Campbell River, British Columbia, Canada|Delta, British Columbia, Canada|Kelowna, British Columbia, Canada|Langley, British Columbia, Canada|New Westminster, British Columbia, Canada|Penticton, British Columbia, Canada|Vancouver, British Columbia, Canada|Victoria, British Columbia, Canada|West Vancouver, British Columbia, Canada|Winnipeg, Manitoba, Canada|Moncton, New Brunswick, Canada|Saint John, New Brunswick, Canada|St. John'S, Newfoundland and Labrador, Canada|Halifax, Nova Scotia, Canada|Sydney, Nova Scotia, Canada|Ajax, Ontario, Canada|Beamsville, Ontario, Canada|Belleville, Ontario, Canada|Brampton, Ontario, Canada|Burlington, Ontario, Canada|Cambridge, Ontario, Canada|Corunna, Ontario, Canada|Courtice, Ontario, Canada|E. London, Ontario, Canada|Etobicoke, Ontario, Canada|Fort Erie, Ontario, Canada|Hamilton, Ontario, Canada|Kitchener, Ontario, Canada|Listowel, Ontario, Canada|London, Ontario, Canada|Markham, Ontario, Canada|Mississauga, Ontario, Canada|North Bay, Ontario, Canada|North York, Ontario, Canada|Oakville, Ontario, Canada|Oshawa, Ontario, Canada|Ottawa, Ontario, Canada|Parry Sound, Ontario, Canada|Richmond Hill, Ontario, Canada|Sarnia, Ontario, Canada|Sault Ste Marie, Ontario, Canada|Scarborough, Ontario, Canada|Strathroy, Ontario, Canada|Sudbury, Ontario, Canada|Thornhill, Ontario, Canada|Thunder Bay, Ontario, Canada|Toronto, Ontario, Canada|Waterloo, Ontario, Canada|Whitby, Ontario, Canada|York, Ontario, Canada|Chicoutimi, Quebec, Canada|Greenfield Park, Quebec, Canada|Joliette, Quebec, Canada|Jonquiere, Quebec, Canada|Lachine, Quebec, Canada|Longueuil, Quebec, Canada|Mirabel, Quebec, Canada|Montreal, Quebec, Canada|Pointe-Claire, Quebec, Canada|Saint-Jerome, Quebec, Canada|Saint-Lambert, Quebec, Canada|Sherbrooke, Quebec, Canada|St-Leonard, Quebec, Canada|North Battleford, Saskatchewan, Canada|Saskatoon, Saskatchewan, Canada|Quebec, Canada|Arica I Region, Chile|Chila, Chile|Concepción Viii, Chile|Osorno X Region, Chile|Osorno X Región, Chile|Rancagua Vi Region, Chile|San Felipe V Region, Chile|Santiago De Chile Rm, Chile|Santiago Rm, Chile|Temuco Ix, Chile|Valdivia X Región, Chile|Viña Del Mar V Región, Chile|Bei Jing, China|Beijing, China|Changchun, China|Changsha, China|Changzhou, China|Chengdu, China|Chongqing, China|Dalian, China|Daqing, China|Guangzhou, China|Haikou, China|Hangzhou, China|Harbin, China|Jinan, China|Nanjing, China|Shanghai, China|Shenyang, China|Su Zhou, China|Suzhou, China|Tianjin, China|Wuhan, China|Xian, China|Barranquilla Atlántico Atlanti, Colombia|Barranquilla, Colombia|Bogota D C, Colombia|Bogota Dc, Colombia|Bogotá Dc Dc, Colombia|Bogotá Dc, Colombia|Cali Valle Del Cauca, Colombia|Cali Valley Del Cauca, Colombia|Medellin Antioquia, Colombia|Medellin, Colombia|Santander, Colombia|Brno 2, Czech Republic|Chomutov, Czech Republic|Hradec Kralove, Czech Republic|Karviná 4, Czech Republic|Kutna Hora N/A, Czech Republic|Liberec, Czech Republic|Litomysl, Czech Republic|Náchod 1, Czech Republic|Olomouc, Czech Republic|Ostrava, Czech Republic|Pardubice, Czech Republic|Praha 10 N/A, Czech Republic|Praha 1, Czech Republic|Praha 2, Czech Republic|Praha 4, Czech Republic|Praha 5, Czech Republic|Praha 8, Czech Republic|Praha, Czech Republic|Slany, Czech Republic|Svitavy 2, Czech Republic|Svitavy, Czech Republic|Trutnov, Czech Republic|Uherské Hradistì 6, Czech Republic|Zlín 1, Czech Republic|Esbjerg, Denmark|Frederiksberg, Denmark|Gentofte, Denmark|Hellerup, Denmark|Helsingør, Denmark|Hvidovre, Denmark|Koege, Denmark|København, Denmark|Næstved, Denmark|Roskilde, Denmark|Slagelse, Denmark|Viborg, Denmark|Helsinki, Finland|Jyväskylä N/A, Finland|Kuopio, Finland|Mikkeli, Finland|Oulu, Finland|Turku, Finland|Albi, France|Arras, France|Bayonne, France|Belfort, France|Besancon N/A, France|Bourg En Bresse, France|Brest, France|Béziers Languedoc-Roussillon, France|Carcassonne, France|Clermont Ferrand, France|Corbeil Essonnes, France|Lille, France|Marseille, France|Montbeliard, France|Montpellier, France|Paris Cedex 14, France|Paris, France|Perpignan, France|Poitiers, France|Saint-Brieuc, France|St Jean De Verges, France|Strasbourg, France|Thionville, France|Toulouse, France|Trelivan, France|Aalen, Germany|Berlin/Spandau, Germany|Berlin, Germany|Biberach, Germany|Bochum, Germany|Bonn, Germany|Chemnitz, Germany|Coburg, Germany|Dachau, Germany|Dortmund, Germany|Dresden, Germany|Duisburg, Germany|Ebersbach, Germany|Eilenburg, Germany|Erfurt, Germany|Essen, Germany|Frankfurt, Germany|Freiburg, Germany|Greifswald, Germany|Halle, Germany|Hamburg, Germany|Hartmannsdorf, Germany|Heidelberg, Germany|Henstedt-Rhen, Germany|Herford, Germany|Homburg/Saar, Germany|Jena, Germany|Julich, Germany|Kamen, Germany|Karlsbad, Germany|Kassel, Germany|Kirchzarten, Germany|Krefeld, Germany|Leipzig, Germany|Ludwigsburg, Germany|Ludwigshafen, Germany|Lüneburg, Germany|Magdeburg, Germany|Mainz, Germany|Mannheim, Germany|Markkleeberg, Germany|Meißen, Germany|Melsungen, Germany|Monchengladbach, Germany|Munchen, Germany|Mühldorf, Germany|Mülheim, Germany|Münster, Germany|Neuwied, Germany|Nienburg, Germany|Nuernberg, Germany|Paderborn, Germany|Potsdam, Germany|Riesa, Germany|Rottweil, Germany|Sachsen, Germany|Siegen, Germany|Ulm, Germany|Wermsdorf, Germany|Witten, Germany|Wolmirstedt, Germany|Wuppertal, Germany|Athens Attica, Greece|Ioannina, Greece|Maroussi Athens, Greece|Patra, Greece|Piraeus Attica, Greece|Tripoli, Greece|Voula Attica, Greece|Aberdeen, Hong Kong|Hk, Hong Kong|Kln, Hong Kong|Sha Tin, Hong Kong|Budapest N/A, Hungary|Budapest Nap, Hungary|Budapest, Hungary|Debrecen County, Hungary|Eger, Hungary|Gyongyos, Hungary|Gyõr, Hungary|Kesckemet, Hungary|Miskolc, Hungary|Nyiregyhaza, Hungary|Pecs, Hungary|Szeged, Hungary|Szekszard, Hungary|Szombathely, Hungary|Veszprem, Hungary|Zalaegerszeg, Hungary|Ahmedabad, India|Bangalore, India|Bikaner, India|Chennai, India|Coimbatore, India|Gandhinagar Guiarat, India|Hyderabad Andra Pradesh, India|Hyderabad, India|Jalandhar, India|Madurai, India|Mangalore, India|Mumbai, India|Mysore, India|New Delhi, India|Pune, India|Suraj, India|Vadodara, India|Vishakapatnam, India|Afula, Israel|Ashkelon, Israel|Hadera, Israel|Haifa, Israel|Holon, Israel|Jerusalem, Israel|Nazareth, Israel|Netanya, Israel|Petach-Tikva, Israel|Petah-Tikva, Israel|Poriya, Israel|Rehovot, Israel|Safed, Israel|Tel Aviv, Israel|Tel Hashomer, Israel|Zerifin, Israel|Anyang, Korea, Republic of|Daegu, Korea, Republic of|Daejeon, Korea, Republic of|Goyang, Korea, Republic of|Kyonggi-Do, Korea, Republic of|Pusan, Korea, Republic of|Seoul, Korea, Republic of|Sungnam, Korea, Republic of|Suwon, Korea, Republic of|Kaunas, Lithuania|Klaipeda, Lithuania|Panevezys, Lithuania|Siauliai, Lithuania|Vilnius, Lithuania|Kelantan, Malaysia|Kuala Lumpur, Malaysia|Sarawak, Malaysia|Aguascalientes, Mexico|Ciudad De Mexico, Mexico|Culiacán Sinaloa/Mèxico, Mexico|Guadalajara, Mexico|Hermosillo, Mexico|Monterrey Nuevo Leòn, Mexico|Monterrey, Mexico|Queretaro, Mexico|San Luis Potosi, Mexico|Sinaloa, Mexico|Zapopan, Mexico|'S-Gravenhage, Netherlands|Alkmaar, Netherlands|Amersfoort, Netherlands|Amsterdam, Netherlands|Blaricum, Netherlands|Delft, Netherlands|Den Bosch, Netherlands|Den Haag, Netherlands|Gc Tilburg, Netherlands|Gouda, Netherlands|Groningen, Netherlands|Haarlem, Netherlands|Heerlen, Netherlands|Hoofddorp, Netherlands|Hoorn Nh, Netherlands|Leeuwarden, Netherlands|Leidschendam, Netherlands|Maastricht, Netherlands|Meppel, Netherlands|Nijmegen, Netherlands|Schiedam, Netherlands|Veldhoven, Netherlands|Christchurch, New Zealand|Dunedin, New Zealand|Grafton, New Zealand|Hamilton, New Zealand|Takapuna Auckland, New Zealand|Wellington, New Zealand|Alesund, Norway|Bergen, Norway|Elverum, Norway|Hamar, Norway|Jessheim, Norway|Lillehammer, Norway|Moss, Norway|Oslo, Norway|Sandefjord, Norway|Sandnes, Norway|Sandvika, Norway|Skedsmokorset, Norway|L41 Lima Lima, Peru|Lima 1 Lima Lima, Peru|Lima, Peru|Cebuu City, Philippines|Davao City, Philippines|Iloilo City, Philippines|Manila City, Philippines|Quezon City, Philippines|Bydgoszcz N/A, Poland|Bydgoszcz, Poland|Gdansk, Poland|Gdynia, Poland|Katowice-Ochojec, Poland|Katowice, Poland|Krakow, Poland|Lodz, Poland|Olawa, Poland|Olsztyn, Poland|Opole, Poland|Ostrowiec N/A, Poland|Piotrkow Trybunalski, Poland|Plock, Poland|Poznan, Poland|Siedlce, Poland|Sieradz N/A, Poland|Skierniewice, Poland|Starogard Gdanski Nap, Poland|Szczecin Nap, Poland|Szczecin, Poland|Torun, Poland|Warsaw, Poland|Warszawa N/A, Poland|Warszawa, Poland|Wloclawek, Poland|Wroclaw N/A, Poland|Wroclaw, Poland|Zyrardow N/A, Poland|Brasov, Romania|Bucharest, Romania|Bucuresti, Romania|Craiova, Romania|Focsani, Romania|Iasi, Romania|Oradea, Romania|Sibiu, Romania|Suceava, Romania|Tg Mures, Romania|Timisoara, Romania|Barnaul, Russian Federation|Chelyabinsk Chelyabinsk Region, Russian Federation|Chelyabinsk, Russian Federation|Ekaterinburg, Russian Federation|Kemerovo, Russian Federation|Krasnoyarsk, Russian Federation|Moscow N/A, Russian Federation|Moscow, Russian Federation|Nizhni Novgorod, Russian Federation|Novosibirsk Nap, Russian Federation|Novosibirsk, Russian Federation|Orenburg, Russian Federation|Perm, Russian Federation|Ryazan, Russian Federation|Saint Petersburg, Russian Federation|Saint-Petersburg, Russian Federation|Saratov, Russian Federation|Smolensk, Russian Federation|St Petersburg, Russian Federation|St. Petersburg, Russian Federation|Tomsk, Russian Federation|Tyumen Tyumen Region, Russian Federation|Yaroslavl Nap, Russian Federation|Yaroslavl, Russian Federation|Singapore, Singapore|Bloemfontein Free State, South Africa|Bloemfontein Orange Free State, South Africa|Cape Town Western Cape, South Africa|Cape Town, South Africa|Centurion Gauteng, South Africa|Durban Kwa Zulu Natal, South Africa|Johannesburg Gauteng, South Africa|Kempton Park Gauteng, South Africa|Port Elizabeth Eastern Cape, South Africa|Pretoria Gauteng, South Africa|Somerset West Western Cape, South Africa|Van Der Bijl Park, South Africa|Worcester Western Cape, South Africa|A Coruna, Spain|Alicante N/A, Spain|Almeria, Spain|Baracaldo Vizcaya, Spain|Barcelona, Spain|Burgos, Spain|Guadalajara, Spain|La Corona, Spain|Madrid, Spain|Malaga, Spain|Oviedo, Spain|Palma De Mallorca, Spain|Pamplona, Spain|Pontevedra, Spain|Sabadell, Spain|San Sebastián Guipúzcoa, Spain|Sevilla, Spain|Terrassa, Spain|Valencia, Spain|Valladolid, Spain|Ljungby, Sweden|Lund, Sweden|Sala, Sweden|Skövde, Sweden|Uppsala, Sweden|Basel Bs, Switzerland|Bruderholz, Switzerland|Geneve, Switzerland|Zurich, Switzerland|Changhua, Taiwan|Kaohsiung, Taiwan|Taichung, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Tamshui, Taiwan|Tao-Yuan, Taiwan|Bangkok Noi, Thailand|Bangkok, Thailand|Chiang Mai, Thailand|Pathumthani, Thailand|Phathumwan, Thailand|Ratchatewi, Thailand|Adana, Turkey|Ankara, Turkey|Antalya, Turkey|Aydin, Turkey|Denizli, Turkey|Diyarbakir, Turkey|Eskisehir, Turkey|Görükle, Turkey|Istanbul, Turkey|Izmir, Turkey|Izmit, Turkey|Kayseri, Turkey|Konya, Turkey|Malatya Nap, Turkey|Mersin, Turkey|Samsun, Turkey|Cherkassy, Ukraine|Chernigiv, Ukraine|Dnepropetrovsk, Ukraine|Dnipropetrovsk, Ukraine|Donetsk, Ukraine|Ivano-Frankivsk, Ukraine|Kharkiv, Ukraine|Kharkov, Ukraine|Kirovograd, Ukraine|Kyiv, Ukraine|Lugansk, Ukraine|Lviv, Ukraine|O1103 Kyiv, Ukraine|Odesa, Ukraine|Poltava, Ukraine|Simferopil, Ukraine|Sumy, Ukraine|Ternopil, Ukraine|Uzhgorod, Ukraine|Vinnitsya, Ukraine|Vinnytsia, Ukraine|Zaporizhzhya, Ukraine|Zhytomyr, Ukraine|Aberdeen, United Kingdom|Belfast, United Kingdom|Birmingham, United Kingdom|Bournemouth, United Kingdom|Cambridgeshire, United Kingdom|Chelmsford, United Kingdom|Chesterfield, United Kingdom|Colchester, United Kingdom|Craigavon, United Kingdom|Devon, United Kingdom|Dundee, United Kingdom|Glasgow, United Kingdom|Harrogate, United Kingdom|Hull, United Kingdom|Leicester, United Kingdom|Lincoln, United Kingdom|Liverpool, United Kingdom|London, United Kingdom|Nottingham, United Kingdom|Plymouth, United Kingdom|Romford, United Kingdom|Sheffield, United Kingdom|Stirling, United Kingdom|Stoke On Trent, United Kingdom|York, United Kingdom|Caracas, Venezuela|Maracaibo Estado Zulia, Venezuela|Maracay Estado Aragua, Venezuela",,"https://ClinicalTrials.gov/show/NCT00403767"
1676,"NCT00402597","Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Patients With Acute Coronary Syndromes (The ATLAS ACS TIMI 46 Trial)",,"Completed","Has Results","Acute Coronary Syndrome","Drug: Rivaroxaban/Placebo|Drug: Placebo|Drug: Rivaroxaban","Thrombolysis in Myocardial Infarction (TIMI) Clinically Significant Bleeding Events (Primary Safety)|The Composite Endpoint of All Cause Death, Myocardial Infarction (MI) (Including Repeat MI), Stroke (Ischemic, Hemorrhagic or Unknown), or Severe Recurrent Ischemia Requiring Revascularization (Primary Efficacy)|The Composite Endpoint of Death (All Cause), Myocardial Infarction (MI) (or Repeat MI), or Stroke|The Composite Endpoint of Cardiovascular Death, Myocardial Infarction (MI), or Stroke|The Number of Deaths (All Cause)|The Composite Endpoint of Death (All Cause), MI (or reMI), Stroke, Severe Recurrent Ischemia Requiring Revascularization, or Thrombolysis in Myocardial Infarction (TIMI) (Major or Minor Bleeding) to Assess the Net Clinical Benefit","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Bayer","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","3490","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CR013417|39039039ACS2001","November 2006","October 2008","October 2008","November 22, 2006","August 29, 2012","October 4, 2012",,,"https://ClinicalTrials.gov/show/NCT00402597"
1677,"NCT00390611","Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer",,"Completed","Has Results","Ovarian Cancer","Drug: Sorafenib|Drug: Paclitaxel|Drug: Carboplatin","2-year Progression-free Survival|Overall Response Rate (ORR)|Overall Survival (OS)|Toxicity of Paclitaxel/Carboplatin vs. Paclitaxel/Carboplatin/Sorafenib","SCRI Development Innovations, LLC|Bayer","Female","18 Years and older   (Adult, Older Adult)","Phase 2","85","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCRI GYN 19|SR05-918","October 2006","July 2012","April 2014","October 20, 2006","December 22, 2014","December 22, 2014","Northeast Arkansas Clinic, Jonesboro, Arkansas, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Holy Cross Hospital, Ft. Lauderdale, Florida, United States|Gulfcoast Oncology Associates, St. Petersburg, Florida, United States|Medical College of Georgia Cancer Specialists, Augusta, Georgia, United States|Providence Medical Group, Terre Haute, Indiana, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|National Capital Clinical Research Consortium, Bethesda, Maryland, United States|St. Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, United States|Oncology Hematology Care, Cincinnati, Ohio, United States|University of Oklahoma, Oklahoma City, Oklahoma, United States|South Carolina Oncology Associates, PA, Columbia, South Carolina, United States|Tennessee Valley Clinical Research, Chattanooga, Tennessee, United States|Family Cancer Center, Collierville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Peninsula Cancer Center, Newport News, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00390611"
1678,"NCT00386321","Yt90 Zevalin and Combination Chemotherapy (Z-CHOP)in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-cell Lymphoma",,"Terminated","No Results Available","Diffuse Large B-cell Lymphoma","Drug: Yttrium 90 -labeled ibritumomab tiuxetan (Zevalin)","2-year progression-free survival and overall survival of patients|Response rate (partial response, complete unconfirmed response, and complete response)in patients|2-year progression-free survival, overall survival and response rate in BCL-2 positive patients","Chulalongkorn University|Bayer","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","10","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TH011103","April 2006","July 2007","January 2010","October 11, 2006",,"November 18, 2010","King Chulalongkorn Memorial Hospital, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT00386321"
1679,"NCT00381004","FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia",,"Completed","Has Results","Chronic Lymphocytic Leukemia","Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Sargramostim|Drug: Rituximab","Participant Overall Response Rate (ORR) at 6 Months Includes Complete Remissions, Partial Remission, or Nodule Partial Remissions.|Number of Participants With Overall Response Includes Complete Remissions, Partial Remission, or Nodule Partial Remissions.|Number of Participants Progression-free","M.D. Anderson Cancer Center|Bayer","All","Child, Adult, Older Adult","Phase 2","60","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2006-0267","September 2006","December 2014","December 2014","September 27, 2006","August 14, 2015","January 14, 2016","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00381004"
1680,"NCT00376077","A Randomized Study of IVIG vs. IVIG With High Dose Methylprednisolone in Childhood ITP.",,"Completed","No Results Available","Immune Thrombocytopenic Purpura","Drug: Methylprednisolone and IVIG|Drug: Placebo and IVIG","The rapidity of rise in Platelet Count|Days to PC falling to < 20 x 109/L|Adverse Effects of therapy|Quality of life changes over time and between the treatment groups","The Hospital for Sick Children|Bayer","All","1 Year to 17 Years   (Child)","Phase 3","32","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1000006180","August 2005","March 2016","April 2016","September 14, 2006",,"May 9, 2016","Hospital for Sick Children, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00376077"
1681,"NCT00373373","Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML",,"Completed","No Results Available","Acute Myeloid Leukemia","Drug: Sorafenib|Drug: Placebo","Median Event Free Survival of all AML patients|Median Event Free Survival of AML patients with Flt3-ITD mutations|Median Event Free Survival of the patients in each of the four strata (Flt3 Non-ITD/NPM1 WT, Flt3 Non-ITD/NPM1 mut, Flt3 ITD/NPM1 WT, Flt3 ITD/NPM1 mut)|Median Overall Survival of AML patients with Flt3-ITD mutations|Median Overall Survival of all AML patients|Rate of Complete Remission in all AML patients|Rate of Molecular Remission in all AML patients|Toxicity|Evidence of Minimal Residual Disease in all AML patients|Development of Biomarkers indicating the course of disease","University Hospital Muenster|Bayer","All","61 Years and older   (Adult, Older Adult)","Phase 2","200","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","KKS/INNERE_A/AML2006|EudraCT Number: 2005-005966-35|Sorafenib in AML","September 2006","July 2009","July 2009","September 8, 2006",,"August 19, 2009","Charité Campus Benjamin Franklin, Med. Klinik III, Berlin, Germany|Klinikum Chemnitz GmbH, Klinik für Innere Medizin III, Chemnitz, Germany|Universitätsklinikum Carl Gustav Carus der TU Dresden, Medizinische Klinik I, Dresden, Germany|St. Johannes Hospital, Medizinische Klinik II, Duisburg, Germany|Universitätsklinikum Essen, Zentrum für Innere Medizin, Medizinische Klinik und Poliklinik für Hämatologie, Essen, Germany|Klinikum der J. W. Goethe-Universität Frankfurt am Main, Medizinische Klinik II, Frankfurt / Main, Germany|Allgemeines Krankenhaus St. Georg, Hämatologische Abteilung, Hamburg, Germany|Universitätsklinikum Heidelberg, Med. Klinik V, Heidelberg, Germany|Klinikum der Universität zu Köln, Klinik I für Innere Medizin, Köln, Germany|Klinikum der Johannes Gutenberg Universität, 3. Medizinische Klinik und Poliklinik, Mainz, Germany|Philipps Universität, Abteilung für Hämatologie, Onkologie und Immunologie, Marburg, Germany|Klinik für Hämatologie und Onkologie Klinikum Minden, Minden, Germany|TU München, Medizinische Klinik III, München, Germany|Universitätsklinikum Münster, Medizinische Klinik A, Münster, Germany|Klinikum Nürnberg, 5. Medizinische Klinik Einheit für Knochenmarktransplantation, Nürnberg, Germany|Universität Regensburg, Abteilung für Hämatologie und Internistische Onkologie, Regensburg, Germany|Robert-Bosch Krankenhaus Stuttgart, Stuttgart, Germany|Julius-Maximilians-Universität Würzburg, Medizinische Klinik und Poliklinik II, Würzburg, Germany",,"https://ClinicalTrials.gov/show/NCT00373373"
1682,"NCT00335257","International Active Surveillance Study of Women Taking Oral Contraceptives (INAS-OC)",,"Completed","Has Results","Contraception",,"Venous Thromboembolism (VTE); Hazard Ratio for DRSP-24 Day vs. Non-DRSP OCs|Arterial Thromboembolism (ATE), Hazard Ratio for DRSP-24 Day vs. Non-DRSP OCs","Center for Epidemiology and Health Research, Germany|Bayer","Female","Child, Adult, Older Adult",,"85109","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ZEG 2005-2","August 2005","January 2013","March 2013","June 9, 2006","November 18, 2014","August 7, 2019","Center for Epidemiology and Health Research, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT00335257"
1683,"NCT00323557","Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients",,"Completed","Has Results","Leukemia","Drug: Sargramostim (GM-CSF)|Biological: Pneumococcal Vaccine","Number of Participants (With Increase) Immune Response to GM-CSF With a Pneumococcal Vaccine","M.D. Anderson Cancer Center|Bayer","All","Child, Adult, Older Adult","Phase 2","39","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2003-0605","June 2004","May 2011","May 2011","May 9, 2006","May 2, 2012","December 5, 2012","UT MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00323557"
1684,"NCT00323323","CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas",,"Completed","No Results Available","Non-Hodgkin's Lymphoma","Drug: CHOP|Drug: Alemtuzumab|Procedure: Plasma Samples","Toxicity and safety of concurrent CHOP and Alemtuzumab|Determine pharmacokinetics of Alemtuzumab|Determine immunosuppressive properties of Alemtuzumab + CHOP|Determine if Fc Receptor-gamma (FcγR) polymorphism is predictive of response or toxicity with Alemtuzumab treatment.","Ohio State University Comprehensive Cancer Center|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","24","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OSU-0303","March 2004","August 2012","October 2016","May 9, 2006",,"January 20, 2017","Ohio State University, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00323323"
1685,"NCT00322218","Study Comparing the Zevalin Regimen With no Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R",,"Unknown status","No Results Available","Lymphoma, Large Cell, Diffuse","Drug: Zevalin Therapeutic Regimen|Other: Observation","Overall survival|Disease-free survival|Health-related quality of life","CTI BioPharma|Bayer","All","60 Years and older   (Adult, Older Adult)","Phase 3","400","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","307940/106-20","May 2006","December 2009","December 2009","May 5, 2006",,"October 23, 2008","Research Site, Mesa, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Scottsdale, Arizona, United States|Research Site, Bakersfield, California, United States|Research Site, Berkeley, California, United States|Research Site, Beverly Hills, California, United States|Research Site, Burbank, California, United States|Research Site, Duarte, California, United States|Research Site, Los Angeles, California, United States|Research Site, Newport Beach, California, United States|Research Site, San Diego, California, United States|Research Site, Vallejo, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Newark, Delaware, United States|Research Site, St. Petersburg, Florida, United States|Research Site, Coeur d'Alene, Idaho, United States|Research Site, Chicago, Illinois, United States|Research Site, Joliet, Illinois, United States|Research Site, Morris,, Illinois, United States|Research Site, Overland Park, Kansas, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Rochester, Minnesota, United States|Research Site, St Louis Park, Minnesota, United States|Research Site, Lebanon, New Hampshire, United States|Research Site, Commack, New York, United States|Research Site, East Setauket, New York, United States|Research Site, New York, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Aberdeen, South Dakota, United States|Research Site, Dallas, Texas, United States|Research Site, Houston,, Texas, United States|Research Site, Norfolk, Virginia, United States|Research Site, Graz, Austria|Research Site, Innsbruck, Austria|Research Site, Brugge, Belgium|Research Site, Gent, Belgium|Research Site, Leuven, Belgium|Research Site, Edmonton, Alberta, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Helsinki, Finland|Research Site, Oulu, Finland|Research Site, Creteil, France|Research Site, Dijon, France|Research Site, Lille Cedex, France|Research Site, Limoges, France|Research Site, Lyon Cedex, France|Research Site, Paris Cedex, France|Research Site, Toulouse Cedex, France|Research Site, Chemnitz, Germany|Research Site, Jena, Germany|Research Site, Karlsruhe, Germany|Research Site, Mainz, Germany|Research Site, Rostock, Germany|Research Site, Wurzburg, Germany|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Szeged, Hungary|Research Site, Dublin, Ireland|Research Site, Galway, Ireland|Research Site, Bologna, Italy|Research Site, Milan, Italy|Research Site, Perugia, Italy|Research Site, Pisa, Italy|Research Site, Torino, Italy|Research Site, Seoul, Korea, Republic of|Research Site, Yonsei, Korea, Republic of|Research Site, Gdansk, Poland|Research Site, Krakow, Poland|Research Site, Poznan, Poland|Research Site, Warsaw, Poland|Research Site, Coimbra, Portugal|Research Site, Lisbon, Portugal|Research Site, Porto, Portugal|Research Site, Singapore, Singapore|Research Site, Madrid, Spain|Research Site, Pamplona, Spain|Research Site, Salamanca, Spain|Research Site, Sevilla, Spain|Research Site, Malmo, Sweden|Research Site, Uddevalla, Sweden|Research Site, Umea, Sweden|Research Site, Bern, Switzerland|Research Site, St Gallen, Switzerland|Research Site, Bangkok, Thailand|Research Site, Leicester, United Kingdom|Research Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00322218"
1686,"NCT00320788","Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)",,"Completed","Has Results","Macular Degeneration","Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)","Mean Change of CR/LT From Baseline at Week 12|Mean Percent Change of CR/LT From Baseline at Week 12|Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) From Baseline at Week 12|Percentage of Participants Who Gained at Least 15 Letters of Vision in the ETDRS Letter Score From Baseline at Week 12","Regeneron Pharmaceuticals|Bayer","All","50 Years and older   (Adult, Older Adult)","Phase 2","159","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","VGFT-OD-0508","April 2006","June 2008","August 2008","May 3, 2006","March 1, 2012","March 1, 2012","Associated Retina Consultants, Phoenix, Arizona, United States|Retina Centers, PC, Tucson, Arizona, United States|Retina Vitreous Associates Medical Group, Beverly Hills, California, United States|Loma Linda University Health Care, Loma Linda, California, United States|Southeast Retina Center, Augusta, Georgia, United States|University of Chicago, Chicago, Illinois, United States|Midwest Eye Institute, Indianapolis, Indiana, United States|Johns Hopkins Hospital School of Medicine, Baltimore, Maryland, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|New England Retina Consultants PC, West Springfield, Massachusetts, United States|Charlotte Eye, Ear, Nose & Throat Asssociates, Charlotte, North Carolina, United States|Dean A. McGee Eye Institute, Oklahoma City, Oklahoma, United States|Retina Northwest PC, Portland, Oregon, United States|Retina Diagnostic and Treatment Assoc., LLC, Philadelphia, Pennsylvania, United States|Black Hills Regional Eye Institute, Rapid City, South Dakota, United States|Retina-Vitreous Associates, P.C., Nashville, Tennessee, United States|Vitreoretinal Consultants Scurlock Tower Texas Medical Center, Houston, Texas, United States|Medical Center Ophthamology, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00320788"
1687,"NCT00320775","Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD",,"Completed","No Results Available","Macular Degeneration","Drug: VEGF Trap","Safety and tolerability, bioeffect|The effect of VEGF Trap administration on excess central retinal/lesion thickness|Best-corrected Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity|Extent of CNV leakage|Anti-VEGF Trap antibodies in the systemic circulation|Plasma levels of VEGF Trap","Regeneron Pharmaceuticals|Bayer","All","50 Years and older   (Adult, Older Adult)","Phase 1","51","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VGFT-OD-0502","June 2005","June 2008","August 2008","May 3, 2006",,"March 18, 2015","Retina Centers, PC, Tuscon, Arizona, United States|Loma Linda University Health Care, Loma Linda, California, United States|University of Chicago, Chicago, Illinois, United States|Johns Hopkins Hospital School of Medicine, Baltimore, Maryland, United States|Charlotte Eye, Ear, Nose & Throat Asssociates, Charlotte, North Carolina, United States|Dean A. McGee Eye Institute, Oklahoma City, Oklahoma, United States|Retina Diagnostic and Treatment Assoc., LLC, Philadelphia, Pennsylvania, United States|Retina-Vitreous Associates, P.C., Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00320775"
1688,"NCT00317564","Betaseron Pregnancy Registry",,"Completed","No Results Available","Birth Defects|Pregnancy Complications|Multiple Sclerosis",,,"Syneos Health|Bayer","Female","Child, Adult, Older Adult",,"113","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","308740","April 2006","April 2012","June 2012","April 25, 2006",,"December 12, 2018","INC Research, Wilmington, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00317564"
1689,"NCT00313482","PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPC",,"Terminated","No Results Available","Hormone Refractory Prostate Cancer","Drug: Sargramostim|Drug: Docetaxel|Drug: Prednisone","To evaluate the effects of the combination of docetaxel/prednisone with sargramostim on progression-free survival in chemotherapy-naïve male patients with hormone-refractory prostate cancer (HRPC).|To evaluate the response (as demonstrated by PSA and/or measurable disease) to the combination of docetaxel/prednisone with sargramostim.|To evaluate the 1-year and 2-year survival following treatment with the combination of docetaxel/prednisone with sargramostim.|To evaluate the safety of the combination of docetaxel/prednisone with sargramostim.","Veeda Oncology|Bayer","Male","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","35","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","I-05-011","April 2006","August 2008","August 2008","April 12, 2006",,"May 11, 2012","Veeda Oncology, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00313482"
1690,"NCT00311870","Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy",,"Completed","No Results Available","Diabetic Nephropathy","Drug: nisoldipine|Drug: lisinopril","change in glomerular filtration rate from study start to study end|blood pressure response|change in urinary albumin excretion rate","Steno Diabetes Center Copenhagen|Bayer","All","18 Years to 55 Years   (Adult)","Phase 4","52","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment","KA 92126","March 1993",,"April 1999","April 6, 2006",,"April 6, 2006","Steno Diabetes Center, Gentofte, Denmark",,"https://ClinicalTrials.gov/show/NCT00311870"
1691,"NCT00272337","Aspirin Dose and Atherosclerosis in Patients With Heart Disease","TAD","Completed","Has Results","Cardiovascular Diseases|Atherosclerosis|Myocardial Infarction","Drug: Aspirin","Change in Nitric Oxide Formation From Baseline to 3 Months.","Florida Atlantic University|Bayer","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 4","37","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","H08-36","October 2006","June 2009","June 2009","January 5, 2006","June 18, 2012","December 28, 2018","Florida Cardiovascular Research, Atlantis, Florida, United States|The Broward Heart Group, P.A., Tamarac, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00272337"
1692,"NCT00272311","Aspirin Dose and Atherosclerosis in Patients With Metabolic Syndrome","PAD","Completed","Has Results","Cardiovascular Diseases|Metabolic Syndrome X|Atherosclerosis","Drug: Aspirin","Change in Nitric Oxide Formation From Baseline to 3 Months","Florida Atlantic University|Bayer","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 4","70","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","H08-35","October 2006","January 2009","January 2009","January 5, 2006","June 19, 2012","February 27, 2019","HeartDrug Research, LLC, Towson, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00272311"
1693,"NCT00256282","Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma",,"Completed","Has Results","Metastatic Melanoma","Drug: Vinorelbine|Drug: Docetaxel|Drug: Sargramostim","Progression-free Survival (PFS) in Patients With AJCC Stage IV Metastatic Melanoma Treated With Docetaxel and Vinorelbine as First-line or Post-first Line (Salvage) Systemic Therapy|Percentage of Patients Alive at One Year","John P. Fruehauf|Bayer|University of California, Irvine","All","18 Years and older   (Adult, Older Adult)","Phase 2","52","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCI 02-23|2002-2763|NCI-2010-00217","April 2003","August 2012","August 2012","November 21, 2005","May 3, 2018","May 3, 2018","Chao Family Comprehensive Cancer Center, Orange, California, United States",,"https://ClinicalTrials.gov/show/NCT00256282"
1694,"NCT00244023","Co-Administering Testosterone With PDE5 Inhibitors in ED Patients Non Responders to PDE5 Inhibitors Alone",,"Completed","No Results Available","Erectile Dysfunction|Hypogonadism","Drug: Testosterone gel|Drug: testosterone|Other: placebo gel","mean change from baseline in the Erectile Function Domain Score of the IIEF (questions 1-5 + 15) on Tadalafil + Testosterone compared to the one on Tadalafil + placebo.|Rate of ""responders"" to treatment|Rate of the patients having achieved a score > 26 at the EFD of the IIEF|Mean scores at Questions 3 and 4 of the IIEF|Mean scores at the 4 other domains of the IIEF (Orgasmic Function, Sexual Desire, Intercourse Satisfaction and Overall Satisfaction Domains), and at the whole IIEF|% of ""YES"" responses at questions 2, 3, 4 and 5 of the SEP|Percentage of ""YES"" responses to the GAQ|Scores at the different domains of the AMS questionnaire","SELARL du Dr Jacques BUVAT|Bayer","Male","45 Years to 80 Years   (Adult, Older Adult)","Phase 3","173","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TADTEST","October 2005","July 2007","July 2007","October 25, 2005",,"August 25, 2008","CETPARP/SelarlJBuvat, Lille, France",,"https://ClinicalTrials.gov/show/NCT00244023"
1695,"NCT00237575","Randomized Phase III Trial of Leukine® vs Neupogen® in Patients Receiving Cisplatin & Gemcitabine for Urothelial Cancer",,"Terminated","No Results Available","Bladder Cancer","Drug: gemcitabine|Drug: cisplatin|Drug: sargramostim|Drug: filgrastim","Efficacy of Leukine & Neupogen to prevent grade 3 & 4 neutropenia in patients receiving cisplatin & gemcitabine: assessed before cycles 3 & 5, then at end of treatment.|Safety of Leukine & Neupogen: evaluated before each cycle & blood work is evaluated weekly throughout the study.|Reduction of grade 3 & 4 hematologic toxicities: evaluated weekly throughout the study.|Reduction of clinical hematologic toxicity including the # of: hospital days required for febrile neutropenia, transfusions & bleeding events, & days of outpatient antibiotics: evaluated throughout the study treatment and until resolved.|Reduction of non-hematologic toxicities: evaluated prior to each cycle.|Enhancement of anti-tumor effects (CR & PR, time to progression, OS & DFS): assessed before cycles 3 & 5, then on day 22 of cycle 6.|Dose intensity as planned vs administered: assessed during each treatment.|Quality of life: evaluated at baseline, pre-cylces 3 & 5, & end of treatment.","University of Kentucky|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","100","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","04-GU-53B","November 2005","March 2006","March 2006","October 12, 2005",,"May 23, 2012","University of Louisville, Louisville, Kentucky, United States|University of Nebraska, Omaha, Nebraska, United States|Montefiore Medical Center, Bronx, New York, United States|New York Medical College, Hawthorne, New York, United States",,"https://ClinicalTrials.gov/show/NCT00237575"
1696,"NCT00230282","Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia",,"Completed","Has Results","Leukemia|B-cell Leukemia|Chronic Leukemia|Chronic Lymphocytic Leukemia (CLL)","Drug: Alemtuzumab|Drug: Fludarabine|Drug: Cytoxan","Number of Subjects Maintaining Partial Response (PR) or Complete Response (CR)|Duration of Response","Steven E. Coutre|Bayer|Stanford University","All","18 Years and older   (Adult, Older Adult)","Phase 2","25","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-13053|31185|80071|HEMCLL0001","July 2004","December 2010","October 2011","September 30, 2005","September 8, 2014","October 6, 2014","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT00230282"
1697,"NCT00226512","To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning",,"Withdrawn","No Results Available","Acute Myeloid Leukemia|Myelodysplastic Syndrome","Drug: Campath-1H /ATG","To determine the efficacy of s.c. Campath-1H or ATG in decreasing the incidence and severity of acute and chronic GVHD in patients with AML and MDS treated with non-myeloablative stem cell transplantation.|Investigate the role of different conditioning regimens on:|Infection, engraftment relapse rate and disease free survival.","Hadassah Medical Organization|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","203","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","230704-HMO-CTIL","July 2004",,,"September 27, 2005",,"April 8, 2011","Hadassah Medical Organization, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT00226512"
1698,"NCT00216931","Treatment of Elevated Arterial Pulmonary Pressure With Inhaled Iloprost",,"Withdrawn","No Results Available","Persistent Pulmonary Hypertension|Respiratory Distress Syndrome","Drug: iloprost","Oxygenation index|Cardiac output","Lund University Hospital|Bayer","All","up to 48 Hours   (Child)","Not Applicable","40","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2004-001551-11","May 2006",,"October 2008","September 22, 2005",,"February 4, 2009","University Hospital in Lund , Department of Pediatrics, Lund, Sweden",,"https://ClinicalTrials.gov/show/NCT00216931"
1699,"NCT00214903","European Active Surveillance Study of Women Taking Hormone Replacement Therapy (HRT)",,"Completed","Has Results","Menopausal Symptoms",,"Venous Thromboembolism (e.g., Deep Venous Thrombosis and Pulmonary Embolism)|Arterial Thromboembolism (e.g., Acute Myocardial Infarction and Stroke)","Center for Epidemiology and Health Research, Germany|Bayer","Female","40 Years and older   (Adult, Older Adult)",,"30597","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ZEG 2000_3","November 2004","May 2011","November 2011","September 22, 2005","November 14, 2014","December 1, 2014","Center for Epidemiology and Health Research, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT00214903"
1700,"NCT00212485","Study to Evaluate the Use of Ultrasound in the Diagnosis of Hemophilic Joint Disease",,"Completed","No Results Available","Inherited Bleeding Disorders","Procedure: Power Doppler Sonography|Procedure: MRI","Comparison of magnetic resonance imaging (MRI) and power Doppler sonograms on patients with target joint|Evaluation of PDS on patients with target joints pre and post synovectomy to assess response to therapeutic intervention|Evaluation of PDS on patients with at least 2 joint bleeds to diagnose early synovitis","New York Presbyterian Hospital|Bayer","All","1 Year to 60 Years   (Child, Adult)","Not Applicable","43","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PDS","September 2005","April 2008","May 2009","September 21, 2005",,"July 1, 2010","New York Presbyterian Hospital/Hospital for Special Surgery, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00212485"
1701,"NCT00208975","Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and Rituximab",,"Terminated","Has Results","Lymphoma","Drug: Mitoxantrone/Cyclophosphamide, Fludarabine, Rituximab and GM-CSF","Number of Patients's Who Had Complete Response and Partial Response to the Treatment of Fludarabine and Cyclophosphamide Followed by GM-CSF and Rituximab.","Emory University|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1048-2001","July 2002","December 2009","September 2011","September 21, 2005","June 28, 2012","June 28, 2012","Emory University Winship Cancer Institute, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT00208975"
1702,"NCT00193466","Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",,"Completed","No Results Available","Non-Hodgkins Lymphoma","Drug: Rituximab|Drug: Fludarabine|Drug: CAMPTH-1H","Complete response rate|Molecular complete response rate|Progression free survival|Overall toxicity","SCRI Development Innovations, LLC|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCRI LYM 21|CAM-217","January 2002","January 2007","April 2008","September 19, 2005",,"December 30, 2010",,,"https://ClinicalTrials.gov/show/NCT00193466"
1703,"NCT00176280","Randomized Phase 2 Trial of Pre-chemotherapy Leukine vs. Leukine-Dexamethasone in Combination With Gemzar & 5-FU in Patients With Metastatic Renal Cell Carcinoma",,"Withdrawn","No Results Available","Renal Cell Carcinoma","Drug: Leukine|Drug: Dexamethasone","% of subjects with CR or PR evaluated after course 2 then every other course using RECIST for both cohorts|Survival (assessed until death)|QOL (evaluated after courses 3 & 5 then every other course)|% of subjects with >/= grade 3 hematopoietic & non-hematopoietic toxicities (assessed 3/week on treatment & continuing until counts recover)|Days with <AGC 500 & platelet (PLC)< 20K mm3, # of febrile neutropenia hospital days, # of transfusions, bleeding & # of outpatient antibiotic days (assessed 3/week on treatment then until counts recover)|Levels of peripheral blood dendritic cell # & function, plasma levels of cytokines including VEGF & TNF alpha (performed on days 1 & 7 of treatment)","University of Kentucky|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","04-GU-51-B","September 2005",,,"September 15, 2005",,"June 18, 2015",,,"https://ClinicalTrials.gov/show/NCT00176280"
1704,"NCT00171587","Study of the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Effects of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer",,"Completed","No Results Available","Tumors|Neoplasm Metastasis","Drug: PTK787/ZK 222584 (vatalanib)","Safety|Tolerability|Pharmacokinetics","Novartis|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","22","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CPTK787 0134/306220","May 2002","March 2007","March 2007","September 15, 2005",,"November 19, 2009","University of Chicago, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT00171587"
1705,"NCT00161590","Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma",,"Completed","No Results Available","T-Cell Lymphoma|Lymphoma, Non-Hodgkin's","Drug: CHOP and alemtuzumab",,"Weill Medical College of Cornell University|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1",,"Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0204-157","July 2004",,,"September 12, 2005",,"October 22, 2008","Weill Medical College of Cornell University, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00161590"
1706,"NCT00139984","Ambulatory Blood Pressure Monitoring for Antihypertensive Treatment Guidance",,"Completed","No Results Available","Hypertension","Device: 24 hour blood pressure measurement","Change in 24-hour systolic blood pressure from baseline to 1 year|Change in 24-hour diastolic blood pressure from baseline to 1 year|Primary outcome measure in patients with treated hypertension at baseline","University Hospital, Basel, Switzerland|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 4","170","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment","EKBB183/03","October 2003",,"May 2007","August 31, 2005",,"February 2, 2017","Medical Outpatient Clinic, University Hospital Basel, Basel, Switzerland|Private Practice, Basel, Switzerland",,"https://ClinicalTrials.gov/show/NCT00139984"
1707,"NCT00137787","Comparing Ciprofloxacin (CPFX) With Cefepime (CFPM) in Febrile Neutropenic Patients With Hematologic Diseases",,"Completed","No Results Available","Febrile Neutropenia","Drug: ciprofloxacin|Drug: cefepime","Treatment efficacy|Toxicity","Center for Supporting Hematology-Oncology Trials|Bayer","All","15 Years to 79 Years   (Child, Adult, Older Adult)","Phase 3","51","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C-SHOT 0402","April 2005","December 2009","May 2010","August 30, 2005",,"June 26, 2018","Nagoya University Graduate School of Medicine, Nagoya, Japan",,"https://ClinicalTrials.gov/show/NCT00137787"
1708,"NCT00117299","PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors Resistant to Imatinib",,"Completed","No Results Available","Sarcoma","Drug: PTK787/ZK222584","Response rate","Helsinki University|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","45","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CPTK787 A2401/300267|GIST PTK787/ZK222584","September 2004","September 2007","January 2009","July 6, 2005",,"May 27, 2010","Helsinki University Central Hospital, Helsinki, Finland",,"https://ClinicalTrials.gov/show/NCT00117299"
1709,"NCT00071396","Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders",,"Completed","Has Results","Chronic Lymphocytic Leukemia","Drug: Campath-1H|Drug: Rituximab","Overall Response","M.D. Anderson Cancer Center|Bayer","All","15 Years and older   (Child, Adult, Older Adult)","Phase 2","48","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ID02-368","October 2002","September 2006","August 2007","October 22, 2003","February 25, 2011","August 7, 2012","University of Texas - MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00071396"
1710,"NCT00056459","Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.",,"Completed","No Results Available","Colorectal Neoplasms|Colonic Neoplasms|Rectal Neoplasms","Drug: Vatalanib","Progression free survival|Time to progression|Time to treatment failure|Best overall response rate|Tolerability and safety profile","Novartis|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","1168","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","CPTK787 0135/306241|CONFIRM 1","February 2003","January 2007",,"March 14, 2003",,"November 19, 2009","Alabama Hematology/Oncology, Birmingham, Alabama, United States|Palo Verde Hematology & Oncology, Glendale, Arizona, United States|Arizona Cancer Center, Tucson, Arizona, United States|Northeast Arkansas Clinic, Jonesboro, Arkansas, United States|Highlands Oncology Group, Springdale, Arkansas, United States|Comprehensive Blood and Cancer Center, Bakersfield, California, United States|Providence St. Joseph Medical Center, Burbank, California, United States|Compassionate Cancer Care Medical Group, Inc, Fountain Valley, California, United States|California Oncology of the Central Valley, Fresno, California, United States|Virginia K. Crosson Cancer Center, Fullerton, California, United States|Ronald Yanagiharaa, M.D., Gilroy, California, United States|Glendale Adventist Medical Center Cancer Center, Glendale, California, United States|Pacific Shores Medical Group, Long Beach, California, United States|Cancer Institute Medical Group, Los Angeles, California, United States|USC/Norris Comprehensive Cancer Care Center, Los Angeles, California, United States|Synergy Hematology-Oncology Medical Associates, Los Angeles, California, United States|UCLA School of Medicine, Los Angeles, California, United States|Eddie Hong-Lung Hu, M.D., Monterey Park, California, United States|North Valley Hematology/Oncology Medical Group, Northridge, California, United States|Ventura County Hematology-Oncology Specialists, Oxnard, California, United States|Wilshire Oncology Medical Group, Pomona, California, United States|Sierra View District Hospital, Porterville, California, United States|The Lucy Curci Cancer Center, Rancho Mirage, California, United States|Cancer Care Associates Medical Group, Inc., Redondo Beach, California, United States|Pacific Hematology Oncology Associates, San Francisco, California, United States|Santa Clara Valley Medical Center, San Jose, California, United States|Sansum Santa Barbara Foundation Medical Clinic, Santa Barbara, California, United States|Santa Barbara Hematology Oncology Medical Group, Inc., Santa Barbara, California, United States|San Diego Cancer Center Medical Group, Vista, California, United States|Colorado Cancer Research Program, Denver, Colorado, United States|Jennifer Caskey, M.D., Wheat Ridge, Colorado, United States|Davis, Posteraro and Wasser, MD's, LLP, Manchester, Connecticut, United States|Connecticut Oncology Group, Middletown, Connecticut, United States|Medical Oncology Hematology Consultants, Newark, Delaware, United States|Washington Oncology-Hematology Center, Washington, District of Columbia, United States|George Washington University Medical Center, Washington, District of Columbia, United States|Boca Raton Comprehensive Cancer Center, Boca Raton, Florida, United States|Florida Cancer Specialists, Ft. Myers, Florida, United States|Memorial Healthcare System, Hollywood, Florida, United States|Florida Oncology Associates, Jacksonville, Florida, United States|Lakeland Regional Cancer Center, Lakeland, Florida, United States|Innovative Medical Research of South Florida, Miami Shores, Florida, United States|Oncology Hematology Group of South Florida, Miami, Florida, United States|Hematology Oncology Associates of Treasure, Port St. Lucie, Florida, United States|Florida Medical Clinic, PA, Zephyrhills, Florida, United States|Peachtree Hematology and Oncology, Atlanta, Georgia, United States|Coastal Hematology & Oncology, Savannah, Georgia, United States|North Idaho Cancer Center, Couer d'Alene, Idaho, United States|Shelby D. Rifkin, M.D., Arlington Heights, Illinois, United States|Monroe Medical Associates, Harvey, Illinois, United States|Oncology Hematology Associates of Central Illinois, PC, Peoria, Illinois, United States|Northshore Cancer Research Association, Skokie, Illinois, United States|Midwest Cancer Research Group, Skokie, Illinois, United States|Hematology-Oncology of Indiana, PC, Indianapolis, Indiana, United States|Associated Physicians & Surgeons Clinic, L.L.C., Terre Haute, Indiana, United States|Markey Clinical Oncology Research Program, Lexington, Kentucky, United States|Norton Healthcare Pavilion, Louisville, Kentucky, United States|Vijay Raghavan, M.D., Louisville, Kentucky, United States|Louisiana Oncology Associates, Lafayette, Louisiana, United States|LSU Medical Center, New Orleans, Louisiana, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|LSU Health Sciences Center, Shreveport, Louisiana, United States|Maine Center for Cancer Medicine & Blood Disorders, Scarborough, Maine, United States|St. Agnes Healthcare, Inc., Baltimore, Maryland, United States|Kaiser Permanente, Rockville, Maryland, United States|St. Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Josephine Ford Cancer Center, Detroit, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Spectrum Health -- Cook Research Dept., Grand Rapids, Michigan, United States|Hematology and Oncology Assoc. of Southern Mississippi, Jackson, Michigan, United States|Providence Cancer Center, Southfield, Michigan, United States|Oncology Care Associates, PLLC, St. Joseph, Michigan, United States|SMDC Health System, Duluth, Minnesota, United States|Minnesota CGOP, Minneapolis, Minnesota, United States|University of Minnesota Cancer Center, Minneapolis, Minnesota, United States|Metro Minnesota CCOP, St. Louis Park, Minnesota, United States|Heartland Hematology/Oncology Associates, Inc., Kansas City, Missouri, United States|Kansas City Oncology and Hematology Group, Kansas City, Missouri, United States|Missouri Cancer Care, PC, St. Charles, Missouri, United States|Saint Louis University, St. Louis, Missouri, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Missouri Baptist Cancer Center, St. Louis, Missouri, United States|Arch Medical Services Incorporated, St. Louis, Missouri, United States|North Central Montana Professional Building, Great Falls, Montana, United States|Montana Cancer Specialists, Missoula, Montana, United States|The Methodist Cancer Center, Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Nevada Cancer Center, Las Vegas, Nevada, United States|The Center for Cancer and Hematologic Disease, Cherry Hill, New Jersey, United States|St. Barnabas Cancer Center, Livingston, New Jersey, United States|Hematology-Oncology Associates of New Jersey, Morristown, New Jersey, United States|Southern Oncology and Hematology Associates, Vineland, New Jersey, United States|Cooper Cancer Institute, Voorhees, New Jersey, United States|New Mexico Cancer Care, Santa Fe, New Mexico, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|CR Wood Cancer Center, Glen Falls, New York, United States|Cancer Research of Long Island, Great Neck, New York, United States|Broome Oncology, Johnson City, New York, United States|New York Oncology Hematology, Latham, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Cancer Center at Nyack Hospital, Nyack, New York, United States|Pluta Cancer Center, Rochester, New York, United States|Carolina Medical Center, Charlotte, North Carolina, United States|Mid-Dakota Clinic PC, Bismarck, North Dakota, United States|Nashat Gabrail, M.D., Canton, Ohio, United States|Mid Ohio Oncology/Hematology, Inc., Columbus, Ohio, United States|Hematology Oncology Consultants, Inc., Columbus, Ohio, United States|Meridia Cancer Institute, Mayfield Heights, Ohio, United States|Cancer Care Associates, Oklahoma City, Oklahoma, United States|Cancer Care Associates, Tulsa, Oklahoma, United States|Kaiser Permanente Oncology Hematology, Portland, Oregon, United States|Hershey Medical Center, Hershey, Pennsylvania, United States|Monogahela Valley Hospital, Monogahela, Pennsylvania, United States|University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States|Allegheny Cancer Center, Pittsburgh, Pennsylvania, United States|Charleston Hematology Oncology, Charleston, South Carolina, United States|Charleston Cancer Center, Charleston, South Carolina, United States|South Carolina Oncology Associates, Columbia, South Carolina, United States|Cancer Center of the Carolinas, Greenville, South Carolina, United States|Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States|The Jones Clinic, Germantown, Tennessee, United States|Baptist Regional Cancer Center, Knoxville, Tennessee, United States|University of Tennessee Cancer Institute, Memphis, Tennessee, United States|Sarah Cannon Cancer Center, Nashville, Tennessee, United States|Southwest Regional Cancer Center, Austin, Texas, United States|Corpus Christi Cancer Center, Corpus Christi, Texas, United States|Center for Oncology Research & Treatment, PA, Dallas, Texas, United States|Oncology Consultants, Houston, Texas, United States|H. Alejandro Preti, MD, PA, Houston, Texas, United States|M.D. Anderson Cancer Center, Houston, Texas, United States|Dr. Lee C. Drinkard, Irving, Texas, United States|Scott & White Hospital, Temple, Texas, United States|North Utah Associates, Ogden, Utah, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Southwestern Vermont Health Care, Bennington, Vermont, United States|Danville Hematology and Oncology, Inc., Danville, Virginia, United States|Northern Virginia Oncology Group, Fairfax, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Cancer Treatment Centers of America, Portsmouth, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Western Washington Medical Group, Everett, Washington, United States|Western Washington Medical Group, Everett, Washington, United States|Cascade Cancer Center, Kirkland, Washington, United States|UW Health -- University of Wisconsin Comp, Madison, Wisconsin, United States|Waukesha Memorial Hospital, Waukesha, Wisconsin, United States|Adelaide, Australia|Garran, Australia|Nedlands, Australia|Wollongong, Australia|Woolloongabba, Australia|Anderlecht, Belgium|Antwerpen, Belgium|Bruxelles, Belgium|Gent, Belgium|Wilrijk, Belgium|Porto Alegre Rs, Brazil|Porto Alegre, Brazil|Salvador, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Hamilton, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Toronto, Ontario, Canada|Sainte-Foy, Quebec, Canada|Brno, Czech Republic|Praha 2, Czech Republic|Praha 5, Czech Republic|Marseille Cedex 05, France|Marseille Cedex 9, France|Strasbourg, France|Augsburg, Germany|Berlin, Germany|Berlin, Germany|Dessau, Germany|Erlangen, Germany|Eschweiler, Germany|Essen, Germany|Frankfurt, Germany|Hannover, Germany|Heidelberg, Germany|Kiel, Germany|Köln, Germany|Leipzig, Germany|Magdeburg, Germany|Budapest, Hungary|Budapest, Hungary|Gyor, Hungary|Szeged, Hungary|Forli, Italy|Genova, Italy|Milano, Italy|Modena, Italy|Roma, Italy|Roma, Italy|Rozzano, Italy|Torino, Italy|Ga Utrecht, Netherlands|Novartis Investigative Site, Hamilton, New Zealand|Palmerston North, New Zealand|Coimbra, Portugal|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Kosice, Slovakia|Novartis Investigative Site, Zilina, Slovakia|Alicante, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Malaga, Spain|Zaragoza, Spain|Stockholm, Sweden|Basel, Switzerland|Bern, Switzerland|Thun, Switzerland|Zurich, Switzerland|Zürich, Switzerland|Tainan, Taiwan|Taipei, Taiwan|Tao-Yuan, Taiwan|Belfast, United Kingdom|Leicester, United Kingdom|Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00056459"
1711,"NCT00056446","Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer",,"Completed","No Results Available","Colorectal Neoplasms|Colonic Neoplasms|Rectal Neoplasms","Drug: Vatalanib","Overall survival|Progression free survival|Time to progression|Time to treatment failure|Tumor response rate|Tolerability and safety profile","Novartis Pharmaceuticals|Bayer|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","855","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","CPTK787 0133/304946","January 2003","January 2007","January 2007","March 14, 2003",,"March 6, 2017","Comprehensive Cancer Institute, Huntsville, Alabama, United States|Alaska Oncology and Hematology, Anchorage, Alaska, United States|Arizona Clinical Research Center, Tucson, Arizona, United States|Northeast Arkansas Clinic, Jonesboro, Arkansas, United States|Arkansas Cancer Research Center, Little Rock, Arkansas, United States|Little Rock Hematology & Oncology, Little Rock, Arkansas, United States|Highlands Oncology Group, Springdale, Arkansas, United States|Comprehensive Blood and Cancer Center, Bakersfield, California, United States|Providence St. Joseph Medical Center, Burbank, California, United States|Compassionate Cancer Care Medical Group, Inc., Fountain Valley, California, United States|California Oncology of the Central Valley, Fresno, California, United States|Virginia K. Crosson Cancer Center, Fullerton, California, United States|Glendale Adventist Medical Center, Glendale, California, United States|Scripps Green Hospital, La Jolla, California, United States|Wilshire Oncology Medical Group, La Verne, California, United States|Pacific Shores Medical Group, Long Beach, California, United States|USC Norris Cancer Center, Los Angeles, California, United States|Synergy Hematology-Oncology Medical Associates, Los Angeles, California, United States|Novartis Investigative Site, Los Angeles, California, United States|UCLA School of Medicine, Los Angeles, California, United States|Eddie Hong-Lung Hu, M.D., Monterey Park, California, United States|North Valley Hematology/Oncology Medical Group, Northridge, California, United States|Medical Oncology Care Associates, Orange, California, United States|Ventura County Hematology-Oncology Specialists, Oxnard, California, United States|Sierra View District Hospital, Porterville, California, United States|Cancer Care Associates Medical Group, Inc., Redondo Beach, California, United States|Santa Clara Valley Medical Center, San Jose, California, United States|Sansum Santa Barbara Foundation Medical Clinic, Santa Barbara, California, United States|Santa Barbara Hematology Oncology Medical Group, Inc., Santa Barbara, California, United States|San Diego Cancer Center Medical Group, Vista, California, United States|Mile High Oncology, Denver, Colorado, United States|Rocky Mountain Cancer Center, Denver, Colorado, United States|Manchester Hematology/Oncology Assoc., Manchester, Connecticut, United States|Washington Oncology/Hematology Center, Washington, District of Columbia, United States|The Center for Hematology and Oncology, Boca Raton, Florida, United States|Florida Cancer Specialists, Ft. Myers, Florida, United States|Hematology Oncology Associates, Lake Worth, Florida, United States|University of Miami School of Medicine, Miami, Florida, United States|Oncology/Hematology Group of South Florida, Miami, Florida, United States|Hematology Oncology Associates of Treasure Coast, Port St. Lucie, Florida, United States|Florida Medical Clinic, Zephyrhills, Florida, United States|Atlanta Cancer Care, Marietta, Georgia, United States|Office of Research, Savannah, Georgia, United States|Coastal Hematology & Oncology, Savannah, Georgia, United States|Lewis Hall Singletary Oncology Center, Thomasville, Georgia, United States|North Idaho Cancer Center, Coeur d'Alene, Idaho, United States|University of Chicago medical Center, Hematology/Oncology, Chicago, Illinois, United States|Oncology Hematology Associates of Central Illinois, PC, Peoria, Illinois, United States|Northshore Cancer Research Association, Skokie, Illinois, United States|Midwest Cancer Research Group, Skokie, Illinois, United States|Fort Wayne Medical Oncology & Hematology, Inc., Fort Wayne, Indiana, United States|Munster Community Hospital, Munster, Indiana, United States|Cotton O'Neil Oncology Clinic, Topeka, Kansas, United States|Vijay Raghaven, M.D., Louisville, Kentucky, United States|Owensboro Medical Health System, Owensboro, Kentucky, United States|Cabrini Center for Cancer Care, Alexandria, Louisiana, United States|LSU Medical Center, New Orleans, Louisiana, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|LSU Health Sciences Center, Shreveport, Louisiana, United States|Maine Center for Cancer Medicine & Blood Disorders, Scarborough, Maine, United States|St. Agnes Healthcare, Baltimore, Maryland, United States|Franklin Square Hospital Center, Baltimore, Maryland, United States|Kaiser Permanente, Rockville, Maryland, United States|Fallon Clinic at Worcester Medical Center, Worcester, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Spectrum Health -- Cook Research Dept., Grand Rapids, Michigan, United States|Providence Cancer Center, Southfield, Michigan, United States|Oncology Care Associates, PLLC, St. Joseph, Michigan, United States|Minnesota CGOP, Minneapolis, Minnesota, United States|Heartland Hematology, Kansas City, Missouri, United States|Missouri Cancer Care, PC, St. Charles, Missouri, United States|Saint Louis University, St. Louis, Missouri, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Missouri Baptist Cancer Center, St. Louis, Missouri, United States|Arch Medical Services Incorporated, St. Louis, Missouri, United States|North Central Montana Professional Building, Great Falls, Montana, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Nevada Cancer Center, Las Vegas, Nevada, United States|NH Oncology-Hematology, PA, Hooksett, New Hampshire, United States|Center for Cancer and Hematologic Disease, Cherry Hill, New Jersey, United States|St. Barnabas Cancer Center, Livingston, New Jersey, United States|Hematology Oncology Associates of Northern New Jersey, Morristown, New Jersey, United States|Cooper Cancer Center, Voorhees, New Jersey, United States|Hematology/Oncology Associates, Albuquerque, New Mexico, United States|New Mexico Oncology/Hematology, Albuquerque, New Mexico, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Hematology/Oncology Associates of Central NY, East Syracuse, New York, United States|Queens Medical Associates, PC, Fresh Meadows, New York, United States|Charles R. Wood Cancer Center, Glens Falls, New York, United States|North Shore University Hospital, Manhasset, New York, United States|St. Vincent's Catholic Medical Centers of New York, New York, New York, United States|Hematology-Oncology Associates of Rockland, Nyack, New York, United States|Pluta Cancer Center, Rochester, New York, United States|James P. Wilmot Cancer Center, Rochester, New York, United States|Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Carolinas Hematology/Oncology Associates, Charlotte, North Carolina, United States|Nashat Gabrail, M.D., Canton, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|Columbus CCOP, Columbus, Ohio, United States|The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Oklahoma Oncology, Inc., Tulsa, Oklahoma, United States|Consultants in Medical Oncology & Hematology, Drexel Hill, Pennsylvania, United States|Hematology & Oncology Associates of NE PA, Dunmore, Pennsylvania, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|Monongahela Valley Hospital, Monongahela, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|UPMC Cancer Pavillion, Pittsburgh, Pennsylvania, United States|Charleston Cancer Center, Charleston, South Carolina, United States|South Carolina Oncology Associates, Columbia, South Carolina, United States|WJB Dom VAMC, Columbia, South Carolina, United States|Cancer Center of the Carolinas, Greenville, South Carolina, United States|Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States|Erlanger Health System, Chattanooga, Tennessee, United States|Clarksville Regional Hematology/Oncology, Clarksville, Tennessee, United States|The Jones Clinic, Germantown, Tennessee, United States|Baptist Regional Cancer Center, Knoxville, Tennessee, United States|University of Tennessee Cancer Institute, Memphis, Tennessee, United States|Sarah Cannon Cancer Center, Nashville, Tennessee, United States|Meharry Medical College, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Vanderbilt University School of Medicine, Nashville, Tennessee, United States|Harrington Cancer Center, Amarillo, Texas, United States|Center for Oncology Research & Treatment, Dallas, Texas, United States|Clinical Hematology & Oncology, Dallas, Texas, United States|Oncology Consultants, Houston, Texas, United States|H. Alejandro Preti, M.D., PA, Houston, Texas, United States|M.D. Anderson Cancer Center, Houston, Texas, United States|South Texas Oncology & Hematology, San Antonio, Texas, United States|Scott & White Hospital, Temple, Texas, United States|Northern Utah Cancer Associates, Ogden, Utah, United States|Southwestern Vermont Health Care, Bennington, Vermont, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Cancer Treatment Centers of America in Hampton Roads, Portsmouth, Virginia, United States|Western Washington Clinic, Everett, Washington, United States|Cascade Cancer Center, Kirkland, Washington, United States|Rainier Oncology, Puyallup, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Swedish Cancer Institute, Seattle, Washington, United States|West Virginia University Health Sciences Center, Morgantown, West Virginia, United States|Waukesha Memorial Hospital, Waukesha, Wisconsin, United States|Kettle Morain Oncology, West Bend, Wisconsin, United States|Novartis Investigative Site, Frankston, Australia|Novartis Investigative Site, Woodville South, Australia|Novartis Investigative Site, St. Veit an der Glan, Austria|Novartis Investigative Site, Antwerpen, Belgium|Novartis Investigative Site, Brasschaat, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Liège, Belgium|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Porto Alegre RS, Brazil|Novartis Investigative Site, Salvador - Ba, Brazil|Novartis Investigative Site, Salvador, Bahia, Brazil|Novartis Investigative Site, Sao Paulo, Brazil|Novartis Investigative Site, Sao Paulo, Brazil|Novartis Investigative Site, Sao Paulo, Brazil|Novartis Investigative Site, Calgary, Alberta, Canada|Novartis Investigative Site, Penticton, British Columbia, Canada|Novartis Investigative Site, Winnepeg, Manitoba, Canada|Novartis Investigative Site, Sydney, Nova Scotia, Canada|Novartis Investigative Site, Barrie, Ontario, Canada|Novartis Investigative Site, Brampton, Ontario, Canada|Novartis Investigative Site, Hamilton, Ontario, Canada|Novartis Investigative Site, Ottawa, Ontario, Canada|Novartis Investigative Site, Sainte-Foy, Ontario, Canada|Novartis Investigative Site, St. Catharines, Ontario, Canada|Novartis Investigative Site, Sudbury, Ontario, Canada|Novartis Investigative Site, Thunder Bay, Ontario, Canada|Toronto, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Windsor, Ontario, Canada|Novartis Investigative Site, Greenfield Park, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Saskatoon, Saskatchewan, Canada|Novartis Investigative Site, Avignon, France|Novartis Investigative Site, Boulogne Cedex, France|Novartis Investigative Site, Lille cedex, France|Novartis Investigative Site, Marseille cedex 05, France|Novartis Investigative Site, Montpellier cedex 5, France|Novartis Investigative Site, Nice cedex 2, France|Novartis Investigative Site, Rennes cedex, France|Novartis Investigative Site, Saint Herblain, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Toulouse cedex, France|Novartis Investigative Site, Augsburg, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bielefeld, Germany|Novartis Investigative Site, Braunschweig, Germany|Novartis Investigative Site, Dessau, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Köln, Germany|Novartis Investigative Site, Magdeburg, Germany|Novartis Investigative Site, München, Germany|Novartis Investigative Site, Neumünster, Germany|Novartis Investigative Site, Trier, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Wiesbaden, Germany|Novartis Investigative Site, ChaiWan, Hong Kong|Novartis Investigative Site, Ancona, Italy|Novartis Investigative Site, Bergamo, Italy|Novartis Investigative Site, Brescia, Italy|Novartis Investigative Site, Cremona, Italy|Novartis Investigative Site, Genova, Italy|Novartis Investigative Site, Livorno, Italy|Novartis Investigative Site, Milano, Italy|Novartis Investigative Site, Milano, Italy|Novartis Investigative Site, Reggio Emilia, Italy|Novartis Investigative Site, Roma, Italy|Novartis Investigative Site, Roma, Italy|Novartis Investigative Site, Rozzano, Italy|Novartis Investigative Site, Auckland, New Zealand|Novartis Investigative Site, Christchurch, New Zealand|Novartis Investigative Site, Wellington, New Zealand|Novartis Investigative Site, Coimbra, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Cordoba, Spain|Novartis Investigative Site, Elche, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Malaga, Spain|Novartis Investigative Site, Zaragoza, Spain|Novartis Investigative Site, Goteborg, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Bern, Switzerland|Novartis Investigative Site, Thun, Switzerland|Novartis Investigative Site, Changhua, Taiwan|Novartis Investigative Site, Kaohsiung, Taiwan|Novartis Investigative Site, Keelung, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Tainan, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Tao-Yuan, Taiwan|Novartis Investigative Site, Belfast, United Kingdom|Novartis Investigative Site, Birmingham, United Kingdom|Novartis Investigative Site, Cardiff, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00056446"
1712,"NCT00050778","A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis",,"Completed","Has Results","Multiple Sclerosis, Relapsing-Remitting","Biological: Interferon beta-1a|Biological: Alemtuzumab 12 mg|Biological: Alemtuzumab 24 mg","Probability of Participants With Sustained Accumulation of Disability (SAD)|Annualized Relapse Rate|Probability of Participants Who Were Relapse Free at 3 Years After Initial Treatment|Percent Change From Baseline in T1 Cerebral Volume at Year 3|Percent Change From Baseline in MRI T2 Lesion Volume at Year 3","Genzyme, a Sanofi Company|Bayer|Sanofi","All","18 Years to 50 Years   (Adult)","Phase 2","334","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","CAMMS223","December 2002","September 2007","January 2010","December 23, 2002","August 25, 2009","January 8, 2015","Mayo Clinic Scottsdale Arizona, Scottsdale, Arizona, United States|Clinical Trials, Inc, Little Rock, Arkansas, United States|East Bay Physicians Medical Group, Berkeley, California, United States|Nerve Pro Research, Irvine, California, United States|Neuro-Therapeutics, Inc., Pasadena, California, United States|Neurological Research Institute of the East Bay, Walnut Creek, California, United States|Neurologic Research Institute/Mile High Research Center, Denver, Colorado, United States|Neurological Service of Orlando, Orlando, Florida, United States|Neurological Associates/ Research Dept., Pompano Beach, Florida, United States|Neurology Clinical Research, Inc., Sunrise, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|Medical Research and Health Education, Columbus, Georgia, United States|Consultants in Neurology, Ltd, Northbrook, Illinois, United States|Fort Wayne Neurological Center, Fort Wayne, Indiana, United States|Associate in Neurology, Lexington, Kentucky, United States|University of Maryland -Maryland Center for MS, Baltimore, Maryland, United States|Wayne State University Department of Neurology, Detroit, Michigan, United States|Michigan Institute for Neurological Disorders, Farmington Hills, Michigan, United States|Michigan Medical P.C. Neurology, Grand Rapids, Michigan, United States|Mayo Clinic Rochester Department of Neurology, Rochester, Minnesota, United States|Nevada Neurological Consultants, Ltd., Las Vegas, Nevada, United States|University Hospital an Medical Center, Stony Brook, New York, United States|ALL-Trials Clinical Research, LLC, Winston-Salem, North Carolina, United States|Neurological Associates of Tulsa, Inc, Tulsa, Oklahoma, United States|Neurosciencies and Pain Research, Allentown, Pennsylvania, United States|Neurology, PC, Knoxville, Tennessee, United States|Baylor College of Medicine, Houston, Texas, United States|Dallas Neurological Associate, Richardson, Texas, United States|Central Texas Neurology Consultants PA, Round Rock, Texas, United States|Integra Clinical Research, LLC, San Antonio, Texas, United States|Neurology Center of San Antonio, San Antonio, Texas, United States|Department of Neurology, University Hospital ""Osijek"", Osijek, Croatia|Department of Neurology, Clinical Hospital Centre ""Rijeka"", Rijeka, Croatia|Department of Neurology, Clinical Hospital Centre ""Zagreb"", Zagreb, Croatia|Department of Neurology, General Hospital ""Sveti Duh"", Zagreb, Croatia|Department of Neurology, University Hopsital ""Sestre Milosrdnice"", Zagreb, Croatia|Centrum Neurologii Klinicznej, Krakow, Poland|Samodzielny Publiczny Zakład Opieki Zdrowotnej, Lodz, Poland|Klinika Neurologii, Lublin, Poland|Oddzial Kliniczny Neurologii, Poznan, Poland|Instytut Psychiatrii i Neurologii, Warszawa, Poland|Katedra i Klinika Neurologii, Warszawa, Poland|Russian State Medical University, Moscow, Russian Federation|Neurology Scientific Center RAMS, Moscow, Russian Federation|Moscow City Hospital #11, Moscow, Russian Federation|Moscow City Hospital #61, Moscow, Russian Federation|Institute of Human brain RAS, St. Petersburg, Russian Federation|St. Petersburg State Pavlov Medical University, St. Petersburg, Russian Federation|Addenbrooke's Hospital, Cambridge, England, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00050778"
1713,"NCT03305224","The Combination Therapy With Ra-223 and Enzalutamide","CORE-OCU","Recruiting","No Results Available","Castration-resistant Prostate Cancer|Bone Metastases","Drug: Ra-223 in combination with enzalutamide","Changes in Alkaline phosphatase (ALP)|Tolerability of Radium-223 therapy|Evaluation for bone metastasis by 18F-NaF-PET|Evaluation for bone metastasis by bone scintigraphy|Overall Survival Rate|Time to occurrence of Symptomatic Skeletal-related Events (SSEs)|Time to occurrence of visceral metastasis|Time to initiation of cytotoxic chemotherapy|Changes in Prostate Specific Antigen (PSA)|Changes From Baseline for Brief Pain Inventory (BPI)|Changes From Baseline for Functional Assessment of Cancer Therapy - Prostate (FACT-P)|Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)","Taro Iguchi, MD, PHD|Bayer Yakuhin, Ltd.|Osaka City University","Male","20 Years and older   (Adult, Older Adult)","Phase 2","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CORE-OCU","October 27, 2017","December 31, 2019","June 30, 2021","October 9, 2017",,"April 9, 2019","Osaka City University Graduate School of Medicine, Osaka, Japan",,"https://ClinicalTrials.gov/show/NCT03305224"
1714,"NCT02024230","Registry for Estimation of Warfarin and Rivaroxaban in Atrial Fibrillation Patients With Coronary Stent Implantation","REWRAPS","Recruiting","No Results Available","Coronary Artery Disease|Atrial Fibrillation|Stroke|Fetal Blood Loss","Drug: Warfarin or Rivaroxaban","composite of adverse events|major bleeding|all-cause death|admission due to congestive heart failure|fatal arrhythmia|electrocardiographic findings|cardiac ultrasound findings|each cardiovascular event used for the primary efficacy outcome measures|non-major clinical relevant bleeding|cardiac or stroke death|non-fatal myocardial infarction|non-fatal stroke|coronary artery revascularization (percutaneous coronary intervention or coronary artery bypass graft)|systemic embolism","Fujita Health University|Bayer Yakuhin, Ltd.","All","20 Years and older   (Adult, Older Adult)",,"600","Other|Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","REWRAPS","May 2014","December 2018","December 2021","December 31, 2013",,"September 14, 2018","Fujita Health University Hospital, Toyoake, Japan",,"https://ClinicalTrials.gov/show/NCT02024230"
1715,"NCT02926222","Regorafenib in Relapsed Glioblastoma","REGOMA","Active, not recruiting","No Results Available","Glioblastoma Multiforme","Drug: Regorafenib|Drug: Lomustine","Overall survival|Progression free survival|Objective response rate|Disease control rate|Toxicity (Graded according to the NCI-Common Terminology Criteria for Adverse Events)","Istituto Oncologico Veneto IRCCS|BAYER S.p.A. - Italia","All","18 Years and older   (Adult, Older Adult)","Phase 2","119","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IOV-GB-1-2014 REGOMA|2014-003722-41","November 2015","July 2017","October 2018","October 6, 2016",,"September 13, 2018","IRCCS ""Saverio de Bellis, Castellana Grotte, BA, Italy|Ospedale di Bellaria, Bologna, BO, Italy|Azienda Ospedaliera ""G.Rummo"", Benevento, BR, Italy|istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori, Cesena, FC, Italy|Istituto Neurologico C. Besta IRCCS, Milano, MI, Italy|Istituto Oncologico Veneto IRCCS, Oncologia Medica 1, Padova, PD, Italy|Ospedale Santa Chiara, Pisa, PI, Italy|Azienda Ospedaliero Universitaria S. Maria della Misericordia, Udine, UD, Italy|Istituto Nazionale Tumori Regina Elena, Roma, Italy|Azienda Ospedaliera Universitaria Città della Salute e della Scienza, Torino, Italy",,"https://ClinicalTrials.gov/show/NCT02926222"
1716,"NCT02459119","Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477)",,"Recruiting","No Results Available","Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)","Drug: Regorafenib","Progression-free survival|Disease response rate|Overall survival|Rate of progression-free survival at 6 months (PFS6)|Number of Participants with Adverse Events","University of Alabama at Birmingham|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma","All","19 Years and older   (Adult, Older Adult)","Phase 2","35","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","F150302002 (UAB 1477)","May 2015","February 2019","December 2019","June 1, 2015",,"April 9, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|Wayne State University, Detroit, Michigan, United States|Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02459119"
1717,"NCT02425683","Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX",,"Terminated","No Results Available","Colorectal Neoplasms|Adenocarcinoma of the Colon|Adenocarcinoma of the Rectum","Drug: Regorafenib","Starting Dose of Regorafenib|Number of Patients Completing Full 6 Cycles|Overall survival|Number of Adverse Events (AEs)|Disease-free survival (DFS)","US Oncology Research|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma","All","18 Years and older   (Adult, Older Adult)","Phase 2","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13050","March 26, 2015","September 21, 2017","September 21, 2017","April 24, 2015",,"October 1, 2018","24 Sites, Including Dallas, TX, Ocala, FL, Denver, CO, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02425683"
1718,"NCT02204267","Impact of Standardized MONitoring for Detection of Atrial Fibrillation in Ischemic Stroke","MonDAFIS","Active, not recruiting","No Results Available","Stroke|Atrial Fibrillation","Other: prolonged ECG monitoring|Device: ECG","Number of patients on oral anticoagulation (NOAC or VKA)|Number of stroke patients with newly detected atrial fibrillation","Charite University, Berlin, Germany|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma","All","18 Years and older   (Adult, Older Adult)","Not Applicable","3470","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","MonDAFIS|EA2/033/14","December 2014","December 2019","December 2019","July 30, 2014",,"August 2, 2019","Charité Universitaetsmedizin Berlin, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT02204267"
1719,"NCT02147691","Finacea 15% and Brimonidine 0.33% Gel in the Treatment of Rosacea - A Pilot Study",,"Completed","Has Results","Acne Rosacea","Drug: Azelaic acid 15%|Drug: Brimonidine 0.33%","Investigator Global Assessment (IGA) at Baseline|IGA|Lesion Counts|Clinician's Erythema Assessment|Erythema Visual Analog Scale (VAS) Assessment (Subject)|Dermatology Life Quality Index (DLQI)|Lesion Count|Erythema|Visual Analog Scale (VAS)|VAS|DLQI","Derm Research, PLLC|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 4","22","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","FIN1302","May 2014","January 2015","February 2015","May 28, 2014","September 30, 2015","September 30, 2015","DermResearch, PLLC, Louisville, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT02147691"
1720,"NCT01360996","Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism","BEYAZ-PCOS","Completed","Has Results","Polycystic Ovary Syndrome","Drug: 3 mg DRSP/20 μg EE","Biochemical Assessment of Hyperandrogenism|Cardiometabolic Measures|Post Therapy BMI.|Biochemical Indicator of B-vitamin Status|Menstrual Cycle Regularity|Adrenal Androgen DHEAS|Oral Disposition Index","Woman's|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma","Female","16 Years to 35 Years   (Child, Adult)","Phase 4","64","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RP 11-003","August 2011","February 2015","February 2015","May 26, 2011","March 31, 2017","March 31, 2017","Woman's Hospital, Baton Rouge, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT01360996"
1721,"NCT01338857","Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas",,"Terminated","Has Results","neurofibromatosis1 (NF1)|Recurrent or Progressive Optic Pathway Gliomas (OPG)|Recurrent or Progressive Low-grade Glioma","Drug: Sorafenib (Nexavar)","Response Rate to Sorafenib|Objective Response Rates","NYU Langone Health|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma","All","2 Years and older   (Child, Adult, Older Adult)","Phase 2","12","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10-00561","April 2011","March 2013","March 2013","April 20, 2011","February 22, 2016","February 17, 2017","New York University Stephen D. Hassenfeld Children's Center for Cancer & Blood Disorders, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01338857"
1722,"NCT01215838","MRI of the Liver With Eovist",,"Terminated","No Results Available","Hepatocellular Carcinoma",,"Accuracy of a new MR protocol in diagnosing HCC and other liver lesions.","University of Washington|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma","All","18 Years and older   (Adult, Older Adult)",,"4","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","DI-2009-1|7160","August 2010","August 2011","January 2012","October 7, 2010",,"October 14, 2013",,,"https://ClinicalTrials.gov/show/NCT01215838"
1723,"NCT01122056","Effect of Aerobic Exercise on Side Effects of Disease Modifying Therapy With Subcutaneous Interferon-b1b in Patients With Multiple Sclerosis",,"Completed","No Results Available","Multiple Sclerosis","Other: Physical exercise training","Multiple Sclerosis Fatigue|Quality of Life|Injection site visual analog scale (0-10)","University of British Columbia|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","128","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Other","H10-00277","May 2010","June 1, 2012","June 1, 2012","May 12, 2010",,"March 3, 2017","Vancouver Coastal Health: University of British Columbia Hospital, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT01122056"
1724,"NCT01009684","International Active Surveillance Study - Safety of Contraceptives: Role of Estrogens","INAS-SCORE","Completed","No Results Available","Contraception",,"Venous Thromboembolic Events (VTE)|Acute Myocardial Infarction (AMI)|Cerebrovascular Accidents (CVA)","Center for Epidemiology and Health Research, Germany|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma","Female","Child, Adult, Older Adult",,"50203","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ZEG2009_01","August 2009","February 2017","June 2017","November 9, 2009",,"June 17, 2019","Berlin Center for Epidemiology and Health Research, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT01009684"
1725,"NCT01005875","Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma","RAD 0901","Terminated","Has Results","Hepatocellular Carcinoma|Liver Cancer","Drug: Sorafenib|Radiation: Stereotactic Body Radiotherapy (SBRT)","Determine the Safety and Tolerability of Sequential SBRT and Sorafenib in Patients With Unresectable Hepatocellular Carcinoma|The Degree of Change in Necrosis and Vascular Permeability Via Dynamic Contrast Enhanced (DCE) and Diffusion-weighted Imaging (DWI) Magnetic Resonance Imaging (MRI) as Measured by Tumor Volume|The Degree of Change in Necrosis and Vascular Permeability Via Dynamic Contrast Enhanced (DCE) and Diffusion-weighted Imaging (DWI) Magnetic Resonance Imaging (MRI) as Measured by Ktrans (Volume Transfer Coefficient).|The Degree of Change in Necrosis and Vascular Permeability Via Dynamic Contrast Enhanced (DCE) and Diffusion-weighted Imaging (DWI) Magnetic Resonance Imaging (MRI) as Measured by Kep. Kep Describes How Fast Contrast Can Redistribute in Tissue.|The Degree of Change in Necrosis and Vascular Permeability Via Dynamic Contrast Enhanced (DCE) and Diffusion-weighted Imaging (DWI) Magnetic Resonance Imaging (MRI) as Measured by ADC (Apparent Diffusion Coefficient).","University of Alabama at Birmingham|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma","All","19 Years and older   (Adult, Older Adult)","Not Applicable","5","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","F090910004","November 2009","December 2012","June 2013","November 1, 2009","June 11, 2014","May 10, 2017","UAB, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT01005875"
1726,"NCT00888277","Bayer/Cognitive Assessments With Multiple Sclerosis Subjects",,"Completed","No Results Available","Multiple Sclerosis, Relapsing-remitting|Multiple Sclerosis, Secondary Progressive",,"SDMT correlation with the findings on the Neuropsychological Battery. The Neuropsychological Battery will confirm that the SDMT is sensitive and specific in identifying MS patients with cognitive findings.|SDMT association with the BDI. The SDMT will be independent of depression.|Overlap of Depression with Cognitive Dysfunction. There will still be identified a high percentage of patients having both cognitive and depressive symptoms.|Lack of association of Cognitive Dysfunction with the Physical Scales of the EDSS.","University of Louisville|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma","All","18 Years to 55 Years   (Adult)",,"74","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","UofL IRB # 09.0167|OICN 090742","May 2009","December 2009","January 2010","April 27, 2009",,"November 4, 2013","University of Louisville, Louisville, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT00888277"
1727,"NCT00483665","Vasovist Endoleak Study",,"Completed","No Results Available","Abdominal Aortic Aneurysm","Procedure: Computed tomography angiography|Procedure: Magnetic resonance imaging",,"UMC Utrecht|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma","All","Child, Adult, Older Adult",,"20","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","UMC_06_112","June 2006",,,"June 7, 2007",,"November 19, 2008","UMC Utrecht, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT00483665"
1728,"NCT00383994","Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation",,"Completed","No Results Available","Lymphoma|Leukemia|Transplantation, Stem Cell|Lymphoid Malignancies|Disorder Related to Transplantation","Drug: GM-CSF|Drug: Rituximab|Biological: NK Cell Infusion","Dose-limiting toxicities (DLTs) for NK cells infusions after non-myeloablative transplantation for lymphoid malignancies","M.D. Anderson Cancer Center|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma","All","Child, Adult, Older Adult","Phase 1","6","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2005-0234|NCI-2012-01375","September 2006","July 22, 2019","July 22, 2019","October 4, 2006",,"July 31, 2019","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00383994"
1729,"NCT00328198","Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia",,"Completed","Has Results","B-Cell Chronic Lymphocytic Leukemia (B-CLL)","Biological: Alemtuzumab","Number of Participants With Best Disease Response as Determined by the Independent Response Review Panel (IRRP)|Percentage of Participants Who Had an Overall Response (OR) as Determined by the Independent Response Review Panel (IRRP)|Kaplan-Meier Estimates of Progression Free Survival as Determined by the Independent Response Review Panel (IRRP)|Kaplan-Meier Estimates of Duration of Response as Determined by the Independent Response Review Panel (IRRP)|Kaplan-Meier Estimates of Overall Survival|Participants With a Minimal Residual Disease (MRD) Status of Negative|Participants With Treatment-Emergent Adverse Events (TEAE)","Genzyme, a Sanofi Company|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2","86","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CAM203|2005-005074-69","May 2006","August 2011","August 2011","May 19, 2006","August 10, 2012","March 13, 2014","Moores Cancer Center, La Jolla, California, United States|Wilshire Oncology Medical Group, La Verne, California, United States|University of Colorado Cancer Center at University of Colorado Health Sciences Center, Aurora, Colorado, United States|Rocky Mountain Cancer Centers, Colorado Springs, Colorado, United States|North Mississippi Hematology & Oncology Associates, Ltd., Tupelo, Mississippi, United States|Mid Ohio Oncology Hematology, Inc., Columbus, Ohio, United States|Joe Arrington Cancer Center, Lubbock, Texas, United States|Academisch Ziekenhuis der Vrije Universiteit Brussel, Brussels, Belgium|Cliniques Universitaires Saint-Luc, Brussels, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|Universitair Ziekenhuis Leuven, Leuven, Belgium|University Hospital Brno, Brno, Czech Republic|University Hospital Hradec Kralove (UH HK), Hradec Kralove, Czech Republic|Hopital Hotel-Dieu, Clermont-Ferrand, France|Hopital Claude Huriez, Lille, France|Hopital Hotel-Dieu, CHU de Nantes-Service d'Hematologie Clinique, Nantes, France|Institute of Hematology, Clinical Centre of Serbia, Belgrade, Serbia|Clinic of Hematology, Clinical Centre Vojvodina Novi Sad, Novi Sad, Serbia|Leeds General Infirmary, Leeds, United Kingdom|Royal Liverpool and Broadgreen Hospitals, Liverpool, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00328198"
1730,"NCT00302848","European Active Surveillance Study (EURAS)",,"Completed","Has Results","Contraception","Drug: Drospirenone|Drug: Levonorgestrel|Drug: Other progestin containing oral contraceptive","Number of Participants With Venous Thromboembolism (VTE)","Center for Epidemiology and Health Research, Germany|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma","Female","Child, Adult, Older Adult",,"59510","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ZEG 2000_1","November 2000",,"December 2005","March 15, 2006","November 20, 2009","November 20, 2009","Center for Epidemiology and Health Research, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT00302848"
1731,"NCT00313118","Mean Values of Oxidative Stress Parameters in Healthy Subjects",,"Withdrawn","No Results Available","Healthy",,,"Selim Orguel|Laboratory Dr. Bayer GmbH, Stuttgart, Germany|University Hospital, Basel, Switzerland","All","18 Years to 80 Years   (Adult, Older Adult)",,"0","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","067-KOA-2005-001","January 2006","September 2010","December 2016","April 11, 2006",,"March 28, 2017","University Eye Clinic Basel, Basel, BS, Switzerland",,"https://ClinicalTrials.gov/show/NCT00313118"
1732,"NCT04025372","INTREPId (INTermediate Risk Erection PreservatIon Trial)",,"Not yet recruiting","No Results Available","Prostate Cancer","Drug: Bicalutamide|Drug: GnRH Agonist|Radiation: Radiation Therapy|Drug: Darolutamide","The percentage of patients with a PSA nadir <= 0.5|The percentage of patients with good erectile function|PSA progression free survival|Metastasis free survival|Cause specific survival|Rate of Toxicity|Quality of Life impact as measured by Expanded Prostate Cancer Index (EPIC)-26|Global health impact as measured by Patient-Reported Outcome Measurement Information System (PROMIS) Global Health Score|Memory as measured by the St. Louis University Mental Status Examination (SLUMS)|Quality of Life impact as measured by Patient-Reported Outcome Measurement Information System (PROMIS) Sexual Function and Satisfaction Measures (SexFS) Brief Profile Version 2.0.","Dana-Farber Cancer Institute|Bayer|GenomeDx Biosciences Corp","Male","18 Years and older   (Adult, Older Adult)","Phase 2","220","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19-202","January 1, 2020","September 1, 2022","September 1, 2027","July 18, 2019",,"December 16, 2019","Beth Israel Deaconness Medical Center, Boston, Massachusetts, United States|Brigham and Women Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04025372"
1733,"NCT03910738","TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis","TOTEM-RRMS","Recruiting","No Results Available","Multiple Sclerosis, Relapsing-Remitting","Drug: Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection|Drug: Placebo 4 mL Solution for Injection|Procedure: MRI|Behavioral: Assessment of impact of MS on cognition; quality of life; fatigue; anxiety/depression and work and activities|Behavioral: Assessment of disability","Change on MRI binary criterion combining thalamic atrophy and modification in transverse diffusivity of lesions|Evolution of the number of T1 hypointense lesions as detected by conventional MRI|Evolution of the volume of T1 hypointense lesions as detected by conventional MRIconventional MRI|Evolution of the number of new or enlarged T2 lesions as detected by conventional MRI|Evolution of the volume of new or enlarged T2 lesions as detected by conventional MRI|Evolution of the total volume of hyper-intensity FLAIR lesion as detected by conventional MRI|Evolution of diffusion tensor imaging (NODDI) as detected by unconventional MRI|Evolution of quantitative magnetization transfer imaging (MPF) as detected by unconventional MRI|Evolution of cognitive performance as measured by Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)|Changes in quality of life as measured by the SF-36 questionnaire|Changes in quality of life related to health as measured by the EQ-5D-3L (European Quality of Life in 3 Dimensions) questionnaire.|Changes in work productivity and daily activities due to MS, as assessed by the WPAI:MS questionnaire (Work Productivity and Activity Impairment in MS).|Changes in fatigue, measured by the Multidimensional Fatigue Impact Scale (MFIS)|Changes in anxiety and depression as measured by the Hospital assessment for Anxiety and Depression Scale (HADS) questionnaire|Evolution of disability measured MS specific Expanded Disability Status scale (EDSS)|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]","University Hospital, Strasbourg, France|Bayer|Fédération Hospitalo-Universitaire NEUROGENYCS","Male","18 Years to 55 Years   (Adult)","Phase 2","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","7109","October 29, 2019","May 2023","May 2023","April 10, 2019",,"November 13, 2019","CHU de Besançon, Besançon, France|CHU Nancy, Nancy, France|CHU de Rennes/Pontchaillou, Rennes, France|CHRU de Strasbourg, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT03910738"
1734,"NCT03737370","Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer",,"Recruiting","No Results Available","Metastatic Castrate Resistant Prostate Cancer","Drug: Docetaxel|Radiation: Radium 223","Incidence of Dose Limiting Toxicities (DLT)|Efficacy, assessed as non-progression/progression rate according to prostate cancer working group (PCWG2) criteria|Progression Free Survival (PFS)|Time to Treatment Failure (TTTF)|Overall Survival|Proportion of Randomized Subjects to Complete Combination Therapy on Schedule per Protocol|Response to treatment, as assessed by prostate-specific antigen (PSA) Kinetics and Objective Responses|Satisfaction, as assessed by Quality of Life Questionnaires|Response to Treatment, as assessed by Bone Bio-marker Outcomes","Tufts Medical Center|Bayer|Lahey Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 1","25","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IIR-US-2016-3279","January 30, 2018","March 31, 2021","October 31, 2021","November 9, 2018",,"May 3, 2019","Lahey Hospital & Medical Center, Boston, Massachusetts, United States|Tufts Medical Center, Boston, Massachusetts, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT03737370/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT03737370/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03737370"
1735,"NCT03711058","Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer",,"Recruiting","No Results Available","Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor Along With Microsatellite Stable (MSS) Colon Cancer|Colon Cancer","Drug: Copanlisib|Drug: Nivolumab","Determine maximum tolerated dose (MTD) of copanlisib with fixed dose nivolumab|6-month objective response rate (ORR) of patients treated with copanlisib and nivolumab|Disease control rate (DCR) status at 6 months.|Duration of response (DOR) status at 6 months.|Progression free survival (PFS) status at 6 months.|Overall survival (OS) status at 6 months.|Number of participants experiencing study drug-related toxicities","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Bayer|Bristol-Myers Squibb","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 1|Phase 2","54","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","J1887|IRB00175864|CA209-8LC","January 10, 2019","January 2021","January 2022","October 18, 2018",,"July 25, 2019","Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03711058"
1736,"NCT03631771","Pediatric Risk of Hypothyroidism With Iodinated Contrast Media",,"Not yet recruiting","No Results Available","Hypothyroidism","Drug: Iohexol|Drug: Iodixanol|Drug: Iopromide|Drug: Ioversol","The proportion of subjects who develop hypothyroidism post-ICM.|Proportion of subjects with changes from baseline in thyroid function tests that exceed the available literature-reported reference change values for these parameters (ca. >60% for TSH and >30% for thyroxine [T4]; [Chaler et al 2012])|Proportion of subjects with abnormal thyroid function tests at each time point.","GE Healthcare|Bayer|Guerbet/Liebel-Flarsheim","All","up to 3 Years   (Child)","Phase 4","508","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","GE-012-103/19476/OPY-44-002","November 2019","August 2024","February 2025","August 15, 2018",,"September 30, 2019",,,"https://ClinicalTrials.gov/show/NCT03631771"
1737,"NCT03522259","Rivaroxaban as Thrombosis Prophylaxis in Bariatric Surgery","BARIVA","Recruiting","No Results Available","Bariatric Surgery","Drug: Rivaroxaban 10 MG Oral Tablet [Xarelto]","Number of patients with symptomatic or asymptomatic VTE|Number of patients with symptomatic VTE within 28 days after bariatric surgery|Number of patients with asymptomatic VTE within 28 days after bariatric surgery|All cause mortality within 28 days after bariatric surgery","University Hospital Inselspital, Berne|Bayer|Janssen Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","260","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","UVCMBS003","July 19, 2018","December 31, 2021","December 31, 2021","May 11, 2018",,"October 30, 2019","Kantonsspital Baden, Baden, Switzerland|University Hospital, Inselspital Berne, Berne, Switzerland|Clinic Beau-Site, Bern, Switzerland",,"https://ClinicalTrials.gov/show/NCT03522259"
1738,"NCT03475953","A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors","REGOMUNE","Recruiting","No Results Available","Colorectal Cancer Not MSI-H or MMR-deficient|GIST|Oesophageal or Gastric Carcinoma|Biliary Tract Cancer|Hepatocellular Carcinoma|Soft-tissue Sarcoma|Thyroid Cancer|Gastro-enteropancreatic Neuroendocrine Tumor","Drug: Phase 1 : Regorafenib|Drug: Phase 1 : Avelumab|Drug: Phase 2 : Regorafenib|Drug: Phase 2 : Avelumab","PHASE I : Recommended phase II dose (RP2D)|PHASE II (7 phase II cohorts) : Assessment of the antitumor activity of regorafenib|PHASE I : Maximum Tolerated Dose (MTD)|PHASE I : Dose Limiting Toxicities (DLT)|PHASE I : Toxicity|PHASE I : Assessment of the antitumor activity of regorafenib - Best overall response|PHASE I :Assessment of the antitumor activity of regorafenib - objective response rate under treatment|PHASE I :Assessment of the antitumor activity of regorafenib - objective response rate|PHASE I :Assessment of the antitumor activity of regorafenib - non-progression|PHASE I :Assessment of the antitumor activity of regorafenib - progression-free survival (PFS)|PHASE I : Assessment of the antitumor activity of regorafenib - overall survival (OS)|PHASE I :Pharmacocinetics (PK) - Area Under Curve (AUC)|PHASE I :Pharmacocinetics (PK) - half-life for regorafenib.|PHASE I :PK - concentration peak for regorafenib.|Phase I: Predictive blood biomarkers analysis (cytokines levels) by ELISA.|Phase I: Predictive blood biomarkers analysis (lymphocytes) by flow cytmetry.|Phase I: Predictive tumor growth factor biomarkers analysis by immunohistochemistry.|Phase I: Adverses events graded using the common toxicity criteria from the NCI v5 to determine the safety profile of regorafenib plus avelumab.|PHASE II : Assessment of the antitumor activity of regorafenib - Best overall response|PHASE II : Assessment of the antitumor activity of regorafenib - objective response rate|PHASE II :Assessment of the antitumor activity of regorafenib - non progression|PHASE II : Assessment of the antitumor activity of regorafenib - Progression-Free Survival (PFS)|PHASE II : Assessment of the antitumor activity of regorafenib - Overall Survival|Phase II: Predictive blood biomarkers analysis (cytokines levels) by ELISA.|Phase II: Predictive blood biomarkers analysis (lymphocytes) by flow cytometry.|Phase II: Predictive tumor growth factor biomarkers analysis by immunohistochemistry.|Phase II: Adverses events graded using the common toxicity criteria from the NCI v5 to determine the safety profile of regorafenib plus avelumab|Predictive metabolomic analysis by liquid chromatography-mass spectrometry","Institut Bergonié|Bayer|Merck KGaA, Darmstadt, Germany","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","362","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IB 2017-01|2016-005175-27","May 4, 2018","November 2020","May 2021","March 23, 2018",,"June 17, 2019","Institut Bergonié, Bordeaux, France|Centre Hospitalier Régional Universitaire - CHU Morvan, Brest, France|Centre Léon Bérard, Lyon, France|Institut de Cancérologie de Montpellier, Montpellier, France|IUCT Oncopôle - Institut Claudius Regaud, Toulouse, France|Institut Gustave Roussy, Villejuif, France",,"https://ClinicalTrials.gov/show/NCT03475953"
1739,"NCT03439891","Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer",,"Recruiting","No Results Available","Stage III Hepatocellular Carcinoma AJCC v8|Stage IIIA Hepatocellular Carcinoma AJCC v8|Stage IIIB Hepatocellular Carcinoma AJCC v7|Stage IIIC Hepatocellular Carcinoma AJCC v7|Stage IV Hepatocellular Carcinoma AJCC v8|Stage IVA Hepatocellular Carcinoma AJCC v8|Stage IVB Hepatocellular Carcinoma AJCC v8","Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Drug: Sorafenib","Maximum tolerated dose (MTD) (Part 1)|Overall response rate (ORR) assessed using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Part 2)|Duration of response (DOR)|Incidence of adverse classified using NCI CTCAE version 4.03|ORR assessed by RECIST 1.1 for overall study|Overall survival (OS)|Progression-free survival (PFS)|Rate of immune-related adverse event (irAE) for combination","Robin Kate Kelley|Bayer|Bristol-Myers Squibb|University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","174523|NCI-2018-00051","February 21, 2018","May 29, 2020","December 31, 2020","February 20, 2018",,"September 4, 2019","University of California, San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT03439891"
1740,"NCT03383614","Safety, Tolerability and PK of Multiple-ascending Doses of Emodepside",,"Completed","No Results Available","Filariasis","Drug: LSF emodepside (BAY 44-4400) oral solution (1mg/mL)","safety and tolerability of emodepside after multiple doses as measured by number of participants with treatment related adverse events|safety and tolerability of emodepside after multiple doses as measured by number of participants with vital signs findings|safety and tolerability of emodepside after multiple doses as measured by number of participants with 12-lead Electrocardiogram findings|safety and tolerability of emodepside after multiple doses as measured by number of participants with clinical laboratory tests findings|safety and tolerability of emodepside after multiple doses as measured by number of participants with ophthalmology assessments findings|safety and tolerability of emodepside after multiple doses as measured by number of participants with physical examination findings|safety and tolerability of emodepside after multiple doses as measured by number of participants with neurological examination findings|pharmacokinetics of emodepside at Day 0 and Day 9 (Cohorts 1 & 2: AUC24 and Cohort 3: AUC12) and at Day 9 : AUCinf|pharmacokinetics of emodepside at Day 0 and Day 9 (Cmax) and at Day 9: AUCinf|pharmacokinetics of emodepside: Ctrough will be derived from the concentration data (Days 1-9)|time-matched profiles of selected pharmacodynamics (PD) markers in plasma after multiple doses of emodepside (Time-matched profiles of glucose, glucagon, insulin, and cortisol + Oral glucose tolerance test (OGTT) )","Drugs for Neglected Diseases|Bayer|Bill and Melinda Gates Foundation","Male","18 Years to 45 Years   (Adult)","Phase 1","24","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","DNDI-EMO-02","November 10, 2017","October 15, 2018","October 15, 2018","December 26, 2017",,"March 1, 2019","Hammersmith Medicines Research Limited, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03383614"
1741,"NCT03383523","Relative Bioavailability Study of Emodepside IR-tablets and Solution",,"Completed","No Results Available","Filariasis","Drug: Emodepside (BAY 44-4400)","PK (AUC0-7d) of two new tablet formulations of emodepside in comparison to the liquid formulation (LSF) oral solution.|PK (Cmax) of two new tablet formulations of emodepside in comparison to the liquid formulation (LSF) oral solution.|safety and tolerability as measured by number of participants with treatment-related adverse events|safety and tolerability as measured by Number of participants with physical examination findings|safety and tolerability as measured by Number of participants with neurological examination findings|safety and tolerability as measured by Number of participants with vital signs findings|safety and tolerability as measured by Number of participants with 12-lead ECG findings|safety and tolerability as measured by Number of participants with clinical laboratory tests findings","Drugs for Neglected Diseases|Bayer|Bill and Melinda Gates Foundation","Male","18 Years to 45 Years   (Adult)","Phase 1","77","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DNDI-EMO-03|2017-003091-31","October 30, 2017","March 26, 2018","March 26, 2018","December 26, 2017",,"June 25, 2018","Hammersmith Medicines Research (HMR) Limited, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03383523"
1742,"NCT03052933","Copanlisib and Gemcitabine in Relapsed/Refractory PTCL",,"Recruiting","No Results Available","Mature T-Cell and NK-Cell Neoplasm","Drug: Copanlisib|Drug: Gemcitabine","Dose limiting toxicity (DLT), Maximum tolerated dose (MTD) for phase I|Objective response rate for phase II|adverse events|Progression-free survival (PFS)|Overall survival (OS)","Chonnam National University Hospital|Bayer|Consortium for Improving Survival of Lymphoma","All","19 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","36","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COPGEM","February 1, 2018","December 2021","December 2021","February 14, 2017",,"April 11, 2018","Chonnam National University Hwasun Hospital, Hwasun-gun, Jeollanam-do, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03052933"
1743,"NCT02877251","Mexican Multidisciplinary Registry of Patients With Venous Thromboembolic Disease","REMMITE","Not yet recruiting","No Results Available","Venous Thromboembolism|Venous Thrombosis|Pulmonary Embolism",,"Major adverse cardiovascular events","Registro Mexicano Multidisciplinario De Pacientes Con Enfermedad Tromboembolica Venosa|Bayer|Webmedica","All","18 Years to 99 Years   (Adult, Older Adult)",,"500","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Other","REMMITE","May 2019","May 2020","December 2020","August 24, 2016",,"April 16, 2019",,,"https://ClinicalTrials.gov/show/NCT02877251"
1744,"NCT02661178","First in Man Clinical Trial of Emodepside (BAY 44-4400)",,"Completed","No Results Available","Healthy Volunteers","Drug: emodepside (BAY 44-4400)|Drug: placebo","Safety and tolerability as measured by adverse events, physical and neurological examination findings, vital signs and 12-lead ECG, and clinical laboratory parameters ; in one cohort - ophthalmological examination findings|The AUC∞ (the area under the plasma drug concentration vs. time curve from time zero to infinity) of emodepside in plasma.|The AUC∞/D (the area under the plasma drug concentration vs. time curve from time zero to infinity, corrected for dose) of emodepside in plasma.|The Cmax (the observed maximum plasma concentration) of emodepside in plasma.|The Cmax/D (the observed maximum plasma concentration, corrected for dose) of emodepside in plasma.|The Cmax,norm (the observed maximum plasma concentration corrected by dose and body weight) of emodepside in plasma.|The Tmax (the time at which Cmax was apparent) of emodepside in plasma.|The t½ (the terminal half-life) of emodepside in plasma.|The MRT (the mean residence time) of emodepside in plasma.|The CL/F (the apparent total clearance from plasma) of emodepside in plasma.|The AUC∞,norm (the area under the concentration-time curve from time zero to infinity corrected by dose and body weight) of emodepside in plasma.|The AUCt (the area under the concentration-time curve from time zero (pre-dose) to the time of last quantifiable concentration) of emodepside in plasma.|The AUC t,norm (the area under the concentration-time curve from time zero (pre-dose) to the time of last quantifiable concentration corrected by dose and body weight) of emodepside in plasma.|The Vz/F (the apparent volume of distribution) of emodepside in plasma.|The lambda-z (the terminal rate constant) of emodepside in plasma.|The AUC t-∞ (the area under the concentration-time curve from time t to infinity) of emodepside in plasma.|The points terminal of emodepside in plasma.|The relative bioavailability (Frel) of the IR (immediate release) tablet of emodepside will be calculated (optionally).|The AUC∞ (the area under the plasma drug concentration vs. time curve from time zero to infinity) of metabolites of emodepside in plasma may be measured|The AUC∞/D (the area under the plasma drug concentration vs. time curve from time zero to infinity, corrected for dose) of metabolites of emodepside in plasma may be measured|The Cmax (the observed maximum plasma concentration) of metabolites of emodepside in plasma may be measured|The Cmax/D (the observed maximum plasma concentration, corrected for dose) of metabolites of emodepside in plasma may be measured|The Cmax,norm (the observed maximum plasma concentration corrected by dose and body weight) of metabolites of emodepside in plasma may be measured|The Tmax (the time at which Cmax was apparent) of metabolites of emodepside in plasma may be measured|The t½ (the terminal half-life) of metabolites of emodepside in plasma may be measured|The AUC∞,norm (the area under the concentration-time curve from time zero to infinity corrected by dose and body weight) of metabolites of emodepside in plasma may be measured|The AUCt (the area under the concentration-time curve from time zero (pre-dose) to the time of last quantifiable concentration) of metabolites of emodepside in plasma may be measured|The AUC t,norm (the area under the concentration-time curve from time zero (pre-dose) to the time of last quantifiable concentration corrected by dose and body weight) of metabolites of emodepside in plasma may be measured|The amount of emodepside, and possibly its metabolites, in urine.|The concentration of emodepside, and possibly its metabolites, in urine.|Possibility to determine the effect of food on the bioavailability of emodepside (BAY 44-4400) after single oral doses administered as solution or IR tablets.","Drugs for Neglected Diseases|Bayer|Bill and Melinda Gates Foundation","Male","18 Years to 55 Years   (Adult)","Phase 1","79","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","DNDI-EMO-001|2015-003592-29","December 2015","March 27, 2017","March 27, 2017","January 22, 2016",,"August 25, 2017","Hammersmith Medicines Research, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02661178"
1745,"NCT02581059","Efficacy of Ginseng for Patients on Regorafenib",,"Terminated","No Results Available","Colorectal Cancer|Palliative Medicine|Supportive Care","Drug: Regorafenib|Dietary Supplement: Ginseng","Subject Fatigue Assessment|Subject Compliance|Characterize Adverse Events (AE)|Subject Retention|Evaluate Response Rate (RR)|Evaluate Overall Survival (OS)","Rodwige J. Desnoyers|Bayer|Hoosier Cancer Research Network","All","18 Years and older   (Adult, Older Adult)","Phase 2","10","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HCRN GI14-191","April 2016","June 22, 2018","June 22, 2018","October 20, 2015",,"June 27, 2018","Indiana Univeristy Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|IU Health Central Indiana Cancer Centers, Indianapolis, Indiana, United States|Altantic Health System, Morristown, New Jersey, United States|Comprehensive Cancer Center at Wake Forest Baptist, Winston-Salem, North Carolina, United States|Gettysburg Cancer Center, Gettysburg, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02581059"
1746,"NCT04176081","Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer","SChLAP/IDC","Not yet recruiting","No Results Available","Prostate Cancer","Drug: Darolutamide|Drug: Degarelix|Radiation: Radiation Therapy","Recurrence Free Survival|Difference in RFS rates (as defined in primary outcome measure) between IDC/SChLAP1 and treatment groups.|Incidence of early biochemical failure as defined by Pheonix criteria (i.e., within first 2 years of follow-up; surrogate of lethal disease).|Rates of positive prostate biopsies (local failure) performed at time of recurrence as per standard of care.|Testosterone levels|Changes in prostate cancer-specific HRQoL as measured by abbreviated EPIC (urinary, bowel, sexual, and hormonal domains) questionnaire, as a function of treatment assignment|Rate of maximal biochemical control, defined as 2 consecutive undetectable PSA (<0.05 ng/mL) during follow-up.|Rates of positive molecular imaging results (local, regional and/or distant failure) performed at time of recurrence as per standard of care.|Changes in prostate cancer-specific HRQoL as measured by SF-12 questionnaire, as a function of treatment assignment","University Health Network, Toronto|Prostate Cancer Canada|Bayer","Male","18 Years and older   (Adult, Older Adult)","Phase 2","208","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SChLAP/IDC Study","January 2020","December 2028","December 2028","November 25, 2019",,"November 25, 2019","UHN Princess Margaret Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04176081"
1747,"NCT02352714","Study of Pain Control With Hormonal IUS Insertion","SOPHI","Completed","No Results Available","Pain","Drug: Paracervical Nerve Block|Drug: Sham Paracervical Block","Self-reported pain","Children's Hospital of Philadelphia|Bayer|University of Pennsylvania","Female","14 Years to 22 Years   (Child, Adult)","Phase 4","98","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","14-011286","January 2015","July 2016","July 2016","February 2, 2015",,"September 14, 2018","The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|The Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University Hospitals, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02352714"
1748,"NCT04156828","Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma",,"Not yet recruiting","No Results Available","Grade 3b Follicular Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Non-Hodgkin's Lymphoma","Drug: Copanlisib|Drug: Gemcitabine|Drug: Carboplatin|Drug: Dexamethasone|Biological: Rituximab|Biological: Pegfilgrastim","Dose limiting toxicity (DLT)|Complete response rate|Objective response rate|Ability to mobilize an adequate number of CD34+ stem cells for autologous stem cell transplant (ASCT)|Ability to proceed with ASCT|Progression free survival (PFS)|Overall survival (OS)|Cell of origin (COO)|Incidence of adverse events","University of Washington|National Cancer Institute (NCI)|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","21","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RG1005097|NCI-2019-07286|P30CA015704","February 3, 2020","July 31, 2022","July 31, 2023","November 8, 2019",,"January 6, 2020","Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04156828"
1749,"NCT04155840","Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",,"Not yet recruiting","No Results Available","Lymphoid Leukemia|Non-Hodgkin's Lymphoma|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma","Drug: Copanlisib|Drug: Copanlisib Hydrochloride|Biological: Rituximab|Drug: Bendamustine|Drug: Bendamustine Hydrochloride","Estimate the marrow minimal residual disease (MRD)-negative rate|Marrow MRD-negative rate|Progression free survival (PFS)|MRD conversion rate among those who are MRD-positive after 4 cycles|Proportion of subjects who experience grade 3+ immune-mediated adverse events or any grade 5 adverse event possibly related to copanlisib","University of Washington|National Cancer Institute (NCI)|Bayer","All","65 Years and older   (Older Adult)","Phase 2","25","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RG1005103|P30CA015704|NCI-2019-07289","February 3, 2020","July 31, 2023","July 31, 2023","November 7, 2019",,"January 6, 2020","Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04155840"
1750,"NCT02299960","Measurement of Endothelial Function and Cardiac Output: New Methods",,"Completed","No Results Available","Heart Failure|Hypertension, Pulmonary|Hypertension|Diabetic Nephropathies","Device: Endo-PAT|Device: NICOM","Test-retest-reliability EndoPAT|Test-retest-reliability circulating endothelial cells|Test-retest-reliability NICOM|Correlation: Cardiac Output on exertion and cardiopulmonary exercise test and 6 Minute Walking test|Correlation: circulating endothelial cells and EndoPAT and endothelial function|Variability of biomarkers of myocardiac remodelling and of cardiorenal syndrome|Correlation cardiac Output on exertion and echocardiography in HFpEF|Clinical feasibility of circulating endothelial cells and EndoPAT","Charite University, Berlin, Germany|Bayer|Health Twist GmbH","All","35 Years to 80 Years   (Adult, Older Adult)",,"101","Other|Industry","Observational","Observational Model: Case Control|Time Perspective: Prospective","ENDO-CEC","August 2014","September 2015","October 2015","November 24, 2014",,"June 10, 2016","Charite Universitaetsmedizin, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT02299960"
1751,"NCT02252705","Mexican Registry of Pulmonary Hypertension","REMEHIP","Unknown status","No Results Available","Pulmonary Hypertension",,"Major adverse cardiovascular events|Cardiovascular death","Remehip|Bayer|Medicaweb, S.A.C.V.","All","2 Years to 90 Years   (Child, Adult, Older Adult)",,"1000","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","REMEHIP","July 2014","December 2017","April 2018","September 30, 2014",,"April 11, 2017",,,"https://ClinicalTrials.gov/show/NCT02252705"
1752,"NCT03969953","Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease","TRACK","Not yet recruiting","No Results Available","Chronic Kidney Diseases|End-Stage Kidney Disease|Cardiovascular Disease","Drug: Rivaroxaban 2.5 Mg Oral Tablet|Other: Placebo","Risk of Major Adverse Cardiac Event (MACE)|Composite outcome of cardiovascular death, non-fatal myocardial infarction, or stroke.|Composite outcome of all-cause death, non-fatal myocardial infarction, stroke, or PAD events.|Composite outcome of all-cause death, non-fatal myocardial infarction, or stroke.|Incidence of Cardiovascular Death|Incidence of Non-Fatal Myocardial Infarction|Incidence of Stroke|Incidence of PAD Events|Net Clinical Benefit - incidence of MACE & Bleeding|Incidence of Venous Thromboembolism","The George Institute|George Clinical Pty Ltd|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","2000","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","0040139","January 2020","January 2025","January 2025","May 31, 2019",,"July 22, 2019",,,"https://ClinicalTrials.gov/show/NCT03969953"
1753,"NCT02164240","Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST","SURE","Active, not recruiting","Has Results","Gastrointestinal Stromal Tumor","Drug: Sunitinib|Drug: Regorafenib","Number of Participants With Serious and Non-Serious Adverse Events|Percentage of Participants With Clinical Benefit|Median Progression Free Survival (mPFS)","Dana-Farber Cancer Institute|Bayer|Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 1","14","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14-149","July 2014","December 2016","May 2020","June 16, 2014","September 12, 2019","September 12, 2019","Dana-Farber Cancer Institute, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02164240"
1754,"NCT02135484","Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases",,"Active, not recruiting","No Results Available","Prostate Cancer","Drug: Alpharadin","Biomarkers in Predicting Overall Survival","M.D. Anderson Cancer Center|Bayer|Prostate Cancer Foundation","Male","18 Years and older   (Adult, Older Adult)","Not Applicable","25","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2013-0933|NCI-2014-02016","September 19, 2014","June 1, 2020","September 2020","May 12, 2014",,"December 23, 2019","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02135484"
1755,"NCT02050919","Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma",,"Active, not recruiting","No Results Available","Pleomorphic Rhabdomyosarcoma|Stage IIB Adult Soft Tissue Sarcoma AJCC v7|Stage III Adult Soft Tissue Sarcoma AJCC v7|Stage IV Adult Soft Tissue Sarcoma AJCC v7","Drug: Epirubicin Hydrochloride|Radiation: External Beam Radiation Therapy|Drug: Ifosfamide|Other: Laboratory Biomarker Analysis|Drug: Sorafenib Tosylate|Procedure: Therapeutic Conventional Surgery","Pathologic response rate, classified as either greater than or equal to 95% necrosis or less than 95% necrosis|Levels of toxicity, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0|Wound complication rate|Overall survival|Overall disease-free survival (stage IIB-III patients)|Distant disease-free survival (stage IIB-III patients)|Local disease-free survival","OHSU Knight Cancer Institute|Bayer|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","20","Other|Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00009464|NCI-2013-02414|P30CA069533","December 3, 2013","May 7, 2018","December 31, 2018","January 31, 2014",,"June 29, 2018","OHSU Knight Cancer Institute, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT02050919"
1756,"NCT02048722","Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma",,"Recruiting","No Results Available","Adult Angiosarcoma|Recurrent Adult Soft Tissue Sarcoma|Stage III Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma","Drug: regorafenib","Progression-Free Survival (PFS) at 4 months|Progression-Free Rate (PFR) at 3 and 6 months|Progression-free survival (PFS)|Overall survival|Response rate (of tumor to treatment)|Rate and duration of tumor control|Number of Grade 1, 2, 3, 4, and 5 Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0)","Northwestern University|Bayer|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","31","Other|Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NU 13S02|NCI-2013-02278|STU00087654|ONC-2013-129|P30CA060553","March 2014","November 2019","February 2020","January 29, 2014",,"September 11, 2018","Sarcoma Oncology Center, Santa Monica, California, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Northwestern University, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|University of Minnesota Medical Center-Fairview, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University-St. Louis, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT02048722"
1757,"NCT03585504","Immediate Versus Delayed Insertion of Implanon in Postpartum Adolescents","Implanon","Completed","Has Results","Contraceptive Usage","Drug: Etonogestrel contraceptive implant","Number of Participants With Contraceptive Implant Continuation at Six Months Postpartum|Number of Participants That Reported They Were Somewhat or Very Satisfied With Their Subjective Bleeding Experience at Six Months Postpartum.|Number of Participants Who Reported That They Were Somewhat or Very Satisfied With the Contraceptive Implant at Six Months Postpartum.","Medical University of South Carolina|American College of Obstetricians and Gynecologists|Bayer","Female","15 Years to 21 Years   (Child, Adult)","Phase 3","81","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","HR #19133","January 2010","January 2013","January 2013","July 13, 2018","October 4, 2018","October 4, 2018","Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03585504"
1758,"NCT01949194","Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers",,"Active, not recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Regorafenib","A biomarker (in blood or tissue) that may be predictive of level of response to regorafenib|Number of participants with adverse events|Progression free survival (PFS) time|Objective Response Rate (RR)","Gerald Batist|Bayer|Quebec Clinical Research Organization in Cancer|Jewish General Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","48","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","QCROC-06","September 2013","October 2018","December 2018","September 24, 2013",,"August 10, 2018","The Moncton Hospital (Horizon Health Network), Moncton, New Brunswick, Canada|Jewish General Hospital, Montreal, Quebec, Canada|St-Mary's Hospital Centre, Montreal, Quebec, Canada|McGill University Health Centre, Montréal, Quebec, Canada|Hopital Maisonneuve-Rosemont, Montreal, Canada",,"https://ClinicalTrials.gov/show/NCT01949194"
1759,"NCT03475979","Abbreviated Breast MRI for Second Breast Cancer Detection in Women With BRCA Mutation Testing",,"Recruiting","No Results Available","Breast Cancer|BRCA1 Mutation|BRCA2 Mutation|Recurrent Breast Cancer|Metachronous Neoplasm",,"Sensitivity and Specificity (co-primary)|Cancer detection rate (CDR)|Positive predictive value (PPV)|Negative predictive value (NPV)|Histopathologic characteristics of secondary breast cancers","Seoul National University Hospital|Korean Society of Breast Imaging & Korean Society For Breast Screening|Bayer","Female","25 Years to 75 Years   (Adult, Older Adult)",,"1564","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","AB-MR for Second Breast Cancer","May 1, 2018","May 2021","May 2022","March 23, 2018",,"March 4, 2019","Seoul National University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03475979"
1760,"NCT01840592","Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib",,"Active, not recruiting","No Results Available","Hepatocellular Carcinoma","Drug: Sorafenib|Drug: Doxorubicin","overall survival|median time to progression|median progression free survival|median overall survival|toxicity","Memorial Sloan Kettering Cancer Center|Bayer|National Comprehensive Cancer Network","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12-259","April 2013","April 2020","April 2020","April 25, 2013",,"May 3, 2019","Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States|Memorial Sloan Kettering West Harrison, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre, New York, United States|Memorial Sloan Kettering Cancer Center at Phelps Memorial Hospital Center, Sleepy Hollow, New York, United States",,"https://ClinicalTrials.gov/show/NCT01840592"
1761,"NCT03305913","Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy","REMETY","Recruiting","No Results Available","Pretreated Metastatic Colorectal Cancer","Drug: TAS 102|Drug: Regorafenib","Maximum Tolerated Dose (MTD)|Overall Response Rate (ORR) according to RECIST 1.1 criteria|Progression-free survival (PFS)|Overall survival (OS)|Incidence of Treatment-Emergent Adverse Events","AIO-Studien-gGmbH|Institut für Klinisch-Onkologische Forschung (IKF) am Krankenhaus Nordwest GmbH|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","18","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0116-ASG|2016-001968-11","July 31, 2017","October 31, 2018","October 30, 2019","October 10, 2017",,"March 6, 2019","Universitätsmedizin Mainz, I.Medizinische Klinik und Poliklinik, Mainz, Germany",,"https://ClinicalTrials.gov/show/NCT03305913"
1762,"NCT03273322","Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure","ADRIFT","Completed","No Results Available","Atrial Fibrillation|Atrial Appendage|Hemorrhage","Drug: Rivaroxaban 10 mg qd|Drug: Rivaroxaban 15 mg qd|Drug: DAPT","Measure of prothrombin fragment 1 + 2|Factor Xa inhibitory activity at day 10|Factor Xa inhibitory activity at day 90|Russel Viper venom enzyme assay|TAT complex|D-Dimers|Prothrombin time (Neoplastin)|Plasma vWf Ag level|Haemorrhagic stroke and bleeding will be safety outcomes TEE with central core lab reading: presence of thrombus, peri-device leak|Composite clinical endpoint combining all clinical outcomes|Death (any cause)|Myocardial infarction (MI)|Stroke (ischaemic stroke, haemorrhagic stroke)|Transient Ischemic Attack (TIA)|Systemic embolism|Extracranial major bleeding or clinically relevant non major bleeding (ISTH definition) at day 90","Assistance Publique - Hôpitaux de Paris|Action Research Group|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","105","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P161102J","September 13, 2017","November 20, 2018","September 30, 2019","September 6, 2017",,"December 13, 2019","Institut de Cardiologie - Hôpital Pitié-Salpêtrière, Paris, France",,"https://ClinicalTrials.gov/show/NCT03273322"
1763,"NCT03192891","Stress CMR Perfusion Imaging in the United States (SPINS) Study","SPINS","Active, not recruiting","No Results Available","Myocardial Ischemia","Diagnostic Test: Stress cardiac magnetic resonance (CMR) perfusion imaging","Mortality|AMI|Late coronary revascularization|Non-fatal cardiac events|Cardiac event-weighted QALY","Society for Cardiovascular Magnetic Resonance|Siemens Healthcare|Bayer","All","35 Years to 85 Years   (Adult, Older Adult)",,"2200","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","SCMR_GRANT_002","March 1, 2017","March 31, 2018","November 30, 2019","June 20, 2017",,"September 12, 2019","University of Illinois, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|University of Kentucky, Lexington, Kentucky, United States|National Heart, Lung, and Blood Institute (NHLBI), Bethesda, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|New York-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States|Ohio State University, Columbus, Ohio, United States|Sharon Regional Health System, Hermitage, Pennsylvania, United States|Houston Methodist, Houston, Texas, United States|San Antonio Military Medical Center - Wilford Hall, San Antonio, Texas, United States|Revere Health, Provo, Utah, United States",,"https://ClinicalTrials.gov/show/NCT03192891"
1764,"NCT03128619","Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer",,"Suspended","No Results Available","Estrogen Receptor Positive|HER2/Neu Negative|Invasive Breast Carcinoma|Multifocal Breast Carcinoma|Postmenopausal|Progesterone Receptor Positive|Stage I Breast Cancer|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage III Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer","Procedure: Biopsy of Breast|Drug: Copanlisib|Other: Laboratory Biomarker Analysis|Drug: Letrozole|Drug: Palbociclib|Other: Pharmacological Study","Change in Ki-67 expression defined as the percent of cells staining positive by validated central assay (Phase II)|Incidence of dose-limiting toxicities (DLT) evaluated according to National Cancer Institute (NCI) CTCAE version 4.0 to determine MTD (Phase Ib)|Clinical objective response rate (ORR) evaluated by RECIST 1.1 using caliper measurements|Gene expression and/or biomarker changes|Incidence of adverse events (AEs) evaluated according to NCI CTCAE version 4.0|pCR rate defined as the percentage of randomized patients with a pCR|The pharmacokinetic (PK) parameter - area under the plasma concentration-time curve (AUC) will be determined for copanlisib in arms A, B, and escalation dose levels.|The pharmacokinetic (PK) parameter - Elimination half-life (t½) will be determined for copanlisib in arms A, B, and escalation dose levels.|The pharmacokinetic (PK) parameter - Maximum plasma concentration (Cmax) will be determined for copanlisib in arms A, B, and escalation dose levels.|The pharmacokinetic (PK) parameter - Minimum plasma concentration of BAY 80-694 will be determined for copanlisib in arms A, B, and escalation dose levels.|The pharmacokinetic (PK) parameter - Time when Cmax occurs (Tmax) will be determined for copanlisib in arms A, B, and escalation dose levels.|The pharmacokinetic (PK) parameter - Average plasma concentration at steady state (Cavg) will be determined for copanlisib in arms A, B, and escalation dose levels.","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)|Bayer","All","19 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","102","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-001271|NCI-2017-00435|P30CA016042","August 2, 2017","August 2, 2020","August 2, 2021","April 25, 2017",,"September 9, 2019","UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT03128619"
1765,"NCT02903160","Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)",,"Recruiting","No Results Available","Prostate Cancer","Drug: Abiraterone acetate|Drug: Prednisone|Drug: Radium-223 dichloride|Drug: cabazitaxel|Drug: Carboplatin|Drug: Enzalutamide","Time to disease progression|Overall survival|PSA response rate|Changes to alkaline phosphatase levels","Icahn School of Medicine at Mount Sinai|Sanofi|Bayer","Male","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO 16-1593|CABAZL07459|ONC-2014-168","January 13, 2017","June 2020","June 2020","September 16, 2016",,"December 9, 2019","Mount Sinai Beth Israel, New York, New York, United States|Mount Sinai West, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02903160"
1766,"NCT02832544","INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Non-Inferiority","INVICTUS-VKA","Recruiting","No Results Available","Rheumatic Heart Disease","Drug: Rivaroxaban (20 mg)|Drug: Vitamin K antagonists (VKA)","Time from randomization to the first occurrence of Stroke or Systemic Embolism|Time from randomization to the first occurrence of Myocardial Infarction (MI)|Time from randomization to time of vascular death","Population Health Research Institute|University of Cape Town|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","4500","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","INVICTUS - VKA","August 22, 2016","July 2020","October 2020","July 14, 2016",,"April 26, 2019","Princess Marina Hospital, Gaborone, Botswana|Cardresearch - Cardiologia Assistencial e de Pesquisa, Belo Horizonte, Minas Gerais, Brazil|Nucleo de Estudios Clinicos - Universidade Federal do Triângulo Mineiro, Uberaba, Minas Gerais, Brazil|Eurolatino Pesquisas Médicas Ltda, Uberlândia, Minas Gerais, Brazil|Clínica Procardio Ltda., Blumenau, Santa Catarina, Brazil|Instituto de Pesquisa Clínica de Campinas, Campinas, Brazil|LOEMA - Instituto de Pesquisa Clínica & Consultores Ltda, Campinas, Brazil|Via Médica Centro Clínico Barroso e Sebba Ltda, Goiania, Brazil|Instituto de Cardiologia do Rio Grande do Sul, Porto Alegre, Brazil|Fundação Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto, Brazil|Instituto do Coração - HCFMUSP, São Paulo, Brazil|Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil|Santa Casa de Misericórdia de Votuporanga, Votuporanga, Brazil|Clinique Coeur Et Vie, Douala, Cameroon|Douala General Hospital, Douala, Cameroon|St. Elizabeth Catholic General Hospital, Cardiac Centre, Kumbo, Cameroon|Hopital Central Yaounde, Yaounde, Cameroon|Liangxiang Hospital, Beijing, Beijing, China|The First Affiliated Hospital/School of Clinical Medicine of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China|Sun Yat-Sen Cardiovascular Hospital, Shenzhen, Guangdong, China|Shunping Xinghe Hospital, Baoding, Hebei, China|Jixi People's Hospital, Jixi, Heilongjiang, China|Tieli People's Hospital, Yichun, Heilongjiang, China|Luoyang Central's Hospital Affiliated to Zhengzhou University, Luoyang, Henan, China|Puyang Oilfield General Hospital, Puyang, Henan, China|Dancheng County People's Hospital, Zhoukou, Henan, China|Suiping Renan Hospital, Zhumadian, Henan, China|Jianshi County People's Hospital, Enshi, Hubei, China|Suqian Peaple's Hospital of Nanjing Drum-Tower Hospital Group, Suqian, Jiangsu, China|Tonghua Central Hospital, Tonghua, Jilin, China|Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning, China|The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China|Ningxia Peple's Hospital, Yinchuan, Ningxia, China|Xi'an Chang'an Hospital, Xi'an, Shanxi, China|Pi County People's Hospital, Chengdu, Sichuan, China|Anyue County People's Hospital, Ziyang, Sichuan, China|Wendeng Central Hospital, Weihai, Wendeng, China|Ninghai People's Hospital, Ningbo, Zhejiang, China|Beijing Anzhen Hospital, Beijing, China|Zhongmou County People's Hospital, Henan, China|Zhengzhou No.7 People's Hospital, Henan, China|The 1st Affiliated Hospital of Zhengzhou University, Henan, China|Zhengzhou 9th People's Hospital, Henan, China|Guangshan County People's Hospital, Henan, China|Wuhan No. 1 Hospital, Wuhan, China|Alexandria University Hospital, Alexandria, Egypt|Assuit General Hospital, Assuit, Egypt|Benha University Cardiology Department, Banha, Egypt|Beni Suef University Hospital, Beni Suef, Egypt|Ain Shams University Hospital, Cairo, Egypt|Kasr El Einy Hospital (Cairo University), Cairo, Egypt|Mehallah Rheumatic Heart Center, El Mahalla El Kubra, Egypt|Specialized Medical Hospital - Mansoura, El Mansura, Egypt|Fayoum General Hospital, Fayoum, Egypt|National Heart Institute, Giza, Egypt|Suez Canal University Hospital, Ismailia, Egypt|El Minia University Hospital, Minya, Egypt|Sohag University, Sohag, Sohag, Egypt|Red Crescent Hospital, Tanta, Egypt|Zagazig University Hospital, Zagazig, Egypt|Hawassa University Referral Hospital, Hawassa, Snnpr, Ethiopia|College of Health Sciences, Addis Ababa University, Black Lion Hospital, Addis Ababa, Ethiopia|Gondar University Hospital, Gondar, Ethiopia|Jimma University Hospital, Jimma, Ethiopia|Mekelle University, Mekelle, Ethiopia|Dr. Ram Manohar Lohia Hospital @ PGIMER, New Delhi, Delhi, India|Govind Ballabh Pant Hospital (GIPMER), New Delhi, Delhi, India|All India Institute of Medical Sciences, New Delhi, Delhi, India|Sri Jayadev Institute of Cardiovascular Sciences and Research, Bangalore, Karnataka, India|SMS Medical College, Jaipur, Rajasthan, India|King George's Medical College, Lucknow, Uttar Pradesh, India|Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India|PGIMER, Chandigarh, India|Jawaharlal Institute of Postgraduate Medical Education & Research (JIPMER), Pondicherry, India|Kazakh National Medical Institute,, Almaty, Kazakhstan|Moi Teaching and Referral Hospital, Eldoret, Kenya|Karen Hospital, Nairobi, Kenya|The Mater Hospital, Nairobi, Kenya|Aga Khan University Hospital, Nairobi, Kenya|Kenyatta National Hospital / University Of Nairobi, Nairobi, Kenya|Clinical Hospital of administrative department of President and Government of Kyrgyz Republic, Bishkek, Kyrgyzstan|National Center of Cardiology and Internal Diseases, Bishkek, Kyrgyzstan|Queen Elizabeth Central Hospital, Blantyre, Malawi|Kumuzu Central Hospital, Lilongwe, Malawi|Mzuzu Central Hospital, Mzuzu, Malawi|Hospital Angeles León, León, Guanajuato, Mexico|Hospital General De Acapulco, Acapulco, Guerrero, Mexico|Hospital General Dr. Jorge Soberon Acevedo.Secretaria de Salud del Estado de Guerrero, Iguala, Guerrero, Mexico|Hospital Bernardette, Guadalajara, Jalisco, Mexico|Centro de Estudios Clínicos de Querétaro S.C., Queretaro, Querétaro, Mexico|Centro para el Desarrollo de la Medicina y Asistencia Especializada S.C., Culiacan, Sinaloa, Mexico|Instituto de Investigación del Hospital Cardiológica Aguascalientes, Aguascalientes, Mexico|Universidad Nacional Autónoma de México. Hospital General de México, Mexico City, Mexico|Instituto Nacional de Cardiología Ignacio Chavez, México, Mexico|Maputo Central Hospital, Maputo, Mozambique|Instituto Nacional de Saude & Universidade Eduardo Mondlane, Maputo, Mozambique|College of Medical Sciences, Bharatpur, Nepal|Chitwan Medical College, Bharatpur, Nepal|Nobel medical college and teaching hospital pvt ltd, Biratnagar, Nepal|Gautam Buddha Community Heart Hospital, Butwal, Nepal|BP Koirala Institute of Health Sciences, Dharan, Nepal|Manmohan Cardiothoracic Vascular and Trasplant Center, IOM, TU, Kathmandu, Nepal|Sahid Gangalal Heart Center, Kathmandu, Nepal|Bheri Zonal Hospital, Nepalgunj, Nepal|Manipal College of Medical Sciences, Pokhara, Nepal|Federal Medical Center, Abeokuta, Nigeria|University of Nigeria Teaching Hospital, Enugu, Nigeria|College of Medicine, University of Ibadan, Ibadan, Nigeria|Jos University Teaching Hospital, Jos, Nigeria|Ahmadu Bello University Teaching Hospital, Kaduna, Nigeria|Aminu Kano University Teaching Hospital, Kano, Nigeria|Department of Medicine, Lagos University Teaching Hospital, Lagos, Nigeria|Ladoke Akintola University of Technology Teaching Hospital, Ogbomoso, Nigeria|Department of Medicine, Delta State University Teaching Hospital, Oghara, Nigeria|Olabisi Onabanjo University Teaching Hospital, Sagamu, Nigeria|Punjab Institute of Cardiology, Lahore, Punjab, Pakistan|Isra University Hospital, Hyderabad, Pakistan|Nishtar Hospital Multan, Multan, Pakistan|Lady Reading Hospital, Peshawar, Pakistan|Rawalpindi Institute of Cardiology, Rawalpindi, Pakistan|Instituto Nacional de Cardiología, Asunción, Paraguay|Hospital Barrio Obrero, Asunción, Paraguay|Hospital Regional de Ciudad Del Este, Ciudad del Este, Paraguay|Hospital Nacional Itaugua, Itaugua, Paraguay|Clinical Hospital, San Lorenzo, Paraguay|Palawan Medical City, Puerto Princesa City, Palawan, Philippines|Philippine General Hospital, Manila, Philippines|Philippine Heart Center, Quezon City, Philippines|Quirino Memorial Medical Center, Quezon City, Philippines|University of Rwanda, Kigali University Teaching Hospital, Kigali, Rwanda|Nelson Mandela Academic Hospital, Mthatha, Eastern Cape, South Africa|Charlotte Maxeke Academic Hospital, Johannesburg, Parktown, South Africa|Sefako Makgatho Health Sciences University, Ga-Rankuwa,, Pretoria, South Africa|Cardiology Research Universitas private hospital, Bloemfontein, South Africa|University of Cape Town, Cape Town, South Africa|Margate Clinical Trial Center, Margate, South Africa|University of Limpopo, Polokwane, South Africa|Port Elizabeth Hospital Complex, Port Elizabeth, South Africa|Chris Hani Baragwanath Hospital, Soweto, South Africa|Alobeid Teaching Hospital, Alobeid, Sudan|Atbara Teaching Hospital, Atbara, Sudan|Ahmed Gasim Hospital, Khartoum, Sudan|Alshaab Teaching Hospital, Khartoum, Sudan|Ahmed Gasim Pediatric Hospital, Khartoum, Sudan|Sudan Heart Center, Khartoum, Sudan|Digna Prince Hospital, Port Sudan, Sudan|Medani Heart Centre, Wad Medani, Sudan|Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania|University of Dodoma Teaching Hospital, Dodoma, Tanzania|Mbeya Zonal Referral Hospital, Mbeya, Tanzania|Uganda Heart Institute, Kampala, Uganda|Livingstone Central Hospital, Livingstone, Zambia|University Teaching Hospital (UTH), Lusaka, Zambia|Ndola Central Hospital, Ndola, Zambia|Mpilo Hospital, National University Science & Technology, Bulawayo, Zimbabwe|Harare Hospital, Harare, Zimbabwe|Parirenyatwa Hospital, Harare, Zimbabwe",,"https://ClinicalTrials.gov/show/NCT02832544"
1767,"NCT02782026","Exhaled Breath Olfactory Signature of Pulmonary Arterial Hypertension","SNOOPY2","Unknown status","No Results Available","Pulmonary Hypertension","Device: Exhaled Breath Olfactory Signature (Artificial Nose)","Volatile organic compounds in exhaled breath in patients of each group detected using sensor array on the basis of cross-reactive gold-nanoparticles coated with organic ligands.","Assistance Publique - Hôpitaux de Paris|Technion, Israel Institute of Technology|Bayer","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","350","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2014-01321-46","March 2016","September 2018","September 2018","May 25, 2016",,"October 2, 2017","AP-HP, Bicêtre Hospital, Le Kremlin-Bicêtre, France",,"https://ClinicalTrials.gov/show/NCT02782026"
1768,"NCT01337492","Pilot Study Sorafenib as Bridge to Orthotopic Liver Transplantation (OLT)",,"Terminated","No Results Available","Carcinoma, Hepatocellular","Drug: Nexavar","Adverse events associated with technical aspects of the operation|Time to progression prior to OLT|Drop Out Rate|Waiting Time","Case Comprehensive Cancer Center|Bayer|Onyx Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","2","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE2209","September 2010","May 2011","January 2012","April 19, 2011",,"March 21, 2012","Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01337492"
1769,"NCT02624700","2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer",,"Active, not recruiting","No Results Available","Breast Cancer|Metastatic Breast Cancer|Recurrent Breast Cancer","Drug: Pemetrexed|Drug: Sorafenib","The percentage of objective response either Partial Response (PR) or Complete Response(CR).|The percentage of progression-free survival (PFS).|To determine the 2-year survival rate after initial study treatment.|The amount of reported Adverse events (AEs).","Virginia Commonwealth University|Eli Lilly and Company|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","13","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-14-10790|HM20005967|NCI-2015-02190","January 28, 2016","July 10, 2019","June 30, 2022","December 8, 2015",,"August 30, 2019","Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02624700"
1770,"NCT02583191","Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients",,"Recruiting","No Results Available","Venous Thromboembolism|Cancer","Drug: Rivaroxaban|Drug: low-molecular heparine","Patient-reported treatment satisfaction (convenience) with Rivaroxaban in the treatment of acute VTE in cancer patients in comparison with the standard treatment with low molecular weight heparin|Rate of symptomatic venous thrombembolism-recurrence within 3 months exploratory analysis for patients with treatment|Exploratory analysis for ""time on treatment""|Subgroup analysis with regard to rate of Pulmonary embolism, venous thrombembolism recurrence and bleedings (major, clinically relevant, minor) according to stratification characteristics|Rate of myocardial infarction and ischemic stroke|Compliance of patients (adherence)|Overall mortality 3 and 6 months after randomization|Quality of Life (Spitzer Index (Spitzer 1981), Anticlot Treatment Scale (ACTS) and TSQM|Rate of clinically relevant bleeding (major + clinically relevant non major) within 3 months|Rate of minor bleedings within 3 months","AIO-Studien-gGmbH|Charite University, Berlin, Germany|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","450","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CONKO-011 AIO-SUP-0115/ass.","March 2016","December 2019","December 2019","October 22, 2015",,"April 18, 2019","Uniklinik, Aachen, Germany",,"https://ClinicalTrials.gov/show/NCT02583191"
1771,"NCT01263951","Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone",,"Active, not recruiting","No Results Available","Differentiated Thyroid Cancer","Drug: Everolimus|Drug: Sorafenib","To determine the efficacy of everolimus and sorafenib (progression free survival, objective response rate and stable disease) in patients with advanced differentiated thyroid cancer who have progressed on sorafenib alone.|To evaluate the secondary endpoints of best response in patients receiving everolimus and sorafenib.|To perform correlative scientific studies to determine the relationship between clinical response to everolimus and sorafenib and multiple parameters including the mutational status of BRAF, N-RAS and other relevant cancer genes in the tumor.|To investigate the effectiveness of mTOR and Raf kinase inhibition in surrogate tissue and tumor samples.|To evaluate the activity of additional signaling pathways in surrogate tissue and tumor samples and explore their relevance to outcome measures.|To evaluate the secondary endpoints of time to disease progression in patients receiving everolimus and sorafenib.|To evaluate the secondary endpoints of duration of response in patients receiving everolimus and sorafenib.","Abramson Cancer Center of the University of Pennsylvania|Bayer|Novartis Pharmaceuticals","All","18 Years to 89 Years   (Adult, Older Adult)","Phase 2","40","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UPCC 19309|812004","November 2010","December 2018","December 2019","December 21, 2010",,"April 11, 2019","Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01263951"
1772,"NCT01222351","Measuring Brain Amyloid Plaque Load in Older Adults Using BAY 94-9172",,"Active, not recruiting","No Results Available","Late Onset Alzheimer Disease","Drug: BAY 94-9172 (Florbetaben)","Changes in amyloid plaque load in the brain of the course of 3 years","New York State Psychiatric Institute|Bayer|National Institute on Aging (NIA)","All","65 Years and older   (Older Adult)","Not Applicable","161","Other|Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","6045/7130R (Bayer)|IND 78868|R01AG037212-01","December 2010","January 2020","January 2029","October 18, 2010",,"May 22, 2019","Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01222351"
1773,"NCT02463799","Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC",,"Active, not recruiting","No Results Available","Prostate Cancer","Drug: Radium-223|Biological: Sipuleucel-T","Immune responses to treatment with sipuleucel-T (with or without Radium-223) measured by peripheral PA2024 T-cell proliferation|To evaluate peripheral antigen-specific T-cell proliferation over time|To evaluate peripheral antigen-specific T-cell activation to sipuleucel-T over time|To evaluate antigen specific antibody response to sipuleucel-T over time|To evaluate sipuleucel-T induced antigen spread (epitope spread) phenomena|To evaluate the sipuleucel-T product immune parameters|To investigate safety of combined use of radium-223 and sipuleucel-T (composite measure of both arms)|To evaluate time to prostate-specific antigen (PSA) progression|To evaluate time to alkaline phosphatase (ALP) progression|To evaluate time to pain progression and first cancer-related opioid use|To evaluate time to radiographic or clinical progression|To evaluate time to first skeletal related event (SRE)|To evaluate time to first chemotherapy use","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Dendreon|Bayer","Male","18 Years and older   (Adult, Older Adult)","Phase 2","36","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","J1522|IRB00056435","February 22, 2016","November 2019","December 2020","June 4, 2015",,"April 4, 2019","Cedars-Sinai Medical Center, Los Angeles, California, United States|Sibley Memorial Hospital, Washington, District of Columbia, United States|Tulane Cancer Center, New Orleans, Louisiana, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Duke University, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02463799"
1774,"NCT02438098","Rivaroxaban in Bariatric Surgery",,"Completed","No Results Available","Prophylaxis of Venous Thromboembolism","Drug: Rivaroxaban 10 mg","Geometric mean ratio of rivaroxaban AUC (after surgery / before surgery)|AUC of rivaroxaban|Cmax of rivaroxaban|Tmax of rivaroxaban|Prothrombin time (PT)|Activated partial thromboplastin time (aPTT)|Prothrombin fragment (F1+F2)|Thrombin-antithrombin-complexes (TAT)|D-Dimers|Thrombin generation","University Hospital Inselspital, Berne|Centre Hospitalier Universitaire Vaudois|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","13","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","025/15","June 2015","November 2015","November 2015","May 8, 2015",,"January 8, 2016","Department of Visceral Surgery and Medicine, University Hospital Bern, Bern, Switzerland",,"https://ClinicalTrials.gov/show/NCT02438098"
1775,"NCT01126645","Sorafenib and Micro-therapy Guided by Primovist Enhanced MRI in Patients With Inoperable Liver Cancer","SORAMIC","Completed","No Results Available","Hepatocellular Carcinoma","Procedure: RFA|Procedure: Radioembolization (SIRT)","time to recurrence|overall survival|Primovist®-enhanced MRI is non-inferior or superior compared with contrast-enhanced multislice CT|quality of life|safety of RFA|safety of SIR Spheres","University of Magdeburg|Bayer|Sirtex Medical","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","529","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EudraCT No. 2009-012576-27","December 2010","January 25, 2018","December 31, 2018","May 20, 2010",,"May 31, 2019","University of Magdeburg, Magdeburg, Germany",,"https://ClinicalTrials.gov/show/NCT01126645"
1776,"NCT02312739","Nitrous Oxide for Pain Management During In-office Transcervical Sterilization","NEST","Completed","Has Results","Contraception|Inhalation of Nitrous Oxide","Procedure: In-office Transcervical Sterilization (Essure®)|Drug: Standard Oral pain medications|Drug: Intramuscular Ketorolac|Drug: Placebo pills|Other: Oxygen|Other: Nitrous Oxide","Change From Baseline in Pain Scale Measurement During and After the Procedure|Pain Scale Measurement - Maximum Pain Experienced|Change From Baseline in Patient Anxiety Scale After the Procedure|Patient Satisfaction (5-point Likert Scale)|Provider Ease of Insertion (0-100mm VAS)","University of New Mexico|Society of Family Planning|Bayer","Female","21 Years and older   (Adult, Older Adult)","Not Applicable","72","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","UNMHSC13-594","February 2014","March 2015","March 2015","December 9, 2014","July 6, 2016","July 6, 2016","UNM Center for Reproductive Health, Albuquerque, New Mexico, United States",,"https://ClinicalTrials.gov/show/NCT02312739"
1777,"NCT00997022","Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients",,"Completed","No Results Available","Hepatocellular Cancer","Drug: Sorafenib","Maximum tolerated dose of daily sorafenib|Duration of disease free survival|Duration of progression free survival","Columbia University|Bayer|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","14","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AAAD3519","May 2009","May 2015","May 2015","October 16, 2009",,"August 10, 2015","University of Southern California, Los Angeles, California, United States|University of California, Los Angeles, Los Angeles, California, United States|Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00997022"
1778,"NCT00936312","Females With Severe or Moderate Hemophilia A or B: an International Multi-center Study",,"Completed","No Results Available","Hemophilia A|Hemophilia B",,"The molecular and cytogenetic etiology of the condition will be compiled. Clinical manifestation demonstrated by the female hemophiliacs will be compared to published data available. Genotype and phenotype will be correlated.","Weill Medical College of Cornell University|Bayer|University Hospital, Bonn","Female","Child, Adult, Older Adult",,"200","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","Intl Female Hemophilia Study","March 2008","August 2011","August 2011","July 10, 2009",,"December 10, 2012","Weill Cornell Medical College, New York, New York, United States|Princess Margaret Hospital for Children, Perth, Australia|University Clinic Bonn, Bonn, Germany|University Clinic Munich, Munich, Germany|Sheba Medical Center, Tel Hashomer, Israel|Instituto G. Gaslini, Genova, Italy|A. Bianchi Bonomi Hemophilia Center, Milan, Italy|Nara Medical University, Nara, Japan|University Hospital Utrecht, Utrecht, Netherlands|Malmo University Hospital, Malmo, Sweden|Changhua Christian Hospital, Chunghua City, Changhua, Taiwan",,"https://ClinicalTrials.gov/show/NCT00936312"
1779,"NCT00858650","Registry of Hypogonadism in Men","RHyMe","Completed","No Results Available","Male Hypogonadism|Androgen Deficiency|Testosterone Deficiency","Other: Standard of Care","Prostate Cancer|PSA, IPSS, and Other Urologic Outcomes|Sexual Function and Hypogonadism Symptoms|Physical Health and Cardiovascular Outcome Measures","New England Research Institutes|Bayer|Besins Healthcare","Male","18 Years and older   (Adult, Older Adult)",,"999","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","RHyMe","March 2009","September 2013","September 2013","March 10, 2009",,"August 24, 2016","University Hospital Halle - Center for Reproductive Medicine and Andrology, Halle (Saale), Germany|Institute of Urology and Andrology, Segeberger Kliniken, Hamburg, Germany|Private Practice of Andrology & Urology, Hamburg, Germany|Klinik fur Innere Medizin,, Herne, Germany|Ospedali Riuniti, Ancona, Italy|Unità di Andrologia DFC AziendaOspedalieraUniversitariaCareggi, Florence, Italy|Hesperia Hospital, Modena, Italy|University of Parma, Parma, Italy|University of Rome - Sapienza, Rome, Italy|Amstelland Hospital, Amstelveen, Netherlands|VU medical centre, department of Urology, Amsterdam, Netherlands|Andros Men's Health Institutes, Arnhem, Netherlands|Erasmus Medical Center - Urology, Rotterdam, Netherlands|Fundacio Puigvert, Barcelona, Spain|Hospital Universitario doce de Octubre, Madrid, Spain|Hospital Universitario Puerta de Hierro- Majadahonda, Madrid, Spain|Hospital Carlos Haya, Malaga, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Urohälsan i Skövde: Gotenborg University, Gotenborg, Sweden|Karolinska University Hospital - Centre for Andrology and Sexual Medicine, Stockholm, Sweden|Barnsley Hospital, Barnsley, United Kingdom|Royal Free Hospital, Hampstead, United Kingdom|Holly Cottage Clinic, Lichfield, United Kingdom|Manchester Royal Infirmary, Manchester, United Kingdom|Royal Victoria Infirmary, Newcastle, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00858650"
1780,"NCT00844883","Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma",,"Completed","Has Results","Hepatocellular Carcinoma|Hepatoma","Drug: sorafenib|Procedure: LC Bead-TACE","Safety Will be Assessed by Grading Toxicities Reported at Intervals Throughout the Study. Higher Grade Toxicities Will be Assessed for Their Degree of Relatedness to the Study Treatment.|Efficacy Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) to Determine Response and Disease Control Rate|Efficacy Assessed by European Association for the Study of the Liver (EASL) Criteria to Determine Response and Disease Control Rate|Efficacy - Median TTP After Combination Treatment With Sorafenib and TACE|Efficacy - Overall Survival (OS) After Combination Treatment With Sorafenib and TACE|Efficacy - Factors Associated With Overall Survival (OS) After Combination Treatment With Sorafenib and TACE","Yale University|Bayer|Biocompatibles UK Ltd","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","J08110","February 2009","March 2015","March 2015","February 16, 2009","August 28, 2017","August 28, 2017","The Johns Hopkins Hospital, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00844883"
1781,"NCT00825734","Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer",,"Completed","Has Results","Metastatic Breast Cancer","Drug: Sorafenib|Drug: Ixabepilone","Progression-Free Survival (PFS)|6-month Progression-Free Survival|Objective Response Rate|Overall Survival (OS)|Number of Patients With Adverse Events as a Measure of of Safety and Tolerability","SCRI Development Innovations, LLC|Bayer|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","83","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCRI BRE 138","March 2009","June 2013","August 2014","January 21, 2009","December 22, 2014","December 22, 2014","Florida Cancer Specialists, Ft. Myers, Florida, United States|Providence Medical Group, Terre Haute, Indiana, United States|RHHP/ Hope Cancer Center, Terre Haute, Indiana, United States|Baptist Hospital East, Louisville, Kentucky, United States|Hematology Oncology Clinic, LLP, Baton Rouge, Louisiana, United States|Mercy Hospital, Portland, Maine, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|National Capital Clinical Research Consortium, Bethesda, Maryland, United States|St. Louis Cancer Care, Chesterfield, Missouri, United States|Portsmouth Regional Hospital, Portsmouth, New Hampshire, United States|Hematology-Oncology Associates of Northern NJ, Morristown, New Jersey, United States|Oncology Hematology Care, Cincinnati, Ohio, United States|South Carolina Oncology Associates, Columbia, South Carolina, United States|Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00825734"
1782,"NCT01896284","Study to Evaluate Efficacy of Aflibercept in Neovascular Age-related Macular Degeneration Patients Non Responders to Anti-Vascular Endothelial Growth Factor","MACBETH","Completed","No Results Available","Wet Macular Degeneration","Drug: 0.5mg aflibercept","Percentage of patients with no fluid on Optical Coherence Tomography (OCT) after loading dose of aflibercept|Changes in best corrected visual acuity (BCVA)after loading dose|Changes in OCT central foveal thickness after loading dose|Anatomic and Visual Acuity outcomes maintained during (every 8 weeks) treatment.|Determine the time to resolution of any intra/sub retinal fluid on OCT|Describe safety of this cohort of patients","Barcelona Macula Foundation|TFS Trial Form Support|Bayer","All","50 Years and older   (Adult, Older Adult)","Phase 4","46","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BMF-AFLI-2013-01|2013-000848-26","July 2013","November 2014","June 2015","July 11, 2013",,"November 23, 2018","Barcelona Macula Foundation, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT01896284"
1783,"NCT00696696","Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer",,"Completed","Has Results","Pancreatic Cancer","Drug: Gemcitabine|Drug: Erlotinib|Drug: Sorafenib","4-month Progression Free Survival (PFS) Rate|Objective Response Rate|Median Overall Survival (mOS)","NYU Langone Health|Bayer|OSI Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","45","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NYU 06-882","September 2007","November 2010","June 2013","June 13, 2008","December 21, 2011","June 30, 2016","Desert Regional Medical Center, Palm Springs, California, United States|Bellevue Hospital, New York, New York, United States|New York University Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00696696"
1784,"NCT00634751","CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma",,"Completed","Has Results","Pancreatic Neoplasms|Bile Duct Neoplasms","Drug: Oxaliplatin|Drug: Capecitabine|Drug: Sorafenib","Overall Response Rate|Progression-free Survival (PFS)|Overall Survival","University of Wisconsin, Madison|Bayer|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","48","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2007-0248|CO07204|H-2007-0248|NCI-2011-00475|A534260|SMPH\MEDICINE\HEM-ONC","February 2008","July 2010","July 2010","March 13, 2008","August 8, 2017","November 26, 2019","University of Wisconsin, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00634751"
1785,"NCT01701817","Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)","ORBIT-AF II","Completed","No Results Available","Atrial Fibrillation","Other: Patients with Atrial Fibrillation","Number of major bleeding events|Number of major adverse cardiac events","Janssen Scientific Affairs, LLC|Duke Clinical Research Institute|Bayer","All","21 Years and older   (Adult, Older Adult)",,"13785","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CR100871|RIVAROXAFL4002","February 20, 2013","July 12, 2017","July 12, 2017","October 5, 2012",,"December 15, 2017","Cullman, Alabama, United States|Dothan, Alabama, United States|Fairhope, Alabama, United States|Mobile, Alabama, United States|Tuscaloosa, Alabama, United States|Avondale, Arizona, United States|Glendale, Arizona, United States|Goodyear, Arizona, United States|Scottsdale, Arizona, United States|Sun City, Arizona, United States|Tucson, Arizona, United States|Alhambra, California, United States|Anaheim, California, United States|Bakersfield, California, United States|Banning, California, United States|Beverly Hills, California, United States|Carlsbad, California, United States|Concord, California, United States|East Palo Alto, California, United States|Fresno, California, United States|Huntington Beach, California, United States|Laguna Hills, California, United States|Larkspur, California, United States|Long Beach, California, United States|Los Alamitos, California, United States|Los Angeles, California, United States|Manhattan Beach, California, United States|Mission Hills, California, United States|Newport Beach, California, United States|Northridge, California, United States|Pasadena, California, United States|Pismo Beach, California, United States|Pomona, California, United States|Poway, California, United States|Rancho Mirage, California, United States|San Pedro, California, United States|Santa Rosa, California, United States|Torrance, California, United States|Ventura, California, United States|Aurora, Colorado, United States|Colorado Springs, Colorado, United States|Lakewood, Colorado, United States|Bridgeport, Connecticut, United States|Guilford, Connecticut, United States|Laurel, Delaware, United States|Newark, Delaware, United States|Washington, District of Columbia, United States|Bay Pines, Florida, United States|Clearwater, Florida, United States|Coral Springs, Florida, United States|Eustis, Florida, United States|Jupiter, Florida, United States|Lakeland, Florida, United States|Miami, Florida, United States|Miramar, Florida, United States|Palm Harbor, Florida, United States|Pensacola, Florida, United States|Port Charlotte, Florida, United States|Tampa, Florida, United States|Wellington, Florida, United States|Alpharetta, Georgia, United States|Athens, Georgia, United States|Atlanta, Georgia, United States|Cumming, Georgia, United States|Gainesville, Georgia, United States|Macon, Georgia, United States|Marietta, Georgia, United States|Rome, Georgia, United States|Smyrna, Georgia, United States|Idaho Falls, Idaho, United States|Pocatello, Idaho, United States|Aurora, Illinois, United States|Hines, Illinois, United States|Melrose Park, Illinois, United States|New Lenox, Illinois, United States|North Chicago, Illinois, United States|Peoria, Illinois, United States|Rock Island, Illinois, United States|Anderson, Indiana, United States|Bloomington, Indiana, United States|Hammond, Indiana, United States|Indianapolis, Indiana, United States|La Porte, Indiana, United States|Munster, Indiana, United States|South Bend, Indiana, United States|Davenport, Iowa, United States|Waterloo, Iowa, United States|Overland Park, Kansas, United States|Elizabethtown, Kentucky, United States|Louisville, Kentucky, United States|Mount Sterling, Kentucky, United States|Alexandria, Louisiana, United States|Bossier City, Louisiana, United States|Natchitoches, Louisiana, United States|New Orleans, Louisiana, United States|Shreveport, Louisiana, United States|Rockport, Maine, United States|Annapolis, Maryland, United States|Baltimore, Maryland, United States|Randallstown, Maryland, United States|Salisbury, Maryland, United States|Fall River, Massachusetts, United States|Alpena, Michigan, United States|Bay City, Michigan, United States|Flint, Michigan, United States|Grand Blanc, Michigan, United States|Lansing, Michigan, United States|Lapeer, Michigan, United States|Mount Clemens, Michigan, United States|Rochester Hills, Michigan, United States|Saint Joseph, Michigan, United States|Traverse City, Michigan, United States|Troy, Michigan, United States|Ypsilanti, Michigan, United States|Minneapolis, Minnesota, United States|Bridgeton, Missouri, United States|Kansas City, Missouri, United States|Fremont, Nebraska, United States|Las Vegas, Nevada, United States|Reno, Nevada, United States|Nashua, New Hampshire, United States|Bridgewater, New Jersey, United States|East Brunswick, New Jersey, United States|Flemington, New Jersey, United States|Linden, New Jersey, United States|Manalapan, New Jersey, United States|Moorestown, New Jersey, United States|Mountain Lakes, New Jersey, United States|Somerset, New Jersey, United States|Toms River, New Jersey, United States|Voorhees, New Jersey, United States|Wayne, New Jersey, United States|Albany, New York, United States|Flushing, New York, United States|Huntington, New York, United States|Jackson Heights, New York, United States|Jamaica, New York, United States|Jamestown, New York, United States|Lake Success, New York, United States|Mineola, New York, United States|Mount Kisco, New York, United States|New York, New York, United States|North Massapequa, New York, United States|Utica, New York, United States|Burlington, North Carolina, United States|Chapel Hill, North Carolina, United States|Durham, North Carolina, United States|Elizabeth City, North Carolina, United States|Greensboro, North Carolina, United States|Pinehurst, North Carolina, United States|Raleigh, North Carolina, United States|Sanford, North Carolina, United States|Spartanburg, North Carolina, United States|Canton, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Mansfield, Ohio, United States|Miamisburg, Ohio, United States|Toledo, Ohio, United States|Worthington, Ohio, United States|Youngstown, Ohio, United States|Tulsa, Oklahoma, United States|Medford, Oregon, United States|Portland, Oregon, United States|Abington, Pennsylvania, United States|Chambersburg, Pennsylvania, United States|Doylestown, Pennsylvania, United States|Ephrata, Pennsylvania, United States|Langhorne, Pennsylvania, United States|Lansdale, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Sayre, Pennsylvania, United States|West Reading, Pennsylvania, United States|Wynnewood, Pennsylvania, United States|Yardley, Pennsylvania, United States|Providence, Rhode Island, United States|Warwick, Rhode Island, United States|Woonsocket, Rhode Island, United States|Charleston, South Carolina, United States|Easley, South Carolina, United States|Lancaster, South Carolina, United States|Bristol, Tennessee, United States|Jackson, Tennessee, United States|Kingsport, Tennessee, United States|Memphis, Tennessee, United States|Nashville, Tennessee, United States|Oak Ridge, Tennessee, United States|Austin, Texas, United States|Beaumont, Texas, United States|Corpus Christi, Texas, United States|Dallas, Texas, United States|Fort Sam Houston, Texas, United States|Fort Worth, Texas, United States|Houston, Texas, United States|Katy, Texas, United States|McKinney, Texas, United States|Odessa, Texas, United States|Palestine, Texas, United States|Plano, Texas, United States|Round Rock, Texas, United States|San Antonio, Texas, United States|Tomball, Texas, United States|Tyler, Texas, United States|Annandale, Virginia, United States|Lynchburg, Virginia, United States|Mechanicsville, Virginia, United States|Midlothian, Virginia, United States|Newport News, Virginia, United States|Virginia Beach, Virginia, United States|Seattle, Washington, United States|Tacoma, Washington, United States|Vancouver, Washington, United States|Walla Walla, Washington, United States|Charleston, West Virginia, United States|La Crosse, Wisconsin, United States|Milwaukee, Wisconsin, United States|Waukesha, Wisconsin, United States|Wausau, Wisconsin, United States|Rio Grande, Puerto Rico|Saint Thomas, Virgin Islands (U.S.)",,"https://ClinicalTrials.gov/show/NCT01701817"
1786,"NCT00616564","Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma",,"Completed","No Results Available","Malignant Melanoma","Drug: GM-CSF","Primary Objective","Mt. Sinai Medical Center, Miami|Bayer|Chiron Corporation","All","16 Years to 90 Years   (Child, Adult, Older Adult)","Phase 2","36","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MEL0105","February 2006","September 2009","September 2009","February 15, 2008",,"May 3, 2012","Jose Lutzky, MD, Miami Beach, Florida, United States|David Lawson, MD, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT00616564"
1787,"NCT00609804","Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib",,"Completed","Has Results","Non-Small Cell Lung Cancer","Drug: Sorafenib|Drug: Erlotinib","Progression-free Survival (PFS)|Overall Response Rate|Number of Participants With Treatment-emergent Adverse Events as a Measure of Safety and Tolerability","SCRI Development Innovations, LLC|Bayer|OSI Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","53","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCRI LUN 162","March 2008","May 2012","November 2014","February 7, 2008","June 2, 2015","April 8, 2016","Florida Cancer Specialists, Fort Myers, Florida, United States|Northeast Georgia Medical Center, Gainesville, Georgia, United States|Wellstar Cancer Research, Marietta, Georgia, United States|Providence Medical Group, Terre Haute, Indiana, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Hematology Oncology Clinic, LLP, Baton Rouge, Louisiana, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|National Capital Clinical Research Consortium, Bethesda, Maryland, United States|Jackson Oncology Associates, Jackson, Mississippi, United States|St. Louis Cancer Care, Chesterfield, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Nebraska Methodist Cancer Center, Omaha, Nebraska, United States|Hematology-Oncology Associates of Northern NJ, Morristown, New Jersey, United States|Associates in Hematology Oncology, Chattanooga, Tennessee, United States|Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00609804"
1788,"NCT00607438","A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer",,"Terminated","No Results Available","Breast Cancer","Drug: Paclitaxel Albumin Nanoparticle for Injectable Suspension (Abraxane)|Drug: Sorafenib (Nexavar)","To evaluate the progression-free survival (PFS)and duration of response of the combination of weekly Abraxane and continuous Nexavar as first-line treatment for patients with locally advanced or metastatic breast cancer.|To evaluate the response rate.|Evaluate the 1 and 2 year survival rate.|Evaluate the toxicities of the combination of Abraxane and Nexavar","Veeda Oncology|Bayer|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","16","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","I-06-025","September 2007","May 2009","May 2009","February 5, 2008",,"May 11, 2012","Veeda Oncology, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00607438"
1789,"NCT01683149","Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies",,"Completed","No Results Available","Solid Tumor","Drug: Topotecan|Drug: Sorafenib","Maximum Tolerated Dose (MTD)|Time to Progression (TTP)|The Number of Participants with Adverse Events as a Measure of Safety and Feasibility","H. Lee Moffitt Cancer Center and Research Institute|Pediatric Cancer Foundation|Bayer","All","3 Years to 18 Years   (Child, Adult)","Phase 1","13","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-16963|ONC-2011-49|Sunshine Project 002","January 2013","January 2016","January 2016","September 11, 2012",,"March 4, 2016","Childrens Hospital Los Angeles, Los Angeles, California, United States|Connecticut Childrens Medical Center, Hartford, Connecticut, United States|Nemours/Alfred I. duPont Hospital for Children, Delaware, Wilmington, Delaware, United States|University of Florida, Gainesville, Gainesville, Florida, United States|Nemours Children's Clinic, Jacksonville, Jacksonville, Florida, United States|University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida, United States|All Children's Hospital, St. Petersburg, St. Petersburg, Florida, United States|Montefiore Medical Center, Children's Hospital at Montefiore, Bronx, New York, United States|Primary Children's Medical Center/Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01683149"
1790,"NCT00597493","Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM",,"Completed","Has Results","Recurrent Glioblastoma Multiforme","Drug: Sorafenib and Temozolomide","6 Month Progression Free Survival (PFS)|Safety and Toxicity of Combination|Pharmacokinetics: C-max|Pharmacokinetics: T-max|Pharmacokinetics: AUC-24","Duke University|Bayer|Schering-Plough","All","18 Years and older   (Adult, Older Adult)","Phase 2","32","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00000464","September 2007","February 2009","December 2010","January 18, 2008","June 24, 2013","June 24, 2013","Duke University Health System, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00597493"
1791,"NCT00526799","Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer",,"Terminated","Has Results","Ovarian Cancer","Drug: Sorafenib|Drug: Topotecan","Maximum Tolerated Dose (MTD)|Percentage of Participants With Response|Progression-free Survival|Clinical Benefit|Duration of Stable Disease","Daniela Matei, MD|Bayer|Hoosier Cancer Research Network","Female","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","30","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GYN06-111","September 2007","January 2010","August 2010","September 10, 2007","March 3, 2016","March 3, 2016","Medical & Surgical Specialists, LLC, Galesburg, Illinois, United States|Oncology Hematology Associates of SW Indiana, Evansville, Indiana, United States|Fort Wayne Oncology & Hematology, Inc, Fort Wayne, Indiana, United States|Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|St. Vincent Hospital Cynecologic Oncology, Indianapolis, Indiana, United States|Arnett Cancer Care, Lafayette, Indiana, United States|Medical Consultants, P.C., Muncie, Indiana, United States|Schwartz Gynecologic Oncology, PLLC, Brightwaters, New York, United States",,"https://ClinicalTrials.gov/show/NCT00526799"
1792,"NCT01529320","Assess Itch Behavior in Nickel Sulphate Sensitized Volunteers",,"Completed","No Results Available","Allergic Contact Eczema","Drug: Adventan® (methylprednisolone aceponate 0,1%)","Mean time to Itch Relief (TR) from the start of treatment, with methylprednisolone aceponate.|Erythema intensity by colorimetry.|Eczema intensity by planimetric morphology (ICDRG scale)|VAS versus time curve (time to reach VAS max from the start of treatment, AUC, dVAS/dT)","Fundacion IMIM|Adknoma Health Research|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","18","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","GIM-MPA-2011-01|2011-005284-25","February 2012","May 2012","May 2012","February 8, 2012",,"May 12, 2016","Dermatology Service, Hospital del Mar, Parc de Salut Mar, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT01529320"
1793,"NCT00473486","Study in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pemetrexed and Carboplatin Plus or Minus Sorafenib","PECASO","Terminated","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: pemetrexed, carboplatin, sorafenib|Drug: pemetrexed, carboplatin, placebo","Ph.1: Identify the recommended phase II dose of sorafenib for combination therapy with carboplatin and pemetrexed|Ph.2: Compare the PFS of carboplatin/pemetrexed + sorafenib or carboplatin/pemetrexed + placebo in patients with stage IIIb or IV non-small cell lung cancer|Ph.1: Determine dose limiting toxicity|Ph 1: Determine the safety profile of the combination treatment|Ph 1: descriptive analysis of efficacy|Ph.2: Compare PFS of carboplatin/pemetrexed + sorafenib or carboplatin/pemetrexed + placebo in patients with stage IIIb or IV NSCLC|Ph 2: Assess time to progression in patients treated with either regimen|Ph 2: Determine the overall survival in patients treated with either regimen|Ph 2: Determine the objective response rate (CR, PR), disease control rate (CR,PR,SD), time to response and duration of response|Ph 2: Identify surrogate markers from the tumor biopsy or resection specimen from the time of diagnosis that predict response|Ph 2: Assess Quality of Life of patients treated with either regimen|Ph 2: Assess feasibility and toxicity profile of this regimen","University Hospital Muenster|Bayer|Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","12","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2006-005970-26|KKS / INNERE_A / NSCLC2006","May 2007","August 2008","January 2010","May 15, 2007",,"January 27, 2010","University of Muenster, Dept. of Medicine, Hematology / Oncology, Muenster, Germany",,"https://ClinicalTrials.gov/show/NCT00473486"
1794,"NCT01490073","The Effect of Nitroglycerin on the Intrauterine Device (IUD) Insertion Experience in Nulliparous Women",,"Completed","Has Results","Contraception|Pain","Drug: Insertion of nitroglycerin ointment|Drug: Insertion of placebo ointment","Patient-reported Pain at Passage of Insertion Device Through Cervix, as Measured on a 100 mm VAS|Provider Ease With Intrauterine Device Insertion Measured on a 100 mm VAS","Oregon Health and Science University|American College of Obstetricians and Gynecologists|Bayer","Female","18 Years to 45 Years   (Adult)","Not Applicable","24","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","7928","March 1, 2012","November 1, 2012","November 1, 2012","December 12, 2011","April 26, 2019","April 26, 2019","Planned Parenthood Columbia Willamette, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT01490073"
1795,"NCT00456716","Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma",,"Completed","No Results Available","Lung Cancer","Drug: sorafenib","Response rate|One-year survival|Median survival|Median progression-free survival|Toxicities","Swedish Medical Center|Bayer|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","5","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CRC 0639","March 2007","December 2008","December 2008","April 5, 2007",,"March 4, 2010","Swedish Cancer Institute, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00456716"
1796,"NCT00445042","Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer",,"Completed","No Results Available","Carcinoma, Renal Cell","Drug: Sorafenib","Tumor progression rate by RECIST criteria|Overall response rate|Time to progression and overall survival","The Methodist Hospital System|Bayer|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","71","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PAC IRB#03-0194-05|Sorafenib-RCC-01","November 2005","September 2008","October 2008","March 8, 2007",,"March 17, 2016","Methodist Hospital - Baylor College of Medicine, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00445042"
1797,"NCT00418496","Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma",,"Completed","No Results Available","Renal Cancer|Melanoma","Drug: Aldesleukin|Drug: Sorafenib","Maximum Tolerated Dose (MTD)|Determine the progression free survival.|Evaluate in a preliminary manner the response rate.","Ohio State University Comprehensive Cancer Center|Bayer|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 1","17","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OSU-06006|NCI-2011-03199","November 8, 2006","February 28, 2013","October 2013","January 4, 2007",,"February 20, 2017","Ohio State University, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00418496"
1798,"NCT00350597","GM-CSF as Adjuvant Therapy of Melanoma",,"Completed","No Results Available","Malignant Melanoma","Drug: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)","1 To describe the effect of GM-CSF adjuvant treatment of 125 ug/m2 once daily for 14 days followed by 14 days rest on immunological function as determined by serum neopterin levels (a measure of macrophage activation) and on serum levels of S100B.|To evaluate if a change of any or all of the immunological parameters over the treatment period is associated with safety and/or clinical outcome as measured by time to disease recurrence, time to disseminated disease and/or survival.|To perform a more detailed immunologic analysis in a sub-set of study participants (6 evaluable patients) to determine the immunologic responses induced by GM-CSF. There are three main immunological analyses to be determined:|a Monocyte cell numbers and activity|b Mature dendritic cell numbers|c Surface markers on peripheral blood mononuclear cells (PBMC) relative to T cells","Northern California Melanoma Center|Bayer|Melanoma Research Institute","All","14 Years and older   (Child, Adult, Older Adult)","Phase 2","50","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GM-CSF 040906","September 2004",,"July 2010","July 11, 2006",,"July 11, 2006","Northern California Melanoma Center, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT00350597"
1799,"NCT01244971","Exercise and Acarbose in Type 2 Diabetes",,"Completed","No Results Available","Diabetes Mellitus Type 2","Drug: Acarbose|Behavioral: Exercise|Other: Exercise + Acarbose","Glycemic control","Karolinska Institutet|The Swedish Research Council|Bayer","All","45 Years to 60 Years   (Adult)","Phase 4","62","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DNR 03-539","January 2004","June 2004",,"November 22, 2010",,"November 22, 2010","Enheten för Metabol Kontroll, Endokrinkliniken, Karolinska University Hospital, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT01244971"
1800,"NCT01236807","MR INFORM - MR Perfusion Imaging to Guide Management of Patients With Stable Coronary Artery Disease",,"Completed","No Results Available","Coronary Artery Disease|Stable Angina|Myocardial Ischaemia","Procedure: MR perfusion guidance|Procedure: FFR guidance","Occurence of major adverse cardiac events (MACE)|Individual MACE|Other adverse events|Course of symptoms (angina, breathlessness)|Cost comparison|changes in LV volumes and function","King's College London|Guy's and St Thomas' NHS Foundation Trust|Bayer","All","18 Years and older   (Adult, Older Adult)","Not Applicable","915","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","MR INFORM-10","December 2010","August 2016","December 2016","November 9, 2010",,"December 28, 2016","King's College, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01236807"
1801,"NCT01226056","Sorafenib in Combination With RAD001 in Advanced Solid Tumors Selected on Molecular Targets",,"Suspended","No Results Available","Advanced Solid Tumors","Drug: RAD001 in combination with sorafenib","Phase I: Maximum Tolerated Dose (MTD)|Phase II: PFS (Progression Free survival) rate|Phase I: Pharmacokinetics profile of both drugs|Phase II: overall survival|Tumor response|Objective Response Rate (ORR)|Incidence and severity of AEs","Southern Europe New Drug Organization|Novartis|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","45","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","S075SORD01","March 2009","September 2012","December 2012","October 21, 2010",,"October 21, 2010","Istituto Europeo di Oncologia,, Milano, Italy",,"https://ClinicalTrials.gov/show/NCT01226056"
1802,"NCT01194869","Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer",,"Terminated","Has Results","Breast Cancer","Drug: Sorafenib|Drug: Cisplatin|Drug: Paclitaxel","Pathologic Complete Response (pCR) at the Time of Surgery After Preoperative Treatment|Clinical Response Rate During Follow-up (Disease Recurrence)|Clinical Response Rate (Complete Pathologic Response Rate After Surgery)","Emory University|Amgen|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","25","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00019781|WCI1590-08","June 2010","June 2015","June 2015","September 3, 2010","July 28, 2016","October 18, 2016","Grady Memorial Hospital, Atlanta, Georgia, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Winship Cancer Institute, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT01194869"
1803,"NCT01190579","Dual Source CT Angiography for Detection of Coronary Artery Stenoses","MEDIC","Unknown status","No Results Available","Coronary Artery Disease",,"Accuracy for the detection of coronary artery stenoses|Safety of Ultravist 370 and Ultravist 300 for coronary CT angiography","University of Erlangen-Nürnberg Medical School|Siemens Medical Solutions|Bayer","All","30 Years to 80 Years   (Adult, Older Adult)",,"398","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","MEDIC","August 2009","December 2010","December 2010","August 27, 2010",,"August 27, 2010","Vejle Medical Center, Vejle, Denmark|University of Erlangen, Erlangen, Germany|Roentgenpraxis Hamburg, Hamburg, Germany|Deutsches Herzzentrum Muenchen, Muenchen, Germany|Klinikum Grosshadern, Munich, Germany|Ravi Bathina, Hyderabad, India|Cardiovascular Institute, Monterrey, Mexico|Tan Tok Seng Hospital, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT01190579"
1804,"NCT01165710","Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)",,"Completed","No Results Available","Atrial Fibrillation","Other: Patients with Atrial Fibrillation (AF)","The primary outcome is stroke or non-CNS (systemic) embolism. Key primary objective is: characterize & describe the AF patient population as a whole, with emphasis on demographics, comorbidities, and risk profiles.|The number of major adverse cardiac events.","Janssen Scientific Affairs, LLC|Duke Clinical Research Institute|Bayer","All","18 Years to 99 Years   (Adult, Older Adult)",,"10179","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CR016327|RIVAROXAFL4001","June 2010","November 2014","December 2014","July 20, 2010",,"January 24, 2017","Birmingham, Alabama, United States|Dothan, Alabama, United States|Huntsville, Alabama, United States|Mobile, Alabama, United States|Montgomery, Alabama, United States|Pell City, Alabama, United States|Tuscaloosa, Alabama, United States|Cottonwood, Arizona, United States|Tucson, Arizona, United States|Fort Smith, Arkansas, United States|Carlsbad, California, United States|Carmichael, California, United States|Corona, California, United States|Laguna Hills, California, United States|Long Beach, California, United States|Los Alamitos, California, United States|Los Angeles, California, United States|Montebello, California, United States|Northridge, California, United States|Orange, California, United States|Oxnard, California, United States|Palo Alto, California, United States|Pismo Beach, California, United States|Pomona, California, United States|San Diego, California, United States|San Ramon, California, United States|Santa Rosa, California, United States|Tarzana, California, United States|Torrance, California, United States|Tustin, California, United States|Ventura, California, United States|Aurora, Colorado, United States|Colorado Springs, Colorado, United States|Golden, Colorado, United States|Newark, Delaware, United States|Seaford, Delaware, United States|Boynton Beach, Florida, United States|Coral Springs, Florida, United States|Deerfield Beach, Florida, United States|Fort Myers, Florida, United States|Fort Walton Beach, Florida, United States|Hollywood, Florida, United States|Jupiter, Florida, United States|Lakeland, Florida, United States|Oakland Park, Florida, United States|Orange Park, Florida, United States|Ormond Beach, Florida, United States|Port Charlotte, Florida, United States|St. Petersburg, Florida, United States|Tallahassee, Florida, United States|Atlanta, Georgia, United States|Decatur, Georgia, United States|Marietta, Georgia, United States|Riverdale, Georgia, United States|Idaho Falls, Idaho, United States|Nampa, Idaho, United States|Aurora, Illinois, United States|Evergreen Park, Illinois, United States|Melrose Park, Illinois, United States|Peoria, Illinois, United States|Rock Island, Illinois, United States|Rockford, Illinois, United States|Urbana, Illinois, United States|Winfield, Illinois, United States|Bloomington, Indiana, United States|Evansville, Indiana, United States|Hammond, Indiana, United States|Indianapolis, Indiana, United States|La Porte, Indiana, United States|South Bend, Indiana, United States|Waterloo, Iowa, United States|Overland Park, Kansas, United States|Crestview Hills, Kentucky, United States|Lexington, Kentucky, United States|Owensboro, Kentucky, United States|Alexandria, Louisiana, United States|Rockport, Maine, United States|Beltsville, Maryland, United States|Salisbury, Maryland, United States|Biddeford, Massachusetts, United States|Bay City, Michigan, United States|Bridgman, Michigan, United States|Commerce Township, Michigan, United States|Grand Blanc, Michigan, United States|Lansing, Michigan, United States|Livonia, Michigan, United States|Mount Clemens, Michigan, United States|Stevensville, Michigan, United States|Traverse City, Michigan, United States|Troy, Michigan, United States|Minneapolis, Minnesota, United States|Anaconda, Montana, United States|Omaha, Nebraska, United States|Las Vegas, Nevada, United States|Bridgewater, New Jersey, United States|Elmer, New Jersey, United States|Haddon Heights, New Jersey, United States|Linden, New Jersey, United States|Nampa, New Jersey, United States|Ridgewood, New Jersey, United States|Sewell, New Jersey, United States|Toms River, New Jersey, United States|Flushing, New York, United States|Huntington, New York, United States|Jamaica, New York, United States|New York, New York, United States|Northport, New York, United States|Calabash, North Carolina, United States|Charlotte, North Carolina, United States|Durham, North Carolina, United States|Greenwood, North Carolina, United States|Jacksonville, North Carolina, United States|Pinehurst, North Carolina, United States|Raleigh, North Carolina, United States|Sanford, North Carolina, United States|Tabor City, North Carolina, United States|Winston Salem, North Carolina, United States|Fargo, North Dakota, United States|Minot, North Dakota, United States|Mansfield, Ohio, United States|Miamisburg, Ohio, United States|Piqua, Ohio, United States|Toledo, Ohio, United States|Worthington, Ohio, United States|Youngstown, Ohio, United States|Abington, Pennsylvania, United States|Beaver, Pennsylvania, United States|Danville, Pennsylvania, United States|Doylestown, Pennsylvania, United States|Erie, Pennsylvania, United States|Lansdale, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Scranton, Pennsylvania, United States|Spring House, Pennsylvania, United States|West Reading, Pennsylvania, United States|Wynnewood, Pennsylvania, United States|Yardley, Pennsylvania, United States|Pawtucket, Rhode Island, United States|Anderson, South Carolina, United States|Easley, South Carolina, United States|Spartanburg, South Carolina, United States|Harriman, Tennessee, United States|Kingsport, Tennessee, United States|Nashville, Tennessee, United States|Arlington, Texas, United States|Beaumont, Texas, United States|Corpus Christi, Texas, United States|Flower Mound, Texas, United States|Fort Worth, Texas, United States|Houston, Texas, United States|Mcallen, Texas, United States|Odessa, Texas, United States|Plano, Texas, United States|San Antonio, Texas, United States|Tomball, Texas, United States|Salt Lake City, Utah, United States|Fredericksburg, Virginia, United States|Lynchburg, Virginia, United States|Midlothian, Virginia, United States|Roanoke, Virginia, United States|Winchester, Virginia, United States|Burien, Washington, United States|Port Orchard, Washington, United States|Spokane, Washington, United States|Tacoma, Washington, United States|Vancouver, Washington, United States|La Crosse, Wisconsin, United States|Madison, Wisconsin, United States|Hato Rey, Puerto Rico|Rio Grande, Puerto Rico|San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT01165710"
1805,"NCT00177138","Use of Campath for Induction and Maintenance Therapy in Pancreas After Kidney Transplantation",,"Terminated","No Results Available","Diabetes Mellitus","Drug: Tacrolimus|Drug: Alemtuzumab","Time-to-event analysis will be used to analyze categorical end points that include graft failure, patient survival, biopsy documented rejection episode and non-compliance.|The continuous outcome variable, weekly or bi-weekly serum creatinine levels, will be analyzed using a two-way repeated-measures analysis of variance.","University of Minnesota|Bayer|Gruessner, Rainer, MD","All","18 Years to 60 Years   (Adult)","Phase 4","9","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0308M51264|Berlex Study No. 107.G0001","July 2004",,"November 2006","September 15, 2005",,"February 7, 2013","University of Minnesota-Fairview, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT00177138"
1806,"NCT00142272","Single Dose Ciprofloxacin in the Treatment of Childhood Cholera:Randomized Controlled Clinical Trial",,"Completed","No Results Available","Cholera","Drug: Ciprofloxacin","Rates of clinical success|Rates of bacteriologic success at test of cure visit.|Duration of diarrhoea.|Rates of clinical relapse.|Rates of bacteriologic relapse.|Duration of faecal excretion of V. cholerae O1 or V. cholerae O139.|Measurements of six-hourly volume of watery stool will be done for the period in which patients are hospitalised.|Proportion of patients requiring unscheduled intravenous fluids.|Frequency of vomiting and its volume.|Frequency of stool per day.|Frequency of vomit per day.|Safety.|PK-assessment of serum and stool.","International Centre for Diarrhoeal Disease Research, Bangladesh|Bayer|NEMC","Male","2 Years to 15 Years   (Child)","Phase 3","180","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ICDDR,B 2000-032","May 2001",,"July 2002","September 2, 2005",,"November 21, 2005","International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh",,"https://ClinicalTrials.gov/show/NCT00142272"
1807,"NCT00948987","Mechanism Based Resistance to Aspirin",,"Completed","No Results Available","Aspirin Resistance|Pharmacological Aspirin Non-responsiveness","Drug: Aspirin","Arachidonic acid induced platelet aggregation|Serum thromboxane B2 concentration Urinary 11-dehydro thromboxane B2 concentration Urinary 2,3 dinor-6 keto PGF1α concentration","University of Pennsylvania|National Institutes of Health (NIH)|Bayer","All","18 Years to 55 Years   (Adult)","Phase 1","400","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","801907|0926","September 2004","October 2009","October 2009","July 30, 2009",,"October 15, 2009",,,"https://ClinicalTrials.gov/show/NCT00948987"
1808,"NCT00942682","Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors",,"Completed","No Results Available","Neuroendocrine Tumor|Carcinoid Tumor|Pancreatic Neuroendocrine Tumor","Drug: Sorafenib|Drug: RAD001","To determine the maximum tolerated dose (MTD) for sorafenib in combination with RAD001 in patients with advanced neuroendocrine tumors.|To determine the dose-limiting toxicities of sorafenib combined with RAD001 in patients with advanced neuroendocrine tumors|To determine the safety and tolerability of the combination of sorafenib and RAD001 in patients with advanced neuroendocrine tumors.|To make a preliminary assessment of the anti-tumor activity of the combination of sorafenib and RAD001 in patients with advanced neuroendocrine tumors.","Dana-Farber Cancer Institute|Novartis|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","21","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09-094","July 2009","March 2013","March 2013","July 21, 2009",,"April 29, 2014","Dana-Farber Cancer Institute, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00942682"
1809,"NCT00801801","Study of Low Dose Chemotherapy Plus Sorafenib as Initial Therapy for Patients With Advanced Non-Squamous Cell NSCLC",,"Terminated","Has Results","Non Squamous Cell Lung Cancer|Non Small Cell Lung Cancer","Drug: Docetaxel + Sorafenib","2-month Progression-free Survival Rate|Response Rate in Poor Performance Status Subjects","Francisco Robert,MD|Sanofi|Bayer|University of Alabama at Birmingham","All","19 Years and older   (Adult, Older Adult)","Phase 2","5","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","F080703006|UAB 0750","January 2008","October 2009","March 2011","December 4, 2008","June 19, 2013","May 17, 2017","University of Alabama at Birmingham, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT00801801"
1810,"NCT00635791","Phase I Study of Vorinostat and Sorafenib in Advanced Cancer",,"Completed","No Results Available","Malignant Solid Tumour|Renal Cell Carcinoma|Non Small Cell Lung Carcinoma","Drug: Sorafenib|Drug: Vorinostat","Maximum tolerated dose (MTD)","University of Colorado, Denver|Merck Sharp & Dohme Corp.|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","36","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","07-0537.cc|NCI-2013-00413","March 2008","October 2011","March 2012","March 14, 2008",,"June 20, 2013","University of Colorado Cancer Center, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT00635791"
1811,"NCT00572078","Sorafenib and Bevacizumab in Combination With Paclitaxel in Patients With Solid Tumors",,"Completed","No Results Available","SOLID TUMORS","Drug: Sorafenib","To evaluate the safety and tolerability and describe the maximum tolerated dose (MTD) of treatment with escalating doses of sorafenib in combination with bevacizumab and paclitaxel for patients with advanced solid tumors.|To evaluate the pharmacokinetics of paclitaxel and sorafenib alone and in combination|To evaluate pharmacodynamic changes a)in tumor vascular parameters and b)in plasma VEGF and soluble VEGF receptor levels, and correlate with clinical outcomes and sorafenib pharmacokinetic (PK) profile.|To evaluate variants in genes of paclitaxel drug-metabolism and drug-transporters P glycoprotein and correlate with PK profile for paclitaxel and with clinical outcomes","Safi Shahda|Genentech, Inc.|Bayer|Indiana University","All","18 Years and older   (Adult, Older Adult)","Phase 1","27","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0706-05 IUCRO-0171","January 23, 2008","January 4, 2011","September 14, 2014","December 12, 2007",,"September 25, 2017","Indiana University Cancer Center, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT00572078"
1812,"NCT00534287","Comparison of Two Antibiotic Regimen (Meropenem Versus Meropenem+Moxifloxacin)in the Treatment of Severe Sepsis and Septic Shock","MaxSep","Completed","No Results Available","Severe Sepsis|Septic Shock","Drug: meropenem|Drug: meropenem, moxifloxacin","Mean total SOFA score|Mortality|ICU and hospital length of stay|Response to therapy|Clinical and microbiological cure|Frequency of adverse events (AEs, SAEs, SUSARs)|Ventilator free days|Days without renal replacement therapy|Vasopressor free days|SOFA-subscores|Antibiotics free days|Costs of antibiotic therapy|Frequency of resistances to antibiotics|Frequency of new infections","Kompetenznetz Sepsis|AstraZeneca|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","600","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EudraCT 2006-006984-21|bmbf grant: 01 KI 01 06","October 2007","April 2010","June 2010","September 24, 2007",,"June 29, 2012","University Hospital Aachen - Dep. of Anesthesiology, Aachen, Germany|Klinikum Augsburg - Dep. of Anesthesiology and Intensive Care Medicine, Augsburg, Germany|Charité Berlin - Dep. of Anesthesiology and Intensive Care Medicine, Berlin, Germany|Charité Berlin - Dep. of Medicine (Cardiology, Angiology, Pneumology), Berlin, Germany|Charité Campus Mitte -Dep.of Infectiology and Pneumonology, Berlin, Germany|Charité Campus Benjamin Franklin - Dep. of Medicine IV, Berlin, Germany|Vivantes Klinikum Neukölln - Cardiology, Berlin, Germany|Vivantes Klinikum Neukölln - Dep. of Anesthesiology, Intensive Care Medicine and Pain Therapy, Berlin, Germany|Charité Berlin - Campus Virchow-Klinikum - Dep. of Nephrology, Berlin, Germany|Ev. Krankenhaus Gilead I - Dep. of Anesthesiology and Intensive Care Medicine, Bielefeld, Germany|University Hospital Bonn - Dep. of Anesthesiology and Intensive Care Medicine, Bonn, Germany|Städtisches Klinikum Brandenburg - Intensive Care Unit, Brandenburg, Germany|Klinikum Darmstadt - Dep. of Anesthesiology, Intensive Care Medicine and Pain Therapy, Darmstadt, Germany|Klinikum Dessau - Dep. of Medicine, Dessau, Germany|Hospital Lippe-Detmold - Dep. of Anesthesiology and Intensive Care Medicine, Detmold, Germany|Krankenhaus Dresden-Friedrichstadt, Dresden, Germany|University Hospital Dresden - Dep. of Anesthesiology and Intensive Care Med., Dresden, Germany|HELIOS Klinikum Erfurt - Dep. of Anesthesiology and Intensive Care Medicine, Erfurt, Germany|University Erlangen-Nürnberg - Dep. of Medicine IV, Erlangen, Germany|University Hospital Freiburg - Dep. of Medicine III, Freiburg, Germany|Ernst-Moritz-Arndt-Universität Greifswald - Dep. of Anesthesiology and Intensive Care Medicine, Greifswald, Germany|Ernst-Moritz-Arndt-Universität Greifswald, Dep. of Internal Medicine B, Greifswald, Germany|Klinik am Eichert - Dep. of Anesthesiology, Intensive Care Medicine, and Pain Therapy, Göppingen, Germany|Georg August Universität Göttingen - Dep. of Anesthesiology and Intensive Care Medicine, Göttingen, Germany|Martin-Luther-Universität Halle-Wittenberg - Dep. of Anesthesiology and Intensive Care Medicine, Halle, Germany|Hospital Martha-Maria Halle-Dölau gGmbH - Dep. of Anesthesiology and Intensive Care Medicine, Halle, Germany|Universitätsklinikum Hamburg-Eppendorf - Dep. of Intensive Care Medicine, Hamburg, Germany|Klinikum Hannover Nordstadt - Dep. of Anesthesiology and Intensive Care Medicine, Hannover, Germany|Medizinische Hochschule Hannover, Dep. of Internal Medicine/ Pneumology, Hannover, Germany|University Hospital Heidelberg - Dep. of Medicine IV, Heidelberg, Germany|University Hospital Heidelberg - Dep. of Visceral and Transplantation Surgery, Heidelberg, Germany|Westküstenklinikum Heide - Dep. of Anesthesiology and Intensive Care Medicine, Heide, Germany|University Hospital Saarland - Deop. of Anesthesiology, Intensive Care Medicine, and Pain Therapy, Homburg/Saar, Germany|University Hospital Jena, Dep. of Anesthesiology and Intensive Care Medicine, Jena, Germany|University Hospital Kiel - Dep. of. Anesthesiology and Intensive Care Medicine, Kiel, Germany|University Hospital Köln - Dep. of Internal Medicine I, Köln, Germany|Hospital Merheim - Dep. of Anesthesiology and Intensive Care Medicine, Köln, Germany|University Hospital Leipzig - Dep. of Anesthesiology and Intensive Care Medicine, Leipzig, Germany|Hospital Ludwigshafen am Rhein - Dep. of Cardiac Surgery, Ludwigshafen, Germany|Klinikum Lüdenscheid - Dep. of Anesthesiology, Luedenscheid, Germany|University Hospital Mannheim - Dep. of Medicine I, Mannheim, Germany|University Hospital Munich - Dep. of Internal Medicine, Munich, Germany|Hospital Munich Harlaching - Dep. of Internal Acute Medicine and Prevention, Munich, Germany|Klinikum rechts der Isar - Dep. of Anesthesiology, Munich, Germany|University Hospital Münster - Dep. of Anesthesiology and Intensive Care Medicine, Münster, Germany|Klinikum Oldenburg - Dep. of Anesthesiology, Intensive Care Medicine, Emergency Medicine, Pain Therapy, Oldenburg, Germany|Klinikum Ernst von Bergmann - Dep. of Anesthesiology and Intensive Care Medicine, Potsdam, Germany|University Hospital Rostock - Dep. of Anesthesiology and Intensive Care Medicine, Rostock, Germany|Ev. Jung-Stilling-Krankenhaus - Dep. of Anesthesiology, Intensive Care Medicine, Emergency Medicine, Siegen, Germany|University Hospital Tübingen - Dep. of Medicine, Tübingen, Germany|University Hospital Ulm - Dep. of Internal Medicine II, Ulm, Germany|Stiftung Juliusspital Würzburg - Dep. of Medicine (Cardiology), Würzburg, Germany",,"https://ClinicalTrials.gov/show/NCT00534287"
1813,"NCT00522301","Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission",,"Terminated","Has Results","Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer","Drug: sorafenib tosylate|Other: immunoenzyme technique|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Other: pharmacological study","Progression-free Survival (PFS) Rate at 12 Months","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Bayer","Female","18 Years to 120 Years   (Adult, Older Adult)","Phase 2","6","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","07-080|P30CA008748|MSKCC-07080|BAYER-MSKCC-07-080","July 2007","March 2008","March 2008","August 29, 2007","February 29, 2016","February 29, 2016","Memorial Sloan - Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00522301"
1814,"NCT00496756","Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer",,"Terminated","Has Results","Kidney Cancer","Drug: Sorafenib","Toxicity of Intrapatient Dose Escalation of Sorafenib Tosylate|Response Rate","University of Nebraska|National Cancer Institute (NCI)|Bayer","All","18 Years to 120 Years   (Adult, Older Adult)","Phase 2","14","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","081-06|P30CA036727|UNMC-08106","March 2007","October 2009","April 2014","July 4, 2007","February 15, 2019","March 12, 2019","UNMC Eppley Cancer Center at the University of Nebraska Medical Center, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT00496756"
1815,"NCT00495755","Campath in Chronic GVHD",,"Completed","Has Results","Chronic Graft-vs.-Host Disease","Drug: Alemtuzumab (Campath)","The Maximum Tolerated Dose (MTD) of a Four-week Course of Alemtuxumab in Chronic GVHD for Patients With an Incomplete Response to Steroids|The Efficacy of a Four-week Course of Alemtuzumab in Patients With Steroid-refractory Chronic GVHD (cGVHD).|The Effect of Alemtuzumab Therapy on Parameters of Cellular and Humoral Immunity in the Late Post Transplant Period. This Information is Exploratory in Nature Only Due to the Heterogeneity of the Anticipated Patient Population.","Dana-Farber Cancer Institute|Genzyme, a Sanofi Company|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","13","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DFCI 07-057","July 2007","October 2011","October 2012","July 3, 2007","August 9, 2013","August 9, 2013","Dana-Farber Cancer Institute, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00495755"
1816,"NCT00483301","A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma",,"Completed","No Results Available","Malignant Melanoma","Drug: Sorafenib (BAY 43-9006)|Drug: ABI-007(Abraxane)","Primary Objective|Secondary Objective","Mt. Sinai Medical Center, Miami|Celgene Corporation|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","34","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MEL0205","May 2007","August 2009","August 2009","June 7, 2007",,"May 3, 2012","Dr. Steven O'Day, Los Angeles, California, United States|Mt. Sinai Medical Center, Miami Beach, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00483301"
1817,"NCT00453193","Alemtuzumab and Pentostatin In T-cell Neoplasms",,"Terminated","Has Results","Lymphoma|Leukemia","Drug: Pentostatin|Drug: Alemtuzumab","Number of Participants With Objective Response","M.D. Anderson Cancer Center|Astex Pharmaceuticals|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","26","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2004-0408","September 2004","March 2010","March 2010","March 28, 2007","March 28, 2011","August 7, 2012","U.T.M.D. Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00453193"
1818,"NCT00449618","Comparison of Awakening Versus Bedtime Dosing of Aspirin in Pre-Hypertension or Mild Essential Hypertension",,"Terminated","No Results Available","High-Normal Blood Pressure|Mild Essential Hypertension","Drug: Aspirin 100 mg|Device: Ambulatory blood pressure monitoring|Procedure: Chronotherapy, timing of medication|Drug: Placebo","To demonstrate the efficacy of bedtime administration of aspirin by testing the hypothesis of superior 24 hour systolic BP (SBP) lowering compared with either aspirin administered on awakening or with placebo at any circadian time|To demonstrate that aspirin at bedtime is more effective than aspirin upon awakening and placebo in terms of 24 hour diastolic BP (DBP) lowering|To demonstrate that aspirin at bedtime is more effective in non-dipper subjects as compared to dippers in terms of nocturnal SBP/DBP lowering, and that this effect is superior to any potential effect on BP of aspirin upon awakening or placebo|To demonstrate that aspirin at bedtime offers a similar safety profile to aspirin upon awakening and to placebo|To demonstrate that compliance with aspirin at bedtime is similar to compliance with either aspirin upon awakening or placebo","University of Vigo|Hospital Clinico Universitario de Santiago|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 4","23","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ASA100-2004/2|2004-004987-65|2006-004652-21","January 2007","December 2008","December 2008","March 20, 2007",,"January 5, 2009","Centro de Salud de A Guarda, La Guardia, Pontevedra, Spain|Centro de Salud de Sardoma, Vigo, Pontevedra, Spain|Centro de Salud de A Doblada, Vigo, Pontevedra, Spain|C.S. Lérez, Pontevedra, Spain|Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain",,"https://ClinicalTrials.gov/show/NCT00449618"
1819,"NCT00411671","BATTLE Program: Sorafenib in Patients With NSCLC",,"Completed","Has Results","Lung Cancer","Drug: Sorafenib","8-Week Disease Control Rate|Progression-Free Survival|Tumor Response Measured Every 8-weeks","M.D. Anderson Cancer Center|United States Department of Defense|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","105","Other|U.S. Fed|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2005-0827","November 2006","November 2012","November 2012","December 14, 2006","February 11, 2016","February 11, 2016","UT MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00411671"
1820,"NCT00411086","Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma",,"Completed","Has Results","Lymphoma","Biological: Rituximab|Biological: Sargramostim (GM-CSF)","Complete Response Rate|Median Progression-Free Survival (PFS)|Overall Response (OR) Rate","M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MDA-2006-0260|P30CA016672|CDR0000521620|NCI-2009-00187","November 2006","November 2016","November 2016","December 13, 2006","December 5, 2017","December 5, 2017","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00411086"
1821,"NCT00392821","Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer",,"Completed","Has Results","Kidney Cancer","Drug: Sorafenib|Drug: RAD001","Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment|Progression-Free Survival.","SCRI Development Innovations, LLC|Novartis|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","78","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCRI GU 44|CRAD001C2480","December 2006","October 2013","October 2013","October 26, 2006","March 26, 2014","March 26, 2014","Florida Hospital Cancer Institute, Orlando, Florida, United States|Northeast Georgia Medical Center, Gainesville, Georgia, United States|Wellstar Cancer Research, Marietta, Georgia, United States|Baptist Hospital East, Louisville, Kentucky, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Research Medical Center, Kansas City, Missouri, United States|Hematology Oncology Associates of Northern NJ, Morristown, New Jersey, United States|Oncology Hematology Care, Cincinnati, Ohio, United States|South Carolina Oncology Associates, PA, Columbia, South Carolina, United States|Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00392821"
1822,"NCT00369967","Quick Start Initiation of the Contraceptive Vaginal Ring in Adolescents",,"Terminated","Has Results","Contraception Desired","Drug: NuvaRing","Continuation With the Contraceptive Method|Method Continuation at 6 Months|Method Continuation at 12 Months|Pregnancy|Bleeding Profile|Patient Satisfaction","Virginia Commonwealth University|American College of Obstetricians and Gynecologists|Bayer","Female","15 Years to 21 Years   (Child, Adult)","Not Applicable","48","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","5120008FN","February 2007","July 2009","July 2010","August 30, 2006","July 22, 2016","July 22, 2016","Virginia Commonwealth University Medical Center, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00369967"
1823,"NCT00260468","Brain Abnormalities in Late-Onset Major Depression",,"Completed","No Results Available","Major Depression","Other: Clinical examination program",,"University of Aarhus|The Danish Medical Research Council|Bayer","All","50 Years and older   (Adult, Older Adult)",,"44","Other|Industry","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","20051050","November 2005",,"December 2008","December 1, 2005",,"October 22, 2009","Centre for Psychiatric Research, Aarhus University Hospital, Risskov, Denmark",,"https://ClinicalTrials.gov/show/NCT00260468"
1824,"NCT00259168","Insulin Resistance and Vessel Function After Meals: Does Early Intervention Make a Difference?",,"Completed","No Results Available","Insulin Resistance|Impaired Fasting Glucose","Drug: Nateglinide","Endothelial function|Metabolic function","Atheline Major-Pedersen|Novartis|Bayer|Bispebjerg Hospital","All","25 Years to 75 Years   (Adult, Older Adult)","Phase 4","70","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","02-005/03","June 2003","March 2006","March 2006","November 29, 2005",,"December 3, 2018","Endothelial laboratory, Cardiology clinic Y-research, H:S Bispebjerg Hospital, Bispebjerg Bakke, Copenhagen, Copenhagen NV, Denmark",,"https://ClinicalTrials.gov/show/NCT00259168"
1825,"NCT00225849","Japanese Primary Prevention Project With Aspirin",,"Unknown status","No Results Available","Hypertension|Hyperlipidemia|Diabetes Mellitus","Drug: Aspirin","Composite event of cerebro/cardiovascular (CV) death, nonfatal cerebral stroke (of any cause) and nonfatal myocardial infarction (MI)|CV death|Non CV death|Nonfatal cerebral stroke|Nonfatal MI|Angina pectoris|Transient ischemic attack|Arteriosclerotic disease requiring surgery or intervention|Extracranial bleeding requiring transfusion or admission|Severe side-effects that lead to interruption of the study medication.","Ministry of Health, Labour and Welfare, Japan|Japan Heart Foundation|Bayer","All","60 Years to 85 Years   (Adult, Older Adult)","Phase 4","10000","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","JPPP-05-07|MHLW2004-CV(Adult disease)-010","March 2005",,"September 2010","September 26, 2005",,"September 26, 2005","Keio University School of Medicine, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT00225849"
1826,"NCT00190060","Study of The Effects of Testosterone in Frail Elderly Men",,"Completed","No Results Available","Frailty|Sarcopenia","Drug: Transdermal testosterone gel (Testogel 1% )|Drug: Matched transdermal placebo gel","Lower limb muscle strength at 6 months|Upper limb muscle strength at 6 months|Quality of life at 6 months|Total and regional lean body mass at 6 months|Improvement in physical performance|Bone Mineral Density","Manchester University NHS Foundation Trust|University of Manchester|Bayer","Male","65 Years and older   (Older Adult)","Phase 4","262","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CMMCHUT PIN 9197|T0053/WTCRF","October 2004","December 31, 2008","December 31, 2008","September 19, 2005",,"August 3, 2018","Wellcome Trust Clinical Research Facility, Manchester Royal Infirmary, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00190060"
1827,"NCT00177970","IVIG Versus Placebo for the Treatment of Patients With Severe C-Diff",,"Terminated","Has Results","Clostridium Difficile-associated Diarrhea (CDAD)","Drug: intravenous immunoglobulin G (IVIG)|Drug: Placebo","1) Normalization of WBC's|2) Decrease of Number of Loose Stools to <3 Per Day Following Treatment|1) 75% Reduction in Abdominal Pain/Tenderness|2) Quantity of Anti-C. Difficile Antibodies in Relationship With Recovery of C. Difficile Diarrhea|3) Correlation Between Antibody Responses as Measured With ELISA (Enzyme Immunoassay) and Recovery of C. Difficile Diarrhea|4) Normalization of Neutrophil Count on CBC With Diff.|5) Normalization of Body Temperature During a 24 Hour Period|6) Patients' Length of Hospital Stay","University of Pittsburgh|Shadyside Hospital Foundation|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 4","14","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","0311034","October 2003","April 2008","April 2008","September 15, 2005","July 15, 2016","October 25, 2016","UPMC McKeesport Hospital and SemperCare Hospital of McKeesport, Inc, Pittsburgh, Pennsylvania, United States|UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States|UPMC St. Margaret Hospital, Pittsburgh, Pennsylvania, United States|UPMC Shadyside Hospital, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00177970"
1828,"NCT00157573","GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer",,"Completed","Has Results","Ovarian Cancer|Fallopian Tube Cancer","Drug: GM-CSF, sargramostim","Median Time to Treatment Termination (TTT)|Median Time to Progression (TTP)|Tumor Response Rate (RR)|Number of Participants With Adverse Events (Toxicity) Grade 3 or 4","Massachusetts General Hospital|Dana-Farber Cancer Institute|Bayer","Female","18 Years and older   (Adult, Older Adult)","Phase 2","72","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","04-305","December 2004","October 2008","April 2010","September 12, 2005","May 8, 2017","May 8, 2017",,,"https://ClinicalTrials.gov/show/NCT00157573"
1829,"NCT00153062","PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes",,"Completed","Has Results","Stroke","Drug: Aggrenox|Drug: Clopidogrel placebo|Drug: Micardis|Drug: Aggrenox placebo|Drug: Clopidogrel|Drug: Micardis placebo","Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Antiplatelet Comparison Only)|Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Telmisartan vs. Placebo Only)|Composite Outcome of Stroke, Myocardial Infarction (MI), or Vascular Death (Antiplatelet Comparison Only)|Composite Outcome of Stroke, Myocardial Infarction, Vascular Death, or New or Worsening Congestive Heart Failure (CHF) (Telmisartan vs. Placebo Only)|Number of Patients With New Onset of Diabetes (Telmisartan vs. Placebo Only)","Boehringer Ingelheim|GlaxoSmithKline|Bayer","All","50 Years and older   (Adult, Older Adult)","Phase 4","20332","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention","9.159","August 2003","April 2008",,"September 12, 2005","September 2, 2009","May 13, 2014","9.159.1101 Boehringer Ingelheim Investigational Site, Birmingham, Alabama, United States|9.159.1173 Boehringer Ingelheim Investigational Site, Huntsville, Alabama, United States|9.159.1058 Boehringer Ingelheim Investigational Site, Mobile, Alabama, United States|9.159.1087 Boehringer Ingelheim Investigational Site, Montgomery, Alabama, United States|9.159.1081 Boehringer Ingelheim Investigational Site, Northport, Alabama, United States|9.159.1022 Boehringer Ingelheim Investigational Site, Phoenix, Arizona, United States|9.159.1133 Boehringer Ingelheim Investigational Site, Phoenix, Arizona, United States|9.159.1149 Boehringer Ingelheim Investigational Site, Phoenix, Arizona, United States|9.159.1137 Boehringer Ingelheim Investigational Site, Tucson, Arizona, United States|9.159.1184 Boehringer Ingelheim Investigational Site, Fayetteville, Arkansas, United States|9.159.1005 Boehringer Ingelheim Investigational Site, Fort Smith, Arkansas, United States|9.159.1136 Boehringer Ingelheim Investigational Site, Jonesboro, Arkansas, United States|9.159.1062 Boehringer Ingelheim Investigational Site, Little Rock, Arkansas, United States|9.159.1040 Boehringer Ingelheim Investigational Site, Berkeley, California, United States|9.159.1180 Boehringer Ingelheim Investigational Site, Carmichael, California, United States|9.159.1114 Boehringer Ingelheim Investigational Site, Irvine, California, United States|9.159.1202 Boehringer Ingelheim Investigational Site, Laguna Hills, California, United States|9.159.1036 Boehringer Ingelheim Investigational Site, Los Angeles, California, United States|9.159.1052 Boehringer Ingelheim Investigational Site, Los Angeles, California, United States|9.159.1100 Boehringer Ingelheim Investigational Site, Los Angeles, California, United States|9.159.1111 Boehringer Ingelheim Investigational Site, Los Angeles, California, United States|9.159.1165 Boehringer Ingelheim Investigational Site, Los Angeles, California, United States|9.159.1134 Boehringer Ingelheim Investigational Site, Oceanside, California, United States|9.159.1002 Boehringer Ingelheim Investigational Site, Palo Alto, California, United States|9.159.1108 Boehringer Ingelheim Investigational Site, Redding, California, United States|9.159.1013 Boehringer Ingelheim Investigational Site, Sacramento, California, United States|9.159.1198 Boehringer Ingelheim Investigational Site, Sacramento, California, United States|9.159.1029 Boehringer Ingelheim Investigational Site, San Diego, California, United States|9.159.1185 Boehringer Ingelheim Investigational Site, San Francisco, California, United States|9.159.1218 Boehringer Ingelheim Investigational Site, San Jose, California, United States|9.159.1179 Boehringer Ingelheim Investigational Site, Santa Rosa, California, United States|9.159.1162 Boehringer Ingelheim Investigational Site, Sylmar, California, United States|9.159.1183 Boehringer Ingelheim Investigational Site, Torrance, California, United States|9.159.1205 Boehringer Ingelheim Investigational Site, Walnut Creek, California, United States|9.159.1118 Boehringer Ingelheim Investigational Site, Denver, Colorado, United States|9.159.1045 Boehringer Ingelheim Investigational Site, Englewood, Colorado, United States|9.159.1038 Boehringer Ingelheim Investigational Site, Danbury, Connecticut, United States|9.159.1196 Boehringer Ingelheim Investigational Site, Fairfield, Connecticut, United States|9.159.1018 Boehringer Ingelheim Investigational Site, Hartford, Connecticut, United States|9.159.1080 Boehringer Ingelheim Investigational Site, Newark, Delaware, United States|9.159.1120 Boehringer Ingelheim Investigational Site, Washington, District of Columbia, United States|9.159.1216 Boehringer Ingelheim Investigational Site, Washington, District of Columbia, United States|9.159.1057 Boehringer Ingelheim Investigational Site, Bay Pines, Florida, United States|9.159.1217 Boehringer Ingelheim Investigational Site, Boca Raton, Florida, United States|9.159.1096 Boehringer Ingelheim Investigational Site, Bradenton, Florida, United States|9.159.1144 Boehringer Ingelheim Investigational Site, Clearwater, Florida, United States|9.159.1007 Boehringer Ingelheim Investigational Site, Ft. Lauderdale, Florida, United States|9.159.1190 Boehringer Ingelheim Investigational Site, Jacksonville, Florida, United States|9.159.1150 Boehringer Ingelheim Investigational Site, Ocala, Florida, United States|9.159.1153 Boehringer Ingelheim Investigational Site, Panama City, Florida, United States|9.159.1041 Boehringer Ingelheim Investigational Site, Plantation, Florida, United States|9.159.1072 Boehringer Ingelheim Investigational Site, Port Charlotte, Florida, United States|9.159.1063 Boehringer Ingelheim Investigational Site, Sarasota, Florida, United States|9.159.1208 Boehringer Ingelheim Investigational Site, Tampa, Florida, United States|9.159.1049 Boehringer Ingelheim Investigational Site, Vero Beach, Florida, United States|9.159.1176 Boehringer Ingelheim Investigational Site, West Palm Beach, Florida, United States|9.159.1071 Boehringer Ingelheim Investigational Site, Atlanta, Georgia, United States|9.159.1079 Boehringer Ingelheim Investigational Site, Augusta, Georgia, United States|9.159.1181 Boehringer Ingelheim Investigational Site, Columbus, Georgia, United States|9.159.1138 Boehringer Ingelheim Investigational Site, Decatur, Georgia, United States|9.159.1070 Boehringer Ingelheim Investigational Site, Rome, Georgia, United States|9.159.1107 Boehringer Ingelheim Investigational Site, Savannah, Georgia, United States|9.159.1189 Boehringer Ingelheim Investigational Site, Boise, Idaho, United States|9.159.1026 University of Illinois, Chicago, Illinois, United States|9.159.1033 Boehringer Ingelheim Investigational Site, Chicago, Illinois, United States|9.159.1060 Boehringer Ingelheim Investigational Site, Chicago, Illinois, United States|9.159.1044 Boehringer Ingelheim Investigational Site, Maywood, Illinois, United States|9.159.1054 Boehringer Ingelheim Investigational Site, Palos Heights, Illinois, United States|9.159.1068 Boehringer Ingelheim Investigational Site, Park Ridge, Illinois, United States|9.159.1178 Boehringer Ingelheim Investigational Site, Peoria, Illinois, United States|9.159.1156 Boehringer Ingelheim Investigational Site, Elkhart, Indiana, United States|9.159.1092 Boehringer Ingelheim Investigational Site, South Bend, Indiana, United States|9.159.1027 Boehringer Ingelheim Investigational Site, Cedar Rapids, Iowa, United States|9.159.1119 Boehringer Ingelheim Investigational Site, Des Moines, Iowa, United States|9.159.1187 Boehringer Ingelheim Investigational Site, Des Moines, Iowa, United States|9.159.1059 Boehringer Ingelheim Investigational Site, Iowa City, Iowa, United States|9.159.1135 Boehringer Ingelheim Investigational Site, Waterloo, Iowa, United States|9.159.1090 Boehringer Ingelheim Investigational Site, Kansas City, Kansas, United States|9.159.1129 Central Baptis Hospital, Lexington, Kentucky, United States|9.159.1131 Boehringer Ingelheim Investigational Site, Lexington, Kentucky, United States|9.159.1206 Boehringer Ingelheim Investigational Site, Lexington, Kentucky, United States|9.159.1212 Boehringer Ingelheim Investigational Site, Lexington, Kentucky, United States|9.159.1091 Boehringer Ingelheim Investigational Site, Louisville, Kentucky, United States|9.159.1147 Boehringer Ingelheim Investigational Site, Louisville, Kentucky, United States|9.159.1106 Boehringer Ingelheim Investigational Site, Baton Rouge, Louisiana, United States|9.159.1194 Boehringer Ingelheim Investigational Site, Marrero, Louisiana, United States|9.159.1083 Boehringer Ingelheim Investigational Site, New Orleans, Louisiana, United States|9.159.1195 Boehringer Ingelheim Investigational Site, Shreveport, Louisiana, United States|9.159.1024 Boehringer Ingelheim Investigational Site, Baltimore, Maryland, United States|9.159.1055 Boehringer Ingelheim Investigational Site, Baltimore, Maryland, United States|9.159.1139 Boehringer Ingelheim Investigational Site, Baltimore, Maryland, United States|9.159.1031 Boehringer Ingelheim Investigational Site, Boston, Massachusetts, United States|9.159.1066 Boehringer Ingelheim Investigational Site, Boston, Massachusetts, United States|9.159.1104 Boehringer Ingelheim Investigational Site, Boston, Massachusetts, United States|9.159.1166 Boehringer Ingelheim Investigational Site, Boston, Massachusetts, United States|9.159.1192 Boehringer Ingelheim Investigational Site, South Weymouth, Massachusetts, United States|9.159.1039 Boehringer Ingelheim Investigational Site, Worchester, Massachusetts, United States|9.159.1019 Boehringer Ingelheim Investigational Site, Detroit, Michigan, United States|9.159.1048 Boehringer Ingelheim Investigational Site, Detroit, Michigan, United States|9.159.1089 Boehringer Ingelheim Investigational Site, Detroit, Michigan, United States|9.159.1078 Boehringer Ingelheim Investigational Site, East Lansing, Michigan, United States|9.159.1143 Boehringer Ingelheim Investigational Site, Grand Rapids, Michigan, United States|9.159.1102 Boehringer Ingelheim Investigational Site, Kalamazoo, Michigan, United States|9.159.1011 Boehringer Ingelheim Investigational Site, Saginaw, Michigan, United States|9.159.1132 Boehringer Ingelheim Investigational Site, Southfield, Michigan, United States|9.159.1088 Boehringer Ingelheim Investigational Site, Duluth, Minnesota, United States|9.159.1158 Boehringer Ingelheim Investigational Site, Duluth, Minnesota, United States|9.159.1084 Boehringer Ingelheim Investigational Site, Golden Valley, Minnesota, United States|9.159.1097 Boehringer Ingelheim Investigational Site, Minneapolis, Minnesota, United States|9.159.1113 Boehringer Ingelheim Investigational Site, Minneapolis, Minnesota, United States|9.159.1128 St. Luke's Hospital MABSI Research, Kansas City, Missouri, United States|9.159.1172 Boehringer Ingelheim Investigational Site, Lees Summit, Missouri, United States|9.159.1174 Boehringer Ingelheim Investigational Site, Saint Louis, Missouri, United States|9.159.1009 Boehringer Ingelheim Investigational Site, Springfield, Missouri, United States|9.159.1182 Boehringer Ingelheim Investigational Site, St. Louis, Missouri, United States|9.159.1191 Boehringer Ingelheim Investigational Site, St. Louis, Missouri, United States|9.159.1146 Boehringer Ingelheim Investigational Site, Great Falls, Montana, United States|9.159.1201 Boehringer Ingelheim Investigational Site, Omaha, Nebraska, United States|9.159.1127 Boehringer Ingelheim Investigational Site, Las Vegas, Nevada, United States|9.159.1188 Boehringer Ingelheim Investigational Site, Reno, Nevada, United States|9.159.1204 Boehringer Ingelheim Investigational Site, Camden, New Jersey, United States|9.159.1203 Boehringer Ingelheim Investigational Site, Edison, New Jersey, United States|9.159.1042 Neurology Consultants of Burlington County, Lumberton, New Jersey, United States|9.159.1209 Boehringer Ingelheim Investigational Site, New Brunswick, New Jersey, United States|9.159.1125 Boehringer Ingelheim Investigational Site, Newark, New Jersey, United States|9.159.1095 Boehringer Ingelheim Investigational Site, Ridgewood, New Jersey, United States|9.159.1170 Boehringer Ingelheim Investigational Site, Albuquerque, New Mexico, United States|9.159.1086 Boehringer Ingelheim Investigational Site, Albany, New York, United States|9.159.1121 Boehringer Ingelheim Investigational Site, Bronx, New York, United States|9.159.1130 Boehringer Ingelheim Investigational Site, Bronx, New York, United States|9.159.1017 Boehringer Ingelheim Investigational Site, Brooklyn, New York, United States|9.159.1064 Boehringer Ingelheim Investigational Site, Brooklyn, New York, United States|9.159.1186 Boehringer Ingelheim Investigational Site, Brooklyn, New York, United States|9.159.1151 Boehringer Ingelheim Investigational Site, Buffalo, New York, United States|9.159.1076 North Shore University Hospital, Manasset, New York, United States|9.159.1037 Boehringer Ingelheim Investigational Site, Mineola, New York, United States|9.159.1220 Boehringer Ingelheim Investigational Site, New Hyde Park, New York, United States|9.159.1001 Boehringer Ingelheim Investigational Site, New York, New York, United States|9.159.1116 Boehringer Ingelheim Investigational Site, New York, New York, United States|9.159.1142 Saint Luke's-Roosevelt Hospital, New York, New York, United States|9.159.1126 Boehringer Ingelheim Investigational Site, Schenectady, New York, United States|9.159.1163 Boehringer Ingelheim Investigational Site, Stony Brook, New York, United States|9.159.1169 Boehringer Ingelheim Investigational Site, Tonawanda, New York, United States|9.159.1065 Boehringer Ingelheim Investigational Site, White Plains, New York, United States|9.159.1099 Boehringer Ingelheim Investigational Site, Asheville, North Carolina, United States|9.159.1046 Boehringer Ingelheim Investigational Site, Chapel Hill, North Carolina, United States|9.159.1094 Boehringer Ingelheim Investigational Site, Durham, North Carolina, United States|9.159.1012 Boehringer Ingelheim Investigational Site, High Point, North Carolina, United States|9.159.1115, Wilmington, North Carolina, United States|9.159.1051 Boehringer Ingelheim Investigational Site, Winston-Salem, North Carolina, United States|9.159.1110 Boehringer Ingelheim Investigational Site, Winston-Salem, North Carolina, United States|9.159.1215 Boehringer Ingelheim Investigational Site, Bismarck, North Dakota, United States|9.159.1152 Boehringer Ingelheim Investigational Site, Fargo, North Dakota, United States|9.159.1159 Boehringer Ingelheim Investigational Site, Akron, Ohio, United States|9.159.1085 Boehringer Ingelheim Investigational Site, Canton, Ohio, United States|9.159.1032 Boehringer Ingelheim Investigational Site, Cincinnati, Ohio, United States|9.159.1025 Boehringer Ingelheim Investigational Site, Cleveland, Ohio, United States|9.159.1177 Boehringer Ingelheim Investigational Site, Cleveland, Ohio, United States|9.159.1008 Boehringer Ingelheim Investigational Site, Columbus, Ohio, United States|9.159.1141 Boehringer Ingelheim Investigational Site, Columbus, Ohio, United States|9.159.1053 Boehringer Ingelheim Investigational Site, Toledo, Ohio, United States|9.159.1122 Boehringer Ingelheim Investigational Site, Youngstown, Ohio, United States|9.159.1199 Boehringer Ingelheim Investigational Site, Oklahoma City, Oklahoma, United States|9.159.1010 Boehringer Ingelheim Investigational Site, Portland, Oregon, United States|9.159.1171 Boehringer Ingelheim Investigational Site, Abington, Pennsylvania, United States|9.159.1210 Boehringer Ingelheim Investigational Site, Allentown, Pennsylvania, United States|9.159.1214 Boehringer Ingelheim Investigational Site, Allentown, Pennsylvania, United States|9.159.1200 Boehringer Ingelheim Investigational Site, Erie, Pennsylvania, United States|9.159.1043 Boehringer Ingelheim Investigational Site, Greensburg, Pennsylvania, United States|9.159.1164 Boehringer Ingelheim Investigational Site, Hershey, Pennsylvania, United States|9.159.1175 Boehringer Ingelheim Investigational Site, Lancaster, Pennsylvania, United States|9.159.1016 Boehringer Ingelheim Investigational Site, Philadelphia, Pennsylvania, United States|9.159.1056 Boehringer Ingelheim Investigational Site, Philadelphia, Pennsylvania, United States|9.159.1074 Boehringer Ingelheim Investigational Site, Philadelphia, Pennsylvania, United States|9.159.1112 Boehringer Ingelheim Investigational Site, Pittsburgh, Pennsylvania, United States|9.159.1148 Boehringer Ingelheim Investigational Site, Upland, Pennsylvania, United States|9.159.1123 Boehringer Ingelheim Investigational Site, Providence, Rhode Island, United States|9.159.1140 Boehringer Ingelheim Investigational Site, Columbia, South Carolina, United States|9.159.1207 Boehringer Ingelheim Investigational Site, Greenville, South Carolina, United States|9.159.1004 Boehringer Ingelheim Investigational Site, Spartanberg, South Carolina, United States|9.159.1006 Boehringer Ingelheim Investigational Site, Bristol, Tennessee, United States|9.159.1154 Boehringer Ingelheim Investigational Site, Knoxville, Tennessee, United States|9.159.1213 Boehringer Ingelheim Investigational Site, Memphis, Tennessee, United States|9.159.1075 Boehringer Ingelheim Investigational Site, Nashville, Tennessee, United States|9.159.1219 Boehringer Ingelheim Investigational Site, Brownwood, Texas, United States|9.159.1155 Boehringer Ingelheim Investigational Site, Dallas, Texas, United States|9.159.1197 Boehringer Ingelheim Investigational Site, Dallas, Texas, United States|9.159.1020 Boehringer Ingelheim Investigational Site, Houston, Texas, United States|9.159.1023 Boehringer Ingelheim Investigational Site, Houston, Texas, United States|9.159.1082 Boehringer Ingelheim Investigational Site, Houston, Texas, United States|9.159.1160 Boehringer Ingelheim Investigational Site, Houston, Texas, United States|9.159.1047 Boehringer Ingelheim Investigational Site, San Antonio, Texas, United States|9.159.1069 Boehringer Ingelheim Investigational Site, Tyler, Texas, United States|9.159.1003 Boehringer Ingelheim Investigational Site, Bountiful, Utah, United States|9.159.1077 Boehringer Ingelheim Investigational Site, Newport News, Virginia, United States|9.159.1021 Boehringer Ingelheim Investigational Site, Richmond, Virginia, United States|9.159.1061 Boehringer Ingelheim Investigational Site, Salem, Virginia, United States|9.159.1014 Boehringer Ingelheim Investigational Site, Seattle, Washington, United States|9.159.1145 Boehringer Ingelheim Investigational Site, Spokane, Washington, United States|9.159.1211 Boehringer Ingelheim Investigational Site, Charleston, West Virginia, United States|9.159.1035 Boehringer Ingelheim Investigational Site, Morgantown, West Virginia, United States|9.159.1030 Boehringer Ingelheim Investigational Site, Marshfield, Wisconsin, United States|9.159.1117 Boehringer Ingelheim Investigational Site, Milwaukee, Wisconsin, United States|9.159.1098 Community Healthcare Clinic Westhill Medical Specialists, Wausau, Wisconsin, United States|9.159.1331 Boehringer Ingelheim Investigational Site, Capital Federal, Argentina|9.159.1333 Boehringer Ingelheim Investigational Site, Capital Federal, Argentina|9.159.1334 Boehringer Ingelheim Investigational Site, Capital Federal, Argentina|9.159.1335 Boehringer Ingelheim Investigational Site, Capital Federal, Argentina|9.159.1336 Boehringer Ingelheim Investigational Site, Capital Federal, Argentina|9.159.1332 Boehringer Ingelheim Investigational Site, Rosario, Sta. Fe, Argentina|9.159.1342 Boehringer Ingelheim Investigational Site, Santa Fe, Argentina|9.159.2444 Boehringer Ingelheim Investigational Site, Gosford, New South Wales, Australia|9.159.2449 Boehringer Ingelheim Investigational Site, New Lambton, New South Wales, Australia|9.159.2448 Boehringer Ingelheim Investigational Site, Westmead, New South Wales, Australia|9.159.2450 Boehringer Ingelheim Investigational Site, Herston, Queensland, Australia|9.159.2452 Boehringer Ingelheim Investigational Site, Southport, Queensland, Australia|9.159.2451 Boehringer Ingelheim Investigational Site, Bedford Park, South Australia, Australia|9.159.2443 Boehringer Ingelheim Investigational Site, Box Hill, Victoria, Australia|9.159.2447 Boehringer Ingelheim Investigational Site, Melbourne, Victoria, Australia|9.159.2445 Boehringer Ingelheim Investigational Site, Parkville, Victoria, Australia|9.159.2446 Boehringer Ingelheim Investigational Site, West Heidelberg, Victoria, Australia|9.159.1515 Boehringer Ingelheim Investigational Site, Graz, Austria|9.159.1519 Boehringer Ingelheim Investigational Site, Graz, Austria|9.159.1517 Boehringer Ingelheim Investigational Site, Innsbruck, Austria|9.159.1516 Boehringer Ingelheim Investigational Site, Linz, Austria|9.159.1518 Boehringer Ingelheim Investigational Site, Ma.Gugging/Klosterneuburg, Austria|9.159.1520 Boehringer Ingelheim Investigational Site, St. Pölten, Austria|9.159.1521 Boehringer Ingelheim Investigational Site, Wien, Austria|9.159.1553 Boehringer Ingelheim Investigational Site, Aalst, Belgium|9.159.1543 Boehringer Ingelheim Investigational Site, Anderlecht, Belgium|9.159.1552 Boehringer Ingelheim Investigational Site, Antwerpen, Belgium|9.159.1546 Boehringer Ingelheim Investigational Site, Bonheiden, Belgium|9.159.1547 Boehringer Ingelheim Investigational Site, Brugge, Belgium|9.159.1550 Boehringer Ingelheim Investigational Site, Bruxelles, Belgium|9.159.1549 Boehringer Ingelheim Investigational Site, Hasselt, Belgium|9.159.1555 Boehringer Ingelheim Investigational Site, Kortrijk, Belgium|9.159.1554 Boehringer Ingelheim Investigational Site, La Louvière, Belgium|9.159.1544 Boehringer Ingelheim Investigational Site, Leuven, Belgium|9.159.1548 Boehringer Ingelheim Investigational Site, Montegnée, Belgium|9.159.1556 Boehringer Ingelheim Investigational Site, Ottignies, Belgium|9.159.1545 Boehringer Ingelheim Investigational Site, Wilrijk, Belgium|9.159.1551 Boehringer Ingelheim Investigational Site, Yvoir, Belgium|9.159.2869 Complexo Hospitalar Universitario Prof Edgard Santos, Salvador, Brazil|9.159.2853 Boehringer Ingelheim Investigational Site, São Paulo, Brazil|9.159.1397 Foothills Medical Centre, Calgary, Alberta, Canada|9.159.1382 Boehringer Ingelheim Investigational Site, Edmonton, Alberta, Canada|9.159.1390 Boehringer Ingelheim Investigational Site, Lethbridge, Alberta, Canada|9.159.1370 Boehringer Ingelheim Investigational Site, Kamloops, British Columbia, Canada|9.159.1368 Boehringer Ingelheim Investigational Site, New Westminster, British Columbia, Canada|9.159.1376 Boehringer Ingelheim Investigational Site, Penticton, British Columbia, Canada|9.159.1387 Boehringer Ingelheim Investigational Site, Vancouver, British Columbia, Canada|9.159.1377 Boehringer Ingelheim Investigational Site, Victoria, British Columbia, Canada|9.159.1355 Boehringer Ingelheim Investigational Site, Winnipeg, Manitoba, Canada|9.159.1394 Boehringer Ingelheim Investigational Site, Winnipeg, Manitoba, Canada|9.159.1356 Boehringer Ingelheim Investigational Site, Saint John, New Brunswick, Canada|9.159.1392 Boehringer Ingelheim Investigational Site, Corner Brook, Newfoundland and Labrador, Canada|9.159.1385 Boehringer Ingelheim Investigational Site, St. John's, Newfoundland and Labrador, Canada|9.159.1373 Boehringer Ingelheim Investigational Site, Sydney, Nova Scotia, Canada|9.159.1393 Boehringer Ingelheim Investigational Site, Barrie, Ontario, Canada|9.159.1395 Boehringer Ingelheim Investigational Site, Hamilton, Ontario, Canada|9.159.1360 Boehringer Ingelheim Investigational Site, Kingston, Ontario, Canada|9.159.1367 Boehringer Ingelheim Investigational Site, London, Ontario, Canada|9.159.1384 Boehringer Ingelheim Investigational Site, London, Ontario, Canada|9.159.1380 Boehringer Ingelheim Investigational Site, Mississauga, Ontario, Canada|9.159.1378 Boehringer Ingelheim Investigational Site, Ottawa, Ontario, Canada|9.159.1381 Ottawa Hospital General Campus, Ottawa, Ontario, Canada|9.159.1366 Boehringer Ingelheim Investigational Site, Richmond Hill, Ontario, Canada|9.159.1365 Boehringer Ingelheim Investigational Site, Scarborough, Ontario, Canada|9.159.1375 Boehringer Ingelheim Investigational Site, Scarborough, Ontario, Canada|9.159.1391 Boehringer Ingelheim Investigational Site, Tecumseh, Ontario, Canada|9.159.1369 Boehringer Ingelheim Investigational Site, Thunder Bay, Ontario, Canada|9.159.1357 Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada|9.159.1379 Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada|9.159.1383 Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada|9.159.1363 Boehringer Ingelheim Investigational Site, Windsor, Ontario, Canada|9.159.1359 Boehringer Ingelheim Investigational Site, Greenfield Park, Quebec, Canada|9.159.1361 Boehringer Ingelheim Investigational Site, Montreal, Quebec, Canada|9.159.1362 Boehringer Ingelheim Investigational Site, Montreal, Quebec, Canada|9.159.1371 Boehringer Ingelheim Investigational Site, Montreal, Quebec, Canada|9.159.1374 Boehringer Ingelheim Investigational Site, Montreal, Quebec, Canada|9.159.1388 Boehringer Ingelheim Investigational Site, Montreal, Quebec, Canada|9.159.1372 Boehringer Ingelheim Investigational Site, Quebec City, Quebec, Canada|9.159.1358 Boehringer Ingelheim Investigational Site, Saguenay, Quebec, Canada|9.159.1364 Boehringer Ingelheim Investigational Site, St. Jerome, Quebec, Canada|9.159.1389 Boehringer Ingelheim Investigational Site, Regina, Saskatchewan, Canada|9.159.1396 Boehringer Ingelheim Investigational Site, Saskatoon, Saskatchewan, Canada|9.159.2490 Boehringer Ingelheim Investigational Site, Beijing, China|9.159.2491 Boehringer Ingelheim Investigational Site, Beijing, China|9.159.2492 Boehringer Ingelheim Investigational Site, Beijing, China|9.159.2493 Boehringer Ingelheim Investigational Site, Beijing, China|9.159.2494 Boehringer Ingelheim Investigational Site, Beijing, China|9.159.2495 Boehringer Ingelheim Investigational Site, Beijing, China|9.159.2496 Boehringer Ingelheim Investigational Site, Beijing, China|9.159.2503 Boehringer Ingelheim Investigational Site, Changchun, Jilin Province, China|9.159.2500 Boehringer Ingelheim Investigational Site, Changsha, Hunan Province, China|9.159.2513 Boehringer Ingelheim Investigational Site, Chengdu, Sichuan Province, China|9.159.2512 Boehringer Ingelheim Investigational Site, Chongqing, China|9.159.2507 Boehringer Ingelheim Investigational Site, Guangzhou, Guangdong Province, China|9.159.2510 Boehringer Ingelheim Investigational Site, Guangzhou, Guangdong Province, China|9.159.2509 Boehringer Ingelheim Investigational Site, Guangzhou, China|9.159.2518 Boehringer Ingelheim Investigational Site, Guangzhou, China|9.159.2521 Boehringer Ingelheim Investigational Site, Guangzhou, China|9.159.2502 Boehringer Ingelheim Investigational Site, Hangzhou, Zhejiang Province, China|9.159.2504 Boehringer Ingelheim Investigational Site, Harbin, Heilongjiang Province, China|9.159.2505 Boehringer Ingelheim Investigational Site, Jinan, Shandong Province, China|9.159.2506 Boehringer Ingelheim Investigational Site, Jinan, Shangdong Province, China|9.159.2517 Boehringer Ingelheim Investigational Site, Nanjing, Jiangsu Province, China|9.159.2519 Boehringer Ingelheim Investigational Site, Nanjing, Jiangsu Province, China|9.159.2520 Boehringer Ingelheim Investigational Site, Nanjing, Jiangsu Province, China|9.159.2483 Boehringer Ingelheim Investigational Site, Shanghai, China|9.159.2484 Boehringer Ingelheim Investigational Site, Shanghai, China|9.159.2485 Boehringer Ingelheim Investigational Site, Shanghai, China|9.159.2486 Boehringer Ingelheim Investigational Site, Shanghai, China|9.159.2487 Boehringer Ingelheim Investigational Site, Shanghai, China|9.159.2488 Boehringer Ingelheim Investigational Site, Shanghai, China|9.159.2489 Boehringer Ingelheim Investigational Site, Shanghai, China|9.159.2516 Boehringer Ingelheim Investigational Site, Suzhou, Jiangsu Province, China|9.159.2497 Boehringer Ingelheim Investigational Site, Tianjin, China|9.159.2501 Boehringer Ingelheim Investigational Site, Wenzhou, Zhejiang Province, China|9.159.2498 Boehringer Ingelheim Investigational Site, Wuhan, Hubei Province, China|9.159.2499 Boehringer Ingelheim Investigational Site, Wuhan, Hubei Province, China|9.159.2515 Boehringer Ingelheim Investigational Site, Xian, Shanxi Province, China|9.159.2514 Boehringer Ingelheim Investigational Site, Xian, Shanxi, China|9.159.2511 Boehringer Ingelheim Investigational Site, Xian, China|9.159.1636 Boehringer Ingelheim Investigational Site, Aarhuc C, Denmark|9.159.1635 Boehringer Ingelheim Investigational Site, Aarhus C, Denmark|9.159.1639 Boehringer Ingelheim Investigational Site, Esbjerg, Denmark|9.159.1634 Boehringer Ingelheim Investigational Site, Frederiksberg, Denmark|9.159.1637 Boehringer Ingelheim Investigational Site, Glostrup, Denmark|9.159.1640 Boehringer Ingelheim Investigational Site, Hellerup, Denmark|9.159.1638 Boehringer Ingelheim Investigational Site, Hvidovre, Denmark|9.159.1633 Boehringer Ingelheim Investigational Site, København NV, Denmark|9.159.1631 Boehringer Ingelheim Investigational Site, København Ø, Denmark|9.159.1632 Boehringer Ingelheim Investigational Site, Odense, Denmark|9.159.2181 Boehringer Ingelheim Investigational Site, Oviedo, El Salvador|9.159.1655 Boehringer Ingelheim Investigational Site, Helsinki, Finland|9.159.1658 Boehringer Ingelheim Investigational Site, Kuopio, Finland|9.159.1659 Boehringer Ingelheim Investigational Site, Lappeenranta, Finland|9.159.1656 Boehringer Ingelheim Investigational Site, Oulu, Finland|9.159.1657 Boehringer Ingelheim Investigational Site, Seinäjoki, Finland|9.159.1680 Boehringer Ingelheim Investigational Site, Lille cedex, France|9.159.1683 Boehringer Ingelheim Investigational Site, Limoges cedex 1, France|9.159.1681 Boehringer Ingelheim Investigational Site, Marseille cedex 05, France|9.159.1679 Boehringer Ingelheim Investigational Site, Nancy, France|9.159.1685 Boehringer Ingelheim Investigational Site, Paris cedex 19, France|9.159.1682 Boehringer Ingelheim Investigational Site, Poitiers cedex, France|9.159.1684 Boehringer Ingelheim Investigational Site, Tours cedex 9, France|9.159.1713 Boehringer Ingelheim Investigational Site, Bad Neustadt/Saale, Germany|9.159.1736 Boehringer Ingelheim Investigational Site, Berlin, Germany|9.159.1732 Boehringer Ingelheim Investigational Site, Braunschweig, Germany|9.159.1726 Boehringer Ingelheim Investigational Site, Cloppenburg, Germany|9.159.1723 Boehringer Ingelheim Investigational Site, Dresden, Germany|9.159.1728 Boehringer Ingelheim Investigational Site, Düsseldorf, Germany|9.159.1707 Boehringer Ingelheim Investigational Site, Essen, Germany|9.159.1738 Boehringer Ingelheim Investigational Site, Freiburg, Germany|9.159.1720 Boehringer Ingelheim Investigational Site, Gießen, Germany|9.159.1722 Boehringer Ingelheim Investigational Site, Hamburg, Germany|9.159.1739 Boehringer Ingelheim Investigational Site, Hamburg, Germany|9.159.1724 Boehringer Ingelheim Investigational Site, Heidelberg, Germany|9.159.1734 Boehringer Ingelheim Investigational Site, Jena, Germany|9.159.1730 Boehringer Ingelheim Investigational Site, Kaiserslautern, Germany|9.159.1737 Boehringer Ingelheim Investigational Site, Köln, Germany|9.159.1717 Boehringer Ingelheim Investigational Site, Leipzig, Germany|9.159.1735 Boehringer Ingelheim Investigational Site, Ludwigshafen am Rhein, Germany|9.159.1712 Boehringer Ingelheim Investigational Site, Magdeburg, Germany|9.159.1710 Boehringer Ingelheim Investigational Site, Mainz, Germany|9.159.1709 Boehringer Ingelheim Investigational Site, Minden, Germany|9.159.1716 Boehringer Ingelheim Investigational Site, Mönchengladbach, Germany|9.159.1718 Boehringer Ingelheim Investigational Site, München, Germany|9.159.1725 Boehringer Ingelheim Investigational Site, München, Germany|9.159.1729 Boehringer Ingelheim Investigational Site, München, Germany|9.159.1727 Boehringer Ingelheim Investigational Site, Münster, Germany|9.159.1711 Boehringer Ingelheim Investigational Site, Nürnberg, Germany|9.159.1719 Boehringer Ingelheim Investigational Site, Regensburg, Germany|9.159.1731 Boehringer Ingelheim Investigational Site, Remscheid, Germany|9.159.1708 Boehringer Ingelheim Investigational Site, Rostock, Germany|9.159.1715 Boehringer Ingelheim Investigational Site, Saarbrücken, Germany|9.159.1714 Boehringer Ingelheim Investigational Site, Siegen, Germany|9.159.1733 Boehringer Ingelheim Investigational Site, Stuttgart, Germany|9.159.1721 Boehringer Ingelheim Investigational Site, Weimar, Germany|9.159.1826 Boehringer Ingelheim Investigational Site, Alexandroupolis, Greece|9.159.1819 Boehringer Ingelheim Investigational Site, Athens, Greece|9.159.1820 Boehringer Ingelheim Investigational Site, Athens, Greece|9.159.1821 Boehringer Ingelheim Investigational Site, Athens, Greece|9.159.1825 Boehringer Ingelheim Investigational Site, Ioannina, Greece|9.159.1824 Boehringer Ingelheim Investigational Site, Patras, Greece|9.159.2713 Boehringer Ingelheim Investigational Site, Hong KoNG, Hong Kong|9.159.2714 Boehringer Ingelheim Investigational Site, Hong Kong, Hong Kong|9.159.2605 Boehringer Ingelheim Investigational Site, Annamalainagar, India|9.159.2603 Boehringer Ingelheim Investigational Site, Bangalore, India|9.159.2620 Boehringer Ingelheim Investigational Site, Bangalore, India|9.159.2616 Boehringer Ingelheim Investigational Site, Bikaner, India|9.159.2618 Boehringer Ingelheim Investigational Site, Calicut, India|9.159.2604 Boehringer Ingelheim Investigational Site, Chennai, India|9.159.2619 Boehringer Ingelheim Investigational Site, Chennai, India|9.159.2625 Boehringer Ingelheim Investigational Site, Chennai, India|9.159.2606 Boehringer Ingelheim Investigational Site, Cochin, India|9.159.2607 Boehringer Ingelheim Investigational Site, Hyderabad, India|9.159.2624 Boehringer Ingelheim Investigational Site, Hyderabad, India|9.159.2630 Boehringer Ingelheim Investigational Site, Hyderabad, India|9.159.2632 Boehringer Ingelheim Investigational Site, Hyderabad, India|9.159.2610 Boehringer Ingelheim Investigational Site, Indore, India|9.159.2615 Boehringer Ingelheim Investigational Site, Jaipur, India|9.159.2617 Boehringer Ingelheim Investigational Site, Jaipur, India|9.159.2612 Boehringer Ingelheim Investigational Site, Jodhpur, India|9.159.2621 Boehringer Ingelheim Investigational Site, Kottayam, India|9.159.2613 Boehringer Ingelheim Investigational Site, Lucknow, India|9.159.2614 Boehringer Ingelheim Investigational Site, Ludhiana, India|9.159.2611 Boehringer Ingelheim Investigational Site, Mumbai, India|9.159.2628 Boehringer Ingelheim Investigational Site, New Delhi, India|9.159.2629 Boehringer Ingelheim Investigational Site, New Delhi, India|9.159.2623 Boehringer Ingelheim Investigational Site, Patiala, India|9.159.2609 Boehringer Ingelheim Investigational Site, Pune, India|9.159.2622 Boehringer Ingelheim Investigational Site, Pune, India|9.159.2627 Boehringer Ingelheim Investigational Site, Secunderabad, India|9.159.2626 Boehringer Ingelheim Investigational Site, Trichy, India|9.159.2631 Boehringer Ingelheim Investigational Site, Visakhapatnam, India|9.159.2608 Boehringer Ingelheim Investigational Site, Wardha, India|9.159.1851 Boehringer Ingelheim Investigational Site, Cork, Ireland|9.159.1852 Boehringer Ingelheim Investigational Site, Dublin 7, Ireland|9.159.2729 Barzilai Medical Center, Ashkelon, Israel|9.159.2721 Neurology Unit, Haifa, Israel|9.159.2724 Rambam Medical Center, Tel-Aviv Medical, Haifa, Israel|9.159.2723 Boehringer Ingelheim Investigational Site, Israel, Israel|9.159.2727 Western Galilee Hospital, Naharia, Israel|9.159.2722 Neurology Unit, Petach Tikva, Israel|9.159.2726 Sheba Medical Center, Tel Hashomer, Israel|9.159.2725 Tel Aviv Medical Center, Tel-Aviv, Israel|9.159.1875 Università degli Studi di Ancona, Ancona, Italy|9.159.1882 Ospedale Brotzu, Cagliari, Italy|9.159.1883 Azienda Ospedaliera S. Anna, Como, Italy|9.159.1871 Azienda Ospedaliera ""Careggi"", Firenze, Italy|9.159.1869 Università degli Studi di Genova, Genova, Italy|9.159.1870 ASL No. 5 di Jesi, Jesi (ancona), Italy|9.159.1865 Ospedale Regionale ""S. Salvatore"", L'aquila, Italy|9.159.1866 Ospedale S. Raffaele, Milano, Italy|9.159.1873 Istituto Scientifico ""S. Luca"", Milano, Italy|9.159.1884 Ospedale S. Carlo Borromeo"", Milano, Italy|9.159.1868 Ospedale ""S. Maria di Loreto Mare"", Napoli, Italy|9.159.1876 Azienda Ospedaliera di Padova -Policlinico Universitario, Padova, Italy|9.159.1874 Ospedale Civico - ARNAS, Palermo, Italy|9.159.1872 Neuromed IRCCS, Pozzilli (IS), Italy|9.159.1879 Policlinico S. Andrea, Roma, Italy|9.159.1881 Università ""La Sapienza"", Roma, Italy|9.159.1877 Azienda Ospedaliera Umberto I, Siracusa, Italy|9.159.1878 Azienda Ospedaliera ""Santo Maria"", Terni, Italy|9.159.1864 Azienda Ospedaliera ""S. Giovanni Battista"", Torino, Italy|9.159.1863 Ospedale di Cattinara, Trieste, Italy|9.159.1867 Presidio Ospedaliero G.Jazzolino, Vibo Valentia, Italy|9.159.1880 Ospedale Civile, Vicenza, Italy|9.159.2964 Boehringer Ingelheim Investigational Site, Adachi-ku, Tokyo, Japan|9.159.2958 Boehringer Ingelheim Investigational Site, Akashi, Hyogo, Japan|9.159.2970 Boehringer Ingelheim Investigational Site, Akashi, Hyogo, Japan|9.159.2965 Boehringer Ingelheim Investigational Site, Ako, Hyogo, Japan|9.159.2968 Boehringer Ingelheim Investigational Site, Aoba-ku, Yokohama, Kanagawa, Japan|9.159.2951 Boehringer Ingelheim Investigational Site, Azumino, Nagano, Japan|9.159.2959 Boehringer Ingelheim Investigational Site, Chitose, Hokkaido, Japan|9.159.2944 Boehringer Ingelheim Investigational Site, Chuo-ku, Kobe, Hyogo, Japan|9.159.2947 Boehringer Ingelheim Investigational Site, Chuo-Ku, Sapporo, Hokkaido, Japan|9.159.2954 Boehringer Ingelheim Investigational Site, Fushimi-ku, Kyoto, Kyoto, Japan|9.159.2942 Boehringer Ingelheim Investigational Site, Habikino, Osaka, Japan|9.159.2948 Boehringer Ingelheim Investigational Site, Higashi-ku, Sapporo, Hokkaido, Japan|9.159.2957 Boehringer Ingelheim Investigational Site, Higashi-osaka, Osaka, Japan|9.159.2940 Boehringer Ingelheim Investigational Site, Higashinari-ku, Osaka, Osaka, Japan|9.159.2973 Boehringer Ingelheim Investigational Site, Higashiyodogawa-ku, Osaka, Osaka, Japan|9.159.2949 Boehringer Ingelheim Investigational Site, Hitachinaka, Ibaraki, Japan|9.159.2953 Boehringer Ingelheim Investigational Site, Iida, Nagano, Japan|9.159.2943 Boehringer Ingelheim Investigational Site, Izumisano, Osaka, Japan|9.159.2963 Boehringer Ingelheim Investigational Site, Jyonan-ku, Fukuoka, Fukuoka, Japan|9.159.2933 Boehringer Ingelheim Investigational Site, Kasama, Ibaraki, Japan|9.159.2955 Boehringer Ingelheim Investigational Site, Kasuga, Fukuoka, Japan|9.159.2938 Boehringer Ingelheim Investigational Site, Kita-ku, Osaka, Osaka, Japan|9.159.2967 Boehringer Ingelheim Investigational Site, Koriyama, Fukushima, Japan|9.159.2969 Boehringer Ingelheim Investigational Site, Kushiro, Hokkaido, Japan|9.159.2952 Boehringer Ingelheim Investigational Site, Matsumoto, Nagano, Japan|9.159.2961 Boehringer Ingelheim Investigational Site, Midori-ku, Yokohama, Kanagawa, Japan|9.159.2934 Boehringer Ingelheim Investigational Site, Moriya, Ibaraki, Japan|9.159.2971 Boehringer Ingelheim Investigational Site, Musashino, Tokyo, Japan|9.159.2962 Boehringer Ingelheim Investigational Site, Nakagawa-ku, Nagoya, Aichi, Japan|9.159.2939 Boehringer Ingelheim Investigational Site, Nishi-yodogawa-ku, Osaka, Osaka, Japan|9.159.2956 Boehringer Ingelheim Investigational Site, Ohnojo, Fukuoka, Japan|9.159.2941 Boehringer Ingelheim Investigational Site, Sakai-ku, Sakai, Osaka, Japan|9.159.2945 Boehringer Ingelheim Investigational Site, Sawara-ku, Fukuoka, Fukuoka, Japan|9.159.2937 Boehringer Ingelheim Investigational Site, Shimogyo-ku, Kyoto, Kyoto, Japan|9.159.2966 Boehringer Ingelheim Investigational Site, Shiroishi, Miyagi, Japan|9.159.2936 Boehringer Ingelheim Investigational Site, Suwa, Nagano, Japan|9.159.2946 Boehringer Ingelheim Investigational Site, Takikawa, Hokkaido, Japan|9.159.2935 Boehringer Ingelheim Investigational Site, Tatebayashi, Gunma, Japan|9.159.2950 Boehringer Ingelheim Investigational Site, Tsuchiura, Ibaraki, Japan|9.159.2972 Boehringer Ingelheim Investigational Site, Yao, Osaka, Japan|9.159.1593 Boehringer Ingelheim Investigational Site, Gwangju, Korea, Republic of|9.159.1595 Boehringer Ingelheim Investigational Site, Incheon, Korea, Republic of|9.159.1592 Boehringer Ingelheim Investigational Site, Kyunggi-do, Korea, Republic of|9.159.1591 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|9.159.1594 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|9.159.1597 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|9.159.1596 Boehringer Ingelheim Investigational Site, Suwon, Korea, Republic of|9.159.2707 Boehringer Ingelheim Investigational Site, Kelantan Darul Naim, Malaysia|9.159.2706 Boehringer Ingelheim Investigational Site, Kuala Lumpur, Malaysia|9.159.2765 Boehringer Ingelheim Investigational Site, Metepec, Mexico|9.159.1960 Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Netherlands|9.159.1945 Medisch Centrum Alkmaar, Alkmaar, Netherlands|9.159.1963 Polikliniek Neurologie, Assen, Netherlands|9.159.1949 Ziekenhuis Gooi-Noord, Blaricum, Netherlands|9.159.1962 Locatie Molengracht, Breda, Netherlands|9.159.1950 HagaZiekenhuis, Den Haag, Netherlands|9.159.1959 Catharina Ziekenhuis, Eindhoven, Netherlands|9.159.1946 Scheper Ziekenhuis, Emmen, Netherlands|9.159.1958 Medisch Spectrum Twente, Enschede, Netherlands|9.159.1943 Umcg, Groningen, Netherlands|9.159.1961 Lokatie Van Swieten, Groningen, Netherlands|9.159.1953 Atrium Medisch Centrum, Heerlen, Netherlands|9.159.1955 Elkerliek Ziekenhuis, Helmond, Netherlands|9.159.1951 Ziekenhuisgroep Twente, Hengelo, Netherlands|9.159.1948 Medisch Centrum Leeuwarden, Leeuwarden, Netherlands|9.159.1952 Rijnland Ziekenhuis, Leiderdorp, Netherlands|9.159.1947 Sint Antonius Ziekenhuis, Nieuwegein, Netherlands|9.159.1964 Canisius-Wilhelmina ziekenhuis, Nijmegen, Netherlands|9.159.1956 TweeSteden Ziekenhuis Tilburg, Tilburg, Netherlands|9.159.1957 Sint Elisabeth Ziekenhuis, Tilburg, Netherlands|9.159.1944 Máxima Medisch Centrum, Veldhoven, Netherlands|9.159.1954 St. Jans Gasthuis, Weert, Netherlands|9.159.2029 Boehringer Ingelheim Investigational Site, Bergen, Norway|9.159.2028 Boehringer Ingelheim Investigational Site, Oslo, Norway|9.159.2027 Boehringer Ingelheim Investigational Site, Trondheim, Norway|9.159.2040 Hospital Fernando Fonseca, Amadora, Portugal|9.159.2039 Centro Hospitalar e Universitário de Coimbra, EPE, Coimbra, Portugal|9.159.2041 Centro Hospitalar de Lisboa Norte, Lisboa, Portugal|9.159.2042 Centro Hospitalar do Porto, Porto, Portugal|9.159.2114 Boehringer Ingelheim Investigational Site, Ekaterinburg, Russian Federation|9.159.2102 Boehringer Ingelheim Investigational Site, Kazan, Russian Federation|9.159.2117 Boehringer Ingelheim Investigational Site, Kemerovo, Russian Federation|9.159.2107 Boehringer Ingelheim Investigational Site, Kirov, Russian Federation|9.159.2116 Boehringer Ingelheim Investigational Site, Krasnoyarsk, Russian Federation|9.159.2079 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|9.159.2080 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|9.159.2081 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|9.159.2082 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|9.159.2083 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|9.159.2084 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|9.159.2085 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|9.159.2087 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|9.159.2088 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|9.159.2089 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|9.159.2090 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|9.159.2091 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|9.159.2092 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|9.159.2093 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|9.159.2095 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|9.159.2098 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|9.159.2101 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|9.159.2105 Boehringer Ingelheim Investigational Site, Nizhnyi Novgorod, Russian Federation|9.159.2115 Boehringer Ingelheim Investigational Site, Novosibirsk, Russian Federation|9.159.2119 Boehringer Ingelheim Investigational Site, Omsk, Russian Federation|9.159.2111 Boehringer Ingelheim Investigational Site, Orel, Russian Federation|9.159.2106 Boehringer Ingelheim Investigational Site, Rostov-na-Donu, Russian Federation|9.159.2108 Boehringer Ingelheim Investigational Site, Samara, Russian Federation|9.159.2109 Boehringer Ingelheim Investigational Site, Saratov, Russian Federation|9.159.2110 Boehringer Ingelheim Investigational Site, Saratov, Russian Federation|9.159.2118 Boehringer Ingelheim Investigational Site, Seversk, Russian Federation|9.159.2086 Boehringer Ingelheim Investigational Site, Smolensk, Russian Federation|9.159.2094 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation|9.159.2097 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation|9.159.2099 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation|9.159.2100 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation|9.159.2120 Boehringer Ingelheim Investigational Site, Ufa, Russian Federation|9.159.2112 Boehringer Ingelheim Investigational Site, Volgograd, Russian Federation|9.159.2113 Boehringer Ingelheim Investigational Site, Volgograd, Russian Federation|9.159.2104 Boehringer Ingelheim Investigational Site, Voronezh, Russian Federation|9.159.2103 Boehringer Ingelheim Investigational Site, Yaroslavl, Russian Federation|9.159.2703 Boehringer Ingelheim Investigational Site, Singapore, Singapore|9.159.2704 Boehringer Ingelheim Investigational Site, Singapore, Singapore|9.159.2705 Boehringer Ingelheim Investigational Site, Singapore, Singapore|9.159.2060 Boehringer Ingelheim Investigational Site, Bloemfontein, South Africa|9.159.2056 Boehringer Ingelheim Investigational Site, Cape Town, South Africa|9.159.2057 Boehringer Ingelheim Investigational Site, Durban, South Africa|9.159.2055 Boehringer Ingelheim Investigational Site, Johannesburg, South Africa|9.159.2061 Boehringer Ingelheim Investigational Site, Johannesburg, South Africa|9.159.2058 Boehringer Ingelheim Investigational Site, Pretoria, South Africa|9.159.2059 Boehringer Ingelheim Investigational Site, Sunninghill, South Africa|9.159.2179 Boehringer Ingelheim Investigational Site, Alicante, Spain|9.159.2177 Boehringer Ingelheim Investigational Site, Barcelona, Spain|9.159.2178 Boehringer Ingelheim Investigational Site, Hospitalet de Llobregat (Barcelona), Spain|9.159.2175 Boehringer Ingelheim Investigational Site, Madrid, Spain|9.159.2176 Boehringer Ingelheim Investigational Site, Madrid, Spain|9.159.2180 Boehringer Ingelheim Investigational Site, Pamplona, Spain|9.159.2223 Boehringer Ingelheim Investigational Site, Borås, Sweden|9.159.2209 Boehringer Ingelheim Investigational Site, Eskilstuna, Sweden|9.159.2204 Boehringer Ingelheim Investigational Site, Göteborg, Sweden|9.159.2205 Boehringer Ingelheim Investigational Site, Göteborg, Sweden|9.159.2728 Neurology Unit, Holon, Sweden|9.159.2210 Boehringer Ingelheim Investigational Site, Jönköping, Sweden|9.159.2206 Boehringer Ingelheim Investigational Site, Lund, Sweden|9.159.2211 Boehringer Ingelheim Investigational Site, Mora, Sweden|9.159.2216 Boehringer Ingelheim Investigational Site, Skellefteå, Sweden|9.159.2215 Boehringer Ingelheim Investigational Site, Skövde, Sweden|9.159.2203 Boehringer Ingelheim Investigational Site, Stockholm, Sweden|9.159.2212 Boehringer Ingelheim Investigational Site, Stockholm, Sweden|9.159.2213 Boehringer Ingelheim Investigational Site, Stockholm, Sweden|9.159.2222 Boehringer Ingelheim Investigational Site, Stockholm, Sweden|9.159.2225 Boehringer Ingelheim Investigational Site, Stockholm, Sweden|9.159.2207 Boehringer Ingelheim Investigational Site, Umeå, Sweden|9.159.2214 Boehringer Ingelheim Investigational Site, Värnamo, Sweden|9.159.2224 Boehringer Ingelheim Investigational Site, Västervik, Sweden|9.159.2208 Boehringer Ingelheim Investigational Site, Örebro, Sweden|9.159.2250 Boehringer Ingelheim Investigational Site, Kaohsiung, Taiwan|9.159.2253 Boehringer Ingelheim Investigational Site, Kaohsiung, Taiwan|9.159.2248 Boehringer Ingelheim Investigational Site, Taichung, Taiwan|9.159.2249 Boehringer Ingelheim Investigational Site, Taichung, Taiwan|9.159.2251 Boehringer Ingelheim Investigational Site, Tainan, Taiwan|9.159.2244 Boehringer Ingelheim Investigational Site, Taipei, Taiwan|9.159.2245 Boehringer Ingelheim Investigational Site, Taipei, Taiwan|9.159.2246 Boehringer Ingelheim Investigational Site, Taipei, Taiwan|9.159.2247 Boehringer Ingelheim Investigational Site, Taipei, Taiwan|9.159.2252 Boehringer Ingelheim Investigational Site, Taipei, Taiwan|9.159.2254 Boehringer Ingelheim Investigational Site, Taipei, Taiwan|9.159.2243 Boehringer Ingelheim Investigational Site, Taoyuan, Taiwan|9.159.2797 Boehringer Ingelheim Investigational Site, Bangkok, Thailand|9.159.2798 Boehringer Ingelheim Investigational Site, Bangkok, Thailand|9.159.2799 Boehringer Ingelheim Investigational Site, Bangkok, Thailand|9.159.2800 Boehringer Ingelheim Investigational Site, Bangkok, Thailand|9.159.2801 Boehringer Ingelheim Investigational Site, Chiang Mai, Thailand|9.159.2830 Boehringer Ingelheim Investigational Site, Ankara, Turkey|9.159.2829 Boehringer Ingelheim Investigational Site, Antalya, Turkey|9.159.2831 Boehringer Ingelheim Investigational Site, Bursa, Turkey|9.159.2827 Boehringer Ingelheim Investigational Site, Eskisehir, Turkey|9.159.2825 Boehringer Ingelheim Investigational Site, Istanbul, Turkey|9.159.2826 Boehringer Ingelheim Investigational Site, Istanbul, Turkey|9.159.2828 Dkuz Eylul Universitesi Tip Fakultesi Noroloji A.B.D., Izmir, Turkey|9.159.2387 Boehringer Ingelheim Investigational Site, Dnepropetrovsk, Ukraine|9.159.2384 Boehringer Ingelheim Investigational Site, Kharkiv, Ukraine|9.159.2385 Boehringer Ingelheim Investigational Site, Kharkiv, Ukraine|9.159.2386 Boehringer Ingelheim Investigational Site, Kharkiv, Ukraine|9.159.2392 Boehringer Ingelheim Investigational Site, Kharkiv, Ukraine|9.159.2379 Boehringer Ingelheim Investigational Site, Kyiv, Ukraine|9.159.2380 Boehringer Ingelheim Investigational Site, Kyiv, Ukraine|9.159.2382 Boehringer Ingelheim Investigational Site, Kyiv, Ukraine|9.159.2389 Boehringer Ingelheim Investigational Site, Odesa, Ukraine|9.159.2390 Boehringer Ingelheim Investigational Site, Odesa, Ukraine|9.159.2391 Boehringer Ingelheim Investigational Site, Vinnytzya, Ukraine|9.159.2388 Boehringer Ingelheim Investigational Site, Zaporizhzhya, Ukraine|9.159.2304 Boehringer Ingelheim Investigational Site, Belfast, United Kingdom|9.159.2297 Boehringer Ingelheim Investigational Site, Birmingham, United Kingdom|9.159.2299 Boehringer Ingelheim Investigational Site, Bournemouth, United Kingdom|9.159.2301 Boehringer Ingelheim Investigational Site, Bristol, United Kingdom|9.159.2298 Boehringer Ingelheim Investigational Site, Dundee, United Kingdom|9.159.2307 Boehringer Ingelheim Investigational Site, Exeter, United Kingdom|9.159.2296 Boehringer Ingelheim Investigational Site, Glasgow, United Kingdom|9.159.2300 Boehringer Ingelheim Investigational Site, Glasgow, United Kingdom|9.159.2287 Boehringer Ingelheim Investigational Site, Harrow, United Kingdom|9.159.2303 Boehringer Ingelheim Investigational Site, Henshingham, Whitehaven, United Kingdom|9.159.2308 Boehringer Ingelheim Investigational Site, Leicester, United Kingdom|9.159.2295 Boehringer Ingelheim Investigational Site, Liverpool, United Kingdom|9.159.2286 Boehringer Ingelheim Investigational Site, London, United Kingdom|9.159.2293 Boehringer Ingelheim Investigational Site, London, United Kingdom|9.159.2294 Boehringer Ingelheim Investigational Site, London, United Kingdom|9.159.2305 Boehringer Ingelheim Investigational Site, Mansfield, United Kingdom|9.159.2290 Boehringer Ingelheim Investigational Site, Newcastle Upon Tyne, United Kingdom|9.159.2288 Boehringer Ingelheim Investigational Site, North Shields, United Kingdom|9.159.2285 Boehringer Ingelheim Investigational Site, Northampton, United Kingdom|9.159.2284 Boehringer Ingelheim Investigational Site, Nottingham, United Kingdom|9.159.2283 Boehringer Ingelheim Investigational Site, Poole, United Kingdom|9.159.2302 Boehringer Ingelheim Investigational Site, Rotherham, United Kingdom|9.159.2292 Boehringer Ingelheim Investigational Site, Sheffield, United Kingdom|9.159.2289 Boehringer Ingelheim Investigational Site, Southampton, United Kingdom|9.159.2306 Boehringer Ingelheim Investigational Site, Stoke on Trent, United Kingdom|9.159.2291 Boehringer Ingelheim Investigational Site, Sunderland, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00153062"
1830,"NCT00144417","TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment",,"Completed","No Results Available","Tuberculosis","Drug: Moxifloxacin (with rifampin, pyrazinamide, and ethambutol)|Drug: isoniazid","• To compare the culture-conversion rate at the end of the intensive phase of therapy of the moxifloxacin regimen vs. that of the isoniazid regimen|To compare the safety and tolerability of the moxifloxacin regimen to that of the isoniazid regimen|To determine the time to culture-conversion of the moxifloxacin regimen and the isoniazid regimen using data from 2-, 4-, 6-, and 8-week cultures|To compare the proportion of patients with any Grade 3 or 4 adverse reactions|To compare adverse events and 2-month culture conversion rates among HIV-infected patients vs. HIV-uninfected patients|To compare the rates of treatment failure of the moxifloxacin regimen and the isoniazid regimen|To determine whether there is delayed toxicity attributable to moxifloxacin (toxicity that becomes evident after the 8 weeks of moxifloxacin therapy)","Centers for Disease Control and Prevention|Global Alliance for TB Drug Development|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","433","U.S. Fed|Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CDC-NCHSTP-4448","February 2006","June 2007","December 2007","September 5, 2005",,"August 3, 2011","Veterans Administration Medical Center of Arkansas, Little Rock, Arkansas, United States|University of Southern California Medical Center, Los Angeles, California, United States|University of California at San Diego, San Diego, California, United States|University of California, San Francincisco, San Francisco, California, United States|Denver Public Health Department, Denver, Colorado, United States|Washington DC Veterans Administration Medical Center, Washington DC, District of Columbia, United States|Emory University School of Medicine, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Hines Veterans Administration Medical Center, Hines, Illinois, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Boston University Medical Center, Boston, Massachusetts, United States|New Jersey School of Medicine, Newark, New Jersey, United States|Columbia University, New York, New York, United States|Harlem Hospital, Columbia University, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Veterans Administration Tennessee Valley Health Care System, Nashville, Tennessee, United States|University of North Texas Health Science Center, Fort Worth, Texas, United States|Houston Veterans Administration Medical Center, Houston, Texas, United States|Audie L Murphy Memorial Veterans Administration Medical Center, San Antonio, Texas, United States|Seattle-King County Health Department, Seattle, Washington, United States|Hopital Universitario Clementino Fraga Filho, Rio de Janeiro, Brazil|University of Manitoba, Winnepeg, Manitoba, Canada|Montreal Chest Institute, Montreal, Quebec, Canada|Nelson R. Mandela School of Medicine, Durban, KwaZulu Natal, South Africa|Agencia de Salut Publica, Barcelona, Spain|Makerere University Medical School, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT00144417"
1831,"NCT00034840","Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose",,"Completed","No Results Available","Hypertension","Drug: telmisartan, valsartan","Change in the 24-hour mean diastolic blood pressure (DBP), as measured by ABPM after a missed dose|Change in the mean DBP during the last 6 hours of the 24-hour dosing interval, as measured by ABPM after an active dose of study medication|Change in 24-hour ABPM mean systolic blood pressure (SBP) after a missed dose|Change in the last 6 hour ABPM mean SBP measured after a dose of active treatment|Changes in ABPM mean DBP and SBP during other periods of the 24-hour dosing interval after an active dose|Changes in ABPM mean DBP and SBP during other periods of the 24-hour dosing interval after a missed dose|Changes in in-clinic mean seated trough DBP and SBP as measured by manual cuff sphygmomanometer after a missed dose|Changes in in-clinic mean seated trough DBP and SBP as measured by manual cuff sphygmomanometer after an active dose|Responder rates based on ABPM|Responder rates based on in-clinic trough cuff blood pressures","Boehringer Ingelheim|GlaxoSmithKline|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 4","490","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","502.327","October 2001","August 2002","August 2002","May 3, 2002",,"November 1, 2013","Memorial Research Medical Clinic, Long Beach, California, United States|National Research Institute, Los Angeles, California, United States|Orange County Research Center, Orange, California, United States|University of Conn. Health Services Center, Hypertension and Vascular Disease, Farmington, Connecticut, United States|Alan Graff, Fort Lauderdale, Florida, United States|Greater Ft. Lauderdale Heart Group Research, Ft. Lauderdale, Florida, United States|Orlando Clinical Research Center, Orlando, Florida, United States|So. Clinical Research and Management, Inc., Augusta, Georgia, United States|Rush Presbyterian/St. Luke's Medical Center, Chicago, Illinois, United States|University of Maryland/Nephrology Clinical Research Unit, Baltimore, Maryland, United States|Washington University, St. Louis, Missouri, United States|Oklahoma Cardiovascular and Hypertension Center, Oklahoma City, Oklahoma, United States|Michael A. Azorr, M.D., Portland, Oregon, United States|Harleysville Medical Associates, Harleysville, Pennsylvania, United States|Trinity Hypertension Research Institute/Punzi Medical Center, Carrollton, Texas, United States|UW Health/Physicians Plus Center for Clinical Trials, Madison, Wisconsin, United States|Heart Health Institute, Calgary, Alberta, Canada|Dr. Dennis O'Keefe, Mount Pearl, Newfoundland and Labrador, Canada|Dr. William Booth, Antigonish, Nova Scotia, Canada|MSHJ Research Assoc., Halifax, Nova Scotia, Canada|Dr. Joseph Berlingieri, Burlington, Ontario, Canada|Dr. William Mahoney, Corunna, Ontario, Canada|BBM Clinical Research Ltd., Courtice, Ontario, Canada|Dr. Richard Tytus, Hamilton, Ontario, Canada|Total Concept Health Care, Kitchener, Ontario, Canada|Centre for Activity and Aging, London, Ontario, Canada|Dr. Martyn Chilvers, Sarnia, Ontario, Canada|Sunnybrook & Women's College Health Centre, Toronto, Ontario, Canada|Theradev Clinical Research, Inc., Granby, Quebec, Canada|Invascor, Longueuil, Longueuil, Quebec, Canada|Hotel Dieu de St-Jerome, Saint Jerome, Quebec, Canada|Centre de Cardiologie, Saint Lambert, Quebec, Canada|Centre Hospital Quebec - PAC CHUL Unite de Recherche, Sainte-Foy, Quebec, Canada|Q&T Research, Sherbrooke, Quebec, Canada|Royal University Hospital, Saskatoon, Saskatchewan, Canada",,"https://ClinicalTrials.gov/show/NCT00034840"
1832,"NCT00608946","Treatment With Copper in Patients With Mild Alzheimer´s Dementia",,"Completed","No Results Available","Alzheimer´s Disease","Dietary Supplement: copper|Dietary Supplement: placebo","change of cognitive function, measured by ADAS-cog|change of beta amyloid in the CSF and volumetric changes in the brain","University Hospital, Saarland|University of Goettingen, Section Neurobiology (Head: Prof. Dr. T. Bayer), Germany","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 2","68","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UKS-PSY-DEM-01","March 2004","August 2007",,"February 6, 2008",,"February 6, 2008",,,"https://ClinicalTrials.gov/show/NCT00608946"
1833,"NCT00908167","Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies",,"Completed","No Results Available","Acute Myeloid Leukemia|Infantile Leukemia (Both AML and ALL)|Myelodysplastic Syndrome|Myelodysplastic/Myeloproliferative Neoplasms|Biphenotypic Leukemia","Drug: Sorafenib|Drug: Cytarabine|Drug: Clofarabine","To characterize a tolerable dose of sorafenib when given in combination with cytarabine and clofarabine in patients with relapsed/refractory hematologic malignancies.","St. Jude Children's Research Hospital|National Cancer Institute (NCI)|Bayer/Onyx","All","up to 31 Years   (Child, Adult)","Phase 1","44","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RELHEM|R01CA138744|NCI-2011-01252","September 2009","June 2015","June 2015","May 25, 2009",,"January 12, 2018","St. Jude Children's Research Hospital, Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00908167"
1834,"NCT03406871","Regorafenib and Nivolumab Simultaneous Combination Therapy","REGONIVO","Active, not recruiting","No Results Available","Advanced and Metastatic Solid Tumor","Drug: Regorafenib|Drug: Nivolumab","RD|Maximum Tolerated Dose(MTD)|ORR|Progression-Free Survival(PFS)|Overall Survival(OS)|Disease Control Rate(DCR)|Incidence of Treatment-Emergent Adverse-Events [Safety and Tolerability]","Kohei Shitara|Ono Pharmaceutical Co. Ltd|Bayer Yakuhin, Ltd.|National Cancer Center Hospital East","All","20 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","48","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EPOC 1603 study","January 25, 2018","April 23, 2019","July 31, 2022","January 23, 2018",,"August 2, 2019","NationalCCHE, Kashiwa, Chiba, Japan",,"https://ClinicalTrials.gov/show/NCT03406871"
1835,"NCT01710267","Rivaroxaban Laboratory Monitoring in Switzerland 2: Therapeutic Dose (RivaMoS 2)","RivaMoS2","Completed","No Results Available","Healthy",,"Evaluation of the effect of RXA on trough and peak RXA conc. values in time|Evaluation of the effect of RXA on coagulation assays in time","Prof. Dr. Dr. med. Walter A. Wuillemin, MD, PhD|Research Foundation, Division of Hematology, Luzerner Kantonsspital, Switzerland|Bayer (Schweiz) AG, Switzerland|Luzerner Kantonsspital","Male","18 Years to 65 Years   (Adult, Older Adult)",,"20","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","12041","March 2013","March 2014","December 2014","October 19, 2012",,"April 1, 2015","Luzerner Kantonsspital, Luzern, LU, Switzerland",,"https://ClinicalTrials.gov/show/NCT01710267"
1836,"NCT01175551","Direct Measurements of Cervical Remodeling for Predicting Preterm Birth",,"Completed","No Results Available","Preterm Birth",,"Preterm birth (delivery at less than 37 weeks)|spontaneous Preterm Birth at less than 37 weeks and less than 34 weeks, small for gestational age (less than the 10% birth weight for gestational age as determined by the Alexander curve), preeclampsia and a composite of neonatal outcomes","University of Pennsylvania|Burroughs Wellcome|Bayer Droegemueller Award in Clinical Research","Female","Child, Adult, Older Adult",,"1207","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","810707","November 2009","November 2011","May 2012","August 5, 2010",,"January 7, 2014","Helen O. Dickens Center for Women, Philadelphia, Pennsylvania, United States|Penn OB/GYN Associates, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01175551"
1837,"NCT01341132","Evaluation of Cirrhosis and Malignant Hepatic Lesions Using Novel MR Contrast Agents",,"Unknown status","No Results Available","Hepatocellular Carcinoma","Procedure: MRI Scan of the Liver enhanced with Eovist",,"San Francisco Veterans Affairs Medical Center|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma|University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)",,"75","U.S. Fed|Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","10-03278","May 2011","June 2012",,"April 25, 2011",,"April 25, 2011","San Francisco VA Medical Center, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT01341132"
1838,"NCT02582749","Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases",,"Terminated","Has Results","Prostate Cancer|Bone Metastases|Prostate Neoplasms","Drug: LHRH agonist/antagonist|Drug: Bicalutamide|Radiation: Radium-223 dichloride","Radiological Progression-Free Survival (rPFS)|Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug, Graded According to NCI Common Terminology Criteria for Adverse Events v 4.0 (CTCAE)|Time to First Skeletal-Related Event (SRE)|Secondary Neoplasms|PSA Complete Response Rates|PSA Partial Response Rates|Median Time to Castration Resistance|2-Year PSA Progression Free Survival (PFS)|2-Year Overall Survival (OS)|12-Week Alkaline Phosphatase (ALP) Normalization|Time to ALP Progression|Change in Pain Over Time|Analgesic Use by WHO Ladder Score","Ajjai Alva, MD|Hoosier Cancer Research Network|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma","Male","18 Years and older   (Adult, Older Adult)","Phase 2","16","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HCRN GU13-170","April 2016","September 14, 2017","September 14, 2017","October 21, 2015","July 9, 2019","July 9, 2019","University of Arizona Cancer Center at Dignity Health St. Joseph's, Phoenix, Arizona, United States|Illinois CancerCare, P. C., Peoria, Illinois, United States|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|IU Health Central Indiana Cancer Centers, Indianapolis, Indiana, United States|University of Iowa Hopital and Clinics, Iowa City, Iowa, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Metro Health Cancer Center, Wyoming, Michigan, United States|GU Research Network, LLC, Omaha, Nebraska, United States|Integrated Medical Professionals, PLLC, Lake Success, New York, United States|University of Texas Medical Branch at Galveston, Galveston, Texas, United States|Clement J. Zablocki VA Medical Center, Milwaukee, Wisconsin, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02582749/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02582749"
1839,"NCT02306824","Berlin Atrial Fibrillation Registry",,"Active, not recruiting","No Results Available","Acute Ischemic Stroke|Atrial Fibrillation",,"Patient self-reported persistence to oral anticoagulants (novel oral anticoagulants or vitamin K antagonists) in stroke patients with AF at 12 months after ischemic stroke or TIA","Charite University, Berlin, Germany|Center for Stroke Research Berlin|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma","All","18 Years and older   (Adult, Older Adult)",,"1080","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","EA2/052/14","December 2014","November 2017","November 2023","December 3, 2014",,"August 2, 2019","Charité - Universitätsmedizin Berlin, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT02306824"
1840,"NCT01234870","Comprehensive Evaluation of Ischemic Heart Disease Using MRI",,"Completed","Has Results","Heart Disease, Ischemic|Atherosclerosis, Coronary","Drug: Gadolinium|Drug: Adenosine","Magnetic Resonance Image Quality Rating|Number of Participants With Adverse Events to Demonstrate Feasibility of a Comprehensive Cardiac Magnetic Resonance Imaging Protocol","Northwestern University|Astellas Pharma US, Inc.|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","40","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CR1_STU00006013|ASCA-9J02","June 2010","January 2012","January 2012","November 4, 2010","September 26, 2014","September 26, 2014","Northwestern University, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01234870"
1841,"NCT03383939","Inhaled A1AT in Adult Stable Bronchiectasis",,"Completed","No Results Available","Bronchiectasis Adult","Drug: Group A|Drug: Group B","Changes from baseline BAL levels of A1AT|Changes from baseline neutrophil elastase in BAL|Changes from baseline neutrophil elastase inhibitory capacity in BAL","Hospital Universitari Vall d'Hebron Research Institute|Bayer|Sociedad Española de Neumología y Cirugía Torácica|Instituto de Salud Carlos III","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care","AC(HG) 44/95","June 1, 1996","September 7, 1999","September 7, 1999","December 27, 2017",,"December 27, 2017",,,"https://ClinicalTrials.gov/show/NCT03383939"
1842,"NCT02861534","A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)","VICTORIA","Completed","No Results Available","Heart Failure|Chronic Heart Failure With Reduced Ejection Fraction","Drug: Vericiguat|Drug: Placebo for Vericiguat","Time to First Occurrence of Composite Endpoint of Cardiovascular (CV) Death or Heart Failure Hospitalization|Time to the First Occurrence of CV Death|Time to the First Occurrence of HF Hospitalization|Time to Total HF Hospitalizations (including frst and recurrent events)|Time to First Occurrence of Composite Endpoint of All-cause Mortality or HF Hospitalization|Time to All-cause Mortality","Merck Sharp & Dohme Corp.|Bayer|Canadian VIGOUR Centre|Duke Clinical Research Institute","All","18 Years and older   (Adult, Older Adult)","Phase 3","5050","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1242-001|2016-000671-25","September 20, 2016","June 18, 2019","September 2, 2019","August 10, 2016",,"November 15, 2019",,,"https://ClinicalTrials.gov/show/NCT02861534"
1843,"NCT02752282","Anticipatory Counseling on LNG-IUS Continuation, Utilization and Satisfaction","ACCCUSS","Active, not recruiting","No Results Available","Vaginal Bleeding|Uterine Cramping","Other: Anticipatory Counseling|Other: Cancer Screening Guidelines","Change in LNG-IUS knowledge, satisfaction and continuation from baseline|Percent of subjects in Phase II who complete all 3 surveys on-time over 6 months compared by recruitment method and site|Number of subjects reporting LNG-IUS discontinuation during the study time frame (6 months) by reason for LNG-IUS removal|LNG-IUS user self-reported satisfaction with video counseling|LNG-IUS user self-reported LNG-IUS healthcare utilization during study period","University of Washington|Bayer|John H. Stroger Hospital|University of California, Los Angeles","Female","18 Years to 45 Years   (Adult)","Not Applicable","178","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other","49648","March 2016","October 2019","December 2019","April 26, 2016",,"April 18, 2019","University of California Los Angeles Medical Center, Los Angeles, California, United States|Stroger Hospital of Cook County, Chicago, Illinois, United States|University of Washington Medical Centers, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02752282"
1844,"NCT02293395","A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome","GEMINI ACS 1","Completed","Has Results","Acute Coronary Syndrome","Drug: Acetylsalicylic acid|Drug: Rivaroxaban|Drug: Clopidogrel|Drug: Ticagrelor","Number of Participants With Non Coronary Artery Bypass Graft-Related (Non CABG-related) Thrombolysis in Myocardial Infarction (TIMI) Clinically Significant Bleeding Events","Janssen Research & Development, LLC|Bayer|Duke Clinical Research Institute|Harvard Medical School","All","18 Years and older   (Adult, Older Adult)","Phase 2","3037","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR106261|RIVAROXACS2002|2014-004266-26","April 20, 2015","October 14, 2016","October 14, 2016","November 18, 2014","November 13, 2017","December 26, 2017","Alexander City, Alabama, United States|Banning, California, United States|Sylmar, California, United States|Aurora, Colorado, United States|Littleton, Colorado, United States|Jupiter, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Pensacola, Florida, United States|Tampa, Florida, United States|Athens, Georgia, United States|Cumming, Georgia, United States|Macon, Georgia, United States|Tucker, Georgia, United States|Boise, Idaho, United States|Coeur d'Alene, Idaho, United States|Jerseyville, Illinois, United States|Indianapolis, Indiana, United States|Munster, Indiana, United States|Bay City, Michigan, United States|Kalamazoo, Michigan, United States|Lansing, Michigan, United States|Mount Clemens, Michigan, United States|Ypsilanti, Michigan, United States|Minneapolis, Minnesota, United States|Columbia, Missouri, United States|Saint Louis, Missouri, United States|Kalispell, Montana, United States|Stony Brook, New York, United States|Rocky Mount, North Carolina, United States|Sanford, North Carolina, United States|Cincinnati, Ohio, United States|Zanesville, Ohio, United States|Bartlesville, Oklahoma, United States|Tulsa, Oklahoma, United States|Abington, Pennsylvania, United States|Langhorne, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Sayre, Pennsylvania, United States|York, Pennsylvania, United States|Rapid City, South Dakota, United States|Oak Ridge, Tennessee, United States|Amarillo, Texas, United States|Fort Sam Houston, Texas, United States|Houston, Texas, United States|Odessa, Texas, United States|San Antonio, Texas, United States|Danville, Virginia, United States|Puyallup, Washington, United States|Buenos Aires, Argentina|Caba, Argentina|Ciudad De Buenos Aires, Argentina|Cordooba, Argentina|Corrientes, Argentina|Córdoba, Argentina|La Plata, Argentina|Mar Del Plata, Argentina|Resistencia, Argentina|Rosario, Argentina|Salta, Argentina|San Martín, Argentina|Santa Fe, Argentina|Brisbane, Australia|Cairns, Australia|Chermside, Australia|Elizabeth Vale, Australia|Herston, Australia|Hobart, Australia|Launceston, Australia|Liverpool, Australia|Murdoch, Australia|Nambour, Australia|New Lambton Heights, Australia|Antwerpen, Belgium|Bonheiden, Belgium|Brasschaat, Belgium|Brugge, Belgium|Edegem, Belgium|Genk, Belgium|Gent, Belgium|Huy, Belgium|Liège, Belgium|Mol, Belgium|Roeselare, Belgium|Ronse, Belgium|Turnhout, Belgium|Belo Horizonte, Brazil|Blumenau, Brazil|Campina Grande Do Sul, Brazil|Campinas, Brazil|Curitiba, Brazil|Marília, Brazil|Passo Fundo, Brazil|Porto Alegre, Brazil|Recife, Brazil|Salvador, Brazil|São José Do Rio Preto, Brazil|São Paulo, Brazil|Tatuí, Brazil|Uberlândia, Brazil|Votuporanga, Brazil|Blagoevgrad, Bulgaria|Burgas, Bulgaria|Haskovo, Bulgaria|Lovech, Bulgaria|Pazardzhik, Bulgaria|Pleven, Bulgaria|Ruse, Bulgaria|Sandanski, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Edmonton, Alberta, Canada|New West Minister, British Columbia, Canada|Victoria, British Columbia, Canada|London, Ontario, Canada|Newmarket, Ontario, Canada|Sudbury, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Saint-Charles-Borromée, Quebec, Canada|Sherbrooke, Quebec, Canada|Québec, Canada|Brno, Czechia|Kolin Iii., Czechia|Ostrava, Czechia|Plzen-Bory, Czechia|Praha 1, Czechia|Praha 2, Czechia|Trebic, Czechia|Znojmo, Czechia|Herlev, Denmark|Koge, Denmark|Silkeborg, Denmark|Besançon, France|Chambray Les Tours, France|Jossigny, France|Le Coudray, France|Lyon, France|Montauban, France|Nantes Cedex 1, France|Nantes, France|Périgueux, France|Balatonfüred, Hungary|Budapest, Hungary|Debrecen, Hungary|Gyula, Hungary|Győr, Hungary|Kaposvar, Hungary|Kecskemét, Hungary|Nyíregyháza, Hungary|Szolnok, Hungary|Székesfehérvár, Hungary|Gifu, Japan|Kagawa, Japan|Kitakyushu-City, Japan|Kobe-Shi, Japan|Kumamoto-Shi, Japan|Kumamoto, Japan|Matsue-Shi, Japan|Nagano-Shi, Japan|Osaka-Shi, Japan|Sayama-Shi, Japan|Tokyo, Japan|Uwajima-Shi, Japan|Yokohama, Japan|Yonago, Japan|Yotsui 2-8-1, Japan|Gwangju, Korea, Republic of|Incheon, Korea, Republic of|Seongnam, Korea, Republic of|Seoul, Korea, Republic of|Suwon, Korea, Republic of|Amersfoort, Netherlands|Amsterdam, Netherlands|Blaricum, Netherlands|Den Haag, Netherlands|Den Helder, Netherlands|Gouda, Netherlands|Groningen, Netherlands|Hoofddorp, Netherlands|Hoogeveen, Netherlands|Nijmegen, Netherlands|Rotterdam, Netherlands|S-Hertogenbosch, Netherlands|Schiedam, Netherlands|Bielsko-Biala, Poland|Bytom, Poland|Chrzanow, Poland|Dabrowa Gornicza, Poland|Gdynia, Poland|Grodzisk Mazowiecki, Poland|Inowrocław, Poland|Kedzierzyn-Kozle, Poland|Kielce, Poland|Koszalin, Poland|Krakow, Poland|Lodz, Poland|Nowy Targ, Poland|Nysa, Poland|Oswiecim, Poland|Polanica Zdroj, Poland|Pulawy, Poland|Tychy, Poland|Warszawa, Poland|Wloclawek, Poland|Barnaul, Russian Federation|Chita, Russian Federation|Ekaterinburg, Russian Federation|Ivanovo, Russian Federation|Kaliningrad, Russian Federation|Kemerovo, Russian Federation|Krasnodar, Russian Federation|Krasnoyarsk, Russian Federation|Moscow, Russian Federation|Nizhniy Novgorod, Russian Federation|Orenburg, Russian Federation|Penza, Russian Federation|Perm, Russian Federation|Rostov On Don, Russian Federation|Saint Petersburg, Russian Federation|Samara, Russian Federation|Syktyvkar, Russian Federation|Tyumen, Russian Federation|A Coruña, Spain|Almería, Spain|Barcelona, Spain|Madrid, Spain|Murcia, Spain|Málaga, Spain|Sant Boi De Llobregat, Spain|Tarragona, Spain|Ávila, Spain|Falun, Sweden|Jönköping, Sweden|Linköping, Sweden|Lund, Sweden|Stockholm, Sweden|Sundsvall, Sweden|Uppsala, Sweden|Örebro, Sweden|Östersund, Sweden|Adana, Turkey|Ankara, Turkey|Aydin, Turkey|Bursa, Turkey|Diyarbakir, Turkey|Eskisehir, Turkey|Istanbul, Turkey|Kahramanmaras, Turkey|Kocaeli, Turkey|Konya, Turkey|Sivas, Turkey|Cherkasy, Ukraine|Dnipropetrovsk, Ukraine|Kharkiv, Ukraine|Kyiv, Ukraine|Lutsk, Ukraine|Lviv, Ukraine|Odesa, Ukraine|Ternopil, Ukraine|Zaporizhzhia, Ukraine|Zhytomyr, Ukraine",,"https://ClinicalTrials.gov/show/NCT02293395"
1845,"NCT02023333","Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma",,"Active, not recruiting","No Results Available","Metastatic Colorectal Adenocarcinoma","Drug: Regorafenib","progression free survival|overall survival|disease control rate|duration of stable disease|toxicity","Memorial Sloan Kettering Cancer Center|Bayer|State University of New York - Downstate Medical Center|Queens Cancer Center of Queens Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","11","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13-211","December 2013","December 2020","December 2020","December 30, 2013",,"October 29, 2019","Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge, New Jersey, United States|Downstate Medical Center, Brooklyn, New York, United States|Memorial Sloan Kettering Cancer Center at Commack, Commack, New York, United States|Queens Cancer Center of Queens Hospital, Jamaica, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre, New York, United States|Memorial Sloan Kettering Cancer Center Sleepy Hollow, Sleepy Hollow, New York, United States",,"https://ClinicalTrials.gov/show/NCT02023333"
1846,"NCT01844947","Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract","VINSOR","Completed","No Results Available","Urothelial Carcinoma|Bladder Cancer|Renal Pelvis Cancer|Ureter Cancer|Urethra Cancer","Drug: Vinflunine|Drug: Sorafenib","Number of patients with adverse events","Dr Anders Ullén|Bayer|Pierre Fabre Laboratories|Nordic Urothelial Cancer Oncology Group|Karolinska University Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","22","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NUCOG III|2011-004289-14","May 2012","October 18, 2017","June 5, 2018","May 3, 2013",,"April 26, 2019","Department of Oncology, Aarhus University Hospital, Aarhus, Denmark|Department of Oncology, Rigshospitalet, Copenhagen, Denmark|Department of Oncology, Karolinska University Hospital, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT01844947"
1847,"NCT02833948","Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)","GALILEO-4D","Completed","Has Results","Aortic Valve Stenosis|Cardiovascular Diseases|Heart Valve Diseases|Ventricular Outflow Obstruction|Thrombosis","Drug: Acetylsalicylic acid|Drug: Clopidogrel|Drug: Rivaroxaban","Rate of Patients With at Least One Prosthetic Leaflet With >50% Motion Reduction as Assessed by Cardiac 4DCT-scan|The Rate of Prosthetic Leaflets With > 50% Motion Reduction as Assessed by Cardiac 4DCT-scan|The Rate of Patients With at Least One Prosthetic Leaflet With Thickening as Assessed by Cardiac 4DCT-scan|The Rate of Prosthetic Leaflets With Thickening as Assessed by Cardiac 4DCT-scan|Aortic Transvalvular Mean Pressure Gradient (mmHg) as Determined by Transthoracic Echocardiography.|Effective Orifice Area (cm^2) as Determined by Transthoracic Echocardiography.|Death Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (HALT) - as Exploratory Analysis.|Death Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (RLM)- as Exploratory Analysis.|Thromboembolic Event Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (HALT)- as Exploratory Analysis.|Thromboembolic Event Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (RLM) - as Exploratory Analysis.","ECRI bv|Rigshospitalet, Denmark|Bayer|Cardialysis BV","All","18 Years and older   (Adult, Older Adult)","Phase 3","231","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","ECRI 006 - H-15016807","May 2016","December 2018","March 6, 2019","July 14, 2016","January 18, 2020","January 18, 2020","Cedars Sinai Medical Center, Los Angeles, California, United States|Mount Sinai M.C, New York, New York, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Texas, Health Science Center, Houston, Texas, United States|University of Alberta Hospital, Edmonton, Canada|Providence Health Care, Vancouver, Canada|Aarhus university hospital, Aarhus, Denmark|Rigshospitalet, Copenhagen, Denmark|Odense University Hospital, Odense, Denmark|Kerckhoff Klinik GmbH, Bad Nauheim, Germany|Charité- Universitätsmedizin Berlin - Campus Mitte, Berlin, Germany|Deutsches Herzzentrum Berlin, Berlin, Germany|St. Johannes Hospital, Dortmund, Germany|Universitätsklinikum Erlangen, Erlangen, Germany|Universitätsklinikum Schleswig-Holstein, Kiel, Germany|Medicin Herzzentrum Lahr/Baden, Lahr, Germany|Herzzentrum Leipzig - Universitätsklinik, Leipzig, Germany|Deutsches Herzzentrum München, München, Germany|Academic Medical Center, Amsterdam, Netherlands|Amphia Zienkenhuis, Breda, Netherlands|Erasmus M.C, Rotterdam, Netherlands|Skåne University Hospital, Lund, Sweden|Karolinska University Hospital, Stockholm, Sweden|University Hospital Basel, Basel, Switzerland|Inselspital, Bern, Switzerland","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT02833948/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02833948"
1848,"NCT02735551","LARC Forward Contraceptive Counseling at MHCC",,"Terminated","Has Results","Contraception","Drug: Long Acting Reversible Contraception (LARC)|Other: Referral for Long Acting Reversible Contraception (LARC)|Other: Prescription for Short-Acting Hormonal Contraception","Number of Participants Reporting Ongoing Use and Satisfaction","Oregon Health and Science University|Merck Sharp & Dohme Corp.|Bayer|Society of Family Planning","Female","17 Years to 30 Years   (Child, Adult)","Phase 4","3","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","OHSU IRB 15715","April 2016","March 13, 2017","March 31, 2017","April 12, 2016","January 3, 2019","November 12, 2019","Mount Hood Community College, Gresham, Oregon, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT02735551/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02735551"
1849,"NCT02570737","Latin American Pulmonary Hypertension Registry","RELAHP","Unknown status","No Results Available","Pulmonary Hypertension",,"Major adverse cardiovascular events|Cardiovascular death","Asociacion Latinoamericana de Torax|Actelion|Bayer|Ferrer Internacional S.A.","All","Child, Adult, Older Adult",,"500","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","Cardioneumology","April 2014","July 2018","April 2019","October 7, 2015",,"January 24, 2017","Hospital Universitario, Fundación Favaloro, Buenos Aires, Argentina|Hospital Clementino Fraga - Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil|Instituto Nacional del Tórax, Universidad de Chile, Santiago, Chile|Clínica Cardio Vid, Medellín, Colombia|Honduras Medical Center, Tegucigalpa, Honduras|Instituto Nacional de Cardiologia ""Dr. Ignacio Chavez"", Mexico city, Tlalpan, Mexico|Hospital Maciel, Montevideo, Uruguay|Hospital de Clínicas Caracas, Caracas, Venezuela",,"https://ClinicalTrials.gov/show/NCT02570737"
1850,"NCT01254890","Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome",,"Completed","Has Results","Leukemia","Drug: Azacitidine|Drug: Sorafenib","Phase I: Maximum Tolerated Dose (MTD) of Sorafenib Given With Azacitidine|Phase II: Number of Participants With Response","M.D. Anderson Cancer Center|Bayer|Onyx Therapeutics, Inc.|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","60","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2010-0511|NCI-2011-00257","January 2011","March 2015","March 2015","December 7, 2010","May 6, 2016","May 6, 2016","UT MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01254890"
1851,"NCT02168829","Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial","OCEAN","Recruiting","No Results Available","Atrial Fibrillation|Stroke","Drug: Rivaroxaban|Drug: Acetylsalicylic acid","Composite of stroke, systemic embolism and covert embolic stroke as detected by cerebral MRI|Clinical, overt stroke|Incidence of one or more covert MRI stroke(s) >15 mm|Composite of all major and minor bleeding|Major bleeding only|Minor bleeding only|Intracranial hemorrhage|Transient ischemic attack|All-cause mortality|Net clinical benefit based on reduction in stroke/TIA rate compared to major bleeding events.|Occurrence of non-primary endpoint MRI changes from baseline to final scan|Neuropsychological testing|Health economics","Ottawa Heart Institute Research Corporation|Canadian Institutes of Health Research (CIHR)|Bayer|Biotronik Canada Inc","All","18 Years and older   (Adult, Older Adult)","Phase 4","1572","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","327494","January 2016","September 2021","December 2021","June 20, 2014",,"May 3, 2019","Canberra Hospital, Canberra, Australian Capital Territory, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|The Alfred Melbourne, Melbourne, Victoria, Australia|Melbourne Health, Melbourne, Victoria, Australia|Heart Rhythm Clinic, Nedlands, Western Australia, Australia|Foothills Medical Centre, Calgary, Alberta, Canada|Royal Columbian/Fraser Clinical Trials, New Westminster, British Columbia, Canada|St. Paul's Hospital, Vancouver, British Columbia, Canada|Victoria Cardiac Arrhythmia Trials Inc., Victoria, British Columbia, Canada|Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|Hamilton Health Sciences Centre, Hamilton, Ontario, Canada|Kingston General Hospital, Kingston, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|Southlake Regional Health Centre, Newmarket, Ontario, Canada|University of Ottawa Heart Institute, Ottawa, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Centre Hospitalier de L'Universite de Montreal (CHUM), Montreal, Quebec, Canada|McGill University Health Centre, Montreal, Quebec, Canada|Montreal Health Institute, Montreal, Quebec, Canada|Institut Universitarie de Cardiologie et de Pneumologie de Quebec, Quebec City, Quebec, Canada|Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada|Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China|Klinikum Coburg, Coburg, Bayern, Germany|Kerckhoff Klinik, Bad Nauheim, Hessen, Germany|Herz- und Diabeteszentrum NRW Ruhr-Universitat Bochum, Bad Oeynhausen, Nordrhein-westfalen, Germany|Klinikum Bielefeld, Bielefeld, Nordrhein-westfalen, Germany|Elektrophysiologie GFO-Kliniken Bonn, Bonn, Nordrhein-westfalen, Germany|Herzzentrum der Universitat Koln, Köln, Nordrhein-westfalen, Germany|Universitatsklinikum Munster Department fur Kardiologie und Angiologie, Munster, Nordrhein-westfalen, Germany|Segeberger Liniken, Bad Segeberg, Schleswig-Holstein, Germany|UKSH Lubeck, Lubeck, Schleswig-Holstein, Germany|Charite - Campus Virchow Klinikum, Berlin, Germany|Universitares Herzzentrum Hamburg, Hamburg, Germany|Herzzentrum Leipzig, Leipzig, Germany|Galilee Medical Centre, Nahariya, Israel",,"https://ClinicalTrials.gov/show/NCT02168829"
1852,"NCT00703365","Efficacy and Safety of Sorafenib (Nexavar) in Combination With Gemcitabine in Advanced Hepatocellular Carcinoma (HCC)",,"Completed","No Results Available","Carcinoma, Hepatocellular","Drug: Sorafenib and Gemcitabine","To evaluate the efficacy (progression free survival (PFS)) of sorafenib in patients with advanced/unresectable HCC.|To evaluate overall, survival, overall response rate (RECIST), time to progression (TTP), disease control rate (DCR) and side-effect profile of sorafenib in combination with gemcitabine in patients suffering from HCC.","Mahidol University|Bayer|Chulalongkorn University|Bumrungrad International Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","45","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12849","February 2008","January 2010","August 2011","June 23, 2008",,"August 29, 2011","Department of Medicine, Siriraj Hospital, Bangkoknoi, Bangkok, Thailand|Medical Oncology Unit, Chulalongkorn Hospital, Patumwan, Bangkok, Thailand|Horizon Regional Cancer Center, Bamrungrad Hospital, Sukhumvit 3, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT00703365"
1853,"NCT00683202","Low-Dose Aspirin in in Vitro Fertilization (IVF) and Intracytoplasmic Sperm Injection (ICSI) Treatments",,"Completed","No Results Available","Pregnancy|Miscarriage Less Than 12 Gestational Weeks|Extrauterine Pregnancy|Preeclampsia|Intrauterine Fetal Growth Restriction","Drug: Acetylsalicylic acid|Drug: Placebo","Pregnancy rate|Uterine artery and spiral artery pulsatility index values","University of Oulu|Bayer|Kuopio University Hospital|Tampere University","Female","18 Years to 39 Years   (Adult)","Not Applicable","374","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","56/2001","March 2001","March 2006","March 2006","May 23, 2008",,"May 23, 2008","University Hospital of Oulu, Department of Obstetrics and Gynecology, Oulu, Finland",,"https://ClinicalTrials.gov/show/NCT00683202"
1854,"NCT03076203","Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)",,"Recruiting","No Results Available","Prostate Carcinoma Metastatic to the Bone|Stage IV Prostate Adenocarcinoma|Hormone-refractory Prostate Cancer","Drug: Niraparib|Radiation: Radium Ra 223 Dichloride","Maximum tolerated dose of niraparib to combine with radium Ra 223 dichloride based on dose limiting toxicities graded by National Cancer Institute, Common Toxicity Criteria, version 4.0","Sidney Kimmel Cancer Center at Thomas Jefferson University|Janssen, LP|Prostate Cancer Clinical Trials Consortium|Bayer|Thomas Jefferson University","Male","18 Years and older   (Adult, Older Adult)","Phase 1","6","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16G.085","September 22, 2017","November 2020","November 2021","March 10, 2017",,"June 13, 2019","University of Alabama, Birmingham, Alabama, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Tulane University, New Orleans, Louisiana, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Reading Hospital, West Reading, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03076203"
1855,"NCT01534260","Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype",,"Completed","Has Results","Acute Myeloid Leukemia","Drug: sorafenib, vorinostat and bortezomib","Number of Patients With Dose Limiting Toxicity|Phase II - Percentage of Patients With a Partial Response or Greater|Phase II - Time to Relapse|Phase II - Treatment-Related Adverse Events Grade 3 or Higher","Hamid Sayar|Millennium Pharmaceuticals, Inc.|Bayer|Merck Sharp & Dohme Corp.|Indiana University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","37","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IUCRO-0327|1110007281","February 10, 2012","August 29, 2016","February 13, 2017","February 16, 2012","August 17, 2018","August 17, 2018","Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT01534260"
1856,"NCT00417248","Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer",,"Terminated","Has Results","Non-Small Cell Lung Cancer","Drug: Cisplatin|Drug: Etoposide|Procedure: Radiotherapy|Drug: Sorafenib","Time to Disease Progression (TTP)|Overall Survival","Nasser Hanna, M.D.|Bayer|Amgen|Walther Cancer Institute|Hoosier Cancer Research Network","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","8","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HOG LUN06-107","June 2007","April 2008","April 2008","December 29, 2006","July 25, 2016","July 25, 2016","Medical & Surgical Specialists, LLC, Galesburg, Illinois, United States|Fort Wayne Oncology & Hematology, Inc, Fort Wayne, Indiana, United States|Center for Cancer Care at Goshen Health System, Goshen, Indiana, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|Horizon Oncology Center, Lafayette, Indiana, United States|Medical Consultants, P.C., Muncie, Indiana, United States|Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States|Oncology Partners Network, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00417248"
1857,"NCT00219908","Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis",,"Terminated","No Results Available","Relapsing-Remitting Multiple Sclerosis","Drug: Mitoxantrone","Time to confirmed progression of at least one EDSS point during the 3 years of the study.|- percentage of patients with confirmed progression of at least one point EDSS (confirmed at 3 and 6 months) during the 3 years of the study,|- annual rate of relapse;|- percentage of relapse-free patients during the study period,|- quality of life,|- percentage of patients without evidence of disease activity on serial MRIs at months 9, 24 and 36 (number of contrast-enhanced lesions on the annual MRIs, change in lesion burden).","Rennes University Hospital|Bayer|Wyeth is now a wholly owned subsidiary of Pfizer|Farmades, Italy",,"18 Years to 45 Years   (Adult)","Phase 2","124","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","981166","July 1999",,"June 2006","September 22, 2005",,"December 22, 2005","Hôpital Cote de Nacre, Caen, France|Hôpital Gabriel Montpied, Clermont-Ferrand, France|CHU Henri Mondor, Creteil, France|Hôpital Général, Dijon, France|CHU Limoges, Limoges, France|Institut Catholique de Lille, Lomme, France|Pierre Weitheimer Hospital, Lyon, France|Chu Timone, Marseille, France|Centre Guy de Chauliac, Montpellier, France|CHU Hôpital Central, Nancy, France|CHU, Nice, France|CHU Pitié-Salpétrière, Paris, France|Hôpital Saint-Anne, Paris, France|Centre Fondation Rotschild, Paris, France|Tenon Hospital, Paris, France|CHU Strasbourg, Strasbourg, France|CHU Purpan, Toulouse, France|Psichiatriche dell'Università di Bari, Policlinico, Bari, Italy|Dipartimento di Scienze Neurologiche e Psichiatriche, Firenze, Italy|Hospedal Civile, Gallarate, Italy|Neuroriabilitazione dell'Università, Genova, Italy|Fondazionz SAN Raffaele del monte tabor, Milano, Italy|Clinica Neurologica Università di Torino, Torino, Italy",,"https://ClinicalTrials.gov/show/NCT00219908"
1858,"NCT02283749","BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases",,"Completed","Has Results","Non Small Cell Lung Cancer With Bone Metastatses","Biological: Xofigo","Number of Symptomatic Skeletal Events (SSE) in Patients Receiving Xofigo With NSCLC and Bone Metastases|Progression-free Survival of Patients With NSCLC and Bone Metastases and Stable or Responding Disease After Front-line Chemotherapy Treated With Xofigo|Overall Survival of Patients With NSCLC and Bone Metastases and Stable or Responding Disease After Front-line Chemotherapy Treated With Xofigo","Angela Taber MD|Rhode Island Hospital|The Miriam Hospital|Bayer|Brown University","All","18 Years and older   (Adult, Older Adult)","Phase 2","5","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BrUOG 301","September 2015","July 5, 2018","November 13, 2018","November 5, 2014","June 8, 2018","January 10, 2019","Rhode Island Hospital and The Miriam Hospital, Providence, Rhode Island, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02283749/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02283749/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02283749"
1859,"NCT02072408","Efficacy and Safety of Intravitreal Vascular Endothelial Growth Factor Trap-eye in Patients With Polyploidal Choroidal Vasculopathy",,"Completed","No Results Available","Polypoidal Choroidal Vasculopathy Without Active Polyp","Drug: aflibercept","Change of best-corrected visual acuity (ETDRS letters)|presence of subretinal hemorrhage|presence of fluid in macula evidenced by optical coherence tomography|change of indocyanine green angiography|Number of eyes which need rescue treatment (photodynamic therapy)|safety outcomes","Samsung Medical Center|Seoul National University Bundang Hospital|Kim's Eye Hospital|Bayer","All","19 Years and older   (Adult, Older Adult)","Phase 4","46","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2013-10-044-002","February 2014","November 2, 2017","November 2, 2017","February 26, 2014",,"September 5, 2018","Seoul National University Bundang Hospital, Seongnam, Gyunggi-do, Korea, Republic of|Konyang University Kim's Eye Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02072408"
1860,"NCT01850095","The Influence of Peripheral Androgen Conversion at Women Adult Acne",,"Unknown status","No Results Available","Acne|Quality of Life","Drug: treatment azelaic acid (azelan)|Drug: dorspirenone/ethynil estradiol","Clinical evaluation of the treatment group|Photographic study of the treatment group","Marco Alexandre Dias da Rocha|Fleury|Associacao Fundo de Incentivo a Psicofarmcologia|Bayer|Federal University of São Paulo","Female","26 Years to 44 Years   (Adult)","Not Applicable","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","1622/11","March 2012","June 2013","January 2015","May 9, 2013",,"May 9, 2013","Federal University of São Paulo-Dermatology, são Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT01850095"
1861,"NCT00632541","A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer",,"Terminated","Has Results","Metastatic Breast Cancer","Drug: Sorafenib|Drug: Bevacizumab|Other: Imaging","Progression-Free Survival|Assess the Clinical Benefit Response: the Proportion of Patients With Clinical Benefit (CR+PR+SD > 6 Months Duration) Will be Assessed at the Completion of the Study.|Assess the Overall Response Rate.|Determine the Adverse Event Profile of Sorafenib Combined With Bevacizumab in This Patient Population.","Hoosier Cancer Research Network|Genentech, Inc.|Bayer|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","18","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BRE06-109","October 2007","March 2009","March 2009","March 10, 2008","January 7, 2016","February 14, 2018","Medical & Surgical Specialists, LLC, Galesburg, Illinois, United States|Oncology Hematology Associates of SW Indiana, Evansville, Indiana, United States|Fort Wayne Oncology & Hematology, Inc, Fort Wayne, Indiana, United States|Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|Quality Cancer Center (MCGOP), Indianapolis, Indiana, United States|Arnett Cancer Care, Lafayette, Indiana, United States|Horizon Oncology Center, Lafayette, Indiana, United States|Medical Consultants, P.C., Muncie, Indiana, United States|Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States|Ireland Cancer Center - University Hospitals of Cleveland, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00632541"
1862,"NCT00496379","ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases",,"Terminated","Has Results","Breast Cancer|CNS Disease","Drug: ZK219477","Objective Response Rate in the Central Nervous System (CNS)|Number of Subjects With Adverse Events (Any Grade)|Objective Response Rate in Non-Central Nervous System (CNS) Sites|Time to Progression at Any Site.|Clinical Benefit Rate.","Nancy Lin, MD|Brigham and Women's Hospital|Bayer|Breast Cancer Research Foundation|Dana-Farber Cancer Institute","Female","18 Years and older   (Adult, Older Adult)","Phase 2","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","06-268","July 2007","October 2009","January 2012","July 4, 2007","March 12, 2013","March 14, 2013","Dana-Farber Cancer Institute, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00496379"
1863,"NCT00405366","Sorafenib in Treating Patients Undergoing Surgery for Stage II, Stage III, or Stage IV Kidney Cancer","NRR","Completed","No Results Available","Kidney Cancer","Drug: sorafenib tosylate","Number of subjects experiencing adverse events while taking sorafenib prior to nephrectomy|Feasibility of neoadjuvant systemic therapy prior to nephrectomy|Response in primary renal tumors|Effects of sorafenib tosylate therapy on gene expression, protein expression, and metabolic profile","UNC Lineberger Comprehensive Cancer Center|Doris Duke Charitable Foundation|Bayer|Amgen","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LCCC 0603|CDR0000550127","November 2006","June 2009","July 2015","November 30, 2006",,"April 18, 2017","Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00405366"
1864,"NCT00178464","Aspirin Prophylaxis in Sickle Cell Disease","START","Completed","Has Results","Sickle Cell Disease","Drug: aspirin","Number of Serious Adverse Events|Number of Adverse Events|# of Subjects Recruited Over Time, Screening Failures, Withdrawal Rates;Compliance (Pill Counts & Labs);Changes in Performance on Neurocognitive Tests; Changes in MRI/MRA; Changes in TCD;Incidences of Stroke, Acute Chest Crises, and Pain Crises","University of Rochester|University of Miami|Bayer|National Institute of Neurological Disorders and Stroke (NINDS)","All","2 Years to 7 Years   (Child)","Phase 1","11","Other|Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09661|5R01NS045948-03","March 2005","April 2009","November 2009","September 15, 2005","January 4, 2012","November 6, 2017",,,"https://ClinicalTrials.gov/show/NCT00178464"
1865,"NCT00164463","TBTC Study 27/28 PK: Moxifloxacin Pharmacokinetics During TB Treatment",,"Completed","No Results Available","Tuberculosis","Drug: Moxifloxacin|Drug: Isoniazid","Compare in healthy volunteers the pharmacokinetics of moxifloxacin alone versus moxifloxacin administered with rifampin.|Compare the pharmacokinetics of moxifloxacin among patients with tuberculosis being treated with multidrug therapy (isoniazid or ethambutol, rifampin, and pyrazinamide) to those of healthy volunteers receiving moxifloxacin plus rifampin.|Determine variation of moxifloxacin pharmacokinetics (PK) among patients with pulmonary TB during treatment.|Compare serum concentrations of isoniazid rifampin and pyrazinamide among patients being treated with moxifloxacin versus patients being treated with ethambutol as the fourth drug in multidrug treatment.|Compare serum concentrations of rifampin, pyrazinamide and ethambutol among patients being treated with moxifloxacin versus patients being treated with isoniazid as the fourth drug|Determine the association between polymorphisms of MDR1 genotype (P-glycoprotein) and rifampin PK parameters.|Determine the effect of polymorphisms of MDR1 genotype and/or rifampin PK on isoniazid PK parameters adjusted for N-acetyltransferase genotype (NAT2).|Determine the effects of polymorphisms of MDR1 and UGT genotypes on moxifloxacin PK parameters.|Determine by multivariate regression analyses the associations between moxifloxacin or rifampin PK parameters and markers of disease severity.","Centers for Disease Control and Prevention|US Department of Veterans Affairs|Bayer|National Institutes of Health (NIH)","All","18 Years and older   (Adult, Older Adult)","Phase 2","72","U.S. Fed|Industry|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CDC-NCHSTP-4222","July 2004","August 2007","August 2007","September 14, 2005",,"June 8, 2011","University of Southern California Medical Center, Los Angeles, California, United States|Johns Hopkins University, Baltimore, Maryland, United States|Duke University Medical Center, Durham, North Carolina, United States|University of North Texas Health Science Center, Fort Worth, Texas, United States|Houston Veterans Administration Medical Center, Houston, Texas, United States|Audie L Murphy Memorial Veterans Administration Medical Center, San Antonio, Texas, United States|University of British Columbia, Vancouver, British Columbia, Canada|Makerere University Medical School, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT00164463"
1866,"NCT00107081","Low-risk Fever and Neutropenia in Children With Cancer: Safety and Efficacy of Oral Antibiotics in an Outpatient Setting",,"Terminated","No Results Available","Fever|Neutropenia|Cancer","Drug: ciprofloxacin and amoxicillin|Procedure: Outpatient management|Drug: i.v. antibiotics|Procedure: inpatient management","Safety: No serious medical complication due to infection (death, treatment in ICU [Intensive Care Unit], potentially life-threatening complication) (non-inferiority-design, limit 3.5%)|Efficacy: Response without rehospitalization or changing randomized antibiotics (non-inferiority design, limit 10%)|Improved prediction of low-risk episodes of fever and neutropenia|Description of characteristics of low-risk episodes of fever and neutropenia|Description of characteristics of high-risk episodes of fever and neutropenia (observational study part)","Swiss Pediatric Oncology Group|Swiss Cancer League|Bayer|GlaxoSmithKline","All","1 Year to 18 Years   (Child, Adult)","Phase 3","70","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SPOG 2003 FN|Umbrella Network Trial 2004.3|OCS - 01466-02-2004","January 2004","December 2007","December 2007","April 5, 2005",,"December 24, 2014","Pediatric Hematology/Oncology, University Children's Hospital, Bonn, Germany|Pediatric Hematology/Oncology, University Children's Hospital, Duesseldorf, Germany|Pediatric Hematology/Oncology, University Children's Hospital, Freiburg, Germany|Pediatric Hematology/Oncology, University Children's Hospital von Hauner, Munich, Germany|Pediatric Hematology/Oncology, University Hospital St. Hedwig, Regensburg, Germany|Pediatric Hematology/Oncology, University Children's Hospital, Groningen, Netherlands|Pediatric Hematology/Oncology, University Children's Hospital, Basel, Switzerland|Pediatric Hematology/Oncology, University Children's Hospital, Bern, Switzerland|Pediatric Hematology/Oncology, University Children's Hospital, Geneva, Switzerland|Pediatric Hematology/Oncology, University Children's Hospital, Lausanne, Switzerland|Pediatric Hematology/Oncology, Children's Hospital, Lucerne, Switzerland|Pediatric Hematology/Oncology, University Children's Hospital, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT00107081"
1867,"NCT00559286","Effect of the Known Antihypertensive Drug Telmisartan on Red Blood Cells and Circulation in the Smallest Blood Vessels","ITEM","Terminated","No Results Available","Arterial Hypertension|Diabetes Mellitus Type 2 IRC or NIR","Drug: Telmisartan","Changes in Elongation-Index (EI) Method: To determine the elongation index (EI) we use the Laser assisted optical rotational cell analyzer (Lorrca).|Improvement of microcirculatory perfusion (using laser doppler measurement)|Improvement of endothelial function (using ultrasound measurements during flow mediated dilation)|Increase in the total blood born NO pool (using reductive gase phase chemiluminescence|Decrease of RBC aggregation (using Laser assisted optical rotational cell analyzer (Lorrca)","RWTH Aachen University|CTCA|Heidelberg University|Bayer","Male","18 Years and older   (Adult, Older Adult)","Phase 4","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AIX-MK-01|EUDRA CT No 2007-002765-12","December 2007","January 2009","January 2009","November 16, 2007",,"January 29, 2009","University Hospital, Aachen, NRW, Germany",,"https://ClinicalTrials.gov/show/NCT00559286"
1868,"NCT00501644","Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer",,"Completed","Has Results","Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer","Drug: Carboplatin|Drug: GM-CSF (Sargramostim)|Drug: Interferon Gamma","Number of Patients With Response","M.D. Anderson Cancer Center|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma|Bristol-Myers Squibb|InterMune","Female","Child, Adult, Older Adult","Phase 2","59","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ID02-231","January 2003","January 2009","January 2009","July 16, 2007","January 10, 2011","August 7, 2012","U.T.M.D. Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00501644"
1869,"NCT00712790","Study of SIR-Spheres Plus Sorafenib as 1st Line Treatment for Non-resectable Primary Hepatocellular Carcinoma (HCC)",,"Completed","No Results Available","Hepatocellular Carcinoma","Drug: Sorafenib|Radiation: SIR-Spheres","Toxicity and safety|Tumour response rate (liver ± any site).|Progression free survival at any site.|Progression free survival in the liver.|Survival|Hepatic and extra-hepatic recurrence rate.|Quality of life.|Rate of downstaging to surgical resection or ablative therapy.","Singapore Clinical Research Institute|National Medical Research Council (NMRC), Singapore|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma|Sirtex Medical","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","35","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NMRC - AHCC05","June 2008","June 2009","April 2014","July 10, 2008",,"January 6, 2016","Seoul National University Bundang Hospital, Seoul, Korea, Republic of|Selayang Hospital, Selangor, Malaysia|Yangon GI & Liver Centre, Yangon, Myanmar|Singapore General Hospital, Singapore, Singapore|National Cancer Centre, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT00712790"
1870,"NCT04136353","Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate","DASL-HiCaP","Not yet recruiting","No Results Available","Prostate Cancer","Drug: Darolutamide|Drug: Placebo oral tablet|Drug: Luteinizing Hormone-Releasing Hormone Analog|Radiation: External Beam Radiotherapy","Metastasis-free survival|Overall survival|Prostate cancer-specific survival|PSA-progression free survival|Time to subsequent hormonal therapy|Time to castration-resistance|Frequency and severity of adverse events (CTCAE V5.0)|Health-related quality of life|Fear of cancer recurrence","University of Sydney|Australian and New Zealand Urogenital and Prostate Cancer Trials Group|Bayer|Cancer Trials Ireland|Canadian Cancer Trials Group","Male","18 Years and older   (Adult, Older Adult)","Phase 3","1100","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ANZUP1801|U1111-1239-0771","January 31, 2020","January 31, 2028","July 31, 2028","October 23, 2019",,"October 23, 2019",,,"https://ClinicalTrials.gov/show/NCT04136353"
1871,"NCT01490203","Evaluation of Remnant Liver Function Using Primovist-enhanced MRI Before Resection/Ablation of Hepatocellular Carcinoma","LiFE","Completed","No Results Available","Carcinoma, Hepatocellular|Liver Dysfunction","Drug: Gd-EOB-DTPA|Procedure: MRI","Correlation of hepatic extraction fraction (HEF) of future remnant liver function (RLF) obtained from Gd-EOB-DTPA enhanced MRI with postoperative ICG R15 clearance test results|Correlation of various functional and volumetric parameters derived from Gd-EOB-DTPA enhanced MRI and clinical liver function tests obtained before and after surgical resection|Analysis of clinical and MRI parameters of postoperative complication and morbidity|Exploratory analysis of MRI parameters and ICG R15 derived from potential liver donors","Seoul National University Hospital|Bayer|Seoul St. Mary's Hospital|Asan Medical Center|Chonnam National University Hospital","All","18 Years and older   (Adult, Older Adult)",,"71","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","LIFE_ISS_2011","December 2011","February 2014","December 2016","December 12, 2011",,"March 23, 2018","Cheonnam University Hwasun Hospital, Hwasun-Gun, Cheonnam Province, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01490203"
1872,"NCT03836339","Assessment of Atrial Fibrillation in Emergency Department","ACFA","Active, not recruiting","No Results Available","Atrial Fibrillation",,"atrial fibrillation type|Troponin value|Brain Natriuretic Peptide (BNP/proBNP) value|Renal Clearance|cardiac echography|antiarythmic drugs|anticoagulant strategy|mortality|atrial fibrillation incidence|stroke incidence|myocardial infarction incidence|hemorrhagic events","RESCUe - RESeau Cardiologie Urgence / RESUVal - RESeau des Urgences de la vallée du Rhône|French Cardiology Society|French Society of Emergency Medicine|Bayer|Boehringer Ingelheim","All","18 Years and older   (Adult, Older Adult)",,"1575","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","2018ACFA10-11","October 1, 2018","December 31, 2019","December 31, 2019","February 11, 2019",,"February 11, 2019","Lucien Hussel Hospital, Vienne, France",,"https://ClinicalTrials.gov/show/NCT03836339"
1873,"NCT01633398","ASIAN HF Registry, A Prospective Observational Study","ASIANHF","Active, not recruiting","No Results Available","Heart Failure","Genetic: Saliva Genetic testing","Incidence (burden) of Sudden Cardiac Deaths (SCD) in Asian patients with HF followed in a representative setting of Asian cardiology centers|Risk factors for SCD among Asian patients with HF|Burden and risk factors of outcomes other than SCD (all-cause and cause-specific mortality and hospitalization)|Sociocultural barriers to device therapy among Asian patients|Genetic variants between the 2 phenotypes of HFrEF Vs HFpEF","Carolyn Lam|Boston Scientific Corporation|Bayer|Translational & Clinical Research by NMRC Singapore|ATTRaCT program by A*STAR BMRC Singapore|National University Health System, Singapore","All","18 Years to 100 Years   (Adult, Older Adult)",,"6377","Other|Industry","Observational","Observational Model: Other|Time Perspective: Prospective","ASIAN HF Registry","September 2012","February 2020","February 2020","July 4, 2012",,"August 24, 2018","Zhongshan Hospital Fudan University, Beijing, China|The Chinese University of Hong Kong, Hong Kong, Hong Kong|Medanta The Medicity, New Delhi, India|National Cardiovascular Centre Harapan Kita Hospital, Jakarta, Indonesia|National Cerebral and Cardiovascular Center, Tokyo, Japan|Korea University Anam Hospital, Seoul, Korea, Republic of|Institut Jantung Negara, Kuala Lumpur, Malaysia|Manila Doctors Hospital, Manila, Philippines|National University Heart Center, Singapore, Singapore|Ramathibodi Hospital, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT01633398"
1874,"NCT02927249","Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy",,"Recruiting","No Results Available","Node Positive HER2 Negative Breast Cancer","Other: Placebo|Drug: Aspirin","Invasive disease-free survival (iDFS)|Overall survival (OS)|Distant disease free survival (DDFS)|Incidence of cardiovascular disease (including cerebrovascular events, myocardial infarction, or coronary artery disease requiring stent placement, angioplasty, or bypass surgery)|Incidence of toxicities, graded using the National Cancer Institute's Common Terminology Criteria for Adverse Events version 4.3","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|United States Department of Defense|Bayer|Canadian Cancer Trials Group","All","18 Years to 69 Years   (Adult, Older Adult)","Phase 3","2936","Other|NIH|U.S. Fed|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","A011502|NCI-2016-00233|U10CA180821-01","December 2016","April 2021",,"October 7, 2016",,"January 9, 2020","University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States|Southern Cancer Center PC-Daphne, Daphne, Alabama, United States|Southern Cancer Center PC-Mobile, Mobile, Alabama, United States|Southern Cancer Center PC-Providence, Mobile, Alabama, United States|Southern Cancer Center PC-Springhill, Mobile, Alabama, United States|Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States|Anchorage Radiation Therapy Center, Anchorage, Alaska, United States|Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States|Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States|Alaska Women's Cancer Care, Anchorage, Alaska, United States|Anchorage Oncology Centre, Anchorage, Alaska, United States|Katmai Oncology Group, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|Fairbanks Memorial Hospital, Fairbanks, Alaska, United States|Arizona Breast Cancer Specialists-Gilbert, Gilbert, Arizona, United States|Virginia G Piper Cancer Care-Glendale, Glendale, Arizona, United States|Kingman Regional Medical Center, Kingman, Arizona, United States|Arizona Center for Cancer Care-Peoria, Peoria, Arizona, United States|Arizona Breast Cancer Specialists-Phoenix, Phoenix, Arizona, United States|Arizona Breast Cancer Specialists, Scottsdale, Arizona, United States|Arizona Breast Cancer Specialists-Scottsdale, Scottsdale, Arizona, United States|Virginia G Piper Cancer Care-Del Camino, Scottsdale, Arizona, United States|Arizona Center for Cancer Care-Surprise, Surprise, Arizona, United States|University of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona, United States|Banner University Medical Center - Tucson, Tucson, Arizona, United States|University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States|Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States|CHI Saint Vincent Cancer Center Hot Springs, Hot Springs, Arkansas, United States|Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro, Arkansas, United States|Kaiser Permanente-Anaheim, Anaheim, California, United States|Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States|PCR Oncology, Arroyo Grande, California, United States|Sutter Auburn Faith Hospital, Auburn, California, United States|Sutter Cancer Centers Radiation Oncology Services-Auburn, Auburn, California, United States|AIS Cancer Center at San Joaquin Community Hospital, Bakersfield, California, United States|Kaiser Permanente-Baldwin Park, Baldwin Park, California, United States|Kaiser Permanente-Bellflower, Bellflower, California, United States|Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States|Mills-Peninsula Medical Center, Burlingame, California, United States|Sutter Cancer Centers Radiation Oncology Services-Cameron Park, Cameron Park, California, United States|Mercy San Juan Medical Center, Carmichael, California, United States|Eden Hospital Medical Center, Castro Valley, California, United States|Enloe Medical Center, Chico, California, United States|Adventist Health Cancer Care Center Chico, Chico, California, United States|Community Cancer Institute, Clovis, California, United States|University Oncology Associates, Clovis, California, United States|City of Hope Corona, Corona, California, United States|UC Irvine Health Cancer Center-Newport, Costa Mesa, California, United States|Sutter Davis Hospital, Davis, California, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|Epic Care-Dublin, Dublin, California, United States|Kaiser Permanente Dublin, Dublin, California, United States|Mercy Cancer Center - Elk Grove, Elk Grove, California, United States|Bay Area Breast Surgeons Inc, Emeryville, California, United States|Epic Care Partners in Cancer Care, Emeryville, California, United States|Kaiser Permanente-Fontana, Fontana, California, United States|Kaiser Permanente-Fremont, Fremont, California, United States|Palo Alto Medical Foundation-Fremont, Fremont, California, United States|Washington Hospital, Fremont, California, United States|Kaiser Permanente-Fresno, Fresno, California, United States|Kaiser Permanente - Harbor City, Harbor City, California, United States|Kaiser Permanente-Irvine, Irvine, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Kaiser Permanente-Cadillac, Los Angeles, California, United States|Contra Costa Regional Medical Center, Martinez, California, United States|Fremont - Rideout Cancer Center, Marysville, California, United States|Mercy UC Davis Cancer Center, Merced, California, United States|Memorial Medical Center, Modesto, California, United States|Kaiser Permanente-Modesto, Modesto, California, United States|Palo Alto Medical Foundation-Camino Division, Mountain View, California, United States|Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View, California, United States|Sutter Cancer Research Consortium, Novato, California, United States|Alta Bates Summit Medical Center - Summit Campus, Oakland, California, United States|Bay Area Tumor Institute, Oakland, California, United States|Kaiser Permanente-Oakland, Oakland, California, United States|Kaiser Permanente-Ontario, Ontario, California, United States|Saint Joseph Hospital - Orange, Orange, California, United States|UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States|Palo Alto Medical Foundation Health Care, Palo Alto, California, United States|Kaiser Permanente - Panorama City, Panorama City, California, United States|Huntington Memorial Hospital, Pasadena, California, United States|Pomona Valley Hospital Medical Center, Pomona, California, United States|Eisenhower Medical Center, Rancho Mirage, California, United States|Kaiser Permanente-Redwood City, Redwood City, California, United States|Kaiser Permanente-Richmond, Richmond, California, United States|Kaiser Permanente-Riverside, Riverside, California, United States|Mercy Cancer Center - Rocklin, Rocklin, California, United States|Kaiser Permanente-Roseville, Roseville, California, United States|Sutter Cancer Centers Radiation Oncology Services-Roseville, Roseville, California, United States|Sutter Roseville Medical Center, Roseville, California, United States|Kaiser Permanente Downtown Commons, Sacramento, California, United States|Mercy Cancer Center - Sacramento, Sacramento, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|Kaiser Permanente-South Sacramento, Sacramento, California, United States|Kaiser Permanente - Sacramento, Sacramento, California, United States|Saint Helena Hospital, Saint Helena, California, United States|Salinas Valley Memorial, Salinas, California, United States|Kaiser Permanente-San Diego Mission, San Diego, California, United States|Kaiser Permanente-San Diego Zion, San Diego, California, United States|Sharp Memorial Hospital, San Diego, California, United States|Zuckerberg San Francisco General Hospital, San Francisco, California, United States|California Pacific Medical Center-Pacific Campus, San Francisco, California, United States|Kaiser Permanente-San Francisco, San Francisco, California, United States|Kaiser Permanente-Santa Teresa-San Jose, San Jose, California, United States|Kaiser Permanente San Leandro, San Leandro, California, United States|Kaiser Permanente-San Marcos, San Marcos, California, United States|Kaiser Permanente-San Rafael, San Rafael, California, United States|Kaiser San Rafael-Gallinas, San Rafael, California, United States|Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California, United States|Palo Alto Medical Foundation-Santa Cruz, Santa Cruz, California, United States|Kaiser Permanente-Santa Rosa, Santa Rosa, California, United States|Saint Joseph Heritage Healthcare-Santa Rosa, Santa Rosa, California, United States|Sutter Pacific Medical Foundation, Santa Rosa, California, United States|City of Hope South Pasadena, South Pasadena, California, United States|Kaiser Permanente-South San Francisco, South San Francisco, California, United States|Saint Joseph's Medical Center, Stockton, California, United States|Kaiser Permanente-Stockton, Stockton, California, United States|Palo Alto Medical Foundation-Sunnyvale, Sunnyvale, California, United States|Gene Upshaw Memorial Tahoe Forest Cancer Center, Truckee, California, United States|City of Hope Upland, Upland, California, United States|Northbay Cancer Center, Vacaville, California, United States|Sutter Cancer Centers Radiation Oncology Services-Vacaville, Vacaville, California, United States|Kaiser Permanente Medical Center-Vacaville, Vacaville, California, United States|Kaiser Permanente-Vallejo, Vallejo, California, United States|Sutter Solano Medical Center/Cancer Center, Vallejo, California, United States|Kaiser Permanente-Walnut Creek, Walnut Creek, California, United States|Epic Care Cyberknife Center, Walnut Creek, California, United States|Kaiser Permanente-Woodland Hills, Woodland Hills, California, United States|Woodland Memorial Hospital, Woodland, California, United States|Rocky Mountain Cancer Centers-Aurora, Aurora, Colorado, United States|The Medical Center of Aurora, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|Boulder Community Hospital, Boulder, Colorado, United States|Rocky Mountain Cancer Centers-Boulder, Boulder, Colorado, United States|Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers-Penrose, Colorado Springs, Colorado, United States|UCHealth Memorial Hospital Central, Colorado Springs, Colorado, United States|Cancer Center of Colorado at Sloan's Lake, Denver, Colorado, United States|Denver Health Medical Center, Denver, Colorado, United States|Kaiser Permanente-Franklin, Denver, Colorado, United States|National Jewish Health-Main Campus, Denver, Colorado, United States|The Women's Imaging Center, Denver, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States|Rocky Mountain Cancer Centers-Midtown, Denver, Colorado, United States|SCL Health Saint Joseph Hospital, Denver, Colorado, United States|Rocky Mountain Cancer Centers-Rose, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|Mercy Medical Center, Durango, Colorado, United States|Southwest Oncology PC, Durango, Colorado, United States|Shaw Cancer Center, Edwards, Colorado, United States|Mountain Blue Cancer Care Center - Swedish, Englewood, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|Poudre Valley Hospital, Fort Collins, Colorado, United States|Valley View Hospital Cancer Center, Glenwood Springs, Colorado, United States|Mountain Blue Cancer Care Center, Golden, Colorado, United States|National Jewish Health-Western Hematology Oncology, Golden, Colorado, United States|Saint Mary's Hospital and Regional Medical Center, Grand Junction, Colorado, United States|Grand Valley Oncology, Grand Junction, Colorado, United States|North Colorado Medical Center, Greeley, Colorado, United States|Rocky Mountain Cancer Centers-Greenwood Village, Greenwood Village, Colorado, United States|UCHealth Highlands Ranch Hospital, Highlands Ranch, Colorado, United States|Good Samaritan Medical Center, Lafayette, Colorado, United States|Kaiser Permanente-Rock Creek, Lafayette, Colorado, United States|Rocky Mountain Cancer Centers-Lakewood, Lakewood, Colorado, United States|Saint Anthony Hospital, Lakewood, Colorado, United States|Rocky Mountain Cancer Centers-Littleton, Littleton, Colorado, United States|Littleton Adventist Hospital, Littleton, Colorado, United States|Kaiser Permanente-Lone Tree, Lone Tree, Colorado, United States|Rocky Mountain Cancer Centers-Sky Ridge, Lone Tree, Colorado, United States|Sky Ridge Medical Center, Lone Tree, Colorado, United States|UCHealth Lone Tree Health Center, Lone Tree, Colorado, United States|Longmont United Hospital, Longmont, Colorado, United States|Rocky Mountain Cancer Centers-Longmont, Longmont, Colorado, United States|McKee Medical Center, Loveland, Colorado, United States|Parker Adventist Hospital, Parker, Colorado, United States|Rocky Mountain Cancer Centers-Parker, Parker, Colorado, United States|Saint Mary Corwin Medical Center, Pueblo, Colorado, United States|Rocky Mountain Cancer Centers - Pueblo, Pueblo, Colorado, United States|National Jewish Health-Northern Hematology Oncology, Thornton, Colorado, United States|Rocky Mountain Cancer Centers-Thornton, Thornton, Colorado, United States|SCL Health Lutheran Medical Center, Wheat Ridge, Colorado, United States|Smilow Cancer Hospital-Derby Care Center, Derby, Connecticut, United States|Smilow Cancer Hospital Care Center-Fairfield, Fairfield, Connecticut, United States|Greenwich Hospital, Greenwich, Connecticut, United States|Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States|Middlesex Hospital, Middletown, Connecticut, United States|Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Yale-New Haven Hospital North Haven Medical Center, North Haven, Connecticut, United States|Smilow Cancer Hospital-Orange Care Center, Orange, Connecticut, United States|Stamford Hospital/Bennett Cancer Center, Stamford, Connecticut, United States|Smilow Cancer Hospital-Torrington Care Center, Torrington, Connecticut, United States|Smilow Cancer Hospital Care Center-Trumbull, Trumbull, Connecticut, United States|Smilow Cancer Hospital-Waterbury Care Center, Waterbury, Connecticut, United States|Lawrence and Memorial Cancer Center, Waterford, Connecticut, United States|Beebe Medical Center, Lewes, Delaware, United States|Delaware Clinical and Laboratory Physicians PA, Newark, Delaware, United States|Helen F Graham Cancer Center, Newark, Delaware, United States|Medical Oncology Hematology Consultants PA, Newark, Delaware, United States|Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States|Beebe Health Campus, Rehoboth Beach, Delaware, United States|Nanticoke Memorial Hospital, Seaford, Delaware, United States|Christiana Care Health System-Wilmington Hospital, Wilmington, Delaware, United States|Kaiser Permanente-Capitol Hill Medical Center, Washington, District of Columbia, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|MedStar Washington Hospital Center, Washington, District of Columbia, United States|Sibley Memorial Hospital, Washington, District of Columbia, United States|Mount Sinai Comprehensive Cancer Center at Aventura, Aventura, Florida, United States|Morton Plant Hospital, Clearwater, Florida, United States|UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States|Halifax Health Medical Center-Centers for Oncology, Daytona Beach, Florida, United States|Broward Health North, Deerfield Beach, Florida, United States|UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States|Holy Cross Hospital, Fort Lauderdale, Florida, United States|Broward Health Medical Center, Fort Lauderdale, Florida, United States|University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States|Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida, United States|Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States|Lakeland Regional Health Hollis Cancer Center, Lakeland, Florida, United States|The Watson Clinic, Lakeland, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|UM Sylvester Comprehensive Cancer Center at Kendall, Miami, Florida, United States|Halifax Health Center for Oncology - Ormond Beach, Ormond Beach, Florida, United States|Memorial Hospital West, Pembroke Pines, Florida, United States|UM Sylvester Comprehensive Cancer Center at Plantation, Plantation, Florida, United States|Halifax Health Center for Oncology - Port Orange, Port Orange, Florida, United States|Indian River Medical Center, Vero Beach, Florida, United States|Phoebe Putney Memorial Hospital, Albany, Georgia, United States|University Cancer and Blood Center LLC, Athens, Georgia, United States|Grady Health System, Atlanta, Georgia, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Piedmont Hospital, Atlanta, Georgia, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|Kaiser Permanente-Glenlake Medical Center, Atlanta, Georgia, United States|Emory Saint Joseph's Hospital, Atlanta, Georgia, United States|Northside Hospital, Atlanta, Georgia, United States|Augusta Oncology Associates PC-D'Antignac, Augusta, Georgia, United States|Augusta Oncology Associates PC-Wheeler, Augusta, Georgia, United States|Augusta University Medical Center, Augusta, Georgia, United States|John B Amos Cancer Center, Columbus, Georgia, United States|Northside Hospital-Forsyth, Cumming, Georgia, United States|Dekalb Medical Center, Decatur, Georgia, United States|Kaiser Permanente-Gwinnett Medical Center, Duluth, Georgia, United States|Piedmont Fayette Hospital, Fayetteville, Georgia, United States|Kaiser Permanente Southwood, Jonesboro, Georgia, United States|Kaiser Permanente TownPark Comprehensive Medical Center, Kennesaw, Georgia, United States|Gwinnett Medical Center, Lawrenceville, Georgia, United States|Medical Center of Central Georgia, Macon, Georgia, United States|Harbin Clinic Medical Oncology and Clinical Research, Rome, Georgia, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|Summit Cancer Care-Memorial, Savannah, Georgia, United States|Lewis Cancer and Research Pavilion at Saint Joseph's/Candler, Savannah, Georgia, United States|Low Country Cancer Care Associates PC, Savannah, Georgia, United States|Summit Cancer Care-Candler, Savannah, Georgia, United States|Lewis Hall Singletary Oncology Center, Thomasville, Georgia, United States|South Georgia Medical Center/Pearlman Cancer Center, Valdosta, Georgia, United States|Hawaii Cancer Care - Savio, 'Aiea, Hawaii, United States|Hawaii Oncology Inc-Pali Momi, 'Aiea, Hawaii, United States|Pali Momi Medical Center, 'Aiea, Hawaii, United States|The Cancer Center of Hawaii-Pali Momi, 'Aiea, Hawaii, United States|Hawaii Cancer Care Inc-POB II, Honolulu, Hawaii, United States|Hawaii Oncology Inc-POB I, Honolulu, Hawaii, United States|Island Urology, Honolulu, Hawaii, United States|Queen's Medical Center, Honolulu, Hawaii, United States|Straub Clinic and Hospital, Honolulu, Hawaii, United States|University of Hawaii Cancer Center, Honolulu, Hawaii, United States|Hawaii Cancer Care Inc-Liliha, Honolulu, Hawaii, United States|Hawaii Oncology Inc-Kuakini, Honolulu, Hawaii, United States|Kuakini Medical Center, Honolulu, Hawaii, United States|The Cancer Center of Hawaii-Liliha, Honolulu, Hawaii, United States|Kaiser Permanente Moanalua Medical Center, Honolulu, Hawaii, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Tripler Army Medical Center, Honolulu, Hawaii, United States|Wilcox Memorial Hospital and Kauai Medical Clinic, Lihue, Hawaii, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho, United States|Kootenai Medical Center, Coeur d'Alene, Idaho, United States|Walter Knox Memorial Hospital, Emmett, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Fruitland, Fruitland, Idaho, United States|Idaho Urologic Institute-Meridian, Meridian, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Meridian, Meridian, Idaho, United States|Saint Alphonsus Medical Center-Nampa, Nampa, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Nampa, Nampa, Idaho, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Kootenai Cancer Clinic, Sandpoint, Idaho, United States|Saint Luke's Mountain States Tumor Institute-Twin Falls, Twin Falls, Idaho, United States|Rush - Copley Medical Center, Aurora, Illinois, United States|Mac Neal Hospital, Berwyn, Illinois, United States|Saint Joseph Medical Center, Bloomington, Illinois, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Memorial Hospital of Carbondale, Carbondale, Illinois, United States|SIH Cancer Institute, Carterville, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|Mount Sinai Hospital Medical Center, Chicago, Illinois, United States|University of Illinois, Chicago, Illinois, United States|Swedish Covenant Hospital, Chicago, Illinois, United States|Presence Resurrection Medical Center, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Weiss Memorial Hospital, Chicago, Illinois, United States|Advocate Illinois Masonic Medical Center, Chicago, Illinois, United States|Carle on Vermilion, Danville, Illinois, United States|Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Northwestern Medicine Cancer Center Kishwaukee, DeKalb, Illinois, United States|Illinois CancerCare-Dixon, Dixon, Illinois, United States|Carle Physician Group-Effingham, Effingham, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|AMITA Health Alexian Brothers Medical Center, Elk Grove Village, Illinois, United States|Elmhurst Memorial Hospital, Elmhurst, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States|Little Company of Mary Hospital, Evergreen Park, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, United States|Northwestern Medicine Cancer Center Delnor, Geneva, Illinois, United States|NorthShore University HealthSystem-Glenbrook Hospital, Glenview, Illinois, United States|Advocate South Suburban Hospital, Hazel Crest, Illinois, United States|NorthShore University HealthSystem-Highland Park Hospital, Highland Park, Illinois, United States|Joliet Oncology-Hematology Associates Limited, Joliet, Illinois, United States|Presence Saint Mary's Hospital, Kankakee, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States|Trinity Medical Center, Moline, Illinois, United States|Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States|Edward Hospital/Cancer Center, Naperville, Illinois, United States|UC Comprehensive Cancer Center at Silver Cross, New Lenox, Illinois, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|University of Chicago Medicine-Orland Park, Orland Park, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Advocate Lutheran General Hospital, Park Ridge, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center, Pekin, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|OSF Saint Francis Radiation Oncology at Peoria Cancer Center, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Valley Radiation Oncology, Peru, Illinois, United States|Edward Hospital/Cancer Center?Plainfield, Plainfield, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|Quincy Medical Group-Clinic, Quincy, Illinois, United States|West Suburban Medical Center, River Forest, Illinois, United States|OSF Saint Anthony Medical Center, Rockford, Illinois, United States|SwedishAmerican Regional Cancer Center/ACT, Rockford, Illinois, United States|Genesis Cancer Center - Silvis, Silvis, Illinois, United States|North Shore Medical Center, Skokie, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Cancer Care Specialists of Illinois-Swansea, Swansea, Illinois, United States|Southwest Illinois Health Services LLP, Swansea, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|The Carle Foundation Hospital, Urbana, Illinois, United States|Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, United States|Rush-Copley Healthcare Center, Yorkville, Illinois, United States|IU Health West Hospital, Avon, Indiana, United States|IU Health North Hospital, Carmel, Indiana, United States|Deaconess Clinic Downtown, Evansville, Indiana, United States|Parkview Hospital Randallia, Fort Wayne, Indiana, United States|Parkview Regional Medical Center, Fort Wayne, Indiana, United States|Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|IU Health Methodist Hospital, Indianapolis, Indiana, United States|Sidney and Lois Eskenazi Hospital, Indianapolis, Indiana, United States|Community Cancer Center East, Indianapolis, Indiana, United States|Community Cancer Center South, Indianapolis, Indiana, United States|Franciscan Health Indianapolis, Indianapolis, Indiana, United States|Community Cancer Center North, Indianapolis, Indiana, United States|Springmill Medical Center, Indianapolis, Indiana, United States|Community Howard Regional Health, Kokomo, Indiana, United States|IU Health Arnett Cancer Care, Lafayette, Indiana, United States|Woodland Cancer Care Center, Michigan City, Indiana, United States|Memorial Regional Cancer Center Day Road, Mishawaka, Indiana, United States|Franciscan Health Mooresville, Mooresville, Indiana, United States|IU Health Ball Memorial Hospital, Muncie, Indiana, United States|The Community Hospital, Munster, Indiana, United States|Chancellor Center for Oncology, Newburgh, Indiana, United States|Reid Health, Richmond, Indiana, United States|Memorial Hospital of South Bend, South Bend, Indiana, United States|Union Hospital, Terre Haute, Indiana, United States|Mary Greeley Medical Center, Ames, Iowa, United States|McFarland Clinic PC - Ames, Ames, Iowa, United States|McFarland Clinic PC-Boone, Boone, Iowa, United States|Mercy Hospital, Cedar Rapids, Iowa, United States|Oncology Associates at Mercy Medical Center, Cedar Rapids, Iowa, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Cancer Center-West Lakes, Clive, Iowa, United States|Alegent Health Mercy Hospital, Council Bluffs, Iowa, United States|Greater Regional Medical Center, Creston, Iowa, United States|Genesis Medical Center - East Campus, Davenport, Iowa, United States|Genesis Cancer Care Institute, Davenport, Iowa, United States|Iowa Cancer Specialists, Davenport, Iowa, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Des Moines, Des Moines, Iowa, United States|Broadlawns Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|Iowa Lutheran Hospital, Des Moines, Iowa, United States|JCHC McCreery Cancer Center, Fairfield, Iowa, United States|McFarland Clinic PC-Trinity Cancer Center, Fort Dodge, Iowa, United States|Trinity Regional Medical Center, Fort Dodge, Iowa, United States|McFarland Clinic PC-Jefferson, Jefferson, Iowa, United States|McFarland Clinic PC-Marshalltown, Marshalltown, Iowa, United States|Mercy Medical Center - North Iowa, Mason City, Iowa, United States|Ottumwa Regional Health Center, Ottumwa, Iowa, United States|Siouxland Regional Cancer Center, Sioux City, Iowa, United States|MercyOne Waterloo Medical Center, Waterloo, Iowa, United States|Methodist West Hospital, West Des Moines, Iowa, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, United States|Cancer Center of Kansas - Chanute, Chanute, Kansas, United States|Coffeyville Regional Medical Center, Coffeyville, Kansas, United States|Cancer Center of Kansas - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas - El Dorado, El Dorado, Kansas, United States|Cancer Center of Kansas - Fort Scott, Fort Scott, Kansas, United States|Central Care Cancer Center - Garden City, Garden City, Kansas, United States|Central Care Cancer Center - Great Bend, Great Bend, Kansas, United States|Hays Medical Center, Hays, Kansas, United States|Cancer Center of Kansas-Independence, Independence, Kansas, United States|University of Kansas Cancer Center-West, Kansas City, Kansas, United States|Cancer Center of Kansas-Kingman, Kingman, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Kansas Institute of Medicine Cancer and Blood Center, Lenexa, Kansas, United States|Minimally Invasive Surgery Hospital, Lenexa, Kansas, United States|Cancer Center of Kansas-Liberal, Liberal, Kansas, United States|Cancer Center of Kansas-Manhattan, Manhattan, Kansas, United States|Cancer Center of Kansas - McPherson, McPherson, Kansas, United States|Cancer Center of Kansas - Newton, Newton, Kansas, United States|Olathe Medical Center, Olathe, Kansas, United States|Menorah Medical Center, Overland Park, Kansas, United States|University of Kansas Cancer Center-Overland Park, Overland Park, Kansas, United States|University of Kansas Hospital-Indian Creek Campus, Overland Park, Kansas, United States|Saint Luke's South Hospital, Overland Park, Kansas, United States|Cancer Center of Kansas - Parsons, Parsons, Kansas, United States|Via Christi Hospital-Pittsburg, Pittsburg, Kansas, United States|Cancer Center of Kansas - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas - Salina, Salina, Kansas, United States|Salina Regional Health Center, Salina, Kansas, United States|Saint Francis Hospital and Medical Center - Topeka, Topeka, Kansas, United States|Cancer Center of Kansas - Wellington, Wellington, Kansas, United States|University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States|Associates In Womens Health, Wichita, Kansas, United States|Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, Kansas, United States|Ascension Via Christi Hospitals Wichita, Wichita, Kansas, United States|Cancer Center of Kansas - Wichita, Wichita, Kansas, United States|Cancer Center of Kansas - Winfield, Winfield, Kansas, United States|King's Daughter's Medical Center, Ashland, Kentucky, United States|Flaget Memorial Hospital, Bardstown, Kentucky, United States|Baptist Health Corbin, Corbin, Kentucky, United States|Commonwealth Cancer Center-Corbin, Corbin, Kentucky, United States|Oncology Hematology Care Inc-Crestview, Crestview Hills, Kentucky, United States|Saint Elizabeth Medical Center South, Edgewood, Kentucky, United States|Hardin Memorial Hospital, Elizabethtown, Kentucky, United States|Saint Elizabeth Fort Thomas, Fort Thomas, Kentucky, United States|Baptist Health Lexington, Lexington, Kentucky, United States|Saint Joseph Radiation Oncology Resource Center, Lexington, Kentucky, United States|Saint Joseph Hospital East, Lexington, Kentucky, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|Saint Joseph London, London, Kentucky, United States|Jewish Hospital, Louisville, Kentucky, United States|Baptist Health Louisville, Louisville, Kentucky, United States|Saints Mary and Elizabeth Hospital, Louisville, Kentucky, United States|Jewish Hospital Medical Center Northeast, Louisville, Kentucky, United States|Baptist Health Madisonville/Merle Mahr Cancer Center, Madisonville, Kentucky, United States|Saint Claire Regional Medical Center, Morehead, Kentucky, United States|Owensboro Health Mitchell Memorial Cancer Center, Owensboro, Kentucky, United States|Baptist Health Paducah, Paducah, Kentucky, United States|Jewish Hospital Medical Center South, Shepherdsville, Kentucky, United States|Christus Saint Frances Cabrini Hospital, Alexandria, Louisiana, United States|LSU Health Baton Rouge-North Clinic, Baton Rouge, Louisiana, United States|Baton Rouge General Medical Center, Baton Rouge, Louisiana, United States|Hematology/Oncology Clinic LLP, Baton Rouge, Louisiana, United States|Louisiana Hematology Oncology Associates LLC, Baton Rouge, Louisiana, United States|Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States|Ochsner Health Center-Summa, Baton Rouge, Louisiana, United States|Our Lady of the Lake Physicians Group - Medical Oncology, Baton Rouge, Louisiana, United States|Medical Center of Baton Rouge, Baton Rouge, Louisiana, United States|Woman's Hospital, Baton Rouge, Louisiana, United States|Ochsner High Grove, Baton Rouge, Louisiana, United States|Northshore Oncology Associates-Covington, Covington, Louisiana, United States|Oncology Center of The South Incorporated, Houma, Louisiana, United States|Terrebonne General Medical Center, Houma, Louisiana, United States|Lallie Kemp Regional Medical Center, Independence, Louisiana, United States|Ochsner Medical Center Kenner, Kenner, Louisiana, United States|University Health-Conway, Monroe, Louisiana, United States|Louisiana State University Health Science Center, New Orleans, Louisiana, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|University Medical Center New Orleans, New Orleans, Louisiana, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|Louisiana State University Health Sciences Center Shreveport, Shreveport, Louisiana, United States|Harold Alfond Center for Cancer Care, Augusta, Maine, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Waldo County General Hospital, Belfast, Maine, United States|MaineHealth/SMHC Cancer Care and Blood Disorders-Biddeford, Biddeford, Maine, United States|Lafayette Family Cancer Center-EMMC, Brewer, Maine, United States|Central Maine Medical Center, Lewiston, Maine, United States|Stephens Memorial Hospital, Norway, Maine, United States|Mercy Hospital, Portland, Maine, United States|Penobscot Bay Medical Center, Rockport, Maine, United States|MaineHealth/SMHC Cancer Care and Blood Disorders-Sanford, Sanford, Maine, United States|Maine Medical Partners - South Portland, South Portland, Maine, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore, Maryland, United States|MedStar Good Samaritan Hospital, Baltimore, Maryland, United States|Kaiser Permanente-Woodlawn Medical Center, Baltimore, Maryland, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|UM Upper Chesapeake Medical Center, Bel Air, Maryland, United States|Suburban Hospital, Bethesda, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|University of Maryland Shore Medical Center at Easton, Easton, Maryland, United States|Union Hospital of Cecil County, Elkton, Maryland, United States|Kaiser Permanente-Gaithersburg Medical Center, Gaithersburg, Maryland, United States|UM Baltimore Washington Medical Center/Tate Cancer Center, Glen Burnie, Maryland, United States|Meritus Medical Center, Hagerstown, Maryland, United States|Kaiser Permanente - Kensington Medical Center, Kensington, Maryland, United States|Kaiser Permanente - Largo Medical Center, Largo, Maryland, United States|Richard A Henson Cancer Institute at Ocean Pines, Ocean Pines, Maryland, United States|MedStar Montgomery Medical Center, Olney, Maryland, United States|Northwest Hospital Center, Randallstown, Maryland, United States|Peninsula Regional Medical Center, Salisbury, Maryland, United States|UM Saint Joseph Medical Center, Towson, Maryland, United States|William E Kahlert Regional Cancer Center/Sinai Hospital, Westminster, Maryland, United States|Beverly Hospital, Beverly, Massachusetts, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Steward Saint Elizabeth's Medical Center, Brighton, Massachusetts, United States|Lahey Hospital and Medical Center, Burlington, Massachusetts, United States|Mass General/North Shore Cancer Center, Danvers, Massachusetts, United States|Simonds-Sinon Regional Cancer Center, Fitchburg, Massachusetts, United States|Addison Gilbert Hospital, Gloucester, Massachusetts, United States|Cape Cod Hospital, Hyannis, Massachusetts, United States|Lowell General Hospital, Lowell, Massachusetts, United States|Dana-Farber/Brigham and Women's Cancer Center at Milford Regional, Milford, Massachusetts, United States|Berkshire Medical Center - Cancer Center, Pittsfield, Massachusetts, United States|Beth Israel Deaconess Hospital-Plymouth, Plymouth, Massachusetts, United States|Dana-Farber/Brigham and Women's Cancer Center at South Shore, South Weymouth, Massachusetts, United States|Mercy Medical Center, Springfield, Massachusetts, United States|Winchester Hospital, Winchester, Massachusetts, United States|UMass Memorial Medical Center - University Campus, Worcester, Massachusetts, United States|Hickman Cancer Center, Adrian, Michigan, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Bronson Battle Creek, Battle Creek, Michigan, United States|McLaren Cancer Institute-Bay City, Bay City, Michigan, United States|McLaren Cancer Institute-Bloomfield, Bloomfield, Michigan, United States|IHA Hematology Oncology Consultants-Brighton, Brighton, Michigan, United States|Saint Joseph Mercy Brighton, Brighton, Michigan, United States|Henry Ford Cancer Institute-Downriver, Brownstown, Michigan, United States|IHA Hematology Oncology Consultants-Canton, Canton, Michigan, United States|Saint Joseph Mercy Canton, Canton, Michigan, United States|Caro Cancer Center, Caro, Michigan, United States|IHA Hematology Oncology Consultants-Chelsea, Chelsea, Michigan, United States|Saint Joseph Mercy Chelsea, Chelsea, Michigan, United States|Hematology Oncology Consultants-Clarkston, Clarkston, Michigan, United States|McLaren Cancer Institute-Clarkston, Clarkston, Michigan, United States|Newland Medical Associates-Clarkston, Clarkston, Michigan, United States|Henry Ford Macomb Hospital-Clinton Township, Clinton Township, Michigan, United States|Beaumont Hospital - Dearborn, Dearborn, Michigan, United States|Henry Ford Medical Center-Fairlane, Dearborn, Michigan, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Ascension Saint John Hospital, Detroit, Michigan, United States|Great Lakes Cancer Management Specialists-Doctors Park, East China Township, Michigan, United States|Green Bay Oncology - Escanaba, Escanaba, Michigan, United States|Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States|Beaumont Hospital - Farmington Hills, Farmington Hills, Michigan, United States|Genesee Cancer and Blood Disease Treatment Center, Flint, Michigan, United States|Genesee Hematology Oncology PC, Flint, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|McLaren Cancer Institute-Flint, Flint, Michigan, United States|Singh and Arora Hematology Oncology PC, Flint, Michigan, United States|Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, Michigan, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Academic Hematology Oncology Specialists, Grosse Pointe Woods, Michigan, United States|Great Lakes Cancer Management Specialists-Van Elslander Cancer Center, Grosse Pointe Woods, Michigan, United States|Michigan Breast Specialists-Grosse Pointe Woods, Grosse Pointe Woods, Michigan, United States|William Beaumont Hospital-Grosse Point, Grosse Pointe, Michigan, United States|Allegiance Health, Jackson, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|McLaren-Greater Lansing, Lansing, Michigan, United States|Mid-Michigan Physicians-Lansing, Lansing, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|McLaren Cancer Institute-Lapeer Region, Lapeer, Michigan, United States|Hope Cancer Clinic, Livonia, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Medical Campus, Macomb, Michigan, United States|Michigan Breast Specialists-Macomb Township, Macomb, Michigan, United States|Saint Mary's Oncology/Hematology Associates of Marlette, Marlette, Michigan, United States|UP Health System Hematology Oncology Marquette, Marquette, Michigan, United States|UP Health System Marquette, Marquette, Michigan, United States|Mid-Michigan Medical Center - Midland, Midland, Michigan, United States|Toledo Clinic Cancer Centers-Monroe, Monroe, Michigan, United States|McLaren Cancer Institute-Macomb, Mount Clemens, Michigan, United States|McLaren Cancer Institute-Central Michigan, Mount Pleasant, Michigan, United States|Mercy Health Mercy Campus, Muskegon, Michigan, United States|Lakeland Hospital Niles, Niles, Michigan, United States|Cancer and Hematology Centers of Western Michigan - Norton Shores, Norton Shores, Michigan, United States|Ascension Providence Hospitals - Novi, Novi, Michigan, United States|Henry Ford Medical Center-Columbus, Novi, Michigan, United States|McLaren Cancer Institute-Northern Michigan, Petoskey, Michigan, United States|21st Century Oncology-Pontiac, Pontiac, Michigan, United States|Hope Cancer Center, Pontiac, Michigan, United States|Newland Medical Associates-Pontiac, Pontiac, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Huron Medical Center PC, Port Huron, Michigan, United States|Lake Huron Medical Center, Port Huron, Michigan, United States|McLaren-Port Huron, Port Huron, Michigan, United States|Spectrum Health Reed City Hospital, Reed City, Michigan, United States|Great Lakes Cancer Management Specialists-Rochester Hills, Rochester Hills, Michigan, United States|Michigan Cancer Specialists, Roseville, Michigan, United States|Oakland Colon and Rectal Association, Royal Oak, Michigan, United States|Cancer Care Associates PC, Royal Oak, Michigan, United States|Comprehensive Medical Center PLLC, Royal Oak, Michigan, United States|Hematology Oncology Consultants PC, Royal Oak, Michigan, United States|Oakland Medical Group, Royal Oak, Michigan, United States|William Beaumont Hospital-Royal Oak, Royal Oak, Michigan, United States|Ascension Saint Mary's Hospital, Saginaw, Michigan, United States|Oncology Hematology Associates of Saginaw Valley PC, Saginaw, Michigan, United States|Lakeland Medical Center Saint Joseph, Saint Joseph, Michigan, United States|Marie Yeager Cancer Center, Saint Joseph, Michigan, United States|Ascension Providence Hospitals - Southfield, Southfield, Michigan, United States|Bhadresh Nayak MD PC-Sterling Heights, Sterling Heights, Michigan, United States|Premier Hematology Oncology Care, Sterling Heights, Michigan, United States|Mitchell Folbe MD PC, Sterling Heights, Michigan, United States|Ascension Saint Joseph Hospital, Tawas City, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Michigan Institute of Urology-Town Center, Troy, Michigan, United States|Claudia BR Herke MD PC, Troy, Michigan, United States|William Beaumont Hospital - Troy, Troy, Michigan, United States|Hematology Oncology Consultants PC-Troy, Troy, Michigan, United States|Advanced Breast Care Center PLLC, Warren, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Professional Building, Warren, Michigan, United States|Macomb Hematology Oncology PC, Warren, Michigan, United States|Michigan Breast Specialists-Warren, Warren, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Henry Ford West Bloomfield Hospital, West Bloomfield, Michigan, United States|Saint Mary's Oncology/Hematology Associates of West Branch, West Branch, Michigan, United States|Metro Health Hospital, Wyoming, Michigan, United States|Huron Gastroenterology PC, Ypsilanti, Michigan, United States|IHA Hematology Oncology Consultants-Ann Arbor, Ypsilanti, Michigan, United States|Riverwood Healthcare Center, Aitkin, Minnesota, United States|Mayo Clinic Health System in Albert Lea, Albert Lea, Minnesota, United States|Sanford Joe Lueken Cancer Center, Bemidji, Minnesota, United States|Essentia Health Saint Joseph's Medical Center, Brainerd, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Cambridge Medical Center, Cambridge, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Essentia Health - Deer River Clinic, Deer River, Minnesota, United States|Essentia Health Saint Mary's - Detroit Lakes Clinic, Detroit Lakes, Minnesota, United States|Essentia Health Cancer Center, Duluth, Minnesota, United States|Essentia Health Saint Mary's Medical Center, Duluth, Minnesota, United States|Miller-Dwan Hospital, Duluth, Minnesota, United States|Saint Luke's Hospital of Duluth, Duluth, Minnesota, United States|Fairview-Southdale Hospital, Edina, Minnesota, United States|Lake Region Healthcare Corporation-Cancer Care, Fergus Falls, Minnesota, United States|Essentia Health - Fosston, Fosston, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Essentia Health Hibbing Clinic, Hibbing, Minnesota, United States|Mayo Clinic Health Systems-Mankato, Mankato, Minnesota, United States|Fairview Maple Grove Medical Center, Maple Grove, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Health Partners Inc, Minneapolis, Minnesota, United States|Monticello Cancer Center, Monticello, Minnesota, United States|New Ulm Medical Center, New Ulm, Minnesota, United States|Essentia Health - Park Rapids, Park Rapids, Minnesota, United States|Fairview Northland Medical Center, Princeton, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Coborn Cancer Center at Saint Cloud Hospital, Saint Cloud, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Essentia Health Sandstone, Sandstone, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Sanford Thief River Falls Medical Center, Thief River Falls, Minnesota, United States|Essentia Health Virginia Clinic, Virginia, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|Sanford Cancer Center Worthington, Worthington, Minnesota, United States|Fairview Lakes Medical Center, Wyoming, Minnesota, United States|Baptist Memorial Hospital and Cancer Center-Golden Triangle, Columbus, Mississippi, United States|Baptist Cancer Center-Grenada, Grenada, Mississippi, United States|Gulfport Memorial Hospital, Gulfport, Mississippi, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Baptist Memorial Hospital and Cancer Center-Union County, New Albany, Mississippi, United States|Baptist Memorial Hospital and Cancer Center-Oxford, Oxford, Mississippi, United States|Baptist Memorial Hospital and Cancer Center-Desoto, Southhaven, Mississippi, United States|Saint Louis Cancer and Breast Institute-Ballwin, Ballwin, Missouri, United States|Central Care Cancer Center - Bolivar, Bolivar, Missouri, United States|Parkland Health Center-Bonne Terre, Bonne Terre, Missouri, United States|Cox Cancer Center Branson, Branson, Missouri, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|Saint Luke's Hospital, Chesterfield, Missouri, United States|University of Missouri - Ellis Fischel, Columbia, Missouri, United States|Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States|Parkland Health Center - Farmington, Farmington, Missouri, United States|Centerpoint Medical Center LLC, Independence, Missouri, United States|Capital Region Southwest Campus, Jefferson City, Missouri, United States|Freeman Health System, Joplin, Missouri, United States|Mercy Hospital Joplin, Joplin, Missouri, United States|Truman Medical Center, Kansas City, Missouri, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|The University of Kansas Cancer Center-South, Kansas City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|The University of Kansas Cancer Center-North, Kansas City, Missouri, United States|The University of Kansas Cancer Center-Lee's Summit, Lee's Summit, Missouri, United States|Saint Luke's East - Lee's Summit, Lee's Summit, Missouri, United States|University of Kansas Cancer Center at North Kansas City Hospital, North Kansas City, Missouri, United States|Delbert Day Cancer Institute at PCRMC, Rolla, Missouri, United States|Mercy Clinic-Rolla-Cancer and Hematology, Rolla, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Saint Louis Cancer and Breast Institute-South City, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mercy Hospital South, Saint Louis, Missouri, United States|Siteman Cancer Center-South County, Saint Louis, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Siteman Cancer Center at Christian Hospital, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Siteman Cancer Center at Saint Peters Hospital, Saint Peters, Missouri, United States|Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|CoxHealth South Hospital, Springfield, Missouri, United States|Missouri Baptist Sullivan Hospital, Sullivan, Missouri, United States|Missouri Baptist Outpatient Center-Sunset Hills, Sunset Hills, Missouri, United States|Mercy Hospital Washington, Washington, Missouri, United States|Community Hospital of Anaconda, Anaconda, Montana, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Saint Vincent Healthcare, Billings, Montana, United States|Saint Vincent Frontier Cancer Center, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Saint James Community Hospital and Cancer Treatment Center, Butte, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Great Falls Clinic, Great Falls, Montana, United States|Saint Peter's Community Hospital, Helena, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|CHI Health Saint Francis, Grand Island, Nebraska, United States|Heartland Hematology and Oncology, Kearney, Nebraska, United States|CHI Health Good Samaritan, Kearney, Nebraska, United States|Nebraska Hematology and Oncology, Lincoln, Nebraska, United States|Nebraska Cancer Research Center, Lincoln, Nebraska, United States|Saint Elizabeth Regional Medical Center, Lincoln, Nebraska, United States|Southeast Nebraska Cancer Center - 68th Street Place, Lincoln, Nebraska, United States|Faith Regional Health Services Carson Cancer Center, Norfolk, Nebraska, United States|Great Plains Health Callahan Cancer Center, North Platte, Nebraska, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Alegent Health Immanuel Medical Center, Omaha, Nebraska, United States|Hematology and Oncology Consultants PC, Omaha, Nebraska, United States|Alegent Health Bergan Mercy Medical Center, Omaha, Nebraska, United States|Nebraska Cancer Specialists - Omaha, Omaha, Nebraska, United States|Alegent Health Lakeside Hospital, Omaha, Nebraska, United States|Oncology Hematology West PC, Omaha, Nebraska, United States|Creighton University Medical Center, Omaha, Nebraska, United States|Midlands Community Hospital, Papillion, Nebraska, United States|Regional West Medical Center Cancer Center, Scottsbluff, Nebraska, United States|Carson Tahoe Regional Medical Center, Carson City, Nevada, United States|Cancer and Blood Specialists-Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada - Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada-Horizon Ridge, Henderson, Nevada, United States|Las Vegas Cancer Center-Henderson, Henderson, Nevada, United States|OptumCare Cancer Care at Seven Hills, Henderson, Nevada, United States|21st Century Oncology-Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada-Southeast Henderson, Henderson, Nevada, United States|Las Vegas Urology - Green Valley, Henderson, Nevada, United States|Las Vegas Urology - Pebble, Henderson, Nevada, United States|Urology Specialists of Nevada - Green Valley, Henderson, Nevada, United States|Las Vegas Urology - Pecos, Las Vegas, Nevada, United States|Desert West Surgery, Las Vegas, Nevada, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|Hope Cancer Care of Nevada, Las Vegas, Nevada, United States|Cancer and Blood Specialists-Shadow, Las Vegas, Nevada, United States|OptumCare Cancer Care at Oakey, Las Vegas, Nevada, United States|Radiation Oncology Centers of Nevada Central, Las Vegas, Nevada, United States|Urology Specialists of Nevada - Central, Las Vegas, Nevada, United States|21st Century Oncology, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway, Las Vegas, Nevada, United States|Sunrise Hospital and Medical Center, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-San Martin, Las Vegas, Nevada, United States|Las Vegas Prostate Cancer Center, Las Vegas, Nevada, United States|Las Vegas Urology - Sunset, Las Vegas, Nevada, United States|Radiation Oncology Centers of Nevada Southeast, Las Vegas, Nevada, United States|Cancer Therapy and Integrative Medicine, Las Vegas, Nevada, United States|21st Century Oncology-Vegas Tenaya, Las Vegas, Nevada, United States|Ann M Wierman MD LTD, Las Vegas, Nevada, United States|Cancer and Blood Specialists-Tenaya, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Northwest, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Tenaya, Las Vegas, Nevada, United States|Las Vegas Urology - Cathedral Rock, Las Vegas, Nevada, United States|Las Vegas Urology - Smoke Ranch, Las Vegas, Nevada, United States|OptumCare Cancer Care at MountainView, Las Vegas, Nevada, United States|Urology Specialists of Nevada - Northwest, Las Vegas, Nevada, United States|Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Town Center, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada-Summerlin, Las Vegas, Nevada, United States|Summerlin Hospital Medical Center, Las Vegas, Nevada, United States|Las Vegas Cancer Center-Medical Center, Las Vegas, Nevada, United States|21st Century Oncology-Fort Apache, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|OptumCare Cancer Care at Fort Apache, Las Vegas, Nevada, United States|Urology Specialists of Nevada - Southwest, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Central Valley, Las Vegas, Nevada, United States|University Cancer Center, Las Vegas, Nevada, United States|Hope Cancer Care of Nevada-Pahrump, Pahrump, Nevada, United States|Renown Regional Medical Center, Reno, Nevada, United States|Saint Mary's Regional Medical Center, Reno, Nevada, United States|Radiation Oncology Associates, Reno, Nevada, United States|New Hampshire Oncology Hematology PA-Concord, Concord, New Hampshire, United States|New Hampshire Oncology Hematology PA-Hooksett, Hooksett, New Hampshire, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|The Dana-Farber Cancer Institute at Londonderry, Londonderry, New Hampshire, United States|Norris Cotton Cancer Center-Manchester, Manchester, New Hampshire, United States|Saint Joseph Hospital, Nashua, New Hampshire, United States|Norris Cotton Cancer Center-Nashua, Nashua, New Hampshire, United States|Portsmouth Regional Hospital, Portsmouth, New Hampshire, United States|Ocean Medical Center, Brick, New Jersey, United States|Englewood Hospital and Medical Center, Englewood, New Jersey, United States|Hunterdon Medical Center, Flemington, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|The Cancer Institute of New Jersey Hamilton, Hamilton, New Jersey, United States|Bayshore Community Hospital, Holmdel, New Jersey, United States|Monmouth Medical Center Southern Campus, Lakewood, New Jersey, United States|Monmouth Medical Center, Long Branch, New Jersey, United States|Southern Ocean County Medical Center, Manahawkin, New Jersey, United States|Morristown Medical Center, Morristown, New Jersey, United States|Virtua Memorial, Mount Holly, New Jersey, United States|Jersey Shore Medical Center, Neptune, New Jersey, United States|Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|Saint Joseph's Regional Medical Center, Paterson, New Jersey, United States|Chilton Medical Center, Pompton, New Jersey, United States|Riverview Medical Center/Booker Cancer Center, Red Bank, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, Somerville, New Jersey, United States|Overlook Hospital, Summit, New Jersey, United States|Community Medical Center, Toms River, New Jersey, United States|Virtua Voorhees, Voorhees, New Jersey, United States|Inspira Medical Center Woodbury, Woodbury, New Jersey, United States|Lovelace Medical Center-Saint Joseph Square, Albuquerque, New Mexico, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Presbyterian Kaseman Hospital, Albuquerque, New Mexico, United States|Memorial Medical Center - Las Cruces, Las Cruces, New Mexico, United States|Presbyterian Rust Medical Center/Jorgensen Cancer Center, Rio Rancho, New Mexico, United States|Christus Saint Vincent Regional Cancer Center, Santa Fe, New Mexico, United States|Hematology Oncology Associates of Central New York-Auburn, Auburn, New York, United States|Lincoln Medical and Mental Health Center, Bronx, New York, United States|Jacobi Hospital, Bronx, New York, United States|Montefiore Medical Center-Einstein Campus, Bronx, New York, United States|Montefiore Medical Center-Weiler Hospital, Bronx, New York, United States|Montefiore Medical Center - Moses Campus, Bronx, New York, United States|Kings County Hospital, Brooklyn, New York, United States|New York-Presbyterian/Brooklyn Methodist Hospital, Brooklyn, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Mary Imogene Bassett Hospital, Cooperstown, New York, United States|Hematology Oncology Associates of Central New York-East Syracuse, East Syracuse, New York, United States|Elmhurst Hospital Center, Elmhurst, New York, United States|Arnot Ogden Medical Center/Falck Cancer Center, Elmira, New York, United States|Glens Falls Hospital, Glens Falls, New York, United States|Queens Hospital Center, Jamaica, New York, United States|Northwell Health/Center for Advanced Medicine, Lake Success, New York, United States|Orange Regional Medical Center, Middletown, New York, United States|NYU Winthrop Hospital, Mineola, New York, United States|Mount Sinai Union Square, New York, New York, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States|Mount Sinai West, New York, New York, United States|Mount Sinai Hospital, New York, New York, United States|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States|NYP/Weill Cornell Medical Center, New York, New York, United States|Nyack Hospital, Nyack, New York, United States|Highland Hospital, Rochester, New York, United States|Rochester General Hospital, Rochester, New York, United States|University of Rochester, Rochester, New York, United States|Staten Island University Hospital, Staten Island, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|State University of New York Upstate Medical University, Syracuse, New York, United States|Hematology Oncology Associates of Central New York-Onondaga Hill, Syracuse, New York, United States|SUNY Upstate Medical Center-Community Campus, Syracuse, New York, United States|Faxton-Saint Luke's Healthcare, Utica, New York, United States|Dickstein Cancer Treatment Center, White Plains, New York, United States|Randolph Hospital, Asheboro, North Carolina, United States|AdventHealth Infusion Center Asheville, Asheville, North Carolina, United States|Gaston Hematology and Oncology Associates-Belmont, Belmont, North Carolina, United States|Cone Health Cancer Center at Alamance Regional, Burlington, North Carolina, United States|Rex Hematology Oncology Associates-Cary, Cary, North Carolina, United States|Waverly Hematology Oncology, Cary, North Carolina, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Novant Health Presbyterian Medical Center, Charlotte, North Carolina, United States|Oncology Specialists of Charlotte, Charlotte, North Carolina, United States|Southern Oncology Specialists-Charlotte, Charlotte, North Carolina, United States|Southeastern Medical Oncology Center-Clinton, Clinton, North Carolina, United States|AdventHealth Infusion Center Haywood, Clyde, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Rex Hematology Oncology Associates-Garner, Garner, North Carolina, United States|CaroMont Regional Medical Center, Gastonia, North Carolina, United States|Gaston Hematology and Oncology Associates, Gastonia, North Carolina, United States|Southeastern Medical Oncology Center-Goldsboro, Goldsboro, North Carolina, United States|Wayne Memorial Hospital, Goldsboro, North Carolina, United States|Cone Health Cancer Center, Greensboro, North Carolina, United States|Hendersonville Hematology and Oncology at Pardee, Hendersonville, North Carolina, United States|Margaret R Pardee Memorial Hospital, Hendersonville, North Carolina, United States|AdventHealth Hendersonville, Hendersonville, North Carolina, United States|Maria Parham Hospital, Henderson, North Carolina, United States|Lake Norman Hematology Oncology Specialists-Huntersville, Huntersville, North Carolina, United States|Southern Oncology Specialists-Huntersville, Huntersville, North Carolina, United States|Onslow Memorial Hospital, Jacksonville, North Carolina, United States|Southeastern Medical Oncology Center-Jacksonville, Jacksonville, North Carolina, United States|Novant Health Oncology Specialists-Kernersville, Kernersville, North Carolina, United States|Scotland Memorial Hospital-Laurinburg Cancer Center, Laurinburg, North Carolina, United States|Southeastern Regional Medical Center, Lumberton, North Carolina, United States|Matthews Radiation Oncology Center, Matthews, North Carolina, United States|Novant Health Cancer Specialists-Matthews, Matthews, North Carolina, United States|Cone Heath Cancer Center at Mebane, Mebane, North Carolina, United States|Lake Norman Hematology Oncology Specialists-Mooresville, Mooresville, North Carolina, United States|Novant Health Oncology Specialists-Mount Airy, Mount Airy, North Carolina, United States|FirstHealth of the Carolinas-Moore Regional Hospital, Pinehurst, North Carolina, United States|Rex Cancer Center, Raleigh, North Carolina, United States|Rex Hematology Oncology Associates-Blue Ridge, Raleigh, North Carolina, United States|Duke Raleigh Hospital, Raleigh, North Carolina, United States|Rex Cancer Center of Wakefield, Raleigh, North Carolina, United States|Annie Penn Memorial Hospital, Reidsville, North Carolina, United States|Carolina Oncology Associates PA, Salisbury, North Carolina, United States|Rowan Regional Medical Center, Salisbury, North Carolina, United States|WG Hefner VA Medical Center, Salisbury, North Carolina, United States|Johnston Memorial Hospital, Smithfield, North Carolina, United States|Novant Health Oncology Specialists-Statesville, Statesville, North Carolina, United States|Novant Health Oncology Specialists-Davidson County, Thomasville, North Carolina, United States|Marion L Shepard Cancer Center at Vidant Beaufort Hospital, Washington, North Carolina, United States|Novant Health Oncology Specialists-Wilkesboro, Wilkesboro, North Carolina, United States|Novant Health Forsyth Medical Center, Winston-Salem, North Carolina, United States|Novant Health Oncology Specialists, Winston-Salem, North Carolina, United States|Winston-Salem Health Care, Winston-Salem, North Carolina, United States|Sanford Bismarck Medical Center, Bismarck, North Dakota, United States|Essentia Health Cancer Center-South University Clinic, Fargo, North Dakota, United States|Sanford South University Medical Center, Fargo, North Dakota, United States|Sanford Broadway Medical Center, Fargo, North Dakota, United States|Sanford Roger Maris Cancer Center, Fargo, North Dakota, United States|Altru Cancer Center, Grand Forks, North Dakota, United States|Essentia Health - Jamestown Clinic, Jamestown, North Dakota, United States|Trinity Cancer Care Center, Minot, North Dakota, United States|Summa Health System - Akron Campus, Akron, Ohio, United States|Cleveland Clinic Akron General, Akron, Ohio, United States|Alliance Cancer Center, Alliance, Ohio, United States|Summa Health System - Barberton Campus, Barberton, Ohio, United States|UHHS-Chagrin Highlands Medical Center, Beachwood, Ohio, United States|Indu and Raj Soin Medical Center, Beavercreek, Ohio, United States|Strecker Cancer Center-Belpre, Belpre, Ohio, United States|Saint Elizabeth Boardman Hospital, Boardman, Ohio, United States|Mercy Medical Center, Canton, Ohio, United States|Aultman Health Foundation, Canton, Ohio, United States|Dayton Physicians LLC-Miami Valley South, Centerville, Ohio, United States|Miami Valley Hospital South, Centerville, Ohio, United States|Geauga Hospital, Chardon, Ohio, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|Oncology Hematology Care Inc-Eden Park, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Mercy West, Cincinnati, Ohio, United States|Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Anderson, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Kenwood, Cincinnati, Ohio, United States|Bethesda North Hospital, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Blue Ash, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Westside, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Anderson, Cincinnati, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Mount Carmel East Hospital, Columbus, Ohio, United States|Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Grant Medical Center, Columbus, Ohio, United States|The Mark H Zangmeister Center, Columbus, Ohio, United States|Mount Carmel Health Center West, Columbus, Ohio, United States|Doctors Hospital, Columbus, Ohio, United States|Good Samaritan Hospital - Dayton, Dayton, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Dayton Physician LLC-Miami Valley Hospital North, Dayton, Ohio, United States|Miami Valley Hospital North, Dayton, Ohio, United States|Delaware Health Center-Grady Cancer Center, Delaware, Ohio, United States|Delaware Radiation Oncology, Delaware, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Dublin Methodist Hospital, Dublin, Ohio, United States|Mercy Cancer Center-Elyria, Elyria, Ohio, United States|Oncology Hematology Care Inc-Healthplex, Fairfield, Ohio, United States|Armes Family Cancer Center, Findlay, Ohio, United States|Blanchard Valley Hospital, Findlay, Ohio, United States|Orion Cancer Care, Findlay, Ohio, United States|Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio, United States|Dayton Physicians LLC-Atrium, Franklin, Ohio, United States|Dayton Physicians LLC-Wayne, Greenville, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Greater Dayton Cancer Center, Kettering, Ohio, United States|First Dayton Cancer Care, Kettering, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|OhioHealth Mansfield Hospital, Mansfield, Ohio, United States|Marietta Memorial Hospital, Marietta, Ohio, United States|OhioHealth Marion General Hospital, Marion, Ohio, United States|Toledo Clinic Cancer Centers-Maumee, Maumee, Ohio, United States|Toledo Radiation Oncology at Northwest Ohio Onocolgy Center, Maumee, Ohio, United States|UH Seidman Cancer Center at Landerbrook Health Center, Mayfield Heights, Ohio, United States|UH Seidman Cancer Center at Lake Health Mentor Campus, Mentor, Ohio, United States|UH Seidman Cancer Center at Southwest General Hospital, Middleburg Heights, Ohio, United States|Dayton Physicians LLC-Signal Point, Middletown, Ohio, United States|Knox Community Hospital, Mount Vernon, Ohio, United States|Licking Memorial Hospital, Newark, Ohio, United States|Newark Radiation Oncology, Newark, Ohio, United States|University Hospitals Parma Medical Center, Parma, Ohio, United States|Mercy Health Perrysburg Cancer Center, Perrysburg, Ohio, United States|Southern Ohio Medical Center, Portsmouth, Ohio, United States|University Hospitals Portage Medical Center, Ravenna, Ohio, United States|UH Seidman Cancer Center at Firelands Regional Medical Center, Sandusky, Ohio, United States|Dayton Physicians LLC-Wilson, Sidney, Ohio, United States|Springfield Regional Cancer Center, Springfield, Ohio, United States|Springfield Regional Medical Center, Springfield, Ohio, United States|Trinity's Tony Teramana Cancer Center, Steubenville, Ohio, United States|ProMedica Flower Hospital, Sylvania, Ohio, United States|Mercy Saint Anne Hospital, Toledo, Ohio, United States|Toledo Clinic Cancer Centers-Toledo, Toledo, Ohio, United States|Dayton Physicians LLC-Upper Valley, Troy, Ohio, United States|Upper Valley Medical Center, Troy, Ohio, United States|University Hospitals Sharon Health Center, Wadsworth, Ohio, United States|Saint Joseph Warren Hospital, Warren, Ohio, United States|Saint Ann's Hospital, Westerville, Ohio, United States|UH Seidman Cancer Center at Saint John Medical Center, Westlake, Ohio, United States|UHHS-Westlake Medical Center, Westlake, Ohio, United States|Wright-Patterson Medical Center, Wright-Patterson Air Force Base, Ohio, United States|Saint Elizabeth Youngstown Hospital, Youngstown, Ohio, United States|Genesis Healthcare System Cancer Care Center, Zanesville, Ohio, United States|Cancer Centers of Southwest Oklahoma Research, Lawton, Oklahoma, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Mercy Hospital Oklahoma City, Oklahoma City, Oklahoma, United States|Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa, Oklahoma, United States|Saint Alphonsus Medical Center-Baker City, Baker City, Oregon, United States|Saint Charles Health System, Bend, Oregon, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Providence Cancer Institute Clackamas Clinic, Clackamas, Oregon, United States|Bay Area Hospital, Coos Bay, Oregon, United States|Good Samaritan Hospital, Corvallis, Oregon, United States|Legacy Mount Hood Medical Center, Gresham, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Saint Alphonsus Medical Center-Ontario, Ontario, Oregon, United States|Providence Willamette Falls Medical Center, Oregon City, Oregon, United States|Legacy Good Samaritan Hospital and Medical Center, Portland, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Kaiser Permanente Northwest, Portland, Oregon, United States|Saint Charles Health System-Redmond, Redmond, Oregon, United States|Legacy Meridian Park Hospital, Tualatin, Oregon, United States|Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, United States|UPMC-Heritage Valley Health System Beaver, Beaver, Pennsylvania, United States|Saint Luke's University Hospital-Bethlehem Campus, Bethlehem, Pennsylvania, United States|Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania, United States|Bryn Mawr Hospital, Bryn Mawr, Pennsylvania, United States|Christiana Care Health System-Concord Health Center, Chadds Ford, Pennsylvania, United States|Chambersburg Hospital, Chambersburg, Pennsylvania, United States|Main Line Health Center-Collegeville, Collegeville, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Mercy Fitzgerald Hospital, Darby, Pennsylvania, United States|Doylestown Hospital, Doylestown, Pennsylvania, United States|Northeast Radiation Oncology Center, Dunmore, Pennsylvania, United States|Fox Chase Cancer Center - East Norriton Hospital Outpatient Center, East Norriton, Pennsylvania, United States|Pocono Medical Center, East Stroudsburg, Pennsylvania, United States|Ephrata Cancer Center, Ephrata, Pennsylvania, United States|Ephrata Community Hospital, Ephrata, Pennsylvania, United States|Main Line Health Center-Exton, Exton, Pennsylvania, United States|Adams Cancer Center, Gettysburg, Pennsylvania, United States|UPMC Cancer Centers - Arnold Palmer Pavilion, Greensburg, Pennsylvania, United States|Cherry Tree Cancer Center, Hanover, Pennsylvania, United States|Geisinger Medical Center-Cancer Center Hazleton, Hazleton, Pennsylvania, United States|Lehigh Valley Hospital-Hazleton, Hazleton, Pennsylvania, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|UPMC-Johnstown/John P. Murtha Regional Cancer Center, Johnstown, Pennsylvania, United States|Saint Mary Medical and Regional Cancer Center, Langhorne, Pennsylvania, United States|Sechler Family Cancer Center, Lebanon, Pennsylvania, United States|Geisinger Medical Oncology-Lewisburg, Lewisburg, Pennsylvania, United States|UPMC Cancer Center at UPMC McKeesport, McKeesport, Pennsylvania, United States|Holy Redeemer Hospital and Medical Center, Meadowbrook, Pennsylvania, United States|Riddle Memorial Hospital, Media, Pennsylvania, United States|UPMC-Coraopolis/Heritage Valley Radiation Oncology, Moon, Pennsylvania, United States|Paoli Memorial Hospital, Paoli, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Mercy Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Nazareth Hospital, Philadelphia, Pennsylvania, United States|Phoenixville Hospital, Phoenixville, Pennsylvania, United States|UPMC-Magee Womens Hospital, Pittsburgh, Pennsylvania, United States|UPMC-Presbyterian Hospital, Pittsburgh, Pennsylvania, United States|UPMC-Saint Margaret, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States|UPMC-Shadyside Hospital, Pittsburgh, Pennsylvania, United States|UPMC-Passavant Hospital, Pittsburgh, Pennsylvania, United States|UPMC-Saint Clair Hospital Cancer Center, Pittsburgh, Pennsylvania, United States|Pottstown Hospital, Pottstown, Pennsylvania, United States|Geisinger Cancer Services-Pottsville, Pottsville, Pennsylvania, United States|Penn State Health Saint Joseph Medical Center, Reading, Pennsylvania, United States|Guthrie Medical Group PC-Robert Packer Hospital, Sayre, Pennsylvania, United States|Community Medical Center, Scranton, Pennsylvania, United States|Geisinger Medical Oncology-Selinsgrove, Selinsgrove, Pennsylvania, United States|UPMC Cancer Center at UPMC Northwest, Seneca, Pennsylvania, United States|Geisinger Medical Group, State College, Pennsylvania, United States|UPMC Uniontown Hospital Radiation Oncology, Uniontown, Pennsylvania, United States|UPMC Washington Hospital Radiation Oncology, Washington, Pennsylvania, United States|Chester County Hospital, West Chester, Pennsylvania, United States|Geisinger Wyoming Valley/Henry Cancer Center, Wilkes-Barre, Pennsylvania, United States|UPMC Susquehanna, Williamsport, Pennsylvania, United States|Lankenau Medical Center, Wynnewood, Pennsylvania, United States|WellSpan Health-York Cancer Center, York, Pennsylvania, United States|WellSpan Health-York Hospital, York, Pennsylvania, United States|Newport Hospital, Newport, Rhode Island, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Women and Infants Hospital, Providence, Rhode Island, United States|Miriam Hospital, Providence, Rhode Island, United States|Kent Hospital, Warwick, Rhode Island, United States|AnMed Health Cancer Center, Anderson, South Carolina, United States|Beaufort Memorial Hospital, Beaufort, South Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Prisma Health Cancer Institute - Laurens, Clinton, South Carolina, United States|Prisma Health Cancer Institute - Easley, Easley, South Carolina, United States|McLeod Regional Medical Center, Florence, South Carolina, United States|Saint Francis Hospital, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Butternut, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Faris, Greenville, South Carolina, United States|Prisma Health Greenville Memorial Hospital, Greenville, South Carolina, United States|Saint Francis Cancer Center, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Eastside, Greenville, South Carolina, United States|Self Regional Healthcare, Greenwood, South Carolina, United States|Prisma Health Cancer Institute - Greer, Greer, South Carolina, United States|South Carolina Cancer Specialists PC, Hilton Head Island, South Carolina, United States|Prisma Health Cancer Institute - Seneca, Seneca, South Carolina, United States|Prisma Health Cancer Institute - Spartanburg, Spartanburg, South Carolina, United States|Lexington Medical Center, West Columbia, South Carolina, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|Wellmont Bristol Regional Medical Center, Bristol, Tennessee, United States|Wellmont Medical Associates Oncology and Hematology-Bristol, Bristol, Tennessee, United States|Memorial Hospital, Chattanooga, Tennessee, United States|Integrity Oncology PLLC-Collierville, Collierville, Tennessee, United States|Cookeville Regional Medical Center, Cookeville, Tennessee, United States|Pulmonary Medicine Center of Chattanooga-Hixson, Hixson, Tennessee, United States|Wellmont Medical Associates Oncology and Hematology-Johnson City, Johnson City, Tennessee, United States|Regional Cancer Center at Indian Path Community Hospital, Kingsport, Tennessee, United States|Wellmont Holston Valley Hospital and Medical Center, Kingsport, Tennessee, United States|University of Tennessee - Knoxville, Knoxville, Tennessee, United States|Baptist Memorial Hospital and Cancer Center-Memphis, Memphis, Tennessee, United States|Baptist Memorial Hospital for Women, Memphis, Tennessee, United States|Family Cancer Center-Memphis, Memphis, Tennessee, United States|Integrity Oncology PLLC-Memphis, Memphis, Tennessee, United States|Meharry Medical College, Nashville, Tennessee, United States|Memorial GYN Plus, Ooltewah, Tennessee, United States|Hendrick Medical Center, Abilene, Texas, United States|Austin Cancer Centers-Central Austin, Austin, Texas, United States|Austin Cancer Centers-Saint David's, Austin, Texas, United States|Austin Cancer Centers-Northwest, Austin, Texas, United States|Saint Joseph Regional Cancer Center, Bryan, Texas, United States|MD Anderson in The Woodlands, Conroe, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|Lyndon Baines Johnson General Hospital, Houston, Texas, United States|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States|Ben Taub General Hospital, Houston, Texas, United States|M D Anderson Cancer Center, Houston, Texas, United States|MD Anderson West Houston, Houston, Texas, United States|Doctor's Hospital of Laredo, Laredo, Texas, United States|MD Anderson League City, League City, Texas, United States|UTMB Cancer Center at Victory Lakes, League City, Texas, United States|UMC Cancer Center / UMC Health System, Lubbock, Texas, United States|Texas Tech University Health Sciences Center-Lubbock, Lubbock, Texas, United States|MD Anderson in Sugar Land, Sugar Land, Texas, United States|Scott and White Memorial Hospital, Temple, Texas, United States|American Fork Hospital / Huntsman Intermountain Cancer Center, American Fork, Utah, United States|Sandra L Maxwell Cancer Center, Cedar City, Utah, United States|Farmington Health Center, Farmington, Utah, United States|Logan Regional Hospital, Logan, Utah, United States|Intermountain Medical Center, Murray, Utah, United States|McKay-Dee Hospital Center, Ogden, Utah, United States|Ogden Regional Medical Center, Ogden, Utah, United States|Utah Valley Regional Medical Center, Provo, Utah, United States|Riverton Hospital, Riverton, Utah, United States|Dixie Medical Center Regional Cancer Center, Saint George, Utah, United States|Utah Cancer Specialists-Salt Lake City, Salt Lake City, Utah, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|LDS Hospital, Salt Lake City, Utah, United States|South Jordan Health Center, South Jordan, Utah, United States|Southwestern Vermont Medical Center, Bennington, Vermont, United States|Central Vermont Medical Center/National Life Cancer Treatment, Berlin, Vermont, United States|University of Vermont Medical Center, Burlington, Vermont, United States|University of Vermont and State Agricultural College, Burlington, Vermont, United States|Norris Cotton Cancer Center-North, Saint Johnsbury, Vermont, United States|Wellmont Medical Associates-Bristol, Bristol, Virginia, United States|Kaiser Permanente-Burke Medical Center, Burke, Virginia, United States|Danville Regional Medical Center, Danville, Virginia, United States|Inova Schar Cancer Institute, Fairfax, Virginia, United States|Inova Fair Oaks Hospital, Fairfax, Virginia, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|Augusta Health Center for Cancer and Blood Disorders, Fishersville, Virginia, United States|Sentara Cancer Institute at Sentara CarePlex Hospital, Hampton, Virginia, United States|Virginia Oncology Associates-Hampton, Hampton, Virginia, United States|Sovah Health Martinsville, Martinsville, Virginia, United States|Kaiser Permanente Tysons Corner Medical Center, McLean, Virginia, United States|Bon Secours Memorial Regional Medical Center, Mechanicsville, Virginia, United States|Bon Secours Saint Francis Medical Center, Midlothian, Virginia, United States|Sentara Leigh Hospital, Norfolk, Virginia, United States|Sentara Norfolk General Hospital, Norfolk, Virginia, United States|Southwest VA Regional Cancer Center, Norton, Virginia, United States|Bon Secours Saint Mary's Hospital, Richmond, Virginia, United States|Bon Secours Cancer Institute at Reynolds Crossing, Richmond, Virginia, United States|Sentara Virginia Beach General Hospital, Virginia Beach, Virginia, United States|Sentara Princess Anne Hospital, Virginia Beach, Virginia, United States|Providence Regional Cancer System-Aberdeen, Aberdeen, Washington, United States|Cancer Care Center at Island Hospital, Anacortes, Washington, United States|MultiCare Auburn Medical Center, Auburn, Washington, United States|Virginia Mason Bainbridge Island Medical Center, Bainbridge Island, Washington, United States|Overlake Hospital Medical Center, Bellevue, Washington, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, United States|Harrison HealthPartners Hematology and Oncology-Bremerton, Bremerton, Washington, United States|Harrison Medical Center, Bremerton, Washington, United States|Highline Medical Center-Main Campus, Burien, Washington, United States|Providence Regional Cancer System-Centralia, Centralia, Washington, United States|Swedish Cancer Institute-Edmonds, Edmonds, Washington, United States|Saint Elizabeth Hospital, Enumclaw, Washington, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Virginia Mason Federal Way Medical Center, Federal Way, Washington, United States|Saint Francis Hospital, Federal Way, Washington, United States|Tacoma/Valley Radiation Oncology Centers-Gig Harbor, Gig Harbor, Washington, United States|MultiCare Gig Harbor Medical Park, Gig Harbor, Washington, United States|Swedish Cancer Institute-Issaquah, Issaquah, Washington, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Northwest Cancer Clinic, Kennewick, Washington, United States|Providence Regional Cancer System-Lacey, Lacey, Washington, United States|Saint Clare Hospital, Lakewood, Washington, United States|PeaceHealth Saint John Medical Center, Longview, Washington, United States|Virginia Mason Lynnwood Medical Center, Lynnwood, Washington, United States|Skagit Valley Hospital Regional Cancer Care Center, Mount Vernon, Washington, United States|Skagit Valley Hospital, Mount Vernon, Washington, United States|Jefferson Healthcare, Port Townsend, Washington, United States|Harrison HealthPartners Hematology and Oncology-Poulsbo, Poulsbo, Washington, United States|Peninsula Cancer Center, Poulsbo, Washington, United States|MultiCare Good Samaritan Hospital, Puyallup, Washington, United States|Tacoma/Valley Radiation Oncology Centers-Puyallup, Puyallup, Washington, United States|Valley Medical Center, Renton, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Pacific Gynecology Specialists, Seattle, Washington, United States|Swedish Medical Center-Ballard Campus, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Kaiser Permanente Washington, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|Swedish Medical Center-Cherry Hill, Seattle, Washington, United States|Seattle Cancer Care Alliance at Northwest Hospital, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|PeaceHealth United General Medical Center, Sedro-Woolley, Washington, United States|Olympic Medical Cancer Care Center, Sequim, Washington, United States|Providence Regional Cancer System-Shelton, Shelton, Washington, United States|MultiCare Deaconess Cancer and Blood Specialty Center - Valley, Spokane Valley, Washington, United States|Rockwood Cancer Treatment Center-DHEC-Downtown, Spokane, Washington, United States|Spokane Valley Cancer Center-Mayfair, Spokane, Washington, United States|MultiCare Deaconess Cancer and Blood Specialty Center - North, Spokane, Washington, United States|Tacoma/Valley Radiation Oncology Centers-Jackson Hall, Tacoma, Washington, United States|Franciscan Research Center-Northwest Medical Plaza, Tacoma, Washington, United States|Mary Bridge Children's Hospital and Health Center, Tacoma, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States|Northwest Medical Specialties PLLC, Tacoma, Washington, United States|Tacoma/Valley Radiation Oncology Centers-Saint Joe's, Tacoma, Washington, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States|Legacy Cancer Institute Medical Oncology and Day Treatment, Vancouver, Washington, United States|Legacy Salmon Creek Hospital, Vancouver, Washington, United States|Providence Saint Mary Regional Cancer Center, Walla Walla, Washington, United States|Wenatchee Valley Hospital and Clinics, Wenatchee, Washington, United States|North Star Lodge Cancer Center at Yakima Valley Memorial Hospital, Yakima, Washington, United States|Providence Regional Cancer System-Yelm, Yelm, Washington, United States|United Hospital Center, Bridgeport, West Virginia, United States|Edwards Comprehensive Cancer Center, Huntington, West Virginia, United States|Saint Mary's Medical Center, Huntington, West Virginia, United States|WVUH-Berkely Medical Center, Martinsburg, West Virginia, United States|West Virginia University Healthcare, Morgantown, West Virginia, United States|Camden Clark Medical Center, Parkersburg, West Virginia, United States|Princeton Community Hospital, Princeton, West Virginia, United States|Radiology Associates of Appleton/ThedaCare Regional Medical Center, Appleton, Wisconsin, United States|ThedaCare Regional Cancer Center, Appleton, Wisconsin, United States|Duluth Clinic Ashland, Ashland, Wisconsin, United States|Northwest Wisconsin Cancer Center, Ashland, Wisconsin, United States|Ascension Southeast Wisconsin Hospital - Elmbrook Campus, Brookfield, Wisconsin, United States|Aurora Cancer Care-Southern Lakes VLCC, Burlington, Wisconsin, United States|Marshfield Clinic-Chippewa Center, Chippewa Falls, Wisconsin, United States|Marshfield Clinic Cancer Center at Sacred Heart, Eau Claire, Wisconsin, United States|Marshfield Medical Center-EC Cancer Center, Eau Claire, Wisconsin, United States|Mayo Clinic Health System-Eau Claire Clinic, Eau Claire, Wisconsin, United States|Saint Agnes Hospital/Agnesian Cancer Center, Fond Du Lac, Wisconsin, United States|Aurora Health Center-Fond du Lac, Fond Du Lac, Wisconsin, United States|Ascension Saint Francis - Reiman Cancer Center, Franklin, Wisconsin, United States|Aurora Health Care Germantown Health Center, Germantown, Wisconsin, United States|Aurora Cancer Care-Grafton, Grafton, Wisconsin, United States|Green Bay Oncology at Saint Vincent Hospital, Green Bay, Wisconsin, United States|Bellin Memorial Hospital, Green Bay, Wisconsin, United States|Saint Vincent Hospital Cancer Center Green Bay, Green Bay, Wisconsin, United States|Green Bay Oncology Limited at Saint Mary's Hospital, Green Bay, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay, Wisconsin, United States|Aurora BayCare Medical Center, Green Bay, Wisconsin, United States|Mercyhealth Hospital and Cancer Center - Janesville, Janesville, Wisconsin, United States|UW Cancer Center Johnson Creek, Johnson Creek, Wisconsin, United States|Aurora Cancer Care-Kenosha South, Kenosha, Wisconsin, United States|Gundersen Lutheran Medical Center, La Crosse, Wisconsin, United States|Mayo Clinic Health System-Franciscan Healthcare, La Crosse, Wisconsin, United States|Marshfield Clinic - Ladysmith Center, Ladysmith, Wisconsin, United States|Dean Hematology and Oncology Clinic, Madison, Wisconsin, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Holy Family Memorial Hospital, Manitowoc, Wisconsin, United States|Aurora Bay Area Medical Group-Marinette, Marinette, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Marinette, Marinette, Wisconsin, United States|Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, United States|Ascension Columbia Saint Mary's Hospital Ozaukee, Mequon, Wisconsin, United States|Aurora Cancer Care-Milwaukee, Milwaukee, Wisconsin, United States|Ascension Columbia Saint Mary's Hospital - Milwaukee, Milwaukee, Wisconsin, United States|Aurora Saint Luke's Medical Center, Milwaukee, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Aurora Sinai Medical Center, Milwaukee, Wisconsin, United States|Marshfield Clinic-Minocqua Center, Minocqua, Wisconsin, United States|ProHealth D N Greenwald Center, Mukwonago, Wisconsin, United States|Cancer Center of Western Wisconsin, New Richmond, Wisconsin, United States|ProHealth Oconomowoc Memorial Hospital, Oconomowoc, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Oconto Falls, Oconto Falls, Wisconsin, United States|Vince Lombardi Cancer Clinic - Oshkosh, Oshkosh, Wisconsin, United States|Ascension All Saints Hospital, Racine, Wisconsin, United States|Aurora Cancer Care-Racine, Racine, Wisconsin, United States|Marshfield Medical Center-Rice Lake, Rice Lake, Wisconsin, United States|HSHS Saint Nicholas Hospital, Sheboygan, Wisconsin, United States|Vince Lombardi Cancer Clinic-Sheboygan, Sheboygan, Wisconsin, United States|Marshfield Clinic Stevens Point Center, Stevens Point, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Sturgeon Bay, Sturgeon Bay, Wisconsin, United States|Green Bay Oncology - Sturgeon Bay, Sturgeon Bay, Wisconsin, United States|Aurora Medical Center in Summit, Summit, Wisconsin, United States|Vince Lombardi Cancer Clinic-Two Rivers, Two Rivers, Wisconsin, United States|ProHealth Waukesha Memorial Hospital, Waukesha, Wisconsin, United States|UW Cancer Center at ProHealth Care, Waukesha, Wisconsin, United States|Marshfield Clinic-Wausau Center, Wausau, Wisconsin, United States|Ascension Medical Group Southeast Wisconsin - Mayfair Road, Wauwatosa, Wisconsin, United States|Aurora Cancer Care-Milwaukee West, Wauwatosa, Wisconsin, United States|Aurora West Allis Medical Center, West Allis, Wisconsin, United States|Marshfield Clinic - Weston Center, Weston, Wisconsin, United States|Marshfield Clinic - Wisconsin Rapids Center, Wisconsin Rapids, Wisconsin, United States|Cheyenne Regional Medical Center-West, Cheyenne, Wyoming, United States|Billings Clinic-Cody, Cody, Wyoming, United States|Welch Cancer Center, Sheridan, Wyoming, United States|Cross Cancer Institute, Edmonton, Alberta, Canada|BCCA-Vancouver Cancer Centre, Vancouver, British Columbia, Canada|The Vitalite Health Network - Dr Leon Richard Oncology Centre, Moncton, New Brunswick, Canada|Atlantic Health Sciences Corporation-Saint John Regional Hospital, Saint John, New Brunswick, Canada|Cambridge Memorial Hospital, Cambridge, Ontario, Canada|Kingston Health Sciences Centre, Kingston, Ontario, Canada|Grand River Regional Cancer Centre at Grand River Hospital, Kitchener, Ontario, Canada|London Regional Cancer Program, London, Ontario, Canada|Odette Cancer Centre- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|PEI Cancer Treatment Centre-Queen Elizabeth Hospital, Charlottetown, Prince Edward Island, Canada|CIUSSSEMTL-Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada|Advance Oncology Center, Aguadilla, Puerto Rico|Doctor's Cancer Center-Arecibo, Arecibo, Puerto Rico|Cancer Center-Metro Medical Center Bayamon, Bayamon, Puerto Rico|Hematologia Oncologia San Pablo, Bayamon, Puerto Rico|HIMA San Pablo Oncologic Hospital, Caguas, Puerto Rico|Doctors Cancer Center, Manati, Puerto Rico|Instituto Oncologia Moderna Ponce, Ponce, Puerto Rico|San Juan Community Oncology Group, San Juan, Puerto Rico|Primary Care Physician Group, San Juan, Puerto Rico|Centro Comprensivo de Cancer de UPR, San Juan, Puerto Rico|San Juan City Hospital, San Juan, Puerto Rico|Centro de Hematologia y Oncologia del Sur, Santa Isabel, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT02927249"
1875,"NCT02795156","Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations",,"Recruiting","No Results Available","Non-small Cell Lung Carcinoma|Urothelial Carcinoma|Gastrointestinal Carcinoma, Non-colon|Upper Aerodigestive Tract Carcinoma","Drug: afatinib|Drug: regorafenib|Drug: Cabozantinib","Overall response rate (ORR)|Clinical benefit rate|Time to treatment failure|Progression-free survival","SCRI Development Innovations, LLC|Foundation Medicine|Boehringer Ingelheim|Bayer|Exelixis","All","18 Years and older   (Adult, Older Adult)","Phase 2","160","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCRI PRO 10","September 28, 2016","December 1, 2020","December 30, 2020","June 9, 2016",,"September 17, 2019","Sarah Cannon Research Institute at HealthOne, Denver, Colorado, United States|Florida Cancer Specialists - South, Fort Myers, Florida, United States|Florida Cancer Specialists - North, Saint Petersburg, Florida, United States|Florida Cancer Specialists - East, West Palm Beach, Florida, United States|Research Medical Center - HCA Midwest, Kansas City, Missouri, United States|Tennesse Oncology, Chattanooga, Tennessee, United States|Tennessee Oncology, Nashville, Tennessee, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02795156"
1876,"NCT02269098","The Synergy to Control Emergency Department Hyperglycemia Program for Type 2 Diabetes","STEP-DM","Completed","Has Results","Diabetes Mellitus, Type 2|Medication Adherence|HYPERGLYCEMIA","Other: Diabetes medication management","Hemoglobin A1C at 4 Weeks|Medication Adherence|Blood Glucose < 180mg/dL|Hypoglycemia","Medstar Health Research Institute|American Diabetes Association|Sanofi|Bayer|Washington Hospital Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","101","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","2011-010","February 2012","September 2013","December 2013","October 20, 2014","January 9, 2017","January 9, 2017","MedStar Washington Hospital Center, Washington, District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT02269098"
1877,"NCT01675076","Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events","BRUISECONTROL2","Completed","No Results Available","Hematoma","Drug: Dabigatran|Drug: Rivaroxaban|Drug: Apixaban","Clinically significant hematoma|Composite of major peri-operative bleeding events and thrombo-embolic events","Ottawa Heart Institute Research Corporation|Boehringer Ingelheim|Heart and Stroke Foundation of Canada|Bayer|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 3","663","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","UOHI-05","January 2013","October 2017","May 2018","August 29, 2012",,"October 7, 2019","Foothills Medical Centre, Calgary, Alberta, Canada|University of Alberta-ECAT Group, Edmonton, Alberta, Canada|Victoria Cardiac Arrhythmia Trials Inc., Victoria, British Columbia, Canada|Hamilton Health Sciences General Campus, Hamilton, Ontario, Canada|Southlake Regional Health Centre, Newmarket, Ontario, Canada|University of Ottawa Heart Institute, Ottawa, Ontario, Canada|Rouge Valley Health System-Centenary Campus, Toronto, Ontario, Canada|Humber River Hospital, Toronto, Ontario, Canada|Montreal Heart Institute, Montreal, Quebec, Canada|Centre Hospitalier de l'Universite de Montreal (CHUM), Hotel Dieu, Montreal, Quebec, Canada|McGill University Health Centre/Montreal General Hospital, Montreal, Quebec, Canada|Hopital Sacre-Coeur, Montreal, Quebec, Canada|Centre Hospitalier Universitaire de Sherbrooke-Hopital Fleurimont, Sherbrooke, Quebec, Canada|Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Quebec, Canada|Galilee Medical Center, Nahariya, Israel",,"https://ClinicalTrials.gov/show/NCT01675076"
1878,"NCT02695810","The PRE-D Trial: Effect of Dapagliflozin, Metformin and Physical Activity in Pre-diabetes",,"Completed","No Results Available","Prediabetic State|Obesity","Drug: Dapagliflozin|Drug: Metformin|Behavioral: Exercise","Mean amplitude of glycaemic excursions (MAGE) as assessed by continuous glucose monitoring|Intra-day glycaemic variability as assessed by continuous overall net glycaemic action (CONGA)|Daily time spent above different glucose concentrations ( e.g. >6.1 mmol/L, >7.0 mmol/L, >7.8 mmol/L, and >11.1 mmol/L)|HbA1c|Glucose concentrations during OGTT|Insulin secretion as assessed by the insulinogenic index|Insulin sensitivity as assessed by the insulin sensitivity index|Body weight (kg)|Body fat (%) as assessed by DEXA scan|Cardiorespiratory fitness as assessed by maximal oxygen uptake (VO2 max)|Respiratory exchange ratio (RER) as assessed by indirect calorimetry|Basal metabolic rate (BMR) as assessed by indirect calorimetry|Time spent sedentary and in moderate-to-vigorous physical activity intensity as assessed by accelerometer|Systolic and diastolic blood pressure|Plasma lipids|Number of self-reported adverse events and side effects|Self-rated health and quality of life as assessed by questionnaire|Sleep habits as assessed by questionnaire|Dietary intake as assessed by a food diary|Adherence to the different interventions as assessed by number of tablets returned or number of training passes completed|Responsiveness to interventions in individuals with different glucose tolerance status (impaired fasting glycaemia vs. impaired glucose tolerance)","Steno Diabetes Center Copenhagen|The Novo Nordic Foundation|Rigshospitalet, Denmark|AstraZeneca|Bayer","All","30 Years to 70 Years   (Adult, Older Adult)","Phase 2","120","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2015-001552-30","February 24, 2016","September 20, 2018","January 13, 2019","March 1, 2016",,"October 7, 2019","Steno Diabetes Center A/S, Gentofte, Denmark",,"https://ClinicalTrials.gov/show/NCT02695810"
1879,"NCT02546622","ATHN 2: Factor Switching Study",,"Recruiting","No Results Available","Hemophilia","Biological: Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013|Biological: Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013","Inhibitor Development|Prevalence of risk factors for inhibitor development|Targeted post-marketing approval safety and efficacy data|Platform for additional substudies","American Thrombosis and Hemostasis Network|Shire|CSL Behring|Bioverativ Therapeutics Inc.|Bayer","All","Child, Adult, Older Adult",,"600","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Other","ATHN 2","September 2015","August 2021","January 2022","September 11, 2015",,"August 7, 2019","University of California San Diego (UCSD), San Diego, California, United States|University of Colorado Denver Hemophilia and Thrombosis Center, Aurora, Colorado, United States|Yale Hemophilia Treatment Center, New Haven, Connecticut, United States|Children's National Medical Center, Washington, District of Columbia, United States|Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States|St. Joseph's Children's Hospital, Tampa, Florida, United States|Children's Healthcare of Atlanta/Emory, Atlanta, Georgia, United States|Bleeding and Clotting Disorders Institute, Peoria, Illinois, United States|Indiana Hemophilia and Thrombosis Center (IHTC), Indianapolis, Indiana, United States|Louisiana Center for Bleeding and Clotting Disorders, New Orleans, Louisiana, United States|Maine Hemophilia and Thrombosis Center, Scarborough, Maine, United States|Johns Hopkins University Medical Center, Baltimore, Maryland, United States|Boston Hemophilia Center at Children's Hospital of Boston, Boston, Massachusetts, United States|University of Michigan Hemophilia and Coagulation Disorders Program, Ann Arbor, Michigan, United States|Michigan State University Center for Bleeding and Clotting Disorders, East Lansing, Michigan, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|Dartmouth-Hitchcock Comprehensive Hemophilia and Thrombosis Center, Lebanon, New Hampshire, United States|Weill Cornell Medicine, New York, New York, United States|Mary M. Gooley Hemophilia Center, Rochester, New York, United States|Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, United States|Pennsylvania Comprehensive Hemophilia and Thrombophilia Program / Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|The Hemophilia Center of Western Pennsylvania, Pittsburgh, Pennsylvania, United States|St Jude Children's Research Hospital, Memphis, Tennessee, United States|UTSW Medical Center at Dallas/Children's Medical Center, Dallas, Texas, United States|Washington Center for Bleeding Disorders Bloodworks Northwest d/b/a Puget Sound Blood Center, Seattle, Washington, United States|Blood Center of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02546622"
1880,"NCT02082548","Clinical Trial to Improve Treatment With Blood Thinners in Patients With Atrial Fibrillation","IMPACT-AF","Completed","No Results Available","Atrial Fibrillation","Other: Educational Intervention","Change in proportion of patients taking oral anticoagulants|Change in proportion of patients able to continue anticoagulation|Change in proportion of patients who are not on anticoagulation at baseline and are on anticoagulation|Death, total|Stroke, hemorrhagic and non-hemorrhagic|Major and non-major clinically relevant bleeding","Duke University|Bristol-Myers Squibb|Daiichi Sankyo, Inc.|Boehringer Ingelheim|Bayer","All","18 Years and older   (Adult, Older Adult)","Not Applicable","2374","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Pro00049709","June 2014","May 9, 2017","May 9, 2017","March 10, 2014",,"November 13, 2017","INECO Neurosciencias Orono, Rosario, Santa Fe, Argentina|Federal University of Sao Paulo, Sao Paulo, Brazil|Peking University First Hospital, Beijing, China|St Johns Medical College, Bangalore, India|University of Medicina and Pharmacy Carol Davila, Bucharest, Romania",,"https://ClinicalTrials.gov/show/NCT02082548"
1881,"NCT00135226","ASCEND: A Study of Cardiovascular Events iN Diabetes",,"Active, not recruiting","Has Results","Diabetes Mellitus","Drug: Aspirin|Drug: Omega-3 Ethyl Esters|Drug: Placebo Aspirin|Drug: Placebo Omega-3 Ethyl Esters","Number of Participants With First Occurrence of Any Serious Vascular Event (SVE)|Number of Participants With First Occurrence of Any Major Bleed (Aspirin Comparison Only)|Number of Participants With Combined End-point of Serious Vascular Events (SVEs) or Revascularizations|Number of Participants With Any Incident Gastrointestinal (GI) Tract Cancer (Aspirin Comparison Only)","University of Oxford|British Heart Foundation|Bayer|EPD Solutions, A Philips Company|Medical Research Council","All","40 Years and older   (Adult, Older Adult)","Phase 4","15480","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CTSUASCEND1|60635500","March 2005","March 12, 2018","July 31, 2037","August 25, 2005","April 26, 2019","April 26, 2019","Clinical Trial Service Unit, University of Oxford, Oxford, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT00135226/SAP_000.pdf|""Study Protocol and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT00135226/Prot_ICF_001.pdf","https://ClinicalTrials.gov/show/NCT00135226"
1882,"NCT01927367","Integrated Management Program Advancing Community Treatment of Atrial Fibrillation","IMPACT-AF","Completed","No Results Available","Atrial Fibrillation","Other: Clinical Decision Support System for AF","Cardiovascular Hospitalization and AF-related Emergency Department Visits|Clinical|Process of Care|Health related quality of life|Costs|Cost Effectiveness","Jafna L Cox|McMaster University|Population Health Research Institute|St. Joseph's Healthcare Hamilton|Bayer|Nova Scotia Health Authority","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1145","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","IMPACT-AF-2013","September 2013","November 2018","November 2018","August 22, 2013",,"February 5, 2019","Capital District Health Authority, Halifax, Nova Scotia, Canada|St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01927367"
1883,"NCT00634634","Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer",,"Active, not recruiting","No Results Available","Metastatic Breast Cancer","Drug: Sorafenib|Drug: Letrozole","find phase II dose of study drugs in pts w/hormone receptor-positive locally advanced or metastatic breast ca. find clinical benefit rate (pts who achieve a CR, PR, or SD in the first-line trt of postmenopausal pts.|time to progression/survival. Assess safety/tolerability. Evaluate growth factor pathways in tumor samples before/after trt. Evaluate change in circulating tumor cells before/after trt. Evaluate change in blood flow before/after treatment","Rutgers, The State University of New Jersey|Rutgers Cancer Institute of New Jersey|National Cancer Institute (NCI)|Bayer|Novartis Pharmaceuticals","Female","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","54","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","040706|NJ 1107|0220070284|NCI-2012-00525","August 11, 2008","May 2021","May 2021","March 13, 2008",,"September 12, 2019","Georgetown University Hospital, Washington, District of Columbia, United States|Emory University, Atlanta, Georgia, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Cooper Hospital/University Medical Center, Voorhees, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT00634634"
1884,"NCT01136005","Bepanthen Versus Cetomacrogol in Epidermal Growth Factor Receptor Inhibitors (EGFRI)","BeCet","Completed","No Results Available","Cancer|Skin Rash","Other: dexpanthenol 5% cream|Other: Cetomacrogol cream","grade 2 or more papulopustular eruption|impact of papulopustular eruptions on HRQoL|patient tolerability and satisfaction of study cream|effectiveness of study cream on the adherence|other dermatological side effects","Impaqtt Foundation|CB Boers ORG|Memorial Sloan Kettering Cancer Center|Leiden University Medical Center|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","160","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Impaqtt-001|M010-025","September 2010","December 2016","March 2017","June 3, 2010",,"November 13, 2017","Medisch Centrum Alkmaar, Alkmaar, Netherlands|Deventer ziekenhuis, Deventer, Netherlands|Admiraal de Ruyter Hospital, Goes, Netherlands|Leiden University Medical Centre, Leiden, Netherlands|Waterland Hospital, Purmerend, Netherlands|Zaans Medisch Centrum, Zaandam, Netherlands",,"https://ClinicalTrials.gov/show/NCT01136005"
1885,"NCT01054105","Effect of BMPR-2 Gene Mutations on Hemodynamic Response by Iloprost Inhalation in Pulmonary Arterial Hypertension","PILGRIM","Completed","No Results Available","Pulmonary Arterial Hypertension","Drug: Iloprost","Cardiopulmonary exercise test parameters|Major cardiovascular Events (cardiovascular mortality, all cause mortality, hospitalization)|Six-minutes walking test|WHO/NYHA class|Echo parameters|NT-proBNP","Gachon University Gil Medical Center|Seoul National University Hospital|Seoul National University Bundang Hospital|The Catholic University of Korea|Bayer","All","20 Years to 80 Years   (Adult, Older Adult)",,"73","Other|Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","WJC-IIT-1001|GIRBA 2278","October 2010","December 25, 2018","December 25, 2018","January 22, 2010",,"December 27, 2018","Soonchunhyang University Bucheon Hospital, Bucheon, Korea, Republic of|Gachon University Gil Hospital, Incheon, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, Korea, Republic of|Catholic University Seoul Saint Mary's Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Sungkyunkwan University Seoul Samsung Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01054105"
1886,"NCT00455897","CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma",,"Terminated","No Results Available","Lymphoma, Non-Hodgkin|Lymphoma, B-Cell|Lymphoma, Diffuse","Drug: GM-CSF|Drug: CHOP|Drug: Rituximab","To determine the safety of GM-CSF when administered in combination with CHOP-R to patients with previously untreated diffuse large B cell non-Hodgkin's lymphoma.|To assess the response rate, 2-year event-free survival and overall survival with CM-CSF and CHOP-R in this patient population|to analyze the biologic activity of GM-CSF at this dosing schedule and timing.","Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|Dana-Farber Cancer Institute|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","3","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","05-342","December 2006","November 2007","July 2011","April 4, 2007",,"January 18, 2018","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00455897"
1887,"NCT00434460","Study of Knowledge Translation of Clinical Practice Guidelines for Ventilator Associated Pneumonia","ABATEVAP","Completed","No Results Available","Ventilator Associated Pneumonia","Behavioral: Education",,"Canadian Critical Care Trials Group|Kingston Health Sciences Centre|Canadian Institutes of Health Research (CIHR)|AstraZeneca|Bayer","All","17 Years and older   (Child, Adult, Older Adult)",,"1320","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ABATE VAP","April 2007",,"July 2010","February 13, 2007",,"September 1, 2010","Geisinger Health Centre, Temple University, Danville, Pennsylvania, United States|Royal Columbian Hospital, University of British Columbia, New Westminister, British Columbia, Canada|St. Paul Hospital, University of British Columbia, Vancouver, British Columbia, Canada|Vancouver Island Health Research Centre, Victoria, British Columbia, Canada|St. Joseph's Healthcare, McMaster University, Hamilton, Ontario, Canada|Kingston General Hospital, Queen's University, Kingston, Ontario, Canada|The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada|Thunder Bay Regional Health Sciences Centre, Thunder Bay, Ontario, Canada|Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada|William Osler Health Centre, Toronto, Ontario, Canada|Hotel Dieu Grace Hospital, Windsor, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00434460"
1888,"NCT02387229","Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF","BRAIN-AF","Recruiting","No Results Available","ATRIAL FIBRILLATION","Drug: Rivaroxaban|Other: standard of care","Composite endpoint of stroke, TIA and neurocognitive decline|Death (total and cardiovascular)|Composite including stroke/transient ischemic attack (TIA) and systemic embolic events|Neurocognitive decline|Hospitalization for cardiovascular (myocardial infarction, heart failure, AF, stroke or unstable angina or other cardiovascular events) or bleeding event","Montreal Heart Institute|Canadian Stroke Prevention Intervention Network|The Montreal Health Innovations Coordinating Center (MHICC)|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma|Montreal Heart Institute Foundation","All","30 Years to 62 Years   (Adult)","Phase 3","3250","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","BRAIN-001","March 2015","February 2022","February 2022","March 12, 2015",,"August 9, 2019","Montreal Heart Institute, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02387229"
1889,"NCT00864383","Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis","REMoxTB","Completed","Has Results","Pulmonary Tuberculosis","Drug: Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin","Combined Failure of Bacteriological Cure and Relapse Within One Year of Completion of Therapy as Defined by Culture Using Solid Media (Lowenstein-Jensen - LJ).|Number of Patients With Grade 3 or 4 Adverse Events (Using a Modified Division of Acquired Immunodeficiency Syndrome National Institute of Allergy and Infectious Diseases [DAIDS] Scale of Adverse Event Reporting)|Combined Failure of Bacteriological Cure and Relapse as Defined by Culture Using Liquid Media (Mycobacteria Growth Indicator Tube-MGIT).|Number of Patients Who Are Culture Negative (Solid LJ Culture)|Number of Patients Who Are Culture Negative (Liquid MGIT Culture)|Time to First Culture Negative Sputum Sample (LJ Solid Media)|Time to First Culture Negative Sputum Sample (MGIT Liquid Media)|Sensitivity Analysis Assuming All Losses to Follow-up and Non-tuberculous Deaths Have an Unfavorable Outcome Using Solid (L-J) Media.|Sensitivity Analyses Assuming All Losses to Follow-up and Non-tuberculous Deaths Have a Favourable Outcome Using Solid (L-J) Media.","Global Alliance for TB Drug Development|European and Developing Countries Clinical Trials Partnership (EDCTP)|University College, London|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","1931","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","REMoxTB|ISRCTN85595810","January 2008","October 2013","February 2014","March 18, 2009","May 25, 2015","March 21, 2017","Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China|Shanghai Pulmonary Hospital, Shanghai, China|TB Institute, Tianjin, China|Nirmal Kumar Jain, Jaipur, Rajasthan, India|Mahatma Gandhi Medical College& Hospital, Jaipur, Rajsthan, India|Ram-Tej Hospital,, Agra, Uttar Pradesh, India|Siddharth Nursing Home,, Agra, Uttar pradesh, India|Rajul Nursing Home, Aligarh, Uttar Pradesh, India|Varshneya Chest Clinic & Eye Care Centre, Aligarh, Uttar Pradesh, India|Dr. Neeraj Gupta Clinic, Firozabad, Uttar Pradesh, India|S.P.S Chauhan Clinic, Firozabad, Uttar Pradesh, India|Dr. R. K. Garg's Clinic,, Gaziabad, Uttar Pradesh, India|Indra Nursing Home and Maternity Centre, Ghaziabad, Uttar Pradesh, India|Dr. AK Singh Clinic, Kanpur, Uttar Pradesh, India|Dr. S. K. Katiyar, Swaroop Nagar,, Kanpur, Uttar Pradesh, India|Guru Tej Bahadur Hospital, Kanpur, Uttar Pradesh, India|Dr. Komal Gupta, Lucknow, Uttar Pradesh, India|New City Hospital and Trauma Centre,, Lucknow, Uttar Pradesh, India|Surya Chest Foundation,, Lucknow, Uttar Pradesh, India|Surya Kant Clinic, Lucknow, Uttar Pradesh, India|Dr. Mahip Saluja Clinic, U.P., Meerut,, Uttar Pradesh, India|Arya Chest Clinic, UP,India, Meerut, Uttar Pradesh, India|Dr. S. P. Sondhi Clinic,, Meerut, Uttar Pradesh, India|Sri Ram Plaza, Meerut, Uttar Pradesh, India|Jigyasa Medical Center, Moradabad, Uttar Pradesh, India|Saanvi MultiSpeciality Clinic,, Moradabad, Uttar Pradesh, India|A-One Hospital, Delhi, India|Dr. D.K. Chauhan, New Delhi, India|Centre for advanced lung and sleep disorders, New Delhi, India|Dr. Mittal's clinic, New Delhi, India|Diligent Hospital, New Delhi, India|Ish Medical Centre and Respiratory Lab,, New Delhi, India|Smt Prakash Devi Memorial Medical Centre,, New Delhi, India|Centre for Respiratory Disease Research at KEMRI, Nairobi, Kenya|Institute of Respiratory Medicine (IPR) Jalan Pahang, Kuala Lumpur, Malaysia|Hospital General de Occidente de la secretaria, Guadalajara, Seattle, Mexico|Madibeng centre for Research, 40 Pienaar Street,, Madibeng, Brits, South Africa|Clinical HIV Research Unit (CHRU), Johannesburg, Westdene, South Africa|Centre for TB Research and Innovation, University of Cape Town Lung Institute, Cape Town, South Africa|Tiervlei Trial Center and University of Stellenbosch, Cape Town, South Africa|Unit for Clinical & Biomedical TB Research, MRC Durban, Durban, South Africa|NIMR Mbeya Medical Research Programme, Mbeya, Tanzania|Kilimanjaro Christian Medical Centre, Moshi, Tanzania|Srinagarind Hospital, Division of Pulmonary Medicine, Khon Kaen University, Khon Kaen, Mueang, Thailand|Chest Disease Institute (CDI), Ministry of Public,, Nonthaburi, Mueang, Thailand|Rajavithi Hospital, Division Of Pulmonary Medicine, Bangkok, Phayathai, Thailand|University Teaching Hospital, Lusaka, Zambia",,"https://ClinicalTrials.gov/show/NCT00864383"
1890,"NCT02334852","Registry of Atrial Fibrillation and Embolic Risk in Mexico","CARMEN-AF","Completed","No Results Available","Atrial Fibrillation",,"Oral anticoagulation","Registro de Fibrilación Auricular y Riesgo Embólico en México|Bayer|Boehringer Ingelheim|Bristol-Myers Squibb|Pfizer|Medicaweb, S.A.C.V.","All","18 Years and older   (Adult, Older Adult)",,"1200","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CARMEN","December 2014","December 2016","March 2017","January 8, 2015",,"April 11, 2017",,,"https://ClinicalTrials.gov/show/NCT02334852"
1891,"NCT00943943","Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations",,"Completed","No Results Available","Acute Myelogenous Leukemia|Leukemia","Drug: G-CSF|Drug: Plerixafor|Drug: Sorafenib","Maximum Tolerated Dose (MTD) of Sorafenib","M.D. Anderson Cancer Center|Bayer|Genzyme, a Sanofi Company|Amgen|National Cancer Institute (NCI)|Georgia Institute of Technology","All","18 Years and older   (Adult, Older Adult)","Phase 1","33","Other|Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2008-0501|R01FD003733|R21CA143805|NCI-2009-01512","October 29, 2010","March 23, 2017","March 23, 2017","July 22, 2009",,"March 29, 2017","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00943943"
1892,"NCT03187132","Development and Validation of a Digital Pain-Reduction Kit for Musculoskeletal Injuries",,"Recruiting","No Results Available","Pain, Acute|Pain, Chronic","Device: Digital Pain Reduction Kit|Device: Active Control","Physical Function|Pain Interference|Work Productivity|Satisfaction with Pain Treatment and Healthcare|Opioid Use","Cedars-Sinai Medical Center|The Travelers Companies, Inc.|Samsung|AppliedVR Inc.|Bayer|Hollywog","All","18 Years and older   (Adult, Older Adult)","Not Applicable","174","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00049015","April 3, 2018","December 5, 2019","December 5, 2019","June 14, 2017",,"June 14, 2019","Cedars-Sinai Medical Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT03187132"
1893,"NCT00813293","Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer",,"Unknown status","No Results Available","Hepatocellular Cancer","Drug: Sorafenib|Procedure: radiofrequency ablation","To prospectively investigate if sorafenib increases the effectiveness of RFA.|To describe the safety and feasibility of sorafenib prior to RFA.|To explore the relationship between MRI and RFA effectiveness|To investigate tumor tissue for changes after sorafenib and to assess for RFA predictors","Beth Israel Deaconess Medical Center|Dana-Farber Cancer Institute|Brigham and Women's Hospital|Bayer|Onyx Therapeutics, Inc.|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","20","Other|Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","08-256|K23CA139005|IST000508","January 2009","December 2016","December 2017","December 23, 2008",,"February 27, 2017","Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00813293"
1894,"NCT01078961","An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma",,"Completed","No Results Available","Melanoma","Drug: bortezomib|Drug: sorafenib","Maximally tolerated dose|Document and summarize toxicities|Anti-tumor activity","Massachusetts General Hospital|Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|Bayer|Millennium Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","11","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09-443|X05297","September 2010","February 2013","June 2016","March 2, 2010",,"June 8, 2016","Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01078961"
1895,"NCT00504491","R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia","R-CHOP","Withdrawn","No Results Available","Chronic Lymphocytic Leukaemia|Patients Resistant to a Purine Analogous|Patients Relapsed With Purines Therapy","Drug: Rituximab-CHOP-Alemtuzumab","Response rate obtained after R-CHOP regimen followed by consolidation therapy with Alemtuzumab, as second line therapy. Haematological and non haematological toxicity will be graded in accordance with the WHO system","CABYC|Francesc Bosch, MD|Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea|Fundacion Clinic per a la Recerca Biomédica|Bayer|Genzyme, a Sanofi Company","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","0","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GELLC-2|2007-003097-26","July 2007","January 2012","June 2012","July 20, 2007",,"December 30, 2011","ICO Badalona, Badalona, Barcelona, Spain|ICO Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Althaia, Manresa, Barcelona, Spain|Corporacion Sanitaria Parc Tauli, Sabadell, Barcelona, Spain|Hospital Clinic i Provincial., Barcelona, Cataluña, Spain|Hospital Universitario de Canarias, La Laguna, Gran Canaria, Spain|Hospital de Son Dureta, Palma de Mallorca, Islas Baleares, Spain|Hospital Francisco de Borja, Gandia, Valencia, Spain|Hospital del Mar, Barcelona, Spain|Hospital Santa Creu i Sant Pau, Barcelona, Spain|Hospital Valle de Hebron, Barcelona, Spain|Hospital de Basurto, Bilbao, Spain|ICO Gerona, Girona, Spain|Hospital Virgen de las Nieves, Granada, Spain|Hospital Arnau de Vilanova, Lleida, Spain|Hospital La Princesa, Madrid, Spain|Hospital Gregorio Marañon, Madrid, Spain|M.D.Anderson Internacional, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital 12 de octubre, Madrid, Spain|Hospital Morales Meseguer, Murcia, Spain|Hospital Clinico de Salamanca, Salamanca, Spain|Hospital Marques de Valdecilla, Santander, Spain|Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Joan XXIII, Tarragona, Spain|Hospital La Fe, Valencia, Spain|Hospital Clinico de Valencia, Valencia, Spain|Hospital Doctor Peset, Valencia, Spain|Hospital General de Valencia, Valencia, Spain|Hospital Miguel Servet, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT00504491"
1896,"NCT01068769","Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor",,"Active, not recruiting","Has Results","Gastrointestinal Stromal Tumor","Drug: regorafenib","Clinical Benefit as Defined by the Composite of Complete Response, Partial Response and Stable Disease Lasting 16 Weeks or More Per RECIST 1.1 as a Measure of Disease Control|Progression-free Survival (PFS)","Suzanne George, MD|Brigham and Women's Hospital|Massachusetts General Hospital|Fox Chase Cancer Center|Oregon Health and Science University|Bayer|Dana-Farber Cancer Institute","All","18 Years and older   (Adult, Older Adult)","Phase 2","34","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09-400","February 2010","June 2012","December 2020","February 15, 2010","February 24, 2014","October 8, 2019","Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Oregon Health Sciences University, Portland, Oregon, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01068769"
1897,"NCT02533960","Registry of Acute Stroke Under Novel Oral Anticoagulants - Prime","RASUNOA-Prime","Recruiting","No Results Available","Ischemic Stroke|Intracerebral Hemorrhage|Oral Anticoagulation|Cardiovascular Diseases|Vascular Diseases","Other: not applicable (observational study)","Primary hypothesis (ischemic stroke substudy)|Primary hypothesis (hemorrhagic stroke substudy)","University Hospital Heidelberg|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma|Boehringer Ingelheim|Bristol-Myers Squibb|Daiichi Sankyo, Inc.|University of Wuerzburg","All","18 Years and older   (Adult, Older Adult)",,"4000","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","RASUNOA-Prime","June 2015","October 2020","October 2020","August 27, 2015",,"October 1, 2019","University Hospital Heidelberg, Heidelberg, Germany",,"https://ClinicalTrials.gov/show/NCT02533960"
1898,"NCT02194842","Phase III Radium 223 mCRPC-PEACE III","PEACE III","Recruiting","No Results Available","Prostate Cancer","Drug: Ra223|Drug: Enzalutamide","radiological progression-free survival|Overall survival|prostate cancer specific survival|First symptomatic skeletal event|Time and incidence of first skeletal progression-free|Time from entry to initiation of next systemic therapy|Treatments elected after first disease progression|Second progression-free survival in sequential regimen|Pain|Time to pain progression|Occurence of adverse events|Time to use of opioid analgesics|Quality of Life","European Organisation for Research and Treatment of Cancer - EORTC|Bayer|Astellas Pharma Europe Ltd.|Academic and Community Cancer Research United|Cancer Trials Ireland|UNICANCER|Canadian Urologic Oncology Group","Male","18 Years and older   (Adult, Older Adult)","Phase 3","560","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EORTC-1333-GUCG|2014-001787-36","October 2015","December 2024","December 2025","July 18, 2014",,"January 18, 2020","Hopital Universitaire Brugmann, Brussels, Belgium|Hopitaux Universitaires Bordet-Erasme - Hopital Universitaire Erasme, Brussels, Belgium|Cliniques Universitaires Saint-Luc, Brussels, Belgium|Universitair Ziekenhuis Antwerpen, Edegem, Belgium|AZ Groeninge Kortrijk, Kortrijk, Belgium|CHU UCL Namur - Site Sainte-Elisabeth, Namur, Belgium|AZ Turnhout, Turnhout, Belgium|CHU Dinant Godinne - UCL Namur, Yvoir, Belgium|CHUM - Centre Hospitalier de l'Université de Montreal - Pavillon Saint-Luc, Montréal, Canada|Chuq-Pavillon Hotel-Dieu De Quebec, Québec, Canada|Rigshospitalet, Copenhagen, Denmark|Institut de Cancerologie de l'Ouest (ICO) - Centre Paul Papin, Angers, France|Assistance Publique - Hopitaux de Paris - CHU Henri Mondor, Créteil, France|Institut J. Paoli & I. Calmettes, Marseille, France|Institut régional du Cancer Montpellier, Montpellier, France|CHU de Nimes - Hopital Caremeau, Nîmes, France|Institut de Cancerologie de l'Ouest (ICO) - Centre Rene Gauducheau, Saint-Herblain, France|Hopitaux Universitaires de Strasbourg - Hôpitaux Universitaires de Strasbourg - Hôpital civil, Strasbourg, France|Gustave Roussy, Villejuif, France|Cork University Hospital, Cork, Ireland|St. Vincent's University Hospital, Dublin, Ireland|Tallaght University Hospital, Dublin, Ireland|Ospedale B.Ramazzini, Carpi, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy|Istituto Europeo di Oncologia, Milano, Italy|Soerlandet Sykehus-Kristiansand, Kristiansand, Norway|Akershus University Hospital, Lørenskog, Norway|Stavanger University Hospital, Stavanger, Norway|University Hospital of North Norway, Tromsø, Norway|Medical University Of Gdansk, Gdańsk, Poland|Maria Sklodowska-Curie Memorial Cancer Centre, Warsaw, Poland|Hospital Del Mar, Barcelona, Spain|Vall d'Hebron Institut d'Oncologia, Barcelona, Spain|Hospital Clinic Universitari de Barcelona, Barcelona, Spain|Hospital De La Santa Creu I Sant Pau, Barcelona, Spain|Hospital Universitario de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain|Hospital Universitario de La Princesa, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario QuironSalud, Madrid, Spain|Complejo Hospitalario de Navarra, Pamplona, Spain|Corporacio Sanitaria Parc Tauli, Sabadell, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Inselspital, Bern, Switzerland|Kantonsspital St Gallen, St Gallen, Switzerland|UniversitaetsSpital Zurich, Zurich, Switzerland|The Christie NHS Foundation Trust, Manchester, United Kingdom|Nottingham University Hospitals NHS Trust - City Hospital, Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02194842"
1899,"NCT01090362","Global Anticoagulant Registry in the Field","GARFIELD-AF","Unknown status","No Results Available","Atrial Fibrillation",,"Death|Systemic embolism|Heart failure|Acute coronary syndromes|Therapy persistence|Patient satisfaction with oral anticoagulant treatment|Bleeding Events|Strokes (Haemorrhagic and thrombotic)","Thrombosis Research Institute|Bayer|University of Birmingham|Brigham and Women's Hospital|Quintiles, Inc.|Advanced Drug and Device Services SAS|Apothecaries Clinical Research","All","18 Years and older   (Adult, Older Adult)",,"55000","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","TRI08888","December 2009","July 2018","July 2018","March 19, 2010",,"December 5, 2014","Prof. Samuel Goldhaber, Boston, Massachusetts, United States|Dr Hector Luciardi, National Co-ordinating Investigator, National University of Tucuman, Tucumán, Argentina|Harry Gibbs, National Co-ordinating Investigator, The Alfred Hospital, Melbourne, Australia|Marianne Brodmann: National Co-ordinating Investigator, Medizinische Universität Graz, Graz, Austria|Dr Frank Cools, National Co-ordinating Investigator, AZ Klina, Brasschaat, Belgium|Dr Antonio Barretto, National Coordinating Investigator, Hospital Santa Marcelina,, Sao Paolo, Brazil|Prof Stuart Connolly and Dr John Eikelboom, National Coodinating Investigators, Mc Master University, Hamilton, Canada|Dr Ramon Corbalan, National Coordinating Investigator, Pontifica Universidad Catolica de Chile, Santiago, Chile|Prof Dayi Hu, National Coordinating Investigator, Peking University People Hospital, Beijing, China|Dr Petr Jansky, National Coordinating Investigator, Cardiovaskular Center, Motol Univesity Hospital, Prague, Czech Republic|Prof Joern Dalsgaard Nielsen, National Coordinating Investigator, Bispebjerg & Frederiksberg Hospitals, Frederiksberg, Denmark|Dr. Hany Ragy, National Coordinating Investigator, Hayat Hospital, Cairo, Egypt|Prof Pekka Raatikainen, National Coordinating Investigator, Univesrsity of Tampere, Tampere, Finland|Prof. Jean-Yues LeHeuzey, National Coordinating Investigator, Hopital Europeen Georges Pompidou, Paris, France|Prof Harald Darius, National oordinating Investigator, Vivantes Klinikum Neukölln, Berlin, Germany|Dr Matyas Keltai, National Coordinating Investigator, Hungarian Institute of Cardiology, Budapest, Hungary|Dr Sanjay Kakkar, National Coordinating Investigator, Jai Medica Pvt Ltd, Bangalore, India|Profs Giancarlo Agnelli and Giuseppe Ambrosio, National Coordinating Investigators, University of Perugia, Perugia, Italy|Professor Yukihiro Koretsune, National Coordinating Investigator, Osaka National Hospital, Osaka, Japan|Prof. Seil Oh, National Coordinating Investigator, National University Hospital, Seoul, Korea, Republic of|Dr Carlos Jerjes Sanchez Diaz, National Coordinating Investigator,Tecnologico de Monterrey, Monterrey, Mexico|Professor Hugo ten Cate, National Coordinating Investigator, Cardiovascular Research Institute Maastricht, Maastricht, Netherlands|Professor Dan Atar, National Coordinating Investigator, Oslo University Hospital, Oslo, Norway|Prof Janina Stępińska, National Coordinating Investigator, Institute of Cardiology, Warsaw, Warsaw, Poland|Professor Elizaveta Panchenko, National Coordinating Investigator, Cardiology Research and Production Center, Moscow, Russian Federation|Dr Toon Wei Lim, National Coordinating Investigator, National University Hospital, Singapore, Singapore|Prof. Barry Jacobson, National Coordinating Investigator, University of the Witwatersrand, Johannesburg, South Africa|Dr Xavier Vinolas, National Coordinating Investigator, Hospital Santa Creu y San Pau, Barcelona, Spain|Dr Marten Rosenqvist, National Coordinating Investigator, Karolinska Institute, Stockholm, Sweden|Dr Jan Steffel, National Coordinating Investigator, University Hospital, Zurich, Switzerland|Prof. Pantep Angchaisuksiri, National Coordinating Investigator, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand|Drs. Ali Oto and Murat Ersanli, National Coordinating Investigators, Hacettepe University & Istambul Cardiology Institute respectively, Istambul, Turkey|Prof. Alexandr Parkhomenko, National Coordinating Investigator, Strazhesko Institute of Cardiology, Kiev, Ukraine|Prof. Wael Al Mahmeed, National Coordinating Investigator, SKMC Cardiac Siences, Abu Dhabi, United Arab Emirates|Prof. David Fitzmaurice, National Coordinating Investigator, University of Birmingham, Birmingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01090362"
1900,"NCT02925234","The Drug Rediscovery Protocol (DRUP Trial)","DRUP","Unknown status","No Results Available","Cancer|Tumors|Neoplasm|Neoplasia","Drug: Panitumumab|Drug: Olaparib|Drug: Dabrafenib|Drug: Nilotinib|Drug: Trametinib|Drug: Erlotinib|Drug: Trastuzumab and Pertuzumab (combination treatment)|Drug: Vemurafenib and Cobimetinib (combination treatment)|Drug: Vismodegib|Drug: Regorafenib|Drug: Nivolumab","Percentage of patients that are treated based on their molecular tumor profile|Objective tumor response|Stable disease|Treatment-related grade≥3 and serious adverse events|Progression-free survival|Overall survival|Duration of treatment on study (time on drug)","The Netherlands Cancer Institute|Amgen|AstraZeneca|Bayer|Bristol-Myers Squibb|Novartis|Roche Pharma AG","All","18 Years and older   (Adult, Older Adult)","Phase 2","400","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M15DRU","August 2016","August 2019","December 2019","October 5, 2016",,"October 5, 2016","Meander Medical Center, Amersfoort, Utrecht, Netherlands|Netherlands Cancer Institute, Amsterdam, Netherlands|AZVU, Amsterdam, Netherlands|Amphia Hospital, Breda, Netherlands|Maxima Medisch Centrum, Eindhoven, Netherlands|Orbis Concern, Geleen, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Maastricht University Medical Center, Maastricht, Netherlands|Radboud umc, NIjmegen, Netherlands|St. Fransicus Gasthuis, Rotterdam, Netherlands|Erasmus MC, Rotterdam, Netherlands|St. Elisabeth, Tilburg, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT02925234"
1901,"NCT01038583","Aspirin in Reducing Events in the Elderly","ASPREE","Active, not recruiting","No Results Available","Functional Disability|Dementia|Heart Disease|Stroke|Cancer|Bleeding|Depression","Drug: 100 mg enteric-coated aspirin|Drug: Placebo","The primary endpoint is death from any cause or incident, dementia or persistent physical disability.|All-cause mortality|Fatal and non fatal cardiovascular events including a) coronary heart disease death, b) non-fatal MI, c) fatal and non-fatal stroke and d) any hospitalization for heart failure|Fatal and non-fatal cancer, excluding non-melanoma skin cancer|Dementia|Mild Cognitive Impairment (MCI; assessed using the Modified Mini-Mental State Examination or 3MS 70 and other cognitive function measures - see below)|Physical disability|Major hemorrhagic events|Depression","Hennepin Healthcare Research Institute.|National Health and Medical Research Council, Australia|Bayer|Monash University|Berman Center for Outcomes and Clinical Research|National Institute on Aging (NIA)|National Cancer Institute (NCI)","All","65 Years and older   (Older Adult)",,"19114","Other|Industry|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","HSR#09-3029|3U01AG029824-07S2","January 2010","December 2017","April 2024","December 24, 2009",,"May 30, 2019","The University of Alabama at Birmingham, Birmingham, Alabama, United States|Palo Alto Medical Foundation Research Institute, Palo Alto, California, United States|Howard University, Washington, District of Columbia, United States|University of Florida Department of Aging and Geriatrics, Gainesville, Florida, United States|Morehouse School of Medicine, Atlanta, Georgia, United States|Emory/ Atlanta VAMC, Atlanta, Georgia, United States|Georgia Health Sciences University, Augusta, Georgia, United States|Rush Alzheimer's Disease Center, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|Kansas University Medical Center, Kansas City, Kansas, United States|Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States|Mary Bird Perkins Our Lady of the Lake Cancer Center, Baton Rouge, Louisiana, United States|LSU Health Sciences- New Orleans, New Orleans, Louisiana, United States|Tulane Medical Center, New Orleans, Louisiana, United States|LSU Health Sciences- Shreveport, Shreveport, Louisiana, United States|University of Michigan, Ann Arbor, Michigan, United States|Wayne State University, Detroit, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Detroit Clinical Research Center, Novi, Michigan, United States|Health Partners Research Foundation, Minneapolis, Minnesota, United States|Phalen Village Clinic, Saint Paul, Minnesota, United States|Central Jersey Medical Center, Elizabeth, New Jersey, United States|Winthrop University Hospital, Mineola, New York, United States|Wake Forest University Baptist Medical Center, Greensboro, North Carolina, United States|The Brody School of Medicine at ECU, Greenville, North Carolina, United States|Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Health Sciences Research Center, Pittsburgh, Pennsylvania, United States|Memorial Hospital of Rhode Island, Pawtucket, Rhode Island, United States|University of Tennessee Health Science Center, Memphis, Tennessee, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of TX Medical Branch, Galveston, Texas, United States|Regional Academic Health Center, Harlingen, Texas, United States|UT Health Science Center at San Antonio, San Antonio, Texas, United States|Clinical Trials Unit, The Canberra Hospital, Garran, Australian Capital Territory, Australia|Illawarra Health and Medical Research Institute, University of Wollongong, Wollongong, New South Wales, Australia|Discipline of General Practice, School of Population Health, University of Adelaide, Adelaide, South Australia, Australia|Greater Green Triangle University, Mount Gambier, South Australia, Australia|University of Tasmania Rural Clinical School, Burnie, Tasmania, Australia|The Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia|University of Tasmania Newnham Campus, Launceston, Tasmania, Australia|Bendigo Regional Clinical School, Bendigo, Victoria, Australia|Geelong Hospital, Geelong, Victoria, Australia|Monash Mildura Regional Clinical School, Mildura, Victoria, Australia|University of Ballarat, Mount Helen, Victoria, Australia|Monash Gippsland Regional Clinical School, Traralgon, Victoria, Australia|The South West Alliance of Rural Health (SWARH), Warrnambool, Victoria, Australia|Gateway Community Health, Wodonga, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT01038583"
1902,"NCT01968798","ASPREE Cancer Endpoints Study","ACES","Active, not recruiting","No Results Available","Cancer","Drug: Aspirin|Drug: Placebo","To examine the effect of daily low-dose aspirin (100 mg) compared to placebo, on specific DNA biomarkers and selected specific incident and recurrent cancer and metastases.","Hennepin Healthcare Research Institute.|National Cancer Institute (NCI)|National Institute on Aging (NIA)|Monash University|Berman Center for Outcomes and Clinical Research|National Health and Medical Research Council, Australia|Bayer","All","65 Years and older   (Older Adult)","Phase 4","14500","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","3U01AG029824-02S1","September 2013","January 2019","April 2024","October 24, 2013",,"May 30, 2019","The University of Alabama at Birmingham, Birmingham, Alabama, United States|Palo Alto Medical Foundation Research Institute, Palo Alto, California, United States|Howard University, Washington, District of Columbia, United States|University of Florida Department of Aging and Geriatrics, Gainesville, Florida, United States|Morehouse School of Medicine, Atlanta, Georgia, United States|Emory/ Atlanta VAMC, Atlanta, Georgia, United States|Georgia Health Sciences University, Augusta, Georgia, United States|Rush Alzheimer's Disease Center, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|Kansas University Medical Center, Kansas City, Kansas, United States|Baton Rouge General, Baton Rouge, Louisiana, United States|Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States|Mary Bird Perkins Our Lady of the Lake Cancer Center, Baton Rouge, Louisiana, United States|Mary Bird Perkins St. Tammany Parish Hospital, Covington, Louisiana, United States|Mary Bird Perkins Terrebonne General Hospital, Houma, Louisiana, United States|LSU Health Sciences- New Orleans, New Orleans, Louisiana, United States|Tulane Medical Center, New Orleans, Louisiana, United States|LSU Health Sciences- Shreveport, Shreveport, Louisiana, United States|University of Michigan, Ann Arbor, Michigan, United States|Wayne State University, Detroit, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Detroit Clinical Research Center, Novi, Michigan, United States|Health Partners Research Foundation, Minneapolis, Minnesota, United States|Phalen Village Clinic, Saint Paul, Minnesota, United States|Central Jersey Medical Center, Elizabeth, New Jersey, United States|New Jersey Medical College, Newark, New Jersey, United States|SUNY Downstate Medical Center, Brooklyn, New York, United States|Winthrop University Hospital, Mineola, New York, United States|Queens Cancer Medical Center, Queens, New York, United States|Wake Forest University Baptist Medical Center, Greensboro, North Carolina, United States|The Brody School of Medicine at ECU, Greenville, North Carolina, United States|Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Health Sciences Research Center, Pittsburgh, Pennsylvania, United States|Memorial Hospital of Rhode Island, Pawtucket, Rhode Island, United States|University of Tennessee Health Science Center, Memphis, Tennessee, United States|Meharry Medical College, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of TX Medical Branch, Galveston, Texas, United States|Regional Academic Health Center, Harlingen, Texas, United States|UT Health Science Center at San Antonio, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01968798"
1903,"NCT03349801","Development of Novel Clinical Endpoints in Intermediate AMD","MACUSTAR","Recruiting","No Results Available","Age Related Macular Degeneration (AMD)","Other: No intervention","Mean change from baseline in best corrected visual acuity (BCVA) using an early treatment diabetic retinopathy study (ETDRS) chart|Mean change from baseline in scotopic and mesopic microperimetry sensitivity|Mean change from baseline in low luminance visual acuity (LLVA)|Mean change from baseline in vanishing optotypes visual acuity (VA)|Mean change from baseline in low luminance deficit (LLD)|Mean change from baseline in absolute rod threshold of the dark adaptation test|Mean change from baseline in rod intercept time of the dark adaptation test|Proportion of subjects with progression in dark adaptation deficit beyond coefficient of repeatability structural|Mean change from baseline in the cube root of drusen volume by spectral-domain optical coherence tomography (SD-OCT)|Mean change from baseline in retinal thickness by spectral-domain optical coherence tomography (SD-OCT)|Focal pigmentary changes captured by colour fundus photography (CFP)|Presence of refractile deposits|Presence of intraretinal cystoid spaces|Presence of localized retinal pigment epithelium (RPE) hypertransmission|Presence of localized disruption of ellipsoid zone|Presence of localized subsidence of the outer plexiform layer and the inner nuclear layer|Presence of hyporeflective wedge-shaped bands|Presence of reticular drusen/subretinal drusenoid deposits and associated local changes as determined by multimodal imaging|Changes in localized fundus autofluorescence signal alterations|Proportion of subjects with reduction in drusen volume|Proportion of subjects with study eye that progressed to geogrphic atrophy (GA) and/or neovascular age-related macular degeneration (nAMD)|Proportion of subjects with conversions to late AMD detected with fluorescein angiography (FA) that could be detected with OCT-A (at equipped sites)|Presence of quiescent choroidal neovascularisation (CNV) as assessed by optical coherence tomography angiography (OCT-A) (at equipped sites)|OCT-A findings (at equipped sites)|Mean change from baseline in patient-reported low luminance visual functioning, as measured by the vision impairment in low luminance (VILL) questionnaire, including the domains of reading & accessing information|Mean change from baseline in patient-reported low luminance visual functioning, as measured by the VILL questionnaire, including the domains of Orientation & mobility (incl. driving)|Mean change from baseline in patient-reported low luminance visual functioning, as measured by the VILL questionnaire, including the domains of safety|Mean change from baseline in patient-reported low luminance visual functioning, as measured by the VILL questionnaire, including the domains of socio-emotional well-being|Change in utility index from baseline as measure by the patient-reported outcome measure (PROM) utility index|Mean change from baseline in patient-reported health status and utility using the EQ-5D-5L questionnaire (EuroQol Group)","Frank G. Holz|Bayer|Moorfields Eye Hospital NHS Foundation Trust|Novartis Pharmaceuticals|Association for Innovation and Biomedical Research on Light and Image|City, University of London|European Clinical Research Infrastructure Network|La Fondation Voir et Entendre|Hoffmann-La Roche|Radboud University|University of Sheffield|University College, London|Carl Zeiss Meditec AG|Innovative Medicines Initiative|University Hospital, Bonn","All","55 Years to 85 Years   (Adult, Older Adult)",,"750","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ECR-AMD-2017-13|MACUSTAR","March 26, 2018","February 28, 2022","February 28, 2022","November 22, 2017",,"December 31, 2018","Righospitalet Copenhagen, Copenhagen, Denmark|Centre Hospitalier Intercommunal de Creteil, Créteil, France|Centre d'Investigation Clinique Centre National d'Ophtalmologie des Quinze-Vingts, Paris, France|University Hospital Bonn, Bonn, Germany|University Hospital Cologne, Cologne, Germany|Department of Ophthalmology, University of Freiburg, Freiburg, Germany|University Eye Hospital Munich, Munich, Germany|St. Franziskus Hospital, Münster, Germany|Universtiy Hospital Tuebingen, Tübingen, Germany|University Eye Hospital Ulm, Ulm, Germany|Luigi Sacco Hospital, Milan, Italy|Ospedale San Raffaele, Milan, Italy|G.B.Bietti Eye Foundation, Rom, Italy|Radboud University Medical Centre, Leiden, Netherlands|Radboud University Medical Centre, Nijmegen, Netherlands|Centre for Clinical Trials, AIBILI, Coimbra, Portugal|Centro Hospitalar de São João, E.P.E., Porto, Portugal|Queen's University Belfast, Belfast, United Kingdom|Gloucestershire Hospitals NHS Foundation Trust, Gloucester, United Kingdom|Moorfields Eye Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03349801"
1904,"NCT02693535","TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","TAPUR","Recruiting","No Results Available","Lymphoma, Non-Hodgkin|Multiple Myeloma|Advanced Solid Tumors","Drug: Crizotinib|Drug: Palbociclib|Drug: Sunitinib|Drug: Temsirolimus|Drug: Trastuzumab and Pertuzumab|Drug: Vemurafenib and Cobimetinib|Drug: Regorafenib|Drug: Olaparib|Drug: Pembrolizumab|Drug: Nivolumab and Ipilimumab|Drug: Abemaciclib|Drug: Afatinib|Drug: Talazoparib","Objective Response Rate defined as % of participants in a cohort with complete or partial response or with stable disease according to standard response criteria|Overall survival (OS)","American Society of Clinical Oncology|AstraZeneca|Bayer|Bristol-Myers Squibb|Eli Lilly and Company|Genentech, Inc.|Merck Sharp & Dohme Corp.|Pfizer|Boehringer Ingelheim","All","12 Years and older   (Child, Adult, Older Adult)","Phase 2","3279","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00014171","March 2016","December 2021",,"February 26, 2016",,"December 13, 2019","University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States|Cancer Treatment Centers of America-Phoenix, Phoenix, Arizona, United States|The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, California, United States|Sutter Cancer Research Consortium, San Francisco, California, United States|University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Cancer Treatment Centers of America - Atlanta, Atlanta, Georgia, United States|Emory University Winship Cancer Institute, Atlanta, Georgia, United States|The Queen's Medical Center (The University of Texas MD Anderson Cancer Center), Honolulu, Hawaii, United States|Cancer Treatment Centers of America-Chicago, Chicago, Illinois, United States|Community Health Network (The University of Texas MD Anderson Cancer Center), Indianapolis, Indiana, United States|Mercy Medical Center (Michigan Cancer Research Consortium), Springfield, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Cancer Research Consortium of West Michigan, Grand Rapids, Michigan, United States|Michigan Cancer Research Consortium, Traverse City, Michigan, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Carolina's HealthCare System's Levine Cancer Institute, Charlotte, North Carolina, United States|Sanford Health- Bismarck, Bismarck, North Dakota, United States|Sanford Health- Fargo, Fargo, North Dakota, United States|Cancer Treatment Centers of America-Tulsa, Tulsa, Oklahoma, United States|Providence Health & Services, Portland, Oregon, United States|Lehigh Valley Health Network Cancer Institute (Michigan Cancer Research Consortium), Allentown, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Cancer Treatment Centers of America-Philadelphia, Philadelphia, Pennsylvania, United States|Sanford Cancer Center Oncology Clinic and Pharmacy, Sioux Falls, South Dakota, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Intermountain Healthcare, Salt Lake City, Utah, United States|Inova Schar Cancer Institute, Fairfax, Virginia, United States|Swedish Cancer Institute, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02693535"
1905,"NCT01015625","Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer","POSYTIVE","Active, not recruiting","No Results Available","Synchronous Metastasized Breast Cancer|Circulating Tumor Cells","Procedure: Surgery|Procedure: Surgery on Demand","to evaluate the median survival of patients with synchronous metastasized breast cancer and the primary tumor in place comparing arm A with local therapy to the primary tumor versus arm B without local therapy|time to distant progression (TTPd)|time to local progression (TTPl)","Austrian Breast & Colorectal Cancer Study Group|Bayer|Amgen|Hoffmann-La Roche|AstraZeneca|Sanofi Aventis GmbH, Austria|Wyeth Lederle Pharma GmbH, Austria|GlaxoSmithKline|Merck Sharp & Dohme GmbH, Austria|Fond of the Viennese Mayor","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","254","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","ABCSG 28 / POSYTIVE|ABCSG 28","October 2010","June 2021","June 2021","November 18, 2009",,"December 19, 2018","Hospital Guessing, Guessing, Burgenland, Austria|Hospital Oberpullendorf, Oberpullendorf, Burgenland, Austria|Ordination Dr. Wette, St. Veit a. d. Glan, Carinthia, Austria|Gynaegological Medical University Graz, Graz, Styria, Austria|Medical University Graz, Oncology, Graz, Styria, Austria|Medical University of Innsbruck, Innsbruck, Tyrol, Austria|Hospital BHS Linz, Coop. Study Group, Linz, Upper Austria, Austria|Hospital Elisabethinen Linz, Linz, Upper Austria, Austria|General Hospital Linz, Linz, Upper Austria, Austria|Klinikum Wels-Grieskirchen GmbH, Wels, Upper Austria, Austria|State Hospital Feldkirch, Feldkirch, Vorarlberg, Austria|Paracelsus Medical University Salzburg-Oncology, Coop. Group, Salzburg, Austria|Medical University of Vienna-General Hospital Vienna, Vienna, Austria|Medical University of Vienna, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT01015625"
1906,"NCT01000844","Joint Outcome Study Continuation for Children With Severe Factor VIII Deficiency","JOSC","Completed","No Results Available","Hemophilia",,"Determine the natuaral history of joint development in hemophilia and the impact of primary or secondary prophylaxis on the prevention, limitation, or reversal of hemophilic arthropathy.","University of Colorado, Denver|Bayer|Rush University Medical Center|Phoenix Children's Hospital|The University of Texas Health Science Center, Houston|Oregon Health and Science University|Emory University|University of Texas Southwestern Medical Center|Prisma Health-Midlands|Indiana University School of Medicine|Intermountain Health Care, Inc.|Ann & Robert H Lurie Children's Hospital of Chicago","Male","8 Years to 18 Years   (Child, Adult)",,"11","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","01-436","November 2009","October 2017","October 2017","October 23, 2009",,"October 31, 2019",,,"https://ClinicalTrials.gov/show/NCT01000844"
1907,"NCT02116036","Rivaroxaban for Antiphospholipid Antibody Syndrome","RAPS","Completed","No Results Available","Antiphospholipid Antibody Syndrome","Drug: Rivaroxaban","Feasibility of identification for enrolment|Feasibility of Consent|Compliance|Bleeding|Thrombosis","St. Joseph's Healthcare Hamilton|Heart and Stroke Foundation of Canada|Bayer|Hamilton Health Sciences Corporation|Jewish General Hospital|University of Alberta|The Ottawa Hospital|Queen Elizabeth II Health Sciences Centre","All","18 Years and older   (Adult, Older Adult)","Phase 4","81","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","G-13-0002011","September 2014","September 30, 2017","September 30, 2017","April 16, 2014",,"October 18, 2017","University of Alberta Hospital, Edmonton, Alberta, Canada|Queen Elizabeth II Hospital, Halifax, Nova Scotia, Canada|Hamilton General Hospital, Hamilton, Ontario, Canada|St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02116036"
1908,"NCT02810795","Dynamic Stress Perfusion CT for Detection of Inducible Myocardial Ischemia","SPECIFIC","Recruiting","No Results Available","Coronary Artery Disease","Other: Diagnostic detection of coronary artery disease","Myocardial perfusion|Presence of myocardial perfusion defect on MPIMRI|Per patient assessment of hemodynamically significant CAD|Ischemia per standardized myocardial segment|Coronary stenosis by CTA per territory (branch)|Coronary stenosis by invasive angiography per territory (branch)|Demographics.|Cardiovascular risk factors|'Image quality, based on the DICOM images measured by experienced readers.""","Erasmus Medical Center|University Hospital Tuebingen|Siemens Medical Solutions|Bayer|University of Erlangen-Nürnberg|University Medical Center Groningen|Mie University|University Hospital, Zürich|Queen Mary University of London|University Hospital Munich","All","21 Years to 75 Years   (Adult, Older Adult)",,"180","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","SPECIFIC","June 7, 2016","July 2019","December 2019","June 23, 2016",,"February 1, 2019","ErasmusMC, Rotterdam, Zuid Holland, Netherlands",,"https://ClinicalTrials.gov/show/NCT02810795"
1909,"NCT04001244","Translational Research in Pelvic Pain","TRiPP","Not yet recruiting","No Results Available","Endometriosis|Bladder Pain Syndrome|Chronic Pain",,"Quantitative Sensory Testing (QST)|Presence of abdominal wall muscle tenderness|Change of pressure pain threshold (PPT)|Area under the curve (AUC) of single day salivary cortisol profile|Change in salivary cortisol|Heart rate (HR)|Change in heart rate|Blood pressure (BP)|Change in Blood pressure|Bladder sensitivity to filling|Volume voided at maximum tolerance|fMRI scan|Pain Catastrophising: Pain Catastrophising Scale (PCS) (Sullivan)|Comorbid psychological distress|Metabolomic data|Proteomic data|Transcriptomic data|Comorbidities|Past trauma|Recent trauma","University of Oxford|Boston Children’s Hospital|Michigan State University|Cork University Hospital|Bayer|Grünenthal GmbH|Esteve|Queen Mary University of London|Aalborg University|Endometriosis.org|International Painful Bladder Foundation|Pelvic Pain Support Network|King's College London|Heidelberg University|University of Edinburgh|University of Jena|Westfälische Wilhelms-Universität Münster|Universidade do Porto","Female","18 Years to 50 Years   (Adult)",,"800","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","TRiPP WP9","June 2019","May 2020","May 2020","June 28, 2019",,"June 28, 2019",,,"https://ClinicalTrials.gov/show/NCT04001244"
1910,"NCT00505245","New Assessment System in Measuring Symptom Distress in Cancer Patients",,"Recruiting","No Results Available","Caregiver|Health Care Provider|Malignant Neoplasm|Physician","Other: Interview|Other: Quality-of-Life Assessment|Other: Questionnaire Administration","Effort Expenditure for Rewards Task (EEfRT) evaluated by questionnaires.|Levels of C-reactive protein and interleukin-6 and the ratios of kynurenine to tryptophan will be compared between high-fatigue and low-fatigue survivors, using independent t-tests.|Change in symptom severity|Change in symptom interference with function|Individual differences in self-reported fatigue assessed by MD Anderson Symptom Inventory-Head and Neck (MDASI-HN)","M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Bayer|Bristol-Myers Squibb|Eli Lilly and Company|Genentech, Inc.|Merck Sharp & Dohme Corp.|National Institutes of Health (NIH)","All","18 Years and older   (Adult, Older Adult)",,"5500","Other|NIH|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","BS99-094|NCI-2018-02461|P30CA016672|R01CA205146","April 13, 1999","April 30, 2020","April 30, 2020","July 23, 2007",,"November 20, 2018","M D Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00505245"
1911,"NCT01740037","IntegRAted Chronic Care Program at Specialized AF Clinic Versus Usual CarE in Patients With Atrial Fibrillation - RACE4","RACE4","Completed","No Results Available","Atrial Fibrillation","Other: Specialized outpatient AF Clinic|Other: Usual Care","The primary endpoint is a composite of unplanned admission to the hospital for any cardiovascular reason and cardiovascular death.|All components of the primary endpoint|All-cause mortality|Total number of unplanned all-cause hospitalizations|Duration of unplanned all-cause hospitalizations|Total number of unplanned cardiovascular hospitalizations|Duration of unplanned cardiovascular hospitalizations|Total number of unplanned hospitalizations related to atrial fibrillation|Duration of unplanned hospitalizations related to atrial fibrillation|Recurrent unplanned cardiovascular hospitalizations|Costs and cost-effectiveness|Implementation of care|Patient Quality of life|Anxiety and/ or depression|Knowledge of AF|Compliance to medication","Maastricht University Medical Center|Stichting Achmea Gezondheidszor|DSW|CZ Fonds|Bayer|Boehringer Ingelheim|Bristol-Myers Squibb|Pfizer|Daiichi Sankyo, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1375","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","METC 11-2-099","December 2012","September 30, 2018","September 30, 2018","December 4, 2012",,"May 28, 2019","Martini Ziekenhuis, Groningen, Netherlands|UMCG, Groningen, Netherlands|Spaarne Gasthuis, Haarlem, Netherlands|Medisch Centrum Leeuwarden, Leeuwarden, Netherlands|MUMC+, Maastricht, Netherlands|Canisius Wilhelmina Ziekenhuis Nijmegen, Nijmegen, Netherlands|Zaans Medisch Centrum, Zaandam, Netherlands|Isala, Zwolle, Netherlands",,"https://ClinicalTrials.gov/show/NCT01740037"
1912,"NCT00822471","Feasibility and Impact of ""ABCs of Diabetes"" Self-Management Education Program at an Urban Public Library",,"Completed","No Results Available","Diabetes|Cardiovascular Disease","Behavioral: Diabetes Self-Management Education","Improvement in the percent of subjects correctly identifying guideline-recommended treatment targets for the ""ABC's of Diabetes"", where A = A1C < 7%; B = BP <130/80mmHg and; and C = LDL-C < 100mg/dl.|increase the percentage of subjects taking medications for A1C, BP and LDL-C management and aspirin;|increase scores on the diabetes self-efficacy scale (DES);|increase percentage of patients with A1C, BP and LDL-C at recommended targets;|Decrease the percentage of participants with self-reported ED visits and hospitalizations for severe hypoglycemia and hyperglycemia.","Medstar Health Research Institute|Medstar Diabetes Institute;|American Diabetes Association|Bayer|CareFirst BlueCross Blue Shield;|District of Columbia, Department of Health Block Grants Program;|Charles and Mary Latham Trust Fund;|Eli Lilly and Company|Hewlett-Packard|Meltzer Entities;|NBC Washington|Novo Nordisk A/S|Aventis Pharmaceuticals|Takeda Pharmaceuticals North America, Inc.|Washington Hospital Center|Pfizer","All","18 Years and older   (Adult, Older Adult)","Not Applicable","360","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2002-288","January 2003","January 2005","July 2005","January 14, 2009",,"January 14, 2009","Washington Hospital Center, Washington, District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT00822471"
1913,"NCT02890147","Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: Case-control","PRECISESADST","Completed","No Results Available","Healthy Subjects",,"Gene expression in total blood|Flow cytometry analysis to determine cell proportions in the total blood mixture in all individuals.|Genotyping|Metabolite determination|Exosome isolation from plasma and urine|Cytokine profile determination|routine autoantibodies in serum|Gene expression methylation in total blood","Fundación Pública Andaluza Progreso y Salud|UCB Biopharma S.P.R.L.|Atrys Health|National Research Council, Spain|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Servicio Cántabro de Salud|August Pi Sunyer Biomedical Research Institute|Karolinska Institutet|KU Leuven|Klinikum der Universität Köln|Hannover Medical School|Medical University of Vienna|Quartz Bio S.A.|Andaluz Health Service|The Cyprus Foundation for Muscular Dystrophy Research|Universidad de Granada|University of Milan|Université Catholique de Louvain|University Hospital, Brest|University of Geneva, Switzerland|Szeged University|Bayer|Institut de Recherches Internationales Servier|Sanofi|Eli Lilly and Company|Charite University, Berlin, Germany|Centro Hospitalar do Porto|Institut d'Investigació Biomèdica de Bellvitge|Innovative Medicines Initiative|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud","All","18 Years and older   (Adult, Older Adult)",,"649","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","PRECISESADS-T","December 2014","October 2017","October 2017","September 7, 2016",,"May 23, 2018","Medical University of Vienna, Vienna, Austria|UZ Leuven - KU Leuven, Department of Rheumatology (KU LEUVEN), Leuven, Belgium|CHRU de Brest, Brest, France|Deutsches Rheuma-Forschungszentrum Berlin (DRFZ), Berlin, Germany|Medizinische Hochschule Hannover, Hannover, Germany|University of Szeged, Szeged, Hungary|Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico (IRCCS), Milan, Italy|UNIMI, Istituto Ortopedico Getano Pini, Milan, Italy|Centro Hospitalar do Porto, Porto, Portugal|Hospital Clinic I Provicia- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain|Hospital Universitario Reina Sofía Andaluz de Salud, Cordoba, Spain|Biobanco del Sistema Sanitario Público de Andalucía (SSPA), Granada, Spain|Hospital Universitario San Cecilio Servicio Andaluz de Salud, Granada, Spain|Hospital Virgen de las Nieves Granada, Granada, Spain|Hospital Regional de Málaga Servicio Andaluz de Salud, Malaga, Spain|Hospital Universitario Marqués de Valdecilla, Servicio Cántabro de Salud, Santander, Spain|Hospitaux Universitaires de Géneve, Geneve, Switzerland",,"https://ClinicalTrials.gov/show/NCT02890147"
1914,"NCT02890134","Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: Inception Cohort","PRECISESADSI","Unknown status","No Results Available","Systemic Autoimmune Diseases",,"Gene expression in total blood|Flow cytometry analysis to determine cell proportions in the total blood mixture in all individuals.|Genotyping|Metabolite determination|Exosome isolation from plasma and urine|Cytokine profile determination|routine autoantibodies in serum|Gene methylation in total blood","Fundación Pública Andaluza Progreso y Salud|UCB Biopharma S.P.R.L.|Atrys Health|National Research Council, Spain|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Servicio Cántabro de Salud|August Pi Sunyer Biomedical Research Institute|Karolinska Institutet|KU Leuven|Klinikum der Universität Köln|Hannover Medical School|Medical University of Vienna|Quartz Bio S.A.|Andaluz Health Service|The Cyprus Foundation for Muscular Dystrophy Research|Universidad de Granada|University of Milan|Université Catholique de Louvain|University Hospital, Brest|University of Geneva, Switzerland|Szeged University|Bayer|Institut de Recherches Internationales Servier|Sanofi|Eli Lilly and Company|Charite University, Berlin, Germany|Centro Hospitalar do Porto|Institut d'Investigació Biomèdica de Bellvitge|Innovative Medicines Initiative|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud","All","18 Years and older   (Adult, Older Adult)",,"200","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","PRECISESADS INCP (RB 15.007)","June 2015","January 2019","January 2019","September 7, 2016",,"December 12, 2016","Université catholique de Louvain - Cliniques Universitaires Saint-Luc (UCL), Brussels, Belgium|UZ Leuven - KU Leuven, Department of Rheumatology (KU LEUVEN), Leuven, Belgium|CHRU de Brest, Brest, France|Deutsches Rheuma-Forschungszentrum Berlin (DRFZ), Berlin, Germany|Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico (IRCCS), Milan, Italy|Hospital Clinic I Provicia- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain|Hospital Universitario Reina Sofía Andaluz de Salud, Cordoba, Spain|Hospital Universitario San Cecilio Servicio Andaluz de Salud, Granada, Spain|Hospital Virgen de las Nieves Granada, Granada, Spain|Hospitaux Universitaires de Géneve (UNIGE), Geneve, Switzerland",,"https://ClinicalTrials.gov/show/NCT02890134"
1915,"NCT02890121","Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases:","PRECISESADS","Completed","No Results Available","Systemic Autoimmune Diseases",,"Gene expression in total blood|Flow cytometry analysis to determine cell proportions in the total blood mixture in all individuals.|Genotyping|Metabolite determination|Exosome isolation from plasma and urine|Cytokine profile determination|routine autoantibodies in serum|Gene methylation in total blood","Fundación Pública Andaluza Progreso y Salud|UCB Biopharma S.P.R.L.|Atrys Health|National Research Council, Spain|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Servicio Cántabro de Salud|August Pi Sunyer Biomedical Research Institute|Karolinska Institutet|KU Leuven|Klinikum der Universität Köln|Hannover Medical School|Medical University of Vienna|Quartz Bio S.A.|Andaluz Health Service|The Cyprus Foundation for Muscular Dystrophy Research|Universidad de Granada|University of Milan|Université Catholique de Louvain|University Hospital, Brest|University of Geneva, Switzerland|Szeged University|Bayer|Institut de Recherches Internationales Servier|Sanofi|Eli Lilly and Company|Charite University, Berlin, Germany|Centro Hospitalar do Porto|Institut d'Investigació Biomèdica de Bellvitge|Innovative Medicines Initiative|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud","All","18 Years and older   (Adult, Older Adult)",,"2006","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","PRECISESADS CS (RB 14.106)","December 2014","October 2017","October 2017","September 7, 2016",,"May 23, 2018","Medical University of Vienna, Vienna, Austria|Université catholique de Louvain - Cliniques Universitaires Saint-Luc, Brussels, Belgium|UZ Leuven - KU Leuven, Department of Rheumatology (KU LEUVEN), Leuven, Belgium|CHRU de Brest, Brest, France|Deutsches Rheuma-Forschungszentrum Berlin (DRFZ), Berlin, Germany|University of Cologne, Cologne, Germany|Medizinische Hochschule Hannover, Hannover, Germany|University of Szeged, Szeged, Hungary|Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico (IRCCS), Milan, Italy|UNIMI, Istituto Ortopedico Getano Pini, Milan, Italy|Centro Hospitalar do Porto, Porto, Portugal|Hospital Clinic I Provicia- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain|Hospital Universitario Reina Sofía Andaluz de Salud, Cordoba, Spain|Hospital Universitario San Cecilio Servicio Andaluz de Salud, Granada, Spain|Hospital Virgen de las Nieves Granada, Granada, Spain|Hospital Regional de Málaga Servicio Andaluz de Salud, Malaga, Spain|Hospital Universitario Marqués de Valdecilla, Servicio Cántabro de Salud, Santander, Spain|Hospitaux Universitaires de Géneve, Geneve, Switzerland",,"https://ClinicalTrials.gov/show/NCT02890121"
1916,"NCT01524705","FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)","FLAT-SUGAR","Completed","No Results Available","Type 2 Diabetes","Drug: ""GLIPULIN:"" [insulin glargine, metformin, exenatide (GLP-1-agonist)]|Drug: Insulin glargine, metformin, prandial insulin","The change in the coefficient of variation of continuous glucose readings, as assessed by CGM.|The secondary trial goal will be to evaluate the frequency of hypoglycemia in the two interventional arms.","University of Washington|Eli Lilly and Company|Sanofi|Astra Zeneca, Bristol-Myers Squibb|DexCom, Inc.|Bayer|Becton, Dickinson and Company|Medicomp|University of Texas|US Department of Veterans Affairs|Biomedical Research Institute of New Mexico","All","40 Years to 75 Years   (Adult, Older Adult)","Phase 4","102","Other|Industry|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","42178-E/G","August 2012","July 2014","July 2014","February 2, 2012",,"September 18, 2014","So Calif. Permanente Medical Group, San Diego, California, United States|University of Miami, Miami, Florida, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|International Diabetes Center, Minneapolis, Minnesota, United States|Washington University, St. Louis, Missouri, United States|Kaledia Health of Western New York, Buffalo, New York, United States|Diabetes Care Center, Durham, North Carolina, United States|Oregon Health and Science University, Portland, Oregon, United States|University of Vermont, Colchester, Vermont, United States|University of Washington, Seattle, Washington, United States|Washington State University Spokane, College of Pharmacy Spokane WA 99202 USA, Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01524705"
1917,"NCT01809015","Evaluation of Oral Anticoagulation With Vitamin K Antagonists - The thrombEVAL Study Programme","thrombEVAL","Completed","No Results Available","Anticoagulant Antagonists, Vitamin K and Other Coagulants Causing Adverse Effects in Therapeutic Use|Atrial Fibrillation|Venous Thromboembolism",,"Time in therapeutic range|Hospitalisation|Net clinical benefit","Johannes Gutenberg University Mainz|Ministry of Health, Rhineland-Palatinate, Germany|Ministry of Economics, Rhineland-Palatinate, Germany|German Federal Ministry of Education and Research|Boehringer Ingelheim|Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company|Sanofi|IMO Institut GmbH|PortaVita BV|The German Heart Foundation|Bayer","All","18 Years and older   (Adult, Older Adult)",,"2318","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","UMCM-2010EPI01","January 2011","March 2018","March 2018","March 12, 2013",,"August 24, 2018","University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Rhineland-Palatinate, Germany",,"https://ClinicalTrials.gov/show/NCT01809015"
1918,"NCT00877643","Routine Versus Aggressive Upstream Rhythm Control for Prevention of Early Atrial Fibrillation in Heart Failure","RACE 3","Active, not recruiting","No Results Available","Atrial Fibrillation","Other: Upstream therapy|Other: Conventional rhythm control","Success of rhythm control strategy consisting of 1) the patient is still in a rhythm control strategy according to the attending physician, and 2) that sinus rhythm is maintained after 1 year of follow-up.|Exploratory randomized long term extension of the RACE 3 study performed to study the long term effects of the two treatment strategies.","I.C. Van Gelder|The Interuniversity Cardiology Institute of the Netherlands|Netherlands Heart Foundation|Dutch Network for Cardiovascular Research|Trial Coordination Center UMC Groningen|Bayer|Boehringer Ingelheim|Medtronic|Biotronik SE & Co. KG|Abbott Medical Devices|Boston Scientific Corporation|AstraZeneca|University Medical Center Groningen","All","40 Years and older   (Adult, Older Adult)","Not Applicable","250","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NHS B 2008 035","May 2009","May 1, 2017","January 2021","April 8, 2009",,"October 29, 2018","Ziekenhuisgroep Twente, Almelo/Hengelo, Netherlands|Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands|Hospital Rijnstate, Arnhem/Velp, Netherlands|Ter Gooi Hospital, Blaricum, Netherlands|Amhia Hospital, Breda, Netherlands|Ommelander Hospital Group, Delfzijl, Netherlands|Deventer Hospital, Deventer, Netherlands|Oosterscheldeziekenhuis, Goes, Netherlands|Martini Hospital, Groningen, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Kennemer Gasthuis, Haarlem, Netherlands|Medical University Center Maastricht, Maastricht, Netherlands|University Medical Center Nijmegen, Nijmegen, Netherlands|Viecuri Hospital, Venlo, Netherlands|Ommelander Hospital Group, Winschoten, Netherlands|City Hospital (Sandwell and West Birmingham Hospitals NHS Trust), Birmingham, United Kingdom|University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|Poole Hospital NHS Foundation Trust, Poole, United Kingdom|Good Hope Hospital (Heart of England NHS Foundation Trust), Sutton Coldfield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00877643"
1919,"NCT00142181","Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia",,"Completed","No Results Available","Lymphoplasmacytic Lymphoma|Waldenstrom's Macroglobulinemia","Drug: Campath-1H","To determine the effectiveness of Campath-1H in treating patients with Waldenstrom's macroglobulinemia.|To determine the safety of Campath-1H.","Dana-Farber Cancer Institute|Brigham and Women's Hospital|Beth Israel Deaconess Medical Center|Massachusetts General Hospital|Bayer|University of California, Los Angeles|Northwestern University|Arizona Oncology Associates","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","27","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","02-079","March 2003","October 2005","June 2008","September 2, 2005",,"December 21, 2012","Beth Isreal Deaconness Medical Center, Boston, Massachusetts, United States|Dana-farber Cancer Insitiute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00142181"
1920,"NCT01315015","Breast Cancer Screening With MRI in Women Aged 50-75 Years With Extremely Dense Breast Tissue: the DENSE Trial",,"Active, not recruiting","No Results Available","Breast Cancer","Other: Contrast enhanced breast MRI","The number of interval cancers will be compared between the MRI group and the control group|The number of MRI screen-detected tumors will be determined|Tumor size, stage and grade distributions, including their histological and molecular subtypes, diagnosed in both study groups will be compared|The referral rate in the MRI study group will be determined|The positive predictive value (and the amount of false-positive diagnoses) of MRI will be determined using the histological diagnosis as the reference test|The number of biopsies per positive MRI will be determined|The mortality rate in the MRI group will be compared with the control group using the MISCAN computer simulation program|The cost-effectiveness of MRI will be estimated using the MISCAN computer simulation program|The impact of MRI screening on quality of life will be assessed using standardized and validated questionnaires","UMC Utrecht|Dutch Breast Cancer Screening Organisations|Dutch Reference Centre for Screening|National Institute for Public Health and the Environment|Antoni van Leeuwenhoek Hospital|University Medical Center Nijmegen|Jeroen Bosch Ziekenhuis|Albert Schweitzer Hospital|Hospital Group Twente (ZGT)|VU University Medical Center|Maastricht University Medical Center|ZonMw: The Netherlands Organisation for Health Research and Development|Dutch Cancer Society|Pink Ribbon Inc.|A Sister's Hope|Bayer|Stichting Kankerpreventie Midden-West|Volpara Solutions","Female","49 Years to 75 Years   (Adult, Older Adult)","Phase 4","36185","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","UMCU DENSE|ZONMW-200320002-UMCU|Pink Ribbon-10074|BSP-DENSE|DCS-UU-2009-4348|DCS-UU-2014-6859","November 2011","December 2019","December 2019","March 15, 2011",,"October 12, 2018","Jeroen Bosch Hospital, 's-Hertogenbosch, Netherlands|Hospital Group Twente (ZGT), Almelo And Hengelo, Netherlands|Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands|VU University Medical Center, Amsterdam, Netherlands|Albert Schweitzer Hospital, Dordrecht, Netherlands|Maastricht University Medical Center, Maastricht, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|UMC Utrecht, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT01315015"
1921,"NCT01107548","Prevention of Stroke and Dementia in Primary Care","INVADE","Terminated","No Results Available","Stroke|Dementia|Disability","Other: Systematic detection of vascular risk factors and subsequent evidence-based treatment","Incidence of long-term care disability|Incidence of stroke|Reduction of cardiovascular risk factors","Technische Universität München|Allgemeine Ortskrankenkasse Bayern (AOK)|Stiftung Deutsche Schlaganfall-Hilfe|Ratiopharm GmbH|Sanofi-Synthelabo|Organon|Teva Pharma GmbH|Bayer|Berlin-Chemie Menarini","All","55 Years and older   (Adult, Older Adult)","Not Applicable","3908","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","080250hb","January 2001","December 2008","March 2010","April 21, 2010",,"February 20, 2012","Depts. of Psychiatry and Neurology, Technische Universität München, Munich, Germany",,"https://ClinicalTrials.gov/show/NCT01107548"
